﻿FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Zandi, S
   Weisskopf, F
   Garweg, JG
   Pfister, IB
   Pruente, C
   Sutter, F
   Hatz, K
AF Zandi, Souska
   Weisskopf, Florian
   Garweg, Justus G.
   Pfister, Isabel B.
   Pruente, Christian
   Sutter, Florian
   Hatz, Katja
TI Pre-Existing RPE Atrophy and Defects in the External Limiting Membrane
   Predict Early Poor Visual Response to Ranibizumab in Neovascular
   Age-Related Macular Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; INTRAVITREAL RANIBIZUMAB; CHOROIDAL
   NEOVASCULARIZATION; SUBGROUP ANALYSIS; TREATMENTS TRIALS; AMD;
   ASSOCIATION; THERAPY; ANCHOR
AB BACKGROUND AND OBJECTIVES: The aim of this study was to identify the rate of early visual acuity poor responders in patients with neovascular age-related macular degeneration (AMD) after the first intravitreal injection of ranibizumab (Lucentis; Genentech, South San Francisco, CA) and to determine potential predictors for early response.
   PATIENTS AND METHODS: Patients with choroidal neovascularization secondary to AMD were evaluated before and 1 month after their first ranibizumab treatment. Early poor responders were defined as eyes gaining less than five letters 1 month after the first injection.
   RESULTS: Following the first ranibizumab injection, 58% of 84 patients gained five or more letters. Beyond 42% poor responders, 31% displayed foveal retinal pigment epithelium (RPE) atrophy and 89% a loss of the external limiting membrane (ELM) integrity at baseline. However, the amount of intraand subretinal fluid, pigment epithelial detachment (PED), and subfoveal fibrosis showed a similar distribution between gainers and poor responders.
   CONCLUSION: Early poor responders present with more RPE atrophy, as well as a loss of the ELM integrity at baseline optical coherence tomography.
C1 [Zandi, Souska; Garweg, Justus G.; Pfister, Isabel B.] Swiss Eye Inst, Bern, Switzerland.
   [Zandi, Souska; Garweg, Justus G.; Pfister, Isabel B.] Lindenhofspital, Berner Augenklin, Bern, Switzerland.
   [Weisskopf, Florian; Hatz, Katja] Vista Klin, Binningen, Switzerland.
   [Garweg, Justus G.] Univ Bern, Bern, Switzerland.
   [Pruente, Christian; Hatz, Katja] Univ Basel, Basel, Switzerland.
   [Pruente, Christian] Kantonsspital Liestal, Dept Ophthalmol, Liestal, Switzerland.
   [Sutter, Florian] Univ Hosp, Univ Eye Hosp, Zurich, Switzerland.
C3 University of Bern; University of Basel; Kantonsspital Baselland;
   University of Zurich; University Zurich Hospital
RP Hatz, K (通讯作者)，Hauptstr 55, CH-4102 Binningen, Switzerland.
EM khatz@vistaklinik.ch
OI Zandi, Souska/0000-0001-9351-4278
FU Novartis Switzerland
FX Drs. Zandi, Weisskopf, Garweg, Pruente, Sutter, and Hatz report having
   received support from Novartis Switzerland. Dr. Pfister reports no
   relevant financial disclosures. The described investigations have been
   supported in part by Novartis Switzerland. The three participating sites
   have further independently received financial compensation from Novartis
   Switzerland for consultancies and contract research.
CR Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Bloch SB, 2013, ACTA OPHTHALMOL, V91, P42, DOI 10.1111/j.1755-3768.2011.02268.x
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Byun YJ, 2010, JPN J OPHTHALMOL, V54, P571, DOI 10.1007/s10384-010-0866-1
   Chhablani J, 2013, INT J OPHTHALMOL-CHI, V6, P62, DOI 10.3980/j.issn.2222-3959.2013.01.13
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P1671, DOI 10.1167/iovs.09-4496
   Garweg JG, OPHTHALMOL IN PRESS
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kang S, 2009, JPN J OPHTHALMOL, V53, P389, DOI 10.1007/s10384-009-0670-y
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Kim YM, 2012, AM J OPHTHALMOL, V154, P164, DOI 10.1016/j.ajo.2012.01.030
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Menghini M, 2010, KLIN MONATSBL AUGENH, V227, P244, DOI 10.1055/s-0029-1245203
   Regillo CD, 2015, AM J OPHTHALMOL, V160, P1014, DOI 10.1016/j.ajo.2015.07.034
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Shin HJ, 2011, RETINA-J RET VIT DIS, V31, P1627, DOI 10.1097/IAE.0b013e31820d3d01
   Singh RP, 2009, BRIT J OPHTHALMOL, V93, P1353, DOI 10.1136/bjo.2008.141879
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
   Ying GS, 2015, OPHTHALMOLOGY, V122, P2523, DOI 10.1016/j.ophtha.2015.08.015
NR 27
TC 7
Z9 8
U1 1
U2 4
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD APR
PY 2017
VL 48
IS 4
BP 326
EP 332
DI 10.3928/23258160-20170329-07
PG 7
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA EW4LN
UT WOS:000402473100009
PM 28419398
DA 2022-11-30
ER

PT J
AU Vofo, BN
   Beykin, G
   Levy, J
   Chowers, I
AF Vofo, Brice Nguedia
   Beykin, Gala
   Levy, Jaime
   Chowers, Itay
TI Long-term outcome of neovascular age-related macular degeneration:
   association between treatment outcome and major risk alleles
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE genetics; retina; macula
ID GROWTH-FACTOR TREATMENT; VISUAL-ACUITY; RANIBIZUMAB; TACHYPHYLAXIS;
   MORPHOLOGY; THERAPY
AB Aims To evaluate the long-term functional and anatomical outcomes of neovascular age-related macular degeneration (nvAMD) treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) for up to 10 years, and to identify associated risk factors. Methods Clinical and optical coherence tomography findings were retrieved for nvAMD cases treated with intravitreal anti-VEGF compounds using a treat-and-extend protocol. In addition, the major risk alleles for AMD in the CFH (rs1061170), HTRA1 (rs1200638) and C3 (rs2230199) genes were genotyped. Results From 276 eligible eyes in 206 patients, 80 eyes (29%) in 66 patients (32.0%) had a follow-up period of >= 8 years and were included in this study. Over a 10-year period, 73.3 +/- 28.0 (mean +/- SD) anti-VEGF injections were administered. Best-corrected visual acuity (BCVA; LogMAR) deteriorated from 0.55 +/- 0.53 at baseline to 1.00 +/- 0.73 at 10 years (p<0.0005). Central subfield thickness (CST) decreased from 415.8 +/- 162.1 mu m at baseline to 323 +/- 113.6 mu m (p<0.0005) after three monthly injections and remained lower than baseline throughout the follow-up period. Visual outcome was associated with BCVA and intraretinal fluid (IRF) at baseline, macular atrophy, and macular thinning at follow-up. The decrease in CST was inversely correlated with the number of CFH and/or C3 risk alleles carried by the patient (Pearson's r: -0.608; p=0.003). Conclusions Patients with nvAMD who received anti-VEGF therapy for 10 years developed substantial vision loss associated with the presence of IRF at baseline and macular atrophy. Major risk alleles for AMD in two complement genes were associated with a reduced long-term reduction in macular thickness.
C1 [Vofo, Brice Nguedia; Beykin, Gala; Levy, Jaime; Chowers, Itay] Hadassah Med Ctr, Dept Ophthalmol, IL-91120 Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Hadassah University Medical Center
RP Chowers, I (通讯作者)，Hadassah Med Ctr, Dept Ophthalmol, IL-91120 Jerusalem, Israel.
EM chowers@hadassah.org.il
OI Levy, Jaime/0000-0003-0043-4354; Vofo, Brice/0000-0002-7759-5909
FU Israel Science Foundation Grant [3485/19]
FX Israel Science Foundation Grant (#3485/19). Neither the sponsor nor the
   funding organisation had a role in designing or conducting this
   research.
CR Arpa C, 2021, BRIT J OPHTHALMOL, V105, P1688, DOI 10.1136/bjophthalmol-2020-317161
   Berg K, 2017, ACTA OPHTHALMOL, V95, P796, DOI 10.1111/aos.13522
   Beykin G, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0019-x
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Calvo P, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/820605
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chandra S, 2020, EYE, V34, P1888, DOI 10.1038/s41433-020-0764-9
   Dervenis N, 2016, CLIN OPHTHALMOL, V10, DOI 10.2147/OPTH.S106734
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gillies M, 2020, AM J OPHTHALMOL, V210, P116, DOI 10.1016/j.ajo.2019.10.007
   Grover S, 2010, INVEST OPHTH VIS SCI, V51, P2644, DOI 10.1167/iovs.09-4774
   Grunin M, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.2.48
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Javidi S, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/3207614
   Kodjikian L, 2018, RETINA-J RET VIT DIS, V38, P1492, DOI 10.1097/IAE.0000000000001736
   Lores-Motta L, 2018, JAMA OPHTHALMOL, V136, P875, DOI 10.1001/jamaophthalmol.2018.2019
   Martin DF, 2020, OPHTHALMOLOGY, V127, pS135, DOI 10.1016/j.ophtha.2020.01.029
   McGuinness MB, 2017, EYE, V31, P1345, DOI 10.1038/eye.2017.139
   Mones J, 2020, OPHTHALMOLOGICA, V243, P1, DOI 10.1159/000502747
   Pedrosa AC, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/4263017
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Schmidt-Erfurth U, 2020, OPHTHALMOLOGY, V127, P1211, DOI 10.1016/j.ophtha.2020.03.010
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Spooner K, 2021, OPHTHALMOL RETINA, V5, P511, DOI 10.1016/j.oret.2020.09.019
   Starr MR, 2020, RETINA-J RET VIT DIS, V40, P1665, DOI 10.1097/IAE.0000000000002668
   Wolff B, 2020, CLIN EXP OPHTHALMOL, V48, P636, DOI 10.1111/ceo.13742
   Yanamadala V, 2010, TRENDS MOL MED, V16, P69, DOI 10.1016/j.molmed.2009.12.001
   Yoshida I, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/5308597
NR 35
TC 1
Z9 1
U1 2
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD NOV
PY 2022
VL 106
IS 11
BP 1555
EP 1560
DI 10.1136/bjophthalmol-2021-319054
EA JUN 2021
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 5U6TH
UT WOS:000726804500001
PM 34083208
DA 2022-11-30
ER

PT J
AU Tode, J
   Richert, E
   Koinzer, S
   Klettner, A
   von der Burchard, C
   Brinkmann, R
   Lucius, R
   Roider, J
AF Tode, Jan
   Richert, Elisabeth
   Koinzer, Stefan
   Klettner, Alexa
   von der Burchard, Claus
   Brinkmann, Ralf
   Lucius, Ralph
   Roider, Johann
TI Thermal Stimulation of the Retina Reduces Bruch's Membrane Thickness in
   Age Related Macular Degeneration Mouse Models
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE thermal stimulation of the retina (TS-R); nondamaging retinal laser
   therapy (NRT); sub-threshold laser therapy; age related macular
   degeneration (AMD); Bruch's membrane; drusen
ID PIGMENT EPITHELIUM; MATRIX METALLOPROTEINASES; TRANSPUPILLARY
   THERMOTHERAPY; CHOROIDAL NEOVASCULARIZATION; PROPHYLACTIC TREATMENT;
   810-NANOMETER LASER; ELIGIBLE PATIENTS; TEMPERATURE RISE; OXIDATIVE
   STRESS; THERAPY SRT
AB Purpose: To investigate the effect of thermal stimulation of the retina (TS-R) on Bruch's membrane (BrM) thickness in age-related macular degeneration (AMD) mouse models as a novel concept for the prophylaxis and treatment of dry AMD.
   Methods: Two knockout AMD mouse models, B6.129P2-Apoe (tm1Unc)/J (ApoE-/-) and B6.129X1-Nfe2I2 (tm1Ywk)/J (NRF2-/-), were chosen. One randomized eye of each mouse in four different groups (two of different age, two of different genotype) of five mice was treated by TS-R (532 nm, 10-ms duration, 50-mu m spot size), the fellow eye served as control. Laser power was titrated to barely visible laser burns, then reduced by 70% to guarantee for thermal elevation without damage to the neuroretina, then applied uniformly to the murine retina. Fundus, optical coherence tomography (OCT), and fluorescein angiography (FLA) images were obtained at the day of treatment and 1 month after treatment. Eyes were enucleated thereafter to analyze BrM thickness by transmission electron microscopy (TEM) in a standardized blinded manner.
   Results: Fundus images revealed that all ApoE-/- and NRF2-/- mice had AMD associated retinal alterations. BrM thickness was increased in untreated controls of both mouse models. Subvisible TS-R laser spots were not detectable by fundus imaging, OCT, or FLA 2 hours or 1 month after laser treatment. TEM revealed a significant reduction of BrM thickness in laser-treated eyes of all four groups compared to their fellow control eyes.
   Conclusions: TS-R reduces BrM thickness in AMD mouse models ApoE-/- and NRF2-/- without damage to the neuroretina. It may become a prophylactic or even therapeutic treatment option for dry AMD.
   Translational Relevance: TS-R may become a prophylactic or even therapeutic treatment option for dry AMD.
C1 [Tode, Jan; Richert, Elisabeth; Koinzer, Stefan; Klettner, Alexa; von der Burchard, Claus; Roider, Johann] Christian Albrechts Univ Kiel, Univ Med Ctr, Dept Ophthalmol, Arnold Heller St 3, D-24105 Kiel, Germany.
   [Brinkmann, Ralf] Univ Lubeck, Inst Biomed Opt, Lubeck, Germany.
   [Brinkmann, Ralf] Med Laser Ctr Lubeck GmbH, Lubeck, Germany.
   [Lucius, Ralph] Christian Albrechts Univ Kiel, Inst Anat, Kiel, Germany.
C3 University of Kiel; Schleswig Holstein University Hospital; University
   of Lubeck; University of Kiel
RP Tode, J (通讯作者)，Christian Albrechts Univ Kiel, Univ Med Ctr, Dept Ophthalmol, Arnold Heller St 3, D-24105 Kiel, Germany.
EM jan.tode@uksh.de
RI Brinkmann, Ralf/E-6701-2012; von der Burchard, Claus/GZG-4104-2022;
   Lucius, Ralph/B-1614-2010; Klettner, Alexa Karina/M-8344-2018;
   Brinkmann, Ralf/HDL-7611-2022
OI Brinkmann, Ralf/0000-0002-0445-8102; Klettner, Alexa/0000-0002-2709-1059
FU German Ministry of Education and Research (BMBF) [13GW0043D]
FX This work was supported by the German Ministry of Education and Research
   (BMBF): Grant 13GW0043D.
CR Ahir A, 2002, INVEST OPHTH VIS SCI, V43, P458
   ALEXANDER JP, 1990, INVEST OPHTH VIS SCI, V31, P2520
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Aredo B, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-014-0221-4
   Benner JD, 2002, AM J OPHTHALMOL, V134, P765, DOI 10.1016/S0002-9394(02)01694-X
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   BIRNGRUBER R, 1985, HEALTH PHYS, V48, P781, DOI 10.1097/00004032-198506000-00006
   Brinkmann R, 2000, LASER SURG MED, V27, P451, DOI 10.1002/1096-9101(2000)27:5<451::AID-LSM1006>3.0.CO;2-1
   Brinkmann R, 2006, Bull Soc Belge Ophtalmol, P51
   Broadhead GK, 2015, NUTR REV, V73, P448, DOI 10.1093/nutrit/nuv005
   Campagne MV, 2016, IMMUNOBIOLOGY, V221, P733, DOI 10.1016/j.imbio.2015.11.007
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Elsner H, 2006, GRAEF ARCH CLIN EXP, V244, P1638, DOI 10.1007/s00417-006-0368-5
   Evans JR, 2014, OPHTHAL PHYSL OPT, V34, P390, DOI 10.1111/opo.12142
   Friberg TR, 2009, OPHTHAL SURG LAS IM, V40, P530, DOI 10.3928/15428877-20091030-01
   Friberg TR, 2006, OPHTHALMOLOGY, V113, P612, DOI 10.1016/j.ophtha.2005.10.066
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Guymer RH, 2014, CLIN EXP OPHTHALMOL, V42, P466, DOI 10.1111/ceo.12247
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Iwami H, 2014, EXP EYE RES, V124, P37, DOI 10.1016/j.exer.2014.04.014
   Jobling AI, 2015, FASEB J, V29, P696, DOI 10.1096/fj.14-262444
   Kandulla J, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2236301
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Koinzer S, 2013, ACTA OPHTHALMOL, V91, pE603, DOI 10.1111/aos.12188
   Koinzer S, 2013, LASER SURG MED, V45, P427, DOI 10.1002/lsm.22163
   Koinzer S, 2012, J BIOPHOTONICS, V5, P889, DOI 10.1002/jbio.201200091
   Koinzer S, 2012, INVEST OPHTH VIS SCI, V53, P3605, DOI 10.1167/iovs.11-8588
   Lavinsky D, 2016, INVEST OPHTH VIS SCI, V57, P2488, DOI 10.1167/iovs.15-18981
   Lavinsky D, 2015, RETINA-J RET VIT DIS, V35, P213, DOI 10.1097/IAE.0000000000000340
   Lavinsky D, 2014, RETINA-J RET VIT DIS, V34, P87, DOI 10.1097/IAE.0b013e3182993edc
   Mainster MA, 2000, OPHTHALMIC SURG LAS, V31, P359
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Mehalow AK, 2003, HUM MOL GENET, V12, P2179, DOI 10.1093/hmg/ddg232
   Mulisch M, 2010, ROMEIS MIKROSKOPISCH
   Neumann J, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1896969
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   Padgett LC, 1997, EXP EYE RES, V64, P927, DOI 10.1006/exer.1997.0287
   Parmeggiani F, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/435607
   Parodi MB, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub2
   Pons M, 2011, INVEST OPHTH VIS SCI, V52, P3842, DOI 10.1167/iovs.10-6254
   Richert E, 2015, INVEST OPHTH VIS SCI, V56
   ROIDER J, 1992, ARCH OPHTHALMOL-CHIC, V110, P1786, DOI 10.1001/archopht.1992.01080240126045
   Roider J, 2010, GRAEF ARCH CLIN EXP, V248, P1263, DOI 10.1007/s00417-010-1356-3
   Schrader WF, 2006, OPHTHALMOLOGE, V103, P742, DOI 10.1007/s00347-006-1418-4
   Segal AW, 2005, ANNU REV IMMUNOL, V23, P197, DOI 10.1146/annurev.immunol.23.021704.115653
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Sramek C, 2011, INVEST OPHTH VIS SCI, V52, P1780, DOI 10.1167/iovs.10-5917
   Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Treumer F, 2012, EXP EYE RES, V97, P63, DOI 10.1016/j.exer.2012.02.011
   Vessey KA, 2012, INVEST OPHTH VIS SCI, V53, P7833, DOI 10.1167/iovs.12-10650
   Vranka JA, 1997, CURR EYE RES, V16, P102, DOI 10.1076/ceyr.16.2.102.5086
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421
   WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705
   Yenari MA, 2005, ANN NY ACAD SCI, V1053, P74, DOI 10.1196/annals.1344.007
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
NR 66
TC 24
Z9 24
U1 2
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD MAY
PY 2018
VL 7
IS 3
AR 2
DI 10.1167/tvst.7.3.2
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GF2HX
UT WOS:000431760300002
PM 29736323
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Lindner, M
   Kosanetzky, S
   Pfau, M
   Nadal, J
   Gordt, LA
   Schmitz-Valckenberg, S
   Schmid, M
   Holz, FG
   Fleckenstein, M
AF Lindner, Moritz
   Kosanetzky, Sebastian
   Pfau, Maximilian
   Nadal, Jennifer
   Goerdt, Lukas A.
   Schmitz-Valckenberg, Steffen
   Schmid, Matthias
   Holz, Frank G.
   Fleckenstein, Monika
CA FAM-Study Grp
TI Local Progression Kinetics of Geographic Atrophy in Age-Related Macular
   Degeneration Are Associated With Atrophy Border Morphology
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE optical coherence tomography; geographic atrophy; age-related macular
   degeneration
ID OPTICAL COHERENCE TOMOGRAPHY; FUNDUS AUTOFLUORESCENCE PATTERNS; VISUAL
   IMPAIRMENT; HIGH-RESOLUTION; MACULOPATHY; PREVALENCE
AB PURPOSE. To assess the impact of distinct atrophy border characteristics based on spectral-domain optical coherence tomography (SD-OCT) imaging on local atrophy progression. METHODS. Patients with geographic atrophy (GA) secondary to AMD were recruited in the context of the Longitudinal Fundus Autofluorescence in Age-related Macular Degeneration and Directional Spread in Geographic Atrophy studies (NCT00393692, NCT02051998). Horizontal and vertical SD-OCT scans were acquired at sequential visits using a device allowing for anatomically accurate registration of follow-up to baseline scans. For quantification of local atrophy progression, the lateral spread of GA (LSGA) was measured. Further, border types were independently graded. Comparison of LSGA between the different border types was performed using linear mixed-effects models. RESULTS. Seventy-two eyes of 49 patients (27 female) aged 74.0 years (Inter quartile range [IQR], 68.1-79.0) were included into this analysis. A total of 258 border sections were analyzed longitudinally over a median period of 1.2 years (IQR, 0.9-1.6). At baseline, 17.1% borders were classified as 'regular', 47.7% as 'irregular', and 35.3% as 'splitting'. Sixty-two percent of the eyes exhibited more than one border type. LSGA was slowest 'regular' borders (62.85 +/- 25.29 mu m/y), followed by 'irregular' borders (91.15 +/- 15.05 mu m/y) and fastest in 'splitting' borders (183.15 +/- 18.17 mu m/y). Differences between the 'splitting' and each other border type were statistically significant (P < 0.001). CONCLUSIONS. The results indicate that SD-OCT-based assessment of local GA border morphology can serve as a predictor for local atrophy progression. These observations help to better understand the natural history and potential pathogenetic factors of GA development and progression.
C1 [Lindner, Moritz; Kosanetzky, Sebastian; Pfau, Maximilian; Goerdt, Lukas A.; Schmitz-Valckenberg, Steffen; Holz, Frank G.; Fleckenstein, Monika] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
   [Lindner, Moritz] Univ Oxford, Sleep & Circadian Neurosci Inst, Nuffield Dept Clin Neurosci, Nuffield Lab Ophthalmol, Oxford, England.
   [Lindner, Moritz] Oxford Univ Hosp NHS Fdn Trust, Oxford Eye Hosp, Oxford, England.
   [Nadal, Jennifer; Schmid, Matthias] Univ Hosp Bonn, Inst Med Biometry Informat & Epidemiol, Bonn, Germany.
C3 University of Bonn; University of Oxford; Oxford University Hospitals
   NHS Foundation Trust; University of Bonn
RP Fleckenstein, M (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM Monika.Fleckenstein@ukbonn.de
RI Pfau, Maximilian/N-1888-2019; Lindner, Moritz/AAC-8639-2021; Walter,
   Peter/L-5982-2018
OI Pfau, Maximilian/0000-0001-9761-9640; Lindner,
   Moritz/0000-0002-4416-3421; Walter, Peter/0000-0001-8745-6593; Schmid,
   Matthias/0000-0002-0788-0317
FU German Research Foundation (DFG; Bonn, Germany) [FL658/4-1, FL658/4-2,
   LI2846/1-1]; BONFOR GEROK Program, Faculty of Medicine, University of
   Bonn [O-137.0022, O-137.0025]
FX Supported by the German Research Foundation (DFG; Bonn, Germany), Grant
   No FL658/4-1 and FL658/4-2 (MF) and LI2846/1-1 (ML); and the BONFOR
   GEROK Program, Faculty of Medicine, University of Bonn, Grant No
   O-137.0022 and O-137.0025 (MP; Bonn, Germany); ML is the Knoop Junior
   Research Fellow at St. Cross College, Oxford, UK.
CR [Anonymous], 2012, LANG ENV STAT COMP
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Brandl C, 2016, OPHTHALMOLOGE, V113, P735, DOI 10.1007/s00347-016-0341-6
   Brar M, 2009, AM J OPHTHALMOL, V148, P439, DOI 10.1016/j.ajo.2009.04.022
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Drexler W, 2004, J BIOMED OPT, V9, P47, DOI 10.1117/1.1629679
   Dreyhaupt J, 2005, OPHTHAL EPIDEMIOL, V12, P353, DOI 10.1080/09286580591005723
   Fleckenstein M, 2010, OPHTHALMOLOGE, V107, P1007, DOI 10.1007/s00347-010-2159-y
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fleckenstein M, 2014, INVEST OPHTH VIS SCI, V55, P2911, DOI 10.1167/iovs.13-13409
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P6552, DOI 10.1167/iovs.11-7298
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P3761, DOI 10.1167/iovs.10-7021
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Helb HM, 2010, ACTA OPHTHALMOL, V88, P842, DOI 10.1111/j.1755-3768.2009.01602.x
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Lindner M, 2015, INVEST OPHTH VIS SCI, V56, P875, DOI 10.1167/iovs.14-14933
   Moussa K, 2013, RETINA-J RET VIT DIS, V33, P1590, DOI 10.1097/IAE.0b013e31828d6052
   Niu SJ, 2016, OPHTHALMOLOGY, V123, P1737, DOI 10.1016/j.ophtha.2016.04.042
   Nunes RP, 2013, OSLI RETINA, V44, P344, DOI 10.3928/23258160-20130715-06
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmitz-Valckenberg S, 2016, RETINA-J RET VIT DIS, V36, P2250, DOI 10.1097/IAE.0000000000001258
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Stetson PF, 2014, INVEST OPHTH VIS SCI, V55, P792, DOI 10.1167/iovs.13-13199
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 36
TC 6
Z9 6
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2018
VL 59
IS 4
SI SI
DI 10.1167/iovs.17-23203
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GB4CK
UT WOS:000429007900002
PM 29558533
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Krilis, M
   Qi, M
   Qi, J
   Wong, JWH
   Guymer, R
   Liew, G
   Hunyor, AP
   Madigan, M
   McCluskey, P
   Weaver, J
   Krilis, SA
   Giannakopoulos, B
AF Krilis, Matthew
   Qi, Miao
   Qi, Jian
   Wong, Jason W. H.
   Guymer, Robyn
   Liew, Gerald
   Hunyor, Alex P.
   Madigan, Michele
   McCluskey, Peter
   Weaver, James
   Krilis, Steven A.
   Giannakopoulos, Bill
TI Dual roles of different redox forms of complement factor H in protecting
   against age related macular degeneration
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Complement factor H; Oxidoreductases; Thioredoxin-1; Age related macular
   degeneration; Free thiols; Reactive oxygen species; Complement
   activation; Lipid peroxidation products
ID HEMOLYTIC-UREMIC SYNDROME; ANTIPHOSPHOLIPID SYNDROME;
   BETA(2)-GLYCOPROTEIN I; BETA-2-GLYCOPROTEIN-I; MALONDIALDEHYDE;
   IDENTIFICATION; POLYMORPHISM; ACTIVATION; SUBSTRATE
AB Complement Factor H (CFH) is an important inhibitor of the alternate complement pathway in Bruch's membrane (BM), located between the choriocapillaris and the retinal pigment epithelium. Furthermore dysfunction of its activity as occurs with certain polymorphisms is associated with an increased risk of age related macular degeneration (AMD).
   The retina is a site of high generation of reactive oxygen species (ROS) and dysfunction of redox homeostasis in this milieu also contributes to AMD pathogenesis. In this study we wanted to explore if CFH exists in distinct redox forms and whether these species have unique protective biological functions. CFH can be reduced by the naturally occurring thioredoxin - 1 in CFH domains 1-4, 17-20. We found a duality of function between the oxidised and reduced forms of CFH. The oxidised form was more efficient in binding to C3b and lipid peroxidation by-products that are known to accumulate in the retinae and activate the alternate complement pathway.
   Oxidised CFH enhances Factor I mediated cleavage of C3 and C3b whereas the reduced form loses this activity. In the setting of oxidative stress (hydrogen peroxide)-mediated death of human retinal pigment epithelial cells as can occur in AMD, the free thiol form of CFH offers a protective function compared to the oxidised form. We found for the first time using a novel ELISA system we have developed for free thiol CFH, that both redox forms of CFH are found in the human plasma. Furthermore there is a distinct ratio of these redox forms in plasma depending if an individual has early or late AMD, with individuals with early AMD having higher levels of the free thiol form compared to late AMD.
C1 [Krilis, Matthew; Hunyor, Alex P.; Madigan, Michele; McCluskey, Peter] Univ Sydney, Save Sight Inst, 8 Macquarie St, Sydney, NSW, Australia.
   [Krilis, Matthew; Hunyor, Alex P.; Madigan, Michele; McCluskey, Peter] Sydney Eye Hosp, 8 Macquarie St, Sydney, NSW, Australia.
   [Qi, Miao; Qi, Jian; Krilis, Steven A.; Giannakopoulos, Bill] St George Hosp, Dept Infect Dis Immunol & Sexual Hlth, 2 South St, Sydney, NSW, Australia.
   [Qi, Miao; Qi, Jian; Weaver, James; Krilis, Steven A.; Giannakopoulos, Bill] Univ New South Wales, St George Hosp, St George & Sutherland Clin Sch, Fac Med, Sydney, NSW, Australia.
   [Wong, Jason W. H.] Univ New South Wales, Prince Wales Clin Sch, Sydney, NSW, Australia.
   [Wong, Jason W. H.] Univ New South Wales, Lowy Canc Res Ctr, Sydney, NSW, Australia.
   [Guymer, Robyn] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, 32 Gisborne St, East Melbourne, Vic, Australia.
   [Liew, Gerald] Univ Sydney, Westmead Inst Med Res, Sydney, NSW, Australia.
   [Madigan, Michele] Univ New South Wales, Sch Optometry & Visual Sci, Sydney, NSW, Australia.
   [Weaver, James] St George Hosp, Dept Cardiol, Sydney, NSW, Australia.
   [Giannakopoulos, Bill] St George Hosp, Dept Rheumatol, Belgrave St, Sydney, NSW, Australia.
C3 University of Sydney; St George Hospital; St George Hospital; University
   of New South Wales Sydney; University of New South Wales Sydney;
   University of New South Wales Sydney; Centre for Eye Research Australia;
   Royal Victorian Eye & Ear Hospital; University of Melbourne; University
   of Sydney; Westmead Institute for Medical Research; University of New
   South Wales Sydney; St George Hospital; St George Hospital
RP Giannakopoulos, B (通讯作者)，Dept Infect Dis Immunol & Sexual Hlth, Level 1,2 South St, Sydney, NSW 2217, Australia.
EM bill.giannakopoulos@unsw.edu.au
RI Hunyor, Alex/AAT-8205-2021; McCluskey, Peter J/H-7607-2013; Liew,
   Gerald/AAB-6870-2022; Wong, Jason/A-9466-2008
OI Hunyor, Alex/0000-0002-8182-6167; McCluskey, Peter
   J/0000-0002-8177-1637; Wong, Jason/0000-0003-2953-7728
FU National Health and Medical Research Council (Australia) [ID1060323];
   Macular Disease Foundation Australia; Blackmores Research Grant
FX This work was supported by a project grant from the National Health and
   Medical Research Council (Australia) ID1060323 and from the Macular
   Disease Foundation Australia and Blackmores Research Grant.
CR Bajic G, 2015, EMBO J, V34, P2735, DOI 10.15252/embj.201591881
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blackmore TK, 1996, J IMMUNOL, V157, P5422
   Caprioli J, 2003, HUM MOL GENET, V12, P3385, DOI 10.1093/hmg/ddg363
   de Cordoba SR, 2008, CLIN EXP IMMUNOL, V151, P1, DOI 10.1111/j.1365-2249.2007.03574.x
   Dragon-Durey MA, 2004, J AM SOC NEPHROL, V15, P787, DOI 10.1097/01.ASN.0000115702.28859.A7
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Giannakopoulos B, 2012, J AUTOIMMUN, V39, P121, DOI 10.1016/j.jaut.2012.05.005
   GORDON DL, 1995, J IMMUNOL, V155, P348
   Gropp K, 2011, BLOOD, V118, P2774, DOI 10.1182/blood-2011-02-339564
   Heinen S, 2009, BLOOD, V114, P2439, DOI 10.1182/blood-2009-02-205641
   Ioannou Y, 2011, ARTHRITIS RHEUM-US, V63, P2774, DOI 10.1002/art.30383
   Ioannou Y, 2010, BLOOD, V116, P1961, DOI 10.1182/blood-2009-04-215335
   Kelly U, 2010, J IMMUNOL, V185, P5486, DOI 10.4049/jimmunol.0903596
   KIKUGAWA K, 1984, LIPIDS, V19, P600, DOI 10.1007/BF02534718
   Krilis M, 2017, ONCOTARGET, V8, P49016, DOI 10.18632/oncotarget.14940
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   MARNETT LJ, 1980, CANCER RES, V40, P276
   Morgan HP, 2011, NAT STRUCT MOL BIOL, V18, P463, DOI 10.1038/nsmb.2018
   Passam FH, 2010, J THROMB HAEMOST, V8, P1754, DOI 10.1111/j.1538-7836.2010.03944.x
   Passam FH, 2010, BLOOD, V116, P1995, DOI 10.1182/blood-2010-02-271494
   Qi M, 2016, ANTIOXID REDOX SIGN, V24, P32, DOI 10.1089/ars.2014.6052
   Reddel SW, 2000, J AUTOIMMUN, V15, P91, DOI 10.1006/jaut.2000.0427
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Vizcaino J.A., 2016, NUCL ACIDS RES, V44, P11033
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Winkler BS, 1999, MOL VIS, V5
NR 29
TC 8
Z9 8
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD DEC
PY 2018
VL 129
BP 237
EP 246
DI 10.1016/j.freeradbiomed.2018.09.034
PG 10
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA HA5GR
UT WOS:000450298400022
PM 30253188
DA 2022-11-30
ER

PT J
AU Regillo, CD
   Busbee, BG
   Ho, AC
   Ding, BY
   Haskova, Z
AF Regillo, Carl D.
   Busbee, Brandon G.
   Ho, Allen C.
   Ding, Beiying
   Haskova, Zdenka
TI Baseline Predictors of 12-Month Treatment Response to Ranibizumab in
   Patients With Wet Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SUBGROUP ANALYSIS; VERTEPORFIN; THERAPY; MARINA
AB PURPOSE: To identify baseline characteristics predictive of visual acuity (VA) outcomes at month 12 (M12) and treatment frequency in the first 12 months of the phase III HARBOR study.
   DESIGN: Retrospective, exploratory analysis of multicenter randomized controlled trial data.
   METHODS: SETTING: Randomized, multicenter. STUDY POPULATION: Patients aged >= 50 years with subfoveal wet age-related macular degeneration (AMD) who had best-corrected VA (BCVA) values measured at baseline and M12. INTERVENTION: Intravitreal ranibizumab 0.5 mg administered monthly (n = 249) or as needed (PRN) after 3 monthly loading doses (n = 251). MAIN OUTCOME MEASURES: BCVA change from baseline at M12, percentage of patients who gained >= 15 letters (3 lines) in BCVA from baseline at M12, and percentage of patients who achieved 20/40 vision (Snellen) at M12 served as the basis for analyzing baseline predictors of observed VA outcomes in the monthly and PRN groups. Total number of ranibizumab PRN injections in the first 12 months was also evaluated. Only variables that were statistically significant (P < .05) remained in the final statistical models.
   RESULTS: Baseline predictors of BCVA change from baseline at M12 and/or percentage of 3-line gainers included lower BCVA, younger age, smaller total choroidal neovascularization (CNV) leakage area, smaller area of occult CNV, and presence of subretinal fluid (SRF). Baseline predictors of >= 20/40 vision at M12 included higher BCVA, smaller total CNV leakage area, and presence of SRF. SRF thickness > 118.25 gm at baseline predicted requiring more ranibizumab injections in the first 12 months of treatment.
   CONCLUSIONS: Select baseline characteristics have predictive value for visual prognosis and treatment frequency in ranibiztunab-treated patients with wet AMD. (C) 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.licenses/by-nc-nd/4.0/).
C1 [Regillo, Carl D.; Ho, Allen C.] Wills Eye Hosp & Res Inst, Mid Atlant Retina, Philadelphia, PA 19107 USA.
   [Busbee, Brandon G.] Centennial Profess Plaza, Tennessee Retina, Nashville, TN USA.
   [Ding, Beiying; Haskova, Zdenka] Genentech Inc, San Francisco, CA 94080 USA.
C3 Jefferson University; Roche Holding; Genentech
RP Regillo, CD (通讯作者)，Wills Eye Hosp & Res Inst, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
EM cregillo@aol.com
OI Ho, Allen/0000-0003-3921-608X
FU GENENTECH, INC, SOUTH SAN FRANCISCO, CA; Allergan; Genentech;
   GlaxoSmithKline; Ophthotech (New York, NY); Regeneron; Thrombogenics;
   Alcon; Janssen; NEI/NIH; Ophthotech
FX GENENTECH, INC, SOUTH SAN FRANCISCO, CA PROVIDED SUPPORT FOR THE STUDY
   AND PARTICIPATED IN the study design; conducting the study; and data
   collection, management, and interpretation. Financial disclosures: Carl
   D. Regillo serves as a consultant for. Allergan (Irvine, CA), Genentech
   (South San Francisco, CA), GlaxoSmithKline (Brentford, United Kingdom),
   Regeneron (Tarrytown, NY), and Thrombogenics (Leuven, Belgium); and
   receives research funding from Allergan, Genentech, GlaxoSmithKline,
   Ophthotech (New York, NY), Regeneron, and Thrombogenics. Brandon G.
   Busbee serves as a consultant for Genentech, Regeneron, and Synergetics
   (O'Fallon, MO); and receives royalties from AKORN (Lake Forest, IL).
   Allen C. Ho serves as a consultant for Alcon (Fort Worth, TX), Allergan,
   Genentech, Janssen (Titusville, NJ; Raritan, NJ), Ophthotech, and
   Regeneron; receives research funding from Alcon, Allergan, Genentech,
   Janssen, NEI/NIH, Ophthotech, and Regeneron; and is a member of the
   speakers bureau for Alcon, Genentech, and Regeneron. Beiying Ding, and
   Zdenka Haskova are employees of Genentech, Inc. All authors attest that
   they meet the current ICMJE criteria for authorship:
CR [Anonymous], 2014, LUC RAN INJ PACK INS
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Breiman L, 1993, CASE DESCRIPTION FEA, V1, P1
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Lally DR, 2012, CURR OPIN OPHTHALMOL, V23, P182, DOI 10.1097/ICU.0b013e328352411c
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 22
TC 48
Z9 49
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD NOV
PY 2015
VL 160
IS 5
BP 1014
EP 1023
DI 10.1016/j.ajo.2015.07.034
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CV0CK
UT WOS:000363914800022
PM 26231305
OA hybrid
DA 2022-11-30
ER

PT J
AU Rennie, CA
   Stinge, A
   King, EA
   Sothirachagan, S
   Osmond, C
   Lotery, AJ
AF Rennie, C. A.
   Stinge, A.
   King, E. A.
   Sothirachagan, S.
   Osmond, C.
   Lotery, A. J.
TI Can genetic risk information for age-related macular degeneration
   influence motivation to stop smoking? A pilot study
SO EYE
LA English
DT Article
DE macular degeneration; smoking; risk factors; smoking cessation; risk
ID CIGARETTE-SMOKING; QUIT SMOKING; SUSCEPTIBILITY; CESSATION; BLINDNESS;
   SMOKERS; ASSOCIATION; PERCEPTIONS; LOC387715; ROTTERDAM
AB Aims Smoking can increase the risk of macular degeneration and this is more than additive if a person also has a genetic risk. The purpose of this study was to examine whether knowledge of genetic risk for age-related macular degeneration (AMD) could influence motivation to quit smoking.
   Methods A questionnaire-based study of hypothetical case scenarios given to 49 smokers without AMD. Participants were randomly allocated to a generic risk, high genetic risk, or low genetic risk of developing AMD scenario.
   Results Forty-seven percent knew of the link between smoking and eye disease. In all, 76%, 67%, and 46% for the high risk, generic, and low risk groups, respectively, would rethink quitting (P for trend = 0.082). In all, 67%, 40%, and 38.5%, respectively, would be likely, very likely, or would definitely quit in the following month (P for trend = 0.023). Few participants (<16% of any group) were very likely to or would definitely attend a quit smoking session with no difference across groups. In all, 75.5% of participants would consider taking a genetic test for AMD.
   Conclusion In this pilot study, a trend was seen for the group given high genetic risk information to be more likely to quit than the generic or low genetic risk groups. Participants were willing to take a genetic test but further work is needed to address the cost benefits of routine genetic testing for risk of AMD. More generic risk information should be given to the public, and health warnings on cigarette packets that 'smoking causes blindness' is a good way to achieve this. Eye (2012) 26, 109-118; doi:10.1038/eye.2011.256; published online 28 October 2011
C1 [Rennie, C. A.] Southampton Gen Hosp, Southampton Eye Unit, Dept Ophthalmol, Southampton SO16 6YD, Hants, England.
   [King, E. A.; Sothirachagan, S.] Univ Southampton, Sch Med, Southampton, Hants, England.
   [Osmond, C.] Univ Southampton, Southampton Gen Hosp, MRC Lifecourse Epidemiol Unit, Southampton, Hants, England.
C3 University of Southampton; University of Southampton; University of
   Southampton
RP Rennie, CA (通讯作者)，Southampton Gen Hosp, Southampton Eye Unit, Dept Ophthalmol, Tremona Rd, Southampton SO16 6YD, Hants, England.
EM christina@crennie.com
OI Osmond, Clive/0000-0002-9054-4655; Lotery, Andrew/0000-0001-5541-4305
FU Medical Research Council [U1475000004] Funding Source: researchfish;
   National Institute for Health Research [NF-SI-0507-10094] Funding
   Source: researchfish
CR Asher MK, 2003, J SUBST ABUSE TREAT, V24, P169, DOI 10.1016/S0740-5472(02)00354-9
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BETTMAN JW, 1958, ARCH OPHTHALMOL-CHIC, V59, P481
   Bidwell G, 2005, EYE, V19, P945, DOI 10.1038/sj.eye.6701955
   Carpenter MJ, 2007, ANN BEHAV MED, V33, P22, DOI 10.1207/s15324796abm3301_3
   Chapman S, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000216
   Dhubhghaill SSN, 2010, ADV EXP MED BIOL, V664, P437, DOI 10.1007/978-1-4419-1399-9_50
   Frosch DL, 2005, CANCER EPIDEM BIOMAR, V14, P1485, DOI 10.1158/1055-9965.EPI-04-0913
   HEATHERTON TF, 1989, BRIT J ADDICT, V84, P791
   HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Kelly SP, 2004, BRIT MED J, V328, P537, DOI 10.1136/bmj.328.7439.537
   Klaver CCW, 1997, ARCH OPHTHALMOL-CHIC, V115, P945, DOI 10.1001/archopht.1997.01100160115033
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Lerman C, 1997, HEALTH PSYCHOL, V16, P87, DOI 10.1037/0278-6133.16.1.87
   Lotery A, 2007, HUM GENET, V122, P219, DOI 10.1007/s00439-007-0406-3
   McBride CM, 2002, CANCER EPIDEM BIOMAR, V11, P521
   Messer K, 2008, AM J PUBLIC HEALTH, V98, P317, DOI 10.2105/AJPH.2007.112060
   Miller CL, 2009, TOB CONTROL, V18, P235, DOI 10.1136/tc.2008.028290
   Moradi P, 2007, BRIT J OPHTHALMOL, V91, P605, DOI 10.1136/bjo.2006.108191
   NHS The Information Centre, STAT NHS STOP SMOK S
   Office for National Statistics, 2008, 40 OFF NAT STAT
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   PROCHASKA JO, 1983, J CONSULT CLIN PSYCH, V51, P390, DOI 10.1037//0022-006X.51.3.390
   PRYOR WA, 1983, SCIENCE, V220, P425, DOI 10.1126/science.6301009
   Sanderson SC, 2007, CLIN GENET, V71, P501, DOI 10.1111/j.1399-0004.2007.00810.x
   Sanderson SC, 2005, PUBLIC UNDERST SCI, V14, P213, DOI 10.1177/0963662505050993
   Sanderson SC, 2005, HEALTH EDUC BEHAV, V32, P640, DOI 10.1177/1090198105278756
   Sanjay S, 2009, CLIN EXP OPHTHALMOL, V37, P795, DOI 10.1111/j.1442-9071.2009.02153.x
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wright AJ, 2006, HEALTH PSYCHOL, V25, P740, DOI 10.1037/0278-6133.25.6.740
NR 38
TC 12
Z9 13
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD JAN
PY 2012
VL 26
IS 1
BP 109
EP 118
DI 10.1038/eye.2011.256
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 892UN
UT WOS:000300311200013
PM 22037055
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Baek, J
   Kim, JH
   Lee, MY
   Lee, WK
AF Baek, Jiwon
   Kim, Jae Hui
   Lee, Mee Yon
   Lee, Won Ki
TI DISEASE ACTIVITY AFTER DEVELOPMENT OF LARGE SUBRETINAL HEMORRHAGE IN
   POLYPOIDAL CHOROIDAL VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE polypoidal choroidal vasculopathy; subretinal hemorrhage; disease
   activity; anti-VEGF
ID TISSUE-PLASMINOGEN ACTIVATOR; MASSIVE SUBMACULAR HEMORRHAGE;
   INTRAVITREAL BEVACIZUMAB; PNEUMATIC DISPLACEMENT; MACULAR DEGENERATION;
   VISUAL PROGNOSIS; NATURAL-HISTORY; RANIBIZUMAB; VITRECTOMY; THERAPY
AB Purpose: To investigate changes in disease activity after a large subretinal hemorrhage in polypoidal choroidal vasculopathy.
   Methods: Fifty-two polypoidal choroidal vasculopathy eyes with large subretinal hemorrhage (at initial presentation [n = 33, Group 1] or developed during follow-up [n = 19, Group 2]) were enrolled. Thirty polypoidal choroidal vasculopathy eyes without subretinal hemorrhage were enrolled as controls. All subretinal hemorrhages were treated with pneumatic displacement. Other active lesions were treated with intravitreal ranibizumab on an as-needed basis. Injection-free period, 1-year injection numbers, and polyp presence on indocyanine green angiography were analyzed.
   Results: The injection frequency significantly diminished after hemorrhage (1.2 +/- 1.8 in Group 1 and 1.1 +/- 2.1 in Group 2) compared with control eyes (3.9 +/- 3.0) in both groups (both P < 0.001) and the prehemorrhage period (4.7 +/- 1.4) in Group 2 (P < 0.001). The median injection-free period after hemorrhage was 12.0 months in both groups. At least one polypoidal lesion disappeared after hemorrhage in 7 of 10 eyes (70%) with comparable indocyanine green angiography.
   Conclusion: The activity of a polypoidal choroidal vasculopathy lesion diminished after a large subretinal hemorrhage, which was associated with rupture of major polyps.
C1 [Baek, Jiwon] Catholic Univ Korea, Dept Ophthalmol & Visual Sci, Bucheon St Marys Hosp, Coll Med, Seoul, South Korea.
   [Kim, Jae Hui] Konyang Univ, Dept Ophthalmol, Kims Eye Hosp, Coll Med, Seoul, South Korea.
   [Lee, Mee Yon] Catholic Univ Korea, Dept Ophthalmol & Visual Sci, Uijeongbu St Marys Hosp, Coll Med, Seoul, South Korea.
   [Lee, Won Ki] Catholic Univ Korea, Dept Ophthalmol & Visual Sci, Seoul St Marys Hosp, Coll Med, 222 Banpodae Ro, Seoul 06591, South Korea.
C3 Catholic University of Korea; Konyang University; Konyang University
   Hospital; Catholic University of Korea; Catholic University of Korea;
   Seoul St. Mary's Hospital
RP Lee, WK (通讯作者)，Catholic Univ Korea, Dept Ophthalmol & Visual Sci, Seoul St Marys Hosp, Coll Med, 222 Banpodae Ro, Seoul 06591, South Korea.
EM wklee@catholic.ac.kr
OI Baek, Jiwon/0000-0001-6736-5379
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Baek J, 2017, RETINA-J RET VIT DIS, V37, P943, DOI 10.1097/IAE.0000000000001284
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Cho JH, 2016, AM J OPHTHALMOL, V169, P79, DOI 10.1016/j.ajo.2016.06.014
   de Silva SR, 2016, EYE, V30, P952, DOI 10.1038/eye.2016.67
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Jung JH, 2010, RETINA-J RET VIT DIS, V30, P865, DOI 10.1097/IAE.0b013e3181c969e9
   Kachi I, 2016, JPN J OPHTHALMOL, V60, P179, DOI 10.1007/s10384-016-0434-4
   Kim HK, 2003, BIOCHEM BIOPH RES CO, V304, P740, DOI 10.1016/S0006-291X(03)00656-9
   Kim HK, 2017, J CELL BIOCHEM, V118, P1132, DOI 10.1002/jcb.25732
   Kim KS, 2011, JPN J OPHTHALMOL, V55, P370, DOI 10.1007/s10384-011-0045-z
   Kimura S, 2015, AM J OPHTHALMOL, V159, P683, DOI 10.1016/j.ajo.2014.12.020
   Kitagawa Y, 2016, OPHTHALMOLOGY, V123, P1278, DOI 10.1016/j.ophtha.2016.01.035
   Kitahashi M, 2014, CLIN OPHTHALMOL, V8, P485, DOI 10.2147/OPTH.S55413
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Kung YH, 2010, J OCUL PHARMACOL TH, V26, P469, DOI 10.1089/jop.2010.0066
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Lin TC, 2016, J CHIN MED ASSOC, V79, P159, DOI 10.1016/j.jcma.2015.11.004
   Saito M, 2011, RETINA-J RET VIT DIS, V31, P1589, DOI 10.1097/IAE.0b013e31820f4b21
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   Ueda-Arakawa N, 2012, JPN J OPHTHALMOL, V56, P589, DOI 10.1007/s10384-012-0191-y
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wakabayashi T, 2012, BRIT J OPHTHALMOL, V96, P394, DOI 10.1136/bjo.2011.204123
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yoon JS, 2007, YONSEI MED J, V48, P225, DOI 10.3349/ymj.2007.48.2.225
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 31
TC 6
Z9 6
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2018
VL 38
IS 10
BP 1993
EP 2000
DI 10.1097/IAE.0000000000001817
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HF1VS
UT WOS:000454005600022
PM 28834950
DA 2022-11-30
ER

PT J
AU Pollreisz, A
   Reiter, GS
   Bogunovic, H
   Baumann, L
   Jakob, A
   Schlanitz, FG
   Sacu, S
   Owsley, C
   Sloan, KR
   Curcio, CA
   Schmidt-Erfurth, U
AF Pollreisz, Andreas
   Reiter, Gregor S.
   Bogunovic, Hrvoje
   Baumann, Lukas
   Jakob, Astrid
   Schlanitz, Ferdinand G.
   Sacu, Stefan
   Owsley, Cynthia
   Sloan, Kenneth R.
   Curcio, Christine A.
   Schmidt-Erfurth, Ursula
TI Topographic Distribution and Progression of Soft Drusen Volume in
   Age-Related Macular Degeneration Implicate Neurobiology of Fovea
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; AMD; Bruch's membrane; drusen;
   computational image analysis; OCT; optical coherence tomography; retinal
   pigment epithelium; soft drusen; fovea; cone photoreceptors; Muller
   glia; macular pigment
ID OPTICAL COHERENCE TOMOGRAPHY; HUMAN RETINA; LAYER SEGMENTATION;
   NATURAL-HISTORY; RISK-FACTORS; EYE DISEASE; OCT IMAGES; FOLLOW-UP;
   PIGMENT; DEPOSITS
AB PURPOSE. To refine estimates of macular soft drusen abundance in eyes with age-related macular degeneration (AMD) and evaluate hypotheses about drusen biogenesis, we investigated topographic distribution and growth rates of drusen by optical coherence tomography (OCT). We compared results to retinal features with similar topographies (cone density and macular pigment) in healthy eyes.
   METHODS. In a prospective study, distribution and growth rates of soft drusen in eyes with AMD were identified by human observers in OCT volumes and analyzed with computer-assistance. Published histologic data for macular cone densities (n = 12 eyes) and in vivo macular pigment optical density (MPOD) measurements in older adults with unremarkable maculae (n = 31; 62 paired eyes, averaged) were revisited. All values were normalized to Early Treatment Diabetic Retinopathy Study (ETDRS) subfield areas.
   RESULTS. Sixty-two eyes of 44 patients were imaged for periods up to 78 months. Soft drusen volume per unit volume at baseline is 24.6-fold and 2.3-fold higher in the central ETDRS subfield than in outer and inner rings, respectively, and grows most prominently there. Corresponding ratios (central versus inner and central versus outer) for cone density in donor eyes is 13.3-fold and 5.1-fold and for MPOD, 24.6 and 23.9-fold, and 3.6 and 3.6-fold.
   CONCLUSIONS. Normalized soft drusen volume in AMD eyes as assessed by OCT is >= 20-fold higher in central ETDRS subfields than in outer rings, paralleling MPOD distribution in healthy eyes. Data on drusen volume support this metric for AMD risk assessment and clinical trial outcome measure. Alignment of different data modalities support the ETDRS grid for standardizing retinal topography in mechanistic studies of drusen biogenesis.
C1 [Pollreisz, Andreas; Reiter, Gregor S.; Bogunovic, Hrvoje; Jakob, Astrid; Schlanitz, Ferdinand G.; Sacu, Stefan; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol & Optometry, Vienna, Austria.
   [Baumann, Lukas] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria.
   [Owsley, Cynthia; Sloan, Kenneth R.; Curcio, Christine A.] Univ Alabama Birmingham, Dept Ophthalmol & Visual Sci, 700 South 18th St,Suite 601, Birmingham, AL 35294 USA.
C3 Medical University of Vienna; Medical University of Vienna; University
   of Alabama System; University of Alabama Birmingham
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Dept Ophthalmol & Visual Sci, 700 South 18th St,Suite 601, Birmingham, AL 35294 USA.
EM christinecurcio@uabmc.edu
OI Reiter, Gregor/0000-0001-7661-4015
FU National Institutes of Health (NIH) [R01 R01EY027948, R01EY029595];
   Macula Foundation; Dorsett Davis Discovery Fund
FX C.A. Curcio was supported by National Institutes of Health (NIH) grants
   R01 R01EY027948 and R01EY029595; institutional support from Research to
   Prevent Blindness Inc., and EyeSight Foundation of Alabama; Macula
   Foundation. C. Owsley was supported by the Dorsett Davis Discovery Fund.
CR Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Ahmad KM, 2003, VISUAL NEUROSCI, V20, P189, DOI 10.1017/S0952523803202091
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P786
   Arshavsky VY, 2012, J BIOL CHEM, V287, P1620, DOI 10.1074/jbc.R111.305243
   Asgari R, 2019, LECT NOTES COMPUT SC, V11764, P192, DOI 10.1007/978-3-030-32239-7_22
   Balaratnasingam C, 2018, OPHTHALMOLOGY, V125, P100, DOI 10.1016/j.ophtha.2017.08.033
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Baumann B, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3499420
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, pBIO141, DOI 10.1167/iovs.17-21789
   Bretillon L, 2008, EXP EYE RES, V87, P521, DOI 10.1016/j.exer.2008.08.010
   Bringmann A, 2018, PROG RETIN EYE RES, V66, P49, DOI 10.1016/j.preteyeres.2018.03.006
   Chavali VRM, 2015, J CLIN MED, V4, P304, DOI 10.3390/jcm4020304
   Chen L, 2020, RETINA-J RET VIT DIS, V40, P1644, DOI 10.1097/IAE.0000000000002893
   Chen Q, 2013, MED IMAGE ANAL, V17, P1058, DOI 10.1016/j.media.2013.06.003
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   Conrady CD, 2017, INVEST OPHTH VIS SCI, V58, P3616, DOI 10.1167/iovs.17-21818
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD182, DOI 10.1167/iovs.18-24883
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Breuk A, 2021, OPHTHALMOLOGY, V128, P1604, DOI 10.1016/j.ophtha.2020.07.037
   de Sisternes L, 2017, BIOMED OPT EXPRESS, V8, P1926, DOI 10.1364/BOE.8.001926
   de Sisternes Luis, 2017, Transl Vis Sci Technol, V6, P12, DOI 10.1167/tvst.6.1.12
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Diniz B, 2015, EYE, V29, P272, DOI 10.1038/eye.2014.260
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Freeman SR, 2010, RETINA-J RET VIT DIS, V30, P431, DOI 10.1097/IAE.0b013e3181bd2f94
   Freund KB, 2011, RETINA-J RET VIT DIS, V31, P13, DOI 10.1097/IAE.0b013e3181ea48ba
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Garrity ST, 2018, INVEST OPHTH VIS SCI, V59, pAMD48, DOI 10.1167/iovs.18-24158
   Garvin MK, 2008, IEEE T MED IMAGING, V27, P1495, DOI 10.1109/TMI.2008.923966
   Govetto A, 2017, AM J OPHTHALMOL, V184, P167, DOI 10.1016/j.ajo.2017.10.011
   Issa PC, 2013, PROG RETIN EYE RES, V34, P49, DOI 10.1016/j.preteyeres.2012.11.002
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Joachim NDL, 2015, JAMA OPHTHALMOL, V133, P698, DOI 10.1001/jamaophthalmol.2015.0498
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Li BX, 2020, P NATL ACAD SCI USA, V117, P12352, DOI 10.1073/pnas.1922793117
   Loane E, 2008, SURV OPHTHALMOL, V53, P68, DOI 10.1016/j.survophthal.2007.10.008
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Molday RS, 2015, J CELL SCI, V128, P4039, DOI 10.1242/jcs.175687
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nanda Tavish, 2019, Retin Cases Brief Rep, V13, P251, DOI 10.1097/ICB.0000000000000583
   Nittala MG, 2012, INVEST OPHTH VIS SCI, V53, P8319, DOI 10.1167/iovs.12-10582
   Pang CE, 2016, RETINA-J RET VIT DIS, V36, P1408, DOI 10.1097/IAE.0000000000001069
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Quinn N, 2019, PROG RETIN EYE RES, V68, P83, DOI 10.1016/j.preteyeres.2018.10.001
   Reiter GS, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.6.11
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snodderly DM, 2002, INVEST OPHTH VIS SCI, V43, P2815
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Steinberg JS, 2015, BRIT J OPHTHALMOL, V99, P1289, DOI 10.1136/bjophthalmol-2014-306535
   Syrbe S, 2018, EXP EYE RES, V167, P110, DOI 10.1016/j.exer.2017.12.004
   Thomas SE, 2016, J LIPID RES, V57, P1865, DOI 10.1194/jlr.M070193
   Thoreson WB, 2019, PHYSIOL REV, V99, P1527, DOI 10.1152/physrev.00027.2018
   Vachali PP, 2013, ARCH BIOCHEM BIOPHYS, V539, P181, DOI 10.1016/j.abb.2013.07.008
   Waldstein SM, 2020, JAMA OPHTHALMOL, V138, P740, DOI 10.1001/jamaophthalmol.2020.1376
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Wang Q, 1996, INVEST OPHTH VIS SCI, V37, P2234
   WASSLE H, 1991, PHYSIOL REV, V71, P447, DOI 10.1152/physrev.1991.71.2.447
   Yang Q, 2010, OPT EXPRESS, V18, P21293, DOI 10.1364/OE.18.021293
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Zarubina AV, 2016, OPHTHALMOLOGY, V123, P1090, DOI 10.1016/j.ophtha.2015.12.034
   Zhang TJ, 2015, AM J OPHTHALMOL, V160, P290, DOI 10.1016/j.ajo.2015.04.034
NR 75
TC 8
Z9 8
U1 1
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2021
VL 62
IS 2
AR 26
DI 10.1167/iovs.62.2.26
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QQ5MM
UT WOS:000624567800026
PM 33605982
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Thurnham, DI
   Nolan, JM
   Howard, AN
   Beatty, S
AF Thurnham, David I.
   Nolan, John M.
   Howard, Alan N.
   Beatty, Stephen
TI Macular response to supplementation with differing xanthophyll
   formulations in subjects with and without age-related macular
   degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Macular pigment; Lutein; Zeaxanthin;
   Meso-zeaxanthin
ID VISUAL PERFORMANCE; ZEAXANTHIN SUPPLEMENTATION; CLINICAL-TRIAL; LUTEIN;
   CAROTENOIDS; PIGMENT; PLACEBO; RETINA; EYE
AB Our aim was to investigate the macular response to three different supplements containing lutein (L), zeaxanthin (Z) and meso-zeaxanthin (MZ) in normal subjects and those with age-related macular degeneration (AMD).
   Macular pigment optical density (MPOD) and serum xanthophyll concentrations were measured in normal (n = 31) and AMD subjects (n = 32), randomly assigned to: group 1 (20 mg L, 2 mg Z, 0.3 mg MZ), group 2 (10 mg L, 2 mg Z, 10 mg MZ) or group 3 (3 mg L, 2 mg Z, 17 mg MZ). MPOD was measured at baseline, 2, 4, 6 and 8 weeks and at 0.25A degrees, 0.5A degrees, 1.0A degrees and 1.75A degrees of eccentricity using customised heterochromatic flicker photometry and serum xanthophylls by HPLC.
   MPOD increased significantly at all eccentricities in each group (p < 0.05), except at 1.75A degrees in group 3 (p = 0.242). There was no difference in MPOD measurements between AMD and normal subjects, except for group 2, where AMD subjects exhibited a greater response at 1.75A degrees (p = 0.012). Final serum concentrations of MZ were positively and significantly related to final MPOD values at each eccentricity in all subjects. Targeted analysis of those subjects receiving the MZ-containing supplements exhibited stronger relationships between serum MZ concentrations and MPOD at 0.25A degrees in group 3 than group 2; in group 2 all associations were positive, but only significant at 1.75A degrees.
   Serum concentrations of MZ were strongly correlated with MPOD after 8 weeks of supplementation with the group 3 formulation, but the inclusion of L in the group 2 formulation may result in greater MPOD augmentation across the spatial profile.
C1 [Thurnham, David I.] Univ Ulster, Northern Ireland Ctr Food & Hlth NICHE, Coleraine BT52 1SA, Londonderry, North Ireland.
   [Nolan, John M.] Waterford Inst Technol, Dept Chem & Life Sci, Macular Pigment Res Grp, Waterford, Ireland.
   [Howard, Alan N.] Howard Fdn, Cambridge, England.
   [Howard, Alan N.] Univ Cambridge Downing Coll, Cambridge CB2 1DQ, England.
   [Beatty, Stephen] Whitfield Clin, Inst Vis Res, Waterford, Ireland.
C3 Ulster University; South East Technological University (SETU);
   University of Cambridge
RP Thurnham, DI (通讯作者)，Univ Ulster, Northern Ireland Ctr Food & Hlth NICHE, Coleraine BT52 1SA, Londonderry, North Ireland.
EM di.thurnham@ulster.ac.uk
RI Nolan, John/N-4921-2014
OI Nolan, John/0000-0002-5503-7084
FU Howard Foundation, Cambridge, UK
FX This clinical trial was funded by the Howard Foundation, Cambridge, UK
CR Beatty S, 2013, OPHTHALMOLOGY, V120, P600, DOI 10.1016/j.ophtha.2012.08.040
   Bhosale P, 2007, BIOCHEMISTRY-US, V46, P9050, DOI 10.1021/bi700558f
   Bhosale P, 2007, INVEST OPHTH VIS SCI, V48, P543, DOI 10.1167/iovs.06-0558
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Hammond BR, 2012, VISION RES, V63, P58, DOI 10.1016/j.visres.2012.04.019
   Johnson EJ, 2005, INVEST OPHTH VIS SCI, V46, P692, DOI 10.1167/iovs.02-1192
   Koh HH, 2004, EXP EYE RES, V79, P21, DOI 10.1016/j.exer.2004.03.001
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Kvansakul J, 2006, OPHTHAL PHYSL OPT, V26, P362, DOI 10.1111/j.1475-1313.2006.00387.x
   Li BX, 2010, ARCH BIOCHEM BIOPHYS, V504, P56, DOI 10.1016/j.abb.2010.07.024
   Loughman J., 2010, J OPTOM, V3, P74
   Loughman J, 2010, VISION RES, V44, P131
   Loughman J, 2012, INVEST OPHTH VIS SCI, V53, P7871, DOI 10.1167/iovs.12-10690
   Ma L, 2012, AM J OPHTHALMOL, V154, P625, DOI 10.1016/j.ajo.2012.04.014
   Stringham JM, 2008, OPTOMETRY VISION SCI, V85, P82, DOI 10.1097/OPX.0b013e318162266e
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
NR 18
TC 24
Z9 24
U1 0
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2015
VL 253
IS 8
BP 1231
EP 1243
DI 10.1007/s00417-014-2811-3
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CN9AA
UT WOS:000358736700005
PM 25311651
DA 2022-11-30
ER

PT J
AU Sigler, EJ
   Randolph, JC
   Calzada, JI
   Charles, S
AF Sigler, E. J.
   Randolph, J. C.
   Calzada, J. I.
   Charles, S.
TI Smoking and choroidal thickness in patients over 65 with early-atrophic
   age-related macular degeneration and normals
SO EYE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; CENTRAL SEROUS CHORIORETINOPATHY;
   CIGARETTE-SMOKING; BLOOD-FLOW; RISK-FACTORS; OXIDATIVE STRESS; AXIAL
   LENGTH; VITAMIN-C; IN-VIVO; NEOVASCULARIZATION
AB Objective To compare macular choroidal thickness between cigarette smokers, those with a history of smoking, and nonsmokers in patients over 65 years of age with early-atrophic age-related macular degeneration (AMD) and normals.
   Methods Prospective, consecutive, observational case series. Enhanced depth imaging spectral domain optical coherence tomography 12-line radial scans were performed and choroidal thickness manually quantified at 84 points in the central 3mm of the macula. Data of normals, soft drusen alone, and soft drusen with additional features of early AMD were compared. A multivariate analysis of variance (MANOVA) model, controlling for age, was constructed to evaluate the effect of smoking history and AMD features on choroidal thickness.
   Results A history of smoking was significantly associated with a thinner choroid across all patients via logistic regression (P = 0.004; O.R. = 12.4). Mean macular choroidal thickness was thinner for smokers (148 +/- 63 mu m) than for nonsmokers (181 +/- 65 mu m) among all diagnosis categories (P 0.003). Subgroup analysis of patients with AMD features revealed a similar decreased choroidal thickness in smokers (121 +/- 41 mu m) compared with nonsmokers (146 +/- 46 mu m, P = 0.006). Bivariate analysis revealed an association between increased pack-years of smoking and a thin choroid across all patients (P<0.001) and among patients with features of early AMD (P<0.001). Both the presence of features of macular degeneration (P<0.001) and a history of smoking (P = 0.024) were associated with decreased choroidal thickness in a MANOVA model.
   Conclusion Chronic cigarette smoke exposure may be associated with decreased choroidal thickness. There may be an anatomic sequelae to chronic tobacco smoke exposure that underlies previously reported AMD risk.
C1 [Sigler, E. J.] Charles Retina Inst, Memphis, TN 38119 USA.
   [Sigler, E. J.; Randolph, J. C.; Calzada, J. I.; Charles, S.] Charles Retina Inst, Memphis, TN 38119 USA.
   Univ Tennessee, Memphis Hamilton Eye Inst, Dept Ophthalmol, Div Vitreoret Surg, Memphis, TN USA.
C3 University of Tennessee System; University of Tennessee Health Science
   Center
RP Sigler, EJ (通讯作者)，Charles Retina Inst, 6401 Poplar Ave,Suite 190, Memphis, TN 38119 USA.
EM ejsigler@gmail.com
FU Research to Prevent Blindness, Tarrytown, New York
FX This work was Supported in part by an unrestricted grant from Research
   to Prevent Blindness, Tarrytown, New York.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Cao L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033008
   Cao L, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-109
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chalon S, 2000, CLIN PHARMACOL THER, V67, P391, DOI 10.1067/mcp.2000.105153
   Chheda LV, 2012, OPHTHALMOLOGY, V119, P333, DOI 10.1016/j.ophtha.2011.08.003
   Dandekar SS, 2006, BRIT J OPHTHALMOL, V90, P724, DOI 10.1136/bjo.2005.086355
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Delcourt C, 2011, INVEST OPHTH VIS SCI, V52, P5955, DOI 10.1167/iovs.10-6235
   Edirisinghe I, 2010, ANN NY ACAD SCI, V1203, P66, DOI 10.1111/j.1749-6632.2010.05601.x
   FUSHIMI H, 1992, DIABETES RES CLIN PR, V16, P191, DOI 10.1016/0168-8227(92)90116-9
   Goldenberg D, 2012, OPHTHAL SURG LAS IM, V43, P296, DOI 10.3928/15428877-20120426-02
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Iida M, 1998, STROKE, V29, P1656, DOI 10.1161/01.STR.29.8.1656
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Kabasawa S, 2011, OPHTHALMOLOGY, V118, P1082, DOI 10.1016/j.ophtha.2010.10.012
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kergoat H, 1999, INVEST OPHTH VIS SCI, V40, P2906
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   KIOWSKI W, 1994, CIRCULATION, V90, P27, DOI 10.1161/01.CIR.90.1.27
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Krupski W C, 1991, Ann Vasc Surg, V5, P291, DOI 10.1007/BF02329389
   Langhans M, 1997, BRIT J OPHTHALMOL, V81, P365, DOI 10.1136/bjo.81.5.365
   LASSILA R, 1988, BRIT MED J, V297, P955, DOI 10.1136/bmj.297.6654.955
   Lee WJ, 2011, RETINA-J RET VIT DIS, V31, P1742, DOI 10.1097/IAE.0b013e3182246e46
   Li XQ, 2011, INVEST OPHTH VIS SCI, V52, P8438, DOI 10.1167/iovs.11-8108
   Manjunath V, 2010, AM J OPHTHALMOL, V150, P325, DOI 10.1016/j.ajo.2010.04.018
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   MOLITERNO DJ, 1994, NEW ENGL J MED, V330, P454, DOI 10.1056/NEJM199402173300702
   Mori F, 2001, BRIT J OPHTHALMOL, V85, P531, DOI 10.1136/bjo.85.5.531
   Nakanishi H, 2010, INVEST OPHTH VIS SCI, V51, P6183, DOI 10.1167/iovs.09-4948
   Nishida Y, 2012, RETINA-J RET VIT DIS, V32, P1229, DOI 10.1097/IAE.0b013e318242b990
   Pons M, 2011, INVEST OPHTH VIS SCI, V52, P3842, DOI 10.1167/iovs.10-6254
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   QUILLEN JE, 1993, J AM COLL CARDIOL, V22, P642, DOI 10.1016/0735-1097(93)90170-6
   Regatieri CV, 2012, RETINA-J RET VIT DIS, V32, P563, DOI [10.1097/IAE.0B013E31822F5678, 10.1097/IAE.0b013e31822f5678]
   Ross RD, 1998, AM J OPHTHALMOL, V125, P71, DOI 10.1016/S0002-9394(99)80237-2
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Schweitzer KS, 2011, AM J PHYSIOL-LUNG C, V301, pL836, DOI 10.1152/ajplung.00385.2010
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Seddon JM, 2010, MOL VIS, V16, P2412
   Sigler EJ, 2013, INVEST OPHTH VIS SCI, V54, P6307, DOI 10.1167/iovs.13-12653
   Sogawa K, 2012, AM J OPHTHALMOL, V153, P1129, DOI 10.1016/j.ajo.2011.11.005
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Wei WB, 2013, OPHTHALMOLOGY, V120, P175, DOI 10.1016/j.ophtha.2012.07.048
   Wimpissinger B, 2004, BRIT J OPHTHALMOL, V88, P776, DOI 10.1136/bjo.2003.031773
   Yoon Sung Sug Sarah, 2010, NCHS Data Brief, P1
NR 56
TC 38
Z9 40
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUL
PY 2014
VL 28
IS 7
BP 838
EP 846
DI 10.1038/eye.2014.100
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AL5LT
UT WOS:000339175900011
PM 24833184
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Lederman, M
   Weiss, A
   Chowers, I
AF Lederman, Michal
   Weiss, Avraham
   Chowers, Itay
TI Association of Neovascular Age-Related Macular Degeneration with
   Specific Gene Expression Patterns in Peripheral White Blood Cells
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; SYSTEMIC-LUPUS-ERYTHEMATOSUS;
   FACTOR-H POLYMORPHISM; C-REACTIVE PROTEIN; BRUCHS MEMBRANE; COMPLEMENT;
   DRUSEN; DISEASE; MICROARRAY; BIOMARKERS
AB PURPOSE. Inflammation probably plays a major role in the pathogenesis of age-related macular degeneration (AMD). The authors evaluated whether AMD is associated with gene expression patterns in white blood cells (WBCs) and whether such a pattern may serve as a biomarker for the disease.
   METHODS. Microarray analysis of gene expression in peripheral WBCs was performed on patients with neovascular AMD (NVAMD; n = 16) and controls (n = 16). Results were validated using quantitative real-time RT-PCR (QPCR) on another set of patients (n = 14) and controls (n = 16), respectively. QPCR findings were evaluated using receiver operator characteristic (ROC) curves and correlated with genotyping for the major risk single nucleotide polymorphisms (SNPs) for AMD in the genes for complement factor H and LOC387715.
   RESULTS. NVAMD-associated expression was identified for eight sequences (false discovery rate [FDR] = 0%) and 167 sequences (FDR = 10%), respectively. There was an enrichment of genes involved in antigen presentation among the AMD-associated genes (P = 0.0029). QPCR confirmed increased expression (1.6- to 4.3-fold) of four genes (HSPA8, IGHG1, ANXA5, VKORC1) in association with NVAMD (P = 0.02-0.0002). Area under the curve for these genes according to ROC analysis ranged from 0.776 to 0.815. Gene expression was not associated with genotyping for risk SNPs or WBC counts.
   CONCLUSIONS. NVAMD is associated with altered gene expression in peripheral WBCs that is not underlined by the major risk SNPs for the disease. Such altered expression may potentially serve as a biomarker for the disease. These data support the involvement of systemic immune response in the pathogenesis of AMD. (Invest Ophthalmol Vis Sci. 2010; 51: 53-58) DOI: 10.1167/iovs.08-3019
C1 [Lederman, Michal; Weiss, Avraham; Chowers, Itay] Hadassah Hebrew Univ, Med Ctr, Dept Ophthalmol, IL-91120 Jerusalem, Israel.
   [Lederman, Michal; Weiss, Avraham; Chowers, Itay] Hebrew Univ Jerusalem, Sch Med, IL-91010 Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Hadassah University Medical Center;
   Hebrew University of Jerusalem
RP Chowers, I (通讯作者)，Hadassah Hebrew Univ, Med Ctr, Dept Ophthalmol, POB 12000, IL-91120 Jerusalem, Israel.
EM chowers@hadassah.org.il
FU Hadassah-Hebrew University Medical Center
FX Supported by a grant from the Hadassah-Hebrew University Medical Center.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Bennett L, 2003, J EXP MED, V197, P711, DOI 10.1084/jem.20021553
   Bernstein SL, 2000, INVEST OPHTH VIS SCI, V41, P2857
   Borovecki F, 2005, P NATL ACAD SCI USA, V102, P11023, DOI 10.1073/pnas.0504921102
   Bowden NA, 2006, SCHIZOPHR RES, V82, P175, DOI 10.1016/j.schres.2005.11.012
   Cederholm A, 2005, IMMUNOBIOLOGY, V210, P761, DOI 10.1016/j.imbio.2005.10.007
   Cervantes-Castaneda RA, 2008, EYE, V22, P777, DOI 10.1038/sj.eye.6702691
   Chowers I, 2003, INVEST OPHTH VIS SCI, V44, P3732, DOI 10.1167/iovs.02-1080
   Chowers I, 2008, MOL VIS, V14, P2263
   Chowers I, 2008, MOL VIS, V14, P1829
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Du XL, 2006, GENOMICS, V87, P693, DOI 10.1016/j.ygeno.2006.02.003
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   GURNE DH, 1991, OPHTHALMOLOGY, V98, P602
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Iglesias AH, 2004, J NEUROIMMUNOL, V150, P163, DOI 10.1016/j.jneuroim.2004.01.017
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Liew G, 2007, OPHTHALMOLOGY, V114, P1793, DOI 10.1016/j.ophtha.2007.04.036
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Markiewski MM, 2007, TRENDS IMMUNOL, V28, P184, DOI 10.1016/j.it.2007.02.006
   Meir T, 2007, INVEST OPHTH VIS SCI, V48, P4890, DOI 10.1167/iovs.07-0215
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Rayborn ME, 2006, ADV EXP MED BIOL, V572, P75
   Reutelingsperger CPM, 1997, CELL MOL LIFE SCI, V53, P527, DOI 10.1007/s000180050067
   Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Wang YB, 2006, CIRCULATION, V113, P1615, DOI 10.1161/CIRCULATIONAHA.105.580167
   Wang YB, 2005, MOL CANCER RES, V3, P317, DOI 10.1158/1541-7786.MCR-04-0221
   Wu KHC, 2007, INVEST OPHTH VIS SCI, V48, P1983, DOI 10.1167/iovs.06-0223
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Q, 2001, MOL VIS, V7, P48
NR 53
TC 21
Z9 21
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2010
VL 51
IS 1
BP 53
EP 58
DI 10.1167/iovs.08-3019
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 539OI
UT WOS:000273264200009
PM 19684010
DA 2022-11-30
ER

PT J
AU Forte, R
   Coscas, F
   Serra, R
   Cabral, D
   Colantuono, D
   Souied, EH
AF Forte, Raimondo
   Coscas, Florence
   Serra, Rita
   Cabral, Diogo
   Colantuono, Donato
   Souied, Eric H.
TI Long-term follow-up of quiescent choroidal neovascularisation associated
   with age-related macular degeneration or pachychoroid disease
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE optical coherence tomography angiography; quiescent; pachychoroid;
   choroid; CNV; AMD
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; ENDOTHELIAL GROWTH-FACTOR;
   SWEPT-SOURCE; NEOVASCULOPATHY; LACUNARITY
AB Aims To evaluate the long-term progression of quiescent type 1 choroidal neovascularisation (CNV) associated with age-related macular degeneration (AMD) or with pachychoroid disease.
   Methods All cases of quiescent type 1 CNV with a minimum follow-up of 12 months seen at the Department of Ophthalmology of University Paris Est, Creteil and at the Centre Ophtalmologique de l'Odeon, Paris, between June 2009 and December 2018 were retrospectively reviewed. Optical coherence tomography angiography (OCT-A) of eyes not showing CNV activation during 24 months was evaluated for quantitative analyses of CNV status biomarkers (fractal dimension, lacunarity, vessel density, aspect ratio, CNV area).
   Results A total of 67 eyes (65 patients, 43 females, mean age 76.63 +/- 9.7 years) with quiescent CNV and a mean follow-up of 49.56 +/- 27.3 (12-112) months were included. Of 28 eyes showing activation of quiescent CNV, 12 eyes with pachychoroid-associated CNV showed reduced visual loss (-3.28 ETDRS letters, p=0.7 vs -13.03 ETDRS letters, p=0.02), greater choroidal thinning (-59.5 mu m, p=0.03 vs - 16.36 mu m, p=0.3) and needed less antivascular endothelial growth factor intravitreal injections (IVI) (0.09 vs 0.21, p=0.01) than 16 eyes with AMD-associated CNV. CNV area was the only OCT-A biomarker to significantly change during 24 months in inactive quiescent CNV (+29.5%, p=0.01, in pachychoroid group and +27.1%, p=0.03, in the AMD group).
   Conclusion In the long-term follow-up, inactive quiescent CNV showed an increase of CNV area without significant changes of the other OCT-A biomarkers. Quiescent type 1 CNV undergoing activation showed greater response to IVI when associated to pachychoroid.
C1 [Forte, Raimondo; Coscas, Florence; Colantuono, Donato; Souied, Eric H.] Univ Paris Est Creteil XII, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Coscas, Florence; Serra, Rita; Cabral, Diogo] Ctr Ophtalmol Odeon, Paris, France.
   [Serra, Rita] Univ Cagliari, Dept Surg Sci, Eye Clin, Cagliari, Italy.
   [Cabral, Diogo] Univ Nova Lisboa, Fac Ciencias Med, NOVA Med Sch, Lisbon, Portugal.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   University of Cagliari; Universidade Nova de Lisboa
RP Forte, R (通讯作者)，Univ Paris Est Creteil XII, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
EM raiforte@gmail.com
OI Reis Cabral, Diogo/0000-0003-1968-3561; SERRA, RITA/0000-0002-6341-1435
CR Al-Sheikh M, 2017, OSLI RETINA, V48, P385, DOI 10.3928/23258160-20170428-04
   Amoroso F, 2018, BRIT J OPHTHALMOL, V102, P821, DOI 10.1136/bjophthalmol-2017-310569
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Carnevali A, 2018, OPHTHALMOL RETINA, V2, P922, DOI 10.1016/j.oret.2018.02.002
   Carnevali A, 2017, OPHTHALMOL RETINA, V1, P328, DOI 10.1016/j.oret.2017.01.003
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Coscas F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205513
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Hata M, 2017, INVEST OPHTH VIS SCI, V58, P292, DOI 10.1167/iovs.16-20967
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Liu BQ, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0791-5
   Masters BR, 2004, ANNU REV BIOMED ENG, V6, P427, DOI 10.1146/annurev.bioeng.6.040803.140100
   Matsumoto H, 2018, JPN J OPHTHALMOL, V62, P144, DOI 10.1007/s10384-018-0562-0
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Ores R, 2014, AM J OPHTHALMOL, V158, P354, DOI 10.1016/j.ajo.2014.04.025
   Padron-Perez N, 2018, INVEST OPHTH VIS SCI, V59, P1119, DOI 10.1167/iovs.17-22144
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Phansalkar Neerad, 2011, 2011 International Conference on Communications and Signal Processing (ICCSP), P218, DOI 10.1109/ICCSP.2011.5739305
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Roberts PK, 2017, RETINA-J RET VIT DIS, V37, P1492, DOI 10.1097/IAE.0000000000001400
   Serra R, 2020, RETINA-J RET VIT DIS, V40, P1224, DOI 10.1097/IAE.0000000000002604
   Smith TG, 1996, J NEUROSCI METH, V69, P123, DOI 10.1016/S0165-0270(96)00080-5
   Tolle CR, 2008, PHYSICA D, V237, P306, DOI 10.1016/j.physd.2007.09.017
   Wang RK, 2007, OPT EXPRESS, V15, P4083, DOI 10.1364/OE.15.004083
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Zhang QQ, 2017, OPHTHALMOL RETINA, V1, P124, DOI 10.1016/j.oret.2016.08.005
NR 28
TC 12
Z9 13
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2020
VL 104
IS 8
BP 1057
EP 1063
DI 10.1136/bjophthalmol-2019-315189
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PK2OA
UT WOS:000602289600006
PM 31662311
DA 2022-11-30
ER

PT J
AU Yang, SS
   Zuo, CG
   Xiao, H
   Mi, L
   Luo, GW
   Xu, XY
   Liu, X
AF Yang, Shasha
   Zuo, Chengguo
   Xiao, Hui
   Mi, Lan
   Luo, Guangwei
   Xu, Xiaoyu
   Liu, Xing
TI Photoreceptor dysfunction in early and intermediate age-related macular
   degeneration assessed with mfERG and spectral domain OCT
SO DOCUMENTA OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Drusen; Photoreceptor; Multifocal
   electroretinography; Optical coherence tomography
ID OPTICAL COHERENCE TOMOGRAPHY; BEAVER-DAM-EYE; MULTIFOCAL
   ELECTRORETINOGRAM; FUNCTIONAL-CHANGES; LAYER THICKNESSES; DRUSEN; ERG;
   RANIBIZUMAB; PROGRESSION; AMPLITUDE
AB Purpose To evaluate the changes of the photoreceptor layer (PRL) thickness with spectral domain optical coherence tomography (SD-OCT) and the retinal function by mfERG, as well as the correlation of morphology and function parameters in subjects with early and intermediate age-related macular degeneration (AMD).
   Methods Subjects with clinical diagnosis of early or intermediate AMD and age-matched healthy subjects were recruited prospectively in this study. Color fundus photography, SD-OCT, and mfERG were conducted. Retinal photoreceptor thickness was measured, and first-order kernel responses were recorded. The differences between AMD group and control group were compared, and the correlations between macular photoreceptor thickness and the mfERG were analyzed.
   Results PRL thickness (mu m) in four areas including foveola and 0.5, 1.5, and 3 mmaway from foveola was 192.48 +/- 17.37, 163.73 +/- 12.95, 130.93 +/- 9.20, and 108.78 +/- 7.81, respectively, in normal eyes, whereas in AMD group, they were 158.61 +/- 45.25, 138.91 +/- 20.92, 118.91 +/- 12.85, and 95.00 +/- 9.64, respectively (P<0.001). The mean amplitude response densities of AMD patients decreased significantly compared to the control group in ring 1-6 (P<0.001). The mean mfERG N1 and P1 latency of AMD patients prolonged compared to the control group, except the ring 1 (P = 0.588 and P = 0.084). The macular PRL thickness was significantly associated with the mfERGN1 and P1 amplitude density in ring 1-4 (r = 0.338-0.533, P<0.01).
   Conclusions PRL thickness decreases are in accordance with the deterioration of retinal electrophysiological activity. The retinal PRL thickness is important parameter to assess of early and intermediate AMD severity.
C1 [Yang, Shasha; Zuo, Chengguo; Xiao, Hui; Mi, Lan; Luo, Guangwei; Xu, Xiaoyu; Liu, Xing] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 South Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Liu, X (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 South Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM liuxing@mail.sysu.edu.cn
FU National Natural Science Foundation of China [81400426]; Science and
   Technology Planning Project of Guangdong Province and Guangzhou City
   [2012B050600032, 2013J4500019]
FX This study was supported by the National Natural Science Foundation of
   China provided financial support in the form of the Young Scholar
   Funding (Grant Number: 81400426). The Science and Technology Planning
   Project of Guangdong Province and Guangzhou City also provided financial
   support in the form of International Cooperation Program (Grant Numbers:
   2012B050600032 and 2013J4500019, respectively). The sponsor had no role
   in the design or conduct of this research.
CR Cunningham ET, 2011, OPHTHALMOLOGY, V118, P2447, DOI 10.1016/j.ophtha.2011.05.026
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2011, INVEST OPHTH VIS SCI, V52, P3943, DOI 10.1167/iovs.10-6377
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Feigl Beatrix, 2005, Clin Exp Optom, V88, P304
   Garcia-Garcia JG, 2013, CLIN OPHTHALMOL, V7, P1303, DOI 10.2147/OPTH.S39258
   Gerth C, 2006, ARCH OPHTHALMOL-CHIC, V124, P345, DOI 10.1001/archopht.124.3.345
   Gerth C, 2003, ARCH OPHTHALMOL-CHIC, V121, P1404, DOI 10.1001/archopht.121.10.1404
   Gibson JM, 2014, EXPERT OPIN DRUG SAF, V13, P1259, DOI 10.1517/14740338.2014.939951
   Goldstein M, 2005, EYE, V19, P1315, DOI 10.1038/sj.eye.6701765
   Greenstein VC, 2015, DOC OPHTHALMOL, V130, P13, DOI 10.1007/s10633-014-9474-6
   Holm K, 2012, GRAEF ARCH CLIN EXP, V250, P1143, DOI 10.1007/s00417-012-1937-4
   Hood DC, 2002, INVEST OPHTH VIS SCI, V43, P1673
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2013, OPHTHALMOLOGY, V120, P1210, DOI 10.1016/j.ophtha.2012.11.041
   Ledolter AA, 2015, DOC OPHTHALMOL, V130, P197, DOI 10.1007/s10633-015-9482-1
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P3568, DOI 10.1364/BOE.5.003568
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
   Wen Y, 2012, INVEST OPHTH VIS SCI, V53, P833, DOI 10.1167/iovs.11-8410
   Wong Ian Yat Hin, 2011, International Ophthalmology, V31, P73, DOI 10.1007/s10792-010-9397-5
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P2100, DOI 10.1167/iovs.14-16210
   Yavas GF, 2014, DOC OPHTHALMOL, V129, P167, DOI 10.1007/s10633-014-9460-z
NR 27
TC 9
Z9 10
U1 0
U2 6
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0012-4486
EI 1573-2622
J9 DOC OPHTHALMOL
JI Doc. Ophthalmol.
PD FEB
PY 2016
VL 132
IS 1
BP 17
EP 26
DI 10.1007/s10633-016-9523-4
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DI2AX
UT WOS:000373299200002
PM 26754967
DA 2022-11-30
ER

PT J
AU Kaarniranta, K
   Koskela, A
   Felszeghy, S
   Kivinen, N
   Salminen, A
   Kauppinen, A
AF Kaarniranta, Kai
   Koskela, Ali
   Felszeghy, Szabolcs
   Kivinen, Niko
   Salminen, Antero
   Kauppinen, Anu
TI Fatty acids and oxidized lipoproteins contribute to autophagy and innate
   immunity responses upon the degeneration of retinal pigment epithelium
   and development of age-related macular degeneration
SO BIOCHIMIE
LA English
DT Review
DE Aging; Autophagy; Degeneration; Fatty acids; Inflammation; Macula;
   Oxidative stress
ID TOLL-LIKE RECEPTOR-3; COMPLEMENT FACTOR-H; DOCOSAHEXAENOIC ACID;
   OXIDATIVE STRESS; NLRP3 INFLAMMASOME; LONG-CHAIN; CELLS; CONSUMPTION;
   ACTIVATION; TLR3
AB Retinal pigment epithelium (RPE) damage is a primary sign in the development of age-related macular degeneration (AMD) the leading cause of blindness in western countries. RPE cells are exposed to chronic oxidative stress due to constant light exposure, active fatty acid metabolism and high oxygen consumption. RPE cells phagocytosize lipid rich photoreceptor outer segment (POS) which is regulated by circadian rhytmn. Docosahexaenoic acid is present in high quantity in POS and increases oxidative stress, while its metabolites have cytoprotective effects in RPE. During RPE aging, reactive oxygen species and oxidized lipoproteins are considered to be major causes of disturbed autophagy clearance that lead to chronic innate immunity response involved in NOD-Like, Toll-Like, Advanced Glycation End product Receptors (NLRP, TLR, RAGE, respectively), pentraxins and complement systems. We discuss role of fatty acids and lipoproteins in the degeneration of RPE and development of AMD. (C) 2018 Published by Elsevier B.V.
C1 [Kaarniranta, Kai; Koskela, Ali; Kivinen, Niko] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, Kuopio, Finland.
   [Kaarniranta, Kai; Kivinen, Niko] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio, Finland.
   [Kaarniranta, Kai] Univ Lodz, Fac Biol & Environm Protect, Dept Mol Genet, Lodz, Poland.
   [Felszeghy, Szabolcs] Univ Eastern Finland, Inst Dent, Kuopio, Finland.
   [Felszeghy, Szabolcs] Univ Eastern Finland, Inst Biomed, Kuopio, Finland.
   [Salminen, Antero] Univ Eastern Finland, Inst Clin Med, Dept Neurol, Kuopio, Finland.
   [Kauppinen, Anu] Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, Kuopio, Finland.
C3 University of Eastern Finland; Kuopio University Hospital; University of
   Eastern Finland; University of Lodz; University of Eastern Finland;
   University of Eastern Finland; University of Eastern Finland; University
   of Eastern Finland
RP Kaarniranta, K (通讯作者)，Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, Kuopio, Finland.
EM kai.kaarniranta@uef.fi
FU European Commission: EC H2020 MSCA - ITN [722717]; Academy of Finland
   [296840]; Finnish Eye Foundation; Sigrid Juselius Foundation; Paivikki
   and Sakari Sohlberg Foundation; Business of Finland; Kuopio University
   Hospital VTR [5503757]; University of Eastern Finland
FX This work was supported by the European Commission: EC H2020 MSCA - ITN
   - 722717; Academy of Finland (296840), the Finnish Eye Foundation, the
   Sigrid Juselius Foundation, the Paivikki and Sakari Sohlberg Foundation,
   the Business of Finland, the Kuopio University Hospital VTR (5503757)
   and University of Eastern Finland.
CR Asatryan A, 2017, J BIOL CHEM, V292, P12390, DOI 10.1074/jbc.R117.783076
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Bazan NG, 2011, ANNU REV NUTR, V31, P321, DOI 10.1146/annurev.nutr.012809.104635
   Blasiak J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5293258
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Boya P, 2013, NAT CELL BIOL, V15, P713, DOI 10.1038/ncb2788
   Chen L, 2016, MOL MED REP, V13, P3249, DOI 10.3892/mmr.2016.4890
   Cho YE, 2009, INVEST OPHTH VIS SCI, V50, P5614, DOI 10.1167/iovs.09-3688
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Elner SG, 2005, INVEST OPHTH VIS SCI, V46, P4627, DOI 10.1167/iovs.05-0658
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   GIBSON NJ, 1993, BIOCHEMISTRY-US, V32, P2438, DOI 10.1021/bi00060a040
   Gnanaguru G, 2016, INVEST OPHTH VIS SCI, V57, P4704, DOI 10.1167/iovs.15-18663
   Greiner RS, 1999, LIPIDS, V34, pS239, DOI 10.1007/BF02562305
   Hibbeln JR, 2007, LANCET, V369, P578, DOI 10.1016/S0140-6736(07)60277-3
   Huang JN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109996
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Johansson I, 2015, AUTOPHAGY, V11, P1636, DOI 10.1080/15548627.2015.1061170
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaarniranta K, 2012, NEUROSCI LETT, V513, P233, DOI 10.1016/j.neulet.2012.02.050
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Kleinman ME, 2012, MOL THER, V20, P101, DOI 10.1038/mt.2011.212
   Klettner A, 2014, ACTA OPHTHALMOL, V92, pe621, DOI 10.1111/aos.12472
   Knott EJ, 2018, CELL MOL NEUROBIOL, V38, P901, DOI 10.1007/s10571-017-0565-2
   Kohno H, 2013, J BIOL CHEM, V288, P15326, DOI 10.1074/jbc.M112.448712
   Koskela A, 2016, NUTRIENTS, V8, DOI 10.3390/nu8050284
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Kumar MV, 2004, J NEUROIMMUNOL, V153, P7, DOI 10.1016/j.jneuroim.2004.04.018
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lawrenson JG, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010015.pub3
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu AH, 2010, J LIPID RES, V51, P3217, DOI 10.1194/jlr.M007518
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Nowak JZ, 2013, PHARMACOL REP, V65, P288, DOI 10.1016/S1734-1140(13)71005-3
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Parmar VM, 2018, STEM CELL RES, V27, P95, DOI 10.1016/j.scr.2018.01.014
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Parzych KR, 2014, ANTIOXID REDOX SIGN, V20, P460, DOI 10.1089/ars.2013.5371
   Patel AK, 2014, MOL CELL NEUROSCI, V63, P38, DOI 10.1016/j.mcn.2014.09.004
   Patel AK, 2013, MOL IMMUNOL, V54, P122, DOI 10.1016/j.molimm.2012.11.005
   Picard E, 2010, AGING-US, V2, P981, DOI 10.18632/aging.100218
   Piippo N, 2014, BBA-MOL CELL RES, V1843, P3038, DOI 10.1016/j.bbamcr.2014.09.015
   Rice DS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7228
   Saadat KASM, 2014, FEBS OPEN BIO, V4, P1007, DOI 10.1016/j.fob.2014.11.003
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   STONE WL, 1979, EXP EYE RES, V28, P387, DOI 10.1016/0014-4835(79)90114-3
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Szatmari-Toth M, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.133
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Wang JJ, 2014, OPHTHALMOLOGY, V121, P667, DOI 10.1016/j.ophtha.2013.10.017
   Wang K, 2017, J BIOCHEM MOL TOXIC, V31, DOI 10.1002/jbt.21887
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Zhu W, 2016, NUTRIENTS, V8, DOI 10.3390/nu8110743
   Zhu Y, 2015, MOL VIS, V21, P1122
NR 64
TC 19
Z9 19
U1 0
U2 10
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0300-9084
EI 1638-6183
J9 BIOCHIMIE
JI Biochimie
PD APR
PY 2019
VL 159
BP 49
EP 54
DI 10.1016/j.biochi.2018.07.010
PG 6
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA HP5DW
UT WOS:000461698100006
PM 30031036
DA 2022-11-30
ER

PT J
AU Bandello, F
   Staurenghi, G
   Ricci, F
   Midena, E
   Viola, F
   Sinibaldi, TL
   Colombo, L
   Peruzzi, E
   Bassanini, S
AF Bandello, Francesco
   Staurenghi, Giovanni
   Ricci, Federico
   Midena, Edoardo
   Viola, Francesco
   Lupieri Sinibaldi, Tommaso
   Colombo, Laura
   Peruzzi, Elena
   Bassanini, Stefania
TI Safety and tolerability of ranibizumab in uni/bilateral neovascular
   age-related macular degeneration: 12-month TWEYEs study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE neovascularisation; retina; vision; age-related macular degeneration;
   unilateral AMD; bilateral AMD; neovascular age-related macular
   degeneration
ID ENDOTHELIAL GROWTH-FACTOR; PREVALENCE; MACULOPATHY; AMD
AB Background To evaluate the safety and tolerability of ranibizumab 0.5 mg in patients with uni/bilateral neovascular age-related macular degeneration (nAMD) and best-corrected visual acuity (BCVA)<2/10 and/or second eye affected, regardless of BCVA. Methods In this 12-month, prospective, multicentre, open-label, single arm, pragmatic interventional study, patients (N=941) aged >= 50 years were to receive ranibizumab as per approved label, monthly until maximum stable visual acuity (VA) was achieved (initially, three or more injections may be required). Thereafter, patients were to be monitored monthly for VA and treatment was to be resumed if VA was reduced due to disease activity. Results Of the 936 patients treated with ranibizumab at least once during the study, 823/113 were unilaterally/bilaterally (not simultaneously) treated . The mean (SD) number of ranibizumab injections during the study was 5.4 (2.9)/10.6 (5.0) injections in uni/bilaterally treated patients. Three systemic drug-related adverse events (AEs) (all serious, all in unilaterally treated patients) and 18 systemic AE of special interest (AESIs) (11 serious, 16/2 in unilaterally/bilaterally treated patients) occurred during the study. The annual incidence rate (AIR) (events/1000 person-years) for systemic drug-related AEs, considering a 15-day/30-day risk period, 11.0/8.5 for unilaterally treated patients. Considering the same risk period, the AIR (events/1000 person-years) for systemic AESIs for unilaterally treated patients was 22.1/19.9. Considering a 30-day risk period, the AIR (events/1000 treated eye-years) of ocular drug-related AEs was 23 and AESIs was 11.5. Conclusions The low incidence of AEs and AESIs demonstrated the good safety and tolerability of ranibizumab in unilaterally/bilaterally treated patients with nAMD in this real-world setting.
C1 [Bandello, Francesco] Univ Vita Salute Hosp San Raffaele, Dept Ophthalmol, Milan, Italy.
   [Staurenghi, Giovanni] Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Milan, Italy.
   [Ricci, Federico] Univ Tor Vergata, Policlin Tor Vergata, UOSD Patol Retin, Rome, Italy.
   [Midena, Edoardo] Univ Padua, Dept Ophthalmol, Padua, Italy.
   [Viola, Francesco] Univ Milan, Dept Clin Sci & CommunityHlth, Ophthalmol Unit, IRCCS Ca GrandaFdn Osped Maggiore Policlin, Milan, Italy.
   [Lupieri Sinibaldi, Tommaso; Colombo, Laura; Peruzzi, Elena; Bassanini, Stefania] Novartis Farma SpA, Origgio, Origgio, Italy.
C3 University of Milan; Luigi Sacco Hospital; University of Rome Tor
   Vergata; Policlin Tor Vergata; University of Padua; University of Milan;
   Novartis
RP Bandello, F (通讯作者)，Univ Vita Salute Hosp San Raffaele, Dept Ophthalmol, Milan, Italy.
EM bandello.francesco@hsr.it
RI viola, francesco/AAK-5583-2020
OI viola, francesco/0000-0003-1208-913X; bandello,
   francesco/0000-0003-3238-9682; Colombo, Laura/0000-0003-3487-5086
CR Agency EM, 2013, SUMM PROD CHAR LUC 1
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Avery RL, 2017, RETINA-J RET VIT DIS, V37, P1847, DOI 10.1097/IAE.0000000000001493
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P7, DOI 10.1136/bjophthalmol-2013-303844
   Barthelmes D, 2014, OPHTHALMOLOGY, V121, P2073, DOI 10.1016/j.ophtha.2014.05.007
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2016, OPHTHALMOLOGY, V123, pS78, DOI 10.1016/j.ophtha.2016.04.056
   Chen HX, 2009, NAT REV CLIN ONCOL, V6, P465, DOI 10.1038/nrclinonc.2009.94
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kandasamy R, 2017, ASIA-PAC J OPHTHALMO, V6, P508, DOI 10.22608/APO.2017262
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Pagliarini S, 2015, ASS RES VIS OPHTH AR
   Pagliarini S, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/857148
   Piermarocchi S, 2011, OPHTHAL EPIDEMIOL, V18, P129, DOI 10.3109/09286586.2011.574334
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Villegas VM, 2017, EXPERT OPIN DRUG DEL, V14, P273, DOI 10.1080/17425247.2016.1213240
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
   Zehetner C, 2015, ACTA OPHTHALMOL, V93, pE154, DOI 10.1111/aos.12604
NR 30
TC 1
Z9 1
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JAN
PY 2020
VL 104
IS 1
BP 64
EP 73
DI 10.1136/bjophthalmol-2019-313907
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KA1YB
UT WOS:000505593600013
PM 31079057
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Mantel, I
   Mosinska, A
   Bergin, C
   Polito, MS
   Guidotti, J
   Apostolopoulos, S
   Ciller, C
   De Zanet, S
AF Mantel, Irmela
   Mosinska, Agata
   Bergin, Ciara
   Polito, Maria Sole
   Guidotti, Jacopo
   Apostolopoulos, Stefanos
   Ciller, Carlos
   De Zanet, Sandro
TI Automated Quantification of Pathological Fluids in Neovascular
   Age-Related Macular Degeneration, and Its Repeatability Using Deep
   Learning
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE age-related macular degeneration; exudation; optical coherence
   tomography; fluid quantification; deep learning algorithm
ID OPTICAL COHERENCE TOMOGRAPHY; DIABETIC-RETINOPATHY; VISUAL-ACUITY
AB Purpose: To develop a reliable algorithm for the automated identification, localization, and volume measurement of exudative manifestations in neovascular age-related macular degeneration (nAMD), including intraretinal (IRF), subretinal fluid (SRF), and pigment epithelium detachment (PED), using a deep-learning approach.
   Methods: One hundred seven spectral domain optical coherence tomography (OCT) cube volumes were extracted from nAMD eyes. Manual annotation of IRF, SRF, and PED was performed. Ninety-two OCT volumes served as training and validation set, and 15 OCT volumes from different patients as test set. The performance of our fluid segmentation method was quantified by means of pixel-wise metrics and volume correlations and compared to other methods. Repeatability was tested on 42 other eyes with five OCT volume scans acquired on the same day.
   Results: The fully automated algorithm achieved good performance for the detection of IRF, SRF, and PED. The area under the curve for detection, sensitivity, and specificity was 0.97, 0.95, and 0.99, respectively. The correlation coefficients for the fluid volumes were 0.99, 0.99, and 0.91, respectively. The Dice score was 0.73, 0.67, and 0.82, respectively. For the largest volume quartiles the Dice scores were >0.90. Including retinal layer segmentation contributed positively to the performance. The repeatability of volume prediction showed a standard deviations of 4.0 nL, 3.5 nL, and 20.0 nL for IRF, SRF, and PED, respectively.
   Conclusions: The deep-learning algorithm can simultaneously acquire a high level of performance for the identification and volume measurements of IRF, SRF, and PED in nAMD, providing accurate and repeatable predictions. Including layer segmentation during training and squeeze-excite block in the network architecture were shown to boost the performance.
   Translational Relevance: Potential applications include measurements of specific fluid compartments with high reproducibility, assistance in treatment decisions, and the diagnostic or scientific evaluation of relevant subgroups.
C1 [Mantel, Irmela; Bergin, Ciara; Polito, Maria Sole; Guidotti, Jacopo] Univ Lausanne, Jules Gonin Eye Hosp, Fdn Asile Aveugles, Dept Ophthalmol, Lausanne, Switzerland.
   [Mosinska, Agata; Apostolopoulos, Stefanos; Ciller, Carlos; De Zanet, Sandro] RetinAI Med AG, Bern, Switzerland.
C3 University of Lausanne
RP Mantel, I (通讯作者)，Jules Gonin Eye Hosp, 15 Ave France,CP 5143, CH-1000 Lausanne 2, Switzerland.
EM irmela.mantel@fa2.ch
CR Abramoff MD, 2016, INVEST OPHTH VIS SCI, V57, P5200, DOI 10.1167/iovs.16-19964
   Apostolopoulos S., 2017, PATHOLOGICAL OCT RET, P294, DOI DOI 10.1007/978-3-319-66179-7_34
   Asgari R, 2019, LECT NOTES COMPUT SC, V11764, P192, DOI 10.1007/978-3-030-32239-7_22
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Fragiotta S, 2018, RETINA-J RET VIT DIS, V38, P245, DOI 10.1097/IAE.0000000000001540
   Goodfellow I.J., 2014, P NEURIPS, DOI DOI 10.1002/RCS.128
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Guo Y, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.54
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Hu J, 2018, PROC CVPR IEEE, P7132, DOI [10.1109/TPAMI.2019.2913372, 10.1109/CVPR.2018.00745]
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Jang LN, 2015, GRAEF ARCH CLIN EXP, V253, P1211, DOI 10.1007/s00417-014-2789-x
   Kingma J., 2014, ARXIV
   Kurmann T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49740-7
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Lee CS, 2017, BIOMED OPT EXPRESS, V8, P3440, DOI 10.1364/BOE.8.003440
   Lee H, 2018, AM J OPHTHALMOL, V191, P64, DOI 10.1016/j.ajo.2018.04.007
   Lu DH, 2019, MED IMAGE ANAL, V54, P100, DOI 10.1016/j.media.2019.02.011
   Parvin P, 2017, GRAEF ARCH CLIN EXP, V255, P2127, DOI 10.1007/s00417-017-3762-2
   Roy AG, 2017, BIOMED OPT EXPRESS, V8, P3627, DOI 10.1364/BOE.8.003627
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   SZEGEDY CH, 2013, INTRIGUING PROPERTIE, V1312, P6199, DOI DOI 10.1109/CVPR.2015.7298594
   Venhuizen FG, 2018, BIOMED OPT EXPRESS, V9, P1545, DOI 10.1364/BOE.9.001545
   Wickremasinghe SS, 2016, RETINA-J RET VIT DIS, V36, P1331, DOI 10.1097/IAE.0000000000000902
NR 26
TC 10
Z9 10
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD APR
PY 2021
VL 10
IS 4
AR 17
DI 10.1167/tvst.10.4.17
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RW0SI
UT WOS:000646234300015
PM 34003996
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Eton, EA
   Wubben, TJ
   Besirli, CG
   Hua, PY
   McGeehan, B
   VanderBeek, BL
AF Eton, Emily A.
   Wubben, Thomas J.
   Besirli, Cagri G.
   Hua, Peiying
   McGeehan, Brendan
   VanderBeek, Brian L.
TI Association of metformin and development of dry age-related macular
   degeneration in a US insurance claims database
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; dry age-related macular degeneration;
   metformin; diabetes mellitus; retrospective cohort study
ID RACIAL-DIFFERENCES; OXIDATIVE STRESS; RISK-FACTORS; PREVALENCE;
   MACULOPATHY; DISEASE
AB Purpose: To assess whether metformin is associated with dry age-related macular degeneration (dAMD) development. Methods: In this retrospective cohort study, patients enrolled in a nationwide U.S. medical insurance claims database from 2002 to 2016 were included if they had diabetes mellitus, were > 55 years old, and were enrolled for > 2 years without a prior AMD diagnosis. The primary exposure was metformin use analyzed as either active or prior use or cumulative metformin dosage over the study period. A time updating Cox proportional hazard regression was used to estimate the hazard ratio of dAMD incidence with metformin exposure. Results: Among 1,007,226 diabetic enrollees, 53.3% were female and 66.4% were white with a mean hemoglobin A1c of 6.8%. Of eligible enrollees, 166,115 (16.5%) were taking metformin at the index date. Over the study period, 29,818 (3.0%) participants developed dAMD. In the active versus prior use of metformin model, active use conferred an increased hazard of developing dAMD (HR, 1.08; 95% CI, 1.04-1.12) while prior use had a decreased hazard (HR, 0.95; 95% CI 0.92-0.98). The cumulative metformin dosage model showed a significant trend toward increased hazard of dAMD incidence with increasing cumulative dosage (p < 0.001), with the lowest dosage quartile having decreased hazard of dAMD incidence (HR, 0.95; 95% CI, 0.91-0.99) and the highest having increased hazard (HR, 1.07; 95% CI, 1.01-1.13). Conclusions: Small, conflicting associations between metformin exposure and development of dAMD were observed depending on cumulative dosage and whether drug use was active, suggesting metformin did not substantially affect the development of dAMD.
C1 [Eton, Emily A.; Wubben, Thomas J.; Besirli, Cagri G.] Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA.
   [Hua, Peiying; McGeehan, Brendan] Univ Penn, Ctr Prevent Ophthalmol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [VanderBeek, Brian L.] Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Perelman Sch Med, 51 N 39th St, Philadelphia, PA 19104 USA.
C3 University of Michigan System; University of Michigan; University of
   Pennsylvania; Pennsylvania Medicine; University of Pennsylvania;
   Pennsylvania Medicine
RP VanderBeek, BL (通讯作者)，Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Perelman Sch Med, 51 N 39th St, Philadelphia, PA 19104 USA.
EM Brian.VanderBeek@pennmedicine.upenn.edu
OI Besirli, Cagri/0000-0001-7154-2024; VanderBeek, Brian
   L./0000-0003-4953-118X; Eton, Emily/0000-0003-4212-7184
FU National Institutes of Health K23 Award [1K23EY025729-01]; University of
   Pennsylvania Core Grant for Vision Research [2P30EY001583]; Research to
   Prevent Blindness; Karen & Herbert Lotman Fund for Macular Vision
   Research Foundation; Paul and Evanina Mackall Foundation
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: National
   Institutes of Health K23 Award (1K23EY025729-01); University of
   Pennsylvania Core Grant for Vision Research (2P30EY001583). Additional
   funding was provided by Research to Prevent Blindness, Karen & Herbert
   Lotman Fund for Macular Vision Research Foundation, and the Paul and
   Evanina Mackall Foundation.
CR Brown EE, 2019, INVEST OPHTH VIS SCI, V60, P1470, DOI 10.1167/iovs.18-26422
   Chen YY, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/1649156
   ClinicalTrials.gov, 2019, METF MIN GEOGR ATR P
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Hahn P, 2013, RETINA-J RET VIT DIS, V33, P911, DOI 10.1097/IAE.0b013e3182831248
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   He MS, 2018, DIABETES CARE, V41, P2202, DOI 10.2337/dc18-0707
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lee H, 2019, YONSEI MED J, V60, P679, DOI 10.3349/ymj.2019.60.7.679
   Lin HC, 2015, JAMA OPHTHALMOL, V133, P915, DOI 10.1001/jamaophthalmol.2015.1440
   Lopez-Bonet E, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122180
   Nesti L, 2017, NUTR METAB CARDIOVAS, V27, P657, DOI 10.1016/j.numecd.2017.04.009
   Qi BX, 2017, CELL MOL NEUROBIOL, V37, P1269, DOI 10.1007/s10571-016-0459-8
   Rena G, 2017, DIABETOLOGIA, V60, P1577, DOI 10.1007/s00125-017-4342-z
   Herran CS, 2018, ORAL ONCOL, V85, P68, DOI 10.1016/j.oraloncology.2018.08.015
   Stewart JM, 2020, OPHTHALMOL RETINA, V4, P1118, DOI 10.1016/j.oret.2020.06.003
   Topouzis F, 2009, BRIT J OPHTHALMOL, V93, P1037, DOI 10.1136/bjo.2008.146316
   VanderBeek BL, 2011, AM J OPHTHALMOL, V152, P273, DOI 10.1016/j.ajo.2011.02.004
   Vassilev ZP, 2015, INVEST OPHTH VIS SCI, V56, P1585, DOI 10.1167/iovs.14-16271
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu L, 2018, P NATL ACAD SCI USA, V115, P10475, DOI 10.1073/pnas.1802724115
   Xu L, 2016, ADV EXP MED BIOL, V854, P425, DOI 10.1007/978-3-319-17121-0_56
   Young BA, 2008, AM J MANAG CARE, V14, P15
   Zhu J, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.008389
NR 35
TC 2
Z9 2
U1 1
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN
PY 2022
VL 32
IS 1
BP 417
EP 423
AR 1120672121997288
DI 10.1177/1120672121997288
EA FEB 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YK3MJ
UT WOS:000678251700001
PM 33607930
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Lin, TZ
   Dans, KC
   Muftuoglu, IK
   Meshi, A
   Amador-Patarroyo, MJ
   Cheng, LY
   Freeman, WR
AF Lin, Tiezhu
   Dans, Kunny C.
   Muftuoglu, Ilkay Kilic
   Meshi, Amit
   Amador-Patarroyo, Manuel J.
   Cheng, Lingyun
   Freeman, William R.
TI Factors associated with extended remission in neovascular age-related
   macular degeneration on pro re nata treatment protocol
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE retina; neovascularisation; macula; imaging; treatment medical
ID ENDOTHELIAL GROWTH-FACTOR; THERAPY; RANIBIZUMAB; VERTEPORFIN;
   PREVALENCE; OUTCOMES; TRIAL; VEGF
AB Aim To show the characteristics and outcomes of patients with neovascular age-related macular degeneration (nAMD) who had extended remission (ER) while on a pro re nata (PRN) treatment protocol. Methods This was a retrospective case-control study of a consecutive series of patients with nAMD treated with a PRN antivascular endothelial growth factor (anti-VEGF) drug regimen. ER was defined as the absence of haemorrhage, intraretinal/subretinal fluid on optical coherence tomography and leakage on fluorescein angiography for 52 weeks after cessation of anti-VEGF therapy. Matching patients with nAMD who did not achieve ER were included as control group. Cox regression analysis was fitted to identify predictors of time to achieve ER and time to recurrence. A logistic regression analysis of baseline characteristics was used to identify predictors of achieving ER. Results Of 830 eyes treated with anti-VEGF monotherapy, 77 (9.2%) eyes achieved ER during a median follow-up of 236 weeks (range 70-525 weeks). Cox regression analysis showed that ER was achieved earlier in eyes with isolated intraretinal fluid (HR, 2.05; 95% CI 1.929 to 4.520; p=0.045) at presentation. Logistic regression analysis showed that type 3 choroidal neovascularisation (OR, 0.090; 95% CI 0.021 to 0.382; p=0.001), thinner choroid (OR, 0.993; 95% CI 0.988 to 0.998; p=0.004) and absence of macular atrophy (OR, 0.233; 95% CI 0.065 to 0.839; p=0.026) at baseline increased the likelihood of achieving ER. Conclusion ER is achievable in 9.2% of patients under PRN therapy for nAMD. At presentation with nAMD, anatomical features on retinal imaging may predict the likelihood of achieving ER and a shorter time to achieve ER.
C1 [Lin, Tiezhu; Dans, Kunny C.; Muftuoglu, Ilkay Kilic; Meshi, Amit; Amador-Patarroyo, Manuel J.; Cheng, Lingyun; Freeman, William R.] Univ Calif San Diego, Shiley Eye Inst, Jacobs Retina Ctr, Ophthalmol, San Diego, CA 92093 USA.
   [Lin, Tiezhu] He Univ, He Eye Hosp, Ophthalmol, Shenyang, Peoples R China.
   [Muftuoglu, Ilkay Kilic] Istanbul Training & Res Hosp, Ophthalmol, Istanbul, Turkey.
   [Meshi, Amit] Rabin Med Ctr, Ophthalmol, Petah Tiqwa, Israel.
   [Amador-Patarroyo, Manuel J.] Inst Barraquer Amer, Escuela Super Oftalmol, Ophthalmol, Bogota, Colombia.
C3 University of California System; University of California San Diego;
   Istanbul Training & Research Hospital; Rabin Medical Center
RP Freeman, WR (通讯作者)，Univ Calif San Diego, Shiley Eye Inst, Jacobs Retina Ctr, Ophthalmol, San Diego, CA 92093 USA.
EM wrfreeman@ucsd.edu
RI lin, Tiezhu/AAY-1971-2020
FU UCSD Vision Research Center Core Grant [P30EY022589]; Research to
   Prevent Blindness, New York (WRF)
FX The study was supported in part by a UCSD Vision Research Center Core
   Grant P30EY022589, an unrestricted fund from Research to Prevent
   Blindness, New York (WRF). The funding organisation had no role in the
   design or conduct of this research.
CR Arendt P, 2019, RETINA-J RET VIT DIS, V39, P27, DOI 10.1097/IAE.0000000000001923
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19780
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Dakin HA, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005094
   Daniel E, 2016, OPHTHALMOLOGY, V123, P609, DOI 10.1016/j.ophtha.2015.10.034
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Hatz K, 2017, C ASE SERIES TREAT E, P67
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lanzetta P, 2018, ACTA OPHTHALMOL, V96, pE911, DOI 10.1111/aos.13751
   Lim Eun-Hae, 2013, Korean J Ophthalmol, V27, P351, DOI 10.3341/kjo.2013.27.5.351
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Muftuoglu IK, 2018, RETINA-J RET VIT DIS, V38, P516, DOI 10.1097/IAE.0000000000001572
   Oishi A, 2011, EUR J OPHTHALMOL, V21, P777, DOI 10.5301/EJO.2011.7430
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rouvas AA, 2010, EYE, V24, P1633, DOI 10.1038/eye.2010.134
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 32
TC 5
Z9 5
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JAN
PY 2020
VL 104
IS 1
BP 58
EP 63
DI 10.1136/bjophthalmol-2018-313447
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KA1YB
UT WOS:000505593600012
PM 31302628
OA Green Published
DA 2022-11-30
ER

PT J
AU Thapa, R
   Bajimaya, S
   Paudyal, G
   Khanal, S
   Tan, S
   Thapa, SS
   van Rens, G
AF Thapa, Raba
   Bajimaya, Sanyam
   Paudyal, Govinda
   Khanal, Shankar
   Tan, Stevie
   Thapa, Suman S.
   van Rens, Ger
TI Population awareness of diabetic eye disease and age related macular
   degeneration in Nepal: the Bhaktapur Retina Study
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Awareness; Age-related macular degeneration; Diabetic retinopathy; Nepal
ID CATARACT-SURGERY; RURAL-POPULATION; SOUTHERN INDIA; PREVALENCE;
   KNOWLEDGE; EPIDEMIOLOGY; SMOKING; MACULOPATHY; RETINOPATHY; BLINDNESS
AB Background: Diabetic retinopathy (DR) and age-related macular degeneration (AMD) are among the leading causes of visual impairment and blindness in developing countries. This study aims to explore the awareness of these retinal diseases in Nepal.
   Method: A population based cross-sectional study conducted among individuals 60 years and older from the Bhaktapur district of Nepal. One thousand consecutive subjects were enrolled and subjected to a structured questionnaire.
   Result: Subject age ranged from 60 to 93 years with a mean of 69.5 years +/- 7.1 (S.D.). Males and females comprised 45.1 and 55.9 % of the population, respectively. The majority was illiterate (78.2 %), and agriculture was the predominant occupation (79.8 %). 12.1 % were aware of the effect of diabetes on the eye, and among them, 99 % were aware that diabetes was a blinding disease caused by DR. 11.5 % of the subjects were aware of DR, and 10.1 % were aware that subjects with diabetes should undergo periodic eye examinations. Only 7.6 % of subjects were aware of AMD. 7.5 and 7.4 % were aware about its aggravation with smoking and sunlight exposure, respectively. Younger age group, males, literates, service holders, best corrected visual acuity >0.3 LogMAR, were each significantly associated with an increase in awareness of diabetic retinopathy. Smokers and those with agricultural occupations were less aware regarding AMD. Those with diabetes, with or without DR were significantly more aware than those not having the disease.
   Conclusion: Among the Bhaktapur population, awareness of DR and AMD was only 11.5 and 7.6 % respectively. Older age groups, females, illiterates, farmers, and those with poor visual acuity were less aware of these blinding diseases. We recommend community-based eye health education programs targeted at raising awareness of these diseases and preventive measures.
C1 [Thapa, Raba; Bajimaya, Sanyam; Paudyal, Govinda; Thapa, Suman S.] Tilganga Inst Ophthalmol, Kathmandu, Nepal.
   [Khanal, Shankar] Tribhuvan Univ, Cent Dept Stat, Kirtipur, Nepal.
   [Tan, Stevie; van Rens, Ger] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands.
C3 Tribhuvan University; Vrije Universiteit Amsterdam
RP Thapa, R (通讯作者)，Tilganga Inst Ophthalmol, POB 561, Kathmandu, Nepal.
EM rabathapa@live.com
RI van Rens, Ger/I-6247-2018
OI Tan, H. Stevie/0000-0001-8368-1048
FU Tilganga Institute of Ophthalmology, Kathmandu, Nepal; Vrije University
   Medical Center, Amsterdam, The Netherlands
FX We would like to acknowledge Tilganga Institute of Ophthalmology,
   Kathmandu, Nepal and Vrije University Medical Center, Amsterdam, The
   Netherlands for funding of this study. Likewise, we would like to
   acknowledge all the patients that participated in this study and the
   Bhaktapur Municipality. Paul S. Bernstein, MD, PhD helped edit the
   manuscript.
CR Addoor Krishna R, 2011, Med J Malaysia, V66, P48
   Amos AF, 1997, DIABET MED S5, V14, P1
   [Anonymous], 1981, OPHTHALMOLOGY, V88, P583
   Attebo K, 1997, AUST NZ J OPHTHALMOL, V25, P283, DOI 10.1111/j.1442-9071.1997.tb01516.x
   Balla SA, 2004, J HLTH RES, V2, P356
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRILLIANT LB, 1985, B WORLD HEALTH ORGAN, V63, P375
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Charkoudian LD, 2008, OPHTHALMOLOGY, V115, P1032, DOI 10.1016/j.ophtha.2007.08.003
   Cimarolli VR, 2012, EDUC GERONTOL, V38, P530, DOI 10.1080/03601277.2011.595286
   Dandona R, 2001, B WORLD HEALTH ORGAN, V79, P96
   Gibson DM, 2012, AM J PREV MED, V43, P48, DOI 10.1016/j.amepre.2012.02.028
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lau JTF, 2002, BRIT J OPHTHALMOL, V86, P1080, DOI 10.1136/bjo.86.10.1080
   Lawrenson JG, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-564
   Livingston PM, 1998, BRIT J OPHTHALMOL, V82, P780, DOI 10.1136/bjo.82.7.780
   Loewenstein A, 2007, RETINA-J RET VIT DIS, V27, P873, DOI 10.1097/IAE.0b013e318050d2ec
   Mohan Deepa, 2005, J Assoc Physicians India, V53, P283
   Mwangi MW, 2011, INT J HUMANIT SOC SC, V21, P140
   Ng WT, 2006, CLIN EXP OPHTHALMOL, V34, P9, DOI 10.1111/j.1442-9071.2006.01141.x
   Nirmalan PK, 2004, ARCH OPHTHALMOL-CHIC, V122, P581, DOI 10.1001/archopht.122.4.581
   Paudyal G, 2008, Nepal Med Coll J, V10, P160
   Rajani K., 2011, INT J BIOL MED RES, V2, P533
   Rani PK, 2008, RURAL REMOTE HEALTH, V8
   Resnikoff S, 2002, B WORLD HEALTH ORGAN, V82, P844
   Sapkota YD, 2006, BRIT J OPHTHALMOL, V90, P411, DOI 10.1136/bjo.2005.082503
   Stevens R, 2014, BRIT J VISUAL IMPA, V32, P77, DOI 10.1177/0264619613519341
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Thapa R, 2015, NEPAL J OPHTHALMOL, V7, P26, DOI 10.3126/nepjoph.v7i1.13163
   Thapa R, 2011, Kathmandu Univ Med J (KUMJ), V9, P165
   Thapa R, 2011, NEPAL J OPHTHALMOL, V3, P102, DOI [http://dx.doi.org/10.3126/nepjoph.v3i2.5260, http://dx.doi.org/10.3126/nepjoph.v3i2.5263, 10.3126/nepjoph.v4i1.5844]
   Thapa SS, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-9
   Thapa SS, 2011, CLIN EXP OPHTHALMOL, V39, P851, DOI 10.1111/j.1442-9071.2011.02576.x
   Thapa SS, 2011, CLIN EXP OPHTHALMOL, V39, P126, DOI 10.1111/j.1442-9071.2010.02429.x
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047
   Woo JH, 2009, ACTA OPHTHALMOL, V87, P262, DOI 10.1111/j.1755-3768.2008.01376.x
   World Health Organization, 2005, PREV BLINDN DIAB MEL
NR 39
TC 23
Z9 23
U1 0
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD DEC 29
PY 2015
VL 15
AR 188
DI 10.1186/s12886-015-0175-z
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DA1AD
UT WOS:000367527800004
PM 26714483
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Seddon, JM
   George, S
   Rosner, B
   Klein, ML
AF Seddon, Johanna M.
   George, Sarah
   Rosner, Bernard
   Klein, Michael L.
TI CFH gene variant, Y402H, and smoking, body mass index, environmental
   associations with advanced age-related macular degeneration
SO HUMAN HEREDITY
LA English
DT Article
DE case-control association analysis; environmental risk factor;
   epidemiologic approaches; gene-environment interaction; genotype;
   macular degeneration
ID FACTOR-H POLYMORPHISM; C-REACTIVE PROTEIN; RISK-FACTORS; MACULOPATHY;
   DIETARY; CAROTENOIDS; SCAN
AB Objectives: We tested the hypothesis that modifiable lifestyle factors alter the genetic susceptibility associated with a common coding variant in the complement factor H (CFH) gene, Y402H, for the leading cause of blindness among the elderly, age-related macular degeneration (AMD). Methods: In this case-control association analysis, Caucasian participants in the multicenter Age-Related Eye Disease Study with advanced AMD (n = 574 cases) or no AMD (n = 280 controls) were evaluated. AMD status was determined by grading of fundus photographs. Risk factors including cigarette smoking and body mass index (BMI) were assessed and DNA specimens were genotyped for the variant in the CFH gene. Unconditional logistic regression analyses were performed. Attributable risks and multivariable AMD risk scores were calculated. Results:The number of risk alleles for Y402H was associated with advanced AMD, with odds ratios (OR) of 2.7 (95% confidence interval (CI) 1.8-3.8) for the CT heterozygous genotype and OR 7.4 (4.7-11.8) for the homozygous CC risk genotype, after controlling for demographic and behavioral risk factors. Current cigarette smoking (OR 5.1) and high BMI >= 30 (OR 2.1) were independently related to AMD, controlling for genotype. The association between AMD and BMI varied dependent on genotype (P interaction = 0.006 for the CT vs. TT genotype). The CC genotype plus higher BMI (OR 5.9) or smoking (OR 10.2) conferred the greatest risks. Gene plus environment risk scores provided an area under the receiver operating characteristic (ROC) curve of 0.70-0.75. Conclusions: Genetic and environmental factors are independently related to advanced AMD, and modifiable factors alter genetic susceptibility. The AMD risk score identifies a highly susceptible population. Copyright (c) 2006 S. Karger AG, Basel.
C1 Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Epidemiol Unit,Dept Ophthalmol, Boston, MA 02114 USA.
   Harvard Univ, Sch Med, Dept Epidemiol, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Channing Lab, Boston, MA 02115 USA.
   Oregon Hlth & Sci Univ, Devers Eye Inst, Macular Degenerat Ctr, Casey Eye Inst, Portland, OR 97201 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Harvard University; Harvard Medical School; Harvard
   University; Harvard Medical School; Devers Eye Institute; Oregon Health
   & Science University
RP Seddon, JM (通讯作者)，Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Epidemiol Unit,Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA.
EM Johanna_Seddon@meei.harvard.edu
FU NCRR NIH HHS [U54 RR 020278] Funding Source: Medline; NEI NIH HHS [R01
   EY 12203, R01 EY 11309] Funding Source: Medline; NATIONAL CENTER FOR
   RESEARCH RESOURCES [U54RR020278] Funding Source: NIH RePORTER; NATIONAL
   EYE INSTITUTE [R01EY011309, R01EY012203] Funding Source: NIH RePORTER
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   D'Agostino RB, 2001, JAMA-J AM MED ASSOC, V286, P180, DOI 10.1001/jama.286.2.180
   DelaPaz MA, 1997, AM J OPHTHALMOL, V124, P331, DOI 10.1016/S0002-9394(14)70825-6
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Rosner B., 2000, FUNDAMENTALS BIOSTAT
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon J. M., 1997, Investigative Ophthalmology and Visual Science, V38, pS676
   Seddon JM, 2006, NUTRITION, V22, P441, DOI 10.1016/j.nut.2005.12.004
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SEDDON JM, 2006, IN PRESS ARCH OPHTHA
   SEDDON JM, 2003, ARCH OPHTHALMOL-CHIC, P124
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Smith GD, 2005, LANCET, V366, P1484, DOI 10.1016/S0140-6736(05)67601-5
   Souied EH, 2005, MOL VIS, V11, P1135
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 34
TC 138
Z9 141
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0001-5652
EI 1423-0062
J9 HUM HERED
JI Hum. Hered.
PY 2006
VL 61
IS 3
BP 157
EP 165
DI 10.1159/000094141
PG 9
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 075ZQ
UT WOS:000239927200004
PM 16816528
DA 2022-11-30
ER

PT J
AU Aghdam, KA
   Pielen, A
   Framme, C
   Junker, B
AF Aghdam, Kaveh Abri
   Pielen, Amelie
   Framme, Carsten
   Junker, Bernd
TI Correlation Between Hyperreflective Foci and Clinical Outcomes in
   Neovascular Age-Related Macular Degeneration After Switching to
   Aflibercept
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE aflibercept; choroidal neovascularization; hyperreflective foci;
   ranibizumab; spectral domain optical coherence tomography
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL-PIGMENT EPITHELIUM; INTRAVITREAL
   BEVACIZUMAB; VEIN OCCLUSION; VEGF-TRAP; EDEMA; DOMAIN; RANIBIZUMAB;
   PROGRESSION; HISTOLOGY
AB PURPOSE. To assess the correlation between hyperreflective foci (HF) and visual and anatomical outcomes in treatment-resistant neovascular age-related macular degeneration (AMD) using spectral-domain optical coherence tomography (SD-OCT).
   METHODS. This was a prospective interventional case series. Thirty-three eyes of 30 consecutive patients with treatment-resistant neovascular AMD were enrolled. Intravitreal aflibercept injections were performed at week 0 (baseline), week 4, and week 8. Spectral-domain OCT images were obtained before each injection and 4 weeks after the third injection. The main focus was on the measurement of choroidal neovascularization (CNV) size in the cross-sectional area in the B-scan through the fovea, and HF number along line segments of 1- and 3-mm length passing through the fovea.
   RESULTS. Mean number of HF in the radius of 500 mu m decreased from 8.36 +/- 7.58 to 4.15 +/- 3.39 (P = 0.02). Mean number of HF in the radius of 1500 mu m was reduced from 21.30 +/- 12.47 to 10.45 +/- 6.34 (P < 0.001). Mean CNV area decreased from 0.35 +/- 0.22 to 0.22 +/- 0.16 mm(2) (P < 0.001). There was a significant positive correlation between HF reduction in the radius of 500 mu m and decrease in central subfield thickness (CST) (r = 0.43, P = 0.01), but no statistically significant correlation was found between HF decline in the radius of 1500 mu m and other parameters.
   CONCLUSIONS. Switching from ranibizumab to aflibercept caused significant decrease in the number of HF 1 month after aflibercept upload, and HF decrease in the radius of 500 mu m was correlated positively with the reduction in CST.
C1 [Aghdam, Kaveh Abri; Pielen, Amelie; Framme, Carsten; Junker, Bernd] Hannover Med Sch, Univ Eye Hosp, Hannover, Germany.
   [Aghdam, Kaveh Abri] Univ Tehran Med Sci, Inst Neurosci, Brain & Spinal Cord Injury Res Ctr, Tehran, Iran.
C3 Hannover Medical School; Tehran University of Medical Sciences
RP Aghdam, KA (通讯作者)，Hannover Med Sch, Carl Neuberg Str 1, D-30625 Hannover, Germany.
EM kaveh.abri@gmail.com
RI Abri Aghdam, Kaveh/M-6352-2018
OI Abri Aghdam, Kaveh/0000-0001-7568-6455; Pielen,
   Amelie/0000-0001-9401-2501
FU Niedersachsen Vorab
FX The authors thank the German Ministry of Lower Saxony for its scientific
   and cultural organization to support our retinal imaging studies in the
   ophthalmology department of Hannover Medical School financed by
   Niedersachsen Vorab.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Akagi-Kurashige Y, 2012, GRAEF ARCH CLIN EXP, V250, P1129, DOI 10.1007/s00417-012-1928-5
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Bolz M, 2009, OPHTHALMOLOGY, V116, P914, DOI 10.1016/j.ophtha.2008.12.039
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Framme C, 2012, INVEST OPHTH VIS SCI, V53, P5814, DOI 10.1167/iovs.12-9950
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P5965, DOI 10.1167/iovs.10-5779
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Huang JJ, 2009, RETINA-J RET VIT DIS, V29, P980, DOI 10.1097/IAE.0b013e3181a2c1a7
   Kang JW, 2014, GRAEF ARCH CLIN EXP, V252, P1413, DOI 10.1007/s00417-014-2595-5
   Kuroda M, 2014, CLIN OPHTHALMOL, V8, P435, DOI 10.2147/OPTH.S58164
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Ogino K, 2012, RETINA-J RET VIT DIS, V32, P77, DOI 10.1097/IAE.0b013e318217ffc7
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Sugar EA, 2011, AM J OPHTHALMOL, V152, P1044, DOI 10.1016/j.ajo.2011.05.028
   Uji A, 2012, AM J OPHTHALMOL, V153, P710, DOI 10.1016/j.ajo.2011.08.041
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3269, DOI 10.1167/iovs.15-16432
   Zhang QX, 2013, SCI REP-UK, V3, DOI 10.1038/srep02644
NR 29
TC 28
Z9 28
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2015
VL 56
IS 11
BP 6448
EP 6455
DI 10.1167/iovs.15-17338
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DB0YQ
UT WOS:000368235100031
PM 26444725
DA 2022-11-30
ER

PT J
AU Broadhead, GK
   Keenan, TDL
   Chew, EY
   Wiley, HE
   Cukras, CA
AF Broadhead, Geoffrey K.
   Keenan, Tiarnan D. L.
   Chew, Emily Y.
   Wiley, Henry E.
   Cukras, Catherine A.
TI Comparison of agents using higher dose anti-VEGF therapy for
   treatment-resistant neovascular age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE AMD; Anti-VEGF; Neovascular AMD; Treatment-resistant
ID 2.0 MG RANIBIZUMAB; ATROPHY INCIDENCE; PROGRESSION; MANAGEMENT
AB Purpose To explore the comparative efficacy and safety of higher dose intravitreal bevacizumab, ranibizumab, or aflibercept for treatment-resistant neovascular age-related macular degeneration (nAMD). Methods Retrospective analysis of 37 eyes of 35 patients with treatment-resistant nAMD divided into 3 cohorts based on high-dose treatment received: 3 mg aflibercept, 0.75 mg or 1.0 mg ranibizumab, and 1.8 mg or 2.5 mg bevacizumab. The eyes were analyzed at standardized time points up to 48 months. Included eyes demonstrated active nAMD with persistent exudation on imaging for at least 6 months with at least 4 anti-VEGF injections during this time. Outcomes included change in visual acuity (VA), central retinal thickness (CRT), intraocular pressure (IOP), retinal morphology, adverse event occurrence, and yearly intravitreal injection (IVI) rate. Results There was no significant difference in VA or IOP change compared to the initiation of high-dose treatment for any agent or comparing between agents at any time point (p > 0.05). CRT improved at month 1, 3, 6, and 12 with all 3 agents (p < 0.05 for all) with a greater CRT reduction seen for ranibizumab than aflibercept at month 6 (p < 0.05), although baseline CRT was greater in the ranibizumab group than the aflibercept group (p < 0.05). Mean absolute CRT was similar at month 6 for all agents (p > 0.05). IVI rates pre- and post-conversion to higher-dose therapy were similar (1 injection per 5.7-6.4 weeks). Mean follow-up was 22.8 months. Conclusions Higher dose therapy may achieve improved anatomic outcomes and maintain vision, but frequent injections are required to achieve this. There was no detected difference in efficacy or safety between agents.
C1 [Broadhead, Geoffrey K.; Keenan, Tiarnan D. L.; Chew, Emily Y.; Wiley, Henry E.; Cukras, Catherine A.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Cukras, CA (通讯作者)，NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
EM cukrasc@nei.nih.gov
FU Intramural Research Program of the NIH, National Eye Institute
FX This research was supported by the Intramural Research Program of the
   NIH, National Eye Institute.
CR Barikian A, 2017, RETINA-J RET VIT DIS, V37, P1337, DOI 10.1097/IAE.0000000000001366
   Broadhead GK, 2014, ACTA OPHTHALMOL, V92, P713, DOI 10.1111/aos.12463
   Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Eshtiaghi A, 2021, RETINA-J RET VIT DIS, V41, P2424, DOI 10.1097/IAE.0000000000003207
   Felfeli T, 2019, BRIT J OPHTHALMOL, V103, P46, DOI 10.1136/bjophthalmol-2018-312603
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Fung AT, 2012, EYE, V26, P1181, DOI 10.1038/eye.2012.174
   Gillies MC, 2020, OPHTHALMOLOGY, V127, P198, DOI 10.1016/j.ophtha.2019.08.023
   Iglicki M, 2021, EYE, V35, P1111, DOI 10.1038/s41433-020-01309-9
   Marquis LM, 2020, GRAEF ARCH CLIN EXP, V258, P1591, DOI 10.1007/s00417-020-04730-8
   Mettu PS, 2021, PROG RETIN EYE RES, V82, DOI 10.1016/j.preteyeres.2020.100906
   Muller S, 2017, GRAEF ARCH CLIN EXP, V255, P2237, DOI 10.1007/s00417-017-3739-1
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Spooner K, 2019, ACTA OPHTHALMOL, V97, pE706, DOI 10.1111/aos.14046
   Spooner KL, 2020, OPHTHALMOLOGY, V127, P1663, DOI 10.1016/j.ophtha.2020.06.019
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   Veritti D, 2013, OPHTHALMOLOGICA, V230, P131, DOI 10.1159/000351651
   Wykoff CC, 2013, OPHTHALMOLOGY, V120, P1945, DOI 10.1016/j.ophtha.2013.06.030
   You QS, 2018, RETINA-J RET VIT DIS, V38, P1156, DOI 10.1097/IAE.0000000000001726
NR 22
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUL
PY 2022
VL 260
IS 7
BP 2239
EP 2247
DI 10.1007/s00417-021-05547-9
EA JAN 2022
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2H0GI
UT WOS:000749094400001
PM 35092447
DA 2022-11-30
ER

PT J
AU Piemarocchi, S
   Varano, M
   Parravano, M
   Oddone, F
   Sartore, M
   Ferrara, R
   Sera, F
   Virgili, G
AF Piemarocchi, Stefano
   Varano, Monica
   Parravano, Mariacristina
   Oddone, Francesco
   Sartore, Mauro
   Ferrara, Roberto
   Sera, Francesco
   Virgili, Gianni
TI Quality of Vision Index: a new method to appraise visual function
   changes in age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Quality of life
ID OCCULT CHOROIDAL NEOVASCULARIZATION; CATARACT-SURGERY OUTCOMES; OF-LIFE;
   FUNCTION-QUESTIONNAIRE; ACUITY MEASUREMENTS; ELDERLY PATIENTS;
   LETTER-CHART; RISK-FACTORS; IMPAIRMENT; RELIABILITY
AB PURPOSE. To explore the correlation between psychophysical measures of visual function and vision-related quality of life (QOL) in exudative age-related macular degeneration (AMD) and to obtain a new quality of vision index expressed as corrected visual acuity (cVA) that is scaled like visual acuity (VA), but that incorporates the weighted contribution of VA, contrast sensitivity (CS), and reading ability.
   METHODS. Visual acuity, CS, and reading ability were measured in 293 patients with AMD in this multicenter prospective study. Vision-related QOL was quantified by the 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25). The validity of the questionnaire was assessed using Rasch analysis. The relationship between psychophysical tests and NEI-VFQ-25 scores was investigated. A cVA index was developed integrating Rasch-scaled NEI-VFQ-25 score with VA, CS, and reading ability as a tool to be used for evaluating vision-related QOL on the same scale as VA.
   RESULTS. A total of 27.5% of the variability of VFQ score was found to be explained by VA alone in patients with AMD. The proportion of Rasch-scaled QOL estimate variance explained by cVA was 33.2% as compared to 27.5% explained by VA and 24.5% by CS, which was a statistically significant improvement in both cases (p=0.015 and p<0.001, respectively). The correlation of reading ability with vision-related QOL was largely mediated by VA and CS and therefore it was not retained in the vision index.
   CONCLUSIONS. Visual acuity is poorly correlated with vision-related QOL in patients with AMD. Even though the new cVA index is a new method which better correlates with vision-related QOL, the major components of the individual perception of vision remain unexplained by common psychometric tests.
C1 [Piemarocchi, Stefano; Sartore, Mauro] Univ Padua, Dept Ophthalmol, Padua, Italy.
   [Varano, Monica; Parravano, Mariacristina; Oddone, Francesco] GB Bietti Eye Fdn IRCCS, Rome, Italy.
   [Ferrara, Roberto] Novartis Farma SpA, Dept Med, Origgio, VA, Italy.
   [Sera, Francesco] Canc Res & Prevent Inst ISPO, Mol & Nutr Epidemiol Unit, Florence, Italy.
   [Virgili, Gianni] Univ Florence, Eye Clin, Dept Otoneuroophthalmol Surg Sci, Florence, Italy.
C3 University of Padua; IRCCS - Fondazione "G.B. Bietti" per lo Studio e la
   Ricerca in Oftalmologia; Novartis; ISPRO Istituto per lo studio, la
   prevenzione e la rete oncologica; University of Florence
RP Parravano, M (通讯作者)，Fdn GB Bietti IRCCS, Via Livenza 3, I-00198 Rome, Italy.
EM criparra@tin.it
RI Varano, Monica/K-8573-2016; Oddone, Francesco/K-8876-2016; Sera,
   Francesco/C-8176-2011; Virgili, Gianni/P-6607-2014
OI Oddone, Francesco/0000-0002-2504-0004; Sera,
   Francesco/0000-0002-8890-6848; Varano, Monica/0000-0002-6530-1563;
   Virgili, Gianni/0000-0002-9960-2989
CR APPLEGATE W B, 1987, Journal of the American Medical Association, V257, P1064, DOI 10.1001/jama.257.8.1064
   ARDITI A, 1993, INVEST OPHTH VIS SCI, V34, P120
   BAILEY IL, 1991, INVEST OPHTH VIS SCI, V32, P422
   BERNTHPETERSEN P, 1981, ACTA OPHTHALMOL, V59, P198
   BERNTHPETERSEN P, 1981, ACTA OPHTHALMOL, V59, P50
   BRENNER MH, 1993, ARCH OPHTHALMOL-CHIC, V111, P680, DOI 10.1001/archopht.1993.01090050114040
   BROWN GC, 1992, ARCH OPHTHALMOL-CHIC, V110, P1251, DOI 10.1001/archopht.1992.01080210069027
   CARABELLESE C, 1993, J AM GERIATR SOC, V41, P401, DOI 10.1111/j.1532-5415.1993.tb06948.x
   CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202
   de Boer MR, 2004, OPHTHAL PHYSL OPT, V24, P257, DOI 10.1111/j.1475-1313.2004.00187.x
   Ergun E, 2003, OPHTHALMOLOGY, V110, P65, DOI 10.1016/S0161-6420(02)01566-X
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Fletcher DC, 1999, J REHABIL RES DEV, V36, P356
   GLYNN RJ, 1991, ARCH OPHTHALMOL-CHIC, V109, P205, DOI 10.1001/archopht.1991.01080020051041
   JAVITT JC, 1993, ARCH OPHTHALMOL-CHIC, V111, P686, DOI 10.1001/archopht.1993.01090050120041
   Kington R, 1997, J GEN INTERN MED, V12, P125
   Lindblad AS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1207
   LOVIEKITCHIN JE, 1988, OPHTHAL PHYSL OPT, V8, P363, DOI 10.1111/j.1475-1313.1988.tb01170.x
   LUNDSTROM M, 1994, BRIT J OPHTHALMOL, V78, P608, DOI 10.1136/bjo.78.8.608
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   MANGIONE CM, 1992, MED CARE, V30, P1111, DOI 10.1097/00005650-199212000-00004
   MANGIONE CM, 1994, ARCH OPHTHALMOL-CHIC, V112, P1419, DOI 10.1001/archopht.1994.01090230033017
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   MARX MS, 1992, J AM GERIATR SOC, V40, P1018, DOI 10.1111/j.1532-5415.1992.tb04479.x
   Massof RW, 2001, SURV OPHTHALMOL, V45, P531, DOI 10.1016/S0039-6257(01)00194-1
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   Miskala PH, 2007, OPHTHAL EPIDEMIOL, V14, P205, DOI 10.1080/09286580701502970
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Pesudovs K, 2003, INVEST OPHTH VIS SCI, V44, P2892, DOI 10.1167/iovs.02-1075
   Pesudovs Konrad, 2006, BMC Ophthalmol, V6, P25, DOI 10.1186/1471-2415-6-25
   Piermarocchi S, 2006, EUR J OPHTHALMOL, V16, P851, DOI 10.1177/112067210601600611
   Reichel MB, 2002, INVEST OPHTH VIS SCI, V43, pU1139
   Rossi GCM, 2003, J GLAUCOMA, V12, P213, DOI 10.1097/00061198-200306000-00006
   SCOTT IU, 1994, ARCH OPHTHALMOL-CHIC, V112, P329, DOI 10.1001/archopht.1994.01090150059023
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026
   STEINBERG EP, 1994, OPHTHALMOLOGY, V101, P1131
   Talic I, 2022, LEARN INSTR, V81, DOI [10.1016/j.learninstruc.2022.101594, 10.1016/j.ajo.2004.02.011]
   TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604
   UHLMANN RF, 1991, J GEN INTERN MED, V6, P126, DOI 10.1007/BF02598307
   VandenBosch ME, 1997, EYE, V11, P411, DOI 10.1038/eye.1997.87
   Virgili G, 2004, INVEST OPHTH VIS SCI, V45, P3418, DOI 10.1167/iovs.04-0390
   West SK, 2002, ARCH OPHTHALMOL-CHIC, V120, P774
NR 42
TC 4
Z9 4
U1 0
U2 4
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN-FEB
PY 2011
VL 21
IS 1
BP 55
EP 66
DI 10.5301/EJO.2010.1519
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 687MI
UT WOS:000284782200009
PM 20640999
DA 2022-11-30
ER

PT J
AU Kent, DL
   Fujii, GY
   Pieramici, DJ
   Reynolds, SM
   Melia, M
   Rossi, JV
   Humayun, MS
   Caffey, S
   De Juan, E
AF Kent, DL
   Fujii, GY
   Pieramici, DJ
   Reynolds, SM
   Melia, M
   Rossi, JV
   Humayun, MS
   Caffey, S
   De Juan, E
TI Angiographic characteristics in patients undergoing macular
   translocation for subfoveal choroidal neovascularization secondary to
   age-related macular degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE choroidal neovascularization; fluorescein angiography; macular
   degeneration; macular translocation
ID FOVEAL TRANSLOCATION; SURGICAL-MANAGEMENT; VISUAL FUNCTION; MACULOPATHY;
   RETINOTOMY
AB Purpose: To review in a standardized fashion pre- and postoperative fluorescein angiographic characteristics in patients undergoing limited macular translocation (LMT) with scleral imbrication to treat subfoveal choroidal neovascularization (SFCNV) secondary to age-related macular degeneration (AMD). The current study was undertaken to assess any potential effects of the translocation procedure on altering the angiographic characteristics of SFCNV before laser photocoagulation.
   Methods: A consecutive series of patients undergoing LMT for AMD was identified retrospectively. The pre- and postoperative fluorescein angiograms were reviewed in a masked fashion. Angiographic characteristics evaluated included pre- and postoperative lesion components, stability of lesion, and the amount of retinal translocation obtained.
   Results: Eighty-eight patients (90 eyes) had angiograms of adequate quality to permit evaluation. Time between the preoperative and the prelaser angiogram ranged from 2 to 84 days (median 7.5 days). Neovascular complexes remained unchanged or decreased in size in 79% of patients. There was no statistically significant difference in lesion size between the pre- and postoperative periods (P = 0.34). Retinal movement ranged from 160 mum to 3,320 mum (median 960 gm), with 61% of cases undergoing effective translocation (i.e., the fovea was moved away from the neovascular complex). None of the lesion components or demographic factors evaluated affected the amount of translocation obtained. Larger lesions were more likely to remain subfoveal following translocation (P = 0.004).
   Conclusion: The size and lesion characteristics appear relatively stable following translocation. Amount of retinal movement is not associated with angiographic lesion characteristics. Only size was associated with achievement of desired translocation in the final model, with large lesions being less likely to achieve desired translocation. In our study group, the amount of retinal translocation was variable with 61% of cases undergoing effective translocation.
C1 Doheny Eye Inst, Doheny Retina Inst, Los Angeles, CA 90033 USA.
   Johns Hopkins Univ, Wilmer Inst, Vitreoretinal Serv, Baltimore, MD USA.
   Calif Retina Res Fdn, Santa Barbara, CA USA.
C3 Doheny Eye Institute; Johns Hopkins University
RP Kent, DL (通讯作者)，Doheny Eye Inst, Doheny Retina Inst, 1450 San Pablo St,DEI 3600, Los Angeles, CA 90033 USA.
CR Akduman L, 1999, RETINA-J RET VIT DIS, V19, P418, DOI 10.1097/00006982-199909000-00009
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Benner JD, 2001, GRAEF ARCH CLIN EXP, V239, P815, DOI 10.1007/s004170100339
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   Deramo VA, 2001, RETINA-J RET VIT DIS, V21, P304, DOI 10.1097/00006982-200108000-00002
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Fujikado T, 2001, AM J OPHTHALMOL, V131, P101, DOI 10.1016/S0002-9394(00)00770-4
   Fujikado T, 1998, AM J OPHTHALMOL, V125, P647, DOI 10.1016/S0002-9394(98)00021-X
   Lewis H, 1999, AM J OPHTHALMOL, V128, P135, DOI 10.1016/S0002-9394(99)00207-X
   Lewis H, 2001, AM J OPHTHALMOL, V132, P156, DOI 10.1016/S0002-9394(01)01088-1
   Ninomiya Y, 1996, AM J OPHTHALMOL, V122, P613, DOI 10.1016/S0002-9394(14)70479-9
   Ohji M, 2001, AM J OPHTHALMOL, V132, P888, DOI 10.1016/S0002-9394(01)01255-7
   Pieramici DJ, 2000, AM J OPHTHALMOL, V130, P419, DOI 10.1016/S0002-9394(00)00533-X
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Toth CA, 2001, RETINA-J RET VIT DIS, V21, P293, DOI 10.1097/00006982-200108000-00001
   Wolf S, 1999, GRAEF ARCH CLIN EXP, V237, P51, DOI 10.1007/s004170050194
NR 20
TC 3
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2003
VL 23
IS 2
BP 152
EP 158
DI 10.1097/00006982-200304000-00003
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 679AK
UT WOS:000182898700003
PM 12707592
DA 2022-11-30
ER

PT J
AU Rayess, N
   Houston, SKS
   Gupta, OP
   Ho, AC
   Regillo, CD
AF Rayess, Nadim
   Houston, S. K. Steven, III
   Gupta, Omesh P.
   Ho, Allen C.
   Regillo, Carl D.
TI Treatment Outcomes After 3 Years in Neovascular Age-Related Macular
   Degeneration Using a Treat-and-Extend Regimen
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID GROWTH-FACTOR THERAPY; DOSING REGIMEN; RANIBIZUMAB; TRIAL
AB PURPOSE: To determine 3-year treatment outcomes after 1 to 3 years of ranibizumab or bevacizumab therapy using a treat-and-extend regimen in patients with neovascular age-related macular degeneration (AMD).
   DESIGN: Retrospective, interventional, consecutive case series.
   METHODS: We treated 212 eyes from 196 patients diagnosed with treatment-naive neovascular AMD between January 2009 and March 2013; they were treated with either ranibizumab or bevacizumab for a minimum of 1 year, using a treat-and-extend regimen. The main outcome measures were change from baseline best-corrected Snellen visual acuity (BCVA), proportion of eyes losing <3 BCVA lines, proportion of eyes gaining BCVA lines, change from baseline central retinal thickness, and mean number of injections at 1, 2 and 3 years of follow-up.
   RESULTS: The mean follow-up period was 1.88 years (median, 2 years). At baseline, mean BCVA was 20/ 139; it improved to 20/79 (P < 0.001) after 1 year of treatment and was maintained at 20/69 and 20/64 at 2 and 3 years follow-up (P < 0.001), respectively. At baseline; mean central retinal thickness was 351 mu m and significantly decreased to 285 mu m, 275 mu m and 276 mu m at 1, 2 and 3 years of follow-up (P < 0.001), respectively. Patients received, on average, 7.6, 5.7 and 5.8 injections over years 1, 2 and 3 of treatment, respectively. At final follow-up, 94% of eyes had lost <3 lines BCVA, and 34.4% of eyes had gained >= 3 lines BCVA.
   CONCLUSIONS: The treat-and-extend regimen is effective in achieving and maintaining visual and anatomic improvements in patients with neovascular AMD for up to 3 years of treatment. (C) 2015 by Elsevier Inc. All rights reserved.
C1 [Rayess, Nadim; Houston, S. K. Steven, III; Gupta, Omesh P.; Ho, Allen C.; Regillo, Carl D.] Wills Eye Hosp & Res Inst, Retina Serv, Philadelphia, PA 19107 USA.
C3 Jefferson University
RP Regillo, CD (通讯作者)，Wills Eye Hosp & Res Inst, Retina Serv, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
EM cregillo@aol.com
OI Ho, Allen/0000-0003-3921-608X
FU Genentech
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST, and the following were reported. Dr
   Houston is a consultant for Genentech; Dr Ho and Dr Regillo are
   consultants for Genentech and receive grant support from Genentech.
   Concept and design of study (N.R., S.K.S.H., O.P.G., A.C.H., C.D.R.);
   Analysis and interpretation of data (N.R., S.K.S.H., O.P.G., A.C.H.,
   C.D.R.); Preparation, review, or approval of article (N.R., S.K.S.H.,
   O.P.G., A.C.H., C.D.R.).
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Levine JP, 2009, RETINA-J RET VIT DIS, V29, P1074, DOI 10.1097/IAE.0b013e3181b09443
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Shienbaum G, 2012, AM J OPHTHALMOL, V153, P468, DOI 10.1016/j.ajo.2011.08.011
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Stone TW, 2013, 2013 PREFERENCES TRE
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
NR 19
TC 85
Z9 86
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JAN
PY 2015
VL 159
IS 1
BP 3
EP 8
DI 10.1016/j.ajo.2014.09.011
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AY7NU
UT WOS:000347747500002
PM 25217859
DA 2022-11-30
ER

PT J
AU Lau, LI
   Liu, CJL
   Wei, YH
AF Lau, Ling-Ing
   Liu, Catherine Jui-ling
   Wei, Yau-Huei
TI Increase of 8-Hydroxy-2 '-Deoxyguanosine in Aqueous Humor of Patients
   with Exudative Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID OXIDATIVE DNA-DAMAGE; VITREOUS LEVELS; ANTIOXIDANT ENZYMES; PIGMENT
   EPITHELIUM; VISUAL IMPAIRMENT; URINARY-EXCRETION; STRESS; MACULOPATHY;
   PREVALENCE; PROGRESSION
AB PURPOSE. Oxidative stress has been implicated as a major contributor to age-related macular degeneration (AMD). 8-Hydroxy- 2'-deoxyguanosine (8-OHdG) is one of the most abundant oxidative products of DNA damage and represents a noninvasive and sensitive biomarker of oxidative stress. The authors investigated the 8-OHdG levels in aqueous humor of patients with exudative AMD.
   METHODS. Twenty-four eyes of 24 patients with active exudative AMD and 31 eyes of 31 age-matched subjects who underwent cataract surgery were enrolled. Aqueous humor samples were collected from all subjects, and the 8-OHdG levels were determined by a commercially available enzyme-linked immunosorbent assay kit. The choroidal neovascularization (CNV) subtype was classified by fluorescein angiography. The macular lesion, including CNV membrane, exudation, and retinal hemorrhage, was measured. The correlation between 8-OHdG level and the clinical features was analyzed.
   RESULTS. The 8-OHdG level in the aqueous humor of AMD patients was significantly higher than it was in controls (0.581 +/- 0.258 ng/mL vs. 0.251 +/- 0.116 ng/mL; P < 0.001), after adjusting for age and lens status. There was no difference in the 8-OHdG levels between AMD patients with classic/predominantly classic and occult/minimally classic CNV (0.591 +/- 0.262 vs. 0.566 +/- 0.266 ng/mL; P = 0.639). The 8-OHdG level in aqueous humor was significantly correlated with the lesion size (rho = 0.492; P = 0.017).
   CONCLUSIONS. The 8-OHdG level in aqueous humor was higher in patients with exudative AMD, and the level was correlated with the area of macular lesion. This suggests that oxidative stress plays an important role in the disease course of AMD. (Invest Ophthalmol Vis Sci. 2010; 51: 5486-5490) DOI: 10.1167/iovs.10-5663
C1 [Wei, Yau-Huei] Natl Yang Ming Univ, Dept Biochem & Mol Biol, Sch Life Sci, Taipei 112, Taiwan.
   [Lau, Ling-Ing; Liu, Catherine Jui-ling] Natl Yang Ming Univ, Sch Med, Dept Ophthalmol, Taipei 112, Taiwan.
   [Wei, Yau-Huei] Mackay Med Coll, Dept Med, Taipei, Taiwan.
   [Lau, Ling-Ing; Liu, Catherine Jui-ling] Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Lau, Ling-Ing; Wei, Yau-Huei] Natl Yang Ming Univ, Sch Med, Inst Clin Med, Taipei 112, Taiwan.
C3 National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung
   University; Mackay Medical College; Taipei Veterans General Hospital;
   National Yang Ming Chiao Tung University
RP Wei, YH (通讯作者)，Natl Yang Ming Univ, Dept Biochem & Mol Biol, Sch Life Sci, 155 Li Nong St,Sect 2, Taipei 112, Taiwan.
EM joeman@ym.edu.tw
RI Wei, Yau-Huei/ABA-6841-2021
OI Wei, Yau-Huei/0000-0002-6429-2546; Lau, Ling-Ing/0000-0001-6956-1496
FU Taipei Veterans General Hospital [V95B1-018]; National Science Council
   [NSC 96-2314-B-075-050-MY2]
FX Supported by Taipei Veterans General Hospital Grant V95B1-018 and
   National Science Council Grant NSC 96-2314-B-075-050-MY2.
CR AMES BN, 1989, FREE RADICAL RES COM, V7, P121, DOI 10.3109/10715768909087933
   Bogdanov M, 2000, FREE RADICAL BIO MED, V29, P652, DOI 10.1016/S0891-5849(00)00349-X
   Chang D, 2008, BIOMED ENVIRON SCI, V21, P286, DOI 10.1016/S0895-3988(08)60043-4
   CHOW CK, 1986, J AM COLL NUTR, V5, P305
   CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003
   COHEN SM, 1994, BRIT J OPHTHALMOL, V78, P791, DOI 10.1136/bjo.78.10.791
   CUTLER RG, 1991, AM J CLIN NUTR, V53, pS373, DOI 10.1093/ajcn/53.1.373S
   Diakowska D, 2007, HEPATO-GASTROENTEROL, V54, P1701
   Dong A, 2006, J CELL PHYSIOL, V208, P516, DOI 10.1002/jcp.20683
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   DORRELL MI, 2009, J CLIN INVEST
   Evereklioglu C, 2003, DOC OPHTHALMOL, V106, P129, DOI 10.1023/A:1022512402811
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   Funatsu H, 2006, OPHTHALMOLOGY, V113, P294, DOI 10.1016/j.ophtha.2005.10.030
   Funatsu H, 2005, GRAEF ARCH CLIN EXP, V243, P3, DOI 10.1007/s00417-004-0950-7
   Gackowski D, 2008, J NEUROL SCI, V266, P57, DOI 10.1016/j.jns.2007.08.041
   GASS JDM, 1997, STEREOSCOPIC ATLAS M, P70
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Ihara Y, 2005, NEUROL RES, V27, P105, DOI 10.1179/016164105X18430
   Isobe C, 2010, J NEUROL, V257, P399, DOI 10.1007/s00415-009-5333-x
   Kanaya S, 2004, BIOFACTORS, V22, P255, DOI 10.1002/biof.5520220151
   Kannan R, 2006, MOL VIS, V12, P1649
   Kasai H, 1997, MUTAT RES-REV MUTAT, V387, P147, DOI 10.1016/S1383-5742(97)00035-5
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kau HC, 2006, EYE, V20, P826, DOI 10.1038/sj.eye.6702064
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kocur I, 2002, BRIT J OPHTHALMOL, V86, P716, DOI 10.1136/bjo.86.7.716
   Kondo T, 2001, HISTOCHEM J, V33, P647, DOI 10.1023/A:1016354417834
   LILES MR, 1991, ARCH OPHTHALMOL-CHIC, V109, P1285, DOI 10.1001/archopht.1991.01080090111033
   Loft S, 1999, METHOD ENZYMOL, V300, P166
   Loft S, 1998, ACTA BIOCHIM POL, V45, P133, DOI 10.18388/abp.1998_4328
   Mecocci P, 1999, FREE RADICAL BIO MED, V26, P303, DOI 10.1016/S0891-5849(98)00208-1
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Muratai T, 2008, FREE RADICAL RES, V42, P221, DOI 10.1080/10715760701877262
   Noma H, 2008, EYE, V22, P42, DOI 10.1038/sj.eye.6702498
   Okamoto A, 2006, MOL CELL BIOL, V26, P1087, DOI 10.1128/MCB.26.3.1087-1097.2006
   Rajesh M, 2003, CURR EYE RES, V27, P103, DOI 10.1076/ceyr.27.2.103.15951
   Sacca SC, 2005, ARCH OPHTHALMOL-CHIC, V123, P458, DOI 10.1001/archopht.123.4.458
   SHIGENAGA MK, 1989, P NATL ACAD SCI USA, V86, P9697, DOI 10.1073/pnas.86.24.9697
   SUZUKI J, 1995, FREE RADICAL BIO MED, V18, P431, DOI 10.1016/0891-5849(94)00152-A
   Suzuki K, 2003, J EPIDEMIOL, V13, P29, DOI 10.2188/jea.13.29
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   TATE DJ, 1993, INVEST OPHTH VIS SCI, V34, P2348
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Tsai CC, 2007, ARCH OPHTHALMOL-CHIC, V125, P1652, DOI 10.1001/archopht.125.12.1652
   Van Remmen H, 2003, EXERC SPORT SCI REV, V31, P149, DOI 10.1097/00003677-200307000-00009
   Wilson LA, 2005, FASEB J, V19, P2085, DOI 10.1096/fj.05-4401fje
   Yen MY, 2004, INVEST OPHTH VIS SCI, V45, P1688, DOI 10.1167/iovs.03-0568
   Yoshida R, 2002, CANCER EPIDEM BIOMAR, V11, P1076
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 52
TC 22
Z9 22
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2010
VL 51
IS 11
BP 5486
EP 5490
DI 10.1167/iovs.10-5663
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 672BQ
UT WOS:000283558400011
PM 20538979
DA 2022-11-30
ER

PT J
AU Lu, FT
   Liu, S
   Hao, QY
   Liu, LX
   Zhang, J
   Chen, XL
   Hu, W
   Huang, P
AF Lu, Feiteng
   Liu, Shuang
   Hao, Qingyun
   Liu, Lixia
   Zhang, Jing
   Chen, Xiaolong
   Hu, Wang
   Huang, Peng
TI Association Between Complement Factor C2/C3/CFB/CFH Polymorphisms and
   Age-Related Macular Degeneration: A Meta-Analysis
SO GENETIC TESTING AND MOLECULAR BIOMARKERS
LA English
DT Article
DE complement system; age-related macular degeneration; single nucleotide
   polymorphism; meta-analysis
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; FACTOR-H GENE; GENOME-WIDE
   ASSOCIATION; HAN CHINESE POPULATION; COMPONENT 2 C2; FACTOR-B BF;
   GEOGRAPHIC ATROPHY; DISEASE ASSOCIATIONS; JAPANESE POPULATION;
   CLINICAL-FEATURES
AB Background: Several previous studies have assessed the contribution of polymorphisms in genes encoding the complement factors C2/C3/CFB/CFH with the risk of age-related macular degeneration (AMD), however the results have been inconsistent. We conducted a meta-analysis to systematically review the potential association between complement factor polymorphisms and AMD. Methods: Studies that investigated associations between C2 (rs547154 and rs9332739), C3 (rs1047286), CFB (rs4151667 and rs641153), and CFH (rs551397 and rs2274700) polymorphisms and AMD were identified by searching PubMed, EMBASE, Web of Science, and Cochrane Library databases for articles published prior to January 1, 2018. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated to evaluate the association between these polymorphisms and AMD using Stata 12.0 software. Q and I-2 statistics were used to evaluate between-study heterogeneity. Publication bias analyses were conducted using Begg's test. We also conducted an ethnic subgroup analysis. Results: A total of 53 studies that included data for 53,774 patients and 56,973 healthy controls were evaluated. The pooled ORs for rs551397, rs2274700, rs4151667, rs641153, rs1047286, rs9332739, and rs547154 in the heterozygote model were 0.53 (95% CI: 0.45-0.61), 0.53 (95% CI: 0.40-0.70), 0.54 (95% CI: 0.46-0.63), 0.48 (95% CI: 0.4-0.57), 1.42 (95% CI: 1.22-1.66), 0.5 (95% CI: 0.45-0.56), and 0.52 (95% CI: 0.43-0.62), respectively. Conclusion: Our findings from this analysis confirmed the protective role of C2/CFB/CFH polymorphisms in the development of AMD, but showed that the single nucleotide polymorphism in C3 was a high-risk factor for AMD. The racial analysis results suggested that the effect of variant alleles was stronger in Caucasians than Asians.
C1 [Lu, Feiteng; Liu, Shuang; Hao, Qingyun] Nanchang Univ, Dept Biochem, Coll Med, Nanchang, Jiangxi, Peoples R China.
   [Liu, Lixia] Youhao Dist Peoples Hosp, Dept Internal Med, Yichun, Peoples R China.
   [Zhang, Jing] Nanchang Univ, Affiliated Hosp 2, Dept Clin Lab, Nanchang, Jiangxi, Peoples R China.
   [Chen, Xiaolong; Hu, Wang; Huang, Peng] Nanchang Univ, Sch Publ Hlth, Dept Epidemiol, 461 Bayi Rd, Nanchang 330006, Jiangxi, Peoples R China.
   [Huang, Peng] Nanchang Univ, Sch Publ Hlth, Jiangxi Prov Key Lab Prevent Med, Nanchang, Jiangxi, Peoples R China.
C3 Nanchang University; Nanchang University; Nanchang University; Nanchang
   University
RP Huang, P (通讯作者)，Nanchang Univ, Sch Publ Hlth, Dept Epidemiol, 461 Bayi Rd, Nanchang 330006, Jiangxi, Peoples R China.
EM huangpengncu@163.com
CR Babanejad M, 2016, OPHTHALMIC GENET, V37, P144, DOI 10.3109/13816810.2014.955585
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Butler JM, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3964-3
   Caire J, 2014, JAMA OPHTHALMOL, V132, P528, DOI 10.1001/jamaophthalmol.2013.8175
   Cantsilieris Stuart, 2009, Recent Pat DNA Gene Seq, V3, P102
   Chen JH, 2013, MOL VIS, V19, P944
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Chu J, 2008, CHINESE MED J-PEKING, V121, P2525, DOI 10.1097/00029330-200812020-00011
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Contreras AV, 2014, MOL VIS, V20, P105
   Craddock N, 2008, MOL PSYCHIATR, V13, P649, DOI 10.1038/mp.2008.45
   Cui L, 2010, INVEST OPHTH VIS SCI, V51, P1116, DOI 10.1167/iovs.09-4265
   de Cordoba SR, 2008, CLIN EXP IMMUNOL, V151, P1, DOI 10.1111/j.1365-2249.2007.03574.x
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Duvvari MR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094165
   Edwards AO, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003813
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Farwick A, 2009, EYE, V23, P2238, DOI 10.1038/eye.2008.426
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   de Almeida LNF, 2009, ARQ BRAS OFTALMOL, V72, P567, DOI 10.1590/S0004-27492009000400027
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hampton T, 2010, JAMA-J AM MED ASSOC, V304, P1541, DOI 10.1001/jama.2010.1411
   Havvas O, 2014, EUR J OPHTHALMOL, V24, P751, DOI 10.5301/ejo.5000427
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Huang L, 2015, EYE, V29, P691, DOI 10.1038/eye.2015.32
   Huang LZ, 2014, INVEST OPHTH VIS SCI, V55, P2534, DOI 10.1167/iovs.13-13437
   Ingram G, 2009, CLIN EXP IMMUNOL, V155, P128, DOI 10.1111/j.1365-2249.2008.03830.x
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Kaur I, 2010, INVEST OPHTH VIS SCI, V51, P59, DOI 10.1167/iovs.09-4135
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kim SJ, 2012, EXP EYE RES, V96, P42, DOI 10.1016/j.exer.2012.01.005
   Kim YH, 2013, OPHTHALMIC GENET, V34, P151, DOI 10.3109/13816810.2012.749287
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Loyet KM, 2012, INVEST OPHTH VIS SCI, V53, P6628, DOI 10.1167/iovs.12-9587
   Lu F, 2013, INVEST OPHTH VIS SCI, V54, P2911, DOI 10.1167/iovs.12-11381
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Martinez-Barricarte R, 2012, INVEST OPHTH VIS SCI, V53, P1087, DOI 10.1167/iovs.11-8709
   McKay GJ, 2009, INVEST OPHTH VIS SCI, V50, P533, DOI 10.1167/iovs.08-2275
   Merle BMJ, 2016, AM J CLIN NUTR, V103, P1135, DOI 10.3945/ajcn.115.117606
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P794, DOI 10.1167/iovs.11-8468
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Park KH, 2009, INVEST OPHTH VIS SCI, V50, P3386, DOI 10.1167/iovs.08-3231
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Pei XT, 2009, CURR EYE RES, V34, P615, DOI 10.1080/02713680903003484
   Restrepo NA, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14246
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Richardson AJ, 2009, INVEST OPHTH VIS SCI, V50, P540, DOI 10.1167/iovs.08-2423
   Rodriguez E, 2014, BIOSCIENCE REP, V34, P635, DOI 10.1042/BSR20140117
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGE, V107, P1016, DOI 10.1007/s00347-010-2160-5
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Seddon JM, 2016, BRIT J OPHTHALMOL, V100, P1731, DOI 10.1136/bjophthalmol-2016-308624
   Seddon JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087047
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Sun C, 2012, CURR EYE RES, V37, P259, DOI 10.3109/02713683.2011.635401
   Tanaka K, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-83
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Wang ZY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088324
   Wu L, 2013, INVEST OPHTH VIS SCI, V54, P170, DOI 10.1167/iovs.12-10453
   Wu MX, 2016, OPHTHALMIC RES, V55, P135, DOI 10.1159/000442257
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu QQ, 2015, GENE, V561, P249, DOI 10.1016/j.gene.2015.02.039
   Zhuang WJ, 2014, OPHTHALMIC GENET, V35, P156, DOI 10.3109/13816810.2014.921314
NR 81
TC 15
Z9 15
U1 0
U2 9
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1945-0265
EI 1945-0257
J9 GENET TEST MOL BIOMA
JI Genet. Test. Mol. Biomark.
PD SEP
PY 2018
VL 22
IS 9
BP 526
EP 540
DI 10.1089/gtmb.2018.0110
PG 15
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA GU1ZB
UT WOS:000445065700004
PM 30179527
DA 2022-11-30
ER

PT J
AU Mockute, R
   Vilkeviciute, A
   Balciuniene, VJ
   Zemaitiene, R
   Liutkeviciene, R
AF Mockute, Ruta
   Vilkeviciute, Alvita
   Balciuniene, Vilma Jurate
   Zemaitiene, Reda
   Liutkeviciene, Rasa
TI ABCA1 rs1883025 and CYP4F2 rs2108622 Gene Polymorphism Association with
   Age-Related Macular Degeneration and Anti-VEGF Treatment
SO MEDICINA-LITHUANIA
LA English
DT Article
DE age-related macular degeneration; rs2108622; rs1883025; gene
   polymorphisms; allele; retinal diseases
ID PREVALENCE; RISK; INTERMEDIATE; CHOLESTEROL; METABOLISM; VARIANTS;
   DEPOSITS; DRUSEN; IMPACT; LIPIDS
AB Background and Objectives: The age-related macular degeneration (AMD) pathophysiology is multifactorial, as it consists of interactions between aging, genetic, and environmental factors. We aimed to determine a relationship between AMD and the genes controlling lipid metabolism, and to assess its association with treatment results. The purpose was to find the ABCA1 rs1883025 and CYP4F2 rs2108622 gene polymorphisms in patients with exudative AMD (eAMD) treated with anti-VEGF. Materials and Methods: The study enroled 104 patients with eAMD and 201 healthy persons in a control group. The genotyping of rs1883025 and rs2108622 was performed using the RT-PCR method. The best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were measured before anti-VEGF therapy, then at three and six months during the therapy, using optical coherence tomography (OCT). The patients were grouped to responders and non-responders according to the changes in BCVA and CRT. Results: The T allele at rs1883025 was more frequent in non-responder eAMD patients compared to responder eAMD patients (41.7% vs. 21.1%; p = 0.009). The analysis of rs2108622 gene polymorphism did not reveal any differences in the distribution of C/C, C/T, and T/T genotypes between the eAMD group and the control group (56.35%, 39.78%, and 3.87% in the eAMD group and 53.33%, 39.05% and 7.62% in the control group, respectively, p = 0.286). The comparison of CRT and BCVA between the rs2108622 genotypes revealed statistically significant differences: CRT was thicker for the CC carriers than for those with CT and TT genotypes (p = 0.030). Conclusion: The rs1883025 T allele was found to play a more significant role in non-responder eAMD patients compared to responder eAMD patients. The rs2108622 genotypes revealed statistically significant differences: CRT was thicker for the CC carriers than for those with CT and TT genotypes.
C1 [Mockute, Ruta; Balciuniene, Vilma Jurate; Zemaitiene, Reda; Liutkeviciene, Rasa] Lithuanian Univ Hlth Sci, Dept Ophthalmol, Med Acad, Eiveniu 2, LT-50009 Kaunas, Lithuania.
   [Vilkeviciute, Alvita; Liutkeviciene, Rasa] Lithuanian Univ Hlth Sci, Neurosci Inst, Med Acad, Eiveniu 2, LT-50009 Kaunas, Lithuania.
C3 Lithuanian University of Health Sciences; Lithuanian University of
   Health Sciences
RP Mockute, R (通讯作者)，Lithuanian Univ Hlth Sci, Dept Ophthalmol, Med Acad, Eiveniu 2, LT-50009 Kaunas, Lithuania.
EM rutikess@gmail.com; alvita.vilkeviciute@lsmuni.lt;
   jurate.balciuniene@kaunoklinikos.lt; reda.zemaitiene@lsmuni.lt;
   rasa.liutkeviciene@lsmuni.lt
FU Research Council of Lithuania [SEN-11/2015]
FX This research was funded by a grant (No. SEN-11/2015) from the Research
   Council of Lithuania.
CR Bretillon L, 2008, INVEST OPHTH VIS SCI, V49, P1307, DOI 10.1167/iovs.07-0808
   Chen GH, 2015, SCI REP-UK, V5, DOI 10.1038/srep14517
   Chen H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042464
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Dashti N, 2006, BRIT J OPHTHALMOL, V90, P1028, DOI 10.1136/bjo.2006.093856
   Fava C, 2012, PROSTAG OTH LIPID M, V98, P75, DOI 10.1016/j.prostaglandins.2011.11.007
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fliesler SJ, 2010, J LIPID RES, V51, P3399, DOI 10.1194/jlr.R010538
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Gess AJ, 2011, SEMIN OPHTHALMOL, V26, P225, DOI 10.3109/08820538.2011.582533
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grassmann F, 2017, GENETICS, V205, P919, DOI 10.1534/genetics.116.195966
   Hasegawa E, 2017, P NATL ACAD SCI USA, V114, pE7545, DOI 10.1073/pnas.1620898114
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   Kubicka-Trzaska Agnieszka, 2016, Klin Oczna, V118, P114
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   Li FT, 2014, OPHTHALMIC RES, V51, P210, DOI 10.1159/000357978
   Li Ge, 2013, IUBMB Life, V65, P505, DOI [10.1002/iub.01165, 10.1002/iub.1165]
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Moreira EF, 2009, INVEST OPHTH VIS SCI, V50, P523, DOI 10.1167/iovs.08-2373
   Oram JF, 2005, PHYSIOL REV, V85, P1343, DOI 10.1152/physrev.00005.2005
   Rendic S, 2015, CHEM RES TOXICOL, V28, P38, DOI 10.1021/tx500444e
   Sakiene Ruta, 2016, Adv Med, V2016, P3917916, DOI 10.1155/2016/3917916
   Singaraja RR, 2003, ARTERIOSCL THROM VAS, V23, P1322, DOI 10.1161/01.ATV.0000078520.89539.77
   Stewart JM, 2003, INVEST OPHTH VIS SCI, V44, pU401
   Storti F, 2019, ELIFE, V8, DOI 10.7554/eLife.45100
   Tatarunas V, 2017, BLOOD COAGUL FIBRIN, V28, P658, DOI 10.1097/MBC.0000000000000658
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Vilkeviciute A, 2020, IN VIVO, V34, P2443, DOI 10.21873/invivo.12059
   Waldman M, 2016, PROSTAG OTH LIPID M, V125, P108, DOI 10.1016/j.prostaglandins.2016.05.007
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang YF, 2016, GRAEF ARCH CLIN EXP, V254, P323, DOI 10.1007/s00417-015-3211-z
   Wickremasinghe SS, 2011, INVEST OPHTH VIS SCI, V52, P4072, DOI 10.1167/iovs.10-6550
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zheng WC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037926
   Zhou YL, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0487-2
NR 43
TC 1
Z9 1
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1010-660X
EI 1648-9144
J9 MEDICINA-LITHUANIA
JI Med. Lith.
PD SEP
PY 2021
VL 57
IS 9
AR 974
DI 10.3390/medicina57090974
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA UV8JK
UT WOS:000699717200001
PM 34577897
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Treder, M
   Lauermann, JL
   Eter, N
AF Treder, Maximilian
   Lauermann, Jost Lennart
   Eter, Nicole
TI Automated detection of exudative age-related macular degeneration in
   spectral domain optical coherence tomography using deep learning
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Deeplearning; Age-related macular degeneration; Deep convolutional
   neural network; Optical coherencetomography; Machine learning
ID DIABETIC-RETINOPATHY
AB Our purpose was to use deep learning for the automated detection of age-related macular degeneration (AMD) in spectral domain optical coherence tomography (SD-OCT).
   A total of 1112 cross-section SD-OCT images of patients with exudative AMD and a healthy control group were used for this study. In the first step, an open-source multi-layer deep convolutional neural network (DCNN), which was pretrained with 1.2 million images from ImageNet, was trained and validated with 1012 cross-section SD-OCT scans (AMD: 701; healthy: 311). During this procedure training accuracy, validation accuracy and cross-entropy were computed. The open-source deep learning framework TensorFlow (TM) (Google Inc., Mountain View, CA, USA) was used to accelerate the deep learning process. In the last step, a created DCNN classifier, using the information of the above mentioned deep learning process, was tested in detecting 100 untrained cross-section SD-OCT images (AMD: 50; healthy: 50). Therefore, an AMD testing score was computed: 0.98 or higher was presumed for AMD.
   After an iteration of 500 training steps, the training accuracy and validation accuracies were 100%, and the cross-entropy was 0.005. The average AMD scores were 0.997 +/- 0.003 in the AMD testing group and 0.9203 +/- 0.085 in the healthy comparison group. The difference between the two groups was highly significant (p < 0.001).
   With a deep learning-based approach using TensorFlow (TM), it is possible to detect AMD in SD-OCT with high sensitivity and specificity. With more image data, an expansion of this classifier for other macular diseases or further details in AMD is possible, suggesting an application for this model as a support in clinical decisions. Another possible future application would involve the individual prediction of the progress and success of therapy for different diseases by automatically detecting hidden image information.
C1 [Treder, Maximilian; Lauermann, Jost Lennart; Eter, Nicole] Univ Munster, Med Ctr, Dept Ophthalmol, Domagkstr 15, D-48149 Munster, Germany.
C3 University of Munster
RP Treder, M (通讯作者)，Univ Munster, Med Ctr, Dept Ophthalmol, Domagkstr 15, D-48149 Munster, Germany.
EM maximilian.treder@ukmuenster.de
CR Abadi M., 2016, TENSORFLOW LARGE SCA
   Abramoff MD, 2016, INVEST OPHTH VIS SCI, V57, P5200, DOI 10.1167/iovs.16-19964
   Alsaih K, 2017, BIOMED ENG ONLINE, V16, DOI 10.1186/s12938-017-0352-9
   Angermueller C, 2016, MOL SYST BIOL, V12, DOI 10.15252/msb.20156651
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, P3240, DOI 10.1167/iovs.16-21053
   Burlina P, 2017, COMPUT BIOL MED, V82, P80, DOI 10.1016/j.compbiomed.2017.01.018
   Chou CF, 2013, AM J PREV MED, V45, P29, DOI 10.1016/j.amepre.2013.02.018
   Cicinelli MV, 2017, SURV OPHTHALMOL
   Deng J, 2009, PROC CVPR IEEE, P248, DOI 10.1109/CVPRW.2009.5206848
   ElTanboly A, 2017, MED PHYS, V44, P914, DOI 10.1002/mp.12071
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gao SS, 2017, BIOMED OPT EXPRESS, V8, P48, DOI 10.1364/BOE.8.000048
   Gerendas BS, 2017, VISION RES, V139, P204, DOI 10.1016/j.visres.2017.03.008
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Kim SJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177726
   Lakhani P, 2017, RADIOLOGY, V284, P574, DOI 10.1148/radiol.2017162326
   Lim Eun-Hae, 2013, Korean J Ophthalmol, V27, P351, DOI 10.3341/kjo.2013.27.5.351
   Miri MS, 2017, MED IMAGE ANAL, V39, P206, DOI 10.1016/j.media.2017.04.007
   Montuoro A, 2017, BIOMED OPT EXPRESS, V8, P1874, DOI 10.1364/BOE.8.001874
   Murugeswari S, 2017, IRISH J MED SCI, V186, P929, DOI 10.1007/s11845-017-1598-8
   Rampasek L, 2016, CELL SYST, V2, P12, DOI 10.1016/j.cels.2016.01.009
   Regatieri Caio V, 2011, Ophthalmic Surg Lasers Imaging, V42 Suppl, pS56, DOI 10.3928/15428877-20110627-05
   Szegedy C., 2016, 2016 IEEE C COMPUTER, P2818, DOI DOI 10.1109/CVPR.2016.308
   van Ginneken B, 2017, RADIOL PHYS TECHNOL, V10, P23, DOI 10.1007/s12194-017-0394-5
   Venhuizen FG, 2017, INVEST OPHTH VIS SCI, V58, P2318, DOI 10.1167/iovs.16-20541
   Vogl WD, 2017, IEEE T MED IMAGING, V36, P1773, DOI 10.1109/TMI.2017.2700213
   Waldstein SM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02971-y
   Wang Y, 2016, BIOMED OPT EXPRESS, V7, P4928, DOI 10.1364/BOE.7.004928
NR 29
TC 117
Z9 124
U1 5
U2 83
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD FEB
PY 2018
VL 256
IS 2
BP 259
EP 265
DI 10.1007/s00417-017-3850-3
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FU2WB
UT WOS:000423709600004
PM 29159541
DA 2022-11-30
ER

PT J
AU Pertile, G
   Claes, C
AF Pertile, G
   Claes, C
TI Macular translocation with 360 degree retinotomy for management of
   age-related macular degeneration with subfoveal choroidal
   neovascularization
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL SEPARATION; SURGICAL REMOVAL; MEMBRANES; RELOCATION
AB PURPOSE: The aim of this study is to evaluate the functional outcome in a group of patients treated with full macular translocation (FMT) with 360,degree retinotomy for treatment of age,related macular degeneration (ARMD) with subfoveal choroidal neovascularization.
   DESIGN: Consecutive interventional case series.
   METHODS: Fifty consecutive eyes (50 patients) with ARMD and subfoveal neovascularization who under. went a FMT in our department from January 1999 to July 2000 are included in this study. Compensatory muscle surgery, as described by Eckardt and associates, was performed on all the eyes. The median follow-up is 21 months (range, 12 to 36; SD, 5.4).
   RESULTS: The best corrected postoperative visual acuity (BCVA) was improved by 2 or more Snellen lines in 33 eyes (66%) and remained stable (+/- 1 line) in 14 eyes (28%). Only 3 eyes (6%) experienced a deterioration of the BCVA of 2 or more lines. The final BCVA was 20/50 or better in 32% of the cases; only 8 eyes (16%) had a final BCVA < 20/200. Thirty-four (68%) patients are able to read newspaper print (3.3/10) with normal (+3 diopters to +4 diopters) or increased (+5 diopters to +8 diopters) reading ads. Other patients are able to read with magnifying systems. Complications included proliferative vitreoretinopathy (PVR) in 9 eyes (18%), recurrent choroidal neovascularization in 5 eyes (10%), diplopia in 3 eyes (6%), choroidal hemorrhage in 2 eyes (4%), macular hole in 1 eye, and temporary hypotony in 1 eye.
   CONCLUSIONS: As 68% of the patients in the study group regained reading vision with reading glasses, FMT can be considered an effective approach in cases of subfoveal choroidal neovascularization. Further investigations are necessary to determine which patients will have the most benefit from this complex therapeutic method. (C) 2002 by Elsevier Science Inc. All rights reserved.
C1 Middelheim Hosp, Zivojnov Fdn, Dept Ophthalmol, B-2020 Antwerp, Belgium.
C3 ZNA Middelheim Hospital
RP Pertile, G (通讯作者)，Middelheim Hosp, Zivojnov Fdn, Dept Ophthalmol, B-2020 Antwerp, Belgium.
RI Pertile, Grazia/AAC-4956-2022
CR Akduman L, 1999, RETINA-J RET VIT DIS, V19, P418, DOI 10.1097/00006982-199909000-00009
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Eckardt U, 1998, KLIN MONATSBL AUGENH, V212, P212, DOI 10.1055/s-2008-1034867
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   Fujii GY, 2000, AM J OPHTHALMOL, V130, P751, DOI 10.1016/S0002-9394(00)00771-6
   Glacet-Bernard A, 2001, AM J OPHTHALMOL, V131, P78, DOI 10.1016/S0002-9394(00)00733-9
   Lumme P, 1994, Eur J Ophthalmol, V4, P151
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P629, DOI 10.1007/BF00921956
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Ninomiya Y, 1996, AM J OPHTHALMOL, V122, P613, DOI 10.1016/S0002-9394(14)70479-9
   ORMEROD LD, 1994, OPHTHALMOLOGY, V101, P1201
   Pastor JC, 1998, SURV OPHTHALMOL, V43, P3, DOI 10.1016/S0039-6257(98)00023-X
   Pollack AL, 2001, AM J OPHTHALMOL, V132, P383, DOI 10.1016/S0002-9394(01)01049-2
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   SINGERMAN LJ, 1989, GRAEF ARCH CLIN EXP, V227, P501, DOI 10.1007/BF02169440
   THOMAS MA, 1994, OPHTHALMOLOGY, V101, P1384
   YANNUZZI LA, 1994, ARCH OPHTHALMOL-CHIC, V112, P462, DOI 10.1001/archopht.1994.01090160038019
NR 23
TC 71
Z9 73
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2002
VL 134
IS 4
BP 560
EP 565
AR PII S0002-9394(02)01641-0
DI 10.1016/S0002-9394(02)01641-0
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 601KY
UT WOS:000178446100009
PM 12383813
DA 2022-11-30
ER

PT J
AU Chaikitmongkol, V
   Kong, J
   Khunsongkiet, P
   Patikulsila, D
   Sachdeva, M
   Chavengsaksongkram, P
   Dejkriengkraikul, C
   Winaikosol, P
   Choovuthayakorn, J
   Watanachai, N
   Kunavisarut, P
   Ingviya, T
   Bressler, NM
AF Chaikitmongkol, Voraporn
   Kong, Jun
   Khunsongkiet, Preeyanuch
   Patikulsila, Direk
   Sachdeva, Mira
   Chavengsaksongkram, Pimploy
   Dejkriengkraikul, Chutikarn
   Winaikosol, Pawara
   Choovuthayakorn, Janejit
   Watanachai, Nawat
   Kunavisarut, Paradee
   Ingviya, Thammasin
   Bressler, Neil M.
TI Sensitivity and Specificity of Potential Diagnostic Features Detected
   Using Fundus Photography, Optical Coherence Tomography, and Fluorescein
   Angiography for Polypoidal Choroidal Vasculopathy
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION
AB ImportanceThe use of indocyanine green angiography (ICGA) is a criterion standard for diagnosing polypoidal choroidal vasculopathy (PCV), an endemic and common cause of vision loss in Asian and African individuals that also presents in white individuals. However, the use of ICGA is expensive, invasive, and not always available at clinical centers. Therefore, knowing the value of certain features detected using fundus photography (FP), optical coherence tomography (OCT), and fluorescein angiography (FA) to diagnose PCV without ICGA could assist ophthalmologists to identify PCV when ICGA is not readily available. ObjectiveTo explore the sensitivity, specificity, and predictive accuracy of potential diagnostic features detected using FP, OCT, and FA in diagnosing PCV without ICGA. Design, Setting, and ParticipantsDeidentified images of FP alone, OCT alone, and FA alone were graded by 3 retina specialists masked to ICGA findings for potentially diagnostic features of PCV prespecified before grading compared with the criterion standard grading of 2 other retina specialists with access simultaneously to FP, OCT, FA and ICGA. Specialists graded images of 124 eyes of 120 patients presenting between January 1, 2013, and December 31, 2016, with newly identified serous or serosanguinous maculopathy who had undergone FP, OCT, FA, and ICGA before treatment at a large referral eye center in Thailand. Main Outcomes and MeasuresSensitivity, specificity, positive predictive value, negative predictive value, and predictive accuracy from the area under the receiver operating characteristic curve (AUC). ResultsThe mean (SD) age of the patients was 57.7 (12.6) years, 52 were women, 68 were men, and the diagnosis (from ICGA) was PCV for 65 eyes (52.4%), central serous chorioretinopathy for 45 eyes (36.3%), and typical neovascular age-related macular degeneration for 12 eyes (9.7%). With the use of FP, a potential diagnostic feature for PCV was notched or hemorrhagic pigment epithelial detachment (AUC, 0.77; 95% CI, 0.70-0.85). With the use of OCT, potential diagnostic features for PCV were pigment epithelial detachment notch (AUC, 0.90; 95% CI, 0.85-0.96), sharply peaked pigment epithelial detachment (AUC, 0.86; 95% CI, 0.80-0.92), and a hyperreflective ring (AUC, 0.86; 95% CI, 0.80-0.92). When at least 2 of these 4 signs were present, the AUC was 0.93 (95% CI, 0.89-0.98), with a sensitivity of 0.95 (95% CI, 0.87-0.99), a specificity of 0.95 (95% CI, 0.82-0.97), a positive predictive value of 0.92 (95% CI, 0.83-0.97), and a negative predictive value of 0.95 (95% CI, 0.86-0.99). Conclusions and RelevanceThese data suggest that the potential diagnostic features detected using FP and OCT provide high sensitivity and specificity for a diagnosis of PCV, especially when at least 2 of 4 highly suggestive signs are present.
   This cohort study explores the sensitivity, specificity, and predictive accuracy of potential diagnostic features detected using fundus photography, optical coherence tomography, and fluorescein angiography in diagnosing polypoidal choroidal vasculopathy without indocyanine green angiography.
   Key PointsQuestionWhat are the potential diagnostic features detected using fundus photography, optical coherence tomography, and fluorescein angiography for polypoidal choroidal vasculopathy without the use of indocyanine green angiography? FindingsIn this cohort study, when at least 2 of the following 4 potential diagnostic signs were graded on deidentified images without the use of indocyanine green angiography, high sensitivity and specificity were noted: notched or hemorrhagic pigment epithelial detachment detected using fundus photography or optical coherence tomography and a sharply peaked pigment epithelial detachment or a hyperreflective ring detected using optical coherence tomography. MeaningThese data suggest that fundus photography and optical coherence tomography provide high sensitivity and specificity for polypoidal choroidal vasculopathy without the use of indocyanine green angiography, especially when at least 2 of 4 highly suggestive signs are present.
C1 [Chaikitmongkol, Voraporn; Khunsongkiet, Preeyanuch; Patikulsila, Direk; Chavengsaksongkram, Pimploy; Choovuthayakorn, Janejit; Watanachai, Nawat; Kunavisarut, Paradee] Chiang Mai Univ, Retina Div, Dept Ophthalmol, Chiang Mai, Thailand.
   [Kong, Jun; Sachdeva, Mira; Bressler, Neil M.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div, Baltimore, MD 21205 USA.
   [Dejkriengkraikul, Chutikarn; Winaikosol, Pawara] Chiang Mai Univ, Dept Ophthalmol, Fac Med, Chiang Mai, Thailand.
   [Ingviya, Thammasin] Prince Songkla Univ, Fac Med, Dept Family Med & Prevent Med, Hat Yai, Thailand.
   [Bressler, Neil M.] JAMA Ophthalmol, Chicago, IL USA.
C3 Chiang Mai University; Johns Hopkins University; Johns Hopkins Medicine;
   Chiang Mai University; Prince of Songkla University
RP Bressler, NM (通讯作者)，Johns Hopkins Univ, Retina Div, Wilmer Eye Inst, 600 NWolfe St,Maumenee 752, Baltimore, MD 21287 USA.
EM nmboffice@jhmi.edu
RI Watanachai, Nawat/AAR-9240-2020
OI Choovuthayakorn, Janejit/0000-0001-5972-0270
FU Research Committee, Faculty of Medicine, Chiang Mai University; James P.
   Gills Professorship; China Research Council
FX This work was supported in part by Research Committee, Faculty of
   Medicine, Chiang Mai University; the James P. Gills Professorship, the
   China Research Council; and unrestricted research funds to the Johns
   Hopkins University School of Medicine Retina Division for Macular
   Degeneration and Related Diseases Research.
CR Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Chaikitmongkol V, 2018, AM J OPHTHALMOL, V192, P77, DOI 10.1016/j.ajo.2018.05.005
   de Carlo TE, 2018, RETINA, DOI [10.1097/IAE.0000000000002139, DOI 10.1097/IAE.000000000000213929561386]
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Tan CS, 2017, JAMA OPHTHALMOL, V135, P1316, DOI 10.1001/jamaophthalmol.2017.4453
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Venables W.N., 2002, MODERN APPL STAT S, DOI 10.1007/978-0-387-21706-2
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
NR 14
TC 28
Z9 28
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUN
PY 2019
VL 137
IS 6
BP 661
EP 667
DI 10.1001/jamaophthalmol.2019.0565
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ID5XL
UT WOS:000471750500014
PM 30973593
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Cao, YQ
   Li, XY
   Tchivelekete, GM
   Li, X
   Zhou, XZ
   He, ZM
   Reilly, J
   Tan, ZJ
   Shu, XH
AF Cao, Yanqun
   Li, Xiao-Ya
   Tchivelekete, Gabriel Mbuta
   Li, Xing
   Zhou, Xinzhi
   He, Zhiming
   Reilly, James
   Tan, Zhoujin
   Shu, Xinhua
TI Bioinformatical and Biochemical Analyses on the Protective Role of
   Traditional Chinese Medicine against Age-Related Macular Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration (AMD); anti-AMD Decoction; network
   pharmacology; oxidative stress; inflammation
ID INFLAMMATION; LUTEOLIN; NETWORKS
AB Purpose Age-related macular degeneration (AMD) is the commonest cause of permanent vision loss in the elderly. Traditional Chinese medicine (TCM) has long been used to treat AMD, although the underlying functional mechanisms are not understood. This study aims to predict the active ingredients through screening the chemical ingredients of anti-AMD decoction and to elucidate the underlying mechanisms. Methods We collected the prescriptions for effective AMD treatment with traditional Chinese medicine and screened several Chinese medicines that were used most frequently in order to compose "anti-AMD decoction." The pharmacologically active ingredients and corresponding targets in this anti-AMD decoction were mined using the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database. Subsequently, the AMD-related targets were identified through the GeneCards database. Network pharmacology was performed to construct the visual network of anti-AMD decoction-AMD protein-protein interaction (PPI). Further, the Autodock software was adopted for molecular docking on the core active ingredients and core targets. The function of core ingredients against oxidative stress and inflammation in retinal pigment epithelial cells was assessed using biochemical assays. Results We screened out 268 active ingredients in anti-AMD decoction corresponding to 258 ingredient targets, combined with 2160 disease targets in AMD, and obtained 129 drug-disease common targets. The key core proteins were predominantly involved in inflammation. Furthermore, molecular docking showed that four potential active ingredients (Quercetin, luteolin, naringenin and hederagenin) had good affinity with the core proteins, IL-6, TNF, VEGFA and MAPK3. Quercetin, luteolin and naringenin demonstrated capacities against oxidative stress and inflammation in human retinal pigment epithelial cells. Conclusions The data suggests that anti-AMD decoction has multiple functional components and targets in treating AMD, possibly mediated by suppression of oxidative stress and inflammation.
C1 [Cao, Yanqun; Li, Xing; He, Zhiming; Shu, Xinhua] Shaoyang Univ, Sch Basic Med Sci, Shaoyang, Hunan, Peoples R China.
   [Li, Xiao-Ya; Tan, Zhoujin] Hunan Univ Chinese Med, Coll Chinese Med, Changsha, Hunan, Peoples R China.
   [Tchivelekete, Gabriel Mbuta; Zhou, Xinzhi; Reilly, James; Shu, Xinhua] Glasgow Caledonian Univ, Dept Biol & Biomed Sci, Glasgow, Lanark, Scotland.
   [Tchivelekete, Gabriel Mbuta] Univ Namibe, Fac Nat Sci, Dept Marine Biol, Namibe, Angola.
C3 Shaoyang University; Hunan University of Chinese Medicine; Glasgow
   Caledonian University
RP Shu, XH (通讯作者)，Shaoyang Univ, Sch Basic Med Sci, Shaoyang, Hunan, Peoples R China.; Tan, ZJ (通讯作者)，Hunan Univ Chinese Med, Coll Chinese Med, Changsha, Hunan, Peoples R China.
EM tanzhjin@sohu.com; Xinhua.Shu@gcu.ac.uk
RI Tan, Zhoujin/V-9258-2019
OI Tan, Zhoujin/0000-0003-3193-073X
FU Lotus Scholarship Program of Hunan Province [2019]; Rosetrees Trust
   [M160, M160-F1, M160-F2]; Sight Research UK [SAC037]; TENOVUS Scotland
   [S20-02]; Chief Scientist Office/the RS Macdonald Charitable Trust
   [SNRF2021]
FX This work was partially supported by the Lotus Scholarship Program of
   Hunan Province [2019], the Rosetrees Trust [M160, M160-F1, M160-F2],
   Sight Research UK [SAC037], TENOVUS Scotland [S20-02] and the Chief
   Scientist Office/the RS Macdonald Charitable Trust [SNRF2021].
CR Alhasani RH, 2018, FOOD CHEM TOXICOL, V112, P76, DOI 10.1016/j.fct.2017.12.037
   Anand David Alexander Victor, 2016, Pharmacogn Rev, V10, P84, DOI 10.4103/0973-7847.194044
   Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x
   Boeing T, 2020, BRIT J PHARMACOL, V177, P2393, DOI 10.1111/bph.14987
   Boezio B, 2017, MOL INFORM, V36, DOI 10.1002/minf.201700048
   Da Pozzo E, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9536148
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Franz M, 2016, BIOINFORMATICS, V32, P309, DOI 10.1093/bioinformatics/btv557
   Gerdes EOW, 2021, MECH AGEING DEV, V200, DOI 10.1016/j.mad.2021.111591
   Goodsell DS, 2020, PROTEIN SCI, V29, P52, DOI 10.1002/pro.3730
   Gopinath B, 2018, J ACAD NUTR DIET, V118, P2311, DOI 10.1016/j.jand.2018.07.012
   Guo X, 2020, INT IMMUNOPHARMACOL, V80, DOI 10.1016/j.intimp.2020.106201
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Huang C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184880
   Hytti M, 2017, J NUTR BIOCHEM, V42, P37, DOI 10.1016/j.jnutbio.2016.12.014
   Hytti M, 2015, SCI REP-UK, V5, DOI 10.1038/srep17645
   Jiang YH, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00512
   Jiao XY, 2021, COMPUT BIOL CHEM, V90, DOI 10.1016/j.compbiolchem.2020.107402
   Kim J, 2018, FOOD FUNCT, V9, P2171, DOI 10.1039/c7fo01958k
   Lee M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112497
   Li YB, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/6012761
   Li YL, 2022, J ETHNOPHARMACOL, V282, DOI 10.1016/j.jep.2021.114531
   Liu JJ, 2019, MED SCI MONITOR, V25, P7735, DOI 10.12659/MSM.919768
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758-2946-6-13
   Salvamani Shamala, 2014, Biomed Res Int, V2014, P480258, DOI 10.1155/2014/480258
   Shen Y, 2010, INT J OPHTHALMOL-CHI, V3, P5, DOI 10.3980/j.issn.2222-3959.2010.01.02
   Song YN, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9100591
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003
   Tohari AM, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8090341
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu JL, 2019, DRUG DES DEV THER, V13, P2413, DOI 10.2147/DDDT.S206355
   Zhang WJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep32400
   Zhang X, 2021, BRIT J PHARMACOL, V178, P3205, DOI 10.1111/bph.15391
   Zhao YS, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/1459497
   Zhou W, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020246
   Zhu RZ, 2021, KOREAN J PHYSIOL PHA, V25, P297, DOI 10.4196/kjpp.2021.25.4.297
   Zoico E, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-02544-0
NR 40
TC 0
Z9 0
U1 4
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD OCT 3
PY 2022
VL 47
IS 10
BP 1450
EP 1462
DI 10.1080/02713683.2022.2108456
EA AUG 2022
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4S2VV
UT WOS:000843076900001
PM 35947018
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Huang, C
   Xu, YS
   Li, XM
   Wang, W
AF Huang, Chen
   Xu, Yongsheng
   Li, Xuemin
   Wang, Wei
TI Vascular endothelial growth factor A polymorphisms and age-related
   macular degeneration: a systematic review and meta-analysis
SO MOLECULAR VISION
LA English
DT Review
ID FACTOR GENE POLYMORPHISMS; CHOROIDAL NEOVASCULARIZATION; VEGF GENE;
   ASSOCIATION; HETEROGENEITY; RANIBIZUMAB; BEVACIZUMAB; MACULOPATHY;
   POPULATION; PEGAPTANIB
AB Purpose: In the present work, the aim was to systematically review all studies about the association of vascular endothelial growth factor A (VEGF-A) polymorphisms with age-related macular degeneration (AMD) and to perform a meta-analysis.
   Methods: Relevant studies were searched using PubMed, Embase, Wanfang (Chinese), VIP (Chinese), and the Chinese National Knowledge Infrastructure databases up to October, 2011. A meta-analysis was conducted using Stata software, version 11.0.
   Results: A total of nine studies with 2,281 AMD cases and 2,820 controls met our eligibility criteria, and meta-analyses of four polymorphisms of the VEGF-A gene (rs1413711, rs833061, rs2010963, and rs3025039) were performed. This meta-analysis revealed moderate evidence supporting an association between the VEGF-A polymorphisms and AMD. For rs1413711, the TT genotype was associated with an increased risk of overall AMD (TT versus CT model, odds ratio (OR) 1.74, 95% confidence interval (CI) 1.22-2.48) and of wet AMD (TT versus CT model, OR 1.82, 95% CI 1.22-2.71; TT versus (CC+CT) model, OR 1.63, 95% CI 1.13-2.35). For rs833061, the C allele (C allele versus T allele, OR 1.72, 95% CI 1.00-2.96) and CC genotype (CC versus TT model, OR 1.77, 95% CI 1.00-3.11) were the risk factors for overall AMD, while the C allele was also associated with an increased risk of wet AMD (C allele versus T allele, OR 1.54, 95% CI 1.03-2.31). No association was observed between AMD risk and the variant genotypes of VEGF-A rs2010963 and rs3025039 polymorphisms in different genetic models.
   Conclusions: The results suggest the VEGF-A rs1413711 and rs833061 polymorphisms may contribute to AMD susceptibility.
C1 [Huang, Chen; Xu, Yongsheng; Li, Xuemin; Wang, Wei] Peking Univ, Hosp 3, Dept Ophthalmol, Beijing 100191, Peoples R China.
   [Huang, Chen] Peking Univ, Hosp 3, Med Res Ctr, Beijing 100191, Peoples R China.
   [Xu, Yongsheng] Peking Univ, Hosp 3, Clin Stem Cell Ctr, Beijing 100191, Peoples R China.
C3 Peking University; Peking University; Peking University
RP Wang, W (通讯作者)，Peking Univ, Hosp 3, Dept Ophthalmol, 49 North Garden Rd, Beijing 100191, Peoples R China.
EM puh3_ww@bjmu.edu.cn
FU National Natural Science Foundation of China [81170888]; Beijing Science
   and Technology Programs (Capital Clinical Application Research Project)
   [D101100050010035]
FX The research was supported by National Natural Science Foundation of
   China (No. 81170888), Beijing Science and Technology Programs (Capital
   Clinical Application Research Project, No. D101100050010035).
CR Almeida LN, 2012, GRAEF ARCH CLIN EXP, V250, P185, DOI 10.1007/s00417-011-1807-5
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boekhoorn SS, 2008, OPHTHALMOLOGY, V115, P1899, DOI 10.1016/j.ophtha.2008.06.026
   Campa C, 2011, CURR DRUG TARGETS, V12, P173, DOI 10.2174/138945011794182674
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chapman JA, 2006, ANN PHARMACOTHER, V40, P1322, DOI 10.1345/aph.1G604
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Fang AM, 2009, MOL VIS, V15, P2710
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Immonen I, 2010, OPHTHALMOLOGY, V117, P103, DOI 10.1016/j.ophtha.2009.06.037
   Janik-Papis K, 2009, EXP MOL PATHOL, V87, P234, DOI 10.1016/j.yexmp.2009.09.005
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Mckay GJ, 2009, OPHTHALMOLOGY, V116, P1227, DOI 10.1016/j.ophtha.2009.01.008
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Qu Y, 2011, OPHTHALMIC RES, V45, P142, DOI 10.1159/000319543
   Richardson AJ, 2007, MOL VIS, V13, P2148
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Stevens A, 2003, CANCER RES, V63, P812
   Tatar O, 2006, ARCH OPHTHALMOL-CHIC, V124, P815, DOI 10.1001/archopht.124.6.815
   Thakkinstian A, 2005, STAT MED, V24, P1291, DOI 10.1002/sim.2010
   Vincenti V, 1996, CIRCULATION, V93, P1493, DOI 10.1161/01.CIR.93.8.1493
   Watson CJ, 2000, CYTOKINE, V12, P1232, DOI 10.1006/cyto.2000.0692
   Zintzaras E, 2005, GENET EPIDEMIOL, V28, P123, DOI 10.1002/gepi.20048
NR 34
TC 22
Z9 24
U1 0
U2 11
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JUN 2
PY 2013
VL 19
BP 1211
EP 1221
PG 11
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 158RB
UT WOS:000319989000001
PM 23761723
DA 2022-11-30
ER

PT J
AU Maaijwee, K
   Heimann, H
   Missotten, T
   Mulder, P
   Joussen, A
   van Meurs, J
AF Maaijwee, Kristel
   Heimann, Heinrich
   Missotten, Tom
   Mulder, Paul
   Joussen, Antonia
   van Meurs, Jan
TI Retinal pigment epithelium and choroid translocation in patients with
   exudative age-related macular degeneration: long-term results
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE RPE-choroid translocation; age-related macular degeneration; long-term
   results
ID OPHTHALMIC FINDINGS; VISUAL IMPAIRMENT; SURGERY; NEOVASCULARIZATION;
   TRANSPLANTATION; RETINOTOMY; RANIBIZUMAB; PREVALENCE; MANAGEMENT;
   LESIONS
AB To study the results of the translocation of a free autologous retinal pigment epithelium (RPE)-choroid graft after removal of a subfoveal choroidal neovascular membrane in patients with exudative age-related macular degeneration (AMD), and to determine whether preoperative variables may predict visual outcome at 1 year after surgery.
   Prospective interventional case series of 84 eyes of 83 consecutive eligible patients with exudative AMD with a minimal follow-up of 1 year after surgery. Of this group, 45, 24 and 11 patients reached a follow-up of respectively 2, 3 and 4 years. Pre- and postoperative evaluation included ETDRS visual acuity (VA), fixation testing and color fundus photography. Preoperative fluorescein angiograms were assessed by masked readers for lesion size, size of hemorrhage and lesion composition according to the MPS criteria. The relationship between lesion composition adjusted for preoperative delay and VA, lesion size, percentage of blood, and visual outcome at 1 year after surgery was analyzed.
   The mean VA (logMAR) improved slightly at 1 and 2 years (0.89, Delta=-0.06), 3 years (0.79,Delta=-0.16) and 4 years (0.74, Delta=-0.21) after surgery. Five patients had a preoperative VA better than 20/80, compared to 19 out of 84, six out of 45, four out of 24 and two out of 11 after 1, 2, 3 and 4 years respectively. Fixation was located on the graft in 62 patients (74%) up to the last examination. Predominantly classic and occult lesions had a significant better prognosis than minimally classic or hemorrhagic (>= 50% blood) lesions. Retinal detachment occurred in seven patients; two caused by rhegmatogenous detachment and five caused by proliferative vitreoretinopathy. In 11 eyes, a recurrent or persisting neovascular membrane was observed.
   An autologous free RPE-choroid graft may stabilize or improve vision in patients with exudative AMD up to 4 years after surgery.
C1 Erasmus Univ, NL-3000 DR Rotterdam, Netherlands.
   Univ Dusseldorf, Dept Ophthalmol, Dusseldorf, Germany.
   Erasmus MC, Dept Epidemiol & Biostat, Rotterdam, Netherlands.
   Royal Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool, Merseyside, England.
   Rotterdam Eye Hosp, Dept Vitreoretinal Surg, Rotterdam, Netherlands.
C3 Erasmus University Rotterdam; Heinrich Heine University Dusseldorf;
   Erasmus University Rotterdam; Erasmus MC; Royal Liverpool & Broadgreen
   University Hospitals NHS Trust; Royal Liverpool University Hospital;
   University of Liverpool; Rotterdam Eye Hospital
RP Maaijwee, K (通讯作者)，Schiedamse Vest 180, NL-3011 BH Rotterdam, Netherlands.
EM kmaaijwee@hotmail.com
RI Heimann, Heinrich/AAP-8747-2020; Joussen, Antonia/AAA-6901-2022
OI Heimann, Heinrich/0000-0002-3298-4644; 
CR Abdel-Meguid A, 2003, BRIT J OPHTHALMOL, V87, P615, DOI 10.1136/bjo.87.5.615
   Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   BIRCH J, 1969, Scandinavian Journal of Plastic and Reconstructive Surgery, V3, P1
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1737, DOI 10.1016/S0161-6420(02)01120-X
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   HINSHAW JR, 1965, ARCH SURG-CHICAGO, V91, P658
   Hubbard GB, 2004, ARCH OPHTHALMOL-CHIC, V122, P1597, DOI 10.1001/archopht.122.11.1597
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Maaijwee K, 2006, OPHTHALMOLOGY, V113, P1471, DOI 10.1016/j.ophtha.2006.04.011
   Maaijwee KJM, 2007, BRIT J OPHTHALMOL, V91, P546, DOI 10.1136/bjo.2006.103259
   MacLaren RE, 2005, OPHTHALMOLOGY, V112, P2081, DOI 10.1016/j.ophtha.2005.06.029
   MacLaren RE, 2007, OPHTHALMOLOGY, V114, P561, DOI 10.1016/j.ophtha.2006.06.049
   Miskala PH, 2004, OPHTHALMOLOGY, V111, P1981, DOI 10.1016/j.ophtha.2004.07.022
   Mruthyunjaya P, 2005, RETINA-J RET VIT DIS, V25, P597, DOI 10.1097/00006982-200507000-00010
   Pawlak D, 2004, AM J OPHTHALMOL, V137, P880, DOI 10.1016/j.ajo.2003.12.041
   Pertile G, 2002, AM J OPHTHALMOL, V134, P560, DOI 10.1016/S0002-9394(02)01641-0
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Stanga PE, 2002, OPHTHALMOLOGY, V109, P1492, DOI 10.1016/S0161-6420(02)01099-0
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Sugino IK, 2003, MOL NEUROBIOL, V28, P177, DOI 10.1385/MN:28:2:177
   van Meurs JC, 2004, BRIT J OPHTHALMOL, V88, P110, DOI 10.1136/bjo.88.1.110
   Van Meurs JC, 2005, ESSENT OPHTHALMOL, P73
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   WORMALD R, 2005, COCHRANE DB SYST REV, V19
NR 37
TC 57
Z9 59
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD NOV
PY 2007
VL 245
IS 11
BP 1681
EP 1689
DI 10.1007/s00417-007-0607-4
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 215BK
UT WOS:000249782200014
PM 17562066
OA hybrid
DA 2022-11-30
ER

PT J
AU Ramkumar, HL
   Zhang, J
   Chan, CC
AF Ramkumar, Hema L.
   Zhang, Jun
   Chan, Chi-Chao
TI Retinal ultrastructure of murine models of dry age-related macular
   degeneration (AMD)
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; AMD Dry Mouse model; Retina;
   Ultrastructure Pathology
ID COMPLEMENT FACTOR-H; FRIZZLED-RELATED PROTEIN; ACCELERATED MOUSE SAM;
   INACTIVE CATHEPSIN-D; C-REACTIVE PROTEIN; KNOCK-IN MICE; HIGH-FAT DIET;
   BRUCHS MEMBRANE; APOLIPOPROTEIN-E; PIGMENT-EPITHELIUM
AB Age-related macular degeneration (AMD) is the most prevalent form of irreversible blindness worldwide in the elderly population. The pathology of dry AMD consists of macular degeneration of photoreceptors and the RPE, lipofuscin (A2E) accumulation, and drusen formation. Mice have been widely used for generating models that simulate human AMD features for investigating the pathogenesis, treatment and prevention of the disease. Although the mouse has no macula, focal atrophy of photorecptors and RPE, lipofuscin accumulation, and increased A2E can develop in aged mouse eyes. However, drusen are rarely seen in mice because of their simpler Bruch's membrane and different process of lipofuscin extrusion compared with humans. Thus, analyzing basal deposits at the ultrastructural level and understanding the ultrastructural pathologic differences between various mouse AMD models are critical to comprehending the significance of research findings and response to possible therapeutic options for dry AMD. Based on the multifactorial pathogenesis of AMD, murine dry AMD models can be classified into three groups. First, genetically engineered mice that target genes related to juvenile macular dystrophies are the most common models, and they include abcr(-/-) (Stargardt disease), transgenic ELOVL4 (Stargardt-3 dominant inheritary disease), Efemp1R345W/(R345W) (Doyne honeycomb retinal dystrophy), and Timp3(s156C/S156C) (Sorsby fundus dystrophy) mice. Other murine models target genes relevant to AMD, including inflammatory genes such as Cfh2(-/-), Ccl2(-/-), and Ccr2(-/-), Cx3cr1(-/-), oxidative stress associated genes such as Sod1(-/-) and Sod2 knockdown, metabolic pathway genes such as neprilysirri(-/-) (amyloid 13), transgenic mcd/mcd (cathepsin D), Cp-/-/Heph(-/Y) (ferroxidase ceruloplasmin/hepaestin, iron metabolism), and transgenic ApoE4 on high fat and high cholesterol diet (lipid metabolism). Second, mice have also been immunologically manipulated by immunization with carboxyethylpyrrole (CEP), an oxidative fragment of DHA found in drusen, and found to present with dry AMD features. Third, natural mouse strains such as arrd2/arrd2 (Mdm gene mutation) and the senescence accelerated mice (SAM) spontaneously develop features of dry AMD like photoreceptor atrophy and thickening of Bruch's membrane.
   All the aforementioned models develop retinal lesions with various features that simulate dry AMD lesions: focal photoreceptor degeneration, abnormal RPE with increased lipofuscin, basal infolding, decreased melanosomes and degeneration. However, Bruch's membrane changes are less common. Most mice develop retinal lesions at an older age (6-24 months, depending on the models), while the Cc12(-/-)/x3cr1(-/-) mice develop lesions by 4-6 weeks. Although murine models present various degrees of retinal and/or RPE degeneration, classical drusen is extremely rare. Using electron microscopy, small drusenoid deposits are found between RPE and Bruch's membrane in a few models including Efemp1(R345W/R345W), Ccl2(-/-)/cx3cr1(-/-), neprilysin(-/-), transgenic mcd/mcd, and ApoE4 transgenic mice on a high fat diet. High A2E levels are measured in the retinas of abcr(-/-), transgenic ELOVL4, and Ccl2(-/-)/cx3cr1(-/-) mice. In summary, murine models provide useful tools for studying AMD pathogenesis and evaluating novel therapies for this disease. This review compares the major dry AMD murine models and discusses retinal pathology at the ultrastructural level. Published by Elsevier Ltd.
C1 [Ramkumar, Hema L.; Zhang, Jun; Chan, Chi-Chao] NEI, Immunopathol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Ramkumar, Hema L.] Howard Hughes Med Inst, Chevy Chase, MD USA.
   [Ramkumar, Hema L.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Howard Hughes Medical Institute; Northwestern University;
   Feinberg School of Medicine
RP Chan, CC (通讯作者)，NEI, Immunopathol Sect, Immunol Lab, NIH, 10 Ctr Dr,10-10N103, Bethesda, MD 20892 USA.
EM chanc@nei.nih.gov
RI Zhang, Jun/K-2424-2012
OI Ramkumar, Hema/0000-0002-1452-0694
FU NEI Intramural Research Program; Howard Hughes Medical Institute;
   NATIONAL EYE INSTITUTE [ZIAEY000222, ZIAEY000418, ZICEY000461] Funding
   Source: NIH RePORTER
FX The NEI Intramural Research Program and Howard Hughes Medical Institute
   provided support. Dr. Robert B. Nussenblatt offered his insight into the
   challenges of AMD research in mice and men.
CR Akhmedov NB, 2000, P NATL ACAD SCI USA, V97, P5551, DOI 10.1073/pnas.97.10.5551
   Aligianis IA, 2002, J MED GENET, V39, P656, DOI 10.1136/jmg.39.9.656
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   ALSENZ J, 1985, BIOCHEM J, V232, P841, DOI 10.1042/bj2320841
   Ambasudhan R, 2004, GENOMICS, V83, P615, DOI 10.1016/j.ygeno.2003.10.004
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   ANDERSON RE, 1970, EXP EYE RES, V10, P339, DOI 10.1016/S0014-4835(70)80046-X
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Behndig A, 1998, INVEST OPHTH VIS SCI, V39, P471
   Bjelik A, 2006, NEUROCHEM INT, V49, P393, DOI 10.1016/j.neuint.2006.01.026
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Bojanowski CM, 2006, ENVIRON MOL MUTAGEN, V47, P594, DOI 10.1002/em.20233
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P245, DOI 10.1002/cne.901880204
   Chader GJ, 2002, VISION RES, V42, P393, DOI 10.1016/S0042-6989(01)00212-7
   Chan CC, 2005, HISTOL HISTOPATHOL, V20, P857, DOI 10.14670/HH-20.857
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   Chang B, 2005, VISUAL NEUROSCI, V22, P587, DOI 10.1017/S0952523805225075
   Chang B, 2002, VISION RES, V42, P517, DOI 10.1016/S0042-6989(01)00146-8
   CHANG B, 1998, INVEST OPHTHALMOL S, V39
   Chang B, 2006, INVEST OPHTH VIS SCI, V47, P5017, DOI 10.1167/iovs.05-1468
   Chang B, 2008, HUM MOL GENET, V17, P3929, DOI 10.1093/hmg/ddn295
   Chen HJ, 2004, BLOOD, V103, P3933, DOI 10.1182/blood-2003-09-3139
   Chen L, 2003, MOL VIS, V9, P151
   Cheng H, 2004, HUM MOL GENET, V13, P1563, DOI 10.1093/hmg/ddh173
   Cherepanoff S, 2006, CLIN EXP OPHTHALMOL, V34, P590, DOI 10.1111/j.1442-9071.2006.01281.x
   Chong NHV, 2000, INVEST OPHTH VIS SCI, V41, P898
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Collins T., 1913, OPHTHALMOSCOPE, V11, P537
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cousins SW, 2003, INVEST OPHTH VIS SCI, V44, P1221, DOI 10.1167/iovs.02-0285
   Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Dentchev T, 2003, MOL VIS, V9, P184
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dithmar S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1643, DOI 10.1001/archopht.119.11.1643
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   DOLY M, 1986, OPHTHALMIC RES, V18, P21, DOI 10.1159/000265409
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Enzinger C, 2004, ANN NEUROL, V55, P563, DOI 10.1002/ana.20027
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Espinosa-Heidmann DG, 2004, INVEST OPHTH VIS SCI, V45, P260, DOI 10.1167/iovs.03-0910
   Ethen CM, 2006, INVEST OPHTH VIS SCI, V47, P2280, DOI 10.1167/iovs.05-1395
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1206, DOI 10.1016/0002-9394(71)90964-0
   FEENEYBURNS L, 1983, T OPHTHAL SOC UK, V103, P416
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Fogarasi M, 2008, MATRIX BIOL, V27, P381, DOI 10.1016/j.matbio.2008.01.008
   Francis PJ, 2008, MOL VIS, V14, P1395
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fu L, 2007, HUM MOL GENET, V16, P2411, DOI 10.1093/hmg/ddm198
   Fujihara M, 2009, EXP EYE RES, V88, P1115, DOI 10.1016/j.exer.2009.01.017
   FULLER PJ, 1991, FASEB J, V5, P3092, DOI 10.1096/fasebj.5.15.1743440
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gosbell AD, 2006, INVEST OPHTH VIS SCI, V47, P2613, DOI 10.1167/iovs.05-0962
   Green RW, 1999, MOL VIS, V5
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Hadziahmetovic M, 2008, INVEST OPHTH VIS SCI, V49, P2728, DOI 10.1167/iovs.07-1472
   Hafezi F, 2000, BRIT J OPHTHALMOL, V84, P922, DOI 10.1136/bjo.84.8.922
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Haider NB, 2000, NAT GENET, V24, P127, DOI 10.1038/72777
   Haider NB, 2001, HUM MOL GENET, V10, P1619, DOI 10.1093/hmg/10.16.1619
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Haley PJ, 2003, TOXICOLOGY, V188, P49, DOI 10.1016/S0300-483X(03)00043-X
   Hawes NL, 2000, INVEST OPHTH VIS SCI, V41, P3149
   HAWES NL, 1999, MOL VIS, V15
   HAYASAKA S, 1983, SURV OPHTHALMOL, V27, P245, DOI 10.1016/0039-6257(83)90125-X
   He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004
   HECKENLIVELY JR, 1995, P NATL ACAD SCI USA, V92, P11100, DOI 10.1073/pnas.92.24.11100
   Herzlich AA, 2008, PPAR RES, V2008, DOI 10.1155/2008/389507
   HOGAN MJ, 1967, ARCH OPHTHALMOL-CHIC, V77, P410, DOI 10.1001/archopht.1967.00980020412022
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hutchison J, 1875, R LOND OPHTHALMOL HO, V8, P231
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Iwata N, 2002, J NEUROSCI RES, V70, P493, DOI 10.1002/jnr.10390
   Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Javitt NB, 2009, CURR OPIN OPHTHALMOL, V20, P151, DOI 10.1097/ICU.0b013e32832af468
   Jeon CJ, 1998, J NEUROSCI, V18, P8936
   Joachim SC, 2007, GRAEF ARCH CLIN EXP, V245, P619, DOI 10.1007/s00417-006-0429-9
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Jones SE, 2000, NEUROREPORT, V11, P3963, DOI 10.1097/00001756-200012180-00012
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kalaria RN, 1997, LANCET, V349, P1174, DOI 10.1016/S0140-6736(05)63052-8
   Kameya S, 2002, HUM MOL GENET, V11, P1879, DOI 10.1093/hmg/11.16.1879
   Karan G, 2005, P NATL ACAD SCI USA, V102, P4164, DOI 10.1073/pnas.0407698102
   KATZ ML, 1986, EXP EYE RES, V42, P293, DOI 10.1016/0014-4835(86)90022-9
   Kawamata T, 1997, EXP GERONTOL, V32, P161, DOI 10.1016/S0531-5565(96)00063-0
   Keeler CE, 1924, P NATL ACAD SCI USA, V10, P329, DOI 10.1073/pnas.10.7.329
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P464, DOI 10.1097/00006982-200208000-00011
   KITADO H, 1994, J GERONTOL, V49, pB247, DOI 10.1093/geronj/49.6.B247
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Kliffen M, 2000, BRIT J OPHTHALMOL, V84, P1415, DOI 10.1136/bjo.84.12.1415
   Klomp LWJ, 1996, HUM MOL GENET, V5, P1989, DOI 10.1093/hmg/5.12.1989
   Klomp LWJ, 1996, J CLIN INVEST, V98, P207, DOI 10.1172/JCI118768
   Kuziel WA, 1997, P NATL ACAD SCI USA, V94, P12053, DOI 10.1073/pnas.94.22.12053
   LEYS A, 1991, GRAEF ARCH CLIN EXP, V229, P406, DOI 10.1007/BF00166300
   Li DY, 2004, BIOCHEM BIOPH RES CO, V318, P253, DOI 10.1016/j.bbrc.2004.04.022
   LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376
   Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935
   Majji AB, 2000, INVEST OPHTH VIS SCI, V41, P3936
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Marmorstein AD, 2007, TRENDS GENET, V23, P225, DOI 10.1016/j.tig.2007.03.001
   Marmorstein LY, 2007, HUM MOL GENET, V16, P2423, DOI 10.1093/hmg/ddm199
   MARTIN DF, 1995, J IMMUNOL, V154, P922
   Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685
   MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705
   McGeer EG, 2005, NEUROBIOL AGING, V26, pS94, DOI 10.1016/j.neurobiolaging.2005.08.008
   McLaughlin PJ, 2007, HUM MOL GENET, V16, P3059, DOI 10.1093/hmg/ddm264
   Melov S, 1998, NAT GENET, V18, P159, DOI 10.1038/ng0298-159
   Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731
   Miceli MV, 2000, CURR EYE RES, V20, P8, DOI 10.1076/0271-3683(200001)20:1;1-H;FT008
   MISHIMA H, 1978, A GRAEF ARCH KLIN EX, V209, P1, DOI 10.1007/BF00419157
   MISHIMA H, 1981, A GRAEF ARCH KLIN EX, V216, P209, DOI 10.1007/BF00408162
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Neuner B, 2009, ADDICT BEHAV, V34, P938, DOI 10.1016/j.addbeh.2009.05.015
   NUSSENBLATT RB, 1983, INT ARCH ALLER A IMM, V70, P289, DOI 10.1159/000233339
   Nussenblatt Robert B, 2002, Int Rev Immunol, V21, P273, DOI 10.1080/08830180212067
   OGATA N, 1992, Nippon Ganka Gakkai Zasshi, V96, P180
   PandaJonas S, 1995, OPHTHALMOLOGY, V102, P1853, DOI 10.1016/S0161-6420(95)30784-1
   PANITCH HS, 1987, LANCET, V1, P893
   Patel BN, 1997, J BIOL CHEM, V272, P20185, DOI 10.1074/jbc.272.32.20185
   Patel BN, 2002, J NEUROSCI, V22, P6578
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   PITAS RE, 1987, J BIOL CHEM, V262, P14352
   PURCELLHUYNH DA, 1995, J CLIN INVEST, V95, P2246, DOI 10.1172/JCI117915
   RAINES MF, 1989, BR J OPHTHALMOL, V73, P411
   Rakoczy PE, 2006, EXP EYE RES, V82, P741, DOI 10.1016/j.exer.2005.10.012
   Rakoczy PE, 1997, BIOCHEM J, V324, P935, DOI 10.1042/bj3240935
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Raz-Prag D, 2006, INVEST OPHTH VIS SCI, V47, P3603, DOI 10.1167/iovs.05-1527
   Rogue RS, 1999, BRAIN RES, V836, P110, DOI 10.1016/S0006-8993(99)01625-X
   Ross RJ, 2008, EXP EYE RES, V86, P675, DOI 10.1016/j.exer.2008.01.014
   Rudolf M, 2004, OPHTHALMOLOGE, V101, P715, DOI 10.1007/s00347-003-0942-8
   Saido TC, 1998, NEUROBIOL AGING, V19, pS69, DOI 10.1016/S0197-4580(98)00033-5
   Sallo FB, 2009, EXP EYE RES, V89, P178, DOI 10.1016/j.exer.2009.03.006
   Sandbach JM, 2001, INVEST OPHTH VIS SCI, V42, P2173
   SANYAL S, 1986, VISION RES, V26, P1177, DOI 10.1016/0042-6989(86)90099-4
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Shelley EJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P483, DOI 10.1001/archophthalmol.2008.622
   Shepherd FA, 2003, LUNG CANCER, V41, pS63, DOI 10.1016/S0169-5002(03)00144-2
   Shoji M, 1998, OPHTHALMIC RES, V30, P172, DOI 10.1159/000055471
   Sickel W, 1972, Adv Exp Med Biol, V24, P101
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   SORSBY A, 1949, BR J OPHTHALMOL, V33
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   Stargardt K., 1909, GRAEFES ARCH CLIN EX, V71, P534, DOI DOI 10.1007/BF01961301
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668
   STONE EM, 1994, ARCH OPHTHALMOL-CHIC, V112, P765, DOI 10.1001/archopht.1994.01090180063036
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Strohmeyer R, 2002, J NEUROIMMUNOL, V131, P135, DOI 10.1016/S0165-5728(02)00272-2
   Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   SZEL A, 1992, J COMP NEUROL, V325, P327, DOI 10.1002/cne.903250302
   Takada Yuriko, 1993, Nippon Ganka Gakkai Zasshi, V97, P595
   Takada Yuriko, 1994, Nippon Ganka Gakkai Zasshi, V98, P955
   Takeda T, 1997, EXP GERONTOL, V32, P105, DOI 10.1016/S0531-5565(96)00036-8
   TAKEDA T, 1994, ARCH GERONTOL GERIAT, V19, P185, DOI 10.1016/0167-4943(94)90039-6
   Timpl R, 2003, NAT REV MOL CELL BIO, V4, P479, DOI 10.1038/nrm1130
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tree M, 1937, Br J Ophthalmol, V21, P65, DOI 10.1136/bjo.21.2.65
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Tuo JS, 2009, AM J PATHOL, V175, P799, DOI 10.2353/ajpath.2009.090089
   Uchihara T, 1997, STROKE, V28, P1948, DOI 10.1161/01.STR.28.10.1948
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Umeda S, 2005, INVEST OPHTH VIS SCI, V46, P683, DOI 10.1167/iovs.04-1031
   Valentine JS, 2005, ANNU REV BIOCHEM, V74, P563, DOI 10.1146/annurev.biochem.72.121801.161647
   VANDENMAAGDENBERG AMJM, 1993, J BIOL CHEM, V268, P10540
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   VANNIE R, 1978, TISSUE ANTIGENS, V12, P106, DOI 10.1111/j.1399-0039.1978.tb01305.x
   Vasireddy V, 2005, MOL VIS, V11, P665
   VASIREDDY V, 2009, EXP EYE RES
   Vasireddy V, 2006, INVEST OPHTH VIS SCI, V47, P4558, DOI 10.1167/iovs.06-0353
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Vulpe CD, 1999, NAT GENET, V21, P195, DOI 10.1038/5979
   Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262
   Weber BHF, 2002, INVEST OPHTH VIS SCI, V43, P2732
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Weller RO, 2003, NEUROL RES, V25, P611, DOI 10.1179/016164103101202057
   Wellington CL, 2004, CLIN GENET, V66, P1, DOI 10.1111/j.0009-9163.2004.00280.x
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   *WHO, 2009, 282 WHO
   WIEDERANDERS B, 1984, MECH AGEING DEV, V24, P265, DOI 10.1016/0047-6374(84)90112-X
   WIKLER KC, 1990, J NEUROSCI, V10, P3390
   Wisniewski T, 1997, NEUROBIOL DIS, V4, P313, DOI 10.1006/nbdi.1997.0147
   WOLFENSBERGER TJ, 1998, RETINAL PIGMENT EPIT, P621
   Won J, 2008, VISUAL NEUROSCI, V25, P563, DOI 10.1017/S0952523808080723
   Wong TY, 2006, BRIT J OPHTHALMOL, V90, P506, DOI 10.1136/bjo.2005.083733
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Xu YK, 1998, CURR BIOL, V8, pR405, DOI 10.1016/S0960-9822(98)70262-3
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
   Zack DJ, 1999, MOL VIS, V5, pU37
   Zhang D, 2005, INVEST OPHTH VIS SCI, V46, P3031, DOI 10.1167/iovs.04-1510
   Zhang D, 2002, BIOGERONTOLOGY, V3, P61, DOI 10.1023/A:1015259413857
   ZHANG J, 2010, SYNAPTIC PATHOLOGY P
   Zhang K, 2001, NAT GENET, V27, P89, DOI 10.1038/83817
NR 231
TC 100
Z9 106
U1 1
U2 26
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD MAY
PY 2010
VL 29
IS 3
BP 169
EP 190
DI 10.1016/j.preteyeres.2010.02.002
PG 22
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 598HT
UT WOS:000277826800001
PM 20206286
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Teper, SJ
   Nowinska, A
   Wylegala, E
AF Teper, Slawomir J.
   Nowinska, Anna
   Wylegala, Edward
TI A69S and R38X ARMS2 and Y402H CFH gene polymorphisms as risk factors for
   neovascular age-related macular degeneration in Poland - a brief report
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE age-related macular susceptibility 2 (ARMS2); complement factor H (CFH);
   age-related macular degeneration; gene polymorphism
ID MESSENGER-RNA; AMD
AB Background: The wet form of age-related macular degeneration (ARMD) is a leading cause of irreversible blindness in Caucasians. Our purpose was to assess influence of gene polymorphisms A69S (rs10490924) and R38X (rs2736911) ARMS2 and Y402 (rs1061170) CFH on wet ARMD risk in a Polish population.
   Material/Methods: 130 unrelated patients (90 with wet ARMD and 40 controls) took part in the study. Dry blood was used for DNA isolation. PCR amplification and gene sequencing were performed. In subjects with R38X and A69S, SNP gene cloning was used to exclude the possible combined variant.
   Results: Homozygous Y402H and A69S conferred a significance risk of wet ARMD in Poland: Y402H odds ratio (OR) was 5.57 (95% confidence interval: 1.58-19.6), p=0.002; and A69S OR was 7.72 (95% confidence interval: 1.73-34.36), p=0.001. R38X is probably more common in healthy subjects: OR was 0.45 (95% confidence interval: 0.19-1.05), p=0.053.
   Conclusions: The etiologic role in ARMD of A69S ARMS2 and Y402H CFH gene variants were confirmed in a Polish population for the first time. R38X variant of ARMS2 seems to be protective from wet ARMD.
C1 [Teper, Slawomir J.; Nowinska, Anna; Wylegala, Edward] OSK, Dept Ophthalmol, Katowice, Poland.
RP Teper, SJ (通讯作者)，OSK Katowice, Dept Ophthalmol, Panewnicka 65 St, PL-40760 Katowice, Poland.
EM s_teper@wp.pl
RI Wylegala, Edward/AAD-3961-2019; Nowinska, Anna K/G-6165-2013; Teper,
   Slawomir/AAQ-1938-2021
OI Nowinska, Anna K/0000-0002-8418-3486; Teper,
   Slawomir/0000-0002-0935-8880
FU Medical University of Silesia in Katowice, Poland (Department of Nursing
   and Social Medical Issues)
FX This study was supported by the Medical University of Silesia in
   Katowice, Poland (Department of Nursing and Social Medical Issues)
CR Allikmets R, 2008, NAT GENET, V40, P820, DOI 10.1038/ng0708-820
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Kowalski M, 2010, MED SCI MONITOR, V16, pCR190
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
NR 11
TC 11
Z9 11
U1 0
U2 3
PU INT SCIENTIFIC LITERATURE, INC
PI SMITHTOWN
PA 361 FOREST LANE, SMITHTOWN, NY 11787 USA
SN 1234-1010
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD FEB
PY 2012
VL 18
IS 2
BP PR1
EP PR3
DI 10.12659/MSM.882447
PG 3
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 942VZ
UT WOS:000304079400001
PM 22293892
OA Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Khanifar, AA
   Koreishi, AF
   Izatt, JA
   Toth, CA
AF Khanifar, Aziz A.
   Koreishi, Anjum F.
   Izatt, Joseph A.
   Toth, Cynthia A.
TI Drusen Ultrastructure Imaging with Spectral Domain Optical Coherence
   Tomography in Age-related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID HIGH-SPEED
AB Purpose: To categorize drusen ultrastructure in age-related macular degeneration (AMD) using spectral domain optical coherence tomography (SDOCT) and correlate the tomographic and photographic drusen appearances.
   Design: Prospective case series.
   Participants: Thirty-one eyes of 31 patients with non-neovascular AMD.
   Methods: Subjects with drusen and a clinical diagnosis of AMD were enrolled in an SDOCT imaging study from August of 2005 to May of 2007. Foveal linear scans were acquired, and the image data were processed for analysis. Drusen were scored by 4 morphologic categories: shape, predominant internal reflectivity, homogeneity, and presence of overlying hyper-reflective foci. The prevalences of each morphologic pattern and combinations of morphologic patterns observed were calculated. The photographic appearance of each druse was compared with the tomographic classification. Interobserver and intraobserver agreement analysis was performed.
   Main Outcome Measures: Prevalence of morphologic parameters using SDOCT.
   Results: Twenty-one eyes of 21 patients had SDOCT B-scans of adequate quality for analysis. On the basis of the above morphologic categories, 17 different drusen patterns were found in 120 total drusen. The most common was convex, homogeneous, with medium internal reflectivity, and without overlying hyper-reflective foci, present in 17 of 21 eyes (81%). Of the 16 eyes (76%) with nonhomogeneous drusen, 5 had a distinct hyper-reflective core. Hyper-reflective foci overlying drusen were in 7 eyes (33%). Although half of the photographically soft-indistinct drusen were convex with medium internal reflectivity and homogeneous without overlying hyper-reflective foci, the other half had significant variability in their tomographic appearance. Both interobserver and intraobserver agreement in drusen grading were high. Readers agreed the most when grading drusen shape and reflectivity, whereas the least agreement was for drusen homogeneity.
   Conclusions: Drusen ultrastructure can be imaged with SDOCT and characterized with a simple grading system. Photographic appearance may predict some but not all tomographic appearances. Trained observers have a high level of agreement with this grading system. These in vivo morphologic characteristics imaged with SDOCT may be distinct subclasses of drusen types, may relate closely to ultrastructural drusen elements identified in cadaveric eyes, and may be useful imaging biomarkers for disease severity or risk of progression. This will require validation from further studies.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2008; 115:1883-1890 (C) 2008 by the American Academy of Ophthalmology.
C1 [Khanifar, Aziz A.; Koreishi, Anjum F.; Toth, Cynthia A.] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   [Izatt, Joseph A.; Toth, Cynthia A.] Duke Univ, Pratt Sch Engn, Dept Biomed Engn, Durham, NC USA.
C3 Duke University; Duke University
RP Toth, CA (通讯作者)，Duke Univ, Ctr Eye, DUMC 3802, Durham, NC 27710 USA.
EM toth0004@mc.duke.edu
RI toth, cynthia a/F-5614-2011; Toth, Cynthia/L-5534-2019; Izatt,
   Joseph/C-9067-2014
OI Toth, Cynthia/0000-0002-2324-0854; Izatt, Joseph/0000-0003-1993-2249
FU NEI NIH HHS [R21 EY017393] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [R21EY017393] Funding Source: NIH RePORTER
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Chen TC, 2005, ARCH OPHTHALMOL-CHIC, V123, P1715, DOI 10.1001/archopht.123.12.1715
   Drexler W, 2003, ARCH OPHTHALMOL-CHIC, V121, P695, DOI 10.1001/archopht.121.5.695
   FARSIU S, 2008, SPIE PHOT W SAN JOS
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Jiao SL, 2005, OPT EXPRESS, V13, P444, DOI 10.1364/OPEX.13.000444
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Laser Institute of America, 2000, AM NAT STAND SAF US
   Pieroni CG, 2006, BRIT J OPHTHALMOL, V90, P191, DOI 10.1136/bjo.2005.076612
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Shields CL, 2006, OPHTHALMOLOGY, V113, P1553, DOI 10.1016/j.ophtha.2006.03.032
   Srinivasan VJ, 2006, OPHTHALMOLOGY, V113, P2054, DOI 10.1016/j.ophtha.2006.05.046
   Stopa M, 2008, RETINA-J RET VIT DIS, V28, P298, DOI 10.1097/IAE.0b013e3181567798
   Thevenaz P, 1998, IEEE T IMAGE PROCESS, V7, P27, DOI 10.1109/83.650848
   Wojtkowski M, 2005, OPHTHALMOLOGY, V112, P1734, DOI 10.1016/j.ophtha.2005.05.023
   Yabushita H, 2002, CIRCULATION, V106, P1640, DOI 10.1161/01.CIR.0000029927.92825.F6
   Yang Y, 2006, PHYS MED BIOL, V51, P1649, DOI 10.1088/0031-9155/51/7/001
NR 20
TC 124
Z9 129
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2008
VL 115
IS 11
BP 1883
EP 1890
DI 10.1016/j.ophtha.2008.04.041
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 365ZO
UT WOS:000260448900005
PM 18722666
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Trinh, M
   Khou, V
   Kalloniatis, M
   Nivison-Smith, L
AF Trinh, Matt
   Khou, Vincent
   Kalloniatis, Michael
   Nivison-Smith, Lisa
TI Location-Specific Thickness Patterns in Intermediate Age-Related Macular
   Degeneration Reveals Anatomical Differences in Multiple Retinal Layers
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; clustering; OCT; thickness;
   topography; anatomy
ID NERVE-FIBER LAYER; OPTICAL COHERENCE TOMOGRAPHY; GANGLION-CELL COMPLEX;
   INNER PLEXIFORM LAYER; SUBRETINAL DRUSENOID DEPOSITS; MEDIATED
   DARK-ADAPTATION; AREAL UNIT PROBLEM; ADAPTIVE OPTICS; RETICULAR
   PSEUDODRUSEN; MOUSE MODEL
AB PURPOSE. To examine individual retinal layers' location-specific patterns of thicknesses in intermediate age-related macular degeneration (iAMD) using optical coherence tomography (OCT).
   METHODS. OCT macular cube scans were retrospectively acquired from 84 iAMD eyes of 84 participants and 84 normal eyes of 84 participants propensity-score matched on age, sex, and spherical equivalent refraction. Thicknesses of the retinal nerve fiber layer (RNFL), ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear layer (INL), outer plexiform layer (OPL), outer nuclear layer + Henle's fiber layer (ONL+HFL), innerand outer-segment layers (IS/OS), and retinal pigment epithelium to Bruch's membrane (RPE-BM) were calculated across an 8 x 8 grid (total 24 degrees x 24 degrees area). Location-specific analysis was performed using cluster( normal) and grid(iAMD)-to-cluster( normal) comparisons.
   RESULTS. In iAMD versus normal eyes, the central RPE-BM was thickened (mean difference +/- SEM up to 27.45% +/- 7.48%, P < 0.001; up to 7.6 SD-from-normal), whereas there was thinned outer (OPL, ONL+HFL, and non-central RPE-BM, up to -6.76% +/- 2.47%, P < 0.001; up to -1.6 SD-from-normal) and inner retina (GCL and IPL, up to -4.83% +/- 1.56%, P < 0.01; up to -1.7 SD-from-normal) with eccentricity-based effects. Interlayer correlations were greater against the ONL+HFL (mean vertical bar r vertical bar +/- SEM 0.19 +/- 0.03, P = 0.14 to < 0.0001) than the RPE-BM (0.09 +/- 0, P = 0.72 to < 0.0001).
   CONCLUSIONS. Location-specific analysis suggests altered retinal anatomy between iAMD and normal eyes. These data could direct clinical diagnosis and monitoring of AMD toward targeted locations.
C1 [Trinh, Matt; Khou, Vincent; Kalloniatis, Michael; Nivison-Smith, Lisa] Univ New South Wales, Ctr Eye Hlth, Sydney, NSW, Australia.
   [Trinh, Matt; Khou, Vincent; Kalloniatis, Michael; Nivison-Smith, Lisa] Univ New South Wales, Sch Optometry & Vis Sci, Sydney, NSW, Australia.
C3 University of New South Wales Sydney; University of New South Wales
   Sydney
RP Nivison-Smith, L (通讯作者)，UNSW Australia, Sch Optometry & Vis Sci, Sydney, NSW 2052, Australia.
EM l.nivison-smith@unsw.edu.au
RI Trinh, Matt/AAV-1249-2021
OI Trinh, Matt/0000-0002-6184-0666
FU Rebecca Cooper Foundation; National Health and Medical Research Council
   of Australia (NHMRC) [1174385]; Australian Research Training Program
   scholarship; Guide Dogs NSW/ACT
FX Supported, in part, by research grants from the Rebecca Cooper
   Foundation and the National Health and Medical Research Council of
   Australia (NHMRC grant no. 1174385) awarded to L.N.S. M.T. and V.K. are
   supported by the Australian Research Training Program scholarship. Guide
   Dogs NSW/ACT provides support for the Centre for Eye Health (the clinic
   of recruitment), a top-up scholarship for V.K., and salary support for
   M.K. and L.N.
CR Abadie A, 2016, ECONOMETRICA, V84, P781, DOI 10.3982/ECTA11293
   Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   Ahnelt PK, 2006, VISUAL NEUROSCI, V23, P429, DOI 10.1017/S095252380623342X
   Ahnelt PK, 1998, EYE, V12, P531, DOI 10.1038/eye.1998.142
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Angst F, 2017, J CLIN EPIDEMIOL, V82, P128, DOI 10.1016/j.jclinepi.2016.11.016
   Armstrong RA, 2014, OPHTHAL PHYSL OPT, V34, P502, DOI 10.1111/opo.12131
   Austin PC, 2011, MULTIVAR BEHAV RES, V46, P399, DOI 10.1080/00273171.2011.568786
   Blumenthal EZ, 2009, EYE, V23, P171, DOI 10.1038/sj.eye.6702942
   Blumenthal EZ, 2004, INVEST OPHTH VIS SCI, V45, P1404, DOI 10.1167/iovs.03-0744
   Bonilha VL, 2008, CLIN OPHTHALMOL, V2, P413
   Boretsky A, 2012, LASER SURG MED, V44, P603, DOI 10.1002/lsm.22070
   Borrelli E, 2017, AM J OPHTHALMOL, V181, P1, DOI 10.1016/j.ajo.2017.06.005
   Brandl C, 2019, INVEST OPHTH VIS SCI, V60, P1581, DOI 10.1167/iovs.18-25332
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Bringmann A, 2018, PROG RETIN EYE RES, V66, P49, DOI 10.1016/j.preteyeres.2018.03.006
   Buzzelli M., 2020, INT ENCY HUMAN GEOGR, P169, DOI [10.1016/B978-0-08-102295-5.10406-8, DOI 10.1016/B978-0-08-102295-5.10406-8]
   Caliendo M, 2008, J ECON SURV, V22, P31, DOI 10.1111/j.1467-6419.2007.00527.x
   Camacho P, 2017, OPHTHALMOLOGICA, V238, P31, DOI 10.1159/000468965
   Chao TI, 1997, J NEUROCYTOL, V26, P439, DOI 10.1023/A:1018525222826
   Chua J, 2013, J COMP NEUROL, V521, P2439, DOI 10.1002/cne.23307
   Cohen J., 1988, STAT POWER ANAL SOCI, V2nd
   Cohen MJ, 2008, INVEST OPHTH VIS SCI, V49, P941, DOI 10.1167/iovs.07-0621
   Cuenca N, 2018, OPHTHALMOLOGY, V125, P407, DOI 10.1016/j.ophtha.2017.09.016
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   CURCIO CA, 1991, J COMP NEUROL, V312, P610, DOI 10.1002/cne.903120411
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   CURCIO CA, 1990, J COMP NEUROL, V300, P5, DOI 10.1002/cne.903000103
   Dagar S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090250
   Dark SJ, 2007, PROG PHYS GEOG, V31, P471, DOI 10.1177/0309133307083294
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   De S, 2007, ARCH OPHTHALMOL-CHIC, V125, P641, DOI 10.1001/archopht.125.5.641
   Dehejia RH, 2002, REV ECON STAT, V84, P151, DOI 10.1162/003465302317331982
   DERKSEN S, 1992, BRIT J MATH STAT PSY, V45, P265, DOI 10.1111/j.2044-8317.1992.tb00992.x
   Dichtl A, 1999, GRAEF ARCH CLIN EXP, V237, P474, DOI 10.1007/s004170050264
   Distler C, 1996, VISION RES, V36, P2381, DOI 10.1016/0042-6989(96)00005-3
   Dodo BI, 2019, J MED SYST, V43, DOI 10.1007/s10916-019-1452-9
   Drasdo N, 2007, VISION RES, V47, P2901, DOI 10.1016/j.visres.2007.01.007
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Ebneter A, 2016, INVEST OPHTH VIS SCI, V57, pOCT299, DOI 10.1167/iovs.15-18865
   Fariss RN, 2000, AM J OPHTHALMOL, V129, P215, DOI 10.1016/S0002-9394(99)00401-8
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Feigl B, 2007, EYE, V21, P689, DOI 10.1038/sj.eye.6702389
   Ferrara D, 2017, INVEST OPHTH VIS SCI, V58, P3519, DOI 10.1167/iovs.17-21696
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Frenkel S, 2005, EYE, V19, P491, DOI 10.1038/sj.eye.6701569
   Godara Pooja, 2010, Ophthalmic Surg Lasers Imaging, V41 Suppl, pS104, DOI 10.3928/15428877-20101031-07
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Gorczynska I, 2009, BRIT J OPHTHALMOL, V93, P603, DOI 10.1136/bjo.2007.136101
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Gu X, 2018, J COMPUT GRAPH STAT, V2, P405, DOI 10.2307/1390693
   Guo SY, 2020, J SOC SOC WORK RES, V11, P463, DOI 10.1086/711393
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.06.004, 10.1016/j.jclinepi.2011.03.017]
   Guymer RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083759
   Hallak JA, 2019, JAMA OPHTHALMOL, V137, P738, DOI 10.1001/jamaophthalmol.2019.0868
   Hartmann KI, 2012, RETINA-J RET VIT DIS, V32, P1492, DOI 10.1097/IAE.0b013e318242b949
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   Heidelberg Engineering GmbH, 2016, SPECTR PROD FAM US M
   Inana G, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1434-6
   Iwama D, 2010, CLIN EXP OPHTHALMOL, V38, P483, DOI 10.1111/j.1442-9071.2010.02294.x
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Jelinski DE, 1996, LANDSCAPE ECOL, V11, P129, DOI 10.1007/BF02447512
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   KAZIS LE, 1989, MED CARE, V27, pS178, DOI 10.1097/00005650-198903001-00015
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Ko TH, 2005, OPHTHALMOLOGY, V112, P1922, DOI 10.1016/j.ophtha.2005.05.027
   Lamin A, 2019, EYE, V33, P428, DOI 10.1038/s41433-018-0234-9
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Lee HJ, 2015, AM J OPHTHALMOL, V160, P283, DOI 10.1016/j.ajo.2015.05.015
   Lee SCS, 2019, INVEST OPHTH VIS SCI, V60, P2848, DOI 10.1167/iovs.19-27217
   Lunt M, 2014, AM J EPIDEMIOL, V179, P226, DOI 10.1093/aje/kwt212
   Machida S, 2008, INVEST OPHTH VIS SCI, V49, P442, DOI 10.1167/iovs.07-0291
   MADIGAN MC, 1994, RETINA-J RET VIT DIS, V14, P65, DOI 10.1097/00006982-199401000-00014
   Maloca PM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220063
   Marc RE, 2008, MOL VIS, V14, P782
   Marc RE, 2007, INVEST OPHTH VIS SCI, V48, P3364, DOI 10.1167/iovs.07-0032
   Trinh M, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-79424-6
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mrejen S, 2014, OPHTHALMOLOGY, V121, P545, DOI 10.1016/j.ophtha.2013.09.026
   Muftuoglu IK, 2018, RETINA-J RET VIT DIS, V38, P1478, DOI 10.1097/IAE.0000000000001759
   Nittala MG, 2019, OSLI RETINA, V50, pE236, DOI 10.3928/23258160-20190905-15
   Nivison-Smith L, 2018, OPTOMETRY VISION SCI, V95, P648, DOI 10.1097/OPX.0000000000001256
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Panneman EL, 2019, NEURO-OPHTHALMOLOGY, V43, P382, DOI 10.1080/01658107.2019.1599027
   Pappuru RR, 2011, INVEST OPHTH VIS SCI, V52, P6743, DOI 10.1167/iovs.10-6723
   Pow DV, 2007, EXP EYE RES, V84, P850, DOI 10.1016/j.exer.2007.01.005
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2014, BRIT J OPHTHALMOL, V98, P1522, DOI 10.1136/bjophthalmol-2014-305455
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Ramon C, 2019, CLIN EXP OPTOM, V102, P601, DOI 10.1111/cxo.12894
   Reumueller A, 2019, INVEST OPHTH VIS SCI, V60, P1144, DOI 10.1167/iovs.18-25702
   Rogala J, 2015, INVEST OPHTH VIS SCI, V56, P1689, DOI 10.1167/iovs.14-16221
   ROSENBAUM PR, 1985, AM STAT, V39, P33, DOI 10.2307/2683903
   RUTTER M, 1994, J CONSULT CLIN PSYCH, V62, P928, DOI 10.1037/0022-006X.62.5.928
   Sadigh S, 2015, CURR EYE RES, V40, P398, DOI 10.3109/02713683.2014.925934
   Sadigh S, 2013, INVEST OPHTH VIS SCI, V54, P1603, DOI 10.1167/iovs.12-11286
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Sassmannshausen M, 2021, OPHTHALMOL RETINA, V5, P241, DOI 10.1016/j.oret.2020.07.019
   Sassmannshausen M, 2018, INVEST OPHTH VIS SCI, V59, P1599, DOI 10.1167/iovs.17-22712
   Savastano MC, 2014, INVEST OPHTH VIS SCI, V55, P560, DOI 10.1167/iovs.13-12172
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Shelley EJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P483, DOI 10.1001/archophthalmol.2008.622
   Shin IH, 2018, RETINA-J RET VIT DIS, V38, P253, DOI 10.1097/IAE.0000000000001535
   Sleiman K, 2017, OPHTHALMOLOGY, V124, P1764, DOI 10.1016/j.ophtha.2017.06.032
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Strettoi E, 2000, P NATL ACAD SCI USA, V97, P11020, DOI 10.1073/pnas.190291097
   Stuart EA, 2010, STAT SCI, V25, P1, DOI 10.1214/09-STS313
   Sullivan R, 2003, INVEST OPHTH VIS SCI, V44, P856, DOI 10.1167/iovs.02-0416
   Sullivan RKP, 2007, INVEST OPHTH VIS SCI, V48, P2782, DOI 10.1167/iovs.06-1283
   Tian J, 2016, J BIOPHOTONICS, V9, P478, DOI 10.1002/jbio.201500239
   Tong J, 2019, AM J OPHTHALMOL, V208, P166, DOI 10.1016/j.ajo.2019.04.020
   Too LK, 2017, ACTA HISTOCHEM, V119, P142, DOI 10.1016/j.acthis.2016.12.003
   Toy BC, 2013, AM J OPHTHALMOL, V156, P532, DOI 10.1016/j.ajo.2013.04.031
   Trinh M, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.4.2
   Trinh M, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.2
   Varela C, 2003, VISION RES, V43, P879, DOI 10.1016/S0042-6989(02)00493-5
   Varma R, 1996, OPHTHALMOLOGY, V103, P2114, DOI 10.1016/S0161-6420(96)30381-3
   Waldstein SM, 2020, JAMA OPHTHALMOL, V138, P740, DOI 10.1001/jamaophthalmol.2020.1376
   Wang H, 2021, CLIN EXP OPTOM, V104, P795, DOI 10.1080/08164622.2021.1878821
   Wong D.W.S., 2004, WORLDMINDS GEOGRAPHI, P571
   Wu KHC, 2003, BRIT J OPHTHALMOL, V87, P1159, DOI 10.1136/bjo.87.9.1159
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P3714, DOI 10.1167/iovs.15-18294
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1445, DOI 10.1016/j.ophtha.2014.01.025
   Xu G Z, 1996, Trans Am Ophthalmol Soc, V94, P411
   Yenice E, 2015, EYE, V29, P1076, DOI 10.1038/eye.2015.86
   Yi K, 2009, BRIT J OPHTHALMOL, V93, P176, DOI 10.1136/bjo.2008.137356
   Yoshioka N, 2017, INVEST OPHTH VIS SCI, V58, P3086, DOI 10.1167/iovs.17-21450
   Zayit-Soudry S, 2013, INVEST OPHTH VIS SCI, V54, P7498, DOI 10.1167/iovs.13-12433
   Zhang T, 2019, ELIFE, V8, DOI 10.7554/eLife.43598
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
NR 140
TC 1
Z9 1
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2021
VL 62
IS 13
AR 13
DI 10.1167/iovs.62.13.13
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA WS1QG
UT WOS:000714963600001
PM 34661608
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ghazi, NG
   Kirk, T
   Allam, S
   Yan, G
AF Ghazi, Nicola G.
   Kirk, Tyler
   Allam, Souha
   Yan, Guofen
TI Quantification of Error in Optical Coherence Tomography Central Macular
   Thickness Measurement in Wet Age-related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL THICKNESS; ARTIFACTS; CATARACT; OCT
AB PURPOSE: To assess error indicators encountered during optical coherence tomography (OCT) automated retinal thickness measurement (RTM) in neovascular age-related macular degeneration (NVAMD) before and after bevacizumab (Avastin; Genentech Inc, South San Francisco, California, USA) treatment.
   DESIGN: Retrospective observational cross-sectional study.
   METHODS: Each of the 6 radial lines of a single Stratus fast macular OCT study before and 3 months following initiation of treatment in 46 eyes with NVAMD, for a total of 552 scans, was evaluated. Error frequency was analyzed relative to the presence of intraretinal, subretinal (SR), and subretinal pigment epithelial (SRPE) fluid. In scans with edge detection kernel (EDK) misplacement, manual caliper measurement of the central macular (CMT) and central foveal (CFT) thicknesses was per, formed and compared to the software,generated values. The frequency of the various types of error indicators, the risk factors for error, and the magnitude of automated RTM error were analyzed.
   RESULTS: Error indicators were found in 91.3% and 71.7% of eyes before and after treatment, respectively (P = .013). Suboptimal signal strength was the most common error indicator. EDK misplacement was the second most common type of error prior to treatment and the least common after treatment (P = .005). Eyes with SR or SRPE fluid were at the highest risk for error, particularly EDK misplacement (P = .039). There was a strong association between the software-generated and caliper-generated CMT and CFT measurements. The software overestimated measurements by up to 32% and underestimated them by up to 15% in the presence of SR and SRPE fluid, respectively.
   CONCLUSIONS: OCT errors are very frequent in NVAMD. SRF is associated with the highest risk and magnitude of error in automated CMT and CFT measurements. Manually adjusted measurements may be more reliable in such eyes. (Am J Ophthalmol 2009;148: 90-96. (C) 2009 by Elsevier Inc. All rights reserved.)
C1 [Ghazi, Nicola G.; Kirk, Tyler; Allam, Souha] Univ Virginia Hlth Syst, Dept Ophthalmol, Charlottesville, VA 22908 USA.
   [Yan, Guofen] Univ Virginia Hlth Syst, Dept Biostat, Charlottesville, VA 22908 USA.
C3 University of Virginia; University of Virginia
RP Ghazi, NG (通讯作者)，Univ Virginia Hlth Syst, Dept Ophthalmol, POB 800715, Charlottesville, VA 22908 USA.
EM ngg6f@virginia.edu
RI Ghazi, Nicola/AAH-4169-2020
OI Ghazi, Nicola/0000-0001-9255-8025
CR Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Ge J, 1999, Yan Ke Xue Bao, V15, P153
   Hougaard JL, 2001, CURR EYE RES, V23, P415
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Joeres S, 2008, OPHTHALMOLOGY, V115, P347, DOI 10.1016/j.ophtha.2007.03.082
   Koozekanani D, 2001, IEEE T MED IMAGING, V20, P900, DOI 10.1109/42.952728
   Leung CKS, 2007, OPHTHALMOLOGY, V114, P263, DOI 10.1016/j.ophtha.2006.06.059
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P1084, DOI 10.1167/iovs.07-1203
   Ray R, 2005, AM J OPHTHALMOL, V139, P18, DOI 10.1016/j.ajo.2004.07.050
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Sadda SR, 2007, INVEST OPHTH VIS SCI, V48, P839, DOI 10.1167/iovs.06-0554
   Savini G, 2006, J GLAUCOMA, V15, P336, DOI 10.1097/01.ijg.0000212244.64584.c2
   SCHUMAN JS, 2004, OPTICAL COHERENCE TO, P3
   Stein DM, 2006, OPHTHALMOLOGY, V113, P985, DOI 10.1016/j.ophtha.2006.02.018
   Strauss RW, 2007, KLIN MONATSBL AUGENH, V224, P47, DOI 10.1055/s-2006-927274
   van Velthoven MEJ, 2006, BRIT J OPHTHALMOL, V90, P1259, DOI 10.1136/bjo.2004.097022
NR 16
TC 14
Z9 14
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2009
VL 148
IS 1
BP 90
EP 96
DI 10.1016/j.ajo.2009.02.017
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 464CE
UT WOS:000267481700015
PM 19403111
DA 2022-11-30
ER

PT J
AU Jaggi, D
   Nagamany, T
   Ebneter, A
   Munk, M
   Wolf, S
   Zinkernagel, M
AF Jaggi, Damian
   Nagamany, Thanoosha
   Ebneter, Andreas
   Munk, Marion
   Wolf, Sebastian
   Zinkernagel, Martin
TI Aflibercept for age-related macular degeneration: 4-year outcomes of a
   'treat-and-extend' regimen with exit-strategy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Neovascularisation; Retina; Vitreous
ID INTRAVITREAL AFLIBERCEPT; RE NATA; RANIBIZUMAB; THERAPY
AB Aim To report long-term outcomes on best-corrected visual acuity (BCVA) and treatment intervals with a treat-and-extend (T&E) regimen in patients with neovascular age-related macular degeneration (nAMD). Methods This observational study included treatment-naive patients with nAMD, treated with aflibercept. A specific T&E protocol without a loading phase and predefined exit criteria was administered. After reaching predefined 'exit-criteria', the treatment period was complete, and patients were observed three monthly. Results Eighty-two patients with a follow-up period of >= 2 years were included. BCVA (mean +/- SD, ETDRS letters) increased from 51.9 +/- 25.2 at baseline to 63.7 +/- 17.7 (p<0.0001) at 1 year, 61.7 +/- 18.5 (p<0.0001) at 2 years, 62.4 +/- 19.5 (p<0.0001, n=61) at 3 years and remained insignificantly higher than baseline at 4 years at 58.5 +/- 24.3 (p=0.22). Central subfield thickness (mean +/- SD, mu m) decreased significantly from 387.5 +/- 107.6 (p<0.0001) at baseline to 291.9 +/- 65.5 (p<0.0001) at 1 year, and remained significantly lower until 4 years at 289.0 +/- 59.4 (p<0.0001). Treatment intervals (mean +/- SD, weeks) could be extended up to 9.3 +/- 3.1 weeks at 1 year and remained at 11.2 +/- 3.5 weeks at 4 years. Twenty-nine (35%) patients reached exit criteria and continued with three monthly observation only. Conclusions After 4 years of treatment, initial vision gains were maintained with a reasonable treatment burden, even without an initial loading phase. Our results on functional outcomes are comparable with large controlled studies.
C1 [Jaggi, Damian; Nagamany, Thanoosha; Ebneter, Andreas; Munk, Marion; Wolf, Sebastian; Zinkernagel, Martin] Univ Bern, Bern Univ Hostpital, Inselspital, Dept Ophthalmol, Bern, Switzerland.
   [Munk, Marion; Wolf, Sebastian; Zinkernagel, Martin] Univ Bern, Bern Univ Hosp, Inselspital, Bern Photog Reading Ctr, Bern, Switzerland.
C3 University of Bern; University Hospital of Bern; University of Bern;
   University Hospital of Bern
RP Zinkernagel, M (通讯作者)，Univ Hosp Bern, CH-3010 Bern, Switzerland.
EM Martin.zinkernagel@insel.ch
CR Adrean SD, 2018, OPHTHALMOLOGY, V125, P1047, DOI 10.1016/j.ophtha.2018.01.012
   Arendt P, 2019, RETINA-J RET VIT DIS, V39, P27, DOI 10.1097/IAE.0000000000001923
   Augsburger M, 2019, GRAEF ARCH CLIN EXP, V257, P1889, DOI 10.1007/s00417-019-04404-0
   Brown MM, 2016, RETINA-J RET VIT DIS, V36, P285, DOI 10.1097/IAE.0000000000000717
   Decroos FC, 2017, AM J OPHTHALMOL, V180, P142, DOI 10.1016/j.ajo.2017.06.002
   Droege KM, 2013, GRAEF ARCH CLIN EXP, V251, P1281, DOI 10.1007/s00417-012-2177-3
   Gayadine-Harricham Y, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/7465270
   Giannakaki-Zimmermann H, 2016, OPHTHALMOLOGICA, V236, P201, DOI 10.1159/000452929
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Itagaki K, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01542-6
   Kaiser PK, 2017, OPHTHALMOL RETINA, V1, P304, DOI 10.1016/j.oret.2017.01.004
   Kertes PJ, 2019, OPHTHALMOLOGY, V126, P841, DOI 10.1016/j.ophtha.2019.01.013
   Khanani AM, 2019, CLIN OPHTHALMOL, V13, P347, DOI 10.2147/OPTH.S191170
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Li E, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012208.pub2
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nishikawa K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39995-5
   Okada M, 2018, AM J OPHTHALMOL, V192, P184, DOI 10.1016/j.ajo.2018.05.026
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Takayama K, 2017, OPHTHALMOLOGICA, V237, P105, DOI 10.1159/000461785
   Traine PG, 2019, OPHTHALMOL RETINA, V3, P393, DOI 10.1016/j.oret.2019.01.018
   Weber M, 2020, BMJ OPEN OPHTHALMOL, V5, DOI 10.1136/bmjophth-2019-000377
   Weber M, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2017-000109
NR 25
TC 6
Z9 6
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB
PY 2022
VL 106
IS 2
BP 246
EP 250
DI 10.1136/bjophthalmol-2020-316514
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YN6FH
UT WOS:000747351900017
PM 33127830
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Wu, ZC
   Luu, CD
   Ab Hodgson, L
   Caruso, E
   Chen, FK
   Chakravarthy, U
   Arnold, JJ
   Heriot, WJ
   Runciman, J
   Guymer, RH
AF Wu, Zhichao
   Luu, Chi D.
   Ab Hodgson, Lauren
   Caruso, Emily
   Chen, Fred K.
   Chakravarthy, Usha
   Arnold, Jennifer J.
   Heriot, Wilson J.
   Runciman, Jim
   Guymer, Robyn H.
TI Examining the added value of microperimetry and low luminance deficit
   for predicting progression in age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Retina; Psychophysics; Diagnostic tests; Investigation; Clinical Trial;
   Macula; Electrophysiology; Prosthesis; Imaging; Public health; Treatment
   Surgery; Vitreous; Stem Cells; Neovascularisation; Treatment Medical;
   Angiogenesis
ID OPTICAL COHERENCE TOMOGRAPHY; TEST-RETEST VARIABILITY; VISUAL FUNCTION;
   ATROPHY
AB Purpose To examine the added predictive value of microperimetric sensitivity and low luminance deficit (LLD; difference between photopic and low luminance visual acuity (VA)) to information from colour fundus photography (CFP) for progression to late age-related macular degeneration (AMD) in individuals with bilateral large drusen. Methods 140 participants with bilateral large drusen underwent baseline microperimetry testing, VA measurements and CFP. They were then reviewed at 6-monthly intervals to 36 months, to determine late AMD progression. Microperimetry pointwise sensitivity SD (PSD), LLD and the presence of pigmentary abnormalities on CFPs were determined. Predictive models based on these parameters were developed and examined. Results Baseline microperimetry PSD and presence of pigmentary abnormalities were both significantly associated with time to develop late AMD (p <= 0.004), but LLD was not (p=0.471). The area under the receiver operating characteristic curve (AUC) for discriminating between eyes that progressed to late AMD based on models using microperimetry PSD (AUC=0.68) and LLD (AUC=0.58) alone was significantly lower than that based on CFP grading for the presence of pigmentary abnormalities (AUC=0.80; both p<0.005). Addition of microperimetry and/or LLD information to a model that included CFP grading did not result in any improvement in its predictive performance (AUC=0.80 for all; all p >= 0.66). Conclusions While microperimetry, but not LLD, was significantly and independently associated with AMD progression at the population level, this study observed that both measures were suboptimal at predicting progression at the individual level when compared to conventional CFP grading and their addition to the latter did not improve predictive performance.
C1 [Wu, Zhichao; Luu, Chi D.; Ab Hodgson, Lauren; Caruso, Emily; Guymer, Robyn H.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Australia.
   [Wu, Zhichao; Luu, Chi D.; Guymer, Robyn H.] Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Vic, Australia.
   [Chen, Fred K.] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Lions Eye Inst, Perth, WA, Australia.
   [Chakravarthy, Usha] Belfast Hlth & Social Care Trust, Belfast, Antrim, North Ireland.
   [Arnold, Jennifer J.] Marsden Eye Res, Sydney, NSW, Australia.
   [Heriot, Wilson J.] Retinol Inst Victoria, Melbourne, Vic, Australia.
   [Runciman, Jim] Adelaide Eye & Retina Ctr, Adelaide, SA, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; Lions Eye Institute; University of Western
   Australia
RP Wu, ZC (通讯作者)，Ctr Eye Res Australia, Level 7,32 Gisborne St, East Melbourne, Australia.
EM wu.z@unimelb.edu.au
OI Chen, Fred/0000-0003-2809-9930
FU National Health & Medical Research Council of Australia [APP1027624,
   GNT1103013, APP1104985, APP1054712, APP1142962]; BUPA Health Foundation
   (Australia); Centre for Eye Research Australia (CERA)
FX This study was supported by National Health & Medical Research Council
   of Australia (project grant no.: APP1027624 (RHG and CDL), and
   fellowship grant no.: GNT1103013 (RHG), APP1104985 (ZW), APP1054712
   (FKC) and APP1142962 (FKC)) and BUPA Health Foundation (Australia) (RHG
   and CDL). CERA receives operational infrastructure support from the
   Victorian Government. The web-based Research Electronic Data Capture
   (REDCap) application and open-source platform OpenClinica allowed secure
   electronic data capture. The study is sponsored by the Centre for Eye
   Research Australia (CERA), an independent medical research institute and
   a not-for-profit company.
CR Cassels NK, 2018, SURV OPHTHALMOL, V63, P40, DOI 10.1016/j.survophthal.2017.05.007
   Chandramohan A, 2016, RETINA-J RET VIT DIS, V36, P1021, DOI 10.1097/IAE.0000000000001002
   Chen FK, 2009, INVEST OPHTH VIS SCI, V50, P3464, DOI 10.1167/iovs.08-2926
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Hsu ST, 2019, OPHTHALMOL RETINA, V3, P637, DOI 10.1016/j.oret.2019.03.010
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lek JJ, 2017, OPHTHALMOL RETINA, V1, P227, DOI 10.1016/j.oret.2016.12.001
   Luu CD, 2012, ARCH OPHTHALMOL-CHIC, V130, P690, DOI 10.1001/archophthalmol.2012.277
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Pencina MJ, 2008, STAT MED, V27, P157, DOI 10.1002/sim.2929
   Pfau M, 2017, INVEST OPHTH VIS SCI, V58, P158, DOI 10.1167/iovs.17-21454
   Royston P, 2006, STATA J, V6, P83, DOI 10.1177/1536867X0600600105
   Sassmannshausen M, 2018, INVEST OPHTH VIS SCI, V59, P1599, DOI 10.1167/iovs.17-22712
   Seddon JM, 2013, JAMA OPHTHALMOL, V131, P448, DOI 10.1001/jamaophthalmol.2013.2578
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2019, OPHTHALMOL RETINA, V3, P1026, DOI 10.1016/j.oret.2019.07.008
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1445, DOI 10.1016/j.ophtha.2014.01.025
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
NR 25
TC 6
Z9 6
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2021
VL 105
IS 5
BP 711
EP 715
DI 10.1136/bjophthalmol-2020-315935
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RQ5IG
UT WOS:000642451300019
PM 32606079
DA 2022-11-30
ER

PT J
AU Landowski, M
   Kelly, U
   Klingeborn, M
   Groelle, M
   Ding, JD
   Grigsby, D
   Rickman, CB
AF Landowski, Michael
   Kelly, Una
   Klingeborn, Mikael
   Groelle, Marybeth
   Ding, Jin-Dong
   Grigsby, Daniel
   Rickman, Catherine Bowes
TI Human complement factor H Y402H polymorphism causes an age-related
   macular degeneration phenotype and lipoprotein dysregulation in mice
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE age-related macular degeneration; complement; lipoproteins; RPE; genetic
   risk
ID C-REACTIVE PROTEIN; HIGH-RISK; ALTERNATIVE PATHWAY; BRUCHS MEMBRANE;
   HEPARAN-SULFATE; PLASMA-LEVELS; CHOLESTEROL; ACTIVATION; GENE; BINDING
AB One of the strongest susceptibility genes for age-related macular degeneration (AMD) is complement factor H (CFH); however, its impact on AMD pathobiology remains unresolved. Here, the effect of the principal AMD-risk-associated CFH variant (Y402H) on the development and progression of age-dependent AMD-like pathologies was determined in vivo. Transgenic mice expressing equal amounts of the full-length normal human CFH Y402 (CFH-Y/0) or the AMD-risk associated CFH H402 (CFH-H/H) variant on a Cfh-/background were aged to 90 weeks and switched from normal diet (ND) to a high fat, cholesterol-enriched (HFC) diet for 8 weeks. The resulting phenotype was compared with age-matched controls maintained on ND. Remarkably, an AMD-like phenotype consisting of vision loss, increased retinal pigmented epithelium (RPE) stress, and increased basal laminar deposits was detected only in aged CFH-H/H mice following the HFC diet. These changes were not observed in aged CFH-Y/0 mice or in younger (36-to 40-weekold) CFH mice of both genotypes fed either diet. Biochemical analyses of aged CFH mice after HFC diet revealed genotype-dependent changes in plasma and eyecup lipoproteins, but not complement activation, which correlated with the AMD-like phenotype in old CFH-H/H mice. Specifically, apolipoproteins B48 and A1 are elevated in the RPE/choroid of the aged CFH-H/H mice compared with agematched control CFH-Y/0 fed a HFC diet. Hence, we demonstrate a functional consequence of the Y402H polymorphism in vivo, which promotes AMD-like pathology development and affects lipoprotein levels in aged mice. These findings support targeting lipoproteins as a viable therapeutic strategy for treating AMD.
C1 [Landowski, Michael; Kelly, Una; Klingeborn, Mikael; Groelle, Marybeth; Ding, Jin-Dong; Grigsby, Daniel; Rickman, Catherine Bowes] Duke Univ, Duke Eye Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   [Rickman, Catherine Bowes] Duke Univ, Dept Cell Biol, Durham, NC 27710 USA.
C3 Duke University; Duke University
RP Rickman, CB (通讯作者)，Duke Univ, Duke Eye Ctr, Dept Ophthalmol, Durham, NC 27710 USA.; Rickman, CB (通讯作者)，Duke Univ, Dept Cell Biol, Durham, NC 27710 USA.
EM bowes007@duke.edu
RI Klingeborn, Mikael/AAC-2471-2019
OI Klingeborn, Mikael/0000-0003-2907-0371; Bowes Rickman,
   Catherine/0000-0002-8555-9596; Landowski, Michael/0000-0003-0151-0689
FU National Eye Institute [R01 EY026161, P30 EY005722]; Research to Prevent
   Blindness/International Retinal Research Foundation Catalyst award for
   Innovative Research Approaches for AMD; Research to Prevent Blindness;
   Macular Degeneration Research Award grant from the BrightFocus
   Foundation; Fighting Blindness Individual Investigator award; NATIONAL
   EYE INSTITUTE [R01EY026161, P30EY005722] Funding Source: NIH RePORTER
FX The authors thank Ying Hao for her expert technical assistance with
   electron microscopy; and Dan Stamer, Scott Cousins, Michael Hauser,
   Daniel Saban, and Yuan Zhuang for their intellectual feedback and
   advice. This work was supported by National Eye Institute funding Grants
   R01 EY026161 (to C.B.R.) and P30 EY005722 (to Duke Eye Center); a
   Research to Prevent Blindness/International Retinal Research Foundation
   Catalyst award for Innovative Research Approaches for AMD (to C.B.R.);
   an unrestricted grant from Research to Prevent Blindness (to the Duke
   Eye Center); a Macular Degeneration Research Award grant from the
   BrightFocus Foundation (to M.K.); and a Fighting Blindness Individual
   Investigator award (to C.B.R.).
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Aredo B, 2015, INVEST OPHTH VIS SCI, V56, P3427, DOI 10.1167/iovs.14-16089
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Chen M, 2016, AGING CELL, V15, P436, DOI 10.1111/acel.12447
   Cheung CMG, 2017, J LIPID RES, V58, P1785, DOI 10.1194/jlr.M073684
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Ding JD, 2015, AM J PATHOL, V185, P29, DOI 10.1016/j.ajpath.2014.08.026
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   DISCIPIO RG, 1992, J IMMUNOL, V149, P2592
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Elner Victor M, 2002, Trans Am Ophthalmol Soc, V100, P301
   Fan Q, 2017, INT J EPIDEMIOL, V46, P1891, DOI 10.1093/ije/dyx189
   FEARON DT, 1978, P NATL ACAD SCI USA, V75, P1971, DOI 10.1073/pnas.75.4.1971
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fujihara M, 2009, EXP EYE RES, V88, P1115, DOI 10.1016/j.exer.2009.01.017
   Garland DL, 2014, HUM MOL GENET, V23, P52, DOI 10.1093/hmg/ddt395
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gordiyenko N, 2004, INVEST OPHTH VIS SCI, V45, P2822, DOI 10.1167/iovs.04-0074
   GUERTIN F, 1994, BBA-LIPID LIPID MET, V1214, P137, DOI 10.1016/0005-2760(94)90037-X
   Guymer RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083759
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hajishengallis G, 2017, NAT IMMUNOL, V18, P1288, DOI 10.1038/ni.3858
   Handa JT, 2017, BBA-MOL CELL BIOL L, V1862, P430, DOI 10.1016/j.bbalip.2016.07.013
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Herrmann R, 2010, J NEUROSCI, V30, P3239, DOI 10.1523/JNEUROSCI.4775-09.2010
   Ji ZS, 1997, J BIOL CHEM, V272, P31285, DOI 10.1074/jbc.272.50.31285
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kelly U, 2010, J IMMUNOL, V185, P5486, DOI 10.4049/jimmunol.0903596
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Li CM, 2005, J LIPID RES, V46, P628, DOI 10.1194/jlr.M400428-JLR200
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mandal NA, 2006, INVEST OPHTH VIS SCI, V47, P4091, DOI 10.1167/iovs.05-1655
   Mange A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034107
   Martin M, 2016, CELL DEATH DIFFER, V23, P903, DOI 10.1038/cdd.2015.164
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   MOLD C, 1984, J IMMUNOL, V133, P882
   Molins B, 2016, SCI REP-UK, V6, DOI 10.1038/srep22889
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Parthasarathy S, 2010, METHODS MOL BIOL, V610, P403, DOI 10.1007/978-1-60327-029-8_24
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Reichhardt MP, 2018, SEMIN IMMUNOL, V38, P54, DOI 10.1016/j.smim.2018.03.003
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rudolf M, 2018, CURR EYE RES, V43, P135, DOI 10.1080/02713683.2017.1370118
   Sarma JV, 2011, CELL TISSUE RES, V343, P227, DOI 10.1007/s00441-010-1034-0
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Silva AS, 2012, MOL VIS, V18, P2288
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Sofat R, 2010, ATHEROSCLEROSIS, V213, P184, DOI 10.1016/j.atherosclerosis.2010.07.021
   Toomey CB, 2018, INVEST OPHTH VIS SCI, V59, P662, DOI 10.1167/iovs.17-23134
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   Ufret-Vincenty RL, 2010, INVEST OPHTH VIS SCI, V51, P5878, DOI 10.1167/iovs.09-4457
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Vergnes L, 2003, J BIOL CHEM, V278, P42774, DOI 10.1074/jbc.M306022200
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yip JLY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132565
   Yu JM, 2007, BIOCHEMISTRY-US, V46, P8451, DOI 10.1021/bi700459a
   Zee RYL, 2006, ATHEROSCLEROSIS, V187, P332, DOI 10.1016/j.atherosclerosis.2005.09.009
   Zheng WC, 2015, J LIPID RES, V56, P81, DOI 10.1194/jlr.M053439
   Zheng WC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037926
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
NR 84
TC 50
Z9 50
U1 1
U2 8
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 26
PY 2019
VL 116
IS 9
BP 3703
EP 3711
DI 10.1073/pnas.1814014116
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HM7YA
UT WOS:000459694400057
PM 30808757
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Merle, BMJ
   Delyfer, MN
   Korobelnik, JF
   Rougier, MB
   Malet, F
   Feart, C
   Le Goff, M
   Peuchant, E
   Letenneur, L
   Dartigues, JF
   Colin, J
   Barberger-Gateau, P
   Delcourt, C
AF Merle, Benedicte M. J.
   Delyfer, Marie-Noelle
   Korobelnik, Jean-Francois
   Rougier, Marie-Benedicte
   Malet, Florence
   Feart, Catherine
   Le Goff, Melanie
   Peuchant, Evelyne
   Letenneur, Luc
   Dartigues, Jean-Francois
   Colin, Joseph
   Barberger-Gateau, Pascale
   Delcourt, Cecile
TI High Concentrations of Plasma n3 Fatty Acids Are Associated with
   Decreased Risk for Late Age-Related Macular Degeneration
SO JOURNAL OF NUTRITION
LA English
DT Article
ID COMPLEMENT FACTOR-H; BASE-LINE-CHARACTERISTICS; 3RD NATIONAL-HEALTH;
   DIETARY-FAT; EICOSAPENTAENOIC ACID; FISH CONSUMPTION; DEPRESSIVE
   SYMPTOMATOLOGY; BORDEAUX SAMPLE; FOOD SOURCES; EYE DISEASE
AB High dietary intakes of n3 (omega 3) polyunsaturated fatty acids (PUFA) and fish have been consistently associated with a decreased risk for age-related macular degeneration (AMD). We assessed the associations of late AMD with plasma n3 PUFA, a nutritional biomarker of n3 PUPA status. The Antioxydants Lipides Essentiels Nutrition et Maladies Occulaires (Alienor) Study is a prospective, population-based study on nutrition and age-related eye diseases performed in 963 residents of Bordeaux (France) aged >= 73 y. Participants had a first eye examination in 2006-2008 and were followed for 31 mo on average. Plasma fatty acids were measured by GC from fasting blood samples collected in 1999-2001. AMD was graded from non-mydriatic color retinal photographs at all examinations and spectral domain optical coherence tomography at follow-up. After adjustment for age, gender, smoking, education, physical activity, plasma HDL-cholesterol, plasma triglycerides, CFH Y402H, apoE4, and ARMS2 A69S polymorphisms, and follow-up time, high plasma total n3 PUFA was associated with a reduced risk for late AMD [OR = 0.62 for 1-SD increase (95% Cl: 0.44-0.88); P = 0.008]. Associations were similar for plasma 18:3n3 [OR = 0.62 (95% Cl: 0.43-0.88); P = 0.008] and n3 long-chain PUFA [OR = 0.65 (95% Cl: 0.46-0.92); P=0.01]. This study gives further support to the potential role of n3 PUFAs in the prevention of late AM D and highlights the necessity of randomized clinical trials to determine more accurately the value of n3 PUFAs as a means of reducing AMD incidence. J. Nutr. 143: 505-511, 2013.
C1 [Merle, Benedicte M. J.; Delyfer, Marie-Noelle; Korobelnik, Jean-Francois; Feart, Catherine; Le Goff, Melanie; Letenneur, Luc; Dartigues, Jean-Francois; Barberger-Gateau, Pascale; Delcourt, Cecile] INSERM, ISPED, Ctr INSERM Epidemiol Biostat U897, Bordeaux, France.
   [Merle, Benedicte M. J.; Delyfer, Marie-Noelle; Korobelnik, Jean-Francois; Feart, Catherine; Le Goff, Melanie; Letenneur, Luc; Dartigues, Jean-Francois; Colin, Joseph; Barberger-Gateau, Pascale; Delcourt, Cecile] Univ Bordeaux, Bordeaux, France.
   [Delyfer, Marie-Noelle; Korobelnik, Jean-Francois; Rougier, Marie-Benedicte; Malet, Florence; Colin, Joseph] CHU Bordeaux, Serv Ophtalmol, Bordeaux, France.
   [Peuchant, Evelyne] INSERM, U876, Bordeaux, France.
   [Peuchant, Evelyne] CHU Bordeaux, Bordeaux, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite de Bordeaux; CHU
   Bordeaux; Institut National de la Sante et de la Recherche Medicale
   (Inserm); CHU Bordeaux
RP Merle, BMJ (通讯作者)，INSERM, ISPED, Ctr INSERM Epidemiol Biostat U897, Bordeaux, France.
EM benedicte.merle@isped.u-bordeaux2.fr
RI Delcourt, Cecile/I-2627-2013; Merle, Benedicte MJ/AAQ-5021-2021;
   LETENNEUR, Luc/T-4424-2019; KOROBELNIK, Jean-Francois/A-5448-2016;
   FEART, Catherine/A-3339-2016; DARTIGUES, Jean François/T-4513-2019;
   Delyfer, Marie-Noelle/T-3304-2019; LE GOFF, Mélanie/A-3541-2016; Merle,
   Benedicte MJ/F-1247-2015
OI Delcourt, Cecile/0000-0002-2099-0481; Merle, Benedicte
   MJ/0000-0003-1332-0954; LETENNEUR, Luc/0000-0002-3274-937X; Merle,
   Benedicte MJ/0000-0003-1332-0954; LE GOFF, Melanie/0000-0003-2848-6287;
   FEART, Catherine/0000-0002-7959-1610
FU Laboratoires Thee (Clermont-Ferrand, France); Fondation Voir et Entendre
   (Paris, France); Conseil Regional d'Aquitaine (Bordeaux, France)
   [20091301029]; Universite Bordeaux (Preciput ANR, Bordeaux, France);
   Association Retina France (Colomiers, France)
FX Supported by Laboratoires Thee (Clermont-Ferrand, France), Fondation
   Voir et Entendre (Paris, France), Conseil Regional d'Aquitaine
   (convention no. 20091301029, Bordeaux, France), Universite Bordeaux
   (Preciput ANR 2008, Bordeaux, France), and Association Retina France
   (Colomiers, France). Laboratoires Thea participated in the design of the
   study but not in the collection, management, statistical analysis, and
   interpretation of the data, nor in the preparation, review, or approval
   of the present manuscript.
CR Alperovitch A, 2003, NEUROEPIDEMIOLOGY, V22, P316, DOI 10.1159/000072920
   Anses, 2011, ACT APP NUTR CONS AC
   Arab L, 2003, J NUTR, V133, p925S, DOI 10.1093/jn/133.3.925S
   Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   Arterburn LM, 2006, AM J CLIN NUTR, V83, p1467S, DOI 10.1093/ajcn/83.6.1467S
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Bazan NG, 2009, J LIPID RES, V50, pS400, DOI 10.1194/jlr.R800068-JLR200
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Carriere I, 2007, INT J VITAM NUTR RES, V77, P57, DOI 10.1024/0300-9831.77.1.57
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Delcourt C, 2007, EUR J CLIN NUTR, V61, P1341, DOI 10.1038/sj.ejcn.1602685
   Delcourt C, 2005, AM J OPHTHALMOL, V140, P924, DOI 10.1016/j.ajo.2005.05.002
   Delcourt C, 2010, J NUTR HEALTH AGING, V14, P854, DOI 10.1007/s12603-010-0131-9
   Delcourt C, 2012, ARCH OPHTHALMOL-CHIC, V130, P1077, DOI 10.1001/archophthalmol.2012.420
   Delcourt C, 2011, INVEST OPHTH VIS SCI, V52, P5955, DOI 10.1167/iovs.10-6235
   Delyfer MN, 2012, INVEST OPHTH VIS SCI, V53, P1204, DOI 10.1167/iovs.11-8721
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Djousse L, 2011, AM J CLIN NUTR, V94, P527, DOI 10.3945/ajcn.111.013334
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Feart C, 2008, AM J CLIN NUTR, V87, P1156, DOI 10.1093/ajcn/87.5.1156
   Feart C, 2007, BRIT J NUTR, V98, P1046, DOI 10.1017/S0007114507756520
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Kroger E, 2009, AM J CLIN NUTR, V90, P184, DOI 10.3945/ajcn.2008.26987
   Lambert JC, 2009, NAT GENET, V41, P1094, DOI 10.1038/ng.439
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Merle B, 2011, INVEST OPHTH VIS SCI, V52, P6004, DOI 10.1167/iovs.11-7254
   Meyer BJ, 2003, LIPIDS, V38, P391, DOI 10.1007/s11745-003-1074-0
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   PEUCHANT E, 1989, ANAL BIOCHEM, V181, P341, DOI 10.1016/0003-2697(89)90254-6
   Robman L, 2007, CAN J OPHTHALMOL, V42, P720, DOI 10.3129/i07-116
   Samieri C, 2008, AM J CLIN NUTR, V88, P714, DOI 10.1093/ajcn/88.3.714
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2009, ARCH OPHTHALMOL-CHIC, V127, P110, DOI 10.1001/archophthalmol.2008.518
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Serra-Majem L, 2012, BRIT J NUTR, V107, pS64, DOI 10.1017/S000711451200147X
   Sioen IA, 2006, LIPIDS, V41, P415, DOI 10.1007/s11745-006-5115-5
   Swenor BK, 2010, OPHTHALMOLOGY, V117, P2395, DOI 10.1016/j.ophtha.2010.03.058
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   Wilk JB, 2012, AM J CLIN NUTR, V96, P882, DOI 10.3945/ajcn.112.042671
   Wolf S, 2010, OPHTHALMOLOGICA, V224, P333, DOI 10.1159/000313814
   ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734
NR 57
TC 52
Z9 52
U1 0
U2 30
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0022-3166
EI 1541-6100
J9 J NUTR
JI J. Nutr.
PD APR
PY 2013
VL 143
IS 4
BP 505
EP 511
DI 10.3945/jn.112.171033
PG 7
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 110JB
UT WOS:000316437300016
PM 23406618
OA Bronze
DA 2022-11-30
ER

PT J
AU Zaliuniene, D
   Paunksnis, A
   Gustiene, O
   Brazdzionyte, J
   Zaliunas, R
AF Zaliuniene, D.
   Paunksnis, A.
   Gustiene, O.
   Brazdzionyte, J.
   Zaliunas, R.
TI Pre- and postoperative C-reactive protein levels in patients with
   cataract and age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; cataract surgery; contrast
   sensitivity; high sensitivity C-reactive protein
ID QUALITY-OF-LIFE; CARDIOVASCULAR-DISEASE; BRUCHS MEMBRANE; VISUAL
   FUNCTION; LENS OPACITIES; RISK-FACTORS; BEAVER DAM; SURGERY;
   MACULOPATHY; INFLAMMATION
AB PURPOSE. To assess whether patients with early or intermediate forms of age-related macular degeneration (AMD) benefit from cataract surgery in terms of visual acuity and contrast sensitivity, and to determine the levels of high sensitivity C-reactive protein (hsCRP) as a systemic marker of inflammation before and after cataract surgery in patients with AMD.
   METHODS. Three groups of patients (n=132) were studied at baseline and 8-12 weeks later: 1) a study group of patients with AMD who underwent cataract surgery (n=47), 2) a control group of patients without ocular comorbidities who underwent cataract surgery (n=36), and 3) a second control group with AMD and no surgery (n=49). Visual acuity (VA) was obtained by letter charts and expressed as decimal notations +/- SD. Contrast sensitivity was measured employing a Ginsburg Box, VSCR-CST-6500. The hsCRP was measured by means of particle enhanced immunonephelometry on a BN Systems.
   RESULTS. Postoperatively in both groups of the operated patients an improvement of VA (0.23+/-0.17 vs 0.64+/-0.25 and 0.23+/-0.18 vs 0.83+/-0.17, respectively, p<0.0001) and contrast sensitivity (at different spatial frequencies, from 1.5 to 18 cycles/degree, p<0.05) was determined. At baseline, the hsCRP level in Group 1 patients was higher than the level in controls (2.67+/-2.36 vs 1.67+/-1.36, p<0.01, or 1.12+/-0.99 mg/L, p<0.0001, respectively). After 8-12 weeks, the hsCRB level only in Group 1 significantly increased (2.67+/-2.36 vs 3.74+/-3.54 mg/L, p<0.05), whereas in the controls it did not change.
   CONCLUSIONS. Patients with AMD benefit from cataract surgery, both in terms of VA and contrast sensitivity. The level of hsCRP is significantly higher in patients with AMD and moderate cataract than in patients with one of these eye disorders. The hsCRP only increases after cataract surgery in patients with AMD.
C1 [Zaliuniene, D.; Paunksnis, A.] Kaunas Univ Med, Dept Ophthalmol, LT-50009 Kaunas, Lithuania.
   [Gustiene, O.; Brazdzionyte, J.; Zaliunas, R.] Kaunas Univ Med, Dept Cardiol, Kaunas, Lithuania.
C3 Lithuanian University of Health Sciences; Lithuanian University of
   Health Sciences
RP Zaliuniene, D (通讯作者)，Kaunas Univ Med, Dept Ophthalmol, LT-50009 Kaunas, Lithuania.
EM r.zaliunas@takas.lt
OI Paunksnis, Alvydas/0000-0002-1224-5588
CR ALEXANDER MF, 1988, ARCH OPHTHALMOL-CHIC, V106, P1543, DOI 10.1001/archopht.1988.01060140711040
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   CHAMBLESS WS, 1979, OPHTHALMOLOGY, V86, P2019
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Cimbalas Andrius, 2003, Medicina (Kaunas), V39, P1237
   Danik JS, 2006, ANN HUM GENET, V70, P705, DOI 10.1111/j.1469-1809.2006.00272.x
   Desai P, 1999, BRIT J OPHTHALMOL, V83, P1336, DOI 10.1136/bjo.83.12.1336
   Dick HB, 2000, OPHTHALMOLOGY, V107, P241, DOI 10.1016/S0161-6420(99)00082-2
   Flach A J, 1998, Trans Am Ophthalmol Soc, V96, P557
   FOSTER CS, 1990, OPHTHALMOLOGY, V88, P163
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Ginsburg Arthur P., 2003, International Ophthalmology Clinics, V43, P5
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GRINDLE CFJ, 1978, T OPHTHAL SOC UK, V98, P172
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   HYKIN PG, 1993, OPHTHALMOLOGY, V100, P394
   Jasinskas Vytautas, 2006, Medicina (Kaunas), V42, P370
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khera A, 2005, J AM COLL CARDIOL, V46, P464, DOI 10.1016/j.jacc.2005.04.051
   Klein BEK, 2006, AM J OPHTHALMOL, V141, P116, DOI 10.1016/j.ajo.2005.08.021
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P191, DOI 10.1001/archopht.1994.01090140067025
   Kraff M C, 1985, J Am Intraocul Implant Soc, V11, P380
   Laidlaw DAH, 1998, LANCET, V352, P925, DOI 10.1016/S0140-6736(97)12536-3
   Laurell CG, 1998, ACTA OPHTHALMOL SCAN, V76, P573, DOI 10.1034/j.1600-0420.1998.760512.x
   LIU IY, 1989, AM J PUBLIC HEALTH, V79, P765, DOI 10.2105/AJPH.79.6.765
   Lundstrom M, 2002, BRIT J OPHTHALMOL, V86, P1330, DOI 10.1136/bjo.86.12.1330
   Lundstrom M, 2001, J CATARACT REFR SURG, V27, P1553, DOI 10.1016/S0886-3350(01)00984-1
   Lundstrom M, 1999, BRIT J OPHTHALMOL, V83, P1272, DOI 10.1136/bjo.83.11.1272
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Moses L, 1978, J Am Intraocul Implant Soc, V4, P17
   NISHI O, 1992, BRIT J OPHTHALMOL, V76, P338, DOI 10.1136/bjo.76.6.338
   Olson RJ, 1998, AM J OPHTHALMOL, V125, P612, DOI 10.1016/S0002-9394(98)00017-8
   Pearson TA, 2003, CIRCULATION, V107, P499, DOI 10.1161/01.CIR.0000052939.59093.45
   PENFOLD P, 1984, AUST J OPHTHALMOL, V12, P23
   PENFOLD PL, 1987, GRAEF ARCH CLIN EXP, V225, P70, DOI 10.1007/BF02155808
   Pollack A, 1998, OPHTHALMIC SURG LAS, V29, P286
   Rifai N, 2004, CLIN CHIM ACTA, V346, P55, DOI 10.1016/j.cccn.2004.02.034
   Schaumberg DA, 1999, ANN EPIDEMIOL, V9, P166, DOI 10.1016/S1047-2797(98)00049-0
   SCHEIN OD, 1995, OPHTHALMOLOGY, V102, P817, DOI 10.1016/S0161-6420(95)30952-9
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   SEVERIN T D, 1988, Ophthalmic Surgery, V19, P116
   Shuttleworth GN, 1998, BRIT J OPHTHALMOL, V82, P611, DOI 10.1136/bjo.82.6.611
   STARK WJ, 1984, SURV OPHTHALMOL, V28, P442, DOI 10.1016/0039-6257(84)90226-1
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   Taylor HR, 2000, BRIT J OPHTHALMOL, V84, P1, DOI 10.1136/bjo.84.1.1
   TIELSCH JM, 1995, ARCH OPHTHALMOL-CHIC, V113, P1312, DOI 10.1001/archopht.1995.01100100100038
   VANDERSCHAFT TL, 1994, BRIT J OPHTHALMOL, V78, P441, DOI 10.1136/bjo.78.6.441
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Wang JJ, 1999, INVEST OPHTH VIS SCI, V40, P12
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 59
TC 7
Z9 8
U1 0
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD NOV-DEC
PY 2007
VL 17
IS 6
BP 919
EP 927
DI 10.1177/112067210701700609
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 265UO
UT WOS:000253386800009
PM 18050118
DA 2022-11-30
ER

PT J
AU Arrigo, A
   Aragona, E
   Capone, L
   Pierro, L
   Romano, F
   Bandello, F
   Parodi, MB
AF Arrigo, Alessandro
   Aragona, Emanuela
   Capone, Luigi
   Pierro, Luisa
   Romano, Francesco
   Bandello, Francesco
   Parodi, Maurizio Battaglia
TI Advanced Optical Coherence Tomography Angiography Analysis of
   Age-related Macular Degeneration Complicated by Onset of Unilateral
   Choroidal Neovascularization
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL VESSEL TORTUOSITY; MECHANISMS; DIAMETER; CHORIOCAPILLARIS;
   PRESSURE
AB PURPOSE: To analyze optical coherence tomography angiography (OCTA) quantitative features in patients affected by new-onset choroidal neovascularization (CNV) in 1 eye and early/intermediate age-related macular degeneration (AMD) in the fellow eye.
   DESIGN: Case-control study.
   METHODS: SETTING: Clinical practice. STUDY POPULATION: Thirty patients and 30 age-matched controls. OBSERVATION PROCEDURES: Both cohorts underwent complete ophthalmologic examination, including bestcorrected visual acuity (BCVA) measurement, biomicroscopy, fluorescein angiography (FA) and indocyanine green angiography (ICGA) examination, optical coherence tomography, and OCTA scans. The 1-way a test with Bonferroni correction was used to assess statistical significance and Tau Kendall's correlation analysis was performed. MAIN OUTCOME MEASURES: BCVA, choroidal thickness, vessel density, vessel tortuosity, vessel dispersion. and vessel rarefaction.
   RESULTS: Mean BCVA was 20/32 for CNV eyes and 20/20 for both fellow and control eyes. Choroidal thickness was 190.33 +/- 63.98 mu m for CNV eyes, 216.83 +/- 50.31 mu m for fellow eyes, and 310.52 +/- 27.13 mu m for controls. The quantitative analysis of retinal vessels revealed significant alterations, especially in the deep capillary plexus and radial peripapillary capillaries, both in CNV and in fellow eyes, compared with controls. In particular, decreased vessel density and tortuosity and increased dispersion and rarefaction were found. Several significant correlations were also found among the quantitative parameters adopted.
   CONCLUSIONS: New postprocessing OCTA parameters are able to detect deep retinal vascular alterations quantitatively, in both CNV-affected and fellow eyes of patients with new-onset CNV. Further investigations are warranted in order to explore the validity of these new approaches on follow-up. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Arrigo, Alessandro; Aragona, Emanuela; Capone, Luigi; Pierro, Luisa; Romano, Francesco; Bandello, Francesco; Parodi, Maurizio Battaglia] Univ Vita Salute, IRCCS Osped San Raffaele, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Arrigo, A (通讯作者)，Univ Vita Salute, IRCCS Osped San Raffaele, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.
EM alessandro.arrigo@hotmail.com
RI bandello, francesco/AAH-2405-2019; Parodi, Maurizio
   Battaglia/K-7876-2016; Pierro, Luisa/AAN-3900-2020; aragona,
   emanuela/AAN-5778-2020
OI bandello, francesco/0000-0003-3238-9682; aragona,
   emanuela/0000-0002-4254-8600; Battaglia Parodi,
   Maurizio/0000-0002-0385-7961; pierro, luisa/0000-0003-2168-5224; Arrigo,
   Alessandro/0000-0003-4715-8414
CR Al-Sheikh Mayss, 2017, Int J Retina Vitreous, V3, P13, DOI 10.1186/s40942-017-0068-9
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Arganda-Carreras I, 2010, MICROSC RES TECHNIQ, V73, P1019, DOI 10.1002/jemt.20829
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Cachulo L, 2011, OPHTHALMOLOGICA, V225, P144, DOI 10.1159/000321064
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chalam K V, 2016, J Ophthalmic Vis Res, V11, P84, DOI 10.4103/2008-322X.180709
   D'Amore A, 2010, BIOMATERIALS, V31, P5345, DOI 10.1016/j.biomaterials.2010.03.052
   Dougherty G, 2010, MED BIOL ENG COMPUT, V48, P87, DOI 10.1007/s11517-009-0559-4
   Farecki ML, 2017, GRAEF ARCH CLIN EXP, V255, P913, DOI 10.1007/s00417-017-3588-y
   Ferrara D, 2017, INVEST OPHTH VIS SCI, V58, P3519, DOI 10.1167/iovs.17-21696
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Grisan E, 2008, IEEE T MED IMAGING, V27, P310, DOI 10.1109/TMI.2007.904657
   Han HC, 2012, J VASC RES, V49, P185, DOI 10.1159/000335123
   Hotaling NA, 2015, BIOMATERIALS, V61, P327, DOI 10.1016/j.biomaterials.2015.05.015
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   KYLSTRA JA, 1986, GRAEF ARCH CLIN EXP, V224, P477, DOI 10.1007/BF02173368
   Liew G, 2008, OPHTHALMOLOGY, V115, P1951, DOI 10.1016/j.ophtha.2008.05.029
   LIU ZQ, 1991, APPL OPTICS, V30, P1369, DOI 10.1364/AO.30.001369
   Ma J, 2017, OPHTHALMOL EYE DIS, V9, DOI 10.1177/1179172116686075
   Manikandan S, 2011, J PHARMACOL PHARMACO, V2, P315, DOI 10.4103/0976-500X.85931
   Mase T, 2016, INVEST OPHTH VIS SCI, V57, pOCT504, DOI 10.1167/iovs.15-18877
   Masters BR, 2004, ANNU REV BIOMED ENG, V6, P427, DOI 10.1146/annurev.bioeng.6.040803.140100
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Tomba E, 2010, IND ENG CHEM RES, V49, P2957, DOI 10.1021/ie901179m
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yanagi Y, 2017, INVEST OPHTH VIS SCI, V58, P3488, DOI 10.1167/iovs.16-21167
NR 31
TC 25
Z9 25
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD NOV
PY 2018
VL 195
BP 233
EP 242
DI 10.1016/j.ajo.2018.08.001
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HA1WZ
UT WOS:000450020300029
PM 30098346
DA 2022-11-30
ER

PT J
AU Kremlitzka, M
   Geerlings, MJ
   de Jong, S
   Bakker, B
   Nilsson, SC
   Fauser, S
   Hoyng, CB
   de Jong, EK
   den Hollander, AI
   Blom, AM
AF Kremlitzka, Mariann
   Geerlings, Maartje J.
   de Jong, Sarah
   Bakker, Bjorn
   Nilsson, Sara C.
   Fauser, Sascha
   Hoyng, Carel B.
   de Jong, Eiko K.
   den Hollander, Anneke I.
   Blom, Anna M.
TI Functional analyses of rare genetic variants in complement component C9
   identified in patients with age-related macular degeneration
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID MEMBRANE-ATTACK-COMPLEX; HIGH-RISK; ACTIVATION; CELLS; GENOTYPES; CFH
AB Age-related macular degeneration (AMD) is a progressive disease of the central retina and the leading cause of irreversible vision loss in the western world. The involvement of abnormal complement activation in AMD has been suggested by association of variants in genes encoding complement proteins with disease development. A low-frequency variant (p. P167S) in the complement component C9 (C9) gene was recently shown to be highly associated with AMD; however, its functional outcome remains largely unexplored. In this study, we reveal five novel rare genetic variants (p. M45L, p. F62S, p. G126R, p. T170I and p. A529T) in C9 in AMD patients, and evaluate their functional effects in vitro together with the previously identified (p. R118Wand p. P167S) C9 variants. Our results demonstrate that the concentration of C9 is significantly elevated in patients' sera carrying the p. M45L, p. F62S, p. P167S and p. A529T variants compared with non-carrier controls. However, no difference can be observed in soluble terminal complement complex levels between the carrier and non-carrier groups. Comparing the polymerization of the C9 variants we reveal that the p. P167S mutant spontaneously aggregates, while the other mutant proteins (except for C9 p. A529T) fail to polymerize in the presence of zinc. Altered polymerization of the p. F62S and p. P167S proteins associated with decreased lysis of sheep erythrocytes and adult retinal pigment epithelial-19 cells by carriers' sera. Our data suggest that the analyzed C9 variants affect only the secretion and polymerization of C9, without influencing its classical lytic activity. Future studies need to be performed to understand the implications of the altered polymerization of C9 in AMD pathology.
C1 [Kremlitzka, Mariann; de Jong, Sarah; Nilsson, Sara C.; Blom, Anna M.] Lund Univ, Dept Translat Med, Div Med Prot Chem, S-21428 Malmo, Sweden.
   [Geerlings, Maartje J.; de Jong, Sarah; Bakker, Bjorn; Hoyng, Carel B.; de Jong, Eiko K.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, NL-6525 EX Nijmegen, Netherlands.
   [Nilsson, Sara C.] Univ Hosp Cologne, Dept Ophthalmol, D-50937 Cologne, Germany.
   [Fauser, Sascha] F Hoffmann La Roche & Cie AG, Basel, Switzerland.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Human Genet, NL-6525 EX Nijmegen, Netherlands.
C3 Lund University; Radboud University Nijmegen; University of Cologne;
   Roche Holding; Radboud University Nijmegen
RP Blom, AM (通讯作者)，Lund Univ, Dept Translat Med, Inga Marie Nilssons St 53, S-21428 Malmo, Sweden.
EM anna.blom@med.lu.se
RI Blom, Anna/B-9607-2009; de Jong, Sarah/B-7706-2018; Blom,
   Anna/AFS-7369-2022; Geerlings, Maartje/P-8309-2015; Hollander, Anneke
   den/N-4911-2014; Geerlings, Maartje/P-3338-2019
OI Blom, Anna/0000-0002-1348-1734; Geerlings, Maartje/0000-0003-1164-3573;
   Geerlings, Maartje/0000-0003-1164-3573; de Jong,
   Sarah/0000-0002-3705-3371
FU Wenner-Gren Foundation; Royal Physiographic Society of Lund [37352];
   Lars Hierta's Memorial Foundation [FO2016-0079]; European Research
   Council under the European Union [310644]; Foundation Fighting Blindness
   USA [C-GE-0811-0548-RAD04]; Swedish Research Council [2016-01142]; grant
   for clinical research (ALF)
FX This work was supported by the Wenner-Gren Foundation, The Royal
   Physiographic Society of Lund (37352) and the Lars Hierta's Memorial
   Foundation (FO2016-0079), awarded to M.K. The research leading to these
   results has received funding from the European Research Council under
   the European Union's Seventh Framework Programme (FP/2007-2013)/ERC
   Grant Agreement n. 310644 (MACULA), the Foundation Fighting Blindness
   USA (grant C-GE-0811-0548-RAD04), the Swedish Research Council
   (2016-01142) and a grant for clinical research (ALF).
CR Chakravarthy U, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c981
   Dudkina NV, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10588
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Geerlings MJ, 2017, JAMA OPHTHALMOL, V135, P39, DOI 10.1001/jamaophthalmol.2016.4604
   Horiuchi T, 1998, J IMMUNOL, V160, P1509
   Kilgore KS, 1997, AM J PATHOL, V150, P2019
   Kunchithapautham K, 2011, J BIOL CHEM, V286, P23717, DOI 10.1074/jbc.M110.214593
   Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057
   Lueck K, 2011, EYE, V25, P1074, DOI 10.1038/eye.2011.109
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Niculescu F, 1999, ATHEROSCLEROSIS, V142, P47, DOI 10.1016/S0021-9150(98)00185-3
   Nishiguchi KM, 2012, INVEST OPHTH VIS SCI, V53, P508, DOI 10.1167/iovs.11-8425
   PODACK ER, 1982, P NATL ACAD SCI-BIOL, V79, P574, DOI 10.1073/pnas.79.2.574
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Ristau T, 2014, INVEST OPHTH VIS SCI, V55, P5228, DOI 10.1167/iovs.14-14299
   Ristau T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093459
   Saksens NTM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0144367
   Saksens NTM, 2016, JAMA OPHTHALMOL, V134, P287, DOI 10.1001/jamaophthalmol.2015.5592
   Samuel W, 2017, MOL VIS, V23, P60
   Schick T, 2017, EYE, V31, P810, DOI 10.1038/eye.2016.328
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Smailhodzic D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112682
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Sonnen Andreas F-P, 2014, Subcell Biochem, V80, P83, DOI 10.1007/978-94-017-8881-6_6
   Tegla CA, 2011, IMMUNOL RES, V51, P45, DOI 10.1007/s12026-011-8239-5
   Triantafilou K, 2013, J CELL SCI, V126, P2903, DOI 10.1242/jcs.124388
   Vlaicu SI, 2013, IMMUNOL RES, V56, P109, DOI 10.1007/s12026-012-8381-8
   Yu Y, 2016, HUM MOL GENET, V25, P5276, DOI 10.1093/hmg/ddw336
NR 33
TC 13
Z9 13
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD AUG 1
PY 2018
VL 27
IS 15
BP 2678
EP 2688
DI 10.1093/hmg/ddy178
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA GP5WD
UT WOS:000440946000007
PM 29767720
OA Bronze
DA 2022-11-30
ER

PT J
AU Kim, HS
   Cho, HJ
   Yoo, SG
   Kim, JH
   Han, JI
   Lee, TG
   Kim, JW
AF Kim, H. S.
   Cho, H. J.
   Yoo, S. G.
   Kim, J. H.
   Han, J. I.
   Lee, T. G.
   Kim, J. W.
TI Intravitreal anti-vascular endothelial growth factor monotherapy for
   large submacular hemorrhage secondary to neovascular age-related macular
   degeneration
SO EYE
LA English
DT Article
ID TISSUE-PLASMINOGEN ACTIVATOR; PNEUMATIC DISPLACEMENT; CHOROIDAL
   NEOVASCULARIZATION; SUBRETINAL HEMORRHAGE; VITREOUS HEMORRHAGE;
   RANIBIZUMAB; INJECTION; BEVACIZUMAB; MANAGEMENT; GAS
AB Purpose To evaluate the efficacy of anti-vascular endothelial growth factor (VEGF) monotherapy for large submacular hemorrhage (SMH) secondary to neovascular age-related macular degeneration (nAMD).
   Methods A total of 49 treatment-naive patients (49 eyes) with large SMH (more than five disc areas (DAs)) secondary to nAMD were retrospectively included. All patients were treated with an initial series of 3 monthly intravitreal anti-VEGF injections, followed by as-needed injections. At the 12-month follow-up, changes in best-corrected visual acuity (BCVA), hemorrhage area, central foveal thickness, and development of vitreous hemorrhage after treatment were evaluated.
   Results The mean SMH area was 13.9 +/- 8.8 disk areas (DAs) and mean symptom duration was 7.25 +/- 5.9 days at baseline. The mean number of injections was 4.49 +/- 1.61. Twelve months after treatment, the mean BCVA significantly improved from 1.14 +/- 0.61 logarithm of the minimum angle of resolution (logMAR; 20/276, Snellen equivalent) to 0.82 +/- 0.53 logMAR (20/132; P = 0.002). Twenty-four eyes (49%) showed improvement of more than three lines of BCVA at 12 months after treatment. Baseline BCVA (odds ratio (OR), 5.119; 95% confidence interval (CI), 1.993-9.545; P = 0.004), duration of symptoms (OR, 0.727; 95% CI, 0.332-0.952; P = 0.024), hemorrhage area (OR, 0.892; 95% CI, 0.721-0.965; P = 0.011), and baseline central foveal thickness (OR, 0.881; 95% CI, 0.722-0.945; P = 0.032) were significantly associated with good visual acuity 12 months after treatment.
   Conclusions Intravitreal anti-VEGF monotherapy is a valuable treatment option for large SMH secondary to nAMD.
C1 [Kim, H. S.; Cho, H. J.; Yoo, S. G.; Kim, J. H.; Han, J. I.; Lee, T. G.; Kim, J. W.] Konyang Univ, Coll Med, Myung Gok Eye Res Inst, Ophthalmol,Kims Eye Hosp, Seoul, South Korea.
C3 Konyang University; Konyang University Hospital
RP Cho, HJ (通讯作者)，Kims Eye Hosp, 156,4ga, Seoul, South Korea.
EM chojoo@kimeye.com
CR Averbukh E, 2000, OPHTHALMOLOGY, V107, P2118, DOI 10.1016/S0161-6420(00)00295-5
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Cho HJ, 2015, RETINA-J RET VIT DIS, V35, P205, DOI 10.1097/IAE.0000000000000295
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P524, DOI 10.1016/j.ajo.2013.04.029
   Fujikawa M, 2013, RETINA-J RET VIT DIS, V33, P1908, DOI 10.1097/IAE.0b013e318287d99d
   Gopalakrishan M, 2007, RETINA-J RET VIT DIS, V27, P329, DOI 10.1097/01.iae.0000231544.43093.40
   Handwerger BA, 2001, ARCH OPHTHALMOL-CHIC, V119, P28
   Hasegawa T, 2010, AM J OPHTHALMOL, V149, P322, DOI 10.1016/j.ajo.2009.09.012
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Iacono P, 2014, RETINA-J RET VIT DIS, V34, P281, DOI 10.1097/IAE.0b013e3182979e33
   Kamei M, 1999, AM J OPHTHALMOL, V128, P739, DOI 10.1016/S0002-9394(99)00239-1
   Kim JH, 2014, OPHTHALMOLOGY, V121, P926, DOI 10.1016/j.ophtha.2013.11.004
   Luke M, 2007, BRIT J OPHTHALMOL, V91, P1077, DOI 10.1136/bjo.2006.111260
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McKibbin M, 2010, EYE, V24, P994, DOI 10.1038/eye.2009.271
   Mizutani T, 2011, GRAEF ARCH CLIN EXP, V249, P1153, DOI 10.1007/s00417-011-1649-1
   Shienbaum G, 2013, AM J OPHTHALMOL, V155, P1009, DOI 10.1016/j.ajo.2013.01.012
   Steel DHW, 2011, BRIT J OPHTHALMOL, V95, P1051, DOI 10.1136/bjo.2010.182253
   Treumer F, 2012, BRIT J OPHTHALMOL, V96, P708, DOI 10.1136/bjophthalmol-2011-300655
   Wu TT, 2011, RETINA-J RET VIT DIS, V31, P2071, DOI 10.1097/IAE.0b013e31822528c8
NR 25
TC 7
Z9 8
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD SEP
PY 2015
VL 29
IS 9
BP 1142
EP 1150
DI 10.1038/eye.2015.131
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CR0XD
UT WOS:000361046000003
PM 26272443
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Little, DM
   Thulborn, KR
   Szlyk, JP
AF Little, Deborah M.
   Thulborn, Keith R.
   Szlyk, Janet P.
TI An fMRI study of saccadic and smooth-pursuit eye movement control in
   patients with age-related macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID PREFERRED RETINAL LOCI; RETINITIS-PIGMENTOSA; CENTRAL SCOTOMAS; VISUAL
   FUNCTION; CORTEX; INDIVIDUALS; MACULOPATHY; PERFORMANCE; PROGRESSION;
   DYSTROPHIES
AB PURPOSE. To compare the cortical networks that underlie oculomotor function in patients with age-related macular degeneration (AMD) with those in normally sighted control subjects, using functional magnetic resonance imaging (fMRI).
   METHODS. Six patients with bilateral geographic retinal atrophy due to AMD ( age range, 55 - 83 years) were recruited for the study. The visual acuities of the patients ranged from 20/76 (0.58 logMAR) to 20/360 (1.26 logMAR). An additional six younger ( age range, 22 - 31 years) and six older (age range, 54 - 78 years) normally sighted individuals were recruited as control subjects. fMRI data were acquired on a 3.0-Tesla, scanner while subjects performed visually guided saccade (VGS) and smooth-pursuit (SmP) tasks.
   RESULTS. Contrasts between VGS and fixation on a stationary target identified a network of activation that included the frontal eye fields ( FEFs),supplementary eye fields (SMA/SEFs), prefrontal cortex (PFC), intraparietal sulci (IPS), and the areas of the visual cortex (MT/V5,V2/V3,and V1) in control subjects and patients. A similar network was identified for comparisons between SmP and periods of fixation. Marked variability was observed in the performance of both tasks across all patients. For both tasks, the patients generally showed increased PFC and IPS activation, with decreased activation in visual cortex compared with the control subjects. The patients showed significantly increased activation of the FEFs and SMA/SEFs in the SmP task, compared with the control subjects.
   CONCLUSIONS. These data suggest that performance of both eye movement tasks required greater involvement of the cortical regions generally implicated in attention and effort in patients with AMD.
C1 [Little, Deborah M.] Univ Illinois, Chicago Coll Med, Dept Neurol & Rehabilitat, Chicago, IL 60612 USA.
   [Little, Deborah M.] Univ Illinois, Chicago Coll Med, Dept Anat & Cell Biol, Chicago, IL 60612 USA.
   [Little, Deborah M.; Szlyk, Janet P.] Univ Illinois, Chicago Coll Med, Dept Ophthalmol & Visual Sci, Chicago, IL 60612 USA.
   [Little, Deborah M.; Szlyk, Janet P.] Univ Illinois, Chicago Coll Med, Dept Psychol, Chicago, IL 60612 USA.
   [Little, Deborah M.] Univ Illinois, Chicago Coll Med, Ctr Stroke Res, Chicago, IL 60612 USA.
   [Little, Deborah M.] Univ Illinois, Chicago Coll Med, Ctr Cognit Med, Chicago, IL 60612 USA.
   [Thulborn, Keith R.] Univ Illinois, Chicago Coll Med, Ctr MR Res, Chicago, IL 60612 USA.
   [Szlyk, Janet P.] Jesse Brown Vet Adm Med Ctr, Res & Dev Serv, Chicago, IL USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical
   Center
RP Little, DM (通讯作者)，Univ Illinois, Chicago Coll Med, Dept Neurol & Rehabilitat, 1645 W Jackson,Suite 400, Chicago, IL 60612 USA.
EM little@uic.edu
RI Thulborn, Keith Raymond/D-9183-2015
OI Thulborn, Keith Raymond/0000-0001-6197-4296
CR Baker CI, 2005, J NEUROSCI, V25, P614, DOI 10.1523/JNEUROSCI.3476-04.2005
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Cohen MS, 1997, NEUROIMAGE, V6, P93, DOI 10.1006/nimg.1997.0278
   Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014
   Crawford JR, 1998, CLIN NEUROPSYCHOL, V12, P482, DOI 10.1076/clin.12.4.482.7241
   CULHAM LE, 1992, OPHTHAL PHYSL OPT, V12, P281, DOI 10.1111/j.1475-1313.1992.tb00398.x
   CUMMINGS RW, 1985, AM J OPTOM PHYS OPT, V62, P833
   Dassonville P, 1997, P NATL ACAD SCI USA, V94, P14015, DOI 10.1073/pnas.94.25.14015
   Deruaz A, 2002, VISION RES, V42, P2947, DOI 10.1016/S0042-6989(02)00354-1
   DeYoe EA, 1996, P NATL ACAD SCI USA, V93, P2382, DOI 10.1073/pnas.93.6.2382
   EDDY WF, 1996, FUNCTIONAL IMAGE ANA
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508
   Frederikse ME, 1999, CEREB CORTEX, V9, P896, DOI 10.1093/cercor/9.8.896
   Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037
   Grosbras MH, 2001, CEREB CORTEX, V11, P936, DOI 10.1093/cercor/11.10.936
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KNOBLAUCH K, 1991, J OPT SOC AM A, V8, P428, DOI 10.1364/JOSAA.8.000428
   Lee CU, 2002, ARCH GEN PSYCHIAT, V59, P775, DOI 10.1001/archpsyc.59.9.775
   LEGGE GE, 1992, INVEST OPHTH VIS SCI, V33, P677
   Lei H, 1997, INVEST OPHTH VIS SCI, V38, P1812
   Luna B, 1998, CEREB CORTEX, V8, P40, DOI 10.1093/cercor/8.1.40
   Petre KL, 2000, OPTOMETRY VISION SCI, V77, P34, DOI 10.1097/00006324-200001000-00011
   RAYNER K, 1979, SCIENCE, V206, P468, DOI 10.1126/science.504987
   RUBIN GS, 1994, VISION RES, V34, P1723, DOI 10.1016/0042-6989(94)90129-5
   Seiple W, 2005, INVEST OPHTH VIS SCI, V46, P2886, DOI 10.1167/iovs.04-1296
   Sokal R., 2000, BIOMETRY, V3rd ed., P451
   Sunness JS, 2004, OPHTHALMOLOGY, V111, P1595, DOI 10.1016/j.ophtha.2003.12.050
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   Szlyk JP, 1997, ARCH OPHTHALMOL-CHIC, V115, P53, DOI 10.1001/archopht.1997.01100150055009
   Szlyk JP, 1998, RETINA-J RET VIT DIS, V18, P360
   Szlyk JP, 2001, OPHTHALMOLOGY, V108, P65, DOI 10.1016/S0161-6420(00)00413-9
   Szlyk JP, 1998, BRIT J OPHTHALMOL, V82, P1372, DOI 10.1136/bjo.82.12.1372
   Szlyk JP, 2004, J VISUAL IMPAIR BLIN, V98, P261
   Thulborn KR, 1999, MAGNET RESON MED, V41, P1039, DOI 10.1002/(SICI)1522-2594(199905)41:5<1039::AID-MRM24>3.3.CO;2-E
   WHITE JM, 1990, INVEST OPHTH VIS SCI, V31, P1149
   WHITTAKER SG, 1993, OPTOMETRY VISION SCI, V70, P54, DOI 10.1097/00006324-199301000-00010
   WHITTAKER SG, 1991, VISION RES, V31, P2209, DOI 10.1016/0042-6989(91)90173-3
   XING J, 1994, VISION RES, V34, P1901, DOI 10.1016/0042-6989(94)90314-X
NR 40
TC 16
Z9 16
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2008
VL 49
IS 4
BP 1728
EP 1735
DI 10.1167/iovs.07-0372
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 282ON
UT WOS:000254577200059
PM 18385097
DA 2022-11-30
ER

PT J
AU Gillies, MC
   Campain, A
   Walton, R
   Simpson, JM
   Arnold, JJ
   Guymer, RH
   McAllister, IL
   Hunyor, AP
   Essex, RW
   Morlet, N
   Barthelmes, D
AF Gillies, Mark C.
   Campain, Anna
   Walton, Richard
   Simpson, Judy M.
   Arnold, Jennifer J.
   Guymer, Robyn H.
   McAllister, Ian L.
   Hunyor, Alex P.
   Essex, Rohan W.
   Morlet, Nigel
   Barthelmes, Daniel
CA Fight Retinal Blindness Study Grp
TI Time to Initial Clinician-Reported Inactivation of Neovascular
   Age-Related Macular Degeneration Treated Primarily with Ranibizumab
SO OPHTHALMOLOGY
LA English
DT Article
ID OUTCOMES; TRIAL
AB Purpose: To characterize in more detail routine treatment patterns of intravitreal ranibizumab for neovascular age-related macular degeneration (nAMD), we analyzed the length of time and the number of injections required until lesions with choroidal neovascularization (CNV) were first graded inactive.
   Design: Database observational study.
   Participants: Treatment-naive eyes receiving predominantly ranibizumab for nAMD in routine clinical practice that were tracked in the Fight Retinal Blindness! observational registry.
   Methods: Eyes treated with ranibizumab were followed until CNV was first reported to be "inactive" (i.e., absence of intraretinal fluid and hemorrhages).
   Main Outcome Measures: The length of time until lesion inactivation occurred and the number of injections required.
   Results: A total of 1096 eyes (65.8% from women) were included in the study. The median number of weeks until a lesion was graded as inactive after beginning treatment was 15 weeks. One to 3 injections were sufficient to inactivate the lesion in 61.1% of eyes. A mean change in visual acuity of +5.5 logarithm of the minimum angle of resolution letters (95% confidence interval, 4.8-6.3) was found from treatment initiation to the time that eyes were reported as inactive. In eyes with a mean treatment frequency less than every 5.3 weeks, a median of only 3 injections (mean - 3.7) were required before lesions with CNV were graded as inactive, but if the mean treatment interval extended beyond 5.3 weeks, the median number of injections required increased sharply to 6 injections (mean, 7 injections). Occult lesions became inactive more slowly than classic lesions.
   Conclusions: Most lesions with CNV became inactive with 3 injections of ranibizumab, but a small proportion remained active for more than 12 months. Injection frequency and lesion type were the main factors that predicted the time and number of injections required to render lesions inactive. (C) 2015 by the American Academy of Ophthalmology.
C1 [Gillies, Mark C.; Campain, Anna; Walton, Richard; Hunyor, Alex P.; Barthelmes, Daniel] Univ Sydney, Sydney Med Sch, Save Sight Inst, Sydney, NSW 2006, Australia.
   [Simpson, Judy M.] Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia.
   [Arnold, Jennifer J.] Marsden Eye Specialists, Parramatta, NSW, Australia.
   [Guymer, Robyn H.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [McAllister, Ian L.] Univ Western Australia, Ctr Ophthalmol & Vis Sci, Lions Eye Inst, Crawley, WA, Australia.
   [Hunyor, Alex P.] Retina Associates, Chatswood, NSW, Australia.
   [Essex, Rohan W.] Australian Natl Univ, Acad Unit Ophthalmol, Acton, ACT, Australia.
   [Morlet, Nigel] Univ Western Australia, Dept Populat Hlth, Perth, WA 6009, Australia.
   [Barthelmes, Daniel] Univ Zurich, Univ Zurich Hosp, Dept Ophthalmol, Zurich, Switzerland.
C3 University of Sydney; University of Sydney; Centre for Eye Research
   Australia; Royal Victorian Eye & Ear Hospital; University of Melbourne;
   Lions Eye Institute; University of Western Australia; Australian
   National University; University of Western Australia; University of
   Zurich; University Zurich Hospital
RP Barthelmes, D (通讯作者)，Univ Zurich Hosp, Dept Ophthalmol, Frauenklin Str 24, CH-8091 Zurich, Switzerland.
EM daniel.barthelmes@usz.ch
RI Hunyor, Alex/AAT-8205-2021
OI Hunyor, Alex/0000-0002-8182-6167; Essex, Rohan/0000-0001-5323-0334;
   Simpson, Judy M/0000-0001-5172-3004; Campain, Anna/0000-0003-1057-0085;
   Guymer, Robyn/0000-0002-9441-4356
FU NHMRC; Advisory board - Novartis; Bayer; Allergan; Novartis
   Pharmaceuticals; Bayer Pharmaceuticals; Walter and Gertrud Siegenthaler
   Foundation, Zurich, Switzerland; Swiss National Foundation; Royal
   Australian; New Zealand College of Ophthalmologists Eye Foundation;
   National Health and Medical Research Council [632663]; Australia (NHRMC)
FX M.C.G.: Sydney Medical Foundation Fellow; Support - NHMRC practitioner
   fellowship; Advisory board - Novartis, Bayer, and Allergan.; J.J.A.:
   Personal fees and nonfinancial support - Novartis Pharmaceuticals and
   Bayer Pharmaceuticals, outside the submitted work.; A.P.H.: Support -
   Novartis and Bayer.; D.B.: Support - Walter and Gertrud Siegenthaler
   Foundation, Zurich, Switzerland, and the Swiss National Foundation.;
   Supported by a grant from the Royal Australian and New Zealand College
   of Ophthalmologists Eye Foundation (2007-2009) and a grant from the
   National Health and Medical Research Council (grant no. 632663),
   Australia (NHRMC 2010-2012). Funding was also provided by Novartis and
   Bayer. These supporting organizations had no role in the design or
   conduct of the research.
CR Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cleveland WS, 1992, STAT MODELS S, V1, P309
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gass JD, 1967, AM J OPHTHALMOL S, V63, P1
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P676, DOI 10.1016/j.ophtha.2013.09.050
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Gillies MC, 2013, INVEST OPHTH VIS SCI, V54, P5754, DOI 10.1167/iovs.13-11993
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2014, OPHTHALMOLOGY, V121, P1414, DOI 10.1016/j.ophtha.2014.01.027
   Hollis S, 1999, BRIT MED J, V319, P670, DOI 10.1136/bmj.319.7211.670
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
NR 18
TC 18
Z9 18
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2015
VL 122
IS 3
BP 589
EP +
DI 10.1016/j.ophtha.2014.10.001
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CC2DF
UT WOS:000350154600029
PM 25458197
DA 2022-11-30
ER

PT J
AU Wu, J
   Uchino, M
   Sastry, SM
   Schaumberg, DA
AF Wu, Juan
   Uchino, Miki
   Sastry, Srinivas M.
   Schaumberg, Debra A.
TI Age-Related Macular Degeneration and the Incidence of Cardiovascular
   Disease: A Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID MYOCARDIAL-INFARCTION; RISK-FACTORS; APOLIPOPROTEIN-E; EYE DISEASE;
   MACULOPATHY; MORTALITY; GENOTYPES; STROKE; GENE
AB Importance: Research has indicated some shared pathogenic mechanisms between age-related macular degeneration (AMD) and cardiovascular disease (CVD). However, results from prior epidemiologic studies have been inconsistent as to whether AMD is predictive of future CVD risk.
   Objective: To systematically review population-based cohort studies of the association between AMD and risk of total CVD and CVD subtypes, coronary heart disease (CHD) and stroke.
   Data Sources: A systematic search of the PubMed and EMBASE databases and reference lists of key retrieved articles up to December 20, 2012 without language restriction.
   Data Extraction: Two reviewers independently extracted data on baseline AMD status, risk estimates of CVD and methods used to assess AMD and CVD. We pooled relative risks using random or fixed effects models as appropriate.
   Results: Thirteen cohort studies (8 prospective and 5 retrospective studies) with a total of 1,593,390 participants with 155,500 CVD events (92,039 stroke and 62,737 CHD) were included in this meta-analysis. Among all studies, early AMD was associated with a 15% (95% CI, 1.08-1.22) increased risk of total CVD. The relative risk was similar but not significant for late AMD (RR, 1.17; 95% CI, 0.98-1.40). In analyses restricted to the subset of prospective studies, the risk associated with early AMD did not appreciably change; however, there was a marked 66% (95% CI, 1.31-2.10) increased risk of CVD among those with late AMD.
   Conclusion: Whereas the results from all cohort studies suggest that both early and late AMD are predictive of a small increase in risk of future CVD, subgroup analyses limited to prospective studies demonstrate a markedly increased risk of CVD among people with late AMD. Retrospective studies using healthcare databases may have inherent methodological limitations that obscure such association. Additional prospective studies are needed to further elucidate the associations between AMD and specific CVD outcomes.
C1 [Wu, Juan] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
   [Uchino, Miki] Keio Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan.
   [Sastry, Srinivas M.] Suburban Hosp, Bethesda, MD USA.
   [Schaumberg, Debra A.] Harvard Univ, Div Prevent Med, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
   [Schaumberg, Debra A.] Univ Utah, Sch Med, Dept Ophthalmol & Visual Sci, Moran Ctr Translat Med,John A Moran Eye Ctr, Salt Lake City, UT USA.
   [Schaumberg, Debra A.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   [Schaumberg, Debra A.] Schepens Eye Res Inst, Boston, MA USA.
C3 Harvard University; Harvard T.H. Chan School of Public Health; Keio
   University; Harvard University; Brigham & Women's Hospital; Harvard
   Medical School; Utah System of Higher Education; University of Utah;
   Harvard University; Harvard T.H. Chan School of Public Health; Harvard
   University; Schepens Eye Research Institute
RP Wu, J (通讯作者)，Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
EM juan.wu@mail.harvard.edu
RI Uchino, Miki/T-9102-2019
FU National Eye Institute [EY021900, EY017362]; Research to Prevent
   Blindness, Inc., New York, NY; NATIONAL EYE INSTITUTE [R01EY017362,
   R01EY021900] Funding Source: NIH RePORTER
FX This work was supported in part by EY021900, and EY017362 from the
   National Eye Institute (Dr. Schaumberg); and by an Unrestricted Grant
   from Research to Prevent Blindness, Inc., New York, NY, to the
   Department of Ophthalmology & Visual Sciences, University of Utah (Dr.
   Schaumberg). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Fernandez AB, 2012, OPHTHALMOLOGY, V119, P765, DOI 10.1016/j.ophtha.2011.09.044
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Golan S, 2011, GRAEF ARCH CLIN EXP, V249, P179, DOI 10.1007/s00417-010-1489-4
   GREENLAND S, 1992, AM J EPIDEMIOL, V135, P1301, DOI 10.1093/oxfordjournals.aje.a116237
   GREENLAND S, 1987, EPIDEMIOL REV, V9, P1
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   Ikram MK, 2012, STROKE, V43, P1681, DOI 10.1161/STROKEAHA.112.654632
   Kardys I, 2006, J AM COLL CARDIOL, V47, P1568, DOI 10.1016/j.jacc.2005.11.076
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Knudtson MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P243, DOI 10.1001/archopht.124.2.243
   Liao DP, 2008, OPEN OPHTHALMOL J, V2, P37, DOI 10.2174/1874364100802010037
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lloyd-Jones D, 2009, CIRCULATION, V119, pE21, DOI 10.1161/CIRCULATIONAHA.108.191261
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Mitta VP, 2013, JAMA OPHTHALMOL, P1
   Nguyen-Khoa BA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1280, DOI 10.1001/archopht.126.9.1280
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Sofat R, 2010, ATHEROSCLEROSIS, V213, P184, DOI 10.1016/j.atherosclerosis.2010.07.021
   Song YQ, 2004, ANN INTERN MED, V141, P137, DOI 10.7326/0003-4819-141-2-200407200-00013
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wieberdink RG, 2011, STROKE, V42, P2138, DOI 10.1161/STROKEAHA.111.616359
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
NR 42
TC 55
Z9 57
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 28
PY 2014
VL 9
IS 3
AR e89600
DI 10.1371/journal.pone.0089600
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AE0TC
UT WOS:000333678100002
PM 24681973
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Auffarth, GU
   Reiter, J
   Leitritz, M
   Bartz-Schmidt, KU
   Hohn, F
   Breyer, D
   Kaymak, H
   Rohrschneider, K
   Khoramnia, R
   Yildirim, TM
AF Auffarth, Gerd U.
   Reiter, Josef
   Leitritz, Martin
   Bartz-Schmidt, Karl-Ulrich
   Hohn, Fabian
   Breyer, Detlev
   Kaymak, Hakan
   Rohrschneider, Klaus
   Khoramnia, Ramin
   Yildirim, Timur M.
TI High-addition segmented refractive bifocal intraocular lens in inactive
   age-related macular degeneration: A multicenter pilot study
SO PLOS ONE
LA English
DT Article
ID TELESCOPIC LENS; END-STAGE; EFFICACY; DISEASE; SAFETY
AB This multicenter, open-label study aimed to determine the safety and functional outcome of a high-addition segmented refractive bifocal intraocular lens (IOL) in late inactive age-related macular degeneration (AMD). Twenty eyes of 20 patients were enrolled and followed until 12 months after the intervention. Patients underwent cataract surgery with implantation of a LS-313 MF80 segmented refractive bifocal intraocular lens with a near addition of +8.0 D (Teleon Surgical Vertriebs GmbH, Berlin, Germany). The main outcome measures were distance corrected near visual acuity (DCNVA) and safety as determined by intra- and post-operative complications. Secondary outcomes included distance corrected visual acuity (CDVA), uncorrected distance visual acuity (UDVA), uncorrected near visual acuity (UNVA), the need for magnification to read newspaper, preferred reading distance, speed and performance (logRAD), as well as patient satisfaction. Mean DCNVA improved from 0.95 (+/- 0.19) to 0.74 (+/- 0.35) logMAR, until 6 months after surgery, P < 0.05. CDVA improved from 0.70 (+/- 0.23) to 0.59 (+/- 0.30) logMAR, UDVA from 0.94 (+/- 0.25) to 0.69 (+/- 0.34) logMAR, UNVA from 1.08 (+/- 0.19) to 0.87 (+/- 0.43) logMAR. The mean need for magnification decreased from 2.9- to 2.3-fold, preferred reading distance from 23 to 20 cm. No intraoperative complications occurred during any of the surgeries. One patient lost > 2 lines of CDVA between 6 and 12 months, in another case, the study IOL was exchanged for a monofocal one due to dysphotopsia and decreased CDVA. Implantation of a segmented refractive bifocal IOL with +8.0 D addition improves near and distance vision in patients with late AMD and has a satisfactory safety profile.
C1 [Auffarth, Gerd U.; Rohrschneider, Klaus; Khoramnia, Ramin; Yildirim, Timur M.] Heidelberg Univ, Int Vis Correct Res Ctr, Dept Ophthalmol, Heidelberg, Germany.
   [Reiter, Josef] Augen MVZ Landshut, Landshut, Germany.
   [Leitritz, Martin; Bartz-Schmidt, Karl-Ulrich] Univ Tubingen, Ctr Ophthalmol, Tubingen, Germany.
   [Hohn, Fabian] Marien Hosp, Osnabruck, Germany.
   [Breyer, Detlev; Kaymak, Hakan] Breyer & Kaymak Augenchirurg, Dusseldorf, Germany.
C3 Ruprecht Karls University Heidelberg; Eberhard Karls University of
   Tubingen; Eberhard Karls University Hospital; St. Marien Hospital
RP Auffarth, GU (通讯作者)，Heidelberg Univ, Int Vis Correct Res Ctr, Dept Ophthalmol, Heidelberg, Germany.
EM gerd.auffarth@med.uni-heidelberg.de
RI Khoramnia, Ramin/AAR-8358-2020
OI Khoramnia, Ramin/0000-0002-6237-7773; Rohrschneider,
   Klaus/0000-0003-1996-7935
FU Oculentis/Teleon Surgical Vertriebs GmbH, Berlin, Germany [OCL/LS-313
   MF80/02]; Physician-Scientist Program of the Heidelberg University,
   Faculty of Medicine; Klaus Tschira Stiftung, Heidelberg, Germany
FX This study was funded by Oculentis/Teleon Surgical Vertriebs GmbH,
   Berlin, Germany, under the protocol number OCL/LS-313 MF80/02. GA
   receives funding from the DKlaus Tschira Stiftung, Heidelberg, Germany.
   TY is funded by the Physician-Scientist Program of the Heidelberg
   University, Faculty of Medicine. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Agarwal A, 2008, J CATARACT REFR SURG, V34, P87, DOI 10.1016/j.jcrs.2007.08.031
   Alio JL, 2004, J CATARACT REFR SURG, V30, P1177, DOI 10.1016/j.jcrs.2003.10.038
   [Anonymous], 2018, AGE RELATED MACULAR
   Borkenstein AF, 2020, CASE REP OPHTHALM, V11, P448, DOI 10.1159/000508914
   Borkenstein AF, 2019, CLIN CASE REP, V7, P74, DOI 10.1002/ccr3.1912
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Boyer D, 2015, CLIN OPHTHALMOL, V9, P1099, DOI 10.2147/OPTH.S86208
   Cionni RJ, 2009, J CATARACT REFR SURG, V35, P1033, DOI 10.1016/j.jcrs.2009.02.018
   Dag MY, 2019, EUR J OPHTHALMOL, V29, P615, DOI 10.1177/1120672118803831
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Grzybowski A, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-5851
   Hengerer FH, 2018, OPHTHALMOL RETINA, V2, P900, DOI 10.1016/j.oret.2018.02.003
   Hengerer FH, 2015, J REFRACT SURG, V31, P158, DOI 10.3928/1081597X-20150220-03
   Holzer MP, 2006, OPHTHALMOLOGE, V103, P661, DOI 10.1007/s00347-006-1382-z
   Hou XW, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.14.13
   Khoramnia R, 2010, OPHTHALMOLOGE, V107, P274, DOI 10.1007/s00347-009-2094-y
   Kretz Florian Tobias Alwin, 2016, Korean J Ophthalmol, V30, P382
   Linz K, 2016, J REFRACT SURG, V32, P526, DOI 10.3928/1081597X-20160603-02
   Lipshitz I, 1997, OPHTHALMIC SURG LAS, V28, P513
   Minetto MA, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041216
   Orzalesi N, 2007, OPHTHALMOLOGY, V114, P860, DOI 10.1016/j.ophtha.2007.01.005
   Potgieter FJ, 2014, J CATARACT REFR SURG, V40, P1085, DOI 10.1016/j.jcrs.2013.10.049
   Qureshi MA, 2015, J CATARACT REFR SURG, V41, P2125, DOI 10.1016/j.jcrs.2015.03.021
   Radner T, 1998, KLIN MONATSBL AUGENH, V213, P174, DOI 10.1055/s-2008-1034969
   Reyes-Ortiz CA, 2005, J AM GERIATR SOC, V53, P681, DOI 10.1111/j.1532-5415.2005.53219.x
   Scharioth GB, 2015, J CATARACT REFR SURG, V41, P1559, DOI 10.1016/j.jcrs.2015.07.018
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Srinivasan S, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000322
   Verghese J, 2003, NEW ENGL J MED, V348, P2508, DOI 10.1056/NEJMoa022252
   Yildirim TM, 2019, KLIN MONATSBL AUGENH, V236, P983, DOI 10.1055/s-0043-119993
NR 30
TC 1
Z9 1
U1 1
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 2
PY 2021
VL 16
IS 9
AR e0256985
DI 10.1371/journal.pone.0256985
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA WG5QV
UT WOS:000707050100081
PM 34473779
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Enz, TJ
   Faes, L
   Bachmann, LM
   Thiel, MA
   Howell, JP
   Boehni, SC
   Bittner, M
   Schmid, MK
AF Enz, Tim J.
   Faes, Livia
   Bachmann, Lucas M.
   Thiel, Michael A.
   Howell, Jeremy P.
   Boehni, Sophie C.
   Bittner, Mario
   Schmid, Martin K.
TI Comparison of macular parameters after femtosecond laser-assisted and
   conventional cataract surgery in age-related macular degeneration
SO JOURNAL OF CATARACT AND REFRACTIVE SURGERY
LA English
DT Article
ID PHACOEMULSIFICATION; CAPSULOTOMY; OUTCOMES; EDEMA
AB Purpose: To evaluate differences in postoperative central macular thickness, central macular volume, corrected distance visual acuity (CDVA), and number of intravitreal anti-vascular endothelial growth factor (VEGF) injections between conventional and femtosecond laser assisted cataract surgery in wet age-related macular degeneration (AMD).
   Setting: Tertiary referral center, Lucerne, Switzerland.
   Design: Retrospective case series.
   Methods: Consecutive patients with AMD and cataract were enrolled between January 2010 and December 2015. Associations between postoperative changes in central macular thickness, central macular volume, CDVA, and number of anti-VEGF injections with type of surgery were assessed statistically.
   Results: The study comprised 140 eyes (110 patients). No differences in postoperative central macular thickness (-9.20 mu m; 95% confidence interval [CI], -41.68 to 23.28; P=.576), central macular volume (-0.08 mm(2); 95% CI, 0.36 to 0.19; P=.553), visual acuity (0.03 logarithm of the minimum angle of resolution; 95% CI, -0.09 to 0.15; P=.647) or postoperative number of anti-VEGF injections (0.30; 95% CI, -0.45 to 1.05; P=.427) were found between the femtosecond laser group and the conventional group over a mean follow-up of 619 days +/- 473 (SD). In the 33 eyes that had optical coherence tomography measurement within a postoperative period of 2 weeks, the central macular volume was significantly lower in femtosecond laser treated eyes (-0.71 mm(2); 95% CI, -1.19 to -0.23; P=.005).
   Conclusions: Overall, the postoperative course between wet AMD after femtosecond laser and conventional cataract surgery was equal. During the early follow-up, femtosecond laser treated eyes had less subclinical macular edema, indicating a possible benefit for patients with macular vulnerability.
C1 [Enz, Tim J.; Thiel, Michael A.; Howell, Jeremy P.; Boehni, Sophie C.; Bittner, Mario; Schmid, Martin K.] Cantonal Hosp Lucerne, Eye Clin, Luzern, Switzerland.
   [Faes, Livia; Bachmann, Lucas M.] Medignition Inc Res Consultants, Zurich, Switzerland.
C3 Lucerne Cantonal Hospital
RP Bachmann, LM (通讯作者)，Medignition Inc, Verena Conzett Str 9, CH-8004 Zurich, Switzerland.
EM bachmann@medignition.ch
FU Novartis Schweiz AG, Basel, Switzerland
FX Dr. Enz was funded by an unrestricted grant from Novartis Schweiz AG,
   Basel, Switzerland.
CR Abell RG, 2015, J CATARACT REFR SURG, V41, P47, DOI 10.1016/j.jcrs.2014.06.025
   Abell RG, 2013, J CATARACT REFR SURG, V39, P1321, DOI 10.1016/j.jcrs.2013.06.009
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Donaldson KE, 2013, J CATARACT REFR SURG, V39, P1753, DOI 10.1016/j.jcrs.2013.09.002
   Dong LM, 2009, ARCH OPHTHALMOL-CHIC, V127, P1412, DOI 10.1001/archophthalmol.2009.152
   Ewe SYP, 2016, OPHTHALMOLOGY, V123, P178, DOI 10.1016/j.ophtha.2015.09.026
   Ewe SYP, 2015, J CATARACT REFR SURG, V41, P2373, DOI 10.1016/j.jcrs.2015.04.031
   Filkom T, 2012, J REFRACT SURG, V28, P540, DOI 10.3928/1081597X-20120703-04
   Friedman NJ, 2011, J CATARACT REFR SURG, V37, P1189, DOI 10.1016/j.jcrs.2011.04.022
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Grixti A, 2014, ISRN OPHTHALMOL, V2014
   Kranitz K, 2012, J REFRACT SURG, V28, P259, DOI 10.3928/1081597X-20120309-01
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Nagy Z, 2009, J REFRACT SURG, V25, P1053, DOI 10.3928/1081597X-20091117-04
   Nagy ZZ, 2012, J CATARACT REFR SURG, V38, P941, DOI 10.1016/j.jcrs.2012.02.031
   Nagy ZZ, 2011, J REFRACT SURG, V27, P564, DOI 10.3928/1081597X-20110607-01
   Saraf SS, 2015, AM J OPHTHALMOL, V160, P487, DOI 10.1016/j.ajo.2015.06.006
   Schultz T, 2013, J REFRACT SURG, V29, P742, DOI 10.3928/1081597X-20131021-03
   Yonekawa Y, 2012, CURR OPIN OPHTHALMOL, V23, P26, DOI 10.1097/ICU.0b013e32834cd5f8
   Yu YH, 2016, CLIN EXP OPHTHALMOL, V44, P472, DOI 10.1111/ceo.12695
NR 20
TC 2
Z9 3
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0886-3350
EI 1873-4502
J9 J CATARACT REFR SURG
JI J. Cataract. Refract. Surg.
PD JAN
PY 2018
VL 44
IS 1
BP 23
EP 27
DI 10.1016/j.jcrs.2017.09.030
PG 5
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA FZ7TJ
UT WOS:000427806700005
PM 29361327
DA 2022-11-30
ER

PT J
AU Day, S
   Acquah, K
   Mruthyunjaya, P
   Grossman, DS
   Lee, PP
   Sloan, FA
AF Day, Shelley
   Acquah, Kofi
   Mruthyunjaya, Prithvi
   Grossman, Daniel S.
   Lee, Paul P.
   Sloan, Frank A.
TI Ocular Complications After Anti-Vascular Endothelial Growth Factor
   Therapy in Medicare Patients With Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL INJECTIONS; PROPENSITY SCORE; VISUAL IMPAIRMENT;
   RANIBIZUMAB; BEVACIZUMAB; ENDOPHTHALMITIS; SAFETY; VALIDATION; CLAIMS
AB PURPOSE: To determine longitudinal rates of ocular complications after anti-vascular endothelial growth factor (VEGF) treatment for neovascular age-related macular degeneration (AMD) in a nationally representative longitudinal sample.
   DESIGN: Retrospective, longitudinal case-control study.
   METHODS: Using the Medicare 5% claims database, diagnoses of neovascular AMD and anti-VEGF injections of ranibizumab, bevacizumab, or pegaptanib were identified from International Classification of Diseases and Current Procedural Terminology procedure codes. Six thousand one hundred fifty-four individuals undergoing anti-VEGF treatment for neovascular AMD (total of 40 903 injections) were compared with 6154 matched controls with neovascular AMD who did not undergo anti-VEGF treatment. Propensity score matching was used to match individuals receiving anti-VEGF injections with controls. Rates of postinjection adverse outcomes (endophthalmitis, rhegmatogenous retinal detachment, retinal tear, uveitis, and vitreous hemorrhage) were analyzed by cumulative incidence and Cox proportional hazards model to control for demographic factors and ocular comorbidities.
   RESULTS: At the 2-year follow-up, the rates of endophthalmitis per injection (0.09%; P < .01), uveitis (0.11%; P < .01), and vitreous hemorrhage per injection (0.23%; P < .01) were significantly higher in the anti-VEGF treatment group. With Cox proportional hazards modeling, the anti-VEGF treatment group had a 102% higher risk of severe ocular complications overall and a 4% increased risk per injection, both of which were statistically significant (P <.01).
   CONCLUSIONS: Rates of endophthalmitis, uveitis, and vitreous hemorrhage were higher in the group treated with anti-VEGF injection than in the control group, although these nevertheless were rare in both groups. The overall risk of severe ocular complications was significantly higher in the anti-VEGF treatment group. (Am J Ophthalmol 2011;152:266-272. (C) 2011 by Elsevier Inc. All rights reserved.)
C1 [Acquah, Kofi; Grossman, Daniel S.; Sloan, Frank A.] Duke Univ, Dept Econ, Durham, NC 27708 USA.
   [Day, Shelley; Mruthyunjaya, Prithvi; Lee, Paul P.] Duke Eye Ctr, Dept Ophthalmol, Durham, NC USA.
C3 Duke University; Duke University
RP Sloan, FA (通讯作者)，Duke Univ, Dept Econ, 236 Social Sci Bldg,Box 90097, Durham, NC 27708 USA.
EM fsloan@duke.edu
OI Day Ghafoori, Shelley/0000-0001-6674-7877; Lee,
   Paul/0000-0002-3338-136X; mruthyunjaya, prithvi/0000-0003-1087-9736
FU NATIONAL INSTITUTE on Aging, Bethesda, Maryland [2R37-AG-17473-05A1];
   Alcon; National Institute of Health; Washington University; NATIONAL
   INSTITUTE ON AGING [R01AG017473, R37AG017473] Funding Source: NIH
   RePORTER
FX PUBLICATION OF THIS ARTICLE WAS SUPPORTED IN PART BY GRANT
   2R37-AG-17473-05A1 FROM THE NATIONAL INSTITUTE on Aging, Bethesda,
   Maryland. The sponsor had no role in the design or conduct of this
   study. Dr Paul Lee has served as a consultant for Allergan, Pfizer, and
   Genentech, and he has received financial support from Alcon, the
   National Institute of Health, and the Washington University Award.
   Involved in Design of study (S.D., K.A., F.A.S., D.S.G., P.P.L.);
   Conduct of study (S.D., K.A., F.A.S., D.S.G.); Collection, management,
   analysis, and interpretation of data (S.D., F.A.S., D.S.G., P.P.L.,
   P.M.); and Preparation, review, or approval of manuscript (S.D., F.A.S.,
   D.S.G., P.P.L., P.M.). The Duke University Institutional Review Board
   approved this study.
CR Austin PC, 2007, STAT MED, V26, P734, DOI 10.1002/sim.2580
   Bhavsar AR, 2009, ARCH OPHTHALMOL-CHIC, V127, P1581, DOI 10.1001/archophthalmol.2009.304
   BOYER DS, 2008, AAO SOE JOINT ANN M
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Cooper GS, 2002, MED CARE S, V40, pIV
   D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B
   Diago T, 2009, RETINA-J RET VIT DIS, V29, P601, DOI 10.1097/IAE.0b013e31819d2591
   Du XLL, 2006, MED CARE, V44, P124, DOI 10.1097/01.mlr.0000196978.34283.a6
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   Fintak DR, 2008, RETINA-J RET VIT DIS, V28, P1395, DOI 10.1097/IAE.0b013e3181884fd2
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   JAVITT JC, 1993, ARCH OPHTHALMOL-CHIC, V111, P605, DOI 10.1001/archopht.1993.01090050039024
   Ladas ID, 2009, RETINA-J RET VIT DIS, V29, P313, DOI 10.1097/IAE.0b013e31819a5f98
   Lima LH, 2009, RETINA-J RET VIT DIS, V29, P1213, DOI 10.1097/IAE.0b013e3181b32d27
   Normand SLT, 2001, J CLIN EPIDEMIOL, V54, P387, DOI 10.1016/S0895-4356(00)00321-8
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sato T, 2010, OPHTHALMOLOGY, V117, P512, DOI 10.1016/j.ophtha.2009.07.041
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
NR 25
TC 117
Z9 121
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD AUG
PY 2011
VL 152
IS 2
BP 266
EP 272
DI 10.1016/j.ajo.2011.01.053
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 799WW
UT WOS:000293317900018
PM 21664593
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Mullins, RE
   Johnson, MN
   Faidley, EA
   Skeie, JM
   Huang, JA
AF Mullins, Robert E.
   Johnson, Micaela N.
   Faidley, Elizabeth A.
   Skeie, Jessica M.
   Huang, Jian
TI Choriocapillaris Vascular Dropout Related to Density of Drusen in Human
   Eyes with Early Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; OCULAR BLOOD-FLOW; BRUCHS MEMBRANE;
   MORPHOMETRIC-ANALYSIS; RISK-FACTORS; CARDIOVASCULAR-DISEASE; POTENTIAL
   ROLE; PATHOGENESIS; DEPOSITS; ATHEROSCLEROSIS
AB PURPOSE. Age-related macular degeneration (AMD) is a common, potentially blinding disease characterized by the presence of extracellular deposits beneath the retinal pigment epithelium (RPE). Choroidal vascular changes have also been noted in AMD. This study examined the relationship between the choroidal vasculature and extent of drusen and other sub-RPE deposits, the key pathologic landmarks of AMD.
   METHODS. Sections of the maculas of 45 human eyes (21 early AMD and 24 age-matched control) were evaluated morphometrically. The cross-sectional area of sub-RPE deposits, vascular density, number of CD45+ leukocytes, and number of "ghost vessels" were determined in a masked fashion and evaluated by regression analysis. In addition, the extramacular vascular density either directly beneath drusen or adjacent to drusen was evaluated in a separate set of donor eyes.
   RESULTS. The vascular density of the choriocapillaris showed a trend toward decreasing in association with AMD status. By linear regression analysis, vascular density was inversely associated with sub-RPE deposit density (r(2) = 0.22, P < 0.01). The number of ghost vessels was negatively correlated with vascular density (r(2) = 0.55, P < 0.001) and positively correlated with sub-RPE deposit density (r(2) = 0.57, P < 0.001). In morphologic studies of extramacular solitary drusen, vascular density beneath drusen was found to be 45% lower than adjacent to drusen (P < 0.01).
   CONCLUSIONS. These findings support the concept that microvascular Changes are related to the pathogenesis of AMD and suggest that vascular endothelial cell loss occurs in association with sub-RPE deposit formation. Whether microvascular events are a cause or consequence of drusen or other deposit formation remains to be determined. (Invest Ophthalmol Vis Sci. 2011;52:1606-1612) DOI:10.1167/iovs.10-6476
C1 [Mullins, Robert E.; Johnson, Micaela N.; Faidley, Elizabeth A.; Skeie, Jessica M.] Carver Coll Med, Dept Ophthalmol & Visual Sci, Iowa City, IA USA.
   [Huang, Jian] Univ Iowa, Dept Stat & Actuarial Sci, Iowa City, IA 52242 USA.
C3 University of Iowa
RP Mullins, RE (通讯作者)，4135E MERF,375 Newton Rd, Iowa City, IA 52242 USA.
EM robert-mullins@uiowa.edu
RI Mullins, Robert F/I-6717-2013
OI Mullins, Robert/0000-0002-5006-0891; HUANG, Jian/0000-0002-5218-9269
FU National Eye Institute [EY017451]; Foundation Fighting Blindness; Macula
   Vision Research Foundation; NATIONAL EYE INSTITUTE [R01EY017451,
   F32EY022280] Funding Source: NIH RePORTER
FX Supported in part by National Eye Institute Grant EY017451, a center
   grant from the Foundation Fighting Blindness, and the Macula Vision
   Research Foundation. REM holds the Hansjoerg E. J. W. Kohler
   Professorship for Best Disease Research.
CR Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   BARTHEL LK, 1990, J HISTOCHEM CYTOCHEM, V38, P1383, DOI 10.1177/38.9.2201738
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Chen SJ, 2001, BRIT J OPHTHALMOL, V85, P1411, DOI 10.1136/bjo.85.12.1411
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Ezzat MK, 2008, BRIT J OPHTHALMOL, V92, P976, DOI 10.1136/bjo.2007.129742
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   FRIEDMAN E, 1963, ARCH OPHTHALMOL-CHIC, V69, P220
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Kochounian H, 2009, EXP EYE RES, V88, P1129, DOI 10.1016/j.exer.2009.01.019
   Kuroki AM, 2002, OPHTHALMIC RES, V34, P200, DOI 10.1159/000063886
   Lengyel I, 2004, INVEST OPHTH VIS SCI, V45, P2886, DOI 10.1167/iovs.03-1083
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Lutty GA, 2005, VISION RES, V45, P3504, DOI 10.1016/j.visres.2005.08.022
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   MIETTINEN M, 1983, AM J CLIN PATHOL, V79, P32, DOI 10.1093/ajcp/79.1.32
   Mori F, 2001, BRIT J OPHTHALMOL, V85, P531, DOI 10.1136/bjo.85.5.531
   Mullins RF, 2006, MOL VIS, V12, P224
   Mullins RF, 2005, MOL VIS, V11, P509
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins Robert F., 2007, International Ophthalmology Clinics, V47, P1, DOI 10.1097/IIO.0b013e31802bd3e6
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Seth A, 2008, INVEST OPHTH VIS SCI, V49, P743, DOI 10.1167/iovs.07-1072
   SKEIE JM, INVEST OPHT IN PRESS
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Stone EM, 2006, NEW ENGL J MED, V355, P1493, DOI 10.1056/NEJMe068191
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   WANG L, PLOS ONE, V5
   WESSA P, 2008, LINEAR REGRESSION GR
   Winkler BS, 1999, MOL VIS, V5
   Wong RW, 2007, RETINA-J RET VIT DIS, V27, P997, DOI 10.1097/IAE.0b013e318074c290
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   ZARBIN MA, RETINA, V30, P1350
NR 60
TC 254
Z9 258
U1 0
U2 14
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2011
VL 52
IS 3
BP 1606
EP 1612
DI 10.1167/iovs.10-6476
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 742SR
UT WOS:000288965300049
PM 21398287
OA Green Published
DA 2022-11-30
ER

PT J
AU Kasahara, E
   Lin, LR
   Ho, YS
   Reddy, VN
AF Kasahara, E
   Lin, LR
   Ho, YS
   Reddy, VN
TI SOD2 protects against oxidation-induced apoptosis in mouse retinal
   pigment epithelium: Implications for age-related macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID MANGANESE SUPEROXIDE-DISMUTASE; FOCAL CEREBRAL-ISCHEMIA; CYTOCHROME-C;
   MITOCHONDRIAL-FUNCTION; MUTANT MICE; CELL-DEATH; STRESS; DAMAGE;
   DISEASES; DEFICIENCY
AB PURPOSE. Oxidative stress from reactive oxygen species (ROS) has been implicated in many diseases, including age-related macular degeneration (AMD), in which the retinal pigment epithelium (RPE) is considered a primary target. Because manganese superoxide dismutase (SOD2), localized in mitochondria, is known to be a key enzyme that protects the cells against oxidative stress, this study was undertaken to examine oxidation-induced apoptosis in cultured RPE cells with various levels of SOD2.
   METHODS. Primary cultures of RPE cells were established from wild-type (WT), heterozygous Sod2-knockout mouse ( HET) and hemizygous Sod2 mice with overexpression of the enzyme ( HEMI). Purity of the RPE cell cultures was verified by immunostaining with antibody to RPE65 and quantified by flow cytometry. Oxidative stress was induced in RPE cells by exposing them to H2O2 (0 - 500 mu M) for 1 hour and reculturing them in normal medium for various times ( 0 - 24 hours). Apoptosis in the RPE was examined by TUNEL staining and quantified by cell-death - detection ELISA. Mitochondrial transmembrane potential (MTP) was measured by a cationic dye, and cytochrome c leakage from mitochondria was analyzed by Western blot analysis.
   RESULTS. More than 95% of the cells in each culture were RPE65 positive, and the relative SOD2 levels in HET, WT, and HEMI cells were 0.6, 1.0, and 3.4, respectively. H2O2-induced apoptotic cell death was both dose and time dependent, and apoptosis in these cells was related to the cellular SOD2 level. Disruption of MTP and release of cytochrome c were observed to occur before apoptotic cell death, and they correlated with cellular SOD2.
   CONCLUSIONS. The results demonstrate a critical role of SOD2 in protection against oxidative challenge. Cells from HET mice showed greater apoptotic cell death, whereas in those from HEMI mice, cell death induced by oxidative injury was suppressed.
C1 Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48105 USA.
   Wayne State Univ, Inst Environm Hlth Sci, Detroit, MI USA.
C3 University of Michigan System; University of Michigan; Wayne State
   University
RP Reddy, VN (通讯作者)，Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, 1000 Wall St, Ann Arbor, MI 48105 USA.
EM venreddy@umich.edu
RI KASAHARA, EMIKO/D-8649-2011
FU NATIONAL EYE INSTITUTE [R01EY000484, P30EY005230, R37EY000484] Funding
   Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
   [R01HL056421] Funding Source: NIH RePORTER; NEI NIH HHS [R01
   EY000484-36, EY 00484, P30 EY005230-13, R01 EY000484, R37 EY000484, F31
   EY007003, EY 07003, P30 EY007003] Funding Source: Medline; NHLBI NIH HHS
   [HL 56421] Funding Source: Medline
CR AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915
   Barron MJ, 2001, INVEST OPHTH VIS SCI, V42, P3016
   Cai JY, 1999, INVEST OPHTH VIS SCI, V40, P959
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527
   Chen ZY, 1998, J MOL CELL CARDIOL, V30, P2281, DOI 10.1006/jmcc.1998.0789
   Fujimura M, 1999, J NEUROSCI, V19, P3414
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710
   Ho YS, 1998, AM J RESP CELL MOL, V18, P538, DOI 10.1165/ajrcmb.18.4.2959
   HO YS, 1988, FEBS LETT, V229, P256, DOI 10.1016/0014-5793(88)81136-0
   Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706
   Jonas EA, 2003, J NEUROSCI, V23, P8423
   Karbowski M, 1999, FREE RADICAL BIO MED, V26, P396, DOI 10.1016/S0891-5849(98)00209-3
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   Kokoszka JE, 2001, P NATL ACAD SCI USA, V98, P2278, DOI 10.1073/pnas.051627098
   Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994
   Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782
   LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Liu L, 2000, BIOL REPROD, V62, P1745, DOI 10.1095/biolreprod62.6.1745
   Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9
   Matsui H, 2003, INVEST OPHTH VIS SCI, V44, P3467, DOI 10.1167/iovs.02-0830
   Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101
   Murakami K, 1998, J NEUROSCI, V18, P205
   Organisciak DT, 1996, INVEST OPHTH VIS SCI, V37, P2243
   Parone P, 2003, ESSAYS BIOCHEM, V39, P41, DOI 10.1042/bse0390041
   Qi XP, 2003, INVEST OPHTH VIS SCI, V44, P1088, DOI 10.1167/iovs.02-0864
   Reddy VN, 2004, EXP EYE RES, V79, P859, DOI 10.1016/j.exer.2004.04.005
   Reddy VN, 2001, INVEST OPHTH VIS SCI, V42, P3247
   Sandbach JM, 2001, INVEST OPHTH VIS SCI, V42, P2173
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Tate DJ, 2002, CURR EYE RES, V24, P12, DOI 10.1076/ceyr.24.1.12.5426
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953
   Williams MD, 1998, J BIOL CHEM, V273, P28510, DOI 10.1074/jbc.273.43.28510
   YANG J, 1997, SCIENCE, V275, P1132
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 40
TC 78
Z9 94
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2005
VL 46
IS 9
BP 3426
EP 3434
DI 10.1167/iovs.05-0344
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 959AH
UT WOS:000231488800054
PM 16123448
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Srinivasan, S
   Swaminathan, G
   Kulothungan, V
   Sharma, T
   Raman, R
AF Srinivasan, Sangeetha
   Swaminathan, Gayathri
   Kulothungan, Vaitheeswaran
   Sharma, Tarun
   Raman, Rajiv
TI The association of smokeless tobacco use and pack-years of smokeless
   tobacco with age-related macular degeneration in Indian population
SO CUTANEOUS AND OCULAR TOXICOLOGY
LA English
DT Article
DE Age-related macular degeneration; pack-years; smokeless tobacco
ID MACULOPATHY; PREVALENCE; NICOTINE
AB Aim: To explore the association of use versus no use and the influence of pack-year use of smokeless tobacco with that of early and late age-related macular degeneration (AMD) in rural and urban south Indian population. We hypothesized that the use and pack-years of use would be significantly associated with both early and late AMD. We therefore sought to examine subjects who gave a history of using smokeless tobacco and we quantified the usage as pack-years, to examine the association with that of early and late AMD.Materials and methods: This was part of Sankara Nethralaya: Rural-Urban Age-related Macular degeneration study (SN-RAM study), which was conducted between 2007 and 2010. Subjects aged 60 years or older or those turning 60 in the present calendar year, with a history of using smokeless tobacco were noted along with duration and number of packs used per day. Smokeless tobacco was defined as chewed-tobacco (loose leaves) and/or snuff (finely chopped tobacco). Subjects underwent detailed ophthalmic evaluation including cataract grading using the Lens Opacities Classification System (LOCS III), 45 degrees 4-field stereoscopic fundus photography and AMD evaluation. Pack-years of smokeless tobacco use was stratified as <15, 15-34 and 35 years; the association of tobacco use and pack-years of use with that of early and late AMD was examined. A p value of <0.05 was considered statistically significant.Results: The number of smokeless tobacco users was significantly higher in rural (n=767) than in urban groups (n=281), p<0.001. Of the 1048 users, 238 subjects (23%) provided details regarding quantification of use. There were no significant differences in the pack-years between rural and urban areas, p=0.756 or that between AMD and no AMD, p=0.562. Use of smokeless tobacco compared with no use was significantly associated with late AMD, OR=3.178, 95%CI: 1.095, 9.227, p=0.033, when adjusted for age, gender, rural-urban differences, presence of diabetes, socioeconomic status, systolic and diastolic blood pressure, total cholesterol, low-density and high-density lipoprotein levels. The association was not significant for early AMD, p=0.582. The pack-years of use did not show a statistically significant association with early or late AMD. Furthermore, out of the 1048 subjects, 547 reported as using areca nut. Of which, 415 (75.8%) subjects had no AMD, 119 (21.7%) showed evidence of early AMD and 13 (2.4%) had late AMD. There was no significant association between the use of areca nut and early AMD, (X-2 (1, N=930)=2.345, p=0.126) or with that of late AMD (X-2 (1, N=761)=0.075, p=0.785).Conclusions: Smokeless tobacco use compared with no use, is associated with late AMD, regardless of the pack-years of use. Tobacco use is a modifiable risk factor. Efforts to reduce or stop the use of smokeless tobacco is indicated in an effort to prevent vision loss with respect to late AMD.
C1 [Srinivasan, Sangeetha; Swaminathan, Gayathri; Kulothungan, Vaitheeswaran; Sharma, Tarun; Raman, Rajiv] Sankara Nethralaya, Shri Bhagwan Mahavir Vitreoretinal Serv, Madras, Tamil Nadu, India.
RP Raman, R (通讯作者)，Sankara Nethralaya, Shri Bhagwan Mahavir Vitreoretinal Serv, Madras, Tamil Nadu, India.
EM rajivpgraman@gmail.com
RI Raman, Rajiv/A-7234-2009
OI Raman, Rajiv/0000-0001-5842-0233
FU Jamshetji Tata trust, Mumbai, India
FX The authors declare no conflicts of interest. This work was funded by
   Jamshetji Tata trust, Mumbai, India.
CR Agarwal S, 2005, OPHTHAL EPIDEMIOL, V12, P143, DOI 10.1080/09286580590932734
   Al-Ibrahim MS, 1990, CLIN METHODS HIST PH
   [Anonymous], 2011, HDB STAT INDIAN EC, P395
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe185, DOI 10.1111/j.1755-3768.2011.02316.x
   Patidar Kalpana A, 2015, J Oral Maxillofac Pathol, V19, P69, DOI 10.4103/0973-029X.157205
   Raman R, 2016, EYE, V30, P688, DOI 10.1038/eye.2016.14
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   Varghese SB, 2011, INVEST OPHTH VIS SCI, V52, P9445, DOI 10.1167/iovs.11-7874
NR 11
TC 4
Z9 4
U1 0
U2 4
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1556-9527
EI 1556-9535
J9 CUTAN OCUL TOXICOL
JI Cutan. Ocul. Toxicol.
PY 2017
VL 36
IS 3
BP 253
EP 258
DI 10.1080/15569527.2016.1265548
PG 6
WC Ophthalmology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Toxicology
GA EZ5WX
UT WOS:000404791400007
PM 27903086
DA 2022-11-30
ER

PT J
AU Hwang, IC
   Bae, JH
   Kim, JM
   Lee, JM
   Nguyen, QD
AF Hwang, In Cheol
   Bae, Jeong Hun
   Kim, Joon Mo
   Lee, Jung Min
   Quan Dong Nguyen
TI Adult body height and age-related macular degeneration in healthy
   individuals: A nationwide population-based survey from Korea
SO PLOS ONE
LA English
DT Article
ID NUTRITION EXAMINATION SURVEY; RISK-FACTORS; HEART-DISEASE; MASS INDEX;
   FOLLOW-UP; STROKE; MORTALITY; MACULOPATHY; PREVALENCE; COHORT
AB We sought to evaluate the relationship between adult body height and risk of age-related macular degeneration (AMD) among healthy Koreans using nationwide population-based data. We analyzed data derived from the Korea National Health and Nutrition Examination Survey 2008-2011. Participants over 40 years of age were included in the sample after excluding individuals with systemic comorbidities or missing relevant data. The presence and severity of AMD were graded using fundus photographs. The relationship between body height and risk of AMD was determined using multiple logistic regression analyses. Among a total of 8,435 participants, 544 (6.45%) had AMD: 502 (5.95%) with early AMD and 42 (0.5%) with late AMD. In multivariate-adjusted analyses, taller body height was significantly associated with a lower prevalence of AMD (odds ratio [OR], 0.89; 95% confidence interval [CI], 0.81-0.99), while body mass index (BMI) was not associated with AMD. An inverse association between body height and risk of AMD was observed most frequently in participants under 65 years of age (OR, 0.81; 95% CI, 0.70-0.94). Furthermore, body height showed an inverse association with risk of AMD among obese participants (BMI.25.0 kg/m(2)) (OR, 0.75; 95% CI, 0.60-0.93). Subgroup analysis by AMD type disclosed a significant inverse association between body height and early AMD (OR, 0.87; 95% CI, 0.79-0.97) but not late AMD. Our results suggest that shorter body height is independently associated with increased risk of AMD, especially early AMD, in a dose-response manner in people who are obese or under 65 years of age.
C1 [Hwang, In Cheol] Gachon Univ, Coll Med, Gil Med Ctr, Dept Family Med, Incheon, South Korea.
   [Bae, Jeong Hun; Kim, Joon Mo; Lee, Jung Min] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Sch Med, Dept Ophthalmol, Seoul, South Korea.
   [Quan Dong Nguyen] Stanford Univ, Sch Med, Byers Eye Inst, Palo Alto, CA 94304 USA.
C3 Gachon University; Sungkyunkwan University (SKKU); Samsung Medical
   Center; Stanford University
RP Bae, JH (通讯作者)，Sungkyunkwan Univ, Kangbuk Samsung Hosp, Sch Med, Dept Ophthalmol, Seoul, South Korea.
EM jhbae94@hotmail.com
OI Bae, Jeong Hun/0000-0001-9028-1528
CR ALLEBECK P, 1992, PUBLIC HEALTH, V106, P375, DOI 10.1016/S0033-3506(05)80186-6
   Allen HL, 2010, NATURE, V467, P832, DOI 10.1038/nature09410
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Bae JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136218
   Batty GD, 2006, ANN ONCOL, V17, P157, DOI 10.1093/annonc/mdj018
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   COOK NR, 1994, AM J EPIDEMIOL, V139, P1066, DOI 10.1093/oxfordjournals.aje.a116950
   Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB
   Curcio CA, 2011, P NATL ACAD SCI USA, V108, P18569, DOI 10.1073/pnas.1115497108
   Di Stefano A F, 2001, Optometry, V72, P619
   Green J, 2011, LANCET ONCOL, V12, P785, DOI 10.1016/S1470-2045(11)70154-1
   Haas P, 2015, ACTA OPHTHALMOL, V93, P533, DOI 10.1111/aos.12670
   Hamburg NM, 2008, AM J CARDIOL, V101, P82, DOI 10.1016/j.amjcard.2007.07.053
   Hozawa A, 2007, STROKE, V38, P22, DOI 10.1161/01.STR.0000251806.01676.60
   Jonas JB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086678
   Kweon S, 2014, INT J EPIDEMIOL, V43, P69, DOI 10.1093/ije/dyt228
   Lavanya R, 2010, INVEST OPHTH VIS SCI, V51, P6247, DOI 10.1167/iovs.10-5229
   Lechanteur YTE, 2012, INVEST OPHTH VIS SCI, V53, P5846, DOI 10.1167/iovs.11-7731
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Montgomery MP, 2010, OPHTHAL EPIDEMIOL, V17, P58, DOI 10.3109/09286580903450353
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nangia V, 2010, GRAEF ARCH CLIN EXP, V248, P1657, DOI 10.1007/s00417-010-1448-0
   Nazari H, 2015, PROG RETIN EYE RES, V48, P1, DOI 10.1016/j.preteyeres.2015.06.004
   Nelson CP, 2015, NEW ENGL J MED, V372, P1608, DOI 10.1056/NEJMoa1404881
   Njolstad I, 1996, CIRCULATION, V94, P2877
   Nuesch E, 2016, INT J EPIDEMIOL, V45, P1927, DOI 10.1093/ije/dyv074
   Oh SW, 2011, DIABETES METAB J, V35, P561, DOI 10.4093/dmj.2011.35.6.561
   Oliveros E, 2014, PROG CARDIOVASC DIS, V56, P426, DOI 10.1016/j.pcad.2013.10.003
   Paajanen TA, 2010, EUR HEART J, V31, P1802, DOI 10.1093/eurheartj/ehq155
   Park CS, 2018, INT J EPIDEMIOL, V47, P289, DOI 10.1093/ije/dyx175
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Schaumberg DA, 2000, AM J CLIN NUTR, V72, P1495
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Schmidt M, 2014, EUR J EPIDEMIOL, V29, P111, DOI 10.1007/s10654-013-9867-y
   Sene A, 2014, TRENDS ENDOCRIN MET, V25, P107, DOI 10.1016/j.tem.2013.10.007
   Shimizu Y, 2013, J PHYSIOL ANTHROPOL, V32, DOI 10.1186/1880-6805-32-19
   Sung J, 2009, AM J EPIDEMIOL, V170, P53, DOI 10.1093/aje/kwp088
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Wannamethee SG, 1998, AM J EPIDEMIOL, V148, P1069
   Xie XW, 2009, GRAEF ARCH CLIN EXP, V247, P1651, DOI 10.1007/s00417-009-1161-z
   Xu L, 2008, AM J OPHTHALMOL, V145, P929, DOI 10.1016/j.ajo.2008.01.004
   Yip JLY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132565
   Yoon Kyung-Chul, 2011, Korean J Ophthalmol, V25, P421, DOI 10.3341/kjo.2011.25.6.421
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
NR 45
TC 2
Z9 2
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 1
PY 2020
VL 15
IS 5
AR e0232593
DI 10.1371/journal.pone.0232593
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA LT3FY
UT WOS:000536957700041
PM 32357183
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Holekamp, NM
   Sadda, S
   Sarraf, D
   Guymer, R
   Hill, L
   Blotner, S
   Spicer, G
   Gune, S
AF Holekamp, Nancy M.
   Sadda, Srinivas
   Sarraf, David
   Guymer, Robyn
   Hill, Lauren
   Blotner, Steve
   Spicer, Galin
   Gune, Shamika
TI Effect of Residual Retinal Fluid on Visual Function in
   Ranibizumab-Treated Neovascular Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID GROWTH-FACTOR THERAPY; 2.0 MG RANIBIZUMAB; INTRAVITREAL RANIBIZUMAB;
   OUTCOMES; BLINDNESS; EFFICACY; EXTEND; SAFETY; ACUITY
AB PURPOSE: To investigate the relationship between retinal fluid and vision in ranibizumab-treated patients with neovascular age-related macular degeneration (nAMD).
   DESIGN: Clinical cohort study using post hoc analysis of clinical trial data.
   METHODS: We assessed data from HARBOR (NCT00891735), a phase III, randomized, controlled trial. We reviewed 917 patients >= 50 years of age with subfoveal nAMD associated with subretinal (SRF) and/or intraretinal fluid (IRF) at baseline, screening, or week 1. The intervention was intravitreal ranibizumab 0.5 or 2.0 mg (all treatment arms pooled). Outcomes included mean best-corrected visual acuity (BCVA) and BCVA change from baseline at months (M) 12 and 24 evaluated by the presence/absence of SRF and/or IRF.
   RESULTS: Baseline BCVA was higher with residual vs resolved SRF at M12 (mean [95% confidence interval {CI}] 58.8 letters [57.2-60.4] vs 53.5 [52.4-54.5]) and M24 (59.3 letters [57.8-60.8] vs 53.5 [52.5-54.5]). Mean BCVA change (adjusted for baseline) to M12 was greater with residual vs resolved SRF (mean difference [95% CI], + 2.4 letters [ + 0.1 to + 4.7]), but lower with residual vs resolved IRF ( -3.5 letters [ -5.8 to -1.2]). Eyes with residual SRF (no IRF) exhibited the largest mean BCVA gains (M12, + 14.1 letters; M24, + 13.2 letters), followed by resolved SRF/IRF (M12, + 10.6 letters; M24, + 10.0 letters), residual SRF/IRF (M12, + 7.2 letters; M24, + 8.5 letters), and residual IRF only (M12, + 5.5 letters; M24, + 3.6 letters).
   CONCLUSIONS: Vision outcomes (adjusted for baseline BCVA) through M24 were better in ranibizumab-treated eyes with residual vs resolved SRF, and worse with residual vs resolved IRF. Presence of residual retinal fluid requires a more complex and nuanced assessment and interpretation in the context of nAMD management. (C) 2021 Elsevier Inc. All rights reserved.
C1 [Holekamp, Nancy M.] Pepose Vis Inst, 1815 Clarkson Rd, Chesterfield, MO 63017 USA.
   Univ Calif Los Angeles, Doheny Eye Inst, Pasadena, CA USA.
   Univ Calif Los Angeles, Stein Eye Inst, Los Angeles, CA USA.
   Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   Univ Melbourne, Dept Surg Ophthalmol, Melbourne, Vic, Australia.
   Genentech Inc, San Francisco, CA 94080 USA.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California System; University of
   California Los Angeles; Centre for Eye Research Australia; Royal
   Victorian Eye & Ear Hospital; University of Melbourne; University of
   Melbourne; Roche Holding; Genentech
RP Holekamp, NM (通讯作者)，Pepose Vis Inst, 1815 Clarkson Rd, Chesterfield, MO 63017 USA.
EM nholekamp@gmail.com
CR American Academy of Ophthalmology Preferred Practice Pattern Retina/Vitreous Committee, AGE RELATED MACULAR
   American Society of Retina Specialists, 2019 MEMB SURV PREF
   Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   Augsburger M, 2019, GRAEF ARCH CLIN EXP, V257, P1889, DOI 10.1007/s00417-019-04404-0
   Borooah S, 2015, EYE, V29, P1156, DOI 10.1038/eye.2015.83
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Ciulla TA, 2018, OPHTHALMOL RETINA, V2, P645, DOI 10.1016/j.oret.2018.01.006
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Essex RW, 2016, OPHTHALMOLOGY, V123, P2393, DOI 10.1016/j.ophtha.2016.07.012
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Hilely A, 2021, BRIT J OPHTHALMOL, V105, P1415, DOI 10.1136/bjophthalmol-2020-317326
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Lek JJ, 2018, OPHTHALMOL RETINA, V2, P792, DOI 10.1016/j.oret.2018.01.005
   Mehta H, 2020, CLIN OPHTHALMOL, V14, P3331, DOI 10.2147/OPTH.S275977
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Varano M, 2015, CLIN OPHTHALMOL, V9, P2243, DOI 10.2147/OPTH.S92548
NR 24
TC 4
Z9 4
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JAN
PY 2022
VL 233
BP 8
EP 17
DI 10.1016/j.ajo.2021.06.029
EA OCT 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WY4VT
UT WOS:000719277300002
PM 34289338
DA 2022-11-30
ER

PT J
AU Nittala, MG
   Ruiz-Garcia, H
   Sadda, SR
AF Nittala, Muneeswar Gupta
   Ruiz-Garcia, Humberto
   Sadda, SriniVas R.
TI Accuracy and Reproducibility of Automated Drusen Segmentation in Eyes
   with Non-Neovascular Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; GEOGRAPHIC ATROPHY; SEVERITY SCALE;
   SD-OCT; SUBANALYSIS
AB PURPOSE. To evaluate the accuracy and reproducibility of drusen quantification by an automated drusen segmentation algorithm in spectral domain optical coherence tomography (SD-OCT) images of eyes with non-neovascular age-related macular degeneration (AMD).
   METHODS. Drusen segmentation was performed using both a commercial automated algorithm (Cirrus OCT RPE analysis tool) and manual segmentation in 44 eyes of 30 subjects with dry AMD who underwent volume OCT scanning. The drusen (space between outer RPE layer and Bruch's membrane) was segmented automatically using an automated RPE tool and manually by 3D-OCTOR software. Drusen area and volume were calculated in all eyes. Age and visual acuity data were also collected. Reproducibility of manual and automated measurements was assessed by intraclass correlation (ICC).
   RESULTS. The mean age of subjects was 78.24 (+/- 9.4; range, 56-97 years). The mean logMAR (logarithm of the minimum angle of resolution) visual acuity was 0.4 (Snellen equivalent, similar to 20/50) (standard deviation, 0.40; range, 0-1.3). The mean (standard deviation) drusen area was 5.05 (3.67) mm(2) with manual segmentation and 4.66 (3.51) mm(2) with the automated RPE tool; the absolute difference was 2.63 (2.5) mm(2). The mean drusen volume was 1.49 (0.42) mm(3) with manual segmentation and 1.42 (0.43) mm(3) with the automated RPE tool; the absolute difference was 1.42 (0.43) mm(3). The agreement between manual and automated measurements of drusen volume (highest ICC = 0.95) was better than the agreement for drusen area (ICC = 0.65).
   CONCLUSIONS. The quantification of drusen area and volume using an automated RPE yielded better agreement for volume than for area when compared with human expert manual segmentation. Using this software, drusen volume measurements may be a useful tool for quantifying drusen burden in clinical trials and clinical practice. (Invest Ophthalmol Vis Sci. 2012;53:8319-8324) DOI:10.1167/iovs.12-10582
C1 [Sadda, SriniVas R.] Doheny Eye Inst, Los Angeles, CA 90033 USA.
   Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
C3 Doheny Eye Institute; University of Southern California
RP Sadda, SR (通讯作者)，Doheny Eye Inst, 1450 San Pablo St, Los Angeles, CA 90033 USA.
EM SSadda@doheny.org
RI Nittala, Muneeswar/AAT-7533-2020
FU Beckman Macular Research Center; Physician Scientist Award from Research
   to Prevent Blindness; Carl Zeiss Meditec; Optos; Optovue, Inc.
FX Supported by the Beckman Macular Research Center and a Physician
   Scientist Award from Research to Prevent Blindness. SriniVas R. Sadda
   shares in royalties from intellectual property licensed to Topcon
   Medical Systems by the Doheny Eye Institute. SriniVas R. Sadda also
   serves on the scientific advisory board for Heidelberg Engineering and
   receives research support from Carl Zeiss Meditec, Optos, and Optovue,
   Inc.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Freeman SR, 2010, RETINA-J RET VIT DIS, V30, P431, DOI 10.1097/IAE.0b013e3181bd2f94
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Sadda SR, 2007, INVEST OPHTH VIS SCI, V48, P839, DOI 10.1167/iovs.06-0554
   Sadda SR, 2010, INVEST OPHTH VIS SCI, V51, P1071, DOI 10.1167/iovs.09-4325
   Schlanitz FG, 2010, INVEST OPHTH VIS SCI, V51, P6715, DOI 10.1167/iovs.10-5288
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Smith RT, 2010, BRIT J OPHTHALMOL, V94, P1618, DOI 10.1136/bjo.2009.166843
   Smith RT, 2005, ARCH OPHTHALMOL-CHIC, V123, P200, DOI 10.1001/archopht.123.2.200
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Wolf-Schnurrbusch UEK, 2008, INVEST OPHTH VIS SCI, V49, P3095, DOI 10.1167/iovs.07-1460
   Yi K, 2009, BRIT J OPHTHALMOL, V93, P176, DOI 10.1136/bjo.2008.137356
NR 21
TC 45
Z9 45
U1 0
U2 8
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2012
VL 53
IS 13
BP 8319
EP 8324
DI 10.1167/iovs.12-10582
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 064EX
UT WOS:000313056000055
PM 23150629
DA 2022-11-30
ER

PT J
AU Wu, J
   Cho, E
   Giovannucci, EL
   Rosner, BA
   Sastry, SM
   Willett, WC
   Schaumberg, DA
AF Wu, Juan
   Cho, Eunyoung
   Giovannucci, Edward L.
   Rosner, Bernard A.
   Sastry, Srinivas M.
   Willett, Walter C.
   Schaumberg, Debra A.
TI Dietary Intakes of Eicosapentaenoic Acid and Docosahexaenoic Acid and
   Risk of Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID FATTY-ACIDS; CIGARETTE-SMOKING; FISH CONSUMPTION; NATIONAL-HEALTH;
   DISEASE; OMEGA-3; ASSOCIATION; MACULOPATHY; POPULATION; PREVALENCE
AB Purpose: To evaluate the associations between intakes of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and the intermediate and advanced stages of age-related macular degeneration (AMD).
   Design: Prospective cohort study.
   Participants: We followed 75 889 women from the Nurses' Health Study and 38 961 men from the Health Professionals Follow-Up Study who were at least 50 years old, from 1984 to 2012 and 1986 to 2010, respectively. Cohort participants are mostly white (>= 95%).
   Methods: We assessed dietary intake by a validated food frequency questionnaire (FFQ) at baseline and every 4 years. We calculated cumulative average intakes of EPA and DHA from FFQs and also computed predicted erythrocyte and plasma scores directly from food intake using regression models. Cox proportional hazards models were used to compute the associations with AMD outcomes.
   Main Outcome Measures: We confirmed 1589 incident intermediate and 1356 advanced AMD cases (primarily neovascular AMD) with a visual acuity of 20/30 or worse, owing primarily to AMD, by medical record review.
   Results: For intermediate AMD, the pooled hazard ratio (HR) between the 2 cohorts for DHA comparing the extreme quintiles of intake was 0.78 (95% confidence interval [CI], 0.66-0.92; P trend, 0.008) and for EPA + DHA was 0.83 (95% CI, 0.71-0.98; P trend, 0.03). The pooled HR for fatty fish, comparing >= 5 servings per week to almost never, was 0.61 (95% CI, 0.46-0.81; P trend, <0.001). For advanced AMD, the pooled HR for DHA was 1.01 (95% CI, 0.84e1.21; P trend, 0.75) and for fatty fish was 0.80 (95% CI, 0.59-1.08; P trend, 0.11). Secondary analyses using predicted erythrocyte and plasma scores of EPA and DHA yielded slightly stronger inverse associations for intermediate AMD and similar results for advanced AMD.
   Conclusions: Higher intakes of EPA and DHA may prevent or delay the occurrence of visually significant intermediate AMD. However, the totality of current evidence for EPA and DHA and advanced AMD is discordant, though there was no association with advanced AMD in the present study. (C) 2017 by the American Academy of Ophthalmology
C1 [Wu, Juan; Giovannucci, Edward L.; Willett, Walter C.] Harvard TH Chan Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.
   [Giovannucci, Edward L.; Willett, Walter C.; Schaumberg, Debra A.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
   [Rosner, Bernard A.] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA.
   [Cho, Eunyoung; Giovannucci, Edward L.; Rosner, Bernard A.; Willett, Walter C.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA.
   [Cho, Eunyoung; Giovannucci, Edward L.; Rosner, Bernard A.; Willett, Walter C.] Harvard Med Sch, Boston, MA USA.
   [Schaumberg, Debra A.] Shire, Global Med Affairs, Ophthalm, Lexington, MA USA.
   [Cho, Eunyoung] Brown Univ, Dept Dermatol, Warren Alpert Med Sch, Providence, RI 02912 USA.
   [Cho, Eunyoung] Brown Sch Publ Hlth, Dept Epidemiol, Providence, RI USA.
   [Sastry, Srinivas M.] Bethesda Retina, Bethesda, MD USA.
   [Schaumberg, Debra A.] Univ Utah, Sch Med, John A Moran Eye Ctr, Ctr Translat Med, Salt Lake City, UT USA.
C3 Harvard University; Harvard T.H. Chan School of Public Health; Harvard
   University; Harvard T.H. Chan School of Public Health; Harvard
   University; Harvard T.H. Chan School of Public Health; Harvard
   University; Brigham & Women's Hospital; Harvard University; Harvard
   Medical School; Shire Pharmaceuticals Limited; Brown University; Brown
   University; Utah System of Higher Education; University of Utah
RP Wu, J (通讯作者)，Harvard TH Chan Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.
EM juan.wu@mail.harvard.edu
RI Cho, Eunyoung/AAV-4469-2020
OI Cho, Eunyoung/0000-0001-6594-2582
FU National Institutes of Health [EY017362, EY013834, EY000365, EY009611,
   EY021900, UM1 CA186107, UM1 CA167552, R01 CA49449]; NATIONAL CANCER
   INSTITUTE [R01CA049449, UM1CA186107, UM1CA167552] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [R01EY021900, R01EY013834, R01EY017362,
   R01EY009611] Funding Source: NIH RePORTER
FX Supported by grants EY017362, EY013834, EY000365, EY009611, EY021900,
   UM1 CA186107 and UM1 CA167552, and R01 CA49449 from the National
   Institutes of Health. The funding organization had no role in the
   following: design and conduct of the study; collection, management,
   analysis, and interpretation of the data; preparation, review, or
   approval of the manuscript; and decision to submit the manuscript for
   publication.
CR Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Cantsilieris S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035255
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiuve SE, 2012, J NUTR, V142, P1009, DOI 10.3945/jn.111.157222
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong EW, 2015, RETINA-J RET VIT DIS, V35, P989, DOI 10.1097/IAE.0000000000000417
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Colditz GA, 1997, J WOMENS HEALTH, V6, P49, DOI 10.1089/jwh.1997.6.49
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Garland M, 1998, AM J CLIN NUTR, V67, P25, DOI 10.1093/ajcn/67.1.25
   Hendrickson SJ, 2013, NUTRIENTS, V5, P4051, DOI 10.3390/nu5104051
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   Hu FB, 1999, AM J EPIDEMIOL, V149, P531, DOI 10.1093/oxfordjournals.aje.a009849
   HUNTER DJ, 1992, AM J EPIDEMIOL, V135, P418, DOI 10.1093/oxfordjournals.aje.a116302
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Merle B, 2011, INVEST OPHTH VIS SCI, V52, P6004, DOI 10.1167/iovs.11-7254
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Merle BMJ, 2013, J NUTR, V143, P505, DOI 10.3945/jn.112.171033
   Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152
   Myers CE, 2014, OPHTHALMOLOGY, V121, P1949, DOI 10.1016/j.ophtha.2014.04.040
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Querques G, 2014, SURV OPHTHALMOL, V59, P532, DOI 10.1016/j.survophthal.2014.01.001
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W
   Ross CM, 2005, J AM BOARD FAM PRACT, V18, P445, DOI 10.3122/jabfm.18.5.445-b
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Srigley CT, 2014, J AGR FOOD CHEM, V62, P7268, DOI 10.1021/jf5016973
   Sun Q, 2007, AM J CLIN NUTR, V86, P74, DOI 10.1093/ajcn/86.1.74
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Willett WC, 1997, AM J CLIN NUTR, V65, P1220, DOI 10.1093/ajcn/65.4.1220S
   WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu J, 2015, JAMA OPHTHALMOL, V133, P1415, DOI 10.1001/jamaophthalmol.2015.3590
NR 49
TC 29
Z9 29
U1 2
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2017
VL 124
IS 5
BP 634
EP 643
DI 10.1016/j.ophtha.2016.12.033
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EW3MT
UT WOS:000402402400016
PM 28153441
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Narayanan, D
   Rodriguez, J
   Wallstrom, G
   Welch, D
   Chapin, M
   Arrigg, P
   Abelson, M
AF Narayanan, Divya
   Rodriguez, John
   Wallstrom, Garrick
   Welch, Donna
   Chapin, Matthew
   Arrigg, Paul
   Abelson, Mark
TI An exploratory study to evaluate visual function endpoints in
   non-advanced age-related macular degeneration
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Visual function; Endpoint; Contrast; Flicker; Reading; AMD
ID FACTOR-H POLYMORPHISM; DARK-ADAPTATION; PREVALENCE; SEVERITY; DISEASE;
   ACUITY
AB Background To prevent irreversible vision loss in age-related macular degeneration (AMD), it is critical to detect retinal dysfunction before permanent structural loss occurs. In the current study we evaluated a series of visual function tests to identify potential endpoints to detect visual dysfunction in non-advanced AMD. Methods A series of visual function tests were performed on 23 non-advanced AMD subjects (AREDS grade 1-4 on simplified scale) and 34 age-matched normals (AREDS grade 0). Tests included some commonly used endpoints such as ETDRS visual acuity (VA), low luminance (LL) 2.0ND ETDRS VA, MNREAD as well as newly developed tests such as the Ora-VCF (TM) test, Ora-tablet reading test, color sensitivity etc. Differences between the two groups were compared for each test. Test-retest repeatability and reproducibility was assessed on a subset of subjects and percent agreement was calculated. Results There was no difference in standard ETDRS VA between non-advanced AMD (0.06 +/- 0.02 logMAR) and normal groups (0.04 +/- 0.02 logMAR) (p = 0.57). LL 2.0 ETDRS VA and MNREAD showed no difference between the groups (p > 0.05). Ora-VCF (TM) test was significantly worse in the non-advanced AMD group compared to normals (0.67 +/- 0.07 in AMD; 0.45 +/- 0.04 in normals,p = 0.005). Non-advanced AMD subjects also had significantly worse reading performance using the Ora-tablet with LL 2.0ND (114.55 +/- 11.22 wpm in AMD; 145.17 +/- 9.55 wpm in normalsp = 0.049). No significant difference between the groups was noted using other tests. Repeatability was 82% for Ora-VCF (TM) test and 92% for Ora-tablet LL 2.0ND reading. Reproducibility was 89% for both Ora-VCF (TM) test and Ora-tablet LL 2.0ND reading. Conclusion While there was no significant difference between non-advanced AMD and normal groups using some current common endpoints such as ETDRS VA, LL 2.0 ETDRS VA or MNREAD, Ora-VCF (TM) test and Ora-tablet LL 2.0ND reading tests were able to identify significant visual dysfunction in non-advanced AMD subjects. These tests show promise as endpoints for AMD studies.
C1 [Narayanan, Divya; Rodriguez, John; Welch, Donna; Chapin, Matthew; Arrigg, Paul; Abelson, Mark] Ora Inc, 300 Brickstone Sq, Andover, MA 01810 USA.
   [Wallstrom, Garrick] Stat & Data Corp, Tempe, AZ USA.
   [Arrigg, Paul] Joslin Diabet Ctr, Boston, MA 02215 USA.
   [Arrigg, Paul; Abelson, Mark] Harvard Med Sch, Ophthalmol, Boston, MA 02115 USA.
   [Abelson, Mark] Massachusetts Eye & Ear, Ophthalmol, Boston, MA USA.
C3 Harvard University; Joslin Diabetes Center, Inc.; Harvard University;
   Harvard Medical School; Harvard University; Massachusetts Eye & Ear
   Infirmary
RP Narayanan, D (通讯作者)，Ora Inc, 300 Brickstone Sq, Andover, MA 01810 USA.
EM dnarayanan@oraclinical.com
CR Akuffo KO, 2017, INVEST OPHTH VIS SCI, V58, P5347, DOI 10.1167/iovs.16-21192
   Ammar MJ, 2020, CURR OPIN OPHTHALMOL, V31, P215, DOI 10.1097/ICU.0000000000000657
   [Anonymous], **NON-TRADITIONAL**
   Bandello Francesco, 2017, F1000Res, V6, P245, DOI 10.12688/f1000research.10664.1
   Cheong AMY, 2008, VISION RES, V48, P577, DOI 10.1016/j.visres.2007.11.022
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Cocce KJ, 2018, AM J OPHTHALMOL, V189, P127, DOI 10.1016/j.ajo.2018.02.012
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595
   Dimitrov PN, 2012, INVEST OPHTH VIS SCI, V53, P5213, DOI 10.1167/iovs.11-8958
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Formaz F, 1997, CURR EYE RES, V16, P1252, DOI 10.1076/ceyr.16.12.1252.5021
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Garrity ST, 2018, INVEST OPHTH VIS SCI, V59, pAMD48, DOI 10.1167/iovs.18-24158
   Habibzadeh F, 2016, BIOCHEM MEDICA, V26, P297, DOI 10.11613/BM.2016.034
   Hanus J, 2016, BRIT J OPHTHALMOL, V100, P122, DOI 10.1136/bjophthalmol-2015-306972
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Jackson Gregory R, 2008, J Ocul Biol Dis Infor, V1, P7, DOI 10.1007/s12177-008-9002-6
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Maier M, 2010, GRAEF ARCH CLIN EXP, V248, P409, DOI 10.1007/s00417-009-1270-8
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Pondorfer SG, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231748
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Sohrab MA, 2011, SEMIN OPHTHALMOL, V26, P156, DOI 10.3109/08820538.2011.570848
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Terheyden JH, 2019, OPHTHALMOLOGE, V116, P1186, DOI 10.1007/s00347-019-0907-1
   Thompson AC, 2018, INVEST OPHTH VIS SCI, V59, P289, DOI 10.1167/iovs.17-22528
   Varadaraj V, 2018, AM J OPHTHALMOL, V186, P138, DOI 10.1016/j.ajo.2017.11.026
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Wallace JM, 2017, J VISION, V17, DOI 10.1167/17.1.33
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Yin J., 2017, BBIJ, DOI [10.15406/bbij.2017.05.00134, DOI 10.15406/BBIJ.2017.05.00134]
NR 43
TC 2
Z9 2
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD OCT 22
PY 2020
VL 20
IS 1
AR 424
DI 10.1186/s12886-020-01683-8
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ON1AV
UT WOS:000586444000002
PM 33092549
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Martin, DF
   Maguire, MG
   Fine, SL
   Ying, GS
   Jaffe, GJ
   Grunwald, JE
   Toth, C
   Redford, M
   Ferris, FL
AF Martin, Daniel F.
   Maguire, Maureen G.
   Fine, Stuart L.
   Ying, Gui-shuang
   Jaffe, Glenn J.
   Grunwald, Juan E.
   Toth, Cynthia
   Redford, Maryann
   Ferris, Frederick L.
CA Comparison Age-related Macular Deg
TI Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related
   Macular Degeneration Two-Year Results
SO OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY;
   VERTEPORFIN; TRIALS
AB Objective: To describe effects of ranibizumab and bevacizumab when administered monthly or as needed for 2 years and to describe the impact of switching to as-needed treatment after 1 year of monthly treatment.
   Design: Multicenter, randomized clinical trial.
   Participants: Patients (n = 1107) who were followed up during year 2 among 1185 patients with neovascular age-related macular degeneration who were enrolled in the clinical trial.
   Interventions: At enrollment, patients were assigned to 4 treatment groups defined by drug (ranibizumab or bevacizumab) and dosing regimen (monthly or as needed). At 1 year, patients initially assigned to monthly treatment were reassigned randomly to monthly or as-needed treatment, without changing the drug assignment.
   Main Outcome Measures: Mean change in visual acuity.
   Results: Among patients following the same regimen for 2 years, mean gain in visual acuity was similar for both drugs (bevacizumab-ranibizumab difference, -1.4 letters; 95% confidence interval [CI], -3.7 to 0.8; P = 0.21). Mean gain was greater for monthly than for as-needed treatment (difference, -2.4 letters; 95% CI, -4.8 to -0.1; P = 0.046). The proportion without fluid ranged from 13.9% in the bevacizumab-as-needed group to 45.5% in the ranibizumab monthly group (drug, P = 0.0003; regimen, P < 0.0001). Switching from monthly to as-needed treatment resulted in greater mean decrease in vision during year 2 (-2.2 letters; P = 0.03) and a lower proportion without fluid (-19%; P < 0.0001). Rates of death and arteriothrombotic events were similar for both drugs (P > 0.60). The proportion of patients with 1 or more systemic serious adverse events was higher with bevacizumab than ranibizumab (39.9% vs. 31.7%; adjusted risk ratio, 1.30; 95% CI, 1.07-1.57; P = 0.009). Most of the excess events have not been associated previously with systemic therapy targeting vascular endothelial growth factor (VEGF).
   Conclusions: Ranibizumab and bevacizumab had similar effects on visual acuity over a 2-year period. Treatment as needed resulted in less gain in visual acuity, whether instituted at enrollment or after 1 year of monthly treatment. There were no differences between drugs in rates of death or arteriothrombotic events. The interpretation of the persistence of higher rates of serious adverse events with bevacizumab is uncertain because of the lack of specificity to conditions associated with inhibition of VEGF. (C) 2012 by the American Academy of Ophthalmology.
C1 [Martin, Daniel F.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
   [Maguire, Maureen G.; Ying, Gui-shuang; Grunwald, Juan E.] Univ Penn, Dept Ophthalmol, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA.
   [Fine, Stuart L.] Univ Colorado, Dept Ophthalmol, Denver, CO 80202 USA.
   [Jaffe, Glenn J.; Toth, Cynthia] Duke Univ, Dept Ophthalmol, Durham, NC USA.
   [Redford, Maryann; Ferris, Frederick L.] NIH, NEI, Bethesda, MD 20892 USA.
C3 Cleveland Clinic Foundation; University of Pennsylvania; University of
   Colorado System; University of Colorado Denver; Duke University;
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Maguire, MG (通讯作者)，Univ Penn, Dept Ophthalmol, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA.
OI Ferris, Frederick/0000-0002-4933-0639
FU National Eye Institute, National Institutes of Health, Department of
   Health and Human Services [U10 EY017823, U10 EY017825, U10 EY017826, U10
   EY017828]
FX Supported by cooperative agreements U10 EY017823, U10 EY017825, U10
   EY017826, and U10 EY017828 from the National Eye Institute, National
   Institutes of Health, Department of Health and Human Services. The
   funding organization participated in the design and conduct of the
   study, data analysis and interpretation, and review of the manuscript.
CR ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   [Anonymous], [No title captured]
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen HX, 2009, NAT REV CLIN ONCOL, V6, P465, DOI 10.1038/nrclinonc.2009.94
   COX DR, 1972, J R STAT SOC B, V34, P187
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nalluri SR, 2008, JAMA-J AM MED ASSOC, V300, P2277, DOI 10.1001/jama.2008.656
   ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rubin D.B., 1987, MULTIPLE IMPUTATION, P1
   ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248
NR 16
TC 28
Z9 28
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2020
VL 127
IS 4
SU S
BP S135
EP S145
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KW0TH
UT WOS:000520885600019
PM 32200813
OA Bronze
DA 2022-11-30
ER

PT J
AU Ho, R
   Song, LD
   Choi, JA
   Jee, D
AF Ho, Ra
   Song, Lina D.
   Choi, Jin A.
   Jee, Donghyun
TI The cost-effectiveness of systematic screening for age-related macular
   degeneration in South Korea
SO PLOS ONE
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; VISUAL
   IMPAIRMENT; NATURAL-HISTORY; ECONOMIC BURDEN; CLINICAL-TRIAL;
   RANIBIZUMAB; VERTEPORFIN; BEVACIZUMAB; AFLIBERCEPT
AB Background
   Interventions that can facilitate early diagnosis of age-related macular degeneration (AMD) will facilitate early treatment and improve clinical outcomes but there has been concerns about additional medical costs to the health care system. An examination through a retina fundus photography by a non-specialist has been suggested as a potential cost-effective alternative to a direct examination by a specialist, but limited scientific data exists on the cost-effectiveness of screening strategies for AMD. Our objective is to conduct an economic evaluation of various population-wide screening strategies for AMD among the South Korean population.
   Methods and findings
   Using a Markov cohort model, we evaluated the cost-effectiveness of four AMD screening strategies (opportunistic examination, opportunistic treatment, systematic photography, and systematic examination) in comparison with status quo (no screening) for South Korean adults. We projected a life time horizon to study a hypothetical cohort of 100,00 persons of age 40 with and without AMD at baseline. The outcome measures were quality-adjusted life-years (QALYs) gained, cost from the societal perspective, and the incremental cost-effectiveness ratio (ICER) of each strategy. Interventions were evaluated at a willingness-to-pay (WTP) threshold of 30,000,000 KRW ($27,538) per QALY gained. Deterministic and probabilistic sensitivity analyses were conducted to address the model uncertainty. Opportunistic examination was strongly dominated because it generated fewer expected QALYs but incurred greater expected cost than the other screening strategies. The mean lifetime expected costs were 289,013 KRW, 363,692 KRW, 9,351,964 KRW, and 12,309,783 KRW, and the mean QALYs gained were 37.73, 37.75, 40.47, 40.68, for no screening, opportunistic treatment, systematic photography, and systematic examination, respectively. The results were most sensitive to the utility weight of mild AMD, the probability of complication from treatment, the cost of being in mild AMD, and the probability of recovery from complication. After eliminating the two weakly dominated strategies, systematic photography was cost-effective at the ICER of 3,310,448 KRW per QALY in comparison to status quo.
   Conclusions
   Under the WTP threshold of 30,000,000 KRW per QALY, systematic photography is cost-effective for screening AMD in South Korean adults. Systematic examination by ophthalmologists generates more expected QALY and cost compared to systematic photography.
C1 [Ho, Ra] Catholic Univ Korea, Bucheon St Marys Hosp, Coll Med, Dept Ophthalmol & Visual Sci, Bucheon, South Korea.
   [Song, Lina D.] Harvard Univ, PhD Program Hlth Policy, Cambridge, MA 02138 USA.
   [Choi, Jin A.; Jee, Donghyun] Catholic Univ Korea, St Vincents Hosp, Coll Med, Dept Ophthalmol & Visual Sci, Seoul, South Korea.
C3 Catholic University of Korea; Harvard University; Catholic University of
   Korea
RP Jee, D (通讯作者)，Catholic Univ Korea, St Vincents Hosp, Coll Med, Dept Ophthalmol & Visual Sci, Seoul, South Korea.
EM donghyunjee@catholic.ac.kr
FU Korea Health Technology R&D Project through the Korea Health Industry
   Development Institute (KHIDI) - Ministry of Health & Welfare, Republic
   of Korea [HC16C2299, HI17C1234]
FX This research was supported by a grant of the Korea Health Technology
   R&D Project through the Korea Health Industry Development Institute
   (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea
   (grant number: HC16C2299 and HI17C1234). The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the KHIDI.
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Brown MM, 2001, OPHTHALMOLOGY, V108, P643, DOI 10.1016/S0161-6420(00)00635-7
   Chan CKW, 2015, OPHTHALMOLOGY, V122, P2278, DOI 10.1016/j.ophtha.2015.06.050
   CHIANG YP, 1992, MILBANK Q, V70, P319, DOI 10.2307/3350062
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Elshout M, 2014, GRAEF ARCH CLIN EXP, V252, P1911, DOI 10.1007/s00417-014-2641-3
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jain S, 2006, EYE, V20, P471, DOI 10.1038/sj.eye.6701916
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   La TY, 2014, CURR EYE RES, V39, P1232, DOI 10.3109/02713683.2014.907431
   Lin DY, 2002, AM J OPHTHALMOL, V134, P204, DOI 10.1016/S0002-9394(02)01522-2
   Loewenstein A, 2007, RETINA-J RET VIT DIS, V27, P873, DOI 10.1097/IAE.0b013e318050d2ec
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Meads C, 2003, Health Technol Assess, V7, pv
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Myers CE, 2014, OPHTHALMOLOGY, V121, P1949, DOI 10.1016/j.ophtha.2014.04.040
   National Health Insurance Service (NHIS) K, HLTH INS GUID
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   Park JH, 2008, INT J CARDIOL, V128, P392, DOI 10.1016/j.ijcard.2007.04.114
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Patel JJ, 2012, J EVAL CLIN PRACT, V18, P247, DOI 10.1111/j.1365-2753.2010.01546.x
   Peto T, 2012, CURR DIABETES REP, V12, P338, DOI 10.1007/s11892-012-0285-4
   Prescott G, 2014, BRIT J OPHTHALMOL, V98, P1042, DOI 10.1136/bjophthalmol-2013-304338
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmid MK, 2015, BRIT J OPHTHALMOL, V99, P141, DOI 10.1136/bjophthalmol-2014-305149
   Sharma S, 2000, CAN J OPHTHALMOL, V35, P267, DOI 10.1016/S0008-4182(00)80077-0
   Singh A, 2007, EYE, V21, P302, DOI 10.1038/sj.eye.6702565
   Smith DH, 2004, BRIT J OPHTHALMOL, V88, P1107, DOI 10.1136/bjo.2003.023986
   Stein Joshua D, 2013, Trans Am Ophthalmol Soc, V111, P56
   Sternberg P, 2004, AM J OPHTHALMOL, V137, P483, DOI 10.1016/j.ajo.2003.11.023
   Tamura H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133628
   van Katwyk S, 2017, VALUE HEALTH, V20, P1034, DOI 10.1016/j.jval.2017.04.015
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wright SE, 2000, CLIN EXP OPHTHALMOL, V28, P140, DOI 10.1046/j.1442-9071.2000.00296.x
   Yazdi MH, 2015, EXPERT OPIN BIOL TH, V15, P1349, DOI 10.1517/14712598.2015.1057565
NR 45
TC 7
Z9 7
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 31
PY 2018
VL 13
IS 10
AR e0206690
DI 10.1371/journal.pone.0206690
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GY7VH
UT WOS:000448823700145
PM 30379971
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Pentek, M
   Brodszky, V
   Biro, Z
   Kolkedi, Z
   Dunai, A
   Nemeth, J
   Baji, P
   Rencz, F
   Gulacsi, L
   Resch, MD
AF Pentek, Marta
   Brodszky, Valentin
   Biro, Zsolt
   Kolkedi, Zsofia
   Dunai, Arpad
   Nemeth, Janos
   Baji, Petra
   Rencz, Fanni
   Gulacsi, Laszlo
   Resch, Miklos D.
TI Subjective health expectations of patients with age-related macular
   degeneration treated with antiVEGF drugs
SO BMC GERIATRICS
LA English
DT Article
DE Age-related macular degeneration; Health-related quality of life; EQ-5D;
   Time trade-off; Subjective life-expectancy; Health expectations
ID QUALITY-OF-LIFE; DIABETIC-RETINOPATHY; STATE UTILITIES; HAPPINESS;
   HUNGARY; DISEASE; FUTURE; LENGTH; EYE
AB Background: Subjective expectations regarding future health may influence patients' judgement of current health and treatment effects, as well as adherence to therapies in chronic diseases. We aimed to explore subjective expectations on longevity and future health-related quality of life (HRQOL) of patients with age-related macular degeneration (AMD) treated with antiVEGF injections and analyse the influencing factors.
   Methods: Consecutive AMD patients in two ophthalmology centres were included. Demographics, clinical characteristics and informal care utilisation were recorded. Current health was evaluated by the EQ-5D generic health status questionnaire and time trade-off (TTO) methods. Happiness was measured on a visual analogue scale (VAS). Subjective life-expectancy and expected EQ-5D status at ages 70, 80 and 90 were surveyed. T-test was applied to compare subgroups and Pearson correlations were performed to analyse relationships between variables.
   Results: One hundred twenty two patients were involved (females 62%) with a mean (SD) age of 75.2 (7.9) years and disease duration of 2.9 (2.5) years. The majority were in AREDS-4 state, the better eye's ETDRS was 64.7 (15.4). EQ-5D and TTO revealed moderate deterioration of health (0.66 vs. 0.72, p = 0.131), happiness VAS was 6.3 (2.2). Correlation between EQ-5D and ETDRS was moderate (R = 0.242, p < 0.05) and having both versus one eye in AREDS-4 resulted lower TTO (0.68 vs. 0.83; p = 0.013). Subjective life-expectancy did not differ significantly from statistical life-expectancy and had no significant impact on TTO. The self-estimated mean EQ-5D score was 0.60, 0.40 and 0.24 for ages 70, 80 and 90 which is lower than the population norm of age-groups 65-74, 75-84 and 85+ (0.77, 0.63 and 0.63, respectively). Age, gender, current EQ-5D, need for informal care and happiness were deterministic factors of subjective health expectations.
   Conclusion: AMD patients with antiVEGF treatment have comparable HRQOL as the age-matched general public but expect a more severe deterioration of health with age. Older patients with worse HRQOL have worse subjective expectations. Exploring patients' health expectations provides an opportunity for ophthalmologists to correct misperceptions and improve the quality of AMD care. Further studies should provide evidences on the relationship between subjective expectations and actual health outcomes, and on its impact on patients' AMD-specific health behaviour.
C1 [Pentek, Marta; Brodszky, Valentin; Baji, Petra; Rencz, Fanni; Gulacsi, Laszlo] Corvinus Univ Budapest, Dept Hlth Econ, Fovam Ter 8, H-1093 Budapest, Hungary.
   [Biro, Zsolt; Kolkedi, Zsofia] Pecs Univ Sci, Dept Ophthalmol, Nyar U 8, H-7624 Pecs, Hungary.
   [Dunai, Arpad; Nemeth, Janos; Resch, Miklos D.] Semmelweis Univ, Dept Ophthalmol, Maria U 39, H-1085 Budapest, Hungary.
   [Rencz, Fanni] Semmelweis Univ, Clin Med Doctoral Sch, Ulloi U 26, H-1085 Budapest, Hungary.
C3 Corvinus University Budapest; University of Pecs; Semmelweis University;
   Semmelweis University
RP Pentek, M (通讯作者)，Corvinus Univ Budapest, Dept Hlth Econ, Fovam Ter 8, H-1093 Budapest, Hungary.
EM marta.pentek@uni-corvinus.hu
OI Baji, Petra/0000-0003-2899-8557; Nemeth, Janos/0000-0001-8575-4888;
   Gulacsi, Laszlo/0000-0002-9285-8746
CR Arnesen T, 2005, HEALTH ECON, V14, P39, DOI 10.1002/hec.895
   Attema AE, EUR J HLTH EC
   Boncz I, 2006, LANCET, V368, P917, DOI 10.1016/S0140-6736(06)69369-0
   Boyers LN, 2015, JAMA OPHTHALMOL, V133, P25, DOI 10.1001/jamaophthalmol.2014.3527
   Boyle J, 2015, PSYCHOL HEALTH MED, V20, P296, DOI 10.1080/13548506.2014.936886
   Brouwer WBF, 2005, SOC SCI MED, V61, P1083, DOI 10.1016/j.socscimed.2005.01.008
   Brown MM, 2014, CURR OPIN OPHTHALMOL, V25, P171, DOI 10.1097/ICU.0000000000000040
   CANTRILL HL, 1984, INT OPHTHALMOL CLIN, V24, P13, DOI 10.1097/00004397-198402440-00004
   Cimarolli VR, 2016, CLIN OPHTHALMOL, V10, P55, DOI 10.2147/OPTH.S80489
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Dawson SR, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-78
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Hodgson N, 2016, MOL PHARM
   Kymes SN, 2009, MINERVA MED, V100, P69
   Mackenzie PJ, 2002, OPHTHALMOLOGY, V109, P720, DOI 10.1016/S0161-6420(01)01021-1
   Ng YK, 1996, SOC INDIC RES, V38, P1, DOI 10.1007/BF00293784
   Pearson Isobel, 2013, J Med Econ, V16, P1307, DOI 10.3111/13696998.2013.839946
   Pentek M, 2014, HEALTH EXPECT, V17, P696, DOI 10.1111/j.1369-7625.2012.00797.x
   Pentek M, 2014, EUR J HEALTH ECON, V15, pS83, DOI 10.1007/s10198-014-0597-1
   Poku E, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-74
   Rappange DR, 2016, HEALTH EXPECT, V19, P121, DOI 10.1111/hex.12335
   Rencz F, 2015, J EUR ACAD DERMATOL, V29, P1398, DOI 10.1111/jdv.12884
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Senra H, 2016, GRAEF ARCH CLIN EXP, V254, P1873, DOI 10.1007/s00417-016-3384-0
   Shah AR, 2016, DEV OPHTHALMOL, V55, P376, DOI 10.1159/000438965
   Stalmeier PFM, 2001, MED DECIS MAKING, V21, P200, DOI 10.1177/02729890122062497
   Szende Agota, 2003, Orv Hetil, V144, P1667
   TORRANCE GW, 1987, J CHRON DIS, V40, P593, DOI 10.1016/0021-9681(87)90019-1
   TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2
   van de Wetering EJ, 2010, J ECON PSYCHOL, V31, P923, DOI 10.1016/j.joep.2010.08.004
   van Nooten FE, 2016, HEALTH QUAL LIFE OUT, V14, DOI 10.1186/s12955-015-0402-6
   VEENHOVEN R, 1991, SOC INDIC RES, V24, P1, DOI 10.1007/BF00292648
   WILLIAMS A, 1990, HEALTH POLICY, V16, P199
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 34
TC 11
Z9 11
U1 0
U2 13
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2318
J9 BMC GERIATR
JI BMC Geriatr.
PD OCT 10
PY 2017
VL 17
AR 233
DI 10.1186/s12877-017-0619-9
PG 9
WC Geriatrics & Gerontology; Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology
GA FJ4CX
UT WOS:000412683500002
PM 29017463
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Terheyden, JH
   Schmitz-Valckenberg, S
   Crabb, DP
   Dunbar, H
   Luhmann, UFO
   Behning, C
   Schmid, M
   Silva, R
   Cunha-Vaz, J
   Tufail, A
   Weissgerber, G
   Leal, S
   Holz, FG
   Finger, RP
AF Terheyden, Jan Henrik
   Schmitz-Valckenberg, Steffen
   Crabb, David P.
   Dunbar, Hannah
   Luhmann, Ulrich F. O.
   Behning, Charlotte
   Schmid, Matthias
   Silva, Rufino
   Cunha-Vaz, Jose
   Tufail, Adnan
   Weissgerber, Georges
   Leal, Sergio
   Holz, Frank G.
   Finger, Robert P.
CA MACUSTAR Consortium
TI Use of Composite End Points in Early and Intermediate Age-Related
   Macular Degeneration Clinical Trials: State-of-the-Art and Future
   Directions
SO OPHTHALMOLOGICA
LA English
DT Review
DE Age-related macular degeneration; Composite end points; Trial outcomes
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL-PIGMENT EPITHELIUM; NIGHTTIME
   LIGHT THERAPY; RETICULAR PSEUDODRUSEN; LONGITUDINAL ANALYSIS; DRUSEN
   VOLUME; PROGRESSION; EYE; THICKNESS; DISEASE
AB The slow progression of early age-related macular degeneration (AMD) stages to advanced AMD requires the use of surrogate end points in clinical trials. The use of combined end points may allow for shorter and smaller trials due to increased precision. We performed a literature search for the use of composite end points as primary outcome measures in clinical studies of early AMD stages. PubMed was searched for composite end points used in early/intermediate AMD studies published during the last 10 years. A total of 673 articles of interest were identified. After reviewing abstracts and applicable full-text articles, 33 articles were eligible and thus included in the qualitative synthesis. The main composite end point categories were: combined structural and functional end points, combined structural end points, combined functional end points and combined multicategorical end points. The majority of the studies included binary composite end points. There was a lack of sensitivity analyses of different end points against accepted outcomes (i.e., progression) in the literature. Various composite outcome measures have been used but there is a lack of standardization. To date no agreement on the optimal approach to implement combined end points in clinical studies of early stages of AMD exists, and no surrogate end points have been accepted for AMD progression.
C1 [Terheyden, Jan Henrik; Schmitz-Valckenberg, Steffen; Holz, Frank G.; Finger, Robert P.] Univ Hosp Bonn, Dept Ophthalmol, Bonn, Germany.
   [Schmitz-Valckenberg, Steffen] Univ Utah, John Moran Eye Ctr, Salt Lake City, UT USA.
   [Crabb, David P.] City Univ London, Sch Hlth Sci, Div Optometry & Visual Sci, London, England.
   [Dunbar, Hannah] UCL Inst Ophthalmol, London, England.
   [Luhmann, Ulrich F. O.] Roche Innovat Ctr, Roche Pharmaceut Res & Early Dev, Translat Med Ophthalmol, Roche Pharma Res & Early Dev, Basel, Switzerland.
   [Behning, Charlotte; Schmid, Matthias] Univ Hosp Bonn, Inst Med Biometry Informat & Epidemiol, Bonn, Germany.
   [Silva, Rufino; Cunha-Vaz, Jose] Assoc Innovat & Biomed Res Light & Image, Coimbra, Portugal.
   [Silva, Rufino] Univ Coimbra, Fac Med, Coimbra Inst Clin & Biomed Res iCBR, Coimbra, Portugal.
   [Silva, Rufino] Ctr Hosp & Univ Coimbra CHUC, Dept Ophthalmol, Coimbra, Portugal.
   [Tufail, Adnan] Moorfields Eye Hosp, London, England.
   [Weissgerber, Georges] Novartis Pharma AG, Basel, Switzerland.
   [Leal, Sergio] Bayer AG, Berlin, Germany.
C3 University of Bonn; Utah System of Higher Education; University of Utah;
   City University London; University of London; University College London;
   Roche Holding; University of Bonn; Universidade de Coimbra; Universidade
   de Coimbra; Universidade de Coimbra; Centro Hospitalar e Universitario
   de Coimbra (CHUC); University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; Novartis; Bayer AG
RP Finger, RP (通讯作者)，Univ Bonn, Dept Ophthalmol, DE-53127 Bonn, Germany.
EM Robert.Finger@ukbonn.de
OI Crabb, David/0000-0001-8754-3902; Tufail, Adnan/0000-0001-6131-7640;
   Schmid, Matthias/0000-0002-0788-0317
FU Innovative Medicines Initiative 2 Joint Undertaking [116076]; European
   Union's Horizon 2020 research and innovation programme; EFPIA
FX This project has received funding from the Innovative Medicines
   Initiative 2 Joint Undertaking 439 under grant agreement No. 116076.
   This Joint Undertaking receives support from the 440 European Union's
   Horizon 2020 research and innovation programme and EFPIA.
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, pBIO141, DOI 10.1167/iovs.17-21789
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Brandl C, 2016, OPHTHALMOLOGE, V113, P735, DOI 10.1007/s00347-016-0341-6
   Bruce CS, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002873
   Burlina PM, 2018, JAMA OPHTHALMOL, V136, P1359, DOI 10.1001/jamaophthalmol.2018.4118
   Chakravarthy U, 2020, OPHTHALMOL RETINA, V4, P662, DOI 10.1016/j.oret.2020.01.012
   Chauhan BC, 2007, EYE, V21, pS34, DOI 10.1038/sj.eye.6702886
   Chew Emily Y, 2013, Ophthalmology, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chi GYH, 2005, FUND CLIN PHARMACOL, V19, P609, DOI 10.1111/j.1472-8206.2005.00370.x
   Chiang TTK, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.6.59
   Cocce KJ, 2018, AM J OPHTHALMOL, V189, P127, DOI 10.1016/j.ajo.2018.02.012
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Csaky K, 2017, INVEST OPHTH VIS SCI, V58, P3456, DOI 10.1167/iovs.17-22339
   Curcio CA, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01467-0
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Garcia CAD, 2013, RETINA-J RET VIT DIS, V33, P1558, DOI 10.1097/IAE.0b013e318285cbd2
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Echols BS, 2020, OPHTHALMOL RETINA, V4, P1059, DOI 10.1016/j.oret.2020.05.001
   Finger RP, 2019, OPHTHALMOLOGICA, V241, P61, DOI 10.1159/000491402
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Gin TJ, 2017, INVEST OPHTH VIS SCI, V58, P2079, DOI 10.1167/iovs.16-20105
   Goldberg R, 2014, AM J MED, V127, P379, DOI 10.1016/j.amjmed.2014.01.011
   Guymer RH, 2014, CLIN EXP OPHTHALMOL, V42, P466, DOI 10.1111/ceo.12247
   Guymer RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083759
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Hsu ST, 2019, OPHTHALMOL RETINA, V3, P637, DOI 10.1016/j.oret.2019.03.010
   Joachim N, 2018, OPHTHALMOL RETINA, V2, P684, DOI 10.1016/j.oret.2017.10.019
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Kim MS, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-71401-3
   Lamin A, 2020, OPHTHALMIC RES, V63, P375, DOI 10.1159/000505628
   Lamin A, 2019, EYE, V33, P910, DOI 10.1038/s41433-019-0338-x
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Liew G, 2016, OPHTHALMOLOGY, V123, P1874, DOI 10.1016/j.ophtha.2016.05.043
   Lu LN, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002967
   McKeague C, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-246
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Myers CE, 2014, OPHTHALMOLOGY, V121, P1949, DOI 10.1016/j.ophtha.2014.04.040
   Nassisi M, 2019, OPHTHALMOLOGY, V126, P1667, DOI 10.1016/j.ophtha.2019.05.016
   Nittala MG, 2019, OPHTHALMOL RETINA, V3, P112, DOI 10.1016/j.oret.2018.09.017
   Piatti A, 2020, EUR J OPHTHALMOL, V30, P376, DOI 10.1177/1120672119836007
   Pondorfer SG, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231748
   Pondorfer SG, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51769-7
   Robinson DG, 2018, INVEST OPHTH VIS SCI, V59, P4531, DOI 10.1167/iovs.18-24284
   Roy NS, 2017, INVEST OPHTH VIS SCI, V58, pBIO1, DOI 10.1167/iovs.17-21709
   Russell RA, 2012, INVEST OPHTH VIS SCI, V53, P2760, DOI 10.1167/iovs.11-7976
   Sankoh AJ, 2014, STAT MED, V33, P4709, DOI 10.1002/sim.6205
   Sassmannshausen M, 2021, OPHTHALMOL RETINA, V5, P241, DOI 10.1016/j.oret.2020.07.019
   Sassmannshausen M, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.10.19
   Schaal KB, 2016, OPHTHALMOLOGY, V123, P1060, DOI 10.1016/j.ophtha.2016.01.034
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Schneider LS, 2020, ALZH DEMENT-DADM, V12, DOI 10.1002/dad2.12017
   Schweitzer D, 2009, OPHTHALMOLOGE, V106, P714, DOI 10.1007/s00347-009-1975-4
   Seddon JM, 2013, JAMA OPHTHALMOL, V131, P448, DOI 10.1001/jamaophthalmol.2013.2578
   Sitnilska V, 2020, OPHTHALMOLOGICA, V243, P444, DOI 10.1159/000507196
   Sleiman K, 2017, OPHTHALMOLOGY, V124, P1764, DOI 10.1016/j.ophtha.2017.06.032
   Terheyden JH, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04595-6
   Thiele S, 2020, OPHTHALMOL RETINA, V4, P31, DOI 10.1016/j.oret.2019.08.003
   Thiele S, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.17-23315
   Tikellis G, 2007, EYE, V21, P169, DOI 10.1038/sj.eye.6702151
   Veerappan M, 2016, OPHTHALMOLOGY, V123, P2554, DOI 10.1016/j.ophtha.2016.08.047
   Villani E, 2020, EYE CONTACT LENS, V46, pS141, DOI 10.1097/ICL.0000000000000650
   Virgili G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub3
   Waldstein SM, 2020, JAMA OPHTHALMOL, V138, P740, DOI 10.1001/jamaophthalmol.2020.1376
   Wickstrom K, 2017, INVEST OPHTH VIS SCI, V58, pBIO27, DOI 10.1167/iovs.17-21778
   Wright C, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.7.49
   Wu ZC, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55345-x
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
NR 71
TC 4
Z9 3
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD NOV
PY 2021
VL 244
IS 5
BP 387
EP 395
DI 10.1159/000513591
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XK8CK
UT WOS:000727686300006
PM 33285549
OA Green Published, Green Accepted, hybrid
DA 2022-11-30
ER

PT J
AU Askou, AL
AF Askou, Anne Louise
TI Development of gene therapy for treatment of age-related macular
   degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; RETINAL-PIGMENT
   EPITHELIUM; LEBER CONGENITAL AMAUROSIS; INDUCED CHOROIDAL
   NEOVASCULARIZATION; HIGH-EFFICIENCY TRANSDUCTION; VASCULAR-PERMEABILITY
   FACTOR; SHORT-INTERFERING RNAS; HUMAN BRUCHS MEMBRANE; ADENOASSOCIATED
   VIRUS
AB Intraocular neovascular diseases are the leading cause of blindness in the Western world in individuals over the age of 50. Age-related macular degeneration(AMD) is one of these diseases. Exudative AMD, the late-stage form, is characterized by abnormal neovessel development, sprouting from the choroid into the avascular subretinal space, where it can suddenly cause irreversible damage to the vulnerable photoreceptor (PR) cells essential for our high-resolution, central vision. The molecular basis of AMD is not well understood, but several growth factors have been implicated including vascular endothelial growth factor (VEGF), and the advent of anti-VEGF therapy has markedly changed the outcome of treatment. However, common to all current therapies for exudative AMD are the complications of repeated monthly intravitreal injections, which must be continued throughout one's lifetime to maintain visual benefits. Additionally, some patients do not benefit from established treatments. Strategies providing long-term suppression of inappropriate ocular angiogenesis are therefore needed, and gene therapy offers a potential powerful technique.
   This study aimed to develop a strategy based on RNA interference (RNAi) for the sustained attenuation of VEGF. We designed a panel of anti-VEGF short hairpin RNAs (shRNA), and based on the most potent shRNAs, microRNA (miRNA)mimicked hairpins were developed. We demonstrated an additive VEGF silencing effect when we combined the miRNAs in a tricistronic miRNA cluster. To meet the requirements for development of medical treatments for AMD with long-term effects, the shRNA/miRNA is expressed from vectors based on adeno-associated virus (AAV) or lentivirus (LV). Both vector systems have been found superior in terms of transduction efficiency and persistence in gene expression in retinal cells.
   The capacity of AAV-encoded RNAi effector molecules to silence endogenous VEGF gene expression was evaluated in mouse models, including the model of laser-induced choroidal neovascularization (CNV), and we found that subretinal administration of self-complementary (sc)-AAV2/8 encoding anti-VEGF shRNAs can impair vessel formation. In parallel, a significant reduction of endogenous VEGF was demonstrated following injection of scAAV2/8 vectors expressing multiple anti-VEGF miRNAs into murine hind limb muscles.
   Furthermore, in an ongoing project we have designed versatile, multigenic LV vectors with combined expression of multiple miRNAs and proteins, including pigment epithelium-derived factor (PEDF), a multifunctional, secreted protein that has anti-angiogenic and neurotrophic functions. Co-expression of miRNAs and proteins from a single viral vector increases safety by minimizing the viral load necessary to obtain a therapeutic effect and thereby reduces the risk of insertional mutagenesis as well as the immune response against viral proteins. Our results co-expression of functional anti-VEGF-miRNAs and PEDF in cell studies, and in vivo studies reveal an efficient retinal pigment epithelium (RPE)-specific gene expression following the incorporation of the vitelliform macular dystrophy 2 (VMD2) promoter, demonstrating the potential applicability of our multigenic LV vectors in ocular anti-VEGF gene therapy, including combination therapy for treatment of exudative AMD.
   In conclusion, these highly promising data clearly demonstrate that viral-encoded RNAi effector molecules can be used for the inhibition of neovascularization and will, in combination with the growing interest of applying DNA-or RNA-based technologies in the clinic, undoubtedly contribute to the development of efficacious long-term gene therapy treatment of intraocular neovascular diseases. (C) 2014 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd
C1 [Askou, Anne Louise] Aarhus Univ, Dept Biomed, Wilhelm Meyers Alle 4, DK-8000 Aarhus, Denmark.
C3 Aarhus University
RP Askou, AL (通讯作者)，Aarhus Univ, Dept Biomed, Wilhelm Meyers Alle 4, DK-8000 Aarhus, Denmark.
EM anne.louise.askou@hum-gen.au.dk
RI Askou, Anne/AGW-2995-2022
OI Askou, Anne Louise/0000-0002-5512-1796
CR Aagaard L, 2008, GENE THER, V15, P1536, DOI 10.1038/gt.2008.147
   Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435
   ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Allocca M, 2007, J VIROL, V81, P11372, DOI 10.1128/JVI.01327-07
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   Apolonia L, 2007, MOL THER, V15, P1947, DOI 10.1038/sj.mt.6300281
   Ashikari M, 2010, INVEST OPHTH VIS SCI, V51, P3820, DOI 10.1167/iovs.09-5121
   Auricchio A, 2002, MOL THER, V6, P490, DOI 10.1006/mthe.2002.0702
   Auricchio A, 2001, HUM MOL GENET, V10, P3075, DOI 10.1093/hmg/10.26.3075
   Bai YJ, 2012, J PHARMACOL EXP THER, V342, P131, DOI 10.1124/jpet.112.192575
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Balaggan KS, 2012, GENE THER, V19, P145, DOI 10.1038/gt.2011.153
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bates DO, 2002, CANCER RES, V62, P4123
   Bayer M, 2008, MOL THER, V16, P1968, DOI 10.1038/mt.2008.199
   Becerra SP, 2013, NAT REV CANCER, V13, P258, DOI 10.1038/nrc3484
   Becerra SP, 2004, EXP EYE RES, V78, P223, DOI 10.1016/j.exer.2003.10.013
   Bek T, 2004, OFTALMOLOGI NORDISK
   Benhar I, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00296
   Bennett J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002865
   Berge M, 2010, AM J PATHOL, V177, P3192, DOI 10.2353/ajpath.2010.100157
   Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374
   Bernatchez PN, 1999, J BIOL CHEM, V274, P31047, DOI 10.1074/jbc.274.43.31047
   Binley K, 2012, HUM GENE THER, V23, P980, DOI 10.1089/hum.2012.008
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Boudreau RL, 2008, RNA, V14, P1834, DOI 10.1261/rna.1062908
   Boudreau RL, 2009, MOL THER, V17, P169, DOI 10.1038/mt.2008.231
   Brafman A, 2004, INVEST OPHTH VIS SCI, V45, P3796, DOI 10.1167/iovs.04-0052
   Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085
   Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173
   Bruewer AR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060218
   Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Cashman SM, 2006, INVEST OPHTH VIS SCI, V47, P3496, DOI 10.1167/iovs.05-1610
   Cayouette M, 1999, NEUROBIOL DIS, V6, P523, DOI 10.1006/nbdi.1999.0263
   Chen Y, 2007, J BIOL CHEM, V282, P34420, DOI 10.1074/jbc.M611289200
   Chung KH, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl143
   Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736
   Cornu TI, 2007, MOL THER, V15, P2107, DOI 10.1038/sj.mt.6300345
   Coutant F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003973
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dalkara D, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005708
   Dalkara D, 2009, MOL THER, V17, P2096, DOI 10.1038/mt.2009.181
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Dickins RA, 2005, NAT GENET, V37, P1289, DOI 10.1038/ng1651
   Du Q, 2009, CANCER RES, V69, P3764, DOI 10.1158/0008-5472.CAN-09-0014
   Ehlert EM, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-20
   ESSER P, 1993, BRIT J OPHTHALMOL, V77, P731, DOI 10.1136/bjo.77.11.731
   Fedorov Y, 2006, RNA, V12, P1188, DOI 10.1261/rna.28106
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Garba AO, 2010, OPHTHALMOL EYE DIS, V2, P75, DOI 10.4137/OED.S4878
   Gaudry M, 1997, BLOOD, V90, P4153, DOI 10.1182/blood.V90.10.4153
   Gehlbach P, 2003, HUM GENE THER, V14, P129, DOI 10.1089/104303403321070829
   Geneser F, 2002, HISTOLOGI MOLEKYLAER
   Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659
   Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gradl D, 1999, MOL CELL BIOL, V19, P5576
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1986, OPHTHALMOLOGY, V93, P1169
   Grimm D, 2006, NATURE, V441, P537, DOI 10.1038/nature04791
   Grimm D, 2010, J CLIN INVEST, V120, P3106, DOI 10.1172/JCI43565
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   Grossniklaus HE, 2000, ARCH OPHTHALMOL-CHIC, V118, P625
   Gu LP, 2010, EXP EYE RES, V91, P433, DOI 10.1016/j.exer.2010.06.019
   Gu S, 2012, CELL, V151, P900, DOI 10.1016/j.cell.2012.09.042
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   GUERRIN M, 1995, J CELL PHYSIOL, V164, P385, DOI 10.1002/jcp.1041640219
   GULCAN HG, 1993, INVEST OPHTH VIS SCI, V34, P3187
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Harmey JH, 1998, ANN SURG ONCOL, V5, P271, DOI 10.1007/BF02303785
   Harper SJ, 2008, NAT REV CANCER, V8, P880, DOI 10.1038/nrc2505
   Hassel D, 2012, CIRC RES, V111, P1421, DOI 10.1161/CIRCRESAHA.112.279711
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   Heale BSE, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni026
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Helvik SA, 2007, BIOINFORMATICS, V23, P142, DOI 10.1093/bioinformatics/btl570
   Hildebrand GD, 2011, PEDIATRIC RETINA, P39, DOI 10.1007/978-3-642-12041-1_2
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Holmes DIR, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-2-209
   Honda M, 2000, GENE THER, V7, P978, DOI 10.1038/sj.gt.3301203
   Hou X, 2010, P NATL ACAD SCI USA, V107, P12216, DOI 10.1073/pnas.1004143107
   HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806
   Huang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071808
   Huang V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008848
   Hussain AA, 2010, EXP EYE RES, V90, P703, DOI 10.1016/j.exer.2010.02.013
   Ideno J, 2007, INT J MOL MED, V19, P75
   Igarashi T, 2014, MOL VIS, V20, P488
   Igarashi T, 2010, HUM GENE THER, V21, P631, DOI 10.1089/hum.2009.153
   Jacobson SG, 2012, ARCH OPHTHALMOL-CHIC, V130, P9, DOI 10.1001/archophthalmol.2011.298
   Kachi S, 2009, HUM GENE THER, V20, P31, DOI 10.1089/hum.2008.046
   Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509
   Karali M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022166
   Kariko K, 2005, IMMUNITY, V23, P165, DOI 10.1016/j.immuni.2005.06.008
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawazoe Y, 2012, EXP EYE RES, V94, P32, DOI 10.1016/j.exer.2011.11.002
   KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Kim VN, 2006, TRENDS GENET, V22, P165, DOI 10.1016/j.tig.2006.01.003
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Kleinman ME, 2012, MOL THER, V20, P101, DOI 10.1038/mt.2011.212
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Konopatskaya O, 2006, MOL VIS, V12, P626
   Kur J, 2012, PROG RETIN EYE RES, V31, P377, DOI 10.1016/j.preteyeres.2012.04.004
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lai CM, 2012, GENE THER, V19, P999, DOI 10.1038/gt.2011.169
   Lai CF, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/637850
   Lai CM, 2005, MOL THER, V12, P659, DOI 10.1016/j.ymthe.2005.04.022
   Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lange T, 2003, J BIOL CHEM, V278, P17164, DOI 10.1074/jbc.M212224200
   Lassota N, 2008, ACTA OPHTHALMOL, V86, P495, DOI [10.1111/j.1600-0420.2007.01127.x, 10.1111/j.1755-3768.2008.01412.x]
   Lee I, 2009, GENOME RES, V19, P1175, DOI 10.1101/gr.089367.108
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Lee SH, 2014, HUM GENE THER METHOD, V25, P83, DOI 10.1089/hgtb.2013.089
   Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957
   Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385
   Lei JX, 1998, BBA-GENE STRUCT EXPR, V1443, P400, DOI 10.1016/S0167-4781(98)00240-1
   Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Li LM, 2007, RNA, V13, P1765, DOI 10.1261/rna.599107
   Li QH, 2008, MOL VIS, V14, P1760
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lutty GA, 1997, AM J PATHOL, V151, P707
   MacLachlan TK, 2011, MOL THER, V19, P326, DOI 10.1038/mt.2010.258
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Maguire AM, 2009, LANCET, V374, P1597, DOI 10.1016/S0140-6736(09)61836-5
   Maik-Rachline G, 2005, BLOOD, V105, P670, DOI 10.1182/blood-2004-04-1569
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Martin JN, 2011, GENE THER, V18, P666, DOI 10.1038/gt.2011.10
   McAnuff MA, 2007, J PHARM SCI-US, V96, P2922, DOI 10.1002/jps.20968
   McBride JL, 2008, P NATL ACAD SCI USA, V105, P5868, DOI 10.1073/pnas.0801775105
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   MILLER H, 1990, INVEST OPHTH VIS SCI, V31, P899
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Miyazaki M, 2011, HUM GENE THER, V22, P559, DOI 10.1089/hum.2010.132
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Murakami Y, 2010, HUM GENE THER, V21, P199, DOI 10.1089/hum.2009.102
   Nagineni CN, 2012, J CELL PHYSIOL, V227, P116, DOI 10.1002/jcp.22708
   Nan R, 2008, J MOL BIOL, V384, P1341, DOI 10.1016/j.jmb.2008.10.030
   Natkunarajah M, 2008, GENE THER, V15, P463, DOI 10.1038/sj.gt.3303074
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Ng YS, 2001, DEV DYNAM, V220, P112, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1093>3.0.CO;2-D
   Notari L, 2005, INVEST OPHTH VIS SCI, V46, P2736, DOI 10.1167/iovs.04-1489
   Notari L, 2006, J BIOL CHEM, V281, P38022, DOI 10.1074/jbc.M600353200
   Nuzzi R, 2013, LOCAL SYSTEMIC COMPL
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Oshima Y, 2004, J CELL PHYSIOL, V201, P393, DOI 10.1002/jcp.20110
   PARK JE, 1994, J BIOL CHEM, V269, P25646
   Park K, 2011, MOL CELL BIOL, V31, P3038, DOI 10.1128/MCB.01211-10
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   PARVER L M, 1991, Eye (London), V5, P181
   Pechan P, 2009, GENE THER, V16, P10, DOI 10.1038/gt.2008.115
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Petrs-Silva H, 2009, MOL THER, V17, P463, DOI 10.1038/mt.2008.269
   Place RF, 2008, P NATL ACAD SCI USA, V105, P1608, DOI 10.1073/pnas.0707594105
   Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151
   Qin WM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009429
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P1867, DOI 10.1016/j.ophtha.2012.03.043
   Rabinowitz JE, 2002, J VIROL, V76, P791, DOI 10.1128/JVI.76.2.791-801.2002
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Reich S, 2003, MOL VIS, V9, P210
   Robert L, 1998, GERONTOLOGY, V44, P307, DOI 10.1159/000022034
   ROBERTS WG, 1995, J CELL SCI, V108, P2369
   Robinson GS, 2001, FASEB J, V15, P1215, DOI 10.1096/fj.00-0598fje
   Rota R, 2004, J GENE MED, V6, P992, DOI 10.1002/jgm.586
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Schubert S, 2005, J MOL BIOL, V348, P883, DOI 10.1016/j.jmb.2005.03.011
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   SHEN H, 1993, BLOOD, V81, P2767
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566
   SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450
   SHWEIKI D, 1995, P NATL ACAD SCI USA, V92, P768, DOI 10.1073/pnas.92.3.768
   Siemerink MJ, 2013, J HISTOCHEM CYTOCHEM, V61, P101, DOI 10.1369/0022155412467635
   Silva JM, 2005, NAT GENET, V37, P1281, DOI 10.1038/ng1650
   Simonelli F, 2010, MOL THER, V18, P643, DOI 10.1038/mt.2009.277
   Singerman L, 2009, RETINA-J RET VIT DIS, V29, pS49, DOI 10.1097/IAE.0b013e3181ad2341
   Skeie JM, 2009, EYE, V23, P747, DOI 10.1038/eye.2008.206
   Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Spranger J, 2001, DIABETES, V50, P2641, DOI 10.2337/diabetes.50.12.2641
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Subramanian P, 2010, ADV EXP MED BIOL, V664, P29, DOI 10.1007/978-1-4419-1399-9_4
   Sugita S, 2010, INVEST OPHTH VIS SCI, V51, P5783, DOI 10.1167/iovs.09-5098
   Surace EM, 2008, VISION RES, V48, P353, DOI 10.1016/j.visres.2007.07.027
   Testa F, 2013, OPHTHALMOLOGY, V120, P1283, DOI 10.1016/j.ophtha.2012.11.048
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   TISCHER E, 1991, J BIOL CHEM, V266, P11947
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180
   Tombran-Tink J, 2004, EXP EYE RES, V78, P945, DOI 10.1016/j.exer.2003.12.013
   TOMBRANTINK J, 1989, INVEST OPHTH VIS SCI, V30, P1700
   Tsao YP, 2006, LIFE SCI, V79, P545, DOI 10.1016/j.lfs.2006.01.041
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   VERZAR F, 1957, GERONTOLOGY, V1, P363, DOI 10.1159/000210714
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304
   Wang JJ, 2010, DIABETES, V59, P2297, DOI 10.2337/db09-1420
   Weber M, 2003, MOL THER, V7, P774, DOI 10.1016/S1525-0016(03)00098-4
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   Williams MA, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009300.pub2
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zamiri Parisa, 2007, Chem Immunol Allergy, V92, P86, DOI 10.1159/000099259
   Zamiri P, 2006, INVEST OPHTH VIS SCI, V47, P3912, DOI 10.1167/iovs.05-1267
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang YJ, 2010, MOL CELL, V39, P133, DOI 10.1016/j.molcel.2010.06.010
   Zhong L, 2008, P NATL ACAD SCI USA, V105, P7827, DOI 10.1073/pnas.0802866105
   Zhou HX, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni061
   Zincarelli C, 2008, MOL THER, V16, P1073, DOI 10.1038/mt.2008.76
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 250
TC 18
Z9 24
U1 3
U2 24
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUL
PY 2014
VL 92
SU THE3
SI SI
BP 1
EP 38
DI 10.1111/aos.12452
PG 38
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA V43SU
UT WOS:000209701900001
PM 24953666
OA Bronze
DA 2022-11-30
ER

PT J
AU Ulas, F
   Balbaba, M
   Ozmen, S
   Celebi, S
   Dogan, U
AF Ulas, Fatih
   Balbaba, Mehmet
   Ozmen, Sedat
   Celebi, Serdal
   Dogan, Umit
TI Association of dehydroepiandrosterone sulfate, serum lipids, C-reactive
   protein and body mass index with age-related macular degeneration
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
ID RISK-FACTORS; ENDOTHELIAL-CELLS; OXIDATIVE STRESS; INFLAMMATION;
   BIOMARKERS; CHOLESTEROL; MACULOPATHY; STEROIDS; ALPHA
AB The present study was designed to evaluate the associations between exudative age-related macular degeneration (AMD) and the serum concentrations of C-reactive protein (CRP), dehydroepiandrosterone sulfate (DHEAS), and lipids as well as the relationship between exudative AMD and body mass index (BMI). This cross-sectional study included of 141 healthy control subjects (70 males and 71 females with a mean age of 71.01 +/- A 3.84 years) and 142 exudative AMD patients (70 males and 72 females with a mean age of 70.92 +/- A 3.60 years). BMI and the serum concentrations of CRP, DHEAS, and lipids were measured in both groups. The data were statistically analysed using the Mann-Whitney U test, Chi squared test, independent sample t test, Cramer's V, point biserial correlation and logistic regression analysis. BMI values and serum concentrations of CRP, total cholesterol, and low-density lipoprotein (LDL) cholesterol were significantly higher in exudative AMD patients compared with normal controls (p values were 0.001, < 0.001, 0.005 and < 0.001, respectively). The serum concentrations of DHEAS were not significantly different between the controls and the exudative AMD patients for the subgroups of either gender (p values in males and females were 0.785 and 0.159, respectively). A logistic regression analysis revealed that the BMI and serum concentration of CRP moderately contributed to the predictive ability of the model (odds ratios were 1.205 and 1.179, respectively). Elevated total cholesterol concentrations and LDL cholesterol concentrations, BMI values and serum concentrations of CRP were associated with exudative AMD. However, no association between the serum DHEAS concentration and exudative AMD was established.
RP Ulas, F (通讯作者)，Abant Izzet Baysal Univ Med, Dept Ophthalmol, TR-14280 Bolu, Turkey.
EM fatihu44@yahoo.com
OI Ulas, Fatih/0000-0003-4468-3985
CR Altman R, 2008, VASC PHARMACOL, V48, P76, DOI 10.1016/j.vph.2007.12.002
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Auchus RJ, 2004, SEMIN REPROD MED, V22, P281, DOI 10.1055/s-2004-861545
   Bastianetto S, 1999, MOL BRAIN RES, V66, P35, DOI 10.1016/S0169-328X(99)00002-9
   Bucolo C, 2005, NEUROREPORT, V16, P1203, DOI 10.1097/00001756-200508010-00014
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Dasari B, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-22
   Defay R, 2004, ANN EPIDEMIOL, V14, P202, DOI 10.1016/S1047-2797(03)00130-3
   Du Clos TW, 2000, ANN MED, V32, P274, DOI 10.3109/07853890009011772
   Gutierrez G, 2007, ATHEROSCLEROSIS, V190, P90, DOI 10.1016/j.atherosclerosis.2006.02.031
   Kim IK, 2008, MOL VIS, V14, P1487
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Legrain S, 2003, DRUG AGING, V20, P949, DOI 10.2165/00002512-200320130-00001
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   Moeini HA, 2005, BRIT J OPHTHALMOL, V89, P964, DOI 10.1136/bjo.2005.066241
   Najafi M, 2011, CARDIOVASC HEMATOL D
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Saggini A, 2011, INT J IMMUNOPATH PH, V24, P567, DOI 10.1177/039463201102400303
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2010, MOL VIS, V16, P2412
   Tamer C, 2007, AM J OPHTHALMOL, V143, P212, DOI 10.1016/j.ajo.2006.09.054
   Tsimikas S, 2006, J AM COLL CARDIOL, V47, pC19, DOI 10.1016/j.jacc.2005.10.066
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
NR 27
TC 17
Z9 18
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD OCT
PY 2013
VL 33
IS 5
BP 485
EP 491
DI 10.1007/s10792-013-9728-4
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 223UP
UT WOS:000324837100007
PM 23377999
DA 2022-11-30
ER

PT J
AU Abdin, AD
   Aljundi, W
   El Jawhari, K
   Suffo, S
   Weinstein, I
   Seitz, B
AF Abdin, Alaa Din
   Aljundi, Wissam
   El Jawhari, Khalil
   Suffo, Shady
   Weinstein, Isabel
   Seitz, Berthold
TI First Year Real Life Experience With Intravitreal Brolucizumab for
   Treatment of Refractory Neovascular Age-Related Macular Degeneration
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE neovascular age-related macular degeneration (nAMD); intraocular
   inflammation; intravitreal brolucizumab; switching therapy; refractory
   macular edema
ID VEGF; INFLAMMATION
AB Purpose: To assess the morphological and functional outcomes within the first year of treatment with intravitreal brolucizumab for refractory neovascular age-related macular degeneration (nAMD).Methods: This retrospective study included 21 eyes from 19 patients with refractory nAMD followed for 12 months. All patients were switched to brolucizumab after treatment with at least two other anti-vascular endothelial growth factors (VEGF). All eyes received 3x brolucizumab 6 mg/0.05 ml intravitreal injections (IVI) monthly as an upload phase. Then eyes received an IVI every 8 weeks with interval adjustment to every 12 weeks if disease activity was not present. Main outcome measures: best corrected visual acuity (BCVA), central macular thickness (CMT) and retinal fluid distribution. In addition, we reported the adverse event rate.Results: The number of previous anti-VEGF IVIs/eye was 36 +/- 22 before switching to brolucizumab. BCVA (ETDRS) was 51 +/- 16 before treatment and 50 +/- 19 at week 52 (p = 0.6). CMT was 374 +/- 158 mu m before treatment and 298 +/- 92 mu m at week 52 (p = 0.01). The number of IVIs/eye decreased from 9.6 +/- 1.9 IVIs in the last year before switching to 6.4 +/- 0.9 IVIs in the first year after switching to brolucizumab (p < 0.001). The rate of eyes with subretinal fluid and pigment epithelial detachment decreased at week 52. Finally, two cases of intraocular inflammation were observed as adverse events.Conclusion: In the first year of treatment, intravitreal brolucizumab was able to stabilize visual acuity with significantly less IVIs in patients with refractory nAMD. It also improved anatomic outcomes in these patients, particularly reducing subretinal fluid and pigment epithelial detachment and subsequently central macular thickness. However, two cases of intraocular inflammation were observed as adverse events.
C1 [Abdin, Alaa Din; Aljundi, Wissam; El Jawhari, Khalil; Suffo, Shady; Weinstein, Isabel; Seitz, Berthold] Saarland Univ Med Ctr UKS, Dept Ophthalmol, Homburg, Germany.
C3 Universitatsklinikum des Saarlandes
RP Abdin, AD (通讯作者)，Saarland Univ Med Ctr UKS, Dept Ophthalmol, Homburg, Germany.
EM alaadin.abdin@uks.eu
CR Abdin AD, 2020, OPHTHALMOLOGE, V117, P50, DOI 10.1007/s00347-019-0911-5
   Anderson WJ, 2021, INT J RETINA VITR, V7, DOI 10.1186/s40942-021-00307-7
   Augustin AJ, 2009, EXPERT OPIN THER TAR, V13, P641, DOI 10.1517/14728220902942322
   Baumal CR, 2021, OPHTHALMOL RETINA, V5, P519, DOI 10.1016/j.oret.2020.09.020
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Book M, 2022, OPHTHALMOLOGE, V119, P258, DOI 10.1007/s00347-021-01474-6
   Bulirsch LM, 2022, BRIT J OPHTHALMOL, V106, P1288, DOI 10.1136/bjophthalmol-2020-318672
   Chakraborty D, 2021, CLIN OPHTHALMOL, V15, P3787, DOI 10.2147/OPTH.S328160
   Dolar-Szczasny J, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.656774
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Enriquez AB, 2021, JAMA OPHTHALMOL, V139, P441, DOI 10.1001/jamaophthalmol.2020.7085
   Exchange S., 2021, NOVARTIS REPORTS ONE
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Gale RP, 2020, BRIT J OPHTHALMOL, V104, P493, DOI 10.1136/bjophthalmol-2019-314251
   German Soc Ophthalmology, 2021, OPHTHALMOLOGE, V118, P31, DOI 10.1007/s00347-020-01188-1
   Haensli C, 2021, J CLIN MED, V10, DOI 10.3390/jcm10122666
   Haug Sara J, 2020, Am J Ophthalmol Case Rep, V18, P100680, DOI 10.1016/j.ajoc.2020.100680
   Holz FG, 2021, OPHTHALMOLOGE, V118, P248, DOI 10.1007/s00347-021-01321-8
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Jain Atul, 2020, Am J Ophthalmol Case Rep, V18, P100687, DOI 10.1016/j.ajoc.2020.100687
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Khanani AM, 2022, JAMA OPHTHALMOL, V140, P20, DOI 10.1001/jamaophthalmol.2021.4585
   Lad EM, 2014, AM J OPHTHALMOL, V158, P537, DOI 10.1016/j.ajo.2014.05.014
   Li E, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012208.pub2
   Markham A, 2019, DRUGS, V79, P1997, DOI 10.1007/s40265-019-01231-9
   Mones J, 2021, OPHTHALMOLOGY, V128, P1050, DOI 10.1016/j.ophtha.2020.11.011
   Montesel A, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.720345
   Platania CBM, 2015, FRONT PHARMACOL, V6, DOI [10.3389/fphar.2015.00248, 10.3389/tphar.7015.00248]
   Plyukhova AA, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051522
   Sharma A, 2021, EYE, V35, P1045, DOI 10.1038/s41433-020-1111-x
   Souied EH, 2016, OPHTHAL EPIDEMIOL, V23, P71, DOI 10.3109/09286586.2015.1090004
   Witkin Andre J, 2020, J Vitreoretin Dis, V4, P269, DOI 10.1177/2474126420930863
NR 33
TC 1
Z9 1
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD MAY 30
PY 2022
VL 13
AR 860784
DI 10.3389/fphar.2022.860784
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 2D0WT
UT WOS:000811278300001
PM 35721125
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Anderson, DH
   Radeke, MJ
   Gallo, NB
   Chapin, EA
   Johnson, PT
   Curletti, CR
   Hancox, LS
   Hu, J
   Ebright, JN
   Malek, G
   Hauser, MA
   Rickman, CB
   Bok, D
   Hageman, GS
   Johnson, LV
AF Anderson, Don H.
   Radeke, Monte J.
   Gallo, Natasha B.
   Chapin, Ethan A.
   Johnson, Patrick T.
   Curletti, Christy R.
   Hancox, Lisa S.
   Hu, Jane
   Ebright, Jessica N.
   Malek, Goldis
   Hauser, Michael A.
   Rickman, Catherine Bowes
   Bok, Dean
   Hageman, Gregory S.
   Johnson, Lincoln V.
TI The pivotal role of the complement system in aging and age-related
   macular degeneration: Hypothesis re-visited
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
DE Macular degeneration; Complement; Retinal pigment epithelium; Factor H;
   Drusen; Gene expression; SNP discovery
ID C-REACTIVE PROTEIN; FACTOR-H POLYMORPHISM; SERPING1 GENE; REGULATORY
   PROTEINS; MEMBRANE ATTACK; BASAL DEPOSITS; HUMAN BRAIN; DRUSEN; RISK;
   DISEASE
AB During the past ten years, dramatic advances have been made in unraveling the biological bases of age-related macular degeneration (AMD), the most common cause of irreversible blindness in western populations. In that timeframe, two distinct lines of evidence emerged which implicated chronic local inflammation and activation of the complement cascade in AMD pathogenesis. First, a number of complement system proteins, complement activators, and complement regulatory proteins were identified as molecular constituents of drusen, the hallmark extracellular deposits associated with early AMD. Subsequently, genetic studies revealed highly significant statistical associations between AMD and variants of several complement pathway-associated genes including: Complement factor H (CFH), complement factor H-related 1 and 3 (CFHR1 and CFHR3), complement factor B (CFB), complement component 2 (C2), and complement component 3 (C3).
   In this article, we revisit our original hypothesis that chronic local inflammatory and immune-mediated events at the level of Bruch's membrane play critical roles in drusen biogenesis and, by extension, in the pathobiology of AMD. Secondly, we report the results of a new screening for additional AMD-associated polymorphisms in a battery of 63 complement-related genes. Third, we identify and characterize the local complement system in the RPE choroid complex thus adding a new dimension of biological complexity to the role of the complement system in ocular aging and AMD. Finally, we evaluate the most salient, recent evidence that bears directly on the role of complement in AMD pathogenesis and progression. Collectively, these recent findings strongly re-affirm the importance of the complement system in AMD. They lay the groundwork for further studies that may lead to the identification of a transcriptional disease signature of AMD, and hasten the development of new therapeutic approaches that will restore the complement-modulating activity that appears to be compromised in genetically susceptible individuals. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Anderson, Don H.; Radeke, Monte J.; Gallo, Natasha B.; Chapin, Ethan A.; Johnson, Patrick T.; Curletti, Christy R.; Johnson, Lincoln V.] Univ Calif Santa Barbara, Ctr Study Macular Degenerat, Neurosci Res Inst, Santa Barbara, CA 93106 USA.
   [Hancox, Lisa S.] Univ Iowa, Dept Microbiol, Carver Coll Med, Iowa City, IA 52242 USA.
   [Hu, Jane; Bok, Dean] Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA.
   [Bok, Dean] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA.
   [Bok, Dean] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA.
   [Ebright, Jessica N.; Malek, Goldis; Hauser, Michael A.; Rickman, Catherine Bowes] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   [Hauser, Michael A.] Duke Univ, Med Ctr, Ctr Human Genet, Durham, NC USA.
   [Hageman, Gregory S.] Univ Utah, John A Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT USA.
   [Rickman, Catherine Bowes] Duke Univ, Dept Cell Biol, Durham, NC USA.
C3 University of California System; University of California Santa Barbara;
   University of Iowa; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; University of
   California System; University of California Los Angeles; University of
   California Los Angeles Medical Center; David Geffen School of Medicine
   at UCLA; University of California System; University of California Los
   Angeles; University of California Los Angeles Medical Center; David
   Geffen School of Medicine at UCLA; Duke University; Duke University;
   Utah System of Higher Education; University of Utah; Duke University
RP Anderson, DH (通讯作者)，Univ Calif Santa Barbara, Ctr Study Macular Degenerat, Neurosci Res Inst, Santa Barbara, CA 93106 USA.
EM d.anders@lifesci.ucsb.edu
OI Bowes Rickman, Catherine/0000-0002-8555-9596; Hancox,
   Lisa/0000-0003-1940-2619; Malek, Goldis/0000-0003-0026-2388
FU NIH [R24 EY017404, EY00331, EY014799]; Dolly Green Endowed Chair in
   Ophthalmology at UCLA; Foundation Fighting Blindness; Ruth and Milton
   Steinbach Fund; Research to prevent Blindness; NATIONAL EYE INSTITUTE
   [R01EY011286, R24EY017404, R24EY014799, P30EY000331, P30EY005722]
   Funding Source: NIH RePORTER
FX This study was supported by NIH R24 EY017404 (GSH, LVJ, DHA), EY00331
   (DB), EY014799 (LVJ), the Dolly Green Endowed Chair in Ophthalmology at
   UCLA (DB), the Foundation Fighting Blindness (CBR), the Ruth and Milton
   Steinbach Fund (CBR), and an unrestricted grants to the Duke Eye Center
   and the University of Utah Department of Ophthalmology and Visual
   Sciences from Research to prevent Blindness.
CR Abrera-Abeleda MA, 2007, KIDNEY INT, V71, P1142, DOI 10.1038/sj.ki.5002235
   Allikmets R, 2009, LANCET, V374, P875, DOI 10.1016/S0140-6736(09)61618-4
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Black S, 2004, J BIOL CHEM, V279, P48487, DOI 10.1074/jbc.R400025200
   Bonifati DM, 2007, MOL IMMUNOL, V44, P999, DOI 10.1016/j.molimm.2006.03.007
   Boon CJF, 2009, MOL IMMUNOL, V46, P1573, DOI 10.1016/j.molimm.2009.02.013
   BORA NS, 1993, INVEST OPHTH VIS SCI, V34, P3579
   Bossi F, 2009, BLOOD, V113, P3640, DOI 10.1182/blood-2008-03-146472
   CHOY LN, 1992, J BIOL CHEM, V267, P12736
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cruyssen BV, 2007, RHEUMATOLOGY, V46, P1792, DOI 10.1093/rheumatology/kem266
   Cunha-Vaz JG, 2004, EXP EYE RES, V78, P715, DOI 10.1016/S0014-4835(03)00213-6
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Davis AE, 2007, IMMUNOBIOLOGY, V212, P313, DOI 10.1016/j.imbio.2006.10.003
   de Cordoba SR, 2008, CLIN EXP IMMUNOL, V151, P1, DOI 10.1111/j.1365-2249.2007.03574.x
   Dentchev T, 2003, MOL VIS, V9, P184
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Dewan A, 2007, CURR OPIN GENET DEV, V17, P228, DOI 10.1016/j.gde.2007.04.004
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2008, ADV EXP MED BIOL, V613, P211, DOI 10.1007/978-0-387-74904-4_24
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2009, EUR J HUM GENET
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fakhrai-Rad H, 2004, GENOME RES, V14, P1404, DOI 10.1101/gr.2373904
   Ferrara DC, 2008, ARCH OPHTHALMOL-CHIC, V126, P1562, DOI 10.1001/archopht.126.11.1562
   GASQUE P, 1995, J IMMUNOL, V154, P4726
   Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GUC D, 1993, RHEUMATOL INT, V13, P139, DOI 10.1007/BF00301260
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   HAGEMAN GS, 2007, ANTIGEN PRESENTING C, P209
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2008, J BIOL CHEM, V283, P30451, DOI 10.1074/jbc.M803648200
   HEINEN S, 2009, BLOOD
   Herbert AP, 2006, ADV EXP MED BIOL, V586, P313
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE
   Hu J, 2001, MOL VIS, V7, P14
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Hummelshoj T, 2008, MOL IMMUNOL, V45, P2508, DOI 10.1016/j.molimm.2008.01.003
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Jha P, 2007, MOL IMMUNOL, V44, P3901, DOI 10.1016/j.molimm.2007.06.145
   Jiang HX, 2001, J EXP MED, V194, P1609, DOI 10.1084/jem.194.11.1609
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   JOHNSON LV, 2003, CHARACTERIZATION BET
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   JOHNSON SA, 1992, NEUROBIOL AGING, V13, P641, DOI 10.1016/0197-4580(92)90086-D
   Jozsi M, 2008, TRENDS IMMUNOL, V29, P380, DOI 10.1016/j.it.2008.04.008
   Khalyfa A, 2007, MOL VIS, V13, P293
   Kittleson MM, 2005, TRENDS CARDIOVAS MED, V15, P130, DOI 10.1016/j.tcm.2005.05.007
   Klee EW, 2008, CLIN LAB MED, V28, P127, DOI 10.1016/j.cll.2007.10.009
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kuehn MH, 2006, EXP EYE RES, V83, P620, DOI 10.1016/j.exer.2006.03.002
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Laufer J, 2001, MOL IMMUNOL, V38, P221, DOI 10.1016/S0161-5890(01)00044-X
   Li CM, 2007, EXP EYE RES, V85, P192, DOI 10.1016/j.exer.2007.04.002
   Li SH, 2004, CIRCULATION, V109, P833, DOI 10.1161/01.CIR.0000117087.27524.0E
   LOFFLER KU, 1995, INVEST OPHTH VIS SCI, V36, P24
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   Lommatzsch A, 2007, GRAEF ARCH CLIN EXP, V245, P1713, DOI 10.1007/s00417-007-0649-7
   Lotery A, 2007, HUM GENET, V122, P219, DOI 10.1007/s00439-007-0406-3
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Markiewski MM, 2007, AM J PATHOL, V171, P715, DOI 10.2353/ajpath.2007.070166
   McLaughlin BJ, 2003, INVEST OPHTH VIS SCI, V44, P3669, DOI 10.1167/iovs.02-0813
   MIHLAN M, 2009, CELL DEATH DIFFER
   Montes T, 2008, MOL IMMUNOL, V45, P2897, DOI 10.1016/j.molimm.2008.01.027
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Morgan BP, 1997, CLIN EXP IMMUNOL, V107, P1, DOI 10.1046/j.1365-2249.1997.d01-890.x
   Mullins RF, 1997, DEGENERATIVE RETINAL DISEASES, P1
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Park KH, 2009, INVEST OPHTH VIS SCI, V50, P3386, DOI 10.1167/iovs.08-3231
   Park KH, 2009, MOL VIS, V15, P200
   PEYMAN GA, 1972, INVEST OPHTH VISUAL, V11, P35
   Radeke MJ, 2007, EXP EYE RES, V85, P366, DOI 10.1016/j.exer.2007.05.006
   REYNOLDS R, 2009, INVEST OPHTHALMOL VI
   Rohrer B, 2007, INVEST OPHTH VIS SCI, V48, P5282, DOI 10.1167/iovs.07-0282
   Sakaguchi H, 2002, EXP EYE RES, V74, P547, DOI 10.1006/exer.2002.1186
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Song D, 1998, NEPHRON, V78, P15, DOI 10.1159/000044876
   Stasi K, 2006, INVEST OPHTH VIS SCI, V47, P1024, DOI 10.1167/iovs.05-0830
   Tang S, 1999, J IMMUNOL, V162, P4336
   TENNER AJ, 1986, BIOCHEM J, V233, P451, DOI 10.1042/bj2330451
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   Vogt SD, 2006, EXP EYE RES, V83, P834, DOI 10.1016/j.exer.2006.04.002
   WALKER DG, 1992, MOL BRAIN RES, V14, P109, DOI 10.1016/0169-328X(92)90017-6
   WHITE RT, 1992, J BIOL CHEM, V267, P9210
   Wolf-Schnurrbusch UEK, 2009, RETINA-J RET VIT DIS, V29, P966, DOI 10.1097/IAE.0b013e3181a2f40f
   Woo THS, 1999, J MICROBIOL METH, V35, P23, DOI 10.1016/S0167-7012(98)00095-5
   Wurzner R, 2000, CLIN EXP IMMUNOL, V121, P8, DOI 10.1046/j.1365-2249.2000.01263.x
   WURZNER R, 1994, J IMMUNOL, V152, P4624
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu JM, 2007, BIOCHEMISTRY-US, V46, P8451, DOI 10.1021/bi700459a
   Zhang H, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-51
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
   Zhou WD, 2001, KIDNEY INT, V59, P1227, DOI 10.1046/j.1523-1755.2001.0590041227.x
   Zipfel PF, 2007, PLOS GENET, V3, P387, DOI 10.1371/journal.pgen.0030041
NR 115
TC 544
Z9 575
U1 3
U2 81
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD MAR
PY 2010
VL 29
IS 2
BP 95
EP 112
DI 10.1016/j.preteyeres.2009.11.003
PG 18
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 576LN
UT WOS:000276146100001
PM 19961953
OA Green Accepted
DA 2022-11-30
ER

PT J
AU McLeod, DS
   Taomoto, M
   Otsuji, T
   Green, WR
   Sunness, JS
   Lutty, GA
AF McLeod, DS
   Taomoto, M
   Otsuji, T
   Green, WR
   Sunness, JS
   Lutty, GA
TI Quantifying changes in RPE and choroidal vasculature in eyes with
   age-related macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; GEOGRAPHIC ATROPHY; MORPHOMETRIC ANALYSIS;
   BRUCHS MEMBRANE; NEOVASCULARIZATION; CHORIOCAPILLARIS; ABNORMALITY; FORM
AB PURPOSE. An image-analysis technique Was developed to quantify changes in the retinal pigment epithelium (RPE) and choriocapillaris in eyes of deceased donors with age-related macular degeneration (AMD).
   METHODS. Both eyes of two donors with AMD and of one normal control donor were used to develop this technique. After removal of the anterior segments, the eyecups were hemisected through the macula, with the disc included in one half of the eyecup. The choroid with RPE cells was dissected from the sclera and incubated for alkaline phosphatase (APase) activity, and the pigment was partially bleached with H2O2, The APase-incubated choroid was flat embedded and sectioned after image and morphometric analyses. Quantitative computer-assisted morphometric analyses of the two AMD-affected eyes (cases 1 and 2) were compared with analysis of the normal eye of a 70-year-old control subject (case 3).
   RESULTS. The right eve in case 1 had geographic atrophy (GA) and demonstrated a large area in the posterior pole with very few RPE cells (90% loss of RPE), but the border of the area of RPE atrophy was not well defined. The density of choroidal blood vessels in this area was reduced 30% to 50%, compared with the same regions in the control eye. No area was completely devoid of choriocapillaris. Clinically undetected choroidal neovascularization (CNV) was observed in the right eve in case 1 in both the periphery and the macula and was generally associated with surviving RPE cells. The right eye in case 2 had GA (areolar RPE atrophy) and demonstrated a reduction in vascular density in the area front disc to macula that was even greater than that in the eye in case 1 (53% reduction in the submacular region). RPE atrophy between the disc and macula was almost complete. The border of the RPE defect was clearly delineated and coincided closely with the area of decreased choroidal vascular density. Surviving choriocapillaris in the area of RPE atrophy was significantly narrower than choriocapillaris in the control subject and in normal areas of the eyes with GA (P < 0.0001).
   CONCLUSIONS. In these eyes with GA, RPE atrophy was more severe than loss of choriocapillaris. Surviving choriocapillaris in areas with complete RPE loss was highly constricted. The association of surviving RPE cells with CNV suggests that RPE cells may furnish a stimulus for new vessel formation or stabilization.
C1 Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Lutty, GA (通讯作者)，Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, 170 Woods Res Bldg,600 N Wolfe St, Baltimore, MD 21287 USA.
EM glutty@jhmi.edu
OI Sunness, Janet/0000-0001-8823-0780
FU NEI NIH HHS [EY-01765, EY-08552] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [R01EY008552, P30EY001765] Funding Source: NIH RePORTER
CR Cao JT, 1998, ARCH OPHTHALMOL-CHIC, V116, P589, DOI 10.1001/archopht.116.5.589
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Fukushima I, 1997, AM J OPHTHALMOL, V124, P473, DOI 10.1016/S0002-9394(14)70863-3
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   MCLEOD DS, 1994, INVEST OPHTH VIS SCI, V35, P3799
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   SAKAMOTO T, 1995, ARCH OPHTHALMOL-CHIC, V113, P512, DOI 10.1001/archopht.1995.01100040134039
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SARKS SH, 2001, RETINA, P1064
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Sunness JS, 1999, MOL VIS, V5
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
NR 19
TC 152
Z9 158
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2002
VL 43
IS 6
BP 1986
EP 1993
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 557VA
UT WOS:000175927800044
PM 12037009
DA 2022-11-30
ER

PT J
AU Nagineni, CN
   Raju, R
   Nagineni, KK
   Kommineni, VK
   Cherukuri, A
   Kutty, RK
   Hooks, JJ
   Detrick, B
AF Nagineni, Chandrasekharam N.
   Raju, Raghavan
   Nagineni, Krishnasai K.
   Kommineni, Vijay K.
   Cherukuri, Aswini
   Kutty, R. Krishnan
   Hooks, John J.
   Detrick, Barbara
TI Resveratrol Suppresses Expression of VEGF by Human Retinal Pigment
   Epithelial Cells: Potential Nutraceutical for Age-related Macular
   Degeneration
SO AGING AND DISEASE
LA English
DT Article
DE Resveratrol; VEGF; SIRT1; Cytokines; Retina; Retinal pigment epithelium;
   Age-related macular degeneration
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULAR MEMBRANES; OCULAR
   NEOVASCULARIZATION; TRANS-RESVERATROL; VISUAL FUNCTION; EYE DISEASE;
   IN-VIVO; THERAPY; DRUSEN; BETA
AB Age-related macular degeneration (AMD) is a sight threating retinal eye disease that affects millions of aging individuals world-wide. Choroid-retinal pigment epithelium (RPE)-neuroretina axis in the posterior compartment of the eye is the primary site of AMD pathology. There are compelling evidence to indicate association of vascular endothelial growth factors (VEGF) to AMD. Here, we report the inhibitory actions of resveratrol (RSV) on inflammatory cytokine, TGF-beta and hypoxia induced VEGF secretion by human retinal pigment epithelial cells (HRPE). HRPE cultures prepared from aged human donor eyes were used for the studies in this report. HRPE secreted both VEGF-A and VEGF-C in small quantities constitutively. Stimulation with a mixture of inflammatory cytokines (IFN-gamma, TNF-alpha, IL-1 beta), significantly increased the secretion of both VEGF-A and VEGF-C. RSV, in a dose dependent (10-50 uM) manner, suppressed VEGF-A and VEGF-C secretion induced by inflammatory cytokines significantly. RT-PCR analysis indicated that effects of RSV on VEGF secretion were possibly due to decreased mRNA levels. TGF-beta. and cobalt chloride (hypoxia mimic) also upregulated HRPE cell production of VEGF-A, and this was inhibited by RSV. In contrast, RSV had no effect on anti-angiogenic molecules, endostatin and pigment epithelial derived factor secretion. Studies using an in vitro scratch assay revealed that wound closure was also inhibited by RSV. These results demonstrate that RSV can suppress VEGF secretion induced by inflammatory cytokines, TGF-beta and hypoxia. Under pathological conditions, over expression of VEGF is known to worsen AMD. Therefore, RSV may be useful as nutraceutical in controlling pathological choroidal neovascularization processes in AMD.
C1 [Nagineni, Chandrasekharam N.; Kommineni, Vijay K.; Hooks, John J.] NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Raju, Raghavan] Georgia Regents Univ, Dept Lab Med, Augusta, GA USA.
   [Raju, Raghavan] Georgia Regents Univ, Dept Imaging & Radiol Sci, Augusta, GA USA.
   [Raju, Raghavan] Georgia Regents Univ, Dept Biochem & Mol Biol, Augusta, GA USA.
   [Nagineni, Krishnasai K.] Univ Maryland, Sch Publ Policy, College Pk, MD 20742 USA.
   [Cherukuri, Aswini; Kutty, R. Krishnan] NEI, Lab Retinal Cell & Mol Biol, NIH, Bethesda, MD 20892 USA.
   [Detrick, Barbara] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); University System of Georgia; Augusta University; University
   System of Georgia; Augusta University; University System of Georgia;
   Augusta University; University System of Maryland; University of
   Maryland College Park; National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI); Johns Hopkins University
RP Detrick, B (通讯作者)，Johns Hopkins Med Inst, Baltimore, MD 21205 USA.
EM naginenic@gmail.com; bdetrick@jhmi.edu
OI Raju, Raghavan/0000-0002-4516-8654
FU National Eye Institute, National Institutes of Health; NIH [GM101927];
   NATIONAL EYE INSTITUTE [ZIAEY000444] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM101927] Funding
   Source: NIH RePORTER
FX This research was supported by intramural research program of the
   National Eye Institute, National Institutes of Health, and extramural
   grants NIH GM101927 (RR).
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   BOK D, 1993, J CELL SCI, P189
   Brakenhielm E, 2001, FASEB J EXPRESS, V10, DOI 1096/fj.01-0028fje
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100
   Chew EY, 2009, ARCH OPHTHALMOL-CHIC, V127, P1678, DOI 10.1001/archophthalmol.2009.312
   Chilov D, 1997, J BIOL CHEM, V272, P25176, DOI 10.1074/jbc.272.40.25176
   Chung SW, 2010, ARCH BIOCHEM BIOPHYS, V501, P79, DOI 10.1016/j.abb.2010.05.003
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   Delmas D, 2011, ANN NY ACAD SCI, V1215, P48, DOI 10.1111/j.1749-6632.2010.05871.x
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Finkel T, 2009, NATURE, V460, P587, DOI 10.1038/nature08197
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Harikumar KB, 2008, CELL CYCLE, V7, P1020, DOI 10.4161/cc.7.8.5740
   Hooks JJ, 2008, J IMMUNOL, V180, P3789, DOI 10.4049/jimmunol.180.6.3789
   Jian BX, 2012, MOL MED, V18, P209, DOI 10.2119/molmed.2011.00365
   Joukov V, 1996, EMBO J, V15, P290
   Kannan R, 2006, MOL VIS, V12, P1649
   Kansagara D, 2011, NUTR SUPPLEMENTS AGE
   Kelly G, 2010, ALTERN MED REV, V15, P245
   Khan AA, 2010, AM J PATHOL, V177, P481, DOI 10.2353/ajpath.2010.090836
   King RE, 2005, CHEM-BIOL INTERACT, V151, P143, DOI 10.1016/j.cbi.2004.11.003
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Li R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023148
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Marmor M. F., 1998, RETINAL PIGMENT EPIT, DOI [10.1098/rsif.2015.0563, DOI 10.1098/RSIF.2015.0563]
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Nagineni CN, 2007, J CELL PHYSIOL, V210, P192, DOI 10.1002/jcp.20839
   Nagineni CN, 2012, J CELL PHYSIOL, V227, P116, DOI 10.1002/jcp.22708
   Nagineni CN, 2010, BIOCHEM BIOPH RES CO, V391, P287, DOI 10.1016/j.bbrc.2009.11.051
   Nagineni CN, 2005, J CELL PHYSIOL, V203, P35, DOI 10.1002/jcp.20213
   Nagineni CN, 2003, J CELL PHYSIOL, V197, P453, DOI 10.1002/jcp.10378
   NAGINENI CN, 1994, CLIN DIAGN LAB IMMUN, V1, P569, DOI 10.1128/CDLI.1.5.569-577.1994
   Noel A, 2007, TRENDS MOL MED, V13, P345, DOI 10.1016/j.molmed.2007.06.005
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Pervaiz S, 2009, ANTIOXID REDOX SIGN, V11, P2851, DOI [10.1089/ars.2008.2412, 10.1089/ARS.2008.2412]
   Pintea A, 2011, J OCUL PHARMACOL TH, V27, P315, DOI 10.1089/jop.2010.0144
   Richer S, 2013, NUTRIENTS, V5, P1989, DOI 10.3390/nu5061989
   Schleicher M, 2013, NUTRIENTS, V5, P2405, DOI 10.3390/nu5072405
   Sonoda S, 2010, AGING-US, V2, P28, DOI 10.18632/aging.100111
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   TISCHER E, 1991, J BIOL CHEM, V266, P11947
   Weikel KA, 2012, MOL ASPECTS MED, V33, P318, DOI 10.1016/j.mam.2012.03.005
   Weis SM, 2005, NATURE, V437, P497, DOI 10.1038/nature03987
   Whitcup SM, 2013, INT J INFLAM, V2013
   Williams LD, 2009, FOOD CHEM TOXICOL, V47, P2170, DOI 10.1016/j.fct.2009.06.002
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang SX, 2007, PROG RETIN EYE RES, V26, P1, DOI 10.1016/j.preteyeres.2006.09.002
NR 66
TC 62
Z9 65
U1 0
U2 17
PU INT SOC AGING & DISEASE
PI FORT WORTH
PA EDITORIAL OFF, 3400 CAMP BOWIE BLVD, FORT WORTH, TX 76106 USA
SN 2152-5250
J9 AGING DIS
JI Aging Dis.
PD APR
PY 2014
VL 5
IS 2
BP 88
EP 100
PG 13
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA AI5KM
UT WOS:000336905200002
PM 24729934
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Schaal, S
   Kaplan, HJ
   Tezel, TH
AF Schaal, Shlomit
   Kaplan, Henry J.
   Tezel, Tongalp H.
TI Is There Tachyphylaxis to Intravitreal Anti-Vascular Endothelial Growth
   Factor Pharmacotherapy in Age-Related Macular Degeneration?
SO OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; VISUAL-ACUITY; EYE DISEASES; ANGIOGENESIS;
   INHIBITORS; PATHWAYS
AB Purpose: To determine whether repetitive injections of intravitreal bevacizumab and/or triamcinolone acetate in patients with exudative age-related macular degeneration (AMD) results in a decrease in biological response.
   Design: Retrospective comparative case series.
   Participants: Forty-three eyes of 43 patients with exudative AMD.
   Methods: Pre- and postinjection optical coherence tomography (OCT) sections of 43 patients with AMD were analyzed to determine the change in the biologic response after each subsequent injection of intravitreal bevacizumab (2.5 mg/100 mu L), preservative-free triamcinolone acetonide (pfTA) (4.0 mg/100 mu L), or a combination of bevacizumab (1.25 mg/50 mu L) and pfTA (2.0 mg/50 mu L). The retinal thickness of each OCT sector was determined and expressed as volume. Standardized volumetric change index (SVCI) was determined to identify a statistically significant change. Pre- and postinjection (6 weeks) SVCI differences were plotted as a function of time to determine the biological response after each intravitreal treatment.
   Main Outcome Measures: Change in SVCI after intravitreal injections and the number of injections required to decrease the biological response by 50% (INJ(50)).
   Results: There was no difference in the age, gender, and preinjection thickness of the retina in each of the 3 groups. The SVCI after intravitreal bevacizumab injections decreased, indicating a possible tachyphylactic response to bevacizumab. This decrease in biological response was partially alleviated with the addition of pfTA. Combination of pfTA and bevacizumab increased the INJ50 from 2.9 with bevacizumab alone to 5.1 injections. A biphasic biologic response was observed with pfTA characterized by a rapid increase in efficacy with the second injection, peaking at the third injection and gradually decreasing afterward.
   Conclusions: Repeated intravitreal injections of bevacizumab in exudative AMD seemed to be associated with decreased bioefficacy. However, combined pharmacotherapy with triamcinolone acetate lessened this effect. Thus, multitargeted pharmacotherapy in exudative AMD may have a therapeutic benefit.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2008; 115:2199-2205 (C) 2008 by the American Academy of Ophthalmology.
C1 [Schaal, Shlomit; Kaplan, Henry J.; Tezel, Tongalp H.] Univ Louisville, Sch Med, Dept Ophthalmol & Visual Sci, Kentucky Lions Eye Ctr, Louisville, KY 40202 USA.
C3 University of Louisville
RP Tezel, TH (通讯作者)，Univ Louisville, Sch Med, Dept Ophthalmol & Visual Sci, Kentucky Lions Eye Ctr, 301 E Muhammad Ali BlVd, Louisville, KY 40202 USA.
EM tongalp.tezel@louisville.edu
FU Prevent Blindness, Inc., New York
FX The author(s) have made the following disclosure(s): Tongalp H. Tezel,
   MD, was Supported in part by it Career Development Award from Research
   to Prevent Blindness, Inc., New York.
CR BLUMENKRANZ MS, 1984, ARCH OPHTHALMOL-CHIC, V102, P598, DOI 10.1001/archopht.1984.01040030470029
   Brown SM, 2004, AM J OPHTHALMOL, V138, P149, DOI 10.1016/j.ajo.2004.02.017
   Cacho I, 2007, OPTOMETRY VISION SCI, V84, P487, DOI 10.1097/OPX.0b013e318073c2f2
   Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X
   Daniel WW., 1995, BIOSTATISTICS FDN AN, P273
   Ebrahem Q, 2006, INVEST OPHTH VIS SCI, V47, P4935, DOI 10.1167/iovs.05-1651
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Gillies MC, 2007, NEW ENGL J MED, V356, P748
   HAMMOND GL, 1990, J CLIN ENDOCR METAB, V71, P34, DOI 10.1210/jcem-71-1-34
   Hoffman B.B., 2001, GOODMAN GILMANS PHAR, P115
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Lee PP, 2003, ARCH OPHTHALMOL-CHIC, V121, P1303, DOI 10.1001/archopht.121.9.1303
   MARMOR MF, 1988, GRAEF ARCH CLIN EXP, V226, P548, DOI 10.1007/BF02169203
   MCINTYRE WR, 1985, J BIOL CHEM, V260, P418
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Riusala A, 2005, GRAEF ARCH CLIN EXP, V243, P947, DOI 10.1007/s00417-005-1161-6
   Shah AR, 2007, AM J OPHTHALMOL, V143, P83, DOI 10.1016/j.ajo.2006.09.043
   Stamm S, 2002, HUM MOL GENET, V11, P2409, DOI 10.1093/hmg/11.20.2409
   Suzuki T, 2001, MOL CELL ENDOCRINOL, V173, P121, DOI 10.1016/S0303-7207(00)00403-2
   Tsagaraki V, 2006, INT J CLIN PRACT, V60, P415, DOI 10.1111/j.1368-5031.2006.00849.x
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   VANBOCKXMEER FM, 1985, RETINA-J RET VIT DIS, V5, P47, DOI 10.1097/00006982-198500510-00010
   West SK, 2000, EPIDEMIOL REV, V22, P64, DOI 10.1093/oxfordjournals.epirev.a018025
NR 24
TC 154
Z9 157
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2008
VL 115
IS 12
BP 2199
EP 2205
DI 10.1016/j.ophtha.2008.07.007
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 381PK
UT WOS:000261548200012
PM 18930553
DA 2022-11-30
ER

PT J
AU Biesemeier, A
   Yoeruek, E
   Eibl, O
   Schraermeyer, U
AF Biesemeier, Antje
   Yoeruek, Efdal
   Eibl, Oliver
   Schraermeyer, Ulrich
TI Iron accumulation in Bruch's membrane and melanosomes of donor eyes with
   age-related macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Melanosome; Bruch's membrane; Hydroxyapatite nanocrystalline
   calcification; Iron; Age related macular degeneration; EDX; Retinal
   pigment epithelium; Choroid; cl Collagenous layer; el Elastic layer
ID RETINAL-PIGMENT EPITHELIUM; HUMAN RPE; FUNDUS AUTOFLUORESCENCE;
   GEOGRAPHIC ATROPHY; OXIDATIVE DAMAGE; POTENTIAL FACTOR; OCULAR MELANIN;
   HUMAN BRAIN; TOXICITY; FEATURES
AB Iron (Fe) accumulation in cytoplasmic storages of the retina and retinal pigment epithelium (RPE) with age has been reported to be a contributing factor to the onset and progression of Age-related Macular Degeneration (AMD). This work investigated whether iron can also be stored in specialized metal-binding melanosomes of the RPE and choroid and in age pigments of the RPE (lipofuscin and melano-lipofuscin). As accumulation of debris in Bruch's membrane is an additional hallmark of AMD, the elemental composition of Bruch's membrane was also investigated. Perimacular sections of the retina-choroid complex of six eyes of AMD donors and of seven age-matched healthy controls were investigated using Analytical Electron Microscopy (AEM). The melanosomes of the RPE and choroidal melanocytes of all AMD donors contained about two times higher iron mole fractions (0.06-0.07 at%) compared to the controls, which showed only minor iron mole fractions at or below the detection limit of 0.02 aft. Only melanosomes that contained iron, showed also significant lead peaks (both AMD and control about 0.08 at%). In addition, the electron-dense part of melanolipofuscin granules in the RPE accumulated iron and lead, both for control and AMD donors. Iron in lipofuscin was below the detection limit. The elastic layer of Bruch's membrane of all AMD donors also contained significantly higher iron mole fractions compared to controls (about 0.08 at% Fe), predominantly in areas that were also rich in calcium (Ca) and phosphorus (P), suggesting calcification. Indeed, five of the six AMD donors but only one of the seven controls showed nanocrystalline hydroxyapatite calcifications. Note that such nanocrystalline material can only be detected in EM samples without heavy metal (osmiumtetroxide, uranylacetate) staining. In conclusion, iron accumulation in melanosomal storages and within calcified Bruch's membrane is more pronounced in donors suffering from AMD compared to age-matched controls. This work underlines the common hypothesis that heavy metal homeostasis plays an important role in age-related neuropathy. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Biesemeier, Antje; Schraermeyer, Ulrich] Univ Tubingen, Ctr Ophthalmol, Sect Expt Vitreoretinal Surg, D-72076 Tubingen, Germany.
   [Yoeruek, Efdal] Univ Tubingen, Ctr Ophthalmol, Cornea Bank, D-72076 Tubingen, Germany.
   [Eibl, Oliver] Univ Tubingen, Inst Appl Phys, D-72076 Tubingen, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; Eberhard Karls University of Tubingen; Eberhard Karls
   University Hospital; Eberhard Karls University of Tubingen
RP Biesemeier, A (通讯作者)，Univ Tubingen, Ctr Ophthalmol, Sect Expt Vitreoretinal Surg, Schleichstr 12-1, D-72076 Tubingen, Germany.
EM Antje.Biesemeier@med.uni-tuebingen.de;
   Efdal.Yoeruek@med.uni-tuebingen.de; Oliver.Eibl@uni-tuebingen.de;
   Ulrich.Schraermeyer@med.uni-tuebingen.de
OI Biesemeier, Antje/0000-0002-3462-8803
FU  [DFG BI 1551/2-1];  [fortune 1957-0-0];  [fortune 2062-0-0]
FX This work was supported by the following grants: DFG BI 1551/2-1,
   fortune 1957-0-0, fortune 2062-0-0. The authors thank Prof. Joe
   Hollyfield and Dr. Vera Bonilha (Retinal Degeneration Histopathology
   Laboratory, Cole Eye Institute - The Cleveland Clinic Foundation), The
   Foundation Fighting Blindness and the University Hospital Tuebingen
   (Drs. Max Warga, Bernhard Hirt) for allocation of eye donations and
   their great help. We are also indebted to the donors and their families.
   Many thanks also to Sigrid Schultheiss for excellent technical
   assistance and Dr. Sylvie Julien, Tatjana Taubitz and Mrs. Judith Birch
   for proofreading.
CR Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Barzegar-Befroei N., 2011, ZINC HUMAN HLTH BIOM, V76, P460
   Biesemeier A., 2012, INVEST OPHTH VIS SCI, V26, P4761
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Biesemeier A, 2011, EXP EYE RES, V93, P29, DOI 10.1016/j.exer.2011.04.004
   Biesemeier A, 2011, MICRON, V42, P461, DOI 10.1016/j.micron.2011.01.004
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Boulton M, 2004, GRAEF ARCH CLIN EXP, V242, P76, DOI 10.1007/s00417-003-0812-8
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   DAVIS WL, 1981, J HISTOCHEM CYTOCHEM, V29, P601, DOI 10.1177/29.5.7252127
   Double K., 2003, METALS IONS NEURODEG, P343
   Dunaief JL, 2005, OPHTHALMOLOGY, V112, P1062, DOI 10.1016/j.ophtha.2004.12.029
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   Eibl O, 2006, MICRON, V37, P262, DOI 10.1016/j.micron.2005.08.006
   Erie JC, 2009, AM J OPHTHALMOL, V148, P890, DOI 10.1016/j.ajo.2009.07.001
   Esivision S., 2002, SOFT IMAGING SYSTEMS
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Flinn JM, 2014, METALLOMICS, V6, P1223, DOI 10.1039/c4mt00058g
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Guo LY, 2014, EXP EYE RES, V129, P31, DOI 10.1016/j.exer.2014.10.012
   Hadziahmetovic M, 2008, INVEST OPHTH VIS SCI, V49, P2728, DOI 10.1167/iovs.07-1472
   Hadziahmetovic M, 2012, INVEST OPHTH VIS SCI, V53, P5231, DOI 10.1167/iovs.12-10204
   Hadziahmetovic M, 2011, INVEST OPHTH VIS SCI, V52, P109, DOI 10.1167/iovs.10-6113
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Hahn P, 2006, NEUROREPORT, V17, P1803, DOI 10.1097/WNR.0b013e3280107776
   He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004
   Herrmann P, 2013, OPHTHALMOLOGE, V110, P377, DOI 10.1007/s00347-012-2779-5
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hong L, 2004, PHOTOCHEM PHOTOBIOL, V80, P477, DOI 10.1562/0031-8655(2004)080<0477:BOMITM>2.0.CO;2
   Hong L, 2007, J PHYS CHEM B, V111, P7938, DOI 10.1021/jp071439h
   JELLINGER KA, 1993, ADV NEUROL, V60, P267
   Junemann AGM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056734
   Kazi TG, 2006, CLIN CHIM ACTA, V369, P52, DOI 10.1016/j.cca.2006.01.003
   LARSSON BS, 1993, PIGM CELL RES, V6, P127, DOI 10.1111/j.1600-0749.1993.tb00591.x
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Loh A, 2009, BBA-GEN SUBJECTS, V1790, P637, DOI 10.1016/j.bbagen.2008.11.001
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Ramonet D, 2006, J NEUROSCI RES, V83, P147, DOI 10.1002/jnr.20711
   Rozanowski B, 2008, PHOTOCHEM PHOTOBIOL, V84, P650, DOI 10.1111/j.1751-1097.2007.00259.x
   Rozanowski B, 2008, INVEST OPHTH VIS SCI, V49, P2838, DOI 10.1167/iovs.08-1700
   SAMUELSON DA, 1993, EXP EYE RES, V56, P63, DOI 10.1006/exer.1993.1009
   SARNA T, 1976, SCIENCE, V192, P1132, DOI 10.1126/science.179142
   SARNA T, 1992, J PHOTOCH PHOTOBIO B, V12, P215, DOI 10.1016/1011-1344(92)85027-R
   Schaumberg DA, 2004, JAMA-J AM MED ASSOC, V292, P2750, DOI 10.1001/jama.292.22.2750
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Schraermeyer U, 1999, EXP EYE RES, V68, P237, DOI 10.1006/exer.1998.0596
   Spraul CW, 1998, OPHTHALMOLOGE, V95, P73, DOI 10.1007/s003470050240
   Synowiec E, 2012, MOL BIOL REP, V39, P7077, DOI 10.1007/s11033-012-1539-6
   Thompson R. B., 2014, INVEST OPHTH VIS SCI, V2014, P55
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   Ugarte M, 2012, METALLOMICS, V4, P1245, DOI 10.1039/c2mt20157g
   VANDERSCHAFT TL, 1992, ARCH OPHTHALMOL-CHIC, V110, P389, DOI 10.1001/archopht.1992.01080150087034
   Vig EK, 2000, J AM GERIATR SOC, V48, P1501, DOI 10.1111/jgs.2000.48.11.1501
   Weinberg ED, 2010, METALLOMICS, V2, P732, DOI 10.1039/c0mt00023j
   Williams D.B., 2009, TRANSMISSION ELECT M, VII
   Wolkow N, 2011, ARCH OPHTHALMOL-CHIC, V129, P1466, DOI 10.1001/archophthalmol.2011.309
   Wong RW, 2007, RETINA-J RET VIT DIS, V27, P997, DOI 10.1097/IAE.0b013e318074c290
   Wysokinski D., GRAEFES ARCH CLIN EX, V250, P1057
   Yuki K, 2009, BIOL TRACE ELEM RES, V132, P1, DOI 10.1007/s12011-009-8376-z
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
   Zatta P, 2003, BRAIN RES BULL, V62, P15, DOI 10.1016/S0361-9230(03)00182-5
   ZECCA L, 1992, BIOCHIM BIOPHYS ACTA, V1138, P6, DOI 10.1016/0925-4439(92)90144-C
   Zecca L, 2008, P NATL ACAD SCI USA, V105, P17567, DOI 10.1073/pnas.0808768105
   Zecca L, 2008, J NEUROCHEM, V106, P1866, DOI 10.1111/j.1471-4159.2008.05541.x
   Zhu XL, 2006, J BIOMED MATER RES A, V79A, P114, DOI 10.1002/jbm.a.30706
NR 68
TC 48
Z9 48
U1 1
U2 18
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD AUG
PY 2015
VL 137
BP 39
EP 49
DI 10.1016/j.exer.2015.05.019
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CO5CI
UT WOS:000359176800005
PM 26026877
DA 2022-11-30
ER

PT J
AU Ma, L
   Ng, TK
   Chen, HY
   Brelen, ME
   Lai, TYY
   Ho, M
   Tam, POS
   Young, AL
   Chen, W
   Tham, CC
   Pang, CP
   Chen, LJ
AF Ma, Li
   Ng, Tsz Kin
   Chen, Haoyu
   Brelen, Marten E.
   Lai, Timothy Y. Y.
   Ho, Mary
   Tam, Pancy O. S.
   Young, Alvin L.
   Chen, Weiqi
   Tham, Clement C.
   Pang, Chi Pui
   Chen, Li Jia
TI Identification and characterization of a novel promoter variant in
   placental growth factor for neovascular age-related macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Placental growth factor; Age-related macular degeneration; Promoter
   deletion variant; Transcription
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; GENE POLYMORPHISMS; HIGH-RISK; RARE;
   ASSOCIATION; TRANSCRIPTION; CONTRIBUTES; PROGRESS; CHINESE; FAMILY
AB Purpose: Intronic variants in the placental growth factor (PGF) gene have been associated with neovascular age-related macular degeneration (AMD). This study is to discover and characterize rare variants in the PGF gene for neovascular AMD.
   Methods: The promoter region, coding sequences and splicing regions of the PGF gene were sequenced in a Hong Kong southern Chinese cohort of 235 neovascular AMD patients and 435 controls. A detected 18 base-pair deletion variant in the promoter region of PGF was analyzed in a Shantou southern Chinese cohort of 189 neovascular AMD patients and 846 controls. The transcription activity of this disease-associated promoter variant was determined in human ARPE-19 cells by promoter-luciferase analysis.
   Results: A novel 18-base-pair deletion mutation in the promoter region of PGF was identified in 3 (1.28%) patients and 1 (0.23%) control subject (OR = 5.61; 95% CI 0.58-54.26) in the Hong Kong cohort, and in 2 (1.06%) patients and 2 (0.24%) controls (OR = 4.51; 95% CI: 0.63-32.25) in the Shantou cohort. In the combined southern Chinese sample, this deletion had a significant association with neovascular AMD (P = 0.026; OR = 5.08, 95% CI: 1.21-21.36). The 18-base-pair deletion was predicted to alter the transcription factor binding sites in the PGF promoter, and higher luciferase expression was detected in ARPE-19 cells transfected with the deletion variant plasmid than those transfected with wild type plasmid (P = 0.0002).
   Conclusions: This study identified a rare, functional promoter variant in the PGF gene that increases PGF transcription activity and confers a 5-fold risk to neovascular AMD.
C1 [Ma, Li; Ng, Tsz Kin; Brelen, Marten E.; Lai, Timothy Y. Y.; Tam, Pancy O. S.; Young, Alvin L.; Tham, Clement C.; Pang, Chi Pui; Chen, Li Jia] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
   [Ng, Tsz Kin; Chen, Haoyu; Chen, Weiqi; Pang, Chi Pui] Shantou Univ, Joint Shantou Int Eye Ctr, Shantou, Guangdong, Peoples R China.
   [Ng, Tsz Kin; Chen, Haoyu; Chen, Weiqi; Pang, Chi Pui] Chinese Univ Hong Kong, Shantou, Guangdong, Peoples R China.
   [Ng, Tsz Kin] Shantou Univ, Med Coll, Shantou, Guangdong, Peoples R China.
   [Ho, Mary; Young, Alvin L.; Chen, Li Jia] Prince Wales Hosp, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
   [Ma, Li] Dalian Med Univ, Affiliated Hosp 1, Dalian, Liaoning, Peoples R China.
C3 Chinese University of Hong Kong; Shantou University; Shantou University;
   Chinese University of Hong Kong; Prince of Wales Hospital; Dalian
   Medical University
RP Chen, LJ (通讯作者)，Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, Kowloon, 147K Argyle St, Hong Kong, Peoples R China.
EM lijia_chen@cuhk.edu.hk
RI Chen, Li Jia/I-5078-2014; Chen, Haoyu/A-7432-2013; Lai, Timothy Y
   Y/AAC-2120-2020; Ng, Tsz Kin/I-8061-2014; Brelen, Marten E./D-1133-2016;
   Tham, Chee Yung Clement/AAD-6528-2020
OI Chen, Li Jia/0000-0003-3500-5840; Chen, Haoyu/0000-0003-0676-4610; Lai,
   Timothy Y Y/0000-0002-7832-6428; Ng, Tsz Kin/0000-0001-7863-7229; Tham,
   Chee Yung Clement/0000-0003-4407-6907
FU National Natural Science Foundation of China [81500764]; General
   Research Fund, Hong Kong [14120516]; Direct Grant of Chinese University
   of Hong Kong Medical Panel, Hong Kong [4054281]; Global Ophthalmology
   Awards Program (GOAP) from Bayer; Liaoning Provincial Natural Science
   Foundation of China [20180540070]; Endowment Fund for Lim Por-Yen Eye
   Genetics Research Centre, Hong Kong
FX This study was supported in part by the National Natural Science
   Foundation of China (81500764 [L.J.C.]), the General Research Fund, Hong
   Kong (14120516 [L.J.C.]), the Direct Grant of Chinese University of Hong
   Kong Medical Panel, Hong Kong (4054281 [L.J.C.]), a research fund from
   the Global Ophthalmology Awards Program (GOAP) from Bayer (L.J.C.), a
   research fund from Liaoning Provincial Natural Science Foundation of
   China (20180540070 [L.M.]), and the Endowment Fund for Lim Por-Yen Eye
   Genetics Research Centre, Hong Kong.
CR Andraweera PH, 2013, J MATERN-FETAL NEO M, V26, P532, DOI 10.3109/14767058.2012.743520
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Castellon R, 2002, EXP EYE RES, V74, P523, DOI 10.1006/exer.2001.1161
   Chang M, 2008, BIOL REPROD, V78, P841, DOI 10.1095/biolreprod.107.065599
   Chen JH, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006090
   Chen LJ, 2016, INVEST OPHTH VIS SCI, V57, P1714, DOI 10.1167/iovs.IOVS-15-18677
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Farre D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hayreh SS, 2008, OPHTHALMOLOGY, V115, P2275, DOI 10.1016/j.ophtha.2008.08.007
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KURITZ SJ, 1988, ANNU REV PUBL HEALTH, V9, P123, DOI 10.1146/annurev.pu.09.050188.001011
   Lee YJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34187-z
   Liang XY, 2012, INVEST OPHTH VIS SCI, V53, P3175, DOI 10.1167/iovs.11-8135
   Liu K, 2014, SCI REP-UK, V4, DOI 10.1038/srep07018
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Ma L, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20575
   Ma L, 2016, INVEST OPHTH VIS SCI, V57, P5758, DOI 10.1167/iovs.16-20175
   Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Ng TK, 2016, SCI REP-UK, V6, DOI 10.1038/srep28639
   Ng TK, 2009, MOL VIS, V15, P2239
   Nongpiur ME, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004089
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Thorleifsson G, 2010, NAT GENET, V42, P906, DOI 10.1038/ng.661
   Traynor K, 2012, AM J HEALTH-SYST PH, V69, P6, DOI 10.2146/news120001
   Wietecha MS, 2013, CURR TOP MICROBIOL, V367, P3, DOI 10.1007/82_2012_287
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zhang Y, 2018, MOL VIS, V24, P340
NR 36
TC 1
Z9 1
U1 1
U2 8
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD OCT
PY 2019
VL 187
AR 107748
DI 10.1016/j.exer.2019.107748
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JB9FO
UT WOS:000488887100003
PM 31377148
DA 2022-11-30
ER

PT J
AU Tekin, MI
   Sekeroglu, MA
   Demirtas, C
   Tekin, K
   Doguizi, S
   Bayraktar, S
   Yilmazbas, P
AF Tekin, Merve Inanc
   Sekeroglu, Mehmet Ali
   Demirtas, Canan
   Tekin, Kemal
   Doguizi, Sibel
   Bayraktar, Serdar
   Yilmazbas, Pelin
TI Brain-Derived Neurotrophic Factor in Patients With Age-Related Macular
   Degeneration and Its Correlation With Retinal Layer Thicknesses
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; brain-derived neurotrophic factor;
   retinal layer thickness
ID PIGMENT EPITHELIAL-CELLS; ALZHEIMERS-DISEASE; AQUEOUS-HUMOR;
   AMYLOID-BETA; INNER RETINA; MULLER CELLS; T-CELLS; BDNF; EXPRESSION;
   PROTECTION
AB PURPOSE. To determine brain-derived neurotrophic factor (BDNF) levels in serum and aqueous humor (AH) and to assess the relationship between BDNF levels and retinal layer thicknesses in age-related macular degeneration (AMD).
   METHODS. A total of 48 AMD patients (AMD group) that was composed of twenty-three nonexudative and 25 exudative patients and 26 control subjects (control group) were included in the study. Serum and All BDNF levels were assessed by ELISA method. Retinal layer thicknesses were calculated by segmentation analysis of optical coherence tomography.
   RESULTS. The mean BDNF levels in AH were found to be significantly lower in both the nonexudative and exudative AMD groups than in the control group (P = 0.003 and P < 0.001, respectively). Optical coherence tomography segmentation analysis revealed that the total average retina pigment epithelium thickness was statistically significantly thinner in the nonexudative AMD group compared with the exudative AMD and control groups (P = 0.001 and P = 0.040, respectively). The total average outer nuclear layer (ONL) thicknesses of nonexudative and exudative AMD cases were reduced compared to control group; however, the decrement was statistically significant only in the nonexudative AMD group (P = 0.009). In the correlation analysis of BDNF levels with retinal layer thicknesses, statistically significant correlations exist between BDNF levels of AH with ONL thicknesses in cases of AMD and with retina pigment epithelium thicknesses in the nonexudative AMD group.
   CONCLUSIONS. BDNF concentrations in All decreased in the AMD group and this decrease correlates with outer retinal layer thicknesses. Low BDNF levels detected in the AMD group may be insufficient to protect the photoreceptors, resulting in thinning of ONL.
C1 [Tekin, Merve Inanc; Sekeroglu, Mehmet Ali; Doguizi, Sibel; Bayraktar, Serdar; Yilmazbas, Pelin] Ankara Ulucanlar Eye Training & Res Hosp, Ankara, Turkey.
   [Demirtas, Canan] Gazi Univ, Dept Med Biochem, Ankara, Turkey.
   [Tekin, Kemal] Kars State Hosp, Dept Ophthalmol, Kars, Turkey.
C3 Ankara Ulucanlar Eye Training & Research Hospital; Gazi University; Kars
   State Hospital
RP Tekin, MI (通讯作者)，Ulucanlar Eye Training & Res Hosp, TR-06240 Ankara, Turkey.
EM mrvn88@hotmail.com
RI Tekin, Kemal/H-9507-2017; Yılmaz, Canan/AAT-7788-2020
OI Tekin, Kemal/0000-0002-7461-6129; Yılmaz, Canan/0000-0002-6799-6522;
   Bayraktar, Serdar/0000-0001-6521-9984
FU Ankara regional branch of Turkish Ophthalmological Association
FX Supported by Ankara regional branch of Turkish Ophthalmological
   Association.
CR Afarid M, 2015, INT J OPHTHALMOL-CHI, V8, P991, DOI 10.3980/j.issn.2222-3959.2015.05.25
   AMES A, 1992, J NEUROSCI, V12, P840, DOI 10.1523/jneurosci.12-03-00840.1992
   Benarroch EE, 2015, NEUROLOGY, V84, P1693, DOI 10.1212/WNL.0000000000001507
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Braun A, 1999, AM J RESP CELL MOL, V21, P537, DOI 10.1165/ajrcmb.21.4.3670
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Cerman E, 2015, TURK J MED SCI, V45, P1004, DOI 10.3906/sag-1406-146
   Ciammola A, 2007, AM J MED GENET B, V144B, P574, DOI 10.1002/ajmg.b.30501
   Dentchev T, 2003, MOL VIS, V9, P184
   Di Polo A, 2000, INVEST OPHTH VIS SCI, V41, P4014
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fujimura H, 2002, THROMB HAEMOSTASIS, V87, P728
   Garcia-Martin E, 2016, ACTA OPHTHALMOL, V94, pE454, DOI 10.1111/aos.12977
   Gauthier R, 2005, INVEST OPHTH VIS SCI, V46, P3383, DOI 10.1167/iovs.05-0362
   Ghaffariyeh A, 2011, OPTOMETRY VISION SCI, V88, P80, DOI 10.1097/OPX.0b013e3181fc329f
   Ghaffariyeh A, 2009, OPTOMETRY, V80, P635, DOI 10.1016/j.optm.2008.09.014
   Gielen A, 2003, SCAND J IMMUNOL, V57, P493, DOI 10.1046/j.1365-3083.2003.01260.x
   Griffin EW, 2011, PHYSIOL BEHAV, V104, P934, DOI 10.1016/j.physbeh.2011.06.005
   Guo M, 2017, RETINA-J RET VIT DIS, V37, P350, DOI 10.1097/IAE.0000000000001132
   Gupta V, 2014, BBA-MOL BASIS DIS, V1842, P1567, DOI 10.1016/j.bbadis.2014.05.026
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Hwang YH, 2016, OPHTHALMOLOGY, V123, P950, DOI 10.1016/j.ophtha.2015.12.032
   Iwabe S, 2007, VET OPHTHALMOL, V10, P12, DOI 10.1111/j.1463-5224.2007.00504.x
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kanato Y, 2009, BIOSCI BIOTECH BIOCH, V73, P2735, DOI 10.1271/bbb.90637
   Kano T, 2002, INVEST OPHTH VIS SCI, V43, P3744
   Kaur C, 2008, PROG RETIN EYE RES, V27, P622, DOI 10.1016/j.preteyeres.2008.09.003
   Kerschensteiner M, 1999, J EXP MED, V189, P865, DOI 10.1084/jem.189.5.865
   Kim BJ, 2017, NEUROLOGY, V89, P1604, DOI 10.1212/WNL.0000000000004500
   Kliffen M, 1996, ARCH OPHTHALMOL-CHIC, V114, P1009, DOI 10.1001/archopht.1996.01100140217021
   Kuiper J, 2015, ACTA OPHTHALMOL, V93, pE680, DOI 10.1111/aos.12733
   LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249
   LaVail MM, 1998, INVEST OPHTH VIS SCI, V39, P592
   Li PC, 2015, CNS NEUROSCI THER, V21, P231, DOI 10.1111/cns.12343
   Liu DX, 2014, BEHAV BRAIN RES, V271, P116, DOI 10.1016/j.bbr.2014.05.068
   LOEFFLER KU, 1993, INVEST OPHTH VIS SCI, V34, P2600
   Mancino R, 2018, CURR NEUROPHARMACOL, V16, P971, DOI 10.2174/1570159X16666171206144045
   Martin KRG, 2003, INVEST OPHTH VIS SCI, V44, P4357, DOI 10.1167/iovs.02-1332
   Mattson MP, 2005, ANNU REV NUTR, V25, P237, DOI 10.1146/annurev.nutr.25.050304.092526
   Molteni R, 2002, NEUROSCIENCE, V112, P803, DOI 10.1016/S0306-4522(02)00123-9
   Noma H, 2010, EUR J OPHTHALMOL, V20, P402, DOI 10.1177/112067211002000222
   ORTINMARTINEZ A, 2014, PLOS ONE, V9, DOI DOI 10.1371/journal.pone.0113798
   Pan WH, 1998, NEUROPHARMACOLOGY, V37, P1553, DOI 10.1016/S0028-3908(98)00141-5
   Qin XY, 2017, MOL PSYCHIATR, V22, P312, DOI 10.1038/mp.2016.62
   Rudzinski M, 2004, J NEUROBIOL, V58, P341, DOI 10.1002/neu.10293
   Saito T, 2009, CURR EYE RES, V34, P580, DOI 10.1080/02713680902972358
   Semkova I, 2002, P NATL ACAD SCI USA, V99, P13090, DOI 10.1073/pnas.202486199
   Shpak AA, 2017, CURR EYE RES, V9, P1
   Skaper Stephen D, 2012, Methods Mol Biol, V846, P1, DOI 10.1007/978-1-61779-536-7_1
   Taylor AW, 1996, NEUROIMMUNOMODULAT, V3, P112, DOI 10.1159/000097235
   Wahlin KJ, 2000, INVEST OPHTH VIS SCI, V41, P927
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   WILBANKS GA, 1992, EUR J IMMUNOL, V22, P1031, DOI 10.1002/eji.1830220423
   Wordinger RJ, 2000, INVEST OPHTH VIS SCI, V41, P3833
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
NR 57
TC 14
Z9 14
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2018
VL 59
IS 7
BP 2833
EP 2840
DI 10.1167/iovs.18-24030
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GI2EY
UT WOS:000434183800018
PM 30025135
OA gold
DA 2022-11-30
ER

PT J
AU Braimah, IZ
   Stewart, M
   Videkar, C
   Dedhia, CJ
   Chhablani, J
AF Braimah, Imoro Zeba
   Stewart, Michael
   Videkar, Chetan
   Dedhia, Chintan J.
   Chhablani, Jay
CA Ziv-aflibercept Study Grp
TI Intravitreal ziv-aflibercept for the treatment of choroidal
   neovascularisation associated with conditions other than age-related
   macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CENTRAL SEROUS CHORIORETINOPATHY; SUBGROUP ANALYSIS; ANGIOID STREAKS;
   RANIBIZUMAB; BEVACIZUMAB
AB Aim To report the short-term outcomes of eyes with choroidal neovascularisation (CNV) associated with causes other than age-related macular degeneration (AMD) after treatment with intravitreal ziv-aflibercept (IVZ) injections.
   Methods This retrospective study included eyes with non-AMD-related CNV that were treated with IVZ (1.25 mg/0.05 mL) on a pro re nata basis. The primary outcome measure is the mean change in best-corrected visual acuity (BCVA) and secondary outcome measures include the mean change in central macular thickness (CMT) and adverse events.
   Results 23 eyes of 19 patients with CNV due to high myopia (9), macular telangiectasia (4), central serous chorioretinopathy (3), choroidal osteoma (2), choroiditis (2), Best's disease (2) and idiopathic (1) were treated. The mean follow-up period was 4 +/- 1.9 months. The median number of IVZ injections was 1 (range, 1-3) and the median treatment-free interval at the time of the final visit was 3 months (range, 1-8). The mean BCVA improved from 0.67 LogMAR to 0.58 LogMAR (p=0.0507). Nine of 23 (39%) eyes had BCVA gains of at least 0.1 LogMAR, 11 (48%) eyes had stable BCVA (within 0.1 LogMAR of baseline) and 3 (13%) eyes had a BCVA decline of at least 0.1 LogMAR at the final visit. The mean CMT improved significantly from baseline until the final visit (22 vs 174.5 mu m; p=0.037). No ocular or systemic adverse events were noted.
   Conclusions IVZ improves CMT in patients with CNV associated with causes other than AMD, but improvements in BCVA are modest.
C1 [Braimah, Imoro Zeba] Univ Ghana, Sch Med & Dent, Coll Hlth Sci, Accra, Ghana.
   [Braimah, Imoro Zeba; Videkar, Chetan; Dedhia, Chintan J.; Chhablani, Jay] LV Prasad Eye Inst, Srimati Kanuri Santhamma Ctr Vitreo Retinal Dis, KAR Campus, Hyderabad, Telangana, India.
   [Stewart, Michael] Mayo Clin, Dept Ophthalmol, Jacksonville, FL 32224 USA.
C3 University of Ghana; L. V. Prasad Eye Institute; Mayo Clinic
RP Chhablani, J (通讯作者)，LV Prasad Eye Inst, Banjara Hills,Rd 2, Hyderabad 500034, Telangana, India.
EM jay.chhablani@gmail.com
RI Braimah, Imoro Zeba/ABB-2168-2020; Narayanan, Raja/AAT-3098-2021
OI Narayanan, Raja/0000-0001-9688-5859; Dedhia,
   Chintan/0000-0001-5475-2089; Braimah, Imoro Zeba/0000-0002-2573-9026
CR Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Broadhead GK, 2015, GRAEF ARCH CLIN EXP, V253, P979, DOI 10.1007/s00417-014-2891-0
   Brown J, 1996, OPHTHALMOLOGY, V103, P1100, DOI 10.1016/S0161-6420(96)30561-7
   Brue C, 2016, EYE, V30, P139, DOI 10.1038/eye.2015.199
   Chhablani J, 2016, RETINA-J RET VIT DIS, V36, P1126, DOI 10.1097/IAE.0000000000000913
   Cohen SY, 1996, OPHTHALMOLOGY, V103, P1241, DOI 10.1016/S0161-6420(96)30515-0
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Loo RH, 2002, RETINA-J RET VIT DIS, V22, P19, DOI 10.1097/00006982-200202000-00004
   Mansour AM, 2016, BRIT J OPHTHALMOL, V100, P1629, DOI 10.1136/bjophthalmol-2015-308319
   Mansour AM, 2015, BRIT J OPHTHALMOL, V99, P1055, DOI 10.1136/bjophthalmol-2014-306319
   Querques L, 2016, EUR J OPHTHALMOL, V26, pE124, DOI 10.5301/ejo.5000759
   Saitta A, 2015, INT OPHTHALMOL, V35, P441, DOI 10.1007/s10792-015-0059-5
   Schmid MK, 2015, BRIT J OPHTHALMOL, V99, P141, DOI 10.1136/bjophthalmol-2014-305149
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Vaz-Pereira S, 2016, EYE, V30, P639, DOI 10.1038/eye.2015.284
   Vaz-Pereira S, 2015, EYE, V29, P1236, DOI 10.1038/eye.2015.92
NR 17
TC 17
Z9 17
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2017
VL 101
IS 9
BP 1201
EP 1205
DI 10.1136/bjophthalmol-2016-309994
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FE5BJ
UT WOS:000408226700009
PM 28119292
DA 2022-11-30
ER

PT J
AU Owen, CG
   Fletcher, AE
   Donoghue, M
   Rudnicka, AR
AF Owen, CG
   Fletcher, AE
   Donoghue, M
   Rudnicka, AR
TI How big is the burden of visual loss caused by age related macular
   degeneration in the United Kingdom?
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BEAVER DAM EYE; RISK-FACTORS; IMPAIRMENT PROJECT; CIGARETTE-SMOKING;
   OLDER-PEOPLE; PREVALENCE; MACULOPATHY; POPULATION; VISION; METAANALYSIS
AB Aims: To predict the burden of blindness, partial sight, and visual impairment (binocular visual acuity 6/18 or less) due to late stage age related macular degeneration (AMD) in the ageing population of the United Kingdom.
   Methods: A systematic review, followed by a request for data, was used to establish a pooled prevalence of AMD and corresponding visual loss. Prevalence figures were applied to the UK population. Using UK population trends, the future burden of AMD over the coming decade was established.
   Results: Pooled data from six studies showed that the prevalence of visual loss caused by AMD increased exponentially from the age of 70-85 years of age, with 3.5% (95% CI 3.0 to 4.1) having visual impairment beyond the age of 75 years. The authors estimate that there are currently 2 14 000 (95% CI 151 000 to 3 10 000) with visual impairment caused by AMD (suitable for registration). This number is expected to increase to 239 000 (95% CI 168 000 to 346 000) by the year 2011. Currently there are 172 000 (95% CI 106 000 to 279 000) and 245 000 (95% CI 163 000 to 364 000) with geographical and neovascular AMD, respectively.
   Conclusions: Estimates of visual impairment agree with official statistics for the number registered partially sighted or blind, caused by AMD, and are well below other figures often cited. Although these estimates are associated with wide confidence intervals (CI) and a number of caveats, they represent the best available data, which can be used to guide health and social care provision for older people in the UK setting. Implications for low vision services are outlined.
C1 St George Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England.
   Univ London London Sch Hyg & Trop Med, Ctr Ageing & Publ Hlth, London WC1E 7HT, England.
   St Bartholomews & Royal London Sch Med & Dent, Wolfson Inst Prevent Med, London EC1M 6BQ, England.
C3 St Georges University London; University of London; London School of
   Hygiene & Tropical Medicine; University of London; Queen Mary University
   London
RP Owen, CG (通讯作者)，St George Hosp, Sch Med, Dept Publ Hlth Sci, Cranmer Terrace, London SW17 0RE, England.
EM c.owen@sghms.ac.uk
OI Rudnicka, Alicja R/0000-0003-0369-8574; Owen,
   Christopher/0000-0003-1135-5977
CR Arnold JJ, 2000, BRIT MED J, V321, P741, DOI 10.1136/bmj.321.7263.741
   Balatsoukas D D, 1995, J R Coll Surg Edinb, V40, P49
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   BRUCE I, 1991, BLIND PARTIALLY SIGH, V1
   Bunce C, 1998, BRIT J OPHTHALMOL, V82, P72, DOI 10.1136/bjo.82.1.72
   Cho EY, 2000, ARCH OPHTHALMOL-CHIC, V118, P681, DOI 10.1001/archopht.118.5.681
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Ciulla TA, 1998, SURV OPHTHALMOL, V43, P134, DOI 10.1016/S0039-6257(98)00014-9
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Department of Health, 2000, NHS PLAN PLAN INV PL
   Department of Health, 1998, MOD SOC SERV PROM IN
   Dickinson AJ, 1997, EYE, V11, P301, DOI 10.1038/eye.1997.66
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   EVANS J, 1995, CAUSES BLINDNESS PAR
   GIBSON JM, 1985, T OPHTHAL SOC UK, V104, P196
   *GOV ACT DEP UK, PROJ POP MID YEARS A
   GRISSO JA, 1991, NEW ENGL J MED, V324, P1326, DOI 10.1056/NEJM199105093241905
   HARRIES U, 1994, J PUBLIC HEALTH MED, V16, P211, DOI 10.1093/oxfordjournals.pubmed.a042959
   Jonasson F, 1987, Acta Ophthalmol Suppl, V182, P40
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Low Vision Consensus Group, 1999, LOW VIS SERV REC FUT
   Margrain TH, 2000, BRIT J OPHTHALMOL, V84, P919, DOI 10.1136/bjo.84.8.919
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   *OFF NAT STAT, 1999, POP TRENDS 96 SUMM 9
   Reidy A, 1998, BRIT MED J, V316, P1643, DOI 10.1136/bmj.316.7145.1643
   ROBINSON R, 1994, BRIT J OPHTHALMOL, V78, P736, DOI 10.1136/bjo.78.10.736
   Rosenberg T, 1996, ACTA OPHTHALMOL SCAN, V74, P399
   Rovner BW, 1996, J AM GERIATR SOC, V44, P181, DOI 10.1111/j.1532-5415.1996.tb02436.x
   *ROYAL NAT I BLIND, 1997, OFF NAT STAT MID 199
   RYAN B, 1999, FRAGMENTED VISION SU
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SHUTTLEWORTH GN, 1995, BRIT J OPHTHALMOL, V79, P719, DOI 10.1136/bjo.79.8.719
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Stuck AE, 1999, SOC SCI MED, V48, P445, DOI 10.1016/S0277-9536(98)00370-0
   THOMPSON SG, 1994, BMJ-BRIT MED J, V309, P1351, DOI 10.1136/bmj.309.6965.1351
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VINDING T, 1990, ACTA OPHTHALMOL, V68, P162
   VINDING T, 1989, ACTA OPHTHALMOL, V67, P609
   Vinding T, 1995, Acta Ophthalmol Scand Suppl, P1
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
   WHITEHEAD A, 1991, STAT MED, V10, P1665, DOI 10.1002/sim.4780101105
   World Health Organization, 2004, INT STAT CLASS DIS H
   WORMALD RPL, 1992, BRIT MED J, V304, P1226, DOI 10.1136/bmj.304.6836.1226
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
NR 52
TC 158
Z9 163
U1 0
U2 31
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2003
VL 87
IS 3
BP 312
EP 317
DI 10.1136/bjo.87.3.312
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 652FE
UT WOS:000181368500017
PM 12598445
OA Green Published, Green Submitted, Bronze
DA 2022-11-30
ER

PT J
AU Si, YH
   Li, SP
   Xu, YJ
   Chen, G
AF Si, Yanhui
   Li, Shunping
   Xu, Yanjiao
   Chen, Gang
TI Validation and comparison of five preference-based measures among
   age-related macular degeneration patients: evidence from mainland China
SO QUALITY OF LIFE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Preference-based assessment;
   Health-related quality of life; Capability wellbeing; Psychometric
   properties
ID QUALITY-OF-LIFE; ECONOMIC EVALUATIONS; HEALTH; UTILITY; IMPACT; INDEX;
   EQ-5D; 15D; QUESTIONNAIRE; INSTRUMENTS
AB Purpose To compare the psychometric properties of five preference-based measures (PBMs) among patients with age-related macular degeneration (AMD) in mainland China, including three health-related quality of life (HRQoL) measures [the 15D, the Assessment of Quality of Life (AQoL)-7D, and EQ-5D-5L] and two capability wellbeing measures [the ICEpop CAPability measure for Adults (ICECAP-A) and ICECAP measure for Older people (ICECAP-O)]. Methods A convenience sampling framework was used to successively recruit inpatients with AMD who attended a large ophthalmic hospital in Jinan, China. Psychometric properties (known-group validity, concurrent validity, and sensitivity) were assessed. The agreements between PBMs were reported. Results A valid sample of 210 AMD inpatients (median duration: 12 months) was analyzed. Overall, the AQoL-7D had the best performance based on the psychometric tests been conducted. Sufficient evidence was found on psychometric properties for other 2 preference-based HRQoL measures. The ICECAP-A outperformed ICECAP-O on known-group validity and concurrent validity whereas opposite results were found on sensitivity. The Bland-Altman plots indicate that there was no pair of PBMs that could be used interchangeably. Conclusions The AQoL-7D had shown better psychometric properties than other four PBMs based on Chinese AMD inpatients. The EQ-5D-5L demonstrated sufficient psychometric properties and given the availability of a Chinese-specific tariff and the recommendations of China guidelines for pharmacoeconomic evaluations, it may be prioritized to be used in China. Capability wellbeing instruments could also be considered given they provide information that goes beyond health. Further evidence on responsiveness and reliability for all five PBMs among AMD patients is required.
C1 [Si, Yanhui; Li, Shunping] Shandong Univ, Cheeloo Coll Med, Ctr Hlth Management & Policy Res, Sch Publ Hlth, Jinan 250012, Peoples R China.
   [Si, Yanhui; Li, Shunping] Shandong Univ, NHC Key Lab Hlth Econ & Policy Res, Jinan 250012, Peoples R China.
   [Li, Shunping] Shandong Univ, Ctr Hlth Preference Res, Jinan 250012, Peoples R China.
   [Xu, Yanjiao] Shandong Univ Tradit Chinese Med, Affiliated Eye Hosp, Jinan 250002, Peoples R China.
   [Chen, Gang] Monash Univ, Ctr Hlth Econ, Monash Business Sch, Melbourne, Vic 3145, Australia.
C3 Shandong University; Shandong University; Shandong University; Shandong
   University of Traditional Chinese Medicine; Monash University
RP Li, SP (通讯作者)，Shandong Univ, Cheeloo Coll Med, Ctr Hlth Management & Policy Res, Sch Publ Hlth, Jinan 250012, Peoples R China.; Li, SP (通讯作者)，Shandong Univ, NHC Key Lab Hlth Econ & Policy Res, Jinan 250012, Peoples R China.; Li, SP (通讯作者)，Shandong Univ, Ctr Hlth Preference Res, Jinan 250012, Peoples R China.
EM lishunping@sdu.edu.cn
FU Development Project of Medicine and Health Science Technology of
   Shandong Province [2017WSB42001]
FX This study was supported by The Development Project of Medicine and
   Health Science Technology of Shandong Province (Grant number
   2017WSB42001).
CR Al-Janabi H, 2012, QUAL LIFE RES, V21, P167, DOI 10.1007/s11136-011-9927-2
   Alanne S, 2015, QUAL LIFE RES, V24, P599, DOI 10.1007/s11136-014-0787-4
   Amartya, 1999, COMMODITIES CAPABILI
   Armbrecht AM, 2004, BRIT J OPHTHALMOL, V88, P1270, DOI 10.1136/bjo.2003.038604
   Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1191/096228099673819272
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Bray N, 2017, ACTA OPHTHALMOL, V95, pE415, DOI 10.1111/aos.13255
   Brazier J, 2017, PHARMACOECONOMICS, V35, pS21, DOI 10.1007/s40273-017-0545-x
   Breheny K, 2020, QUAL LIFE RES, V29, P1935, DOI 10.1007/s11136-020-02443-3
   Chen G, 2018, SOC INDIC RES, V140, P175, DOI 10.1007/s11205-017-1788-9
   Coast J, 2008, SOC SCI MED, V67, P874, DOI 10.1016/j.socscimed.2008.05.015
   Coast J, 2008, HEALTH ECON, V17, P667, DOI 10.1002/hec.1359
   COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155
   Combs R, 2013, EUR J HUM GENET, V21, P1209, DOI 10.1038/ejhg.2013.19
   Eong KGA, 2012, EYE, V26, P379, DOI 10.1038/eye.2011.218
   Espallargues M, 2005, INVEST OPHTH VIS SCI, V46, P4016, DOI 10.1167/iovs.05-0072
   Flynn TN, 2015, HEALTH ECON, V24, P258, DOI 10.1002/hec.3014
   Freemantle N, 1997, BMJ-BRIT MED J, V315, P689, DOI [10.1136/bmj.315.7109.689a, DOI 10.1136/BMJ.315.7109.689A]
   Gandhi M, 2019, PATIENT, V12, P383, DOI 10.1007/s40271-018-00354-7
   Garin O., 2014, ENCY QUALITY LIFE WE, P631, DOI [10.1007/978-94-007-0753-5_296, DOI 10.1007/978-94-007-0753-5_296]
   Hahl J, 2002, QUAL LIFE RES, V11, P427, DOI 10.1023/A:1015684100227
   Helter TM, 2020, QUAL LIFE RES, V29, P1433, DOI 10.1007/s11136-019-02393-5
   Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x
   Hopkins W, 2000, CALCULATIONS RELIABI
   Kvam AK, 2011, EUR J HAEMATOL, V87, P330, DOI 10.1111/j.1600-0609.2011.01665.x
   Liu G, 2020, CHINA GUIDELINES PHA
   Lloyd A, 2008, DIABETIC MED, V25, P618, DOI 10.1111/j.1464-5491.2008.02430.x
   Luo N, 2017, VALUE HEALTH, V20, P662, DOI 10.1016/j.jval.2016.11.016
   Luo N, 2015, VALUE HEALTH, V18, P1037, DOI 10.1016/j.jval.2015.08.002
   Luo N, 2009, MED CARE, V47, P53, DOI 10.1097/MLR.0b013e31817d92f8
   Ma YY, 2015, J CATARACT REFR SURG, V41, P1248, DOI 10.1016/j.jcrs.2014.09.046
   Makai P, 2014, SOC SCI MED, V102, P83, DOI 10.1016/j.socscimed.2013.11.050
   Michel YA, 2019, QUAL LIFE RES, V28, P1129, DOI 10.1007/s11136-018-2043-9
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mitchell PM, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-034569
   NICE, DEV NICE GUID MAN 20
   Pickles K, 2019, SOC SCI MED, V240, DOI 10.1016/j.socscimed.2019.112560
   Richardson J, 2012, OPHTHAL EPIDEMIOL, V19, P172, DOI 10.3109/09286586.2012.674613
   Sahel JA, 2007, ARCH OPHTHALMOL-CHIC, V125, P945, DOI 10.1001/archopht.125.7.945
   SCOTT IU, 1994, ARCH OPHTHALMOL-CHIC, V112, P329, DOI 10.1001/archopht.1994.01090150059023
   Senra H, 2019, AM J GERIAT PSYCHIAT, V27, P755, DOI 10.1016/j.jagp.2019.03.001
   Sintonen H, 2001, ANN MED, V33, P328, DOI 10.3109/07853890109002086
   Sintonen H., 1995, 42 NAT CTR HLTH PROG
   Song PG, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.020703
   SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615
   Tang CX, 2018, HEALTH QUAL LIFE OUT, V16, DOI 10.1186/s12955-018-0865-3
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Terwee CB, 2007, J CLIN EPIDEMIOL, V60, P34, DOI 10.1016/j.jclinepi.2006.03.012
   Tosh J, 2012, VALUE HEALTH, V15, P118, DOI 10.1016/j.jval.2011.08.002
   WILLIAMS A, 1990, HEALTH POLICY, V16, P199
   Wolffsohn JS, 2000, AM J OPHTHALMOL, V130, P793, DOI 10.1016/S0002-9394(00)00610-3
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wormald R, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub2
   Zhang YL, 2014, QUAL LIFE RES, V23, P2319, DOI 10.1007/s11136-014-0674-z
   Zhao FL, 2010, VALUE HEALTH, V13, P649, DOI 10.1111/j.1524-4733.2010.00728.x
   Zou H, 2005, QUAL LIFE RES, V14, P1633, DOI 10.1007/s11136-004-0026-5
NR 56
TC 0
Z9 0
U1 1
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0962-9343
EI 1573-2649
J9 QUAL LIFE RES
JI Qual. Life Res.
PD MAY
PY 2022
VL 31
IS 5
BP 1561
EP 1572
DI 10.1007/s11136-021-03047-1
EA DEC 2021
PG 12
WC Health Care Sciences & Services; Health Policy & Services; Public,
   Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA 0Q0KD
UT WOS:000724662700001
PM 34853992
DA 2022-11-30
ER

PT J
AU Garcia-Finana, M
   Murjaneh, S
   Mahmood, S
   Harding, SP
AF Garcia-Finana, M.
   Murjaneh, S.
   Mahmood, S.
   Harding, S. P.
TI Baseline clinical measures and early response predict success in
   verteporfin photodynamic therapy for neovascular age-related macular
   degeneration
SO EYE
LA English
DT Article
DE contrast sensitivity; longitudinal linear mixed-effects model;
   neovascular age-related macular degeneration; verteporfin photodynamic
   therapy; visual acuity
ID CONTRAST SENSITIVITY; CHOROIDAL NEOVASCULARIZATION; RANIBIZUMAB;
   MACULOPATHY; PREVALENCE
AB Purpose To analyse the influence of baseline clinical characteristics on the outcome of verteporfin photodynamic therapy (VPDT) for neovascular age-related macular degeneration (nAMD).
   Methods A total of 1008 patients commencing VPDT for nAMD in a single UK centre entered a prospective observational study between 1999 and 2006 and were followed for 2 years. Longitudinal linear mixed-effects modelling was applied to assess the influence of baseline covariates, such as best corrected visual acuity (BCVA), contrast sensitivity (CS), age, lesion size, and lesion type, on changes of BCVA over time in patients after VPDT. A logistic regression analysis was used to analyse clinical features significantly associated with treatment failure.
   Results Study eye BCVA was significantly better on average throughout the course of treatment in patients with better baseline BCVA and CS in the study eye (P<0.001 and P<0.01, respectively) and lower age (P = 0.01). Mean BCVA showed a significant reduction over time with a significant quadratic relationship between 0 and 6 months and with stabilisation between 6 and 9 months. Patients with better BCVA and worse CS at baseline, and those in whom BCVA dropped during the first 3 months of follow-up, were more likely to lose >= 15 letters after 12 months.
   Conclusions Findings from our large longitudinal data set provide estimates of likely outcome based on baseline features and response at 3 months in patients commencing a course of VPDT for nAMD. Statistical modelling built up for this large data set can be applicable to other studies in ophthalmology research. Eye (2010) 24, 1213-1219; doi:10.1038/eye.2009.319; published online 15 January 2010
C1 [Harding, S. P.] Univ Liverpool, Ophthalmol Res Grp, Sch Clin Sci, Ophthalmol Res Unit,Fac Hlth & Life Sci, Liverpool L69 3GA, Merseyside, England.
   [Garcia-Finana, M.] Univ Liverpool, Fac Hlth & Life Sci, Ctr Med Stat & Hlth Evaluat, Liverpool L69 3GA, Merseyside, England.
   [Murjaneh, S.; Harding, S. P.] Royal Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool, Merseyside, England.
   [Mahmood, S.] Manchester Royal Eye Hosp, Manchester M13 9WH, Lancs, England.
C3 University of Liverpool; University of Liverpool; Royal Liverpool &
   Broadgreen University Hospitals NHS Trust; Royal Liverpool University
   Hospital; University of Liverpool; Manchester Royal Eye Hospital
RP Harding, SP (通讯作者)，Univ Liverpool, Ophthalmol Res Grp, Sch Clin Sci, Ophthalmol Res Unit,Fac Hlth & Life Sci, 3rd Floor,Univ Clin Dept Bldg,Daulby St, Liverpool L69 3GA, Merseyside, England.
EM s.p.harding@liv.ac.uk
RI Mahmood, Sajjad/AAK-7645-2021
OI Harding, Simon/0000-0003-4676-1158
FU Foundation for the Prevention of Blindness; St Paul's Eye Unit at the
   Royal Liverpool University Hospital; National Coordinating Centre for
   Health Technology Assessment [07/36/01]
FX We acknowledge funding from The Foundation for the Prevention of
   Blindness and from the St Paul's Eye Unit at the Royal Liverpool
   University Hospital. We are grateful to Professor Paula Williamson for
   her useful input during earlier discussions on this study. Data from
   some of the patients reported in this paper observed between May 2004
   and September 2007 have contributed to a larger data set in the
   Verteporfin Photodynamic Cohort Study, funded by National Coordinating
   Centre for Health Technology Assessment (NHS Clinical Trials), ref
   07/36/01.
CR [Anonymous], 1991, OPHTHALMOLOGY, V98, P741
   Bansback N, 2007, QUAL LIFE RES, V16, P533, DOI 10.1007/s11136-006-9126-8
   Barnes RM, 2004, EYE, V18, P809, DOI 10.1038/sj.eye.6701329
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buggage RR, 1999, ARCH OPHTHALMOL-CHIC, V117, P1239
   Chalupa L.M., 2003, VISUAL NEUROSCIENCES
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Mones J, 2005, EYE, V19, P1142, DOI 10.1038/sj.eye.6701717
   Murjaneh S, 2009, BRIT J OPHTHALMOL, V93, P468, DOI 10.1136/bjo.2008.141366
   OWSLEY C, 1981, INVEST OPHTH VIS SCI, V21, P362
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Ziemssen F, 2008, GRAEF ARCH CLIN EXP, V246, P653, DOI 10.1007/s00417-007-0726-y
NR 18
TC 2
Z9 2
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUL
PY 2010
VL 24
IS 7
BP 1213
EP 1219
DI 10.1038/eye.2009.319
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 626OT
UT WOS:000279976000014
PM 20075972
DA 2022-11-30
ER

PT J
AU Lee, S
   Song, SJ
   Yu, HG
AF Lee, Sangmoon
   Song, Su Jeong
   Yu, Hyeong Gon
TI Current Smoking Is Associated with a Poor Visual Acuity Improvement
   after Intravitreal Ranibizumab Therapy in Patients with Exudative
   Age-Related Macular Degeneration
SO JOURNAL OF KOREAN MEDICAL SCIENCE
LA English
DT Article
DE Exudative Age-Related Macular Degeneration; Ranibizumab; Cigarette
   Smoking
ID CHOROIDAL NEOVASCULARIZATION; CIGARETTE-SMOKING; RISK-FACTORS; CLINICAL
   MEASURES; SUBGROUP ANALYSIS; NICOTINE; GROWTH; ATHEROSCLEROSIS;
   BEVACIZUMAB; EXPRESSION
AB In this study, the risk factors that may influence visual improvement after intravitreal ranibizumab (IVR) treatment for exudative age-related macular degeneration (AMD) were examined. From 2008 to 2012, 420 patients (448 eyes) with exudative AMD were prospectively registered at Seoul National University Hospital. From this group of patients, 125 eyes were included in this study. All patients were treated with 3 consecutive IVR injections. The visual acuity (VA) was evaluated at baseline and 1 month after the third ranibizumab injection. To evaluate the risk factors associated with VA improvement after IVR, patient demographic data and systemic risk factors were analyzed. Patients were divided into a poor VA improvement group and a good VA improvement group, with reference to the median visual improvement in all eyes. Among 125 eyes, 66 eyes (52.8%) were included in the responder group and 59 eyes (47.2%) in the non-responder group. The median VA improvement after 3 monthly ranibizumab injections was -0.05 logMAR. Multivariate analyses revealed that current smoking (adjusted OR, 7.540; 95% CI, 1.732-32.823) was independently associated with poor VA improvement after IVR treatment for exudative AMD. In conclusion, cigarette smoking is an independent risk factor for lower VA gains with IVR treatment for exudative AMD.
C1 [Lee, Sangmoon; Yu, Hyeong Gon] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul Natl Univ Hosp, Seoul, South Korea.
   [Song, Su Jeong] Sungkyunkwan Univ, Sch Med, Dept Ophthalmol, Kangbuk Samsung Hosp, Seoul, South Korea.
C3 Seoul National University (SNU); Seoul National University Hospital;
   Sungkyunkwan University (SKKU); Samsung Medical Center
RP Yu, HG (通讯作者)，Seoul Natl Univ Hosp, Dept Ophthalmol, 101 Daehak Ro, Seoul 110744, South Korea.
EM hgonyu@snu.ac.kr
OI Yu, Hyeong Gon/0000-0002-1795-202X
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 1992, Arch Ophthalmol, V110, P1701
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Conklin BS, 2002, AM J PATHOL, V160, P413, DOI 10.1016/S0002-9440(10)64859-6
   Dhubhghaill SSN, 2010, ADV EXP MED BIOL, V664, P437, DOI 10.1007/978-1-4419-1399-9_50
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Heeschen C, 2001, NAT MED, V7, P833, DOI 10.1038/89961
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Unver YB, 2009, EYE, V23, P453, DOI 10.1038/eye.2008.349
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wickremasinghe SS, 2011, INVEST OPHTH VIS SCI, V52, P4072, DOI 10.1167/iovs.10-6550
NR 22
TC 16
Z9 20
U1 0
U2 7
PU KOREAN ACAD MEDICAL SCIENCES
PI SEOUL
PA 302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA
SN 1011-8934
EI 1598-6357
J9 J KOREAN MED SCI
JI J. Korean Med. Sci.
PD MAY
PY 2013
VL 28
IS 5
BP 769
EP 774
DI 10.3346/jkms.2013.28.5.769
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 148AO
UT WOS:000319214600021
PM 23678271
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Garip, R
   Cinar, AK
   Cinar, AC
   Sakallioglu, AK
   Guclu, H
   Gurlu, V
AF Garip, Ruveyde
   Cinar, Ayca K.
   Cinar, Abdulkadir C.
   Sakallioglu, Ahmet Kursad
   Guclu, Hande
   Gurlu, Vuslat
TI Prognostic factors associated with the course of vitreomacular traction
   in eyes with age-related macular degeneration
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Article
DE Age related macular degeneration; Optical coherence tomography;
   Vitreomacular traction
ID SPONTANEOUS RESOLUTION; SPONTANEOUS RELEASE; ADHESION; RANIBIZUMAB;
   INTERFACE
AB Clinical relevance: Vitreomacular traction(VMT) is a clinical syndrome that can cause decreased vision and may affect the treatment response in cases of age-related macular degeneration(AMD). Factors affecting the course of VMT in AMD cases will guide the clinician in terms of patient management.Background: The aim of this study was to determine the prevalence of VMT in patients with AMD, to evaluate the natural course of VMT, and to investigate factors associated with the prognosis of VMT in eyes with AMD.Methods: This retrospective case series was conducted with 55 eyes of 46 patients who were diagnosed as having AMD accompanying with VMT. Demographic data, complete ophthalmologic examination findings, type of AMD, receiving an intravitreal injection(IVI), number of IVIs, and the presence of complete spontaneous release were obtained from the medical records of the patients. The horizontal length of VMT(HLVMT), central macular thickness(CMT), the horizontal length of choroidal neovascularization(HLCNV) were evaluated from spectral -domain optical coherence tomography(SD-OCT) images.Results: Spontaneous release was observed in 7(28%) eyes of the exudative AMD group and 10(33.3%) eyes of the nonexudative AMD group. On the last visit, the HLVMT was increased in 22(40%) of the eyes and a decrease in HLVMT was observed in 8(14.5%) of the eyes. In the remaining 12(21.8%) eyes had unchanged HLVMT. In all eyes with CNV, the area of VMT corresponded in 100% with localization of the CNV complex. No significant difference was found between the eyes with spontaneous release and persistent traction in terms of the type of AMD, IVI, HLVMT, age, gender, and crystalline lens status. Conclusion: In this study, VMT was observed at higher rates in eyes with exudative AMD compared to the eyes with nonexudative AMD. However, spontaneous release rates were found close to those with idiopathic VMT independently of the type of AMD, HLVMT, and IVI.
C1 [Garip, Ruveyde; Cinar, Ayca K.; Cinar, Abdulkadir C.; Sakallioglu, Ahmet Kursad; Guclu, Hande; Gurlu, Vuslat] Trakya Univ, Dept Ophthalmol, Sch Med, Edirne, Turkey.
C3 Trakya University
RP Garip, R; Cinar, AK (通讯作者)，Trakya Univ, Dept Ophthalmol, Sch Med, Edirne, Turkey.
EM ruveydegarip@gmail.com; aycakupeli@gmail.com
FU  [T?TF-BAEK 2020/358]
FX This study was approved by the Human Clinical Research and Ethics
   committee of Trakya University School of Medidicine (Approvel code:
   T?TF-BAEK 2020/358) .
CR Abdillahi H, 2014, OPHTHALMOLOGY, V121, P1734, DOI 10.1016/j.ophtha.2014.03.036
   Almeida DRP, 2015, RETINA-J RET VIT DIS, V35, P492, DOI 10.1097/IAE.0000000000000346
   Dimopoulos S, 2015, BRIT J OPHTHALMOL, V99, P350, DOI 10.1136/bjophthalmol-2014-304961
   Duker JS, 2013, OPHTHALMOLOGY, V120, P2611, DOI 10.1016/j.ophtha.2013.07.042
   Errera MH, 2018, OPHTHALMOLOGY, V125, P701, DOI 10.1016/j.ophtha.2017.10.035
   Gao M, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000009345
   Garg A, 2022, RETINA-J RET VIT DIS, V42, P1219, DOI 10.1097/IAE.0000000000003513
   Geck U, 2013, GRAEF ARCH CLIN EXP, V251, P1691, DOI 10.1007/s00417-013-2266-y
   Green-Simms AE, 2011, SEMIN OPHTHALMOL, V26, P137, DOI 10.3109/08820538.2011.559512
   HIKICHI T, 1995, AM J OPHTHALMOL, V119, P55, DOI 10.1016/S0002-9394(14)73813-9
   Kimura S, 2016, GRAEF ARCH CLIN EXP, V254, P1731, DOI 10.1007/s00417-016-3314-1
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Krebs I, 2011, BRIT J OPHTHALMOL, V95, P1415, DOI 10.1136/bjo.2010.192385
   Lee Kang Hoon, 2015, Korean J Ophthalmol, V29, P396, DOI 10.3341/kjo.2015.29.6.396
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Odrobina D, 2011, RETINA-J RET VIT DIS, V31, P324, DOI 10.1097/IAE.0b013e3181eef08c
   Petrou P, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/9457670
   Rotsos T, 2010, BRIT J OPHTHALMOL, V94, P1205, DOI 10.1136/bjo.2009.173765
   Rouvas A, 2008, EUR J OPHTHALMOL, V18, P301, DOI 10.1177/112067210801800223
   Sadiq MA, 2016, OPHTHALMOLOGY, V123, P324, DOI 10.1016/j.ophtha.2015.09.032
   Schulze S, 2008, ACTA OPHTHALMOL, V86, P470, DOI 10.1111/j.1755-3768.2008.01210.x
   Simpson ARH, 2012, SURV OPHTHALMOL, V57, P498, DOI 10.1016/j.survophthal.2012.01.011
   Veloso CE, 2015, OPHTHALMOLOGY, V122, P1569, DOI 10.1016/j.ophtha.2015.04.028
   Zhang ZQ, 2015, CAN J OPHTHALMOL, V50, P172, DOI 10.1016/j.jcjo.2014.12.003
NR 25
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1572-1000
EI 1873-1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD DEC
PY 2022
VL 40
AR 103025
DI 10.1016/j.pdpdt.2022.103025
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 4W9KW
UT WOS:000860474600005
PM 35870775
DA 2022-11-30
ER

PT J
AU Munk, MR
   Ceklic, L
   Ebneter, A
   Huf, W
   Wolf, S
   Zinkernagel, MS
AF Munk, Marion R.
   Ceklic, Lala
   Ebneter, Andreas
   Huf, Wolfgang
   Wolf, Sebastian
   Zinkernagel, Martin S.
TI Macular atrophy in patients with long-term anti-VEGF treatment for
   neovascular age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE aflibercept; geographic atrophy; intravitreal injection; ranibizumab;
   retinal pigment epithelium atrophy; wet age-related macular degeneration
ID ENDOTHELIAL GROWTH-FACTOR; OPTICAL COHERENCE TOMOGRAPHY; RETINAL-PIGMENT
   EPITHELIUM; GEOGRAPHIC ATROPHY; FUNDUS AUTOFLUORESCENCE; VITREOMACULAR
   INTERFACE; TREATMENTS TRIALS; FACTOR THERAPY; RANIBIZUMAB; OUTCOMES
AB PurposeTo identify the prevalence and progression of macular atrophy (MA) in neovascular age-related macular degeneration (AMD) patients under long-term anti-vascular endothelial growth factor (VEGF) therapy and to determine risk factors.
   MethodThis retrospective study included patients with neovascular AMD and 30 anti-VEGF injections. Macular atrophy (MA) was measured using near infrared and spectral-domain optical coherence tomography (SD-OCT). Yearly growth rate was estimated using square-root transformation to adjust for baseline area and allow for linearization of growth rate. Multiple regression with Akaike information criterion (AIC) as model selection criterion was used to estimate the influence of various parameters on MA area.
   ResultsForty-nine eyes (47 patients, mean age 7714) were included with a mean of 48 +/- 13 intravitreal anti-VEGF injections (ranibizumab:37 +/- 11, aflibercept:11 +/- 6, mean number of injections/year 8 +/- 2.1) over a mean treatment period of 6.2 +/- 1.3years (range 4-8.5). Mean best-corrected visual acuity improved from 57 +/- 17 letters at baseline (= treatment start) to 60 +/- 16 letters at last follow-up. The MA prevalence within and outside the choroidal neovascularization (CNV) border at initial measurement was 45% and increased to 74%. Mean MA area increased from 1.8 +/- 2.7mm(2) within and 0.5 +/- 0.98mm(2) outside the CNV boundary to 2.7 +/- 3.4mm(2) and 1.7 +/- 1.8mm(2), respectively. Multivariate regression determined posterior vitreous detachment (PVD) and presence/development of intraretinal cysts (IRCs) as significant factors for total MA size (R-2 = 0.16, p=0.02). Macular atrophy (MA) area outside the CNV border was best explained by the presence of reticular pseudodrusen (RPD) and IRC (R-2 = 0.24, p=0.02).
   ConclusionA majority of patients show MA after long-term anti-VEGF treatment. Reticular pseudodrusen (RPD), IRC and PVD but not number of injections or treatment duration seem to be associated with the MA size.
C1 [Munk, Marion R.; Ceklic, Lala; Ebneter, Andreas; Wolf, Sebastian; Zinkernagel, Martin S.] Univ Bern, Univ Hosp Bern, Inselspital, Dept Ophthalmol,Dept Clin Res, Bern, Switzerland.
   [Munk, Marion R.; Ceklic, Lala; Wolf, Sebastian; Zinkernagel, Martin S.] Univ Hosp Bern, Bern Photog Reading Ctr, Bern, Switzerland.
   [Munk, Marion R.] Northwestern Univ, Dept Ophthalmol, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Huf, Wolfgang] Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria.
C3 University of Bern; University Hospital of Bern; University of Bern;
   University Hospital of Bern; Northwestern University; Feinberg School of
   Medicine; Medical University of Vienna
RP Munk, MR (通讯作者)，Inselspital Bern, Univ Freiburgerstr 4, CH-3010 Bern, Switzerland.
EM marion_munk@hotmail.com
RI Zinkernagel, Martin/C-3799-2017; Wolf, Sebastian/B-8782-2008; Ebneter,
   Andreas/C-5226-2017
OI Zinkernagel, Martin/0000-0002-5622-114X; Wolf,
   Sebastian/0000-0002-7467-7028; Ebneter, Andreas/0000-0001-6666-2558;
   Zinkernagel, Martin S./0000-0003-3447-2359
CR Abdillahi H, 2014, OPHTHALMOLOGY, V121, P1734, DOI 10.1016/j.ophtha.2014.03.036
   Alten F, 2015, BRIT J OPHTHALMOL, V99, P717, DOI 10.1136/bjophthalmol-2014-305339
   Arcinue CA, 2015, AM J OPHTHALMOL, V159, P426, DOI 10.1016/j.ajo.2014.11.022
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Duker JS, 2013, OPHTHALMOLOGY, V120, P2611, DOI 10.1016/j.ophtha.2013.07.042
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Forte R, 2012, ACTA OPHTHALMOL, V90, pE281, DOI 10.1111/j.1755-3768.2011.02331.x
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hoerster R, 2014, RETINA-J RET VIT DIS, V34, P1767, DOI 10.1097/IAE.0000000000000188
   Hogg RE, 2014, OPTOMETRY VISION SCI, V91, P854, DOI 10.1097/OPX.0000000000000287
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Kumar N, 2013, OPHTHALMOLOGY, V120, P334, DOI 10.1016/j.ophtha.2012.07.076
   Lala C, 2013, ACTA OPHTHALMOL, V91, P526, DOI 10.1111/j.1755-3768.2012.02457.x
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Mayr-Sponer U, 2013, OPHTHALMOLOGY, V120, P2620, DOI 10.1016/j.ophtha.2013.05.032
   Menke MN, 2014, BRIT J OPHTHALMOL, V98, P1197, DOI 10.1136/bjophthalmol-2013-304775
   Munk MR, 2015, ACTA OPHTHALMOL, V93, pE561, DOI 10.1111/aos.12699
   Munk MR, 2014, RETINA-J RET VIT DIS, V34, P2218, DOI 10.1097/IAE.0000000000000228
   Munk MR, 2013, RETINA-J RET VIT DIS, V33, P1673, DOI 10.1097/IAE.0b013e318285cc52
   Parodi MB, 2015, BRIT J OPHTHALMOL, V99, P1268, DOI 10.1136/bjophthalmol-2014-305783
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Sarks J, 2006, BRIT J OPHTHALMOL, V90, P442, DOI 10.1136/bjo.2005.083022
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Stefansson E, 2009, GRAEF ARCH CLIN EXP, V247, P147, DOI 10.1007/s00417-008-0980-7
   Sulzbacher F, 2015, INVEST OPHTH VIS SCI, V56, P1158, DOI 10.1167/iovs.14-14298
   Tanaka E, 2015, OPHTHALMOLOGY, V122, P153, DOI 10.1016/j.ophtha.2014.07.046
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
NR 39
TC 71
Z9 73
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2016
VL 94
IS 8
BP E757
EP E764
DI 10.1111/aos.13157
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ED1AR
UT WOS:000388576400018
PM 27417506
DA 2022-11-30
ER

PT J
AU Yan, HG
   Sun, WY
   Mruthyunjaya, P
   Beadle, B
   Yu, WH
   Kanwal, B
   MacDonald, CA
   Liu, W
AF Yan, Huagang
   Sun, Weiyuan
   Mruthyunjaya, Prithvi
   Beadle, Beth
   Yu, Weihong
   Kanwal, Bushra
   MacDonald, Carolyn A.
   Liu, Wu
TI Dosimetry modeling of focused kV x-ray radiotherapy for wet age-related
   macular degeneration
SO MEDICAL PHYSICS
LA English
DT Article
DE age-related macular degeneration; focused x ray; Monte Carlo simulation
ID PROTON-BEAM IRRADIATION; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION;
   MICROBEAM RADIATION-THERAPY; INDUCED OPTIC NEUROPATHY; STEREOTACTIC
   RADIOTHERAPY; EPIMACULAR BRACHYTHERAPY; INTRAVITREAL INJECTION;
   ENDOTHELIAL-CELLS; CONTROLLED-TRIAL; FOLLOW-UP
AB Purpose: Wet (neovascular) age-related macular degeneration (AMD) is the leading cause of blindness in the United States. The mainstay treatment requires monthly intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) drugs, associated with multiple visits, high cost, and the risk of procedural injury and infection. Anti-VEGF drugs inhibit the formation of neovasculature but do not directly attack it. Radiotherapy can destroy neovasculature and potentially also inhibit wet-AMD associated inflammation and fibrosis not addressed by VEGF inhibitors. However, the current collimation-based radiotherapy device uses fixed 4 mm beams, which are prone to overtreat or undertreat the choroidal neovascularization (CNV) lesions because of their various sizes and shapes. This simulation study evaluates personalized conformal treatment with focused kV radiation using cutting-edge polycapillary x-ray optics.
   Methods: Simulation of the polycapillary optics was achieved via Monte Carlo (MC)-based three-dimensional (3D) geometric ray tracing. Phase-space files modeling the focused photons were generated. The method was previously verified by phantom measurements. The ultrasmall similar to 0.2 mm beam focal spot perpendicular to the beam direction enables spatially fractionated grid therapy, which has been shown to preferentially damage abnormal neovascular blood vessels vs normal ones. Geant4-based MC simulations of scanning while rotating beam delivery were performed to conformally treat three clinical cases of large, medium, and small CNV lesions with regular and grid deliveries. Dose delivery uncertainties due to positioning errors were analyzed, including +/- 0.75 mm displacement in the three orthogonal directions and +/- 5 degrees vertical/horizontal rotation of the eyeball.
   Results: The simulated CNV treatments by 60-kVp focused x-ray beams show highly conformal delivery of dose to the lesion plus margin (0.75 mm) with sharp dose fall-offs and controllable spatial modulation patterns. The 90%-10% isodose penumbra is <0.5 mm. With a prescription dose of 16 Gy to the lesions, the critical structure doses are well below the tolerance. The average CNV dose varies within 10% (mostly within 4%) due to 0.75-mm linear displacements and 5-degree gaze angle rotation of the eyeball.
   Conclusion: Focused kV technique allows personalized treatment of CNV lesions and reduces unwanted radiation to adjacent healthy tissue. The simulated dose distribution is superior to currently available techniques. (c) 2020 American Association of Physicists in Medicine
C1 [Yan, Huagang] Capital Med Univ, Sch Biomed Engn, Beijing 100069, Peoples R China.
   [Sun, Weiyuan; MacDonald, Carolyn A.] SUNY Albany, Dept Phys, Albany, NY 12222 USA.
   [Mruthyunjaya, Prithvi] Stanford Univ, Dept Ophthalmol, Sch Med, Stanford, CA 94305 USA.
   [Beadle, Beth; Liu, Wu] Stanford Univ, Dept Radiat Oncol, Sch Med, Stanford, CA 94305 USA.
   [Yu, Weihong] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, Key Lab Ocular Fundus Dis, Beijing 100730, Peoples R China.
   [Kanwal, Bushra] Univ Punjab, Ctr High Energy Phys, Lahore, Pakistan.
C3 Capital Medical University; State University of New York (SUNY) System;
   State University of New York (SUNY) Albany; Stanford University;
   Stanford University; Chinese Academy of Medical Sciences - Peking Union
   Medical College; Peking Union Medical College Hospital; University of
   Punjab
RP Liu, W (通讯作者)，Stanford Univ, Dept Radiat Oncol, Sch Med, Stanford, CA 94305 USA.
EM wuliu@stanford.edu
RI MacDonald, Carolyn/ABE-2016-2020
OI MacDonald, Carolyn/0000-0002-2492-0333; mruthyunjaya,
   prithvi/0000-0003-1087-9736; Beadle, Beth/0000-0001-5497-2831
CR Abbas H, 2014, MED PHYS, V41, DOI 10.1118/1.4866224
   Adams J A, 1999, Med Dosim, V24, P233, DOI 10.1016/S0958-3947(99)00024-2
   Agostinelli S, 2003, NUCL INSTRUM METH A, V506, P250, DOI 10.1016/S0168-9002(03)01368-8
   Asur R, 2015, CANCER LETT, V356, P52, DOI 10.1016/j.canlet.2013.10.032
   Avila MP, 2012, RETINA-J RET VIT DIS, V32, P10, DOI 10.1097/IAE.0b013e31822528fc
   Bielajew A., 2013, MONTE CARLO TECHNIQU, P3
   Bouchet A, 2015, PHYS MEDICA, V31, P634, DOI 10.1016/j.ejmp.2015.04.014
   Brand C, 2018, EYE, V32, P1345, DOI 10.1038/s41433-018-0080-9
   CHAKRAVARTHY U, 1989, CURR EYE RES, V8, P337, DOI 10.3109/02713688908996381
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Crosbie JC, 2010, INT J RADIAT ONCOL, V77, P886, DOI 10.1016/j.ijrobp.2010.01.035
   DEGOWIN RL, 1974, J LAB CLIN MED, V84, P42
   Deng H, 2007, PHYS MED BIOL, V52, P2729, DOI 10.1088/0031-9155/52/10/007
   Dugel PU, 2013, OPHTHALMOLOGY, V120, P317, DOI 10.1016/j.ophtha.2012.07.068
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Finger PT, 2008, INT J RADIAT ONCOL, V70, P974, DOI 10.1016/j.ijrobp.2007.11.045
   Finger PT, 2003, BRIT J OPHTHALMOL, V87, P1497, DOI 10.1136/bjo.87.12.1497
   Finger PT, 1998, ARCH OPHTHALMOL-CHIC, V116, P1507, DOI 10.1001/archopht.116.11.1507
   Flaxel CJ, 2000, EYE, V14, P155, DOI 10.1038/eye.2000.46
   Freiberg FJ, 2019, BRIT J OPHTHALMOL, V103, P469, DOI 10.1136/bjophthalmol-2018-311865
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gertner M, 2010, MED PHYS, V37, P600, DOI 10.1118/1.3291648
   Girkin CA, 1997, OPHTHALMOLOGY, V104, P1634, DOI 10.1016/S0161-6420(97)30084-0
   Group COMS, 1995, COLL OC MEL STUD MAN
   Gupta A, 2008, RETINA-J RET VIT DIS, V28, P964, DOI 10.1097/IAE.0b013e3181706302
   Hanlon J, 2009, MED PHYS, V36, P3671, DOI 10.1118/1.3168554
   HART PM, 1995, BRIT J OPHTHALMOL, V79, P562, DOI 10.1136/bjo.79.6.562
   Hart PM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1029
   Hopewell JW, 2000, RADIOTHER ONCOL, V56, P283, DOI 10.1016/S0167-8140(00)00236-X
   Hwang JC, 2011, OPHTHAL SURG LAS IM, V42, DOI 10.3928/15428877-20100924-01
   Jackson TL, 2016, OPHTHALMOLOGY, V123, P1287, DOI 10.1016/j.ophtha.2016.02.028
   Jackson TL, 2015, OPHTHALMOLOGY, V122, P138, DOI 10.1016/j.ophtha.2014.07.043
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1893, DOI 10.1016/j.ophtha.2013.02.016
   JOHNSON LK, 1982, ANAL QUANT CYTOL, V4, P188
   Kishan AU, 2013, INT J RADIAT ONCOL, V85, P583, DOI 10.1016/j.ijrobp.2012.07.2352
   Leavitt JA, 2013, INT J RADIAT ONCOL, V87, P524, DOI 10.1016/j.ijrobp.2013.06.2047
   Lee C, 2008, MED PHYS, V35, P5151, DOI 10.1118/1.2990780
   MacDonald Carolyn A., 2010, X-Ray and Optics Instrumentation, DOI 10.1155/2010/867049
   MacDonald SJ, 2000, CLIN ORTHOP RELAT R, P30
   Miller Joan W, 2017, US Ophthalmic Rev, V10, P119, DOI 10.17925/USOR.2017.10.02.119
   NCRP, 1999, 130 NCRP
   Neffendorf JE, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1676-7
   Neffendorf JE, 2015, CLIN OPHTHALMOL, V9, P1829, DOI 10.2147/OPTH.S75638
   Neuner G, 2012, INT J RADIAT ONCOL, V82, P1642, DOI 10.1016/j.ijrobp.2011.01.065
   Park SS, 2012, RETINA-J RET VIT DIS, V32, P956, DOI 10.1097/IAE.0b013e31822a8d6a
   Petrarca Robert, 2014, Retina, V34, P874, DOI 10.1097/IAE.0000000000000026
   Pollock BE, 2014, NEUROSURGERY, V75, P456, DOI 10.1227/NEU.0000000000000457
   Punnoose J, 2016, MED PHYS, V43, P4711, DOI 10.1118/1.4955438
   Rath BK, 1998, J APPL PHYS, V83, P7424, DOI 10.1063/1.367986
   Rodel F, 2015, CANCER LETT, V356, P105, DOI 10.1016/j.canlet.2013.09.015
   Salvat F., 2015, NUCL EN AG DAT BANK
   Schmitz R, 2011, PROC SPIE, V8141, DOI 10.1117/12.894730
   Sechopoulos I, 2018, MED PHYS, V45, pe1, DOI 10.1002/mp.12702
   Senan S, 2007, ONCOLOGIST, V12, P465, DOI 10.1634/theoncologist.12-4-465
   Solomon SG, 2014, FRONT NEURAL CIRCUIT, V8, DOI 10.3389/fncir.2014.00096
   Stafford SL, 2003, INT J RADIAT ONCOL, V55, P1177, DOI 10.1016/S0360-3016(02)04380-8
   Taddei PJ, 2010, PHYS MED BIOL, V55, P7037, DOI 10.1088/0031-9155/55/23/S06
   Trikha R, 2011, RETINA-J RET VIT DIS, V31, P1303, DOI 10.1097/IAE.0b013e318203ee46
   van Asten F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197670
   Wang L, 1999, P SOC PHOTO-OPT INS, V3767, P102, DOI 10.1117/12.371107
   WILLIAMSON JF, 1987, MED PHYS, V14, P567, DOI 10.1118/1.596069
   Yan HG, 2018, MED PHYS, V45, P4720, DOI 10.1002/mp.13144
   Zambarakji HJ, 2006, OPHTHALMOLOGY, V113, P2012, DOI 10.1016/j.ophtha.2006.05.036
NR 63
TC 1
Z9 1
U1 1
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0094-2405
EI 2473-4209
J9 MED PHYS
JI Med. Phys.
PD OCT
PY 2020
VL 47
IS 10
BP 5123
EP 5134
DI 10.1002/mp.14404
EA AUG 2020
PG 12
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA OS5EZ
UT WOS:000558589300001
PM 32683708
DA 2022-11-30
ER

PT J
AU Valmaggia, C
   Ries, G
   Ballinari, P
AF Valmaggia, C
   Ries, G
   Ballinari, P
TI Radiotherapy for subfoveal choroidal neovascularization in age-related
   macular degeneration: A randomized clinical trial
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID LOW-DOSE RADIATION; IRRADIATION; TELETHERAPY; MANAGEMENT; MEMBRANES;
   THERAPY; DAMAGE
AB PURPOSE: To report results of 18-month follow up of external beam radiation therapy with photons for subfoveal classic or occult choroidal neovascularization (CNV) in age-related macular degeneration (ARMD).
   DESIGN: Randomized clinical trial.
   METHODS: A total of 161 patients with subfoveal CNV in ARMD were recruited in a prospective double-masked study. The posterior pole of the afflicted eye was given 1 Gy (4 x 0.25 Gy) in the control group and 8 Gy (4 X 2 Gy) or 16 Gy (4 X 4 Gy) in the treatment groups. At the time of treatment, and 6, 12, and 18 months post treatment, best-corrected visual acuity (BCVA), reading ability, and CNV size were measured.
   RESULTS: At the completion of the study 150 (93.2%), 139 (86.3%), and 137 (85.1%) patients were followed for 6, 12, and 18 months, respectively. The mean number of lines lost in the BCVA was -1.69, -2.2, and -3.23 in the 1 Gy group; -94, -1.25, and -1.73 in the 8 Gy group; -0.51, -0.67, and - 1.93 in the 16 Gy group. The difference was significant after 12 months W = .016 for 8 Gy vs. 1 Gy; P = .006 for 16 Gy vs. 1 Gy), and 18 months (P = .011 for 8 Gy vs. 1 Gy; P = .05 for 16 Gy vs. I Gy). The patients with classic CNV, or with an initial distance visual acuity greater than or equal to20/100, benefited more from treatment. A significant difference was not found between control group and treatment groups in the reading ability and in the CNV size. No radiation-associated side effects were reported thus far.
   CONCLUSION: The number of lines lost in the BCVA was less in the 8 Gy and 16 Gy treatment groups than in the control group during the complete follow up examination. Radiation therapy with 8 Gy and 16 Gy, without showing any difference in efficacy, resulted in a near stabilization of the BCVA in patients with subfoveal classic or occult CNV in ARMD. Further studies are necessary to determine the significance of repeated radiotherapy series with a dose of 8 Gy to improve the effect on the CNV size and thereby to prolong stabilization of distance visual acuity. (C) 2002 by Elsevier Science Inc. All rights reserved.
C1 Kantonsspital St Gallen, Dept Ophthalmol, St Gallen, Switzerland.
   Kantonsspital St Gallen, Dept Radiat Oncol, St Gallen, Switzerland.
   Univ Bern, Dept Psychol, Bern, Switzerland.
C3 Kantonsspital St. Gallen; Kantonsspital St. Gallen; University of Bern
RP Valmaggia, C (通讯作者)，Sonnenbergstr 36, CH-9030 Abtwil, Switzerland.
EM valmaggia@freesurf.ch
CR ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   ALLEN JB, 1981, LANCET, V2, P1193
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   ARCHAMBEAU J, 1988, INT J RADIAT ONCOL, V15, P1125
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Bach M, 1998, KLIN MONATSBL AUGENH, V212, P190, DOI 10.1055/s-2008-1034863
   Bergink GJ, 1998, GRAEF ARCH CLIN EXP, V236, P321, DOI 10.1007/s004170050085
   BISCHOFF PM, 1995, RETINA-J RET VIT DIS, V15, P91, DOI 10.1097/00006982-199515020-00002
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2000, AM J OPHTHALMOL, V130, P387
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   Chakravarthy U, 2000, BRIT J RADIOL, V73, P305, DOI 10.1259/bjr.73.867.10817048
   Char DH, 1999, AM J OPHTHALMOL, V127, P574, DOI 10.1016/S0002-9394(99)00038-0
   DuBosar R, 1999, J Ophthalmic Nurs Technol, V18, P60
   FELTEN G, 1968, THESIS U AUGENKLINIK
   Fine SL, 2001, ARCH OPHTHALMOL-CHIC, V119, P275
   GORDON KB, 1995, INT J RADIAT ONCOL, V31, P1123, DOI 10.1016/0360-3016(95)00062-4
   GUYER DR, 1986, ARCH OPHTHALMOL-CHIC, V104, P702, DOI 10.1001/archopht.1986.01050170092029
   Haas A, 2000, J NEUROSURG, V93, P172, DOI 10.3171/jns.2000.93.supplement_3.0172
   HAIMOVITZFRIEDMAN A, 1991, CANCER RES, V51, P2552
   Hart PM, 1997, FRONT RADIAT THER ON, V30, P229
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   Jaakkola A, 1999, ACTA OPHTHALMOL SCAN, V77, P57, DOI 10.1034/j.1600-0420.1999.770113.x
   Kobayashi H, 2000, AM J OPHTHALMOL, V130, P617, DOI 10.1016/S0002-9394(00)00534-1
   Lipowsky H H, 1988, Adv Exp Med Biol, V242, P85
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   Marcus DM, 2001, ARCH OPHTHALMOL-CHIC, V119, P171
   Moyers MF, 1999, MED PHYS, V26, P777, DOI 10.1118/1.598587
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   Postgens H, 1997, GRAEF ARCH CLIN EXP, V235, P656, DOI 10.1007/BF00946943
   RAICU M, 1993, MUTAGENESIS, V8, P335, DOI 10.1093/mutage/8.4.335
   Schilling H, 1997, BRIT J OPHTHALMOL, V81, P267, DOI 10.1136/bjo.81.4.267
   Sheils WC, 2001, MED RAD DIA IMG, P187
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Teichmann K D, 1997, Eur J Med Res, V2, P445
   Tholen AM, 1998, OPHTHALMOLOGE, V95, P691, DOI 10.1007/s003470050337
   TRAUZETTELKLOSI.S, 1997, AGE REALTED MACULAR, P180
   Valmaggia C, 1997, DOC OPHTHALMOL, V93, P317, DOI 10.1007/BF02569069
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   Wolf S, 1999, GRAEF ARCH CLIN EXP, V237, P51, DOI 10.1007/s004170050194
   YANNUZZI LA, 1994, ARCH OPHTHALMOL-CHIC, V112, P462, DOI 10.1001/archopht.1994.01090160038019
NR 44
TC 37
Z9 38
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2002
VL 133
IS 4
BP 521
EP 529
AR PII S0002-9394(02)01336-3
DI 10.1016/S0002-9394(02)01336-3
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 538DE
UT WOS:000174798200012
PM 11931786
DA 2022-11-30
ER

PT J
AU Klein, ML
   Francis, PJ
   Rosner, B
   Reynolds, R
   Hamon, SC
   Schultz, DW
   Ott, J
   Seddon, JM
AF Klein, Michael L.
   Francis, Peter J.
   Rosner, Bernard
   Reynolds, Robyn
   Hamon, Sara C.
   Schultz, Dennis W.
   Ott, Jurg
   Seddon, Johanna M.
TI CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and
   zinc for age-related macular degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; OXIDATIVE STRESS; FACTOR-I; POLYMORPHISM; VARIANT;
   RISK; SUSCEPTIBILITY; ASSOCIATION; PHARMACOGENOMICS; PROTEIN
AB Objective: To determine if CFH and LOC387715/ARMS2 genotypes influence treatment response to AREDS-type nutritional supplementation with antioxidants and zinc.
   Design: Retrospective analysis of participants in a randomized, controlled clinical trial, the Age-Related Eye Disease Study (AREDS).
   Participants and/or Controls: Eight hundred seventy-six AREDS study participants who were considered at high risk for developing advanced age-related macular degeneration (AMD). Methods
   : Using DNA extracted from venous blood of 876 white participants in AREDS categories 3 and 4, that is, those considered to be at high risk for progression to advanced AMD, the authors genotyped for the single nucleotide polymorphisms in the CFH (Y402H, rs1061170) and LOC387715/ARMS2 (A69S, rs10490924) genes. The authors performed adjusted unconditional logistic regression analysis and assessed interactions of these genotypes to determine the relationship between CFH and LOC387715/ARMS2 genotype and treatment with antioxidants plus zinc.
   Main Outcome Measures: Interaction between genetic variants and treatment response as determined by progression from high-risk to advanced AMD.
   Results: Progression occurred in 264 of 876 patients from AREDS category 3 (intermediate AMD) to category 4 or 5 (unilateral or bilateral advanced AMD, respectively), or from category 4 to category 5. A treatment interaction was observed between the CFH Y402H genotype and supplementation with antioxidants plus zinc (CC; P = 0.03). An interaction (P = 0.004) was observed in the AREDS treatment groups taking zinc when compared with the groups taking no zinc, but not in groups taking antioxidants compared with those taking no antioxidants (P = 0.59). There were no significant treatment interactions observed with LOC387715/ARMS2.
   Conclusions: The findings of this study indicate that an individual's response to AREDS supplements may be related to CFH genotype. This could have clinical relevance by predicting treatment outcome and potentially preventing unwanted side effects in those who may not benefit. Corroboration of these analyses is needed before considering modification of current management. This is among the first pharmacogenetic studies to suggest interaction between genotype and treatment.
C1 [Reynolds, Robyn; Seddon, Johanna M.] Tufts Univ New England Med Ctr, Ophthalm Epidemiol & Genet Serv, Boston, MA USA.
   [Klein, Michael L.; Francis, Peter J.; Schultz, Dennis W.] Oregon Hlth & Sci Univ, Casey Eye Int, Macular Degenerat Ctr, Portland, OR 97239 USA.
   [Rosner, Bernard] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
   [Hamon, Sara C.; Ott, Jurg] Rockefeller Univ, Lab Stat Genet, New York, NY 10021 USA.
   [Ott, Jurg] Chinese Acad Sci, Beijing Inst Genom, Beijing, Peoples R China.
C3 Tufts Medical Center; Oregon Health & Science University; Harvard
   University; Harvard T.H. Chan School of Public Health; Rockefeller
   University; Chinese Academy of Sciences; Beijing Institute of Genomics,
   CAS
RP Klein, ML (通讯作者)，Oregon Hlth & Sci Univ, Casey Eye Int, Macular Degenerat Ctr, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
EM kleinm@ohsu.edu; jseddon@tufts-nemc.org
FU NATIONAL EYE INSTITUTE [R01EY021532, R01EY011309, R01EY012203] Funding
   Source: NIH RePORTER; NEI NIH HHS [R01 EY021532, R01-EY11309,
   R01-EY12203] Funding Source: Medline
CR Arranz M J, 2001, Am J Pharmacogenomics, V1, P3, DOI 10.2165/00129785-200101010-00001
   Barry ELR, 2006, J NATL CANCER I, V98, P1494, DOI 10.1093/jnci/djj398
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Blom AM, 2003, ARCH BIOCHEM BIOPHYS, V418, P108, DOI 10.1016/j.abb.2003.08.018
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Depondt C, 2006, PHARMACOGENOMICS, V7, P731, DOI 10.2217/14622416.7.5.731
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gorin MB, 2007, ARCH OPHTHALMOL-CHIC, V125, P21, DOI 10.1001/archopht.125.1.21
   Grant SFA, 2007, EXPERT REV MOL DIAGN, V7, P371, DOI 10.1586/14737159.7.4.371
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hess KR, 2006, J CLIN ONCOL, V24, P4236, DOI 10.1200/JCO.2006.05.6861
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kang HJ, 2004, CLIN EXP IMMUNOL, V136, P194, DOI 10.1111/j.1365-2249.2004.02450.x
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kumar RE, 2002, MOL IMMUNOL, V39, P69, DOI 10.1016/S0161-5890(02)00046-9
   Lerer Bernard, 2006, Dialogues Clin Neurosci, V8, P85
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Manunta P, 2006, J AM SOC NEPHROL, V17, pS30, DOI 10.1681/ASN.2005121346
   Mares JA, 2006, ARCH OPHTHALMOL-CHIC, V124, P1339, DOI 10.1001/archopht.124.9.1339
   PERKINS SJ, 1991, BIOCHEMISTRY-US, V30, P2847, DOI 10.1021/bi00225a017
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Scheurig AC, 2008, EUR J CLIN NUTR, V62, P127, DOI 10.1038/sj.ejcn.1602687
   Seddon JM, 2007, AM J CLIN NUTR, V85, p304S, DOI 10.1093/ajcn/85.1.304S
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Soames CJ, 1997, BIOCHEM J, V326, P553, DOI 10.1042/bj3260553
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Vaziri ND, 2006, NAT CLIN PRACT NEPHR, V2, P582, DOI 10.1038/ncpneph0283
   Weiss ST, 2006, PHARMACOGENOMICS J, V6, P311, DOI 10.1038/sj.tpj.6500387
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu JM, 2007, BIOCHEMISTRY-US, V46, P8451, DOI 10.1021/bi700459a
NR 40
TC 129
Z9 134
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2008
VL 115
IS 6
BP 1019
EP 1025
DI 10.1016/j.ophtha.2008.01.036
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 306XX
UT WOS:000256282800015
PM 18423869
DA 2022-11-30
ER

PT J
AU Thill, M
   Berna, MJ
   Kunst, F
   Wege, H
   Strunnikova, NV
   Gordiyenko, N
   Grierson, R
   Richard, G
   Csaky, KG
AF Thill, Michelle
   Berna, Marc J.
   Kunst, Frank
   Wege, Henning
   Strunnikova, Natalya V.
   Gordiyenko, Natalya
   Grierson, Rebecca
   Richard, Gisbert
   Csaky, Karl G.
TI SU5416 induces premature senescence in endothelial progenitor cells from
   patients with age-related macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; HEMATOPOIETIC STEM-CELLS;
   FIBROBLAST GROWTH FACTOR-2; RECEPTOR 2 INHIBITOR; SMOOTH-MUSCLE-CELLS;
   PROTEIN-KINASE-C; IN-VIVO; REPLICATIVE SENESCENCE; TELOMERASE
   INACTIVATION; DIFFERENTIAL REGULATION
AB Purpose: We recently demonstrated increased frequency and growth potential of late outgrowth endothelial progenitor cells (OECs) in patients with neovascular age-related macular degeneration (nvAMD). This study investigated the effects of short-and long-term in vitro inhibition of vascular endothelial growth factor (VEGF) Receptor-2 (VEGFR-2) signaling by SU5416 and other inhibitors of the VEGF signaling pathway in OECs.
   Methods: OECs, from the peripheral blood of patients with nvAMD, and human umbilical vein endothelial cells were grown in the presence of SU5416, other VEGFR-2 tyrosine kinase inhibitors (TKIs), and inhibitors of phosphatidylinositol 3'-Kinase (PI3K)/protein kinase B (Akt) and protein kinase C (PKC) in complete angiogenic medium. Apotosis was assessed after 48 h using the fluorescein isothiocyanate Annexin V method. Cell counts were performed for 10 days, and features of senescence were analyzed using senescence-associated beta-galactosidase staining, the telomeric repeat amplification protocol for telomerase activity, Southern blot analysis for mean telomere length, flow cytometric analysis for cell-cycle arrest, and western blot for p53 and p21. Control OECs, cells treated for 7 days with inhibitors, as well as naturally senescent OECs were analyzed for expression of different endothelial antigens, including VEGFR-2 and the receptor for stromal cell-derived factor 1, chemokine receptor 4 (CXCR-4). Migration in vitro to VEGF and stromal cell-derived factor 1 of OECs was assessed.
   Results: SU5416, other VEGFR-2 TKIs, and inhibitors of PI3K, Akt, and PKC induced apoptosis, inhibited long-term proliferation, reduced telomerase activity, and induced premature senescence and cell-cycle arrest in OECs as well as in human umbilical vein endothelial cells. Naturally senescent cells and cells rendered senescent by VEGFR-2 TKIs had reduced VEGFR-2 and CXCR-4 expression and demonstrated reduced migratory ability to VEGF.
   Conclusions: This study demonstrates apoptosis upon short-term inhibition and inhibition of long-term survival of OECs from patients with nvAMD by SU5416, presumably via PI3K/Akt and/or PKC-mediated reduction in telomerase activity and subsequent induction of premature senescence, which is accompanied by impaired endothelial activity. Therefore, induction of premature senescence in endothelial cells may represent a potential therapeutic target in nvAMD.
C1 [Thill, Michelle; Kunst, Frank; Grierson, Rebecca; Richard, Gisbert] Univ Hosp Hamburg Eppendorf, Klin & Poliklin Augenheilkunde, D-20246 Hamburg, Germany.
   [Berna, Marc J.; Wege, Henning] Univ Hosp Hamburg Eppendorf, Med Klin 1, D-20246 Hamburg, Germany.
   [Strunnikova, Natalya V.; Gordiyenko, Natalya] NEI, NIH, Bethesda, MD 20892 USA.
   [Csaky, Karl G.] Duke Univ, Duke Univ Eye Ctr, Durham, NC USA.
C3 University of Hamburg; University Medical Center Hamburg-Eppendorf;
   University of Hamburg; University Medical Center Hamburg-Eppendorf;
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Duke University
RP Thill, M (通讯作者)，Univ Hosp Hamburg Eppendorf, Klin & Poliklin Augenheilkunde, Martinistr 52, D-20246 Hamburg, Germany.
EM mthill@uke.de
FU Ministry of Culture, Higher Education and Research of Luxembourg [BFR
   04/109]
FX This work was partly supported by a grant (BFR 04/109) from the Ministry
   of Culture, Higher Education and Research of Luxembourg to M. Thill. We
   thank the nurses and staff of the NIH Eye Clinic and we are grateful to
   the patients who participated in this study.
CR Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964
   AUGUSTINVOSS HG, 1993, J CELL PHYSIOL, V157, P279, DOI 10.1002/jcp.1041570210
   Bladier C, 1997, CELL GROWTH DIFFER, V8, P589
   Breitschopf K, 2001, FEBS LETT, V493, P21, DOI 10.1016/S0014-5793(01)02272-4
   Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Cavallaro Ugo, 2000, Molecular Cell Biology Research Communications, V4, P203, DOI 10.1006/mcbr.2001.0278
   Chan-Ling T, 2006, AM J PATHOL, V168, P1031, DOI 10.2353/ajpath.2006.050697
   Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599
   Chen QM, 2000, BIOCHEM J, V347, P543, DOI 10.1042/0264-6021:3470543
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Csaky KG, 2004, EXP EYE RES, V78, P1107, DOI 10.1016/j.exer.2004.01.010
   De Falco E, 2004, BLOOD, V104, P3472, DOI 10.1182/blood-2003-12-4423
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   Doukas J, 2008, J CELL PHYSIOL, V216, P29, DOI 10.1002/jcp.21426
   Erusalimsky J D, 2006, Handb Exp Pharmacol, P213
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P369, DOI 10.1016/j.exer.2004.10.005
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P4914, DOI 10.1167/iovs.03-0371
   Fong TAT, 1999, CANCER RES, V59, P99
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   Gewirtz DA, 2008, BIOCHEM PHARMACOL, V76, P947, DOI 10.1016/j.bcp.2008.06.024
   Glade-Bender J, 2003, EXPERT OPIN BIOL TH, V3, P263, DOI 10.1517/eobt.3.2.263.21157
   Hampel B, 2004, EXP GERONTOL, V39, P1713, DOI 10.1016/j.exger.2004.05.010
   Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005
   HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9
   Hoffmann J, 2001, CIRC RES, V89, P709, DOI 10.1161/hh2001.097796
   Imanishi T, 2006, ATHEROSCLEROSIS, V189, P288, DOI 10.1016/j.atherosclerosis.2005.12.031
   Itokawa T, 2002, MOL CANCER THER, V1, P295
   Kalashnik L, 2000, MECH AGEING DEV, V120, P23, DOI 10.1016/S0047-6374(00)00179-2
   Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698
   Kurz DJ, 2003, ARTERIOSCL THROM VAS, V23, P748, DOI 10.1161/01.ATV.0000069624.55424.61
   Li B, 2006, FASEB J, V20, P1495, DOI 10.1096/fj.05-5137fje
   Li Y, 2006, INVEST OPHTH VIS SCI, V47, P1646, DOI 10.1167/iovs.05-1092
   MACIAG T, 1981, J CELL BIOL, V91, P420, DOI 10.1083/jcb.91.2.420
   MATSUDA T, 1992, J CELL PHYSIOL, V150, P510, DOI 10.1002/jcp.1041500311
   Mendel DB, 2000, ANTI-CANCER DRUG DES, V15, P29
   Mendel DB, 2000, CLIN CANCER RES, V6, P4848
   Moore MAS, 2001, ANN NY ACAD SCI, V938, P36
   Murayama T, 2002, EXP HEMATOL, V30, P967, DOI 10.1016/S0301-472X(02)00867-6
   Palanki MSS, 2008, J MED CHEM, V51, P1546, DOI 10.1021/jm7011276
   Pammer J, 2006, LAB INVEST, V86, P997, DOI 10.1038/labinvest.3700461
   Parkinson EK, 2007, BIODRUGS, V21, P375, DOI 10.2165/00063030-200721060-00005
   Petit I, 2007, TRENDS IMMUNOL, V28, P299, DOI 10.1016/j.it.2007.05.007
   Roninson IB, 2003, CANCER RES, V63, P2705
   ROSEN EM, 1981, J CELL PHYSIOL, V107, P123, DOI 10.1002/jcp.1041070114
   Sengupta N, 2003, INVEST OPHTH VIS SCI, V44, P4908, DOI 10.1167/iovs.03-0342
   Shaheen RM, 1999, CANCER RES, V59, P5412
   Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5
   Sheridan CM, 2006, INVEST OPHTH VIS SCI, V47, P1642, DOI 10.1167/iovs.05-0779
   Smolich BD, 2001, BLOOD, V97, P1413, DOI 10.1182/blood.V97.5.1413
   Takahashi H, 2006, J OCUL PHARMACOL TH, V22, P213, DOI 10.1089/jop.2006.22.213
   Takahashi H, 2008, CURR EYE RES, V33, P1002, DOI 10.1080/02713680802492440
   Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527
   Takeda A, 2003, GRAEF ARCH CLIN EXP, V241, P765, DOI 10.1007/s00417-003-0688-7
   Thill M, 2008, INVEST OPHTH VIS SCI, V49, P2696, DOI 10.1167/iovs.07-0955
   Trivier E, 2004, ANN NY ACAD SCI, V1019, P111, DOI 10.1196/annals.1297.020
   van der Loo B, 1998, EXP CELL RES, V241, P309, DOI 10.1006/excr.1998.4035
   Wagner M, 2001, EXP GERONTOL, V36, P1327, DOI 10.1016/S0531-5565(01)00105-X
   Walter S, 2003, CRIT REV ONCOL HEMAT, V46, pS41, DOI 10.1016/S1040-8428(03)00063-5
   Watanabe Y, 1997, ONCOGENE, V14, P2025, DOI 10.1038/sj.onc.1201033
   Wege H, 2003, GASTROENTEROLOGY, V124, P432, DOI 10.1053/gast.2003.50064
   Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096
   Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006
   Yodoi Y, 2007, INVEST OPHTH VIS SCI, V48, P5464, DOI 10.1167/iovs.07-0093
   Zaccagnini G, 2005, J BIOL CHEM, V280, P14790, DOI 10.1074/jbc.M414644200
   Zhou XM, 2006, MECH AGEING DEV, V127, P779, DOI 10.1016/j.mad.2006.07.003
   Zhu JH, 2006, J MOL CELL CARDIOL, V40, P648, DOI 10.1016/j.yjmcc.2006.01.011
   Zimmermann S, 2007, CELL MOL LIFE SCI, V64, P906, DOI 10.1007/s00018-007-6481-8
NR 68
TC 9
Z9 9
U1 0
U2 3
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JAN 10
PY 2011
VL 17
IS 11-12
BP 85
EP 98
PG 14
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 707VH
UT WOS:000286316800002
PM 21245959
DA 2022-11-30
ER

PT J
AU Mehta, A
   Steel, DH
   Muldrew, A
   Peto, T
   Reeves, BC
   Evans, R
   Chakravarthy, U
AF Mehta, Alexander
   Steel, David H.
   Muldrew, Alyson
   Peto, Tunde
   Reeves, Barnaby C.
   Evans, Rebecca
   Chakravarthy, Usha
CA IVAN Study Investigators
TI Associations and Outcomes of Patients with Submacular Hemorrhage
   Secondary to Age-related Macular Degeneration in the IVAN Trial
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL ANGIOMATOUS PROLIFERATION; SUBRETINAL HEMORRHAGE; CHOROIDAL
   NEOVASCULARIZATION; INTRAOCULAR HEMORRHAGE; NATURAL-HISTORY;
   RANIBIZUMAB; EYES; LESIONS; BLOOD; RISK
AB PURPOSE: To compare demographics, visual acuity (VA) and retinal morphology between those with, and without baseline submacular hemorrhage (SMH) for patients enrolled in the Inhibit VEGF in Age-related Choroidal Neovascularization trial (IVAN).
   DESIGN: Secondary analyses of a randomized, controlled trial of image and clinical data.
   METHODS: Setting; The IVAN trial collected data in 23 UK hospitals. Study population; IVAN study eyes (with untreated neovascular age-related macular degeneration at randomization) with at least 12 months of follow-up and adequate imaging. Intervention; Study eyes were randomly assigned between monthly ranibizumab, as-needed ranibizumab, monthly bevacizumab, or as-needed bevacizumab. Imaging at baseline was graded independently for the presence, type, position, and extent of SMH. Main outcome measures; The main outcome measures were VA (primary outcome), subretinal fibrosis, atrophic scarring, and retinal thickness outcomes at 12 and 24 months
   RESULTS: Of 605 IVAN trial participants, 535 were included in this analysis. Patients with SMH at baseline (286 [53%]) were older (P = .010) and affected eyes were more likely to have intraretinal fluid present (P = .038). The VA was significantly worse in those with baseline SMH at month 0 (P < .001; estimate of difference 6 letters; 95% CIs, 4-8 letters), but the difference decreased and was not significant at month 12 or 24. No significant association was found between baseline SMH and subretinal fibrosis, atrophic scarring, or central retinal thickness.
   CONCLUSIONS: The presence of SMH at baseline was associated with age, intraretinal fluid, and decreased baseline VA. By month 12, VA was no longer significantly different in those who presented with SMH at baseline. (C) 2021 Elsevier Inc. All rights reserved.
C1 [Mehta, Alexander; Steel, David H.] Newcastle Univ, Biosci Inst, Newcastle Upon Tyne, Tyne & Wear, England.
   [Steel, David H.] Sunderland Eye Infirm, Sunderland, England.
   [Muldrew, Alyson; Peto, Tunde; Chakravarthy, Usha] Queens Univ Belfast, Inst Clin Sci, Belfast, Antrim, North Ireland.
   [Reeves, Barnaby C.; Evans, Rebecca] Univ Bristol, Bristol Trials Ctr, Bristol, Avon, England.
C3 Newcastle University - UK; Queens University Belfast; University of
   Bristol
RP Steel, DH (通讯作者)，Sunderland Eye Infirm, Dept Ophthalmol, Queen Alexandra Rd, Sunderland SR2 9HP, England.
EM david.steel@newcastle.ac.uk
RI ; Peto, Tunde/M-2081-2013; Steel, David/I-8053-2015
OI Chakravarthy, Usha/0000-0002-2606-3734; Evans,
   Rebecca/0000-0002-7119-8187; Peto, Tunde/0000-0001-6265-0381; Reeves,
   Barnaby/0000-0002-5101-9487; Mehta, Alexander/0000-0003-0578-816X;
   Steel, David/0000-0001-8734-3089
FU National Institute for Health Research Health Technology Assessment
   programme [07/36/01]
FX The IVAN trial was funded by the National Institute for Health Research
   Health Technology Assessment programme (project number 07/36/01). No
   additional funding has been received for this study.
CR Altaweel MM, 2015, OPHTHALMOLOGY, V122, P391, DOI 10.1016/j.ophtha.2014.08.020
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Caceres JA, 2012, EMERG MED CLIN N AM, V30, P771, DOI 10.1016/j.emc.2012.06.003
   Chakravarthy U, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19780
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chang MA, 2010, RETINA-J RET VIT DIS, V30, P1171, DOI 10.1097/IAE.0b013e3181dd6d8a
   Daniel E, 2016, OPHTHALMOLOGY, V123, P609, DOI 10.1016/j.ophtha.2015.10.034
   Forte R, 2009, EYE, V23, P2071, DOI 10.1038/eye.2008.363
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Jani B, 2006, POSTGRAD MED J, V82, P357, DOI 10.1136/pgmj.2005.036053
   Jonas JB, 1999, SURV OPHTHALMOL, V43, P293, DOI 10.1016/S0039-6257(98)00049-6
   Kiernan DF, 2010, RETINA-J RET VIT DIS, V30, P1573, DOI 10.1097/IAE.0b013e3181e2266d
   Kim JH, 2014, BRIT J OPHTHALMOL, V98, P1066, DOI 10.1136/bjophthalmol-2013-304405
   Kim Kun Hae, 2015, Korean J Ophthalmol, V29, P315, DOI 10.3341/kjo.2015.29.5.315
   KLEIN ML, 1991, JAMA-J AM MED ASSOC, V266, P2279
   Kuhli-Hattenbach C, 2010, AM J OPHTHALMOL, V149, P316, DOI 10.1016/j.ajo.2009.08.033
   Li TM, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03137-x
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McBain VA, 2011, RETINA-J RET VIT DIS, V31, P1043, DOI 10.1097/IAE.0b013e3181fe54c7
   Moon SW, 2013, J OCUL PHARMACOL TH, V29, P556, DOI 10.1089/jop.2012.0148
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shin JY, 2015, AM J OPHTHALMOL, V159, P904, DOI 10.1016/j.ajo.2015.01.024
   Shultz RW, 2011, SEMIN OPHTHALMOL, V26, P361, DOI 10.3109/08820538.2011.585368
   Solomon SD, 2007, ARCH OPHTHALMOL-CHIC, V125, P1323
   Stanescu-Segall D, 2016, SURV OPHTHALMOL, V61, P18, DOI 10.1016/j.survophthal.2015.04.004
   Steel DHW, 2011, BRIT J OPHTHALMOL, V95, P1051, DOI 10.1136/bjo.2010.182253
   Tilanus MAD, 2000, GRAEF ARCH CLIN EXP, V238, P482, DOI 10.1007/PL00007887
   van Meurs JC, 2020, EYE, V34, P997, DOI 10.1038/s41433-019-0719-1
   Varshney N, 2013, CAN J OPHTHALMOL, V48, P210, DOI 10.1016/j.jcjo.2013.01.023
   Wang Y, 2006, BRIT J OPHTHALMOL, V90, P353, DOI 10.1136/bjo.2005.081521
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Ying GS, 2016, OPHTHALMOLOGY, V123, P352, DOI 10.1016/j.ophtha.2015.09.046
NR 35
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2022
VL 236
BP 89
EP 98
DI 10.1016/j.ajo.2021.09.033
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4X3ZY
UT WOS:000860785500010
PM 34626573
OA Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Jabs, DA
   Van Natta, ML
   Trang, G
   Jones, NG
   Milush, JM
   Cheu, R
   Klatt, NR
   Danis, RP
   Hunt, PW
AF Jabs, Douglas A.
   Van Natta, Mark L.
   Trang, Garrett
   Jones, Norman G.
   Milush, Jeffrey M.
   Cheu, Ryan
   Klatt, Nichole R.
   Danis, Ronald P.
   Hunt, Peter W.
TI Association of Age-related Macular Degeneration With Mortality in
   Patients With Acquired Immunodeficiency Syndrome; Role of Systemic
   Inflammation
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID C-REACTIVE PROTEIN; ANTIRETROVIRAL THERAPY; HIV-INFECTION; INDOLEAMINE
   2,3-DIOXYGENASE; COLLABORATIVE ANALYSIS; PREDICT MORTALITY; ACTIVATION;
   RISK; MORBIDITY; DISEASE
AB PURPOSE: To evaluate the relationships among age-related macular degeneration (AMD), mortality, and biomarkers of systemic inflammation in patients with acquired immunodeficiency syndrome (AIDS).
   DESIGN: Case-control study.
   METHODS: In participants with intermediate-stage AMD at enrollment in the Longitudinal Study of the Ocular Complications of AIDS (LSOCA) and 2:1 controls matched for age and sex, cryopreserved baseline plasma specimens were assayed for biomarkers of inflammation, including high-sensitivity C-reactive protein (CRP), interleukin (IL)-6, interferon-7 inducible protein (IP)-10, soluble CD14 (sCD14), soluble CD163 (sCD163), kynurenine/tryptophan (KT) ratio, and intestinal fatty acid binding protein (I-FABP). Main outcome measure was mortality.
   RESULTS: The study included 189 patients with AMD and 385 controls. In the unadjusted analysis, AMD was associated with mortality (hazard ratio [HR] 1.48; 95% confidence interval [CI] 1.02, 2.15; P = .04). In an adjusted analysis, CRP (HR 1.36; 95% CI 1.08, 1.71; P = .009), IL-6 (HR 1.45; 95% CI 1.11, 1.90; P = .006), and IP-10 (HR 1.41; 95% CI 1.08, 1.84; P = .01) were associated with mortality. In a Cox regression analysis adjusted for human immunodeficiency virus load, blood CD4+ T cell level, CRP, IL-6, and IP-10, the association of AMD with mortality was attenuated (HR 1.08; 95% CI 0.73, 1.59; P = .70), primarily by the addition of the inflammatory biomarkers.
   CONCLUSIONS: These data suggest that the increased mortality observed in patients with AIDS with AMD is, at least in part, a result of systemic inflammation. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Jabs, Douglas A.] Icahn Sch Med Mt Sinai, Dept Ophthalmol, One Gustave L Levy Pl,Box 1183, New York, NY 10029 USA.
   [Jabs, Douglas A.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY USA.
   [Jabs, Douglas A.; Van Natta, Mark L.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Trang, Garrett; Jones, Norman G.; Milush, Jeffrey M.; Hunt, Peter W.] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA USA.
   [Cheu, Ryan] Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA.
   [Klatt, Nichole R.] Univ Miami, Miller Sch Med, Dept Pediat, Miami, FL 33136 USA.
   [Danis, Ronald P.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med & Publ Hlth, Madison, WI USA.
C3 Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at
   Mount Sinai; Johns Hopkins University; Johns Hopkins Bloomberg School of
   Public Health; University of California System; University of California
   San Francisco; University of Washington; University of Washington
   Seattle; University of Miami; University of Wisconsin System; University
   of Wisconsin Madison
RP Jabs, DA (通讯作者)，Icahn Sch Med Mt Sinai, Dept Ophthalmol, One Gustave L Levy Pl,Box 1183, New York, NY 10029 USA.
EM douglas.jabs@mssm.edu
RI Hunt, Peter W./P-2976-2017
OI Hunt, Peter W./0000-0002-4571-4870
FU NATIONAL EYE INSTITUTE, THE NATIONAL INSTITUTES OF Health, Bethesda,
   Maryland, USA [EY025093]; NATIONAL EYE INSTITUTE [R01EY025093] Funding
   Source: NIH RePORTER
FX SUPPORTED BY GRANT EY025093 FROM THE NATIONAL EYE INSTITUTE, THE
   NATIONAL INSTITUTES OF Health, Bethesda, Maryland, USA.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Age-Related Eye Disease Study 2 Research Group, 2018, OPHTHALMOLOGY, V125, P512
   Ancuta P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002516
   Boasso A, 2007, BLOOD, V109, P3351, DOI 10.1182/blood-2006-07-034785
   Boulware DR, 2011, J INFECT DIS, V203, P1637, DOI 10.1093/infdis/jir134
   Byakwaga H, 2014, J INFECT DIS, V210, P383, DOI 10.1093/infdis/jiu115
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Cooney EL, 2002, CLIN INFECT DIS, V34, P224, DOI 10.1086/323898
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Deeks SG, 2011, ANNU REV MED, V62, P141, DOI 10.1146/annurev-med-042909-093756
   French MA, 2009, J INFECT DIS, V200, P1212, DOI 10.1086/605890
   Gill J, 2010, CLIN INFECT DIS, V50, P1387, DOI 10.1086/652283
   Harris TB, 1999, AM J MED, V106, P506, DOI 10.1016/S0002-9343(99)00066-2
   Hogg R, 2008, LANCET, V372, P293, DOI 10.1016/S0140-6736(08)61113-7
   Hunt PW, 2014, J INFECT DIS, V210, P1228, DOI 10.1093/infdis/jiu238
   Jabs DA, 2007, OPHTHALMOLOGY, V114, P780, DOI 10.1016/j.ophtha.2006.11.008
   Jabs DA, 2017, AM J OPHTHALMOL, V179, P151, DOI 10.1016/j.ajo.2017.05.004
   Jabs DA, 2015, AM J OPHTHALMOL, V159, P1115, DOI 10.1016/j.ajo.2015.01.037
   Jabs DA, 2011, AM J OPHTHALMOL, V151, P198, DOI 10.1016/j.ajo.2010.10.018
   Kaplan RC, 2007, CLIN INFECT DIS, V45, P1074, DOI 10.1086/521935
   Kilpatrick RD, 2008, J IMMUNOL, V180, P1499, DOI 10.4049/jimmunol.180.3.1499
   Knudsen TB, 2016, J INFECT DIS, V214, P1198, DOI 10.1093/infdis/jiw263
   Kuller LH, 2008, PLOS MED, V5, P1496, DOI 10.1371/journal.pmed.0050203
   Lederman MM, 2013, ADV IMMUNOL, V119, P51, DOI 10.1016/B978-0-12-407707-2.00002-3
   Lee S, 2017, J INFECT DIS, V215, P1270, DOI 10.1093/infdis/jix113
   Lohse N, 2007, ANN INTERN MED, V146, P87, DOI 10.7326/0003-4819-146-2-200701160-00003
   McGuinness MB, 2017, OPHTHAL EPIDEMIOL, V24, P141, DOI 10.1080/09286586.2016.1259422
   Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303
   Murphy EL, 2001, ANN INTERN MED, V135, P17, DOI 10.7326/0003-4819-135-1-200107030-00005
   Nassar K, 2013, GRAEFES ARCH CLIN EX, V253, P699
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Pathai S, 2014, J GERONTOL A-BIOL, V69, P833, DOI 10.1093/gerona/glt168
   Pertovaara M, 2006, MECH AGEING DEV, V127, P497, DOI 10.1016/j.mad.2006.01.020
NR 33
TC 5
Z9 5
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2019
VL 199
BP 230
EP 237
DI 10.1016/j.ajo.2018.12.002
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HO5VU
UT WOS:000460997100027
PM 30552890
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Boekhoorn, SS
   Isaacs, A
   Uitterlinden, AG
   van Duijn, CM
   Hofman, A
   de Jong, PTVM
   Vingerling, JR
AF Boekhoorn, Sharmila S.
   Isaacs, Aaron
   Uitterlinden, Andre G.
   van Duijn, Cornelia M.
   Hofman, Albert
   de Jong, Paulus T. V. M.
   Vingerling, Johannes R.
TI Polymorphisms in the Vascular Endothelial Growth Factor Gene and Risk of
   Age-related Macular Degeneration The Rotterdam Study
SO OPHTHALMOLOGY
LA English
DT Article
ID VISUAL IMPAIRMENT; VEGF; MACULOPATHY; ASSOCIATION; PREVALENCE;
   BLINDNESS; GENOTYPE; LEVEL
AB Purpose: Vascular endothelial growth factor (VEGF) is an important regulator of angiogenesis and a target for inhibition therapy in wet age-related macular degeneration (AMD). The purpose of this study was to examine whether genetic variation in the VEGF gene is associated with AMD and, especially, with its wet end stage.
   Design: Prospective population-based cohort study.
   Participants: Four thousand two hundred twenty-eight participants aged 55 years and older.
   Methods: AMD was classified according to a modified International Classification System using fundus color images. Genotypes and haplotypes were determined for 3 functional VEGF single nucleotide polymorphisms (SNPs): C-2578A, G-1154A, and G-634C. Cox proportional hazards regression analyses were used to investigate possible associations between the individual SNPs and incident AMD. The Haplo.Stats program was used to test the associations between VEGF gene haplotypes and incident AMD.
   Main Outcome Measure: AMD
   Results: Of 4228 participants at risk for incident early and late AMD for whom blood specimens were available for VEGF genotyping, incident early AMD developed in 514 and incident late AMD developed in 89 (35 dry and 54 wet) after a mean follow-up of 7.4 years. None of the SNPs showed a significant association with incident early or late AMD, especially not with incident wet AMD. Haplotype analyses also detected no associations.
   Conclusions: The a priori hypothesis that 3 common SNPs in the VEGF gene would be a risk factor for AMD, especially the wet form, could not be confirmed.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2008; 115:1899-1903 (C) 2008 by the American Academy of Ophthalmology.
C1 [Boekhoorn, Sharmila S.; Isaacs, Aaron; Uitterlinden, Andre G.; van Duijn, Cornelia M.; Hofman, Albert; de Jong, Paulus T. V. M.; Vingerling, Johannes R.] Erasmus MC, Dept Epidemiol & Biostat, Rotterdam, Netherlands.
   [Uitterlinden, Andre G.] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.
   [de Jong, Paulus T. V. M.] KNAW, Netherlands Inst Neurosci, Amsterdam, Netherlands.
   [de Jong, Paulus T. V. M.] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands.
   [Vingerling, Johannes R.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
C3 Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam;
   Erasmus MC; Royal Netherlands Academy of Arts & Sciences; Netherlands
   Institute for Neuroscience (NIN-KNAW); University of Amsterdam; Academic
   Medical Center Amsterdam; Erasmus University Rotterdam; Erasmus MC
RP Vingerling, JR (通讯作者)，POB 2040, NL-3000 CA Rotterdam, Netherlands.
EM j.vingerling@erasmusmc.nl
OI Van Duijn, Cornelia/0000-0002-2374-9204
CR Ahn JK, 2005, AM J OPHTHALMOL, V139, P923, DOI 10.1016/j.ajo.2004.10.055
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Awata T, 2004, DIABETES CARE, V27, P2184, DOI 10.2337/diacare.27.9.2184
   Balasubramanian L, 2006, CURR OPIN ONCOL, V18, P354, DOI 10.1097/01.cco.0000228741.64541.ca
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Boekhoorn SS, 2007, INVEST OPHTH VIS SCI, V48, P1012, DOI 10.1167/iovs.06-0577
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Del Bo R, 2005, ANN NEUROL, V57, P373, DOI 10.1002/ana.20390
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Epstein MP, 2003, AM J HUM GENET, V73, P1316, DOI 10.1086/380204
   Ferrante M, 2006, INFLAMM BOWEL DIS, V12, P870, DOI 10.1097/01.mib.0000235095.01608.10
   Ferrara N, 2001, ACTA HAEMATOL-BASEL, V106, P148, DOI 10.1159/000046610
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2000, RECENT PROG HORM RES, V55, P15
   Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Hofman A, 2007, EUR J EPIDEMIOL, V22, P819, DOI 10.1007/s10654-007-9199-x
   Jacobs EJ, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1400
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Lake SL, 2003, HUM HERED, V55, P56, DOI 10.1159/000071811
   Pettipher R, 2002, PHARMACOGENOMICS, V3, P257, DOI 10.1517/14622416.3.2.257
   Shahbazi M, 2002, J AM SOC NEPHROL, V13, P260, DOI 10.1681/ASN.V131260
   TIELSCH JM, 1995, NEW ENGL J MED, V332, P1205, DOI 10.1056/NEJM199505043321806
   Van Der Meer P, 2005, J CARD FAIL, V11, P279, DOI 10.1016/j.cardfail.2004.11.006
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3
   Watson WH, 2000, ANNU REV NUTR, V20, P485, DOI 10.1146/annurev.nutr.20.1.485
   Yamamori M, 2004, BIOCHEM BIOPH RES CO, V325, P144, DOI 10.1016/j.bbrc.2004.10.005
NR 34
TC 44
Z9 46
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2008
VL 115
IS 11
BP 1899
EP 1903
DI 10.1016/j.ophtha.2008.06.026
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 365ZO
UT WOS:000260448900007
PM 18708255
DA 2022-11-30
ER

PT J
AU Wu, ZC
   Ayton, LN
   Luu, CD
   Guymer, RH
AF Wu, Zhichao
   Ayton, Lauren N.
   Luu, Chi D.
   Guymer, Robyn H.
TI Longitudinal Changes in Microperimetry and Low Luminance Visual Acuity
   in Age-Related Macular Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; GEOGRAPHIC ATROPHY; FUNDUS
   AUTOFLUORESCENCE; DRUSEN; MACULOPATHY; RANIBIZUMAB; DYSFUNCTION;
   PROGRESSION
AB IMPORTANCE There is a need for more sensitive measures of disease in intermediate age-related macular degeneration (AMD) to evaluate novel interventions more effectively and expediently.
   OBJECTIVE To determine if microperimetry and low luminance visual acuity can detect functional changes over a short duration of follow-up.
   DESIGN, SETTING, AND PARTICIPANTS Prospective longitudinal examination of 49 participants with consecutive AMD and 10 healthy participants in a research clinic from May 1, 2012, to December 31, 2013. Forty-one participants had intermediate AMD, 8 had nonfoveal geographic atrophy due to AMD. Participants underwent microperimetry examinations in 1 eye during a 12-month period at 6-month intervals for participants with AMD and at baseline and 12 months for control participants; low luminance visual acuity was performed at baseline and at 12 months for all participants. Changes in pathological features of intermediate AMD eyes were determined using side-by-side comparisons of color fundus photographs from the initial and final visit as remaining stable, progressed, or improved.
   MAIN OUTCOMES AND MEASURES Microperimetric sensitivity and low luminance visual acuity.
   RESULTS A reduction in mean (SE) microperimetric pointwise sensitivity was identified at 12 months compared with the baseline for intermediate AMD eyes graded as stable (-0.31 dB [0.10 dB]; P =.003) or worsened (-0.42 dB [0.12 dB]; P <.001) and an improvement in mean (SE) pointwise sensitivity was identified in eyes graded as improved (1.13 dB [0.23 dB]; P <.001). A reduction in mean (SE) pointwise sensitivity was identified in eyes with nonfoveal geographic atrophy at both 6 months (-1.41 dB [0.22 dB]; P <.001) and 12 months compared with the baseline (-2.56 dB [0.22 dB]; P <.001) while a change in mean (SE) pointwise sensitivity was not identified over the 12-month period for control participants (-0.11 dB [0.11 dB]; P =.34). No changes in best-corrected visual acuity or low luminance visual acuity were identified in all groups over the 12-month period (P >=.07).
   CONCLUSIONS AND RELEVANCE Microperimetry detected subtle changes in visual function over a 12-month period in eyes with intermediate AMD but visual acuity measures did not identify any such changes. These findings suggest that microperimetry is worth exploring as a method for assessing the efficacy of novel interventions for intermediate AMD potentially requiring a shorter duration of follow-up.
C1 [Wu, Zhichao; Ayton, Lauren N.; Luu, Chi D.; Guymer, Robyn H.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic 3002, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP Wu, ZC (通讯作者)，Univ Melbourne, Macular Res Unit, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, 32 Gisborne St,Level 1, East Melbourne, Vic 3002, Australia.
EM wu.z@unimelb.edu.au
RI Ayton, Lauren/AAV-2977-2021
OI Ayton, Lauren/0000-0001-9907-084X; Guymer, Robyn/0000-0002-9441-4356;
   Luu, Chi/0000-0002-7604-7097
CR Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   CHENG AS, 1993, OPTOMETRY VISION SCI, V70, P89, DOI 10.1097/00006324-199302000-00001
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Hartmann KI, 2012, RETINA-J RET VIT DIS, V32, P1492, DOI 10.1097/IAE.0b013e318242b949
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Lesmes Luis Andres, 2013, Drug Discov Today Ther Strateg, V10, pe43, DOI 10.1016/j.ddstr.2012.11.002
   Meleth AD, 2011, INVEST OPHTH VIS SCI, V52, P1119, DOI 10.1167/iovs.10-6075
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Parravano M, 2009, RETINA-J RET VIT DIS, V29, P329, DOI 10.1097/IAE.0b013e31819093e6
   Pilotto E, 2013, BRIT J OPHTHALMOL, V97, P622, DOI 10.1136/bjophthalmol-2012-302633
   Puell MC, 2012, INVEST OPHTH VIS SCI, V53, P7310, DOI 10.1167/iovs.11-8649
   Sallo FB, 2009, BRIT J OPHTHALMOL, V93, P1345, DOI 10.1136/bjo.2008.150334
   Shelley EJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P483, DOI 10.1001/archophthalmol.2008.622
   Squirrell DM, 2010, RETINA-J RET VIT DIS, V30, P436, DOI 10.1097/IAE.0b013e3181bd2f29
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Tikellis G, 2007, EYE, V21, P169, DOI 10.1038/sj.eye.6702151
   Toy BC, 2013, AM J OPHTHALMOL, V156, P532, DOI 10.1016/j.ajo.2013.04.031
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Wu ZC, 2014, INVEST OPHTH VIS SCI, V55, P6431, DOI 10.1167/iovs.14-14407
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1445, DOI 10.1016/j.ophtha.2014.01.025
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yehoshua Z, 2013, INVEST OPHTH VIS SCI, V54, P2429, DOI 10.1167/iovs.12-11569
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
NR 31
TC 54
Z9 54
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD APR
PY 2015
VL 133
IS 4
BP 442
EP 448
DI 10.1001/jamaophthalmol.2014.5963
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CI8CK
UT WOS:000354995100022
PM 25632841
OA Bronze
DA 2022-11-30
ER

PT J
AU Eleftheriadou, M
   Vazquez-Alfageme, C
   Citu, CM
   Crosby-Nwaobi, R
   Sivaprasad, S
   Hykin, P
   Hamilton, RD
   Patel, PJ
AF Eleftheriadou, Maria
   Vazquez-Alfageme, Clara
   Citu, Cristina Maria
   Crosby-Nwaobi, Roxanne
   Sivaprasad, Sobha
   Hykin, Philip
   Hamilton, Robin D.
   Patel, Praveen J.
TI Long-Term Outcomes of Aflibercept Treatment for Neovascular Age-Related
   Macular Degeneration in a Clinical Setting
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RANIBIZUMAB
AB PURPOSE: To report 2-year treatment outcomes with intravitreal aflibercept for neovascular age-related macular degeneration (nAMD) in routine clinical practice.
   DESIGN: Retrospective, nonrandomized, interventional case series.
   METHODS: Retrospective analysis of electronic medical record (EMR) notes (OpenEyes) and paper case notes and review of spectral-domain optical coherence tomography (SDOCT) imaging of patients with consecutively treated eyes with previously untreated nAMD. Patients were commenced on aflibercept injections in 1 or both eyes from October 1, 2013 to December 31, 2013. Data including age, sex, visual acuity (VA) measured on Early Treatment Diabetic Retinopathy Study charts, injection episodes, and complications were recorded. Additionally,.SDOCT data, including presence or absence of macular fluid and automated central subfield macular thickness (CSMT) at year 1 and 2, were recorded.
   RESULTS: Of the 109 eyes of 102 patients treated, data from 94 eyes of 88 patients were available at 2-year follow-up (86% of patients). In the analysis of 2-year outcomes, there were 58 women (65.9%); the mean (+/- standard deviation) age was 77.5 +/- 8 years. Over the 2 years, these eyes received a median of 12 (mean, 11.4 +/- 4) injections at a median of 100 (mean, 99.3 +/- 5.3) weeks of follow-up. The mean VA changed from 55.9 +/- 15 letters at baseline to 61.3 +/- 16.9 letters (VA gain 5.4 letters) at 1 year and to 61 +/- 17.1 letters (VA gain 5.1 +/- 14.9 letters) at 2 years. The reduction in CSMT was 79 mu m with absence of macular fluid in 72.7% of the 88 eyes with SDOCT data available at 2-year follow-up.
   CONCLUSIONS: The VA and SDOCT results compare favorably with outcomes seen in randomized controlled trials. The results suggest that good long-term outcomes can be achieved using aflibercept for nAMD in clinical settings. (C) 2016 Elsevier Inc. All rights reserved.
C1 Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.
   UCL Inst Ophthalmol, London, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London
RP Patel, PJ (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, 162 City Rd, London EC1V 2PD, England.
EM praveen.patel@moorfields.nhs.uk
RI Sivaprasad, S./D-6876-2015
OI Sivaprasad, S./0000-0001-8952-0659; Vazquez-Alfageme,
   Clara/0000-0003-2921-5024
FU Department of Health's NIHR Biomedical Research Centre at Moorfields Eye
   Hospital; UCL Institute of Ophthalmology
FX DRS ELEFTHERIADOU, VAZQUEZ-ALFAGEME, CROSBY-NWAOBI, SIVAPRASAD, HYKIN,
   HAMILTON, AND Patel have received a proportion of their funding from the
   Department of Health's NIHR Biomedical Research Centre at Moorfields Eye
   Hospital and UCL Institute of Ophthalmology. The views expressed in the
   publication are those of the authors and not necessarily those of the
   Department of Health.
CR Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P676, DOI 10.1016/j.ophtha.2013.09.050
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Pushpoth S, 2012, BRIT J OPHTHALMOL, V96, P1469, DOI 10.1136/bjophthalmol-2012-302167
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
NR 13
TC 30
Z9 35
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2017
VL 174
BP 160
EP 168
DI 10.1016/j.ajo.2016.09.038
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EJ3YN
UT WOS:000393148800019
PM 27746298
DA 2022-11-30
ER

PT J
AU Sura, AA
   Chen, L
   Messinger, JD
   Swain, TA
   McGwin, G
   Freund, KB
   Curcio, CA
AF Sura, Amol A.
   Chen, Ling
   Messinger, Jeffrey D.
   Swain, Thomas A.
   McGwin, Gerald, Jr.
   Freund, K. Bailey
   Curcio, Christine A.
TI Measuring the Contributions of Basal Laminar Deposit and Bruch's
   Membrane in Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE basal laminar deposit; basal laminar deposit (BLamD); age-related
   macular degeneration (AMD); age-related macular degeneration;
   histopathology; histology; retinal pigment epithelium; Bruch's membrane;
   basal linear deposit; drusen; optical coherence tomography (OCT);
   segmentation; neovascularization
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL-PIGMENT EPITHELIUM; LINEAR
   DEPOSIT; CHOROIDAL NEOVASCULARIZATION; MORPHOMETRIC-ANALYSIS; MALATTIA
   LEVENTINESE; GEOGRAPHIC ATROPHY; DRUSEN VOLUME; OUTER RETINA; IV
   COLLAGEN
AB PURPOSE. Basal laminar deposit (BLamD) is a consistent finding in age-related macular degeneration (AMD). We quantified BLamD thickness, appearance, and topography in eyes of aged donors with and without AMD and evaluated its relationship to other components of the retinal pigment epithelium-basal lamina/Bruch's membrane (RPE-BL-BrM) complex.
   METHODS. Donor eyes (n = 132) were classified as normal (n = 54), early to intermediate AMD (n = 24), geographic atrophy (GA; n = 13), and neovascular AMD (NV; n = 41). In high-resolution histology, we assessed RPE, BLamD, and BrM thicknesses and phenotypes at 3309 predefined locations in the central (foveal and perifovea) and superior (perifoveal) sections. Pre-mortem optical coherence tomography (OCT) imaging of a 90-year-old woman was compared to postmortem histopathology.
   RESULTS. In non-atrophic areas of AMD eyes, the RPE-BLamD is thick (normal = 13.7 mu m, early-intermediate = 16.8 mu m, GA = 17.4 mu m, NV = 18.7 mu m), because the BLamD is thick (normal = 0.3 mu m, early-intermediate = 5.5 mu m, GA = 4.1 mu m, NV = 5.3 mu m). RPE layer thickness is similar across these stages. Disease-associated variants of BLamD (thick, late, basal mounds) cluster subfoveally. A thick BLamD is visible on OCT as a hyporeflective split in the RPE-BL-BrM complex. BrM is thin (3.5 mu m) in NV (normal = 4.2 mu m, early to intermediate = 4.4 mu m, and GA = 4.2 mu m).
   CONCLUSIONS. The RPE-BL-BrM complex is thick in AMD, driven by the accumulation and expansion of BLamD rather than expansion of either three-layer BrM, RPE-BL, or RPE. BLamD is clinically appreciable by OCT in some patients as a non-neovascular "split RPEBL-BrM complex" or "double-layer sign." BLamD may contribute toward the formation and progression of high-risk drusen yet also exhibit protective properties.
C1 [Sura, Amol A.; Chen, Ling; Messinger, Jeffrey D.; Swain, Thomas A.; McGwin, Gerald, Jr.; Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol & Visual Sci, Birmingham, AL 35294 USA.
   [Chen, Ling] Chongqing Med Univ, Affiliated Hosp 1, Chongqing Key Lab Ophthalmol, Chongqing, Peoples R China.
   [Chen, Ling] Chongqing Eye Inst, Chongqing, Peoples R China.
   [Swain, Thomas A.; McGwin, Gerald, Jr.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.
   [Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Freund, K. Bailey] Univ Tsukuba, Dept Ophthalmol, Fac Med, Ibaraki, Japan.
   [Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Freund, K. Bailey] NYU, Dept Ophthalmol, Langone Sch Med, 550 1St Ave, New York, NY 10016 USA.
   [Freund, K. Bailey] Columbia Univ Coll Phys & Surg, Harkness Eye Inst, 630 W 168th St, New York, NY 10032 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   Chongqing Medical University; University of Alabama System; University
   of Alabama Birmingham; Vitreous Retina Macula Consultants of New York;
   University of Tsukuba; Manhattan Eye Ear & Throat Hospital; New York
   University; NYU Langone Medical Center; Columbia University
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Dept Ophthalmol & Visual Sci, EyeSight Fdn, Alabama Vis Res Labs,Sch Med, 1670 Univ Blvd,Room 360, Birmingham, AL 35294 USA.
EM christinecurcio@uabmc.edu
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU National Institutes of Health (NIH) [R01EY06019, P30 EY003039]; EyeSight
   Foundation of Alabama; International Retinal Research Foundation; Edward
   N. and Della L. Thome Foundation; Arnold and Mabel Beckman Initiative
   for Macular Research; Research to Prevent Blindness
FX The Project MACULA website and the recovery of human donor eyes for
   research has been supported by National Institutes of Health (NIH)
   grants R01EY06019 and P30 EY003039, EyeSight Foundation of Alabama,
   International Retinal Research Foundation, Edward N. and Della L. Thome
   Foundation, the Arnold and Mabel Beckman Initiative for Macular
   Research, and Research to Prevent Blindness. Purchase of the slide
   scanner was made possible by the Carl G. and Pauline Buck Trust.
CR [Anonymous], 1997, DIAGNOSIS TREATMENT
   Balaratnasingam C, 2018, OPHTHALMOLOGY, V125, P100, DOI 10.1016/j.ophtha.2017.08.033
   Balaratnasingam C, 2016, AM J OPHTHALMOL, V172, P28, DOI 10.1016/j.ajo.2016.09.008
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Bergen AAB, 2000, NAT GENET, V25, P228, DOI 10.1038/76109
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, pBIO141, DOI 10.1167/iovs.17-21789
   Bressler NM, 2006, AGE RELATED MACULAR, VII, P1041
   Castro-Rodriguez JA, 2018, PEDIATR PULM, V53, P824, DOI 10.1002/ppul.23968
   Chekuri A, 2019, AGING CELL, V18, DOI 10.1111/acel.13011
   Chen L, 2003, BRIT J OPHTHALMOL, V87, P212, DOI 10.1136/bjo.87.2.212
   Chen L, 2020, OPHTHALMOLOGY, V127, P931, DOI 10.1016/j.ophtha.2020.01.040
   Chen L, 2020, RETINA-J RET VIT DIS, V40, P618, DOI 10.1097/IAE.0000000000002657
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Cuenca N, 2018, OPHTHALMOLOGY, V125, P407, DOI 10.1016/j.ophtha.2017.09.016
   Cukras C, 2016, RETINA-J RET VIT DIS, V36, P2348, DOI 10.1097/IAE.0000000000001113
   Cunningham A, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0853-8
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Curcio CA, 2012, RETINA
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   FEENEYBURNS L, 1985, AM J OPHTHALMOL, V100, P686, DOI 10.1016/0002-9394(85)90625-7
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P3761, DOI 10.1167/iovs.10-7021
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Galloway CA, 2017, P NATL ACAD SCI USA, V114, pE8214, DOI 10.1073/pnas.1710430114
   Garland DL, 2014, HUM MOL GENET, V23, P52, DOI 10.1093/hmg/ddt395
   Gass JD., 1977, STEREOSCOPIC ATLAS M, V2
   Gass JDM, 1967, AM J OPHTHALMOL, V63, P45
   Gliem M, 2015, INVEST OPHTH VIS SCI, V56, P2664, DOI 10.1167/iovs.14-15733
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12711
   Gubbiotti MA, 2017, MATRIX BIOL, V57-58, P285, DOI 10.1016/j.matbio.2016.09.003
   GUYTON JR, 1988, J HISTOCHEM CYTOCHEM, V36, P1319, DOI 10.1177/36.10.2458408
   Halfter W, 2015, FEBS J, V282, P4466, DOI 10.1111/febs.13495
   Han QX, 2017, FRONT MED-PRC, V11, P319, DOI 10.1007/s11684-017-0569-9
   Hayward C, 2003, HUM MOL GENET, V12, P2657, DOI 10.1093/hmg/ddg289
   Jean-Charles A, 2016, OPHTHALMOLOGY, V123, P2196, DOI 10.1016/j.ophtha.2016.06.028
   Jean-Charles A, 2013, RETINA-J RET VIT DIS, V33, P1041, DOI 10.1097/IAE.0b013e3182733ff3
   Jiang M, 2015, J CELL BIOL, V210, P595, DOI 10.1083/jcb.201410112
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   KILLINGSWORTH MC, 1995, GRAEF ARCH CLIN EXP, V233, P313, DOI 10.1007/BF00200479
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Knupp C, 2002, J STRUCT BIOL, V137, P31, DOI 10.1006/jsbi.2002.4449
   Knupp C, 2000, J STRUCT BIOL, V129, P38, DOI 10.1006/jsbi.1999.4202
   Lee B, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.7.12
   Li ML, 2019, RETINA-J RET VIT DIS, V39, P802, DOI 10.1097/IAE.0000000000002461
   Li MY, 2014, HUM MOL GENET, V23, P4001, DOI 10.1093/hmg/ddu114
   LOFFLER KU, 1986, GRAEF ARCH CLIN EXP, V224, P493, DOI 10.1007/BF02154735
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mak KM, 2017, ANAT REC, V300, P1371, DOI 10.1002/ar.23567
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   Marmorstein Lihua, 2004, Ophthalmic Genet, V25, P219, DOI 10.1080/13816810490498305
   MARSHALL GE, 1992, BRIT J OPHTHALMOL, V76, P607, DOI 10.1136/bjo.76.10.607
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Meunier I, 2016, HUM MOL GENET, V25, P916, DOI 10.1093/hmg/ddv624
   Milam AH, 2000, OPHTHALMOLOGY, V107, P2256, DOI 10.1016/S0161-6420(00)00419-X
   Molina-Pallete Rodrigo, 2021, Retin Cases Brief Rep, V15, P294, DOI 10.1097/ICB.0000000000000789
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Ooto S, 2014, JAMA OPHTHALMOL, V132, P806, DOI 10.1001/jamaophthalmol.2014.1871
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Pollreisz A, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.8.13
   Pollreisz A, 2018, EXP EYE RES, V166, P131, DOI 10.1016/j.exer.2017.10.018
   Pozzi A, 2017, MATRIX BIOL, V57-58, P1, DOI 10.1016/j.matbio.2016.12.009
   Querques G, 2015, RETINA-J RET VIT DIS, V35, P1735, DOI 10.1097/IAE.0000000000000553
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x
   SARKS SH, 1975, MED J AUSTRALIA, V2, P602, DOI 10.5694/j.1326-5377.1975.tb106118.x
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Sayegh RG, 2014, BRIT J OPHTHALMOL, V98, P1050, DOI 10.1136/bjophthalmol-2014-305195
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schultz R, 2018, INVEST OPHTH VIS SCI, V59
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Shirazi MF, 2020, BIOMED OPT EXPRESS, V11, P4520, DOI 10.1364/BOE.393906
   Sleiman K, 2017, OPHTHALMOLOGY, V124, P1764, DOI 10.1016/j.ophtha.2017.06.032
   Sohn EH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086538
   Song DL, 2018, INVEST OPHTH VIS SCI, V59, P3405, DOI 10.1167/iovs.18-24133
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Steinberg JS, 2013, INVEST OPHTH VIS SCI, V54, P4054, DOI 10.1167/iovs.12-11538
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Tan ACS, 2017, INVEST OPHTH VIS SCI, V58, P2349, DOI 10.1167/iovs.16-21237
   van den Brink H, 2018, STROKE, V49, P1899, DOI 10.1161/STROKEAHA.118.020810
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   VANDERSCHAFT TL, 1993, GRAEF ARCH CLIN EXP, V231, P470, DOI 10.1007/BF02044234
   Waldstein SM, 2020, JAMA OPHTHALMOL, V138, P740, DOI 10.1001/jamaophthalmol.2020.1376
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang Q, 1996, INVEST OPHTH VIS SCI, V37, P2234
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1445, DOI 10.1016/j.ophtha.2014.01.025
   Yiu G, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.2.32
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
NR 106
TC 30
Z9 30
U1 2
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2020
VL 61
IS 13
AR 19
DI 10.1167/iovs.61.13.19
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PA0NK
UT WOS:000595313500011
PM 33186466
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Jurgens, F
   Rothaus, K
   Faatz, H
   Heimes-Bussmann, B
   Pauleikhoff, D
   Lommatzsch, AP
AF Juergens, Frauke
   Rothaus, Kai
   Faatz, Henrik
   Heimes-Bussmann, Britta
   Pauleikhoff, Daniel
   Lommatzsch, Albrecht Peter
TI Quantification of Early and Intermediate Age-related Macular
   Degeneration Using OCT "en face" Presentation
SO KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
LA English
DT Article
DE early and intermediate AMD; drusen area; number of drusen
ID OPTICAL COHERENCE TOMOGRAPHY; DRUSEN AREA; SEGMENTATION; CLASSIFICATION;
   AMD
AB Background Early and intermediate age-related macular degeneration (AMD) results in drusen deposits under the retinal pigment epithelium (RPE). These early stages of AMD exhibit different risks of progressing to late AMD. To date, early AMD has been classified and quantified by fundus photography. This does not appear to be sensitive enough for clinical trials studying the impact on drusen. SD-OCTwith two-dimensional rendering of the segmented slices analysed allows for en face imaging of the drusen. The present trial studied the potential of quantifying early and intermediate AMD by en-face optical coherence tomography (OCT).
   Material and Methods Thirty- one eyes of 29 patients in different stages of early and intermediate AMD were studied. To this end, fundus photographs (Kowa VX-10i, Kowa, Tokyo, Japan) and en-face OCT images (RTVue XR Avanti, Optovue, Inc., Fremont, CA, USA) were taken. First, different segmentation levels (6 mu m underneath the RPE, on the RPE, 6 mu m and 9 mu m above the RPE) and different layer thicknesses (5 mu m, 10 mu m, 20 mu m and 30 mu m) were analysed to determine the best segmentation for visualising drusen. Drusen were marked manually and their number and surface area calculated. This analysis was then compared with the standardised drusen analyses on fundus photography. Additional changes in early and intermediate AMD such as pigment epithelial detachments (PEDs) and subretinal drusenoid deposits (SDD) as well as small atrophies were also documented and compared.
   Outcomes The best segmentation for delineating the drusen on the en- face OCT images was found to be a segmentation 6 mu m underneath the RPE with a slice thickness of 20 mu m. Comparison of drusen quantification on en-face OCT images with the standardised drusen analysis on fundus photography revealed particularly good similarity. Other changes in early and intermediate AMD, such as PEDs, SDD and small atrophies, were easier to assess on the en-face OCT images.
   Conclusions The analysis and quantification of drusen from en-face OCT images with 20 mu m segmentation at 6 mu m underneath the RPE allows differentiated quantification of various drusen characteristics. Moreover, other changes in early and intermediate AMD can also be analysed. In future observational and clinical trials, this could help quantify drusen.
C1 [Juergens, Frauke; Rothaus, Kai; Faatz, Henrik; Heimes-Bussmann, Britta; Pauleikhoff, Daniel; Lommatzsch, Albrecht Peter] Augenzentrum St Franziskus Hosp Munster, Retinol, Hohenzollernring 74, D-48145 Munster, Germany.
   [Pauleikhoff, Daniel; Lommatzsch, Albrecht Peter] Univ Duisburg Essen, Zentrum Augenheilkunde, Duisburg, Germany.
C3 University of Duisburg Essen
RP Jurgens, F (通讯作者)，Augenzentrum St Franziskus Hosp Munster, Retinol, Hohenzollernring 74, D-48145 Munster, Germany.
EM frauke.juergens@gmx.de
OI Rothaus, Kai/0000-0002-4288-8795; Heimes-Bussmann,
   Britta/0000-0003-3898-1679
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Burlina P, 2017, COMPUT BIOL MED, V82, P80, DOI 10.1016/j.compbiomed.2017.01.018
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Deutsche Ophthalmologische Gesellschaft, 2015, KLIN MONBL AUGENHEIL, V232, P196, DOI [10.1055/s-0034, DOI 10.1055/S-0034-1396155]
   Diniz B, 2014, RETINA-J RET VIT DIS, V34, P55, DOI 10.1097/IAE.0b013e31829d0015
   Fang LY, 2017, BIOMED OPT EXPRESS, V8, P2732, DOI 10.1364/BOE.8.002732
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fleckenstein M, 2011, ALTERSABHANGIGE MAKU, P125, DOI [10.1007/978-3-642-20870-6_8, DOI 10.1007/978-3-642-20870-6_8]
   Freeman SR, 2010, RETINA-J RET VIT DIS, V30, P431, DOI 10.1097/IAE.0b013e3181bd2f94
   Gregori G, 2014, INVEST OPHTH VIS SCI, V55, P7662, DOI 10.1167/iovs.14-15273
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Heimann H, 2010, ATLAS AUGENHINTERGRU, DOI [10.1055/ b-0034-40446, DOI 10.1055/B-0034-40446]
   Kellner S, 2013, TEIL 2 MORPHOLOGISCH, V3, P219, DOI 10.1055/s-0032
   Kumari K, 2015, ADV IMAGE VIDEO PROC, V3, P28, DOI [10.14738/aivp.33.1291, DOI 10.14738/AIVP.33.1291]
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Nathoo NA, 2014, AM J OPHTHALMOL, V158, P757, DOI 10.1016/j.ajo.2014.06.021
   Nittala MG, 2012, INVEST OPHTH VIS SCI, V53, P8319, DOI 10.1167/iovs.12-10582
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Treder M, 2019, KLIN MONATSBL AUGENH, V236, P1418, DOI 10.1055/a-1012-2036
   van Grinsven MJJP, 2013, INVEST OPHTH VIS SCI, V54, P3019, DOI 10.1167/iovs.12-11449
   Venhuizen FG, 2017, INVEST OPHTH VIS SCI, V58, P2318, DOI 10.1167/iovs.16-20541
   von Strachwitz CN, 2013, OPHTHALMOLOGE, V110, P555, DOI 10.1007/s00347-012-2757-y
   Yehoshua Z, 2013, INVEST OPHTH VIS SCI, V54, P2429, DOI 10.1167/iovs.12-11569
NR 26
TC 0
Z9 0
U1 0
U2 3
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0023-2165
EI 1439-3999
J9 KLIN MONATSBL AUGENH
JI Klinische Monatsblat. Augenheilkunde
PD JAN
PY 2022
VL 239
IS 01
BP 79
EP 85
DI 10.1055/a-1327-3633
EA JAN 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0O9WM
UT WOS:000615349900001
PM 33513622
DA 2022-11-30
ER

PT J
AU Tan, CS
   Heussen, F
   Sadda, SR
AF Tan, Colin S.
   Heussen, Florian
   Sadda, SriniVas R.
TI Peripheral Autofluorescence and Clinical Findings in Neovascular and
   Non-neovascular Age-related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; FIELD FLUORESCEIN ANGIOGRAPHY; SCANNING
   LASER OPHTHALMOSCOPY; FUNDUS AUTOFLUORESCENCE; GEOGRAPHIC ATROPHY;
   VISUAL IMPAIRMENT; DIABETIC-RETINOPATHY; JUNCTIONAL ZONE; OCULAR FUNDUS;
   EYE DISEASES
AB Purpose: To characterize peripheral fundus autofluorescence (FAF) abnormalities in patients with age-related macular degeneration (AMD), correlate these with clinical findings, and identify risk factors associated with these FAF abnormalities.
   Design: Clinic-based, cross-sectional study.
   Participants: A total of 119 consecutive patients: 100 patients with AMD (200 eyes) and 19 patients without AMD (38 eyes).
   Methods: In a prospective study performed at the Doheny Eye Institute, University of Southern California, widefield 200-degree FAF and color images were obtained by the Optos 200Tx Ultra-Widefield device (Optos, Dunfermline, Scotland) using a standardized imaging protocol. The FAF images were captured centered on the fovea, and additional images were captured after steering the field of view inferiorly and superiorly. All FAF and color images were graded independently by 2 masked ophthalmologists with respect to the presence, location, extent, and type of peripheral (defined as outside the central 30 degrees) FAF abnormality.
   Main Outcome Measures: Presence and type of peripheral FAF abnormalities.
   Results: Peripheral FAF abnormalities were evident in 164 eyes (68.9%), with several distinct FAF patterns identified: granular (46.2%), mottled (34.0%), and nummular (18.1%). A 90% concordance of FAF patterns was observed between both eyes. Abnormal FAF occurred more frequently in neovascular compared with non-neovascular AMD or normal eyes (86% vs. 72.8% vs. 18.4%, respectively, P < 0.001). Significant risk factors for peripheral FAF abnormalities were AMD type (neovascular AMD odds ratio [OR], 12.7 and non-neovascular AMD OR, 6.2 compared with normal eyes, P < 0.001), older age (OR, 6.5; 95% confidence interval [CI], 2.4-17.8; P < 0.001 for the oldest quartile compared with the youngest), and female sex (OR, 4.1; 95% CI, 1.9-8.9; P < 0.001). Clinical features on color photography were detected in 174 eyes (73.1%): peripheral drusen (51.7%), retinal pigment epithelium (RPE) depigmentation (34.9%), RPE hyperpigmentation (branching reticular pigmentation) (22.7%), and atrophic patches (16.8%). There was a high correlation between specific FAF and clinical findings: granular FAF with peripheral drusen (P < 0.001) and mottled FAF with RPE depigmentation (P < 0.001).
   Conclusions: Several distinct patterns of peripheral FAF abnormalities were observed in 68.9% of patients, with AMD type, female sex, and age being independent risk factors. The peripheral FAF patterns correlate strongly with specific clinical features seen in eyes with AMD. (C) 2013 by the American Academy of Ophthalmology.
C1 [Tan, Colin S.; Heussen, Florian; Sadda, SriniVas R.] Univ So Calif, Doheny Eye Inst, Los Angeles, CA USA.
   Tan Tock Seng Hosp, Dept Ophthalmol, Singapore, Singapore.
   [Tan, Colin S.] Natl Healthcare Grp Eye Inst, Fundus Image Reading Ctr, Singapore, Singapore.
C3 Doheny Eye Institute; University of Southern California; Tan Tock Seng
   Hospital
RP Sadda, SR (通讯作者)，Doheny Eye Inst DEI 3623, 1450 San Pablo St, Los Angeles, CA 90033 USA.
EM SSadda@doheny.org
RI Tan, Colin S/K-8972-2012
OI Tan, Colin S/0000-0003-3088-5690; Heussen, Florian
   Moritz/0000-0003-0536-9870
FU National Institutes of Health [EY03040]; National Eye Institute [R01
   EY014375]; National Healthcare Group Clinician Leadership in Research
   Grant [CLR-09006]; NATIONAL EYE INSTITUTE [R21EY015914, P30EY003040,
   R01EY014375] Funding Source: NIH RePORTER
FX Supported in part by National Institutes of Health Grant EY03040,
   National Eye Institute Grant R01 EY014375, (Dr. Sadda), and the National
   Healthcare Group Clinician Leadership in Research Grant CLR-09006 (Dr.
   Tan).
CR Bellmann C, 2002, ARCH OPHTHALMOL-CHIC, V120, P579, DOI 10.1001/archopht.120.5.579
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Bindewald A, 2004, AM J OPHTHALMOL, V137, P556, DOI 10.1016/j.ajo.2003.08.004
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Chen RWS, 2012, AM J OPHTHALMOL, V153, P143, DOI 10.1016/j.ajo.2011.06.018
   Cho MHE, 2011, RETINA-J RET VIT DIS, V31, P738, DOI 10.1097/IAE.0b013e3181f049ec
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Csutak A, 2010, EYE, V24, P1568, DOI 10.1038/eye.2010.85
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Fujinami K, 2011, ARCH OPHTHALMOL-CHIC, V129, P597, DOI 10.1001/archophthalmol.2011.96
   Fujiwara T, 2010, RETINA-J RET VIT DIS, V30, P1206, DOI 10.1097/IAE.0b013e3181e097f0
   Gomes NL, 2009, INVEST OPHTH VIS SCI, V50, P3953, DOI 10.1167/iovs.08-2657
   Heussen FM, 2012, INVEST OPHTH VIS SCI, V53, P6526, DOI 10.1167/iovs.12-9909
   Heussen FM, 2011, OPHTHAL SURG LAS IM, V42, P272, DOI 10.3928/15428877-20110505-01
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Jorzik JJ, 2005, RETINA-J RET VIT DIS, V25, P405, DOI 10.1097/00006982-200506000-00003
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Maberley DAL, 2006, EYE, V20, P341, DOI 10.1038/sj.eye.6701879
   Manivannan A, 2005, AM J OPHTHALMOL, V140, P525, DOI 10.1016/j.ajo.2005.02.055
   Neubauer AS, 2008, GRAEF ARCH CLIN EXP, V246, P229, DOI 10.1007/s00417-007-0631-4
   Nissen KR, 2003, OPHTHAL EPIDEMIOL, V10, P279, DOI 10.1076/opep.10.4.279.15909
   Prasad PS, 2010, OPHTHALMOLOGY, V117, P780, DOI 10.1016/j.ophtha.2009.09.019
   Prokofyeva E, 2012, OPHTHALMIC RES, V47, P171, DOI 10.1159/000329603
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Reznicek L, 2012, INVEST OPHTH VIS SCI, V53, P2193, DOI 10.1167/iovs.11-8483
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Shah SP, 2009, SEMIN OPHTHALMOL, V24, P37, DOI 10.1080/08820530802520210
   Slotnick S, 2012, OPTOMETRY VISION SCI, V89, pE575, DOI 10.1097/OPX.0b013e318250835d
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P829, DOI 10.1097/IAE.0b013e31820c841e
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Wessel MM, 2012, BRIT J OPHTHALMOL, V96, P694, DOI 10.1136/bjophthalmol-2011-300774
   Wessel MM, 2012, RETINA-J RET VIT DIS, V32, P785, DOI 10.1097/IAE.0b013e3182278b64
   Wong TY, 2006, BRIT J OPHTHALMOL, V90, P506, DOI 10.1136/bjo.2005.083733
   Xu L, 2006, OPHTHALMOLOGY, V113, P1134, DOI 10.1016/j.ophtha.2006.01.035
NR 40
TC 64
Z9 68
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2013
VL 120
IS 6
BP 1271
EP 1277
DI 10.1016/j.ophtha.2012.12.002
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 167RJ
UT WOS:000320650700034
PM 23433790
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Galan, A
   Ferlin, A
   Caretti, L
   Buson, G
   Sato, G
   Frigo, AC
   Foresta, C
AF Galan, Alessandro
   Ferlin, Alberto
   Caretti, Luigi
   Buson, Genny
   Sato, Giovanni
   Frigo, Anna Chiara
   Foresta, Carlo
TI Association of Age-related Macular Degeneration with Polymorphisms in
   Vascular Endothelial Growth Factor and Its Receptor
SO OPHTHALMOLOGY
LA English
DT Article
ID FACTOR GENE; VEGF; MACULOPATHY; DISEASE; EYE
AB Objective: To analyze the association between age-related macular degeneration (AMD) and polymorphisms in vascular endothelial growth factor (VEGF) and VEGF receptor KDR gene polymorphisms. A complex, multifactorial disease in which genetic and environmental factors interact, AMD is the leading cause of blindness in the elderly. Vascular endothelial growth factor (VEGF), a key regulator of angiogenesis, is considered an important factor for the pathogenetic processes of AMD. Previous studies investigated the possible association between VEGF-A gene polymorphisms and AMD, with contrasting data. No study examined the possible role of VEGF receptor KDR gene polymorphisms.
   Design: Case-control study.
   Participants and Controls: We enrolled 226 AMD cases and 248 controls from an ophthalmology hospital center.
   Methods: Genotypying for 16 polymorphic markers (single nucleotide polymorphisms [SNPs]) in VEGF-A and KDR genes.
   Main Outcome Measures: Distribution of genotypes in AMD cases and controls.
   Results: Two polymorphisms (rs833069 in intron 2 of the VEGF-A gene, rs2071559 in the promoter of the KDR gene) were significantly associated with risk of AMD. In particular, for VEGF-A rs833069 the AMD risk was increased >5-fold for G homozygotes compared with homozygous carriage of the A allele. For KDR rs2071559 the AMD risk was increased >3-fold for T homozygotes compared with homozygous carriage of the C allele. Carriers of risk alleles for both markers have a >6-fold increased risk of AMD with respect to carriers of non-risk alleles.
   Conclusions: We expand previous data on the association of AMD with VEGF-A gene variations and identify for the first time an association with variations in the KDR gene. Because the SNP-604T-bearing KDR promoter has higher transcription activity, our findings further support the role of the VEGF pathway in the pathophysiology of AMD. It is possible that applications of haplotype/genotype analysis in these genes will play a role in risk assessment and pharmacogenomic approaches to AMD diagnosis and management.
C1 [Ferlin, Alberto; Buson, Genny; Foresta, Carlo] Univ Padua, Dept Histol Microbiol & Med Biotechnol, Sect Clin Pathol, I-35121 Padua, Italy.
   [Ferlin, Alberto; Buson, Genny; Foresta, Carlo] Ctr Male Gamete Cryopreservat, I-35121 Padua, Italy.
   [Galan, Alessandro; Caretti, Luigi; Sato, Giovanni] S Antonio Hosp, Dept Ophthalmol, Padua, Italy.
   [Frigo, Anna Chiara] Univ Padua, Dept Environm Med & Publ Hlth, I-35121 Padua, Italy.
C3 University of Padua; ULSS 6 Euganea; Ospedale Sant'antonio Padova;
   University of Padua
RP Foresta, C (通讯作者)，Univ Padua, Dept Histol Microbiol & Med Biotechnol, Sect Clin Pathol, Via Gabelli 63, I-35121 Padua, Italy.
EM carlo.foresta@unipd.it
RI Ferlin, Alberto/AAO-3541-2020
OI Ferlin, Alberto/0000-0001-5817-8141
FU Veneto Region [296/08]
FX Supported by grant no. 296/08 from the Veneto Region. The funding
   organization had no role in the design or conduct of this research.
CR Ayoub T, 2009, J ROY SOC MED, V102, P56, DOI 10.1258/jrsm.2009.080298
   Boekhoorn SS, 2008, OPHTHALMOLOGY, V115, P1899, DOI 10.1016/j.ophtha.2008.06.026
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Mckay GJ, 2009, OPHTHALMOLOGY, V116, P1227, DOI 10.1016/j.ophtha.2009.01.008
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Phillips CO, 2009, ARCH INTERN MED, V169, P1180, DOI 10.1001/archinternmed.2009.195
   Richardson AJ, 2007, MOL VIS, V13, P2148
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Wang Y, 2007, J AM COLL CARDIOL, V50, P760, DOI 10.1016/j.jacc.2007.04.074
NR 14
TC 56
Z9 61
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2010
VL 117
IS 9
BP 1769
EP 1774
DI 10.1016/j.ophtha.2010.01.030
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 646DY
UT WOS:000281518100016
PM 20471686
DA 2022-11-30
ER

PT J
AU Lains, I
   Wang, J
   Providencia, J
   Mach, S
   Gil, P
   Gil, J
   Marques, M
   Armstrong, G
   Garas, S
   Barreto, P
   Kim, IK
   Vavvas, DG
   Miller, JW
   Husain, D
   Silva, R
   Miller, JB
AF Lains, Ines
   Wang, Jay
   Providencia, Joana
   Mach, Steven
   Gil, Pedro
   Gil, Joao
   Marques, Marco
   Armstrong, Grayson
   Garas, Shady
   Barreto, Patricia
   Kim, Ivana K.
   Vavvas, Demetrios G.
   Miller, Joan W.
   Husain, Deeba
   Silva, Rufino
   Miller, John B.
TI Choroidal Changes Associated With Subretinal Drusenoid Deposits in
   Age-related Macular Degeneration Using Swept-source Optical Coherence
   Tomography
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RETICULAR PSEUDODRUSEN; SPECTRAL-DOMAIN; POSTERIOR SEGMENT; SOURCE OCT;
   THICKNESS; EYES; PREVALENCE; DISEASE; VOLUME; CHORIOCAPILLARIS
AB PURPOSE: To compare choroidal vascular features of eyes with and without subretinal drusenoid deposits (SDD), using swept-source optical coherence tomography (SS OCT).
   DESIGN: Multicenter, cross-sectional study.
   METHODS: We prospectively recruited patients with intermediate age-related macular degeneration (AMD), without other vitreoretinal pathology. All participants underwent complete ophthalmic examination, color fundus photography. (used for AMD staging), and spectral-domain OCT (to evaluate the presence of SDD). SS OCT was used to obtain automatic macular choroidal thickness (CT) maps, according to the Early Treatment Diabetic Retinopathy Study (ETDRS) sectors. For data analysis, we considered mean choroidal thickness as the arithmetic mean value of the 9 ETDRS sectors. SS OCT en face images of choroidal vasculature were also captured and converted to binary images. Choroidal vascular density (CVD) was calculated as a percent area occupied by choroidal vessels in a 6-mm diameter submacular circular. Choroidal vessel volume was calculated by multiplying the average CVD by macular area and CT. Multilevel mixed linear models (to account for the inclusion of 2 eyes of same subject) were performed for analysis.
   RESULTS: We included 186 eyes (n = 118 subjects), 94 (50.5%) presenting SDD. Multiple regression analysis revealed that, controlling for age, eyes with SDD presented a statistically thinner mean CT (beta = -21.9, P = .006) and CT in all the individual ETDRS fields (beta <= -18.79, P <= .026). Mean choroidal vessel volume was also significantly reduced in eyes with SDD (beta = -0.003, P = .007). No significant associations were observed with mean CVD.
   CONCLUSION: In subjects with intermediate AMD, choroidal thickness and vessel volume are reduced in the presence of subretinal drusenoid deposits. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Lains, Ines; Wang, Jay; Mach, Steven; Armstrong, Grayson; Garas, Shady; Kim, Ivana K.; Vavvas, Demetrios G.; Miller, Joan W.; Husain, Deeba; Miller, John B.] Harvard Med Sch, Retina Serv, Massachusetts Eye & Ear, Dept Ophthalmol, Boston, MA 02114 USA.
   [Lains, Ines; Gil, Pedro; Gil, Joao; Silva, Rufino] Univ Coimbra, Fac Med, Coimbra, Portugal.
   [Lains, Ines; Providencia, Joana; Gil, Pedro; Gil, Joao; Marques, Marco; Silva, Rufino] Ctr Hosp & Univ Coimbra, Coimbra, Portugal.
   [Lains, Ines; Providencia, Joana; Gil, Pedro; Gil, Joao; Marques, Marco; Barreto, Patricia; Silva, Rufino] Assoc Innovat & Biomed Res Light, Coimbra, Portugal.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Universidade de Coimbra; Universidade de Coimbra; Centro
   Hospitalar e Universitario de Coimbra (CHUC); Universidade de Coimbra
RP Miller, JB (通讯作者)，Harvard Med Sch, Mass Eye & Ear Retina Serv, 243 Charles St, Boston, MA 02114 USA.
EM john_miller@meei.harvard.edu
RI Silva, Rufino M/J-2817-2012; Armstrong, Grayson/AAA-5655-2021; Miller,
   John J/GZG-5663-2022; Gil, Pedro/N-9909-2016
OI Silva, Rufino M/0000-0001-8676-0833; Armstrong,
   Grayson/0000-0001-9102-5868; Vavvas, Demetrios/0000-0002-8622-6478; Gil,
   Pedro/0000-0002-6683-6818; Providencia, Joana/0000-0003-1312-7978;
   Quadrado Gil, Joao/0000-0001-9032-1008; Husain,
   Deeba/0000-0002-8494-0950; Lains, Ines/0000-0002-8136-4724; Kim,
   Ivana/0000-0003-0310-6129
FU MILLER RETINA RESEARCH FUND; MILLER CHAMPALIMAUD VISION Award;
   Portuguese Foundation for Science and Technology/Harvard Medical School
   Portugal Program [HMSP-ICJ/006/2013]; NATIONAL EYE INSTITUTE
   [T32EY007145, R01EY030088] Funding Source: NIH RePORTER
FX THE MILLER RETINA RESEARCH FUND (MASS. EYE AND EAR) AND THE MILLER
   CHAMPALIMAUD VISION Award (Mass. Eye and Ear) (to J.W.M.); Portuguese
   Foundation for Science and Technology/Harvard Medical School Portugal
   Program (HMSP-ICJ/006/2013) (to I.L.)
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Alonso-Caneiro D, 2013, BIOMED OPT EXPRESS, V4, P2795, DOI 10.1364/BOE.4.002795
   Alten F, 2016, GRAEF ARCH CLIN EXP, V254, P2165, DOI 10.1007/s00417-016-3375-1
   Alten F, 2013, INVEST OPHTH VIS SCI, V54, P3250, DOI 10.1167/iovs.13-11923
   Alten F, 2012, RETINA-J RET VIT DIS, V32, P1727, DOI 10.1097/IAE.0b013e3182475b03
   Bonate PL, 2011, PHARMACOKINETIC-PHARMACODYNAMIC MODELING AND SIMULATION, SECOND EDITION, P189, DOI 10.1007/978-1-4419-9485-1_6
   Burton P, 1998, STAT MED, V17, P1261, DOI 10.1002/(SICI)1097-0258(19980615)17:11<1261::AID-SIM846>3.0.CO;2-Z
   Cachulo MD, 2015, OPHTHALMOLOGICA, V233, P119, DOI 10.1159/000371584
   Capuano V, 2016, BRIT J OPHTHALMOL, V100, P677, DOI 10.1136/bjophthalmol-2015-307169
   Cheng H, 2016, CURR EYE RES, V41, P1492, DOI 10.3109/02713683.2015.1127391
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Copete S, 2014, BRIT J OPHTHALMOL, V98, P334, DOI 10.1136/bjophthalmol-2013-303904
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Ellabban AA, 2012, AM J OPHTHALMOL, V153, P1133, DOI 10.1016/j.ajo.2011.12.013
   Ferrara D, 2016, PROG RETIN EYE RES, V52, P130, DOI 10.1016/j.preteyeres.2015.10.002
   Ferrara D, 2014, OPHTHALMOLOGY, V121, P719, DOI 10.1016/j.ophtha.2013.10.014
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Gil JQ, 2017, EYE, V31, P364, DOI 10.1038/eye.2016.207
   Haas P, 2014, INVEST OPHTH VIS SCI, V55, P2674, DOI 10.1167/iovs.13-13338
   Hirata M, 2011, INVEST OPHTH VIS SCI, V52, P4971, DOI 10.1167/iovs.11-7729
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Jirarattanasopa P, 2012, OPHTHALMOLOGY, V119, P1666, DOI 10.1016/j.ophtha.2012.02.021
   Kim JH, 2014, EYE, V28, P825, DOI 10.1038/eye.2014.102
   Lains I, 2017, RETINA
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Matsuo Y, 2013, INVEST OPHTH VIS SCI, V54, P7630, DOI 10.1167/iovs.13-13135
   Michalewski J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/639160
   Motaghiannezam R, 2012, INVEST OPHTH VIS SCI, V53, P2337, DOI 10.1167/iovs.11-7823
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   Park HYL, 2014, AM J OPHTHALMOL, V157, P550, DOI 10.1016/j.ajo.2013.11.008
   Patel V, 2011, RETINA, V30, P1441
   Philip A-M, 2016, BR J OPHTHALMOL
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Sivaprasad S, 2016, SURV OPHTHALMOL, V61, P521, DOI 10.1016/j.survophthal.2016.02.005
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Tan CSH, 2015, BRIT J OPHTHALMOL, V99, P354, DOI 10.1136/bjophthalmol-2014-305331
   Ueda-Arakawa N, 2014, AM J OPHTHALMOL, V157, P994, DOI 10.1016/j.ajo.2014.01.018
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yun C, 2016, GRAEF ARCH CLIN EXP, V254, P427, DOI 10.1007/s00417-015-3054-7
   Zheng F, 2016, INVEST OPHTH VIS SCI, V57, P6256, DOI 10.1167/iovs.16-20161
NR 46
TC 25
Z9 25
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD AUG
PY 2017
VL 180
BP 55
EP 63
DI 10.1016/j.ajo.2017.05.021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FC6ZK
UT WOS:000406990000009
PM 28579063
DA 2022-11-30
ER

PT J
AU Dugel, PU
   Jaffe, GJ
   Sallstig, P
   Warburton, J
   Weichselberger, A
   Wieland, M
   Singerman, L
AF Dugel, Pravin U.
   Jaffe, Glenn J.
   Sallstig, Peter
   Warburton, James
   Weichselberger, Andreas
   Wieland, Mark
   Singerman, Lawrence
TI Brolucizumab Versus Aflibercept in Participants with Neovascular
   Age-Related Macular Degeneration: A Randomized Trial
SO OPHTHALMOLOGY
LA English
DT Article
ID BLINDNESS
AB Purpose: To compare the efficacy and safety of brolucizumab with aflibercept to treat neovascular age-related macular degeneration (AMD).
   Design: Prospective, randomized, double-masked, multicenter, 2-arm, phase 2 study. Participants: Eighty-nine treatment-naive participants, aged >= 50 years, with active choroidal neovascularization secondary to AMD.
   Methods: Eligible participants were randomized 1: 1 to intravitreal brolucizumab (6 mg/50 mu l) or aflibercept (2 mg/50 ml). Both groups received 3 monthly loading doses and were then treated every 8 weeks (q8) with assessment up to week 40. In the brolucizumab group, the final q8 cycle was extended to enable 2 cycles of treatment every 12 weeks (q12; to week 56); participants on aflibercept continued on q8. Unscheduled treatments were allowed at the investigator's discretion.
   Main Outcome Measures: The primary and secondary hypotheses were noninferiority (margin: 5 letters at a 1-sided alpha level 0.1) in best-corrected visual acuity (BCVA) change from baseline of brolucizumab versus aflibercept at weeks 12 and 16, respectively. BCVA, central subfield thickness (CSFT), and morphologic features were assessed throughout the study.
   Results: The mean BCVA change from baseline (letters) with brolucizumab was noninferior to aflibercept at week 12 (5.75 and 6.89, respectively [80% confidence interval for treatment difference, -4.19 to 1.93]) and week 16 (6.04 and 6.62 [-3.72 to 2.56]), with no notable differences up to week 40. Outcomes exploring disease activity during the q8 treatment cycles suggest greater stability of the brolucizumab participants, supported by receipt of fewer unscheduled treatments versus aflibercept (6 vs. 15) and more stable CSFT reductions. In addition, from post hoc analysis, a greater proportion of brolucizumab-treated eyes had resolved intraretinal and subretinal fluid compared with aflibercept-treated eyes. Approximately 50% of brolucizumab-treated eyes had stable BCVA during the q12 cycles. Brolucizumab and aflibercept adverse events were comparable.
   Conclusions: During the matched q8 phase, the BCVA in brolucizumab-treated eyes appeared comparable to aflibercept-treated eyes, with more stable CSFT reductions, receipt of fewer unscheduled treatments, and higher rates of fluid resolution. The brolucizumab safety profile was similar to aflibercept over 56 weeks of treatment. A 12-week treatment cycle for brolucizumab may be viable in a relevant proportion of eyes. (C) 2017 by the American Academy of Ophthalmology.
C1 [Dugel, Pravin U.] Retinal Consultants Arizona, 1101 E Missouri Ave, Phoenix, AZ 85014 USA.
   [Dugel, Pravin U.] Univ Southern Calif, USC Roski Eye Inst, Keck Sch Med, Los Angeles, CA USA.
   [Jaffe, Glenn J.] Duke Univ, Dept Ophthalmol, Durham, NC USA.
   [Sallstig, Peter; Weichselberger, Andreas] Alcon Res Ltd, Ft Worth, TX USA.
   [Warburton, James] Novartis Pharmaceut, Basel, Switzerland.
   [Wieland, Mark] Northern Calif Retina Vitreous Associates, Mountain View, CA USA.
   [Wieland, Mark] Stanford Univ, Stanford, CA 94305 USA.
   [Singerman, Lawrence] Case Western Reserve Univ, Sch Med, Cleveland, OH USA.
   [Singerman, Lawrence] Bascom Palmer Eye Inst, Miami, FL 33136 USA.
C3 University of Southern California; Duke University; Novartis; Alcon;
   Novartis; Stanford University; Case Western Reserve University; Bascom
   Palmer Eye Institute
RP Dugel, PU (通讯作者)，Retinal Consultants Arizona, 1101 E Missouri Ave, Phoenix, AZ 85014 USA.
EM pdugel@gmail.com
FU Abbot; AMO; Aerpio Therapeutics; Alcon; Acucela; Allergan; Apellis
   Pharmaceuticals; Digisight Technologies; Lowy Medical Research
   Institute; National Eye Institute of the National Institutes of Health;
   Novartis Pharmaceuticals; Ohr Pharmaceutical Inc; Ophthea; Ophthotech;
   Roche-Genentech; Tyrogenix; Alcon Research, Ltd; Fort Worth, TX
FX P.D.: Financial relationships - Abbot, AMO, Aerpio Therapeutics, Alcon;
   Consultant for Alimera Sciences, Allergan, Annidis, Acucela, ArcticAx,
   Avalanche Biotechnologies, Clearside Biomedical, DigiSight Technologies,
   DOSE Medical, Genentech, Graybug Vision, Lutronic, Lux BioSciences,
   Neurotech, Novartis, OD-OS, Omeros, Ophthotech, Ophthea, Optovue, ORA,
   Regeneron, Roche, Pentavision, Shire Human Genetic Therapies, Stealth
   Bio Therapeutics, Thrombogenics, TopCon; Minor stock shareholder -
   Alimera Sciences, Aerpio Therapeutics, Annidis, DigiSight Technologies,
   Ophthotech, TrueVision.; L.S.: Grants - Acucela, Alcon, Allergan,
   Apellis Pharmaceuticals, Digisight Technologies, Lowy Medical Research
   Institute, National Eye Institute of the National Institutes of Health,
   Novartis Pharmaceuticals, Ohr Pharmaceutical Inc, Ophthea, Ophthotech,
   Roche-Genentech, Tyrogenix; Stock options - Ohr Pharmaceuticals Inc,
   Ophthotech.; Funded by Alcon Research, Ltd, Fort Worth, TX. Alcon
   participated in the design and conduct of the study, data management,
   data analysis, interpretation of the data, and preparation and approval
   of the manuscript. Medical writing assistance (provided by David
   Christiansen, PhD, Little Cricket Consulting, LLC, Stockton, NJ) was
   funded by Alcon Research, Ltd.
CR American Academy of Ophthalmology Retina/ Vitreous Panel, PREF PRACT PATT GUID
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Gaudreault J., 2012, INVEST OPHTHALMOL VI, V53, P3025
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Jonas JB, 2014, AM J OPHTHALMOL, V158, P808, DOI 10.1016/j.ajo.2014.06.012
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Tietz J, 2015, INVEST OPHTH VIS SCI, V56
NR 9
TC 120
Z9 124
U1 1
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2017
VL 124
IS 9
BP 1296
EP 1304
DI 10.1016/j.ophtha.2017.03.057
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FD8RT
UT WOS:000407792500014
PM 28551167
DA 2022-11-30
ER

PT J
AU Christenbury, JG
   Folgar, FA
   O'Connell, RV
   Chiu, SJ
   Farsiu, S
   Toth, CA
AF Christenbury, Joseph G.
   Folgar, Francisco A.
   O'Connell, Rachelle V.
   Chiu, Stephanie J.
   Farsiu, Sina
   Toth, Cynthia A.
CA Age-related Eye Dis Study 2 Ancill
TI Progression of Intermediate Age-related Macular Degeneration with
   Proliferation and Inner Retinal Migration of Hyperreflective Foci
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; FACTOR-H POLYMORPHISM; GEOGRAPHIC ATROPHY;
   AUTOMATIC SEGMENTATION; PIGMENT EPITHELIUM; SD-OCT; DRUSEN; MACULOPATHY;
   AMD; MICROGLIA
AB Purpose: Drusen and migrating retinal pigment epithelium have been associated with hyperreflective foci (HF) detected by spectral-domain optical coherence tomography (SD-OCT). This study sought to quantify the change in intraretinal HF distribution and its correlation with age-related macular degeneration (AMD) disease progression.
   Design: Prospective observational study from the multicenter Age-Related Eye Disease Study 2 (AREDS2) Ancillary SD-OCT Study.
   Participants: Patients (n = 299) with 1 enrolled eye with intermediate AMD and baseline SD-OCT, followed by SD-OCT imaging at 1-year and 2-year visits.
   Methods: The number and location of HF were scored in SD-OCT scans of all 299 eyes. The change in transverse (horizontal) and axial (vertical) distribution of HF in the macula were evaluated with pairwise signed-rank tests. Two-year inner retinal HF migration was determined by the change in HF-weighted axial distribution (AxD) score calculated for each eye. The correlation of HF with SD-OCT features of AMD progression was evaluated with logistic regression analysis.
   Main Outcome Measures: The mean change in number of HF, transverse and axial distribution of HF in the macula, and AxD per eye.
   Results: In 299 study eyes, the 2-year increase in the number of HF (P<0.001) and the AxD (P<0.001) per eye represented longitudinal proliferation and shift to inner retinal layers, respectively. Eyes with geographic atrophy (GA) at 2 years were correlated with the presence of baseline HF (P<0.001; odds ratio [OR], 4.72; 95% confidence interval [CI], 2.43-9.80), greater number of baseline HF (P<0.001; OR, 1.61 per HF; 95% CI, 1.32-2.00), and greater baseline AxD (P<0.001; OR, 1.58 per AxD point; 95% CI, 1.29-1.95).
   Conclusions: Proliferation and inner retinal migration of SD-OCT HF occurred during follow-up in eyes with intermediate AMD. These characteristics were associated with greater incidence of GA at year 2; therefore, SD-OCT HF proliferation and migration may serve as biomarkers for AMD progression.
C1 [Christenbury, Joseph G.; Folgar, Francisco A.; O'Connell, Rachelle V.; Farsiu, Sina; Toth, Cynthia A.] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   [Chiu, Stephanie J.; Farsiu, Sina; Toth, Cynthia A.] Duke Univ, Dept Biomed Engn, Durham, NC 27710 USA.
C3 Duke University; Duke University
RP Toth, CA (通讯作者)，Duke Univ, Ctr Eye, Dept Ophthalmol, DUMC 3802, Durham, NC 27710 USA.
EM cynthia.toth@dm.duke.edu
RI Toth, Cynthia/L-5534-2019; toth, cynthia a/F-5614-2011
OI Toth, Cynthia/0000-0002-2324-0854; Farsiu, Sina/0000-0003-4872-2902
FU Genentech; Bioptigen; Physical Sciences Inc.; Genentech [IST-4400S];
   Alcon Laboratories; American Health Assistance Foundation; National
   Institutes of Health [P30 EY-005722]; Research to Prevent Blindness;
   NATIONAL EYE INSTITUTE [P30EY005722] Funding Source: NIH RePORTER
FX The author(s) have made the following disclosure(s): C.A.T.: Genentech
   (research support), Bioptigen (research support), Physical Sciences Inc.
   (research support). Duke University has an equity and intellectual
   property interest in Bioptigen. S.J.C., S.F., and C.A.T. have patents
   pending on image processing. The remaining authors do not have any
   financial disclosures.; The AREDS2 Ancillary SD-OCT Study
   (ClinicalTrials.gov identifier: NCT00734487) is supported in part by
   Bioptigen (equipment), Genentech (IST-4400S grant), and Alcon
   Laboratories (unrestricted startup grant). The laboratory of S.F. is
   supported in part by the American Health Assistance Foundation (research
   support) and the National Institutes of Health (P30 EY-005722 grant).
   The laboratories of both C.A.T. and S.F. are supported by Research to
   Prevent Blindness (unrestricted grant).
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Jin ML, 2000, INVEST OPHTH VIS SCI, V41, P4324
   Kehler AK, 2012, CURR EYE RES, V37, P500, DOI 10.3109/02713683.2012.663855
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Mitsuhiro MRKH, 2003, ACTA OPHTHALMOL SCAN, V81, P630, DOI 10.1111/j.1395-3907.2003.00170.x
   Pieroni CG, 2006, BRIT J OPHTHALMOL, V90, P191, DOI 10.1136/bjo.2005.076612
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Venza I, 2012, AGING CLIN EXP RES, V24, P21, DOI 10.3275/7659
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Zamiri Parisa, 2007, Chem Immunol Allergy, V92, P86, DOI 10.1159/000099259
NR 32
TC 137
Z9 139
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2013
VL 120
IS 5
BP 1038
EP 1045
DI 10.1016/j.ophtha.2012.10.018
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 140VE
UT WOS:000318683400023
PM 23352193
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Koss, MJ
   Scholtz, S
   Haeussler-Sinangin, Y
   Singh, P
   Koch, FH
AF Koss, M. J.
   Scholtz, S.
   Haeussler-Sinangin, Y.
   Singh, P.
   Koch, F. H.
TI Combined Intravitreal Pharmacosurgery in Patients with Occult Choroidal
   Neovascularization Secondary to Wet Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Bevacizumab; Occult choroidal
   neovascularization; Triamcinolone; Limited vitrectomy
ID GROWTH-FACTOR; COMBINATION THERAPY; TRIAMCINOLONE ACETONIDE;
   PHOTODYNAMIC THERAPY; TRIPLE THERAPY; VITRECTOMY; VERTEPORFIN;
   RANIBIZUMAB; OXYGENATION; EXPRESSION
AB Aim: The aim was to investigate the efficacy and safety of combined intravitreal therapy in patients with occult choroidal neovascularization (CNV) secondary to wet age-related macular degeneration (AMD) over 6 months. Methods: In this prospective pilot study of a case series, 106 patients (mean age 75.4 years) with predominantly occult CNVs were treated with a 1.5-ml core pars plana vitrectomy with intravitreal injections of triamcinolone (8 mg), bevacizumab (1.25 mg) and balanced salt solution. The best-corrected visual acuity (BCVA; logMar), central macular thickness (optical coherence tomography), and intraocular pressure (IOP; Goldmann tonometry) were assessed at baseline and follow-up visits. Results: Statistically significant increases in BCVA (vs. baseline) were observed at 2 months (mean +0.9; standard deviation +/- 0.6 lines), 4 months (+1.3; +/- 0.7), and 6 months (+1.2; +/- 0.7) after the initial combined intravitreal therapy in 96/106 patients. At 6 months, BCVA had deteriorated in 20 of 96 (20.8%) patients by <2.5 lines, remained stable in 38 of 96 (39.6%) and improved in 31 (32.3%) patients by 1-3 lines, and in 7 (7.3%) patients by 1 3 lines. The mean central retinal thickness decreased by -41.2% (-195; +/- 46 mu m) over 6 months. 55% demanded intravitreal anti-vascular endothelial growth factor (VEGF) treatment after initial therapy. Increases in IOP were managed by eye drops in 11 (10%) patients with no other adverse event occurring. Conclusion: After the combined intravitreal therapy, including two drugs and a limited core vitrectomy, a significant and sustained improvement in vision of patients with occult CNVs was observed over 6 months. In 45% of the initially treated patients, anti-VEGF therapy did not have to be continued, which might be attributed to both the pharmacological effects of the drugs and the physiological changes induced by the vitrectomy (posterior vitreous detachment, liquefaction, and oxygen redistribution). Copyright (C) 2009 S. Karger AG, Basel
C1 [Koss, M. J.; Scholtz, S.; Haeussler-Sinangin, Y.; Singh, P.; Koch, F. H.] Univ Frankfurt, Dept Ophthalmol, DE-60590 Frankfurt, Germany.
C3 Goethe University Frankfurt
RP Koss, MJ (通讯作者)，Univ Frankfurt, Dept Ophthalmol, Theodor Stern Kai 7, DE-60590 Frankfurt, Germany.
EM michael.koss@kgu.de
FU Adolf Messer Foundation, Konigstein, Germany
FX F. H. Koch received funding from Insight Instruments, Stuart, Fla., USA,
   for travel expenses with regard to scientific meetings and conferences.
   The research group is supported by the Adolf Messer Foundation,
   Konigstein, Germany.
CR Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Augustin AJ, 2007, DRUG AGING, V24, P979, DOI 10.2165/00002512-200724120-00002
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Azad Rajvardhan, 2007, Indian Journal of Ophthalmology, V55, P441
   Barbazetto IA, 2004, EXP EYE RES, V78, P917, DOI 10.1016/j.exer.2004.01.003
   Blair N P, 2000, Trans Am Ophthalmol Soc, V98, P305
   Bradley John, 2007, Angiogenesis, V10, P141, DOI 10.1007/s10456-007-9069-x
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P369, DOI 10.1016/j.exer.2004.10.005
   Fuseya Miki, 2007, Retin Cases Brief Rep, V1, P160, DOI 10.1097/01.ICB.0000279649.37443.70
   GOTTSCH JD, 1990, INVEST OPHTH VIS SCI, V31, P1674
   GRINDLE CFJ, 1978, T OPHTHAL SOC UK, V98, P172
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   HERBORT T, 2009, ANN M ASS RES VIS OP
   Holekamp NM, 2005, AM J OPHTHALMOL, V139, P302, DOI 10.1016/j.ajo.2004.09.046
   KOROTKIN A, 2006, EMERGING PROBLEM REC
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Liggett PE, 2006, AM J OPHTHALMOL, V142, P1072, DOI 10.1016/j.ajo.2006.07.029
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Pournaras CJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P1553, DOI 10.1001/archopht.1997.01100160723009
   Relf M, 1997, CANCER RES, V57, P963
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruiz-Moreno JM, 2006, EUR J OPHTHALMOL, V16, P426, DOI 10.1177/112067210601600311
   SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   STEFANSSON E, 1982, RETINA-J RET VIT DIS, V2, P159, DOI 10.1097/00006982-198200230-00006
   STEFANSSON E, 1990, INVEST OPHTH VIS SCI, V31, P284
   Stefansson E, 2009, GRAEF ARCH CLIN EXP, V247, P147, DOI 10.1007/s00417-008-0980-7
   Takeda AL, 2007, BRIT J OPHTHALMOL, V91, P1177, DOI 10.1136/bjo.2007.118562
   WILSON CA, 1994, ARCH OPHTHALMOL-CHIC, V112, P839, DOI 10.1001/archopht.1994.01090180139048
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 34
TC 11
Z9 12
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2010
VL 224
IS 2
BP 72
EP 78
DI 10.1159/000235724
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 491ID
UT WOS:000269571200002
PM 19707030
DA 2022-11-30
ER

PT J
AU Mantel, I
   Borgo, A
   Guidotti, J
   Forestier, E
   Kirsch, O
   Derradji, Y
   Waridel, P
   Burdet, F
   Mehl, F
   Schweizer, C
   Roduit, R
AF Mantel, Irmela
   Borgo, Angelica
   Guidotti, Jacopo
   Forestier, Edwige
   Kirsch, Olga
   Derradji, Yasmine
   Waridel, Patrice
   Burdet, Frederic
   Mehl, Florence
   Schweizer, Claude
   Roduit, Raphael
TI Molecular Biomarkers of Neovascular Age-Related Macular Degeneration
   With Incomplete Response to Anti-Vascular Endothelial Growth Factor
   Treatment
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE age-related macular degeneration (AMD); angiogenic factors;
   Inflammation; Soluble vascular cell adhesion molecule-1 (sVCAM-1);
   interleukin-6 (IL-6); bioactive interleukin-12 (IL-12p40); plasminogen
   ctivator inhibitor type 1 (PAI-1); hepatocyte growth factor (HGF)
ID ACTIVATOR INHIBITOR TYPE-1; HEPATOCYTE GROWTH; GENE-EXPRESSION;
   AQUEOUS-HUMOR; RANIBIZUMAB; VEGF; QUANTIFICATION; CYTOKINES; THERAPY;
   PROTEIN
AB The standard treatment for neovascular age-related macular degeneration (nAMD) consists of intravitreal anti-vascular endothelial growth factors (VEGF). However, for some patients, even maximal anti-VEGF treatment does not entirely suppress exudative activity. The goal of this study was to identify molecular biomarkers in nAMD with incomplete response to anti-VEGF treatment. Aqueous humor (AH) samples were collected from three groups of patients: 17 patients with nAMD responding incompletely to anti-VEGF (18 eyes), 17 patients affected by nAMD with normal treatment response (21 eyes), and 16 control patients without any retinopathy (16 eyes). Proteomic and multiplex analyses were performed on these samples. Proteomic analyses showed that nAMD patients with incomplete anti-VEGF response displayed an increased inflammatory response, complement activation, cytolysis, protein-lipid complex, and vasculature development pathways. Multiplex analyses revealed a significant increase of soluble vascular cell adhesion molecule-1 (sVCAM-1) [ p = 0.001], interleukin-6 (IL-6) [ p = 0.009], bioactive interleukin-12 (IL-12p40) [ p = 0.03], plasminogen activator inhibitor type 1 (PAI-1) [ p = 0.004], and hepatocyte growth factor (HGF) [ p = 0.004] levels in incomplete responders in comparison to normal responders. Interestingly, the same biomarkers showed a high intercorrelation with r2 values between 0.58 and 0.94. In addition, we confirmed by AlphaLISA the increase of sVCAM-1 [ p < 0.0001] and IL-6 [ p = 0.043] in the incomplete responder group. Incomplete responders in nAMD are associated with activated angiogenic and inflammatory pathways. The residual exudative activity of nAMD despite maximal anti-VEGF treatment may be related to both angiogenic and inflammatory responses requiring specific adjuvant therapy. Data are available via ProteomeXchange with identifier PXD02247
C1 [Mantel, Irmela; Borgo, Angelica; Guidotti, Jacopo; Forestier, Edwige; Kirsch, Olga; Derradji, Yasmine; Schweizer, Claude; Roduit, Raphael] Univ Lausanne, Jules Gonin Eye Hosp, Dept Ophthalmol, Lausanne, Switzerland.
   [Waridel, Patrice] Univ Lausanne, Prot Anal Facil, Lausanne, Switzerland.
   [Burdet, Frederic; Mehl, Florence] Swiss Inst Bioinformat, Lausanne, Switzerland.
C3 University of Lausanne; University of Lausanne; Swiss Institute of
   Bioinformatics
RP Mantel, I; Roduit, R (通讯作者)，Univ Lausanne, Jules Gonin Eye Hosp, Dept Ophthalmol, Lausanne, Switzerland.
EM irmela.mantel@fa2.ch; raphael.roduit@fa2.ch
RI mehl, florence/Q-6651-2019
OI mehl, florence/0000-0002-9619-1707; Roduit, Raphael/0000-0001-7440-2799
FU Gelbert Foundation; "Art & Vie" Foundation; Foundation "Asile des
   aveugles"
FX RR is supported by the Gelbert Foundation and the "Art & Vie"
   Foundation. The study was supported by an internal grant of the
   Foundation "Asile des aveugles."
CR BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bertelmann T, 2013, GRAEF ARCH CLIN EXP, V251, P2697, DOI 10.1007/s00417-013-2374-8
   Bontzos G, 2020, OPHTHALMOL RETINA, V4, P1138, DOI 10.1016/j.oret.2019.11.004
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cabral T, 2018, OPHTHALMOL RETINA, V2, P31, DOI 10.1016/j.oret.2017.04.004
   Cai WY, 2000, INVEST OPHTH VIS SCI, V41, P1885
   Calvo P, 2015, BRIT J OPHTHALMOL, V99, P723, DOI 10.1136/bjophthalmol-2014-305684
   Chalam KV, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/502174
   Cox J, 2014, MOL CELL PROTEOMICS, V13, P2513, DOI 10.1074/mcp.M113.031591
   Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j
   Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511
   Dias JRD, 2011, BRIT J OPHTHALMOL, V95, P1631, DOI 10.1136/bjo.2010.186361
   Fogli S, 2018, EYE, V32, P1010, DOI 10.1038/s41433-018-0021-7
   Hebert AS, 2014, MOL CELL PROTEOMICS, V13, P339, DOI 10.1074/mcp.M113.034769
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Imagawa S, 2006, ARTERIOSCL THROM VAS, V26, P2407, DOI 10.1161/01.ATV.0000240318.61359.e3
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Knickelbein Jared E, 2015, Int Ophthalmol Clin, V55, P63, DOI 10.1097/IIO.0000000000000073
   Kulak NA, 2014, NAT METHODS, V11, P319, DOI [10.1038/NMETH.2834, 10.1038/nmeth.2834]
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lambert V, 2001, FASEB J, V15, P1021, DOI 10.1096/fj.00-0393com
   Litwinska Z, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00286
   Liu F, 2016, MOL VIS, V22, P352
   Mantel I, 2014, BRIT J OPHTHALMOL, V98, P1192, DOI 10.1136/bjophthalmol-2013-304556
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nassar K, 2013, INVEST OPHTH VIS SCI, V54
   Nielsen MK, 2019, INVEST OPHTH VIS SCI, V60, P202, DOI 10.1167/iovs.18-25878
   Pongsachareonnont P, 2018, CLIN OPHTHALMOL, V12, P1877, DOI 10.2147/OPTH.S171636
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sato T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19594-6
   Schwanhausser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Stanley AC, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000158
   Tyanova S, 2016, NAT METHODS, V13, P731, DOI [10.1038/NMETH.3901, 10.1038/nmeth.3901]
   Wakshull E, 2018, INVEST OPHTH VIS SCI, V59, P4106, DOI 10.1167/iovs.18-24792
   Wei Z, 2018, CELL SIGNAL, V44, P118, DOI 10.1016/j.cellsig.2018.01.015
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
NR 41
TC 5
Z9 5
U1 1
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD DEC 29
PY 2020
VL 11
AR 594087
DI 10.3389/fphar.2020.594087
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA PR3XX
UT WOS:000607173000001
PM 33447243
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Bhatt, P
   Narvekar, P
   Lalani, R
   Chougule, MB
   Pathak, Y
   Sutariya, V
AF Bhatt, Priyanka
   Narvekar, Priya
   Lalani, Rohan
   Chougule, Mahavir Bhupal
   Pathak, Yashwant
   Sutariya, Vijaykumar
TI An in vitro Assessment of Thermo-Reversible Gel Formulation Containing
   Sunitinib Nanoparticles for Neovascular Age-Related Macular Degeneration
SO AAPS PHARMSCITECH
LA English
DT Article
DE sunitinib; PLGA nanoparticles; sustained release; ocular delivery;
   intravitreal; VEGF
ID DRUG-DELIVERY; THERAPY; PLGA; BEVACIZUMAB; INHIBITOR; PROGRESS; VEGF
AB Anti-vascular endothelial growth factor agents have been widely used to treat several eye diseases including age-related macular degeneration (AMD). An approach to maximize the local concentration of drug at the target site and minimize systemic exposure is to be sought. Sunitinib malate, a multiple receptor tyrosine kinase inhibitor was encapsulated in poly(lactic-co-glycolic acid) nanoparticles to impart sustained release. The residence time in vitreal fluid was further increased by incorporating nanoparticles in thermo-reversible gel. Nanoparticles were characterized using TEM, DSC, FTIR, and in vitro drug release profile. The cytotoxicity of the formulation was assessed on ARPE-19 cells using the MTT assay. The cellular uptake, wound scratch assay, and VEGF expression levels were determined in in vitro settings. The optimized formulation had a particle size of 164.5 nm and zeta potential of - 18.27 mV. The entrapment efficiency of 72.0% +/- 3.5% and percent drug loading of 9.1 +/- 0.7% were achieved. The viability of ARPE-19 cells was greater than 90% for gel loaded, as such and blank nanoparticles at 10 mu M and 20 mu M concentration tested, whereas for drug solution viability was found to be 83% and 71% respectively at above concentration. The cell viability results suggest the compatibility of the developed formulation. Evaluation of cellular uptake, wound scratch assay, and VEGF expression levels for the developed formulations indicated that the formulation had higher uptake, superior anti-angiogenic potential, and prolonged inhibition of VEGF activity compared with drug solution. The results showed successful development of sunitinib-loaded nanoparticle-based thermo-reversible gel which may be used for the treatment of neovascular AMD.
C1 [Bhatt, Priyanka; Narvekar, Priya; Pathak, Yashwant; Sutariya, Vijaykumar] Univ S Florida, Dept Pharmaceut Sci, 12901 Bruce B Downs Blvd,MDC30, Tampa, FL USA.
   [Lalani, Rohan] Maharaja Sayajirao Univ Baroda, Fac Pharm, Vadodara 390001, Gujarat, India.
   [Chougule, Mahavir Bhupal] Univ Mississippi, Sch Pharm, 1018 TCRC Univ, Oxford, MS 38677 USA.
   [Pathak, Yashwant] Airlangga Univ, Fac Pharm, Surabaya, Indonesia.
C3 State University System of Florida; University of South Florida;
   Maharaja Sayajirao University Baroda; University of Mississippi;
   Airlangga University
RP Sutariya, V (通讯作者)，Univ S Florida, Dept Pharmaceut Sci, 12901 Bruce B Downs Blvd,MDC30, Tampa, FL USA.
EM vsutariy@health.usf.edu
RI pathak, yashwant/AAN-3177-2021; Bhatt, Priyanka/I-8381-2019
OI Bhatt, Priyanka/0000-0001-9012-7096; Lalani, Dr
   Rohan/0000-0001-8348-6795
FU Param Bhakti Healthcare and Research [FHT 17-20]
FX The authors would like to thank High Tech Corridor Matching Grant
   Program (FHT 17-20) with Param Bhakti Healthcare and Research for
   providing necessary funding for this work.
CR Al Gwairi Othman, 2016, J OPHTHALMOLOGY, V2016, P1
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Alshetaili AS, 2018, TROP J PHARM RES, V17, P1263, DOI 10.4314/tjpr.v17i7.6
   Ambasta RK, 2011, VASC CELL, V3, DOI 10.1186/2045-824X-3-26
   Bhatt P, 2018, INT J PHARMACEUT, V536, P95, DOI 10.1016/j.ijpharm.2017.11.048
   Bhatt P, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.AM2016-2065
   Bhatt P, 2015, DRUG DELIV, V22, P849, DOI 10.3109/10717544.2014.898348
   Carmeliet P, 2005, ONCOLOGY-BASEL, V69, P4, DOI 10.1159/000088478
   Mena AC, 2010, ANTI-CANCER DRUG, V21, pS3, DOI 10.1097/01.cad.0000361534.44052.c5
   Chou R, 2016, JAMA-J AM MED ASSOC, V315, P915, DOI 10.1001/jama.2016.0783
   Day S, 2011, AM J OPHTHALMOL, V152, P266, DOI 10.1016/j.ajo.2011.01.053
   del Amo EM, 2017, PROG RETIN EYE RES, V57, P134, DOI 10.1016/j.preteyeres.2016.12.001
   Espana-Serrano L, 2016, MOL THER-NUCL ACIDS, V5, DOI 10.1038/mtna.2016.90
   Gaudana R, 2009, PHARM RES-DORDR, V26, P1197, DOI 10.1007/s11095-008-9694-0
   Goel PN, 2011, MOL CELL BIOCHEM, V358, P141, DOI 10.1007/s11010-011-0929-8
   Halasz K, 2019, CURR DRUG DELIV, V16, P153, DOI 10.2174/1567201815666181017095708
   Hirani A, 2016, PHARM DEV TECHNOL, V21, P61, DOI 10.3109/10837450.2014.965326
   Hoare TR, 2008, POLYMER, V49, P1993, DOI 10.1016/j.polymer.2008.01.027
   Hulkower Keren I, 2011, Pharmaceutics, V3, P107, DOI 10.3390/pharmaceutics3010107
   Huo MR, 2017, J CONTROL RELEASE, V245, P81, DOI 10.1016/j.jconrel.2016.11.013
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kim KL, 2017, INVEST OPHTH VIS SCI, V58, P3592, DOI 10.1167/iovs.17-21416
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Le Tourneau Christophe, 2007, Ther Clin Risk Manag, V3, P341, DOI 10.2147/tcrm.2007.3.2.341
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377
   Medina C, 2007, BRIT J PHARMACOL, V150, P552, DOI 10.1038/sj.bjp.0707130
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Patel J, 2018, J MICROENCAPSUL, V35, P204, DOI 10.1080/02652048.2018.1453560
   Patil SV, 2016, RSC ADV, V6, P110206, DOI 10.1039/c6ra23614f
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Pieramici DJ, 2015, DIABETIC RETINOPATHY, V56
   Pirooznia N, 2012, J NANOBIOTECHNOL, V10, DOI 10.1186/1477-3155-10-20
   Pozarowska D, 2016, CENT EUR J IMMUNOL, V41, P311, DOI 10.5114/ceji.2016.63132
   Sadat S.M., 2016, J BIOMATER NANOBIOTE, V7, P91, DOI DOI 10.4236/JBNB.2016.72011
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Schwartz SG, 2014, EXPERT OPIN DRUG DEL, V11, P61, DOI 10.1517/17425247.2013.859135
   Semete B, 2010, NANOMED-NANOTECHNOL, V6, P662, DOI 10.1016/j.nano.2010.02.002
   Senger DR, ANGIOGENESIS, V3
   Shang Q, 2015, RSC ADV, V5, P75025, DOI 10.1039/c5ra12262g
   Sharma S, 2012, CAN J OPHTHALMOL, V47, P275, DOI 10.1016/j.jcjo.2012.03.026
   Singh R, 2015, DRUG DEV IND PHARM, V41, P1888, DOI 10.3109/03639045.2015.1019355
   Stevenson CL, 2012, ADV DRUG DELIVER REV, V64, P1590, DOI 10.1016/j.addr.2012.02.005
   Tandel H, 2018, IN VITRO IN VIVO TOO, DOI [10. 1201/b2244, DOI 10.1201/B2244]
   Yewale C, 2018, J DRUG DELIV SCI TEC, V45, P334, DOI 10.1016/j.jddst.2018.03.027
   Zhang C, 2004, COLLOID SURFACE B, V39, P69, DOI 10.1016/j.colsurfb.2004.09.002
NR 48
TC 27
Z9 27
U1 1
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1530-9932
J9 AAPS PHARMSCITECH
JI AAPS PharmSciTech
PD AUG 9
PY 2019
VL 20
IS 7
AR 281
DI 10.1208/s12249-019-1474-0
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA IQ1ER
UT WOS:000480493200003
PM 31399890
DA 2022-11-30
ER

PT J
AU Hikichi, T
   Agarie, M
AF Hikichi, Taiichi
   Agarie, Mitsuko
TI Reduced Vessel Density of the Choriocapillaris during Anti-Vascular
   Endothelial Growth Factor Therapy for Neovascular Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE anti-VEGF; choriocapillaris; neovascular age-related macular
   degeneration; optical coherence tomography angiography; vessel density
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   VERTEPORFIN PHOTODYNAMIC THERAPY; RETINAL-PIGMENT EPITHELIUM; FOVEAL
   AVASCULAR ZONE; ANTI-VEGF TREATMENT; QUANTITATIVE-ANALYSIS; VASCULAR
   DENSITY; RANIBIZUMAB; ATROPHY
AB PURPOSE. To investigate macular vascular alterations by using optical coherence tomography angiography (OCTA) in patients with a history of long-term anti-vascular endothelial growth factor (VEGF) therapy for neovascular age-related macular degeneration (nAMD).
   METHODS. Japanese patients with nAMD with a history of long-term anti-VEGF monotherapy at study entry were studied retrospectively. OCTA images were obtained, and the vessel densities (mm(-1)) of the superficial capillary plexus, deep capillary plexus (DCP), choriocapillaris (CC), and the plexus foveal avascular zone area (mm(2)) were calculated.
   RESULTS. One hundred twenty-four eyes (124 patients) were included. The mean +/- standard deviation follow-up period between the first and last OCTA imaging sessions was 14.5 +/- 3.1 months; the duration of the anti-VEGF monotherapy before the first OCTA imaging session was 68.0 +/- 23.6 months, with a mean of 3.6 +/- 3.0 injections during the follow-up period. The vessel densities of the DCP and CC significantly decreased (P = 0.001 and P = 0.009, respectively) from 10.62 +/- 2.72 mm(-1) and 11.84 +/- 1.79 mm(-1) to 9.44 +/- 2.88 mm(-1) and 11.18 +/- 2.12 mm(-1). Such findings were not observed in 63 control eyes.
   CONCLUSIONS. The DCP and CC deteriorate during treatment. This information may guide future treatment strategies for nAMD, such as the need to protect the capillaries to maintain visual acuity after long-term treatment. Prospective, controlled trials are required to confirm our findings.
C1 [Hikichi, Taiichi] Hikichi Eye Clin, Sapporo, Hokkaido, Japan.
   [Agarie, Mitsuko] Carl Zeiss Meditec Co Ltd, Tokyo, Japan.
C3 Carl Zeiss AG
RP Hikichi, T (通讯作者)，Hikichi Eye Clin, Kita Ku, 7-1 Kita 7 Nishi 5, Sapporo, Hokkaido 0600807, Japan.
EM thikichi@hikichi-eye.jp
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anand-Apte B, 2010, ENCY EYE, P9
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Campbell JP, 2017, SCI REP-UK, V7, DOI 10.1038/srep42201
   DelPriore LV, 1996, AM J OPHTHALMOL, V122, P629, DOI 10.1016/S0002-9394(14)70481-7
   Falavarjani KG, 2017, INVEST OPHTH VIS SCI, V58, P30, DOI 10.1167/iovs.16-20579
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Gao SS, 2016, INVEST OPHTH VIS SCI, V57, pOCT27, DOI 10.1167/iovs.15-19043
   Garrity ST, 2017, INVEST OPHTH VIS SCI, V58, P5548, DOI 10.1167/iovs.17-22036
   Hata M, 2017, INVEST OPHTH VIS SCI, V58, P292, DOI 10.1167/iovs.16-20967
   Iafe NA, 2016, INVEST OPHTH VIS SCI, V57, P5780, DOI 10.1167/iovs.16-20045
   Jia YL, 2015, P NATL ACAD SCI USA, V112, pE2395, DOI 10.1073/pnas.1500185112
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Kuroda Y, 2016, AM J OPHTHALMOL, V161, P94, DOI 10.1016/j.ajo.2015.09.032
   Lee B, 2018, INVEST OPHTH VIS SCI, V59, P5246, DOI 10.1167/iovs.17-23600
   Lee J, 2016, OPHTHALMOLOGY, V123, P2368, DOI 10.1016/j.ophtha.2016.07.010
   Lee MY, 2013, AM J OPHTHALMOL, V156, P343, DOI 10.1016/j.ajo.2013.04.001
   Leonard DS, 1997, INVEST OPHTH VIS SCI, V38, P1094
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Moon BG, 2018, OPHTHALMOL RETINA, V2, P235, DOI 10.1016/j.oret.2017.07.003
   Munk MR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177059
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Park SJ, 2016, INVEST OPHTH VIS SCI, V57, P2612, DOI 10.1167/iovs.16-19204
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2016, DEV OPHTHALMOL, V56, P18, DOI 10.1159/000442773
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Shahlaee A, 2016, AM J OPHTHALMOL, V165, P39, DOI 10.1016/j.ajo.2016.02.018
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Stavrev V., 2018, OPEN J OPHTHALMOL, V8, P133, DOI [10.4236/ojoph.2018.83017, DOI 10.4236/OJOPH.2018.83017]
   Suzuki N, 2016, INVEST OPHTH VIS SCI, V57, P5681, DOI 10.1167/iovs-16-20648
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Uji A, 2017, OPHTHALMOLOGY, V124, P944, DOI 10.1016/j.ophtha.2017.02.006
   Wang Q, 2016, AM J OPHTHALMOL, V168, P95, DOI 10.1016/j.ajo.2016.05.005
   Yu J, 2015, INVEST OPHTH VIS SCI, V56, P3212, DOI 10.1167/iovs.14-16270
   Zhang QQ, 2017, OPHTHALMOL RETINA, V1, P124, DOI 10.1016/j.oret.2016.08.005
NR 51
TC 21
Z9 21
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2019
VL 60
IS 4
BP 1088
EP 1095
DI 10.1167/iovs.18-24522
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HQ4PB
UT WOS:000462392500025
PM 30901385
OA gold
DA 2022-11-30
ER

PT J
AU Veritti, D
   Sarao, V
   Lanzetta, P
AF Veritti, Daniele
   Sarao, Valentina
   Lanzetta, Paolo
TI Bevacizumab and Triamcinolone Acetonide for Choroidal Neovascularization
   Due to Age-Related Macular Degeneration Unresponsive to Antivascular
   Endothelial Growth Factors
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB; COMPLEMENT; PATHOGENESIS; THERAPIES; DRUSEN
AB Purpose: To evaluate the safety and efficacy of a combined approach using an antivascular endothelial growth factor (VEGF) agent (bevacizumab) and a steroid (triamcinolone acetonide) for treating choroidal neovascularization (CNV) due to age-related macular degeneration (AMD) unresponsive to anti-VEGF monotherapy.
   Methods: Retrospective case series. We analyzed 25 eyes with CNV due to AMD who received a combination of intravitreal bevacizumab (1 mg) and triamcinolone (4 mg). Results were assessed at 7 days, 1, 3, 6, 9, and 12 months by best-corrected visual acuity (BCVA) measurement, fluorescein angiography, indocyanine green angiography, and optical coherence tomography (OCT). Retreatment with intravitreal bevacizumab or combination therapy was considered at investigator discretion at every follow-up visit.
   Results: A mean BCVA improvement of 0.18 (95% CI: 0.05; 0.3) logMAR was reported between baseline and the 12-month measurement (P < 0.01). An opposite trend toward progressive loss of BCVA, from 1.08 to 1.31 logMAR, had been observed in the 6 months before starting the combination therapy, in spite of regular treatment with anti-VEGFs (P < 0.0001). OCT measurements showed a 139-mu m (95% CI: 76; 203) decrease in mean central retinal thickness (P < 0.01). On average, patients required 1.8 additional treatments. Five (20%) cases of intraocular pressure elevation were successfully treated with medications.
   Conclusions: Combination therapy with intravitreal bevacizumab and triamcinolone acetonide proved to be a safe and effective option for CNV unresponsive to anti-VEGF monotherapy. The combined treatment reversed the preoperative trend toward losing vision, and a significant anatomic improvement was seen by OCT.
C1 [Veritti, Daniele; Sarao, Valentina; Lanzetta, Paolo] Univ Udine, Dept Ophthalmol, I-33100 Udine, Italy.
C3 University of Udine
RP Lanzetta, P (通讯作者)，Univ Udine, Dept Ophthalmol, Piazza Santa Maria Misericordia, I-33100 Udine, Italy.
EM paolo.lanzetta@uniud.it
OI VERITTI, Daniele/0000-0003-0148-5348
CR Chan-Ling T, 2008, RETINAL AND CHOROIDAL ANGIOGENESIS, P119, DOI 10.1007/978-1-4020-6780-8_6
   Colucciello M, 2008, J OCUL PHARMACOL TH, V24, P15, DOI 10.1089/jop.2007.0080
   Donoso LA, 2010, SURV OPHTHALMOL, V55, P227, DOI 10.1016/j.survophthal.2009.11.001
   el Matri L, 2010, GRAEF ARCH CLIN EXP, V248, P779, DOI 10.1007/s00417-010-1302-4
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P537, DOI 10.1136/bjo.2007.123190
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   He S, 2003, ARCH OPHTHALMOL-CHIC, V121, P1283, DOI 10.1001/archopht.121.9.1283
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Kothary PC, 2010, ADV EXP MED BIOL, V664, P419, DOI 10.1007/978-1-4419-1399-9_48
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nagy JA, 2007, ANNU REV PATHOL-MECH, V2, P251, DOI 10.1146/annurev.pathol.2.010506.134925
   Nissen NN, 1998, AM J PATHOL, V152, P1445
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Provis JM, 1997, EXP EYE RES, V65, P555, DOI 10.1006/exer.1997.0365
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Tao Y, 2010, J OCUL PHARMACOL TH, V26, P207, DOI 10.1089/jop.2009.0131
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zipfel PF, 2010, ADV EXP MED BIOL, V703, P9, DOI 10.1007/978-1-4419-5635-4_2
NR 19
TC 13
Z9 14
U1 0
U2 6
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD MAY
PY 2013
VL 29
IS 4
BP 437
EP 441
DI 10.1089/jop.2012.0173
PG 5
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 134ON
UT WOS:000318221900013
PM 23215753
DA 2022-11-30
ER

PT J
AU Ruiz-Moreno, JM
   Montero, JA
AF Ruiz-Moreno, JM
   Montero, JA
TI Sequential combined therapy for treatment of choroidal
   neovascularization in age-related macular degeneration: Photodynamic
   therapy and thermal laser photocoagulation
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE choroidal neovascularization; photodynamic therapy; thermal laser
   photocoagulation
ID RANDOMIZED CLINICAL-TRIALS; VERTEPORFIN THERAPY; MACULOPATHY;
   JUXTAFOVEAL; PREVALENCE
AB PURPOSE. To analyze the results achieved after treating extrafoveal choroidal neovascularization (CNV) recurrences with thermal laser photocoagulation (TLP) in patients who had previously undergone photodynamic therapy (PDT).
   PATIENTS AND METHODS. Seven eyes (seven patients: four women and three men) that had been initially treated by PDT for CNV associated with age-related macular degeneration (ARMD) and then developed extrafoveal recurrences were treated with green argon TLP. All patients underwent a complete ophthalmologic evaluation and fluorescein angiography. Mean age was 74.4 +/- 4.4 years (range, 69 to 81 years). Five right eyes and two left eyes were treated. Mean follow-up after the beginning of the treatment with PDT was 18.0 +/- 3.5 months (range, 11 to 22 months). Follow-up after TLP was 6.8 +/- 1.0 months (range, 6 to 8 months).
   RESULTS. Mean best-corrected visual acuity (BCVA) before treatment was 20/150 (range 20/400 to 20/40). After PDT it was 20/281 (range, 20/400 to 20/80), with a mean of 3.1 +/- 0.8 treatments (range, 2 to 4). After TLP, BCVA was 20/233 (range, 20/400 to 20/80), with no statistically significant difference from BCVA after PDT (p=0.06, Student's t-test paired data). In all cases total closure of CNV was achieved after only one session of TLP.
   CONCLUSIONS. TLP could be helpful in association with multiple sessions of PDT in order to achieve a complete closure of subfoveal CNV secondary to ARMD. Further studies are required to confirm our findings.
C1 Univ Miguel Hernandez, Div Oftalmol, Sch Med, Dept Ophthalmol, Alicante 03550, Spain.
   Inst Oftalmol Alicante, Vitreoretinal Unit, Alicante, Spain.
C3 Universidad Miguel Hernandez de Elche
RP Ruiz-Moreno, JM (通讯作者)，Univ Miguel Hernandez, Div Oftalmol, Sch Med, Dept Ophthalmol, Campus San Juan, Alicante 03550, Spain.
RI Ruiz-Moreno, José M/E-4644-2016
OI Ruiz-Moreno, Jose M/0000-0001-9636-0788
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Bunse A, 2000, KLIN MONATSBL AUGENH, V216, P158, DOI 10.1055/s-2000-10537
   CHISHOLM IH, 1983, T OPHTHAL SOC UK, V3, P354
   COSCAS G, 1991, DEGENERESCENCES MACU, P396
   Falcone P, 1998, OPHTHALMIC SURG LAS, V29, P933
   Gass J D, 1971, Trans Am Acad Ophthalmol Otolaryngol, V75, P580
   GREEN WR, 1992, OPHTHALMOLOGY, V100, P1519
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Jampol LM, 2002, AM J OPHTHALMOL, V134, P99, DOI 10.1016/S0002-9394(02)01463-0
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   Margherio RR, 2000, RETINA-J RET VIT DIS, V20, P325, DOI 10.1097/00006982-200007000-00001
   Matsuda Satoshi, 2002, Nippon Ganka Gakkai Zasshi, V106, P708
   Ruiz-Moreno JM, 2003, BRIT J OPHTHALMOL, V87, P856, DOI 10.1136/bjo.87.7.856
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Schnurrbusch UEK, 2001, BRIT J OPHTHALMOL, V85, P1086, DOI 10.1136/bjo.85.9.1086
   Soubrane G, 1987, Bull Soc Ophtalmol Fr, V87, P249
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   2002, RETINA, V22, P6
NR 21
TC 0
Z9 1
U1 0
U2 0
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD OCT
PY 2003
VL 13
IS 8
BP 681
EP 686
DI 10.1177/112067210301300803
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 739HK
UT WOS:000186338900003
PM 14620171
DA 2022-11-30
ER

PT J
AU Hussain, RM
   Shaukat, BA
   Ciulla, LM
   Berrocal, AM
   Sridhar, J
AF Hussain, Rehan M.
   Shaukat, Bilal A.
   Ciulla, Lauren M.
   Berrocal, Audina M.
   Sridhar, Jayanth
TI Vascular Endothelial Growth Factor Antagonists: Promising Players in the
   Treatment of Neovascular Age-Related Macular Degeneration
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Review
DE ADVM-022; age-related macular degeneration; abicipar pegol; CLS-AX;
   conbercept; faricimab; GB-102; KSI-301; PAN-90806; OTX-TKI; ranibizumab
   port delivery system; RGX-314; VEGF
ID DAILY CLINICAL-PRACTICE; REAL-WORLD OUTCOMES; VISUAL-ACUITY;
   INTRAVITREAL RANIBIZUMAB; FACTOR THERAPY; EXTEND; VEGF; BEVACIZUMAB;
   INJECTION; LIFE
AB Neovascular age-related macular degeneration (nAMD) treatment has been revolutionized by the introduction of vascular endothelial growth factor antagonists (anti-VEGF), but the need for frequent intravitreal injections poses a heavy burden to patients and physicians. Evolving anti-VEGF therapies include longer duration agents, approaches that target multiple pathways, topical anti-VEGF agents, sustained-release, and genetic therapies. Abicipar pegol, a designed ankyrin repeat protein (DARPin), demonstrated the ability to maintain stable visual acuity with 12-week dosing, but was not approved by the FDA due to higher than usual rates of intraocular inflammation. Conbercept, a recombinant anti-VEGF fusion protein, has been approved in China, and is in Phase 3 trials globally. KSI-301 is an anti-VEGF antibody biopolymer conjugate that allowed 66% of nAMD patients to maintain at least a 6-month treatment-free interval in Phase 1b studies. OPT-302, an inhibitor of VEGF-C/D, will be tested in phase 3 studies that compare anti-VEGF-A monotherapy against combination therapy with OPT-302. Faricimab is a bispecific anti-VEGF/Ang-2 antibody that upregulates the Tie-2 signaling pathway and promotes vascular stability; it is undergoing phase 3 trials with potential for 12- or 16-week dosing. PAN-90806 is a topical anti-VEGF agent that showed the ability to reduce injection frequency by 79% compared to ranibizumab monotherapy in a phase 1/2a trial. Sustained-release anti-VEGF therapies include the ranibizumab Port Delivery System (in phase 3 studies), GB-102 (Phase 2b), OTX-TKI (phase 1), and Durasert (preclinical). Suprachoroidal delivery of the tyrosine kinase inhibitor, axitinib, is in preclinical studies. Genetic therapies in phase 1 studies include RGX-314 and ADVM-022, which introduce a viral vector that modifies the retina's cellular apparatus to create an anti-VEGF biofactory, potentially serving as a one-time treatment. Further investigation is warranted for drugs and delivery systems that hope to advance visual outcomes and reduce treatment burden of nAMD.
C1 [Hussain, Rehan M.; Shaukat, Bilal A.] Retina Associates Ltd, 133 E Brush Hill Rd,Suite 300, Elmhurst, IL 60126 USA.
   [Shaukat, Bilal A.] Cook Cty Hosp, Dept Ophthalmol, Chicago, IL 60612 USA.
   [Ciulla, Lauren M.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Berrocal, Audina M.; Sridhar, Jayanth] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
C3 John H Stroger Junior Hospital Cook County; Northwestern University;
   Feinberg School of Medicine; Bascom Palmer Eye Institute; University of
   Miami
RP Hussain, RM (通讯作者)，Retina Associates Ltd, 133 E Brush Hill Rd,Suite 300, Elmhurst, IL 60126 USA.
EM Rhussain27@gmail.com
CR Al-Khersan H, 2019, EXPERT OPIN PHARMACO, V20, P1879, DOI 10.1080/14656566.2019.1636031
   [Anonymous], 2017, OCULAR SURG NEWS
   [Anonymous], 2020, EYEWIRE NEWS
   [Anonymous], 2020, Ocular Surgery News
   [Anonymous], 2019, GRAYBUG VISION PRESE
   [Anonymous], 2020, PHASE 3 DATA SHOW PO
   Arevalo JF, 2016, RETINA-J RET VIT DIS, V36, P859, DOI 10.1097/IAE.0000000000000827
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Baumal CR, 2020, OPHTHALMOLOGY, V127, P1345, DOI 10.1016/j.ophtha.2020.04.017
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bhattacharya D, 2015, EXP MOL PATHOL, V98, P455, DOI 10.1016/j.yexmp.2015.03.026
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cabral T, 2018, OPHTHALMOL RETINA, V2, P31, DOI 10.1016/j.oret.2017.04.004
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Chaney P., 2019, P OPHTH INN SUMM SAN
   Ciulla TA, 2020, OPHTHALMOL RETINA, V4, P19, DOI 10.1016/j.oret.2019.05.017
   Ciulla TA, 2018, OPHTHALMOL RETINA, V2, P1179, DOI 10.1016/j.oret.2018.06.004
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Csaky KG, 2015, OPHTHALMOLOGY, V122, P579, DOI 10.1016/j.ophtha.2014.09.036
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Davis S, 1999, CURR TOP MICROBIOL, V237, P173
   Delaney-Gesing A., 2021, OPHTHALMOLOGY T 0303
   Dugel PU, 2020, OPHTHALMOL RETINA, V4, P250, DOI 10.1016/j.oret.2019.10.008
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dunn EN, 2017, OSLI RETINA, V48, P100, DOI 10.3928/23258160-20170130-02
   Fachinger G, 1999, ONCOGENE, V18, P5948, DOI 10.1038/sj.onc.1202992
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GASS JDM, 1967, AM J OPHTHALMOL, V63, P573
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hansen TM, 2010, CELL SIGNAL, V22, P527, DOI 10.1016/j.cellsig.2009.11.007
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Helzner J, 2021, OPTHEA CLEARED 2 PHA
   Helzner J., 2018, RETINAL PHYS
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Hussain RM, 2020, EXPERT OPIN BIOL TH, V20, P999, DOI 10.1080/14712598.2020.1782379
   Hussain RM, 2019, EXPERT OPIN INV DRUG, V28, P861, DOI 10.1080/13543784.2019.1667333
   Hussain RM, 2017, OSLI RETINA, V48, P780, DOI 10.3928/23258160-20170928-01
   Hussain RM, 2017, EXPERT OPIN EMERG DR, V22, P235, DOI 10.1080/14728214.2017.1362390
   Jaffe GJ, 2017, OPHTHALMOLOGY, V124, P224, DOI 10.1016/j.ophtha.2016.10.010
   Joussen AM, 2019, BRIT J CLIN PHARMACO, V85, P347, DOI 10.1111/bcp.13794
   Khanani AM, ANG EX DEG VIRT M 2
   Khanani AM, 2020, JAMA OPHTHALMOL, V138, P964, DOI 10.1001/jamaophthalmol.2020.2699
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Moore NA, 2017, EXPERT OPIN BIOL TH, V17, P1235, DOI 10.1080/14712598.2017.1356817
   Rai-Roche S, 2021, LOA UPDATE CHENGDU K
   Rakic JM, 2013, CLIN OPHTHALMOL, V7, P1849, DOI 10.2147/OPTH.S49385
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross AH, 2013, EYE, V27, P56, DOI 10.1038/eye.2012.225
   Samanta A, 2020, ASIA-PAC J OPHTHALMO, V9, P250, DOI 10.1097/APO.0000000000000291
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Smith AG, 2014, EXPERT OPIN EMERG DR, V19, P157, DOI 10.1517/14728214.2014.884559
   Souied EH, 2015, RETINA-J RET VIT DIS, V35, P1743, DOI 10.1097/IAE.0000000000000548
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   van Asten F, 2015, ACTA OPHTHALMOL, V93, P126, DOI 10.1111/aos.12610
   Wan CR, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13020288
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Yeh S, 2020, OPHTHALMOLOGY, V127, P948, DOI 10.1016/j.ophtha.2020.01.006
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
NR 70
TC 10
Z9 10
U1 1
U2 2
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2021
VL 15
BP 2653
EP 2665
DI 10.2147/DDDT.S295223
PG 13
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA TB1GX
UT WOS:000667692500001
PM 34188445
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Cohen, SY
   Souied, EH
   Weber, M
   Dupeyron, G
   de Pouvourville, G
   Lievre, M
   Ponthieux, A
AF Cohen, Salomon-Yves
   Souied, Eric H.
   Weber, Michel
   Dupeyron, Gerard
   de Pouvourville, Gerard
   Lievre, Michel
   Ponthieux, Anne
TI Patient characteristics and treatment of neovascular age-related macular
   degeneration in France: the LUEUR1 observational study
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Neovascularisation; Epidemiology; Retina; Age-related macular
   degeneration; Ranibizumab; LUEUR
ID RANDOMIZED CLINICAL-TRIAL; VISION-RELATED FUNCTION; CHOROIDAL
   NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; RISK-FACTORS; RANIBIZUMAB;
   VERTEPORFIN; PREVALENCE; SECONDARY
AB Background Age-related macular degeneration is the primary cause of blindness in developed countries. Current treatments of this degenerative disease mainly include laser, photodynamic therapy with verteporfin and administration of antivascular endothelial growth factors. The LUEUR (LUcentis (R) En Utilisation Reelle) study is composed of a cross-sectional part (LUEUR1), which examined the current management of wet AMD in France, and a follow-up part (LUEUR2), which will assess the development of patients treated for wet AMD over 4 years. Here we describe the results of LUEUR1.
   Methods Patients with wet AMD were enrolled during a routine medical examination in LUEUR1, a cross-sectional, observational, prospective, multicentre study. Investigators recorded patient demographics, visual acuity, characteristics of wet AMD lesions, date of AMD diagnosis, comorbidities, previous treatments, treatments prescribed at inclusion, and low vision rehabilitation.
   Results A total of 72 investigators recruited 1,019 patients with wet AMD, corresponding to 1,405 eyes affected by the disease. The mean age of patients was 78.7 +/- 7.3 years. Most were female (62.3%) and non-smokers (66.9%). The mean visual acuity was 49.12 +/- 24.18 Early Treatment Diabetic Retinopathy Study letters. Most eyes showed occult (52.8%) and subfoveal (84.6%) choroidal neovascularisation. Bilateral wet AMD affected 37.9% of patients. The median time since diagnosis was 12 months. Ranibizumab-based therapy (67.3%) and photodynamic therapy (29.8%) were the most frequent previous treatments. Prior to inclusion, 5.6% of patients had low vision rehabilitation. When a treatment was prescribed on the day of inclusion, it was most often ranibizumab (89.0% of all treatments at inclusion).
   Conclusions The results of this study illustrate the impact of anti-vascular endothelial growth factor therapies on the treatment of wet AMD in a real-life context. Specifically, ranibizumab-based therapy appears to have largely replaced laser photocoagulation and verteporfin-based photodynamic therapy.
C1 [Ponthieux, Anne] Novartis Pharma SAS, F-92506 Rueil Malmaison, France.
   [Cohen, Salomon-Yves] Ctr Ophtalmol Imagerie & Laser, F-75015 Paris, France.
   [Souied, Eric H.] Creteil Univ, Eye Clin, Fac Med Henri Mondor, F-94000 Creteil, France.
   [Weber, Michel] Hotel Dieu Univ Hosp, Dept Ophthalmol, F-44093 Nantes 1, France.
   [Dupeyron, Gerard] Univ Nimes Hosp, Dept Ophthalmol, F-30029 Nimes 9, France.
   [de Pouvourville, Gerard] ESSEC, Hlth Econ, F-95021 Cergy Pontoise, France.
   [Lievre, Michel] Univ Lyon 1, Dept Clin Pharmacol, Serv Pharmacol Clin, Fac Med, F-69008 Lyon, France.
C3 Novartis; Assistance Publique Hopitaux Paris (APHP); Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire
   Henri-Mondor - APHP; Nantes Universite; CHU de Nantes; Universite de
   Montpellier; CHU de Nimes; ESSEC Business School; UDICE-French Research
   Universities; Universite Claude Bernard Lyon 1; Universite de
   Franche-Comte
RP Ponthieux, A (通讯作者)，Novartis Pharma SAS, 2&4 Rue Lionel Terray,BP 308, F-92506 Rueil Malmaison, France.
EM anne.ponthieux@novartis.com
FU Novartis Pharma SAS, France
FX This study was sponsored by Novartis Pharma SAS, France. SY Cohen, G De
   Pouvourville, G Dupeyron, M Lievre, E Souied and M Weber are consultants
   for Novartis Pharma, France. A Ponthieux is an employee of Novartis
   Pharma, France. The authors have full control of all primary data, and
   they agree to allow Graefe's Archive for Clinical and Experimental
   Ophthalmology to review their data upon request.
CR *ANAES, TRAIT DEG MAC LIEE A
   Baird PN, 2009, CLIN EXP OPHTHALMOL, V37, P814, DOI 10.1111/j.1442-9071.2009.02136.x
   Beutel J, 2009, EXPERT OPIN EMERG DR, V14, P341, DOI [10.1517/14728210902824141, 10.1517/14728210902824141 ]
   Bonastre J, 2003, PHARMACOECONOMICS, V21, P181, DOI 10.2165/00019053-200321030-00003
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Ergun E, 2004, RETINA-J RET VIT DIS, V24, P13, DOI 10.1097/00006982-200402000-00002
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Hubschman JP, 2009, CLIN OPHTHALMOL, V3, P155
   Leveziel N, 2008, INVEST OPHTH VIS SCI, V49, P3090, DOI 10.1167/iovs.07-1540
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   Solomon SD, 2007, ARCH OPHTHALMOL-CHIC, V125, P1323
   van Velthoven MEJ, 2006, GRAEF ARCH CLIN EXP, V244, P1119, DOI 10.1007/s00417-005-0209-y
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   ZANLONGHI X, 2003, OCTOPUS MULTIMEDIA, P101
   Zawinka C, 2005, RETINA-J RET VIT DIS, V25, P324, DOI 10.1097/00006982-200504000-00012
NR 26
TC 6
Z9 6
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD APR
PY 2011
VL 249
IS 4
BP 521
EP 527
DI 10.1007/s00417-010-1553-0
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 756SJ
UT WOS:000290034700008
PM 21057805
DA 2022-11-30
ER

PT J
AU Alsaih, K
   Yusoff, MZ
   Tang, TB
   Faye, I
   Meriaudeau, F
AF Alsaih, K.
   Yusoff, M. Z.
   Tang, T. B.
   Faye, I
   Meriaudeau, F.
TI Deep learning architectures analysis for age-related macular
   degeneration segmentation on optical coherence tomography scans
SO COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE
LA English
DT Article
DE Retinal fluids; Segmentation; SD-OCT volumes; deep learning; Patches
ID RETINAL LAYER; FLUID SEGMENTATION; QUANTIFICATION; RANIBIZUMAB; REGIMEN;
   EDEMA
AB Background and objectives: Aged people usually are more to be diagnosed with retinal diseases in developed countries. Retinal capillaries leakage into the retina swells and causes an acute vision loss, which is called age-related macular degeneration (AMD). The disease can not be adequately diagnosed solely using fundus images as depth information is not available. The variations in retina volume assist in monitoring ophthalmological abnormalities. Therefore, high-fidelity AMD segmentation in optical coherence tomography (OCT) imaging modality has raised the attention of researchers as well as those of the medical doctors. Many methods across the years encompassing machine learning approaches and convolutional neural networks (CNN) strategies have been proposed for object detection and image segmentation.
   Methods: In this paper, we analyze four wide-spread deep learning models designed for the segmentation of three retinal fluids outputting dense predictions in the RETOUCH challenge data. We aim to demonstrate how a patch-based approach could push the performance for each method. Besides, we also evaluate the methods using the OPTIMA challenge dataset for generalizing network performance. The analysis is driven into two sections: the comparison between the four approaches and the significance of patching the images.
   Results: The performance of networks trained on the RETOUCH dataset is higher than human performance. The analysis further generalized the performance of the best network obtained by fine-tuning it and achieved a mean Dice similarity coefficient (DSC) of 0.85. Out of the three types of fluids, intraretinal fluid (IRF) is more recognized, and the highest DSC value of 0.922 is achieved using Spectralis dataset. Additionally, the highest average DSC score is 0.84, which is achieved by PaDeeplabv3+ model using Cirrus dataset.
   Conclusions: The proposed method segments the three fluids in the retina with high DSC value. Finetuning the networks trained on the RETOUCH dataset makes the network perform better and faster than training from scratch. Enriching the networks with inputting a variety of shapes by extracting patches helped to segment the fluids better than using a full image. (C) 2020 The Authors. Published by Elsevier B.V.
C1 [Alsaih, K.; Yusoff, M. Z.; Tang, T. B.; Faye, I] Univ Teknol PETRONAS, Ctr Intelligent Signal & Imaging Res CISIR, Bandar Seri Iskandar 32610, Perak, Malaysia.
   [Meriaudeau, F.] Univ Bourgogne Franche Comte, ImViA Iftim, Besancon, France.
C3 Universiti Teknologi Petronas; Universite de Bourgogne
RP Alsaih, K (通讯作者)，Univ Teknol PETRONAS, Ctr Intelligent Signal & Imaging Res CISIR, Bandar Seri Iskandar 32610, Perak, Malaysia.
EM khaledalsaih@gmail.com
FU Fundamental Research Grant Scheme (FRGS) Ministry of Education (MOE),
   Malaysia [FRGS/1/2017/TK04/UTP/01/1]
FX This project was supported by the Fundamental Research Grant Scheme
   (FRGS) grant FRGS/1/2017/TK04/UTP/01/1 Ministry of Education (MOE),
   Malaysia.
CR Alsaih K., 2018, 2018 INT C INTELLIGE, P1
   Alsaih K, 2017, BIOMED ENG ONLINE, V16, DOI 10.1186/s12938-017-0352-9
   Apostolopoulos S., 2017, MICCAI RETINAL OCT F
   Badrinarayanan V, 2017, IEEE T PATTERN ANAL, V39, P2481, DOI 10.1109/TPAMI.2016.2644615
   Bogunovic H, 2019, IEEE T MED IMAGING, V38, P1858, DOI 10.1109/TMI.2019.2901398
   Chen L, 2018, PROCEEDINGS OF THE 2ND INTERNATIONAL CONFERENCE ON COMPUTER SCIENCE AND APPLICATION ENGINEERING (CSAE2018), DOI 10.1145/3207677.3278067
   Chen LB, 2017, IEEE INT SYMP NANO, P1, DOI 10.1109/NANOARCH.2017.8053709
   Chen Q., 2017, MICCAI RETINAL OCT F
   Chen XJ, 2012, IEEE T MED IMAGING, V31, P1521, DOI 10.1109/TMI.2012.2191302
   Chollet F, 2017, PROC CVPR IEEE, P1800, DOI 10.1109/CVPR.2017.195
   Dabov K, 2007, IEEE T IMAGE PROCESS, V16, P2080, DOI 10.1109/TIP.2007.901238
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Girish GN, 2019, IEEE ENG MED BIO, P2027, DOI 10.1109/EMBC.2019.8857333
   Girish GN, 2019, IEEE J BIOMED HEALTH, V23, P296, DOI 10.1109/JBHI.2018.2810379
   Gopinath K, 2019, IEEE J BIOMED HEALTH, V23, P273, DOI 10.1109/JBHI.2018.2793534
   Hassan B, 2019, CONFERENCE PROCEEDINGS OF 2019 5TH INTERNATIONAL CONFERENCE ON CONTROL, AUTOMATION AND ROBOTICS (ICCAR), P325, DOI 10.1109/ICCAR.2019.8813311
   He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90
   Hoyng C.B., 2015, MED IMAGE COMPUT COM
   Kafieh R, 2013, MED IMAGE ANAL, V17, P907, DOI 10.1016/j.media.2013.05.006
   Kajic V, 2010, OPT EXPRESS, V18, P14730, DOI 10.1364/OE.18.014730
   Kang S.H., 2017, MICCAI RETINAL OCT F
   Krizhevsky A., 2012, ADV NEURAL INF PROCE, P1097, DOI DOI 10.1145/3065386
   Lee CS, 2017, BIOMED OPT EXPRESS, V8, P3440, DOI 10.1364/BOE.8.003440
   Liu XM, 2019, IEEE J BIOMED HEALTH, V23, P1404, DOI 10.1109/JBHI.2018.2856276
   Long J, 2015, PROC CVPR IEEE, P3431, DOI 10.1109/CVPR.2015.7298965
   Lu D., 2017, MICCAI RETINAL OCT F
   Montuoro A, 2017, BIOMED OPT EXPRESS, V8, P1874, DOI 10.1364/BOE.8.001874
   Morley D., 2017, MICCAI RETINAL OCT F
   Rashno A., 2017, MICCAI RETINAL OCT F
   Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28
   Roy AG, 2017, BIOMED OPT EXPRESS, V8, P3627, DOI 10.1364/BOE.8.003627
   Russakovsky O, 2015, INT J COMPUT VISION, V115, P211, DOI 10.1007/s11263-015-0816-y
   Sandler M, 2018, PROC CVPR IEEE, P4510, DOI 10.1109/CVPR.2018.00474
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Schlegl Thomas, 2015, Inf Process Med Imaging, V24, P437, DOI 10.1007/978-3-319-19992-4_34
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Simonyan K., 2014, PREPRINT, DOI DOI 10.48550/ARXIV.1409.1556
   Tennakoon R., 2017, MICCAI RETINAL OCT F
   Venhuizen FG, 2018, BIOMED OPT EXPRESS, V9, P1545, DOI 10.1364/BOE.9.001545
   Warfield SK, 2004, IEEE T MED IMAGING, V23, P903, DOI 10.1109/TMI.2004.828354
   Wu J, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/3898750
   Yadav S., 2017, P MICCAI RET OCT FLU
NR 44
TC 12
Z9 12
U1 0
U2 17
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0169-2607
EI 1872-7565
J9 COMPUT METH PROG BIO
JI Comput. Meth. Programs Biomed.
PD OCT
PY 2020
VL 195
AR 105566
DI 10.1016/j.cmpb.2020.105566
PG 14
WC Computer Science, Interdisciplinary Applications; Computer Science,
   Theory & Methods; Engineering, Biomedical; Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Medical Informatics
GA NP4GH
UT WOS:000570135300005
PM 32504911
OA hybrid
DA 2022-11-30
ER

PT J
AU Yasukawa, T
   Mori, R
   Sawa, M
   Shinojima, A
   Hara, C
   Sekiryu, T
   Oshima, Y
   Saito, M
   Sugano, Y
   Kato, A
   Ashikari, M
   Hirano, Y
   Asato, H
   Nakamura, M
   Matsuno, K
   Kuno, N
   Kimura, E
   Nishiyama, T
   Yuzawa, M
   Ishibashi, T
   Ogura, Y
   Iida, T
   Gomi, F
AF Yasukawa, Tsutomu
   Mori, Ryusaburo
   Sawa, Miki
   Shinojima, Ari
   Hara, Chikako
   Sekiryu, Tetsuju
   Oshima, Yuji
   Saito, Masaaki
   Sugano, Yukinori
   Kato, Aki
   Ashikari, Masayuki
   Hirano, Yoshio
   Asato, Hitomi
   Nakamura, Mayumi
   Matsuno, Kiyoshi
   Kuno, Noriyuki
   Kimura, Erika
   Nishiyama, Takeshi
   Yuzawa, Mitsuko
   Ishibashi, Tatsuro
   Ogura, Yuichiro
   Iida, Tomohiro
   Gomi, Fumi
TI Fundus autofluorescence and retinal sensitivity in fellow eyes of
   age-related macular degeneration in Japan
SO PLOS ONE
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; PIGMENT EPITHELIUM PHENOTYPES;
   GEOGRAPHIC ATROPHY; VISUAL FUNCTION; LOW LUMINANCE; RISK-FACTORS;
   MICROPERIMETRY; RANIBIZUMAB; PREVALENCE; CLASSIFICATION
AB Purpose
   Abnormal fundus autofluorescence (FAF) potentially precedes onset of late age-related macular degeneration (AMD) in Caucasian patients. Many differences exist between Asian and Caucasian patients regarding AMD types and severity, gender, and genetic backgrounds. We investigated the characteristics of abnormal FAF and retinal sensitivity in the fellow eyes of Japanese patients with unilateral neovascular AMD.
   Methods
   Sixty-six patients with unilateral neovascular AMD and abnormal FAF in the fellow eye were enrolled in this multicenter, prospective, observational study. The best-corrected visual acuity, fundus photographs, FAF images, and retinal sensitivity on microperimetry were measured periodically for 12 months. The FAF images were classified into eight patterns based on the International Fundus Autofluorescence Classification Group. The points measured by microperimetry were superimposed onto the FAF images and fundus photographs and classified as "within," "close," and "distant," based on the distance from the abnormal FAF and other findings. The relationship between the location of the baseline abnormal FAF and retinal sensitivity was investigated.
   Results
   In Japanese patients, patchy (33.3%) and focally increased (30.3%) patterns predominated in the abnormal FAF. Intermediate-to-large drusen was associated predominantly with hyperfluorescence and hypofluorescence. Neovascular AMD developed within 1 year in six (9.1%) eyes, the mean baseline retinal sensitivity of which was 12.8 +/- 4.7 dB, significantly (p<0.002) lower than the other eyes. In 44 of the other 60 eyes, microperimetry was measurable at baseline and month 12 and the mean retinal sensitivity improved significantly from 13.5 +/- 4.4 to 13.9 +/- 4.8 dB (p<0.001), possibly associated with lifestyle changes (e.g., smoking cessation, antioxidant and zinc supplementation). The mean retinal sensitivities of points within and close to the abnormal FAF were 9.9 and 11.7 dB, respectively, which were significantly lower than the 14.0 dB of the points distant from the abnormal FAF.
   Conclusion
   In Japanese patients, patchy and focally increased patterns predominated in the abnormal FAF. The retinal sensitivity was lower close to/within the abnormal FAF. FAF and microperimetry are useful to assess macular function before development of neovascular AMD or geographic atrophy.
C1 [Yasukawa, Tsutomu; Kato, Aki; Ashikari, Masayuki; Hirano, Yoshio; Ogura, Yuichiro] Nagoya City Univ, Grad Sch Med Sci, Dept Ophthalmol & Visual Sci, Nagoya, Aichi, Japan.
   [Mori, Ryusaburo; Shinojima, Ari; Yuzawa, Mitsuko] Nihon Univ, Sch Med, Dept Visual Sci, Div Ophthalmol, Tokyo, Japan.
   [Sawa, Miki; Hara, Chikako; Gomi, Fumi] Osaka Univ, Grad Sch Med, Dept Ophthalmol, Osaka, Japan.
   [Sekiryu, Tetsuju; Saito, Masaaki; Sugano, Yukinori; Iida, Tomohiro] Fukushima Med Univ, Sch Med, Dept Ophthalmol, Fukushima, Japan.
   [Oshima, Yuji; Asato, Hitomi; Ishibashi, Tatsuro] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Fukuoka, Fukuoka, Japan.
   [Saito, Masaaki] Akita Univ, Grad Sch Med, Dept Ophthalmol, Akita, Japan.
   [Saito, Masaaki] Akita Univ, Fac Med, Akita, Japan.
   [Nakamura, Mayumi; Matsuno, Kiyoshi; Kuno, Noriyuki; Kimura, Erika] Santen Pharmaceut Co Ltd, Ikoma, Japan.
   [Kuno, Noriyuki] Japan Innovat Therapeut Inc, Nagoya, Aichi, Japan.
   [Nishiyama, Takeshi] Aichi Med Univ, Sch Med, Dept Publ Hlth, Nagakute, Aichi, Japan.
   [Iida, Tomohiro] Tokyo Womens Med Univ, Dept Ophthalmol, Tokyo, Japan.
   [Gomi, Fumi] Hyogo Coll Med, Dept Ophthalmol, Nishinomiya, Hyogo, Japan.
C3 Nagoya City University; Nihon University; Osaka University; Fukushima
   Medical University; Kyushu University; Akita University; Akita
   University; Santen Pharmaceutical Co Ltd; Aichi Medical University;
   Tokyo Women's Medical University; Hyogo College of Medicine
RP Yasukawa, T (通讯作者)，Nagoya City Univ, Grad Sch Med Sci, Dept Ophthalmol & Visual Sci, Nagoya, Aichi, Japan.
EM yasukawa@med.nagoya-cu.ac.jp
RI Saito, Masaaki/ABI-2783-2020; Shinojima, Ari/AAR-4442-2021
OI Saito, Masaaki/0000-0003-1494-6350; Shinojima, Ari/0000-0003-2322-0332;
   Gomi, Fumi/0000-0003-0807-8817; Yasukawa, Tsutomu/0000-0001-9913-1905;
   Hirano, Yoshio/0000-0002-9173-0839
CR Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Batioglu F, 2014, OPTOMETRY VISION SCI, V91, P950, DOI 10.1097/OPX.0000000000000321
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler NM, 2012, RETINA-J RET VIT DIS, V32, P1821, DOI 10.1097/IAE.0b013e31825db6ba
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 2006, AGE RELATED MACULAR, VII, P1041
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen FK, 2009, INVEST OPHTH VIS SCI, V50, P3464, DOI 10.1167/iovs.08-2926
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Einbock W, 2005, GRAEF ARCH CLIN EXP, V243, P300, DOI 10.1007/s00417-004-1027-3
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gliem M, 2016, JAMA OPHTHALMOL, V134, P817, DOI 10.1001/jamaophthalmol.2016.1475
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Gurka MJ, 2006, AM STAT, V60, P19, DOI 10.1198/000313006X90396
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Huang LL, 2016, NAT GENET, V48, P640, DOI 10.1038/ng.3546
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Nagai H, 2015, J CATARACT REFR SURG, V41, P1855, DOI 10.1016/j.jcrs.2015.01.017
   Nakata I, 2013, AM J OPHTHALMOL, V156, P1002, DOI 10.1016/j.ajo.2013.06.007
   Oishi M, 2017, INVEST OPHTH VIS SCI, V58, P3303, DOI 10.1167/iovs.17-21498
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakurada Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149978
   Sasamoto Y, 2011, GRAEF ARCH CLIN EXP, V249, P1847, DOI 10.1007/s00417-011-1780-z
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Steinberg JS, 2016, AM J OPHTHALMOL, V168, P52, DOI 10.1016/j.ajo.2016.04.025
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tamakoshi A, 1997, BRIT J OPHTHALMOL, V81, P901, DOI 10.1136/bjo.81.10.901
   Tanaka K, 2011, MOL VIS, V17, P2751
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Ueta T, 2011, OPHTHALMOLOGY, V118, P2093, DOI 10.1016/j.ophtha.2011.06.001
   Uyama M, 2000, BRIT J OPHTHALMOL, V84, P1018, DOI 10.1136/bjo.84.9.1018
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P3714, DOI 10.1167/iovs.15-18294
   Yazdanie M, 2017, OPHTHALMOLOGY, V124, P1332, DOI 10.1016/j.ophtha.2017.05.005
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS12, DOI 10.1097/IAE.0000000000001276
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS26, DOI 10.1097/IAE.0000000000001330
NR 49
TC 3
Z9 3
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 28
PY 2019
VL 14
IS 2
AR e0213161
DI 10.1371/journal.pone.0213161
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HN7LS
UT WOS:000460371500086
PM 30818384
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Manjunath, V
   Goren, J
   Fujimoto, JG
   Duker, JS
AF Manjunath, Varsha
   Goren, Jordana
   Fujimoto, James G.
   Duker, Jay S.
TI Analysis of Choroidal Thickness in Age-Related Macular Degeneration
   Using Spectral-Domain Optical Coherence Tomography
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BLOOD-FLOW; VISUAL IMPAIRMENT; PREVALENCE; RABBIT; EYES; POPULATION;
   MODULATION; SEVERITY; PRESSURE
AB PURPOSE: To understand the relationship between choroidal thickness and various disease factors in patients with age-related macular degeneration (AMD) using spectral-domain optical coherence tomography.
   DESIGN: Cross-sectional, retrospective analysis.
   METHODS: : Fifty-seven eyes of 47 patients with wet and dry AVID seen between November 2009 and January 2010 at the New England Eye Center, Boston, Massachusetts, were analyzed. Choroidal thickness was measured by 2 independent observers at 11 sites with high-definition horizontal 1-line raster scans through the foveal center. A retrospective chart review was performed to obtain data concerning duration of disease, number of intravitreal anti-vascular endothelial growth factor injections, visual acuity, lens status, and concomitant retinal pathologic features. The Pearson correlation and Student t test were used for statistical analysis for assessment of choroidal thickness changes in wet and dry AMD.
   RESULTS: The choroid in eyes with wet and dry AMD demonstrated a wide range of thicknesses above and below the normal mean (range, 77.5 to 399.5 mu m; standard deviation [SD], 90.2). Nearly one third (33.3%) of the eyes with AMD measured less than 1 SD below the mean. Eyes with wet AMD demonstrated a mean subfoveal choroidal thickness of 194.6 mu m (SD, 88.4; n = 40) compared with 213.4 mu m (SD, 92.2; n = 17) in the dry AMD group. The choroidal thickness in eyes with dry AMD was correlated inversely with age (r = -0.703; P = .002); however, analysis of the number of intravitreal anti-vascular endothelial growth factor injections, number of years of disease, and visual acuity failed to demonstrate any significant correlations with choroidal thickness.
   CONCLUSIONS: This study demonstrated that choroidal thickness can be measured by spectral-domain optical coherence tomography and that variable choroidal thickness exists among patients with the clinical diagnosis of wet and dry AMD. However, it is unclear at this time why in some eyes, choroidal thickness either increases or decreases with the disease. Further studies need to be carried out to understand the significance of choroidal thickness with respect to visual function and disease progression over time. (Am J Ophthalmol 2011;152: 663-668. (C) 2011 by Elsevier Inc. All rights reserved.)
C1 [Duker, Jay S.] Tufts Med Ctr, New England Eye Ctr, Dept Ophthalmol, Boston, MA 02111 USA.
   [Fujimoto, James G.] MIT, Elect Res Lab, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
C3 Tufts Medical Center; Massachusetts Institute of Technology (MIT)
RP Duker, JS (通讯作者)，Tufts Med Ctr, New England Eye Ctr, Dept Ophthalmol, 800 Washington St,Box 450, Boston, MA 02111 USA.
EM JDuker@tuftsmedicalcenter.org
FU National Institutes of Health, Bethesda, Maryland [R01-EY11289-23,
   R0I-EY13178-10, R01-EY013516-07]; Air Force Office of Scientific
   Research, Arlington, Virginia [FA9550-07-1-0101, FA9550-07-1-0014];
   Massachusetts Lions Eye Research Fund, Inc, New Bedford, Massachusetts;
   Carl Zeiss Meditec, Inc; Optovue Corporation; Topcon Medical Systems,
   Inc.; RESEARCH TO PREVENT BLINDNESS CHALLENGE GRANT; NATIONAL EYE
   INSTITUTE [R01EY013178, R01EY011289, R01EY013516] Funding Source: NIH
   RePORTER
FX PUBLICATION OF THIS ARTICLE WAS SUPPORTED IN PART BY A RESEARCH TO
   PREVENT BLINDNESS CHALLENGE GRANT TO the New England Eye
   Center/Department of Ophthalmology, Tufts University School of Medicine,
   Boston, Massachusetts; Grants R01-EY11289-23, R0I-EY13178-10, and
   R01-EY013516-07 from the National Institutes of Health, Bethesda,
   Maryland; Grants FA9550-07-1-0101 and FA9550-07-1-0014 from the Air
   Force Office of Scientific Research, Arlington, Virginia; and the
   Massachusetts Lions Eye Research Fund, Inc, New Bedford, Massachusetts.
   Dr Duker receives research support from Carl Zeiss Meditec, Inc, Optovue
   Corporation, and Topcon Medical Systems, Inc. Dr Fujimoto receives
   royalties from intellectual property owned by MIT and licensed to Carl
   Zeiss Meditec, Inc, and Light Labs Imaging. Dr Fujimoto also is a
   scientific advisor and has stock options in Optovue. The authors did not
   receive any financial support for their work on this study. Involved in
   Design and conduct of study (V.M., J.G., J.S.D.); Collection,
   management, analysis, and interpretation of data (V.M., J.G., J.S.D.);
   and Preparation and review of manuscript (V.M., J.G., J.G.F., J.S.D.).
   The study was approved by the Institutional Review Board of the Tufts
   Medical Center and complied with the Health Insurance Portability and
   Accountability Act.
CR Bhutto IA, 2010, EXP EYE RES, V90, P155, DOI 10.1016/j.exer.2009.10.004
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Drexler W, 2008, PROG RETIN EYE RES, V27, P45, DOI 10.1016/j.preteyeres.2007.07.005
   Ferguson RD, 2004, OPT LETT, V29, P2139, DOI 10.1364/OL.29.002139
   FLUGELKOCH C, 1994, INVEST OPHTH VIS SCI, V35, P4268
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   KIEL JW, 1995, INVEST OPHTH VIS SCI, V36, P579
   Kiel JW, 1999, EXP EYE RES, V69, P413, DOI 10.1006/exer.1999.0717
   Kiel JW, 2000, EXP EYE RES, V71, P543, DOI 10.1006/exer.2000.0911
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Lutjen-Drecoll E, 2006, EXP EYE RES, V82, P357, DOI 10.1016/j.exer.2005.09.015
   Manjunath V, 2010, AM J OPHTHALMOL, V150, P325, DOI 10.1016/j.ajo.2010.04.018
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Potsaid B, 2008, OPT EXPRESS, V16, P15149, DOI 10.1364/OE.16.015149
   Pournaras CJ, 2006, INVEST OPHTH VIS SCI, V47, P1581, DOI 10.1167/iovs.05-0434
   Reiner A, 2003, EXP EYE RES, V76, P273, DOI 10.1016/S0014-4835(02)00316-0
   Sander B, 2005, BRIT J OPHTHALMOL, V89, P207, DOI 10.1136/bjo.2004.045989
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Yamada M, 2010, OPHTHAL EPIDEMIOL, V17, P50, DOI 10.3109/09286580903450346
NR 31
TC 192
Z9 196
U1 0
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2011
VL 152
IS 4
BP 663
EP 668
DI 10.1016/j.ajo.2011.03.008
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 830LF
UT WOS:000295657800020
PM 21708378
OA Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Grewal, MK
   Sivapathasuntharam, C
   Chandra, S
   Gurudas, S
   Chong, V
   Bird, A
   Jeffery, G
   Sivaprasad, S
AF Grewal, Manjot K.
   Sivapathasuntharam, Chrishne
   Chandra, Shruti
   Gurudas, Sarega
   Chong, Victor
   Bird, Alan
   Jeffery, Glen
   Sivaprasad, Sobha
TI A Pilot Study Evaluating the Effects of 670 nm Photobiomodulation in
   Healthy Ageing and Age-Related Macular Degeneration
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE photobiomodulation; age-related macular degeneration; 670 nm; dark
   adaptation; reticular pseudodrusen; subretinal drusenoid deposits;
   scotopic thresholds; optical coherence tomography
ID ROD FUNCTION; LIGHT; ASSOCIATIONS; MEMBRANE
AB Limited evidence suggests that the application of 670 nm of red light alters the course of aged decline. A previous report on 18 patients showed regression of drusen and improvement in visual functions in patients with intermediate age-related macular degeneration (AMD) by 12 months. We evaluated the functional and structural effects of applying 670 nm light to 31 patients with intermediate AMD and 11 people aged 55 years or above with normal retina. The study eyes were treated daily in the morning with a 670 nm hand-held light source housed in a torch-like tube that emitted energy equivalent to 40 mW/cm(2) or 4.8J/ cm(2) for 2 min at the viewing aperture. Visual function in terms of best-corrected visual acuity, low luminance visual acuity, scotopic thresholds and rod-intercept time were compared between baseline and 1, 3, 6 and 12 months. Structural changes on optical coherence tomography OCT and colour photographs were also assessed. Five withdrew consent voluntarily due to the intensity of the study visit assessments and two developed neovascular AMD and were excluded from further treatment and the analysis. In normal ageing, there was an improvement in scotopic thresholds in the group with no AMD by 1.77dB (p = 0.03) and no other parameters showed any clinically significant change. In eyes with intermediate AMD, there was no significant improvement in any functional or structural changes at any time point up to 12 months although the compliance was good. This pilot study shows that photobiomodulation with 670 nm has no effect in patients who have already progressed to intermediate AMD.
C1 [Grewal, Manjot K.; Sivapathasuntharam, Chrishne; Chandra, Shruti; Gurudas, Sarega; Bird, Alan; Jeffery, Glen; Sivaprasad, Sobha] UCL, Inst Ophthalmol, London EC1V 9EL, England.
   [Grewal, Manjot K.; Chandra, Shruti; Sivaprasad, Sobha] Moorfields Eye Hosp, NIHR Moorfields Biomed Res Ctr, London EC1V 2PD, England.
   [Chong, Victor] Eretina Ltd, 8 Spruce Dene, Hazlemere HP15 7QF, Bucks, England.
C3 University of London; University College London; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust
RP Sivaprasad, S (通讯作者)，UCL, Inst Ophthalmol, London EC1V 9EL, England.; Sivaprasad, S (通讯作者)，Moorfields Eye Hosp, NIHR Moorfields Biomed Res Ctr, London EC1V 2PD, England.
EM m.grewal@ucl.ac.uk; chrishnepriya.sivapathasuntharam.14@ucl.ac.uk;
   shruti.chandra.18@ucl.ac.uk; sarega.gurudas.17@ucl.ac.uk;
   victor@eretina.org; alan.bird@ucl.ac.uk; g.jeffery@ucl.ac.uk;
   sobha.sivaprasad@nhs.net
RI Sivaprasad, S./D-6876-2015
OI Sivaprasad, S./0000-0001-8952-0659
FU Fight For Sight Charity [1409]; Moorfields Eye Charity
FX This research was funded by Fight For Sight Charity, grant number 1409
   and Moorfields Eye Charity.
CR Calaza KC, 2015, NEUROBIOL AGING, V36, P2869, DOI 10.1016/j.neurobiolaging.2015.06.010
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   El Massri N, 2018, NEUROBIOL AGING, V66, P131, DOI 10.1016/j.neurobiolaging.2018.02.019
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flynn OJ, 2018, INVEST OPHTH VIS SCI, V59, P2411, DOI 10.1167/iovs.17-22874
   Gkotsi D, 2014, EXP EYE RES, V122, P50, DOI 10.1016/j.exer.2014.02.023
   Hamblin M.R., 2006, P SOC PHOTO-OPT INS, V6140, P1, DOI DOI 10.1117/12.646294
   Ivandic BT, 2008, PHOTOMED LASER SURG, V26, P241, DOI 10.1089/pho.2007.2132
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Johnstone DM, 2015, NEURAL REGEN RES, V10, P349, DOI 10.4103/1673-5374.153673
   Kam JH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49121-0
   Karu T, 1999, J PHOTOCH PHOTOBIO B, V49, P1, DOI 10.1016/S1011-1344(98)00219-X
   Karu TI, 2005, J PHOTOCH PHOTOBIO B, V81, P98, DOI 10.1016/j.jphotobiol.2005.07.002
   Ko F, 2017, OPHTHALMOLOGY, V124, P105, DOI 10.1016/j.ophtha.2016.07.033
   Kokkinopoulos I, 2013, NEUROBIOL AGING, V34, P602, DOI 10.1016/j.neurobiolaging.2012.04.014
   Merry GF, 2017, ACTA OPHTHALMOL, V95, pE270, DOI 10.1111/aos.13354
   Owsley C, 2014, INVEST OPHTH VIS SCI, V55, P4776, DOI 10.1167/iovs.14-14502
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Sivapathasuntharam C, 2019, EXP EYE RES, V185, DOI 10.1016/j.exer.2019.107691
   Sivapathasuntharam C, 2017, NEUROBIOL AGING, V52, P66, DOI 10.1016/j.neurobiolaging.2017.01.001
   Sivaprasad S, 2016, SURV OPHTHALMOL, V61, P521, DOI 10.1016/j.survophthal.2016.02.005
   Stone J, 2008, BRAIN RES, V1189, P58, DOI 10.1016/j.brainres.2007.10.083
   Tan R, 2018, INVEST OPHTH VIS SCI, V59, P4154, DOI 10.1167/iovs.18-23970
   Tang J, 2013, INVEST OPHTH VIS SCI, V54, P3681, DOI 10.1167/iovs.12-11018
NR 24
TC 7
Z9 7
U1 2
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD APR
PY 2020
VL 9
IS 4
AR 1001
DI 10.3390/jcm9041001
PG 13
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA LL8RF
UT WOS:000531821000108
PM 32252424
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hu, CC
   Ho, JD
   Lin, HC
AF Hu, Chao-Chien
   Ho, Jau-Der
   Lin, Herng-Ching
TI Neovascular Age-Related Macular Degeneration and the Risk of Stroke A
   5-Year Population-Based Follow-Up Study
SO STROKE
LA English
DT Article
DE AMD; neovascular age-related macular degeneration; stroke
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; CARDIOVASCULAR-DISEASE; VISUAL
   IMPAIRMENT; UNITED-STATES; EYE; PREVALENCE; MACULOPATHY; MEMBRANE;
   ACUITY
AB Background and Purpose-Using a nationwide population-based data set from Taiwan, this study investigated the relationship between neovascular age-related macular degeneration (AMD) and the risk of stroke over a 5-year period.
   Method-The study cohort comprised 209 patients who received treatment for AMD between 1999 and 2001. We randomly selected 1045 subjects matched with the study cohort in terms of age and gender for comparison. Cox proportional hazard regressions were performed to compare the 5-year stroke-free survival rate.
   Results-Among the sampled patients, 142 patients (11.3%) had strokes during the 5-year follow-up period, 38 (18.2% of the patients with AMD) from the study cohort and 104 (9.9% of patients in the comparison cohort) from the comparison cohort. After adjusting for the patient's age, gender, monthly income, level of urbanization, and the geographic region of the community in which the patient resided and comorbidities, the hazard ratio for stroke during the follow-up period was 2.01 (P=0.001) times greater for patients with AMD than for patients without AMD. The adjusted hazard ratio for stroke during the follow-up period was 2.21 (P=0.001) times higher for patients with AMD >= 65 years old compared with the same age group in the comparison cohort. However, no significant difference was observed in the risk of stroke between patients with AMD <65 years of age and comparison patients in the same age group.
   Conclusion-We conclude that neovascular AMD is associated with a higher risk of stroke for patients with AMD >= 65 years old. (Stroke. 2010;41:613-617.)
C1 [Lin, Herng-Ching] Taipei Med Univ, Sch Hlth Care Adm, Taipei 110, Taiwan.
   [Hu, Chao-Chien] Fu Jen Catholic Univ, Sch Med, Hsingchuang, Taiwan.
   [Hu, Chao-Chien; Ho, Jau-Der] Taipei Med Univ Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Hu, Chao-Chien; Ho, Jau-Der] Taipei Med Univ, Dept Ophthalmol, Taipei, Taiwan.
   [Hu, Chao-Chien] Shin Kong Wu Ho Su Mem Hosp, Dept Ophthalmol, Taipei, Taiwan.
C3 Taipei Medical University; Fu Jen Catholic University; Taipei Medical
   University; Taipei Medical University Hospital; Taipei Medical
   University; Shin Kong Wu Ho Su Memorial Hospital
RP Lin, HC (通讯作者)，Taipei Med Univ, Sch Hlth Care Adm, 250 Wu Hsing St, Taipei 110, Taiwan.
EM henry11111@tmu.edu.tw
FU  [SKH-TMU-98]
FX This study was supported by grant SKH-TMU-98.
CR Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Dafer Rima M, 2007, Semin Ophthalmol, V22, P201, DOI 10.1080/08820530701543024
   Di Napoli M, 2001, STROKE, V32, P1444, DOI 10.1161/01.STR.32.6.1443-a
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Gentile R, 2006, ANN INTERN MED, V145, p[98, 551]
   Gentile Ronald, 2007, Surv Ophthalmol, V52, P551, DOI 10.1016/j.survophthal.2007.06.002
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Kuehn BM, 2005, JAMA-J AM MED ASSOC, V293, P1841, DOI 10.1001/jama.293.15.1841
   Liao DP, 2008, OPEN OPHTHALMOL J, V2, P37, DOI 10.2174/1874364100802010037
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Wong TY, 2009, AM J OPHTHALMOL, V148, P327, DOI 10.1016/j.ajo.2009.05.012
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
NR 29
TC 50
Z9 50
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD APR
PY 2010
VL 41
IS 4
BP 613
EP 617
DI 10.1161/STROKEAHA.109.571000
PG 5
WC Clinical Neurology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 575XU
UT WOS:000276106100012
PM 20150546
OA Bronze
DA 2022-11-30
ER

PT J
AU Venkatesh, P
   Gupta, RK
   Verma, L
   Tewari, HK
AF Venkatesh, P
   Gupta, RK
   Verma, L
   Tewari, HK
TI Evaluation of trans-scleral diode laser using diopexy probe for
   subfoveal choroidal neovascular membrane in age-related macular
   degeneration
SO JOURNAL OF CLINICAL LASER MEDICINE & SURGERY
LA English
DT Article
ID POSTERIOR CILIARY ARTERY; PHOTODYNAMIC THERAPY; OCCLUSION;
   PHOTOCOAGULATION; VERTEPORFIN; LESIONS; REPAIR
AB Objective: To evaluate safety and short-term visual and fluorescein angiographic effects of trans-scleral diode laser photocoagulation in patients with subfoveal choroidal neovascularization from age-related macular degeneration (ARMD). Background Data: The visual outcome following treatment of subfoveal choroidal neovascularization in ARMD is still unsatisfactory. Various forms of therapy such as laser treatment, photodynamic therapy, radiation therapy, transpupillary thermotherapy, and surgical excision have been tried with variable results. Materials and Methods: Patients with subfoveal choroidal neovascularization were treated with trans-scleral diode laser using the diopexy probe under indirect ophthalmoscopic visualization and followed up at 2, 6, and 12 weeks. Standardized protocol refraction, visual acuity testing, reading speed, contrast requirement measurement, ophthalmic examinations, color fundus photographs, and fluorescein angiogram were used to evaluate the results of treatment. Results: Eighteen eyes of 18 patients were included in the study between April 2000 and May 2002. At 12 weeks, 81.5% patients showed stabilization ( 5 letters) in letter visual acuity score, and one patient showed improvement (gain of more than five letters) in letter visual acuity score. Reading speed levels and contrast requirement were found to be similar to pre-laser level at 3 months follow-up. At 12 weeks, moderate fluorescein leakage was seen in one eye, minimal leakage was seen in five eyes, absence of leakage was seen in 10 eyes, and progression was seen in two eyes. Conclusion: Transcleral diode laser treatment of subfoveal choroidal neovascular membranes in ARMD may be an effective as well as safe alternative in the management of these patients.
C1 All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, India.
C3 All India Institute of Medical Sciences (AIIMS) New Delhi; Dr. Rajendra
   Prasad Centre for Ophthalmic Sciences
RP Tewari, HK (通讯作者)，All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, India.
EM hktewari1@yahoo.com
CR AMALRIC P, 1971, CR S INT ANG FLUOR, P193
   ANDERSON DR, 1974, ARCH OPHTHALMOL-CHIC, V92, P422, DOI 10.1001/archopht.1974.01010010434013
   APPLE DJ, 1973, AM J OPHTHALMOL, V75, P595, DOI 10.1016/0002-9394(73)90812-X
   ARCHER DB, 1980, T OPHTHAL SOC UK, V100, P363
   BISCHOFF PM, 1983, AM J OPHTHALMOL, V96, P398, DOI 10.1016/S0002-9394(14)77839-0
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   GHAFOUR IM, 1983, BRIT J OPHTHALMOL, V67, P209, DOI 10.1136/bjo.67.4.209
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   HAYREH SS, 1972, BRIT J OPHTHALMOL, V56, P719, DOI 10.1136/bjo.56.10.719
   HAYREH SS, 1972, BRIT J OPHTHALMOL, V56, P736, DOI 10.1136/bjo.56.10.736
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   *MPS GROUP, 1991, ARCH OPHTHALMOL-CHIC, V109, P1219
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   PERRY DD, 1984, INVEST OPHTH VIS SCI, V25, P1019
   PERRY DD, 1982, AM J OPHTHALMOL, V93, P787, DOI 10.1016/0002-9394(82)90475-5
   Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707
   SCHUBERT HD, 1997, FUNDAMENTALS INDOCYA, P21
NR 17
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1044-5471
J9 J CLIN LASER MED SUR
JI J. Clin. Laser Med. Sur.
PD APR
PY 2004
VL 22
IS 2
BP 91
EP 97
DI 10.1089/104454704774076136
PG 7
WC Engineering, Biomedical; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Surgery
GA 821TY
UT WOS:000221486800003
PM 15165382
DA 2022-11-30
ER

PT J
AU Kim, J
   Kim, DW
   Kim, DH
   Ryu, SY
   Chung, EJ
AF Kim, Jiwon
   Kim, Dong Wook
   Kim, Dae Hyun
   Ryu, Sun Young
   Chung, Eun Jee
TI Risk of stroke associated with intravitreal ranibizumab injections in
   age-related macular degeneration: a nationwide case-crossover study
SO EYE
LA English
DT Article
ID CEREBROVASCULAR ACCIDENTS; MYOCARDIAL-INFARCTION; SYSTEMIC SAFETY;
   THERAPY
AB Objective To evaluate the risk of stroke associated with intravitreal ranibizumab in age-related macular degeneration (AMD). Methods A nationwide retrospective case-crossover study was performed using data from the Korean National Health Insurance Service (KNHIS) database, which included patients with exudative AMD in South Korea (n = 41,860). The index date was the date of hospitalization for stroke. We defined the case period as 60 days and four control periods before the index date. A pharmacy prescription database was searched for ranibizumab use during the case and control periods. We calculated adjusted odds ratios (ORs) and 95% confidence intervals (CIs) with a conditional logistic regression model. Results A total of 865 patients with AMD and incident stroke were included. Of all the patients, 12.02% had been treated during the preceding 60-day case period, compared with 9.25-10.29% during control periods. The adjusted OR of stroke associated with intravitreal ranibizumab during the case period was 1.285 (95% CI 0.979-1.686) (p = 0.07). In the subgroup analysis, the risk of hemorrhagic stroke had an OR of 2.252 (95% CI 1.068-4.749, p = 0.033). Further analyses based on patient gender, age, and different risk periods of 15 and 30 days yielded no increase in the risk of stroke associated with intravitreal ranibizumab. Conclusions This case-crossover analysis revealed no evidence of increased risk of hospitalization for stroke within 60 days of intravitreal ranibizumab injection in AMD patients. A secondary analysis indicated the possibility of an increased risk of hemorrhagic stroke, with borderline significance. Further research is needed regarding the underlying biological mechanisms and drug safety.
C1 [Kim, Jiwon; Ryu, Sun Young; Chung, Eun Jee] Ilsan Hosp, Natl Hlth Insurance Serv, Dept Ophthalmol, Goyang, South Korea.
   [Kim, Dong Wook] Natl Hlth Insurance Serv, Dept Big Data, Wonju, South Korea.
   [Kim, Dae Hyun] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA.
C3 National Health Insurance Service; NHIS Ilsan Hospital; National Health
   Insurance Service; Harvard University; Brigham & Women's Hospital;
   Harvard Medical School
RP Chung, EJ (通讯作者)，Ilsan Hosp, Natl Hlth Insurance Serv, Dept Ophthalmol, Goyang, South Korea.
EM eunjee95@nhimc.or.kr
OI /0000-0003-4544-4265
FU National Health Insurance Ilsan Hospital grant [NHIMC 2015-02-015]
FX This work was supported by a National Health Insurance Ilsan Hospital
   grant (NHIMC 2015-02-015). This study used data from the NHIS-NCS
   2002-2013 (NHIS-2015-1-070), which was released by the KNHIS. The
   authors alone are responsible for the content and writing of this
   article.
CR Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler NM, 2012, RETINA-J RET VIT DIS, V32, P1821, DOI 10.1097/IAE.0b013e31825db6ba
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campbell RJ, 2012, OPHTHALMOLOGY, V119, P1604, DOI 10.1016/j.ophtha.2012.05.028
   Campbell RJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e4203
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Dugel PU, 2018, OPHTHALMOL RETINA, V2, P667, DOI 10.1016/j.oret.2018.01.010
   Kamba T, 2007, BRIT J CANCER, V96, P1788, DOI 10.1038/sj.bjc.6603813
   Kim HY, 2012, BIOMASS BIOENERG, V42, P10, DOI 10.1016/j.biombioe.2012.03.018
   Lee WJA, 2017, PHARMACOEPIDEM DR S, V26, P1277, DOI 10.1002/pds.4299
   Park JK., 2000, KOREAN J PREV MED, V33, P76, DOI DOI 10.1161/01.STR.0000078562.82918.F6
   Pratt NL, 2014, DRUG SAFETY, V37, P1021, DOI 10.1007/s40264-014-0231-2
   Rim TH, 2016, RETINA-J RET VIT DIS, V36, P2166, DOI 10.1097/IAE.0000000000001084
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Tunon J, 2009, SURV OPHTHALMOL, V54, P339, DOI 10.1016/j.survophthal.2009.02.003
   Ueta T, 2014, OPHTHALMOLOGY, V121, P2193, DOI 10.1016/j.ophtha.2014.05.022
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   Wieberdink RG, 2011, STROKE, V42, P2138, DOI 10.1161/STROKEAHA.111.616359
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
   Zarbin MA, 2018, OPHTHALMOL RETINA, V2, P1087, DOI 10.1016/j.oret.2018.04.018
NR 20
TC 4
Z9 4
U1 0
U2 0
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD FEB
PY 2021
VL 35
IS 2
BP 601
EP 607
DI 10.1038/s41433-020-0911-3
EA MAY 2020
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PX7VQ
UT WOS:000530278200006
PM 32367002
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Li, S
   Liu, N
   Lin, L
   Sun, ED
   Li, JD
   Li, PK
AF Li, Shang
   Liu, Na
   Lin, Li
   Sun, Er-Dan
   Li, Jian-Da
   Li, Peng-Kun
TI Macular pigment and serum zeaxanthin levels with Goji berry supplement
   in early age-related macular degeneration
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Goji berry; zeaxanthin; early age-related macular degeneration
ID VISUAL-ACUITY; PRIMATE RETINAS; BARBARUM L.; LUTEIN; CAROTENOIDS; TRIAL;
   EYES
AB AIM: To evaluate the efficacy of Goji berry supplementation on improving macular pigment, serum zeaxanthin levels and visual acuity in patients with early age-related macular degeneration (AMD).
   METHODS: A total of 114 patients (aged from 51 to 92y, mean age 69.53 +/- 8.41y) with early AMD were enrolled in our prospective, randomized controlled study. The included patients were assigned randomly to the Goji group (n=57) with 25 g of Goji berries supplementation per day for 90d and the control group (n=57) with their normal diet for 90d. Macular pigment optical density (MPOD) was measured using heterochromatic flicker photometry (HFP). The levels of serum lutein (L)/zeaxanthin (Z) were analyzed using high-performance liquid chromatography (HPLC). MPOD, serum L/Z levels and best corrected visual acuity (BCVA) were recorded at baseline and 90d.
   RESULTS: In the Goji group, there were no statistically significant differences in the serum L levels between the baseline (0.199 +/- 0.149 mu mol/mL) and 90d (0.203 +/- 0.181 mu mol/mL) (t=-0.186, P=0.850); however the serum Z levels were increased at 90d (0.101 +/- 0.087 mu mol/mL) compared with those at the baseline (0.029 +/- 0.032 mu mol/mL) (t=6.412, P<0.001). Patients treated with Goji berry for 90d showed an elevated MPOD (0.877 +/- 0.202 DU) from the baseline (0.731 +/- 0.205 DU) (t=-4.741, P=0.000). In contrast to the control group, the serum Z levels and MPOD were higher in the Goji group at 90d (both P<0.05). At 90d, patients with Goji berry supplementation had a relative decrease in BCVA (0.21 +/- 0.18 logMAR) compared with the baseline (0.27 +/- 0.20) (t=2.397, P=0.020).
   CONCLUSION: Overall, daily supplementation with Goji berry for 90d improves MPOD by increasing serum Z levels rather than serum L levels in early AMD patients. Goji berry may be an effective therapeutic intervention for preventing the progression of early AMD.
C1 [Li, Shang] Capital Med Univ Beijing, Beijing YouAn Hosp, Dept Ophthalmol, Beijing 100069, Peoples R China.
   [Liu, Na; Sun, Er-Dan; Li, Jian-Da; Li, Peng-Kun] Capital Med Univ, Chinese Rehabil Sci Inst, Dept Ophthalmol, China Rehabil Res Ctr, Beijing 100068, Peoples R China.
   [Lin, Li] China Acad Chinese Med Sci, Xiyuan Hosp, Res Ctr, Beijing 100091, Peoples R China.
C3 Capital Medical University; Capital Medical University; China Academy of
   Chinese Medical Sciences; Xiyuan Hospital, CACMS
RP Liu, N (通讯作者)，China Rehabil Res Ctr, Dept Ophthalmol, Jiaomen North Rd, Beijing 100068, Peoples R China.
EM 13718166697@163.com
FU Special Foundation for Public Welfare Research of China [2013CZ-9]
FX Supported by Special Foundation for Public Welfare Research of China
   (No. 2013CZ-9).
CR Bucheli P, 2011, OPTOMETRY VISION SCI, V88, P257, DOI 10.1097/OPX.0b013e318205a18f
   Cheng CY, 2005, BRIT J NUTR, V93, P123, DOI 10.1079/BJN20041284
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Connor WE, 2007, INVEST OPHTH VIS SCI, V48, P4226, DOI 10.1167/iovs.06-1275
   Elfervig LS, 1998, NURS PRACT FORUM, V9, P4
   Gabriel HE, 2006, CANCER EPIDEM BIOMAR, V15, P993, DOI 10.1158/1055-9965.EPI-05-0664
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Hammond CJ, 2012, INVEST OPHTH VIS SCI, V53, P4963, DOI 10.1167/iovs.12-9618
   Hempel J, 2017, FOOD CHEM, V218, P525, DOI 10.1016/j.foodchem.2016.09.065
   Hollyfield JG, 2010, INVEST OPHTH VIS SCI, V51, P1276, DOI 10.1167/iovs.09-4478
   Huang YM, 2015, BRIT J OPHTHALMOL, V99, P371, DOI 10.1136/bjophthalmol-2014-305503
   Huang YM, 2013, NUTRITION, V29, P387, DOI 10.1016/j.nut.2012.06.009
   Johnson EJ, 2005, NUTR REV, V63, P9, DOI 10.1301/nr.2004.janr.9-15
   Johnson EJ, 2005, INVEST OPHTH VIS SCI, V46, P692, DOI 10.1167/iovs.02-1192
   Kaya S, 2012, ACTA OPHTHALMOL, V90, pe399, DOI 10.1111/j.1755-3768.2012.02423.x
   Kim SR, 2006, EXP EYE RES, V82, P828, DOI 10.1016/j.exer.2005.10.004
   Kuo HK, 2011, GRAEF ARCH CLIN EXP, V249, P601, DOI 10.1007/s00417-010-1461-3
   Li BX, 2010, ARCH BIOCHEM BIOPHYS, V504, P56, DOI 10.1016/j.abb.2010.07.024
   Ma L, 2016, NUTRIENTS, V8, DOI 10.3390/nu8070426
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Merle BMJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079848
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   Potterat O, 2010, PLANTA MED, V76, P7, DOI 10.1055/s-0029-1186218
   Puell MC, 2013, ACTA OPHTHALMOL, V91, pE298, DOI 10.1111/aos.12067
   Renzi LM, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-33
   Scripsema NK, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/865179
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Subramanian ML, 2009, AM J OPHTHALMOL, V148, P875, DOI 10.1016/j.ajo.2009.07.009
NR 29
TC 13
Z9 13
U1 1
U2 17
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD JUN 18
PY 2018
VL 11
IS 6
BP 970
EP 975
DI 10.18240/ijo.2018.06.12
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GM0BY
UT WOS:000437711600012
PM 29977809
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Krebs, I
   Hagen, S
   Brannath, W
   Haas, P
   Womastek, I
   de Salvo, G
   Ansari-Shahrezaei, S
   Binder, S
AF Krebs, Ilse
   Hagen, Stefan
   Brannath, Werner
   Haas, Paulina
   Womastek, Irene
   de Salvo, Gabriella
   Ansari-Shahrezaei, Siamak
   Binder, Susanne
TI Repeatability and Reproducibility of Retinal Thickness Measurements by
   Optical Coherence Tomography in Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID RANIBIZUMAB; STRATUS
AB Purpose: To evaluate the repeatability and reproducibility of retinal thickness measurements in exudative age-related macular degeneration (AMD) using Stratus optical coherence tomography (OCT) (Carl Zeiss Meditec, Inc., Dublin, CA).
   Design: Prospective, observational case series.
   Participants: A total of 200 eyes of 200 subjects with exudative AMD.
   Methods: Macular thickness and fast macular thickness programs of Stratus OCT were performed twice by the same examiners or 2 different examiners. The sequence of examiners was randomized 1:1:1:1. The variability of 1-mm subfield central retinal thickness (CRT), center point thickness (CPT), and retinal volume (RV) was calculated.
   Main Outcome Measures: Interobserver and intraobserver variability of retinal thickness measurements.
   Results: Ninety-nine patients/eyes were enrolled in study arm 1 (repeated by the same examiner), and 101 patients/eyes were enrolled in study arm 2 (repeated by different examiners). Values of CPT, CRT, and RV were well correlated (interclass correlation coefficient, 0.71-0.93) in both study arms, revealing better results for the macular thickness program than for the fast macular thickness program. Threshold algorithm line failures were significantly correlated to the absolute differences of 2 repeated measurements for CPT, CRT, and RV but not with manually corrected maximum retinal thickness (MRT). Maximum retinal thickness was significantly influenced by the examiner performing the measurement. Age, lesion composition, examiner performing OCT examination, and sequence of examination had no significant influence.
   Conclusions: The repeatability and reproducibility of retinal thickness measurements were high, presenting better results for CRT and RV versus CPT, and for the macular thickness program versus the fast macular thickness program. The reliability of retinal thickness measurement was most frequently affected by algorithm line failures and fixation problems. A possible solution may be manually corrected measurement, such as MRT.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2010; 117: 1577-1584 (C) 2010 by the American Academy of Ophthalmology.
C1 [Krebs, Ilse; Hagen, Stefan; Haas, Paulina; de Salvo, Gabriella; Ansari-Shahrezaei, Siamak; Binder, Susanne] Rudolf Fdn Clin, Dept Ophthalmol, A-1030 Vienna, Austria.
   [Krebs, Ilse; Hagen, Stefan; Ansari-Shahrezaei, Siamak; Binder, Susanne] Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Vienna, Austria.
   [Brannath, Werner; Womastek, Irene] Med Univ, Core Unit Med Stat & Informat, Vienna, Austria.
C3 Ludwig Boltzmann Institute
RP Krebs, I (通讯作者)，Rudolf Fdn Clin, Dept Ophthalmol, Juchgasse 25, A-1030 Vienna, Austria.
EM Ilse.Krebs@wienkav.at
RI De Salvo, Gabriella/AAY-5016-2020
OI DE SALVO, Gabriella/0000-0002-1185-6942
FU Ludwig Boltzmann Institute, Vienna, Austria
FX Supported by unrestricted research grant from the Ludwig Boltzmann
   Institute, Vienna, Austria (SB).
CR Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Browning DJ, 2004, AM J OPHTHALMOL, V138, P477, DOI 10.1016/j.ajo.2004.03.014
   Eriksson U, 2009, ACTA OPHTHALMOL, V87, P725, DOI 10.1111/j.1755-3768.2008.01345.x
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Krebs I, 2008, BRIT J OPHTHALMOL, V92, P933, DOI 10.1136/bjo.2007.128447
   Krebs I, 2008, GRAEF ARCH CLIN EXP, V246, P811, DOI 10.1007/s00417-007-0755-6
   Krebs I, 2009, INVEST OPHTH VIS SCI, V50, P995, DOI 10.1167/iovs.08-2617
   Krzystolik MG, 2007, OPHTHALMOLOGY, V114, P1520, DOI 10.1016/j.ophtha.2006.10.055
   Malamos P, 2009, INVEST OPHTH VIS SCI, V50, P4926, DOI 10.1167/iovs.09-3610
   Massin P, 2001, ARCH OPHTHALMOL-CHIC, V119, P1135, DOI 10.1001/archopht.119.8.1135
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P1084, DOI 10.1167/iovs.07-1203
   Polito A, 2005, ARCH OPHTHALMOL-CHIC, V123, P1330, DOI 10.1001/archopht.123.10.1330
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Taban M, 2009, OPHTHALMOLOGY, V116, P964, DOI 10.1016/j.ophtha.2008.12.033
NR 17
TC 36
Z9 37
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2010
VL 117
IS 8
BP 1577
EP 1584
DI 10.1016/j.ophtha.2010.04.032
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 634QU
UT WOS:000280598900019
PM 20557937
DA 2022-11-30
ER

PT J
AU Loewenstein, A
   Malach, R
   Goldstein, M
   Leibovitch, I
   Barak, A
   Baruch, E
   Alster, Y
   Rafaeli, O
   Avni, I
   Yassur, Y
AF Loewenstein, A
   Malach, R
   Goldstein, M
   Leibovitch, I
   Barak, A
   Baruch, E
   Alster, Y
   Rafaeli, O
   Avni, I
   Yassur, Y
TI Replacing the Amsler grid - A new method for monitoring patients with
   age-related macular degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID NEOVASCULAR MEMBRANES; VISION; EYE; MACULOPATHY
AB Purpose: To investigate a method that uses hyperacuity, the Macular Computerized Psychophysical Test (MCPT), to evaluate the central macular visual field in patients with age-related macular degeneration (AMD).
   Design: Prospective case-control study of a diagnostic test.
   Participants and Controls: One hundred eight eyes of 108 Patients with AMD and 51 eyes of 51 age-matched patients with no retinal disease. Patients with AMD included 32 (30%) patients with choroidal neovascularization (CNV), 23 (21%) with geographic atrophy (GA), 35 (32%) with AMD with high-risk characteristics (HRC), and 18 (17%) with early AMD with non-HRC.
   Testing: Each subject underwent the MCPT, in which a virtual line composed of dots (white dots on a black background, maximal contrast) is flashed across different macular loci to a perifoveal radius of 7degrees. Patients' responses were recorded and automatically analyzed using a specific algorithm developed before the onset of the study. All patients also underwent a supervised Amsler grid examination on the encounter before or after the MCPT in random order.
   Main Outcome Measures: Distortion, scotoma, or blurring perceived by the patient after a swift change of fixation was considered positive on the MCPT. Any perception of distortion, scotoma, or blurring was considered positive on the Amsler grid.
   Results: Of the 32 patients with CNV, 30 (94%) were found positive on the MCPT and 11 (34%) were found positive on the Amsler grid. Of the 23 GA patients, 21 (91%) were found positive on the MCPT and 7 (30%) were found positive on the Amsler grid. Of the 35 HRC patients, 28 (80%) were found positive on the MCPT and 3 (9%) were found positive on the Amsler grid, and of the 18 early AMD with non-HRC patients, 8 (44%) were found positive on the MCPT and 3 (17%) were found positive on the Amsler grid. Of the 51 controls, 3 (6%) were positive on the MCPT and 1 (2%) was positive on the Amsler grid.
   Conclusions: The MCPT was superior to the Amsler grid in detecting AMD-related lesions in this cohort. Studies are underway to determine whether the MCPT is feasible for home monitoring to provide early detection of progression to CNV.
C1 Tel Aviv Med Ctr & Sch Med, Dept Ophthalmol, IL-64239 Tel Aviv, Israel.
   Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.
   Notal Vis LTD, Tel Aviv, Israel.
   Maccabi Eye Inst, Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Weizmann Institute of
   Science
RP Loewenstein, A (通讯作者)，Tel Aviv Med Ctr & Sch Med, Dept Ophthalmol, 6 Weizman St, IL-64239 Tel Aviv, Israel.
CR ACHARD OA, 1995, AM J OPHTHALMOL, V120, P322, DOI 10.1016/S0002-9394(14)72162-2
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   BARALDI P, 1986, INT OPHTHALMOL, V9, P173, DOI 10.1007/BF00159846
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRESSLER NM, 1995, OPHTHALMOLOGY, V102, P1206, DOI 10.1016/S0161-6420(95)30889-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER NM, 1987, ARCH OPHTHALMOL-CHIC, V105, P209
   ENOCH JM, 1984, ARCH OPHTHALMOL-CHIC, V102, P1164, DOI 10.1001/archopht.1984.01040030942019
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FINE AM, 1986, ARCH OPHTHALMOL-CHIC, V104, P513
   FINE SL, 1985, OPHTHALMOLOGY, V92, P603
   GILBERT CD, 1992, NATURE, V356, P150, DOI 10.1038/356150a0
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   KAAS JH, 1990, SCIENCE, V248, P229, DOI 10.1126/science.2326637
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   LAKSHMINARAYANAN V, 1992, OPTOMETRY VISION SCI, V69, P423, DOI 10.1097/00006324-199206000-00002
   *MAC DEG PHOT THER, 2000, IN PRESS ARCH OPHTHA, V118, P488
   Parkes L, 2001, NAT NEUROSCI, V4, P739, DOI 10.1038/89532
   PIZZARELLO LD, 1987, OPHTHALMOLOGY, V94, P1191
   ROY MS, 1985, OPHTHALMOLOGICA, V191, P215, DOI 10.1159/000309590
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   SCHUCHARD RA, 1993, ARCH OPHTHALMOL-CHIC, V111, P776, DOI 10.1001/archopht.1993.01090060064024
   WALL M, 1986, ARCH OPHTHALMOL-CHIC, V104, P520, DOI 10.1001/archopht.1986.01050160076015
   WESTHEIMER G, 1979, INVEST OPHTH VIS SCI, V18, P893
NR 27
TC 82
Z9 84
U1 0
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2003
VL 110
IS 5
BP 966
EP 970
DI 10.1016/S0161-6420(03)00074-5
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 676LY
UT WOS:000182754600030
PM 12750099
DA 2022-11-30
ER

PT J
AU Solberg, Y
   Dysli, C
   Escher, P
   Berger, L
   Wolf, S
   Zinkernagel, MS
AF Solberg, Yasmin
   Dysli, Chantal
   Escher, Pascal
   Berger, Lisa
   Wolf, Sebastian
   Zinkernagel, Martin S.
TI Fluorescence Lifetime Patterns of Retinal Pigment Epithelium Atrophy in
   Patients with Stargardt Disease and Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Fluorescence lifetime imaging ophthalmoscopy; Fluorescence lifetimes;
   Stargardt disease; Age-related macular degeneration; Atrophy
ID OPTICAL COHERENCE TOMOGRAPHY; QUANTITATIVE FUNDUS AUTOFLUORESCENCE;
   GEOGRAPHIC ATROPHY; DARK ATROPHY; OPHTHALMOSCOPE; DRUSEN
AB Purpose: To investigate whether autofluorescence lifetime patterns within retinal pigment epithelium (RPE) atrophy differ between age-related macular degeneration (AMD) and Stargardt disease (STGD). Methods: Mean retinal autofluorescence lifetimes were measured in a short and a long spectral channel (SSC: 498-560 nm; LSC: 560-720 nm). Mean retinal fluorescence lifetimes were analyzed with corresponding clinical features, fundus images, fundus autofluorescence intensity images, and optical coherence tomography. Mean fluorescence lifetime values of atrophic areas were compared between the two cohorts and within the same patient to adjacent nonatrophic regions. Results: Mean fluorescence lifetimes within areas with RPE atrophy of 13 patients with STGD (mean age +/- SEM 43.7 +/- 5 years) and 30 patients with geographic atrophy (mean age: 78 +/- 2 years) were analyzed and compared to age-matched healthy participants. The mean area of RPE atrophy in STGD and AMD was 6.6 +/- 2.3 mm(2) (range: 0.66-33.17 mm(2)) and 17.5 +/- 3.8 mm(2) (range: 0.58-50.02 mm(2)), respectively. In patients with AMD, atrophic areas revealed significantly longer mean fluorescence lifetime values as compared with patients with STGD (SSC: 997 +/- 60 vs. 363 +/- 26 ps; LSC: 880 +/- 46 vs. 393 +/- 23 ps; p < 0.0001). Conclusions: This study established that RPE atrophy in patients secondary to STGD and AMD display distinctive mean fluorescence lifetime characteristics. As retinal fluorescence lifetimes within areas of RPE atrophy were significantly longer in AMD patients, the analysis of specific lifetime patterns may provide additional insight into the disease processes and the pathogenetic mechanisms in the development of atrophic patches in AMD and STGD.
C1 Bern Univ Hosp, Dept Ophthalmol, Inselspital, Bern, Switzerland.
   Univ Bern, Dept Biomed Res, Bern, Switzerland.
C3 University of Bern; University Hospital of Bern; University of Bern
RP Solberg, Y (通讯作者)，Univ Hosp Bern, CH-3010 Bern, Switzerland.
EM y.solberg@sunrise.ch
RI Wolf, Sebastian/B-8782-2008
OI Wolf, Sebastian/0000-0002-7467-7028
FU Heidelberg Engineering GmbH, Germany
FX The authors received nonfinancial support from Heidelberg Engineering
   GmbH, Germany.
CR Ablonczy Z, 2014, FASEB J, V28, P2369, DOI 10.1096/fj.13-248021
   [Anonymous], 1909, GRAEFES ARCH OPTHALM, P534
   Bonilha VL, 2008, CLIN OPHTHALMOL, V2, P413
   Burke TR, 2014, INVEST OPHTH VIS SCI, V55, P2841, DOI 10.1167/iovs.13-13624
   Cideciyan AV, 2004, HUM MOL GENET, V13, P525, DOI 10.1093/hmg/ddh048
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Dysli C, 2017, INVEST OPHTH VIS SCI, V58, P4856, DOI 10.1167/iovs.17-22184
   Dysli C, 2017, PROG RETIN EYE RES, V60, P120, DOI 10.1016/j.preteyeres.2017.06.005
   Dysli C, 2016, INVEST OPHTH VIS SCI, V57, P2479, DOI 10.1167/iovs.15-18381
   Dysli C, 2016, INVEST OPHTH VIS SCI, V57, P832, DOI 10.1167/iovs.15-18033
   Dysli C, 2014, INVEST OPHTH VIS SCI, V55, P2106, DOI 10.1167/iovs.13-13627
   Fujinami K, 2015, OPHTHALMOLOGY, V122, P326, DOI 10.1016/j.ophtha.2014.08.012
   Giani A, 2012, INVEST OPHTH VIS SCI, V53, P3999, DOI 10.1167/iovs.11-9258
   Gliem M, 2016, JAMA OPHTHALMOL, V134, P817, DOI 10.1001/jamaophthalmol.2016.1475
   Gomes NL, 2009, INVEST OPHTH VIS SCI, V50, P3953, DOI 10.1167/iovs.08-2657
   HENKIND P, 1983, T OPHTHAL SOC UK, V103, P444
   Jaffe GJ, 2015, AM J OPHTHALMOL, V160, P1226, DOI 10.1016/j.ajo.2015.08.024
   Lambertus S, 2016, INVEST OPHTH VIS SCI, V57, P5186, DOI 10.1167/iovs.16-19833
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Pellegrini M, 2016, OPHTHALMOLOGY, V123, P1879, DOI 10.1016/j.ophtha.2016.05.041
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Sauer L, 2018, INVEST OPHTH VIS SCI, V59, pAMD65, DOI 10.1167/iovs.17-23764
   Sauer L, 2018, ACTA OPHTHALMOL, V96, P257, DOI 10.1111/aos.13587
   Sauer L, 2017, ACTA OPHTHALMOL, V95, P481, DOI 10.1111/aos.13269
   Sauer L, 2015, INVEST OPHTH VIS SCI, V56, P4668, DOI 10.1167/iovs.14-15335
   Schmitz-Valckenberg S, 2008, AM J OPHTHALMOL, V146, P183, DOI 10.1016/j.ajo.2008.04.006
   Schweitzer D, 2007, MICROSC RES TECHNIQ, V70, P410, DOI 10.1002/jemt.20427
   Schweitzer D, 2002, OPHTHALMOLOGE, V99, P774, DOI 10.1007/s00347-002-0656-3
   Sunness JS, 1999, MOL VIS, V5
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Wong WT, 2009, AM J OPHTHALMOL, V148, P573, DOI 10.1016/j.ajo.2009.04.030
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS12, DOI 10.1097/IAE.0000000000001276
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
NR 34
TC 4
Z9 4
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD MAY
PY 2020
VL 243
IS 3
BP 195
EP 206
DI 10.1159/000503567
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LO2CU
UT WOS:000533434600005
PM 31743906
DA 2022-11-30
ER

PT J
AU Frimpong-Boateng, A
   Bunse, A
   Rufer, F
   Roider, J
AF Frimpong-Boateng, Adjoa
   Bunse, Arnd
   Ruefer, Florian
   Roider, Johann
TI Photodynamic therapy with intravitreal application of triamcinolone
   acetonide in age-related macular degeneration: functional results in 54
   patients
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; anti-VEGF therapy; photodynamic
   therapy; triamcinolone acetonide
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; CLINICAL-TRIALS; INJECTION;
   VERTEPORFIN; PEGAPTANIB; EXPRESSION; VEGF
AB This study aimed to investigate the functional results, efficacy and complications after photodynamic therapy (PDT) combined with intravitreal triamcinolone acetonide injection (IVTA) in patients with choroidal neovascularization (CNV) caused by age-related macular degeneration (AMD).
   A retrospective analysis of clinical data for 54 patients with CNV resulting from AMD was carried out. All patients had a follow-up of 12 months. The patients were treated with standardized PDT and IVTA (4 mg) as a first-line treatment or following PDT failure. Visual acuity (VA), greatest linear diameter (GLD) of the CNV and foveal thickness were evaluated.
   Mean VA at baseline was 0.8 logMAR (0.4-1.4). After 12 months VA improved (> 2 lines) in 20.4% of patients and stabilized (+/- 2 lines) in 64.8%. There was no statistical significance in VA outcome between patients undergoing first-line treatment and patients with PDT failure; however, fewer PDT treatments were required to stop CNV activity in patients undergoing first-line treatment. At 12 months, a reduction in foveal thickness was seen in 67.7% of patients and a reduction in CNV GLD in 32.7%. Complications occurred in 22% of patients and included a transient rise in intraocular pressure, cataract and sterile hypopyon.
   Our analysis shows that fewer PDT treatments were required to stop CNV activity when triamcinolone was used as first-line treatment. We can thus conclude that PDT combines synergistically with IVTA and the combination may lead to a cost reduction compared with PDT therapy alone. The overall complication rate of 22% is high and must be compared with complication rates caused by new intravitreal anti-VEGF (vascular endothelial growth factor) drugs in combination with PDT.
C1 [Frimpong-Boateng, Adjoa; Bunse, Arnd; Ruefer, Florian; Roider, Johann] Univ Schleswig Holstein, Ophthalmol Clin, D-24105 Kiel, Germany.
C3 University of Kiel; Schleswig Holstein University Hospital
RP Frimpong-Boateng, A (通讯作者)，Univ Schleswig Holstein, Ophthalmol Clin, Campus Kiel,Hegewischstr 2, D-24105 Kiel, Germany.
EM afrimpong@ophthalmol.uni-kiel.de
RI Roider, Johann/E-4513-2010
CR ANTOSZYK AN, 1993, GRAEF ARCH CLIN EXP, V231, P34, DOI 10.1007/BF01681698
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Beer PM, 2003, OPHTHALMOLOGY, V110, P681, DOI 10.1016/S0161-6420(02)01969-3
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BROWN DM, 2006, ASS RES VIS OPHTH 30
   Chan WM, 2006, BRIT J OPHTHALMOL, V90, P337, DOI 10.1136/bjo.2005.081299
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   FOLKMAN J, 1987, ANN SURG, V206, P374, DOI 10.1097/00000658-198709000-00016
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HEIER JS, 2006, ASS RES VIS OPHTH 30
   Jonas JB, 2003, ARCH OPHTHALMOL-CHIC, V121, P57
   Jonas JB, 2005, ACTA OPHTHALMOL SCAN, V83, P645, DOI 10.1111/j.1600-0420.2005.00592.x
   Jonas JB, 2003, ARCH OPHTHALMOL-CHIC, V121, P1663, DOI 10.1001/archopht.121.11.1663-b
   Krebs I, 2006, GRAEF ARCH CLIN EXP, V244, P863, DOI 10.1007/s00417-005-0155-8
   Kyto JP, 2005, ACTA OPHTHALMOL SCAN, V83, P605, DOI 10.1111/j.1600-0420.2005.00477.x
   Nicolo M, 2006, RETINA-J RET VIT DIS, V26, P58, DOI 10.1097/00006982-200601000-00010
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Smithen LM, 2004, AM J OPHTHALMOL, V138, P884, DOI 10.1016/j.ajo.2004.05.073
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   *VIP STUD GROUP, 2002, OPHTHALMOLOGY, V131, P541
NR 22
TC 13
Z9 14
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAR
PY 2009
VL 87
IS 2
BP 183
EP 187
DI 10.1111/j.1755-3768.2008.01213.x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 412SR
UT WOS:000263745000011
PM 18547278
OA Bronze
DA 2022-11-30
ER

PT J
AU Sato, T
   Takeuchi, M
   Karasawa, Y
   Enoki, T
   Ito, M
AF Sato, Tomohito
   Takeuchi, Masaru
   Karasawa, Yoko
   Enoki, Toshio
   Ito, Masataka
TI Intraocular inflammatory cytokines in patients with neovascular
   age-related macular degeneration before and after initiation of
   intravitreal injection of anti-VEGF inhibitor
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; AQUEOUS-HUMOR LEVELS; POLYPOIDAL CHOROIDAL
   VASCULOPATHY; INTERFERON-GAMMA; EYE DISEASE; INDUCIBLE PROTEIN-10;
   VITREOUS LEVELS; IN-VIVO; RECEPTOR; CELLS
AB Age-related macular degeneration (AMD) is a cause of blindness in people older than 50 years. Accumulating evidence indicates the involvement of systemic and local inflammation in the pathogenesis and progression of AMD. Aflibercept is an anti-vascular endothelial growth factor (VEGF) inhibitor, and intravitreal injection of aflibercept (IVA) is the approved treatments of neovascular AMD (nAMD), but the effect on inflammatory response remains unclear. The aim of our study was to investigate the profiles of inflammatory cytokines in the aqueous humor of nAMD patients before and after initiation of IVA. In nAMD patients, IP-10 level was significantly higher and IL-6 level was significantly lower compared with those of cataract patients as controls. Logistic regression analysis identified IP-10 as a positive factor and IL-6 a negative factor associated with the pathogenesis of nAMD. In addition, IP-10 level correlated positively with the mean thickness of macula in the central 1-mm diameter circle. After initiation of IVA, IP-10 level was further elevated, and correlated negatively with VEGF level. These data suggest that IP-10 plays a critical role as an antiangiogenic factor and at the same time an inflammatory factor in the pathogenesis and pathophysiology of nAMD eyes at onset and after IVA initiation.
C1 [Sato, Tomohito; Takeuchi, Masaru; Karasawa, Yoko] Natl Def Med Coll, Dept Ophthalmol, Tokorozawa, Saitama, Japan.
   [Ito, Masataka] Natl Def Med Coll, Dept Dev Anat & Regenerat Biol, Tokorozawa, Saitama, Japan.
   [Enoki, Toshio] Enoki Eye Clin, Sayama, Saitama, Japan.
C3 National Defense Medical College - Japan; National Defense Medical
   College - Japan
RP Ito, M (通讯作者)，Natl Def Med Coll, Dept Dev Anat & Regenerat Biol, Tokorozawa, Saitama, Japan.
EM masatake@ndmc.ac.jp
OI Takeuchi, Masaru/0000-0002-4913-7089
FU Japan Society for the Promotion of Science [16K11337]
FX This work was supported by Grant-in-Aid 16K11337 for Scientific Research
   from the Japan Society for the Promotion of Science.
CR Agawa T, 2014, RETINA-J RET VIT DIS, V34, P1811, DOI 10.1097/IAE.0000000000000157
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   ANGIOLILLO AL, 1995, J EXP MED, V182, P155, DOI 10.1084/jem.182.1.155
   [Anonymous], 1987, Int Ophthalmol Clin, V27, P265
   Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336
   Bhisitkul RB, 2006, BRIT J OPHTHALMOL, V90, P1542, DOI 10.1136/bjo.2006.098426
   Bodnar RJ, 2006, CIRC RES, V98, P617, DOI 10.1161/01.RES.0000209968.66606.10
   Boulday G, 2006, J IMMUNOL, V176, P3098, DOI 10.4049/jimmunol.176.5.3098
   Boyd SR, 2002, BRIT J OPHTHALMOL, V86, P448, DOI 10.1136/bjo.86.4.448
   Calvo P, 2015, BRIT J OPHTHALMOL, V99, P723, DOI 10.1136/bjophthalmol-2014-305684
   Cha DM, 2013, INVEST OPHTH VIS SCI, V54, P7038, DOI 10.1167/iovs.13-12730
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Falk MK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112473
   Fauser S, 2014, AM J OPHTHALMOL, V158, P532, DOI 10.1016/j.ajo.2014.05.025
   Fujimura S, 2012, INVEST OPHTH VIS SCI, V53, P1999, DOI 10.1167/iovs.11-8232
   Funatsu H, 2005, GRAEF ARCH CLIN EXP, V243, P3, DOI 10.1007/s00417-004-0950-7
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heller EA, 2006, CIRCULATION, V113, P2301, DOI 10.1161/CIRCULATIONAHA.105.605121
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   HOLZINGER C, 1993, IMMUNOL LETT, V35, P109, DOI 10.1016/0165-2478(93)90078-G
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Lasagni L, 2003, J EXP MED, V197, P1537, DOI 10.1084/jem.20021897
   Mizutani T, 2013, INVEST OPHTH VIS SCI, V54, P1564, DOI 10.1167/iovs.11-9095
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Neumann B, 1998, IMMUNOLOGY, V95, P512
   Noma H, 2008, EYE, V22, P42, DOI 10.1038/sj.eye.6702498
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Perez VL, 2015, TRENDS IMMUNOL, V36, P354, DOI 10.1016/j.it.2015.04.003
   Pokharel A, 2016, CLIN OPHTHALMOL, V10, P511, DOI 10.2147/OPTH.S95956
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rezar-Dreindl S, 2016, INVEST OPHTH VIS SCI, V57, P4144, DOI 10.1167/iovs.16-19772
   Romagnani P, 2001, J CLIN INVEST, V107, P53, DOI 10.1172/JCI9775
   Sakamoto S, 2017, BR J OPHTHALMOL
   Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Shibuya M, 2015, ENDOCR METAB IMMUNE, V15, P135, DOI 10.2174/1871530315666150316121956
   Shiraha H, 1999, J CELL BIOL, V146, P243
   Singh A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00741-4
   Sophie Raafay, 2012, Biol Ther, V2, P3, DOI 10.1007/s13554-012-0003-4
   Tager AM, 2004, AM J RESP CELL MOL, V31, P395, DOI 10.1165/rcmb.2004-0175OC
   Takahashi H, 2016, INVEST OPHTH VIS SCI, V57, P462, DOI 10.1167/iovs.15-18245
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tilg H, 1997, IMMUNOL TODAY, V18, P428, DOI 10.1016/S0167-5699(97)01103-1
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tugues S, 2015, CELL DEATH DIFFER, V22, P237, DOI 10.1038/cdd.2014.134
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
NR 54
TC 41
Z9 42
U1 0
U2 5
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 18
PY 2018
VL 8
AR 1098
DI 10.1038/s41598-018-19594-6
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FS9LI
UT WOS:000422739300061
PM 29348424
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Chalam, KV
   Grover, S
   Sambhav, K
   Balaiya, S
   Murthy, RK
AF Chalam, Kakarla V.
   Grover, Sandeep
   Sambhav, Kumar
   Balaiya, Sankarathi
   Murthy, Ravi K.
TI Aqueous Interleukin-6 Levels Are Superior to Vascular Endothelial Growth
   Factor in Predicting Therapeutic Response to Bevacizumab in Age-Related
   Macular Degeneration
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VITREOUS LEVELS; CYTOKINES; FLUID; EDEMA; HUMOR; EYES; AMD
AB Objective. To prospectively evaluate the effect of intravitreal bevacizumab on aqueous levels of interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF) in patients with exudative age-related macular degeneration (AMD) and correlate clinical outcomes with cytokine levels. Methods. 30 eyes of 30 patients with exudative AMD underwent intravitreal injection of bevacizumab three times at monthly intervals. The aqueous samples prior to the 1st injection (baseline) and 3rd injection were analyzed for VEGF and IL-6 levels. Subjects were subgrouped based upon change in the central subfield (CSF) macular thickness on SD-OCT at 8 weeks. Group 1 included patients (n = 14) with a decrease in CSF thickness greater than 10% from the baseline (improved group). Group 2 included patients (n = 16) who had a decrease in CSF thickness 10% or less (treatment-resistant). Results. In subgroup analysis, in both groups 1 and 2 patients, compared to aqueous VEGF, aqueous IL-6 levels showed a better correlation with CSF thickness on SD-OCT (r = 0.72 and 0.71, resp.). Conclusions. Aqueous IL-6 may be an important marker of treatment response or resistance in wet macular degeneration. Future therapeutic strategies may include targeted treatment against both VEGF and IL-6, in patients who do not respond to anti-VEGF treatment alone.
C1 [Chalam, Kakarla V.; Grover, Sandeep; Sambhav, Kumar; Balaiya, Sankarathi; Murthy, Ravi K.] Univ Florida, Coll Med, Dept Ophthalmol, Jacksonville, FL 32209 USA.
C3 State University System of Florida; University of Florida
RP Chalam, KV (通讯作者)，Univ Florida, Coll Med, Dept Ophthalmol, 580 W 8th St,Tower 2, Jacksonville, FL 32209 USA.
EM kchalam@jax.ufl.edu
RI Chalam, kakarla/K-7507-2019; Sambhav, Kumar/AAR-7929-2021
OI Chalam, K V/0000-0002-0004-9416
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Browning DJ, 2008, AM J OPHTHALMOL, V145, P889, DOI 10.1016/j.ajo.2008.01.007
   Chalam KV, 2010, RETINA-J RET VIT DIS, V30, P815, DOI 10.1097/IAE.0b013e3181c70153
   Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Duh EJ, 2004, AM J OPHTHALMOL, V137, P668, DOI 10.1016/j.ajo.2003.11.015
   Funk M, 2010, RETINA-J RET VIT DIS, V30, P1412, DOI 10.1097/IAE.0b013e3181e095c0
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Green W R, 1999, Mol Vis, V5, P27
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Noma H, 2008, EYE, V22, P42, DOI 10.1038/sj.eye.6702498
   Roh MI, 2010, GRAEF ARCH CLIN EXP, V248, P635, DOI 10.1007/s00417-009-1254-8
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Saidi A, 2009, INT J CANCER, V125, P1054, DOI 10.1002/ijc.24380
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Sharma RK, 2010, MOL VIS, V16, P2175
NR 22
TC 29
Z9 29
U1 0
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2014
VL 2014
AR 502174
DI 10.1155/2014/502174
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AL6MM
UT WOS:000339246800001
PM 25110587
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Kent, D
AF Kent, D.
TI The pathogenesis of age-related macular degeneration is not inflammatory
   mediated but is instead due to immunosenescence-related failure of
   tissue repair
SO MEDICAL HYPOTHESES
LA English
DT Article
ID FACTOR-H POLYMORPHISM; BRUCHS MEMBRANE; CLINICAL-TRIAL; COMPLEMENT
   INHIBITION; DRUSEN; PROTEIN; COMMON; CELLS; RISK; AUTOANTIBODIES
AB A natural consequence of everyday tissue metabolism is cell injury or stress. This injury activates a canonical immune-mediated inflammatory response in order to achieve tissue repair so that homeostasis is maintained. With aging there is increased tissue injury and therefore increasing demands placed on an immune system, which itself is aging (immunosenescence). Thus, the increased reparative demands are reflected by an increased inflammatory load both locally and systemically. Eventually, if the reparative demands are excessive, the aging immune system is overwhelmed and disease ensues. In the macula this age-related failure in repair gives rise to age-related macular degeneration (AMD). The hypothesis proposed herein is therefore, that AMD is due to age-related failure of tissue repair and the chronic inflammation associated with this failure ('inflammaging') is both a surrogate and biomarker of this reparative failure and not in itself the primary cause of disease. Such a hypothesis can be applied to all the diseases of aging and by extension suggests that effective therapies should be aimed at facilitating repair through immunotherapy, possibly and perhaps controversially, through the promotion of inflammation rather than the current approach of its inhibition (anti-inflammatory strategies), the latter which can ultimately only hinder the repair process and thereby lead to the persistence of disease.
C1 [Kent, D.] Vis Clin, 7 Circular Rd, Kilkenny R95 XC98, Ireland.
   [Kent, D.] Univ Coll Dublin, UCD Sch Biomol & Biomed Sci, Dublin, Ireland.
C3 University College Dublin
RP Kent, D (通讯作者)，Vis Clin, 7 Circular Rd, Kilkenny R95 XC98, Ireland.
EM David.kent@thevisionclinic.ie
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Bonafe M, 2012, BIOESSAYS, V34, P40, DOI 10.1002/bies.201100104
   Breitner JCS, 2009, NEUROLOGY, V72, P1899, DOI 10.1212/WNL.0b013e3181a18691
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Caballero S, 2017, INVEST OPHTH VIS SCI, V58, P5164, DOI 10.1167/iovs.16-20736
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P1031, DOI 10.1001/jamaophthalmol.2014.2009
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   CLARK RAF, 1993, J DERMATOL SURG ONC, V19, P693, DOI 10.1111/j.1524-4725.1993.tb00413.x
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cudkowicz ME, 2006, ANN NEUROL, V60, P22, DOI 10.1002/ana.20903
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Garcia CAD, 2014, OSLI RETINA, V45, P18, DOI 10.3928/23258160-20131217-01
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Franceschi C, 2000, ANN NY ACAD SCI, V908, P244
   Franceschi C, 2014, J GERONTOL A-BIOL, V69, pS4, DOI 10.1093/gerona/glu057
   Fulop T, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01960
   Fulop T, 2016, REV INVEST CLIN, V68, P84
   Gordon PH, 2007, LANCET NEUROL, V6, P1045, DOI 10.1016/S1474-4422(07)70270-3
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   GURNE DH, 1991, OPHTHALMOLOGY, V98, P602
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hollyfield JG, 2010, MOL NEUROBIOL, V41, P290, DOI 10.1007/s12035-010-8110-z
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Howcroft TK, 2013, AGING-US, V5, P84, DOI 10.18632/aging.100531
   Iannaccone A, 2015, PLOS ONE, V10
   Iannaccone A, 2017, EXP EYE RES, V155, P64, DOI 10.1016/j.exer.2016.12.006
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kent D, 2003, MOL VIS, V9, P747
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Knobbe CA, 2017, MED HYPOTHESES, V109, P184, DOI 10.1016/j.mehy.2017.10.010
   MAINSTER MA, 1987, EYE-T OPHTH SOC UK, V1, P304, DOI 10.1038/eye.1987.49
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Monti D, 2017, MECH AGEING DEV, V165, P129, DOI 10.1016/j.mad.2016.12.008
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Numan MS, 2015, INT J ENV RES PUB HE, V12, P2289, DOI 10.3390/ijerph120202289
   O'Koren EG, 2019, IMMUNITY, V50, P723, DOI 10.1016/j.immuni.2019.02.007
   Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125
   PENFOLD PL, 1986, INVEST OPHTH VIS SCI, V27, P364
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Rodrigues M, 2019, PHYSIOL REV, V99, P665, DOI 10.1152/physrev.00067.2017
   Roh JS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e27
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schwartz M, 2020, J IMMUNOL, V204, P243, DOI 10.4049/jimmunol.1900844
   Schwartz M, 2010, NAT REV NEUROL, V6, P405, DOI 10.1038/nrneurol.2010.71
   Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Takeuchi A, 1998, EUR J NEUROSCI, V10, P1613, DOI 10.1046/j.1460-9568.1998.00168.x
   Thomas R, 2020, IMMUN AGEING, V17, DOI 10.1186/s12979-020-0173-8
   Varadhan R, 2014, J GERONTOL A-BIOL, V69, P165, DOI 10.1093/gerona/glt023
   Voigt V, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14618-z
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
NR 69
TC 2
Z9 2
U1 0
U2 4
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD JAN
PY 2021
VL 146
AR 110392
DI 10.1016/j.mehy.2020.110392
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA PY7ZX
UT WOS:000612262600002
PM 33246696
DA 2022-11-30
ER

PT J
AU Ahmadi, A
   Ghanbari, H
   Soheilian, M
   Naseri, M
AF Ahmadi, Amrollah
   Ghanbari, Heshmatollah
   Soheilian, Masoud
   Naseri, Mohsen
TI THE EFFECT OF HESA-A (NATURAL DRUG) ON VISUAL ACUITY IN AGE RELATED
   MACULAR DEGENERATION: A RANDOMIZED DOUBLE BLIND CONTROLLED CLINICAL
   TRIAL
SO AFRICAN JOURNAL OF TRADITIONAL COMPLEMENTARY AND ALTERNATIVE MEDICINES
LA English
DT Article
DE age related macular degeneration; HESA-A
ID INTRAVITREAL TRIAMCINOLONE; PHOTODYNAMIC THERAPY; MACULOPATHY;
   PREVALENCE; EYE
AB We investigated the clinical efficacy and safety of HESA-A ( a drug of herbal-marine origin) in the treatment of age related macular degeneration (AMD). In a randomized double blind clinical trial 280 eyes of 280 ( 157 F, 123 M) patients with wet and dry AMD were randomly assigned in treatment or placebo groups. Patients in treatment group received HESA-A tablet 25 mg/Kg twice a day orally and controls received placebo with the same method for 4 weeks. Visual acuity at baseline and after one month of treatment was measured and compared between two groups. All patients were followed up for 5 months after treatment. Mean patients' age was 69.06 +/- 8.49 years. At the end of study visual acuity improved significantly from 1.69 +/- 0.65 LogMar to 1.03 +/- 0.40 LogMar in treatment group but not in controls ( P: 0.000 and P: 0.67 in treatment and control groups respectively). No drug reaction or recurrence was reported during the study and 5-month post treatment follow up period in HESA-A treated group. This study showed significant efficacy and safety of HESA-A in improvement of visual acuity in AMD patients in short term.
C1 [Ahmadi, Amrollah] Med Sci Univ Tehran, Res Ctr, Inst Canc, Tehran, Iran.
   [Ghanbari, Heshmatollah] Isfahan Univ Med Sci, Dept Ophthalmol, Esfahan, Iran.
   [Soheilian, Masoud] Shahid Beheshti Univ Med Sci, Dept Ophthalmol, Tehran, Iran.
   [Naseri, Mohsen] Shahed Univ, Dep Pharmacol, Tehran, Iran.
C3 Tehran University of Medical Sciences; Isfahan University Medical
   Science; Shahid Beheshti University Medical Sciences; Shahed University
RP Ahmadi, A (通讯作者)，Med Sci Univ Tehran, Res Ctr, Inst Canc, POB 13185-1678, Tehran, Iran.
EM swt_f@yahoo.com
RI ghanbari, Heshmatollah Ollah/C-6408-2018; Soheilian,
   Masoud/AAW-4743-2020; ghanbari, heshmatollah/B-5517-2018
OI ghanbari, heshmatollah/0000-0001-8781-5568; Soheilian,
   Masoud/0000-0001-7508-426X
CR Ahmadi A, 2005, DRUG EXP CLIN RES, V31, P1
   Ahmadi A, 2001, P 1 NAT C CANC RES O, P5
   AHMADI A, 2003, DARU, V11, P3
   AHMADI A, 2001, MED J ISLAM ACAD SCI, V14, P145
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Giuliari GP, 2007, CAN J OPHTHALMOL, V42, P629, DOI 10.3129/canjophthalmol.i07-086
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Imrie FR, 2007, AGE AGEING, V36, P8, DOI 10.1093/ageing/afl135
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KOROTKIN A, 2006, INVEST OPHTHALMOL VI, V47
   Kyo Tetsuhiro, 2007, Nippon Ganka Gakkai Zasshi, V111, P315
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nirmalan PK, 2004, ARCH OPHTHALMOL-CHIC, V122, P581, DOI 10.1001/archopht.122.4.581
   Ruiz-Moreno JM, 2006, RETINA-J RET VIT DIS, V26, P602, DOI 10.1097/00006982-200607000-00003
   Sadeghi Aliabadi H, 2001, MED J ISLAM ACAD SCI, V13, P55
   Schmidt-Erfurth UM, 2007, PROG RETIN EYE RES, V26, P437, DOI 10.1016/j.preteyeres.2007.03.002
   Spaide R, 2006, OPHTHALMOLOGY, V113, P160, DOI 10.1016/j.ophtha.2005.10.023
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 20
TC 3
Z9 3
U1 0
U2 3
PU AFRICAN NETWORKS ETHNOMEDICINES
PI ILE-IFE
PA OBAFEMI AWOLOWO UNIV,CLEMENT O ADEWUNMI, DRUG RES PROD UNIT, FAC
   PHARMACY, ILE-IFE, 00000, NIGERIA
SN 0189-6016
J9 AFR J TRADIT COMPLEM
JI Afr. J. Tradit. Complement. Alt. M.
PY 2009
VL 6
IS 4
BP 549
EP 553
PG 5
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA 518FB
UT WOS:000271674800007
PM 20606776
DA 2022-11-30
ER

PT J
AU Cao, X
   Sanchez, JC
   Dinabandhu, A
   Guo, CY
   Patel, TP
   Yang, ZY
   Hu, MW
   Chen, LJ
   Wang, YF
   Malik, D
   Jee, K
   Daoud, YJ
   Handa, JT
   Zhang, H
   Qian, J
   Montaner, S
   Sodhi, A
AF Cao, Xuan
   Sanchez, Jaron Castillo
   Dinabandhu, Aumreetam
   Guo, Chuanyu
   Patel, Tapan P.
   Yang, Zhiyong
   Hu, Ming-Wen
   Chen, Lijun
   Wang, Yuefan
   Malik, Danyal
   Jee, Kathleen
   Daoud, Yassine J.
   Handa, James T.
   Zhang, Hui
   Qian, Jiang
   Montaner, Silvia
   Sodhi, Akrit
TI Aqueous proteins help predict the response of patients with neovascular
   age-related macular degeneration to anti-VEGF therapy
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID TREAT-AND-EXTEND; ENDOTHELIAL GROWTH-FACTOR; COMPLEMENT FACTOR-H; BRUCHS
   MEMBRANE; RANIBIZUMAB; REGIMEN; DRUSEN; ACCUMULATION; CHOLESTEROL;
   GENETICS
AB BACKGROUND. To reduce the treatment burden for patients with neovascular age-related macular degeneration (nvAMD), emerging therapies targeting vascular endothelial growth factor (VEGF) are being designed to extend the interval between treatments, thereby minimizing the number of intraocular injections. However, which patients will benefit from longer-acting agents is not clear.
   METHODS. Eyes with nvAMD (n = 122) underwent 3 consecutive monthly injections with currently available anti-VEGF therapies, followed by a treat-and-extend protocol. Patients who remained quiescent 12 weeks from their prior treatment entered a treatment pause and were switched to pro re nata (PRN) treatment (based on vision, clinical exam, and/or imaging studies). Proteomic analysis was performed on aqueous fluid to identify proteins that correlate with patients' response to treatment.
   RESULTS. At the end of 1 year, 38 of 122 eyes (31%) entered a treatment pause (>= 30 weeks). Conversely, 21 of 122 eyes (17%) failed extension and required monthly treatment at the end of year 1. Proteomic analysis of aqueous fluid identified proteins that correlated with patients' response to treatment, including proteins previously implicated in AMD pathogenesis. Interestingly, apolipoprotein-B100 (ApoB100), a principal component of drusen implicated in the progression of nonneovascular AMD, was increased in treated patients who required less frequent injections. ApoB100 expression was higher in AMD eyes compared with controls but was lower in eyes that develop choroidal neovascularization (CNV), consistent with a protective role. Accordingly, mice overexpressing ApoB100 were partially protected from laser-induced CNV.
   CONCLUSION. Aqueous biomarkers could help identify patients with nvAMD who may not require or benefit from long-term treatment with anti-VEGF therapy.
C1 [Cao, Xuan; Sanchez, Jaron Castillo; Dinabandhu, Aumreetam; Guo, Chuanyu; Patel, Tapan P.; Yang, Zhiyong; Hu, Ming-Wen; Malik, Danyal; Jee, Kathleen; Daoud, Yassine J.; Handa, James T.; Qian, Jiang; Sodhi, Akrit] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
   [Dinabandhu, Aumreetam; Montaner, Silvia] Univ Maryland, Sch Dent, Dept Oncol & Diagnost Sci, Baltimore, MD 21201 USA.
   [Dinabandhu, Aumreetam; Montaner, Silvia] Univ Maryland, Sch Med, Dept Pathol, Greenebaum Canc Ctr, Baltimore, MD 21201 USA.
   [Chen, Lijun; Wang, Yuefan; Zhang, Hui] Johns Hopkins Univ, Dept Pathol, Baltimore, MD USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; University System of
   Maryland; University of Maryland Baltimore; University System of
   Maryland; University of Maryland Baltimore; Johns Hopkins University
RP Sodhi, A (通讯作者)，Johns Hopkins Sch Med, Wilmer Eye Inst, 400 N Broadway St,Smith Bldg 4039, Baltimore, MD 21287 USA.
EM asodhi1@jhmi.edu
OI Dinabandhu, Aumreetam/0000-0002-2879-5031; Wang,
   Yuefan/0000-0001-5731-6143
FU National Eye Institute, National Institutes of Health [R01EY029750,
   R01EY025705, R01 EY27961]; Research to Prevent Blindness, Inc.; Alcon
   Research Institute; Johns Hopkins University
FX This work was supported by the National Eye Institute, National
   Institutes of Health grants R01EY029750, R01EY025705, and R01 EY27961;
   the Research to Prevent Blindness, Inc.; the Alcon Research Institute;
   and Johns Hopkins University through the Robert Bond Welch and Branna
   and Irving Sisenwein professorships in ophthalmology.
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Adrean SD, 2018, OPHTHALMOL RETINA, V2, P225, DOI 10.1016/j.oret.2017.07.009
   Ammar MJ, 2020, CURR OPIN OPHTHALMOL, V31, P215, DOI 10.1097/ICU.0000000000000657
   Arendt P, 2019, RETINA-J RET VIT DIS, V39, P27, DOI 10.1097/IAE.0000000000001923
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Augsburger M, 2019, GRAEF ARCH CLIN EXP, V257, P1889, DOI 10.1007/s00417-019-04404-0
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Ciulla TA, 2020, OPHTHALMOL RETINA, V4, P19, DOI 10.1016/j.oret.2019.05.017
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Farese RV, 1996, P NATL ACAD SCI USA, V93, P6393, DOI 10.1073/pnas.93.13.6393
   Forsythe JA, 1996, MOL CELL BIOL, V16, P4604
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fujihara M, 2014, INVEST OPHTH VIS SCI, V55, P7285, DOI 10.1167/iovs.14-15195
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Harvey PT, 2003, GERONTOLOGY, V49, P1, DOI 10.1159/000066507
   Hatz K, 2016, BRIT J OPHTHALMOL, V100, P1341, DOI 10.1136/bjophthalmol-2015-307299
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Iglicki M, 2021, EYE, V35, P1111, DOI 10.1038/s41433-020-01309-9
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Kertes PJ, 2020, JAMA OPHTHALMOL, V138, P244, DOI 10.1001/jamaophthalmol.2019.5540
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Li CM, 2005, J LIPID RES, V46, P628, DOI 10.1194/jlr.M400428-JLR200
   Li E, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012208.pub2
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Malik D, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.37880
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moisseiev E, 2018, CURR PHARM DESIGN, V24, P4860, DOI 10.2174/1381612825666190123165216
   Nguyen DH, 2013, DISCOV MED, V15, P343
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   SENGER DR, 1986, CANCER RES, V46, P5629
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Skerka C, 2013, MOL IMMUNOL, V56, P170, DOI 10.1016/j.molimm.2013.06.001
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Spooner KL, 2018, CLIN OPHTHALMOL, V12, P2483, DOI 10.2147/OPTH.S185052
   Tadayoni R, 2021, OPHTHALMOLOGICA, V244, P93, DOI 10.1159/000513048
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   Usui-Ouchi A, 2019, J CLIN INVEST, V129, P3032, DOI 10.1172/JCI129862
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   Wu TH, 2010, LAB INVEST, V90, P963, DOI 10.1038/labinvest.2010.87
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 48
TC 2
Z9 2
U1 1
U2 4
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JAN 18
PY 2022
VL 132
IS 2
AR e144469
DI 10.1172/JCI144469
PG 17
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA YM5LU
UT WOS:000746616900001
PM 34874918
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Prasuhn, M
   Kurz, M
   Grisanti, S
   Holzhey, A
   Ranjbar, M
AF Prasuhn, Michelle
   Kurz, Maximilian
   Grisanti, Salvatore
   Holzhey, Annekatrin
   Ranjbar, Mahdy
TI Three-year clinical and optical coherence tomography follow-up after
   stereotactic radiotherapy for neovascular age-related macular
   degeneration
SO ADVANCES IN MEDICAL SCIENCES
LA English
DT Article
DE Stereotactic radiotherapy; Neovascular AMD; Optical coherence
   tomography; Subfoveal choroidal thickness
ID SUBFOVEAL CHOROIDAL THICKNESS; GROWTH-FACTOR THERAPY; POTENTIAL
   PREDICTOR; RADIATION-THERAPY; VISUAL-ACUITY; OUTCOMES; ATROPHY;
   CHORIOCAPILLARIS; ANCHOR; MARINA
AB Purpose: The long-term clinical outcome of adjuvant stereotactic radiotherapy (SRT) in neovascular age-related macular degeneration (nAMD) patients was evaluated.
   Methods: This case-control study included patients with unilateral nAMD, who underwent SRT complementary to standard anti-VEGF treatment. Only patients with monthly follow-up over at least three years were considered. Number of intravitreal injections, visual acuity (VA), central retinal thickness (CRT), and subfoveal choroidal thickness (SFCT) were evaluated and compared to baseline as well as to an age- and gender-matched control group, who received anti-VEGF monotherapy.
   Results: Twenty patients were irradiated and had complete follow-up. Cumulatively, SRT patients needed significantly less injections than non-irradiated ones over three years (14 vs. 18, p = 0.014), while median VA did not show statistically significant changes (0.4 logMAR at baseline to 0.65 logMAR at final follow-up, p = 0.061). CRT remained steady, but SFCT showed a continuous thinning of almost 50 mu m (p = 0.031) in irradiated patients over three years. Multiple linear regression analysis revealed that SFCT and VA at time of irradiation are significant prognostic factors of VA change in SRT patients over the following three years (F(2,17) = 23.946, p< 0.001, R-2 of 0.738).
   Conclusions: SRT significantly reduced the cumulative anti-VEGF treatment burden over three years, however, this was mainly driven by the results of the first year after irradiation. A thinner SFCT at time of irradiation was associated with poorer visual outcome. While further research and investigation are warranted to elucidate the underlying pathogenesis, SFCT could be a potential biomarker when evaluating a patient's suitability for SRT.
C1 [Prasuhn, Michelle; Kurz, Maximilian; Grisanti, Salvatore; Ranjbar, Mahdy] Univ Lubeck, Dept Ophthalmol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.
   [Prasuhn, Michelle; Kurz, Maximilian; Holzhey, Annekatrin; Ranjbar, Mahdy] Univ Lubeck, Lab Angiogenesis & Ocular Cell Transplantat, Lubeck, Germany.
C3 University of Lubeck; University of Lubeck
RP Ranjbar, M (通讯作者)，Univ Lubeck, Dept Ophthalmol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.
EM eye.research101@gmail.com
OI Prasuhn, Michelle/0000-0001-7304-2963
CR Adrian ML, 2019, ACTA OPHTHALMOL, V97, P91, DOI 10.1111/aos.13864
   Amoaku WMK, 1995, EYE, V9, P738, DOI 10.1038/eye.1995.187
   Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Baxter JM, 2016, EYE, V30, P698, DOI 10.1038/eye.2016.18
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Branchini L, 2013, JAMA OPHTHALMOL, V131, P693, DOI 10.1001/jamaophthalmol.2013.692
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Chandra S, 2020, EYE, V34, P1888, DOI 10.1038/s41433-020-0764-9
   Cho HJ, 2020, BRIT J OPHTHALMOL, V104, P1443, DOI 10.1136/bjophthalmol-2019-315496
   Ehlken C, 2018, CLIN OPHTHALMOL, V12, P11, DOI 10.2147/OPTH.S151611
   Fan WY, 2018, GRAEF ARCH CLIN EXP, V256, P511, DOI 10.1007/s00417-017-3888-2
   Freiberg FJ, 2019, BRIT J OPHTHALMOL, V103, P469, DOI 10.1136/bjophthalmol-2018-311865
   Gesellschaft Deutsche Ophthalmologische, 2015, Klin Monbl Augenheilkd, V232, P202, DOI 10.1055/s-0034-1396162
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Hikichi T, 2019, INVEST OPHTH VIS SCI, V60, P1088, DOI 10.1167/iovs.18-24522
   Holz FG, 1997, FRONT RADIAT THER ON, V30, P238
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Inan S, 2019, CURR EYE RES, V44, P908, DOI 10.1080/02713683.2019.1600195
   Jackson TL, 2015, RETINA-J RET VIT DIS, V35, P194, DOI 10.1097/IAE.0000000000000283
   Jackson TL, 2015, OPHTHALMOLOGY, V122, P138, DOI 10.1016/j.ophtha.2014.07.043
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1893, DOI 10.1016/j.ophtha.2013.02.016
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Kurz M, 2019, KLIN MONATSBL AUGENH, V236, P892, DOI 10.1055/s-0043-115903
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   McKean-Cowdin R, 2010, OPHTHALMOLOGY, V117, P1900, DOI 10.1016/j.ophtha.2010.01.059
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moshfeghi DM, 2011, BRIT J OPHTHALMOL, V95, P185, DOI 10.1136/bjo.2009.163907
   Mukkamala LK, 2020, EYE, V34, P2271, DOI 10.1038/s41433-020-0807-2
   Neffendorf JE, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1676-7
   Neffendorf JE, 2015, CLIN OPHTHALMOL, V9, P1829, DOI 10.2147/OPTH.S75638
   Petrarca R, 2011, CLIN OPHTHALMOL, V5, P57, DOI 10.2147/OPTH.S16444
   Ranjbar M, 2018, OSLI RETINA, V49, P320, DOI 10.3928/23258160-20180501-05
   Ranjbar M, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005729
   Ranjbar M, 2019, J CURR OPHTHALMOL, V31, P92, DOI 10.1016/j.joco.2018.12.004
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Siegfried F, 2019, ACTA OPHTHALMOL, V97, pE1062, DOI 10.1111/aos.14140
   Veluswamy B, 2020, CLIN OPHTHALMOL, V14, P1565, DOI 10.2147/OPTH.S256009
   Wecker T, 2017, BRIT J OPHTHALMOL, V101, P353, DOI 10.1136/bjophthalmol-2016-308668
   Ying GS, 2018, OPHTHALMOL RETINA, V2, P525, DOI 10.1016/j.oret.2017.10.003
NR 40
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER URBAN & PARTNER SP Z O O
PI WROCLAW
PA UL MIGDALOWA 4, LOK 59, WROCLAW, 02-796, POLAND
SN 1896-1126
EI 1898-4002
J9 ADV MED SCI-POLAND
JI Adv. Med. Sci.
PD MAR
PY 2021
VL 66
IS 1
BP 215
EP 220
DI 10.1016/j.advms.2021.03.002
EA MAR 2021
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA RW0MG
UT WOS:000646218100027
PM 33730635
DA 2022-11-30
ER

PT J
AU Lee, AY
   Lee, CS
   Blazes, MS
   Owen, JP
   Bagdasarova, Y
   Wu, Y
   Spaide, T
   Yanagihara, RT
   Kihara, Y
   Clark, ME
   Kwon, M
   Owsley, C
   Curcio, CA
AF Lee, Aaron Y.
   Lee, Cecilia S.
   Blazes, Marian S.
   Owen, Julia P.
   Bagdasarova, Yelena
   Wu, Yue
   Spaide, Theodore
   Yanagihara, Ryan T.
   Kihara, Yuka
   Clark, Mark E.
   Kwon, MiYoung
   Owsley, Cynthia
   Curcio, Christine A.
TI Exploring a Structural Basis for Delayed Rod-Mediated Dark Adaptation in
   Age-Related Macular Degeneration Via Deep Learning
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE deep learning; age-related macular degeneration; biomarker; spectral
   domain optical coherence tomography; drusen; rod-mediated dark
   adaptation
ID OPTICAL COHERENCE TOMOGRAPHY; BRUCHS MEMBRANE; PROGRESSION; RETINA;
   CHORIOCAPILLARIS; RANIBIZUMAB; BIOMARKER; DISEASES; IMAGES
AB Purpose: Delayed rod-mediated dark adaptation (RMDA) is a functional biomarker for incipient age-related macular degeneration (AMD). We used anatomically restricted spectral domain optical coherence tomography (SD-OCT) imaging data to localize de novo imaging features associated with and to test hypotheses about delayed RMDA.
   Methods: Rod intercept time (RIT) was measured in participants with and without AMD at 5 degrees from the fovea, and macular SD-OCT images were obtained. A deep learning model was trained with anatomically restricted information using a single representative B-scan through the fovea of each eye. Mean-occlusion masking was utilized to isolate the relevant imaging features.
   Results: The model identified hyporeflective outer retinal bands on macular SD-OCT associated with delayed RMDA. The validation mean standard error (MSE) registered to the fovea! B-scan localized the lowest error to 0.5 mm temporal to the fovea center, within an overall low-error region across the rod-free zone and adjoining parafovea. Mean absolute error (MAE) on the test set was 4.71 minutes (8.8% of the dynamic range).
   Conclusions: We report a novel framework for imaging biomarker discovery using deep learning and demonstrate its ability to identify and localize a previously undescribed biomarker in retinal imaging. The hyporeflective outer retinal bands in central macula on SD-OCT demonstrate a structural basis for dysfunctional rod vision that correlates to published histopathologic findings.
   Translational Relevance: This agnostic approach to anatomic biomarker discovery strengthens the rationale for RMDA as an outcome measure in early AMD clinical trials, and also expands the utility of deep learning beyond automated diagnosis to fundamental discovery.
C1 [Lee, Aaron Y.; Lee, Cecilia S.; Blazes, Marian S.; Owen, Julia P.; Bagdasarova, Yelena; Wu, Yue; Spaide, Theodore; Yanagihara, Ryan T.; Kihara, Yuka] Univ Washington, Sch Med, Dept Ophthalmol, Seattle, WA 98104 USA.
   [Clark, Mark E.; Owsley, Cynthia; Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol & Visual Sci, Birmingham, AL USA.
   [Kwon, MiYoung] Northeastern Univ, Dept Psychol, Boston, MA 02115 USA.
C3 University of Washington; University of Washington Seattle; University
   of Alabama System; University of Alabama Birmingham; Northeastern
   University
RP Lee, AY (通讯作者)，Univ Washington, 325 Ninth Ave,Box 359608, Seattle, WA 98104 USA.
EM leeay@uw.edu
RI Wu, Yue/AAJ-7041-2021
OI Wu, Yue/0000-0002-2917-5862; Lee, Aaron/0000-0002-7452-1648; Yanagihara,
   Ryan/0000-0001-6898-9335
FU NIH/NEI [K23EY029246, R01AG060942, R01AG04212, R01EY029595, R01EY03039];
   EyeSight Foundation of Alabama; Dorsett Davis Discovery Fund; Alfreda J.
   Schueler Trust; Research to Prevent Blindness (RPB); RPB/Lions Clubs
   International Foundation low vision research grant
FX Supported by NIH/NEI K23EY029246, R01AG060942, R01AG04212, R01EY029595,
   R01EY03039, EyeSight Foundation of Alabama, the Dorsett Davis Discovery
   Fund, Alfreda J. Schueler Trust, and an unrestricted grant, CDA from
   Research to Prevent Blindness (RPB), and RPB/Lions Clubs International
   Foundation low vision research grant. The sponsors/funding organizations
   had no role in the design or conduct of this research.
CR Abramoff MD, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0040-6
   [Anonymous], 1991, Ophthalmology, V98, P786
   Brown CN, 2019, METABOLITES, V9, DOI 10.3390/metabo9010004
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Burlina PM, 2018, JAMA OPHTHALMOL, V136, P1359, DOI 10.1001/jamaophthalmol.2018.4118
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Burlina P, 2018, JAMA OPHTHALMOL, V136, P1305, DOI 10.1001/jamaophthalmol.2018.3799
   Chen KG, 2019, OPHTHALMOLOGY, V126, P856, DOI 10.1016/j.ophtha.2018.09.039
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Crosson JN, 2019, OPHTHALMOL RETINA, V3, P670, DOI 10.1016/j.oret.2019.03.019
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Curcio CA, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01467-0
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Dozat T., INCORPORATING NESTER
   Echols BS, 2020, OPHTHALMOL RETINA, V4, P1059, DOI 10.1016/j.oret.2020.05.001
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Glorot X., 2010, P 13 INT C ART INT S, V9, P249
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Jackson Gregory R, 2008, J Ocul Biol Dis Infor, V1, P7, DOI 10.1007/s12177-008-9002-6
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Kihara Y, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.8029
   KOSNIK W, 1988, J GERONTOL, V43, pP63, DOI 10.1093/geronj/43.3.P63
   Lains I, 2018, OPHTHALMOLOGY, V125, P245, DOI 10.1016/j.ophtha.2017.08.008
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Lee CS, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42042-y
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Li BX, 2020, P NATL ACAD SCI USA, V117, P12352, DOI 10.1073/pnas.1922793117
   Litts KM, 2015, INVEST OPHTH VIS SCI, V56, P2243, DOI 10.1167/iovs.14-15838
   Mullins RF, 2019, OPHTHALMOLOGY, V126, P591, DOI 10.1016/j.ophtha.2018.10.037
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Nassisi M, 2019, OPHTHALMOLOGY, V126, P1667, DOI 10.1016/j.ophtha.2019.05.016
   Neely D, 2017, RETINA-J RET VIT DIS, V37, P1329, DOI 10.1097/IAE.0000000000001454
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Peng YF, 2019, OPHTHALMOLOGY, V126, P565, DOI 10.1016/j.ophtha.2018.11.015
   Pollreisz A, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.8.13
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rowan S, 2017, P NATL ACAD SCI USA, V114, pE4472, DOI 10.1073/pnas.1702302114
   SAMY CN, 1989, VISUAL NEUROSCI, V3, P281, DOI 10.1017/S0952523800010038
   Schultz R, 2018, INVEST OPHTH VIS SCI, V59
   Selvaraju RR, 2017 IEEE INT C COMP
   Shirazi MF, 2020, BIOMED OPT EXPRESS, V11, P4520, DOI 10.1364/BOE.393906
   Simonyan Karen, 2013, DEEP INSIDE CONVOLUT
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Waldstein SM, 2020, JAMA OPHTHALMOL, V138, P740, DOI 10.1001/jamaophthalmol.2020.1376
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Yiu G, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.2.32
NR 58
TC 5
Z9 5
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD JAN
PY 2020
VL 9
IS 2
AR 62
DI 10.1167/tvst.9.2.62
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PG1FX
UT WOS:000599489500048
PM 33344065
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Michalska-Malecka, K
   Kabiesz, A
   Kimsa, MW
   Strzalka-Mrozik, B
   Forminska-Kapuscik, M
   Nita, M
   Mazurek, U
AF Michalska-Malecka, Katarzyna
   Kabiesz, Adam
   Kimsa, Malgorzata W.
   Strzalka-Mrozik, Barbara
   Forminska-Kapuscik, Maria
   Nita, Malgorzata
   Mazurek, Urszula
TI Effects of intravitreal ranibizumab on the untreated eye and systemic
   gene expression profile in age-related macular degeneration
SO CLINICAL INTERVENTIONS IN AGING
LA English
DT Article
DE ranibizumab; contralateral eye; central retinal thickness;
   oligonucleotide microarray
ID ENDOTHELIAL GROWTH-FACTOR; ANTI-VEGF INJECTION; BEVACIZUMAB;
   PHARMACOKINETICS; AFLIBERCEPT; BIOMARKERS; RUBEOSIS; OUTCOMES; DISEASE;
   SERUM
AB The purpose of this study was to evaluate the systemic effects of intravitreal ranibizumab (Lucentis) treatment in patients with neovascular age-related macular degeneration (AMD). The impact of intravitreal ranibizumab injections on central retinal thickness (CRT) of treated and contralateral untreated eyes, and differences in gene expression patterns in the peripheral blood mononuclear cells were analyzed. The study included 29 patients aged 50 years old and over with diagnosed neovascular AMD. The treatment was defined as 0.5 mg of ranibizumab injected intravitreally in the form of one injection every month during the period of 3 months. CRT was measured by optical coherence tomography. The gene expression profile was assigned using oligonucleotide microarrays of Affymetrix HG-U133A. Studies have shown that there was a change of CRT between treated and untreated eyes, and there were differences in CRT at baseline and after 1, 2, and 3 months of ranibizumab treatment. Three months after intravitreal injection, mean CRT was reduced in the treated eyes from 331.97 +/- 123.62 to 254.31 +/- 58.75 mu m, while mean CRT in the untreated fellow eyes reduced from 251.07 +/- 40.29 to 235.45 +/- 36.21 mu m at the same time. Furthermore, the research has shown that among all transcripts, 3,097 expresses change after the ranibizumab treatment in relation to controls. Among these transcripts, 1,339 were up-regulated, whereas 1,758 were down-regulated. Our results show the potential systemic effects of anti-VEGF therapy for AMD. Moreover, our study indicated different gene expression in peripheral blood mononuclear cells before and after intravitreal ranibizumab treatment.
C1 [Michalska-Malecka, Katarzyna] Med Univ Silesia, Dept Clin Ophthalmol, Ceglana St 35, Katowice, Poland.
   [Michalska-Malecka, Katarzyna; Kabiesz, Adam; Forminska-Kapuscik, Maria] Med Univ Silesia, Independent Publ Clin Hosp, Univ Ctr Ophthalmol & Oncol, Katowice, Poland.
   [Kimsa, Malgorzata W.; Strzalka-Mrozik, Barbara; Mazurek, Urszula] Med Univ Silesia, Div Lab Med Sosnowiec, Sch Pharm, Dept Mol Biol, Katowice, Poland.
   [Forminska-Kapuscik, Maria] Med Univ Silesia, Clin Dept Children Ophthalmol, Katowice, Poland.
   [Nita, Malgorzata] Domest & Specialized Med Ctr Dilmed, Katowice, Poland.
C3 Medical University Silesia; Medical University Silesia; Medical
   University Silesia; Medical University Silesia
RP Michalska-Malecka, K (通讯作者)，Med Univ Silesia, Dept Clin Ophthalmol, Ceglana St 35, Katowice, Poland.
EM k.michalska.malecka@gmail.com
OI STRZALKA-MROZIK, BARBARA/0000-0001-9854-2569; Mazurek,
   Urszula/0000-0003-1181-4934; MICHALSKA-MALECKA,
   KATARZYNA/0000-0002-0550-8386; Kimsa-Furdzik,
   Malgorzata/0000-0003-1985-2038
FU PL-Grid Infrastructure
FX This research was supported in part by PL-Grid Infrastructure
   (http://www.plgrid.pl/en).
CR Acharya NR, 2011, RETINA-J RET VIT DIS, V31, P1871, DOI 10.1097/IAE.0b013e318213da43
   Al-Dhibi H, 2009, J AAPOS, V13, P400, DOI 10.1016/j.jaapos.2009.03.006
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P7, DOI 10.1136/bjophthalmol-2013-303844
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Brown DM, 2014, RETINA-J RET VIT DIS, V34, P1728, DOI 10.1097/IAE.0000000000000191
   Campbell RJ, 2012, OPHTHALMOLOGY, V119, P1604, DOI 10.1016/j.ophtha.2012.05.028
   Canan H, 2014, CLIN INTERV AGING, V9, P141, DOI 10.2147/CIA.S56863
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Chavan R, 2014, CLIN OPHTHALMOL, V8, P717, DOI 10.2147/OPTH.S60763
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Christoforidis J, 2012, CLIN OPHTHALMOL, V6, P61, DOI 10.2147/OPTH.S28275
   Christoforidis JB, 2013, CLIN OPHTHALMOL, V7, P185, DOI 10.2147/OPTH.S40537
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P166, DOI 10.1097/ICU.0b013e328329d173
   Couturier A, 2014, MOL VIS, V20, P908
   Dabir SS, 2014, INDIAN J OPHTHALMOL, V62, P66, DOI 10.4103/0301-4738.126186
   Emerson MV, 2008, CLIN OPHTHALMOL, V2, P377
   Falk MK, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-22
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Golan Shani, 2014, BMC Res Notes, V7, P617, DOI 10.1186/1756-0500-7-617
   Hosseini H, 2012, RETINA-J RET VIT DIS, V32, P967, DOI 10.1097/IAE.0b013e31822c28d6
   Hwang DJ, 2012, J KOREAN MED SCI, V27, P1580, DOI 10.3346/jkms.2012.27.12.1580
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Lim LS, 2011, AM J OPHTHALMOL, V152, P329, DOI 10.1016/j.ajo.2011.05.040
   Luke J, 2013, GRAEF ARCH CLIN EXP, V251, P371, DOI 10.1007/s00417-012-2184-4
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Moisseiev E, 2015, RETINA-J RET VIT DIS, V35, P1323, DOI 10.1097/IAE.0000000000000500
   Moisseiev E, 2014, GRAEF ARCH CLIN EXP, V252, P331, DOI 10.1007/s00417-013-2495-0
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Nita M, 2014, MED SCI MONITOR, V20, P875, DOI 10.12659/MSM.890031
   Orchel J, 2012, INT J GYNECOL CANCER, V22, P937, DOI 10.1097/IGC.0b013e318259d8da
   Pescosolido N, 2014, JSM BIOTECHNOL BIOEN, V2, P1038
   Regnier S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102309
   Rotsos T, 2014, INT OPHTHALMOL, V34, P1271, DOI 10.1007/s10792-014-9921-0
   Rouvas A, 2009, OPHTHALMOLOGICA, V223, P383, DOI 10.1159/000228590
   Sharma Ashish, 2013, Retin Cases Brief Rep, V7, P217, DOI 10.1097/ICB.0b013e31828993a1
   Sizmaz S, 2014, EUR J OPHTHALMOL, V24, P904, DOI 10.5301/ejo.5000478
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   Wang Donghyun, 2014, Korean J Ophthalmol, V28, P32, DOI 10.3341/kjo.2014.28.1.32
   Wang XY, 2014, AM J OPHTHALMOL, V158, P738, DOI 10.1016/j.ajo.2014.06.009
   Wong TY, 2009, AM J OPHTHALMOL, V148, P327, DOI 10.1016/j.ajo.2009.05.012
   Wu ZQ, 2008, ANN ACAD MED SINGAP, V37, P591
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
   Zehetner C, 2015, ACTA OPHTHALMOL, V93, pE154, DOI 10.1111/aos.12604
NR 45
TC 13
Z9 13
U1 1
U2 10
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 1178-1998
J9 CLIN INTERV AGING
JI Clin. Interv. Aging
PY 2016
VL 11
BP 357
EP 365
DI 10.2147/CIA.S93820
PG 9
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA DH5WD
UT WOS:000372862100001
PM 27069359
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Fung, AE
   Lalwani, GA
   Rosenfeld, PJ
   Dubovy, SR
   Michels, S
   Feuer, WJ
   Puliafito, CA
   Davis, JL
   Flynn, HW
   Esquiabro, M
AF Fung, Anne E.
   Lalwani, Geeta A.
   Rosenfeld, Philip J.
   Dubovy, Sander R.
   Michels, Stephan
   Feuer, William J.
   Puliafito, Carmen A.
   Davis, Janet L.
   Flynn, Harry W., Jr.
   Esquiabro, Maria
TI An optical coherence tomography-guided, variable dosing regimen with
   intravitreal ranibizumab (lucentis) for neovascular age-related macular
   degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB PURPOSE: To evaluate an optical coherence tomogra, phy (OCT)-guided, variable,dosing regimen with intravitreal ranibizumab for the treatment of patients with neovascular age-related macular degeneration (AMD).
   center dot DESIGN: Open-label, prospective, single-center, nonrandomized, investigator, sponsored clinical study.
   center dot METHODS: In this two,year study, neovascular AMD patients with subfoveal choroidal neovascularization (CNV) (n = 40) and a central retinal thickness of at least 300 mu m as measured by OCT were enrolled to receive three consecutive monthly intravitreal injections of ranibizumab (0.5 mg). Thereafter, retreatment with ranibizumab was performed if one of the following changes was observed between visits: a loss of five letters in conjunction with fluid in the macula as detected by OCT, an increase in OCT central retinal thickness of at least 100 mu m, new-onset classic CNV, new macular hemorrhage, or persistent macular fluid detected by OCT at least one month after the previous injection of ranibizumab.
   center dot RESULTS: At month 12, the mean visual acuity improved by 9.3 letters (P < .001) and the mean OCT central retinal thickness decreased by 178 mu m (P < .001). Visual acuity improved 15 or more letters in 35% of patients. These visual acuity and OCT outcomes were achieved with an average of 5.6 injections over 12 months. After a fluid,free macula was achieved, the mean injection,free interval was 4.5 months before another reinjection was necessary.
   center dot CONCLUSION: This OCT-guided, variable-dosing regimen with ranibizumab resulted in visual acuity outcomes similar to the Phase III clinical studies, but required fewer intravitreal injections. OCT appears useful for determining when retreatment with ranibizumab is necessary.
C1 Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   Calif Pacific Med Ctr, Pacific Eye Associates, San Francisco, CA USA.
   Univ Vienna, Hosp Eye, Vienna, Austria.
C3 Bascom Palmer Eye Institute; University of Miami; California Pacific
   Medical Center; University of Vienna
RP Rosenfeld, PJ (通讯作者)，Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@med.miami.edu
RI Davis, Janet L/GPC-8037-2022
OI Davis, Janet L/0000-0001-6395-5881
FU NEI NIH HHS [P30 EY014801] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [P30EY014801] Funding Source: NIH RePORTER
CR Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HEIER JS, 2006, OPHTHALMOLOGY, V113, P642
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
NR 7
TC 790
Z9 836
U1 2
U2 42
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2007
VL 143
IS 4
BP 566
EP 583
DI 10.1016/j.ajo.2007.01.028
PG 18
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 154WE
UT WOS:000245537800003
PM 17386270
DA 2022-11-30
ER

PT J
AU Querques, L
   Querques, G
   Forte, R
   Souied, EH
AF Querques, Lea
   Querques, Giuseppe
   Forte, Raimondo
   Souied, Eric H.
TI Microperimetric Correlations of Autofluorescence and Optical Coherence
   Tomography Imaging in Dry Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID FUNDUS AUTOFLUORESCENCE; FLUORESCENCE
AB center dot PURPOSE: To investigate the microperimetric correlations of autofluorescence imaging and optical coherence tomography (OCT) in dry age-related macular degeneration (AMD).
   center dot DESIGN: Retrospective, observational, cross-sectional study.
   center dot METHODS: Consecutive patients with dry AMD underwent a complete ophthalmologic examination, including best-corrected visual acuity (BCVA), blue fundus autofluorescence (FAF), near-infrared autofluorescence, and spectral-domain (SD)-OCT with integrated microperimetry.
   center dot RESULTS: A total of 58 eyes of 29 patients (21 women; mean age 73 +/- 9 years) were included. Mean BCVA was 0.28 +/- 0.3 logarithm of the minimal angle of resolution (logMAR). Overall, 2842 points were analyzed as regards FAF and near-infrared autofluorescence patterns, the status of inner segment/outer segment (IS/OS) interface, and retinal sensitivity. We observed a good correlation between the FAF and near-infrared autofluorescence patterns for all the points graded (increased FAF/near-infrared autofluorescence, Pearson rho = 0.6, P =.02; decreased FAF/near-infrared autofluorescence, Pearson rho = 0.7, P = .01; normal FAF/near-infrared autofluorescence, Pearson rho = 0.7, P = .01). Mean retinal sensitivity was significantly reduced in cases of decreased FAF (4.73 +/- 2.23 dB) or increased FAF (4.75 +/- 2.39 dB) compared with normal FAF (7.44 +/- 2.34 dB) (P = .001). Mean retinal sensitivity was significantly reduced in case of decreased near-infrared autofluorescence (3.87 +/- 2.28 dB), compared with increased near-infrared autofluorescence (5.76 +/- 2.44 dB) (P = .02); mean retinal sensitivity in case of increased near-infrared autofluorescence was significantly reduced compared with normal near-infrared autofluorescence (7.15 +/- 2.38 dB) (P = .002). On SD-OCT, there was a high inverse correlation between retinal sensitivity and rate of disruptions in IS/OS interface (Pearson rho = 0.72, P = .001).
   center dot CONCLUSION: A reduced retinal sensitivity consistently correlates with decreased FAF/near-infrared autofluorescence and a disrupted IS/OS interface. Increased near-infrared autofluorescence may represent a useful method for detection of retinal abnormalities early in dry AMD development. (Am J Ophthalmol 2012;153: 1110-1115. (C) 2012 by Elsevier Inc. All rights reserved.)
C1 [Querques, Lea; Querques, Giuseppe; Forte, Raimondo; Souied, Eric H.] Univ Paris Est Creteil, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, Creteil, France.
   [Querques, Lea] Univ Vita Salute San Raffaele, Dept Ophthalmol, Hosp San Raffaele, Milan, Italy.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Querques, G (通讯作者)，Univ Paris 12, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, 40 Ave Verdun, F-94000 Creteil, France.
EM giuseppe.querques@hotmail.it
OI Querques, Giuseppe/0000-0002-3292-9581
FU Bausch Lomb - Chauvin; Novartis; Alcon
FX Dr Souied has received consulting and lecture support from Bausch & Lomb
   - Chauvin, Novartis, and Alcon. Involved in design and conduct of the
   study (G.Q., E.H.S.); collection, management, analysis (L.Q., G.Q.,
   R.F.), and interpretation of the data (L.Q., G.Q., R.F., E.H.S.); and
   preparation (L.Q., G.Q., R.F.), review, or approval of the manuscript
   (G.Q., E.H.S.). Written informed consent according to the tenets of the
   Declaration of Helsinki was obtained from each patient enrolled. French
   Society of Ophthalmology Ethics Committee approval was obtained for the
   retrospective review of data. This study has been performed in
   accordance with the ethical standards set forth in the Declaration of
   Helsinki.
CR Bartlett H, 2007, SURV OPHTHALMOL, V52, P655, DOI 10.1016/j.survophthal.2007.08.022
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Dinc UA, 2008, EUR J OPHTHALMOL, V18, P595, DOI 10.1177/112067210801800416
   Gibbs D, 2009, INVEST OPHTH VIS SCI, V50, P4386, DOI 10.1167/iovs.09-3471
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Kellner U, 2010, RETINA-J RET VIT DIS, V30, P6, DOI 10.1097/IAE.0b013e3181b8348b
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Landa G, 2010, OPHTHALMIC RES, V43, P92, DOI 10.1159/000247593
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   Pirbhai A, 2005, AM J OPHTHALMOL, V139, P455, DOI 10.1016/j.ajo.2004.09.077
   Schmitz-Valckenberg S, 2011, INVEST OPHTHALMOL VI, V52, P1
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Schmitz-Valckenberg S, 2008, AM J OPHTHALMOL, V146, P183, DOI 10.1016/j.ajo.2008.04.006
   Schmitz-Valckenberg S, 2011, BRIT J OPHTHALMOL, V95, P1134, DOI 10.1136/bjo.2010.189498
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Weinberger AWA, 2006, INVEST OPHTH VIS SCI, V47, P3098, DOI 10.1167/iovs.05-1104
NR 19
TC 41
Z9 41
U1 2
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUN
PY 2012
VL 153
IS 6
BP 1110
EP 1115
DI 10.1016/j.ajo.2011.11.002
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 953US
UT WOS:000304899300015
PM 22321805
DA 2022-11-30
ER

PT J
AU Wang, AL
   Lukas, TJ
   Yuan, M
   Du, N
   Handa, JT
   Neufeld, AH
AF Wang, Ai Ling
   Lukas, Thomas J.
   Yuan, Ming
   Du, Nga
   Handa, James T.
   Neufeld, Arthur H.
TI Changes in Retinal Pigment Epithelium Related to Cigarette Smoke:
   Possible Relevance to Smoking as a Risk Factor for Age-Related Macular
   Degeneration
SO PLOS ONE
LA English
DT Article
AB Age-related Macular Degeneration (AMD) is a major cause of central vision loss in the elderly and smoking is a primary risk factor associated with the prevalence and incidence of AMD. To better understand the cellular and molecular bases for the association between smoking and AMD, we determined the effects of Benzo(a) Pyrene (B(a) P), a toxic element in cigarette smoke, on cultured retinal pigment epithelia (RPE) and we examined the RPE/choroid from mice exposed to chronic cigarette smoke. We measured: mitochondrial DNA (mtDNA) damage, phagocytic activity, lysosomal enzymes, exosome markers and selected complement pathway components. In the presence of a non-cytotoxic dose of B(a) P, there was extensive mtDNA damage but no nuclear DNA damage. RPE phagocytic activity was not altered but there were increased lysosomal activity, exocytotic activity and complement pathway components. Retinas from mice exposed to cigarette smoke contained markers for mtDNA damage, exosomes and complement pathway components surrounding Bruch's membrane. Markers for these processes are found in drusen from AMD patients. Thus, smoking may cause damage to mtDNA and increased degradative processes in the RPE. These altered cell biological processes in the RPE may contribute to the formation of drusen in individuals who are cigarette smokers and underlie susceptibility to genetic mutations associated with AMD.
RP Wang, AL (通讯作者)，Northwestern Univ, Sch Med, Dept Ophthalmol, Forsythe Lab Invest Aging Retina, Chicago, IL 60611 USA.
EM a-wang@northwestern.edu
FU NATIONAL EYE INSTITUTE [R01EY014005, R01EY019904] Funding Source: NIH
   RePORTER; NEI NIH HHS [EY14005, R01 EY019904, R01 EY014005-06A2, R01
   EY014005] Funding Source: Medline
CR BACKER JM, 1980, SCIENCE, V209, P297, DOI 10.1126/science.6770466
   BOULTON M, 1994, BRIT J OPHTHALMOL, V78, P125, DOI 10.1136/bjo.78.2.125
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Chang YG, 2007, J CELL SCI, V120, P3053, DOI 10.1242/jcs.006361
   CHEN H, 2009, INVEST OPHTHALMOL VI
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Cingle KA, 1996, CURR EYE RES, V15, P433, DOI 10.3109/02713689608995834
   CONNEY AH, 1982, CANCER RES, V42, P4875
   DING X, 2008, PROG RETIN EYE RES
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Finnemann SC, 1999, J EXP MED, V190, P861, DOI 10.1084/jem.190.6.861
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50
   Patton WP, 2002, EXP EYE RES, V74, P513, DOI 10.1006/exer.2001.1160
   Rakoczy PE, 1999, EXP EYE RES, V69, P367, DOI 10.1006/exer.1999.0700
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Niel G, 2006, J BIOCHEM, V140, P13, DOI 10.1093/jb/mvj128
   Verdugo ME, 1997, EXP EYE RES, V65, P231, DOI 10.1006/exer.1997.0325
   Wang A.L., 2008, NEUROBIOL AGING
   Wang AL, 2008, MOL VIS, V14, P644
   WANG AL, 2008, PLOS ONE
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
NR 36
TC 58
Z9 61
U1 2
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 24
PY 2009
VL 4
IS 4
AR e5304
DI 10.1371/journal.pone.0005304
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 437VG
UT WOS:000265514400005
PM 19390692
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Lains, I
   Kelly, RS
   Miller, JB
   Silva, R
   Vavvas, DG
   Kim, IK
   Murta, JN
   Lasky-Su, J
   Miller, JW
   Husain, D
AF Lains, Ines
   Kelly, Rachel S.
   Miller, John B.
   Silva, Rufino
   Vavvas, Demetrios G.
   Kim, Ivana K.
   Murta, Joaquim N.
   Lasky-Su, Jessica
   Miller, Joan W.
   Husain, Deeba
TI Human Plasma Metabolomics Study across All Stages of Age-Related Macular
   Degeneration Identifies Potential Lipid Biomarkers
SO OPHTHALMOLOGY
LA English
DT Article
ID C-REACTIVE PROTEIN; ALZHEIMERS-DISEASE; STATISTICAL-ANALYSIS; OXIDATIVE
   STRESS; METABOLISM; METABONOMICS; ASSOCIATION; MEDIATORS; EYE;
   GLYCEROPHOSPHOLIPIDS
AB Purpose: To characterize the plasma metabolomic profile of patients with age-related macular degeneration (AMD) using mass spectrometry (MS).
   Design: Cross-sectional observational study.
   Participants: We prospectively recruited participants with a diagnosis of AMD and a control group (> 50 years of age) without any vitreoretinal disease.
   Methods: All participants underwent color fundus photography, used for AMD diagnosis and staging, according to the Age-Related Eye Disease Study classification scheme. Fasting blood samples were collected and plasma was analyzed by Metabolon, Inc. (Durham, NC), using ultrahigh-performance liquid chromatography (UPLC) and high-resolution MS. Metabolon's hardware and software were used to identify peaks and control quality. Principal component analysis and multivariate regression were performed to assess differences in the metabolomic profiles of AMD patients versus controls, while controlling for potential confounders. For biological interpretation, pathway enrichment analysis of significant metabolites was performed using MetaboAnalyst.
   Main Outcome Measures: The primary outcome measures were levels of plasma metabolites in participants with AMD compared with controls and among different AMD severity stages.
   Results: We included 90 participants with AMD (30 with early AMD, 30 with intermediate AMD, and 30 with late AMD) and 30 controls. Using UPLC and MS, 878 biochemicals were identified. Multivariate logistic regression identified 87 metabolites with levels that differed significantly between AMD patients and controls. Most of these metabolites (82.8%; n = 72), including the most significant metabolites, belonged to the lipid pathways. Analysis of variance revealed that of the 87 metabolites, 48 (55.2%) also were significantly different across the different stages of AMD. A significant enrichment of the glycerophospholipids pathway was identified (P = 4.7 x 10(-9)) among these metabolites.
   Conclusions: Participants withAMDhave altered plasma metabolomic profiles comparedwith controls. Our data suggest that the most significant metabolites map to the glycerophospholipid pathway. These findings have the potential to improve our understanding of AMD pathogenesis, to support the development of plasma-based metabolomics biomarkers of AMD, and to identify novel targets for treatment of this blinding disease. (C) 2017 by the American Academy of Ophthalmology
C1 [Lains, Ines; Miller, John B.; Vavvas, Demetrios G.; Kim, Ivana K.; Miller, Joan W.; Husain, Deeba] Harvard Med Sch, Dept Ophthalmol, Harvard Ophthalmol AMD Ctr Excellence, Retina Serv,Massachusetts Eye & Ear, Boston, MA 02114 USA.
   [Lains, Ines; Silva, Rufino; Murta, Joaquim N.] Univ Coimbra, Fac Med, Coimbra, Portugal.
   [Lains, Ines; Silva, Rufino; Murta, Joaquim N.] Assoc Innovat & Biomed Res Light & Image AIBILI, Assoc Innovat & Biomed Res Light, Coimbra, Portugal.
   [Lains, Ines; Silva, Rufino; Murta, Joaquim N.] Ctr Hosp & Univ Coimbra, Coimbra, Portugal.
   [Kelly, Rachel S.; Lasky-Su, Jessica] Brigham & Womens Hosp, Syst Genet & Genom Unit, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA.
   [Kelly, Rachel S.; Lasky-Su, Jessica] Harvard Med Sch, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Universidade de Coimbra; Universidade de Coimbra;
   Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra
   (CHUC); Harvard University; Brigham & Women's Hospital; Harvard
   University; Harvard Medical School
RP Husain, D (通讯作者)，Harvard Med Sch, Massachusetts Eye & Ear, Retina Serv, 243 Charles St, Boston, MA 02114 USA.
EM Deeba_Husain@meei.harvard.edu
RI Miller, John J/GZG-5663-2022; kelly, rachel/H-4505-2017; Silva, Rufino
   M/J-2817-2012; Murta, Joaquim/V-5494-2017
OI kelly, rachel/0000-0003-3023-1822; Silva, Rufino M/0000-0001-8676-0833;
   Vavvas, Demetrios/0000-0002-8622-6478; Husain,
   Deeba/0000-0002-8494-0950; Kim, Ivana/0000-0003-0310-6129; Murta,
   Joaquim/0000-0001-8926-5176; Lains, Ines/0000-0002-8136-4724
FU Genentech; Allergan; Iconic Therapeutics; Alcon; Lowy Medical Research
   Institute, Ltd.; Miller Retina Research Fund; Champalimaud Vision Award;
   Research to Prevent Blindness, Inc., New York, New York; Portuguese
   Foundation for Science and Technology/Harvard Medical School Portugal
   Program [HMSP-ICJ/006/2013]; NATIONAL EYE INSTITUTE [P30EY014104]
   Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
   [R01HL123915] Funding Source: NIH RePORTER
FX I.K.K.: Financial support - Genentech, Allergan, Iconic Therapeutics;
   J.N.M.: Financial support - Alcon; J.W.M.: Consultant - Amgen, Inc.,
   KalVista Pharmaceuticals, Ltd., Maculogix, Inc., Biogen Idec, Inc.,
   Alcon Research Council; Financial support - Lowy Medical Research
   Institute, Ltd.; Patents - Valeant Pharmaceuticals, ONL Therapeutics
   LLC; Supported by the Miller Retina Research Fund (to Massachusetts Eye
   and Ear); the Champalimaud Vision Award (to J.W.M.); Research to Prevent
   Blindness, Inc., New York, New York (unrestricted departmental grant);
   and the Portuguese Foundation for Science and Technology/Harvard Medical
   School Portugal Program (grant no.: HMSP-ICJ/006/2013). None of the
   aforementioned funding organizations had any role in the design or
   conduct of this research.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Barnes S, 2016, J MASS SPECTROM, V51, P535, DOI 10.1002/jms.3780
   Beckonert O, 2007, NAT PROTOC, V2, P2692, DOI 10.1038/nprot.2007.376
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chi YY, 2014, STAT MED, V33, P812, DOI 10.1002/sim.5986
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Delgado R, 2014, J NEUROSCI, V34, P6679, DOI 10.1523/JNEUROSCI.0513-14.2014
   Dessi A, 2015, BEST PRACT RES CL OB, V29, P156, DOI 10.1016/j.bpobgyn.2014.04.023
   Emwas Abdul-Hamid M, 2015, Methods Mol Biol, V1277, P161, DOI 10.1007/978-1-4939-2377-9_13
   Ermilov VV, 2016, ADV EXP MED BIOL, V854, P119, DOI 10.1007/978-3-319-17121-0_17
   Farooqui AA, 2000, CHEM PHYS LIPIDS, V106, P1, DOI 10.1016/S0009-3084(00)00128-6
   Farooqui AA, 2007, J NEUROSCI RES, V85, P1834, DOI 10.1002/jnr.21268
   Farooqui AA, 2012, J ALZHEIMERS DIS, V30, pS163, DOI 10.3233/JAD-2011-111085
   Fiehn O, 2002, PLANT MOL BIOL, V48, P155, DOI 10.1023/A:1013713905833
   Fliesler SJ, 2010, J LIPID RES, V51, P3399, DOI 10.1194/jlr.R010538
   Frank RN, 2002, AM J OPHTHALMOL, V133, P693, DOI 10.1016/S0002-9394(02)01321-1
   Frisardi V, 2011, PROG LIPID RES, V50, P313, DOI 10.1016/j.plipres.2011.06.001
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Giusto NM, 2010, J LIPID RES, V51, P685, DOI 10.1194/jlr.R001891
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Hopiavuori BR, 2017, J LIPID RES, V58, P668, DOI 10.1194/jlr.M070714
   Horrocks LA, 1999, PHARMACOL RES, V40, P211, DOI 10.1006/phrs.1999.0495
   Junot C, 2014, MASS SPECTROM REV, V33, P471, DOI 10.1002/mas.21401
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kalita-de Croft P, 2016, ADV ANAT PATHOL, V23, P356, DOI 10.1097/PAP.0000000000000128
   Kelly RS, 2017, BBA-MOL BASIS DIS, V1863, P1590, DOI 10.1016/j.bbadis.2017.02.006
   Klein J, 2000, J NEURAL TRANSM, V107, P1027, DOI 10.1007/s007020070051
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Kosicek M, 2013, INT J MOL SCI, V14, P1310, DOI 10.3390/ijms14011310
   Lima AR, 2016, TRANSL ONCOL, V9, P357, DOI 10.1016/j.tranon.2016.05.004
   Mapstone M, 2017, NEUROBIOL AGING, V51, P148, DOI 10.1016/j.neurobiolaging.2016.11.007
   Mapstone M, 2014, NAT MED, V20, P415, DOI 10.1038/nm.3466
   Mazzone PJ, 2016, J THORAC ONCOL, V11, P72, DOI 10.1016/j.jtho.2015.09.002
   Midelfart A, 2009, ACTA OPHTHALMOL, V87, P697, DOI 10.1111/j.1755-3768.2009.01516.x
   Miller JW, 2016, INVEST OPHTH VIS SCI, V57, P6911, DOI 10.1167/iovs.16-21201
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303
   Nicholson JK, 2012, NATURE, V491, P384, DOI 10.1038/nature11708
   Nicholson JK, 1999, XENOBIOTICA, V29, P1181, DOI 10.1080/004982599238047
   Nicholson JK, 2003, NAT REV DRUG DISCOV, V2, P668, DOI 10.1038/nrd1157
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Osborn MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072737
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Proitsi P, 2017, ALZHEIMERS DEMENT, V13, P140, DOI 10.1016/j.jalz.2016.08.003
   Psychogios N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016957
   Sivak JM, 2013, INVEST OPHTH VIS SCI, V54, P871, DOI 10.1167/iovs.12-10827
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Suhre K, 2012, NAT REV GENET, V13, P759, DOI 10.1038/nrg3314
   Tan SZ, 2016, EYE, V30, P773, DOI 10.1038/eye.2016.37
   Ugurlu N, 2013, CURR EYE RES, V38, P497, DOI 10.3109/02713683.2013.774023
   Walter A, 2004, NEUROBIOL AGING, V25, P1299, DOI 10.1016/j.neurobiolaging.2004.02.016
   Wang YF, 2016, NUTRIENTS, V8, DOI 10.3390/nu8100663
   Whiley L, 2014, NEUROBIOL AGING, V35, P271, DOI 10.1016/j.neurobiolaging.2013.08.001
   Wishart DS, 2016, NAT REV DRUG DISCOV, V15, P473, DOI 10.1038/nrd.2016.32
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xia Jianguo, 2016, Curr Protoc Bioinformatics, V55, DOI 10.1002/cpbi.11
   Yin PY, 2013, CLIN CHEM, V59, P833, DOI 10.1373/clinchem.2012.199257
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Young Stephen P, 2009, J Ocul Biol Dis Infor, V2, P235
NR 63
TC 48
Z9 51
U1 2
U2 33
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2018
VL 125
IS 2
BP 245
EP 254
DI 10.1016/j.ophtha.2017.08.008
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FT0FN
UT WOS:000422797600024
PM 28916333
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Lou, LX
   Hu, KM
   Jin, K
   Zhang, SZ
   Ye, J
AF Lou, Li-Xia
   Hu, Kai-Min
   Jin, Kai
   Zhang, Su-Zhan
   Ye, Juan
TI The Relationship Between Hepatic Lipase Gene Variant and Advanced
   Age-Related Macular Degeneration A Meta-analysis
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; COMPLEMENT FACTOR-H; BODY-MASS INDEX;
   RISK-FACTORS; COMMON VARIANTS; BRUCHS MEMBRANE; DIETARY LUTEIN;
   SUSCEPTIBILITY; PROGRESSION; LIPC
AB IMPORTANCE To date, no consistency exists across studies that have evaluated the relationship between hepatic lipase gene (LIPC) rs10468017 variant and advanced age-related macular degeneration (AMD).
   OBJECTIVE To summarize all relevant evidence for a relationship between LIPC variant and advanced AMD.
   DATA SOURCES The PubMed and Embase databases were searched for studies potentially eligible in any language published up to September 15, 2013.
   STUDY SELECTION Case-control studies of 2 or more comparison groups that included patients with advanced AMD (choroidal neovascularization or geographic atrophy).
   DATA EXTRACTION AND SYNTHESIS Allele frequencies and genotype distributions of rs10468017 variant.
   MAIN OUTCOMES AND MEASURES Summary odds ratios (ORs) and 95% CIs were estimated under different genetic models using meta-analytic methods. A stratified analysis by advanced AMD subtypes and race/ethnicity was performed, as well as a sensitivity analysis.
   RESULTS Data from 10 case-control studies were included in the meta-analysis. The rs10468017 variant (C. T) showed significant summary ORs of 0.81 (95% CI, 0.75-0.88), 0.83 (95% CI, 0.70-0.98), and 0.60 (95% CI, 0.44-0.81) under the allelic (T vs C), heterozygous (TC vs CC), and homozygous (TT vs CC) models, respectively. Carrying at least 1 copy of the T allele decreased the risk of choroidal neovascularization and geographic atrophy by 20%(OR, 0.80; 95% CI, 0.74-0.87) and 29% (OR, 0.71; 95% CI, 0.59-0.86), respectively. The pooled OR for white race/ethnicity under an allelic model was 0.80 (95% CI, 0.74-0.87). The sensitivity analysis indicated the robustness of our findings, and no evidence of publication bias was observed in our meta-analysis.
   CONCLUSIONS AND RELEVANCE Our meta-analysis indicates that LIPC rs10468017 variant is associated with a reduced risk of advanced AMD. This finding may lead to insights regarding the pathogenesis, prevention, and treatment of AMD.
C1 [Lou, Li-Xia; Jin, Kai; Ye, Juan] Zhejiang Univ, Affiliated Hosp 2, Coll Med, Dept Ophthalmol, Hangzhou 310009, Zhejiang, Peoples R China.
   [Hu, Kai-Min; Zhang, Su-Zhan] Zhejiang Univ, Affiliated Hosp 2, Coll Med, Dept Oncol, Hangzhou 310009, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University
RP Ye, J (通讯作者)，Zhejiang Univ, Affiliated Hosp 2, Coll Med, Dept Ophthalmol, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.
EM yejuan@zju.edu.cn
RI Jin, Kai/S-9997-2019
FU Natural Science Foundation of China [81070756]; National Twelfth
   Five-Year Plan for Science and Technology Support of China
   [2012BAI08B01]; Program for New-Century Excellent Talents in
   Universities of China [NCET-11-0161]; Zhejiang Provincial Program for
   Cultivation of High-level Innovative Health Talents [2012C13023-2];
   Specialized Key Science and Technology Foundation of Zhejiang Provincial
   Science and Technology Department; Zhejiang Provincial Key Project of
   Medicine and Health [2011ZDA014]
FX This study was supported by grant 81070756 from the Natural Science
   Foundation of China, by grant 2012BAI08B01 from the National Twelfth
   Five-Year Plan for Science and Technology Support of China, by grant
   NCET-11-0161 from the Program for New-Century Excellent Talents in
   Universities of China, by the Zhejiang Provincial Program for
   Cultivation of High-level Innovative Health Talents, by grant
   2012C13023-2 from the Specialized Key Science and Technology Foundation
   of Zhejiang Provincial Science and Technology Department, and by grant
   2011ZDA014 from the Zhejiang Provincial Key Project of Medicine and
   Health.
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   DerSimonian R, 2007, CONTEMP CLIN TRIALS, V28, P105, DOI 10.1016/j.cct.2006.04.004
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hong Eun Pyo, 2012, Genomics & Informatics, V10, P117, DOI 10.5808/GI.2012.10.2.117
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kriston L, 2013, INT J METH PSYCH RES, V22, P1, DOI 10.1002/mpr.1377
   Lechanteur YTE, 2012, INVEST OPHTH VIS SCI, V53, P5846, DOI 10.1167/iovs.11-7731
   Lee J, 2013, EYE, V27, P266, DOI 10.1038/eye.2012.276
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu MM, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-13
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Peter I, 2011, AM J OPHTHALMOL, V152, P1005, DOI 10.1016/j.ajo.2011.05.016
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Santamarina-Fojo S, 2004, ARTERIOSCL THROM VAS, V24, P1750, DOI 10.1161/01.ATV.0000140818.00570.2d
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2010, MOL VIS, V16, P2412
   Sivaprasad S, 2005, CLIN EXP OPHTHALMOL, V33, P518, DOI 10.1111/j.1442-9071.2005.01074.x
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Wang W, 2007, AM J CLIN NUTR, V85, P762, DOI 10.1093/ajcn/85.3.762
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
NR 39
TC 2
Z9 2
U1 0
U2 9
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD OCT
PY 2014
VL 132
IS 10
BP 1226
EP 1231
DI 10.1001/jamaophthalmol.2014.1752
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AQ8FZ
UT WOS:000343061000014
PM 25010633
OA Bronze
DA 2022-11-30
ER

PT J
AU Jiang, Y
   Qi, SX
AF Jiang, Yang
   Qi, Shixin
TI Diagnostic Value of Spectral-Domain Optical Coherence Tomography for
   Polypoidal Choroidal Vasculopathy: A Systematic Review and Meta-Analysis
SO FRONTIERS IN MEDICINE
LA English
DT Review
DE spectral-domain optical coherence tomography; polypoidal choroidal
   vasculopathy; sensitivity; specificity; diagnostic value; meta-analysis
ID MACULAR DEGENERATION; ANGIOGRAPHY
AB Purpose: To evaluate the diagnostic value of spectral-domain optical coherence tomography (SD-OCT) for polypoidal choroidal vasculopathy (PCV). Methods: A search of electronic databases was conducted from 2010 to 2021 to review the relevant literature on SD-OCT to identify PCV and other lesions causing serious or serosanguinous retinal pigment epithelial detachment (PED), specifically neovascular age-related macular degeneration (nvAMD). The QUADAS-2 scale was used to evaluate the quality of the literature. We performed a meta-analysis, including heterogeneity tests, analyze and synthesize the study data, meta-regression analysis, subgroup analysis, Fagan's plot, sensitivity analysis and publication bias tests. Results: A total of 12 related studies involving 1,348 eyes were included in this study, and the random-effects model was used for meta-analysis. The results showed that the pooled sensitivity of SD-OCT in the diagnosis of PCV was 0.87 (95% CI: 0.84-0.89), the pooled specificity was 0.83 (95% CI: 0.80-0.86), and the pooled positive/negative likelihood ratios were 5.38 (95% CI: 3.28-8.80) and 0.16 (95% CI: 0.10-0.25), respectively. The diagnostic odds ratio (DOR) was 36.07 (95% CI: 15.98-81.40), and the area under the sROC curve (AUC) was 0.9429. When the pre-test probability was set at 20%, the post-test positive and negative probabilities were 58% and 4%, respectively. Meta-regression indicated that race was the primary source of heterogeneity (P < 0.05). The Deeks' funnel plot showed no significant publication bias in this study (P > 0.05). Conclusion: SD-OCT has high sensitivity and specificity for the diagnosis of PCV, as well as significant clinical applicability. Since color fundus photography (CFP) is more clinically available and can improve the diagnostic efficacy, we recommend SD-OCT combined with CFP to diagnose PCV, especially without indocyanine green angiography (ICGA).
C1 [Jiang, Yang; Qi, Shixin] Tianjin Baodi Hosp, Dept Ophthalmol, Tianjin, Peoples R China.
   [Jiang, Yang; Qi, Shixin] Tianjin Med Univ, Baodi Clin Coll, Tianjin, Peoples R China.
C3 Tianjin Medical University
RP Qi, SX (通讯作者)，Tianjin Baodi Hosp, Dept Ophthalmol, Tianjin, Peoples R China.; Qi, SX (通讯作者)，Tianjin Med Univ, Baodi Clin Coll, Tianjin, Peoples R China.
EM qshxin@126.com
CR Alshahrani ST, 2014, CLIN OPHTHALMOL, V8, P1689, DOI 10.2147/OPTH.S68471
   Anantharaman G, 2018, INDIAN J OPHTHALMOL, V66, P896, DOI 10.4103/ijo.IJO_1136_17
   Cackett P, 2010, EYE, V24, P789, DOI 10.1038/eye.2009.214
   Chaikitmongkol V, 2019, JAMA OPHTHALMOL, V137, P661, DOI 10.1001/jamaophthalmol.2019.0565
   Chaikitmongkol V, 2018, AM J OPHTHALMOL, V192, P77, DOI 10.1016/j.ajo.2018.05.005
   Chang Young Suk, 2016, Korean J Ophthalmol, V30, P198, DOI 10.3341/kjo.2016.30.3.198
   Cheung CMG, 2019, RETINA-J RET VIT DIS, V39, P1655, DOI 10.1097/IAE.0000000000002228
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Eraydin B, 2021, INT OPHTHALMOL, V41, P659, DOI 10.1007/s10792-020-01622-y
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Lains I., 2014, ARVO ANN M ABSTRACT, V55, P3915
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Liao M., 2018, CHINA PRAC MED, V13, P22, DOI [10.14163/j.cnki.11-5547/r.2018.18.010, DOI 10.14163/J.CNKI.11-5547/R.2018.18.010]
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   Liu R., 2012, CHIN J OCUL FUNDUS D, V9, P533, DOI [10.3760/cma.j.issn.1005-1015.2012.05.029, DOI 10.3760/CMA.J.ISSN.1005-1015.2012.05.029]
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   McInnes MDF, 2018, JAMA-J AM MED ASSOC, V319, P388, DOI 10.1001/jama.2017.19163
   Palkar AH, 2019, TAIWAN J OPHTHALMOL, V9, P72, DOI 10.4103/tjo.tjo_35_18
   Sato T, 2004, RETINA-J RET VIT DIS, V24, P910, DOI 10.1097/00006982-200412000-00011
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Takahashi Y, 2018, JPN J OPHTHALMOL, V62, P576, DOI 10.1007/s10384-018-0615-4
   Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
   [夏松 Xia Song], 2020, [中华实验眼科杂志, Chinese Journal of Experimental Ophthalmology], V38, P55
   Yang JY, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1244-5
   Zhang S., 2019, INT J OPHTHALMOL-CHI, V19, P950, DOI [10.3980/j.issn.1672-5123.2019.6.13, DOI 10.3980/J.ISSN.1672-5123.2019.6.13]
   Zhang Yi, 2016, Nan Fang Yi Ke Da Xue Xue Bao, V37, P165
   [周楠(综述) Zhou Nan], 2019, [中华实验眼科杂志, Chinese Journal of Experimental Ophthalmology], V37, P77
NR 35
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD JUN 15
PY 2022
VL 9
AR 878946
DI 10.3389/fmed.2022.878946
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 2N5KO
UT WOS:000818417800001
PM 35783657
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kataja, M
   Hujanen, P
   Huhtala, H
   Kaarniranta, K
   Tuulonen, A
   Uusitalo-Jarvinen, H
AF Kataja, Maria
   Hujanen, Pekko
   Huhtala, Heini
   Kaarniranta, Kai
   Tuulonen, Anja
   Uusitalo-Jarvinen, Hannele
TI Outcome of anti-vascular endothelial growth factor therapy for
   neovascular age-related macular degeneration in real-life setting
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE degeneration; macula; neovascularisation; treatment medical; retina
ID RANIBIZUMAB; BEVACIZUMAB; INJECTIONS; SAFETY; TRIAL; AMD
AB Aims To evaluate outcome of anti-vascular endothelial growth factor (VEGF) therapy for the treatment of neovascular age-related macular degeneration (nAMD) in the real-life setting and to compare incidence of ocular serious adverse events (SAE) after injections administered by nurses and physicians.
   Methods Retrospective, single-centre study. Medical records of patients receiving anti-VEGF treatment for nAMD between 2008 and 2013 with three-loading-dose regimen were evaluated. Outcome measures were baseline visual acuity (VA), change in VA, number of intravitreal injections, incidence of ocular SAE and patients' baseline characteristics affecting VA change. In addition, the number of injections per 1000 citizens living in the serving area and per individuals over 65years old were estimated.
   Results 1349 eyes in 1117 patients received a total of 11562 intravitreal anti-VEGF injections. Twenty-one per cent of patients received treatment for both eyes. The mean baseline Snellen VA was 0.32. The mean change of VA from baseline was +2, +2and 0 Early Treatment Diabetic Retinopathy Study letters and the mean numbers of injections were 5.7, 4.7 and 4.9 at years 1, 2 and 3, respectively. There was a negative correlation between baseline VA and change of VA. Incidence of endophthalmitis was 0.086%. No difference in the incidence of ocular SAE was identified between injections given by nurses or by physicians. The number of intravitreal injections per all citizens was 9 per 1000 inhabitants and 45 per 1000 inhabitants over 65years.
   Conclusion The VA was maintained at the baseline level (+/- 0 letters) with the mean of 15.3 anti-VEGF injections in real-world clinical practice during 3-year follow-up.
C1 [Kataja, Maria; Hujanen, Pekko; Tuulonen, Anja; Uusitalo-Jarvinen, Hannele] Tampere Univ Hosp, Tays Eye Ctr, Tampere 33521, Finland.
   [Kataja, Maria; Uusitalo-Jarvinen, Hannele] Univ Tampere, Dept Ophthalmol, Tampere, Finland.
   [Huhtala, Heini] Univ Tampere, Sch Hlth Sci, Tampere, Finland.
   [Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Kuopio, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio, Finland.
C3 Tampere University; Tampere University Hospital; Tampere University;
   Tampere University; University of Eastern Finland; Kuopio University
   Hospital; University of Eastern Finland
RP Uusitalo-Jarvinen, H (通讯作者)，Tampere Univ Hosp, Tays Eye Ctr, Tampere 33521, Finland.
EM llhauus@uta.fi
OI Hujanen, Pekko/0000-0002-5932-1568; Kataja, Maria/0000-0002-0583-0738
FU Competitive Research Funding of the Pirkanmaa Hospital District
FX The study was supported by the Competitive Research Funding of the
   Pirkanmaa Hospital District.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Erie JC, 2016, OPHTHALMOLOGY, V123, P1257, DOI 10.1016/j.ophtha.2016.02.015
   Gerding H, 2016, KLIN MONATSBL AUGENH, V233, P471, DOI 10.1055/s-0041-111835
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Hasler PW, 2015, ACTA OPHTHALMOL, V93, P122, DOI 10.1111/aos.12589
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2016, EYE, V30, P1063, DOI 10.1038/eye.2016.90
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Lad EM, 2014, AM J OPHTHALMOL, V158, P537, DOI 10.1016/j.ajo.2014.05.014
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Santarelli M, 2015, EXPERT OPIN PHARMACO, V16, P1769, DOI 10.1517/14656566.2015.1067679
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Simcock P, 2014, EYE, V28, P1161, DOI 10.1038/eye.2014.153
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Tuulonen A, 2012, OVERVIEW EVALUATION
   Tuuminen R, 2017, ACTA OPHTHALMOL, V95, DOI 10.1111/aos.13501
NR 25
TC 22
Z9 22
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUL
PY 2018
VL 102
IS 7
BP 959
EP 965
DI 10.1136/bjophthalmol-2017-311055
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GN9TV
UT WOS:000439552400019
PM 29074495
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Merle, BMJ
   Maubaret, C
   Korobelnik, JF
   Delyfer, MN
   Rougier, MB
   Lambert, JC
   Amouyel, P
   Malet, F
   Le Goff, M
   Dartigues, JF
   Barberger-Gateau, P
   Delcourt, C
AF Merle, Benedicte M. J.
   Maubaret, Cecilia
   Korobelnik, Jean-Francois
   Delyfer, Marie-Noelle
   Rougier, Marie-Benedicte
   Lambert, Jean-Charles
   Amouyel, Philippe
   Malet, Florence
   Le Goff, Melanie
   Dartigues, Jean-Francois
   Barberger-Gateau, Pascale
   Delcourt, Cecile
TI Association of HDL-Related Loci with Age-Related Macular Degeneration
   and Plasma Lutein and Zeaxanthin: the Alienor Study
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; GENETIC-VARIANTS; HEPATIC LIPASE; RISK-FACTORS;
   COMMON VARIANTS; MACULOPATHY; CAROTENOIDS; LIPOPROTEIN; PREVALENCE;
   SMOKING
AB Background: Several genes implicated in high-density lipoprotein (HDL) metabolism have been reported to be associated with age-related macular degeneration (AMD). Furthermore, HDL transport the two carotenoids, lutein and zeaxanthin, which are highly suspected to play a key-role in the protection against AMD. The objective is to confirm the associations of HDL-related loci with AMD and to assess their associations with plasma lutein and zeaxanthin concentrations.
   Methods: Alienor study is a prospective population-based study on nutrition and age-related eye diseases performed in 963 elderly residents of Bordeaux, France. AMD was graded according to the international classification, from non-mydriatic colour retinal photographs. Plasma lutein and zeaxanthin were determined by normal-phase high-performance liquid chromatography. The following polymorphisms were studied: rs493258 and rs10468017 (LIPC), rs3764261 (CETP), rs12678919 (LPL) and rs1883025 (ABCA1).
   Results: After multivariate adjustment, the TT genotype of the LIPC rs493258 variant was significantly associated with a reduced risk for early and late AMD (OR=0.64, 95% CI: 0.41-0.99; p=0.049 and OR=0.26, 95% CI: 0.08-0.85; p=0.03, respectively), and with higher plasma zeaxanthin concentrations (p=0.03), while plasma lipids were not significantly different according to this SNP. Besides, the LPL variant was associated with early AMD (OR=0.67, 95% CI: 0.45-1.00; p=0.05) and both with plasma lipids and plasma lutein (p=0.047). Associations of LIPC rs10468017, CETP and ABCA1 polymorphisms with AMD did not reach statistical significance.
   Conclusion: These findings suggest that LIPC and LPL genes could both modify the risk for AMD and the metabolism of lutein and zeaxanthin.
C1 [Merle, Benedicte M. J.; Maubaret, Cecilia; Korobelnik, Jean-Francois; Delyfer, Marie-Noelle; Le Goff, Melanie; Dartigues, Jean-Francois; Barberger-Gateau, Pascale; Delcourt, Cecile] INSERM, ISPED, Ctr INSERM, Epidemiol Biostat U897, Bordeaux, France.
   [Merle, Benedicte M. J.; Maubaret, Cecilia; Korobelnik, Jean-Francois; Delyfer, Marie-Noelle; Le Goff, Melanie; Dartigues, Jean-Francois; Barberger-Gateau, Pascale; Delcourt, Cecile] Univ Bordeaux, Bordeaux, France.
   [Korobelnik, Jean-Francois; Delyfer, Marie-Noelle; Rougier, Marie-Benedicte; Malet, Florence] CHU Bordeaux, Serv Ophtalmol, Bordeaux, France.
   [Lambert, Jean-Charles; Amouyel, Philippe] INSERM, U744, F-59045 Lille, France.
   [Lambert, Jean-Charles; Amouyel, Philippe] Inst Pasteur, F-59019 Lille, France.
   [Lambert, Jean-Charles; Amouyel, Philippe] Univ Lille Nord France, Lille, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite de Bordeaux; CHU
   Bordeaux; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Universite de Lille - ISITE; Universite de Lille; Le Reseau
   International des Instituts Pasteur (RIIP); Universite de Lille - ISITE;
   Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille
RP Merle, BMJ (通讯作者)，INSERM, ISPED, Ctr INSERM, Epidemiol Biostat U897, Bordeaux, France.
EM benedicte.merle@isped.u-bordeaux2.fr
RI Merle, Benedicte MJ/AAQ-5021-2021; Delyfer, Marie-Noelle/T-3304-2019;
   DARTIGUES, Jean François/T-4513-2019; lambert, jean-charles/F-8787-2013;
   LE GOFF, Mélanie/A-3541-2016; Lambert, jean-charles/A-9553-2014;
   KOROBELNIK, Jean-Francois/A-5448-2016; Delcourt, Cecile/I-2627-2013;
   Merle, Benedicte MJ/F-1247-2015
OI Merle, Benedicte MJ/0000-0003-1332-0954; lambert,
   jean-charles/0000-0003-0829-7817; Lambert,
   jean-charles/0000-0003-0829-7817; Delcourt, Cecile/0000-0002-2099-0481;
   Merle, Benedicte MJ/0000-0003-1332-0954; Amouyel,
   Philippe/0000-0001-9088-234X; LE GOFF, Melanie/0000-0003-2848-6287
FU Fondation Voir et Entendre (Paris, France); Conseil Regional d'Aquitaine
   (Bordeaux, France) [20091301029]; Fondation pour la recherche medicale,
   France (FRM)
FX Laboratoires Thea participated in the design of the study, but had no
   role in the data collection and analysis, decision to publish or
   preparation of the manuscript. Others funders: Fondation Voir et
   Entendre (Paris, France), Conseil Regional d'Aquitaine (Convention no
   20091301029, Bordeaux, France) and Fondation pour la recherche medicale,
   France (FRM) had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Abalain JH, 2002, CLIN CHIM ACTA, V326, P97, DOI 10.1016/S0009-8981(02)00288-7
   Alperovitch A, 2003, NEUROEPIDEMIOLOGY, V22, P316, DOI 10.1159/000072920
   Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Borel P, 2012, MOL NUTR FOOD RES, V56, P228, DOI 10.1002/mnfr.201100322
   Borel P, 2011, ANN MED, V43, P47, DOI 10.3109/07853890.2010.531757
   Borel P, 2009, BRIT J NUTR, V101, P680, DOI 10.1017/S0007114508030754
   Chan D, 1998, OPTOMETRY VISION SCI, V75, P476, DOI 10.1097/00006324-199807000-00015
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   CLEVIDENCE BA, 1993, METHOD ENZYMOL, V214, P33
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Delcourt C, 2010, J NUTR HEALTH AGING, V14, P854, DOI 10.1007/s12603-010-0131-9
   Delcourt C, 2012, ARCH OPHTHALMOL-CHIC, V130, P1077, DOI 10.1001/archophthalmol.2012.420
   Delcourt C, 2011, INVEST OPHTH VIS SCI, V52, P5955, DOI 10.1167/iovs.10-6235
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Hartmann D, 2004, AM J CLIN NUTR, V79, P410
   Kathiresan S, 2009, NAT GENET, V41, P56, DOI 10.1038/ng.291
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Lambert JC, 2009, NAT GENET, V41, P1094, DOI 10.1038/ng.439
   Li Y, 2010, GENET EPIDEMIOL, V34, P816, DOI 10.1002/gepi.20533
   Li Y, 2009, ANNU REV GENOM HUM G, V10, P387, DOI 10.1146/annurev.genom.9.081307.164242
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Meyers KJ, 2013, INVEST OPHTH VIS SCI, V54, P2333, DOI [10.1167/iovs.12-10867, 10.1167/iovs.13-13216]
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nowak M, 2005, CLIN EXP MED, V4, P183, DOI 10.1007/s10238-004-0054-z
   Peter I, 2011, AM J OPHTHALMOL, V152, P1005, DOI 10.1016/j.ajo.2011.05.016
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Seddon JM, 2010, MOL VIS, V16, P2412
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Tyssandier V, 2002, INT J VITAM NUTR RES, V72, P300, DOI 10.1024/0300-9831.72.5.300
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wachter A, 2004, OPHTHALMOLOGE, V101, P50, DOI 10.1007/s00347-003-0868-1
   Whitehead AJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P1038, DOI 10.1001/archopht.124.7.1038
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
   2013, JAMA, P1
NR 55
TC 36
Z9 37
U1 0
U2 20
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 6
PY 2013
VL 8
IS 11
AR e79848
DI 10.1371/journal.pone.0079848
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 247XD
UT WOS:000326656200092
PM 24223199
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Arora, S
   McKibbin, M
AF Arora, S.
   McKibbin, M.
TI One-year outcome after intravitreal ranibizumab for large, serous
   pigment epithelial detachment secondary to age-related macular
   degeneration
SO EYE
LA English
DT Article
DE pigment epithelial detachment; age-related macular degeneration;
   ranibizumab
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY;
   VERTEPORFIN
AB Aim To report the effects of intravitreal ranibizumab therapy for large, serous pigment epithelial detachment (PED), secondary to age-related macular degeneration, and occupying more than 50% of the total lesion area.
   Materials and methods In a retrospective case series, visual acuity, ocular coherence tomography (OCT), and safety data were collected for 19 eyes of 19 patients, with serous PED and evidence of disease progression. Intravitreal ranibizumab of 0.5mg was given with a loading phase of three consecutive monthly injections, followed by monthly review with further treatment, as indicated according to visual acuity and OCT findings. The change in visual acuity and maximum PED height from baseline to month 12 was determined.
   Results Moderate visual loss was avoided in 18/19 eyes (95%) at the 12-month examination. In all, 12 eyes (63%) had an increase in ETDRS letter score from baseline, and five eyes (26%) had a gain of 15 or more letters. Although there was a trend for the PED height to reduce with treatment, in none of the cases was the PED seen to resolve completely. There was no difference in functional or anatomical outcome between the avascular and vascularised serous PED. A single eye developed a retinal pigment epithelium rip, complicated by extensive sub-retinal haemorrhage, during the study period.
   Conclusions Visual acuity outcomes of intravitreal ranibizumab for large serous PED are comparable to those seen in multicentre, phase 3 trials of other lesion types, and were obtained without the need for either monthly, fixed treatment, or for continued treatment until the PED resolves. Eye (2011) 25, 1034-1038; doi:10.1038/eye.2011.115; published online 20 May 2011
C1 [Arora, S.; McKibbin, M.] St James Univ Hosp, Eye Dept, Eye Clin, Leeds, W Yorkshire, England.
C3 Saint James's University Hospital
RP Arora, S (通讯作者)，9 Alma Close, Kirkella HU107LH, East Yorkshire, England.
EM seemaarora@doctors.org.uk
CR [Anonymous], 1999, ARCH OPHTHALMOL, V117, P1329
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Lommatzsch A, 2009, EYE, V23, P2163, DOI 10.1038/eye.2008.425
   RITTER M, 2009, EYE LOND, V24, P962
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
NR 7
TC 23
Z9 24
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD AUG
PY 2011
VL 25
IS 8
BP 1034
EP 1038
DI 10.1038/eye.2011.115
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 806BG
UT WOS:000293775400012
PM 21597485
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Huang, G
   Li, H
   Lai, S
   Xiao, JL
   Wang, L
   Xu, HJ
   Lei, CT
   Zhang, JL
   Yu, M
   Shuai, P
   Liu, YP
   Shi, Y
   Wang, KJ
   Gong, B
AF Huang, Guo
   Li, Huan
   Lai, Shuang
   Xiao, Jialing
   Wang, Liang
   Xu, Huijuan
   Lei, Chuntao
   Zhang, Jinglan
   Yu, Man
   Shuai, Ping
   Liu, Yuping
   Shi, Yi
   Wang, Kaijie
   Gong, Bo
TI HTRA1 rs11528744, BCRA1 rs9928736, and B3GLCT rs4381465 are associated
   with age-related macular degeneration in a Chinese population
SO FRONTIERS IN GENETICS
LA English
DT Article
DE single nucleotide polymorphisms (SNPs); age-related macular degeneration
   (AMD); case-control study; HTRA1; BCRA1; B3GLCT
ID GENOME-WIDE ASSOCIATION; HIGH-RISK; TYROSINE PHOSPHORYLATION; SEVERITY
   SCALE; RARE; VARIANTS; DISEASE; CONFERS; PROTEIN; CELLS
AB Purpose: Age-related macular degeneration (AMD) is a leading cause of vision loss. A Previous study based on the co-localization analysis of the genome-wide association study (GWAS) and eQTL genetic signals have reported that single nucleotide polymorphisms (SNPs), including rs760975, rs11528744, rs3761159, rs7212510, rs6965458, rs7559693, rs56108400, rs28495773, rs9928736, rs11777697, rs4381465 are associated with AMD in Americans. The aim of this study was to investigate the association of these SNPs in a Han Chinese population. Methods: There were 576 patients with wet AMD and 572 healthy controls collected in this study. All SNPs were genotyped by flight mass spectrum. Hardy-Weinberg equilibrium was applied to evaluate allele distributions for both AMD and control groups. The genotype and allele frequencies were evaluated using the chi(2) tests. Odds ratio (OR) and 95% confidence intervals (95% CI) were calculated for the risk of genotype and allele. Results: Three of the 11 SNPs (rs11528744 in HTRA1, rs9928736 in BCRA1 and rs4381465 in B3GLCT) were found to be significantly associated with AMD in the allelic model (corrected p = 0.001, OR = 1.391, 95%CI = 1.179-1.640 for rs11528744; corrected p = 0.004, OR = 0.695, 95%CI = 0.544-0.888 for rs9928736; corrected p = 0.002, OR = 0.614, 95%CI = 0.448-0.841 for rs4381465). There were no differences for the remaining eight SNPs between AMD cases and healthy controls. Conclusion: Our results showed that HTRA1 rs11528744, BCRA1 rs9928736, and B3GLCT rs4381465 were associated with wet AMD, suggesting that HTRA1, BCRA1, and B3GLCT genes may be involved in the development of AMD.
C1 [Huang, Guo; Li, Huan; Lai, Shuang; Xiao, Jialing; Wang, Liang; Xu, Huijuan; Zhang, Jinglan; Shuai, Ping; Liu, Yuping; Shi, Yi; Gong, Bo] Univ Elect Sci & Technol China, Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Human Dis Genes Key Lab Sichuan Prov, Chengdu, Sichuan, Peoples R China.
   [Huang, Guo; Li, Huan; Lai, Shuang; Xiao, Jialing; Wang, Liang; Xu, Huijuan; Zhang, Jinglan; Shuai, Ping; Liu, Yuping; Shi, Yi; Gong, Bo] Univ Elect Sci & Technol China, Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Inst Lab Med, Chengdu, Sichuan, Peoples R China.
   [Huang, Guo; Li, Huan; Xiao, Jialing; Gong, Bo] Univ Elect Sci & Technol China, Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Dept Hlth Management, Chengdu, Sichuan, Peoples R China.
   [Huang, Guo; Li, Huan; Xiao, Jialing; Gong, Bo] Univ Elect Sci & Technol China, Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Res Unit Blindness Prevent Chinese Acad Med Sci 20, Chengdu, Sichuan, Peoples R China.
   [Lei, Chuntao; Yu, Man] Univ Elect Sci & Technol China, Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Dept Ophthalmol, Chengdu, Sichuan, Peoples R China.
   [Wang, Kaijie] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Ophthalmol & Visual Sci Key Lab, Beijing, Peoples R China.
C3 Sichuan Provincial People's Hospital; University of Electronic Science &
   Technology of China; Sichuan Provincial People's Hospital; University of
   Electronic Science & Technology of China; Sichuan Provincial People's
   Hospital; University of Electronic Science & Technology of China;
   Sichuan Provincial People's Hospital; University of Electronic Science &
   Technology of China; Sichuan Provincial People's Hospital; University of
   Electronic Science & Technology of China; Capital Medical University
RP Gong, B (通讯作者)，Univ Elect Sci & Technol China, Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Human Dis Genes Key Lab Sichuan Prov, Chengdu, Sichuan, Peoples R China.; Gong, B (通讯作者)，Univ Elect Sci & Technol China, Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Inst Lab Med, Chengdu, Sichuan, Peoples R China.; Gong, B (通讯作者)，Univ Elect Sci & Technol China, Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Dept Hlth Management, Chengdu, Sichuan, Peoples R China.; Gong, B (通讯作者)，Univ Elect Sci & Technol China, Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Res Unit Blindness Prevent Chinese Acad Med Sci 20, Chengdu, Sichuan, Peoples R China.; Wang, KJ (通讯作者)，Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Ophthalmol & Visual Sci Key Lab, Beijing, Peoples R China.
EM gongbo@med.uestc.edu.cn; kjwang@ccmu.edu.cn
FU National Natural Science Foundation of China [81790643, 82121003,
   81870683, 82070928]; Department of Science and Technology of Sichuan
   Province [2021YFS0369, 2021JDGD0036, 2021YFS0404, 2022NSFSC1585,
   2020YJ0460, 2022JDTD0024]; Department of Sichuan Provincial Health
   [19PJ117, 18PJ348]; Chengdu Science and Technology Bureau
   [2022-YF05-01625-SN]; CAMS Innovation Fund for Medical Sciences
   [2019-12M-5-032]
FX This work was supported by the National Natural Science Foundation of
   China (81790643, 82121003, 81870683, and 82070928), the Department of
   Science and Technology of Sichuan Province (2021YFS0369, 2021JDGD0036,
   2021YFS0404, 2022NSFSC1585, 2020YJ0460, and 2022JDTD0024), the
   Department of Sichuan Provincial Health (19PJ117, 18PJ348), the Chengdu
   Science and Technology Bureau (2022-YF05-01625-SN), the CAMS Innovation
   Fund for Medical Sciences (2019-12M-5-032).
CR Age-Related Eye Disease Study Research Group, 2001, AM J OPHTHALMOL, V131, P167, DOI [10.1016/s0002-9394(00)00732-7, DOI 10.1016/S0002-9394(00)00732-7]
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Deng YH, 2022, GENES DIS, V9, P62, DOI 10.1016/j.gendis.2021.02.009
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Friedrich U, 2015, HUM MOL GENET, V24, P6361, DOI 10.1093/hmg/ddv346
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713
   Lauwen S, 2021, EXP EYE RES, V213, DOI 10.1016/j.exer.2021.108798
   Neupane S, 2021, GLYCOBIOLOGY, V31, P988, DOI 10.1093/glycob/cwab033
   Orozco LD, 2020, CELL REP, V30, P1246, DOI 10.1016/j.celrep.2019.12.082
   Ratnapriya R, 2020, HUM MOL GENET, V29, P2022, DOI 10.1093/hmg/ddaa057
   Ratnapriya R, 2019, NAT GENET, V51, P606, DOI 10.1038/s41588-019-0351-9
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629
   Riccomagno MM, 2014, NEURON, V81, P779, DOI 10.1016/j.neuron.2014.01.036
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu YL, 2008, MOL VIS, V14, P1373
   Yoshida S, 2003, TRENDS MICROBIOL, V11, P139, DOI 10.1016/S0966-842X(03)00023-4
   Yoshida S, 2002, EMBO J, V21, P2923, DOI 10.1093/emboj/cdf319
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
NR 27
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1664-8021
J9 FRONT GENET
JI Front. Genet.
PD SEP 29
PY 2022
VL 13
AR 997840
DI 10.3389/fgene.2022.997840
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 5N9NV
UT WOS:000872113600001
PM 36263425
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Cao, SJ
   Ko, A
   Partanen, M
   Pakzad-Vaezi, K
   Merkur, AB
   Albiani, DA
   Kirker, AW
   Wang, AK
   Cui, JZ
   Forooghian, F
   Matsubara, JA
AF Cao, Sijia
   Ko, Ashley
   Partanen, Marita
   Pakzad-Vaezi, Kaivon
   Merkur, Andrew B.
   Albiani, David A.
   Kirker, Andrew W.
   Wang, Aikun
   Cui, Jing Z.
   Forooghian, Farzin
   Matsubara, Joanne A.
TI Relationship between Systemic Cytokines and Complement Factor H Y402H
   Polymorphism in Patients With Dry Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTERLEUKIN-6 GENE-EXPRESSION; CHOROIDAL THICKNESS; TNF-ALPHA; RISK;
   ACTIVATION; DISEASES; DRUSEN; EYES; CHORIOCAPILLARIS; PERMEABILITY
AB PURPOSE: To investigate the relationship between systemic cytokines, the complement factor H (CFH) Y402H polymorphism, drusen load, and subfoveal choroidal thickness in patients with dry age-related macular degeneration (AMD).
   DESIGN: Cross-sectional study.
   METHODS: Forty-four dry AMD patients under care of the Retina Service at the University of British Columbia were enrolled. Drusen load was measured with an automated software algorithm in spectral-domain optical coherence tomography; subfoveal choroidal thickness was measured manually using enhanced depth imaging. Bio-Plex suspension assays (Bio-Rad Laboratories) were used to analyze cytokines in plasma and CFH Y402H was genotyped. Statistical analyses included analysis of covariance and Pearson correlation, corrected for multiple comparisons.
   RESULTS: The levels of 3 of 4 studied cytokines were significantly different among patients with CC, CT, or TT variants of the CFH Y402H polymorphism (P < .01). Patients with the at-risk CC variant had higher systemic levels of interleukin-6, interleukin-18, and tumor necrosis factor a than those with the CT variants, the TT variant, or both (P < .01). Interleukin-1 beta did not reach significance (P = .02), but did demonstrate a consistent trend. No correlation was found between plasma cytokines and drusen load or choroidal thickness (all P > .15).
   CONCLUSIONS: The elevated systemic levels of selected proinflammatory cytokines, including those representing products of inflammasome activation, were associated with the CC at-risk variant of the Y402H polymorphism and suggest that genetic factors regulate the inflammatory status in dry AMD patients. Our data support the central role of inflammation in the pathogenesis of AMD and provide further evidence of a systemic involvement in AMD etiology. ((C) 2013 by Elsevier Inc. All rights reserved.)
C1 [Cao, Sijia; Ko, Ashley; Pakzad-Vaezi, Kaivon; Merkur, Andrew B.; Albiani, David A.; Kirker, Andrew W.; Cui, Jing Z.; Forooghian, Farzin; Matsubara, Joanne A.] Univ British Columbia, Eye Care Ctr, Dept Ophthalmol & Visual Sci, Vancouver, BC V5Z 1M9, Canada.
   [Partanen, Marita] Univ British Columbia, Dept Educ & Counselling Psychol & Special Educ, Vancouver, BC V5Z 1M9, Canada.
C3 University of British Columbia; University of British Columbia
RP Matsubara, JA (通讯作者)，Eye Care Ctr, Dept Ophthalmol & Visual Sci, 2550 Willow St, Vancouver, BC V5Z 3N9, Canada.
EM jms@mail.ubc.ca
RI Partanen, Marita/AAU-8108-2020
OI Partanen, Marita/0000-0003-1018-9778
FU Canadian National Institute for the Blind, Toronto, ON, Canada; Canadian
   Institute of Health Research, Ottawa, ON, Canada [CIHR MOP 97806]
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST and none were reported. This research
   was supported by a New Researcher Grant from the Canadian National
   Institute for the Blind, Toronto, ON, Canada, and by Grant CIHR MOP
   97806 from the Canadian Institute of Health Research, Ottawa, ON,
   Canada. Involved in Concept and design of study (A.K., F.F., J.A.M.,
   S.C.); Recruitment of patients (A.B.M., D.A.A., A.W.K.); Conduct of
   study (A.K., A.W., J.Z.C., K.P.-V., S.C.); Analysis and interpretation
   of data (A.W., J.A.M., M.P., S.C.); Statistical expertise (M.P.);
   Obtaining funding (F.F., J.A.M.); Writing article (J.A.M., S.C.);
   Critical revision of article (A.K., F.F., J.Z.C., M.P.); and Final
   approval of article (J.A.M., F.F.). The authors thank Carl Zeiss
   Meditec, Inc, for use of the Cirrus SD OCT machine and software.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Bamforth SD, 1997, INVEST OPHTH VIS SCI, V38, P25
   Bamforth SD, 1996, ACTA NEUROPATHOL, V91, P624, DOI 10.1007/s004010050476
   Bradley DT, 2011, EYE, V25, P683, DOI 10.1038/eye.2011.37
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Duchini A, 1996, J INVEST MED, V44, P474
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ELNER SG, 1991, LAB INVEST, V64, P819
   ELNER VM, 1992, EXP EYE RES, V54, P361, DOI 10.1016/0014-4835(92)90048-W
   ERSHLER WB, 1993, LYMPHOKINE CYTOK RES, V12, P225
   Ershler WB, 2000, ANNU REV MED, V51, P245, DOI 10.1146/annurev.med.51.1.245
   Gangnon RE, 2012, ARCH OPHTHALMOL-CHIC, V130, P1169, DOI 10.1001/archophthalmol.2012.693
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Ko A, 2013, RETINA-J RET VIT DIS, V33, P1005, DOI 10.1097/IAE.0b013e31827d266e
   Lauer N, 2011, J IMMUNOL, V187, P4374, DOI 10.4049/jimmunol.1002488
   Lin T, 2013, CYTOKINE, V62, P369, DOI 10.1016/j.cyto.2013.03.027
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Markiewski MM, 2007, AM J PATHOL, V171, P715, DOI 10.2353/ajpath.2007.070166
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Mooijaart SP, 2007, EXP GERONTOL, V42, P1116, DOI 10.1016/j.exger.2007.08.001
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   NAGINENI CN, 1994, CLIN DIAGN LAB IMMUN, V1, P569, DOI 10.1128/CDLI.1.5.569-577.1994
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Priya RR, 2012, OPHTHALMOLOGY, V119, P2526, DOI 10.1016/j.ophtha.2012.06.042
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rink L, 1998, MECH AGEING DEV, V102, P199, DOI 10.1016/S0047-6374(97)00153-X
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Shanmugam N, 2008, DIABETES, V57, P879, DOI 10.2337/db07-1204
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Takabayashi T, 1998, J INFECT DIS, V177, P1622, DOI 10.1086/515316
   Takabayashi T, 1996, J IMMUNOL, V156, P3455
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wang JCC, 2012, MOL VIS, V18, P3049
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Yehoshua Zohar, 2010, Ophthalmic Surg Lasers Imaging, V41 Suppl, pS6, DOI 10.3928/15428877-20101031-19
   Zhang XH, 2007, BLOOD, V110, P228, DOI 10.1182/blood-2006-12-063636
NR 51
TC 50
Z9 52
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2013
VL 156
IS 6
BP 1176
EP 1183
DI 10.1016/j.ajo.2013.08.003
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 261OQ
UT WOS:000327674900015
PM 24083687
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Tamiya, R
   Miyake, M
   Kido, A
   Hiragi, S
   Tamura, H
   Kuroda, T
   Tsujikawa, A
AF Tamiya, Ryosuke
   Miyake, Masahiro
   Kido, Ai
   Hiragi, Shusuke
   Tamura, Hiroshi
   Kuroda, Tomohiro
   Tsujikawa, Akitaka
TI Validation study of the claims-based definition for age-related macular
   degeneration at a single university hospital in Japan
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Electronic medical record; Claim database; Validation; Clinical
   research; NDB
AB Purpose To evaluate the efficacy of the claims'-based definition of age-related macular degeneration (AMD) in detecting clinically-diagnosed AMD. Study design A validation study using cross-sectional data. Methods Seven hundred clinically-diagnosed AMD patients and seven hundred non-AMD individuals were randomly selected from patients at the Kyoto University Hospital's ophthalmology outpatient clinic between January 2011 and December 2017. We evaluated the sensitivity, specificity, and positive/negative likelihood ratio of eight different claims'-based definitions of AMD for detecting clinically-diagnosed AMD. These definitions consist of the diagnosis name (AMD) in combination with (1) fluorescent fundus angiography, and/or (2) treatment of AMD, and (3) the exclusion of patients who had a diagnosis of central serous chorioretinopathy (CSC) or myopic choroidal neovascularization. Results Defining by the diagnosis name AMD in the claims' data showed the highest accuracy (sensitivity 94.9%, specificity 92.6%, accuracy 93.7%). Combining the diagnosis name AMD with fluorescence fundus angiography and/or anti-vascular endothelial growth factor (anti VEGF) treatment increased the specificity at the expense of sensitivity. Notably, the combination with AMD treatment achieved a specificity of 98.3%. Conclusion The current validation study elucidated the high accuracy of the disease name (AMD) in the claims' data for identifying clinically-diagnosed AMD at a single university hospital. Although drawing wider conclusions may be limited, the results of this study contribute to creating real-world evidence in ophthalmology, based on the National Database of Health Insurance Claims in Japan.
C1 [Tamiya, Ryosuke] Osaka Red Cross Hosp, Dept Ophthalmol, Osaka, Japan.
   [Tamiya, Ryosuke; Miyake, Masahiro; Kido, Ai; Tamura, Hiroshi; Tsujikawa, Akitaka] Kyoto Univ Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Shogoin, Kyoto 6068507, Japan.
   [Hiragi, Shusuke; Tamura, Hiroshi; Kuroda, Tomohiro] Kyoto Univ Hosp, Div Med Informat & Adm Planning, Kyoto, Japan.
C3 Osaka Red Cross Hospital; Kyoto University; Kyoto University
RP Miyake, M (通讯作者)，Kyoto Univ Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Shogoin, Kyoto 6068507, Japan.
EM miyakem@kuhp.kyoto-u.ac.jp
RI TAMURA, Hiroshi/H-1855-2011; Hiragi, Shusuke/AAF-4310-2019; HIRAGI,
   Shusuke/GYA-3171-2022
OI TAMURA, Hiroshi/0000-0002-7740-2732; Hiragi,
   Shusuke/0000-0003-1629-6195; 
CR Ando T, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3727-0
   Cheng CL, 2014, J EPIDEMIOL, V24, P500, DOI 10.2188/jea.JE20140076
   Hosoda Y, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0712-z
   Hosoda Y, 2018, P NATL ACAD SCI USA, V115, P6261, DOI 10.1073/pnas.1802212115
   Ikegami N, 2011, LANCET, V378, P1106, DOI 10.1016/S0140-6736(11)60828-3
   Kato G, 2017, T JPN SOC MED BIOL E, V55, P143, DOI DOI 10.11239/JSMBE.55.143
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kern DM, 2015, INT J CHRONIC OBSTR, V10, P1417, DOI 10.2147/COPD.S83135
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kwon S, 2009, HEALTH POLICY PLANN, V24, P63, DOI 10.1093/heapol/czn037
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Miyake M, 2014, INVEST OPHTH VIS SCI, V55, P3223, DOI 10.1167/iovs.14-14059
   Miyake M, 2014, OPHTHALMOLOGY, V121, P225, DOI 10.1016/j.ophtha.2013.06.043
   Nakata I, 2013, AM J OPHTHALMOL, V156, P1002, DOI 10.1016/j.ajo.2013.06.007
   Park SJ, 2015, OPHTHALMOLOGY, V122, P2063, DOI 10.1016/j.ophtha.2015.06.018
   Shinichiro K, 2018, NATL DATABASE HLTH I, DOI 10.1101/280008
   Smith, 1995, BLUE MOUNT EYE STUDY, V102, P1450
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wu TY, 2010, LONDON J PRIM CARE, V3, P115, DOI 10.1080/17571472.2010.11493315
NR 21
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD MAY
PY 2021
VL 65
IS 3
BP 388
EP 394
DI 10.1007/s10384-021-00816-w
EA MAR 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RV2FS
UT WOS:000630260600001
PM 33735404
DA 2022-11-30
ER

PT J
AU Augustin, AJ
   Offermann, I
   Lutz, J
   Schmidt-Erfurth, U
   Tornambe, P
AF Augustin, AJ
   Offermann, I
   Lutz, J
   Schmidt-Erfurth, U
   Tornambe, P
TI Comparison of the original Amsler grid with the modified Amsler grid -
   Result for patients with age-related macular degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
AB Purpose: To compare the sensitivity of the original Amsler grid presenting white lines on a black background with that of the modified standard version of the grid presenting black lines on a white background in the detection of visual disturbances.
   Patients and Methods: One hundred eighty-two patients (182 eyes) with dry and exudative age-related macular degeneration and a history of metamorphopsia were instructed to use an Amsler grid. None of the patients were familiar with an Amsler grid or had used it previously. If the disease was present in both eyes, one eye was chosen as the study eye by randomization. Both grid types were presented and used for documentation of central visual field changes. The sequence of presentation of the respective grid was also chosen by randomization. Original Amsler grid questions were used for grading ("metamorphomas" and "scotomas"). Visual acuity of patients ranged from 0.1 to 0.7. Subgroup analysis was performed based on the visual acuity levels.
   Results: For the overall study population, the original Amsler grid provided significantly better results than the modified version. Evaluation of data for the different subgroups showed no significant difference between patients with visual acuity ranging from 0.1 to 0.3. For patients with visual acuity of 0.5 or better, the original Amsler grid was significantly more informative and reliable than the modified version.
   Conclusion: For patients with macular diseases, use of the original Amsler grid (white lines on a black background) should be recommended. This is particularly important for patients with visual acuity of 0.5 or better.
C1 Dept Ophthalmol, D-76133 Karlsruhe, Germany.
   Univ Wurzburg, Dept Physiol, D-8700 Wurzburg, Germany.
   Univ Vienna, Dept Ophthalmol, Vienna, Austria.
   Retina Res Fdn San Diego, San Diego, CA USA.
C3 University of Wurzburg; University of Vienna
RP Augustin, AJ (通讯作者)，Dept Ophthalmol, Moltkestr 9, D-76133 Karlsruhe, Germany.
EM 106020.560@compuserve.com
OI Augustin, Prof. Dr. Albert J./0000-0003-1591-0536
CR AMSLER M, 1947, OPHTHALMOLOGICA, V114, P248, DOI 10.1159/000300476
   AMSLER M, 1953, BRIT J OPHTHALMOL, V37, P521, DOI 10.1136/bjo.37.9.521
   Amsler M., 1949, T OPHTHAL SOC UK, V69, P397
   CHESNUTT DA, 2002, AMSLER GRID WHITE BL
   YANNUZZI LA, 1988, B NEW YORK ACAD MED, V64, P955
NR 5
TC 19
Z9 22
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2005
VL 25
IS 4
BP 443
EP 445
DI 10.1097/00006982-200506000-00008
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 008AN
UT WOS:000235012700008
PM 15933590
DA 2022-11-30
ER

PT J
AU Marakis, TP
   Koutsandrea, C
   Chatzistefanou, KI
   Tountas, Y
AF Marakis, Theodoros P.
   Koutsandrea, Chrysanthi
   Chatzistefanou, Klio I.
   Tountas, Yannis
TI Treatment satisfaction of patients with neovascular age-related macular
   degeneration treated with anti-vascular endothelial growth factor agents
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Treatment satisfaction questionnaire;
   Psychometric properties; Predictors; Greece
ID QUALITY-OF-LIFE; VISUAL-ACUITY; REAL-LIFE; INTRAVITREAL RANIBIZUMAB;
   CLINICAL-PRACTICE; LETTER-CHART; PREVALENCE; VISION; OUTCOMES; IMPACT
AB Purpose To assess the psychometric properties of the Greek Macular Disease Treatment Satisfaction Questionnaire (MacTSQ) and evaluate the factors that influence treatment satisfaction of patients with neovascular age-related macular degeneration (nAMD).
   Methods The MacTSQ was translated into Greek and administered to 176 patients. All patients completed the SF-12 Health Survey and the Macular disease Dependent Quality of Life Questionnaire (MacDQoL) and underwent vision measurements. For test-retest reliability, a subset of 19 participants completed the MacTSQ twice, two weeks apart. Stepwise multiple linear regression analyses were performed to identify predictors of treatment satisfaction. Change in MacTSQ scores over time was assessed on 83 patients who completed the MacTSQ at a follow-up visit, one year later.
   Results The intraclass correlation coefficients between the first and second test-retest administration ranged from 0.88 to 0.98 for the items and total score. Internal reliability of the total score was adequate (Cronbach's a = 0.837). Principal component analysis revealed three subscales (effectiveness, information provision and convenience, impact). The MacTSQ score showed significant correlations with SF-12 summary scales and MacDQoL scores (rho = 0.16-0.27). The most important factor that determined the satisfaction was mental health. Distance visual acuity (VA) in better eye was the best predictor of the effectiveness subscale, and the total number of injections was a negative predictor for the convenience subscale. Treatment satisfaction increased at one-year follow-up, despite the deterioration in distance VA.
   Conclusions The Greek MacTSQ is a reliable and valid instrument for assessing nAMD patients' perceptions of treatment satisfaction, especially using its three new subscales. Treatment satisfaction is multifactorial and was primarily determined by patients' mental health status.
C1 [Marakis, Theodoros P.; Koutsandrea, Chrysanthi; Chatzistefanou, Klio I.] Univ Athens, Athens Gen Hosp G Gennimatas, Dept Ophthalmol 1, Med Sch, Athens, Greece.
   [Tountas, Yannis] Univ Athens, Dept Hyg & Epidemiol, Ctr Hlth Serv Res, Med Sch, Athens, Greece.
C3 National & Kapodistrian University of Athens; National & Kapodistrian
   University of Athens
RP Marakis, TP (通讯作者)，Univ Athens, Athens Gen Hosp G Gennimatas, Dept Ophthalmol 1, Med Sch, Athens, Greece.
EM theomarakis@yahoo.gr; kliochat@med.uoa.gr; ytountas@med.uoa.gr
CR Amoaku WM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128403
   ARDITI A, 1993, INVEST OPHTH VIS SCI, V34, P120
   Au CPY, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0071-6
   Bertelmann T, 2016, HEALTH QUAL LIFE OUT, V14, DOI 10.1186/s12955-016-0536-1
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Boyle Jessica, 2018, Psychol Health Med, V23, P127, DOI 10.1080/13548506.2016.1274040
   Boyle J, 2015, PSYCHOL HEALTH MED, V20, P296, DOI 10.1080/13548506.2014.936886
   BRADLEY C, 1990, DIABETIC MED, V7, P445, DOI 10.1111/j.1464-5491.1990.tb01421.x
   Brose LS, 2009, PSYCHOL HEALTH MED, V14, P740, DOI 10.1080/13548500903431485
   Burton AE, 2013, BRIT J VISUAL IMPA, V31, P178, DOI 10.1177/0264619613490517
   Casten R, 2010, ARCH OPHTHALMOL-CHIC, V128, P506, DOI 10.1001/archophthalmol.2010.24
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chatziralli I, 2016, SCIENCEDIRECT, V32, P1
   Cimarolli VR, 2016, CLIN OPHTHALMOL, V10, P55, DOI 10.2147/OPTH.S80489
   Droege KM, 2013, GRAEF ARCH CLIN EXP, V251, P1281, DOI 10.1007/s00417-012-2177-3
   Dubuc S, 2009, CAN J OPHTHALMOL, V44, P680, DOI 10.3129/i09-163
   Economou M, 2016, SOC PSYCH PSYCH EPID, V51, P1015, DOI 10.1007/s00127-016-1238-z
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1246, DOI 10.1016/j.ophtha.2013.12.032
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Gohil R, 2016, PATIENT PREFER ADHER, V10, P949, DOI 10.2147/PPA.S105536
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Horton JC, 1997, SURV OPHTHALMOL, V42, P169, DOI 10.1016/S0039-6257(97)00055-6
   Inoue M, 2014, CLIN OPHTHALMOL, V8, P1711, DOI 10.2147/OPTH.S68293
   Kontodimopoulos N, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-55
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Marakis TP, 2017, QUAL LIFE RES, V26, P183, DOI 10.1007/s11136-016-1407-2
   McCloud C, 2015, EYE, V29, P1561, DOI 10.1038/eye.2015.167
   Mitchell J, 2007, QUAL LIFE RES, V120, P2
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Mitchell Jan, 2005, Health Qual Life Outcomes, V3, P25, DOI 10.1186/1477-7525-3-25
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Rifkin L, 2012, RETINA-J RET VIT DIS, V32, P696, DOI 10.1097/IAE.0b013e3182252ad3
   Rodriguez Ramirez M, 2014, Arch Soc Esp Oftalmol, V89, P477, DOI 10.1016/j.oftal.2014.05.010
   Senra H, 2016, GRAEF ARCH CLIN EXP, V254, P1873, DOI 10.1007/s00417-016-3384-0
   Sloan FA, 2014, JAMA OPHTHALMOL, V132, P456, DOI 10.1001/jamaophthalmol.2013.7647
   Souied EH, 2015, RETINA-J RET VIT DIS, V35, P1743, DOI 10.1097/IAE.0000000000000548
   Terwee CB, 2007, J CLIN EPIDEMIOL, V60, P34, DOI 10.1016/j.jclinepi.2006.03.012
   Thetford C, 2013, BRIT J VISUAL IMPA, V31, P89, DOI 10.1177/0264619613481778
   Topouzis F, 2006, AM J OPHTHALMOL, V142, P1076, DOI 10.1016/j.ajo.2006.07.042
   Ware JE, 1994, SF 36 PHYS MENTAL HL
   Wild D, 2009, VALUE HEALTH, V12, P430, DOI 10.1111/j.1524-4733.2008.00471.x
NR 43
TC 3
Z9 3
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD APR
PY 2018
VL 38
IS 2
BP 565
EP 576
DI 10.1007/s10792-017-0492-8
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA GE6AD
UT WOS:000431304900017
PM 28285389
DA 2022-11-30
ER

PT J
AU Wykoff, CC
   Ou, WC
   Croft, DE
   Payne, JF
   Brown, DM
   Clark, WL
   Abdelfattah, NS
   Sadda, SR
AF Wykoff, Charles C.
   Ou, William C.
   Croft, Daniel E.
   Payne, John F.
   Brown, David M.
   Clark, W. Lloyd
   Abdelfattah, Nizar Saleh
   Sadda, SriniVas R.
CA TREX-AMD Study Grp
TI Neovascular age-related macular degeneration management in the third
   year: final results from the TREX-AMD randomised trial
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE clinical trial; retina
ID DOSING REGIMEN; RANIBIZUMAB; EXTEND; EFFICACY; THERAPY; SAFETY
AB Background/Aims Prospectively evaluate outcomes in the third year of neovascular age-related macular degeneration (AMD) management using ranibizumab with continued treat and extend (TREX) dosing compared with monthly visits with retreatment upon evidence of exudative disease activity (PRN, pro re nata).
   Methods Subjects with treatment-naive neovascular AMD were randomised 1:2 to Monthly or TREX and managed through 2years. In the third year, subjects randomised to Monthly were managed PRN while subjects randomised to TREX were continued on TREX dosing or transitioned to PRN after achieving an interval of 12weeks between visits.
   Results Sixty subjects enrolled and 46 (77%) completed month 36 (M36). Transition from Monthly to PRN was associated with a decline in best corrected visual acuity (BCVA) (+10.5 letters (month 24) to +5.4 (M36, p=0.09)); three (15%) subjects required no dosing during year 3, and 47% (114/243) of possible PRN injections were delivered, yielding a mean of 6.1 injections during year 3. Among the 9 (23%) TREX subjects transitioned to PRN, the need for ongoing anti-vascular endothelial growth factor retreatments was small, with 4 (4%) intravitreal injections being delivered among 106 PRN visits; this subgroup displayed an inferior BCVA trajectory compared with the remainder of subjects. Outcomes among subjects continued on TREX were more favourable, with a mean gain of +5.0 letters at M36.
   Conclusions Upon transition to PRN, subjects randomised to monthly dosing experienced a decline in BCVA. Among subjects initially randomised to TREX who transitioned to PRN after achieving a 12-week interval between visits, the overall need for additional treatment was low.
   Trial registration number NCT01748292, Results.
C1 [Wykoff, Charles C.; Ou, William C.; Croft, Daniel E.; Brown, David M.] Retina Consultants Houston, Houston, TX 77030 USA.
   [Wykoff, Charles C.; Brown, David M.] Houston Methodist Hosp, Blanton Eye Inst, Houston, TX 77030 USA.
   [Wykoff, Charles C.; Brown, David M.] Weill Cornell Med Coll, Houston, TX 77030 USA.
   [Payne, John F.; Clark, W. Lloyd] Palmetto Retina Ctr, W Columbia, SC USA.
   [Abdelfattah, Nizar Saleh; Sadda, SriniVas R.] Doheny Eye Inst, Doheny Image Reading Ctr, Los Angeles, CA USA.
   [Abdelfattah, Nizar Saleh; Sadda, SriniVas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
C3 The Methodist Hospital System; The Methodist Hospital - Houston; Cornell
   University; Doheny Eye Institute; University of California System;
   University of California Los Angeles; University of California Los
   Angeles Medical Center; David Geffen School of Medicine at UCLA
RP Wykoff, CC (通讯作者)，Retina Consultants Houston, Houston, TX 77030 USA.; Wykoff, CC (通讯作者)，Houston Methodist Hosp, Blanton Eye Inst, Houston, TX 77030 USA.; Wykoff, CC (通讯作者)，Weill Cornell Med Coll, Houston, TX 77030 USA.
EM ccwmd@houstonretina.com
RI Abdelfattah, Nizar Saleh/H-6908-2019
OI Abdelfattah, Nizar Saleh/0000-0002-9396-3054; Wang,
   Rui/0000-0002-0900-7714; Ou, William/0000-0003-1997-1360
FU Genentech, Inc., South San Francisco, CA
FX Research grant from Genentech, Inc., South San Francisco, CA. The
   funding organisation had no role in the design or conduct of this
   research.
CR Abdelfattah NS, 2017, OPHTHALMOLOGY, V124, P215, DOI 10.1016/j.ophtha.2016.10.002
   Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Croft DE, 2016, AM J OPHTHALMOL, V169, pXIV, DOI 10.1016/j.ajo.2016.06.040
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P1856, DOI 10.1016/j.ophtha.2016.05.016
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
   Wykoff CC, 2017, OPHTHALMOLO IN PRESS
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 23
TC 32
Z9 33
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD APR
PY 2018
VL 102
IS 4
BP 460
EP 464
DI 10.1136/bjophthalmol-2017-310822
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GC4DD
UT WOS:000429732500008
PM 28779006
DA 2022-11-30
ER

PT J
AU Freeman, EE
   Munoz, B
   West, SK
   Tielsch, JM
   Schein, OD
AF Freeman, EE
   Munoz, B
   West, SK
   Tielsch, JM
   Schein, OD
TI Is there an association between cataract surgery and age-related macular
   degeneration? Data from three population-based studies
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BALTIMORE EYE SURVEY; VISUAL IMPAIRMENT; URBAN-POPULATION; LENS
   OPACITIES; MACULOPATHY; PREVALENCE; BLINDNESS; OUTCOMES; PROJECT
AB PURPOSE: To determine whether cataract surgery is associated with an increased prevalence of age-related macular degeneration (AMD) in three independent population-based data sets.
   DESIGN: Cross-sectional study.
   METHODS: Data were used from the Salisbury Eye Evaluation (2,520 subjects from Salisbury, Maryland, aged 65 to 84 years), the Proyecto VER (4,774 Hispanic subjects from Arizona aged 40 years and older), and the Baltimore Eye Survey (4,396 subjects from Baltimore, Maryland, aged 40 and older). The main outcome measure was AMD as determined by retinal photographs or clinical examination. 0
   RESULTS: A history of cataract surgery was associated with an increased prevalence of late AMD in all three data sets after adjusting for age, race, sex, and smoking, but odds ratios (OR) were not individually statistically significant. The OR for the combined analysis was 1.7 (95% confidence interval: 1.1-2.6). Having a severe cataract in the eye was also associated with a slightly higher prevalence of late AMD, although the combined OR was not statistically significant (OR = 1.4; 95% confidence interval, 0.8%-2.4). Overall, increasing time since cataract surgery was not associated with late AMD.
   CONCLUSIONS: A history of cataract surgery may be associated with an increased prevalence of late AMD. However, having a severe cataract in the eye may also be associated with a higher prevalence of late AMD. Additional research is needed to investigate whether a causal relationship exists between cataract surgery and AMD or whether this relationship is due to residual confounding or bias. (C) 2003 by Elsevier Inc. All rights reserved.
C1 Johns Hopkins Univ, Wilmer Eye Inst, Dana Ctr Prevent Ophthalmol, Sch Med, Baltimore, MD 21218 USA.
   Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Bloomberg School of Public Health
RP Schein, OD (通讯作者)，Johns Hopkins Univ Hosp, 600 N Wolfe St,116 Wilmer Bldg, Baltimore, MD 21287 USA.
OI Freeman, Ellen/0000-0002-1403-8427; Tielsch, James/0000-0002-1151-060X
FU NATIONAL EYE INSTITUTE [K24EY000395] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE ON AGING [R01AG016294] Funding Source: NIH RePORTER;
   NEI NIH HHS [K24EY00395, EY11283] Funding Source: Medline; NIA NIH HHS
   [AG16294] Funding Source: Medline
CR Diggle P., 2002, J AM STAT ASSOC, V90, DOI DOI 10.2307/2983303
   HYMAN L, 1987, EYE, V1, P330, DOI 10.1038/eye.1987.53
   Hyman L, 1992, AGE RELATED MACULAR, P1
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P191, DOI 10.1001/archopht.1994.01090140067025
   LIU IY, 1989, AM J PUBLIC HEALTH, V79, P765, DOI 10.2105/AJPH.79.6.765
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   STEINBERG EP, 1994, OPHTHALMOLOGY, V101, P1131
   STEINBERG EP, 1993, ARCH OPHTHALMOL-CHIC, V111, P1041, DOI 10.1001/archopht.1993.01090080037016
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   TAYLOR HR, 1989, AUST NZ J OPHTHALMOL, V17, P81, DOI 10.1111/j.1442-9071.1989.tb00492.x
   TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048
   VANDERSCHAFT TL, 1994, BRIT J OPHTHALMOL, V78, P441, DOI 10.1136/bjo.78.6.441
   Wang J J, 1999, Ophthalmic Epidemiol, V6, P317, DOI 10.1076/opep.6.4.317.4182
   WEST SK, 1988, INVEST OPHTH VIS SCI, V29, P73
   West SK, 1997, INVEST OPHTH VIS SCI, V38, P72
   West SK, 2001, DIABETES CARE, V24, P1204, DOI 10.2337/diacare.24.7.1204
   ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248
NR 20
TC 92
Z9 102
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUN
PY 2003
VL 135
IS 6
BP 849
EP 856
DI 10.1016/S0002-9394(02)02253-5
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 686GF
UT WOS:000183312500014
PM 12788126
DA 2022-11-30
ER

PT J
AU Little, K
   Llorian-Salvador, M
   Tang, M
   Du, X
   Marry, S
   Chen, M
   Xu, HP
AF Little, Karis
   Llorian-Salvador, Maria
   Tang, Miao
   Du, Xuan
   Marry, Stephen
   Chen, Mei
   Xu, Heping
TI Macrophage to myofibroblast transition contributes to subretinal
   fibrosis secondary to neovascular age-related macular degeneration
SO JOURNAL OF NEUROINFLAMMATION
LA English
DT Article
DE Age-related macular degeneration; Retinal fibrosis; Macrophage to
   myofibroblast transition; Inflammation; Complement
ID PIGMENT EPITHELIAL-CELLS; COMPLEMENT; EXPRESSION; RISK; C3A
AB Background: Macular fibrosis causes irreparable vision loss in neovascular age-related macular degeneration (nAMD) even with anti-vascular endothelial growth factor (VEGF) therapy. Inflammation is known to play an important role in macular fibrosis although the underlying mechanism remains poorly defined. The aim of this study was to understand how infiltrating macrophages and complement proteins may contribute to macular fibrosis.
   Methods: Subretinal fibrosis was induced in C57BL/6J mice using the two-stage laser protocol developed by our group. The eyes were collected at 10, 20, 30 and 40 days after the second laser and processed for immunohistochemistry for infiltrating macrophages (F4/80 and Iba-1), complement components (C3a and C3aR) and fibrovascular lesions (collagen-1, Isolectin B4 and alpha-SMA). Human retinal sections with macular fibrosis were also used in the study. Bone marrow-derived macrophages (BMDMs) from C57BL/6J mice were treated with recombinant C3a, C5a or TGF-beta for 48 and 96 h. qPCR, Western blot and immunohistochemistry were used to examine the expression of myofibroblast markers. The involvement of C3a-C3aR pathway in macrophage to myofibroblast transition (MMT) and subretinal fibrosis was further investigated using a C3aR antagonist (C3aRA) and a C3a blocking antibody in vitro and in vivo.
   Results: Approximately 20 similar to 30% of F4/80(+) (or Iba-1(+)) infiltrating macrophages co-expressed alpha-SMA in subretinal fibrotic lesions both in human nAMD eyes and in the mouse model. TGF-beta and C3a, but not C5a treatment, significantly upregulated expression of alpha-SMA, fibronectin and collagen-1 in BMDMs. C3a-induced upregulation of alpha-SMA, fibronectin and collagen-1 in BMDMs was prevented by C3aRA treatment. In the two-stage laser model of induced subretinal fibrosis, treatment with C3a blocking antibody but not C3aRA significantly reduced vascular leakage and Isolectin B4(+) lesions. The treatment did not significantly alter collagen-1(+) fibrotic lesions.
   Conclusions: MMT plays a role in macular fibrosis secondary to nAMD. MMT can be induced by TGF-beta and C3a but not C5a. Further research is required to fully understand the role of MMT in macular fibrosis.
C1 [Little, Karis; Llorian-Salvador, Maria; Tang, Miao; Du, Xuan; Marry, Stephen; Chen, Mei; Xu, Heping] Queens Univ Belfast, Sch Med Dent & Biomed Sci, Wellcome Wolfson Inst Expt Med, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.
C3 Queens University Belfast
RP Xu, HP (通讯作者)，Queens Univ Belfast, Sch Med Dent & Biomed Sci, Wellcome Wolfson Inst Expt Med, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.
EM heping.xu@qub.ac.uk
RI Xu, Heping/A-4430-2008; Llorián-Salvador, Maía/HDM-6846-2022; Llorian
   Salvador, Maria/GYV-1848-2022
OI Xu, Heping/0000-0003-4000-931X; Marry, Stephen/0000-0002-0769-1444;
   Llorian-Salvador, Maria/0000-0002-1120-6579
FU Fight for Sight [5057/5058]; Department for the Economy (DfE) of
   Northern Ireland, UK; European Union's Horizon 2020 research and
   innovation programme under the Marie Sklodowska-Curie grant [722717]
FX This study was supported by a grant from (1) Fight for Sight
   (5057/5058); (2) the Department for the Economy (DfE) of Northern
   Ireland, UK; and (3) the European Union's Horizon 2020 research and
   innovation programme under the Marie Sklodowska-Curie grant agreement No
   722717.
CR American Academy of Family Physicians, 2016, WORKFL RED EHR IMPL, P1
   Bloch SB, 2013, AM J OPHTHALMOL, V156, P116, DOI 10.1016/j.ajo.2013.02.012
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chen M, 2013, INVEST OPHTH VIS SCI, V54, P682, DOI 10.1167/iovs.12-10888
   Chen SN, 2019, INT J NETW DISTRIB C, V8, P16, DOI 10.2991/ijndc.k.191118.001
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P369, DOI 10.1016/j.exer.2004.10.005
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hams E, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00597
   Hombrebueno JR, 2015, SCI REP-UK, V5, DOI 10.1038/srep18316
   Ishikawa K, 2016, AM J PATHOL, V186, P859, DOI 10.1016/j.ajpath.2015.11.014
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Little K, 2018, EBIOMEDICINE, P1
   Little K, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.4.3
   Liu J, 2020, J NEUROSCI RES, V98, P1498, DOI 10.1002/jnr.24618
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Luo C, 2013, EXP EYE RES, V112, P93, DOI 10.1016/j.exer.2013.04.016
   Meng XM, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.402
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Pardali E, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102157
   Rosenfield PJ, 2006, NEW ENGL J MED, V355, P1
   Skeie JM, 2009, EYE, V23, P747, DOI 10.1038/eye.2008.206
   Souied EH, 2016, DEV OPHTHALMOL, V56, P86, DOI 10.1159/000442783
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
   Sugita S, 2009, ARCH IMMUNOL THER EX, V57, P263, DOI 10.1007/s00005-009-0030-0
   Tang ZY, 2009, J AM SOC NEPHROL, V20, P593, DOI 10.1681/ASN.2008040434
   Viola F, 2009, RETINA-J RET VIT DIS, V29, P732, DOI 10.1097/IAE.0b013e3181a395cb
   Wang S, 2016, ONCOTARGET, V7, P8809, DOI 10.18632/oncotarget.6604
   Wang YY, 2017, J AM SOC NEPHROL, V28, P2053, DOI 10.1681/ASN.2016050573
   Weiclenbusch M, 2012, J INNATE IMMUN, V4, P463, DOI 10.1159/000336717
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu HP, 2016, EUR J PHARMACOL, V787, P94, DOI 10.1016/j.ejphar.2016.03.001
   Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5
   Yang Y, 2013, 2013 IEEE INTERNATIONAL CONFERENCE ON ROBOTICS AND BIOMIMETICS (ROBIO), P625, DOI 10.1109/ROBIO.2013.6739529
NR 40
TC 21
Z9 21
U1 2
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1742-2094
J9 J NEUROINFLAMM
JI J. Neuroinflamm.
PD DEC 25
PY 2020
VL 17
IS 1
AR 355
DI 10.1186/s12974-020-02033-7
PG 12
WC Immunology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Neurosciences & Neurology
GA PA6FX
UT WOS:000595730100002
PM 33239022
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Rohwer, K
   Neupane, S
   Bittkau, KS
   Perez, MG
   Dorschmann, P
   Roider, J
   Alban, S
   Klettner, A
AF Rohwer, Kevin
   Neupane, Sandesh
   Bittkau, Kaya Saskia
   Perez, Mayra Galarza
   Doerschmann, Philipp
   Roider, Johann
   Alban, Susanne
   Klettner, Alexa
TI Effects of Crude Fucus distichus Subspecies evanescens Fucoidan Extract
   on Retinal Pigment Epithelium Cells?Implications for Use in Age-Related
   Macular Degeneration
SO MARINE DRUGS
LA English
DT Article
DE Fucus distichus subsp; evanescens; fucoidan; retinal pigment epithelium;
   VEGF; oxidative stress; phagocytosis
ID OXIDATIVE STRESS; BROWN-ALGAE; IN-VITRO; POLYSACCHARIDES; INFLAMMATION;
   INHIBITION; INTERFERENCE; ANTIOXIDANT; ACTIVATION; PROTEIN
AB Fucoidan extracts may have beneficial effects in age-related macular degeneration (AMD). Over-the-counter fucoidan preparations are generally undefined, crude extracts. In this study, we investigated the effect of a crude fucoidan extract from Fucus distichus subspecies evanescens (Fe) on the retinal pigment epithelium (RPE). Fe extract was investigated for chemical composition and molar mass. It was tested in primary RPE and RPE cell line ARPE19. Oxidative stress was induced with tert-butyl hydroperoxide, cell viability evaluated with MTT assay, VEGF secretion assessed in ELISA. Phagocytosis was evaluated in a fluorescence microscopic assay. Wound healing ability was tested in a scratch assay. Additionally, the inhibition of elastase and complement system by Fe extract was studied. The Fe extract contained about 61.9% fucose and high amounts of uronic acids (26.2%). The sulfate content was not as high as expected (6.9%). It was not toxic and not protective against oxidative stress. However, Fe extract was able to reduce VEGF secretion in ARPE19. Phagocytosis was also reduced. Concerning wound healing, a delay could be observed in higher concentrations. While some beneficial effects could be found, it seems to interfere with RPE function, which may reduce its beneficial effects in AMD treatment.
C1 [Rohwer, Kevin; Doerschmann, Philipp; Roider, Johann; Klettner, Alexa] Univ Kiel, Univ Med Ctr, Dept Ophthalmol, D-24105 Kiel, Germany.
   [Neupane, Sandesh; Bittkau, Kaya Saskia; Perez, Mayra Galarza; Alban, Susanne] Univ Kiel, Pharmaceut Inst, Dept Pharmaceut Biol, D-24105 Kiel, Germany.
C3 University of Kiel; Schleswig Holstein University Hospital; University
   of Kiel
RP Klettner, A (通讯作者)，Univ Kiel, Univ Med Ctr, Dept Ophthalmol, D-24105 Kiel, Germany.
EM k.rohwer@live.de; sneupane@pharmazie.uni-kiel.de;
   kbittkau@pharmazie.uni-kiel.de; mperez@pharmazie.uni-kiel.de;
   Philipp.Doerschmann@uksh.de; Johann.Roider@uksh.de;
   salban@pharmazie.uni-kiel.de; AlexaKarina.Klettner@uksh.de
RI Neupane, Sandesh/X-3267-2019
OI Klettner, Alexa/0000-0002-2709-1059; Alban, Susanne/0000-0003-1993-3751;
   Neupane, Sandesh/0000-0002-5167-9848
FU Baltic Blue Biotechnology Alliance (InterReg5b); FucoSan Health from the
   Sea Project - EU InterReg-Deutschland-Denmark; European Fond of Regional
   Development
FX This study has been conducted with funding of the Baltic Blue
   Biotechnology Alliance (InterReg5b) and with funding of the FucoSan
   Health from the Sea Project, supported by EU
   InterReg-Deutschland-Denmark and the European Fond of Regional
   Development.
CR ALBERSHEIM PETER, 1967, CARBOHYD RES, V5, P340, DOI 10.1016/S0008-6215(00)80510-8
   Anastyuk SD, 2012, CARBOHYD POLYM, V87, P186, DOI 10.1016/j.carbpol.2011.07.036
   Becker M, 2003, THROMB HAEMOSTASIS, V89, P915, DOI 10.1055/s-0037-1613479
   Bellezza I, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01280
   Bilan MI, 2002, CARBOHYD RES, V337, P719, DOI 10.1016/S0008-6215(02)00053-8
   Bittkau KS, 2019, MAR DRUGS, V17, DOI 10.3390/md17080441
   BLAKENEY AB, 1983, CARBOHYD RES, V113, P291, DOI 10.1016/0008-6215(83)88244-5
   Blasi MA, 1999, INVEST OPHTH VIS SCI, V40, P3012
   Sanchez-Rangel JC, 2013, ANAL METHODS-UK, V5, P5990, DOI 10.1039/c3ay41125g
   Chen HJ, 2016, CANCER LETT, V382, P44, DOI 10.1016/j.canlet.2016.08.020
   Copland DA, 2018, INVEST OPHTH VIS SCI, V59, pAMD83, DOI 10.1167/iovs.18-23893
   Cumashi A, 2007, GLYCOBIOLOGY, V17, P541, DOI 10.1093/glycob/cwm014
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Dithmer M, 2017, MAR DRUGS, V15, DOI 10.3390/md15070193
   Dithmer M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089150
   Dorschmann P, 2019, MAR DRUGS, V17, DOI 10.3390/md17050258
   FILISETTICOZZI TMCC, 1991, ANAL BIOCHEM, V197, P157, DOI 10.1016/0003-2697(91)90372-Z
   Fitton JH, 2015, MAR DRUGS, V13, P5920, DOI 10.3390/md13095920
   Gerhauser C, 2003, MUTAT RES-FUND MOL M, V523, P163, DOI 10.1016/S0027-5107(02)00332-9
   Groth I, 2008, PLANTA MED, V74, P852, DOI 10.1055/s-2008-1074549
   Handa JT, 2017, BBA-MOL CELL BIOL L, V1862, P430, DOI 10.1016/j.bbalip.2016.07.013
   Kim EA, 2014, CARBOHYD POLYM, V102, P185, DOI 10.1016/j.carbpol.2013.11.022
   Kim H, 2019, BIOMED PHARMACOTHER, V109, P1718, DOI 10.1016/j.biopha.2018.11.015
   Kim KJ, 2012, FITOTERAPIA, V83, P1628, DOI 10.1016/j.fitote.2012.09.014
   Klettner A, 2008, INVEST OPHTH VIS SCI, V49, P4523, DOI 10.1167/iovs.08-2055
   Klettner A, 2016, MAR DRUGS, V14, DOI 10.3390/md14020031
   Klettner Alexa, 2015, Med Monatsschr Pharm, V38, P258
   Klettner Alexa, 2012, Front Biosci (Schol Ed), V4, P392
   Klettner A, 2011, OPHTHALMIC RES, V46, P88, DOI 10.1159/000323271
   Koinzer S, 2015, CURR EYE RES, V40, P853, DOI 10.3109/02713683.2014.961613
   Koyanagi S, 2003, BIOCHEM PHARMACOL, V65, P173, DOI 10.1016/S0006-2952(02)01478-8
   Kuznetsova TA, 2014, MAR DRUGS, V12, P886, DOI 10.3390/md12020886
   Lahrsen E, 2018, CARBOHYD POLYM, V192, P208, DOI 10.1016/j.carbpol.2018.03.056
   Li B, 2008, MOLECULES, V13, P1671, DOI 10.3390/molecules13081671
   Li CM, 2011, FOOD CHEM TOXICOL, V49, P2090, DOI 10.1016/j.fct.2011.05.022
   Makarenkova ID, 2012, B EXP BIOL MED+, V154, P241, DOI 10.1007/s10517-012-1922-2
   Mariotti F, 2008, CRIT REV FOOD SCI, V48, P177, DOI 10.1080/10408390701279749
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Nowak JZ, 2013, PHARMACOL REP, V65, P288, DOI 10.1016/S1734-1140(13)71005-3
   Park MK, 2011, MAR DRUGS, V9, P1359, DOI 10.3390/md9081359
   Riss T. L., 2004, CELL VIABILITY ASSAY
   Rui X, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1885-y
   Ryu MJ, 2016, MOL MED REP, V14, P3255, DOI 10.3892/mmr.2016.5623
   Sanjeewa KKA, 2017, CARBOHYD POLYM, V177, P451, DOI 10.1016/j.carbpol.2017.09.005
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schneider T, 2015, GLYCOBIOLOGY, V25, P812, DOI 10.1093/glycob/cwv022
   Skriptsova AV, 2012, MAR BIOTECHNOL, V14, P304, DOI 10.1007/s10126-011-9413-4
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Ustyuzhanina NE, 2014, GLYCOBIOLOGY, V24, P1265, DOI 10.1093/glycob/cwu063
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Vishchuk OS, 2013, FOOD CHEM, V141, P1211, DOI 10.1016/j.foodchem.2013.03.065
   Wang YQ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19124050
   Wiencke AK, 2003, ACTA OPHTHALMOL SCAN, V81, P170, DOI 10.1034/j.1600-0420.2003.00030.x
   Yokota T, 2016, J NUTR BIOCHEM, V32, P46, DOI 10.1016/j.jnutbio.2016.01.011
NR 54
TC 14
Z9 14
U1 2
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-3397
J9 MAR DRUGS
JI Mar. Drugs
PD SEP
PY 2019
VL 17
IS 9
AR 538
DI 10.3390/md17090538
PG 14
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA JA6NS
UT WOS:000487959700035
PM 31527536
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Gao, L
   Liu, J
   Zhang, P
   Ma, JH
   Wang, H
AF Gao, Lei
   Liu, Jian
   Zhang, Peng
   Ma, Jianhua
   Wang, Hong
TI Clinical outcomes of 1+PRN and 3+Q3M regimens of intravitreal conbercept
   injection for exudative age-related macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID FUSION PROTEIN; RISK-FACTORS; RANIBIZUMAB; VEGF; AFLIBERCEPT; SAFETY;
   BEVACIZUMAB; EXPRESSION; EFFICACY; THERAPY
AB This retrospective study aimed to analyze the clinical outcomes of two regimens of intravitreal injections of conbercept [1+pro re nata (PRN) and 3+Q3M] for the therapy of exudative age-related macular degeneration (AMD). In total, 105 eyes diagnosed with exudative AMD were enrolled. The eyes in the 1+PRN group (n=51) received intravitreal injection of conbercept one time, followed by PRN retreatment. The eyes in the 3+Q3M group (n=54) received intravitreal injection of conbercept on three consecutive monthly, subsequently, once every three months for three times. After treatment, patients were followed up for 12 months. The best-corrected visual acuity (BCVA), central retinal thickness (CRT), and choroidal neovascularization (CNV) leakage area were compared before and after treatment. Moreover, the number of injections and adverse reactions were recorded. Compared with the 1+PRN group, BCVA was significantly improved and CRT was remarkably decreased in the 3+Q3M group at 3, 6 and 12 months after operation. The disappeared or reduced CNV leakage area (93%) of the 3+Q3M group was higher than that of the 1+PRN group at the last follow-up. Moreover, the mean numbers of conbercept injections of the 1+PRN group were less than the 3+Q3M group. During the follow-up, there were no serious adverse reactions or ocular complications. This study reveals that intravitreal injection of conbercept using 3+Q3M regimen has certain advantages than 1+PRN regimen in extending drug delivery interval, improving patient's vision, and reducing CRT.
C1 [Gao, Lei; Liu, Jian; Zhang, Peng] Jinan 2nd Peoples Hosp, Dept Ophthalmol, Jinan 250001, Shandong, Peoples R China.
   [Ma, Jianhua] Shandong Invalids Gen Hosp, Dept Ophthalmol, Jinan 250001, Shandong, Peoples R China.
   [Wang, Hong] Shandong Univ, Qilu Hosp, Dept Ophthalmol, Jinan 250001, Shandong, Peoples R China.
C3 Shandong University
RP Wang, H (通讯作者)，Shandong Univ, Qilu Hosp, Dept Ophthalmol, Jinan 250001, Shandong, Peoples R China.
EM redbaby@sdu.edu.cn
CR Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chen E, 2011, RETINA-J RET VIT DIS, V31, P1525, DOI 10.1097/IAE.0b013e318221594a
   Chen HX, 2009, NAT REV CLIN ONCOL, V6, P465, DOI 10.1038/nrclinonc.2009.94
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Danis P., 2014, ANG EX DEG
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Ford KM, 2012, MOL VIS, V18, P519
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Giacomelli Giovanni, 2014, Retina, V34, P860, DOI 10.1097/IAE.0000000000000007
   Hanus J, 2016, BRIT J OPHTHALMOL, V100, P122, DOI 10.1136/bjophthalmol-2015-306972
   Hassan M, 2016, EXPERT OPIN BIOL TH, V16, P699, DOI 10.1517/14712598.2016.1167182
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Johnston SS, 2013, ADV THER, V30, P1111, DOI 10.1007/s12325-013-0078-4
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Li H, 2012, EXP EYE RES, V97, P154, DOI 10.1016/j.exer.2011.09.002
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Papadopoulos Z, 2019, EUROPEAN J OPHTHALMO
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmid MK, 2015, BRIT J OPHTHALMOL, V99, P141, DOI 10.1136/bjophthalmol-2014-305149
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schutze C, 2015, AM J OPHTHALMOL, V159, P1100, DOI 10.1016/j.ajo.2015.02.020
   Semeraro F, 2019, BRIT J CLIN PHARM
   Thapa R, 2017, CLIN OPHTHALMOL, V11, P963, DOI 10.2147/OPTH.S132338
   Ueta T, 2014, OPHTHALMOLOGY, V121, P2193, DOI 10.1016/j.ophtha.2014.05.022
   Vedula SS, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub2
   Wang Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070544
   Wu BH, 2019, INT J OPHTHALMOL-CHI, V12, P252, DOI 10.18240/ijo.2019.02.11
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Wu ZG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057642
   Yang W, 2018, MICROSC RES TECHNIQ, V81, P384, DOI 10.1002/jemt.22989
   Yonekawa Y, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017178
   Zhang M, 2008, MOL VIS, V14, P37
   Zhang M, 2011, OPHTHALMOLOGY, V118, P672, DOI 10.1016/j.ophtha.2010.08.008
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
   Zhang X, 2007, INT J OPHTHALMOL, V7, P1674
NR 38
TC 1
Z9 1
U1 4
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 14
PY 2020
VL 10
IS 1
AR 8010
DI 10.1038/s41598-020-65000-5
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA NA8BG
UT WOS:000560041600011
PM 32409739
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Rim, PHH
   de Vasconcellos, JPC
   de Melo, MB
   Medina, FMC
   Sacconi, DPD
   Lana, TP
   Hirata, FE
   Magna, LA
   Marques-de-Faria, AP
AF Rim, Priscila H. H.
   de Vasconcellos, Jose Paulo C.
   de Melo, Monica B.
   Medina, Flavio M. C.
   Sacconi, Daniela P. D.
   Lana, Tamires P.
   Hirata, Fabio E.
   Magna, Luis A.
   Marques-de-Faria, Antonia P.
TI Correlation between genetic and environmental risk factors for
   age-related macular degeneration in Brazilian patients
SO PLOS ONE
LA English
DT Article
ID COMPLEMENT FACTOR-H; LONG-TERM INCIDENCE; Y402H POLYMORPHISM;
   PHYSICAL-ACTIVITY; CATARACT-SURGERY; ASSOCIATION; SUSCEPTIBILITY;
   MACULOPATHY; DISEASE; HTRA1
AB Purpose To analyze the correlations between age-related macular degeneration (AMD) and genetic and environmental risk factors for in a Brazilian population. Design Cross-sectional study with a control group. Methods We collected data on 236 participants 50 years of age or older (141 with AMD and 95 controls without the disease). Data was obtained using a questionnaire and included information on demographics, ocular and medical history, family history of AMD, lifestyle, and smoking and drinking habits. Genetic evaluations included direct sequencing for the LOC387715 (rs10490924) variant, as well as PCR and enzymatic digestion for the CFH Y402H (rs1061170) and HTRA1 (rs11200638) variants. We performed a risk assessment of environmental risk factors and genetic variants associated with AMD and determined correlations between AMD and the data collected using multiple linear regression analysis. Results Of the 141 AMD cases, 99 (70%) had advanced AMD in at least one eye (57% neovascular AMD and 13% geographic atrophy), and 42 (30%) had not-advanced AMD. Family history of AMD (OR: 6.58; 95% CI: 1.94-22.31), presence of cardiovascular disease (CVD) (OR: 2.39; 95% CI: 1.08-5.28), low physical activity level (OR: 1.39; 95% CI: 0.82-2.37), and high serum cholesterol (OR: 1.49; 95% CI: 0.84-2.65) were associated with an increased risk for AMD. There was a significant association between CVD and incidence of advanced AMD (OR: 2.29; 95% CI 0.81-6.44). The OR for the risk allele of the LOC387715 gene, the CFH gene and the HTRA1 gene were 2.21 (95% CI: 1.47-3.35), 2.27 (95% CI: 1.52-3.37), and 2.76 (95% CI: 1.89-4.03), respectively. In the stepwise multiple linear regression analyses, the HTRA1 and CFH risk alleles, family history of AMD, the LOC387715 risk allele, and CVD were associated with an increased risk of AMD for a total of 25.6% contribution to the AMD phenotype. Conclusions The analysis correlating environmental and genetic risk factors such as family history of AMD, and CVD and the variants of HTRA1, CFH, and LOC387715 genes showed an expressive contribution for the development of AMD among this admixed population.
C1 [Rim, Priscila H. H.; de Vasconcellos, Jose Paulo C.; Hirata, Fabio E.] Univ Campinas UNICAMP, Sch Med Sci, Dept Ophthalmol, Campinas, SP, Brazil.
   [de Melo, Monica B.; Sacconi, Daniela P. D.; Lana, Tamires P.] Univ Campinas UNICAMP, Ctr Mol Biol & Genet Engn CBMEG, Lab Human Genet, Campinas, SP, Brazil.
   [Medina, Flavio M. C.] Rio de Janeiro State Univ UERJ, Sch Med Sci, Dept Ophthalmol, Rio De Janeiro, RJ, Brazil.
   [Magna, Luis A.; Marques-de-Faria, Antonia P.] Univ Campinas UNICAMP, Sch Med Sci, Dept Med Genet, Campinas, SP, Brazil.
C3 Universidade Estadual de Campinas; Universidade Estadual de Campinas;
   Universidade do Estado do Rio de Janeiro; Universidade Estadual de
   Campinas
RP Rim, PHH (通讯作者)，Univ Campinas UNICAMP, Sch Med Sci, Dept Ophthalmol, Campinas, SP, Brazil.
EM priscilarim@gmail.com
OI RIM, PRISCILA HAE HYUN/0000-0002-6046-6377
CR Almeida LN, 2013, OPHTHALMIC RES, V50, P117, DOI 10.1159/000350549
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Ferreira CCD, 2010, ARQ BRAS CARDIOL, V95, P621, DOI 10.1590/S0066-782X2010005000141
   Sacconi DPD, 2016, OPHTHALMIC GENET, V37, P459, DOI 10.3109/13816810.2015.1120315
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Francis PJ, 2011, CLIN OPHTHALMOL, V5, P1127, DOI 10.2147/OPTH.S11627
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Hanus J, 2016, BRIT J OPHTHALMOL, V100, P122, DOI 10.1136/bjophthalmol-2015-306972
   Hirata FE, 2015, OPHTHALMIC GENET, V36, P224, DOI 10.3109/13816810.2013.867449
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Lana TP, 2018, OPHTHALMIC GENET, V39, P46, DOI 10.1080/13816810.2017.1354382
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Limburg H, 2008, BRIT J OPHTHALMOL, V92, P315, DOI 10.1136/bjo.2007.125906
   Medina FM, 2019, OPHTHALMIC RES, V61, P168, DOI 10.1159/000475995
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Shahid H, 2012, BRIT J OPHTHALMOL, V96, P427, DOI 10.1136/bjophthalmol-2011-300193
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Teixeira AG, 2010, ACTA OPHTHALMOL, V88, pE165, DOI 10.1111/j.1755-3768.2010.01932.x
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tong Y, 2010, MOL VIS, V16, P1958
   Veloso Carlos Eduardo, 2014, Rev. Col. Bras. Cir., V41, P386, DOI 10.1590/0100-69912014006002
   Williams PT, 2009, INVEST OPHTH VIS SCI, V50, P101, DOI 10.1167/iovs.08-2165
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
NR 37
TC 0
Z9 0
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PY 2022
VL 17
IS 6
AR e0268795
DI 10.1371/journal.pone.0268795
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 3H8VI
UT WOS:000832307900010
PM 35657810
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Goff, MJ
   Johnson, RN
   McDonald, HR
   Ai, E
   Jumper, JM
   Fu, A
AF Goff, Mitchell J.
   Johnson, Robert N.
   McDonald, H. Richard
   Ai, Everett
   Jumper, J. Michael
   Fu, Arthur
TI Intravitreal bevacizumab for previously treated choroidal
   neovascularization from age-related macular degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE intravitreal bevacizumab; choroidal neovascularization; age-related
   macular degeneration
ID COHERENCE TOMOGRAPHY FINDINGS; AVASTIN; RANIBIZUMAB; INJECTION; THERAPY
AB Purpose: To report the optical coherence tomography (OCT) findings and visual results in a series of patients treated with intravitreal bevacizumab for choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD), and to determine if a difference in treatment effect exists between previously treated and treatment naive patients.
   Methods: A retrospective review of all patients treated with intravitreal bevacizumab for CNV from AMD with visual acuity greater than or equal to 20/320 between September 2005 and February 2006 was performed. OCT data recorded included central macular thickness and the presence or absence of cystic intraretinal fluid, subretinal fluid, or pigment epithelial detachment at the time of the initial injection, at 1-week, 1-month, and 3-month intervals, as well as at the end of follow-up. Visual acuity measurements were recorded using Early Treatment Diabetic Retinopathy Study charts. Any ocular or systemic adverse events were recorded. Statistical analysis was performed to determine if OCT and visual acuity results were significant and to determine if a difference in outcomes existed between previously treated patients and treatment naive patients.
   Results: Fifty-four eyes of 51 patients treated with intravitreal bevacizumab for CNV from AMD were identified. A total of 178 injections were performed. Mean number of days of follow-up was 138 with 91 % of patients having at least 90 days of follow-up. Seventy percent of patients had undergone previous treatment for CNV. The mean number of intravitreal bevacizumab injections per eye was 3.3. Combined treatment with photodynamic therapy was provided in 20% of cases at the initial intravitreal injection. OCT data for all patients revealed an initial mean thickness of 362 Am, which was decreased at 1 week to 278 Am (P = 0.001), 235 Am at 1 month (P < 0.0001), 238 Am at 3 months (P = 0.0004), and 244 Am for the end of follow-up (P < 0.0001). Cystic retinal edema, subretinal fluid, and pigment epithelial detachment resolved in the majority of cases, but pigment epithelial detachment frequently took longer to resolve. Initial mean visual acuity was 20/125 (IogMAR 0.8), and final mean visual acuity was 20/100 (IogMAR 0.7) (P = 0.03). There was no difference in OCT or visual acuity outcomes (P = 0.62 and P = 0.28, respectively) between previously treated and treatment naive patients. There was no difference in OCT or visual acuity outcomes (P = 0.67 and P = 0.21, respectively) between patients who received combination therapy and those who received monotherapy with intravitreal bevacizumab. No systemic or ocular adverse events were recorded.
   Conclusion: Intravitreal bevacizumab for CNV from AMD results in a rapid decrease in OCT-measured retinal thickness in a majority of cases. Visual acuity also improved in this series, suggesting a potential corresponding visual benefit. This series suggests that previously treated and treatment naive patients have similar outcomes.
C1 Calif Pacific Med Ctr, Pacific Vis Fdn, San Francisco, CA USA.
C3 California Pacific Medical Center
RP Johnson, RN (通讯作者)，185 Berry St,Suite 130, San Francisco, CA 94107 USA.
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   MILLER JW, 2005, AM SOC RET SPEC M JU
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
NR 14
TC 57
Z9 61
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR-MAY
PY 2007
VL 27
IS 4
BP 432
EP 438
DI 10.1097/IAE.0b013e318042b53f
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 171AA
UT WOS:000246706100005
PM 17420694
DA 2022-11-30
ER

PT J
AU Klein, R
   Klein, BE
   Knudtson, MD
   Wong, TY
   Shankar, A
   Tsai, MY
AF Klein, R
   Klein, BE
   Knudtson, MD
   Wong, TY
   Shankar, A
   Tsai, MY
TI Systemic markers of inflammation, endothelial dysfunction, and
   age-related maculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BEAVER-DAM EYE; C-REACTIVE PROTEIN; CHLAMYDIA-PNEUMONIAE INFECTION;
   MACULAR DEGENERATION; RISK-FACTORS; CARDIOVASCULAR-DISEASE; 5-YEAR
   INCIDENCE; VISUAL-ACUITY; ASSOCIATION; POPULATION
AB PURPOSE: To examine the association of systemic markers of inflammatory disease and endothelial dysfunction with age-related maculopathy (ARM).
   DESIGN: (1) Nested case,control analysis of prevalent ARM and (2) prospective analyses of incident ARM in a random sample of a population,based cohort.
   METHODS: Standardized protocols for blood collection, measurement of markers, administration of a questionnaire, and gradings of stereoscopic color fundus photography to determine ARM were used. Standard univariate and multivariate analyses were performed. PARTICIPANTS: Included in the nested case,control study were 188 cases with moderate to advanced ARM and 195 controls matched for age, gender, and current smoking status at a baseline examination from 1988 to 1990, and living in Beaver Dam, Wisconsin. Included in the prospective analyses as a random sample of 321 persons were those who participated in a 5,year and/or 10,year follow-up. MAIN OUTCOME MEASURES: Prevalent and incident ARM.
   RESULTS: Serum C,reactive protein, amyloid A, interleukin-6, tumor necrosis factor-alpha, intracellular adhesion molecule, E-selectin, folate, and Chlamydia pneumoniae IgG antibody were not associated with either prevalent or incident ARM.
   CONCLUSION: Contrary to other reports, we cannot confirm a strong or consistent relationship of markers of inflammation and endothelial dysfunction with ARM.
C1 Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
   Univ Melbourne, Dept Ophthalmol, Melbourne, Vic, Australia.
   Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Melbourne; University of Minnesota System; University of
   Minnesota Twin Cities
RP Klein, R (通讯作者)，Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, 610 N Walnut St,460 WARF, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wisc.edu
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Tsai, Michael/0000-0001-7553-3408
FU NEI NIH HHS [EY06594] Funding Source: Medline
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   [Anonymous], [No title captured]
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1143, DOI 10.1001/archopht.119.8.1143
   ERNST E, 1987, JAMA-J AM MED ASSOC, V257, P2318, DOI 10.1001/jama.257.17.2318
   Flower L, 2000, CYTOKINE, V12, P1712, DOI 10.1006/cyto.2000.0764
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hosmer DW, 1989, APPL LOGISTIC REGRES, P238
   Ishida O, 2003, BRIT J OPHTHALMOL, V87, P523, DOI 10.1136/bjo.87.5.523
   Jonas JB, 2004, ARCH OPHTHALMOL-CHIC, V122, P218, DOI 10.1001/archopht.122.2.218
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   KANNEL WB, 1992, JAMA-J AM MED ASSOC, V267, P1253, DOI 10.1001/jama.267.9.1253
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P674, DOI 10.1001/archopht.121.5.674
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   KLEIN R, 1995, BEAVER DAM EYE STUDY, V2
   KLEIN R, 1999, AGE RELATED MACULAR, P31
   KLEIN R, 1991, BEAVER DAM EYE STUDY
   Ledue TB, 2003, CLIN CHEM, V49, P1258, DOI 10.1373/49.8.1258
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Morrison HI, 1996, JAMA-J AM MED ASSOC, V275, P1893, DOI 10.1001/jama.275.24.1893
   PENFOLD PL, 1986, INVEST OPHTH VIS SCI, V27, P364
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   SARKS SH, 1985, PATTERNS MACULAR DEG, P87
   *SAS I INC, 1999, SAT STAT US GUID VER
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   STARKEBAUM G, 1986, J CLIN INVEST, V77, P1370, DOI 10.1172/JCI112442
   THAVASU PW, 1992, J IMMUNOL METHODS, V153, P115, DOI 10.1016/0022-1759(92)90313-I
   Wilkins J, 1998, CLIN CHEM, V44, P1358
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yeh DC, 2004, INVEST OPHTH VIS SCI, V45, P2368, DOI 10.1167/iovs.03-0981
NR 47
TC 74
Z9 81
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2005
VL 140
IS 1
BP 35
EP 44
DI 10.1016/j.ajo.2005.01.051
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 949IN
UT WOS:000230778700006
PM 15939388
DA 2022-11-30
ER

PT J
AU Sun, YW
   Song, RX
   Ai, YL
   Zhu, JJ
   He, J
   Dang, MY
   Li, H
AF Sun, Yiwen
   Song, Ruixia
   Ai, Yanliang
   Zhu, Jianjun
   He, Jun
   Dang, Minyan
   Li, Hui
TI APOE2 promotes the development and progression of subretinal
   neovascularization in age-related macular degeneration via MAPKs
   signaling pathway
SO SAUDI JOURNAL OF BIOLOGICAL SCIENCES
LA English
DT Article
DE APOE2; nvAMD; MAPKs pathway; Inflammatory cytokines
ID RETINAL-PIGMENT EPITHELIUM; APOLIPOPROTEIN-E; CHOROIDAL
   NEOVASCULARIZATION; INFLAMMATION; ISOFORMS; KINASE; SERUM; VEGF; MICE
AB Background: Neovascular age-related macular degeneration (nvAMD) is one of the main pathological features of wet AMD. Apolipoprotein E2 is involved in the formation of nvAMD but the molecular mechanism has not been reported.
   Methods: The APOE alleles in AMD patients were detected by genotyping. Mouse models were divided into 4 groups according to transfection different gene segments and laser-induced treatment. APOE2, VEGF, PDGF-BB, b-FGF and inflammatory cytokines (including p-NF-kappa beta, TNF-alpha, IL-1 beta and IL-6) were tested by ELISA in mice retinal lysate. The formation of nvAMD in the indicated treatment groups at 3rd, 7th and 14th day after laser-induced damage were detected by FFA. Besides, qRT-PCR was used to determine the mRNA levels of p38, JNK and ERK in ARPE-19 cells. Finally, the inflammatory cytokines and MAPK proteins (including P38, p-P38, JNK, p-JNK, ERK and p-ERK) were detected by western blot.
   Results: The statistics of APOE alleles showed that APOE2 allele carriers were more likely to nvAMD. VEGF, PDGF-BB, b-FGF and related inflammatory cytokines were up-regulated significantly after treatment with APOE2, which were reduced after silencing the MAPK family genes, however. Further, the expression levels of neovascular growth factors and inflammatory cytokines were highly consistent between mouse models and ARPE-19 cells. Besides, the phosphorylation levels of p38, JNK and ERK were affected by APOE2.
   Conclusion: nvAMD was affected directly by the overexpression of VEGF, PDGF-BB and b-FGF, which were regulated by APOE2 through activating MAPKs pathway. (C) 2020 The Author(s). Published by Elsevier B.V.
C1 [Sun, Yiwen; Song, Ruixia; Ai, Yanliang; Zhu, Jianjun; He, Jun] Chengwu Cty Peoples Hosp, Dept Ophthalmol, 66 Bole St, Heze 274200, Shandong, Peoples R China.
   [Dang, Minyan] City Univ Hong Kong, Dept Biomed Sci, Kowloon Tong, Hong Kong, Peoples R China.
   [Li, Hui] Heze Municipal Hosp, Dept Ophthalmol, 2888 Caozhou West Rd, Heze 274000, Shandong, Peoples R China.
C3 City University of Hong Kong
RP Li, H (通讯作者)，Heze Municipal Hosp, Dept Ophthalmol, 2888 Caozhou West Rd, Heze 274000, Shandong, Peoples R China.
EM zhan19707cc@163.com
CR Balser C, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1419-2
   Blasiak Janusz, 2013, Front Biosci (Schol Ed), V5, P412
   Busch M, 2018, OPHTHALMOLOGICA, V239, P215, DOI 10.1159/000486404
   Feng M, 2017, BIOMED PHARMACOTHER, V93, P721, DOI 10.1016/j.biopha.2017.07.002
   Kyosseva SV, 2016, OPHTHALMOL EYE DIS, V8, P23, DOI 10.4137/OED.S32200
   Lee SJ, 2007, J MICROBIOL BIOTECHN, V17, P1024
   Levy O, 2015, J NEUROSCI, V35, P13568, DOI 10.1523/JNEUROSCI.2468-15.2015
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Li L, 2020, J CELL PHYSIOL, V235, P1259, DOI 10.1002/jcp.29041
   Liu Y, 2017, ONCOTARGET, V8, P979, DOI 10.18632/oncotarget.13518
   Lotery Goverdhan Thomson, 2013, DRUG DISCOV TODAY DI, V10
   Nagai N, 2009, INVEST OPHTH VIS SCI, V50, P1903, DOI 10.1167/iovs.08-2383
   Novais EA, 2016, AM J OPHTHALMOL, V164, P80, DOI 10.1016/j.ajo.2016.01.011
   Qureshi IZ, 2017, J PAK MED ASSOC, V67, P852
   Roduit R, 2008, APOPTOSIS, V13, P343, DOI 10.1007/s10495-008-0179-8
   SanGiovanni JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071239
   Shah SM, 2006, INVEST OPHTH VIS SCI, V47, P5460, DOI 10.1167/iovs.06-0012
   Siedlecki J, 2017, GRAEF ARCH CLIN EXP, V255, P963, DOI 10.1007/s00417-017-3595-z
   Stewart MW, 2013, EXPERT REV OPHTHALMO, V8, P527, DOI 10.1586/17469899.2013.854705
   Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972
   Tate CM, 2013, J BIOL CHEM, V288, P6743, DOI 10.1074/jbc.M112.425553
   Toops KA, 2016, ADV EXP MED BIOL, V854, P3, DOI 10.1007/978-3-319-17121-0_1
   Vyas D, 2014, ONCOTARGETS THER, V7, P1015, DOI 10.2147/OTT.S60114
   Wang Bartosh, 2014, MAPKS MODULATE RPE R, V3
   Wickremasinghe SS, 2011, INVEST OPHTH VIS SCI, V52, P4072, DOI 10.1167/iovs.10-6550
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yanagi Y, 2019, EYE, V33, P34, DOI 10.1038/s41433-018-0225-x
   Yang P, 2017, INVEST OPHTH VIS SCI, V58, P3073, DOI 10.1167/iovs.16-20083
   Zhang JY, 2019, J OCUL PHARMACOL TH, V35, P116, DOI 10.1089/jop.2018.0092
NR 29
TC 3
Z9 4
U1 2
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1319-562X
EI 2213-7106
J9 SAUDI J BIOL SCI
JI Saudi J. Biol. Sci.
PD OCT
PY 2020
VL 27
IS 10
BP 2770
EP 2777
DI 10.1016/j.sjbs.2020.06.037
PG 8
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA NQ6JT
UT WOS:000570978100007
PM 32994736
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Tew, TB
   Lai, TT
   Hsieh, YT
   Ho, TC
   Yang, CM
   Yang, CH
AF Tew, Teck Boon
   Lai, Tso-Ting
   Hsieh, Yi-Ting
   Ho, Tzyy-Chang
   Yang, Chung-May
   Yang, Chang-Hao
TI Comparison of different morphologies of choroidal neovascularization
   evaluated by ocular coherence tomography angiography in age-related
   macular degeneration
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; anti-vascular endothelial growth
   factor; choroidal neovascularisation; ocular coherence tomography
   angiography; retinal imaging
ID INDOCYANINE-GREEN ANGIOGRAPHY; FLUORESCEIN ANGIOGRAPHY; PACHYCHOROID
   NEOVASCULOPATHY; RANIBIZUMAB; BIOMARKERS; THERAPY; AFLIBERCEPT
AB Importance The clinical implications of different morphologies of choroidal neovascularization (CNV), as evaluated by ocular coherence tomography angiography (OCTA) in neovascular age-related macular degeneration (nAMD), are lacking. Background To describe the morphology of CNV in nAMD using OCTA, and to compare the visual prognosis and other structural OCT biomarkers between different morphologic patterns. Design Retrospective cohort study. Participants One hundred and forty eyes with nAMD treated with anti-vascular endothelial growth factor (VEGF). Methods Patients were examined using OCTA prior to and at 3, 6 and 12 months after receiving anti-VEGF therapy. Main Outcome Measures Best-corrected visual acuity (BCVA) and morphologic retinal features. Results Organized CNV was identified in 110/140 eyes (78.6%) using OCTA. These CNV complexes could be divided into three OCTA patterns: the 'medusa' pattern (n = 41), characterized by branching vessels radiating in all directions; the 'seafan' pattern (n = 43), characterized by branching vessels radiating to one side of the lesion; and the 'tangled' pattern (n = 26), characterized by globular entwined vessels without a main trunk. At baseline, the eyes with the tangled pattern were from younger patients (P= .031) with better BCVA (P= .007). There were also fewer intraretinal cysts (P= .021), less fibrovascular pigment epithelial detachment (P= .009), and more pachychoroid (P= .007) in eyes with the tangled pattern on OCT. At 12 months post-treatment, patients with the tangled CNV pattern also showed greater visual improvement than patients with the other two patterns (P= .049). Conclusions and Relevance Using OCTA, distinct morphologies of CNV in nAMD patients were identified. These different patterns might be useful predictors for the prognosis of nAMD patients after anti-VEGF therapy.
C1 [Tew, Teck Boon; Lai, Tso-Ting; Hsieh, Yi-Ting; Ho, Tzyy-Chang; Yang, Chung-May; Yang, Chang-Hao] Natl Taiwan Univ Hosp, Dept Ophthalmol, 7 Chun Shan S Rd, Taipei 100, Taiwan.
   [Tew, Teck Boon] Natl Taiwan Univ Hosp, Dept Ophthalmol, Hsinchu Branch, Hsinchu, Taiwan.
   [Ho, Tzyy-Chang; Yang, Chung-May; Yang, Chang-Hao] Natl Taiwan Univ, Dept Ophthalmol, Coll Med, Taipei, Taiwan.
C3 National Taiwan University; National Taiwan University Hospital;
   National Taiwan University; National Taiwan University Hospital;
   National Taiwan University
RP Yang, CH (通讯作者)，Natl Taiwan Univ Hosp, Dept Ophthalmol, 7 Chun Shan S Rd, Taipei 100, Taiwan.
EM chyangoph@ntu.edu.tw
RI Yang, Chang-Hao/AAR-3759-2021
OI Tew, Teck-Boon/0000-0003-3216-9540; Lai, Tso-Ting/0000-0002-8247-7018;
   YANG, CHUNG-MAY/0000-0003-4082-420X; YANG,
   CHANG-HAO/0000-0002-4328-8716; Hsieh, Yi-Ting/0000-0003-2258-154X
CR Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   Bloch SB, 2013, ACTA OPHTHALMOL, V91, P42, DOI 10.1111/j.1755-3768.2011.02268.x
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Eandi CM, 2017, INVEST OPHTH VIS SCI, V58, P3690, DOI 10.1167/iovs.17-21941
   Ersoz MG, 2018, BRIT J OPHTHALMOL, V102, P473, DOI 10.1136/bjophthalmol-2017-310724
   Forte R, 2020, BRIT J OPHTHALMOL, V104, P1057, DOI 10.1136/bjophthalmol-2019-315189
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Hata M, 2017, INVEST OPHTH VIS SCI, V58, P292, DOI 10.1167/iovs.16-20967
   Huang D, 2015, RETINA-J RET VIT DIS, V35, P2260, DOI 10.1097/IAE.0000000000000846
   Inoue M, 2016, INVEST OPHTH VIS SCI, V57, pOCT314, DOI 10.1167/iovs.15-18900
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Khanani AM, 2018, RETINA-J RET VIT DIS, V38, P2103, DOI 10.1097/IAE.0000000000002195
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lai TT, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36704-6
   Liang MC, 2016, RETINA-J RET VIT DIS, V36, P2265, DOI 10.1097/IAE.0000000000001102
   Lindner M, 2016, INVEST OPHTH VIS SCI, V57, P6342, DOI 10.1167/iovs.16-19741
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsumoto H, 2018, JPN J OPHTHALMOL, V62, P144, DOI 10.1007/s10384-018-0562-0
   Miere A, 2019, RETINA-J RET VIT DIS, V39, P548, DOI 10.1097/IAE.0000000000001964
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schneider U, 1996, GER J OPHTHALMOL, V5, P6
   Semoun O, 2009, BRIT J OPHTHALMOL, V93, P182, DOI 10.1136/bjo.2008.145235
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Sulzbacher F, 2011, AM J OPHTHALMOL, V152, P799, DOI 10.1016/j.ajo.2011.04.011
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Watzke RC, 2000, OPHTHALMOLOGY, V107, P1601, DOI 10.1016/S0161-6420(00)00218-9
   Wolf S, 1996, GER J OPHTHALMOL, V5, P251
NR 33
TC 2
Z9 2
U1 1
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD SEP
PY 2020
VL 48
IS 7
BP 927
EP 937
DI 10.1111/ceo.13797
EA JUN 2020
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NY9LU
UT WOS:000541426800001
PM 32458526
DA 2022-11-30
ER

PT J
AU McGuinness, MB
   Fraser, RG
   Tan, R
   Luu, CD
   Guymer, RH
AF McGuinness, Myra B.
   Fraser, Rogan G.
   Tan, Rose
   Luu, Chi D.
   Guymer, Robyn H.
TI Relationship Between Rod-Mediated Sensitivity, Low-Luminance Visual
   Acuity, and Night Vision Questionnaire in Age-Related Macular
   Degeneration
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE age-related macular degeneration; rods; dark adaptation; visual field;
   night vision
ID SUBRETINAL DRUSENOID DEPOSITS; DARK-ADAPTATION; RETICULAR PSEUDODRUSEN;
   DYSFUNCTION
AB Purpose: To quantify the association between dark adaptation parameters and other clinical measures of visual function among people with and without early and intermediate age-related macular degeneration (AMD).
   Methods: In this cross-sectional study, participants underwent multimodal imaging and visual function testing, including best-corrected visual acuity (BCVA), low-luminance visual acuity (LLVA), low-luminance deficit (LLD = BCVA - LLVA) and the 10-item Night Vision Questionnaire (NVQ-10). Dynamic and static dark-adapted chromatic perimetry (DACP) was performed. Sensitivity difference was defined as the difference in sensitivity between the 505-nm and 625-nm stimuli. Rod intercept time (RIT) was estimated as the time required to reach a threshold of -3 log candelas/meter(2) with the 505-nm stimulus following bleaching. The magnitude of association between the DACP parameters and other clinical tests was estimated via mixed-effects regression.
   Results: A total of 51 participants (aged 51-88 years, 65% female, 39% with AMD) were included. RIT was found to be negatively associated with BCVA (P < 0.001), LLVA (P = 0.005), and NVQ-10 score (P = 0.028) but not LLD (P = 0.763). There was no evidence of an association between sensitivity difference and any of the clinical measures (P >= 0.081).
   Conclusions: Reduced rod function, as determined by RIT, was associated with lower NVQ-10 scores (designed to interrogate rod-mediated function) and with worse BCVA and LLVA (measures of cone function).
   Translational Relevance: Decreasing rod function maybe indicative of more generalized photoreceptor dysfunction involving cones. Further development of questionnaires to target function in scotopic conditions may provide an easier to administer test without the need to perform perimetric tests of rod function.
C1 [McGuinness, Myra B.; Fraser, Rogan G.; Tan, Rose; Luu, Chi D.; Guymer, Robyn H.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic, Australia.
   [Tan, Rose; Luu, Chi D.; Guymer, Robyn H.] Univ Melbourne, Dept Surg Ophthalmol, East Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP McGuinness, MB (通讯作者)，Ctr Eye Res Australia, Level 7,Peter Howson Wing,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM myra.mcguinness@uninnelb.edu.au
RI McGuinness, Myra/G-4900-2017
OI McGuinness, Myra/0000-0002-5422-040X; Rose, Rose/0000-0002-7351-2774
FU Macular Disease Foundation Australia; Australia Awards Scholarship;
   National Health and Medical Research Council (NHMRC) [1103013];
   Victorian government
FX Supported by Macular Disease Foundation Australia, Australia Awards
   Scholarship (RT), National Health and Medical Research Council (NHMRC)
   Fellowship (#1103013, RHG). The Centre for Eye Research Australia
   receives Operational Infrastructure Support from the Victorian
   government.
CR Chandramohan A, 2016, RETINA-J RET VIT DIS, V36, P1021, DOI 10.1097/IAE.0000000000001002
   Cocce KJ, 2018, AM J OPHTHALMOL, V189, P127, DOI 10.1016/j.ajo.2018.02.012
   Colville D, 2003, AM J KIDNEY DIS, V42, DOI 10.1016/S0272-6386(03)00665-6
   Danuso F., 1991, SG1 NONLINEAR REGRES
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2019, OPHTHALMOLOGICA, V241, P61, DOI 10.1159/000491402
   Finger RP, 2011, INVEST OPHTH VIS SCI, V52, P8241, DOI 10.1167/iovs.11-7858
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Fraser RG, 2016, INVEST OPHTH VIS SCI, V57, P5436, DOI 10.1167/iovs.16-19295
   Gattamorta KA, 2012, INT J TEST, V12, P252, DOI 10.1080/15305058.2011.630546
   Hussaini SH, 1998, EYE, V12, P419, DOI 10.1038/eye.1998.99
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Jackson Gregory R, 2008, J Ocul Biol Dis Infor, V1, P7, DOI 10.1007/s12177-008-9002-6
   Kimlin JA, 2016, OPHTHAL PHYSL OPT, V36, P465, DOI 10.1111/opo.12307
   KLEIN R, 1983, OPHTHALMOLOGY, V90, P1357
   LAMB TD, 1981, VISION RES, V21, P1773, DOI 10.1016/0042-6989(81)90211-X
   McGuinness MB, 2019, TRANSL VIS SCI TECHN, V8
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Myers AM, 2008, ARCH PHYS MED REHAB, V89, P630, DOI 10.1016/j.apmr.2007.09.037
   Nguyen CT, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.17-23084
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.3.15
   Pianta MJ, 2000, J PHYSIOL-LONDON, V528, P591, DOI 10.1111/j.1469-7793.2000.00591.x
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Tan R, 2018, INVEST OPHTH VIS SCI, V59, P4154, DOI 10.1167/iovs.18-23970
   Tan RS, 2019, INVEST OPHTH VIS SCI, V60, P1511, DOI 10.1167/iovs.18-26385
   Tan RS, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.3.3
   Thylefors B, 2002, OPHTHALMIC EPIDEMIOL, V9, P83, DOI 10.1076/opep.9.2.83.1523
   Wu ZC, 2016, BRIT J OPHTHALMOL, V100, P395, DOI 10.1136/bjophthalmol-2015-306621
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
   Yazdanie M, 2017, OPHTHALMOLOGY, V124, P1332, DOI 10.1016/j.ophtha.2017.05.005
   Ying GS, 2008, OPHTHALMOLOGY, V115, P1876, DOI 10.1016/j.ophtha.2008.05.023
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 40
TC 3
Z9 3
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD MAY
PY 2020
VL 9
IS 6
AR 30
DI 10.1167/tvst.9.6.30
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MJ6NY
UT WOS:000548205800001
PM 32821527
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Boyle, J
   Vukicevic, M
   Koklanis, K
   Itsiopoulos, C
   Rees, G
AF Boyle, Jessica
   Vukicevic, Meri
   Koklanis, Konstandina
   Itsiopoulos, Catherine
   Rees, Gwyneth
TI Experiences of patients undergoing repeated intravitreal anti-vascular
   endothelial growth factor injections for neovascular age-related macular
   degeneration
SO PSYCHOLOGY HEALTH & MEDICINE
LA English
DT Article
DE Age-related macular degeneration; exudative maculopathies; neovascular;
   intravitreal injection; anti-VEGF; treatment; patient experience; burden
ID ANTI-VEGF DRUGS; REAL-LIFE; RANIBIZUMAB
AB Current therapy to slow disease progression in patients with neovascular age-related macular degeneration (AMD) entails regular intravitreal anti-vascular endothelial growth factor (VEGF) injections, often indefinitely. Little is known about the burden imposed on patients by this repetitive treatment schedule and how this can be best managed. The aim of this study was to explore the psychosocial impact of repeated intravitreal injections on patients with neovascular AMD. Forty patients (16 males, 24 females) with neovascular AMD undergoing anti-VEGF treatment were recruited using purposive sampling from a private ophthalmology practice and public hospital in Melbourne. Patients were surveyed using the Macular Disease Treatment Satisfaction Questionnaire (MacTSQ; Bradley, Health Psychology Research Unit, Surrey, England) and underwent semi-structured, one-on-one interviews. Interview topics were: treatment burden and satisfaction; tolerability; barriers to adherence; treatment motivation; and patient education. Interviews were audio recorded and thematic analysis performed using NVivo 10 (QSR International, Doncaster, Australia). Patients recognised the importance of treatment to preserve eyesight, yet experienced significant psychosocial and practical burden from the treatment schedule. Important issues included treatment-related anxiety, financial considerations and transport burden placed on relatives or carers. Many patients were restricted to sedentary activities post-injection owing to treatment side effects. Patients prioritised treatment, often sacrificing family, travel and social commitments owing to a fear of losing eyesight if treatment was not received. Whilst anti-VEGF injections represent the current mainstay of treatment for neovascular AMD, the ongoing treatment protocol imposes significant burden on patients. An understanding of the factors that contribute to the burden of treatment may help inform strategies to lessen its impact and assist patients to better manage the challenges of treatment.
C1 [Boyle, Jessica; Vukicevic, Meri; Koklanis, Konstandina] La Trobe Univ, Dept Community & Clin Allied Hlth, Melbourne, Vic, Australia.
   [Boyle, Jessica; Vukicevic, Meri] Cabrini Med Hosp, Eye Surg Associates, Malvern, Australia.
   [Koklanis, Konstandina] Royal Childrens Hosp, Dept Ophthalmol, Melbourne, Vic, Australia.
   [Itsiopoulos, Catherine] La Trobe Univ, Dept Rehabil Nutr & Sport, Melbourne, Vic, Australia.
   [Rees, Gwyneth] Royal Victorian Eye & Ear Hosp, Ctr Eye Res, East Melbourne, Australia.
   [Rees, Gwyneth] Univ Melbourne, Dept Surg, Melbourne, Vic, Australia.
C3 La Trobe University; Cabrini Health; Royal Children's Hospital
   Melbourne; La Trobe University; Centre for Eye Research Australia; Royal
   Victorian Eye & Ear Hospital; University of Melbourne
RP Boyle, J (通讯作者)，La Trobe Univ, Dept Community & Clin Allied Hlth, Melbourne, Vic, Australia.; Boyle, J (通讯作者)，Cabrini Med Hosp, Eye Surg Associates, Malvern, Australia.
EM jess.boyle@latrobe.edu.au
OI Vukicevic, Meri/0000-0002-0887-6248
FU Bayer Australia Ltd; Orthoptics Australia (Victorian Branch) Small
   Project Research Grant; La Trobe University Postgraduate Support Grant;
   La Trobe University Postgraduate Research Scholarship
FX This work was supported by an investigator-initiated research grant from
   Bayer Australia Ltd, an Orthoptics Australia (Victorian Branch) Small
   Project Research Grant and a La Trobe University Postgraduate Support
   Grant. This research was carried out whilst the first author was the
   recipient holder of a La Trobe University Postgraduate Research
   Scholarship. The authors do not have any financial interest in the
   material presented.
CR Avci R., 2013, ASRS 31 ANN M TOR
   Blaha GR, 2011, RETINA-J RET VIT DIS, V31, P535, DOI 10.1097/IAE.0b013e3181eac724
   Boyle J, 2015, PSYCHOL HEALTH MED, V20, P296, DOI 10.1080/13548506.2014.936886
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Charmaz Kathy, 2014, CONSTRUCTING GROUNDE, V2nd
   Chua P., 2009, OPHTHALMOLOGY, V116, P939, DOI [10.1016/j.ophtha.2008.12.025, DOI 10.1016/J.OPHTHA.2008.12.025]
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Droege KM, 2013, GRAEF ARCH CLIN EXP, V251, P1281, DOI 10.1007/s00417-012-2177-3
   Gohil R, 2016, PATIENT PREFER ADHER, V10, P949, DOI 10.2147/PPA.S105536
   Henriksen K., 2013, INT J OPHTHALMIC PRA, V1, P68, DOI [10.12968/ijop.2010.1.2.68, DOI 10.12968/ijop.2010.1.2.68, DOI 10.12968/IJOP.2010.1.2.68]
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   LaHood BR, 2011, CLIN EXP OPHTHALMOL, V39, P184, DOI 10.1111/j.1442-9071.2010.02432.x
   Mitchell J., 2007, INT SOC QUAL LIF RES
   Regillo CD, 2014, RETINA TODAY, P63
   Rifkin L, 2012, RETINA-J RET VIT DIS, V32, P696, DOI 10.1097/IAE.0b013e3182252ad3
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Roth DB, 2006, AM J OPHTHALMOL, V142, P492, DOI 10.1016/j.ajo.2006.03.042
   Royal College of Ophthalmologists (UK), 2013, AG REL MAC DEG GUID
   Semeraro F, 2013, DRUG DES DEV THER, V7, P711, DOI 10.2147/DDDT.S40215
   Semeraro F, 2015, CURR DRUG METAB, V16, P572, DOI 10.2174/1389200216666151001120831
   Semeraro F, 2014, EXPERT OPIN DRUG SAF, V13, P785, DOI 10.1517/14740338.2014.911284
   Tailor R, 2011, CLIN OPHTHALMOL, V5, P1499, DOI 10.2147/OPTH.S24358
   Thetford C, 2013, BRIT J VISUAL IMPA, V31, P89, DOI 10.1177/0264619613481778
   Yau GL, 2011, AM J OPHTHALMOL, V151, P333, DOI 10.1016/j.ajo.2010.08.031
   Zinkernagel MS, 2015, INVEST OPHTH VIS SCI, V56, P1894, DOI 10.1167/iovs.14-16204
NR 27
TC 38
Z9 38
U1 1
U2 19
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1354-8506
EI 1465-3966
J9 PSYCHOL HEALTH MED
JI Psychol. Health Med.
PY 2018
VL 23
IS 2
BP 127
EP 140
DI 10.1080/13548506.2016.1274040
PG 14
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health
GA FP4RU
UT WOS:000417604900001
DA 2022-11-30
ER

PT J
AU Patel, PJ
   Chen, FK
   Da Cruz, L
   Rubin, GS
   Tufail, A
AF Patel, Praveen J.
   Chen, Fred K.
   Da Cruz, Lyndon
   Rubin, Gary S.
   Tufail, Adnan
CA ABC Trial Study Grp
TI Contrast Sensitivity Outcomes in the ABC Trial: A Randomized Trial of
   Bevacizumab for Neovascular Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; VISUAL-ACUITY; PHOTODYNAMIC THERAPY;
   VERTEPORFIN; RANIBIZUMAB; ASSOCIATION; IMPAIRMENT; PERCEPTION;
   DISABILITY; SEE
AB PURPOSE. To report the impact of intravitreous bevacizumab therapy on contrast sensitivity in patients with neovascular age-related macular degeneration (nAMD).
   METHODS. This was a prospective, multicenter, double-masked, randomized, controlled trial of 131 patients with nAMD. The patients with nAMD had received intravitreal bevacizumab (n = 65) or standard therapy (n = 66) in the study eye with a 6-week cycle of assessment. The bevacizumab treatment was 1.25 mg/0.05 mL, given as three initial treatments with further retreatment as needed according to standard retreatment criteria and a 1-year (54-week) follow-up. Contrast sensitivity was determined during the study using a Pelli-Robson chart.
   RESULTS. At the week-54 examination, bevacizumab-treated patients were more likely to gain at least 6 letters or more of contrast sensitivity than the patients receiving standard care (23 [35.4%] versus 10 [15.2%], P = 0.009). In addition the bevacizumab-treated patients were less likely to lose 6 or more letters with a better mean letter change at week 54 than the patients receiving standard care (3 [4.6%] versus 14 [21.2%], and +4.0 versus -0.7 letters; P < 0.05 for both comparisons).
   CONCLUSIONS. Consistent with the visual acuity outcomes, bevacizumab improved the chances of a clinically relevant gain in contrast sensitivity in the study population. Given the association between contrast sensitivity and visual disability, the beneficial effects of bevacizumab therapy on contrast sensitivity outcomes are expected to have a favorable impact on patients' daily activities. (www.controlledtrials.com number, ISRCTN83325075.) (Invest Ophthalmol Vis Sci. 2011;52:3089-3093) DOI:10.1167/iovs.10-6208
C1 [Patel, Praveen J.; Chen, Fred K.; Da Cruz, Lyndon; Rubin, Gary S.; Tufail, Adnan] Moorfields Eye Hosp, NIHR, Biomed Res Ctr Ophthalmol, London EC1V 2PD, England.
   [Patel, Praveen J.; Chen, Fred K.; Da Cruz, Lyndon; Rubin, Gary S.; Tufail, Adnan] UCL Inst Ophthalmol, London EC1V 2PD, England.
C3 University of London; King's College London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; University of London;
   University College London
RP Patel, PJ (通讯作者)，Moorfields Eye Hosp, NIHR, Biomed Res Ctr Ophthalmol, 162 City Rd, London EC1V 2PD, England.
EM praveen.patel@moorfields.nhs.uk
RI , Fred/B-8158-2013; Aslam, Tariq/A-8532-2016
OI , Fred/0000-0003-2809-9930; Richardson, Matthew/0000-0002-7390-9480;
   Sivaprasad, Sobha/0000-0001-8952-0659; Fraser-Bell,
   Samantha/0000-0001-5646-9359; Aslam, Tariq/0000-0002-9739-7280; Bunce,
   Catey/0000-0002-0935-3713; Tufail, Adnan/0000-0001-6131-7640
FU Special Trustees of Moorfields Eye Hospital; Department of Health's NIHR
   Biomedical Research Centre for Ophthalmology at Moorfields Eye Hospital;
   UCL Institute of Ophthalmology; Medical Research Council [G0700729B]
   Funding Source: researchfish
FX Supported by The Special Trustees of Moorfields Eye Hospital. This
   research has received a proportion of its funding from the Department of
   Health's NIHR Biomedical Research Centre for Ophthalmology at Moorfields
   Eye Hospital and UCL Institute of Ophthalmology. The views expressed in
   the publication are those of the authors and not necessarily those of
   the Department of Health.
CR Bansback N, 2007, QUAL LIFE RES, V16, P533, DOI 10.1007/s11136-006-9126-8
   Bellmann C, 2003, GRAEF ARCH CLIN EXP, V241, P968, DOI 10.1007/s00417-003-0689-6
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   ELLIOTT DB, 1991, CLIN VISION SCI, V6, P471
   Fletcher DC, 2006, OPTOMETRY VISION SCI, V83, P178, DOI 10.1097/01.opx.0000204510.08026.7f
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   OWSLEY C, 1987, BRIT J OPHTHALMOL, V71, P791, DOI 10.1136/bjo.71.10.791
   OWSLEY C, 1981, INVEST OPHTH VIS SCI, V21, P362
   Patel PJ, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-56
   Patel PJ, 2009, INVEST OPHTH VIS SCI, V50, P2621, DOI 10.1167/iovs.08-2407
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rubin GS, 2002, RETINA-J RET VIT DIS, V22, P536, DOI 10.1097/00006982-200210000-00002
   Rubin GS, 2001, INVEST OPHTH VIS SCI, V42, P64
   Rubin GS, 1997, INVEST OPHTH VIS SCI, V38, P557
   RUBIN GS, 1994, OPTOMETRY VISION SCI, V71, P750, DOI 10.1097/00006324-199412000-00005
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
NR 17
TC 14
Z9 14
U1 0
U2 9
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2011
VL 52
IS 6
BP 3089
EP 3093
DI 10.1167/iovs.10-6208
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 770PN
UT WOS:000291100800030
PM 21310910
DA 2022-11-30
ER

PT J
AU Biswas, L
   Ibrahim, KS
   Li, X
   Zhou, XZ
   Zeng, ZH
   Craft, J
   Shu, XH
AF Biswas, Lincoln
   Ibrahim, Khalid Subhi
   Li, Xing
   Zhou, Xinzhi
   Zeng, Zhihong
   Craft, John
   Shu, Xinhua
TI Effect of a TSPO ligand on retinal pigment epithelial cholesterol
   homeostasis in high-fat fed mice, implication for age-related macular
   degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE TSPO ligand; Etifoxine; Cholesterol homeostasis; Retinal pigment
   epithelial cells; Age related macular degeneration
ID GUT MICROBIOTA; OXIDATIVE STRESS; DIET; OBESITY; INFLAMMATION;
   METABOLISM; DISEASE; EFFLUX; AMD; PURIFICATION
AB Age-related Macular Degeneration (AMD) is a major cause of sight impairment in the elderly with complex aetiology involving genetics and environment and with limited therapeutic options which have limited efficacy. We have previously shown in a mouse-model of the condition, induced by feeding a high fat diet, that adverse effects of the diet can be reversed by co-administration of the TSPO activator, etifoxine. We extend those observations showing improvements in retinal pigment epithelial (RPE) cells with decreased lipids and enhanced expression of cholesterol metabolism and transport enzymes. Further, etifoxine decreased levels of reactive oxygen species (ROS) in RPE and inflammatory cytokines in RPE and serum. With respect to gut microbiome, we found that organisms abundant in the high fat condition (e.g. in the genus Anaerotruncus and Oscillospira) and implicated in AMD, were much less abundant after etifoxine treatment. The changes in gut flora were associated with the predicted production of metabolites of benefit to the retina including tryptophan and other amino acids and taurine, an essential component of the retina necessary to counteract ROS. These novel observations strengthen earlier conclusions that the mechanisms behind improvements in etifoxine-induced retinal physiology involve an interaction between effects on the host and the gut microbiome.
C1 [Biswas, Lincoln; Ibrahim, Khalid Subhi; Zhou, Xinzhi; Craft, John; Shu, Xinhua] Glasgow Caledonian Univ, Dept Biol & Biomed Sci, Glasgow, Lanark, Scotland.
   [Shu, Xinhua] Glasgow Caledonian Univ, Dept Vis Sci, Glasgow, Lanark, Scotland.
   [Li, Xing; Shu, Xinhua] Shaoyang Univ, Sch Basic Med Sci, Shaoyang 422000, Peoples R China.
   [Zeng, Zhihong] Changsha Univ, Coll Biol & Environm Engn, Changsha 410022, Hunan, Peoples R China.
   [Ibrahim, Khalid Subhi] Univ Zakho, Fac Sci, Dept Biol, Duhok, Kurdistan Regio, Iraq.
C3 Glasgow Caledonian University; Glasgow Caledonian University; Shaoyang
   University; Changsha University
RP Shu, XH (通讯作者)，Glasgow Caledonian Univ, Dept Biol & Biomed Sci, Glasgow, Lanark, Scotland.
EM xinhua.shu@gcu.ac.uk
RI Zeng, Zhihong/HEV-8703-2022
OI IBRAHIM, KHALID/0000-0002-8585-3429
FU Rosetrees Trust [M160, M160-F1, M160-F2]; National Eye Research Centre
   [SAC037]; Tenovus Scotland [S20-02]; Scottish Universities Life Sciences
   Alliance; Lotus Scholarship Program of Hunan Province (2019)
FX This work was supported by the Rosetrees Trust (M160, M160-F1, M160-F2),
   National Eye Research Centre (SAC037), Tenovus Scotland (S20-02),
   Scottish Universities Life Sciences Alliance and the Lotus Scholarship
   Program of Hunan Province (2019). X.S. is a visiting professor to
   Shaoyang University.
CR Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Agus A, 2018, CELL HOST MICROBE, V23, P716, DOI 10.1016/j.chom.2018.05.003
   Al-Janabi A, 2018, EYE, V32, P981, DOI 10.1038/s41433-018-0066-7
   Alkhalaf LM, 2015, CHEM BIOL, V22, P317, DOI 10.1016/j.chembiol.2015.02.005
   Andriessen EMMA, 2016, EMBO MOL MED, V8, P1366, DOI 10.15252/emmm.201606531
   Arfuzir NNN, 2018, NEURAL REGEN RES, V13, P2014, DOI 10.4103/1673-5374.239450
   Barathi VA, 2014, INVEST OPHTH VIS SCI, V55, P460, DOI 10.1167/iovs.13-11636
   Barouei J, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201700184
   BEAN B, 1977, J BACTERIOL, V130, P571, DOI 10.1128/JB.130.1.571-574.1977
   Bischoff SC, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/s12876-014-0189-7
   Biswas L, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123740
   Biswas L, 2017, HUM MOL GENET, V26, P4327, DOI 10.1093/hmg/ddx319
   Cani PD, 2008, DIABETES, V57, P1470, DOI 10.2337/db07-1403
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Clarke SF, 2012, GUT MICROBES, V3, P186, DOI 10.4161/gmic.20168
   Crusell MKW, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0472-x
   Cui J, 2012, NUTRITION, V28, P275, DOI 10.1016/j.nut.2011.10.016
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Dasari B, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-22
   Ershov AV, 2000, J NEUROSCI RES, V60, P328, DOI 10.1002/(SICI)1097-4547(20000501)60:3<328::AID-JNR7>3.0.CO;2-5
   Fischbach MA, 2016, CELL, V164, P1288, DOI 10.1016/j.cell.2016.02.037
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Froger N, 2014, PROG RETIN EYE RES, V41, P44, DOI 10.1016/j.preteyeres.2014.03.001
   Froger N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042017
   Fukui Hiroshi, 2016, Inflamm Intest Dis, V1, P135, DOI 10.1159/000447252
   Gao HC, 2019, BBA-MOL BASIS DIS, V1865, DOI 10.1016/j.bbadis.2019.165541
   Grassmann F, 2015, EUR J PHARM BIOPHARM, V95, P194, DOI 10.1016/j.ejpb.2015.04.039
   Gupta R, 2004, APPL MICROBIOL BIOT, V64, P763, DOI 10.1007/s00253-004-1568-8
   Hermann M, 2012, ACTA OPHTHALMOL, V90, pe500, DOI 10.1111/j.1755-3768.2011.02347.x
   Hills RD, 2019, NUTRIENTS, V11, DOI 10.3390/nu11071613
   Ibrahim KS, 2020, BIOCHEM PHARMACOL, V180, DOI 10.1016/j.bcp.2020.114151
   Johnson EL, 2017, J MOL MED, V95, P1, DOI 10.1007/s00109-016-1492-2
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Kho ZY, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01835
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Lagkouvardos I, 2019, MICROBIOME, V7, DOI 10.1186/s40168-019-0637-2
   Langille MGI, 2013, NAT BIOTECHNOL, V31, P814, DOI 10.1038/nbt.2676
   Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/4441022a
   Luissint AC, 2016, GASTROENTEROLOGY, V151, P616, DOI 10.1053/j.gastro.2016.07.008
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Martin CR, 2018, CELL MOL GASTROENTER, V6, P133, DOI 10.1016/j.jcmgh.2018.04.003
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mohr AE, 2020, J INT SOC SPORT NUTR, V17, DOI 10.1186/s12970-020-00353-w
   Morton JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10656-5
   Nagai N, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-01483-2
   Nashine S, 2020, AGING-US, V12, P9031, DOI 10.18632/aging.103164
   Natividad JM, 2018, CELL METAB, V28, P737, DOI 10.1016/j.cmet.2018.07.001
   O'Mahony SM, 2015, BEHAV BRAIN RES, V277, P32, DOI 10.1016/j.bbr.2014.07.027
   Oshitari T, 2002, NEUROREPORT, V13, P2109, DOI 10.1097/00001756-200211150-00023
   Ozal SA, 2018, CURR EYE RES, V43, P1169, DOI 10.1080/02713683.2018.1481517
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Qiao Y, 2013, APPL MICROBIOL BIOT, V97, P1689, DOI 10.1007/s00253-012-4323-6
   RAETZ CRH, 1976, J BACTERIOL, V125, P855, DOI 10.1128/JB.125.3.855-863.1976
   Rinninella E, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111677
   Rodriguez-Carrio J, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00823
   Rowan S, 2018, GUT MICROBES, V9, P452, DOI 10.1080/19490976.2018.1435247
   Rowan S, 2017, P NATL ACAD SCI USA, V114, pE4472, DOI 10.1073/pnas.1702302114
   Rowland I, 2018, EUR J NUTR, V57, P1, DOI 10.1007/s00394-017-1445-8
   Rudolf M, 2009, J HISTOCHEM CYTOCHEM, V57, P731, DOI 10.1369/jhc.2009.953448
   Schoeler M, 2019, REV ENDOCR METAB DIS, V20, P461, DOI 10.1007/s11154-019-09512-0
   Seidel U, 2019, MOL NUTR FOOD RES, V63, DOI 10.1002/mnfr.201800569
   Senghor B, 2018, HUM MICROBIOM J, V7, P1, DOI DOI 10.1016/J.HUMIC.2018.01.001
   Serino M, 2012, GUT, V61, P543, DOI 10.1136/gutjnl-2011-301012
   Shoelson SE, 2007, GASTROENTEROLOGY, V132, P2169, DOI 10.1053/j.gastro.2007.03.059
   Storti F, 2017, EXP EYE RES, V165, P65, DOI 10.1016/j.exer.2017.09.008
   Tang JP, 2009, BIORESOURCE TECHNOL, V100, P4848, DOI 10.1016/j.biortech.2009.04.045
   Tao Y, 2019, DRUG DES DEV THER, V13, P2689, DOI 10.2147/DDDT.S194169
   Tarchick MJ, 2019, EXP EYE RES, V180, P63, DOI 10.1016/j.exer.2018.11.020
   Tawarayama H, 2022, OCUL IMMUNOL INFLAMM, V30, P789, DOI 10.1080/09273948.2020.1833224
   Togo A. H., 2019, New Microbes and New Infections, V29, P100508, DOI 10.1016/j.nmni.2019.01.004
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Tuzcu M, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0524-1
   Vacca M, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8040573
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   Velazquez KT, 2019, WORLD J HEPATOL, V11, P619, DOI 10.4254/wjh.v11.i8.619
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Yang RL, 2008, NUTRITION, V24, P582, DOI 10.1016/j.nut.2008.02.002
   Yee KH, 2019, DIABETIC MED, V36, P784, DOI 10.1111/dme.13928
   Zhang MY, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60160-w
   Zinkernagel M.S., 2017, SCI CREP, V7, P1
NR 84
TC 5
Z9 5
U1 0
U2 4
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUL
PY 2021
VL 208
AR 108625
DI 10.1016/j.exer.2021.108625
EA MAY 2021
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SV3WE
UT WOS:000663751900004
PM 34022174
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Virgili, G
   Novielli, N
   Menchini, F
   Murro, V
   Giacomelli, G
AF Virgili, Gianni
   Novielli, Nicola
   Menchini, Francesca
   Murro, Vittoria
   Giacomelli, Giovanni
TI Pharmacological Treatments for Neovascular Age-Related Macular
   Degeneration: Can Mixed Treatment Comparison Meta-Analysis be Useful?
SO CURRENT DRUG TARGETS
LA English
DT Review
DE Age related macular degeneration; mixed treatments; multivariate
   analysis
ID RANIBIZUMAB; VERTEPORFIN; TRIAL
AB Objective: To investigate the use of mixed treatment comparison (MTC) meta-analysis models to summarize results from randomized clinical trials (RCTs) on approved pharmacological treatments for neovascular age-related macular degeneration (AMD). Methods: The number of patients with visual loss or visual gain of 3 or more lines of visual acuity (15 ETDRS letters) at 1 year was extracted from 10 RCTs including patients with neovascular AMD and comparing at least one of the following drugs to sham treatment (1080 control patients, 8 studies) or to each other: verteporfin photodynamic therapy (PDT, 1124 patients, 4 studies), pegaptanib (904 patients, 2 twin studies), ranibizumab (984 patients, 4 studies). Both frequentist and Bayesian methods were used to conduct MTCs. Results: Direct and indirect evidence was available and found to be overall in good agreement for the comparisons: PDT vs. control, ranibizumab vs. control, ranibizumab vs. PDT. Bayesian model fit was better for a model including a covariate coding for the PIER study ranibizumab regimen, i.e. quarterly injections after three initial monthly doses. In the MTC model, monthly ranibizumab was superior to PDT and pegaptanib, and could not be shown to be better than PIER ranibizumab regarding visual loss, being estimates imprecise. Ranibizumab PIER retreatment regimen was better than PDT and pegaptanib regarding visual loss, whereas an advantage over them regarding visual gain was suggested by a frequentist MTC approach, but not by a Bayesian approach, which was more conservative. A limitation of our MTC model was that only two twin studies connected pegaptanib to the treatment network, and only one study was available for the PIER ranibizumab regimen. Conclusion: The clinically heterogeneous and sparse typology of the evidence is a limitation to carry out MTC meta-analysis of approved pharmacological treatments for neovascular AMD. Ranibizumab was found to be the most effective treatment compared to PDT and pegaptanib, although this superiority cannot be demonstrated regarding visual gain for the PIER ranibizumab regimen in a Bayesian analytic setting. We did not find RCTs which investigated the current ranibizumab as needed retreatment regimen approved in Europe.
C1 [Virgili, Gianni; Murro, Vittoria; Giacomelli, Giovanni] Univ Florence, Dept Ophthalmol, I-50134 Florence, Italy.
   [Novielli, Nicola] Univ Leicester, Dept Hlth Sci, Leicester LE1 7RH, Leics, England.
   [Menchini, Francesca] Univ Udine, Dept Ophthalmol, I-33100 Udine, Italy.
C3 University of Florence; University of Leicester; University of Udine
RP Virgili, G (通讯作者)，Univ Florence, Dept Ophthalmol, V Le Morgagni 85, I-50134 Florence, Italy.
EM gianni.virgili@unifi.it
RI murro, vittoria/K-1309-2018; giacomelli, giovanni/ABC-6173-2020;
   Virgili, Gianni/P-6607-2014
OI murro, vittoria/0000-0002-9249-4460; Virgili,
   Gianni/0000-0002-9960-2989; Novielli, Nicola/0000-0001-9314-7092
FU US National Institute of Health
FX Finally, we found no studies comparing ranibizumab to bevacizumab that
   could be included in our review. As seen in www.clinicaltrials.gov,
   several trials are ongoing, the largest of which is the Comparison of
   Age-Related Macular Degeneration Treatments Trials: Lucentis-Avastin
   Trial (CATT), funded by the US National Institute of Health. This study
   compares two retreatment regimens of each drug after three loading
   injections: monthly vs. as needed, i.e. guided by clinical evaluation in
   monthly controls. Such studies will be relevant to clinical practice
   since off-label administration of bevacizumab is in fact largely used in
   patients affected by neovascular AMD.
CR Ades AE, 2003, STAT MED, V22, P2995, DOI 10.1002/sim.1566
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Borm GF, 2009, J CLIN EPIDEMIOL, V62, P711, DOI 10.1016/j.jclinepi.2008.09.013
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Eandi CM, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006928.pub2
   Evans JR, 2009, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858
   Geltzer A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005022.pub2
   Giansanti F, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006931.pub2
   Glenny AM, 2005, HEALTH TECHNOL ASSES, V9, P1
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Kaiser PK, 2009, CURR MED RES OPIN, V25, P1853, DOI 10.1185/03007990903038616
   Lu G, 2004, STAT MED, V23, P3105, DOI 10.1002/sim.1875
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Reddy U, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005138.pub2
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Salanti G, 2008, ANN INTERN MED, V148, P544, DOI 10.7326/0003-4819-148-7-200804010-00011
   Sivagnanavel V, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004004.PUB2
   Song FJ, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1147
   Spiegelhalter DJ, 2002, J R STAT SOC B, V64, P583, DOI 10.1111/1467-9868.00353
   Sterne JAC, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2393
   Thorpe KE, 2009, J CLIN EPIDEMIOL, V62, P464, DOI [10.1016/j.jclinepi.2008.12.011, 10.1503/cmaj.090523]
   Treweek S, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-37
   Vedula SS, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub2
   Vierron E, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-39
   Virgili G, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004763.pub2
   Wells GA, 2009, INDIRECT EVIDENCE IN
   Wormald R, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub3
NR 34
TC 3
Z9 3
U1 0
U2 3
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-4501
EI 1873-5592
J9 CURR DRUG TARGETS
JI Curr. Drug Targets
PD FEB
PY 2011
VL 12
IS 2
BP 212
EP 220
DI 10.2174/138945011794182665
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 720RX
UT WOS:000287299000009
PM 20887240
DA 2022-11-30
ER

PT J
AU Sanchez-Thorin, JC
AF Sanchez-Thorin, Juan Camilo
TI Cost-minimization Analysis of Ranibizumab versus Aflibercept in the
   Treatment of Neovascular Age-related Macular Degeneration in Colombia
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE age-related macular degeneration; macula; macular degeneration;
   cost-minimization analysis; anti-angiogenic therapy; anti-VEGF therapy;
   ranibizumab; aflibercept; pharmaco-economic analysis
ID METAANALYSIS
AB Background In 2020 Colombia may expect to have close to 231,700 patients with neovascular age-related macular degeneration (ARMD). Treatment of neovascular ARMD involves the sequential Intra-vitreal injections of anti-vascular endothelial growth factor (anti-VEGF therapy) medications. The efficacy and safety of anti-VEGF therapy on a treat-and-extend (T&E) dosing scheme are similar when ranibizumab or aflibercept are administered.Objective: A cost-minimization analysis from the payer`s perspective in Colombia projects treatment expenses of anti-VEGF therapy using aflibercept or ranibizumab on T&E regimens for the treatment of neovascular ARMD.Methods: A model projects the expenses of the compared treatment regimens for two and five-year periods beginning on February 2020. The model used information from clinical trials, case series and meta-analyses on the compared treatment regimens, demographic, epidemiologic and economic data originated from the Colombian government sources. A 3% discount rate was applied.Results: Projected cost differences in favor of ranibizumab after two and five-year treatment periods beginning February 2020 could be close to U.S. $ 4,861 and U.S $ 7,241 per treated eye, respectively. If all patients with unilateral and bilateral neovascular ARMD in Colombia were to receive appropriate anti-VEGF therapy for two years, the projected expected cost difference in favor of ranibizumab could be close to U.S. $ 462,717,092 dollars.Conclusion: Within the Colombian healthcare setting anti-VEGF therapy on a T&E regimen utilizing ranibizumab for neovascular ARMD may be cost-saving compared with employing aflibercept. Despite cost favorability, ranibizumab should not be the only therapeutic option since in clinical practice alternatives are required.
C1 [Sanchez-Thorin, Juan Camilo] Fdn Santa Fe Bogota, Dept Ophthalmol, Bogota, Colombia.
RP Sanchez-Thorin, JC (通讯作者)，Fdn Santa Fe Bogota, Dept Ophthalmol, Bogota, Colombia.
EM jcsanchezthorin@gmail.com
CR Elshout M, 2014, GRAEF ARCH CLIN EXP, V252, P1911, DOI 10.1007/s00417-014-2641-3
   Galvez M, 2009, IEEE ENER CONV, P48, DOI 10.1109/ECCE.2009.5316475
   Gillies MC, 2020, OPHTHALMOLOGY, V127, P198, DOI 10.1016/j.ophtha.2019.08.023
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Hernandez L, 2018, J MANAG CARE SPEC PH, V24, P608, DOI 10.18553/jmcp.2018.24.7.608
   Husereau D, 2013, VALUE HEALTH, V16, P231, DOI 10.1016/j.jval.2013.02.002
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Low A, 2019, BRIT J OPHTHALMOL, V103, P442, DOI 10.1136/bjophthalmol-2018-312691
   Mantel I, 2018, SURV OPHTHALMOL, V63, P638, DOI 10.1016/j.survophthal.2018.02.004
   Mulligan K, 2020, JAMA OPHTHALMOL, V138, P40, DOI 10.1001/jamaophthalmol.2019.4557
   Nguyen CL, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0785-3
   Parikh R, 2019, JAMA OPHTHALMOL, V137, P914, DOI 10.1001/jamaophthalmol.2019.1947
   Pongsachareonnont P, 2018, CLIN OPHTHALMOL, V12, P1877, DOI 10.2147/OPTH.S171636
   Schmier JK, 2016, PHARMACOECONOMICS, V34, P259, DOI 10.1007/s40273-015-0347-y
   Takura T, 2018, INTERNAL MED, V57, P1191, DOI 10.2169/internalmedicine.9835-17
   Traine PG, 2019, OPHTHALMOL RETINA
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhang Y, 2017, INVEST OPHTH VIS SCI, V58, P5616, DOI 10.1167/iovs.17-22471
   Zheng DD, 2014, INVEST OPHTH VIS SCI, V55, P5144, DOI 10.1167/iovs.14-14202
NR 19
TC 0
Z9 1
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD NOV 1
PY 2020
VL 27
IS 6
BP 482
EP 486
DI 10.1080/09286586.2020.1783687
EA JUL 2020
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OA2EI
UT WOS:000552578600001
PM 32715820
DA 2022-11-30
ER

PT J
AU Parvin, P
   Zola, M
   Dirani, A
   Ambresin, A
   Mantel, I
AF Parvin, Parmis
   Zola, Marta
   Dirani, Ali
   Ambresin, Aude
   Mantel, Irmela
TI Two-year outcome of an observe-and-plan regimen for neovascular
   age-related macular degeneration treated with Aflibercept
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Aflibercept; Anti-VEGF;
   Observe-and-plan regimen; Treat and extend regimen; Clinical burden;
   Chronic care management
ID INTRAVITREAL RANIBIZUMAB; CLINICAL BURDEN; BEVACIZUMAB; DETACHMENT;
   INJECTION; TRIALS; TEARS
AB The purpose of our study was to investigate the two-year outcome of Aflibercept treatment for neovascular age-related macular degeneration (nAMD), using the Observe-and-Plan regimen, an individually planned treatment regimen, based on the predictability of an individual's need for retreatment, aiming to reduce the clinical burden.
   Our prospective study used the Observe-and-Plan regimen with Aflibercept to treat nAMD: Three loading doses, followed by monthly observation visits until the disease-recurrence interval was determined, which then was shortened by 2 weeks in a treatment plan for the next three injections without intermediate monitoring visits. The subsequent treatment plans were adjusted according to periodically assessed disease activity. The primary outcome measures were visual acuity changes, number of injections, and number of monitoring visits.
   The study included 112 eyes of 102 patients with a mean age of 80.7 years (SD 7.6). Mean visual acuity (VA) improved from 61.8 ETDRS letters (20/60(+2)) at baseline, by 8.5, 8.0, and 6.2 letters at months 3, 12 and 24, respectively. Mean central retinal thickness was 438um at baseline, and reduced by 152um, 155um, and 150um at months 3, 12 and 24, respectively. The mean number of injections was 8.7 and 6.5 in the first and second year, respectively. The mean number of monitoring visits after baseline was 3.8 and 2.8 during the first and second year, respectively.
   The Observe-and-Plan regimen significantly improved VA, while fewer monitoring visits were needed as compared to other variable dosing regimens, thus reducing the workload for chronic care management of nAMD.
C1 [Parvin, Parmis; Zola, Marta; Dirani, Ali; Ambresin, Aude; Mantel, Irmela] Univ Lausanne, Jules Gonin Eye Hosp, Dept Ophthalmol, Fdn Asile Aveugles, Lausanne, Switzerland.
C3 University of Lausanne
RP Mantel, I (通讯作者)，Univ Lausanne, Jules Gonin Eye Hosp, Dept Ophthalmol, Fdn Asile Aveugles, Lausanne, Switzerland.
EM irmela.mantel@fa2.ch
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Cho HJ, 2016, AM J OPHTHALMOL, V166, P112, DOI 10.1016/j.ajo.2016.03.039
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gianniou C, 2015, EYE, V29, P450, DOI 10.1038/eye.2014.321
   Gianniou C, 2015, EYE, V29, P342, DOI 10.1038/eye.2014.258
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Mantel I, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.3.6
   Mantel I, 2014, BRIT J OPHTHALMOL, V98, P1192, DOI 10.1136/bjophthalmol-2013-304556
   Mantel I, 2013, GRAEF ARCH CLIN EXP, V251, P697, DOI 10.1007/s00417-012-2090-9
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Weinberger AWA, 2007, AM J OPHTHALMOL, V144, P294, DOI 10.1016/j.ajo.2007.03.024
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 22
TC 23
Z9 23
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD NOV
PY 2017
VL 255
IS 11
BP 2127
EP 2134
DI 10.1007/s00417-017-3762-2
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FJ8HR
UT WOS:000413006000006
PM 28798980
OA Green Published
DA 2022-11-30
ER

PT J
AU Fraser, RG
   Tan, R
   Ayton, LN
   Caruso, E
   Guymer, RH
   Luu, CD
AF Fraser, Rogan G.
   Tan, Rose
   Ayton, Lauren N.
   Caruso, Emily
   Guymer, Robyn H.
   Luu, Chi D.
TI Assessment of Retinotopic Rod Photoreceptor Function Using a
   Dark-Adapted Chromatic Perimeter in Intermediate Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; dark adaptation; retina
ID LUMINANCE VISUAL-ACUITY; ADAPTATION; MICROPERIMETRY; SENSITIVITY;
   ATROPHY
AB PURPOSE. We determine the feasibility of using a dark-adapted chromatic (DAC) perimeter to obtain dark-adapted static and dynamic rod function at multiple retinal locations, and compare these functional parameters between subjects with intermediate age-related macular degeneration (AMD) and normal controls.
   METHODS. Perimetric dark-adapted retinal sensitivities for the 505 and 620 nm stimuli across 7 retinal locations within the central 128 were repeatedly measured after exposing to a single photobleach in 22 intermediate AMD subjects and 8 controls. The sensitivities for each stimulus at 20 minutes after bleach and the sensitivity difference between the stimuli were used to determine static rod function. Sensitivities for the 505 nm stimulus at various times within the initial 20 minutes after bleach were used to estimate the rod criterion time to determine rod function dynamics. The static and dynamic rod functional parameters were compared between AMD and control eyes.
   RESULTS. Compared to the control eyes, AMD eyes had a reduction in retinal sensitivities for the 505 nm (P < 0.001) and 620 nm (P < 0.001) stimuli, a reduction in sensitivity difference (P < 0.001), and an increased in rod criterion time (P < 0.001). Region within the central 68 appeared to be the most defective and AMD eyes with reticular pseudodrusen (RPD) seemed to have worse function than eyes without RPD.
   CONCLUSIONS. It is feasible to use a DAC perimeter to study dark-adapted static and dynamic rod-mediated function at multiple retinal loci. Static and dynamic rod function were abnormal in intermediate AMD and more so in eyes with RPD, particularly within the central 6 degrees retina.
C1 Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic, Australia.
   Univ Melbourne, Dept Surg Ophthalmol, Parkville, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP Luu, CD (通讯作者)，Ctr Eye Res Australia, Level 1,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM cluu@unimelb.edu.au
RI Ayton, Lauren/AAV-2977-2021
OI Ayton, Lauren/0000-0001-9907-084X; Luu, Chi/0000-0002-7604-7097; Rose,
   Rose/0000-0002-7351-2774; Guymer, Robyn/0000-0002-9441-4356
FU Beckman Initiative for Macular Research grant; Macular Disease
   Foundation Australia grant
FX Supported by a Beckman Initiative for Macular Research grant and a
   Macular Disease Foundation Australia grant. The Centre for Eye Research
   Australia (CERA) receives Operational Infrastructure Support from the
   Victorian Government.
CR Colville D, 2003, AM J KIDNEY DIS, V42, DOI 10.1016/S0272-6386(03)00665-6
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Hussaini SH, 1998, EYE, V12, P419, DOI 10.1038/eye.1998.99
   Jackson GR, 2014, OPTOMETRY VISION SCI, V91, P925, DOI 10.1097/OPX.0000000000000247
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   KLEIN R, 1983, OPHTHALMOLOGY, V90, P1357
   LAMB TD, 1981, VISION RES, V21, P1773, DOI 10.1016/0042-6989(81)90211-X
   Luu CD, 2013, INVEST OPHTH VIS SCI, V54, P3560, DOI 10.1167/iovs.12-10465
   MASSOF RW, 1979, INVEST OPHTH VIS SCI, V18, P263
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Owsley C, 2014, INVEST OPHTH VIS SCI, V55, P4776, DOI 10.1167/iovs.14-14502
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   SUNNESS JS, 1989, OPHTHALMOLOGY, V96, P375, DOI 10.1016/S0161-6420(89)32883-1
   WALD G, 1945, SCIENCE, V101, P653, DOI 10.1126/science.101.2635.653
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Wu ZC, 2014, INVEST OPHTH VIS SCI, V55, P6431, DOI 10.1167/iovs.14-14407
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Ying GS, 2008, OPHTHALMOLOGY, V115, P1876, DOI 10.1016/j.ophtha.2008.05.023
   ZEAVIN BH, 1956, AM J OPHTHALMOL, V42, P253, DOI 10.1016/0002-9394(56)90377-4
NR 28
TC 32
Z9 32
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2016
VL 57
IS 13
BP 5436
EP 5442
DI 10.1167/iovs.16-19295
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EI4ND
UT WOS:000392469600050
PM 27756079
OA gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Lamoureux, EL
   Hooper, CY
   Lim, L
   Pallant, JF
   Hunt, N
   Keeffe, JE
   Guymer, RH
AF Lamoureux, Ecosse L.
   Hooper, Claire Y.
   Lim, Lyndell
   Pallant, Julie F.
   Hunt, Nicola
   Keeffe, Jill E.
   Guymer, Robyn H.
TI Impact of cataract surgery on quality of life in patients with early
   age-related macular degeneration
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE cataract surgery; age-related macular degeneration; quality of life;
   Rasch analysis; visual acuity
ID VISION IMPAIRMENT QUESTIONNAIRE; PSYCHOMETRIC PROPERTIES; VISUAL
   FUNCTION; RASCH; MACULOPATHY; PREVALENCE; PARTICIPATION; POPULATION
AB Purpose. To investigate if cataract surgery improves overall and specific areas of quality of life (QoL) in patients with early age-related macular degeneration (AMD) using the impact of vision impairment (IVI) questionnaire.
   Methods. Patients with visually significant cataract and early AMD, who were being considered for cataract surgery in the study eye, were recruited. Eligible patients were randomized to either "early surgery" or "standard surgery" (standard cataract surgery waiting time of 6 months) groups. The IVI, sociodemographic, and clinical data were collected. Rasch analysis was used to estimate QoL person measures at baseline and follow-up. The data were analyzed using repeated measures ANOVA. Effect sizes were calculated using Cohen's d coefficient.
   Results. Fifty six patients (mean age = 78.5 years and visual acuity = 6/15) had one eye randomly allocated to either the early surgery (n = 29) or standard surgery (n = 27) groups. At follow-up, significant interaction effects were found for the overall IVI score [F(1,54) = 17.7; p < 0.001], the emotional well-being [F(1,54) = 13.4; p = 0.001], mobility and independence [F(1,54) = 13.4;p = 0.001], and reading and accessing information subscales [F(1,54) = 13.1;p = 0.001]. The standard surgery group systematically recorded worse scores at 6 months on all QoL measures whereas the early surgery group recorded significant gains (p < 0.001; Cohen's d = 0.66 to 0.91) on all of them. Visual acuity in the study eye significantly improved in the early surgery group only (Cohen's d = 1.1; p < 0.05) and improvement in log MAR lines read was identified as the single independent predictor of enhanced QoL explaining between 26 and 34% of the variance in the IVI scores.
   Conclusions. Cataract surgery is justified in patients with early AMD. It brings significant improvements in visual acuity, aspects of daily living, and overall QoL.
C1 Univ Melbourne, Dept Ophthalmol, CERA, Melbourne, Vic 3002, Australia.
   Univ Melbourne, Sch Rural Hlth, Parkville, Vic 3052, Australia.
   Vis CRC, Sydney, NSW, Australia.
C3 University of Melbourne; University of Melbourne
RP Lamoureux, EL (通讯作者)，Univ Melbourne, Dept Ophthalmol, CERA, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM ecosse@unimelb.edu.au
RI Lamoureux, Ecosse/Z-5482-2019
OI Guymer, Robyn/0000-0002-9441-4356; Lim, Lyndell/0000-0003-2491-685X
CR ABITBOL O, 2004, J FR OPTHTALMOL, V27
   Andrich D, 2003, RUMM 2020
   Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   Bond T. G., 2021, APPL RASCH MODEL FUN, V4th
   Cohen J., 1988, STAT POWER ANAL SOCI, V2nd
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   de Boer MR, 2004, OPHTHAL PHYSL OPT, V24, P257, DOI 10.1111/j.1475-1313.2004.00187.x
   Garamendi E, 2006, VISION RES, V46, P1375, DOI 10.1016/j.visres.2005.07.007
   Garamendi E, 2005, J CATARACT REFR SURG, V31, P1537, DOI 10.1016/j.jcrs.2004.12.059
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Lamoureux EL, 2007, INVEST OPHTH VIS SCI, V48, P1001, DOI 10.1167/iovs.06-0361
   Lamoureux EL, 2006, INVEST OPHTH VIS SCI, V47, P4732, DOI 10.1167/iovs.06-0220
   Lamoureux EL, 2004, ARCH OPHTHALMOL-CHIC, V122, P84, DOI 10.1001/archopht.122.1.84
   Lamoureux EL, 2004, AM J OPHTHALMOL, V137, P265, DOI 10.1016/j.ajo.2003.08.003
   LEIBOWITZ H, 1973, SURV OPHTHALMOL, V24, P335
   Lundstrom M, 2002, BRIT J OPHTHALMOL, V86, P1330, DOI 10.1136/bjo.86.12.1330
   Margolis MK, 2002, PHARMACOECONOMICS, V20, P791, DOI 10.2165/00019053-200220120-00001
   Massof RW, 2001, SURV OPHTHALMOL, V45, P531, DOI 10.1016/S0039-6257(01)00194-1
   MASTERS GN, 1982, PSYCHOMETRIKA, V47, P149, DOI 10.1007/BF02296272
   Norquist JM, 2004, MED CARE, V42, P25, DOI 10.1097/01.mlr.0000103530.13056.88
   Pesudovs Konrad, 2006, BMC Ophthalmol, V6, P25, DOI 10.1186/1471-2415-6-25
   Pollack A, 1998, OPHTHALMIC SURG LAS, V29, P286
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Shuttleworth GN, 1998, BRIT J OPHTHALMOL, V82, P611, DOI 10.1136/bjo.82.6.611
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang J J, 1999, Ophthalmic Epidemiol, V6, P317, DOI 10.1076/opep.6.4.317.4182
   Weih LM, 2002, INVEST OPHTH VIS SCI, V43, P927
   Wolfe E W, 1999, J Outcome Meas, V3, P134
NR 34
TC 46
Z9 48
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD AUG
PY 2007
VL 84
IS 8
BP 683
EP 688
DI 10.1097/OPX.0b013e31812f755f
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 203UT
UT WOS:000249000200006
PM 17700333
DA 2022-11-30
ER

PT J
AU Wysokinski, D
   Danisz, K
   Blasiak, J
   Dorecka, M
   Romaniuk, D
   Szaflik, J
   Szaflik, JP
AF Wysokinski, Daniel
   Danisz, Katarzyna
   Blasiak, Janusz
   Dorecka, Mariola
   Romaniuk, Dorota
   Szaflik, Jerzy
   Szaflik, Jacek Pawel
TI An association of transferrin gene polymorphism and serum transferrin
   levels with age-related macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE AMD; transferrin; iron; genetic polymorphism; oxidative stress; BMI;
   smoking
ID INDUCED OXIDATIVE STRESS; BODY-MASS INDEX; LIPID-PEROXIDATION;
   IRON-METABOLISM; DNA-DAMAGE; BOUND IRON; SMOKING; RISK; PATHOGENESIS;
   EXPRESSION
AB Age-related macular degeneration (AMD) is a degenerative disease of the eye, triggered by the damage of the macular cells. In the Western world it is the most frequent cause of blindness in the elderly. Oxidative stress is proved to play a key role in AMD pathogenesis and since iron accumulation has been found in AMD maculas, it may accelerate the oxidative processes in this tissue. In the present work we investigated the association between four polymorphisms of the transferrin gene (rs8177178; rs8177179; rs4481157; rs1130459) and AMD in dependence on the transferrin protein and iron serum levels. We employed PCR-RFLP (polymerase chain reaction - restriction fragment length polymorphism) for genotype determination, ELISA assay for serum transferrin evaluation and colorimetric assay for measurement of iron concentration in the serum. We found that advanced age and AMD family history may be independent risk factors for AMD (1.02, p < 0.05 and 8.88, p < 0.001, respectively). At the rs4481157 site The GG genotype of the rs4481157 polymorphism decreased the risk of dry AMD (OR 0.50; p < 0.05), while the GA increased this risk (OR 1.07: p < 0.05). Moreover, the GA genotype of this polymorphism decreased the risk of progression to the wet form (OR 0.63; p < 0.05). The analysis of the gene-environment interactions showed that the rs4481157 polymorphism modulates the AMD risk among obese (BMI above 30) individuals. In the former smokers group we observed a moderate association between rs4481157 polymorphism and AMD risk while this association in current smokers was stronger. We found also that the serum level of transferrin was higher in the AMD group (p < 0.001) than in the control, but the total serum iron levels did not differ between both groups. We found that the serum transferrin was associated with the rs8177178 (p < 0.001) and rs4481157 (p < 0.01) polymorphisms, and the common variant (CC) of both sites was related to a lower level of transferrin. Presented data may contribute to the involvement of iron homeostasis in AMD risk. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Wysokinski, Daniel; Danisz, Katarzyna; Blasiak, Janusz] Univ Lodz, Dept Mol Genet, PL-90236 Lodz, Poland.
   [Dorecka, Mariola; Romaniuk, Dorota] Med Univ Silesia, Dept Ophthalmol, PL-40514 Katowice, Poland.
   [Szaflik, Jerzy; Szaflik, Jacek Pawel] Med Univ Warsaw, Dept Ophthalmol, Samodzielny Publi Klin Szpital Okulisty, PL-03709 Warsaw, Poland.
C3 University of Lodz; Medical University Silesia; Medical University of
   Warsaw
RP Szaflik, JP (通讯作者)，Med Univ Warsaw, Dept Ophthalmol, Sierakowskiego 13, PL-03710 Warsaw, Poland.
EM szaflik@ophthalmology.pl
OI Blasiak, Janusz/0000-0001-9539-9584; Dorecka,
   Mariola/0000-0003-1768-9628; Szaflik, Jerzy/0000-0002-7601-1326
FU Polish Ministry of Science and Higher Education [N N402 248 336];
   European Union under the European Social Fund: "HUMAN - BEST INVESTMENT"
FX This work was supported by grant N N402 248 336 from Polish Ministry of
   Science and Higher Education.; Daniel Wysokinski is a recipient of D-RIM
   2nd edition fellowship co-funded by the European Union under the
   European Social Fund: "HUMAN - BEST INVESTMENT".
CR Adrian GS, 1996, J GERONTOL A-BIOL, V51, pB66, DOI 10.1093/gerona/51A.1.B66
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Ayala-Haedo JA, 2010, ANN HUM GENET, V74, P195, DOI 10.1111/j.1469-1809.2010.00570.x
   Ayene IS, 2007, INT J RADIAT BIOL, V83, P195, DOI 10.1080/09553000601146956
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Berg Daniela, 2006, Top Magn Reson Imaging, V17, P5, DOI 10.1097/01.rmr.0000245461.90406.ad
   Beutler E, 2000, BLOOD, V96, P4071, DOI 10.1182/blood.V96.13.4071.h8004071_4071_4074
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Breuer W, 2000, TRANSFUS SCI, V23, P185, DOI 10.1016/S0955-3886(00)00087-4
   Brissot P., 2011, BIOCHIM BIOPHYS ACTA, V1820, P403
   Bush AI, 2008, EUR BIOPHYS J BIOPHY, V37, P241, DOI 10.1007/s00249-007-0228-1
   BUYS SS, 1991, BLOOD, V78, P3288
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Cepeda-Lopez AC, 2010, INT J VITAM NUTR RES, V80, P263, DOI 10.1024/0300-9831/a000033
   Chiu CJ, 2011, INVEST OPHTH VIS SCI, V52, P9099, DOI 10.1167/iovs.11-7782
   Chowers I, 2006, INVEST OPHTH VIS SCI, V47, P2135, DOI 10.1167/iovs.05-1135
   Chu J, 2008, CHINESE MED J-PEKING, V121, P2525, DOI 10.1097/00029330-200812020-00011
   Clark SF, 2008, NUTR CLIN PRACT, V23, P128, DOI 10.1177/0884533608314536
   Coleman H, 2007, CURR OPIN OPHTHALMOL, V18, P220, DOI 10.1097/ICU.0b013e32814a586b
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   DARGEL R, 1992, EXP TOXICOL PATHOL, V44, P169, DOI 10.1016/S0940-2993(11)80202-2
   DeLaPaz MA, 1996, CURR EYE RES, V15, P273, DOI 10.3109/02713689609007621
   Delcourt C, 2011, INVEST OPHTH VIS SCI, V52, P5955, DOI 10.1167/iovs.10-6235
   Donovan A, 2006, PHYSIOLOGY, V21, P115, DOI 10.1152/physiol.00052.2005
   Dunaief JL, 2005, OPHTHALMOLOGY, V112, P1062, DOI 10.1016/j.ophtha.2004.12.029
   Ellervik C, 2012, J INTERN MED, V271, P51, DOI 10.1111/j.1365-2796.2011.02404.x
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fuortes, 1972, PHYSL PHOTORECEPTOR, VVolume 7/2, P667
   Galaris D, 2008, CRIT REV CL LAB SCI, V45, P1, DOI [10.1080/10408360701713104, 10.1080/10408360701713104 ]
   Ganguli A, 2009, RENAL FAILURE, V31, P106, DOI 10.1080/08860220802599106
   Gao XS, 2010, FREE RADICAL BIO MED, V49, P401, DOI 10.1016/j.freeradbiomed.2010.04.033
   Garrick MD, 2011, GENES NUTR, V6, P45, DOI 10.1007/s12263-010-0184-8
   Garrick MD, 2009, BBA-GEN SUBJECTS, V1790, P309, DOI 10.1016/j.bbagen.2009.03.018
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gurzau ES, 2003, ECOTOX ENVIRON SAFE, V56, P190, DOI 10.1016/S0147-6513(03)00062-9
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Janssen MCH, 2009, BEST PRACT RES CL GA, V23, P171, DOI 10.1016/j.bpg.2009.02.004
   Jia SP, 2008, J PHYS CHEM B, V112, P4461, DOI 10.1021/jp711528z
   Johnson EJ, 2005, NUTR REV, V63, P9, DOI 10.1301/nr.2004.janr.9-15
   Jomova K, 2011, TOXICOLOGY, V283, P65, DOI 10.1016/j.tox.2011.03.001
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Keys SA, 1999, EXP EYE RES, V68, P693, DOI 10.1006/exer.1999.0657
   Killilea DW, 2004, ANN NY ACAD SCI, V1019, P365, DOI 10.1196/annals.1297.063
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Kohgo Y, 2008, INT J HEMATOL, V88, P7, DOI 10.1007/s12185-008-0120-5
   Kolahdooz F, 2010, AM J CLIN NUTR, V91, P1752, DOI 10.3945/ajcn.2009.28415
   Kowaltowski AJ, 2009, FREE RADICAL BIO MED, V47, P333, DOI 10.1016/j.freeradbiomed.2009.05.004
   Lecureuil C, 2004, HUM REPROD, V19, P1300, DOI 10.1093/humrep/deh297
   Lee DH, 2006, DIABETES CARE, V29, P1090, DOI 10.2337/DC05-2471
   Lee PH, 2008, NUCLEIC ACIDS RES, V36, pD820, DOI 10.1093/nar/gkm904
   Lehmann DJ, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2010.07.018
   Liochev SI, 2002, REDOX REP, V7, P55, DOI 10.1179/135100002125000190
   Luciani N, 2011, OBESITY, V19, P1545, DOI 10.1038/oby.2011.12
   Luciano M, 2010, BEHAV GENET, V40, P518, DOI 10.1007/s10519-009-9326-4
   Lukinova N, 2009, INVEST OPHTH VIS SCI, V50, P1440, DOI 10.1167/iovs.08-2545
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Martin PM, 2006, INVEST OPHTH VIS SCI, V47, P4238, DOI 10.1167/iovs.06-0026
   McConnell V, 2005, Ulster Med J, V74, P82
   Meerang M, 2009, INT J CANCER, V125, P759, DOI 10.1002/ijc.24412
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Munch IC, 2007, INVEST OPHTH VIS SCI, V48, P833, DOI 10.1167/iovs.06-0529
   Munoz M, 2009, WORLD J GASTROENTERO, V15, P4617, DOI 10.3748/wjg.15.4617
   Murdaugh LS, 2010, J MASS SPECTROM, V45, P1139, DOI 10.1002/jms.1795
   Nadadur SS, 2008, INDIAN J MED RES, V128, P533
   Neuner B, 2009, ADDICT BEHAV, V34, P938, DOI 10.1016/j.addbeh.2009.05.015
   Oliveira BF, 2010, THESCIENTIFICWORLDJO, V10, P1121, DOI 10.1100/tsw.2010.94
   ORGANISCIAK DT, 1992, CURR EYE RES, V11, P231, DOI 10.3109/02713689209001774
   ORGANISCIAK DT, 1977, INVEST OPHTH VIS SCI, V16, P188
   Parisi V, 2008, OPHTHALMOLOGY, V115, P324, DOI 10.1016/j.ophtha.2007.05.029
   Parkkinen J, 2002, VOX SANG, V83, P321, DOI 10.1111/j.1423-0410.2002.tb05327.x
   Peeters A, 2008, ARCH OPHTHALMOL-CHIC, V126, P1554, DOI 10.1001/archopht.126.11.1554
   Picard E, 2008, MOL VIS, V14, P928
   Picard E, 2010, MOL VIS, V16, P2612
   Qu M, 2008, J PSYCHIATR RES, V42, P877, DOI 10.1016/j.jpsychires.2007.10.005
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   Salvi SM, 2006, POSTGRAD MED J, V82, P581, DOI 10.1136/pgmj.2005.040857
   Santos PCJL, 2012, INT J MOL SCI, V13, P1497, DOI 10.3390/ijms13021497
   Santovito A, 2012, INT J IMMUNOGENET, V39, P291, DOI 10.1111/j.1744-313X.2012.01086.x
   Sawyer DE, 2003, MUTAT RES-FUND MOL M, V529, P21, DOI 10.1016/S0027-5107(03)00101-5
   Sebastiani G, 2011, METALLOMICS, V3, P971, DOI 10.1039/c1mt00082a
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2010, MOL VIS, V16, P2412
   Sellis D, 2011, P NATL ACAD SCI USA, V108, P20666, DOI 10.1073/pnas.1114573108
   Shahid H, 2012, BRIT J OPHTHALMOL, V96, P427, DOI 10.1136/bjophthalmol-2011-300193
   Shvartsman M, 2007, AM J PHYSIOL-CELL PH, V293, pC1383, DOI 10.1152/ajpcell.00054.2007
   Siah Chiang W, 2006, Clin Biochem Rev, V27, P5
   Sliney DH, 2002, INT J TOXICOL, V21, P501, DOI 10.1080/10915810290169927
   Srivastava S, 1995, BIOCHEM BIOPH RES CO, V217, P741, DOI 10.1006/bbrc.1995.2835
   Stadtman ER, 2000, ANN NY ACAD SCI, V899, P191
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Theil EC, 2009, CHEM REV, V109, P4568, DOI 10.1021/cr900052g
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Umur EE, 2011, GERIATR GERONTOL INT, V11, P504, DOI 10.1111/j.1447-0594.2011.00694.x
   Walker BL, 2001, INT REV CYTOL, V211, P241, DOI 10.1016/S0074-7696(01)11020-X
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005304
   Yamada Y, 2011, INT J GYNECOL CANCER, V21, P1200, DOI 10.1097/IGC.0b013e318222cfdd
   Yefimova MG, 2000, INVEST OPHTH VIS SCI, V41, P2343
   Zafon C, 2010, OBES REV, V11, P322, DOI 10.1111/j.1467-789X.2009.00638.x
   Zakin MM, 2002, DEV NEUROSCI-BASEL, V24, P222, DOI 10.1159/000065690
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zecca L, 2004, NAT REV NEUROSCI, V5, P863, DOI 10.1038/nrn1537
NR 107
TC 20
Z9 20
U1 0
U2 10
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JAN
PY 2013
VL 106
BP 14
EP 23
DI 10.1016/j.exer.2012.10.003
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 079BT
UT WOS:000314145900003
PM 23089144
DA 2022-11-30
ER

PT J
AU Cocce, KJ
   Stinnett, SS
   Luhmann, UFO
   Vajzovic, L
   Horne, A
   Schuman, SG
   Toth, CA
   Cousins, SW
   Lad, EM
AF Cocce, Kimberly J.
   Stinnett, Sandra S.
   Luhmann, Ulrich F. O.
   Vajzovic, Lejla
   Horne, Anupama
   Schuman, Stefanie G.
   Toth, Cynthia A.
   Cousins, Scott W.
   Lad, Eleonora M.
TI Visual Function Metrics in Early and Intermediate Dry Age-related
   Macular Degeneration for Use as Clinical Trial Endpoints
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PIGMENT OPTICAL-DENSITY; LOW-LUMINANCE; GEOGRAPHIC ATROPHY; MACULOPATHY;
   ACUITY; EYES; AUTOFLUORESCENCE; MICROPERIMETRY; ZEAXANTHIN; VISION
AB PURPOSE: To evaluate and quantify visual function metrics to be used as endpoints of age-related macular degeneration (AMD) stages and visual acuity (VA) loss in patients with early and intermediate AMD.
   DESIGN: Cross-sectional analysis of baseline data from a prospective study.
   METHODS: One hundred and one patients were enrolled at Duke Eye Center: 80 patients with early AMD (Age-Related Eye Disease Study [AREDS] stage 2 [n = 33] and intermediate stage 3 [n = 47]) and 21 age-matched, normal controls. A dilated retinal examination, macular pigment optical density measurements, and several functional assessments (best-corrected visual acuity, macular integrity assessment mesopic microperimety, dark adaptometry, low-luminance visual acuity [LLVA] [standard using a log 2.0 neutral density filter and computerized method], and cone contrast test [CCT]) were performed. Low-luminance deficit (LLD) was defined as the difference in numbers of letters read at standard vs low luminance. Group comparisons were performed to evaluate differences between the control and the early and intermediate AMD groups using 2-sided significance tests.
   RESULTS: Functional measures that significantly distinguished between normal and intermediate AMD were standard and computerized (0.5 cd/m(2)) LLVA, percent reduced threshold and average threshold on microperimetry, CCTs, and rod intercept on dark adaptation (P < .05). The intermediate group demonstrated deficits in microperimetry reduced threshhold, computerized LLD2, and dark adaptation (P < .05) relative to early AMD.
   CONCLUSIONS: Our study suggests that LLVA, microperimetry, CCT, and dark adaptation may serve as
   functional measures differentiating early-to-intermediate stages of dry AMD. (Am J Ophthalmol 2018;189:127-138. (c) 2018 Elsevier Inc. All rights reserved.)
C1 [Cocce, Kimberly J.; Stinnett, Sandra S.; Vajzovic, Lejla; Horne, Anupama; Schuman, Stefanie G.; Toth, Cynthia A.; Cousins, Scott W.; Lad, Eleonora M.] Duke Univ, Med Ctr, Dept Ophthalmol, DUMC 3802, Durham, NC 27710 USA.
   [Luhmann, Ulrich F. O.] Roche Innovat Ctr Basel, Roche Pharmaceut Res & Early Dev, Translat Med Neurosci & Ophthalmol & Rare Dis Bio, Basel, Switzerland.
C3 Duke University; Roche Holding
RP Lad, EM (通讯作者)，Duke Univ, Med Ctr, Dept Ophthalmol, DUMC 3802, Durham, NC 27710 USA.
EM nora.lad@duke.edu
RI Toth, Cynthia/L-5534-2019
OI Toth, Cynthia/0000-0002-2324-0854; Luhmann, Ulrich
   F.O./0000-0002-1993-1951; Stinnett, Sandra/0000-0001-7192-0195
FU NATIONAL INSTITUTES OF HEALTH/NATIONAL EYE INSTITUTE, Bethesda, MD
   [K23EY026988]; Research to Prevent Blindness, New York, NY; Duke
   University; NATIONAL EYE INSTITUTE [K23EY026988] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007171]
   Funding Source: NIH RePORTER
FX THIS WORK WAS SUPPORTED BY THE NATIONAL INSTITUTES OF HEALTH/NATIONAL
   EYE INSTITUTE, Bethesda, MD (K23EY026988), Research to Prevent
   Blindness, New York, NY, and, through Duke University, and industry
   support from Hoffmann La Roche, Basel, Switzerland.
CR Althouse AD, 2016, ANN THORAC SURG, V101, P1644, DOI 10.1016/j.athoracsur.2015.11.024
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P741
   BONE RA, 1992, VISION RES, V32, P105, DOI 10.1016/0042-6989(92)90118-3
   Carr AJF, 2013, TRENDS NEUROSCI, V36, P385, DOI 10.1016/j.tins.2013.03.006
   Chandramohan A, 2016, RETINA-J RET VIT DIS, V36, P1021, DOI 10.1097/IAE.0000000000001002
   Cohen SY, 2012, RETINA-J RET VIT DIS, V32, P834, DOI 10.1097/IAE.0b013e31822058a3
   Dennison JL, 2013, EXP EYE RES, V116, P190, DOI 10.1016/j.exer.2013.08.014
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   HIRSCH J, 1989, VISION RES, V29, P1095, DOI 10.1016/0042-6989(89)90058-8
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Jaffe GJ, 2015, AM J OPHTHALMOL, V160, P1226, DOI 10.1016/j.ajo.2015.08.024
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Kauper K, 2012, INVEST OPHTH VIS SCI, V53, P7484, DOI 10.1167/iovs.12-9970
   Li BX, 2010, ARCH BIOCHEM BIOPHYS, V504, P56, DOI 10.1016/j.abb.2010.07.024
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Ortman J., 2015, PROJECTIONS SIZE COM
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Owsley C, 2016, CURR EYE RES, V41, P266, DOI 10.3109/02713683.2015.1011282
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   Puell MC, 2012, INVEST OPHTH VIS SCI, V53, P7310, DOI 10.1167/iovs.11-8649
   Rabin J, 2011, INVEST OPHTH VIS SCI, V52, P816, DOI 10.1167/iovs.10-6283
   Raman R, 2012, EYE, V26, P950, DOI 10.1038/eye.2012.69
   Ren XT, 2015, INT J OPHTHALMOL-CHI, V8, P1190, DOI 10.3980/j.issn.2222-3959.2015.06.20
   Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010
   Rothman KJ, 2014, J GEN INTERN MED, V29, P1060, DOI 10.1007/s11606-013-2755-z
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Tsika C, 2011, ACTA OPHTHALMOL, V89, pE573, DOI 10.1111/j.1755-3768.2011.02170.x
   Vujosevic S, 2011, OPHTHALMOLOGICA, V225, P155, DOI 10.1159/000320340
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wrona M, 2004, FREE RADICAL BIO MED, V36, P1094, DOI 10.1016/j.freeradbiomed.2004.02.005
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
NR 41
TC 52
Z9 54
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2018
VL 189
BP 127
EP 138
DI 10.1016/j.ajo.2018.02.012
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GE8HR
UT WOS:000431473300019
PM 29477964
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Lee, E
   Singh, MS
   Jones, HE
   Ahmed, B
   Andolina, IM
   Clements, JTC
   Luong, V
   Munro, PM
   Lawton, MP
   Grieve, KL
   Aylward, GW
   Sillito, AM
   MacLaren, RE
AF Lee, Edward
   Singh, Mandeep S.
   Jones, Helen E.
   Ahmed, Bashir
   Andolina, Ian M.
   Clements, Jake T. C.
   Vy Luong
   Munro, Peter M.
   Lawton, Martin P.
   Grieve, Kenneth L.
   Aylward, George W.
   Sillito, Adam M.
   MacLaren, Robert E.
TI Assessment of 180 degrees Rotation of the Choroid as a Novel Surgical
   Treatment for Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; AUTOLOGOUS TRANSPLANTATION; TRANSLOCATION;
   GRAFT; RETINOTOMY; RPE; RANIBIZUMAB; SECONDARY; MEMBRANE; ANATOMY
AB PURPOSE. Our objective was to examine the feasibility of rotating choriocapillaris, Bruch's membrane (BM), and retinal pigment epithelium (RPE) through 180 degrees on a vascular pedicle and to assess revascularization and tissue preservation postoperatively. Such an approach could be used in the treatment of age-related macular degeneration where there is focal disease at the macula with healthy tissues located peripherally.
   METHODS. Successful surgery was performed in six rhesus macaque monkeys, which have a very similar choroidal blood supply to humans. After inducing a retinal detachment, the recurrent branch of the long posterior ciliary artery was used as a pedicle around which a graft stretching to the temporal equator was rotated. Retina was reattached over the rotated graft and eyes were followed up for up to 6 months with repeated angiography and optical coherence tomography (OCT). The morphology of retinal cells and BM were assessed by immunohistochemistry and electron microscopy.
   RESULTS. Revascularization of the choroid was limited, with reestablishment of drainage to the vortex veins seen in only one case. There was a secondary loss of the RPE and outer retina evident on histological analysis three months after surgery. The underlying BM however remained intact.
   CONCLUSIONS. Pedicled choroidal rotation surgery is technically feasible in vivo with intraoperative control of bleeding. However, lack of graft revascularization with the technique in its current form leads to neuroretinal and RPE tissue loss, and graft shrinkage. We found no evidence that rotational grafts are likely to improve the outcomes presently achieved with free graft techniques. (Invest Ophthalmol Vis Sci. 2012;53:2523-2532) DOI:10.1167/iovs.11-8674
C1 [Singh, Mandeep S.; MacLaren, Robert E.] Univ Oxford, Oxford OX3 9DU, England.
   [Lee, Edward; Singh, Mandeep S.; Jones, Helen E.; Ahmed, Bashir; Andolina, Ian M.; Clements, Jake T. C.; Vy Luong; Munro, Peter M.; Lawton, Martin P.; Aylward, George W.; Sillito, Adam M.; MacLaren, Robert E.] UCL, Inst Ophthalmol, London, England.
   [Lee, Edward; Singh, Mandeep S.; Jones, Helen E.; Ahmed, Bashir; Andolina, Ian M.; Clements, Jake T. C.; Vy Luong; Munro, Peter M.; Lawton, Martin P.; Aylward, George W.; Sillito, Adam M.; MacLaren, Robert E.] Moorfields Eye Hosp, Natl Inst Hlth Res, Biomed Res Ctr, London, England.
   [Singh, Mandeep S.; MacLaren, Robert E.] Oxford Eye Hosp, Natl Inst Hlth Res, Biomed Res Ctr, Oxford, England.
   [Grieve, Kenneth L.] Univ Manchester, Fac Life Sci, Manchester, Lancs, England.
C3 University of Oxford; University of London; University College London;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of Oxford; University of Manchester
RP MacLaren, RE (通讯作者)，Univ Oxford, West Wing, Oxford OX3 9DU, England.
EM enquiries@eye.ox.ac.uk
RI Singh, Mandeep/AAS-8842-2021; Andolina, Ian Max/S-7179-2019
OI Singh, Mandeep/0000-0003-1749-0088; Andolina, Ian
   Max/0000-0001-9985-3414; MacLaren, Robert/0000-0002-3096-4682
FU Medical Research Council UK [G0601588]; The Health Foundation and
   Medical Research Council [G0701535]; MRC [G0601588, G0701535] Funding
   Source: UKRI; Medical Research Council [G0701535, G0601588] Funding
   Source: researchfish
FX Supported primarily by the Medical Research Council UK (G0601588 awarded
   to REM, GWA, and AMS), assisted by the National Institute for Health
   Research Biomedical Research Centre, the Royal College of Surgeons of
   Edinburgh, the Special Trustees of Moorfields Eye Hospital, the Oxford
   Stem Cell Institute, The Health Foundation and Medical Research Council
   Grant G0701535.
CR Adler R, 1999, MOL VIS, V5
   Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   Aisenbrey S, 2007, ARCH OPHTHALMOL-CHIC, V125, P1367, DOI 10.1001/archopht.125.10.1367
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   Bowne SJ, 2011, EUR J HUM GENET, V19, P1074, DOI 10.1038/ejhg.2011.86
   Braun RD, 1997, AM J PHYSIOL-HEART C, V272, pH1444, DOI 10.1152/ajpheart.1997.272.3.H1444
   Bunce C, 2008, EYE, V22, P905, DOI 10.1038/sj.eye.6702767
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Cereda MG, 2010, GRAEF ARCH CLIN EXP, V248, P37, DOI 10.1007/s00417-009-1201-8
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Chen FK, 2008, INVEST OPHTH VIS SCI, V49, P3143, DOI 10.1167/iovs.07-1648
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Fang XY, 2001, AM J OPHTHALMOL, V131, P481, DOI 10.1016/S0002-9394(00)00899-0
   Faude F, 2001, INVEST OPHTH VIS SCI, V42, P1328
   Gibran S, 2009, GRAEF ARCH CLIN EXP, V247, P187, DOI 10.1007/s00417-008-0958-5
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   HAYREH SS, 1983, INT OPHTHALMOL, V6, P85, DOI 10.1007/BF00127636
   HAYREH SS, 1975, BRIT J OPHTHALMOL, V59, P631, DOI 10.1136/bjo.59.11.631
   Joussen AM, 2007, OPHTHALMOLOGY, V114, P551, DOI 10.1016/j.ophtha.2006.08.016
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   Lee E, 2011, BRIT J OPHTHALMOL, V95, P445, DOI 10.1136/bjo.2009.171918
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Maaijwee K, 2008, BRIT J OPHTHALMOL, V92, P526, DOI 10.1136/bjo.2007.131383
   Maaijwee K, 2007, GRAEF ARCH CLIN EXP, V245, P1681, DOI 10.1007/s00417-007-0607-4
   Maaijwee KJM, 2007, BRIT J OPHTHALMOL, V91, P546, DOI 10.1136/bjo.2006.103259
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MacLaren RE, 2005, OPHTHALMOLOGY, V112, P2081, DOI 10.1016/j.ophtha.2005.06.029
   MacLaren RE, 2007, OPHTHALMOLOGY, V114, P561, DOI 10.1016/j.ophtha.2006.06.049
   Mata NL, 2002, NEURON, V36, P69, DOI 10.1016/S0896-6273(02)00912-1
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   OLVER JM, 1990, EYE, V4, P262, DOI 10.1038/eye.1990.38
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schraermeyer U, 2001, CELL TRANSPLANT, V10, P673, DOI 10.3727/000000001783986215
   Stanga PE, 2002, OPHTHALMOLOGY, V109, P1492, DOI 10.1016/S0161-6420(02)01099-0
   Treumer F, 2007, BRIT J OPHTHALMOL, V91, P349, DOI 10.1136/bjo.2006.102152
   van Meurs JC, 2004, BRIT J OPHTHALMOL, V88, P110, DOI 10.1136/bjo.88.1.110
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   van Zeeburg EJT, 2011, INVEST OPHTH VIS SCI, V52, P5881, DOI 10.1167/iovs.11-7245
   Wolf S, 1999, GRAEF ARCH CLIN EXP, V237, P51, DOI 10.1007/s004170050194
   Zhang TR, 2009, INVEST OPHTH VIS SCI, V50, P2982, DOI 10.1167/iovs.08-2131
NR 48
TC 0
Z9 0
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2012
VL 53
IS 6
BP 2523
EP 2532
DI 10.1167/iovs.11-8674
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 953JY
UT WOS:000304864600001
PM 22427591
DA 2022-11-30
ER

PT J
AU Campochiaro, PA
   Nguyen, QD
   Shah, SM
   Klein, ML
   Holz, E
   Frank, RN
   Saperstein, DA
   Gupta, A
   Stout, JT
   Macko, J
   DiBartolomeo, R
   Wei, LL
AF Campochiaro, PA
   Nguyen, QD
   Shah, SM
   Klein, ML
   Holz, E
   Frank, RN
   Saperstein, DA
   Gupta, A
   Stout, JT
   Macko, J
   DiBartolomeo, R
   Wei, LL
TI Adenoviral vector-delivered pigment epithelium-derived factor for
   neovascular age-related macular degeneration: Results of a phase I
   clinical trial
SO HUMAN GENE THERAPY
LA English
DT Article
ID GENE-TRANSFER
AB Twenty-eight patients with advanced neovascular age-related macular degeneration (AMD) were given a single intravitreous injection of an E1-, partial E3-, E4-deleted adenoviral vector expressing human pigment epithelium-derived factor (AdPEDF.11). Doses ranging from 10(6) to 10(9.5) particle units (PU) were investigated. There were no serious adverse events related to AdPEDF.11 and no dose-limiting toxicities. Signs of mild, transient intraocular inflammation occurred in 25% of patients, but there was no severe inflammation. Six patients experienced increased intraocular pressure that was easily controlled by topical medication. All adenoviral cultures were negative. At 3 and 6 months after injection, 55 and 50%, respectively, of patients treated with 10(6)-10(7.5) PU and 94 and 71% of patients treated with 10(8)-10(9.5) PU had no change or improvement in lesion size from baseline. The median increase in lesion size at 6 and 12 months was 0.5 and 1.0 disk areas in the low-dose group compared with 0 and 0 disk areas in the high-dose group. These data suggest the possibility of antiangiogenic activity that may last for several months after a single intravitreous injection of doses greater than 108 PU of AdPEDF.11. This study provides evidence that adenoviral vector-mediated ocular gene transfer is a viable approach for the treatment of ocular disorders and that further studies investigating the efficacy of AdPEDF.11 in patients with neovascular AMD should be performed.
C1 Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21287 USA.
   Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA.
   Baylor Coll Med, Cullen Eye Inst, Houston, TX 77030 USA.
   Wayne State Univ, Kresge Eye Inst, Detroit, MI 48201 USA.
   Univ Washington, Seattle, WA 98195 USA.
   Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90095 USA.
   GenVec, Gaithersburg, MD 20878 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Oregon Health &
   Science University; Baylor College of Medicine; Wayne State University;
   University of Washington; University of Washington Seattle; University
   of California System; University of California Los Angeles
RP Campochiaro, PA (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Maumenee 719,600 N Wolfe St, Baltimore, MD 21287 USA.
EM pcampo@jhmi.edu
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1991, Ophthalmology, V98, P786
   Chevez-Barrios P, 2005, J CLIN ONCOL, V23, P7927, DOI 10.1200/JCO.2004.00.1883
   Gehlbach P, 2003, GENE THER, V10, P637, DOI 10.1038/sj.gt.3301931
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   MILLER J, 2005, AM SOC RET SPEC 23 A
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Rasmussen H, 2001, Hum Gene Ther, V12, P2029
   Saishin Y, 2005, HUM GENE THER, V16, P473, DOI 10.1089/hum.2005.16.473
NR 14
TC 268
Z9 306
U1 0
U2 13
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1043-0342
EI 1557-7422
J9 HUM GENE THER
JI Hum. Gene Ther.
PD FEB
PY 2006
VL 17
IS 2
BP 167
EP 176
DI 10.1089/hum.2006.17.167
PG 10
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 012VC
UT WOS:000235368000004
PM 16454650
DA 2022-11-30
ER

PT J
AU Whitmore, SS
   Braun, TA
   Skeie, JM
   Haas, CM
   Sohn, EH
   Stone, EM
   Scheetz, TE
   Mullins, RF
AF Whitmore, S. Scott
   Braun, Terry A.
   Skeie, Jessica M.
   Haas, Christine M.
   Sohn, Elliott H.
   Stone, Edwin M.
   Scheetz, Todd E.
   Mullins, Robert F.
TI Altered gene expression in dry age-related macular degeneration suggests
   early loss of choroidal endothelial cells
SO MOLECULAR VISION
LA English
DT Article
ID COMPLEMENT FACTOR-H; RETINAL-PIGMENT EPITHELIUM; RISK; SUSCEPTIBILITY;
   VARIANT; POLYMORPHISM; DENSITY; DRUSEN; LOCI; CHORIOCAPILLARIS
AB Purpose: Age-related macular degeneration (AMD) is a major cause of blindness in developed countries. The molecular pathogenesis of early events in AMD is poorly understood. We investigated differential gene expression in samples of human retinal pigment epithelium (RPE) and choroid from early AMD and control maculas with exon-based arrays.
   Methods: Gene expression levels in nine human donor eyes with early AMD and nine control human donor eyes were assessed using Affymetrix Human Exon ST 1.0 arrays. Two controls did not pass quality control and were removed. Differentially expressed genes were annotated using the Database for Annotation, Visualization and Integrated Discovery (DAVID), and gene set enrichment analysis (GSEA) was performed on RPE-specific and endothelium-associated gene sets. The complement factor H (CFH) genotype was also assessed, and differential expression was analyzed regarding high AMD risk (YH/HH) and low AMD risk (YY) genotypes.
   Results: Seventy-five genes were identified as differentially expressed (raw p value <0.01; >= 50% fold change, mean log(2) expression level in AMD or control >= median of all average gene expression values); however, no genes were significant (adj. p value <0.01) after correction for multiple hypothesis testing. Of 52 genes with decreased expression in AMD (fold change <0.5; raw p value <0.01), 18 genes were identified by DAVID analysis as associated with vision or neurologic processes. The GSEA of the RPE-associated and endothelium-associated genes revealed a significant decrease in genes typically expressed by endothelial cells in the early AMD group compared to controls, consistent with previous histologic and proteomic studies. Analysis of the CFH genotype indicated decreased expression of ADAMTS9 in eyes with high-risk genotypes (fold change = -2.61; raw p value=0.0008).
   Conclusions: GSEA results suggest that RPE transcripts are preserved or elevated in early AMD, concomitant with loss of endothelial cell marker expression. These results are consistent with the notion that choroidal endothelial cell dropout or dedifferentiation occurs early in the pathogenesis of AMD.
C1 [Whitmore, S. Scott; Braun, Terry A.; Skeie, Jessica M.; Haas, Christine M.; Sohn, Elliott H.; Stone, Edwin M.; Scheetz, Todd E.; Mullins, Robert F.] Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA USA.
   [Whitmore, S. Scott; Braun, Terry A.; Skeie, Jessica M.; Haas, Christine M.; Sohn, Elliott H.; Stone, Edwin M.; Scheetz, Todd E.; Mullins, Robert F.] Univ Iowa, Stephen A Wynn Inst Vis Res, Iowa City, IA USA.
   [Braun, Terry A.; Scheetz, Todd E.] Univ Iowa, Dept Biomed Engn, Iowa City, IA 52242 USA.
C3 University of Iowa; University of Iowa; University of Iowa
RP Mullins, RF (通讯作者)，4135E MERF,375 Newton Rd, Iowa City, IA 52242 USA.
EM robert-mullins@uiowa.edu
RI Mullins, Robert F/I-6717-2013
OI Whitmore, S. Scott/0000-0003-0161-9625; Sohn,
   Elliott/0000-0002-3778-9362; Mullins, Robert/0000-0002-5006-0891;
   Scheetz, Todd/0000-0002-1965-5811; Stone, Edwin M./0000-0003-3343-4414
FU National Institutes of Health [R01EY017451, R01EY016822]; Alcon
   Research, Ltd.; Hansjoerg E.J.W Kolder, MD, PhD. Professorship for Best
   Disease Research; Howard Hughes Medical Institute; NATIONAL EYE
   INSTITUTE [F32EY022280, R01EY016822, R01EY017451] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008629]
   Funding Source: NIH RePORTER
FX The National Institutes of Health R01 grants R01EY017451 and
   R01EY016822; the authors thank the eye donors and their families, and
   the Iowa Lions Eye Bank for their key role in providing human donor eyes
   for research. Supported in part by: Alcon Research, Ltd.; the Hansjoerg
   E.J.W Kolder, MD, PhD. Professorship for Best Disease Research; and the
   Howard Hughes Medical Institute.
CR Affymetrix. Alternative transcript analysis methods for exon arrays, 2005, AFF WHIT
   Almulki L, 2010, EXP EYE RES, V90, P26, DOI 10.1016/j.exer.2009.09.005
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bernat JA, 2006, HUM MOL GENET, V15, P2098, DOI 10.1093/hmg/ddl133
   Bevitt DJ, 2003, BBA-GENE STRUCT EXPR, V1626, P83, DOI 10.1016/S0167-4781(03)00047-2
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bonilha VL, 2006, ADV EXP MED BIOL, V572, P519
   Booij Judith C, 2010, PLoS One, V5, pe9341, DOI 10.1371/journal.pone.0009341
   Chen C, 2011, PLOS ONE, V6
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Emig D, 2010, NUCLEIC ACIDS RES, V38, pW755, DOI 10.1093/nar/gkq405
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gentleman R, 2005, STAT BIOL HEALTH, P189
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   HAGEMAN GS, 1991, P NATL ACAD SCI USA, V88, P2716, DOI 10.1073/pnas.88.7.2716
   HAGEMAN GS, 1995, ARCH OPHTHALMOL-CHIC, V113, P655, DOI 10.1001/archopht.1995.01100050123041
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Hunter A, 2012, INVEST OPHTH VIS SCI, V53, P2089, DOI 10.1167/iovs.11-8449
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kauffmann Audrey, 2009, Bioinformatics, V25, P415, DOI 10.1093/bioinformatics/btn647
   Kinsella RJ, 2011, DATABASE-OXFORD, DOI 10.1093/database/bar030
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Koo BH, 2010, AM J PATHOL, V176, P1494, DOI 10.2353/ajpath.2010.090655
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Leek JT, 2010, NAT REV GENET, V11, P733, DOI 10.1038/nrg2825
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   MCLEOD DS, 1995, AM J PATHOL, V147, P642
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Mullins RF, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-58
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Otani A, 1999, INVEST OPHTH VIS SCI, V40, P1912
   R Core Team, 2011, R LANG ENV STAT COMP
   Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500
   Rickman CB, 2006, INVEST OPHTH VIS SCI, V47, P2305, DOI 10.1167/iovs.05-1437
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Smoot ME, 2011, BIOINFORMATICS, V27, P431, DOI 10.1093/bioinformatics/btq675
   STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Swiderski RE, 2007, INVEST OPHTH VIS SCI, V48, P3329, DOI 10.1167/iovs.06-1477
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   van Soest SS, 2007, MOL VIS, V13, P1608
   Walker WL, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-494
   Wang L, 2010, PLOS ONE, V5
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 67
TC 47
Z9 49
U1 0
U2 2
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD NOV 16
PY 2013
VL 19
BP 2274
EP 2297
PG 24
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 272LY
UT WOS:000328463400003
PM 24265543
DA 2022-11-30
ER

PT J
AU Witkin, AJ
   Vuong, LN
   Srinivasan, VJ
   Gorczynska, I
   Reichel, E
   Baumal, CR
   Rogers, AH
   Schuman, JS
   Fujimoto, JG
   Duker, JS
AF Witkin, Andre J.
   Vuong, Laurel N.
   Srinivasan, Vivek J.
   Gorczynska, Iwona
   Reichel, Elias
   Baumal, Caroline R.
   Rogers, Adam H.
   Schuman, Joel S.
   Fujimoto, James G.
   Duker, Jay S.
TI High-speed Ultrahigh Resolution Optical Coherence Tomography before and
   after Ranibizumab for Age-related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID OCCULT CHOROIDAL NEOVASCULARIZATION; TRIAL
AB Objective: To evaluate intraretinal anatomy in patients with exudative age-related macular degeneration (AMD) using high-speed ultrahigh resolution optical coherence tomography (hsUHR-OCT) before and 1 month after intravitreal injection of ranibizumab.
   Design: Retrospective case series.
   Participants: Twelve eyes of 12 patients.
   Methods: A broad bandwidth superluminescent diode laser light source and spectral/Fourier domain signal detection were used to create a prototype hsUHR-OCT instrument with 3.5 mu m axial image resolution and approximately 25,000 lines/second acquisition speed. Twelve eyes of 12 patients with exudative AMD were imaged with hsUHR-OCT before and 1 month after intravitreal ranibizumab injection. High pixel density and raster-scanned 3-dimensional (3D) OCT data sets were generated. Three-dimensional imaging software was used to calculate subretinal/retinal pigment epithelium fluid volume and volume of the fibrovascular lesion.
   Main Outcome Measures: Qualitative and quantitative analysis of hsUHR-OCT images and 3D data sets.
   Results: All eyes had some degree of normalization of macular contour after intravitreal ranibizumab. The inner/outer photoreceptor segment junction visualized on hsUHR-OCT was discontinuous, overlying the fibrovascular lesion in all 12 of 12 eyes both before and after treatment; 9 of 12 eyes had focal areas of thinning of the outer nuclear layer, which remained after treatment. Volumetric measurements were possible in 8 of 12 eyes with 3D-rendering software. Fibrovascular lesion volume did not change significantly after treatment.
   Conclusions: hsUHR-OCT is capable of unprecedented imaging speed and resolution, making it a valuable instrument in measuring in vivo intraretinal pathology. All 12 eyes had some normalization of macular contour. Fibrovascular lesion volume did not change significantly 1 month after treatment, suggesting that ranibizumab does not cause much initial regression of preexisting neovascular tissue. Photoreceptor abnormalities remained in all patients after treatment of wet AMD, suggesting that although ranibizumab improves overall retinal architecture, some photoreceptor damage may be irreversible.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2009;116:956-963 (C) 2009 by the American Academy of Ophthalmology.
C1 [Witkin, Andre J.; Vuong, Laurel N.; Gorczynska, Iwona; Reichel, Elias; Baumal, Caroline R.; Rogers, Adam H.; Duker, Jay S.] Tufts Med Ctr, Boston, MA 02111 USA.
   [Srinivasan, Vivek J.; Gorczynska, Iwona; Fujimoto, James G.] MIT, Boston, MA USA.
   [Schuman, Joel S.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
C3 Tufts Medical Center; Massachusetts Institute of Technology (MIT);
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh
RP Witkin, AJ (通讯作者)，Tufts Med Ctr, 800 Washington St,Box 450, Boston, MA 02111 USA.
EM AJWitkin@Gmail.com
RI Schuman, Joel S/M-2389-2019; Schuman, Joel S/K-7304-2012; Gorczynska,
   Iwona M./P-9367-2015
OI Schuman, Joel S/0000-0002-8885-3766; Schuman, Joel
   S/0000-0002-8885-3766; Gorczynska, Iwona M./0000-0002-6120-8791
FU National Institutes of Health [R01-EY11289-21, R01-EY13178-07,
   P30-EY008098]; National Science Foundation [BES0522845]; Air Force
   Office of Scientific Research [FA9550-07-1-0101]; NATIONAL EYE INSTITUTE
   [R01EY011289, R01EY013178, P30EY008098] Funding Source: NIH RePORTER
FX Financial support provided by National Institutes of Health
   R01-EY11289-21, R01-EY13178-07; P30-EY008098; National Science
   Foundation BES0522845; Air Force Office of Scientific Research, Medical
   Free Electron Laser Program contract FA9550-07-1-0101. The sponsors had
   no role in the design or conduct of this research.
CR Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Choma MA, 2003, OPT EXPRESS, V11, P2183, DOI 10.1364/OE.11.002183
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Hughes EH, 2005, AM J OPHTHALMOL, V139, P344, DOI 10.1016/j.ajo.2004.07.058
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Leitgeb R, 2003, OPT EXPRESS, V11, P889, DOI 10.1364/OE.11.000889
   Pieroni CG, 2006, BRIT J OPHTHALMOL, V90, P191, DOI 10.1136/bjo.2005.076612
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Srinivasan VJ, 2006, OPHTHALMOLOGY, V113, P2054, DOI 10.1016/j.ophtha.2006.05.046
   Stewart MW, 2007, RETINA-J RET VIT DIS, V27, P1196, DOI 10.1097/IAE.0b013e318158ea28
   Wojtkowski M, 2005, OPHTHALMOLOGY, V112, P1734, DOI 10.1016/j.ophtha.2005.05.023
   Yun SH, 2003, OPT EXPRESS, V11, P3598, DOI 10.1364/OE.11.003598
NR 20
TC 35
Z9 37
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2009
VL 116
IS 5
BP 956
EP 963
DI 10.1016/j.ophtha.2008.12.018
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 508DI
UT WOS:000270907500021
PM 19410953
OA Green Accepted
DA 2022-11-30
ER

PT J
AU McGwin, G
   Modjarrad, K
   Hall, TA
   Xie, AY
   Owsley, C
AF McGwin, G
   Modjarrad, K
   Hall, TA
   Xie, AY
   Owsley, C
TI 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the
   presence of age-related macular degeneration in the cardiovascular
   health study
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID 5-YEAR INCIDENCE; RISK-FACTORS; MEDICATION USE; STATIN USE; MACULOPATHY;
   CHOLESTEROL; ATHEROSCLEROSIS; OSTEOPOROSIS; DISEASE
AB Objective: To evaluate both the use of cholesterol-lowering medications as a group and the use of statins specifically with regard to the risk of age-related macular degeneration (AMD).
   Methods: A case-control study was conducted using data from the Cardiovascular Health Study, a population-based prospective study of adults enrolled from 4 communities in the United States in 1989 and 1990. Individuals with AMD (cases) and those without AMD (controls) were compared with regard to their use of cholesterol-lowering medications and statins.
   Results: Nearly equal proportions of cases and controls used cholesterol-lowering medications, both before adjustment (odds ratio, 0.92; 95% confidence interval, 0.70-1.21) and after adjustment for selected confounding variables (age, sex, and race) (odds ratio, 1.35; 95% confidence interval, 0.98-1.87). Statin use was also found to be similar among cases and controls (odds ratio, 0.98; 95% confidence interval, 0.73-1.30). After controlling for the aforementioned 3 confounders (odds ratio, 1.40 95% confidence interval, 0.99-1.98), we noted a modest trend for statin users to have an increased risk of AMD.
   Conclusion: The results suggest that no association exists between having used cholesterol-lowering medications and AMD. However, there was a suggestion that statin use might increase the risk of AMD.
C1 Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol & Int Hlth, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, Sch Med, Dept Surg, Div Gen Surg,Sect Trauma Burns & Surg Crit Care, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP McGwin, G (通讯作者)，Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, 700 S 18th St,Suite 609, Birmingham, AL 35294 USA.
EM mcgwin@uab.edu
RI Owsley, Cynthia/B-7986-2014
FU NATIONAL EYE INSTITUTE [R21EY014071] Funding Source: NIH RePORTER; NEI
   NIH HHS [R21 EY 14071] Funding Source: Medline
CR Abalain JH, 2002, CLIN CHIM ACTA, V326, P97, DOI 10.1016/S0009-8981(02)00288-7
   [Anonymous], [No title captured]
   *ARIC STUD RES GRO, 2000, ARIC RET PHOT PROT M
   Bauer DC, 2004, ARCH INTERN MED, V164, P146, DOI 10.1001/archinte.164.2.146
   Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Fried Linda P., 1991, Annals of Epidemiology, V1, P263
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143
   Grundy SM, 2004, CIRCULATION, V110, P227, DOI 10.1161/01.CIR.0000133317.49796.0E
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   HENNEKENS CH, 2001, CLIN CARDIOL S, V24, P2
   Hubbard LD, 1999, OPHTHALMOLOGY, V106, P2269, DOI 10.1016/S0161-6420(99)90525-0
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Kliffen M, 2000, BRIT J OPHTHALMOL, V84, P1415, DOI 10.1136/bjo.84.12.1415
   MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   Milani Richard V, 2004, Am J Geriatr Cardiol, V13, P25
   Miller LJ, 2004, ANN PHARMACOTHER, V38, P91, DOI 10.1345/aph.1D104
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Schlienger RG, 2003, DRUG AGING, V20, P321, DOI 10.2165/00002512-200320050-00002
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Tell G S, 1993, Ann Epidemiol, V3, P358, DOI 10.1016/1047-2797(93)90062-9
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Waldman A, 2003, DRUGS, V63, P139, DOI 10.2165/00003495-200363020-00002
   Werner N, 2002, BASIC RES CARDIOL, V97, P105, DOI 10.1007/s003950200000
   Wirleitner B, 2004, J AM COLL CARDIOL, V43, P1132, DOI 10.1016/j.jacc.2003.12.029
   Yang CC, 2003, ARCH INTERN MED, V163, P1926, DOI 10.1001/archinte.163.16.1926
NR 40
TC 39
Z9 40
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JAN
PY 2006
VL 124
IS 1
BP 33
EP 37
DI 10.1001/archopht.124.1.33
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 000WQ
UT WOS:000234493500004
PM 16401782
DA 2022-11-30
ER

PT J
AU Grunwald, JE
   Daniel, E
   Huang, JY
   Ying, GS
   Maguire, MG
   Toth, CA
   Jaffe, GJ
   Fine, SL
   Blodi, B
   Klein, ML
   Martin, AA
   Hagstrom, SA
   Martin, DF
AF Grunwald, Juan E.
   Daniel, Ebenezer
   Huang, Jiayan
   Ying, Gui-shuang
   Maguire, Maureen G.
   Toth, Cynthia A.
   Jaffe, Glenn J.
   Fine, Stuart L.
   Blodi, Barbara
   Klein, Michael L.
   Martin, Alison A.
   Hagstrom, Stephanie A.
   Martin, Daniel F.
CA CATT Res Grp
TI Risk of Geographic Atrophy in the Comparison of Age-related Macular
   Degeneration Treatments Trials
SO OPHTHALMOLOGY
LA English
DT Article
ID RANIBIZUMAB; BEVACIZUMAB; PROGRESSION; SUSCEPTIBILITY; DISEASE; AREA;
   CATT; AMD
AB Purpose: To describe risk factors for geographic atrophy (GA) in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).
   Design: Cohort within a randomized clinical trial.
   Participants: We analyzed 1024 CATT patients with no GA visible on color fundus photographs (CFPs) and/or fluorescein angiograms (FAs) at enrollment.
   Methods: Eyes were assigned to ranibizumab (0.5 mg) or bevacizumab (1.25 mg) treatment and to a 2-year monthly or pro re nata (PRN) injection regimen, or monthly injections for 1 year and PRN for 1 year. Demographic, genetic, and baseline ocular characteristics and lesion features of CFP/FA and optical coherence tomography (OCT) were evaluated as risk factors for GA through 2 years of follow-up. Time-dependent Cox proportional hazard models were used to estimate adjusted hazard ratios (aHRs).
   Main Outcome Measures: Development of GA.
   Results: By 2 years, GA developed in 187 of 1024 patients (18.3%). Baseline risk factors for GA development included baseline visual acuity (VA) <= 20/200 (aHR, 2.65; 95% confidence interval [CI], 1.43-4.93), retinal angiomatous proliferation (RAP; aHR, 1.69; 95% CI, 1.16-2.47), GA in the fellow eye (aHR, 2.07; 95% CI, 1.40-3.08), and intraretinal fluid at the foveal center (aHR, 2.10; 95% CI, 1.34-3.31). Baseline factors associated with lower risk for GA development included blocked fluorescence (aHR, 0.49; 95% CI, 0.29-0.82), OCT measurements of subretinal fluid thickness of >25 mu (aHR, 0.52; 95% CI, 0.35-0.78), subretinal tissue complex thickness of >275 compared with <= 75 mu (aHR, 0.31; 95% CI, 0.19-0.50), and vitreomacular attachment (aHR, 0.55; 95% CI, 0.31-0.97). Ranibizumab compared with bevacizumab had a higher risk (aHR, 1.43; 95% CI, 1.06-1.93), and monthly dosing had a higher risk (aHR, 1.59; 95% CI, 1.17-2.16) than PRN dosing. There were no strong associations between development of GA and the presence of risk alleles for CFH, ARMS 2, HTRA1, C3, or TLR3.
   Conclusions: Approximately one fifth of CATT patients developed GA within 2 years of treatment. Independent baseline risk factors included poor VA, RAP, foveal intraretinal fluid, monthly dosing, and treatment with ranibizumab. Anti-vascular endothelial growth factor therapy may have a role in the development of GA. (C) 2014 by the American Academy of Ophthalmology.
C1 [Grunwald, Juan E.; Daniel, Ebenezer; Huang, Jiayan; Ying, Gui-shuang; Maguire, Maureen G.] Univ Penn, Dept Ophthalmol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Toth, Cynthia A.; Jaffe, Glenn J.] Duke Univ, Dept Ophthalmol, Durham, NC USA.
   [Toth, Cynthia A.] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA.
   [Jaffe, Glenn J.] Duke Univ, Ctr Eye, Duke Reading Ctr, Durham, NC USA.
   [Fine, Stuart L.] Univ Colorado Denver, Dept Ophthalmol, Aurora, CO USA.
   [Blodi, Barbara] Univ Wisconsin, Dept Ophthalmol, Madison, WI USA.
   [Klein, Michael L.] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR USA.
   [Martin, Alison A.; Hagstrom, Stephanie A.; Martin, Daniel F.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; Duke University; Duke
   University; Duke University; Children's Hospital Colorado; University of
   Colorado System; University of Colorado Anschutz Medical Campus;
   University of Wisconsin System; University of Wisconsin Madison; Oregon
   Health & Science University; Cleveland Clinic Foundation
RP Grunwald, JE (通讯作者)，Univ Penn, Dept Ophthalmol, 51 North 39th St, Philadelphia, PA 19104 USA.
EM juangrun@mail.med.upenn.edu
RI Mitchell, Paul/P-1498-2014; Toth, Cynthia/L-5534-2019
OI Toth, Cynthia/0000-0002-2324-0854; Daniel, Ebenezer/0000-0002-2027-2316
FU National Eye Institute, National Institutes of Health, Department of
   Health and Human Services [U10 EY017823, U10 EY017825, U10 EY017826, U10
   EY017828]; NATIONAL EYE INSTITUTE [U10EY017826] Funding Source: NIH
   RePORTER
FX Supported by cooperative agreements U10 EY017823, U10 EY017825, U10
   EY017826, and U10 EY017828 from the National Eye Institute, National
   Institutes of Health, Department of Health and Human Services.
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Brader HS, 2011, INVEST OPHTH VIS SCI, V52, P9218, DOI 10.1167/iovs.11-7493
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   DeCroos FC, 2012, OPHTHALMOLOGY, V119, P2549, DOI 10.1016/j.ophtha.2012.06.040
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Green W R, 1999, Mol Vis, V5, P27
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Khanifar AA, 2012, RETINA-J RET VIT DIS, V32, P1884, DOI 10.1097/IAE.0b013e3182509778
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mauschitz MM, 2012, INVEST OPHTH VIS SCI, V53, P4932, DOI 10.1167/iovs.12-9711
   McBain VA, 2011, RETINA-J RET VIT DIS, V31, P1043, DOI 10.1097/IAE.0b013e3181fe54c7
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Sarks J, 2006, BRIT J OPHTHALMOL, V90, P442, DOI 10.1136/bjo.2005.083022
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   Sunness JS, 1999, MOL VIS, V5
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
NR 30
TC 380
Z9 389
U1 0
U2 34
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2014
VL 121
IS 1
BP 150
EP 161
DI 10.1016/j.ophtha.2013.08.015
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 282KG
UT WOS:000329169500029
PM 24084496
OA Green Accepted
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Cahill, MT
   Banks, AD
   Stinnett, SS
   Toth, CA
AF Cahill, MT
   Banks, AD
   Stinnett, SS
   Toth, CA
TI Vision-related quality of life in patients with bilateral severe age
   related macular degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID VISUAL FUNCTION QUESTIONNAIRE; TRANSLOCATION; ACUITY; INDEX
AB Purpose: To determine the quality Of life (QOL) of patients with bilateral severe age-related macular degeneration (AMD) before macular translocation with 360degrees peripheral retinectomy.
   Design: Prospective, consecutive, noncomparative case series.
   Methods: An observational study assessed vision-related and general health QOL using the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) and the Medical Outcomes Study 12-item short form (SF-12) surveys, respectively. Mean QOL scores were correlated with patient age, duration of vision loss, and visual function. Mean QOL scores in study patients were compared with mean QOL scores in groups of patients with low vision, patients with AMD of varying severity, and reference populations.
   Main Outcome Measures: National Eye Institute VFQ-25 and SF-12 QOL scores.
   Results: Seventy patients with a mean age of 76.4 years were studied. Mean distance visual acuity (VA) was 62.4 (Early Treatment Diabetic Retinopathy Study letters), mean near VA was 0.81 (logarithm of the minimum angle of resolution), and mean reading speed was 74.9 words per minute. Important NEI VFQ-25 quality of vision subscales (general vision, difficulty with distance tasks, difficulty with near tasks) and vision-specific subscales (dependency, role difficulties, mental health, social function limitations) tended to correlate negatively with increasing patient age and duration of vision loss, but correlated positively with better VA and reading speed. The mean QOL scores for these important quality of vision and vision-specific subscales were significantly worse than or similar to mean scores in patients with low vision, and significantly worse than scores in patients with AMD of varying severity and a reference population. The mean SF-12 physical composite score in study patients was similar to that seen in patients with AMD of varying severity, but significantly higher than that in patients with low vision and a reference population. The SF-12 mental composite score in study patients was similar to those of all 3 comparison groups.
   Conclusions: Patients with bilateral severe AMD have vision-related QOL similar to that of patients with low vision but significantly worse than those of patients with AMD of varying severity and persons without eye disease. This inability to perform vision-related daily tasks is not related to general health problems. (C) 2005 by the American Academy of Ophthalmology.
C1 Duke Univ, Ctr Eye, Durham, NC 27710 USA.
C3 Duke University
RP Toth, CA (通讯作者)，Duke Univ, Ctr Eye, Erwin Rd,POB 3802, Durham, NC 27710 USA.
EM toth0004@mc.duke.edu
RI Toth, Cynthia/L-5534-2019; toth, cynthia a/F-5614-2011
OI Toth, Cynthia/0000-0002-2324-0854; Stinnett, Sandra/0000-0001-7192-0195
FU NATIONAL EYE INSTITUTE [R21EY011725] Funding Source: NIH RePORTER; NEI
   NIH HHS [EY11725] Funding Source: Medline
CR ALEXANDER MF, 1988, ARCH OPHTHALMOL-CHIC, V106, P1543, DOI 10.1001/archopht.1988.01060140711040
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   Bass E, 2000, AM J OPHTHALMOL, V130, P408
   BROWN B, 1984, AM J OPTOM PHYS OPT, V61, P265
   Brown CD, 2000, PROC BRIGHTON CROP, V1-3, P85
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Brown GC, 2000, CAN J OPHTHALMOL, V35, P127, DOI 10.1016/S0008-4182(00)80005-8
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Globe DR, 2002, OPHTHALMOLOGY, V109, P1793, DOI 10.1016/S0161-6420(02)01124-7
   Hart PM, 1999, BRIT J OPHTHALMOL, V83, P1115, DOI 10.1136/bjo.83.10.1115
   Lai JC, 2002, ARCH OPHTHALMOL-CHIC, V120, P1317, DOI 10.1001/archopht.120.10.1317
   Mackenzie PJ, 2002, OPHTHALMOLOGY, V109, P720, DOI 10.1016/S0161-6420(01)01021-1
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   MANGIONE CM, 1992, MED CARE, V30, P1111, DOI 10.1097/00005650-199212000-00004
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   *SAS I, 2000, SAS COMP PROGR VERS
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026
   Toth CA, 2001, RETINA-J RET VIT DIS, V21, P293, DOI 10.1097/00006982-200108000-00001
   WARE JE, 2000, SCORE SF 12 PHYS MEN
NR 24
TC 135
Z9 140
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2005
VL 112
IS 1
BP 152
EP 158
DI 10.1016/j.ophtha.2004.06.036
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 886QG
UT WOS:000226242800026
PM 15629836
DA 2022-11-30
ER

PT J
AU McCormick, R
   Pearce, I
   Kaye, S
   Haneef, A
AF McCormick, Rachel
   Pearce, Ian
   Kaye, Stephen
   Haneef, Atikah
TI Optimisation of a Novel Bio-Substrate as a Treatment for Atrophic
   Age-Related Macular Degeneration
SO FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
LA English
DT Article
DE AMD; electrospinning; electrospraying; nanoparticles; sustained release;
   composite; substrate; coaxial
ID RETINAL-PIGMENT EPITHELIUM; BRUCHS MEMBRANE; SCAFFOLDS; AMD
AB Atrophic age-related macular degeneration (AMD) is the most common form of AMD accounting for 90% of patients. During atrophic AMD the waste/exchange pathway between the blood supply (choroid) and the retinal pigment epithelium (RPE) is compromised. This results in atrophy and death of the RPE cells and subsequently the photoreceptors leading to central blindness. Although the mechanisms behind AMD are unknown, the growth of fatty deposits known as drusen, have been shown to play a role in the disease. There is currently no treatment or cure for atrophic AMD. Much research focuses on developing a synthetic substrate in order to transplant healthy cells to the native Bruch's membrane (BM), however, the diseased native BM and related structures still leave potential for transplanted cells to succumb to disease. In this proof-of-concept work we electrospun poly(ethylene terephthalate) (PET) to fabricate a nanofibrous cytocompatible synthetic BM. The apical surface of the membrane was cultured with ARPE-19 cells and the underside was decorated with poly(lactic acid-co-glycolic acid) (PLGA) or poly(glycolic acid) (PGA) degradable nanoparticles by electrospraying. The membrane exhibited hydrophilicity, high tensile strength and structurally resembled the native BM. ARPE-19 cells were able to form a monolayer on the surface of the membrane and no cell invasion into the membrane was seen. The presence of both PLGA and PGA nanoparticles increased ARPE-19 cell metabolism but had no effect on cell viability. There was a decrease in pH of ARPE-19 cell culture media 7 days following culturing with the PLGA nanoparticles but this change was eliminated by 2 weeks; PGA nanoparticles had no effect on cell culture media pH. The fluorescent dye FITC was encapsulated into nanoparticles and showed sustained release from PLGA nanoparticles for 2 weeks and PGA nanoparticles for 1 day. Future work will focus on encapsulating biologically active moieties to target drusen. This could allow this novel bioactive substrate to be a potential treatment for atrophic AMD that would function two-fold: deliver the required monolayer of healthy RPE cells to the macula on a synthetic BM and remove diseased structures within the retina, restoring the waste/exchange pathway and preventing vision loss.
C1 [McCormick, Rachel; Kaye, Stephen; Haneef, Atikah] Univ Liverpool, Inst Life Course & Med Sci, Dept Eye & Vis Sci, Liverpool, Merseyside, England.
   [Pearce, Ian; Kaye, Stephen] Royal Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool, Merseyside, England.
C3 University of Liverpool; Royal Liverpool & Broadgreen University
   Hospitals NHS Trust; Royal Liverpool University Hospital; University of
   Liverpool
RP Haneef, A (通讯作者)，Univ Liverpool, Inst Life Course & Med Sci, Dept Eye & Vis Sci, Liverpool, Merseyside, England.
EM atikahh@liverpool.ac.uk
FU EPSRC [EP/S001468/1]
FX This work was funded by the EPSRC, Grant reference number: EP/S001468/1.
CR Brandl C, 2014, NEUROMOL MED, V16, P551, DOI 10.1007/s12017-014-8308-8
   Chen L, 2018, CHINESE J POLYM SCI, V36, P1063, DOI 10.1007/s10118-018-2112-0
   Chen X., 2020, CURR EYE RES, V30, P1
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Curcio C.A., 2013, RETINA-J RET VIT DIS, V5th, P465
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Del Priore LV, 2006, PROG RETIN EYE RES, V25, P539, DOI 10.1016/j.preteyeres.2006.08.001
   Haneef AS, 2015, INT J POLYM MATER PO, V64, P320, DOI 10.1080/00914037.2014.945206
   Kawai F, 2019, APPL MICROBIOL BIOT, V103, P4253, DOI 10.1007/s00253-019-09717-y
   KITTREDGE A, 2018, JOVE J VIS EXP AUG, V0138
   Kurokawa N, 2018, J APPL POLYM SCI, V135, DOI 10.1002/app.45429
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Liu ZP, 2014, BIOMATERIALS, V35, P2837, DOI 10.1016/j.biomaterials.2013.12.069
   Lu B, 2012, BIOMED MICRODEVICES, V14, P659, DOI 10.1007/s10544-012-9645-8
   Moore TL, 2015, CHEM SOC REV, V44, P6287, DOI 10.1039/c4cs00487f
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Park SY, 2008, J BIOL CHEM, V283, P10593, DOI 10.1074/jbc.M709105200
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Rudolf M, 2019, INVEST OPHTH VIS SCI, V60, P461, DOI 10.1167/iovs.18-25786
   Sharma N, 2016, ASIAN J PHARM SCI, V11, P404, DOI 10.1016/j.ajps.2015.09.004
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Surrao DC, 2017, ACTA BIOMATER, V64, P357, DOI 10.1016/j.actbio.2017.09.032
   Tan E. Y. S., 2019, 60 SCAFFOLDS RETINAL
   Thomson HAJ, 2011, BRIT J OPHTHALMOL, V95, P563, DOI 10.1136/bjo.2009.166728
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   White CE, 2017, J TISSUE ENG, V8, DOI 10.1177/2041731417720841
   YAMAMOTO T, 1989, BRIT J OPHTHALMOL, V73, P162, DOI 10.1136/bjo.73.3.162
   Yeste J, 2018, J BIOL ENG, V12, DOI 10.1186/s13036-018-0108-5
NR 29
TC 4
Z9 4
U1 1
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-4185
J9 FRONT BIOENG BIOTECH
JI Front. Bioeng. Biotechnol.
PD MAY 15
PY 2020
VL 8
AR 456
DI 10.3389/fbioe.2020.00456
PG 14
WC Biotechnology & Applied Microbiology; Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA MW0QU
UT WOS:000556753000001
PM 32500067
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Kitagawa, Y
   Shimada, H
   Mori, R
   Tanaka, K
   Yuzawa, M
AF Kitagawa, Yorihisa
   Shimada, Hiroyuki
   Mori, Ryusaburo
   Tanaka, Kouji
   Yuzawa, Mitsuko
TI Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas
   Injection for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; PNEUMATIC DISPLACEMENT; MACULAR
   DEGENERATION; SUBRETINAL HEMORRHAGE; PHOTODYNAMIC THERAPY; RETINAL
   TOXICITY; VITRECTOMY; BEVACIZUMAB; MANAGEMENT; AFLIBERCEPT
AB Purpose: To investigate the efficacy of intravitreal injection of recombinant tissue plasminogen activator (rtPA), ranibizumab, and gas without vitrectomy for submacular hemorrhage.
   Design: Prospective, interventional, consecutive case series.
   Participants: Twenty consecutive patients (20 eyes) with submacular hemorrhage secondary to exudative age-related macular degeneration (AMD) or polypoidal choroidal vasculopathy (PCV).
   Methods: Ranibizumab, rt-PA (25 mu g/0.05 ml), and 100% perfluoropropane (0.3 ml) were injected intravitreally, followed by 2-day prone positioning.
   Main Outcome Measures: The primary outcome measure was best-corrected visual acuity (BCVA) 6 months after treatment. Secondary outcome measures included central retinal thickness (CRT), central pigment epithelial detachment (PED) thickness, central ellipsoid zone, recurrence rate, and complications.
   Results: Underlying disease was exudative AMD in 1 eye and PCV in 19 eyes. Submacular hemorrhage ranged in size from 2 to 31 disc diameters. Complete displacement of submacular hemorrhage was achieved in 17 eyes (85%), and partial displacement was achieved in 3 eyes (15%). Snellen BCVA improved from 20/139 before treatment to 20/ 65 at 6 months (P = 0.0061). Mean change in Early Treatment Diabetic Retinopathy Study score from baseline was + 13 letters (P = 0.0040). Mean CRT decreased from 599 mm before treatment to 208 mm at 6 months (P < 0.0001), and central PED thickness decreased from 188 to 88 mm (P = 0.0140). Three eyes developed vitreous hemorrhage, and 1 eye developed retinal detachment; all were treated surgically, and Snellen BCVA improved at 6 months (P = 0.0012). Recurrence was observed in 10 eyes (50%) within 6 months, but visual acuity was preserved with intravitreal injection of antievascular endothelial growth factor (VEGF) pro re nata (PRN). The factors that affect BCVA at 6 months after treatment were pre- and posttreatment central ellipsoid zone (P = 0.0366 and P = 0.0424), pretreatment BCVA (P = 0.0015), and pre-and posttreatment central PED thickness (P = 0.0046, P = 0.0021).
   Conclusions: Subretinal hemorrhage treatment by intravitreal injection of rt-PA, ranibizumab, and gas is useful to achieve hemorrhage displacement and lesion improvement. To preserve visual acuity, early detection of posttreatment recurrence and intravitreal anti-VEGF injection PRN are necessary. (C) 2016 by the American Academy of Ophthalmology.
C1 [Kitagawa, Yorihisa; Shimada, Hiroyuki; Mori, Ryusaburo; Tanaka, Kouji; Yuzawa, Mitsuko] Nihon Univ, Sch Med, Dept Ophthalmol, Chiyoda Ku, Tokyo, Japan.
C3 Nihon University
RP Shimada, H (通讯作者)，Nihon Univ Hosp, Dept Ophthalmol, Chiyoda Ku, 1-6 Surugadai, Tokyo 1018309, Japan.
EM sshimada@olive.ocn.ne.jp
CR Ahn SJ, 2014, INVEST OPHTH VIS SCI, V55, P567, DOI 10.1167/iovs.13-13054
   Arias L, 2010, CLIN OPHTHALMOL, V4, P67
   Chan WM, 2005, CLIN EXP OPHTHALMOL, V33, P611, DOI 10.1111/j.1442-9071.2005.01105.x
   Chang W, 2014, AM J OPHTHALMOL, V157, P1250, DOI 10.1016/j.ajo.2014.02.007
   Christoforidis JB, 2013, RETINA-J RET VIT DIS, V33, P946, DOI 10.1097/IAE.0b013e3182753b12
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Guthoff R, 2011, RETINA-J RET VIT DIS, V31, P36, DOI 10.1097/IAE.0b013e3181e37884
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Hirashima T, 2015, RETINA-J RET VIT DIS, V35, P1969, DOI 10.1097/IAE.0000000000000574
   Hosokawa M, 2015, BRIT J OPHTHALMOL, V99, P1087, DOI 10.1136/bjophthalmol-2014-305275
   Hrach CJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P659
   JOHNSON MW, 1990, ARCH OPHTHALMOL-CHIC, V108, P259, DOI 10.1001/archopht.1990.01070040111042
   Jung JH, 2010, RETINA-J RET VIT DIS, V30, P865, DOI 10.1097/IAE.0b013e3181c969e9
   Kadonosono K, 2015, OPHTHALMOLOGY, V122, P123, DOI 10.1016/j.ophtha.2014.07.027
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Kimura S, 2015, AM J OPHTHALMOL, V159, P683, DOI 10.1016/j.ajo.2014.12.020
   Kitahashi M, 2014, CLIN OPHTHALMOL, V8, P485, DOI 10.2147/OPTH.S55413
   Klettner A, 2015, BRIT J OPHTHALMOL, V99, P864, DOI 10.1136/bjophthalmol-2014-306454
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Mayer WJ, 2013, ACTA OPHTHALMOL, V91, P274, DOI 10.1111/j.1755-3768.2011.02264.x
   Mizutani T, 2011, GRAEF ARCH CLIN EXP, V249, P1153, DOI 10.1007/s00417-011-1649-1
   Sacu S, 2009, EYE, V23, P1404, DOI 10.1038/eye.2008.267
   Schulze SD, 2002, GRAEF ARCH CLIN EXP, V240, P717, DOI 10.1007/s00417-002-0516-5
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shimada H, 2013, GRAEF ARCH CLIN EXP, V251, P1885, DOI 10.1007/s00417-013-2274-y
   Shin JY, 2015, AM J OPHTHALMOL, V159, P904, DOI 10.1016/j.ajo.2015.01.024
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Spaide RF, 1994, RETINA, V15, P100
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Treumer F, 2010, BRIT J OPHTHALMOL, V94, P48, DOI 10.1136/bjo.2009.164707
   Treumer F, 2012, BRIT J OPHTHALMOL, V96, P708, DOI 10.1136/bjophthalmol-2011-300655
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   van Zeeburg EJT, 2015, OPHTHALMOLOGICA, V233, P134, DOI 10.1159/000380829
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
NR 36
TC 18
Z9 22
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2016
VL 123
IS 6
BP 1278
EP 1286
DI 10.1016/j.ophtha.2016.01.035
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DM7BD
UT WOS:000376506400024
PM 26949121
DA 2022-11-30
ER

PT J
AU Zucchiatti, I
   Parodi, MB
   Pierro, L
   Cicinelli, MV
   Gagliardi, M
   Castellino, N
   Bandello, F
AF Zucchiatti, Ilaria
   Parodi, Maurizio Battaglia
   Pierro, Luisa
   Cicinelli, Maria Vittoria
   Gagliardi, Marco
   Castellino, Niccolo
   Bandello, Francesco
TI Macular Ganglion Cell Complex and Retinal Nerve Fiber Layer Comparison
   in Different Stages of Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; MORPHOMETRIC ANALYSIS; THICKNESS; EYES;
   CHORIOCAPILLARIS; DRUSEN
AB PURPOSE: To employ optical coherence tomography (OCT) to analyze the morphologic changes in the inner retina in different categories of age-related macular degeneration (AMD).
   DESIGN: Observational cross-sectional study.
   METHODS: Single-center study. Inclusion criteria were age over 50, diagnosis of Age-Related Eye Disease Study (AREDS) category 2 and 3, naive neovascular AMD, and atrophic AMD. Healthy patients of similar age acted as a control group. Primary outcome measures were the changes in ganglion cell complex (GCC) and retinal nerve fiber layer (RNFL). Secondary outcomes included modifications of rim area and cup-to-disc ratio.
   RESULTS: One hundred and thirty eyes of 130 patients were recruited: 26 eyes for AREDS category 2, 26 for AREDS category 3, 26 for neovascular AMD, 26 with atrophic AMD, and 26 controls. Mean peripapillary RNFL thickness was significantly lower in neovascular AMD, compared to controls (P=.004); peripapillary RNFL did not significantly vary among AREDS category 2 and 3 and atrophic AMID groups, compared to controls. Mean GCC thickness was higher in the control group, becoming progressively thinner up to neovascular and atrophic AMID groups (P<.0001). Rim area was significantly thinner in the neovascular AMID group compared with controls (P=.047); cup-to-disc ratio was higher in the neovascular AMID group compared with the control group (P=.047).
   CONCLUSIONS: This study demonstrates that eyes with neovascular AMD display reduced RNFL and GCC thickness. RNFL is partially spared in atrophic advanced AMD. The identification of alteration in RNFL and GCC thickness may reveal useful for future therapeutic implications. (C) 2015 by Elsevier Inc. All rights reserved.
C1 [Zucchiatti, Ilaria; Parodi, Maurizio Battaglia; Pierro, Luisa; Cicinelli, Maria Vittoria; Gagliardi, Marco; Castellino, Niccolo; Bandello, Francesco] Univ Vita Salute, San Raffaele Sci Inst, Dept Ophthalmol, I-20132 Milan, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Zucchiatti, I (通讯作者)，Univ Vita Salute, San Raffaele Sci Inst, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.
EM ilaria.zucchiatti@gmail.com
RI Zucchiatti, Ilaria/ABA-7083-2020; Parodi, Maurizio
   Battaglia/K-7876-2016; Gagliardi, Marco/AAN-4364-2020; Castellino,
   Niccolò/AAC-4717-2022; Pierro, Luisa/AAN-3900-2020; bandello,
   francesco/AAH-2405-2019; cicinelli, maria vittoria/M-1611-2019
OI Gagliardi, Marco/0000-0001-8779-607X; bandello,
   francesco/0000-0003-3238-9682; cicinelli, maria
   vittoria/0000-0003-2938-0409; Battaglia Parodi,
   Maurizio/0000-0002-0385-7961; Zucchiatti, Ilaria/0000-0003-1142-1970;
   pierro, luisa/0000-0003-2168-5224; Castellino,
   Niccolo/0000-0003-1818-6686
CR Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   Akagi-Kurashige Y, 2012, GRAEF ARCH CLIN EXP, V250, P1129, DOI 10.1007/s00417-012-1928-5
   Boretsky A, 2012, LASER SURG MED, V44, P603, DOI 10.1002/lsm.22070
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Feigl B, 2007, EYE, V21, P689, DOI 10.1038/sj.eye.6702389
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Garas A, 2013, J GLAUCOMA, V22, P195, DOI 10.1097/IJG.0b013e31824083e6
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Hall ER, 2006, AM J OPHTHALMOL, V141, P494, DOI 10.1016/j.ajo.2005.10.049
   Hendrickson A, 2015, BRAIN STRUCT FUNCT, V220, P351, DOI 10.1007/s00429-013-0659-7
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P471, DOI 10.1097/00006982-200208000-00012
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P464, DOI 10.1097/00006982-200208000-00011
   Ko A, 2013, RETINA-J RET VIT DIS, V33, P1005, DOI 10.1097/IAE.0b013e31827d266e
   Law SK, 2004, AM J OPHTHALMOL, V138, P38, DOI 10.1016/j.ajo.2004.02.021
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Martinez-de-la-Casa JM, 2012, INVEST OPHTH VIS SCI, V53, P6214, DOI 10.1167/iovs.12-9875
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Parlak M, 2014, INT OPHTHALMOL
   Savastano MC, 2014, INVEST OPHTH VIS SCI, V55, P560, DOI 10.1167/iovs.13-12172
   Shin HJ, 2014, INVEST OPHTH VIS SCI, V55, P2403, DOI 10.1167/iovs.13-13769
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Yuda K, 2010, GRAEF ARCH CLIN EXP, V248, P353, DOI 10.1007/s00417-009-1222-3
NR 26
TC 55
Z9 56
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2015
VL 160
IS 3
BP 602
EP 607
DI 10.1016/j.ajo.2015.05.030
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CP6AG
UT WOS:000359966100026
PM 26052088
DA 2022-11-30
ER

PT J
AU Nordgaard, CL
   Berg, KM
   Kapphahn, R
   Reilly, C
   Feng, X
   Olsen, TW
   Ferrington, DA
AF Nordgaard, CL
   Berg, KM
   Kapphahn, R
   Reilly, C
   Feng, X
   Olsen, TW
   Ferrington, DA
TI Proteomics of the retinal pigment epithelium reveals altered protein
   expression at progressive stages of age-related macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID ALPHA-A-CRYSTALLIN; FACTOR-H POLYMORPHISM; OXIDATIVE STRESS; GRADING
   SYSTEM; ACID; PROLIFERATION; PREVALENCE; METABOLISM; DISULFIDE;
   APOPTOSIS
AB PURPOSE. Age-related macular degeneration (AMD) is characterized clinically by changes in the retinal pigment epithelium (RPE), formation of drusen between the RPE and the underlying vasculature, geographic atrophy, and choroidal neovascularization. Later clinical stages are accompanied by impaired central vision. A limited understanding of the molecular events responsible for AMD has constrained the development of effective treatments. A proteomics approach was used to investigate the underlying mechanisms of AMD and to identify proteins exhibiting significant changes in expression with disease onset and progression.
   METHODS. Human donor eyes were categorized into one of four progressive stages of AMD. Proteins from the RPE were resolved and quantified by two-dimensional (2-D) gel electrophoresis. Proteins exhibiting significant expression changes at different disease stages were identified by matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry. 2-D and semiquantitative one dimensional (1-D) Western blot analyses were used to determine whether changes identified by the proteomic analysis were specific for a protein subpopulation or representative of the entire protein population.
   RESULTs. Proteins were identified from several critical pathways that changed at early and late disease stages, indicating potential causal mechanisms and secondary consequences of AMD, respectively. Proteins involved in protecting from stress-induced protein unfolding and aggregation, mitochondrial trafficking and refolding, and regulating apoptosis changed early in the disease process. Late-stage changes occurred in proteins that regulate retinoic acid and regeneration of the rhodopsin chromophore.
   CONCLUSIONS. These results provide the first direct evidence of AMD stage-specific changes in human RPE protein expression and provide a basis for functional investigation of AMD that may ultimately suggest new therapeutic strategies.
C1 Univ Minnesota, Dept Ophthalmol, Minneapolis, MN 55455 USA.
   Univ Minnesota, Div Biostat, Minneapolis, MN 55455 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities
RP Ferrington, DA (通讯作者)，380 Lions Res Bldg,2001 6th St SE, Minneapolis, MN 55455 USA.
EM ferri013@umn.edu
OI Ferrington, Deborah/0000-0003-2561-7464
FU NEI NIH HHS [EY014176] Funding Source: Medline; NIA NIH HHS [R01
   AG025392, AG025392] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [R03EY014176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING
   [R01AG025392] Funding Source: NIH RePORTER
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Beausoleil SA, 2004, P NATL ACAD SCI USA, V101, P12130, DOI 10.1073/pnas.0404720101
   Beere HM, 2004, J CELL SCI, V117, P2641, DOI 10.1242/jcs.01284
   BERGER JW, 1999, AGE RELATED MACULAR
   Cherian M, 1997, J BIOL CHEM, V272, P29099, DOI 10.1074/jbc.272.46.29099
   Colvis C, 2002, ARCH BIOCHEM BIOPHYS, V397, P319, DOI 10.1006/abbi.2001.2669
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ethen CM, 2005, INVEST OPHTH VIS SCI, V46, P769, DOI 10.1167/iovs.04-0810
   Ferrington DA, 1998, J BIOL CHEM, V273, P5885, DOI 10.1074/jbc.273.10.5885
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hanson SRA, 2000, EXP EYE RES, V71, P195, DOI 10.1006/exer.2000.0868
   Hoppe G, 2004, EXP EYE RES, V78, P1085, DOI 10.1016/j.exer.2004.02.001
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Janssen JJM, 2000, NEUROREPORT, V11, P1571, DOI 10.1097/00001756-200005150-00040
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kapphahn RJ, 2003, BIOCHEMISTRY-US, V42, P15310, DOI 10.1021/bi034774e
   Kishi H, 2001, CELL BIOL INT, V25, P1125, DOI 10.1006/cbir.2001.0795
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lehmann Erich L., 2006, TESTING STAT HYPOTHE
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Liu JP, 2004, EXP EYE RES, V79, P393, DOI 10.1016/j.exer.2004.06.015
   Marmor M. F., 1998, RETINAL PIGMENT EPIT, DOI [10.1098/rsif.2015.0563, DOI 10.1098/RSIF.2015.0563]
   Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119
   Mori M, 2004, AM J PATHOL, V164, P701, DOI 10.1016/S0002-9440(10)63157-4
   Napoli JL, 1996, CLIN IMMUNOL IMMUNOP, V80, pS52, DOI 10.1006/clin.1996.0142
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Ralat LA, 2004, J BIOL CHEM, V279, P50204, DOI 10.1074/jbc.M407445200
   Ryan MT, 2002, ADV PROTEIN CHEM, V59, P223
   Thompson DA, 2003, PROG RETIN EYE RES, V22, P683, DOI 10.1016/S1350-9462(03)00051-X
   Tombran-Tink J, 2004, EXP EYE RES, V78, P945, DOI 10.1016/j.exer.2003.12.013
   Uchida H, 2005, EXP EYE RES, V80, P23, DOI 10.1016/j.exer.2004.08.004
   Ueda Y, 2002, INVEST OPHTH VIS SCI, V43, P205
   United States Census Bureau, 2004, US INT PROJ AG SEX R
   Voos W, 2002, BBA-MOL CELL RES, V1592, P51, DOI 10.1016/S0167-4889(02)00264-1
   Wang T, 2001, J BIOL CHEM, V276, P20999, DOI 10.1074/jbc.M101355200
   Winkler BS, 1999, MOL VIS, V5
   Won JY, 2004, METABOLISM, V53, P1007, DOI 10.1016/j.metabol.2003.12.015
   Yasunari T, 1999, OPHTHALMIC RES, V31, P24, DOI 10.1159/000055509
   Zalk R, 2005, BIOCHEM J, V386, P73, DOI 10.1042/BJ20041356
NR 50
TC 113
Z9 123
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2006
VL 47
IS 3
BP 815
EP 822
DI 10.1167/iovs.05-0976
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 020FR
UT WOS:000235894300006
PM 16505012
DA 2022-11-30
ER

PT J
AU Wons, J
   Wirth, MA
   Graf, N
   Becker, MD
   Michels, S
AF Wons, Juliana
   Wirth, Magdalena A.
   Graf, Nicole
   Becker, Matthias D.
   Michels, Stephan
TI Comparison of Progression Rate of Retinal Pigment Epithelium Loss in
   Patients with Neovascular Age-Related Macular Degeneration Treated with
   Ranibizumab and Aflibercept
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID GEOGRAPHIC ATROPHY; CHOROIDAL THICKNESS; GROWTH
AB Purpose. Retinal pigment epithelium (RPE) loss in neovascular age-related macular degeneration (nAMD) seem to have a linear progression but might be influenced by the treatment. The purpose of the study is the comparison of RPE loss over three years in patients treated with intravitreal ranibizumab to patients who were switched to aflibercept. Methods. A retrospective analysis with 96 eyes switched to aflibercept was conducted. The progression rate of RPE loss was evaluated in patients who showed atrophy one year prior to switch (n = 17) or on switch date (n = 19). The RPE loss was evaluated by spectral domain optical coherence tomography (SD-OCT). Further, 22 eyes from patients treated with ranibizumab were compared. Results. The median yearly progression of RPE loss after square root transformation showed no significant difference in the year prior to switch compared to the year after switch (p = 0 854). In patients who received only ranibizumab, the median yearly progression of RPE loss was 0.15 mm/y, for aflibercept patients, 0.13 mm/y. This difference was not statistically significant (p = 0 172). Conclusions. There seems to be a linear progression rate of RPE loss in patients treated with ranibizumab as well as in patients with aflibercept. No significant increase of progression rate was found after switch to aflibercept.
C1 [Wons, Juliana; Wirth, Magdalena A.; Becker, Matthias D.; Michels, Stephan] City Hosp Triemli, Zurich, Switzerland.
   [Graf, Nicole] Graf Biostat, Winterthur, Switzerland.
   [Michels, Stephan] Univ Zurich, Zurich, Switzerland.
C3 Triemli Hospital; University of Zurich
RP Wons, J (通讯作者)，City Hosp Triemli, Zurich, Switzerland.
EM julianabarbara.wons@triemli.zuerich.ch
RI Becker, Matthias/A-8733-2014
OI Wons, Juliana/0000-0002-2194-126X
FU "Stiftung wissenschaftliche Forschung, Fonds Ophthalmologie, City
   Hospital Triemli"; Werner H. Spross Foundation
FX The study was supported by the "Stiftung wissenschaftliche Forschung,
   Fonds Ophthalmologie, City Hospital Triemli," and the Werner H. Spross
   Foundation.
CR Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Danis RP, 2015, CLIN OPHTHALMOL, V9, P2159, DOI 10.2147/OPTH.S92359
   Fauser S, 2016, BRIT J OPHTHALMOL, V100, P1494, DOI 10.1136/bjophthalmol-2015-308264
   Freund KB, 2013, EXPERT OPIN PHARMACO, V14, P1017, DOI 10.1517/14656566.2013.787410
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Lindner M, 2015, INVEST OPHTH VIS SCI, V56, P875, DOI 10.1167/iovs.14-14933
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mazaraki K, 2015, BRIT J OPHTHALMOL, V99, P1341, DOI 10.1136/bjophthalmol-2015-306636
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Regatieri C. V., 2011, OPHTHAL SURG LAS IM, V42, P56
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
NR 15
TC 6
Z9 6
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2017
VL 2017
AR 7432739
DI 10.1155/2017/7432739
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EN8ZQ
UT WOS:000396289200001
PM 28316836
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Waksmunski, AR
   Grunin, M
   Kinzy, TG
   Igo, RP
   Haines, JL
   Bailey, JNC
AF Waksmunski, Andrea R.
   Grunin, Michelle
   Kinzy, Tyler G.
   Igo, Robert P., Jr.
   Haines, Jonathan L.
   Bailey, Jessica N. Cooke
TI Statistical driver genes as a means to uncover missing heritability for
   age-related macular degeneration
SO BMC MEDICAL GENOMICS
LA English
DT Article
DE Genome-wide association study; Pathway analysis; Statistical driver
   gene; GREML; Heritability
ID GENOME-WIDE ASSOCIATION; PATHWAY ANALYSIS; RISK; GENETICS; ALLELES
AB Background: Age-related macular degeneration (AMD) is a progressive retinal disease contributing to blindness worldwide. Multiple estimates for AMD heritability (h(2)) exist; however, a substantial proportion ofh(2)is not attributable to known genomic loci. The International AMD Genomics Consortium (IAMDGC) gathered the largest dataset of advanced AMD (ADV) cases and controls available and identified 34 loci containing 52 independent risk variants defining known AMDh(2). To better define AMD heterogeneity, we used Pathway Analysis by Randomization Incorporating Structure (PARIS) on the IAMDGC data and identified 8 statistical driver genes (SDGs), including 2 novel SDGs not discovered by the IAMDGC. We chose to further investigate these pathway-based risk genes and determine their contribution to ADVh(2), as well as the differential ADV subtypeh(2).
   Methods: We performed genomic-relatedness-based restricted maximum-likelihood (GREML) analyses on ADV, geographic atrophy (GA), and choroidal neovascularization (CNV) subtypes to investigate theh(2)of genotyped variants on the full DNA array chip, 34 risk loci (n = 2758 common variants), 52 variants from the IAMDGC 2016 GWAS, and the 8 SDGs, specifically the novel 2 SDGs,PPARAandPLCG2.
   Results: Via GREML, full chiph(2)was 44.05% for ADV, 46.37% for GA, and 62.03% for CNV. The lead 52 variants'h(2)(ADV: 14.52%, GA: 8.02%, CNV: 13.62%) and 34 locih(2)(ADV: 13.73%, GA: 8.81%, CNV: 12.89%) indicate that known variants contribute similar to 14% to ADVh(2). SDG variants account for a small percentage of ADV, GA, and CNV heritability, but estimates based on the combination of SDGs and the 34 known loci are similar to those calculated for known loci alone. We identified modest epistatic interactions among variants in the 2 SDGs and the 52 IAMDGC variants, including modest interactions between variants inPPARAandPLCG2.
   Conclusions: Pathway analyses, which leverage biological relationships among genes in a pathway, may be useful in identifying additional loci that contribute to the heritability of complex disorders in a non-additive manner. Heritability analyses of these loci, especially amongst disease subtypes, may provide clues to the importance of specific genes to the genetic architecture of AMD.
C1 [Waksmunski, Andrea R.; Haines, Jonathan L.] Case Western Reserve Univ, Dept Genet & Genome Sci, Cleveland, OH 44106 USA.
   [Waksmunski, Andrea R.; Grunin, Michelle; Haines, Jonathan L.; Bailey, Jessica N. Cooke] Case Western Reserve Univ, Cleveland Inst Computat Biol, Cleveland, OH 44106 USA.
   [Waksmunski, Andrea R.; Grunin, Michelle; Kinzy, Tyler G.; Igo, Robert P., Jr.; Haines, Jonathan L.; Bailey, Jessica N. Cooke] Case Western Reserve Univ, Dept Populat & Quantitat Hlth Sci, Cleveland, OH 44106 USA.
C3 Case Western Reserve University; Case Western Reserve University; Case
   Western Reserve University
RP Bailey, JNC (通讯作者)，Case Western Reserve Univ, Cleveland Inst Computat Biol, Cleveland, OH 44106 USA.; Bailey, JNC (通讯作者)，Case Western Reserve Univ, Dept Populat & Quantitat Hlth Sci, Cleveland, OH 44106 USA.
EM jnc43@case.edu
RI Grunin, Michelle/O-6044-2019; Cooke Bailey, Jessica Nicole/AFQ-5925-2022
OI Grunin, Michelle/0000-0002-3155-2858; Cooke Bailey, Jessica
   Nicole/0000-0002-4001-8702; Waksmunski, Andrea/0000-0001-7223-7371
FU NIH Visual Sciences Training Program [T32EY007157-18]; Hebrew
   University/Hans and Alice Jay Sussman Fund; Clinical and Translational
   Science Collaborative of Cleveland from the National Center for
   Advancing Translational Sciences (NCATS) component of the National
   Institutes of Health [KL2TR0002547]; NIH roadmap for Medical Research; 
   [1X01HG00693401];  [R01 EY022310]
FX This study and the main consortium work was supported by 1X01HG00693401
   and R01 EY022310. MG acknowledges the support of a postdoctoral NIH
   Visual Sciences Training Program T32EY007157-18 and a Postdoctoral Women
   Fellowship from Hebrew University/Hans and Alice Jay Sussman Fund. JNCB
   and TGK were supported by the Clinical and Translational Science
   Collaborative of Cleveland, KL2TR0002547 from the National Center for
   Advancing Translational Sciences (NCATS) component of the National
   Institutes of Health and NIH roadmap for Medical Research. The funding
   bodies did not play a role in the design of the study and collection,
   data analysis and interpretation, and writing of the manuscript.
CR Arnold M, 2015, BIOINFORMATICS, V31, P1334, DOI 10.1093/bioinformatics/btu779
   Ayoub T, 2009, J ROY SOC MED, V102, P56, DOI 10.1258/jrsm.2009.080298
   Butkiewicz M, 2016, BIOINFORMATICS, V32, P2361, DOI 10.1093/bioinformatics/btw130
   Cascella R, 2018, PROG RETIN EYE RES, V63, P132, DOI 10.1016/j.preteyeres.2017.11.004
   Cascella Raffaella, 2018, Oncotarget, V9, P7812, DOI 10.18632/oncotarget.23241
   Chang CC, 2015, GIGASCIENCE, V4, DOI 10.1186/s13742-015-0047-8
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Farkas MH, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-486
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Hall JB, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0760-4
   Hirschhorn JN, 2005, NAT REV GENET, V6, P95, DOI 10.1038/nrg1521
   Machiela MJ, 2015, BIOINFORMATICS, V31, P3555, DOI 10.1093/bioinformatics/btv402
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Ratnapriya R, 2019, NAT GENET, V51, P606, DOI 10.1038/s41588-019-0351-9
   Rickman CB, 2006, INVEST OPHTH VIS SCI, V47, P2305, DOI 10.1167/iovs.05-1437
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   So HC, 2011, GENET EPIDEMIOL, V35, P310, DOI 10.1002/gepi.20579
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   Visscher PM, 2008, NAT REV GENET, V9, P255, DOI 10.1038/nrg2322
   Visscher PM, 2017, AM J HUM GENET, V101, P5, DOI 10.1016/j.ajhg.2017.06.005
   Waksmunski AR, 2019, INVEST OPHTH VIS SCI, V60, P4041, DOI 10.1167/iovs.19-27827
   White Marquitta J, 2019, Curr Protoc Hum Genet, V100, pe79, DOI 10.1002/cphg.79
   Winkler TW, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194321
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang JA, 2011, AM J HUM GENET, V88, P76, DOI 10.1016/j.ajhg.2010.11.011
   Yaspan BL, 2011, CURR PROTOC HUM GENE, VChapter 1, pUnit1 20
   Yaspan BL, 2011, HUM GENET, V129, P563, DOI 10.1007/s00439-011-0956-2
NR 32
TC 0
Z9 0
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1755-8794
J9 BMC MED GENOMICS
JI BMC Med. Genomics
PD JUL 6
PY 2020
VL 13
IS 1
AR 95
DI 10.1186/s12920-020-00747-4
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA MP2CJ
UT WOS:000552017000002
PM 32631374
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Maberley, DAL
   Zhang, R
   Ding, L
   Flatt, AH
   Etminan, M
   Hewitt, M
AF Maberley, David A. L.
   Zhang, Ruth
   Ding, Lillian
   Flatt, Alexandra H.
   Etminan, Mahyar
   Hewitt, Maria
TI One-year effectiveness study of intravitreous bevacizumab in neovascular
   age-related macular degeneration: a population-based retrospective
   cohort study
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID PREVALENCE
AB Objective: To assess effectiveness of intravitreous bevacizumab in a cohort of patients with neovascular age-related macular degeneration (nAMD) in British Columbia, Canada.
   Design: Retrospective cohort study.
   Participants: Patients with new-onset AMD who completed 1 year of bevacizumab treatment.
   Methods: A cohort of 4507 patients with nAMD (5174 eyes) aged 50 years and older treated on an as-needed basis with bevacizumab was followed from June 1, 2010, to May 31, 2014, and then evaluated after completing a follow-up treatment at 1 year. Descriptive statistics were used to characterize eyes treated with bevacizumab. Multivariable regression models were used to quantify visual acuity (VA) changes over time, adjusting for baseline prognostic variables.
   Results: On average, patients received 8.6 injections (SD 2.4) per eye during the year of treatment. There was an average gain of 5.2 letters over the 1-year study period. Among eyes treated with bevacizumab, improvement in VA was greater for eyes with poorer baseline VA and for eyes receiving more injections. The odds ratio for VA at 1 year was 9.35 (95% CI 6.00-14.6) for eyes with VA 20/50-20/80 versus 20/20-20/40 and increased to 74.5 (95% CI 47.7-116.4) for eyes 20/400 or worse versus 20/20-20/40.
   Conclusion: Intravitreous bevacizumab is effective in treating nAMD, especially for eyes with poor baseline VA. Gains in VA were greatest by month 3 and were generally maintained thereafter.
C1 [Maberley, David A. L.; Etminan, Mahyar] Univ British Columbia, Dept Ophthalmol & Visual Sci, Vancouver, BC, Canada.
   [Zhang, Ruth; Ding, Lillian; Flatt, Alexandra H.] Prov Hlth Serv Author, BC Prov Retinal Dis Treatment Program, Vancouver, BC, Canada.
C3 University of British Columbia
RP Etminan, M (通讯作者)，Univ British Columbia, Eye Care Ctr, Room 323-2550 Willow St, Vancouver, BC V5Z 3N9, Canada.
CR Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   CAMPBELL RJ, 2012, BMJ-BRIT MED J, V344, DOI DOI 10.1136/BMJ.E4203
   Etminan M, 2016, AM J OPHTHALMOL, V166, P205, DOI 10.1016/j.ajo.2016.03.026
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13
   Maberley DAL, 2006, EYE, V20, P341, DOI 10.1038/sj.eye.6701879
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
NR 10
TC 4
Z9 4
U1 0
U2 0
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD DEC
PY 2018
VL 53
IS 6
BP 627
EP 631
DI 10.1016/j.jcjo.2018.01.013
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HC4JT
UT WOS:000451770300034
PM 30502989
DA 2022-11-30
ER

PT J
AU Matsumoto, H
   Hiroe, T
   Morimoto, M
   Mimura, K
   Ito, A
   Akiyama, H
AF Matsumoto, Hidetaka
   Hiroe, Takashi
   Morimoto, Masahiro
   Mimura, Kensuke
   Ito, Arisa
   Akiyama, Hideo
TI Efficacy of treat-and-extend regimen with aflibercept for pachychoroid
   neovasculopathy and Type 1 neovascular age-related macular degeneration
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Pachychoroid neovasculopathy (PNV); Age-related macular degeneration
   (AMD); Type 1 neovascularization; Anti-vascular endothelial growth
   factor (VEGF); Treat-and-extend
ID ENDOTHELIAL GROWTH-FACTOR; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   ANGIOMATOUS PROLIFERATION; PHOTODYNAMIC THERAPY; RANIBIZUMAB; THICKNESS;
   VERTEPORFIN
AB To evaluate the efficacy of intravitreal aflibercept therapy using a treat-and-extend regimen on treatment-na < ve pachychoroid neovasculopathy (PNV) and Type 1 neovascular age-related macular degeneration (AMD).
   We retrospectively studied 42 eyes with PNV and 60 eyes with Type 1 neovascular AMD. We assessed best-corrected visual acuity (BCVA), central macular thickness (CMT), central choroidal thickness (CCT), and total number of injections over 2 years.
   The BCVA and CMT improvements during the 2-year treatment period did not differ significantly between PNV and AMD; however, CCT decreased significantly in PNV than in AMD (P < 0.05). Management of PNV required significantly fewer injections than AMD during the 2-year period (P < 0.05). There were no significant differences in BCVA, CMT and CCT changes between PNV with and without polypoidal lesions (28 vs. 14 eyes) during the 2 year period. Significantly fewer injections were needed for PNV with polypoidal lesions than for PNV without (P < 0.01). There were no significant differences in BCVA, CMT and CCT changes, or in the number of injections during the 2-year treatment period, between AMD with and without polypoidal lesions (30 vs. 30 eyes).
   Treat-and-extend regimen of intravitreal aflibercept injection may be equally effective in terms of improvement of BCVA and exudative changes both in eyes with PNV and those with Type 1 neovascular AMD requiring fewer injections for the former. Among eyes with PNV, those with polypoidal lesions needed fewer injections than those without polypoidal lesions.
C1 [Matsumoto, Hidetaka; Hiroe, Takashi; Morimoto, Masahiro; Mimura, Kensuke; Ito, Arisa; Akiyama, Hideo] Gunma Univ, Sch Med, Dept Ophthalmol, 3-39-15 Showa Machi, Maebashi, Gunma 3718511, Japan.
C3 Gunma University
RP Matsumoto, H (通讯作者)，Gunma Univ, Sch Med, Dept Ophthalmol, 3-39-15 Showa Machi, Maebashi, Gunma 3718511, Japan.
EM hide-m@gunma-u.ac.jp
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Gass J., 1997, STEREOSCOPIC ATLAS M, V4th ed., P26
   Hata M, 2017, INVEST OPHTH VIS SCI, V58, P292, DOI 10.1167/iovs.16-20967
   Hood JD, 1998, AM J PHYSIOL-HEART C, V274, pH1054
   Kim YK, 2015, AM J OPHTHALMOL, V160, P72, DOI 10.1016/j.ajo.2015.04.011
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Matsumoto H, 2016, RETINA-J RET VIT DIS, V36, P2282, DOI 10.1097/IAE.0000000000001104
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Yanai H., 2015, STATCEL USEFUL ADD I
NR 24
TC 49
Z9 49
U1 0
U2 1
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD MAR
PY 2018
VL 62
IS 2
BP 144
EP 150
DI 10.1007/s10384-018-0562-0
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FY6AZ
UT WOS:000426923200005
PM 29411171
DA 2022-11-30
ER

PT J
AU Li, H
   Yan, ZG
   Cao, H
   Wang, YS
AF Li, Hong
   Yan, Zhenguo
   Cao, Hong
   Wang, Yusheng
TI Effective mobilisation of bone marrow-derived cells through proteolytic
   activity: A new treatment strategy for age-related macular degeneration
SO MEDICAL HYPOTHESES
LA English
DT Article
ID HEMATOPOIETIC STEM-CELLS; ENDOTHELIAL PROGENITOR CELLS;
   ANGIOTENSIN-CONVERTING ENZYME; RETINAL-PIGMENT EPITHELIUM; EXPERIMENTAL
   CHOROIDAL NEOVASCULARIZATION; FACTOR-I; BRUCHS MEMBRANE; STROMAL CELLS;
   PEPTIDASE-IV; INHIBITION
AB Selective targeting of bone marrow-derived cells (BMCs) has been heralded as a promising avenue for age-related macular degeneration (AMD) therapeutics. Many researchers have demonstrated that the function of circulating BMCs is related to disease severity in patients with AMD. Transplanted BMCs are able to transdifferentiate into retina-specific cells to replace those lost due to damage or degeneration in the pathologic process of experimental models of AMD, which may provide beneficial effects in patients with AMD. However, a major barrier to transferring the use of BMCs into clinical practice is the limited quantity of BMCs in the peripheral circulation. Technology has not yet reached a stage where ex vivo-expanded BMCs can be routinely used for cell therapy. A feasible strategy to circumvent this issue of BMC scarcity is to increase the mobilisation of autologous BMCs from the patient's bone marrow into the blood circulation. Extensive studies have demonstrated that the SDF-1/CXCR4 axis is a key regulator for BMC mobilisation. Moreover, abrogation of the SDF-1/CXCR4 axis by proteolytic modification can efficiently increase BMC mobilisation. We speculate that BMC mobilisation by proteolytic enzymes May supply a sufficient amount of autologous cells to repair and regenerate injured and degenerated the retinal pigment epithelium (RPE), photoreceptors, or other retina-specific cells, which could prevent AMD progression. If the BMC mobilisation strategy is used to treat AMD, it may overcome the existing problems of transferring BMC-based therapy into the clinic and become a particularly feasible therapeutic approach for AMD. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Li, Hong; Wang, Yusheng] Fourth Mil Med Univ, Dept Ophthalmol, Eye Inst Chinese PLA, Xijing Hosp, Xian 710032, Peoples R China.
   [Li, Hong; Yan, Zhenguo; Cao, Hong] Gen Hosp Lanzhou Mil Command, Dept Ophthalmol, Lanzhou 730050, Peoples R China.
C3 Air Force Military Medical University
RP Wang, YS (通讯作者)，Fourth Mil Med Univ, Dept Ophthalmol, 17 Changle W Rd, Xian 710032, Peoples R China.
EM wangys010@126.com
CR Aicher A, 2005, HYPERTENSION, V45, P321, DOI 10.1161/01.HYP.0000154789.28695.ea
   Antonio N, 2010, EUR J CLIN PHARMACOL, V66, P219, DOI 10.1007/s00228-009-0764-y
   Asahara T, 2006, J MOL CELL CARDIOL, V41, P8, DOI 10.1016/j.yjmcc.2006.04.015
   Augustin AJ, 2009, CLIN OPHTHALMOL, V3, P175
   Bauvois B, 2004, ONCOGENE, V23, P317, DOI 10.1038/sj.onc.1207124
   Broxmeyer HE, 2005, J EXP MED, V201, P1307, DOI 10.1084/jem.20041385
   Caballero S, 2004, GRAEF ARCH CLIN EXP, V242, P85, DOI 10.1007/s00417-003-0813-7
   Calzi SL, 2010, MICROVASC RES, V79, P207, DOI 10.1016/j.mvr.2010.02.011
   Campbell TB, 2008, FRONT BIOSCI-LANDMRK, V13, P1795, DOI 10.2741/2800
   Caputo M, 2011, CURR DRUG TARGETS, V12, P234, DOI 10.2174/138945011794182791
   Chan-Ling T, 2006, AM J PATHOL, V168, P1031, DOI 10.2353/ajpath.2006.050697
   Chiou SH, 2005, BIOCHEM BIOPH RES CO, V326, P578, DOI 10.1016/j.bbrc.2004.11.061
   Christopher MJ, 2009, BLOOD, V114, P1331, DOI 10.1182/blood-2008-10-184754
   Christopherson KW, 2004, SCIENCE, V305, P1000, DOI 10.1126/science.1097071
   Christopherson KW, 2003, EXP HEMATOL, V31, P1126, DOI 10.1016/j.exphem.2003.07.002
   Christopherson KW, 2003, BLOOD, V101, P4680, DOI 10.1182/blood-2002-12-3893
   Christopherson KW, 2002, J IMMUNOL, V169, P7000, DOI 10.4049/jimmunol.169.12.7000
   Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996
   Csaky KG, 2004, EXP EYE RES, V78, P1107, DOI 10.1016/j.exer.2004.01.010
   Dar A, 2006, EXP HEMATOL, V34, P967, DOI 10.1016/j.exphem.2006.04.002
   Del Priore LV, 2002, CURR EYE RES, V25, P79
   Dimmeler S, 2008, CIRC RES, V102, P1319, DOI 10.1161/CIRCRESAHA.108.175943
   Dimmeler S, 2010, ARTERIOSCL THROM VAS, V30, P1088, DOI 10.1161/ATVBAHA.109.191668
   Ebrahimian TG, 2005, ARTERIOSCL THROM VAS, V25, P65, DOI 10.1161/01.ATV.0000149377.90852.d8
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P4914, DOI 10.1167/iovs.03-0371
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Grant MB, 2002, NAT MED, V8, P607, DOI 10.1038/nm0602-607
   Harris JR, 2006, INVEST OPHTH VIS SCI, V47, P2108, DOI 10.1167/iovs.05-0928
   Hattori K, 2001, BLOOD, V97, P3354, DOI 10.1182/blood.V97.11.3354
   Hubel Kai, 2004, Support Cancer Ther, V1, P165, DOI 10.3816/SCT.2004.n.008
   Jonas JB, 2008, ACTA OPHTHALMOL, V86, P225, DOI 10.1111/j.1600-0420.2007.00987.x
   Kaneko H, 2008, INVEST OPHTH VIS SCI, V49, P4162, DOI 10.1167/iovs.08-1738
   Kent D, 2003, MOL VIS, V9, P747
   Kicic A, 2003, J NEUROSCI, V23, P7742
   Kociok N, 2005, GRAEF ARCH CLIN EXP, V243, P187, DOI 10.1007/s00417-004-1062-0
   Kojima C, 2007, J PHARMACOL EXP THER, V323, P855, DOI 10.1124/jpet.107.127944
   Kucia M, 2004, J MOL HISTOL, V35, P233
   Lapidot T, 2005, BLOOD, V106, P1901, DOI 10.1182/blood-2005-04-1417
   Lapidot T, 2002, EXP HEMATOL, V30, P973, DOI 10.1016/S0301-472X(02)00883-4
   Lecomte J, 2011, CELL MOL LIFE SCI, V68, P677, DOI 10.1007/s00018-010-0476-6
   Lee E, 2010, INVEST OPHTH VIS SCI, V51, P3666, DOI 10.1167/iovs.09-3802
   Lefebvre J, 2002, HYPERTENSION, V39, P460, DOI 10.1161/hy0202.103054
   Lemoli RM, 2008, HAEMATOLOGICA, V93, P321, DOI 10.3324/haematol.12616
   Li Y, 1966, INVEST OPHTH VIS SCI, V47, P1646
   Li Y, 2007, INVEST OPHTH VIS SCI, V48, P4321, DOI 10.1167/iovs.06-1015
   Minamino K, 2005, NEUROREPORT, V16, P1255, DOI 10.1097/01.wnr.0000176517.96475.18
   Moll NM, 2010, EXPERT REV HEMATOL, V3, P315, DOI [10.1586/ehm.10.16, 10.1586/EHM.10.16]
   Moravski CJ, 2003, AM J PATHOL, V162, P151, DOI 10.1016/S0002-9440(10)63806-0
   Moravski CJ, 2000, HYPERTENSION, V36, P1099, DOI 10.1161/01.HYP.36.6.1099
   Muller P, 2009, CARDIOVASC RES, V83, P106, DOI 10.1093/cvr/cvp123
   Muther PS, 2010, INVEST OPHTH VIS SCI, V51, P4831, DOI 10.1167/iovs.09-4923
   Nagai N, 2007, INVEST OPHTH VIS SCI, V48, P2321, DOI 10.1167/iovs.06-1296
   Nervi B, 2006, J CELL BIOCHEM, V99, P690, DOI 10.1002/jcb.21043
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Otani A, 2004, J CLIN INVEST, V114, P765, DOI 10.1172/JCI200421686
   Pitchford SC, 2009, CELL STEM CELL, V4, P62, DOI 10.1016/j.stem.2008.10.017
   Sadir R, 2004, J BIOL CHEM, V279, P43854, DOI 10.1074/jbc.M405392200
   Sasahara M, 2008, AM J PATHOL, V172, P1693, DOI 10.2353/ajpath.2008.080024
   Sasahara M, 2009, INVEST OPHTH VIS SCI, V50, P1575, DOI 10.1167/iovs.08-1900
   Sharma M, 2011, STEM CELLS DEV, V20, P933, DOI 10.1089/scd.2010.0263
   Shih CC, 2000, J HEMATOTH STEM CELL, V9, P621, DOI 10.1089/15258160050196650
   Sieveking DP, 2009, VASC MED, V14, P153, DOI 10.1177/1358863X08098698
   Silva RLE, 2007, FASEB J, V21, P3219, DOI 10.1096/fj.06-7359com
   Smadja DM, 2007, CELL BIOL TOXICOL, V23, P223, DOI 10.1007/s10565-007-0177-6
   Stein JD, 2003, BRIT J OPHTHALMOL, V87, P8, DOI 10.1136/bjo.87.1.8
   Sweeney EA, 2002, BLOOD, V99, P44, DOI 10.1182/blood.V99.1.44
   Takahashi H, 2004, BIOCHEM BIOPH RES CO, V320, P372, DOI 10.1016/j.bbrc.2004.05.177
   Tezel TH, 2004, TRENDS MOL MED, V10, P417, DOI 10.1016/j.molmed.2004.07.004
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P467
   Thill M, 2008, INVEST OPHTH VIS SCI, V49, P2696, DOI 10.1167/iovs.07-0955
   Tomita M, 2002, STEM CELLS, V20, P279, DOI 10.1634/stemcells.20-4-279
   Valenzuela-Fernandez A, 2002, J BIOL CHEM, V277, P15677, DOI 10.1074/jbc.M111388200
   Wang CH, 2006, J MOL CELL CARDIOL, V41, P34, DOI 10.1016/j.yjmcc.2006.03.006
   Winkler IG, 2006, EXP HEMATOL, V34, P996, DOI 10.1016/j.exphem.2006.04.005
   Yodoi Y, 2007, INVEST OPHTH VIS SCI, V48, P5464, DOI 10.1167/iovs.07-0093
NR 75
TC 2
Z9 2
U1 0
U2 10
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD FEB
PY 2012
VL 78
IS 2
BP 286
EP 290
DI 10.1016/j.mehy.2011.11.003
PG 5
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 898KP
UT WOS:000300741600023
PM 22129485
DA 2022-11-30
ER

PT J
AU Schmitz-Valckenberg, S
   Bultmann, S
   Dreyhaupt, J
   Bindewald, A
   Holz, FG
   Rohrschneider, K
AF Schmitz-Valckenberg, S
   Bultmann, S
   Dreyhaupt, J
   Bindewald, A
   Holz, FG
   Rohrschneider, K
TI Fundus autofluorescence and fundus perimetry in the junctional zone of
   geographic atrophy in patients with age-related macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID SCANNING LASER OPHTHALMOSCOPE; RETINAL-PIGMENT EPITHELIUM;
   VISUAL-ACUITY; STARGARDTS-DISEASE; RPE CELLS; LIPOFUSCIN;
   PHOTOCOAGULATION; MACULOPATHY; COMPONENT; PATTERNS
AB PURPOSE. To investigate retinal sensitivity in the junctional zone of geographic atrophy (GA), with variations in fundus autofluorescence (FAF) in patients with advanced age-related macular degeneration (AMD).
   METHODS. The spatial distribution and intensity of FAF were recorded with a confocal scanning laser ophthalmoscope (SLO). Eyes had normal background FAF (group 1) or increased FAF ( group 2) surrounding the atrophic patches. Retinal sensitivity was assessed by applying light stimuli with static automated full-threshold fundus perimetry with a modified SLO. Threshold sensitivities were compared with age-matched normal sensitivities.
   RESULTS. Thirty-nine eyes of 39 patients with GA were included. Group 2 had a higher percentage of all test points outside the GA area, with decreased retinal sensitivity (44.9% +/- 28.7%) compared with group 1 (20.7% +/- 12.7%; P = 0.0063; multiple regression model; outcome variable is retinal sensitivity; covariates are group affiliation and GA area). Within group 2, the average percentage of stimuli in areas of normal FAF with reduced sensitivity was 38.0% +/- 33.0%, whereas the average percentage of stimuli in areas of elevated FAF with reduced sensitivity was 52.6% +/- 29.7% (P = 0.023, Wilcoxon signed rank test).
   CONCLUSIONS. Areas of increased FAF outside GA may be associated with variable degrees of loss of retinal sensitivity and suggest a functional correlate of excessive accumulation of retinal pigment epithelium lipofuscin in AMD. Combining in vivo recording of FAF and retinal sensitivity, using SLO technology, may give important clues in the understanding of mechanisms of disease.
C1 Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
   Univ Heidelberg, Inst Med Biometry & Appl Informat, Heidelberg, Germany.
   Univ Heidelberg, Dept Ophthalmol, Heidelberg, Germany.
C3 University of Bonn; Ruprecht Karls University Heidelberg; Ruprecht Karls
   University Heidelberg
RP Holz, FG (通讯作者)，Univ Bonn, Dept Ophthalmol, Abbe Str 2, D-53127 Bonn, Germany.
EM frank.holz@ukb.uni-bonn.de
OI Bindewald-Wittich, Almut/0000-0002-8151-3953; Rohrschneider,
   Klaus/0000-0003-1996-7935
CR Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Bellmann C, 1997, OPHTHALMOLOGE, V94, P385, DOI 10.1007/s003470050130
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   BOULTON M, 1989, INVEST OPHTH VIS SCI, V30, P82
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P2327
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   FEENEYBURNS L, 1980, AM J OPHTHALMOL, V90, P783, DOI 10.1016/S0002-9394(14)75193-1
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 1998, AM J OPHTHALMOL, V125, P227, DOI 10.1016/S0002-9394(99)80095-6
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Katz ML, 1996, MECH AGEING DEV, V92, P159, DOI 10.1016/S0047-6374(96)01817-9
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   MAGUIRE P, 1986, AM J OPHTHALMOL, V102, P621, DOI 10.1016/0002-9394(86)90535-0
   Rohrschneider K, 1998, AM J OPHTHALMOL, V126, P52, DOI 10.1016/S0002-9394(98)00065-8
   Rohrschneider K, 1997, BRIT J OPHTHALMOL, V81, P568, DOI 10.1136/bjo.81.7.568
   ROHRSCHNEIDER K, 1995, GRAEF ARCH CLIN EXP, V233, P743, DOI 10.1007/BF00184084
   Rohrschneider K, 1997, OPHTHALMOLOGE, V94, P624, DOI 10.1007/s003470050171
   Rohrschneider K, 1995, Ger J Ophthalmol, V4, P197
   Rohrschneider K, 2000, AM J OPHTHALMOL, V129, P27, DOI 10.1016/S0002-9394(99)00270-6
   Rohrschneider K, 1999, PERIMETRY UPDATE 199, P453
   RUCKMANN A, 1997, INVEST OPHTH VIS SCI, V38, P478
   RUCKMANN AV, 1995, BR J OPHTHALMOL, V79, P407
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Solbach U, 1997, RETINA-J RET VIT DIS, V17, P385
   SUNNESS JS, 1995, INVEST OPHTH VIS SCI, V36, P1863
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   SUNNESS JS, 1988, ARCH OPHTHALMOL-CHIC, V106, P1081, DOI 10.1001/archopht.1988.01060140237032
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
NR 37
TC 131
Z9 136
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2004
VL 45
IS 12
BP 4470
EP 4476
DI 10.1167/iovs.03-1311
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 873GZ
UT WOS:000225269200032
PM 15557456
DA 2022-11-30
ER

PT J
AU Nesper, PL
   Soetikno, BT
   Treister, AD
   Fawzi, AA
AF Nesper, Peter L.
   Soetikno, Brian T.
   Treister, Alison D.
   Fawzi, Amani A.
TI Volume-Rendered Projection-Resolved OCT Angiography: 3D Lesion
   Complexity Is Associated With Therapy Response in Wet Age-Related
   Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE choroidal neovascularization; OCT; optical coherence tomography
   angiography; AMD
ID OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL NEOVASCULAR MEMBRANES;
   RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR; BEVACIZUMAB
   AVASTIN; RANIBIZUMAB; FEATURES; VASCULOPATHY; PROGRESSION; DETACHMENT
AB PURPOSE. To explore whether quantitative three-dimensional (3D) analysis of choroidal neovascularization (CNV) using projection-resolved optical coherence tomography angiography (PR-OCTA) is associated with treatment response in neovascular age-related macular degeneration (nAMD).
   METHODS. Retrospective, cross-sectional study of 51 eyes of 49 patients undergoing individualized anti-VEGF therapy for nAMD. Patients were classified as "good'' or "poor'' responders, requiring injections at less or more frequently than 6-week intervals, respectively. Cross-sectional PR-OCTA images were used to measure the distance between Bruch's membrane and highest CNV flow signal. The number of flow layers within the CNV and the distance between these flow layers (CNV flow thickness) were also analyzed. Two masked, independent graders measured the PR-OCTA parameters. We used 3D volume-rendered PR-OCTA to confirm the number of CNV flow layers and further evaluate CNV complexity.
   RESULTS. Poor responders had significantly greater distance between Bruch's membrane and highest CNV flow signal (P < 0.01), greater number of CNV flow layers (P = 0.022), and greater CNV flow thickness (P < 0.01). Volume-rendered PR-OCTA images confirmed the number of CNV flow layers.
   CONCLUSIONS. Cross-sectional and 3D volume-rendered PR-OCTA provides a novel approach for quantifying CNV complexity. Our results suggest that CNV acquiring more complex 3D vascular structure are associated with more frequent long-term anti-VEGF therapy, reflecting a particular pattern of normalization or complex CNV remodeling process that characterizes these less responsive eyes.
C1 [Nesper, Peter L.; Soetikno, Brian T.; Treister, Alison D.; Fawzi, Amani A.] Northwestern Univ, Dept Ophthalmol, Feinberg Sch Med, 645 N Michigan Ave,Suite 440, Chicago, IL 60611 USA.
   [Soetikno, Brian T.] Northwestern Univ, Dept Biomed Engn, Funct Opt Imaging Lab, Evanston, IL 60208 USA.
   [Soetikno, Brian T.] Northwestern Univ, Feinberg Sch Med, Med Scientist Training Program, Chicago, IL 60611 USA.
C3 Northwestern University; Feinberg School of Medicine; Northwestern
   University; Northwestern University; Feinberg School of Medicine
RP Fawzi, AA (通讯作者)，Northwestern Univ, Dept Ophthalmol, Feinberg Sch Med, 645 N Michigan Ave,Suite 440, Chicago, IL 60611 USA.
EM afawzimd@gmail.com
RI fawzi, amani/AAA-9199-2021
OI fawzi, amani/0000-0002-9568-3558
FU National Institutes of Health [DP3DK108248, F30EY026472]; NATIONAL EYE
   INSTITUTE [F30EY026472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE
   OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [DP3DK108248] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
   [T32GM008152] Funding Source: NIH RePORTER
FX Supported in part by National Institutes of Health DP3DK108248 (AAF) and
   F30EY026472 (BTS), and research instrument support by Optovue, Inc.
   (Fremont, CA, USA). The funders had no role in study design, data
   collection and analysis, data interpretation, decision to publish, or
   preparation of the manuscript.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   El Ameen A, 2015, RETINA-J RET VIT DIS, V35, P2212, DOI 10.1097/IAE.0000000000000773
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Green RW, 1999, MOL VIS, V5
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Huang D, 2015, RETINA-J RET VIT DIS, V35, P2260, DOI 10.1097/IAE.0000000000000846
   Hwang TS, 2016, JAMA OPHTHALMOL, V134, P1411, DOI 10.1001/jamaophthalmol.2016.4272
   Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Korb C, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-84
   Kraus MF, 2014, BIOMED OPT EXPRESS, V5, P2591, DOI 10.1364/BOE.5.002591
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2275, DOI 10.1097/IAE.0000000000000819
   Nesper PL, 2017, RETINA, DOI [10.1097/IAE.0000000000001863, DOI 10.1097/IAE.0000000000001]
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Rahimy E, 2014, RETINA-J RET VIT DIS, V34, P1289, DOI 10.1097/IAE.0000000000000130
   Roberts PK, 2017, BRIT J OPHTHALMOL, V101, P1361, DOI 10.1136/bjophthalmol-2016-310004
   Roberts PK, 2017, RETINA-J RET VIT DIS, V37, P1492, DOI 10.1097/IAE.0000000000001400
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Submacular Surgery Trials Research Group, 2005, ARCH OPHTHALMOL-CHIC, V123, P914, DOI DOI 10.1001/archopht.123.7.914
   Veronese C, 2016, RETINA-J RET VIT DIS, V36, P645, DOI 10.1097/IAE.0000000000000914
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zhang M, 2016, BIOMED OPT EXPRESS, V7, P816, DOI 10.1364/BOE.7.000816
NR 47
TC 15
Z9 16
U1 1
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2018
VL 59
IS 5
BP 1944
EP 1952
DI 10.1167/iovs.17-23361
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GC1LF
UT WOS:000429542700006
PM 29677356
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Veloso, CE
   Kanadani, TM
   Pereira, FB
   Nehemy, MB
AF Veloso, Carlos E.
   Kanadani, Tereza M.
   Pereira, Frederico B.
   Nehemy, Marcio B.
TI Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor
   Injections in Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID ADHESION; TRACTION; OCRIPLASMIN; RISK; OCT; EYE
AB Purpose: To evaluate the incidence of posterior vitreous detachment (PVD) induced by intravitreal injections of antievascular endothelial growth factor (VEGF) agents in cases of neovascular age-related macular degeneration (AMD).
   Design: Cohort study conducted at a single tertiary referral vitreoretinal practice.
   Participants: A total of 396 eyes of 295 patients were diagnosed with neovascular AMD between 2009 and 2014. A total of 125 eyes of 112 patients met the inclusion criteria and were evaluated in this study.
   Methods: This study included patients with neovascular AMD who presented vitreomacular adhesion (VMA) detected by spectral-domain optical coherence tomography (OCT) at baseline. Eyes with VMA were classified according to the diameter of vitreous attachment to the macular surface measured by OCT, with attachment of <= 1500 mu m defined as focal and attachment of > 1500 mu m defined as broad. All patients received at least 3 monthly intravitreal injections of anti-VEGF agents. Follow-up visits were performed 1 month after each intravitreal injection and included OCT analysis to evaluate the incidence of PVD.
   Main Outcome Measures: Posterior vitreous detachment induced by anti-VEGF injections.
   Results: The mean follow-up period was 21.3 months (range, 3-59 months). The mean number of intravitreal injections was 8.3 (range, 3-29 injections). Intravitreal drugs used in the study were ranibizumab (51.5%), bevacizumab (33.5%), and aflibercept (15.0%). Seven eyes (5.6%) developed PVD after intravitreal drug injection (3 eyes after the first intravitreal injection: bevacizumab in 1 and ranibizumab in 2; 2 eyes after the second injection: ranibizumab in 1 and bevacizumab in 1; 1 eye after the fourth injection: ranibizumab; and 1 eye after the sixth injection: aflibercept). A total of 118 eyes remained with persistent VMA. All 7 eyes that developed PVD were classified as having focal VMA, with the diameter of vitreous attachment ranging from 210 to 1146 mm (mean, 600 mm).
   Conclusions: Intravitreal injections of commonly used anti-VEGF intravitreal drugs rarely induce PVD in patients with neovascular AMD. Eyes with focal VMA have a greater chance to develop PVD than eyes with a broad area of VMA. (C) 2015 by the American Academy of Ophthalmology.
C1 [Veloso, Carlos E.; Kanadani, Tereza M.; Pereira, Frederico B.; Nehemy, Marcio B.] Univ Fed Minas Gerais, Dept Ophthalmol, Retina Sect, Belo Horizonte, MG, Brazil.
C3 Universidade Federal de Minas Gerais
RP Veloso, CE (通讯作者)，Rua Otoni 881-13 Andar, BR-30150270 Belo Horizonte, MG, Brazil.
EM cerveloso@hotmail.com
RI Nehemy, Marcio/ABD-5089-2021; Veloso, Carlos Eduardo dos
   Reis/E-1815-2016
OI Veloso, Carlos Eduardo dos Reis/0000-0002-8817-7200; Nehemy,
   Marcio/0000-0002-4104-0346
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   DeCroos FC, 2012, INVEST OPHTH VIS SCI, V53, P6504, DOI 10.1167/iovs.12-10370
   Duker JS, 2013, OPHTHALMOLOGY, V120, P2611, DOI 10.1016/j.ophtha.2013.07.042
   Geck U, 2013, GRAEF ARCH CLIN EXP, V251, P1691, DOI 10.1007/s00417-013-2266-y
   John VJ, 2014, RETINA-J RET VIT DIS, V34, P442, DOI 10.1097/IAE.0b013e3182a15f8b
   Koizumi H, 2008, AM J OPHTHALMOL, V145, P509, DOI 10.1016/j.ajo.2007.10.014
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Maier M, 2012, KLIN MONATSBL AUGENH, V229, P1030, DOI 10.1055/s-0032-1315305
   Mayr-Sponer U, 2013, OPHTHALMOLOGY, V120, P2620, DOI 10.1016/j.ophtha.2013.05.032
   Nomura Y, 2011, OPHTHALMOLOGY, V118, P853, DOI 10.1016/j.ophtha.2010.09.001
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Schulze S, 2008, ACTA OPHTHALMOL, V86, P470, DOI 10.1111/j.1755-3768.2008.01210.x
   Simpson ARH, 2012, SURV OPHTHALMOL, V57, P498, DOI 10.1016/j.survophthal.2012.01.011
   Stalmans P, 2012, NEW ENGL J MED, V367, P606, DOI 10.1056/NEJMoa1110823
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 16
TC 26
Z9 27
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2015
VL 122
IS 8
BP 1569
EP 1572
DI 10.1016/j.ophtha.2015.04.028
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CN3JV
UT WOS:000358322900014
PM 26038338
DA 2022-11-30
ER

PT J
AU Prahs, P
   Walter, A
   Regler, R
   Theisen-Kunde, D
   Birngruber, R
   Brinkmann, R
   Framme, C
AF Prahs, Philipp
   Walter, Andreas
   Regler, Roman
   Theisen-Kunde, Dirk
   Birngruber, Reginald
   Brinkmann, Ralf
   Framme, Carsten
TI Selective retina therapy (SRT) in patients with geographic atrophy due
   to age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Geographic atrophy; AMD; RPE; Laser photocoagulation; SRT; Selective
   retina treatment
ID RPE LASER TREATMENT; PIGMENT EPITHELIUM; FUNDUS AUTOFLUORESCENCE;
   10-YEAR INCIDENCE; PHOTOCOAGULATION; PROGRESSION; MACULOPATHY;
   LIPOFUSCIN; DISEASES; CULTURE
AB For geographic atrophy (GA) due to age-related macular degeneration (AMD) there is so far no approved treatment option. Usually, increased autofluorescence (AF) levels of different patterns adjacent to the atrophic area indicate lipofuscin-laden retinal pigment epithelium (RPE) cells at a high risk for apoptosis. Herein, SRT was used to selectively treat these cells to stimulate RPE proliferation, in order to reduce or ideally stop further growth of the atrophic area.
   Six eyes of six patients with bilateral equally pronounced GA were treated by SRT, while the fellow eye served as control. Irradiation was performed using a prototype SRT laser (Medical Laser Center Lubeck, Nd:YLF laser; 527 nm; 200 ns/1.7 A mu s pulse duration; 30 repetitive pulses at 100 Hz). Test lesions with increasing energies were applied at the lower vessel arcade to determine the individual angiographic and ophthalmoscopic threshold radiant exposures. Treatment was then performed in the area of increased AF adjacent to the GA using energies between both thresholds. The GA progression rates of treated and fellow eyes were evaluated.
   After a 1-year follow-up, a progression of the atrophic area was observed in the treated eyes (0.7-8.0 mm(2)/yr, mean 3.0 mm(2)/yr; 46%/yr) whereas the progression rates of the fellow eyes were insignificantly lower (0.46-4.04 mm(2)/yr, mean 1.9 mm(2)/yr; 30%/yr; p = 0.134). The progression rate in the treated eyes of two patients increased significantly, while in the other four patients, the progression rates were nearly the same between both eyes. Moreover, one of these two eyes showed an unexpected RPE reaction after treatment, since all laser lesions led to RPE atrophy and thus an accelerated enlargement of the GA occurred.
   SRT in the hyperautofluorescent areas of GA was not able to stop or slow down the progression of GA. However, modified treatment strategies might be more promising, e.g. placing the spots outside the hyperautofluorescent areas where RPE apoptosis is postulated. Moreover, SRT studies on GA might be more successfully performed on specific subgroups of GA, based on autofluorescence and other findings.
C1 [Prahs, Philipp; Walter, Andreas; Regler, Roman; Framme, Carsten] Univ Eye Hosp Regensburg, D-93042 Regensburg, Germany.
   [Theisen-Kunde, Dirk; Birngruber, Reginald; Brinkmann, Ralf] Med Laser Ctr Lubeck GmbH, D-23562 Lubeck, Germany.
   [Framme, Carsten] Univ Eye Hosp Bern, Inselspital, Bern, Switzerland.
C3 University of Regensburg; University of Bern; University Hospital of
   Bern
RP Prahs, P (通讯作者)，Univ Eye Hosp Regensburg, Franz Josef Strauss Allee 11, D-93042 Regensburg, Germany.
EM philipp@prahs.net
RI Birngruber, Reginald/Q-2342-2016; Brinkmann, Ralf/HDL-7611-2022;
   Brinkmann, Ralf/E-6701-2012
OI Brinkmann, Ralf/0000-0002-0445-8102
FU Dr. Werner Jackstaedt Foundation in Wuppertal, Germany
FX The authors would like to thank the Dr. Werner Jackstaedt Foundation in
   Wuppertal, Germany, for the generous financial support of this ongoing
   study.
CR Brinkmann R, 2006, Bull Soc Belge Ophtalmol, P51
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   DELPRIORE LV, 1989, ARCH OPHTHALMOL-CHIC, V107, P119, DOI 10.1001/archopht.1989.01070010121039
   Elsner H, 2006, GRAEF ARCH CLIN EXP, V244, P1638, DOI 10.1007/s00417-006-0368-5
   Elsner H, 2006, OPHTHALMOLOGE, V103, P856, DOI 10.1007/s00347-006-1414-8
   Framme C, 2004, OPHTHAL SURG LAS IM, V35, P131, DOI 10.3928/1542-8877-20040301-08
   Framme C, 2004, LASER SURG MED, V34, P206, DOI 10.1002/lsm.20022
   Framme C, 2002, BRIT J OPHTHALMOL, V86, P1099, DOI 10.1136/bjo.86.10.1099
   Framme C, 2002, OPHTHALMOLOGICA, V216, P320, DOI 10.1159/000066184
   Framme C, 2008, LASER SURG MED, V40, P616, DOI 10.1002/lsm.20685
   Framme C, 2009, CURR EYE RES, V34, P568, DOI 10.1080/02713680902964892
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gabel V. P., 1978, 23 CONCILIUM OPHTHAL, P658
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Roider J, 2000, BRIT J OPHTHALMOL, V84, P40, DOI 10.1136/bjo.84.1.40
   Roider J, 1999, GRAEF ARCH CLIN EXP, V237, P45, DOI 10.1007/s004170050193
   Roider J, 1999, ARCH OPHTHALMOL-CHIC, V117, P1028
   ROIDER J, 1992, ARCH OPHTHALMOL-CHIC, V110, P1786, DOI 10.1001/archopht.1992.01080240126045
   Schuele G, 2005, J BIOMED OPT, V10, DOI 10.1117/1.2136327
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   WALLOW IH, 1984, ARCH OPHTHALMOL-CHIC, V102, P126
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
NR 26
TC 18
Z9 20
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2010
VL 248
IS 5
BP 651
EP 658
DI 10.1007/s00417-009-1208-1
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 575ML
UT WOS:000276071100005
PM 20024687
OA Green Published
DA 2022-11-30
ER

PT J
AU Ugurlu, SK
   Altundal, AEK
   Ekin, MA
AF Ugurlu, S. Karadeniz
   Altundal, A. E. Kocakaya
   Ekin, M. Altin
TI Comparison of vision-related quality of life in primary open-angle
   glaucoma and dry-type age-related macular degeneration
SO EYE
LA English
DT Article
ID VISUAL FUNCTION QUESTIONNAIRE; CONTRAST SENSITIVITY; FIELD LOSS; HEALTH
   SURVEY; SEE PROJECT; EYE; MACULOPATHY; IMPAIRMENT; DIAGNOSIS;
   CONSTRUCTION
AB Purpose To compare quality of life (QoL) in patients with primary open-angle glaucoma (POAG) and dry-type age-related macular degeneration (AMD) with similar best-corrected visual acuity.
   Methods Age-, sex-, and visual acuity-matched POAG and dry AMD patients were included in the study. Each patient performed 24-2 and 10-2 SITA standard visual field tests. Contrast sensitivity was evaluated with CSV-1000 HGT instrument. The 25 item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) was used to analyze QoL. Overall and subscale scores were converted to scores between 0 and 100, the higher scores indicating better vision-related QoL.
   Results Overall NEI-VFQ-25 scores were 86.44 and 84.66 in glaucoma and AMD groups, respectively (P=0.244). The highest scores were obtained in 'vision-related dependency' subgroup in glaucoma and 'color and peripheral vision' in AMD group, whereas the lowest scores were noted 'in peripheral vision' in both glaucoma and AMD patients. Glaucoma patients had significantly lower scores in ocular pain, color vision, and peripheral vision subgroups compared with the AMD group, whereas AMD patients had lower scores in near and distance vision activities, vision-related social activity, and dependency subgroups. Contrast sensitivity results and mean defect values showed correlation with NEI-VFQ-25 scores in both groups.
   Conclusions Glaucoma and AMD patients with similar visual acuity experienced similar overall impairment in QoL. However, glaucoma patients described more difficulty with peripheral vision and ocular pain, whereas AMD patients complained more about near and distance vision and dependency items.
C1 [Ugurlu, S. Karadeniz; Altundal, A. E. Kocakaya; Ekin, M. Altin] Izmir Katip Celebi Univ, Ataturk Teaching & Res Hosp, Dept Ophthalmol, TR-35170 Izmir, Turkey.
C3 Ankara Ataturk Training & Research Hospital; Izmir Ataturk Training &
   Research Hospital; Izmir Katip Celebi University
RP Ugurlu, SK (通讯作者)，Izmir Katip Celebi Univ, Ataturk Teaching & Res Hosp, Dept Ophthalmol, TR-35170 Izmir, Turkey.
EM ugurluseyda@yahoo.com
CR Bansback N, 2007, QUAL LIFE RES, V16, P533, DOI 10.1007/s11136-006-9126-8
   Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Choudhury F, 2016, JAMA OPHTHALMOL, V134, P683, DOI 10.1001/jamaophthalmol.2016.0794
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Evans DW, CONTRAST SENSITIVITY
   Evans K, 2009, CLIN OPHTHALMOL, V3, P433
   Faria BM, 2015, RETINA-J RET VIT DIS, V35, P1465, DOI 10.1097/IAE.0000000000000474
   Glen FC, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-19
   Gutierrez P, 1997, ARCH OPHTHALMOL-CHIC, V115, P777, DOI 10.1001/archopht.1997.01100150779014
   Hawkins AS, 2003, J GLAUCOMA, V12, P134, DOI 10.1097/00061198-200304000-00008
   Hays R D, 1993, Health Econ, V2, P217, DOI 10.1002/hec.4730020305
   Hyman LG, 2005, OPHTHALMOLOGY, V112, P1505, DOI 10.1016/j.ophtha.2005.03.028
   Jampel H D, 2001, Trans Am Ophthalmol Soc, V99, P301
   Jampel HD, 2002, J GLAUCOMA, V11, P154, DOI 10.1097/00061198-200204000-00012
   Korth MJ, 2000, KLIN MONATSBL AUGENH, V216, P360, DOI 10.1055/s-2000-10582
   Labiris G, 2010, J GLAUCOMA, V19, P39, DOI 10.1097/IJG.0b013e31819d5cf7
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   MCHORNEY CA, 1995, MED CARE, V33, P15, DOI 10.1097/00005650-199501000-00002
   McKean-Cowdin R, 2007, AM J OPHTHALMOL, V143, P1013, DOI 10.1016/j.ajo.2007.02.022
   Mills R P, 1998, Trans Am Ophthalmol Soc, V96, P753
   Mills RP, 2006, AM J OPHTHALMOL, V141, P24, DOI 10.1016/j.ajo.2005.07.044
   Orta AOF, 2015, J GLAUCOMA, V24, pe121, DOI 10.1097/IJG.0000000000000225
   Parrish R K 2nd, 1996, Trans Am Ophthalmol Soc, V94, P919
   Parrish RK, 1997, ARCH OPHTHALMOL-CHIC, V115, P1447, DOI 10.1001/archopht.1997.01100160617016
   Peters D, 2015, ACTA OPHTHALMOL, V93, P745, DOI 10.1111/aos.12839
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Ramulu P, 2009, CURR OPIN OPHTHALMOL, V20, P92, DOI 10.1097/ICU.0b013e32832401a9
   Richman J, 2010, OPHTHAL EPIDEMIOL, V17, P144, DOI 10.3109/09286581003734878
   Ringsdorf L, 2006, J GLAUCOMA, V15, P414, DOI 10.1097/01.ijg.0000212252.72207.c2
   Rubin GS, 2001, INVEST OPHTH VIS SCI, V42, P64
   Sahel JA, 2007, ARCH OPHTHALMOL-CHIC, V125, P945, DOI 10.1001/archopht.125.7.945
   Sawada H, 2011, CLIN OPHTHALMOL, V5, P259, DOI 10.2147/OPTH.S16989
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   Spaeth G, 2006, AM J OPHTHALMOL, V141, pS3, DOI 10.1016/j.ajo.2005.07.075
   Spaeth GL, 2006, AM J OPHTHALMOL, V141, P147, DOI 10.1016/j.ajo.2005.08.026
   Suzukamo Yoshimi, 2005, Health Qual Life Outcomes, V3, P65, DOI 10.1186/1477-7525-3-65
   Thayaparan AJ, 2013, MED EDUC ONLINE, V18, DOI 10.3402/meo.v18i0.21747
   Toprak AB, 2005, OPHTHAL EPIDEMIOL, V12, P259, DOI 10.1080/09286580590967763
   Velten IM, 1999, BRIT J OPHTHALMOL, V83, P199, DOI 10.1136/bjo.83.2.199
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003
   West SK, 2002, ARCH OPHTHALMOL-CHIC, V120, P774
   Wolfram C, 2013, OPHTHALMOLOGICA, V229, P227, DOI 10.1159/000350553
   Wren PA, 2009, J GLAUCOMA, V18, P403, DOI 10.1097/IJG.0b013e3181879e63
   Yuzawa M, 2013, CLIN OPHTHALMOL, V7, P1325, DOI 10.2147/OPTH.S45248
NR 49
TC 10
Z9 10
U1 0
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAR
PY 2017
VL 31
IS 3
BP 395
EP 405
DI 10.1038/eye.2016.219
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EN4QG
UT WOS:000395991400011
PM 27813519
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Lawrenson, JG
   Evans, JR
   Downie, LE
AF Lawrenson, John G.
   Evans, Jennifer R.
   Downie, Laura E.
TI A Critical Appraisal of National and International Clinical Practice
   Guidelines Reporting Nutritional Recommendations for Age-Related Macular
   Degeneration: Are Recommendations Evidence-Based?
SO NUTRIENTS
LA English
DT Article
DE clinical practice guidelines; systematic reviews; age-related macular
   degeneration; nutritional supplements; diet; nutrition; AGREE II
ID PRIMARY PREVENTION; FISH INTAKE; SUPPLEMENTATION; PROGRESSION; ZINC; AMD
AB Eye care professionals should have access to high quality clinical practice guidelines that ideally are underpinned by evidence from robust systematic reviews of relevant research. The aim of this study was to identify clinical guidelines with recommendations pertaining to dietary modification and/or nutritional supplementation for age-related macular degeneration (AMD), and to evaluate the overall quality of the guidelines using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument. We also mapped recommendations to existing systematic review evidence. A comprehensive search was undertaken using bibliographic databases and other electronic resources for eligible guidelines. Quality appraisal was undertaken to generate scores for each of the six AGREE II domains, and mapping of extracted nutritional recommendations was performed for systematic reviews published up to March 2017. We identified 13 national and international guidelines, developed or updated between 2004 and 2019. These varied substantially in quality. The lowest scoring AGREE II domains were for Rigour of Development', Applicability' (which measures implementation strategies to improve uptake of recommendations), and Editorial Independence'. Only four guidelines used evidence from systematic reviews to support their nutritional recommendations. In conclusion, there is significant scope for improving current Clinical Practice Guidelines for AMD, and guideline developers should use evidence from existing high quality systematic reviews to inform clinical recommendations.
C1 [Lawrenson, John G.] City Univ London, Div Optometry & Visual Sci, Northampton Sq, London EC1V OHB, England.
   [Evans, Jennifer R.] London Sch Hyg & Trop Med, Dept Clin Res, Int Ctr Eye Hlth, Keppel St, London WC1E 7HT, England.
   [Downie, Laura E.] Univ Melbourne, Dept Optometry & Vis Sci, Parkville, Vic 3010, Australia.
C3 City University London; University of London; London School of Hygiene &
   Tropical Medicine; University of Melbourne
RP Lawrenson, JG (通讯作者)，City Univ London, Div Optometry & Visual Sci, Northampton Sq, London EC1V OHB, England.
EM j.g.lawrenson@city.ac.uk; Jennifer.Evans@lshtm.ac.uk;
   ldownie@unimelb.edu.au
RI ; Evans, Jennifer/F-4672-2012
OI Downie, Laura/0000-0002-1596-2259; Evans, Jennifer/0000-0002-6137-2030;
   Lawrenson, John/0000-0002-2031-6390
CR Armstrong MJ, 2017, HEALTH EXPECT, V20, P3, DOI 10.1111/hex.12467
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Brouwers MC, 2010, CAN MED ASSOC J, V182, pE472, DOI 10.1503/cmaj.091716
   Chapman NA, 2019, CLIN EXP OPHTHALMOL, V47, P106, DOI 10.1111/ceo.13343
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Cruess AF, 2012, CAN J OPHTHALMOL, V47, P227, DOI 10.1016/j.jcjo.2012.03.007
   Deutsche Ophthalmologische Gesellschaft, 2015, Klin Monbl Augenheilkd, V232, P196, DOI 10.1055/s-0034-1396155
   Downie LE, 2018, JAMA OPHTHALMOL, V136, P1051, DOI 10.1001/jamaophthalmol.2018.2620
   Downie LE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124533
   Downie LE, 2014, OPTOMETRY VISION SCI, V91, P821, DOI 10.1097/OPX.0000000000000285
   Evans J, 2008, EYE, V22, P751, DOI 10.1038/eye.2008.100
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub3
   Evans JR, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001775.pub2
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Gorusupudi A, 2017, ADV NUTR, V8, P40, DOI 10.3945/an.116.013177
   Graham R, 2011, CLIN PRACTICE GUIDEL, P290
   Hodge WG, 2007, RETINA-J RET VIT DIS, V27, P216, DOI 10.1097/01.iae.0000233322.83713.2d
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Lawrenson JG, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-564
   Lawrenson JG, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010015.pub2
   Lindsley K, 2016, OPHTHALMOLOGY, V123, P884, DOI 10.1016/j.ophtha.2015.12.004
   Ma L, 2016, NUTRIENTS, V8, DOI 10.3390/nu8070426
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Optometry Australia, 2019, 2019 CLIN PRACT GUID
   Ruiz-Moreno J.M., 2009, Arch Soc Esp Oftalmol, V84, P333
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   Schunemann Holger J, 2006, Health Res Policy Syst, V4, P22, DOI 10.1186/1478-4505-4-22
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Sin HPY, 2013, ACTA OPHTHALMOL, V91, P6, DOI 10.1111/j.1755-3768.2011.02357.x
   Srinivasan S, 2017, EYE, V31, P846, DOI 10.1038/eye.2017.72
   Vishwanathan R, 2013, INVEST OPHTH VIS SCI, V54, P3985, DOI 10.1167/iovs.12-11552
   Wallace J, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001220
   Wang X, 2014, OPHTHALMIC RES, V52, P198, DOI 10.1159/000363327
   Wormald R, 2018, OPHTHAL EPIDEMIOL, V25, P27, DOI 10.1080/09286586.2017.1337913
NR 39
TC 8
Z9 8
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD APR
PY 2019
VL 11
IS 4
AR 823
DI 10.3390/nu11040823
PG 14
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA HX9SX
UT WOS:000467749800116
PM 30979051
OA Green Published, gold, Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Chen, Q
   Jiang, N
   Zhang, YH
   Ye, SH
   Liang, X
   Wang, X
   Lin, X
   Zong, RR
   Chen, HY
   Liu, ZG
AF Chen, Qian
   Jiang, Nan
   Zhang, Yuhan
   Ye, Sihao
   Liang, Xu
   Wang, Xin
   Lin, Xiang
   Zong, Rongrong
   Chen, Haoyu
   Liu, Zuguo
TI Fenofibrate Inhibits Subretinal Fibrosis Through Suppressing
   TGF-beta-Smad2/3 signaling and Wnt signaling in Neovascular Age-Related
   Macular Degeneration
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE Fenofibrate; subretinal fibrosis; neovascular age-related macular
   degeneration; Wnt signaling; connective tissue growth factor; very
   low&#8208; density lipoprotein receptor
ID TISSUE-GROWTH-FACTOR; DENSITY-LIPOPROTEIN RECEPTOR; PROLIFERATIVE
   VITREORETINAL DISEASES; TGF-BETA; PPAR-ALPHA; FACTOR CTGF; EXPRESSION;
   ANGIOGENESIS; REGULATOR; PATHWAY
AB Subretinal fibrosis is a common pathological change that causes vision loss in neovascular age-related macular degeneration (nAMD). Treatment modalities for subretinal fibrosis are limited. In the present study, the effects of fenofibrate, a specific peroxisome proliferator-activated receptor alpha agonist, on subretinal fibrosis of nAMD were tested, and its molecular mechanisms of action were delineated. Collagen deposition and protein expression of fibrotic markers, such as vimentin, collagen-1, alpha-smooth muscle actin, and fibronectin, were increased in very low-density lipoprotein receptor (VLDLR) knockout mouse, indicating Vldlr ( -/- ) mice can be used as a model for subretinal fibrosis. Fenofibrate suppressed subretinal fibrosis of Vldlr ( -/- ) mice by reducing collagen deposition and protein expression of fibrotic markers. Two fibrotic pathways, TGF-beta-Smad2/3 signaling and Wnt signaling, were significantly up-regulated, while inhibited by fenofibrate in Vldlr ( -/- ) retinas. Moreover, fenofibrate significantly reduced the downstream connective tissue growth factor (CTGF) expression of these two pathways. Muller cells were a major source of CTGF in Vldlr ( -/- ) retinas. Fenofibrate was capable of suppressing Muller cell activation and thus reducing the release of CTGF in Vldlr ( -/- ) retinas. In cultured Muller cells, fenofibrate reversed TGF-beta 2-induced up-regulation of Wnt signaling and CTGF expression. These findings suggested that fenofibrate inhibits subretinal fibrosis by suppressing TGF-beta-Smad2/3 signaling and Wnt signaling and reducing CTGF expression, and thus, fenofibrate could be a potential treatment for nAMD with subretinal fibrosis.
C1 [Chen, Qian; Jiang, Nan; Zhang, Yuhan; Ye, Sihao; Liang, Xu; Wang, Xin; Lin, Xiang; Zong, Rongrong; Liu, Zuguo] Xiamen Univ, Xiangan Hosp, Eye Inst, Sch Med,Dept Ophthalmol,Fujian Prov Key Lab Ophth, Xiamen, Peoples R China.
   [Chen, Qian; Liu, Zuguo] Xiamen Univ, Affiliated Xiamen Eye Ctr, Xiamen, Peoples R China.
   [Chen, Haoyu] Joint Shantou Int Eye Ctr Shantou Univ & Chinese, Shantou, Peoples R China.
C3 Xiamen University; Xiamen University
RP Chen, Q; Liu, ZG (通讯作者)，Xiamen Univ, Xiangan Hosp, Eye Inst, Sch Med,Dept Ophthalmol,Fujian Prov Key Lab Ophth, Xiamen, Peoples R China.; Chen, Q; Liu, ZG (通讯作者)，Xiamen Univ, Affiliated Xiamen Eye Ctr, Xiamen, Peoples R China.
EM qchen2@xmu.edu.cn; zuguoliu@xmu.edu.cn
RI Chen, Haoyu/A-7432-2013
OI Chen, Haoyu/0000-0003-0676-4610
FU National Science Foundation for Young Scientists of China [31807795];
   National Key R&D program of China [2018YFA0107302]; Natural Science
   Foundation of Fujian Province [2019J01017]
FX This study was supported by grants from the National Science Foundation
   for Young Scientists of China (Grant NO. 31807795), National Key R&D
   program of China (Grant NO. 2018YFA0107302) and Natural Science
   Foundation of Fujian Province (Grant NO. 2019J01017).
CR Beljaars L, 2017, AM J PHYSIOL-GASTR L, V312, pG219, DOI 10.1152/ajpgi.00160.2016
   Blyszczuk P, 2017, EUR HEART J, V38, P1413, DOI 10.1093/eurheartj/ehw116
   Brown WV, 2007, AM J CARDIOL, V99, p19C, DOI 10.1016/j.amjcard.2006.11.017
   Burgy O, 2018, MATRIX BIOL, V68-69, P67, DOI 10.1016/j.matbio.2018.03.017
   Cao Q, 2019, INT J OPHTHALMOL-CHI, V12, P1832, DOI 10.18240/ijo.2019.12.03
   Chen Q, 2016, MOL CELL BIOL, V36, P2645, DOI 10.1128/MCB.00235-16
   Chen Y, 2007, J BIOL CHEM, V282, P34420, DOI 10.1074/jbc.M611289200
   Cheng R, 2016, DIABETES, V65, P3730, DOI 10.2337/db16-0426
   Dessein A, 2009, J EXP MED, V206, P2321, DOI 10.1084/jem.20090383
   Ding LX, 2014, AM J PATHOL, V184, P2709, DOI 10.1016/j.ajpath.2014.06.021
   Fan CY, 1998, J BIOL CHEM, V273, P15639, DOI 10.1074/jbc.273.25.15639
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   Germer A, 1997, NEUROREPORT, V8, P3067, DOI 10.1097/00001756-199709290-00012
   He SK, 2008, INVEST OPHTH VIS SCI, V49, P4078, DOI 10.1167/iovs.07-1302
   He WC, 2009, J AM SOC NEPHROL, V20, P765, DOI 10.1681/ASN.2008060566
   Hu HH, 2018, CHEM-BIOL INTERACT, V292, P76, DOI 10.1016/j.cbi.2018.07.008
   Hu WZ, 2008, INVEST OPHTH VIS SCI, V49, P407, DOI 10.1167/iovs.07-0870
   Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141
   Ihn H, 2002, CURR OPIN RHEUMATOL, V14, P681, DOI 10.1097/00002281-200211000-00009
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Joyal JS, 2016, NAT MED, V22, P439, DOI 10.1038/nm.4059
   Keech AC, 2007, LANCET, V370, P1687, DOI 10.1016/S0140-6736(07)61607-9
   Kita T, 2008, P NATL ACAD SCI USA, V105, P17504, DOI 10.1073/pnas.0804054105
   Kita T, 2007, DIABETES, V56, P231, DOI 10.2337/db06-0581
   Konigshoff M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002142
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Kuiper EJ, 2008, J HISTOCHEM CYTOCHEM, V56, P785, DOI 10.1369/jhc.2008.950980
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lipson KE, 2012, FIBROGENESIS TISSUE, V5, DOI 10.1186/1755-1536-5-S1-S24
   Liu Y, 2013, J BIOL CHEM, V288, P30708, DOI 10.1074/jbc.M113.478685
   Liu ZP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay1371
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   Meng XM, 2016, NAT REV NEPHROL, V12, P325, DOI 10.1038/nrneph.2016.48
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moran E, 2014, INVEST OPHTH VIS SCI, V55, P4568, DOI 10.1167/iovs.13-13127
   Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353
   Paw M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092571
   Pearsall EA, 2017, BMC BIOL, V15, DOI 10.1186/s12915-017-0451-x
   Qiu FF, 2017, INVEST OPHTH VIS SCI, V58, P5065, DOI 10.1167/iovs.17-22091
   Raghu G, 2016, EUR RESPIR J, V47, P1481, DOI 10.1183/13993003.01030-2015
   Saika S, 2008, PROG RETIN EYE RES, V27, P177, DOI 10.1016/j.preteyeres.2007.12.002
   Steinhart Z, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.146589
   Sun Y, 2017, J EXP MED, V214, P1753, DOI 10.1084/jem.20161645
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Tosi GM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113363
   Xu L, 2017, J CELL MOL MED, V21, P1545, DOI 10.1111/jcmm.13085
   Zhang JJ, 2016, CLIN SCI, V130, P625, DOI 10.1042/CS20150623
NR 47
TC 2
Z9 2
U1 3
U2 9
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD NOV 17
PY 2020
VL 11
AR 580884
DI 10.3389/fphar.2020.580884
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA OZ3HJ
UT WOS:000594820900001
PM 33442383
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Zareparsi, S
   Reddick, AC
   Branham, KEH
   Moore, KB
   Jessup, L
   Thoms, S
   Smith-Wheelock, M
   Yashar, BM
   Swaroop, A
AF Zareparsi, S
   Reddick, AC
   Branham, KEH
   Moore, KB
   Jessup, L
   Thoms, S
   Smith-Wheelock, M
   Yashar, BM
   Swaroop, A
TI Association of apolipoprotein E alleles with susceptibility to
   age-related macular degeneration in a large cohort from a single center
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID E GENE; FAMILIAL AGGREGATION; STARGARDT-DISEASE; EPSILON-4 ALLELE;
   GENOME SCAN; MACULOPATHY; POPULATION; RISK; POLYMORPHISMS; EPITHELIUM
AB PURPOSE. To examine the effect of apolipoprotein E (APOE) alleles on age-related macular degeneration (AMD) risk and on age at diagnosis of AMD in a large patient cohort recruited from a single center.
   METHODS. The frequency of APOE alleles was analyzed in 632 unrelated AMD patients and 206 unrelated controls, all of whom were of white ancestry. The presence or absence of disease symptoms in all patients and controls was based on clinical examination and/or ophthalmic records. The association with APOE was explored in the context of AMD subtypes, family history status, possible interaction with smoking, and distribution of age at diagnosis of AMD.
   RESULTS. The frequency of the epsilon4 allele was significantly reduced in patients compared with controls (0.10 vs. 0.14, P less than or equal to 0.02). Gender- and age-adjusted odds ratios indicated that epsilon4-carriers have significantly lower risk of developing AMD compared to epsilon3epsilon3 subjects (OR = 0.55, 95% CI: 0.37-0.82, P = 0.004). In the cohort, AMD patients with a positive family history exhibited a significant 3.5 years earlier age at diagnosis (P = 0.001); however, APOE alleles did not appear to modulate the age at diagnosis of AMD.
   CONCLUSIONS. The association between the APOE-epsilon4 allele and a reduced risk of AMD was established in a large cohort with sufficient statistical power. How distinct APOE alleles affect AMD susceptibility warrants further investigation.
C1 Univ Michigan, Dept Ophthalmol & Visual Sci, WK Kellogg Eye Ctr, Ann Arbor, MI 48105 USA.
   Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan
RP Swaroop, A (通讯作者)，Univ Michigan, Dept Ophthalmol & Visual Sci, WK Kellogg Eye Ctr, 1000 Wall St, Ann Arbor, MI 48105 USA.
EM swaroop@umich.edu
RI Branham, Kari/AAA-8336-2022
OI Swaroop, Anand/0000-0002-1975-1141; Yashar, Beverly
   M./0000-0003-0807-3258; Branham, Kari/0000-0002-2492-254X
FU NATIONAL EYE INSTITUTE [F32EY014085] Funding Source: NIH RePORTER; NEI
   NIH HHS [F32-EY014085] Funding Source: Medline
CR ABECASIS GR, IN PRESS AM J HUM GE
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Gorin MB, 1999, MOL VIS, V5, pU31
   HIXSON JE, 1990, J LIPID RES, V31, P545
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Nguyen-Legros J, 2000, INT REV CYTOL, V196, P245
   ORDOVAS JM, 1987, J LIPID RES, V28, P371
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   Schellenberg G D, 2000, Curr Psychiatry Rep, V2, P158, DOI 10.1007/s11920-000-0061-z
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmidt S, 2000, MOL VIS, V6, P287
   SCHMIDT S, 2002, OPHTHALMIC GENET, V23, P20
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Zareparsi S, 2002, AM J MED GENET, V107, P156, DOI 10.1002/ajmg.10111
NR 35
TC 101
Z9 108
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2004
VL 45
IS 5
BP 1306
EP 1310
DI 10.1167/iovs.03-1253
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 816BF
UT WOS:000221084700005
PM 15111581
DA 2022-11-30
ER

PT J
AU Bhuachalla, BN
   McGarrigle, CA
   O'Leary, N
   Akuffo, KO
   Peto, T
   Beatty, S
   Kenny, RA
AF Bhuachalla, Blaithin Ni
   McGarrigle, Christine A.
   O'Leary, Neil
   Akuffo, Kwadwo Owusu
   Peto, Tunde
   Beatty, Stephen
   Kenny, Rose Anne
TI Orthostatic hypertension as a risk factor for age-related macular
   degeneration: Evidence from the Irish longitudinal study on ageing
SO EXPERIMENTAL GERONTOLOGY
LA English
DT Article
DE Age-related macular degeneration; Orthostatic hypertension;
   Hypertension; Pathogenesis; Risk factors
ID BLOOD-PRESSURE RESPONSE; COGNITIVE IMPAIRMENT; CARDIOVASCULAR RISK;
   VISUAL FUNCTION; DISEASE; MECHANISMS; EPIDEMIOLOGY; ASSOCIATION;
   HYPOTENSION; POPULATION
AB Purpose: Age related macular degeneration (AMD) is a leading cause of irreversible visual loss in developed countries. It is associated with vascular risk factors including hypertension. Dysregulated blood pressure (BP) behaviour including orthostatic hypertension (OHTN), hypotension (OH) and BP variability (BPV) are associated with end-organ damage, particularly in the brain. We investigated if abnormal orthostatic BP (OBP) was a risk factor for AMD, for which a vascular aetiology is implicated.
   Methods: A nationally representative, cross-sectional study was carried out 2009/2010 in The Irish Longitudinal Study on Ageing (TILDA). Beat-to-beat BP data, measured by digital photoplethysmography during active stand, was used to characterise OBP behaviour in the 30-110 s after standing. OH, OHTN, BPV and normal stabilisation recovery phenotypes were defined. AMD was identified following masked grading of 45 degrees monoscopic colour retinal photographs, which were centred on the macula and taken with a NIDEK AFC-210 non-mydriatic auto-fundus camera. The relationship between OBP recovery phenotypes and AMD in 3750 adults aged >= 50 years was investigated using multivariate logistic regression models, adjusted for traditional AMD risk factors.
   Results: From 30 to 110 s post active stand, systolic and diastolic OHTN was associated with increased odds of AMD after adjustment for demographics, health behaviours including smoking, family history of AMD, self-report (SR) diabetes, SR cataracts, objective hypertension and prescribed antihypertensives. No evidence of heterogeneity of OHTN effect was found between those who were hypertensive to those who were normotensive.
   Conclusions: This study provides evidence that OHTN may be an independent cardiovascular risk factor for AMD.
C1 [Bhuachalla, Blaithin Ni] St James Hosp, Sch Med, Dept Med Gerontol, Trinity Ctr Hlth Sci,Trinity Coll Dublin, Old Stone Bldg,Jamess St, Dublin 8, Ireland.
   [McGarrigle, Christine A.; O'Leary, Neil; Kenny, Rose Anne] Trinity Coll Dublin, Irish Longitudinal Study Ageing TILDA, Coll Green, Dublin 2, Ireland.
   [Akuffo, Kwadwo Owusu; Beatty, Stephen] Waterford Inst Technol, Macular Pigment Res Grp, Vis Res Ctr, Carriganore House, Waterford, Ireland.
   [Peto, Tunde] Moorfields Eye Hosp Natl Hlth Serv Fdn Trust, Biomed Res Ctr, Natl Inst Hlth Res, Reading Ctr,Dept Res & Dev, London, England.
   [Peto, Tunde] UCL Inst Ophthalmol, London, England.
   [Kenny, Rose Anne] St James Hosp, Sch Med, Discipline Med Gerontol, Trinity Ctr Hlth Sci,Trinity Coll Dublin, Old Stone Bldg,Jamess St, Dublin 8, Ireland.
C3 Trinity College Dublin; Trinity College Dublin; South East Technological
   University (SETU); University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; University of London;
   University College London; Trinity College Dublin
RP McGarrigle, CA (通讯作者)，Trinity Coll Dublin, Irish Longitudinal Study Ageing TILDA, Coll Green, Dublin 2, Ireland.
EM nibhuacb@tcd.ie; Christine.McGarrigle@tcd.ie; olearyne@tcd.ie;
   kakuffo@wit.ie; Tunde.Peto@moorfields.nhs.uk; sbeatty@wit.ie;
   rkenny@tcd.ie
RI Akuffo, Kwadwo Owusu/J-2036-2019; Peto, Tunde/G-8812-2018; McGarrigle,
   Christine/J-8331-2017
OI Akuffo, Kwadwo Owusu/0000-0001-6683-249X; Peto,
   Tunde/0000-0001-6265-0381; McGarrigle, Christine/0000-0001-5814-5673;
   Kenny, Rose Anne/0000-0002-9336-8124; O'Leary, Neil/0000-0002-2765-7016
FU Atlantic Philanthropies; Irish Life Plc; Irish Government; NIHR BMRC at
   Moorfields Eye Hospital Foundation Trust; UCL Institute of Ophthalmology
FX The authors report no conflicts of interest. Informed consent was
   obtained for all participants, and all protocols and procedures were
   approved by the institutional review board. TILDA is funded by The
   Atlantic Philanthropies, Irish Life Plc and the Irish Government. Dr
   Peto was funded by the NIHR BMRC at Moorfields Eye Hospital Foundation
   Trust and the UCL Institute of Ophthalmology. No funder played a role in
   the design, execution, analysis and interpretation of data or in the
   writing of this paper. The authors would like to thank all the
   participants in the study, the TILDA research, the team of interviewers
   and the study nurses and administrators.
CR Akuffo KO, 2017, BRIT J OPHTHALMOL, V101, P190, DOI 10.1136/bjophthalmol-2016-308418
   Akuffo KO, 2015, BRIT J OPHTHALMOL, V99, P1037, DOI 10.1136/bjophthalmol-2014-305768
   Angelousi A, 2014, J HYPERTENS, V32, P1562, DOI 10.1097/HJH.0000000000000235
   Bhuachalla BN, 2015, CLIN AUTON RES, V25, P373, DOI 10.1007/s10286-015-0315-9
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Cascella R, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/582842
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Cohen DL, 2014, J CLIN HYPERTENS, V16, P847, DOI 10.1111/jch.12438
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Fan CW, 2012, BLOOD PRESS MONIT, V17, P160, DOI 10.1097/MBP.0b013e328356821f
   Fan XH, 2010, AM J HYPERTENS, V23, P829, DOI 10.1038/ajh.2010.76
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Finucane C, 2014, CIRCULATION, V130, P1780, DOI 10.1161/CIRCULATIONAHA.114.009831
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Hayakawa T, 2015, J AM GERIATR SOC, V63, P1868, DOI 10.1111/jgs.13596
   Ikram MK, 2012, STROKE, V43, P1681, DOI 10.1161/STROKEAHA.112.654632
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Kario K, 1998, HYPERTENSION, V31, P77, DOI 10.1161/01.HYP.31.1.77
   Kario K, 2003, J CARDIOVASC PHARM, V42, pS87, DOI 10.1097/00005344-200312001-00019
   Kario K, 2013, NAT REV NEPHROL, V9, P726, DOI 10.1038/nrneph.2013.224
   Kearney PM, 2011, INT J EPIDEMIOL, V40, P877, DOI 10.1093/ije/dyr116
   Kennelly S, 2012, INT J GERIATR PSYCH, V27, P415, DOI 10.1002/gps.2735
   Kenny RA, 2013, J AM GERIATR SOC, V61, pS279, DOI [10.1111/jgs.12195, 10.1111/jgs.12200]
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kur J, 2012, PROG RETIN EYE RES, V31, P377, DOI 10.1016/j.preteyeres.2012.04.004
   Mancia G, 2007, J HYPERTENS, V25, P1751, DOI 10.1097/HJH.0b013e3282f0580f
   MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121
   Mehrabian S, 2010, J NEUROL SCI, V299, P45, DOI 10.1016/j.jns.2010.08.056
   Mendrinos E, 2009, ACTA OPHTHALMOL, V87, P290, DOI 10.1111/j.1755-3768.2008.01247.x
   Mori F, 2001, BRIT J OPHTHALMOL, V85, P531, DOI 10.1136/bjo.85.5.531
   Nardo CJ, 1999, HYPERTENSION, V33, P1123, DOI 10.1161/01.HYP.33.5.1123
   Nolan JM, 2014, J ALZHEIMERS DIS, V42, P1191, DOI 10.3233/JAD-140507
   Romero-Ortuno R, 2013, BMC GERIATR, V13, DOI 10.1186/1471-2318-13-73
   Rothwell PM, 2010, LANCET, V375, P895, DOI 10.1016/S0140-6736(10)60308-X
   Sivak JM, 2013, INVEST OPHTH VIS SCI, V54, P871, DOI 10.1167/iovs.12-10827
   The National Agency for the prevention of Blindness (IAPB), 2017, AVOIDABLE BLINDNESS
   Thomas RJ, 2003, MAYO CLIN PROC, V78, P951
   Vassilev ZP, 2015, INVEST OPHTH VIS SCI, V56, P1585, DOI 10.1167/iovs.14-16271
   Vriz O, 1997, AM J HYPERTENS, V10, P546, DOI 10.1016/S0895-7061(96)00489-X
   Whelan BJ, 2013, J AM GERIATR SOC, V61, pS265, DOI 10.1111/jgs.12199
   Wong T, 2007, LANCET, V369, P425, DOI 10.1016/S0140-6736(07)60198-6
   World Health Organisation, 2010, GLOBAL STATUS REPORT, P2011
   Wu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089600
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
   Yano Y, 2012, CURR HYPERTENS REP, V14, P219, DOI 10.1007/s11906-012-0261-z
   Yatsuya H, 2011, HYPERTENSION, V57, P167, DOI 10.1161/HYPERTENSIONAHA.110.161844
NR 48
TC 6
Z9 7
U1 0
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0531-5565
EI 1873-6815
J9 EXP GERONTOL
JI Exp. Gerontol.
PD JUN
PY 2018
VL 106
BP 80
EP 87
DI 10.1016/j.exger.2018.02.029
PG 8
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA GD4JI
UT WOS:000430469000012
PM 29501627
DA 2022-11-30
ER

PT J
AU Cukras, C
   Wang, YD
   Meyerle, CB
   Forooghian, F
   Chew, EY
   Wong, WT
AF Cukras, C.
   Wang, Y. D.
   Meyerle, C. B.
   Forooghian, F.
   Chew, E. Y.
   Wong, W. T.
TI Optical coherence tomography-based decision making in exudative
   age-related macular degeneration: comparison of time- vs spectral-domain
   devices
SO EYE
LA English
DT Article
DE age-related macular degeneration; optical coherence tomography; clinical
   trials; neovascularization; anti-angiogenic treatment
ID RETINAL THICKNESS MEASUREMENTS; BEVACIZUMAB AVASTIN THERAPY;
   REPRODUCIBILITY; REPEATABILITY; RANIBIZUMAB; AGREEMENT
AB Purpose To determine whether optical coherence tomography (OCT) device-type influences clinical grading of OCT imaging in the context of exudative age-related macular degeneration (AMD).
   Methods Ninety-six paired OCT scans from 49 patients with active exudative AMD were obtained on both the time-domain Stratus OCT system and the spectral-domain Cirrus OCT system at the same visit. Three independent graders judged each scan for the presence of intraretinal fluid (IRF) or subretinal fluid (SRF). The degree of grader consensus was evaluated and the ability of the systems to detect the presence of disease activity was analysed.
   Results Cirrus OCT generated a higher degree of inter-grader consensus than Stratus OCT with higher intraclass correlation coefficients for all parameters analysed. A pair-wise comparison of Cirrus OCT with Stratus OCT systems revealed that Cirrus-based gradings more frequently reported the presence of SRF and IRF and detected overall neovascular activity at a higher rate (P<0.05) compared with Stratus-based gradings.
   Conclusions The choice of time-domain (Stratus) vs spectra-domain (Cirrus) OCT systems has a measurable impact on clinical decision making in exudative AMD. Spectral-domain OCT systems may be able to generate more consensus in clinical interpretation and, in particular cases, detect disease activity not detected by time-domain systems. Clinical trials using OCT-based clinical evaluations of exudative AMD may need to account for these inter-system differences in planning and analysis. Eye (2010) 24, 775-783; doi:10.1038/eye.2009.211; published online 21 August 2009
C1 [Wang, Y. D.; Wong, W. T.] NEI, Unit Neuron Glia Interact, NIH, Bethesda, MD 20892 USA.
   [Cukras, C.; Meyerle, C. B.; Forooghian, F.; Chew, E. Y.] NEI, Div Epidemiol & Clin Res, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI)
RP Wong, WT (通讯作者)，NEI, Unit Neuron Glia Interact, NIH, 6 Ctr Dr,Bldg 6,Room 215, Bethesda, MD 20892 USA.
EM wongw@nei.nih.gov
RI Wong, Wai/B-6118-2017
OI Wong, Wai/0000-0003-0681-4016
FU National Eye Institute; NATIONAL EYE INSTITUTE [ZIEEY000487,
   ZIAEY000494, ZIAEY000497] Funding Source: NIH RePORTER
FX This work has been supported by the National Eye Institute Intramural
   Research Program.
CR Bernardes R, 2008, INVEST OPHTH VIS SCI, V49, P2046, DOI 10.1167/iovs.07-0467
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Danis RP, 2008, ARCH OPHTHALMOL-CHIC, V126, P45, DOI 10.1001/archopht.126.1.45
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Holz FG, 2003, OPHTHALMOLOGY, V110, P400, DOI 10.1016/S0161-6420(02)01770-0
   Jaffe GJ, 2004, AM J OPHTHALMOL, V137, P156, DOI 10.1016/S0002-9394(03)00792-X
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Keane PA, 2009, INVEST OPHTH VIS SCI, V50, P3378, DOI 10.1167/iovs.08-2728
   Massin P, 2001, ARCH OPHTHALMOL-CHIC, V119, P1135, DOI 10.1001/archopht.119.8.1135
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Polito A, 2005, ARCH OPHTHALMOL-CHIC, V123, P1330, DOI 10.1001/archopht.123.10.1330
   Sayanagi K, 2009, OPHTHALMOLOGY, V116, P947, DOI 10.1016/j.ophtha.2008.11.002
   Taban M, 2009, OPHTHALMOLOGY, V116, P964, DOI 10.1016/j.ophtha.2008.12.033
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
   Zhang N, 2007, AM J OPHTHALMOL, V144, P37, DOI 10.1016/j.ajo.2007.03.056
NR 16
TC 34
Z9 34
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD MAY
PY 2010
VL 24
IS 5
BP 775
EP 783
DI 10.1038/eye.2009.211
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 595EG
UT WOS:000277592900004
PM 19696804
OA Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Aubin, G
   Elalouf, K
   Hogan, M
   Altschuler, A
   Murphy, KJ
   Wittich, W
AF Aubin, Gabrielle
   Elalouf, Karine
   Hogan, Mariah
   Altschuler, Aviva
   Murphy, Kelly J.
   Wittich, Walter
TI Usability and Accessibility of the ArtontheBrain((TM)) Virtual
   Recreation Activity for Older Adults With Low Vision Due to Age-Related
   Macular Degeneration
SO INQUIRY-THE JOURNAL OF HEALTH CARE ORGANIZATION PROVISION AND FINANCING
LA English
DT Article
DE low vision; accessibility; mobile application; aging; vision
   rehabilitation
ID COGNITIVE FUNCTION; VISUAL IMPAIRMENT; REHABILITATION; PARTICIPATION;
   LEISURE; PROGRAM; DECLINE; PEOPLE
AB Experiencing visual art can inspire, be an overall positive leisure activity, and has been linked to improved cognition, especially in older adults. Access to artwork in a museum environment can comprise a variety of barriers, including difficulties linked to its visual experience for persons that are visually impaired. The present study explored the barriers and facilitators experienced by 15 older adults (age 65 to 93) living with age-related macular degeneration when using an iPad to access ArtontheBrain((TM)), a virtual art museum recreation experience created by members of this team. Using the Concurrent Think Aloud method, participants were asked to continuously comment on their experiences with the application while being audio/video recorded. Indeed, codes were determined by identifying frequently stated and emphasized ideas or behaviors of participants using the ArtontheBrain((TM)) application. Transcripts underwent thematic analysis and indicated that the main access barriers were linked to control of the contrast, magnification, and the tactile interface on the tablet device. The learn and play activities as well as the text-to-speech feature were identified as facilitators for ArtontheBrain((TM)) engagement. The present findings should also be considered in the larger context of application development, as this study provides insight pertaining to the needs of low vision individuals regarding usability and accessibility.
C1 [Aubin, Gabrielle; Elalouf, Karine; Hogan, Mariah; Wittich, Walter] Univ Montreal, Sch Optometry, Rue Jean Brillant,Bur 260-7, Montreal, PQ H3T 1P1, Canada.
   [Altschuler, Aviva; Murphy, Kelly J.] Baycrest Hlth Sci, Toronto, ON, Canada.
   [Murphy, Kelly J.] Univ Toronto, Dept Psychol, Toronto, ON, Canada.
   [Wittich, Walter] CIUSSS Ctr Ouest Lile de Montreal, Ctr Readaptat Lethbridge Layton Mackay, Montreal, PQ, Canada.
   [Wittich, Walter] CISSS Monteregie Ctr, Inst Nazareth & Louis Braille, Longueuil, PQ, Canada.
   [Wittich, Walter] Ctr Rech Interdisciplinaire Readaptat Montreal Me, Montreal, PQ, Canada.
C3 Universite de Montreal; University of Toronto; University Toronto
   Affiliates; Baycrest; University of Toronto; Universite de Montreal
RP Aubin, G (通讯作者)，Univ Montreal, Sch Optometry, Rue Jean Brillant,Bur 260-7, Montreal, PQ H3T 1P1, Canada.
EM gabrielle.aubin@umontreal.ca
FU Centre for Aging and Brain Health Innovation (CABHI)
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This work was
   supported by the Centre for Aging and Brain Health Innovation (CABHI)
   Researcher-Clinician Partnership Program.
CR Adams KB, 2011, AGEING SOC, V31, P683, DOI 10.1017/S0144686X10001091
   Albers MW, 2015, ALZHEIMERS DEMENT, V11, P70, DOI 10.1016/j.jalz.2014.04.514
   Alqawlaq Samih, 2019, Exp Eye Res, V183, P88, DOI 10.1016/j.exer.2018.11.005
   Berends L, 2005, ADDICT RES THEORY, V13, P373, DOI 10.1080/16066350500102237
   Borsci S, 2009, ASSIST TECHNOL RES S, V25, P421, DOI 10.3233/978-1-60750-042-1-421
   Botner E, 2018, THER RECREAT J, V52, P126, DOI 10.18666/TRJ-2018-V52-I2-8664
   Canadian Association of Optometrists, 2015, AMD AG REL MAC DEG
   Dean S, 2017, BRIT J OPHTHALMOL, V101, P700, DOI 10.1136/bjophthalmol-2016-309955
   Fischer ME, 2016, J AM GERIATR SOC, V64, P1981, DOI 10.1111/jgs.14308
   Forrester JV, 1997, BRIT J OPHTHALMOL, V81, P809, DOI 10.1136/bjo.81.10.809
   Giguere C, 2020, J ACOUST SOC AM, V147, pEL252, DOI 10.1121/10.0000825
   Gopinath B, 2014, MATURITAS, V77, P263, DOI 10.1016/j.maturitas.2013.12.001
   Gordon K, 2015, CAN J OPHTHALMOL, V50, P85, DOI 10.1016/j.jcjo.2014.11.009
   Government of Canada SC, 2017, COMP AG PYR
   HEINEMANN AW, 1988, GERONTOLOGIST, V28, P181, DOI 10.1093/geront/28.2.181
   Joe J, 2013, J BIOMED INFORM, V46, P947, DOI 10.1016/j.jbi.2013.06.008
   Lai SW, 2017, INT PSYCHOGERIATR, V29, P1535, DOI 10.1017/S1041610217000801
   Lamoureux EL, 2004, AM J OPHTHALMOL, V137, P265, DOI 10.1016/j.ajo.2003.08.003
   Leat SJ, 2006, OPHTHAL PHYSL OPT, V26, P392, DOI 10.1111/j.1475-1313.2006.00383.x
   LEGGE GE, 1992, INVEST OPHTH VIS SCI, V33, P677
   LINDENBERGER U, 1994, PSYCHOL AGING, V9, P339, DOI 10.1037/0882-7974.9.3.339
   Lindenberger U, 2001, PSYCHOL AGING, V16, P196, DOI 10.1037//0882-7974.16.2.196
   MANCIL RM, 1989, J VISUAL IMPAIR BLIN, V83, P253
   McDonnall MC, 2016, J VISUAL IMPAIR BLIN, V110, P399
   Mesquita S, 2016, DISABIL SOC, V31, P373, DOI 10.1080/09687599.2016.1167671
   Midena E, 2022, EYE, V36, P182, DOI 10.1038/s41433-021-01470-9
   Monge ZA, 2016, NEUROSCI BIOBEHAV R, V69, P166, DOI 10.1016/j.neubiorev.2016.07.031
   Morrice E, 2017, EYE, V31, P865, DOI 10.1038/eye.2016.309
   Murphy KJ, 2021, J APPL GERONTOL, V40, P519, DOI 10.1177/0733464820967195
   Nouchi R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029676
   Owen AM, 2010, NATURE, V465, P775, DOI 10.1038/nature09042
   Owsley C, 1999, SURV OPHTHALMOL, V43, P535, DOI 10.1016/S0039-6257(99)00035-1
   Ranganathan VK, 2001, J AM GERIATR SOC, V49, P1478, DOI 10.1046/j.1532-5415.2001.4911240.x
   Regie de l'assurance maladie du Quebec, 2006, VIS AIDS RAMQ
   Rogers MAM, 2010, AM J EPIDEMIOL, V171, P728, DOI 10.1093/aje/kwp453
   Rubin GS, 2001, EYE, V15, P430, DOI 10.1038/eye.2001.148
   Scialfa CT, 2002, CAN J EXP PSYCHOL, V56, P153, DOI 10.1037/h0087393
   Simons DJ, 2016, PSYCHOL SCI PUBL INT, V17, P103, DOI 10.1177/1529100616661983
   Spierer O, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002423
   St-Amour L, 2019, OPTOMETRY VISION SCI, V96, P345, DOI 10.1097/OPX.0000000000001374
   Stefano F, 2010, COGN PROCESS, V11, P263, DOI 10.1007/s10339-009-0347-y
   Straus SE, 2013, KNOWLEDGE TRANSLATION IN HEALTH CARE: MOVING FROM EVIDENCE TO PRACTICE, 2ND EDITION, P1, DOI 10.1002/9781118413555
   Tilvis RS, 2004, J GERONTOL A-BIOL, V59, P268
   UHLMANN RF, 1991, J GEN INTERN MED, V6, P126, DOI 10.1007/BF02598307
   Vaismoradi M, 2013, NURS HEALTH SCI, V15, P398, DOI 10.1111/nhs.12048
   Vance DE, 2016, J NEUROSCI NURS, V48, pE2, DOI 10.1097/JNN.0000000000000197
   Varin M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18419-2
   Vucinic V, 2020, RES DEV DISABIL, V102, DOI 10.1016/j.ridd.2020.103673
   Wittich W, 2018, OPTOMETRY VISION SCI, V95, P704, DOI 10.1097/OPX.0000000000001269
   Wittich W, 2010, J VISUAL IMPAIR BLIN, V104, P360, DOI 10.1177/0145482X1010400606
   Zhou LX, 2016, CLIN INTERV AGING, V11, P215, DOI 10.2147/CIA.S102213
NR 51
TC 0
Z9 0
U1 1
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0046-9580
EI 1945-7243
J9 INQUIRY-J HEALTH CAR
JI Inquiry-J. Health Care Organ. Provis. Financ.
PD JAN 1
PY 2022
VL 59
AR 00469580211067446
DI 10.1177/00469580211067446
PG 15
WC Health Care Sciences & Services; Health Policy & Services
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services
GA YD6BU
UT WOS:000740526200001
PM 34985349
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Grassmann, F
   Weber, BHF
   Veitia, RA
AF Grassmann, Felix
   Weber, Bernhard H. F.
   Veitia, Reiner A.
TI Insights into the loss of the Y chromosome with age in control
   individuals and in patients with age-related macular degeneration using
   genotyping microarray data
SO HUMAN GENETICS
LA English
DT Article
ID MOSAIC LOSS; MEN; GENETICS; COMMON; BLOOD; RISK
AB The extent of aneuploidy of the sex chromosomes increases with age in human leukocytes. Here, we re-explore the dynamics of normal loss of the Y chromosome (LOY) with age based on microarray data using two exponential models and two different ways to estimate the fraction of LOY. This analysis shows the existence of a significant correlation between the fraction of LOY estimated from molecular cytogenetics and genotyping microarray data. Although the specific estimates of the parameters for the two exponential models are different from those derived from cytogenetics data, the present analysis in an independent dataset of normal individuals confirms that X0 cells have a selective advantage over XY cells. Moreover, patients with age-related macular degeneration display higher fraction of LOY values and seem to have a predisposition to lose their Y chromosome even at young ages compared to control individuals. As there are no data available for the same individuals at different time points, the parameters reported here are average values drawn from population analyses.
C1 [Grassmann, Felix] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.
   [Grassmann, Felix; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, Regensburg, Germany.
   [Veitia, Reiner A.] Univ Paris Diderot, Inst Jacques Monod, 15 Rue Helene Brion, F-75013 Paris, France.
   [Veitia, Reiner A.] Univ Paris, Paris, France.
C3 Karolinska Institutet; University of Regensburg; UDICE-French Research
   Universities; Universite Paris Cite; UDICE-French Research Universities;
   Universite Paris Cite
RP Veitia, RA (通讯作者)，Univ Paris Diderot, Inst Jacques Monod, 15 Rue Helene Brion, F-75013 Paris, France.; Veitia, RA (通讯作者)，Univ Paris, Paris, France.
EM reiner.veitia@ijm.fr
OI Grassmann, Felix/0000-0003-1390-7528
FU Fondation Pour la recherche médicale [DEQ20150331757] Funding Source:
   Medline; Universität Regensburg [TG77] Funding Source: Medline
CR Burgess S, 2017, OPHTHALMOLOGY
   Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   CROW J F, 1970, P591, DOI 10.1093/bioinformatics/btr330
   Dumanski JP, 2016, AM J HUM GENET, V98, P1208, DOI 10.1016/j.ajhg.2016.05.014
   Ersoy L, 2014, INVEST OPHTH VIS SCI, V55, P1842, DOI 10.1167/iovs.13-13420
   Felix G, 2019, JAMA OPHTHALMOL
   FITZGERALD PH, 1977, HUM GENET, V39, P329, DOI 10.1007/BF00295428
   Forsberg LA, 2019, EUR J HUM GENET, V27, P17, DOI 10.1038/s41431-018-0261-9
   Forsberg LA, 2014, NAT GENET, V46, P624, DOI 10.1038/ng.2966
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Grassmann F, 2019, EUR J HUM GENET, V27, P36, DOI 10.1038/s41431-018-0238-8
   Grassmann F, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0418-0
   Grassmann F, 2017, GENETICS, V205, P919, DOI 10.1534/genetics.116.195966
   Grassmann F, 2015, EUR J PHARM BIOPHARM, V95, P194, DOI 10.1016/j.ejpb.2015.04.039
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   GUTTENBACH M, 1995, AM J HUM GENET, V57, P1143
   Herens C, 1999, CLIN LAB HAEMATOL, V21, P17, DOI 10.1046/j.1365-2257.1999.00173.x
   Hirata T, 2018, NEUROPSYCH DIS TREAT, V14, P2115, DOI 10.2147/NDT.S172886
   JACOBS PA, 1963, NATURE, V197, P1080, DOI 10.1038/1971080a0
   Klein ML, 2010, OPHTHALMOLOGY, V117, p1559e1
   Loftfield E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30759-1
   Qin N, 2019, J THORAC ONCOL, V14, P37, DOI 10.1016/j.jtho.2018.09.013
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Veitia RA, 2019, J MOL CELL BIOL, V11, P719, DOI 10.1093/jmcb/mjz014
   Veitia RA, 2018, EUR J HUM GENET, V26, P1875, DOI 10.1038/s41431-018-0225-0
   Verhulst PF., 1838, CORRES MATH PHYS, V10, P113, DOI DOI 10.1007/BF02309004
   Wong JYY, 2018, ENVIRON INT, V116, P239, DOI 10.1016/j.envint.2018.04.030
   Wright DJ, 2017, NAT GENET, V49, P674, DOI 10.1038/ng.3821
   Zhou WY, 2016, NAT GENET, V48, P563, DOI 10.1038/ng.3545
   Zink F, 2017, BLOOD, V130, P742, DOI 10.1182/blood-2017-02-769869
NR 31
TC 10
Z9 10
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0340-6717
EI 1432-1203
J9 HUM GENET
JI Hum. Genet.
PD MAR
PY 2020
VL 139
IS 3
SI SI
BP 401
EP 407
DI 10.1007/s00439-019-02029-1
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA KN0FC
UT WOS:000514514000009
PM 31134332
DA 2022-11-30
ER

PT J
AU Bermond, K
   von der Emde, L
   Tarau, IS
   Bourauel, L
   Heintzmann, R
   Holz, FG
   Curcio, CA
   Sloan, KR
   Ach, T
AF Bermond, Katharina
   von der Emde, Leon
   Tarau, Ioana-Sandra
   Bourauel, Leonie
   Heintzmann, Rainer
   Holz, Frank G.
   Curcio, Christine A.
   Sloan, Kenneth R.
   Ach, Thomas
TI Autofluorescent Organelles Within the Retinal Pigment Epithelium in
   Human Donor Eyes With and Without Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE autofluorescence; lipofuscin; structured illumination microscopy;
   confocal fluorescence microscopy; melanosomes; melanolipofuscin
ID QUANTITATIVE FUNDUS AUTOFLUORESCENCE; OPTICAL COHERENCE TOMOGRAPHY;
   LIPOFUSCIN; INTERMEDIATE; DRUSEN; PROGRESSION; ADAPTATION; VISION;
   CONES; RODS
AB PURPOSE. Human retinal pigment epithelium (RPE) cells contain lipofuscin, melanolipofuscin, and melanosome organelles that impact clinical autofluorescence (AF) imaging. Here, we quantified the effect of age-related macular degeneration (AMD) on granule count and histologic AF of RPE cell bodies.
   METHODS. Seven AMD-affected human RPE-Bruch's membrane flatmounts (early and intermediate = 3, late dry = 1, and neovascular = 3) were imaged at fovea, perifovea, and near periphery using structured illumination and confocal AF microscopy (excitation 488 nm) and compared to RPE-flatmounts with unremarkable macula (n = 7, >80 years). Subsequently, granules were marked with computer assistance, and classified by their AF properties. The AF/cell was calculated from confocal images. The total number of granules and AF/cell was analyzed implementing a mixed effect analysis of covariance (ANCOVA).
   RESULTS. A total of 152 AMD-affected RPE cells were analyzed (fovea = 22, perifovea = 60, and near-periphery = 70). AMD-affected RPE cells showed increased variability in size and a significantly increased granule load independent of the retinal location (fovea: P = 0.02, perifovea: P = 0.04, and near periphery: P < 0.01). The lipofuscin fraction of total organelles decreased and the melanolipofuscin fraction increased in AMD, at all locations (especially the fovea). AF was significantly lower in AMD-affected cells (fovea: <0.01, perifovea: <0.01, and near periphery: 0.02).
   CONCLUSIONS. In AMD RPE, lipofuscin was proportionately lowest in the fovea, a location also known to be affected by accumulation of soft drusen and preservation of conemediated visual acuity. Enlarged RPE cell bodies displayed increased net granule count but diminished total AF. Future studies should also assess the impact on AF imaging of RPE apical processes containing melanosomes.
C1 [Bermond, Katharina] Ludwigshafen Hosp, Dept Ophthalmol, Ludwigshafen, Germany.
   [von der Emde, Leon; Bourauel, Leonie; Holz, Frank G.; Ach, Thomas] Univ Hosp Bonn, Dept Ophthalmol, Bonn, Germany.
   [Tarau, Ioana-Sandra] Univ Hosp Wurzburg, Dept Ophthalmol, Wurzburg, Germany.
   [Heintzmann, Rainer] Leibniz Inst Photon Technol, Jena, Germany.
   [Heintzmann, Rainer] Friedrich Schiller Univ Jena, Inst Phys Chem, Jena, Germany.
   [Heintzmann, Rainer] Friedrich Schiller Univ Jena, Abbe Ctr Photon, Jena, Germany.
   [Curcio, Christine A.; Sloan, Kenneth R.] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL USA.
C3 Ludwigshafen Hospital; University of Bonn; University of Wurzburg;
   Leibniz Institut fur Photonische Technologien; Friedrich Schiller
   University of Jena; Friedrich Schiller University of Jena; University of
   Alabama System; University of Alabama Birmingham
RP Ach, T (通讯作者)，Univ Hosp Bonn, FEBO, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM thomas.ach@ukbonn.de
FU Dr. Werner Jackstadt Foundation; NIH/NEI [R01EY06109]
FX Supported by Dr. Werner Jackstadt Foundation (TA) and NIH/NEI
   1R01EY027948-01 (T.A. and C.A.C.); human eye tissues were supported by
   NIH/NEI R01EY06109 (C.A.C.).
CR Ablonczy Z, 2013, ARCH BIOCHEM BIOPHYS, V539, P196, DOI 10.1016/j.abb.2013.08.005
   Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Anderson DMG, 2020, J AM SOC MASS SPECTR, V31, P2426, DOI 10.1021/jasms.0c00119
   Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   Bermond K, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.5.35
   Cao DF, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.10.34
   Chen L, 2021, OPHTHALMOL RETINA, V5, P1085, DOI 10.1016/j.oret.2021.01.012
   Chen L, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.1.33
   Chen M, 2016, AGING CELL, V15, P436, DOI 10.1111/acel.12447
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Freund KB, 2013, JAMA OPHTHALMOL, V131, P1645, DOI 10.1001/jamaophthalmol.2013.5030
   Gambril JA, 2019, INVEST OPHTH VIS SCI, V60, P2481, DOI 10.1167/iovs.19-26949
   Gliem M, 2016, JAMA OPHTHALMOL, V134, P817, DOI 10.1001/jamaophthalmol.2016.1475
   Greenberg JP, 2013, INVEST OPHTH VIS SCI, V54, P5684, DOI 10.1167/iovs.13-12445
   Grieve K, 2018, BIOMED OPT EXPRESS, V9, P5946, DOI 10.1364/BOE.9.005946
   Holmen IC, 2019, OPHTHALMOL RETINA, V3, P724, DOI 10.1016/j.oret.2019.04.011
   Julien S, 2012, NEUROBIOL AGING, V33, P2390, DOI 10.1016/j.neurobiolaging.2011.12.009
   Julien-Schraermeyer S, 2020, PHARMACOL RES PERSPE, V8, DOI 10.1002/prp2.683
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Kim I T, 1998, Korean J Ophthalmol, V12, P85
   Lacroix B, 2012, J PATHOL, V226, P338, DOI 10.1002/path.3013
   Ma L, 2011, J BIOL CHEM, V286, P7966, DOI 10.1074/jbc.M110.178657
   Miura M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03529-8
   Neubauer AS, 2006, GRAEF ARCH CLIN EXP, V244, P342, DOI 10.1007/s00417-005-0056-x
   Orellana-Rios J, 2018, OSLI RETINA, V49, pS34, DOI 10.3928/23258160-20180814-06
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Pollreisz A, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.2.26
   Pollreisz A, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.8.13
   Pollreisz A, 2018, EXP EYE RES, V166, P131, DOI 10.1016/j.exer.2017.10.018
   Polyak S.L., 1941, RETINA ANATOMY HISTO
   Provis JM, 2013, PROG RETIN EYE RES, V35, P63, DOI 10.1016/j.preteyeres.2013.01.005
   Racz B, 2018, J BIOL CHEM, V293, P11574, DOI 10.1074/jbc.RA118.002062
   Reiter GS, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-92309-6
   Reiter GS, 2021, RETINA-J RET VIT DIS, V41, P1236, DOI 10.1097/IAE.0000000000002995
   Reiter GS, 2019, INVEST OPHTH VIS SCI, V60, P1937, DOI 10.1167/iovs.19-26566
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Starnes AC, 2016, VISUAL NEUROSCI, V33, DOI 10.1017/S0952523815000310
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sura AA, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.13.19
   Taubitz T, 2019, EBIOMEDICINE, V48, P592, DOI 10.1016/j.ebiom.2019.09.048
   Thoreson WB, 2019, PHYSIOL REV, V99, P1527, DOI 10.1152/physrev.00027.2018
   TSO MOM, 1968, ARCH OPHTHALMOL-CHIC, V80, P214, DOI 10.1001/archopht.1968.00980050216012
   von der Emde L, 2021, RETINA-J RET VIT DIS, V41, P694, DOI 10.1097/IAE.0000000000002923
   von der Emde L, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.1.7
   Von Ruckmann A, 2002, AM J OPHTHALMOL, V133, P780, DOI 10.1016/S0002-9394(02)01428-9
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
NR 56
TC 0
Z9 0
U1 2
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2022
VL 63
IS 1
DI 10.1167/iovs.63.1.23
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YM5AF
UT WOS:000746586400001
PM 35050307
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU McLeish, B
   Morris, A
   Karpoor, M
   Babar, T
   Narendran, N
   Yang, Y
AF McLeish, Bethan
   Morris, Anna
   Karpoor, Meena
   Babar, Tehmoor
   Narendran, Niro
   Yang, Yit
TI Novel metrics for evaluating decision making in a 'Treat and Extend'
   regimen for neovascular age related macular degeneration
SO EYE
LA English
DT Article
ID 2-YEAR OUTCOMES; INTRAVITREAL AFLIBERCEPT; PROSPECTIVE TRIAL; THERAPY;
   RANIBIZUMAB
AB Background The primary aim was to investigate outcome of the decision making on duration of injection intervals between injection visits over the first 2 years of a treat and extend regimen. Method Consecutive patients receiving Aflibercept for treatment naive neovascular age-related macular degeneration between 01.01.2016 and 15.07.2017 were identified from our departmental register. Retrospective data collected on all visits over 24 months were classified into three groups: (A) Without Interval Decision Events (IDE)" Injection only" (B) IDE resulting in injection intervals of <5 weeks and (C) IDE resulting in intervals of >5 weeks. The primary outcome was number of successful IDE relative to the total visits in Group C. Successful decision making was defined as absence of worsening of visual acuity (>5 L) or central retinal thickness (>50 microns) at the subsequent visit. Secondary visual and anatomical outcomes at 24 months were also evaluated. Results Data from 56 eyes of 50 patients were included in the study. Visual acuity improved by +7.11 L at 24 months. Forty one patients with unilateral therapy made 721 visits: 280 visits (38.8%) were group A; 164 visits (22.8%) were group B and 277 visits (38.4%) were group C. Average interval in Group C was 8.9 weeks (range 5-15). The success rate of extension was 95.31% (264/277 visits). Conclusion These metrics for evaluating the decision making aspect of disease activity monitoring may be useful for monitoring performance and have given us a more realistic view and expectations of what can be achieved using this regime to optimise the timing of injections.
C1 [McLeish, Bethan; Karpoor, Meena; Babar, Tehmoor; Narendran, Niro; Yang, Yit] New Cross Hosp, Dept Ophthalmol, Wolverhampton WV10 0QP, England.
   [Morris, Anna] Cardiff Univ, Univ Wales Hosp, Sch Med, Cardiff, Wales.
C3 New Cross Hospital; Cardiff University
RP Karpoor, M (通讯作者)，New Cross Hosp, Dept Ophthalmol, Wolverhampton WV10 0QP, England.
EM Meena.Karpoor@nhs.net
OI Karpoor, Meena/0000-0002-0716-6770; McLeish, Bethan/0000-0001-6131-9312
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Augsburger M, 2019, GRAEF ARCH CLIN EXP, V257, P1889, DOI 10.1007/s00417-019-04404-0
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bhandari S, 2020, OPHTHALMOLOGY, V127, P369, DOI 10.1016/j.ophtha.2019.10.006
   Decroos FC, 2017, AM J OPHTHALMOL, V180, P142, DOI 10.1016/j.ajo.2017.06.002
   Gemenetzi M, 2017, OPHTHALMOL THER, V6, P79, DOI 10.1007/s40123-017-0087-5
   Gillies MC, 2020, OPHTHALMOLOGY, V127, P198, DOI 10.1016/j.ophtha.2019.08.023
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Khurana RN, 2019, AM J OPHTHALMOL, V200, P161, DOI 10.1016/j.ajo.2019.01.005
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Martin DF, 2020, OPHTHALMOLOGY, V127, pS135, DOI 10.1016/j.ophtha.2020.01.029
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Maruko I, 2020, OPHTHALMOL RETINA, V4, P767, DOI 10.1016/j.oret.2020.03.010
   Mekjavic PJ, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-1005-x
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Okada M, 2018, AM J OPHTHALMOL, V192, P184, DOI 10.1016/j.ajo.2018.05.026
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Taipale C, 2020, ADV THER, V37, P2256, DOI 10.1007/s12325-020-01312-2
   Taipale C, 2020, ACTA OPHTHALMOL, V98, P267, DOI 10.1111/aos.14231
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
   Traine PG, 2019, OPHTHALMOL RETINA, V3, P393, DOI 10.1016/j.oret.2019.01.018
   Tsunekawa Y, 2021, JPN J OPHTHALMOL, V65, P69, DOI 10.1007/s10384-020-00783-8
   Ventrice P, 2013, J PHARMACOL PHARMACO, V4, pS38, DOI 10.4103/0976-500X.120947
   Villegas VM, 2017, EXPERT OPIN DRUG DEL, V14, P273, DOI 10.1080/17425247.2016.1213240
   Wakuta M, 2020, GRAEF ARCH CLIN EXP, V258, P1663, DOI 10.1007/s00417-020-04745-1
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 30
TC 0
Z9 0
U1 0
U2 1
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD OCT
PY 2022
VL 36
IS 10
BP 1994
EP 1999
DI 10.1038/s41433-021-01785-7
EA OCT 2021
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4S0NN
UT WOS:000706563700003
PM 34642497
DA 2022-11-30
ER

PT J
AU Flynn, OJ
   Cukras, CA
   Jeffrey, BG
AF Flynn, Oliver J.
   Cukras, Catherine A.
   Jeffrey, Brett G.
TI Characterization of Rod Function Phenotypes Across a Range of
   Age-Related Macular Degeneration Severities and Subretinal Drusenoid
   Deposits
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE dark adaptation; scotopic thresholds; age-related macular degeneration;
   subretinal drusenoid deposits; AMD; SDD; rod intercept time; RIT
ID MEDIATED DARK-ADAPTATION; RETINITIS-PIGMENTOSA; RETICULAR PSEUDODRUSEN;
   GEOGRAPHIC-ATROPHY; RETINAL FUNCTION; A-WAVE; MACULOPATHY; SENSITIVITY;
   VISION; ELECTRORETINOGRAM
AB PURPOSE. To examine spatial changes in rod-mediated function in relationship to local structural changes across the central retina in eyes with a spectrum of age-related macular degeneration (AMD) disease severity.
   METHODS. Participants were categorized into five AMD severity groups based on fundus features. Scotopic thresholds were measured at 14 loci spanning +/- 188 along the vertical meridian from one eye of each of 42 participants (mean = 71.7 +/- 9.9 years). Following a 30% bleach, dark adaptation was measured at eight loci (+/- 128). Rod intercept time (RIT) was defined from the time to detect a -3.1 log cd/m(2) stimulus. RITslope was defined from the linear fit of RIT with decreasing retinal eccentricity. The presence of subretinal drusenoid deposits (SDD), ellipsoid (EZ) band disruption, and drusen at the test loci was evaluated using optical coherence tomography.
   RESULTS. Scotopic thresholds indicated greater rod function loss in the macula, which correlated with increasing AMD group severity. RITslope, which captures the spatial change in the rate of dark adaptation, increased with AMD severity (P < 0.0001). Three rod function phenotypes emerged: RF1, normal rod function; RF2, normal scotopic thresholds but slowed dark adaptation; and RF3, elevated scotopic thresholds with slowed dark adaptation. Dark adaptation was slowed at all loci with SDD or EZ band disruption, and at 32% of loci with no local structural changes.
   CONCLUSIONS. Three rod function phenotypes were defined from combined measurement of scotopic threshold and dark adaptation. Spatial changes in dark adaptation across the macula were captured with RITslope, which may be a useful outcome measure for functional studies of AMD.
C1 [Flynn, Oliver J.; Jeffrey, Brett G.] NEI, Ophthalm Genet & Visual Funct Branch, NIH, 10 Ctr Dr, Bethesda, MD 20892 USA.
   [Cukras, Catherine A.] NEI, Div Epidemiol & Clin Res, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI)
RP Jeffrey, BG (通讯作者)，NEI, Ophthalm Genet & Visual Funct Branch, NIH, 10 Ctr Dr, Bethesda, MD 20892 USA.
EM jeffreybg@nei.nih.gov
OI Flynn, Oliver/0000-0001-5416-0630
FU National Eye Institute Intramural Research Program, National Institutes
   of Health, Bethesda, Maryland, United States; NATIONAL EYE INSTITUTE
   [ZIAEY000552] Funding Source: NIH RePORTER
FX Supported by the National Eye Institute Intramural Research Program,
   National Institutes of Health, Bethesda, Maryland, United States.
CR ALPERN M, 1974, J PHYSIOL-LONDON, V237, P341, DOI 10.1113/jphysiol.1974.sp010485
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Dimitrov PN, 2012, INVEST OPHTH VIS SCI, V53, P5213, DOI 10.1167/iovs.11-8958
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Fraser RG, 2016, INVEST OPHTH VIS SCI, V57, P5436, DOI 10.1167/iovs.16-19295
   Hanus J, 2016, BRIT J OPHTHALMOL, V100, P122, DOI 10.1136/bjophthalmol-2015-306972
   Jackson GR, 2004, INVEST OPHTH VIS SCI, V45, P3271, DOI 10.1167/iovs.04-0019
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jackson GR, 2000, VISION RES, V40, P2467, DOI 10.1016/S0042-6989(00)00108-5
   Jackson GR, 2014, OPTOMETRY VISION SCI, V91, P925, DOI 10.1097/OPX.0000000000000247
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Jackson Gregory R, 2008, J Ocul Biol Dis Infor, V1, P7, DOI 10.1007/s12177-008-9002-6
   JACOBSON SG, 1986, OPHTHALMOLOGY, V93, P1604
   Lains I, 2017, OPHTHALMOLOGY, V124, P1340, DOI 10.1016/j.ophtha.2017.03.061
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   LAMB TD, 1981, VISION RES, V21, P1773, DOI 10.1016/0042-6989(81)90211-X
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   MASSOF RW, 1979, INVEST OPHTH VIS SCI, V18, P263
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2015, CURR EYE RES, V41, P1
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Owsley C, 2014, INVEST OPHTH VIS SCI, V55, P4776, DOI 10.1167/iovs.14-14502
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   RUSHTON WAH, 1972, VISION RES, V12, P1073, DOI 10.1016/0042-6989(72)90098-3
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   SUNNESS JS, 1985, ARCH OPHTHALMOL-CHIC, V103, P811
   Thomas MM, 1999, J PHYSIOL-LONDON, V518, P479, DOI 10.1111/j.1469-7793.1999.0479p.x
   Wyszecki G., 2000, COLOR SCI CONCEPTS M
   ZEAVIN BH, 1956, AM J OPHTHALMOL, V42, P253, DOI 10.1016/0002-9394(56)90377-4
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
NR 43
TC 20
Z9 20
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2018
VL 59
IS 6
BP 2411
EP 2421
DI 10.1167/iovs.17-22874
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GH0GL
UT WOS:000433080400002
PM 29847647
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Busbee, BG
   Ho, AC
   Brown, DM
   Heier, JS
   Suner, IJ
   Li, ZR
   Rubio, RG
   Lai, P
AF Busbee, Brandon G.
   Ho, Allen C.
   Brown, David M.
   Heier, Jeffrey S.
   Suner, Ivan J.
   Li, Zhengrong
   Rubio, Roman G.
   Lai, Phillip
CA HARBOR Study Grp
TI Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in
   Patients with Subfoveal Neovascular Age-related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL RANIBIZUMAB; VERTEPORFIN;
   LUCENTIS; TRIAL
AB Objective: To evaluate the 12-month efficacy and safety of intravitreal ranibizumab 0.5 mg and 2.0 mg administered monthly and on an as-needed (PRN) basis in treatment-naive patients with subfoveal neovascular age-related macular degeneration (wet AMD).
   Design: A 24-month, phase III, randomized, multicenter, double-masked, dose-response study.
   Participants: Patients aged >= 50 years with subfoveal wet AMD.
   Methods: Patients (n = 1098) were randomized to receive ranibizumab 0.5 mg or 2.0 mg intravitreal injections administered monthly or on a PRN basis after 3 monthly loading doses.
   Main Outcome Measures: The primary efficacy end point was the mean change from baseline in best-corrected visual acuity (BCVA) at month 12. Key secondary end points included the mean number of ranibizumab injections, the mean change from baseline in central foveal thickness (CFT) over time, and the proportion of patients who gained >= 15 letters of BCVA. Unless otherwise specified, end point analyses were performed using the last-observation-carried-forward method to impute missing data.
   Results: At month 12, the mean change from baseline in BCVA for the 4 groups was +10.1 letters (0.5 mg monthly), +8.2 letters (0.5 mg PRN), +9.2 letters (2.0 mg monthly), and +8.6 letters (2.0 mg PRN). The proportion of patients who gained >= 15 letters from baseline at month 12 in the 4 groups was 34.5%, 30.2%, 36.1%, and 33.0%, respectively. The mean change from baseline in CFT at month 12 in the 4 groups was -172.0 mu m, -161.2 mu m, -163.3 mu m, and -172.4 mu m, respectively. The mean number of injections was 7.7 and 6.9 for the 0.5-mg PRN and 2.0-mg PRN groups, respectively. Ocular and systemic safety profiles were consistent with previous ranibizumab trials in AMD and comparable between groups.
   Conclusions: At month 12, the ranibizumab 2.0 mg monthly group did not meet the prespecified superiority comparison and the ranibizumab 0.5 mg and 2.0 mg PRN groups did not meet the prespecified noninferiority (NI) comparison. However, all treatment groups demonstrated clinically meaningful visual improvement (+8.2 to +10.1 letters) and improved anatomic outcomes, with the PRN groups requiring approximately 4 fewer injections (6.9-7.7) than the monthly groups (11.2-11.3). No new safety events were observed despite a 4-fold dose escalation in the study. The pHase III, double-masked, multicenter, randomized, Active treatment-controlled study of the efficacy and safety of 0.5 mg and 2.0 mg Ranibizumab administered monthly or on an as-needed Basis (PRN) in patients with subfoveal neOvasculaR age-related macular degeneration (HARBOR) study confirmed that ranibizumab 0.5 mg dosed monthly provides optimum results in patients with wet AMD.
C1 [Busbee, Brandon G.] Tennessee Retina, Nashville, TN 37203 USA.
   [Ho, Allen C.] Wills Eye Inst, Mid Atlantic Retina, Philadelphia, PA USA.
   [Brown, David M.] Retina Consultants Houston, Houston, TX USA.
   [Heier, Jeffrey S.] Ophthalm Consultants Boston, Boston, MA USA.
   [Suner, Ivan J.] Retina Associates Florida, Tampa, FL USA.
   [Li, Zhengrong; Rubio, Roman G.; Lai, Phillip] Genentech Inc, San Francisco, CA 94080 USA.
C3 Jefferson University; Ophthalmic Consultants of Boston; Roche Holding;
   Genentech
RP Busbee, BG (通讯作者)，Tennessee Retina, Centennial Profess Plaza,345 23rd Ave North,Suite, Nashville, TN 37203 USA.
EM bgbusbee@yahoo.com
OI Ho, Allen/0000-0003-3921-608X; Kiss, Szilard/0000-0003-3433-8432;
   Ciulla, Thomas/0000-0001-5557-6777
FU Genentech; Alcon; Allergan; National Eye Institute/National Institutes
   of Health; NeoVista; Ophthotech; Oraya; PRN; QLT; Regeneron; Second
   Sight; Abbott; Alimera; Eli Lilly; GlaxoSmithKline; Novartis;
   Thrombogenics; Fovea; Genzyme; Neurotech; Ophthalmic Consultants of
   Boston; Paloma; Genentech, Inc. (South San Francisco, CA)
FX The author(s) have made the following disclosure(s): B.G.B. has served
   as a consultant for Alimera, Elan, Genentech, Synergetics, and
   Thrombogenics; has received research funding from Genentech; is a member
   of the speakers bureau for Genentech and Regeneron; and has received
   royalties from AKORN. A.C.H. has served as a consultant for Alcon,
   Allergan, Centocor/Johnson & Johnson, Genentech, Merck, NeoVista,
   Ophthotech, Oraya, Paloma, PRN, QLT, Regeneron, and Thrombogenics; has
   received research funding from Alcon, Allergan, Genentech, National Eye
   Institute/National Institutes of Health, NeoVista, Ophthotech, Oraya,
   PRN, QLT, Regeneron, and Second Sight; and is a member of the speakers
   bureau for Alcon, Genentech, and Regeneron. D. M. B. has served as a
   consultant for Alcon, Alimera, Allergan, Genentech, Novartis, Regeneron,
   and Thrombogenics; has received research funding from Abbott, Alcon,
   Alimera, Allergan, Eli Lilly, Genentech, GlaxoSmithKline, Ophthotech,
   Novartis, Regeneron, and Thrombogenics; and is a member of the speakers
   bureau for Genentech and Regeneron. J.S.H. has served as a consultant
   for Acucela, Allergan, Bayer, Forsight, Fovea, Genentech, Genzyme,
   GlaxoSmithKline, LPath, Neovista, Oraya, Paloma, QLT, Quark, and
   Regeneron; and has received research funding from Alcon, Alimera,
   Allergan, Fovea, Genentech, Genzyme, GlaxoSmithKline, Neovista,
   Neurotech, Novartis, Ophthalmic Consultants of Boston, Ophthotech,
   Paloma, and Regeneron. I.J.S. has served as a consultant for Genentech,
   Eyetech, Regeneron, and Thrombogenics; has received research funding
   from Genentech; is a member of the speakers bureau for Genentech, Optos,
   and Regeneron; and is a board member of Optos. Z.L., R.G.R., and P.L.
   are employees of Genentech. Support for third-party writing assistance
   for this manuscript provided by Linda Merkel, PhD, and Michelle Kelly,
   PhD, of UBC-Envision Group, and was provided by Genentech, Inc.;
   Genentech, Inc. (South San Francisco, CA) provided support for the study
   and participated in the study design; conducting the study; and data
   collection, management, and interpretation.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen HX, 2009, NAT REV CLIN ONCOL, V6, P465, DOI 10.1038/nrclinonc.2009.94
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Hoang QV, 2012, OPHTHALMOLOGY, V119, P321, DOI 10.1016/j.ophtha.2011.08.011
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Ophthalmologic Drugs Advisory Committee, 2011, VEGF TRAP EYE AFL OP, V61, P76
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 21
TC 351
Z9 368
U1 1
U2 26
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2013
VL 120
IS 5
BP 1046
EP 1056
DI 10.1016/j.ophtha.2012.10.014
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 140VE
UT WOS:000318683400024
PM 23352196
OA hybrid
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Lima, LH
   Merriam, JE
   Freund, KB
   Barbazetto, IA
   Spaide, RF
   Yannuzzi, LA
   Allikmets, R
AF Lima, Luiz H.
   Merriam, Joanna E.
   Freund, K. Bailey
   Barbazetto, Irene A.
   Spaide, Richard F.
   Yannuzzi, Lawrence A.
   Allikmets, Rando
TI Elastin rs2301995 Polymorphism is not Associated with Polypoidal
   Choroidal Vasculopathy in Caucasians
SO OPHTHALMIC GENETICS
LA English
DT Article
ID MACULAR DEGENERATION; SUSCEPTIBILITY; HAPLOTYPE; DISEASE
AB Methods: Association analysis of allele and genotype frequencies, determined by TaqMan assays, was performed for the rs2301995 haplotype-tagging single nucleotide polymorphism (htSNP) in the ELN locus in fifty-six patients with PCV, 368 patients with advanced age-related macular degeneration (AMD) and 368 age- and ethnically-matched unaffected controls.
   Results: The ELN rs2301995 SNP was not statistically significantly associated with the PCV phenotype (P == 0.9). The frequency of the minor allele of the rs2301995 SNP was practically identical in the PCV, AMD and control groups (6.3% vs. 5.4% vs. 7.1%).
   Conclusion: The PCV phenotype in European-American patients is not associated with rs2301995 SNP in the ELN locus.
C1 [Allikmets, Rando] Columbia Univ, Eye Inst Res Addit, Dept Pathol & Cell Biol, New York, NY 10032 USA.
   [Lima, Luiz H.; Freund, K. Bailey; Barbazetto, Irene A.; Spaide, Richard F.; Yannuzzi, Lawrence A.] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retina Res Ctr, New York, NY USA.
   [Lima, Luiz H.; Freund, K. Bailey; Barbazetto, Irene A.; Spaide, Richard F.; Yannuzzi, Lawrence A.] Macula Consultants New York, Vitreous, Retina, New York, NY USA.
   [Lima, Luiz H.] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
   [Merriam, Joanna E.; Freund, K. Bailey; Yannuzzi, Lawrence A.] Columbia Univ, Dept Ophthalmol, New York, NY 10032 USA.
C3 Columbia University; Manhattan Eye Ear & Throat Hospital; Vitreous
   Retina Macula Consultants of New York; Universidade Federal de Sao Paulo
   (UNIFESP); Columbia University
RP Allikmets, R (通讯作者)，Columbia Univ, Eye Inst Res Addit, Dept Pathol & Cell Biol, 160 Ft Washington Ave,7th Floor,Room 715, New York, NY 10032 USA.
EM rla22@columbia.edu
RI Lima, Luiz H/V-4940-2017; Spaide, Richard/ABD-7368-2020; Allikmets,
   Rando/ABD-4533-2021; Freund, K. Bailey/V-7488-2018
OI Lima, Luiz H/0000-0001-7304-909X; Freund, K. Bailey/0000-0002-7888-9773
FU NEI NIH HHS [R01 EY013435] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [R01EY013435] Funding Source: NIH RePORTER
CR Akagawa H, 2006, HUM MOL GENET, V15, P1722, DOI 10.1093/hmg/ddl096
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Karnik SK, 2003, DEVELOPMENT, V130, P411, DOI 10.1242/dev.00223
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 12
TC 12
Z9 12
U1 0
U2 0
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1381-6810
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD JUN
PY 2011
VL 32
IS 2
BP 80
EP 82
DI 10.3109/13816810.2010.544362
PG 3
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA 762OE
UT WOS:000290488500003
PM 21391811
DA 2022-11-30
ER

PT J
AU Brucher, VC
   Storp, JJ
   Kerschke, L
   Nelis, P
   Eter, N
   Alnawaiseh, M
AF Bruecher, Viktoria C.
   Storp, Jens J.
   Kerschke, Laura
   Nelis, Pieter
   Eter, Nicole
   Alnawaiseh, Maged
TI Influence of mydriasis on optical coherence tomography angiography
   imaging in patients with age-related macular degeneration
SO PLOS ONE
LA English
DT Article
ID NERVE-FIBER LAYER; THICKNESS MEASUREMENTS; PUPIL-DILATION; VASCULAR
   DENSITY; CHORIOCAPILLARIS; REPEATABILITY; DOMAIN; REPRODUCIBILITY;
   ARTIFACTS; CATARACT
AB Purpose
   To evaluate the effect of topical mydriatic eye drops on optical coherence tomography angiography (OCTA) parameters in patients with age-related macular degeneration (AMD).
   Methods
   27 eyes of 27 patients suffering from AMD were included in this cross-sectional study. Patients with >=-4.5 diopters spherical equivalent, corneal opacities or dense cataract preventing high-quality imaging were excluded. Whole-en-face scans of the superficial capillary plexus (SCP) and deep capillary plexus (DCP) in the central 3x3mm foveal region as well as whole-en-face and peripapillary scans of the radial peripapillary capillaries (RPC) were generated using OCTA (AngioVue (R), Optovue). Imaging was first conducted with patients' eyes in miosis, then in mydriasis after instillation of a dilating eye drop (0.5% tropicamide, 2.5% phenylephrine-HCl). Main outcome measures were flow density (FD), foveal avascular zone (FAZ), signal strength index (SSI) and motion artifact score (MAS).
   Results
   Our results reveal that in AMD patients there is no significant difference between FD measurements taken in miosis and those taken in mydriasis around the SCP (p = 0.198), DCP (p = 0.458), RPC whole-en-face (p = 0.275) and RPC peripapillary (p = 0.503). Measurements taken in these two states appear to be equivalent for assessment of FD (90%CI within +/- 0.05). No significant difference was found either in the area of the FAZ (p = 0.338) or in the SSI (p = 0.371) before and after the instillation of tropicamide/phenylephrine. MAS was significantly lower after the application of mydriatic eye drops (p = 0.003).
   Conclusions
   Our findings reveal that neither measurements of FD nor measurements of the FAZ area changed significantly in AMD patients after the application of tropicamide/phenylephrine. Since MAS improved significantly in dilation, mydriatic examination is recommended. Nevertheless, a comparison of OCTA metrics from images taken with different pupil states (miosis versus mydriasis) is valid for clinical trials.
C1 [Bruecher, Viktoria C.; Storp, Jens J.; Nelis, Pieter; Eter, Nicole; Alnawaiseh, Maged] Univ Munster, Dept Ophthalmol, Med Ctr, Munster, North Rhine Wes, Germany.
   [Kerschke, Laura] Univ Munster, Dept Biometry & Clin Res, Med Ctr, Munster, North Rhine Wes, Germany.
C3 University of Munster; University of Munster
RP Brucher, VC (通讯作者)，Univ Munster, Dept Ophthalmol, Med Ctr, Munster, North Rhine Wes, Germany.
EM viktoria.bruecher@ukmuenter.de
RI Kerschke, Laura/S-5289-2016
OI Kerschke, Laura/0000-0002-1195-7399
CR Al-Sheikh Mayss, 2017, Int J Retina Vitreous, V3, P13, DOI 10.1186/s40942-017-0068-9
   Al-Sheikh M, 2017, BRIT J OPHTHALMOL, V101, P449, DOI 10.1136/bjophthalmol-2016-308764
   Alnawaiseh M, 2018, OPHTHALMOLOGE, V115, P659, DOI 10.1007/s00347-017-0539-2
   Alnawaiseh M, 2019, RETINA-J RET VIT DIS, V39, P210, DOI 10.1097/IAE.000000000000190
   Alnawaiseh M, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2056-3
   Alnawaiseh M, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0789-z
   Alnawaiseh M, 2017, RETINA-J RET VIT DIS, V37, P1642, DOI 10.1097/IAE.0000000000001419
   Alten F, 2016, GRAEF ARCH CLIN EXP, V254, P2165, DOI 10.1007/s00417-016-3375-1
   Borrelli E, 2018, AM J OPHTHALMOL, V196, P34, DOI 10.1016/j.ajo.2018.08.014
   Camino A, 2016, BIOMED OPT EXPRESS, V7, P3905, DOI 10.1364/BOE.7.003905
   Cheng CSM, 2011, CLIN EXP OPHTHALMOL, V39, P215, DOI 10.1111/j.1442-9071.2010.02460.x
   Cheng JY, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00996
   Chua J, 2019, J HYPERTENS, V37, P572, DOI 10.1097/HJH.0000000000001916
   Falavarjani KG, 2017, BRIT J OPHTHALMOL, V101, P989, DOI 10.1136/bjophthalmol-2016-309678
   Falavarjani KG, 2017, BRIT J OPHTHALMOL, V101, P564, DOI 10.1136/bjophthalmol-2016-309104
   Garas A, 2010, OPHTHALMOLOGY, V117, P738, DOI 10.1016/j.ophtha.2009.08.039
   Hollo G, 2018, J GLAUCOMA, V27, pE133, DOI 10.1097/IJG.0000000000000983
   Hsu SY, 2008, J GLAUCOMA, V17, P30, DOI 10.1097/IJG.0b013e31811243b4
   Hwang TS, 2016, JAMA OPHTHALMOL, V134, P367, DOI 10.1001/jamaophthalmol.2015.5658
   Iafe NA, 2016, INVEST OPHTH VIS SCI, V57, P5780, DOI 10.1167/iovs.16-20045
   Kashani AH, 2017, PROG RETIN EYE RES, V60, P66, DOI 10.1016/j.preteyeres.2017.07.002
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Lauermann JL, 2018, GRAEF ARCH CLIN EXP, V256, P1807, DOI 10.1007/s00417-018-4053-2
   Lauermann JL, 2017, GRAEF ARCH CLIN EXP, V255, P1535, DOI 10.1007/s00417-017-3684-z
   LEE CH, 2018, BR J OPHTHALMOL, DOI DOI 10.1136/BJOPHTHALMOL-2018-312516
   Lee MW, 2019, BRIT J OPHTHALMOL, V103, P704, DOI 10.1136/bjophthalmol-2018-312516
   Lei JQ, 2017, JAMA OPHTHALMOL, V135, P1092, DOI 10.1001/jamaophthalmol.2017.3431
   Ma J, 2017, OPHTHALMOL EYE DIS, V9, DOI 10.1177/1179172116686075
   Manalastas PIC, 2017, J GLAUCOMA, V26, P851, DOI 10.1097/IJG.0000000000000768
   Mansouri K, 2018, J GLAUCOMA, V27, P336, DOI 10.1097/IJG.0000000000000914
   Massa GC, 2010, EYE, V24, P1498, DOI 10.1038/eye.2010.72
   Milani P, 2018, GRAEF ARCH CLIN EXP, V256, P1419, DOI 10.1007/s00417-018-4012-y
   Mwanza JC, 2013, INT OPHTHALMOL, V33, P335, DOI 10.1007/s10792-012-9689-z
   Nassisi M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212563
   Nassisi M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207638
   Nassisi M, 2019, BRIT J OPHTHALMOL, V103, P911, DOI 10.1136/bjophthalmol-2018-312643
   Perrott-Reynolds R, 2019, EYE, V33, P274, DOI 10.1038/s41433-018-0229-6
   Polak K, 2000, BRIT J OPHTHALMOL, V84, P1285, DOI 10.1136/bjo.84.11.1285
   Roemer S, 2019, RETINA-J RET VIT DIS, V39, P2384, DOI 10.1097/IAE.0000000000002321
   Rosen RB, 2019, AM J OPHTHALMOL
   Rotsos T, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008110
   Sacconi R, 2019, BRIT J OPHTHALMOL, V103, P1320, DOI 10.1136/bjophthalmol-2018-313004
   Savini G, 2010, EYE, V24, P1503, DOI 10.1038/eye.2010.66
   Savini G, 2006, J GLAUCOMA, V15, P336, DOI 10.1097/01.ijg.0000212244.64584.c2
   SCHUIRMANN DJ, 1987, J PHARMACOKINET BIOP, V15, P657, DOI 10.1007/BF01068419
   Smith M, 2007, BRIT J OPHTHALMOL, V91, P1686, DOI 10.1136/bjo.2006.113134
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Sung MS, 2018, AM J OPHTHALMOL, V192, P157, DOI 10.1016/j.ajo.2018.05.022
   Tanga L, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0168-y
   Wang Q, 2016, AM J OPHTHALMOL, V168, P95, DOI 10.1016/j.ajo.2016.05.005
   Wang XL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159911
   Yang Y, 2016, INVEST OPHTH VIS SCI, V57, P6020, DOI 10.1167/iovs.16-19542
   Yanik Odabas O, 2018, RETINA-J RET VIT DIS, V38, P1238, DOI 10.1097/IAE.0000000000001671
   Zafar S, 2004, J GLAUCOMA, V13, P34, DOI 10.1097/00061198-200402000-00007
   2001, AM J OPHTHALMOL, V132, P668, DOI DOI 10.1016/S0002-9394(01)01218-1
NR 57
TC 8
Z9 8
U1 1
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 4
PY 2019
VL 14
IS 10
AR e0223452
DI 10.1371/journal.pone.0223452
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA LM7CZ
UT WOS:000532407600037
PM 31584983
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Barthelmes, D
   Campain, A
   Nguyen, P
   Arnold, JJ
   McAllister, IL
   Simpson, JM
   Hunyor, AP
   Guymer, R
   Essex, RW
   Morlet, N
   Gillies, MC
AF Barthelmes, Daniel
   Campain, Anna
   Phuc Nguyen
   Arnold, Jennifer J.
   McAllister, Ian L.
   Simpson, Judy M.
   Hunyor, Alex P.
   Guymer, Robyn
   Essex, Rohan W.
   Morlet, Nigel
   Gillies, Mark C.
CA Fight Retinal Blindness Project
TI Effects of switching from ranibizumab to aflibercept in eyes with
   exudative age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VEGF-TRAP; INTRAVITREAL AFLIBERCEPT; TERM OUTCOMES; BEVACIZUMAB;
   TACHYPHYLAXIS; RECURRENT
AB Aims To examine 12-month outcomes of eyes switching from intravitreal ranibizumab to aflibercept for neovascular age-related macular degeneration (nAMD).
   Methods Database observational study of eyes with nAMD tracked by the Fight Retinal Blindness outcome registry that received ranibizumab for at least 12 months before switching to aflibercept and followed for at least 12 months after the switch. Visual acuity (VA) recorded at 12 months after the switch was analysed using locally weighted scatterplot smoothing curves. Lesion activity was graded according to a prospectively identified definition. Main outcomes were change in VA and treatment intervals 12 months after the treatment switch. Secondary outcomes included change in activity grading, effect of duration of treatment before switching and analysis of eyes that switched back.
   Results A total of 384 eyes switched from ranibizumab to aflibercept after a mean duration of 39.8 months on the original treatment. The mean VA did not change from the time of switching treatment (63.4, SD 15.9 logarithm of the minimum angle of resolution letters) to 12 months later (63.3, SD 16.7). While 10% of eyes gained 10 or more letters 12 months after the switch, 13% lost the same amount. The mean number of injections decreased by around one injection in the 12 months after switching (p<0.001), with a decrease in the proportion of choroidal neovascular membrane lesions that were graded as active. Eyes that had been treated for the longest time (49 or more months) before switching had worse vision at the point of switch but neither change in VA nor treatment interval was different between groups. The small proportion (6.9%) of eyes that switched back again to ranibizumab had already lost a mean of 5.2 letters from the first switch to the switch back and continued to lose vision at a similar rate for at least 6 months.
   Conclusions The mean VA of eyes that switched treatments from ranibizumab to aflibercept was not different 12 months later. There was a modest increase in treatment intervals and a somewhat greater proportion of eyes that were graded as inactive after the switch.
C1 [Barthelmes, Daniel; Campain, Anna; Phuc Nguyen; Hunyor, Alex P.; Gillies, Mark C.] Univ Sydney, Sydney Med Sch, Save Sight Inst, Sydney, NSW, Australia.
   [Barthelmes, Daniel] Univ Zurich, Univ Zurich Hosp, Dept Ophthalmol, Zurich, Switzerland.
   [Arnold, Jennifer J.] Marsden Eye Specialists, Parramatta, Australia.
   [McAllister, Ian L.] Univ Western Australia, Lions Eye Inst, Ctr Ophthalmol & Vis Sci, Perth, WA, Australia.
   [Simpson, Judy M.] Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW, Australia.
   [Hunyor, Alex P.] Retina Associates, Chatswood, NSW, Australia.
   [Guymer, Robyn] Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, Melbourne, Vic, Australia.
   [Essex, Rohan W.] Canberra Hosp, Dept Ophthalmol, Garran, ACT, Australia.
   [Morlet, Nigel] Univ Western Australia, Dept Populat Hlth, Perth, WA, Australia.
C3 University of Sydney; University of Zurich; University Zurich Hospital;
   Lions Eye Institute; University of Western Australia; University of
   Sydney; Centre for Eye Research Australia; Royal Victorian Eye & Ear
   Hospital; University of Melbourne; Australian National University;
   Canberra Hospital; University of Western Australia
RP Barthelmes, D (通讯作者)，Univ Zurich Hosp, Dept Ophthalmol, Frauenklin Str 24, CH-8091 Zurich, Switzerland.
EM dbar8165@uni.sydney.edu.au
RI Hunyor, Alex/AAT-8205-2021
OI Hunyor, Alex/0000-0002-8182-6167; Fraser-Bell,
   Samantha/0000-0001-5646-9359; Essex, Rohan/0000-0001-5323-0334; Guymer,
   Robyn/0000-0002-9441-4356; Campain, Anna/0000-0003-1057-0085
FU Royal Australian NZ College of Ophthalmologists Eye Foundation; National
   Health and Medical Research Council, Australia (NHRMC)
FX This work was supported by a grant from the Royal Australian NZ College
   of Ophthalmologists Eye Foundation (2007-2009) and a grant from the
   National Health and Medical Research Council, Australia (NHRMC
   2010-1012).
CR Arcinue CA, 2015, AM J OPHTHALMOL, V159, P426, DOI 10.1016/j.ajo.2014.11.022
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Cleveland W, 1992, STAT MODELS, DOI 10.1201/9780203738535
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rubin DB, 2007, STAT MED, V26, P20, DOI 10.1002/sim.2739
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 25
TC 30
Z9 30
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2016
VL 100
IS 12
BP 1640
EP 1645
DI 10.1136/bjophthalmol-2015-308090
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EC7XD
UT WOS:000388353500010
PM 26994110
OA Green Published
DA 2022-11-30
ER

PT J
AU Cho, HJ
   Park, SM
   Kim, J
   Nah, SK
   Lee, J
   Lee, DW
   Kim, JW
AF Cho, Han Joo
   Park, Sang Min
   Kim, Jaemin
   Nah, Seung Kwan
   Lee, Jihyun
   Lee, Dong Won
   Kim, Jong Woo
TI Progression of macular atrophy in patients undergoing anti-vascular
   endothelial growth factor therapy for neovascular age-related macular
   degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; macular
   atrophy; retinal pigment epithelium; vascular endothelial growth factor
ID GEOGRAPHIC ATROPHY; RANIBIZUMAB INJECTIONS; RETICULAR PSEUDODRUSEN;
   CHORIOCAPILLARIS; DISEASE; RISK; EYE
AB Purpose To assess differences in the progression of macular atrophy (MA) between neovascular age-related macular degeneration (AMD) subtypes and to identify the risk factors associated with the foveal involvement among patients with MA undergoing long-term anti-vascular endothelial growth factor (VEGF) treatment. Methods Eighty eyes of 80 patients with neovascular AMD who developed incident MA following anti-VEGF therapy were retrospectively included. Macular atrophy (MA) was quantified using autofluoresence (AF) images within 24 months after the onset of MA, and the enlargement rate was compared between neovascular AMD subtypes. Regression models were constructed to explore relationships between foveal involvement in MA and baseline characteristics. Results The growth rate of MA was 0.18 mm(2)/year for type 1 neovascularization (NV), 0.24 mm(2)/year for type 2 NV, and 1.21 mm(2)/year for type 3 NV; differences between groups were significant (p = 0.022). Multivariate logistic regression analysis revealed that thin subfoveal choroidal thickness (p = 0.028), presence of subretinal drusenoid deposit (p = 0.005), type 2 or 3 NV (p = 0.023), and geographic atrophy in the fellow eye (p = 0.035) were significant risk factors for MA with foveal involvement. The number of injections showed no significant association with the progression or the foveal involvement in MA. Conclusions The progression of MA in patients with neovascular AMD undergoing anti-VEGF treatment differed significantly depending on the subtype of neovascularization. The risk of foveal involvement in MA was associated with the baseline factors or phenotype of neovascular AMD rather than with injection frequency of anti-VEGF.
C1 [Cho, Han Joo; Park, Sang Min; Kim, Jaemin; Nah, Seung Kwan; Lee, Jihyun; Lee, Dong Won; Kim, Jong Woo] Konyang Univ, Kims Eye Hosp, Coll Med, Seoul, South Korea.
C3 Konyang University; Konyang University Hospital
RP Cho, HJ (通讯作者)，Kims Eye Hosp, 156,4ga Yeongdeungpo Dong, Seoul, South Korea.
EM chojoo@kimeye.com
OI Cho, Han Joo/0000-0001-7336-5762
FU Kim's Eye Hospital Research Center
FX The authors have no proprietary or commercial interests in any of the
   materials discussed in this article. This study is supported by Kim's
   Eye Hospital Research Center.
CR Abdelfattah NS, 2017, OPHTHALMOLOGY, V124, P215, DOI 10.1016/j.ophtha.2016.10.002
   Alten F, 2016, GRAEF ARCH CLIN EXP, V254, P2165, DOI 10.1007/s00417-016-3375-1
   Beck M, 2016, AM J OPHTHALMOL, V167, P10, DOI 10.1016/j.ajo.2016.04.003
   Borrelli E, 2018, PROG RETIN EYE RES, V67, P30, DOI 10.1016/j.preteyeres.2018.07.002
   Borrelli E, 2018, RETINA-J RET VIT DIS, V38, P1968, DOI 10.1097/IAE.0000000000002198
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chen L, 2020, OPHTHALMOLOGY, V127, P931, DOI 10.1016/j.ophtha.2020.01.040
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Cho HJ, 2020, BRIT J OPHTHALMOL, V104, P1443, DOI 10.1136/bjophthalmol-2019-315496
   Cho HJ, 2018, RETINA-J RET VIT DIS, V38, P2150, DOI 10.1097/IAE.0000000000001862
   Christakis PG, 2020, OPHTHALMOLOGY, V127, P784, DOI 10.1016/j.ophtha.2019.11.016
   Daniel E, 2016, OPHTHALMOLOGY, V123, P609, DOI 10.1016/j.ophtha.2015.10.034
   Feuer WJ, 2013, JAMA OPHTHALMOL, V131, P110, DOI 10.1001/jamaophthalmol.2013.572
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Gune S, 2020, OPHTHALMOLOGY, V127, P523, DOI 10.1016/j.ophtha.2019.09.030
   Horani M, 2020, OPHTHALMOL THER, V9, P35, DOI 10.1007/s40123-019-00227-8
   Kaszubski P, 2016, OPHTHALMIC RES, V55, P185, DOI 10.1159/000443209
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mantel I, 2019, RETINA-J RET VIT DIS, V39, P906, DOI 10.1097/IAE.0000000000002054
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Wolf-Schnurrbusch UEK, 2011, INVEST OPHTH VIS SCI, V52, P9497, DOI 10.1167/iovs.11-8346
NR 30
TC 9
Z9 9
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUN
PY 2021
VL 99
IS 4
BP E540
EP E546
DI 10.1111/aos.14631
EA SEP 2020
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SZ5CP
UT WOS:000573584500001
PM 32996674
DA 2022-11-30
ER

PT J
AU Rosenfeld, PJ
   Windsor, MA
   Feuer, WJ
   Sun, SJJ
   Frick, KD
   Swanson, EA
   Huang, D
AF Rosenfeld, Philip J.
   Windsor, Matthew A.
   Feuer, William J.
   Sun, Sissi J. J.
   Frick, Kevin D.
   Swanson, Eric A.
   Huang, David
TI Estimating Medicare and Patient Savings From the Use of Bevacizumab for
   the Treatment of Exudative Age-related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; INTRAVITREAL AFLIBERCEPT; RANIBIZUMAB;
   INJECTION; AVASTIN
AB PURPOSE: The Medicare cost savings from the use of bevacizumab in the United States for the treatment of exudative age-related macular degeneration (AMD) were estimated by replacing the use of bevacizumab with ranibizumab and aflibercept.
   DESIGN: Retrospective trend study.
   METHODS: Main outcome measures were spending by Medicare as tracked by Current Procedural Terminology (CPT) codes for intravitreal injections (67028) and treatment-specific J-codes (J0178, J2778, J9035, J3490, and J3590) for inhibitors of vascular endothelial growth factor. These claims were identified from the Medicare Provider Utilization and Payment Data from the Centers for Medicare and Medicaid Services among fee-for-service (FFS) Medicare beneficiaries from 2012 to 2015. The 2008 claims were acquired from the 100% fee-for-service (FFS) Part B Medicare Claims File.
   RESULTS: The use of bevacizumab from 2008 to 2015 resulted in an estimated savings of $17.3 billion, which corresponded to a $13.8 billion savings to Medicare and a $3.5 billion savings to patients. This amount underestimated the actual cost savings to Medicare providers, since approximately 30% of Medicare-eligible recipients received care within Medicare Advantage plans and were not included in this analysis.
   CONCLUSIONS: The cost savings from the use of bevacizumab from 2008 to 2015 for Medicare fee-for-service patients undergoing treatment for exudative AMD was estimated at $17.3 billion. Additional savings over the $17.3 billion would have accrued from the use of bevacizumab if diagnostic categories such as diabetic macular edema and retinal vein occlusion were included in this study. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Rosenfeld, Philip J.; Feuer, William J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
   [Windsor, Matthew A.] Assoc Res Vis & Ophthalmol, Rockville, MD USA.
   [Sun, Sissi J. J.; Frick, Kevin D.] Johns Hopkins Carey Business Sch, Baltimore, MD USA.
   [Swanson, Eric A.] MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Huang, David] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA.
C3 Bascom Palmer Eye Institute; University of Miami; Johns Hopkins
   University; Massachusetts Institute of Technology (MIT); Oregon Health &
   Science University
RP Rosenfeld, PJ (通讯作者)，Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@miami.edu
OI Windsor, Matthew A./0000-0002-0014-6101; Frick,
   Kevin/0000-0002-0178-5319
FU RESEARCH TO PREVENT BLINDness (New York, New York, USA); National
   Institutes of Health (Bethesda, Maryland, USA) [P30EY014801]; NATIONAL
   EYE INSTITUTE [P30EY014801] Funding Source: NIH RePORTER
FX PHILIP J. ROSENFELD WAS SUPPORTED BY AN UNRESTRICTED GRANT FROM RESEARCH
   TO PREVENT BLINDness (New York, New York, USA) and the National
   Institutes of Health (Bethesda, Maryland, USA) Center Core Grant
   P30EY014801.
CR [Anonymous], 2017, MED PROV UT PAYM DAT
   [Anonymous], 2015, MEDICARE B
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Elshout M, 2014, GRAEF ARCH CLIN EXP, V252, P1911, DOI 10.1007/s00417-014-2641-3
   Erie JC, 2016, OPHTHALMOLOGY, V123, P1257, DOI 10.1016/j.ophtha.2016.02.015
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gonzalez S, 2012, AM J OPHTHALMOL, V153, P196, DOI 10.1016/j.ajo.2011.11.023
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Park DH, 2017, INT OPHTHALMOL, V37, P1205, DOI 10.1007/s10792-016-0391-4
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Shaikh AH, 2015, OSLI RETINA, V46, P62, DOI 10.3928/23258160-20150101-10
   Stewart MW, 2016, AM J OPHTHALMOL, V170, P228, DOI 10.1016/j.ajo.2016.05.023
   VanderBeek BL, 2015, JAMA OPHTHALMOL, V133, P1159, DOI 10.1001/jamaophthalmol.2015.2556
   Windsor MA, 2018, AM J OPHTHALMOL, V185, P115, DOI 10.1016/j.ajo.2017.09.027
   Wykoff CC, 2018, BRIT J OPHTHALMOL, V102, P460, DOI 10.1136/bjophthalmol-2017-310822
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 26
TC 19
Z9 19
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2018
VL 191
BP 135
EP 139
DI 10.1016/j.ajo.2018.04.008
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GL7MX
UT WOS:000437387100022
PM 29655642
DA 2022-11-30
ER

PT J
AU Quan, YL
   Zhou, AY
   Feng, ZH
AF Quan, Yan-Long
   Zhou, Ai-Yi
   Feng, Zhao-Hui
TI Association between complementary factor H Y402H polymorphisms and
   age-related macular degeneration in Chinese: Systematic review and
   meta-analysis
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; complement factor H polymorphism;
   meta-analysis; Chinese population
ID GENE POLYMORPHISMS; PREVALENCE; CFH; MACULOPATHY; HTRA1; RISK;
   SUSCEPTIBILITY; POPULATION; SMOKING; C2
AB AIM: Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world and complement factor H (CFH) polymorphism has been found to associate with the AMD. To investigate whether the Y402H variant in CFH is associated with AMD in Chinese populations, a systematic review and meta-analysis were performed to estimate the magnitude of the gene effect and the possible mode of action.
   METHODS: A meta-analysis was performed using data available from ten case-control studies assessing association between the CFH Y402H polymorphism and AMD in Chinese populations involving 1538 AMD. Data extraction and study quality assessment were performed in duplicate. Summary odds ratios (ORs) and 95% confidence intervals (CIs) an allele contrast and genotype contrast were estimated usingfixed- effects models. The Q-statistic test was used to assess heterogeneity, and Funnel plot was used to evaluate publication bias.
   RESULTS: Seven of ten case-control studies were neovascular AMD, and few studies came from west and north of China. There was strong evidence for association between CFH and AMD in Chinese population, with those having risk allele C 2.35 times more likely to have AMD than subjects with T allele. Evidence of publication bias was not observed in our meta-analysis.
   CONCLUSION: This meta-analysis summarizes the strong evidence for an association between CFH and AMD in Chinese and indicates each C allele increasing the odds of AMD by 2.33-fold. But more evidences about the relation between CFH polymorphism and different type of Chinese AMD from various district were needed.
C1 [Quan, Yan-Long; Zhou, Ai-Yi; Feng, Zhao-Hui] Xi An Jiao Tong Univ, Dept Ophthalmol, Affiliated Hosp 2, Coll Med, Xian 710004, Shaanxi Provinc, Peoples R China.
C3 Xi'an Jiaotong University
RP Quan, YL (通讯作者)，Xi An Jiao Tong Univ, Dept Ophthalmol, Affiliated Hosp 2, Coll Med, Xian 710004, Shaanxi Provinc, Peoples R China.
EM sandy_chow@126.com
CR Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Chen LJ, 2006, MOL VIS, V12, P1536
   Cheng CL, 2009, SINGAP MED J, V50, P126
   Chu J, 2008, CHINESE MED J-PEKING, V121, P2525, DOI 10.1097/00029330-200812020-00011
   Delcourt C, 2011, INVEST OPHTH VIS SCI, V52, P5955, DOI 10.1167/iovs.10-6235
   Dong L, 2011, NEUROSCI LETT, V488, P283, DOI 10.1016/j.neulet.2010.11.048
   Donoso LA, 2010, SURV OPHTHALMOL, V55, P227, DOI 10.1016/j.survophthal.2009.11.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   Fisher SA, 2007, BRIT J OPHTHALMOL, V91, P576, DOI 10.1136/bjo.2006.105577
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gao Y, 2010, RETINA-J RET VIT DIS, V30, P443, DOI 10.1097/IAE.0b013e3181c2e086
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1995, ARCH OPHTHALMOL-CHIC, V113, P333, DOI 10.1001/archopht.1995.01100030089026
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lin JM, 2008, RETINA-J RET VIT DIS, V28, P1416, DOI 10.1097/IAE.0b013e318184661d
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Michon JJ, 2002, BRIT J OPHTHALMOL, V86, P133, DOI 10.1136/bjo.86.2.133
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Nonyane BAS, 2010, INVEST OPHTH VIS SCI, V51, P2393, DOI 10.1167/iovs.09-4228
   Pei XT, 2009, CURR EYE RES, V34, P615, DOI 10.1080/02713680903003484
   Souied EH, 2005, MOL VIS, V11, P1135
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Xing C, 2008, GENES IMMUN, V9, P231, DOI 10.1038/gene.2008.10
   Xu L, 2008, OPHTHALMOLOGICA, V222, P378, DOI 10.1159/000151468
   Xu YL, 2008, MOL VIS, V14, P1373
   Yang X, 2010, BRIT J OPHTHALMOL, V94, P1211, DOI 10.1136/bjo.2009.165811
NR 32
TC 13
Z9 16
U1 0
U2 2
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD APR 18
PY 2012
VL 5
IS 2
BP 242
EP 246
DI 10.3980/j.issn.2222-3959.2012.02.25
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 929PI
UT WOS:000303077500026
PM 22762059
DA 2022-11-30
ER

PT J
AU Mueller, S
   Agostini, H
   Ehlken, C
   Bauer-Steinhusen, U
   Hasanbasic, Z
   Wilke, T
AF Mueller, Sabrina
   Agostini, Hansjuergen
   Ehlken, Christoph
   Bauer-Steinhusen, Ulrike
   Hasanbasic, Zoran
   Wilke, Thomas
TI Patient Preferences in the Treatment of Neovascular Age-Related Macular
   Degeneration A Discrete Choice Experiment
SO OPHTHALMOLOGY
LA English
DT Article
ID RANIBIZUMAB
AB Purpose: The objective of our study was to investigate preferences of patients with neovascular age-related macular degeneration (nAMD) for different anti-vascular endothelial growth factor (VEGF) treatment schemes.
   Design: We used a discrete choice experiment (DCE) design as part of a telephone interview.
   Participants: Patients with nAMD aged at least 50 years were included in the study.
   Methods: Telephone interviews were done between November 2012 and October 2013.
   Main Outcome Measures: In our DCE survey, we measured patient preferences toward specific levels of attributes that describe different options in the everyday intravitreal injection treatment setting: (1) treatment scheme; (2) change of visual acuity (VA); and (3) time the patient needs for each visit to the eye specialist.
   Results: A total of 284 patients with nAMD with a mean age of 77.4 +/- 7.1 years (women: 59.9%) completed the DCE interviews. Of them, 22.9% had poor VA at study inclusion, 54.9% had moderate VA, and 14.1% had good VA; VA was not available for 8.1% of the patients. Generally, patients preferred the attribute levels "improvement in VA" and "short time per specialist visit." The results for the attribute "treatment scheme" were inconclusive because none of the attribute levels (injections every 4 weeks, every 8 weeks, and pro re nata) were associated with statistically significant utility differences. This also mirrors the relative importance of the different attributes in patient decisions: "Change of VA" influenced decision making for a treatment option in 73.6% of cases; "waiting, treatment, and travel time" influenced decision making in 21.0% of cases; and "treatment scheme" influenced decision making for a treatment option in 5.4% of cases. To obtain improved VA instead of a worsening VA, patients in our study stated to be willing to accept a very long time needed per physician visit of 21.2 hours (8.5 hours for improved rather than stable VA and 12.7 hours for stable VA rather than worsening VA).
   Conclusions: To prevent deterioration of VA, patients with nAMD seem to be willing to accept a high treatment burden with regular intravitreal injections at short intervals and long periods of waiting, treatment, and traveling for their consultations. (C) 2016 by the American Academy of Ophthalmology.
C1 [Mueller, Sabrina] Univ Wismar, Inst Pharmakookon & Arzneimittellogist IPAM, Wismar, Germany.
   [Agostini, Hansjuergen; Ehlken, Christoph] Univ Freiburg, Med Ctr, Ctr Eye, Baden, Switzerland.
   [Bauer-Steinhusen, Ulrike; Hasanbasic, Zoran] Bayer HealthCare Germany, Med Abt Ophthalmol, Leverkusen, Germany.
C3 Bayer AG; Bayer Healthcare Pharmaceuticals
RP Mueller, S (通讯作者)，Inst Pharmakookon & Arzneimittellogist, Alter Holzhafen 19, D-23966 Wismar, Germany.
EM sabrina.mueller@ipam-wismar.de
OI Hasanbasic, Zoran/0000-0003-0673-012X
FU Bayer; Allergan; Bayer Healthcare; Molecular Partners; Novartis; Roche;
   Zeiss Meditec; Bayer Vital GmbH, Leverkusen, Germany
FX The author(s) have made the following disclosure(s): S.M.: Staff member
   of IPAM; IPAM work in this study was sponsored by Bayer.; H.A.: Project-
   or study-related financial support - Allergan, Bayer Healthcare,
   Molecular Partners, Novartis, Roche, and Zeiss Meditec.; Supported by
   Bayer Vital GmbH, Leverkusen, Germany. The sponsor participated in the
   project lead, design of the study and multivariate analyses, clinical
   interpretation of results, and writing all parts of the article.
CR [Anonymous], 2013, CLIN INTERV AGING, V8, P467
   Clark MD, 2014, PHARMACOECONOMICS, V32, P883, DOI 10.1007/s40273-014-0170-x
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Droege KM, 2014, GRAEF ARCH CLIN EXP, V252, P31, DOI 10.1007/s00417-013-2412-6
   Ehlken C, 2014, OPHTHALMOLOGE S1, P29
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Horne R, 1999, J PSYCHOSOM RES, V47, P491, DOI 10.1016/S0022-3999(99)00058-6
   Johnson FR, 2013, VALUE HEALTH, V16, P3, DOI 10.1016/j.jval.2012.08.2223
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McFadden D, 1973, CONDITIONAL LOGIT AN, DOI DOI 10.1108/EB028592
   Pfarr Christian, 2014, Dev Health Econ Public Policy, V12, P27
   Roodhooft J M J, 2002, Bull Soc Belge Ophtalmol, P19
   Ryan M, 1997, HEALTH ECON, V6, P261, DOI 10.1002/(SICI)1099-1050(199705)6:3<261::AID-HEC262>3.3.CO;2-E
   Ryan Mandy, 2003, Appl Health Econ Health Policy, V2, P55
   Stellungnahme von DOG, 2014, ANTIVEGF THER BEI NE
   Wilke T, 2011, VALUE HEALTH, V14, P1092, DOI 10.1016/j.jval.2011.06.002
   Wolf A, 2014, GRAEF ARCH CLIN EXP, V252, P647, DOI 10.1007/s00417-013-2562-6
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Zhu L., 2008, DISCRETE BRAND CHOIC
   Ziemssen F, 2015, OPHTHALMOLOGE, V112, P246, DOI 10.1007/s00347-014-3217-7
   Zwerina K., 1996, GEN METHOD CONSTRUCT
NR 21
TC 38
Z9 38
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2016
VL 123
IS 4
BP 876
EP 883
DI 10.1016/j.ophtha.2015.12.001
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DH3WU
UT WOS:000372718300032
PM 26778346
OA Bronze
DA 2022-11-30
ER

PT J
AU Dow, ER
   Keenan, TDL
   Lad, EM
   Lee, AY
   Lee, CS
   Loewenstein, A
   Eydelman, MB
   Chew, EY
   Keane, PA
   Lim, JI
AF Dow, Eliot R.
   Keenan, Tiarnan D. L.
   Lad, Eleonora M.
   Lee, Aaron Y.
   Lee, Cecilia S.
   Loewenstein, Anat
   Eydelman, Malvina B.
   Chew, Emily Y.
   Keane, Pearse A.
   Lim, Jennifer, I
CA Collaborative Community Ophthalmic
   Working Grp Artificial Intelligenc
TI The Collaborative Community on Ophthalmic Imaging Roadmap for Artificial
   Intelligence in Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
DE Artificial intelligence; Age-related macular degeneration; Deep
   learning; Machine learning; OCT
ID OPTICAL COHERENCE TOMOGRAPHY; SEVERITY SCALE; CLASSIFICATION;
   PREDICTION; QUANTIFICATION; VALIDATION; DISEASES; SYSTEM; IMAGES; FLUID
AB Objective: Health care systems worldwide are challenged to provide adequate care for the 200 million individuals with age-related macular degeneration (AMD). Artificial intelligence (AI) has the potential to make a significant, positive impact on the diagnosis and management of patients with AMD; however, the development of effective AI devices for clinical care faces numerous considerations and challenges, a fact evidenced by a current absence of Food and Drug Administration (FDA)-approved AI devices for AMD.
   Purpose: To delineate the state of AI for AMD, including current data, standards, achievements, and challenges.
   Methods: Members of the Collaborative Community on Ophthalmic Imaging Working Group for AI in AMD attended an inaugural meeting on September 7, 2020, to discuss the topic. Subsequently, they undertook a comprehensive review of the medical literature relevant to the topic. Members engaged in meetings and discussion through December 2021 to synthesize the information and arrive at a consensus.
   Results: Existing infrastructure for robust AI development for AMD includes several large, labeled data sets of color fundus photography and OCT images; however, image data often do not contain the metadata necessary for the development of reliable, valid, and generalizable models. Data sharing for AMD model development is made difficult by restrictions on data privacy and security, although potential solutions are under investigation. Computing resources may be adequate for current applications, but knowledge of machine learning development may be scarce in many clinical ophthalmology settings. Despite these challenges, researchers have produced promising AI models for AMD for screening, diagnosis, prediction, and monitoring. Future goals include defining benchmarks to facilitate regulatory authorization and subsequent clinical setting generalization.
   Conclusions: Delivering an FDA-authorized, AI-based device for clinical care in AMD involves numerous considerations, including the identification of an appropriate clinical application; acquisition and development of a large, high-quality data set; development of the AI architecture; training and validation of the model; and functional interactions between the model output and clinical end user. The research efforts undertaken to date represent starting points for the medical devices that eventually will benefit providers, health care systems, and patients. Published by Elsevier on behalf of the American Academy of Ophthalmology
C1 [Dow, Eliot R.] Stanford Univ, Byers Eye Inst, Palo Alto, CA 94304 USA.
   [Keenan, Tiarnan D. L.; Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Lad, Eleonora M.] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   [Lee, Aaron Y.; Lee, Cecilia S.] Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA.
   [Loewenstein, Anat] Tel Aviv Med Ctr & Sch Med, Div Ophthalmol, Tel Aviv, Israel.
   [Eydelman, Malvina B.] US FDA, Off Hlth Technol 1, Ctr Devices & Radiol Hlth, Silver Spring, MD USA.
   [Keane, Pearse A.] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London EC1V 2PD, England.
   [Keane, Pearse A.] UCL Inst Ophthalmol, London EC1V 2PD, England.
   [Lim, Jennifer, I] Univ Illinois, Dept Ophthalmol, 1855 W Taylor St, Chicago, IL 60612 USA.
C3 Stanford University; National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI); Duke University; University of Washington;
   University of Washington Seattle; Tel Aviv University; Sackler Faculty
   of Medicine; US Food & Drug Administration (FDA); University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   University of London; University College London; University of Illinois
   System; University of Illinois Chicago; University of Illinois Chicago
   Hospital
RP Keane, PA (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London EC1V 2PD, England.; Keane, PA (通讯作者)，UCL Inst Ophthalmol, London EC1V 2PD, England.; Lim, JI (通讯作者)，Univ Illinois, Dept Ophthalmol, 1855 W Taylor St, Chicago, IL 60612 USA.; Chew, EY (通讯作者)，NEI, Div Epidemiol & Clin Applicat, NIH, CRC, Bldg 10,Room 3-2531,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov; Pearse.Keane@moodields.nhs.uk; jennylim@uic.edu
OI Chew, Emily/0000-0003-0999-9802; Keane, Pearse/0000-0002-9239-745X;
   Keenan, Tiarnan/0000-0002-2253-1772
FU National Institutes of Health, Bethesda, Maryland [K23EY029246,
   R01AG060942]; United States Department of Veterans Affairs [I01
   CX002116]; Moorfields Eye Charity, London, United Kingdom [R190028A];
   United Kingdom Research & Innovation Future Leaders Fellowship
   [MR/T019050/1]; University of Illinois at Chicago, Chicago, Illinois
   (National Institute of Health) [EY01792]; Research to Prevent Blindness,
   Inc, New York, New York
FX Supported by the National Institutes of Health, Bethesda, Maryland
   (grant nos.: K23EY029246 [A.Y.L.], R01AG060942 [C.S.L.], employment
   [T.D.L.K., E.Y.C.]); United States Department of Veterans Affairs (merit
   award no.: I01 CX002116 [E.M.L.]); Moorfields Eye Charity, London,
   United Kingdom (Career Development Award no.: R190028A [P.A.K.]); United
   Kingdom Research & Innovation Future Leaders Fellowship (grant no.:
   MR/T019050/1 [P.A.K.]); University of Illinois at Chicago, Chicago,
   Illinois (core grant no.: National Institute of Health grant EY01792
   [J.I.L.]); and Research to Prevent Blindness, Inc, New York, New York
   (unrestricted grant [J.I.L.]).
CR Abramoff MD, 2022, OPHTHALMOLOGY, V129, pE14, DOI 10.1016/j.ophtha.2021.08.023
   Abramoff MD, 2020, TELEMED E-HEALTH, V26, P544, DOI 10.1089/tmj.2020.0008
   Banerjee I, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72359-y
   Bek T, 2018, GRAEF ARCH CLIN EXP, V256, P2061, DOI 10.1007/s00417-018-4100-z
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, pBIO141, DOI 10.1167/iovs.17-21789
   Burlina P, TRANSL VIS SCI TECHN, V10, P13
   Burlina PM, 2019, JAMA OPHTHALMOL, V137, P258, DOI 10.1001/jamaophthalmol.2018.6156
   Burlina PM, 2018, JAMA OPHTHALMOL, V136, P1359, DOI 10.1001/jamaophthalmol.2018.4118
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Cohen JF, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012799
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Domalpally A, 2019, OPHTHALMOLOGY, V126, P1659, DOI 10.1016/j.ophtha.2019.07.022
   Faes L, 2019, LANCET DIGIT HEALTH, V1, pE232, DOI 10.1016/S2589-7500(19)30108-6
   Fedus William, 2021, ARXIV
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gonzalez-Gonzalo C, 2020, ACTA OPHTHALMOL, V98, P368, DOI 10.1111/aos.14306
   Henriksen BS, 2020, AM J OPHTHALMOL, V211, P191, DOI 10.1016/j.ajo.2019.11.030
   Ho AC, 2021, J CLIN MED, V10, DOI 10.3390/jcm10071355
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Hosoda Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75451-5
   International Medical Device Regulators Forum, 2014, SOFTW MED DEV POSS F
   Kashani AH, 2010, AM J OPHTHALMOL, V149, P496, DOI 10.1016/j.ajo.2009.09.025
   Keane P, LANCET, V397, P1254
   Keenan TDL, 2021, OPHTHALMOL SCI, V2, DOI 100034
   Keenan TD, 2018, OPHTHALMOLOGY, V125, P1913, DOI 10.1016/j.ophtha.2018.05.028
   Keenan TDL, 2021, OPHTHALMOLOGY, V128, P100, DOI [10.1016/j.opatha.2020.06.038, 10.1016/j.ophtha.2020.06.038]
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Khan SM, 2021, LANCET DIGIT HEALTH, V3, pE51, DOI 10.1016/S2589-7500(20)30240-5
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Korot E, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-89743-x
   Korot E, 2021, NAT MACH INTELL, V3, P288, DOI 10.1038/s42256-021-00305-2
   Kundu S, 2021, COMMUNITY MED, V1, P8
   Lechanteur Y, 2021, ASS RES VIS OPHTH AN
   Lee AY, 2021, OPHTHALMOLOGY, V128, P969, DOI 10.1016/j.ophtha.2021.03.003
   Lee CS, 2020, LANCET DIGIT HEALTH, V2, pE279, DOI 10.1016/S2589-7500(20)30102-3
   Linkous JD, 2004, TELEMED J E-HEALTH, V10, P469, DOI 10.1089/tmj.2004.10.469
   Liu XX, 2020, NAT MED, V26, P1364, DOI 10.1038/s41591-020-1034-x
   Mailman MD, 2007, NAT GENET, V39, P1181, DOI 10.1038/ng1007-1181
   Maloca PM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220063
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Mehta N, 2020, JAMA OPHTHALMOL, V138, P1017, DOI 10.1001/jamaophthalmol.2020.2769
   Mishra Z, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66355-5
   Moraes G, 2021, OPHTHALMOLOGY, V128, P693, DOI 10.1016/j.ophtha.2020.09.025
   Neely DC, 2017, JAMA OPHTHALMOL, V135, P570, DOI 10.1001/jamaophthalmol.2017.0830
   Open Data Institute, INSIGHT EXPL ACC EYE
   Pandit RR, 2020, OPHTHALMOLOGY, V127, P1580, DOI 10.1016/j.ophtha.2020.04.016
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Peng YF, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-00317-z
   Peng YF, 2019, OPHTHALMOLOGY, V126, P565, DOI 10.1016/j.ophtha.2018.11.015
   Pfau M, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.7.30
   Rivera SC, 2020, NAT MED, V26, P1351, DOI 10.1038/s41591-020-1037-7
   Saha S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47390-3
   Schmidt-Erfurth U, 2020, OPHTHALMOLOGY, V127, P1211, DOI 10.1016/j.ophtha.2020.03.010
   Schmitz-Valckenberg S, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.2.3
   Thirona, 2020, RETCAD WHITEPAPER
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P2053, DOI 10.1007/s00417-018-4098-2
   United Kingdom National Health Service, NAT DAT OPT OUT
   United States Food and Drug Administration, 2017, SOFTW MED DEV SAMD C
   United States Food and Drug Administration, 2021, PREM NOT 510 K
   United States Food and Drug Administration, 2017, EV REP AG SPEC DAT M, P1
   Verana Health, 2021, IRIS REG EHR INT MIP
   Vokinger KN, 2021, LANCET DIGIT HEALTH, V3, pE337, DOI 10.1016/S2589-7500(21)00076-5
   von der Emde L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47565-y
   Waldstein SM, 2020, JAMA OPHTHALMOL, V138, P740, DOI 10.1001/jamaophthalmol.2020.1376
   Wang J, 2020, BIOMED OPT EXPRESS, V11, P927, DOI 10.1364/BOE.379977
   Windsor MA, 2018, AM J OPHTHALMOL, V185, P115, DOI 10.1016/j.ajo.2017.09.027
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu ZY, 2021, BRIT J OPHTHALMOL, V105, P561, DOI 10.1136/bjophthalmol-2020-315817
   Yan Q, 2020, NAT MACH INTELL, V2, P141, DOI 10.1038/s42256-020-0154-9
   Yanagihara RT, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.11
   Yang JY, 2020, GRAEF ARCH CLIN EXP, V258, P17, DOI 10.1007/s00417-019-04493-x
   Yim J, 2020, NAT MED, V26, P892, DOI 10.1038/s41591-020-0867-7
   Zhang GY, 2021, LANCET DIGIT HEALTH, V3, pE665, DOI 10.1016/S2589-7500(21)00134-5
NR 77
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2022
VL 129
IS 5
BP E43
EP E59
DI 10.1016/j.ophtha.2022.01.002
PG 17
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0Z8NA
UT WOS:000791327000001
PM 35016892
DA 2022-11-30
ER

PT J
AU van Romunde, SHM
   Polito, A
   Bertazzi, L
   Guerriero, M
   Pertile, G
AF van Romunde, Saskia H. M.
   Polito, Antonio
   Bertazzi, Laura
   Guerriero, Massimo
   Pertile, Grazia
TI Long-Term Results of Full Macular Translocation for Choroidal
   Neovascularization in Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID 360-DEGREES PERIPHERAL RETINECTOMY; RANDOMIZED CLINICAL-TRIAL;
   VISION-RELATED FUNCTION; QUALITY-OF-LIFE; PHOTODYNAMIC THERAPY; VISUAL
   FUNCTION; FOLLOW-UP; OPHTHALMIC FINDINGS; FMT-PDT; RETINOTOMY
AB Purpose: To investigate the long-term outcome of full macular translocation (FMT) for neovascular age-related macular degeneration (AMD) and to identify predictive factors.
   Design: Retrospective, uncontrolled case series.
   Participants: Patients were considered for FMT if they had low vision in the fellow eye and choroidal neovascularization (CNV) along with (1) no response to vascular endothelial growth factor (VEGF) inhibitors, (2) retinal pigment epithelium (RPE) tear, (3) subretinal hemorrhage, (4) foveal scar tissue of recent onset, or (5) CNV before the availability of VEGF inhibitors. From 2004 through 2012, a total of 255 patients underwent FMT. Exclusion criteria were patients younger than 60 years, FMT for disease other than AMD, and a follow-up of less than 12 months.
   Methods: Preoperative, annual, and last distance best-corrected visual acuity (BCVA) were obtained retrospectively from patient files. Complications were recorded using funduscopy, optical coherence tomography, autofluorescence, and angiography.
   Main Outcome Measures: Distance BCVA at 1 year and 5 years after surgery and at last visit compared with preoperative BCVA.
   Results: One hundred fifty-eight patients (mean follow-up, 45 months) were included. Median BCVA improved from 0.90 logarithm of the minimum angle of resolution (logMAR) before surgery to 0.70 logMAR 1 year after FMT (2 lines gained; P = 0.000). In a subgroup of 56 patients followed up for 5 years or more, median BCVA improved from 0.95 logMAR before surgery to 0.70 logMAR 1 year after surgery, and remained improved 5 years after FMT with a median BCVA of 0.80 logMAR (1.5 lines gained compared with preoperative BCVA; P = 0.000). The main complications were foveal RPE atrophy (n = 73; 47%) and CNV recurrence (n = 47; 30%). Foveal RPE atrophy (odds ratio [OR], 7.0), CNV recurrence (OR, 2.6), and proliferative vitreoretinopathy (PVR; OR, 17.6) were statistically significant predictors (P < 0.05) for losing 1 line or more at last visit.
   Conclusions: In this study, BCVA was improved up to 5 years after FMT. Foveal RPE atrophy, CNV recurrence, and PVR carried a worse prognosis. In patients who are unlikely to benefit from VEGF inhibitors, FMT can be considered for second eyes with neovascular AMD. (C) 2015 by the American Academy of Ophthalmology.
C1 [van Romunde, Saskia H. M.; Polito, Antonio; Bertazzi, Laura; Pertile, Grazia] Sacro Cuore Don Calabria Hosp, Dept Ophthalmol, Verona, Italy.
   [Guerriero, Massimo] Univ Verona, Dept Comp Sci, I-37100 Verona, Italy.
C3 IRCCS Sacro Cuore Don Calabria; University of Verona
RP van Romunde, SHM (通讯作者)，Sacrocuore Hosp, Via Don Sempreboni 5, I-37024 Verona, Italy.
EM saskia.vanromunde@gmail.com
RI Pertile, Grazia/AAC-4956-2022
OI Guerriero, Massimo/0000-0003-1310-539X
FU Hospital Sacro Cuore - Don Calabria, Verona, Italy
FX Supported by the Hospital Sacro Cuore - Don Calabria, Verona, Italy. The
   funding organization had no role in the design or conduct of this
   research.
CR Abdel-Meguid A, 2003, BRIT J OPHTHALMOL, V87, P615, DOI 10.1136/bjo.87.5.615
   Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   Aisenbrey S, 2007, ARCH OPHTHALMOL-CHIC, V125, P1367, DOI 10.1001/archopht.125.10.1367
   Baer CA, 2008, RETINA-J RET VIT DIS, V28, P1221, DOI 10.1097/IAE.0b013e31817d5bce
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Cahill MT, 2005, ARCH OPHTHALMOL-CHIC, V123, P935, DOI 10.1001/archopht.123.7.935
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P144, DOI 10.1016/j.ophtha.2004.06.035
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Chen FK, 2010, BRIT J OPHTHALMOL, V94, P1337, DOI 10.1136/bjo.2009.172593
   Chen FK, 2009, INVEST OPHTH VIS SCI, V50, P1848, DOI 10.1167/iovs.08-2845
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Eckardt C, 2002, RETINA-J RET VIT DIS, V22, P786, DOI 10.1097/00006982-200212000-00017
   Gelisken F, 2007, GRAEF ARCH CLIN EXP, V245, P1085, DOI 10.1007/s00417-006-0524-y
   Glacet-Bernard A, 2001, AM J OPHTHALMOL, V131, P78, DOI 10.1016/S0002-9394(00)00733-9
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Lai JC, 2002, ARCH OPHTHALMOL-CHIC, V120, P1317, DOI 10.1001/archopht.120.10.1317
   Luke M, 2009, GRAEF ARCH CLIN EXP, V247, P745, DOI 10.1007/s00417-009-1050-5
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P629, DOI 10.1007/BF00921956
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   Pertile G, 2002, AM J OPHTHALMOL, V134, P560, DOI 10.1016/S0002-9394(02)01641-0
   Polito A, 2011, BRIT J OPHTHALMOL, V95, P74, DOI 10.1136/bjo.2009.170381
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Takeuchi K, 2012, EYE, V26, P52, DOI 10.1038/eye.2011.302
   Toth CA, 2004, GRAEF ARCH CLIN EXP, V242, P541, DOI 10.1007/s00417-004-0867-1
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yamada Y, 2010, AM J OPHTHALMOL, V149, P453, DOI 10.1016/j.ajo.2009.09.014
NR 29
TC 16
Z9 18
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2015
VL 122
IS 7
BP 1366
EP 1374
DI 10.1016/j.ophtha.2015.03.012
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CL0HI
UT WOS:000356621700019
PM 25881514
DA 2022-11-30
ER

PT J
AU Arnold, JJ
   Campain, A
   Barthelmes, D
   Simpson, JM
   Guymer, RH
   Hunyor, AP
   McAllister, IL
   Essex, RW
   Morlet, N
   Gillies, MC
AF Arnold, Jennifer J.
   Campain, Anna
   Barthelmes, Daniel
   Simpson, Judy M.
   Guymer, Robyn H.
   Hunyor, Alex P.
   McAllister, Ian L.
   Essex, Rohan W.
   Morlet, Nigel
   Gillies, Mark C.
CA Fight Retinal Blindness Study Grp
TI Two-Year Outcomes of "Treat and Extend" Intravitreal Therapy for
   Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID 2.0 MG RANIBIZUMAB; BEVACIZUMAB; EFFICACY; REGIMEN; SAFETY
AB Purpose: To report 24-month outcomes of anti-vascular endothelial growth factor (VEGF) therapy for treatment-naive eyes with neovascular age-related macular degeneration (nAMD) using a treat and extend treatment regimen in routine clinical practice.
   Design: Database observational study.
   Participants: We included treatment-naive eyes receiving predominantly ranibizumab for nAMD in routine clinical practice treated using a treat and extend regimen that were tracked in the Fight Retinal Blindness observational registry.
   Methods: A cohort of eyes treated by practitioners using exclusively a treat and extend regimen was extracted from the Fight Retinal Blindness observational registry.
   Main Outcome Measures: Change in visual acuity (VA) over 2 years and number of injections and visits.
   Results: Data from 1198 eyes from 1011 patients receiving anti-VEGF therapy using a treat and extend regimen for treatment-naive nAMD between January 2007 and December 2012 and with 24-month follow-up were included in the analysis. Mean VA increased by +5.3 logarithm of the minimum angle of resolution letters from 56.5 letters (20/80+1) at initial visit to 61.8 (20/60+2) letters at 24 months. Mean VA gains improved and number of injections increased with successive years from +2.7 letters for eyes commencing in 2007 after a mean of 9.7 injections in 2 years, to +7.8 letters for eyes commencing in 2012 after a mean of 14.2 injections over 2 years. The proportion of eyes with VA >20/40 increased from 27% when starting treatment to 45% after 24 months; the proportion with vision of <20/200 remained unchanged (13% initial, 11% at 24 months). Of the included eyes, 90.5% avoided a vision loss of >= 15 letters. There was an overall mean of 13.0 injections over the 24 months, 7.5 injections in the first year and 5.5 in the second year, with a mean of 14.8 clinic visits.
   Conclusions: These data indicate that eyes managed in routine clinical practice with a treat and extend regimen can achieve good visual outcomes while decreasing the burden of treatments and clinic visits. (C) 2015 by the American Academy of Ophthalmology.
C1 [Campain, Anna; Barthelmes, Daniel; Hunyor, Alex P.] Univ Sydney, Sydney Med Sch, Save Sight Inst, Sydney, NSW 2006, Australia.
   [Barthelmes, Daniel] Univ Zurich, Univ Zurich Hosp, Dept Ophthalmol, Zurich, Switzerland.
   [Simpson, Judy M.] Univ Sydney, Sch Publ Hlth, Sydney, NSW, Australia.
   [Guymer, Robyn H.] Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, Melbourne, Vic 3010, Australia.
   [Hunyor, Alex P.] Retina Associates, Chatswood, NSW, Australia.
   [McAllister, Ian L.] Univ Western Australia, Lions Eye Inst, Ctr Ophthalmol & Vis Sci, Nedlands, WA 6009, Australia.
   [Essex, Rohan W.] Australian Natl Univ, Acad Unit Ophthalmol, Canberra, ACT, Australia.
   [Morlet, Nigel] Univ Western Australia, Dept Populat Hlth, Perth, WA 6009, Australia.
C3 University of Sydney; University of Zurich; University Zurich Hospital;
   University of Sydney; Centre for Eye Research Australia; Royal Victorian
   Eye & Ear Hospital; University of Melbourne; Lions Eye Institute;
   University of Western Australia; Australian National University;
   University of Western Australia
RP Barthelmes, D (通讯作者)，Univ Zurich Hosp, Dept Ophthalmol, Frauenklin Str 24, CH-8091 Zurich, Switzerland.
EM daniel.barthelmes@usz.ch
RI Hunyor, Alex/AAT-8205-2021
OI Hunyor, Alex/0000-0002-8182-6167; Guymer, Robyn/0000-0002-9441-4356;
   Essex, Rohan/0000-0001-5323-0334; Campain, Anna/0000-0003-1057-0085;
   Simpson, Judy M/0000-0001-5172-3004
FU Royal Australian NZ College of Ophthalmologists Eye Foundation; National
   Health and Medical Research Council, Australia (NHRMC) [632663]; NHMRC
FX Supported by a grant from the Royal Australian NZ College of
   Ophthalmologists Eye Foundation (2007-2009) and a grant from the
   National Health and Medical Research Council (grant no. 632663),
   Australia (NHRMC 2010-2012). The authors state they have no conflicts of
   interest to declare. Mark Gillies is a Sydney Medical Foundation Fellow
   and is supported by an NHMRC practitioner fellowship.
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   [Anonymous], 2012, R LANG ENV STAT COMP
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Cleveland W, 1992, STAT MODELS, DOI 10.1201/9780203738535
   Gillies MC, 2013, INVEST OPHTH VIS SCI, V54, P5754, DOI 10.1167/iovs.13-11993
   Gillies MC, 2013, RETINA, V34, P188
   Gillies MC, 2015, OPHTHALMOLOGY, V122
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2013, OPHTHALMOLOGY, V120, P209
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Muether PS, 2013, AM J OPHTHALMOL, V156, P989, DOI 10.1016/j.ajo.2013.06.020
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shienbaum G, 2012, AM J OPHTHALMOL, V153, P468, DOI 10.1016/j.ajo.2011.08.011
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Stone TW, 2014, ASRS 2014 PREFERENCE
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Vaze A, 2004, RETINA, V34, P1774
NR 25
TC 129
Z9 131
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2015
VL 122
IS 6
BP 1212
EP 1219
DI 10.1016/j.ophtha.2015.02.009
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CI9OJ
UT WOS:000355099200027
PM 25846847
DA 2022-11-30
ER

PT J
AU Jackson, TL
   Dugel, PU
   Bebchuk, JD
   Smith, KR
   Petrarca, R
   Slakter, JS
   Jaffe, GJ
   Nau, JA
AF Jackson, Timothy L.
   Dugel, Pravin U.
   Bebchuk, Judith D.
   Smith, Kelly R.
   Petrarca, Robert
   Slakter, Jason S.
   Jaffe, Glenn J.
   Nau, Jeffrey A.
CA CABERNET Study Grp
TI Epimacular Brachytherapy for Neovascular Age-related Macular
   Degeneration (CABERNET) Fluorescein Angiography and Optical Coherence
   Tomography
SO OPHTHALMOLOGY
LA English
DT Article
ID EPIRETINAL BRACHYTHERAPY; SAFETY; BEVACIZUMAB; SECONDARY; MERITAGE
AB Purpose: To report the fluorescein angiography (FA) and optical coherence tomography (OCT) results of a clinical trial of epimacular brachytherapy (EMBT) used for the treatment of neovascular age-related macular degeneration (AMD).
   Design: Pivotal multicenter, active-controlled, randomized clinical trial.
   Participants: A total of 494 participants with treatment-naive, neovascular AMD.
   Methods: Participants with classic, minimally classic, and occult lesions were randomized to receive (a) EMBT and 2 mandated monthly ranibizumab injections followed by pro re nata (PRN) ranibizumab or (b) 3 mandated monthly ranibizumab injections followed by mandated quarterly plus PRN ranibizumab. Participants underwent FA at screening and at months 1, 6, 12, 18, and 24. Optical coherence tomography scans were undertaken monthly for 24 months. The FA and OCT images were analyzed at respective independent reading centers.
   Main Outcome Measures: Change at 24 months in mean FA total lesion size and choroidal neovascularization (CNV) size and change in mean OCT centerpoint thickness.
   Results: The mean (standard deviation) changes in FA total lesion size in the EMBT and control arms were +1.9 (8.7) and -3.0 (7.2) mm(2), respectively, with a mean change in total CNV size of +0.4 (8.4) and -4.7 (6.5) mm(2), respectively. Mean (standard deviation) changes in OCT centerpoint thickness were -144 (246) and -221 (185) mu m, respectively. Retrospective subgroup analyses showed no significant difference between treatment arms in mean centerpoint thickness in some subgroups, including eyes with classic lesions. The control arm showed a significantly larger reduction in mean total lesion size and mean CNV size than the EMBT arm in all subgroups analyzed. Nine eyes in the EMBT arm showed features consistent with mild, nonproliferative radiation retinopathy, but with a mean gain of 5.0 Early Treatment Diabetic Retinopathy Study letters.
   Conclusions: Both FA and OCT suggest that EMBT with PRN ranibizumab results in an inferior structural outcome than quarterly plus PRN ranibizumab. Some subgroup analyses suggest that classic lesions may be more responsive than occult lesions, although generally both subgroups are inferior to ranibizumab. A nonvision- threatening radiation retinopathy occurs in 2.9% of eyes over 24 months, but longer follow-up is needed. (C) 2013 by the American Academy of Ophthalmology.
C1 [Jackson, Timothy L.; Petrarca, Robert] Kings Coll London, London, England.
   [Dugel, Pravin U.] Retinal Consultants Arizona, Phoenix, AZ USA.
   [Bebchuk, Judith D.; Smith, Kelly R.] Stat Collaborat Inc, Washington, DC USA.
   [Slakter, Jason S.] Digital Angiog Reading Ctr, New York, NY USA.
   [Jaffe, Glenn J.] Duke Univ, Ctr Eye, Duke Reading Ctr, Durham, NC USA.
   [Nau, Jeffrey A.] NeoVista Inc, Newark, CA USA.
C3 University of London; King's College London; Duke University
RP Jackson, TL (通讯作者)，Kings Coll Hosp London, Dept Ophthalmol, Kings Coll London, London SE5 9RS, England.
EM t.jackson1@nhs.net
OI Jackson, Timothy/0000-0001-7618-1555; Petrarca,
   Robert/0000-0001-8693-3423
FU NeoVista, Inc.
FX The author(s) have made the following disclosure(s): The sponsor
   (NeoVista, Inc.) participated in the design, conduct, data collection,
   data management, data analysis, interpretation of the data, preparation,
   review, and approval of the manuscript. T.L.J. and P.U.D.'s employer
   received contract research funding for patients enrolled in this study
   from NeoVista, Inc., the manufacturer of the investigational device
   under study. P.U.D. is a minor shareholder of NeoVista, Inc. J.A.N. was
   an employee of NeoVista, Inc. J.D.B. and K.R.S.'s employer received
   funding from NeoVista, Inc. The reading centers that employ J.S.S. and
   G.J.J. received contract research funding from NeoVista, Inc. Funding:
   Sponsored by NeoVista, Inc.
CR Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   Avila MP, 2012, RETINA-J RET VIT DIS, V32, P10, DOI 10.1097/IAE.0b013e31822528fc
   CHAKRAVARTHY U, 1989, CURR EYE RES, V8, P337, DOI 10.3109/02713688908996381
   DEGOWIN RL, 1974, J LAB CLIN MED, V84, P42
   Dugel PU, 2013, OPHTHALMOLOGY, V120, P317, DOI 10.1016/j.ophtha.2012.07.068
   Dugel PU, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.014
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Maguire AM, 2001, RETINA, V2, P1509
   Navarro Rafael, 2011, Retin Cases Brief Rep, V5, P352, DOI 10.1097/ICB.0b013e3181fff2a6
   Petrarca R, RETINA IN PRESS
   Petrarca R, 2013, OPHTHALMOLOGY, V120, P328, DOI 10.1016/j.ophtha.2012.07.091
   Wang S, 2012, OPHTHALMOLOGY, V119, P2592, DOI 10.1016/j.ophtha.2012.06.031
NR 12
TC 18
Z9 19
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2013
VL 120
IS 8
BP 1597
EP 1603
DI 10.1016/j.ophtha.2013.01.074
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 196LW
UT WOS:000322778000021
PM 23490325
DA 2022-11-30
ER

PT J
AU Liu, YY
   Bin, Y
   Wang, X
   Peng, H
AF Liu, Yan-Yao
   Bin, Yue
   Wang, Xing
   Peng, Hui
TI Increased serum levels of soluble CD146 and vascular endothelial growth
   factor receptor 2 in patients with exudative age-related macular
   degeneration
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; soluble CD146; vascular endothelial
   growth factor receptor 2; serum
ID NF-KAPPA-B; ANGIOGENESIS; BIOMARKERS; NEOVASCULARIZATION;
   CLASSIFICATION; INFLAMMATION; ACTIVATION; MOLECULE; MARKER
AB AIM: To investigate serum levels of soluble CD146 (sCD146) and vascular endothelial growth factor receptor 2 (VEGFR2) in patients with age-related macular degeneration (AMD).
   METHODS: Eighty-eight patients with exudative AMD and 45 sex- and age-matched healthy controls were enrolled in this study conducted in China. Serum samples was obtained from the patients with exudative AMD and from the controls. Serum sCD146 and VEGFR2 protein levels were measured using an enzyme-linked immunosorbent assay.
   RESULTS: We found that serum sCD146 and VEGFR2 protein levels were significantly higher in the patients with exudative AMD group than in the controls (t=3.859, P<0.001 and t=3.829, P<0.001, respectively). Serum sCD146 levels were significantly higher in patients with classic choroidal neovascularization (CNV) than in those with occult CNV (t=9.899, P<0.001). There was a significant difference in the trend for exudative AMD in the highest versus lowest quartile of circulating sCD146 levels (chi(2)=10.29, P=0.001). The receiver operating characteristic curve analysis showed that the area under the curve was 0.696 for sCD146 (95%CI: 0.601-0.791) with an optimum diagnostic cut-off value of 157.16 ng/mL, a sensitivity of 55.7%, and a specificity of 82.2%.
   CONCLUSION: The serum sCD146 level increases and may be a biomarker for exudative AMD.
C1 [Liu, Yan-Yao; Bin, Yue; Wang, Xing; Peng, Hui] Chongqing Med Univ, Dept Ophthalmol, Affiliated Hosp 1, 1 Youyi Rd, Chongqing 400016, Peoples R China.
   [Liu, Yan-Yao; Bin, Yue; Wang, Xing; Peng, Hui] Chongqing Eye Inst, Chongqing Key Lab Ophthalmol, Chongqing 400016, Peoples R China.
C3 Chongqing Medical University
RP Peng, H (通讯作者)，Chongqing Med Univ, Dept Ophthalmol, Affiliated Hosp 1, 1 Youyi Rd, Chongqing 400016, Peoples R China.
EM pengh9@sina.com
FU National Natural Science Foundation of China [81670881]
FX Supported by the National Natural Science Foundation of China (No.
   81670881).
CR Arrigo M, 2017, CLIN CHEM, V63, P386, DOI 10.1373/clinchem.2016.260471
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bu PC, 2006, MOL CANCER THER, V5, P2872, DOI 10.1158/1535-7163.MCT-06-0260
   Cervellati F, 2014, FREE RADICAL RES, V48, P303, DOI 10.3109/10715762.2013.867484
   Chen X, 2018, BIOMED PHARMACOTHER, V101, P87, DOI 10.1016/j.biopha.2018.02.054
   Dai BL, 2017, INFLAMM RES, V66, P523, DOI 10.1007/s00011-017-1036-4
   Diedrichs-Mohring M, 2018, PROG RETIN EYE RES, V65, P107, DOI 10.1016/j.preteyeres.2018.02.003
   Donato AJ, 2015, J MOL CELL CARDIOL, V89, P122, DOI 10.1016/j.yjmcc.2015.01.021
   Dufies M, 2018, THERANOSTICS, V8, P2447, DOI 10.7150/thno.23002
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gehlbach P, 2003, HUM GENE THER, V14, P129, DOI 10.1089/104303403321070829
   Harhouri K, 2010, BLOOD, V115, P3843, DOI 10.1182/blood-2009-06-229591
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Ito T, 2017, CLIN RHEUMATOL, V36, P119, DOI 10.1007/s10067-016-3434-3
   Jiang TX, 2012, BLOOD, V120, P2330, DOI 10.1182/blood-2012-01-406108
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Li JX, 2012, NAT CELL BIOL, V14, P999, DOI 10.1038/ncb2562
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu D, 2016, ONCOTARGET, V7, P40704, DOI 10.18632/oncotarget.9930
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Qian YN, 2014, CNS NEUROSCI THER, V20, P438, DOI 10.1111/cns.12234
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Russo MA, 2015, ENDOCR METAB IMMUNE, V15, P171, DOI 10.2174/1871530315666150316120112
   Sharma NK, 2012, DNA CELL BIOL, V31, P1618, DOI 10.1089/dna.2012.1786
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Song RP, 2014, HEPATOLOGY, V60, P1659, DOI 10.1002/hep.27312
   Stalin J, 2016, CARDIOVASC RES, V111, P240, DOI 10.1093/cvr/cvw096
   Taniguchi K, 2018, NAT REV IMMUNOL, V18, P309, DOI 10.1038/nri.2017.142
   Tsai DC, 2006, OPHTHALMOLOGICA, V220, P246, DOI 10.1159/000093079
   Wang P, 2013, MOL CELL BIOL, V33, P3689, DOI 10.1128/MCB.00343-13
   Wang ZQ, 2013, CANCER LETT, V330, P150, DOI 10.1016/j.canlet.2012.11.049
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
   Zeng QQ, 2014, PROTEIN CELL, V5, P445, DOI 10.1007/s13238-014-0047-y
   Zhang ZH, 2016, SCI REP-UK, V6, DOI 10.1038/srep38326
NR 37
TC 4
Z9 5
U1 1
U2 5
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD MAR 18
PY 2019
VL 12
IS 3
BP 457
EP 463
DI 10.18240/ijo.2019.03.17
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HP3SJ
UT WOS:000461597300017
PM 30918816
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Chen, KG
   Alvarez, JA
   Yazdanie, M
   Papudesu, C
   Wong, WT
   Wiley, HE
   Keenan, TD
   Chew, EY
   Ferris, FL
   Cukras, CA
AF Chen, Katherine G.
   Alvarez, Jason A.
   Yazdanie, Mohammad
   Papudesu, Chandana
   Wong, Wai T.
   Wiley, Henry E.
   Keenan, Tiarnan D.
   Chew, Emily Y.
   Ferris, Frederick L., III
   Cukras, Catherine A.
TI Longitudinal Study of Dark Adaptation as a Functional Outcome Measure
   for Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID SUBRETINAL DRUSENOID DEPOSITS; RETICULAR PSEUDODRUSEN;
   GEOGRAPHIC-ATROPHY; FELLOW-EYES; LOW LUMINANCE; RISK-FACTOR;
   ASSOCIATION; DISEASE; AUTOFLUORESCENCE; QUESTIONNAIRE
AB Purpose: To investigate the natural history of dark adaptation (DA) function as measured by the change in rod intercept time (RIT) over 4 years and to correlate RIT change with age-related macular degeneration (AMD) severity.
   Design: Longitudinal, single-center, observational study.
   Participants: A total of 77 participants aged >= 50 years with a range of AMD seventies.
   Methods: Participants each contributing a single study eye to the analysis were assigned into person-based AMD severity groups based on fundus characteristics (drusen, pigmentary changes, late AMD, and subretinal drusenoid deposits [SDDs]). The DA function was assessed in study eyes at baseline and 3, 6, 12, 18, 24, 36, and 48 months. Mean change in DA function over time was calculated using the slope of linear regression fits of longitudinal RIT data. Patient-reported responses on a Low Luminance Questionnaire (LLQ) were obtained at baseline and yearly. Nonparametric statistical testing was performed on all comparisons.
   Main Outcome Measure: The RIT, defined as the time taken after a photobleach for visual sensitivity to recover detection of a 5 x 10(-3) cd/m(2) stimulus (a decrease of 3 log units), was monitored in study eyes over 4 years, and the mean rate of change was computed.
   Results: Longitudinal analysis of 65 study eyes followed on the standard testing protocol (mean age, 71 +/- 9.3 years; 49% were female) revealed that higher rates of RIT prolongation were correlated with AMD severity group assignment at baseline (P = 0.026) and with severity group assignments at year 4 (P = 0.0011). Study eyes that developed SDD during follow-up demonstrated higher rates of RIT prolongation relative to those that did not (P < 0.0001). Overall, higher rates of RIT prolongation were significantly correlated with greater 4-year decreases in LLQ scores (total mean score, P = 0.0032).
   Conclusions: Longitudinal decline in DA function, which correlated with patient-reported functional deficits, was accelerated in eyes with greater AMD severity and especially in eyes with SDD both at baseline and at 4 years. The RIT prolongation as a measure of changing DA function may be a functional outcome measure in AMD clinical studies. Published by Elsevier on behalf of the American Academy of Ophthalmology
C1 [Chen, Katherine G.; Alvarez, Jason A.; Yazdanie, Mohammad; Papudesu, Chandana; Wong, Wai T.; Wiley, Henry E.; Keenan, Tiarnan D.; Chew, Emily Y.; Ferris, Frederick L., III; Cukras, Catherine A.] NEI, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Cukras, CA (通讯作者)，NEI, Div Epidemiol & Clin Res, NIH, Bethesda, MD 20892 USA.; Cukras, CA (通讯作者)，NEI, Ophthalm Genet & Visual Funct Branch, NIH, Bethesda, MD 20892 USA.
EM cukrasc@nei.nih.gov
RI ; Wong, Wai/B-6118-2017
OI Ferris, Frederick/0000-0002-4933-0639; Wong, Wai/0000-0003-0681-4016;
   Chew, Emily/0000-0003-0999-9802; Chen, Katherine/0000-0002-7001-5043
FU National Eye Institute Intramural Research Program, National Institutes
   of Health (NIH), Bethesda, Maryland; NIH Medical Research Scholars
   Program; NIH; Doris Duke Charitable Foundation; American Association for
   Dental Research; Colgate-Palmolive Company; Genentech; NATIONAL EYE
   INSTITUTE [ZIAEY000509] Funding Source: NIH RePORTER
FX Supported by the National Eye Institute Intramural Research Program,
   National Institutes of Health (NIH), Bethesda, Maryland; and the NIH
   Medical Research Scholars Program, a public-private partnership
   supported jointly by the NIH and generous contributions to the
   Foundation for the NIH from the Doris Duke Charitable Foundation, the
   American Association for Dental Research, the Colgate-Palmolive Company,
   Genentech, Elsevier, and other private donors.
CR ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Bunt-Milam A H, 1985, Prog Clin Biol Res, V190, P151
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   CUSTIS PH, 1993, CURR OPIN OPHTHALMOL, V4, P7, DOI 10.1097/00055735-199306000-00003
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Planas MG, 2016, INVEST OPHTH VIS SCI, V57
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Jackson GR, 2014, OPTOMETRY VISION SCI, V91, P925, DOI 10.1097/OPX.0000000000000247
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Jackson Gregory R, 2008, J Ocul Biol Dis Infor, V1, P7, DOI 10.1007/s12177-008-9002-6
   Lains I, 2017, OPHTHALMOLOGY, V124, P1340, DOI 10.1016/j.ophtha.2017.03.061
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P1310, DOI 10.1167/iovs.05-1292
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Owsley C, 2015, CURR EYE RES, V41, P1
   Owsley C, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.3.15
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Owsley C, 2014, INVEST OPHTH VIS SCI, V55, P4776, DOI 10.1167/iovs.14-14502
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Steinberg JS, 2013, INVEST OPHTH VIS SCI, V54, P4054, DOI 10.1167/iovs.12-11538
   Thorell MR, 2015, OSLI RETINA, V46, P513, DOI 10.3928/23258160-20150521-02
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Xu XY, 2017, AM J OPHTHALMOL, V175, P87, DOI 10.1016/j.ajo.2016.11.021
   Yazdanie M, 2017, OPHTHALMOLOGY, V124, P1332, DOI 10.1016/j.ophtha.2017.05.005
   Ying GS, 2008, OPHTHALMOLOGY, V115, P1876, DOI 10.1016/j.ophtha.2008.05.023
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
   Zhou Q, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149030
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
   1999, BEHAV RES METHODS IN, V31, P712
NR 48
TC 27
Z9 27
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2019
VL 126
IS 6
BP 856
EP 865
DI 10.1016/j.ophtha.2018.09.039
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HY6YD
UT WOS:000468275600022
PM 30278196
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Solomon, SD
   Jefferys, JL
   Hawkins, BS
   Bressler, NM
   Bressler, SB
AF Solomon, Sharon D.
   Jefferys, Joan L.
   Hawkins, Barbara S.
   Bressler, Neil M.
   Bressler, Susan B.
CA Submacular Surg Trials Res Grp
TI Incident choroidal Neovascularization in fellow eyes of patients with
   unilateral subfoveal choroidal Neovascularization secondary to
   age-related macular degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID REPORT NO. 11; OPHTHALMIC FINDINGS; VISUAL-ACUITY; LESION SIZE;
   VERTEPORFIN; RANIBIZUMAB; SURGERY; THERAPY; TRIAL
AB Objective: To describe incident choroidal neovascular lesions in fellow eyes of participants in the Submacular Surgery Trials who had age- related macular degeneration ( AMD).
   Methods: Review of baseline fluorescein angiograms confirmed the absence of neovascular AMD in fellow eyes of 364 participants at risk. Subjects were eligible for a minimum of 2 years of follow- up with angiograms of eyes at risk reevaluated to estimate incidence rates of choroidal neovascularization ( CNV) and to characterize these lesions.
   Main Outcome Measures: Incidence of CNV during follow- up, characteristics of the incident lesion ( composition, size, and location), and visual acuity at the time of incidence.
   Results: Incident lesions were confirmed in 98 fellow eyes of participants, yielding 2- and 4- year cumulative incidence rates of 22% and 37%. Incident lesions were predominantly CNV in 87 fellow eyes ( 90%), extrafoveal in 29 fellow eyes ( 30%), and juxtafoveal in 9 fellow eyes ( 9%). Occultwithout classic CNV lesions were found in 64 eyes ( 67%), minimally classic CNV and predominantly classic CNV lesions in 12 eyes ( 13%) each, and predominantly blood lesions in 4 eyes ( 4%). Nearly two- thirds of all incident lesions were 3 disc areas or smaller in size. Median visual acuity decreased from 20/ 25 at baseline to 20/ 250 at the 4- year follow- up in fellow eyes with incident CNV.
   Conclusions and Application to Clinical Practice: Frequent angiographic follow- up of fellow eyes at risk for CNV may lead to earlier detection and treatment of neovascular AMD and better visual acuity outcomes.
C1 Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA.
   Wilmer Eye Inst, Baltimore, MD USA.
C3 Johns Hopkins University; Johns Hopkins University; Johns Hopkins
   Medicine
RP Solomon, SD (通讯作者)，Johns Hopkins Univ, Sch Med, 550 N Broadway,Ste 115, Baltimore, MD 21205 USA.
EM nmboffice@jhmi.edu
CR ARMITAGE P, 1987, STATISTICAL METHODS, P372
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   CHANG B, 1995, OPHTHALMOLOGY, V102, P1380, DOI 10.1016/S0161-6420(95)30860-3
   Fleiss JL, 1981, STATISTICAL METHODS, P217
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   McNemar Q, 1947, PSYCHOMETRIKA, V12, P153, DOI 10.1007/BF02295996
   Niffenegger J, 1998, OPHTHALMOLOGY, V105, P1364
   Pearson K, 1900, PHILOS MAG, V50, P157, DOI 10.1080/14786440009463897
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
NR 20
TC 34
Z9 34
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD OCT
PY 2007
VL 125
IS 10
BP 1323
EP 1330
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 218EK
UT WOS:000249998600001
DA 2022-11-30
ER

PT J
AU Kaarniranta, K
   Salminen, A
AF Kaarniranta, Kai
   Salminen, Antero
TI NF-kappa B signaling as a putative target for omega-3 metabolites in the
   prevention of age-related macular degeneration (AMD)
SO EXPERIMENTAL GERONTOLOGY
LA English
DT Review
DE Age-related macular degeneration; NF-kappa B; omega-Fatty acids;
   Inflammation; Retinal pigment epithelium
ID POLYUNSATURATED FATTY-ACIDS; CELL-SURVIVAL; INFLAMMATION; MACULOPATHY;
   ACTIVATION; RECEPTOR; DISEASE; RISK
AB Age-related macular degeneration (AMD) is the major reason of blindness of the elderly all over the world. AMD is characterized by a progressive loss of central vision attributable to degenerative and neovascular changes in the macula, the highly specialized region of the retina responsible for sharp and color visual acuity. Degeneration and cell death of retinal pigment epithelial cells (RPE) cause secondarily adverse effects on neural retina leading to visual loss. Most AMD patients cannot benefit from any treatment modalities. The prevalence of AMD is rising as a consequence of the aging of the population. As the RPE cells age, they are subject to continued oxidative stress and this believed to induce inflammation and progression of AMD. Interestingly, many clinical trials have revealed that dietary intakes of omega-3 fatty acids can reduce the risk of both early and late AMD, although their molecular targets in cellular signaling in AMD pathology are not understood. Recently, it has been proposed that the omega-3 fatty acid metabolites, resolvins and protectins, function as endogenous anti-inflammatory compounds. In this review, we propose that resolvins and protectins mediate their beneficial effects by preventing NF-kappa B signaling and this that may represent a new target for regulating the inflammatory responses in AMD. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Kaarniranta, Kai] Univ Kuopio, Dept Ophthalmol, Inst Clin Med, FIN-70211 Kuopio, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, FIN-70211 Kuopio, Finland.
   [Salminen, Antero] Univ Kuopio, Dept Neurol, Inst Clin Med, FIN-70211 Kuopio, Finland.
   [Salminen, Antero] Kuopio Univ Hosp, Dept Neurol, FIN-70211 Kuopio, Finland.
C3 University of Eastern Finland; Kuopio University Hospital; University of
   Eastern Finland; Kuopio University Hospital
RP Kaarniranta, K (通讯作者)，Univ Kuopio, Dept Ophthalmol, Inst Clin Med, POB 1627, FIN-70211 Kuopio, Finland.
EM kaarnira@messi.uku.fi
OI Kaarniranta, Kai/0000-0003-2600-8679
CR Ariel A, 2007, TRENDS IMMUNOL, V28, P176, DOI 10.1016/j.it.2007.02.007
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506
   Bazan N G, 1989, Prog Clin Biol Res, V312, P95
   Bazan N. G., 2009, PROSTAGLANDINS LEUKO
   Bazan NG, 2005, BRAIN PATHOL, V15, P159
   Bazan NG, 2006, TRENDS NEUROSCI, V29, P263, DOI 10.1016/j.tins.2006.03.005
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Chung HY, 2009, AGEING RES REV, V8, P18, DOI 10.1016/j.arr.2008.07.002
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   GIBSON NJ, 1993, BIOCHEMISTRY-US, V32, P2438, DOI 10.1021/bi00060a040
   Hasturk H, 2007, J IMMUNOL, V179, P7021, DOI 10.4049/jimmunol.179.10.7021
   Holz F.G., 2004, AGE RELATED MACULAR, P24
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Koto T, 2007, INVEST OPHTH VIS SCI, V48, P4328, DOI 10.1167/iovs.06-1148
   Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101
   Mukherjee PK, 2007, P NATL ACAD SCI USA, V104, P13152, DOI 10.1073/pnas.0705949104
   Paimela T, 2007, IMMUNOL LETT, V110, P139, DOI 10.1016/j.imlet.2007.04.008
   Robinson LE, 2007, APPL PHYSIOL NUTR ME, V32, P1008, DOI 10.1139/H07-087
   Salminen A, 2008, CELL MOL LIFE SCI, V65, P1049, DOI 10.1007/s00018-008-7461-3
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Schmidt-Erfurth UM, 2007, PROG RETIN EYE RES, V26, P437, DOI 10.1016/j.preteyeres.2007.03.002
   Schwab JM, 2007, NATURE, V447, P869, DOI 10.1038/nature05877
   Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294
   Serhan CN, 2007, ANNU REV IMMUNOL, V25, P101, DOI 10.1146/annurev.immunol.25.022106.141647
   STONE WL, 1979, EXP EYE RES, V28, P387, DOI 10.1016/0014-4835(79)90114-3
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
NR 34
TC 37
Z9 38
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0531-5565
EI 1873-6815
J9 EXP GERONTOL
JI Exp. Gerontol.
PD NOV
PY 2009
VL 44
IS 11
BP 685
EP 688
DI 10.1016/j.exger.2009.09.002
PG 4
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 525IF
UT WOS:000272207900001
PM 19751815
DA 2022-11-30
ER

PT J
AU Sabeti, F
   Lane, J
   Rohan, EMF
   Essex, RW
   McKone, E
   Maddess, T
AF Sabeti, Faran
   Lane, Jo
   Rohan, Emilie M. F.
   Essex, Rohan W.
   McKone, Elinor
   Maddess, Ted
TI Relationships between retinal structure and function and vision-related
   quality of life measures in advanced age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Retinal function; Retinal structure; Age-related macular degeneration;
   Quality of life
ID VISUAL FUNCTION; GLAUCOMA; EYES
AB Purpose To evaluate the association between ophthalmic structure/function measures and five standardized quality of life (QoL) instruments, in patients with advanced age-related macular degeneration (AMD).
   Methods We examined 20 AMD patients (ages 66-93 years) recruited from the Canberra Hospital Ophthalmology Department. Visual function measures included low and high contrast visual acuity (LCVA and HCVA) and measures from 10-2 Matrix visual fields (VF). Optical coherence tomography (OCT) quantified central retinal thickness (CRT), average macular thickness (AT), and retinal nerve fibre layer thickness (RNFL). The QoL instruments were the macular degeneration-related quality of life (MacDQoL), the National Eye Institute Visual Functioning Questionnaire (VFQ), its two face-recognition questions (A6 and 11), and the Geriatric Depression Scale (GDS). Pearson correlations, Canonical Correlation Analysis (CCA), and cross-validated stepwise-regression were used to examine the relationships between structure/function measures and the QoL instruments.
   Results The selected models for the five instruments had R-2 ranging from 0.65 +/- 0.12 to 0.90 +/- 0.05 (mean +/- SD) and median F-statistics > 188. HCVA was strongly associated with all QoL except the GDS, for which CRT, AT and RNFL figured highly. RNFL was most important for MacDQoL, and -2nd for VFQ question-A6. Centrally weighted VF measures were rarely selected but global VF measures were common, especially for the overall NEI-VFQ questionnaire. CCA revealed that the structure/function measures and QoL instruments contained 2 statistically independent mechanisms.
   Conclusions In patients with advanced AMD, CRT and HCVA were strong determinants of QoL instruments in AMD patients.
C1 [Sabeti, Faran; Rohan, Emilie M. F.; Maddess, Ted] Australian Natl Univ, John Curtin Sch Med Res JCSMR, Canberra, ACT, Australia.
   [Sabeti, Faran] Univ Canberra, Fac Hlth, Discipline Optometry, Bruce, ACT 2617, Australia.
   [Lane, Jo; McKone, Elinor] Australian Natl Univ, Res Sch Psychol, Canberra, ACT, Australia.
   [Lane, Jo; McKone, Elinor] Australian Natl Univ, ARC Ctr Excellence Cognit & Its Disorders, Canberra, ACT, Australia.
   [Essex, Rohan W.] Canberra Hosp, Canberra, ACT, Australia.
   [Essex, Rohan W.] ANU Med Sch, Acad Unit Ophthalmol, Canberra, ACT, Australia.
C3 Australian National University; John Curtin School of Medical Research;
   University of Canberra; Australian National University; Australian
   National University; Australian National University; Canberra Hospital;
   Australian National University
RP Sabeti, F (通讯作者)，Australian Natl Univ, John Curtin Sch Med Res JCSMR, Canberra, ACT, Australia.; Sabeti, F (通讯作者)，Univ Canberra, Fac Hlth, Discipline Optometry, Bruce, ACT 2617, Australia.
EM faran.sabeti@canberra.edu.au; jo.lane@anu.edu.au;
   emilie.rohan@anu.edu.au; rohan.essex@act.gov.au;
   elinor.mckone@anu.edu.au; ted.maddess@anu.edu.au
RI Maddess, Teddy L/A-3200-2008
OI Maddess, Teddy L/0000-0003-4591-3658; Lane, Jo/0000-0002-2518-1050;
   SABETI, Faran/0000-0001-9187-7569
FU Australian Research Council through the ARC Centre of Excellence in
   Cognition and its disorders [CE110001021, DP150100684]; NHMRC [1028560];
   Rebecca Cooper Medical Foundation [PG2018040]
FX This research was supported by the Australian Research Council through
   the ARC Centre of Excellence in Cognition and its disorders
   (CE110001021, DP150100684), NHMRC Project grant (1028560) and Rebecca
   Cooper Medical Foundation Grant (PG2018040).
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Anderson AJ, 2011, OPTOMETRY VISION SCI, V88, P806, DOI 10.1097/OPX.0b013e31821861bd
   Asper Lisa, 2000, Clin Exp Optom, V83, P49
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Bennion AE, 2012, SOC SCI MED, V75, P976, DOI 10.1016/j.socscimed.2012.04.023
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   BULLIMORE MA, 1991, INVEST OPHTH VIS SCI, V32, P2020
   Carkeet A, 2001, OPTOMETRY VISION SCI, V78, P529, DOI 10.1097/00006324-200107000-00017
   Csaky K, 2017, INVEST OPHTH VIS SCI, V58, P3456, DOI 10.1167/iovs.17-22339
   CURCIO CA, 1990, J COMP NEUROL, V300, P5, DOI 10.1002/cne.903000103
   Davis JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028800
   EFRON B, 1979, ANN STAT, V7, P1, DOI 10.1214/aos/1176344552
   Evans BJW, 2007, OPHTHAL PHYSL OPT, V27, P417, DOI 10.1111/j.1475-1313.2007.00488.x
   FERRIS FL, 1993, AM J OPHTHALMOL, V116, P735
   Gupta N, 2006, BRIT J OPHTHALMOL, V90, P674, DOI 10.1136/bjo.2005.086769
   Han Y, 2004, ARCH OPHTHALMOL-CHIC, V122, P1809, DOI 10.1001/archopht.122.12.1809
   Hazel CA, 2000, INVEST OPHTH VIS SCI, V41, P1309
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Lane J, 2019, J VISION, V19, DOI 10.1167/19.6.18
   Lane J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209218
   Lane J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33543-3
   Macular Degeneration Foundation, 2011, CLEAR OUTL AG REL MA
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Mitchell J, 2004, QUAL LIFE RES, V13, P1548, DOI 10.1023/B:QURE.0000031348.51292.4a
   Nassisi M, 2019, OPHTHALMOLOGY, V126, P1667, DOI 10.1016/j.ophtha.2019.05.016
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Owen VMF, 2008, INVEST OPHTH VIS SCI, V49, P2449, DOI 10.1167/iovs.07-0877
   Reilly, 2015, T VIS SCI TECH, V4, DOI 10.1167/tvst.1164.1163.1167
   Sabeti F, 2017, SCI REP-UK, V7, DOI 10.1038/srep45847
   Sabeti F, 2012, INVEST OPHTH VIS SCI, V53, P253, DOI 10.1167/iovs.11-8004
   SHEIKH J I, 1986, Clinical Gerontologist, V5, P165
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   World Health Organization, 2015, PREV BLINDN VIS IMP
   Xu JA, 2019, J GLAUCOMA, V28, P42, DOI 10.1097/IJG.0000000000001102
   YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4
NR 38
TC 1
Z9 1
U1 1
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD DEC
PY 2021
VL 259
IS 12
BP 3687
EP 3696
DI 10.1007/s00417-021-05296-9
EA JUL 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WW6CP
UT WOS:000670854700004
PM 34236475
DA 2022-11-30
ER

PT J
AU Sizmaz, S
   Kucukerdonmez, C
   Kal, A
   Pinarci, EY
   Canan, H
   Yilmaz, G
AF Sizmaz, Selcuk
   Kucukerdonmez, Cem
   Kal, All
   Pinarci, Eylem Yaman
   Canan, Handan
   Yilmaz, Gursel
TI Retinal and choroidal thickness changes after single anti-VEGF injection
   in neovascular age-related macular degeneration: ranibizumab vs
   bevacizumab
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Bevacizumab; Choroidal thickness; Optical coherence tomography;
   Ranibizumab
ID OPTICAL COHERENCE TOMOGRAPHY; OCULAR BLOOD-FLOW; INTRAVITREAL
   BEVACIZUMAB; AVASTIN
AB Purpose: To evaluate and compare the effects of single intravitreal injection of ranibizumab and bevacizumab on central retinal and choroidal thickness in patients with neovascular age-related macular degeneration (AMD).
   Methods: Forty eyes of 40 patients with neovascular AMD that underwent intravitreal injection of vascular endothelial growth factor inhibitors (anti-VEGFs) were included. Patients were randomized into 2 groups: 20 eyes received ranibizumab and 20 eyes received bevacizumab injection. Central retinal and choroidal thicknesses of all eyes at baseline and 1 month postinjection scans were measured with Fourier-domain optical coherence tomography (OCT). Student t test and Mann-Whitney U test were used to compare the data.
   Results: The mean central retinal thickness (CRT) showed significant decrease after single injection of ranibizumab (from 345.0 mu m to 253.5 mu m, p<0.01) and bevacizumab (from 329.5 mu m to 251.0 mu m, p<0.01) at the first month, respectively. There was no significant difference regarding the CRT change between groups (p = 0.39). The mean choroidal thickness decreased from 158.6 mu m (115-317) to 155.5 mu m (111-322) in the ranibizumab group and from 211.5 mu m (143-284) to 201.5 mu m (93-338) in bevacizumab group. The decrease was not significant between groups (p = 0.35).
   Conclusions: Intravitreal injection of both ranibizumab and bevacizumab provided a significant decrease in CRT; however, the agents caused no significant change in choroidal thickness. Additionally, no difference between ranibizumab versus bevacizumab was observed related to macular edema inhibition.
C1 [Sizmaz, Selcuk] Cukurova Univ, Sch Med, Dept Ophthalmol, Adana, Turkey.
   [Kucukerdonmez, Cem] Izmir Univ, Sch Med, Dept Ophthalmol, Izmir, Turkey.
   [Kal, All; Pinarci, Eylem Yaman; Canan, Handan; Yilmaz, Gursel] Baskent Univ, Sch Med, Dept Ophthalmol, TR-06490 Ankara, Turkey.
C3 Cukurova University; Izmir University; Baskent University
RP Sizmaz, S (通讯作者)，Cukurova Univ, Tip Fak Goz Hastaliklari AD, Adana, Turkey.
EM ssizmaz@cu.edu.tr
RI Canan, Handan/AAB-6394-2021; Yılmaz, Gürsel/AAK-6987-2021
OI Canan, Handan/0000-0002-5877-6536; Yılmaz, Gürsel/0000-0002-2589-7294
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bhisitkul RB, 2006, BRIT J OPHTHALMOL, V90, P1542, DOI 10.1136/bjo.2006.098426
   Bonnin P, 2010, ACTA OPHTHALMOL, V88, P641, DOI 10.1111/j.1755-3768.2009.01526.x
   Branchini L, 2012, OPHTHALMOLOGY, V119, P119, DOI 10.1016/j.ophtha.2011.07.002
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Ellabban AA, 2012, CLIN OPHTHALMOL, V6, P837, DOI 10.2147/OPTH.S30907
   Fitzgerald MEC, 2002, EXP EYE RES, V74, P561, DOI 10.1006/exer.2002.1142
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Harris A, 1999, PROG RETIN EYE RES, V18, P669
   Hirooka K, 2012, BMC OPHTHALMOL, V12, DOI 10.1186/1471-2415-12-29
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Ikuno Y, 2009, INVEST OPHTH VIS SCI, V50, P3876, DOI 10.1167/iovs.08-3325
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kim DY, 2013, ACTA OPHTHALMOL, V91, P183, DOI 10.1111/j.1755-3768.2011.02305.x
   Lally DR, 2012, CURR OPIN OPHTHALMOL, V23, P182, DOI 10.1097/ICU.0b013e328352411c
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Manjunath V, 2010, AM J OPHTHALMOL, V150, P325, DOI 10.1016/j.ajo.2010.04.018
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P510, DOI 10.1097/IAE.0b013e3181eef053
   Maruko I, 2010, OPHTHALMOLOGY, V117, P1792, DOI 10.1016/j.ophtha.2010.01.023
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Papadopoulou DN, 2009, OPHTHALMOLOGY, V116, P1755, DOI 10.1016/j.ophtha.2009.03.017
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2010, RETINA-J RET VIT DIS, V30, P1390, DOI 10.1097/IAE.0b013e3181e44599
   Sogawa K, 2012, AM J OPHTHALMOL, V153, P1129, DOI 10.1016/j.ajo.2011.11.005
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Storkebaum E, 2004, J CLIN INVEST, V113, P14, DOI 10.1172/JCI200420682
   Tan CS, 2012, INVEST OPHTH VIS SCI, V53, P261, DOI 10.1167/iovs.11-8782
   Tilton RG, 1999, INVEST OPHTH VIS SCI, V40, P689
   Vance SK, 2011, RETINA-J RET VIT DIS, V31, P332, DOI 10.1097/IAE.0b013e3181eef0ae
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Yeoh J, 2010, GRAEF ARCH CLIN EXP, V248, P1719, DOI 10.1007/s00417-010-1437-3
   Zampros I, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/319728
NR 42
TC 18
Z9 18
U1 0
U2 8
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD NOV-DEC
PY 2014
VL 24
IS 6
BP 904
EP 910
DI 10.5301/ejo.5000478
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AX0FA
UT WOS:000346627400015
PM 24803153
DA 2022-11-30
ER

PT J
AU Talks, J
   Koshy, Z
   Chatzinikolas, K
AF Talks, James
   Koshy, Zachariah
   Chatzinikolas, Konstantinos
TI Use of optical coherence tomography, fluorescein angiography and
   indocyanine green angiography in a screening clinic for wet age-related
   macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL ANGIOMATOUS PROLIFERATION; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   PHOTODYNAMIC THERAPY; NEOVASCULARIZATION
AB Aims: To assess the utility of optical coherence tomography (OCT) in a nurse-led, fast-track clinic for new age-related macular degeneration (AMD) referrals, and to see how often indocyanine green angiography (ICGA) led to an additional diagnosis to that provided by fundus fluorescein angiography (FFA).
   Method: Retrospective audit of a consecutive series of 134 new patients referred with suspected wet AMD. When visual acuity was > 6/60 an OCT was performed. If the OCT was consistent with "wet'' AMD, the patient underwent simultaneous FFA/ICGA. The sensitivity and specificity of this clinic was calculated. The number of additional diagnoses made using ICGA was recorded.
   Results: 23/134 (17.16%) patients had OCT only and were not subsequently found to have wet AMD. FFA/ICGA was performed in 111 patients, showing wet AMD in 90 (81%) patients. OCT as used in our clinic had a sensitivity of 1 and a specificity of 0.65 for detecting wet AMD. ICGA provided additional diagnoses in 19 (14.17%) patients. ICGA detected a specific vascular abnormality in 58% of the occult lesions.
   Conclusions: OCT proved to be an effective screening tool for wet AMD in this clinic, with excellent sensitivity and reasonable specificity. ICGA provided an additional diagnosis in a significant number of cases, but did not define a vascular abnormality in all occult cases.
C1 Royal Victoria Infirm, Dept Ophthalmol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
C3 Newcastle University - UK
RP Talks, J (通讯作者)，Royal Victoria Infirm, Dept Ophthalmol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
EM james.talks@newcastle.ac.uk
OI Talks, James/0000-0001-6126-6476
CR Brancato R, 2002, EUR J OPHTHALMOL, V12, P467, DOI 10.5301/EJO.2008.2283
   Fernandes LHS, 2002, RETINA-J RET VIT DIS, V22, P557, DOI 10.1097/00006982-200210000-00005
   Hassenstein A, 2001, KLIN MONATSBL AUGENH, V218, P503, DOI 10.1055/s-2001-16293
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Helbig H, 2005, KLIN MONATSBL AUGENH, V222, P202, DOI 10.1055/s-2005-858011
   Kramer M, 2000, AM J OPHTHALMOL, V129, P495, DOI 10.1016/S0002-9394(99)00388-8
   MICHELS S, 2006, EXPERT OPIN INV DRUG, V15, P479
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Otsuji T, 2000, OPHTHALMIC SURG LAS, V31, P210
   Salinas-Alaman A, 2005, AM J OPHTHALMOL, V140, P23, DOI 10.1016/j.ajo.2005.01.044
   Sandhu SS, 2005, BRIT J OPHTHALMOL, V89, P967, DOI 10.1136/bjo.2004.060863
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   *TREATM AG REL MAC, 2002, ARCH OPHTHALMOL-CHIC, V120, P443
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 14
TC 29
Z9 30
U1 0
U2 4
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2007
VL 91
IS 5
BP 600
EP 601
DI 10.1136/bjo.2006.108043
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 158XW
UT WOS:000245829900013
PM 17151058
OA Green Published
DA 2022-11-30
ER

PT J
AU Shankar, A
   Mitchell, P
   Rochtchina, E
   Tan, J
   Wang, JJ
AF Shankar, Anoop
   Mitchell, Paul
   Rochtchina, Elena
   Tan, Jennifer
   Wang, Jie Jin
TI Association between circulating white blood cell count and long-term
   incidence of age-related macular degeneration - The Blue Mountains eye
   study
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE aged; Australia; inflammation; leukocyte count; macular degeneration
ID COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN; CHOROIDAL NEOVASCULARIZATION;
   INTRAVITREAL TRIAMCINOLONE; CARDIOVASCULAR HEALTH; INFLAMMATORY MARKERS;
   LEUKOCYTE COUNT; GRADING SYSTEM; RISK-FACTORS; MACULOPATHY
AB Inflammatory processes are implicated in the development and progression of age-related macular degeneration (AMD). However, there are limited data on longitudinal associations between systemic markers of inflammation and AMD. The authors examined the prospective relation between the circulating white blood cell (WBC) count and early and late AMD in a population-based cohort of 3,654 participants, aged 49-97 years, in the Blue Mountains region, Australia. The main outcome of interest was the 10-year incidence of early and late AMD among individuals free from corresponding disease at the baseline (1992-1994). An elevated baseline WBC count was associated with early AMD incidence, independent of smoking and other major confounders. The multivariable relative risk comparing tertile 3 of WBC count (> 6.7 x 10(9) cells/liter) with tertile 1 (<= 5.5 x 10(9) cells/liter) was 1.85 (95% confidence interval: 1.33, 2.58). The association between WBC count and early AMD was present consistently in analyses of different early AMD lesions, including incident pigmentary abnormalities and soft indistinct/reticular drusen. Moreover, this association persisted in subgroup analyses by gender and smoking. An elevated WBC count at baseline was not consistently associated with late AMD incidence. This study provides population-based evidence supporting a longitudinal association between the circulating WBC count, a widely available marker of inflammation, and incidence of early AMD.
C1 Natl Univ Singapore, Dept Community Occupat & Family Med, Singapore 117597, Singapore.
   Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Sydney, NSW 2006, Australia.
   Univ Sydney, Westmead Millennium Inst, Sydney, NSW 2006, Australia.
C3 National University of Singapore; University of Sydney; University of
   Sydney; Westmead Institute for Medical Research
RP Shankar, A (通讯作者)，Natl Univ Singapore, Dept Community Occupat & Family Med, Singapore 117597, Singapore.
EM ashankar@nus.edu.sg
RI Wang, Jie Jin/P-1499-2014; Mitchell, Paul/P-1498-2014; wang,
   jie/GRS-0942-2022
OI Wang, Jie Jin/0000-0001-9491-4898; 
CR Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Dasch B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1501, DOI 10.1001/archopht.123.11.1501
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FRIEDMAN GD, 1973, ARCH ENVIRON HEALTH, V26, P137, DOI 10.1080/00039896.1973.10666241
   Gottlieb JL, 2002, JAMA-J AM MED ASSOC, V288, P2233, DOI 10.1001/jama.288.18.2233
   GRAHAM EM, 1987, BRIT J OPHTHALMOL, V71, P826, DOI 10.1136/bjo.71.11.826
   GREEN WR, 1986, OPHTHALMOLOGY, V93, P1169
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hosmer DW, 1989, APPL LOGISTIC REGRES, P238
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P674, DOI 10.1001/archopht.121.5.674
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Margolis KL, 2005, ARCH INTERN MED, V165, P500, DOI 10.1001/archinte.165.5.500
   McGeer PL, 2005, NEUROBIOL AGING, V26, P1199, DOI 10.1016/j.neurobiolaging.2005.02.003
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Palmer HE, 1996, EUR J CLIN INVEST, V26, P686, DOI 10.1111/j.1365-2362.1996.tb02154.x
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   PENFOLD PL, 1957, GRAEFES ARCH CLIN EX, V225, P70
   Pickup JC, 1998, DIABETOLOGIA, V41, P1241, DOI 10.1007/s001250051058
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   SEREGARD S, 1994, GRAEF ARCH CLIN EXP, V232, P325, DOI 10.1007/BF00175983
   Shankar A, 2006, ARCH INTERN MED, V166, P188, DOI 10.1001/archinte.166.2.188
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 43
TC 52
Z9 52
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
EI 1476-6256
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD FEB 15
PY 2007
VL 165
IS 4
BP 375
EP 382
DI 10.1093/aje/kwk022
PG 8
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health
GA 134ZQ
UT WOS:000244123800003
PM 17110636
OA Bronze
DA 2022-11-30
ER

PT J
AU Krezel, AK
   Hogg, RE
   Krezel, S
   Fallis, R
   Azuara-Blanco, A
AF Krezel, A. K.
   Hogg, R. E.
   Krezel, S.
   Fallis, R.
   Azuara-Blanco, A.
TI Design characteristic of randomised controlled trials for geographic
   atrophy in age-related macular degeneration: selection of outcomes and
   sample size calculation
SO EYE
LA English
DT Article
ID CLINICAL-TRIALS; QUALITY; GUIDELINES; VISION
AB Purpose The selection of suitable outcomes and sample size calculation are critical factors in the design of a randomised controlled trial (RCT). The goal of this study was to identify the range of outcomes and information on sample size calculation in RCTs on geographic atrophy (GA).
   Methods We carried out a systematic review of age-related macular degeneration (AMD) RCTs. We searched MEDLINE, EMBASE, Scopus, Cochrane Library, www.controlledtrials.com, and www.ClinicalTrials.gov. Two independent reviewers screened records. One reviewer collected data and the second reviewer appraised 10% of collected data. We scanned references lists of selected papers to include other relevant RCTs.
   Results Literature and registry search identified 3816 abstracts of journal articles and 493 records from trial registries. From a total of 177 RCTs on all types of AMD, 23 RCTs on GA were included. Eighty-one clinical outcomes were identified. Visual acuity (VA) was the most frequently used outcome, presented in 18 out of 23 RCTs and followed by the measures of lesion area. For sample size analysis, 8 GA RCTs were included. None of them provided sufficient Information on sample size calculations.
   Conclusions This systematic review illustrates a lack of standardisation in terms of outcome reporting in GA trials and issues regarding sample size calculation. These limitations significantly hamper attempts to compare outcomes across studies and also perform meta-analyses.
C1 [Krezel, A. K.; Hogg, R. E.; Azuara-Blanco, A.] Queens Univ Belfast, Ctr Med Expt, Belfast, Antrim, North Ireland.
   [Krezel, S.] Queens Univ Belfast, Belfast, Antrim, North Ireland.
   [Fallis, R.] Queens Univ Belfast, Med Lib, Belfast, Antrim, North Ireland.
C3 Queens University Belfast; Queens University Belfast; Queens University
   Belfast
RP Krezel, AK (通讯作者)，Royal Victoria Hosp, Inst Clin Sci, Ctr Med Expt, Block A,Grosvenor Rd, Belfast BT1 26BA, Antrim, North Ireland.
EM akrezel01@qub.ac.uk
RI Fallis, Richard/W-1006-2018; Hogg, Ruth E./ABC-9602-2020
OI Fallis, Richard/0000-0003-4089-7994; Hogg, Ruth E./0000-0001-9413-2669;
   Azuara-Blanco, Augusto/0000-0002-4805-9322
CR Beck RW, 2007, OPHTHALMOLOGY, V114, P1804, DOI 10.1016/j.ophtha.2007.06.047
   Burzykowski T, 2011, PHARM STAT, V10, P115, DOI 10.1002/pst.419
   Clarke M, 2008, PLOS MED, V5, P521, DOI 10.1371/journal.pmed.0050102
   Cook JA, 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18280
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   Dwan K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003081
   Fung AE, 2009, OPHTHALMOLOGY, V116, P286, DOI 10.1016/j.ophtha.2008.09.014
   Goodall EA, 2009, EYE, V23, P1589, DOI 10.1038/eye.2009.105
   Hislop J, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001645
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Ismail R, 2014, BRIT J OPHTHALMOL, V98, P464, DOI 10.1136/bjophthalmol-2013-304323
   Krezel AK, 2015, BRIT J OPHTHALMOL, V99, P1560, DOI 10.1136/bjophthalmol-2014-306544
   Lenth RV, 2001, AM STAT, V55, P187, DOI 10.1198/000313001317098149
   Lesmes Luis Andres, 2013, Drug Discov Today Ther Strateg, V10, pe43, DOI 10.1016/j.ddstr.2012.11.002
   Schulz KF, 2011, INT J SURG, V9, P672, DOI 10.1016/j.ijsu.2011.09.004
   Sibbald B, 1998, BRIT MED J, V316, P201
   Slakter JS, 2005, SURV OPHTHALMOL, V50, P263, DOI 10.1016/j.survophthal.2005.02.007
   Tetzlaff JM, 2012, SYST REV-LONDON, V1, DOI 10.1186/2046-4053-1-43
   Tugwell P, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-38
   Velez-Montoya R, 2013, RETINA-J RET VIT DIS, V33, P1487, DOI 10.1097/IAE.0b013e318271f265
   Williamson P, 2012, J HEALTH SERV RES PO, V17, P1, DOI 10.1258/jhsrp.2011.011131
   Williamson PR, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-132
   Wittes J, 2009, OPHTHALMOLOGY, V116, pS8, DOI 10.1016/j.ophtha.2009.06.050
   Zhong Baoliang, 2009, J Thorac Dis, V1, P51
NR 24
TC 3
Z9 3
U1 0
U2 2
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD NOV
PY 2015
VL 29
IS 11
BP 1458
EP 1463
DI 10.1038/eye.2015.132
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CW5HZ
UT WOS:000365027600010
PM 26206532
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Chakravarthy, U
   Bailey, CC
   Johnston, RL
   McKibbin, M
   Khan, RS
   Mahmood, S
   Downey, L
   Dhingra, N
   Brand, C
   Brittain, CJ
   Willis, JR
   Rabhi, S
   Muthutantri, A
   Cantrell, RA
AF Chakravarthy, Usha
   Bailey, Clare C.
   Johnston, Robert L.
   McKibbin, Martin
   Khan, Rehna S.
   Mahmood, Sajjad
   Downey, Louise
   Dhingra, Narendra
   Brand, Christopher
   Brittain, Christopher J.
   Willis, Jeffrey R.
   Rabhi, Sarah
   Muthutantri, Anushini
   Cantrell, Ronald A.
TI Characterizing Disease Burden and Progression of Geographic Atrophy
   Secondary to Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID VISUAL-ACUITY LOSS; EYE DISEASE; BLINDNESS; METAANALYSIS; MACULOPATHY;
   ENLARGEMENT; PREVALENCE; OUTCOMES; FORM
AB Purpose: To understand levels of disease burden and progression in a real-world setting among patients from the United Kingdom with bilateral geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
   Design: Retrospective cohort analysis of a multicenter electronic medical record (EMR) database.
   Participants: Patients who were aged >= 50 years with bilateral GA and no history of choroidal neovascularization (CNV) and who attended 1 of 10 clinical sites using the EMR.
   Methods: A deidentified data set was constructed from the records held at the 10 sites. An algorithm was used to extract cases with a GA diagnosis, of which 1901 had bilateral GA and form the basis of this report. A sample of records randomly selected from each center was used to validate disease definitions.
   Main Outcome Measures: Progression to blindness (visual acuity [VA] < 20 letters or Snellen 3/60 in the better-seeing eye), driving ineligibility (VA <= 70 letters or Snellen 6/12 in the better-seeing eye), progression to CNV, loss of 10 or more letters, and mean change in VA over time.
   Results: At first record of GA, 7.1% had a VA in the better-seeing eye equal to or lower than the cutoff for blindness registration and 71.1% had a VA that would have rendered them ineligible to drive. Over time, 16% became legally blind (median time to outcome, 6.2 years) and 66.7% became ineligible to drive (median time to outcome, 1.6 years). In the worse-seeing eye, 40.1% lost >= 10 letters in 2.4 years. Among patients with baseline and 24-month VA measurements, mean VA decline was 6.1 letters in the worse-seeing eye (n = 413) and 12.4 letters in the better-seeing eye (n = 414). The rate of progression to CNV in either eye was 7.4% per patient-year.
   Conclusions: At initial diagnosis, based on VA in the better-seeing eye, a high proportion of patients with bilateral GA were ineligible to drive and approximately 7% were eligible for UK blindness registration. The subsequent reduction in VA that occurred in the better-seeing eye would render a further two-thirds ineligible to drive. These findings emphasize the severity of the visual disability associated with GA secondary to AMD. Ophthalmology (C) 2018 by the American Academy of Ophthalmology.
C1 [Chakravarthy, Usha] Queens Univ Belfast, Royal Victoria Hosp, Belfast, Antrim, North Ireland.
   [Bailey, Clare C.] Univ Hosp Bristol Natl Hlth Serv Fdn Trust, Bristol, Avon, England.
   [Johnston, Robert L.] Cheltenham Gen Hosp, Gloucestershire Eye Unit, Cheltenham, Glos, England.
   [McKibbin, Martin] Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England.
   [Khan, Rehna S.] Calderdale & Huddersfield NHS Fdn Trust, Huddersfield, W Yorkshire, England.
   [Mahmood, Sajjad] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester, Lancs, England.
   [Downey, Louise] Hull & East Yorkshire Hosp NHS Trust, Kingston Upon Hull, N Humberside, England.
   [Dhingra, Narendra] Mid Yorkshire Hosp NHS Trust, Wakefield, England.
   [Brand, Christopher] Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, S Yorkshire, England.
   [Brittain, Christopher J.; Willis, Jeffrey R.; Cantrell, Ronald A.] Genentech Inc, San Francisco, CA 94080 USA.
   [Willis, Jeffrey R.] UC Davis Med Ctr, Dept Ophthalmol, Sacramento, CA USA.
   [Rabhi, Sarah; Muthutantri, Anushini] QuintilesIMS, London, England.
C3 Queens University Belfast; Gloucestershire Hospitals NHS Foundation
   Trust; Cheltenham General Hospital; University of Leeds; University of
   Manchester; University of Sheffield; Roche Holding; Genentech;
   University of California System; University of California Davis; IQVIA
RP Chakravarthy, U (通讯作者)，Queens Univ Belfast, Royal Victoria Hosp, Dept Ophthalmol, Belfast BT12 6BA, Antrim, North Ireland.
EM U.Chakravarthy@qub.ac.uk
RI Mahmood, Sajjad/AAK-7645-2021
OI McKibbin, Martin/0000-0003-4388-243X; Chakravarthy,
   Usha/0000-0002-2606-3734
FU Alcon Laboratories; Allergan; Bayer; Novartis; Alimera Sciences; Roche;
   NIHR (NHS); Oraya (Zeiss); F. Hoffmann-La Roche Ltd., Basel, Switzerland
FX M.M.: Research support - Alcon Laboratories; Advisory board - Bayer,
   Novartis; Lecture fees - Allergan, Bayer, Novartis; Travel and
   educational support - Allergan, Bayer, Novartis.; R.S.K.: Advisory board
   - Alimera Sciences; Grants and speaker fees - Alimera Sciences, Bayer,
   Novartis.; L.D.: Research support - Allergan, Bayer, Novartis, Roche;
   Advisory board - Alcon, Alimera Sciences, Allergan, Bayer, Novartis,
   Oraya; Lecture fees - Alimera Sciences, Bayer, Novartis; Travel expenses
   - Allergan, Bayer, Novartis.; N.D.: Travel and educational grant -
   Allergan, Bayer, Novartis.; C.B.: Research support - Alimera Sciences,
   Allergan, NIHR (NHS), Novartis, Oraya (Zeiss), Roche; Advisory board -
   Bayer, Novartis, Oraya (Zeiss); Lecture fees - Novartis, Oraya (Zeiss);
   Travel and educational support - Bayer, Novartis, Oraya (Zeiss).; F.
   Hoffmann-La Roche Ltd., Basel, Switzerland, provided support for the
   analysis and participated in the design, conduct, management, and
   interpretation of the data.
CR [Anonymous], DRIV EYES RUL
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Borooah S, 2015, EYE, V29, P1156, DOI 10.1038/eye.2015.83
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Centers for Disease Control and Prevention, 2016, INT CLASS DIS 10 REV
   Centers for Disease Control and Prevention National Center for Health Statistics, 2018, INT CLASS DIS 10 REV
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   InternationalCouncil of Ophthalmology, VIS REQ DRIV SAF EMP
   Joachim N, 2013, OPHTHALMOLOGY, V120, P2042, DOI 10.1016/j.ophtha.2013.03.029
   Kimel M, 2016, INVEST OPHTH VIS SCI, V57, P6298, DOI 10.1167/iovs.16-20361
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Medisoft Limited, 2017, MED OPHTH
   Royal National Institute for the Blind, 2022, RNIB CRIT CERT
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Sadda SR, 2016, RETINA-J RET VIT DIS, V36, P1806, DOI 10.1097/IAE.0000000000001283
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Sengupta S, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/1471-2415-15-9
   Sjostrand J, 2011, ACTA OPHTHALMOL, V89, P116, DOI 10.1111/j.1755-3768.2009.01653.x
   Skaat A, 2012, AM J OPHTHALMOL, V153, P214, DOI 10.1016/j.ajo.2011.08.035
   Sloan FA, 2014, JAMA OPHTHALMOL, V132, P456, DOI 10.1001/jamaophthalmol.2013.7647
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   World Health Organization, CHANG DEF BLINDN
   World Health Organization, 2017, ICD 11 BET DRAFT MOR
NR 36
TC 48
Z9 48
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2018
VL 125
IS 6
BP 842
EP 849
DI 10.1016/j.ophtha.2017.11.036
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GG0MB
UT WOS:000432371600019
PM 29366564
OA hybrid
DA 2022-11-30
ER

PT J
AU McGwin, G
   Owsley, C
   Curcio, CA
   Crain, RJ
AF McGwin, G
   Owsley, C
   Curcio, CA
   Crain, RJ
TI The association between statin use and age related maculopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; MACULAR DEGENERATION; BRUCHS MEMBRANE;
   CHOROIDAL NEOVASCULARIZATION; RISK-FACTORS; CHOLESTEROL; DRUSEN;
   INHIBITORS; HYPOTHESIS; DEPOSITS
AB Aims: To evaluate the association between age related maculopathy (ARM) and statin use.
   Methods: A nested case-control study among patients at the Veterans Affairs Medical Center in Birmingham, Alabama, with newly diagnosed ARM (cases) between 1997 to 2001 were selected and age matched to non-ARM controls.
   Results: 550 incident cases of ARM were identified and matched to 5500 controls. Overall, cases were 70% (OR 0.30, 95% CI 0.21 to 0.45) less likely to have received and filled a statin prescription relative to the controls. This association was present among both current and past (OR 0.34, 95% CI 0.21 to 0.53 and OR 0.26, 95% CI 0.14 to 0.47, respectively) statin users. When considering use of statin and/or non-statin lipid lowering medications, a significant risk reduction was observed for statin only users (OR 0.30, 95% CI 0.20 to 0.45) and combined statin and non- statin users (OR 0.20, 95% CI 0.06 to 0.64); there was no significant association for non-statin only users (OR 0.47, 95% CI 0.20 to 1.13).
   Conclusions: The results of this study suggest that subjects with ARM were significantly less likely to have filled a statin prescription. Future clinical research initiatives should include a clinical trial to provide direct evidence of the effectiveness of statins in lowering the incidence and progression of ARM.
C1 Univ Alabama, Sch Med, Dept Ophthalmol, Birmingham, AL 35294 USA.
   Univ Alabama, Sch Publ Hlth, Dept Epidemiol & Int Hlth, Birmingham, AL 35294 USA.
   Univ Alabama, Dept Surg, Div Gen Surg, Sect Trauma Burns & Surg Crit Care, Birmingham, AL 35294 USA.
   Birmingham Dept Vet Affairs Med Ctr, Birmingham, AL USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP McGwin, G (通讯作者)，Univ Alabama, Sch Med, Dept Ophthalmol, 700 S 18th St,Suite 609, Birmingham, AL 35294 USA.
FU NEI NIH HHS [R21-EY14071, R01-EY061109, R21 EY014071, R01 EY006109]
   Funding Source: Medline; NIA NIH HHS [R01 AG004212, R01-AG04212] Funding
   Source: Medline; NATIONAL EYE INSTITUTE [R21EY014071, R01EY006109]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG004212]
   Funding Source: NIH RePORTER
CR Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Capeans C, 2001, GRAEF ARCH CLIN EXP, V239, P188, DOI 10.1007/s004170000250
   Comparato C, 2001, NUTR METAB CARDIOVAS, V11, P328
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Dithmar S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1643, DOI 10.1001/archopht.119.11.1643
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1206, DOI 10.1016/0002-9394(71)90964-0
   Fine SL, 2001, ARCH OPHTHALMOL-CHIC, V119, P275
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 2000, ARCH OPHTHALMOL-CHIC, V118, P625
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   HAVEL RJ, 2001, METABOLIC MOL BASIS, V2, P2707
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   MALEK G, IN PRESS AM J PATHOL
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   Miceli MV, 2000, CURR EYE RES, V20, P8, DOI 10.1076/0271-3683(200001)20:1;1-H;FT008
   Moulton K S, 2001, Curr Atheroscler Rep, V3, P225, DOI 10.1007/s11883-001-0065-0
   NAPOLI P, 2001, BMJ
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Qi JH, 2002, J BIOL CHEM, V277, P13394, DOI 10.1074/jbc.M110870200
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Takemoto M, 2001, ARTERIOSCL THROM VAS, V21, P1712, DOI 10.1161/hq1101.098486
   van Leeuwen R, 2001, BRIT MED J, V323, P1308, DOI 10.1136/bmj.323.7324.1308a
   WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551
NR 37
TC 87
Z9 95
U1 0
U2 2
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2003
VL 87
IS 9
BP 1121
EP 1125
DI 10.1136/bjo.87.9.1121
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 713EB
UT WOS:000184842500016
PM 12928279
OA Green Published, Bronze, Green Submitted
DA 2022-11-30
ER

PT J
AU de Jong, EK
   Breukink, MB
   Schellevis, RL
   Bakker, B
   Mohr, JK
   Fauser, S
   Keunen, JEE
   Hoyng, CB
   den Hollander, AI
   Boon, CJF
AF de Jong, Eiko K.
   Breukink, Myrte B.
   Schellevis, Rosa L.
   Bakker, Bjorn
   Mohr, Jacqueline K.
   Fauser, Sascha
   Keunen, Jan E. E.
   Hoyng, Carel B.
   den Hollander, Anneke I.
   Boon, Camiel J. F.
TI Chronic Central Serous Chorioretinopathy Is Associated with Genetic
   Variants Implicated in Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; POLYPOIDAL CHOROIDAL VASCULOPATHY; RETINAL-PIGMENT
   EPITHELIOPATHY; SMOOTH-MUSCLE-CELLS; VIII COLLAGEN; SUSCEPTIBILITY;
   UPDATE; PATHOPHYSIOLOGY; ADRENOMEDULLIN; ACTIVATION
AB Purpose: In this study, single nucleotide polymorphisms (SNPs) at 19 loci, previously associated with age-related macular degeneration (AMD), were systematically tested for association in patients with chronic central serous chorioretinopathy (cCSC). In addition, we evaluated the effect of detailed phenotyping on these genetic associations.
   Design: Case-control study.
   Participants: We included 292 cCSC patients, 1147 AMD patients, and 1311 control individuals.
   Methods: We genotyped SNPs at 19 AMD-associated loci and 6 additional SNPs at the complement factor H (CFH) locus. Phenotyping of all patients was based on fundoscopy, spectral-domain optical coherence tomography, fluorescein angiography (FA), and indocyanine green angiography.
   Main Outcome Measures: We measured the allele frequencies of 25 AMD-associated SNPs and CFH haplotype frequencies in patients with cCSC and the effect of phenotypic subdivision of cCSC on genetic associations.
   Results: One SNP in ARMS2 (rs10490924) was significant after Bonferroni correction (P-unadjusted = 0.002; odds ratio [OR] = 0.64). The SNPs at 3 other AMD loci (CFH, TNFRSF10A, ADAMTS9) showed a trend toward association with typical cCSC. Further analysis of the CFH locus identified 2 SNPs that significantly conferred increased risk for cCSC and 1 that was protective. The CFH-H3 haplotype was also found to be protective (P = 0.01; OR = 0.54). Using multimodal imaging, 197 patients were classified as having typical cCSC, 52 patients had unilateral abnormalities on FA that were otherwise typical of cCSC, and 43 patients had a clinical picture that could be compatible with cCSC, but with features that could also indicate other macular diseases. Significant differences of the minor allele frequencies of the tested SNPs were observed between these 3 phenotypic subgroups.
   Conclusions: Chronic CSC is associated with genetic variants in ARMS2 and CFH, indicating a genetic and pathophysiologic overlap between cCSC and AMD. Intriguingly, alleles in ARMS2 and CFH that confer risk of AMD may be protective for cCSC, and alleles in CFH that are protective for AMD confer risk for cCSC. Significant differences in allele frequencies were found among the phenotypic subgroups for several SNPs, illustrating the importance of correct clinical classification. (C) 2015 by the American Academy of Ophthalmology.
C1 [de Jong, Eiko K.; Breukink, Myrte B.; Schellevis, Rosa L.; Bakker, Bjorn; Mohr, Jacqueline K.; Keunen, Jan E. E.; Hoyng, Carel B.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Nijmegen, Netherlands.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, Nijmegen, Netherlands.
   [Boon, Camiel J. F.] Leiden Univ, Med Ctr, Dept Ophthalmol, NL-2333 ZA Leiden, Netherlands.
   [Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany.
C3 Radboud University Nijmegen; Radboud University Nijmegen; Leiden
   University; Leiden University Medical Center (LUMC); Leiden University -
   Excl LUMC; University of Cologne
RP Boon, CJF (通讯作者)，Leiden Univ, Med Ctr, Dept Ophthalmol, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.
EM C.J.F.Boon@lumc.nl
RI de Jong, Eiko/P-3407-2015; Bakker, Bjorn/E-2842-2016; Schellevis,
   Rosa/I-9371-2016; Keunen, J.E.E./H-8061-2014; Hollander, Anneke
   den/N-4911-2014; Hoyng, C.B./H-8050-2014; Boon, CJF/P-7534-2014
OI de Jong, Eiko/0000-0001-6520-0407; Schellevis, Rosa/0000-0002-6939-8358;
   Boon, CJF/0000-0002-6737-7932
FU Macula Vision Research Foundation; MD Fonds; Landelijke Stichting voor
   Blinden en Slechtzienden; Gelderse Blindenstichting; Stichting
   Nederlands Oogheelkundig Onderzoek; Stichting Blindenhulp; Stichting
   A.F. Deutman Oogheelkunde Researchfonds; Nijmeegse Oogonderzoek
   Stichting; Janivo Stichting and Oogfonds
FX Supported by the Macula Vision Research Foundation, MD Fonds, Landelijke
   Stichting voor Blinden en Slechtzienden, Gelderse Blindenstichting,
   Stichting Nederlands Oogheelkundig Onderzoek, Stichting Blindenhulp,
   Stichting A.F. Deutman Oogheelkunde Researchfonds, Nijmeegse
   Oogonderzoek Stichting, Janivo Stichting and Oogfonds. The sponsor or
   funding organization had no role in the design or conduct of this
   research. The authors have no proprietary or commercial interest in any
   materials discussed in this article.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Boon CJF, 2009, MOL IMMUNOL, V46, P1573, DOI 10.1016/j.molimm.2009.02.013
   Bouzas EA, 2002, SURV OPHTHALMOL, V47, P431, DOI 10.1016/S0039-6257(02)00338-7
   Buga AM, 2014, FRONT AGING NEUROSCI, V6, DOI [10.3389/fnagi.2014.00130, 10.3389/fnagi.2014.00044]
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Crowder R. N., 2012, Experimental Oncology, V34, P160
   Dorner GT, 2003, INVEST OPHTH VIS SCI, V44, P3947, DOI 10.1167/iovs.02-0855
   Eandi CM, 2005, RETINA-J RET VIT DIS, V25, P989, DOI 10.1097/00006982-200512000-00006
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Gemenetzi M, 2010, EYE, V24, P1743, DOI 10.1038/eye.2010.130
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Kavurma MM, 2008, J BIOL CHEM, V283, P7754, DOI 10.1074/jbc.M706927200
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koo BH, 2010, AM J PATHOL, V176, P1494, DOI 10.2353/ajpath.2010.090655
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Liew G, 2013, CLIN EXP OPHTHALMOL, V41, P201, DOI 10.1111/j.1442-9071.2012.02848.x
   Loo RH, 2002, RETINA-J RET VIT DIS, V22, P19, DOI 10.1097/00006982-200202000-00004
   Loyet KM, 2012, INVEST OPHTH VIS SCI, V53, P6628, DOI 10.1167/iovs.12-9587
   MacBeath JRE, 1996, BIOCHEM J, V319, P993, DOI 10.1042/bj3190993
   Miki A, 2014, OPHTHALMOLOGY, V121, P1067, DOI 10.1016/j.ophtha.2013.11.020
   Nicholson B, 2013, SURV OPHTHALMOL, V58, P103, DOI 10.1016/j.survophthal.2012.07.004
   Oosterhuis JA, 1996, GRAEF ARCH CLIN EXP, V234, P337, DOI 10.1007/BF00220710
   Park DW, 1998, EUR J OPHTHALMOL, V8, P42, DOI 10.1177/112067219800800110
   Park Han Sang, 2012, Korean J Ophthalmol, V26, P15, DOI 10.3341/kjo.2012.26.1.15
   Plenz GAM, 2003, ATHEROSCLEROSIS, V166, P1, DOI 10.1016/S0021-9150(01)00766-3
   POLAK BCP, 1995, BRIT J OPHTHALMOL, V79, P922, DOI 10.1136/bjo.79.10.922
   Quin G, 2013, CLIN EXP OPHTHALMOL, V41, P187, DOI 10.1111/j.1442-9071.2012.02847.x
   Ristau T, 2014, INVEST OPHTH VIS SCI, V55, P210, DOI 10.1167/iovs.13-13248
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010
   Schubert C, 2014, HUM MUTAT, V35, P859, DOI 10.1002/humu.22551
   Spaide RF, 1996, OPHTHALMOLOGY, V103, P2070, DOI 10.1016/S0161-6420(96)30386-2
   Tittl M, 2005, INVEST OPHTH VIS SCI, V46, P4717, DOI 10.1167/iovs.05-0268
   Told R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060424
   Udono-Fujimori R, 2003, REGUL PEPTIDES, V112, P95, DOI 10.1016/S0167-0115(03)00027-2
   VONWINNING CHOM, 1982, OPHTHALMOLOGICA, V185, P7, DOI 10.1159/000309216
   Wang M, 2008, ACTA OPHTHALMOL, V86, P126, DOI 10.1111/j.1600-0420.2007.00889.x
   Wang MSM, 2002, AM J OPHTHALMOL, V133, P787, DOI 10.1016/S0002-9394(02)01438-1
   Weenink AC, 2001, OPHTHALMOLOGICA, V215, P183, DOI 10.1159/000050855
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yannuzzi LA, 2010, AM J OPHTHALMOL, V149, P361, DOI 10.1016/j.ajo.2009.11.017
NR 44
TC 82
Z9 83
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2015
VL 122
IS 3
BP 562
EP 570
DI 10.1016/j.ophtha.2014.09.026
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CC2DF
UT WOS:000350154600026
PM 25439433
DA 2022-11-30
ER

PT J
AU Altinbay, D
   Idil, A
   Sahli, E
AF Altinbay, Deniz
   Idil, Aysun
   Sahli, Esra
TI How Much Do Clinical and Microperimetric Findings Affect Reading Speed
   in Low Vision Patients with Age-related Macular Degeneration?
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Low vision rehabilitation; microperimetry; reading speed; preferred
   retinal locus; central scotoma
ID PREFERRED RETINAL LOCI; CHOROIDAL NEOVASCULARIZATION; FIXATION PATTERNS;
   CENTRAL SCOTOMAS; TURKISH VERSION; PSYCHOPHYSICS; EYES; VALIDATION; SIZE
AB Purpose: To investigate the factors affecting the reading speed of patients with central scotoma due to age-related macular degeneration (AMD).
   Materials and Methods: We included 63 eyes of 63 patients with AMD who applied to our low vision clinic between August 2018 and September 2019 in this prospective study. We evaluated socio-demographic characteristics, eye examination findings and Minnesota Low Vision Reading Test (MNREAD) results. We used the MAIA microperimeter device to evaluate the properties of the preferred retinal locus for fixation (PRL) of the patients. Evaluations included the assessment of the effects of all parameters on reading speed.
   Results: The PRL was most commonly in the nasal (31%) and superior (26%) quadrants. Twenty-nine percent of the cases preferred the left visual field. PRL localization had no effect on reading speed, whereas, fixation stability, educational status, presence of foveal absolute scotoma, reading acuity and duration of reading interruption were found to have the most significant effects. Multiple regression analysis showed that reading speed decreased by 67 units in the presence of unstable fixation, by 17 units in the presence of foveal absolute scotoma, by 3 units with every 0.1 increase in logMAR value, and by 1.7 units with every 1-year increase in reading interruption. Additionally, being a university graduate was associated with an increased reading speed (by 18 units)
   Conclusion: Increased reading performance is one of the factors that can improve quality of life. The factors found to affect the reading speed in the current study may guide the rehabilitation process in low vision patients.
C1 [Altinbay, Deniz] Niv Eye Ctr, Dept Ophthalmol, Adana, Turkey.
   [Altinbay, Deniz; Idil, Aysun; Sahli, Esra] Ankara Univ, Fac Med, Vis Studies & Low Vis Rehabil Unit, Dept Ophthalmol, Ankara, Turkey.
C3 Ankara University
RP Altinbay, D (通讯作者)，Ozel Niv Goz Merkezi, Sumer,69023 Sk 2-A, TR-01140 Adana, Turkey.
EM denizaltinbay01@gmail.com
RI Şahlı, Esra/AAW-4371-2021
OI Altinbay, Deniz/0000-0002-3976-4361; Idil, Sefay
   Aysun/0000-0002-5979-9158
FU Ankara University Scientific Research Projects Directorate [18L0230015]
FX This research was supported by Ankara University Scientific Research
   Projects Directorate [Project number 18L0230015].
CR Antunes-Foschini RMS, 2018, ARQ BRAS OFTALMOL, V81, P401, DOI 10.5935/0004-2749.20180078
   Brussee T, 2018, OPTOMETRY VISION SCI, V95, P183, DOI 10.1097/OPX.0000000000001178
   Calabrese A, 2016, JAMA OPHTHALMOL, V134, P398, DOI 10.1001/jamaophthalmol.2015.6097
   Calabrese A, 2011, INVEST OPHTH VIS SCI, V52, P2417, DOI 10.1167/iovs.09-5056
   Chung STL, 1998, VISION RES, V38, P2949, DOI 10.1016/S0042-6989(98)00072-8
   Crossland MD, 2004, OPHTHAL PHYSL OPT, V24, P327, DOI 10.1111/j.1475-1313.2004.00213.x
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   Erbezci M, 2018, RETINA-J RET VIT DIS, V38, P2372, DOI 10.1097/IAE.0000000000001897
   Ergun E, 2003, OPHTHALMOLOGY, V110, P65, DOI 10.1016/S0161-6420(02)01566-X
   Finger RP, 2009, INVEST OPHTH VIS SCI, V50, P1366, DOI 10.1167/iovs.08-2032
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   Fletcher DC, 1999, J REHABIL RES DEV, V36, P356
   Fujii GY, 2003, AM J OPHTHALMOL, V136, P1067, DOI 10.1016/S0002-9394(03)00663-9
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1737, DOI 10.1016/S0161-6420(02)01120-X
   Giacomelli G, 2013, INVEST OPHTH VIS SCI, V54, P4403, DOI 10.1167/iovs.12-10734
   Greenstein VC, 2008, RETINA-J RET VIT DIS, V28, P1234, DOI 10.1097/IAE.0b013e31817c1b47
   Idil SA, 2011, TURK J MED SCI, V41, P565, DOI 10.3906/sag-1008-1
   KLEEN SR, 1981, AM J OPTOM PHYS OPT, V58, P200
   LEGGE GE, 1985, VISION RES, V25, P239, DOI 10.1016/0042-6989(85)90117-8
   Legge GE, 1997, VISION RES, V37, P1999, DOI 10.1016/S0042-6989(97)00017-5
   Legge GE, 2001, VISION RES, V41, P725, DOI 10.1016/S0042-6989(00)00295-9
   Markowitz SN, 2010, CAN J OPHTHALMOL, V45, P58, DOI 10.3129/i09-244
   Midena E, 2017, EYE, V31, P985, DOI 10.1038/eye.2017.34
   Molina-Martin A, 2018, SEMIN OPHTHALMOL, V33, P620, DOI 10.1080/08820538.2017.1375125
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   Ramrattan RS, 2001, ARCH OPHTHALMOL-CHIC, V119, P1788, DOI 10.1001/archopht.119.12.1788
   Rodriguez-Aranda C, 2003, CLIN NEUROPSYCHOL, V17, P203, DOI 10.1076/clin.17.2.203.16508
   Rodriguez-Galietero A, 2005, J CATARACT REFR SURG, V31, P1736, DOI 10.1016/j.jcrs.2005.02.039
   Schuchard RA, 2005, CAN J OPHTHALMOL, V40, P303, DOI 10.1016/S0008-4182(05)80073-0
   SCHUCHARD RA, 1994, OPHTHALMOLOGY CLIN N, V7, P243
   Sunness JS, 2005, AM J OPHTHALMOL, V140, P1085, DOI 10.1016/j.ajo.2005.07.040
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   Tarita-Nistor L, 2008, RETINA-J RET VIT DIS, V28, P125, DOI 10.1097/IAE.0b013e3180ed4571
   Tarita-Nistor L, 2009, VISUAL NEUROSCI, V26, P487, DOI 10.1017/S0952523809990265
   Toprak AB, 2005, OPHTHAL EPIDEMIOL, V12, P259, DOI 10.1080/09286580590967763
   Trauzettel-Klosinski S, 2011, DTSCH ARZTEBL INT, V108, P871, DOI 10.3238/arztebl.2011.0871
   Trauzettel-Klosinski S, 2010, J NEURO-OPHTHALMOL, V30, P73, DOI 10.1097/WNO.0b013e3181ce7e8f
   TrauzettelKlosinski S, 1997, NEURO-OPHTHALMOLOGY, V18, P117, DOI 10.3109/01658109709044129
   Verdina T, 2013, EUR J OPHTHALMOL, V23, P723, DOI 10.5301/ejo.5000291
   WHITE JM, 1990, INVEST OPHTH VIS SCI, V31, P1149
   WHITTAKER SG, 1993, OPTOMETRY VISION SCI, V70, P54, DOI 10.1097/00006324-199301000-00010
   2005, NIPPON GANKA GAKKAI, V109, P83
NR 42
TC 2
Z9 2
U1 2
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PY 2021
VL 46
IS 10
BP 1581
EP 1588
DI 10.1080/02713683.2021.1896740
EA MAR 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YZ2DH
UT WOS:000627629500001
PM 33632033
DA 2022-11-30
ER

PT J
AU Tode, J
   Richert, E
   Koinzer, S
   Klettner, A
   von der Burchard, C
   Brinkmann, R
   Lucius, R
   Roider, J
AF Tode, Jan
   Richert, Elisabeth
   Koinzer, Stefan
   Klettner, Alexa
   von der Burchard, Claus
   Brinkmann, Ralf
   Lucius, Ralph
   Roider, Johann
TI Selective Retina Therapy Reduces Bruch's Membrane Thickness and Retinal
   Pigment Epithelium Pathology in Age-Related Macular Degeneration Mouse
   Models
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE subthreshold laser therapy; selective retina therapy (SRT); drusen; RPE
   morphology; dry AMD
ID MATRIX METALLOPROTEINASES; PROPHYLACTIC TREATMENT; 810-NANOMETER LASER;
   SRT; NANOSECOND; DOSIMETRY; DRUSEN; CELLS; EYES; MICE
AB Purpose: To investigate the effect of selective retina therapy (SRT) on age-related macular degeneration (AMD)-like alterations of retinal pigment epithelium (RPE) and Bruch's membrane (BrM) in AMD mouse models as therapeutic approach for the treatment of dry AMD.
   Methods: In B6.129P2-Apoe(tm1Unc)/J (ApoE(-/-)) and B6.129X1-Nfe212(tm1Ywk)/J (NRF2(-/-)), one randomized eye of each mouse in groups of 15 mice was treated by SRT (532 nm, 300 ms, similar to 1.4-mu s pulse, 100 Hz, 50-mu m spot), the fellow eye and healthy C57BL/6J mice served as controls. Clinical examinations were obtained at treatment day and 1 month later, followed by enucleation to analyze BrM thickness and ultrastructural RPE morphology.
   Results: Nearly all ApoE(-/-) and NRF2(-/-) mice showed AMD-like retinal alterations. BrM thickness was increased in both mouse models, RPE had vacuoles within the cell body and shortened apical microvilli. SRT neither affected neuroretinal anatomy nor function. BrM thickness as well as AMD-like ultrastructural alterations of the RPE were significantly reduced in laser-treated eyes compared with fellow control and untreated control eyes.
   Conclusions: SRT reduces BrM thickness and AMD-like RPE alterations in AMD mouse models without damage to structural or functional properties of neuroretina. It may be a prophylactic or therapeutic option for dry AMD.
   Translational Relevance: SRT shows therapeutic effectivity in murine AMD models and might therefore become an option for the treatment of dry AMD.
C1 [Tode, Jan; Richert, Elisabeth; Koinzer, Stefan; Klettner, Alexa; von der Burchard, Claus; Roider, Johann] Christian Albrechts Univ Kiel, Univ Med Ctr, Dept Ophthalmol, Arnold Heller Str 3, D-24105 Kiel, Germany.
   [Brinkmann, Ralf] Univ Lubeck, Inst Biomed Opt, Peter Monnik Weg 4, Lubeck, Germany.
   [Brinkmann, Ralf] Med Laser Ctr Lubeck GmbH, Peter Monnik Weg 4, Lubeck, Germany.
   [Lucius, Ralph] Christian Albrechts Univ Kiel, Inst Anat, Olshausenstr 40, Kiel, Germany.
C3 University of Kiel; Schleswig Holstein University Hospital; University
   of Lubeck; University of Kiel
RP Tode, J (通讯作者)，Christian Albrechts Univ Kiel, Univ Med Ctr, Dept Ophthalmol, Arnold Heller Str 3, D-24105 Kiel, Germany.
EM jan.tode@uksh.de
RI Brinkmann, Ralf/HDL-7611-2022; Brinkmann, Ralf/E-6701-2012; von der
   Burchard, Claus/GZG-4104-2022
OI Brinkmann, Ralf/0000-0002-0445-8102; Klettner, Alexa/0000-0002-2709-1059
FU German Ministry of Education and Research (BMBF) [13GW0043D]
FX Supported by the German Ministry of Education and Research (BMBF) Grant
   13GW0043D.
CR Ahir A, 2002, INVEST OPHTH VIS SCI, V43, P458
   Aredo B, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-014-0221-4
   Brinkmann R, 2000, LASER SURG MED, V27, P451, DOI 10.1002/1096-9101(2000)27:5<451::AID-LSM1006>3.0.CO;2-1
   Brinkmann R, 2006, Bull Soc Belge Ophtalmol, P51
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Elsner H, 2006, GRAEF ARCH CLIN EXP, V244, P1638, DOI 10.1007/s00417-006-0368-5
   Evans JR, 2014, OPHTHAL PHYSL OPT, V34, P390, DOI 10.1111/opo.12142
   Friberg TR, 2009, OPHTHAL SURG LAS IM, V40, P530, DOI 10.3928/15428877-20091030-01
   Friberg TR, 2006, OPHTHALMOLOGY, V113, P612, DOI 10.1016/j.ophtha.2005.10.066
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Huang H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173716
   Jobling AI, 2015, FASEB J, V29, P696, DOI 10.1096/fj.14-262444
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   KATZ ML, 1984, EXP EYE RES, V38, P137, DOI 10.1016/0014-4835(84)90098-8
   Koinzer S, 2008, GRAEF ARCH CLIN EXP, V246, P1373, DOI 10.1007/s00417-008-0860-1
   Lavinsky D, 2016, INVEST OPHTH VIS SCI, V57, P2488, DOI 10.1167/iovs.15-18981
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Mehalow AK, 2003, HUM MOL GENET, V12, P2179, DOI 10.1093/hmg/ddg232
   Minhee K, 2018, GRAEF ARCH CLIN EXP, V256, P1639, DOI 10.1007/s00417-018-4067-9
   Neumann J, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1896969
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   Park YG, 2017, GRAEF ARCH CLIN EXP, V255, P1375, DOI 10.1007/s00417-017-3672-3
   Parodi MB, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub2
   Richert E, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.17-23163
   Richert E, 2015, INVEST OPHTH VIS SCI, V56
   Roider J, 1999, ARCH OPHTHALMOL-CHIC, V117, P1028
   ROIDER J, 1992, ARCH OPHTHALMOL-CHIC, V110, P1786, DOI 10.1001/archopht.1992.01080240126045
   Roider J, 2010, GRAEF ARCH CLIN EXP, V248, P1263, DOI 10.1007/s00417-010-1356-3
   Schrader WF, 2006, OPHTHALMOLOGE, V103, P742, DOI 10.1007/s00347-006-1418-4
   Schrodl F, 2001, EXP EYE RES, V72, P137, DOI 10.1006/exer.2000.0940
   Schuele G, 2005, J BIOMED OPT, V10, DOI 10.1117/1.2136327
   Seifert E, 2018, J BIOMED OPT, V23, DOI 10.1117/1.JBO.23.11.115002
   Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463
   Tode J, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.3.2
   Treumer F, 2012, EXP EYE RES, V97, P63, DOI 10.1016/j.exer.2012.02.011
   Vessey KA, 2012, INVEST OPHTH VIS SCI, V53, P7833, DOI 10.1167/iovs.12-10650
   WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P1310, DOI 10.1167/iovs.15-18682
   Yasui A, 2017, GRAEF ARCH CLIN EXP, V255, P243, DOI 10.1007/s00417-016-3441-8
   Zhao Z, 2001, PLOS ONE, V6
NR 42
TC 8
Z9 8
U1 2
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD NOV
PY 2019
VL 8
IS 6
AR 11
DI 10.1167/tvst.8.6.11
PG 18
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JV3YC
UT WOS:000502300800001
PM 31737435
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Qiu, S
   Wei, YT
   Zhou, XZ
   Jiang, ZX
   Zhang, T
   Jiang, XT
   Zhang, SC
AF Qiu, Suo
   Wei, Yantao
   Zhou, Xuezhi
   Jiang, Zhaoxin
   Zhang, Ting
   Jiang, Xintong
   Zhang, Shaochong
TI Intravitreal injection of docosahexaenoic acid attenuated photoreceptor
   cell injury in a NaIO3-induced age-related macular degeneration rat
   model
SO NEUROSCIENCE LETTERS
LA English
DT Article
DE Age-related macular degeneration; Docosahexaenoic acid; Intravitreal
   injection; Safety; Efficacy
ID RANDOMIZED CLINICAL-TRIAL; SPINAL-CORD; GENETIC SUSCEPTIBILITY;
   FATTY-ACIDS; LONG-CHAIN; SUPPLEMENTATION; OMEGA-3-FATTY-ACIDS; RETINA;
   BRAIN; PAIN
AB In most studies, the major supplement docosahexaenoic acid (DHA) is administered orally or intraperitoneally. In this study, we proposed to assess the safety and efficacy of the intravitreal injection of DHA in an age-related macular degeneration (AMD) rat model. Different concentrations of DHA were injected into the vitreous body. Histopathology and terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) analysis showed that there was no difference in thickness, observable structure, or apoptosis among the untreated, normal saline, and DHA groups (0.2,1.0, 5.0 and 10 mu g). However, GFAP expression was increased in the 10 mu g group. To investigate whether intravitreal injection of DHA could protect photoreceptors, we developed a NaIO3-induced retinal damage model in adult rats. Decreases in deformation and thickness were observed in the outer nuclear layer (ONL) after NaIO3 administration but were improved with DHA injection. The NaIO3 group showed a substantial reduction in the number of nuclei in ONL, whereas the DHA group showed an increase. Additionally, significant increases in SOD activity and Nrf2 expression were observed after DHA injection; GFAP and NF-KB expression levels were markedly decreased by DHA injection. Moreover, Western blotting showed that Bax, cleaved caspase-3 and CHOP were notably increased in the NaIO3 group but were significantly decreased by DHA injection. Collectively, intravitreal injection of DHA is safe and effective in select doses in a NaIO3-induced AMD rat model. The current results suggest that intravitreal injection of DHA may be a new avenue for the treatment of AMD. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Qiu, Suo; Wei, Yantao; Zhou, Xuezhi; Jiang, Zhaoxin; Zhang, Ting; Jiang, Xintong; Zhang, Shaochong] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Zhang, SC (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
EM zhshaochong@sohu.com
OI Zhou, Xuezhi/0000-0002-4501-1817
FU National Natural Science Foundation of China [81570865]
FX This survey was endorsed by the Fund for the National Natural Science
   Foundation of China (81570865). We thank Dr. Jingxuan Kang of the
   Laboratory for Lipid Medicine and Technology of Harvard Medical School
   for valuable suggestions regarding this project.
CR Bazan NG, 2006, TRENDS NEUROSCI, V29, P263, DOI 10.1016/j.tins.2006.03.005
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dolz-Marco R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096872
   Dyall SC, 2008, NEUROMOL MED, V10, P219, DOI 10.1007/s12017-008-8036-z
   Fang IM, 2014, MOL NUTR FOOD RES, V58, P2053, DOI 10.1002/mnfr.201400196
   Gao JQ, 2016, J NUTR BIOCHEM, V35, P87, DOI 10.1016/j.jnutbio.2016.07.003
   Gazaryan IG, 2016, NEURAL REGEN RES, V11, P1708, DOI 10.4103/1673-5374.194706
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gerstenblith AT, 2013, JAMA OPHTHALMOL, V131, P365, DOI 10.1001/jamaophthalmol.2013.642
   Harvey LD, 2015, ASN NEURO, V7, DOI 10.1177/1759091415618969
   Hoffman DR, 2014, JAMA OPHTHALMOL, V132, P866, DOI 10.1001/jamaophthalmol.2014.1634
   Lee TKM, 2010, CAN J OPHTHALMOL, V45, P514, DOI 10.3129/i10-028
   Lewis GP, 2003, INT REV CYTOL, V230, P263, DOI 10.1016/S0074-7696(03)30005-1
   Li F, 2001, J MOL NEUROSCI, V16, P205, DOI 10.1385/JMN:16:2-3:205
   Lien EL, 2009, PROSTAG LEUKOTR ESS, V81, P125, DOI 10.1016/j.plefa.2009.05.004
   Lim SN, 2013, EXP NEUROL, V239, P13, DOI 10.1016/j.expneurol.2012.09.015
   Liu AH, 2010, J LIPID RES, V51, P3217, DOI 10.1194/jlr.M007518
   Lu Y, 2013, NEUROSCIENCE, V241, P22, DOI 10.1016/j.neuroscience.2013.03.003
   Manzhulo IV, 2016, J NEUROIMMUNOL, V298, P90, DOI 10.1016/j.jneuroim.2016.07.015
   Munoz IG, 2005, PROTEIN SCI, V14, P387, DOI 10.1110/ps.04979505
   Nakamoto K, 2017, YAKUGAKU ZASSHI, V137, P199, DOI 10.1248/yakushi.16-00208
   Nandipati KC, 2017, MOL CELL BIOCHEM, V426, P27, DOI 10.1007/s11010-016-2878-8
   Naqshbandi A, 2013, HUM EXP TOXICOL, V32, P385, DOI 10.1177/0960327112438929
   Paterniti I, 2014, J NEUROINFLAMM, V11, DOI [10.1186/1742-2094-11-6, 10.1186/s12974-014-0136-0]
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   Rotstein NP, 2003, INVEST OPHTH VIS SCI, V44, P2252, DOI 10.1167/iovs.02-0901
   Sam MR, 2017, NUTR CANCER, V69, P64, DOI 10.1080/01635581.2017.1247884
   SCOTT BL, 1989, P NATL ACAD SCI USA, V86, P2903, DOI 10.1073/pnas.86.8.2903
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Wang JJ, 2014, OPHTHALMOLOGY, V121, P667, DOI 10.1016/j.ophtha.2013.10.017
   Zhang MJ, 2014, J NEUROSCI, V34, P1903, DOI 10.1523/JNEUROSCI.4043-13.2014
NR 33
TC 3
Z9 3
U1 3
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3940
EI 1872-7972
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD SEP 14
PY 2017
VL 657
BP 53
EP 61
DI 10.1016/j.neulet.2017.07.041
PG 9
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA FI3HQ
UT WOS:000411849000010
PM 28751206
DA 2022-11-30
ER

PT J
AU Bansback, N
   Davis, S
   Brazier, J
AF Bansback, N.
   Davis, S.
   Brazier, J.
TI Using contrast sensitivity to estimate the cost-effectiveness of
   verteporfin in patients with predominantly classic age-related macular
   degeneration
SO EYE
LA English
DT Review
DE verteporfin; photodynamic therapy; age related macular degeneration;
   economics; cost effectiveness; costs
ID PHOTODYNAMIC THERAPY; UTILITY; EYES
AB To re-evaluate the cost-effectiveness of photodynamic therapy with verteporfin (Visudyne (R), Novartis AG, Switzerland) in patients with predominantly classic and classic choroidal neovascularization (CNV) owing to age-related macular degeneration (AMD), using new evidence on the impact of contrast sensitivity on health status.
   Method A health economic model is used to synthesise the evidence on contrast sensitivity and treatment rates from the TAP Investigation with health state utilities and costs. Impairment of visual function is estimated using a Markov model to predict transitions between states of contrast sensitivity. Each state is associated with costs and a health state utility. Total expected costs and benefits for a cohort of patients over a defined number of cycles are calculated. The expected health state utility for each disease state was estimated using results from a study of 209 patients with AMD in Sheffield. The model includes the costs associated with treatment and monitoring in the verteporfin treatment arm and costs offset by delaying the deterioration of visual function.
   Results Beyond 3 years, the annual costs of the verteporfin arm are estimated to be less than the annual costs of the control arm, owing to the cost associated with higher blindness prevalence in the control arm. Over time, the results show that both the incremental utility and cost decreases. By 10 years, the estimated incremental cost-effectiveness is approximately 20 pound 996 per Quality-Adjusted Life Years.
   Conclusion The results of this study suggest that the verteporfin therapy in the treatment for patients with predominantly classic and classic CNV owing to AMD is encouraging.
C1 [Bansback, N.; Davis, S.; Brazier, J.] Univ Sheffield, ScHARR, Sheffield S1 4DA, S Yorkshire, England.
C3 University of Sheffield
RP Bansback, N (通讯作者)，Univ Sheffield, ScHARR, 30 Regent St, Sheffield S1 4DA, S Yorkshire, England.
EM n.j.bansback@sheffield.ac.uk
RI Davis, Sarah/A-2801-2010; brazier, john e/B-1936-2008
OI Brazier, John/0000-0001-8645-4780; Davis, Sarah/0000-0002-6609-4287;
   Bansback, Nick/0000-0002-1510-3462
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2003, EYE, V17, P717, DOI 10.1038/sj.eye.6700460
   BANSBACK N, 2006, QUAL LIFE RES
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Briggs A, 1998, PHARMACOECONOMICS, V13, P397, DOI 10.2165/00019053-199813040-00003
   Briggs AH, 2000, PHARMACOECONOMICS, V17, P479, DOI 10.2165/00019053-200017050-00006
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Drummond MF., 2015, METHODS EC EVALUATIO, V4
   Espallargues M, 2005, INVEST OPHTH VIS SCI, V46, P4016, DOI 10.1167/iovs.05-0072
   Faubert J, 2000, J AM GERIATR SOC, V48, P375, DOI 10.1111/j.1532-5415.2000.tb04693.x
   Feeny D, 2002, MED CARE, V40, P113, DOI 10.1097/00005650-200202000-00006
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Gold MR., 1996, COST EFFECTIVENESS H
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P982, DOI 10.1136/bjo.2003.039131
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Meads C, 2003, BRIT J OPHTHALMOL, V87, P1201, DOI 10.1136/bjo.87.10.1201
   Meads C, 2003, HEALTH TECHNOL ASSES, V7, p[v, 1], DOI [10.3310/hta7090, DOI 10.3310/hta7090]
   Mones J, 2005, EYE, V19, P1142, DOI 10.1038/sj.eye.6701717
   National Institute for Clinical Excellence, 2004, GUID METH TECHN APPR
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   RABIN J, 1995, OPHTHAL PHYSL OPT, V15, P45, DOI 10.1046/j.1475-1313.1995.9592791.x
   Rubin, 1989, OPHTHALMOL CLIN N AM, V2, P357
   Rubin GS, 2002, RETINA-J RET VIT DIS, V22, P536, DOI 10.1097/00006982-200210000-00002
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Smith DH, 2004, BRIT J OPHTHALMOL, V88, P1107, DOI 10.1136/bjo.2003.023986
   Valberg A, 2002, J OPT SOC AM A, V19, P223, DOI 10.1364/JOSAA.19.000223
   WINYARD S, 2004, 23 RNIB
NR 28
TC 22
Z9 22
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD DEC
PY 2007
VL 21
IS 12
BP 1455
EP 1463
DI 10.1038/sj.eye.6702636
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 240ZL
UT WOS:000251626600002
PM 17086167
OA Bronze
DA 2022-11-30
ER

PT J
AU Solomon, SD
   Jefferys, JL
   Hawkins, BS
   Bressler, NA
   Bressler, SB
AF Solomon, Sharon D.
   Jefferys, Joan L.
   Hawkins, Barbara S.
   Bressler, Neil A.
   Bressler, Susan B.
CA Submacular Surg Trials
TI RISK FACTORS FOR SECOND EYE PROGRESSION TO ADVANCED AGE-RELATED MACULAR
   DEGENERATION SST Report No. 21 Submacular Surgery Trials Research Group
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID POOLED FINDINGS
AB Objective: To identify characteristics predictive of progression to advanced age-related macular degeneration (AMD) in second (fellow) eyes of participants in the Submacular Surgery Trials (SST) who had unilateral neovascular AMD at study entry.
   Methods: Review of baseline fluorescein angiograms confirmed the absence of advanced AMD in 370 fellow eyes. All participants were eligible for 2 years of follow-up; follow-up angiograms of eyes at risk were evaluated to estimate incidence rates of advanced AMD. Baseline nonocular and ocular AMD characteristics were evaluated to identify those that predicted development of advanced AMD.
   Results: Of 110 eyes that progressed to advanced AMD, choroidal neovascularization (CNV) developed in 98 eyes and foveal geographic atrophy (GA) in 15 eyes. No nonocular characteristic (age, gender, history of hypertension or smoking) or ocular feature of the study eye at baseline (lesion composition, lesion size, or visual acuity) was predictive of progression to advanced AMD in this cohort. Multivariate analysis identified three baseline fellow eye ocular features that had a significant and independent relationship with progression to advanced AMD: drusen size, focal hyperpigmentation, and nonfoveal GA.
   Conclusion: Recognition of factors that predict advanced AMD in the second eye may identify those individuals at greater risk of progression so that treatment can be provided before vision is severely compromised. RETINA 29:1080-1090, 2009
C1 [Solomon, Sharon D.] Wilmer Eye Inst, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Solomon, SD (通讯作者)，Wilmer Eye Inst, 600 N Wolfe St,M-740, Baltimore, MD 21287 USA.
EM ssolomon1@jhmi.edu
FU National Eye Institute, National Institutes of Health; U.S. Department
   of Health and Human Services, Bethesda, Maryland [U10 EY11547, EY11557,
   EY11558]; Johns Hopkins University, Baltimore, Maryland; NATIONAL EYE
   INSTITUTE [U10EY011547, U10EY011557, U10EY011558] Funding Source: NIH
   RePORTER
FX The Submacular Surgery Trials were sponsored by the National Eye
   Institute, National Institutes of Health, U.S. Department of Health and
   Human Services, Bethesda, Maryland (cooperative agreements U 10 EY11547,
   EY11557, EY11558 with the Johns Hopkins University, Baltimore,
   Maryland). The Submacular Surgery Trials are registered at
   www.clinicaltrials.gov (NCT00000150).
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   [Anonymous], 2005, ARCH OPHTHALMOL-CHIC, V123, P1570, DOI DOI 10.1001/ARCHOPHT.123.11.1570
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   COX DR, 1972, J R STAT SOC B, V34, P187
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   *MAC PHOT STUD GRO, 1997, ARCH OPHTHALMOL-CHIC, V111, P741
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Submacular Surgery Trials Research Group, 2007, Arch Ophthalmol, V125, P1323
   Talic I, 2022, LEARN INSTR, V81, DOI [10.1016/j.learninstruc.2022.101594, 10.1016/j.ajo.2004.02.011]
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
NR 17
TC 24
Z9 24
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2009
VL 29
IS 8
BP 1080
EP 1090
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 497IG
UT WOS:000270051800005
PM 19734762
DA 2022-11-30
ER

PT J
AU Gu, H
   Sun, ED
   Cui, L
   Yang, XF
   Lim, A
   Xu, J
   Snellingen, T
   Liu, XP
   Wang, NL
   Liu, NP
AF Gu, Hong
   Sun, Erdan
   Cui, Lei
   Yang, Xiufen
   Lim, Apiradee
   Xu, Jun
   Snellingen, Torkel
   Liu, Xipu
   Wang, Ningli
   Liu, Ningpu
TI ASSOCIATION OF GLUTATHIONE S-TRANSFERASE PI ISOFORM SINGLE-NUCLEOTIDE
   POLYMORPHISMS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION IN A
   CHINESE POPULATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE pi isoform of glutathione S-transferase (GSTP1) gene; age-related
   macular degeneration; Chinese; single-nucleotide polymorphism
ID HUMAN RETINA; BINDING-PROTEIN; ZEAXANTHIN; LUTEIN; GSTP1; GENE; PIGMENT;
   RISK; M1; DISEASE
AB Purpose: To investigate the association between single-nucleotide polymorphisms in the pi isoform of glutathione S-transferase (GSTP1) gene and the risk of exudative age-related macular degeneration (AMD) in a Chinese case-control cohort.
   Methods: A total of 131 Chinese patients with exudative AMD and 138 control individuals were recruited. Genomic DNA was extracted from venous blood leukocytes. Two common nonsynonymous single-nucleotide polymorphisms in GSTP1 (rs1695 and rs1138272) were genotyped by polymerase chain reaction followed by allele-specific restriction enzyme digestion and direct sequencing.
   Results: Significant association with exudative AMD was detected for single-nucleotide polymorphism, rs1695 (P = 0.019). The risk G allele frequencies were 21.8% in AMD patients and 12.7% in control subjects (P = 0.007). Compared with the wild-type AA genotype, odds ratio for the risk of AMD was 1.91 (95% confidence interval, 1.09-3.35) for the heterozygous AG genotype and 2.52 (95% confidence interval, 0.6-10.61) for the homozygous GG genotype. In contrast, rs1138272 was not associated with exudative AMD (P = 1.00). The risk G allele frequencies of rs1138272 were 0.4% in AMD patients and 0.4% in control subjects (P = 1.00).
   Conclusion: Our data suggest that the GSTP1 variant rs1695 moderately increases the risk of exudative AMD. The variant rs1138272 was rare and was not associated with exudative AMD in this Chinese cohort. RETINA 32:1967-1972, 2012
C1 [Gu, Hong; Sun, Erdan; Cui, Lei; Yang, Xiufen; Xu, Jun; Wang, Ningli; Liu, Ningpu] Capital Med Univ, Beijing Tongren Eye Ctr, Beijing Tongren Hosp, Beijing Ophthalmol & Visual Sci Key Lab, Beijing 100730, Peoples R China.
   [Lim, Apiradee] Prince Songkla Univ, Dept Math & Comp Sci, Fac Sci & Technol, Pattani, Thailand.
   [Snellingen, Torkel; Liu, Xipu] Sekwa Eye Hosp, Beijing, Peoples R China.
   [Liu, Xipu] Tsinghua Univ, Dept Ophthalmol, Hosp 1, Beijing 100084, Peoples R China.
C3 Capital Medical University; Prince of Songkla University; Tsinghua
   University
RP Liu, NP (通讯作者)，Capital Med Univ, Beijing Tongren Eye Ctr, Beijing Tongren Hosp, Beijing Ophthalmol & Visual Sci Key Lab, 1 Dong Jiao Min Xiang, Beijing 100730, Peoples R China.
EM liuningpu@gmail.com
FU National Basic Research Program of China (973 Program) [2007CB512201];
   Beijing Education Commission [KZ201110025028]; National Natural Science
   Foundation of China [81070734]
FX Supported in part by the National Basic Research Program of China (973
   Program) Grant 2007CB512201, the Beijing Education Commission Grant
   KZ201110025028, and the National Natural Science Foundation of China
   Grant 81070734.
CR AliOsman F, 1997, J BIOL CHEM, V272, P10004
   Bernardini S, 2005, CLIN CHEM, V51, P944, DOI 10.1373/clinchem.2004.045955
   Bhosale P, 2005, BBA-MOL BASIS DIS, V1740, P116, DOI 10.1016/j.bbadis.2005.02.002
   Bhosale P, 2004, J BIOL CHEM, V279, P49447, DOI 10.1074/jbc.M405334200
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   Board PG, 1997, BIOCHEM J, V328, P929
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   BONE RA, 1992, METHOD ENZYMOL, V213, P360
   Cho HJ, 2005, J KOREAN MED SCI, V20, P1089, DOI 10.3346/jkms.2005.20.6.1089
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fryer AA, 2000, AM J RESP CRIT CARE, V161, P1437, DOI 10.1164/ajrccm.161.5.9903006
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Guven M, 2011, OPHTHALMIC RES, V46, P31, DOI 10.1159/000321940
   Henderson CJ, 1998, CHEM-BIOL INTERACT, V112, P69, DOI 10.1016/S0009-2797(97)00176-2
   Johansson AS, 1998, J MOL BIOL, V278, P687, DOI 10.1006/jmbi.1998.1708
   Juronen E, 2000, INVEST OPHTH VIS SCI, V41, P2262
   Kellen E, 2007, AM J EPIDEMIOL, V165, P1221, DOI 10.1093/aje/kwm003
   Kitteringham NR, 2007, BBA-GEN SUBJECTS, V1770, P1240, DOI 10.1016/j.bbagen.2007.05.001
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Moyer AM, 2008, CANCER RES, V68, P4791, DOI 10.1158/0008-5472.CAN-07-6724
   Mozaffarieh M, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-20
   Oz O, 2006, EUR J OPHTHALMOL, V16, P105
   R Development Core Team, 2020, R VERS 4 0 3 LANG EN
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   Robman L, 2007, CAN J OPHTHALMOL, V42, P720, DOI 10.3129/i07-116
   Trieschmann M, 2008, EYE, V22, P132, DOI 10.1038/sj.eye.6702780
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   Zhong SL, 2006, EUR J PHARM SCI, V28, P77, DOI 10.1016/j.ejps.2006.01.002
NR 29
TC 2
Z9 2
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2012
VL 32
IS 9
BP 1967
EP 1972
DI 10.1097/IAE.0b013e31824dae04
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 012EH
UT WOS:000309217800033
PM 22487578
DA 2022-11-30
ER

PT J
AU Singh, A
   Subhi, Y
   Nielsen, MK
   Falk, MK
   Matzen, SMH
   Sellebjerg, F
   Sorensen, TL
AF Singh, Amardeep
   Subhi, Yousif
   Nielsen, Marie Krogh
   Falk, Mads Kruger
   Matzen, Sara Maj Hyldig
   Sellebjerg, Finn
   Sorensen, Torben Lykke
TI Systemic frequencies of T helper 1 and T helper 17 cells in patients
   with age-related macular degeneration: A case-control study
SO SCIENTIFIC REPORTS
LA English
DT Article
ID TH17 CELLS; PERIPHERAL-BLOOD; IMMUNE CELLS; EXPRESSION; INFLAMMATION;
   ACTIVATION; DISEASE; MODEL; NEOVASCULARIZATION; PATHOGENESIS
AB Age-related macular degeneration (AMD) is a degenerative disease of the retina and a leading cause of irreversible vision loss. We investigated the systemic differences in the frequency of T helper (Th) 1 and Th17 cells in patients with non-exudative and exudative AMD and compared to age-matched controls. Flow cytometry was used to determine the systemic frequency of Th1 (CD4(+)CXCR3(+)IL12RB2(+)) and Th17 (CD4(+)CCR6(+)IL23R(+)) cells, and percentage of CD4(+) T-cells expressing CXCR3, IL12RB2, CCR6, IL23R, and co-expressing CXCR3 and CCR6. The frequency of Th1 cells and CXCR3(+)CD4(+) T-cells was lower in patients with exudative AMD. A significant age-dependent decrement in Th1 was observed in controls, but not in non-exudative or exudative AMD. This may be related to the CXCR3(+)CD4(+) T-cells, which showed similar pattern in controls, but not in non-exudative or exudative AMD. No significant group differences were observed for the frequency of Th17 cells. Correlation networks found several differences between controls and AMD. These data suggests the involvement of the adaptive immune system in AMD and supports the notion of AMD as a systemic disease. Our observations warrant further investigation into the role of the adaptive immune system in the pathogenesis of AMD.
C1 [Singh, Amardeep; Subhi, Yousif; Nielsen, Marie Krogh; Falk, Mads Kruger; Sorensen, Torben Lykke] Zealand Univ Hosp, Dept Ophthalmol, Clin Eye Res Unit, Roskilde, Denmark.
   [Singh, Amardeep] Skane Univ Hosp Malmo Lund, Dept Ophthalmol, Lund, Sweden.
   [Subhi, Yousif; Nielsen, Marie Krogh; Sellebjerg, Finn; Sorensen, Torben Lykke] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
   [Matzen, Sara Maj Hyldig] Zealand Univ Hosp, Dept Clin Biochem, Roskilde, Denmark.
   [Sellebjerg, Finn] Rigshosp, Natl Univ Hosp, Danish Multiple Sclerosis Ctr, Dept Neurol, Copenhagen, Denmark.
C3 Lund University; Skane University Hospital; University of Copenhagen;
   Rigshospitalet; University of Copenhagen
RP Sorensen, TL (通讯作者)，Zealand Univ Hosp, Dept Ophthalmol, Clin Eye Res Unit, Roskilde, Denmark.; Sorensen, TL (通讯作者)，Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
EM tlso@regionsjaelland.dk
RI Subhi, Yousif/ABG-6330-2020; Singh, Amardeep/ABI-4544-2020
OI Subhi, Yousif/0000-0001-6620-5365; Sellebjerg, Finn/0000-0002-1333-9623;
   Matzen, Sara/0000-0003-4213-3672; Krogh Nielsen,
   Marie/0000-0003-3804-7296
FU Region Zealand's Research Fund; Velux Foundation; Danish Eye Research
   Foundation; Fight for Sight Denmark; Beckett Foundation; Synoptik
   Foundation
FX This study was funded by Region Zealand's Research Fund, the Velux
   Foundation, the Danish Eye Research Foundation, Fight for Sight Denmark,
   the Beckett Foundation, and the Synoptik Foundation. The funding
   organizations had no role in the design or conduct of this research.
CR Ardeljan D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095900
   Browne TC, 2013, J IMMUNOL, V190, P2241, DOI 10.4049/jimmunol.1200947
   Burgisser P, 2007, CYTOM PART A, V71A, P632, DOI 10.1002/cyto.a.20414
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Chen M, 2010, INVEST OPHTH VIS SCI, V51, P5888, DOI 10.1167/iovs.09-5103
   Christensen JR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057820
   Cruz-Guilloty F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088201
   Damsker JM, 2010, ANN NY ACAD SCI, V1183, P211, DOI 10.1111/j.1749-6632.2009.05133.x
   Detrick B, 2010, IMMUNOL RES, V47, P153, DOI 10.1007/s12026-009-8146-1
   Dong C, 2011, EXP MOL MED, V43, P1, DOI 10.3858/emm.2011.43.1.007
   Ezzat MK, 2008, BRIT J OPHTHALMOL, V92, P976, DOI 10.1136/bjo.2007.129742
   Faber C, 2013, OPHTHALMOLOGY, V120, P2310, DOI 10.1016/j.ophtha.2013.04.014
   Falk MK, 2014, INVEST OPHTH VIS SCI, V55, P4050, DOI 10.1167/iovs.14-14107
   Falk MK, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-22
   Freedman ND, 2008, LANCET ONCOL, V9, P649, DOI 10.1016/S1470-2045(08)70154-2
   Haas P, 2011, AM J OPHTHALMOL, V152, P396, DOI 10.1016/j.ajo.2011.02.017
   Hasegawa E, 2013, J IMMUNOL, V190, P1778, DOI 10.4049/jimmunol.1202495
   Hata T, 2011, CARDIOVASC RES, V90, P364, DOI 10.1093/cvr/cvq397
   Hieshima K, 1997, J BIOL CHEM, V272, P5846, DOI 10.1074/jbc.272.9.5846
   Hirota K, 2007, J EXP MED, V204, P2803, DOI 10.1084/jem.20071397
   Jiang Kailun, 2013, J Clin Exp Ophthalmol, VSuppl 2, P0071
   Jonas JB, 2014, AM J OPHTHALMOL, V158, P808, DOI 10.1016/j.ajo.2014.06.012
   Korn T, 2007, SEMIN IMMUNOL, V19, P362, DOI 10.1016/j.smim.2007.10.007
   Lechner J, 2015, SCI REP-UK, V5, DOI 10.1038/srep16754
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Madelung CF, 2015, CLIN OPHTHALMOL, V9, DOI 10.2147/OPTH.S82116
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   ORSON FM, 1989, CELL IMMUNOL, V124, P278, DOI 10.1016/0008-8749(89)90131-7
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Reynolds AD, 2010, J IMMUNOL, V184, P2261, DOI 10.4049/jimmunol.0901852
   Rifai N, 2001, CLIN CHEM, V47, P403
   Rink L, 1998, MECH AGEING DEV, V102, P199, DOI 10.1016/S0047-6374(97)00153-X
   Rosas LE, 2005, EUR J IMMUNOL, V35, P515, DOI 10.1002/eji.200425422
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Singh A, 2013, OPHTHALMOLOGY, V120, P1029, DOI 10.1016/j.ophtha.2012.11.002
   Singh A, 2012, AM J OPHTHALMOL, V154, P193, DOI 10.1016/j.ajo.2012.01.036
   Subhi Y, 2017, ACTA OPHTHALMOL, V95, P472, DOI 10.1111/aos.13330
   Subhi Y, 2016, DAN MED J, V63
   Subhi Y, 2014, CLIN OPHTHALMOL, V8, P15, DOI 10.2147/OPTH.S55080
   Subhi Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091227
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yamazaki T, 2008, J IMMUNOL, V181, P8391, DOI 10.4049/jimmunol.181.12.8391
   Yates-Binder CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040812
   Zhang SR, 2015, INFLAMMATION, V38, P658, DOI 10.1007/s10753-014-9973-3
NR 51
TC 18
Z9 18
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD APR 4
PY 2017
VL 7
AR 605
DI 10.1038/s41598-017-00741-4
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EQ5ZU
UT WOS:000398162400016
PM 28377586
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Taipale, C
   Grzybowski, A
   Tuuminen, R
AF Taipale, Claudia
   Grzybowski, Andrzej
   Tuuminen, Raimo
TI Effect of cataract surgery on quality of life for patients with severe
   vision impairment due to age-related macular degeneration
SO ANNALS OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Age-related macular degeneration (AMD); cataract surgery; geographic
   atrophy (GA); vision impairment; vision-related quality of life
   (vision-related QoL)
ID VISUAL FUNCTION; OUTCOMES; ACUITY; EYES
AB Background: To determine whether patients with severe vision impairment due to advanced age-related macular degeneration (AMD) benefit from bilateral cataract surgery in terms of vision-related quality of life (QoL). Methods: A prospective interventional single-center study. Ten patients with severe vision impairment due to advanced bilateral AMD were included. The preoperative corrected distance visual acuity (CDVA) was >= 1.0/>= 1.0 LogMAR units on Snellen chart and <20/<20 points on Early Treatment Diabetic Retinopathy Study (ETDRS) chart. Patients were not on active treatment for wet AMD as the treatment was expected to have no effect or benefit. The patients were scheduled for immediate sequential bilateral cataract surgery, with target refraction emmetropia (SN60WF, Alcon). Vision-related QoL was measured with National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) preoperatively, at 3 months and 1 year. Results: The mean age of the patients was 82.56.2 years. The mean NEI VFQ-25 overall composite score changed from 44.0 +/- 7.1 preoperatively to 54.9 +/- 13.7 at 3 months and to 56.9 +/- 15.6 at 1 year (P=0.045, Friedman test). During the 1-year follow-up, there was an improvement in the subscale scores indicating difficulty with peripheral vision, mental health symptoms, and role difficulties due to vision (P<0.05 for all, Wilcoxon sign-rank test). Conclusions: Cataract surgery may improve the vision-related QoL in patients with severe vision impairment due to bilateral advanced AMD.
C1 [Taipale, Claudia; Tuuminen, Raimo] Univ Helsinki, Helsinki Retina Res Grp, Helsinki, Finland.
   [Taipale, Claudia] Helsinki Univ Hosp, Dept Ophthalmol, Helsinki, Finland.
   [Grzybowski, Andrzej] Univ Warmia & Mazury, Dept Ophthalmol, Olsztyn, Poland.
   [Grzybowski, Andrzej] Inst Res Ophthalmol, Fdn Ophthalmol Dev, Poznan, Poland.
   [Tuuminen, Raimo] Kymenlaakso Cent Hosp, Unit Ophthalmol, Kotkantie 41, FI-48210 Kotka, Finland.
C3 University of Helsinki; University of Helsinki; Helsinki University
   Central Hospital; University of Warmia & Mazury
RP Tuuminen, R (通讯作者)，Kymenlaakso Cent Hosp, Unit Ophthalmol, Kotkantie 41, FI-48210 Kotka, Finland.
EM raimo.tuuminen@helsinki.fi
RI Grzybowski, A/E-4486-2010
OI Grzybowski, A/0000-0002-3724-2391
FU Mary and Georg C. Ehrnrooth foundation; Sokeain Ystavatry; Finnish Eye
   Foundation; Finnish Medical Foundation; Finnish Ophthalmological
   Society; Ervald and Hilda Nissi Foundation; Paulo Foundation; Waldemar
   von Frenckell Foundation; HUS Specific Catchment Area (ERVA) Clinical
   Research Grants
FX The study was supported by grants from the Mary and Georg C. Ehrnrooth
   foundation, Sokeain Ystavatry, the Finnish Eye Foundation, Finnish
   Medical Foundation, Finnish Ophthalmological Society, Ervald and Hilda
   Nissi Foundation, the Paulo Foundation, the Waldemar von Frenckell
   Foundation and the HUS Specific Catchment Area (ERVA) Clinical Research
   Grants.
CR Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   Dag MY, 2019, EUR J OPHTHALMOL, V29, P615, DOI 10.1177/1120672118803831
   Danni R, 2019, AM J OPHTHALMOL, V198, P37, DOI 10.1016/j.ajo.2018.09.030
   El Mallah MK, 2001, OPTOMETRY VISION SCI, V78, P683, DOI 10.1097/00006324-200109000-00014
   Kanthan GL, 2011, CLIN EXP OPHTHALMOL, V39, P201, DOI 10.1111/j.1442-9071.2010.02440.x
   Kessel L, 2015, ACTA OPHTHALMOL, V93, P593, DOI 10.1111/aos.12665
   Lamoureux EL, 2011, CURR OPIN OPHTHALMOL, V22, P19, DOI 10.1097/ICU.0b013e3283414284
   Lundstrom M, 2002, BRIT J OPHTHALMOL, V86, P1330, DOI 10.1136/bjo.86.12.1330
   Lundstrom M, 2013, J CATARACT REFR SURG, V39, P673, DOI 10.1016/j.jcrs.2012.11.026
   Ma YY, 2015, J CATARACT REFR SURG, V41, P1248, DOI 10.1016/j.jcrs.2014.09.046
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Monestam E, 1999, J CATARACT REFR SURG, V25, P1127, DOI 10.1016/S0886-3350(99)00135-2
   Monestam E, 2012, J CATARACT REFR SURG, V38, P409, DOI 10.1016/j.jcrs.2011.09.041
   Pham TQ, 2007, EYE, V21, P324, DOI 10.1038/sj.eye.6702171
   Schulze-Bonsel K, 2006, INVEST OPHTH VIS SCI, V47, P1236, DOI 10.1167/iovs.05-0981
   Stock MV, 2015, INVEST OPHTH VIS SCI, V56, P2536, DOI 10.1167/iovs.14-16069
   Teh BL, 2017, SURV OPHTHALMOL, V62, P346, DOI 10.1016/j.survophthal.2016.12.003
   Thylefors B, 2002, OPHTHALMIC EPIDEMIOL, V9, P83, DOI 10.1076/opep.9.2.83.1523
   Tuuminen R, 2017, ACTA OPHTHALMOL, V95, DOI 10.1111/aos.13501
   World Health Organization, 2019, WORLD REP VIS
NR 21
TC 4
Z9 4
U1 0
U2 0
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2305-5839
EI 2305-5847
J9 ANN TRANSL MED
JI ANN. TRANSL. MED.
PD NOV
PY 2020
VL 8
IS 22
AR 1543
DI 10.21037/atm-2020-965
PG 7
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA PE4UL
UT WOS:000598361800002
PM 33313288
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Leandro, JE
   Beato, J
   Pedrosa, AC
   Pinheiro-Costa, J
   Falcao, M
   Falcao-Reis, F
   Carneiro, AM
AF Esteves Leandro, Joao
   Beato, Joao
   Pedrosa, Ana Catarina
   Pinheiro-Costa, Joao
   Falcao, Manuel
   Falcao-Reis, Fernando
   Carneiro, Angela M.
TI Clinical Characteristics of the Charles Bonnet Syndrome in Patients with
   Neovascular Age-Related Macular Degeneration: The Importance of Early
   Detection
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Charles Bonnet syndrome; Low vision;
   Negative outcome; Visual hallucinations
ID COMPLEX VISUAL HALLUCINATIONS; BONNET,CHARLES HALLUCINATIONS;
   PREVALENCE; ANATOMY
AB Purpose:We investigated the characteristics, prognosis, and clinical outcome of the Charles Bonnet syndrome (CBS) in patients with neovascular age-related macular degeneration (AMD).Methods:Five hundred psychiatrically healthy patients with neovascular AMD were screened for CBS. The individuals that fulfilled the inclusion criteria were systematically interviewed using a structured questionnaire that covered the impact, prognosis, risk factors, phenomenology, symptoms, and knowledge about the syndrome. A control group of 45 patients was used for comparison. Demographic data, current medication, and ocular risk factors were collected in all patients.Results:Forty-five patients with CBS were identified. The majority of patients reported images that consisted of colored (62%) animals (44%) or faces (42%) that lasted for seconds (53%). Most patients reported a self-limited disease with a median duration of symptoms between 9 and 11.5 months, with only 7% knowing about CBS at symptom onset. The degree of visual deficit did not predict the characteristics, complexity, frequency, duration, or impact of visual hallucinations. One-third of patients reported negative outcome, which was associated with shorter duration of CBS (p= 0.023), fear-inducing images (p< 0.001), and impact on daily activities (p= 0.015).Conclusion:The prevalence of CBS in neovascular AMD patients is high and clinically relevant. Patients with recent onset of visual hallucinations and describing fear-inducing images are at greater risk for negative outcome. Periodic screening may minimize the negative consequences of this disease.
C1 [Esteves Leandro, Joao; Beato, Joao; Pedrosa, Ana Catarina; Pinheiro-Costa, Joao; Falcao, Manuel; Falcao-Reis, Fernando; Carneiro, Angela M.] Sao Joao Hosp, Dept Ophthalmol, Ave Prof Hernani Monteiro, P-4202451 Porto, Portugal.
   [Beato, Joao; Falcao, Manuel; Falcao-Reis, Fernando; Carneiro, Angela M.] Univ Porto, Dept Surg & Physiol, Fac Med, Porto, Portugal.
   [Pinheiro-Costa, Joao] Univ Porto, Dept Anat, Fac Med, Porto, Portugal.
C3 Sao Joao Hospital; Universidade do Porto; Universidade do Porto
RP Leandro, JE (通讯作者)，Sao Joao Hosp, Dept Ophthalmol, Ave Prof Hernani Monteiro, P-4202451 Porto, Portugal.
EM joaoedpl@gmail.com
OI Beato, Joao/0000-0003-3820-4597; Falcao, Manuel/0000-0003-4718-0910
CR Abbou EJ, 2007, INVEST OPHTH VIS SCI, V48, P1416, DOI 10.1167/iovs.06-0942
   BROWN GC, 1992, ARCH OPHTHALMOL-CHIC, V110, P1251, DOI 10.1001/archopht.1992.01080210069027
   Burke W, 2002, J NEUROL NEUROSUR PS, V73, P535, DOI 10.1136/jnnp.73.5.535
   COLE MG, 1992, CAN J PSYCHIAT, V37, P267, DOI 10.1177/070674379203700411
   Cox TM, 2014, BRIT J OPHTHALMOL, V98, P1236, DOI 10.1136/bjophthalmol-2014-304920
   DAMASMORA J, 1982, PSYCHOL MED, V12, P251, DOI 10.1017/S0033291700046584
   Ffytche DH, 1998, NAT NEUROSCI, V1, P738, DOI 10.1038/3738
   Fraunfelder F, 2008, INDEX SIDE EFFECTS A, P315
   GOLD K, 1989, COMPR PSYCHIAT, V30, P90, DOI 10.1016/0010-440X(89)90122-3
   Hanneken AM, 2013, INVEST OPHTH VIS SCI, V54, P1485, DOI 10.1167/iovs.12-11091
   Hartney KE, 2011, J PSYCHIATR PRACT, V17, P137, DOI 10.1097/01.pra.0000396067.87343.fb
   Hedges TR, 2007, SURV OPHTHALMOL, V52, P111, DOI 10.1016/j.survophthal.2006.10.007
   Holroyd S, 1996, J NERV MENT DIS, V184, P188, DOI 10.1097/00005053-199603000-00008
   HOLROYD S, 1994, J NERV MENT DIS, V182, P273, DOI 10.1097/00005053-199405000-00004
   HOLROYD S, 1992, AM J PSYCHIAT, V149, P1701
   Jackson ML, 2010, EYE, V24, P1303, DOI 10.1038/eye.2010.12
   Khan JC, 2008, OPHTHAL EPIDEMIOL, V15, P202, DOI 10.1080/09286580801939320
   KOLMEL HW, 1985, J NEUROL NEUROSUR PS, V48, P29, DOI 10.1136/jnnp.48.1.29
   Lannon SP, 2006, VIS IMPAIR RES, V8, P9, DOI DOI 10.1080/13882350600805761
   Leandro JE, 2017, INVEST OPHTH VIS SCI, V58, P4138, DOI 10.1167/iovs.16-21270
   Menon GJ, 2003, SURV OPHTHALMOL, V48, P58, DOI 10.1016/S0039-6257(02)00414-9
   Meyer CH, 2007, AM J OPHTHALMOL, V143, P169, DOI 10.1016/j.ajo.2006.08.003
   Nesher R, 2001, J GLAUCOMA, V10, P396, DOI 10.1097/00061198-200110000-00006
   PODOLL K, 1989, FORTSCHR NEUROL PSYC, V57, P43, DOI 10.1055/s-2007-1000744
   Santhouse AM, 2000, BRAIN, V123, P2055, DOI 10.1093/brain/123.10.2055
   Santos-Bueso E, 2015, REV NEUROLOGIA, V60, P337, DOI 10.33588/rn.6008.2014542
   Santos-Bueso E, 2014, EUR J OPHTHALMOL, V24, P960, DOI 10.5301/ejo.5000483
   Teunisse RJ, 1999, COMPR PSYCHIAT, V40, P315, DOI 10.1016/S0010-440X(99)90133-5
   Teunisse RJ, 1996, LANCET, V347, P794, DOI 10.1016/S0140-6736(96)90869-7
   TEUNISSE RJ, 1994, COMPR PSYCHIAT, V35, P70, DOI 10.1016/0010-440X(94)90172-4
   Vandenbroucke JP, 2007, EPIDEMIOLOGY, V18, P805, DOI 10.1097/EDE.0b013e3181577511
   Vukicevic M, 2008, CLIN EXP OPHTHALMOL, V36, P659, DOI [10.1111/j.1442-9071.2008.01814.x, 10.1111/j.1442-9071.2008.01864.x]
NR 32
TC 2
Z9 2
U1 0
U2 6
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PD AUG
PY 2020
VL 63
IS 5
BP 466
EP 473
DI 10.1159/000506137
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA ND5TM
UT WOS:000561962200004
PM 31986513
DA 2022-11-30
ER

PT J
AU Ulusoy, MO
   Kal, A
   Yilmaz, G
AF Ulusoy, Mahmut Oguz
   Kal, Ali
   Yilmaz, Gursel
TI Comparison of the effects of anti-vascular endothelial growth factor
   treatments on pigment epithelial detachment in age-related macular
   degeneration
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Pigment epithelial detachment;
   Anti-VEGF; Ranibizumab; Aflibercept
AB Purpose The aim of this study is to compare structural and visual outcomes of naive neovascular age-related macular degeneration patients with significant pigment epithelial detachment (PED), treated with ranibizumab and aflibercept. Methods This was a retrospective case series that included 33 naive patients treated with ranibizumab and 25 with aflibercept. The patients were followed with pro re nata (PRN) after first three intravitreal injections. LogMAR visual acuity, PED height and radius on spectral domain optical coherence tomography findings were compared. Results Baseline mean PED height was 270.39 +/- 114.14 mu m and 315.24 +/- 115.8 mu m (p = 0.14); baseline mean PED radius was 2063.64 +/- 942.75 mu m and 1958.88 +/- 452.22 mu m (p = 0.61); and baseline BCVA was 1.16 +/- 0.73 and 1.09 +/- 0.69 (p = 0.73), for ranibizumab, and aflibercept group, respectively. In aflibercept group, there was statistically significant decrease in PED height at first, third and 12th months. In PED radius, decrease was greater in aflibercept group, however not significant. In addition, in aflibercept group visual acuity was better at all three months; however, none of them were significant. Conclusion Although the maximum improvement was seen at third month, final visual acuity and parameters of PED were better in aflibercept group. The efficacy of the both drug to choroidal neovascularization was known; however, in cases with significant PED, aflibercept can be consider for the first-level treatment.
C1 [Ulusoy, Mahmut Oguz; Kal, Ali] Baskent Univ, Dept Ophthalmol, Sch Med, Konya Res Hosp, TR-42000 Konya, Turkey.
   [Yilmaz, Gursel] Baskent Univ, Dept Ophthalmol, Sch Med, Ankara, Turkey.
C3 Baskent University; Konya Egitim Training & Research Hospital; Baskent
   University
RP Ulusoy, MO (通讯作者)，Baskent Univ, Dept Ophthalmol, Sch Med, Konya Res Hosp, TR-42000 Konya, Turkey.
EM drmoguz@gmail.com
RI Kal, Ali/AAJ-4936-2021; Yılmaz, Gürsel/AAK-6987-2021
OI Kal, Ali/0000-0001-7544-5790; Yılmaz, Gürsel/0000-0002-2589-7294
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Au A, 2017, BRIT J OPHTHALMOL, V101, P970, DOI 10.1136/bjophthalmol-2016-309434
   Balaskas K, 2017, RETINA-J RET VIT DIS, V37, P1297, DOI 10.1097/IAE.0000000000001342
   Branchini L, 2012, OPHTHALMOLOGY, V119, P119, DOI 10.1016/j.ophtha.2011.07.002
   Broadhead GK, 2015, RETINA-J RET VIT DIS, V35, P975, DOI 10.1097/IAE.0000000000000409
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cho HJ, 2016, AM J OPHTHALMOL, V166, P112, DOI 10.1016/j.ajo.2016.03.039
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   De Massougnes S, 2016, RETINA-J RET VIT DIS, V36, P881, DOI 10.1097/IAE.0000000000000813
   Dirani A, 2015, AM J OPHTHALMOL, V160, P732, DOI 10.1016/j.ajo.2015.06.025
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gess AJ, 2011, SEMIN OPHTHALMOL, V26, P225, DOI 10.3109/08820538.2011.582533
   Kalouda P, 2015, SEMIN OPHTHALMOL, V30, P6, DOI 10.3109/08820538.2013.807852
   Kocak I, 2017, INT OPHTHALMOL, V37, P531, DOI 10.1007/s10792-016-0294-4
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2141, DOI 10.1016/j.ophtha.2009.04.030
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Patel KH, 2013, EYE, V27, P664, DOI 10.1038/eye.2013.31
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   POLINER LS, 1986, OPHTHALMOLOGY, V93, P543
   Punjabi OS, 2013, BRIT J OPHTHALMOL, V97, P1024, DOI 10.1136/bjophthalmol-2013-303155
   Ritter M, 2010, EYE, V24, P962, DOI 10.1038/eye.2009.265
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarraf D, 2016, OPHTHALMOLOGY, V123, P2213, DOI 10.1016/j.ophtha.2016.07.007
   Tozer K, 2013, OPHTHALMOLOGY, V120, P2029, DOI 10.1016/j.ophtha.2013.03.016
   Veritti D, 2013, OPHTHALMOLOGICA, V230, P131, DOI 10.1159/000351651
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
NR 28
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD APR
PY 2021
VL 41
IS 4
BP 1363
EP 1372
DI 10.1007/s10792-021-01695-3
EA JAN 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RK9JZ
UT WOS:000610007800002
PM 33481151
DA 2022-11-30
ER

PT J
AU Chatziralli, I
   Regan, SO
   Mohamed, R
   Talks, J
   Sivaprasad, S
AF Chatziralli, Irini
   Regan, Shane O.
   Mohamed, Ryian
   Talks, James
   Sivaprasad, Sobha
CA UK Aflibercept Users Grp
TI Intravitreal aflibercept for neovascular age-related macular
   degeneration in patients aged 90 years or older: 2-year visual acuity
   outcomes
SO EYE
LA English
DT Article
ID RANIBIZUMAB; DISEASE; EYE
AB Purpose The purpose of this study was to investigate the efficacy of intravitreal aflibercept for neovascular age-related macular degeneration (nAMD) in very elderly patients aged 90 years or older at 2 years after treatment initiation.
   Methods In this multicentre retrospective data analysis from electronic medical record, consecutive treatment-naive patients with nAMD treated with aflibercept with at least 2 years follow-up were stratified into those aged < 90 years (Group I) and an older cohort aged 90 and over (Group II). We compared the visual acuity (EDTRS letters) outcomes at 4 weekly intervals between the two groups over a 2-year period.
   Results The mean visual acuity of Group I at presentation was 56.3 ETDRS letters versus 52.8 letters in Group II. Maximal visual acuity was achieved in both the groups by 6 months after initiating treatment (4.7 vs. 4.0 letters gain). By 2 years, the mean visual acuity of the older cohort fell marginally below their baseline visual acuity (0.8 letter loss), while Group I presented +2.1 letters gain. The number of injections given and the retention rate of the older cohort were no different to the rest of the patients.
   Conclusions Very old patients with nAMD benefited from aflibercept, but not to the same degree as the younger patients. The study showed that, on an average, the very elderly patients were able to adhere to the intensive anti-VEGF treatment regimens.
C1 [Chatziralli, Irini; Sivaprasad, Sobha] Moorfields Eye Hosp Natl Hlth Serv Fdn Trust, Natl Inst Hlth Res, Biomed Res Ctr, London, England.
   [Regan, Shane O.] Univ Hosp Limerick, Limerick, Ireland.
   [Mohamed, Ryian] Univ Coll London Hosp NHS Trust, London, England.
   [Talks, James] Newcastle Upon Tyne Hosp Fdn NHS Trust, Newcastle Upon Tyne, Tyne & Wear, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of Limerick; University College London
   Hospitals NHS Foundation Trust; University of London; University College
   London; Newcastle Upon Tyne Hospitals NHS Foundation Trust
RP Sivaprasad, S (通讯作者)，Moorfields Eye Hosp Natl Hlth Serv Fdn Trust, Natl Inst Hlth Res, Biomed Res Ctr, London, England.
EM senswathi@aol.com
RI Mohamed, Ryian/L-9132-2019; Sivaprasad, S./D-6876-2015; Chatziralli,
   Irini/AAG-4779-2020
OI Mohamed, Ryian/0000-0001-8555-4659; Sivaprasad, S./0000-0001-8952-0659;
   Chatziralli, Irini/0000-0001-8523-1024; Talks, James/0000-0001-6126-6476
FU Bayer; Allergan; Novartis
FX Irini Chatziralli, James Talks and Sobha Sivaprasad have received travel
   grants, research grants and speaker fees, and attended advisory board
   meetings of Bayer, Allergan and Novartis. The remaining authors declare
   that they have no conflict of interest.
CR Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Bunce C, 2010, EYE, V24, P1692, DOI 10.1038/eye.2010.122
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Myall DJ, 2017, PARKINSONISM RELAT D, V42, P78, DOI 10.1016/j.parkreldis.2017.06.018
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Pushpoth S, 2012, BRIT J OPHTHALMOL, V96, P1469, DOI 10.1136/bjophthalmol-2012-302167
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
NR 16
TC 3
Z9 4
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD SEP
PY 2018
VL 32
IS 9
BP 1523
EP 1529
DI 10.1038/s41433-018-0114-3
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GT3MQ
UT WOS:000444407600016
PM 29867156
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Zvi, D
   Zur, D
   Schwartz, S
   Cohen, S
   Saranga, A
   Loewenstein, A
   Goldstein, M
AF Zvi, Dana
   Zur, Dinah
   Schwartz, Shula
   Cohen, Shai
   Saranga, Avi
   Loewenstein, Anat
   Goldstein, Michaella
TI Additive Value of a Face-to-Face Visit to Virtual Remote Decision in
   Patients with Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Management; Optical coherence
   tomography; Ophthalmology; Telemedicine; Virtual evaluation
ID TREAT-AND-EXTEND; RANIBIZUMAB; TELEMEDICINE; BEVACIZUMAB; REGIMENS;
   EFFICACY; CLINICS; SAFETY
AB Introduction: The increasing high prevalence of neovascular age-related macular degeneration (nvAMD) in the aging population combined with the need for frequent monitoring and treatment for many years, especially in the COVID-19 era, raises the need to establish an effective, reliable, and safe follow-up and treatment model. This study evaluates the difference in treatment decisions comparing between the gold standard face-to-face clinical examination and virtual evaluation approach based only on visual acuity (VA) and optical coherence tomography (OCT) scans without clinical fundoscopic examination in nvAMD patients. Methods: A single-center retrospective cohort study was conducted that compared an original "face-to-face" visit treatment decision regarding the need for anti-vascular endothelial growth factor drug, interval, and treatment regimen based on routine VA, spectral domain OCT imaging, and dilated fundus examination to two "virtual" treatment decisions based on evaluation of OCT scans and previous medical records before and after revealing VA data on the same nvAMD patients eyes. Results: About 169 eyes of 114 patients were included in the study. Forty-nine patients (43%) suffered from bilateral nvAMD and had both eyes included in the study. Agreement between the "face-to-face visit treatment decision" and "virtual treatment decision" was noted in 74.6% and 71.6% eyes before and after revealing the patient's VA in the study visit, respectively. Conclusions: Virtual evaluation results in similar treatment decisions for nvAMD patients compared to standard face-to-face clinical examination.
C1 [Zvi, Dana; Zur, Dinah; Schwartz, Shula; Cohen, Shai; Saranga, Avi; Loewenstein, Anat; Goldstein, Michaella] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Med Ctr, Div Ophthalmol, Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine
RP Zvi, D (通讯作者)，Tel Aviv Univ, Sackler Fac Med, Tel Aviv Med Ctr, Div Ophthalmol, Tel Aviv, Israel.
EM lobermand@gmail.com
RI Meyer, Carsten/A-3981-2017
OI Meyer, Carsten/0000-0002-0530-5298
CR Adelman RA, 2010, J OCUL PHARMACOL TH, V26, P105, DOI 10.1089/jop.2009.0076
   Andonegui J, 2016, RETINA-J RET VIT DIS, V36, P279, DOI 10.1097/IAE.0000000000000729
   Aweidah H, 2020, CLIN OPHTHALMOL, V14, P3421, DOI 10.2147/OPTH.S276276
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Brady CJ, 2020, TELEMED E-HEALTH, V26, P565, DOI 10.1089/tmj.2020.0011
   Clarke J, 2017, BRIT J OPHTHALMOL, V101, P892, DOI 10.1136/bjophthalmol-2016-308993
   Corradetti G, 2020, OPHTHALMOL RETINA, V4, P757, DOI 10.1016/j.oret.2020.05.015
   Fierson WM, 2015, PEDIATRICS, V135, pE238, DOI 10.1542/peds.2014-0978
   Hadziahmetovic M, 2019, JAMA OPHTHALMOL, V137, P802, DOI 10.1001/jamaophthalmol.2019.1203
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Jani PD, 2017, JAMA OPHTHALMOL, V135, P706, DOI 10.1001/jamaophthalmol.2017.1150
   Kang SJ, 2020, INFECT CHEMOTHER, V52, P154, DOI 10.3947/ic.2020.52.2.154
   Li B, 2015, JAMA OPHTHALMOL, V133, P276, DOI 10.1001/jamaophthalmol.2014.5014
   Li JPO, 2021, PROG RETIN EYE RES, V82, DOI 10.1016/j.preteyeres.2020.100900
   Mammo DA, 2020, OPHTHALMOL RETINA, V4, P973, DOI 10.1016/j.oret.2020.03.028
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McNabb RP, 2016, BRIT J OPHTHALMOL, V100, P1377, DOI 10.1136/bjophthalmol-2015-307480
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Patel Y, 2020, OPHTHALMOL RETINA, V4, P141, DOI 10.1016/j.oret.2019.09.006
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Querques G, 2011, AM J OPHTHALMOL, V152, P100, DOI 10.1016/j.ajo.2011.01.027
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Sommer AC, 2020, GRAEF ARCH CLIN EXP, V258, P2341, DOI 10.1007/s00417-020-04879-2
   Starr MR, 2019, AM J OPHTHALMOL, V208, P206, DOI 10.1016/j.ajo.2019.03.021
   Trivizki O, 2020, AM J OPHTHALMOL, V219, P222, DOI 10.1016/j.ajo.2020.06.028
   Tsaousis KT, 2016, ACTA OPHTHALMOL, V94, pe353, DOI 10.1111/aos.12832
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 29
TC 0
Z9 0
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD AUG
PY 2022
VL 245
IS 4
BP 385
EP 392
DI 10.1159/000522273
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3N5ZL
UT WOS:000836226400010
PM 35114671
OA hybrid
DA 2022-11-30
ER

PT J
AU Arf, S
   Muslubas, IS
   Hocaoglu, M
   Ersoz, MG
   Karacorlu, M
AF Arf, Serra
   Muslubas, Isil Sayman
   Hocaoglu, Mumin
   Ersoz, Mehmet Giray
   Karacorlu, Murat
TI Features of neovascularization in pachychoroid neovasculopathy compared
   with type 1 neovascular age-related macular degeneration on optical
   coherence tomography angiography
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Pachychoroid neovasculopathy; Type 1 neovascularization; Exudative
   age-related macular degeneration; Optical coherence tomography
   angiography
ID CENTRAL SEROUS CHORIORETINOPATHY; CHOROIDAL NEOVASCULARIZATION
AB Purpose To compare neovascular membrane features of pachychoroid neovasculopathy (PNV) and type 1 neovascular age-related macular degeneration (nAMD) using optical coherence tomography angiography (OCTA). Design Retrospective study. Methods We assessed 34 treatment-naive eyes with a diagnosis of PNV and 36 treatment-naive eyes with a diagnosis of type 1 nAMD. Morphological patterns of neovascular membranes were categorized, and lesion sizes and flow areas were calculated by using en face images on the AngioVue (Optovue) OCTA system. Results Statistically significant differences were found between groups in age (P=0.001), baseline best corrected visual acuity (P=0.005), and baseline subfoveal choroidal thickness (P<0.001). However, there were no statistically significant differences in membrane morphology (P=0.86), lesion size (P=0.80), or flow area (P=0.96). All membranes that could be detected by OCTA could also be detected by indocyanine green angiography (ICGA). However, OCTA could not identify the neovascularization in 11.8% of the eyes with PNV and 16.7% of the eyes with nAMD, which could be identified on ICGA images. Conclusions PNV is seen in younger patients and in patients with thicker choroids, but in terms of morphological characteristics and vessel density, membranes detected by OCTA are not different from those of nAMD. Dye angiography remains the gold standard for identifying neovascularization, especially in treatment-naive patients, owing to blockage of fluid and hemorrhage and scattering of OCTA signals.
C1 [Arf, Serra; Muslubas, Isil Sayman; Hocaoglu, Mumin; Ersoz, Mehmet Giray; Karacorlu, Murat] Istanbul Retina Inst, Unimed Ctr 19-7, TR-34349 Istanbul, Turkey.
C3 Istanbul Retina Enstitusu
RP Karacorlu, M (通讯作者)，Istanbul Retina Inst, Unimed Ctr 19-7, TR-34349 Istanbul, Turkey.
EM mkaracorlu@gmail.com
RI Karaçorlu, Murat/AFK-0782-2022; Karaçorlu, Murat/AAF-7763-2022
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Bonini MA, 2015, JAMA OPHTHALMOL, V133, P899, DOI 10.1001/jamaophthalmol.2015.1320
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Dansingani KK, 2016, OPHTHALMOLOGY, V123, P2628, DOI 10.1016/j.ophtha.2016.06.060
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   Ersoz MG, 2018, RETINA-J RET VIT DIS, V38, P1668, DOI 10.1097/IAE.0000000000001773
   Faridi A, 2017, OPHTHALMOL RETINA, V1, P294, DOI 10.1016/j.oret.2017.02.007
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Hata M, 2017, INVEST OPHTH VIS SCI, V58, P292, DOI 10.1167/iovs.16-20967
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Karacorlu M, 2019, EYE, V33, P1280, DOI 10.1038/s41433-019-0415-1
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lupidi M, 2018, EUR J OPHTHALMOL, V28, P349, DOI 10.1177/1120672118766807
   Matsumoto H, 2018, JPN J OPHTHALMOL, V62, P144, DOI 10.1007/s10384-018-0562-0
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Terao N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28484-w
NR 21
TC 8
Z9 8
U1 0
U2 2
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD MAY
PY 2020
VL 64
IS 3
BP 257
EP 264
DI 10.1007/s10384-020-00730-7
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LP4QN
UT WOS:000534303800004
PM 32157483
DA 2022-11-30
ER

PT J
AU Sakalar, YB
   Senturk, S
   Yildirim, M
   Keklikci, U
   Alakus, MF
   Unlu, K
AF Sakalar, Yildirim Bayezit
   Senturk, Senem
   Yildirim, Mine
   Keklikci, Ugur
   Alakus, Mehmet Fuat
   Unlu, Kaan
TI Evaluation of retrobulbar blood flow by color doppler ultrasonography
   after intravitreal ranibizumab injection in patients with neovascular
   age-related macular degeneration
SO JOURNAL OF CLINICAL ULTRASOUND
LA English
DT Article
DE color Doppler ultrasonography; retrobulbar blood flow; age-related
   macular degeneration; ranibizumab; eye
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RANDOMIZED CLINICAL-TRIALS;
   ENDOTHELIAL GROWTH-FACTOR; BEVACIZUMAB AVASTIN(R); RETINAL ARTERY;
   MACULOPATHY; EYE; PHARMACOKINETICS; PREVALENCE; THERAPY
AB Purpose. This study aimed to evaluate the changes in retrobulbar blood flow by using color Doppler sonography in patients who had undergone intravitreal ranibizumab injection for neovascular age-related macular degeneration (AMD). Methods. The study comprised 37 AMD patients who had undergone intravitreal 0.5 mg ranibizumab injection. The ophthalmic artery, central retinal artery, and short lateral posterior ciliary artery of both eyes of patients were evaluated by color Doppler sonography. Peak systolic velocity, end-diastolic velocity, and resistance index were calculated before injection, and after injection on day 7 and day 30. The pre- and postinjection values were compared using Wilcoxon signed rank test. Results. In a comparison with the preinjection values of peak systolic velocity, end-diastolic velocity, and resistance index, the postinjection values at both day 7 and day 30 showed no statistically significant difference in ophthalmic artery, lateral posterior ciliary artery, and central retinal artery (p > 0.05). Similarly, for the same parameters, pre- and postinjection values in the uninjected fellow eye showed no statistically significant difference (P > 0.05). Conclusions. Intravitreal ranibizumab injection for neovascular AMD does not cause a significant change in the retrobulbar blood flow in either the injected eye or the fellow eye. (C) 2012 Wiley Periodicals, Inc. J Clin Ultrasound 2013; Published online in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/jcu.21989
C1 [Senturk, Senem] Istanbul Medeniyet Univ, Goztepe Educ & Res Hosp, Dept Radiol, Istanbul, Turkey.
   [Sakalar, Yildirim Bayezit; Yildirim, Mine; Keklikci, Ugur; Alakus, Mehmet Fuat; Unlu, Kaan] Dicle Univ, Fac Med, Dept Ophthalmol, Diyarbakir, Turkey.
C3 Istanbul Goztepe Training and Research Hospital; Istanbul Medeniyet
   University; Dicle University
RP Senturk, S (通讯作者)，Istanbul Medeniyet Univ, Goztepe Educ & Res Hosp, Dept Radiol, Istanbul, Turkey.
CR Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bonnin P, 2010, ACTA OPHTHALMOL, V88, P641, DOI 10.1111/j.1755-3768.2009.01526.x
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cekic Osman, 2007, International Ophthalmology, V27, P313, DOI 10.1007/s10792-007-9080-7
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Dimitrova G, 2002, EYE, V16, P580, DOI 10.1038/sj.eye.6700161
   Dimitrova G, 2010, SURV OPHTHALMOL, V55, P193, DOI 10.1016/j.survophthal.2009.06.010
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   GRANT EG, 1989, AM J ROENTGENOL, V152, P707, DOI 10.2214/ajr.152.4.707
   GUTHOFF RF, 1991, ARCH OPHTHALMOL-CHIC, V109, P532, DOI 10.1001/archopht.1991.01080040100037
   Harris A, 2000, ARCH OPHTHALMOL-CHIC, V118, P1076, DOI 10.1001/archopht.118.8.1076
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   LIEB WE, 1991, ARCH OPHTHALMOL-CHIC, V109, P527, DOI 10.1001/archopht.1991.01080040095036
   Lieb WE, 1998, RADIOL CLIN N AM, V36, P1059, DOI 10.1016/S0033-8389(05)70231-1
   Mete A, 2010, J CLIN ULTRASOUND, V38, P66, DOI 10.1002/jcu.20650
   Mori F, 2001, BRIT J OPHTHALMOL, V85, P531, DOI 10.1136/bjo.85.5.531
   Myint K, 2006, ACTA OPHTHALMOL SCAN, V84, P328, DOI 10.1111/j.1600-0420.2005.00623.x
   Ozkan BR, 2008, CURR EYE RES, V33, P804, DOI 10.1080/02713680802344708
   Parodi MB, 2010, EUR J OPHTHALMOL, V20, P1076, DOI 10.1177/112067211002000609
   Schmidt-Erfurth U, 2010, EXPERT OPIN DRUG SAF, V9, P149, DOI 10.1517/14740330903418422
   TAMAKI Y, 1993, JPN J OPHTHALMOL, V37, P385
   Tano Y, 2010, ACTA OPHTHALMOL, V88, P309, DOI 10.1111/j.1755-3768.2009.01843.x
   von Hanno T, 2010, ACTA OPHTHALMOL, V88, P263, DOI 10.1111/j.1755-3768.2008.01406.x
   Williamson TH, 1996, SURV OPHTHALMOL, V40, P255, DOI 10.1016/S0039-6257(96)82001-7
   WILLIAMSON TH, 1995, BRIT J OPHTHALMOL, V79, P17, DOI 10.1136/bjo.79.1.17
   2002, RETINA, V22, P6
NR 41
TC 8
Z9 8
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0091-2751
J9 J CLIN ULTRASOUND
JI J. Clin. Ultrasound
PD JAN
PY 2013
VL 41
IS 1
BP 32
EP 37
DI 10.1002/jcu.21989
PG 6
WC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
GA 057BK
UT WOS:000312536600005
PM 23055187
DA 2022-11-30
ER

PT J
AU Ritter, M
   Elledge, J
   Simader, C
   Deak, GG
   Benesch, T
   Blodi, BA
   Schmidt-Erfurth, UM
AF Ritter, Markus
   Elledge, Julee
   Simader, Christian
   Deak, Gabor G.
   Benesch, Thomas
   Blodi, Barbara A.
   Schmidt-Erfurth, Ursula M.
TI Evaluation of optical coherence tomography findings in age-related
   macular degeneration: a reproducibility study of two independent reading
   centres
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; EDEMA; AGREEMENT; DISEASES
AB Background/aims To determine the reproducibility among readers of two independent certified centres, the Vienna Reading Center (VRC) and the University of Wisconsin-Madison Reading Center (UW-FPRC) for optical coherence tomography (OCT) images in age-related macular degeneration (AMD).
   Methods Fast macular thickness scans and 6 mm cross hair scans were obtained from 100 eyes with all subtypes of AMD using Stratus OCT. Consensus readings were performed by two certified OCT readers of each reading center using their grading protocol. Common variables of both grading protocols, such as presence of cystoid spaces, subretinal fluid, vitreomacular traction and retinal pigment epithelial detachment, were compared using kappa statistics. In addition, the intraclass correlation coefficient (ICC) was calculated for centre point thickness (CPT) of values re-measured manually in the presence of alignment errors.
   Results The reproducibility was dependent on the variable measured with a kappa value of 0.81 for the presence of cystoid spaces, 0.78 for the presence of subretinal fluid and 0.795 for the presence of vitreomacular traction. The lowest reproducibility was found for the presence of retinal pigment epithelial detachment with a kappa value of 0.51. The CPT was remeasured in 29 out of 100 scans at both sites with an ICC of the re-measured thicknesses of 0.92.
   Conclusion OCT scan data are crucial in monitoring treatment efficacy in AMD clinical trials. For comparison of results obtained by different reading centers, the inter-reading center reproducibility is essential. Although the reproducibility is generally high, the reliability depends on the selected morphological parameters.
C1 [Ritter, Markus; Simader, Christian; Deak, Gabor G.; Schmidt-Erfurth, Ursula M.] Med Univ Vienna, Dept Ophthalmol, Vienna, Austria.
   [Elledge, Julee; Blodi, Barbara A.] Univ Wisconsin, Dept Ophthalmol, Madison, WI USA.
   [Benesch, Thomas] Med Univ Vienna, Dept Med Stat, Vienna, Austria.
C3 Medical University of Vienna; University of Wisconsin System; University
   of Wisconsin Madison; Medical University of Vienna
RP Schmidt-Erfurth, UM (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
OI Schmidt-Erfurth, Ursula/0000-0002-7788-7311; Simader,
   Christian/0000-0002-1784-2883; Ritter, Markus/0000-0003-1406-8340
CR Baumal C R, 1999, Curr Opin Ophthalmol, V10, P182, DOI 10.1097/00055735-199906000-00006
   Domalpally A, 2009, RETINA-J RET VIT DIS, V29, P775, DOI 10.1097/IAE.0b013e3181a0848b
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Holz FG, 2009, INVEST OPHTHALMOL VI, P50
   Hubbard LD, 2004, AM J OPHTHALMOL, V137, P426, DOI 10.1016/j.ajo.2003.10.002
   KRYSTOLIK MG, 2007, OPHTHALMOLOGY, V114, P1520
   Massin P, 2003, AM J OPHTHALMOL, V135, P169, DOI 10.1016/S0002-9394(02)01837-8
   Panozzo Giacomo, 2003, Semin Ophthalmol, V18, P74, DOI 10.1076/soph.18.2.74.15854
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Rivellese M, 2000, OPHTHALMIC SURG LAS, V31, P192
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   SCHLINGEMANN RO, 2009, INVEST OPHTHALMOL VI, V50
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   Scott IU, 2008, RETINA-J RET VIT DIS, V28, P36, DOI 10.1097/IAE.0b013e31815e9385
   Zhang N, 2007, AM J OPHTHALMOL, V144, P37, DOI 10.1016/j.ajo.2007.03.056
   [No title captured], DOI DOI 10.2307/2529310
NR 17
TC 29
Z9 29
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2011
VL 95
IS 3
BP 381
EP 385
DI 10.1136/bjo.2009.175976
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 722NY
UT WOS:000287440400016
PM 20805123
OA Green Submitted, Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Introini, U
   Gimeno, AT
   Scotti, F
   Setaccioli, M
   Giatsidis, S
   Bandello, F
AF Introini, Ugo
   Gimeno, Ana Torres
   Scotti, Fabrizio
   Setaccioli, Marco
   Giatsidis, Silvia
   Bandello, Francesco
TI Vascularized retinal pigment epithelial detachment in age-related
   macular degeneration: treatment and RPE tear incidence
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Retinal pigment epithelial detachment;
   Choroidal neovascularization; Retinal angiomatous proliferation; RPE
   tear; antiVEGF
ID OCCULT CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL TRIAMCINOLONE
   ACETONIDE; PHOTODYNAMIC THERAPY; VERTEPORFIN; BEVACIZUMAB; RANIBIZUMAB;
   INJECTION; SECONDARY; AMD
AB To review vascularized-pigment epithelial detachment (V-PED) treatment visual outcome, and to assess acute retinal pigment epithelium (RPE) tear incidence.
   One hundred and thirty-two eyes of 125 consecutive patients with age-related macular degeneration and V-PED were included. Ninety-four eyes (71.2%) were associated with choroidal new vessels (CNV), 38 (28.8%) with retinal angiomatous proliferation (RAP). Patients, treated over a 10-year period with the time-current therapy, received: verteporfin photodynamic therapy (PDT) (group 1, 38 eyes), combined intravitreal triamcinolone acetonide (IVTA) and PDT (group 2, 44 eyes) or intravitreal anti-VEGF injection (bevacizumab or ranibizumab) (group 3, 50 eyes).
   Mean follow-up was 20.5 months. At month 12, all eyes treated with PDT or with IVTA and PDT showed a mean significant severe visual decrease. Eyes with CNV lost -0.67 and -0.37 logMAR (p < 0.01 and p < 0.01 respectively), and eyes with RAP -0.55 and -0.31 logMAR (p < 0.01 and p = 0.01 respectively). RPE tear occurred in 14 eyes (36.8%) and in six eyes (13.6%) in groups 1 and 2 respectively. Eyes treated with anti-VEGF therapy showed slight mean visual acuity decrease at month 12. Those with CNV had a mean baseline best-corrected visual acuity (BCVA) of 0.36 +/- A 0.24 logMAR, final of 0.44 +/- A 0.30 logMAR (-0.08 logMAR, n.s.). In eyes with RAP, mean baseline BCVA was 0.58 +/- A 0.39 logMAR, final was 0.78 +/- A 0.47 logMAR (-0.20 logMAR, n.s.). RPE tear occurred in 14 eyes (36.8%). Patients with either V-PED with CNV or a better baseline BCVA showed greater risk of acute RPE tear (p = 0.01 and p = 0.003 respectively).
   Effective treatment for vascularized PED is still lacking. Until now, only stabilization of the disease has been achieved using anti-VEGF therapy, but the risk of RPE tear can further hamper our expectations. Baseline characteristics are helpful for prognosis, but patients must be informed of the uncertain response. New therapeutic strategies are needed.
C1 [Introini, Ugo; Giatsidis, Silvia; Bandello, Francesco] Univ Vita Salute, San Raffaele Sci Inst, Dept Ophthalmol, I-20132 Milan, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Introini, U (通讯作者)，Univ Vita Salute, San Raffaele Sci Inst, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.
EM introini.ugo@hsr.it; torresgimeno.ana@hsr.it; scotti.fabrizio@hsr.it;
   marcosetaccioli@yahoo.com; silviagiatsidis@hotmail.com;
   bandello.francesco@hsr.it
RI bandello, francesco/AAH-2405-2019
OI bandello, francesco/0000-0003-3238-9682; Setaccioli,
   Marco/0000-0002-0500-8728
CR Arias L, 2010, CLIN OPHTHALMOL, V4, P369
   Arora S, 2011, EYE, V25, P1034, DOI 10.1038/eye.2011.115
   Axer-Siegel R, 2004, ARCH OPHTHALMOL-CHIC, V122, P453, DOI 10.1001/archopht.122.4.453
   Axer-Siegel R, 2006, OPHTHAL SURG LAS IM, V37, P455, DOI 10.3928/15428877-20061101-02
   Boscia F, 2004, AM J OPHTHALMOL, V138, P1077, DOI 10.1016/j.ajo.2004.06.072
   Boscia F, 2006, GRAEF ARCH CLIN EXP, V244, P1224, DOI 10.1007/s00417-005-0205-2
   Brancato R, 2000, RETINA-J RET VIT DIS, V20, P134, DOI 10.1097/00006982-200003000-00004
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   COSCAS G, 1990, ARCH OPHTHALMOL-CHIC, V108, P1687, DOI 10.1001/archopht.1990.01070140041025
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   Ergun E, 2006, AM J OPHTHALMOL, V142, P10, DOI 10.1016/j.ajo.2006.02.048
   GASS JDM, 1984, AM J OPHTHALMOL, V98, P700
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Goldstein M, 2005, EYE, V19, P1315, DOI 10.1038/sj.eye.6701765
   Kook D, 2008, OPHTHALMOLOGE, V105, P158, DOI 10.1007/s00347-007-1561-6
   Lai TYY, 2007, GRAEF ARCH CLIN EXP, V245, P1877, DOI 10.1007/s00417-007-0679-1
   Leitritz M, 2008, EYE, V22, P1504, DOI 10.1038/eye.2008.145
   Lommatzsch A, 2009, EYE, V23, P2163, DOI 10.1038/eye.2008.425
   Meyer CH, 2001, GRAEF ARCH CLIN EXP, V239, P325, DOI 10.1007/s004170100259
   Meyerle CB, 2007, RETINA-J RET VIT DIS, V27, P451, DOI 10.1097/IAE.0b013e318030ea80
   Michels S, 2006, AM J OPHTHALMOL, V141, P396, DOI 10.1016/j.ajo.2005.08.046
   Nicolo M, 2006, EUR J OPHTHALMOL, V16, P770, DOI 10.1177/112067210601600521
   Pece A, 2001, RETINA-J RET VIT DIS, V21, P661, DOI 10.1097/00006982-200112000-00017
   Pece A, 2007, RETINA-J RET VIT DIS, V27, P342, DOI 10.1097/01.iae.0000239253.78495.8c
   Ritter M, 2010, EYE, V24, P962, DOI 10.1038/eye.2009.265
   Ruppenstein M, 2010, OPHTHALMOLOGE, V107, P827, DOI 10.1007/s00347-010-2166-z
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Smith BT, 2009, RETINA-J RET VIT DIS, V29, P335, DOI 10.1097/IAE.0b013e318195cad5
   Spandau UHM, 2006, AM J OPHTHALMOL, V142, P1068, DOI 10.1016/j.ajo.2006.06.048
   Wasmuth S, 2010, OPHTHALMOLOGE, V107, P1109, DOI 10.1007/s00347-010-2142-7
   Wygnanski-Jaffe T, 2006, OPHTHAL SURG LAS IM, V37, P358, DOI 10.3928/15428877-20060901-01
   YANNUZZI LA, 1994, RETINA-J RET VIT DIS, V14, P99, DOI 10.1097/00006982-199414020-00003
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
NR 37
TC 32
Z9 37
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD SEP
PY 2012
VL 250
IS 9
BP 1283
EP 1292
DI 10.1007/s00417-012-1955-2
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 995FS
UT WOS:000307993900005
PM 22350060
DA 2022-11-30
ER

PT J
AU Nahavandipour, A
   Nielsen, MK
   Sorensen, TL
   Subhi, Y
AF Nahavandipour, Arvin
   Krogh Nielsen, Marie
   Sorensen, Torben L.
   Subhi, Yousif
TI Systemic levels of interleukin-6 in patients with age-related macular
   degeneration: a systematic review and meta-analysis
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
DE age-related macular degeneration; inflammation; interleukin-6; plasma;
   serum
ID ENDOTHELIAL DYSFUNCTION; INFLAMMATORY MARKERS; RISK-FACTORS; FACTOR-B;
   ASSOCIATION; POPULATION; IL-6; CELLS; POLYMORPHISMS; ACTIVATION
AB Age-related macular degeneration (AMD) is the most prevalent cause of irreversible vision loss in industrialized countries. Several studies have investigated systemic interleukin-6 (IL-6) levels of patients with AMD. In this study, we systemically reviewed the literature to provide an overview of the field and used meta-analyses to provide a summary estimate of the standardized mean difference (SMD) of systemic IL-6 between patients with AMD and control individuals. We searched the literature databases PubMed/MEDLINE, Embase, Web of Science and the Cochrane Central on 1 June 2019 for relevant studies on humans. Two authors independently extracted data and evaluated risk of bias. We identified 19 studies for the qualitative review with a total of more than 3586 individuals (1865 controls and 1721 with AMD). We found an overall random-effects SMD in systemic IL-6 levels 0.63 (95% CI: 0.28 to 0.99, p = 0.0005) corresponding to a medium effect size. In a subgroup analysis, we found that early AMD was not strongly associated with elevated IL-6 levels (0.12, 95% CI: -0.01 to 0.24, p = 0.06), which was in contrast to the significantly elevated IL-6 levels in patients with geographic atrophy (1.21, 95% CI: 0.41 to 2.01, p = 0.003) and patients with neovascular AMD (0.99, 95% CI: 0.34 to 1.63, p = 0.003). Our results show that the evidence today suggests an increased systemic IL-6 in patients with AMD, but that this may be a phenomenon more closely related to the late subtypes of AMD.
C1 [Nahavandipour, Arvin; Krogh Nielsen, Marie; Sorensen, Torben L.; Subhi, Yousif] Zealand Univ Hosp, Dept Ophthalmol, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
   [Sorensen, Torben L.] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
   [Subhi, Yousif] Rigshosp Glostrup, Dept Ophthalmol, Glostrup, Denmark.
C3 University of Copenhagen
RP Subhi, Y (通讯作者)，Zealand Univ Hosp, Dept Ophthalmol, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
EM ysubhi@gmail.com
RI Subhi, Yousif/ABG-6330-2020
OI Subhi, Yousif/0000-0001-6620-5365; Krogh Nielsen,
   Marie/0000-0003-3804-7296
CR Agrawal R, 2019, INVEST OPHTH VIS SCI, V60, P376, DOI 10.1167/iovs.18-24387
   Ambreen F, 2015, MOL VIS, V21, P985
   Aoki A, 2015, INVEST OPHTH VIS SCI, V56, P2580, DOI 10.1167/iovs.14-16339
   Arroba AI, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00203
   Bak M, 2017, JAMA OPHTHALMOL, V135, P835, DOI 10.1001/jamaophthalmol.2017.2011
   Balne PK, 2018, DATA BRIEF, V19, P1570, DOI 10.1016/j.dib.2018.05.085
   Black RJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166468
   Bruunsgaard H, 2006, DAN MED BULL, V53, P285
   Budiene B, 2018, OPHTHALMIC GENET, V39, P463, DOI 10.1080/13816810.2018.1484928
   Camelo S, 2016, OPHTHALMOLOGICA, V236, P53, DOI 10.1159/000446587
   Chang JR, 2011, OPHTHALMOLOGY, V118, P2113, DOI 10.1016/j.ophtha.2011.03.032
   Chen M, 2016, CURR MOL MED, V16, P412, DOI 10.2174/1566524016666160324130031
   Chen M, 2008, EXP EYE RES, V87, P543, DOI 10.1016/j.exer.2008.09.005
   Cohen J., 1988, STAT POWER ANAL SOCI, V2nd
   Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736
   Colak E, 2017, J CLIN BIOCHEM NUTR, V60, P100, DOI 10.3164/jcbn.16-30
   Cuenca N, 2014, PROG RETIN EYE RES, V43, P17, DOI 10.1016/j.preteyeres.2014.07.001
   Eandi CM, 2016, ELIFE, V5, DOI 10.7554/eLife.16490
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fauser S, 2015, ACTA OPHTHALMOL, V93, P734, DOI 10.1111/aos.12770
   Fischer WH, 1999, J IMMUNOL, V162, P453
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Furuya-Kanamori L, 2018, INT J EVID-BASED HEA, V16, P195, DOI 10.1097/XEB.0000000000000141
   Haas P, 2015, ACTA OPHTHALMOL, V93, P533, DOI 10.1111/aos.12670
   Hamedani AG, 2019, OPHTHAL EPIDEMIOL, V26, P279, DOI 10.1080/09286586.2019.1611879
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT., 2019, COCHRANE HDB SYSTEMA
   Jabs DA, 2015, AM J OPHTHALMOL, V159, P1115, DOI 10.1016/j.ajo.2015.01.037
   Jones SA, 2005, J INTERF CYTOK RES, V25, P241, DOI 10.1089/jir.2005.25.241
   KATZ Y, 1989, EUR J IMMUNOL, V19, P983, DOI 10.1002/eji.1830190605
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Li J, 2019, EXP CELL RES, V388, P111811
   Lin SY, 2017, ANN ONCOL, V28, P2575, DOI 10.1093/annonc/mdx402
   Litwinska Z, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00286
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1186/2046-4053-4-1, 10.1136/bmj.b2535, 10.1136/bmj.i4086]
   Nakamura R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8847
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Niazi S, 2019, ACTA OPHTHALMOL, V97, P558, DOI 10.1111/aos.14072
   Nielsen MK, 2019, INVEST OPHTH VIS SCI, V60, P202, DOI 10.1167/iovs.18-25878
   Nielsen MK, 2019, CLIN EXP OPHTHALMOL, V47, P69, DOI 10.1111/ceo.13362
   Raoul W, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-87
   Rashid K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01975
   Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9
   Sawilowsky SS, 2009, J MOD APPL STAT METH, V8, P597, DOI 10.22237/jmasm/1257035100
   Schnabolk G, 2019, INVEST OPHTH VIS SCI, V60, P3520, DOI 10.1167/iovs.18-26444
   Sedeh FB, 2017, DAN MED J, V64
   Singh JA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199562
   Spindler J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203337
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Subhi Y, 2019, IMMUN AGEING, V16, DOI 10.1186/s12979-019-0160-0
   Subhi Y, 2019, ACTA OPHTHALMOL, V97, P99, DOI 10.1111/aos.13886
   Subhi Y, 2017, AGING-US, V9, P2436, DOI 10.18632/aging.101329
   Subhi Y, 2014, CLIN OPHTHALMOL, V8, P15, DOI 10.2147/OPTH.S55080
   Terao N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28484-w
   Tsai DC, 2015, OPHTHALMOLOGY, V122, P2327, DOI 10.1016/j.ophtha.2015.07.033
   Wassmann S, 2004, CIRC RES, V94, P534, DOI 10.1161/01.RES.0000115557.25127.8D
   Watson C, 1996, CLIN EXP IMMUNOL, V105, P112, DOI 10.1046/j.1365-2249.1996.d01-717.x
   Wu KHC, 2007, INVEST OPHTH VIS SCI, V48, P1983, DOI 10.1167/iovs.06-0223
   Ye J, 2012, INVEST OPHTH VIS SCI, V53, P3885, DOI 10.1167/iovs.12-9820
   Yi QY, 2020, ACTA OPHTHALMOL, V98, pE309, DOI 10.1111/aos.14248
   Yildirim Z, 2012, INT J GERONTOL, V6, P101, DOI 10.1016/j.ijge.2012.01.018
   Yildiz BK, 2016, OPHTHALMIC RES, V56, P132, DOI 10.1159/000446186
   Zeng Xiantao, 2015, J Evid Based Med, V8, P2, DOI 10.1111/jebm.12141
   Zhou HY, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-019-1278-8
NR 67
TC 8
Z9 8
U1 1
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD AUG
PY 2020
VL 98
IS 5
BP 434
EP 444
DI 10.1111/aos.14402
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ML4LC
UT WOS:000549438500002
PM 32180348
DA 2022-11-30
ER

PT J
AU Kaiser, PK
AF Kaiser, Peter K.
CA TAP Study Grp
TI Verteporfin therapy of subfoveal choroidal neovascularization in
   age-related macular degeneration: 5-year results of two randomized
   clinical trials with an open-label extension - TAP Report No. 8
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
ID PHOTODYNAMIC THERAPY
AB Purpose: To report vision and safety outcomes up to 5 years from an extension of the Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Investigation evaluating verteporfin therapy in patients with subfoveal choroidal neovascularization (CNV) in age-related macular degeneration.
   Methods: Patients who completed the 2-year randomized, placebo-controlled portion of the TAP Investigation could participate in the open-label extension study for an additional 3 years. Patients in the study extension received open-label verteporfin therapy in the study eye, fellow eye or both eyes, irrespective of original treatment assignment to placebo or verteporfin, if leakage from CNV was evident on fluorescein angiography. Follow-up visits occurred at 3-month intervals through to month 48, with a final follow-up visit at month 60.
   Results: Of the 402 verteporfin-treated patients in the randomized trials, 320 (80%) enrolled in the extension study; 193 (60%) of these completed the extension study up to 5 years. Patients received an average of approximately two treatments during the 3 years of the extension study. Seventy-seven (62%) of the 124 verteporfin-treated patients with predominantly classic lesions at baseline who enrolled in the extension completed the month 60 examination. Twenty-six (34%) of these 77 patients had lost 3 or more lines of visual acuity by month 24 and 27 (35%) had lost this amount of vision by month 60; the mean change in visual acuity from baseline was also similar at the month 24 and month 60 examinations (-1.5 and -1.6 lines, respectively). When visual acuity results were examined for all extension patients who received verteporfin at baseline, regardless of baseline lesion composition and extension study completion status, a similar pattern of visual acuity stabilization was evident. Few additional instances of infusion-related back pain or photosensitivity reactions were reported from month 24 to month 60. No additional safety issues were noted after bilateral treatment.
   Conclusions: Vision outcomes remained relatively stable from month 24 to month 60 even though the treatment rate was low during this period. The TAP Study Group identified no new safety concerns to preclude repeating verteporfin therapy as described in this study through 5 years.
C1 Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation
RP Kaiser, PK (通讯作者)，Cleveland Clin Fdn, Cole Eye Inst, 9500 Euclid Ave,Desk i3, Cleveland, OH 44195 USA.
EM pkkaiser@aol.com
OI Kaiser, Peter/0000-0001-5126-045X
CR Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   2004, RETINA, V24, P1
   2005, ARCH OPHTHALMOL, V123, P1283
NR 6
TC 81
Z9 92
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD SEP
PY 2006
VL 244
IS 9
BP 1132
EP 1142
DI 10.1007/s00417-005-0199-9
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 076LH
UT WOS:000239959000012
PM 16538452
DA 2022-11-30
ER

PT J
AU Gurubaran, IS
   Viiri, J
   Koskela, A
   Hyttinen, JMT
   Paterno, JJ
   Kis, G
   Antal, M
   Urtti, A
   Kauppinen, A
   Felszeghy, S
   Kaarniranta, K
AF Gurubaran, Iswariyaraja Sridevi
   Viiri, Johanna
   Koskela, Ali
   Hyttinen, Juha M. T.
   Paterno, Jussi J.
   Kis, Greta
   Antal, Miklos
   Urtti, Arto
   Kauppinen, Anu
   Felszeghy, Szabolcs
   Kaarniranta, Kai
TI Mitophagy in the Retinal Pigment Epithelium of Dry Age-Related Macular
   Degeneration Investigated in the NFE2L2/PGC-1 alpha(-/-) Mouse Model
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE ageing; oxidative stress; mitochondrial damage; age-related macular
   disease; mitophagy; autolysosomal fusion; protein aggregates
ID PARKIN-MEDIATED MITOPHAGY; NEURODEGENERATIVE DISEASES; DAMAGED
   MITOCHONDRIA; THERAPEUTIC-TARGET; OXIDATIVE STRESS; PINK1; PROTEIN;
   AUTOPHAGY; UBIQUITIN; DEGRADATION
AB Increased oxidative stress and mitochondrial damage are observed in protein aggregation diseases, such as age-related macular degeneration (AMD). We have recently reported elevated levels of oxidative stress markers, damaged mitochondria, accumulating lysosomal lipofuscin and extracellular drusen-like structures in the retinal pigment epithelial cells (RPE) of the dry AMD-resembling NFE2L2/PGC1 alpha double knockout (dKO) mouse model. Here, we provide evidence of a disturbance in the autolysosomal machinery handling mitochondrial clearance in the RPE cells of one-year-old NFE2L2/PGC1 alpha-deficient mice. Confocal immunohistochemical analysis revealed an upregulation of autophagosome marker microtubule-associated proteins 1A/1B light chain 3B (LC3B) as well as numerous mitophagy markers, such as PTE-induced putative kinase 1 (PINK1) and E3 ubiquitin ligase (PARKIN) together with damaged mitochondria. However, we detected no evidence of increased autolysosome formation in transmission electron micrographs or of colocalization of lysosomal marker LAMP2 (lysosome-associated membrane protein 2) and the mitochondrial marker ATP synthase beta in confocal micrographs. Interestingly, we observed an upregulation of late autolysosomal fusion Ras-related protein (Rab7) in the perinuclear space of RPE cells together with autofluorescence aggregates. Our results reveal that there is at least a relative decrease of mitophagy in the RPE cells of NFE2L2/PGC1 alpha dKO mice. This further supports the hypothesis that mitophagy is a putative therapy target in AMD-like pathology.
C1 [Gurubaran, Iswariyaraja Sridevi; Viiri, Johanna; Koskela, Ali; Hyttinen, Juha M. T.; Paterno, Jussi J.] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, Kuopio 70211, Finland.
   [Kis, Greta; Antal, Miklos] Univ Debrecen, Med & Hlth Sci Ctr, Dept Anat Histol & Embryol, Fac Med, Nagyerdei Krt 98, H-4032 Debrecen, Hungary.
   [Urtti, Arto; Kauppinen, Anu] Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, Kuopio 70210, Finland.
   [Felszeghy, Szabolcs] Univ Eastern Finland, Inst Dent & Biomed, Kuopio 70211, Finland.
   [Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Kuopio 70029, Finland.
   [Kaarniranta, Kai] Univ Eastern Finland, Kuopio Univ Hosp, Kuopio 70029, Finland.
C3 University of Eastern Finland; University of Debrecen; University of
   Eastern Finland; University of Eastern Finland; University of Eastern
   Finland; Kuopio University Hospital; University of Eastern Finland
RP Kaarniranta, K (通讯作者)，Univ Eastern Finland, Dept Ophthalmol, Kuopio 70029, Finland.; Kaarniranta, K (通讯作者)，Univ Eastern Finland, Kuopio Univ Hosp, Kuopio 70029, Finland.
EM raja.sridevigurubaran@uef.fi; johanna.viiri@uef.fi; ali.koskela@uef.fi;
   Juha.Hyttinen@uef.fi; Jussi.Paterno@kuh.fi; greta@anat.med.unideb.hu;
   antal@anat.med.unideb.hu; arto.urtti@uef.fi; anu.kauppinen@uef.fi;
   Szabolcs.Felszeghy@uef.fi; kai.kaarniranta@uef.fi
RI Paterno, Jussi/AAY-5526-2020
OI Paterno, Jussi/0000-0002-5442-4314; Hyttinen, Juha/0000-0002-3414-4032;
   Antal, Miklos/0000-0002-2457-7387; Sridevi Gurubaran,
   Iswariyaraja/0000-0003-1863-9550
FU European Union [722717]; Academy of Finland [296840]; Kuopio University
   Hospital VTR grant [5503743]; Sigrid Juselius Foundation; Paivikki and
   Sakari Sohlberg Foundation; University of Eastern Finland; Finnish
   Cultural Foundation; Finnish Eye Foundation
FX This project has received funding from the European Union's Horizon 2020
   research and innovation programme under the Marie Sklodowska-Curie grant
   agreement No. 722717, the Academy of Finland (296840), the Kuopio
   University Hospital VTR grant (5503743), the Sigrid Juselius Foundation,
   the Paivikki and Sakari Sohlberg Foundation, the University of Eastern
   Finland strategical support, the Finnish Cultural Foundation, and the
   Finnish Eye Foundation.
CR Al Gwairi O, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/2913612
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anding AL, 2017, DEV CELL, V41, P10, DOI 10.1016/j.devcel.2017.02.016
   Blasiak J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010210
   Brandl C, 2016, OPHTHALMOLOGE, V113, P735, DOI 10.1007/s00347-016-0341-6
   Chan NC, 2011, HUM MOL GENET, V20, P1726, DOI 10.1093/hmg/ddr048
   Chen Y, 2013, SCIENCE, V340, P471, DOI 10.1126/science.1231031
   Cherra SJ, 2010, J CELL BIOL, V190, P533, DOI 10.1083/jcb.201002108
   Cianfanelli V, 2015, NAT CELL BIOL, V17, P20, DOI 10.1038/ncb3072
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Durcan TM, 2015, GENE DEV, V29, P989, DOI 10.1101/gad.262758.115
   Eid N, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00100
   Eid N, 2013, J MOL HISTOL, V44, P311, DOI 10.1007/s10735-013-9483-x
   Eldred GE, 1995, GERONTOLOGY, V41, P15
   Enns Gregory M. Enns, 2018, J. inborn errors metab. screen., V6, pe170024, DOI 10.1177/2326409817752961
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Gatica D, 2018, NAT CELL BIOL, V20, P233, DOI 10.1038/s41556-018-0037-z
   Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012
   Greene JC, 2003, P NATL ACAD SCI USA, V100, P4078, DOI 10.1073/pnas.0737556100
   Hanna RA, 2012, J BIOL CHEM, V287, P19094, DOI 10.1074/jbc.M111.322933
   Hohn A, 2013, J PROTEOMICS, V92, P132, DOI 10.1016/j.jprot.2013.01.004
   Jin SM, 2012, J CELL SCI, V125, P795, DOI 10.1242/jcs.093849
   Jin SM, 2010, J CELL BIOL, V191, P933, DOI 10.1083/jcb.201008084
   Johansen T, 2020, J MOL BIOL, V432, P80, DOI 10.1016/j.jmb.2019.07.016
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kaarniranta Kai, 2010, Front Biosci (Elite Ed), V2, P1374
   Kane LA, 2014, J CELL BIOL, V205, P143, DOI 10.1083/jcb.201402104
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kazlauskaite A, 2015, EMBO REP, V16, P939, DOI 10.15252/embr.201540352
   Kim GH, 2015, EXP NEUROBIOL, V24, P325, DOI 10.5607/en.2015.24.4.325
   Kim JY, 2011, APOPTOSIS, V16, P114, DOI 10.1007/s10495-010-0550-4
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kondapalli C, 2012, OPEN BIOL, V2, DOI 10.1098/rsob.120080
   Korovila I, 2017, REDOX BIOL, V13, P550, DOI 10.1016/j.redox.2017.07.008
   Koyano F, 2014, NATURE, V510, P162, DOI 10.1038/nature13392
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Lee SY, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.266
   Li YJ, 2019, EMBO J, V38, DOI 10.15252/embj.201798786
   Liang HY, 2006, ADV PHYSIOL EDUC, V30, P145, DOI 10.1152/advan.00052.2006
   Lin YC, 2018, J OCUL PHARMACOL TH, V34, P500, DOI 10.1089/jop.2017.0073
   Lindner AB, 2009, BBA-GEN SUBJECTS, V1790, P980, DOI 10.1016/j.bbagen.2009.06.005
   Liu L, 2012, NAT CELL BIOL, V14, P177, DOI 10.1038/ncb2422
   Matsuda N, 2010, J CELL BIOL, V189, P211, DOI 10.1083/jcb.200910140
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McWilliams TG, 2018, OPEN BIOL, V8, DOI 10.1098/rsob.180108
   Moisoi N, 2014, NEUROPHARMACOLOGY, V77, P350, DOI 10.1016/j.neuropharm.2013.10.009
   Murakawa T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8527
   NAGY I, 1994, MICROSC RES TECHNIQ, V28, P60, DOI 10.1002/jemt.1070280107
   Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125
   Narendra DP, 2010, AUTOPHAGY, V6, P1090, DOI 10.4161/auto.6.8.13426
   Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200
   Novak I, 2010, EMBO REP, V11, P45, DOI 10.1038/embor.2009.256
   Press M, 2019, MECH AGEING DEV, V177, P46, DOI 10.1016/j.mad.2018.03.010
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Reddy PH, 2011, CURR ALZHEIMER RES, V8, P393
   Reddy PH, 2009, CNS SPECTRUMS, V14, P8, DOI 10.1017/S1092852900024901
   Regmi SG, 2014, AGING-US, V6, P118, DOI 10.18632/aging.100639
   Roberts RL, 1999, J CELL SCI, V112, P3667
   Sarraf SA, 2013, NATURE, V496, P372, DOI 10.1038/nature12043
   Shaid S, 2013, CELL DEATH DIFFER, V20, P21, DOI 10.1038/cdd.2012.72
   Sharma V, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00147
   Shiba-Fukushima K, 2012, SCI REP-UK, V2, DOI 10.1038/srep01002
   Strappazzon F, 2011, EMBO J, V30, P1195, DOI 10.1038/emboj.2011.49
   Svenning S, 2013, ESSAYS BIOCHEM, V55, P79, DOI [10.1042/bse0550079, 10.1042/BSE0550079]
   Szatmari Z, 2014, AUTOPHAGY, V10, P1154, DOI 10.4161/auto.29395
   Terman A, 1998, APMIS, V106, P265, DOI 10.1111/j.1699-0463.1998.tb01346.x
   Truban D, 2017, J PARKINSON DIS, V7, P13, DOI 10.3233/JPD-160989
   Uttara B, 2009, CURR NEUROPHARMACOL, V7, P65, DOI 10.2174/157015909787602823
   Van Humbeeck C, 2011, J NEUROSCI, V31, P10249, DOI 10.1523/JNEUROSCI.1917-11.2011
   Vieira OV, 2003, MOL CELL BIOL, V23, P2501, DOI 10.1128/MCB.23.7.2501-2514.2003
   Wang XN, 2011, CELL, V147, P893, DOI 10.1016/j.cell.2011.10.018
   Westermann B, 2010, NAT REV MOL CELL BIO, V11, P872, DOI 10.1038/nrm3013
   Wong YC, 2014, P NATL ACAD SCI USA, V111, pE4439, DOI 10.1073/pnas.1405752111
   Youle RJ, 2012, SCIENCE, V337, P1062, DOI 10.1126/science.1219855
   Zaffagnini G, 2016, J MOL BIOL, V428, P1714, DOI 10.1016/j.jmb.2016.02.004
   Zhang YP, 2019, BIOMED PHARMACOTHER, V111, P1315, DOI 10.1016/j.biopha.2019.01.034
NR 78
TC 17
Z9 17
U1 2
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAR
PY 2020
VL 21
IS 6
AR 1976
DI 10.3390/ijms21061976
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA LJ0UU
UT WOS:000529890200072
PM 32183173
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Clark, SJ
   Bishop, PN
AF Clark, Simon J.
   Bishop, Paul N.
TI Role of Factor H and Related Proteins in Regulating Complement
   Activation in the Macula, and Relevance to Age-Related Macular
   Degeneration
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE age-related macular degeneration; complement factor H; factor H; factor
   H-like protein 1; factor H related proteins
ID BRUCHS MEMBRANE IMPLICATIONS; AMINO-ACID-SEQUENCE; ADULT HUMAN RETINA;
   ALTERNATIVE PATHWAY; C-TERMINUS; DIFFERENTIAL DISTRIBUTION;
   HEPARAN-SULFATE; HIGH-RISK; RECOGNITION; POLYMORPHISM
AB The recent revolution in age-related macular degeneration (AMD) genetics has demonstrated that genetic alterations affecting the alternative pathway of the complement cascade have a major influence on AMD risk. One of the two most important genetic loci is on chromosome 1 and contains genes encoding complement factor H (FH) and the factor H related proteins (FHR proteins). In macular tissue, especially Bruch's membrane, relatively high levels of a truncated splice variant of FH called factor H-like protein 1 (FHL-1) are present. Here we discuss how genetic variations may alter the amounts, or by altering their protein sequences, the functions of these proteins. In particular, the common Y402H polymorphism affects the ability of FHL-1 and FH to localize to Bruch's membrane and the inner choroid because it alters the ability of these complement regulators to bind heparan sulphate (HS) in these structures. In addition, there is an age-related loss of HS from Bruch's membrane. We hypothesize that a combination of poor binding of the 402H variants of FHL-1 and FH to Bruch's membrane, combined with a decrease in binding due to age-related HS loss, eventually results in insufficient FHL-1 and FH binding to Bruch's membrane. This could result in complement activation, inflammation and thereby predispose to AMD.
C1 [Clark, Simon J.; Bishop, Paul N.] Univ Manchester, Ctr Hearing & Vis Res, AV Hill Bldg,Oxford Rd, Manchester M13 9PL, Lancs, England.
   [Clark, Simon J.; Bishop, Paul N.] Univ Manchester, Inst Human Dev, Manchester M13 9PL, Lancs, England.
   [Clark, Simon J.; Bishop, Paul N.] Univ Manchester, Ctr Adv Discovery & Expt Therapeut, Manchester M13 9WL, Lancs, England.
   [Clark, Simon J.; Bishop, Paul N.] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester M13 9WL, Lancs, England.
   [Bishop, Paul N.] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Royal Eye Hosp, Manchester M13 9WH, Lancs, England.
C3 University of Manchester; University of Manchester; University of
   Manchester; University of Manchester; Manchester Royal Eye Hospital;
   University of Manchester
RP Bishop, PN (通讯作者)，Univ Manchester, Ctr Hearing & Vis Res, AV Hill Bldg,Oxford Rd, Manchester M13 9PL, Lancs, England.
EM Simon.Clark-3@manchester.ac.uk; Paul.Bishop@manchester.ac.uk
OI Clark, Simon/0000-0001-8394-8355; Bishop, Paul/0000-0001-7937-7932
FU MRC [MR/K024418/1]; Manchester Biomedical Research Centre; MRC
   [MR/K004441/1, G0900538] Funding Source: UKRI; Medical Research Council
   [G0900538, MR/K024418/1, MR/K004441/1] Funding Source: researchfish;
   Fight for Sight [1517/18] Funding Source: researchfish
FX Simon J. Clark is supported by an MRC Career Development Fellowship
   (MR/K024418/1). The authors acknowledge support from Manchester
   Biomedical Research Centre.
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ansari M, 2013, HUM MOL GENET, V22, P4857, DOI 10.1093/hmg/ddt336
   Bruinsma IB, 2010, ACTA NEUROPATHOL, V119, P211, DOI 10.1007/s00401-009-0577-1
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2014, J IMMUNOL, V193, P4962, DOI 10.4049/jimmunol.1401613
   Clark SJ, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00412
   Clark SJ, 2013, J IMMUNOL, V190, P2049, DOI 10.4049/jimmunol.1201751
   Clark SJ, 2011, INVEST OPHTH VIS SCI, V52, P6511, DOI 10.1167/iovs.11-7909
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   DAY AJ, 1988, IMMUNOGENETICS, V27, P211, DOI 10.1007/BF00346588
   de Jorge EG, 2013, P NATL ACAD SCI USA, V110, P4685, DOI 10.1073/pnas.1219260110
   Eberhardt HU, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078617
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Feyzi E, 1998, J BIOL CHEM, V273, P13395, DOI 10.1074/jbc.273.22.13395
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   GENNARO R, 1986, EUR J BIOCHEM, V155, P77, DOI 10.1111/j.1432-1033.1986.tb09460.x
   Haapasalo K, 2008, MOL MICROBIOL, V70, P583, DOI 10.1111/j.1365-2958.2008.06347.x
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hebecker M, 2012, J BIOL CHEM, V287, P19528, DOI 10.1074/jbc.M112.364471
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jozsi M, 2005, EUR J HUM GENET, V13, P321, DOI 10.1038/sj.ejhg.5201324
   Jozsi M, 2007, MOL IMMUNOL, V44, P2697, DOI 10.1016/j.molimm.2006.12.001
   Jozsi M, 2006, J AM SOC NEPHROL, V17, P170, DOI 10.1681/ASN.2005080868
   Keenan TDL, 2014, INVEST OPHTH VIS SCI, V55, P5370, DOI 10.1167/iovs.14-14126
   Keenan TDL, 2012, INVEST OPHTH VIS SCI, V53, P7528, DOI 10.1167/iovs.12-10797
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Oppermann M, 2006, CLIN EXP IMMUNOL, V144, P342, DOI 10.1111/j.1365-2249.2006.03071.x
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593
   Ritter M, 2010, BRIT J OPHTHALMOL, V94, P1112, DOI 10.1136/bjo.2009.159475
   Sanchez-Corral P, 2002, AM J HUM GENET, V71, P1285, DOI 10.1086/344515
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Smith RJH, 2011, MOL IMMUNOL, V48, P1604, DOI 10.1016/j.molimm.2011.04.005
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Strohmeyer R, 2002, J NEUROIMMUNOL, V131, P135, DOI 10.1016/S0165-5728(02)00272-2
   Taylor CM, 2001, LANCET, V358, P1200, DOI 10.1016/S0140-6736(01)06339-5
   Taylor KR, 2006, FASEB J, V20, P9, DOI 10.1096/fj.05-4682rev
   Tortajada A, 2013, J CLIN INVEST, V123, P2434, DOI 10.1172/JCI68280
   Ugarte M, 2013, SURV OPHTHALMOL, V58, P585, DOI 10.1016/j.survophthal.2012.12.002
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
NR 56
TC 29
Z9 31
U1 0
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD JAN
PY 2015
VL 4
IS 1
BP 18
EP 31
DI 10.3390/jcm4010018
PG 14
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CT9II
UT WOS:000363130100002
PM 25729613
OA Green Published, Green Accepted, gold
DA 2022-11-30
ER

PT J
AU Nam, J
   Ly, A
   Kalloniatis, M
   Nivison-Smith, L
AF Nam, Judy
   Ly, Angelica
   Kalloniatis, Michael
   Nivison-Smith, Lisa
TI Multispectral pattern recognition measures change in drusen area in
   age-related macular degeneration with high congruency to expert graders
SO SCIENTIFIC REPORTS
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; AMINO-ACID SIGNATURES; GEOGRAPHIC-ATROPHY;
   RETICULAR PSEUDODRUSEN; COLLABORATIVE CARE; CLINICAL-TRIAL; SD-OCT;
   PROGRESSION; EYES; DISEASE
AB Drusen are a hallmark lesion of age-related macular degeneration (AMD) and changes in their area and/or volume are strongly associated with disease progression. Assessment of longitudinal change in drusen size in clinical practice however is limited to a single commercial tool or manual inspection by clinicians. In this study we analysed change in drusen area in 33 eyes with intermediate AMD across two separate visits using a novel technique known as multispectral pattern recognition for en face retinal images from various imaging modalities (infrared (815 nm), fundus autofluorescence (488 nm) and green (532 nm) scanning laser ophthalmoscopy). We found 91% (30/33 eyes) agreement in the direction of drusen change for multispectral pattern recognition relative to expert graders who graded eyes as having drusen progression, regression or being stable. Multispectral pattern recognition showed 100% sensitivity (22/22 eyes) and 73% specificity (8/11 eyes). In comparison, we found only 70% (23/33 eyes) agreement in the direction of drusen change with a commercially available change analysis software, the Cirrus Advanced RPE Analysis relative to expert graders, with a sensitivity 64% (14/22 eyes) and specificity of 82% (9/11 eyes). Total drusen area or amount of change between visits had no significant effect on agreement. This suggests multispectral pattern recognition can quantify longitudinal change in drusen area from multimodal imaging with greater congruency to expert graders than a commercially available platform based on a single imaging modality. Considering the association of drusen area and disease progression, this method could aid clinical assessment and monitoring of AMD.
C1 [Nam, Judy; Ly, Angelica; Kalloniatis, Michael; Nivison-Smith, Lisa] Univ New South Wales, Ctr Eye Hlth, Sydney, NSW 2052, Australia.
   [Nam, Judy; Ly, Angelica; Kalloniatis, Michael; Nivison-Smith, Lisa] Univ New South Wales, Sch Optometry & Vis Sci, Sydney, NSW 2052, Australia.
C3 University of New South Wales Sydney; University of New South Wales
   Sydney
RP Nivison-Smith, L (通讯作者)，Univ New South Wales, Ctr Eye Hlth, Sydney, NSW 2052, Australia.; Nivison-Smith, L (通讯作者)，Univ New South Wales, Sch Optometry & Vis Sci, Sydney, NSW 2052, Australia.
EM l.nivison-smith@unsw.edu.au
FU Rebecca Cooper Foundation; National Health and Medical Research Council
   of Australia (NHMRC) [1174385]
FX This work was supported, in part, by research grants from the Rebecca
   Cooper Foundation and the National Health and Medical Research Council
   of Australia (NHMRC grant #1174385) awarded to LNS. Guide Dogs NSW/ACT
   provides support for the Centre for Eye Health (the clinic of
   recruitment) and salary support for AL and MK.
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chua J, 2013, EXP NEUROL, V250, P74, DOI 10.1016/j.expneurol.2013.09.007
   Cozzi M, 2020, OPHTHALMOL RETINA, V4, P987, DOI 10.1016/j.oret.2020.04.013
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Diniz B, 2014, RETINA-J RET VIT DIS, V34, P55, DOI 10.1097/IAE.0b013e31829d0015
   Elsner AE, 1996, VISION RES, V36, P191, DOI 10.1016/0042-6989(95)00100-E
   Farinha C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051329
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Garrity ST, 2018, INVEST OPHTH VIS SCI, V59, pAMD48, DOI 10.1167/iovs.18-24158
   Glaser T, 2013, INVEST OPHTH VIS SCI, V54
   Gregori G, 2014, INVEST OPHTH VIS SCI, V55, P7662, DOI 10.1167/iovs.14-15273
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Guymer R, 2020, CLIN EXP OPHTHALMOL, V48, P983, DOI 10.1111/ceo.13837
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Hill E, 2001, CEREB CORTEX, V11, P679, DOI 10.1093/cercor/11.8.679
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Jamous KF, 2015, CLIN EXP OPHTHALMOL, V43, P308, DOI 10.1111/ceo.12466
   Jiang XS, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.4.11
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Kalloniatis M, 1996, J NEUROSCI, V16, P6807
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Lamin A, 2019, EYE, V33, P910, DOI 10.1038/s41433-019-0338-x
   Lee N, 2010, IEEE ENG MED BIO, P5363, DOI 10.1109/IEMBS.2010.5626463
   Ly A, 2019, CLIN EXP OPTOM, V102, P242, DOI 10.1111/cxo.12847
   Ly A, 2018, INVEST OPHTH VIS SCI, V59, P1790, DOI 10.1167/iovs.17-23076
   Ly A, 2018, CLIN EXP OPTOM, V101, P172, DOI 10.1111/cxo.12624
   Ly A, 2018, CLIN EXP OPTOM, V101, P243, DOI 10.1111/cxo.12607
   Ly A, 2017, OPHTHAL PHYSL OPT, V37, P661, DOI 10.1111/opo.12413
   Ly A, 2017, OPTOMETRY VISION SCI, V94, P246, DOI 10.1097/OPX.0000000000000997
   Ly A, 2016, OPHTHAL PHYSL OPT, V36, P632, DOI 10.1111/opo.12322
   Ly A, 2016, OPHTHAL PHYSL OPT, V36, P303, DOI 10.1111/opo.12283
   MARC RE, 1995, J NEUROSCI, V15, P5106
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Nathoo NA, 2014, AM J OPHTHALMOL, V158, P757, DOI 10.1016/j.ajo.2014.06.021
   Nittala MG, 2012, INVEST OPHTH VIS SCI, V53, P8319, DOI 10.1167/iovs.12-10582
   Nivison-Smith L, 2014, OPTOMETRY VISION SCI, V91, P832, DOI 10.1097/OPX.0000000000000281
   Optometry Australia, 2019, CLIN PRACT GUID DIAG
   Royal Australian and New Zealand College of Ophthalmologists, 2018, RANZCO REF PATHW AMD
   Schaal KB, 2016, OPHTHALMOLOGY, V123, P1060, DOI 10.1016/j.ophtha.2016.01.034
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Swain P. H., 1973, 1st International Joint Conference on Pattern Recognition, P536
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wu ZC, 2020, OPHTHALMOL RETINA, V4, P568, DOI 10.1016/j.oret.2019.12.011
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Yehoshua Z, 2013, INVEST OPHTH VIS SCI, V54, P2429, DOI 10.1167/iovs.12-11569
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Zeiss, 2018, CIRRUS HD OCT US MAN
NR 51
TC 0
Z9 0
U1 0
U2 0
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 6
PY 2022
VL 12
IS 1
AR 7442
DI 10.1038/s41598-022-11070-6
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 1A5WC
UT WOS:000791825700027
PM 35524159
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU De Silva, T
   Chew, EY
   Hotaling, N
   Cukras, CA
AF De Silva, Tharindu
   Chew, Emily Y.
   Hotaling, Nathan
   Cukras, Catherine A.
TI Deep-learning based multi-modal retinal image registration for the
   longitudinal analysis of patients with age-related macular degeneration
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
AB This work reports a deep-learning based registration algorithm that aligns multi-modal retinal images collected from longitudinal clinical studies to achieve accuracy and robustness required for analysis of structural changes in large-scale clinical data. Deep-learning networks that mirror the architecture of conventional feature-point-based registration were evaluated with different networks that solved for registration affine parameters, image patch displacements, and patch displacements within the region of overlap. The ground truth images for deep learning-based approaches were derived from successful conventional feature-based registration. Cross-sectional and longitudinal affine registrations were performed across color fundus photography (CFP), fundus autofluorescence (FAF), and infrared reflectance (IR) image modalities. For mono-modality longitudinal registration, the conventional feature-based registration method achieved mean errors in the range of 39-53 mu m (depending on the modality) whereas the deep learning method with region overlap prediction exhibited mean errors in the range 54-59 mu m. For cross-sectional multi-modality registration, the conventional method exhibited gross failures with large errors in more than 50% of the cases while the proposed deep-learning method achieved robust performance with no gross failures and mean errors in the range 66-69 mu m. Thus, the deep learning-based method achieved superior overall performance across all modalities. The accuracy and robustness reported in this work provide important advances that will facilitate clinical research and enable a detailed study of the progression of retinal diseases such as age-related macular degeneration. (C) 2020 Optical Society of America under the terms of the OSA Open Access Publishing Agreement
C1 [De Silva, Tharindu; Chew, Emily Y.; Cukras, Catherine A.] NEI, NIH, Bethesda, MD 20892 USA.
   [Hotaling, Nathan] NIH, Natl Ctr Adv Translat Sci, Bldg 10, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Center
   for Advancing Translational Sciences (NCATS)
RP Hotaling, N (通讯作者)，NIH, Natl Ctr Adv Translat Sci, Bldg 10, Bethesda, MD 20892 USA.
EM nathan.hotaling@nih.gov; cukrasc@nei.nih.gov
FU National Eye Institute Intramural Research Program, National Institutes
   of Health [EY000509-10]
FX National Eye Institute Intramural Research Program, National Institutes
   of Health (EY000509-10).
CR Arcadu F, 2019, NPJ DIGIT MED, V2, DOI 10.1038/s41746-019-0172-3
   Arikan M., 2019, DEEP LEARNING BASED, P75
   Balakrishnan G, 2019, IEEE T MED IMAGING, V38, P1788, DOI 10.1109/TMI.2019.2897538
   Burlina P., 2016, P INT S BIOM IM
   Cao X., 2020, HDB MEDICAL IMAGE CO, P319, DOI DOI 10.1016/B978-0-12-816176-0.00019-3
   Cao XH, 2018, IEEE T IMAGE PROCESS, V27, P3500, DOI 10.1109/TIP.2018.2820424
   Chanwimaluang T, 2006, IEEE T INF TECHNOL B, V10, P129, DOI 10.1109/TITB.2005.856859
   Cheng X, 2018, COMP M BIO BIO E-IV, V6, P248, DOI 10.1080/21681163.2015.1135299
   De Silva T, 2016, PHYS MED BIOL, V61, P3009, DOI 10.1088/0031-9155/61/8/3009
   De Silva T. S., 2020, MED IMAGING 2020 IMA, P106
   De Silva T, 2017, IEEE T MED IMAGING, V36, P2010, DOI 10.1109/TMI.2017.2703150
   de Vos B. D., 2019, MED IMAGE ANAL
   Friedman D. S., 2004, ARCH OPHTHALMOL
   Ghassabi Z, 2013, EURASIP J IMAGE VIDE, DOI 10.1186/1687-5281-2013-25
   Grabner M., 2006, LECT NOTES COMPUTER
   Hernandez-Matas C, 2017, COMPUT MED IMAG GRAP, V55, P95, DOI 10.1016/j.compmedimag.2016.06.006
   HORN BKP, 1987, J OPT SOC AM A, V4, P629, DOI 10.1364/JOSAA.4.000629
   Lee J., 2019, P IEEE INT C COMP VI
   Li Z, 2018, BIOMED OPT EXPRESS, V9, P410, DOI 10.1364/BOE.9.000410
   Miao S, 2016, IEEE T MED IMAGING, V35, P1352, DOI 10.1109/TMI.2016.2521800
   Parekar J, 2016, 2016 INTERNATIONAL CONFERENCE ON SIGNAL AND INFORMATION PROCESSING (ICONSIP)
   Rabbani H., 2015, INVESTIG OPHTHALMOL
   Ramli R, 2017, J HEALTHC ENG, V2017, DOI 10.1155/2017/1489524
   Rocco I, 2017, PROC CVPR IEEE, P39, DOI 10.1109/CVPR.2017.12
   Roche A, 2001, IEEE T MED IMAGING, V20, P1038, DOI 10.1109/42.959301
   Stewart CV, 2003, IEEE T MED IMAGING, V22, P1379, DOI 10.1109/TMI.2003.819276
   Tang HL, 2018, J MED IMAG HEALTH IN, V8, P240, DOI 10.1166/jmihi.2018.2283
   Wang G, 2015, BIOMED SIGNAL PROCES, V19, P68, DOI 10.1016/j.bspc.2015.03.004
   Wang S., 2017, DEEP LEARNING MED IM
   Zheng JA, 2011, IEEE T INF TECHNOL B, V15, P221, DOI 10.1109/TITB.2010.2091145
NR 30
TC 11
Z9 12
U1 1
U2 16
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD JAN 1
PY 2021
VL 12
IS 1
BP 619
EP 636
DI 10.1364/BOE.408573
PG 18
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA PO1EJ
UT WOS:000604913400001
PM 33520392
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Cabral, D
   Coscas, F
   Pereira, T
   Francais, C
   Geraldes, C
   Laiginhas, R
   Rodrigues, C
   Kashi, AK
   Nogueira, V
   Falcao, M
   Papoila, AL
   Lupidi, M
   Coscas, G
   Cohen, SY
   Souied, E
AF Cabral, Diogo
   Coscas, Florence
   Pereira, Telmo
   Francais, Catherine
   Geraldes, Carlos
   Laiginhas, Rita
   Rodrigues, Catarina
   Kashi, Alexis Khorrami
   Nogueira, Vanda
   Falcao, Manuel
   Papoila, Ana Luisa
   Lupidi, Marco
   Coscas, Gabriel
   Cohen, Salomon Yves
   Souied, Eric
TI Quantitative Optical Coherence Tomography Angiography Biomarkers in a
   Treat-and-Extend Dosing Regimen in Neovascular Age-Related Macular
   Degeneration
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE age-related macular degeneration; treat-and-extend protocol; choroidal
   neovascularization; optical coherence tomography angiography;
   anti-vascular endothelial growth factor
ID CHOROIDAL NEOVASCULARIZATION; TREATMENT RESPONSE; RANIBIZUMAB
AB Purpose: To evaluate the association between quantitative optical coherence tomography angiography (OCT-A) parameters and clinical outcomes in treatment-naive neovascular age-related macular degeneration (nAMD) patients treated with a treat-and-extend dosing regimen on a 12-month follow-up interval.
   Methods: Observational, prospective study of consecutive patients. The treatment protocol was based on a loading dose of three anti-vascular endothelial growth factor (VEGF) intravitreal injections (IVI) followed by a treat-and-extend regimen. Eyes were evaluated by swept-source OCT-A at baseline, 1 month after the loading dose and at 12 months. A quantitative analysis was issued for fractal dimension (FD), lacunarity index (LAC), blood flow surface area (SA), and vessel density (VD). An association of these parameters with the anatomic response and functional responses, and IVI number at 12 months of follow-up was assessed. A level of significance alpha = 0.05 was considered.
   Results: Sixty-four patients were included, 52 of whom (81%) completed the 12-month study protocol. The median number of injections at 12 months was 7 (P-25 -P-75 : 6-12). FD and SA were reduced 1 month after the loading dose of anti-VEGF (P < 0.001). The generalized linear models using baseline FD and baseline SA achieved the best performance in discriminating a lower treatment burden (area under the curve [AUC] = 0.78; 95% confidence interval [CI]: 0.64-0.91 and AUC = 0.76; 95% CI: 0.63-0.90, respectively).
   Conclusions: Baseline OCT-A may provide useful biomarkers for the treatment burden in nAMD.
C1 [Cabral, Diogo; Coscas, Florence; Francais, Catherine; Kashi, Alexis Khorrami; Coscas, Gabriel] Ctr Ophtalmol Odeon, 113 Bd St Germain, F-75006 Paris, France.
   [Cabral, Diogo; Pereira, Telmo; Geraldes, Carlos; Papoila, Ana Luisa] Univ Nova Lisboa, Fac Ciencias Med, CEDOC, NOVA Med Sch, Lisbon, Portugal.
   [Cabral, Diogo; Rodrigues, Catarina; Nogueira, Vanda] Inst Oftalmol Dr Gama Pinto, Lisbon, Portugal.
   [Coscas, Florence; Kashi, Alexis Khorrami; Coscas, Gabriel; Cohen, Salomon Yves; Souied, Eric] Univ Paris Est Creteil XII, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Laiginhas, Rita] Univ Porto, Ctr Hosp Entre O Douro & Vouga, Porto, Portugal.
   [Laiginhas, Rita] Univ Porto, Fac Med, Porto, Portugal.
   [Falcao, Manuel] Univ Porto, Ctr Hosp Sao Joao, Porto, Portugal.
   [Falcao, Manuel] Univ Porto, Dept Surg & Physiol, Fac Med, Porto, Portugal.
   [Lupidi, Marco] Univ Perugia, S Maria Misericordia Hosp, Dept Surg & Biomed Sci, Sect Ophthalmol, Perugia, Italy.
C3 Universidade Nova de Lisboa; Universite Paris-Est-Creteil-Val-de-Marne
   (UPEC); CHI Creteil; Universidade do Porto; Universidade do Porto; Sao
   Joao Hospital; Universidade do Porto; Universidade do Porto; University
   of Perugia
RP Coscas, F (通讯作者)，Ctr Ophtalmol Odeon, 113 Bd St Germain, F-75006 Paris, France.
EM coscas.f@gmail.com
RI Geraldes, Carlos/A-4358-2019; Falcao/AAQ-8509-2020; Papoila, Ana
   Luisa/S-2515-2016
OI Geraldes, Carlos/0000-0002-1551-6531; Falcao/0000-0003-4718-0910;
   Pereira, Telmo/0000-0002-6903-9187; Papoila, Ana
   Luisa/0000-0002-2918-8364; Reis Cabral, Diogo/0000-0003-1968-3561;
   Rodrigues, Catarina/0000-0002-6097-2114; Laiginhas,
   Rita/0000-0001-7275-6470
CR Ahmed D, 2019, RETINA, V38, P2143
   Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Cabral D, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.3.7
   Coscas F, 2019, BRIT J OPHTHALMOL, V103, P1342, DOI 10.1136/bjophthalmol-2018-313065
   Coscas F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205513
   Coscas G, 2015, OPHTHALMIC RES, V54, P57, DOI 10.1159/000433547
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Costanzo E, 2016, INVEST OPHTH VIS SCI, V57, pOCT307, DOI 10.1167/iovs.15-18830
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Gemenetzi M, 2017, OPHTHALMOL THER, V6, P79, DOI 10.1007/s40123-017-0087-5
   Gess AJ, 2011, SEMIN OPHTHALMOL, V26, P225, DOI 10.3109/08820538.2011.582533
   Hara C, 2019, BRIT J OPHTHALMOL, V103, P623, DOI 10.1136/bjophthalmol-2018-312275
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   LEE MJ, 2018, BR J OPHTHALMOL, DOI [DOI 10.1186/S13661-017-0918-2, DOI 10.1136/BJOPHTHALMOL-2018-312516]
   Masters BR, 2004, ANNU REV BIOMED ENG, V6, P427, DOI 10.1146/annurev.bioeng.6.040803.140100
   McClintic SM, 2018, OPHTHALMOL RETINA, V2, P931, DOI 10.1016/j.oret.2018.01.014
   McCullagh P., 1989, GEN LINEAR MODELS MO
   Miere A, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/3751702
   Munk MR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177059
   Roberts PK, 2017, RETINA-J RET VIT DIS, V37, P1492, DOI 10.1097/IAE.0000000000001400
   Schmidt-Erfurth U, 2018, OPHTHALMOL RETINA, V2, P24, DOI 10.1016/j.oret.2017.03.015
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Smith TG, 1996, J NEUROSCI METH, V69, P123, DOI 10.1016/S0165-0270(96)00080-5
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Xu D, 2018, AM J OPHTHALMOL, V187, P10, DOI 10.1016/j.ajo.2017.12.005
   Zheng F, 2017, INVEST OPHTH VIS SCI, V58, P5098, DOI 10.1167/iovs.17-22506
NR 30
TC 4
Z9 4
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD FEB
PY 2020
VL 9
IS 3
AR 18
DI 10.1167/tvst.9.3.18
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KT5WC
UT WOS:000519084200005
PM 32714644
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Grassmann, F
   Friedrich, U
   Fauser, S
   Schick, T
   Milenkovic, A
   Schulz, HL
   von Strachwitz, CN
   Bettecken, T
   Lichtner, P
   Meitinger, T
   Arend, N
   Wolf, A
   Haritoglou, C
   Rudolph, G
   Chakravarthy, U
   Silvestri, G
   McKay, GJ
   Freitag-Wolf, S
   Krawczak, M
   Smith, RT
   Merriam, JC
   Merriam, JE
   Allikmets, R
   Heid, IM
   Weber, BHF
AF Grassmann, Felix
   Friedrich, Ulrike
   Fauser, Sascha
   Schick, Tina
   Milenkovic, Andrea
   Schulz, Heidi L.
   von Strachwitz, Claudia N.
   Bettecken, Thomas
   Lichtner, Peter
   Meitinger, Thomas
   Arend, Nicole
   Wolf, Armin
   Haritoglou, Christos
   Rudolph, Guenther
   Chakravarthy, Usha
   Silvestri, Giuliana
   McKay, Gareth J.
   Freitag-Wolf, Sandra
   Krawczak, Michael
   Smith, R. Theodore
   Merriam, John C.
   Merriam, Joanna E.
   Allikmets, Rando
   Heid, Iris M.
   Weber, Bernhard H. F.
TI A Candidate Gene Association Study Identifies DAPL1 as a Female-Specific
   Susceptibility Locus for Age-Related Macular Degeneration (AMD)
SO NEUROMOLECULAR MEDICINE
LA English
DT Article
DE Age-related macular degeneration; Death-associated protein-like 1;
   DAPL1; Canonical DAPL1 isoforms; Genetic association study
ID GENOME-WIDE ASSOCIATION; QUANTITATIVE TRAITS; RISK; DISEASE; PROTEIN;
   STAGE; SNP
AB Age-related macular degeneration (AMD) is the leading cause of blindness among white caucasians over the age of 50 years with a prevalence rate expected to increase markedly with an anticipated increase in the life span of the world population. To further expand our knowledge of the genetic architecture of the disease, we pursued a candidate gene approach assessing 25 genes and a total of 109 variants. Of these, synonymous single nucleotide polymorphism (SNP) rs17810398 located in death-associated protein-like 1 (DAPL1) was found to be associated with AMD in a joint analysis of 3,229 cases and 2,835 controls from five studies [combined P (ADJ) = 1.15 x 10(-6), OR 1.332 (1.187-1.496)]. This association was characterized by a highly significant sex difference (P (diff) = 0.0032) in that it was clearly confined to females with genome-wide significance [P (ADJ) = 2.62 x 10(-8), OR 1.541 (1.324-1.796); males: P (ADJ) = 0.382, OR 1.084 (0.905-1.298)]. By targeted resequencing of risk and non-risk associated haplotypes in the DAPL1 locus, we identified additional potentially functional risk variants, namely a common 897-bp deletion and a SNP predicted to affect a putative binding site of an exonic splicing enhancer. We show that the risk haplotype correlates with a reduced retinal transcript level of two, less frequent, non-canonical DAPL1 isoforms. DAPL1 plays a role in epithelial differentiation and may be involved in apoptotic processes thereby suggesting a possible novel pathway in AMD pathogenesis.
C1 [Grassmann, Felix; Friedrich, Ulrike; Milenkovic, Andrea; Schulz, Heidi L.; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, D-93053 Regensburg, Germany.
   [Fauser, Sascha; Schick, Tina] Univ Hosp Cologne, Dept Ophthalmol, D-53127 Cologne, Germany.
   [von Strachwitz, Claudia N.] EyeCtr Southwest, D-70563 Stuttgart, Germany.
   [Bettecken, Thomas] Max Planck Inst Psychiat, D-80804 Munich, Germany.
   [Lichtner, Peter; Meitinger, Thomas] Helmholtz Zentrum Munich, Inst Human Genet, D-85764 Neuherberg, Germany.
   [Meitinger, Thomas] Tech Univ Munich, Inst Human Genet, D-81675 Munich, Germany.
   [Arend, Nicole; Wolf, Armin; Haritoglou, Christos; Rudolph, Guenther] Univ Munich, Univ Eye Hosp, D-80336 Munich, Germany.
   [Chakravarthy, Usha; Silvestri, Giuliana] Queens Univ Belfast, Ctr Med Expt, Belfast BT12 6BA, Antrim, North Ireland.
   [McKay, Gareth J.] Queens Univ Belfast, Ctr Publ Hlth, Belfast BT12 6BA, Antrim, North Ireland.
   [Freitag-Wolf, Sandra; Krawczak, Michael] Univ Kiel, Inst Med Informat & Stat, D-24105 Kiel, Germany.
   [Smith, R. Theodore; Merriam, John C.; Merriam, Joanna E.; Allikmets, Rando] Columbia Univ, Dept Ophthalmol, New York, NY 10032 USA.
   [Smith, R. Theodore] NYU, Dept Ophthalmol, Sch Med, New York, NY 10016 USA.
   [Allikmets, Rando] Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10032 USA.
   [Heid, Iris M.] Univ Regensburg, Dept Genet Epidemiol, D-93053 Regensburg, Germany.
C3 University of Regensburg; University of Cologne; Max Planck Society;
   Helmholtz Association; Helmholtz-Center Munich - German Research Center
   for Environmental Health; Technical University of Munich; University of
   Munich; Queens University Belfast; Queens University Belfast; University
   of Kiel; Columbia University; New York University; Columbia University;
   University of Regensburg
RP Weber, BHF (通讯作者)，Univ Regensburg, Inst Human Genet, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.
EM bweb@klinik.uni-regensburg.de
RI McKay, Gareth/AAZ-2601-2020; Meitinger, Thomas/O-1318-2015; Krawczak,
   Michael/A-8964-2010; Allikmets, Rando/ABD-4533-2021
OI McKay, Gareth/0000-0001-8197-6280; Krawczak,
   Michael/0000-0003-2603-1502; Meitinger, Thomas/0000-0002-8838-8403;
   Chakravarthy, Usha/0000-0002-2606-3734; smith,
   theodore/0000-0002-1693-943X; Weber, Bernhard H.F./0000-0002-8808-7723;
   Grassmann, Felix/0000-0003-1390-7528
FU Deutsche Forschungsgemeinschaft [WE 1259/19-1, WE 1259/19-2]; Alcon
   Research Institute; National Eye Institute/NIH [EY013435, EY019007];
   Macula Vision Research Foundation; Research to Prevent Blindness, Inc.;
   Guide Dogs for the Blind Association UK Macular Disease Society
   [2008-5a]; Medical Research Council [MC_CF023241] Funding Source:
   researchfish; NATIONAL EYE INSTITUTE [R01EY013435, P30EY019007] Funding
   Source: NIH RePORTER
FX We thank all patients and control individuals for their participation in
   the study, Kerstin Meier and Jurgen Kaschkoto (Institute of Human
   Genetics, University of Regensburg) for technical support, and Lars G.
   Fritsche (Department of Biostatistics, University of Michigan School of
   Public Health, Ann Arbor, Michigan) and Thomas Winkler (Institute of
   Epidemiology, University of Regensburg, Regensburg) for help with
   computational tools and data analysis. This study was supported partly
   by the Deutsche Forschungsgemeinschaft (WE 1259/19-1 and WE 1259/19-2 to
   BHFW), the Alcon Research Institute (to BHFW and RA), by grants from the
   National Eye Institute/NIH EY013435 and EY019007 (to RA); the Macula
   Vision Research Foundation (to RA); an unrestricted grant to the
   Department of Ophthalmology, Columbia University, from Research to
   Prevent Blindness, Inc. (to RA), and the Guide Dogs for the Blind
   Association UK (2008-5a) Macular Disease Society (to US, GS, GJM).
CR Amos W, 2011, P ROY SOC B-BIOL SCI, V278, P1183, DOI 10.1098/rspb.2010.1920
   Behrens G, 2011, GENET EPIDEMIOL, V35, P867, DOI 10.1002/gepi.20637
   Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616
   DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15
   Delaneau O, 2013, NAT METHODS, V10, P5, DOI 10.1038/nmeth.2307
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Flachsbart F, 2010, MUTAT RES-FUND MOL M, V694, P13, DOI 10.1016/j.mrfmmm.2010.08.006
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fu WQ, 2013, CURR OPIN GENET DEV, V23, P678, DOI 10.1016/j.gde.2013.10.008
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Howie BN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000529
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Luna A, 2007, BIOINFORMATICS, V23, P774, DOI 10.1093/bioinformatics/btl657
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Schulz HL, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-50
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   SULLIVAN KM, 1993, BIOTECHNIQUES, V15, P636
   Sun L, 2006, J CELL PHYSIOL, V206, P103, DOI 10.1002/jcp.20433
   Troutbeck R, 2012, CLIN EXP OPHTHALMOL, V40, P18, DOI 10.1111/j.1442-9071.2011.02581.x
   Wilkening S, 2009, GENOMICS, V93, P415, DOI 10.1016/j.ygeno.2008.12.011
   Xu ZL, 2009, NUCLEIC ACIDS RES, V37, pW600, DOI 10.1093/nar/gkp290
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zarbin MA, 2014, DEV OPHTHALMOL, V53, P1, DOI 10.1159/000358536
NR 28
TC 17
Z9 19
U1 0
U2 4
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1535-1084
EI 1559-1174
J9 NEUROMOL MED
JI Neuromol. Med.
PD JUN
PY 2015
VL 17
IS 2
BP 111
EP 120
DI 10.1007/s12017-015-8342-1
PG 10
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA CH7AI
UT WOS:000354187600003
PM 25680934
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Tuo, JS
   Ning, BT
   Bojanowski, CM
   Lin, ZN
   Ross, RJ
   Reed, GF
   Shen, DF
   Jiao, XD
   Zhou, M
   Chew, EY
   Kadlubar, FF
   Chan, CC
AF Tuo, Jingsheng
   Ning, Baitang
   Bojanowski, Christine M.
   Lin, Zhong-Ning
   Ross, Robert J.
   Reed, George F.
   Shen, Defen
   Jiao, Xiaodong
   Zhou, Min
   Chew, Emily Y.
   Kadlubar, Fred F.
   Chan, Chi-Chao
TI Synergic effect of polymorphisms in ERCC6 5 ' flanking region and
   complement factor H on age-related macular degeneration predisposition
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE Cockayne syndrome; single nucleoticle polymorphism; gene regulation;
   interaction; DNA repair
ID BASE EXCISION-REPAIR; OXIDATIVE STRESS; DNA-REPAIR; OVEREXPRESSION;
   MACULOPATHY; RISK; SUSCEPTIBILITY; PREVALENCE; VARIANT; DAMAGE
AB This study investigates age-related macular degeneration (AMD) genetic risk factors through identification of a functional single-nucleotide polymorphism (SNP) and its disease association. We chose ERCC6 because of its roles in the aging process, DNA repair, and ocular degeneration from the gene disruption. Bioinformatics indicated a putative binding-element alteration on the sequence containing C-6530 > G SNP in the 5 ' flanking region of ERCC6 from Sp1 on the C allele to SP1, GATA-1, and OCT-1 on the G allele. Electrophoretic mobility shift assays displayed distinctive C and G allele-binding patterns to nuclear proteins. Luciferase expression was higher in the vector construct containing the G allele than that containing the C allele. A cohort of 460 advanced AMD cases and 269 age-matched controls was examined along with pathologically diagnosed 57 AMD and 18 age-matched non-AMD archived cases. ERCC6 C-6530 > G was associated with AMD susceptibility, both independently and through interaction with an SNP (rs380390) in the complement factor H (CFH) intron reported to be highly associated with AMD. A disease odds ratio of 23 was conferred by homozygozity for risk alleles at both ERCC6 and CFH compared with homozygozity for nonrisk alleles. Enhanced ERCC6 expression was observed in lymphocytes from healthy donors bearing ERCC6 C-6530 > G alleles. Intense immunostaining of ERCC6 was also found in AMD eyes from ERCC6 C-6530 > G carriers. The strong AMD predisposition conferred by the ERCC6 and CFH SNPs may result from biological epistasis, because ERCC6 functions in universal transcription as a component of RNA pol I transcription complex.
C1 NEI, Immunol Lab, Sect Immunopathol, NIH, Bethesda, MD 20892 USA.
   NEI, Div Epidemiol & Clin Res, NIH, Bethesda, MD 20892 USA.
   NEI, Opthtalm Genet & Visual Funct Branch, Sect Ophthalm Mol Genet, Bethesda, MD 20892 USA.
   Natl Ctr Toxicol Res, Div Phamacogenom & Mol Epidemiol, Jefferson, AR 72079 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); National Institutes of Health (NIH) - USA; NIH National
   Eye Institute (NEI); US Food & Drug Administration (FDA)
RP Chan, CC (通讯作者)，NEI, Immunol Lab, Sect Immunopathol, NIH, 10-10N103,10 Ctr Dr, Bethesda, MD 20892 USA.
EM chanc@nei.nih.gov
OI Ning, Baitang/0000-0003-0798-0331; Tuo, Jingsheng/0000-0002-1372-7810
FU NATIONAL EYE INSTITUTE [Z01EY000222, Z01EY000418] Funding Source: NIH
   RePORTER; Intramural NIH HHS [Z99 EY999999] Funding Source: Medline
CR AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BORAZ R A, 1991, Pediatric Dentistry, V13, P227
   Bradsher J, 2002, MOL CELL, V10, P819, DOI 10.1016/S1097-2765(02)00678-0
   Chan CC, 2005, HISTOL HISTOPATHOL, V20, P857, DOI 10.14670/HH-20.857
   Conaway JW, 1999, ANNU REV BIOCHEM, V68, P301, DOI 10.1146/annurev.biochem.68.1.301
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   de Jong PTVM, 2001, EYE, V15, P396, DOI 10.1038/eye.2001.143
   Dollfus H, 2003, SURV OPHTHALMOL, V48, P107, DOI 10.1016/S0039-6257(02)00400-9
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Fishel ML, 2003, CANCER RES, V63, P608
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Frosina G, 2000, EUR J BIOCHEM, V267, P2135, DOI 10.1046/j.1432-1327.2000.01266.x
   Frosina G, 2001, CARCINOGENESIS, V22, P1335, DOI 10.1093/carcin/22.9.1335
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hanawalt PC, 2000, NATURE, V405, P415, DOI 10.1038/35013197
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim PM, 2001, NUCLEIC ACIDS RES, V29, P4352, DOI 10.1093/nar/29.21.4352
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   LEVIN PS, 1983, ARCH OPHTHALMOL-CHIC, V101, P1093
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Moore JH, 2005, NAT GENET, V37, P13, DOI 10.1038/ng0105-13
   Rime M, 2004, MOL CANCER THER, V3, P955
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Soames CJ, 1997, BIOCHEM J, V326, P553, DOI 10.1042/bj3260553
   Tornaletti S, 1999, BIOCHIMIE, V81, P139, DOI 10.1016/S0300-9084(99)80046-7
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   TRABOULSI EI, 1992, AM J OPHTHALMOL, V114, P579, DOI 10.1016/S0002-9394(14)74486-1
   Tuo J, 2001, J BIOL CHEM, V276, P45772, DOI 10.1074/jbc.M107888200
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   Tuo JS, 2002, DNA REPAIR, V1, P913, DOI 10.1016/S1568-7864(02)00116-7
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Winkler BS, 1999, MOL VIS, V5
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 49
TC 86
Z9 91
U1 0
U2 1
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 13
PY 2006
VL 103
IS 24
BP 9256
EP 9261
DI 10.1073/pnas.0603485103
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 054ID
UT WOS:000238369100064
PM 16754848
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Shin, HT
   Yoon, BW
   Seo, JH
AF Shin, Hyun-Tae
   Yoon, Byung Woo
   Seo, Je Hyun
TI Comparison of risk allele frequencies of single nucleotide polymorphisms
   associated with age-related macular degeneration in different ethnic
   groups
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Allele frequency; Single nucleotide
   polymorphism; Genetic risk scores; Prevalence
ID NUTRITION EXAMINATION SURVEY; GENOME-WIDE ASSOCIATION; NATIONAL-HEALTH;
   PREVALENCE; DISEASE; SUSCEPTIBILITY; GENETICS; KOREA
AB Background The prevalence of age-related macular degeneration (AMD) varies from 6.8 to 18.3% for all forms of AMD and from 0.6 to 2.6% for late AMD according to race, suggesting the existence of genetic differences among races. The purpose of this study was to determine the genetic causes of differences in the prevalence of AMD among individuals of different races. Methods We collected 138 AMD-associated single nucleotide polymorphisms (SNPs) from a genome-wide association studies catalog. Their population-level allele frequencies were derived based on the 1000 Genomes Project and Korean Reference Genome Database. We used Fisher's exact tests to assess whether the effect allele at a given SNP was significantly enriched or depleted in the database. Results European, American, and South Asian populations showed similar heatmap patterns, whereas East Asian, and Korean populations had distinct patterns. Korean populations exhibited patterns that were different from those of the other groups; rs5754227 (SYN3), rs1626340 (TGFBR1/COL15A1), rs3750846(ARMS2/HTRA1), and rs9564692 (B3GALTL) were enriched, whereas rs2230199 (C3) and rs73036519 (EXOC3L2/MARK4) were depleted in Koreans; these SNPs are associated with late AMD. The genetic risk score calculated from allele frequencies was not less in East Asians than in Europeans. Conclusion The prevalence of AMD is lower in Asians than in Europeans. However, our study showed that genetic risk scores in East Asians were similar to those in Europeans, which may explain why the global projected number of people with AMD by 2040 is in largest for East Asians, including Koreans.
C1 [Shin, Hyun-Tae; Seo, Je Hyun] Vet Med Res Inst, Vet Hlth Serv, Med Ctr, Jinhwangdo Ro 61 Gil 53, Seoul 05368, South Korea.
   [Shin, Hyun-Tae] Inha Univ, Sch Med, Dept Dermatol, Inha Ro 100, Incheon 22212, South Korea.
   [Yoon, Byung Woo] Inje Univ, Seoul Paik Hosp, Dept Internal Med, Div Oncol, Mareunnae Ro 9, Seoul 04551, South Korea.
C3 Inha University; Inje University
RP Seo, JH (通讯作者)，Vet Med Res Inst, Vet Hlth Serv, Med Ctr, Jinhwangdo Ro 61 Gil 53, Seoul 05368, South Korea.
EM jazmin2@naver.com
OI Seo, Je Hyun/0000-0003-3127-7160
FU VHS Medical Center Research Grant [VHSMC19033]
FX This study was supported by a VHS Medical Center Research Grant (grant
   no.: VHSMC19033). The sponsor or funding organization had no role in the
   design or conduct of this study.
CR Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393
   Baas AF, 2010, EUR J HUM GENET, V18, P240, DOI 10.1038/ejhg.2009.141
   Carlson CS, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001661
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P1101, DOI 10.1167/iovs.13-13096
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Domalpally A, 2019, OPHTHALMOLOGY, V126, P1659, DOI 10.1016/j.ophtha.2019.07.022
   Domingue BW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101596
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gottlieb JL, 2002, JAMA-J AM MED ASSOC, V288, P2233, DOI 10.1001/jama.288.18.2233
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kim J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23837-x
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mao LY, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-4262-9
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Oguido APMT, 2008, ARQ BRAS OFTALMOL, V71, P375, DOI 10.1590/S0004-27492008000300013
   Park SJ, 2015, OPHTHALMOLOGY, V122, P2063, DOI 10.1016/j.ophtha.2015.06.018
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Pasche B, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-57
   Pinese M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14079-0
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woo SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132771
NR 37
TC 7
Z9 7
U1 1
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD FEB 22
PY 2021
VL 21
IS 1
AR 97
DI 10.1186/s12886-021-01830-9
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QM7AH
UT WOS:000621927400001
PM 33618707
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Makita, LS
   Muniz, BC
   da Silva, ABR
   Bajano, FF
   Hirata, FE
   do Amaral, M
   Rim, PHH
   de Carvalho-Siqueira, GQ
   de Vasconcellos, JPC
   de Melo, MB
   Medina, FM
AF Makita, Lana Sayuri
   Muniz, Bernardo Carvalho
   Roque da Silva, Alicia Buffoni
   Bajano, Flavia Fialho
   Hirata, Fabio Endo
   do Amaral, Marcelo
   Rim, Priscila Hae Hyun
   de Carvalho-Siqueira, Gabriela Queila
   Cabral de Vasconcellos, Jose Paulo
   de Melo, Monica Barbosa
   Mac Cord Medina, Flavio
TI Interleukin-1 beta-31 (rs1143627) genetic variant and the risk of
   age-related macular degeneration in the Brazilian population
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Age- related macular degeneration (AMD); cytokine; IL-1B; rs1143627;
   single-nucleotide polymorphism (SNP)
ID POLYMORPHISMS; ASSOCIATION; KERATOCONUS; PROMOTER
AB Background: Age-related macular degeneration (AMD) is a multifactorial disease and one of the main causes of blindness in people over 50 years old. The etiology and pathophysiology of AMD are not well understood. The aim of this study was to investigate whether the rs1143627 variant allele of IL1B, which encodes Interleukin (IL)-1 beta, a key cytokine, mediates immune and inflammatory responses. Methods: A case-control study was conducted with 397 AMD patients and 402 controls in Brazil. IL1B genotyping was carried out with TaqMan (R) genotyping assay. Differences in IL1B allele frequencies and genotypes were evaluated between patients and controls and between wet and dry subgroups of AMD. Relationships between allele presence/genotype and disease risk are reported as odds ratios (ORs) with 95% confidence intervals (CIs). Results: Genotype proportions for the rs1143627 variant allele of IL1B were similar between AMD patients and controls (p = .21), with 84.38% of AMD patients and 79.60% of the controls carrying the variant allele. We observed a trend toward the variant allele being associated with AMD risk (OR = 1.38, 95% CI 0.95-2.03, p = .08), as well as a trend toward the variant allele being associated with increased risk for wet AMD in particular (OR = 1.23, 95% CI 0.96-1.56, p = .08). Conclusions: The rs1443627 variant was not associated with AMD risk in this Brazilian population sample. Larger studies are warranted to determine whether the trends observed in this study reflect a relationship between this variant and risk of AMD, especially wet AMD.
C1 [Makita, Lana Sayuri; Mac Cord Medina, Flavio] Univ State Rio de Janeiro UERJ, Fac Med Sci, Dept Ophthalmol, Rio De Janeiro, Brazil.
   [Muniz, Bernardo Carvalho] Santa Teresa Hosp, Dept Radiol, Petropolis, RJ, Brazil.
   [Roque da Silva, Alicia Buffoni; Hirata, Fabio Endo; Rim, Priscila Hae Hyun; Cabral de Vasconcellos, Jose Paulo] Univ Estadual Campinas, Fac Med Sci, Dept Ophthalmol, UNICAMP, Campinas, Brazil.
   [Bajano, Flavia Fialho; de Carvalho-Siqueira, Gabriela Queila; de Melo, Monica Barbosa] Univ Estadual Campinas, Ctr Mol Biol & Genet Engn, Lab Human Genet, UNICAMP, Campinas, Brazil.
   [do Amaral, Marcelo] Univ State Rio de Janeiro UERJ, Inst Math & Stat, Rio De Janeiro, Brazil.
C3 Universidade do Estado do Rio de Janeiro; Universidade Estadual de
   Campinas; Universidade Estadual de Campinas; Universidade do Estado do
   Rio de Janeiro
RP Makita, LS (通讯作者)，Univ State Rio de Janeiro UERJ, Fac Med Sci, Dept Ophthalmol, Rua Gen Osorio 89,Apto 1203, BR-25620160 Petropolis, RJ, Brazil.
EM lanasayuri@gmail.com
RI Medina, Flavio/AFM-1303-2022; MELO, MONICA/A-7776-2018
OI Makita, Lana Sayuri/0000-0002-5002-8314; MELO,
   MONICA/0000-0002-1801-5441; RIM, PRISCILA HAE HYUN/0000-0002-6046-6377;
   Roque, Alicia/0000-0002-0876-0675
FU Brazilian Research Council (CNPQ -National Council for Scientific and
   Technological Development)
FX This research was partially supported by Brazilian Research Council
   (CNPQ -National Council for Scientific and Technological Development).
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Celkova L, 2015, J CLIN MED, V4, P172, DOI 10.3390/jcm4010172
   Conselho Brasileiro de Oftalmologia, 2019, CENS OFT COND SAUD O
   Doyle SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007616
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Kim SH, 2008, MOL VIS, V14, P2109
   Kutty RK, 2016, MOL VIS, V22, P1156
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Li H, 2017, CLIN TRANSL ONCOL, V19, P1018, DOI 10.1007/s12094-017-1634-1
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Lopez-Castejon G, 2011, CYTOKINE GROWTH F R, V22, P189, DOI 10.1016/j.cytogfr.2011.10.001
   Medina FM, 2019, OPHTHALMIC RES, V61, P168, DOI 10.1159/000475995
   Mikami T, 2013, MOL VIS, V19, P845
   Nabil KM, 2019, CLIN OPHTHALMOL, V13, P2217, DOI 10.2147/OPTH.S220723
   Natoli R, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0175-y
   Oliveira MB, 2018, EXP BIOL MED, V243, P1083, DOI 10.1177/1535370218809709
   Rech TF, 2020, IMMUNOL INVEST, V49, P585, DOI 10.1080/08820139.2019.1710532
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Shevchenko A V, 2016, Vestn Oftalmol, V132, P8, DOI 10.17116/oftalma201613228-13
   Shwu-Jiuan S, 2012, TAIWAN J OPHTHALMOLO, V2, P51, DOI [10.1016/j.tjo.2012.02.002, DOI 10.1016/J.TJO.2012.02.002]
   Wang Y, 2016, CURR EYE RES, V41, P630, DOI 10.3109/02713683.2015.1045083
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wooff Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01618
   Zhang SR, 2015, INFLAMMATION, V38, P658, DOI 10.1007/s10753-014-9973-3
   Zhang SJ, 2016, INVEST OPHTH VIS SCI, V57, P312, DOI 10.1167/iovs.15-17578
   Zhao M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125150
NR 28
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD SEP 3
PY 2021
VL 42
IS 5
BP 533
EP 538
DI 10.1080/13816810.2021.1929337
EA JUN 2021
PG 6
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA US0KS
UT WOS:000662071000001
PM 34132166
DA 2022-11-30
ER

PT J
AU Toklu, Y
   Cakmak, HB
   Raza, S
   Anayol, A
   Asik, E
   Simsek, S
AF Toklu, Yasin
   Cakmak, Hasan Basri
   Raza, Sabri
   Anayol, Alpaslan
   Asik, Elif
   Simsek, Saban
TI Short-term effects of intravitreal bevacizumab (Avastin (R)) on
   retrobulbar hemodynamics in patients with neovascular age-related
   macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE bevacizumab; colour Doppler imaging; retrobulbar blood flow
ID INJECTION
AB Purpose: To evaluate the short-term effects of intravitreal bevacizumab on retrobulbar hemodynamics in patients with neovascular age-related macular degeneration (AMD).
   Methods: This study was carried out at Ataturk Training and Research Hospital 1st Ophthalmology Clinic, Ankara. Fourteen patients with neovascular AMD, who were treated with intravitreal injection of bevacizumab, were included in this study. Peak systolic velocity (PSV), end-diastolic velocity (EDV) and resistivity index (RI) were measured with colour Doppler imaging (CDI) in the ophthalmic artery, central retinal artery (CRA) and posterior ciliary artery.
   Results: The mean age of the 14 patients was 78 +/- 9 (64-87). Of the 14 patients, eight were men and six were women. Colour Doppler imaging measurements of EDV (p = 0.015) and RI (p = 0.009) parameters of CRA revealed statistically significant difference among all three periods. End-diastolic velocity values decreased at the end of the 1st week and returned close to preoperative values at the end of the 1st month after the procedure. Also, EDV of posterior ciliary artery (PCA) decreased at the end of the 1st week and returned close to preoperative values at the end of the 1st month after the procedure. Resistivity index of PCA showed a temporary increase at the end of the 1st week and returned close to preoperative values at the end of the 1st month after the procedure.
   Conclusion: Injection of bevacizumab decreased blood velocities of CRA and PCA and increased RI of CRA and PCA in the early postoperative period and returned to preoperative values at the end of the first month.
C1 [Toklu, Yasin; Cakmak, Hasan Basri; Raza, Sabri; Anayol, Alpaslan; Simsek, Saban] Ataturk Training & Res Hosp, Eye Clin, Ankara, Turkey.
   [Asik, Elif] Ataturk Training & Res Hosp, Dept Radiol, Ankara, Turkey.
C3 Ankara Ataturk Training & Research Hospital; Ankara Ataturk Training &
   Research Hospital
RP Raza, S (通讯作者)，Ankara Ataturk Egitim Arastirma Hastanesi, TR-06800 Ankara, Turkey.
EM sabri_raza@yahoo.com
OI CAKMAK, HASAN BASRI/0000-0001-6877-8773
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bonnin P, 2010, ACTA OPHTHALMOL, V88, P641, DOI 10.1111/j.1755-3768.2009.01526.x
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Cohen MH, 2007, ONCOLOGIST, V12, P356, DOI 10.1634/theoncologist.12-3-356
   Dimitrova G, 2002, EYE, V16, P580, DOI 10.1038/sj.eye.6700161
   Ehrlich R, 2010, GRAEF ARCH CLIN EXP, V248, P375, DOI 10.1007/s00417-009-1211-6
   GREENFIELD DS, 1995, OPHTHALMOLOGY, V102, P1598
   Hoeh AE, 2009, GRAEF ARCH CLIN EXP, V247, P1635, DOI 10.1007/s00417-009-1151-1
   Hsu J, 2007, RETINA-J RET VIT DIS, V27, P1013, DOI 10.1097/IAE.0b013e318050ca7c
   Huang ZL, 2010, OPHTHALMOLOGICA, V224, P86, DOI 10.1159/000235726
   Kilickap S, 2003, J CLIN ONCOL, V21, P3542, DOI 10.1200/JCO.2003.99.046
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   Matthiessen ET, 2004, EYE, V18, P400, DOI 10.1038/sj.eye.6700651
   Mete A, 2010, J CLIN ULTRASOUND, V38, P66, DOI 10.1002/jcu.20650
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086
   Scott IU, 2007, OPHTHALMOLOGY, V114, P1860, DOI 10.1016/j.ophtha.2007.05.062
   Shimomura Y, 2009, GRAEF ARCH CLIN EXP, V247, P1089, DOI 10.1007/s00417-009-1054-1
   Soliman W, 2008, ACTA OPHTHALMOL, V86, P365, DOI 10.1111/j.1600-0420.2007.01057.x
   Zachary I, 2001, AM J PHYSIOL-CELL PH, V280, pC1375, DOI 10.1152/ajpcell.2001.280.6.C1375
NR 20
TC 19
Z9 20
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD FEB
PY 2011
VL 89
IS 1
BP E41
EP E45
DI 10.1111/j.1755-3768.2010.02075.x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 711YL
UT WOS:000286628100006
PM 21232081
OA Bronze
DA 2022-11-30
ER

PT J
AU Richardson, AJ
   Islam, FMA
   Guymer, RH
   Cain, M
   Baird, PN
AF Richardson, Andrea J.
   Islam, F. M. Amirul
   Guymer, Robyn H.
   Cain, Melinda
   Baird, Paul N.
TI A tag-single nucleotide polymorphisms approach to the vascular
   endothelial growth factor-A gene in age-related macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID FACTOR-H POLYMORPHISM; VEGF; MACULOPATHY; EXPRESSION; VARIANT
AB Purpose: Age-related macular degeneration (AMD) is the leading cause of poor vision in the developed world, and its pathogenesis remains unknown. The most devastating form of end stage disease is neovascular or wet AMD, where there is abnormal growth of new blood vessels under the retina. Vascular endothelial growth factor (VEGF) is thought to be a major player in the stimulus of this abnormal growth of blood vessels. We undertook a case-control association study to investigate the VEGF-A gene, a known angiogenic gene that has previously been associated with AMD.
   Methods: We recruited 577 individuals with AMD (early, atrophic, and neovascular AMD) and 173 ethnically matched controls for our study. We employed a tag-single nucleotide polymorphisms (tSNP) approach to investigate this gene using a series of seven tSNPs that encompassed the coding region of the VEGF gene as well as its promoter. Alleles were determined by a MALDI-TOF based approach followed by statistical analysis.
   Results: One SNP (rs3024997) showed evidence of departure from Hardy-Weinberg equilibrium in only the AMD cases. Therefore, it was retained for further analysis. All other SNPs in our study showed no departure from Hardy-Weinberg equilibrium. No association was found between any of the VEGF tSNPs analysed in our study and AMD nor any of its sub-types.
   Conclusions: Using a tSNP approach, we found no evidence of an association of these SNPs within the VEGF-A gene being associated with either AMD or any of its subtypes in our population.
C1 [Richardson, Andrea J.; Islam, F. M. Amirul; Guymer, Robyn H.; Cain, Melinda; Baird, Paul N.] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
C3 Centre for Eye Research Australia; University of Melbourne
RP Richardson, AJ (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM andreajr@unimelb.edu.au
RI Islam, Fakir M Amirul/P-6665-2015
OI Islam, Fakir M Amirul/0000-0003-3897-3302; Guymer,
   Robyn/0000-0002-9441-4356; Baird, Paul/0000-0002-1305-3502
CR Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Carter KW, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-60
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   DEJONG PT, 2007, IOVS, V48
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Ikeda Y, 2006, EXP EYE RES, V83, P1031, DOI 10.1016/j.exer.2006.05.007
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Perrin RM, 2005, DIABETOLOGIA, V48, P2422, DOI 10.1007/s00125-005-1951-8
   SMITH SR, 2007, IOVS, V48
   Taylor HR, 2005, MED J AUSTRALIA, V182, P565, DOI 10.5694/j.1326-5377.2005.tb06815.x
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
NR 18
TC 39
Z9 40
U1 0
U2 2
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD NOV 26
PY 2007
VL 13
IS 242-45
BP 2148
EP 2152
PG 5
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 310QW
UT WOS:000256546100003
PM 18079689
DA 2022-11-30
ER

PT J
AU Taipale, C
   Lindholm, JM
   Laine, I
   Tuuminen, R
AF Taipale, Claudia
   Lindholm, Juha-Matti
   Laine, Ilkka
   Tuuminen, Raimo
TI Comparison of two different treat-and-extend protocols with aflibercept
   in wet age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE aflibercept; anti-vascular endothelial growth factor; treat-and-extend
   regimen; wet age-related macular degeneration
ID VEGF-TRAP; RANIBIZUMAB; BEVACIZUMAB; THERAPY; EYE
AB Purpose To optimize the aflibercept treat-and-extend protocol in wet age-related macular degeneration (wAMD).
   Methods A prospective randomized clinical trial consisting of 52 eyes from 52 patients with treatment-naive wAMD. Patients received three monthly aflibercept injections and were then randomized 1:1 to two different dosing protocols. In treat-and-extend protocol with moderate extensions (T&Em), after the loading phase the treatment interval was extended 1 week at a time up to 12 weeks and then by 2 weeks up to 16 weeks. In treat-and-extend protocol with rapid extensions (T&Er), the interval was first extended to 8 weeks and then by 2 weeks at a time up to 16 weeks. Main outcome measure was the number of given aflibercept injections.
   Results Fifty (96%) patients completed the 1-year follow-up. Patient and ophthalmic baseline variables were comparable between the study groups. At 1 year, central subfield macular thickness reduced by 194.3 +/- 153.6 mu m in T&Em protocol, compared with 194.2 +/- 176.6 mu m in T&Er (p = 0.997). Eyes with T&Em gained 10.3 +/- 11.5 letters from baseline and eyes with T&Er 11.4 +/- 10.6 letters (p = 0.434), and dry macula was observed in 72% of eyes with T&Em compared to 68% with T&Er (p = 0.758). At 1 year, the treatment interval was 8.5 +/- 2.2 weeks in T&Em and 10.3 +/- 2.8 weeks in T&Er (p = 0.017), and the total number of injections 8.64 +/- 1.58 and 6.96 +/- 0.79, respectively (p < 0.001). In the rapid extensions protocol, 48% of eyes reached a 12-week treatment interval or beyond at 1 year.
   Conclusions At one year, the anatomical and functional responses were comparable between the moderate and rapid extensions protocols, with fewer aflibercept injections in the rapid extension protocol.
C1 [Taipale, Claudia; Lindholm, Juha-Matti; Laine, Ilkka; Tuuminen, Raimo] Univ Helsinki, Helsinki Retina Res Grp, Helsinki, Finland.
   [Taipale, Claudia; Lindholm, Juha-Matti] Helsinki Univ Hosp, Dept Ophthalmol, Helsinki, Finland.
   [Laine, Ilkka; Tuuminen, Raimo] Kymenlaakso Cent Hosp, Dept Ophthalmol, Kotka, Finland.
C3 University of Helsinki; University of Helsinki; Helsinki University
   Central Hospital
RP Tuuminen, R (通讯作者)，Kymenlaakso Cent Hosp, Unit Ophthalmol, Kotkantie 41, FI-48210 Kotka, Finland.
EM raimo.tuuminen@helsinki.fi
OI Tuuminen, Raimo/0000-0003-1550-8125; Laine, Ilkka/0000-0002-1496-9862;
   Taipale, Claudia/0000-0001-9424-8872
FU Finnish Eye Foundation; Finnish Ophthalmological Society; Nissi
   Foundation; Orion Research Foundation; Mary and Georg C. Ehrnrooth
   foundation, Sokeain Ystavat ry; Paulo Foundation; Waldemar von Frenckell
   Foundation, Glaukooma tukisaatio LUX; HUS Specific Catchment Area (ERVA)
   Clinical Research Grants
FX The study was supported by grants from the Finnish Eye Foundation,
   Finnish Ophthalmological Society, the Nissi Foundation, Orion Research
   Foundation, the Mary and Georg C. Ehrnrooth foundation, Sokeain Ystavat
   ry, the Paulo Foundation, the Waldemar von Frenckell Foundation,
   Glaukooma tukisaatio LUX and the HUS Specific Catchment Area (ERVA)
   Clinical Research Grants. We would like to thank Ms. Reetta Osterberg
   and Ms. Enni Sarkka for their work as research assistant.
CR Berg K, 2017, ACTA OPHTHALMOL
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Decroos FC, 2017, AM J OPHTHALMOL, V180, P142, DOI 10.1016/j.ajo.2017.06.002
   Guymer RH, 2018, OPHTHALMOLOGY
   Haga A, 2018, ACTA OPHTHALMOL, V96, pE393, DOI 10.1111/aos.13607
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Lotery A, 2017, EYE, V31, P1697, DOI 10.1038/eye.2017.143
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Spaide RF, 2009, AM J OPHTHALMOL, V148, P1, DOI 10.1016/j.ajo.2009.04.010
   Tuulonen A, 2016, ACTA OPHTHALMOL, V94, P730, DOI 10.1111/aos.13168
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 21
TC 5
Z9 6
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAY
PY 2020
VL 98
IS 3
BP 267
EP 273
DI 10.1111/aos.14231
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LH4QT
UT WOS:000528770500009
PM 31421024
DA 2022-11-30
ER

PT J
AU Ozyurt, A
   Kocak, N
   Akan, P
   Calan, OG
   Ozturk, T
   Kaya, M
   Karahan, E
   Kaynak, S
AF Ozyurt, Ayhan
   Kocak, Nilufer
   Akan, Pinar
   Calan, Ozlem Gursoy
   Ozturk, Taylan
   Kaya, Mahmut
   Karahan, Eyup
   Kaynak, Suleyman
TI Comparison of macular pigment optical density in patients with dry and
   wet age-related macular degeneration
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; macular pigment optical density; serum
   lutein; serum zeaxanthin
ID HETEROCHROMATIC FLICKER PHOTOMETRY; CAROTENOID LEVELS; DONOR EYES;
   MACULOPATHY; POPULATION; ZEAXANTHIN; LUTEIN; RISK; LIGHT;
   AUTOFLUORESCENCE
AB Aim: The aim of the study was to evaluate the macular pigment optical density (MPOD) levels in patients with wet age-related macular degeneration (AMD), dry AMD, and also in healthy controls. Settings and Design: This study was conducted at Department of Ophthalmology, and the study design was a prospective study. Patients and Methods: Forty-eight patients with wet AMD, 51 patients with dry AMD, and 50 controls were included in the study. All patients were naive to both previous lutein or zeaxanthin administration and any previous intravitreal injections. Fundus reflectance (VISUCAM 500, reflectance of a single 460 nm wavelength) was used to measure the MPOD levels. Three groups were compared regarding age, gender, serum lutein, and zeaxanthin concentrations as well as MPOD levels. Results: Serum lutein and zeaxanthin levels were significantly higher in control group when compared with wet AMD (Group 1) and dry AMD (Group 2) (P = 0.001 and P < 0.001, respectively). Mean MPOD was found to be similar in all of the three study subgroups (P = 0.630). However, maximum MPOD was significantly higher in control group when compared with Group 1 and 2 (P = 0.003). There was no correlation between serum lutein or zeaxanthin concentrations and mean MPOD levels (P = 0.815, r = 0.014 and P = 0.461, r = 0.043, respectively), but there was a weak correlation between serum zeaxanthin concentration and maximum MPOD level (P = 0.042, r = 0.124). Maximum MPOD level was found to be correlated with the level of AMD (Group 1, 2, and 3; r = 0.184, P = 0.041). Conclusion: Maximum MPOD level was found to be lower in patients with AMD when compared with control cases. Mean MPOD and maximum MPOD levels were similar in wet and dry AMD Groups. These results can be applied clinically keeping in mind that MPOD measurements with one wavelength reflectometry may not be completely reliable.
C1 [Ozyurt, Ayhan; Kocak, Nilufer; Ozturk, Taylan; Kaya, Mahmut; Kaynak, Suleyman] Dokuz Eylul Univ, Sch Med, Dept Ophthalmol, Izmir, Turkey.
   [Akan, Pinar; Calan, Ozlem Gursoy] Dokuz Eylul Univ, Sch Med, Dept Biochem, Izmir, Turkey.
   [Karahan, Eyup] Karatas Hosp, Dept Ophthalmol, Izmir, Turkey.
C3 Dokuz Eylul University; Dokuz Eylul University
RP Kaya, M (通讯作者)，Mithatpasa Cad 2,338 D 12, TR-35220 Izmir, Turkey.
EM mahmutkaya78@yahoo.com
RI AKAN, Pinar/A-1135-2018; karahan, eyyup/U-2977-2017; GURSOY DORUK,
   OZLEM/AFO-7245-2022; Ozturk, Taylan/AAC-6680-2019
OI AKAN, Pinar/0000-0001-9211-1944; GURSOY DORUK,
   OZLEM/0000-0002-1312-3777; Ozturk, Taylan/0000-0001-6633-0553
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2002, INVEST OPHTH VIS SCI, V43, P1928
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Bhosale P, 2007, INVEST OPHTH VIS SCI, V48, P543, DOI 10.1167/iovs.06-0558
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Ciulla TA, 2004, AM J OPHTHALMOL, V138, P582, DOI 10.1016/j.ajo.2004.05.057
   Davies NP, 2004, PROG RETIN EYE RES, V23, P533, DOI 10.1016/j.preteyeres.2004.05.004
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   Dennison JL, 2013, EXP EYE RES, V116, P190, DOI 10.1016/j.exer.2013.08.014
   Hammer M, 2003, OPHTHALMOLOGE, V100, P611, DOI 10.1007/s00347-002-0782-y
   Hebert JR, 1998, PUBLIC HEALTH NUTR, V1, P123, DOI 10.1079/PHN19980019
   Howells O, 2011, GRAEF ARCH CLIN EXP, V249, P315, DOI 10.1007/s00417-010-1577-5
   Jahn C, 2005, GRAEF ARCH CLIN EXP, V243, P222, DOI 10.1007/s00417-004-0995-7
   Kanis MJ, 2008, INVEST OPHTH VIS SCI, V49, P2077, DOI 10.1167/iovs.07-1181
   Kanis MJ, 2007, GRAEF ARCH CLIN EXP, V245, P767, DOI 10.1007/s00417-006-0478-0
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   LaRowe TL, 2008, OPHTHALMOLOGY, V115, P876, DOI 10.1016/j.ophtha.2007.06.015
   Loane E, 2008, BRIT J OPHTHALMOL, V92, P1163, DOI 10.1136/bjo.2007.135566
   Loane E, 2008, SURV OPHTHALMOL, V53, P68, DOI 10.1016/j.survophthal.2007.10.008
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Mellerio J, 2002, CURR EYE RES, V25, P37, DOI 10.1076/ceyr.25.1.37.9961
   Obana A, 2008, OPHTHALMOLOGY, V115, P147, DOI 10.1016/j.ophtha.2007.02.028
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Thomson LR, 2002, INVEST OPHTH VIS SCI, V43, P3538
   Thomson LR, 2002, EXP EYE RES, V75, P529, DOI 10.1006/exer.2002.2050
   Trieschmann M, 2008, EYE, V22, P132, DOI 10.1038/sj.eye.6702780
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   WERNER JS, 1987, VISION RES, V27, P257, DOI 10.1016/0042-6989(87)90188-X
   Wustemeyer H, 2003, GRAEF ARCH CLIN EXP, V241, P647, DOI 10.1007/s00417-003-0730-9
NR 35
TC 9
Z9 10
U1 0
U2 10
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD JUN
PY 2017
VL 65
IS 6
BP 477
EP 481
DI 10.4103/ijo.IJO_365_16
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EZ5FW
UT WOS:000404739900010
PM 28643712
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Jonas, JB
   Kreissig, I
   Degenring, RF
AF Jonas, JB
   Kreissig, I
   Degenring, RF
TI Factors influencing visual acuity after intravitreal triamcinolone
   acetonide as treatment of exudative age related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CRYSTALLINE CORTISONE; CHOROIDAL NEOVASCULARIZATION; ADJUNCTIVE
   TREATMENT; PHOTODYNAMIC THERAPY; INJECTION; EDEMA; ENDOPHTHALMITIS;
   VERTEPORFIN; INHIBITION; RECURRENCE
AB Aim: To evaluate factors influencing change in visual acuity (VA) after intravitreal injection of triamcinolone acetonide as treatment of exudative age related macular degeneration (AMD).
   Methods: This prospective, interventional, comparative non-randomised clinical case series study included 94 patients (99 eyes) showing progressive exudative AMD with occult (n=61 eyes), minimally classic (n=18), predominantly classic (n=1), or totally classic (n=8) subfoveal neovascularisation. Mean follow up was 8.5 (SD 4.7) months (median, 7.3 months; range 3.1-24.5 months). All patients received an intravitreal injection of 20-25 mg of triamcinolone acetonide.
   Results: An increase in best VA of at least one line on the Snellen charts was found in 63 (63.1%) eyes. Correspondingly, mean VA increased significantly (p<0.001) from 0.17 (SD 0.13) to 0.22 (SD 0.17) after the injection. Postoperative increase in VA was significantly (p<0.001) and negatively correlated with preoperative VA (correlation coefficient, -0.49). Gain in visual acuity was significantly (p=0.009) higher if preoperative visual acuity was less than 0.08 (gain: 3.2 (SD 2.9) Snellen lines) than if preoperative VA ranged between 0.08 and 0.20 (gain: 1.2 (SD 2.2) Snellen lines). Change in VA was significantly (p=0.016) less if preoperative VA was higher than 0.20 (change: -0.8 (SD 3.4) Snellen lines). Maximal gain in VA was significantly (p=0.035) larger in eyes with retinal pigment epithelium detachment than in eyes with minimally classic subfoveal neovascularisation. This was statistically independent of age (p=0.99), refractive error (p=0.88), sex (p=0.92), and duration of follow up (p=0.46).
   Conclusions: Gain in VA after intravitreal injection of 20-25 mg of triamcinolone acetonide is significantly and negatively correlated with preoperative VA. It is significantly larger in eyes with retinal pigment epithelium detachment than in eyes with minimally classic subfoveal neovascularisation.
C1 Heidelberg Univ, Dept Ophthalmol, Fac Clin Med Mannheim, D-6900 Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg
RP Jonas, JB (通讯作者)，Heidelberg Univ, Augenklin, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM Jost.Jonas@ma.augen.uni-heidelberg.de
CR Antcliff RJ, 2001, OPHTHALMOLOGY, V108, P765, DOI 10.1016/S0161-6420(00)00658-8
   ANTOSZYK AN, 1993, GRAEF ARCH CLIN EXP, V231, P34, DOI 10.1007/BF01681698
   Beer PM, 2003, OPHTHALMOLOGY, V110, P681, DOI 10.1016/S0161-6420(02)01969-3
   Benhamou N, 2003, AM J OPHTHALMOL, V135, P246, DOI 10.1016/S0002-9394(02)01938-4
   Benz MS, 2003, ARCH OPHTHALMOL-CHIC, V121, P271
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Conway MD, 2003, J CATARACT REFR SURG, V29, P27, DOI 10.1016/S0886-3350(02)01441-4
   Danis RP, 1996, OPHTHALMOLOGY, V103, P2099, DOI 10.1016/S0161-6420(96)30383-7
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Degenring RF, 2003, BRIT J OPHTHALMOL, V87, P361, DOI 10.1136/bjo.87.3.361
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Greenberg PB, 2002, BRIT J OPHTHALMOL, V86, P247, DOI 10.1136/bjo.86.2.247
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   Jonas JB, 2003, ARCH OPHTHALMOL-CHIC, V121, P57
   Jonas JB, 2001, AM J OPHTHALMOL, V132, P425, DOI 10.1016/S0002-9394(01)01010-8
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P24, DOI 10.1136/bjo.87.1.24
   Jonas JB, 2000, BRIT J OPHTHALMOL, V84, P1064, DOI 10.1136/bjo.84.9.1064
   Jonas JB, 2004, AM J OPHTHALMOL, V137, P560, DOI 10.1016/j.ajo.2003.08.012
   Jonas JB, 2003, AM J OPHTHALMOL, V136, P384, DOI 10.1016/S0002-9394(03)00230-7
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Jonas JB, 2002, BRIT J OPHTHALMOL, V86, P1066, DOI 10.1136/bjo.86.9.1066
   Jonas JB, 2002, BRIT J OPHTHALMOL, V86, P1450, DOI 10.1136/bjo.86.12.1450-a
   Jonas JB, 2002, GRAEF ARCH CLIN EXP, V240, P782, DOI 10.1007/s00417-002-0529-0
   Jonas JB, 2002, GRAEF ARCH CLIN EXP, V240, P872, DOI 10.1007/s00417-002-0547-y
   Jonas JB, 2001, J GLAUCOMA, V10, P284, DOI 10.1097/00061198-200108000-00007
   Jonas JB, 2001, GRAEF ARCH CLIN EXP, V239, P464, DOI 10.1007/s004170100293
   Jonas JB, 2001, AM J OPHTHALMOL, V131, P468, DOI 10.1016/S0002-9394(00)00882-5
   Martidis A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1380
   Martidis A, 2002, OPHTHALMOLOGY, V109, P920, DOI 10.1016/S0161-6420(02)00975-2
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Penfold PL, 2002, INVEST OPHTH VIS SCI, V43, P3125
   Penfold PL, 2002, BRIT J OPHTHALMOL, V86, P600, DOI 10.1136/bjo.86.6.600
   Penfold PL, 2001, CLIN EXP OPHTHALMOL, V29, P188, DOI 10.1046/j.1442-9071.2001.00407.x
   Penn JS, 2001, INVEST OPHTH VIS SCI, V42, P283
   Peyman GA, 2000, RETINA-J RET VIT DIS, V20, P554, DOI 10.1097/00006982-200005000-00024
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Sutter FKP, 2003, BRIT J OPHTHALMOL, V87, P972, DOI 10.1136/bjo.87.8.972
   TANO Y, 1980, AM J OPHTHALMOL, V89, P131, DOI 10.1016/0002-9394(80)90239-1
   TANO Y, 1980, AM J OPHTHALMOL, V90, P810, DOI 10.1016/S0002-9394(14)75196-7
   Wingate RJB, 1999, AUST NZ J OPHTHALMOL, V27, P431
   Young S, 2001, CLIN EXP OPHTHALMOL, V29, P2, DOI 10.1046/j.1442-9071.2001.00360.x
NR 46
TC 35
Z9 36
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2004
VL 88
IS 12
BP 1557
EP 1562
DI 10.1136/bjo.2003.039552
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 871VP
UT WOS:000225165000021
PM 15548812
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Leu, ST
   Batni, S
   Radeke, MJ
   Johnson, LV
   Anderson, DH
   Clegg, DO
AF Leu, ST
   Batni, S
   Radeke, MJ
   Johnson, LV
   Anderson, DH
   Clegg, DO
TI Drusen are cold spots for proteolysis: Expression of matrix
   metalloproteinases and their tissue inhibitor proteins in age-related
   macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE matrix metalloproteinase; tissue inhibitor of metalloproteinase; retinal
   pigment epithelium; drusen; age-related macular degeneration;
   collagenase; gelatinase; in situ zymography; neurodegeneration; retina;
   choroids; Bruch's membrane
ID RETINAL-PIGMENT EPITHELIUM; SORSBYS FUNDUS DYSTROPHY; BEAVER DAM EYE;
   BRUCHS MEMBRANE; INTERPHOTORECEPTOR MATRIX; STARGARDT-DISEASE;
   GELATINASE-A; TIMP-3; MACULOPATHY; GENE
AB Drusen are abnormal extracellular matrix deposits characteristic of age-related macular degeneration (AMD), a leading cause of blindness in the aging human population. The mechanisms underlying drusen formation are not well characterized. The purpose of this study was to examine the expression of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in drusen, and in the surrounding cells and tissue. To assess the extent of MMP and TIMP expression by retinal pigment epithelial (RPE) cells, cDNA arrays were screened with probes generated from cultured human RPE cells. The distribution of MMP-1, -2 and -3 and TIMP-1, -2, -3 and -4 was determined using immunohistochemistry in human RPE choroid from donor eyes with and without a clinical history of AMD. Gelatinase activity was assessed in unfixed frozen sections using in situ zymography. in cultured RPE cells, expression of 10 MMP and all four known TIMP mRNAs was detected. MMP immunoreactivity was widespread in the RPE choroid, but was absent from the interior of drusen. TIMP-3. but not other TIMPs, was detected in the drusen interior, Likewise, metal ion dependent gelatinase activity could be detected in RPE choroid, but not in drusen. These results show that, while metalloproteinase activity is widespread throughout the RPE choroid, drusen are cold spots for proteolysis. The data lead to the speculation that high TIMP-3 concentrations within drusen could inhibit MMPs and as a result slow the proteolytic degradation of these deposits. (C) 2002 Elsevier Science Ltd.
C1 Univ Calif Santa Barbara, Neurosci Res Inst, Ctr Study Macular Degenerat, Santa Barbara, CA 93106 USA.
   Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.
C3 University of California System; University of California Santa Barbara;
   University of California System; University of California Santa Barbara
RP Clegg, DO (通讯作者)，Univ Calif Santa Barbara, Neurosci Res Inst, Ctr Study Macular Degenerat, Santa Barbara, CA 93106 USA.
FU NATIONAL EYE INSTITUTE [R01EY011521, R01EY006916, R55EY006916,
   R01EY011527] Funding Source: NIH RePORTER; NEI NIH HHS [EY11527,
   EY06916, EY11521, EY0973] Funding Source: Medline
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   ALEXANDER JP, 1990, INVEST OPHTH VIS SCI, V31, P2520
   Allikmets R, 2000, AM J HUM GENET, V67, P793, DOI 10.1086/303100
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   ARMSTRONG PW, 1994, CAN J CARDIOL, V10, P214
   Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496
   Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4
   BRINCKERHOFF C E, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P145
   Brown PD, 2000, EXPERT OPIN INV DRUG, V9, P2167, DOI 10.1517/13543784.9.9.2167
   Chong NHV, 2000, INVEST OPHTH VIS SCI, V41, P898
   DelaPaz MA, 1997, INVEST OPHTH VIS SCI, V38, P1060
   EGAN KM, 1994, PRINCIPLES PRACTICE
   Fariss RN, 1998, BRIT J OPHTHALMOL, V82, P1329, DOI 10.1136/bjo.82.11.1329
   Fariss RN, 1997, AM J PATHOL, V150, P323
   Gomez DE, 1997, EUR J CELL BIOL, V74, P111
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Jomary C, 1997, NEUROREPORT, V8, P2169, DOI 10.1097/00001756-199707070-00015
   Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kvanta A, 2000, CURR EYE RES, V21, P684, DOI 10.1076/0271-3683(200009)21:3;1-R;FT684
   Langton KP, 2000, J BIOL CHEM, V275, P27027
   Lin H, 1998, INVEST OPHTH VIS SCI, V39, P1703
   LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C
   Mullins RF, 1997, OPHTHALMOLOGY, V104, P288, DOI 10.1016/S0161-6420(97)30322-4
   NEWSOME DA, 1987, AM J OPHTHALMOL, V104, P373, DOI 10.1016/0002-9394(87)90227-3
   Nie GY, 1999, J BIOCHEM BIOPH METH, V40, P81, DOI 10.1016/S0165-022X(99)00019-6
   Noji Y, 2001, CLIN CHEM LAB MED, V39, P380, DOI 10.1515/CCLM.2001.060
   Padgett LC, 1997, EXP EYE RES, V64, P927, DOI 10.1006/exer.1997.0287
   Parsons SL, 1997, BRIT J SURG, V84, P160, DOI 10.1046/j.1365-2168.1997.02719.x
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Plantner JJ, 1998, EXP EYE RES, V67, P637, DOI 10.1006/exer.1998.0552
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Ruiz A, 1996, BIOCHEM BIOPH RES CO, V226, P467, DOI 10.1006/bbrc.1996.1379
   SARKS SH, 2001, RETINA, P1064
   SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Sethi CS, 2000, BRIT J OPHTHALMOL, V84, P654, DOI 10.1136/bjo.84.6.654
   Smine A, 1997, CURR EYE RES, V16, P925, DOI 10.1076/ceyr.16.9.925.5044
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Takahashi T, 2000, AM J OPHTHALMOL, V130, P774, DOI 10.1016/S0002-9394(00)00772-8
   Vranka JA, 1997, CURR EYE RES, V16, P102, DOI 10.1076/ceyr.16.2.102.5086
   Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Webster AR, 2001, INVEST OPHTH VIS SCI, V42, P1179
   YANG TT, 1992, P NATL ACAD SCI USA, V89, P10676, DOI 10.1073/pnas.89.22.10676
NR 49
TC 52
Z9 56
U1 0
U2 1
PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
J9 EXP EYE RES
JI Exp. Eye Res.
PD JAN
PY 2002
VL 74
IS 1
BP 141
EP 154
DI 10.1006/exer.2001.1112
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 542JX
UT WOS:000175040700015
PM 11878827
DA 2022-11-30
ER

PT J
AU Adam, MK
   Rayess, N
   Rahimy, E
   Maguire, JI
   Hsu, J
AF Adam, Murtaza K.
   Rayess, Nadim
   Rahimy, Ehsan
   Maguire, Joseph I.
   Hsu, Jason
TI Radial versus raster spectral-domain optical coherence tomography scan
   patterns for detection of macular fluid in neovascular age-related
   macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID EXTEND REGIMEN; BEVACIZUMAB; OUTCOMES
AB Background/aims To compare the 12-line radial to the 25-line raster spectral-domain optical coherence tomography (SD-OCT) acquisition patterns at detecting intraretinal or subretinal fluid in eyes with neovascular age-related macular degeneration (AMD).
   Methods Retrospective cross-sectional analysis of 200 eyes with neovascular AMD. Sequential 12-line radial and 25-line raster scans were evaluated for the presence of intraretinal/subretinal fluid.
   Results A total of 394 SD-OCT scans were interpreted (1.97 scans per eye). The 12-line radial detected intraretinal/subretinal fluid in all but 7 of 394 scans (1.7%; 95% CI 0.7% to 3.6%), resulting in a sensitivity of 98.3%. The 25-line raster detected intraretinal/subretinal fluid in all but 10 of 394 scans (2.5%; 95% CI 1.2% to 4.6%), resulting in a sensitivity of 97.5%. This small difference in fluid detection between the two acquisition patterns for neovascular AMD was not found to be statistically significant (p=0.6276).
   Conclusions The 12-line radial scan is statistically comparable with the 25-line raster scan in detecting the presence of intraretinal/subretinal fluid in neovascular AMD. The 12-line radial SD-OCT pattern alone may be adequate to guide day-to-day clinical decisions in a more time-efficient manner.
C1 [Adam, Murtaza K.; Rayess, Nadim; Rahimy, Ehsan; Maguire, Joseph I.; Hsu, Jason] Thomas Jefferson Univ, Retina Serv Wills Eye Hosp, Mid Atlantic Retina, Philadelphia, PA 19107 USA.
C3 Jefferson University
RP Adam, MK (通讯作者)，Thomas Jefferson Univ, Retina Serv Wills Eye Hosp, Mid Atlantic Retina, Philadelphia, PA 19107 USA.
EM murtaza.adam@gmail.com
OI Adam, Murtaza/0000-0003-2689-7111; Rahimy, Ehsan/0000-0001-8446-7078
FU Ophthotech; Santec; Heed Ophthalmic Foundation
FX Unrelated to this study, JH is a consultant for Xoma and Optovue. He
   also receives grant support from Ophthotech and Santec. JIM is a
   consultant for Genentech and Regeneron. He also serves on an advisory
   board for Genentech.; MA was supported by a grant from the Heed
   Ophthalmic Foundation.
CR Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rahimy E, 2014, AM J OPHTHALMOL, V158, P345, DOI 10.1016/j.ajo.2014.05.013
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Shienbaum G, 2012, AM J OPHTHALMOL, V153, P468, DOI 10.1016/j.ajo.2011.08.011
   Sonmez K, 2011, RETINA-J RET VIT DIS, V31, P645, DOI 10.1097/IAE.0b013e3182012d18
NR 7
TC 7
Z9 7
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD APR
PY 2016
VL 100
IS 4
BP 491
EP 494
DI 10.1136/bjophthalmol-2014-306561
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DH0JA
UT WOS:000372469300010
PM 26261232
DA 2022-11-30
ER

PT J
AU Franzco, FKC
   Uppal, GS
   MacLaren, RE
   Coffey, PJ
   Rubin, GS
   Tufail, A
   Aylward, GW
   Da Cruz, L
AF Franzco, Fred K. Chen
   Uppal, Gurmit S.
   MacLaren, Robert E.
   Coffey, Peter J.
   Rubin, Gary S.
   Tufail, Adnan
   Aylward, G. William
   Da Cruz, Lyndon
TI Long-term visual and microperimetry outcomes following autologous
   retinal pigment epithelium choroid graft for neovascular age-related
   macular degeneration
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE AMD; microperimetry; RPE; transplantation; vitreoretinal surgery
ID SCANNING LASER OPHTHALMOSCOPE; OPTICAL COHERENCE TOMOGRAPHY;
   TRANSLOCATION SURGERY; FUNDUS AUTOFLUORESCENCE; PATIENT SELECTION; RPE;
   TRANSPLANTATION; DISEASE; RANIBIZUMAB
AB To describe the 2- to 4-year visual and microperimetry outcomes of autologous retinal pigment epithelium (RPE)-choroid graft in patients with neovascular age-related macular degeneration (AMD).
   In this retrospective cohort study, 12 patients with subfoveal neovascular AMD who had undergone autologous RPE-choroid graft between August 2004 and June 2005 were reviewed. Change in visual acuity (VA), contrast sensitivity (CS), fixation stability and retinal sensitivity on microperimetry after 2-3 years and the rates of late postoperative complications were examined.
   Patients were followed for 26-48 months (mean, 39). Median preoperative VA (logMAR) was 0.87 but declined to 1.43 (1 year), 1.46 (2 years) and 1.38 (3 years), P = 0.001. Median CS (logCS) was 0.75 preoperatively but declined to 0.45 at 2 years. Six patients had serial microperimetry. Fixation stability declined in 1 but improved in 2 patients. All 6 had decline in retinal sensitivity over the graft during follow up. Retinal detachment did not occur after 12 months but 8 developed epiretinal membrane, 12 had cystic retinal change over the graft and 4 developed recurrent choroidal neovascularization. However, 10 grafts retained autofluorescence signal at 18-48 months of follow up.
   Autologous RPE-choroid graft can maintain VA, stable fixation and retinal sensitivity in some patients for over 3 years. The spatial correlation between graft autofluorescence, outer retinal structures on optical coherence tomography and retinal sensitivity are consistent with photoreceptor cell rescue. However, we caution the use of this technique as there is high complication rate and delayed loss of retinal function.
C1 [Franzco, Fred K. Chen; Uppal, Gurmit S.; MacLaren, Robert E.; Coffey, Peter J.; Tufail, Adnan; Aylward, G. William; Da Cruz, Lyndon] Moorfields Eye Hosp, London EC1V 2PD, England.
   [Franzco, Fred K. Chen; MacLaren, Robert E.; Coffey, Peter J.; Rubin, Gary S.; Da Cruz, Lyndon] UCL Inst Ophthalmol, London, England.
   [MacLaren, Robert E.; Rubin, Gary S.] NIHR Biomed Res Ctr Ophthalmol, London, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   University of London; University College London
RP Franzco, FKC (通讯作者)，Moorfields Eye Hosp, 162 City Rd, London EC1V 2PD, England.
EM fred.chen@moorfields.nhs.uk
RI , Fred/B-8158-2013
OI , Fred/0000-0003-2809-9930; MacLaren, Robert/0000-0002-3096-4682;
   Tufail, Adnan/0000-0001-6131-7640; Coffey, Peter/0000-0002-5427-2939
FU MRC [G0601588] Funding Source: UKRI; Medical Research Council [G0601588]
   Funding Source: Medline
CR Aisenbrey S, 2007, ARCH OPHTHALMOL-CHIC, V125, P1367, DOI 10.1001/archopht.125.10.1367
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen FK, 2008, INVEST OPHTH VIS SCI, V49, P3143, DOI 10.1167/iovs.07-1648
   Convento E, 2007, PERIMETRY FUNDUS INT, P229
   Crossland MD, 2004, OPHTHAL PHYSL OPT, V24, P327, DOI 10.1111/j.1475-1313.2004.00213.x
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1737, DOI 10.1016/S0161-6420(02)01120-X
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Heussen FMA, 2008, EYE, V22, P799, DOI 10.1038/sj.eye.6702823
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   Maaijwee K, 2008, BRIT J OPHTHALMOL, V92, P526, DOI 10.1136/bjo.2007.131383
   Maaijwee K, 2008, INVEST OPHTH VIS SCI, V49, P758, DOI 10.1167/iovs.07-0510
   Maaijwee K, 2007, GRAEF ARCH CLIN EXP, V245, P1681, DOI 10.1007/s00417-007-0607-4
   MacLaren RE, 2005, OPHTHALMOLOGY, V112, P2081, DOI 10.1016/j.ophtha.2005.06.029
   MacLaren RE, 2007, OPHTHALMOLOGY, V114, P561, DOI 10.1016/j.ophtha.2006.06.049
   Midena Edoardo, 2004, Semin Ophthalmol, V19, P55, DOI 10.1080/08820530490882896
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Stanga PE, 2002, OPHTHALMOLOGY, V109, P1492, DOI 10.1016/S0161-6420(02)01099-0
   Toth CA, 2004, GRAEF ARCH CLIN EXP, V242, P541, DOI 10.1007/s00417-004-0867-1
   Toth CA, 1997, ARCH OPHTHALMOL-CHIC, V115, P1425, DOI 10.1001/archopht.1997.01100160595012
   Treumer F, 2007, OPHTHALMOLOGE, V104, P795, DOI 10.1007/s00347-007-1562-5
   Treumer F, 2007, BRIT J OPHTHALMOL, V91, P349, DOI 10.1136/bjo.2006.102152
   Uppal G, 2007, CLIN EXP OPHTHALMOL, V35, P448, DOI 10.1111/j.1442-9071.2007.01528.x
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
NR 33
TC 41
Z9 44
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD APR
PY 2009
VL 37
IS 3
BP 275
EP 285
DI 10.1111/j.1442-9071.2009.01915.x
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 440NW
UT WOS:000265708000006
PM 19459869
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Azar, G
   Wolff, B
   De Bats, F
   Halfon, J
   Streho, M
   Tick, S
   Castelnovo, L
   Michel, G
   Masse, H
   Vasseur, V
   Sahyoun, M
   Mauget-Faysse, M
AF Azar, Georges
   Wolff, Benjamin
   De Bats, Flore
   Halfon, Jeremie
   Streho, Mate
   Tick, Sarah
   Castelnovo, Laurent
   Michel, Guillaume
   Masse, Helene
   Vasseur, Vivien
   Sahyoun, Marwan
   Mauget-Faysse, Martine
TI Morphological Predictive Features on Spectral-Domain Optical Coherence
   Tomography for Visual Outcomes in Neovascular Age-Related Macular
   Degeneration Treated with Ranibizumab
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID SUBGROUP ANALYSIS; HIGH-SPEED; BEVACIZUMAB; PROGNOSIS; THERAPY; ANCHOR;
   ASSOCIATION; VERTEPORFIN; EFFICACY; SUBTYPES
AB Purpose. To identify spectral-domain optical coherence tomography (SD-OCT) predictive morphological features for the outcome of Ranibizumab therapy for neovascular age-related macular degeneration (AMD). Methods. This is a retrospective multicentric study that involved 64 eyes with naive AMD. Patients who received three monthly intravitreal injections of Ranibizumab were stratified into (1) "responders" [>= 5 letters gain on Early Treatment Diabetic Retinopathy Study (ETDRS) scale] and (2) "nonresponders" (< 5 letters gain). Best-corrected visual acuity (BCVA) and SD-OCT morphological features were compared at baseline and one month after three consecutive injections of Ranibizumab. Univariate and multivariate analyses were carried out to correlate these morphological features with the change in BCVA. Results. Among the 64 patients enrolled, 40 (62.5%) were "responders" and 24 (37.5%) "nonresponders". Age, sex, and BCVA were comparable between both groups. A multivariate correlational analysis found that subfoveal choroidal thickness (SFCT) and the presence of pigment epithelial detachment (PED) > 250 mu m at baseline were two independent prognostic indicators of final BCVA. No other SD-OCT morphological studied features seem to affect final BCVA after Ranibizumab treatment. Conclusion. SFCT and the presence of PED > 250 mu m are two significant biomarkers that may predict improvement after Ranibizumab therapy for AMD. These markers may guide ophthalmologists' treatment decision under financial constraints and limited time.
C1 [Azar, Georges; Sahyoun, Marwan] Eye & Ear Hosp Int, Beirut, Lebanon.
   [Azar, Georges; Sahyoun, Marwan] Holy Spirit Univ Kaslik USEK, Fac Med, Lebanon, NH USA.
   [Azar, Georges; Sahyoun, Marwan] St Joseph Univ USJ, Fac Med, Beirut, Lebanon.
   [Wolff, Benjamin; Vasseur, Vivien; Mauget-Faysse, Martine] Rothschild Ophthalmol Fdn, 25 Rue Manin, F-75940 Paris 19, France.
   [De Bats, Flore] Pole Vis Ctr, Clin Val dOuest, 39 Chemin Vern, F-69130 Ecully, France.
   [Halfon, Jeremie] Halles Tours Ophthalmol Ctr, 13 Pl Gaston Paillhou, F-37000 Tours, France.
   [Streho, Mate] Explore Vis Ctr, 2 Rue Grandes Terres, F-92500 Rueil Malmaison, France.
   [Tick, Sarah] Quinze Vingts Ophthalmol Natl Ctr, 28 Rue Charenton, F-75571 Paris, France.
   [Castelnovo, Laurent; Michel, Guillaume] Maison Rouge Ophthalmol Ctr, 6 Rue Eglise, F-67000 Strasbourg, France.
   [Masse, Helene] Nantes Univ, Hosp Ctr, 8 Quai Moncousu, F-44000 Nantes, France.
C3 CHNO des Quinze-Vingts; UDICE-French Research Universities; Sorbonne
   Universite; Nantes Universite
RP Azar, G (通讯作者)，Eye & Ear Hosp Int, Beirut, Lebanon.; Azar, G (通讯作者)，Holy Spirit Univ Kaslik USEK, Fac Med, Lebanon, NH USA.; Azar, G (通讯作者)，St Joseph Univ USJ, Fac Med, Beirut, Lebanon.
EM georgesazar@hotmail.com
OI wolff, benjamin/0000-0003-4709-692X
CR Ahlers C, 2009, ACTA OPHTHALMOL, V87, P511, DOI 10.1111/j.1755-3768.2008.01468.x
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2009, AM J OPHTHALMOL, V148, P59, DOI 10.1016/j.ajo.2009.02.006
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chae B, 2015, INVEST OPHTH VIS SCI, V56, P5040, DOI 10.1167/iovs.15-16494
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Coscas G, 2013, OPHTHALMOLOGICA, V229, P32, DOI 10.1159/000342159
   Dervenis N, 2016, CLIN OPHTHALMOL, V10, DOI 10.2147/OPTH.S106734
   Gamulescu MA, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/851648
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hirami Y, 2009, JPN J OPHTHALMOL, V53, P396, DOI 10.1007/s10384-009-0669-4
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mathew R, 2013, AM J OPHTHALMOL, V155, P720, DOI 10.1016/j.ajo.2012.11.003
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Ristau T., 2012, J CLIN EXPT OPHTHALM, V4, DOI [10.4172/2155-9570.1000264, DOI 10.4172/2155-9570.1000264]
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Sayanagi K, 2009, BRIT J OPHTHALMOL, V93, P622, DOI 10.1136/bjo.2008.151977
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Segal O, 2016, RETINA-J RET VIT DIS, V36, P259, DOI 10.1097/IAE.0000000000000690
   Shah VP, 2014, RETINA-J RET VIT DIS, V34, P1281, DOI 10.1097/IAE.0000000000000166
   Singh RP, 2009, BRIT J OPHTHALMOL, V93, P1353, DOI 10.1136/bjo.2008.141879
   Spaide RF, 2012, OPHTHALMOLOGY, V119, P2203, DOI 10.1016/j.ophtha.2012.09.009
   Srinivasan VJ, 2008, INVEST OPHTH VIS SCI, V49, P1571, DOI 10.1167/iovs.07-0838
   Teper SJ, 2010, MOL VIS, V16, P2598
   Tian J, 2012, PHARMACOGENOMICS, V13, P779, DOI [10.2217/PGS.12.53, 10.2217/pgs.12.53]
   Veerappan M, 2016, OPHTHALMOLOGY, V123, P2554, DOI 10.1016/j.ophtha.2016.08.047
   Witkin AJ, 2009, OPHTHALMOLOGY, V116, P956, DOI 10.1016/j.ophtha.2008.12.018
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 40
TC 2
Z9 2
U1 0
U2 8
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2018
VL 2018
AR 7438083
DI 10.1155/2018/7438083
PG 9
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA GM0QF
UT WOS:000437758900001
PM 30046605
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Schmidt-Erfurth, U
   Kiss, C
   Sacu, S
AF Schmidt-Erfurth, Ursula
   Kiss, Christopher
   Sacu, Stefan
TI The role of choroidal hypoperfusion associated with photodynamic therapy
   in neovascular age-related macular degeneration and the consequences for
   combination strategies
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
DE Photodynamic therapy; Antiangiogenic therapy; Age-related macular
   degeneration; Hypoperfusion
ID RANDOMIZED CLINICAL-TRIALS; LIPOPROTEIN-DELIVERED BENZOPORPHYRIN;
   VERTEPORFIN THERAPY; VISUAL-ACUITY; INTRAVITREAL TRIAMCINOLONE;
   ENDOTHELIAL-CELLS; TRIPLE THERAPY; TAP; RANIBIZUMAB; MACULOPATHY
AB The clinical benefits of verteporfin therapy have been documented in a wide variety of patients with choroidal neovascularization (CNV) due to age-related macular degeneration (AMD), and there is encouraging evidence of improved outcomes when this angicrocclusive modality is combined with antiangiogenic agents. Although the clinical benefits of verteporfin mono- and combination therapy are well established, there has been concern that treatment with verteporfin results in hypoperfusion in the treated area and that concomitant use of antiangiogenic agents could prolong this effect. However, despite well-documented occurrences of hypoperfusion on fluorescein and indocyanine green angiography, there is little evidence of associations with functional impairment or other adverse effects. It has also been suggested that hypoperfusion might actually help to reduce recanalization of CNV and permit neuronal recovery by decreasing exposure to oxygen and oxidative radicals. The reduced need for frequent retreatments clearly has a major appeal due to the lower costs associated with fewer interventions and reduced burden of clinical monitoring and diagnostic reevaluations. Ongoing evaluation in randomized clinical trials will provide further clarification on the effect of verteporfin plus ranibizumab compared with ranibizumab monotherapy in terms of visual acuity, anatomical outcomes, treatment frequency, and health economics. The results of these large-scale clinical trials will provide a strong basis for determining the benefits and risks of combination therapy. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Schmidt-Erfurth, Ursula; Kiss, Christopher; Sacu, Stefan] Med Univ Vienna, Dept Ophthalmol, A-1090 Vienna, Austria.
C3 Medical University of Vienna
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
OI Schmidt-Erfurth, Ursula/0000-0002-7788-7311
CR ALLISON BA, 1994, BRIT J CANCER, V69, P833, DOI 10.1038/bjc.1994.162
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Barber PA, 1998, NEUROLOGY, V51, P418, DOI 10.1212/WNL.51.2.418
   Blaha GR, 2008, OPHTHAL SURG LAS IM, V39, P6, DOI 10.3928/15428877-20080101-02
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BROWN DM, 2006, INVEST OPHTH VIS SCI, V46, P2963
   CARDILLO RF, 2003, RETINA, V23, P752
   Costa RA, 2003, RETINA-J RET VIT DIS, V23, P159, DOI 10.1097/00006982-200304000-00004
   Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889
   *EUR MED AG, 2007, SUMM PROD CHAR
   *FDA, 2007, VIS VERT INJ
   Feigl B, 2005, DOC OPHTHALMOL, V111, P135, DOI 10.1007/s10633-005-5319-7
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FOGELMAN AM, 1988, SEMIN THROMB HEMOST, V14, P206, DOI 10.1055/s-2007-1002778
   GAFFNEY J, 1985, J CELL SCI, V79, P317
   Gelisken F, 2004, BRIT J OPHTHALMOL, V88, P207, DOI 10.1136/bjo.2003.018754
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Grisanti S, 2004, AM J OPHTHALMOL, V137, P914, DOI 10.1016/j.ajo.2003.12.049
   Guyer DR, 1996, OPHTHALMOLOGY, V103, P2054, DOI 10.1016/S0161-6420(96)30388-6
   Heier JS, 2005, AM SOC RET SPEC 23 A
   Husain D, 1996, ARCH OPHTHALMOL-CHIC, V114, P978, DOI 10.1001/archopht.1996.01100140186012
   Imaizumi M, 2002, STROKE, V33, P2217, DOI 10.1161/01.STR.0000027638.19392.7E
   Iriyama A, 2008, GRAEF ARCH CLIN EXP, V246, P339, DOI 10.1007/s00417-007-0667-5
   Isola V, 2006, AM J OPHTHALMOL, V142, P680, DOI 10.1016/j.ajo.2006.04.028
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   KAISER PK, 2007, INVEST OPHTH VIS SCI, V48, P2870
   Kim IK, 2006, INVEST OPHTH VIS SCI, V47, P357, DOI 10.1167/iovs.04-0087
   Kiss CG, 2007, INVEST OPHTH VIS SCI, V48, P4544
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Kramer M, 1996, OPHTHALMOLOGY, V103, P427
   Liggett PE, 2006, AM J OPHTHALMOL, V142, P1072, DOI 10.1016/j.ajo.2006.07.029
   Lo Giudice G, 2008, EUR J OPHTHALMOL, V18, P652, DOI 10.1177/112067210801800429
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   MILLER JW, 1995, ARCH OPHTHALMOL-CHIC, V113, P810, DOI 10.1001/archopht.1995.01100060136048
   Postelmans L, 2004, AM J OPHTHALMOL, V138, P803, DOI 10.1016/j.ajo.2004.06.033
   Recchia FM, 2006, RETINA-J RET VIT DIS, V26, P1042, DOI 10.1097/01.iae.0000254894.94013.d8
   Reinke MH, 1999, OPHTHALMOLOGY, V106, P1915, DOI 10.1016/S0161-6420(99)90401-3
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2005, OPHTHALMOLOGY, V112, P2061, DOI 10.1016/j.ophtha.2005.09.007
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 1998, GRAEF ARCH CLIN EXP, V236, P365, DOI 10.1007/s004170050092
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   Schmidt-Erfurth UM, 2007, PROG RETIN EYE RES, V26, P437, DOI 10.1016/j.preteyeres.2007.03.002
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P89
   SCHMIDTERFURTH U, 1995, LASER SURG MED, V17, P178, DOI 10.1002/lsm.1900170207
   Singh CN, 2008, RETINA-J RET VIT DIS, V28, P789, DOI 10.1097/IAE.0b013e31817082d7
   *TAP VIP STUD GROU, 2004, RETINA, V24, P1
   VANDENBERGH H, 2006, INVEST OPHTHALMOL VI, V47
   WISE RJS, 1983, BRAIN, V106, P197, DOI 10.1093/brain/106.1.197
NR 62
TC 26
Z9 29
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD MAR
PY 2009
VL 28
IS 2
BP 145
EP 154
DI 10.1016/j.preteyeres.2009.01.001
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 418IS
UT WOS:000264142500003
PM 19272333
DA 2022-11-30
ER

PT J
AU Corradetti, G
   Byon, I
   Corvi, F
   Cozzi, M
   Staurenghi, G
   Sadda, SR
AF Corradetti, Giulia
   Byon, Iksoo
   Corvi, Federico
   Cozzi, Mariano
   Staurenghi, Giovanni
   Sadda, SriniVas R.
TI Retro mode illumination for detecting and quantifying the area of
   geographic atrophy in non-neovascular age-related macular degeneration
SO EYE
LA English
DT Article
ID FUNDUS AUTOFLUORESCENCE IMAGES; SCANNING LASER OPHTHALMOSCOPY;
   END-POINTS; PROGRESSION; SECONDARY; DISEASE; OCT; PHOTOGRAPHS; DRUSEN;
   LIGHT
AB Purpose To evaluate the ability of retro mode illumination imaging for quantifying atrophy compared to confocal color fundus photography (c-CFP), green light fundus autofluorescence (G-FAF), blue light fundus autofluorescence (B-FAF) using the scanning laser ophthalmoscope (SLO) Mirante device by Nidek (Nidek Co., Ltd, Gamogori, Japan). Methods Eyes with clinical evidence of geographic atrophy (GA) associated with non-neovascular age-related macular degeneration, evaluated at the Doheny Eye Centers-UCLA and Hospital Sacco Milan, were included in this prospective, cross-sectional study. All eyes were imaged with multiple retinal imaging modalities using the SLO Nidek Mirante device: c-CFP, G-FAF, B-FAF, retro mode illumination deviated-right (RMDR), and deviated-left (RMDL). Masked graders measured the GA lesion on each modality and inter-modality and inter-grader repeatability were assessed. Results The mean (SD) area of GA measured 9.76 (3.82) mm(2), 9.75 (3.91) mm(2), 9.76 (3.92) mm(2), 9.82 (3.87) mm(2), and 9.81 (3.86) mm(2) using c-CFP, G-FAF, B-FAF, RMDR, and RMDL, respectively (p = 0.2). Inter-modality correlation was high (Pearson's r > 0.9 and p < 0.0001). Agreement between graders was excellent for all modalities. Conclusions Retro mode imaging demonstrated good agreement for measuring GA compared to other imaging modalities, with a high level of repeatability. Given that retro mode imaging uses infrared light and is comfortable, it may prove to be a useful tool for the assessment of GA in the clinic.
C1 [Corradetti, Giulia; Byon, Iksoo; Corvi, Federico; Sadda, SriniVas R.] Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Corradetti, Giulia] Univ Calif Los Angeles, Stein Eye Inst, Retina Disorders & Ophthalm Genet, Los Angeles, CA USA.
   [Corradetti, Giulia; Sadda, SriniVas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Byon, Iksoo] Pusan Natl Univ, Res Inst Convergence Biomed Sci & Technol, Dept Ophthalmol, Yangsan Hosp,Sch Med, Yangsan, South Korea.
   [Corvi, Federico; Cozzi, Mariano; Staurenghi, Giovanni] Univ Milan, Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Eye Clin, Milan, Italy.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Pusan National
   University; Pusan National University Hospital; University of Milan;
   Luigi Sacco Hospital
RP Sadda, SR (通讯作者)，Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.; Sadda, SR (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
EM SSadda@doheny.org
OI Corvi, Federico/0000-0002-2661-5500; Cozzi, Mariano/0000-0001-7777-2461;
   Byon, Iksoo/0000-0002-2638-8192
CR Acton JH, 2011, ACTA OPHTHALMOL, V89, pE404, DOI 10.1111/j.1755-3768.2011.02123.x
   Arnault E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071398
   Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Borrelli E, 2019, BRIT J OPHTHALMOL, V103, P610, DOI 10.1136/bjophthalmol-2018-311849
   Cleland SC, 2021, OPHTHALMOL RETINA, V5, P41, DOI 10.1016/j.oret.2020.07.006
   Cozzi M, 2020, OPHTHALMOL RETINA, V4, P987, DOI 10.1016/j.oret.2020.04.013
   Csaky K, 2017, INVEST OPHTH VIS SCI, V58, P3456, DOI 10.1167/iovs.17-22339
   Diniz B, 2013, BRIT J OPHTHALMOL, V97, P285, DOI 10.1136/bjophthalmol-2012-302575
   Domalpally A, 2016, OPHTHALMOLOGY, V123, P2401, DOI 10.1016/j.ophtha.2016.06.025
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Gass JD, 1970, STEREOSCOPIC ATLAS M
   Hammer M, 2008, GRAEF ARCH CLIN EXP, V246, P979, DOI 10.1007/s00417-008-0789-4
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Khanifar AA, 2012, RETINA-J RET VIT DIS, V32, P1884, DOI 10.1097/IAE.0b013e3182509778
   Ohkoshi K, 2010, AM J OPHTHALMOL, V150, P856, DOI 10.1016/j.ajo.2010.06.022
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sadda SR, 2016, RETINA-J RET VIT DIS, V36, P1806, DOI 10.1097/IAE.0000000000001283
   Schmitz-Valckenberg S, 2002, GRAEF ARCH CLIN EXP, V240, P73, DOI 10.1007/s00417-001-0413-3
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2016, RETINA-J RET VIT DIS, V36, P2250, DOI 10.1097/IAE.0000000000001258
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   von Ruckmann A, 1998, KLIN MONATSBL AUGENH, V213, P81, DOI 10.1055/s-2008-1034951
   Wolffe M, 2016, EYE, V30, P186, DOI 10.1038/eye.2015.247
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yehoshua Z, 2015, OSLI RETINA, V46, P413, DOI 10.3928/23258160-20150422-03
   Yehoshua Z, 2013, OSLI RETINA, V44, P127, DOI 10.3928/23258160-20130313-05
   Youssef PN, 2011, EYE, V25, P1, DOI 10.1038/eye.2010.149
NR 35
TC 2
Z9 2
U1 0
U2 0
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD AUG
PY 2022
VL 36
IS 8
BP 1560
EP 1566
DI 10.1038/s41433-021-01670-3
EA JUL 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3D1FT
UT WOS:000673436700002
PM 34262164
DA 2022-11-30
ER

PT J
AU Rashno, A
   Nazari, B
   Koozekanani, DD
   Drayna, PM
   Sadri, S
   Rabbani, H
   Parhi, KK
AF Rashno, Abdolreza
   Nazari, Behzad
   Koozekanani, Dara D.
   Drayna, Paul M.
   Sadri, Saeed
   Rabbani, Hossein
   Parhi, Keshab K.
TI Fully-automated segmentation of fluid regions in exudative age-related
   macular degeneration subjects: Kernel graph cut in neutrosophic domain
SO PLOS ONE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; IMAGE SEGMENTATION; OCT IMAGES; LAYER
   SEGMENTATION; SUBRETINAL FLUID; EDEMA; SET; ALGORITHMS; RETINA
AB A fully-automated method based on graph shortest path, graph cut and neutrosophic (NS) sets is presented for fluid segmentation in OCT volumes for exudative age related macular degeneration (EAMD) subjects. The proposed method includes three main steps: 1) The inner limiting membrane (ILM) and the retinal pigment epithelium (RPE) layers are segmented using proposed methods based on graph shortest path in NS domain. A flattened RPE boundary is calculated such that all three types of fluid regions, intra-retinal, sub-retinal and sub-RPE, are located above it. 2) Seed points for fluid (object) and tissue (background) are initialized for graph cut by the proposed automated method. 3) A new cost function is proposed in kernel space, and is minimized with max-flow/min-cut algorithms, leading to a binary segmentation. Important properties of the proposed steps are proven and quantitative performance of each step is analyzed separately. The proposed method is evaluated using a publicly available dataset referred as Optima and a local dataset from the UMN clinic. For fluid segmentation in 2D individual slices, the proposed method outperforms the previously proposed methods by 18%, 21% with respect to the dice coefficient and sensitivity, respectively, on the Optima dataset, and by 16%, 11% and 12% with respect to the dice coefficient, sensitivity and precision, respectively, on the local UMN dataset. Finally, for 3D fluid volume segmentation, the proposed method achieves true positive rate (TPR) and false positive rate (FPR) of 90% and 0.74%, respectively, with a correlation of 95% between automated and expert manual segmentations using linear regression analysis.
C1 [Rashno, Abdolreza; Nazari, Behzad; Sadri, Saeed] Isfahan Univ Technol, Dept Elect & Comp Engn, Esfahan, Iran.
   [Rashno, Abdolreza; Parhi, Keshab K.] Univ Minnesota, Dept Elect & Comp Engn, Minneapolis, MN USA.
   [Koozekanani, Dara D.; Drayna, Paul M.] Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN USA.
   [Rabbani, Hossein] Isfahan Univ Med Sci, Dept Biomed Engn, Med Image & Signal Proc Res Ctr, Esfahan, Iran.
C3 Isfahan University of Technology; University of Minnesota System;
   University of Minnesota Twin Cities; University of Minnesota System;
   University of Minnesota Twin Cities; Isfahan University Medical Science
RP Parhi, KK (通讯作者)，Univ Minnesota, Dept Elect & Comp Engn, Minneapolis, MN USA.
EM parhi@umn.edu
RI Parhi, Keshab K./AAQ-1793-2021; Rabbani, Hossein/O-4987-2019; Rashno,
   Abdolreza/ABY-2305-2022; Rabbani, Hossein/H-7515-2014
OI Rabbani, Hossein/0000-0002-0551-3636; Rashno,
   Abdolreza/0000-0003-0014-5050; Rabbani, Hossein/0000-0002-0551-3636
FU Minnesota Lions Foundation [UMF14601]; Research to Prevent Blindness
FX This research was supported in part by the Minnesota Lions Foundation
   under grant UMF14601 and by the Research to Prevent Blindness.
CR Behbehani R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172120
   Ben Salah M, 2011, IEEE T IMAGE PROCESS, V20, P545, DOI 10.1109/TIP.2010.2066982
   Bogunovic H, 2015, P OPHTHALMIC MED IMA
   Boykov Y, 2004, IEEE T PATTERN ANAL, V26, P1124, DOI 10.1109/TPAMI.2004.60
   Boykov Y, 2006, INT J COMPUT VISION, V70, P109, DOI 10.1007/s11263-006-7934-5
   Boykov YY, 2001, EIGHTH IEEE INTERNATIONAL CONFERENCE ON COMPUTER VISION, VOL I, PROCEEDINGS, P105, DOI 10.1109/ICCV.2001.937505
   Chen XJ, 2012, IEEE T MED IMAGING, V31, P1521, DOI 10.1109/TMI.2012.2191302
   Chiu SJ, 2015, BIOMED OPT EXPRESS, V6, P1172, DOI 10.1364/BOE.6.001172
   Chiu SJ, 2012, BIOMED OPT EXPRESS, V3, P1127, DOI 10.1364/BOE.3.001127
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Coscas G, 2010, OPTICAL COHERENCE TOMOGRAPHY IN AGE-RELATED MACULAR DEGENERATION: OCT IN AMD, SECOND EDITION, P1
   Doleisi M, 2010, ANAL BIOMEDICAL SIGN
   Esmaeili Mahdad, 2016, J Med Signals Sens, V6, P166
   Fernandez DC, 2005, IEEE T MED IMAGING, V24, P929, DOI 10.1109/TMI.2005.848655
   Gonzalez A, 2013, COMP MED SY, P397, DOI 10.1109/CBMS.2013.6627825
   Guo YH, 2015, PATTERN RECOGN, V48, P2710, DOI 10.1016/j.patcog.2015.02.018
   Guo YH, 2014, COMPUT ELECTR ENG, V40, P3, DOI 10.1016/j.compeleceng.2014.04.020
   Guo YH, 2009, PATTERN RECOGN, V42, P587, DOI 10.1016/j.patcog.2008.10.002
   Heshmati A, 2016, IET IMAGE PROCESS, V10, P464, DOI 10.1049/iet-ipr.2015.0738
   Huang YJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082922
   Kafieh R, 2013, MED IMAGE ANAL, V17, P907, DOI 10.1016/j.media.2013.05.006
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Kohler J, 2017, INVEST OPHTH VIS SCI, V58
   Lang A, 2015, BIOMED OPT EXPRESS, V6, P155, DOI 10.1364/BOE.6.000155
   Lin D, 2016, PLOS ONE, V11
   Muller KR, 2001, IEEE T NEURAL NETWOR, V12, P181, DOI 10.1109/72.914517
   Parhi KK, 2017, INVEST OPHTH VIS SCI, V58
   Peng B, 2013, PATTERN RECOGN, V46, P1020, DOI 10.1016/j.patcog.2012.09.015
   Pilch M, 2013, INVEST OPHTH VIS SCI, V54, P4385, DOI 10.1167/iovs.12-11396
   Quellec G, 2010, IEEE T MED IMAGING, V29, P1321, DOI 10.1109/TMI.2010.2047023
   Rashno A, 2017, IEEE T BIOMEDICAL EN
   Rashno A, 2017, INVEST OPHTH VIS SCI, V58
   Rashno A, 2017, 2017 3RD INTERNATIONAL CONFERENCE ON PATTERN RECOGNITION AND IMAGE ANALYSIS (IPRIA), P50, DOI 10.1109/PRIA.2017.7983063
   Roychowdhury S, 2013, IEEE ENG MED BIO, P1426, DOI 10.1109/EMBC.2013.6609778
   Sengur A, 2011, COMPUT VIS IMAGE UND, V115, P1134, DOI 10.1016/j.cviu.2011.04.001
   Shan J, 2012, MED PHYS, V39, P5669, DOI 10.1118/1.4747271
   Sisternes L, 2015, MACHINE LEARNING APR
   Smarandache F, 2005, NEUTROSOPHY NEUTROSO
   Swingle EK, 2014, SPIE MED IMAGING
   Swingle EK, 2015, SPIE MED IMAGING
   Terry T, 2016, PLOS ONE, V11
   Tian J., 2015, PLOS ONE, V10
   Venhuizena FG, 2015, VENDOR INDEPENDENT C
   Wang J, 2016, BIOMED OPT EXPRESS, V7, P1577, DOI 10.1364/BOE.7.001577
   Wang T, 2016, INFORM SCIENCES, V358, P92, DOI 10.1016/j.ins.2016.04.017
   Wieclawek W, 2015, 2015 22ND INTERNATIONAL CONFERENCE MIXED DESIGN OF INTEGRATED CIRCUITS & SYSTEMS (MIXDES), P79, DOI 10.1109/MIXDES.2015.7208485
   Wilkins GR, 2012, IEEE T BIO-MED ENG, V59, P1109, DOI 10.1109/TBME.2012.2184759
   Xu XY, 2015, IEEE T MED IMAGING, V34, P1616, DOI 10.1109/TMI.2015.2408632
   Yang Q, 2010, OPT EXPRESS, V18, P21293, DOI 10.1364/OE.18.021293
   Zhang L, 2015, I S BIOMED IMAGING, P1494, DOI 10.1109/ISBI.2015.7164160
   Zhang M, 2010, SIGNAL PROCESS, V90, P1510, DOI 10.1016/j.sigpro.2009.10.021
   Zheng YL, 2013, AM J OPHTHALMOL, V155, P277, DOI 10.1016/j.ajo.2012.07.030
NR 52
TC 20
Z9 20
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 23
PY 2017
VL 12
IS 10
AR e0186949
DI 10.1371/journal.pone.0186949
PG 26
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FK3RE
UT WOS:000413403000053
PM 29059257
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Anastasopoulos, E
   Kakoulidou, A
   Coleman, AL
   Sinsheimer, JS
   Wilson, MR
   Yu, F
   Salonikiou, A
   Koskosas, A
   Pappas, T
   Founti, P
   Lambropoulos, A
   Topouzis, F
AF Anastasopoulos, Eleftherios
   Kakoulidou, Anastasia
   Coleman, Anne L.
   Sinsheimer, Janet S.
   Wilson, M. Roy
   Yu, Fei
   Salonikiou, Aggeliki
   Koskosas, Archimidis
   Pappas, Theofanis
   Founti, Panayiota
   Lambropoulos, Alexandros
   Topouzis, Fotis
TI Association of Sequence Variation in the CX3CR1 Gene with Geographic
   Atrophy Age-related Macular Degeneration in a Greek Population
SO CURRENT EYE RESEARCH
LA English
DT Article
DE AMD; CX3CR1; Genetics; Greek; Geographic atrophy
ID COMPLEMENT FACTOR-H; RECEPTOR CX(3)CR1; POLYMORPHISM; FRACTALKINE; RISK;
   CHEMOKINE; DISEASE; SUSCEPTIBILITY; MACULOPATHY; PROGRESSION
AB Purpose: To explore the association of two single nucleotide polymorphisms (SNPs) in the CX3CR1 gene with grades of age-related macular degeneration (AMD) in a population-based setting.
   Methods: The Thessaloniki Eye study is a cross-sectional population-based epidemiologic study of chronic eye diseases in Thessaloniki, Greece. A total of 371 subjects were included and classified according to their AMD status. Subjects with AMD Grades 0-1 (n = 188) were compared to those with AMD Grades 2-3 (n = 138), to those with AMD Grade 4 (geographic atrophy) (n = 20) and to those with AMD Grade 5 (neovascular AMD) (n = 25) with regard to the presence of CX3CR1 polymorphisms (V249I and T280M). Polychotomous logistic regression analysis adjusted for age, gender, and smoking was conducted and the log-additive allelic model was preferred.
   Results: Participants with AMD Grade 4 were approximately three times more likely to carry the VI249 and nine times more likely to carry the II249 alleles, compared to those with AMD Grades 0-1, whereas those with AMD Grades 2-3 or Grade 5 did not differ. The T280M polymorphism was not associated with either AMD Grades 2-3 or AMD Grades 4 or 5.
   Conclusion: In this Greek population, after adjusting for known risk factors, increased risk of geographic atrophy (GA) AMD among the carriers of the V249I polymorphism in the CX3CR1 gene was found. Our study failed to reveal any association with the T280M polymorphism reported in previous studies. Additional studies in different ethnic populations using standardized methodology are needed in order to confirm this association.
C1 [Anastasopoulos, Eleftherios; Salonikiou, Aggeliki; Koskosas, Archimidis; Pappas, Theofanis; Founti, Panayiota; Topouzis, Fotis] Aristotle Univ Thessaloniki, Dept Ophthalmol A, AHEPA Hosp, Sch Med, Thessaloniki 54636, Greece.
   [Kakoulidou, Anastasia] Aristotle Univ Thessaloniki, Mol Biol Lab, Sch Med, Papageorgiou Reg Hosp, Thessaloniki 54636, Greece.
   [Coleman, Anne L.; Yu, Fei; Lambropoulos, Alexandros] Univ Calif Los Angeles, Jules Stein Eye Inst, Ctr Eye Epidemiol, David Geoffen Sch Med, Los Angeles, CA 90024 USA.
   [Sinsheimer, Janet S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Dept Biomath, Los Angeles, CA 90095 USA.
   [Sinsheimer, Janet S.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA.
   [Wilson, M. Roy] Univ Colorado, Sch Med, Denver, CO USA.
C3 Aristotle University of Thessaloniki; Ahepa University Hospital;
   Aristotle University of Thessaloniki; Papageorgiou Hospital; University
   of California System; University of California Los Angeles; University
   of California Los Angeles Medical Center; David Geffen School of
   Medicine at UCLA; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; University of
   California System; University of California Los Angeles; University of
   Colorado System; University of Colorado Anschutz Medical Campus;
   University of Colorado Denver
RP Topouzis, F (通讯作者)，Aristotle Univ Thessaloniki, Dept Ophthalmol A, AHEPA Hosp, Sch Med, St Kiriakidi 1, Thessaloniki 54636, Greece.
EM ftopouzis@otenet.gr
OI Topouzis, Fotis/0000-0002-8966-537X
FU International Glaucoma Association, London, UK; UCLA Center for Eye
   Epidemiology, Los Angeles, CA; Health Future Foundation, Creighton
   University, Omaha, NE; Texas Tech University Health Sciences Center,
   Lubbock, TX; Pfizer, Inc., New York, NY; Pharmacia Hellas, Athens,
   Greece; Applied Genetics and Biotechnology Postgraduate's programme of
   the School of Biology, Aristotle University of Thessaloniki; NATIONAL
   INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053275] Funding Source: NIH
   RePORTER
FX The Thessaloniki Eye Study is supported in part by: International
   Glaucoma Association, London, UK; UCLA Center for Eye Epidemiology, Los
   Angeles, CA; Health Future Foundation, Creighton University, Omaha, NE;
   Texas Tech University Health Sciences Center, Lubbock, TX; Pfizer, Inc.,
   New York, NY; Pharmacia Hellas, Athens, Greece. The genetic analysis was
   supported also by: Applied Genetics and Biotechnology Postgraduate's
   programme of the School of Biology, Aristotle University of
   Thessaloniki. All the grants were unrestricted.
CR Bayley JP, 2003, TISSUE ANTIGENS, V62, P170, DOI 10.1034/j.1399-0039.2003.00073.x
   Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Chakravarthy U, 2006, BMJ-BRIT MED J, V333, P869, DOI 10.1136/bmj.39009.366736.80
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Echigo T, 2004, J ALLERGY CLIN IMMUN, V113, P940, DOI 10.1016/j.jaci.2004.02.030
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Faure S, 2000, SCIENCE, V287, P2274, DOI 10.1126/science.287.5461.2274
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   McDermott DH, 2001, CIRC RES, V89, P401, DOI 10.1161/hh1701.095642
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Moatti D, 2001, BLOOD, V97, P1925, DOI 10.1182/blood.V97.7.1925
   Nomiyama H, 1998, CYTOGENET CELL GENET, V81, P10, DOI 10.1159/000015000
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Tarozzo G, 2002, EUR J NEUROSCI, V15, P1663, DOI 10.1046/j.1460-9568.2002.02007.x
   Topouzis F, 2007, AM J OPHTHALMOL, V144, P511, DOI 10.1016/j.ajo.2007.06.029
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   Yang X, 2010, BRIT J OPHTHALMOL, V94, P1211, DOI 10.1136/bjo.2009.165811
   Zerbib J, 2011, EXP EYE RES, V93, P382, DOI 10.1016/j.exer.2011.05.005
NR 29
TC 11
Z9 11
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD DEC
PY 2012
VL 37
IS 12
BP 1148
EP 1155
DI 10.3109/02713683.2012.705413
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 043MA
UT WOS:000311546500011
PM 22816662
DA 2022-11-30
ER

PT J
AU Hagbi-Levi, S
   Tiosano, L
   Rinsky, B
   Levinger, N
   Elbaz-Hayoun, S
   Carmi, S
   Grunin, M
   Chowers, I
AF Hagbi-Levi, Shira
   Tiosano, Liran
   Rinsky, Batya
   Levinger, Nadav
   Elbaz-Hayoun, Sarah
   Carmi, Shai
   Grunin, Michelle
   Chowers, Itay
TI Anti-tumor necrosis factor alpha reduces the proangiogenic effects of
   activated macrophages derived from patients with age-related macular
   degeneration
SO MOLECULAR VISION
LA English
DT Article
ID TUMOR-ASSOCIATED MACROPHAGES; ENDOTHELIAL GROWTH-FACTOR; TNF-ALPHA;
   CHOROIDAL NEOVASCULARIZATION; INFILTRATING MACROPHAGES; VEGF EXPRESSION;
   MONOCYTES; POLARIZATION; INFLIXIMAB; INFLAMMATION
AB Purpose: Macrophages are believed to promote choroidal neovascularization (CNV) in neovascular age-related macular degeneration (nvAMD); however, the underlying proangiogenic mechanism is poorly understood. Therefore, we exam-ined this mechanism in proinflammatory macrophages derived from patients with nvAMD.
   Methods: Monocytes were isolated from patients with nvAMD and polarized to form an M1 proangiogenic phenotype. We then screened for the role of proangiogenic cytokines expressed by these macrophages, including TNF-alpha, VEGF, IL-6, IL-8, and IL-1 beta, using an ex vivo choroid sprouting assay and an in vivo rodent model of laser-induced CNV (LI-CNV). We also examined the value of inhibiting TNF-alpha inhibition with respect to reducing the proangiogenic effects of M1 macrophages. Finally, we analyzed the macrophage cytokine expression database to evaluate the feasibility of modulating the expression of TNF-alpha.
   Results: The cytokines above are expressed at high levels in patient-derived M1 macrophages. However, among the cytokines tested only TNF-alpha significantly increased choroid sprouting. Moreover, adoptive intravitreal transfer of M1 macrophages significantly increased LI-CNV, and blocking TNF-alpha abolished the proangiogenic effects of M1 macro-phages in both models. An analysis of cytokine expression revealed that >50% of TNF-alpha expression is determined by modifiable factors.
   Conclusions: Blocking TNF-alpha can reduce the proangiogenic effects of M1 macrophages in nvAMD. Thus, activated macrophages may represent a potential therapeutic target for altering TNF-alpha expression in nvAMD.
C1 [Hagbi-Levi, Shira; Rinsky, Batya; Elbaz-Hayoun, Sarah; Grunin, Michelle; Chowers, Itay] Hadassah Hebrew Univ Med Ctr, Dept Ophthalmol, POB 12000, IL-91120 Jerusalem, Israel.
   [Hagbi-Levi, Shira; Tiosano, Liran; Rinsky, Batya; Levinger, Nadav; Elbaz-Hayoun, Sarah; Grunin, Michelle] Hebrew Univ Jerusalem, Jerusalem, Israel.
   [Carmi, Shai] Braun Sch Publ Hlth & Community Med, Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Hebrew University of Jerusalem
RP Chowers, I (通讯作者)，Hadassah Hebrew Univ Med Ctr, Dept Ophthalmol, POB 12000, IL-91120 Jerusalem, Israel.
EM chowers@hadassah.org.il
FU Israel Science Foundation [1006/13]; Israeli Ministry of Health [9184]
FX This study was supported in part by grants from the Israel Science
   Foundation (#1006/13) and the Israeli Ministry of Health (#9184). These
   funding sources had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript. The raw
   data used in this study will be made available upon reasonable request
   to the corresponding author at (chowers@hadassah.org.il).
CR Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Beykin G, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0019-x
   Bouhlel MA, 2007, CELL METAB, V6, P137, DOI 10.1016/j.cmet.2007.06.010
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Chalmers SA, 2015, DISCOV MED, V20, P43
   Collins TJ, 2007, BIOTECHNIQUES, V43, P25, DOI 10.2144/000112517
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Gelinas L, 2011, J RENIN-ANGIO-ALDO S, V12, P295, DOI 10.1177/1470320310391332
   Georgoudaki AM, 2016, CELL REP, V15, P2000, DOI 10.1016/j.celrep.2016.04.084
   Giansanti F, 2008, INVEST OPHTH VIS SCI, V49, P1151, DOI 10.1167/iovs.07-0932
   Grattendick KJ, 2008, INT IMMUNOPHARMACOL, V8, P679, DOI 10.1016/j.intimp.2008.01.013
   Grunin M, 2014, ADV EXP MED BIOL, V801, P199, DOI 10.1007/978-1-4614-3209-8_26
   Hagbi-Levi S, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/8535273
   Hagbi-Levi S, 2017, NEUROBIOL AGING, V51, P71, DOI 10.1016/j.neurobiolaging.2016.11.018
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kataoka K, 2011, INVEST OPHTH VIS SCI, V52, P1431, DOI 10.1167/iovs.10-5798
   Kawanaka N, 2002, ARTHRITIS RHEUM, V46, P2578, DOI 10.1002/art.10545
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   Krause TA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094313
   Lederman M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087751
   Liyanage SE, 2016, ARTERIOSCL THROM VAS, V36, P19, DOI 10.1161/ATVBAHA.115.306681
   Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5
   Markomichelakis NN, 2005, AM J OPHTHALMOL, V139, P537, DOI 10.1016/j.ajo.2004.09.058
   Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   Panni RZ, 2013, IMMUNOTHERAPY-UK, V5, P1075, DOI 10.2217/imt.13.102
   Patel SK, 2015, THERANOSTICS, V5, P150, DOI 10.7150/thno.9476
   Pelegrin P, 2009, EMBO J, V28, P2114, DOI 10.1038/emboj.2009.163
   Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138
   Ries CH, 2015, CURR OPIN PHARMACOL, V23, P45, DOI 10.1016/j.coph.2015.05.008
   Robertson MJ, 2002, INVEST OPHTH VIS SCI, V43, P2250
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Shao Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069552
   Song J, 2018, INVEST OPHTH VIS SCI, V59, P3747, DOI 10.1167/iovs.18-23892
   Theodossiadis PG, 2009, AM J OPHTHALMOL, V147, P825, DOI 10.1016/j.ajo.2008.12.004
   Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Wang HB, 2016, MOL VIS, V22, P116
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Xu JW, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109606
   Yang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep30933
   Zandi S, 2015, CELL REP, V10, P1173, DOI 10.1016/j.celrep.2015.01.050
NR 51
TC 1
Z9 1
U1 1
U2 3
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD NOV 19
PY 2021
VL 27
BP 622
EP 631
PG 10
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA XC7JH
UT WOS:000722185000001
PM 34924742
DA 2022-11-30
ER

PT J
AU Jeon, HL
   Byun, SJ
   Pratt, NL
   Sultana, J
   Park, SJ
   Shin, JY
AF Jeon, Ha-Lim
   Byun, Seong Jun
   Pratt, Nicole L.
   Sultana, Janet
   Park, Sang Jun
   Shin, Ju-Young
TI Cardiovascular risk in patients receiving ranibizumab for exudative
   age-related macular degeneration: a nationwide self-controlled
   case-series study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE degeneration; drugs; epidemiology; pharmacology; treatment medical
AB Aims
   To identify the association between ranibizumab and risk of stroke and acute myocardial infarction (AMI) in patients with exudative age-related macular degeneration (AMD).
   Methods
   We identified patients aged >= 45 years who received ranibizumab for exudative AMD from the Korean National Health Insurance database. Of these, we selected patients suffering stroke or AMI for the self-controlled case series. We estimated incidence rate ratios (IRR) for stroke or AMI by comparing incidence rates of ranibizumab-exposed periods to that of baseline using conditional Poisson regression. The risks of haemorrhagic and ischaemic strokes were also calculated separately.
   Results
   Among 33 134 patients receiving ranibizumab, 2397 patients had stroke or AMI. The risk of stroke (IRR=0.83, 95% CI 0.75 to 0.91) was not increased during the overall exposed period; however, there was a marginally elevated risk in >= 57 days exposed period (IRR=1.14, 95% CI 1.001 to 1.31). When analysing by the types of stroke, no increased risks of haemorrhagic (IRR=1.01, 95% CI 0.80 to 1.26) and ischaemic stroke (IRR=0.78, 95% CI 0.71 to 0.86) were observed during the exposed period, although the risks of ischaemic and haemorrhagic stroke were slightly elevated during >= 57 days exposed period. We could not find an association between ranibizumab and AMI.
   Conclusions
   Ranibizumab intravitreal injections did not increase the overall risk of stroke or AMI. Although the cardiovascular risk in patient receiving ranibizumab seems to be low, continuous monthly use of ranibizumab for high-risk patients should be judged carefully.
C1 [Jeon, Ha-Lim; Byun, Seong Jun; Shin, Ju-Young] Sungkyunkwan Univ, Sch Pharm, Suwon, Gyeonggi Do, South Korea.
   [Byun, Seong Jun; Park, Sang Jun] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Bundang Hosp, Seongnam, South Korea.
   [Pratt, Nicole L.] Univ South Australia, Qual Use Med & Pharm Res Ctr, Clin & Hlth Sci, Adelaide, SA, Australia.
   [Sultana, Janet] Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, Messina, Sicily, Italy.
C3 Sungkyunkwan University (SKKU); Seoul National University (SNU);
   University of South Australia; University of Messina
RP Shin, JY (通讯作者)，Sungkyunkwan Univ, Sch Pharm, Suwon, Gyeonggi Do, South Korea.; Park, SJ (通讯作者)，Seoul Natl Univ, Coll Med, Dept Ophthalmol, Bundang Hosp, Seongnam, South Korea.
EM sangjunpark@snu.ac.kr; shin.jy@skku.edu
RI Park, Sang Jun/C-3234-2015; Pratt, Nicole/A-1348-2011
OI Park, Sang Jun/0000-0003-0542-2758; Pratt, Nicole/0000-0001-8730-8910;
   Jeon, Ha-Lim/0000-0002-9429-8711
FU Korea Health Technology R&D Project through the Korea Health Industry
   Development Institute - Ministry of Health & Welfare, Republic of Korea
   [HI19C0373]; national Research Foundation of Korea (NRF) - Korea
   government (Ministry of Science and Information & Communication
   Technology, MSIT) [NRF-2020R1C1C1003527]; Australian National Health and
   Medical Research Council [GNT1157506]
FX This research was partially supported by a grant of the Korea Health
   Technology R&D Project through the Korea Health Industry Development
   Institute funded by the Ministry of Health & Welfare, Republic of Korea
   (No. HI19C0373) and the national Research Foundation of Korea (NRF)
   grant funded by the Korea government (Ministry of Science and
   Information & Communication Technology, MSIT) (No.
   NRF--2020R1C1C1003527). NP was funded by Australian National Health and
   Medical Research Council Project Grant GNT1157506.
CR Burke A.P., 2015, PATHOLOGY ACUTE MYOC
   Campbell RJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e4203
   Dalvin LA, 2019, JAMA OPHTHALMOL, V137, P483, DOI 10.1001/jamaophthalmol.2018.6891
   Elice F, 2010, THROMB RES, V125, pS55, DOI 10.1016/S0049-3848(10)70014-1
   Harris MI, 1998, DIABETES CARE, V21, pC11, DOI 10.2337/diacare.21.3.C11
   Hoffman H., 2018, TIMELINE STROKE RECO
   Kamba T, 2007, BRIT J CANCER, V96, P1788, DOI 10.1038/sj.bjc.6603813
   Kilickap S, 2003, J CLIN ONCOL, V21, P3542, DOI 10.1200/JCO.2003.99.046
   Kim HJ, 2015, INFLAMM BOWEL DIS, V21, P623, DOI 10.1097/MIB.0000000000000313
   Kim S, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4666-0
   Kimm H, 2012, KOREAN CIRC J, V42, P10, DOI 10.4070/kcj.2012.42.1.10
   Ng WY, 2015, AM J OPHTHALMOL, V159, P557, DOI 10.1016/j.ajo.2014.12.005
   Pandey AK, 2018, HYPERTENSION, V71, pE1, DOI 10.1161/HYPERTENSIONAHA.117.10271
   Park JK., 2000, KOREAN J PREV MED, V33, P76, DOI DOI 10.1161/01.STR.0000078562.82918.F6
   Park SJ, 2015, OPHTHALMOLOGY, V122, P2063, DOI 10.1016/j.ophtha.2015.06.018
   Petersen I, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i4515
   Pratt NL, 2014, DRUG SAFETY, V37, P1021, DOI 10.1007/s40264-014-0231-2
   Rim TH, 2016, RETINA-J RET VIT DIS, V36, P2166, DOI 10.1097/IAE.0000000000001084
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Salcedo-Villanueva G, 2019, INT OPHTHALMOL, V39, P2023, DOI 10.1007/s10792-018-1038-4
   Sangroongruangsri S, 2018, CLIN DRUG INVEST, V38, P853, DOI 10.1007/s40261-018-0678-5
   Schlenker MB, 2015, AM J OPHTHALMOL, V160, P569, DOI 10.1016/j.ajo.2015.06.011
   Seong SC, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016640
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Solomon SD, 2016, OPHTHALMOLOGY, V123, P70, DOI 10.1016/j.ophtha.2015.09.002
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Thulliez M, 2018, JAMA OPHTHALMOL, V136, P557, DOI 10.1001/jamaophthalmol.2018.0002
   Tunon J, 2009, SURV OPHTHALMOL, V54, P339, DOI 10.1016/j.survophthal.2009.02.003
   Whitaker HJ, 2006, STAT MED, V25, P1768, DOI 10.1002/sim.2302
   Whitaker HJ, 2009, STAT METHODS MED RES, V18, P7, DOI 10.1177/0962280208092342
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yashkin AP, 2016, OPHTHALMOLOGY, V123, P2225, DOI 10.1016/j.ophtha.2016.06.053
NR 32
TC 4
Z9 4
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD APR
PY 2021
VL 105
IS 4
BP 543
EP 548
DI 10.1136/bjophthalmol-2020-316373
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RF3VI
UT WOS:000634768800017
PM 32522792
DA 2022-11-30
ER

PT J
AU Mehta, H
   Tufail, A
   Daien, V
   Lee, AY
   Nguyen, V
   Ozturk, M
   Barthelmes, D
   Gillies, MC
AF Mehta, Hemal
   Tufail, Adnan
   Daien, Vincent
   Lee, Aaron Y.
   Vuong Nguyen
   Ozturk, Mehmet
   Barthelmes, Daniel
   Gillies, Mark C.
TI Real-world outcomes in patients with neovascular age-related macular
   degeneration treated with intravitreal vascular endothelial growth
   factor inhibitors
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE Age-related macular degeneration; Neovascular; Vascular endothelial
   growth factor inhibitor; Real-world outcomes; Registry
ID VISUAL-ACUITY OUTCOMES; RANDOMIZED CLINICAL-TRIAL; POSTERIOR CAPSULE
   RUPTURE; ANTI-VEGF TREATMENT; LONG-TERM OUTCOMES; QUALITY-OF-LIFE;
   RANIBIZUMAB TREATMENT; CHOROIDAL NEOVASCULARIZATION; CATARACT-SURGERY;
   DIABETIC-RETINOPATHY
AB Clinical trials identified intravitreal vascular endothelial growth factor inhibitors (anti-VEGF agents) have the potential to stabilise or even improve visual acuity outcomes in neovascular age-related macular degeneration (AMD), a sight-threatening disease. Real-world evidence allows us to assess whether results from randomised controlled trials can be applied to the general population. We describe the development of global registries, in particular the Fight Retinal Blindness! registry that originated in Australia, the United Kingdom AMD Electronic Medical Records User Group and the IRIS registry in the USA. Real-world observations relating to efficacy, safety and resource utilisation of intravitreal anti-VEGF therapy for neovascular AMD are then summarised. Novel observations that would have been challenging to identify in a clinical trial setting are then highlighted, including the risk of late disease reactivation, outcomes in second versus first treated eyes, and the increased risk of posterior capsular rupture during cataract surgery in patients who have received intravitreal anti-VEGF therapy. We conclude by exploring future directions in the field. This includes the development of a global consensus on real-world outcome measures to allow greater comparison of results. Real-world neovascular AMD outcome registries can be linked with other databases to determine systemic safety or genetic predictors of treatment efficacy. Machine learning offers opportunities to extract useful insights from "Big Data" often collected in these registries. Real-world registries could be used by drug regulatory authorities and industry as an alternative to more costly and time-consuming phase 4 clinical trials, potentially allowing medication costs to be based on outcomes achieved.
C1 [Mehta, Hemal; Daien, Vincent; Vuong Nguyen; Barthelmes, Daniel; Gillies, Mark C.] Univ Sydney, Save Sight Inst, Macula Res Grp, 8 Macquarie St, Sydney, NSW 2000, Australia.
   [Mehta, Hemal; Ozturk, Mehmet] Royal Free London NHS Fdn Trust, London, England.
   [Tufail, Adnan] Moorfields Eye Hosp NHS Fdn, London, England.
   [Tufail, Adnan] UCL, Inst Ophthalmol, London, England.
   [Daien, Vincent] Univ Montpellier, Montpellier, France.
   [Daien, Vincent] INSERM 1061, Montpellier, France.
   [Lee, Aaron Y.] Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA.
   [Barthelmes, Daniel] Univ Zurich, Univ Hosp Zurich, Dept Ophthalmol, Zurich, Switzerland.
C3 University of Sydney; University of London; University College London;
   Royal Free London NHS Foundation Trust; University of London; University
   College London; Moorfields Eye Hospital NHS Foundation Trust; University
   of London; University College London; Universite de Montpellier;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite de Montpellier; University of Washington; University of
   Washington Seattle; University of Zurich; University Zurich Hospital
RP Gillies, MC (通讯作者)，Univ Sydney, Save Sight Inst, Macula Res Grp, 8 Macquarie St, Sydney, NSW 2000, Australia.
EM mark.gillies@sydney.edu.au
RI Lee, Aaron/AAT-2839-2020; DAIEN, Vincent/Z-5516-2019
OI DAIEN, Vincent/0000-0001-5675-0861; Tufail, Adnan/0000-0001-6131-7640;
   Lee, Aaron/0000-0002-7452-1648; Nguyen, Vuong/0000-0001-9070-9803
FU Royal Free Charity, London, UK
FX We are grateful for a grant from Royal Free Charity, London, UK to
   support Open Access Publication of this work. They had no involvement in
   study design; in the collection, analysis and interpretation of data; in
   the writing of the report; and in the decision to submit the article for
   publication.
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   [Anonymous], 2009, OXFORD CTR EVIDENCE
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avery RL, 2016, JAMA OPHTHALMOL, V134, P21, DOI 10.1001/jamaophthalmol.2015.4070
   BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Barthelmes D, 2016, BRIT J OPHTHALMOL, V100, P1640, DOI 10.1136/bjophthalmol-2015-308090
   Barthelmes D, 2015, BRIT J OPHTHALMOL, V99, P359, DOI 10.1136/bjophthalmol-2014-305514
   Barthelmes D, 2014, OPHTHALMOLOGY, V121, P2073, DOI 10.1016/j.ophtha.2014.05.007
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Black N, 1996, BRIT MED J, V312, P1215
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Borooah S, 2015, EYE, V29, P1156, DOI 10.1038/eye.2015.83
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Brand C., 2017, 17 EURETINA C BARC S
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Bressler SB, 2015, JAMA OPHTHALMOL, V133, P589, DOI 10.1001/jamaophthalmol.2015.186
   Briggs A, 2003, HEALTH ECON, V12, P377, DOI 10.1002/hec.766
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Butt T, 2017, APPL HEALTH ECON HEA, V15, P23, DOI 10.1007/s40258-016-0275-9
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chavan R, 2014, CLIN OPHTHALMOL, V8, P717, DOI 10.2147/OPTH.S60763
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Daien V, 2018, OPHTHALMOLOGY, V125, P66, DOI 10.1016/j.ophtha.2017.07.005
   Day AC, 2015, EYE, V29, P552, DOI 10.1038/eye.2015.3
   De Fauw J., 2017, F1000RESEARCH, V5, P1573
   E.M.A, 2016, WORKSH ID OPP BIG DA
   Eadie BD, 2017, JAMA OPHTHALMOL, V135, P363, DOI 10.1001/jamaophthalmol.2017.0059
   Eleftheriadou M, 2017, AM J OPHTHALMOL, V174, P160, DOI 10.1016/j.ajo.2016.09.038
   Esen F, 2016, AM J OPHTHALMOL, V169, P68, DOI 10.1016/j.ajo.2016.06.019
   Essex RW, 2016, OPHTHALMOLOGY, V123, P2393, DOI 10.1016/j.ophtha.2016.07.012
   Evans JR, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004004.pub3
   F.D.A, 2005, MAC PEG SOD INJ DRUG
   F.D.A, 2016, US REAL WORLD EV SUP
   Falkenstein IA, 2008, OPHTHALMOLOGY, V115, P319, DOI 10.1016/j.ophtha.2007.05.028
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Fileta JB, 2014, OSLI RETINA, V45, P143, DOI 10.3928/23258160-20140306-08
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1246, DOI 10.1016/j.ophtha.2013.12.032
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Frennesson CI, 2014, ACTA OPHTHALMOL, V92, P216, DOI 10.1111/aos.12091
   Furberg CD, 2001, CURR CONTR TRIALS C, V2, P205, DOI 10.1186/CVM-2-5-205
   Gabai A, 2014, EUR J OPHTHALMOL, V24, P396, DOI 10.5301/ejo.5000385
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   Gillies M, 2015, CLIN EXP OPHTHALMOL, V43, P108
   Gillies MC, 2017, OPHTHALMOLOGY, V124, pE31, DOI 10.1016/j.ophtha.2016.05.054
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P589, DOI 10.1016/j.ophtha.2014.10.001
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Goldberg RA, 2013, OPHTHALMOLOGY, V120, P1448, DOI 10.1016/j.ophtha.2012.12.009
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Hahn P, 2016, EYE, V30, P1101, DOI 10.1038/eye.2016.109
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heimes B, 2011, GRAEF ARCH CLIN EXP, V249, P639, DOI 10.1007/s00417-010-1524-5
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149
   Holz F., 2017, 17 EURETINA C BARC S
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   HUBEL DH, 1963, J NEUROPHYSIOL, V26, P994, DOI 10.1152/jn.1963.26.6.994
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnston RL, 2017, ADV THER, V34, P703, DOI 10.1007/s12325-017-0483-1
   Johnston RL, 2016, OPHTHALMOLOGY, V123, P2386, DOI 10.1016/j.ophtha.2016.07.037
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kamba T, 2007, BRIT J CANCER, V96, P1788, DOI 10.1038/sj.bjc.6603813
   Keenan TDL, 2013, BRIT J OPHTHALMOL, V97, P1168, DOI 10.1136/bjophthalmol-2013-303233
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Kumar A, 2011, BRIT J OPHTHALMOL, V95, P530, DOI 10.1136/bjo.2009.171868
   Lains I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177749
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lamoureux EL, 2007, INVEST OPHTH VIS SCI, V48, P1001, DOI 10.1167/iovs.06-0361
   Lee AY, 2017, BRIT J OPHTHALMOL, V101, P1683, DOI 10.1136/bjophthalmol-2016-309818
   Lee AY, 2016, OPHTHALMOLOGY, V123, P1252, DOI 10.1016/j.ophtha.2016.02.014
   Lee AY, 2015, BRIT J OPHTHALMOL, V99, P1045, DOI 10.1136/bjophthalmol-2014-306229
   Lee CS, 2018, RETINA-J RET VIT DIS, V38, P951, DOI 10.1097/IAE.0000000000001637
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Li P, 2015, JAMA-J AM MED ASSOC, V314, P1966, DOI 10.1001/jama.2015.15281
   Liew G, 2016, EYE, V30, P1462, DOI 10.1038/eye.2016.149
   Lotery A, 2017, EYE, V31, P1697, DOI 10.1038/eye.2017.143
   Lum Flora, 2002, Jt Comm J Qual Improv, V28, P108
   Madhusudhana KC, 2016, BRIT J OPHTHALMOL, V100, P1617, DOI 10.1136/bjophthalmol-2015-308077
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Marella M, 2010, INVEST OPHTH VIS SCI, V51, P2878, DOI 10.1167/iovs.09-4494
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McNamara RL, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.001767
   Menghini M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042014
   Michaelson I.C., 1948, T OPHTHALMOL SOC, V68, P137
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Miller JW, 1997, DIABETES METAB REV, V13, P37, DOI 10.1002/(SICI)1099-0895(199703)13:1<37::AID-DMR174>3.0.CO;2-K
   Minassian DC, 2011, BRIT J OPHTHALMOL, V95, P1433, DOI 10.1136/bjo.2010.195370
   Molnar FJ, 2008, CAN MED ASSOC J, V179, P751, DOI 10.1503/cmaj.080820
   Murphy Kevin P., 2012, ADAPTIVE COMPUTATION
   National Institute for Health and Care Excellence (NICE), 2008, RAN PEG TREATM AG RE
   National Institute for Health and Care Excellence (NICE), 2013, AFL SOL INJ TREAT WE
   Ng WY, 2015, AM J OPHTHALMOL, V159, P557, DOI 10.1016/j.ajo.2014.12.005
   Ozturk M, 2018, CLIN EXP OPHTHALMOL, V46, P407, DOI 10.1111/ceo.13085
   Parangi S, 1996, P NATL ACAD SCI USA, V93, P2002, DOI 10.1073/pnas.93.5.2002
   Pecen PE, 2015, CURR OPIN OPHTHALMOL, V26, P188, DOI 10.1097/ICU.0000000000000147
   Pushpoth S, 2012, BRIT J OPHTHALMOL, V96, P1469, DOI 10.1136/bjophthalmol-2012-302167
   Razavi H, 2015, CLIN EXP OPHTHALMOL, V43, P707, DOI 10.1111/ceo.12658
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Ross AH, 2013, EYE, V27, P56, DOI 10.1038/eye.2012.225
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Salathe M, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002616
   Salathe M, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002199
   Schmidt-Erfurth U., 2017, OPHTHALMOL RETINA, V2, P24
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Shalchi Z, 2017, AM J OPHTHALMOL, V177, P77, DOI 10.1016/j.ajo.2017.02.006
   Sherman RE, 2016, NEW ENGL J MED, V375, P2293, DOI 10.1056/NEJMsb1609216
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Souied EH, 2015, RETINA-J RET VIT DIS, V35, P1743, DOI 10.1097/IAE.0000000000000548
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Sparrow JM, 2012, EYE, V26, P821, DOI 10.1038/eye.2012.51
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   STROBE, 2007, STROBE CHECKL 2007 V
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Thijssen VLJL, 2006, P NATL ACAD SCI USA, V103, P15975, DOI 10.1073/pnas.0603883103
   Tolentino MJ, 2002, AM J OPHTHALMOL, V133, P373, DOI 10.1016/S0002-9394(01)01381-2
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   van Asten F, 2015, ACTA OPHTHALMOL, V93, P126, DOI 10.1111/aos.12610
   Vaze A, 2014, ACTA OPHTHALMOL, V92, pe697, DOI 10.1111/aos.12417
   Virgili G, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007419.pub4
   Watson S., 2017, OUTCOMES CORNEAL CRO
   Westborg I.A.S., 2014, INVEST OPHTH VIS SCI, V55, P1
   Westborg I, 2017, RETINA-J RET VIT DIS, V37, P2035, DOI 10.1097/IAE.0000000000001431
   Willis J, 2017, OPHTHALMOLOGY, V124, P935, DOI 10.1016/j.ophtha.2017.02.018
   Wolf A, 2014, GRAEF ARCH CLIN EXP, V252, P647, DOI 10.1007/s00417-013-2562-6
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wood Angela M, 2004, Clin Trials, V1, P368
   Wykoff C.C., 2017, RETINA, V1, P8
   Yang Y, 2017, OPHTHALMOL THER, V6, P175, DOI 10.1007/s40123-017-0091-9
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
NR 158
TC 136
Z9 139
U1 2
U2 24
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD JUL
PY 2018
VL 65
BP 127
EP 146
DI 10.1016/j.preteyeres.2017.12.002
PG 20
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GP4ZO
UT WOS:000440881100007
PM 29305324
OA Green Accepted, hybrid
DA 2022-11-30
ER

PT J
AU Neale, BM
   Fagerness, J
   Reynolds, R
   Sobrin, L
   Parker, M
   Raychaudhuri, S
   Tan, PL
   Oh, EC
   Merriam, JE
   Souied, E
   Bernstein, PS
   Li, BX
   Frederick, JM
   Zhang, K
   Brantley, MA
   Lee, AY
   Zack, DJ
   Campochiaro, B
   Campochiaro, P
   Ripke, S
   Smith, RT
   Barile, GR
   Katsanis, N
   Allikmets, R
   Daly, MJ
   Seddon, JM
AF Neale, Benjamin M.
   Fagerness, Jesen
   Reynolds, Robyn
   Sobrin, Lucia
   Parker, Margaret
   Raychaudhuri, Soumya
   Tan, Perciliz L.
   Oh, Edwin C.
   Merriam, Joanna E.
   Souied, Eric
   Bernstein, Paul S.
   Li, Binxing
   Frederick, Jeanne M.
   Zhang, Kang
   Brantley, Milam A., Jr.
   Lee, Aaron Y.
   Zack, Donald J.
   Campochiaro, Betsy
   Campochiaro, Peter
   Ripke, Stephan
   Smith, R. Theodore
   Barile, Gaetano R.
   Katsanis, Nicholas
   Allikmets, Rando
   Daly, Mark J.
   Seddon, Johanna M.
TI Genome-wide association study of advanced age-related macular
   degeneration identifies a role of the hepatic lipase gene (LIPC)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE complex disease; HDL; lipid pathway; retinal degeneration
ID COMPLEMENT FACTOR-H; VARIANT; RISK; SUSCEPTIBILITY; POLYMORPHISM;
   INCREASES; HAPLOTYPE; LINKAGE; POWER; CFH
AB Advanced age-related macular degeneration (AMD) is the leading cause of late onset blindness. We present results of a genome-wide association study of 979 advanced AMD cases and 1,709 controls using the Affymetrix 6.0 platform with replication in seven additional cohorts (totaling 5,789 unrelated cases and 4,234 unrelated controls). We also present a comprehensive analysis of copy-number variations and polymorphisms for AMD. Our discovery data implicated the association between AMD and a variant in the hepatic lipase gene (LIPC) in the high-density lipoprotein cholesterol (HDL) pathway (discovery P = 4.53e-05 for rs493258). Our LIPC association was strongest for a functional promoter variant, rs10468017, (P = 1.34e-08), that influences LIPC expression and serum HDL levels with a protective effect of the minor T allele (HDL increasing) for advanced wet and dry AMD. The association we found with LIPC was corroborated by the Michigan/Penn/Mayo genome-wide association study; the locus near the tissue inhibitor of metalloproteinase 3 was corroborated by our replication cohort for rs9621532 with P = 3.71e-09. We observed weaker associations with other HDL loci (ABCA1, P = 9.73e-04; cholesterylester transfer protein, P = 1.41e-03; FADS1-3, P = 2.69e-02). Based on a lack of consistent association between HDL increasing alleles and AMD risk, the LIPC association may not be the result of an effect on HDL levels, but it could represent a pleiotropic effect of the same functional component. Results implicate different biologic pathways than previously reported and provide new avenues for prevention and treatment of AMD.
C1 [Neale, Benjamin M.; Fagerness, Jesen; Raychaudhuri, Soumya; Ripke, Stephan; Daly, Mark J.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
   [Neale, Benjamin M.; Fagerness, Jesen; Raychaudhuri, Soumya; Ripke, Stephan; Daly, Mark J.] Harvard & Massachusetts Inst Technol, Broad Inst, Program Med & Populat Genet, Cambridge, MA 02142 USA.
   [Neale, Benjamin M.] Kings Coll London, Inst Psychiat, Social Genet & Dev Psychiat Ctr, London SE5 8AF, England.
   [Reynolds, Robyn; Parker, Margaret] Tufts Univ, Sch Med, Tufts Med Ctr, Ophthalm Epidemiol & Genet Serv,New England Eye C, Boston, MA 02111 USA.
   [Sobrin, Lucia] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA.
   [Tan, Perciliz L.; Oh, Edwin C.; Zack, Donald J.; Campochiaro, Betsy; Campochiaro, Peter] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, McKusick Nathans Inst Genet Med,Dept Ophthalmol, Baltimore, MD 21205 USA.
   [Merriam, Joanna E.; Smith, R. Theodore; Barile, Gaetano R.; Allikmets, Rando] Columbia Univ, Dept Ophthalmol, New York, NY 10032 USA.
   [Souied, Eric] Univ Paris 12, Dept Ophthalmol, Hop Intercommunal Creteil, F-94000 Creteil, France.
   [Bernstein, Paul S.; Li, Binxing; Frederick, Jeanne M.; Zhang, Kang] Univ Utah, Sch Med, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.
   [Zhang, Kang] Univ Calif San Diego, Inst Genom Med, San Diego, CA 92093 USA.
   [Zhang, Kang] Univ Calif San Diego, Shiley Eye Ctr, San Diego, CA 92093 USA.
   [Brantley, Milam A., Jr.; Lee, Aaron Y.] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.
   [Brantley, Milam A., Jr.] Barnes Retina Inst, St Louis, MO 63144 USA.
   [Katsanis, Nicholas] Duke Univ, Ctr Human Dis Modeling, Durham, NC 27710 USA.
   [Katsanis, Nicholas] Duke Univ, Dept Cell Biol, Durham, NC 27710 USA.
   [Katsanis, Nicholas] Duke Univ, Dept Pediat, Durham, NC 27710 USA.
   [Allikmets, Rando] Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10032 USA.
   [Seddon, Johanna M.] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
C3 Harvard University; Massachusetts General Hospital; Harvard University;
   Massachusetts Institute of Technology (MIT); Broad Institute; University
   of London; King's College London; Tufts Medical Center; Tufts
   University; Harvard University; Harvard Medical School; Massachusetts
   Eye & Ear Infirmary; Johns Hopkins University; Johns Hopkins Medicine;
   Columbia University; Universite Paris-Est-Creteil-Val-de-Marne (UPEC);
   CHI Creteil; Utah System of Higher Education; University of Utah;
   University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   Washington University (WUSTL); Washington University (WUSTL); Duke
   University; Duke University; Duke University; Columbia University; Tufts
   University
RP Daly, MJ (通讯作者)，Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
EM mjdaly@chgr.mgh.harvard.edu; jseddon@tuftsmedicalcenter.org
RI Allikmets, Rando/ABD-4533-2021; Li, Binxing/ABB-7775-2020; Zhang,
   Kang/Y-2740-2019; Li, Binxing/C-9153-2012; Katsanis,
   Nicholas/E-1837-2012; Lee, Aaron/AAT-2839-2020; Daly, Mark
   J/B-2453-2017; Ripke, Stephan/AAK-5486-2021
OI Li, Binxing/0000-0002-0715-7495; Zhang, Kang/0000-0002-4549-1697; Daly,
   Mark J/0000-0002-0949-8752; 
FU National Institutes of Health [R01-EY11309, R01-EY13435, R24-EY017404,
   K12-EY16335, R01 HL087676, R01-EY11600, U54 RR020278]; Massachusetts
   Lions Eye Research Fund, Inc.; Research to Prevent Blindness, Inc.;
   Macula Vision Research Foundation; Kaplen Foundation; Widgeon Point
   Charitable Foundation; Alcon Research institute; Fight for Sight;
   Ophthalmic Epidemiology and Genetics Service, New England Eye Center,
   Tufts Medical Center, Tufts University School of Medicine; NATIONAL
   CENTER FOR RESEARCH RESOURCES [U54RR020278] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [R01EY011309, R01EY009769, R01EY013435,
   K12EY016335, R24EY017404, R01EY011600] Funding Source: NIH RePORTER;
   NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL087676] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND
   SKIN DISEASES [K08AR055688] Funding Source: NIH RePORTER
FX We appreciate the contribution of an anonymous donor to the research of
   J.M.S., without whom this genome-wide association study would not have
   been possible. We thank the participants and numerous ophthalmologists
   throughout the country who participated in this study, the Age Related
   Eye Disease Study Research Group, Daniel Mirel at the Broad Institute
   Center for Genotyping and Analysis for help with the execution of the
   SNP genotyping. We thank the Michigan/Penn/Mayo genome-wide association
   study group for providing results from their study for some of our top
   SNPs. We thank the MIGen study for the use of their genotype data, and
   the Brigham Research Institute for the contribution of control DNA
   samples. This research was supported in part by Grants R01-EY11309,
   R01-EY13435, R24-EY017404, K12-EY16335, R01 HL087676, R01-EY11600, and
   U54 RR020278 from the National Institutes of Health, Massachusetts Lions
   Eye Research Fund, Inc., unrestricted grants and a Career Development
   Award from Research to Prevent Blindness, Inc., Macula Vision Research
   Foundation, Kaplen Foundation, Widgeon Point Charitable Foundation,
   Alcon Research institute, Fight for Sight postdoctoral award, and the
   Macular Degeneration Research Fund of the Ophthalmic Epidemiology and
   Genetics Service, New England Eye Center, Tufts Medical Center, Tufts
   University School of Medicine.
CR Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   DelaPaz MA, 1997, INVEST OPHTH VIS SCI, V38, P1060
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grarup N, 2008, J CLIN ENDOCR METAB, V93, P2294, DOI 10.1210/jc.2007-2815
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hasham SN, 2006, CLIN CHIM ACTA, V372, P179, DOI 10.1016/j.cca.2006.04.020
   Kathiresan S, 2009, NAT GENET, V41, P56, DOI 10.1038/ng.291
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Pe'er I, 2006, NAT GENET, V38, P663, DOI 10.1038/ng1816
   Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Qi JH, 2009, J BIOL CHEM, V284, P19927, DOI 10.1074/jbc.M109.013763
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rufibach LE, 2006, J LIPID RES, V47, P1463, DOI 10.1194/jlr.M600082-JLR200
   Seddon J, 2007, PRINCIPLES PRACTICE, P413
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   TAMURA Y, 1991, INVEST OPHTH VIS SCI, V32, P2636
   Thiagalingam A, 1997, GENOMICS, V45, P630, DOI 10.1006/geno.1997.5001
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 30
TC 322
Z9 339
U1 0
U2 11
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 20
PY 2010
VL 107
IS 16
BP 7395
EP 7400
DI 10.1073/pnas.0912019107
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 586FU
UT WOS:000276892300053
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Newsom, RSB
   McAlister, JC
   Saeed, M
   El-Ghonemy, K
   McHugh, JDA
AF Newsom, RSB
   McAlister, JC
   Saeed, M
   El-Ghonemy, K
   McHugh, JDA
TI Results 28 months following transpupillary thermotherapy for classic and
   occult choroidal neovascularization in patients with age-related macular
   degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID PIGMENT EPITHELIAL TEAR; PHOTODYNAMIC THERAPY; PHOTOCOAGULATION;
   VERTEPORFIN; MANAGEMENT; INDUCTION; APOPTOSIS; RETINA
AB square BACKGROUND AND OBJECTIVE: To report the outcome of patients 28 months following treatment with transpupillary thermotherapy (TTT) for classic and occult choroidal neovascularization (CNV) secondary to age-related macular degeneration.
   square PATIENTS AND METHODS: A nonrandomized pilot trial of 36 eyes of 33 patients was performed. Eyes with angiographically defined CNV, 11 predominantly classical and 25 predominantly occult, were treated with large spot diode laser (810 nm) TTT for 1 minute, the end point being no or minimal visible change. Outcome was assessed with best-corrected LogMAR visual acuity, clinical examination, and fluorescein angiography.
   square RESULTS: Patients were observed for a mean of 28.7 months (range, 18 to 40 months). The mean change in LogMAR visual acuity for predominantlyclassic membranes was -1.91 (standard deviation [SD] = 4-3) and 5 of 11 (45.5%) eyes had a loss of 3 or more LogMAR lines. Predominantly classic membranes were closed in 9 of 11 eyes and stabilized in 2 of 11 eyes. The mean change in LogMAR visual acuity for predominantly occult membranes was -1.48 (SD = 6.3) and 10 of 25 (40%) patients had a loss of 3 lines or more. Predominantly occult CNV was stabilized in 25 of 25 cases, and recurrence developed in 2 of 25 cases; one of the latter developed classic CNV.
   square CONCLUSIONS: The medium-term results for patients treated with TTT for both occult and classic CNV show good stability, with little visual loss and few recurrences. These data confirm the original findings of this study.
C1 Kings Coll Hosp London, London, England.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital
RP Newsom, RSB (通讯作者)，Southampton Eye Unit, Tremona Rd, Southampton SO16 6YD, Hants, England.
OI newsom, Richard/0000-0002-2221-0653
CR Algvere PV, 2003, ACTA OPHTHALMOL SCAN, V81, P110, DOI 10.1034/j.1600-0420.2003.00041.x
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Beintema MR, 2001, BRIT J OPHTHALMOL, V85, P708, DOI 10.1136/bjo.85.6.708
   Belzacq AS, 2001, CANCER RES, V61, P1260
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Currie ZI, 2000, RETINA-J RET VIT DIS, V20, P620, DOI 10.1097/00006982-200011000-00006
   Dean DO, 1999, INVEST OPHTH VIS SCI, V40, P2952
   Desatnik H, 2000, RETINA-J RET VIT DIS, V20, P143, DOI 10.1097/00006982-200003000-00005
   Desmettre T, 2001, INVEST OPHTH VIS SCI, V42, P2976
   Ding QX, 2001, J NEUROCHEM, V77, P1010, DOI 10.1046/j.1471-4159.2001.00302.x
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Hart PM, 1996, BRIT J OPHTHALMOL, V80, P1046, DOI 10.1136/bjo.80.12.1046
   Hunt DWC, 1999, IMMUNOPHARMACOLOGY, V41, P31, DOI 10.1016/S0162-3109(98)00051-4
   Husain D, 1999, INVEST OPHTH VIS SCI, V40, P2322
   Jaattela M, 1999, ANN MED, V31, P261, DOI 10.3109/07853899908995889
   JourneedeKorver JG, 1997, BRIT J OPHTHALMOL, V81, P234, DOI 10.1136/bjo.81.3.234
   Kaga T, 2001, RETINA-J RET VIT DIS, V21, P172, DOI 10.1097/00006982-200104000-00012
   Kurohane K, 2001, CANCER LETT, V167, P49, DOI 10.1016/S0304-3835(01)00475-X
   LEVY JG, 1994, SEMIN ONCOL, V21, P4
   Mainster M A, 1999, Semin Ophthalmol, V14, P200
   Mainster MA, 2000, OPHTHALMIC SURG LAS, V31, P359
   Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0
   Momma T, 1998, CANCER RES, V58, P5425
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   Noffke AS, 2001, ARCH OPHTHALMOL-CHIC, V119, P143
   Parmar DN, 2000, OPHTHALMIC SURG LAS, V31, P334
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Schnurrbusch UEK, 2001, BRIT J OPHTHALMOL, V85, P1086, DOI 10.1136/bjo.85.9.1086
   Sickenberg M, 2001, OPHTHALMOLOGICA, V215, P247, DOI 10.1159/000050869
   Sliney DH., 1992, LASERS LIGHT OPHTHAL, V5, P17
   Thompson JT, 2001, AM J OPHTHALMOL, V131, P662, DOI 10.1016/S0002-9394(00)00879-5
   TYTELL M, 1994, J NEUROSCI RES, V38, P19, DOI 10.1002/jnr.490380105
   *VERT PHOT THERP S, 2001, AM J OPHTHALMOL, V13, P541
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   WELCH WJ, 1993, SCI AM, V268, P56, DOI 10.1038/scientificamerican0593-56
   WHITACRE MM, 1994, LASER SURG MED, V15, P62, DOI 10.1002/lsm.1900150109
   Wolf S, 1999, GRAEF ARCH CLIN EXP, V237, P51, DOI 10.1007/s004170050194
   YEO JH, 1988, OPHTHALMOLOGY, V95, P8
NR 42
TC 8
Z9 11
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
EI 1938-2375
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD MAR-APR
PY 2005
VL 36
IS 2
BP 94
EP 102
DI 10.3928/1542-8877-20050301-03
PG 9
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 906QB
UT WOS:000227655800001
PM 15792308
DA 2022-11-30
ER

PT J
AU Ricci, F
   Calabrese, A
   Regine, F
   Missiroli, F
   Ciardella, AP
AF Ricci, Federico
   Calabrese, Antonio
   Regine, Federico
   Missiroli, Filippo
   Ciardella, Antonio P.
TI COMBINED REDUCED FLUENCE PHOTODYNAMIC THERAPY AND INTRAVITREAL
   RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE polypoidal choroidal vasculopathy (PCV); ranibizumab; reduced fluence
   photodynamic therapy (PDT)
ID MACULAR DEGENERATION; VERTEPORFIN; CFH
AB Purpose: We performed a prospective noncomparative study to report the results of reduced fluence photodynamic therapy (PDT) combined with intravitreal ranibizumab in patients with polypoidal choroidal vasculopathy with active exudation and hemorrhage.
   Methods: Seventeen polypoidal choroidal vasculopathy eyes were treated, and follow-up for all patients was 12 months. Photodynamic therapy was administered with reduced fluence (exposure time of 70 '') and followed (48 hours later) by intravitreal ranibizumab (0.5 mg in 50 mu L). Intravitreal ranibizumab, with or without reduced fluence PDT, was repeated as indicated by clinical and angiographic findings.
   Results: During the follow-up, the mean best-corrected visual acuity significantly improved from 0.45 +/- 0.29 logarithm of the minimum angle of resolution at baseline to 0.29 +/- 0.28 logarithm of the minimum angle of resolution at 12 months. The mean total macular volume (documented by optical coherence tomography retinal map examination) decreased from 7.5 +/- 1.18 mm(3) to 6.7 +/- 0.8 mm(3). In 95% of the cases, best-corrected visual acuity remained stable or improved.
   Conclusion: Reduced fluence PDT limits laser exposure, minimizing the risks of PDT-induced adverse effects. Intravitreal injections of ranibizumab 0.5 mg reduced bleeding and leakage in polypoidal choroidal vasculopathy eyes and interfere with rebound upregulation of vascular endothelial growth factor because of PDT-induced choroidal hypoperfusion. Combined treatment may improve treatment outcomes in polypoidal choroidal vasculopathy while minimizing ocular and systemic complications of treatment. RETINA 32:1280-1288, 2012
C1 [Ricci, Federico; Calabrese, Antonio; Regine, Federico; Missiroli, Filippo] Univ Roma Tor Vergata, Unita Operat Dipartimentale Patol Retin Policlin, I-00161 Rome, Italy.
   [Ciardella, Antonio P.] St Orsola Marcello Malpighi Hosp, Unita Operat Oftalmol, Bologna, Italy.
C3 University of Rome Tor Vergata; IRCCS Azienda Ospedaliero-Universitaria
   di Bologna
RP Ricci, F (通讯作者)，Univ Roma Tor Vergata, Unita Operat Dipartimentale Patol Retin Policlin, Via Giorgio Baglivi 5D, I-00161 Rome, Italy.
EM federico.ricci@uniroma2.it
RI ricci, federico/AAC-3836-2020
OI ricci, federico/0000-0002-4224-9280
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Ricci F, 2009, ARCH OPHTHALMOL-CHIC, V127, P1368, DOI 10.1001/archophthalmol.2009.237
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yamashita A, 2010, AM J OPHTHALMOL, V149, P465, DOI 10.1016/j.ajo.2009.09.020
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 26
TC 27
Z9 29
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2012
VL 32
IS 7
BP 1280
EP 1288
DI 10.1097/IAE.0b013e318236e835
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 965QK
UT WOS:000305782100008
PM 22218148
DA 2022-11-30
ER

PT J
AU Patel, PJ
   Jayaram, H
   Eleftheriadou, M
   Vazquez-Alfageme, C
   Islam, N
   Rubin, GS
   Pal, B
   Addison, PK
   Hamilton, R
   Degli Esposti, S
AF Patel, Praveen J.
   Jayaram, Hari
   Eleftheriadou, Maria
   Vazquez-Alfageme, Clara
   Islam, Niaz
   Rubin, Gary S.
   Pal, Bishwanath
   Addison, Peter K.
   Hamilton, Robin
   Degli Esposti, Simona
TI Individualizing Therapy for Neovascular Age-Related Macular Degeneration
   with Aflibercept (VITAL): A Two-Year Prospective, Interventional
   Single-Centre Trial
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Article
DE Aflibercept; Neovascular age-related macular degeneration; Reading
   ability; Treat and extend
ID CHOROIDAL THICKNESS; INTRAVITREAL AFLIBERCEPT; VISUAL FUNCTION;
   OUTCOMES; RANIBIZUMAB; TREAT; EYES; INJECTION
AB Aims To report the mean change in Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) and reading performance (reading acuity and maximum reading speed (MRS) using the MNREAD test) between baseline and 24 months in treatment-naive patients with neovascular age-related macular degeneration (nAMD) treated with intravitreal aflibercept injections. Methods A prospective, open-label, interventional non-randomised case series with 24 months' duration. Patients were recruited to the study from medical retina clinics at Moorfields Eye Hospital. Intravitreal injections of 2.0 mg aflibercept in the study eye were administered using a fixed dosing regimen during the first year and a treat-and-extend treatment regimen during the second year of treatment. Results Fifty patients were enrolled with a mean age (SD) of 78.7 (7.6) years; a mean BCVA of 62.8 ETDRS letters; mean reading acuity of 0.52 logMAR; mean maximum reading speed (MRS) of 141.3 words per minute and a central macular thickness of 322.6 mu m at baseline. The mean improvement in BCVA was 6.4 letters for the 44 patients (88%) for whom data was available at 2 years. The mean improvement in reading acuity was 0.13 logMAR with an improvement in MRS of 2.9 words per minute. The mean reduction in CRT from baseline was 104.8 mu m. Conclusions Aflibercept treatment of nAMD using fixed dosing in year 1 and treat and extend in year 2 leads to improvements in reading ability, visual acuity and retinal morphology which were maintained to 2 years of treatment.
C1 [Patel, Praveen J.; Jayaram, Hari; Eleftheriadou, Maria; Vazquez-Alfageme, Clara; Islam, Niaz; Rubin, Gary S.; Pal, Bishwanath; Addison, Peter K.; Hamilton, Robin; Degli Esposti, Simona] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, UCL Inst Ophthalmol, London, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust
RP Patel, PJ (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, UCL Inst Ophthalmol, London, England.
EM Praveen.Patel1@nhs.net
FU Bayer UK; NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS
   Foundation Trust; UCL Institute of Ophthalmology; NIHR Moorfields
   Clinical Research Facility
FX The research was funded by Bayer UK and supported by the NIHR Biomedical
   Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL
   Institute of Ophthalmology and the NIHR Moorfields Clinical Research
   Facility. The views expressed are those of the author(s) and not
   necessarily those of the NHS, the NIHR or the Department of Health. No
   funding or sponsorship was received for the publication of this article.
CR Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   BULLIMORE MA, 1991, INVEST OPHTH VIS SCI, V32, P2020
   Cho HJ, 2016, AM J OPHTHALMOL, V166, P112, DOI 10.1016/j.ajo.2016.03.039
   Daniel E, 2016, OPHTHALMOLOGY, V123, P609, DOI 10.1016/j.ophtha.2015.10.034
   Decroos FC, 2017, AM J OPHTHALMOL, V180, P142, DOI 10.1016/j.ajo.2017.06.002
   Eleftheriadou M, 2017, AM J OPHTHALMOL, V174, P160, DOI 10.1016/j.ajo.2016.09.038
   Elliott DB, 1997, INVEST OPHTH VIS SCI, V38, P2566
   Epstein D, 2016, RETINA-J RET VIT DIS, V36, P1773, DOI 10.1097/IAE.0000000000000978
   Gharbiya M, 2018, CURR EYE RES, V43, P391, DOI 10.1080/02713683.2017.1405045
   Hazel CA, 2000, INVEST OPHTH VIS SCI, V41, P1309
   Kawashima Y, 2017, AM J OPHTHALMOL, V181, P61, DOI 10.1016/j.ajo.2017.06.015
   Kaya F, 2017, J FR OPHTALMOL, V40, P832, DOI 10.1016/j.jfo.2017.04.014
   Lorentzen TD, 2018, RETINA-J RET VIT DIS, V38, P2363, DOI 10.1097/IAE.0000000000001872
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mazaraki K, 2015, BRIT J OPHTHALMOL, V99, P1341, DOI 10.1136/bjophthalmol-2015-306636
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   Mrejen S, 2015, J CLIN MED, V4, P1380, DOI 10.3390/jcm4071380
   Patel PJ, 2011, INVEST OPHTH VIS SCI, V52, P3854, DOI 10.1167/iovs.10-6601
   Pokroy R, 2018, RETINA-J RET VIT DIS, V38, P1485, DOI 10.1097/IAE.0000000000001748
   Rae S, 2015, CLIN EXP OPTOM, V98, P459, DOI 10.1111/cxo.12292
   Rubin GS, 2013, VISION RES, V90, P43, DOI 10.1016/j.visres.2013.02.015
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Tan CS, 2016, BRIT J OPHTHALMOL, V100, P995, DOI 10.1136/bjophthalmol-2015-307541
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Wykoff CC, 2018, BRIT J OPHTHALMOL, V102, P460, DOI 10.1136/bjophthalmol-2017-310822
NR 25
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD SEP
PY 2020
VL 9
IS 3
BP 563
EP 576
DI 10.1007/s40123-020-00267-5
EA JUN 2020
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MV3HE
UT WOS:000541212200001
PM 32557168
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Aleci, C
   Cossu, G
   Belcastro, E
   Canavese, L
AF Aleci, Carlo
   Cossu, Gabriele
   Belcastro, Elena
   Canavese, Lorenzo
TI The optokinetic response is effective to assess objective visual acuity
   in patients with cataract and age-related macular degeneration
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Cataract; Optokinetic nystagmus;
   Oktotype; Test-retest reliability; Visual acuity
ID CARD PROCEDURE; PREFERENTIAL LOOKING; NYSTAGMUS TEST; INFANTS
AB Purpose To estimate objective visual acuity in subjects suffering from cataract and age-related macular degeneration via the optokinetic response evoked by a non-conventional induction method (oktotype); in addition, to compare such objective outcome with the subjective acuity based on the ETDRS charts. Methods Patients were presented with 13 sequences of symbols arranged horizontally to form a serial pattern, moving from left to right at a constant rate. In each sequence, the size of the stimuli was reduced progressively, while the operator checked for the disappearance of the optokinetic response via a small video camera mounted on the test lens frame. The minimum angular size of the serial pattern able to evoke the optokinetic response (MAER) was referred to as the objective visual acuity of the subject. Results Correlation between logMAER and logMAR was significant in the cataract and macular degeneration group (R-cat(2) = 0.70, p < .0001; R-AMD(2) = 0.63, p < .0007). In the two samples, the correspondence between subjective and objective visual acuity (as, respectively, decimal units and arbitrary decimal units) was satisfactory (concordance correlation coefficient: cataract group = 0.91 and AMD group = 0.93). Test-retest reliability of the oktotype was good for the cataract group and moderate for the AMD sample (J 0.81 and 0.59, respectively). Conclusion The oktotype seems a promising tool to objectively assess visual acuity in noncooperating subjects with cataract or macular degeneration. Further research on other clinical conditions is needed to clarify the suitability of the procedure in the clinical setting.
C1 [Aleci, Carlo; Cossu, Gabriele; Canavese, Lorenzo] Univ Turin, Molinette Hosp, Dept Ophthalmol, Serv Orthopt, Via Cherasco 23, I-10126 Turin, Italy.
   [Aleci, Carlo; Cossu, Gabriele; Canavese, Lorenzo] Ophthalm Hosp, Serv Neuroophthalmol, Via Juvarra 19, I-10100 Turin, Italy.
   [Belcastro, Elena] Ophthalm Hosp, Dept Pediat Ophthalmol, Serv Orthopt, Via Juvarra 19, I-10100 Turin, Italy.
C3 A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni
   Battista-Molinette; University of Turin
RP Aleci, C (通讯作者)，Univ Turin, Molinette Hosp, Dept Ophthalmol, Serv Orthopt, Via Cherasco 23, I-10126 Turin, Italy.
EM carlo.aleci@unito.it
OI Belcastro, Elena/0000-0003-3876-3591; Aleci, Carlo/0000-0003-4589-6675
CR ABADI RV, 1991, VISION RES, V31, P2219, DOI 10.1016/0042-6989(91)90174-4
   Aleci C, 2017, INT OPHTHALMOL
   Altman DG., 1991, PRACTICAL STAT MED R, P1991
   Bach M, 2008, BRIT J OPHTHALMOL, V92, P396, DOI 10.1136/bjo.2007.130245
   COURAGE ML, 1990, OPTOMETRY VISION SCI, V67, P713, DOI 10.1097/00006324-199009000-00011
   FIELDER AR, 1992, OPHTHALMIC PAED GEN, V13, P101, DOI 10.3109/13816819209087610
   GEER I, 1993, OPTOMETRY VISION SCI, V70, P552, DOI 10.1097/00006324-199307000-00006
   GORMAN JJ, 1957, PEDIATRICS, V19, P1088
   Han SB, 2011, INVEST OPHTH VIS SCI, V52, P7492, DOI 10.1167/iovs.11-7663
   Han SB, 2011, GRAEF ARCH CLIN EXP, V249, P1379, DOI 10.1007/s00417-011-1705-x
   Hyon JY, 2010, INVEST OPHTH VIS SCI, V51, P752, DOI 10.1167/iovs.09-4362
   Jeon J, 2012, BMC OPHTHALMOL, V12, DOI 10.1186/1471-2415-12-36
   KHAN SG, 1976, ARCH OPHTHALMOL-CHIC, V94, P2086
   KIM MS, 2000, J KOREAN OPHTHALMOL, V41, P871
   Ludvigh E, 1953, 0010750101 NM US NAV
   MCDONALD M, 1986, AM J OPTOM PHYS OPT, V63, P127
   MCDONALD M, 1985, INVEST OPHTH VIS SCI, V26, P1158
   MILLODOT M, 1969, AMER J OPT ARCH AM A, V46, P938
   MILLODOT M, 1973, ARCH OPHTHALMOL-CHIC, V90, P449
   Miyoshi T, 1984, Acta Otolaryngol Suppl, V419, P53
   QUINN GE, 1993, OPHTHALMOLOGY, V100, P488
   Shin YJ, 2006, AM J OPHTHALMOL, V141, P327, DOI 10.1016/j.ajo.2005.09.025
   SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420
   STEELE M, 1989, AM J OPHTHALMOL, V108, P572, DOI 10.1016/0002-9394(89)90436-4
   TELLER DY, 1979, INFANT BEHAV DEV, V2, P135, DOI 10.1016/S0163-6383(79)80016-8
   TOWLE VL, 1977, INVEST OPHTH VIS SCI, V16, P1073
   TYLER CW, 1979, INVEST OPHTH VIS SCI, V18, P703
   Wester ST, 2007, INVEST OPHTH VIS SCI, V48, P4542, DOI 10.1167/iovs.06-1206
NR 28
TC 2
Z9 2
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD AUG
PY 2019
VL 39
IS 8
BP 1783
EP 1792
DI 10.1007/s10792-018-1001-4
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IS4OY
UT WOS:000482134100015
PM 30109530
DA 2022-11-30
ER

PT J
AU Zhang, K
   Hopkins, JJ
   Heier, JS
   Birch, DG
   Halperin, LS
   Albini, TA
   Brown, DM
   Jaffe, GJ
   Tao, W
   Williams, GA
AF Zhang, Kang
   Hopkins, Jill J.
   Heier, Jeffrey S.
   Birch, David G.
   Halperin, Lawrence S.
   Albini, Thomas A.
   Brown, David M.
   Jaffe, Glenn J.
   Tao, Weng
   Williams, George A.
TI Ciliary neurotrophic factor delivered by encapsulated cell intraocular
   implants for treatment of geographic atrophy in age-related macular
   degeneration
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE apoptosis; retina; photoreceptor degeneration
ID PHOTORECEPTOR DEGENERATION; RETINAL-DEGENERATION; CNTF RECEPTOR;
   GENE-TRANSFER; CYTOKINES; MOUSE; ENLARGEMENT; TRIAL
AB There is no treatment available for vision loss associated with advanced dry age-related macular degeneration (AMD) or geographic atrophy (GA). In a pilot, proof of concept phase 2 study, we evaluated ciliary neurotrophic factor (CNTF) delivered via an intraocular encapsulated cell technology implant for the treatment of GA. We designed a multicenter, 1-y, double-masked, sham-controlled dose-ranging study. Patients with GA were randomly assigned to receive a high-or low-dose implant or sham surgery. The primary endpoint was the change in best corrected visual acuity (BCVA) at 12 mo. CNTF treatment resulted in a dose-dependent increase in retinal thickness. This change was followed by visual acuity stabilization (loss of less than 15 letters) in the high-dose group (96.3%) compared with low-dose (83.3%) and sham (75%) group. A subgroup analysis of those with baseline BCVA at 20/63 or better revealed that 100% of patients in the high-dose group lost < 15 letters compared with 55.6% in the combined low-dose/sham group (P = 0.033). There was a 0.8 mean letter gain in the high-dose group compared with a 9.7 mean letter loss in the combined low-dose/sham group (P = 0.0315). Both the implant and the implant procedure were well-tolerated. These findings suggest that CNTF delivered by the encapsulated cell technology implant appears to slow the progression of vision loss in GA, especially in eyes with 20/63 or better vision at baseline.
C1 [Zhang, Kang] Univ Calif San Diego, Shiley Eye Ctr, La Jolla, CA 92093 USA.
   [Zhang, Kang] Univ Calif San Diego, Inst Genom Med, La Jolla, CA 92093 USA.
   [Zhang, Kang] Sichuan Univ, W China Hosp, Mol Med Res Ctr, Chengdu 610041, Peoples R China.
   [Zhang, Kang] Sichuan Univ, W China Hosp, Dept Ophthalmol, Chengdu 610041, Peoples R China.
   [Hopkins, Jill J.] Retina Vitreous Associates Med Grp, Los Angeles, CA 90017 USA.
   [Heier, Jeffrey S.] Ophthalm Consultants Boston, Boston, MA 02114 USA.
   [Birch, David G.] Retina Fdn SW, Dallas, TX 75231 USA.
   [Halperin, Lawrence S.] Retina Grp Florida, Ft Lauderdale, FL 33334 USA.
   [Albini, Thomas A.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Brown, David M.] Vitreoretinal Consultants, Texas Med Ctr Off, Houston, TX 77030 USA.
   [Jaffe, Glenn J.] Duke Univ, Ctr Eye, Durham, NC 27710 USA.
   [Tao, Weng] Neurotech USA, Lincoln, RI 02865 USA.
   [Williams, George A.] Beaumont Eye Inst, Royal Oak, MI 48073 USA.
C3 University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   Sichuan University; Sichuan University; Retina Vitreous Associates
   Medical Group; Ophthalmic Consultants of Boston; Retina Foundation of
   the Southwest; Bascom Palmer Eye Institute; University of Miami; Duke
   University
RP Zhang, K (通讯作者)，Univ Calif San Diego, Shiley Eye Ctr, La Jolla, CA 92093 USA.
EM kang.zhang@gmail.com
RI Zhang, Kang/Y-2740-2019
OI Zhang, Kang/0000-0002-4549-1697; Halperin, Lawrence/0000-0002-7959-2306;
   Albini, Thomas/0000-0003-2199-9047; Birch, David/0000-0002-6594-2897
FU Chinese National 985 Project; West China Hospital; NEI/NIH; Macula
   Vision Research Foundation; Research to Prevent Blindness (RPB);
   Burroughs Wellcome Fund; RPB; NATIONAL EYE INSTITUTE [R01EY021374,
   R01EY018660] Funding Source: NIH RePORTER
FX We thank the patients who participated in this study, their families,
   and the research team at each site; the members of the data safety
   monitoring committee: Donald J. D'Amico, MD (chair); Thomas R. Friberg,
   MD; Alan M. Laties, MD; Raymond Iezzi, MD, MS; and David C. Musch, PhD.;
   the members of Duke University Optical Coherence Tomography Reading
   Center, the members of RADIARC Reading Center, Janet Sunness for GA
   lesion area grading, and the members of Neurotech clinical research team
   for their invaluable assistance in the conduct of this study. Original
   design for this study protocol was developed through a Clinical Trials
   Agreement (612) between Neurotech USA, Inc. and the National Eye
   Institute (NEI), National Institutes of Health (NIH). The protocol was
   designed by Ronald A. Bush, PhD, NEI; Rafael Caruso, MD, NEI; Emily Y.
   Chew, MD, NEI; Frederick L. Ferris III, MD, NEI; Paul A. Sieving, MD,
   PhD, NEI; W.T., MD, PhD, Neurotech USA, Inc.; and Santa J. Tumminia,
   PhD, NEI. K.Z. is the chair of this study. The following investigators
   are members of the CNTF2 GA study group: Rand Spencer, MD, David Boyer,
   MD; Roger Novack, MD; Firas Rahhal, MD; Thomas Chu, MD; Albert Vitale,
   MD; Paul Bernstein, MD; Mike Teske, MD; and Bruce Garretson, MD K.Z. is
   supported by grants from Chinese National 985 Project to Sichuan
   University and West China Hospital, NEI/NIH, the Macula Vision Research
   Foundation, Research to Prevent Blindness (RPB), Burroughs Wellcome Fund
   Clinician Translational Award, and RPB Lew Wasserman Merit Award. Dr.
   Zhang is a RPB Senior Investigator.
CR Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bush RA, 2004, INVEST OPHTH VIS SCI, V45, P2420, DOI 10.1167/iovs.03-1342
   Cayouette M, 1997, HUM GENE THER, V8, P423, DOI 10.1089/hum.1997.8.4-423
   Cayouette M, 1998, J NEUROSCI, V18, P9282
   FAKTOROVICH EG, 1990, NATURE, V347, P83, DOI 10.1038/347083a0
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fuhrmann S, 2003, J COMP NEUROL, V461, P111, DOI 10.1002/cne.10701
   FUHRMANN S, 1995, DEVELOPMENT, V121, P2695
   LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249
   LaVail MM, 1998, INVEST OPHTH VIS SCI, V39, P592
   Li YW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009495
   Lujan BJ, 2011, INVEST OPHTH VIS SCI, V52, P1486, DOI 10.1167/iovs.10-5946
   Marmor MF, 2004, DOC OPHTHALMOL, V108, P107, DOI 10.1023/B:DOOP.0000036793.44912.45
   MCDONALD NQ, 1995, EMBO J, V14, P2689, DOI 10.1002/j.1460-2075.1995.tb07269.x
   PANAYOTATOS N, 1995, J BIOL CHEM, V270, P14007, DOI 10.1074/jbc.270.23.14007
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103
   STAHL N, 1994, J NEUROBIOL, V25, P1454, DOI 10.1002/neu.480251111
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Talcott KE, 2011, INVEST OPHTH VIS SCI, V52, P2219, DOI 10.1167/iovs.10-6479
   Tao W, 2002, INVEST OPHTH VIS SCI, V43, P3292
   Tao Weng, 2006, Expert Opin Biol Ther, V6, P717, DOI 10.1517/14712598.6.7.717
   2001, ARCH OPHTHALMOL, V119, P1417
NR 27
TC 204
Z9 213
U1 0
U2 14
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 12
PY 2011
VL 108
IS 15
BP 6241
EP 6245
DI 10.1073/pnas.1018987108
PG 5
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 748SZ
UT WOS:000289413600062
PM 21444807
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Wang, AL
   Lukas, TJ
   Yuan, M
   Du, N
   Tso, MO
   Neufeld, AH
AF Wang, Ai Ling
   Lukas, Thomas J.
   Yuan, Ming
   Du, Nga
   Tso, Mark O.
   Neufeld, Arthur H.
TI Autophagy and Exosomes in the Aged Retinal Pigment Epithelium: Possible
   Relevance to Drusen Formation and Age-Related Macular Degeneration
SO PLOS ONE
LA English
DT Article
AB Age-related macular degeneration (AMD) is a major cause of loss of central vision in the elderly. The formation of drusen, an extracellular, amorphous deposit of material on Bruch's membrane in the macula of the retina, occurs early in the course of the disease. Although some of the molecular components of drusen are known, there is no understanding of the cell biology that leads to the formation of drusen. We have previously demonstrated increased mitochondrial DNA (mtDNA) damage and decreased DNA repair enzyme capabilities in the rodent RPE/choroid with age. In this study, we found that drusen in AMD donor eyes contain markers for autophagy and exosomes. Furthermore, these markers are also found in the region of Bruch's membrane in old mice. By in vitro modeling increased mtDNA damage induced by rotenone, an inhibitor of mitochondrial complex I, in the RPE, we found that the phagocytic activity was not altered but that there were: 1) increased autophagic markers, 2) decreased lysosomal activity, 3) increased exocytotic activity and 4) release of chemoattractants. Exosomes released by the stressed RPE are coated with complement and can bind complement factor H, mutations of which are associated with AMD. We speculate that increased autophagy and the release of intracellular proteins via exosomes by the aged RPE may contribute to the formation of drusen. Molecular and cellular changes in the old RPE may underlie susceptibility to genetic mutations that are found in AMD patients and may be associated with the pathogenesis of AMD in the elderly.
C1 [Wang, Ai Ling; Lukas, Thomas J.; Yuan, Ming; Du, Nga; Tso, Mark O.; Neufeld, Arthur H.] Northwestern Univ, Sch Med, Dept Ophthalmol, Forsythe Lab Invest Aging Retina, Chicago, IL 60611 USA.
C3 Northwestern University
RP Wang, AL (通讯作者)，Northwestern Univ, Sch Med, Dept Ophthalmol, Forsythe Lab Invest Aging Retina, Chicago, IL 60611 USA.
EM a-neufeld@northwestern.edu
FU NIH [EY12017]; Forsythe Foundation; RPB; NATIONAL EYE INSTITUTE
   [R01EY012017] Funding Source: NIH RePORTER
FX This work was supported by NIH grant EY12017, a generous gift from the
   Forsythe Foundation and an unrestricted grant from RPB. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR BOK D, 1993, J CELL SCI, P189
   BOULTON M, 1994, BRIT J OPHTHALMOL, V78, P125, DOI 10.1136/bjo.78.2.125
   Chang YG, 2007, J CELL SCI, V120, P3053, DOI 10.1242/jcs.006361
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Deretic V, 2008, SCI AM, V298, P74, DOI 10.1038/scientificamerican0508-74
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Finnemann SC, 1999, J EXP MED, V190, P861, DOI 10.1084/jem.190.6.861
   Fischer R, 2006, CHEMBIOCHEM, V7, P1428, DOI 10.1002/cbic.200600209
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Indo HP, 2007, MITOCHONDRION, V7, P106, DOI 10.1016/j.mito.2006.11.026
   Kim I, 2007, ARCH BIOCHEM BIOPHYS, V462, P245, DOI 10.1016/j.abb.2007.03.034
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Knott AB, 2008, NAT REV NEUROSCI, V9, P505, DOI 10.1038/nrn2417
   Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723
   Li J, 2005, J NEUROCHEM, V92, P462, DOI 10.1111/j.1471-4159.2004.02872.x
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Li NY, 2003, J BIOL CHEM, V278, P8516, DOI 10.1074/jbc.M210432200
   McCray BA, 2008, NEUROSIGNALS, V16, P75, DOI 10.1159/000109761
   Mizushima N, 1998, J BIOL CHEM, V273, P33889, DOI 10.1074/jbc.273.51.33889
   MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Olver Christine, 2007, V43, P99, DOI 10.1007/978-1-4020-5943-8_7
   Ping JA, 2004, J CHROMATOGR B, V805, P297, DOI 10.1016/j.jchromb.2004.03.008
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Santos Janine H, 2006, Methods Mol Biol, V314, P183
   Sherer TB, 2003, J NEUROSCI, V23, P10756, DOI 10.1523/jneurosci.23-34-10756.2003
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Teshima K, 2005, ANAL BIOCHEM, V338, P12, DOI 10.1016/j.ab.2004.12.007
   Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Wang AL, 2008, MOL VIS, V14, P644
NR 34
TC 234
Z9 247
U1 0
U2 38
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 8
PY 2009
VL 4
IS 1
AR e4160
DI 10.1371/journal.pone.0004160
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 437FZ
UT WOS:000265473500007
PM 19129916
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Young, M
   Chui, LC
   Fallah, N
   Or, C
   Merkur, AB
   Kirker, AW
   Albiani, DA
   Forooghian, F
AF Young, Mei
   Chui, Lica
   Fallah, Nader
   Or, Chris
   Merkur, Andrew B.
   Kirker, Andrew W.
   Albiani, David A.
   Forooghian, Farzin
TI EXACERBATION OF CHOROIDAL AND RETINAL PIGMENT EPITHELIAL ATROPHY AFTER
   ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT IN NEOVASCULAR
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; atrophy; choroid; bevacizumab; optical
   coherence tomography; progression; ranibizumab; retinal pigment
   epithelium; retrospective; vascular endothelial growth factor
ID GEOGRAPHIC ATROPHY; RANIBIZUMAB; PROGRESSION; PATHOLOGY
AB Purpose: To study the progression of retinal pigment epithelium (RPE) and choroidal atrophy in patients with neovascular age-related macular degeneration (AMD) and to assess for a possible association with the number and type of anti-vascular endothelial growth factor treatments.
   Methods: Patients with neovascular AMD and a minimum of 1-year follow-up were reviewed. Fellow eyes with nonneovascular AMD were used as control eyes. Retinal pigment epithelial atrophy area and choroidal thickness were determined using spectral-domain optical coherence tomography. Multivariable regression models were used for statistical analyses.
   Results: A total of 415 eyes were included in the study, with a mean follow-up of 2.2 years. Eyes with neovascular AMD had greater progression of RPE atrophy and choroidal atrophy compared with those with nonneovascular AMD (P < 0.001). Progression of RPE atrophy and choroidal atrophy was independently associated with the total number of injections of bevacizumab and ranibizumab (all P values <= 0.001). In the subgroup of 84 eyes with neovascular AMD and without RPE atrophy at baseline, only bevacizumab was associated with the progression of RPE atrophy (P = 0.003). This study likely lacked statistical power to detect an association with ranibizumab in this subgroup.
   Conclusion: Retinal pigment epithelial atrophy and choroidal atrophy in neovascular AMD seem to be exacerbated by anti-vascular endothelial growth factor treatment. Possible differences between bevacizumab and ranibizumab require further investigation.
C1 [Young, Mei; Chui, Lica; Or, Chris; Merkur, Andrew B.; Kirker, Andrew W.; Albiani, David A.; Forooghian, Farzin] Univ British Columbia, Dept Ophthalmol & Visual Sci, Vancouver, BC V6Z 1Y6, Canada.
   [Fallah, Nader] Rick Hansen Inst, Vancouver, BC, Canada.
C3 University of British Columbia
RP Forooghian, F (通讯作者)，Univ British Columbia, St Pauls Hosp, Dept Ophthalmol & Visual Sci, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.
EM farzin.forooghian@gmail.com
RI Fallah, Nader/D-4145-2012
OI Fallah, Nader/0000-0002-7746-4773
CR Branchini L, 2013, JAMA OPHTHALMOL, V131, P693, DOI 10.1001/jamaophthalmol.2013.692
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Drexler W, 2003, ARCH OPHTHALMOL-CHIC, V121, P695, DOI 10.1001/archopht.121.5.695
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Joachim N, 2013, OPHTHALMOLOGY, V120, P2042, DOI 10.1016/j.ophtha.2013.03.029
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Lujan BJ, 2009, OPHTHAL SURG LAS IM, V40, P96, DOI 10.3928/15428877-20090301-16
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Maruko I, 2010, OPHTHALMOLOGY, V117, P1792, DOI 10.1016/j.ophtha.2010.01.023
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Sunness JS, 1999, MOL VIS, V5
NR 21
TC 57
Z9 62
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2014
VL 34
IS 7
BP 1308
EP 1315
DI 10.1097/IAE.0000000000000081
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AK9UG
UT WOS:000338772600007
PM 24451923
DA 2022-11-30
ER

PT J
AU Zhang, YC
   Chen, AM
   Zou, MJ
   Yang, ZL
   Zheng, DY
   Fan, M
   Jin, GM
AF Zhang, Yichi
   Chen, Aiming
   Zou, Minjie
   Yang, Zhenlan
   Zheng, Danying
   Fan, Min
   Jin, Guangming
TI Disease burden of age-related macular degeneration in China from 1990 to
   2019: findings from the global burden of disease study
SO JOURNAL OF GLOBAL HEALTH
LA English
DT Article
ID PREVALENCE
AB Background To evaluate the disease burden of age-related macular degeneration (AMD) in terms of disability-adjusted life years (DALY) in China from 1990 to 2019.
   Methods: Prevalence of blindness and vision loss due to AMD and DALY number, rate, and age-standardized rates of AMD were collected from the Global Burden of Disease Study 2019 database. The characters of variables were analyzed between China and its neighboring countries.
   Results From 1990 to 2019, the all-age number and rate for AMD prevalence and DALYs increased significantly in China, while the age standardized DALYs rate in 2019 showed a decrease of 3.63% compared with that in 1990. Females were found to have a higher prevalence and DALYs than males. The 65-69 age group had the highest AMD DALYs number, while the DALYs rate showed a positive association with age. In 2019, when compared to neighboring countries, the age standardized prevalence rate of AMD in China was ranked second after Pakistan, while the age standardized DALYs rate ranked second after Pakistan and India.
   Conclusions Despite a small decrease in age standardized DALYs rate in China in the past three decades, the disease burden of AMD is still considerable and much higher compared to neighboring developed countries. Optimizing health services allocation is needed to further reduce this burden.
C1 [Zhang, Yichi; Yang, Zhenlan] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Ophthalmol, Guangzhou, Peoples R China.
   [Chen, Aiming] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Pharm, Zhuhai, Peoples R China.
   [Zou, Minjie; Zheng, Danying; Jin, Guangming] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Peoples R China.
   [Fan, Min] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Gen Intens Care Unit, Guangzhou 510000, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University;
   Sun Yat Sen University
RP Jin, GM (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Peoples R China.; Fan, M (通讯作者)，Sun Yat Sen Univ, Affiliated Hosp 3, Dept Gen Intens Care Unit, Guangzhou 510000, Peoples R China.
EM fanmin5@mail.sysu.edu.cn; jingm@mail2.sysu.edu.cn
OI Jin, Guangming/0000-0001-9994-6338
FU National Natural Science Foundation of China [81900841]; GuangDong Basic
   and Applied Basic Research Foundation [2021A1515011673]
FX This work was supported by National Natural Science Foundation of China
   (81900841) and the GuangDong Basic and Applied Basic Research Foundation
   (2021A1515011673).
CR Abbafati C, 2020, LANCET, V396, P1204, DOI 10.1016/S0140-6736(20)30925-9
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Chakravarthy U, 2020, JAMA-J AM MED ASSOC, V324, P794, DOI 10.1001/jama.2020.5576
   Chen R, 2019, BIOSCI TRENDS, V13, P287, DOI 10.5582/bst.2019.01213
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Guymer R, 2020, CLIN EXP OPHTHALMOL, V48, P983, DOI 10.1111/ceo.13837
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin XL, 2021, EUR J OPHTHALMOL, V31, P1161, DOI 10.1177/1120672120927256
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   Marakis TP, 2022, EUR J OPHTHALMOL, V32, P481, DOI 10.1177/1120672120972625
   Mehta H, 2020, CLIN OPHTHALMOL, V14, P3331, DOI 10.2147/OPTH.S275977
   Meng XD, 2021, ACTA OPHTHALMOL, V99, pE136, DOI 10.1111/aos.14523
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Muller PL, 2021, OPHTHALMOLOGICA, V244, P42, DOI 10.1159/000510727
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Ricci F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218242
   Song PG, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.020703
   Sun CC, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-037028
   Tower J, 2017, TRENDS ENDOCRIN MET, V28, P735, DOI 10.1016/j.tem.2017.07.002
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhou M, 2021, BRIT J OPHTHALMOL, V105, P1427, DOI 10.1136/bjophthalmol-2020-316820
NR 23
TC 1
Z9 1
U1 1
U2 5
PU INT SOC GLOBAL HEALTH
PI EDINBURGH
PA CALEDONIAN EXCHANGE, 19A CANNING ST, EDINBURGH, ENGLAND
SN 2047-2978
EI 2047-2986
J9 J GLOB HEALTH
JI J. Glob. Health
PY 2021
VL 11
AR 08009
DI 10.7189/jogh.11.08009
PG 6
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health
GA ZG7ZZ
UT WOS:000760474600062
PM 34737869
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Parekh, N
   Chappell, RJ
   Millen, AE
   Albert, DM
   Mares, JA
AF Parekh, Niyati
   Chappell, Richard J.
   Millen, Amy E.
   Albert, Daniel M.
   Mares, Julie A.
TI Association between vitamin D and age-related macular degeneration in
   the third National Health and Nutrition Examination Survey, 1988 through
   1994
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; BLUE-MOUNTAINS-EYE; C-REACTIVE PROTEIN;
   DIETARY-FAT; UNITED-STATES; RISK-FACTORS; MONONUCLEAR-CELLS; DRUSEN
   FORMATION; 5-YEAR INCIDENCE; DOWN-REGULATION
AB Objective: To evaluate the associations between levels of vitamin D (25-hydroxyvitamin D) in serum and prevalent age-related macular degeneration (AMD).
   Methods and Design: Cross-sectional associations of serum vitamin D and early and advanced AMD, assessed from nonmydriatic funclus photographs, were evaluated in the third National Health and Nutrition Examination Survey, a multistage nationally representative probability sample of noninstitutionalized individuals (N = 7752; 11% with AMD).
   Results: Levels of serum vitamin D were inversely associated with early AMD but not advanced AMD. The odds ratio (OR) and 95% confidence interval (CI) for early AMD among participants in the highest vs lowest quintile of serum vitamin D was 0.64 (95% CI, 0.5-0.8; P trend < .001). Exploratory analyses were conducted to evaluate associations with important food and supplemental sources of vitamin D. Milk intake was inversely associated with early AMD (OR, 0.75; 95% CI, 0.6-0.9). Fish intake was inversely associated with advanced AMD (OR, 0.41; 95% CI, 0.2-0.9). Consistent use vs nonuse of vitamin D from supplements was inversely associated with early AMD only in individuals who did not consume milk daily (early AMD: OR, 0.67; 95% CI, 0.5-0.9).
   Conclusion: This study provides evidence that vitamin D may protect against AMD. Additional studies are needed to confirm these findings.
C1 Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
   Univ Wisconsin, Dept Stat & Biostat, Madison, WI 53726 USA.
   Univ Med & Dent New Jersey, Canc Inst New Jersey, New Brunswick, NJ USA.
   SUNY Buffalo, Dept Social & Prevent Med, Buffalo, NY USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison; Rutgers
   State University New Brunswick; Rutgers State University Medical Center;
   Rutgers Cancer Institute of New Jersey; State University of New York
   (SUNY) System; State University of New York (SUNY) Buffalo
RP Mares, JA (通讯作者)，Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, 1063 WARF,610 N Walnut St, Madison, WI 53726 USA.
EM jmarespe@wisc.edu
RI Parekh, Niyati/ABF-4933-2020
OI Parekh, Niyati/0000-0002-1334-0528
FU NEI NIH HHS [EY 13018, EY 11722] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [R01EY011722, U10EY013018] Funding Source: NIH RePORTER
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   [Anonymous], 1996, NHANES 3 REFERENCE M
   Bernardi RJ, 2002, ENDOCRINOLOGY, V143, P2508, DOI 10.1210/en.143.7.2508
   Calvo MS, 2004, AM J CLIN NUTR, V80, p1710S, DOI 10.1093/ajcn/80.6.1710S
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   D'Ambrosio D, 1998, J CLIN INVEST, V101, P252, DOI 10.1172/JCI1050
   Dawson-Hughes B, 2004, AM J CLIN NUTR, V80, p1763S, DOI 10.1093/ajcn/80.6.1763S
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Ezzati TM, 1992, VITAL HLTH STAT 2, V2, P1
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gorin MB, 2007, ARCH OPHTHALMOL-CHIC, V125, P21, DOI 10.1001/archopht.125.1.21
   Gunter EW., 1996, LAB METHODS USED 3 N
   Gunter EW, 1996, LABORATORY PROCEDURE
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hayes CE, 2003, CELL MOL BIOL, V49, P277
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   HOLICK MF, 1990, J NUTR, V120, P1464, DOI 10.1093/jn/120.suppl_11.1464
   Holick MF, 2004, AM J CLIN NUTR, V79, P362
   Iseki K, 1999, INT J CANCER, V81, P730, DOI 10.1002/(SICI)1097-0215(19990531)81:5&lt;730::AID-IJC11&gt;3.0.CO;2-Q
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1642, DOI 10.1001/archopht.122.11.1642
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P674, DOI 10.1001/archopht.121.5.674
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   LEFEBVRE DC, 2003, J NEUROSCI RES, V71, P575, DOI DOI 10.1002/JNR.10491
   Looker AC, 2002, BONE, V30, P771, DOI 10.1016/S8756-3282(02)00692-0
   MACLAUGHLIN J, 1985, J CLIN INVEST, V76, P1536, DOI 10.1172/JCI112134
   MANOLAGAS SC, 1986, J CLIN ENDOCR METAB, V63, P394, DOI 10.1210/jcem-63-2-394
   MARES J, 2003, CAROTENOIDS HLTH DIS, P19
   Mares-Perlman JA, 2002, J NUTR, V132, p518S, DOI 10.1093/jn/132.3.518S
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Merlino LA, 2004, ARTHRITIS RHEUM-US, V50, P72, DOI 10.1002/art.11434
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Moore C, 2004, J AM DIET ASSOC, V104, P980, DOI 10.1016/j.jada.2004.03.028
   MULLER K, 1991, INT J IMMUNOPHARMACO, V13, P525, DOI 10.1016/0192-0561(91)90072-F
   Schulte CMS, 2004, ALIMENT PHARM THERAP, V20, P43, DOI 10.1111/j.1365-2036.2004.02057.x
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   SHOKRAVI MT, 1995, INVEST OPHTH VIS SCI, V36, P83
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Takahashi K, 2002, IMMUNOPHARM IMMUNOT, V24, P1, DOI 10.1081/IPH-120003399
   Tangpricha Vin, 2004, Endocr Pract, V10, P292
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   THOMASSET M, 1994, PATHOL BIOL, V42, P163
   Timms PM, 2002, QJM-INT J MED, V95, P787, DOI 10.1093/qjmed/95.12.787
   Topilski I, 2004, EUR J IMMUNOL, V34, P1068, DOI 10.1002/eji.200324532
   Trebble TM, 2004, AM J CLIN NUTR, V80, P1137, DOI 10.1093/ajcn/80.5.1137
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wirostko E, 2004, ACTA OPHTHALMOL SCAN, V82, P243, DOI 10.1111/j.1600-0420.2004.00150d.x
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zhang AB, 2004, CHINESE MED J-PEKING, V117, P408
NR 68
TC 114
Z9 118
U1 0
U2 11
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD MAY
PY 2007
VL 125
IS 5
BP 661
EP 669
DI 10.1001/archopht.125.5.661
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 165XI
UT WOS:000246340200010
PM 17502506
OA Bronze
DA 2022-11-30
ER

PT J
AU Vilkeviciute, A
   Cebatoriene, D
   Kriauciuniene, L
   Zemaitiene, R
   Liutkeviciene, R
AF Vilkeviciute, Alvita
   Cebatoriene, Dzastina
   Kriauciuniene, Loresa
   Zemaitiene, Reda
   Liutkeviciene, Rasa
TI IL-9 and IL-10 Single-Nucleotide Variants and Serum Levels in
   Age-Related Macular Degeneration in the Caucasian Population
SO MEDIATORS OF INFLAMMATION
LA English
DT Article
ID THAN-G POLYMORPHISM; GENE POLYMORPHISMS; T-CELLS; INCREASED RISK;
   INTERLEUKIN-10; INFLAMMATION; ASSOCIATION; EXPRESSION; CYTOKINES;
   RECEPTOR
AB Considering the immunological impairment in age-related macular degeneration (AMD), we aimed to determine the associations of IL-9 rs1859430, rs2069870, rs11741137, rs2069885, and rs2069884 and IL-10 rs1800871, rs1800872, and rs1800896 polymorphisms and their haplotypes, as well as the serum levels of IL-9 and IL-10 with AMD. 1209 participants were enrolled in our study. SNPs were genotyped using TaqMan SNP genotyping assays by real-time PCR method. IL-9 and IL-10 serum levels were evaluated using ELISA kits. Our study results have shown that haplotypes A-G-C-G-G and G-A-T-A-T of IL-9 SNPs are associated with the decreased odds of early AMD occurrence (p=0.035 and p=0.015, respectively). A set of rare haplotypes was associated with the decreased odds of exudative AMD occurrence (p=0.033). Also, IL-10 serum levels were lower in exudative AMD than in controls (p=0.049), patients with early AMD (p=0.017), and atrophic AMD (p=0.008). Furthermore, exudative AMD patients with IL-10 rs1800896 CT and TT genotypes had lower IL-10 serum concentrations than those with wild-type (CC) genotype (p=0.048). In conclusion, our study suggests that IL-10 serum levels can be associated with a minor allele at IL-10 rs1800896 and exudative AMD. The haplotypes of IL-9 SNPs were also associated with the decreased odds of early and exudative AMD.
C1 [Vilkeviciute, Alvita; Kriauciuniene, Loresa; Liutkeviciene, Rasa] Lithuanian Univ Hlth Sci, Med Acad, Neurosci Inst, Eiveniu St 2, LT-50161 Kaunas, Lithuania.
   [Cebatoriene, Dzastina; Kriauciuniene, Loresa; Zemaitiene, Reda; Liutkeviciene, Rasa] Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, Eiveniu St 2, LT-50161 Kaunas, Lithuania.
C3 Lithuanian University of Health Sciences; Lithuanian University of
   Health Sciences
RP Vilkeviciute, A (通讯作者)，Lithuanian Univ Hlth Sci, Med Acad, Neurosci Inst, Eiveniu St 2, LT-50161 Kaunas, Lithuania.
EM alvita.vilkeviciute@lsmuni.lt
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Agrawal R, 2019, INVEST OPHTH VIS SCI, V60, P376, DOI 10.1167/iovs.18-24387
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Aschard H, 2009, GENES IMMUN, V10, P559, DOI 10.1038/gene.2009.46
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Chakraborty S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092113
   Chen LX, 2020, EUR REV MED PHARMACO, V24, P6931, DOI 10.26355/eurrev_202006_21684
   Chitnis T, 2017, J CLIN INVEST, V127, P3577, DOI 10.1172/JCI90609
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Dardalhon V, 2008, NAT IMMUNOL, V9, P1347, DOI 10.1038/ni.1677
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   Early SB, 2009, GENES IMMUN, V10, P341, DOI 10.1038/gene.2009.28
   Elyaman W, 2009, P NATL ACAD SCI USA, V106, P12885, DOI 10.1073/pnas.0812530106
   Fatahi F, 2016, ANN MED HEALTH SCI R, V6, P216, DOI 10.4103/amhsr.amhsr_485_14
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Freidin M. B., 2002, Genetika, V38, P1710
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gao P, 2017, ONCOTARGET, V8, P69139, DOI 10.18632/oncotarget.19932
   Hamilton TA, 2002, IMMUNOL RES, V25, P229, DOI 10.1385/IR:25:3:229
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   He LZ, 2013, AM J PATHOL, V182, P2407, DOI 10.1016/j.ajpath.2013.02.032
   Hoebee B, 2004, J INFECT DIS, V189, P239, DOI 10.1086/380908
   HULTNER L, 1990, EUR J IMMUNOL, V20, P1413, DOI 10.1002/eji.1830200632
   Iyer SS, 2012, CRIT REV IMMUNOL, V32, P23, DOI 10.1615/CritRevImmunol.v32.i1.30
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Knoops L, 2004, GROWTH FACTORS, V22, P207, DOI 10.1080/08977190410001720879
   Koch S, 2017, SEMIN IMMUNOPATHOL, V39, P55, DOI 10.1007/s00281-016-0601-1
   Lauretta R, 2018, INT J ENDOCRINOL, V2018, DOI 10.1155/2018/4847376
   LEBEAU MM, 1993, P NATL ACAD SCI USA, V90, P5484, DOI 10.1073/pnas.90.12.5484
   Li XC, 1998, TRANSPLANTATION, V66, P265
   Lin T, 2013, CYTOKINE, V62, P369, DOI 10.1016/j.cyto.2013.03.027
   Litwinska Z, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00286
   Liutkeviciene R, 2017, GENE, V636, P30, DOI 10.1016/j.gene.2017.09.022
   Medina FM, 2015, OPHTHALMIC RES, V54, P169, DOI 10.1159/000439172
   Mickevicius T, 2020, IN VIVO, V34, P2499, DOI 10.21873/invivo.12066
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Namkung JH, 2011, J DERMATOL SCI, V62, P16, DOI 10.1016/j.jdermsci.2011.01.007
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Noelle RJ, 2010, NAT REV IMMUNOL, V10, P683, DOI 10.1038/nri2848
   Odegaard AO, 2016, CARDIOVASC DIABETOL, V15, DOI 10.1186/s12933-016-0369-6
   Ouyang WJ, 2011, ANNU REV IMMUNOL, V29, P71, DOI 10.1146/annurev-immunol-031210-101312
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Pongsachareonnont P, 2018, CLIN OPHTHALMOL, V12, P1877, DOI 10.2147/OPTH.S171636
   Rullo J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60674-3
   Ryan S., 2006, DAVID HINTON CW RETI, V4th
   Sasaki M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18487-4
   Sato T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19594-6
   SCHMITT E, 1989, EUR J IMMUNOL, V19, P2167, DOI 10.1002/eji.1830191130
   Schurks M, 2009, J PAIN, V10, P759, DOI 10.1016/j.jpain.2009.01.326
   Schuurhof A, 2010, PEDIATR PULM, V45, P608, DOI 10.1002/ppul.21229
   Shevchenko A V, 2016, Vestn Oftalmol, V132, P8, DOI 10.17116/oftalma201613228-13
   Singh N, 2019, ANN AFR MED, V18, P121, DOI 10.4103/aam.aam_56_18
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sole X, 2006, BIOINFORMATICS, V22, P1928, DOI 10.1093/bioinformatics/btl268
   Sordillo JE, 2015, J ALLERGY CLIN IMMUN, V136, P885, DOI 10.1016/j.jaci.2015.02.035
   Subhi Y, 2019, ACTA OPHTHALMOL, V97, P99, DOI 10.1111/aos.13886
   Sun JM, 2013, ASIAN PAC J CANCER P, V14, P3443, DOI 10.7314/APJCP.2013.14.6.3443
   ten Berge JC, 2019, ACTA OPHTHALMOL, V97, P185, DOI 10.1111/aos.13899
   Thomas CJ, 2013, TRENDS IMMUNOL, V34, P317, DOI 10.1016/j.it.2013.02.008
   Trifunovic J, 2015, BIOCHEM MEDICA, V25, P36, DOI 10.11613/BM.2015.004
   Tsai YY, 2008, INVEST OPHTH VIS SCI, V49, P693, DOI 10.1167/iovs.07-0125
   Turner DM, 1997, EUR J IMMUNOGENET, V24, P1, DOI 10.1111/j.1365-2370.1997.tb00001.x
   UYTTENHOVE C, 1988, P NATL ACAD SCI USA, V85, P6934, DOI 10.1073/pnas.85.18.6934
   Vilkeviciute A, 2020, IN VIVO, V34, P2443, DOI 10.21873/invivo.12059
   Wills-Karp M, 2010, MUCOSAL IMMUNOL, V3, P104, DOI 10.1038/mi.2009.138
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu QW, 2019, MOL IMMUNOL, V114, P243, DOI 10.1016/j.molimm.2019.07.028
   Xiao X, 2012, NAT IMMUNOL, V13, P981, DOI 10.1038/ni.2390
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yin J, 2015, DIS ESOPHAGUS, V28, P291, DOI 10.1111/dote.12189
   Zhang M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59244-4
   Zhang Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131248
   Zhou HY, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-019-1278-8
   Zhu W, 2010, J ENDOCRINOL INVEST, V33, P751, DOI [10.3275/6937, 10.1007/BF03346682]
NR 77
TC 3
Z9 3
U1 2
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0962-9351
EI 1466-1861
J9 MEDIAT INFLAMM
JI Mediat. Inflamm.
PD APR 13
PY 2021
VL 2021
AR 6622934
DI 10.1155/2021/6622934
PG 13
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Immunology
GA ZA5IP
UT WOS:000756197400001
PM 33953642
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU O'Connor, S
   Treanor, C
   Ward, E
   Wickens, R
   O'Connell, A
   Culliford, L
   Rogers, C
   Gidman, E
   Peto, T
   Knox, P
   Burton, B
   Lotery, A
   Sivaprasad, S
   Reeves, B
   Hogg, R
   Donnelly, M
AF O'Connor, Sean
   Treanor, Charlene
   Ward, Elizabeth
   Wickens, Robin
   O'Connell, Abby
   Culliford, Lucy
   Rogers, Chris
   Gidman, Eleanor
   Peto, Tunde
   Knox, Paul
   Burton, Benjamin
   Lotery, Andrew
   Sivaprasad, Sobha
   Reeves, Barnaby
   Hogg, Ruth
   Donnelly, Michael
CA MONARCH Study Grp
TI The COVID-19 Pandemic and Ophthalmic Care: A Qualitative Study of
   Patients with Neovascular Age-Related Macular Degeneration (nAMD)
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE COVID-19; patient perspective; ophthalmic care; qualitative methods
ID EXPERIENCES; MANAGEMENT; INTERVIEWS
AB Concerns have been expressed about the relationship between reduced levels of health care utilisation and the COVID-19 pandemic. This study aimed to elicit and explore the views of patients with neovascular age-related macular degeneration (nAMD) regarding the COVID-19 pandemic and their ophthalmic care. Semi-structured telephone interviews were conducted with thirty-five patients with nAMD taking part in a larger diagnostic accuracy study of home-monitoring tests. Participants were recruited using maximum variation sampling to capture a range of key characteristics including age, gender and time since initial treatment. Transcribed interview data were analysed using a deductive and inductive thematic approach. Three themes emerged from the analysis: i. access to eye clinic care. ii. COVID-19-mitigating factors and care delivery and iii. social and personal circumstances. Participants reported anxieties about cancelled or delayed appointments, limited communication from clinic-based services about appointments, and the impact of this on their ongoing care. Despite these concerns, there was apprehension about attending appointments due to infection risk and a perception that nAMD patients are a 'high risk' group. Views of those who attended clinics during the study period were, however, positive, with social distancing and infection control measures providing reassurance. These findings contribute to our understanding about experiences of patients with nAMD during the COVID-19 pandemic and may have potential implications for future planning of care services in similar circumstances. Innovative approaches may be required to address issues related to access to care, including concerns about delayed or cancelled appointments.
C1 [O'Connor, Sean] Queens Univ Belfast, Sch Psychol, Belfast BT7 1NN, Antrim, North Ireland.
   [Treanor, Charlene; Peto, Tunde; Hogg, Ruth; Donnelly, Michael] Queens Univ Belfast, Ctr Publ Hlth, Belfast BT12 6BA, Antrim, North Ireland.
   [Ward, Elizabeth; Wickens, Robin; Culliford, Lucy; Rogers, Chris; Gidman, Eleanor; Reeves, Barnaby] Univ Bristol, Bristol Royal Infirm, Bristol Trials Ctr CTEU, Bristol BS2 8HW, Avon, England.
   [Wickens, Robin] Univ Southampton, Southampton Clin Trials Unit, Univ Rd, Southampton SO17 1BJ, Hants, England.
   [O'Connell, Abby] Univ Exeter, Exeter Clin Trials Unit EXECTU, St Lukes Campus, Exeter EX1 2LT, Devon, England.
   [Knox, Paul] Univ Liverpool, Dept Eye & Vis Sci, Liverpool L7 8TX, Merseyside, England.
   [Burton, Benjamin] James Paget Univ Hosp NHS Fdn Trust, Great Yarmouth NR31 6LA, Norfolk, England.
   [Lotery, Andrew] Univ Southampton, Fac Med, Dept Clin & Expt Sci, Southampton SO16 6YD, Hants, England.
   [Sivaprasad, Sobha] Moorfields Eye Hosp NHS Fdn Trust, NIHR Moorfields Biomed Res Ctr, London EC1V 2PD, England.
C3 Queens University Belfast; Queens University Belfast; Bristol Royal
   Infirmary; University of Bristol; University of Southampton; University
   of Exeter; University of Liverpool; University of Southampton;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust
RP O'Connor, S (通讯作者)，Queens Univ Belfast, Sch Psychol, Belfast BT7 1NN, Antrim, North Ireland.
EM s.oconnor@qub.ac.uk; c.treanor@qub.ac.uk; elizabeth.ward5@uhbw.nhs.uk;
   r.a.wickens@soton.ac.uk; aj.oconnell@exeter.ac.uk;
   lucy.culliford@bristol.ac.uk; chris.rogers@bristol.ac.uk;
   eleanor.gidman@bristol.ac.uk; t.peto@qub.ac.uk; pcknox@liverpool.ac.uk;
   ben.burton@jpaget.nhs.uk; a.j.lotery@soton.ac.uk;
   sobha.sivaprasad@nhs.net; barney.reeves@bristol.ac.uk;
   r.e.hogg@qub.ac.uk; michael.donnelly@qub.ac.uk
RI ; Peto, Tunde/M-2081-2013
OI Hogg, Ruth/0000-0001-9413-2669; Sivaprasad, Sobha/0000-0001-8952-0659;
   Burton, Ben/0000-0001-9579-9078; Gidman, Eleanor/0000-0002-5261-5213;
   Rogers, Chris/0000-0002-9624-2615; O'Connell, Abby/0000-0001-7598-927X;
   Peto, Tunde/0000-0001-6265-0381; O'Connor, Sean R/0000-0001-6805-8899;
   Reeves, Barnaby/0000-0002-5101-9487; Lotery, Andrew/0000-0001-5541-4305;
   Wickens, Robin/0000-0003-4374-3747
FU National Institute for Health Research, Health Technology Assessment
   (HTA) Programme [15/97/02]
FX This project was funded by the National Institute for Health Research,
   Health Technology Assessment (HTA) Programme (ref 15/97/02). The views
   and opinions are the authors' and do not necessarily reflect the HTA
   programme, NIHR, NHS or the Department of Health and Social Care.
   Institutional Review Board Statement: Ethical approval was acquired from
   the National Research Ethics Service (IRAS ref: 232253 REC ref:
   17/NI/0235).
CR Assarroudi A, 2018, J RES NURS, V23, P42, DOI 10.1177/1744987117741667
   Boyle J, 2018, PSYCHOL HEALTH MED, V23, P127, DOI 10.1080/13548506.2016.1274040
   Chang JE, 2021, MILBANK Q, V99, P340, DOI 10.1111/1468-0009.12509
   Chen DA, 2022, TELEMED E-HEALTH, V28, P798, DOI 10.1089/tmj.2021.0392
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   Dassieu L, 2021, INT J EQUITY HEALTH, V20, DOI 10.1186/s12939-021-01496-1
   dell'Omo R, 2021, EUR J OPHTHALMOL, V31, P2252, DOI 10.1177/1120672120953074
   Diegoli H, 2020, STROKE, V51, P2315, DOI 10.1161/STROKEAHA.120.030481
   Eubank S, 2020, B MATH BIOL, V82, DOI 10.1007/s11538-020-00726-x
   GOV, UK COR COVID 19 GUID
   Grannell A, 2020, CLIN OBES, V10, DOI 10.1111/cob.12406
   Keenan TDL, 2021, ADV EXP MED BIOL, V1256, P1, DOI 10.1007/978-3-030-66014-7_1
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Lindeke-Myers A, 2021, JAMA OPHTHALMOL, V139, P508, DOI 10.1001/jamaophthalmol.2021.0114
   Mueller AL, 2020, AGING-US, V12, P9959, DOI 10.18632/aging.103344
   Renosa MDC, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2020-004193
   Ricci F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218242
   Roy CM, 2021, EUR J PUBLIC HEALTH, V31, P634, DOI 10.1093/eurpub/ckab047
   Rozon JP, 2021, CLIN OPHTHALMOL, V15, P1153, DOI 10.2147/OPTH.S300239
   Saarijarvi M, 2021, EUR J CARDIOVASC NUR, V20, P392, DOI 10.1093/eurjcn/zvab038
   Saldana J., 2018, OXFORD HDB QUALITATI, V2nd ed.
   Sekhon M, 2018, BRIT J HEALTH PSYCH, V23, P519, DOI 10.1111/bjhp.12295
   Shao J, 2016, DEV OPHTHALMOL, V55, P125, DOI 10.1159/000438969
   Shi CH, 2020, DIABET METAB SYND OB, V13, P3713, DOI 10.2147/DMSO.S268481
   Sim SS, 2021, ASIA-PAC J OPHTHALMO, V10, P39, DOI 10.1097/APO.0000000000000363
   Stone LG, 2020, GRAEF ARCH CLIN EXP, V258, P2639, DOI 10.1007/s00417-020-04849-8
   Taylor DJ, 2020, EYE, V34, P461, DOI 10.1038/s41433-019-0445-8
   Thetford C, 2013, BRIT J VISUAL IMPA, V31, P89, DOI 10.1177/0264619613481778
   Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042
   Townsend D, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007400
   Vindrola-Padros C, 2020, QUAL HEALTH RES, V30, P2192, DOI 10.1177/1049732320951526
   Ward E, 2021, EYE, V35, P592, DOI 10.1038/s41433-020-0910-4
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
NR 34
TC 1
Z9 1
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD AUG
PY 2022
VL 19
IS 15
AR 9488
DI 10.3390/ijerph19159488
PG 10
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA 3S1GK
UT WOS:000839350800001
PM 35954844
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Myint, K
   Armbrecht, AM
   Mon, S
   Dhillon, B
AF Myint, Kyaw
   Armbrecht, Ana Maria
   Mon, Sue
   Dhillon, Baljean
TI Transpupillary thermotherapy for the treatment of occult CNV in
   age-related macular degeneration: a prospective randomized controlled
   pilot study
SO ACTA OPHTHALMOLOGICA SCANDINAVICA
LA English
DT Article
DE transpupillary thermotherapy (TTT); occult choroidal neovascular
   membrane (occult CNV); age-related macular degeneration (AMD)
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; PHOTOCOAGULATION
AB Purpose: To evaluate whether transpupillary thermotherapy (TTT) reduces the risk of moderate visual loss in patients with occult choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
   Methods: A group of 25 patients were recruited and randomized into TTT or placebo groups. Patients were included if they had a subfoveal purely or predominantly (> 50%) occult CNV secondary to AMD with best corrected visual acuity (BCVA) of 6/60 or better and the lesion was not larger than 4.5 mm. Treatment was carried out using an 810-nm Oculight diode laser with a fixed spot size covering the whole lesion according to the standard protocol. The same procedure was used for the control group, except that the power was set at zero. The patients were followed up at 6 weeks, 3 months and then every 6 months for up to 2 years. A maximum of three treatments were administered in both groups if there was evidence of persistent leakage from CNV.
   Results: At the 12-month follow-up, there was no significant difference in the mean values for BCVA distance and near or contrast sensitivity between the treatment and control groups. The Mann-Whitney test was used to assess the differences in BCVA and contrast sensitivity between the groups, both at baseline and at the 12-month follow-up. No statistically significant difference was found; both groups lost on average two lines of BCVA.
   Conclusion: Transpupillary thermotherapy appeared to have been of no benefit in preventing further visual loss in patients with occult CNV in this pilot study.
RP Myint, K (通讯作者)，Princess Alexandra Eye Pavil,Chalmers St, Edinburgh EH3 9HA, Midlothian, Scotland.
EM kmyintuk@yahoo.co.uk
CR Ahuja RM, 2001, INVEST OPHTH VIS SCI, V42, pS443
   Berger JW, 1997, LASER SURG MED, V20, P409, DOI 10.1002/(SICI)1096-9101(1997)20:4<409::AID-LSM6>3.0.CO;2-U
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   Campos CC, 2001, INVEST OPHTH VIS SCI, V42, pS443
   Gustavsson C, 2005, ACTA OPHTHALMOL SCAN, V83, P148, DOI 10.1111/j.1600-0420.2005.00427.x
   Hykin PG, 1998, OPHTHALMOLOGY, V105, P1425, DOI 10.1016/S0161-6420(98)98023-X
   KLEIN R, 1999, AGE RELATED MACULAR, P31
   Maguire MG, 1999, AGE RELATED MACULAR, P17
   Mainster MA, 2000, OPHTHALMIC SURG LAS, V31, P359
   Ming Y, 2004, INVEST OPHTH VIS SCI, V45, P1969, DOI 10.1167/iovs.03-1329
   Nagpal Manish, 2003, Indian Journal of Ophthalmology, V51, P243
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   Olsen TW, 2001, INVEST OPHTH VIS SCI, V42, pS311
   REICEL E, 1994, OPHTHALMIC SURG, V25, P365
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   Reichel E., 2005, INVEST OPHTH VIS SCI, V46, P2311
   Sanders JB, 2001, INVEST OPHTH VIS SCI, V42, pS513
   SPARROW JM, 1986, INT OPHTHALMOL, V9, P207, DOI 10.1007/BF00137534
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
   Tang J, 2001, INVEST OPHTH VIS SCI, V42, pS442
   THOMAS A, 2001, INVEST OPHTHALMOL  S, V42, P442
   ULBIG M, 1993, BR J OPHTHALMOL, V79, P318
   ULBIG MW, 1993, BRIT J OPHTHALMOL, V77, P218, DOI 10.1136/bjo.77.4.218
NR 25
TC 8
Z9 11
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1395-3907
J9 ACTA OPHTHALMOL SCAN
JI Acta Ophthalmol. Scand.
PD JUN
PY 2006
VL 84
IS 3
BP 328
EP 332
DI 10.1111/j.1600-0420.2005.00623.x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 043NO
UT WOS:000237608100011
PM 16704693
DA 2022-11-30
ER

PT J
AU van Asten, F
   Chiu, CY
   Agron, E
   Clemons, TE
   Ratnapriya, R
   Swaroop, A
   Klein, ML
   Fan, RZ
   Chew, EY
AF van Asten, Freekje
   Chiu, Chi-Yang
   Agron, Elvira
   Clemons, Traci E.
   Ratnapriya, Rinki
   Swaroop, Anand
   Klein, Michael L.
   Fan, Ruzong
   Chew, Emily Y.
CA Age-Related Eye Dis Study 2 Res Gr
TI No CFH or ARMS2 Interaction with Omega-3 Fatty Acids, Low versus High
   Zinc, or beta-Carotene versus Lutein and Zeaxanthin on Progression of
   Age-Related Macular Degeneration in the Age-Related Eye Disease Study 2
   Age-Related Eye Disease Study 2 Report No. 18
SO OPHTHALMOLOGY
LA English
DT Article
ID GENETIC RISK; AREDS SUPPLEMENTS; ANTIOXIDANTS; ASSOCIATION; GENOTYPES;
   PHENOTYPE
AB Purpose: To assess whether genotypes at 2 major loci associated with age-related macular degeneration (AMD), complement factor H (CFH), or age-related maculopathy susceptibility 2 (ARMS2), modify the response to oral nutrients for the treatment of AMD in the Age-Related Eye Disease Study 2 (AREDS2).
   Design: Post hoc analysis of a randomized trial.
   Participants: White AREDS2 participants.
   Methods: AREDS2 participants (n = 4203) with bilateral large drusen or late AMD in 1 eye were assigned randomly to lutein and zeaxanthin, omega-3 fatty acids, both, or placebo, and most also received the AREDS supplements. A secondary randomization assessed modified AREDS supplements in 4 treatment arms: lower zinc dosage, omission of beta-carotene, both, or no modification. To evaluate the progression to late AMD, fundus photographs were obtained at baseline and annual study visits, and history of treatment for late AMD was obtained at study visits and 6-month interim telephone calls. Participants were genotyped for the single-nucleotide polymorphisms rs1061170 in CFH and rs10490924 in ARMS2. Bivariate frailty models using both eyes were conducted, including a gene-supplement interaction term and adjusting for age, gender, level of education, and smoking status. The main treatment effects, as well as the direct comparison between lutein plus zeaxanthin and b-carotene, were assessed for genotype interaction.
   Main Outcome Measures: The interaction between genotype and the response to AREDS2 supplements regarding progression to late AMD, any geographic atrophy (GA), and neovascular AMD.
   Results: Complete data were available for 2775 eyes without baseline late AMD (1684 participants). The participants (mean age +/- standard deviation, 72.1 +/- 7.7 years; 58.5% female) were followed up for a median of 5 years. The ARMS2 risk allele was associated significantly with progression to late AMD and neovascular AMD (P = 2.40 x 10(-5) and P = 0.002, respectively), but not any GA (P = 0.097). The CFH risk allele was not associated with AMD progression. Genotype did not modify significantly the response to any of the AREDS2 supplements.
   Conclusions: CFH and ARMS2 risk alleles do not modify the response to the AREDS2 nutrient supplements with respect to the progression to late AMD (GA and neovascular AMD). Published by Elsevier on behalf of the American Academy of Ophthalmology
C1 [van Asten, Freekje; Ratnapriya, Rinki; Swaroop, Anand] NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Bethesda, MD 20892 USA.
   [Chiu, Chi-Yang] Univ Tennessee, Ctr Hlth Sci, Prevent Med & Genet, Genom & Informat, Memphis, TN 38163 USA.
   [Agron, Elvira; Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, NIH, Bldg 10-CRC,Room 3-2531,10 Ctr Dr, Bethesda, MD 20892 USA.
   [Clemons, Traci E.] EMMES Co, Biostat, Rockville, MD USA.
   [Klein, Michael L.] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA.
   [Fan, Ruzong] Georgetown Univ, Med Ctr, Dept Biostat Bioinformat & Biomath, Washington, DC 20007 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); University of Tennessee System; University of Tennessee Health
   Science Center; National Institutes of Health (NIH) - USA; NIH National
   Eye Institute (NEI); Oregon Health & Science University; Georgetown
   University
RP Chew, EY (通讯作者)，NEI, Div Epidemiol & Clin Applicat, NIH, Bldg 10-CRC,Room 3-2531,10 Ctr Dr, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
RI SanGiovanni, John Paul/AAU-3895-2020
OI Ratnapriya, Rinki/0000-0002-0469-4631; Chiu,
   Chi-Yang/0000-0002-4837-3194
FU Intramural Research Program of the National Eye Institute, National
   Institutes of Health, Bethesda, Maryland [EY000546,
   HHS-N-260-2005-00007-C, NO1-EY-5-0007, NOI-EY-0-2127]; Office of Dietary
   Supplements, National Center for Complementary and Alternative Medicine;
   National Institute on Aging; National Heart, Lung, and Blood Institute;
   National Institute of Neurological Disorders and Stroke; Intramural
   Research Program of the National Eye Institute [EY000546]; Nederlandse
   Oogonderzoek Stichting; Dr. P. Binkhorst Stichting; Stichting
   Dondersfonds; Prins Bernhard Cultuurfonds; Stichting A.F. Deutman
   Oogheelkunde Researchfonds; AREDS1; AREDS2; NATIONAL EYE INSTITUTE
   [ZIAEY000474, ZIAEY000546] Funding Source: NIH RePORTER
FX Supported by the Intramural Research Program of the National Eye
   Institute, National Institutes of Health, Bethesda, Maryland (grant
   nos.: EY000546, AREDS2 contract HHS-N-260-2005-00007-C, ADB contract
   NO1-EY-5-0007, and AREDS contract NOI-EY-0-2127); and the following
   National Institutes of Health institutes (funds contributed to AREDS2
   contracts): Office of Dietary Supplements, National Center for
   Complementary and Alternative Medicine; National Institute on
   Aging;National Heart, Lung, and Blood Institute; and National Institute
   of Neurological Disorders and Stroke. The AREDS1 and AREDS2 sponsor and
   funding organization participated in the design and conduct of the
   study; data collection, management, analysis, and interpretation; and
   the preparation, review, and approval of the manuscript. Also supported
   by the Intramural Research Program of the National Eye Institute (grant
   no.: EY000546 [T.E.C., M.L.K., E.Y.C.]); the Nederlandse Oogonderzoek
   Stichting (F.v.A.); Dr. P. Binkhorst Stichting (F.v.A.); Stichting
   Dondersfonds (F.v.A.); Prins Bernhard Cultuurfonds (F.v.A.); and
   Stichting A.F. Deutman Oogheelkunde Researchfonds (F.v.A.). These
   organizations had no role in the design or conduct of this research. The
   National Institutes of Health holds a royalty-bearing license issued to
   Bausch and Lomb for the Age-Related Eye Disease Study Supplement.
CR Assel MJ, 2018, OPHTHALMOLOGY, V125, P391, DOI 10.1016/j.ophtha.2017.09.008
   Awh CC, 2015, OPHTHALMOLOGY, V122, P162, DOI 10.1016/j.ophtha.2014.07.049
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Chew EY, 2015, OPHTHALMOLOGY, V122, P212, DOI 10.1016/j.ophtha.2014.10.012
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Dietzel M, 2014, GRAEF ARCH CLIN EXP, V252, P1273, DOI 10.1007/s00417-014-2690-7
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Merle BMJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130816
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   Ripatti S, 2000, BIOMETRICS, V56, P1016, DOI 10.1111/j.0006-341X.2000.01016.x
   Seddon JM, 2016, BRIT J OPHTHALMOL, V100, P1731, DOI 10.1136/bjophthalmol-2016-308624
   Stone EM, 2015, JAMA OPHTHALMOL, V133, P598, DOI 10.1001/jamaophthalmol.2015.0369
   Therne TM, 2014, MODELING SURVIVAL DA
   van Asten F, 2018, OPHTHALMOLOGY, V125, P559, DOI 10.1016/j.ophtha.2017.09.023
   Vavvas DG, 2018, P NATL ACAD SCI USA, V115, pE696, DOI 10.1073/pnas.1718059115
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
NR 22
TC 12
Z9 12
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2019
VL 126
IS 11
BP 1541
EP 1548
DI 10.1016/j.ophtha.2019.06.004
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JE9EY
UT WOS:000490992500019
PM 31358387
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Figurska, M
   Matysik-Wozniak, A
   Adamiec-Mroczek, J
   Dolar-Szczasny, J
   Misiuk-Hojlo, M
   Teper, S
   Swiech-Zubilewicz, A
   Ulinska, M
   Rejdak, R
   Rekas, M
AF Figurska, Malgorzata
   Matysik-Wozniak, Anna
   Adamiec-Mroczek, Joanna
   Dolar-Szczasny, Joanna
   Misiuk-Hojlo, Marta
   Teper, Slawomir
   Swiech-Zubilewicz, Anna
   Ulinska, Magdalena
   Rejdak, Robert
   Rekas, Marek
TI One-year outcomes of the Polish treatment program for the wet form of
   age-related macular degeneration using intravitreal therapy
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; choroidal neovascularization; Polish
   National Treatment Program
ID VISUAL-ACUITY OUTCOMES; VEGF-TRAP; RANIBIZUMAB; AMD; AFLIBERCEPT;
   BEVACIZUMAB; PREDICTORS
AB Purpose:
   To report 12-month outcomes of a Polish National Treatment Program using aflibercept and ranibizumab in eyes with wet, age-related macular degeneration in routine clinical practice.
   Material and Methods:
   This was a non-randomized, retrospective, observational multicenter study. Anonymous data contained in the electronic Therapeutic Program Monitoring System were utilized in this study.
   Results:
   The study population consisted of 2828 eyes from 2718 patients. The median age was 76.0 [70.0, 81.0] years; 61.7% were female. Best corrected visual acuity increased from 58.86 [50.05, 69.95] letters to 65.1 [50.1, 73.9] letters (p < 0.001). The median change in best corrected visual acuity was 0.0 [-4.0, 12.2] letters: 2.9 [-2.9, 15.1] letters for treatment-naive eyes and 0.0 [-4.0, 8.8] letters for those continuing treatment (p < 0.001). The median central retinal thickness was significantly reduced from 341.0 [281.0, 422.0] to 275.0 [221.0, 344.0] mu m (p < 0.001). The median number of visits was 9.0 [8.0, 9.0]. The median number of injections was 7.0 [6.0, 8.0]: 8.0 [7.0, 8.0] for treatment-naive eyes and 6.0 [5.0, 7.0] for those continuing treatment (p < 0.001).
   Conclusion:
   Eyes treated as part of the Polish therapeutic program gained functional stability and morphological improvement. Treatment-naive eyes showed the greatest functional benefit.
C1 [Figurska, Malgorzata; Rekas, Marek] Cent Clin Hosp Minist Natl Def, Mil Inst Med, Dept Ophthalmol, Szaserow St 128, Warsaw, Poland.
   [Matysik-Wozniak, Anna; Rejdak, Robert] Med Univ Lublin, Dept Gen Ophthalmol, Independent Publ Teaching Hosp 1, Lublin, Poland.
   [Adamiec-Mroczek, Joanna; Misiuk-Hojlo, Marta] Wroclaw Med Univ, Dept & Clin Ophthalmol, Wroclaw, Poland.
   [Dolar-Szczasny, Joanna; Swiech-Zubilewicz, Anna] Med Univ Lublin, Dept Vitreoretinal Surg, Independent Publ Teaching Hosp 1, Lublin, Poland.
   [Teper, Slawomir] Dist Railway Hosp Katowice, Dept Ophthalmol, Katowice, Poland.
   [Ulinska, Magdalena] Med Univ Warsaw, SPKSO Ophthalm Hosp, Dept Ophthalmol, Warsaw, Poland.
C3 Military Institute of Aviation Medicine; Medical University of Lublin;
   Wroclaw Medical University; Medical University of Lublin; Medical
   University of Warsaw
RP Figurska, M (通讯作者)，Cent Clin Hosp Minist Natl Def, Mil Inst Med, Dept Ophthalmol, Szaserow St 128, Warsaw, Poland.
EM malgorzata-figurska@wp.pl
RI Adamiec-Mroczek, Joanna/ABA-1121-2021; Teper, Slawomir/AAQ-1938-2021
OI Adamiec-Mroczek, Joanna/0000-0002-6804-358X; Teper,
   Slawomir/0000-0002-0935-8880; Matysik-Wozniak, Anna/0000-0003-0865-6541;
   Swiech-Zubilewicz, Anna/0000-0002-2238-6966; Rejdak,
   Robert/0000-0003-3321-2723; Misiuk - Hojlo, Marta/0000-0002-4020-3203
CR Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2013, EYE, V27, P1429, DOI 10.1038/eye.2013.233
   Edbom-Kolarz A, 2012, HYG PUBLIC HLTH, V47, P37
   Figurska M, 2016, OKULISTYKA, V19, P65
   Framme C, 2018, OPHTHALMOL RETINA, V2, P539, DOI 10.1016/j.oret.2017.09.017
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Holz FG, 2016, EYE, V30, P1063, DOI 10.1038/eye.2016.90
   Holz FG, 2017, OPHTHALMIC RES, V58, P49, DOI 10.1159/000449001
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Kaiser PK, 2017, OPHTHALMOL RETINA, V1, P304, DOI 10.1016/j.oret.2017.01.004
   Korb CA, 2014, GRAEF ARCH CLIN EXP, V252, P1403, DOI 10.1007/s00417-014-2591-9
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Menon G, 2009, EYE, V23, pS1, DOI 10.1038/eye.2009.13
   R Core Team, 2017, LANG ENV STAT COMP
   Rasmussen A, 2015, ACTA OPHTHALMOL, V93, P616, DOI 10.1111/aos.12781
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Villegas VM, 2017, EXPERT OPIN DRUG DEL, V14, P273, DOI 10.1080/17425247.2016.1213240
   Weber M, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2017-000109
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 29
TC 5
Z9 5
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAY
PY 2020
VL 30
IS 3
BP 586
EP 594
DI 10.1177/1120672119874598
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LM6YG
UT WOS:000532395300031
PM 32347762
DA 2022-11-30
ER

PT J
AU Zhou, JY
   Huang, YQ
   Zhang, XY
   Zheng, PF
   Li, P
   Chen, Y
   Shu, L
AF Zhou, Jian-Ying
   Huang, Yi-Qian
   Zhang, Xiao-Yan
   Zheng, Pei-Fen
   Li, Peng
   Chen, Yan
   Shu, Long
TI Association study of toll-like receptors 4 polymorphisms and the risk of
   age-related macular degeneration: a meta-analysis
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Toll-like receptor 4; age-related macular degeneration; polymorphism;
   meta analysis
ID PIGMENT EPITHELIUM-CELLS; TLR4; ACTIVATION
AB Background Toll-like receptor 4 (rs4986790, rs4986791) single nucleotide polymorphisms (SNPs) have been shown to be associated with age-related macular degeneration (AMD), but the results are still inconclusive. The present meta-analysis was conducted to evaluate the association between SNPs of TLR4 gene and AMD susceptibility. Methods Relevant articles were obtained through computer retrieval of Pubmed, Embase, Chinese National Knowledge Infrastructure and China wanfang database. Eligible articles were selected according to the inclusion and exclusion criteria, and quality scores were made for them by NOS-scale. Relevant data were extracted for meta-analysis. The combined OR value and 95% confidence interval were used to evaluate the strength of the correlation. Funnel plot and Egger's regression were used to evaluate publication bias. All analyses were performed using STATA 11.0 software. Results A total of nine case-control studies were included in this meta-analysis. After combination, an significant association was found between rs4986790 polymorphism and AMD susceptibility in heterozygote model (AG vs. AA, OR = 1.400, 95%CI = 1.049-1.867,P= .022) and dominant model (GG+AG vs. AA, OR = 1.365, 95%CI = 1.028-1.813,P= .032). There was no association found between rs4986791 polymorphism and AMD susceptibility in all genetic models (allP> .05). Funnel plot and Egger's regression analysis showed no publication bias existed in this study. Conclusions Meta-analysis suggested that there is an association between TLR4 gene rs4986790 polymorphism and AMD susceptibility, while no association between rs4986791 polymorphism and AMD susceptibility.
C1 [Zhou, Jian-Ying; Huang, Yi-Qian; Zheng, Pei-Fen] Zhejiang Hosp, Dept Digest, Hangzhou, Zhejiang, Peoples R China.
   [Zhang, Xiao-Yan; Zheng, Pei-Fen; Shu, Long] Zhejiang Hosp, Dept Nutr, Hangzhou 310013, Zhejiang, Peoples R China.
   [Li, Peng; Chen, Yan] Zhoushan Municipal Ctr Dis Control & Prevent, Dept Sch Hlth, Zhoushan, Zhejiang, Peoples R China.
RP Shu, L (通讯作者)，Zhejiang Hosp, Dept Nutr, Hangzhou 310013, Zhejiang, Peoples R China.
EM shulong19880920@163.com
FU Natural Science Foundation of Zhejiang [LY17H030008]; ministry of
   education [2014PYA002]; Traditional Chinese Medicine Research Project of
   Zhejiang [2020ZB009]; Medical and Health research fund project of
   Zhejiang Province [2017KY190]; Zhoushan Science and Technology Project
   [2019C31080]
FX This study was supported by the Natural Science Foundation of Zhejiang
   [No. LY17H030008], The joint construction of projects by provinces and
   the ministry of education [No. 2014PYA002], Traditional Chinese Medicine
   Research Project of Zhejiang [No.2020ZB009], and Medical and Health
   research fund project of Zhejiang Province [No. 2017KY190], and Zhoushan
   Science and Technology Project [No. 2019C31080].
CR Balistreri CR, 2009, J CLIN IMMUNOL, V29, P406, DOI 10.1007/s10875-009-9297-5
   Chakrabarti S, 2006, INVEST OPHTH VIS SCI, V47, P43, DOI 10.1167/iovs.05-0912
   Chen C, 2017, MOL MED REP, V15, P2289, DOI 10.3892/mmr.2017.6252
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Cho YE, 2009, INVEST OPHTH VIS SCI, V50, P5614, DOI 10.1167/iovs.09-3688
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Despriet DDG, 2008, INVEST OPHTH VIS SCI, V49, P364, DOI 10.1167/iovs.07-0656
   Edwards AO, 2008, INVEST OPHTH VIS SCI, V49, P1652, DOI 10.1167/iovs.07-1378
   Frederick Paul A, 2014, Curr Ophthalmol Rep, V2, P14
   Gorin MB, 1999, MOL VIS, V5, pU31
   Guven M, 2016, CURR EYE RES, V41, P856, DOI 10.3109/02713683.2015.1067326
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863
   Klettner A, 2013, ACTA OPHTHALMOL, V91, pE211, DOI 10.1111/aos.12031
   Manoukian S, 2018, J HOSP INFECT
   Sarli A, 2017, CLIN OPHTHALMOL, V11, P1347, DOI 10.2147/OPTH.S134538
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xiao S, 2018, ONCOTARGETS THER, V11, P2419, DOI 10.2147/OTT.S156505
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
NR 21
TC 1
Z9 1
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD NOV 1
PY 2020
VL 41
IS 6
BP 579
EP 584
DI 10.1080/13816810.2020.1814348
EA AUG 2020
PG 6
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA OU3ES
UT WOS:000562698400001
PM 32844696
DA 2022-11-30
ER

PT J
AU McMahon, O
   Hallam, TM
   Patel, S
   Harris, CL
   Menny, A
   Zelek, WM
   Widjajahakim, R
   Java, A
   Cox, TE
   Tzoumas, N
   Steel, DHW
   Shuttleworth, VG
   Smith-Jackson, K
   Brocklebank, V
   Griffiths, H
   Cree, AJ
   Atkinson, JP
   Lotery, AJ
   Bubeck, D
   Morgan, BP
   Marchbank, KJ
   Seddon, JM
   Kavanagh, D
AF McMahon, O.
   Hallam, T. M.
   Patel, S.
   Harris, C. L.
   Menny, A.
   Zelek, W. M.
   Widjajahakim, R.
   Java, A.
   Cox, T. E.
   Tzoumas, N.
   Steel, D. H. W.
   Shuttleworth, V. G.
   Smith-Jackson, K.
   Brocklebank, V
   Griffiths, H.
   Cree, A. J.
   Atkinson, J. P.
   Lotery, A. J.
   Bubeck, D.
   Morgan, B. P.
   Marchbank, K. J.
   Seddon, J. M.
   Kavanagh, D.
TI The rare C9 P167S risk variant for age-related macular degeneration
   increases polymerization of the terminal component of the complement
   cascade
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID MEMBRANE ATTACK COMPLEX; FACTOR-H POLYMORPHISM; FACTOR-I; GENE;
   ASSOCIATION; DEFICIENCY; MUTATION; DISEASE; EPIDEMIOLOGY; MACULOPATHY
AB Age-related macular degeneration (AMD) is a complex neurodegenerative eye disease with behavioral and genetic etiology and is the leading cause of irreversible vision loss among elderly Caucasians. Functionally significant genetic variants in the alternative pathway of complement have been strongly linked to disease. More recently, a rare variant in the terminal pathway of complement has been associated with increased risk, Complement component 9 (C9) P167S. To assess the functional consequence of this variant, C9 levels were measured in two independent cohorts of AMD patients. In both cohorts, it was demonstrated that the P167S variant was associated with low C9 plasma levels. Further analysis showed that patients with advanced AMD had elevated sC5b-9 compared to those with non-advanced AMD, although this was not associated with the P167S polymorphism. Electron microscopy of membrane attack complexes (MACS) generated using recombinantly produced wild type or P167S C9 demonstrated identical MAC ring structures. In functional assays, the P167S variant displayed a higher propensity to polymerize and a small increase in its ability to induce hemolysis of sheep erythrocytes when added to C9-depleted serum. The demonstration that this C9 P167S AMD risk polymorphism displays increased polymerization and functional activity provides a rationale for the gene therapy trials of sCD59 to inhibit the terminal pathway of complement in AMD that are underway.
C1 [McMahon, O.; Hallam, T. M.; Harris, C. L.; Cox, T. E.; Shuttleworth, V. G.; Smith-Jackson, K.; Brocklebank, V; Marchbank, K. J.; Kavanagh, D.] Newcastle Univ, Translat & Clin Res Inst, Complement Therapeut Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [McMahon, O.; Hallam, T. M.; Harris, C. L.; Cox, T. E.; Shuttleworth, V. G.; Smith-Jackson, K.; Brocklebank, V; Marchbank, K. J.; Kavanagh, D.] Royal Victoria Infirm, Natl Renal Complement Therapeut Ctr, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
   [Patel, S.; Widjajahakim, R.; Seddon, J. M.] Univ Massachusetts, Dept Ophthalmol & Visual Sci, Sch Med, Worcester, MA 01655 USA.
   [Menny, A.; Bubeck, D.] Imperial Coll London, Dept Life Sci, Sir Ernst Chain Bldg, London SW7 2AZ, England.
   [Zelek, W. M.; Morgan, B. P.] Cardiff Univ, Sch Med, Syst Immun Res Inst, Div Infect & Immun, Heath Pk, Cardiff CF14 4XN, Wales.
   [Java, A.; Atkinson, J. P.] Washington Univ, Dept Med, Div Nephrol, St Louis, MO 63110 USA.
   [Java, A.; Atkinson, J. P.] Washington Univ, Dept Med, Div Rheumatol, St Louis, MO 63110 USA.
   [Tzoumas, N.; Steel, D. H. W.] Newcastle Univ, Biosci Inst, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
   [Griffiths, H.; Cree, A. J.; Lotery, A. J.] Univ Southampton, Fac Med, Clin & Expt Sci, Southampton SO16 6YD, Hants, England.
C3 Newcastle University - UK; Newcastle University - UK; University of
   Massachusetts System; University of Massachusetts Worcester; Imperial
   College London; Cardiff University; Washington University (WUSTL);
   Washington University (WUSTL); Newcastle University - UK; University of
   Southampton
RP Seddon, JM (通讯作者)，Univ Massachusetts, Sch Med, 55 Lake Ave North,S3-119, Worcester, MA 01655 USA.; Kavanagh, D (通讯作者)，Royal Victoria Infirm, Natl Renal Complement Therapeut Ctr, aHUS Serv, Bldg 26,Queen Victoria Rd, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
EM johanna_seddon@yahoo.com; david.kavanagh@ncl.ac.uk
RI Menny, Anaïs/AAP-4155-2021
OI Menny, Anaïs/0000-0002-6044-4119; Lotery, Andrew/0000-0001-5541-4305;
   Tzoumas, Nikolaos/0000-0003-2081-6042; Hallam,
   Thomas/0000-0002-4632-9640; marchbank, kevin james/0000-0003-1312-5411
FU NIHR Newcastle Biomedical Research Centre at Newcastle upon Tyne
   Hospitals NHS Foundation Trust; US National Institutes of Health
   [R01-EY011309, R01-EY028602]; American Macular Degeneration Foundation;
   Macular Degeneration Research Fund; University of Massachusetts Medical
   School, Worcester, MA, USA; Northern Counties Kidney Research Fund;
   Newcastle Healthcare Charites; Kidney Research UK project grant
   [RP7/2015]; Fight for Sight [1564/1565]; Wellcome Trust; Medical
   Research Council and Kidney Research UK; Complement UK; MRC Discovery
   Medicine North; NIHR Senior Investigator; Newcastle University; CRUK
   Career Establishment Award [C26409/A16099]
FX NIHR Newcastle Biomedical Research Centre at Newcastle upon Tyne
   Hospitals NHS Foundation Trust; J.M.S was funded by US National
   Institutes of Health (grants R01-EY011309 and R01-EY028602), American
   Macular Degeneration Foundation, and Macular Degeneration Research Fund,
   University of Massachusetts Medical School, Worcester, MA, USA (J.M.S.);
   K.J.M. was funded by the Northern Counties Kidney Research Fund, the
   Newcastle Healthcare Charites and a Kidney Research UK project grant
   (RP7/2015). D.K. was funded by Fight for Sight (1564/1565), the Wellcome
   Trust, the Medical Research Council and Kidney Research UK. T.M.H. was
   funded by Complement UK; T.E.C. is funded by MRC Discovery Medicine
   North; A.J.L. is an NIHR Senior Investigator. C.L.H. was funded by
   Newcastle University. D.B. and A.M. was supported by a CRUK Career
   Establishment Award (C26409/A16099) to D.B.
CR Alexander P, 2014, MOL VIS, V20, P1253
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Cerniauskas E, 2020, STEM CELL TRANSL MED, V9, P1585, DOI 10.1002/sctm.20-0211
   da Costa MG, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02664
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Falcao DA, 2008, SCAND J IMMUNOL, V68, P445, DOI 10.1111/j.1365-3083.2008.02152.x
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Geerlings MJ, 2017, JAMA OPHTHALMOL, V135, P39, DOI 10.1001/jamaophthalmol.2016.4604
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hallam D, 2017, STEM CELLS, V35, P2305, DOI 10.1002/stem.2708
   Hallam TM, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.6.18
   Harboe M, 2004, CLIN EXP IMMUNOL, V138, P439, DOI 10.1111/j.1365-2249.2004.02627.x
   Horiuchi T, 1998, J IMMUNOL, V160, P1509
   Ingram G, 2012, MULT SCLER J, V18, P1401, DOI 10.1177/1352458512438238
   Java A, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.9.37
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Kira R, 1999, J HUM GENET, V44, P109, DOI 10.1007/s100380050119
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kremlitzka M, 2018, HUM MOL GENET, V27, P2678, DOI 10.1093/hmg/ddy178
   Kumar-Singh R, 2019, EXP EYE RES, V184, P266, DOI 10.1016/j.exer.2019.05.006
   Lewis LA, 2014, VIRULENCE, V5, P98, DOI 10.4161/viru.26515
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Menny A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07653-5
   Morgan Angharad R, 2017, BMC Res Notes, V10, P559, DOI 10.1186/s13104-017-2885-1
   MORGAN BP, 1983, CLIN CHIM ACTA, V134, P85, DOI 10.1016/0009-8981(83)90187-0
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   NIELSEN HE, 1992, APMIS, V100, P1053, DOI 10.1111/j.1699-0463.1992.tb04040.x
   Nishiguchi KM, 2012, INVEST OPHTH VIS SCI, V53, P508, DOI 10.1167/iovs.11-8425
   OLEESKY DA, 1986, CLIN ENDOCRINOL, V25, P623, DOI 10.1111/j.1365-2265.1986.tb03617.x
   Parsons ES, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10058-7
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Saksens NTM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0144367
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2019, AM J OPHTHALMOL, V198, P223, DOI 10.1016/j.ajo.2018.10.022
   Seddon JM, 2017, INVEST OPHTH VIS SCI, V58, P6513, DOI 10.1167/iovs.17-23544
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Seddon JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087047
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Spicer BA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05717-0
   Tzoumas N, 2021, SURV OPHTHALMOL, V66, P378, DOI 10.1016/j.survophthal.2020.10.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   Zeng SM, 2016, J PATHOL, V238, P446, DOI 10.1002/path.4669
NR 59
TC 6
Z9 6
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JUL 1
PY 2021
VL 30
IS 13
BP 1188
EP 1199
DI 10.1093/hmg/ddab086
EA MAR 2021
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA TF7XA
UT WOS:000670929100002
PM 33783477
OA Green Published, Green Accepted, hybrid
DA 2022-11-30
ER

PT J
AU Zhang, YH
   Wang, XL
   Clark, ME
   Curcio, CA
   Owsley, C
AF Zhang, Yuhua
   Wang, Xiaolin
   Clark, Mark E.
   Curcio, Christine A.
   Owsley, Cynthia
TI Imaging of Age-Related Macular Degeneration by Adaptive Optics Scanning
   Laser Ophthalmoscopy in Eyes With Aged Lenses or Intraocular Lenses
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE adaptive optics scanning laser ophthalmoscopy; lens opacity; cataract;
   retina; photoreceptors
ID SUBRETINAL DRUSENOID DEPOSITS; DARK-ADAPTATION; CONE STRUCTURE; ROD;
   DISEASE; PHOTOGRAPHS; SYSTEM; OPACIFICATION; ABERRATIONS; IMPROVEMENT
AB Purpose: To assess the performance of adaptive optics scanning laser ophthalmoscopy (AOSLO) in a large sample of eyes with or without age-related macular degeneration (AMD) and with cataracts or intraocular lenses (IOLs).
   Methods: Patients with various degrees of AMD and age-similar normal subjects underwent fundus photography. Cataract severity and IOL clarity were assessed by fundus reflex photographs. In phakic eyes, lenticular opacity was graded as nuclear, cortical, or posterior subcapsular cataract. In eyes with IOLs, lens clarity was assessed by posterior capsule opacification (PCO). Quality of AOSLO images of the macular photoreceptor mosaic was classified as good, adequate or inadequate by human graders in a subjective assessment of cone visibility.
   Results: A total of 159 eyes in 80 subjects (41 males, 39 females, aged 72.5 +/- 11.5 years, 16 normals) were examined. Seventy-nine eyes had IOLs, and 80 eyes were phakic. AOSLO produced good images in 91 eyes (57%), adequate images in eight eyes (5%), and inadequate images in 27 eyes (17%). AOSLO did not acquire images in 33 eyes (21%), because of dense lenticular opacity, widespread PCO, or problems specific to individual subjects.
   Conclusions: AOSLO images considered at least Adequate or better for visualizing cone photoreceptors were acquired from 62% of study eyes.
   Translational Relevance: AOSLO can be used as an additional imaging modality to investigate the structure of cone photoreceptors in research on visual function in AMD and in clinical trials involving older patients.
C1 [Zhang, Yuhua] Univ Calif Los Angeles, Dept Ophthalmol, Los Angeles, CA 90033 USA.
   [Zhang, Yuhua; Wang, Xiaolin] Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Clark, Mark E.; Curcio, Christine A.; Owsley, Cynthia] Univ Alabama Birmingham, Dept Ophthalmol & Visual Sci, Birmingham, AL USA.
C3 University of California System; University of California Los Angeles;
   Doheny Eye Institute; University of Alabama System; University of
   Alabama Birmingham
RP Zhang, YH (通讯作者)，Univ Calif Los Angeles, Doheny Eye Inst, Dept Ophthalmol, 1355 San Pablo St, Los Angeles, CA 90033 USA.
EM yzhang@doheny.org
FU NIH [R01EY024378, R21EY027948, R01EY029595, R01AG04212, P30EY003039]
FX Supported by NIH R01EY024378, R21EY027948, R01EY029595, R01AG04212,
   P30EY003039, and institutional support from Doheny Eye Institute,
   Research to Prevent Blindness, EyeSight Foundation of Alabama, the Carl
   G. and Pauline Buck Trust, the Alfreda J. Schueler Trust, and the
   Dorsett Davis Discovery Fund. The funding organizations had no role in
   the design or conduct of this research.
CR Amano S, 2004, AM J OPHTHALMOL, V137, P988, DOI 10.1016/j.ajo.2004.01.005
   [Anonymous], 2000, Community Eye Health, V13, P17
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Birren J.E., 1950, J GERONTOL, V5, P216, DOI [10.1093/geronj/5.3.216, DOI 10.1093/GERONJ/5.3.216]
   Burns SA, 2019, PROG RETIN EYE RES, V68, P1, DOI 10.1016/j.preteyeres.2018.08.002
   Chen L, 2020, RETINA-J RET VIT DIS, V40, P618, DOI 10.1097/IAE.0000000000002657
   Chew EY, 2010, OPHTHALMOLOGY, V117, P2112, DOI 10.1016/j.ophtha.2010.02.033
   Chui TYP, 2012, BIOMED OPT EXPRESS, V3, P2537, DOI 10.1364/BOE.3.002537
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Cooper RF, 2011, BIOMED OPT EXPRESS, V2, P2577, DOI 10.1364/BOE.2.002577
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   CURCIO CA, 1990, J COMP NEUROL, V300, P5, DOI 10.1002/cne.903000103
   Curcio CA, 2019, OPHTHALMOLOGY, V126, P866, DOI 10.1016/j.ophtha.2018.12.024
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Diaz-Santana L, 2003, OPT EXPRESS, V11, P2597, DOI 10.1364/OE.11.002597
   Domalpally A, 2013, INVEST OPHTH VIS SCI, V54, P5989, DOI 10.1167/iovs.13-12301
   Dubra A, 2011, BIOMED OPT EXPRESS, V2, P1864, DOI 10.1364/BOE.2.001864
   Erie JC, 1998, J CATARACT REFR SURG, V24, P1239, DOI 10.1016/S0886-3350(98)80019-9
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Fujikado T, 2004, AM J OPHTHALMOL, V138, P143, DOI 10.1016/j.ajo.2004.01.051
   Hofer H, 2001, OPT EXPRESS, V8, P631, DOI 10.1364/OE.8.000631
   Hofer H, 2001, J OPT SOC AM A, V18, P497, DOI 10.1364/JOSAA.18.000497
   Hollick EJ, 1999, OPHTHALMOLOGY, V106, P49, DOI 10.1016/S0161-6420(99)90047-7
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Khambhiphant B, 2015, CLIN OPHTHALMOL, V9, P557, DOI 10.2147/OPTH.S80220
   KLEIN BEK, 1990, OPHTHALMOLOGY, V97, P1428
   KOSNIK W, 1985, PERCEPT PSYCHOPHYS, V38, P554, DOI 10.3758/BF03207065
   KOSNIK W, 1987, PSYCHOL AGING, V2, P302, DOI 10.1037/0882-7974.2.3.302
   Land ME, 2014, OPTOMETRY VISION SCI, V91, P939, DOI 10.1097/OPX.0000000000000323
   Li KY, 2009, P AMER CONTR CONF, P3848, DOI 10.1109/ACC.2009.5159832
   Liang JZ, 1997, J OPT SOC AM A, V14, P2884, DOI 10.1364/JOSAA.14.002884
   Marcos S, 2017, VISION RES, V132, P3, DOI 10.1016/j.visres.2017.01.006
   Meadway A, 2013, OPT EXPRESS, V21, P29792, DOI 10.1364/OE.21.029792
   Merino D, 2011, BIOMED OPT EXPRESS, V2, P2189, DOI 10.1364/BOE.2.002189
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mira-Agudelo A, 2009, OPHTHAL PHYSL OPT, V29, P256, DOI 10.1111/j.1475-1313.2009.00655.x
   Nirmaier T, 2003, OPT EXPRESS, V11, P2704, DOI 10.1364/OE.11.002704
   Owsley C, 2013, J GERONTOL A-BIOL, V68, P567, DOI 10.1093/gerona/gls185
   Paques M, 2018, PROG RETIN EYE RES, V66, P1, DOI 10.1016/j.preteyeres.2018.07.001
   Rocha KM, 2007, J CATARACT REFR SURG, V33, P1442, DOI 10.1016/j.jcrs.2007.03.059
   Roorda A, 2002, OPT EXPRESS, V10, P405, DOI 10.1364/OE.10.000405
   Roorda A, 2015, ANNU REV VIS SCI, V1, P19, DOI 10.1146/annurev-vision-082114-035357
   Roorda A, 2002, J VISION, V2, P404, DOI 10.1167/2.5.4
   Rossi EA, 2017, P NATL ACAD SCI USA, V114, P586, DOI 10.1073/pnas.1613445114
   Sachdev N, 2004, J CATARACT REFR SURG, V30, P1642, DOI 10.1016/j.jcrs.2004.02.048
   Schaumberg DA, 1998, OPHTHALMOLOGY, V105, P1213, DOI 10.1016/S0161-6420(98)97023-3
   Scoles D, 2017, RETINA-J RET VIT DIS, V37, P741, DOI 10.1097/IAE.0000000000001203
   Scoles D, 2014, INVEST OPHTH VIS SCI, V55, P4244, DOI 10.1167/iovs.14-14542
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Vogel CR, 2006, OPT EXPRESS, V14, P487, DOI 10.1364/OPEX.14.000487
   Wells-Gray EM, 2016, EYE, V30, P1135, DOI 10.1038/eye.2016.107
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Yu YM, 2014, CHIN OPT LETT, V12, DOI [10.3788/COL201412.110602, 10.3788/COL201412.100601]
   Yu YX, 2015, OPT EXPRESS, V23, P23035, DOI 10.1364/OE.23.023035
   Zayit-Soudry S, 2013, INVEST OPHTH VIS SCI, V54, P7498, DOI 10.1167/iovs.13-12433
   Zhang YH, 2006, OPT LETT, V31, P1268, DOI 10.1364/OL.31.001268
   Zhang YH, 2020, OPHTHALMOL RETINA, V4, P274, DOI 10.1016/j.oret.2019.10.012
   Zhang YH, 2018, RETINA-J RET VIT DIS, V38, P29, DOI 10.1097/IAE.0000000000001504
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 62
TC 3
Z9 3
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD JUL
PY 2020
VL 9
IS 8
AR 41
DI 10.1167/tvst.9.8.41
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MY9IV
UT WOS:000558734000015
PM 32855887
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Chew, EY
   Clemons, TE
   Harrington, M
   Bressler, SB
   Elman, MJ
   Kim, JE
   Garfinkel, R
   Heier, JS
   Brucker, A
   Boyer, D
AF Chew, Emily Y.
   Clemons, Traci E.
   Harrington, Molly
   Bressler, Susan B.
   Elman, Michael J.
   Kim, Judy E.
   Garfinkel, Richard
   Heier, Jeffrey S.
   Brucker, Alexander
   Boyer, David
CA AREDS2-HOME Study Res Grp
TI EFFECTIVENESS OF DIFFERENT MONITORING MODALITIES IN THE DETECTION OF
   NEOVASCULAR AGE-RELATED MACULAR DEGENERATION The Home Study, Report
   Number 3
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; incident choroidal neovascularization;
   telemonitoring
ID RANDOMIZED-TRIAL; EYE HOME; RANIBIZUMAB; DEVICE
AB Purpose: To determine the effectiveness of different monitoring modalities to detect incident neovascularization associated with age-related macular degeneration (AMD).
   Methods: Secondary analyses compared the rates of detecting incident neovascular AMD in prescheduled office visits versus office visits triggered by monitoring device or by symptom realization in a randomized trial evaluating home telemonitoring device plus standard care (device arm) versus standard care alone.
   Results: At prescheduled office visits, neovascular AMD was detected in 14/1927 visits (0.7%, 95% confidence interval [CI]: 0.4%-1.1%) and 14/1949 visits (0.7%, 95% CI: 0.3%-1.1%) in the device and standard care alone arms, respectively. Thirty-seven participants with neovascular AMD were detected in 318 office visits (11.6%, 95% CI: 8.1%-15.2%) triggered by device or symptom realization and 17 neovascular AMD in 65 office visits (26%, 95% CI: 15.5%-36.8%) triggered by symptom realization in the device and standard care alone arms, respectively. The home device strategy had a higher neovascular-AMD detection rate than prescheduled office visits (relative risk = 16.0 [95% CI: 8.8-29.3]). Neovascular AMD detected at triggered visits were associated with less vision loss from baseline in the device arm versus standard care alone arm (-3 letters vs. -11.5 letters, respectively, P = 0.03).
   Conclusion: Telemonitoring may alter the management of patients with AMD and improve vision outcomes.
C1 [Chew, Emily Y.] NEI, Clin Trials Branch, NIH, Bethesda, MD 20892 USA.
   [Clemons, Traci E.; Harrington, Molly] EMMES Corp, Rockville, MD USA.
   [Bressler, Susan B.] Johns Hopkins Univ, Wilmer Eye Inst, Retina Div, Baltimore, MD 21218 USA.
   [Elman, Michael J.] Elman Retina Grp, Baltimore, MD USA.
   [Kim, Judy E.] Med Coll Wisconsin, Dept Ophthalmol, Milwaukee, WI 53226 USA.
   [Garfinkel, Richard] Retina Grp Washington, Washington, DC USA.
   [Heier, Jeffrey S.] Ophthalm Consultants Boston, Boston, MA USA.
   [Brucker, Alexander] Scheie Eye Inst, Philadelphia, PA USA.
   [Boyer, David] Retina Vitreous Associates Med Grp, Los Angeles, CA USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Emmes Corporation; Johns Hopkins University; Johns Hopkins
   Medicine; Medical College of Wisconsin; Ophthalmic Consultants of
   Boston; University of Pennsylvania; Pennsylvania Medicine; Retina
   Vitreous Associates Medical Group
RP Chew, EY (通讯作者)，NEI, NIH, Bldg 10,CRC Room 3-2531,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
OI Elman, Michael/0000-0001-7726-9508
FU Notal Vision Ltd; National Eye Institute, National Institutes of Health,
   Bethesda, Maryland (CTA) [CTA-00833]; National Eye Institute, National
   Institutes of Health [HHS-N-260-2005-00007-C, N01-EY-5-0007]; NATIONAL
   EYE INSTITUTE [ZIAEY000489] Funding Source: NIH RePORTER
FX Supported by Notal Vision Ltd through a clinical trial agreement with
   the National Eye Institute, National Institutes of Health, Bethesda,
   Maryland (CTA no: CTA-00833) and a service agreement with EMMES
   Corporation. The Age-Related Eye Disease Study 2 study is supported by
   the intramural program funds and contracts from the National Eye
   Institute, National Institutes of Health (contract nos:
   HHS-N-260-2005-00007-C, N01-EY-5-0007).
CR American Academy of Ophthalmology Retina/Vitreous Panel, 2014, PREF PRACT PATT GUID
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chew EY, 2014, CONTEMP CLIN TRIALS, V37, P294, DOI 10.1016/j.cct.2014.02.003
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Han DP, 2014, JAMA OPHTHALMOL, V132, P1167, DOI 10.1001/jamaophthalmol.2014.1405
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 8
TC 16
Z9 16
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2016
VL 36
IS 8
BP 1542
EP 1547
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DS7MI
UT WOS:000380967200033
PM 27243927
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Khandhadia, S
   Hakobyan, S
   Heng, LZ
   Gibson, J
   Adams, DH
   Alexander, GJ
   Gibson, JM
   Martin, KR
   Menon, G
   Nash, K
   Sivaprasad, S
   Ennis, S
   Cree, AJ
   Morgan, BP
   Lotery, AJ
AF Khandhadia, Samir
   Hakobyan, Svetlana
   Heng, Ling Z.
   Gibson, Jane
   Adams, David H.
   Alexander, Graeme J.
   Gibson, Jonathan M.
   Martin, Keith R.
   Menon, Geeta
   Nash, Kathryn
   Sivaprasad, Sobha
   Ennis, Sarah
   Cree, Angela J.
   Morgan, B. Paul
   Lotery, Andrew J.
TI Age-related Macular Degeneration and Modification of Systemic Complement
   Factor H Production Through Liver Transplantation
SO OPHTHALMOLOGY
LA English
DT Article
ID HEMOLYTIC-UREMIC SYNDROME; POLYMORPHISM; RISK; MACULOPATHY; PROGRESSION;
   EXPRESSION; PROTEINS; Y402H
AB Purpose: To investigate whether modification of liver complement factor H (CFH) production, by alteration of liver CFH Y402H genotype through liver transplantation (LT), influences the development of age-related macular degeneration (AMD).
   Design: Multicenter, cross-sectional study.
   Participants: We recruited 223 Western European patients >= 55 years old who had undergone LT >= 5 years previously.
   Methods: We determined AMD status using a standard grading system. Recipient CFH Y402H genotype was obtained from DNA extracted from recipient blood samples. Donor CFH Y402H genotype was inferred from recipient plasma CFH Y402H protein allotype, measured using enzyme-linked immunosorbent assays. This approach was verified by genotyping donor tissue from a subgroup of patients. Systemic complement activity was ascertained by measuring levels of plasma complement proteins using an enzyme-linked immunosorbent assay, including substrates (C3, C4), activation products (C3a, C4a, and terminal complement complex), and regulators (total CFH, C1 inhibitor).
   Main Outcome Measures: We evaluated AMD status and recipient and donor CFH Y402H genotype.
   Results: In LT patients, AMD was associated with recipient CFH Y402H genotype (P = 0.036; odds ratio [OR], 1.6; 95% confidence interval [CI], 1.0-2.4) but not with donor CFH Y402H genotype (P = 0.626), after controlling for age, sex, smoking status, and body mass index. Recipient plasma CFH Y402H protein allotype predicted donor CFH Y402H genotype with 100% accuracy (n = 49). Plasma complement protein or activation product levels were similar in LT patients with and without AMD. Compared with previously reported prevalence figures (Rotterdam Study), LT patients demonstrated a high prevalence of both AMD (64.6% vs 37.1%; OR, 3.09; P < 0.001) and the CFH Y402H sequence variation (41.9% vs 36.2%; OR, 1.27; P = 0.014).
   Conclusions: Presence of AMD is not associated with modification of hepatic CFH production. In addition, AMD is not associated with systemic complement activity in LT patients. These findings suggest that local intraocular complement activity is of greater importance in AMD pathogenesis. The high AMD prevalence observed in LT patients may be associated with the increased frequency of the CFH Y402H sequence variation. (C) 2013 by the American Academy of Ophthalmology.
C1 [Khandhadia, Samir; Gibson, Jane; Ennis, Sarah; Cree, Angela J.; Lotery, Andrew J.] Univ Southampton, Fac Med, Southampton SO16 6YD, Hants, England.
   [Hakobyan, Svetlana; Morgan, B. Paul] Cardiff Univ, Sch Med, Cardiff CF10 3AX, S Glam, Wales.
   [Heng, Ling Z.] UCL, Inst Ophthalmol, London, England.
   [Adams, David H.] Univ Birmingham, Liver Res Ctr, Birmingham, W Midlands, England.
   [Adams, David H.] Univ Birmingham, NIHR Liver Biomed Res Unit, Birmingham, W Midlands, England.
   [Alexander, Graeme J.] Addenbrookes Hosp, Univ Dept Med, Cambridge, England.
   [Gibson, Jonathan M.] Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England.
   [Martin, Keith R.] Univ Cambridge, Dept Ophthalmol, Cambridge, England.
   [Martin, Keith R.] Univ Cambridge, NIHR Biomed Res Ctr, Cambridge, England.
   [Menon, Geeta] Frimley Pk Hosp NHS Fdn Trust, Frimley Pk, England.
   [Nash, Kathryn] Southampton Univ Hosp, Dept Hepatol, Southampton, Hants, England.
   [Sivaprasad, Sobha] Kings Coll Hosp London, Dept Ophthalmol, London, England.
C3 University of Southampton; Cardiff University; University of London;
   University College London; University of Birmingham; University of
   Birmingham; Cambridge University Hospitals NHS Foundation Trust;
   Addenbrooke's Hospital; University of Cambridge; Aston University;
   University of Cambridge; University of Cambridge; University of
   Southampton; King's College Hospital NHS Foundation Trust; King's
   College Hospital
RP Lotery, AJ (通讯作者)，Univ Southampton, Clin Neurosci Res Grp, Fac Med, Sir Henry Wellcome Labs,Univ Hosp Southampton, South Block,Mailpoint 806,Level D, Southampton SO16 6YD, Hants, England.
EM A.J.Lotery@soton.ac.uk
RI Heng, Ling Zhi/AAA-2451-2021; Adams, David H/C-9092-2009; Sivaprasad,
   S./D-6876-2015; Gibson, Jane/I-1630-2012
OI Adams, David H/0000-0001-6776-0336; Sivaprasad, S./0000-0001-8952-0659;
   Gibson, Jane/0000-0002-0973-8285; Morgan, Paul/0000-0003-4075-7676;
   Cree, Angela/0000-0002-1987-8900; Gibson, Jonathan
   M/0000-0002-9281-5244; Lotery, Andrew/0000-0001-5541-4305
FU TFC Frost Charitable Trust, Claygate, UK [256590]; Gift of Sight
   charity, Southampton, UK; Novartis Pharmaceuticals, Frimley, UK;
   Wellcome Trust; Brian Mercer Charitable Trust; National Institute for
   Health Research [NF-SI-0507-10094, NF-SI-0512-10080] Funding Source:
   researchfish; Alzheimer&quot;s Society [104] Funding Source:
   researchfish
FX Supported by the TFC Frost Charitable Trust, Claygate, UK (registered
   charity number: 256590), the Gift of Sight charity, Southampton, UK
   (www.giftofsight.org.uk), an unrestricted educational grant from
   Novartis Pharmaceuticals, Frimley, UK, and the Wellcome Trust (use of
   the Clinical Research Facility at Queen Elizabeth Hospital, Birmingham,
   UK; Addenbrookes' Hospital, Cambridge, UK; University Hospital
   Southampton, Southampton, UK), and The Brian Mercer Charitable Trust.
   The funding organizations had no role in the design or conduct of this
   research.
CR Barak V, 2009, J AUTOIMMUN, V33, P178, DOI 10.1016/j.jaut.2009.09.010
   Bomback AS, 2012, CLIN J AM SOC NEPHRO, V7, P748, DOI 10.2215/CJN.12901211
   Bykov I, 2007, CLIN IMMUNOL, V124, P213, DOI 10.1016/j.clim.2007.05.008
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gibson J, 2012, IMMUNOBIOLOGY, V217, P251, DOI 10.1016/j.imbio.2011.07.015
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2010, KIDNEY INT, V78, P782, DOI 10.1038/ki.2010.275
   Halme J, 2009, MOL IMMUNOL, V46, P2284, DOI 10.1016/j.molimm.2009.04.005
   Honda S, 2010, J OPHTHALMOL, V2010, DOI 10.1155/2010/206837
   Kanmura S, 2010, J GASTROENTEROL, V45, P459, DOI 10.1007/s00535-009-0160-5
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lyzogubov VV, 2010, AM J PATHOL, V177, P1870, DOI 10.2353/ajpath.2010.091168
   McGeer PL, 2005, NEUROBIOL AGING, V26, P1199, DOI 10.1016/j.neurobiolaging.2005.02.003
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Muller-Eberhard H J, 1980, Adv Immunol, V29, P1, DOI 10.1016/S0065-2776(08)60042-5
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Nonyane BAS, 2010, INVEST OPHTH VIS SCI, V51, P2393, DOI 10.1167/iovs.09-4228
   Remuzzi G, 2002, LANCET, V359, P1671, DOI 10.1016/S0140-6736(02)08560-4
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593
   Schmeling A, 1999, INT J LEGAL MED, V112, P364, DOI 10.1007/s004140050301
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   SCHULZ TF, 1986, MOL IMMUNOL, V23, P1243, DOI 10.1016/0161-5890(86)90158-6
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
NR 32
TC 30
Z9 30
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2013
VL 120
IS 8
BP 1612
EP 1618
DI 10.1016/j.ophtha.2013.01.004
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 196LW
UT WOS:000322778000023
PM 23562165
DA 2022-11-30
ER

PT J
AU Dehghan, S
   Mirshahi, R
   Shoae-Hassani, A
   Naseripour, M
AF Dehghan, Samaneh
   Mirshahi, Reza
   Shoae-Hassani, Alireza
   Naseripour, Masood
TI Human-induced pluripotent stem cells-derived retinal pigmented
   epithelium, a new horizon for cells-based therapies for age-related
   macular degeneration
SO STEM CELL RESEARCH & THERAPY
LA English
DT Review
DE Cell therapy; Age-related macular degeneration; Retinal pigmented
   epithelium; Induced pluripotent stem cells; Retina; Clinical trial; RPE
   transplantation; Small chemical molecules
ID DIRECTED DIFFERENTIATION; DISEASE; GENERATION; IPSC; TRANSPLANTATION;
   PATHOGENESIS; VISION
AB Retinal pigment epithelium (RPE) degeneration is the hallmark of age-related macular degeneration (AMD). AMD, as one of the most common causes of irreversible visual impairment worldwide, remains in need of an appropriate approach to restore retinal function. Wet AMD, which is characterized by neovascular formation, can be stabilized by currently available therapies, including laser photocoagulation, photodynamic therapy, and intraocular injections of anti-VEFG (anti-vascular endothelial growth factor) therapy or a combination of these modalities. Unlike wet AMD, there is no effective therapy for progressive dry (non-neovascular) AMD. However, stem cell-based therapies, a part of regenerative medicine, have shown promising results for retinal degenerative diseases such as AMD. The goal of RPE cell therapy is to return the normal structure and function of the retina by re-establishing its interaction with photoreceptors, which is essential to vision. Considering the limited source of naturally occurring RPE cells, recent progress in stem cell research has allowed the generation of RPE cells from human pluripotent cells, both embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSC). Since iPSCs face neither ethical arguments nor significant immunological considerations when compared to ESCs, they open a new horizon for cell therapy of AMD. The current study aims to discuss AMD, review the protocols for making human iPSCs-derived RPEs, and summarize recent developments in the field of iPSC-derived RPEs cell therapy.
C1 [Dehghan, Samaneh; Shoae-Hassani, Alireza; Naseripour, Masood] Iran Univ Med Sci, Stem Cell & Regenerat Med Res Ctr, Tehran, Iran.
   [Dehghan, Samaneh; Mirshahi, Reza; Naseripour, Masood] Iran Univ Med Sci, Rassoul Akram Hosp, Five Senses Hlth Inst, Eye Res Ctr, Tehran, Iran.
C3 Iran University of Medical Sciences; Iran University of Medical Sciences
RP Naseripour, M (通讯作者)，Iran Univ Med Sci, Stem Cell & Regenerat Med Res Ctr, Tehran, Iran.
EM masoodnp@yahoo.com
RI Farhang Dehghan, Somayeh/S-6983-2017
OI Farhang Dehghan, Somayeh/0000-0002-6607-6396
CR Algvere PV, 1997, ACTA OPHTHALMOL SCAN, V75, P1
   Ammar MJ, 2020, CURR OPIN OPHTHALMOL, V31, P215, DOI 10.1097/ICU.0000000000000657
   Andrews PW, 2015, REGEN MED, V10, P1, DOI [10.2217/RME.14.93, 10.2217/rme.14.93]
   Araki R, 2013, NATURE, V494, P100, DOI 10.1038/nature11807
   Baradaran-Rafii A, 2020, CELL TISSUE BANK, V21, P339, DOI 10.1007/s10561-020-09826-3
   Bharti K, 2011, PIGM CELL MELANOMA R, V24, P21, DOI 10.1111/j.1755-148X.2010.00772.x
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Brandl C, 2019, METHODS MOL BIOL, V1834, P87, DOI 10.1007/978-1-4939-8669-9_6
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Chagastelles PC, 2011, KIDNEY INT SUPPL, V1, P63, DOI 10.1038/kisup.2011.15
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Choudhary P, 2017, STEM CELL TRANSL MED, V6, P490, DOI 10.5966/sctm.2016-0088
   Cotrim CC, 2020, ARQ BRAS OFTALMOL, V83, P160, DOI 10.5935/0004-2749.20200037
   Cunningham J, 2017, JAAPA-J AM ACAD PHYS, V30, P18, DOI 10.1097/01.JAA.0000512227.85313.05
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Dakhore S, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/7396905
   de Guimaraes TAC, 2022, BRIT J OPHTHALMOL, V106, P297, DOI 10.1136/bjophthalmol-2020-318452
   Dewell TE, 2021, STEM CELL RES, V53, DOI 10.1016/j.scr.2021.102368
   DiLoreto D, 1996, EXP NEUROL, V140, P37
   Dowey SN, 2012, NAT PROTOC, V7, P2013, DOI 10.1038/nprot.2012.121
   Fernandopulle Michael S, 2018, Curr Protoc Cell Biol, V79, pe51, DOI 10.1002/cpcb.51
   Ferrer M, 2014, STEM CELL TRANSL MED, V3, P911, DOI 10.5966/sctm.2013-0192
   Foltz LP, 2017, JOVE-J VIS EXP, DOI 10.3791/56274
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Garcia-Onrubia L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165934
   Gymrek M, 2013, SCIENCE, V339, P321, DOI 10.1126/science.1229566
   Heng LZ, 2013, DIABETIC MED, V30, P640, DOI 10.1111/dme.12089
   HOOK EB, 1977, AM J HUM GENET, V29, P94
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Ikelle L, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00743
   Ilic D, 2016, REGEN MED, V11, P747, DOI 10.2217/rme-2016-0153
   Ivanov IV, 2018, J BIOPHOTONICS, V11, DOI 10.1002/jbio.201700377
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kniggendorf V, 2020, ARQ BRAS OFTALMOL, V83, P552, DOI 10.5935/0004-2749.20200082
   Kuriyan AE, 2017, NEW ENGL J MED, V376, P1047, DOI 10.1056/NEJMoa1609583
   Kuroda T, 2019, STEM CELL RES, V39, DOI 10.1016/j.scr.2019.101514
   Ladewig J, 2013, NAT REV MOL CELL BIO, V14, P225, DOI 10.1038/nrm3543
   Leach LL, 2016, J OCUL PHARMACOL TH, V32, P317, DOI 10.1089/jop.2016.0022
   Leach LL, 2015, INVEST OPHTH VIS SCI, V56, P1002, DOI 10.1167/iovs.14-15835
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin TC, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/9428176
   Liu G, 2020, STEM CELL REV REP, V16, P3, DOI 10.1007/s12015-019-09935-x
   Mandai M, 2017, STEM CELL REP, V8, P69, DOI 10.1016/j.stemcr.2016.12.008
   Maruotti J, 2015, P NATL ACAD SCI USA, V112, P10950, DOI 10.1073/pnas.1422818112
   Merkle FT, 2017, NATURE, V545, P229, DOI 10.1038/nature22312
   Meyer JS, 2011, STEM CELLS, V29, P1206, DOI 10.1002/stem.674
   Michalska-Malecka K, 2015, EUR GERIATR MED, V6, P69, DOI 10.1016/j.eurger.2014.09.007
   Michelet F, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-1568-3
   Moradi S, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1455-y
   Morizur L, 2020, MOL CELL NEUROSCI, V107, DOI 10.1016/j.mcn.2020.103523
   Nazari H, 2015, PROG RETIN EYE RES, V48, P1, DOI 10.1016/j.preteyeres.2015.06.004
   Oner A, 2018, TURK OFTALMOL DERG, V48, P33, DOI 10.4274/tjo.89972
   Phelan MA, 2020, TISSUE ENG PART C-ME, V26, P433, DOI [10.1089/ten.tec.2020.0072, 10.1089/ten.TEC.2020.0072]
   Regent F, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47123-6
   Reyes AP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15326-5
   Fernandes AR, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23052592
   Sharma R, 2020, ANNU REV PHARMACOL, V60, P553, DOI 10.1146/annurev-pharmtox-010919-023245
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   Simo R, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/190724
   Singh MS, 2020, PROG RETIN EYE RES, V75, DOI 10.1016/j.preteyeres.2019.100779
   Sohn EH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11791
   Stacey GN, 2007, CULTURE HUMAN STEM C, P121
   Sugita S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186507
   Sugita S, 2016, STEM CELL REP, V7, P619, DOI 10.1016/j.stemcr.2016.08.011
   Sugita S, 2016, STEM CELL REP, V7, P635, DOI 10.1016/j.stemcr.2016.08.010
   Suri R, 2020, EUR J PHARM SCI, V153, DOI 10.1016/j.ejps.2020.105489
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Taylor CJ, 2011, PHILOS T R SOC B, V366, P2312, DOI 10.1098/rstb.2011.0030
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Wiley LA, 2015, PROG RETIN EYE RES, V44, P15, DOI 10.1016/j.preteyeres.2014.10.002
   Wu N, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/2361763
   Yang JM, 2021, EXP MOL MED, V53, P631, DOI 10.1038/s12276-021-00588-w
   Yang M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197279
   Ye K, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70979-y
   Zahabi A, 2012, STEM CELLS DEV, V21, P2262, DOI 10.1089/scd.2011.0599
   Zakrzewski W, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1165-5
   Zarbin M, 2019, STEM CELL TRANSL MED, V8, P466, DOI 10.1002/sctm.18-0282
   Zhu DL, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01608-8
   Zhu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054552
NR 82
TC 1
Z9 1
U1 10
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1757-6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD MAY 26
PY 2022
VL 13
IS 1
AR 217
DI 10.1186/s13287-022-02894-0
PG 19
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 1U7OV
UT WOS:000805598100005
PM 35619143
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hussain, RM
   O'Leary, P
   Eichenbaum, DA
   Hariprasad, SM
AF Hussain, R. M.
   O'Leary, P.
   Eichenbaum, D. A.
   Hariprasad, S. M.
TI Faricimab Anti-Ang-2/anti-VEGF-A bispecific antibody Treatment of
   diabetic macular edema Treatment of wet age-related macular degeneration
SO DRUGS OF THE FUTURE
LA English
DT Article
DE Tie-2/angiopoietin pathway; Angiopoietin-2; Vascular endothelial growth
   factor A; Bispecific antibody; Neovascular age-related macular
   degeneration; Diabetic macular edema; Faricimab; RG-7716
ID ENDOTHELIAL GROWTH-FACTOR; DIABETIC MACULAR EDEMA; ANGIOPOIETIN-2;
   RETINOPATHY; DEGENERATION; RECEPTOR; VEGF; EXPRESSION;
   NEOVASCULARIZATION; ANGIOGENESIS
AB The Tie-2/angiopoietin pathway is a potential therapeutic target in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Activation of the Tie-2 receptor via angiopoietin-1 (Ang-1) maintains vascular stability to limit exudation. Ang-2, a competitive antagonist to Ang-1, and VE-PTP (vascular endothelial protein tyrosine phosphatase), an endothelial-specific phosphatase, interfere with the Tie-2/Ang-1 axis, resulting in vascular leakage. Faricimab is a novel bispecific antibody that simultaneously inhibits vascular endothelial growth factor A (VEGF-A) and Ang-2 and is administered by intravitreal injection. It was shown to be safe and efficacious when administered with 4 monthly loading doses followed by 12- and 16-week dosing intervals, while being compared to monthly ranibizumab injections in the phase 11 AVENUE and STAIRWAY trials for nAMD and the BOULEVARD trial for DME. In the STAIRWAY trial, the assessment at 24 weeks showed that 65% of patients treated with faricimab had no protocol-defined nAMD disease activity 12 weeks after last injection. It is currently in phase III trials for nAMD (LUCERNE and TENAYA) and DME (RHINE and YOSEMITE), which compare 12- and 16-week dosing of faricimab against 8-week dosing of aflibercept. Faricimab shows promise to reduce treatment burden and improve visual outcomes in nAMD and DME, with potential to treat cases refractory to currently available treatment options.
C1 [Hussain, R. M.; O'Leary, P.] Retina Associates Ltd, Elmhurst, IL USA.
   [Eichenbaum, D. A.] Univ S Florida, Coll Med, Tampa, FL 33620 USA.
   [Hariprasad, S. M.] Univ Chicago, Chicago, IL 60637 USA.
C3 State University System of Florida; University of South Florida;
   University of Chicago
RP Hussain, RM (通讯作者)，Retina Associates Ophthalmol, 133 E Brush Hill Rd,Suite 300, Elmhurst, IL 60126 USA.
EM rhussain27@gmail.com
CR Al-Khersan H, 2019, EXPERT OPIN PHARMACO, V20, P1879, DOI 10.1080/14656566.2019.1636031
   Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233
   Augustin HG, 2009, NAT REV MOL CELL BIO, V10, P165, DOI 10.1038/nrm2639
   Baumal CR., 2020, OPHTHALMOLOGY
   Brown D.M, 2016, ANN M AM AC OPHTH OC
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Campochiaro PA, 2016, CURR DIABETES REP, V16, DOI 10.1007/s11892-016-0816-5
   Chakravarthy U, 2017, OPHTHALMOL RETINA, V1, P474, DOI 10.1016/j.oret.2017.03.003
   Ciulla TA, 2003, DIABETES CARE, V26, P2653, DOI 10.2337/diacare.26.9.2653
   Ciulla TA, 2002, ACTA OPHTHALMOL SCAN, V80, P468, DOI 10.1034/j.1600-0420.2002.800503.x
   Ciulla TA, 2020, OPHTHALMOL RETINA, V4, P19, DOI 10.1016/j.oret.2019.05.017
   Ciulla TA, 2018, OPHTHALMOL RETINA, V2, P1179, DOI 10.1016/j.oret.2018.06.004
   Csaky K.G., 2019, ANN M AM AC OPHTH OC
   Ehrlich R, 2010, ACTA OPHTHALMOL, V88, P279, DOI 10.1111/j.1755-3768.2008.01501.x
   Fachinger G, 1999, ONCOGENE, V18, P5948, DOI 10.1038/sj.onc.1202992
   Fauser S., 2018, 15 ANN ANG EX DEG M
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FERRIS FL, 1984, SURV OPHTHALMOL, V28, P452, DOI 10.1016/0039-6257(84)90227-3
   Foxton RH, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201810204
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Frye M, 2015, J EXP MED, V212, P2267, DOI 10.1084/jem.20150718
   Gass J.D., 1967, AM J OPHTHALMOL, V63, P1
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hammes HP, 2011, DIABETES, V60, P9, DOI 10.2337/db10-0454
   Helzner J., 2018, RETINAL PHYS
   Hussain RM, 2017, EXPERT OPIN EMERG DR, V22, P235, DOI 10.1080/14728214.2017.1362390
   Hussain RM, 2016, EXPERT OPIN BIOL TH, V16, P365, DOI 10.1517/14712598.2016.1131265
   Khanani A.M, 2018, ANN M AM AC OPHTH OC
   Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200
   Kirkner R.M., 2018, WHATS NEXT BISPECIFI
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P7
   Lee J, 2014, INVEST OPHTH VIS SCI, V55, P2191, DOI 10.1167/iovs.14-13897
   Lee SG, 2012, CLIN EXP OPHTHALMOL, V40, pE47, DOI 10.1111/j.1442-9071.2011.02695.x
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Loukovaara S, 2013, ACTA OPHTHALMOL, V91, P531, DOI 10.1111/j.1755-3768.2012.02473.x
   Menden H, 2015, J BIOL CHEM, V290, P5449, DOI 10.1074/jbc.M114.600692
   Moisseiev E, 2020, EYE, V34, P605, DOI 10.1038/s41433-019-0584-y
   Morello CA, 2007, AM J HEALTH-SYST PH, V64, pS3, DOI 10.2146/ajhp070330
   Nambu H, 2005, J CELL PHYSIOL, V204, P227, DOI 10.1002/jcp.20292
   Nambu H, 2004, GENE THER, V11, P865, DOI 10.1038/sj.gt.3302230
   Oh H, 1999, J BIOL CHEM, V274, P15732, DOI 10.1074/jbc.274.22.15732
   Ohashi H, 2004, MOL VIS, V10, P608
   Orfanos SE, 2007, CRIT CARE MED, V35, P199, DOI 10.1097/01.CCM.0000251640.77679.D7
   Oshima Y, 2005, FASEB J, V19, P963, DOI 10.1096/fj.04-2209fje
   Oshima Y, 2004, J CELL PHYSIOL, V199, P412, DOI 10.1002/jcp.10442
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Park SW, 2014, DIABETES, V63, P3057, DOI 10.2337/db13-1942
   PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x
   Rangasamy S, 2011, INVEST OPHTH VIS SCI, V52, P3784, DOI 10.1167/iovs.10-6386
   Regula JT, 2016, EMBO MOL MED, V8, P1265, DOI 10.15252/emmm.201505889
   Sahni J, 2019, OPHTHALMOLOGY, V126, P1155, DOI 10.1016/j.ophtha.2019.03.023
   Schaefer W, 2011, P NATL ACAD SCI USA, V108, P11187, DOI 10.1073/pnas.1019002108
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Sugimachi K, 2003, J CLIN PATHOL, V56, P854, DOI 10.1136/jcp.56.11.854
   Tait CR, 2004, J PATHOL, V204, P1, DOI 10.1002/path.1618
   Watanabe D, 2005, AM J OPHTHALMOL, V139, P476, DOI 10.1016/j.ajo.2004.10.004
   Ziegler T, 2013, J CLIN INVEST, V123, P3436, DOI 10.1172/JCI66549
NR 57
TC 0
Z9 1
U1 0
U2 6
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 0377-8282
EI 2013-0368
J9 DRUG FUTURE
JI Drug Future
PD JUL
PY 2020
VL 45
IS 7
BP 449
EP 457
DI 10.1358/dof.2020.45.7.3127028
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA MN1LU
UT WOS:000550610800001
DA 2022-11-30
ER

PT J
AU Qin, L
   Mroczkowska, SA
   Ekart, A
   Patel, SR
   Gibson, JM
   Gherghel, D
AF Qin, Lu
   Mroczkowska, Stephanie A.
   Ekart, Aniko
   Patel, Sunni R.
   Gibson, Jonathan M.
   Gherghel, Doina
TI Patients with early age-related macular degeneration exhibit signs of
   macro- and micro-vascular disease and abnormal blood glutathione levels
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Retinal vascular function; Oxidative
   stress; Cardiovascular risk
ID ENDOTHELIAL GROWTH-FACTOR; INTIMA-MEDIA THICKNESS; PULSE-WAVE ANALYSIS;
   CARDIOVASCULAR-DISEASE; RISK-FACTORS; ATHEROSCLEROSIS RISK; OXIDATIVE
   STRESS; VESSEL DIAMETER; PLASMA; DYSFUNCTION
AB This pilot study aimed to investigate systemic and retinal vascular function and their relationship to circulatory markers of cardiovascular risk in early age-related macular degeneration (AMD) patients without any already diagnosed systemic vascular pathologies.
   Fourteen patients diagnosed with early AMD and 14 age- and gender-matched healthy controls underwent blood pressure, carotid intima-media thickness (C-IMT) and peripheral arterial stiffness measurements. Retinal vascular reactivity was assessed by means of dynamic retinal vessel analysis (DVA) using a modified protocol. Blood analyses were conducted for glutathione levels and plasma levels of total cholesterol (CHOL), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG).
   The AMD patients showed significantly greater C-IMT (p = 0.029) and augmentation index (AIx) (p = 0.042) than the age-matched controls. In addition, they demonstrated a shallower retinal arterial dilation slope (Slope (AD)) (p = 0.005) and a longer retinal venous reaction time (RT) to flickering light (p = 0.026). Blood analyses also revealed that AMD patients exhibited higher oxidized glutathione (GSSG) (p = 0.024), lower redox index (p = 0.043) and higher LDL-C (p = 0.033) levels than the controls. Venous RT parameter correlated positively with blood GSSG levels (r = 0.58, p = 0.038) in AMD subjects, but not in the controls (p > 0.05).
   Patients diagnosed with early AMD exhibit signs of systemic and retinal vascular alterations that correlated with known risk markers for future cardiovascular morbidity.
C1 [Qin, Lu; Mroczkowska, Stephanie A.; Patel, Sunni R.; Gibson, Jonathan M.; Gherghel, Doina] Aston Univ, Sch Life & Hlth Sci, Ophthalm Res Grp, Vasc Res Lab, Birmingham B4 7ET, W Midlands, England.
   [Ekart, Aniko] Aston Univ, Sch Engn & Appl Sci, Birmingham B4 7ET, W Midlands, England.
C3 Aston University; Aston University
RP Gherghel, D (通讯作者)，Aston Univ, Sch Life & Hlth Sci, Ophthalm Res Grp, Vasc Res Lab, Birmingham B4 7ET, W Midlands, England.
EM d.gherghel@aston.ac.uk
OI Gherghel, Doina/0000-0001-9439-5573; Mroczkowska,
   Stephanie/0000-0001-6984-4189; Gibson, Jonathan M/0000-0002-9281-5244;
   Ekart, Aniko/0000-0001-6967-5397
CR Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bhutto IA, 2010, EXP EYE RES, V90, P155, DOI 10.1016/j.exer.2009.10.004
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Cheung N, 2007, ARCH OPHTHALMOL-CHIC, V125, P1241, DOI 10.1001/archopht.125.9.1241
   De Vriese AS, 2000, BRIT J PHARMACOL, V130, P963, DOI 10.1038/sj.bjp.0703393
   Donald AE, 2006, J AM COLL CARDIOL, V48, P1846, DOI 10.1016/j.jacc.2006.07.039
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   Gates PE, 2009, EXP PHYSIOL, V94, P311, DOI 10.1113/expphysiol.2008.043349
   Heitmar R, 2010, INVEST OPHTH VIS SCI, V51, P5833, DOI 10.1167/iovs.09-5136
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   Jeganathan VSE, 2008, AM J OPHTHALMOL, V146, P954, DOI 10.1016/j.ajo.2008.07.006
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Kotliar KE, 2004, GRAEF ARCH CLIN EXP, V242, P377, DOI 10.1007/s00417-003-0847-x
   Kotliar KE, 2011, MICROVASC RES, V81, P123, DOI 10.1016/j.mvr.2010.11.007
   Lanzl IM, 2011, ACTA OPHTHALMOL, V89, P472, DOI 10.1111/j.1755-3768.2009.01718.x
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Matsuoka H, 2001, DIABETES RES CLIN PR, V54, pS65, DOI 10.1016/S0168-8227(01)00337-0
   Mitchell GF, 2005, CIRCULATION, V112, P3722, DOI 10.1161/CIRCULATIONAHA.105.551168
   Mroczkowska S, 2012, ACTA OPHTHALMOL, V90, pE553, DOI 10.1111/j.1755-3768.2012.02494.x
   Nagel E, 2004, INVEST OPHTH VIS SCI, V45, P1486, DOI 10.1167/iovs.03-0667
   Nagineni CN, 2012, J CELL PHYSIOL, V227, P116, DOI 10.1002/jcp.22708
   O'Rourke MF, 2001, BRIT J CLIN PHARMACO, V51, P507, DOI 10.1046/j.0306-5251.2001.01400.x
   Patel SR, 2011, BRIT J OPHTHALMOL, V95, P1573, DOI 10.1136/bjo.2010.201665
   Qin L, 2011, INVEST OPHTH VIS SCI, V52, P5029, DOI 10.1167/iovs.11-7240
   Rebrin I, 2008, ADV DRUG DELIVER REV, V60, P1545, DOI 10.1016/j.addr.2008.06.001
   Rosendorff C, 2002, J HUM HYPERTENS, V16, pS26, DOI 10.1038/sj.jhh.1001337
   Rubira Marcelo Custodio, 2007, J Clin Hypertens (Greenwich), V9, P859
   Samiec PS, 1998, FREE RADICAL BIO MED, V24, P699, DOI 10.1016/S0891-5849(97)00286-4
   Sato E, 2006, GRAEF ARCH CLIN EXP, V244, P963, DOI 10.1007/s00417-005-0201-6
   Simon A, 2002, J HYPERTENS, V20, P159, DOI 10.1097/00004872-200202000-00001
   Skinner S, 2011, SPHYGMOCOR MANUAL CL
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Totan Y, 2001, BRIT J OPHTHALMOL, V85, P1426, DOI 10.1136/bjo.85.12.1426
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wang W, 1998, PHARMACOL REV, V50, P335
   Wilkinson IB, 1998, J HYPERTENS, V16, P2079, DOI 10.1097/00004872-199816121-00033
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Yoshinaga K, 2011, J NUCL CARDIOL, V18, P486, DOI 10.1007/s12350-011-9370-3
   Zaliuniene D, 2008, EUR J OPHTHALMOL, V18, P384, DOI 10.1177/112067210801800312
   Zhang B, 2006, BRAIN RES, V1124, P176, DOI 10.1016/j.brainres.2006.09.067
NR 44
TC 13
Z9 14
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JAN
PY 2014
VL 252
IS 1
BP 23
EP 30
DI 10.1007/s00417-013-2418-0
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 283JY
UT WOS:000329243500005
PM 23842712
DA 2022-11-30
ER

PT J
AU Oubraham, H
   Cohen, SY
   Samimi, S
   Marotte, D
   Bouzaher, I
   Bonicel, P
   Fajnkuchen, F
   Tadayoni, R
AF Oubraham, Hassiba
   Cohen, Salomon Y.
   Samimi, Sepideh
   Marotte, David
   Bouzaher, Ines
   Bonicel, Pierre
   Fajnkuchen, Franck
   Tadayoni, Ramin
TI INJECT AND EXTEND DOSING VERSUS DOSING AS NEEDED A Comparative
   Retrospective Study of Ranibizumab in Exudative Age-Related Macular
   Degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; antivascular endothelial growth
   factor; choroidal neovascularization; ranibizumab
ID RETINAL ANGIOMATOUS PROLIFERATION; INTRAVITREAL RANIBIZUMAB;
   PHOTODYNAMIC THERAPY; VERTEPORFIN
AB Purpose: The purpose of this study was to compare two strategies for retreatment with ranibizumab in exudative age-related macular degeneration.
   Method: Two series of consecutive patients treated with ranibizumab in a hospital-based department of ophthalmology were analyzed retrospectively: the first series (n = 52), after as-needed reinjections (PRN group) and the second (n = 38) after reinjections according to the Inject and Extend dosing method (IaE group). Patients' baseline characteristics, type of choroidal neovascularization, and Early Treatment Diabetic Retinopathy Study initial and final visual acuity (at 52 +/- 4 weeks) were recorded in each group. Groups were compared by the Mann-Whitney U test or Fisher's exact test.
   Results: Groups were well balanced at baseline for age (P = 0.58), sex (P = 0.66), laterality (P > 0.99), and initial visual acuity (P = 0.33). At 1 year, the mean gain in visual acuity was greater in the IaE group than in the PRN group (+10.8 +/- 8.8 vs. +2.3 +/- 17.4 letters, P = 0.036), but eyes in the IaE group were given significantly more injections (7.8 +/- 1.3 vs. 5.2 +/- 1.9 injections, P < 0.001). The number of follow-up visits attended was similar (8.5 +/- 1.1 vs. 8.8 +/- 1.5, P = 0.2085).
   Conclusion: Patients reinjected by the IaE dosing method had a far better visual outcome but after more injections. RETINA 31:26-30, 2011
C1 [Cohen, Salomon Y.; Fajnkuchen, Franck] Ctr Ophtalmol Imagerie & Laser, F-75015 Paris, France.
   [Oubraham, Hassiba; Samimi, Sepideh; Marotte, David; Bouzaher, Ines; Bonicel, Pierre] Ctr Hosp, Dept Ophthalmol, Orleans, France.
   [Cohen, Salomon Y.; Tadayoni, Ramin] Univ Paris Diderot, Paris, France.
   [Cohen, Salomon Y.; Tadayoni, Ramin] Hop Lariboisiere, Assistance Publ Hop Paris, Dept Ophthalmol, F-75475 Paris, France.
C3 Centre Hospitalier Regional d'Orleans; UDICE-French Research
   Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris
   (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP;
   UDICE-French Research Universities; Aix-Marseille Universite; Assistance
   Publique-Hopitaux de Marseille; Universite Paris Cite
RP Cohen, SY (通讯作者)，Ctr Ophtalmol Imagerie & Laser, 11 Rue Antoine Bourdelle, F-75015 Paris, France.
EM sycsyc75@gmail.com
CR Boscia F, 2006, GRAEF ARCH CLIN EXP, V244, P1224, DOI 10.1007/s00417-005-0205-2
   Bottoni F, 2005, ARCH OPHTHALMOL-CHIC, V123, P1644, DOI 10.1001/archopht.123.12.1644
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Freund KB, 2006, ARCH OPHTHALMOL-CHIC, V124, P487, DOI 10.1001/archopht.124.4.487
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Hemeida TS, 2009, BR J OPHTHALMOL 1023
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Kang S, 2009, JPN J OPHTHALMOL, V53, P389, DOI 10.1007/s10384-009-0670-y
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Spaide RF, 2009, AM J OPHTHALMOL, V148, P1, DOI 10.1016/j.ajo.2009.04.010
NR 16
TC 116
Z9 117
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2011
VL 31
IS 1
BP 26
EP 30
DI 10.1097/IAE.0b013e3181de5609
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 699TG
UT WOS:000285685100004
PM 20890246
DA 2022-11-30
ER

PT J
AU de Jong, S
   de Breuk, A
   Volokhina, EB
   Bakker, B
   Garanto, A
   Fauser, S
   Katti, S
   Hoyng, CB
   Lechanteur, YTE
   van den Heuvel, LP
   den Hollander, AI
AF de Jong, Sarah
   de Breuk, Anita
   Volokhina, Elena B.
   Bakker, Bjorn
   Garanto, Alejandro
   Fauser, Sascha
   Katti, Suresh
   Hoyng, Carel B.
   Lechanteur, Yara T. E.
   van den Heuvel, Lambert P.
   den Hollander, Anneke, I
TI Systemic complement levels in patients with age-related macular
   degeneration carrying rare or low-frequency variants in the CFH gene
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID HEMOLYTIC-UREMIC SYNDROME; MEMBRANE ATTACK COMPLEX; H-LIKE PROTEIN-1;
   FUNCTIONAL-CHARACTERIZATION; ACTIVATION; MUTATIONS; MACULOPATHY;
   DISEASE; ASSOCIATIONS; REGULATOR
AB Age-related macular degeneration (AMD) is a major cause of vision loss among the elderly in the Western world. Genetic variants in the complement factor H (CFH) gene are associated with AMD, but the functional consequences of many of these variants are currently unknown. In this study, we aimed to determine the effect of 64 rare and low-frequency variants in the CFH gene on systemic levels of factor H (FH) and complement activation marker C3bBbP using plasma samples of 252 carriers and 159 non-carriers. Individuals carrying a heterozygous nonsense, frameshift or missense variant in CFH presented with significantly decreased FH levels and significantly increased C3bBbP levels in plasma compared to non-carrier controls. FH and C3bBbP plasma levels were relatively stable over time in samples collected during follow-up visits. Decreased FH and increased C3bBbP concentrations were observed in carriers compared to non-carriers of CFH variants among different AMD stages, with the exception of C3bBbP levels in advanced AMD stages, which were equally high in carriers and non-carriers. In AMD families, FH levels were decreased in carriers compared to non-carriers, but C3bBbP levels did not differ. Rare variants in the CFH gene can lead to reduced FH levels or reduced FH function as measured by increased C3bBbP levels. The effects of individual variants in the CFH gene reported in this study will improve the interpretation of rare and low-frequency variants observed in AMD patients in clinical practice.
C1 [de Jong, Sarah; de Breuk, Anita; Bakker, Bjorn; Hoyng, Carel B.; Lechanteur, Yara T. E.; den Hollander, Anneke, I] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, NL-6525 GA Nijmegen, Netherlands.
   [Volokhina, Elena B.; Garanto, Alejandro; van den Heuvel, Lambert P.] Radboud Univ Nijmegen, Amalia Childrens Hosp, Med Ctr, NL-6525 GA Nijmegen, Netherlands.
   [Volokhina, Elena B.; Garanto, Alejandro; van den Heuvel, Lambert P.] Radboud Univ Nijmegen, Radboud Inst Mol Life Sci, Med Ctr, NL-6525 GA Nijmegen, Netherlands.
   [Volokhina, Elena B.; Garanto, Alejandro; van den Heuvel, Lambert P.] Radboud Univ Nijmegen, Med Ctr, Dept Lab Med, NL-6525 GA Nijmegen, Netherlands.
   [Garanto, Alejandro; den Hollander, Anneke, I] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 GA Nijmegen, Netherlands.
   [Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, D-50937 Cologne, Germany.
   [Fauser, Sascha] F Hoffmann La Roche & Cie AG, CH-4070 Basel, Switzerland.
   [Katti, Suresh] Gemini Therapeut Inc, Cambridge, MA 02139 USA.
C3 Radboud University Nijmegen; Radboud University Nijmegen; Radboud
   University Nijmegen; Radboud University Nijmegen; Radboud University
   Nijmegen; University of Cologne; Roche Holding
RP den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 GA Nijmegen, Netherlands.; den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 GA Nijmegen, Netherlands.
EM anneke.denhollander@radboudumc.nl
RI Bakker, Bjorn/E-2842-2016; Garanto, Alejandro/D-5022-2014
OI Garanto, Alejandro/0000-0001-5721-1560; de Jong,
   Sarah/0000-0002-3705-3371
FU Dutch Research Council [016.Vici.170.024]; Gemini Therapeutics, Inc.
FX Dutch Research Council (016.Vici.170.024 to A.I.d.H.), and a
   collaborative research agreement with Gemini Therapeutics, Inc.
CR Altay L, 2019, EYE, V33, P1859, DOI 10.1038/s41433-019-0501-4
   Bergseth G, 2013, MOL IMMUNOL, V56, P232, DOI 10.1016/j.molimm.2013.05.221
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Breuk A., 2020, OPHTHALMOLOGY
   Clark SJ, 2014, J IMMUNOL, V193, P4962, DOI 10.4049/jimmunol.1401613
   Colijn JM, 2021, OPHTHALMOLOGY, V128, P1039, DOI 10.1016/j.ophtha.2020.11.024
   Corominas J, 2018, OPHTHALMOLOGY, V125, P1433, DOI 10.1016/j.ophtha.2018.03.040
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   de Guimaraes TAC, 2022, BRIT J OPHTHALMOL, V106, P297, DOI 10.1136/bjophthalmol-2020-318452
   de Jong S, 2021, PROG RETIN EYE RES, V84, DOI 10.1016/j.preteyeres.2021.100952
   de Jong S, 2020, HUM MOL GENET, V29, P2313, DOI 10.1093/hmg/ddaa114
   Dragon-Durey MA, 2004, J AM SOC NEPHROL, V15, P787, DOI 10.1097/01.ASN.0000115702.28859.A7
   Fakhouri F, 2008, BLOOD, V112, P4542, DOI 10.1182/blood-2008-03-144691
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Geerlings MJ, 2018, CLIN GENET, V94, P330, DOI 10.1111/cge.13392
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Geerlings MJ, 2017, JAMA OPHTHALMOL, V135, P39, DOI 10.1001/jamaophthalmol.2016.4604
   Heesterbeek TJ, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.18
   Holter JC, 2020, P NATL ACAD SCI USA, V117, P25018, DOI 10.1073/pnas.2010540117
   Java A, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.9.37
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kersten E, 2017, JAMA OPHTHALMOL, V135, P1037, DOI 10.1001/jamaophthalmol.2017.3195
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Kuhn S, 1996, EUR J IMMUNOL, V26, P2383, DOI 10.1002/eji.1830261017
   Manders P., 2018, OPEN J BIORESOUR, V5, P2, DOI [10.5334/ojb.36, DOI 10.5334/OJB.36]
   Merinero HM, 2018, KIDNEY INT, V93, P470, DOI 10.1016/j.kint.2017.07.015
   Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00262
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Neumann HPH, 2003, J MED GENET, V40, P676, DOI 10.1136/jmg.40.9.676
   Orrem HL, 2018, ESC HEART FAIL, V5, P292, DOI 10.1002/ehf2.12266
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ristau T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093459
   Ristau T, 2014, INVEST OPHTH VIS SCI, V55, P210, DOI 10.1167/iovs.13-13248
   Sanchez-Corral P, 2002, AM J HUM GENET, V71, P1285, DOI 10.1086/344515
   Schick T, 2017, EYE, V31, P810, DOI 10.1038/eye.2016.328
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Sellier-Leclerc AL, 2007, J AM SOC NEPHROL, V18, P2392, DOI 10.1681/ASN.2006080811
   Servais A, 2012, KIDNEY INT, V82, P454, DOI 10.1038/ki.2012.63
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Stahl AL, 2008, BLOOD, V111, P5307, DOI 10.1182/blood-2007-08-106153
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   Tortajada A, 2012, KIDNEY INT, V81, P56, DOI 10.1038/ki.2011.291
   van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3
   Volokhina EB, 2015, CLIN EXP IMMUNOL, V181, P306, DOI 10.1111/cei.12426
   Volokhina E, 2012, PEDIATR NEPHROL, V27, P1519, DOI 10.1007/s00467-012-2183-z
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zipfel PF, 1999, IMMUNOL TODAY, V20, P135, DOI 10.1016/S0167-5699(98)01432-7
NR 51
TC 2
Z9 2
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD FEB 3
PY 2022
VL 31
IS 3
BP 455
EP 470
DI 10.1093/hmg/ddab256
EA NOV 2021
PG 16
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 0E6IY
UT WOS:000776784300011
PM 34508573
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Abdolrahimzadeh, S
   Gharbiya, M
   Formisano, M
   Bertini, F
   Cerini, A
   Pacella, E
AF Abdolrahimzadeh, Solmaz
   Gharbiya, Magda
   Formisano, Martina
   Bertini, Fabrizio
   Cerini, Alberto
   Pacella, Elena
TI Anti-Vascular Endothelial Growth Factor Intravitreal Therapy and Macular
   Ganglion Cell Layer Thickness in Patients with Neovascular Age-Related
   Macular Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age related macular degeneration; anti-vascular endothelial growth
   factor; ganglion cell layer; retinal segmentation; spectral domain
   optical coherence tomography
ID NERVE-FIBER LAYER; INNER PLEXIFORM LAYER; COHERENCE TOMOGRAPHY EVIDENCE;
   FACTOR-A; BEVACIZUMAB; EYES; RANIBIZUMAB; INJECTIONS; SURVIVAL
AB Purpose: To assess macular ganglion cell layer (GCL) thickness in patients treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) for exudative age-related macular degeneration (AMD). Materials and Methods: This was a two-year retrospective institutional case series where records of patients treated with anti-VEGF injections for unilateral AMD were reviewed for BCVA, intraocular pressure, and spectral domain optical coherence tomography. Macular GCL thickness was evaluated with automated retinal segmentation based on ETDRS grid rings. Retinal layer segmentation was carefully assessed and manually corrected for any misalignment. Results: 48 eyes of 24 patients with unilateral exudative AMD were included. The mean number of anti-VEGF injections was 10.4 +/- 3.2. Fellow eyes were classified as AREDS category one and two. There was significant thinning of the 3-mm macular GCL in treated compared with fellow eyes at one and two years (P = .03 and P = .04, respectively). GCL thickness compared to baseline showed a significant decrease at one and two years in treated (P = .01 and <0.0001) and at two years in untreated fellow eyes (P = .02). Conclusions: There is a decrease of macular GCL thickness in eyes with exudative AMD treated with anti-VEGF intravitreal injections in comparison with fellow eyes. There is longitudinal thinning of the GCL from baseline in eyes with both treated exudative and non-treated early AMD.
C1 [Abdolrahimzadeh, Solmaz] Sapienza Univ Rome, St Andrea Hosp, NESMOS Dept, Ophthalmol Unit, Via Grottarossa 1035-1039, I-00189 Rome, Italy.
   [Gharbiya, Magda; Formisano, Martina; Bertini, Fabrizio; Cerini, Alberto; Pacella, Elena] Sapienza Univ Rome, Policlin Umberto 1, Dept Sense Organs, Ophthalmol Unit, Rome, Italy.
C3 Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; Sapienza
   University Rome; University Hospital Sapienza Rome
RP Abdolrahimzadeh, S (通讯作者)，Sapienza Univ Rome, St Andrea Hosp, NESMOS Dept, Ophthalmol Unit, Via Grottarossa 1035-1039, I-00189 Rome, Italy.
EM solmaz.abdolrahimzadeh@uniroma1.it
RI Gharbiya, Magda/AAS-1182-2021
OI PACELLA, ELENA/0000-0002-5431-6399; Gharbiya, Magda/0000-0002-4991-9689
CR Abdolrahimzadeh S, 2016, RETINA-J RET VIT DIS, V36, P2329, DOI 10.1097/IAE.0000000000001097
   Abdolrahimzadeh S, 2016, RETINA-J RET VIT DIS, V36, P75, DOI 10.1097/IAE.0000000000000650
   Beck M, 2016, AM J OPHTHALMOL, V167, P10, DOI 10.1016/j.ajo.2016.04.003
   Cheng CK, 2009, RETINA-J RET VIT DIS, V29, P306, DOI 10.1097/IAE.0b013e3181909404
   D'Amore PA, 2007, AM J PATHOL, V171, P14, DOI 10.2353/ajpath.2007.070385
   Demirel S, 2015, CURR EYE RES, V40, P87, DOI 10.3109/02713683.2014.917190
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P1044, DOI 10.1097/IAE.0b013e3180592ba6
   Feigl B, 2007, EYE, V21, P689, DOI 10.1038/sj.eye.6702389
   Hammel N, 2017, AM J OPHTHALMOL, V178, P38, DOI 10.1016/j.ajo.2017.03.008
   Hendrickson A, 2015, BRAIN STRUCT FUNCT, V220, P351, DOI 10.1007/s00429-013-0659-7
   Horsley MB, 2010, AM J OPHTHALMOL, V150, P558, DOI 10.1016/j.ajo.2010.04.029
   Hosseini H, 2012, RETINA-J RET VIT DIS, V32, P967, DOI 10.1097/IAE.0b013e31822c28d6
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Lee WJ, 2017, J GLAUCOMA, V26, P980, DOI 10.1097/IJG.0000000000000776
   Martinez-de-la-Casa JM, 2012, INVEST OPHTH VIS SCI, V53, P6214, DOI 10.1167/iovs.12-9875
   Muftuoglu IK, 2018, GRAEF ARCH CLIN EXP, V256, P2035, DOI 10.1007/s00417-018-4093-7
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Parlak M, 2015, INT OPHTHALMOL, V35, P473, DOI 10.1007/s10792-014-9972-2
   Perdicchi A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/268796
   Rouvas A, 2009, OPHTHALMOLOGICA, V223, P383, DOI 10.1159/000228590
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Saleh R, 2017, GRAEF ARCH CLIN EXP, V255, P817, DOI 10.1007/s00417-017-3590-4
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Sharma NS, 2015, EYE, V29, P291, DOI 10.1038/eye.2014.265
   Shin HY, 2013, INVEST OPHTH VIS SCI, V54, P7344, DOI 10.1167/iovs.13-12667
   Shin HJ, 2016, INVEST OPHTH VIS SCI, V57, P1798, DOI 10.1167/iovs.15-18404
   Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092
   Yau GL, 2015, CAN J OPHTHALMOL, V50, P345, DOI 10.1016/j.jcjo.2015.01.008
   Zachary I, 2005, NEUROSIGNALS, V14, P207, DOI 10.1159/000088637
   Zayit-Soudry S, 2010, RETINA-J RET VIT DIS, V30, P671, DOI 10.1097/IAE.0b013e3181c0858c
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
NR 33
TC 6
Z9 6
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD SEP 2
PY 2019
VL 44
IS 9
BP 1000
EP 1005
DI 10.1080/02713683.2019.1610179
EA MAY 2019
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IU5EG
UT WOS:000470608000001
PM 30999772
DA 2022-11-30
ER

PT J
AU Maesa, JM
   Banos-Alvarez, E
   Rosario-Lozano, MP
   Blasco-Amaro, JA
AF Maesa, Jose-Maria
   Banos-Alvarez, Elena
   Rosario-Lozano, Maria-Piedad
   Blasco-Amaro, Juan-Antonio
TI Diagnostic accuracy of optical coherence tomography angiography in the
   detection of neovasculature in age-related macular degeneration: a
   meta-analysis
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
DE age-related macular degeneration; angiography; choroidal
   neovascularization; optical coherence tomography
ID EYE
AB This work is a systematic review and meta-analysis to evaluate the diagnostic accuracy of optical coherence tomography angiography (OCTA) in the identification of choroidal neovascularization due to age-related macular degeneration (AMD) in comparison with fluorescein angiography (FA). A systematic search of the literature was carried out on Medline, EMBASE, Web of Science, Cochrane Library and Center for Reviews and Dissemination. Studies comparing OCTA with FA for the diagnosis of choroidal neovascularization due to AMD that included data on the diagnostic validity of the test or the data necessary for its calculation were selected. The QUADAS-2 tool was used to assess the risk of bias in selected studies. The quantitative analysis of the results was performed by meta-analysis. Seven primary studies were included. The quality of the evidence was good. The total population included in the meta-analysis comprised 553 eyes, with a cumulative sensitivity and specificity of 85.9% (95% CI 81.9-89.3%) and 89% (95% CI 83.5-93.2%), respectively, cumulative positive and negative likelihood ratios of 8.36 and 0.15, respectively (95% CI of 3.05-22.890 and 0.09-0.24, respectively), and a cumulative diagnostic odds ratio of 67.21 (95% CI 22.58-200.05). The evidence obtained does not demonstrate the superiority of OCTA over FA. Its use as a support technique could improve patient flow and reduce the number of FA.
C1 [Maesa, Jose-Maria; Banos-Alvarez, Elena; Rosario-Lozano, Maria-Piedad; Blasco-Amaro, Juan-Antonio] Fdn Andaluza Progreso & Salud, Hlth Technol Assessment Area Andalusia, Amer Vespucio 15, Seville 41092, Spain.
RP Maesa, JM (通讯作者)，Fdn Andaluza Progreso & Salud, Hlth Technol Assessment Area Andalusia, Amer Vespucio 15, Seville 41092, Spain.
EM josem.maesa@juntadeandalucia.es
OI Blasco Amaro, Juan Antonio/0000-0002-5500-8187
FU Ministry of Health, Consume and Social Welfare
FX This study received funding from Ministry of Health, Consume and Social
   Welfare within the activities of annual Work Plan of Spanish Network of
   Health Technology Assessment Agencies.
CR Ahmed D, 2018, RETINA-J RET VIT DIS, V38, P2143, DOI 10.1097/IAE.0000000000001832
   An L, 2008, OPT EXPRESS, V16, P11438, DOI 10.1364/OE.16.011438
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Coscas G, 2016, DEV OPHTHALMOL, V56, P1, DOI 10.1159/000442768
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   de Carlo Talisa E, 2015, Int J Retina Vitreous, V1, P5
   Faes L, 2019, EYE, V33, P1327, DOI 10.1038/s41433-019-0421-3
   Faridi A, 2017, OPHTHALMOL RETINA, V1, P294, DOI 10.1016/j.oret.2017.02.007
   Gong JW, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/7521478
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Lopez-Saez MP, 1998, ANN ALLERG ASTHMA IM, V81, P428, DOI 10.1016/S1081-1206(10)63140-7
   National Institute for Health and Care Excellence (NICE), 2018, NICE GUID NG 82 AG R
   Nikolopoulou E, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/6724818
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Ruiz Moreno JM., 2014, GUIAS PRACTICA CLIN
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Stanga PE, 2016, DEV OPHTHALMOL, V56, P13, DOI 10.1159/000442771
   SuYnchezGonzuYlez, 2015, GACETA ARTICULO CIEN, P8
   Told R, 2018, INVEST OPHTH VIS SCI, V59, P2393, DOI 10.1167/iovs.17-22902
   Urrutia G, 2010, MED CLIN-BARCELONA, V135, P507, DOI 10.1016/j.medcli.2010.01.015
   Usman M, 2019, CUREUS, V11, DOI 10.7759/cureus.6485
   Vallejo E., 2018, SOC COLOMBIANA OFTAL, V51, P63
   Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009
NR 24
TC 0
Z9 0
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAR
PY 2022
VL 100
IS 2
BP E368
EP E376
DI 10.1111/aos.14979
EA JUL 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YX9MP
UT WOS:000678837900001
PM 34309204
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Sigler, EJ
   Randolph, JC
AF Sigler, Eric J.
   Randolph, John C.
TI Comparison of Macular Choroidal Thickness Among Patients Older Than Age
   65 With Early Atrophic Age-Related Macular Degeneration and Normals
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; age-related choroidal atrophy;
   choroid; choroidal thickness; drusen; enhanced depth imaging;
   spectral-domain optical coherence tomography
ID OPTICAL COHERENCE TOMOGRAPHY; ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT
   EPITHELIUM; BLOOD-FLOW; SUBRETINAL NEOVASCULARIZATION;
   MORPHOMETRIC-ANALYSIS; BRUCHS MEMBRANE; AXIAL LENGTH; RISK-FACTORS;
   VITAMIN-C
AB PURPOSE. To compare macular choroidal thickness between patients older than 65 years with early atrophic age-related macular degeneration (AMD) and normals.
   METHODS. This was a consecutive, cross-sectional observational study. Enhanced depth imaging spectral-domain optical coherence tomography using horizontal raster scanning at 12 locations throughout the macula was performed in one eye of consecutive patients presenting with large soft drusen alone, drusen with additional features of early AMD, or a normal fundus. Choroidal thickness was measured at 7 points for each raster scan in the central 3 mm of the macula (total 84 points per eye). In addition, a single subfoveolar measurement was obtained for each eye.
   RESULTS. One hundred fifty eyes of 150 patients were included. There was no significant difference between mean refractive error for each diagnosis category via one-way ANOVA (P = 0.451). Mean macular choroidal thickness (CT) was 235 +/- 49 mu m (range, 125-334 mu m; drusen group, and 115 +/- 40 mu m (range, 22-256 mu m; median = 112 mu m) for patients with AMD. Mean macular CT was significantly different via one-way ANOVA among all diagnosis categories (P < 0.001).
   CONCLUSIONS. The presence of features of early AMD without geographic atrophy and/or soft drusen alone is associated with decreased mean macular CT in vivo compared to that in patients with no chorioretinal pathology. Using enhanced depth imaging, measurement of a single subfoveolar choroidal thickness is highly correlated to mean central macular CT.
C1 [Sigler, Eric J.; Randolph, John C.] Charles Retina Inst, Memphis, TN 38119 USA.
   [Sigler, Eric J.; Randolph, John C.] Univ Tennessee, Ctr Hlth Sci, Hamilton Eye Inst, Div Vitreoretinal Surg, Memphis, TN 38163 USA.
C3 University of Tennessee System; University of Tennessee Health Science
   Center
RP Sigler, EJ (通讯作者)，Charles Retina Inst, 6401 Poplar Ave,Suite 190, Memphis, TN 38119 USA.
EM ejsigler@gmail.com
CR Ahn SJ, 2013, INVEST OPHTH VIS SCI, V54, P2115, DOI 10.1167/iovs.12-11542
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Branchini L, 2012, OPHTHALMOLOGY, V119, P119, DOI 10.1016/j.ophtha.2011.07.002
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Chen FK, 2012, INVEST OPHTH VIS SCI, V53, P975, DOI 10.1167/iovs.11-8771
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Cui JZ, 2000, GRAEF ARCH CLIN EXP, V238, P326, DOI 10.1007/s004170050360
   ELDIRINI AA, 1991, RETINA-J RET VIT DIS, V11, P244, DOI 10.1097/00006982-199111020-00010
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Goldenberg D, 2012, OPHTHAL SURG LAS IM, V43, P296, DOI 10.3928/15428877-20120426-02
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Hirata M, 2011, INVEST OPHTH VIS SCI, V52, P4971, DOI 10.1167/iovs.11-7729
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P3721, DOI 10.1167/iovs.09-3493
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   KIMURA H, 1995, INVEST OPHTH VIS SCI, V36, P2110
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   KORTE GE, 1989, INT REV CYTOL, V114, P221
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Li XQ, 2011, INVEST OPHTH VIS SCI, V52, P8438, DOI 10.1167/iovs.11-8108
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Manjunath V, 2010, AM J OPHTHALMOL, V150, P325, DOI 10.1016/j.ajo.2010.04.018
   Manjunath V, 2010, RETINA-J RET VIT DIS, V30, P1320, DOI 10.1097/IAE.0b013e3181e798b1
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   McCourt Emily A, 2010, Ophthalmic Surg Lasers Imaging, V41 Suppl, pS28, DOI 10.3928/15428877-20101031-14
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   MILLER H, 1985, AM J OPHTHALMOL, V99, P263, DOI 10.1016/0002-9394(85)90354-X
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mori F, 2001, BRIT J OPHTHALMOL, V85, P531, DOI 10.1136/bjo.85.5.531
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Sogawa K, 2012, AM J OPHTHALMOL, V153, P1129, DOI 10.1016/j.ajo.2011.11.005
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Switzer DW, 2012, RETINA-J RET VIT DIS, V32, P1265, DOI 10.1097/IAE.0b013e31824453ac
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
NR 47
TC 41
Z9 41
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2013
VL 54
IS 9
BP 6307
EP 6313
DI 10.1167/iovs.13-12653
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 228EV
UT WOS:000325169500047
PM 23982844
DA 2022-11-30
ER

PT J
AU Li, YB
   Xu, LA
   Jonas, JB
   Yang, H
   Ma, YN
   Li, JJ
AF Li, Yibin
   Xu, Liang
   Jonas, Jost B.
   Yang, Hua
   Ma, Yingnan
   Li, Jianjun
TI Prevalence of age-related maculopathy in the adult population in China:
   The Beijing eye study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VISUAL IMPAIRMENT PROJECT; BLUE MOUNTAINS EYE; MACULAR DEGENERATION;
   UNITED-STATES; LOW-VISION; BLINDNESS; URBAN; TAIWAN; SAMPLE; BALTIMORE
AB OBJECTIVE: To evaluate the prevalence of age-related maculopathy (ARM) in adult Chinese living in rural or urban regions of mainland China.
   DESIGN: Population-based prevalence study.
   METHODS: The study included 4439 subjects (aged 40 or more years) out of 5324 subjects invited to participate (response rate 83.4%). It was held in rural and urban regions of Greater Beijing. The participants underwent a detailed ophthalmic examination including fundus photography. All fundus photographs were graded by the Wisconsin Age,Related Maculopathy Grading System.
   RESULTS: Fundus photographs were available for 4376 (98.6%) subjects. Early ARM was present in 122 (1.4%) of 8655 (95% confidence interval [CI] 1.16% to 1.66%) eyes or 63 (1.4%) of 4376 (95% CI 1.09% to 1.79%) subjects, late ARM in 12 (0-14%) of 8655 (95% CI 0.06% to 0.22%) eyes or seven (0.2%) of 4376 (95% CI 0.04% to 0.28%) subjects, and exudative ARM as part of late ARM in seven (0.1%) of 8655 (95% CI 0.02% to 0.14%) eyes or six (0.1%) of 4376 (95% CI 0.03% to 0.25%) subjects. The prevalence of early ARM, late ARM, and exudative ARM, respectively, increased from 0.61%, 0.07%, and 0.07% in the 40-to-44-year age group, to 1.66%, 0.26%, and 0.26% in the 55,to 59-year group, and to 2.99%, 0.90%, and 0.60% in the group aged 75 years and older. ARM was causative for visual impairment (best-corrected visual acuity in the better eye, < 20/60 and >= 20/400) or blindness (visual acuity < 20/400) in one subject (0.023%).
   CONCLUSIONS: Visual impairment due to ARM was relatively uncommon in the adult Chinese population in rural and urban regions.
C1 Capital Univ Med Sci, Beijing Inst Ophthalmol, Tongren Eye Ctr, Beijing 100005, Peoples R China.
   Heidelberg Univ, Dept Ophthalmol, Fac Clin Med, D-6800 Mannheim, Germany.
C3 Capital Medical University; Ruprecht Karls University Heidelberg
RP Li, YB (通讯作者)，Capital Univ Med Sci, Beijing Inst Ophthalmol, Tongren Eye Ctr, 17 Hougou St, Beijing 100005, Peoples R China.
EM xuliang5918@yahoo.com.cn; Jost.Jonas@augen.ma.uni-heidelberg.de
CR Buch H, 2001, OPHTHALMOLOGY, V108, P2347, DOI 10.1016/S0161-6420(01)00823-5
   Cedrone C, 2003, OPHTHALMOLOGY, V110, P584, DOI 10.1016/S0161-6420(02)01898-5
   Chang TS, 1999, CAN J OPHTHALMOL, V34, P266
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Dineen BP, 2003, BRIT J OPHTHALMOL, V87, P820, DOI 10.1136/bjo.87.7.820
   Fotouhi A, 2004, BRIT J OPHTHALMOL, V88, P740, DOI 10.1136/bjo.2003.031153
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P1019, DOI 10.1001/archopht.122.7.1019
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Hyman L, 2001, OPHTHALMOLOGY, V108, P1751, DOI 10.1016/S0161-6420(01)00590-5
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P1126, DOI 10.1016/S0161-6420(13)30905-1
   Lim JI, 1998, RETINA-J RET VIT DIS, V18, P435
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Munoz B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1575, DOI 10.1001/archopht.123.11.1575
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   Rodriguez J, 2002, OPHTHALMOLOGY, V109, P737, DOI 10.1016/S0161-6420(01)01008-9
   Saw SM, 2004, OPHTHALMOLOGY, V111, P1161, DOI 10.1016/j.ophtha.2003.09.040
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   SIVAPRASAD S, IN PRESS EYE
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Thulasiraj RD, 2003, OPHTHALMOLOGY, V110, P1491, DOI 10.1016/S0161-6420(03)00565-7
   Tsai CY, 2005, JPN J OPHTHALMOL, V49, P166, DOI 10.1007/s10384-004-0164-x
   Tsai SY, 2003, OPHTHALMOLOGY, V110, P1089, DOI 10.1016/S0161-6420(03)00243-4
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Varma R, 2004, OPHTHALMOLOGY, V111, P1132, DOI 10.1016/j.ophtha.2004.02.002
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   WANG Y, IN PRESS AM J OPHTHA
   Xu L, 2006, AM J OPHTHALMOL, V141, P591, DOI 10.1016/j.ajo.2005.10.018
   Xu L, 2005, OPHTHALMOLOGY, V112, P1676, DOI 10.1016/j.ophtha.2005.05.015
   Xu L, 2005, BRIT J OPHTHALMOL, V89, P1089, DOI 10.1136/bjo.2005.068429
   Zou Hai-dong, 2005, Zhonghua Yan Ke Za Zhi, V41, P15
   Zou Haidong, 2002, Zhonghua Yan Ke Za Zhi, V38, P744
NR 42
TC 104
Z9 114
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD NOV
PY 2006
VL 142
IS 5
BP 788
EP 793
DI 10.1016/j.ajo.2006.06.001
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 107AK
UT WOS:000242142900011
PM 16989759
DA 2022-11-30
ER

PT J
AU Vemala, R
   Sivaprasad, S
   Barbur, JL
AF Vemala, Roopa
   Sivaprasad, Sobha
   Barbur, John L.
TI Detection of Early Loss of Color Vision in Age-Related Macular
   Degeneration - With Emphasis on Drusen and Reticular Pseudodrusen
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE reticular pseudodrusen; functional markers; soft drusen
AB PURPOSE. To evaluate chromatic sensitivity in patients with age-related macular degeneration (AMD) characterized by drusen and reticular pseudodrusen. To investigate whether the severity of color vision loss can distinguish between various stages of AMD and hence be used as an index of progression toward advanced AMD.
   METHODS. Chromatic sensitivity was measured by using the Color Assessment and Diagnosis (CAD) test in asymptomatic individuals with early and intermediate AMD and compared to normative data. All study participants had logMAR visual acuity of 0.3 or better. The CAD thresholds measured in eyes with and without reticular pseudodrusen were also compared and related to central macular thickness (CMT). Student's t-test P values < 0.05 were considered significant.
   RESULTS. All early-and intermediate-AMD eyes (n = 90) had chromatic sensitivity loss in either RG (red/green) or YB (yellow/blue), or both (P < 0.0001) as compared to age-matched normal subjects. The eyes exhibited a range of CAD thresholds affecting both color mechanisms, but YB color thresholds were in general higher than RG thresholds (P < 0.001). Intermediate-AMD patients exhibited large intersubject variability. In general, eyes with reticular pseudodrusen and eyes with CMT < 200 mu m had significantly higher CAD thresholds.
   CONCLUSIONS. The anatomic integrity of cone photoreceptors remains relatively unaffected in early and intermediate stages of AMD. The processing of cone signals in the retina can, however, be heavily disrupted with subsequent loss of both YB and RG chromatic sensitivity. The greatest losses were observed in eyes with reticular pseudodrusen.
C1 [Vemala, Roopa; Sivaprasad, Sobha] Kings Coll Hosp London, Denmark Hill, London, England.
   [Vemala, Roopa; Barbur, John L.] City Univ London, Sch Hlth Sci, Appl Vis Res Ctr, London, England.
   [Sivaprasad, Sobha] NIHR Moorfields Biomed Res Ctr, London, England.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital;
   City University London
RP Barbur, JL (通讯作者)，City Univ London, Opt & Visual Sci, London, England.
EM J.L.Barbur@city.ac.uk
RI Sivaprasad, S./D-6876-2015
OI Sivaprasad, S./0000-0001-8952-0659; Barbur, John/0000-0002-2187-5004
FU Kings College Hospital; National Institute for Health Research (NIHR)
   Biomedical Research Centre based at Moorfields Eye Hospital NHS
   Foundation Trust; UCL Institute of Ophthalmology; City, University of
   London
FX The authors thank City, University of London and Kings College Hospital
   for financial support with the doctoral studentship (to RV) and the
   equipment provided for this project.; Supported by the National
   Institute for Health Research (NIHR) Biomedical Research Centre based at
   Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of
   Ophthalmology. The views expressed are those of the author(s) and not
   necessarily those of the NHS, the NIHR, or the Department of Health.
CR Alten F, 2015, BRIT J OPHTHALMOL, V99, P717, DOI 10.1136/bjophthalmol-2014-305339
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Barbur JL, 2003, PROG BRAIN RES, V144, P243, DOI 10.1016/S0079-6123(03)14401-7
   BARBUR JL, 1994, P ROY SOC B-BIOL SCI, V258, P327, DOI 10.1098/rspb.1994.0181
   Barbur JL, 1997, DOC OPHTH P, V59, P439
   Barbur JL, 2017, BR MED B, V122, P1
   Barbur JL, 2015, HANDBOOK OF COLOR PSYCHOLOGY, P180
   Barbur JL, 2011, EXPERT REV OPHTHALMO, V6, P409, DOI 10.1586/EOP.11.32
   Barbur JL, 2012, J OPT SOC AM A, V29, pA27, DOI 10.1364/JOSAA.29.000A27
   BOYCOTT BB, 1991, EUR J NEUROSCI, V3, P1069, DOI 10.1111/j.1460-9568.1991.tb00043.x
   Chen JS, 2016, OSLI RETINA, V47, P708, DOI 10.3928/23258160-20160808-03
   CHYLACK LT, 1989, ARCH OPHTHALMOL-CHIC, V107, P991, DOI 10.1001/archopht.1989.01070020053028
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Harlow, 2006, CIE EXP S CIE P 75 Y
   Hering E., 1964, OUTLINES THEORY LIGH
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kolb Helga, 1991, P128
   Maynard ML, 2016, ACTA OPHTHALMOL, V94, pE772, DOI 10.1111/aos.13112
   Midena E, 2017, EYE, V31, P985, DOI 10.1038/eye.2017.34
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mrejen S, 2014, OPHTHALMOLOGY, V121, P545, DOI 10.1016/j.ophtha.2013.09.026
   Naysan J, 2016, RETINA-J RET VIT DIS, V36, P449, DOI 10.1097/IAE.0000000000000758
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   O'Neill-Biba M, 2010, OPHTHAL PHYSL OPT, V30, P705, DOI 10.1111/j.1475-1313.2010.00775.x
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Ratnam K, 2013, INVEST OPHTH VIS SCI, V54, P5836, DOI 10.1167/iovs.13-12557
   Rauscher FG, 2013, CELL TISSUE RES, V353, P297, DOI 10.1007/s00441-013-1675-x
   Rodriguez-Carmona M, 2006, OPHTHAL PHYSL OPT, V26, P137, DOI 10.1111/j.1475-1313.2006.00386.x
   Rodriguez-Carmona M, 2017, TEXT INST BOOK SER, P43, DOI 10.1016/B978-0-08-101270-3.00003-5
   Rodriguez-Carmona M, 2012, AVIAT SPACE ENVIR MD, V83, P19, DOI 10.3357/ASEM.3111.2012
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Sivaprasad S, 2016, SURV OPHTHALMOL, V61, P521, DOI 10.1016/j.survophthal.2016.02.005
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   VERRIEST G, 1963, J OPT SOC AM, V53, P185, DOI 10.1364/JOSA.53.000185
   Vujosevic S, 2017, GRAEF ARCH CLIN EXP, V255, P301, DOI 10.1007/s00417-016-3466-z
   Walkey HC, 2001, COLOR RES APPL, V26, pS36, DOI 10.1002/1520-6378(2001)26:1+<::AID-COL9>3.3.CO;2-J
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1445, DOI 10.1016/j.ophtha.2014.01.025
NR 51
TC 11
Z9 11
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2017
VL 58
IS 6
SI SI
BP 247
EP 254
DI 10.1167/iovs.17-21771
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA VI3AO
UT WOS:000468834100012
PM 28846119
OA Green Accepted, gold
DA 2022-11-30
ER

PT J
AU Beykin, G
   Grunin, M
   Averbukh, E
   Banin, E
   Hemo, Y
   Chowers, I
AF Beykin, Gala
   Grunin, Michelle
   Averbukh, Edward
   Banin, Eyal
   Hemo, Yitzchak
   Chowers, Itay
TI Bevacizumab treatment for neovascular age-related macular degeneration
   in the setting of a clinic: "real life" long-term outcome
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Neovascular age-related macular degeneration; Anti-vascular endothelial
   growth factor; Bevacizumab; Long-term
ID COMPLEMENT FACTOR-H; INTRAVITREAL BEVACIZUMAB; PHOTODYNAMIC THERAPY;
   RANIBIZUMAB; TACHYPHYLAXIS; ASSOCIATION; VARIANTS; PHARMACOGENETICS;
   POLYMORPHISM; PHENOTYPE
AB Background: To evaluate the long-term outcome of bevacizumab therapy for neovascular age related macular degeneration (NVAMD) in the setting of a clinic.
   Methods: Consecutive group of NVAMD patients who were treated in a single 3rd referral center with bevacizumab using a loading dosage of 3 monthly injections followed by variable dosing for at least 48 months were retrospectively evaluated. Genotyping was performed for CFH (rs1061170), HTRA1 (rs1200638), and C3 (rs2230199). Main outcome measures included functional and morphological treatment outcomes as well as their risk allele associations.
   Results: Out of 128 patients who started bevacizumab treatment over 4 years before the study endpoint [mean (+/- SD): 60 +/- 10.9 months], 75 eyes of 67 (52.3%) patients, were still followed. Mean best corrected visual acuity (BCVA) (LogMAR +/- SEM) improved from 0.66 +/- 0.07 at baseline to 0.48 +/- 0.05 (p = 0.012) at 1 year, but deteriorated from the 3rd year on and at the final exam reduced to 0.69 +/- 0.07 (p = 0.6, compared with initial BCVA). Macular thickness mirrored visual acuity (VA) changes showing initial thinning followed by thickening from the 3rd year on. Individuals carrying the CFH risk -allele had a mean thickening (microns +/- SEM) of 66.9 +/- 70.4 versus a mean thinning of 76.8 +/- 22 in non-carriers (p = 0.015).
   Conclusions: Bevacizumab therapy for NVAMD using a flexible treatment algorithm in a "real life" clinical setting initially obtained VA gain and thinning of the macula that were maintained for two years, but were lost later on.
C1 [Beykin, Gala; Grunin, Michelle; Averbukh, Edward; Banin, Eyal; Hemo, Yitzchak; Chowers, Itay] Hadassah Hebrew Univ Med Ctr, Dept Ophthalmol, IL-91120 Jerusalem, Israel.
C3 Hebrew University of Jerusalem
RP Chowers, I (通讯作者)，Hadassah Hebrew Univ Med Ctr, Dept Ophthalmol, IL-91120 Jerusalem, Israel.
EM chowers@hadassah.org.il
RI Grunin, Michelle/O-6044-2019
OI Grunin, Michelle/0000-0002-3155-2858
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Calabresi PA, 2007, NEUROLOGY, V69, P1391, DOI 10.1212/01.wnl.0000277457.17420.b5
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chowers I, 2008, MOL VIS, V14, P2263
   Chowers I, 2008, MOL VIS, V14, P1829
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Fox EJ, 2007, NEUROLOGIST, V13, P355, DOI 10.1097/NRL.0b013e318148c08e
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Grover S, 2010, INVEST OPHTH VIS SCI, V51, P2644, DOI 10.1167/iovs.09-4774
   Grover S, 2009, AM J OPHTHALMOL, V148, P266, DOI 10.1016/j.ajo.2009.03.006
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Imai Daisuke, 2010, J Ocul Biol Dis Infor, V3, P53, DOI 10.1007/s12177-010-9055-1
   Kanoff J, 2013, SEMIN OPHTHALMOL, V28, P355, DOI 10.3109/08820538.2013.825292
   Lotery AJ, 2013, OPHTHALMOLOGY, V120, P2637, DOI 10.1016/j.ophtha.2013.07.046
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Pushpoth S, 2012, BRIT J OPHTHALMOL, V96, P1469, DOI 10.1136/bjophthalmol-2012-302167
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Svenson M, 2007, RHEUMATOLOGY, V46, P1828, DOI 10.1093/rheumatology/kem261
   Tian J, 2012, PHARMACOGENOMICS, V13, P779, DOI [10.2217/PGS.12.53, 10.2217/pgs.12.53]
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zhao L, 2013, CURR MOL MED, V13, P929, DOI 10.2174/15665240113139990048
NR 35
TC 7
Z9 7
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD APR 11
PY 2015
VL 15
AR 39
DI 10.1186/s12886-015-0019-x
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CG2SF
UT WOS:000353124300001
PM 25881145
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Jun, GG
   Nicolaou, M
   Morrison, MA
   Buros, J
   Morgan, DJ
   Radeke, MJ
   Yonekawa, Y
   Tsironi, EE
   Kotoula, MG
   Zacharaki, F
   Mollema, N
   Yuan, Y
   Miller, JW
   Haider, NB
   Hageman, GS
   Kim, IK
   Schaumberg, DA
   Farrer, LA
   DeAngelis, MM
AF Jun, Gyungah
   Nicolaou, Michael
   Morrison, Margaux A.
   Buros, Jacqueline
   Morgan, Denise J.
   Radeke, Monte J.
   Yonekawa, Yoshihiro
   Tsironi, Evangelia E.
   Kotoula, Maria G.
   Zacharaki, Fani
   Mollema, Nissa
   Yuan, Yang
   Miller, Joan W.
   Haider, Neena B.
   Hageman, Gregory S.
   Kim, Ivana K.
   Schaumberg, Debra A.
   Farrer, Lindsay A.
   DeAngelis, Margaret M.
TI Influence of ROBO1 and RORA on Risk of Age-Related Macular Degeneration
   Reveals Genetically Distinct Phenotypes in Disease Pathophysiology
SO PLOS ONE
LA English
DT Article
ID COMPLEMENT FACTOR-H; GENE-EXPRESSION; AXON GUIDANCE; SMOKING; DRUSEN;
   ALPHA; SUSCEPTIBILITY; POLYMORPHISM; VARIANT; COMMON
AB ROBO1 is a strong candidate gene for age-related macular degeneration (AMD) based upon its location under a linkage peak on chromosome 3p12, its expression pattern, and its purported function in a pathway that includes RORA, a gene previously associated with risk for neovascular AMD. Previously, we observed that expression of ROBO1 and RORA is down-regulated among wet AMD cases, as compared to their unaffected siblings. Thus, we hypothesized that contribution of association signals in ROBO1, and interaction between these two genes may be important for both wet and dry AMD. We evaluated association of 19 single nucleotide polymorphisms (SNPs) in ROBO1 with wet and dry stages of AMD in a sibling cohort and a Greek case-control cohort containing 491 wet AMD cases, 174 dry AMD cases and 411 controls. Association signals and interaction results were replicated in an independent prospective cohort (1070 controls, 164 wet AMD cases, 293 dry AMD cases). The most significantly associated ROBO1 SNPs were rs1387665 under an additive model (meta P = 0.028) for wet AMD and rs9309833 under a recessive model (meta P = 6x10(-4)) for dry AMD. Further analyses revealed interaction between ROBO1 rs9309833 and RORA rs8034864 for both wet and dry AMD (interaction P<0.05). These studies were further supported by whole transcriptome expression profile studies from 66 human donor eyes and chromatin immunoprecipitation assays from mouse retinas. These findings suggest that distinct ROBO1 variants may influence the risk of wet and dry AMD, and the effects of ROBO1 on AMD risk may be modulated by RORA variants.
C1 [Jun, Gyungah; Nicolaou, Michael; Buros, Jacqueline; Farrer, Lindsay A.] Boston Univ, Sch Med, Boston, MA 02118 USA.
   [Morrison, Margaux A.; Yonekawa, Yoshihiro; Miller, Joan W.; Kim, Ivana K.; DeAngelis, Margaret M.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
   [Morrison, Margaux A.; Morgan, Denise J.; Hageman, Gregory S.; DeAngelis, Margaret M.] Univ Utah, Ctr Translat Med, John Moran Eye Ctr, Salt Lake City, UT USA.
   [Radeke, Monte J.] Univ Calif Santa Barbara, Neurosci Res Inst, Ctr Study Macular Degenerat, Santa Barbara, CA 93106 USA.
   [Yonekawa, Yoshihiro] Weill Cornell Med Coll, New York, NY USA.
   [Tsironi, Evangelia E.; Kotoula, Maria G.; Zacharaki, Fani] Univ Thessaly, Larisa, Greece.
   [Mollema, Nissa; Yuan, Yang; Haider, Neena B.] Univ Nebraska Med Ctr, Omaha, NE USA.
   [Schaumberg, Debra A.] Brigham & Womens Hosp, Harvard Med Sch, Div Prevent Med, Boston, MA 02115 USA.
   [Jun, Gyungah; Nicolaou, Michael; Buros, Jacqueline; Schaumberg, Debra A.; Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Boston, MA 02118 USA.
C3 Boston University; Harvard University; Massachusetts Eye & Ear
   Infirmary; Utah System of Higher Education; University of Utah;
   University of California System; University of California Santa Barbara;
   Cornell University; University of Thessaly; University of Nebraska
   System; University of Nebraska Medical Center; Harvard University;
   Brigham & Women's Hospital; Harvard Medical School; Boston University
RP Jun, GG (通讯作者)，Boston Univ, Sch Med, Boston, MA 02118 USA.
EM Margaret.DeAngelis@utah.edu
RI Farrer, Lindsay/AAS-1035-2020; Kotoula, Maria/Y-6539-2019; DeAngelis,
   e/J-7863-2015; Nicolaou, Michael/AAU-1054-2021
OI Farrer, Lindsay/0000-0001-5533-4225; Buros,
   Jacqueline/0000-0001-9588-4889; Jun, Gyungah/0000-0002-3230-8697; Kim,
   Ivana/0000-0003-0310-6129
FU Thome Memorial Foundation; Bank of America N.A.; Lincy Foundation;
   Massachusetts Lions; Friends of the Massachusetts Eye and Ear Infirmary;
   Genetics of Age-related Macular Degeneration Fund; Research to Prevent
   Blindness; Hope for Vision; National Institutes of Health [EY014458,
   EY14104, EY017362, EY017404]; Massachusetts Eye and Ear Infirmary;
   NATIONAL EYE INSTITUTE [R24EY017404, P30EY014800, R01EY017362,
   R01EY014458, P30EY014104] Funding Source: NIH RePORTER
FX This work was supported by grants from the Thome Memorial Foundation;
   Bank of America N.A.; Lincy Foundation; the Massachusetts Lions; Friends
   of the Massachusetts Eye and Ear Infirmary; the Massachusetts Eye and
   Ear Infirmary; Genetics of Age-related Macular Degeneration Fund;
   Unrestricted Grant from Research to Prevent Blindness to the Department
   of Ophthalmology and Visual Sciences, University of Utah; Hope for
   Vision; and the National Institutes of Health (EY014458, EY14104,
   EY017362, EY017404). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anitha A, 2008, AM J MED GENET B, V147B, P1019, DOI 10.1002/ajmg.b.30697
   Bates TC, 2011, BEHAV GENET, V41, P50, DOI 10.1007/s10519-010-9402-9
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen HY, 2010, ADV EXP MED BIOL, V664, P457, DOI 10.1007/978-1-4419-1399-9_52
   Chen MH, 2010, BIOINFORMATICS, V26, P580, DOI 10.1093/bioinformatics/btp710
   CHEN W, 2010, P NATL ACAD SCI US
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dudbridge F, 2003, GENET EPIDEMIOL, V25, P115, DOI 10.1002/gepi.10252
   Dudbridge F, 2008, HUM HERED, V66, P87, DOI 10.1159/000119108
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Erskine L, 2000, J NEUROSCI, V20, P4975
   Fujieda H, 2009, J NEUROCHEM, V108, P91, DOI 10.1111/j.1471-4159.2008.05739.x
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haider NB, 2009, EXP EYE RES, V89, P365, DOI 10.1016/j.exer.2009.04.006
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamdi HK, 2003, FRONT BIOSCI-LANDMRK, V8, pE305, DOI 10.2741/1019
   Hamilton BA, 1996, NATURE, V379, P736, DOI 10.1038/379736a0
   Huang LZ, 2010, INVEST OPHTH VIS SCI, V51, P3193, DOI 10.1167/iovs.09-3779
   Huang LZ, 2009, CURR EYE RES, V34, P1019, DOI 10.3109/02713680903308495
   Huang LZ, 2009, EXP EYE RES, V88, P583, DOI 10.1016/j.exer.2008.11.016
   Ip BK, 2010, J ANAT, V217, P300, DOI 10.1111/j.1469-7580.2010.01259.x
   Jetten Anton M, 2009, Nucl Recept Signal, V7, pe003, DOI 10.1621/nrs.07003
   Jun G, 2005, INVEST OPHTH VIS SCI, V46, P3081, DOI 10.1167/iovs.04-1360
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Liu AH, 2010, J LIPID RES, V51, P3217, DOI 10.1194/jlr.M007518
   Melen E, 2010, J ALLERGY CLIN IMMUN, V126, P631, DOI 10.1016/j.jaci.2010.06.030
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nguyen A, 2010, FASEB J, V24, P3036, DOI 10.1096/fj.10-154484
   Plachez C, 2008, MOL CELL NEUROSCI, V37, P719, DOI 10.1016/j.mcn.2007.12.017
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   Schaumberg DA, 2010, ARCH OPHTHALMOL-CHIC, V128, P1462, DOI 10.1001/archophthalmol.2010.261
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Silveira AC, 2010, VISION RES, V50, P698, DOI 10.1016/j.visres.2009.09.016
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Wang YJ, 2010, J BIOL CHEM, V285, P15668, DOI 10.1074/jbc.M110.102160
   Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
NR 49
TC 23
Z9 23
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 6
PY 2011
VL 6
IS 10
AR e25775
DI 10.1371/journal.pone.0025775
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 834NO
UT WOS:000295968700018
PM 21998696
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Singh, R
   Chauhan, R
   Saxena, A
   Shah, A
   Mondal, L
   Bakhle, D
   Shah, C
   Shah, A
   Deoghare, S
   Krishnan, N
   Godse, N
AF Singh, Ramandeep
   Chauhan, Rohan
   Saxena, Ashish
   Shah, Anup
   Mondal, Laxshmi
   Bakhle, Dhananjay
   Shah, Chirag
   Shah, Arpit
   Deoghare, Shashank
   Krishnan, Neelakant
   Godse, Neelima
TI A prospective, randomized, parallel group, double blind, multicenter
   study to compare the efficacy, safety and immunogenicity of Lupin's
   Ranibizumab with Lucentis (R) in patients with neovascular age-related
   macular degeneration
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Biosimilar; immunogenicity; Lucentis (R); neovascular age-related
   macular degeneration (n-AMD); ranibizumab
ID BIOSIMILARS; BEVACIZUMAB
AB Purpose: The present study compares the efficacy, safety, and immunogenicity of Lupin's biosimilar ranibizumab with that of Lucentis (R) in patients with neovascular age-related macular degeneration. Methods: This prospective, double-blind, multi-centric phase-III study was conducted across 19 centers in India. A total of 202 patients with neovascular age-related macular degeneration were randomized (1:1) to receive either Lupin's biosimilar ranibizumab or Lucentis (R), 0.5 mg, as an intravitreous injection once every month for 3 months. The primary efficacy endpoint was the proportion of patients who lost fewer than 15 letters from baseline in best-corrected visual acuity. The safety profile included assessment of adverse events, ophthalmic examination, physical and systemic examination, and vital parameters. The immunogenicity assessment was based on evaluation of anti-drug antibodies. Results: Overall, 174 patients (87 [86.14%] in each group) completed the study. The demographics and baseline characteristics were comparable between the treatment groups. The proportion of patients losing fewer than 15 letters from baseline best corrected visual acuity score in the study eye was comparable between two groups. The difference between Lupin's ranibizumab and Lucentis (R) for the proportion of patients who lost fewer than 15 letters was within the predefined equivalence margin (intention-to-treat population: 1.0%; 95% confidence interval [CI], -3.3% to 5.4% and per protocol population: 1.2%; 95% CI, -3.2% to 6.4%). The incidence of treatment-emergent adverse events was comparable, and 11 (10.89%) patients in Lupin's ranibizumab and 19 (18.81%) patients in Lucentis (R) group had at least one treatment-emergent adverse event. The immunogenicity incidence as assessed by proportion of patients with positive anti-drug antibodies was numerically lower in Lupin's ranibizumab (4.95%) than Lucentis (R) (12.87%). Conclusion: Lupin's biosimilar ranibizumab demonstrated therapeutic equivalence, desirable safety, and favorable immunogenicity profile compared to Lucentis (R).
C1 [Singh, Ramandeep] Postgrad Inst Med Educ & Res PGIMER, Dept Ophthalmol, Chandigarh, India.
   [Chauhan, Rohan] Rising Retina Clin, Vitreo Retinal Surg Dept Ophthalmol, Ahmadabad, Gujarat, India.
   [Saxena, Ashish] Kanoria Hosp & Res Ctr, Dept Ophthalmol, Gandhinagar, Gujarat, India.
   [Shah, Anup] Dhadiwal Hosp, Dept Ophthalmol, Nasik, Maharashtra, India.
   [Mondal, Laxshmi] Reg Inst Opthalmol, Dept Ophthalmol, Kolkata, India.
   [Bakhle, Dhananjay; Shah, Chirag; Shah, Arpit; Deoghare, Shashank; Krishnan, Neelakant; Godse, Neelima] Lupin Ltd, Med Res Dept, Pune, Maharashtra, India.
C3 Post Graduate Institute of Medical Education & Research (PGIMER),
   Chandigarh
RP Shah, C (通讯作者)，Lupin Ltd, Lupin Res Pk,Survey 46 A-47 A, Pune 411042, Maharashtra, India.
EM chiragshah@lupin.com
CR Amoaku WM, 2015, EYE, V29, P1397, DOI 10.1038/eye.2015.159
   [Anonymous], BLINDNESS VISION IMP
   [Anonymous], 2007, EMEA SCI DISCUSSION
   Bressler NM, 2021, JAMA OPHTHALMOL, V139, P678, DOI 10.1001/jamaophthalmol.2021.1043
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   European Medicines Agency (EMA), 2015, GUID IMM ASS BIOT DE
   Kim JS, 2015, EXPERT REV CLIN IMMU, V11, pS33, DOI 10.1586/1744666X.2015.1090312
   Kirchhoff CF, 2017, BIOTECHNOL BIOENG, V114, P2696, DOI 10.1002/bit.26438
   Phadikar Prateep, 2017, Int J Retina Vitreous, V3, P1, DOI 10.1186/s40942-016-0054-7
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Rathore Anurag, 2012, PDA J Pharm Sci Technol, V66, P393, DOI 10.5731/pdajpst.2012.00886
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schiestl M, 2017, DRUG DES DEV THER, V11, P1509, DOI 10.2147/DDDT.S130318
   Sharma A, 2021, EYE, V35, P1292, DOI 10.1038/s41433-020-01227-w
   Sharma A, 2019, INDIAN J OPHTHALMOL, V67, P1384, DOI 10.4103/ijo.IJO_430_19
   Spitzer MS, 2008, CLIN OPHTHALMOL, V2, P1
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   Tan CS, 2017, CHOROIDAL DISORDERS, P89, DOI 10.1016/B978-0-12-805313-3.00007-7
   Triplitt Curtis, 2017, Clin Diabetes, V35, P209, DOI 10.2337/cd16-0072
   US Food and Drug Administration, DRUGS FDA FDA APPROV
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 22
TC 2
Z9 2
U1 3
U2 3
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD AUG
PY 2022
VL 70
IS 8
BP 3008
EP 3014
DI 10.4103/ijo.IJO_2118_21
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4D6HV
UT WOS:000847240800049
PM 35918962
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Naseripour, M
   Falavarjani, KG
   Oladi, MR
   Modarres, M
AF Naseripour, Masood
   Falavarjani, Khalil Ghasemi
   Oladi, Mohammad Reza
   Modarres, Mehdi
TI Testing Toxicity of Intravitreal Bevacizumab (Avastin) used for the
   Treatment of Choroidal Neovascularization Associated with Age-Related
   Macular Degeneration: A Full Field ERG Study
SO IRANIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Bevacizumab; Age-related Macular Degeneration; Choroidal
   Neovascularization; Electroretinography
ID RETINA STUDY-GROUP; RABBIT EYES; FOLLOW-UP; INJECTION; SAFETY; EDEMA;
   RANIBIZUMAB; SECONDARY
AB Purpose: To evaluate the toxic retinal effects of intravitreal bevacizumab used for the treatment of exudative age-related macular degeneration (AMD) using Ganzfeld Electroretinography (G-ERG)
   Methods: In this prospective comparative interventional study, 23 patients with active choroidal neovascularization (CNV) associated with AMD were enrolled. Patients were received intravitreal injections of either 2.5 (12 patients) or 1.25 mg (11 patients) of intravitreal bevacizumab. Patients underwent complete ophthalmic examination including visual acuity testing, and G-ERG, at baseline, at one week, at one month, and at three months after intravitreal bevacizumab.
   Results: Best corrected visual acuity (BCVA) significantly increased from 1.34 +/- 0.59 (logMAR) in preinjection examination to 1.07 +/- 0.47 (logMAR) at one month (P=0.01), and 1.03 +/- 0.46 (logMAR) at three months (P=0.001). G-ERG did not show any significant change in the waveform parameters following intravitreal injection of bevacizumab. No significant difference was found between the two groups in the amount of change in visual acuity and G-ERG recordings of postinjection measurements.
   Conclusion: Intravitreal bevacizumab did not appear toxic to the retina based on G-ERG recordings.
C1 [Naseripour, Masood; Falavarjani, Khalil Ghasemi; Oladi, Mohammad Reza; Modarres, Mehdi] Iran Univ Med Sci, Eye Res Ctr, Rassoul Akram Hosp, Tehran, Iran.
C3 Iran University of Medical Sciences
RP Falavarjani, KG (通讯作者)，Iran Univ Med Sci, Eye Res Ctr, Rassoul Akram Hosp, Tehran, Iran.
EM drghasemi@yahoo.com
RI Falavarjani, Khalil Ghasemi/I-4029-2019; Naseripour, Masood/A-6998-2018;
   Naseripour, Masood/P-8976-2018
OI Naseripour, Masood/0000-0003-1217-3470; Ghasemi Falavarjani,
   Khalil/0000-0001-5221-1844
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Arevalo JF, 2007, OPHTHALMOLOGY, V114, P743, DOI 10.1016/j.ophtha.2006.12.028
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Feiner L, 2006, RETINA-J RET VIT DIS, V26, P882, DOI 10.1097/01.iae.0000230717.85319.f5
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Inan UU, 2007, INVEST OPHTH VIS SCI, V48, P1773, DOI 10.1167/iovs.06-0828
   Luke M, 2006, BRIT J OPHTHALMOL, V90, P1178, DOI 10.1136/bjo.2006.094995
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Marmor MF, 2004, DOC OPHTHALMOL, V108, P107, DOI 10.1023/B:DOOP.0000036793.44912.45
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Michels S, 2006, BRIT J OPHTHALMOL, V90, P1333, DOI 10.1136/bjo.2006.102293
   Moschos MM, 2007, DOC OPHTHALMOL, V114, P37, DOI 10.1007/s10633-006-9036-7
   RICH AM, 2006, RETINA, V26, P495
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Shetty R, 2008, DOC OPHTHALMOL, V116, P129, DOI 10.1007/s10633-007-9090-9
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Walter P, 1999, GRAEF ARCH CLIN EXP, V237, P962, DOI 10.1007/s004170050331
   Wu LT, 2008, RETINA-J RET VIT DIS, V28, P212, DOI 10.1097/IAE.0b013e3181619bee
   Ziemssen Focke, 2008, International Ophthalmology, V28, P101, DOI 10.1007/s10792-007-9122-1
NR 25
TC 0
Z9 0
U1 0
U2 1
PU IRANIAN SOC OPHTHALMOLOGY
PI TEHRAN
PA NORTH KARGAR AVE, 2ND FLR, NO 4, HOMA ALLEY, TEHRAN, 1418654743, IRAN
SN 1735-4153
J9 IRAN J OPHTHALMOL
JI Iran. J. Ophthalmol.
PY 2009
VL 21
IS 3
BP 49
EP 55
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 581JH
UT WOS:000276518100010
DA 2022-11-30
ER

PT J
AU Jackson, TL
   Bunce, C
   Desai, R
   Hillenkamp, J
   Lee, CN
   Lois, N
   Peto, T
   Reeves, BC
   Steel, DH
   Edwards, RT
   van Meurs, JC
   Wafa, H
   Wang, YZ
AF Jackson, Timothy L.
   Bunce, Catey
   Desai, Riti
   Hillenkamp, Jost
   Lee, Chan Ning
   Lois, Noemi
   Peto, Tunde
   Reeves, Barnaby C.
   Steel, David H.
   Edwards, Rhiannon T.
   van Meurs, Jan C.
   Wafa, Hatem
   Wang, Yanzhong
TI Vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas
   for submacular haemorrhage secondary to Exudative Age-Related macular
   degeneration (TIGER): study protocol for a phase 3, pan-European,
   two-group, non-commercial, active-control, observer-masked, superiority,
   randomised controlled surgical trial
SO TRIALS
LA English
DT Article
DE Neovascular age-related macular degeneration; Submacular haemorrhage;
   Alteplase; Tissue plasminogen activator; Pars plana vitrectomy; Gas
   tamponade; Surgery; Randomised controlled trial; Aflibercept;
   Anti-vascular endothelial growth factor (anti-VEGF); Economic analysis;
   Cost-effectiveness; Quality-adjusted life year (QALY)
ID EPIMACULAR BRACHYTHERAPY; RANIBIZUMAB; AFLIBERCEPT; EYE
AB Background: Neovascular (wet) age-related macular degeneration (AMD) can be associated with large submacular haemorrhage (SMH). The natural history of SMH is very poor, with typically marked and permanent loss of central vision in the affected eye. Practice surveys indicate varied management approaches including observation, intravitreal anti-vascular endothelial growth factor therapy, intravitreal gas to pneumatically displace SMH, intravitreal alteplase (tissue plasminogen activator, TPA) to dissolve the clot, subretinal TPA via vitrectomy, and varying combinations thereof. No large, published, randomised controlled trials have compared these management options.
   Methods: TIGER is a phase 3, pan-European, two-group, active-control, observer-masked, superiority, randomised controlled surgical trial. Eligible participants have large, fovea-involving SMH of no more than 15 days duration due to treatment-naive or previously treated neovascular AMD, including idiopathic polypoidal choroidal vasculopathy and retinal angiomatous proliferation. A total of 210 participants are randomised in a 1:1 ratio to pars plana vitrectomy, offlabel subretinal TPA up to 25 mu g in 0.25 ml, intravitreal 20% sulfahexafluoride gas and intravitreal aflibercept, or intravitreal aflibercept monotherapy. Aflibercept 2 mg is administered to both groups monthly for 3 doses, then 2monthly to month 12. The primary efficacy outcome is the proportion of participants with best-corrected visual acuity (BCVA) gain of >= 10 Early Treatment Diabetic Retinopathy (ETDRS) letters in the study eye at month 12. Secondary efficacy outcomes (at 6 and 12 months unless noted otherwise) are proportion of participants with a BCVA gain of >= 10 ETDRS letters at 6 months, mean ETDRS BCVA, Radner maximum reading speed, National Eye Institute 25-item Visual Function Questionnaire composite score, EQ-5D-5L with vision bolt-on score, Short Warwick and Edinburgh Mental Wellbeing score, scotoma size on Humphrey field analyser, and presence/absence of subfoveal fibrosis and/or atrophy and area of fibrosis/atrophy using independent reading centre multimodal image analysis (12 months only). Key safety outcomes are adverse events, serious adverse events, and important medical events, coded using the Medical Dictionary for Regulatory Activities Preferred Terms.
   Discussion: The best management of SMH is unknown. TIGER aims to establish if the benefits of SMH surgery outweigh the risks, relative to aflibercept monotherapy.
C1 [Jackson, Timothy L.] Kings Coll London, Fac Life Sci & Med, London, England.
   [Bunce, Catey] Royal Marsden NHS Fdn Trust, London, England.
   [Bunce, Catey] Royal Marsden NHS Fdn Trust, Surrey, England.
   [Desai, Riti; Lee, Chan Ning] Kings Coll Hosp NHS Fdn Trust, Dept Ophthalmol, London, England.
   [Hillenkamp, Jost] Univ Wurzburg, Dept Ophthalmol, Wurzburg, Germany.
   [Lois, Noemi] Queens Univ, Wellcome Wolfson Inst Expt Med, Belfast, Antrim, North Ireland.
   [Peto, Tunde] Queens Univ Belfast, Network Ophthalm Reading Ctr UK, Belfast, Antrim, North Ireland.
   [Reeves, Barnaby C.] Univ Bristol, Bristol, Avon, England.
   [Steel, David H.] Newcastle Univ, Biosci Inst, Newcastle Upon Tyne, Tyne & Wear, England.
   [Edwards, Rhiannon T.] Bangor Univ, Ctr Hlth Econ & Med Evaluat, Bangor, Gwynedd, Wales.
   [van Meurs, Jan C.] Rotterdam Eye Hosp, Rotterdam, Netherlands.
   [van Meurs, Jan C.] Erasmus MC, Rotterdam, Netherlands.
   [Wafa, Hatem; Wang, Yanzhong] Kings Coll London, Fac Life Sci & Med, Populat Hlth Sci, London, England.
C3 University of London; King's College London; Royal Marsden NHS
   Foundation Trust; Royal Marsden NHS Foundation Trust; King's College
   Hospital NHS Foundation Trust; University of Wurzburg; Queens University
   Belfast; Queens University Belfast; University of Bristol; Newcastle
   University - UK; Bangor University; Rotterdam Eye Hospital; Erasmus
   University Rotterdam; Erasmus MC; University of London; King's College
   London
RP Jackson, TL (通讯作者)，Kings Coll London, Fac Life Sci & Med, London, England.
EM t.jackson1@nhs.net
RI Wang, Yanzhong/GRY-3114-2022
OI Wafa, Hatem/0000-0002-9951-0435; Jackson, Timothy/0000-0001-7618-1555;
   Desai, Riti/0000-0001-6425-0648; Wang, Yanzhong/0000-0002-0768-1676
FU Fight for Sight; EURETINA; National Institute for Health Research
   through its Clinical Research Network
FX EURETINA sought to facilitate a study of vitrectomy, TPA and gas for
   submacular haemorrhage secondary to wet AMD. It commissioned Fight for
   Sight to establish a pan-European competition seeking bids to run the
   study, and to administer the award. King's College London was awarded
   the research grant from Fight for Sight. To help facilitate set-up prior
   to the main grant commencing, EURETINA provided King's College London a
   smaller start-up research grant. Different prospective sites were known
   to use different intravitreal drugs to treat wet AMD, and therefore
   Bayer was approached and agreed to provide and distribute free
   aflibercept to sites that required it, to standardise background
   treatment. In the UK, sites are additionally supported by the National
   Institute for Health Research through its Clinical Research Network. A
   copy of the funding letter of support is included in Appendix 10.
CR Al-Hity A, 2018, EYE
   BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   Bokinni Y, 2015, EYE, V29, P1085, DOI 10.1038/eye.2015.94
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Carpenter J, 2007, MISSING DATA RANDOMI, V1, P199
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Commission E, RARE DIS
   De Jong JH, 2016, RETINA-J RET VIT DIS, V36, P914, DOI 10.1097/IAE.0000000000000954
   Dugel PU, 2013, OPHTHALMOLOGY, V120, P317, DOI 10.1016/j.ophtha.2012.07.068
   Gonzalez-Lopez JJ, 2016, EYE, V30, P929, DOI 10.1038/eye.2016.65
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jackson TL, 2016, OPHTHALMOLOGY, V123, P1287, DOI 10.1016/j.ophtha.2016.02.028
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1893, DOI 10.1016/j.ophtha.2013.02.016
   Klettner A, 2015, BRIT J OPHTHALMOL, V99, P864, DOI 10.1136/bjophthalmol-2014-306454
   Kunavisarut P, 2018, ASIA-PAC J OPHTHALMO, V7, P109, DOI 10.22608/APO.2017389
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   McGowan GF, 2014, INVEST OPHTH VIS SCI, V55
   Mosely JEMA, 2011, VISUAL FUNCTION ENDP
   National Institute for Health and Care Excellence (NICE), 2008, RAN PEG TREATM AG RE
   Neffendorf JE, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1676-7
   NICE, 2013, TA294 MAC DEG WET AG
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   Quartilho A, 2016, EYE, V30, P602, DOI 10.1038/eye.2015.288
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Stanescu-Segall D, 2016, SURV OPHTHALMOL, V61, P18, DOI 10.1016/j.survophthal.2015.04.004
   Stifter E, 2004, GRAEF ARCH CLIN EXP, V242, P31, DOI 10.1007/s00417-003-0776-8
   Treweek S, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000013.pub6
   Whitham D, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2940-9
NR 28
TC 3
Z9 3
U1 1
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JAN 31
PY 2022
VL 23
IS 1
AR 99
DI 10.1186/s13063-021-05966-3
PG 23
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA YS2LQ
UT WOS:000750514500010
PM 35101110
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hirakawa, M
   Tanaka, M
   Tanaka, Y
   Okubo, A
   Koriyama, C
   Tsuji, M
   Akiba, S
   Miyamoto, K
   Hillebrand, G
   Yamashita, T
   Sakamoto, T
AF Hirakawa, M.
   Tanaka, M.
   Tanaka, Y.
   Okubo, A.
   Koriyama, C.
   Tsuji, M.
   Akiba, S.
   Miyamoto, K.
   Hillebrand, G.
   Yamashita, T.
   Sakamoto, T.
TI Age-related maculopathy and sunlight exposure evaluated by objective
   measurement
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BEAVER DAM EYE; SKIN SUN SENSITIVITY; MACULAR DEGENERATION;
   RISK-FACTORS; IRIS COLOR; 10-YEAR INCIDENCE; LIGHT; SMOKING; SYSTEM
AB Aim: To study the relationship between age-related maculopathy (ARM) and exposure to sunlight using an objective method.
   Methods: In a case-control study of Japanese men aged >= 50 years (67 controls without ophthalmic disease and 148 with ARM), those with ARM were separated into groups of early (n = 75) and late (n = 73) ARM. Facial wrinkle length and area of hyperpigmentation, which are considered to be associated with exposure to sun, were measured using imaging with computer-based image analysis. Skin tone was also measured on the upper inner arm, which is not exposed to sun. Early and late ARM association with skin measurements was then evaluated.
   Results: Significantly more facial wrinkling (p = 0.047, odds ratio 3.8; 95% CI 1.01 to 13.97) and less facial hyperpigmentation (p = 0.035, odds ratio 0.3; 95% CI 0.08 to 0.92) was present in late ARM cases. The relationship between skin tone and ARM risk was not statistically significant.
   Conclusions: This objective method showed that lifetime exposure to sunlight is an important factor in the progression of late ARM. An individual's reaction to sunlight exposure may have a role in ARM progression in addition to total lifetime exposure to sunlight.
C1 [Hirakawa, M.; Tanaka, M.; Tanaka, Y.; Okubo, A.; Yamashita, T.; Sakamoto, T.] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Ophthalmol, Kagoshima 8908520, Japan.
   [Koriyama, C.; Tsuji, M.; Akiba, S.] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Epidemiol & Prevent Med, Kagoshima 8908520, Japan.
   [Miyamoto, K.; Hillebrand, G.] Procter & Gamble Co, Kobe, Hyogo, Japan.
C3 Kagoshima University; Kagoshima University; Procter & Gamble
RP Sakamoto, T (通讯作者)，Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Ophthalmol, 8-35-1, Kagoshima 8908520, Japan.
EM tsakamot@m3.kufm.kagoshima-u.ac.jp
RI Hillebrand, Greg/AAD-6384-2019
OI Akiba, Suminori/0000-0001-9004-3167
CR Agar N, 2005, MUTAT RES-FUND MOL M, V571, P121, DOI 10.1016/j.mrfmmm.2004.11.016
   Akiba S, 1999, J Epidemiol, V9, pS136
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   Delcourt C, 2001, ARCH OPHTHALMOL-CHIC, V119, P1463
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Fisher GJ, 1997, NEW ENGL J MED, V337, P1419, DOI 10.1056/NEJM199711133372003
   FITZPATRICK TB, 1988, ARCH DERMATOL, V124, P869, DOI 10.1001/archderm.124.6.869
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Hillebrand GG, 2001, J DERMATOL SCI, V27, pS42
   HILLEBRAND GG, 2006, ETHNIC SKIN HAIR, P105
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Kokkinou D, 2005, GRAEF ARCH CLIN EXP, V243, P1050, DOI 10.1007/s00417-005-1197-7
   Meyers S M, 1994, Trans Am Ophthalmol Soc, V92, P775
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   Miyamoto K, 2002, J COSMET SCI, V53, P62
   Nilsson SEG, 2003, DOC OPHTHALMOL, V106, P13, DOI 10.1023/A:1022419606629
   PRIGNOT J, 1987, EUR J RESPIR DIS, V70, P1
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Tomany SC, 2003, OPHTHALMOLOGY, V110, P1526, DOI 10.1016/S0161-6420(03)00539-6
   WARREN R, 1991, J AM ACAD DERMATOL, V25, P751, DOI 10.1016/S0190-9622(08)80964-4
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 29
TC 33
Z9 33
U1 0
U2 11
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2008
VL 92
IS 5
BP 630
EP 634
DI 10.1136/bjo.2007.130575
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 293MC
UT WOS:000255338400011
PM 18441173
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Vojnikovic, B
   Micovic, V
   Coklo, M
   Vojnikovic, D
AF Vojnikovic, Bozidar
   Micovic, Vladimir
   Coklo, Miran
   Vojnikovic, Davor
TI Sun Exposure and Visual Field Damage among Children on the Adriatic
   Island Rab - Possible Initial Risk Factor in Development of Age-Related
   Macular Degeneration
SO COLLEGIUM ANTROPOLOGICUM
LA English
DT Article
DE age-related macular degeneration; children; sun exposure; visual field
   damage
ID RADIATION
AB The Adriatic Island Rab, situated in the northern part of the Croatian sea, is more strongly exposed to sunlight (especially from May to October) than the other parts of Croatia and most of the European countries. As consequences of higher solar radiation, significant percentage of Pseudoexfoliation of lens capsula occurs in 15% and fundus picture of AMD (Age-Related Macular Degeneration) in 18% of agriculturalists and fishermen (45-70 years old). We previously presented the first clinical study showing that in AMD the peripheral visual field is also damaged. In this clinical study we examined 68 children (8-15 years old), including following procedures: vision correction, slit lamp examination, visual field in technic of isopters and profile quantitative perimetry (meridian retinal thresholds examination) using Kowa automated perimeter. In 15% of examinees we found strictly foveal "degeneration", and changes of visual fields: higher meridian thresholds and typical changes with invagination of isopters. It is very interesting that these children with damaged visual field and fundus picture do not protect their eyes from the sunlight during summertime. We suggest the possibility of the influence of higher sun radiation as one of the risk factors in the earlier development of future AMD.
C1 [Vojnikovic, Bozidar] Croatian Assoc Protect Non Ionizing Radiat Albert, Rijeka, Croatia.
   [Micovic, Vladimir] Univ Hosp Rijeka, Sch Med, Dept Publ Hlth, Rijeka, Croatia.
   [Coklo, Miran] Univ Rijeka, Sch Med, Dept Forens Med, Rijeka, Croatia.
   [Vojnikovic, Davor] Opt Studio Albert Einstein, Rijeka, Croatia.
C3 University of Rijeka; University of Rijeka
RP Vojnikovic, B (通讯作者)，Eye Polyclin Dr B Vojnikovic, Antuna Barca 3B, Rijeka 51000, Croatia.
EM decv@decv.com
RI Mićović, Vladimir/R-4240-2018
OI Mićović, Vladimir/0000-0002-0973-4823
CR Heck DE, 2004, TOXICOL APPL PHARM, V195, P288, DOI 10.1016/j.taap.2003.09.028
   RODNEY B, 2005, CONCEPTS BIOCH
   VOJNIKOVIC B, 2005, EINSTEINOV ZAKON ELE
   Vojnikovic B, 2007, COLLEGIUM ANTROPOL, V31, P43
NR 4
TC 13
Z9 13
U1 0
U2 8
PU COLLEGIUM ANTROPOLOGICUM
PI ZAGREB
PA INST ANTHROPOLOGICAL RESEARCH, GAJEVA 32, PO BOX 290, HR-10000 ZAGREB,
   CROATIA
SN 0350-6134
J9 COLLEGIUM ANTROPOL
JI Coll. Anthropol.
PD SEP
PY 2009
VL 33
IS 3
BP 747
EP 749
PG 3
WC Anthropology
WE Social Science Citation Index (SSCI)
SC Anthropology
GA 510IP
UT WOS:000271082000007
PM 19860099
DA 2022-11-30
ER

PT J
AU Millen, AE
   Meyers, KJ
   Liu, Z
   Engelman, CD
   Wallace, RB
   LeBlanc, ES
   Tinker, LF
   Iyengar, SK
   Robinson, JG
   Sarto, GE
   Mares, JA
AF Millen, Amy E.
   Meyers, Kristin J.
   Liu, Zhe
   Engelman, Corinne D.
   Wallace, Robert B.
   LeBlanc, Erin S.
   Tinker, Lesley F.
   Iyengar, Sudha K.
   Robinson, Jennifer G.
   Sarto, Gloria E.
   Mares, Julie A.
TI Association Between Vitamin D Status and Age-Related Macular
   Degeneration by Genetic Risk
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID LONG-TERM INCIDENCE; C-REACTIVE PROTEIN; 1,25-DIHYDROXYVITAMIN D-3; EYE
   DISEASE; DIETARY ANTIOXIDANTS; INFLAMMATORY MARKERS; COMPLEMENT CONTROL;
   FISH CONSUMPTION; FAT INTAKE; FACTOR-I
AB IMPORTANCE Deficient 25-hydroxyvitamin D (25[OH] D) concentrations have been associated with increased odds of age-related macular degeneration (AMD).
   OBJECTIVE To examine whether this association is modified by genetic risk for AMD and whether there is an association between AMD and single-nucleotide polymorphisms of genes involved in vitamin D transport, metabolism, and genomic function.
   DESIGN, SETTING, AND PARTICIPANTS Postmenopausal women (N = 913) who were participants of the Carotenoids in Age-Related Eye Disease Study (CAREDS) (aged 54 to <75 years) with available serum 25(OH) D concentrations (assessed October 1, 1993, to December 31, 1998), genetic data, and measures of AMD (n = 142) assessed at CAREDS baseline from May 14, 2001, through January 31, 2004, were studied.
   MAIN OUTCOMES AND MEASURES Prevalent early or late AMD was determined from graded, stereoscopic fundus photographs. Logistic regression was used to estimate odds ratios (ORs) and 95% CIs for AMD by the joint effects of 25(OH) D (<12, >= 12 to <20, >= 20 to <30, and >= 30 ng/mL) and risk genotype (noncarrier, 1 risk allele, or 2 risk alleles). The referent group was noncarriers with adequate vitamin D status (>= 30 ng/mL). Joint effect ORs were adjusted for age, smoking, iris pigmentation, self-reported cardiovascular disease, self-reported diabetes status, and hormone use. Additive and multiplicative interactions were assessed using the synergy index (SI) and an interaction term, respectively. To examine the association between AMD and variants in vitamin D-related genes, age-adjusted ORs and 95% CIs were estimated using logistic regression.
   RESULTS Among the 913 women, 550 had adequate levels of vitamin D (>= 20 ng/mL), 275 had inadequate levels (>= 12 to <20 mg/mL), and 88 had deficient levels (<12 ng/mL). A 6.7-fold increased odds of AMD (95% CI, 1.6-28.2) was observed among women with deficient vitamin D status (25[OH] D <12 ng/mL) and 2 risk alleles for CFH Y402H (SI for additive interaction, 1.4; 95% CI, 1.1-1.7; P for multiplicative interaction = .25). Significant additive (SI, 1.4; 95% CI, 1.1-1.7) and multiplicative interactions (P = .02) were observed for deficient women with 2 high-risk CFI (rs10033900) alleles (OR, 6.3; 95% CI, 1.6-24.2). The odds of AMD did not differ by genotype of candidate vitamin D genes.
   CONCLUSIONS AND RELEVANCE In this study, the odds of AMD were highest in those with deficient vitamin D status and 2 risk alleles for the CFH and CFI genotypes, suggesting a synergistic effect between vitamin D status and complement cascade protein function. Limited sample size led to wide CIs. Findings may be due to chance or explained by residual confounding.
C1 [Millen, Amy E.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Epidemiol & Environm Hlth, Buffalo, NY 14260 USA.
   [Meyers, Kristin J.; Liu, Zhe; Mares, Julie A.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI 53706 USA.
   [Engelman, Corinne D.] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI 53706 USA.
   [Wallace, Robert B.] Univ Iowa, Dept Epidemiol, Iowa City, IA USA.
   [LeBlanc, Erin S.] Kaiser Permanente Res, Ctr Hlth Res, Portland, OR USA.
   [Tinker, Lesley F.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA.
   [Iyengar, Sudha K.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   [Robinson, Jennifer G.] Univ Iowa, Dept Epidemiol, Coll Publ Hlth, Iowa City, IA USA.
   [Sarto, Gloria E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Obstet & Gynecol, Madison, WI 53706 USA.
C3 State University of New York (SUNY) System; State University of New York
   (SUNY) Buffalo; University of Wisconsin System; University of Wisconsin
   Madison; University of Wisconsin System; University of Wisconsin
   Madison; University of Iowa; Kaiser Permanente; Fred Hutchinson Cancer
   Center; Case Western Reserve University; University of Iowa; University
   of Wisconsin System; University of Wisconsin Madison
RP Millen, AE (通讯作者)，SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Epidemiol & Environm Hlth, 270 Farber Hall, Buffalo, NY 14214 USA.
EM aemillen@buffalo.edu
RI /S-1190-2019; , Jennifer/AAD-8336-2019
OI /0000-0001-7488-250X; 
FU National Eye Institute of the National Institutes of Health [EY013018,
   EY016886]; Research to Prevent Blindness; Retina Research Foundation;
   National Heart, Lung, and Blood Institute, National Institutes of
   Health, US Department of Health and Human Services [HHSN268201100046C,
   HHSN268201100001C, HHSN268201100002C, HHSN268201100003C,
   HHSN268201100004C, HHSN271201100004C]; NATIONAL CANCER INSTITUTE
   [P30CA015704] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE
   [U10EY013018, R01EY016886] Funding Source: NIH RePORTER
FX Carotenoids in Age-Related Eye Disease Study is supported by grants
   EY013018 and EY016886 from the National Eye Institute of the National
   Institutes of Health, the Research to Prevent Blindness, and the Retina
   Research Foundation. The Women's Health Initiative program is funded by
   contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C,
   HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C from the
   National Heart, Lung, and Blood Institute, National Institutes of
   Health, US Department of Health and Human Services.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Ahn J, 2010, HUM MOL GENET, V19, P2739, DOI 10.1093/hmg/ddq155
   Alsalem JA, 2014, INVEST OPHTH VIS SCI, V55, P2140, DOI 10.1167/iovs.13-13019
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   [Anonymous], SAS STAT 9 2 US GUID
   Barouch Fina C., 2007, International Ophthalmology Clinics, V47, P185, DOI 10.1097/IIO.0b013e3180377936
   BHALLA AK, 1986, CELL IMMUNOL, V98, P311, DOI 10.1016/0008-8749(86)90291-1
   BLAND JM, 1995, BRIT MED J, V310, P170, DOI 10.1136/bmj.310.6973.170
   Cantorna MT, 1996, P NATL ACAD SCI USA, V93, P7861, DOI 10.1073/pnas.93.15.7861
   Cantorna MT, 1998, J NUTR, V128, P68, DOI 10.1093/jn/128.1.68
   CATTERALL CF, 1987, BIOCHEM J, V242, P849, DOI 10.1042/bj2420849
   Chen S, 2007, J IMMUNOL, V179, P1634, DOI 10.4049/jimmunol.179.3.1634
   Chiu CJ, 2011, INVEST OPHTH VIS SCI, V52, P9099, DOI 10.1167/iovs.11-7782
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Cutolo M, 2007, AUTOIMMUN REV, V7, P59, DOI 10.1016/j.autrev.2007.07.001
   D'Ambrosio D, 1998, J CLIN INVEST, V101, P252, DOI 10.1172/JCI1050
   d'Hellencourt CL, 2003, J NEUROSCI RES, V71, P575, DOI 10.1002/jnr.10491
   Daniel C, 2008, J PHARMACOL EXP THER, V324, P23, DOI 10.1124/jpet.107.127209
   Day S, 2012, ARCH OPHTHALMOL-CHIC, V130, P1070, DOI 10.1001/archophthalmol.2012.439
   Engelman CD, 2013, J NUTR, V143, P17, DOI 10.3945/jn.112.169482
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Golan S, 2011, EYE, V25, P1122, DOI 10.1038/eye.2011.174
   Graffe A, 2012, J AM GERIATR SOC, V60, P1367, DOI 10.1111/j.1532-5415.2012.04015.x
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Holick MF, 2005, SOUTH MED J, V98, P1024, DOI 10.1097/01.SMJ.0000140865.32054.DB
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   HOSMER DW, 1992, EPIDEMIOLOGY, V3, P452, DOI 10.1097/00001648-199209000-00012
   Institute of Medicine, 2011, DIETARY REFERENCE IN, DOI [10.17226/13050, DOI 10.17226/13050]
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P674, DOI 10.1001/archopht.121.5.674
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Laurie CC, 2010, GENET EPIDEMIOL, V34, P591, DOI 10.1002/gepi.20516
   Lee V, 2012, NEUROBIOL AGING, V33, P2382, DOI 10.1016/j.neurobiolaging.2011.12.002
   Mares JA, 2006, AM J CLIN NUTR, V84, P1107
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Mark BL, 2006, J AM DIET ASSOC, V106, P418, DOI 10.1016/j.jada.2005.12.009
   MATHIEU C, 1995, ENDOCRINOLOGY, V136, P866, DOI 10.1210/en.136.3.866
   Meyers KJ, 2013, INVEST OPHTH VIS SCI, V54, P2333, DOI [10.1167/iovs.12-10867, 10.1167/iovs.13-13216]
   Mihlan M, 2009, CELL DEATH DIFFER, V16, P1630, DOI 10.1038/cdd.2009.103
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Mora JR, 2008, NAT REV IMMUNOL, V8, P685, DOI 10.1038/nri2378
   Morrison Margaux A., 2011, Human Genomics, V5, P538
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Penna G, 2000, J IMMUNOL, V164, P2405, DOI 10.4049/jimmunol.164.5.2405
   Ramagopalan SV, 2010, GENOME RES, V20, P1352, DOI 10.1101/gr.107920.110
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   RIGBY WFC, 1984, J CLIN INVEST, V74, P1451, DOI 10.1172/JCI111557
   RIGBY WFC, 1987, J CLIN INVEST, V79, P1659, DOI 10.1172/JCI113004
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Singh A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070948
   Szklo M, 2014, EPIDEMIOLOGY BASICS, P185
   Tang J, 2009, J IMMUNOL, V182, P4624, DOI 10.4049/jimmunol.0801543
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Thakkinstian A, 2011, AM J EPIDEMIOL, V173, P1365, DOI 10.1093/aje/kwr025
   Ting AYC, 2009, CURR OPIN OPHTHALMOL, V20, P369, DOI 10.1097/ICU.0b013e32832f8016
   Uitterlinden AG, 2004, GENE, V338, P143, DOI 10.1016/j.gene.2004.05.014
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Wang JJ, 2014, OPHTHALMOLOGY, V121, P667, DOI 10.1016/j.ophtha.2013.10.017
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   Wang TJ, 2010, LANCET, V376, P180, DOI 10.1016/S0140-6736(10)60588-0
   Willett W, 2013, NUTR EPIDEMIOLOGY, P334
   Yin K, 2014, J INFLAMM RES, V7, P69, DOI 10.2147/JIR.S63898
   Zhang XH, 2011, AM J EPIDEMIOL, V174, P459, DOI 10.1093/aje/kwr115
NR 71
TC 31
Z9 31
U1 0
U2 13
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD OCT
PY 2015
VL 133
IS 10
BP 1171
EP 1179
DI 10.1001/jamaophthalmol.2015.2715
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CT7AL
UT WOS:000362965300016
PM 26312598
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Litwinska, Z
   Sobus, A
   Luczkowska, K
   Grabowicz, A
   Mozolewska-Piotrowska, K
   Safranow, K
   Kawa, MP
   Machalinski, B
   Machalinska, A
AF Litwinska, Zofia
   Sobus, Anna
   Luczkowska, Karolina
   Grabowicz, Aleksandra
   Mozolewska-Piotrowska, Katarzyna
   Safranow, Krzysztof
   Kawa, Milosz Piotr
   Machalinski, Boguslaw
   Machalinska, Anna
TI The Interplay Between Systemic Inflammatory Factors and MicroRNAs in
   Age-Related Macular Degeneration
SO FRONTIERS IN AGING NEUROSCIENCE
LA English
DT Article
DE macular degeneration; miRNA; cytokines; interleukin; inflammation
ID PIGMENT EPITHELIAL-CELLS; ENDOTHELIAL GROWTH-FACTOR; COMPLEMENT
   ACTIVATION; CYTOKINES; DISEASE; EXPRESSION; AMD; NEUTROPHIL/LYMPHOCYTE;
   NEOVASCULARIZATION; INTERLEUKIN-6
AB We aimed to explore the expression of systemic inflammatory factors and selected intracellular miRNAs that regulate inflammatory signaling pathways potentially involved in age-related macular degeneration (AMD) pathogenesis. A total of 179 patients with wet AMD, 175 with dry AMD and 121 controls were enrolled in the study. Soluble inflammatory factors were analyzed in plasma samples using Luminex technology. Expression of selected miRNAs was analyzed in isolated nucleated peripheral blood cells (PBNCs) using real-time qPCR. Wet AMD was an independent factor associated with higher concentrations of IL-6 (beta = +0.24, p = 0.0004), GM-CSF (beta = +0.31, p < 0.001), IFN-gamma (beta = +0.58, p < 0.001), higher expression of miRNA-23a-3p (beta = +0.60, p < 0.0001), miRNA-30b (beta = +0.32, p < 0.0001), miRNA-191-5p (beta = +0.28, p < 0.0001) and lower concentration of IL-1 beta (beta = -0.25, p = 0.0003), IL-5 (beta = -0.45, p < 0.001), IL-10 (beta = -0.45, p < 0.001), IL-12 (beta = -0.35, p < 0.001), lower expression of miRNA-16-5p (beta = -0.31, p < 0.0001), miRNA-17-3p (beta = -0.18, p = 0.01), miRNA-150-5p (beta = -0.18, p = 0.01) and miRNA-155-5p (beta = -0.47, p < 0.0001). Multivariate analysis revealed that dry AMD was an independent factor associated with higher concentration of GM-CSF (beta = +0.34, p < 0.001), IL-6 (beta = +0.13, p = 0.05), higher expression of miRNA-23a-3p (beta = +0.60, p < 0.0001), miRNA-126-3p (beta = +0.23, p = 0.0005), miRNA-126-5p (beta = +0.16, p = 0.01), miRNA 146a (beta = +0.14, p = 0.03), and mRNA191-5p (beta = +0.15, p = 0.03) and lower concentrations of TNF-alpha (beta = +0.24, p = 0.0004), IL-1 beta (beta = -0.39, p < 0.001), IL-2 (beta = -0.20, p = 0.003), IL-5 (beta = -0.54, p < 0.001), IL-10 (beta = -0.56, p < 0.001), IL-12 (beta = -0.51, p < 0.001), lower expression of miRNA-16-5p (beta = -0.23, p = 0.0004), miRNA-17-3p (beta = -0.20, p = 0.003) and miRNA-17-5p (beta = -0.19, p = 0.004). Negative correlations between visual acuity and WBC, lymphocyte count, TNF-alpha, IL-1 beta, IL-2, IL-4, IL-6, IL-10 concentrations and miRNA-191-5p, as well as positive correlations between visual acuity and miRNA-126-3p, -126-5p, and -155-5p PBNCs expression were found in AMD patients. No such correlations were found in the control group. Our results may suggest the role of both intra- and extracellular mechanisms implicated in inflammatory response regulation in multifactorial AMD pathogenesis.
C1 [Litwinska, Zofia; Sobus, Anna; Luczkowska, Karolina; Kawa, Milosz Piotr; Machalinski, Boguslaw] Pomeranian Med Univ, Dept Gen Pathol, Szczecin, Poland.
   [Grabowicz, Aleksandra; Mozolewska-Piotrowska, Katarzyna; Machalinska, Anna] Pomeranian Med Univ, Dept Ophthalmol 1, Szczecin, Poland.
   [Safranow, Krzysztof] Pomeranian Med Univ, Dept Biochem & Med Chem, Szczecin, Poland.
C3 Pomeranian Medical University; Pomeranian Medical University; Pomeranian
   Medical University
RP Machalinska, A (通讯作者)，Pomeranian Med Univ, Dept Ophthalmol 1, Szczecin, Poland.
EM annam@pum.edu.pl
RI Safranow, Krzysztof/B-5127-2015
OI Safranow, Krzysztof/0000-0001-9415-2758; Machalinski,
   Boguslaw/0000-0002-6013-0419; Ulanczyk, Zofia/0000-0003-0451-8723
FU European Union funds from the European Union Regional Development Fund;
   Interreg Cooperation Program V A Mecklenburg-Western
   Pomerania/Brandenburg/Poland for 2014-2020: "Consolidating cross-border
   cooperation through exchange of knowledge and skills in the field of
   modern diagnostic imaging methods in ophthalmology"; Polish National
   Science Center Grant [UMO-2013/09/B/NZ7/04031]; Polish National Centre
   for Research and Development [STRATEGMED1/234261/2NCBR/2014]
FX This work was supported by European Union funds from the European Union
   Regional Development Fund, Interreg Cooperation Program V A
   Mecklenburg-Western Pomerania/Brandenburg/Poland for 2014-2020:
   "Consolidating cross-border cooperation through exchange of knowledge
   and skills in the field of modern diagnostic imaging methods in
   ophthalmology", Polish National Science Center Grant No.
   UMO-2013/09/B/NZ7/04031 (to AM) and Polish National Centre for Research
   and Development (Grant Number: STRATEGMED1/234261/2NCBR/2014).
CR Alexandrov PN, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00181
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008-5472.CAN-04-0496
   Ardekani Ali M., 2010, Avicenna Journal of Medical Biotechnology, V2, P161
   Arroba AI, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00203
   Ayoub T, 2009, J ROY SOC MED, V102, P56, DOI 10.1258/jrsm.2009.080298
   Bandyopadhyay S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109525
   Berber P, 2017, MOL DIAGN THER, V21, P31, DOI 10.1007/s40291-016-0234-z
   Bronevetsky Y, 2013, IMMUNOL REV, V253, P304, DOI 10.1111/imr.12059
   Cao SJ, 2013, AM J OPHTHALMOL, V156, P1176, DOI 10.1016/j.ajo.2013.08.003
   Ceppi M, 2009, P NATL ACAD SCI USA, V106, P2735, DOI 10.1073/pnas.0811073106
   Crabb JW, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017194
   Cuenca N, 2014, PROG RETIN EYE RES, V43, P17, DOI 10.1016/j.preteyeres.2014.07.001
   Dai R, 2011, TRANSL RES, V157, P163, DOI 10.1016/j.trsl.2011.01.007
   Damico FM, 2012, ARQ BRAS OFTALMOL, V75, P71, DOI 10.1590/S0004-27492012000100016
   Engels BM, 2006, ONCOGENE, V25, P6163, DOI 10.1038/sj.onc.1209909
   Ertekin S, 2014, MOL VIS, V20, P1057
   Feehan M, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-83
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Guenther SPW, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.08.22
   Hamilton JA, 2008, NAT REV IMMUNOL, V8, P533, DOI 10.1038/nri2356
   Hegner C., 1916, KLIN MONATSBL AUGENH, V57, P27
   Hunter P, 2012, EMBO REP, V13, P968, DOI 10.1038/embor.2012.142
   Ilhan N, 2015, OCUL IMMUNOL INFLAMM, V23, P287, DOI 10.3109/09273948.2014.921715
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Karlstetter M, 2014, HUM MOL GENET, V23, P5197, DOI 10.1093/hmg/ddu242
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kawa M, 2014, J BIOCH PHARM RES, V2, P21
   Kawa MP, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/483960
   Kim J, 2004, P NATL ACAD SCI USA, V101, P360, DOI 10.1073/pnas.2333854100
   Kohlhaas S, 2009, J IMMUNOL, V182, P2578, DOI 10.4049/jimmunol.0803162
   Kroesen BJ, 2015, IMMUNOLOGY, V144, P1, DOI 10.1111/imm.12367
   Kumar P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069807
   Kuo G, 2019, J FORMOS MED ASSOC, V118, P2, DOI 10.1016/j.jfma.2018.04.013
   Kutty RK, 2013, MOL VIS, V19, P737
   Kutty RK, 2010, BIOCHEM BIOPH RES CO, V402, P390, DOI 10.1016/j.bbrc.2010.10.042
   Lin JB, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120157
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lykken EA, 2016, J BIOL CHEM, V291, P23532, DOI 10.1074/jbc.M116.741264
   Machalinska A, 2012, ACTA OPHTHALMOL, V90, P695, DOI 10.1111/j.1755-3768.2011.02295.x
   Machalinska A, 2009, OPHTHALMIC RES, V42, P54, DOI 10.1159/000219686
   McEvoy J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042739
   McLeod DS, 2016, INVEST OPHTH VIS SCI, V57, P5843, DOI 10.1167/iovs.16-20049
   Nagpal N, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00099
   Natoli R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01666
   Nebel C, 2017, BIOCHEM BIOPH RES CO, V484, P681, DOI 10.1016/j.bbrc.2017.01.176
   Niazi S, 2019, ACTA OPHTHALMOL, V97, P558, DOI 10.1111/aos.14072
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Ohki Y, 2005, FASEB J, V19, P2005, DOI 10.1096/fj.04-3496fje
   PENFOLD P, 1984, AUST J OPHTHALMOL, V12, P23
   Pinna A, 2019, OCUL IMMUNOL INFLAMM, V27, P932, DOI 10.1080/09273948.2018.1485960
   Pogue AI, 2018, CELL MOL NEUROBIOL, V38, P1021, DOI 10.1007/s10571-017-0572-3
   Pongsachareonnont P, 2018, CLIN OPHTHALMOL, V12, P1877, DOI 10.2147/OPTH.S171636
   Rashid K, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00176
   Rodriguez A, 2007, SCIENCE, V316, P608, DOI 10.1126/science.1139253
   Romano GL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00168
   Sato T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19594-6
   Scholz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0422-5
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Sengul EA, 2017, INT J OPHTHALMOL-CHI, V10, P754, DOI 10.18240/ijo.2017.05.16
   Shachar I, 2013, J LEUKOCYTE BIOL, V93, P51, DOI 10.1189/jlb.0612293
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Tahamtan A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01377
   Tufekci KU, 2011, AUTOIMMUN DIS, V2011, DOI 10.4061/2011/807426
   Wang J, 2015, PROCEEDINGS 3RD IAPR ASIAN CONFERENCE ON PATTERN RECOGNITION ACPR 2015, P21, DOI 10.1109/ACPR.2015.7486458
   Wang JY, 2009, J CELL PHYSIOL, V220, P119, DOI 10.1002/jcp.21742
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu XY, 2014, J CELL BIOCHEM, V115, P1928, DOI 10.1002/jcb.24864
   Wu XC, 2016, SCI REP-UK, V6, DOI 10.1038/srep19000
   Wu Y, 2017, J PERIODONTOL, V88, pE179, DOI 10.1902/jop.2017.170091
   Yan LL, 2015, J BIOL CHEM, V290, P23264, DOI 10.1074/jbc.M115.646950
   Yuan K, 2016, INT IMMUNOPHARMACOL, V40, P339, DOI 10.1016/j.intimp.2016.09.011
   Zhao L, 2015, EMBO MOL MED, V7, P1179, DOI 10.15252/emmm.201505298
   Zhou QB, 2016, MOL THER, V24, P1823, DOI 10.1038/mt.2016.108
   Zhuang Z, 2015, MOL VIS, V21, P1173
NR 81
TC 27
Z9 27
U1 0
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-4365
J9 FRONT AGING NEUROSCI
JI Front. Aging Neurosci.
PD OCT 22
PY 2019
VL 11
AR 286
DI 10.3389/fnagi.2019.00286
PG 13
WC Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA JK1XR
UT WOS:000494641400001
PM 31695606
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Greve, MDJ
   Hinz, BJ
   Schulha, M
   Wakeman, B
   Colgon, G
   Schwanke, B
   Dalton, K
   Rosenfeld, P
   Dubovy, S
   Lewis, ML
   Rodriguez, B
   Muniz, N
   Torres, A
   Galvez, M
   Lipka, K
   Hess, D
   Cubillas, A
   Rams-McPhee, I
   Lim, J
   Flaxel, C
   Padilla, M
   Perez, E
   Walonker, F
   Garcia, J
   Thomas, M
   Soucek, P
   Kuchynka, P
   Cihelkova, I
   Firichova, L
   Sotolova, L
   Polak, V
   Immonen, I
   Tommila, P
   Ranta, P
   Sankila, EM
   Lemberg, S
   Orth, D
   Civantos, J
   Drefcinski, T
   Roark, T
   Violetto, C
   Figliulo, C
   Bryant, D
   Harvey, P
   Escover, M
   Flores, J
   Leuschner, D
   Bolychuk, S
   Brown, I
   Fischer, M
   Whitfield, K
   Grizzard, S
   Hammer, M
   Corydon, I
   Echevery, J
   Hardy, M
   Shepard, M
   Traynorm, J
   Santos, M
   Ma, C
   Dreyer, R
   Bartholomew, P
   DeShazer, D
   Raunig, W
   Johnson, M
   Logan, J
   Wohlsein, H
   Boyer, D
   Chu, T
   Gallemore, R
   Novack, R
   Thomas, E
   Martinez, J
   Gould, S
   Smucker, A
   Thayer, D
   Sanguinet, J
   Rosa, R
   Kriegel, M
   Whiteis, J
   Hinkle, S
   Rios, D
   Methvin, G
   deVarona, J
   Fish, G
   Jost, B
   Pierce, SAD
   Arnwine, J
   Sanchez, B
   Ellenich, P
   Aguado, H
   Schachat, A
   Bressler, SB
   Bressler, NM
   Nesbitt, P
   Orr, P
   Eager, A
   Seabrook, S
   Sheehan, S
   Belt, J
   Falk, R
   McDonald, J
   Cain, D
   Emmert, D
   Herring, M
   Menchini, U
   Virgili, G
   Arena, MC
   Pieri, B
   Galeotti, L
   Potter, M
   Gillies, D
   Pardhan, Z
   Harrison, BJ
   Hall, L
   Slakter, J
   Spaide, R
   Sorenson, J
   Saroj, N
   Daly, J
   Scott, E
   Scolero, M
   Schnipper, E
   Agresta, E
   Riff, M
   Mittra, R
   Ryan, E
   Enloe, J
   Oestreich, N
   Moos, M
   Mayleben, L
   Neist, R
   Gamblain, J
   Cheshier, H
   Greven, C
   Slusher, M
   Winnicki, J
   McHugh, K
   Yang, YC
   Masadiq, M
   Brown, A
   Nosek, J
   Bhogal, BS
   Hughes, S
   Bressler, SB
   Bressler, NM
   Davies, KA
   Denbow, RL
   Manos, KS
   Sadda, S
   Smith, RE
   Solomon, SD
   Thibeault, SK
   Tian, Y
   Phillips, DA
   Hartnett, MM
   Hawse, PL
   Orr, PR
   Porter, T
   Biagi, H
   Black, N
   Crocker, SA
   Ford, K
   Hrbolich, J
   Jennings, L
   Kavoosi, M
   Kaye, M
   Klanc, Z
   Mowbray-Martin, K
   Murray, L
   Olsen, B
   Plante, V
   Poslusna, K
   Ryan, B
   Stapleton-Hayes, T
   Ulbricht, C
   Wilson, W
   Lima, MD
   Meer, K
   Reaves, A
   Azab, M
   Buskard, N
   Butchofsky, R
   Galipeau, D
   Hao, Y
   Naor, J
   Ronyecz, E
   Strong, HA
   Su, XY
   Taylor, R
   Vannier, S
   Wolin, M
   Boyer, DS
   Bressler, NM
   Bressler, SB
   Cihelkova, I
   Immonen, I
   Lim, JI
   Menchni, U
   Naor, J
   Potter, MJ
   Rosenfeld, P
   Slakter, CS
   Soucek, P
   Strong, HA
   Yang, YC
   Beck, R
   Chakravarthy, U
   Jampol, L
   Maguire, M
   Meredith, T
   Stirpe, M
   Bressler, NM
   Altaweel, M
   Boyer, DS
   Bressler, SB
   Kaiser, P
   Mone, J
   Rosenfeld, PJ
   Slakter, J
   Stur, M
AF Greve, MDJ
   Hinz, BJ
   Schulha, M
   Wakeman, B
   Colgon, G
   Schwanke, B
   Dalton, K
   Rosenfeld, P
   Dubovy, S
   Lewis, ML
   Rodriguez, B
   Muniz, N
   Torres, A
   Galvez, M
   Lipka, K
   Hess, D
   Cubillas, A
   Rams-McPhee, I
   Lim, J
   Flaxel, C
   Padilla, M
   Perez, E
   Walonker, F
   Garcia, J
   Thomas, M
   Soucek, P
   Kuchynka, P
   Cihelkova, I
   Firichova, L
   Sotolova, L
   Polak, V
   Immonen, I
   Tommila, P
   Ranta, P
   Sankila, EM
   Lemberg, S
   Orth, D
   Civantos, J
   Drefcinski, T
   Roark, T
   Violetto, C
   Figliulo, C
   Bryant, D
   Harvey, P
   Escover, M
   Flores, J
   Leuschner, D
   Bolychuk, S
   Brown, I
   Fischer, M
   Whitfield, K
   Grizzard, S
   Hammer, M
   Corydon, I
   Echevery, J
   Hardy, M
   Shepard, M
   Traynorm, J
   Santos, M
   Ma, C
   Dreyer, R
   Bartholomew, P
   DeShazer, D
   Raunig, W
   Johnson, M
   Logan, J
   Wohlsein, H
   Boyer, D
   Chu, T
   Gallemore, R
   Novack, R
   Thomas, E
   Martinez, J
   Gould, S
   Smucker, A
   Thayer, D
   Sanguinet, J
   Rosa, R
   Kriegel, M
   Whiteis, J
   Hinkle, S
   Rios, D
   Methvin, G
   deVarona, J
   Fish, G
   Jost, B
   Pierce, SAD
   Arnwine, J
   Sanchez, B
   Ellenich, P
   Aguado, H
   Schachat, A
   Bressler, SB
   Bressler, NM
   Nesbitt, P
   Orr, P
   Eager, A
   Seabrook, S
   Sheehan, S
   Belt, J
   Falk, R
   McDonald, J
   Cain, D
   Emmert, D
   Herring, M
   Menchini, U
   Virgili, G
   Arena, MC
   Pieri, B
   Galeotti, L
   Potter, M
   Gillies, D
   Pardhan, Z
   Harrison, BJ
   Hall, L
   Slakter, J
   Spaide, R
   Sorenson, J
   Saroj, N
   Daly, J
   Scott, E
   Scolero, M
   Schnipper, E
   Agresta, E
   Riff, M
   Mittra, R
   Ryan, E
   Enloe, J
   Oestreich, N
   Moos, M
   Mayleben, L
   Neist, R
   Gamblain, J
   Cheshier, H
   Greven, C
   Slusher, M
   Winnicki, J
   McHugh, K
   Yang, YC
   Masadiq, M
   Brown, A
   Nosek, J
   Bhogal, BS
   Hughes, S
   Bressler, SB
   Bressler, NM
   Davies, KA
   Denbow, RL
   Manos, KS
   Sadda, S
   Smith, RE
   Solomon, SD
   Thibeault, SK
   Tian, Y
   Phillips, DA
   Hartnett, MM
   Hawse, PL
   Orr, PR
   Porter, T
   Biagi, H
   Black, N
   Crocker, SA
   Ford, K
   Hrbolich, J
   Jennings, L
   Kavoosi, M
   Kaye, M
   Klanc, Z
   Mowbray-Martin, K
   Murray, L
   Olsen, B
   Plante, V
   Poslusna, K
   Ryan, B
   Stapleton-Hayes, T
   Ulbricht, C
   Wilson, W
   Lima, MD
   Meer, K
   Reaves, A
   Azab, M
   Buskard, N
   Butchofsky, R
   Galipeau, D
   Hao, Y
   Naor, J
   Ronyecz, E
   Strong, HA
   Su, XY
   Taylor, R
   Vannier, S
   Wolin, M
   Boyer, DS
   Bressler, NM
   Bressler, SB
   Cihelkova, I
   Immonen, I
   Lim, JI
   Menchni, U
   Naor, J
   Potter, MJ
   Rosenfeld, P
   Slakter, CS
   Soucek, P
   Strong, HA
   Yang, YC
   Beck, R
   Chakravarthy, U
   Jampol, L
   Maguire, M
   Meredith, T
   Stirpe, M
   Bressler, NM
   Altaweel, M
   Boyer, DS
   Bressler, SB
   Kaiser, P
   Mone, J
   Rosenfeld, PJ
   Slakter, J
   Stur, M
CA Visudyne Minimally Classic Choroid
TI Verteporfin therapy of subfoveal minimally classic choroidal
   neovascularization in age-related macular degeneration - 2-year results
   of a randomized clinical trial
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID REPORT NO. 3; PHOTODYNAMIC THERAPY; VISUAL-ACUITY; TAP; GUIDELINES;
   LESIONS
AB Objective: To compare the treatment effect and safety of photodynamic therapy with verteporfin using a standard (SF) or reduced (RF) light fluence rate with that of placebo therapy in patients with subfoveal minimally classic choroidal neovascularization (CNV) with age-related macular degeneration.
   Design: Phase 2, multicenter, double-masked, placebo-controlled, randomized clinical trial.
   Setting: Nineteen ophthalmology practices in North America and Europe.
   Participants: Patients with initial best-corrected visual acuity of at least 20/250 and a lesion size of no greater than 6 Macular Photocoagulation Study (MPS) disc areas.
   Methods: We randomly assigned 117 patients (1:1:1) to verteporfin infusion (6 mg/m(2)) and light application with an RF rate (300 mW/cm(2)) for 83 seconds (light dose of 25J/cm(2)) or an SF rate (600 mW/cm(2)) for 83 seconds (light dose of 50 J/cm(2)) or to placebo infusion with RF or SF. Treatment was repeated every 3 months if the treating physician noted fluorescein leakage from CNV on angiography. Patients in whom a predominantly classic lesion developed could receive open-label standard verteporfin treatment. Best-corrected visual acuity was measured every 3 months, and angiographic changes were assessed by the Photograph Reading Center through the 3-month examination unless an ocular adverse event or conversion to a predominantly classic lesion was identified by an investigator. Safety was assessed throughout the study. All outcomes were on an intent-to-treat basis.
   Results: One hundred three (88%) of 117 patients completed the 24-month examination. Twelve (30%) of 40 patients assigned to placebo received open-label standard verteporfin treatment after confirmation of presence of predominantly classic CNV. At month 12, a loss of at least 3 lines of visual acuity occurred in 5 (14%) of 36 eyes assigned to RF and 10 (28%) of 36 eyes assigned to SF, compared with 18 (47%) of 38 eyes assigned to placebo (RF, P =.002; SF,P = .08; RF + SF, P = .004). At month 24, this loss occurred in 9 (26%) of 34 eyes assigned to RE and 17 (53%) of 32 assigned to SF, compared with 23 (62%) of 37 eyes assigned to placebo (RE, P = .003; SF, P = .45; RE + SF, P = .03). Progression to predominantly classic CNV by 24 months was more common in the placebo group (11 [28%] of 39 patients compared with 2 [5%] of 38 in the RF group [P = .007] and 1 [3%] of 37 in the SF group [P = .002]). No unexpected ocular or systemic adverse events were identified. Treatment-related, usually transient visual disturbances were 13% with SF, 10% with placebo, and 5% with RE.
   Conclusions: Verteporfin therapy safely reduced the risks of losing at least 15 letters (>= 3 lines) of visual acuity and progression to predominantly classic CNV for at least 2 years in individuals with subfoveal minimally classic lesions due to age-related macular degeneration measuring 6 MPS disc areas or less. Based on the overall evidence available on verteporfin therapy for these lesions, the VIM Study Group would consider recommending verteporfin therapy for relatively small minimally classic lesions similar to those enrolled in the VIM Trial.
C1 Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Dept Ophthalmol, Baltimore, MD 21205 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Bressler, NM (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Dept Ophthalmol, Suite 115,550 N Boradway, Baltimore, MD 21205 USA.
EM nmboffice@jhmi.edu
RI Rios, Daniela/AFL-1675-2022; Mittra, Robert/AAC-8249-2021; Spaide,
   Richard/ABD-7368-2020; Rios, Daniela/GMW-9768-2022
OI Rios, Daniela/0000-0002-9162-3654; Rios, Daniela/0000-0002-9162-3654
CR *AM AC OPHTH RET P, PREF PRACT PATT AG R
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chow S.-C., 1998, DESIGN ANAL CLIN TRI
   Henderson BW, 2004, CANCER RES, V64, P2120, DOI 10.1158/0008-5472.CAN-03-3513
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Rubin GS, 2002, RETINA-J RET VIT DIS, V22, P536, DOI 10.1097/00006982-200210000-00002
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   *US DEP HHS, DEC MEM OC PHOT THER
   *VERT ROUNDT 2000, 2002, RETINA, V22, P6
NR 17
TC 150
Z9 155
U1 0
U2 12
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD APR
PY 2005
VL 123
IS 4
BP 448
EP 457
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 913FQ
UT WOS:000228137400002
PM 15824216
DA 2022-11-30
ER

PT J
AU Zarubina, AV
   Gal-Or, O
   Huisinghj, CE
   Owsley, C
   Freund, KB
AF Zarubina, Anna V.
   Gal-Or, Orly
   Huisinghj, Carrie E.
   Owsley, Cynthia
   Freund, K. Bailey
TI Macular Atrophy Development and Subretinal Drusenoid Deposits in
   Anti-Vascular Endothelial Growth Factor Treated Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE anti-VEGF; geographic atrophy; neovascular age-related macular
   degeneration; reticular pseudodrusen; subretinal drusenoid deposits
ID RETINAL-PIGMENT EPITHELIUM; OPTICAL COHERENCE TOMOGRAPHY; GEOGRAPHIC
   ATROPHY; RETICULAR PSEUDODRUSEN; CLINICAL CHARACTERISTICS; 7-YEAR
   OUTCOMES; FELLOW EYES; PREVALENCE; PROGRESSION; ASSOCIATION
AB PURPOSE. To explore the association between presence of subretinal drusenoid deposits (SDD) at baseline in eyes with neovascular age-related macular degeneration (nAMD) with the development of macular atrophy (MA) during anti-vascular endothelial growth factor (VEGF) therapy.
   METHODS. There were 74 eyes without pre-existing MA receiving anti-VEGF therapy for nAMD for 2 years or longer analyzed. At least two image modalities that included spectral-domain optical coherence tomography, near-infrared reflectance, fluorescein angiography, and color fundus photos were used to assess for SDD presence, phenotype (dot and ribbon), and location, neovascularization type, and MA. Logistic regression models using generalized estimating equations assessed the association between SDD and the development of MA adjusting for age, neovascularization type, and choroidal thickness.
   RESULTS. SDD were present in 46 eyes (63%) at baseline. MA developed in 38 eyes (51%) during the mean of 4.7 + 1.2 years of follow-up. Compared with eyes without SDD, those with SDD at baseline were 3.0 times (95% confidence interval [CI] 1.1-8.5, P = 0.0343) more likely to develop MA. Eyes with SDD present in the inferior macula and inferior extramacular fields at baseline were 3.0 times and 6.5 times more likely to develop MA at follow-up than eyes without SDD in these locations (95% CI 1.0-8.9, P = 0.0461 and 95% CI 1.3-32.4, P = 0.0218, respectively). MA development was not associated with a specific SDD phenotype.
   CONCLUSIONS. MA frequently developed in eyes during anti-VEGF treatment. SDD were independently associated with MA development. The extension of SDD into the inferior fundus, particularly in the inferior extramacular field, conferred higher odds of subsequent MA development.
C1 [Zarubina, Anna V.; Huisinghj, Carrie E.; Owsley, Cynthia] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL USA.
   [Gal-Or, Orly; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, 460 Pk Ave, New York, NY 10022 USA.
   [Gal-Or, Orly] Rabin Med Ctr, Petah Tiqwa, Israel.
   [Freund, K. Bailey] NYU, Sch Med, Dept Ophthalmol, New York, NY USA.
C3 University of Alabama System; University of Alabama Birmingham; Vitreous
   Retina Macula Consultants of New York; Rabin Medical Center; New York
   University
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU National Institutes of Health (Bethesda, MD, USA) [R01AG04212]; Macula
   Foundation, Inc. (New York, NY, USA); Research to Prevent Blindness (New
   York, NY, USA); EyeSight Foundation of Alabama (Birmingham, AL, USA);
   Dorsett Davis Discovery Fund (Birmingham, AL, USA); NATIONAL INSTITUTE
   ON AGING [R01AG004212] Funding Source: NIH RePORTER
FX Supported by grants from the National Institutes of Health (R01AG04212;
   Bethesda, MD, USA), the Macula Foundation, Inc. (New York, NY, USA),
   Research to Prevent Blindness (New York, NY, USA), the EyeSight
   Foundation of Alabama (Birmingham, AL, USA), and the Dorsett Davis
   Discovery Fund (Birmingham, AL, USA).
CR Abdelfattah NS, 2016, RETINA-J RET VIT DIS, V36, P1843, DOI 10.1097/IAE.0000000000001059
   Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Adler R, 1999, MOL VIS, V5
   Alten F, 2013, INVEST OPHTH VIS SCI, V54, P3250, DOI 10.1167/iovs.13-11923
   Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   De Bats F, 2016, RETINA-J RET VIT DIS, V36, P46, DOI 10.1097/IAE.0000000000000648
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Forte R, 2012, ACTA OPHTHALMOL, V90, pE281, DOI 10.1111/j.1755-3768.2011.02331.x
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Huisingh C, 2016, INVEST OPHTH VIS SCI, V57, P739, DOI 10.1167/iovs.15-18316
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kim JH, 2015, RETINA-J RET VIT DIS, V35, P2604, DOI 10.1097/IAE.0000000000000633
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Kumar N, 2013, OPHTHALMOLOGY, V120, P334, DOI 10.1016/j.ophtha.2012.07.076
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Lee MY, 2012, BRIT J OPHTHALMOL, V96, P1222, DOI 10.1136/bjophthalmol-2011-301207
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Marsiglia M, 2015, RETINA-J RET VIT DIS, V35, P966, DOI 10.1097/IAE.0000000000000460
   Matsumoto H, 2016, RETINA-J RET VIT DIS, V36, P2282, DOI 10.1097/IAE.0000000000001104
   McBain VA, 2011, RETINA-J RET VIT DIS, V31, P1043, DOI 10.1097/IAE.0b013e3181fe54c7
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Oak ASW, 2014, RETINA-J RET VIT DIS, V34, P825, DOI 10.1097/IAE.0000000000000121
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Rastogi N, 2016, SURV OPHTHALMOL, V61, P422, DOI 10.1016/j.survophthal.2015.10.003
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Sarks J, 2006, BRIT J OPHTHALMOL, V90, P442, DOI 10.1136/bjo.2005.083022
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schutze C, 2015, AM J OPHTHALMOL, V159, P1100, DOI 10.1016/j.ajo.2015.02.020
   Seth A, 2008, INVEST OPHTH VIS SCI, V49, P743, DOI 10.1167/iovs.07-1072
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Steinberg JS, 2015, BRIT J OPHTHALMOL, V99, P1289, DOI 10.1136/bjophthalmol-2014-306535
   Steinberg JS, 2015, INVEST OPHTH VIS SCI, V56, P4267, DOI 10.1167/iovs.15-16657
   Steinberg JS, 2015, OPHTHALMOLOGICA, V233, P35, DOI 10.1159/000368168
   Sundaram V., 2009, TRAINING OPHTHALMOLO
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Xu XY, 2017, AM J OPHTHALMOL, V175, P87, DOI 10.1016/j.ajo.2016.11.021
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS12, DOI 10.1097/IAE.0000000000001276
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS26, DOI 10.1097/IAE.0000000000001330
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zarubina AV, 2016, OPHTHALMOLOGY, V123, P1090, DOI 10.1016/j.ophtha.2015.12.034
   Zhang YH, 2018, RETINA-J RET VIT DIS, V38, P29, DOI 10.1097/IAE.0000000000001504
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 69
TC 10
Z9 10
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2017
VL 58
IS 14
BP 6038
EP 6045
DI 10.1167/iovs.17-22378
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FY4GV
UT WOS:000426781300004
PM 29196768
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Dighe, S
   Zhao, JW
   Steffen, L
   Mares, JA
   Meuer, SM
   Klein, BEK
   Klein, R
   Millen, AE
AF Dighe, Shruti
   Zhao, Jiwei
   Steffen, Lyn
   Mares, J. A.
   Meuer, Stacy M.
   Klein, Barbara E. K.
   Klein, Ronald
   Millen, Amy E.
TI Diet patterns and the incidence of age-related macular degeneration in
   the Atherosclerosis Risk in Communities (ARIC) study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE incident age-related macular degeneration; late age-related macular
   degeneration; dietary patterns; Western pattern; Prudent pattern; food
   groups
ID MEDITERRANEAN DIET; VITAMIN-D; ASSOCIATION; REPRODUCIBILITY;
   PROGRESSION; VALIDITY; DRUSEN; ADULTS; TRIAL; SCORE
AB Background
   Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss among the elderly.
   Objective
   This study aimed to determine the association between dietary patterns and food groups (used to make them) with the 18-year incidence of AMD.
   Methods
   ARIC (Atherosclerosis Risk in Communities) participants who showed change in AMD lesions between retinal photographs taken at visit 3 and visit 5 were graded side by side to determine incident AMD (any=144; early=117; late=27). A 66-line item food frequency questionnaire, administered at visit 1 and visit 3, was used to identify 29 food groups. Principal component analysis was used to derive dietary patterns from average food group servings. Logistic regression was used to estimate ORs and 95% CIs for incident AMD (any, early and late) by tertiles of dietary pattern scores, adjusted for age, race, education, total calories and smoking status. P-trend was estimated using continuous scores.
   Results
   Western (unhealthy) and Prudent (healthy) dietary patterns were identified. No significant associations were observed between either dietary pattern and incident any or incident early AMD. However, a threefold higher incidence of late AMD was observed among participants with a Western pattern score above, as compared with below, the median (OR=3.44 (95% CI 1.33 to 8.87), p-trend=0.014). The risk of developing late AMD was decreased, but not statistically significant, among participants with a Prudent pattern score above, as compared with below, the median (OR=0.51 (95% CI 0.22 to 1.18), p-trend=0.054).
   Conclusions
   Diet patterns were not significantly associated with incident any or incident early AMD. However, consumption of a Western pattern diet may be a risk factor for development of late AMD.
C1 [Dighe, Shruti; Millen, Amy E.] Univ Buffalo State Univ New York, Sch Publ Hlth & Hlth Profess, Dept Epidemiol & Environm Hlth, Buffalo, NY 14214 USA.
   [Zhao, Jiwei] Univ Buffalo State Univ New York, Sch Publ Hlth & Hlth Profess, Dept Biostat, Buffalo, NY USA.
   [Steffen, Lyn] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
   [Mares, J. A.; Meuer, Stacy M.; Klein, Barbara E. K.; Klein, Ronald] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med & Publ Hlth, Madison, WI USA.
C3 State University of New York (SUNY) System; State University of New York
   (SUNY) Buffalo; State University of New York (SUNY) System; State
   University of New York (SUNY) Buffalo; University of Minnesota System;
   University of Minnesota Twin Cities; University of Wisconsin System;
   University of Wisconsin Madison
RP Millen, AE (通讯作者)，Univ Buffalo State Univ New York, Sch Publ Hlth & Hlth Profess, Dept Epidemiol & Environm Hlth, Buffalo, NY 14214 USA.
EM aemillen@buffalo.edu
OI Steffen, Lyn M/0000-0002-4053-6729; Dighe, Shruti/0000-0002-6654-521X
FU National Institutes of Health (NIH) National Institute on Aging [R01
   AG041776]; National Heart, Lung, and Blood Institute, National
   Institutes of Health, Department of Health and Human Services
   [HHSN268201700001I, HHSN268201700002I, HHSN268201700003I,
   HHSN268201700004I, HHSN268201700005I]; NIH (NHLBI) [U012U01HL096812,
   2U01HL096814, 2U01HL096899, 2U01HL096902, 2U01HL096917]; NHLBI
   [R01-HL70825]; National Human Genome Research Institute [U01HG004402];
   National Institutes of Health [HHSN268200625226C]; NIH Roadmap for
   Medical Research; NIH [UL1RR025005]; NIH (NINDS) [U012U01HL096812,
   2U01HL096814, 2U01HL096899, 2U01HL096902, 2U01HL096917]; NIH (NIA)
   [U012U01HL096812, 2U01HL096814, 2U01HL096899, 2U01HL096902,
   2U01HL096917]; NIH (NIDCD) [U012U01HL096812, 2U01HL096814, 2U01HL096899,
   2U01HL096902, 2U01HL096917];  [R01HL087641];  [R01HL086694]
FX This research is supported by the National Institutes of Health (NIH)
   National Institute on Aging grant number R01 AG041776. The
   Atherosclerosis Risk in Communities study has been funded in whole or in
   part with Federal funds from the National Heart, Lung, and Blood
   Institute, National Institutes of Health, Department of Health and Human
   Services (contract numbers HHSN268201700001I, HHSN268201700002I,
   HHSN268201700003I, HHSN268201700004I and HHSN268201700005I).
   Neurocognitive data are collected by U012U01HL096812, 2U01HL096814,
   2U01HL096899, 2U01HL096902 and 2U01HL096917 from the NIH (NHLBI, NINDS,
   NIA and NIDCD), and with previous brain MRI examinations funded by
   R01-HL70825 from the NHLBI. R01HL087641, R01HL086694; National Human
   Genome Research Institute contract U01HG004402; and National Institutes
   of Health contract HHSN268200625226C. Infrastructure was partly
   supported by Grant Number UL1RR025005, a component of the NIH and NIH
   Roadmap for Medical Research.
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   ARIC, VIS 5 NEUR STUD NCS, P14
   Atherosclerosis Risk in Communities (ARIC) Cohort, AR NEUR STUD RET IM
   Atherosclerosis risk in Communities study description, ARIC STUD DES
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiu CJ, 2017, INVEST OPHTH VIS SCI, V58, P1404, DOI 10.1167/iovs.16-20454
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Chiu CJ, 2009, OPHTHALMOLOGY, V116, P939, DOI 10.1016/j.ophtha.2008.12.025
   Chong EWT, 2009, AM J EPIDEMIOL, V169, P867, DOI 10.1093/aje/kwn393
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Gottesman RF, 2014, AM J EPIDEMIOL, V179, P956, DOI 10.1093/aje/kwu020
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Hogg RE, 2017, OPHTHALMOLOGY, V124, P82, DOI 10.1016/j.ophtha.2016.09.019
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Hu FB, 1999, AM J CLIN NUTR, V69, P243
   Islam FMA, 2014, OPHTHALMOLOGY, V121, P1428, DOI 10.1016/j.ophtha.2014.01.002
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Julie A, 2017, NUTR PREVENTION TREA
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1642, DOI 10.1001/archopht.122.11.1642
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lin H, 2017, OPHTHAL EPIDEMIOL, V24, P311, DOI 10.1080/09286586.2017.1290259
   Lutsey PL, 2008, CIRCULATION, V117, P754, DOI 10.1161/CIRCULATIONAHA.107.716159
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Montgomery MP, 2010, OPHTHAL EPIDEMIOL, V17, P58, DOI 10.3109/09286580903450353
   National Heart Lung and Blood Insitute of the National Institutes of Health. Atherosclerosis Risk in Communities (ARIC) Cohort, ATH RISK COMM ARIC C
   Ogilvie RP, 2017, AM J CLIN NUTR, V105, P651, DOI 10.3945/ajcn.116.137497
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Psaty BM, 2009, CIRC-CARDIOVASC GENE, V2, P73, DOI 10.1161/CIRCGENETICS.108.829747
   Robinson K.N, 2001, TRENDS VISION HEARIN
   Rovner BW, 2014, OPHTHALMOLOGY, V121, P2204, DOI 10.1016/j.ophtha.2014.05.002
   SAS Institute Inc, 2008, PRINCOMP PROC SAS ST
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086
   WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184
   Wood JM, 2011, INVEST OPHTH VIS SCI, V52, P5088, DOI 10.1167/iovs.10-6644
   Wu J, 2017, AM J CLIN NUTR, V105, P1483, DOI 10.3945/ajcn.116.143453
NR 46
TC 8
Z9 8
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2020
VL 104
IS 8
BP 1070
EP 1076
DI 10.1136/bjophthalmol-2019-314813
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PK2OA
UT WOS:000602289600008
PM 31810976
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Gillies, MC
   Walton, R
   Liong, J
   Arnold, JJ
   McAllister, I
   Morlet, N
   Hunyor, A
   Guymer, R
   Keeffe, J
   Essex, R
   Herrera-Bond, A
   Glastonbury, B
   Simpson, JM
   Barthelmes, D
AF Gillies, Mark C.
   Walton, Richard
   Liong, Julines
   Arnold, Jennifer J.
   McAllister, Ian
   Morlet, Nigel
   Hunyor, Alex
   Guymer, Robyn
   Keeffe, Jill
   Essex, Rohan
   Herrera-Bond, Amparo
   Glastonbury, Briony
   Simpson, Judy M.
   Barthelmes, Daniel
TI EFFICIENT CAPTURE OF HIGH-QUALITY DATA ON OUTCOMES OF TREATMENT FOR
   MACULAR DISEASES The Fight Retinal Blindness! Project
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE patient outcome registry; age-related macular degeneration;
   postmarketing observational study; vascular endothelial growth factor
   inhibitors
ID VEIN OCCLUSION; DEGENERATION; RANIBIZUMAB; EDEMA; BEVACIZUMAB;
   REGISTRIES; CATARACT
AB Purpose: To describe the development of a web-based high-quality data collection tool to track the outcomes of treatment of macular disease in routine practice.
   Methods: Testing of a larger data collection tool established which fields a clinician would reliably fill out. The program, which was developed using freely available software, consists of modules interacting with a core system. The module for neovascular age-related macular degeneration is described here.
   Results: Data for initial visits can be entered within 30 seconds, 15 seconds for follow-up visits. Fifteen centers from Australia, New Zealand, and Switzerland are currently contributing data. Finalized data from 2,052 eyes of 1,693 participants dating from January 2006 were analyzed. Median (25th and 75th percentiles) visual acuity at the index visit was 55 (41, 68) logarithm of the minimum angle of resolution letters with the following lesion types: minimally classic 17.2%, predominantly classic 24.6%, occult 52.0%, idiopathic polypoidal choroidal vasculopathy 1.2%, and retinal angiomatous proliferation 3.2%.
   Conclusion: This software tool will facilitate the collection of large amounts of data on the routine use of treatments of neovascular age-related macular degeneration. This will allow us to analyze important potentially modifiable variables, such as the effect of different treatment patterns on visual outcomes, and to evaluate new treatments as they are introduced into practice.
C1 [Gillies, Mark C.; Walton, Richard; Herrera-Bond, Amparo; Glastonbury, Briony; Barthelmes, Daniel] Univ Sydney, Save Sight Inst, Sydney Med Sch, Sydney, NSW 2006, Australia.
   [Liong, Julines] Univ Sydney, Sydney, NSW 2006, Australia.
   [Arnold, Jennifer J.] Marsden Eye Specialists, Parramatta, NSW, Australia.
   [McAllister, Ian] Univ Western Australia, Lions Eye Inst, Ctr Ophthalmol & Vis Sci, Perth, WA 6009, Australia.
   [Morlet, Nigel] Univ Western Australia, Dept Populat Hlth, Perth, WA 6009, Australia.
   [Hunyor, Alex] Retina Associates, Sydney, NSW, Australia.
   [Guymer, Robyn; Keeffe, Jill] Univ Melbourne, Dept Ophthalmol, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, Melbourne, Vic, Australia.
   [Essex, Rohan] Canberra Hosp, Dept Ophthalmol, Canberra, ACT, Australia.
   [Simpson, Judy M.] Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW 2006, Australia.
   [Barthelmes, Daniel] Univ Zurich Hosp, Dept Ophthalmol, CH-8091 Zurich, Switzerland.
C3 University of Sydney; University of Sydney; Lions Eye Institute;
   University of Western Australia; University of Western Australia; Centre
   for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; Australian National University; Canberra
   Hospital; University of Sydney; University of Zurich; University Zurich
   Hospital
RP Gillies, MC (通讯作者)，Save Sight Inst, South Block,8 Macquarie St, Sydney, NSW 2000, Australia.
EM mark.gillies@sydney.edu.au
RI Hunyor, Alex/AAT-8205-2021
OI Hunyor, Alex/0000-0002-8182-6167; Essex, Rohan/0000-0001-5323-0334;
   Simpson, Judy M/0000-0001-5172-3004; Guymer, Robyn/0000-0002-9441-4356
FU Eye Foundation; National Health and Medical Research Council, Australia
   (NHRMC); National Health and Medical Research Council; Walter and
   Gertrud Siegenthaler Foundation Zurich, Switzerland; Swiss National
   Foundation
FX Supported by a grant from the Eye Foundation (2007-2009) and a grant
   from the National Health and Medical Research Council, Australia (NHRMC
   2010-1012).; M. C. Gillies is a Sydney Medical Foundation Fellow, M. C.
   Gillies and R. Guymer are supported by the National Health and Medical
   Research Council practitioner fellowships. D. Barthelmes was supported
   by the Walter and Gertrud Siegenthaler Foundation Zurich, Switzerland,
   and the Swiss National Foundation.
CR Abegg M, 2008, BMC OPHTHALMOL, V8, DOI 10.1186/1471-2415-8-18
   ACSQHC, 2008, OP PRINC TECHN STAND
   [Anonymous], 1994, Arch Ophthalmol, V112, P500
   Behndig A, 2011, J CATARACT REFR SURG, V37, P1539, DOI 10.1016/j.jcrs.2011.05.021
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2012, OPHTHALMOLOGY, V119, P2125, DOI 10.1016/j.ophtha.2012.04.030
   Derosa Giuseppe, 2012, Curr Mol Pharmacol, V5, P272
   Do DV, 2011, OPHTHALMOLOGY, V118, P1819, DOI 10.1016/j.ophtha.2011.02.018
   Ehlers JP, 2011, RETINA-J RET VIT DIS, V31, P1856, DOI 10.1097/IAE.0b013e31820d59a5
   Finger RP, 2012, OPHTHALMOLOGE, V109, P474, DOI 10.1007/s00347-012-2554-7
   Furberg CD, 2001, CURR CONTR TRIALS C, V2, P205, DOI 10.1186/CVM-2-5-205
   Gillies MC, 2006, OPHTHALMOLOGY, V113, P1533, DOI 10.1016/j.ophtha.2006.02.065
   Glicklich RE, 2007, REGISTRIES EVALUATIN
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   Kennedy L, 2004, PHARMACOECONOMICS, V22, P551, DOI 10.2165/00019053-200422090-00001
   Lundstrom M, 2012, J CATARACT REFR SURG, V38, P1086, DOI 10.1016/j.jcrs.2012.03.006
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McNeil JJ, 2010, MED J AUSTRALIA, V192, P244, DOI 10.5694/j.1326-5377.2010.tb03499.x
   Mitchell P, 2011, OPHTHALMOLOGY, V118, P615, DOI 10.1016/j.ophtha.2011.01.031
   *NHMRC, 2003, DOES QUAL ASS HLTH C
   R: A Language and Environment for Statistical Computing, 2006, R LANG ENV STAT COMP
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sedrakyan A, 2012, LANCET, V379, P1174, DOI 10.1016/S0140-6736(12)60372-9
   Weih LM, 2002, INVEST OPHTH VIS SCI, V43, P927
   Williams KA, 2008, TRANSPLANTATION, V86, P1720, DOI 10.1097/TP.0b013e3181903b0a
NR 27
TC 87
Z9 87
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2014
VL 34
IS 1
BP 188
EP 195
DI 10.1097/IAE.0b013e318296b271
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AI6CZ
UT WOS:000336958700028
PM 23836194
OA Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Kaya, C
   Pfister, IB
   Gerhardt, C
   Garweg, JG
AF Kaya, Cagdas
   Pfister, Isabel B.
   Gerhardt, Christin
   Garweg, Justus G.
TI Outcome of treatment for neovascular age-related macular degeneration by
   practice-based ophthalmologists compared with a macula clinic
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Exudative age-related macular degeneration; Choroidal
   neovascularization; Ranibizumab; Aflibercept; Treat and extend;
   Delegation; Treatment burden
ID EXTEND INTRAVITREAL THERAPY; 2-YEAR OUTCOMES; RANIBIZUMAB; BEVACIZUMAB;
   REGIMEN; PREVALENCE
AB Purpose The aim of this study was to compare neovascular age-related macular degeneration (nAMD) treatment outcomes between ophthalmological practices and a specialized macula clinic. Methods In this case series, we included 347 treatment-naive eyes with nAMD (332 patients). All patients received intravitreal anti-VEGF treatment using ranibizumab or aflibercept at the discretion of the treating physician using a treat-and-extend protocol either by one of 28 practice-based ophthalmologists (group 1; n = 215 eyes) or at a macula clinic (group 2; n = 132 eyes) over 24 months. Results Baseline characteristics of the patients in the two groups, including age, initial BCVA (group 1 58.2 +/- 18.5, group 2 60.8 +/- 16.1 ETDRS letters; p = 0.32), and baseline CRT, were comparable. By end of the observation period, both groups presented similar BCVA (group 1 67.4 +/- 19.3, group 2 66.8 +/- 17.2 letters; p = 0.51), visual gains (group 1 7.8 +/- 16.9, group 2 5.8 +/- 14.4 letters; p = 0.11), CRT values (group 1 259.6 +/- 80.5, group 2 277.4 +/- 87.1 mu m; p = 0.10), and number of injections (group 1 13.0 +/- 4.5, group 2 11.6 +/- 4.1 injections; p = 0.09), as well as portion of eyes with stable disease (absence of any intraretinal fluid and absence or stability of subretinal fluid and pigment epithelial detachment: group 1 78% (n = 128), group 2 75% (n = 95); p = 0.63). However, there was a significant difference regarding the number of examinations (group 1 12.8 +/- 5.0, group 2 9.7 +/- 3.1 visits; p = 0.0005). Conclusions nAMD treatment delivered by practice-based ophthalmologists is reasonable regarding functional outcomes and reduces the indirect treatment burden, which is partially outweighed by significantly more clinical examinations in ophthalmological practices.
C1 [Kaya, Cagdas; Pfister, Isabel B.; Gerhardt, Christin] Berner Augenklin Lindenhofspital, Rotkreuz, Switzerland.
   [Pfister, Isabel B.; Gerhardt, Christin; Garweg, Justus G.] Univ Hosp Bern, Dept Ophthalmol, Bern, Switzerland.
   [Garweg, Justus G.] Swiss Eye Inst, Bremgartenstr 119, CH-3012 Bern, Switzerland.
C3 University of Bern; University Hospital of Bern
RP Garweg, JG (通讯作者)，Univ Hosp Bern, Dept Ophthalmol, Bern, Switzerland.; Garweg, JG (通讯作者)，Swiss Eye Inst, Bremgartenstr 119, CH-3012 Bern, Switzerland.
EM Justus.garweg@swiss-eye-institute.com
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   DeCroos FC, 2016, ASS RES VIS OPHTH AR
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Essex RW, 2019, BRIT J OPHTHALMOL, V103, P1158, DOI 10.1136/bjophthalmol-2018-311852
   Fung AT, 2012, EYE, V26, P1181, DOI 10.1038/eye.2012.174
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Michelotti MM, 2014, CLIN OPHTHALMOL, V8, P755, DOI 10.2147/OPTH.S59982
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rush RB, 2014, AM J OPHTHALMOL, V158, P337, DOI 10.1016/j.ajo.2014.05.007
   Rush RB, 2014, RETINA-J RET VIT DIS, V34, P846, DOI 10.1097/IAE.0000000000000033
   Samalia P, 2016, NEW ZEAL MED J, V129, P32
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Shienbaum G, 2012, AM J OPHTHALMOL, V153, P468, DOI 10.1016/j.ajo.2011.08.011
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
   Wolf-Schnurrbusch UEK, 2009, INVEST OPHTH VIS SCI, V50, P3432, DOI 10.1167/iovs.08-2970
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2018, BRIT J OPHTHALMOL, V102, P460, DOI 10.1136/bjophthalmol-2017-310822
NR 28
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUL
PY 2020
VL 258
IS 7
BP 1405
EP 1410
DI 10.1007/s00417-020-04667-y
EA APR 2020
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LZ6OV
UT WOS:000524623300001
PM 32266472
DA 2022-11-30
ER

PT J
AU Li, Y
   Wang, JW
   Zhong, XJ
   Tian, Z
   Wu, PP
   Zhao, WB
   Jin, CJ
AF Li, Ying
   Wang, JiWen
   Zhong, XiaoJing
   Tian, Zhen
   Wu, Peipei
   Zhao, Wenbo
   Jin, Chenjin
TI Refractive Error and Risk of Early or Late Age-Related Macular
   Degeneration: A Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID 5-YEAR INCIDENCE; AXIAL LENGTH; MACULOPATHY; PREVALENCE; ASSOCIATIONS;
   POPULATION; RIGIDITY; DISEASE; EYES
AB Objective: To summarize relevant evidence investigating the associations between refractive error and age-related macular degeneration (AMD).
   Design: Systematic review and meta-analysis.
   Methods: We searched Medline, Web of Science, and Cochrane databases as well as the reference lists of retrieved articles to identify studies that met the inclusion criteria. Extracted data were combined using a random-effects meta-analysis. Studies that were pertinent to our topic but did not meet the criteria for quantitative analysis were reported in a systematic review instead.
   Main outcome measures: Pooled odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between refractive error (hyperopia, myopia, per-diopter increase in spherical equivalent [SE] toward hyperopia, per-millimeter increase in axial length [AL]) and AMD (early and late, prevalent and incident).
   Results: Fourteen studies comprising over 5800 patients were eligible. Significant associations were found between hyperopia, myopia, per-diopter increase in SE, per-millimeter increase in AL, and prevalent early AMD. The pooled ORs and 95% CIs were 1.13 (1.06-1.20), 0.75 (0.56-0.94), 1.10 (1.07-1.14), and 0.79 (0.73-0.85), respectively. The per-diopter increase in SE was also significantly associated with early AMD incidence (OR, 1.06; 95% CI, 1.02-1.10). However, no significant association was found between hyperopia or myopia and early AMD incidence. Furthermore, neither prevalent nor incident late AMD was associated with refractive error. Considerable heterogeneity was found among studies investigating the association between myopia and prevalent early AMD (P = 0.001, I-2 = 72.2%). Geographic location might play a role; the heterogeneity became non-significant after stratifying these studies into Asian and non-Asian subgroups.
   Conclusion: Refractive error is associated with early AMD but not with late AMD. More large-scale longitudinal studies are needed to further investigate such associations.
C1 [Li, Ying; Zhong, XiaoJing; Tian, Zhen; Wu, Peipei; Zhao, Wenbo; Jin, Chenjin] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510275, Guangdong, Peoples R China.
   [Wang, JiWen] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Neurosurg, Guangzhou 510275, Guangdong, Peoples R China.
   [Wang, JiWen] Sun Yat Sen Univ, Affiliated Hosp 1, Pituitary Tumor Ctr, Guangzhou 510275, Guangdong, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University
RP Jin, CJ (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510275, Guangdong, Peoples R China.
EM jinchj@mail.sysu.edu.cn
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 1992, Arch Ophthalmol, V110, P1701
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boker T, 1993, Ger J Ophthalmol, V2, P10
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Erke MG, 2012, OPHTHALMOLOGY, V119, P1737, DOI 10.1016/j.ophtha.2012.03.016
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Fraser-Bell S, 2010, AM J OPHTHALMOL, V149, P735, DOI 10.1016/j.ajo.2009.11.013
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   Gemmy CC, 2012, AM J OPHTHALMOL
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Hamling J, 2008, STAT MED, V27, P954, DOI 10.1002/sim.3013
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Higgins JPT, 2009, J R STAT SOC A STAT, V172, P137, DOI 10.1111/j.1467-985X.2008.00552.x
   Ikram MK, 2003, INVEST OPHTH VIS SCI, V44, P3778, DOI 10.1167/iovs.03-0120
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe185, DOI 10.1111/j.1755-3768.2011.02316.x
   Jonas JB, 2010, OPHTHALMOLOGY, V117, P2234, DOI 10.1016/j.ophtha.2009.12.006
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lavanya R, 2010, INVEST OPHTH VIS SCI, V51, P6247, DOI 10.1167/iovs.10-5229
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Pallikaris IG, 2006, AM J OPHTHALMOL, V141, P611, DOI 10.1016/j.ajo.2005.11.010
   Pan CW, 2013, OPHTHALMOLOGY, V120, P284, DOI 10.1016/j.ophtha.2012.07.065
   Pan CW, 2013, OPHTHALMOLOGY
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   SANDBERG MA, 1993, OPHTHALMOLOGY, V100, P1009
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Tao Y, 2010, EYE, V24, P648, DOI 10.1038/eye.2009.160
   Ulvik SO, 2005, ACTA OPHTHALMOL SCAN, V83, P419, DOI 10.1111/J.1600-0420.2005.00520.x
   Wang JJ, 2004, CLIN EXP OPHTHALMOL, V32, P255, DOI 10.1111/j.1442-9071.2004.00813.x
   Wang JJ, 1998, INVEST OPHTH VIS SCI, V39, P2167
   WANG Q, 1994, INVEST OPHTH VIS SCI, V35, P4344
   Wong TY, 2002, INVEST OPHTH VIS SCI, V43, P2869
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Xu L, 2007, OPHTHALMOLOGY, V114, P121, DOI 10.1016/j.ophtha.2006.05.071
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
NR 45
TC 9
Z9 9
U1 0
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 6
PY 2014
VL 9
IS 3
AR e90897
DI 10.1371/journal.pone.0090897
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AC4ID
UT WOS:000332483600103
PM 24603619
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU McDonnell, EC
   Heussen, FM
   Ruiz-Garcia, H
   Ouyang, Y
   Narala, R
   Walsh, AC
   Sadda, SR
AF McDonnell, Emma C.
   Heussen, Florian M.
   Ruiz-Garcia, Humberto
   Ouyang, Yanling
   Narala, Ramsudha
   Walsh, Alexander C.
   Sadda, Srinivas R.
TI Effect of anti-VEGF treatment on choroidal thickness over time in
   patients with neovascular age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Choriocapillaris; Image analysis;
   Optical coherence tomography
ID ENDOTHELIAL GROWTH-FACTOR; OPTICAL COHERENCE TOMOGRAPHY; CENTRAL SEROUS
   CHORIORETINOPATHY; EPITHELIUM-DERIVED FACTOR; VASCULOPATHY; RANIBIZUMAB;
   VERTEPORFIN; BEVACIZUMAB
AB Purpose: To evaluate change in subfoveal choroidal thickness (SCT) as measured by spectral-domain optical coherence tomography (SD-OCT) in patients with neovascular age-related macular degeneration (NVAMD) undergoing anti-vascular endothelial growth factor (VEGF) therapy.
   Methods: Patients with a diagnosis of NVAMD were retrospectively reviewed to identify those who had at least 12 months of follow-up. The SCT was manually measured from Bruch membrane to the choroid-sclera junction at baseline and last follow-up. Only cases in which the choroid was fully visible were included in quantitative analyses. The SCT measurements were correlated with other characteristics including number and duration of treatments.
   Results: Sixty eyes of 47 patients with a follow-up of 23.8 months (SD 7.3) met study inclusion criteria, and 49 eyes of 40 patients received anti-VEGF treatment. Mean age was 83.7 years, and 52% were female. Treated eyes received a mean of 7.8 (SD 7.3) intravitreal anti-VEGF injections. The SCT at baseline was 126.7 mu m (SD 50.6) for untreated and 136.2 mu m (SD 57.6) for treated eyes. The SCT showed a decrease over time in both groups, with a mean rate of reduction of 6.0 mu m (p<0.0002) in treated eyes and 3.6 mu m (p = 0.3741) in untreated eyes. However, the change in SCT did not differ between the groups (p = 0.5113), and did not correlate with the number of re-treatments (p = 0.552), visual acuity at baseline (p = 0.618), or change in visual acuity over time (p = 0.429).
   Conclusions: Although choroidal thickness decreased over time in eyes with NVAMD, anti-VEGF therapy did not appear to accelerate or otherwise alter this decline.
C1 [McDonnell, Emma C.; Heussen, Florian M.; Ruiz-Garcia, Humberto; Ouyang, Yanling; Narala, Ramsudha; Walsh, Alexander C.; Sadda, Srinivas R.] Doheny Eye Inst, Los Angeles, CA 90033 USA.
   [McDonnell, Emma C.; Heussen, Florian M.; Ruiz-Garcia, Humberto; Ouyang, Yanling; Narala, Ramsudha; Walsh, Alexander C.; Sadda, Srinivas R.] Univ Calif Los Angeles, Los Angeles, CA USA.
   [Heussen, Florian M.; Ouyang, Yanling] Charite, Berlin, Germany.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; Free University of Berlin; Humboldt University
   of Berlin; Charite Universitatsmedizin Berlin
RP McDonnell, EC (通讯作者)，Johns Hopkins Univ, Sch Med, 733 N Monument St Suite 147, Baltimore, MD 21205 USA.
EM emmacmcdonnell@gmail.com
OI Heussen, Florian Moritz/0000-0003-0536-9870
FU NIH [EY03040]; NEI [R01 EY014375]; Research to Prevent Blindness; DFG
   [He 6094/1-1]; NATIONAL EYE INSTITUTE [P30EY003040, R01EY014375] Funding
   Source: NIH RePORTER
FX Supported in part by NIH grant EY03040, NEI grant R01 EY014375, Research
   to Prevent Blindness, and DFG grant He 6094/1-1.
CR Ahn JK, 2009, AM J OPHTHALMOL, V148, P718, DOI 10.1016/j.ajo.2009.06.012
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan WM, 2008, RETINA-J RET VIT DIS, V28, P1308, DOI 10.1097/IAE.0b013e31818358b2
   Delaey C, 2000, OPHTHALMIC RES, V32, P249, DOI 10.1159/000055622
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Hu WZ, 2009, EXP EYE RES, V88, P79, DOI 10.1016/j.exer.2008.10.014
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Le YZ, 2010, J NEUROCHEM, V112, P1584, DOI 10.1111/j.1471-4159.2010.06573.x
   Lujan BJ, 2009, OPHTHAL SURG LAS IM, V40, P96, DOI 10.3928/15428877-20090301-16
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P510, DOI 10.1097/IAE.0b013e3181eef053
   Maruko I, 2010, OPHTHALMOLOGY, V117, P1792, DOI 10.1016/j.ophtha.2010.01.023
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shima C, 2008, ACTA OPHTHALMOL, V86, P372, DOI 10.1111/j.1600-0420.2007.01067.x
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Vance SK, 2011, RETINA-J RET VIT DIS, V31, P332, DOI 10.1097/IAE.0b013e3181eef0ae
   Zhu Q, 2008, OPHTHALMOLOGY, V115, P1750, DOI 10.1016/j.ophtha.2008.04.023
NR 24
TC 12
Z9 14
U1 0
U2 3
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD NOV-DEC
PY 2014
VL 24
IS 6
BP 897
EP 903
DI 10.5301/ejo.5000509
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AX0FA
UT WOS:000346627400014
PM 25044137
DA 2022-11-30
ER

PT J
AU Abdel-Meguid, A
   Lappas, A
   Hartmann, K
   Auer, F
   Schrage, N
   Thumann, G
   Kirchhof, B
AF Abdel-Meguid, A
   Lappas, A
   Hartmann, K
   Auer, F
   Schrage, N
   Thumann, G
   Kirchhof, B
TI One year follow up of macular translocation with 360 degree retinotomy
   in patients with age related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULAR MEMBRANES; SUBRETINAL HEMORRHAGE; FOVEAL
   TRANSLOCATION; SURGICAL-MANAGEMENT; MUSCLE SURGERY
AB Aim: To evaluate the benefits of macular translocation with 360 degree retinotomy in patients with exudative age related macular degeneration (ARMD).
   Methods: A consecutive interventional case series was performed on patients who underwent macular translocation between June 1997 and January 2000 at the department of ophthalmology, University of Aachen, Germany. A retrospective pilot study was set up with a minimum follow up of 12 months in 39 consecutive patients with subfoveal choroidal neovascularisation secondary to ARMD. The surgical technique included pars plana vitrectomy, induction of retinal detachment, 360 degree retinotomy, removal of the choroidal neovascular membranes (CNVM), macular translocation, peripheral laser retinopexy, and silicone oil endotamponade.
   Results: 18 patients showed predominantly occult CNVM, six patients had predominantly classic CNVM, and 15 showed subretinal haemorrhage. At the 12 month follow up 13 patients (33%) showed an improvement in visual acuity of more than three lines (logMAR scale), 18 patients (46%) retained stable visual acuity with a change of equal or less than three lines (logMAR scale), and eight patients (21%) showed a decrease in visual acuity of more than three lines (logMAR scale). Recurrence of CNVM was observed in three (8%) eyes at 5-11 months postoperatively. Other complications included proliferative vitreoretinopathy with retinal detachment (n=10), peripheral epiretinal membranes (n=9), macular pucker (n=2), corneal decompensation (n=2), and hypotony (n=11). 18 patients (46%) complained about persistent diplopia.
   Conclusion: Macular translocation surgery is able to maintain or improve distant vision in the majority of patients with exudative ARMD. Proliferative vitreoretinopathy and diplopia are the two major complications. A prospective randomised controlled trial comparing macular translocation with observation for patients with the occult form of exudative ARMD may be justified.
C1 Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, D-50931 Cologne, Germany.
   Univ Aachen, Dept Ophthalmol, D-5100 Aachen, Germany.
C3 University of Cologne; RWTH Aachen University
RP Kirchhof, B (通讯作者)，Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, Joseph Stelzmann Str 9, D-50931 Cologne, Germany.
RI schrage, norbert/AAM-9263-2021
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   CHAMBERLIN JA, 1989, OPHTHALMOLOGY, V96, P1526
   de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Eckardt U, 1998, KLIN MONATSBL AUGENH, V212, P212, DOI 10.1055/s-2008-1034867
   ECKARDT U, 2001, OPHTHALMOLOGE S1, V98, P27
   Eong KGA, 2001, AM J OPHTHALMOL, V131, P244, DOI 10.1016/S0002-9394(00)00788-1
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Fricke J, 2000, GRAEF ARCH CLIN EXP, V238, P664, DOI 10.1007/s004170000170
   Fujikado T, 2001, AM J OPHTHALMOL, V131, P101, DOI 10.1016/S0002-9394(00)00770-4
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   GROSSNIKLAUS HE, 1994, OPHTHALMOLOGY, V101, P1099
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   HERZAU V, 1983, Z PRAKT AUGNHEILKD, V4, P279
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   KAHN HA, 1973, USDHEW NIH73427 PUBL, P73
   LAMBERT HM, 1992, AM J OPHTHALMOL, V113, P257, DOI 10.1016/S0002-9394(14)71576-4
   Lappas A, 2000, GRAEF ARCH CLIN EXP, V238, P631, DOI 10.1007/s004170000149
   LINDSEY P, 1983, INVEST OPHTHALMOL  S, V24, P242
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P489
   Melberg NS, 1996, RETINA-J RET VIT DIS, V16, P190, DOI 10.1097/00006982-199616030-00002
   Ninomiya Y, 1996, AM J OPHTHALMOL, V122, P613, DOI 10.1016/S0002-9394(14)70479-9
   Scheider A, 1999, GRAEF ARCH CLIN EXP, V237, P10, DOI 10.1007/s004170050187
   Seaber JH, 1997, GRAEF ARCH CLIN EXP, V235, P76, DOI 10.1007/BF00941733
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   TIEDEMAN J, 1985, INVEST OPHTHALMOL  S, V26, P59
   Wolf S, 1999, GRAEF ARCH CLIN EXP, V237, P51, DOI 10.1007/s004170050194
NR 30
TC 61
Z9 62
U1 0
U2 7
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2003
VL 87
IS 5
BP 615
EP 621
DI 10.1136/bjo.87.5.615
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 671MT
UT WOS:000182469100025
PM 12714406
OA Green Submitted, Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Birke, K
   Lipo, E
   Birke, MT
   Kumar-Singh, R
AF Birke, Kerstin
   Lipo, Erion
   Birke, Marco T.
   Kumar-Singh, Rajendra
TI Topical Application of PPADS Inhibits Complement Activation and
   Choroidal Neovascularization in a Model of Age-Related Macular
   Degeneration
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; MEMBRANE-ATTACK-COMPLEX; FACTOR-H
   POLYMORPHISM; RECEPTOR; VEGF; IMMUNOLOGY; EXPRESSION; PAZOPANIB;
   DISEASE; RETINA
AB Age-related macular degeneration (AMD) is the most common cause of blindness among the elderly. AMD patients have elevated levels of membrane attack complex (MAC) in their choroidal blood vessels and retinal pigment epithelium (RPE). MAC forms pores in cell membranes. Low levels of MAC result in an elevation of cytokine release such as vascular endothelial growth factor (VEGF) that promotes the formation of choroidal neovascularization (CNV). High levels of MAC result in cell lysis and RPE degeneration is a hallmark of advanced AMD. The current standard of care for CNV associated with wet AMD is intravitreal injection of anti-VEGF molecules every 4 to 12 weeks. Such injections have significant side effects. Recently, it has been found that membrane pore-forming proteins such as a-haemolysin can mediate their toxic effects through auto-and paracrine signaling and that complement-induced lysis is amplified through ATP release followed by P2X receptor activation. We hypothesized that attenuation of P2X receptor activation may lead to a reduction in MAC deposition and consequent formation of CNV. Hence, in this study we investigated topical application of the purinergic P2X antagonist Pyridoxalphosphate-6-azophenyl-2',4'-disulphonic acid (PPADS) as a potential treatment for AMD. We found that 4.17 mu M PPADS inhibited formation of HUVEC master junctions and master segments by 74.7%. In a human complement mediated cell lysis assay, 104 mM PPADS enabled almost complete protection of Hepa1c1c7 cells from 1% normal human serum mediated cell lysis. Daily topical application of 4.17 mM PPADS for 3 days attenuated the progression of laser induced CNV in mice by 41.8% and attenuated the deposition of MAC at the site of the laser injury by 19.7%. Our data have implications for the future treatment of AMD and potentially other ocular disorders involving CNV such as angioid streaks, choroidal rupture and high myopia.
C1 [Birke, Kerstin; Lipo, Erion; Birke, Marco T.; Kumar-Singh, Rajendra] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
C3 Tufts University
RP Kumar-Singh, R (通讯作者)，Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
EM Rajendra.Kumar-Singh@tufts.edu
OI Lipo, Erion/0000-0002-3179-0688; Kumar-Singh,
   Rajendra/0000-0002-7754-0713
FU Ellison Foundation; Virginia B Smith Trust; National Institute of
   Health/National Eye Institute [EY021805, EY013837]; Department of
   Defense/Telemedicine and Advanced Technology Research Center; Lions Eye
   Foundation; Research to Prevent Blindness; NATIONAL EYE INSTITUTE
   [R01EY013837, R01EY021805] Funding Source: NIH RePORTER
FX This study was supported by grants to R. K. S. from The Ellison
   Foundation, The Virginia B Smith Trust, The National Institute of
   Health/National Eye Institute (EY021805 and EY013837), The Department of
   Defense/Telemedicine and Advanced Technology Research Center and grants
   to the Department of Ophthalmology at Tufts University School of
   Medicine from the Lions Eye Foundation and Research to Prevent
   Blindness. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ament CS, 2006, ARCH OPHTHALMOL-CHIC, V124, P957, DOI 10.1001/archopht.124.7.957
   Bee YS, 2010, MOL VIS, V16, P756
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Brand CS, 2012, EYE, V26, pS1, DOI 10.1038/eye.2012.32
   Cashman SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019078
   Casten RJ, 2013, CURR OPIN OPHTHALMOL, V24, P239, DOI 10.1097/ICU.0b013e32835f8e55
   Cloutier F, 2012, INVEST OPHTH VIS SCI, V53, P1195, DOI 10.1167/iovs.11-9064
   Coddou C, 2011, PHARMACOL REV, V63, P641, DOI 10.1124/pr.110.003129
   Coddou C, 2009, J NEUROSCI, V29, P12284, DOI 10.1523/JNEUROSCI.2096-09.2009
   DAVIES A, 1993, IMMUNOL RES, V12, P258, DOI 10.1007/BF02918257
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferrara N, 2010, NAT MED, V16, P1107, DOI 10.1038/nm1010-1107
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Georgalas Ilias, 2009, Ther Clin Risk Manag, V5, P81
   Goldstein JE, 2012, ARCH OPHTHALMOL-CHIC, V130, P1028, DOI 10.1001/archophthalmol.2012.1197
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HALPERIN JA, 1993, J CLIN INVEST, V91, P1974, DOI 10.1172/JCI116418
   Hejl JL, 2013, PFLUG ARCH EUR J PHY, V465, P529, DOI 10.1007/s00424-012-1174-z
   Iwase T, 2013, INVEST OPHTH VIS SCI, V54, P503, DOI 10.1167/iovs.12-10473
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Keane PA, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/483034
   Kiuchi K, 2008, INVEST OPHTH VIS SCI, V49, P1705, DOI 10.1167/iovs.07-0089
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kunchithapautham K, 2012, ADV EXP MED BIOL, V723, P23, DOI 10.1007/978-1-4614-0631-0_4
   LAMBRECHT G, 1992, EUR J PHARMACOL, V217, P217, DOI 10.1016/0014-2999(92)90877-7
   Larsen CK, 2011, J MEMBRANE BIOL, V244, P131, DOI 10.1007/s00232-011-9406-2
   Lazarus Alon, 2011, Proc Am Thorac Soc, V8, P508, DOI 10.1513/pats.201102-021MW
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Montero JA, 2010, CURR DRUG TARGETS, V11, P630
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Munksgaard PS, 2012, CELL MICROBIOL, V14, P1904, DOI 10.1111/cmi.12021
   Nishiguchi KM, 2012, INVEST OPHTH VIS SCI, V53, P508, DOI 10.1167/iovs.11-8425
   Robbie SJ, 2013, INVEST OPHTH VIS SCI, V54, P1490, DOI 10.1167/iovs.12-10169
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Sarman S, 2008, CURR EYE RES, V33, P285, DOI 10.1080/02713680701885470
   Sheu SJ, 2009, MOL VIS, V15, P1897
   Shima C, 2008, ACTA OPHTHALMOL, V86, P372, DOI 10.1111/j.1600-0420.2007.01067.x
   Skals M, 2011, PFLUG ARCH EUR J PHY, V462, P669, DOI 10.1007/s00424-011-1010-x
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Wu T, 2011, AM J PHYSIOL-HEART C, V301, pH69, DOI 10.1152/ajpheart.01035.2010
   Yafai Y, 2011, EUR J PHARMACOL, V666, P12, DOI 10.1016/j.ejphar.2011.05.016
NR 50
TC 17
Z9 17
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 9
PY 2013
VL 8
IS 10
AR e76766
DI 10.1371/journal.pone.0076766
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 236PJ
UT WOS:000325810900083
PM 24130789
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Nguyen, QD
   Campochiaro, PA
   Shah, SM
   Browning, DJ
   Hudson, HL
   Sonkin, PL
   Hariprasad, SM
   Kaiser, PK
   Slakter, J
   Haller, JA
   Do, DV
   Mieler, W
   Chu, KR
   Ingerman, A
   Vitti, R
   Berliner, AJ
   Cedarbaum, J
AF Quan Dong Nguyen
   Campochiaro, Peter A.
   Shah, Syed Mahmood
   Browning, David J.
   Hudson, Henry L.
   Sonkin, Peter L.
   Hariprasad, Seenu M.
   Kaiser, Peter K.
   Slakter, Jason
   Haller, Julia A.
   Do, Diana V.
   Mieler, William
   Chu, Karen
   Ingerman, Avner
   Vitti, Robert
   Berliner, Alyson J.
   Cedarbaum, Jesse
CA CLEAR-IT 1 Investigators
TI Evaluation of Very High- and Very Low-Dose Intravitreal Aflibercept in
   Patients with Neovascular Age-Related Macular Degeneration
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; VEGF;
   RANIBIZUMAB; MODEL
AB Purpose: To determine bioactivity and duration of effect of intravitreal aflibercept injection (also known as vascular endothelial growth factor Trap-Eye) for neovascular age-related macular degeneration (AMD).
   Methods: In this double-masked, phase 1 study, 28 patients with lesions <= 12 disc areas, >= 50% active choroidal neovascularization (CNV), and best corrected visual acuity (BCVA) <= 20/40 were randomized 1: 1 to a single intravitreal injection of aflibercept 0.15 or 4 mg. The primary end point was the change from baseline in central retinal/lesion thickness (CR/LT) at week-8. Secondary outcomes were the change from baseline BCVA, the change in CNV lesion size and area of leakage, and proportion of patients requiring repeat injection at 8 weeks.
   Results: Mean percent decrease in CR/LT for the 4-mg and 0.15-mg groups was, respectively, 34.2 versus 13.3 at week 4 (P = 0.0065), 23.8 versus 5.9 at week 6 (P = 0.0380), and 25.2% versus 11.3% at week 8 (P = 0.150). The 4-mg group gained a mean of 4.5 letters in BCVA (6/14 patients gaining >= 10 letters) versus 1.1 letters in 0.15-mg group (1/14 gaining >= 10 letters) at week 8. Fewer patients needed retreatment in the 4-mg group at week 8. No serious adverse event or ocular inflammation was reported in either group.
   Conclusions: Intravitreal aflibercept 4 mg had a safety profile similar to that of the very low dose 0.15 mg, and was well-tolerated. The 4-mg dose significantly reduced foveal thickening at weeks 4 and 6, significantly improved BCVA at weeks 6, and reduced the need for repeat injection after 8 weeks compared with intravitreal aflibercept 0.15mg in neovascular AMD patients.
C1 [Quan Dong Nguyen; Campochiaro, Peter A.; Shah, Syed Mahmood; Haller, Julia A.; Do, Diana V.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21287 USA.
   [Browning, David J.] Charlotte Eye Ear Nose & Throat Associates PA, Charlotte, NC USA.
   [Hudson, Henry L.] Retina Ctr PC, Tucson, AZ USA.
   [Sonkin, Peter L.] Tennessee Retina PC, Nashville, TN USA.
   [Hariprasad, Seenu M.; Mieler, William] Univ Chicago, Chicago, IL 60637 USA.
   [Kaiser, Peter K.] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
   [Slakter, Jason] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Chu, Karen; Ingerman, Avner; Vitti, Robert; Berliner, Alyson J.; Cedarbaum, Jesse] Regeneron Pharmaceut Inc, Tarrytown, NY USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; University of Chicago;
   Cleveland Clinic Foundation; Vitreous Retina Macula Consultants of New
   York; Regeneron
RP Nguyen, QD (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, 600 N Wolfe St,Maumenee 745, Baltimore, MD 21287 USA.
EM qnguyen4@jhmi.edu
RI Shah, Syed/K-2672-2018
OI Kaiser, Peter/0000-0001-5126-045X
FU Regeneron Pharmaceutical, Inc., Tarrytown, NY; Bayer Healthcare AG;
   Regeneron; Alcon; Allergan; Bayer; OD-OS; Optos; Bayer Healthcare
FX This study was sponsored by Regeneron Pharmaceutical, Inc., Tarrytown,
   NY, and Bayer Healthcare AG.; Financial disclosures are as follows: Dr.
   Berliner: Equity ownership: Regeneron; current employment by the
   commercial entity that sponsored the study: Regeneron. Dr. Browning:
   Current grant support: Regeneron. Dr. Campochiaro: Consulting fees or
   paid advisory boards: Regeneron. Dr. Cedarbaum: Equity ownership:
   Regeneron; previous employment by the commercial entity that sponsored
   the study: Regeneron; patents, royalties: Regeneron. Ms. Chu: Equity
   ownership: Regeneron; current employment by the commercial entity that
   sponsored the study: Regeneron. Dr. Do: Current grant support:
   Regeneron. Dr. Haller: Consulting fees or paid advisory boards:
   Regeneron. Dr. Hariprasad: Consulting fees: Alcon, Allergan, Bayer,
   OD-OS, and Optos; member of the Speaker's Bureau for Alcon, Allergan,
   Regeneron, and Genentech. Dr. Hudson: Consulting fees or paid advisory
   boards: Regeneron; equity ownership: Regeneron; lecture fees: Regeneron.
   Dr. Ingerman: Previous employment by the commercial entity that
   sponsored the study: Regeneron. Dr. Kaiser: Consulting fees or paid
   advisory boards: Regeneron; lecture fees: Regeneron; current grant
   support to Cole Eye Inst: Regeneron. Dr. Mieler: No applicable
   disclosures. Dr. Nguyen: Current grant support: Regeneron. Dr. Shah: No
   applicable disclosures. Dr. Slakter: Lecture fees: Regeneron; current
   grant support: Regeneron, Bayer Healthcare. Dr. Sonkin: No applicable
   disclosures. Dr. Vitti: Equity ownership: Regeneron; current employment
   by the commercial entity that sponsored the study: Regeneron.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2141, DOI 10.1016/j.ophtha.2009.04.030
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
NR 11
TC 14
Z9 16
U1 1
U2 13
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD DEC
PY 2012
VL 28
IS 6
BP 581
EP 588
DI 10.1089/jop.2011.0261
PG 8
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 047GS
UT WOS:000311827800006
PM 22775078
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Hollyfield, JG
   Perez, VL
   Salomon, RG
AF Hollyfield, Joe G.
   Perez, Victor L.
   Salomon, Robert G.
TI A Hapten Generated from an Oxidation Fragment of Docosahexaenoic Acid Is
   Sufficient to Initiate Age-Related Macular Degeneration
SO MOLECULAR NEUROBIOLOGY
LA English
DT Article
DE Inflammation; Retina; Oxidative damage; Age-related macular
   degeneration; Fatty acid
ID EXPERIMENTAL AUTOIMMUNE UVEORETINITIS; RETINAL-PIGMENT EPITHELIUM;
   FACTOR-H POLYMORPHISM; BRUCHS MEMBRANE; CIGARETTE-SMOKING; COMPLEMENT
   ACTIVATION; DRUSEN; PHOSPHOLIPIDS; LIGHT; MACULOPATHY
AB The protein adduct carboxyethylpyrrole (CEP) is present in age-related macular degeneration (AMD) eye tissue and in the blood of AMD patients at higher levels than found in age-matched non-AMD tissues. Autoantibodies to CEP are also higher in AMD blood samples than in controls. To test the hypothesis that this hapten is causally involved in initiating an inflammatory response in AMD, we immunized C57BL/6J mice with mouse serum albumin (MSA) adducted with CEP. Immunized mice develop antibodies to CEP, fix complement component-3 in Bruch's membrane, accumulate drusen below the retinal pigment epithelium during aging, show decreased a- and b-wave amplitudes in response to light, and develop lesions in the retinal pigment epithelium mimicking geographic atrophy, the blinding end-stage condition characteristic of the dry form of AMD. Inflammatory cells are present in the region of lesions and may be actively involved in the pathology observed. We conclude that early immunization of mice with CEP-adducted MSA sensitizes these animals to the ongoing production of CEP adducts in the outer retina where DHA is abundant and the conditions for oxidative damage are permissive. In response to this early sensitization, the immune system mounts a complement-mediated attack on the cells of the outer retina where CEP adducts are formed. This animal model for AMD is the first that was developed from an inflammatory signal discovered in eye tissue and blood from AMD patients. It provides a novel opportunity for dissecting the early pathology of AMD and the immune response contributing to this disorder. The availability of a mouse with a mechanistically based AMD-like disease that progresses rapidly is highly desirable. Such a model will allow for the efficient preclinical testing of the much-needed therapeutics quickly and inexpensively.
C1 [Hollyfield, Joe G.] Cleveland Clin, Cole Eye Inst, Lerner Coll Med, Cleveland, OH 44106 USA.
   [Perez, Victor L.] Univ Miami, Sch Med, Bascom Palmer Eye Inst, Miami, FL USA.
   [Salomon, Robert G.] Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA.
C3 Case Western Reserve University; Cleveland Clinic Foundation; Bascom
   Palmer Eye Institute; University of Miami; Case Western Reserve
   University
RP Hollyfield, JG (通讯作者)，Cleveland Clin, Cole Eye Inst, Lerner Coll Med, Cleveland, OH 44106 USA.
EM hollyfj@ccf.org
RI Salomon, Robert G/C-3463-2008
OI Salomon, Robert/0000-0001-9456-3557
FU State of Ohio BRTT Program, Columbus, Ohio; Foundation Fighting
   Blindness, Owings Mills, Maryland; Research to Prevent Blindness, New
   York, NY; National Institutes of Health, Bethesda, Maryland [EY014240,
   EY015638, EY014912, GM21249]; NATIONAL EYE INSTITUTE [R24EY015638,
   R01EY016813, R01EY014240, K08EY014912, R56EY014240] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021249]
   Funding Source: NIH RePORTER
FX Supported by the State of Ohio BRTT Program, Columbus, Ohio; a Research
   Center Grant from the Foundation Fighting Blindness, Owings Mills,
   Maryland; a Challenge Grant from Research to Prevent Blindness, New
   York, NY; and by grants from the National Institutes of Health,
   Bethesda, Maryland, [EY014240 (JGH), EY015638 (JGH), EY014912 (VLP), and
   GM21249 (RGS)]. We thank Xiaoping (Annie) Yang, Mary E. Rayborn, Karen
   G. Shadrach, Vera L. Bonilha, and Yong Li for their help with the
   microscopy and immunology performed in these studies. We also thank Lisa
   Kuttner-Kondo, John W. Crabb, Bela Anand-Apte, and Neal S. Peachey for
   discussions and valuable comments during the course of these studies.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   ANDERSON RE, 1970, EXP EYE RES, V10, P339, DOI 10.1016/S0014-4835(70)80046-X
   ANDERSON RE, 1976, EXP EYE RES, V23, P149, DOI 10.1016/0014-4835(76)90198-6
   [Anonymous], 1987, STEREOSCOPIC ATLAS M
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bando H, 2007, EXP EYE RES, V84, P135, DOI 10.1016/j.exer.2006.09.008
   BESHARSE JC, 1979, INVEST OPHTH VIS SCI, V18, P1019
   Brame CJ, 2004, J BIOL CHEM, V279, P13447, DOI 10.1074/jbc.M313349200
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   CASPI RR, 1990, J AUTOIMMUN, V3, P237, DOI 10.1016/0896-8411(90)90143-G
   Caspi RR, 2003, IMMUNOL RES, V27, P149, DOI 10.1385/IR:27:2-3:149
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   de Kozak Yvonne, 2002, Int Rev Immunol, V21, P231
   de Turco EBR, 1999, J NEUROSCI RES, V57, P479
   Doyne R., 1899, T OPHTHAL SOC UK, V19, P71
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   FOX GM, 1987, CLIN IMMUNOL IMMUNOP, V43, P256, DOI 10.1016/0090-1229(87)90133-4
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GORDON WC, 1992, CURR EYE RES, V11, P73, DOI 10.3109/02713689209069169
   GOTTSCH JD, 1993, ARCH OPHTHALMOL-CHIC, V111, P126, DOI 10.1001/archopht.1993.01090010130039
   Goyal J, 1997, J BIOL CHEM, V272, P16231, DOI 10.1074/jbc.272.26.16231
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Gu XR, 2003, J ORG CHEM, V68, P3749, DOI 10.1021/jo026721t
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HIROSE S, 1987, EXP EYE RES, V45, P695, DOI 10.1016/S0014-4835(87)80118-5
   Hollyfield JG, 2003, ADV EXP MED BIOL, V533, P83
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Hussain AA, 2002, J OPT SOC AM A, V19, P166, DOI 10.1364/JOSAA.19.000166
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kaur K, 1997, CHEM RES TOXICOL, V10, P1387, DOI 10.1021/tx970112c
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   LAVAIL MM, 1976, EXP EYE RES, V23, P277, DOI 10.1016/0014-4835(76)90209-8
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   MEYERS SM, 1988, ARCH OPHTHALMOL-CHIC, V106, P651
   MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Nakata K, 2005, EXP EYE RES, V80, P821, DOI 10.1016/j.exer.2004.12.011
   Nussenblatt Robert B, 2002, Int Rev Immunol, V21, P273, DOI 10.1080/08830180212067
   PEAKMAN M, 1989, J CLIN PATHOL, V42, P1018, DOI 10.1136/jcp.42.10.1018
   Rayborn ME, 2006, ADV EXP MED BIOL, V572, P75
   Sakaguchi H, 2002, EXP EYE RES, V74, P547, DOI 10.1006/exer.2002.1186
   Salomon RG, 1997, CHEM RES TOXICOL, V10, P750, DOI 10.1021/tx970016b
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Solberg Y, 1998, SURV OPHTHALMOL, V42, P535, DOI 10.1016/S0039-6257(98)00002-2
   Sun MJ, 2006, J BIOL CHEM, V281, P4222, DOI 10.1074/jbc.M509769200
   VINDING T, 1990, ACTA OPHTHALMOL, V68, P410
NR 63
TC 69
Z9 71
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0893-7648
EI 1559-1182
J9 MOL NEUROBIOL
JI Mol. Neurobiol.
PD JUN
PY 2010
VL 41
IS 2-3
SI SI
BP 290
EP 298
DI 10.1007/s12035-010-8110-z
PG 9
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 601WI
UT WOS:000278095800024
PM 20221855
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Marcus, DM
   Singh, H
   Lott, MN
   Singh, J
   Marcus, MD
AF Marcus, Dennis M.
   Singh, Harinderjit
   Lott, McGregor N.
   Singh, Jasleen
   Marcus, Madison D.
TI INTRAVITREAL RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY IN
   NON-ASIAN PATIENTS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE polypoidal choroidal vasculopathy; ranibizumab
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; MACULAR
   DEGENERATION; PHOTODYNAMIC THERAPY; BEVACIZUMAB; EFFICACY;
   NEOVASCULARIZATION; VERTEPORFIN; INJECTION
AB Purpose: To determine safety, tolerability, and efficacy of intravitreal ranibizumab in the treatment of polypoidal choroidal vasculopathy in a non-Asian population.
   Methods: Phase I/II, prospective, open-label, single-center, nonrandomized, uncontrolled, consecutive, interventional case series of 20 eyes in 19 patients with exudative active polypoidal choroidal vasculopathy. Eyes received 3 monthly intravitreal ranibizumab injections (0.3 or 0.5 mg), with additional ranibizumab injections, observation, or alternative treatments at investigators' discretion, through 24 months. Main outcome measures were ocular and systemic safety and mean change from baseline in best-corrected visual acuity and center point thickness.
   Results: Visually significant ocular adverse events included cataract progression (n = 3), mild vitreous hemorrhage (n = 2), and macular hole (n = 1). No systemic drug-related adverse events were observed. Mean baseline best-corrected visual acuity was 20/127 (range, 20/16-20/500) and center point thickness was 298 mu m. Mean best-corrected visual acuity increased from baseline by 1.2 Snellen lines at 12 months and 24 months. Mean center point thickness decreased by 53 mu m and 67 mu m from baseline at 12 months and 24 months, respectively.
   Conclusion: Intravitreal ranibizumab was well tolerated in non-Asian patients with polypoidal choroidal vasculopathy; the majority of eyes experienced improvements in best-corrected visual acuity and center point thickness after ranibizumab treatment. RETINA 33:35-47, 2013
C1 [Marcus, Dennis M.; Singh, Harinderjit; Marcus, Madison D.] SE Retina Ctr, Augusta, GA USA.
   [Marcus, Dennis M.] Univ S Carolina, Sch Med, Dept Ophthalmol, Columbia, SC USA.
   [Lott, McGregor N.] Mayo Clin Hlth Syst, Waycross, GA USA.
   [Singh, Jasleen] Northwestern Univ, Dept Ophthalmol, Chicago, IL 60611 USA.
C3 University of South Carolina; University of South Carolina System;
   University of South Carolina Columbia; Northwestern University
RP Marcus, DM (通讯作者)，3685 Wheeler Rd, Augusta, GA 30909 USA.
EM dmarcus@southeastretina.com
FU Genentech, Inc., South San Francisco, CA; Genentech, Inc.; Genentech;
   Regeneron; Ophthotech; Allergan; Thrombogenics; Eli Lilly; Pfizer;
   Neovista
FX This study was funded as an investigator-initiated trial by Genentech,
   Inc., South San Francisco, CA. Editorial support was provided by
   Christina McManus, PhD, Envision Scientific Solutions, funded by
   Genentech, Inc. Drs D. M. Marcus and H. Singh have received research
   support from Genentech, Regeneron, Ophthotech, Allergan, Thrombogenics,
   Eli Lilly, Pfizer, and Neovista.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lai TY, 2010, ASS RES VIS OPHTH AN
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Reche-Frutos J, 2008, EUR J OPHTHALMOL, V18, P645, DOI 10.1177/112067210801800427
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Song JH, 2009, OPHTHALMOLOGICA, V223, P85, DOI 10.1159/000175312
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
NR 30
TC 14
Z9 15
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2013
VL 33
IS 1
BP 35
EP 47
DI 10.1097/IAE.0b013e3182618be0
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 069GE
UT WOS:000313422500005
PM 22990319
DA 2022-11-30
ER

PT J
AU Aoki, A
   Inoue, M
   Nguyen, E
   Obata, R
   Kadonosono, K
   Shinkai, S
   Hashimoto, H
   Sasaki, S
   Yanagi, Y
AF Aoki, Aya
   Inoue, Maiko
   Nguyen, Elizabeth
   Obata, Ryo
   Kadonosono, Kazuaki
   Shinkai, Shoji
   Hashimoto, Hideki
   Sasaki, Satoshi
   Yanagi, Yasuo
TI Dietary n-3 Fatty Acid, alpha-Tocopherol, Zinc, vitamin D, vitamin C,
   and beta-carotene are Associated with Age-Related Macular Degeneration
   in Japan
SO SCIENTIFIC REPORTS
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; HISTORY QUESTIONNAIRES; VALIDITY;
   POPULATION; PREVALENCE; NUTRITION; PATTERNS; FISH
AB This case-control study reports the association between nutrient intake and neovascular age-related macular degeneration (AMD) in Japan. The nutrient intake of 161 neovascular AMD cases from two university hospitals and 369 population-based control subjects from a cohort study was assessed using a brief-type self-administered questionnaire on diet history, which required respondent recall of the usual intake of 58 foods during the preceding month. Energy-adjusted nutrient intake values were compared between the groups. Logistic regression analysis was used to estimate odds ratios (ORs) and 95% CIs adjusted for smoking history, age, sex, chronic disease history, supplement use, and alcohol consumption. Logistic regression analysis demonstrated that low intakes of n-3 fatty acid, alpha-tocopherol, zinc, vitamin D, vitamin C, and beta-carotene were associated with neovascular AMD (Trend P < 0.0001 for n-3 fatty acid, Trend P < 0.0001 for alpha-tocopherol, Trend P < 0.0001 for zinc, Trend P = 0.002 for vitamin D, Trend P = 0.04 for vitamin C, Trend P = 0.0004 for beta-carotene). There was no association with retinol or cryptoxanthin intake and neovascular AMD (P = 0.67, 0.06).
C1 [Aoki, Aya; Obata, Ryo; Yanagi, Yasuo] Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Tokyo, Japan.
   [Aoki, Aya; Obata, Ryo; Yanagi, Yasuo] Univ Tokyo, Fac Med, Tokyo 113, Japan.
   [Inoue, Maiko; Kadonosono, Kazuaki] Yokohama City Univ, Med Ctr, Yokohama, Kanagawa 232, Japan.
   [Nguyen, Elizabeth; Sasaki, Satoshi] Univ Tokyo, Sch Publ Hlth, Dept Social & Prevent Med, Tokyo, Japan.
   [Aoki, Aya; Shinkai, Shoji] Tokyo Metropolitan Inst Gerontol, Tokyo, Japan.
   [Hashimoto, Hideki] Univ Tokyo, Sch Publ Hlth, Dept Hlth Econ & Epidemiol Res, Tokyo, Japan.
   [Yanagi, Yasuo] Singapore Natl Eye Ctr, 11 Third Hosp Ave, Singapore 168751, Singapore.
   [Yanagi, Yasuo] Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
C3 University of Tokyo; University of Tokyo; Yokohama City University;
   University of Tokyo; Tokyo Metropolitan Institute of Gerontology;
   University of Tokyo; Singapore National Eye Center; National University
   of Singapore; Singapore National Eye Center
RP Aoki, A (通讯作者)，Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Tokyo, Japan.; Aoki, A (通讯作者)，Univ Tokyo, Fac Med, Tokyo 113, Japan.; Aoki, A (通讯作者)，Tokyo Metropolitan Inst Gerontol, Tokyo, Japan.
EM iriayap2@gmail.com
RI Yanagi, Yasuo/AAA-5441-2022; Yanagi, Yasuo/AAF-2670-2020
OI Yanagi, Yasuo/0000-0002-0362-7285
FU Japan Society for the Promotion of Science [25861663]
FX This work was supported in part by a Grant-in-Aid from the Japan Society
   for the Promotion of Science to A. A. (Grant # 25861663).
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kobayashi S, 2012, J EPIDEMIOL, V22, P151, DOI 10.2188/jea.JE20110075
   Kobayashi S, 2011, PUBLIC HEALTH NUTR, V14, P1200, DOI 10.1017/S1368980011000504
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Michikawa T, 2009, ASIA PAC J CLIN NUTR, V18, P1
   Murayama H, 2012, J EPIDEMIOL, V22, P551, DOI 10.2188/jea.JE20120015
   Nakamura K, 2002, NUTRITION, V18, P415, DOI 10.1016/S0899-9007(02)00751-7
   Nakata I, 2013, AM J OPHTHALMOL, V156, P1002, DOI 10.1016/j.ajo.2013.06.007
   Nan R, 2013, J BIOL CHEM, V288, P19197, DOI 10.1074/jbc.M113.476143
   Okubo H, 2010, PUBLIC HEALTH NUTR, V13, P1080, DOI 10.1017/S1368980009993211
   Pahl L, 2013, EXP EYE RES, V116, P234, DOI 10.1016/j.exer.2013.09.012
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2009, ARCH OPHTHALMOL-CHIC, V127, P110, DOI 10.1001/archophthalmol.2008.518
   Schleicher M, 2013, NUTRIENTS, V5, P2405, DOI 10.3390/nu5072405
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Shiraishi M, 2015, MATERN CHILD NUTR, V11, P525, DOI 10.1111/mcn.12063
   Shiraishi M, 2013, INT J FOOD SCI NUTR, V64, P694, DOI 10.3109/09637486.2013.775225
   Shiraishi M, 2013, NUTR RES, V33, P473, DOI 10.1016/j.nutres.2013.04.002
   Sugano M, 2000, AM J CLIN NUTR, V71, p189S, DOI 10.1093/ajcn/71.1.189S
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Vishwanathan R, 2013, INVEST OPHTH VIS SCI, V54, P3985, DOI 10.1167/iovs.12-11552
   Willett WC, 1997, AM J CLIN NUTR, V65, P1220, DOI 10.1093/ajcn/65.4.1220S
   Yamada M, 2010, OPHTHAL EPIDEMIOL, V17, P50, DOI 10.3109/09286580903450346
NR 34
TC 49
Z9 50
U1 0
U2 22
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 5
PY 2016
VL 6
AR 20723
DI 10.1038/srep20723
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DC9LG
UT WOS:000369542500002
PM 26846575
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lee, C
   Chell, E
   Gertner, M
   Hansen, S
   Howell, RW
   Hanlon, J
   Bolch, WE
AF Lee, Choonsik
   Chell, Erik
   Gertner, Michael
   Hansen, Steven
   Howell, Roger W.
   Hanlon, Justin
   Bolch, Wesley E.
TI Dosimetry characterization of a multibeam radiotherapy treatment for
   age-related macular degeneration
SO MEDICAL PHYSICS
LA English
DT Article
DE age-related macular degeneration; radiation treatment; Monte Carlo
   method; eye phantom; dose volume histogram
ID CHOROIDAL NEOVASCULARIZATION; COMPUTATIONAL PHANTOMS
AB Age-related macular degeneration (ARMD) is a major health problem worldwide. Advanced ARMD, which ultimately leads to profound vision loss, has dry and wet forms, which account for 20% and 80% of cases involving severe vision loss, respectively. A new device and approach for radiation treatment of ARMD has been recently developed by Oraya Therapeutics, Inc. (Newark, CA). The goal of the present study is to provide a initial dosimetry characterization of the proposed radiotherapy treatment via Monte Carlo radiation transport simulation. A 3D eye model including cornea, anterior chamber, lens, orbit, fat, sclera, choroid, retina, vitreous, macula, and optic nerve was carefully designed. The eye model was imported into the MCNPX2.5 Monte Carlo code and radiation transport simulations were undertaken to obtain absorbed doses and dose volume histograms (DVH) to targeted and nontargeted structures within the eye. Three different studies were undertaken to investigate (1) available beam angles that maximized the dose to the macula target tissue, simultaneously minimizing dose to normal tissues, (2) the energy dependency of the DVH for different x-ray energies (80, 100, and 120 kVp), and (3) the optimal focal spot size among options of 0.0, 0.4, 1.0, and 5.5 mm. All results were scaled to give 8 Gy to the macula volume, which is the current treatment requirement. Eight beam treatment angles are currently under investigation. In all eight beam angles, the source-to-target distance is 13 cm, and the polar angle of entry is 30 degrees from the geometric axis of the eye. The azimuthal angle changes in eight increments of 45 degrees in a clockwise fashion, such that an azimuthal angle of 0 degrees corresponds to the 12 o'clock position when viewing the treated eye. Based on considerations of nontarget tissue avoidance, as well as facial-anatomical restrictions on beam delivery, treatment azimuthal angles between 135 degrees and 225 degrees would be available for this treatment system (i.e., directly upward and entering the eye from below). At beam directions approaching 225 degrees and higher, some dose contribution to the optic nerve would result under the assumption that the optic nerve is tilted cranially above the geometric axis in a given patient, a feature not typically seen in past studies. A total treatment dose of 24 Gy would be delivered in three 8 Gy treatments at these selected azimuthal angles. Dose coefficients, defined as the macula radiation absorbed dose per unit air kerma in units of Gy/Gy, were 16% higher for 120 kVp x-ray beams in comparison to those at 80 kVp, thus requiring only 86% of the integrated tube current (mAs) for equivalent dose delivery. When 0.0, 0.4, and 1.0 mm focal spot sizes were used, the dose profiles in the macula are very similar and relatively uniform, whereas a 5.5 mm focal spot size produced a more nonuniform dose profile. The results of this study demonstrate the therapeutic promise of this device and provide important information for further design and clinical implementation for radiotherapy treatments for ARMD. (C) 2008 American Association of Physicists in Medicine. [DOI: 10.1118/1.2990780]
C1 [Lee, Choonsik; Hanlon, Justin; Bolch, Wesley E.] Univ Florida, Dept Nucl & Radiol Engn, Gainesville, FL 32611 USA.
   [Bolch, Wesley E.] Univ Florida, Dept Biomed Engn, Gainesville, FL 32611 USA.
   [Chell, Erik; Gertner, Michael; Hansen, Steven] Oraya Therapeut Inc, Newark, CA 94560 USA.
   [Howell, Roger W.] Univ Med & Dent New Jersey, Dept Radiol, Newark, NJ 07103 USA.
C3 State University System of Florida; University of Florida; State
   University System of Florida; University of Florida; Rutgers State
   University New Brunswick; Rutgers State University Medical Center
RP Bolch, WE (通讯作者)，Univ Florida, Dept Nucl & Radiol Engn, Gainesville, FL 32611 USA.
EM wbolch@ufl.edu
RI Howell, Roger/GXZ-5412-2022; Lee, Choonsik/C-9023-2015; Howell, Roger
   W/AAO-2086-2020
OI Lee, Choonsik/0000-0003-4289-9870; Howell, Roger W/0000-0002-7057-8110
FU University of Florida (UF); University of Medicine and Dentistry of New
   Jersey (UMDNJ)
FX This study was conducted at the University of Florida (UF) and at the
   University of Medicine and Dentistry of New Jersey (UMDNJ) under
   financial support from Oraya Therapeutics, Inc. of Newark, CA.
CR Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   CAPONE A, 2005, INVEST OPHTHALMOL VI, V46
   Churei Hisahiko, 2004, Radiat Med, V22, P398
   Cranley K., 1997, 78 I PHYS
   Cristy M., 1987, ORNLTM8381, V1-7
   Crocker I, 2005, RADIOTHER ONCOL, V75, pS58
   Girkin CA, 1997, OPHTHALMOLOGY, V104, P1634, DOI 10.1016/S0161-6420(97)30084-0
   Goverdhan SV, 2005, EYE, V19, P1137, DOI 10.1038/sj.eye.6701744
   Haas A, 2000, J NEUROSURG, V93, P172, DOI 10.3171/jns.2000.93.supplement_3.0172
   Hayashi M, 2005, J NEUROSURG, V102, P200, DOI 10.3171/jns.2005.102.s_supplement.0200
   HEIER JS, 2007, 2007 ANN M AM AC OPH
   Henderson MA, 2007, STEREOT FUNCT NEUROS, V85, P11, DOI 10.1159/000096634
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   HUBBARD G, 2004, INVEST OPHTH VIS SCI, V45, P5139
   Lee C, 2008, MED PHYS, V35, P2366, DOI 10.1118/1.2912178
   Lee C, 2007, RADIAT PROT DOSIM, V127, P227, DOI 10.1093/rpd/ncm277
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Marcus D, 2004, AM J OPHTHALMOL, V138, P818, DOI 10.1016/j.ajo.2004.06.081
   Morris B, 2007, POSTGRAD MED J, V83, P301, DOI 10.1136/pgmj.2006.052944
   MURPHY RP, 1986, OPHTHALMOLOGY, V93, P969
   NCRP, 1999, 130 NCRP
   Pelowitz DB, 2005, MCNPX USERS MANUAL V
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schwarz F, 2008, J MED IMAG RADIAT ON, V52, P269, DOI 10.1111/j.1440-1673.2008.01936.x
   SINGH RP, 2008, 2008 ANN M AM AC OPH
   Stafford SL, 2003, INT J RADIAT ONCOL, V55, P1177, DOI 10.1016/S0360-3016(02)04380-8
   UNSOLD R, 1980, AM J ROENTGENOL, V135, P767, DOI 10.2214/ajr.135.4.767
   White DR, 1992, J INT COMM RAD UNITS, V1, pNP
   Zambarakji HJ, 2006, OPHTHALMOLOGY, V113, P2012, DOI 10.1016/j.ophtha.2006.05.036
NR 30
TC 26
Z9 26
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0094-2405
EI 2473-4209
J9 MED PHYS
JI Med. Phys.
PD NOV
PY 2008
VL 35
IS 11
BP 5151
EP 5160
DI 10.1118/1.2990780
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA 366LZ
UT WOS:000260484400042
PM 19070249
DA 2022-11-30
ER

PT J
AU Sekeroglu, MA
   Hekimsoy, HK
   Ceran, TH
   Doguizi, S
AF Sekeroglu, Mehmet Ali
   Kilinc Hekimsoy, Hilal
   Horozoglu Ceran, Tugce
   Doguizi, Sibel
TI Treatment of neovascular age related macular degeneration during
   COVID-19 pandemic: The short term consequences of unintended lapses
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Anti-VEGF agents; COVID-19 pandemic; neovascular age related macular
   degeneration
ID GROWTH-FACTOR INHIBITORS
AB Aim: To investigate the short-term effects of COVID-19 pandemic related unintended treatment lapses on neovascular age related macular degeneration (nAMD) patients. Methods: In this prospective cross-sectional study, 140 patients who had at least one anti-vascular endothelial growth factor (VEGF) injection for nAMD within 12 months before COVID-19 pandemic and who had at least 3 months of unintended lapse for control visits during pandemic were recruited and underwent a detailed opthalmological examination and optical coherence tomography imaging. Results: Of these 140 eyes, 113 (80.7%) were active with presence of either intraretinal and/or subretinal fluid and necessitated intravitreal anti-VEGF injections; and 20 (14.3%) of them complicated with subretinal hemorrhage. The mean interval of clinical visits and intravitreal antiVEGF injections were found to be prolonged during COVID-19 pandemics, which demonstrates a statistically significant lapse for both (p = 0.001 and p = 0.003 consecutively). The decreased visual acuity due to lapse was positively correlated with number of intravitreal anti-VEGF injections at last 6 months before COVID-19 pandemic (r = 0.217, p = 0.010) and central subfoveal thickness at first post-COVID-19 visit (r = 0.175, p = 0.038); and negatively correlated with follow-up duration (r = -0.231, p = 0.006) and number of control visits (r = -0.243, p = 0.004). Fifteen (16.9%) of the 89 patients who had drusen in the fellow eye before COVID-19 pandemic evolved to nAMD with an accompanying subretinal and/or intraretinal fluid. Conclusion: Unintended lapses during COVID-19 pandemic resulted with poor functional and structural outcomes for nAMD patients, especially for those at the beginning of the treatment period and who still have an unstable clinical course.
C1 [Sekeroglu, Mehmet Ali; Kilinc Hekimsoy, Hilal; Horozoglu Ceran, Tugce; Doguizi, Sibel] Univ Hlth Sci, Ulucanlar Eye Training & Res Hosp, Ophthalmol Clin, Ankara, Turkey.
C3 Ankara Ulucanlar Eye Training & Research Hospital; University of Health
   Sciences Turkey
RP Sekeroglu, MA (通讯作者)，Univ Hlth Sci, Ulucanlar Eye Training & Res Hosp, TR-06240 Ankara, Turkey.
EM msekeroglu@yahoo.com
RI Kılınç, Hilal/GQB-0245-2022
OI SEKEROGLU, MEHMET ALI/0000-0002-0467-1480; Horozoglu Ceran,
   Tugce/0000-0003-2132-3098
CR American Academy of Ophthalmology, 2020, IMP COR UPD OPHTH
   Ciulla TA, 2020, OPHTHALMOL RETINA, V4, P19, DOI 10.1016/j.oret.2019.05.017
   Dervenis N, 2021, EYE, V35, P1783, DOI 10.1038/s41433-020-1106-7
   Greenlee TE, 2021, RETINA-J RET VIT DIS, V41, P581, DOI 10.1097/IAE.0000000000002888
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Holz FG, 2020, RETINA-J RET VIT DIS, V40, P1673, DOI 10.1097/IAE.0000000000002670
   Jorstad OK, 2020, ACTA OPHTHALMOL, V98, pE388, DOI 10.1111/aos.14426
   Korobelnik JF, 2020, GRAEF ARCH CLIN EXP, V258, P1149, DOI 10.1007/s00417-020-04703-x
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Ramakrishnan MS, 2020, JAMA OPHTHALMOL, V138, P237, DOI 10.1001/jamaophthalmol.2019.4577
   Romano F, 2020, OPHTHALMOL RETINA, V4, P1209, DOI 10.1016/j.oret.2020.06.027
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shmueli O, 2020, EYE, V34, P1165, DOI 10.1038/s41433-020-0925-x
   Soares RR, 2020, OPHTHALMOL RETINA, V4, P134, DOI 10.1016/j.oret.2019.07.010
   Stone LG, 2020, GRAEF ARCH CLIN EXP, V258, P2639, DOI 10.1007/s00417-020-04849-8
   Teo KYC, 2020, OPHTHALMOL RETINA, V4, P871, DOI 10.1016/j.oret.2020.03.017
   The Royal College of Ophthalmologists, 2020, MED RET MAN PLANS CO
   Vaze A, 2014, RETINA-J RET VIT DIS, V34, P1774, DOI 10.1097/IAE.0000000000000173
   Veritti D, 2020, EUR J OPHTHALMOL, V30, P621, DOI 10.1177/1120672120927865
   Weber M, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01468-z
   Weiss M, 2018, RETINA-J RET VIT DIS, V38, P2293, DOI 10.1097/IAE.0000000000001892
   Wickham L, 2020, EYE, V34, P1189, DOI 10.1038/s41433-020-0957-2
   Wong TY, 2020, RETINA-J RET VIT DIS, V40, P599, DOI 10.1097/IAE.0000000000002768
   Yalamanchili SP, 2020, AM J OPHTHALMOL, V219, P215, DOI 10.1016/j.ajo.2020.06.040
NR 26
TC 7
Z9 7
U1 1
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAR
PY 2022
VL 32
IS 2
BP 1064
EP 1072
AR 11206721211010613
DI 10.1177/11206721211010613
EA APR 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZU0VX
UT WOS:000677798900001
PM 33863263
OA Green Published
DA 2022-11-30
ER

PT J
AU Pfau, M
   Muller, PL
   von der Emde, L
   Lindner, M
   Moller, PT
   Fleckenstein, M
   Holz, FG
   Schmitz-Valckenberg, S
AF Pfau, Maximilian
   Mueller, Philipp L.
   von der Emde, Leon
   Lindner, Moritz
   Moeller, Philipp T.
   Fleckenstein, Monika
   Holz, Frank G.
   Schmitz-Valckenberg, Steffen
TI MESOPIC AND DARK-ADAPTED TWO-COLOR FUNDUS-CONTROLLED PERIMETRY IN
   GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE microperimetry; dark-adapted two-color perimetry; scotopic sensitivity;
   macular disease; geographic atrophy
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL SENSITIVITY; VISUAL-ACUITY;
   MICROPERIMETRY; AUTOFLUORESCENCE; PROGRESSION; VULNERABILITY;
   ENLARGEMENT; DISEASE; TRIAL
AB Purpose: To investigate retinal sensitivity in the junctional zone of geographic atrophy (GA) secondary to age-related macular degeneration using patient-tailored perimetry grids for mesopic and dark-adapted two-color fundus-controlled perimetry. Methods: Twenty-five eyes with GA of 25 patients (prospective, natural-history Directional Spread in Geographic Atrophy study [DSGA; NCT02051998]) and 40 eyes of 40 normal subjects were included. Patient-tailored perimetry grids were generated using annotated fundus autofluorescence data. Customized software positioned test-points along iso-hulls surrounding the GA boundary at distances of 0.43 degrees, 0.86 degrees, 1.29 degrees, 2.15 degrees, and 3.01 degrees. The grids were used for duplicate mesopic and dark-adapted two-color (cyan and red) fundus-controlled perimetry. Age-adjusted reference-data were obtained through regression analysis of normative data followed by spatial interpolation. Results: The mean sensitivity loss for mesopic testing decreased with the distance to GA (-10.3 dB [0.43 degrees], -8.2 dB [0.86 degrees], -7.1 dB [1.29 degrees], -6.8 dB [2.15 degrees], and -6.6 dB [3.01 degrees]; P < 0.01). Dark-adapted cyan sensitivity loss exceeded dark-adapted red sensitivity loss for all iso-hulls (-14.8 vs. -11.7 dB, -13.5 vs. -10.1 dB, -12.8 vs. -9.1 dB, -11.6 vs. -8.2 dB, -10.7 vs. -8.0 dB; P < 0.01). Conclusion: Patient-tailored fundus-controlled perimetry grids allowed for testing of retinal function in the junctional zone of GA with high spatial resolution. A distinct decrease in mesopic sensitivity loss between 0.43 degrees (125 mu m) and 1.29 degrees (375 mu m) was observed that leveled off at more distant test-points. In proximity to the GA boundary, the results indicate that rod exceeded cone dysfunction.
C1 [Pfau, Maximilian; Mueller, Philipp L.; von der Emde, Leon; Lindner, Moritz; Moeller, Philipp T.; Fleckenstein, Monika; Holz, Frank G.; Schmitz-Valckenberg, Steffen] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
   [Pfau, Maximilian; Moeller, Philipp T.; Fleckenstein, Monika; Holz, Frank G.; Schmitz-Valckenberg, Steffen] Univ Bonn, GRADE Reading Ctr, Bonn, Germany.
   [Mueller, Philipp L.] Univ Bonn, Ctr Rare Dis, Bonn, Germany.
   [Lindner, Moritz] Nuffield Univ Oxford, Sleep & Circadian Neurosci Inst, Dept Clin Neurosci, Nuffield Lab Ophthalmol, Oxford, England.
C3 University of Bonn; University of Bonn; University of Bonn; University
   of Oxford
RP Schmitz-Valckenberg, S (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM steffen.schmitz-vakkenberg@ukbbonn.de
RI Müller, Philipp L./P-3350-2019; Lindner, Moritz/AAC-8639-2021
OI Lindner, Moritz/0000-0002-4416-3421
FU BONFOR Program of the Faculty of Medicine, University of Bonn
   [O-137.0022, O-137.0025, O-137.0023]; German Research Foundation
   [658/4-1, 658/4-2, 2846/1-1, MU4279/1-1]
FX Supported by the BONFOR Program of the Faculty of Medicine, University
   of Bonn (Grant No. O-137.0022 and O-137.0025 to M.P., Grant No.
   O-137.0023 to P.L.M.) and by the German Research Foundation (Grant No.
   658/4-1 and 658/4-2 to M.F., 2846/1-1 to M.L., and MU4279/1-1 to P.M.).
CR Chen FK, 2011, RETINA-J RET VIT DIS, V31, P371, DOI 10.1097/IAE.0b013e3181e46af3
   Cideciyan AV, 2012, INVEST OPHTH VIS SCI, V53, P841, DOI 10.1167/iovs.11-8415
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Denniss J, 2016, INVEST OPHTH VIS SCI, V57, P5449, DOI 10.1167/iovs.16-20222
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Gass J D, 1972, Trans Am Ophthalmol Soc, V70, P409
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Hariri AH, 2016, AM J OPHTHALMOL, V168, P122, DOI 10.1016/j.ajo.2016.05.007
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jaffe GJ, 2015, AM J OPHTHALMOL, V160, P1226, DOI 10.1016/j.ajo.2015.08.024
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lindner M, 2017, INVEST OPHTH VIS SCI, V58, pBIO61, DOI 10.1167/iovs.16-21210
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Mauschitz MM, 2012, INVEST OPHTH VIS SCI, V53, P4932, DOI 10.1167/iovs.12-9711
   Meleth AD, 2011, INVEST OPHTH VIS SCI, V52, P1119, DOI 10.1167/iovs.10-6075
   Olsson J, 1997, ACTA OPHTHALMOL SCAN, V75, P181
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Pfau M, 2017, INVEST OPHTH VIS SCI, V58, P158, DOI 10.1167/iovs.17-21454
   Pfau M, 2018, BRIT J OPHTHALMOL, V102, P1054, DOI 10.1136/bjophthalmol-2017-311012
   Pfau M, 2017, INVEST OPHTH VIS SCI, V58, pBIO121, DOI 10.1167/iovs.17-21764
   Pfau M, 2017, OPHTHALMOLOGICA, V237, P42, DOI 10.1159/000453079
   Pilotto E, 2013, CAN J OPHTHALMOL, V48, P386, DOI 10.1016/j.jcjo.2013.03.022
   Querques L, 2012, AM J OPHTHALMOL, V153, P1110, DOI 10.1016/j.ajo.2011.11.002
   Rohrschneider K, 2008, PROG RETIN EYE RES, V27, P536, DOI 10.1016/j.preteyeres.2008.07.003
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sayegh RG, 2014, BRIT J OPHTHALMOL, V98, P1050, DOI 10.1136/bjophthalmol-2014-305195
   Sayegh RG, 2017, AM J OPHTHALMOL, V179, P118, DOI 10.1016/j.ajo.2017.03.031
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGICA, V235, P215, DOI 10.1159/000445217
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Simunovic MP, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.3.10
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Steinberg JS, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.4.7
   STEINMAN RM, 1965, J OPT SOC AM, V55, P1158, DOI 10.1364/JOSA.55.001158
   Sunness Janet S, 2008, Retin Cases Brief Rep, V2, P205, DOI 10.1097/ICB.0b013e31806011e6
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness Janet S, 2008, Retin Cases Brief Rep, V2, P83, DOI 10.1097/IAE.0b013e31802fa25d
   Sunness JS, 1999, MOL VIS, V5
   SUNNESS JS, 1988, ARCH OPHTHALMOL-CHIC, V106, P1081, DOI 10.1001/archopht.1988.01060140237032
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Takahashi A, 2016, AM J OPHTHALMOL, V168, P260, DOI 10.1016/j.ajo.2016.06.006
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS26, DOI 10.1097/IAE.0000000000001330
NR 55
TC 26
Z9 26
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2020
VL 40
IS 1
BP 169
EP 180
DI 10.1097/IAE.0000000000002337
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LA1PT
UT WOS:000523727600021
PM 30300264
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Nielsen, MK
   Subhi, Y
   Molbech, CR
   Falk, MK
   Nissen, MH
   Sorensen, TL
AF Nielsen, Marie Krogh
   Subhi, Yousif
   Molbech, Christopher Rue
   Falk, Mads Kruger
   Nissen, Mogens Holst
   Sorensen, Torben Lykke
TI Systemic Levels of Interleukin-6 Correlate With Progression Rate of
   Geographic Atrophy Secondary to Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE geographic atrophy; age-related macular degeneration; chronic
   inflammation; inflammaging; interleukin 6
ID C-REACTIVE PROTEIN; COMPLEMENT FACTOR-H; PHYSICAL-ACTIVITY; RECEPTOR;
   CELLS; INFLAMMATION; ASSOCIATION; MARKERS; DISEASE; RISK
AB PURPOSE. Geographic atrophy (GA) is a clinical phenotype of late age-related macular degeneration (AMD) with no current treatment available. In this study, we investigated markers of chronic inflammation in plasma of patients with GA and how these relate to progression rate.
   METHODS. We prospectively included 42 patients with GA, 41 patients with neovascular AMD, and 27 healthy controls. We quantified levels of interleukin (IL)-1b, IL-6, IL-8, tumor necrosis factor (TNF) receptor 2, and C-reactive protein (CRP). We adapted an inflammation summary score to cluster conceptually related markers of chronic inflammation. Enlargement rate of the atrophic lesion was measured from fundus autofluorescence images performed at baseline and after 1 year.
   RESULTS. Patients with GA showed an increase in proinflammatory markers of IL-6 (P = 0.009), TNF receptor 2 (P = 0.013), and CRP (P = 0.017) compared to healthy controls. We found that IL-8 levels were markedly higher in patients with GA when compared to patients with neovascular AMD (P = 0.013). The inflammation summary score was high in patients with neovascular AMD (P = 0.024), but even higher in patients with GA (< 0.001), when compared to healthy controls. GA enlargement was measured in 36 patients, who completed follow-up. Plasma levels of IL-6 had a moderate but significant correlation with GA enlargement rate (R 2 = 0.23, P = 0.0035).
   CONCLUSIONS. Markers of chronic inflammation strongly associates with presence of GA secondary to AMD. Plasma IL-6 possesses predictive ability of progression and constitutes the first known plasma biomarker of disease activity in GA. These findings shed light into a poorly understood clinical phenotype of AMD and highlights the important role of chronic inflammation in GA.
C1 [Nielsen, Marie Krogh; Subhi, Yousif; Molbech, Christopher Rue; Falk, Mads Kruger; Sorensen, Torben Lykke] Zealand Univ Hosp, Dept Ophthalmol, Clin Eye Res Div, Roskilde, Denmark.
   [Nielsen, Marie Krogh; Subhi, Yousif; Molbech, Christopher Rue; Falk, Mads Kruger; Nissen, Mogens Holst; Sorensen, Torben Lykke] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
   [Nissen, Mogens Holst] Univ Copenhagen, Dept Immunol & Microbiol, Eye Res Unit, Copenhagen, Denmark.
C3 University of Copenhagen; University of Copenhagen
RP Nielsen, MK (通讯作者)，Zealand Univ Hosp, Dept Ophthalmol, Clin Eye Res Div, Roskilde, Denmark.; Nielsen, MK (通讯作者)，Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
EM mrrm@regionsjaelland.dk
RI Subhi, Yousif/ABG-6330-2020
OI Subhi, Yousif/0000-0001-6620-5365; Krogh Nielsen,
   Marie/0000-0003-3804-7296
FU Velux Foundation; Ojenfonden; Region Zealand
FX Supported by The Velux Foundation, Ojenfonden, and the Region Zealand.
   None of the funding bodies had any role in design, execution, or
   interpretation of the research performed.
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Bunce C, 2014, BRIT J OPHTHALMOL, V98, P408, DOI 10.1136/bjophthalmol-2013-304587
   Campisi J, 2011, CURR OPIN GENET DEV, V21, P107, DOI 10.1016/j.gde.2010.10.005
   Charo IF, 2006, NEW ENGL J MED, V354, P610, DOI 10.1056/NEJMra052723
   Cohen J., 1988, STAT POWER ANAL SOCI, V2nd
   Colak E, 2017, J CLIN BIOCHEM NUTR, V60, P100, DOI 10.3164/jcbn.16-30
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Corlier F, 2018, NEUROIMAGE, V172, P118, DOI 10.1016/j.neuroimage.2017.12.027
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   De Felice FG, 2014, DIABETES, V63, P2262, DOI 10.2337/db13-1954
   Faber C, 2015, ACTA OPHTHALMOL, V93, P242, DOI 10.1111/aos.12581
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Feuer WJ, 2013, JAMA OPHTHALMOL, V131, P110, DOI 10.1001/jamaophthalmol.2013.572
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Franceschi C, 2000, ANN NY ACAD SCI, V908, P244
   FRASCA D, 2016, BIOGERONTOLOGY, V17, P7, DOI DOI 10.1007/S10522-015-9578-8
   Freund A, 2010, TRENDS MOL MED, V16, P238, DOI 10.1016/j.molmed.2010.03.003
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Ghanemi A, 2018, CYTOKINE, V112, P132, DOI 10.1016/j.cyto.2018.06.034
   Goczalik I, 2008, INVEST OPHTH VIS SCI, V49, P4578, DOI 10.1167/iovs.08-1887
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Haas P, 2015, ACTA OPHTHALMOL, V93, P533, DOI 10.1111/aos.12670
   Heink S, 2017, NAT IMMUNOL, V18, P74, DOI 10.1038/ni.3632
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Jostock T, 2001, EUR J BIOCHEM, V268, P160, DOI 10.1046/j.1432-1327.2001.01867.x
   Juel HB, 2012, INVEST OPHTH VIS SCI, V53, P8472, DOI 10.1167/iovs.12-9963
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Liu YJ, 2010, NEUROBIOL AGING, V31, P175, DOI 10.1016/j.neurobiolaging.2008.03.024
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   NARAZAKI M, 1993, BLOOD, V82, P1120, DOI 10.1182/blood.V82.4.1120.bloodjournal8241120
   Nikolich-Zugich J, 2008, NAT REV IMMUNOL, V8, P512, DOI 10.1038/nri2318
   Powell N, 2015, GASTROENTEROLOGY, V149, P456, DOI 10.1053/j.gastro.2015.04.017
   Rifai N, 2001, CLIN CHEM, V47, P28
   ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Subhi Yousif, 2016, Dan Med J, V63
   Subhi Y, 2014, CLIN OPHTHALMOL, V8, P15, DOI 10.2147/OPTH.S55080
   TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8
   Touhami S, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1106-8
   van Woudenbergh GJ, 2013, AM J CLIN NUTR, V98, P1533, DOI 10.3945/ajcn.112.056333
   Wu R, 2018, METABOLISM, V83, P18, DOI 10.1016/j.metabol.2018.01.002
   Yasuma TR, 2010, MOL VIS, V16, P2923
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Zhang SJ, 2016, INVEST OPHTH VIS SCI, V57, P312, DOI 10.1167/iovs.15-17578
NR 52
TC 35
Z9 35
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2019
VL 60
IS 1
BP 202
EP 208
DI 10.1167/iovs.18-25878
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HH9WS
UT WOS:000456092300017
PM 30644965
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ho, CYD
   Wu, ZC
   Turpin, A
   Lawson, DJ
   Luu, CD
   McKendrick, AM
   Guymer, RH
AF Ho, Chi Yun Doreen
   Wu, Zhichao
   Turpin, Andrew
   Lawson, David J.
   Luu, Chi D.
   McKendrick, Allison M.
   Guymer, Robyn H.
TI A Tablet-Based Retinal Function Test in Neovascular Age-Related Macular
   Degeneration Eyes and At-Risk Fellow Eye
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE age-related macular degeneration; tablet-device; home monitoring
ID TEST-RETEST VARIABILITY; SUBGROUP ANALYSIS; VISUAL OUTCOMES;
   MICROPERIMETRY; RANIBIZUMAB; SENSITIVITY; RELIABILITY; PERIMETRY
AB Purpose: To determine the feasibility of a tablet-based application to detect changes in retinal sensitivity and correlations with underlying pathology in neovascular age-related macular degeneration (nAMD) eyes undergoing treatment and in at-risk fellow eyes.
   Method: Participants with nAMD in at least one eye were recruited, examined, and imaged using spectral-domain optical coherence tomography (SD-OCT). Retinal sensitivity was measured within the central 5 degrees at 12 locations using a customized test delivered on an iPad. Test points were superimposed on SD-OCT locations to investigate structure/function relationships.
   Results: Included in the study were 53 nAMD eyes and 21 at-risk fellow eyes. In nAMD eyes, the mean retinal sensitivity was 24.1 +/- 1.8 dB with reduced retinal sensitivity associated with the presence of atrophy (P < 0.01), retinal pigment epithelium (RPE) disruption (P < 0.01), and absent ellipsoid zone (EZ) (P < 0.01), but not with the presence of subretinal fluid (P = 0.94) nor intraretinal fluid (P = 0.52). In at-risk eyes, the average retinal sensitivity was 28.8 +/- 0.6 dB, with reduced sensitivity significantly associated with the presence of drusen, atrophy, RPE disruption, and absent EZ (P < 0.01).
   Conclusion: The tablet-based test of retinal sensitivity was able to be performed by an elderly cohort with nAMD. The ability to correlate differences in sensitivity with pathology is encouraging when considering using the tablet devices as a home monitoring tool with remote surveillance. Dual pathology often present with retinal fluid confounded our ability to correlate fluid with sensitivity.
   Translational Relevance: These findings highlight the potential of tablet-based devices in performing visual function measures as a home monitoring tool with remote surveillance for the earlier detection of nAMD.
C1 [Ho, Chi Yun Doreen; Wu, Zhichao; Luu, Chi D.; Guymer, Robyn H.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Australia.
   [Ho, Chi Yun Doreen; Wu, Zhichao; Luu, Chi D.; Guymer, Robyn H.] Univ Melbourne, Dept Surg Ophthalmol, Melbourne, Vic, Australia.
   [Turpin, Andrew; Lawson, David J.] Univ Melbourne, Dept Comp & Informat Syst, Melbourne, Vic, Australia.
   [McKendrick, Allison M.] Univ Melbourne, Dept Optometry & Vis Sci, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; University of Melbourne; University of
   Melbourne
RP Ho, CYD (通讯作者)，Ctr Eye Res Australia, Level 1,32 Gisborne St, Melbourne, Vic 3002, Australia.
EM cy.doreen.ho@gmail.com
RI McKendrick, Allison M/A-2114-2008
OI McKendrick, Allison/0000-0003-1972-1222; Guymer,
   Robyn/0000-0002-9441-4356
FU National Health and Medical Research Council [1104985, 1103013]
FX Supported by National Health and Medical Research Council Early Career
   Fellowship Grant 1104985 (ZW) and Research Fellowship 1103013 (RHG).
   CERA receives operational infrastructure support from the Victorian
   Government.
CR Bhardwaj V, 2013, J CLIN DIAGN RES, V7, P2211, DOI 10.7860/JCDR/2013/7015.3473
   Birt CM, 1997, OPHTHALMOLOGY, V104, P1126, DOI 10.1016/S0161-6420(97)30173-0
   Bittner A, 2014, J CLIN ESP OPHTHALMO, V5
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Chen FK, 2009, INVEST OPHTH VIS SCI, V50, P3464, DOI 10.1167/iovs.08-2926
   Chew EY, 2014, CONTEMP CLIN TRIALS, V37, P294, DOI 10.1016/j.cct.2014.02.003
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Hartmann KI, 2015, OSLI RETINA, V46, P824, DOI 10.3928/23258160-20150909-06
   Hautamaki A, 2014, ACTA OPHTHALMOL, V92, P51, DOI 10.1111/j.1755-3768.2012.02556.x
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2013, RETINA-J RET VIT DIS, V33, P1863, DOI 10.1097/IAE.0b013e3182899258
   Keane PA, 2015, CLIN OPHTHALMOL, V9, P353, DOI 10.2147/OPTH.S59012
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Liu L, 2014, OPTOMETRY VISION SCI, V91, P956, DOI 10.1097/OPX.0000000000000324
   Loewenstein A, 2003, OPHTHALMOLOGY, V110, P966, DOI 10.1016/S0161-6420(03)00074-5
   Loewenstein A, 2007, RETINA-J RET VIT DIS, V27, P873, DOI 10.1097/IAE.0b013e318050d2ec
   McCamy MB, 2013, PEERJ, V1, DOI 10.7717/peerj.9
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Mitchell P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101072
   Rauch R, 2012, RETINA-J RET VIT DIS, V32, P1260, DOI 10.1097/IAE.0b013e3182018df6
   Remky A, 2005, BRIT J OPHTHALMOL, V89, P464, DOI 10.1136/bjo.2004.050260
   Rohrschneider K, 1998, AM J OPHTHALMOL, V126, P52, DOI 10.1016/S0002-9394(98)00065-8
   Sulzbacher F, 2013, INVEST OPHTH VIS SCI, V54, P1310, DOI 10.1167/iovs.12-11046
   Sulzbacher F, 2012, INVEST OPHTH VIS SCI, V53, P6448, DOI 10.1167/iovs.11-9162
   Takamine Y, 1998, GRAEF ARCH CLIN EXP, V236, P285, DOI 10.1007/s004170050079
   Turpin A, 2014, J VISION, V14, DOI 10.1167/14.3.16
   Wang SJ, 2015, MATH PROBL ENG, V2015, DOI 10.1155/2015/892304
   Weingessel B, 2009, EYE, V23, P1052, DOI 10.1038/eye.2008.237
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P115, DOI 10.1167/iovs.14-15614
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1445, DOI 10.1016/j.ophtha.2014.01.025
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 34
TC 9
Z9 9
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD MAR
PY 2018
VL 7
IS 2
AR 2
DI 10.1167/tvst.7.2.2
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FZ1WI
UT WOS:000427367800002
PM 29520334
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Zhu, W
   Wu, Y
   Meng, YF
   Xing, Q
   Tao, JJ
   Lu, J
AF Zhu, Wei
   Wu, Yan
   Meng, Yi-Fang
   Xing, Qian
   Tao, Jian-Jun
   Lu, Jiong
TI Fish Consumption and Age-Related Macular Degeneration Incidence: A
   Meta-Analysis and Systematic Review of Prospective Cohort Studies
SO NUTRIENTS
LA English
DT Review
DE age-related macular degeneration; fish; nutrients; meta-analysis
ID DIETARY FATTY-ACIDS; LONG-TERM INCIDENCE; RISK; SUPPLEMENTATION;
   ASSOCIATION; ZEAXANTHIN; HEALTH; LUTEIN; PROGRESSION; SMOKING
AB The association between fish consumption and risk of age-related macular degeneration (AMD) is still unclear. The aim of the current meta-analysis and systematic review was to quantitatively evaluate findings from observational studies on fish consumption and the risk of AMD. Relevant studies were identified by searching electronic databases (Medline and EMBASE) and reviewing the reference lists of relevant articles up to August, 2016. Prospective cohort studies that reported relative risks (RRs) and 95% confidence intervals (CIs) for the link between fish consumption and risk of AMD were included. A total of 4202 cases with 128,988 individuals from eight cohort studies were identified in the current meta-analysis. The meta-analyzed RR was 0.76 (95% CI, 0.65-0.90) when any AMD was considered. Subgroup analyses by AMD stages showed that fish consumption would reduce the risk of both early (RR, 0.83; 95% CI, 0.72-0.96) and late (RR; 0.76; 95% CI, 0.60-0.97) AMD. When stratified by the follow-up duration, fish consumption was a protective factor of AMD in both over 10 years (n = 5; RR, 0.81; 95% CI, 0.67-0.97) and less than 10 years (n = 3; RR, 0.70; 95% CI, 0.51 to 0.97) follow-up duration. Stratified analyses by fish type demonstrated that dark meat fish (RR, 0.68, 95% CI, 0.46-0.99), especially tuna fish (RR, 0.58; 95% CI, 95% CI, 0.47-0.71) intake was associated with reduced AMD risk. Evidence of a linear association between dose of fish consumption and risk of AMD was demonstrated. The results of this meta-analysis demonstrated that fish consumption can reduce AMD risk. Advanced, well-designed, randomized clinical trials are required in order to validate the conclusions in this study.
C1 [Zhu, Wei; Meng, Yi-Fang; Xing, Qian; Tao, Jian-Jun; Lu, Jiong] Changshu 2 Peoples Hosp, Dept Ophthalmol, Changshu 215500, Peoples R China.
   [Wu, Yan] Soochow Univ, Hosp 1, Dept Ophthalmol, Suzhou 215000, Peoples R China.
C3 Soochow University - China
RP Lu, J (通讯作者)，Changshu 2 Peoples Hosp, Dept Ophthalmol, Changshu 215500, Peoples R China.
EM shzhuwei0722@163.com; txwuyan@suda.edu.cn; meng_yi_fang@163.com;
   drzheng_gu@163.com; prxuming@163.com; cslujiong@163.com
CR Akuffo KO, 2015, EYE, V29, P902, DOI 10.1038/eye.2015.64
   Akuffo KO, 2014, OPHTHAL EPIDEMIOL, V21, P111, DOI 10.3109/09286586.2014.888085
   Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Brasky TM, 2013, JNCI-J NATL CANCER I, V105, P1132, DOI 10.1093/jnci/djt174
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Cialdella-Kam L, 2016, NUTRIENTS, V8, DOI 10.3390/nu8050277
   Dawczynski J, 2013, GRAEF ARCH CLIN EXP, V251, P2711, DOI 10.1007/s00417-013-2376-6
   Gong YF, 2016, NUTRIENTS, V8, DOI 10.3390/nu8060357
   HARRELL FE, 1988, J NATL CANCER I, V80, P1198, DOI 10.1093/jnci/80.15.1198
   Iannaccone A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145323
   Kabasawa S, 2011, OPHTHALMOLOGY, V118, P1082, DOI 10.1016/j.ophtha.2010.10.012
   Larsson SC, 2010, JAMA-J AM MED ASSOC, V303, P1077, DOI 10.1001/jama.2010.263
   Lawrenson J. G., 2015, COCHRANE DB SYST REV, V11
   Ma L, 2016, NUTRIENTS, V8, DOI 10.3390/nu8070426
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Merle BMJ, 2013, J NUTR, V143, P505, DOI 10.3945/jn.112.171033
   Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]
   Montgomery MP, 2010, OPHTHAL EPIDEMIOL, V17, P58, DOI 10.3109/09286580903450353
   Mozaffarian D, 2006, JAMA-J AM MED ASSOC, V296, P1885, DOI 10.1001/jama.296.15.1885
   NETTLETON JA, 1991, J AM DIET ASSOC, V91, P331
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Querques G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149219
   Robman L, 2007, CAN J OPHTHALMOL, V42, P720, DOI 10.3129/i07-116
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Saksens NTM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0144367
   SanGiovanni John Paul, 2008, Arch Ophthalmol, V126, P1274, DOI 10.1001/archopht.126.9.1274
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Wang JJ, 2014, OPHTHALMOLOGY, V121, P667, DOI 10.1016/j.ophtha.2013.10.017
NR 46
TC 24
Z9 24
U1 1
U2 11
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD NOV
PY 2016
VL 8
IS 11
AR 743
DI 10.3390/nu8110743
PG 14
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA ED2IE
UT WOS:000388666400074
PM 27879656
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Bhutto, IA
   Baba, T
   Merges, C
   Juriasinghani, V
   McLeod, DS
   Lutty, GA
AF Bhutto, Imran A.
   Baba, Takayuki
   Merges, Carol
   Juriasinghani, Vikash
   McLeod, D. Scott
   Lutty, Gerard A.
TI C-reactive protein and complement factor H in aged human eyes and eyes
   with age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID AORTIC ENDOTHELIAL-CELLS; EPITHELIAL-CELLS; DRUSEN FORMATION; DISEASE;
   RISK; CRP; CHORIOCAPILLARIS; LOCALIZATION; PATHOGENESIS; INFLAMMATION
AB Background There is increasing evidence that inflammation and immune-mediated processes (complement activation) play an important role in age-related macular degeneration (AMD) pathogenesis. A genetic variation in the gene encoding complement factor H (CFH) and plasma levels of C-reactive protein (CRP), a systemic marker of subclinical inflammation, have consistently been shown to be associated with an increased risk for AMD. In the present study, we examined the immunolocalisation of CRP and CFH in aged control human donor eyes (n = 10; mean age 79 years) and eyes with AMD (n = 18; mean age 83 years).
   Methods Alkaline phosphatase immunohistochemistry was performed using polyclonal antibodies against CRP and CFH on cryopreserved tissue sections from disc/macular blocks. Three independent masked observers scored the reaction product (0-8).
   Results In aged control eyes, the retinal pigment epithelium/Bruch's membrane/choriocapillaris (RPE/BrM/CC) complex including intercapillary septa (ICS) had the most prominent immunostaining for CRP and CFH. CRP was significantly higher than controls in BrM/CC/ICS and choroidal stroma in early and wet AMD eyes (p<0.05). In contrast, CFH was significantly lower in BrM/CC/ICS complex of AMD choroids than in controls (p<0.05). Interestingly, CRP and CFH were significantly reduced in BrM/CC/ICS complex in atrophic area of macula in geographical atrophy (p<0.05). Drusen and basal laminar deposits were intensely positive for CRP and CFH.
   Conclusion These immunohistochemical findings show that changes in distribution and relative levels of CRP and CFH were evident in early and late AMD eyes. This suggests that high levels of CRP and insufficient CFH at the retina/choroid interface may lead to uncontrolled complement activation with associated cell and tissue damage. This study supports the hypothesis that inflammation and immune-mediated mechanisms are involved in the pathogenesis of AMD.
C1 [Bhutto, Imran A.; Baba, Takayuki; Merges, Carol; Juriasinghani, Vikash; McLeod, D. Scott; Lutty, Gerard A.] Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, Dept Ophthalmol, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Lutty, GA (通讯作者)，Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, Dept Ophthalmol, M041 Smith Bldg,400 N Broadway, Baltimore, MD 21287 USA.
EM galutty@jhmi.edu
RI VIKASH, ,/B-2293-2016
OI VIKASH, ,/0000-0001-6063-1558
FU NIH [EY-01765, R01-EY016151]; Research to Prevent Blindness; Foundation
   Fighting Blindness; American Health Assistance Foundation; Altsheler
   Durell Foundation; RPB Senior Scientific Investigator Award; NATIONAL
   EYE INSTITUTE [R01EY016151, P30EY001765] Funding Source: NIH RePORTER
FX This work was supported by NIH grants: EY-01765 (Wilmer) and
   R01-EY016151 (GAL), unrestricted funds from Research to Prevent
   Blindness (Wilmer), the Foundation Fighting Blindness (GAL), American
   Health Assistance Foundation (GL), and the Altsheler Durell Foundation.
   GAL received an RPB Senior Scientific Investigator Award.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   BARNA BP, 1984, CANCER RES, V44, P305
   Bhutto IA, 2004, INVEST OPHTH VIS SCI, V45, P1544, DOI 10.1167/iovs.03-0862
   Bhutto IA, 2010, EXP EYE RES, V90, P155, DOI 10.1016/j.exer.2009.10.004
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Dehghan A, 2007, DIABETES CARE, V30, P2695, DOI 10.2337/dc07-0348
   Devaraj S, 2005, ARTERIOSCL THROM VAS, V25, P1359, DOI 10.1161/01.ATV.0000168573.10844.ae
   Devaraj S, 2006, AM J PHYSIOL-HEART C, V291, pH1170, DOI 10.1152/ajpheart.00150.2006
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FIEDEL BA, 1985, BLOOD, V65, P264
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   KAPLAN MH, 1974, J IMMUNOL, V112, P2135
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   LUTTY GA, 1993, INVEST OPHTH VIS SCI, V34, P477
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Mullins RF, 2006, MOL VIS, V12, P224
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Pearson TA, 2003, CIRCULATION, V107, P499, DOI 10.1161/01.CIR.0000052939.59093.45
   Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Venugopal SK, 2002, CIRCULATION, V106, P1439, DOI 10.1161/01.CIR.0000033116.22237.F9
   Yeh ETH, 2004, CIRCULATION, V109, P11, DOI 10.1161/01.CIR.0000129507.12719.80
NR 31
TC 91
Z9 91
U1 0
U2 10
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2011
VL 95
IS 9
BP 1323
EP 1330
DI 10.1136/bjo.2010.199216
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 809HU
UT WOS:000294043200028
PM 21633121
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Bonnin, P
   Pournaras, JAC
   Makowiecka, K
   Krivosic, V
   Kedra, AW
   Le Gargasson, JF
   Gaudric, A
   Levy, BI
   Cohen, YS
   Tadayoni, R
   Massin, P
AF Bonnin, Philippe
   Pournaras, Jean-Antoine C.
   Makowiecka, Katarzyna
   Krivosic, Valerie
   Kedra, Antoni W.
   Le Gargasson, Jean-Francois
   Gaudric, Alain
   Levy, Bernard I.
   Cohen, Yves S.
   Tadayoni, Ramin
   Massin, Pascale
TI Ultrasound assessment of ocular vascular effects of repeated
   intravitreal injections of ranibizumab for wet age-related macular
   degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; anti-angiogenic therapy; central
   retinal artery; ciliary artery; ophthalmic artery
ID ANTI-VEGF TREATMENT; RETINAL BLOOD-FLOW; ISCHEMIC SYNDROME; BEVACIZUMAB;
   DISEASE; EYE
AB Purpose: Determine the effect of repeated intravitreal injections of ranibizumab (0.5 mg; 0.05 ml) on retrobulbar blood flow velocities (BFVs) using ultrasound imaging quantification in twenty patients with exudative age-related macular degeneration treated for 6 months.
   Methods: Visualacuity(ETDRS), central macular thickness(OCT), peak-systolic, end-diastolic and mean-BFVs in central retinal (CRA), temporal posterior ciliary (TPCA) and ophthalmic (OA) arteries were measured before, 2 days, 3 weeks and 6 months after the first injection. Patients were examined monthly and received 1-5 additional injections depending on ophthalmologic examination results.
   Results: Six months after the first injection, a significant increase in visual acuity 50.9 +/- 25.9 versus 44.4 +/- 21.7 (p < 0.01) and decrease in mean central macular thickness 267 +/- 74 versus 377 +/- 115 mu m (p < 0.001) were observed compared to baseline. Although mean-BFVs decreased by 16% +/- 3% in CRA and 20% +/- 5% in TPCA (p < 0.001) 2 days after the first injection, no significant change was seen thereafter. Mean-BFVs in OA decreased by 19% +/- 5% at week 3 (p < 0.001). However, the smallest number of injections (two injections) was associated with the longest time interval between the last injection and month 6 (20 weeks) and with the best return to baseline levels for mean-BFVs in CRA, suggesting that ranibizumab had reversible effects on native retinal vascular supply after its discontinuation. Moreover, a significant correlation between the number of injections and percentage of changes in mean-BFVs in CRA was observed at month 6 (R = 0.74, p < 0.001) unlike TPCA or OA.
   Conclusion: Ranibizumab could impair the native choroidal and retinal vascular networks, but its effect seems reversible after its discontinuation.
C1 [Bonnin, Philippe; Makowiecka, Katarzyna; Kedra, Antoni W.; Le Gargasson, Jean-Francois; Levy, Bernard I.] Paris Diderot Univ, Lariboisiere Hosp, AP HP, Sorbonne Paris Cite,Dept Clin Physiol Funct Inves, Paris, France.
   [Bonnin, Philippe] Paris Diderot Univ, Lariboisiere Hosp, Sorbonne Paris Cite, INSERM,U965, Paris, France.
   [Pournaras, Jean-Antoine C.; Krivosic, Valerie; Gaudric, Alain; Cohen, Yves S.; Tadayoni, Ramin; Massin, Pascale] Paris Diderot Univ, Lariboisiere Hosp, AP HP, Sorbonne Paris Cite,Dept Ophthalmol, Paris, France.
   [Pournaras, Jean-Antoine C.] Univ Lausanne, Jules Gonin Ophthalmol Hosp, Lausanne, Switzerland.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities;
   Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP);
   Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut
   National de la Sante et de la Recherche Medicale (Inserm); UDICE-French
   Research Universities; Universite Paris Cite; Assistance Publique
   Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal
   - APHP; UDICE-French Research Universities; Universite Paris Cite;
   University of Lausanne
RP Massin, P (通讯作者)，Hop Lariboisiere, Dept Ophthalmol, 2 Rue Ambroise Pare, F-75475 Paris 10, France.
EM pascale.massin@lrb.aphp.fr
RI Bonnin, Philippe/Y-5872-2019
OI Bonnin, Philippe/0000-0003-3184-3740; Gaudric, Alain/0000-0002-2486-4722
CR Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1181
   Bonnin P, 2010, ACTA OPHTHALMOL, V88, P641, DOI 10.1111/j.1755-3768.2009.01526.x
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Huang ZL, 2010, OPHTHALMOLOGICA, V224, P86, DOI 10.1159/000235726
   Kamba T, 2007, BRIT J CANCER, V96, P1788, DOI 10.1038/sj.bjc.6603813
   Kim KS, 2008, ACTA OPHTHALMOL, V86, DOI 10.1111/j.1755-3768.2008.01175.x
   Kofoed PK, 2010, ACTA OPHTHALMOL, V88, P808, DOI 10.1111/j.1755-3768.2009.01612.x
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   KU DD, 1993, AM J PHYSIOL, V265, P586
   Manousaridis K, 2012, BRIT J OPHTHALMOL, V96, P179, DOI 10.1136/bjophthalmol-2011-301087
   Mendrinos E, 2013, ACTA OPHTHALMOL, V91, pE184, DOI 10.1111/aos.12008
   Micieli JA, 2012, ACTA OPHTHALMOL, V90, pE13, DOI 10.1111/j.1755-3768.2011.02209.x
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Mourad JJ, 2008, ANN ONCOL, V19, P927, DOI 10.1093/annonc/mdm550
   Neubauer AS, 2007, OPHTHALMOLOGY, V114, P2096, DOI 10.1016/j.ophtha.2007.05.057
   Papadopoulou DN, 2009, OPHTHALMOLOGY, V116, P1755, DOI 10.1016/j.ophtha.2009.03.017
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Plange N, 2003, BRIT J OPHTHALMOL, V87, P731, DOI 10.1136/bjo.87.6.731
   Pournaras CJ, 2008, PROG RETIN EYE RES, V27, P284, DOI 10.1016/j.preteyeres.2008.02.002
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sacu S, 2011, INVEST OPHTH VIS SCI, V52, P3046, DOI 10.1167/iovs.10-5842
   Shima C, 2008, ACTA OPHTHALMOL, V86, P372, DOI 10.1111/j.1600-0420.2007.01067.x
   Steeghs N, 2010, ANN ONCOL, V21, P1100, DOI 10.1093/annonc/mdp417
   Talty Patrick, 2012, Retin Cases Brief Rep, V6, P65, DOI 10.1097/ICB.0b013e3182051efb
   Tilton RG, 1999, INVEST OPHTH VIS SCI, V40, P689
   Van der Reis MI, 2011, RETINA-J RET VIT DIS, V31, P1449, DOI 10.1097/IAE.0b013e3182278ab4
NR 27
TC 8
Z9 8
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD AUG
PY 2014
VL 92
IS 5
BP E382
EP E387
DI 10.1111/aos.12356
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AL9SZ
UT WOS:000339482700010
PM 25043792
OA Bronze
DA 2022-11-30
ER

PT J
AU Caramoy, A
   Kirchhof, B
   Fauser, S
AF Caramoy, Albert
   Kirchhof, Bernd
   Fauser, Sascha
TI Retinal Pigment Epithelium Tears Secondary to Age-Related Macular
   Degeneration A Simultaneous Confocal Scanning Laser Ophthalmoscopy and
   Spectral-Domain Optical Coherence Tomography Study
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID COHERENCE TOMOGRAPHY; BEVACIZUMAB; DETACHMENT; TRANSLOCATION;
   INJECTIONS; RESOLUTION; THERAPY
AB Objective: To describe the morphology of retinal pigment epithelium (RPE) tears secondary to age-related macular degeneration by using high-resolution, spectral-domain optical coherence tomography (SD-OCT).
   Methods: For simultaneous topographic and tomographic in vivo imaging, confocal scanning laser ophthalmoscopy and spectral-domain optical coherence tomography were applied in combination. Retina over the RPE-denuded area was particularly examined for signs of viable photoreceptors.
   Results: A total of 26 patients (28 eyes) were included in the study. The mean (SD) age of patients was 78 (8) years (age range, 62-91 years). In cases with recent RPE tears, external limiting membrane, photoreceptor inner and outer segment junction, and nonatrophic outer nuclear layer could be identified in the retina on the RPE-denuded area. Intact external limiting membrane, photoreceptor inner and outer segment junction, and nonatrophic outer nuclear layer could be seen in 1 patient for up to 325 days after the RPE tear. In fibrotic older RPE tears, these structures were atrophic.
   Conclusions: In this study, signs for viable photoreceptors could be identified for up to 325 days after an RPE tear using spectral-domain optical coherence tomography. This finding is important to consider in future therapies aimed at rescuing photoreceptors after RPE tears.
C1 [Caramoy, Albert; Kirchhof, Bernd; Fauser, Sascha] Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, D-50924 Cologne, Germany.
C3 University of Cologne
RP Caramoy, A (通讯作者)，Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, Kerpenerstr 62, D-50924 Cologne, Germany.
EM acaramoy@yahoo.co.uk
CR Arroyo JG, 2005, AM J OPHTHALMOL, V139, P605, DOI 10.1016/j.ajo.2004.11.046
   CARAMOY A, ACTA OPHTHA IN PRESS
   Cebulla CM, 2010, EXP EYE RES, V90, P521, DOI 10.1016/j.exer.2010.01.008
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P857, DOI 10.1097/IAE.0b013e3180342c42
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chen YL, 2009, OPT EXPRESS, V17, P4046, DOI 10.1364/OE.17.004046
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   Giovannini A, 2000, RETINA-J RET VIT DIS, V20, P37, DOI 10.1097/00006982-200001000-00007
   Helb HM, 2010, ACTA OPHTHALMOL, V88, P842, DOI 10.1111/j.1755-3768.2009.01602.x
   Kiss C, 2007, ACTA OPHTHALMOL SCAN, V85, P902, DOI 10.1111/j.1600-0420.2007.00928.x
   Kook D, 2008, OPHTHALMOLOGE, V105, P158, DOI 10.1007/s00347-007-1561-6
   Lee GKY, 2007, GRAEF ARCH CLIN EXP, V245, P1225, DOI 10.1007/s00417-007-0536-2
   Leitritz M, 2008, EYE, V22, P1504, DOI 10.1038/eye.2008.145
   Maaijwee K, 2008, BRIT J OPHTHALMOL, V92, P526, DOI 10.1136/bjo.2007.131383
   Matsumoto H, 2009, AM J OPHTHALMOL, V148, P105, DOI 10.1016/j.ajo.2009.01.018
   Pece A, 2010, OPHTHALMOLOGICA, V224, P159, DOI 10.1159/000236910
   Peiretti E, 2006, RETINA-J RET VIT DIS, V26, P1097, DOI 10.1097/01.iae.0000233328.68999.5f
   Polito A, 2011, BRIT J OPHTHALMOL, V95, P74, DOI 10.1136/bjo.2009.170381
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Sayanagi K, 2009, BRIT J OPHTHALMOL, V93, P622, DOI 10.1136/bjo.2008.151977
   Smith BT, 2009, RETINA-J RET VIT DIS, V29, P335, DOI 10.1097/IAE.0b013e318195cad5
NR 24
TC 11
Z9 12
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD MAY
PY 2011
VL 129
IS 5
BP 575
EP 579
DI 10.1001/archophthalmol.2011.105
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 761XU
UT WOS:000290437100005
PM 21555609
OA Bronze
DA 2022-11-30
ER

PT J
AU Mun, Y
   Park, KH
   Park, SJ
   Woo, SJ
AF Mun, Yongseok
   Park, Kyu Hyung
   Park, Sang Jun
   Woo, Se Joon
TI Efficacy of anti-vascular endothelial growth factor agents for treating
   neovascular age-related macular degeneration in vitrectomized eyes
SO PLOS ONE
LA English
DT Article
ID RETINAL VEIN OCCLUSION; INTRAOCULAR PHARMACOKINETICS; INTRAVITREAL
   BEVACIZUMAB; RANIBIZUMAB; EDEMA
AB Purpose To evaluate the efficacy of intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents for treatment of neovascular age-related macular degeneration (nAMD) in vitrectomized eyes.
   Methods The medical records were reviewed of nAMD patients treated with anti-VEGF agents who previously underwent pars plana vitrectomy (PPV). PPV was performed with complete posterior vitreous detachment induction.
   Results A total of 44 eyes from 44 patients were included. The mean central foveal thickness (CFT) was 478.50 156.93 mu m at baseline, 414.25 +/- 143.55 mu m (86.6% of baseline) at 1 month after first injection (P < 0.001), and 386.75 <plus/minus> 141.45 mu m (80.8% of baseline) after monthly multiple injections (2.30 +/- 1.07; range, 1-5) (P < 0.001). The mean logarithm of the minimum angle of resolution best-corrected visual acuity visual acuity (BCVA) was 0.85 <plus/minus> 0.57 at baseline, 0.86 +/- 0.63 after the first injection, and 0.84 +/- 0.64 after monthly multiple injections. BCVA improved in 39.5% at 1 month after first injection and 45.2% at 1 month after monthly multiple injections. In the subgroup analysis, CFT of eyes with the posterior capsule decreased significantly to 85.8% and 79.8% of baseline values at 1 month after the first injection and after monthly multiple injections, respectively. CFT of eyes without the posterior capsule decreased to 91.6% and 87.4% of baseline values at 1 month after the first injection and after monthly multiple injections, respectively, without statistical significance.
   Conclusion Monthly injections of Intravitreal anti-VEGF agents induced favorable anatomical improvement and vision maintenance in vitrectomized eyes with nAMD.
C1 [Mun, Yongseok; Park, Kyu Hyung; Park, Sang Jun; Woo, Se Joon] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul, South Korea.
   [Mun, Yongseok; Park, Kyu Hyung; Park, Sang Jun; Woo, Se Joon] Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU)
RP Woo, SJ (通讯作者)，Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul, South Korea.; Woo, SJ (通讯作者)，Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea.
EM sejoon1@snu.ac.kr
RI Park, Sang Jun/C-3234-2015; Woo, Se Joon/I-7357-2013
OI Park, Sang Jun/0000-0003-0542-2758; Woo, Se Joon/0000-0003-3692-7169;
   Mun, Yongseok/0000-0003-0123-0361
FU National Research Foundation (NRF) [2020R1F1A1072795]; NRF Bio & Medical
   Technology Development Program [2018M3A9B5021319]; Korean government
   (MSIT); Seoul National University Bundang Hospital [13-2019-003]
FX This study was supported by the National Research Foundation (NRF) grant
   2020R1F1A1072795, the NRF Bio & Medical Technology Development Program
   (Grant No. 2018M3A9B5021319) funded by the Korean government (MSIT) and
   a research grant from Seoul National University Bundang Hospital
   (13-2019-003). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Ahn J, 2013, J OCUL PHARMACOL TH, V29, P612, DOI 10.1089/jop.2013.0009
   Ahn SJ, 2014, INVEST OPHTH VIS SCI, V55, P567, DOI 10.1167/iovs.13-13054
   Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002
   Bressler SB, 2015, RETINA-J RET VIT DIS, V35, P2516, DOI 10.1097/IAE.0000000000000617
   Christoforidis JB, 2013, RETINA-J RET VIT DIS, V33, P946, DOI 10.1097/IAE.0b013e3182753b12
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Ferrara N, 2009, EUR CYTOKINE NETW, V20, P158, DOI 10.1684/ecn.2009.0170
   Forouhi NG., 2010, MEDICINE, V38, P602, DOI [10.1016/j.mpmed.2010.08.007, DOI 10.1016/J.MPMED.2010.08.007]
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2020, RETINA-J RET VIT DIS, V40, P1673, DOI 10.1097/IAE.0000000000002670
   Jung JJ, 2016, ACTA OPHTHALMOL, V94, pE249, DOI 10.1111/aos.12840
   Kakinoki M, 2012, INVEST OPHTH VIS SCI, V53, P5877, DOI 10.1167/iovs.12-10164
   Knudsen LL, 2001, GRAEF ARCH CLIN EXP, V239, P832, DOI 10.1007/s004170100355
   Kondo Mineo, 2007, Retin Cases Brief Rep, V1, P195, DOI 10.1097/ICB.0b013e318154b734
   Lange C, 2009, GRAEF ARCH CLIN EXP, V247, P137, DOI 10.1007/s00417-008-0926-0
   Laugesen CS, 2017, ACTA OPHTHALMOL, V95, P28, DOI 10.1111/aos.13160
   Lee SS, 2010, INVEST OPHTH VIS SCI, V51, P2135, DOI 10.1167/iovs.09-3582
   McCannel CA, 2009, OPHTHALMOLOGY, V116, P1366, DOI 10.1016/j.ophtha.2009.01.052
   Mitchell P, 1997, OPHTHALMOLOGY, V104, P1033, DOI 10.1016/S0161-6420(97)30190-0
   Niwa Y, 2015, INVEST OPHTH VIS SCI, V56, P6501, DOI 10.1167/iovs.15-17279
   Noma H, 2015, INVEST OPHTH VIS SCI, V56, P1122, DOI 10.1167/iovs.14-15789
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1274, DOI 10.1016/j.ophtha.2013.12.024
   Park SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080174
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schramm K, 2014, ACTA OPHTHALMOL, V92, P465, DOI 10.1111/aos.12326
   Scupola A, 2015, OPHTHALMOLOGICA, V234, P101, DOI 10.1159/000434732
   Short BG, 2008, TOXICOL PATHOL, V36, P49, DOI 10.1177/0192623307310955
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Treuting P. M., 2012, COMP ANATOMY HISTOLO, P395, DOI [10.1016/8978-0-12-802900-8.00021-X, DOI 10.1016/8978-0-12-802900-8.00021-X]
   Woo Se Joon, 2019, Korean J Ophthalmol, V33, P150, DOI 10.3341/kjo.2018.0081
   Yancopoulos GD, 2010, CELL, V143, P13, DOI 10.1016/j.cell.2010.09.028
   Yanyali A, 2007, AM J OPHTHALMOL, V144, P124, DOI 10.1016/j.ajo.2007.02.048
NR 33
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 10
PY 2021
VL 16
IS 6
AR e0252006
DI 10.1371/journal.pone.0252006
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA SW6SA
UT WOS:000664642700015
PM 34111133
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Sassmannshausen, M
   Pfau, M
   Thiele, S
   Fimmers, R
   Steinberg, JS
   Fleckenstein, M
   Holz, FG
   Schmitz-Valckenberg, S
AF Sassmannshausen, Marlene
   Pfau, Maximilian
   Thiele, Sarah
   Fimmers, Rolf
   Steinberg, Julia S.
   Fleckenstein, Monika
   Holz, Frank G.
   Schmitz-Valckenberg, Steffen
TI Longitudinal Analysis of Structural and Functional Changes in Presence
   of Reticular Pseudodrusen Associated With Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE fundus-controlled perimetry; microperimetry; scotopic; mesopic; MP-1S;
   age-related macular degeneration; SD-OCT; retinal imaging; reticular
   pseudodrusen; RPD; subretinal drusenoid deposits; SDD
ID SUBRETINAL DRUSENOID DEPOSITS; ROD FUNCTION; MULTIFOCAL
   ELECTRORETINOGRAPHY; FUNDUS AUTOFLUORESCENCE; MICROPERIMETRY; EYES
AB PURPOSE. To examine longitudinal changes of retinal thickness and retinal sensitivity in patients with intermediate age-related macular degeneration (iAMD) and predominantly reticular pseudodrusen (RPD).
   METHODS. At baseline 30 eyes of 25 iAMD patients underwent optical coherence tomography imaging, mesopic and scotopic fundus-controlled perimetry (FCP) with follow-up examinations at month 12 (20 eyes), 24 (12 eyes), and 36 (11 eyes). Thicknesses of different retinal layers and results of FCP testing (n = 56 stimuli) were spatially and longitudinally analyzed using linear mixed-effects models.
   RESULTS. At baseline, the thickness of the partial outer retinal layer (pORL, 70.21 vs. 77.47 mu m) and both mesopic (16.60 vs. 18.72 dB) and scotopic (12.14 vs. 18.67 dB) retinal sensitivity were decreased in areas with RPD compared with unremarkable areas (P < 0.001). Over three years, mean change of pORL was -0.66 normative standard deviation (SD; i.e., z-score, P < 0.001) for regions with existing RPD, -0.40 SD (P < 0.001) for regions with new occurring RPD, and -0.17 SD (P = 0.041) in unremarkable regions. Decrease of scotopic and mesopic sensitivity over three years was more pronounced in areas with existing (-3.51 and -7.76 dB) and new occurring RPD (-2.06 and -5.97 dB). Structure-function analysis revealed that 1 SD decrease of pORL thickness was associated with a sensitivity reduction of 3.47 dB in scotopic and 0.79 dB in mesopic testing.
   CONCLUSIONS. This study demonstrates progressive outer retinal degeneration and impairment of photoreceptor function in eyes with iAMD and RPD over three years. Preservation of outer retinal thickness and reduction of RPD formation may constitute meaningful surrogate endpoints in interventional trials on eyes with AMD and RPD aiming to slow outer retinal degeneration.
C1 [Sassmannshausen, Marlene; Pfau, Maximilian; Thiele, Sarah; Steinberg, Julia S.; Fleckenstein, Monika; Holz, Frank G.; Schmitz-Valckenberg, Steffen] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
   [Sassmannshausen, Marlene; Pfau, Maximilian; Thiele, Sarah; Holz, Frank G.; Schmitz-Valckenberg, Steffen] GRADE Reading Ctr, Bonn, Germany.
   [Pfau, Maximilian] Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA.
   [Fimmers, Rolf] Univ Bonn, Med Fac, Inst Med Biometry Informat & Epidemiol, Bonn, Germany.
   [Fleckenstein, Monika; Schmitz-Valckenberg, Steffen] Univ Utah, John A Moran Eye Ctr, Salt Lake City, UT USA.
C3 University of Bonn; Stanford University; University of Bonn; Utah System
   of Higher Education; University of Utah
RP Schmitz-Valckenberg, S (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM steffen.schmitz-valckenberg@ukb.uni-bonn.de
FU Rudolf and Anna Katharina Eichenauer-Foundation; German Research
   Foundation (Deutsche Forschungsgemeinschaft) [PF 950/1-1]; Research to
   Prevent Blindness, New York, NY
FX Supported by research grants of the Rudolf and Anna Katharina
   Eichenauer-Foundation, the German Research Foundation (Deutsche
   Forschungsgemeinschaft PF 950/1-1) and in part by an Unrestricted Grant
   from Research to Prevent Blindness, New York, NY, to the Department of
   Ophthalmology & Visual Sciences, University of Utah.
CR Alten F, 2014, INVEST OPHTH VIS SCI, V55, P6073, DOI 10.1167/iovs.13-13804
   Alten F, 2012, INVEST OPHTH VIS SCI, V53, P6263, DOI 10.1167/iovs.12-10094
   Auge J, 2014, OPHTHALMOLOGE, V111, P765, DOI 10.1007/s00347-013-2965-0
   Chen L, 2020, RETINA-J RET VIT DIS, V40, P618, DOI 10.1097/IAE.0000000000002657
   Cocce KJ, 2018, AM J OPHTHALMOL, V189, P127, DOI 10.1016/j.ajo.2018.02.012
   Csaky KG, 2019, SURV OPHTHALMOL, V64, P353, DOI 10.1016/j.survophthal.2019.01.014
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Fleckenstein M, 2014, INVEST OPHTH VIS SCI, V55, P2911, DOI 10.1167/iovs.13-13409
   Flynn OJ, 2018, INVEST OPHTH VIS SCI, V59, P2411, DOI 10.1167/iovs.17-22874
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Haj Najeeb B, 2020, RETINA
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Kim JH, 2020, RETINA-J RET VIT DIS, V40, P1124, DOI 10.1097/IAE.0000000000002489
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   McGuinness MB, 2017, EYE, V31, P1345, DOI 10.1038/eye.2017.139
   Midena E, 2017, EYE, V31, P985, DOI 10.1038/eye.2017.34
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   Nguyen CT, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.17-23084
   Ooto S, 2013, AM J OPHTHALMOL, V156, P1184, DOI 10.1016/j.ajo.2013.06.036
   Pfau M, 2018, EYE, V32, P1819, DOI 10.1038/s41433-018-0183-3
   Pondorfer SG, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51769-7
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Ramon C, 2019, CLIN EXP OPTOM, V102, P601, DOI 10.1111/cxo.12894
   Sadda SR, 2020, OPHTHALMOLOGY, V127, P648, DOI 10.1016/j.ophtha.2019.11.010
   Sadigh S, 2013, INVEST OPHTH VIS SCI, V54, P1603, DOI 10.1167/iovs.12-11286
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Steinberg JS, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.4.7
   Steinberg JS, 2016, AM J OPHTHALMOL, V168, P52, DOI 10.1016/j.ajo.2016.04.025
   Steinberg JS, 2015, BRIT J OPHTHALMOL, V99, P1289, DOI 10.1136/bjophthalmol-2014-306535
   Steinberg JS, 2015, INVEST OPHTH VIS SCI, V56, P4267, DOI 10.1167/iovs.15-16657
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   Tan R, 2018, INVEST OPHTH VIS SCI, V59, P4154, DOI 10.1167/iovs.18-23970
   Tan RS, 2019, INVEST OPHTH VIS SCI, V60, P1511, DOI 10.1167/iovs.18-26385
   Welker Susanne G, 2018, Invest Ophthalmol Vis Sci, V59, pAMD152, DOI 10.1167/iovs.18-23878
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P3714, DOI 10.1167/iovs.15-18294
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P2100, DOI 10.1167/iovs.14-16210
   Zhang YH, 2020, OPHTHALMOL RETINA, V4, P274, DOI 10.1016/j.oret.2019.10.012
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 47
TC 14
Z9 14
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2020
VL 61
IS 10
AR 19
DI 10.1167/iovs.61.10.19
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NI3HZ
UT WOS:000565248700011
PM 32780863
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Cashman, SM
   Ramo, K
   Kumar-Singh, R
AF Cashman, Siobhan M.
   Ramo, Kasmir
   Kumar-Singh, Rajendra
TI A Non Membrane-Targeted Human Soluble CD59 Attenuates Choroidal
   Neovascularization in a Model of Age Related Macular Degeneration
SO PLOS ONE
LA English
DT Article
ID ADENOVIRUS-MEDIATED DELIVERY; COMPLEMENT-SYSTEM; POTENTIAL THERAPY;
   ATTACK COMPLEX; IN-VIVO; 2 PARTS; RECOMBINANT; VECTORS; DEFICIENCY;
   DISEASE
AB Age related macular degeneration (AMD) is the most common cause of blindness amongst the elderly. Approximately 10% of AMD patients suffer from an advanced form of AMD characterized by choroidal neovascularization (CNV). Recent evidence implicates a significant role for complement in the pathogenesis of AMD. Activation of complement terminates in the incorporation of the membrane attack complex (MAC) in biological membranes and subsequent cell lysis. Elevated levels of MAC have been documented on choroidal blood vessels and retinal pigment epithelium (RPE) of AMD patients. CD59 is a naturally occurring membrane bound inhibitor of MAC formation. Previously we have shown that membrane bound human CD59 delivered to the RPE cells of mice via an adenovirus vector can protect those cells from human complement mediated lysis ex vivo. However, application of those observations to choroidal blood vessels are limited because protection from MAC-mediated lysis was restricted only to the cells originally transduced by the vector. Here we demonstrate that subretinal delivery of an adenovirus vector expressing a transgene for a soluble non-membrane binding form of human CD59 can attenuate the formation of laser-induced choroidal neovascularization and murine MAC formation in mice even when the region of vector delivery is distal to the site of laser induced CNV. Furthermore, this same recombinant transgene delivered to the intravitreal space of mice by an adeno-associated virus vector (AAV) can also attenuate laser-induced CNV. To our knowledge, this is the first demonstration of a non-membrane targeting CD59 having biological potency in any animal model of disease in vivo. We propose that the above approaches warrant further exploration as potential approaches for alleviating complement mediated damage to ocular tissues in AMD.
C1 [Cashman, Siobhan M.; Ramo, Kasmir; Kumar-Singh, Rajendra] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
C3 Tufts University
RP Cashman, SM (通讯作者)，Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
EM rajendra.kumar-singh@tufts.edu
OI Kumar-Singh, Rajendra/0000-0002-7754-0713
FU Ellison Foundation; Virginia B. Smith Trust; NIH/NEI [EY014991,
   EY013887]; Lions Eye Foundation; Research to Prevent Blindness; NATIONAL
   EYE INSTITUTE [R01EY014991] Funding Source: NIH RePORTER
FX This study was funded by grants to R.K.-S. from The Ellison Foundation,
   The Virginia B. Smith Trust, NIH/NEI (EY014991 and EY013887) and grants
   to the Department of Ophthalmology at Tufts University from the Lions
   Eye Foundation and Research to Prevent Blindness. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Appledorn DM, 2008, GENE THER, V15, P1606, DOI 10.1038/gt.2008.114
   BENZAQUEN LR, 1994, J EXP MED, V179, P985, DOI 10.1084/jem.179.3.985
   Bora NS, 2007, J IMMUNOL, V178, P1783, DOI 10.4049/jimmunol.178.3.1783
   Bora NS, 2010, J BIOL CHEM, V285, P33826, DOI 10.1074/jbc.M110.153130
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Cashman SM, 2007, MOL THER, V15, P1640, DOI 10.1038/sj.mt.6300203
   Cashman SM, 2006, INVEST OPHTH VIS SCI, V47, P3496, DOI 10.1167/iovs.05-1610
   Chevez-Barrios P, 2005, J CLIN ONCOL, V23, P7927, DOI 10.1200/JCO.2004.00.1883
   Colella P, 2009, TRENDS MOL MED, V15, P23, DOI 10.1016/j.molmed.2008.11.003
   DAVIES A, 1989, J EXP MED, V170, P637, DOI 10.1084/jem.170.3.637
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215
   Fijen CAP, 1999, CLIN INFECT DIS, V28, P98, DOI 10.1086/515075
   Fijen CAP, 1998, J CLIN MICROBIOL, V36, P2342, DOI 10.1128/JCM.36.8.2342-2345.1998
   Fraser DA, 2003, J BIOL CHEM, V278, P48921, DOI 10.1074/jbc.M302598200
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   HALPERIN JA, 1993, J CLIN INVEST, V91, P1974, DOI 10.1172/JCI116418
   Homann C, 1997, GUT, V40, P544, DOI 10.1136/gut.40.4.544
   ILDEFONSO CJ, MOL THER, V18, P1885
   Jiang H, 2004, MOL THER, V10, P1140, DOI 10.1016/j.ymthe.2004.08.015
   Jiang HY, 2006, MOL THER, V14, P452, DOI 10.1016/j.ymthe.2006.05.004
   Kim IH, 2001, P NATL ACAD SCI USA, V98, P13282, DOI 10.1073/pnas.241506298
   LEHTO T, 1993, J IMMUNOL, V151, P4941
   Lukason M, 2011, MOL THER, V19, P260, DOI 10.1038/mt.2010.230
   MacLachlan TK, 2011, MOL THER, V19, P326, DOI 10.1038/mt.2010.258
   MERI S, 1990, IMMUNOLOGY, V71, P1
   Michels Stephan, 2006, Expert Opin Investig Drugs, V15, P779, DOI 10.1517/13543784.15.7.779
   Mizuno M, 2001, ARTHRITIS RHEUM-US, V44, P2425, DOI 10.1002/1529-0131(200110)44:10<2425::AID-ART407>3.0.CO;2-4
   Ramo K, 2008, INVEST OPHTH VIS SCI, V49, P4126, DOI 10.1167/iovs.08-2025
   Ricklin D, 2007, NAT BIOTECHNOL, V25, P1265, DOI 10.1038/nbt1342
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   ROLLINS SA, 1990, J IMMUNOL, V144, P3478
   Rosen AM, 2010, ADV EXP MED BIOL, V703, P75, DOI 10.1007/978-1-4419-5635-4_6
   Sohn JH, 2000, INVEST OPHTH VIS SCI, V41, pS674
   SUGITA Y, 1994, IMMUNOLOGY, V82, P34
   VAKEVA A, 1994, IMMUNOLOGY, V82, P28
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
NR 41
TC 80
Z9 86
U1 1
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 28
PY 2011
VL 6
IS 4
AR e19078
DI 10.1371/journal.pone.0019078
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 756NX
UT WOS:000290020700022
PM 21552568
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Dhingra, N
   Upasani, D
   Ghanchi, F
AF Dhingra, Narendra
   Upasani, Deepa
   Ghanchi, Faruque
TI Patterns of treatment discontinuation in patients receiving
   anti-vascular endothelial growth factor for neovascular age-related
   macular degeneration
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Anti VEGF; nAMD; treatment discontinuation
ID FACTOR THERAPY; RANIBIZUMAB; OUTCOMES; VEGF; ANCHOR; MARINA
AB Purpose: To report the reasons for treatment discontinuation within 5 years in patients receiving intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for neovascular age-related macular degeneration (nAMD). Methods: A retrospective case-notes review of patients commenced on anti-VEGF for nAMD who failed to complete 5 years of follow-up was undertaken. The reasons for treatment discontinuation, baseline age, baseline visual acuity (VA) in Early Treatment Diabetic Retinopathy Study (ETDRS) letters, and the VA change at the last follow-up were recorded. Age-specific all-cause mortality was calculated for deceased patients. Results: Of the 1177 patients, 551 patients (46.8%) failed to complete the 5-year follow-up. The reasons for treatment discontinuation were death (251), early discharge due to stable disease (110), further treatment deemed futile (100), failure to attend (15), ill health (14), patient choice (7), and transfer of care (1). In 53 patients, no reason was documented. The mean baseline age of those who completed the 5-year follow-up (77.4 +/- 7.8 years, 95% confidence interval (CI): 76.8-77.9) was significantly lower than those who discontinued the treatment for any reason (82 +/- 7.7 years, 95% CI: 81.4-82.6) (P < 0.0001). Survival analysis showed that baseline VA was not a factor in treatment discontinuation; however, visual stability (& PLUSMN;5 letters from baseline) was associated with treatment continuation. The age-specific all-cause mortality in deceased patients was lower than that in the general population. Conclusion: At 5 years, only 53% of patients remained in active care, and death was the most common reason for treatment discontinuation. Lower baseline age and VA stability during therapy were associated with treatment continuation.
C1 [Dhingra, Narendra; Upasani, Deepa; Ghanchi, Faruque] Bradford Teaching Hosp, NHS Fdn Trust, Eye Ctr, Macula Serv, WF1 2DG, Duckworth Lane, Bradford BD9 6RJ, England.
   [Dhingra, Narendra] Pinderfields Gen Hosp, Eye Ctr, Mid Yorkshire NHS Trust, Wakefield, PQ, Canada.
RP Dhingra, N (通讯作者)，Pinderfields Gen Hosp, Eye Ctr, Mid Yorkshire NHS Trust, Wakefield, PQ, Canada.
EM narendra.dhingra@nhs.net
CR Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   [Anonymous], PHE ANAL ONS MORTALI
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2013, EYE, V27, P1429, DOI 10.1038/eye.2013.233
   Chandra S, 2021, EYE, V35, P409, DOI 10.1038/s41433-020-0851-y
   Chandra S, 2020, EYE, V34, P1888, DOI 10.1038/s41433-020-0764-9
   Cvetkova NP, 2016, CLIN OPHTHALMOL, V10, P1047, DOI 10.2147/OPTH.S101050
   Dalvin LA, 2019, JAMA OPHTHALMOL, V137, P483, DOI 10.1001/jamaophthalmol.2018.6891
   Evans RN, 2020, OPHTHALMOLOGY, V127, P1191, DOI 10.1016/j.ophtha.2020.03.020
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Gale R, 2016, OPHTHALMOLOGICA, V236, P193, DOI 10.1159/000451065
   Gillies M, 2020, AM J OPHTHALMOL, V210, P116, DOI 10.1016/j.ajo.2019.10.007
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kataja M, 2018, BRIT J OPHTHALMOL, V102, P959, DOI 10.1136/bjophthalmol-2017-311055
   Kelkar A, 2020, INDIAN J OPHTHALMOL, V68, P2143, DOI 10.4103/ijo.IJO_1866_19
   Mehta H, 2020, CLIN OPHTHALMOL, V14, P3331, DOI 10.2147/OPTH.S275977
   Mekjavic PJ, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00125
   Mitchell P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101072
   Mones J, 2020, OPHTHALMOLOGICA, V243, P1, DOI 10.1159/000502747
   Obeid A, 2018, JAMA OPHTHALMOL, V136, P1251, DOI 10.1001/jamaophthalmol.2018.3578
   Oishi A, 2011, EUR J OPHTHALMOL, V21, P777, DOI 10.5301/EJO.2011.7430
   Okada M, 2021, OPHTHALMOLOGY, V128, P234, DOI 10.1016/j.ophtha.2020.07.060
   Pedrosa AC, 2016, CLIN OPHTHALMOL, V10, P541, DOI 10.2147/OPTH.S90913
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Soares RR, 2020, OPHTHALMOL RETINA, V4, P134, DOI 10.1016/j.oret.2019.07.010
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   Subhi Y, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/7194927
   Vaze A, 2014, RETINA-J RET VIT DIS, V34, P1774, DOI 10.1097/IAE.0000000000000173
   Wolff B, 2020, CLIN EXP OPHTHALMOL, V48, P636, DOI 10.1111/ceo.13742
   Wong DT, 2020, RETINA-J RET VIT DIS, V40, P1010, DOI 10.1097/IAE.0000000000002713
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yashkin AP, 2016, OPHTHALMOLOGY, V123, P2225, DOI 10.1016/j.ophtha.2016.06.053
NR 34
TC 1
Z9 1
U1 1
U2 1
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD JUN
PY 2022
VL 70
IS 6
BP 2065
EP 2070
DI 10.4103/ijo.IJO_3066_21
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3H8KT
UT WOS:000832280100036
PM 35647983
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kelbsch, C
   Lange, J
   Wilhelm, H
   Wilhelm, B
   Peters, T
   Kempf, M
   Kuehlewein, L
   Stingl, K
AF Kelbsch, Carina
   Lange, Jakob
   Wilhelm, Helmut
   Wilhelm, Barbara
   Peters, Tobias
   Kempf, Melanie
   Kuehlewein, Laura
   Stingl, Krunoslav
TI Chromatic Pupil Campimetry Reveals Functional Defects in Exudative
   Age-Related Macular Degeneration with Differences Related to Disease
   Activity
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE pupil campimetry; pupillometry; objective measurement; retinal function;
   age-related macular degeneration; exudative AMD
ID FLICKER PERIMETRY; RETINAL FUNCTION; PUPILLOGRAPHY; DIAGNOSIS; RESPONSES
AB Purpose: The purpose of this study was to use chromatic pupil campimetry (CPC) for an objective evaluation of local retinal function in exudative age-related macular degeneration (AMD) and to assess disease activity.
   Methods: Gaze-controlled CPC was performed in 19 subjects with optical coherence tomography-confirmed exudative AMD (75 +/- 4 years; 11 women) and the results compared with those of an age-matched control group (n=11; 72 +/- 6 years; 8 women). Local retinal function was evaluated by measuring pupil responses to 3 degrees red stimuli (60 cd/m(2), 1 second) at 41 positions covering 30 degrees of the central visual field on a dim blue background (test duration 6 minutes). Primary outcome parameters were relative maximal pupil constriction amplitude (% from baseline) and latency to constriction onset.
   Results: Pupil constriction amplitudes were significantly reduced in the macular region, and especially in the fovea in AMD(16%+/- 4.7%; mean +/- standard deviation), compared with the control group (24%+/- 6%; P=0.00036). Receiver operating characteristic values were 0.84 for the constriction amplitude in the fovea, and 0.9 for the steepness angle between periphery and center. Mean latency to constriction onset in the fovea in AMD was significantly longer (333 +/- 53 ms; normals 273 +/- 59 ms, P=0.0072), and particularly in the active compared with the inactive status of exudative AMD (P=0.01).
   Conclusions: CPC detected functional changes in exudative AMD with high sensitivity. Time dynamics of active exudative AMD differed from disease inactivity.
   Translational Relevance: With the combination of short recording time, objectiveness of the measurement and gaze-correction for fixation problems, this method presents a suitable complement to the currently used clinical functional tests of the macula.
C1 [Kelbsch, Carina; Wilhelm, Helmut; Kempf, Melanie; Kuehlewein, Laura; Stingl, Krunoslav] Univ Tubingen, Univ Eye Hosp, Ctr Ophthalmol, Elfriede Aulhorn Str 7, D-72076 Tubingen, Germany.
   [Kelbsch, Carina; Lange, Jakob; Wilhelm, Helmut; Wilhelm, Barbara; Peters, Tobias; Stingl, Krunoslav] Univ Tubingen, Ctr Ophthalmol, Pupil Res Grp, Tubingen, Germany.
   [Kuehlewein, Laura] Univ Tubingen, Ctr Ophthalmol, Inst Ophthalm Res, Tubingen, Germany.
   [Kempf, Melanie; Stingl, Krunoslav] Univ Tubingen, Ctr Rare Eye Dis, Tubingen, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; Eberhard Karls University of Tubingen; Eberhard Karls
   University Hospital; Eberhard Karls University of Tubingen; Eberhard
   Karls University Hospital; Eberhard Karls University of Tubingen
RP Kelbsch, C (通讯作者)，Univ Tubingen, Univ Eye Hosp, Ctr Ophthalmol, Elfriede Aulhorn Str 7, D-72076 Tubingen, Germany.
EM carina.kelbsch@med.uni-tuebingen.de
CR Ben Ner D, 2019, CLIN OPHTHALMOL, V13, P465, DOI 10.2147/OPTH.S191486
   Cassels NK, 2018, SURV OPHTHALMOL, V63, P40, DOI 10.1016/j.survophthal.2017.05.007
   Feigl B, 2014, OPTOMETRY VISION SCI, V91, P894, DOI 10.1097/OPX.0000000000000284
   Feigl B, 2011, INVEST OPHTH VIS SCI, V52, P4362, DOI 10.1167/iovs.10-7069
   Fotiou D F, 2007, Electromyogr Clin Neurophysiol, V47, P11
   Kardon R, 2011, OPHTHALMOLOGY, V118, P376, DOI 10.1016/j.ophtha.2010.06.033
   Kelbsch C, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.6.19
   Kelbsch C, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00129
   Kelbsch C, 2017, ACTA OPHTHALMOL, V95, pE261, DOI 10.1111/aos.13259
   Kelbsch C, 2016, GRAEF ARCH CLIN EXP, V254, P1361, DOI 10.1007/s00417-016-3351-9
   Luu CD, 2013, INVEST OPHTH VIS SCI, V54, P3560, DOI 10.1167/iovs.12-10465
   Maynard ML, 2015, INVEST OPHTH VIS SCI, V56, P6906, DOI 10.1167/iovs.15-17357
   Naber M, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00558
   Najjar RP, 2018, OPHTHALMOLOGY, V125, P1362, DOI 10.1016/j.ophtha.2018.02.024
   Nowomiejska Katarzyna, 2007, Klin Oczna, V109, P131
   Phipps JA, 2004, INVEST OPHTH VIS SCI, V45, P3355, DOI 10.1167/iovs.04-0253
   Rajan MS, 2002, J ROY SOC MED, V95, P498, DOI 10.1258/jrsm.95.10.498
   Rosli Y, 2012, VISION RES, V69, P42, DOI 10.1016/j.visres.2012.07.019
   Sabeti F, 2013, GRAEF ARCH CLIN EXP, V251, P1707, DOI 10.1007/s00417-013-2273-z
   Sabeti F, 2012, INVEST OPHTH VIS SCI, V53, P253, DOI 10.1167/iovs.11-8004
   Schmid R, 2005, EUR J NEUROL, V12, P602, DOI 10.1111/j.1468-1331.2005.01048.x
   Skorkovska K, 2009, GRAEF ARCH CLIN EXP, V247, P847, DOI 10.1007/s00417-008-1015-0
   Stingl K, 2018, BIOMED ENG-BIOMED TE, V63, P729, DOI 10.1515/bmt-2017-0029
   Tan L, 2001, VISION RES, V41, P1073, DOI 10.1016/S0042-6989(01)00030-X
NR 24
TC 3
Z9 3
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD MAY
PY 2020
VL 9
IS 6
AR 5
DI 10.1167/tvst.9.6.5
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MJ5LW
UT WOS:000548132700001
PM 32821502
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Bandello, F
   Corvi, F
   La Spina, C
   Benatti, L
   Querques, L
   Capuano, V
   Naysan, J
   Chen, XJ
   Sarraf, D
   Parodi, MB
   Souied, E
   Freund, KB
   Querques, G
AF Bandello, Francesco
   Corvi, Federico
   La Spina, Carlo
   Benatti, Lucia
   Querques, Lea
   Capuano, Vittorio
   Naysan, Jonathan
   Chen, Xuejing
   Sarraf, David
   Parodi, Maurizio Battaglia
   Souied, Eric
   Freund, K. Bailey
   Querques, Giuseppe
TI Outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular
   age-related macular degeneration and diabetic retinopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; RANIBIZUMAB PLUS PROMPT; DEFERRED LASER;
   CHOROIDAL NEOVASCULARIZATION; TRAP-EYE; EDEMA; CLASSIFICATION; SEVERITY;
   ANCHOR
AB Purpose To investigate the outcomes of intravitreal antivascular endothelial growth factor (VEGF) therapy in eyes with both neovascular age-related macular degeneration (AMD) and diabetic retinopathy (DR).
   Methods Patients from four high-volume referral centres who presented with neovascular AMD and DR, and received intravitreal anti-VEGF therapy, were included. Data retrieved from medical records and multimodal imaging were analysed.
   Results Forty-one eyes of 38 patients (21 male, 17 female; mean age 78 +/- 8 years) were enrolled. Median follow-up was 28 +/- 19 (12-72) months with a mean of 9.2 +/- 7.4 intravitreal anti-VEGF injections per eye were administrated. Best-corrected visual acuity (BCVA) was 0.5 +/- 0.3 logMAR; it improved significantly at 1 year (0.3 +/- 0.3 logMAR; p=0.02) and returned to baseline values at last follow-up visit (0.6 +/- 0.4 logMAR; p=0.26). Mean central macular thickness (CMT) significantly decreased from 408 +/- 150 mu m to 328 +/- 104 mu m at 1 year (p=0.021) and to 335 +/- 127 mu m at last follow-up visit (p=0.032). The baseline severity of DR was graded as mild non-proliferative DR (NPDR) in 21 (51%) eyes, moderate NPDR in 14 (34%), severe NPDR in 4 (10%) and inactive proliferative DR in 2 (5%). At last follow-up visit, one eye graded as moderate NPDR improved to mild, one eye graded as severe NPDR improved to mild and one eye graded as severe NPDR was inactivated due to panretinal photocoagulation.
   Conclusions Outcomes analysis of intravitreal anti-VEGF therapy for eyes with both neovascular AMD and DR showed stabilisation of BCVA and reduction of CMT, along with stable or improved DR stage throughout follow-up.
C1 [Bandello, Francesco; Corvi, Federico; La Spina, Carlo; Benatti, Lucia; Querques, Lea; Parodi, Maurizio Battaglia; Querques, Giuseppe] Univ Vita Salute San Raffaele, Dept Ophthalmol, IRCCS San Raffaele Sci, Milan, Italy.
   [Capuano, Vittorio; Souied, Eric; Querques, Giuseppe] Univ Paris Est Creteil, Hop Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Naysan, Jonathan; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Naysan, Jonathan; Freund, K. Bailey] NYU, Dept Ophthalmol, Sch Med, 550 1St Ave, New York, NY 10016 USA.
   [Chen, Xuejing; Sarraf, David] Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA.
C3 Vita-Salute San Raffaele University; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Vitreous Retina
   Macula Consultants of New York; New York University; University of
   California System; University of California Los Angeles; University of
   California Los Angeles Medical Center; David Geffen School of Medicine
   at UCLA; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); VA Greater Los Angeles Healthcare System
RP Querques, G (通讯作者)，Univ Vita Salute, Osped San Raffaele, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.
EM giuseppe.querques@hotmail.it
RI bandello, francesco/AAH-2405-2019; Benatti, Lucia/AAZ-3035-2020; Parodi,
   Maurizio Battaglia/K-7876-2016; Corvi, Federico/AAD-7691-2021; Freund,
   K. Bailey/V-7488-2018
OI bandello, francesco/0000-0003-3238-9682; Corvi,
   Federico/0000-0002-2661-5500; chen, xuejing/0000-0001-6827-0152;
   Querques, Giuseppe/0000-0002-3292-9581; Freund, K.
   Bailey/0000-0002-7888-9773
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Antcliff R J, 1999, Semin Ophthalmol, V14, P223, DOI 10.3109/08820539909069541
   Bhavsar AR, 2014, JAMA OPHTHALMOL, V132, P889, DOI 10.1001/jamaophthalmol.2014.287
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Carmeliet P, 2004, J INTERN MED, V255, P538, DOI 10.1111/j.1365-2796.2003.01297.x
   Chaikitmongkol V, 2013, JAMA OPHTHALMOL, V131, P260, DOI 10.1001/jamaophthalmol.2013.1733
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P4430, DOI 10.1167/iovs.14-14379
   Ciulla TA, 2003, DIABETES CARE, V26, P2653, DOI 10.2337/diacare.26.9.2653
   Elman MJ, 2012, OPHTHALMOLOGY, V119, P2312, DOI 10.1016/j.ophtha.2012.08.022
   Elman MJ, 2011, OPHTHALMOLOGY, V118, P609, DOI 10.1016/j.ophtha.2010.12.033
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Han SY, 2015, DIABETES METAB J, V39, P46, DOI 10.4093/dmj.2015.39.1.46
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Ip MS, 2015, OPHTHALMOLOGY, V122, P367, DOI 10.1016/j.ophtha.2014.08.048
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Massin P, 2010, DIABETES CARE, V33, P2399, DOI 10.2337/dc10-0493
   Mitchell P, 2011, OPHTHALMOLOGY, V118, P615, DOI 10.1016/j.ophtha.2011.01.031
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2175, DOI 10.1016/j.ophtha.2009.04.023
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Wilkinson CP, 2003, OPHTHALMOLOGY, V110, P1677, DOI 10.1016/S0161-6420(03)00475-5
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 31
TC 5
Z9 6
U1 0
U2 7
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2016
VL 100
IS 12
BP 1611
EP 1616
DI 10.1136/bjophthalmol-2016-308400
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EC7XD
UT WOS:000388353500005
PM 26951773
DA 2022-11-30
ER

PT J
AU Framme, C
   Wolf, S
   Wolf-Schnurrbusch, U
AF Framme, Carsten
   Wolf, Sebastian
   Wolf-Schnurrbusch, Ute
TI Small Dense Particles in the Retina Observable by Spectral-Domain
   Optical Coherence Tomography in Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID CELL-MIGRATION; RANIBIZUMAB; PROLIFERATION; DETACHMENT; THERAPY;
   MELANIN; OCT; AMD
AB PURPOSE. To observe detailed changes in neurosensory retinal structure after anti-VEGF upload in age-related macular degeneration (AMD), by using spectral domain optical coherence tomography (SD-OCT).
   METHODS. The retinal structure was observed by using SD-OCT in 61 patients, before and 1 month after the third ranibizumab injection (upload phase). The main focus of attention was a subjective determination of the amount and behavior of the numerous small, dense particles (SDPs) frequently observed within the outer and inner neurosensory layers in eyes with neovascular AMD. The Spearman rho correlation was used for statistical analysis.
   RESULTS. In all eyes, various amounts of SDPs were seen within the neurosensory layer of the foveal and parafoveal area. In 54%, the amount of SDPs became significantly less after ranibizumab therapy (stable, 41%; higher, 5%). SDP reduction correlated positively with the reduction of retinal disease according to OCT (P = 0.000), with central foveal thickness (P = 0.040), and with the improvement in best corrected visual acuity (BCVA; P = 0.006). The baseline amount of SDPs also correlated positively with the increase in BCVA (P = 0.005).
   CONCLUSIONS. The origin of the SDPs observable in SD-OCT is unknown, but they may represent migrating RPE cells or leukocytes, indicating a certain status of retinal inflammation. The amount of SDPs is substantially reduced after ranibizumab upload therapy and correlates positively with BCVA. Moreover, an initial large number of SDPs may indicate a higher grade of inflammation, but the presence of a high number enhances the effect of ranibizumab therapy. Thus, the amount of SDPs before treatment may be a predictive factor for the therapy's outcome. (Invest Ophthalmol Vis Sci. 2010;51:5965-5969) DOI:10.1167/iovs.10-5779
C1 [Framme, Carsten; Wolf, Sebastian; Wolf-Schnurrbusch, Ute] Univ Eye Hosp, CH-3010 Bern, Switzerland.
RP Framme, C (通讯作者)，Univ Eye Hosp, Freiburgstr 10, CH-3010 Bern, Switzerland.
EM carsten.framme@insel.ch
RI Wolf, Sebastian/B-8782-2008
OI Wolf, Sebastian/0000-0002-7467-7028
CR ANDERSON DH, 1981, INVEST OPHTH VIS SCI, V21, P10
   Bolz M, 2008, OPHTHALMOLOGE, V105, P650, DOI 10.1007/s00347-007-1639-1
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   CAMPOCHIARO PA, 1985, ARCH OPHTHALMOL-CHIC, V103, P1403
   Crafoord S, 2000, GRAEF ARCH CLIN EXP, V238, P682, DOI 10.1007/s004170000131
   CROUCH ER, 1974, AM J OPHTHALMOL, V78, P251, DOI 10.1016/0002-9394(74)90085-3
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P1671, DOI 10.1167/iovs.09-4496
   Framme C, 2009, CURR EYE RES, V34, P568, DOI 10.1080/02713680902964892
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Golbaz I, 2009, OPHTHALMOLOGE, V106, P1103, DOI 10.1007/s00347-008-1880-2
   GREEN WR, 2001, RETINA, P1882
   HILTON GF, 1974, ARCH OPHTHALMOL-CHIC, V91, P445, DOI 10.1001/archopht.1974.03900060459006
   Hogg PA, 2002, INVEST OPHTH VIS SCI, V43, P2749
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   LI ZY, 1995, OPHTHALMOLOGY, V102, P805, DOI 10.1016/S0161-6420(95)30953-0
   LOPEZ PF, 1995, ARCH OPHTHALMOL-CHIC, V113, P1437, DOI 10.1001/archopht.1995.01100110097032
   MACHEMER R, 1975, AM J OPHTHALMOL, V80, P1
   NGUYENTAN JQ, 1989, RETINA-J RET VIT DIS, V9, P203, DOI 10.1097/00006982-198909030-00008
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Sayanagi K, 2009, OPHTHALMOLOGY, V116, P947, DOI 10.1016/j.ophtha.2008.11.002
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   2007, OPHTHALMOLOGE, V104, P628
NR 29
TC 59
Z9 61
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2010
VL 51
IS 11
BP 5965
EP 5969
DI 10.1167/iovs.10-5779
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 672BQ
UT WOS:000283558400072
PM 20574019
DA 2022-11-30
ER

PT J
AU Cohen, SY
   Dubois, L
   Tadayoni, R
   Fainkuchen, F
   Nghiem-Buffet, S
   Delahaye-Mazza, C
   Guiberteau, B
   Quentel, G
AF Cohen, Salomon Y.
   Dubois, Lise
   Tadayoni, Ramin
   Fainkuchen, Franck
   Nghiem-Buffet, Sylvia
   Delahaye-Mazza, Corinne
   Guiberteau, Brigitte
   Quentel, Gabriel
TI Results of One-Year's Treatment with Ranibizumab for Exudative
   Age-related Macular Degeneration in a Clinical Setting
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB PURPOSE: To evaluate the results of 1 year of treatment with intravitreal ranibizumab for exudative age-related macular degeneration (AMD) in a clinical setting.
   DESIGN: Nonrandomized, single-center, retrospective, interventional case series.
   METHODS: Retrospective analysis of consecutive charts and angiograms of patients with previously untreated exudative AMD, treated in one or both eyes with ranibizumab between January 2 and October 31, 2007. The following were recorded for each patient: age at presentation, gender, treated eye, type of choroidal neovascularization, visual acuity (VA) measured on an Early Treatment Diabetic Retinopathy Study chart at baseline and at 52 +/- 6 weeks, the number of performed intravitreal (IVT) injections, and follow-up examinations.
   RESULTS: The 122 patients comprised 85 women (70%) and 37 men ranging in age from 56 to 91 years (mean +/- standard deviation, 78.3 +/- 7). In all, 124 eyes were treated on a pro re nata basis after 1 or 3 initial IVT injections. The mean number of IVT injections was 3.79 +/- 1.39 (range, I to 7). The mean number of follow-up visits was 8.07 +/- 1.44 (range, 4 to 12). Mean VA standard deviation changed from 56.15 +/- 14 to 56.89 +/- 17 letters (VA gain, +0.7 letters).
   CONCLUSIONS: The results showed that VA stabilized rather than improved and compared unfavorably with the gains found in randomized clinical trials and the Prospective Optical Coherence Tomography Imaging of Patients with Neovascular AMD Treated with intraOcular Ranibizumab (PrONTO) Study. However in this study, patients were examined less frequently and were treated far less frequently. The present results suggest that a long, regular follow-up is necessary for patients treated with ranibizumab to obtain and preserve significant visual gain, and not only to achieve visual stabilization. (Am J Ophthalmol 2009;148:409-413. (C) 2009 by Elsevier Inc. All rights reserved.)
C1 [Cohen, Salomon Y.; Dubois, Lise; Fainkuchen, Franck; Nghiem-Buffet, Sylvia; Delahaye-Mazza, Corinne; Guiberteau, Brigitte; Quentel, Gabriel] Ctr Ophtalmol Imagerie & Laser, F-75015 Paris, France.
   [Cohen, Salomon Y.; Tadayoni, Ramin] Hop Lariboisiere, AP HP, Paris, France.
   Univ Paris 07, F-75221 Paris 05, France.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities;
   Universite Paris Cite; UDICE-French Research Universities; Universite
   Paris Cite
RP Cohen, SY (通讯作者)，Ctr Ophtalmol Imagerie & Laser, 11 Rue Antoine Bourdelle, F-75015 Paris, France.
EM sycohen@club-internet.fr
CR Bhatnagar P, 2007, RETINA-J RET VIT DIS, V27, P846, DOI 10.1097/IAE.0b013e31813c68b7
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Cohen SY, 2008, GRAEF ARCH CLIN EXP, V246, P1527, DOI 10.1007/s00417-008-0890-8
   Cohen SY, 2007, J FR OPHTALMOL, V30, P330, DOI 10.1016/S0181-5512(07)89602-1
   Fletcher EC, 2008, OPHTHALMOLOGY, V115, P2192, DOI 10.1016/j.ophtha.2008.07.018
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Lai TYY, 2007, GRAEF ARCH CLIN EXP, V245, P1877, DOI 10.1007/s00417-007-0679-1
   Mantel I, 2008, OPHTHALMOLOGICA, V222, P321, DOI 10.1159/000144075
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
NR 14
TC 117
Z9 121
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2009
VL 148
IS 3
BP 409
EP 413
DI 10.1016/j.ajo.2009.04.001
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 493RK
UT WOS:000269755400013
PM 19477713
DA 2022-11-30
ER

PT J
AU Landa, G
   Amde, W
   Doshi, V
   Ali, A
   McGevna, L
   Gentile, RC
   Muldoon, TO
   Walsh, JB
   Rosen, RB
AF Landa, Gennady
   Amde, Wendewessen
   Doshi, Vatsal
   Ali, Amro
   McGevna, Laura
   Gentile, Ronald C.
   Muldoon, Thomas O.
   Walsh, Joseph B.
   Rosen, Richard B.
TI Comparative Study of Intravitreal Bevacizumab (Avastin) versus
   Ranibizumab (Lucentis) in the Treatment of Neovascular Age-Related
   Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Bevacizumab (Avastin); Ranibizumab (Lucentis); Neovascular age-related
   macular degeneration; Choroidal neovascularization
ID VERTEPORFIN PHOTODYNAMIC THERAPY; CHOROIDAL NEOVASCULARIZATION; SUBGROUP
   ANALYSIS; PREVALENCE; INJECTIONS; SAFETY
AB Aims: To compare the safety and efficacy of 2 anti-vascular-endothelial-growth-factor agents - bevacizumab (Avastin) versus ranibizumab (Lucentis) - in the treatment of patients with neovascular age-related macular degeneration (AMD). Methods: Retrospective analysis of patients who received intravitreal injections of bevacizumab or ranibizumab for neovascular AMD. Primary outcome measures were best-corrected visual acuity (BCVA) and central foveal thickness (CFT) assessed by Spectral Domain scanning laser ophthalmoscope-optical coherence tomography (SD-OCT). A secondary outcome measure was the report of any adverse events in the 2 groups. Results: The number of injections in the bevacizumab group was 184 (average of 4.7 per eye) compared to 187 in the ranibizumab group (average of 5.5 per eye). The mean logMAR equivalent of BCVA at 1 month after the injection improved by 0.18 in the bevacizumab group (p = 0.009) and by 0.13 in the ranibizumab group (p = 0.004). The average SD-OCT CFT decreased from 325 +/- 72 to 300 +/- 69 mu m in the bevacizumab group (p = 0.016) and from 307 +/- 57 to 289 +/- 56 mu m in the ranibizumab group (p = 0.017). In the bevacizumab group, there was 1 event of lower extremity pain (0.54%) and 1 event of increased arterial blood pressure (0.54%). In the ranibizumab group, there were 2 events of transiently increased intraocular pressure (1.1%) and 1 event (0.53%) of intraocular inflammation following injection. Conclusions: Bevacizumab and ranibizumab treatments resulted in similar gains in visual acuity and reduction in macular thickness, documented each month following injection. Intravitreal bevacizumab appears to be as safe and effective as intravitreal ranibizumab in the treatment of exudative AMD. Copyright (c) 2009 S. Karger AG, Basel
C1 [Landa, Gennady; Amde, Wendewessen; Doshi, Vatsal; Ali, Amro; Gentile, Ronald C.; Muldoon, Thomas O.; Walsh, Joseph B.; Rosen, Richard B.] New York Eye & Ear Infirm, Dept Ophthalmol, Retina Ctr, New York, NY 10003 USA.
   [Landa, Gennady; Doshi, Vatsal; Gentile, Ronald C.; Muldoon, Thomas O.; Walsh, Joseph B.; Rosen, Richard B.] New York Med Coll, Dept Ophthalmol, Valhalla, NY 10595 USA.
   [McGevna, Laura] Univ Vermont, Coll Med, Burlington, VT USA.
C3 New York Eye & Ear Infirmary of Mount Sinai; New York Medical College;
   University of Vermont
RP Rosen, RB (通讯作者)，New York Eye & Ear Infirm, Dept Ophthalmol, Retina Ctr, 310 E 14th St, New York, NY 10003 USA.
EM rrosen@nyee.edu
CR Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Buch H, 2001, OPHTHALMOLOGY, V108, P2347, DOI 10.1016/S0161-6420(01)00823-5
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Mojica G, 2008, BRIT J OPHTHALMOL, V92, P584, DOI 10.1136/bjo.2007.126193
   Pilu S, 2008, AM J OPHTHALMOL, V145, P879, DOI 10.1016/j.ajo.2007.12.036
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
NR 19
TC 46
Z9 47
U1 0
U2 8
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2009
VL 223
IS 6
BP 370
EP 375
DI 10.1159/000227783
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 513WE
UT WOS:000271354000005
PM 19590252
DA 2022-11-30
ER

PT J
AU Vavvas, DG
   Daniels, AB
   Kapsala, ZG
   Goldfarb, JW
   Ganotakis, E
   Loewenstein, JI
   Young, LH
   Gragoudas, ES
   Eliott, D
   Kim, IK
   Tsilimbaris, MK
   Miller, JW
AF Vavvas, Demetrios G.
   Daniels, Anthony B.
   Kapsala, Zoi G.
   Goldfarb, Jeremy W.
   Ganotakis, Emmanuel
   Loewenstein, John I.
   Young, Lucy H.
   Gragoudas, Evangelos S.
   Eliott, Dean
   Kim, Ivana K.
   Tsilimbaris, Miltiadis K.
   Miller, Joan W.
TI Regression of Some High-risk Features of Age-related Macular
   Degeneration (AMD) in Patients Receiving Intensive Statin Treatment
SO EBIOMEDICINE
LA English
DT Article
DE AMD; Statins; High-dose; Reversal; Soft-drusen; Vision gain
ID LIPID-LOWERING THERAPY; LOW-DENSITY-LIPOPROTEIN; BRUCHS MEMBRANE;
   CORONARY ATHEROSCLEROSIS; CHOLESTEROL EFFLUX; DRUSEN; DISEASE;
   PROGRESSION; INHIBITION; REDUCTASE
AB Importance: Age-related macular degeneration (AMD) remains the leading cause of blindness in developed countries, and affects more than 150 million worldwide. Despite effective anti-angiogenic therapies for the less prevalent neovascular form of AMD, treatments are lacking for the more prevalent dry form. Similarities in risk factors and pathogenesis between AMD and atherosclerosis have led investigators to study the effects of statins on AMD incidence and progression with mixed results. A limitation of these studies has been the heterogeneity of AMD disease and the lack of standardization in statin dosage.
   Objective: We were interested in studying the effects of high-dose statins, similar to those showing regression of atherosclerotic plaques, in AMD.
   Design: Pilot multicenter open-label prospective clinical study of 26 patients with diagnosis of AMD and the presence of many large, soft drusenoid deposits. Patients received 80 mg of atorvastatin daily and were monitored at baseline and every 3 months with complete ophthalmologic exam, best corrected visual acuity (VA), fundus photographs, optical coherence tomography (OCT), and bloodwork (AST, ALT, CPK, total cholesterol, TSH, creatinine, as well as a pregnancy test for premenopausal women).
   Results: Twenty-three subjects completed a minimum follow-up of 12 months. High-dose atorvastatin resulted in regression of drusen deposits associated with vision gain (+3.3 letters, p = 0.06) in 10 patients. No subjects progressed to advanced neovascular AMD.
   Conclusions: High-dose statins may result in resolution of drusenoid pigment epithelial detachments (PEDs) and improvement in VA, without atrophy or neovascularization in a high-risk subgroup of AMD patients. Confirmation from larger studies is warranted. (C) 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
C1 Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv,Dept Ophthalmol, Boston, MA USA.
   Univ Crete, Dept Ophthalmol, Retina Serv, Iraklion, Crete, Greece.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; University of Crete
RP Vavvas, DG; Daniels, AB; Tsilimbaris, MK; Miller, JW (通讯作者)，243 Charles St, Boston, MA 02114 USA.
EM vavvas@meei.harvard.edu; joan_miller@meei.harvard.edu
OI GANOTAKIS, EMMANUEL/0000-0001-8093-7562; Tsilimbaris,
   Miltiadis/0000-0002-0130-1150; Young, Lucy/0000-0001-8634-7512; Kim,
   Ivana/0000-0003-0310-6129; Vavvas, Demetrios/0000-0002-8622-6478
FU Yeatts Family foundation; Mass. Eye and Ear Neovascular AMD funds;
   Loefflers Family foundation; Research to Prevent Blindness Foundation;
   NATIONAL EYE INSTITUTE [P30EY014104] Funding Source: NIH RePORTER
FX We like to thank Wendy Chao Ph.D. for professional editing of the
   manuscript. The study was supported by the Yeatts Family foundation, the
   Mass. Eye and Ear Neovascular AMD funds, the Loefflers Family
   foundation, and the Research to Prevent Blindness Foundation (DGV and
   JWM). The funders had no role in study design, data collection, data
   analysis, interpretation, or writing of the report.
CR ARAD Y, 1990, J LIPID RES, V31, P567
   Barathi VA, 2014, INVEST OPHTH VIS SCI, V55, P460, DOI 10.1167/iovs.13-11636
   BILHEIMER DW, 1983, P NATL ACAD SCI-BIOL, V80, P4124, DOI 10.1073/pnas.80.13.4124
   Brader HS, 2013, OPHTHALMOLOGY, V120, P1871, DOI 10.1016/j.ophtha.2013.01.049
   Cankova Z, 2011, EXP EYE RES, V93, P947, DOI 10.1016/j.exer.2011.10.016
   Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Chitose T, 2014, ATHEROSCLEROSIS, V237, P251, DOI 10.1016/j.atherosclerosis.2014.08.053
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Crabb JW, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017194
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Garcia CAD, 2014, OSLI RETINA, V45, P18, DOI 10.3928/23258160-20131217-01
   Ethier CR, 2004, ANNU REV BIOMED ENG, V6, P249, DOI 10.1146/annurev.bioeng.6.040803.140055
   Fong CW, 2014, EUR J MED CHEM, V85, P661, DOI 10.1016/j.ejmech.2014.08.037
   Friberg TR, 2006, OPHTHALMOLOGY, V113, P612, DOI 10.1016/j.ophtha.2005.10.066
   FRIEDMAN E, 1964, INVEST OPHTH VISUAL, V3, P539
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gehlbach P, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub2
   Gehlbach P, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub4
   Guymer RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083759
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Hollyfield JG, 2010, INVEST OPHTH VIS SCI, V51, P1276, DOI 10.1167/iovs.09-4478
   Hussain AA, 2010, EXP EYE RES, V90, P703, DOI 10.1016/j.exer.2010.02.013
   Ito T, 2002, CARDIOVASC DRUG THER, V16, P121, DOI 10.1023/A:1015701415588
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Khush KK, 2004, CLEV CLIN J MED, V71, P609, DOI 10.3949/ccjm.71.8.609
   Kim KJ, 2012, INVEST OPHTH VIS SCI, V53, P6456, DOI 10.1167/iovs.12-9658
   Kino T, 2005, EUR J CLIN INVEST, V35, P508, DOI 10.1111/j.1365-2362.2005.01539.x
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Kramer CM, 2011, JACC-CARDIOVASC IMAG, V4, P987, DOI 10.1016/j.jcmg.2011.06.014
   LINSENMEIER RA, 1992, J GEN PHYSIOL, V99, P177, DOI 10.1085/jgp.99.2.177
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nicholls SJ, 2011, NEW ENGL J MED, V365, P2078, DOI 10.1056/NEJMoa1110874
   Nissen SE, 2005, AM J CARDIOL, V96, p61F, DOI 10.1016/j.amjcard.2005.07.013
   Nissen SE, 2006, JAMA-J AM MED ASSOC, V295, P1556, DOI 10.1001/jama.295.13.jpc60002
   Nissen SE, 2004, JAMA-J AM MED ASSOC, V291, P1071, DOI 10.1001/jama.291.9.1071
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Pitt B, 1999, NEW ENGL J MED, V341, P70, DOI 10.1056/NEJM199907083410202
   Profumo E, 2014, CURR TOP MED CHEM, V14, P2542, DOI 10.2174/1568026614666141203130324
   Qian JQ, 2011, J CELL BIOCHEM, V112, P2480, DOI 10.1002/jcb.23173
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Robinson R, 2011, INVEST OPHTH VIS SCI, V52, P7423, DOI 10.1167/iovs.11-7912
   Rodriguez IR, 2014, EXP EYE RES, V128, P151, DOI 10.1016/j.exer.2014.09.009
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Sene A, 2015, TRENDS MOL MED, V21, P43, DOI 10.1016/j.molmed.2014.10.005
   Sene A, 2014, TRENDS ENDOCRIN MET, V25, P107, DOI 10.1016/j.tem.2013.10.007
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Sivaprasad S, 2005, CLIN EXP OPHTHALMOL, V33, P518, DOI 10.1111/j.1442-9071.2005.01074.x
   Suzuki M, 2007, MOL VIS, V13, P772
   Suzuki M, 2012, J CELL SCI, V125, P2407, DOI 10.1242/jcs.097683
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P685, DOI 10.1016/j.ajo.2006.11.021
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   VanderBeek BL, 2013, RETINA-J RET VIT DIS, V33, P414, DOI 10.1097/IAE.0b013e318276e0cf
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Winkler B S, 1999, Mol Vis, V5, P32
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu TH, 2010, J NEUROCHEM, V114, P1734, DOI 10.1111/j.1471-4159.2010.06884.x
   Yamada K, 2007, INVEST OPHTH VIS SCI, V48, P1839, DOI 10.1167/iovs.06-1085
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Yip JLY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132565
   Yu CM, 2007, HEART, V93, P933, DOI 10.1136/hrt.2006.102848
   Zhao XQ, 2011, JACC-CARDIOVASC IMAG, V4, P977, DOI 10.1016/j.jcmg.2011.06.013
NR 74
TC 78
Z9 83
U1 0
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352-3964
J9 EBIOMEDICINE
JI EBioMedicine
PD MAR
PY 2016
VL 5
BP 198
EP 203
DI 10.1016/j.ebiom.2016.01.033
PG 6
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA DK7AW
UT WOS:000375078200035
PM 27077128
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Sofat, R
   Casas, JP
   Webster, AR
   Bird, AC
   Mann, SS
   Yates, JRW
   Moore, AT
   Sepp, T
   Cipriani, V
   Bunce, C
   Khan, JC
   Shahid, H
   Swaroop, A
   Abecasis, G
   Branham, KEH
   Zareparsi, S
   Bergen, AA
   Klaver, CCW
   Baas, DC
   Zhang, K
   Chen, YH
   Gibbs, D
   Weber, BHF
   Keilhauer, CN
   Fritsche, LG
   Lotery, A
   Cree, AJ
   Griffiths, HL
   Bhattacharya, SS
   Chen, LL
   Jenkins, SA
   Peto, T
   Lathrop, M
   Leveillard, T
   Gorin, MB
   Weeks, DE
   Ortube, MC
   Ferrell, RE
   Jakobsdottir, J
   Conley, YP
   Rahu, M
   Seland, JH
   Soubrane, G
   Topouzis, F
   Vioque, J
   Tomazzoli, L
   Young, I
   Whittaker, J
   Chakravarthy, U
   de Jong, PTVM
   Smeeth, L
   Fletcher, A
   Hingorani, AD
AF Sofat, Reecha
   Casas, Juan P.
   Webster, Andrew R.
   Bird, Alan C.
   Mann, Samantha S.
   Yates, John R. W.
   Moore, Anthony T.
   Sepp, Tiina
   Cipriani, Valentina
   Bunce, Catey
   Khan, Jane C.
   Shahid, Humma
   Swaroop, Anand
   Abecasis, Goncalo
   Branham, Kari E. H.
   Zareparsi, Sepideh
   Bergen, Arthur A.
   Klaver, Caroline C. W.
   Baas, Dominique C.
   Zhang, Kang
   Chen, Yuhong
   Gibbs, Daniel
   Weber, Bernhard H. F.
   Keilhauer, Claudia N.
   Fritsche, Lars G.
   Lotery, Andrew
   Cree, Angela J.
   Griffiths, Helen L.
   Bhattacharya, Shomi S.
   Chen, Li L.
   Jenkins, Sharon A.
   Peto, Tunde
   Lathrop, Mark
   Leveillard, Thierry
   Gorin, Michael B.
   Weeks, Daniel E.
   Ortube, Maria Carolina
   Ferrell, Robert E.
   Jakobsdottir, Johanna
   Conley, Yvette P.
   Rahu, Mati
   Seland, Johan H.
   Soubrane, Gisele
   Topouzis, Fotis
   Vioque, Jesus
   Tomazzoli, Laura
   Young, Ian
   Whittaker, John
   Chakravarthy, Usha
   de Jong, Paulus T. V. M.
   Smeeth, Liam
   Fletcher, Astrid
   Hingorani, Aroon D.
TI Complement factor H genetic variant and age-related macular
   degeneration: effect size, modifiers and relationship to disease subtype
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE Age-related macular degeneration (AMD); Complement factor H gene;
   meta-ananlysis
ID FACTOR HY402H POLYMORPHISM; C-REACTIVE PROTEIN; JAPANESE POPULATION;
   Y402H VARIANT; HEMICENTIN-1 GENES; CIGARETTE-SMOKING; CHROMOSOME 10Q26;
   NO ASSOCIATION; RISK-FACTORS; CFH GENE
AB Background Variation in the complement factor H gene (CFH) is associated with risk of late age-related macular degeneration (AMD). Previous studies have been case-control studies in populations of European ancestry with little differentiation in AMD subtype, and insufficient power to confirm or refute effect modification by smoking.
   Methods To precisely quantify the association of the single nucleotide polymorphism (SNP rs1061170, 'Y402H') with risk of AMD among studies with differing study designs, participant ancestry and AMD grade and to investigate effect modification by smoking, we report two unpublished genetic association studies (n = 2759) combined with data from 24 published studies (26 studies, 26 494 individuals, including 14 174 cases of AMD) of European ancestry, 10 of which provided individual-level data used to test gene-smoking interaction; and 16 published studies from non-European ancestry.
   Results In individuals of European ancestry, there was a significant association between Y402H and late-AMD with a per-allele odds ratio (OR) of 2.27 [95% confidence interval (CI) 2.10-2.45; P = 1.1 x 10(-161)]. There was no evidence of effect modification by smoking (P = 0.75). The frequency of Y402H varied by ancestral origin and the association with AMD in non-Europeans was less clear, limited by paucity of studies.
   Conclusion The Y402H variant confers a 2-fold higher risk of late-AMD per copy in individuals of European descent. This was stable to stratification by study design and AMD classification and not modified by smoking. The lack of association in non-Europeans requires further verification. These findings are of direct relevance for disease prediction. New research is needed to ascertain if differences in circulating levels, expression or activity of factor H protein explain the genetic association.
C1 [Casas, Juan P.; Hingorani, Aroon D.] UCL, Dept Epidemiol & Publ Hlth, Genet Epidemiol Grp, London WC1E 6BT, England.
   [Sofat, Reecha; Hingorani, Aroon D.] UCL, Dept Med, Ctr Clin Pharmacol, London WC1E 6BT, England.
   [Casas, Juan P.; Whittaker, John; Smeeth, Liam; Fletcher, Astrid] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London WC1, England.
   [Webster, Andrew R.; Bird, Alan C.; Mann, Samantha S.; Yates, John R. W.; Moore, Anthony T.; Sepp, Tiina; Cipriani, Valentina; Bunce, Catey; Bhattacharya, Shomi S.; Chen, Li L.; Jenkins, Sharon A.; Peto, Tunde] UCL, Inst Ophthalmol, London WC1E 6BT, England.
   [Webster, Andrew R.; Bird, Alan C.; Mann, Samantha S.; Yates, John R. W.; Moore, Anthony T.; Cipriani, Valentina; Bunce, Catey; Bhattacharya, Shomi S.; Chen, Li L.; Jenkins, Sharon A.; Peto, Tunde] Moorfields Eye Hosp, London, England.
   [Yates, John R. W.; Khan, Jane C.; Shahid, Humma] Univ Cambridge, Cambridge Inst Med Res, Dept Med Genet, Cambridge, England.
   [Swaroop, Anand; Branham, Kari E. H.; Zareparsi, Sepideh] Univ Michigan, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA.
   [Swaroop, Anand] NEI, N NRL, NIH, Bethesda, MD 20892 USA.
   [Swaroop, Anand] Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA.
   [Abecasis, Goncalo] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA.
   [Zhang, Kang; Chen, Yuhong] Univ Calif San Diego, Dept Ophthalmol, La Jolla, CA 92093 USA.
   [Zhang, Kang; Chen, Yuhong] Univ Calif San Diego, Inst Genom Med, La Jolla, CA 92093 USA.
   [Zhang, Kang; Chen, Yuhong; Gibbs, Daniel] Univ Utah, Sch Med, Dept Ophthalmol & Visual Sci, Moran Eye Ctr, Salt Lake City, UT USA.
   [Weber, Bernhard H. F.; Fritsche, Lars G.] Univ Regensburg, Inst Human Genet, D-8400 Regensburg, Germany.
   [Keilhauer, Claudia N.] Univ Wurzburg, Hosp Eye, Wurzburg, Germany.
   [Lotery, Andrew; Cree, Angela J.; Griffiths, Helen L.] Univ Southampton, Southampton Gen Hosp, Div Clin Neurosci, Southampton SO9 5NH, Hants, England.
   [Lathrop, Mark] Ctr Natl Genotypage, F-91057 Evry, France.
   [Lathrop, Mark] Fdn Jean Dausset Ceph, F-75010 Paris, France.
   [Leveillard, Thierry] UPMC Univ Paris 06, CNRS, INSERM, U968,UMR S 968,Inst Vis,UMR 7210, F-75012 Paris, France.
   [Gorin, Michael B.; Ortube, Maria Carolina] Univ Calif Los Angeles, Jules Stein Eye Inst, David Geffen Sch Med, Los Angeles, CA 90024 USA.
   [Weeks, Daniel E.; Ferrell, Robert E.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA.
   [Weeks, Daniel E.; Ferrell, Robert E.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.
   [Jakobsdottir, Johanna] Univ Chicago, Dept Stat, Chicago, IL 60637 USA.
   [Seland, Johan H.] Univ Bergen, Stavanger Univ Hosp, Stavanger, Norway.
   [Soubrane, Gisele] Univ Paris, Serv Ophtalmol, Paris, France.
   [Topouzis, Fotis] Aristotle Univ Thessaloniki, AHEPA Hosp, Dept Ophthalmol A, GR-54006 Thessaloniki, Greece.
   [Vioque, Jesus] Univ Miguel Hernandez, Elche, Spain.
   [Vioque, Jesus] Dpto Salud Publ, Alacant 03550, Spain.
   [Tomazzoli, Laura] Univ Verona, Osped Borgo Trento, Sez Oftalmol, Dipartimento Sci Neurol & Vis, I-37124 Verona, Italy.
   [Young, Ian] Royal Victoria Hosp, Ctr Publ Hlth, Belfast BT12 6BJ, Antrim, North Ireland.
   [Whittaker, John] GlaxoSmithKline Inc, Med Res Ctr, Stat Platforms & Technol, Stevenage SG1 2NY, Herts, England.
   [Chakravarthy, Usha] Queens Univ Belfast, Inst Clin Sci, Ctr Vis & Vasc Sci, Belfast BT7 1NN, Antrim, North Ireland.
C3 University of London; University College London; University of London;
   University College London; University of London; London School of
   Hygiene & Tropical Medicine; University of London; University College
   London; University of London; University College London; Moorfields Eye
   Hospital NHS Foundation Trust; University of Cambridge; University of
   Michigan System; University of Michigan; National Institutes of Health
   (NIH) - USA; NIH National Eye Institute (NEI); University of Michigan
   System; University of Michigan; University of Michigan System;
   University of Michigan; University of California System; University of
   California San Diego; University of California System; University of
   California San Diego; Utah System of Higher Education; University of
   Utah; University of Regensburg; University of Wurzburg; University of
   Southampton; CEA; UDICE-French Research Universities; Universite Paris
   Saclay; Foundation Jean Dausset-CEPH; Centre National de la Recherche
   Scientifique (CNRS); CNRS - National Institute for Biology (INSB);
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Sorbonne Universite; Universite
   Paris Cite; University of California System; University of California
   Los Angeles; University of California Los Angeles Medical Center; David
   Geffen School of Medicine at UCLA; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; University of Chicago; Stavanger University Hospital;
   University of Bergen; UDICE-French Research Universities; Universite
   Paris Cite; Aristotle University of Thessaloniki; Ahepa University
   Hospital; Universidad Miguel Hernandez de Elche; Universidad Miguel
   Hernandez de Elche; University of Verona; Azienda Ospedaliera
   Universitaria Integrata Verona; GlaxoSmithKline; Queens University
   Belfast
RP Hingorani, AD (通讯作者)，UCL, Dept Epidemiol & Publ Hlth, Genet Epidemiol Grp, 1-19 Torrington Pl, London WC1E 6BT, England.
EM a.hingorani@ucl.ac.uk
RI Weeks, Daniel E/B-2995-2012; Zhang, Kang/Y-2740-2019; Bhattacharya,
   Shom/N-2926-2016; Peto, Tunde/G-8812-2018; Fritsche, Lars
   G/AAF-9387-2019; Bergen, Arthur/J-3637-2013; Klaver, Caroline
   C.W./A-2013-2016; Cipriani, Valentina/A-8549-2012; Branham,
   Kari/AAA-8336-2022; Rahu, Mati/A-9981-2008; Whittaker, John
   C/B-8609-2012; Léveillard, Thierry/AAR-1804-2020; Vioque,
   Jesus/A-1066-2008; Smeeth, Liam/X-5862-2018
OI Weeks, Daniel E/0000-0001-9410-7228; Zhang, Kang/0000-0002-4549-1697;
   Bhattacharya, Shom/0000-0002-1601-6344; Peto, Tunde/0000-0001-6265-0381;
   Fritsche, Lars G/0000-0002-2110-1690; Cipriani,
   Valentina/0000-0002-0839-9955; Whittaker, John C/0000-0002-3529-2379;
   Léveillard, Thierry/0000-0001-5692-8770; Vioque,
   Jesus/0000-0002-2284-148X; Abecasis, Goncalo/0000-0003-1509-1825;
   Conley, Yvette/0000-0002-1784-6067; Chakravarthy,
   Usha/0000-0002-2606-3734; Lotery, Andrew/0000-0001-5541-4305; Baas,
   Dominique C./0000-0003-0989-9828; Young, Ian/0000-0003-3890-3152; Sofat,
   Reecha/0000-0002-0242-6115; Smeeth, Liam/0000-0002-9168-6022; Weber,
   Bernhard H.F./0000-0002-8808-7723; Topouzis, Fotis/0000-0002-8966-537X;
   Branham, Kari/0000-0002-2492-254X; Hingorani, Aroon/0000-0001-8365-0081;
   Cree, Angela/0000-0002-1987-8900; Swaroop, Anand/0000-0002-1975-1141;
   Klaver, Caroline/0000-0002-2355-5258; Bergen,
   Arthur/0000-0002-6333-9576; Bunce, Catey/0000-0002-0935-3713;
   Jakobsdottir, Johanna/0000-0002-8019-9683
FU Medical Research Council [G0601354, G0000682]; British Heart Foundation
   [FS/07/011, FS 05/125]; Guide Dogs for the Blind Association; UK
   Department of Health's NIHR Biomedical Research Centre for Ophthalmology
   at Moorfields Eye Hospital; UCL Institute of Ophthalmology; Fight for
   Sight UK; German Research Foundation [WE1259/18-1, WE1259/19-1]; Ruth
   and Milton Steinbach Foundation, New York; Alcon Research Institute,
   Fort Worth; Medical Research Council, UK [G0000067]; NIH [EY-016862, R01
   EY9859]; Macula Vision Research Foundation; Harold Falls Professorship;
   ANVVB; Netherlands Macula Fund; LSBS; Research for Prevent Blindness,
   New York; American Health Assistance Foundation; University of
   California, Los Angeles; Macular Vision Research Foundation; British
   Council for Prevention of Blindness; Macular Disease Society; Estonian
   Ministry of Education and Science [01921112s02, SF0940026s07]; Alcon; 
   [EUQLK6-CT-1999-02094]; NATIONAL EYE INSTITUTE [R01EY009859,
   ZIAEY000475, R01EY016862] Funding Source: NIH RePORTER; British Heart
   Foundation [PG/09/022/26739] Funding Source: researchfish; Medical
   Research Council [G0000067] Funding Source: researchfish; National
   Institute for Health Research [NF-SI-0507-10094, NF-SI-0510-10090]
   Funding Source: researchfish; MRC [G0601354, G0000067] Funding Source:
   UKRI
FX This work was supported by a Medical Research Council Biomarkers Award
   G0601354. R.S. was supported by a British Heart Foundation
   (Schillingford) Clinical Training Fellowship (FS/07/011). A.D.H. was
   supported by British Heart Foundation Senior Fellowship (FS 05/125).
   V.C. is funded by a grant from the Guide Dogs for the Blind Association.
   A.M., A.W. and J.Y. receive funding from the UK Department of Health's
   NIHR Biomedical Research Centre for Ophthalmology at Moorfields Eye
   Hospital and UCL Institute of Ophthalmology. The views expressed in the
   publication are those of the authors and not necessarily those of the
   Department of Health. The Moorfields Study in addition was funded by the
   Medical Research Council (Award number G0000682), the Mercer Fund (Fight
   for Sight UK). L.S. holds a Wellcome Trust Senior Research Fellowship.
   EUREYE was funded by EUQLK6-CT-1999-02094. B.H.F.W. is supported by
   grants from the German Research Foundation (WE1259/18-1, WE1259/19-1),
   the Ruth and Milton Steinbach Foundation, New York and the Alcon
   Research Institute, Fort Worth. Cambridge AMD Study was funded by Grant
   G0000067 from the Medical Research Council, UK. AS and GA received
   funding from the NIH EY-016862, AS received funding from Macula Vision
   Research Foundation and the Harold Falls Professorship. A.A.B. is
   supported by the ANVVB, the Netherlands Macula Fund and the LSBS. The
   Pittsburgh Study was funded by the National Institutes of Health grant
   NIH R01 EY9859, Research for Prevent Blindness, New York, and the
   American Health Assistance Foundation and the Harold and Pauline Price
   Endowed Professorship (to Professor Gorin) at University of California,
   Los Angeles. Andrew Lotery is funded by the Macular Vision Research
   Foundation, The British Council for Prevention of Blindness and the
   Macular Disease Society. Mati Rahu is funded by the Estonian Ministry of
   Education and Science (target funding 01921112s02 and SF0940026s07).
   A.D.H. has provided non-remunerated advice to GlaxoSmithKline and London
   Genetics and has received honoraria for speaking at educational meetings
   on cardiovascular risk which have been donated in whole or part to
   charity. J.W. is 90% employed at GlaxoSmithKline whilst retaining a 10%
   appointment at the London School of Hygiene and Tropical Medicine.
   P.T.V.M. de.J. and B.H.F.W. have unrestricted research awards from
   Alcon.
CR [Anonymous], 2007, NATURE, V447, P661
   Augood C, 2004, OPHTHAL EPIDEMIOL, V11, P117, DOI 10.1076/opep.11.2.117.28160
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chen LJ, 2006, MOL VIS, V12, P1536
   Clayton D, 2001, LANCET, V358, P1356, DOI 10.1016/S0140-6736(01)06418-2
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Droz I, 2008, BRIT J OPHTHALMOL, V92, P513, DOI 10.1136/bjo.2007.127811
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2007, BRIT J OPHTHALMOL, V91, P966, DOI 10.1136/bjo.2007.114090
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Fisher SA, 2007, BRIT J OPHTHALMOL, V91, P576, DOI 10.1136/bjo.2006.105577
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2008, J BIOL CHEM, V283, P30451, DOI 10.1074/jbc.M803648200
   Hindroff LA, 2011, CATALOG PUBLISHED GE
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Ioannidis JPA, 2008, INT J EPIDEMIOL, V37, P120, DOI 10.1093/ije/dym159
   Ioannidis JPA, 2005, J CLIN EPIDEMIOL, V58, P543, DOI 10.1016/j.jclinepi.2004.10.019
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Lin JM, 2008, RETINA-J RET VIT DIS, V28, P1416, DOI 10.1097/IAE.0b013e318184661d
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Okamoto H, 2006, MOL VIS, V12, P156
   Palomaki GE, 2010, JAMA-J AM MED ASSOC, V303, P648, DOI 10.1001/jama.2010.118
   Pulido JS, 2007, MAYO CLIN PROC, V82, P301, DOI 10.4065/82.3.301
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Scott WK, 2007, OPHTHALMOLOGY, V114, P1151, DOI 10.1016/j.ophtha.2006.08.054
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Seitsonen S, 2006, MOL VIS, V12, P796
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Souied EH, 2005, MOL VIS, V11, P1135
   Tanimoto S, 2007, NEUROSCI LETT, V414, P71, DOI 10.1016/j.neulet.2006.12.011
   Tedeschi-Blok N, 2007, OPHTHALMOLOGY, V114, P99, DOI 10.1016/j.ophtha.2006.07.043
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   Weger M, 2007, MOL VIS, V13, P1274
   Xing C, 2008, GENES IMMUN, V9, P231, DOI 10.1038/gene.2008.10
   Xu YL, 2008, MOL VIS, V14, P1373
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Ziskind A, 2008, OPHTHALMIC GENET, V29, P117, DOI 10.1080/13816810802216472
NR 58
TC 67
Z9 68
U1 0
U2 21
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0300-5771
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PD FEB
PY 2012
VL 41
IS 1
BP 250
EP 262
DI 10.1093/ije/dyr204
PG 13
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health
GA 915LH
UT WOS:000302026800030
PM 22253316
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Soheilian, M
   Movaseghi, M
   Ramezani, A
   Peyman, GA
AF Soheilian, Masoud
   Movaseghi, Mehryar
   Ramezani, Alireza
   Peyman, Gholam A.
TI Pilot study of safety and effect of combined intravitreal bevacizumab
   and methotrexate for neovascular age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Bevacizumab; Choroidal
   neovascularization; Methotrexate
ID CHOROIDAL NEOVASCULARIZATION; RHEUMATOID-ARTHRITIS; CYTOKINE PRODUCTION;
   INTRAOCULAR METHOTREXATE; VISUAL IMPAIRMENT; INDUCED APOPTOSIS;
   UNITED-STATES; INHIBITION; DISEASE; PREVALENCE
AB PURPOSE. To evaluate the safety and effect of combined intravitreal methotrexate and bevacizumab on choroidal neovascularization in age-related macular degeneration (AMD).
   METHODS. Seven eyes of 7 patients (4 female; mean age 65.43 +/- 5.96 years) with choroidal neovascularization secondary to AMD were studied. Patients received intravitreal injection of methotrexate and bevacizumab and were examined every 1.5 months. Reinjections were performed with bevacizumab only.
   RESULTS. Three patients had 3 months, 3 had 4.5 months, and 1 had 8 months of follow-up. Mean number of reinjections was 2.0. In all patients, best-corrected visual acuity (BCVA) improved compared to baseline. Central macular thickness (CMT) decreased in all but one patient who had no reduced visual acuity. Mean BCVA (logMAR) was 1.27 +/- 0.43 D at baseline, 1.1 +/- 0.38 D at week 6, and 0.93 +/- 0.31 D at month 3. Mean BCVA in 3 patients at 4.5 months was 1.1 +/- 0.15 D. There were statistically significant differences between BCVA before injection and at week 6 (p=0.017), 3 months (p=0.005), and 4.5 months (p=0.04). Mean baseline CMT was 389 +/- 177 mu m, 371 +/- 154 mu m at 6 weeks, and 317 +/- 108 mu m at 3 months. Mean CMT in 3 patients at 4.5 months was 266 +/- 66 mu m. There were no statistically significant differences between baseline CMT and after treatment. No scar formation, increase of scar, or adverse reaction to methotrexate injection were seen.
   CONCLUSIONS. Addition of intravitreal methotrexate to bevacizumab was safe in 7 eyes of 7 patients. It may enhance the therapeutic effect in regression of neovascularization in AMD and may reduce development of a fibrous component and disciform scar formation.
C1 [Soheilian, Masoud; Movaseghi, Mehryar; Ramezani, Alireza] Shaheed Beheshti Med Univ, Labbafinejad Med Ctr, Ophthalm Res Ctr, Tehran 16666, Iran.
   [Soheilian, Masoud; Movaseghi, Mehryar; Ramezani, Alireza] Shaheed Beheshti Med Univ, Labbafinejad Med Ctr, Dept Ophthalmol, Tehran 16666, Iran.
   [Soheilian, Masoud; Ramezani, Alireza] Negah Eye Hosp, Tehran, Iran.
   [Peyman, Gholam A.] Tulane Univ, Hlth Sci Ctr, Dept Ophthalmol, New Orleans, LA 70118 USA.
   [Peyman, Gholam A.] Univ Arizona, Dept Ophthalmol, Phoenix, AZ USA.
C3 Shahid Beheshti University Medical Sciences; Shahid Beheshti University
   Medical Sciences; Tulane University; University of Arizona
RP Soheilian, M (通讯作者)，Shaheed Beheshti Med Univ, Labbafinejad Med Ctr, Ophthalm Res Ctr, Pasdaran Ave,Boostan 9 St, Tehran 16666, Iran.
EM masoud_soheilian@yahoo.com
RI Ramezani, Alireza/AAZ-2606-2020; Ramezani, Alireza/AAF-4834-2020;
   Soheilian, Masoud/AAW-4743-2020
OI Ramezani, Alireza/0000-0002-1925-1251; Soheilian,
   Masoud/0000-0001-7508-426X
FU Ophthalmic Research Center of Shahid Beheshti Medical University,
   Tehran, Iran
FX Supported by Ophthalmic Research Center of Shahid Beheshti Medical
   University, Tehran, Iran.
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cronstein BN, 2005, PHARMACOL REV, V57, P163, DOI 10.1124/pr.57.2.3
   de Lathouder S, 2004, NUCLEOS NUCLEOT NUCL, V23, P1089, DOI 10.1081/NCN-200027365
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Egan LJ, 1996, MAYO CLIN PROC, V71, P69, DOI 10.4065/71.1.69
   Fiehn C, 2005, RHEUMATOL INT, V25, P108, DOI 10.1007/s00296-003-0408-y
   Frenkel S, 2008, BRIT J OPHTHALMOL, V92, P383, DOI 10.1136/bjo.2007.127928
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gerards AH, 2003, RHEUMATOLOGY, V42, P1189, DOI 10.1093/rheumatology/keg323
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Green W R, 1999, Mol Vis, V5, P27
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hardwig PW, 2006, AM J OPHTHALMOL, V142, P883, DOI 10.1016/j.ajo.2006.06.002
   Hasko G, 2004, TRENDS IMMUNOL, V25, P33, DOI 10.1016/j.it.2003.11.003
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Hsu PC, 2006, APOPTOSIS, V11, P389, DOI 10.1007/s10495-006-4002-0
   Huang CC, 2005, APOPTOSIS, V10, P895, DOI 10.1007/s10495-005-2947-z
   Johnston A, 2005, CLIN IMMUNOL, V114, P154, DOI 10.1016/j.clim.2004.09.001
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Kraan MC, 2004, ANN RHEUM DIS, V63, P1056, DOI 10.1136/ard.2003.014738
   Kusabe T, 2005, RHEUMATOL INT, V25, P625, DOI 10.1007/s00296-005-0624-8
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   MARTENET AC, 1980, KLIN MONATSBL AUGENH, V176, P648, DOI 10.1055/s-2008-1057524
   Otani A, 1999, INVEST OPHTH VIS SCI, V40, pS705
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Samson CM, 2001, OPHTHALMOLOGY, V108, P1134, DOI 10.1016/S0161-6420(01)00576-0
   Solomon S, 2004, RHEUMATOL INT, V24, P71, DOI 10.1007/s00296-003-0333-0
   Taylor SRJ, 2009, OPHTHALMOLOGY, V116, P797, DOI 10.1016/j.ophtha.2008.10.033
   Winter-Vann AM, 2003, P NATL ACAD SCI USA, V100, P6529, DOI 10.1073/pnas.1135239100
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   WONG VG, 1966, ARCH OPHTHALMOL-CHIC, V76, P66
   Zhu Q, 2008, OPHTHALMOLOGY, V115, P1750, DOI 10.1016/j.ophtha.2008.04.023
NR 35
TC 12
Z9 13
U1 0
U2 1
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN-FEB
PY 2011
VL 21
IS 1
BP 77
EP 82
DI 10.5301/EJO.2010.5696
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 687MI
UT WOS:000284782200012
PM 20872362
DA 2022-11-30
ER

PT J
AU Tulka, S
   Knippschild, S
   Funck, S
   Goetjes, I
   Uluk, Y
   Baulig, C
AF Tulka, Sabrina
   Knippschild, Stephanie
   Funck, Sina
   Goetjes, Isabelle
   Uluk, Yasmin
   Baulig, Christine
TI Reporting of statistical sample size calculations in publications of
   trials on age-related macular degeneration, glaucoma and cataract
SO PLOS ONE
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIALS; CLINICAL-TRIALS; QUALITY; JOURNALS
AB Background Transparent and complete publications of randomised controlled trials (RCT) ought to comply with the guidelines of the CONSORT Statement, which stipulates sample size calculation as an important aspect of trial planning. The objective of this study was to analyse and compare the reporting of statistical sample size calculations in RCT papers on the treatment of age-related macular degeneration (AMD), glaucoma and cataract published in 2018.
   Material and methods This study comprises a total of 113 RCT papers (RCT-P) published in 2018 (AMD: 14, glaucoma: 28, cataract: 71), in English or German, and identified through an internet-based literature search in PubMed and EMBASE. The primary outcome measure of the study was the number of trials providing a complete description of the underlying sample case calculation on the basis of the variables required (significance level, expected outcomes, power, and resulting sample size).
   Results Of the RCTs reviewed, 64% (AMD), 61% (glaucoma) and 31% (cataract) provided a justification of the number of patients included. A complete description of the described studies' sample size calculation including all the necessary values (primary outcome measure of this study) was described by 21% of the AMD, 29% of the cataract and 18% of the glaucoma RCT publications (in total: 24 of 113 (21%) at a confidence interval of 95%: [13%; 29%]).
   Conclusion All three treatment areas analysed lacked reporting quality regarding the justification of the number of patients included in a clinical trial based on a sample size calculation required for ethical reasons. More than half of all RCT publications reviewed did not provide all of the required information on statistical sample size calculation, and thus lacked transparency and completeness. It is therefore urgently required to involve methodologists in a study's planning and publishing processes to ensure that methodology descriptions are transparent and of high quality.
C1 [Tulka, Sabrina; Knippschild, Stephanie; Funck, Sina; Goetjes, Isabelle; Uluk, Yasmin; Baulig, Christine] Witten Herdecke Univ, Fac Hlth, Chair Med Biometry & Epidemiol IMBE, Witten, Germany.
RP Tulka, S (通讯作者)，Witten Herdecke Univ, Fac Hlth, Chair Med Biometry & Epidemiol IMBE, Witten, Germany.
EM Sabrina.Tulka@uni-wh.de
RI Prof. Dr. Baulig, Christine/HDN-2311-2022
CR Abdulatif M, 2015, BRIT J ANAESTH, V115, P699, DOI 10.1093/bja/aev166
   Bariani GM, 2015, AM J CLIN ONCOL-CANC, V38, P570, DOI 10.1097/01.coc.0000436085.23342.2d
   Charles P, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1732
   Chow JTY, 2018, CAN J ANESTH, V65, P611, DOI 10.1007/s12630-018-1109-z
   Huang YQ, 2018, J OTOLARYNGOL-HEAD N, V47, DOI 10.1186/s40463-018-0277-8
   Koletsi D, 2014, EUR J ORTHODONT, V36, P67, DOI 10.1093/ejo/cjt005
   Koletsi D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085949
   Krummenauer F, 2002, KLIN MONBL AUGENHEIL, V202, P362
   Lee PH, 2020, EUR J INTERN MED, V77, P139, DOI 10.1016/j.ejim.2020.04.057
   Lee PH, 2017, EUR J INTERN MED, V40, P16, DOI 10.1016/j.ejim.2016.10.008
   Loguercio AD, 2017, BRAZ ORAL RES, V31, P100, DOI 10.1590/1807-3107BOR-2017.vol31.0060
   Moher David, 2010, J Clin Epidemiol, V63, pe1, DOI [10.1136/bmj.c869, 10.1016/j.jclinepi.2010.03.004]
   Rohrig B, 2010, DTSCH ARZTEBL INT, V107, P552, DOI 10.3238/arztebl.2010.0552
   Satpute Sachin, 2016, Perspect Clin Res, V7, P128, DOI 10.4103/2229-3485.184816
   Schumacher M., 2007, METHODIK KLINISCHER, P3
   Tulka S, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-030312
   Tulka S, 2020, OPHTHALMOLOGE, V117, P125, DOI 10.1007/s00347-019-0924-0
   Zhang J, 2016, ORTHOP TRAUMATOL-SUR, V102, P933, DOI 10.1016/j.otsr.2016.05.018
NR 18
TC 2
Z9 2
U1 1
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 4
PY 2021
VL 16
IS 6
AR e0252640
DI 10.1371/journal.pone.0252640
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA SW6RB
UT WOS:000664640100099
PM 34086796
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Brown, GC
   Brown, MM
   Rapuano, SB
   Boyer, D
AF Brown, Gary C.
   Brown, Melissa M.
   Rapuano, Sara B.
   Boyer, David
TI A Cost-Benefit Analysis of VEGF-Inhibitor Therapy for Neovascular
   Age-Related Macular Degeneration in the United States
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BUDGET IMPACT ANALYSIS; LONG-TERM OUTCOMES; RANIBIZUMAB; BEVACIZUMAB;
   PREVALENCE; MARINA; EYE
AB PURPOSE: To perform a societal cost-benefit analysis comparing intravitreal bevacizumab (Avastin), ranibizumab (Lucentis), and aflibercept (Eylea) monotherapies for treating neovascular age-related macular degeneration (NVAMD).
   DESIGN: Cost-benefit analysis.
   METHODS: Center for Value-Based Medicine using published clinical trial and Medicare data. Patient population: 168,400 estimated 2018 U.S. patients with new onset NVAMD. Procedure(s): cost-benefit analysis using 2018 U.S. real dollars. Outcome measurements: 11-year direct ophthalmic medical costs expended for bevacizumab, ranibizumab, and aflibercept monotherapies were compared with ophthalmic and nonophthalmic direct medical, direct nonmedical, and indirect medical (productivity) costs saved by the therapies.
   RESULTS: Bevacizumab monotherapy had an individual, 11-year $14,772 treatment cost and net $357,680 societal return (11-year 2,421% return on investment [ROI]). Ranibizumab therapy cost $106,582 and returned $265,870 to society (249% ROI), whereas aflibercept treatment cost $61,811 and returned $310,611 to society (503% ROI). The 2018 NVAMD overall treatment cohort, 11-year net societal gain was $28.5 billion to patients and insurers, with $24.2 billion (84.9%) coming from bevacizumab therapy, $0.7 billion (2.5%) from ranibizumab therapy, and $3.6 billion (12.6%) from aflibercept therapy. Substituting bevacizumab for ranibizumab and aflibercept in the 2018 new onset NVAMD patients would save an estimated $1.343 billion over 11 years. Vascular endothelial growth factor-inhibitor (VEGF-I) therapy in 2018 should contribute $12.2 billion to the Gross Domestic Product over 11 years. Late treatment would decrease this by 78% to $2.7 billion.
   CONCLUSIONS: Intravitreal NVAMD bevacizumab, ranibizumab and aflibercept monotherapies accrue considerable financial, ROIs to patients and insurers as they increase national wealth. (Am J Ophthalmol 2021;223: 405-429. (c) 2020 Elsevier Inc. All rights reserved.)
C1 [Brown, Gary C.; Brown, Melissa M.; Rapuano, Sara B.] Ctr Value Based Med, Box 3417, Hilton Head Isl, SC 29928 USA.
   [Brown, Gary C.; Brown, Melissa M.; Rapuano, Sara B.] Jefferson Med Univ, Wills Eye Hosp, Philadelphia, PA USA.
   [Brown, Gary C.; Brown, Melissa M.] Emory Univ, Sch Med, Dept Ophthalmol, Atlanta, GA 30322 USA.
   [Boyer, David] Retina Vitreous Associates Med Grp, Los Angeles, CA USA.
C3 Jefferson University; Emory University; Retina Vitreous Associates
   Medical Group
RP Brown, GC (通讯作者)，Ctr Value Based Med, Box 3417, Hilton Head Isl, SC 29928 USA.
EM gary0514@gmail.com
CR Arias E, 2017, NATL VITAL STAT REPO, V68, P10
   Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   Barendregt JJ, 1997, NEW ENGL J MED, V337, P1052, DOI 10.1056/NEJM199710093371506
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brault M.W., 2012, AM DISABILITIES 2010, P1
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown G, 2017, OPHTHALMOL RETINA, V1, P404, DOI 10.1016/j.oret.2017.01.018
   Brown GC, 2020, AM J OPHTHALMOL, V218, P225, DOI 10.1016/j.ajo.2020.05.029
   Brown Gary C, 2015, Int J Retina Vitreous, V1, P19, DOI 10.1186/s40942-015-0016-5
   Brown GC, 2015, OPHTHALMOLOGY, V122, P1416, DOI 10.1016/j.ophtha.2015.03.032
   Brown GC, 2013, OPHTHALMOLOGY, V120, P2367, DOI 10.1016/j.ophtha.2013.04.030
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Brown MM, 2016, RETINA-J RET VIT DIS, V36, P285, DOI 10.1097/IAE.0000000000000717
   Brown MM, 2005, EVIDENCE BASED VALUE, P151
   Bureau of Labor Statistics, EMPL STAT CIV NON PO
   Centers for Medicaid and Medicare Services, MED B
   Centers for Medicare and Medicaid Services, LIC US CURR PROC TER
   Centers for Medicare and Medicaid Services, PHYS SUPP NAT DAT B
   Chen GH, 2015, RETINA-J RET VIT DIS, V35, P187, DOI 10.1097/IAE.0000000000000301
   Christ SL, 2014, JAMA OPHTHALMOL, V132, P1400, DOI 10.1001/jamaophthalmol.2014.2847
   Ciulla TA, 2020, OPHTHALMOL RETINA, V4, P19, DOI 10.1016/j.oret.2019.05.017
   Countryeconomy.com, 2019, US US GDPGROSS DOMES
   Cox J, 2017, CNBC
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Garattini L, 2011, EUR J HEALTH ECON, V12, P499, DOI 10.1007/s10198-011-0348-5
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hsia Ning-Yi, 2015, Taiwan J Ophthalmol, V5, P128, DOI 10.1016/j.tjo.2015.05.001
   Investopedia, GROSS DOMESTIC PRODU
   Javitt JC, 2007, OPHTHALMOLOGY, V114, P238, DOI 10.1016/j.ophtha.2006.07.054
   Kaiser Family Foundation, 2018, EMPLOYER HLTH BENEFI
   Kertes PJ, 2020, JAMA OPHTHALMOL, V138, P244, DOI 10.1001/jamaophthalmol.2019.5540
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McGrath LA, 2013, ASIA-PAC J OPHTHALMO, V2, P295, DOI 10.1097/APO.0b013e31829dc65a
   MedicareAdvantage.com, WHAT IS AV COST MED
   Medicaremall.com, 2018, MED B
   Mekjavic PJ, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00125
   Morse LR, 2017, AM AC OPHTH 2017 ANN
   Mulligan K, 2020, JAMA OPHTHALMOL, V138, P40, DOI 10.1001/jamaophthalmol.2019.4557
   Nguyen CL, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0785-3
   Nordhaus WD, 2002, HLTH NATIONS CONTRIB, P37
   Okada M, 2018, AM J OPHTHALMOL, V192, P184, DOI 10.1016/j.ajo.2018.05.026
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   Rayess N, 2016, AM J OPHTHALMOL, V165, P88, DOI 10.1016/j.ajo.2016.02.028
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sanders GD, 2016, JAMA-J AM MED ASSOC, V316, P1093, DOI 10.1001/jama.2016.12195
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Shah AR, 2007, AM J OPHTHALMOL, V143, P83, DOI 10.1016/j.ajo.2006.09.043
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Smithen Lindsay M, 2004, Curr Opin Ophthalmol, V15, P173, DOI 10.1097/01.icu.0000120673.27548.52
   Soliman MK, COCHRANE DB SYST REV, V2
   Sullivan SD, 2014, VALUE HEALTH, V17, P5, DOI 10.1016/j.jval.2013.08.2291
   Suner I, 2019, RET SOC 52 ANN SCI M
   U.S. Bureau of Labor Statistics, CPI ALL URB CONS CPI
   U.S. Food and Drug Administration, HIGHL PRESCR INF
   US Census Bureau, 2018, HLTH INSURANCE COVER
   Vu HTV, 2005, BRIT J OPHTHALMOL, V89, P360, DOI 10.1136/bjo.2004.047498
   Webb Anthony, 2010, WHAT IS DISTRIBUTION, P10
   Wu Annie M, 2018, Am J Ophthalmol Case Rep, V11, P105, DOI 10.1016/j.ajoc.2018.06.005
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
   Zhang XZ, 2010, JAMA-J AM MED ASSOC, V304, P649, DOI 10.1001/jama.2010.1111
NR 66
TC 2
Z9 3
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2021
VL 223
BP 405
EP 429
DI 10.1016/j.ajo.2020.07.010
EA MAR 2021
PG 25
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QZ9BI
UT WOS:000631013300001
PM 32681907
DA 2022-11-30
ER

PT J
AU Dolz-Marco, R
   Gal-Or, O
   Freund, KB
AF Dolz-Marco, Rosa
   Gal-Or, Orly
   Freund, K. Bailey
TI Choroidal Thickness Influences Near-Infrared Reflectance Intensity in
   Eyes With Geographic Atrophy Due To Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE choroidal thickness; geographic atrophy; infrared imaging; multimodal
   imaging; near-infrared reflectance
ID OPTICAL COHERENCE TOMOGRAPHY; NATURAL-HISTORY; OCULAR FUNDUS;
   MACULOPATHY; ABNORMALITIES; PROGRESSION; POPULATION; PREVALENCE;
   PATHOLOGY; SECONDARY
AB PURPOSE. To evaluate the effects of retinal and choroidal thickness on near-infrared reflectance (NIR) scanning laser ophthalmoscopy in eyes with geographic atrophy (GA) secondary to non-neovascular age-related macular degeneration (AMD).
   METHODS. This was a cross-sectional review of the clinical records and multimodal imaging data of eyes diagnosed with GA secondary to non-neovascular AMD. Imaging modalities included color fundus photography, fundus autofluorescence, NIR, and structural spectral-domain optical coherence tomography (SD-OCT). On SD-OCT images, the foveal retina thickness and the subfoveal choroidal thickness were measured by two independent readers. Near-infrared reflectance intensity within areas of GA was subjectively graded as hyperreflective, isoreflective, or hyporeflective and objectively estimated by using ImageJ to calculate the mean gray scale value within each GA area. A linear regression analysis was performed to model the relationship between mean NIR gray scale value and retinal and choroidal thickness.
   RESULTS. One hundred four eyes of 104 patients with a mean age of 81.3 years (SD: +/- 8.3) were included. The area of GA was hyperreflective on NIR in 88 eyes (85%), isoreflective in 13 eyes (12%), and hyporeflective in 3 eyes (3%). The mean foveal retinal thickness was 101.5 mu m (SD: +/- 54) showing no significant relationship with mean NIR (P = 0.464); and the mean subfoveal choroidal thickness was 172.6 mu m (SD: +/- 114.7) showing a statistically significant relationship with mean NIR intensity in the linear regression analysis (r = 0.590; r(2) = 0.348; P < 0.00001).
   CONCLUSIONS. Variations in choroidal thickness appear to influence NIR intensity in areas of GA and have the potential to affect image interpretation. The recognition of this relationship may provide useful information regarding choroidal thickness.
C1 [Dolz-Marco, Rosa; Gal-Or, Orly; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, 460 Pk Ave, New York, NY 10022 USA.
   [Dolz-Marco, Rosa; Gal-Or, Orly; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Freund, K. Bailey] Columbia Univ Coll Phys & Surg, Dept Ophthalmol, Edward S Harkness Eye Inst, New York, NY 10032 USA.
   [Freund, K. Bailey] NYU, Dept Ophthalmol, Sch Med, 550 1St Ave, New York, NY 10016 USA.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital; Columbia University; New York University
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI ; Freund, K. Bailey/V-7488-2018
OI Dolz-Marco, Rosa/0000-0002-2963-2541; Freund, K.
   Bailey/0000-0002-7888-9773
FU LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear, and
   Throat Hospital, New York, New York, United States; Macula Foundation,
   Inc., New York, New York, United States
FX Supported by the LuEsther T. Mertz Retinal Research Center, Manhattan
   Eye, Ear, and Throat Hospital, New York, New York, United States, and
   The Macula Foundation, Inc., New York, New York, United States.
CR Albertus DL, 2013, JAMA OPHTHALMOL, V131, P1004, DOI 10.1001/jamaophthalmol.2013.4007
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bhavsar KV, 2016, SURV OPHTHALMOL, V61, P538, DOI 10.1016/j.survophthal.2016.03.003
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   DALLOW RL, 1974, ARCH OPHTHALMOL-CHIC, V92, P254
   ELSNER AE, 1992, APPL OPTICS, V31, P3697, DOI 10.1364/AO.31.003697
   Elsner AE, 1996, VISION RES, V36, P191, DOI 10.1016/0042-6989(95)00100-E
   Forte R, 2012, ACTA OPHTHALMOL, V90, pE281, DOI 10.1111/j.1755-3768.2011.02331.x
   Gobel AP, 2011, OPHTHALMOLOGICA, V226, P182, DOI 10.1159/000330420
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P58, DOI 10.1016/S0161-6420(96)30731-8
   Hassenstein A, 2009, CLIN EXP OPHTHALMOL, V37, P130, DOI 10.1111/j.1442-9071.2009.02017.x
   Helb HM, 2010, ACTA OPHTHALMOL, V88, P842, DOI 10.1111/j.1755-3768.2009.01602.x
   Issa PC, 2009, INVEST OPHTH VIS SCI, V50, P5913, DOI 10.1167/iovs.09-3541
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kunze C, 1999, OPHTHALMOLOGY, V106, P1830, DOI 10.1016/S0161-6420(99)90364-0
   Lindner M, 2015, INVEST OPHTH VIS SCI, V56, P875, DOI 10.1167/iovs.14-14933
   Liu CF, 2014, EYE, V28, P1437, DOI 10.1038/eye.2014.221
   Miura M, 2002, RETINA-J RET VIT DIS, V22, P300, DOI 10.1097/00006982-200206000-00008
   Pang CE, 2014, AM J OPHTHALMOL, V158, P171, DOI 10.1016/j.ajo.2014.03.003
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Semoun O, 2009, BRIT J OPHTHALMOL, V93, P182, DOI 10.1136/bjo.2008.145235
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Theelen T, 2009, GRAEF ARCH CLIN EXP, V247, P1625, DOI 10.1007/s00417-009-1148-9
   Vagge A, 2015, ACTA OPHTHALMOL, V93, pE667, DOI 10.1111/aos.12750
   Viola F, 2012, OPHTHALMOLOGY, V119, P369, DOI 10.1016/j.ophtha.2011.07.046
   Yu SQ, 2015, AM J OPHTHALMOL, V159, P53, DOI 10.1016/j.ajo.2014.09.027
NR 28
TC 8
Z9 8
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2016
VL 57
IS 14
BP 6440
EP 6446
DI 10.1167/iovs.16-20265
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EI3HG
UT WOS:000392380000076
PM 27893108
OA gold
DA 2022-11-30
ER

PT J
AU Pirbhai, A
   Sheidow, T
   Hooper, P
AF Pirbhai, A
   Sheidow, T
   Hooper, P
TI Prospective evaluation of digital non-stereo color fundus photography as
   a screening tool in age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; DIABETIC-RETINOPATHY;
   COST-EFFECTIVENESS; MACULOPATHY; PREVALENCE; SLIDES; BAY; EYE
AB center dot PURPOSE: To evaluate mydriatic, non,stereo digital color fundus photographs as a screening tool for identifying and classifying exudative age-related macular de, generation (AMD).
   center dot DESIGN: Prospective case series.
   center dot METHODS: Digital color fundus photographs were obtained from patients seen in the AMD screening clinic over a 9,month period at the Ivey Eye Institute in London, Ontario. Photographs for eligible patients were separated by eye, cataloged, blinded, and randomly labeled before interpretation by an experienced vitreoretinal surgeon. Exact agreement, sensitivity, specificity, positive predictive value, and negative predictive value of the fundus photographs in diagnosing, classifying, and managing cases of suspected exudative AMD were then calculated against gold standard clinical examination and fluorescein angiography.
   center dot RESULTS: A total of 223 images were used from 118 eligible patients. Exact agreement between photographic evaluation and gold standard ranged from 89.2% (presence of pigment epithelial detachment (PED)) to 82.5% (evidence of retinal pigment epithelium geographic atrophy). Sensitivities ranged from 89.2% (presence of choroidal neovascular membrane (CNVM)) to 40.0% (presence of PED). Specificities ranged from 94.1% (presence of PED) to 86.8% (presence of retinal pigment epithelium geographic atrophy). Positive predictive value ranged from 86.1% (presence of CNVM) to 40.0% (presence of PED). Negative predictive value ranged from 94.1% (presence of PED) to 88.9% (presence of CNVM). As a screening tool for high-risk dry changes and active exudative changes, overall sensitivity specificity, positive predictive value, and negative predictive value were 82.1%, 79.1%, 70.4%, and 88.0%, respectively.
   center dot CONCLUSIONS: Digital, non-stereo color fundus photographs are highly sensitive and have high negative predictive value as a screening tool. Very few treatable lesions are missed using telemedicine in age-related macular degeneration. (c) 2005 by Elsevier Inc. All rights reserved.
C1 Univ Western Ontario, Dept Ophthalmol, London, ON, Canada.
   Univ Western Ontario, Dept Ophthalmol, London, England.
C3 Western University (University of Western Ontario); Western University
   (University of Western Ontario)
RP Sheidow, T (通讯作者)，Ivey Eye Inst, 750 Commiss Rd E, London, ON N6A 4G5, Canada.
EM tom.sheidow@lhsc.on.ca
OI Sheidow, Tom/0000-0001-6370-1857
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   British Diabetic Association, 1967, EPH546 BRIT DIAB ASS
   JAVITT JC, 1989, OPHTHALMOLOGY, V96, P255
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Liesenfeld B, 2000, DIABETES CARE, V23, P345, DOI 10.2337/diacare.23.3.345
   Lim JI, 2002, RETINA-J RET VIT DIS, V22, P59, DOI 10.1097/00006982-200202000-00011
   Lin D Y, 1999, Diabetes Technol Ther, V1, P477, DOI 10.1089/152091599317035
   Maberley D, 2003, CAN J OPHTHALMOL, V38, P349
   Maberley D, 2003, CAN MED ASSOC J, V168, P160
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   PIZZARELLO LD, 1987, OPHTHALMOLOGY, V94, P1191
   Rosner B, 1995, FUNDAMENTALS BIOSTAT, P423
   Rudnisky CJ, 2002, OPHTHALMOLOGY, V109, P267, DOI 10.1016/S0161-6420(01)00933-2
   Scholl HPN, 2004, OPHTHALMOLOGY, V111, P125, DOI 10.1016/j.ophtha.2003.05.003
   Sharma S, 2001, CAN J OPHTHALMOL, V36, P7, DOI 10.1016/S0008-4182(01)80060-0
   SINGER DE, 1992, ANN INTERN MED, V116, P660, DOI 10.7326/0003-4819-116-8-660
   Soubrane G, 2001, BRIT J OPHTHALMOL, V85, P483, DOI 10.1136/bjo.85.4.483
   van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 22
TC 59
Z9 59
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2005
VL 139
IS 3
BP 455
EP 461
DI 10.1016/j.ajo.2004.09.077
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 907GO
UT WOS:000227704200006
PM 15767053
DA 2022-11-30
ER

PT J
AU Brynskov, T
   Munch, IC
   Larsen, TM
   Erngaard, I
   Sorensen, TL
AF Brynskov, Troels
   Munch, Inger Christine
   Larsen, Tobias Malte
   Erngaard, Iiv
   Sorensen, Torben Lykke
TI Real-world 10-year experiences with intravitreal treatment with
   ranibizumab and aflibercept for neovascular age-related macular
   degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE anti-vascular endothelial growth factor; long-term; neovascular
   age-related macular degeneration; real-world; retina; wet age-related
   macular degeneration
ID CHOROIDAL NEOVASCULARIZATION; FOLLOW-UP; OUTCOMES; VERTEPORFIN;
   BLINDNESS; MARINA; TRIAL; EYE
AB Purpose To report 10-year, real-world experiences with intravitreal therapy (IVT) using vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration (nAMD). Methods Retrospective single-centre review of IVT-log 2007-2019 with a treatment-as-needed regimen and ETDRS visual acuity charts. Results The 4,678 treatment-naive eyes of 3,668 patients received a mean of 5.4 IVT in the first year and 4.0-4.3 IVT yearly thereafter. Baseline mean best corrected visual acuity (BCVA) was 57.9 (+/- 16.4) letters (6/18) that improved a mean +2.1 (+/- 0.2) letters at the first follow-up visit and gradually declined to -5.0 (+/- 2.2) letters after 10 years. At baseline, there were 29% with BCVA >= 6/12. This proportion increased to 31-37% until year 9. There were 8% with BCVA loss of >= 3 lines at the first follow-up visit increasing to 34% after 10 years. Poorer baseline BCVA was associated with larger increase in BCVA (p < 0.0001, multiple linear regression). The 2,566 (55%) discontinued eyes had a mean baseline BCVA of 56.9 (+/- 16.4) letters compared with 61.5 (+/- 15.9) letters for eyes remaining in treatment. In year 0-7, the discontinued eyes lost an additional mean 2-4 letters (last observation carried forward) but were similar thereafter. There were 12.6% (74 of 585 eligible eyes) that were still in treatment after 10 years. At baseline, 10% had bilateral nAMD. Of patients with unilateral presentation, 17% had received fellow-eye IVT after 5 years. Conclusion A treatment-as-needed regimen stabilized BCVA in active nAMD up to 10 years in most eyes. Baseline BCVA was the most important prognostic factor.
C1 [Brynskov, Troels; Munch, Inger Christine; Sorensen, Torben Lykke] Zealand Univ Hosp Roskilde, Dept Ophthalmol, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
   [Brynskov, Troels] Rigshosp, Glostrup Hosp, Dept Ophthalmol, Glostrup, Denmark.
   [Munch, Inger Christine; Sorensen, Torben Lykke] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark.
   [Larsen, Tobias Malte; Erngaard, Iiv] Univ Southern Denmark, Fac Hlth Sci, Odense, Denmark.
C3 Rigshospitalet; University of Copenhagen; University of Copenhagen;
   University of Southern Denmark
RP Brynskov, T (通讯作者)，Zealand Univ Hosp Roskilde, Dept Ophthalmol, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
EM troels@brynskov.com
OI Larsen, Tobias Malte/0000-0002-2606-5131
CR Berg K, 2017, ACTA OPHTHALMOL, V95, P796, DOI 10.1111/aos.13522
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brynskov T, 2014, RETINA-J RET VIT DIS, V34, P951, DOI 10.1097/IAE.0000000000000071
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   International Council of Ophthalmology (ICO), 2006, VIS REQ DRIV SAF, P1
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kumar A, 2011, BRIT J OPHTHALMOL, V95, P530, DOI 10.1136/bjo.2009.171868
   Mantel I, 2014, BRIT J OPHTHALMOL, V98, P1192, DOI 10.1136/bjophthalmol-2013-304556
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   Westborg I, 2017, ACTA OPHTHALMOL, V95, P787, DOI 10.1111/aos.13539
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 29
TC 25
Z9 25
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAR
PY 2020
VL 98
IS 2
BP 132
EP 138
DI 10.1111/aos.14183
EA JUL 2019
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KS3BI
UT WOS:000477194900001
PM 31282617
OA Green Published
DA 2022-11-30
ER

PT J
AU Stanislovaitiene, D
   Zaliuniene, D
   Krisciukaitis, A
   Petrolis, R
   Smalinskiene, A
   Lesauskaite, V
   Tamosiunas, A
   Lesauskaite, V
AF Stanislovaitiene, Daiva
   Zaliuniene, Dalia
   Krisciukaitis, Algimantas
   Petrolis, Robertas
   Smalinskiene, Alina
   Lesauskaite, Vita
   Tamosiunas, Abdonas
   Lesauskaite, Vaiva
TI SCARB1 rs5888 is associated with the risk of age-related macular
   degeneration susceptibility and an impaired macular area
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Age-related macular degeneration (ARMD); area of macular lesion;
   oxidative stress; scavenger receptor class B type 1 gene (SCARB1);
   single nucleotide polymorphism (SNP)
ID CORONARY-HEART-DISEASE; SCAVENGER RECEPTORS; LIPOPROTEIN; PROFILE
AB Background: Age-related macular degeneration (ARMD), a progressive retinal disease, is responsible for an impaired central vision in about 180 million people worldwide. Current options for ARMD prevention and treatment are limited due to an incomplete understanding of disease etiopathogenesis. We aimed to test the hypothesis that the single nucleotide polymorphism rs5888 of SCARB1 gene reflecting lipid and antioxidant micronutrient metabolism pathways is associated with ARMD susceptibility and to evaluate if there is any relation between SCARB1 rs5888 and the macular lesion area.
   Materials and methods: The prospective case-control study included patients with ARMD (n = 215) and the reference group (n = 238) drawn from a random sample of the Lithuanian population (n = 1436). The genotyping test of SCARB1 rs5888 was carried out using the real-time polymerase chain reaction method.
   Results: Regression analysis adjusted by gender and age demonstrated that SCARB1 rs5888 TT genotype significantly decreased the odds for ARMD development (OR: 0.61, 95%; CI: 0.380-0.981, p = 0.04). A smoking habit and leading an outdoor life are associated with larger macular lesion areas in ARMD patients (0.54 (0.00-39.06) vs. 3.09 (0.02-19.30) and 0.27 (0.00-34.57) vs. 0.75 (0.00-39.06), respectively). In late stage ARMD subjects with CT genotype, the macular lesion area was larger than in TT carriers (7.64 (0.49-39.06) mm(2) vs. 5.02 (0.03-37.06) mm(2), p = 0.006).
   Conclusions: SCARB1 rs5888 and environmental oxidative stress have a prominent role in ARMD susceptibility, early ARMD progression to advanced stage disease and even in the outcome of the diseasean area of macular lesion.
C1 [Stanislovaitiene, Daiva; Zaliuniene, Dalia] Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, Kaunas, Lithuania.
   [Krisciukaitis, Algimantas; Petrolis, Robertas] Lithuanian Univ Hlth Sci, Med Acad, Neurosci Inst, Kaunas, Lithuania.
   [Smalinskiene, Alina; Tamosiunas, Abdonas; Lesauskaite, Vaiva] Lithuanian Univ Hlth Sci, Med Acad, Inst Cardiol, Kaunas, Lithuania.
   [Lesauskaite, Vita] Lithuanian Univ Hlth Sci, Med Acad, Dept Geriatr, Kaunas, Lithuania.
C3 Lithuanian University of Health Sciences; Lithuanian University of
   Health Sciences; Lithuanian University of Health Sciences; Lithuanian
   University of Health Sciences
RP Stanislovaitiene, D (通讯作者)，Lithuania Univ Hlth Sci, Med Acad, Dept Ophthalmol, Eiveniu 2, LT-50009 Kaunas, Lithuania.
EM daiva@eur.lt
RI Tamosiunas, Abdonas/AAD-4274-2021
OI Lesauskaite, Vaiva/0000-0003-2736-3111
FU Lithuanian Science Council [MIP-10330, MIP-98]
FX The study was supported by a research grant from the Lithuanian Science
   Council (grant no. MIP-10330; MIP-98).
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Bencic G, 2005, COLLEGIUM ANTROPOL, V29, P91
   Duncan KG, 2002, BIOCHEM BIOPH RES CO, V292, P1017, DOI 10.1006/bbrc.2002.6756
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Fischer T., 2012, J NEUROSCI BEHAV HLT, V4, P42
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Kamei M, 2007, INVEST OPHTH VIS SCI, V48, P1801, DOI 10.1167/iovs.06-0699
   Keilhauer CN, 2013, EUR J MED GENET, V56, P72, DOI 10.1016/j.ejmg.2012.10.005
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Krisciukaitis A, 2014, BIOIMAGING: PROCEEDINGS OF THE INTERNATIONAL CONFERENCE ON BIOIMAGING, P66, DOI 10.5220/0004910500660069
   Loane E, 2010, INVEST OPHTH VIS SCI, V51, P5897, DOI 10.1167/iovs.09-4878
   Peasey A, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-255
   Petrolis R., 2009, BIOM ENG P INT C KAU, P153
   Rodriguez-Esparragon F, 2005, ARTERIOSCL THROM VAS, V25, P854, DOI 10.1161/01.ATV.0000157581.88838.03
   Stanislovaitiene D, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-24
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Suzuki M, 2007, MOL VIS, V13, P772
   Suzuki M, 2012, J CELL SCI, V125, P2407, DOI 10.1242/jcs.097683
   Tanaka T, 2007, J NUTR, V137, P578, DOI 10.1093/jn/137.3.578
   Thomas S, 2016, FASEB J S1, V30, P689
   Trivino A, 2012, OCULAR DIS, P1
   Zerbib J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007341
NR 24
TC 2
Z9 2
U1 1
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PY 2017
VL 38
IS 3
BP 233
EP 237
DI 10.1080/13816810.2016.1203442
PG 5
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA EW7CF
UT WOS:000402666700007
PM 27428740
DA 2022-11-30
ER

PT J
AU Kashani, AH
   Keane, PA
   Dustin, L
   Walsh, AC
   Sadda, SR
AF Kashani, Amir H.
   Keane, Pearse A.
   Dustin, Laurie
   Walsh, Alexander C.
   Sadda, Srinivas R.
TI Quantitative Subanalysis of Cystoid Spaces and Outer Nuclear Layer Using
   Optical Coherence Tomography in Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL TRIAMCINOLONE
   ACETONIDE; FOVEAL PHOTORECEPTOR LAYER; RETINAL VEIN OCCLUSION;
   VISUAL-ACUITY; MORPHOMETRIC ANALYSIS; DIABETIC-RETINOPATHY; LASER
   TREATMENT; EDEMA; RANIBIZUMAB
AB PURPOSE. To use optical coherence tomography (OCT) to quantify intraretinal cystoid spaces (ICSs) and the outer nuclear layer (ONL) in patients with neovascular age-related macular degeneration (AMD) and to investigate the correlation of these parameters with visual acuity.
   METHODS. StratusOCT (Carl Zeiss Meditec, Inc., Dublin, CA) images were collected from 53 patients receiving their initial treatment with intravitreous ranibizumab. Images were analyzed with custom software (OCTOR) that allows accurate manual segmentation of OCT B-scans and provides thickness/volume measurements of ICS, ONL, neurosensory retina, pigment epithelial detachments (PEDs), subretinal fluid (SRF), and subretinal tissue (SRT). Univariate and multivariate analyses were used to correlate OCT parameters with best corrected Snellen visual acuity. Reproducibility was assessed with weighted kappa statistics and intraclass correlation coefficients.
   RESULTS. A multivariate linear regression model with adjusted R-2 showed that ONL volume and SRT thickness significantly correlated with Snellen visual acuity (R-2 = 0.15, P = 0.002 and R-2 = 0.19, P = 0.001, respectively) with an overall model R-2 of 0.34. Adjustment of ONL volume for ICS did not improve correlation with visual acuity, and ICS volume did not independently correlate with visual acuity. Weighted kappa statistics showed excellent intergrader agreement for both ICS and ONL measurements.
   CONCLUSIONS. The results suggest that an increased total volume of the ONL is associated with decreased visual acuity in neovascular AMD and that the total volume of ICS does not correlate with visual acuity. Although the correlations detected in this study are modest, quantitative subanalysis of OCT images may be of greater clinical relevance in the context of more advanced OCT technology. (Invest Ophthalmol Vis Sci. 2009;50:3366-3373) DOI:10.1167/iovs.08-2691
C1 [Kashani, Amir H.; Keane, Pearse A.; Walsh, Alexander C.; Sadda, Srinivas R.] Univ So Calif, Doheny Image Reading Ctr, Doheny Eye Inst, Los Angeles, CA 90033 USA.
   [Dustin, Laurie] Univ So Calif, Stat Consultat & Res Ctr, Dept Preventat Med, Keck Sch Med, Los Angeles, CA 90033 USA.
C3 Doheny Eye Institute; University of Southern California; University of
   Southern California
RP Sadda, SR (通讯作者)，Univ So Calif, Doheny Image Reading Ctr, Doheny Eye Inst, 3623 1450 San Pablo St, Los Angeles, CA 90033 USA.
EM sadda@usc.edu
RI Keane, Pearse/AAE-5709-2019; Keane, Pearse A/H-1860-2011
OI Keane, Pearse/0000-0002-9239-745X; 
FU National Institutes of Health [EY03040]; National Eye Institute [R01
   EY014375]; NATIONAL EYE INSTITUTE [R21EY015914, P30EY003040,
   R01EY014375] Funding Source: NIH RePORTER
FX Supported in part by National Institutes of Health Grant EY03040 and
   National Eye Institute Grant R01 EY014375.
CR Bandello F, 2005, BRIT J OPHTHALMOL, V89, P864, DOI 10.1136/bjo.2004.051060
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Browning DJ, 2007, OPHTHALMOLOGY, V114, P525, DOI 10.1016/j.ophtha.2006.06.052
   Catier A, 2005, AM J OPHTHALMOL, V140, P200, DOI 10.1016/j.ajo.2005.02.053
   Falkenstein IA, 2008, OPHTHALMOLOGY, V115, P319, DOI 10.1016/j.ophtha.2007.05.028
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Goebel W, 2002, RETINA-J RET VIT DIS, V22, P759, DOI 10.1097/00006982-200212000-00012
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P1019, DOI 10.1001/archopht.1995.01100080071031
   Joeres S, 2008, OPHTHALMOLOGY, V115, P347, DOI 10.1016/j.ophtha.2007.03.082
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Keane PA, 2008, BRIT J OPHTHALMOL, V92, P1081, DOI 10.1136/bjo.2008.138891
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P471, DOI 10.1097/00006982-200208000-00012
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P464, DOI 10.1097/00006982-200208000-00011
   Laursen ML, 2004, BRIT J OPHTHALMOL, V88, P1173, DOI 10.1136/bjo.2003.040949
   Martidis A, 2002, OPHTHALMOLOGY, V109, P920, DOI 10.1016/S0161-6420(02)00975-2
   Massin P, 2004, OPHTHALMOLOGY, V111, P218, DOI 10.1016/j.ophtha.2003.05.037
   Massin P, 2003, AM J OPHTHALMOL, V135, P169, DOI 10.1016/S0002-9394(02)01837-8
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Ota M, 2008, AM J OPHTHALMOL, V145, P273, DOI 10.1016/j.ajo.2007.09.019
   Ota M, 2007, BRIT J OPHTHALMOL, V91, P1644, DOI 10.1136/bjo.2007.118497
   Otani T, 2001, AM J OPHTHALMOL, V131, P50, DOI 10.1016/S0002-9394(00)00661-9
   Ozdemir H, 2005, AM J OPHTHALMOL, V140, P251, DOI 10.1016/j.ajo.2005.03.004
   REGILLO CD, 2008, AM J OPHTHALMOL, V145
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Sadda SR, 2007, INVEST OPHTH VIS SCI, V48, P839, DOI 10.1167/iovs.06-0554
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
NR 33
TC 45
Z9 45
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2009
VL 50
IS 7
BP 3366
EP 3373
DI 10.1167/iovs.08-2691
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 461SP
UT WOS:000267292100043
PM 19168893
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Fallico, M
   Lotery, AJ
   Longo, A
   Avitabile, T
   Bonfiglio, V
   Russo, A
   Castellino, N
   Parisi, G
   Pulvirenti, A
   Eandi, C
   Cennamo, G
   Furino, C
   Cicinelli, MV
   Alovisi, C
   Reibaldi, M
AF Fallico, Matteo
   Lotery, Andrew J.
   Longo, Antonio
   Avitabile, Teresio
   Bonfiglio, Vincenza
   Russo, Andrea
   Castellino, Nicolo
   Parisi, Guglielmo
   Pulvirenti, Alfredo
   Eandi, Chiara
   Cennamo, Gilda
   Furino, Claudio
   Cicinelli, Maria Vittoria
   Alovisi, Camilla
   Reibaldi, Michele
TI Treat and extend versus fixed regimen in neovascular age related macular
   degeneration: A systematic review and meta-analysis
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE Age-related macular degeneration; retina; retina; medical therapies;
   pharmacology; vitreous; retinal disease; pediatric ophthalmology;
   retinal pathology; research
ID INTRAVITREAL RANIBIZUMAB; DOSING REGIMEN; VISUAL-ACUITY; OUTCOMES;
   THERAPY; TRIAL
AB Purpose: To compare efficacy of treat and extend (T&E) versus fixed regimen treatment protocols in neovascular age-related macular degeneration (nAMD). Methods: Randomized clinical trials (RCTs) comparing T&E versus fixed regimen protocols for nAMD were systematically searched. Primary outcome was to compare the mean best corrected visual acuity (BCVA) change in T&E regimen versus fixed regimen. Secondary outcomes were change in the mean optical coherence tomography (OCT) central retinal thickness (CRT) and mean number of injections. Standardized mean difference (SMD) along with 95% confidence intervals (CIs) were calculated. Random-effect models were used for meta-analyses. Results: Four RCTs were included, with a total of 649 and 621 eyes in the T&E and fixed regimen cohort at 12 months, and 267 and 249 eyes at 24 months. Pooled analysis of mean BCVA change included all four RCTs at 12 months and two RCTs at 24 months, showing no difference between the two groups (12-month: SMD = 0.08, 95% CI: -0.20 to 0.35, p = 0.55; 24-month: SMD = 0.04, 95% CI: -0.13 to 0.21, p = 0.64). Pooled analysis of OCT CRT change at 12 months included three studies, showing no difference between the two groups (SMD = 0.03, 95% CI: -0.46 to 0.51, p = 0.91). Pooled analysis of mean injection number included all four RCTs at 12 months and two RCTs at 24 months, showing significant difference between the two groups (12-month: SMD = -1.11, 95% CI: -1.67 to -0.56, p < 0.001; 24-month: SMD = -1.34, 95% CI: -1.54 to -1.15, p < 0.001). Conclusion: A T&E regimen proved as effective as a fixed dosage regimen throughout a 24-month follow-up and with a lower number of injections.
C1 [Fallico, Matteo; Longo, Antonio; Avitabile, Teresio; Bonfiglio, Vincenza; Russo, Andrea; Castellino, Nicolo; Parisi, Guglielmo] Univ Catania, Dept Ophthalmol, Catania, Italy.
   [Fallico, Matteo; Lotery, Andrew J.] Southampton Univ Hosp, Eye Unit, Southampton, Hants, England.
   [Lotery, Andrew J.] Univ Southampton, Fac Med, Southampton, Hants, England.
   [Pulvirenti, Alfredo] Univ Catania, Dept Clin & Expt Med, Sicily, Italy.
   [Eandi, Chiara; Alovisi, Camilla; Reibaldi, Michele] Univ Torino, Dept Surg Sci, Eye Clin, Via Cherasco 23, I-10126 Turin, Piemonte, Italy.
   [Cennamo, Gilda] Univ Naples Federico II, Dept Publ Hlth, Naples, Campania, Italy.
   [Furino, Claudio] Univ Bari, Dept Ophthalmol, Bari, Italy.
   [Cicinelli, Maria Vittoria] Univ Vita Salute, Dept Ophthalmol, IRCCS San Raffaele, Milan, Italy.
C3 University of Catania; University of Southampton; University of
   Southampton; University of Catania; University of Turin; University of
   Naples Federico II; Universita degli Studi di Bari Aldo Moro;
   Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Reibaldi, M (通讯作者)，Univ Torino, Dept Surg Sci, Eye Clin, Via Cherasco 23, I-10126 Turin, Piemonte, Italy.
EM mreibaldi@libero.it
RI cicinelli, maria vittoria/M-1611-2019; Parisi, Guglielmo/AAC-3933-2022;
   Fallico, Matteo/AAC-5284-2022; Avitabile, Teresio/AAC-6076-2022; Longo,
   Antonio/AAC-6092-2022; Castellino, Niccolò/AAC-4717-2022; Russo,
   Andrea/AAC-5349-2022
OI cicinelli, maria vittoria/0000-0003-2938-0409; Parisi,
   Guglielmo/0000-0003-0795-618X; Russo, Andrea/0000-0002-7725-5971; LONGO,
   Antonio/0000-0002-9525-1800; Lotery, Andrew/0000-0001-5541-4305
CR American Society of Retina Specialists, 2014, ANN PREF TRENDS SURV
   Amoaku W, 2012, EYE, V26, pS2, DOI 10.1038/eye.2011.343
   [Anonymous], 2010, AGR ECOSYST ENVIRON, DOI DOI 10.1016/j.agee.2010.01.006
   Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Bhandari S, 2020, OPHTHALMOLOGY, V127, P369, DOI 10.1016/j.ophtha.2019.10.006
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fallico M, 2020, EYE, V34, P683, DOI 10.1038/s41433-019-0576-y
   Fallico M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201010
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gale RP, 2019, EYE, V33, DOI 10.1038/s41433-018-0300-3
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P676, DOI 10.1016/j.ophtha.2013.09.050
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Gupta B, 2011, BRIT J OPHTHALMOL, V95, P386, DOI 10.1136/bjo.2010.179499
   Haga A, 2018, ACTA OPHTHALMOL, V96, pE393, DOI 10.1111/aos.13607
   Hanemoto T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189035
   HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kertes PJ, 2020, JAMA OPHTHALMOL, V138, P244, DOI 10.1001/jamaophthalmol.2019.5540
   Kertes PJ, 2019, OPHTHALMOLOGY, V126, P841, DOI 10.1016/j.ophtha.2019.01.013
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Menon G, 2013, EYE, V27, P959, DOI 10.1038/eye.2013.93
   Okada M, 2018, AM J OPHTHALMOL, V192, P184, DOI 10.1016/j.ajo.2018.05.026
   Patel PJ, 2017, CLIN OPHTHALMOL, V11, P1957, DOI 10.2147/OPTH.S145732
   Reibaldi M, 2020, JAMA OPHTHALMOL, V138, P50, DOI 10.1001/jamaophthalmol.2019.4636
   Reibaldi M, 2019, J CLIN MED, V8, DOI 10.3390/jcm8071031
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rufai SR, 2017, EYE, V31, P1337, DOI 10.1038/eye.2017.67
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Wykoff CC, 2018, BRIT J OPHTHALMOL, V102, P460, DOI 10.1136/bjophthalmol-2017-310822
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 40
TC 3
Z9 3
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD SEP
PY 2021
VL 31
IS 5
BP 2496
EP 2504
AR 1120672120964699
DI 10.1177/1120672120964699
EA OCT 2020
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XG9FP
UT WOS:000678257800001
PM 33118382
DA 2022-11-30
ER

PT J
AU Taylor, DJ
   Hobby, AE
   Binns, AM
   Crabb, DP
AF Taylor, Deanna J.
   Hobby, Angharad E.
   Binns, Alison M.
   Crabb, David P.
TI How does age-related macular degeneration affect real-world visual
   ability and quality of life? A systematic review
SO BMJ OPEN
LA English
DT Review
ID COMPUTER TASK ACCURACY; CENTRAL VISION LOSS; OLDER-ADULTS; DEPRESSIVE
   SYMPTOMS; EYE DISEASE; WATERLOO VISION; UTILITY VALUES; PSYCHOSOCIAL
   ADAPTATION; PSYCHOLOGICAL CONTROL; SCENE CATEGORIZATION
AB Objectives: To review systematically the evidence of age-related macular degeneration (AMD) affecting real-world visual ability and quality of life (QoL). To explore trends in specific topics within this body of the literature.
   Design: Systematic review.
   Methods: A systematic literature search was carried out using MEDLINE, EMBASE, CINAHL, PsycINFO, PsychARTICLES and Health and Psychosocial Instruments for articles published up to January 2015 for studies including people diagnosed with AMD, assessing real-world visual ability or QoL as an outcome. Two researchers screened studies for eligibility. Details of eligible studies including study design, characteristics of study population and outcomes measured were recorded in a data extraction table. All included studies underwent quality appraisal using the Mixed Methods Appraisal Tool 2011 Version (MMAT).
   Results: From 5284 studies, 123 were eligible for inclusion. A range of approaches were identified, including performance-based methods, quantitative and qualitative patient-reported outcome measures (PROMs). AMD negatively affects tasks including mobility, face recognition, perception of scenes, computer use, meal preparation, shopping, cleaning, watching TV, reading, driving and, in some cases, self-care. There is evidence for higher rates of depression among people with AMD than among community dwelling elderly. A number of adaptation strategies have been associated with AMD of varying duration. Much of the research fails to report the type of AMD studied (59% of included studies) or the duration of disease in participants (74%). Of those that do report type studied, the breakdown is as follows: wet AMD 20%, dry AMD 4% and both types 17%.
   Conclusions: There are many publications highlighting the negative effects of AMD in various domains of life. Future research should focus on delivering some of this research knowledge into patient management and clinical trials and differentiating between the types of AMD.
C1 [Taylor, Deanna J.; Hobby, Angharad E.; Binns, Alison M.; Crabb, David P.] Univ London, Div Optometry & Visual Sci, Sch Hlth Sci, London, England.
C3 University of London
RP Crabb, DP (通讯作者)，Univ London, Div Optometry & Visual Sci, Sch Hlth Sci, London, England.
EM David.Crabb.1@city.ac.uk
OI Binns, Alison/0000-0001-8621-498X; Hobby, Angharad/0000-0002-6007-2685;
   Crabb, David/0000-0001-8754-3902; Taylor, Deanna/0000-0001-8261-5225
FU Roche Products, UK
FX This work was supported by an unrestricted investigator initiated
   research grant from Roche Products, UK.
CR Alexander MS, 2014, OPTOMETRY VISION SCI, V91, P990, DOI 10.1097/OPX.0000000000000316
   Alexander MS, 2014, OPTOMETRY VISION SCI, V91, P975, DOI 10.1097/OPX.0000000000000286
   ALEXANDER MF, 1988, ARCH OPHTHALMOL-CHIC, V106, P1543, DOI 10.1001/archopht.1988.01060140711040
   Arnold J, 2002, RETINA-J RET VIT DIS, V22, P6
   Aspinall PA, 2014, BRIT J OPHTHALMOL, V98, P1393, DOI 10.1136/bjophthalmol-2014-305032
   Augustin A, 2007, INVEST OPHTH VIS SCI, V48, P1498, DOI 10.1167/iovs.06-0761
   Backman H, 2002, J VISUAL IMPAIR BLIN, V96, P345, DOI 10.1177/0145482X0209600506
   Banerjee A, 2008, INDIAN J OPHTHALMOL, V56, P469
   Bansback N, 2007, QUAL LIFE RES, V16, P533, DOI 10.1007/s11136-006-9126-8
   Bass EB, 2004, ARCH OPHTHALMOL-CHIC, V122, P1856
   Bennion AE, 2012, SOC SCI MED, V75, P976, DOI 10.1016/j.socscimed.2012.04.023
   Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   Berman K, 2006, INT PSYCHOGERIATR, V18, P415, DOI 10.1017/S1041610205002905
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bordier C, 2011, OPHTHAL PHYSL OPT, V31, P203, DOI 10.1111/j.1475-1313.2011.00820.x
   Boucart M, 2008, VISUAL NEUROSCI, V25, P603, DOI 10.1017/S0952523808080656
   Boucart M, 2013, INVEST OPHTH VIS SCI, V54, P1950, DOI 10.1167/iovs.12-9680
   Boucart M, 2008, VISUAL NEUROSCI, V25, P685, DOI 10.1017/S0952523808080826
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   BROWN B, 1986, AM J OPTOM PHYS OPT, V63, P733
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown GC, 2000, CAN J OPHTHALMOL, V35, P127, DOI 10.1016/S0008-4182(00)80005-8
   Brown MM, 2003, SURV OPHTHALMOL, V48, P204, DOI 10.1016/S0039-6257(02)00457-5
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   BULLIMORE MA, 1991, INVEST OPHTH VIS SCI, V32, P2020
   Burton AE, 2015, J HEALTH PSYCHOL, V20, P1285, DOI 10.1177/1359105313511134
   Butt T, 2013, OPTOMETRY VISION SCI, V90, P855, DOI 10.1097/OPX.0b013e3182962318
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Casten RJ, 2002, J VISUAL IMPAIR BLIN, V96, P399, DOI 10.1177/0145482X0209600603
   Cavar I, 2014, ACTA CLIN CROAT, V53, P79
   Chen YL, 2009, OPT EXPRESS, V17, P4046, DOI 10.1364/OE.17.004046
   Chia EM, 2004, INVEST OPHTH VIS SCI, V45, P71, DOI 10.1167/iovs.03-0661
   Cimarolli VR, 2012, CLIN REHABIL, V26, P748, DOI 10.1177/0269215511429162
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Coleman AL, 2010, AM J OPHTHALMOL, V150, P683, DOI 10.1016/j.ajo.2010.05.030
   Cruess A, 2007, CAN J OPHTHALMOL, V42, P836, DOI 10.3129/i07-153
   Curriero FC, 2013, JAMA OPHTHALMOL, V131, P1420, DOI 10.1001/jamaophthalmol.2013.4471
   DAVIS C, 1995, J VISUAL IMPAIR BLIN, V89, P16
   Dawson SR, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-78
   DeCarlo DK, 2003, OPTOMETRY VISION SCI, V80, P207, DOI 10.1097/00006324-200303000-00010
   ELLIOTT DB, 1995, OPHTHAL PHYSL OPT, V15, P553, DOI 10.1016/0275-5408(95)00025-9
   Eramudugolla R, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00056
   Espallargues M, 2005, INVEST OPHTH VIS SCI, V46, P4016, DOI 10.1167/iovs.05-0072
   Esteban JJN, 2008, QUAL LIFE RES, V17, P37, DOI 10.1007/s11136-007-9280-7
   Felce D, 1997, J INTELL DISABIL RES, V41, P126, DOI 10.1111/j.1365-2788.1997.tb00689.x
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fletcher DC, 2008, J VISUAL IMPAIR BLIN, V102, P656, DOI 10.1177/0145482X0810201010
   Friedman SM, 1999, INVEST OPHTH VIS SCI, V40, P858
   Geruschat DR, 2006, OPTOMETRY VISION SCI, V83, P550, DOI 10.1097/01.opx.0000232219.23362.a6
   Geruschat DR, 2011, OPTOMETRY VISION SCI, V88, P208, DOI 10.1097/OPX.0b013e3182045988
   Gopinath B, 2014, MATURITAS, V77, P263, DOI 10.1016/j.maturitas.2013.12.001
   GURALNIK JM, 1989, J GERONTOL, V44, pM141, DOI 10.1093/geronj/44.5.M141
   GUYATT GH, 1986, CAN MED ASSOC J, V134, P889
   GUYATT GH, 1993, ANN INTERN MED, V118, P622, DOI 10.7326/0003-4819-118-8-199304150-00009
   Hammell KW, 2004, SPINAL CORD, V42, P491, DOI 10.1038/sj.sc.3101636
   Harvey A.S., 1993, J OCCUP SCI, V1, P27, DOI DOI 10.1080/14427591.1993.9686381
   Hassan SE, 2005, OPTOMETRY VISION SCI, V82, P18
   Hassan SE, 2002, OPTOMETRY VISION SCI, V79, P697, DOI 10.1097/00006324-200211000-00007
   Hassan SE, 2012, INVEST OPHTH VIS SCI, V53, P6137, DOI 10.1167/iovs.12-10023
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   HECKHAUSEN J, 1995, PSYCHOL REV, V102, P284, DOI 10.1037/0033-295X.102.2.284
   Hochberg C, 2012, INVEST OPHTH VIS SCI, V53, P3201, DOI 10.1167/iovs.12-9469
   Ivanoff SD, 2000, SCAND J OCCUP THER, V7, P148
   Jacko J. A., 2002, Universal Access in the Information Society, V1, P197, DOI 10.1007/s102090100015
   Jacko JA, 2005, INT J HUM-COMPUT INT, V18, P183, DOI 10.1207/s15327590ijhc1802_4
   Jacko JA, 2000, P HUM FACTORS ERGON, V44, P116
   JACKO JA, 2001, P 9 INT C HUM COMP I
   Jivraj J, 2013, CAN J OPHTHALMOL, V48, P269, DOI 10.1016/j.jcjo.2013.03.007
   Johnson T, 2014, SEMIN OPHTHALMOL, V29, P202, DOI 10.3109/08820538.2013.821500
   Kanonidou E, 2011, HIPPOKRATIA, V15, P103
   Kim LA, 2012, AM J PATHOL, V181, P376, DOI 10.1016/j.ajpath.2012.06.006
   Kleinschmidt JJ, 1999, J VISUAL IMPAIR BLIN, V93, P69, DOI 10.1177/0145482X9909300202
   Knudtson MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P807, DOI 10.1001/archopht.123.6.807
   Kotecha A, 2013, INVEST OPHTH VIS SCI, V54, P5408, DOI 10.1167/iovs.12-12026
   Kuyk T, 1999, J REHABIL RES DEV, V36, P303
   KUYKEN W, 1994, INT J MENT HEALTH, V23, P24, DOI 10.1080/00207411.1994.11449286
   Kymes SM, 2007, OPTOMETRY VISION SCI, V84, P809, DOI 10.1097/OPX.0b013e3181337638
   Lamoureux EL, 2008, OPHTHAL EPIDEMIOL, V15, P105, DOI 10.1080/09286580701840354
   Lamoureux EL, 2011, BRIT J OPHTHALMOL, V95, P666, DOI 10.1136/bjo.2010.185207
   Lin JC, 2012, J FORMOS MED ASSOC, V111, P572, DOI 10.1016/j.jfma.2011.09.021
   Lopez-Miguel A, 2013, OPHTHALMOLOGICA, V230, P69, DOI 10.1159/000351652
   Lotery A, 2007, BRIT J OPHTHALMOL, V91, P1303, DOI 10.1136/bjo.2007.116939
   LOVIEKITCHIN JE, 1986, AM J OPTOM PHYS OPT, V63, P366
   Maguire M, 2004, OPHTHALMOLOGY, V111, P1307
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Marback RF, 2007, CLINICS, V62, P573, DOI 10.1590/S1807-59322007000500007
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Mathew R, 2011, CLIN EXP OPHTHALMOL, V39, P82
   Mathew RS, 2011, OPHTHAL PHYSL OPT, V31, P375, DOI 10.1111/j.1475-1313.2011.00848.x
   McCloud C, 2014, OPTOMETRY VISION SCI, V91, P966, DOI 10.1097/OPX.0000000000000320
   McGwin G, 2013, BRIT J OPHTHALMOL, V97, P1173, DOI 10.1136/bjophthalmol-2013-303601
   Mejico LJ, 2004, AM J OPHTHALMOL, V137, P908, DOI 10.1016/j.ajo.2003.12.038
   Mitchell J., 2006, HEALTH QUAL LIFE OUT, V21, P4
   Moore LW, 2000, WESTERN J NURS RES, V22, P571, DOI 10.1177/01939450022044601
   Moore LW, 2005, APPL NURS RES, V18, P110, DOI 10.1016/j.apnr.2004.06.014
   Moore LW, 2003, J ADV NURS, V43, P10
   Moore LW, 2000, WESTERN J NURS RES, V22, P588
   Musel B, 2011, VISUAL NEUROSCI, V28, P529, DOI 10.1017/S0952523811000435
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Owsley C, 2006, REHABIL PSYCHOL, V51, P23, DOI 10.1037/0090-5550.51.1.23
   Pace R, 2012, INT J NURS STUD, V49, P47, DOI 10.1016/j.ijnurstu.2011.07.002
   Patrick D, 2011, COCHRANE HDB SYSTEMA
   PATRICK DL, 1990, ANNU REV PUBL HEALTH, V11, P165
   Peek STM, 2014, INT J MED INFORM, V83, P235, DOI 10.1016/j.ijmedinf.2014.01.004
   Pieper MJC, 2013, AGEING RES REV, V12, P1042, DOI 10.1016/j.arr.2013.05.002
   Pinquart M, 2011, BRIT J VISUAL IMPA, V29, P27, DOI 10.1177/0264619610389572
   Poku E, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-74
   Popescu ML, 2012, INVEST OPHTH VIS SCI, V53, P2308, DOI 10.1167/iovs.11-9330
   Popescu ML, 2011, INVEST OPHTH VIS SCI, V52, P7168, DOI 10.1167/iovs.11-7564
   Renzi C, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007002
   Rovner BW, 2006, OPHTHALMOLOGY, V113, P1743, DOI 10.1016/j.ophtha.2006.05.033
   Rovner BW, 2014, J VISUAL IMPAIR BLIN, V108, P187
   Rovner BW, 2011, ARCH OPHTHALMOL-CHIC, V129, P885, DOI 10.1001/archophthalmol.2011.146
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   Rovner BW, 2001, J AM GERIATR SOC, V49, P1097, DOI 10.1046/j.1532-5415.2001.49215.x
   Ruiz-Moreno JM, 2008, CURR MED RES OPIN, V24, P2103, DOI [10.1185/03007990802214300 , 10.1185/03007990802214300]
   Sahel JA, 2007, ARCH OPHTHALMOL-CHIC, V125, P945, DOI 10.1001/archopht.125.7.945
   Scaffa Marjorie E, 2008, Am J Occup Ther, V62, P694
   Schilling OK, 2006, PSYCHOL AGING, V21, P703, DOI 10.1037/0882-7974.21.4.703
   Schilling OK, 2013, J GERONTOL B-PSYCHOL, V68, P750, DOI 10.1093/geronb/gbs118
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Scott IU, 2002, AM J OPHTHALMOL, V134, P857, DOI 10.1016/S0002-9394(02)01795-6
   Scott IU, 2002, AM J OPHTHALMOL, V133, P350, DOI 10.1016/S0002-9394(01)01406-4
   Seiple W, 2013, OPTOMETRY VISION SCI, V90, P45, DOI 10.1097/OPX.0b013e3182794775
   Seland JH, 2011, ACTA OPHTHALMOL, V89, P608, DOI 10.1111/j.1755-3768.2009.01794.x
   Sengupta S, 2014, OPHTHALMOLOGY, V121, P727, DOI 10.1016/j.ophtha.2013.09.042
   Siaudvytyte L, 2012, MEDICINA-LITHUANIA, V48, P109, DOI 10.3390/medicina48020015
   Smith TM, 2008, J VISUAL IMPAIR BLIN, V102, P725
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   SPAULDING SJ, 1994, OPTOMETRY VISION SCI, V71, P770, DOI 10.1097/00006324-199412000-00007
   SPAULDING SJ, 1995, GAIT POSTURE, V3, P227
   Stanford P, 2009, BRIT J VISUAL IMPA, V27, P129, DOI 10.1177/0264619609102216
   Stein JD, 2003, BRIT J OPHTHALMOL, V87, P8, DOI 10.1136/bjo.87.1.8
   Stevenson MR, 2004, BRIT J OPHTHALMOL, V88, P1125, DOI 10.1136/bjo.2003.032383
   Sun C, 2007, OPHTHAL EPIDEMIOL, V14, P127, DOI 10.1080/09286580601186742
   Szabo SM, 2010, OSTEOPOROSIS INT, V21, P855, DOI 10.1007/s00198-009-1025-8
   Szabo SM, 2008, J AM GERIATR SOC, V56, P800, DOI 10.1111/j.1532-5415.2008.01666.x
   SZLYK JP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1033, DOI 10.1001/archopht.1995.01100080085033
   Tejeria L, 2002, BRIT J OPHTHALMOL, V86, P1019, DOI 10.1136/bjo.86.9.1019
   Tran THC, 2014, OPTOMETRY VISION SCI, V91, P1012, DOI 10.1097/OPX.0000000000000313
   Thi HCT, 2012, OPTOMETRY VISION SCI, V89, P419, DOI 10.1097/OPX.0b013e31824c3a21
   Thi HCT, 2011, INVEST OPHTH VIS SCI, V52, P1655, DOI 10.1167/iovs.10-6003
   Thi HCT, 2010, INVEST OPHTH VIS SCI, V51, P6868, DOI 10.1167/iovs.10-5517
   Thibaut M, 2014, VISION RES, V98, P46, DOI 10.1016/j.visres.2014.03.004
   Timberlake GT, 2013, OPTOMETRY VISION SCI, V90, P455, DOI 10.1097/OPX.0b013e31828e92eb
   Timberlake GT, 2011, INVEST OPHTH VIS SCI, V52, P2540, DOI 10.1167/iovs.10-6062
   Tolman J, 2005, GERONTOLOGIST, V45, P747, DOI 10.1093/geront/45.6.747
   Tosh J, 2012, VALUE HEALTH, V15, P118, DOI 10.1016/j.jval.2011.08.002
   van Landingham SW, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-10
   Wahl H, 2005, INT C, V1282, P326
   Wahl HW, 2007, J GERONTOL B-PSYCHOL, V62, pP90, DOI 10.1093/geronb/62.2.P90
   Wahl HW, 2004, PSYCHOL AGING, V19, P235, DOI 10.1037/0882-7974.19.1.235
   Wahl HW, 2003, EUR PSYCHOL, V8, P168, DOI 10.1027//1016-9040.8.3.168
   Wang MY, 2012, INVEST OPHTH VIS SCI, V53, P7967, DOI 10.1167/iovs.12-10701
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
   Wong EYH, 2004, J VISUAL IMPAIR BLIN, V98, P629, DOI 10.1177/0145482X0409801007
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wood JM, 2011, INVEST OPHTH VIS SCI, V52, P5088, DOI 10.1167/iovs.10-6644
   Wood JM, 2009, INVEST OPHTH VIS SCI, V50, P482, DOI 10.1167/iovs.08-1942
   Yanagi Y, 2011, JPN J OPHTHALMOL, V55, P35, DOI 10.1007/s10384-010-0893-y
   Yuzawa M, 2013, CLIN OPHTHALMOL, V7, P1325, DOI 10.2147/OPTH.S45248
NR 163
TC 109
Z9 110
U1 1
U2 25
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2016
VL 6
IS 12
AR e011504
DI 10.1136/bmjopen-2016-011504
PG 13
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC General & Internal Medicine
GA EG8JS
UT WOS:000391303600148
PM 27913556
OA Green Published, Green Accepted, gold
DA 2022-11-30
ER

PT J
AU Cohen, SY
   Lamarque, F
   Saucet, JC
   Provent, P
   Langram, C
   LeGargasson, JF
AF Cohen, SY
   Lamarque, F
   Saucet, JC
   Provent, P
   Langram, C
   LeGargasson, JF
TI Filling-in phenomenon in patients with age-related macular degeneration:
   differences regarding uni- or bilaterality of central scotoma
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
ID PRIMARY VISUAL-CORTEX; CORTICAL PLASTICITY; ADULT MONKEY;
   REORGANIZATION; FIELD; CONNECTIONS; IMPROVEMENT; COMPLETION; RETINA; CAT
AB Purpose. The purpose of this study was to explore the presence of the filling-in phenomenon in patients with uni- or bilateral central scotoma (CS) resulting from natural history or laser photocoagulation of choroidal neovascularization in age-related macular degeneration (AMD). Methods. Sixteen consecutive patients with unilateral CS and 14 patients with bilateral CS were assessed (44 eyes) with a scanning laser ophthalmoscope (SLO). Scotoma was delineated by scotometry with a point (1degreesx1degrees) moving radially from the periphery to the center of the lesion. In addition, patients underwent a line test, consisting of a horizontal line moving vertically and a vertical line moving horizontally, from the periphery to the center. The lines were longer than the macular lesion and were projected onto the retina. Patients were asked to indicate when the lines seemed interrupted. The perceptual filling-in phenomenon was considered to be present when limits of the perceived scotoma, determined by the line test, were smaller than those assessed by scotometry. In patients with bilateral CS, the results were analyzed to distinguish the less or more severely affected eye. Results. In all eyes, the limits of the scotoma obtained with the scotometry test corresponded to the anatomic edges of the macular lesion. In patients with bilateral CS, the filling-in phenomenon was observed in 12 out of 14 (85%) less severely affected eyes, but only in one (7%) of their more severely affected eyes. In patients with unilateral CS, the phenomenon was observed in only one out of 16 (6%) eyes. Conclusion. These results suggest that the filling-in phenomenon mostly occurs in patients with bilateral central scotoma, and almost always in their less affected eye. Thus, it did usually not occur in an eye if the fellow eye was better.
C1 INSERM, U483, Lab Biophys Vis, F-75010 Paris, France.
   Hop Lariboisiere, Dept Ophthalmol, Macular Degenerat & Low Vis Rehabil Unit, F-75475 Paris, France.
   Conservatoire Natl Arts & Metiers, Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities;
   Universite Paris Cite; heSam Universite; Conservatoire National Arts &
   Metiers (CNAM)
RP LeGargasson, JF (通讯作者)，INSERM, U483, Lab Biophys Vis, 10 Ave Verdun, F-75010 Paris, France.
EM legargas@idf.ext.jussieu.fr
OI Lamarque, Frederic/0000-0002-9341-4725
CR ACHARD OA, 1995, AM J OPHTHALMOL, V120, P322, DOI 10.1016/S0002-9394(14)72162-2
   CHINO YM, 1992, VISION RES, V32, P789, DOI 10.1016/0042-6989(92)90021-A
   COHEN SY, 2000, GUIDE PRATIQUE REEDU, P64
   COHENSABAN J, 1984, INNOV TECH BIOL MED, V5, P116
   COSCAS G, 1991, ARCH OPHTHALMOL-CHIC, V109, P1258, DOI 10.1001/archopht.1991.01080090082028
   DARIANSMITH C, 1995, J NEUROSCI, V15, P1631, DOI 10.1523/JNEUROSCI.15-03-01631.1995
   DAS A, 1995, NATURE, V375, P780, DOI 10.1038/375780a0
   De Weerd P, 1998, VISION RES, V38, P2721, DOI 10.1016/S0042-6989(97)00432-X
   DEWEERD P, 1995, NATURE, V377, P731
   Doris N, 2001, BRIT J OPHTHALMOL, V85, P184, DOI 10.1136/bjo.85.2.184
   Dosso AA, 2000, DIABETES CARE, V23, P1855, DOI 10.2337/diacare.23.12.1855b
   El Mallah MK, 2000, BRIT J OPHTHALMOL, V84, P952, DOI 10.1136/bjo.84.9.952
   Fasce F, 1997, INT OPHTHALMOL, V20, P251
   GILBERT CD, 1992, NATURE, V356, P150, DOI 10.1038/356150a0
   GRUSSER OJ, 1991, VISION VISUAL DYSFUN, P151
   HEINEN SJ, 1992, VISION RES, V32, P365, DOI 10.1016/0042-6989(92)90145-9
   HENDRY SHC, 1992, VISUAL NEUROSCI, V9, P445, DOI 10.1017/S0952523800011251
   KAAS JH, 1995, NATURE, V375, P735, DOI 10.1038/375735a0
   LEGARGASSON JF, 1994, DOC OPHTHALMOL, V86, P227, DOI 10.1007/BF01203546
   LEVITT JB, 1994, J COMP NEUROL, V342, P551, DOI 10.1002/cne.903420405
   MARSHALL J, 1979, BRIT J OPHTHALMOL, V63, P657, DOI 10.1136/bjo.63.10.657
   PETTET MW, 1992, P NATL ACAD SCI USA, V89, P8366, DOI 10.1073/pnas.89.17.8366
   RAMACHANDRAN VS, 1991, NATURE, V350, P699, DOI 10.1038/350699a0
   Safran AB, 1999, J NEURO-OPHTHALMOL, V19, P84
   Safran AB, 1999, BRIT J OPHTHALMOL, V83, P137, DOI 10.1136/bjo.83.2.137
   Safran AB, 1999, BRIT J OPHTHALMOL, V83, P1341, DOI 10.1136/bjo.83.12.1341
   SCHUCHARD RA, 1993, ARCH OPHTHALMOL-CHIC, V111, P776, DOI 10.1001/archopht.1993.01090060064024
   SERGENT J, 1988, BRAIN, V111, P347, DOI 10.1093/brain/111.2.347
   SINGERMAN LJ, 1985, RETINA-J RET VIT DIS, V5, P135, DOI 10.1097/00006982-198500530-00001
   SPILLMANN L, 1992, VISION RES, V32, P1941, DOI 10.1016/0042-6989(92)90053-L
   SUNNESS JS, 1995, INVEST OPHTH VIS SCI, V36, P1863
   Sunness JS, 2000, RETINA-J RET VIT DIS, V20, P162, DOI 10.1097/00006982-200002000-00009
   TRIPATHY SP, 1995, VISUAL NEUROSCI, V12, P385, DOI 10.1017/S0952523800008051
NR 33
TC 21
Z9 21
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2003
VL 241
IS 10
BP 785
EP 791
DI 10.1007/s00417-003-0744-3
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 742WZ
UT WOS:000186542200001
PM 12928905
DA 2022-11-30
ER

PT J
AU Gin, TJ
   Luu, CD
   Guymer, RH
AF Gin, Thomas J.
   Luu, Chi D.
   Guymer, Robyn H.
TI Central Retinal Function as Measured by the Multifocal Electroretinogram
   and Flicker Perimetry in Early Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID MACULOPATHY; SENSITIVITY; CONE; EYES; DRUSEN; SYSTEM
AB PURPOSE. To determine the retinal function in early age-related macular degeneration (AMD) assessed by the multifocal electroretinogram (mfERG) and flicker perimetry and to seek a relationship between local objective mfERG parameters and subjective flicker perimetry thresholds.
   METHODS. mfERG and flicker perimetry were performed in 15 patients (15 eyes) with early AMD and 14 controls (14 eyes) of similar age. The mfERG P1 response amplitude density (nV/deg(2)) and P1 implicit time of the first-order kernel and the flicker thresholds of each concentric ring were analyzed. The relationship between individual mfERG responses and the corresponding individual flicker sensitivity outcomes was determined.
   RESULTS. The mfERG response amplitude of the central ring (ring 1) was significantly reduced in early AMD eyes compared with the controls (P = 0.009). No significant difference in mfERG amplitude between early AMD and control eyes was detected in the other rings. The mfERG implicit time was significantly increased in the early AMD eyes but only within the central four rings of 12 degrees. A significant reduction in flicker sensitivity was also detected in early AMD eyes but only within the central 6 degrees. There was a significant, moderate correlation (r = -0.477; P < 0.001) between local mfERG latency and flicker sensitivity from the same tested locations within the central 6 degrees. There was a weak correlation (r = 0.200; P < 0.014) between mfERG amplitude and flicker sensitivity.
   CONCLUSIONS. Both mfERG and flicker perimetry show abnormal retinal function, but only in the very central macula, in early AMD. A novel relationship between mfERG and flicker sensitivity should enhance the clinical monitoring of disease progression. (Invest Ophthalmol Vis Sci. 2011;52:9267-9274) DOI: 10.1167/iovs.11-8517
C1 [Luu, Chi D.] Univ Melbourne, Ctr Eye Res Australia, Macular Res Unit, Royal Victorian Eye & Ear Hosp, Melbourne, Vic 3002, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP Luu, CD (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, Macular Res Unit, Royal Victorian Eye & Ear Hosp, Level 1,32 Gisborne St, Melbourne, Vic 3002, Australia.
EM cluu@unimelb.edu.au
RI Luu, Chi/A-3307-2013
OI Guymer, Robyn/0000-0002-9441-4356; Gin, Thomas/0000-0003-0339-2743; Luu,
   Chi/0000-0002-7604-7097
FU National Health and Medical Research Practitioner Fellowship (RHG);
   Macular Vision Loss Support Society of Australia; NHMRC Centre for
   Clinical Research (CERA). [529923]
FX Supported by a National Health and Medical Research Practitioner
   Fellowship (RHG), the Macular Vision Loss Support Society of Australia,
   Operational Infrastructure Support from the Victorian Government (CERA),
   and NHMRC Centre for Clinical Research Excellence Award 529923 (CERA).
CR Berrow EJ, 2010, DOC OPHTHALMOL, V121, P51, DOI 10.1007/s10633-010-9226-1
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chen CZ, 2004, DOC OPHTHALMOL, V109, P1
   Dinc UA, 2008, EUR J OPHTHALMOL, V18, P595, DOI 10.1177/112067210801800416
   Feigl B, 2005, EYE, V19, P1169, DOI 10.1038/sj.eye.6701711
   Feigl B, 2004, CURR EYE RES, V29, P327, DOI 10.1080/02713680490516198
   Feigl Beatrix, 2005, Clin Exp Optom, V88, P304
   Gerth C, 2006, ARCH OPHTHALMOL-CHIC, V124, P345, DOI 10.1001/archopht.124.3.345
   Gerth C, 2003, ARCH OPHTHALMOL-CHIC, V121, P1404, DOI 10.1001/archopht.121.10.1404
   Heinemann-Vernaleken B, 2001, GRAEF ARCH CLIN EXP, V239, P556, DOI 10.1007/s004170100308
   Hood DC, 2000, PROG RETIN EYE RES, V19, P607, DOI 10.1016/S1350-9462(00)00013-6
   HUANG S, 2000, DOC OPHTHALMOL, V101, P115
   Iwama D, 2010, CLIN EXP OPHTHALMOL, V38, P483, DOI 10.1111/j.1442-9071.2010.02294.x
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3136
   MAYER MJ, 1994, INVEST OPHTH VIS SCI, V35, P1138
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3143
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Olson JH, 2011, SEMIN OPHTHALMOL, V26, P131, DOI 10.3109/08820538.2011.577131
   Palmowski AM, 1999, OPHTHALMOLOGE, V96, P166, DOI 10.1007/s003470050389
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   Parks Stuart, 1996, Documenta Ophthalmologica, V92, P281, DOI 10.1007/BF02584082
   Phipps JA, 2004, INVEST OPHTH VIS SCI, V45, P3355, DOI 10.1167/iovs.04-0253
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Seiple W, 2003, INVEST OPHTH VIS SCI, V44, P1783, DOI 10.1167/iovs.02-0518
   TAYLOR HR, 1989, AUST NZ J OPHTHALMOL, V17, P81, DOI 10.1111/j.1442-9071.1989.tb00492.x
NR 27
TC 30
Z9 31
U1 0
U2 9
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2011
VL 52
IS 12
BP 9267
EP 9274
DI 10.1167/iovs.11-8517
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 856IB
UT WOS:000297631400063
PM 22039238
DA 2022-11-30
ER

PT J
AU Kourlas, H
   Abrams, P
AF Kourlas, Helen
   Abrams, Paris
TI Ranibizumab for the treatment of neovascular age-related macular
   degeneration: A review
SO CLINICAL THERAPEUTICS
LA English
DT Review
DE age-related macular degeneration; ARMD; ranibizurnab; choroidal
   neovascularization
ID PATHOGENESIS; VERTEPORFIN; THERAPY
AB Background: Choroidal neovascular (wet) age-related macular degeneration (ARMD) is becoming more prevalent worldwide as life expectancy continues to increase. Rambizumab for intravitreal injection is an inhibitor of human vascular endothelial growth factor A approved by the US Food and Drug Administration for the treatment of ARMD in June 2006. The actions of rambizumab result in reduced cell proliferation, reduced formation of new blood vessels, and minimization of vascular leakage.
   Objective: This paper reviews the pharmacologic and pharmacokinetic properties, clinical efficacy, and safety profile of rambizumab, and pharmacoeconomic considerations associated with its use.
   Methods: MEDLINE (1966-December 2006) and International Pharmaceutical Abstracts (1970-December 2007) were searched for original research studies (Phase I, II, III, and IIIb), abstracts, and review articles concerning ranibizumab. The search terms were choroidal neovascularization, macular degeneration, Lucentis, ranibizumab, retinal degeneration, and vascular endothelial growth factor. Preference was given to Phase II/III studies. Selected information from the manufacturer of ranibizumab was also included.
   Results: The efficacy of ranibizumab has been studied in 3 large clinical trials having the same primary efficacy end point, the proportion of patients losing <15 letters from baseline at 12 months (Early Treatment of Diabetic Retinopathy Study chart). A multicenter, Phase III, randomized, double-blind, sham-controlled, 24-month clinical trial evaluated ranibizumab 0.3 and 0.5 mg in 716 patients with minimally classic or occult choroidal neovascularization (CNV) associated with ARMD. The results for the primary efficacy end point were 94.5% and 94.6% in the ranibizumab 0.3- and 0.5-mg groups, respectively, compared with 62.2% in the sham-injection group (P < 0.001, both ranibizumab groups vs sham injection); at 24 months, the corresponding proportions were 92.0%, 90.0%, and 52.9% (P < 0.001, both ranibizumab groups vs sham injection),. A 2-year, Phase I/II, single-masked (masked patient and visual acuity examiner, unmasked investigator), multicenter trial evaluated the tolerability and efficacy of the combination of rambizumab 0.5 mg and verteporfin photodynamic therapy (PDT) compared with verteporfin PDT alone in 162 patients with predominantly classic CNV. For the primary efficacy end point, the results were 90.5% for rambizurnab + PDT and 67.9% for PDT alone (P < 0.001). Receipt of rambizurnab + PDT was also associated with improved visual acuity, with 23.8% of patients gaining >= 15 letters from baseline, compared with 5.4% of those who received PDT alone (P = 0.003). Finally, an international Phase III, doubleblind, active-controlled study compared ranibizumab 0.3 and 0.5 mg with verteporfin PDT in 423 patients with predominantly classic lesions associated with CNV secondary to ARMD. For the primary efficacy end point, the results were 35.7% for ranibizumab 0.3 mg, 40.3% for ranibizumab 0.5 mg, and 5.6% for verteporfin PDT (P < 0.001). Serious adverse ocular events, which occurred in association with <0. 1 % of intravitreal injections in these trials, included retinal detachment and endophthalmitis. Less serious adverse ocular reactions occurring in <2% of patients included intraocular inflammation and increased intraocular pressure.
   Conclusion: The findings of these 3 large clinical trials suggest that ranibizumab was effective and well tolerated in patients with ARMD.
C1 Long Isl Univ, Dept Pharm Practice, Arnold & Marie Schwartz Coll Pharm & Hlth Sci, Brooklyn, NY 11201 USA.
   New York Harbor Healthcare Syst, Dept Vet Affairs, New York, NY USA.
C3 Long Island University-Brooklyn Campus
RP Kourlas, H (通讯作者)，Long Isl Univ, Dept Pharm Practice, Arnold & Marie Schwartz Coll Pharm & Hlth Sci, 75 Dekalb Ave, Brooklyn, NY 11201 USA.
EM Helen.Kourlas@llu.edu
CR Arroyo JG, AGE RELATED MACULAR
   Bourla DH, 2006, J AM GERIATR SOC, V54, P1130, DOI 10.1111/j.1532-5415.2006.00771.x
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DUGEL PU, 2006, MANAG CARE S7, V15, P7
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   FLEMING T, 2007, DRUG TOPICS REDBOOK, P475
   Heier, 2007, ARCH OPHTHALMOL-CHIC, V125, P138
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   HEIER JS, 2006, OPHTHALMOLOGY, V113, P642
   Kourlas H, 2006, CLIN THER, V28, P36, DOI 10.1016/j.clinthera.2006.01.009
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothen Michelle, 2005, Ophthalmol Clin North Am, V18, P561
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   2006, LUCENTIS PACKAGE INS
   2006, MACUGEN PACKAGE INSE
NR 24
TC 66
Z9 70
U1 0
U2 13
PU ELSEVIER
PI BRIDGEWATER
PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA
SN 0149-2918
EI 1879-114X
J9 CLIN THER
JI Clin. Ther.
PD SEP
PY 2007
VL 29
IS 9
BP 1850
EP 1861
DI 10.1016/j.clinthera.2007.09.008
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 222GH
UT WOS:000250283700004
PM 18035187
DA 2022-11-30
ER

PT J
AU Kim, JH
   Kim, JR
   Kang, SW
   Kim, SJ
   Ha, HS
AF Kim, Jae Hui
   Kim, Jae Ryung
   Kang, Se Woong
   Kim, Sang Jin
   Ha, Hyo Shin
TI Thinner Choroid and Greater Drusen Extent in Retinal Angiomatous
   Proliferation Than in Typical Exudative Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BLOOD-FLOW; NEOVASCULARIZATION; THICKNESS; RISK; CHORIOCAPILLARIS; EYES
AB PURPOSE: To compare choroidal thickness and extent and density of drusen between eyes with typical exudative age-related macular degeneration (AMD) and eyes with retinal angiomatous proliferation (RAP).
   DESIGN: Observational case series.
   METHODS: Twenty-four eyes with typical exudative AMD and 20 eyes with RAP were included. Subfoveal choroidal thickness was measured using enhanced depth imaging optical coherence tomography. Eyes were classified into 3 groups according to the extent of drusen distribution in the fundus photograph. Density of drusen was estimated based on optical coherence tomography images of the fellow eye. The proportion of the length beneath the drusen per the entire length of the Bruch membrane was defined as the density of drusen. Subfoveal choroidal thickness, extent of drusen distribution, and the density of drusen were compared between typical exudative AMD and RAP.
   RESULTS: Mean +/- standard deviation subfoveal choroidal thickness in eyes with typical exudative AMD and eyes with RAP was 184.9 +/- 68.5 pm and 139.0 +/- 65.5 mu m, respectively (P = .035). The mean density of drusen was 0.06 +/- 0.08 and 0.24 +/- 0.12, respectively (P < .001). In the typical exudative AMD group, 19, 3, and 2 eyes were included in the small extent group (< one third), intermediate extent group (one third to two thirds), and large extent group (> two thirds), respectively. In the RAP group, 3, 14, and 3 eyes were included in each aforementioned group, respectively (P = .001).
   CONCLUSIONS: The thinner subfoveal choroidal thickness and greater extent and density of drusen in RAP than the typical exudative AMD may suggest compromised choroidal perfusion in the development of RAP. (Am J Ophthalmol 2013;155:743-749. (C) 2013 by Elsevier Inc. All rights reserved.)
C1 [Kim, Jae Hui; Kim, Jae Ryung; Kang, Se Woong; Kim, Sang Jin; Ha, Hyo Shin] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, Seoul 135710, South Korea.
C3 Sungkyunkwan University (SKKU); Samsung Medical Center
RP Kang, SW (通讯作者)，Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, 50 Irwon Dong, Seoul 135710, South Korea.
EM swkang@skku.edu
RI Kim, Jaeryung/AAB-6693-2022
OI Kim, Jaeryung/0000-0002-8003-5849
CR Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P258, DOI 10.1016/j.ajo.2003.08.009
   BARONDES M, 1990, BRIT J OPHTHALMOL, V74, P180, DOI 10.1136/bjo.74.3.180
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Bottoni F, 2005, ARCH OPHTHALMOL-CHIC, V123, P1644, DOI 10.1001/archopht.123.12.1644
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Koizumi H, 2008, GRAEF ARCH CLIN EXP, V246, P515, DOI 10.1007/s00417-007-0705-3
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   McBain VA, 2011, RETINA-J RET VIT DIS, V31, P1043, DOI 10.1097/IAE.0b013e3181fe54c7
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
NR 26
TC 70
Z9 72
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2013
VL 155
IS 4
BP 743
EP 749
DI 10.1016/j.ajo.2012.11.001
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 118JS
UT WOS:000317022400018
PM 23317655
DA 2022-11-30
ER

PT J
AU Waldstein, SM
   Coulibaly, L
   Riedl, S
   Sadeghipour, A
   Gerendas, BS
   Schmidt-Erfurth, UM
AF Waldstein, Sebastian M.
   Coulibaly, Leonard
   Riedl, Sophie
   Sadeghipour, Amir
   Gerendas, Bianca S.
   Schmidt-Erfurth, Ursula Margarethe
TI Effect of posterior vitreous detachment on treat-and-extend versus
   monthly ranibizumab for neovascular age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE retina; imaging; macula; neovascularisation; vitreous
ID AL. VITREOMACULAR ADHESION; INTRAVITREAL THERAPY; TREATMENT OUTCOMES;
   INTERFACE; RISK; VEGF; PHARMACOKINETICS; TRACTION
AB Aims To investigate the impact of posterior vitreous detachment (PVD) on the efficacy of treat-and-extend (T&E) ranibizumab in neovascular age-related macular degeneration. Methods In a post hoc analysis of a randomised controlled clinical trial, spectral-domain optical coherence tomography images of treatment-naive patients randomised to receive T&E (n=265) or monthly (n=264) ranibizumab for 12 months were included. Certified, masked graders diagnosed the presence or the absence of complete PVD. The main outcome measures were the mean change in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) at month 12, the number of administered ranibizumab injections and the proportion of patients extended to more than 8 weeks. Results At baseline, complete PVD was present in 51% and 56% of patients in the monthly and T&E arms, respectively. Mean change in BCVA at month 12 was +9.0 (PVD) vs +9.5 letters (no PVD, p=0.78) in monthly treated eyes, and +6.0 (PVD) vs +7.5 letters (no PVD, p=0.42) in T&E treated eyes. Conversely, mean change in CRT at month 12 was -174 (PVD) vs -173 mu m (no PVD, p=0.98) in the monthly arm, and -175 (PVD) vs -164 mu m (no PVD, p=0.58) in the T&E arm. In T&E treated patients, the median number of injections was eight vs nine (p=0.035). 71% of PVD eyes were extended successfully, compared with 55% of eyes without PVD (p=0.005). Conclusion PVD was not found to impact functional and anatomical outcomes of T&E ranibizumab therapy. However, patients without a complete PVD required more retreatments and were significantly less likely to be successfully extended.
C1 [Waldstein, Sebastian M.; Coulibaly, Leonard; Riedl, Sophie; Sadeghipour, Amir; Gerendas, Bianca S.; Schmidt-Erfurth, Ursula Margarethe] Med Univ Vienna, Dept Ophthalmol, Vienna Reading Ctr, Christian Doppler Lab Ophthalm Image Anal, Vienna, Austria.
C3 Medical University of Vienna
RP Schmidt-Erfurth, UM (通讯作者)，Med Univ Vienna, Dept Opththalmol, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
OI Gerendas, Bianca S./0000-0001-8940-8130; Schmidt-Erfurth,
   Ursula/0000-0002-7788-7311; Waldstein, Sebastian/0000-0003-2899-6279
FU Austrian Federal Ministry for Digital and Economic Affairs; National
   Foundation for Research, Technology and Development; Novartis Pharma AG,
   Basel, Switzerland
FX The financial support by the Austrian Federal Ministry for Digital and
   Economic Affairs and the National Foundation for Research, Technology
   and Development is gratefully acknowledged. The study was partially
   funded by Novartis Pharma AG, Basel, Switzerland. Novartis participated
   in the final review and approval of the manuscript.
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Cuilla TA, 2015, OPHTHALMOLOGY, V122, P1203, DOI 10.1016/j.ophtha.2015.02.031
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Edington M, 2017, EXPERT OPIN DRUG MET, V13, P1217, DOI 10.1080/17425255.2017.1404987
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Geck U, 2013, GRAEFES ARCH CLIN EX, P1
   Gil P, 2018, OPHTHALMOLOGICA, V240, P29, DOI 10.1159/000488010
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Houston SK, 2015, RETINA-J RET VIT DIS, V35, P1757, DOI 10.1097/IAE.0000000000000663
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Maggio E, 2018, OPHTHALMOLOGY, V125, pE6, DOI 10.1016/j.ophtha.2017.07.027
   Maggio E, 2017, OPHTHALMOLOGY, V124, P657, DOI 10.1016/j.ophtha.2017.01.018
   Mayr-Sponer U, 2013, OPHTHALMOLOGY, V120, P2620, DOI 10.1016/j.ophtha.2013.05.032
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Munk MR, 2015, ACTA OPHTHALMOL, V93, pE561, DOI 10.1111/aos.12699
   Nomura Y, 2014, JPN J OPHTHALMOL, V58, P443, DOI 10.1007/s10384-014-0333-5
   Sadiq MA, 2016, OPHTHALMOLOGY, V123, P324, DOI 10.1016/j.ophtha.2015.09.032
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schubert H D, 1989, Prog Clin Biol Res, V312, P277
   Sebag J, 2018, OPHTHALMOLOGY, V125, pE6, DOI 10.1016/j.ophtha.2017.07.026
   Sebag J, 2008, Dev Ophthalmol, V42, P5, DOI 10.1159/000138754
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Stalmans P, 2012, NEW ENGL J MED, V367, P606, DOI 10.1056/NEJMoa1110823
   Stone TW., 2018, ASRS 2018 PREFERENCE
   Suzuki H, 2017, CLIN OPHTHALMOL, V11, P1471, DOI 10.2147/OPTH.S141779
   Takahashi H, 2015, BRIT J OPHTHALMOL, V99, P1065, DOI 10.1136/bjophthalmol-2014-306051
   Veloso CE, 2015, OPHTHALMOLOGY, V122, P1569, DOI 10.1016/j.ophtha.2015.04.028
   Waldstein SM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02971-y
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
   Waldstein SM, 2014, AM J OPHTHALMOL, V158, P328, DOI 10.1016/j.ajo.2014.04.028
   Waldstein SM, 2012, RETINA-J RET VIT DIS, V32, P424, DOI 10.1097/IAE.0b013e3182278b80
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Xie P, 2017, BRIT J OPHTHALMOL, V101, P1003, DOI 10.1136/bjophthalmol-2017-310155
NR 38
TC 2
Z9 2
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUL
PY 2020
VL 104
IS 7
BP 899
EP 903
DI 10.1136/bjophthalmol-2019-314661
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MG3WX
UT WOS:000545965300004
PM 31563866
DA 2022-11-30
ER

PT J
AU Nguyen, CL
   Oh, LJ
   Wong, E
   Wei, J
   Chilov, M
AF Nguyen, Chu Luan
   Oh, Lawrence J.
   Wong, Eugene
   Wei, Joe
   Chilov, Michael
TI Anti-vascular endothelial growth factor for neovascular age-related
   macular degeneration: a meta-analysis of randomized controlled trials
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Anti-vascular endothelial growth factor; Neovascular age-related macular
   degeneration; Meta-analysis; Randomized controlled trials
ID PHOTODYNAMIC THERAPY; RANIBIZUMAB; BEVACIZUMAB; VERTEPORFIN
AB Background: To evaluate the relative efficacy and safety of anti-vascular endothelial growth factor (anti-VEGF) agents for the treatment of neovascular age-related macular degeneration (AMD).
   Methods: Systematic literature review identifying RCTs comparing anti-VEGF agents to another treatment published before June 2016. Efficacy assessed by mean change in best corrected visual acuity (BCVA) and central macular thickness (CMT) from baseline at up to 2 years followup. Safety assessed by proportions of patients with death, arteriothrombotic and venous thrombotic events, and at least one serious systemic adverse event at up to 2 years of followup.
   Results: Fifteen RCTs selected for meta-analysis (8320 patients). Two trials compared pegaptanib, and three trials compared ranibizumab versus control. Eight trials compared bevacizumab with ranibizumab. Two trials compared aflibercept with ranibizumab. There were no significant differences between bevacizumab and ranibizumab for BCVA at 1 or 2 years (weighted mean difference = -0.57, 95% CI -1.55 to 0.41, P = 0.25 and weighted mean difference = -0.76, 95% CI -2.25 to 0.73, P = 0.32, respectively). Ranibizumab was more effective in reducing CMT at 1 year (weighted mean difference = 4.49, 95% CI 1.13 to 7.84, P = 0.009). Risk ratios comparing rates of serious systemic adverse events at 1 and 2 years were slightly out of favour for bevacizumab. Aflibercept compared with ranibizumab demonstrated similar mean change in BCVA, reduction in CMT, and safety at 1 year.
   Conclusions: Bevacizumab and ranibizumab had equivalent efficacy for BCVA, while ranibizumab had greater reduction in CMT and less rate of serious systemic adverse events. Aflibercept and ranibizumab had comparable efficacy for BCVA and CMT. This provides information to balance comparable effects on vision and risk of adverse events between anti-VEGF agents.
C1 [Nguyen, Chu Luan; Oh, Lawrence J.; Wong, Eugene; Wei, Joe; Chilov, Michael] Univ Sydney, Sydney, NSW 2006, Australia.
   [Nguyen, Chu Luan] Royal North Shore Hosp, Reserve Rd, St Leonards, NSW 2065, Australia.
C3 University of Sydney; Royal North Shore Hospital
RP Nguyen, CL (通讯作者)，Univ Sydney, Sydney, NSW 2006, Australia.; Nguyen, CL (通讯作者)，Royal North Shore Hosp, Reserve Rd, St Leonards, NSW 2065, Australia.
EM chuluannguyen@gmail.com
OI Nguyen, Chu Luan/0000-0002-4630-6182; Wei, Joe/0000-0003-1944-1079
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Ba J, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S86269
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Biswas P, 2011, INDIAN J OPHTHALMOL, V59, P191, DOI 10.4103/0301-4738.81023
   Bressler SB, INTRO UNDERSTANDING
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen GH, 2015, RETINA-J RET VIT DIS, V35, P187, DOI 10.1097/IAE.0000000000000301
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hanhart J, 2018, GRAEF ARCH CLIN EXP, V256, P651, DOI 10.1007/s00417-018-3917-9
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049
   Kodjikian L, 2013, OPHTHALMOLOGY
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Li E, 2016, TREATMENT SCHEDULES
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sacu S, 2009, EYE, V23, P2223, DOI 10.1038/eye.2008.423
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Schauwvlieghe AME, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153052
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Solomon SD, 2014, COCHRANE DB SYST REV, V8, P1
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   Subramanian ML, 2009, AM J OPHTHALMOL, V148, P875, DOI 10.1016/j.ajo.2009.07.009
   Thulliez M, 2018, JAMA OPHTHALMOL
   Thulliez M, 2018, JAMA OPHTHALMOL, V136, P557, DOI 10.1001/jamaophthalmol.2018.0002
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Vedula SS, 2008, COCHRANE DB SYST REV, V2
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 41
TC 31
Z9 34
U1 0
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD MAY 30
PY 2018
VL 18
AR 130
DI 10.1186/s12886-018-0785-3
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GH8WQ
UT WOS:000433950100003
PM 29843663
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Chung, SD
   Ho, JD
   Hu, CC
   Lin, HC
   Sheu, JJ
AF Chung, Shiu-Dong
   Ho, Jau-Der
   Hu, Chao-Chien
   Lin, Herng-Ching
   Sheu, Jau-Jiuan
TI Increased Risk of Parkinson Disease Following a Diagnosis of Neovascular
   Age-Related Macular Degeneration: A Retrospective Cohort Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VASCULAR PARKINSONISM; OXIDATIVE STRESS; INFLAMMATION; PREVALENCE;
   MECHANISMS; PATHOGENESIS; MACULOPATHY; PATHWAYS; TAIWAN; SYSTEM
AB PURPOSE: To investigate the risk for Parkinson disease during a 3-year follow-up period after a diagnosis of neovascular age-related macular degeneration (AMD) using a nationwide population-based dataset in Taiwan.
   DESIGN: A retrospective matched-cohort study.
   METHODS: We identified 877subjects with neovascular AMD as the study cohort and randomly selected 8770 subjects for a comparison cohort. Each subject was individually followed for a 3-year period to identify those who subsequently developed Parkinson disease. Stratified Cox proportional hazard regressions were performed as a means of comparing the 3-year risk of subsequent Parkinson disease between the study and comparison cohorts.
   RESULTS: The incidence rate of Parkinson disease was 5.32 (95% confidence interval [CI]: 3.03-8.72) per 1000 person-years in patients with neovascular AMD and 2.09 (95% CI: 1.59-2.70) per 1000 person-years in comparison patients. The log-rank test indicated that subjects with neovascular AMD had a significantly lower 3-year Parkinson disease-free survival rate than comparison subjects (P <.001). After censoring cases in which patients died during the follow-up period and adjusting for monthly income, geographic region, hypertension, diabetes, hyperlipidemia, and coronary heart disease, the hazard ratio of Parkinson disease during the 3-year follow-up period for subjects with neovascular AMD was 2.57 (95% CI: 1.42-4.64) that of comparison subjects.
   CONCLUSION: In this study, subjects with neovascular AMD were found to be at a significant risk of Parkinson disease during a 3-year follow-up period after their diagnosis among Taiwanese Chinese. Further study is needed to confirm our findings and explore the underlying pathomechanism. (C) 2014 by Elsevier Inc. All rights reserved.
C1 [Chung, Shiu-Dong] Far Eastern Mem Hosp, Div Urol, Dept Surg, Taipei, Taiwan.
   [Chung, Shiu-Dong; Lin, Herng-Ching] Taipei Med Univ Hosp, Sleep Res Ctr, Taipei 110, Taiwan.
   [Ho, Jau-Der] Taipei Med Univ Hosp, Dept Ophthalmol, Taipei 110, Taiwan.
   [Sheu, Jau-Jiuan] Taipei Med Univ Hosp, Dept Neurol, Taipei 110, Taiwan.
   [Hu, Chao-Chien] Shin Kong Wu Ho Su Mem Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Hu, Chao-Chien] Fu Jen Catholic Univ, Sch Med, Hsingchuang, Taiwan.
   [Sheu, Jau-Jiuan] Taipei Med Univ, Dept Neurol, Sch Med, Coll Med, Taipei, Taiwan.
C3 Far Eastern Memorial Hospital; Taipei Medical University; Taipei Medical
   University Hospital; Taipei Medical University; Taipei Medical
   University Hospital; Taipei Medical University; Taipei Medical
   University Hospital; Shin Kong Wu Ho Su Memorial Hospital; Fu Jen
   Catholic University; Taipei Medical University
RP Sheu, JJ (通讯作者)，Taipei Med Univ Hosp, Dept Neurol, 252 Wu Hsing St, Taipei 110, Taiwan.
EM jjs2239@tmu.edu.tw
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   BALLARD PA, 1985, NEUROLOGY, V35, P949, DOI 10.1212/WNL.35.7.949
   Barcia C, 2009, J NEURAL TRANSM-SUPP, P245, DOI 10.1007/978-3-211-92660-4_19
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Burbulla LF, 2011, J NEUROL SCI, V306, P1, DOI 10.1016/j.jns.2011.04.005
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Casals J, 1998, J NEURAL TRANSM, V105, P645, DOI 10.1007/s007020050086
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Cheng CL, 2011, PHARMACOEPIDEM DR S, V20, P236, DOI 10.1002/pds.2087
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Gao HM, 2011, PROG NEUROBIOL, V94, P1, DOI 10.1016/j.pneurobio.2011.03.005
   Ho YS, 2012, CURR PHARM DESIGN, V18, P15, DOI 10.2174/138161212798919039
   Howcroft TK, 2013, AGING-US, V5, P84, DOI 10.18632/aging.100531
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kang JH, 2011, LIVER INT, V31, P685, DOI 10.1111/j.1478-3231.2010.02432.x
   Kang JH, 2010, ANN RHEUM DIS, V69, P1165, DOI 10.1136/ard.2009.116178
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Maetzler W, 2007, NEUROLOGY, V68, P414, DOI 10.1212/01.wnl.0000250230.86581.ea
   MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285
   Mena MA, 2006, EXPERT OPIN DRUG SAF, V5, P759, DOI 10.1517/14740338.5.6.759
   Miller RL, 2009, NEUROCHEM RES, V34, P55, DOI 10.1007/s11064-008-9656-2
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   Thanvi B, 2005, AGE AGEING, V34, P114, DOI 10.1093/ageing/afi025
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Whitton PS, 2007, BRIT J PHARMACOL, V150, P963, DOI 10.1038/sj.bjp.0707167
   Winikates J, 1999, ARCH NEUROL-CHICAGO, V56, P98, DOI 10.1001/archneur.56.1.98
   Wong E, 2010, NAT NEUROSCI, V13, P805, DOI 10.1038/nn.2575
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
NR 39
TC 21
Z9 21
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2014
VL 157
IS 2
BP 464
EP 469
DI 10.1016/j.ajo.2013.09.026
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 299SN
UT WOS:000330416100030
PM 24315292
DA 2022-11-30
ER

PT J
AU Odergren, A
   Algvere, PV
   Seregard, S
   Kvanta, A
AF Odergren, A.
   Algvere, P. V.
   Seregard, S.
   Kvanta, A.
TI A prospective randomised study on low-dose transpupillary thermotherapy
   versus photodynamic therapy for neovascular age-related macular
   degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; VERTEPORFIN THERAPY; OCCULT;
   RANIBIZUMAB; TRIAL; MOUSE; SIZE; EYES; TAP
AB Aim: To compare the efficacy of low-dose transpupillary thermotherapy (TTT) and verteporfin photodynamic therapy (PDT) in patients with occult neovascular age-related macular degeneration (AMD).
   Methods: Patients were randomised to receive either low-dose TTT (136 mW/mm) (and sham PDT) (n = 52) or PDT (and sham TTT) (n = 46) with retreatment if leakage was documented by fluorescein angiography. At baseline and at every follow-up, best corrected visual acuity (BCVA) was measured with the Early Treatment Diabetic Retinopathy Study (ETDRS) chart, lesion size on fluorescein angiography and foveal thickness with optical coherence tomography. The primary outcome measure was the proportion of patients who lost < 15 letters at 12 months' follow-up. Secondary outcome measures included the proportion of patients who gained >= 0 letters, the change in mean lesion size and the change in foveal thickness at 12 months' follow-up.
   Results: The percent of patients losing fewer than 15 letters at 12 months was 75.0% in the TTT group and 73.9% in the PDT group (p > 0.05). The percent of patients with preserved or improved BCVA was 36.5% in the TTT group versus 23.9% in the PDT group (p > 0.05). The mean decrease in foveal thickness was 15% for TTT and 24% (p > 0.05) for PDT-treated patients, and the mean increase in total lesion area was -0.7% and -1.1% (p > 0.05), respectively.
   Conclusion: In this prospective, randomised trial low-dose TTT and PDT appeared to be equally efficient at stabilising visual acuity in patients with occult neovascular AMD. Low-dose TTT may be considered as an alternative to PDT in this set of patients and also as an adjuvant to pharmacotherapy.
C1 [Odergren, A.; Algvere, P. V.; Seregard, S.; Kvanta, A.] St Eriks Eye Hosp, Karolinska Inst, Vitreoretinal Dept, SE-11282 Stockholm, Sweden.
C3 Karolinska Institutet
RP Odergren, A (通讯作者)，St Eriks Eye Hosp, Karolinska Inst, Vitreoretinal Dept, Polhemsgatan 50, SE-11282 Stockholm, Sweden.
EM odergren@sankterik.se
CR Algvere P V, 2001, Semin Ophthalmol, V16, P90, DOI 10.1076/soph.16.2.90.4210
   Algvere PV, 2003, ACTA OPHTHALMOL SCAN, V81, P110, DOI 10.1034/j.1600-0420.2003.00041.x
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Costa RA, 2007, GRAEF ARCH CLIN EXP, V245, P1273, DOI 10.1007/s00417-007-0557-x
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Lanzetta P, 2002, OPHTHALMOLOGY, V109, P1098, DOI 10.1016/S0161-6420(02)01034-5
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Mainster M A, 2001, Semin Ophthalmol, V16, P55, DOI 10.1076/soph.16.2.55.4213
   Mainster MA, 2000, OPHTHALMIC SURG LAS, V31, P359
   MILLER JW, 1995, ARCH OPHTHALMOL-CHIC, V113, P810, DOI 10.1001/archopht.1995.01100060136048
   Ming Y, 2004, INVEST OPHTH VIS SCI, V45, P1969, DOI 10.1167/iovs.03-1329
   Odergren A, 2006, CURR EYE RES, V31, P765, DOI 10.1080/02713680600865045
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   REICHEL E, 2005, INVEST OPHTHALMOL VI
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Stolba U, 2006, BRIT J OPHTHALMOL, V90, P158, DOI 10.1136/bjo.2005.076422
   Thach AB, 2003, ARCH OPHTHALMOL-CHIC, V121, P817, DOI 10.1001/archopht.121.6.817
   Zacks DN, 2002, INVEST OPHTH VIS SCI, V43, P2384
NR 24
TC 7
Z9 7
U1 0
U2 1
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2008
VL 92
IS 6
BP 757
EP 761
DI 10.1136/bjo.2007.133561
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 308RJ
UT WOS:000256407400008
PM 18356266
DA 2022-11-30
ER

PT J
AU Li, Y
   Fu, J
   Liu, JW
   Feng, HY
   Chen, XY
AF Li, Yao
   Fu, Jing
   Liu, Jiawen
   Feng, Huayin
   Chen, Xueyi
TI Diagnostic Markers and Molecular Dysregulation Mechanisms in the Retinal
   Pigmented Epithelium and Retina of Age-Related Macular Degeneration
SO JOURNAL OF HEALTHCARE ENGINEERING
LA English
DT Article
ID JUVENILE MYELOMONOCYTIC LEUKEMIA; MITOCHONDRIAL-DNA DAMAGE; PTPN11;
   SUSCEPTIBILITY; POLYMORPHISM; PREVALENCE; RISK; ASSOCIATION; MUTATIONS;
   VARIANT
AB Age-related macular degeneration (AMD) is a chronic and progressive macular degeneration disease, which can also lead to serious visual loss. In our research, we aim to efficiently identify biomarkers relevant for AMD diagnosis. We collected the gene expression data of retinal segmented epithelium (RPE) and retina tissues of GSE29801 and GSE135092 and performed differential expression analysis. The differentially expressed genes (DEGs) related to the RPE and retina in the two sets of data were identified and enriched by intersection analysis. A PPI network was constructed for intersection genes, and the top 20 genes with the largest connectivity in the network were selected as candidate genes. The LASSO model was used to identify key genes from candidate genes, and the nomogram and ROC curve were used to evaluate the diagnostic ability of key genes. We identified 464 intersection genes associated with RPE and 509 intersection genes associated with retina. The TGF-beta signaling pathway was enriched by RPE-related DEGs, while oxidative phosphorylation was enriched by retina-related DEGs. Among the candidate genes of RPE, the LASSO model identified 7 key genes. MAPK1 and LUM can predict the clinical diagnosis of AMD. Among the candidate genes of retina, the LASSO model identified four key genes. PTPN11 has the highest predictive diagnostic value. The results suggest that the imbalance mechanism of RPE in AMD may be related to the TGF-beta signaling pathway, and the imbalance mechanism of the retina may be related to oxidative phosphorylation. MAPK1 and LUM are potential diagnostic markers of RPE, and PTPN11 is a potential diagnostic marker of the retina. Also, our results provide a theoretical basis for better understanding the molecular mechanisms of AMD onset and treatment in the future.
C1 [Li, Yao; Fu, Jing; Feng, Huayin; Chen, Xueyi] Xinjiang Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Urumqi 830054, Xinjiang, Peoples R China.
   [Liu, Jiawen] Jiangmen Cent Hosp, Jiangmen 529000, Guangdong, Peoples R China.
C3 Xinjiang Medical University
RP Chen, XY (通讯作者)，Xinjiang Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Urumqi 830054, Xinjiang, Peoples R China.
EM liyao@xydyfy.org.cn; 77368620@qq.com; 1445647648@qq.com;
   402466347@qq.com; chenxueyi@xydyfy.org.cn
CR Bhuiyan A, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.25
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Dalvin LA, 2019, JAMA OPHTHALMOL, V137, P483, DOI 10.1001/jamaophthalmol.2018.6891
   Ennis S, 2010, EUR J HUM GENET, V18, P15, DOI 10.1038/ejhg.2009.113
   Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Genovese T, 2008, J PHARMACOL EXP THER, V325, P100, DOI 10.1124/jpet.107.131060
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hautamaki A, 2013, RETINA-J RET VIT DIS, V33, P1815, DOI 10.1097/IAE.0b013e318285cf92
   HIBLER CP, 1968, J PARASITOL, V54, P1095, DOI 10.2307/3276970
   Hishida A, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-51
   Jakovljevic G, 2010, COLLEGIUM ANTROPOL, V34, P251
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Kim YJ, 2014, J KOREAN MED SCI, V29, P1699, DOI 10.3346/jkms.2014.29.12.1699
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   Kyosseva SV, 2016, OPHTHALMOL EYE DIS, V8, P23, DOI 10.4137/OED.S32200
   Kyu HH, 2018, LANCET, V392, P1859, DOI [10.1016/S0140-6736(18)32335-3, 10.1016/s0140-6736(18)32335-3]
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin HJ, 2010, INVEST OPHTH VIS SCI, V51, P96, DOI 10.1167/iovs.09-3612
   Liutkeviciene R, 2015, OPHTHALMIC GENET, V36, P149, DOI 10.3109/13816810.2013.838274
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Majava M, 2007, HUM MUTAT, V28, P336, DOI 10.1002/humu.20444
   McBrien NA, 2003, PROG RETIN EYE RES, V22, P307, DOI 10.1016/S1350-9462(02)00063-0
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   Narumi Y, 2009, J CLIN IMMUNOL, V29, P303, DOI 10.1007/s10875-008-9272-6
   Notomi S, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0255213
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Radeke MJ, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0183-x
   Rimayanti U, 2014, GRAEF ARCH CLIN EXP, V252, P563, DOI 10.1007/s00417-013-2496-z
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Saika Shizuya, 2009, Front Biosci (Schol Ed), V1, P376, DOI 10.2741/e32
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156
   Vitale S, 2020, JAMA OPHTHALMOL, V138, P610, DOI 10.1001/jamaophthalmol.2020.0824
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zhang FJ, 2009, J OPHTHALMOL, V2009, DOI 10.1155/2009/514306
NR 48
TC 1
Z9 1
U1 0
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2040-2295
EI 2040-2309
J9 J HEALTHC ENG
JI J. Healthc. Eng.
PD FEB 10
PY 2022
VL 2022
AR 3787567
DI 10.1155/2022/3787567
PG 9
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services
GA ZR1HX
UT WOS:000767544400001
PM 35186229
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Cheung, R
   Chun, J
   Sheidow, T
   Motolko, M
   Malvankar-Mehta, MS
AF Cheung, Ronald
   Chun, Jacob
   Sheidow, Tom
   Motolko, Michael
   Malvankar-Mehta, Monali S.
TI Diagnostic accuracy of current machine learning classifiers for
   age-related macular degeneration: a systematic review and meta-analysis
SO EYE
LA English
DT Review
ID DIABETIC-RETINOPATHY; AUTOMATED DETECTION; EYE DISEASES; VALIDATION;
   PROGRESS; IMAGES; IMPACT; EDEMA; AMD
AB Background and objective The objective of this study was to systematically review and meta-analyze the diagnostic accuracy of current machine learning classifiers for age-related macular degeneration (AMD). Artificial intelligence diagnostic algorithms can automatically detect and diagnose AMD through training data from large sets of fundus or OCT images. The use of AI algorithms is a powerful tool, and it is a method of obtaining a cost-effective, simple, and fast diagnosis of AMD. Methods MEDLINE, EMBASE, CINAHL, and ProQuest Dissertations and Theses were searched systematically and thoroughly. Conferences held through Association for Research in Vision and Ophthalmology, American Academy of Ophthalmology, and Canadian Society of Ophthalmology were searched. Studies were screened using Covidence software and data on sensitivity, specificity and area under curve were extracted from the included studies. STATA 15.0 was used to conduct the meta-analysis. Results Our search strategy identified 307 records from online databases and 174 records from gray literature. Total of 13 records, 64,798 subjects (and 612,429 images), were used for the quantitative analysis. The pooled estimate for sensitivity was 0.918 [95% CI: 0.678, 0.98] and specificity was 0.888 [95% CI: 0.578, 0.98] for AMD screening using machine learning classifiers. The relative odds of a positive screen test in AMD cases were 89.74 [95% CI: 3.05-2641.59] times more likely than a negative screen test in non-AMD cases. The positive likelihood ratio was 8.22 [95% CI: 1.52-44.48] and the negative likelihood ratio was 0.09 [95% CI: 0.02-0.52]. Conclusion The included studies show promising results for the diagnostic accuracy of the machine learning classifiers for AMD and its implementation in clinical settings.
C1 [Cheung, Ronald; Malvankar-Mehta, Monali S.] Univ Western Ontario, Schulich Sch Med & Dent, Dept Epidemiol & Biostat, London, ON, Canada.
   [Chun, Jacob] Univ Western Ontario, Fac Sci, London, ON, Canada.
   [Sheidow, Tom; Motolko, Michael; Malvankar-Mehta, Monali S.] Univ Western Ontario, Schulich Sch Med & Dent, Dept Ophthalmol, London, ON, Canada.
C3 Western University (University of Western Ontario); Western University
   (University of Western Ontario); Western University (University of
   Western Ontario)
RP Malvankar-Mehta, MS (通讯作者)，Univ Western Ontario, Schulich Sch Med & Dent, Dept Epidemiol & Biostat, London, ON, Canada.; Malvankar-Mehta, MS (通讯作者)，Univ Western Ontario, Schulich Sch Med & Dent, Dept Ophthalmol, London, ON, Canada.
EM monali.malvankar@sjhc.london.on.ca
OI Sheidow, Tom/0000-0001-6370-1857; Cheung, Ronald/0000-0002-1723-8838
CR ALTMAN DG, 1994, BRIT MED J, V308, P1552, DOI 10.1136/bmj.308.6943.1552
   Burlina PM, 2019, JAMA OPHTHALMOL, V137, P258, DOI 10.1001/jamaophthalmol.2018.6156
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Cheung R, 2021, PSYCHOL REP, V124, P2139, DOI 10.1177/0033294120954135
   Chou CF, 2013, AM J PREV MED, V45, P29, DOI 10.1016/j.amepre.2013.02.018
   DEWA CS, 2014, BMC HEALTH SERV RES, V14
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fraccaro P, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/1471-2415-15-10
   Gao XT, 2015, IEEE T BIO-MED ENG, V62, P2693, DOI 10.1109/TBME.2015.2444389
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Hassan T, 2018, J MED SYST, V42, DOI 10.1007/s10916-018-1078-3
   Hwang DK, 2019, THERANOSTICS, V9, P232, DOI 10.7150/thno.28447
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Lamminen H, 2003, ACTA OPHTHALMOL SCAN, V81, P105, DOI 10.1034/j.1600-0420.2003.00045.x
   Lamoureux EL, 2011, BRIT J OPHTHALMOL, V95, P666, DOI 10.1136/bjo.2010.185207
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Li F, 2019, GRAEF ARCH CLIN EXP, V257, P495, DOI 10.1007/s00417-018-04224-8
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu YY, 2011, INVEST OPHTH VIS SCI, V52, P8316, DOI 10.1167/iovs.10-7012
   Lu W, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/5278196
   Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]
   Murtagh P, 2020, INT J OPHTHALMOL-CHI, V13, P149, DOI 10.18240/ijo.2020.01.22
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Saleem SM, 2020, AM J OPHTHALMOL, V216, P237, DOI 10.1016/j.ajo.2020.04.029
   Shanafelt TD, 2012, ARCH INTERN MED, V172, P1377, DOI 10.1001/archinternmed.2012.3199
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P3568, DOI 10.1364/BOE.5.003568
   Tan JH, 2018, FUTURE GENER COMP SY, V87, P127, DOI 10.1016/j.future.2018.05.001
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P259, DOI 10.1007/s00417-017-3850-3
   Ullah W, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000020306
   Wang Y, 2016, BIOMED OPT EXPRESS, V7, P4928, DOI 10.1364/BOE.7.004928
   Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009
   Yannuzzi LA, 2004, AM J OPHTHALMOL, V137, P511, DOI 10.1016/j.ajo.2003.12.035
   Yoo TK, 2019, MED BIOL ENG COMPUT, V57, P677, DOI 10.1007/s11517-018-1915-z
   2005, ARCH OPHTHALMOL-CHIC, V123, P1570
NR 37
TC 6
Z9 6
U1 1
U2 9
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAY
PY 2022
VL 36
IS 5
BP 994
EP 1004
DI 10.1038/s41433-021-01540-y
EA MAY 2021
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0V6DU
UT WOS:000647959800005
PM 33958739
DA 2022-11-30
ER

PT J
AU Mao, XY
   Wu, WB
   Fang, WY
   Liu, QH
AF Mao Xiying
   Wu Wenbo
   Fang Wangyi
   Liu Qinghuai
TI Association of Apolipoprotein E Polymorphisms with Age-related Macular
   Degeneration Subtypes: An Updated Systematic Review and Meta-analysis
SO ARCHIVES OF MEDICAL RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Apolipoprotein E; Single nucleotide
   polymorphism; biomarkers; Meta-analysis
ID TRANSGENIC MICE; E GENE; EPSILON-4 ALLELE; APOE; SUSCEPTIBILITY; DRUSEN;
   EPIDEMIOLOGY; ACCUMULATION; INFLAMMATION; EXPRESSION
AB Background and Aims. Age-related macular degeneration (AMD) is the worldwide leading cause of blindness among the elderly, especially in developed countries. The possible association between apolipoprotein E (ApoE) polymorphism (epsilon 2, epsilon 3, epsilon 4) and AMD has been extensively investigated with conflicting results, especially when specifying different clinical phenotypes of AMD. Herein, we conducted a meta-analysis by integrating several recent large-sample studies to verify the effect of ApoE polymorphisms on AMD subtypes.
   Methods. The retrieve for targeted literature was conducted based on the PubMed, Embase, Cochrane library, and Web of Science. Summary odds ratio (OR) and its 95% confidence intervals (CIs) were used for estimation of risk. The p-value was adjusted due to the multiple comparison.
   Results. A total of 12 studies included in the final summary analysis, including 13842 cases and 38647 controls. ApoE epsilon 4 carrier was inversely associated with early stage AMD (OR = 0.889, 95% CI = 0.82-0.97), geographic atrophy (OR = 0.594, 95% CI = 0.43-0.83) and neovascular AMD (OR = 0.670, 95% CI = 0.58-0.76). Stratification analysis by ethnicity revealed that the ApoE 4 carriers was associated with neovascular AMD in both Caucasians (OR = 0.62, 95% CI = 0.47-0.83) and East Asians (OR = 0.68, 95% CI = 0.58-0.79). A significant association of ApoE epsilon 2 carriers was only found with early AMD in Black and East Asian population, however small samples and limited studies restrict its generalization.
   Conclusion. Our meta-analysis revealed a significantly protective role of epsilon 4 on each subtypes of AMD, but no supportive evidence of the association of epsilon 2 with AMD. Thus, further studies with larger samples are needed to understand the precise role of epsilon 2 on AMD susceptibility. (C) 2017 IMSS. Published by Elsevier Inc.
C1 [Mao Xiying; Fang Wangyi; Liu Qinghuai] Nanjing Med Univ, Dept Ophthalmol, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China.
   [Wu Wenbo] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Dept Occupat & Environm Hlth, Wuhan, Hubei, Peoples R China.
C3 Nanjing Medical University; Huazhong University of Science & Technology
RP Liu, QH (通讯作者)，Nanjing Med Univ, Dept Ophthalmol, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China.
EM liuqh0545@126.com
OI Wu, Wenbo/0000-0002-7418-7766
CR Adams MKM, 2012, AM J EPIDEMIOL, V175, P511, DOI 10.1093/aje/kwr329
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Attia J, 2003, J CLIN EPIDEMIOL, V56, P297, DOI 10.1016/S0895-4356(03)00011-8
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Bales KR, 2009, J NEUROSCI, V29, P6771, DOI 10.1523/JNEUROSCI.0887-09.2009
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gotoh N, 2004, AM J OPHTHALMOL, V138, P567, DOI 10.1016/j.ajo.2004.05.025
   Heeren J, 2004, J BIOL CHEM, V279, P55483, DOI 10.1074/jbc.M409324200
   Huang YD, 2010, CURR OPIN LIPIDOL, V21, P337, DOI 10.1097/MOL.0b013e32833af368
   Jo DH, 2015, GENET MOL RES, V14, P1855, DOI 10.4238/2015.March.13.14
   KESANIEMI YA, 1987, J CLIN INVEST, V80, P578, DOI 10.1172/JCI113107
   Lee SJ, 2007, J MICROBIOL BIOTECHN, V17, P1024
   Levy O, 2015, J NEUROSCI, V35, P13568, DOI 10.1523/JNEUROSCI.2468-15.2015
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Losonczy G, 2011, ACTA OPHTHALMOL, V89, P255, DOI 10.1111/j.1755-3768.2009.01687.x
   Ma L, 2016, SCI REP-UK, V6, DOI 10.1038/srep19718
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   Nita M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930671
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Riddell DR, 2008, J NEUROSCI, V28, P11445, DOI 10.1523/JNEUROSCI.1972-08.2008
   Shen L, 2015, INVEST OPHTH VIS SCI, V56, P4290, DOI 10.1167/iovs.15-16533
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Sun E, 2011, MOL VIS, V17, P997
   Thakkinstian A, 2005, AM J EPIDEMIOL, V162, P201, DOI 10.1093/aje/kwi184
   Thakkinstian A, 2006, AM J EPIDEMIOL, V164, P813, DOI 10.1093/aje/kwj279
   Tikellis G, 2007, ARCH OPHTHALMOL-CHIC, V125, P68, DOI 10.1001/archopht.125.1.68
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Vos T, 2015, LANCET, V386, P743, DOI 10.1016/S0140-6736(15)60692-4
   Wan XA, 2010, BIOINFORMATICS, V26, P2517, DOI 10.1093/bioinformatics/btq486
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 39
TC 17
Z9 17
U1 1
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0188-4409
EI 1873-5487
J9 ARCH MED RES
JI Arch. Med. Res.
PD MAY
PY 2017
VL 48
IS 4
BP 370
EP 377
DI 10.1016/j.arcmed.2017.08.002
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FO6XK
UT WOS:000417012300008
PM 28889998
DA 2022-11-30
ER

PT J
AU Vilkeviciute, A
   Bastikaityte, N
   Mockute, R
   Cebatoriene, D
   Kriauciuniene, L
   Balciuniene, J
   Zemaitiene, R
   Liutkeviciene, R
AF Vilkeviciute, Alvita
   Bastikaityte, Neringa
   Mockute, Ruta
   Cebatoriene, Dzastina
   Kriauciuniene, Loresa
   Balciuniene, Jurate
   Zemaitiene, Reda
   Liutkeviciene, Rasa
TI The Role of SNPs in IL1RL1 and IL1RAP Genes in Age-related Macular
   Degeneration Development and Treatment Efficacy
SO IN VIVO
LA English
DT Article
DE Age-related macular degeneration; IL1RL1 rs1041973; IL1RAP rs4624606;
   gene polymorphisms; treatment
ID RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN-1 RECEPTOR; STEM-CELLS; ST2;
   ASSOCIATION; VARIANTS; DISEASE; ASTHMA; POLYMORPHISMS; EXPRESSION
AB Background: Age-related macular degeneration (AMD) affects the central part of the retina and causes blindness. In developed countries, AMD occurs in people over 50 years old. Important factors for AMD pathogenesis are an immune response, inflammation, and genetic factors. This study aimed to determine the impact of IL1RL1 rs1041973 and IL1RAP rs4624606 single nucleotide polymorphisms (SNPs) on the occurrence of AMD and the outcome of treatment with aflibercept and bevacizumab. Patients and Methods: 563 patients with AMD and 281 healthy candidates were evaluated. Patients with exudative AMD were treated with intravitreal bevacizumab and aflibercept and, after 6 months based on the changes in bestcorrected visual acuity and central macular thickness, were classified as 'responders' or 'poor-responders'. Genotyping of IL1RL1 rs1041973 and IL1RAP rs4624606 was accomplished using real-time PCR. Age was compared using the Mann-Whitney U-test. Categorical data (gender, genotype, and allele distributions) compared between groups using the x2 test or the Fisher's exact test. Associations of gene polymorphisms were calculated using logistic regression analysis with adjustment for age in exudative and atrophic AMD analysis. An adjusted significance threshold for multiple comparisons a=0.025 was applied. Results: Statistically significant differences in the distribution of IL1RAP rs4624606 genotypes (TT, TA and AA) were found between males with atrophic AMD and controls: 50%, 42.9% and 7.1% vs. 69.7%, 30.3% and 0%, respectively, p=0.015. Moreover, we found that 'responders' had a significantly better best-corrected visual acuity than 'poor-responders' before treatment (p=0.032). The central macular thickness was significantly lower in exudative AMD patients with IL1RL1 rs1041973 AA genotype than in wild type and heterozygous (CC+CA) genotype carriers before treatment (p=0.017). Conclusion: IL1RAP rs4624606 may be associated with atrophic AMD in males while IL1RL1 rs1041973 may play a protective role against macular thickening in exudative AMD patients.
C1 [Vilkeviciute, Alvita; Kriauciuniene, Loresa; Liutkeviciene, Rasa] Lithuanian Univ Hlth Sci, Med Acad, Neurosci Inst, Kaunas, Lithuania.
   [Bastikaityte, Neringa] Lithuanian Univ Hlth Sci, Med Acad, Kaunas, Lithuania.
   [Mockute, Ruta; Cebatoriene, Dzastina; Kriauciuniene, Loresa; Balciuniene, Jurate; Zemaitiene, Reda; Liutkeviciene, Rasa] Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, Kaunas, Lithuania.
C3 Lithuanian University of Health Sciences; Lithuanian University of
   Health Sciences; Lithuanian University of Health Sciences
RP Vilkeviciute, A (通讯作者)，Lithuanian Univ Hlth Sci, Med Acad, Neurosci Inst, Lab Ophthalmol, Eiveniu 2, LT-50161 Kaunas, Lithuania.
EM alvita.vilkeviciute@lsmuni.lt
OI Balciuniene, Vilma Jurate/0000-0001-6126-9351
CR Askmyr M, 2013, BLOOD, V121, P3709, DOI 10.1182/blood-2012-09-458935
   Barreyro L, 2012, BLOOD, V120, P1290, DOI 10.1182/blood-2012-01-404699
   Brint EK, 2004, NAT IMMUNOL, V5, P373, DOI 10.1038/ni1050
   Dale M, 1998, GENOMICS, V47, P325, DOI 10.1006/geno.1997.5113
   Dale M, 1999, GENOMICS, V57, P177, DOI 10.1006/geno.1999.5767
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Eggers KM, 2010, AM HEART J, V159, P788, DOI 10.1016/j.ahj.2010.02.022
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Garlanda C, 2013, IMMUNITY, V39, P1003, DOI 10.1016/j.immuni.2013.11.010
   Goldbach-Mansky R, 2009, J ALLERGY CLIN IMMUN, V124, P1141, DOI 10.1016/j.jaci.2009.11.016
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323
   Hacker S, 2009, J CLIN LAB ANAL, V23, P372, DOI 10.1002/jcla.20348
   Ho TC, 2016, BLOOD, V128, P1671, DOI 10.1182/blood-2016-02-695312
   Kim JJ, 2011, HUM GENET, V129, P487, DOI 10.1007/s00439-010-0937-x
   Kim SS, 2012, HEPATO-GASTROENTEROL, V59, P190, DOI 10.5754/hge10375
   Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P474, DOI 10.1006/bbrc.1997.6810
   Kumaramanickavel G, 2016, ASIA-PAC J OPHTHALMO, V5, P229, DOI 10.1097/APO.0000000000000223
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liutkeviciene R, 2017, GENE, V636, P30, DOI 10.1016/j.gene.2017.09.022
   Lohning M, 1998, P NATL ACAD SCI USA, V95, P6930, DOI 10.1073/pnas.95.12.6930
   Marneros AG, 2016, EMBO MOL MED, V8, P208, DOI 10.15252/emmm.201505613
   Martinez-Rumayor A, 2008, AM J CLIN PATHOL, V130, P578, DOI 10.1309/WMG2BFRC97MKKQKP
   Menon R, 2010, ANN HUM GENET, V74, P165, DOI 10.1111/j.1469-1809.2010.00562.x
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Nakki A, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-50
   O'Neill L.A., 2000, SCI STKE, V2000, pRE1, DOI DOI 10.1126/STKE.2000.44.RE1
   Oshikawa K, 2001, AM J RESP CRIT CARE, V164, P277, DOI 10.1164/ajrccm.164.2.2008120
   Ramanan VK, 2015, BRAIN, V138, P3076, DOI 10.1093/brain/awv231
   Reijmerink NE, 2008, J ALLERGY CLIN IMMUN, V122, P651, DOI 10.1016/j.jaci.2008.06.030
   Sadovnik I, 2017, EXP HEMATOL, V51, P17, DOI 10.1016/j.exphem.2017.04.003
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Szerafin T, 2009, THORAC CARDIOV SURG, V57, P25, DOI 10.1055/s-2008-1039044
   Theodoropoulou S, 2017, J PATHOL, V241, P45, DOI 10.1002/path.4816
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu FQ, 2014, INT J MOL SCI, V15, P23227, DOI 10.3390/ijms151223227
   Zheng SL, 2006, PROSTATE, V66, P1556, DOI 10.1002/pros.20496
   Zhu GH, 2008, EUR J HUM GENET, V16, P1083, DOI 10.1038/ejhg.2008.67
   2001, AM J OPHTHALMOL, V132, P668, DOI DOI 10.1016/S0002-9394(01)01218-1
NR 41
TC 4
Z9 4
U1 0
U2 0
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0258-851X
EI 1791-7549
J9 IN VIVO
JI In Vivo
PD SEP-OCT
PY 2020
VL 34
IS 5
BP 2443
EP 2451
DI 10.21873/invivo.12059
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA NW4LM
UT WOS:000574979900001
PM 32871771
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Rinsky, B
   Hagbi-Levi, S
   Elbaz-Hayoun, S
   Grunin, M
   Chowers, I
AF Rinsky, Batya
   Hagbi-Levi, Shira
   Elbaz-Hayoun, Sarah
   Grunin, Michelle
   Chowers, Itay
TI Characterizing the effect of supplements on the phenotype of cultured
   macrophages from patients with age-related macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID PERIPHERAL-BLOOD MONOCYTES; CARNOSIC ACID; TNF-ALPHA; POLARIZATION;
   EXPRESSION; ACTIVATION; PROMOTES; LUTEIN; NEOVASCULARIZATION; CELLS
AB Purpose: Oral vitamin and mineral supplements reduce the risk of visual loss in age-related macular degeneration (AMD). However, the pathways that mediate this beneficial effect are poorly understood. Macrophages may exert oxidative, inflammatory, and angiogenic effects in the context of AMD. We aim to assess if oral supplements can modulate the macrophage phenotype in this disease.
   Methods: Monocytes were isolated from patients with neovascular AMD (nvAMD), cultured, matured to macrophages, and polarized to classical [M1 (stimulated by IFN. and lipopolysaccharide (LPS))] and alternative [M2 (stimulated with IL-4 and IL-13)] phenotypes. Combinations of antioxidants including lutein+ zeaxanthin (1 mu M; 0.2 mu M), zinc (10 mu M), carnosic acid (2 mu M), beta-carotene (2 mu M), and standardized tomato extract containing lycopene and other tomato phytonutrients were added to the culture media. Levels of anti-inflammatory, antioxidant, and pro-angiogenic gene and protein expression were then evaluated.
   Results: Combinations of lutein and carnosic acid with zinc and standardized tomato extract or with beta-carotene yielded an antioxidative, anti-inflammatory, and antiangiogenic effect in M1 and M2 macrophages. These effects manifested in the upregulation of antioxidative genes (HMOX1, SOD1) and the downregulation of pro-angiogenic genes and pro-inflammatory genes (SDF-1, TNF-alpha, IL-6, MCP-1). Lutein monotherapy or a combination of lutein and zinc had less effect on the expression of these genes.
   Conclusions: Combinations of supplements can modify the expression of genes and proteins that may be relevant for the involvement of macrophages in the pathogenesis of AMD. Further studies are required to evaluate if the modulation of the macrophage phenotype partially accounts for the beneficial effect of oral supplements in AMD and if modification of the AREDS formula can improve its effect on macrophages.
C1 [Rinsky, Batya; Hagbi-Levi, Shira; Elbaz-Hayoun, Sarah; Grunin, Michelle; Chowers, Itay] Hadassah Hebrew Univ, Med Ctr, Dept Ophthalmol, POB 12000, IL-91120 Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Hadassah University Medical Center
RP Chowers, I (通讯作者)，Hadassah Hebrew Univ, Med Ctr, Dept Ophthalmol, POB 12000, IL-91120 Jerusalem, Israel.
EM chowers@hadassah.org.il
RI Grunin, Michelle/O-6044-2019
OI Grunin, Michelle/0000-0002-3155-2858; Hagbi-Levi,
   Shira/0000-0002-2891-0079
FU Lycored Inc.
FX We thank Dr. Liran Tiosano for his excellent advice and statistical help
   for the biostatistics portion of this article. This research was funded
   by a grant from Lycored Inc. The authors declare no other financial or
   nonfinancial competing interests.
CR Akaboshi T, 2014, MOL NUTR FOOD RES, V58, P1291, DOI 10.1002/mnfr.201300753
   Allavena P, 1998, EUR J IMMUNOL, V28, P359, DOI 10.1002/(SICI)1521-4141(199801)28:01<359::AID-IMMU359>3.0.CO;2-4
   [Anonymous], 1999, CONTROL CLIN TRIALS, DOI 10.1016/S0197-2456(99)00031-8
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Apte RS, 2010, ADV EXP MED BIOL, V664, P15, DOI 10.1007/978-1-4419-1399-9_2
   Bouhlel MA, 2007, CELL METAB, V6, P137, DOI 10.1016/j.cmet.2007.06.010
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P4914, DOI 10.1167/iovs.03-0371
   Gelinas L, 2011, J RENIN-ANGIO-ALDO S, V12, P295, DOI 10.1177/1470320310391332
   Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733
   Grunin M, 2016, SCI REP-UK, V6, DOI 10.1038/srep29046
   Grunin M, 2012, INVEST OPHTH VIS SCI, V53, P5292, DOI 10.1167/iovs.11-9165
   Hadad N, 2012, FREE RADICAL BIO MED, V53, P1381, DOI 10.1016/j.freeradbiomed.2012.07.078
   Hagbi-Levi S, 2017, NEUROBIOL AGING
   Jiao HH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143952
   Kamoshita M, 2016, SCI REP-UK, V6, DOI 10.1038/srep30226
   Lederman M, 2010, INVEST OPHTH VIS SCI, V51, P53, DOI 10.1167/iovs.08-3019
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Liyanage SE, 2016, ARTERIOSCL THROM VAS, V36, P19, DOI 10.1161/ATVBAHA.115.306681
   Mantovani A, 2005, IMMUNITY, V23, P344, DOI 10.1016/j.immuni.2005.10.001
   Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5
   Martinez F. O., 2014, F1000PRIME REPORTS, V6, P13
   Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532
   Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692
   Nakamura R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8847
   Pelegrin P, 2009, EMBO J, V28, P2114, DOI 10.1038/emboj.2009.163
   PENFOLD P, 1984, AUST J OPHTHALMOL, V12, P23
   Rezaie T, 2012, INVEST OPHTH VIS SCI, V53, P7847, DOI 10.1167/iovs.12-10793
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   Schwager J, 2016, MOLECULES, V21, DOI 10.3390/molecules21040465
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Sica A, 2015, CELL MOL LIFE SCI, V72, P4111, DOI 10.1007/s00018-015-1995-y
   Sica A, 2014, HEPATOLOGY, V59, P2034, DOI 10.1002/hep.26754
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   Wang HB, 2016, MOL VIS, V22, P116
   Winkler BS, 1999, MOL VIS, V5
   Wu WQ, 2015, MOL NUTR FOOD RES, V59, P1663, DOI 10.1002/mnfr.201500109
   Zandi S, 2015, CELL REP, V10, P1173, DOI 10.1016/j.celrep.2015.01.050
NR 42
TC 7
Z9 7
U1 0
U2 5
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD DEC 6
PY 2017
VL 23
BP 889
EP 899
PG 11
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA FQ1CC
UT WOS:000418092700001
PM 29259394
DA 2022-11-30
ER

PT J
AU Ebneter, A
   Gekkiev, B
   Chanana, B
   Wolf, S
   Zinkernagel, MS
AF Ebneter, Andreas
   Gekkiev, Boris
   Chanana, Bhuvan
   Wolf, Sebastian
   Zinkernagel, Martin S.
TI The Presence of Intra- or Subretinal Fluid during the Loading Phase in
   the Treatment of Exudative Age-Related Macular Degeneration with
   Intravitreal Ranibizumab Assessed by Optical Coherence Tomography
SO OPHTHALMOLOGICA
LA English
DT Article
DE Exudative age-related macular degeneration; Anti-vascular endothelial
   growth factor; Spectral-domain optical coherence tomography; Retinal
   fluid; Scan protocol
ID CONSENSUS
AB Purpose: To assess intra- and subretinal fluid during the loading phase with intravitreal ranibizumab in exudative age-related macular degeneration and to quantify the accuracy of crosshair scan spectral-domain optical coherence tomography with regard to retinal fluid. Methods: This is a retrospective study of 31 treatment-naive patients who received 3 monthly intravitreal ranibizumab injections. Visual acuity and the presence of retinal fluid were assessed at each visit using volume and crosshair scan protocols. Results: Visual acuity improved and central retinal thickness decreased significantly during the loading phase. However, retinal fluid persisted in two thirds of the patients. The accuracy of the crosshair scan to detect fluid was 93%. Conclusions: A substantial proportion of eyes had persistent fluid after 3 months of ranibizumab injections. However, visual improvement was independent of residual fluid. Message: Cross-hair scans detect relevant collections of retinal fluid accurately and may be sufficient in daily clinical practice. (C) 2015 S. Karger AG, Basel
C1 [Ebneter, Andreas; Gekkiev, Boris; Chanana, Bhuvan; Wolf, Sebastian; Zinkernagel, Martin S.] Univ Bern, Inselspital, Dept Ophthalmol, CH-3010 Bern, Switzerland.
   [Chanana, Bhuvan] Univ Coll Med Sci, Dept Ophthalmol, Delhi 110095, India.
C3 University of Bern; University Hospital of Bern; University of Delhi;
   University College of Medical Sciences
RP Ebneter, A (通讯作者)，Inselspital Bern, Univ Klin Augenheilkunde, CH-3010 Bern, Switzerland.
EM ebneter.andreas@gmail.com
RI Ebneter, Andreas/C-5226-2017; Wolf, Sebastian/B-8782-2008; Zinkernagel,
   Martin/C-3799-2017
OI Ebneter, Andreas/0000-0001-6666-2558; Wolf,
   Sebastian/0000-0002-7467-7028; Zinkernagel, Martin/0000-0002-5622-114X;
   Zinkernagel, Martin S./0000-0003-3447-2359
FU Bayer AG; Heidelberg Engineering; Optos plc
FX A.E.: lecture fees from Bayer AG; B.G.: none; B.C.: none; S.W.:
   consultant/advisor at and financial support from Heidelberg Engineering,
   consultant/advisor at Zeiss, consultant/advisor at Novartis AG,
   consultant/advisor at Bayer AG, and consultant/advisor at and financial
   support from Optos plc; M.S.Z.: financial support from Heidelberg
   Engineering, consultant/advisor at Novartis AG, and consultant/advisor
   at Bayer AG.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cruess AF, 2012, CAN J OPHTHALMOL, V47, P227, DOI 10.1016/j.jcjo.2012.03.007
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Koh A, 2011, SINGAP MED J, V52, P232
   Lally DR, 2012, CURR OPIN OPHTHALMOL, V23, P182, DOI 10.1097/ICU.0b013e328352411c
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Veritti D, 2012, OPHTHALMOLOGICA, V227, P11, DOI 10.1159/000337154
NR 11
TC 6
Z9 7
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2015
VL 234
IS 2
BP 61
EP 66
DI 10.1159/000430103
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CR9NR
UT WOS:000361684200001
PM 25998752
OA Green Published
DA 2022-11-30
ER

PT J
AU Grunwald, JE
   Pistilli, M
   Ying, GS
   Maguire, MG
   Daniel, E
   Martin, DF
AF Grunwald, Juan E.
   Pistilli, Maxwell
   Ying, Gui-shuang
   Maguire, Maureen G.
   Daniel, Ebenezer
   Martin, Daniel F.
CA Comparison Age Related Macular Deg
TI Growth of Geographic Atrophy in the Comparison of Age-related Macular
   Degeneration Treatments Trials
SO OPHTHALMOLOGY
LA English
DT Article
ID PIGMENT EPITHELIAL ATROPHY; PROGRESSION; RANIBIZUMAB; BEVACIZUMAB; RISK;
   SUSCEPTIBILITY; DISEASE; ARMS2; RPE; CFH
AB Purpose: To evaluate the growth of geographic atrophy (GA) during anti-vascular endothelial growth factor (VEGF) therapy.
   Design: Cohort within a clinical trial.
   Participants: Patients included in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).
   Methods: Participants were randomly assigned to injections of ranibizumab or bevacizumab and to a 2-year dosing regimen of monthly or pro re nata (PRN) or to monthly for 1 year and PRN the following year. Digital color photographs and fluorescein angiograms at baseline and 1 and 2 years were evaluated for GA, and the total area of GA was measured by 2 graders masked to treatment; differences were adjudicated. Multivariate linear mixed models of the annual change in the square root of the area included baseline demographic, treatment, and ocular characteristics on imaging as candidate risk factors.
   Main Outcome Measures: Geographic atrophy growth rate.
   Results: Among 1185 participants, 86 (7.3%) had GA at baseline, 120 (10.1%) developed GA during year 1, and 36 (3.0%) developed GA during year 2. Among 194 eyes evaluable for growth, the rate was 0.43 mm/yr (standard error [SE], +/- 0.03 mm/year). In multivariate analysis, the growth rate was 0.37 mm/year in eyes receiving bevacizumab and 0.49 mm/year in eyes receiving ranibizumab (difference, 0.11 mm/yr; 95% confidence interval [CI], 0.01-0.22; P = 0.03). Growth rate did not differ between eyes treated monthly and PRN (P = 0.85). Eyes with subfoveal choroidal neovascularization (CNV) lesions had a lower growth rate than eyes with nonsubfoveal CNV lesions (difference, 0.12; 95% CI, 0.01-0.22; P = 0.03). Eyes with GA farther from the fovea had higher growth rates by 0.14 (95% CI, 0.01-27) mm/year for every millimeter farther from the fovea. The growth rate was 0.58 mm/year for eyes with predominantly classic lesions, 0.41 mm/year for eyes with minimally classic lesions, and 0.30 mm/year for eyes with occult only lesions (P < 0.01). The growth rate in eyes having a fellow eye with GA was higher by 0.13 mm/year (95% CI, 0.01-0.24; P = 0.03) than in eyes without GA in the fellow eye. Eyes with epiretinal membrane had a higher growth rate than eyes without epiretinal membrane (difference, 0.16; 95% CI, 0.03-0.30; P = 0.02).
   Conclusions: Geographic atrophy growth depends on several ocular factors. Ranibizumab may accelerate GA growth. (C) 2015 by the American Academy of Ophthalmology.
C1 [Grunwald, Juan E.; Pistilli, Maxwell; Ying, Gui-shuang; Maguire, Maureen G.; Daniel, Ebenezer] Univ Penn, Perelman Sch Med, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Martin, Daniel F.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; Cleveland Clinic
   Foundation
RP Grunwald, JE (通讯作者)，Univ Penn, Dept Ophthalmol, 51 North 39th St, Philadelphia, PA 19104 USA.
EM juangrun@mail.med.upenn.edu
FU National Eye Institute, National Institutes of Health, Department of
   Health and Human Services [U10 EY017823, U10 EY017825, U10 EY017826, U10
   EY017828]; NATIONAL EYE INSTITUTE [U10EY017823, U10EY017828,
   U10EY017826] Funding Source: NIH RePORTER
FX Supported by cooperative agreements U10 EY017823, U10 EY017825, U10
   EY017826, and U10 EY017828 from the National Eye Institute, National
   Institutes of Health, Department of Health and Human Services.
   www.clinicaltrials.gov identifier, NCT00593450.
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Caire J, 2014, JAMA OPHTHALMOL, V132, P528, DOI 10.1001/jamaophthalmol.2013.8175
   DeCroos FC, 2012, OPHTHALMOLOGY, V119, P2549, DOI 10.1016/j.ophtha.2012.06.040
   Domalpally A, 2013, OPHTHALMOLOGY, V120, P2666, DOI 10.1016/j.ophtha.2013.07.047
   Feuer WJ, 2013, JAMA OPHTHALMOL, V131, P110, DOI 10.1001/jamaophthalmol.2013.572
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Joachim N, 2013, OPHTHALMOLOGY, V120, P2042, DOI 10.1016/j.ophtha.2013.03.029
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mauschitz MM, 2012, INVEST OPHTH VIS SCI, V53, P4932, DOI 10.1167/iovs.12-9711
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Rasband W., 2015, IMAGEJ
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
NR 30
TC 157
Z9 161
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2015
VL 122
IS 4
BP 809
EP 816
DI 10.1016/j.ophtha.2014.11.007
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CE3EX
UT WOS:000351710100029
PM 25542520
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Li, XX
   Chen, YX
   Zhang, JJ
   Xu, X
   Zhang, F
   Cheung, CMG
   Yu, R
   Kazmi, H
   Sowade, O
   Zeitz, O
AF Li, Xiaoxin
   Chen, Youxin
   Zhang, Junjun
   Xu, Xun
   Zhang, Feng
   Cheung, Chui Ming Gemmy
   Yu, Rui
   Kazmi, Husain
   Sowade, Olaf
   Zeitz, Oliver
CA SIGHT Study Grp
TI Intravitreal Aflibercept Versus Photodynamic Therapy in Chinese Patients
   with Neovascular Age-Related Macular Degeneration: Outcomes of the SIGHT
   Study
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
DE intravitreal aflibercept; SIGHT; neovascular age-related macular
   degeneration; photodynamic therapy
ID VERTEPORFIN; RANIBIZUMAB; ANCHOR; VEGF
AB Purpose: SIGHT compared intravitreal aflibercept injections (IAI) with photodynamic therapy (PDT) in Chinese patients with predominantly classic choroidal neovascularization (CNV) secondary to neovascular age-related macular degeneration (nAMD).
   Methods: Patients were randomized 3:1 to IAI (2 mg every 8 weeks after 3 initial monthly injections)/sham PDT or active PDT/sham IAI (with switch to IAI at week 28). We report the primary outcome (mean change in best-corrected visual acuity [BCVA] at week 28) and final 52-week outcomes.
   Results: Patients were randomized to IAI (n = 228) or PDT (n = 76) (mean age: 65.1 years). Mean BCVA change was +14.0 (IAI) versus +3.9 letters (PDT -> IAI) (week 28) and +15.2 versus +8.9 letters (between-group difference: 6.2 letters; P = 0.0009) (week 52); mean reduction in central retinal thickness was -189.6 versus -170.0 mu m (week 52). The greatest improvements in BCVA with IAI were in youngest patients (<65 years), and in those with a smaller active component of the CNV lesion (<50% of lesion size). The most common ocular treatment-emergent adverse events (study eye; IAI vs. PDT -> IAI) were macular fibrosis (11.8% vs. 6.6%) and visual acuity reduced (6.6% vs. 21.1%). Three treatment-emergent Antiplatelet Trialists' Collaboration-defined arterial thromboembolic events were observed but none was considered drug related.
   Conclusions: IAI demonstrated superiority over PDT in Chinese nAMD patients. The benefits of IAI were maintained through week 52 in all patients, including subgroups, and in patients who switched from PDT to IAI. The incidence of adverse events was consistent with the known safety profile of IAI.
C1 [Li, Xiaoxin] Peking Univ, Peoples Hosp, Peoples Eye Ctr, Dept Ophthalmol, 11 Xizhimen South St, Beijing 100044, Peoples R China.
   [Chen, Youxin] Peking Union Med Colleague Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Zhang, Junjun] Sichuan Univ, West China Hosp, West China Sch Med, Dept Ophthalmol, Chengdu, Peoples R China.
   [Xu, Xun] Shanghai Gen Hosp, Dept Ophthalmol, Shanghai, Peoples R China.
   [Zhang, Feng] CMU, Beijing Tongren Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Cheung, Chui Ming Gemmy] Singapore Eye Res Inst, Dept Ophthalmol, Singapore, Singapore.
   [Yu, Rui] Bayer US, Dept Ophthalmol, Whippany, NY USA.
   [Kazmi, Husain] Regeneron Pharmaceut Inc, Ophthalmol, Tarrytown, NY 10591 USA.
   [Sowade, Olaf; Zeitz, Oliver] Bayer AG, Dev, Pharmaceut, Berlin, Germany.
C3 Peking University; Chinese Academy of Medical Sciences - Peking Union
   Medical College; Peking Union Medical College Hospital; Sichuan
   University; Capital Medical University; National University of
   Singapore; Singapore National Eye Center; Regeneron; Bayer AG
RP Li, XX (通讯作者)，Peking Univ, Peoples Hosp, Peoples Eye Ctr, Dept Ophthalmol, 11 Xizhimen South St, Beijing 100044, Peoples R China.
EM dr_lixiaoxin@163.com
RI Zeitz, Oliver/AAJ-9728-2021
OI Cheung, Chui Ming Gemmy/0000-0003-3358-3516
FU Bayer Pharmaceuticals
FX The following investigators were members of the SIGHT study group in
   China: Xiaoxin Li, People's Eye Center, Peking University People's
   Hospital, Beijing, China. Youxin Chen, Peking Union Medical Colleague
   Hospital, Beijing, China. Junjun Zhang, West China School of
   Medicine/West China Hospital, Sichuan University, Chengdu, China. Xun
   Xu, Shanghai General Hospital, Shanghai, China. Feng Zhang, Beijing
   Tongren Hospital, Beijing, China. Zhizhong Ma, Peking University Third
   Hospital, Beijing, China. Gezhi Xu, Eye and ENT Hospital of Fudan
   University, Shanghai, China. Xiaoling Liu, The Affiliated Eye Hospital
   of Wenzhou Medical College, Zhejiang, China. Changxian Yi, Zhongshan
   Ophthalmic Center, Guangdong, China. Yusheng Wang, Xijing Hospital,
   Xi'an, China. Ke Yao, Zhejiang, China. Luosheng Tang, Hunan, China.
   Haifeng Xu, Qingdao Eye Hospital, Qingdao, China. Xiaorong Li, Tianjin,
   China. Medical writing assistance was provided by PAREXEL and was funded
   by Bayer Pharmaceuticals. The study was funded by Bayer Pharmaceuticals.
   The sponsor or funding organization participated in the design and
   conduct of the study, data collection, data management, data analysis,
   interpretation of the data, and preparation of article.
CR Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown D. M, 2006, INVEST OPHTH VIS SCI, V47, P2963
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chen You-xin, 2007, Zhonghua Yan Ke Za Zhi, V43, P198
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Sivaprasad S, 2006, EYE, V20, P43, DOI 10.1038/sj.eye.6701787
   Suner IJ, 2009, INVEST OPHTH VIS SCI, V50, P3629, DOI 10.1167/iovs.08-3225
   Wong T. Y, 2014, WORLD OPHTH C TOK JA
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yoon JU, 2010, RETINA-J RET VIT DIS, V30, P418, DOI 10.1097/IAE.0b013e3181bd2fe4
NR 14
TC 4
Z9 4
U1 0
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD JUL-AUG
PY 2017
VL 33
IS 6
BP 435
EP 444
DI 10.1089/jop.2016.0071
PG 10
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA EZ8NM
UT WOS:000404983300003
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Toth, LA
   Stevenson, M
   Chakravarthy, U
AF Toth, Levente A.
   Stevenson, Michael
   Chakravarthy, Usha
TI ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR
   AGE-RELATED MACULAR DEGENERATION Outcomes in Eyes With Poor Initial
   Vision
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; predictors of visual outcome;
   inhibition of vascular endothelial growth factor
ID SUBGROUP ANALYSIS; RANIBIZUMAB; MARINA; BEVACIZUMAB
AB Purpose:To assess the effect of anti-vascular endothelial growth factor treatment on visual acuity outcome in patients with neovascular age-related macular degeneration presenting with very low vision.Methods:Retrospective analysis of electronic patient care record of 420 eyes treated with ranibizumab between March 2010 and June 2013. The authors classified the extracted sample into 3 categories based on the initial best-corrected visual acuity (BCVA) as measured on the Early Treatment Diabetic Retinopathy Study charts: 0 to 35 letters, 36 to 69 letters, and 70 letters. Best BCVA achieved in Year 1, and average BCVA over 36 months was computed. The neovascular lesion type, area of lesion, the presence or absence of hemorrhage, retinal pigment epithelium tear, and atrophy were systematically graded as was extent of fibrosis on a categorical scale of 0 to 4. Regression analysis was performed with the best BCVA achieved in Year 1 as the outcome variable and initial BCVA, person, and lesion characteristics as explanatory variables.Results:The mean change in BCVA from the initial visit to the best-attained BCVA during Year 1 was highly statistically significant with an improvement of 9.95 letters. The improvement from initial BCVA to average BCVA over 36 months was 4.01 letters. Regression analysis identified atrophy and fibrosis as predictors of best BCVA, with the model having an r(2) of 0.71.Conclusion:Our study supports the use of anti-vascular endothelial growth factor agents even in eyes with low visual acuity particularly when fibrosis and atrophy are absent and suggests algorithms to predict outcome for combinations of visual acuity and lesion characteristics across the full visual acuity range.
C1 [Toth, Levente A.; Chakravarthy, Usha] Belfast Hlth & Social Care Trust, Ophthalmol Serv Directorate, Belfast, Antrim, North Ireland.
   [Toth, Levente A.; Stevenson, Michael; Chakravarthy, Usha] Queens Univ Belfast, Sch Med Dent & Biomed Sci, Ctr Med Expt, Belfast BT12 6BA, Antrim, North Ireland.
C3 Queens University Belfast
RP Chakravarthy, U (通讯作者)，Queens Univ Belfast, Inst Clin Sci, Ctr Expt Med Dent & Biomed Sci, Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland.
EM U.chakravarthy@qub.ac.uk
OI Chakravarthy, Usha/0000-0002-2606-3734
FU Bayer; Novartis
FX L. A. Toth: Conference attendance, travel grants from Bayer. U.
   Chakravarthy: Grants to employing institution from Novartis and Bayer.
   Attendance at advisory boards, Bayer, Roche, Genentech and Alimera
   Sciences. M. Stevenson has no financial/conflicting interests to
   disclose.
CR [Anonymous], 2008, NICE TECHNOLOGY APPR
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Filho CADG, 2013, OPHTHAL SURG LAS IM, V44, P204, DOI 10.3928/23258160-20130313-12
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2011, CURR MED RES OPIN, V27, P1465, DOI 10.1185/03007995.2011.585394
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Stevenson MR, 2004, BRIT J OPHTHALMOL, V88, P1125, DOI 10.1136/bjo.2003.032383
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 21
TC 13
Z9 13
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2015
VL 35
IS 10
BP 1957
EP 1963
DI 10.1097/IAE.0000000000000583
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CS6US
UT WOS:000362219000005
PM 25946692
DA 2022-11-30
ER

PT J
AU Liakopoulos, S
   Spital, G
   Brinkmann, CK
   Schick, T
   Ziemssen, F
   Voegeler, J
   Koch, M
   Kirchhof, B
   Holz, FG
   Pauleikhoff, D
   Schmitz-Valckenberg, S
AF Liakopoulos, Sandra
   Spital, Georg
   Brinkmann, Christian K.
   Schick, Tina
   Ziemssen, Focke
   Voegeler, Jessica
   Koch, Mirja
   Kirchhof, Bernd
   Holz, Frank G.
   Pauleikhoff, Daniel
   Schmitz-Valckenberg, Steffen
TI ORCA study: real-world versus reading centre assessment of disease
   activity of neovascular age-related macular degeneration (nAMD)
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE macula; neovascularisation; retina
ID VISUAL-ACUITY; RANIBIZUMAB; THERAPY; VERTEPORFIN; EFFICACY; SAFETY
AB Background/aims The prospective, non-interventional ORCA module of the OCEAN study (Observation of Treatment Patterns with Lucentis in Approved Indications) evaluated the qualiy of spectral domain-optical coherence tomography (SD-OCT) image interpretation and treatment decisions by clinicians in Germany and the impact on visual outcomes over 24 months in patients with neovascular age-related macular degeneration (nAMD).
   Methods 2286 SD-OCT scans of 205 eyes were independently evaluated by clinicians and reading centres (RCs) regarding signs of choroidal neovascularisation (CNV) activity, including presence of intraretinal fluid, subretinal fluid, and/or increase in pigment epithelial detachments. Agreement between clinicians and RCs was calculated. Treatment decisions by clinicians and the impact on treatment outcomes were evaluated.
   Results CNV activity was detected by RCs on 1578 scans (69.0%) and by clinicians on 1392 scans (60.9%), with agreement in 74.9% of cases. Of the 1578 scans with RC detected CNV activity, anti-vascular endothelial growth factor injections were performed by clinicians in only 35.5% (560/1578). In 19.7% of cases (311/1578), lack of treatment was justified by patients request, termination criteria or chronic cystoid spaces without other signs for CNV activity. In 44.8% of cases (707/1578) with RC detected CNV activity, clinicians claimed no treatment was necessary despite having correctly detected CNV activity in about 2/3 of these cases. In 34% of cases with presumed undertreatment, visual acuity declined in the following visit.
   Conclusion Although broad agreement on CNV activity parameters was observed between clinicians and RCs, correct identification of CNV activity did not always lead to the initiation of (re-)treatment. To preserve vision over time, correct interpretation of SD-OCT scans and careful retreatment decisions are required.
C1 [Liakopoulos, Sandra; Kirchhof, Bernd] Univ Cologne, Fac Med, Dept Ophthalmol, Cologne, Germany.
   [Liakopoulos, Sandra; Kirchhof, Bernd] Univ Hosp Cologne, Cologne, Germany.
   [Spital, Georg] St Franziskus Hosp Muenster, Eye Ctr, M3 Reading Ctr, Munster, Germany.
   [Brinkmann, Christian K.; Holz, Frank G.; Schmitz-Valckenberg, Steffen] Rhein Friedrich Wilhelms Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Schick, Tina] Univ Cologne, Ophthalmol, Cologne, Germany.
   [Ziemssen, Focke] Eberhard Karl Univ Tuebingen, Dept Ophthalmol, Tubingen, Germany.
   [Voegeler, Jessica; Koch, Mirja] Novartis Pharma GmbH, Nurnberg, Germany.
   [Pauleikhoff, Daniel] St Franzikus Hosp, Dept Ophthalmol, Munster, Germany.
C3 University of Cologne; University of Cologne; St. Franziskus-Hospital;
   University of Bonn; University of Cologne; Eberhard Karls University of
   Tubingen; Eberhard Karls University Hospital; Novartis; St.
   Franziskus-Hospital
RP Liakopoulos, S (通讯作者)，Univ Cologne, Dept Ophthalmol, D-50924 Cologne, Germany.
EM sandra.liakopoulos@uk-koeln.de
RI Ziemssen, Focke/AAY-1686-2021
FU Novartis Pharma GmbH, Nuremberg, Germany
FX This study was developed and funded by Novartis Pharma GmbH, Nuremberg,
   Germany.
CR Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Berens P, 2019, NATURE, V565, P429, DOI 10.1038/d41586-019-00231-9
   Berufsverband der Augenarzte Deutschlands e. V Deutsche Ophthalmologische Gesellschaft Retinologische Gesellschaft, 2018, KLIN MONBL AUGENHEIL, V235
   Brinkmann CK, 2019, OPHTHALMOLOGE, V116, P753, DOI 10.1007/s00347-018-0805-y
   Brinkmann CK, 2018, OPHTHALMOLOGE
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2016, OPHTHALMOLOGY, V123, P1731, DOI 10.1016/j.ophtha.2016.04.005
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Heimes B, 2016, OPHTHALMOLOGE, V113, P570, DOI 10.1007/s00347-016-0224-x
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Korb CA, 2014, GRAEF ARCH CLIN EXP, V252, P1403, DOI 10.1007/s00417-014-2591-9
   Krause L, 2013, CURR MED RES OPIN, V29, P1391, DOI 10.1185/03007995.2013.832184
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P259, DOI 10.1007/s00417-017-3850-3
   Ziemssen F, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0401-y
   Ziemssen F, 2016, OPHTHALMOLOGE, V113, P143, DOI 10.1007/s00347-015-0099-2
   Ziemssen F, 2015, OPHTHALMOLOGE, V112, P246, DOI 10.1007/s00347-014-3217-7
NR 24
TC 4
Z9 4
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD NOV
PY 2020
VL 104
IS 11
BP 1573
EP 1578
DI 10.1136/bjophthalmol-2019-315717
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OJ5CN
UT WOS:000583979400005
PM 32066561
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Kersten, E
   Dammeier, S
   Ajana, S
   Groenewoud, JMM
   Codrea, M
   Klose, F
   Lechanteur, YT
   Fauser, S
   Ueffing, M
   Delcourt, C
   Hoyng, CB
   de Jong, EK
   den Hollander, AI
   Arango-Gonzalez, B
   Arndt, V
   Bhatia, V
   Bhattacharya, SS
   Biarnes, M
   Borrell, A
   Buhren, S
   Calado, SM
   Colijn, JM
   Cougnard-Gregoire, A
   de Jong, E
   De la Cerda, B
   Diaz-Corrales, FJ
   Diether, S
   Emri, E
   Endermann, T
   Ferraro, L
   Garcia, M
   Heesterbeek, TJ
   Honisch, S
   Iacone, R
   Kilger, E
   Klaver, CCW
   Langen, H
   Lengyel, I
   Luthert, P
   Maugeais, C
   Meester-Smoor, M
   Merle, B
   Mones, J
   Nogoceke, E
   Peto, T
   Pool, F
   Rodriguez, E
   Bartz-Schmidt, KU
   van Leeuwen, EM
   Verzijden, T
   Zumbansen, M
AF Kersten, Eveline
   Dammeier, Sascha
   Ajana, Soufiane
   Groenewoud, Joannes M. M.
   Codrea, Marius
   Klose, Franziska
   Lechanteur, Yara T.
   Fauser, Sascha
   Ueffing, Marius
   Delcourt, Cecile
   Hoyng, Carel B.
   de Jong, Eiko K.
   den Hollander, Anneke I.
   Arango-Gonzalez, Blanca
   Arndt, Verena
   Bhatia, Vaibhav
   Bhattacharya, Shomi S.
   Biarnes, Marc
   Borrell, Anna
   Buhren, Sebastian
   Calado, Sofia M.
   Colijn, Johanna M.
   Cougnard-Gregoire, Audrey
   de Jong, Eiko
   De la Cerda, Berta
   Diaz-Corrales, F. J.
   Diether, Sigrid
   Emri, Eszter
   Endermann, Tanja
   Ferraro, Lucia
   Garcia, Miriam
   Heesterbeek, Thomas J.
   Honisch, Sabina
   Iacone, Roberto
   Kilger, Ellen
   Klaver, Caroline C. W.
   Langen, Hanno
   Lengyel, Imre
   Luthert, Phil
   Maugeais, Cyrille
   Meester-Smoor, Magda
   Merle, Benedicte
   Mones, Jordi
   Nogoceke, Everson
   Peto, Tunde
   Pool, Fran
   Rodriguez, Eduardo
   Bartz-Schmidt, Karl Ulrich
   van Leeuwen, Elisabeth M.
   Verzijden, Timo
   Zumbansen, Markus
CA Eye-Risk Consortium
TI Metabolomics in serum of patients with non-advanced age-related macular
   degeneration reveals aberrations in the glutamine pathway
SO PLOS ONE
LA English
DT Article
ID SYSTEMIC COMPLEMENT ACTIVATION; PREVALENCE
AB Age-related macular degeneration (AMD) is a common, progressive multifactorial vision-threatening disease and many genetic and environmental risk factors have been identified. The risk of AMD is influenced by lifestyle and diet, which may be reflected by an altered metabolic profile. Therefore, measurements of metabolites could identify biomarkers for AMD, and could aid in identifying high-risk individuals. Hypothesis-free technologies such as metabolomics have a great potential to uncover biomarkers or pathways that contribute to disease pathophysiology. To date, only a limited number of metabolomic studies have been performed in AMD. Here, we aim to contribute to the discovery of novel biomarkers and metabolic pathways for AMD using a targeted metabolomics approach of 188 metabolites. This study focuses on non-advanced AMD, since there is a need for biomarkers for the early stages of disease before severe visual loss has occurred. Targeted metabolomics was performed in 72 patients with early or intermediate AMD and 72 control individuals, and metabolites predictive for AMD were identified by a sparse partial least squares discriminant analysis. In our cohort, we identified four metabolite variables that were most predictive for early and intermediate stages of AMD. Increased glutamine and phosphatidylcholine diacyl C28:1 levels were detected in non-advanced AMD cases compared to controls, while the rate of glutaminolysis and the glutamine to glutamate ratio were reduced in non-advanced AMD. The association of glutamine with non-advanced AMD corroborates a recent report demonstrating an elevated glutamine level in early AMD using a different metabolomics technique. In conclusion, this study indicates that metabolomics is a suitable method for the discovery of biomarker candidates for AMD. In the future, larger metabolomics studies could add to the discovery of novel biomarkers in yet unknown AMD pathways and expand our insights in AMD pathophysiology.
C1 [Kersten, Eveline; Lechanteur, Yara T.; Hoyng, Carel B.; de Jong, Eiko K.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Nijmegen, Netherlands.
   [Dammeier, Sascha; Klose, Franziska; Ueffing, Marius] Univ Tubingen, Core Facil Med Bioanalyt, Inst Ophthalm Res, Tubingen, Germany.
   [Ajana, Soufiane; Delcourt, Cecile] Univ Bordeaux, Bordeaux Populat Hlth Res Ctr, INSERM, LEHA Team,UMR 1219, Bordeaux, France.
   [Groenewoud, Joannes M. M.] Radboud Univ Nijmegen, Med Ctr, Dept Epidemiol Biostat & Hlth Technol Assessment, Nijmegen, Netherlands.
   [Codrea, Marius] Univ Tubingen, Quantitat Biol Ctr, Tubingen, Germany.
   [Fauser, Sascha] F Hoffmann La Roche & Cie AG, Basel, Switzerland.
   [Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Human Genet, Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Eberhard Karls University of Tubingen;
   Eberhard Karls University Hospital; Institut National de la Sante et de
   la Recherche Medicale (Inserm); UDICE-French Research Universities;
   Universite de Bordeaux; Radboud University Nijmegen; Eberhard Karls
   University of Tubingen; Roche Holding; University of Cologne; Radboud
   University Nijmegen
RP den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Nijmegen, Netherlands.; den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Human Genet, Nijmegen, Netherlands.
EM Anneke.denhollander@radboudumc.nl
RI Calado, Sofia M./K-2202-2016; Lehtimäki, Terho/AAD-1094-2022;
   COUGNARD-GREGOIRE, Audrey/T-4443-2019; Delcourt, Cecile/I-2627-2013;
   Merle, Benedicte MJ/F-1247-2015; Ajana, Soufiane/AAH-5181-2021;
   Lechanteur, Yara/ABB-6875-2020; Arango-Gonzalez, Blanca/AAR-7427-2021;
   Kersten, Eveline/P-8173-2015; Groenewoud, Hans JMM/R-3588-2017; Lengyel,
   Imre/B-5217-2009
OI Calado, Sofia M./0000-0001-5509-4145; Lehtimäki,
   Terho/0000-0002-2555-4427; COUGNARD-GREGOIRE,
   Audrey/0000-0002-1494-5764; Delcourt, Cecile/0000-0002-2099-0481; Merle,
   Benedicte MJ/0000-0003-1332-0954; Lechanteur, Yara/0000-0003-0951-4625;
   Arango-Gonzalez, Blanca/0000-0002-9045-182X; Groenewoud, Hans
   JMM/0000-0002-4974-150X; Lengyel, Imre/0000-0001-7467-2174; Mones,
   Jordi/0000-0003-3685-2160
FU European Union's Horizon 2020 research and innovation programme [634479]
FX This project has received funding from the European Union's Horizon 2020
   research and innovation programme under grant agreement No. 634479
   (EYE-RISK). La Roche AG provided support in the form of salary for S.F.,
   but did not have any additional role in the study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript. The specific roles of S.F. are articulated in the 'author
   contributions' section.
CR Aledo JC, 2004, BIOESSAYS, V26, P778, DOI 10.1002/bies.20063
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Calder PC, 1999, AMINO ACIDS, V17, P227, DOI 10.1007/BF01366922
   Camelo S, 2014, AUTOIMMUN DIS, V2014, DOI 10.1155/2014/532487
   Cao KAL, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-253
   Carayol M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135437
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cheung CMG, 2017, J LIPID RES, V58, P1785, DOI 10.1194/jlr.M073684
   Cole LK, 2012, BBA-MOL CELL BIOL L, V1821, P754, DOI 10.1016/j.bbalip.2011.09.009
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Eandi CM, 2016, EUR J PHARMACOL, V787, P78, DOI 10.1016/j.ejphar.2016.03.002
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Ghanizadeh A, 2013, DIS MARKERS, V2013, DOI 10.1155/2013/536521
   Hastie T., 2009, ELEMENTS STAT LEARNI, V2
   Jove M, 2014, FASEB J, V28, P5163, DOI 10.1096/fj.14-253187
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Kohler I, 2017, EUR J PHARM SCI, V109, pS15, DOI 10.1016/j.ejps.2017.05.018
   Kosmides Alyssa K., 2013, Critical Reviews in Biomedical Engineering, V41, P205
   Lains I, 2019, PROG RETIN EYE RES, V69, P57, DOI 10.1016/j.preteyeres.2018.11.002
   Lains I, 2018, OPHTHALMOLOGY, V125, P245, DOI 10.1016/j.ophtha.2017.08.008
   Lains I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177749
   Lauwen S, 2017, INVEST OPHTH VIS SCI, V58, pBIO88, DOI 10.1167/iovs.17-21809
   Leibowitz A, 2012, INT J MOL SCI, V13, P10041, DOI 10.3390/ijms130810041
   Luo D, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0555-7
   Ma DWL, 2016, NUTR DIABETES, V6, DOI 10.1038/nutd.2016.27
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Osborn MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072737
   Ozerova IN, 2007, B EXP BIOL MED+, V143, P320, DOI 10.1007/s10517-007-0100-4
   Paun CC, 2015, INVEST OPHTH VIS SCI, V56, P7766, DOI 10.1167/iovs.15-17035
   Ristau T, 2014, INVEST OPHTH VIS SCI, V55, P210, DOI 10.1167/iovs.13-13248
   Rodriguez-Cuenca S, 2017, PROG LIPID RES, V66, P14, DOI 10.1016/j.plipres.2017.01.002
   Saunier V, 2018, JAMA OPHTHALMOL, V136, P473, DOI 10.1001/jamaophthalmol.2018.0504
   Sheldon AL, 2007, NEUROCHEM INT, V51, P333, DOI 10.1016/j.neuint.2007.03.012
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Wang YF, 2016, NUTRIENTS, V8, DOI 10.3390/nu8100663
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 39
TC 13
Z9 13
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 20
PY 2019
VL 14
IS 6
AR e0218457
DI 10.1371/journal.pone.0218457
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA IW3PH
UT WOS:000484893500051
PM 31220133
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Chen, FK
   Patel, PJ
   Coffey, PJ
   Tufail, A
   Da Cruz, L
AF Chen, Fred K.
   Patel, Praveen J.
   Coffey, Peter J.
   Tufail, Adnan
   Da Cruz, Lyndon
TI Increased Fundus Autofluorescence Associated with Outer Segment
   Shortening in Macular Translocation Model of Neovascular Age-Related
   Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL NEOVASCULARIZATION; 360-DEGREES
   RETINOTOMY; SURGERY; PIGMENT; EDEMA; EYES
AB PURPOSE. To report the frequency and origins of increased fundus autofluorescence (AF) in age-related macular degeneration using the model of macular translocation.
   METHODS. In this retrospective observational case series, postoperative serial fundus AF images from 40 consecutive patients were examined. The origin of well-delineated increased AF changes was explored by examining simultaneous spectraldomain optical coherence tomography (SD-OCT) scans and coregistered microperimetry.
   RESULTS. AF images were taken between a mean of 13 and 36 months. Seven patients were excluded from analysis because of lack of postoperative AF imaging or extensive macular RPE atrophy. Of the remaining patients, 9 had masking pattern of foveal AF, 21 had small, round increased AF lesions in the fovea, and 3 had a near normal pattern of foveal hypo-AF. Parafoveal increased AF was seen in all 33 patients in 1 of 3 patterns: well-delineated homogenous increased AF patches (17), curvilinear increased AF bands (4), and speckled increased AF (12). Simultaneous SD-OCT showed loss of signal from the interface of the inner and outer segments of the photoreceptor cell layer with variable loss of outer nuclear layer thickness. Microperimetry showed subnormal retinal sensitivity in regions with increased AF. Parafoveal increased AF size remained stable for 2 to 5 years of follow-up.
   CONCLUSIONS. SD-OCT and microperimetry changes observed after translocation may be attributed to shortening of the outer segments. A corresponding reduction of visual pigment in the shortened outer segments may lead to an unmasking effect. Increased AF in some macular diseases may be attributed to unmasking of AF rather than to increased fluorophores within abnormal retina. (Invest Ophthalmol Vis Sci. 2010; 51: 4207-4212) DOI:10.1167/iovs.09-4728
C1 [Chen, Fred K.; Patel, Praveen J.; Tufail, Adnan] Moorfields Eye Hosp, Med Retina Serv, London EC1V 2PD, England.
   [Chen, Fred K.; Patel, Praveen J.; Coffey, Peter J.; Tufail, Adnan; Da Cruz, Lyndon] UCL, Inst Ophthalmol, London, England.
   [Chen, Fred K.; Patel, Praveen J.; Coffey, Peter J.; Tufail, Adnan; Da Cruz, Lyndon] Biomed Res Ctr Ophthalmol, Natl Inst Hlth Res, London, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   University of London; University College London
RP Chen, FK (通讯作者)，Moorfields Eye Hosp, Med Retina Serv, 162 City Rd, London EC1V 2PD, England.
EM fkchen02@yahoo.com
RI , Fred/B-8158-2013
OI , Fred/0000-0003-2809-9930; Coffey, Peter/0000-0002-5427-2939; Tufail,
   Adnan/0000-0001-6131-7640
FU London Project to Cure Blindness; MRC [G1000730] Funding Source: UKRI;
   Medical Research Council [G1000730] Funding Source: researchfish
FX Supported by the London Project to Cure Blindness.
CR Baffi J, 2000, INVEST OPHTH VIS SCI, V41, P3582
   Bessho K, 2009, GRAEF ARCH CLIN EXP, V247, P729, DOI 10.1007/s00417-008-1033-y
   Chieh JJ, 2008, RETINA-J RET VIT DIS, V28, P1522, DOI 10.1097/IAE.0b013e318186c634
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Drexler W, 2003, ARCH OPHTHALMOL-CHIC, V121, P695, DOI 10.1001/archopht.121.5.695
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Fang XY, 2004, AM J OPHTHALMOL, V137, P1034, DOI 10.1016/j.ajo.2004.01.013
   Fisher SK, 2005, PROG RETIN EYE RES, V24, P395, DOI 10.1016/j.preteyeres.2004.10.004
   Liang JZ, 1997, J OPT SOC AM A, V14, P2884, DOI 10.1364/JOSAA.14.002884
   Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9
   McBain VA, 2008, BRIT J OPHTHALMOL, V92, P946, DOI 10.1136/bjo.2007.129957
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   Sawa M, 2008, GRAEF ARCH CLIN EXP, V246, P1087, DOI 10.1007/s00417-008-0835-2
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Solbach U, 1997, RETINA-J RET VIT DIS, V17, P385
   Terasaki H, 2004, INVEST OPHTH VIS SCI, V45, P567, DOI 10.1167/iovs.03-0187
   Terasaki H, 2003, OPHTHALMOLOGY, V110, P2403, DOI 10.1016/S0161-6420(03)00829-7
   Theelen T, 2008, EXP EYE RES, V86, P296, DOI 10.1016/j.exer.2007.10.022
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Wakabayashi T, 2008, ACTA OPHTHALMOL, V86, P897, DOI 10.1111/j.1755-3768.2007.01163.x
NR 21
TC 8
Z9 9
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2010
VL 51
IS 8
BP 4207
EP 4212
DI 10.1167/iovs.09-4728
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 629JT
UT WOS:000280194100053
PM 20220058
DA 2022-11-30
ER

PT J
AU Yuan, XL
   Gu, XR
   Crabb, JS
   Yue, XZ
   Shadrach, K
   Hollyfield, JG
   Crabb, JW
AF Yuan, Xianglin
   Gu, Xiaorong
   Crabb, John S.
   Yue, Xiuzhen
   Shadrach, Karen
   Hollyfield, Joe G.
   Crabb, John W.
TI Quantitative Proteomics: Comparison of the Macular Bruch
   Membrane/Choroid Complex from Age-related Macular Degeneration and
   Normal Eyes
SO MOLECULAR & CELLULAR PROTEOMICS
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; GLYCATION END-PRODUCTS; OXIDATIVE DAMAGE;
   RAT RETINA; DRUSEN; BIOMARKERS; LIPOFUSCIN; PENTOSIDINE; NITRATION;
   IMMUNITY
AB A quantitative proteomics analysis of the macular Bruch membrane/choroid complex was pursued for insights into the molecular mechanisms of age-related macular degeneration (AMD). Protein in trephine samples from the macular region of 10 early/mid-stage dry AMD, six advanced dry AMD, eight wet AMD, and 25 normal control post-mortem eyes was analyzed by LC MS/MS iTRAQ ( isobaric tags for relative and absolute quantitation) technology. A total of 901 proteins was quantified, including 556 proteins from >= 3 AMD samples. Most proteins differed little in amount between AMD and control samples and therefore reflect the proteome of normal macular tissues of average age 81. A total of 56 proteins were found to be elevated and 43 were found to be reduced in AMD tissues relative to controls. Analysis by category of disease progression revealed up to 16 proteins elevated or decreased in each category. About 60% of the elevated proteins are involved in immune response and host defense, including many complement proteins and damage-associated molecular pattern proteins such as alpha-defensins 1-3, protein S100s, crystallins, histones, and galectin-3. Four retinoid processing proteins were elevated only in early/mid-stage AMD, supporting a role for retinoids in AMD initiation. Proteins uniquely decreased in early/mid-stage AMD implicate hematologic malfunctions and weakened extracellular matrix integrity and cellular interactions. Galectin-3, a receptor for advanced glycation end products, was the most significantly elevated protein in advanced dry AMD, supporting a role for advanced glycation end products in dry AMD progression. The results endorse inflammatory processes in both early and advanced AMD pathology, implicate different pathways of progression to advanced dry and wet AMD, and provide a new database for hypothesis-driven and discovery-based studies of AMD. Molecular & Cellular Proteomics 9:1031-1046, 2010.
C1 [Yuan, Xianglin; Gu, Xiaorong; Crabb, John S.; Yue, Xiuzhen; Shadrach, Karen; Hollyfield, Joe G.; Crabb, John W.] Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA.
   [Yuan, Xianglin; Gu, Xiaorong; Crabb, John S.; Yue, Xiuzhen; Shadrach, Karen; Hollyfield, Joe G.; Crabb, John W.] Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA.
   [Crabb, John W.] Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA.
   [Hollyfield, Joe G.; Crabb, John W.] Case Western Reserve Univ, Cleveland Clin, Dept Ophthalmol, Lerner Coll Med, Cleveland, OH 44106 USA.
   [Hollyfield, Joe G.; Crabb, John W.] Case Western Reserve Univ, Cleveland Clin, Dept Mol Med, Lerner Coll Med, Cleveland, OH 44106 USA.
C3 Cleveland Clinic Foundation; Cleveland Clinic Foundation; Case Western
   Reserve University; Case Western Reserve University; Cleveland Clinic
   Foundation; Case Western Reserve University; Cleveland Clinic Foundation
RP Crabb, JW (通讯作者)，Cleveland Clin Fdn I 31, Cole Eye Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM Crabbj@ccf.org
FU National Institutes of Health [EY14239, EY14240, EY15638]; Ohio
   Biomedical Research Technology [05-29]; Foundation Fighting Blindness;
   Llura and Gordon Gund Foundation; Research to Prevent Blindness (RPB);
   Steinbach; Genentech; Cleveland Clinic Foundation; NATIONAL EYE
   INSTITUTE [R56EY014240, R24EY015638, R01EY014239, R01EY014240] Funding
   Source: NIH RePORTER
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants EY14239, EY14240, and EY15638. This work was also
   supported by Ohio Biomedical Research Technology Transfer Grant 05-29, a
   research center grant from The Foundation Fighting Blindness, the Llura
   and Gordon Gund Foundation, a challenge grant from Research to Prevent
   Blindness (RPB), an RPB senior investigator award (to J. W. C.), a
   Steinbach award (to J. W. C.), Genentech, and The Cleveland Clinic
   Foundation.
CR Alcazar O, 2009, MOL CELL PROTEOMICS, V8, P2201, DOI 10.1074/mcp.M900203-MCP200
   An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Berrier AL, 2007, J CELL PHYSIOL, V213, P565, DOI 10.1002/jcp.21237
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Cheresh DA, 2008, ONCOGENE, V27, P6285, DOI 10.1038/onc.2008.304
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   DIXON WJ, 1953, BIOMETRICS, V9, P74, DOI 10.2307/3001634
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GOLDBERG MF, 1976, INVEST OPHTH VISUAL, V15, P443
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hammes HP, 1999, INVEST OPHTH VIS SCI, V40, P1855
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Knott AB, 2008, NAT REV NEUROSCI, V9, P505, DOI 10.1038/nrn2417
   Lotze MT, 2007, IMMUNOL REV, V220, P60, DOI 10.1111/j.1600-065X.2007.00579.x
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Marshall J., 1998, RETINAL PIGMENT EPIT, P669
   Miyagi M, 2002, MOL CELL PROTEOMICS, V1, P293, DOI 10.1074/mcp.M100034-MCP200
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nakata K, 2005, EXP EYE RES, V80, P821, DOI 10.1016/j.exer.2004.12.011
   Ng KP, 2008, MOL CELL PROTEOMICS, V7, P1397, DOI 10.1074/mcp.M700525-MCP200
   Ni JQ, 2009, MOL CELL PROTEOMICS, V8, P1921, DOI 10.1074/mcp.M900127-MCP200
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Okamoto T, 2002, MICROVASC RES, V63, P186, DOI 10.1006/mvre.2001.2371
   OLIVER C, 2007, SUBCELLULAR PROTEOMI, P99
   Pisetsky David S, 2007, Proc Am Thorac Soc, V4, P258, DOI 10.1513/pats.200701-027AW
   Pugliese G, 2001, FASEB J, V15, P2471, DOI 10.1096/fj.01-0006com
   *R DEV TEAM, 2008, R LANG ENV STAT COMP
   RORABACHER DB, 1991, ANAL CHEM, V63, P139, DOI 10.1021/ac00002a010
   Ross PL, 2004, MOL CELL PROTEOMICS, V3, P1154, DOI 10.1074/mcp.M400129-MCP200
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Saari JC, 2008, EYE RETINA VISUAL SY, P721
   Sakaguchi H, 2002, EXP EYE RES, V74, P547, DOI 10.1006/exer.2002.1186
   Sarthy VP, 1998, INVEST OPHTH VIS SCI, V39, P212
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Shen D, 2009, BRIT J OPHTHALMOL, V93, P405, DOI 10.1136/bjo.2008.145383
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Urban CF, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000639
   Vogel R, 2009, INVEST OPHTHALMOL VI, P50
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   West KA, 2003, MOL CELL PROTEOMICS, V2, P37, DOI 10.1074/mcp.D200001-MCP200
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
   Zhan XQ, 2008, MOL CELL PROTEOMICS, V7, P864, DOI 10.1074/mcp.M700417-MCP200
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 59
TC 106
Z9 118
U1 0
U2 11
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 1535-9476
J9 MOL CELL PROTEOMICS
JI Mol. Cell. Proteomics
PD JUN
PY 2010
VL 9
IS 6
BP 1031
EP 1046
DI 10.1074/mcp.M900523-MCP200
PG 16
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 618ZZ
UT WOS:000279396900001
PM 20177130
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Cho, HJ
   Lim, SH
   Kim, J
   Lee, J
   Lee, DW
   Kim, JW
AF Cho, Han Joo
   Lim, Soo Hyun
   Kim, Jaemin
   Lee, Jihyun
   Lee, Dong Won
   Kim, Jong Woo
TI Assessing the long-term evolution of type 3 neovascularization in
   age-related macular degeneration using optical coherence tomography
   angiography
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularization; Optical
   coherence tomography angiography; Retinal angiomatous proliferation;
   Type 3 neovascularization; Vascular endothelial growth factor
AB Purpose To analyze the evolution of type 3 neovascularization in eyes with age-related macular degeneration during anti-vascular endothelial growth factor (VEGF) treatment using optical coherence tomography angiography (OCTA) analysis. Methods Forty-one treatment-naive eyes (37 patients) with type 3 neovascularization were retrospectively included in the study. The growth and morphological changes in the type 3 lesions, which were recorded using OCTA, were compared across time. Results The high-flow signal of the lesion on OCTA was significantly increased at the sub-retinal pigment epithelium (RPE) and the choriocapillaris during anti-VEGF treatment. The detection rate of the flow signal in the sub-RPE increased from 50.0% at baseline and 51.2% at 12 months to 65.9% at 24 months (P = 0.013). The flow signal extending into the choriocapillaris was detected in 0% of the eyes at baseline, 9.8% of the eyes at 12 months, and 17.1% of the eyes at 24 months (P = 0.018). The presence of subretinal drusenoid deposits (SDD) was significantly more frequent in the group with extension into the choriocapillaris (100%) than in the group without (61.8%, P = 0.036). For the four eyes with extension into the choroid, the morphological feature of the lesion on en face OCTA evolved into a tangled vascular network, similar to type 1 neovascularization. Conclusion OCTA analysis revealed that type 3 neovascularization gradually extended downward toward the sub-RPE and choroid during anti-VEGF treatment. The extension of the lesion into the choriocapillaris, suggesting retinal-choroidal anastomosis, was significantly more frequent in eyes with SDD.
C1 [Cho, Han Joo; Lim, Soo Hyun; Kim, Jaemin; Lee, Jihyun; Lee, Dong Won; Kim, Jong Woo] Konyang Univ, Kims Eye Hosp, Coll Med, 156,4ga Yeongdeungpo Dong, Seoul, South Korea.
C3 Konyang University; Konyang University Hospital
RP Cho, HJ (通讯作者)，Konyang Univ, Kims Eye Hosp, Coll Med, 156,4ga Yeongdeungpo Dong, Seoul, South Korea.
EM chojoo@kimeye.com
OI Cho, Han Joo/0000-0001-7336-5762
CR Alten F, 2016, GRAEF ARCH CLIN EXP, V254, P2165, DOI 10.1007/s00417-016-3375-1
   Borrelli E, 2018, PROG RETIN EYE RES, V67, P30, DOI 10.1016/j.preteyeres.2018.07.002
   Campbell JP, 2017, SCI REP-UK, V7, DOI 10.1038/srep42201
   Campochiaro PA, 2012, GENE THER, V19, P121, DOI 10.1038/gt.2011.164
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Cho HJ, 2018, RETINA-J RET VIT DIS, V38, P2150, DOI 10.1097/IAE.0000000000001862
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Han JW, 2020, RETINA-J RET VIT DIS, V40, P1245, DOI 10.1097/IAE.0000000000002562
   Kim JH, 2018, RETINA-J RET VIT DIS, V38, P2356, DOI 10.1097/IAE.0000000000001876
   Kim JH, 2018, SEMIN OPHTHALMOL, V33, P820, DOI 10.1080/08820538.2018.1511814
   Kim JM, 2019, SEMIN OPHTHALMOL, V34, P168, DOI 10.1080/08820538.2019.1620791
   Kuehlewein L, 2015, RETINA-J RET VIT DIS, V35, P2229, DOI 10.1097/IAE.0000000000000835
   Lee JH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186272
   Li ML, 2018, OPHTHALMOLOGY, V125, P276, DOI 10.1016/j.ophtha.2017.08.019
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2236, DOI 10.1097/IAE.0000000000000834
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Pilotto E, 2019, BRIT J OPHTHALMOL, V103, P67, DOI 10.1136/bjophthalmol-2017-311752
   Querques G, 2015, RETINA-J RET VIT DIS, V35, P603, DOI 10.1097/IAE.0000000000000487
   Spaide RF, 2019, RETINA-J RET VIT DIS, V39, P1451, DOI 10.1097/IAE.0000000000002412
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Su D, 2016, RETINA-J RET VIT DIS, V36, pS40, DOI 10.1097/IAE.0000000000001268
   Tan ACS, 2017, RETINA-J RET VIT DIS, V37, P234, DOI 10.1097/IAE.0000000000001343
   Xu D, 2018, AM J OPHTHALMOL, V187, P10, DOI 10.1016/j.ajo.2017.12.005
NR 26
TC 1
Z9 1
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD SEP
PY 2021
VL 259
IS 9
BP 2605
EP 2613
DI 10.1007/s00417-021-05163-7
EA MAR 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UD4CF
UT WOS:000630997000004
PM 33744984
DA 2022-11-30
ER

PT J
AU Jin, HL
   Lee, SC
   Kwonc, YS
   Choung, SY
   Jeong, KW
AF Jin, Hong Lan
   Lee, Sung-Chan
   Kwon, Yong Sam
   Choung, Se-Young
   Jeong, Kwang Won
TI A novel fluorescence-based assay for measuring A2E removal from human
   retinal pigment epithelial cells to screen for age-related macular
   degeneration inhibitors
SO JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
LA English
DT Article
DE A2E; Age-related macular degeneration; ARPE-19; Lipofuscin; Blue light
ID LIGHT-INDUCED DAMAGE; LIPOFUSCIN FLUOROPHORE; RPE LIPOFUSCIN;
   ACCUMULATION; ACTIVATION; MECHANISMS; COMPONENT; INDIVIDUALS;
   INVOLVEMENT; PROTECTION
AB Age-related macular degeneration (AMD) is a common retinal disease that leads to irreversible central vision loss in the elderly population. Recent studies have identified many factors related to the development of dry AMD, such as aging, cigarette smoking, genetic predispositions, and oxidative stress, eventually inducing the accumulation of lipofuscin, which is one of the most critical risk factors. One of the major lipofuscins in retinal pigment epithelial (RPE) cells is N-retinylidene-N-retinylethanolamine (also known as A2E), a pyridinium bis-retinoid. Currently there is a lack of effective therapy to prevent or restore vision loss caused by dry AMD. Recent studies have shown that 430 nm blue light induces the oxidation of A2E and the activation of caspase-3 to subsequently cause the death of RPE cells, suggesting that removal of A2E from retinal pigment cells might be critical for preventing AMD. Here, we developed a fluorescence-labeled A2E analog (A2E-BDP) that functions similar to A2E in RPE cells, but is more sensitive to detection than A2E. A2E-BDP-based tracing of intracellular A2E will be helpful, not only for studying the accumulation and removal of A2E in human RPE cells but also for identifying possible inhibitors of AMD. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Jin, Hong Lan; Jeong, Kwang Won] Gachon Univ, Gachon Inst Pharmaceut Sci, Coll Pharm, Inchon 406840, South Korea.
   [Lee, Sung-Chan] AptaBio Therapeut Inc, Yongin 446908, South Korea.
   [Kwon, Yong Sam] Dong A ST Co Ltd, Res Inst, Gyeonggi 446905, South Korea.
   [Choung, Se-Young] Kyung Hee Univ, Dept Prevent Pharm & Toxicol, Dept Life & Nanopharmaceut Sci Pharm, Coll Pharm, Seoul, South Korea.
C3 Gachon University; Kyung Hee University
RP Jeong, KW (通讯作者)，Gachon Univ, Gachon Inst Pharmaceut Sci, Coll Pharm, 7-45 Songdo Dong, Inchon 406840, South Korea.
EM sychoung@khu.ac.kr; kwjeong@gachon.ac.kr
RI Choung, Young/AAH-9208-2020
OI Choung, Se Young/0000-0001-7619-6263
FU technology Innovation Industrial Program (Development of functional food
   product for improving age-related macular degeneration and extending
   global market) - Ministry of Trade, Industry and Energy (MOTIE, Korea)
   [10048028]; Korea Evaluation Institute of Industrial Technology (KEIT)
FX This work was supported by the technology Innovation Industrial Program
   (10048028, Development of functional food product for improving
   age-related macular degeneration and extending global market.) funded by
   the Ministry of Trade, Industry and Energy (MOTIE, Korea) & Korea
   Evaluation Institute of Industrial Technology (KEIT).
CR Abi-Mosleh L, 2009, P NATL ACAD SCI USA, V106, P19316, DOI 10.1073/pnas.0910916106
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Bakall B, 2007, EXP EYE RES, V85, P34, DOI 10.1016/j.exer.2007.02.018
   Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   Carson D, 2008, J CATARACT REFR SURG, V34, P1785, DOI 10.1016/j.jcrs.2008.06.034
   Chew EY, 2013, JAMA OPHTHALMOL, V131, P843, DOI 10.1001/jamaophthalmol.2013.4412
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Iriyama A, 2009, J CELL PHYSIOL, V220, P469, DOI 10.1002/jcp.21792
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Liu J, 2008, INVEST OPHTH VIS SCI, V49, P772, DOI 10.1167/iovs.07-0675
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Ma L, 2010, J SCI FOOD AGR, V90, P2, DOI 10.1002/jsfa.3785
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   Mihai DM, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.314
   Moiseyev G, 2010, P NATL ACAD SCI USA, V107, P17551, DOI 10.1073/pnas.1008769107
   Nociari MM, 2014, P NATL ACAD SCI USA, V111, pE1402, DOI 10.1073/pnas.1400530111
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Plafker SM, 2012, INT REV CEL MOL BIO, V298, P135, DOI 10.1016/B978-0-12-394309-5.00004-3
   Poliakov E, 2014, MOL VIS, V20, P285
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Sparrow JR, 2008, ADV EXP MED BIOL, V613, P393, DOI 10.1007/978-0-387-74904-4_46
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Wu YL, 2011, J AM CHEM SOC, V133, P849, DOI 10.1021/ja107195u
   Wu YL, 2010, P NATL ACAD SCI USA, V107, P7275, DOI 10.1073/pnas.0913112107
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
   Yonova-Doing E, 2013, EXP EYE RES, V115, P172, DOI 10.1016/j.exer.2013.07.020
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zhao Z, 2014, FOOD CHEM TOXICOL, V74, P216, DOI 10.1016/j.fct.2014.10.001
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhou JL, 2005, EXP EYE RES, V80, P567, DOI 10.1016/j.exer.2004.11.009
NR 44
TC 16
Z9 16
U1 0
U2 23
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0731-7085
EI 1873-264X
J9 J PHARMACEUT BIOMED
JI J. Pharm. Biomed. Anal.
PD JAN 5
PY 2016
VL 117
BP 560
EP 567
DI 10.1016/j.jpba.2015.10.010
PG 8
WC Chemistry, Analytical; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA CW6YX
UT WOS:000365145500067
PM 26604166
DA 2022-11-30
ER

PT J
AU Shastry, BS
AF Shastry, Barkur S.
TI Assessment of the contribution of the LOC387715 gene polymorphism in a
   family with exudative age-related macular degeneration and heterozygous
   CFH variant (Y402H)
SO JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE polymorphism; disease; degeneration; gene; variant; susceptibility
ID COMPLEMENT FACTOR-H; CHOROIDAL NEOVASCULARIZATION; GEOGRAPHIC ATROPHY;
   CIGARETTE-SMOKING; RISK; MACULOPATHY; SUSCEPTIBILITY; AGGREGATION;
   ASSOCIATION; DETERMINANT
AB Age-related macular degeneration (AMD) is a common cause of visual impairment in the elderly population in developed countries. The etiology of AMD is not completely understood but environmental and genetic factors have been implicated in the disease. Recently it has been documented that variations in the complement factor H (CFH) and LOC 387715 genes are the major risk factors that predispose individuals to dry and wet AMD. To investigate further the genetic contribution to AMD, we have analyzed the LOC 387715 gene in a non-smoking family with an exudative AMD and a heterozygous mutation (Y402H) in the CFH gene. Direct sequencing of the amplified product of exon 1 of the LOC 387715 gene identified a previously reported missense mutation (A69S) in this family. The affected individual is homozygous for the mutation and this sequence alteration was not identified in six age-matched controls. On the basis of this and other results it is tempting to speculate that the combined effect of variants in the CFH and LOC 387715 genes may contribute to the AMD phenotype in this family. Further studies on these and other susceptibility genes may provide clues on variable phenotypes, new preventive strategies and treatment options for AMD.
C1 Oakland Univ, Dept Biol Sci, Rochester, MI 48309 USA.
C3 Oakland University
RP Shastry, BS (通讯作者)，Oakland Univ, Dept Biol Sci, Rochester, MI 48309 USA.
EM shastry@oakland.edu
CR Barral S, 2006, INVEST OPHTH VIS SCI, V47, P5453, DOI 10.1167/iovs.06-0655
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   DeJong PTVM, 1997, AM J OPHTHALMOL, V124, P862, DOI 10.1016/S0002-9394(14)71715-5
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   LI L, 2006, INVEST OPHTH VIS SCI, V47, P3242
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shastry BS, 2006, OPHTHALMOLOGICA, V220, P291, DOI 10.1159/000094617
   Shastry BS, 1999, OPHTHALMOLOGICA, V213, P165, DOI 10.1159/000027413
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
NR 21
TC 12
Z9 12
U1 0
U2 2
PU SPRINGER TOKYO
PI TOKYO
PA 3-3-13, HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN
SN 1434-5161
J9 J HUM GENET
JI J. Hum. Genet.
PD APR
PY 2007
VL 52
IS 4
BP 384
EP 387
DI 10.1007/s10038-007-0120-y
PG 4
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 150RZ
UT WOS:000245236400014
PM 17285240
OA Bronze
DA 2022-11-30
ER

PT J
AU Medina, FM
   da Motta, AAL
   Takahashi, WY
   Carricondo, PC
   Motta, MMD
   Melo, MB
   Vasconcellos, JPC
AF Medina, Flavio Mac Cord
   Lopes da Motta, Augusto Alves
   Takahashi, Walter Y.
   Carricondo, Pedro Carlos
   dos Santos Motta, Mario Martins
   Melo, Monica B.
   Vasconcellos, Jose Paulo C.
TI Pharmacogenetic Effect of Complement Factor H Gene Polymorphism in
   Response to the Initial Intravitreal Injection of Bevacizumab for Wet
   Age-Related Macular Degeneration
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Bevacizumab; Pharmacogenetics;
   Complement factor H gene
ID ASSOCIATION; Y402H; RANIBIZUMAB; PROGRESSION; POPULATION; PREVALENCE;
   VARIANT; RISK; AMD
AB Purpose: To compare the functional and morphological response to the initial intravitreal (IV) injection of bevacizumab in exudative age-related macular degeneration (AMD) patients with the complement factor H (CFH) gene polymorphism T1277C in the Brazilian population. Methods: Twenty-five unrelated patients with treatment-naive exudative AMD underwent an IVT injection of 1.25 mg bevacizumab at the initial presentation (DO) and were reexamined 7 days (D7) and 28 days (D28) later. The time and extent of visual acuity (VA) and central retinal thickness (CRT) changes were evaluated according to the presence of the T1277C polymorphism. Results: In the homozygous risk group (CC), VA improvement was detected mostly from D7 to D28, while in the heterozygous (CT) and homozygous for the wild-type allele (TT) groups, functional response occurred earlier, from DO to D7. Morphological response to the first IVT injection of bevacizunnab was significant in the CT and TT groups, while the CC group presented no significant change in CRT up to D28. Conclusion: The CC variant of the CFH gene polymorphism T1277C is related to delayed functional and limited morphological response to the initial IVT injection of bevacizumab in exudative AMD patients in a sample of the Brazilian population. (C) 2015 S. Karger AG, Basel
C1 [Medina, Flavio Mac Cord; Melo, Monica B.; Vasconcellos, Jose Paulo C.] Univ Estadual Campinas, UNICAMP, Campinas, Brazil.
   [Medina, Flavio Mac Cord; dos Santos Motta, Mario Martins] Hosp Fed Serv Estado, HSE, Rio De Janeiro, Brazil.
   [Lopes da Motta, Augusto Alves; Takahashi, Walter Y.; Carricondo, Pedro Carlos] Univ Sao Paulo, Sao Paulo, Brazil.
C3 Universidade Estadual de Campinas; Universidade de Sao Paulo
RP Medina, FM (通讯作者)，Ave Alexandre Ferreira 444,Ap 101 Lagoa, BR-22470220 Rio De Janeiro, RJ, Brazil.
EM fmaccord@hotmail.com
RI Medina, Flavio/AFM-1303-2022; Carricondo, Pedro/F-8783-2013
OI Carricondo, Pedro/0000-0002-2916-205X
CR Augustin AJ, 2009, EXPERT OPIN THER TAR, V13, P641, DOI 10.1517/14728220902942322
   Bolz M, 2010, BRIT J OPHTHALMOL, V94, P185, DOI 10.1136/bjo.2008.143974
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Djordjevic N, 2011, J CLIN PHARMACOL, V51, P994, DOI 10.1177/0091270010377630
   Ferraz D, 2010, EUR J OPHTHALMOL, V20, P740, DOI 10.1177/112067211002000415
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Gangnon RE, 2012, ARCH OPHTHALMOL-CHIC, V130, P1169, DOI 10.1001/archophthalmol.2012.693
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Lazzeri S, 2013, PHARMACOGENOMICS, V14, P1239, DOI 10.2217/pgs.13.100
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Medina FM, 2014, ANN M ASS RES VIS OP
   MinesandGeosciencesBureau, 2010, GEOLOGYOFTHEPHILIPPI, V2
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Silva AS, 2012, MOL VIS, V18, P2288
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Tian J, 2012, PHARMACOGENOMICS, V13, P779, DOI [10.2217/PGS.12.53, 10.2217/pgs.12.53]
NR 26
TC 15
Z9 17
U1 1
U2 9
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2015
VL 54
IS 4
BP 169
EP 174
DI 10.1159/000439172
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CX0IE
UT WOS:000365379300001
PM 26439641
DA 2022-11-30
ER

PT J
AU Mylonas, G
   Ahlers, C
   Malamos, P
   Golbaz, I
   Deak, G
   Schuetze, C
   Sacu, S
   Schmidt-Erfurth, U
AF Mylonas, G.
   Ahlers, C.
   Malamos, P.
   Golbaz, I.
   Deak, G.
   Schuetze, C.
   Sacu, Stefan
   Schmidt-Erfurth, U.
TI Comparison of retinal thickness measurements and segmentation
   performance of four different spectral and time domain OCT devices in
   neovascular age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC
   THERAPY; INTRAVITREAL BEVACIZUMAB; REPRODUCIBILITY; DISEASES; EDEMA
AB Aims: To evaluate the reliability of different optical coherence tomography (OCT) devices and scanning patterns in the assessment of retinal thickness and segmentation performance in neovascular age-related macular degeneration (nAMD).
   Methods: 28 eyes with nAMD and 10 healthy eyes were imaged using conventional time domain (TD) OCT as well as three spectral-domain (SD) OCT systems. Radial scans of 6 mm in size were compared between Stratus and Topcon OCT, in addition to raster scans of all three SD-OCT devices. Retinal thickness values were analysed.
   Results: Spectralis SD-OCT demonstrated the highest values of all OCT devices in central millimetre thickness (CMMT), and Topcon OCT raster scans showed the lowest values. Significant correlations could be found between the CMMT measurements of Cirrus and Spectralis OCT (r = 0.87). Analyses showed best segmentation for Cirrus and Spectralis SD-OCTs. Cirrus 200x200x1024 scans showed 4% and Stratus OCT 38% moderate or severe segmentation errors.
   Conclusion: Retinal thickness values were generally higher in SD-OCT analysis. Different performances of automatic retinal thickness analysis indicate the potential of different software algorithms to quantify retinal morphology in nAMD. Further development of current algorithms may improve quantification of retinal thickness detection in the future even further.
C1 [Mylonas, G.; Ahlers, C.; Malamos, P.; Golbaz, I.; Deak, G.; Schuetze, C.; Sacu, Stefan; Schmidt-Erfurth, U.] Med Univ Vienna, Dept Ophthalmol, A-1090 Vienna, Austria.
C3 Medical University of Vienna
RP Sacu, S (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Waehringer Guertel 18 20, A-1090 Vienna, Austria.
EM stefan.sacu@meduniwien.ac.at
OI Schmidt-Erfurth, Ursula/0000-0002-7788-7311
CR Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Baumann M, 1998, OPHTHALMIC SURG LAS, V29, P280
   COSCAS G, 2004, J FR OPHTALMOL, V27
   Ferrari TM, 2004, EUR J OPHTHALMOL, V14, P321, DOI 10.1177/112067210401400407
   Goff MJ, 2007, RETINA-J RET VIT DIS, V27, P432, DOI 10.1097/IAE.0b013e318042b53f
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Krebs I, 2005, BRIT J OPHTHALMOL, V89, P1184, DOI 10.1136/bjo.2005.067389
   MASSIN P, 2001, ARCH OPHTHALMOL-CHIC, V240, P361
   Montero JA, 2003, GRAEF ARCH CLIN EXP, V241, P797, DOI 10.1007/s00417-003-0752-3
   Paunescu LA, 2004, INVEST OPHTH VIS SCI, V45, P1716, DOI 10.1167/iovs.03-0514
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Sahni J, 2005, BRIT J OPHTHALMOL, V89, P316, DOI 10.1136/bjo.2004.043364
   Salinas-Alaman A, 2005, AM J OPHTHALMOL, V140, P23, DOI 10.1016/j.ajo.2005.01.044
   Schmidt-Erfurth U, 2005, INVEST OPHTH VIS SCI, V46, P3393, DOI 10.1167/iovs.05-0370
   Srinivasan VJ, 2006, OPHTHALMOLOGY, V113, P2054, DOI 10.1016/j.ophtha.2006.05.046
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   Wilkins JR, 1996, OPHTHALMOLOGY, V103, P2142, DOI 10.1016/S0161-6420(96)30377-1
   Wojtkowski M, 2004, AM J OPHTHALMOL, V138, P412, DOI 10.1016/j.ajo.2004.04.049
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
NR 21
TC 58
Z9 59
U1 1
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD NOV
PY 2009
VL 93
IS 11
BP 1453
EP 1460
DI 10.1136/bjo.2008.153643
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 510MF
UT WOS:000271091900010
PM 19520692
DA 2022-11-30
ER

PT J
AU Kherani, S
   Scott, AW
   Wenick, AS
   Zimmer-Galler, I
   Brady, CJ
   Sodhi, A
   Meyerle, C
   Solomon, SD
   Shaukat, R
   Channa, R
   Adeyemo, O
   Handa, JT
   Wang, JX
   Campochiaro, PA
AF Kherani, Saleema
   Scott, Adrienne W.
   Wenick, Adam S.
   Zimmer-Galler, Ingrid
   Brady, Christopher J.
   Sodhi, Akrit
   Meyerle, Catherine
   Solomon, Sharon D.
   Shaukat, Rimsha
   Channa, Roomasa
   Adeyemo, Olukemi
   Handa, James T.
   Wang, Jiangxia
   Campochiaro, Peter A.
TI Shortest Distance From Fovea to Subfoveal Hemorrhage Border Is Important
   in Patients With Neovascular Age-related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID TISSUE-PLASMINOGEN ACTIVATOR; THICK SUBMACULAR HEMORRHAGE; SUBRETINAL
   HEMORRHAGE; PNEUMATIC DISPLACEMENT; NATURAL-HISTORY; MANAGEMENT;
   LESIONS; RANIBIZUMAB; INJECTION
AB PURPOSE: To identify factors influencing visual outcome in patients with neovascular age-related macular degeneration (NVAMD) and subfoveal hemorrhage (SFH) treated with anti-vascular endothelial growth factor (VEGF) agents.
   DESIGN: Retrospective case series.
   METHODS: Anti-VEGF-treated eyes with SFH > 1 disc area (DA) were identified (n = 16) and changes in visual acuity (VA) and central subfield thickness (CST) from baseline to last follow-up, along with SFH area, thickness, minimum distance from fovea to SFH border, and time to resolution, were determined.
   RESULTS: At baseline, mean (+/- standard error of the mean) size and thickness of SFH were 14.9 +/- 2.8 DA and 386.6 +/- 46.9 mu m, and mean Snellen VA and CST were 20/250 and 591.7 +/- 57.0 mu m. Median follow-up was 47.6 months. While more than 50% of patients had VA >= 20/200 at baseline and all time points through week 48, the percentage of patients with VA >= 20/50 increased to 30%-40% at months 6 and 12 and remained stable through month 48. Spearman rank correlation demonstrated 2 independent variables that correlated with good visual outcome, smaller area of SFH at baseline (r = -0.630; P = .009), and high frequency of anti-VEGF injections (r = 0.646; P = .007). In exceptional patients with good visual outcome despite large baseline SFH, shortest distance between the fovea and hemorrhage border significantly correlated with baseline VA (r = -0.503, P = .047) and final VA (r = -0.575, P = .02).
   CONCLUSIONS: Patients with NVAMD and thick SFH, but short distance between fovea and uninvolved retina, can have good visual outcomes when given frequent anti-VEGF injections. (c) 2018 Elsevier Inc. All rights reserved.
C1 [Kherani, Saleema; Scott, Adrienne W.; Wenick, Adam S.; Zimmer-Galler, Ingrid; Brady, Christopher J.; Sodhi, Akrit; Meyerle, Catherine; Solomon, Sharon D.; Shaukat, Rimsha; Channa, Roomasa; Adeyemo, Olukemi; Handa, James T.; Campochiaro, Peter A.] Johns Hopkins Univ, Wilmer Eye Inst, Sch Med, Baltimore, MD 21287 USA.
   [Wang, Jiangxia] Johns Hopkins Bloomberg Sch Publ Hlth, Johns Hopkins Biostat Ctr, Dept Biostat, Baltimore, MD USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Bloomberg School of Public Health
RP Campochiaro, PA (通讯作者)，Johns Hopkins Univ, Sch Med, Maumenee 815,600 N Wolfe St, Baltimore, MD 21287 USA.
EM pcampo@jhmi.edu
RI C, Roomasa/AAK-5176-2020; Kherani, Saleema/AAD-8723-2019
FU  [EY01765]
FX SUPPORTED BY BIOSTATISTICS CORE GRANT EY01765 TO THE WILMER EYE
   INSTITUTE.
CR Altaweel MM, 2015, OPHTHALMOLOGY, V122, P391, DOI 10.1016/j.ophtha.2014.08.020
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Chang MA, 2010, RETINA-J RET VIT DIS, V30, P1171, DOI 10.1097/IAE.0b013e3181dd6d8a
   Chang W, 2014, AM J OPHTHALMOL, V157, P1250, DOI 10.1016/j.ajo.2014.02.007
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Iacono P, 2014, RETINA-J RET VIT DIS, V34, P281, DOI 10.1097/IAE.0b013e3182979e33
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Kim HS, 2015, EYE, V29, P1142, DOI 10.1038/eye.2015.131
   Kim JH, 2014, OPHTHALMOLOGY, V121, P926, DOI 10.1016/j.ophtha.2013.11.004
   Kim Kun Hae, 2015, Korean J Ophthalmol, V29, P315, DOI 10.3341/kjo.2015.29.5.315
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shienbaum G, 2013, AM J OPHTHALMOL, V155, P1009, DOI 10.1016/j.ajo.2013.01.012
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Treumer F, 2012, BRIT J OPHTHALMOL, V96, P708, DOI 10.1136/bjophthalmol-2011-300655
NR 19
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2018
VL 189
BP 86
EP 95
DI 10.1016/j.ajo.2018.02.015
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GE8HR
UT WOS:000431473300014
PM 29499174
DA 2022-11-30
ER

PT J
AU Souied, EH
   Dugel, PU
   Ferreira, A
   Hashmonay, R
   Lu, JS
   Kelly, SP
AF Souied, Eric H.
   Dugel, Pravin U.
   Ferreira, Alberto
   Hashmonay, Ron
   Lu, Jingsong
   Kelly, Simon P.
TI Severe Ocular Inflammation Following Ranibizumab or Aflibercept
   Injections for Age-Related Macular Degeneration: A Retrospective Claims
   Database Analysis
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Aflibercept; anti-VEGF therapy; endophthalmitis; neovascular age-related
   macular degeneration; claims database; intravitreal injection
ID INTRAVITREAL INJECTION; ANTIBIOTIC-PROPHYLAXIS; RISK-FACTORS; TIME
   TRENDS; WET AMD; ENDOPHTHALMITIS; BLINDNESS; OUTCOMES; VEGF; BEVACIZUMAB
AB Purpose: Intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents including ranibizumab and aflibercept are used to treat patients with ocular disorders such as neovascular age-related macular degeneration (nAMD); however, the injections are associated with rare instances of severe ocular inflammation. This study compared severe ocular inflammation rates in patients treated with ranibizumab versus aflibercept.
   Methods: United States physician-level claims data covering an 18-month period for each therapy were analyzed. The primary analysis compared severe ocular inflammation event rates per 1000 injections. Sensitivity and subgroup analyses evaluated the impact of factors including intraocular surgery, intravitreal antibiotic administration, and previous intravitreal injections.
   Results: The analysis included 432,794 injection claims (ranibizumab n = 253,647, aflibercept n = 179,147); significantly, more unique severe ocular inflammation events occurred in patients receiving aflibercept than ranibizumab (1.06/1000 injections, 95% confidence interval [CI], 0.91-1.21, vs. 0.64/1000 injections, 95% CI 0.54-0.74; p < 0.0001). Comparable results were observed for analyses of patients who had undergone glaucoma or cataract surgeries, had antibiotic-associated endophthalmitis, had non-antibiotic-associated endophthalmitis, and were non-treatment-naive. In contrast, no significant differences in severe ocular inflammation claims were recorded in treatment-naive patients who had no record of anti-VEGF treatment in the 6 months preceding the index claim. No significant change occurred in the rate of severe ocular inflammation claims over time following ranibizumab treatment.
   Conclusions: Severe ocular inflammation was more frequent following intravitreal injection with aflibercept than with ranibizumab during routine clinical use in patients with nAMD. This highlights the importance of real-world, post-approval, observational monitoring of novel medicines, and may aid clinical decision-making, including choice of anti-VEGF agent.
C1 [Souied, Eric H.] Univ Paris Est, Ctr Hosp Intercommunal Creteil, Creteil, France.
   [Dugel, Pravin U.] Retinal Consultants Arizona, Phoenix, AZ USA.
   [Dugel, Pravin U.] Univ So Calif, Keck Sch Med, USC Eye Inst, Los Angeles, CA 90033 USA.
   [Ferreira, Alberto; Hashmonay, Ron] Novartis Pharma AG, Basel, Switzerland.
   [Lu, Jingsong] IMS Hlth, Plymouth, Devon, England.
   [Kelly, Simon P.] Royal Bolton Hosp NHS Fdn Trust, Bolton, England.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   University of Southern California; Novartis; Royal Bolton Hospital
RP Souied, EH (通讯作者)，Ctr Hosp Intercommunal Creteil, 40 Ave Verdun, F-94000 Creteil, France.
EM eric.souied@chicreteil.fr
FU Allergan; Bayer AG; Novartis Pharma AG; Heidelberg Pharma; Novartis
   Pharma AG, Basel, Switzerland
FX Eric H. Souied has received payment for consultancy, travel, and review
   activities from Allergan, Bayer AG, and Novartis Pharma AG; has been an
   advisory board member and consultant for Thea; and has received payment
   for lectures and travel from Heidelberg Pharma. Pravin U. Dugel is a
   consultant to Alcon, Genentech, Novartis Pharma AG, and Ophthotech.
   Alberto Ferreira and Ron Hashmonay are employees of Novartis Pharma AG
   and own shares in the company. Jingsong Lu is an employee of IMS Health,
   which has received funding from Novartis Pharma AG. Simon P. Kelly has
   received payment for consultancy and travel expenses from Bayer AG and
   Novartis Pharma AG, and has been an advisory board member and received
   payment for lectures from Novartis Pharma AG.; This study was supported
   by funding from Novartis Pharma AG, Basel, Switzerland.
CR Agrawal S, 2013, MEDIATORS INFLAMMATI, V2013
   American Academy of Ophthalmology Retina Panel, 2008, PREF PRACT PATT GUID
   Ang GS, 2010, BRIT J OPHTHALMOL, V94, P1571, DOI 10.1136/bjo.2009.163923
   [Anonymous], 2011, AG REL MAC DEG MAN R
   [Anonymous], 2013, LUC SUMM PROD CHAR
   [Anonymous], 2013, EYL PRESCR INF
   [Anonymous], 2012, POT BEV REL STER END
   [Anonymous], 2013, EYL SUMM PROD CHAR
   [Anonymous], 2013, LUC PRESCR INF
   Belkin M, 2013, AM J OPHTHALMOL, V155, P404, DOI 10.1016/j.ajo.2012.09.017
   Bhatt SS, 2011, RETINA-J RET VIT DIS, V31, P2032, DOI 10.1097/IAE.0b013e31820f4b4f
   Bhavsar AR, 2009, ARCH OPHTHALMOL-CHIC, V127, P1581, DOI 10.1001/archophthalmol.2009.304
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Boyer DS, 2013, THER ADV ENDOCRINOL, V4, P151, DOI 10.1177/2042018813512360
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Cackett P, 2013, INVEST OPHTH VIS SCI, V54
   Cao H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071731
   Cavalcante LL, 2010, CLIN OPHTHALMOL, V4, P519
   Cheung CSY, 2012, OPHTHALMOLOGY, V119, P1609, DOI 10.1016/j.ophtha.2012.02.014
   Claessen H, 2012, EUR J EPIDEMIOL, V27, P519, DOI 10.1007/s10654-012-9705-7
   Daha NA, 2011, MOL IMMUNOL, V48, P1656, DOI 10.1016/j.molimm.2011.04.024
   Diago T, 2009, RETINA-J RET VIT DIS, V29, P601, DOI 10.1097/IAE.0b013e31819d2591
   Dollin M, 2014, ASS RES VIS OPHTH AR
   Dreyer NA, 2014, J MANAG CARE SPEC PH, V20, P301, DOI 10.18553/jmcp.2014.20.3.301
   Eifrig CWG, 2002, OPHTHALMIC SURG LAS, V33, P373
   Fintak DR, 2008, RETINA-J RET VIT DIS, V28, P1395, DOI 10.1097/IAE.0b013e3181884fd2
   Fukami Tomomi, 2011, Nippon Ganka Gakkai Zasshi, V115, P706
   Gillies MC, 2013, INVEST OPHTH VIS SCI, V54, P5754, DOI 10.1167/iovs.13-11993
   Glanville J, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-7
   Goldberg RA, 2013, OPHTHALMOLOGY, V120, P1448, DOI 10.1016/j.ophtha.2012.12.009
   Hahn P, 2013, OPHTHALMOLOGY, V120, P1100, DOI 10.1016/j.ophtha.2012.11.018
   Ho AC, 2012, OPHTHALMOLOGY, V119, P2179, DOI 10.1016/j.ophtha.2012.07.058
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Keenan TDL, 2013, BRIT J OPHTHALMOL, V97, P1168, DOI 10.1136/bjophthalmol-2013-303233
   Kernt M, 2010, CLIN OPHTHALMOL, V4, P121
   Kiss S, 2014, ASS RES VIS OPHTH AR
   Klein KS, 2009, OPHTHALMOLOGY, V116, P1225, DOI 10.1016/j.ophtha.2009.02.031
   Lyall DAM, 2012, EYE, V26, P1517, DOI 10.1038/eye.2012.199
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McCannel CA, 2011, RETINA-J RET VIT DIS, V31, P654, DOI 10.1097/IAE.0b013e31820a67e4
   Menon G, 2009, EYE, V23, pS1, DOI 10.1038/eye.2009.13
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Moshfeghi AA, 2011, RETINA-J RET VIT DIS, V31, P662, DOI 10.1097/IAE.0b013e31821067c4
   Murinello S, 2014, INVEST OPHTH VIS SCI, V55, P247, DOI 10.1167/iovs.13-11821
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Peyman GA, 2009, RETINA-J RET VIT DIS, V29, P875, DOI 10.1097/IAE.0b013e3181a94f01
   Pielen A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078538
   Pilu S, 2008, AM J OPHTHALMOL, V145, P879, DOI 10.1016/j.ajo.2007.12.036
   Rostron E, 2012, EYE, V26, P933, DOI 10.1038/eye.2012.61
   Royal College of Ophthalmologists (UK), 2013, AG REL MAC DEG GUID
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Shah CP, 2011, OPHTHALMOLOGY, V118, P2028, DOI 10.1016/j.ophtha.2011.02.034
   Skaat A, 2012, AM J OPHTHALMOL, V153, P214, DOI 10.1016/j.ajo.2011.08.035
   Sloan FA, 2014, JAMA OPHTHALMOL, V132, P456, DOI 10.1001/jamaophthalmol.2013.7647
   Storey P, 2014, OPHTHALMOLOGY, V121, P283, DOI 10.1016/j.ophtha.2013.08.037
   Tabandeh H, 2014, RETINA-J RET VIT DIS, V34, P18, DOI 10.1097/IAE.0000000000000008
   Tatar O, 2008, ARCH OPHTHALMOL-CHIC, V126, P782, DOI 10.1001/archopht.126.6.782
NR 57
TC 33
Z9 34
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD MAR 3
PY 2016
VL 23
IS 2
BP 71
EP 79
DI 10.3109/09286586.2015.1090004
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DH4FU
UT WOS:000372741700002
PM 26855278
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Kaur, I
   Cantsilieris, S
   Katta, S
   Richardson, AJ
   Schache, M
   Pappuru, RR
   Narayanan, R
   Mathai, A
   Majji, AB
   Tindill, N
   Guymer, RH
   Chakrabarti, S
   Baird, PN
AF Kaur, Inderjeet
   Cantsilieris, Stuart
   Katta, Saritha
   Richardson, Andrea J.
   Schache, Maria
   Pappuru, Rajeev R.
   Narayanan, Raja
   Mathai, Annie
   Majji, Ajit B.
   Tindill, Nicole
   Guymer, Robyn H.
   Chakrabarti, Subhabrata
   Baird, Paul N.
TI Association of the del443ins54 at the ARMS2 locus in Indian and
   Australian cohorts with age-related macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID MESSENGER-RNA; HTRA1; RISK; CFH; SUSCEPTIBILITY; POLYMORPHISM;
   POPULATION; RS11200638; EXPRESSION; LOC387715
AB Purpose: The ARMS2/HTRA1 genes at the 10q26 locus have been associated with risk of age-related macular degeneration (AMD), with the most significantly associated variants being A69S (rs10490924), del443ins54 (EU427539) and rs11200638. We wished to explore the association of the del443ins54 in two ethnically different populations from India and Australia.
   Methods: The del443ins54 was screened in a large cohort of similar to 1500 subjects from these two populations by a combination of PCR-based agarose gel electrophoresis and validated by resequencing. Statistical analysis comprised the calculations of allele, genotype and haplotype frequencies along with their p values and corresponding odds ratios (OR), and 95% confidence intervals (95% CI) and measures of linkage disequilibrium (LD).
   Results: The del443ins54 was significantly associated with AMD in both the Indian (p=1.74x10(-13); OR=2.80, 95% CI, 2.12-3.70) and Australian cohorts (p=2.78x10(-30); OR=3.15, 95% CI, 2.58-3.86). These associations were similar to those previously identified for the A69S and the rs11200638 variant in these populations that also exhibited high degrees of LD (D' of 0.87-0.99). A major risk haplotype of "T-indel-A" (p=5.7x10(-16); OR=3.16, 95% CI, 2.34-4.19 and p=6.33x10(-30); OR=3.15, 95% CI, 2.57-3.85) and a protective haplotype of "G-wild type-G" (p=2.35x10(-11); OR=0.39, 95% CI, 0.29-0.52 and p=1.02x10(-30); OR=0.31, 95% CI, 0.25-0.38) were identified in the Indian and Australian cohorts, respectively.
   Conclusions: These data provide an independent replication of the association of del443ins54 variant in two different ethnicities, despite differences in allele and haplotype frequencies between them. High levels of LD in both populations limit further genetic dissection of this region in AMD.
C1 [Kaur, Inderjeet; Katta, Saritha; Chakrabarti, Subhabrata] Hyderabad Eye Res Fdn, LV Prasad Eye Inst, Hyderabad, Andhra Pradesh, India.
   [Cantsilieris, Stuart; Richardson, Andrea J.; Schache, Maria; Tindill, Nicole; Guymer, Robyn H.; Baird, Paul N.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Pappuru, Rajeev R.; Narayanan, Raja; Mathai, Annie; Majji, Ajit B.] Hyderabad Eye Inst, LV Prasad Eye Inst, Hyderabad, Andhra Pradesh, India.
C3 L. V. Prasad Eye Institute; Centre for Eye Research Australia; Royal
   Victorian Eye & Ear Hospital; University of Melbourne; L. V. Prasad Eye
   Institute
RP Chakrabarti, S (通讯作者)，LV Prasad Eye Inst, Brien Holden Eye Res Ctr, Champalimaud Translat Ctr, Kallam Anji Reddy Mol Genet Lab, Hyderabad 500034, Andhra Pradesh, India.
EM subho@lvpei.org
RI Narayanan, Raja/AAT-3098-2021; Kaur, Inderjeet/ABD-1833-2021;
   Chakrabarti, Subhabrata/F-2468-2015
OI Narayanan, Raja/0000-0001-9688-5859; Chakrabarti,
   Subhabrata/0000-0003-3717-4963; Baird, Paul/0000-0002-1305-3502; Guymer,
   Robyn/0000-0002-9441-4356
FU Council of Scientific and Industrial Research (CSIR), Government of
   India; Australia-India Strategic Research Fund (AISRF); Department of
   Biotechnology (DBT), Government of India; Department of Innovation,
   Industry, Science and Research (DIISR), Government of Australia;
   National Health and Medical Research Council (NHMRC) Centre for Clinical
   Research Excellence [529923]
FX The authors thank all the Australian and Indian patients and the normal
   volunteers for their participation and Drs. Nazimul Hussain, Taraprasad
   Das, Anjli Hussain and Avinash Pathangay for their help in collecting
   some of the earlier patients' data. RHG and PNB acknowledge an NHMRC
   Practitioner Award and NHMRC Fellowship, respectively. SK and Stuart
   Cantsilieris acknowledge a Senior Research Fellowship of the Council of
   Scientific and Industrial Research (CSIR), Government of India, and an
   Australian Postgraduate Award, respectively. CERA receives Operational
   Infrastructure Support from the Victorian Government, Australia. Grant
   support: This work was supported by the Australia-India Strategic
   Research Fund (AISRF) jointly funded through the Department of
   Biotechnology (DBT), Government of India (SC and IK) and the Department
   of Innovation, Industry, Science and Research (DIISR), Government of
   Australia (PNB and RHG), the National Health and Medical Research
   Council (NHMRC) Centre for Clinical Research Excellence #529923 -
   Translational Clinical Research in Major Eye Diseases.
CR Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Hadley D, 2010, INVEST OPHTH VIS SCI, V51, P2191, DOI 10.1167/iovs.09-3798
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Ricci F, 2009, ARCH OPHTHALMOL-CHIC, V127, P1368, DOI 10.1001/archophthalmol.2009.237
   Richardson AJ, 2010, INVEST OPHTH VIS SCI, V51, P4932, DOI 10.1167/iovs.09-5114
   Sudmant PH, 2010, SCIENCE, V330, P641, DOI 10.1126/science.1197005
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Wang GF, 2010, ARCH OPHTHALMOL-CHIC, V128, P1491, DOI 10.1001/archophthalmol.2010.256
   Wang GF, 2010, HUM GENET, V127, P595, DOI 10.1007/s00439-010-0805-8
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
NR 19
TC 7
Z9 7
U1 0
U2 1
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD APR 5
PY 2013
VL 19
BP 822
EP 828
PG 7
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 126HU
UT WOS:000317605300001
PM 23592919
DA 2022-11-30
ER

PT J
AU Orr, P
   Rentz, AM
   Margolis, MK
   Revicki, DA
   Dolan, CM
   Colman, S
   Fine, JT
   Bressler, NM
AF Orr, Peggy
   Rentz, Anne M.
   Margolis, Mary Kay
   Revicki, Dennis A.
   Dolan, Chantal M.
   Colman, Shoshana
   Fine, Jennifer T.
   Bressler, Neil M.
TI Validation of the National Eye Institute Visual Function
   Questionnaire-25 (NEI VFQ-25) in Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID QUALITY-OF-LIFE; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RANIBIZUMAB;
   VISION; TRIAL; ACUITY; HEALTH
AB PURPOSE. Patient-reported measures of visual function are increasingly incorporated into clinical trials of new treatments for age-related macular degeneration (AMD). Limited information is available regarding the associations between distance visual acuity (VA), reading speed, or contrast sensitivity and the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) subscales judged relevant to these measures. This study's objective was to evaluate such associations along with questions on restricted activity days.
   METHODS. This cross-sectional study was conducted in patients with clinical diagnoses of neovascular AMD. Patient-reported outcome measures included the NEI VFQ-25 and restricted activity days. Clinical assessments included best-corrected visual acuity (BCVA), reading speed, and contrast sensitivity. The better-seeing eye was defined based on the BCVA of each patient. Psychometric properties of the NEI VFQ-25 were examined; analyses a priori focused on the Near Activities, Distance Activities, and Vision-Specific Dependency subscales.
   RESULTS. The final study group included 92 participants (mean age, 78 years). Cronbach's alpha for the subscales ranged from 0.67 to 0.92. The NEI VFQ-25 overall composite, Near Activities, Distance Activities, and Vision-Specific Dependency scores were correlated with BCVA (r = -0.48 to -0.54, all P < 0.0001), reading speed (r = 0.43 to 0.56, all P < 0.0001), and contrast sensitivity (r = -0.39 to -0.46, all P < 0.001) of the better-seeing eye and with restricted activity days (r = -0.52 to -0.55, all P < 0.0001).
   CONCLUSIONS. This study provides additional evidence supporting the validity of the NEI VFQ-25 in neovascular AMD patients by demonstrating correlations with a spectrum of vision measurements and a daily function measure. (Invest Ophthalmol Vis Sci. 2011;52:3354-3359) DOI:10.1167/iovs.10-5645
C1 [Orr, Peggy; Bressler, Neil M.] Johns Hopkins Univ, Wilmer Eye Inst, Retina Div, Dept Ophthalmol,Sch Med, Baltimore, MD 21287 USA.
   [Rentz, Anne M.; Margolis, Mary Kay; Revicki, Dennis A.] United BioSource Corp, Ctr Hlth Outcomes Res, Bethesda, MD USA.
   [Dolan, Chantal M.; Colman, Shoshana; Fine, Jennifer T.] Genentech Inc, San Francisco, CA 94080 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; United Biosource
   Corporation; Roche Holding; Genentech
RP Bressler, NM (通讯作者)，Johns Hopkins Univ, Wilmer Eye Inst, Retina Div, Dept Ophthalmol,Sch Med, 600 N Wolfe St, Baltimore, MD 21287 USA.
EM nmboffice@jhmi.edu
FU Genentech, Inc. [A2-3787-000]; Novartis [A2-4071-000]; United Biosource
   [A2-3787-000]
FX Supported by Genentech, Inc. (A2-3787-000), Novartis (A2-4071-000), and
   United Biosource (A2-3787-000).
CR Bass EB, 2004, ARCH OPHTHALMOL-CHIC, V122, P1856
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Childs AL, 2004, OPHTHALMOLOGY, V111, P2007, DOI 10.1016/j.ophtha.2004.07.024
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Cohen J., 1988, STAT POWER ANAL SOCI, V2nd
   Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Finger RP, 2008, QUAL LIFE RES, V17, P559, DOI 10.1007/s11136-008-9327-4
   Gill TM, 2001, ANN INTERN MED, V135, P313, DOI 10.7326/0003-4819-135-5-200109040-00007
   Hawkins BS, 2004, ARCH OPHTHALMOL-CHIC, V122, P1616, DOI 10.1001/archopht.122.11.1616
   Hays RD., 2005, ASSESSING QUALITY LI, V2, P25
   Mackenzie PJ, 2002, OPHTHALMOLOGY, V109, P720, DOI 10.1016/S0161-6420(01)01021-1
   Maguire M, 2004, OPHTHALMOLOGY, V111, P1307
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   MANGIONE CM, 2010, NEI VFQ25 SCORING AL
   MATCHAR DB, 2006, MEASURING QUALITY LI
   Mejico LJ, 2004, AM J OPHTHALMOL, V137, P908, DOI 10.1016/j.ajo.2003.12.038
   Miskala PH, 2004, ARCH OPHTHALMOL-CHIC, V122, P758, DOI 10.1001/archopht.122.5.758
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   REVICKI DA, 1994, MED CARE, V32, P401, DOI 10.1097/00005650-199404000-00008
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   *SST, 1998, MAN PROC
NR 25
TC 69
Z9 71
U1 0
U2 7
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2011
VL 52
IS 6
BP 3354
EP 3359
DI 10.1167/iovs.10-5645
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 770PN
UT WOS:000291100800063
PM 21282568
DA 2022-11-30
ER

PT J
AU Kim, M
   Kim, ES
   Seo, KH
   Yu, SY
   Kwak, HW
AF Kim, Moosang
   Kim, Eung Suk
   Seo, Kyung Hoon
   Yu, Seung-Young
   Kwak, Hyung-Woo
TI Change of retinal pigment epithelial atrophy ater anti-vascular
   endothelial growth factor treatment in exudative age-related macular
   degeneration
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Anti-vascular endothelial growth factor; exudative age-related macular
   degeneration; retinal pigment epithelial atrophy
ID GEOGRAPHIC ATROPHY; FUNDUS AUTOFLUORESCENCE; TREATMENTS TRIALS;
   RANIBIZUMAB; PROGRESSION
AB Purpose: The study aimed to investigate the quantitative changes of retinal pigment epithelial (RPE) atrophy during a 24-month follow-up period of anti-vascular endothelial growth factor (VEGF) for exudative age-related macular degeneration (AMD). Materials and Methods: This is a retrospective study. Sixty-five eyes of 62 consecutive patients with naive exudative AMD who had received treatment with anti-VEGF therapy and followed for more 24 months were enrolled. All patients received three initial monthly injections of anti-VEGF (ranibizumab or bevacizumab), followed by pro re nata or treat-and-extend protocol. Color fundus image, optical coherence tomography, and fundus autofluorescence were evaluated for RPE atrophy. Multiple regression analysis was performed to investigate the predictive factors found during univariate analysis to identify an association with increased RPE atrophic areas. Results: The mean number of anti-VEGF treatments was 9.18. RPE atrophic area was 1.293 +/- 1.298 mm(2) at baseline and enlarged to 2.394 +/- 1.940 mm(2) ater 24 months, which differed significantly (P = 0.001). Multiple regression analysis revealed that larger areas of RPE atrophy at month 4 and larger numbers of anti-VEGF treatments were associated with increased RPE atrophic areas. Conclusions: RPE atrophy progresses in eyes with exudative AMD during anti-VEGF treatment. Larger areas of RPE atrophy at month 4 and larger numbers of anti-VEGF injections were associated with an increased risk of progression of RPE atrophy the following treatment. These findings may be useful to clinicians using intravitreal anti-VEGF for the treatment of exudative AMD, both for selecting an appropriate treatment plan and for predicting the progression of RPE atrophy.
C1 [Kim, Moosang] Kangwon Natl Univ, Sch Med, Dept Ophthalmol, Chunchon, South Korea.
   [Kim, Eung Suk; Seo, Kyung Hoon; Yu, Seung-Young; Kwak, Hyung-Woo] Kyung Hee Univ, Kyung Hee Univ Hosp, Dept Ophthalmol, Seoul, South Korea.
C3 Kangwon National University; Kyung Hee University; Kyung Hee University
   Hospital
RP Yu, SY (通讯作者)，Kyung Hee Univ, Kyung Hee Univ Hosp, Dept Ophthalmol, Seoul, South Korea.
EM syyu@khu.ac.kr
FU Kangwon National University Hospital Grant
FX This study was supported by 2015 Kangwon National University Hospital
   Grant.
CR [Anonymous], 2012, J CLIN INVEST, V122, P4213
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Biarnes M, 2015, AM J OPHTHALMOL, V160, P345, DOI 10.1016/j.ajo.2015.05.009
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Veritti D, 2012, OPHTHALMOLOGICA, V227, P11, DOI 10.1159/000337154
NR 16
TC 8
Z9 8
U1 0
U2 1
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD JUN
PY 2016
VL 64
IS 6
BP 427
EP 433
DI 10.4103/0301-4738.187659
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DX4AZ
UT WOS:000384321600004
PM 27488150
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kelly, U
   Yu, L
   Kumar, P
   Ding, JD
   Jiang, HX
   Hageman, GS
   Arshavsky, VY
   Frank, MM
   Hauser, MA
   Rickman, CB
AF Kelly, Una
   Yu, Ling
   Kumar, Pallavi
   Ding, Jin-Dong
   Jiang, Haixiang
   Hageman, Gregory S.
   Arshavsky, Vadim Y.
   Frank, Michael M.
   Hauser, Michael A.
   Rickman, Catherine Bowes
TI Heparan Sulfate, Including That in Bruch's Membrane, Inhibits the
   Complement Alternative Pathway: Implications for Age-Related Macular
   Degeneration
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID SHORT CONSENSUS REPEAT; FACTOR-H POLYMORPHISM; C-REACTIVE PROTEIN;
   BINDING-SITES; FACTOR-I; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS;
   MOLECULAR-MECHANISMS; REGULATORY DOMAINS; TARGET RECOGNITION;
   IDENTIFICATION
AB An imbalance between activation and inhibition of the complement system has been implicated in the etiologies of numerous common diseases. Allotypic variants of a key complement fluid-phase regulatory protein, complement factor H (CFH), are strongly associated with age-related macular degeneration (AMD), a leading cause of worldwide visual dysfunction, although its specific role in AMD pathogenesis is still not clear. CFH was isolated from individuals carrying combinations of two of the nonsynonymous coding variants most strongly associated with AMD risk, V62/H402 (risk haplotype variants), I62/Y402 (nonrisk haplotype variants), and V62/Y402. These proteins were used in two functional assays (cell surface- and fluid-phase-based) measuring cofactor activity of CFH in the factor I-mediated cleavage of C3b. Although no variant-specific differences in the cofactor activity were detected, when heparan sulfate (HS) was added to these assays, it accelerated the rate of C3b cleavage, and this effect could be modulated by degree of HS sulfation. Bruch's membrane/choroid, a site of tissue damage in AMD, contains high concentrations of glycosaminoglycans, including HS. Addition of human Bruch's membrane/choroid to the fluid-phase assay accelerated the C3b cleavage, and this effect was lost posttreatment of the tissue with heparinase III. Binding of CFH variants to Bruch's membrane/choroid isolated from elderly, non-AMD donor eyes, was similar, as was the functional activity of bound CFH. These findings refine our understanding of interactions of HS and complement and support the hypothesis that these interactions play a role in the transition between normal aging and AMD in Bruch's membrane/choroid. The Journal of Immunology, 2010, 185: 5486-5494.
C1 [Rickman, Catherine Bowes] Duke Univ, Med Ctr, Dept Ophthalmol, Albert Eye Res Inst, Durham, NC 27710 USA.
   [Jiang, Haixiang; Frank, Michael M.] Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA.
   [Hauser, Michael A.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
   [Hauser, Michael A.] Duke Univ, Med Ctr, Ctr Human Genet, Durham, NC 27710 USA.
   [Rickman, Catherine Bowes] Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.
   [Kumar, Pallavi] Hosp Univ Penn, Dept Internal Med, Philadelphia, PA 19104 USA.
   [Hageman, Gregory S.] Univ Utah, John A Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84112 USA.
C3 Duke University; Duke University; Duke University; Duke University; Duke
   University; University of Pennsylvania; Pennsylvania Medicine; Utah
   System of Higher Education; University of Utah
RP Rickman, CB (通讯作者)，Duke Univ, Med Ctr, Dept Ophthalmol, Albert Eye Res Inst, Room 5010,Box 3802,Erwin Rd, Durham, NC 27710 USA.
EM bowes007@duke.edu
RI Ding, Jindong/B-3324-2008
OI Ding, Jindong/0000-0003-0427-0369; Bowes Rickman,
   Catherine/0000-0002-8555-9596
FU Lev Pharmaceuticals; Alcon Research Ltd.; Pfizer; Waratha
   Pharmaceuticals; CSL Behring; National Institutes of Health [R01
   EY019038, P30 EY005722, R24 EY017404, 5-P41-RR05351]; Research to
   Prevent Blindness, Inc.; Foundation Fighting Blindness; Ruth and Milton
   Steinbach Fund; Macular Vision Research Foundation; University of Miami;
   Vanderbilt University [NEI EY012118]; NATIONAL CENTER FOR RESEARCH
   RESOURCES [P41RR005351] Funding Source: NIH RePORTER; NATIONAL EYE
   INSTITUTE [P30EY014800, R24EY017404, U10EY012118, R01EY019038,
   P30EY005722, R01EY012118] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF GENERAL MEDICAL SCIENCES [P41GM103390] Funding Source: NIH
   RePORTER
FX G.S.H. has a financial interest in, and is the Chief Scientific Officer,
   of Optherion, Inc. M.M.F. has consultant arrangements with Lev
   Pharmaceuticals, CSL Behring, Jerini, and Dyax and has received research
   support from Lev Pharmaceuticals and CSL Behring. C.B.R. has consultant
   arrangements with Pfizer and has received research support from Alcon
   Research Ltd., Pfizer, and Waratha Pharmaceuticals.; This work was
   supported by National Institutes of Health Grants R01 EY019038 (to
   C.B.R.), P30 EY005722 (to Duke Eye Center), and R24 EY017404 (to
   G.S.H.), by Research to Prevent Blindness, Inc. Core Grants (to the Duke
   Eye Center and John A. Moran Eye Center), the Research to Prevent
   Blindness, Inc. Special Scholars Award (to C.B.R.), the Foundation
   Fighting Blindness (to C.B.R.), the Ruth and Milton Steinbach Fund (to
   C.B.R.), and the Macular Vision Research Foundation (to C.B.R.). The
   disaccharide analysis of the glycosaminoglycans performed by the Azadi
   laboratory was supported by National Institutes of Health Grant
   5-P41-RR05351 to the Complex Carbohydrate Research Center. A grant from
   Drs. Margaret Pericak-Vance (University of Miami) and Jonathan Haines
   (Vanderbilt University) (NEI EY012118) funded collection of a portion of
   the samples used in this work.
CR ALSENZ J, 1984, BIOCHEM J, V224, P389, DOI 10.1042/bj2240389
   Appel GB, 2005, J AM SOC NEPHROL, V16, P1392, DOI 10.1681/ASN.2005010078
   Blackmore TK, 1996, J IMMUNOL, V157, P5422
   Blackmore TK, 1998, J IMMUNOL, V160, P3342
   Boon CJF, 2009, MOL IMMUNOL, V46, P1573, DOI 10.1016/j.molimm.2009.02.013
   CALL TW, 1990, EXP EYE RES, V51, P451, DOI 10.1016/0014-4835(90)90158-Q
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   CLARK SJ, 2008, INVEST OPHTH VIS SCI, V49, pE5159
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   DISCIPIO RG, 1992, J IMMUNOL, V149, P2592
   DUVALLYOUNG J, 1989, BRIT J OPHTHALMOL, V73, P297, DOI 10.1136/bjo.73.4.297
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferreira VP, 2006, J IMMUNOL, V177, P6308, DOI 10.4049/jimmunol.177.9.6308
   GAITHER TA, 1979, J IMMUNOL, V123, P1195
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   GORDON DL, 1995, J IMMUNOL, V155, P348
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200
   Herbert AP, 2006, J BIOL CHEM, V281, P16512, DOI 10.1074/jbc.M513611200
   HEWITT AT, 1989, INVEST OPHTH VIS SCI, V30, P478
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE
   Jarva H, 1999, J IMMUNOL, V163, P3957
   Jokiranta TS, 2000, J BIOL CHEM, V275, P27657
   Jokiranta TS, 1996, FEBS LETT, V393, P297
   Kavanagh D, 2008, ANNU REV MED, V59, P293, DOI 10.1146/annurev.med.59.060106.185110
   Kelly U, 2009, INVEST OPHTH VIS SCI, V50, P1540, DOI 10.1167/iovs.08-2782
   Klein BEK, 2002, OPHTHALMOLOGY, V109, P2052, DOI 10.1016/S0161-6420(02)01249-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KUHN S, 1995, J IMMUNOL, V155, P5663
   Lawrence R, 2008, NAT METHODS, V5, P291, DOI 10.1038/nmeth0408-291
   MAYER MM, 1961, EXPT IMMUNOCHEMISTRY, V3, P133
   MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982
   Nadanaka S, 2008, J BIOCHEM, V144, P7, DOI 10.1093/jb/mvn040
   Oppermann M, 2006, CLIN EXP IMMUNOL, V144, P342, DOI 10.1111/j.1365-2249.2006.03071.x
   Ormsby RJ, 2006, MOL IMMUNOL, V43, P1624, DOI 10.1016/j.molimm.2005.09.012
   Pangburn MK, 2009, J IMMUNOL, V182, P1061, DOI 10.4049/jimmunol.182.2.1061
   Pangburn MK, 2000, IMMUNOPHARMACOLOGY, V49, P149, DOI 10.1016/S0162-3109(00)80300-8
   Pangburn MK, 2000, J IMMUNOL, V164, P4742, DOI 10.4049/jimmunol.164.9.4742
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Rabenstein DL, 2002, NAT PROD REP, V19, P312, DOI 10.1039/b100916h
   REID KBM, 1993, METHOD ENZYMOL, V223, P1
   Rose KL, 2008, J CLIN INVEST, V118, P608, DOI 10.1172/JCI32525
   Saunders RE, 2006, HUM MUTAT, V27, P21, DOI 10.1002/humu.20268
   Schmidt CQ, 2008, J IMMUNOL, V181, P2610, DOI 10.4049/jimmunol.181.4.2610
   SCOTT JE, 1980, BIOCHEM J, V187, P887, DOI 10.1042/bj1870887
   Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996
   Soames CJ, 1997, BIOCHEM J, V326, P553, DOI 10.1042/bj3260553
   Verdugo ME, 1997, EXP EYE RES, V65, P231, DOI 10.1006/exer.1997.0325
   Wei Z, 2005, J BIOL CHEM, V280, P15742, DOI 10.1074/jbc.M501102200
NR 50
TC 39
Z9 39
U1 0
U2 2
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD NOV 1
PY 2010
VL 185
IS 9
BP 5486
EP 5494
DI 10.4049/jimmunol.0903596
PG 9
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 668DL
UT WOS:000283248700062
PM 20876352
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Chen, YY
   Shen, YC
   Lai, YJ
   Wang, CY
   Lin, KH
   Feng, SC
   Liang, CY
   Wei, LC
   Chou, P
AF Chen, Yu-Yen
   Shen, Ying-Cheng
   Lai, Yun-Ju
   Wang, Chun-Yuan
   Lin, Keng-Hung
   Feng, Shih-Chao
   Liang, Chiao-Ying
   Wei, Li-Chen
   Chou, Pesus
TI Association between Metformin and a Lower Risk of Age-Related Macular
   Degeneration in Patients with Type 2 Diabetes
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OXIDATIVE STRESS; CHOROIDAL NEOVASCULARIZATION; GLUCOSE CONTROL;
   CANCER-RISK; INFLAMMATION; INHIBITION; DISEASE; MARKERS; IMPACT; RPE
AB Purpose. This population-based, retrospective cohort study was to investigate whether metformin is associated with a lower risk of subsequent age-related macular degeneration (AMD) in patients with type 2 diabetes. Methods. Using the Taiwan National Health Insurance Research Database from 2001 to 2013, 68205 subjects with type 2 diabetes were enrolled in the study cohort. Among them, 45524 were metformin users and 22681 were nonusers. The metformin and nonmetformin groups were followed until the end of 2013. Cox regression analyses were used to estimate hazard ratios (HRs) for AMD development associated with metformin use. Confounders included for adjustment were age, sex, and comorbidities (hypertension, hyperlipidemia, coronary artery disease, obesity, diabetic retinopathy, chronic kidney disease, and insulin treatment). Furthermore, propensity score (PS) matching method was used to choose the matched sample, and PS-adjusted Cox regression was performed. Finally, how HRs changed according to metformin treatment duration and dose was also evaluated in the metformin group. Results. After adjusting for confounders, the metformin group had a significantly lower risk of AMD (adjusted HR=0.54; 95% confidence interval [CI], 0.50-0.58). In the PS-matched sample, the significance remained (adjusted HR=0.57; 95% CI, 0.52-0.63). In the metformin group, the adjusted HRs for the second (1.5-4 years) and third (>= 4 years) tertiles of metformin treatment duration were 0.52 and 0.14, respectively, compared with the first tertile (<1.5 years). We also found significant trends of lower HRs (all p-value for trend <0.05) with increasing total and average doses. Conclusions. Among patients with type 2 diabetes, those who use metformin are at a significantly lower risk of developing AMD relative to individuals who do not use metformin. Also, the trend of a significantly lower AMD risk was found with a higher dose of metformin.
C1 [Chen, Yu-Yen; Shen, Ying-Cheng; Wang, Chun-Yuan; Lin, Keng-Hung; Feng, Shih-Chao; Liang, Chiao-Ying; Wei, Li-Chen] Taichung Vet Gen Hosp, Dept Ophthalmol, Taichung 407, Taiwan.
   [Chen, Yu-Yen; Lai, Yun-Ju; Wang, Chun-Yuan; Chou, Pesus] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan.
   [Chen, Yu-Yen; Chou, Pesus] Natl Yang Ming Univ, Community Med Res Ctr, Taipei 112, Taiwan.
   [Chen, Yu-Yen; Chou, Pesus] Natl Yang Ming Univ, Inst Publ Hlth, Taipei 112, Taiwan.
   [Lai, Yun-Ju] Taichung Vet Gen Hosp, Puli Branch, Dept Internal Med, Div Endocrinol & Metab, Nantou 545, Taiwan.
   [Lai, Yun-Ju] Natl Taiwan Univ Sport, Dept Exercise Hlth Sci, Taichung 404, Taiwan.
C3 Taichung Veterans General Hospital; National Yang Ming Chiao Tung
   University; National Yang Ming Chiao Tung University; National Yang Ming
   Chiao Tung University; Taichung Veterans General Hospital; National
   Taiwan University of Sport
RP Chen, YY (通讯作者)，Taichung Vet Gen Hosp, Dept Ophthalmol, Taichung 407, Taiwan.; Chen, YY (通讯作者)，Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan.; Chen, YY (通讯作者)，Natl Yang Ming Univ, Community Med Res Ctr, Taipei 112, Taiwan.; Chen, YY (通讯作者)，Natl Yang Ming Univ, Inst Publ Hlth, Taipei 112, Taiwan.
EM yuyenchen.phd@gmail.com
RI Lai, Yun-Ju/AAX-4990-2020
OI Liang, Chiao-Ying/0000-0001-9943-8202; Wei, Li-chen/0000-0002-9781-6940;
   Chen, Yu-Yen/0000-0003-0891-3819; Lin, Keng-Hung/0000-0001-7973-9841
CR Akirav EM, 2011, DIABETES, V60, P876, DOI 10.2337/db10-0793
   Batchuluun B, 2014, ATHEROSCLEROSIS, V232, P156, DOI 10.1016/j.atherosclerosis.2013.10.025
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Bordini HP, 2017, MOL CARCINOGEN, V56, P913, DOI 10.1002/mc.22545
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Cabreiro F, 2013, CELL, V153, P228, DOI 10.1016/j.cell.2013.02.035
   Cameron AR, 2016, CIRC RES, V119, P652, DOI 10.1161/CIRCRESAHA.116.308445
   Cavar I, 2014, ACTA CLIN CROAT, V53, P79
   Das UN, 2016, ARCH MED SCI, V12, P1142, DOI 10.5114/aoms.2016.61918
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Esteghamati A, 2013, CLIN NUTR, V32, P179, DOI 10.1016/j.clnu.2012.08.006
   Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7
   Holman RR, 2008, NEW ENGL J MED, V359, P1577, DOI 10.1056/NEJMoa0806470
   Hong J, 2013, DIABETES CARE, V36, P1304, DOI 10.2337/dc12-0719
   Hou XG, 2010, BIOCHEM BIOPH RES CO, V396, P199, DOI 10.1016/j.bbrc.2010.04.017
   Kirpichnikov D, 2002, ANN INTERN MED, V137, P25, DOI 10.7326/0003-4819-137-1-200207020-00009
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Lin CF, 2013, IMMUNOPHARM IMMUNOT, V35, P669, DOI 10.3109/08923973.2013.837059
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Maraldi T, 2010, INT J ONCOL, V36, P1581, DOI 10.3892/ijo_00000645
   Martin-Montalvo A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3192
   Masuda T, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9208489
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Roussel R, 2010, ARCH INTERN MED, V170, P1892, DOI 10.1001/archinternmed.2010.409
   Saisho Y, 2015, ENDOCR METAB IMMUNE, V15, P196, DOI 10.2174/1871530315666150316124019
   Tessier D, 1999, METABOLISM, V48, P897, DOI 10.1016/S0026-0495(99)90226-3
   Thomas J, 2015, SOUTH MED J, V108, P502, DOI 10.14423/SMJ.0000000000000329
   Tsai CH, 2013, BBA-GEN SUBJECTS, V1830, P2649, DOI 10.1016/j.bbagen.2012.12.017
   Tseng CH, 2017, ONCOTARGET, V8, P41132, DOI 10.18632/oncotarget.17066
   Tseng CH, 2017, ONCOTARGET, V8, P18802, DOI 10.18632/oncotarget.13390
   Tseng CH, 2016, AGING-US, V8, P1636, DOI 10.18632/aging.101019
   Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8
   Wang HB, 2016, MOL VIS, V22, P116
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 37
TC 17
Z9 19
U1 0
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD OCT 31
PY 2019
VL 2019
AR 1649156
DI 10.1155/2019/1649156
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JN5YU
UT WOS:000496974400002
PM 31781371
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Freiberg, FJ
   Michels, S
   Muldrew, A
   Slakter, J
   O'Shaughnessy, D
   Czeszynski, A
   Danielson, L
   Jackson, TL
   Chakravarthy, U
AF Freiberg, Florentina Joyce
   Michels, Stephan
   Muldrew, Alyson
   Slakter, Jason
   O'Shaughnessy, Denis
   Czeszynski, Alan
   Danielson, Linda
   Jackson, Timothy L.
   Chakravarthy, Usha
TI Microvascular abnormalities secondary to radiation therapy in
   neovascular age-related macular degeneration: findings from the INTREPID
   clinical trial
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID STEREOTACTIC RADIOTHERAPY; RANIBIZUMAB; RETINOPATHY
AB Purpose To report the incidence and features of retinal microvascular abnormalities (MVAs) occurring secondary to stereotactic radiotherapy (SRT) in a randomised double-masked sham-controlled clinical trial at 21 European sites.
   Methods Two hundred and thirty participants with neovascular age-related macular degeneration (AMD) treated with at least three intravitreal antivascular endothelial growth factor (anti-VEGF) injections prior to enrolment, and demonstrating a continuing need for re-treatment. Interventions: 16 Gy, 24 Gy or sham SRT. All three groups received pro re nata anti-VEGF injections if the lesion was judged to be active at review visits. Colour fundus images from baseline and 6 months and fluorescein angiograms from baseline and annual visits were graded for measures of morphological outcome and safety using a prespecified protocol with accompanying definitions to distinguish RT-related MVA from non-specific retinal vessel abnormalities that are known to occur in neovascular AMD. The main outcome measure was MVA detected by months 12, 24 and 36 after enrolment.
   Results The frequency of MVAs in the combined SRT arms was 0% in year 1, 13.1% in year 2 and 30.3% in year 3. The area of MVA was small and the mean change in visual acuity in year 2 was similar in a subset of SRT eyes with MVAs, versus those without MVAs. MVA was considered to have possibly contributed to vision loss in 2 of 18 cases with MVA in year 2, and 5 of 37 cases in year 3.
   Conclusion Treatment with SRT is associated with development of subtle MVAs that have little or no impact on visual outcome. These findings can help clinicians recognise the retinal MVAs that occur in response to SRT.
C1 [Freiberg, Florentina Joyce; Michels, Stephan] City Hosp Triemli, Dept Ophthalmol, Zurich, Switzerland.
   [Michels, Stephan] Univ Zurich, Augenklin, Zurich, Switzerland.
   [Muldrew, Alyson] Queens Univ Belfast, Cent Angiog Resource Facil, Belfast, Antrim, North Ireland.
   [Slakter, Jason] Retina Vitreous Consultants New York, Digital Angiog Reading Ctr, New York, NY USA.
   [O'Shaughnessy, Denis] Aura, Clin Dev, 85 Bolton St, Cambridge, MA USA.
   [Czeszynski, Alan] Neurovis Imaging LLC, Dept Res & Dev, 1395 Garden Highway, Sacramento, CA 95833 USA.
   [Danielson, Linda] Int Inst Drug Dev, Louvain La Neuve, Belgium.
   [Jackson, Timothy L.] Kings Coll London, Ophthalmol, London, England.
   [Chakravarthy, Usha] Queens Univ Belfast, Ctr Med Expt, Belfast BT12 6BA, Antrim, North Ireland.
C3 Triemli Hospital; University of Zurich; Queens University Belfast;
   International Drug Development Institute; University of London; King's
   College London; Queens University Belfast
RP Chakravarthy, U (通讯作者)，Queens Univ Belfast, Ctr Med Expt, Belfast BT12 6BA, Antrim, North Ireland.
EM u.chakravarthy@qub.ac.uk
RI Becker, Matthias/A-8733-2014
OI Jackson, Timothy/0000-0001-7618-1555; Czeszynski,
   Alan/0000-0001-8690-8367
FU Oraya Therapeutics
FX This study was funded and sponsored by Oraya Therapeutics. The sponsor
   was responsible for the design and conduct of the study. The sponsor
   played no role in the development of the reading center grading
   protocols.
CR AMOAKU WMK, 1990, EYE, V4, P657, DOI 10.1038/eye.1990.93
   Archer D B, 1994, Curr Opin Ophthalmol, V5, P59, DOI 10.1097/00055735-199406000-00011
   ARCHER DB, 1993, EYE, V7, P1, DOI 10.1038/eye.1993.3
   Brenner DJ, 2008, SEMIN RADIAT ONCOL, V18, P234, DOI 10.1016/j.semradonc.2008.04.004
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   BROWN GC, 1982, OPHTHALMOLOGY, V89, P1494
   CHAKRAVARTHY U, 1989, CURR EYE RES, V8, P337, DOI 10.3109/02713688908996381
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Dugel PU, 2013, OPHTHALMOLOGY, V120, P317, DOI 10.1016/j.ophtha.2012.07.068
   Flickinger John C, 2007, Prog Neurol Surg, V20, P28, DOI 10.1159/000100093
   Hall EJ, 2000, RADIOBIOLOGY RADIOLO, P387
   Hart PM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1029
   Jackson TL, 2015, OPHTHALMOLOGY, V122, P138, DOI 10.1016/j.ophtha.2014.07.043
   Jackson TL, 2014, RETINA-J RET VIT DIS, V34, P568, DOI 10.1097/IAE.0b013e3182a487be
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1893, DOI 10.1016/j.ophtha.2013.02.016
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   KREBS IP, 1992, HISTOL HISTOPATHOL, V7, P101
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   PARSONS JT, 1994, INT J RADIAT ONCOL, V30, P765, DOI 10.1016/0360-3016(94)90347-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Subhash HM, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.2.021103
NR 21
TC 9
Z9 9
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD APR
PY 2019
VL 103
IS 4
BP 469
EP 474
DI 10.1136/bjophthalmol-2018-311865
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ID7OE
UT WOS:000471871400006
PM 29930098
OA Bronze, Green Submitted
DA 2022-11-30
ER

PT J
AU Talks, JS
   James, P
   Sivaprasad, S
   Johnston, RL
   McKibbin, M
AF Talks, J. S.
   James, P.
   Sivaprasad, S.
   Johnston, R. L.
   McKibbin, M.
CA UK Aflibercept Users Grp
TI Appropriateness of quality standards for meaningful intercentre
   comparisons of aflibercept service provision for neovascular age-related
   macular degeneration
SO EYE
LA English
DT Article
ID RANIBIZUMAB; OUTCOMES; TRIAL; DELAY
AB Purpose Real-world data give different information on health-care delivery compared with randomised controlled trials. We aimed to evaluate the appropriateness of possible quality standards for intersite comparisons of outcomes of providing Aflibercept for neovascular age-related macular degeneration (nAMD) in clinical practice.
   Patients and methods Retrospective data analysis from an electronic medical record. A consecutive series of treatment-naive patients initiated on aflibercept for nAMD, in the UK from March 2013 to October 2015. Age, visual acuity (VA) at baseline and 1 year, and injection episodes were remotely extracted in an anonymised format.
   Results The mean baseline VA was 54.3 letters, ranging from 51.3 to 58.1 between different centres, in 5620 eyes taken from 12 centres. Out of these, 3360 were initiated on treatment more than a year before. The percentage with <35 letters at baseline was 19.9-3% and that with > 70 letters was 24.8-10.7%. Eyes with >= 70 letters at 1 year ranged from 20.2 to 42.9% and those with <35 ranged from 4.5 to 21.6% across different sites. Injection rates in 1 year varied from 5.5 to 8.6, and data available at 1 year also varied from 82.3 to 46.4%.
   Conclusions Significant variation was found between sites attempting to provide the same therapeutic regime. For fair comparisons between sites, we recommend that both VA measures and process measures, such as injection numbers, retention rates, and discharge policies, are used. More work is required to explain the differences. Such real world data are not generated in the same way as a randomised clinical trial, and maybe best used to help improve service provision.
C1 [Talks, J. S.] Newcastle Upon Tyne Hosp NHS Fdn Trust, Newcastle Eye Ctr, Newcastle Upon Tyne, Tyne & Wear, England.
   [James, P.] Newcastle Univ, Inst Hlth & Soc, Newcastle Upon Tyne, Tyne & Wear, England.
   [Sivaprasad, S.] Kings Coll Hosp NHS Fdn Trust, London, England.
   [Sivaprasad, S.] NIHR Moorfields Biomed Res Ctr, London, England.
   [Johnston, R. L.] Gloucestershire Hosp NHS Fdn Trust, London, England.
   [McKibbin, M.] Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England.
C3 Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle University
   - UK; King's College Hospital NHS Foundation Trust; Gloucestershire
   Hospitals NHS Foundation Trust; University of Leeds
RP Talks, JS (通讯作者)，Newcastle Upon Tyne Hosp NHS Fdn Trust, Eye Ctr, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
EM Jamestalks093@googlemail.corn
RI Sivaprasad, S./D-6876-2015
OI Sivaprasad, S./0000-0001-8952-0659; McKibbin,
   Martin/0000-0003-4388-243X; Talks, James/0000-0001-6126-6476
FU Bayer; Novartis; Allergan
FX Medisoft and Newcastle Upon Tyne Hospitals NHS Foundation Trust received
   support for data extraction and analysis from Bayer. The authors have
   received travel bursaries and attended advisory boards for Bayer,
   Novartis, and Allergan.
CR Arias L, 2009, EYE, V23, P326, DOI 10.1038/sj.eye.6703053
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Freund BK, 2015, RETINA, V35, P1489
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P676, DOI 10.1016/j.ophtha.2013.09.050
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Liew G, 2016, EYE, V30, P1462, DOI 10.1038/eye.2016.149
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Pagliarini S, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/857148
   Pushpoth S, 2012, BRIT J OPHTHALMOL, V96, P1469, DOI 10.1136/bjophthalmol-2012-302167
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothwell PM, 2005, LANCET, V365, P82, DOI 10.1016/S0140-6736(04)17670-8
   Sherman RE, 2016, NEW ENGL J MED, V375, P2293, DOI 10.1056/NEJMsb1609216
   SINGAL AG, 2014, CLIN TRANSL GASTROEN, V5
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
NR 21
TC 9
Z9 9
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD NOV
PY 2017
VL 31
IS 11
BP 1613
EP 1620
DI 10.1038/eye.2017.86
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FM1QK
UT WOS:000414754600017
PM 28643799
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Reiter, GS
   Told, R
   Baratsits, M
   Hecht, A
   Schlanitz, FG
   Sacu, S
   Schmidt-Erfurth, U
AF Reiter, Gregor Sebastian
   Told, Reinhard
   Baratsits, Magdalena
   Hecht, Alexander
   Schlanitz, Ferdinand Georg
   Sacu, Stefan
   Schmidt-Erfurth, Ursula
TI Repeatability and reliability of quantitative fundus autofluorescence
   imaging in patients with early and intermediate age-related macular
   degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE quantitative fundus autofluorescence; qAF; validation; age-related
   macular degeneration; AMD; drusen
ID RETINAL-PIGMENT EPITHELIUM; SPATIAL-DISTRIBUTION; FOLLOW-UP; LIPOFUSCIN;
   DRUSEN; CLASSIFICATION; FLUORESCENCE; AGREEMENT; DENSITY; EYES
AB Purpose Quantification of fundus autofluorescence has only recently become available. We report our findings on the evaluation of the repeatability and reliability of quantitative fundus autofluorescence (qAF) measurements in patients with early and intermediate age-related macular degeneration (AMD), using the first approved and commercially available instrument. Methods A total of 43 eyes of 22 patients (aged between 52 and 84 years) diagnosed with early and intermediate AMD were included. All eyes were imaged at day 1, 3 months and 6 months using a modified scanning laser ophthalmoscope, equipped with an internal fluorescent reference. Mean qAF values were calculated for the fovea and for each concentric ring of the Delori pattern. Repeatability and reliability were calculated using Bland-Altman analysis and intraclass correlation (ICC). Results The mean patient age was 73.5 +/- 7.9 years. Sixteen patients (73%) were female. qAF repeatability of the eight segments in the middle ring of the Delori pattern (qAF(M8)) for between sessions was +/- 8.2%. Agreement at 3- and 6-month follow-up in eyes without retinal changes was +/- 8.3% and +/- 9.8%, respectively. Reliability of qAF(M8) was high for all images acquired [ICC = 0.98 (CI: 0.96-0.99), 0.97 (0.93-0.99) and 0.98 (0.92-0.99)]. Agreement at 3- and 6-month follow-up in eyes with retinal changes was +/- 18.1% and +/- 20.2%, respectively. Intraclass correlation (ICC) was slightly lower in eyes with retinal changes at 0.93 (0.84-0.97) and 0.96 (0.91-0.98), respectively. Conclusions Quantitative autofluorescence shows excellent repeatability and reliability as well as follow-up agreement in patients with early and intermediate AMD without retinal changes. This is relevant when conducting longitudinal studies using qAF.
C1 [Reiter, Gregor Sebastian; Told, Reinhard; Baratsits, Magdalena; Hecht, Alexander; Schlanitz, Ferdinand Georg; Sacu, Stefan; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol & Optometry, Vienna Trial Ctr, Vienna, Austria.
C3 Medical University of Vienna
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol & Optometry, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
OI Told, Reinhard/0000-0003-2046-7081; Reiter, Gregor/0000-0001-7661-4015
CR Ablonczy Z, 2013, INVEST OPHTH VIS SCI, V54, P5535, DOI 10.1167/iovs.13-12250
   Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Ach T, 2012, BRIT J OPHTHALMOL, V96, P1141, DOI 10.1136/bjophthalmol-2012-301547
   Adler R, 1999, MOL VIS, V5
   [Anonymous], EYE
   Armenti ST, 2016, JOVE-J VIS EXP, DOI 10.3791/53577
   Bartlett JW, 2008, ULTRASOUND OBST GYN, V31, P466, DOI 10.1002/uog.5256
   Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1191/096228099673819272
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Burke TR, 2014, INVEST OPHTH VIS SCI, V55, P2841, DOI 10.1167/iovs.13-13624
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Delori FC, 2004, ARCH BIOCHEM BIOPHYS, V430, P156, DOI 10.1016/j.abb.2004.05.016
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   Delori F, 2011, INVEST OPHTH VIS SCI, V52, P9379, DOI 10.1167/iovs.11-8319
   Duncker T, 2014, INVEST OPHTH VIS SCI, V55, P1471, DOI 10.1167/iovs.13-13834
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gliem M, 2016, JAMA OPHTHALMOL, V134, P817, DOI 10.1001/jamaophthalmol.2016.1475
   Greenberg JP, 2013, INVEST OPHTH VIS SCI, V54, P5684, DOI 10.1167/iovs.13-12445
   Joachim NDL, 2015, JAMA OPHTHALMOL, V133, P698, DOI 10.1001/jamaophthalmol.2015.0498
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Muller PL, 2015, INVEST OPHTH VIS SCI, V56, P8179, DOI 10.1167/iovs.15-17629
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Pichi F, 2018, ACTA OPHTHALMOL, V96, pE549, DOI 10.1111/aos.13602
   Rossberger S, 2013, BRIT J OPHTHALMOL, V97, P518, DOI 10.1136/bjophthalmol-2012-302350
   Sauer L, 2018, ACTA OPHTHALMOL, V96, P257, DOI 10.1111/aos.13587
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Tong YH, 2016, RETINA-J RET VIT DIS, V36, pS127, DOI 10.1097/IAE.0000000000001325
   van de Kraats J, 2007, J OPT SOC AM A, V24, P1842, DOI 10.1364/JOSAA.24.001842
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   Yamamoto K, 2012, INVEST OPHTH VIS SCI, V53, P3536, DOI 10.1167/iovs.12-9535
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
NR 37
TC 14
Z9 14
U1 1
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUN
PY 2019
VL 97
IS 4
BP E526
EP E532
DI 10.1111/aos.13987
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HV7WE
UT WOS:000466191000020
PM 30549203
DA 2022-11-30
ER

PT J
AU Unlu, C
   Erdogan, G
   Gunay, BO
   Kardes, E
   Akcay, BIS
   Ergin, A
AF Unlu, Cihan
   Erdogan, Gurkan
   Gunay, Betul Onal
   Kardes, Esra
   Akcay, Betul Ilkay Sezgin
   Ergin, Ahmet
TI Subfoveal choroidal thickness changes after intravitreal bevacizumab
   injection for neovascular age-related macular degeneration and diabetic
   macular edema
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Choroidal thickness; Diabetic macular edema; Enhanced depth imaging;
   Intravitreal bevacizumab; Neovascular AMD; Optical coherence tomography
ID ENDOTHELIAL GROWTH-FACTOR; OPTICAL COHERENCE TOMOGRAPHY; RETINAL-PIGMENT
   EPITHELIUM; FACTOR-A; RANIBIZUMAB; THERAPY; PHARMACOKINETICS; VEGF;
   CHORIOCAPILLARIS; RETINOPATHY
AB The purpose of this study was to investigate the changes in subfoveal choroidal thickness (SFCT) after intravitreal injection of bevacizumab (IVB) for neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME). This retrospective, consecutive, interventional case series study included 43 eyes [21 affected eyes with neovascular AMD (AMD group) and 22 affected eyes with DME (DME group)] which were treated with 1.25 mg/0.5 ml IVB and 43 untreated fellow eyes of 43 patients. SFCT was measured in all 86 eyes at baseline before IVB injection and at day 1, week 1, and month 1 after injection by use of enhanced depth imaging optical coherence tomography (EDI OCT). Central foveal thickness (CFT) and best-corrected visual acuity were analyzed at baseline and during follow-up visits. Main outcome measure was change in SFCT in 1 month after treatment. All 43 eyes treated with IVB showed a significant reduction in SFCT. Mean SFCT in treated eyes decreased from 237.1 +/- 75.3 A mu m at baseline to 214.0 +/- 65.7 A mu m at day 1, 205.4 +/- 59.7 at week 1, and 222.7 +/- 73.3 at month 1, whereas SFCT in fellow eyes changed from 228.4 +/- 63.6 at baseline to 224.5 +/- 68.5 at day 1, 220.4 +/- 72.1 at week 1, and 226.9 +/- 74.0 at month 1. SFCT demonstrated a similar trend toward decrease in both groups. CFT decreased significantly and visual acuity improved significantly. SFCT decreased significantly in AMD and DME eyes following injection. The decreasing effect of bevacizumab on choroidal thickness was highest at first week and continued to the end of first month after injection.
C1 [Unlu, Cihan; Erdogan, Gurkan; Gunay, Betul Onal; Kardes, Esra; Akcay, Betul Ilkay Sezgin; Ergin, Ahmet] Umraniye Training & Res Hosp, Bengisu Evleri Sitesi D2-2 Bengisu Cad, Istanbul, Turkey.
C3 Istanbul Umraniye Training & Research Hospital
RP Unlu, C (通讯作者)，Umraniye Training & Res Hosp, Bengisu Evleri Sitesi D2-2 Bengisu Cad, Istanbul, Turkey.
EM drcihanunlu@yahoo.com
RI Gunay, Betul Onal/AAZ-6040-2020; Erdogan, Gurkan/AAV-3972-2021; sezgin
   Akcay, Betül ilkay/AAB-7265-2022; ünlü, cihan/AAJ-1492-2021; kardeş,
   esra/AAB-9501-2022
OI Gunay, Betul Onal/0000-0001-5465-2635; Erdogan,
   Gurkan/0000-0003-4155-0407; 
CR Abouammoh M, 2011, CURR OPIN OPHTHALMOL, V22, P152, DOI 10.1097/ICU.0b013e32834595d0
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bhisitkul RB, 2006, BRIT J OPHTHALMOL, V90, P1542, DOI 10.1136/bjo.2006.098426
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Cao JT, 1998, ARCH OPHTHALMOL-CHIC, V116, P589, DOI 10.1001/archopht.116.5.589
   Cao XS, 2014, RETINA-J RET VIT DIS, V34, P1554, DOI 10.1097/IAE.0000000000000122
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   CUNHAVAZ J, 1975, BRIT J OPHTHALMOL, V59, P649, DOI 10.1136/bjo.59.11.649
   *EARL TREATM DIAB, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI DOI 10.1001/ARCHOPHT.1985.01050120030015
   El-Mollayess GM, 2011, SEMIN OPHTHALMOL, V26, P69, DOI 10.3109/08820538.2010.545100
   Ellabban AA, 2012, CLIN OPHTHALMOL, V6, P837, DOI 10.2147/OPTH.S30907
   Ferrara N, 2000, RECENT PROG HORM RES, V55, P15
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   FRYCZKOWSKI AW, 1988, ANN OPHTHALMOL, V20, P299
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Jonas JB, 2014, RETINA-J RET VIT DIS, V34, P1149, DOI 10.1097/IAE.0000000000000035
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Lains I, 2014, RETINA-J RET VIT DIS, V34, P1199, DOI 10.1097/IAE.0000000000000053
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   Lutty G, 1999, MOL VIS, V5
   Maharaj ASR, 2007, MICROVASC RES, V74, P100, DOI 10.1016/j.mvr.2007.03.004
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruko I, 2013, AM J OPHTHALMOL, V156, P548, DOI 10.1016/j.ajo.2013.03.041
   Mrejen S, 2013, SURV OPHTHALMOL, V58, P387, DOI 10.1016/j.survophthal.2012.12.001
   Nicholson B, 2013, SURV OPHTHALMOL, V58, P103, DOI 10.1016/j.survophthal.2012.07.004
   Nishide T, 2013, GRAEF ARCH CLIN EXP, V251, P2415, DOI 10.1007/s00417-013-2419-z
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Pournaras CJ, 2008, PROG RETIN EYE RES, V27, P284, DOI 10.1016/j.preteyeres.2008.02.002
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P6017, DOI 10.1167/iovs.12-9692
   Rajendram R, 2012, ARCH OPHTHALMOL-CHIC, V130, P972, DOI 10.1001/archophthalmol.2012.393
   Regatieri CV, 2012, RETINA-J RET VIT DIS, V32, P563, DOI [10.1097/IAE.0B013E31822F5678, 10.1097/IAE.0b013e31822f5678]
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Sivaprasad S, 2013, BRIT J OPHTHALMOL, V97, P1177, DOI 10.1136/bjophthalmol-2013-303168
   Sizmaz S, 2014, EUR J OPHTHALMOL, V24, P904, DOI 10.5301/ejo.5000478
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Stewart MW, 2012, MAYO CLIN PROC, V87, P77, DOI 10.1016/j.mayocp.2011.10.001
   Ternant D, 2005, EXPERT OPIN BIOL TH, V5, pS37, DOI 10.1517/14712598.5.1.S37
   Thomas BJ, 2013, CAN J OPHTHALMOL, V48, P22, DOI 10.1016/j.jcjo.2012.11.012
   Vujosevic S, 2012, RETINA-J RET VIT DIS, V32, P1781, DOI 10.1097/IAE.0b013e31825db73d
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Yiu G, 2014, AM J OPHTHALMOL, V158, P745, DOI 10.1016/j.ajo.2014.06.006
   Zheng YF, 2012, INDIAN J OPHTHALMOL, V60, P428, DOI 10.4103/0301-4738.100542
   Zhu Q, 2008, OPHTHALMOLOGY, V115, P1750, DOI 10.1016/j.ophtha.2008.04.023
NR 51
TC 5
Z9 6
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD FEB
PY 2017
VL 37
IS 1
BP 147
EP 158
DI 10.1007/s10792-016-0242-3
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EK8FR
UT WOS:000394159800021
PM 27154721
DA 2022-11-30
ER

PT J
AU Marakis, TP
   Koutsandrea, C
   Poulou, MS
AF Marakis, Theodoros P.
   Koutsandrea, Chrysanthi
   Poulou, Maria S.
TI The impact of vision impairment on vision-related quality of life of
   patients with neovascular age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; retina; epidemiology; biostatistics;
   retina; medical therapies; socioeconomics and education in medicine;
   ophthalmology; epidemiology; risk factors
ID LETTER-CHART; QUESTIONNAIRE; RELIABILITY; SYMPTOMS; ANXIETY; PEOPLE
AB Purpose: To investigate the validity and reliability of the Greek Impact of Vision Impairment Questionnaire (IVI) and to explore the predictors of vision-related quality of life (VRQoL) in individuals with neovascular age-related macular degeneration (nAMD). Methods: About 191 patients completed the IVI and the SF-12 Health Survey, and were assessed on visual exams. A random group of 20 participants completed the IVI twice with a 2 weeks interval, to assess test-retest reliability. About 102 patients completed the IVI 1 year later in a follow-up examination. Rasch analysis was used to evaluate response category functioning, scale precision, unidimensionality, scale targeting and differential item functioning. Stepwise multiple linear regression analyses identified predictors of VRQoL. Results: Test-retest reliability of IVI items was calculated from 0.86 to 0.98. The six response categories were merged into four to figure out disordered thresholds. Rasch analysis concluded in three scales: Mobility and Independence, Reading and Accessing Information, and Emotional Wellbeing. Regarding convergent validity, the IVI scores had significant associations with SF-12 components (rho = 0.28-0.47) and measurements of visual acuity (rho = 0.39-0.66). Worse VRQoL at 1 year follow-up was correlated with decline in distance and near VA. Distance VA and the SF-12 components were common predictors for all three subscales. The duration of disease was a significant predictor for the emotional subscale. Conclusion: The Greek IVI was found to assess AMD patients' perceptions of VRQoL in a valid, reliable and responsive to eyesight manner. VRQoL was mainly established by patients' distance VA and mental health.
C1 [Marakis, Theodoros P.; Koutsandrea, Chrysanthi] Univ Athens, Athens Gen Hosp G Gennimatas, Dept Ophthalmol 1, Sch Med, Athens, Greece.
   [Poulou, Maria S.] Univ Patras, Dept Educ Sci & Early Childhood Educ, Patras, Western Greece, Greece.
C3 Athens Medical School; National & Kapodistrian University of Athens;
   University of Patras
RP Marakis, TP (通讯作者)，Univ Athens, Athens Gen Hosp G Gennimatas, Dept Ophthalmol 1, Sch Med, Athens, Greece.
EM theomarakis@yahoo.gr
OI MARAKIS, THEODOROS/0000-0003-2359-8984
CR Ang M, 2018, BRIT J OPHTHALMOL, V102, P878, DOI 10.1136/bjophthalmol-2017-310745
   ARDITI A, 1993, INVEST OPHTH VIS SCI, V34, P120
   Bertelmann T, 2016, HEALTH QUAL LIFE OUT, V14, DOI 10.1186/s12955-016-0536-1
   Bond T.G., 2015, APPL RASCH MODEL FUN
   Bourne RRA, 2018, BRIT J OPHTHALMOL, V102, P575, DOI 10.1136/bjophthalmol-2017-311258
   Chatziralli I, 2017, SEMIN OPHTHALMOL, V32, P772, DOI 10.1080/08820538.2016.1181192
   Cimarolli VR, 2016, CLIN OPHTHALMOL, V10, P55, DOI 10.2147/OPTH.S80489
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Fenwick EK, 2018, BRIT J OPHTHALMOL, V102, P377, DOI 10.1136/bjophthalmol-2017-310532
   Fenwick EK, 2016, QUAL LIFE RES, V25, P871, DOI 10.1007/s11136-015-1141-1
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1246, DOI 10.1016/j.ophtha.2013.12.032
   Finger RP, 2011, INVEST OPHTH VIS SCI, V52, P3613, DOI 10.1167/iovs.10-7127
   Goldstein JE, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.6.38
   Gothwal VK, 2013, INVEST OPHTH VIS SCI, V54, P2902, DOI 10.1167/iovs.12-10783
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Heesterbeek TJ, 2017, OPHTHAL PHYSL OPT, V37, P385, DOI 10.1111/opo.12388
   Horton JC, 1997, SURV OPHTHALMOL, V42, P169, DOI 10.1016/S0039-6257(97)00055-6
   Khadka J, 2012, HEALTH QUAL LIFE OUT, V10, DOI 10.1186/1477-7525-10-80
   Kontodimopoulos N, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-55
   Labiris G, 2008, BMC OPHTHALMOL, V8, DOI 10.1186/1471-2415-8-4
   Lamoureux EL, 2006, INVEST OPHTH VIS SCI, V47, P4732, DOI 10.1167/iovs.06-0220
   Lamoureux EL, 2004, AM J OPHTHALMOL, V137, P265, DOI 10.1016/j.ajo.2003.08.003
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Marakis TP, 2017, QUAL LIFE RES, V26, P183, DOI 10.1007/s11136-016-1407-2
   Matamoros E, 2015, OPHTHALMOLOGICA, V234, P151, DOI 10.1159/000433448
   Mitchell Jan, 2005, Health Qual Life Outcomes, V3, P25, DOI 10.1186/1477-7525-3-25
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Ratanasukon M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155509
   Rees G, 2010, INVEST OPHTH VIS SCI, V51, P2891, DOI 10.1167/iovs.09-5080
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Selivanova A, 2019, OPTOMETRY VISION SCI, V96, P87, DOI 10.1097/OPX.0000000000001327
   Senra H, 2019, AM J GERIAT PSYCHIAT, V27, P755, DOI 10.1016/j.jagp.2019.03.001
   Sturrock BA, 2015, INVEST OPHTH VIS SCI, V56, P2416, DOI 10.1167/iovs.14-16223
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Terwee CB, 2007, J CLIN EPIDEMIOL, V60, P34, DOI 10.1016/j.jclinepi.2006.03.012
   van Asten F, 2015, ACTA OPHTHALMOL, V93, P126, DOI 10.1111/aos.12610
   Ware JE, 1994, SF 36 PHYS MENTAL HL
   Weih LM, 2002, INVEST OPHTH VIS SCI, V43, P927
   Wild D, 2005, VALUE HEALTH, V8, P94, DOI 10.1111/j.1524-4733.2005.04054.x
NR 41
TC 3
Z9 3
U1 1
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN
PY 2022
VL 32
IS 1
BP 481
EP 490
AR 1120672120972625
DI 10.1177/1120672120972625
EA NOV 2020
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YK3MJ
UT WOS:000677787600001
PM 33213182
DA 2022-11-30
ER

PT J
AU Beirne, RO
   McConnell, E
AF Beirne, Raymond O.
   McConnell, Emma
TI Investigation of the relationship between macular pigment levels and
   rod-mediated dark adaptation in intermediate age-related macular
   degeneration
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Article
DE age-related macular degeneration; macular pigment; rods
ID OPTICAL-DENSITY; SPATIAL PROFILE; OLDER-ADULTS; EYE DISEASE; ZEAXANTHIN;
   LUTEIN; HEALTH
AB Background It has been shown that rod-mediated dark adaptation is significantly delayed in ageing, a change which is exacerbated in age-related macular degeneration (AMD). Levels of lutein and zeaxanthin, the two main constituents of macular pigment have been found in rod outer segments, indicating that the macular pigment may have an influence on rod-mediated dark adaptation. The aim of this study was to determine if rod-mediated dark adaptation is associated with central macular pigment levels in individuals with intermediate stage AMD. Methods A cross-sectional observational study included individuals with acuity better than 6/15 Snellen and intermediate stage AMD based on graded fundus photographs using an internationally accepted grading scale. Rod-mediated dark adaptation was assessed at five degrees eccentricity in the superior retina (inferior visual field) using the rod intercept time measure from the MacuLogix AdaptDx. Macular pigment optical density was measured at 0.5 degrees eccentricity using a heterochromatic flicker photometry-based method. Results Twenty-seven individuals (mean age 76.7 years) with intermediate stage AMD and 23 age-matched normal controls (mean age 74.0 years) were recruited. Rod-mediated dark adaptation was significantly delayed in intermediate stage AMD compared with healthy controls (32.9 minutes versus 10.7 minutes, p < 0.01). There was no statistically significant correlation between the rod intercept time and the level of macular pigment in those with intermediate AMD (r = -0.04, p = 0.85). Conclusion The results did not support the hypothesis that higher macular pigment is associated with improved rod-mediated performance or that higher levels of macular pigment protect rod-mediated function in intermediate AMD.
C1 [Beirne, Raymond O.; McConnell, Emma] Univ Ulster, Sch Biomed Sci, Dept Optometry & Vis Sci, Vis Sci Res Grp, Coleraine, Londonderry, North Ireland.
C3 Ulster University
RP Beirne, RO (通讯作者)，Univ Ulster, Sch Biomed Sci, Dept Optometry & Vis Sci, Vis Sci Res Grp, Coleraine, Londonderry, North Ireland.
EM r.beirne@ulster.ac.uk
OI McConnell, Emma/0000-0002-6180-418X
FU Macular Society (UK)
FX This study was supported by a research grant from the Macular Society
   (UK).
CR Barker FM, 2011, INVEST OPHTH VIS SCI, V52, P3934, DOI 10.1167/iovs.10-5898
   Beirne RO, 2014, GRAEF ARCH CLIN EXP, V252, P383, DOI 10.1007/s00417-013-2471-8
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Dietzel M, 2011, INVEST OPHTH VIS SCI, V52, P3452, DOI 10.1167/iovs.10-6713
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   IJSPEERT JK, 1990, VISION RES, V30, P699, DOI 10.1016/0042-6989(90)90096-4
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jackson GR, 2014, OPTOMETRY VISION SCI, V91, P925, DOI 10.1097/OPX.0000000000000247
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Jackson Gregory R, 2008, J Ocul Biol Dis Infor, V1, P7, DOI 10.1007/s12177-008-9002-6
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Kanis MJ, 2007, GRAEF ARCH CLIN EXP, V245, P767, DOI 10.1007/s00417-006-0478-0
   Kaya S, 2012, ACTA OPHTHALMOL, V90, pe399, DOI 10.1111/j.1755-3768.2012.02423.x
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   LaRowe TL, 2008, OPHTHALMOLOGY, V115, P876, DOI 10.1016/j.ophtha.2007.06.015
   Loane E, 2008, BRIT J OPHTHALMOL, V92, P1163, DOI 10.1136/bjo.2007.135566
   Loughman J, 2010, VISION RES, V50, P1249, DOI 10.1016/j.visres.2010.04.009
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Owsley C, 2014, INVEST OPHTH VIS SCI, V55, P4776, DOI 10.1167/iovs.14-14502
   Patryas L, 2014, GRAEF ARCH CLIN EXP, V252, P657, DOI 10.1007/s00417-014-2564-z
   POKORNY J, 1987, APPL OPTICS, V26, P1437, DOI 10.1364/AO.26.001437
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   Robson AG, 2003, VISION RES, V43, P1765, DOI 10.1016/S0042-6989(03)00280-3
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   Sommerburg O, 1999, CURR EYE RES, V19, P491, DOI 10.1076/ceyr.19.6.491.5276
   Stringham JM, 2008, EXP EYE RES, V87, P445, DOI 10.1016/j.exer.2008.08.005
   Stringham JM, 2015, INVEST OPHTH VIS SCI, V56, P2459, DOI 10.1167/iovs.14-15716
   Suzuki M, 2007, MOL VIS, V13, P772
   Weale RA, 2007, OPHTHAL PHYSL OPT, V27, P1, DOI 10.1111/j.1475-1313.2006.00452.x
   Wooten BR, 2002, PROG RETIN EYE RES, V21, P225, DOI 10.1016/S1350-9462(02)00003-4
   Wooten BR, 1999, INVEST OPHTH VIS SCI, V40, P2481
   Zarubina AV, 2018, CURR EYE RES, V43, P913, DOI 10.1080/02713683.2018.1460380
NR 39
TC 3
Z9 3
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD NOV
PY 2019
VL 102
IS 6
BP 611
EP 616
DI 10.1111/cxo.12882
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JH5OX
UT WOS:000492819000012
PM 30791135
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Hageman, GS
   Anderson, DH
   Johnson, LV
   Hancox, LS
   Taiber, AJ
   Hardisty, LI
   Hageman, JL
   Stockman, HA
   Borchardt, JD
   Gehrs, KM
   Smith, RJH
   Silvestri, G
   Russell, SR
   Klaver, CCW
   Barbazetto, I
   Chang, S
   Yannuzzi, LA
   Barile, GR
   Merriam, JC
   Smith, RT
   Olsh, AK
   Bergeron, J
   Zernant, J
   Merriam, JE
   Gold, B
   Dean, M
   Allikmets, R
AF Hageman, GS
   Anderson, DH
   Johnson, LV
   Hancox, LS
   Taiber, AJ
   Hardisty, LI
   Hageman, JL
   Stockman, HA
   Borchardt, JD
   Gehrs, KM
   Smith, RJH
   Silvestri, G
   Russell, SR
   Klaver, CCW
   Barbazetto, I
   Chang, S
   Yannuzzi, LA
   Barile, GR
   Merriam, JC
   Smith, RT
   Olsh, AK
   Bergeron, J
   Zernant, J
   Merriam, JE
   Gold, B
   Dean, M
   Allikmets, R
TI A common haplotype in the complement regulatory gene factor H (HF1/CFH)
   predisposes individuals to age-related macular degeneration
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID HEMOLYTIC-UREMIC SYNDROME; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS;
   CHOROIDAL NEOVASCULARIZATION; SUSCEPTIBILITY LOCI; APOLIPOPROTEIN-E;
   DRUSEN FORMATION; LARGE FAMILY; DISEASE; MACULOPATHY; ACTIVATION
AB Age-related macular degeneration (AMD) is the most frequent cause of irreversible blindness in the elderly in developed countries. Our previous studies implicated activation of complement in the formation of drusen, the hallmark lesion of AMD. Here, we show that factor H (HF1), the major inhibitor of the alternative complement pathway, accumulates within drusen and is synthesized by the retinal pigmented epithelium. Because previous linkage analyses identified chromosome 1q25-32, which harbors the factor H gene (HF1/CFH), as an AMD susceptibility locus, we analyzed HF1 for genetic variation in two independent cohorts comprised of approximate to 900 AMD cases and 400 matched controls. We found association of eight common HF1 SNPs with AMD; two common missense variants exhibit highly significant associations (162V, chi(2) = 26.1 and P = 3.2 x 10(-7) and Y402H, chi(2) = 54.4 and P = 1.6 x 10(-13)). Haplotype analysis reveals that multiple HF1 variants confer elevated or reduced risk of AMD. One common at-risk haplotype is present at a frequency of 50% in AMD cases and 29% in controls [odds ratio (OR) = 2.46, 95% confidence interval (1.95-3.11)]. Homozygotes for this haplotype account for 24% of cases and 8% of controls [OR = 3.51, 95% confidence interval (2.13-5.78)]. Several protective haplotypes are also identified (OR = 0.44-0.55), further implicating HF1 function in the pathogenetic mechanisms underlying AMD. We propose that genetic variation in a regulator of the alternative complement pathway, when combined with a triggering event, such as infection, underlie a major proportion of AMD in the human population.
C1 Univ Iowa, Dept Ophthalmol & Visual Sci, Cell Biol & Funct Genom Lab, Iowa City, IA 52240 USA.
   Univ Calif Santa Barbara, Ctr Study Macular Degenerat, Santa Barbara, CA 93106 USA.
   Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA.
   Queens Univ Belfast, Interdept Nutr Genet, Belfast BT7 1NN, Antrim, North Ireland.
   Queens Univ Belfast, Dept Otolaryngol Head & Neck Surg, Belfast BT7 1NN, Antrim, North Ireland.
   Queens Univ Belfast, Dept Ophthalmol, Div Surg & Perioperat Care, Belfast BT7 1NN, Antrim, North Ireland.
   Erasmus Univ, Dept Ophthalmol, NL-3000 DR Rotterdam, Netherlands.
   Erasmus Univ, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands.
   Netherlands Ophthalm Res Inst, NL-3000 DR Rotterdam, Netherlands.
   NCI, Lab Genom Divers, Frederick, MD 21702 USA.
   NCI, Sci Applicat Int Corp, Frederick, MD 21702 USA.
   Columbia Univ, Dept Ophthalmol, New York, NY 10027 USA.
   Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10027 USA.
C3 University of Iowa; University of California System; University of
   California Santa Barbara; University of California System; University of
   California Santa Barbara; Queens University Belfast; Queens University
   Belfast; Queens University Belfast; Erasmus University Rotterdam;
   Erasmus University Rotterdam; Royal Netherlands Academy of Arts &
   Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); National
   Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI);
   National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI); Science Applications International Corporation (SAIC); Columbia
   University; Columbia University
RP Allikmets, R (通讯作者)，Univ Iowa, Dept Ophthalmol & Visual Sci, Cell Biol & Funct Genom Lab, 11190E PFP,200 Hawkins Dr, Iowa City, IA 52240 USA.
EM ria22@columbia.edu
RI Dean, Michael/R-7501-2019; Mohammed, Imran/J-8271-2012; Klaver, Caroline
   C.W./A-2013-2016; Dean, Michael C/G-8172-2012; Allikmets,
   Rando/ABD-4533-2021
OI Mohammed, Imran/0000-0002-8412-0768; Dean, Michael
   C/0000-0003-2234-0631; smith, theodore/0000-0002-1693-943X; Gehrs,
   Karen/0000-0003-4510-9678; Hancox, Lisa/0000-0003-1940-2619; Silvestri,
   Giuliana/0000-0001-5662-5374; Russell, Stephen/0000-0003-3776-1367;
   Smith, Richard/0000-0003-1201-6731; Klaver, Caroline/0000-0002-2355-5258
FU NCI NIH HHS [N01-CO-12400, N01CO12400] Funding Source: Medline; NEI NIH
   HHS [R01 EY013435, EY11515, R01 EY011515, EY11521, EY13435, EY11527, R01
   EY011527, R01 EY011521] Funding Source: Medline; NATIONAL CANCER
   INSTITUTE [Z01BC005725, Z01BC005652] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTE [R01EY013435, R01EY011515, R01EY011521,
   R01EY011527] Funding Source: NIH RePORTER
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Caprioli J, 2003, HUM MOL GENET, V12, P3385, DOI 10.1093/hmg/ddg363
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Colville D, 2003, AM J KIDNEY DIS, V42, DOI 10.1016/S0272-6386(03)00665-6
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Gold B, 2004, CANCER RES, V64, P8891, DOI 10.1158/0008-5472.CAN-04-1256
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hayashi M, 2004, Ophthalmic Genet, V25, P111
   Hu J, 2001, MOL VIS, V7, P14
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   KEW RR, 1985, J CLIN INVEST, V75, P1000, DOI 10.1172/JCI111760
   KINOSHITA T, 1991, IMMUNOL TODAY, V12, P291, DOI 10.1016/0167-5699(91)90001-A
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein Michael L, 2003, Ophthalmol Clin North Am, V16, P567, DOI 10.1016/S0896-1549(03)00063-4
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   McAvoy CE, 2005, EYE, V19, P985, DOI 10.1038/sj.eye.6701697
   Miller DM, 2004, AM J OPHTHALMOL, V138, P323, DOI 10.1016/j.ajo.2004.03.018
   Morgan BP, 1999, CRIT REV IMMUNOL, V19, P173
   MORGAN BP, 1991, IMMUNOL TODAY, V12, P301, DOI 10.1016/0167-5699(91)90003-C
   Mullins RF, 1997, OPHTHALMOLOGY, V104, P288, DOI 10.1016/S0161-6420(97)30322-4
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Neary JJ, 2002, J AM SOC NEPHROL, V13, P2052, DOI 10.1097/01.ASN.0000022006.49966.F8
   OBRIEN C, 1993, BRIT J OPHTHALMOL, V77, P778, DOI 10.1136/bjo.77.12.778
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Schwertz R, 2001, PEDIAT ALLERG IMM-UK, V12, P166, DOI 10.1034/j.1399-3038.2001.012003166.x
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Thomas PD, 2004, P NATL ACAD SCI USA, V101, P15398, DOI 10.1073/pnas.0404380101
   Torzewski J, 1997, ATHEROSCLEROSIS, V132, P131, DOI 10.1016/S0021-9150(97)00100-7
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Wang ZF, 2004, CELL, V119, P831, DOI 10.1016/j.cell.2004.11.010
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Zipfel PF, 2002, BIOCHEM SOC T, V30, P971, DOI 10.1042/bst0300971
   Zipfel PF, 2001, INT IMMUNOPHARMACOL, V1, P461, DOI 10.1016/S1567-5769(00)00047-3
   Zipfel PF, 2001, TRENDS IMMUNOL, V22, P345, DOI 10.1016/S1471-4906(01)01972-X
   Zipfel PF, 2001, SEMIN THROMB HEMOST, V27, P191, DOI 10.1055/s-2001-15248
NR 56
TC 1567
Z9 1690
U1 1
U2 65
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 17
PY 2005
VL 102
IS 20
BP 7227
EP 7232
DI 10.1073/pnas.0501536102
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 928SO
UT WOS:000229292200032
PM 15870199
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Hayward, C
   Shu, XH
   Lennon, A
   Barran, P
   Zareparsi, S
   Sawyer, L
   Hendry, G
   Dhillon, B
   Milam, AH
   Luthert, PJ
   Swaroop, A
   Hastie, ND
   Jacobson, SG
   Wright, AF
AF Hayward, C
   Shu, XH
   Lennon, A
   Barran, P
   Zareparsi, S
   Sawyer, L
   Hendry, G
   Dhillon, B
   Milam, AH
   Luthert, PJ
   Swaroop, A
   Hastie, ND
   Jacobson, SG
   Wright, AF
TI Mutation in a short-chain collagen gene, CTRP5, results in extracellular
   deposit formation in late-onset retinal degeneration: a genetic model
   for age-related macular degeneration
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID SORSBYS FUNDUS DYSTROPHY; METAPHYSEAL CHONDRODYSPLASIA;
   METALLOPROTEINASES-3 TIMP3; RETINITIS-PIGMENTOSA; CRYSTAL-STRUCTURE;
   TISSUE INHIBITOR; DARK-ADAPTATION; DISEASE; PROTEIN; EXPRESSION
AB A primary feature of age-related macular degeneration (AMD) is the presence of extracellular deposits between the retinal pigment epithelium (RPE) and underlying Bruch's membrane, leading to RPE dysfunction, photoreceptor death and severe visual loss. AMD accounts for about 50% of blind registrations in Western countries and is a common, genetically complex disorder. Very little is known regarding its molecular basis. Late-onset retinal degeneration (L-ORD) is an autosomal dominant disorder with striking clinical and pathological similarity to AMD. Here we show that L-ORD is genetically heterogeneous and that a proposed founder mutation in the CTRP5 (C1QTNF5) gene, which encodes a novel short-chain collagen, changes a highly conserved serine to arginine (Ser163Arg) in 7/14 L-ORD families and 0/1000 control individuals. The mutation occurs in the gC1q domain of CTRP5 and results in abnormal high molecular weight aggregate formation which may alter its higher-order structure and interactions. These results indicate a novel disease mechanism involving abnormal adhesion between RPE and Bruch's membrane.
C1 Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland.
   Univ Penn, Sch Med, Scheie Eye Inst, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   Univ Edinburgh, Sch Chem, Edinburgh, Midlothian, Scotland.
   Univ Michigan, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA.
   Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA.
   Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh, Midlothian, Scotland.
   Univ Edinburgh, Royal Infirm Edinburgh, Dept Ophthalmol, Edinburgh EH3 9YW, Midlothian, Scotland.
   UCL, Inst Ophthalmol, Dept Pathol, London, England.
C3 University of Edinburgh; University of Pennsylvania; Pennsylvania
   Medicine; University of Edinburgh; University of Michigan System;
   University of Michigan; University of Michigan System; University of
   Michigan; University of Edinburgh; Royal Infirmary of Edinburgh;
   University of Edinburgh; University of London; University College London
RP Wright, AF (通讯作者)，Western Gen Hosp, MRC, Human Genet Unit, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.
EM alan.wright@hgu.mrc.ac.uk
RI Hayward, Caroline/M-8818-2016
OI Hayward, Caroline/0000-0002-9405-9550; Jacobson,
   Samuel/0000-0003-2122-169X; Luthert, Philip/0000-0001-7276-6898;
   Swaroop, Anand/0000-0002-1975-1141
FU NATIONAL EYE INSTITUTE [R01EY013203, U10EY013729, R01EY013385] Funding
   Source: NIH RePORTER; NEI NIH HHS [EY13385, EY13203, EY13729] Funding
   Source: Medline
CR AGARWAL N, 1995, CYTOGENET CELL GENET, V69, P71, DOI 10.1159/000133941
   Angius A, 2000, ARCH OPHTHALMOL-CHIC, V118, P674
   Arris CE, 2003, BBA-MOL BASIS DIS, V1638, P20, DOI 10.1016/S0925-4439(03)00036-X
   Biswas S, 2001, HUM MOL GENET, V10, P2415, DOI 10.1093/hmg/10.21.2415
   Bogin O, 2002, STRUCTURE, V10, P165, DOI 10.1016/S0969-2126(02)00697-4
   BROSNAHAN DM, 1994, OPHTHALMOLOGY, V101, P38
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   DUVALL J, 1986, GRAEF ARCH CLIN EXP, V224, P299, DOI 10.1007/BF02143075
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Haimovici R, 2002, GRAEF ARCH CLIN EXP, V240, P90, DOI 10.1007/s00417-001-0417-z
   Jacobson SG, 2001, INVEST OPHTH VIS SCI, V42, P1882
   Kameya S, 2002, HUM MOL GENET, V11, P1879, DOI 10.1093/hmg/11.16.1879
   Kishore U, 2000, IMMUNOPHARMACOLOGY, V49, P159, DOI 10.1016/S0162-3109(00)80301-X
   Kishore U, 2002, IMMUNOBIOLOGY, V205, P355, DOI 10.1078/0171-2985-00138
   Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917
   Kuntz CA, 1996, INVEST OPHTH VIS SCI, V37, P1772
   KWAN APL, 1991, J CELL BIOL, V114, P597, DOI 10.1083/jcb.114.3.597
   LATHROP GM, 1988, AM J HUM GENET, V42, P498
   Marks DS, 1999, J BIOL CHEM, V274, P3632, DOI 10.1074/jbc.274.6.3632
   Milam AH, 2000, OPHTHALMOLOGY, V107, P2256, DOI 10.1016/S0161-6420(00)00419-X
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846
   SEDDON JM, 2001, RETINA, P1039
   Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   VANSOEST S, 1994, GENOMICS, V22, P499, DOI 10.1006/geno.1994.1422
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Wijesuriya SD, 1996, GENOME RES, V6, P92, DOI 10.1101/gr.6.2.92
   Wright A, 2003, TRENDS GENET, V19, P97, DOI 10.1016/S0168-9525(02)00033-1
   [No title captured]
NR 32
TC 141
Z9 142
U1 1
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD OCT 15
PY 2003
VL 12
IS 20
BP 2657
EP 2667
DI 10.1093/hmg/ddg289
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 733RE
UT WOS:000186013800009
PM 12944416
OA Bronze
DA 2022-11-30
ER

PT J
AU Rees, A
   Zekite, A
   Bunce, C
   Patel, PJ
AF Rees, A.
   Zekite, A.
   Bunce, C.
   Patel, P. J.
TI How many people in England and Wales are registered partially sighted or
   blind because of age-related macular degeneration?
SO EYE
LA English
DT Article
ID RANIBIZUMAB
AB Purpose The purpose of the study was to determine what proportion of new certifications between 1 April 2007 and 31 March 2008 could be attributed to age-related macular degeneration (AMD) and to describe the AMD-certified population in England and Wales.
   Methods An electronic version of the Certificate of Vision Impairment form (CVI), the ECVI, was used at the certifications office to transfer information from the paper-based certificates into a database. The electronic certifications data set was queried for all certificates completed between 1 April 2007 and 31 March 2008 with the main cause of certifiable visual loss being AMD or with the main cause of certifiable visual loss being multiple pathology but a contributory cause being AMD. The electronic data set was adapted so that a distinction could be made between geographic atrophy (GA) and neovascular AMD (nAMD).
   Results The Certifications Office received 23 185 CVIs between April 2007 and March 2008, of whom 9823 (42%) were people registered severely sight impaired (SSI) and 12 607 (52%) were certified as sight impaired (SI). AMD contributed to 13 000 causes of registration on the CVI forms during this period and was the main cause in 11 015 people. In these 11 015 people, GA accounted for 49.3%, nAMD 35.1%, and AMD not specified 15.7%.
   Conclusions The data in this report provide detailed information on CVI registration due to AMD before the widespread adoption of ranibizumab therapy in NHS practice and provide an insight into the burden of vision loss due to AMD at a time of great change in the management of nAMD.
C1 [Rees, A.] Moorfields Eye Hosp, NHS Fdn Trust, NIHR Biomed Res Ctr, London EC1V 2PD, England.
   UCL, Inst Ophthalmol, London, England.
C3 Oxford University Hospitals NHS Foundation Trust; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   University of London; University College London
RP Rees, A (通讯作者)，Moorfields Eye Hosp, NHS Fdn Trust, NIHR Biomed Res Ctr, 162 City Rd, London EC1V 2PD, England.
EM angela.rees@moorfields.nhs.uk
OI Bunce, Catey/0000-0002-0935-3713
FU Guide Dogs; Macular Disease Society; NIHR; Medical Research Council
   [MR/K006584/1] Funding Source: researchfish
FX This study was supported by a grant from Guide Dogs, the Macular Disease
   Society, and NIHR support. The views expressed in this paper are those
   of the author and not necessarily any funding body or the Department of
   Health. The data captured by the CVI are DH copyright and this work was
   made possible by collaboration with the Royal College of
   Ophthalmologists.
CR Betancourt JR, 2003, PUBLIC HEALTH REP, V118, P293, DOI 10.1093/phr/118.4.293
   Bloch SB, AM J OPHTHALMOL, V153, P209
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Bunce C, 2010, EYE, V24, P1692, DOI 10.1038/eye.2010.122
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, P1508
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Department of Health and Social Security, 1979, REP PUBL HLTH MED SU, V129
   Government Statistical Service, CAUS BLINDN PART SIG
   Government Statistical Service, POP EST UK ENGL WAL
   Klein R, 2013, AM J OPHTHALMOL, V156, P1010, DOI 10.1016/j.ajo.2013.06.004
   Leamon S, 2012, VIS UK C
   Lievesley N., FUTURE AGEING ETHNIC
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rostron E, 2012, EYE, V26, P933, DOI 10.1038/eye.2012.61
   Sorsby A., 1953, CAUSES BLINDNESS ENG
   Sorsby A., 1966, REPORTS PUBLIC HLTH, V114
   Sorsby A., 1972, REPORTS PUBLIC HLTH, V128
   Sorsby A., 1956, BLINDNESS ENGLAND 19
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
NR 22
TC 18
Z9 18
U1 0
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUL
PY 2014
VL 28
IS 7
BP 832
EP 837
DI 10.1038/eye.2014.103
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AL5LT
UT WOS:000339175900010
PM 24788009
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Sun, CC
   Huang, TS
   Fu, TS
   Lee, CY
   Chen, BY
   Chen, FP
AF Sun, Chi Chin
   Huang, Ting-Shuo
   Fu, Tsai-Sheng
   Lee, Chia-Yi
   Chen, Bing-Yu
   Chen, Fang-Ping
TI Association of age-related macular degeneration on fracture risks among
   osteoporosis population: a nationwide population-based cohort study
SO BMJ OPEN
LA English
DT Article
DE ophthalmology; epidemiology; medical retina; bone diseases; hip; trauma
   management
ID HIP FRACTURE; VISUAL IMPAIRMENT; PREVALENCE; EPIDEMIOLOGY; MANAGEMENT;
   MORTALITY; PEOPLE; TAIWAN; ACUITY; FALLS
AB Objectives Visual impairment is an important risk factor for fracture in the elderly population. Age-related macular degeneration (AMD) is the leading cause of irreversible visual impairment in elderly people. This study was conducted to explore the relationship between AMD and incident fractures in patients with osteoporosis (OS). Design Retrospective analysis of Taiwan's National Health Insurance Research Database (NHIRD). Setting A multicenter study conducted in Taiwan. Participants and controls The current study used the NHIRD in Taiwan between 1996 and 2011. A total of 13 584 and 54 336 patients with OS were enrolled in the AMD group and the non-AMD group, respectively. Intervention Patients with OS were included from the Taiwan's NHIRD after exclusion, and each patient with AMD was matched for age, sex and comorbidities to four patients with non-AMD OS, who served as the control group. A Cox proportional hazard model was used for the multivariable analysis. Primary outcome measures Transitions for OS to spine fracture, OS to hip fracture, OS to humero-radio-ulnar fracture and OS to death. Results The risks of spine and hip fractures were significantly higher in the AMD group (HR=1.09, 95% CI=1.04 to 1.15, p<0.001; HR=1.18; 95% CI=1.08 to 1.30, p=0.001, respectively) than in the non-AMD group. The incidence of humero-radio-ulnar fracture between AMD and non-AMD individuals was similar (HR=0.98; 95% CI=0.90 to 1.06; p=0.599). However, the risk of death was higher in patients with OS with older age, male sex and all types of comorbidity (p<0.05), except for hyperthyroidism (p=0.200). Conclusion Patients with OS with AMD had a greater risk of spine and hip fractures than did patients without AMD.
C1 [Sun, Chi Chin] Chang Gung Mem Hosp, Dept Ophthalmol, Keelung, Taiwan.
   [Sun, Chi Chin] Chang Gung Univ, Coll Med, Sch Med, Taoyuan, Taiwan.
   [Sun, Chi Chin; Chen, Bing-Yu] Chang Gung Mem Hosp, Dept Med Res & Dev, Keelung, Taiwan.
   [Huang, Ting-Shuo] Chang Gung Mem Hosp, Dept Gen Surg, Keelung, Taiwan.
   [Fu, Tsai-Sheng] Chang Gung Mem Hosp, Dept Orthped Surg, Keelung, Taiwan.
   [Lee, Chia-Yi] Show Chwan Mem Hosp, Dept Ophthalmol, Changhua, Taiwan.
   [Chen, Fang-Ping] Chang Gung Mem Hosp, Dept Obstet & Gynecol, Keelung, Taiwan.
C3 Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial
   Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital;
   Show Chwan Memorial Hospital; Chang Gung Memorial Hospital
RP Chen, FP (通讯作者)，Chang Gung Mem Hosp, Dept Obstet & Gynecol, Keelung, Taiwan.
EM fangping@cgmh.org.tw
RI Huang, Ting-Shuo/ABD-3205-2021; huang, ting/GRR-3141-2022
OI Huang, Ting-Shuo/0000-0002-2932-6878; 
FU Chang Gung Medical Research Foundation [CMRPG2D0371, CMRPG2D0372,
   CMRPG2D0373, CLRPG2G0081, CLRPG2G0082, CLRPG2G0083]
FX This study was supported by Chang Gung Medical Research Foundation to
   CCS (CMRPG2D0371, CMRPG2D0372, CMRPG2D0373, CLRPG2G0081, CLRPG2G0082 and
   CLRPG2G0083).
CR Almeida LRS, 2017, J PARKINSON DIS, V7, P313, DOI 10.3233/JPD-160934
   Anastasopoulos E, 2006, AM J OPHTHALMOL, V142, P1081, DOI 10.1016/j.ajo.2006.06.058
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Bahrs C, 2014, INT ORTHOP, V38, P1697, DOI 10.1007/s00264-014-2362-6
   Christoforidis JB, 2011, CURR DRUG TARGETS, V12, P221
   Chung SD, 2017, ACTA OPHTHALMOL, V95, pe800, DOI 10.1111/aos.13281
   Cox A, 2005, EYE, V19, P652, DOI 10.1038/sj.eye.6701610
   CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140-6736(02)08657-9
   Curtis EM, 2017, BONE, V104, P29, DOI 10.1016/j.bone.2017.01.024
   DargentMolina P, 1996, LANCET, V348, P145, DOI 10.1016/S0140-6736(96)01440-7
   Ekholm R, 2006, J BONE JOINT SURG BR, V88B, P1469, DOI 10.1302/0301-620X.88B11.17634
   Ensrud KE, 2011, NEW ENGL J MED, V364, P1634, DOI 10.1056/NEJMcp1009697
   Groff H, 2020, HIP INT, V30, P204, DOI 10.1177/1120700019835160
   Hong T, 2013, OPHTHALMOLOGY, V120, P2091, DOI 10.1016/j.ophtha.2013.03.032
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Ivers RQ, 2003, J AM GERIATR SOC, V51, P356, DOI 10.1046/j.1532-5415.2003.51109.x
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P1499
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546
   Klein R, 2013, OPHTHALMOLOGY, V120, P1210, DOI 10.1016/j.ophtha.2012.11.041
   Kwan MMS, 2011, J AM GERIATR SOC, V59, P536, DOI 10.1111/j.1532-5415.2010.03286.x
   Leucht P, 2009, INJURY, V40, P166, DOI 10.1016/j.injury.2008.06.040
   Loriaut P, 2014, OPHTHALMIC RES, V52, P212, DOI 10.1159/000362881
   McCarthy J, 2016, AM FAM PHYSICIAN, V94, P44
   Meunier A, 2019, GERIATR PSYCHOL NEUR, V17, P153, DOI 10.1684/pnv.2018.0769
   Pi HY, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/8612143
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sozen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048
   Tsai DC, 2015, OPHTHALMOLOGY, V122, P2327, DOI 10.1016/j.ophtha.2015.07.033
   van Landingham SW, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-10
   Varadaraj V, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.4.14
   Wilde C, 2017, EYE, V31, P1042, DOI 10.1038/eye.2017.30
   Wolinsky FD, 1997, AM J PUBLIC HEALTH, V87, P398, DOI 10.2105/AJPH.87.3.398
   Yang NP, 2006, HEALTH POLICY, V75, P329, DOI 10.1016/j.healthpol.2005.04.009
NR 35
TC 2
Z9 2
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2020
VL 10
IS 9
AR e037028
DI 10.1136/bmjopen-2020-037028
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC General & Internal Medicine
GA NW0KN
UT WOS:000574698500022
PM 32948557
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wang, X
   Jiang, CH
   Zhang, Y
   Gong, Y
   Chen, XF
   Zhang, MN
AF Wang, Xin
   Jiang, Caihui
   Zhang, Ying
   Gong, Yan
   Chen, Xiaofei
   Zhang, Maonian
TI Role of Lutein Supplementation in the Management of Age-Related Macular
   Degeneration: Meta-Analysis of Randomized Controlled Trials
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Macular degeneration; Macular pigment optical density; Visual acuity;
   Lutein; Randomized controlled trials
ID PIGMENT OPTICAL-DENSITY; VISUAL-ACUITY; DOCOSAHEXAENOIC ACID;
   ZEAXANTHIN; SERUM; RISK; CAROTENOIDS; MACULOPATHY; LIPOPROTEINS;
   ANTIOXIDANTS
AB Objective:The conduct of this meta-analysis aimed at examining the individual role of lutein as a dietary supplement in improving conditions of age-related macular degeneration (AMD) from the data generated from randomized controlled trials (RCTs). Method:The literature search was made in multiple electronic databases. Eligibility criteria were RCTs that recruited AMD patients or individuals at risk and evaluated lutein supplementation efficacy against placebo. The quality of the trials was assessed by using the Jadad scale. The meta-analysis was conducted under the fixed effect model with RevMan software by calculating the mean differences of the changes from baseline of both lutein and placebo groups. Parameters of interest were macular pigment optical density (MPOD) and visual acuity (VA) in logMAR (minimum angle of resolution). Heterogeneity was determined by X-2 and I-2 and publication bias was assessed by visual examination of funnel plots. Results: After following predetermined inclusion and exclusion criteria, five RCTs that recruited 445 participants were selected for the meta-analysis. It has been found that lutein treatment was associated with a significant improvement in MPOD, with mean differences between lutein and placebo groups in the changes from baseline of 0.09 (95% CI: 0.06, 0.12; p < 0.00001). VA also improved with a mean difference between lutein and placebo groups in the changes from baseline of -0.04 (95% CI-0.07, 0.00; p = 0.05). Statistical heterogeneity was not apparent. Conclusion: A statistically highly significant effect of lutein supplementation has been observed for improving the MPOD, whereas the improvement in VA was milder. A daily dose of 10 mg was found as effective as higher doses in this meta-analysis. However, the number of input studies is not adequate for conclusive evidence. (C) 2014 S. Karger AG, Basel
C1 [Wang, Xin; Jiang, Caihui; Zhang, Ying; Gong, Yan; Chen, Xiaofei; Zhang, Maonian] Chinese Peoples Liberat Army, Dept Ophthalmol, Gen Hosp, Beijing 100853, Peoples R China.
   [Wang, Xin] Chinese Peoples Liberat Army, Gen Armaments Dept, Command Huang Si Clin, Beijing 100853, Peoples R China.
C3 Chinese People's Liberation Army General Hospital
RP Zhang, MN (通讯作者)，Chinese Peoples Liberat Army, Dept Ophthalmol, Gen Hosp, 28 Fuxing Rd, Beijing 100853, Peoples R China.
EM Zhangmaonian_2000@163.com
CR Arnold C, 2013, JAMA OPHTHALMOL, V131, P564, DOI 10.1001/jamaophthalmol.2013.2851
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   Cardinault N, 2005, CLIN CHIM ACTA, V357, P34, DOI 10.1016/j.cccn.2005.01.030
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dasch B, 2005, GRAEF ARCH CLIN EXP, V243, P1028, DOI 10.1007/s00417-005-1176-z
   Dawczynski J, 2013, GRAEF ARCH CLIN EXP, V251, P2711, DOI 10.1007/s00417-013-2376-6
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Garcia-Layana A, 2013, NUTRIENTS, V5, P543, DOI 10.3390/nu5020543
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Huang YM, 2013, NUTRITION, V29, P387, DOI 10.1016/j.nut.2012.06.009
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Johnson EJ, 2005, NUTR REV, V63, P9, DOI 10.1301/nr.2004.janr.9-15
   Johnson EJ, 2008, AM J CLIN NUTR, V87, P1521, DOI 10.1093/ajcn/87.5.1521
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Landrum J T, 1997, Adv Pharmacol, V38, P537
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   MANGELS AR, 1993, J AM DIET ASSOC, V93, P284, DOI 10.1016/0002-8223(93)91553-3
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   National Eye Institute, STAT AND DAT
   PALOZZA P, 1992, METHOD ENZYMOL, V213, P403
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Richer Stuart, 2007, Optometry, V78, P213, DOI 10.1016/j.optm.2006.10.019
   Richer SP, 2011, OPTOMETRY, V82, P667, DOI 10.1016/j.optm.2011.08.008
   Rosenthal JM, 2006, INVEST OPHTH VIS SCI, V47, P5227, DOI 10.1167/iovs.05-1513
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Simonelli F, 2002, CLIN CHIM ACTA, V320, P111, DOI 10.1016/S0009-8981(02)00056-6
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Zeimer M, 2012, INVEST OPHTH VIS SCI, V53, P4852, DOI 10.1167/iovs.12-9713
NR 45
TC 20
Z9 20
U1 0
U2 20
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2014
VL 52
IS 4
BP 198
EP 205
DI 10.1159/000363327
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AU5WU
UT WOS:000345675200003
PM 25358528
DA 2022-11-30
ER

PT J
AU Semkova, I
   Kreppel, F
   Welsandt, G
   Luther, T
   Kozlowski, J
   Janicki, H
   Kochanek, S
   Schraermeyer, U
AF Semkova, I
   Kreppel, F
   Welsandt, G
   Luther, T
   Kozlowski, J
   Janicki, H
   Kochanek, S
   Schraermeyer, U
TI Autologous transplantation of genetically modified iris pigment
   epithelial cells: A promising concept for the treatment of age-related
   macular degeneration and other disorders of the eye
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; INDUCED RETINOPATHY; GENE-EXPRESSION;
   DYSTROPHIC RATS; IN-VITRO; RESCUE; ANGIOGENESIS; SECRETION; EXCISION;
   REMOVAL
AB Age-related macular degeneration (ARMD) is the leading cause for visual impairment and blindness in the elder population. Laser photocoagulation, photodynamic therapy and excision of neovascular membranes have met with limited success. Submacular transplantation of autologous iris pigment epithelial (IPE) cells has been proposed to replace the damaged retinal pigment epithelium following surgical removal of the membranes. We tested our hypothesis that the subretinal transplantation of genetically modified autologous IPE cells expressing biological therapeutics might be a promising strategy for the treatment of ARMD and other retinal disorders. Pigment epithelium-derived factor (PEDF) has strong antiangiogenic and neuroprotective activities in the eye. Subretinal transplantation of PEDF expressing IPE cells inhibited pathological choroidal neovascularization in rat models of laser-induced rupture of Bruch's membrane and of oxygen induced ischemic retinopathy. PEDF expressing IPE transplants also increased the survival and preserved rhodopsin expression of photoreceptor cells in the RCS rat, a model of retinal degeneration. These findings suggest a promising concept for the treatment of ARMD and other retinal disorders.
C1 Univ Cologne, Ctr Mol Med Cologne, ZMMK, D-50931 Cologne, Germany.
   Univ Cologne, Ctr Ophthalmol, Dept Retinal Surg, D-50931 Cologne, Germany.
   Univ Cologne, Inst Anat, D-50931 Cologne, Germany.
C3 University of Cologne; University of Cologne; University of Cologne
RP Kochanek, S (通讯作者)，Univ Cologne, Ctr Mol Med Cologne, ZMMK, Kerpener Str 34, D-50931 Cologne, Germany.
EM Stefan.Kochanek@medizin.uni-koein.de
CR Burcin MM, 1999, P NATL ACAD SCI USA, V96, P355, DOI 10.1073/pnas.96.2.355
   Cao W, 1999, J NEUROSCI RES, V57, P789, DOI 10.1002/(SICI)1097-4547(19990915)57:6<789::AID-JNR4>3.0.CO;2-M
   Castellarin AA, 1998, BRIT J OPHTHALMOL, V82, P480, DOI 10.1136/bjo.82.5.480
   Cayouette M, 1999, NEUROBIOL DIS, V6, P523, DOI 10.1006/nbdi.1999.0263
   Chang CW, 1997, INVEST OPHTH VIS SCI, V38, P188
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Dinser R, 2001, HISTOCHEM CELL BIOL, V116, P69
   FLANNERY JG, 1990, EXP EYE RES, V51, P717, DOI 10.1016/0014-4835(90)90057-2
   Hoffmann S, 1998, GRAEF ARCH CLIN EXP, V236, P779, DOI 10.1007/s004170050158
   HU DN, 1992, INVEST OPHTH VIS SCI, V33, P2443
   Karakousis PC, 2001, MOL VIS, V7, P154
   Karnabatidis D, 2001, ACTA RADIOL, V42, P333, DOI 10.1080/028418501127346747
   Kochanek S, 1999, HUM GENE THER, V10, P2451, DOI 10.1089/10430349950016807
   Kociok N, 1998, EXP EYE RES, V67, P237, DOI 10.1006/exer.1998.0517
   Kreppel F, 2002, INVEST OPHTH VIS SCI, V43, P1965
   Lappas A, 2000, GRAEF ARCH CLIN EXP, V238, P631, DOI 10.1007/s004170000149
   LI LX, 1990, PROG BRAIN RES, V82, P179
   McMenamin PG, 2000, INVEST OPHTH VIS SCI, V41, P3043
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Ortego J, 1996, INVEST OPHTH VIS SCI, V37, P2759
   Parks RJ, 1996, P NATL ACAD SCI USA, V93, P13565, DOI 10.1073/pnas.93.24.13565
   PIGNOLO RJ, 1993, J BIOL CHEM, V268, P8949
   Rezai KA, 1997, EXP EYE RES, V65, P23, DOI 10.1006/exer.1997.0307
   Schraermeyer U, 1997, EXP EYE RES, V65, P277, DOI 10.1006/exer.1997.0339
   Schraermeyer U, 1999, INVEST OPHTH VIS SCI, V40, P1545
   SHEEDLO HJ, 1992, INT REV CYTOL, V138, P1, DOI 10.1016/S0074-7696(08)61586-7
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398
   Tang SQ, 1999, J CELL BIOL, V147, P1073, DOI 10.1083/jcb.147.5.1073
   Thumann G, 2000, ARCH OPHTHALMOL-CHIC, V118, P1350
   TOMBRANTINK J, 1995, J NEUROSCI, V15, P4992
NR 32
TC 63
Z9 80
U1 0
U2 0
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 1
PY 2002
VL 99
IS 20
BP 13090
EP 13095
DI 10.1073/pnas.202486199
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 600LK
UT WOS:000178391700107
PM 12239351
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Ogura, Y
   Terasaki, H
   Gomi, F
   Yuzawa, M
   Iida, T
   Honda, M
   Nishijo, K
   Sowade, O
   Komori, T
   Schmidt-Erfurth, U
   Simader, C
   Chong, V
AF Ogura, Yuichiro
   Terasaki, Hiroko
   Gomi, Fumi
   Yuzawa, Mitsuko
   Iida, Tomohiro
   Honda, Miki
   Nishijo, Koichi
   Sowade, Olaf
   Komori, Tetsushi
   Schmidt-Erfurth, Ursula
   Simader, Christian
   Chong, Victor
CA VIEW 2 Investigators
TI Efficacy and safety of intravitreal aflibercept injection in wet
   age-related macular degeneration: outcomes in the Japanese subgroup of
   the VIEW 2 study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; EXTEND-I; RANIBIZUMAB;
   NEOVASCULARIZATION; BEVACIZUMAB; POPULATION; PREVALENCE; EYE
AB Background/aims To evaluate efficacy and safety of intravitreal aflibercept (IVT-AFL) in Japanese patients with wet age-related macular degeneration (wAMD) from the VIEW 2 trial.
   Methods In this double-masked study, patients were randomised to: 0.5 mg IVT-AFL every 4 weeks (0.5q4); 2 mg IVT-AFL every 4 weeks (2q4); 2 mg IVT-AFL every 8 weeks (2q8) after 3 monthly injections; or 0.5 mg ranibizumab every 4 weeks (Rq4). Main efficacy outcomes included vision maintenance and best-corrected visual acuity (BCVA) at week 52.
   Results At week 52, all Japanese patients in the IVTAFL groups (n=70) maintained vision, compared with 96% of Japanese patients (n=23/24) treated with ranibizumab. Japanese patients in all treatment groups showed improvement in BCVA after treatment. The Rq4, 2q4 and 2q8 groups experienced similar gains in BCVA from baseline. The 0.5q4 group had higher gains due to an unexpected drop in BCVA between screening and baseline. Central retinal thickness and mean area of choroidal neovascularisation decreased in all treatment groups with similar magnitude. Ocular treatment-emergent adverse events were balanced across treatment groups.
   Conclusions IVT-AFL was effective and well tolerated in Japanese patients. Outcomes in this population were consistent with those in the overall VIEW 2 population.
C1 [Ogura, Yuichiro] Nagoya City Univ, Grad Sch Med Sci, Dept Ophthalmol & Visual Sci, Nagoya, Aichi 4678602, Japan.
   [Terasaki, Hiroko] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Nagoya, Aichi 4648601, Japan.
   [Gomi, Fumi] Osaka Univ, Grad Sch Med, Dept Ophthalmol, Osaka, Japan.
   [Yuzawa, Mitsuko] Nihon Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan.
   [Iida, Tomohiro] Tokyo Womens Med Univ, Dept Ophthalmol, Tokyo, Japan.
   [Honda, Miki] Juntendo Univ, Urayasu Hosp, Dept Ophthalmol, Chiba, Japan.
   [Nishijo, Koichi; Komori, Tetsushi] Bayer Yakuhin Ltd, Osaka, Japan.
   [Sowade, Olaf] Bayer HealthCare Pharmaceut, Berlin, Germany.
   [Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol & Optometry, Vienna, Austria.
   [Simader, Christian] Med Univ Vienna, Vienna Reading Ctr VRC, Vienna, Austria.
   [Chong, Victor] Univ Oxford, Oxford Eye Hosp, Oxford, England.
C3 Nagoya City University; Nagoya University; Osaka University; Nihon
   University; Tokyo Women's Medical University; Juntendo University; Bayer
   AG; Bayer AG; Bayer Healthcare Pharmaceuticals; Medical University of
   Vienna; Medical University of Vienna; University of Oxford
RP Ogura, Y (通讯作者)，Nagoya City Univ, Grad Sch Med Sci, Dept Ophthalmol & Visual Sci, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678602, Japan.
EM vitreous.surgeon@gmail.com
RI Terasaki, Hiroko/M-5054-2014; Chong, Victor/Q-6565-2018
OI Chong, Victor/0000-0002-7693-522X; Gomi, Fumi/0000-0003-0807-8817;
   Schmidt-Erfurth, Ursula/0000-0002-7788-7311
FU HealthCare Pharmaceuticals, Berlin, Germany; Regeneron Pharmaceuticals,
   Inc. Tarrytown, New York, USA
FX The VIEW 2 study was supported by Bayer HealthCare Pharmaceuticals,
   Berlin, Germany, and Regeneron Pharmaceuticals, Inc. Tarrytown, New
   York, USA.
CR Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kawasaki R, 2011, OPHTHAL EPIDEMIOL, V18, P253, DOI 10.3109/09286586.2011.602505
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsumiya W, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-10
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Saito M, 2012, RETINA-J RET VIT DIS, V32, P1250, DOI 10.1097/IAE.0b013e318236e503
   Suzuki M, 2010, JPN J OPHTHALMOL, V54, P124, DOI 10.1007/s10384-009-0775-3
   Tano Y, 2011, ACTA OPHTHALMOL, V89, P208, DOI 10.1111/j.1755-3768.2010.02065.x
   Tano Y, 2010, ACTA OPHTHALMOL, V88, P309, DOI 10.1111/j.1755-3768.2009.01843.x
   Uyama M, 2000, BRIT J OPHTHALMOL, V84, P1018, DOI 10.1136/bjo.84.9.1018
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 17
TC 33
Z9 35
U1 0
U2 12
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JAN
PY 2015
VL 99
IS 1
BP 92
EP 97
DI 10.1136/bjophthalmol-2014-305076
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AW6CW
UT WOS:000346358000019
PM 25107900
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Chatziralli, I
   Nicholson, L
   Vrizidou, E
   Koutsiouki, C
   Menon, D
   Sergentanis, TN
   Citu, MC
   Hamilton, R
   Patel, PJ
   Hykin, P
   Sivaprasad, S
AF Chatziralli, Irini
   Nicholson, Luke
   Vrizidou, Eleni
   Koutsiouki, Chysoula
   Menon, Deepthy
   Sergentanis, Theodoros N.
   Citu, Maria Cristina
   Hamilton, Robin
   Patel, Praveen J.
   Hykin, Phil
   Sivaprasad, Sobha
TI Predictors of Outcome in Patients with Neovascular Age-Related Macular
   Degeneration Switched from Ranibizumab to 8-Weekly Aflibercept
SO OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL AFLIBERCEPT; CHOROIDAL NEOVASCULARIZATION;
   CLINICAL-OUTCOMES; BEVACIZUMAB; THERAPY; EYES; AMD; INJECTION; EFFICACY;
   TRIALS
AB Purpose: The purpose of this study was to evaluate the outcomes over 12 months in patients with neovascular age-related macular degeneration (nAMD) with insufficient response to ranibizumab who were switched directly to 8-weekly fixed dosing of aflibercept without a loading phase.
   Design: Retrospective interventional study.
   Participants: Consecutive patients with nAMD who were switched from pro re nata (PRN) intravitreal ranibizumab to 8-weekly fixed aflibercept because of persistent disease activity from November 1, 2013, to September 30, 2014, were included.
   Methods: Demographic data, visual acuity (VA), and spectral-domain optical coherence tomography characteristics over time were evaluated to determine the prognostic indicators of final visual outcome at 12 months.
   Main Outcome Measures: The VA, central subfield thickness (CST), presence of macular fluid at month 12 compared with baseline, and the definition of prognostic indicators of final visual outcome at month 12.
   Results: A total of 431 patients (447 eyes) were included in this study. There was no statistically significant difference in VA between baseline and month 12 (P = 0.79), whereas the CST significantly decreased at month 12 compared with baseline (P < 0.001). At the 12-month follow-up, 48.3% of eyes had no macular fluid compared with 8.5% at baseline. The mean number of injections at month 12 was 6.8 +/- 1.75. Poor prognostic indicators included increasing age, increasing CST, the presence of intraretinal fluid, pigment epithelial detachment, and subfoveal thickening.
   Conclusions: Patients who have not yet "responded" to PRN ranibizumab seem to exhibit retinal dehydration after switching to aflibercept, whereas there was no demonstration of VA benefit. Baseline features at the point of switching can independently predict outcomes. (C) 2016 by the American Academy of Ophthalmology.
C1 [Chatziralli, Irini; Nicholson, Luke; Vrizidou, Eleni; Koutsiouki, Chysoula; Menon, Deepthy; Citu, Maria Cristina; Hamilton, Robin; Patel, Praveen J.; Hykin, Phil; Sivaprasad, Sobha] Moorfields Eye Hosp Natl Hlth Serv Fdn Trust, Natl Inst Hlth Res, Biomed Res Ctr, London, England.
   [Chatziralli, Irini; Nicholson, Luke; Vrizidou, Eleni; Koutsiouki, Chysoula; Menon, Deepthy; Citu, Maria Cristina; Hamilton, Robin; Patel, Praveen J.; Hykin, Phil; Sivaprasad, Sobha] UCL Inst Ophthalmol, London, England.
   [Sergentanis, Theodoros N.] Univ Athens, Dept Epidemiol & Biostat, Athens, Greece.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   National & Kapodistrian University of Athens
RP Sivaprasad, S (通讯作者)，NIHR Moorfields Biomed Res Ctr, Med Retina, 162 City Rd, London EC1V 2PD, England.
EM senswathi@aol.com
RI Sergentanis, Theodoros N./AAD-8303-2019; Sivaprasad, S./D-6876-2015;
   Chatziralli, Irini/AAG-4779-2020
OI Sergentanis, Theodoros N./0000-0002-9355-5528; Sivaprasad,
   S./0000-0001-8952-0659; Chatziralli, Irini/0000-0001-8523-1024;
   Nicholson, Luke/0000-0001-6685-4402
FU Bayer; Novartis; Allergan
FX R.H.: Consultant - Novartis Pharmaceutical, Bayer Healthcare, Allergan,
   Ellex; Grants - Bayer, Novartis, Allergan; Lecturer - Bayer, Novartis,
   Allergan, Ellex, Haag-Streit; Payments outside the submitted work -
   Novartis, Bayer, Allergan, Ellex.
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Aghdam KA, 2015, INVEST OPHTH VIS SCI, V56, P6448, DOI 10.1167/iovs.15-17338
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Bhavsar KV, 2014, SAUDI J OPHTHALMOL, V28, P129, DOI 10.1016/j.sjopt.2014.03.001
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Bohni SC, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0101-4
   Bu SC, 2014, RETINA-J RET VIT DIS, V34, P2317, DOI 10.1097/IAE.0000000000000349
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Coscas G, 2013, OPHTHALMOLOGICA, V229, P32, DOI 10.1159/000342159
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Dirani A, 2015, AM J OPHTHALMOL, V160, P732, DOI 10.1016/j.ajo.2015.06.025
   Duker JS, 2013, OPHTHALMOLOGY, V120, P2611, DOI 10.1016/j.ophtha.2013.07.042
   Ferrone PJ, 2014, BRIT J OPHTHALMOL, V98, P17, DOI 10.1136/bjophthalmol-2013-304474
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Gambon R, 2014, KLIN MONATSBL AUGENH, V231, P423, DOI 10.1055/s-0034-1368292
   Gamulescu MA, 2010, J OCUL PHARMACOL TH, V26, P213, DOI 10.1089/jop.2009.0126
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heussen FM, 2014, GRAEF ARCH CLIN EXP, V252, P909, DOI 10.1007/s00417-013-2553-7
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Major JC, 2015, CAN J OPHTHALMOL, V50, P373, DOI 10.1016/j.jcjo.2014.12.012
   Mazaraki K, 2015, BRIT J OPHTHALMOL, V99, P1341, DOI 10.1136/bjophthalmol-2015-306636
   Narayan DS, 2015, INDIAN J OPHTHALMOL, V63, P832, DOI 10.4103/0301-4738.171964
   Ogura Y, 2015, BRIT J OPHTHALMOL, V99, P92, DOI 10.1136/bjophthalmol-2014-305076
   Patel KH, 2013, EYE, V27, P664, DOI 10.1038/eye.2013.31
   Pinheiro-Costa J, 2015, OPHTHALMOLOGICA, V233, P155, DOI 10.1159/000381221
   Roberts P, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14293
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rouvas A, 2009, OPHTHALMOLOGICA, V223, P383, DOI 10.1159/000228590
   Schachat AP, 2013, AM J OPHTHALMOL, V156, P1, DOI 10.1016/j.ajo.2013.04.009
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schulz KF, 2002, ANN INTERN MED, V136, P254, DOI 10.7326/0003-4819-136-3-200202050-00022
   SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Singh RP, 2015, CLIN OPHTHALMOL, V9, P1759, DOI 10.2147/OPTH.S87043
   Stewart MW, 2012, CLIN OPHTHALMOL, V6, P1175, DOI 10.2147/OPTH.S33372
   Sulzbacher F, 2015, INVEST OPHTH VIS SCI, V56, P1158, DOI 10.1167/iovs.14-14298
   Thorell MR, 2014, OSLI RETINA, V45, P526, DOI 10.3928/23258160-20141118-07
   Wang Donghyun, 2014, Korean J Ophthalmol, V28, P32, DOI 10.3341/kjo.2014.28.1.32
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 46
TC 20
Z9 20
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2016
VL 123
IS 8
BP 1762
EP 1770
DI 10.1016/j.ophtha.2016.05.002
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DS4MC
UT WOS:000380754200034
PM 27289179
DA 2022-11-30
ER

PT J
AU Shiragami, C
   Ono, A
   Kobayashi, M
   Manabe, S
   Yamashita, A
   Shiraga, F
AF Shiragami, Chieko
   Ono, Aoi
   Kobayashi, Mamoru
   Manabe, Saki
   Yamashita, Ayana
   Shiraga, Fumio
TI Effect of Switching Therapy to Pegaptanib in Eyes With the Persistent
   Cases of Exudative Age-Related Macular Degeneration
SO MEDICINE
LA English
DT Article
ID PDGF-B; RANIBIZUMAB; VEGF; AFLIBERCEPT; OUTCOMES; TACHYPHYLAXIS;
   BEVACIZUMAB; SURVIVAL; MARINA; TRIAL
AB Purpose of this study was to evaluate the efficacy of switching to pegaptanib monotherapy for persistent cases of exudative age-related macular degeneration (AMD).
   Out of 296 eyes of 296 patients treated with ranibizumab or ranibizumab combined with photodynamic therapy (PDT), 50 eyes of 50 AMD patients were found to be resistant to these treatments. Over a 12-month period, intravitreal pegaptanib (IVP) 0.3mg was administered at intervals of 6 weeks until the exudation disappeared prospectively. All patients were examined with the following tests: best-corrected visual acuity (BCVA) and central retinal thickness (CRT), determined at the initial visit, before the first IVP (baseline), and at 12 months. The factors responsible for achieving dry macula with IVP were examined statistically.
   The rate of persistent cases with intravitreal ranibizumab (IVR) and/or PDT was 17.0%. The mean number of IVPs administered was 5.4 (range, 2-9). Logarithm of the minimal angle of resolution BCVA at 12 months was stable or improved by >= 0.3 in 49 eyes (98.0%), with a significant improvement noted between the baseline and final BCVA (P = 0.01, paired t test). The CRT (mean +/- standard deviation) was 446.9 +/- 150.6 mu m at the initial visit, 414.5 +/- 146.5 mu m at baseline, and 318.7 +/- 99.0 mu m at 12 months. There was a significant decrease in the mean CRT between the measurements at baseline and at 12 months after the first IVP (P = 0.002, Bonferroni correction). At 12 months, the exudative change was completely resolved in 27 eyes (54.0%) and reduced in 21 eyes (42.0%). The number of previous IVR treatments was significantly correlated with dry macula at 12 months.
   After switching therapy to pegaptanib in persistent cases of AMD, most patients maintained or improved their BCVA and exhibited a positive treatment response at 12 months.
C1 [Shiragami, Chieko; Ono, Aoi; Kobayashi, Mamoru; Manabe, Saki; Yamashita, Ayana] Kagawa Univ, Fac Med, Dept Ophthalmol, Miki, Kagawa 7610793, Japan.
   [Shiraga, Fumio] Okayama Univ, Sch Med, Dept Ophthalmol, Okayama 7008530, Japan.
C3 Kagawa University; Okayama University
RP Shiragami, C (通讯作者)，Kagawa Univ, Fac Med, Dept Ophthalmol, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.
EM chappi@kms.ac.jp
CR Altaweel M M, 2007, INVEST OPHTH VIS SCI, V48, pE
   Apte RS, 2007, OPHTHALMOLOGY, V114, P1702, DOI 10.1016/j.ophtha.2007.02.021
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Gerhardt H., 2008, ORGANOGENESIS, V4, P24124
   Heussen FM, 2014, GRAEF ARCH CLIN EXP, V252, P909, DOI 10.1007/s00417-013-2553-7
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Hoffman B.B., 2001, GOODMAN GILMANS PHAR, P115
   Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Reinmuth N, 2001, FASEB J, V15, P1239, DOI 10.1096/fj.00-0693fje
   Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruhrberg C, 2002, GENE DEV, V16, P2684, DOI 10.1101/gad.242002
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Soker S, 1997, J BIOL CHEM, V272, P31582, DOI 10.1074/jbc.272.50.31582
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Takeda AL, 2007, BRIT J OPHTHALMOL, V91, P1177, DOI 10.1136/bjo.2007.118562
   The CATT Research Group, 2011, NEW ENGL J MED, P1
NR 26
TC 9
Z9 9
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD OCT
PY 2014
VL 93
IS 18
AR e116
DI 10.1097/MD.0000000000000116
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA AS2ZS
UT WOS:000344145600003
PM 25319441
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Havvas, O
   Marioli, DI
   Deli, A
   Zarkadis, IK
   Pharmakakis, N
AF Havvas, Ooannis
   Marioli, Dimitra I.
   Deli, Angeliki
   Zarkadis, Ioannis K.
   Pharmakakis, Nikolaos
TI Complement C3, C2, and factor B gene polymorphisms and age-related
   macular degeneration in a Greek cohort study
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; C2/C3; CFB; CFH; Complement; Single
   nucleotide polymorphism
ID FACTOR-H POLYMORPHISM; GENOME-WIDE ASSOCIATION; COMPONENT 2 C2;
   SUSCEPTIBILITY; VARIANTS; DISEASE; RISK; CFB; MECHANISMS; HAPLOTYPE
AB Purpose: To elucidate whether polymorphisms of C2, C3, and CFB genes are major genetic determinants of age-related macular degeneration (AMD) in a Greek population.
   Methods: This was a case-control association study comprising 120 Greek patients with early and late-stage AMD and 140 independent controls of Caucasian origin. All participants were genotyped for rs547154, rs2230199, rs641153, and rs12614 polymorphisms by a combination of PCR and direct DNA sequencing assays.
   Results: The frequency of the rs2230199 G allele (minor allele) was significantly higher in patients with AMD in comparison with controls (0.34 vs 0.22, p = 0.0031) and similar to the frequency of other reported populations. There was a significant difference in the frequencies of the rs2230199 genotypes among cases and controls (p = 0.0055), rs2230199 was found to be a significant predictor of advanced AMD status (odds ratio 6.41, confidence interval [Cl] 2.72-15.09, p<0.0001; area under the curve 0.706, Cl 0.61-0.78, p<0.0001]). For the other single nucleotide polymorphism (SNP) loci, the allele and genotype frequencies did not reach statistical significance. The minor allele frequencies in controls and cases were similar and still much lower than the frequencies reported in other populations.
   Conclusions: The rs547154, rs641153, and rs12614 SNPs were not associated with AMD development in Greek patients, However, this finding should be viewed with caution as the particular polymorphisms presented with very low frequencies in the Greek population. Finally, the replication of the reported associations of C3 with AMD suggests that the presence of the C3 G allele could serve as a high-risk genetic marker for the development of AMD and the progression of the disease to the advanced clinical stage.
C1 [Havvas, Ooannis; Deli, Angeliki; Pharmakakis, Nikolaos] Univ Patras, Sch Med, Dept Ophthalmol, GR-26110 Patras, Greece.
   [Marioli, Dimitra I.; Zarkadis, Ioannis K.] Univ Patras, Sch Med, Dept Biol, GR-26110 Patras, Greece.
C3 University of Patras; University of Patras
RP Pharmakakis, N (通讯作者)，Univ Patras, Sch Med, Dept Ophthalmol, Rion 26500, Greece.
EM n.farmakakis@gmail.com
FU University of Patras
FX Supported by the University of Patras.
CR Appel GB, 2005, J AM SOC NEPHROL, V16, P1392, DOI 10.1681/ASN.2005010078
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chanock SJ, 2007, NATURE, V447, P655, DOI 10.1038/447655a
   Chu J, 2008, CHINESE MED J-PEKING, V121, P2525, DOI 10.1097/00029330-200812020-00011
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Edwards AO, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003813
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Farwick A, 2009, EYE, V23, P2238, DOI 10.1038/eye.2008.426
   FINN JE, 1994, NEPHROL DIAL TRANSPL, V9, P1564
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jun GG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025775
   Kaur I, 2010, INVEST OPHTH VIS SCI, V51, P59, DOI 10.1167/iovs.09-4135
   Kim SJ, 2012, EXP EYE RES, V96, P42, DOI 10.1016/j.exer.2012.01.005
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Marioli DI, 2009, GRAEF ARCH CLIN EXP, V247, P1547, DOI 10.1007/s00417-009-1129-z
   Morrison Margaux A., 2011, Human Genomics, V5, P538
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P794, DOI 10.1167/iovs.11-8468
   Park KH, 2009, INVEST OPHTH VIS SCI, V50, P3386, DOI 10.1167/iovs.08-3231
   RAMBAUSEK M, 1987, Nephrology Dialysis Transplantation, V2, P208
   Richardson AJ, 2009, INVEST OPHTH VIS SCI, V50, P540, DOI 10.1167/iovs.08-2423
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Silveira AC, 2010, VISION RES, V50, P698, DOI 10.1016/j.visres.2009.09.016
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Sundaresan P, 2012, INVEST OPHTH VIS SCI, V53, P7492, DOI 10.1167/iovs.12-10073
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Thakkinstian A, 2011, AM J EPIDEMIOL, V173, P1365, DOI 10.1093/aje/kwr025
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 44
TC 5
Z9 5
U1 0
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD SEP-OCT
PY 2014
VL 24
IS 5
BP 751
EP 760
DI 10.5301/ejo.5000427
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AR0OH
UT WOS:000343270700017
PM 24519512
DA 2022-11-30
ER

PT J
AU Lueck, K
   Wasmuth, S
   Williams, J
   Hughes, TR
   Morgan, BP
   Lommatzsch, A
   Greenwood, J
   Moss, SE
   Pauleikhoff, D
AF Lueck, K.
   Wasmuth, S.
   Williams, J.
   Hughes, T. R.
   Morgan, B. P.
   Lommatzsch, A.
   Greenwood, J.
   Moss, S. E.
   Pauleikhoff, D.
TI Sub-lytic C5b-9 induces functional changes in retinal pigment epithelial
   cells consistent with age-related macular degeneration
SO EYE
LA English
DT Article
DE age-related macular degeneration; retinal pigment epithelial cells;
   membrane attack complex; complement
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; MEMBRANE ATTACK COMPLEX; C-REACTIVE
   PROTEIN; EXTRACELLULAR-MATRIX; VITRONECTIN GENE; EXPRESSION; VEGF; IL-8;
   SECRETION; INTERLEUKIN-8
AB Purpose There is evidence for complement dysfunction in age-related macular degeneration (AMD). Complement activation leads to formation of the membrane attack complex (MAC), known to assemble on retinal pigment epithelial (RPE) cells. Therefore, the effect of sub-lytic MAC on RPE cells was examined with regard to pro-inflammatory or pro-angiogenic mediators relevant in AMD.
   Methods For sub-lytic MAC induction, RPE cells were incubated with an antiserum to complement regulatory protein CD59, followed by normal human serum (NHS) to induce 5% cell death, measured by a viability assay. MAC formation was evaluated by immunofluorescence and FACS analysis. Interleukin (IL)-6, -8, monocytic chemoattractant protein-1 (MCP-1), and vascular endothelial growth factor (VEGF) were quantified by enzyme-linked immunosorbent assay (ELISA). Intracellular MCP-1 was analysed by immunofluorescence, vitronectin by western blotting, and gelatinolytic matrix metalloproteinases (MMPs) by zymography.
   Results Incubation of RPE cells with the CD59 antiserum followed by 5% NHS induced sub-lytic amounts of MAC, verified by FACS and immunofluorescence. This treatment stimulated the cells to release IL-6, -8, MCP-1, and VEGF. MCP-1 staining, production of vitronectin, and gelatinolytic MMPs were also elevated in response to sub-lytic MAC.
   Conclusions MAC assembly on RPE cells increases the IL-6, -8, and MCP-1 production. Therefore, sub-lytic MAC might have a significant role in generating a pro-inflammatory microenvironment, contributing to the development of AMD. Enhanced vitronectin might be a protective mechanism against MAC deposition. In addition, the increased expression of gelatinolytic MMPs and pro-angiogenic VEGF may be associated with neovascular processes and late AMD. Eye (2011) 25, 1074-1082; doi:10.1038/eye.2011.109; published online 20 May 2011
C1 [Lueck, K.; Wasmuth, S.; Pauleikhoff, D.] St Franziskus Hosp, Ophtha Lab, Dept Ophthalmol, Munster, Germany.
   [Williams, J.; Greenwood, J.; Moss, S. E.] UCL Inst Ophthalmol, Dept Cell Biol, London, England.
   [Hughes, T. R.; Morgan, B. P.] Cardiff Univ, Dept Med Biochem & Immunol, Complement Biol Grp, Sch Med, Cardiff, S Glam, Wales.
C3 St. Franziskus-Hospital; University of London; University College
   London; Cardiff University
RP Pauleikhoff, D (通讯作者)，Augenaerzte St Franziskus Hosp, Hohenzollernring 74, D-48145 Munster, Nrw, Germany.
EM dapauleikhoff@muenster.de
OI Morgan, Paul/0000-0003-4075-7676; Greenwood, John/0000-0003-4496-2984
FU DAAD; Voltmann Foundation; Akademie des Sehens
FX We would like to express our sincere appreciation to Grazyna Galatowicz
   at UCL Institute of Ophthalmology London and Maren Hennig at Ophtha-Lab
   Department of Ophthalmology Muenster for their help with the FACS
   analysis. This work was supported by DAAD and Voltmann Foundation.
   Funding: 'DAAD', 'Akademie des Sehens', and Voltmann Foundation.
CR Ajuebor MN, 1998, BRIT J PHARMACOL, V125, P319, DOI 10.1038/sj.bjp.0702071
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 1999, INVEST OPHTH VIS SCI, V40, P3305
   Berglin L, 2003, INVEST OPHTH VIS SCI, V44, P403, DOI 10.1167/iovs.02-0180
   Biswas PS, 2006, EXP EYE RES, V82, P46, DOI 10.1016/j.exer.2005.05.001
   Bohana-Kashtan O, 2004, MOL IMMUNOL, V41, P583, DOI 10.1016/j.molimm.2004.04.007
   BORA NS, 1994, INVEST OPHTH VIS SCI, V34, P3579
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   CHEN Y, 2009, MOL IMMUNOL, V46, P326
   Chen YW, 2007, EUR J IMMUNOL, V37, P167, DOI 10.1002/eji.200636285
   Cortright DN, 2009, CURR EYE RES, V34, P57, DOI 10.1080/02713680802546658
   Cybulsky AV, 2005, AM J PHYSIOL-RENAL, V289, pF593, DOI 10.1152/ajprenal.00066.2005
   DEBOER JH, 1992, CURR EYE RES, V11, P181, DOI 10.3109/02713689208999530
   DEVOS AF, 1992, CURR EYE RES, V11, P581, DOI 10.3109/02713689209001814
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   ELNER VM, 1990, AM J PATHOL, V136, P745
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Fosbrink M, 2005, IMMUNOL RES, V31, P37, DOI 10.1385/IR:31:1:37
   Fosbrink M, 2009, EXP MOL PATHOL, V86, P87, DOI 10.1016/j.yexmp.2008.12.005
   Fukuoka Y, 2003, CLIN EXP IMMUNOL, V131, P248, DOI 10.1046/j.1365-2249.2003.02087.x
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   HAGEMAN GS, 2005, P NATL ACAD SCI USA, V43, P582
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Holtkamp GM, 1998, CLIN EXP IMMUNOL, V112, P34
   Kilgore KS, 1996, AM J PATHOL, V149, P953
   Kilgore KS, 1997, AM J PATHOL, V150, P2019
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kresse H, 2001, J CELL PHYSIOL, V189, P266, DOI 10.1002/jcp.10030
   KUPPNER MC, 1995, IMMUNOLOGY, V84, P265
   Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Li JJ, 2009, AM J PHYSIOL-RENAL, V297, pF200, DOI 10.1152/ajprenal.90649.2008
   Li WB, 2010, MED SCI MONITOR, V16, pBR17
   LI YP, 1994, J IMMUNOL, V152, P2995
   McGeer Edith G, 2005, Neurobiol Aging, V26 Suppl 1, P94, DOI 10.1016/j.neurobiolaging.2005.08.008
   Miwa T, 2001, INT IMMUNOPHARMACOL, V1, P445, DOI 10.1016/S1567-5769(00)00043-6
   Mullins RF, 2006, MOL VIS, V12, P224
   Niculescu F, 2001, IMMUNOL RES, V24, P191, DOI 10.1385/IR:24:2:191
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   PODACK ER, 1979, J BIOL CHEM, V254, P9908
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Shankland SJ, 1999, KIDNEY INT, V56, P538, DOI 10.1046/j.1523-1755.1999.00560.x
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Stamenkovic I, 2003, J PATHOL, V200, P448, DOI 10.1002/path.1400
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995
   Tramontini NL, 2002, INFLAMMATION, V26, P311, DOI 10.1023/A:1021420903355
   TSCHOPP J, 1988, P NATL ACAD SCI USA, V85, P4814
   Wasmuth S, 2009, INVEST OPHTH VIS SCI, V50, P5304, DOI 10.1167/iovs.08-3326
   Yang P, 2009, INVEST OPHTH VIS SCI, V50, P3473, DOI 10.1167/iovs.08-3202
NR 54
TC 53
Z9 53
U1 1
U2 9
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD AUG
PY 2011
VL 25
IS 8
BP 1074
EP 1082
DI 10.1038/eye.2011.109
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 806BG
UT WOS:000293775400019
PM 21597483
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Machalinska, A
   Safranow, K
   Dziedziejko, V
   Mozolewska-Piotrowska, K
   Paczkowska, E
   Klos, P
   Pius, E
   Grymula, K
   Wiszniewska, B
   Karczewicz, D
   Machalinski, B
AF Machalinska, Anna
   Safranow, Krzysztof
   Dziedziejko, Violetta
   Mozolewska-Piotrowska, Katarzyna
   Paczkowska, Edyta
   Klos, Patrycja
   Pius, Ewa
   Grymula, Katarzyna
   Wiszniewska, Barbara
   Karczewicz, Danuta
   Machalinski, Boguslaw
TI Different Populations of Circulating Endothelial Cells in Patients with
   Age-Related Macular Degeneration: A Novel Insight into Pathogenesis
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID INDUCED RETINAL DEGENERATION; PROGENITOR CELLS; CHOROIDAL
   NEOVASCULARIZATION; BONE-MARROW; CARDIOVASCULAR-DISEASE; GROWTH-FACTOR;
   FACTOR-I; VISUAL IMPAIRMENT; RISK-FACTORS; STEM-CELLS
AB PURPOSE. Circulating endothelial cells (CECs) and endothelial progenitor cells (EPCs) may serve as novel markers of endothelial dysfunction. The presence and clinical implications of CECs and the expression of endothelin (ET)-1, one of the most potent vasoconstrictors, have not been evaluated in patients with the neovascular form of age-related macular degeneration (AMD). This study was conducted to determine the different populations of endothelial cells (ECs) in the peripheral blood of AMD patients and to correlate these findings with the expression of ET-1 and the cytokines and growth factors responsible for EC migration and function.
   METHODS. Peripheral blood samples were collected from 29 patients with diagnosed neovascular AMD and from 38 healthy control subjects. CD133(-)CD144(+) CECs and CD34(+)CD133(+)CD144(+) EPCs were counted and analyzed by flow cytometry. The intracellular expression of ET-1 in peripheral blood nuclear cells (PBNCs) was studied by using qRT-PCR, Western blot, and immunocytofluorescence assays, and ET-1, IGF-1, VEGF, SDF-1, and HGF plasma concentrations were measured in enzyme-linked immunosorbent assays.
   RESULTS. Increased CECs and EPCs were found in the AMD patients compared with the counts in healthy individuals. The expression of intracellular ET-1 was significantly elevated in PBNCs from the AMD patients compared with the control subjects. In addition a significantly higher plasma concentration of IGF-1 was observed, but a lower SDF-1 level in the group of AMD patients.
   CONCLUSIONS. These findings suggest that circulating endothelial cells, together with high ET-1 content, may contribute to the development of AMD. Further prospective investigations on the mechanism involved may be relevant to the potential treatment of this disease. (Invest Ophthalmol Vis Sci. 2011; 52: 93-100) DOI:10.1167/iovs.10-5756
C1 [Paczkowska, Edyta; Klos, Patrycja; Pius, Ewa; Grymula, Katarzyna; Machalinski, Boguslaw] Pomeranian Med Univ, Dept Gen Pathol, PL-70111 Szczecin, Poland.
   [Machalinska, Anna; Wiszniewska, Barbara] Pomeranian Med Univ, Dept Histol & Embryol, PL-70111 Szczecin, Poland.
   [Machalinska, Anna; Mozolewska-Piotrowska, Katarzyna; Karczewicz, Danuta] Pomeranian Med Univ, Dept Ophthalmol, PL-70111 Szczecin, Poland.
   [Safranow, Krzysztof; Dziedziejko, Violetta] Pomeranian Med Univ, Dept Biochem & Med Chem, PL-70111 Szczecin, Poland.
C3 Pomeranian Medical University; Pomeranian Medical University; Pomeranian
   Medical University; Pomeranian Medical University
RP Machalinski, B (通讯作者)，Pomeranian Med Univ, Dept Gen Pathol, Powstancow Wlkp 72, PL-70111 Szczecin, Poland.
EM annam@sci.pam.szczecin.pl; machalin@sci.pam.szczecin.pl
RI Machalinska, Anna/P-6701-2014; Paczkowska, Edyta/AAX-2347-2021; Grymuła,
   Katarzyna/M-8352-2014; Machaliński, Bogusław/P-3025-2014; Paczkowska,
   Edyta/N-1209-2014; Kłos, Patrycja/C-6205-2017; Safranow,
   Krzysztof/B-5127-2015; Pius-Sadowska, Ewa/O-8254-2014; Dziedziejko,
   Violetta V./A-7626-2015; Wiszniewska, Barbara/O-3644-2014
OI Grymuła, Katarzyna/0000-0003-1445-6562; Paczkowska,
   Edyta/0000-0001-7052-9741; Kłos, Patrycja/0000-0002-0686-3953; Safranow,
   Krzysztof/0000-0001-9415-2758; Pius-Sadowska, Ewa/0000-0003-3106-8705;
   Dziedziejko, Violetta V./0000-0003-4809-415X; Wiszniewska,
   Barbara/0000-0002-9064-6969; Machalinski, Boguslaw/0000-0002-6013-0419
FU Polish Ministry of Science and Higher Education [NN402172137]
FX This work was supported by Grant NN402172137 from the Polish Ministry of
   Science and Higher Education (AM).
CR Adamiec-Mroczek J, 2010, CYTOKINE, V49, P269, DOI 10.1016/j.cyto.2009.11.004
   Beerepoot LV, 2004, ANN ONCOL, V15, P139, DOI 10.1093/annonc/mdh017
   Bhutto IA, 2006, BRIT J OPHTHALMOL, V90, P906, DOI 10.1136/bjo.2006.090357
   Boos CJ, 2006, J AM COLL CARDIOL, V48, P1538, DOI 10.1016/j.jacc.2006.02.078
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   Clancy R M, 2000, Curr Rheumatol Rep, V2, P39, DOI 10.1007/s11926-996-0067-6
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   De Falco E, 2004, BLOOD, V104, P3472, DOI 10.1182/blood-2003-12-4423
   DILLS DG, 1991, DIABETES, V40, P1725, DOI 10.2337/diabetes.40.12.1725
   Erdbruegger U, 2006, CLIN CHIM ACTA, V373, P17, DOI 10.1016/j.cca.2006.05.016
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P4914, DOI 10.1167/iovs.03-0371
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Feletou M, 2006, AM J PHYSIOL-HEART C, V291, pH985, DOI 10.1152/ajpheart.00292.2006
   Fox A, 2008, BRIT J SURG, V95, P244, DOI 10.1002/bjs.5913
   Furstenberger G, 2006, BRIT J CANCER, V94, P524, DOI 10.1038/sj.bjc.6602952
   GRANT M, 1986, DIABETES, V35, P416, DOI 10.2337/diabetes.35.4.416
   Haefliger IO, 2001, PROG RETIN EYE RES, V20, P209, DOI 10.1016/S1350-9462(00)00020-3
   Hellstrom A, 2001, P NATL ACAD SCI USA, V98, P5804, DOI 10.1073/pnas.101113998
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Leone AM, 2009, EUR HEART J, V30, P890, DOI 10.1093/eurheartj/ehp078
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   McClung JA, 2005, DIABETOLOGIA, V48, P345, DOI 10.1007/s00125-004-1647-5
   Nadar SK, 2005, THROMB HAEMOSTASIS, V94, P707
   Pang IH, 1997, P SOC EXP BIOL MED, V215, P21
   Prasanna G, 2002, INVEST OPHTH VIS SCI, V43, P2704
   Real Carla, 2008, Cardiovascular & Hematological Disorders - Drug Targets, V8, P185, DOI 10.2174/187152908785849071
   Roldan-Pallares M, 2005, MOL VIS, V11, P461
   Sengupta N, 2003, INVEST OPHTH VIS SCI, V44, pU349
   Sengupta N, 2005, INVEST OPHTH VIS SCI, V46, P343, DOI 10.1167/iovs.04-0153
   Shah R, 2007, EUR J INTERN MED, V18, P272, DOI 10.1016/j.ejim.2007.04.002
   Smith LEH, 1999, NAT MED, V5, P1390, DOI 10.1038/70963
   Smythe J, 2008, TISSUE ENG PT C-METH, V14, P59, DOI 10.1089/tec.2007.0251
   Thill M, 2008, INVEST OPHTH VIS SCI, V49, P2696, DOI 10.1167/iovs.07-0955
   Tomita M, 2004, STEM CELLS, V22, P21, DOI 10.1634/stemcells.22-1-21
   Torbidoni V, 2005, EXP EYE RES, V81, P265, DOI 10.1016/j.exer.2004.12.024
   Torbidoni V, 2006, EXP BIOL MED, V231, P1095
   van Weel V, 2007, ARTERIOSCL THROM VAS, V27, P1426, DOI 10.1161/ATVBAHA.107.139642
   Versari D, 2009, DIABETES CARE, V32, pS314, DOI 10.2337/dc09-S330
   Xiao QZ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000975
   Xiao QZ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004061
   YAMAGISHI S, 1993, BIOCHEM BIOPH RES CO, V191, P840, DOI 10.1006/bbrc.1993.1293
   Yamaguchi J, 2003, CIRCULATION, V107, P1322, DOI 10.1161/01.CIR.0000055313.77510.22
   Yodoi Y, 2007, INVEST OPHTH VIS SCI, V48, P5464, DOI 10.1167/iovs.07-0093
   Zheng H, 2007, J CARDIOVASC PHARM, V50, P274, DOI 10.1097/FJC.0b013e318093ec8f
NR 44
TC 27
Z9 28
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2011
VL 52
IS 1
BP 93
EP 100
DI 10.1167/iovs.10-5756
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 702VW
UT WOS:000285925000014
PM 20720219
DA 2022-11-30
ER

PT J
AU Kawashima-Kumagai, K
   Yamashiro, K
   Yoshikawa, M
   Miyake, M
   Ming, GCC
   Fan, Q
   Koh, JY
   Saito, M
   Sugahara-Kuroda, M
   Oishi, M
   Akagi-Kurashige, Y
   Nakata, I
   Nakanishi, H
   Gotoh, N
   Oishi, A
   Tamura, H
   Ooto, S
   Tsujikawa, A
   Kurimoto, Y
   Sekiryu, T
   Matsuda, F
   Khor, CC
   Cheng, CY
   Wong, TY
   Yoshimura, N
AF Kawashima-Kumagai, Kyoko
   Yamashiro, Kenji
   Yoshikawa, Munemitsu
   Miyake, Masahiro
   Ming, Gemmy Cheung Chui
   Fan, Qiao
   Koh, Jia Yu
   Saito, Masaaki
   Sugahara-Kuroda, Masako
   Oishi, Maho
   Akagi-Kurashige, Yumiko
   Nakata, Isao
   Nakanishi, Hideo
   Gotoh, Norimoto
   Oishi, Akio
   Tamura, Hiroshi
   Ooto, Sotaro
   Tsujikawa, Akitaka
   Kurimoto, Yasuo
   Sekiryu, Tetsuju
   Matsuda, Fumihiko
   Khor, Chiea-Chuen
   Cheng, Ching-Yu
   Wong, Tien Yin
   Yoshimura, Nagahisa
TI A genome-wide association study identified a novel genetic loci
   STON1-GTF2A1L/LHCGR/FSHR for bilaterality of neovascular age-related
   macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; CORONARY HEART-DISEASE; CLINICAL
   CHARACTERISTICS; REPRODUCTIVE FACTORS; REPLACEMENT THERAPY; CHINESE
   PATIENTS; ARMS2 GENOTYPE; EYE; POLYMORPHISM; CHOLESTEROL
AB Bilateral neovascular age-related macular degeneration (AMD) causes much more handicaps for patients than unilateral neovascular AMD. Although several AMD-susceptibility genes have been evaluated for their associations to bilaterality, genome-wide association study (GWAS) on bilaterality has been rarely reported. In the present study, we performed GWAS using neovascular AMD cases in East Asian. The discovery stage compared 581,252 single nucleotide polymorphisms (SNPs) between 803 unilateral and 321 bilateral Japanese cases but no SNP showed genome-wide significance, while SNPs at six regions showed P-value <1.0 x 10(-5), STON1-GTF2A1L/LHCGR/FSHR, PLXNA1, CTNNA3, ARMS2/HTRA1, LHFP, and FLJ38725. The first replication study for these six regions comparing 36 bilateral and 132 unilateral Japanese cases confirmed significant associations of rs4482537 (STON1-GTF2A1L/LHCGR/FSHR), rs2284665 (ARMS2/HTRA1), and rs8002574 (LHFP) to bilaterality. In the second replication study comparing 24 bilateral and 78 unilateral cases from Singapore, rs4482537 (STON1-GTF2A1L/LHCGR/FSHR) only showed significant association. Meta-analysis of discovery and replication studies confirmed genome-wide level significant association (P = 2.61 x 10(-9)) of rs4482537 (STON1-GTF2A1L/LHCGR/FSHR) and strong associations (P = 5.76 x 10(-7) and 9.73 x 10(-7), respectively) of rs2284665 (ARMS2/HTRA1) and rs8002574 (LHFP). Our GWAS for neovascular AMD bilaterality found new genetic loci STON1-GTF2A1L/LHCGR/FSHR and confirmed the previously reported association of ARMS2/HTRA1.
C1 [Kawashima-Kumagai, Kyoko; Yamashiro, Kenji; Yoshikawa, Munemitsu; Miyake, Masahiro; Sugahara-Kuroda, Masako; Oishi, Maho; Akagi-Kurashige, Yumiko; Nakata, Isao; Nakanishi, Hideo; Oishi, Akio; Tamura, Hiroshi; Ooto, Sotaro; Tsujikawa, Akitaka; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
   [Yoshikawa, Munemitsu; Miyake, Masahiro; Gotoh, Norimoto; Matsuda, Fumihiko] Kyoto Univ, Grad Sch Med, Ctr Genom Med, Kyoto, Japan.
   [Ming, Gemmy Cheung Chui; Fan, Qiao; Koh, Jia Yu; Khor, Chiea-Chuen; Cheng, Ching-Yu; Wong, Tien Yin] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Saito, Masaaki; Sekiryu, Tetsuju] Fukushima Med Univ, Dept Ophthalmol, Fukushima, Japan.
   [Tsujikawa, Akitaka] Kagawa Univ, Dept Ophthalmol, Kagawa, Japan.
   [Kurimoto, Yasuo] Kobe City Gen Hosp, Dept Ophthalmol, Kobe, Hyogo, Japan.
   [Khor, Chiea-Chuen; Wong, Tien Yin] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore.
   [Khor, Chiea-Chuen; Wong, Tien Yin] Natl Univ Hlth Syst, Singapore, Singapore.
   [Khor, Chiea-Chuen] Genome Inst Singapore, Div Human Genet, Singapore, Singapore.
   [Cheng, Ching-Yu; Wong, Tien Yin] Natl Univ Singapore, Duke NUS Grad Med Sch, Ophthalmol & Visual Sci Acad Clin Program, Singapore, Singapore.
   [Cheng, Ching-Yu; Wong, Tien Yin] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, Singapore.
C3 Kyoto University; Kyoto University; National University of Singapore;
   Singapore National Eye Center; Fukushima Medical University; Kagawa
   University; Kobe City Medical Center General Hospital; National
   University of Singapore; National University of Singapore; Agency for
   Science Technology & Research (A*STAR); A*STAR - Genome Institute of
   Singapore (GIS); National University of Singapore; National University
   of Singapore
RP Yamashiro, K (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
EM yamashro@kuhp.kyoto-u.ac.jp
RI Cheng, Ching-Yu/Y-2229-2019; TAMURA, Hiroshi/H-1855-2011; Wong, Tien
   Yin/AAC-9724-2020; Miyake, Masahiro/V-1261-2019; Saito,
   Masaaki/ABI-2783-2020; Oishi, Akio/AAE-9996-2020
OI Cheng, Ching-Yu/0000-0003-0655-885X; TAMURA,
   Hiroshi/0000-0002-7740-2732; Wong, Tien Yin/0000-0002-8448-1264; Miyake,
   Masahiro/0000-0001-7410-3764; Saito, Masaaki/0000-0003-1494-6350; Oishi,
   Akio/0000-0002-0977-9458; Koh, Jia Yu/0000-0001-8772-8392; Yamashiro,
   Kenji/0000-0001-9354-8558; Sekiryu, Tetsuju/0000-0001-8042-2729; Cheung,
   Chui Ming Gemmy/0000-0003-3358-3516; Tsujikawa,
   Akitaka/0000-0003-0779-7799; Ming, Guo-li/0000-0002-2517-6075
FU Japan Society for the Promotion of Science, Tokyo, Japan [24592624];
   Japan National Society for the Prevention of Blindness, Tokyo, Japan;
   National Medical Research Council in Singapore, Singapore [CSA/033/2012]
FX Supported in part by grants-in-aid for scientific research (No.
   24592624) from the Japan Society for the Promotion of Science, Tokyo,
   Japan, and the Japan National Society for the Prevention of Blindness,
   Tokyo, Japan. This research was also supported by the National Medical
   Research Council in Singapore (CSA/033/2012), Singapore.
CR Boekhoorn SS, 2007, INVEST OPHTH VIS SCI, V48, P1012, DOI 10.1167/iovs.06-0577
   BUSH TL, 1988, CLIN CHEM, V34, pB60
   Chen HY, 2008, VISION RES, V48, P690, DOI 10.1016/j.visres.2007.10.014
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Dukic-Stefanovic S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052567
   Feskanich D, 2008, ARCH OPHTHALMOL-CHIC, V126, P519, DOI 10.1001/archopht.126.4.519
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Freeman EE, 2005, OPHTHAL EPIDEMIOL, V12, P37, DOI 10.1080/09286580490907779
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Hirasawa M, 2011, MOL VIS, V17, P1222
   Hou J, 2011, GRAEF ARCH CLIN EXP, V249, P975, DOI 10.1007/s00417-010-1575-7
   Huang LZ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7687
   Ishikawa K., 2015, EXP EYE RES
   Kavanagh K, 2009, ARTERIOSCL THROM VAS, V29, P1471, DOI 10.1161/ATVBAHA.109.191825
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   Maritzen T, 2010, TRAFFIC, V11, P8, DOI 10.1111/j.1600-0854.2009.00971.x
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Melville SA, 2012, ANN NEUROL, V72, P65, DOI 10.1002/ana.23644
   Nagaishi M, 2012, AM J PATHOL, V180, P1816, DOI 10.1016/j.ajpath.2012.01.027
   Nakata I, 2015, SCI REP-UK, V5, DOI 10.1038/srep09345
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Pai ASI, 2009, ARCH OPHTHALMOL-CHIC, V127, P1339, DOI 10.1001/archophthalmol.2009.239
   Petit MMR, 1999, GENOMICS, V57, P438, DOI 10.1006/geno.1999.5778
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010
   Schwartz SG, 2012, RETINA-J RET VIT DIS, V32, P1486, DOI 10.1097/IAE.0b013e318240a540
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P
   Tamura H, 2012, AM J OPHTHALMOL, V154, P542, DOI 10.1016/j.ajo.2012.03.042
   Tedeschi-Blok N, 2007, OPHTHALMOLOGY, V114, P99, DOI 10.1016/j.ophtha.2006.07.043
   Xu XD, 2014, MOL BIOL REP, V41, P4493, DOI 10.1007/s11033-014-3320-5
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Zeidler MP, 1996, GENE DEV, V10, P50, DOI 10.1101/gad.10.1.50
NR 39
TC 4
Z9 4
U1 0
U2 2
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 3
PY 2017
VL 7
AR 7173
DI 10.1038/s41598-017-07526-9
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FC5NR
UT WOS:000406889500002
PM 28775256
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Miyazaki, M
   Kiyohara, Y
   Yoshida, A
   Iida, M
   Nose, Y
   Ishibashi, T
AF Miyazaki, M
   Kiyohara, Y
   Yoshida, A
   Iida, M
   Nose, Y
   Ishibashi, T
TI The 5-year incidence and risk factors for age-related maculopathy in a
   general Japanese population: The Hisayama study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID BLUE-MOUNTAINS EYE; BEAVER DAM EYE; MACULAR DEGENERATION;
   CIGARETTE-SMOKING; GRADING SYSTEM; VISUAL-ACUITY; PREVALENCE; AUSTRALIA;
   DRUSEN
AB PURPOSE. To estimate the 5-year incidence and risk factors for age-related maculopathy (ARM) in a representative older Japanese population.
   METHODS. A population-based cohort study was conducted in 1998 on 1482 Hisayama residents aged 50 years or older, and 961 of these subjects attended the 5-year follow-up examinations in 2003. At both time points, the characteristics of ARM were determined by grading color fundus photographs according to the Wisconsin Age-Related Maculopathy Grading System. Using these cohort data, logistic regression analyses were performed to determine the risk factors for ARM. Nine possible risk factors were examined: age, sex, hypertension, diabetes, hyperlipidemia, smoking, alcohol intake, body mass index, and white blood cell count.
   RESULTS. The 5-year incidence of early ARM was 8.5%, and that of late ARM was 0.8%. Men were found to have a significantly higher incidence of late ARM than did women. The incidence of both early and late ARM increased significantly with age. Multiple logistic regression analysis showed that age and smoking were significantly associated with early and late ARM.
   CONCLUSIONS. The results suggest that the overall 5-year incidence of early ARM is 8.0% and that of late ARM is 0.8% in the general Japanese population and that higher age and smoking are relevant risk factors for early and late ARM in the Japanese.
C1 Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Higashi Ku, Fukuoka 8128582, Japan.
   Kyushu Univ, Grad Sch Med Sci, Dept Med & Clin Sci, Fukuoka 8128582, Japan.
   Kyushu Univ, Grad Sch Med Sci, Dept Med Informat Sci, Fukuoka 8128582, Japan.
C3 Kyushu University; Kyushu University; Kyushu University
RP Miyazaki, M (通讯作者)，Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
EM miho-m@info.med.kyushu-u.ac.jp
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1686
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   OHMURA T, 1993, DIABETOLOGIA, V36, P1198, DOI 10.1007/BF00401066
   RITTER LL, 1995, AM J OPHTHALMOL, V120, P190, DOI 10.1016/S0002-9394(14)72607-8
   *SAS I INC, 1989, SAS STAT US GUID VER, V2, P1247
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   SMITH W, 2001, OPHTHALMOLOGY, V108, P2224
   Sparrow JM, 1997, EYE, V11, P315, DOI 10.1038/eye.1997.67
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   Yuzawa M, 1997, INT OPHTHALMOL, V21, P1, DOI 10.1023/A:1005845521424
NR 27
TC 74
Z9 82
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2005
VL 46
IS 6
BP 1907
EP 1910
DI 10.1167/iovs.04-0923
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 931SD
UT WOS:000229504600005
PM 15914602
DA 2022-11-30
ER

PT J
AU Winiarczyk, M
   Winiarczyk, D
   Michalak, K
   Kaarniranta, K
   Adaszek, L
   Winiarczyk, S
   Mackiewicz, J
AF Winiarczyk, Mateusz
   Winiarczyk, Dagmara
   Michalak, Katarzyna
   Kaarniranta, Kai
   Adaszek, Lukasz
   Winiarczyk, Stanislaw
   Mackiewicz, Jerzy
TI Dysregulated Tear Film Proteins in Macular Edema Due to the Neovascular
   Age-Related Macular Degeneration Are Involved in the Regulation of
   Protein Clearance, Inflammation, and Neovascularization
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE age-related macular degeneration; AMD; proteomics; tear film; tear film
   proteome; protein clearance; neovascularization; neovascular AMD
ID ALPHA-ENOLASE; ANNEXIN; AUTOANTIBODIES; ACTIVATION; BIOMARKERS;
   ANTIBODIES; PATHOLOGY; ROLES
AB Macular edema and its further complications due to the leakage from the choroidal neovascularization in course of the age-related macular degeneration (AMD) is a leading cause of blindness among elderly individuals in developed countries. Changes in tear film proteomic composition have been reported to occur in various ophthalmic and systemic diseases. There is an evidence that the acute form of neovascular AMD may be reflected in the tear film composition. Tear film was collected with Schirmer strips from patients with neovascular AMD and sex- and age-matched control patients. Two-dimensional electrophoresis was performed followed by MALDI-TOF mass spectrometry for identification of differentially expressed proteins. Quantitative analysis of the differential electrophoretic spots was performed with Delta2D software. Altogether, 11 significantly differentially expressed proteins were identified; of those, 8 were downregulated, and 3 were upregulated in the tear film of neovascular AMD patients. The differentially expressed proteins identified in tear film were involved in signaling pathways associated with impaired protein clearance, persistent inflammation, and neovascularization. Tear film protein analysis is a novel way to screen AMD-related biomarkers.
C1 [Winiarczyk, Mateusz; Mackiewicz, Jerzy] Med Univ Lublin, Dept Vitreoretinal Surg, PL-20079 Lublin, Poland.
   [Winiarczyk, Dagmara; Michalak, Katarzyna; Adaszek, Lukasz; Winiarczyk, Stanislaw] Univ Life Sci Lublin, Dept Epizootiol, PL-20400 Lublin, Poland.
   [Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Kuopio 70211, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Kuopio 70211, Finland.
C3 Medical University of Lublin; University of Life Sciences in Lublin;
   University of Eastern Finland; Kuopio University Hospital; University of
   Eastern Finland
RP Winiarczyk, M (通讯作者)，Med Univ Lublin, Dept Vitreoretinal Surg, PL-20079 Lublin, Poland.
EM mateuszwiniarczyk@umlub.pl; winiarczykdm@gmail.com; artica@wp.pl;
   kai.kaarniranta@uef.fi; lukasz.adaszek@up.lublin.pl; genp53@interia.pl;
   jerzymackiewicz@umlub.pl
OI Adaszek, Lukasz/0000-0003-0261-2695; Mackiewicz,
   Jerzy/0000-0003-0984-8908; Winiarczyk, Stanislaw/0000-0002-8468-2154;
   Winiarczyk, Mateusz/0000-0001-9704-3848; Michalak,
   Katarzyna/0000-0002-4249-9810; Winiarczyk, Dagmara/0000-0002-1257-869X
FU Polish National Science Centre (NCN); Preludium grant
   [UMO-2017/25/N/NZ5/01875, UMO-2016/23/N/NZ5/02576]
FX This work was supported by the Polish National Science Centre (NCN).
   M.W. was supported by Preludium grant number UMO-2017/25/N/NZ5/01875.
   D.W. was supported by Preludium grant number UMO-2016/23/N/NZ5/02576.
   The research materials supporting this publication can be accessed by
   contacting the corresponding authors.
CR Ablamowicz AF, 2017, MOL VIS, V23, P529
   Adamus G, 1996, CLIN IMMUNOL IMMUNOP, V78, P120, DOI 10.1006/clin.1996.0021
   Adamus G, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-154
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Ang WJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221481
   Canas F, 2015, THROMB RES, V135, P226, DOI 10.1016/j.thromres.2014.11.034
   Chen WR, 2018, FASEB J, V32
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   D'Acquisto F, 2007, BLOOD, V109, P1095, DOI 10.1182/blood-2006-05-022798
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Dot C, 2005, AM J OPHTHALMOL, V139, P746, DOI 10.1016/j.ajo.2004.10.044
   Eastlake K, 2018, EXP EYE RES, V177, P197, DOI 10.1016/j.exer.2018.08.016
   El-Mollayess GM, 2011, SEMIN OPHTHALMOL, V26, P69, DOI 10.3109/08820538.2010.545100
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Gawecki M, 2019, J CLIN MED, V8, DOI 10.3390/jcm8091398
   Gonzalez N, 2012, MOL VIS, V18, P1572
   Green-Church KB, 2008, MOL VIS, V14, P456
   Gutmann DAP, 2010, TRENDS BIOCHEM SCI, V35, P36, DOI 10.1016/j.tibs.2009.07.009
   Hambright D, 2012, MOL VIS, V18, P920
   Hikage F, 2021, EXP CELL RES, V403, DOI 10.1016/j.yexcr.2021.112581
   Hodges LM, 2011, PHARMACOGENET GENOM, V21, P152, DOI 10.1097/FPC.0b013e3283385a1c
   Iaccarino L, 2011, AUTOIMMUN REV, V10, P553, DOI 10.1016/j.autrev.2011.04.007
   Joachim SC, 2007, GRAEF ARCH CLIN EXP, V245, P619, DOI 10.1007/s00417-006-0429-9
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kang GY, 2014, J PROTEOME RES, V13, P581, DOI 10.1021/pr400751k
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Klaassen I, 2013, PROG RETIN EYE RES, V34, P19, DOI 10.1016/j.preteyeres.2013.02.001
   Lee WK, 2021, CANCER DRUG RESIST, V4, P424, DOI 10.20517/cdr.2020.114
   Li KJ, 2010, GRAEF ARCH CLIN EXP, V248, P853, DOI 10.1007/s00417-009-1275-3
   Mirzaei M, 2019, MOL NEUROBIOL, V56, P6017, DOI 10.1007/s12035-019-1479-4
   Morgan CA, 2015, J MED CHEM, V58, P1964, DOI 10.1021/jm501900s
   Morohoshi K, 2009, J AUTOIMMUN, V33, P247, DOI 10.1016/j.jaut.2009.09.003
   Ni SM, 2017, ONCOTARGET, V8, P61253, DOI 10.18632/oncotarget.18056
   Posa A, 2013, ANN ANAT, V195, P137, DOI 10.1016/j.aanat.2012.10.001
   Rentka A, 2017, ANN CLIN BIOCHEM, V54, P521, DOI 10.1177/0004563217695843
   Rentka A, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/573681
   Sanches JM, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010121
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h
   Singh RK, 2019, STEM CELLS DEV, V28, P1151, DOI 10.1089/scd.2019.0090
   Sreekumar PG, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10050661
   Stifter J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188444
   Stomberski CT, 2019, J BIOL CHEM, V294, P18285, DOI 10.1074/jbc.RA119.011067
   Tew KD, 2007, BIOCHEM PHARMACOL, V73, P1257, DOI 10.1016/j.bcp.2006.09.027
   White IJ, 2006, EMBO J, V25, P1, DOI 10.1038/sj.emboj.7600759
   Winiarczyk M, 2018, GRAEF ARCH CLIN EXP, V256, P1127, DOI 10.1007/s00417-018-3984-y
   Xi YF, 2020, BIOMED PHARMACOTHER, V130, DOI 10.1016/j.biopha.2020.110591
   Yang ZY, 2007, INVEST OPHTH VIS SCI, V48, P5539, DOI 10.1167/iovs.07-0542
   Yazid S, 2015, J AUTOIMMUN, V58, P1, DOI 10.1016/j.jaut.2014.12.004
   Zhu JF, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1204-7
NR 50
TC 4
Z9 4
U1 3
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD JUL
PY 2021
VL 10
IS 14
AR 3060
DI 10.3390/jcm10143060
PG 13
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA TN4LF
UT WOS:000676207500001
PM 34300228
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Schmid-Kubista, KE
   Tosakulwong, N
   Wu, YH
   Ryu, E
   Hecker, LA
   Baratz, KH
   Brown, WL
   Edwards, AO
AF Schmid-Kubista, Katharina E.
   Tosakulwong, Nirubol
   Wu, Yanhong
   Ryu, Euijung
   Hecker, Laura A.
   Baratz, Keith H.
   Brown, William L.
   Edwards, Albert O.
TI Contribution of Copy Number Variation in the Regulation of Complement
   Activation Locus to Development of Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID DEPENDENT PROBE AMPLIFICATION; FACTOR-H POLYMORPHISM; RISK; GENE;
   SUSCEPTIBILITY; GENOME; PREDISPOSES; MACULOPATHY; VARIANTS; DISEASE
AB PURPOSE. To develop an assay for determining the number of copies of the genes encoding complement factor H related 3 (CFHR3) and 1 (CFHR1) and determine the contribution of copy number variation (CNV) at CFHR3 and CFHR1 to the development of age-related macular degeneration (AMD).
   METHODS. A multiplex ligation-dependent probe amplification (MLPA) assay was developed to quantify the number of copies of CFHR3 and CFHR1 in humans. Subjects with (n = 252) and without (n = 249) AMD were genotyped using the assay, and the impact on AMD risk was evaluated.
   RESULTS. The MLPA assay provided a consistent estimate of the number of copies of CFHR3 and CFHR1 in 500 of the 501 samples. Four different combinations of CNVs were observed with frequencies as follows: both CFHR3 and CFHR1 deletion (14%), CFHR3-only deletion (0.4%), CFHR1-only deletion (1.1%), and CFHR1 duplication (0.1%). Deletion of both copies of CFHR3 and CFHR1 decreased the odds of having AMD eightfold (95% CI 2-36) and always occurred on a protective haplotype, never on the risk haplotype tagged by the Y402H risk allele in CFH. The protection conferred by deletion of CFHR3 and CFHR1 could not be distinguished from the absence of the risk haplotype.
   CONCLUSIONS. Both deletions and duplications of genes in the regulation of complement activation locus segregated in Caucasians. Deletion of CFHR3 and CFHR1 protected against the development of AMD at least in part because the deletion tagged a protective haplotype and did not occur on the risk haplotype. (Invest Ophthalmol Vis Sci. 2009;50:5070-5079) DOI:10.1167/iovs.09-3975
C1 [Schmid-Kubista, Katharina E.; Tosakulwong, Nirubol; Hecker, Laura A.; Baratz, Keith H.; Brown, William L.; Edwards, Albert O.] Mayo Clin, Dept Ophthalmol, Rochester, MN 55905 USA.
   [Wu, Yanhong] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA.
   [Ryu, Euijung] Mayo Clin, Dept Biomed Stat & Informat, Rochester, MN 55905 USA.
C3 Mayo Clinic; Mayo Clinic; Mayo Clinic
RP Edwards, AO (通讯作者)，Mayo Clin, Dept Ophthalmol, 200 1st St SW, Rochester, MN 55905 USA.
EM edwardslab@mayo.edu
RI Brown, William/GXN-2777-2022
FU Max Kade Foundation, New York, NY; National Eye Institute, Bethesda, MD
   [EY014467]; Foundation Fighting Blindness, Owings Mills, MD; American
   Health Assistance Foundation, Clarksburg, MD; Research to Prevent
   Blindness, New York, NY; Mayo Foundation, Rochester, MN; NATIONAL EYE
   INSTITUTE [R01EY014467] Funding Source: NIH RePORTER
FX Supported by the Max Kade Foundation, New York, NY; Grant EY014467 from
   the National Eye Institute, Bethesda, MD; the Foundation Fighting
   Blindness, Owings Mills, MD; the American Health Assistance Foundation,
   Clarksburg, MD; unrestricted departmental grants from Research to
   Prevent Blindness, New York, NY; and the Mayo Foundation, Rochester, MN.
CR Aitman TJ, 2006, NATURE, V439, P851, DOI 10.1038/nature04489
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   Edwards AO, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003813
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fanciulli M, 2007, NAT GENET, V39, P721, DOI 10.1038/ng2046
   Fellermann K, 2006, AM J HUM GENET, V79, P439, DOI 10.1086/505915
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gonzalez E, 2005, SCIENCE, V307, P1434, DOI 10.1126/science.1101160
   Gonzalez JR, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-261
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Henrichsen CN, 2009, HUM MOL GENET, V18, pR1, DOI 10.1093/hmg/ddp011
   Hollox EJ, 2008, GENOME RES, V18, P1686, DOI 10.1101/gr.080945.108
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jankowski Stephane, 2008, J Biomol Tech, V19, P238
   Jozsi M, 2008, BLOOD, V111, P1512, DOI 10.1182/blood-2007-09-109876
   Kehrer-Sawatzki H, 2007, BIOESSAYS, V29, P311, DOI 10.1002/bies.20554
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   McKinney C, 2008, ANN RHEUM DIS, V67, P409, DOI 10.1136/ard.2007.075028
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Park KH, 2009, INVEST OPHTH VIS SCI, V50, P3386, DOI 10.1167/iovs.08-3231
   Park KH, 2009, MOL VIS, V15, P200
   Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056
   Shen YP, 2009, J GENET GENOMICS, V36, P257, DOI 10.1016/S1673-8527(08)60113-7
   SWAROOP A, 2009, ANN REV GENOMICS HUM
   Yang Y, 2007, AM J HUM GENET, V80, P1037, DOI 10.1086/518257
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zipfel PF, 2007, PLOS GENET, V3, P387, DOI 10.1371/journal.pgen.0030041
NR 38
TC 35
Z9 36
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2009
VL 50
IS 11
BP 5070
EP 5079
DI 10.1167/iovs.09-3975
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 514XH
UT WOS:000271429200007
PM 19553609
DA 2022-11-30
ER

PT J
AU Rim, TH
   Cheng, CY
   Kim, DW
   Kim, SS
   Wong, TY
AF Rim, Tyler Hyungtaek
   Cheng, Ching-Yu
   Kim, Dong Wook
   Kim, Sung Soo
   Wong, Tien Y.
TI A nationwide cohort study of cigarette smoking and risk of neovascular
   age-related macular degeneration in East Asian men
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SINGAPORE MALAY EYE; BLUE-MOUNTAINS EYE; LONG-TERM INCIDENCE; BEAVER DAM
   EYE; JAPANESE POPULATION; 5-YEAR INCIDENCE; TOBACCO CONTROL;
   BEIJING-EYE; MACULOPATHY; PREVALENCE
AB Background Few longitudinal studies have evaluated the relationship between cigarette smoking and risk of neovascular age-related macular degeneration (AMD) among Asian populations. This study aimed to prospectively evaluate the association between cigarette smoking and risk of neovascular AMD among Korean men.
   Methods Men between the ages of 45 and 79 years included in the Korea National Health Insurance Service database from 2002 through 2013. We compared hazard ratios (HR) for neovascular AMD between 64 560 past/current and 64 560 never smokers by 1:1 propensity-matched analysis and 85 267 past/current and 72 347 never smokers by unmatched cohort and propensity-adjusted analysis.
   Results The risk of neovascular AMD among past/ current smokers was 50% higher than that among never smokers (propensity-adjusted whole cohort analysis: HR, 1.48; 95% CI 1.22 to 1.79; propensity-matched analysis: HR, 1.50; 95% CI 1.22 to 1.84), with the risk more pronounced among current than past smokers (current vs past smokers: propensity-adjusted whole cohort analysis, HR, 1.66; 95% CI 1.35 to 2.04 vs HR, 1.15, 95% CI 0.87 to 1.52; propensity-matched analysis, HR, 1.65; 95% CI 1.32 to 2.05 vs HR, 1.21; 95% CI 0.90 to 1.63). Duration of smoking and daily cigarette consumption was associated with the incidence of neovascular AMD in a dose-dependent manner (p<0.001 for trend).
   Conclusions Cigarette smoking is associated with a strong risk of neovascular AMD among Korean men. These data highlight the public health impact of smoking on blindness in Asia.
C1 [Rim, Tyler Hyungtaek; Kim, Sung Soo] Yonsei Univ, Coll Med, Dept Ophthalmol, Severance Hosp,Inst Vis Res, 50 Yonsei Ro, Seoul 120752, South Korea.
   [Rim, Tyler Hyungtaek] Natl Hlth Insurance Serv Ilsan Hosp, Dept Ophthalmol, Gyeonggi Do, South Korea.
   [Cheng, Ching-Yu; Wong, Tien Y.] Duke NUS Med Sch, Ophthalmol & Visual Sci Acad Clin Program Eye ACP, Singapore, Singapore.
   [Cheng, Ching-Yu; Wong, Tien Y.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Cheng, Ching-Yu; Wong, Tien Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, Singapore.
   [Kim, Dong Wook] Natl Hlth Insurance Serv Ilsan Hosp, Dept Policy Res Affairs, Goyang, Gyeonggi Do, South Korea.
   [Kim, Sung Soo] Yonsei Univ, Yonsei Healthcare Big Data Based Knowledge Integr, Coll Med, Seoul, South Korea.
   [Kim, Sung Soo] Yonsei Univ, Inst Convergence Sci, Coll Med, Seoul, South Korea.
C3 Yonsei University; Yonsei University Health System; National Health
   Insurance Service; National University of Singapore; National University
   of Singapore; Singapore National Eye Center; National University of
   Singapore; National Health Insurance Service; Yonsei University; Yonsei
   University Health System; Yonsei University; Yonsei University Health
   System
RP Kim, SS (通讯作者)，Yonsei Univ, Coll Med, Dept Ophthalmol, Severance Hosp,Inst Vis Res, 50 Yonsei Ro, Seoul 120752, South Korea.; Wong, TY (通讯作者)，Singapore Natl Eye Ctr, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM semekim@yuhs.ac; wong.tien.yin@singhealth.com.sg
RI Cheng, Ching-Yu/Y-2229-2019; Wong, Tien Yin/AAC-9724-2020
OI Cheng, Ching-Yu/0000-0003-0655-885X; Wong, Tien Yin/0000-0002-8448-1264;
   Rim, Tyler Hyungtaek/0000-0001-6465-2620; Kim, Sung
   Soo/0000-0002-0574-7993
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 2016, WHO GLOB REP TRENDS
   Aoki A, 2015, INVEST OPHTH VIS SCI, V56, P2580, DOI 10.1167/iovs.14-16339
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Cackett P, 2008, BRIT J OPHTHALMOL, V92, P1312, DOI 10.1136/bjo.2007.136077
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Islami F, 2015, TRANSL LUNG CANCER R, V4, P327, DOI 10.3978/j.issn.2218-6751.2015.08.04
   Jung-Choi KH, 2012, TOB CONTROL, V21, P536, DOI 10.1136/tobaccocontrol-2011-050012
   Kabasawa S, 2011, OPHTHALMOLOGY, V118, P1082, DOI 10.1016/j.ophtha.2010.10.012
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Lavanya R, 2010, INVEST OPHTH VIS SCI, V51, P6247, DOI 10.1167/iovs.10-5229
   Levy D, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1134
   Mackay J, 2013, LANCET, V381, P1581, DOI 10.1016/S0140-6736(13)60854-5
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Pan CW, 2013, OPHTHALMOLOGY, V120, P2058, DOI 10.1016/j.ophtha.2013.03.028
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Rim TH, 2016, RETINA-J RET VIT DIS, V36, P2166, DOI 10.1097/IAE.0000000000001084
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Thun M, 2012, TOB CONTROL, V21, P96, DOI 10.1136/tobaccocontrol-2011-050294
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
NR 42
TC 18
Z9 18
U1 0
U2 8
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2017
VL 101
IS 10
BP 1367
EP 1373
DI 10.1136/bjophthalmol-2016-309952
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FI1GT
UT WOS:000411681700013
PM 28292774
DA 2022-11-30
ER

PT J
AU Koh, HH
   Murray, IJ
   Nolan, D
   Carden, D
   Feather, J
   Beatty, S
AF Koh, HH
   Murray, IJ
   Nolan, D
   Carden, D
   Feather, J
   Beatty, S
TI Plasma and macular response to lutein supplement in subjects with and
   without age-related maculopathy: a pilot study
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE macular pigment optical density; age-related maculopathy; plasma lutein
   concentration; lutein supplements
ID PIGMENT; PATHOGENESIS
AB There is a growing body of evidence which suggests that macular pigment (MP), which is entirely of dietary origin, protects against age-related maculopathy. We evaluated the effect of a daily 20 mg lutein ester (equivalent of 10 mg/day free lutein) supplement in patients with early age-related maculopathy (ARM), in terms of macular pigment optical density (MPOD) and plasma concentrations of lutein. MPOD was measured using a flicker photometric technique in seven ARM sufferers and six age-matched controls over a period of supplementation which lasted 18-20 weeks. Plasma lutein increased from a mean (SD) baseline concentration of 182 (127) ng ml(-1) to a peak of 1077 (165) ng ml(-1) in ARM patients, and from 152 (57) to 1110 (605) ng ml(-1) in control subjects. Mean MPOD had increased significantly from baseline of 0(.)24 to a peak of 0(.)31 in ARM sufferers. This mean increment of 0(.)07 was the same for the age-matched controls (baseline: 0(.)20: peak: 0(.)27). The augmentation of MP, and plasma concentrations of lutein, following supplementation in subjects with ARM provides the first evidence the disease is not associated with intestinal malabsorption of the relevant macular carotenoids, and that a diseased macula can accumulate and stabilise lutein and/or zeaxanthin. Furthermore, these results suggest that the beneficial effects of lutein supplementation, if any, may be extended to subjects with established ARM. (C) 2004 Elsevier Ltd. All rights reserved.
C1 Singapore Polytech, Sch Chem & Life Sci, Optometry Sect, Singapore 139651, Singapore.
   Univ Manchester, Dept Optometry & Neurosci, Manchester M60 1QD, Lancs, England.
   Manchester Royal Eye Hosp, Manchester M13 9WH, Lancs, England.
   Waterford Reg Hosp, Dept Opthalmol, Waterford, Ireland.
C3 Singapore Polytechnic; University of Manchester; Manchester Royal Eye
   Hospital
RP Koh, HH (通讯作者)，Singapore Polytech, Sch Chem & Life Sci, Optometry Sect, 500 Dover Rd, Singapore 139651, Singapore.
EM hhkoh@sp.edu.sg
CR Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2000, OPHTHAL PHYSL OPT, V20, P105, DOI 10.1016/S0275-5408(99)00039-3
   BEATTY S, 2000, CME OPHTHALMOL, V41, P221
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   Bone RA, 2000, EXP EYE RES, V71, P239, DOI 10.1006/exer.2000.0870
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   FEENEYBURNS L, 1990, AM J OPHTHALMOL, V109, P265, DOI 10.1016/S0002-9394(14)74549-0
   FERRISS JB, 1983, HDB HYPERTENSION, V2, P132
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   GELLERMANN W, 2002, ARVO ABSTR
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KHACHIK F, 1995, J CELL BIOCHEM, P236
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   VANKUIJK EF, 2002, ARVO ABSTR
   Wyszecki G., 1982, COLOUR SCI CONCEPTS
   Yemelyanov AY, 2001, EXP EYE RES, V72, P381, DOI 10.1006/exer.2000.0965
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
NR 29
TC 117
Z9 126
U1 2
U2 23
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUL
PY 2004
VL 79
IS 1
BP 21
EP 27
DI 10.1016/j.exer.2004.03.001
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 831EK
UT WOS:000222175900004
PM 15183097
DA 2022-11-30
ER

PT J
AU Munch, IC
   Toft, U
   Linneberg, A
   Larsen, M
AF Munch, Inger Christine
   Toft, Ulla
   Linneberg, Allan
   Larsen, Michael
TI Precursors of age-related macular degeneration: associations with
   vitamin A and interaction with CFHY402H in the Inter99 Eye Study
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; AMD; beta-carotene; complement factor
   H; diet; vitamin A
AB PurposeTo investigate associations of very early age-related macular degeneration (AMD) with daily intake of vitamin A, beta-carotene, vitamin E, vitamin C, zinc and copper and interactions with AMD-associated polymorphisms in complement factor H (CFHY402H) and ARMS2/LOC387715.
   MethodsCross-sectional study of 848 subjects aged 30-60years from the Inter99 Eye Study. Daily intake of vitamins and minerals was estimated from a 198-item food frequency questionnaire. Digital fundus photographs were recorded in red-free illumination and graded for macular drusen >63m and numerous (>20) small hard macular drusen as a mean of both eyes.
   ResultsHigher intake of vitamin A increased the risk of having macular drusen >63m with odds ratio=1.82 (CI95 1.02-3.24, p=0.042) comparing participants in the highest quartile of vitamin A intake with participants in the lowest quartile, adjusted for recruitment group, age and sex. There was a significant interaction with CFHY402H (p=0.038). Among 504 participants with CFHY402H, the relative risk of having macular drusen >63m was increased in participants in the highest quartile of vitamin A intake (odds ratio=2.58; CI95 1.16-5.73, p=0.020) and in the second highest quartile (odds ratio=3.27; CI95 1.50-7.13, p=0.0029) compared with the lowest quartile. Further adjusting for total fat intake, energy intake, plasma cholesterol, body mass index (BMI), smoking, alcohol intake, education and physical activity strengthened the association.
   ConclusionsIn this cross-sectional study, a higher intake of vitamin A increased the risk of macular drusen >63m in subjects with CFHY402H. The study supports that vitamin A may be a risk factor for early AMD.
C1 [Munch, Inger Christine] Zealand Univ Hosp, Dept Ophthalmol, Sygehusvej 10, DK-4000 Roskilde, Denmark.
   [Munch, Inger Christine; Linneberg, Allan; Larsen, Michael] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark.
   [Toft, Ulla; Linneberg, Allan] Capital Reg Denmark, Res Ctr Prevent & Hlth, Copenhagen, Denmark.
   [Larsen, Michael] Rigshosp, Dept Ophthalmol, Glostrup, Denmark.
C3 University of Copenhagen; Rigshospitalet
RP Munch, IC (通讯作者)，Zealand Univ Hosp, Dept Ophthalmol, Sygehusvej 10, DK-4000 Roskilde, Denmark.
EM icm@dadlnet.dk
RI Toft, Ulla/AAH-2589-2020; Larsen, Michael/E-9620-2010; Munch, Inger
   Christine/E-9652-2010
OI Toft, Ulla/0000-0001-7770-8419; Larsen, Michael/0000-0002-5172-5891;
   Linneberg, Allan/0000-0002-0994-0184
FU Danish Medical Research Council; Danish Centre for Evaluation and Health
   Technology Assessment; Novo Nordisk; Copenhagen County; Danish Heart
   Foundation; Danish Diabetes Association; Danish Pharmaceutical
   Association; Augustinus Foundation; Ib Henriksen Foundation; Becket
   Foundation; GlaxoSmithKline; University of Copenhagen; Velux Foundation;
   Ojenforeningen
FX The study was supported by the Danish Medical Research Council, the
   Danish Centre for Evaluation and Health Technology Assessment, Novo
   Nordisk, Copenhagen County, the Danish Heart Foundation, the Danish
   Diabetes Association, the Danish Pharmaceutical Association, the
   Augustinus Foundation, the Ib Henriksen Foundation, the Becket
   Foundation, GlaxoSmithKline, the University of Copenhagen, the Velux
   Foundation and Ojenforeningen.
NR 0
TC 4
Z9 4
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2016
VL 94
IS 7
BP 657
EP 662
DI 10.1111/aos.13198
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EA5BI
UT WOS:000386631400024
PM 27502478
OA Bronze
DA 2022-11-30
ER

PT J
AU Nan, R
   Farabella, I
   Schumacher, FF
   Miller, A
   Gor, J
   Martin, ACR
   Jones, DT
   Lengyel, I
   Perkins, SJ
AF Nan, Ruodan
   Farabella, Irene
   Schumacher, Felix F.
   Miller, Ami
   Gor, Jayesh
   Martin, Andrew C. R.
   Jones, David T.
   Lengyel, Imre
   Perkins, Stephen J.
TI Zinc Binding to the Tyr402 and His402 Allotypes of Complement Factor H:
   Possible Implications for Age-Related Macular Degeneration
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article
DE X-ray scattering; ultracentrifugation; molecular modelling; age-related
   maculardegeneration; retinal pigment epithelium
ID C-REACTIVE PROTEIN; REGULATOR FACTOR-H; FACTOR-I; CRYSTAL-STRUCTURE;
   X-RAY; ANALYTICAL ULTRACENTRIFUGATION; SEDIMENTATION-VELOCITY;
   ALTERNATIVE PATHWAY; NEUTRON-SCATTERING; SELF-ASSOCIATION
AB The Tyr402His polymorphism of complement factor H (FH) with 20 short complement regulator (SCR) domains is associated with age-related macular degeneration (AMD). How FH contributes to disease pathology is not clear. Both FH and high concentrations of zinc are found in drusen deposits, the key feature of AMD. Heterozygous FH is inhibited by zinc, which causes FH to aggregate. Here, zinc binding to homozygous FH was studied. By analytical ultracentrifugation, large amounts of oligomers were observed with both the native Tyr402 and the AMD-risk His402 homozygous allotypes of FH and both the recombinant SCR-6/8 allotypes with Tyr/His402. X-ray scattering also showed that both FH and SCR-6/8 allotypes strongly aggregated at > 10 mu M zinc. The SCR-1/5 and SCR-16/20 fragments were less likely to bind zinc. These observations were supported by bioinformatics predictions. Starting from known zinc binding sites in crystal structures, we predicted 202 putative partial surface zinc binding sites in FH, most of which were in SCR-6. Metal site prediction web servers also suggested that SCR-6 and other domains bind zinc. Predicted SCR-6/8 dimer structures showed that zinc binding sites could be formed at the protein protein interface that would lead to daisy-chained oligomers. It was concluded that zinc binds weakly to FH at multiple surface locations, most probably within the functionally important SCR-6/8 domains, and this explains why zinc inhibits FH activity. Given the high pathophysiological levels of bioavailable zinc present in subretinal deposits, we discuss how zinc binding to FH may contribute to deposit formation and inflammation associated with AMD. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Nan, Ruodan; Farabella, Irene; Schumacher, Felix F.; Miller, Ami; Gor, Jayesh; Martin, Andrew C. R.; Jones, David T.; Perkins, Stephen J.] UCL, Div Biosci, Dept Biol Mol & Struct, London WC1E 6BT, England.
   [Lengyel, Imre] UCL, UCL Inst Ophthalmol, Dept Ocular Biol & Therapeut, London EC1V 9EL, England.
C3 University of London; University College London; University of London;
   University College London
RP Perkins, SJ (通讯作者)，UCL, Div Biosci, Dept Biol Mol & Struct, Darwin Bldg,Gower St, London WC1E 6BT, England.
EM s.perkins@medsch.ucl.ac.uk
RI Lengyel, Imre/B-5217-2009; Farabella, Irene/AAQ-1380-2021; Farabella,
   Irene/K-5489-2015
OI Lengyel, Imre/0000-0001-7467-2174; Farabella, Irene/0000-0002-7473-6227;
   Martin, Andrew/0000-0002-2835-2572
FU Medical Research Council; Biotechnology and Biological Sciences Research
   Council; Mercer Fund of the Fight for Sight Charity; Wellcome Trust;
   Fight for Sight; Bill Brown Charitable Trust; BBSRC [BB/E013104/1]
   Funding Source: UKRI; MRC [G0801724] Funding Source: UKRI; Biotechnology
   and Biological Sciences Research Council [BB/E013104/1] Funding Source:
   researchfish; Medical Research Council [G0801724] Funding Source:
   researchfish
FX We are very grateful to Prof. A. C. Bird for useful discussions, Dr. A.
   Shukla and Dr. T. Narayanan (European Synchrotron Radiation Facility)
   for excellent instrumental support, and Prof. R. B. Sim for the MRC-OX23
   and MRC-OX21 affinity columns. We thank the Medical Research Council
   (R.N.), the Biotechnology and Biological Sciences Research Council (R.N.
   and A.M.), the Mercer Fund of the Fight for Sight Charity (R.N.), and
   the Wellcome Trust (I.F. and F.S.) for project grant, graduate
   studentship and equipment grant support. I.L. thanks the Mercer Fund
   from Fight for Sight, the Special Trustees of Moorfields Eye Hospital,
   and the Bill Brown Charitable Trust for support.
CR *AG REL EY DIS STU, 2002, J NUTR, V132, P687
   An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Aslam M, 2001, J MOL BIOL, V309, P1117, DOI 10.1006/jmbi.2001.4720
   Auld DS, 2001, BIOMETALS, V14, P271, DOI 10.1023/A:1012976615056
   Babor M, 2008, PROTEINS, V70, P208, DOI 10.1002/prot.21587
   BARLOW PN, 1993, J MOL BIOL, V232, P268, DOI 10.1006/jmbi.1993.1381
   BIRD AC, 1992, BRIT J OPHTHALMOL, V76, P166, DOI 10.1136/bjo.76.3.166
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blom AM, 2003, ARCH BIOCHEM BIOPHYS, V418, P108, DOI 10.1016/j.abb.2003.08.018
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Cole JL, 2008, METHOD CELL BIOL, V84, P143, DOI 10.1016/S0091-679X(07)84006-4
   Colvin RA, 2010, METALLOMICS, V2, P306, DOI 10.1039/b926662c
   Comeau SR, 2004, BIOINFORMATICS, V20, P45, DOI 10.1093/bioinformatics/btg371
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   CROSSLEY LG, 1980, BIOCHEM J, V191, P173, DOI 10.1042/bj1910173
   DAY AJ, 1986, BIOCHEM SOC T, V14, P73, DOI 10.1042/bst0140073
   DODDS AW, 1993, METHOD ENZYMOL, V223, P46
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fernando AN, 2007, J MOL BIOL, V368, P564, DOI 10.1016/j.jmb.2007.02.038
   Ferreira VP, 2010, MOL IMMUNOL, V47, P2187, DOI 10.1016/j.molimm.2010.05.007
   GALIN MA, 1962, INVEST OPHTH VISUAL, V1, P142
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Gray JJ, 2006, CURR OPIN STRUC BIOL, V16, P183, DOI 10.1016/j.sbi.2006.03.003
   Gray JJ, 2003, J MOL BIOL, V331, P281, DOI 10.1016/S0022-2836(03)00670-3
   Guymer R., 1998, RETINAL PIGMENT EPIT, P693
   Haase H, 2010, CELLULAR AND MOLECULAR BIOLOGY OF METALS, P181, DOI 10.1201/9781420059984-c8
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hattink J, 2006, ENVIRON TOXICOL CHEM, V25, P87, DOI 10.1897/04-355R.1
   Hocking HG, 2008, J BIOL CHEM, V283, P9475, DOI 10.1074/jbc.M709587200
   HORSTMANN RD, 1988, P NATL ACAD SCI USA, V85, P1657, DOI 10.1073/pnas.85.5.1657
   HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0
   Jokiranta TS, 2006, EMBO J, V25, P1784, DOI 10.1038/sj.emboj.7601052
   Karpusas M, 1997, P NATL ACAD SCI USA, V94, P11813, DOI 10.1073/pnas.94.22.11813
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krezel A, 2006, J BIOL INORG CHEM, V11, P1049, DOI 10.1007/s00775-006-0150-5
   Law SKA, 1995, COMPLEMENT
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Lengyel I, 2008, EXPERT REV OPHTHALMO, V3, P1, DOI 10.1586/17469899.3.1.1
   Lu J, 2008, BIOCHEM SOC T, V36, P1317, DOI 10.1042/BST0361317
   Lyskov S, 2008, NUCLEIC ACIDS RES, V36, pW233, DOI 10.1093/nar/gkn216
   Maret W, 2009, CHEM REV, V109, P4682, DOI 10.1021/cr800556u
   Mendez R, 2005, PROTEINS, V60, P150, DOI 10.1002/prot.20551
   Nan RD, 2008, J MOL BIOL, V375, P891, DOI 10.1016/j.jmb.2007.11.015
   Nan R, 2010, MOL IMMUNOL, V47, P2263, DOI 10.1016/j.molimm.2010.05.195
   Nan R, 2008, J MOL BIOL, V384, P1341, DOI 10.1016/j.jmb.2008.10.030
   Narayanan T, 2001, NUCL INSTRUM METH A, V467, P1005, DOI 10.1016/S0168-9002(01)00553-8
   NEWSOME DA, 1992, CURR EYE RES, V11, P213, DOI 10.3109/02713689209001772
   Nieba L, 1997, ANAL BIOCHEM, V252, P217, DOI 10.1006/abio.1997.2326
   Okemefuna AI, 2008, J MOL BIOL, V375, P80, DOI 10.1016/j.jmb.2007.09.026
   Okemefuna AI, 2010, J BIOL CHEM, V285, P1053, DOI 10.1074/jbc.M109.044529
   Okemefuna AI, 2009, J MOL BIOL, V391, P119, DOI 10.1016/j.jmb.2009.06.013
   Okemefuna AI, 2009, J MOL BIOL, V391, P98, DOI 10.1016/j.jmb.2009.06.010
   Oppermann M, 2006, CLIN EXP IMMUNOL, V144, P342, DOI 10.1111/j.1365-2249.2006.03071.x
   Pangburn MK, 2000, IMMUNOPHARMACOLOGY, V49, P149, DOI 10.1016/S0162-3109(00)80300-8
   PERKINS SJ, 1986, EUR J BIOCHEM, V157, P155, DOI 10.1111/j.1432-1033.1986.tb09652.x
   PERKINS SJ, 1991, BIOCHEMISTRY-US, V30, P2847, DOI 10.1021/bi00225a017
   Perkins SJ, 2008, METHOD CELL BIOL, V84, P375, DOI 10.1016/S0091-679X(07)84013-1
   Perkins SJ, 2010, ADV EXP MED BIOL, V703, P25, DOI 10.1007/978-1-4419-5635-4_3
   Perkins SJ, 2010, BIOCHEM SOC T, V38, P894, DOI 10.1042/BST0380894
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Ritchie DW, 2003, PROTEINS, V52, P98, DOI 10.1002/prot.10379
   Saunders RE, 2007, HUM MUTAT, V28, P222, DOI 10.1002/humu.20435
   Schmidt CQ, 2008, J IMMUNOL, V181, P2610, DOI 10.4049/jimmunol.181.4.2610
   Schneider MC, 2009, NATURE, V458, P890, DOI 10.1038/nature07769
   Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481
   Schuck P, 1998, BIOPHYS J, V75, P1503, DOI 10.1016/S0006-3495(98)74069-X
   Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0
   SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X
   Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996
   SIM RB, 1993, METHOD ENZYMOL, V223, P13
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Soares DC, 2005, STRUCTURAL BIOLOGY OF THE COMPLEMENT SYSTEM, P19
   Sodhi JS, 2004, J MOL BIOL, V342, P307, DOI 10.1016/j.jmb.2004.07.019
   SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0
   Strohmeyer R, 2002, J NEUROIMMUNOL, V131, P135, DOI 10.1016/S0165-5728(02)00272-2
   Sugio S, 1999, PROTEIN ENG, V12, P439, DOI 10.1093/protein/12.6.439
   Tsiftsoglou SA, 2004, J IMMUNOL, V173, P367, DOI 10.4049/jimmunol.173.1.367
   Ugarte M, 2001, PROG NEUROBIOL, V64, P219, DOI 10.1016/S0301-0082(00)00057-5
   Ullman CG, 1998, MOL IMMUNOL, V35, P503, DOI 10.1016/S0161-5890(98)00052-2
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Yano JK, 2000, J BIOL CHEM, V275, P31086, DOI 10.1074/jbc.M004281200
   Zetterberg M, 2008, AM J MED GENET B, V147B, P720, DOI 10.1002/ajmg.b.30668
NR 90
TC 30
Z9 30
U1 0
U2 2
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
EI 1089-8638
J9 J MOL BIOL
JI J. Mol. Biol.
PD MAY 13
PY 2011
VL 408
IS 4
BP 714
EP 735
DI 10.1016/j.jmb.2011.03.006
PG 22
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 762SK
UT WOS:000290501200010
PM 21396937
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Pawlak, D
   Glacet-Bernard, A
   Papp, M
   Roquet, W
   Coscas, G
   Soubrane, G
AF Pawlak, D
   Glacet-Bernard, A
   Papp, M
   Roquet, W
   Coscas, G
   Soubrane, G
TI Limited macular translocation compared with photodynamic therapy in the
   management of subfoveal choroidal neovascularization in age-related
   macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL SEPARATION; RETINOTOMY; RELOCATION
AB PURPOSE: To compare the visual outcome of macular translocation (MT) versus photodynamic therapy (PDT) for subfoveal predominantly classic neovascularization in age-related macular degeneration (AMD).
   DESIGN: Nonrandomized clinical trial.
   METHODS: Retrospective review of 65 consecutive patients with subfoveal neovascularization due to AMD. The follow,up was at least 6 months. Main outcome criteria were final best corrected visual acuity and the gain in visual acuity.
   RESULTS: A total of 29 eyes were treated with PDT with verteporfin, and 36 underwent MT with chorioscleral infolding. Both groups were similar for age, refraction, and lesion size. The initial visual acuity was lower in the MT group than in the PDT group (20/200 versus 20/100). Mean follow,up was 11 months for the PDT group and 14 months for the MT group. The mean displacement of the fovea after translocation was 1,274 mum (range, 250 to 1,900 mum). Mean number of retreatment by PDT was 2.5. At 1 year, both groups had the same final visual acuity (20/200), but the improvement was more favorable in the MT group (gain of 0.7 line in the MT group versus loss of 3.4 lines in the PDT group, P =.007). One eye in the PDT group (4.3%) had a gain of 3 lines or more versus eight eyes (38%) in the MT group; the lesion size was larger in the PDT group than in MT group (P =.036).
   CONCLUSION: In this retrospective study, MT seemed to allow a better preservation of visual acuity than PDT in subfoveal neovascularization due to AMD. Further larger and controlled studies are required.
C1 Univ Paris 12, Hop Henri Mondor, Assistance Publ Hop Paris, Univ Eye Clin Creteil, F-94010 Creteil, France.
   Univ Paris 12, Intercommunal Hosp, Assistance Publ Hop Paris, Univ Eye Clin Creteil, Creteil, France.
C3 Assistance Publique Hopitaux Paris (APHP); Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire
   Henri-Mondor - APHP; UDICE-French Research Universities; Aix-Marseille
   Universite; Assistance Publique-Hopitaux de Marseille; Assistance
   Publique Hopitaux Paris (APHP); Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire
   Henri-Mondor - APHP; UDICE-French Research Universities; Aix-Marseille
   Universite; Assistance Publique-Hopitaux de Marseille; CHI Creteil
RP Pawlak, D (通讯作者)，Hop Intecommunal Creteil, Serv Ophtalmol, 40 Ave Verdun, F-94010 Creteil, France.
EM dompawlak@aol.com
OI GLACET-BERNARD, AGNES/0000-0002-2251-9124
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   COSCAS G, 1991, ARCH OPHTHALMOL-CHIC, V109, P1258, DOI 10.1001/archopht.1991.01080090082028
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Glacet-Bernard A, 2001, AM J OPHTHALMOL, V131, P78, DOI 10.1016/S0002-9394(00)00733-9
   HYMAN L, 1987, EYE, V1, P330, DOI 10.1038/eye.1987.53
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Lewis H, 1999, AM J OPHTHALMOL, V128, P135, DOI 10.1016/S0002-9394(99)00207-X
   Lewis H, 2001, AM J OPHTHALMOL, V132, P156, DOI 10.1016/S0002-9394(01)01088-1
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P629, DOI 10.1007/BF00921956
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Ohji M, 2001, AM J OPHTHALMOL, V132, P888, DOI 10.1016/S0002-9394(01)01255-7
   Pieramici DJ, 2000, AM J OPHTHALMOL, V130, P419, DOI 10.1016/S0002-9394(00)00533-X
   Simon P, 2002, J FR OPHTALMOL, V25, P694
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   THOMAS MA, 1992, OPHTHALMOLOGY, V99, P952
NR 20
TC 12
Z9 12
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2004
VL 137
IS 5
BP 880
EP 887
DI 10.1016/j.ajo.2003.12.041
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 820KA
UT WOS:000221386400012
PM 15126153
DA 2022-11-30
ER

PT J
AU Alagorie, AR
   Verma, A
   Nassisi, M
   Sadda, SR
AF Alagorie, Ahmed Roshdy
   Verma, Aditya
   Nassisi, Marco
   Sadda, Srinivas R.
TI Quantitative Assessment of Choriocapillaris Flow Deficits in Eyes with
   Advanced Age-Related Macular Degeneration Versus Healthy Eyes
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL BLOOD-FLOW; GEOGRAPHIC ATROPHY;
   BRUCHS MEMBRANE; RISK-FACTORS; ANGIOGRAPHY; NEOVASCULARIZATION;
   PROGRESSION; VARIANT; IMAGE
AB PURPOSE: To compare choriocapillaris (CC) flow deficits in eyes with geographic atrophy (GA) or choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD) and age-matched healthy control subjects.
   DESIGN: Cross-sectional study.
   METHODS: Patients with GA due to AMD, CNV due to AMD, and age-matched healthy subjects presenting to the Doheny-UCLA Eye Centers were enrolled in this cross-sectional institutional review board-approved study. Swept-source optical coherence tomography angiography was performed using a Zeiss PLEX Elite instrument with a 6 x 6-mm scan pattern centered on the fovea. Two repeated volume scans were acquired to allow for image averaging. The instrument predefined en face slab of the CC was used to isolate and display the CC. Both the structural and optical coherence tomography angiography slabs from this location were exported for averaging and signal compensation using Image J. The resultant image was then binarized. The CC flow deficit percentage (FD%) was computed in 4 peripheral 1 x 1-mm squares located at the corners of the images to allow comparison between equidistant regions unaffected by atrophy or CNV.
   RESULTS: Twenty eyes of 20 subjects were enrolled in each of the 3 groups (CNV, GA, normal) for this study. The average CC FD% of the 4 peripheral squares was 17.24% +/- 2.86% in GA eyes, 15.55% +/- 1.03% in CNV eyes, and 15.31% +/- 0.93% in healthy controls of a similar age. The FD% in GA eyes was significantly greater than in both normal eyes and eyes with CNV (p = 0.012 and 0.038 respectively). The difference in FD% was not significantly different between CNV eyes and normal eyes for the tested peripheral macular regions (P = .678).
   CONCLUSIONS: The CC in peripheral macular regions in eyes with GA shows greater impairment than in eyes with CNV. ((C) 2019 Elsevier Inc. All rights reserved.)
C1 [Alagorie, Ahmed Roshdy; Verma, Aditya; Nassisi, Marco; Sadda, Srinivas R.] Doheny Eye Inst, Doheny Image Reading Ctr, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Alagorie, Ahmed Roshdy; Verma, Aditya; Nassisi, Marco; Sadda, Srinivas R.] UCLA, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA USA.
   [Alagorie, Ahmed Roshdy] Tanta Univ, Fac Med, Dept Ophthalmol, Tanta, Egypt.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Egyptian Knowledge Bank
   (EKB); Tanta University
RP Sadda, SR (通讯作者)，1355 San Pablo St,Suite 211, Los Angeles, CA 90033 USA.
EM SSadda@doheny.org
RI Nassisi, Marco/P-9939-2019; Alagorie, Ahmed/AAW-5304-2020; Verma,
   Aditya/AGK-6502-2022
OI Nassisi, Marco/0000-0002-9354-9005; Alagorie, Ahmed/0000-0001-5489-0617;
   
CR Arya M, 2018, EYE VISION, V5, DOI 10.1186/s40662-018-0118-x
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Borrelli E, 2018, AM J OPHTHALMOL, V196, P34, DOI 10.1016/j.ajo.2018.08.014
   Borrelli E, 2018, PROG RETIN EYE RES, V67, P30, DOI 10.1016/j.preteyeres.2018.07.002
   Borrelli E, 2018, RETINA-J RET VIT DIS, V38, P1968, DOI 10.1097/IAE.0000000000002198
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Chen TC, 2005, ARCH OPHTHALMOL-CHIC, V123, P1715, DOI 10.1001/archopht.123.12.1715
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Christenbury JG, 2018, RETINA-J RET VIT DIS, V38, P1276, DOI 10.1097/IAE.0000000000001766
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Complications Age-Related Macular, 2008, OPHTHALMOLOGY, V115, P1474, DOI 10.1016/j.ophtha.2008.03.008
   Corbelli E, 2017, INVEST OPHTH VIS SCI, V58, P5201, DOI 10.1167/iovs.17-22508
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Ferrara D, 2017, INVEST OPHTH VIS SCI, V58, P3519, DOI 10.1167/iovs.17-21696
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Gangnon RE, 2012, ARCH OPHTHALMOL-CHIC, V130, P1169, DOI 10.1001/archophthalmol.2012.693
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lujan BJ, 2009, OPHTHAL SURG LAS IM, V40, P96, DOI 10.3928/15428877-20090301-16
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   MCLEOD DS, 1994, INVEST OPHTH VIS SCI, V35, P3799
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Moreira-Neto CA, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/8125267
   Nasir MA, 1997, BRIT J OPHTHALMOL, V81, P481, DOI 10.1136/bjo.81.6.481
   Nassisi M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212563
   Nassisi M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207638
   Nassisi M, 2019, BRIT J OPHTHALMOL, V103, P911, DOI 10.1136/bjophthalmol-2018-312643
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Saade C, 2014, BRIT J OPHTHALMOL, V98, P1729, DOI 10.1136/bjophthalmol-2014-305005
   Sacconi R, 2018, RETINA-J RET VIT DIS, V38, P2350, DOI 10.1097/IAE.0000000000001873
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Schwartz SG, 2012, RETINA-J RET VIT DIS, V32, P1486, DOI 10.1097/IAE.0b013e318240a540
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Spaide RF, 2017, RETINA-J RET VIT DIS, V37, P2008, DOI 10.1097/IAE.0000000000001497
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Uji A, 2017, JAMA OPHTHALMOL, V135, P1197, DOI 10.1001/jamaophthalmol.2017.3904
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
NR 49
TC 32
Z9 33
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2019
VL 205
BP 132
EP 139
DI 10.1016/j.ajo.2019.04.037
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JA3YV
UT WOS:000487766400016
PM 31078531
DA 2022-11-30
ER

PT J
AU Pogue, AI
   Lukiw, WJ
AF Pogue, Aileen I.
   Lukiw, Walter J.
TI Up-regulated Pro-inflammatory MicroRNAs (miRNAs) in Alzheimer's disease
   (AD) and Age-Related Macular Degeneration (AMD)
SO CELLULAR AND MOLECULAR NEUROBIOLOGY
LA English
DT Article
DE Alzheimer's disease; Age-related macular degeneration; MicroRNA-mRNA
   integration; Neurotrophic signaling; Phagocytosis; Prion disease;
   Synaptogenesis
ID NF-KAPPA-B; SENSITIVE MIRNA-146A; AMYLOID-BETA; BRAIN; EXPRESSION;
   INCREASE; FETAL; CNS
AB Alzheimer's disease (AD) of the brain neocortex and age-related macular degeneration (AMD) of the retina are two complex neurodegenerative disorders, which (i) involve the progressive dysregulation and deterioration of multiple neurobiological signaling pathways, (ii) exhibit the temporal accumulation of pro-inflammatory lesions including the amyloid beta (A beta) peptide-containing senile plaques of AD and the drusen of AMD, and (iii) culminate in an insidious inflammatory neurodegeneration ending, respectively, in neural cell atrophy and death and progressive loss of cognition and central visual function. Recent independent research studies have indicated that AD and AMD share common, pathological signaling defects and disease mechanisms at the molecular genetic level. Using high-integrity total RNA samples pooled from AD brain and AMD retina, microfluidic hybridization miRNA arrays, and bioinformatics, the current study was undertaken to quantify microRNA (miRNA) speciation and complexity common to both AD and AMD. These small non-coding (sncRNAs) are known to post-transcriptionally regulate multiple neurobiological pathways and an abundance of research information has already been generated on the roles of these miRNAs in pathological situations involving inflammatory neuropathology and neural cell decline. Here, for the first time, we report the sequence and abundance of a septet of sncRNAs including miRNA-7, miRNA-9-1, miRNA-23a/miRNA-27a, miRNA-34a, miRNA-125b-1, miRNA-146a, and miRNA-155 that are significantly increased in abundance and common to both AD-affected superior temporal lobe neocortex (Brodmann A22) and the AMD-affected macular region of the retina. Bioinformatics, miRNA-mRNA complementarity, next-gen RNA sequencing, and feature alignment analysis further indicate that these 7 up-regulated miRNAs have the potential to interact with and down-regulate similar to 9460 target messenger RNAs (mRNAs; about 3.5% of the genome) involved in the synchronization of amyloid production and clearance, phagocytosis, innate-immune, pro-inflammatory, and neurotrophic signaling and/or synaptogenesis in diseased tissues.
C1 [Pogue, Aileen I.; Lukiw, Walter J.] Alchem Biotech Res, Toronto, ON, Canada.
   [Lukiw, Walter J.] Louisiana State Univ, Hlth Sci Ctr, Sch Med, Neurosci Ctr, New Orleans, LA 70112 USA.
   [Lukiw, Walter J.] Louisiana State Univ, Sch Med, Hlth Sci Ctr, Dept Neurol, New Orleans, LA 70112 USA.
   [Lukiw, Walter J.] Louisiana State Univ, Hlth Sci Ctr, Dept Ophthalmol, Sch Med, New Orleans, LA 70112 USA.
   [Lukiw, Walter J.] Louisiana State Univ, Hlth Sci Ctr, LSU Neurosci Ctr, 2020 Gravier St,Suite 904, New Orleans, LA 70112 USA.
C3 Louisiana State University System; Louisiana State University Health
   Sciences Center New Orleans; Louisiana State University System;
   Louisiana State University Health Sciences Center New Orleans; Louisiana
   State University System; Louisiana State University Health Sciences
   Center New Orleans; Louisiana State University System; Louisiana State
   University Health Sciences Center New Orleans
RP Lukiw, WJ (通讯作者)，Alchem Biotech Res, Toronto, ON, Canada.; Lukiw, WJ (通讯作者)，Louisiana State Univ, Hlth Sci Ctr, Sch Med, Neurosci Ctr, New Orleans, LA 70112 USA.; Lukiw, WJ (通讯作者)，Louisiana State Univ, Sch Med, Hlth Sci Ctr, Dept Neurol, New Orleans, LA 70112 USA.; Lukiw, WJ (通讯作者)，Louisiana State Univ, Hlth Sci Ctr, Dept Ophthalmol, Sch Med, New Orleans, LA 70112 USA.; Lukiw, WJ (通讯作者)，Louisiana State Univ, Hlth Sci Ctr, LSU Neurosci Ctr, 2020 Gravier St,Suite 904, New Orleans, LA 70112 USA.
EM wlukiw@lsuhsc.edu
FU Research to Prevent Blindness (RPB); Louisiana Biotechnology Research
   Network (LBRN); NIH [NEI EY006311, NIA AG18031, NIA AG038834]; NATIONAL
   INSTITUTE ON AGING [R01AG038834] Funding Source: NIH RePORTER
FX The work reported in this paper was presented in part at the Vavilov
   Institute of General Genetics Autumn 2016 Seminar Series (sic) in
   Moscow, RUSSIA October 2016 and at the Society for Neuroscience (SFN)
   Annual Meeting, Washington DC, USA November 2017. Sincere thanks are
   extended to Drs PN Alexandrov, JG Cui, F Culicchia, W Poon, K Navel, C
   Hebel, C Eicken, and the late Dr. JM Hill to for helpful discussions in
   this research area, for short post-mortem interval (PMI) human brain and
   retinal tissues or extracts, and for initial bioinformatics and data
   interpretation, and to D Guillot for expert technical assistance and
   medical artwork. Thanks are also extended to the University of
   California at Irvine Brain Bank, the University of Maryland Brain and
   Tissue Bank, and the LSU School of Medicine-archived brain nucleic acid
   source, and the many neuropathologists, physicians, and researchers of
   the US and Canada who have provided high-quality, short post-mortem
   interval (PMI) human CNS or extracted tissue fractions for scientific
   study. Research on the microRNAs, pro-inflammatory and pathogenic
   signaling in the Lukiw laboratory involving the microbiome, the
   innate-immune response, neuroinflammation, and amyloidogenesis in AD,
   prion, and in other neurological diseases was supported through an
   unrestricted grant to the LSU Eye Center from Research to Prevent
   Blindness (RPB), the Louisiana Biotechnology Research Network (LBRN),
   and NIH grants NEI EY006311, NIA AG18031, and NIA AG038834 (WJL).
   Additional data related to this paper may be requested from the authors.
CR Alexandrov Peter N, 2012, Int J Biochem Mol Biol, V3, P365
   Alzheimer's Association, 2017, ALZH DIS FACTS FIG
   Ambros V, 2001, CELL, V107, P823, DOI 10.1016/S0092-8674(01)00616-X
   Arnes M, 2017, J NEUROGENET, V31, P216, DOI 10.1080/01677063.2017.1338696
   Arora A, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471-213X-10-1
   Bagyinszky E, 2017, J NEUROL SCI, V376, P242, DOI 10.1016/j.jns.2017.03.031
   Barker KR, 2017, MOL MED, V23, DOI 10.2119/molmed.2016.00139
   Berber P, 2017, MOL DIAGN THER, V21, P31, DOI 10.1007/s40291-016-0234-z
   Bhattacharjee S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150211
   Bhattacharjee S, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00153
   Biscetti Leonardo, 2017, Front Biosci (Elite Ed), V9, P174
   Boonen RACM, 2009, AGEING RES REV, V8, P71, DOI 10.1016/j.arr.2008.11.003
   Centanin L, 2014, DEVELOPMENT, V141, P241, DOI 10.1242/dev.083642
   Chen L L, 2017, Zhonghua Yan Ke Za Zhi, V53, P144, DOI 10.3760/cma.j.issn.0412-4081.2017.02.014
   Cisternas P, 2017, NEUROSCI BIOBEHAV R, V80, P316, DOI 10.1016/j.neubiorev.2017.06.004
   Clement C, 2016, MOL NEUROBIOL, V53, P1322, DOI 10.1007/s12035-015-9105-6
   Colangelo V, 2002, J NEUROSCI RES, V70, P462, DOI 10.1002/jnr.10351
   Coleman BM, 2015, SEMIN CELL DEV BIOL, V40, P89, DOI 10.1016/j.semcdb.2015.02.007
   Cui JG, 2010, J BIOL CHEM, V285, P38951, DOI 10.1074/jbc.M110.178848
   Devier DJ, 2015, FRONT MOL NEUROSCI, V8, DOI [10.3389/fnmol.2015.00005, 10.3389/fnmo1.2015.00005]
   Ermilov VV, 2016, ADV EXP MED BIOL, V854, P119, DOI 10.1007/978-3-319-17121-0_17
   Frost S, 2016, CURR ALZHEIMER RES, V13, P1259, DOI 10.2174/1567205013666160603003800
   Ginge C, 2017, PLOS ONE, V12, DOI [10.1371/journal.pone.0167969, DOI 10.1371/JOURNAL.PONE.0167969]
   Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267
   Gupta V, 2016, CELL MOL LIFE SCI, V73, P4279, DOI 10.1007/s00018-016-2295-x
   Harti M, 2013, FRONT MOL NEUROSCI, V6, DOI 10.3389/fnmol.2013.00051
   Hill JM, 2016, NEUROCHEM RES, V41, P96, DOI 10.1007/s11064-015-1734-7
   Hill JM, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00232
   Hill JM, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00043
   Hill JM, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00347
   Ho AC, 2017, JAMA OPHTHALMOL, V135, P268, DOI 10.1001/jamaophthalmol.2016.5314
   Hussain A, 2017, COMPUT INTEL NEUROSC, V2017, DOI 10.1155/2017/7430125
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kozomara A, 2014, NUCLEIC ACIDS RES, V42, pD68, DOI 10.1093/nar/gkt1181
   Lehmann SM, 2012, NAT NEUROSCI, V15, P827, DOI 10.1038/nn.3113
   Li YY, 2011, NEUROSCI LETT, V487, P94, DOI 10.1016/j.neulet.2010.09.079
   Li YY, 2015, NEUROREPORT, V23, P168, DOI [10.1097/WNR.0b013e32834f4eb4, DOI 10.1097/WNR.OB013E32834F4EB4]
   Lukiw WJ, 2011, J TOXICOL ENV HEAL A, V74, P1460, DOI 10.1080/15287394.2011.618973
   Lukiw WJ, 2008, J BIOL CHEM, V283, P31315, DOI 10.1074/jbc.M805371200
   Lukiw WJ, 2007, NEUROREPORT, V18, P297, DOI 10.1097/WNR.0b013e3280148e8b
   Lukiw Walter J., 2012, Frontiers in Genetics, V3, P166, DOI 10.3389/fgene.2012.00166
   Lukiw WJ, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00133
   Lukiw WJ, 2012, NEUROREPORT, V23, P621, DOI [10.1097/00001756-201207110-00009, 10.1097/WNR.0b013e32835542b0]
   Lukiw WJ, 2012, EXP NEUROL, V235, P484, DOI 10.1016/j.expneurol.2011.11.022
   Lukiw Walter J, 2012, Int J Biochem Mol Biol, V3, P105
   Lynn SA, 2017, NEURAL REGEN RES, V12, P538, DOI 10.4103/1673-5374.205083
   Masuzzo A, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00127
   Nolan JM, 2014, J ALZHEIMERS DIS, V42, P1191, DOI 10.3233/JAD-140507
   Petes C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01075
   Pogue AI, 2010, NEUROSCI LETT, V476, P18, DOI 10.1016/j.neulet.2010.03.054
   Pogue AI, 2011, J INORG BIOCHEM, V105, P1434, DOI 10.1016/j.jinorgbio.2011.05.012
   Rappaport N, 2017, NUCLEIC ACIDS RES, V45, pD877, DOI 10.1093/nar/gkw1012
   Romano GL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00168
   Ruegger S, 2012, TRENDS BIOCHEM SCI, V37, P436, DOI 10.1016/j.tibs.2012.07.002
   Selkoe DJ, 2016, EMBO MOL MED, V8, P595, DOI 10.15252/emmm.201606210
   Sethi P, 2009, NEUROSCI LETT, V459, P100, DOI 10.1016/j.neulet.2009.04.052
   Shamsuzzama, 2016, MOL NEUROBIOL, V53, P2787, DOI 10.1007/s12035-015-9145-y
   Sheng C, 2018, FRONT BIOSCI-LANDMRK, V23, P1272, DOI 10.2741/4643
   Smit-McBride Z, 2014, MOL VIS, V20, P1569
   Talks SJ, 2017, ASIA-PAC J OPHTHALMO, V6, P498, DOI 10.22608/APO.2017305
   Wang XY, 2009, BRAIN RES BULL, V80, P268, DOI 10.1016/j.brainresbull.2009.08.006
   Williams MA, 2014, J ALZHEIMERS DIS, V42, P909, DOI 10.3233/JAD-140243
   Wostyn P, 2016, CELL MOL LIFE SCI, V73, P4299, DOI 10.1007/s00018-016-2348-1
   Yan LL, 2015, J BIOL CHEM, V290, P23264, DOI 10.1074/jbc.M115.646950
   Yuan HY, 2017, PLACENTA, V51, P49, DOI 10.1016/j.placenta.2017.01.128
   Yuan Y, 2015, ADV EXP MED BIOL, V887, P157, DOI 10.1007/978-3-319-22380-3_9
   Zhao Y, 2015, CELL BIOCHEM BIOPHYS, V72, P481, DOI 10.1007/s12013-014-0491-6
   Zhao YY, 2017, AUTOMAT SOFTW ENG, V24, P393, DOI 10.1007/s10515-016-0198-6
   Zhao YH, 2016, GENES-BASEL, V7, DOI 10.3390/genes7120116
   Zhao YH, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00140
   Zhao YH, 2015, INT J MOL SCI, V16, P30105, DOI 10.3390/ijms161226223
NR 71
TC 60
Z9 63
U1 2
U2 22
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0272-4340
EI 1573-6830
J9 CELL MOL NEUROBIOL
JI Cell. Mol. Neurobiol.
PD JUL
PY 2018
VL 38
IS 5
BP 1021
EP 1031
DI 10.1007/s10571-017-0572-3
PG 11
WC Cell Biology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Neurosciences & Neurology
GA GH6AQ
UT WOS:000433521700005
PM 29302837
DA 2022-11-30
ER

PT J
AU Yorgun, MA
   Toklu, Y
   Kar, ME
   Cakmak, BH
AF Yorgun, Mucella Arikan
   Toklu, Yasin
   Kar, Meltem Ece
   Cakmak, Basri Hasan
TI Effect of cataract surgery in patients with neovascular age-related
   macular degeneration: further evidence from disciform scars
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Cataract surgery; Disciform scar; Neovascular age-related macular
   degeneration
ID ENDOTHELIAL GROWTH-FACTOR; VISUAL-ACUITY; CHOROIDAL NEOVASCULARIZATION;
   RANIBIZUMAB; MACULOPATHY; DISEASE; TRIALS; RISK; EYE
AB Purpose To evaluate the effect of cataract surgery on disease activation and visual outcomes in neovascular age-related macular degeneration (AMD).
   Methods In this retrospective case-control study, study arm consisted of neovascular AMD patients, who underwent phacoemulsification surgery. Patients did not have any disease activation at least 6 months before the inclusion, and all had at least 12-month follow-up thereafter. Control group consisted of phakic patients, who did not undergo eye surgery during the study period. Primary outcomes were the presence of the disease activation and the change in best-corrected visual acuity (BCVA).
   Results A total of 114 neovascular AMD patients [55 (48%) in exudative group and 59 (52%) in disciform group] were included. Preoperative logMAR BCVA was significantly improved after cataract surgery [0.8 (0.6-1.0) vs. 0.4 (0.4-0.7), P < 0.001 in exudative AMD; 1.85 (1.1-1.9) vs. 1.09 (0.8-1.9), P = 0.001 in disciform scar], but this improvement was not maintained during the study period in patients with both exudative AMD and disciform scar [0.6 (0.3-1.1), P = 0.313 in exudative AMD; 1.30 (1-1.9), P = 0.03 in disciform scar]. The incidence of disease activation was not statistically significant between surgery and control groups in patients with exudative AMD [5 (25%) patients in surgery group and 8 (22%) patients in the control group, P = 0.886, Cox proportional hazards regression analysis]. In disciform scar, disease activation was observed in 4 (17%) patients in the surgery group; however, no patient in the control group had disease activation (P = 0.009, HRs could not be estimated, 95% CI 0.001-43.49, Cox proportional hazards regression analysis).
   Conclusion Cataract surgery has benefit on early postoperative visual improvement in patients with neovascular AMD. The incidence of disease activation was not affected after surgery in exudative AMD.
C1 [Yorgun, Mucella Arikan; Toklu, Yasin; Kar, Meltem Ece] Yildirim Beyazit Univ, Ankara Ataturk Educ & Res Hosp, Dept Ophthalmol, Ankara, Turkey.
   [Cakmak, Basri Hasan] Hacettepe Univ, Dept Ophthalmol, Fac Med, Ankara, Turkey.
C3 Ankara Ataturk Training & Research Hospital; Yildirim Beyazit
   University; Hacettepe University
RP Yorgun, MA (通讯作者)，Yildirim Beyazit Univ, Ankara Ataturk Educ & Res Hosp, Dept Ophthalmol, Ankara, Turkey.
EM mcllarkn@yahoo.com
RI Kars, Meltem Ece/GLU-1436-2022
OI Kars, Meltem Ece/0000-0001-5922-5608; CAKMAK, HASAN
   BASRI/0000-0001-6877-8773
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   El Mallah MK, 2001, OPTOMETRY VISION SCI, V78, P683, DOI 10.1097/00006324-200109000-00014
   Fletcher DC, 2006, OPTOMETRY VISION SCI, V83, P178, DOI 10.1097/01.opx.0000204510.08026.7f
   Forooghian F, 2009, OPHTHALMOLOGY, V116, P2093, DOI 10.1016/j.ophtha.2009.04.033
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Greenstein VC, 2008, RETINA-J RET VIT DIS, V28, P1234, DOI 10.1097/IAE.0b013e31817c1b47
   Grixti A, 2014, ISRN OPHTHALMOL, V2014, DOI DOI 10.1155/2014/417603.
   Hartnett ME, 2009, AM J OPHTHALMOL, V148, P895, DOI 10.1016/j.ajo.2009.07.014
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Hooper CY, 2009, CLIN EXP OPHTHALMOL, V37, P570, DOI 10.1111/j.1442-9071.2009.02095.x
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kessel L, 2015, ACTA OPHTHALMOL, V93, P593, DOI 10.1111/aos.12665
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lee TG, 2014, GRAEF ARCH CLIN EXP, V252, P1573, DOI 10.1007/s00417-014-2624-4
   LIU IY, 1989, AM J PUBLIC HEALTH, V79, P765, DOI 10.2105/AJPH.79.6.765
   Ma YY, 2015, J CATARACT REFR SURG, V41, P1248, DOI 10.1016/j.jcrs.2014.09.046
   Midena Edoardo, 2004, Semin Ophthalmol, V19, P55, DOI 10.1080/08820530490882896
   Muzyka-Wozniak M, 2011, EUR J OPHTHALMOL, V21, P766, DOI 10.5301/EJO.2011.6389
   Noda Y, 2014, AM J OPHTHALMOL, V158, P455, DOI 10.1016/j.ajo.2014.05.016
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, AM J OPHTHALMOL, V152, P793, DOI 10.1016/j.ajo.2011.04.025
   Saraf SS, 2015, AM J OPHTHALMOL, V160, P487, DOI 10.1016/j.ajo.2015.06.006
   Schulze-Bonsel K, 2006, INVEST OPHTH VIS SCI, V47, P1236, DOI 10.1167/iovs.05-0981
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Syam PP, 2004, EYE, V18, P59, DOI 10.1038/sj.eye.6700521
   Tabandeh H, 2012, J CATARACT REFR SURG, V38, P677, DOI 10.1016/j.jcrs.2011.10.036
   Ueta T, 2012, ARTERIOSCL THROM VAS, V32, P1366, DOI 10.1161/ATVBAHA.112.248021
NR 28
TC 2
Z9 2
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD APR
PY 2018
VL 38
IS 2
BP 459
EP 467
DI 10.1007/s10792-017-0480-z
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GE6AD
UT WOS:000431304900007
PM 28255836
DA 2022-11-30
ER

PT J
AU Lashkari, K
   Teague, GC
   Beattie, U
   Betts, J
   Kumar, S
   McLaughlin, MM
   Lopez, FJ
AF Lashkari, Kameran
   Teague, Gianna C.
   Beattie, Ursula
   Betts, Joanna
   Kumar, Sanjay
   McLaughlin, Megan M.
   Lopez, Francisco J.
TI Plasma biomarkers of the amyloid pathway are associated with geographic
   atrophy secondary to age-related macular degeneration
SO PLOS ONE
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; ALZHEIMERS-DISEASE; INFLAMMASOME ACTIVATION;
   COMPLEMENT ACTIVATION; HIGH-RISK; BETA; PREVALENCE; DEPOSITS; DRUSEN;
   EYES
AB Geographic atrophy (GA) is an advanced form of dry age-related macular degeneration (AMD), in which local inflammation and hyperactivity of the complement pathway have been implicated in its pathophysiology. This study explores whether any surrogate biomarkers are specifically associated with GA. Plasma from subjects with GA, intermediate dry AMD and non-AMD control were evaluated in 2 cohorts. Cohort 1 was assayed in a 320-analyte Luminex library. Statistical analysis was performed using non-parametric and parametric methods (Kruskal-Wallis, principal component analysis, partial least squares and multivariate analysis of variance (MANOVA) and univariate ANCOVAs). Bioinformatic analysis was conducted and identified connections to the amyloid pathway. Statistically significant biomarkers identified in Cohort 1 were then re-evaluated in Cohort 2 using individual ELISA and multiplexing. Of 320 analytes in Cohort 1, 273 were rendered measurable, of which 56 were identified as changing. Among these markers, 40 were identified in univariate ANCOVAs. Serum amyloid precursor protein (sAPP) was analyzed by a separate ELISA and included in further analyses. The 40 biomarkers, sAPP and amyloid-beta (A beta) (1-42) (included for comparison) were evaluated in Cohort 2. This resulted in 11 statistically significant biomarkers, including sAPP and A beta(1-40), but not A beta(1-42). Other biomarkers identified included serum proteases- tissue plasminogen activator, tumor-associated trypsinogen inhibitor, matrix metalloproteinases 7 and 9, and non-proteases- insulin-like growth factor binding protein 6, AXL receptor tyrosine kinase, omentin, pentraxin-3 and osteopontin. Findings suggest that there is a preferential processing of APP to A beta(1-40) over A beta(1-42), and a potential role for the carboxylase activity of the gamma-secretase protein, which preferentially splices sAPP beta to A beta(1-40). Other markers are associated with the breakdown and remodeling of the extracellular matrix, and loss of homeostasis, possibly within the photoreceptor-retinal pigment epithelium-choriocapillaris complex. These data suggest novel disease pathways associated with GA pathogenesis and could provide potential novel targets for treatment of GA.
C1 [Lashkari, Kameran; Teague, Gianna C.; Beattie, Ursula] Harvard Med Sch, Schepens Eye Res Inst Mass Eye & Ear, Boston, MA 02115 USA.
   [Betts, Joanna; Kumar, Sanjay; McLaughlin, Megan M.; Lopez, Francisco J.] GlaxoSmithKline, Alternat Discovery & Dev, King Of Prussia, PA USA.
   [Lashkari, Kameran] Univ Massachusetts, Dept Bioengn, Dartmouth, NS, Canada.
   [Betts, Joanna] GlaxoSmithKline, Computat Biol, Stevenage, Herts, England.
   [Kumar, Sanjay] GlaxoSmithKline, Novel Human Genet Res Unit, King Of Prussia, PA USA.
   [McLaughlin, Megan M.] GlaxoSmithKline, Dev, King Of Prussia, PA USA.
   [Lopez, Francisco J.] Allergan Abbvie Co, Clin Dev Ophthalmol, Irvine, CA USA.
C3 Harvard University; Harvard Medical School; GlaxoSmithKline;
   GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline
RP Lashkari, K (通讯作者)，Harvard Med Sch, Schepens Eye Res Inst Mass Eye & Ear, Boston, MA 02115 USA.; Lashkari, K (通讯作者)，Univ Massachusetts, Dept Bioengn, Dartmouth, NS, Canada.
EM klashkari@umassd.edu
OI Beattie, Ursula/0000-0002-7131-3712
FU GlaxoSmithKline, King of Prussia, PA, USA [4100112]; GlaxoSmithKline
FX This work was supported by Grant 4100112, GlaxoSmithKline, King of
   Prussia, PA, USA (https//us gsk corn) awarded to KL. Coauthors, JB, SK,
   MMcLM and FJL received funding from GlaxoSmithKline in the form of
   salaries. The funders of this study had no role in data collection and
   analysis or the decision to publish. GlaxoSmithKline authors contributed
   to study design, the interpretation of results and preparation of the
   manuscript.
CR Almonte AG, 2011, BRAIN RES, V1407, P107, DOI 10.1016/j.brainres.2011.06.042
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   [Anonymous], 2018, MODERN RETINA
   Ardeljan D, 2011, DRUG FUTURE, V36, P713, DOI 10.1358/dof.2011.36.9.1678338
   Bednar A, 2013, INVEST OPHTH VIS SCI, P54
   Benjamini Y, 2001, ANN STAT, V29, P1165
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Box GEP, 1964, J ROYAL STAT SOC B, V26, P42
   Box GEPH, 1974, TECHNOMETRICS, V16, P5
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   C.T. R, 2013, LANG ENV STAT COMP
   Campbell JC, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0075302 24086502, DOI 10.1371/JOURNAL.PONE.0075302 24086502]
   Cha DM, 2013, INVEST OPHTH VIS SCI, V54, P7038, DOI 10.1167/iovs.13-12730
   Chang SW, 2016, FRONT MOL NEUROSCI, V9, DOI 10.3389/fnmol.2016.00058
   Crabb JW, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017194
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cuchillo-Ibanez I, 2015, MOL NEURODEGENER, V10, DOI 10.1186/1750-1326-10-2
   Daigo K, 2016, IMMUNOL REV, V274, P202, DOI 10.1111/imr.12476
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Demars MP, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt77
   Deng L., 2019, FRONT MOL NEUROSCI, V12, P14
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fandos Noelia, 2017, Alzheimers Dement (Amst), V8, P179, DOI 10.1016/j.dadm.2017.07.004
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Grassmann F, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0548-0
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Inoue K, 2017, CELL REP, V21, P1727, DOI 10.1016/j.celrep.2017.10.075
   Jeffrey Cheng QEG, 2018, OPHTHALMOLOGY RETINA, V2, P8
   Johnson AJ, 2007, CLIN VACCINE IMMUNOL, V14, P1084, DOI 10.1128/CVI.00115-07
   Juel HB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132800
   Kovacs K, 2015, INVEST OPHTH VIS SCI, V56, P6523, DOI 10.1167/iovs.15-16793
   Kremlitzka M, 2018, HUM MOL GENET, V27, P2678, DOI 10.1093/hmg/ddy178
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lashkari K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195751
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Miriam F-F, 2010, BIOCHIM BIOPHYS ACTA, V1803, P3, DOI DOI 10.1016/J.BBAMCR.2009.07.004
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Murphy MP, 2010, J ALZHEIMERS DIS, V19, P311, DOI [10.3233/JAD-2009-1221, 10.3233/JAD-2010-1221]
   Nielsen M.K. SY, 2019, ACTA OPHTHALMOL, V97, P7, DOI [10.1111/aos.13859, DOI 10.1111/AOS.13859]
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Rabenstein M, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0098-x
   Rabiolo A, 2017, CLIN OPHTHALMOL, V11, P1707, DOI 10.2147/OPTH.S130165
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rosenfeld PJ, 2018, OPHTHALMOL RETINA, V2, P1028, DOI 10.1016/j.oret.2018.03.001
   Ross RJ, 2007, EXPERT REV OPHTHALMO, V2, P443, DOI 10.1586/17469899.2.3.443
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Sadda SR, 2016, RETINA-J RET VIT DIS, V36, P1806, DOI 10.1097/IAE.0000000000001283
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seth A, 2008, INVEST OPHTH VIS SCI, V49, P743, DOI 10.1167/iovs.07-1072
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Song HM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149269
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Thinakaran G, 2008, J BIOL CHEM, V283, P29615, DOI 10.1074/jbc.R800019200
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Wang JY, 2008, J IMMUNOL, V181, P712, DOI 10.4049/jimmunol.181.1.712
   Wang JY, 2009, J CELL PHYSIOL, V220, P119, DOI 10.1002/jcp.21742
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS26, DOI 10.1097/IAE.0000000000001330
   Zhao Q, 2010, ELECTRON J BIOTECHN, V13, DOI 10.2225/vol13-issue5-fulltext-2
   Zhao YH, 2015, MOL NEUROBIOL, V52, P533, DOI 10.1007/s12035-014-8886-3
NR 64
TC 7
Z9 7
U1 2
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 7
PY 2020
VL 15
IS 8
AR e0236283
DI 10.1371/journal.pone.0236283
PG 24
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA NC2FE
UT WOS:000561029000064
PM 32764794
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU McGuinness, MB
   Karahalios, A
   Kasza, J
   Guymer, RH
   Finger, RP
   Simpson, JA
AF McGuinness, Myra B.
   Karahalios, Amalia
   Kasza, Jessica
   Guymer, Robyn H.
   Finger, Robert P.
   Simpson, Julie A.
TI Survival Bias When Assessing Risk Factors for Age-Related Macular
   Degeneration: A Tutorial with Application to the Exposure of Smoking
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Age-related macular degeneration; causal methodology; death; smoking;
   survival bias
ID CAUSAL INFERENCE; PRINCIPAL STRATIFICATION; VISUAL IMPAIRMENT;
   MORTALITY; PATTERNS; OUTCOMES; DISEASE
AB Purpose: We illustrate the effect of survival bias when investigating risk factors for eye disease in elderly populations for whom death is a competing risk. Our investigation focuses on the relationship between smoking and late age-related macular degeneration (AMD) in an observational study impacted by censoring due to death.
   Methods: Statistical methodology to calculate the survivor average causal effect (SACE) as a sensitivity analysis is described, including example statistical computing code for Stata and R. To demonstrate this method, we examine the causal effect of smoking history at baseline (1990-1994) on the presence of late AMD at the third study wave (2003-2007) using data from the Melbourne Collaborative Cohort Study.
   Results: Of the 40,506 participants eligible for inclusion, 38,092 (94%) survived until the start of the third study wave, 20,752 (51%) were graded for AMD (60% female, aged 47-85 years, mean 65 +/- 8.7 years). Late AMD was detected in 122 participants. Logistic regression showed strong evidence of an increased risk of late AMD for current smokers compared to non-smokers (adjusted naive odds ratio 2.99, 95% confidence interval, CI, 1.74-5.13). Among participants expected to be alive at the start of follow-up regardless of their smoking status, the estimated SACE odds ratio comparing current smokers to non-smokers was at least 3.42 (95% CI 1.57-5.15).
   Conclusions: Survival bias can attenuate associations between harmful exposures and diseases of aging. Estimation of the SACE using a sensitivity analysis approach should be considered when conducting epidemiological research within elderly populations.
C1 [McGuinness, Myra B.; Guymer, Robyn H.; Finger, Robert P.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Australia.
   [McGuinness, Myra B.; Karahalios, Amalia; Simpson, Julie A.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Ctr Epidemiol & Biostat, Melbourne, Vic, Australia.
   [McGuinness, Myra B.; Guymer, Robyn H.; Finger, Robert P.] Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Australia.
   [Kasza, Jessica] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia.
   [Finger, Robert P.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Simpson, Julie A.] Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; University of Melbourne; Monash University;
   University of Bonn; Cancer Council Victoria
RP McGuinness, MB (通讯作者)，Ctr Eye Res Australia, Level 1,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM myra.mcguinness@unimelb.edu.au
RI McGuinness, Myra/G-4900-2017; /AAB-3060-2019
OI McGuinness, Myra/0000-0002-5422-040X; Finger, Robert
   P/0000-0003-4253-7597; Guymer, Robyn/0000-0002-9441-4356
FU VicHealth; National Health & Medical Research Council of Australia
   (NHMRC) [209057]; Capacity Building Grant [251533]; Enabling Grant
   [396414]; Ophthalmic Research Institute of Australia; American Health
   Assistance Foundation [M2008-082]; Jack Brockhoff Foundation; John Reid
   Charitable Trust; Perpetual Trustees; Australian Postgraduate Award;
   National Health and Medical Research Council (NHMRC) [1104975]; NHMRC
   Principal Research Fellowship [1103013]; Cancer Council of Victoria;
   Victorian Centre for Biostatistics (NHMRC: Centre of Research Excellence
   grant) [1035261]; Cancer Council Victoria
FX Cohort recruitment was funded by VicHealth and Cancer Council Victoria.
   Further Melbourne Collaborative Cohort Study funding: the National
   Health & Medical Research Council of Australia (NHMRC) Program Grant
   209057, Capacity Building Grant 251533 and Enabling Grant 396414. The
   ophthalmic component was funded by the Ophthalmic Research Institute of
   Australia; American Health Assistance Foundation (M2008-082), Jack
   Brockhoff Foundation, John Reid Charitable Trust, Perpetual Trustees. M.
   McGuinness is funded by an Australian Postgraduate Award and a
   studentship courtesy of Victorian Centre for Biostatistics (NHMRC:
   Centre of Research Excellence grant 1035261). J. Simpson is funded by a
   National Health and Medical Research Council (NHMRC) Senior Research
   Fellowship 1104975, and R. Guymer by a NHMRC Principal Research
   Fellowship 1103013. This work was supported by infrastructure from the
   Cancer Council of Victoria. CERA receives operational infrastructure
   support from the Victorian government. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR ABS, 2011, SOC IND AR SEIFA
   Aung KZ, 2009, OPHTHAL EPIDEMIOL, V16, P254, DOI [10.3109/09286580902864419, 10.1080/09286580902864419]
   Banks E, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0281-z
   Carpenter J, 2000, STAT MED, V19, P1141, DOI 10.1002/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chiba Y., 2012, J BIOMET BIOSTAT, V3, P116
   Chiba Y, 2011, AM J EPIDEMIOL, V173, P745, DOI 10.1093/aje/kwq418
   COX DR, 1958, ANN MATH STAT, V29, P357, DOI 10.1214/aoms/1177706618
   Cugati S, 2007, ARCH OPHTHALMOL-CHIC, V125, P917, DOI 10.1001/archopht.125.7.917
   Dandona R, 2001, BRIT J OPHTHALMOL, V85, P1484, DOI 10.1136/bjo.85.12.1484
   Dawid AP, 2000, J AM STAT ASSOC, V95, P407, DOI 10.2307/2669377
   Egleston BL, 2007, BIOSTATISTICS, V8, P526, DOI 10.1093/biostatistics/kxl027
   Fagerstrom K, 2002, DRUGS, V62, P1, DOI 10.2165/00003495-200262002-00001
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Frangakis CE, 2002, BIOMETRICS, V58, P21, DOI 10.1111/j.0006-341X.2002.00021.x
   Giles GG., 1990, P NUTR AUST, V15, P94
   Glymour MM, 2008, NEUROPSYCHOL REV, V18, P194, DOI 10.1007/s11065-008-9066-x
   Gohdes DM, 2005, PREVENT CHRONIC DIS, V2, P1
   Hayden D, 2005, BIOMETRICS, V61, P305, DOI 10.1111/j.0006-341X.2005.030227.x
   IMBENS GW, 1994, ECONOMETRICA, V62, P467, DOI 10.2307/2951620
   Islam FMA, 2014, OPHTHALMOLOGY, V121, P1428, DOI 10.1016/j.ophtha.2014.01.002
   Klein R, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12789
   Knudtson MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P243, DOI 10.1001/archopht.124.2.243
   Mitchell P, 2011, EYES FUTURE CLEAR OU
   Robins J M, 1995, Lifetime Data Anal, V1, P241, DOI 10.1007/BF00985759
   ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41
   RUBIN DB, 1976, BIOMETRIKA, V63, P581, DOI 10.2307/2335739
   RUBIN DB, 1974, J EDUC PSYCHOL, V66, P688, DOI 10.1037/h0037350
   Rubin DB, 2000, J AM STAT ASSOC, V95, P435, DOI 10.2307/2669382
   RUBIN DB, 1980, J AM STAT ASSOC, V75, P591, DOI 10.2307/2287653
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039
   Williamson EJ, 2014, RESPIROLOGY, V19, P303, DOI 10.1111/resp.12238
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhang JNL, 2003, J EDUC BEHAV STAT, V28, P353, DOI 10.3102/10769986028004353
NR 35
TC 7
Z9 7
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD AUG
PY 2017
VL 24
IS 4
BP 229
EP 238
DI 10.1080/09286586.2016.1276934
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA FA4FT
UT WOS:000405399900005
PM 28287849
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Kim, M
   Lee, SJ
   Han, J
   Yu, SY
   Kwak, HW
AF Kim, Moosang
   Lee, Seung Jun
   Han, Jisang
   Yu, Seung-Young
   Kwak, Hyung Woo
TI Segmentation error and macular thickness measurements obtained with
   spectral-domain optical coherence tomography devices in neovascular
   age-related macular degeneration
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Central macular thickness; neovascular age-related macular degeneration;
   segmentation error; spectral-domain optical coherence tomography
ID HIGH-SPEED; INSTRUMENTS; EYES
AB Purpose: To evaluate frequency and severity of segmentation errors of two spectral-domain optical coherence tomography (SD-OCT) devices and error effect on central macular thickness (CMT) measurements. Materials and Methods: Twenty-seven eyes of 25 patients with neovascular age-related macular degeneration, examined using the Cirrus HD-OCT and Spectralis HRA + OCT, were retrospectively reviewed. Macular cube 512 x 128 and 5-line raster scans were performed with the Cirrus and 512 x 25 volume scans with the Spectralis. Frequency and severity of segmentation errors were compared between scans. Results: Segmentation error frequency was 47.4% (baseline), 40.7% (1 month), 40.7% (2 months), and 48.1% (6 months) for the Cirrus, and 59.3%, 62.2%, 57.8%, and 63.7%, respectively, for the Spectralis, differing significantly between devices at all examinations (P < 0.05), except at baseline. Average error score was 1.21 +/- 1.65 (baseline), 0.79 +/- 1.18 (1 month), 0.74 +/- 1.12 (2 months), and 0.96 +/- 1.11 (6 months) for the Cirrus, and 1.73 +/- 1.50, 1.54 +/- 1.35, 1.38 +/- 1.40, and 1.49 +/- 1.30, respectively, for the Spectralis, differing significantly at 1 month and 2 months (P < 0.02). Automated and manual CMT measurements by the Spectralis were larger than those by the Cirrus. Conclusions: The Cirrus HD-OCT had a lower frequency and severity of segmentation error than the Spectralis HRA + OCT. SD-OCT error should be considered when evaluating retinal thickness.
C1 [Kim, Moosang; Lee, Seung Jun] Kangwon Natl Univ Hosp, Dept Ophthalmol, Chunchon, South Korea.
   [Han, Jisang; Yu, Seung-Young; Kwak, Hyung Woo] Kyung Hee Univ Hosp, Dept Ophthalmol, Seoul, South Korea.
C3 Kangwon National University; Kangwon National University Hospital; Kyung
   Hee University; Kyung Hee University Hospital
RP Yu, SY (通讯作者)，1 Hoegi Dong, Seoul 130702, South Korea.
EM syyu@khu.ac.kr
CR Alam S, 2006, OPHTHALMOLOGY, V113, P1425, DOI 10.1016/j.ophtha.2006.03.020
   Fujimoto JG., 2004, OPTICAL COHERENCE TO, V2nd
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Giani A, 2010, RETINA-J RET VIT DIS, V30, P607, DOI 10.1097/IAE.0b013e3181c2e09d
   Han IC, 2009, AM J OPHTHALMOL, V147, P847, DOI 10.1016/j.ajo.2008.11.019
   Ho J, ASSESSMENT ARTIFACTS
   Keane PA, 2009, BRIT J OPHTHALMOL, V93, P1461, DOI 10.1136/bjo.2008.155846
   Keane PA, 2009, INVEST OPHTH VIS SCI, V50, P3378, DOI 10.1167/iovs.08-2728
   Pons ME, 2005, OPHTHALMOLOGY, V112, P1079, DOI 10.1016/j.ophtha.2004.11.061
   Ray R, 2005, AM J OPHTHALMOL, V139, P18, DOI 10.1016/j.ajo.2004.07.050
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Schmidt-Erfurth U, 2005, INVEST OPHTH VIS SCI, V46, P3393, DOI 10.1167/iovs.05-0370
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Srinivasan VJ, 2008, INVEST OPHTH VIS SCI, V49, P1571, DOI 10.1167/iovs.07-0838
   Wojtkowski M, 2005, OPHTHALMOLOGY, V112, P1734, DOI 10.1016/j.ophtha.2005.05.023
   Wojtkowski M, 2004, AM J OPHTHALMOL, V138, P412, DOI 10.1016/j.ajo.2004.04.049
   Wolf-Schnurrbusch UEK, 2009, INVEST OPHTH VIS SCI, V50, P3432, DOI 10.1167/iovs.08-2970
NR 17
TC 14
Z9 14
U1 0
U2 9
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0301-4738
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD MAY
PY 2013
VL 61
IS 5
BP 213
EP 217
DI 10.4103/0301-4738.97075
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 173HZ
UT WOS:000321071200006
PM 23314254
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Evans, JR
AF Evans, J. R.
TI Antioxidant vitamin and mineral supplements for slowing the progression
   of age-related macular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID ORAL ZINC; MACULOPATHY; PREVALENCE; EYE
AB Background
   It has been proposed that antioxidants may prevent cellular damage in the retina by reacting with free radicals that are produced in the process of light absorption.
   Objectives
   The objective of this review was to assess the effects of antioxidant vitamin or mineral supplementation, or both, on the progression of age-related macular degeneration (AMD).
   Search strategy
   We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (2005, Issue 4); MEDLINE (1966 to January 2006); SIGLE (1980 to March 2005); EMBASE (1980 to January 2005); NRR (2005, Issue 4); AMED (1985 to January 2006); and PubMed (24 January 2006 covering last 60 days), reference lists of identified reports and the Science Citation Index. We contacted investigators and experts in the field for details of unpublished studies.
   Selection criteria
   We included randomised trials comparing antioxidant vitamin or mineral supplemention (alone or in combination) to a control intervention in people with AMD.
   Data collection and analysis
   The author extracted data and assessed trial quality. Where appropriate, data were pooled using a random-effects model unless three or fewer trials were available in which case a fixed-effects model was used.
   Main results
   Eight trials were included in this review. The majority of people were randomised in one trial (AREDS in the USA) that found a beneficial effect of antioxidant (beta-carotene, vitamin C and vitamin E) and zinc supplementation on progression to advanced AMD (adjusted odds ratio 0.68, 99% confidence interval 0.49 to 0.93). People taking supplements were less likely to lose 15 or more letters of visual acuity (adjusted odds ratio 0.77, 99% confidence interval 0.58 to 1.03). Hospitalisation for genito-urinary problems was more common in people taking zinc and yellowing of skin was more common in people taking antioxidants. The other trials were, in general, small and the results were inconsistent.
   Authors' conclusions
   The evidence as to the effectiveness of antioxidant vitamin and mineral supplementation in halting the progression of AMD comes mainly from one large trial in the USA. The generalisability of these findings to other populations with different nutritional status is not known. Further large, well-conducted randomised controlled trials in other populations are required. Long-term harm from supplementation cannot be ruled out. Beta-carotene has been found to increase the risk of lung cancer in smokers; vitamin E has been associated with an increased risk of heart failure in people with vascular disease or diabetes.
C1 Univ London London Sch Hyg & Trop Med, Int Ctr Eye Hlth, London WC1E 7HT, England.
C3 University of London; London School of Hygiene & Tropical Medicine
RP Evans, JR (通讯作者)，Univ London London Sch Hyg & Trop Med, Int Ctr Eye Hlth, Keppel St, London WC1E 7HT, England.
EM jennifer.evans@lshtm.ac.uk
RI Evans, Jennifer/F-4672-2012
OI Evans, Jennifer/0000-0002-6137-2030
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   [Anonymous], 1980, EARL TREATM DIAB RET, P1
   *ARMSG, 1995, SURVEYS OPHTHALMOLOG, V39, P367
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   CHRISTEN WG, 1996, ANN EPIDEMIOLOG 0106, P60
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Evans J., 1996, HEALTH TRENDS, V28, P5
   EVNAS JR, 1999, COCHRANE DB SYST REV, P253, DOI DOI 10.1002/14651858.CD000253
   Garrett S K, 1999, Ophthalmic Epidemiol, V6, P195, DOI 10.1076/opep.6.3.195.1500
   Holz F., 1993, GER J OPHTHALMOL, V2, P391
   KAISER HJ, 1995, OPHTHALMOLOGICA, V209, P302, DOI 10.1159/000310646
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lonn E, 2005, JAMA-J AM MED ASSOC, V293, P1338, DOI 10.1001/jama.293.11.1338
   Macdonald GM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub2
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   RICHER S, 1996, J AM OPTOMETRIC ASS, V0067
   Richer S, 1996, J Am Optom Assoc, V67, P30
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Robman LD, 1999, AUST NZ J OPHTHALMOL, V27, P410
   Stur M, 1996, INVEST OPHTH VIS SCI, V37, P1225
   Taylor HR, 2001, INVEST OPHTH VIS SCI, V42, pS311
   VANNAS S, 1958, Acta Ophthalmol (Copenh), V36, P601
   Wang H., 2004, ZHONGGUO LINCHUANT K, V8, P1290
NR 28
TC 61
Z9 66
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2006
IS 2
AR CD000254
DI 10.1002/14651858.CD000254.pub2
PG 29
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 034MC
UT WOS:000236932100076
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Dong, Y
   Wan, GM
   Yan, PS
   Chen, Y
   Wang, WZ
   Peng, GH
AF Dong, Yi
   Wan, Guangming
   Yan, Panshi
   Chen, Yue
   Wang, Wenzhan
   Peng, Guanghua
TI Effect of anti-VEGF drugs combined with photodynamic therapy in the
   treatment of age-related macular degeneration
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE age-related macular degeneration; anti-vascular endothelial growth
   factor; drugs; photodynamic therapy
ID INTRAVITREAL BEVACIZUMAB AVASTIN(R); RETROBULBAR BLOOD-FLOW
AB We analyzed the effects of anti-vascular endothelial growth factor (VEGF) drugs combined with photodynamic therapy (PDT) in the treatment of age-related macular degeneration (AMD). Ninety-six cases (192 eyes) of AMD were included in this study and randomly divided into the observation group and control group (n=48 cases per group). The control group was administered the treatment of Lucentis intravitreal injection alone and the observation group was administered Lucentis combined with PDT. The therapeutic effects were compared. The best corrected visual acuity of patients in the two groups increased gradually after treatment. Patients in the observation group had a significantly higher visual acuity when compared to the control group 1 and 6 months post-operation. The differences were statistically significant (P<0.05). The proportion of patients with vision improvement in the observation group was higher than that in the control group from 1 to 6 months; differences were statistically significant (P<0.05). Through detection by color Doppler ultrasound within 6 months after treatment, we observed that the peak systolic velocity and arterial end diastolic velocity of retrobulbar optic nerve bitemporal PCA of the observation group were higher than those of the control group. The values of arterial resistance index and pulsatility index of the observation group were lower than those of control group. The differences were statistically significant (P<0.05). Six months after treatment, the value of central foveal thickness of the observation group was lower than that of the control group, the value of mean sensitivity of visual field parameter 10 and 4 was higher in the observation group than in the control group, and the absolute value of mean defects in the observation group were lower than that of the control group. In summary, the differences were statistically significant (P<0.05). Anti-VEGF drugs combined with PDT can optimize the overall vision of patients with AMD, improve hemodynamic parameters and reduce visual field defects.
C1 [Dong, Yi; Wan, Guangming; Yan, Panshi; Chen, Yue; Wang, Wenzhan; Peng, Guanghua] Zhengzhou Univ, Affiliated Hosp 1, Dept Ophthalmol, 1 Jianshe East Rd, Zhengzhou 450052, Henan, Peoples R China.
   [Peng, Guanghua] Chinese Peoples Liberat Army Gen Hosp, Beijing 100853, Peoples R China.
C3 Zhengzhou University; Chinese People's Liberation Army General Hospital
RP Peng, GH (通讯作者)，Zhengzhou Univ, Affiliated Hosp 1, Dept Ophthalmol, 1 Jianshe East Rd, Zhengzhou 450052, Henan, Peoples R China.
EM peng_guanghua1@163.com
RI Huang, Yifei/ABE-7566-2020
CR Arias Luis, 2016, Clin Ophthalmol, V10, P861, DOI 10.2147/OPTH.S106092
   Arnold JJ., 2016, BMJ CLIN EVID, V2016
   Catchpole T, 2016, EXP EYE RES, V148, P45, DOI 10.1016/j.exer.2016.05.025
   Cho HJ, 2016, AM J OPHTHALMOL, V166, P112, DOI 10.1016/j.ajo.2016.03.039
   Colombeau L, 2016, TOP CURR CHEM, V370, P113, DOI 10.1007/978-3-319-22942-3_4
   Heimes B, 2016, OPHTHALMOLOGE, V6
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Lee Jung Pil, 2016, Korean J Ophthalmol, V30, P192, DOI 10.3341/kjo.2016.30.3.192
   MacDonald DA, 2016, ANGIOGENESIS, V19, P389, DOI 10.1007/s10456-016-9515-8
   Mete A, 2010, J CLIN ULTRASOUND, V38, P66, DOI 10.1002/jcu.20650
   Newman DK, 2016, EYE, V30, P202, DOI 10.1038/eye.2015.251
   Novais EA, 2016, J OPHTHALMOL, V2016
   Otsuji T, 2016, CLIN OPHTHALMOL, V10, P431, DOI 10.2147/OPTH.S102171
   Sakalar YB, 2013, J CLIN ULTRASOUND, V41, P32, DOI 10.1002/jcu.21989
   Scherer KM, 2016, ANTI-CANCER AGENT ME, V13, P17
   Senra H, 2016, GRAEFES ARCH CLIN EX, V4, P12
   Shahin M, 2014, CUTAN OCUL TOXICOL, V33, P49, DOI 10.3109/15569527.2013.796478
   Smith T, 2016, JAMA OPHTHALMOL, V134, P824, DOI 10.1001/jamaophthalmol.2016.1466
   Teper SJ, 2016, PHOTODIAGN PHOTODYN, V13, P108, DOI 10.1016/j.pdpdt.2016.01.006
   Toklu Y, 2011, ACTA OPHTHALMOL, V89, pE41, DOI 10.1111/j.1755-3768.2010.02075.x
   Ueda K, 2016, P NATL ACAD SCI USA, V113, P6904, DOI 10.1073/pnas.1524774113
   Uzun S, 2016, GRAEFES ARCH CLIN EX, V2, P15
   Wu B, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/7689862
NR 23
TC 6
Z9 6
U1 0
U2 11
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-0981
EI 1792-1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD DEC
PY 2016
VL 12
IS 6
BP 3923
EP 3926
DI 10.3892/etm.2016.3886
PN B
PG 4
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA EG5IC
UT WOS:000391076500016
PM 28105123
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Obata, R
   Yanagi, Y
   Inoue, T
   Yasuda, M
   Oshima, Y
   Sawaguchi, S
   Iwase, A
   Araie, M
AF Obata, Ryo
   Yanagi, Yasuo
   Inoue, Tatsuya
   Yasuda, Miho
   Oshima, Yuji
   Sawaguchi, Shoichi
   Iwase, Aiko
   Araie, Makoto
TI Prevalence and factors associated with age-related macular degeneration
   in a southwestern island population of Japan: the Kumejima Study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID NUTRITION EXAMINATION SURVEY; RISK-FACTORS; CHINESE POPULATION;
   NATIONAL-HEALTH; MACULOPATHY; EYE; SINGAPORE; INDIANS
AB Aims To evaluate the prevalence of and factors associated with age-related macular degeneration (AMD) in a rural population of southwestern Japan.
   Methods This population-based cross-sectional study of all residents aged 40 years or older was conducted on the island of Kumejima, Okinawa, Japan. Of 4632 eligible residents, 3762 completed a comprehensive questionnaire and underwent ocular examination (participant rate, 81.2%). A non-mydriatic fundus photograph was used to grade AMD lesions according to the Wisconsin protocol. Prevalence of AMD was calculated and factors associated with AMD were identified by logistic regression.
   Results Of 3068 subjects with gradable photographs, 469 had early AMD and 4 had late AMD. Age-adjusted prevalence was 13.4% for any AMD, 13.3% for early AMD and 0.09% for late AMD. In multivariate analysis, any AMD was positively associated with age (OR 1.04 per year, 95% CI 1.03 to 1.05), male sex (OR 1.42, 95% CI 1.14 to 1.75) and history of cataract surgery (OR 1.35, 95% CI 1.00 to 1.82) and was negatively associated with longer axial length (OR 0.85 per millimetre, 95% CI 0.74 to 0.96). Early AMD similarly showed significant associations with these same factors.
   Conclusions Prevalence of early or late AMD in a southwestern island population of Japan was 13.4% or 0.09%. Our data suggest relatively high prevalence for early AMD and low prevalence for late AMD in this sample of rural Japanese population. Significant factors associated with any or early AMD were mostly similar to that of previous studies.
C1 [Obata, Ryo; Inoue, Tatsuya] Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Tokyo, Japan.
   [Yanagi, Yasuo] Singapore Natl Eye Ctr, Dept Med Retina, Singapore, Singapore.
   [Yanagi, Yasuo] Singapore Eye Res Inst, Singapore, Singapore.
   [Yanagi, Yasuo] Duke NUS Natl Univ Singapore, Grad Med Sch, Singapore, Singapore.
   [Yasuda, Miho; Oshima, Yuji] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Fukuoka, Fukuoka, Japan.
   [Sawaguchi, Shoichi] Univ Ryukyus, Dept Ophthalmol, Grad Sch Med, Nishihara, Okinawa, Japan.
   [Iwase, Aiko] Tajimi Iwase Eye Clin, Tajimi, Japan.
   [Araie, Makoto] Mutual Aid Assoc Publ Sch Teachers, Kanto Cent Hosp, Tokyo, Japan.
C3 University of Tokyo; Singapore National Eye Center; National University
   of Singapore; Singapore National Eye Center; Kyushu University;
   University of Ryukyus
RP Obata, R (通讯作者)，Univ Tokyo, Dept Ophthalmol, Sch Med, Tokyo 1138655, Japan.
EM robata-tky@umin.ac.jp
RI Yanagi, Yasuo/AAA-5441-2022; Yanagi, Yasuo/AAF-2670-2020
OI Yanagi, Yasuo/0000-0002-0362-7285
CR Aoki A, 2015, INVEST OPHTH VIS SCI, V56, P2580, DOI 10.1167/iovs.14-16339
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P764, DOI 10.1016/j.ajo.2012.10.013
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   Gopinath B, 2017, BR J OPHTHALMOL, V101
   Huang EJC, 2014, EYE, V28, P705, DOI 10.1038/eye.2014.55
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   La TY, 2014, CURR EYE RES, V39, P1232, DOI 10.3109/02713683.2014.907431
   Lavanya R, 2010, INVEST OPHTH VIS SCI, V51, P6247, DOI 10.1167/iovs.10-5229
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nakata I, 2013, AM J OPHTHALMOL, V156, P1002, DOI 10.1016/j.ajo.2013.06.007
   Nomura Y, 2015, JPN J OPHTHALMOL, V59, P261, DOI 10.1007/s10384-015-0387-z
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Park SJ, 2016, JAMA OPHTHALMOL, V134, P621, DOI 10.1001/jamaophthalmol.2016.0453
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Raman R, 2016, EYE, V30, P688, DOI 10.1038/eye.2016.14
   Sawaguchi S, 2012, OPHTHALMOLOGY, V119, P1134, DOI 10.1016/j.ophtha.2011.12.038
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Shiroma H, 2009, AM J OPHTHALMOL, V148, P766, DOI 10.1016/j.ajo.2009.06.006
   Varma R, 2016, JAMA OPHTHALMOL, V134, P571, DOI 10.1001/jamaophthalmol.2016.0588
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Wang JJ, 1998, BRIT J OPHTHALMOL, V82, P743, DOI 10.1136/bjo.82.7.743
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong TY, 2001, AM J OPHTHALMOL, V131, P176, DOI 10.1016/S0002-9394(00)00703-0
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   World, 2000, STAND STAND POP SEER
   Ye HH, 2014, INVEST OPHTH VIS SCI, V55, P6374, DOI 10.1167/iovs.14-14899
NR 34
TC 7
Z9 7
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2018
VL 102
IS 8
BP 1047
EP 1053
DI 10.1136/bjophthalmol-2016-309980
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GU2OK
UT WOS:000445109400007
PM 29146756
DA 2022-11-30
ER

PT J
AU Legocki, AT
   Adhi, M
   Weber, ML
   Duker, JS
AF Legocki, Alex T.
   Adhi, Mehreen
   Weber, Marissa L.
   Duker, Jay S.
TI Choroidal Morphology and Vascular Analysis in Eyes With Neovascular
   Age-Related Macular Degeneration Using Spectral-Domain Optical Coherence
   Tomography
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID GROWTH-FACTOR THERAPY; THICKNESS; LAYERS; RANIBIZUMAB; ANGIOGRAPHY;
   FEATURES
AB BACKGROUND AND OBJECTIVE: To describe morphology and vascular layer thickness of the choroid in eyes with neovascular age-related macular degeneration (AMD) using spectral-domain optical coherence tomography (SD-OCT).
   PATIENTS AND METHODS: Cross-sectional, retrospective analysis of 15 eyes with neovascular AMD and 11 healthy age matched eyes that underwent single horizontal, high-definition raster line imaging using high-definition SD-OCT. Two independent graders assessed choroid morphology and measured the thickness of individual vascular layers of the choroid beneath the fovea.
   RESULTS: Normal concave choroidal contour was found in 13.3% of eyes with neovascular AMD and 100% of healthy eyes. The thickest point of the choroid was located beneath the foveal center in 20% of eyes and focal thinning was observed in 40% of eyes with neovascular AMD, compared to 91% and 0% of healthy eyes, respectively. Subfoveal total choroidal thickness, large choroidal vessel layer thickness, and the medium choroidal vessel/choriocapillaris layer thickness were reduced in eyes with neovascular AMD compared to healthy eyes (205.7 mu m +/- 17.08 mu m versus 281.3 mu m +/- 19.29 mu m, P = .007; 174.1 mu m +/- 16.34 mu m versus 244.5 mu m 19.51 mu m, P = .01; and 31.53 mu m +/- 3.67 mu m verus 51.9 mu m +/- 1.94 mu m, P = .0002, respectively).
   CONCLUSION: Choroidal morphology is altered in eyes with neovascular AMD as assessed on SDOCT. Choroidal thinning in neovascular AMD involves all its vascular layers. These morphological and vascular changes may have clinical implications in the diagnosis and monitoring of eyes with neovascular AMD.
C1 [Legocki, Alex T.; Adhi, Mehreen; Duker, Jay S.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
   [Adhi, Mehreen; Weber, Marissa L.; Duker, Jay S.] Tufts Med Ctr, New England Eye Ctr, 800 Washington St, Boston, MA 02111 USA.
C3 Tufts University; Tufts Medical Center
RP Duker, JS (通讯作者)，Tufts Med Ctr, New England Eye Ctr, 800 Washington St, Boston, MA 02111 USA.
EM jduker@tuftsmedicalcenter.org
RI Adhi, Mehreen/AAS-9733-2021
FU Massachusetts Lions Eye Research Fund; Carl Zeiss Meditec; Topcon;
   Optovue
FX Supported in part by the Massachusetts Lions Eye Research Fund.; Dr.
   Duker is a consultant for and receives research support from Carl Zeiss
   Meditec, Topcon, and Optovue. The remaining authors report no relevant
   financial disclosures.
CR Adhi M, 2015, AM J OPHTHALMOL, V160, P1276, DOI 10.1016/j.ajo.2015.08.025
   Adhi M, 2014, RETINA-J RET VIT DIS, V34, P306, DOI 10.1097/IAE.0b013e3182993e09
   Adhi M, 2013, JAMA OPHTHALMOL, V131, P1267, DOI 10.1001/jamaophthalmol.2013.4321
   Adhi M, 2013, OSLI RETINA, V44, P252, DOI 10.3928/23258160-20130503-08
   Branchini L, 2013, JAMA OPHTHALMOL, V131, P693, DOI 10.1001/jamaophthalmol.2013.692
   Branchini LA, 2013, OPHTHALMOLOGY, V120, P1901, DOI 10.1016/j.ophtha.2013.01.066
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   De Niro JE, 2014, RETINA-J RET VIT DIS, V34, P1163, DOI 10.1097/IAE.0000000000000077
   Ellabban AA, 2012, CLIN OPHTHALMOL, V6, P837, DOI 10.2147/OPTH.S30907
   Flores-Moreno I, 2015, BRIT J OPHTHALMOL, V99, P1260, DOI 10.1136/bjophthalmol-2014-306422
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Gharbiya M, 2015, J OCUL PHARMACOL TH, V31, P357, DOI 10.1089/jop.2014.0160
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Hirata M, 2011, INVEST OPHTH VIS SCI, V52, P4971, DOI 10.1167/iovs.11-7729
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Lau T, 2015, INDIAN J OPHTHALMOL, V63, P378, DOI 10.4103/0301-4738.159860
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Manjunath V, 2010, AM J OPHTHALMOL, V150, P325, DOI 10.1016/j.ajo.2010.04.018
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Povazay B, 2003, OPT EXPRESS, V11, P1980, DOI 10.1364/OE.11.001980
   Regatieri CV, 2012, RETINA-J RET VIT DIS, V32, P865, DOI 10.1097/IAE.0b013e318251a3a8
   Sayanagi K, 2011, J CLIN EXP OPHTHALMO, V2, P2
   Schwartz DM, 2014, OPHTHALMOLOGY, V121, P180, DOI 10.1016/j.ophtha.2013.09.002
   Sohrab M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048631
   Srinivasan VJ, 2008, INVEST OPHTH VIS SCI, V49, P5103, DOI 10.1167/iovs.08-2127
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Zhang L, 2012, INVEST OPHTH VIS SCI, V53, P7510, DOI 10.1167/iovs.12-10311
NR 32
TC 6
Z9 6
U1 0
U2 6
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD JUL
PY 2016
VL 47
IS 7
BP 618
EP 625
DI 10.3928/23258160-20160707-02
PG 8
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA EJ3FP
UT WOS:000393098300002
PM 27434892
DA 2022-11-30
ER

PT J
AU Ach, T
   Tolstik, E
   Messinger, JD
   Zarubina, AV
   Heintzmann, R
   Curcio, CA
AF Ach, Thomas
   Tolstik, Elen
   Messinger, Jeffrey D.
   Zarubina, Anna V.
   Heintzmann, Rainer
   Curcio, Christine A.
TI Lipofuscin Redistribution and Loss Accompanied by Cytoskeletal Stress in
   Retinal Pigment Epithelium of Eyes With Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE AMD; lipofuscin; melanolipofuscin; autofluorescence; granule
ID OPTICAL COHERENCE TOMOGRAPHY; QUANTITATIVE FUNDUS AUTOFLUORESCENCE;
   HUMAN RPE; GEOGRAPHIC ATROPHY; OXIDATIVE STRESS; DRUSEN FORMATION;
   GRADING SYSTEM; BASAL DEPOSITS; CELL-DEATH; MODEL
AB PURPOSE. Lipofuscin (LF) and melanolipofuscin (MLF) of the retinal pigment epithelium (RPE) are the principal sources of autofluorescence (AF) signals in clinical fundus-AF imaging. Few details about the subcellular distribution of AF organelles in AMD are available. We describe the impact of aging and AMD on RPE morphology revealed by the distribution of AF LF/MLF granules and actin cytoskeleton in human tissues.
   METHODS. Thirty-five RPE-Bruch's membrane flatmounts from 35 donors were prepared (postmortem: <= 4 hours). Ex vivo fundus examination at the time of accession revealed either absence of chorioretinal pathologies (10 tissues; mean age: 83.0 +/- 2.6 years) or stages of AMD (25 tissues; 85.0 +/- 5.8 years): early AMD, geographic atrophy, and late exudative AMD. Retinal pigment epithelium cytoskeleton was labeled with AlexaFluor647-Phalloidin. Tissues were imaged on a spinning-disk fluorescence microscope and a high-resolution structured illumination microscope.
   RESULTS. Age-related macular degeneration impacts individual RPE cells by (1) lipofuscin redistribution by (i) degranulation (granule-by-granule loss) and/or (ii) aggregation and apparent shedding into the extracellular space; (2) enlarged RPE cell area and conversion from convex to irregular and sometimes concave polygons; and (3) cytoskeleton derangement including separations and breaks around subretinal deposits, thickening, and stress fibers.
   CONCLUSIONS. We report an extensive and systematic en face analysis of LF/MLF-AF in AMD eyes. Redistribution and loss of AF granules are among the earliest AMD changes and could reduce fundus AF signal attributable to RPE at these locations. Data can enhance the interpretation of clinical fundus-AF and provide a basis for future quantitative studies.
C1 [Ach, Thomas; Messinger, Jeffrey D.; Zarubina, Anna V.; Curcio, Christine A.] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL 35294 USA.
   [Ach, Thomas] Univ Hosp Wurzburg, Dept Ophthalmol, D-97080 Wurzburg, Germany.
   [Tolstik, Elen; Heintzmann, Rainer] Leibniz Inst Photon Technol, Jena, Germany.
   [Tolstik, Elen; Heintzmann, Rainer] Univ Jena, Inst Phys Chem, D-07743 Jena, Germany.
   [Tolstik, Elen; Heintzmann, Rainer] Univ Jena, Abbe Ctr Photon, D-07743 Jena, Germany.
   [Heintzmann, Rainer] Kings Coll London, Randall Div Cell & Mol Biophys, London, England.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Wurzburg; Leibniz Institut fur Photonische Technologien;
   Friedrich Schiller University of Jena; Friedrich Schiller University of
   Jena; University of London; King's College London
RP Ach, T (通讯作者)，Univ Hosp Wurzburg, Dept Ophthalmol, Josef Schneider Str 11, D-97080 Wurzburg, Germany.
EM ach_t@ukw.de
RI Ach, Thomas/AAE-7870-2021; Heintzmann, Rainer/AAY-4849-2020
OI Ach, Thomas/0000-0001-6583-8283; Heintzmann, Rainer/0000-0002-4950-1936;
   Tolstik, Dr. Elen/0000-0003-0873-4335
FU German Research Foundation (Bonn, Germany) DFG [AC265/1-1]; National
   Institutes of Health (Bethesda, MD, USA) [R01 EY06109]; NEI Grant [R01
   EY015520]; Research to Prevent Blindness (New York, NY, USA); EyeSight
   Foundation of Alabama (Birmingham, AL, USA); NATIONAL EYE INSTITUTE
   [R01EY006109, R01EY015520] Funding Source: NIH RePORTER
FX Supported by grants from the German Research Foundation (Bonn, Germany)
   DFG #AC265/1-1 (TA); National Institutes of Health (Bethesda, MD, USA)
   Grant R01 EY06109 (CAC); NEI Grant R01 EY015520 (R. Theodore Smith, MD,
   PhD, NY, USA); Research to Prevent Blindness (New York, NY, USA) (CAC);
   and the EyeSight Foundation of Alabama (Birmingham, AL, USA) (CAC).
CR Abbe E, 1873, ARCH MIKROSKOPISCHE, V9, P6
   Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Ach T, 2012, BRIT J OPHTHALMOL, V96, P1141, DOI 10.1136/bjophthalmol-2012-301547
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson M, 2006, VET OPHTHALMOL, V9, P201, DOI 10.1111/j.1463-5224.2006.00463.x
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   Burke JM, 2005, MOL INTERV, V5, P241, DOI 10.1124/mi.5.4.7
   Burke TR, 2014, INVEST OPHTH VIS SCI, V55, P2841, DOI 10.1167/iovs.13-13624
   Chen M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061381
   Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022818
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Delori F, 2011, INVEST OPHTH VIS SCI, V52, P9379, DOI 10.1167/iovs.11-8319
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Dorey K, 1993, RETINAL DEGENERATION, P3
   Double KL, 2008, CELL MOL LIFE SCI, V65, P1669, DOI 10.1007/s00018-008-7581-9
   Dubra A, 2011, BIOMED OPT EXPRESS, V2, P1864, DOI 10.1364/BOE.2.001864
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   FEENEYBURNS L, 1985, AM J OPHTHALMOL, V100, P686, DOI 10.1016/0002-9394(85)90625-7
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   FEENEYBURNS L, 1987, INVEST OPHTH VIS SCI, V28, P1138
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Galluzzi L, 2015, CELL DEATH DIFFER, V22, P58, DOI 10.1038/cdd.2014.137
   Gangalum RK, 2011, J BIOL CHEM, V286, P3261, DOI 10.1074/jbc.M110.160135
   Gouras P, 2011, EXP EYE RES, V93, P937, DOI 10.1016/j.exer.2011.10.011
   Gourlay CW, 2005, NAT REV MOL CELL BIO, V6, P583, DOI 10.1038/nrm1682
   Gray Douglas A, 2005, Sci Aging Knowledge Environ, V2005, pre1, DOI 10.1126/sageke.2005.5.re1
   Greenberg JP, 2013, INVEST OPHTH VIS SCI, V54, P5684, DOI 10.1167/iovs.13-12445
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   He LZ, 2014, AM J PATHOL, V184, P1660, DOI 10.1016/j.ajpath.2014.02.007
   Heintzmann R., 2006, CELL BIOL LAB HDB, V3, P29
   HERGOTT GJ, 1989, CELL MOTIL CYTOSKEL, V13, P83, DOI 10.1002/cm.970130203
   Ho TC, 2006, BIOCHEM BIOPH RES CO, V342, P372, DOI 10.1016/j.bbrc.2006.01.164
   Hoffmann EK, 2009, PHYSIOL REV, V89, P193, DOI 10.1152/physrev.00037.2007
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Holz F.G., 2007, ATLAS FUNDUS AUTOFLU, V1st ed.
   Hu P, 2013, P NATL ACAD SCI USA, V110, pE4069, DOI 10.1073/pnas.1307574110
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Katz ML, 2002, ARCH GERONTOL GERIAT, V34, P169, DOI 10.1016/S0167-4943(02)00005-5
   Keller JN, 2004, INT J BIOCHEM CELL B, V36, P2376, DOI 10.1016/j.biocel.2004.05.003
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33
   Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303
   Kim Y, 2014, P NATL ACAD SCI USA, V111, P16082, DOI 10.1073/pnas.1403814111
   Lakkaraju A, 2008, TRENDS CELL BIOL, V18, P199, DOI 10.1016/j.tcb.2008.03.002
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Mao HY, 2014, INVEST OPHTH VIS SCI, V55, P4613, DOI 10.1167/iovs.14-14633
   Mazzitello KI, 2009, PHYS REV E, V80, DOI 10.1103/PhysRevE.80.051908
   Mustafi D, 2011, FASEB J, V25, P3157, DOI 10.1096/fj.11-186767
   ORLOW SJ, 1995, J INVEST DERMATOL, V105, P3, DOI 10.1111/1523-1747.ep12312291
   Pellegrin S, 2007, J CELL SCI, V120, P3491, DOI 10.1242/jcs.018473
   Polyak S.L., 1941, RETINA ANATOMY HISTO
   Rape AD, 2011, BIOMATERIALS, V32, P2043, DOI 10.1016/j.biomaterials.2010.11.044
   Rossberger S, 2013, BRIT J OPHTHALMOL, V97, P518, DOI 10.1136/bjophthalmol-2012-302350
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Schraermeyer U, 1999, PIGM CELL RES, V12, P219, DOI 10.1111/j.1600-0749.1999.tb00755.x
   Scoles D, 2013, BIOMED OPT EXPRESS, V4, P1710, DOI 10.1364/BOE.4.001710
   Seehafer SS, 2006, NEUROBIOL AGING, V27, P576, DOI 10.1016/j.neurobiolaging.2005.12.006
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Sreekumar PG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012578
   Sulzer D, 2008, J NEUROCHEM, V106, P24, DOI 10.1111/j.1471-4159.2008.05385.x
   Sweigard JH, 2011, GENE THER, V18, P613, DOI 10.1038/gt.2011.6
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Thanos A, 2012, AM J PATHOL, V180, P1917, DOI 10.1016/j.ajpath.2012.01.017
   Tojkander S, 2012, J CELL SCI, V125, P1855, DOI 10.1242/jcs.098087
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3269, DOI 10.1167/iovs.15-16432
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
NR 89
TC 114
Z9 114
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2015
VL 56
IS 5
BP 3242
EP 3252
DI 10.1167/iovs.14-16274
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CK7UJ
UT WOS:000356439200059
PM 25758814
OA Green Published
DA 2022-11-30
ER

PT J
AU Uppal, G
   Feely, MP
   Crossland, MD
   Membrey, L
   Lee, J
   da Cruz, L
   Rubin, GS
AF Uppal, Gurmit
   Feely, Mary P.
   Crossland, Michael D.
   Membrey, Luke
   Lee, John
   da Cruz, Lyndon
   Rubin, Gary S.
TI Assessment of Reading Behavior with an Infrared Eye Tracker after 360
   degrees Macular Translocation for Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; FIXATION STABILITY; VISUAL
   FUNCTION; HUMAN RETINA; CLINICOPATHOLOGICAL CORRELATION; PERIPHERAL
   RETINECTOMY; LOW-VISION; DISEASE; RETINOTOMY; SENSITIVITY
AB PURPOSE. Macular translocation (MT360) is complex surgery used to restore reading in exudative age-related macular degeneration (AMD). MT360 involves retinal rotation and subsequent oculomotor globe counterrotation and is not without significant surgical risk. This study attempts to gauge the optimal potential of MT360 in restoring reading ability and describe the quality and extent of recovery.
   METHODS. The six best outcomes were examined from a consecutive series of 23 MT360 cases. Reading behavior and fixation characteristics were examined with an infrared eye tracker. Results were compared to age-matched normal subjects and patients with untreated exudative and nonexudative AMD. Retinal sensitivity was examined with microperimetry to establish threshold visual function.
   RESULTS. MT360 produced significant improvements in visual function over untreated disease and approximated normal function for reading speed and fixation quality. Relative to the comparative groups, eye tracking revealed the MT360 cohort generated a greater number of horizontal and vertical saccades, of longer latency and reduced velocity. In contrast, saccadic behavior when reading (forward and regressive saccades) closely matched normal function. Microperimetry revealed a reduction in the central scotoma with three patients recovering normal foveal sensitivity.
   CONCLUSIONS. Near normal reading function is recovered despite profound surgical disruption to the anatomy (retinal/oculomotor). MT360 restores foveal function sufficient to produce a single stable locus of fixation, with marked reduction of the central scotoma. Despite the limitations on saccadic function, the quality of reading saccadic behavior is maintained with good reading ability. Oculomotor surgery appears not to limit reading ability, and the results of retinal surgery approximate normal macular function. (Invest Ophthalmol Vis Sci. 2011; 52: 6486-6496) DOI: 10.1167/iovs.10-5879
C1 [Uppal, Gurmit; Feely, Mary P.; Crossland, Michael D.; Membrey, Luke; Lee, John; da Cruz, Lyndon] Moorfields Eye Hosp, London EC1V, England.
   [Uppal, Gurmit; Feely, Mary P.; Crossland, Michael D.; da Cruz, Lyndon; Rubin, Gary S.] Inst Ophthalmol, London, England.
   [Rubin, Gary S.] Biomed Res Ctr Ophthalmol, London, England.
C3 University of London; University College London; University of London;
   University College London
RP Uppal, G (通讯作者)，Moorfields Eye Hosp, 162 City Rd, London EC1V, England.
EM gurmit.uppal@moorfields.nhs.uk
RI Crossland, Michael D/B-5600-2008
OI Crossland, Michael D/0000-0001-6833-6043
FU Moorfields Eye Hospital
FX Supported by the Special Trustees of Moorfields Eye Hospital.
CR Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Bellmann C, 2004, OPHTHALMOLOGY, V111, P2265, DOI 10.1016/j.ophtha.2004.06.019
   BOULTON M, 1994, BRIT J OPHTHALMOL, V78, P125, DOI 10.1136/bjo.78.2.125
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   BRESSLER SB, 1992, ARCH OPHTHALMOL-CHIC, V110, P827, DOI 10.1001/archopht.1992.01080180099035
   Crossland MD, 2006, VISION RES, V46, P590, DOI 10.1016/j.visres.2005.05.015
   Crossland MD, 2005, OPTOMETRY VISION SCI, V82, P11
   Crossland MD, 2004, OPHTHAL PHYSL OPT, V24, P327, DOI 10.1111/j.1475-1313.2004.00213.x
   Crossland MD, 2002, OPTOMETRY VISION SCI, V79, P735, DOI 10.1097/00006324-200211000-00011
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   Crossland MD, 2004, VISION RES, V44, P1537, DOI 10.1016/j.visres.2004.01.006
   CULHAM LE, 1993, CLIN VISION SCI, V8, P551
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   DELAPAZ M, 1992, INVEST OPHTH VIS SCI, V33, P3497
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Eckardt C, 2002, RETINA-J RET VIT DIS, V22, P786, DOI 10.1097/00006982-200212000-00017
   EISNER A, 1987, INVEST OPHTH VIS SCI, V28, P1832
   Elliott DB, 1997, INVEST OPHTH VIS SCI, V38, P2566
   Fujikado T, 2002, AM J OPHTHALMOL, V134, P849, DOI 10.1016/S0002-9394(02)01756-7
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Green W R, 1999, Mol Vis, V5, P27
   Hazel CA, 2000, INVEST OPHTH VIS SCI, V41, P1309
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jackson GR, 1998, VISION RES, V38, P3655, DOI 10.1016/S0042-6989(98)00044-3
   Lai JC, 2002, ARCH OPHTHALMOL-CHIC, V120, P1317, DOI 10.1001/archopht.120.10.1317
   LEGGE GE, 1985, VISION RES, V25, P253, DOI 10.1016/0042-6989(85)90118-X
   LEGGE GE, 1992, INVEST OPHTH VIS SCI, V33, P677
   Luke C, 2003, GRAEF ARCH CLIN EXP, V241, P710, DOI 10.1007/s00417-003-0709-6
   Luke C, 2001, BRIT J OPHTHALMOL, V85, P928, DOI 10.1136/bjo.85.8.928
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P629, DOI 10.1007/BF00921956
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   MCMAHON TT, 1991, INVEST OPHTH VIS SCI, V32, P567
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   MIDENA E, 1994, DOC OPHTHALMOL, V88, P179, DOI 10.1007/BF01204616
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   Pertile G, 2002, AM J OPHTHALMOL, V134, P560, DOI 10.1016/S0002-9394(02)01641-0
   Rohrschneider K, 1995, Ger J Ophthalmol, V4, P197
   RUBIN GS, 1994, OPTOMETRY VISION SCI, V71, P750, DOI 10.1097/00006324-199412000-00005
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SUNNESS JS, 1985, ARCH OPHTHALMOL-CHIC, V103, P811
   SUNNESS JS, 1988, ARCH OPHTHALMOL-CHIC, V106, P1081, DOI 10.1001/archopht.1988.01060140237032
   TIMBERLAKE GT, 1986, INVEST OPHTH VIS SCI, V27, P1137
   Toth CA, 2004, GRAEF ARCH CLIN EXP, V242, P541, DOI 10.1007/s00417-004-0867-1
   Uppal G, 2007, CLIN EXP OPHTHALMOL, V35, P448, DOI 10.1111/j.1442-9071.2007.01528.x
   VANDERSCHAFT TL, 1993, GRAEF ARCH CLIN EXP, V231, P470, DOI 10.1007/BF02044234
   Varano M, 1998, Semin Ophthalmol, V13, P203, DOI 10.3109/08820539809056054
   WHITE JM, 1990, INVEST OPHTH VIS SCI, V31, P1149
   WHITTAKER SG, 1993, OPTOMETRY VISION SCI, V70, P54, DOI 10.1097/00006324-199301000-00010
   WHITTAKER SG, 1991, VISION RES, V31, P2209, DOI 10.1016/0042-6989(91)90173-3
NR 52
TC 7
Z9 7
U1 0
U2 9
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2011
VL 52
IS 9
BP 6486
EP 6496
DI 10.1167/iovs.10-5879
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 815SI
UT WOS:000294548300018
PM 21596822
DA 2022-11-30
ER

PT J
AU Yang, WZ
   Song, CY
   Gao, M
   Wang, SN
   Yu, HN
   Li, Y
AF Yang, Weizhou
   Song, Chunyuan
   Gao, Meng
   Wang, Shuna
   Yu, Haonan
   Li, Yan
TI Effects of smoking on the retina of patients with dry age-related
   macular degeneration by optical coherence tomography angiography
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Optical coherence tomography angiography; Dry age-related macular
   degeneration; Smoking; Retina; Retinal vessel density
ID CIGARETTE-SMOKING; QUANTIFICATION; MACULOPATHY; THICKNESS; NICOTINE;
   DENSITY; SIGNS
AB Background The macula of the retina is analysed using optical coherence tomography angiography (OCTA) to provide clinical basis and explain the mechanism of smoking as a risk factor in dry age-related macular degeneration (AMD). Methods This cross-sectional study included 49 normal control nonsmokers, 12 normal control smokers, 38 dry AMD nonsmokers and 35 dry AMD smokers. The foveal avascular zone (FAZ), foveal density (FD) in a 300 mu m region around FAZ, vessel densities of the superficial (SCP) and deep (DCP) capillary plexuses and central fovea retinal thickness (FRT) were compared using OCTA. The bivariate correlation analysis was used to evaluate the effect of pack-year history on retina-related indices. Results The vessel densities of whole, foveal and parafoveal of SCP and whole and parafoveal of DCP in the control nonsmoking group were all significantly higher than those in the dry AMD nonsmoking group (all P < 0.05), whereas the whole vessel density of SCP in the normal smoking group was higher than that in the dry AMD smoking group (P = 0.04). The thickness values of the inner and full-layer FRT in the normal nonsmoking group were significantly thicker than those in the dry AMD nonsmoking group (all P < 0.01). The pack-year history was negatively correlated with the parafoveal vessel density of DCP (r = - 0.224, P < 0.01). Conclusions FD, SCP, DCP and FRT are sensitive indices for the detection of early and intermediate dry AMD. DCP is a sensitive indicator that reflects the effects of smoking on the retina. Considerable changes are observed in retinal vessels, suggesting that dry AMD may affect the retinal tissue to a certain extent.
C1 [Yang, Weizhou; Song, Chunyuan; Gao, Meng; Wang, Shuna; Yu, Haonan; Li, Yan] Weifang Med Univ, Ctr Eye, Affiliated Hosp, 288 Shengli East St, Weifang 261035, Peoples R China.
C3 Weifang Medical University
RP Li, Y (通讯作者)，Weifang Med Univ, Ctr Eye, Affiliated Hosp, 288 Shengli East St, Weifang 261035, Peoples R China.
EM liyanmails@126.com
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Alten F, 2017, GRAEF ARCH CLIN EXP, V255, P2347, DOI 10.1007/s00417-017-3813-8
   Arya M, 2018, EYE VISION, V5, DOI 10.1186/s40662-018-0118-x
   BOOYSE FM, 1981, AM J PATHOL, V102, P229
   Ciloglu E, 2020, J CURR OPHTHALMOL, V32, P53, DOI 10.1016/j.joco.2019.09.002
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD182, DOI 10.1167/iovs.18-24883
   Dervisogullan MS, 2015, CUTAN OCUL TOXICOL, V34, P217, DOI 10.3109/15569527.2014.950380
   Durbin MK, 2017, JAMA OPHTHALMOL, V135, P370, DOI 10.1001/jamaophthalmol.2017.0080
   Febo MD, 2020, CLIN EXP OPTOM, V103, P838, DOI 10.1111/cxo.13070
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Forshaw TRJ, 2021, ACTA OPHTHALMOL, V99, pE253, DOI 10.1111/aos.14571
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Gozlan J, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006427
   Jia YL, 2015, P NATL ACAD SCI USA, V112, pE2395, DOI 10.1073/pnas.1500185112
   Krupski W C, 1991, Ann Vasc Surg, V5, P291, DOI 10.1007/BF02329389
   Lee B, 2018, INVEST OPHTH VIS SCI, V59, P5246, DOI 10.1167/iovs.17-23600
   Lee SC, 2020, AM J OPHTHALMOL, V212, P7, DOI 10.1016/j.ajo.2019.11.031
   Liew G, 2006, OPHTHALMOLOGY, V113, P1481, DOI 10.1016/j.ophtha.2006.03.051
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moschos MM, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/2905789
   Nakahara T, 2015, EXP EYE RES, V135, P134, DOI 10.1016/j.exer.2015.02.020
   Orellana-Rios J, 2018, OSLI RETINA, V49, pS34, DOI 10.3928/23258160-20180814-06
   QUILLEN JE, 1993, J AM COLL CARDIOL, V22, P642, DOI 10.1016/0735-1097(93)90170-6
   Rogala J, 2015, INVEST OPHTH VIS SCI, V56, P1689, DOI 10.1167/iovs.14-16221
   Shin YI, 2020, OPHTHALMOLOGICA, V243, P145, DOI 10.1159/000503295
   Somasundaran S, 2020, CLIN EXP OPHTHALMOL, V48, P1043, DOI 10.1111/ceo.13834
   Stavrev V., 2018, OPEN J OPHTHALMOL, V8, P133, DOI [10.4236/ojoph.2018.83017, DOI 10.4236/OJOPH.2018.83017]
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Wang JJ, 2004, BRIT J OPHTHALMOL, V88, P104, DOI 10.1136/bjo.88.1.104
   Wei X, 2019, INVEST OPHTH VIS SCI, V60, P1316, DOI 10.1167/iovs.18-25764
   Wong SS, 2017, AM J OPHTHALMOL, V184, P108, DOI 10.1016/j.ajo.2017.10.005
   Yang K, 2012, GRAEF ARCH CLIN EXP, V250, P741, DOI 10.1007/s00417-011-1824-4
   ZIMMERMAN M, 1987, ATHEROSCLEROSIS, V63, P33, DOI 10.1016/0021-9150(87)90079-7
NR 34
TC 0
Z9 0
U1 3
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JUL 22
PY 2022
VL 22
IS 1
AR 315
DI 10.1186/s12886-022-02525-5
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3D1AF
UT WOS:000829042700001
PM 35869464
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Mruthyunjaya, P
   Stinnett, SS
   Toth, CA
AF Mruthyunjaya, P
   Stinnett, SS
   Toth, CA
TI Impact of fluorescein angiographic characteristics of macular lesions on
   outcomes after macular translocation 360 degrees surgery in eyes with
   age-related macular degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration (AMD); choroidal neovascularization
   (CNV); classic CNV; fluorescein angiography; lesion size; lesion
   composition; macular translocation; occult CNV; photodynamic therapy;
   retinal rotation; retinal surgery; subretinal hemorrhage
ID CHOROIDAL NEOVASCULARIZATION SECONDARY; PERIPHERAL RETINECTOMY;
   VERTEPORFIN; RETINOTOMY; THERAPY; SIZE; TAP
AB Purpose: To evaluate the relationship between preoperative lesion size and composition and visual outcomes at 1 year after macular translocation surgery with 360 degrees peripheral retinectomy (MT360) for neovascular age-related macular degeneration (AMD).
   Methods: A prospective, interventional, consecutive, noncomparative case series of 64 patients with bilateral neovascular AMD treated with MT360 in the eye with more recent vision loss. Masked reviewers graded preoperative fluorescein angiograms for lesion size in Macular Photocoagulation Study disk areas (MPS DAs) and predominant lesion composition (classic or occult choroidal neovascularization or subretinal hemorrhage). Median changes in distance and near visual acuities and reading speed at 12 months after surgery were analyzed with respect to lesion size and composition.
   Results: There was no significant difference between the outcomes for small-, medium- or large-sized preoperative lesions. Patients in each predominant lesion composition group had median improvement in visual outcomes with significant improvement in near visual acuity and reading speed for predominantly classic and occult lesions.
   Conclusion: MT360 stabilizes or improves visual function in patients with neovascular AMD irrespective of lesion size categories and with a variety of lesion compositions. Removal of the subretinal lesion and repositioning of the fovea over a healthier retinal pigment epithelial bed may account for these improvements.
C1 Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC 27710 USA.
   Duke Univ, Dept Biomed Engn, Durham, NC 27710 USA.
C3 Duke University; Duke University; Duke University
RP Toth, CA (通讯作者)，Duke Univ, Ctr Eye, Box 3802 Erwin Rd, Durham, NC 27710 USA.
EM toth0004@mc.duke.edu
RI Toth, Cynthia/L-5534-2019; toth, cynthia a/F-5614-2011
OI Toth, Cynthia/0000-0002-2324-0854; Stinnett, Sandra/0000-0001-7192-0195;
   mruthyunjaya, prithvi/0000-0003-1087-9736
FU NEI NIH HHS [EY 11725] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [R21EY011725] Funding Source: NIH RePORTER
CR Abdel-Meguid A, 2003, BRIT J OPHTHALMOL, V87, P615, DOI 10.1136/bjo.87.5.615
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2000, ARCH OPHTHALMOL-CHIC, V118, P488
   Ergun E, 2003, OPHTHALMOLOGY, V110, P65, DOI 10.1016/S0161-6420(02)01566-X
   *GROUP TOA RMDWPTT, 1999, ARCH OPHTHALMOL-CHIC, V1117, P1329
   Kent DL, 2003, RETINA-J RET VIT DIS, V23, P152, DOI 10.1097/00006982-200304000-00003
   Lai JC, 2002, ARCH OPHTHALMOL-CHIC, V120, P1317, DOI 10.1001/archopht.120.10.1317
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   Machemer R, 1998, AM J OPHTHALMOL, V125, P698, DOI 10.1016/S0002-9394(98)00020-8
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   *SUBM SURG TRIALS, 1998, SST MAN PROC
   Toth CA, 2001, RETINA-J RET VIT DIS, V21, P293, DOI 10.1097/00006982-200108000-00001
   TOTH CA, 2004, IN PRESS GRAEFES ARC
NR 14
TC 12
Z9 12
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL-AUG
PY 2005
VL 25
IS 5
BP 597
EP 607
DI 10.1097/00006982-200507000-00010
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 008AO
UT WOS:000235012800010
PM 16077357
DA 2022-11-30
ER

PT J
AU Minassian, DC
   Reidy, A
   Lightstone, A
   Desai, P
AF Minassian, Darwin C.
   Reidy, Angela
   Lightstone, Anita
   Desai, Parul
TI Modelling the prevalence of age-related macular degeneration (2010-2020)
   in the UK: expected impact of anti-vascular endothelial growth factor
   (VEGF) therapy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VISUAL IMPAIRMENT; OLDER-PEOPLE; ADD-ON; MACULOPATHY; RANIBIZUMAB;
   MANAGEMENT; COMMUNITY; BRITAIN; TRIAL
AB Aims To project the number of cases with age-related macular degeneration (AMD) and the numbers with attributable sight loss in the UK in 2010-2020, taking into account the expected beneficial effect of the new anti-vascular endothelial growth factor (VEGF) therapies.
   Methods A 'system dynamics' approach was used in constructing the model to simulate the dynamics of the disease in large populations. The model computed the pool of affected cases over the simulation period, taking into account the expected demographic changes. Other determinants taken into account included: prevalence; incidence; mortality; and the expected efficacy and coverage of anti-VEGF treatment.
   Results In the UK, 608 213 persons in 2010 are estimated to have AMD, and this is expected to increase to 755 867 by the end of the decade. Numbers with sight loss from AMD are expected to rise from 223 224 in 2010 to 291 982 by 2020. Cases with sight loss due to neovascular AMD are expected to increase from 145 697 to 189 890 by the end of the decade.
   Conclusions The model predicts that the beneficial effects of the treatment would be outweighed by the strong anticipated demographic 'ageing' effect. This reaffirms the importance of continuing efforts to develop more effective and more broadly applicable therapies for AMD.
C1 [Minassian, Darwin C.] UCL, Inst Ophthalmol, Div Epidemiol & Genet, London EC1V 9EL, England.
   [Reidy, Angela] London Metropolitan Univ, Dept Appl Social Studies, London, England.
   [Lightstone, Anita] UK Vis Strategy Royal Natl Inst Blind People, London, England.
   [Desai, Parul] Moorfields Eye Hosp, London, England.
C3 University of London; University College London; London Metropolitan
   University; University of London; University College London; Moorfields
   Eye Hospital NHS Foundation Trust
RP Minassian, DC (通讯作者)，UCL, Inst Ophthalmol, Div Epidemiol & Genet, Bath St, London EC1V 9EL, England.
EM d.minassian@ucl.ac.uk
FU Royal National Institute of Blind People (RNIB)
FX The study was funded by the Royal National Institute of Blind People
   (RNIB).
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRAILSFORD SC, 2008, P 2008 WINT SIM C WI
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Bunce C, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-58
   Elandt-Johnson RC., 1980, SURVIVAL MODELS DATA
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   Evans JR, 2004, BRIT J OPHTHALMOL, V88, P365, DOI 10.1136/bjo.2003.019927
   Forrester J.W., 1961, IND DYNAMICS
   Forrester JW., 1960, COLLECTED PAPERS JAY, P45
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   National Institute for Health and Clinical Excellence, 2008, NICE TECHN APPR GUID
   *OPHTH SCI COMM RO, 2008, RAN CLIN GUID COMM C
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Smith AF, 2010, BRIT J OPHTHALMOL, V94, P1116, DOI 10.1136/bjo.2010.179945
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   WOLSTENHOLME EF, 1990, SYSTEM ENQUIRY SYSTE, P1
NR 19
TC 47
Z9 47
U1 0
U2 20
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2011
VL 95
IS 10
BP 1433
EP 1436
DI 10.1136/bjo.2010.195370
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 822VL
UT WOS:000295078000021
PM 21317425
DA 2022-11-30
ER

PT J
AU Rufai, SR
   Almuhtaseb, H
   Paul, RM
   Stuart, BL
   Kendrick, T
   Lee, H
   Lotery, AJ
AF Rufai, S. R.
   Almuhtaseb, H.
   Paul, R. M.
   Stuart, B. L.
   Kendrick, T.
   Lee, H.
   Lotery, A. J.
TI A systematic review to assess the 'treat-and-extend' dosing regimen for
   neovascular age-related macular degeneration using ranibizumab
SO EYE
LA English
DT Review
ID PROSPECTIVE TRIAL; VERTEPORFIN; PREVALENCE; OUTCOMES; THERAPY; EYE
AB Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed world. Monthly or as-needed (PRN) dosing strategies of intravitreal ranibizumab have been established as efficacious treatment options for neovascular AMD. More recently, the 'treat-and-extend' dosing regimen (TREX) is being adopted in clinical practice as it represents a patient-centric and economical option, reducing treatment burden by extending injection intervals when possible. However, the efficacy of TREX using ranibizumab monotherapy remains to be defined. Therefore, we performed a systematic review to assess the current evidence for TREX using ranibizumab by searching MEDLINE, Embase and PubMed. Of the 1733 articles identified, nine TREX studies were included in our analysis (n = 748 eyes). Average patient age was 79.25 (range: 77.34-82.00; SD: 7.27). Baseline BCVA ranged from 48.5-68.9 ETDRS letters. BCVA improvement was 8.92 letters at 1 year (range: 6.5-11.5; SD: 7.54), as a weighted mean accounting for numbers of study eyes. The weighted mean number of injections at one year was 8.60 (range: 7.3-12.0; SD: 1.73). Previously, the landmark ANCHOR and MARINA trials reported gains of 11.3 and 7.2 letters, respectively, using monthly ranibizumab. Chin-Yee et al reported a gain of 3.5 ETDRS letters with 5.3 (S.D. 0.66) PRN ranibizumab injections as weighted means at 1 year in their recent systematic review. Our analysis suggests that TREX delivers visual outcomes superior to PRN and approaches similar efficacy to monthly injections. Further RCTs are needed to fully evaluate the efficacy and economy of TREX in the long-term.
C1 [Rufai, S. R.; Almuhtaseb, H.; Paul, R. M.; Stuart, B. L.; Kendrick, T.; Lee, H.; Lotery, A. J.] Univ Southampton, Fac Med, Southampton, Hants, England.
   [Rufai, S. R.; Almuhtaseb, H.; Lee, H.; Lotery, A. J.] Univ Hosp Southampton, Southampton Eye Unit, Tremona Rd, Southampton SO16 6YD, Hants, England.
C3 University of Southampton
RP Lotery, AJ (通讯作者)，Univ Hosp Southampton, Southampton Eye Unit, Tremona Rd, Southampton SO16 6YD, Hants, England.
EM A.J.Lotery@soton.ac.uk
RI Rufai, Sohaib/ABA-4740-2020; Kendrick, Tony/H-8558-2014
OI Rufai, Sohaib/0000-0001-8134-6393; Stuart, Beth/0000-0001-5432-7437;
   Kendrick, Tony/0000-0003-1618-9381; Lee, Helena/0000-0002-2573-9536;
   Lotery, Andrew/0000-0001-5541-4305; Paul, Richard/0000-0002-3480-5232
FU UK National Institute for Health Research (NIHR) Academic Foundation; UK
   NIHR Academic Clinical Lectureship in ophthalmology; National Institute
   for Health Research [ACF-2016-11-001, CL-2014-26-003, NF-SI-0515-10020]
   Funding Source: researchfish
FX We thank the authors of the included studies for providing further data
   where required for our study. SRR was supported by a UK National
   Institute for Health Research (NIHR) Academic Foundation post supervised
   by TK and BLS. HL was supported by a UK NIHR Academic Clinical
   Lectureship in ophthalmology.
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   [Anonymous], 2011, COCHRANE HDB SYSTEMA
   [Anonymous], 2012, VISION 2020 AMD SERV
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bowling B., 2015, CORNEA CLIN OPHTHALM, V8th
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Calvo P, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/820605
   Chen GH, 2015, RETINA-J RET VIT DIS, V35, P187, DOI 10.1097/IAE.0000000000000301
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   European Medicines Agency (EMA), LUC 10 MG ML SOL INJ
   Ferrara N, 2009, EUR CYTOKINE NETW, V20, P158, DOI 10.1684/ecn.2009.0170
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Mrejen S, 2015, J CLIN MED, V4, P1380, DOI 10.3390/jcm4071380
   NHS England and NHS Improvement, NHS NAT TAR PAYM SYS
   NICE, GUID SCOP AG REL MAC
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Oxford Centre for Evidence-Based Medicine, LEVELS EVIDENCE
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Shalaby AK, 2016, EYE, V30, P1404, DOI 10.1038/eye.2016.154
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 36
TC 41
Z9 44
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD SEP
PY 2017
VL 31
IS 9
SI SI
BP 1337
EP 1344
DI 10.1038/eye.2017.67
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FG7JZ
UT WOS:000410594600013
PM 28475181
OA Green Accepted, Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Miyake, M
   Yamashiro, K
   Tamura, H
   Kumagai, K
   Saito, M
   Sugahara-Kuroda, M
   Yoshikawa, M
   Oishi, M
   Akagi-Kurashige, Y
   Nakata, I
   Nakanishi, H
   Gotoh, N
   Oishi, A
   Matsuda, F
   Yamada, R
   Khor, CC
   Kurimoto, Y
   Sekiryu, T
   Tsujikawa, A
   Yoshimura, N
AF Miyake, Masahiro
   Yamashiro, Kenji
   Tamura, Hiroshi
   Kumagai, Kyoko
   Saito, Masaaki
   Sugahara-Kuroda, Masako
   Yoshikawa, Munemitsu
   Oishi, Maho
   Akagi-Kurashige, Yumiko
   Nakata, Isao
   Nakanishi, Hideo
   Gotoh, Norimoto
   Oishi, Akio
   Matsuda, Fumihiko
   Yamada, Ryo
   Khor, Chiea-Chuen
   Kurimoto, Yasuo
   Sekiryu, Tetsuju
   Tsujikawa, Akitaka
   Yoshimura, Nagahisa
TI The Contribution of Genetic Architecture to the 10-Year Incidence of
   Age-Related Macular Degeneration in the Fellow Eye
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; genetics; second-eye involvement;
   bilateral AMD
ID COMPLEMENT FACTOR-H; GENOME-WIDE ASSOCIATION; RISK-FACTORS; CHOROIDAL
   NEOVASCULARIZATION; SUSCEPTIBILITY; POLYMORPHISM; VARIANTS; PREVALENCE;
   LOCI; BILATERALITY
AB PURPOSE. To correlate a genetic risk score based on age-related macular degeneration (AMD) susceptibility genes with the risk of AMD in the second eye.
   METHODS. This is a retrospective, open cohort study consisting of 891 unilateral AMD patients, who were followed for at least 12 months and recruited from three institutes. DNAs were genotyped using Illumina OmniExpress, HumanOmni2.5-8, and/or HumanExome. Survival analyses and Cox proportional hazard models were used to examine the association between 11 AMD susceptibility genes and the duration until second-eye involvement in 499 samples from Kyoto University, which were replicated in two other cohorts. Genetic risk score (GRS) was also evaluated.
   RESULTS. The ARMS2 rs10490924 recessive model (hazard ratio [HR](meta) = 2.04; P-meta = 3.4 x 10(-3)) and CFH rs800292 additive model (HRmeta = 1.77; P-meta = 0.013) revealed significant associations with second-eye involvement. The dominant model of TNFRSF10A rs13278062, VEGFA rs943080, and CFI rs4698775 showed consistent effects across three datasets (I-2 = 0%; HRmeta = 1.46, 1.30, 1.51, respectively). The GRS using these five single nucleotide polymorphisms (SNPs) was also significantly associated (HRmeta [per score] = 2.42; P = 2.2 x 10(-5); I-2 = 0%). After 10 years from the first visit, the patients within the top 10% by GRS showed a 51% hazard rate, in contrast to 2.3% among patients within the lowest 10% by GRS.
   CONCLUSIONS. We demonstrated that the GRS using ARMS2, CFH, TNFRSF10A, VEGFA, and CFI was significantly associated with second-eye involvement. Genetic risk has high predictive ability for second-eye involvement of AMD.
C1 [Miyake, Masahiro; Yamashiro, Kenji; Tamura, Hiroshi; Kumagai, Kyoko; Sugahara-Kuroda, Masako; Yoshikawa, Munemitsu; Oishi, Maho; Akagi-Kurashige, Yumiko; Nakanishi, Hideo; Gotoh, Norimoto; Oishi, Akio; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto 6068507, Japan.
   [Miyake, Masahiro; Yoshikawa, Munemitsu; Akagi-Kurashige, Yumiko; Gotoh, Norimoto; Matsuda, Fumihiko; Yamada, Ryo] Kyoto Univ, Grad Sch Med, Ctr Genom Med, Kyoto 6068507, Japan.
   [Saito, Masaaki; Sekiryu, Tetsuju] Fukushima Med Univ, Dept Ophthalmol, Fukushima, Japan.
   [Nakata, Isao] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
   [Oishi, Akio; Kurimoto, Yasuo] Kobe City Med Ctr Gen Hosp, Kobe, Hyogo, Japan.
   [Khor, Chiea-Chuen] Genome Inst Singapore, Div Human Genet, Singapore, Singapore.
   [Tsujikawa, Akitaka] Kagawa Univ, Dept Ophthalmol, Takamatsu, Kagawa 760, Japan.
C3 Kyoto University; Kyoto University; Fukushima Medical University;
   Harvard University; Massachusetts Eye & Ear Infirmary; Kobe City Medical
   Center General Hospital; Agency for Science Technology & Research
   (A*STAR); A*STAR - Genome Institute of Singapore (GIS); Kagawa
   University
RP Yamashiro, K (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Kawahara, Kyoto 6068507, Japan.
EM yamashro@kuhp.kyoto-u.ac.jp
RI Oishi, Akio/AAE-9996-2020; Saito, Masaaki/ABI-2783-2020; TAMURA,
   Hiroshi/H-1855-2011; Miyake, Masahiro/V-1261-2019
OI Oishi, Akio/0000-0002-0977-9458; Saito, Masaaki/0000-0003-1494-6350;
   TAMURA, Hiroshi/0000-0002-7740-2732; Miyake,
   Masahiro/0000-0001-7410-3764; Yamashiro, Kenji/0000-0001-9354-8558;
   Khor, Chiea Chuen/0000-0002-1128-4729; Sekiryu,
   Tetsuju/0000-0001-8042-2729; Yamada, Ryo/0000-0002-1587-630X; Tsujikawa,
   Akitaka/0000-0003-0779-7799
CR Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Chen HY, 2008, VISION RES, V48, P690, DOI 10.1016/j.visres.2007.10.014
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Clemons Traci E, 2005, Ophthalmology, V112, P533
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hata M, 2015, GRAEF ARCH CLIN EXP, V253, P221, DOI 10.1007/s00417-014-2688-1
   Islam FMA, 2014, OPHTHALMOLOGY, V121, P1428, DOI 10.1016/j.ophtha.2014.01.002
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kawashima Y, 2015, GRAEF ARCH CLIN EXP, V253, P1471, DOI 10.1007/s00417-014-2838-5
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Leveziel N, 2010, INVEST OPHTH VIS SCI, V51, P2620, DOI 10.1167/iovs.09-4423
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Miyake M, 2014, INVEST OPHTH VIS SCI, V55, P3223, DOI 10.1167/iovs.14-14059
   Nakata I, 2013, INVEST OPHTH VIS SCI, V54, P6068, DOI 10.1167/iovs.13-11605
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P6576, DOI 10.1167/iovs.12-10219
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P794, DOI 10.1167/iovs.11-8468
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Pai ASI, 2009, ARCH OPHTHALMOL-CHIC, V127, P1339, DOI 10.1001/archophthalmol.2009.239
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1598
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010
   Schwartz SG, 2012, RETINA-J RET VIT DIS, V32, P1486, DOI 10.1097/IAE.0b013e318240a540
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Tamura H, 2012, AM J OPHTHALMOL, V154, P542, DOI 10.1016/j.ajo.2012.03.042
   Tedeschi-Blok N, 2007, OPHTHALMOLOGY, V114, P99, DOI 10.1016/j.ophtha.2006.07.043
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Wang JJ, 2014, OPHTHALMOLOGY, V121, P667, DOI 10.1016/j.ophtha.2013.10.017
   Yanagisawa S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028847
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Yuzawa Mitsuko, 2004, Nippon Ganka Gakkai Zasshi, V108, P368
NR 47
TC 9
Z9 10
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2015
VL 56
IS 9
BP 5353
EP 5361
DI 10.1167/iovs.14-16020
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CT5WW
UT WOS:000362882800042
PM 26275133
DA 2022-11-30
ER

PT J
AU Poku, E
   Brazier, J
   Carlton, J
   Ferreira, A
AF Poku, Edith
   Brazier, John
   Carlton, Jill
   Ferreira, Alberto
TI Health state utilities in patients with diabetic retinopathy, diabetic
   macular oedema and age-related macular degeneration: a systematic review
SO BMC OPHTHALMOLOGY
LA English
DT Review
DE Health utility; Visual acuity; Diabetic retinopathy; Age-related macular
   degeneration
ID QUALITY-OF-LIFE; VISUAL FUNCTION QUESTIONNAIRE; PREFERENCE-BASED
   MEASURES; TIME TRADE-OFF; STANDARD GAMBLE; IMPACT; VALUES;
   CLASSIFICATION; VALIDITY; TYPE-1
AB Background: Health state utility values (HSUVs) are important in the assessment of the cost effectiveness of new interventions. In the case of visual conditions, models generally tend have tended to be built around a set of health states defined by visual acuity (VA). The aim of this review was to assess the impact of VA on HSUVs in patients with diabetic retinopathy, diabetic macular oedema or age-related macular degeneration.
   Methods: A systematic literature search was undertaken in major bibliographic databases to identify articles reporting on the relationship between HSUVs and vision. Data were extracted for population characteristics, visual levels and estimated utilities. Evidence from reported statistical models, where available, was considered in the evaluation of vision in the better-seeing eye and the worse-seeing eye. Due to the heterogeneity of included studies, a narrative synthesis was undertaken.
   Results: Of the 17 relevant studies, 9 studies had data that could be used in the analysis of the impact of vision on HSUVs. Visual loss was associated with a marked impact on health utilities. However, the relationship was not comparable between conditions or by measure of HSUVs. Key results included the finding that overall, self-rated time-trade off estimates were more likely to discriminate between different VA levels than EQ-5D values. Additionally, a stronger correlation was observed between HSUVs and better-seeing eye VA compared to worse-seeing eye VA.
   Conclusions: Visual acuity has a significant impact on HSUVs. Nevertheless, care must be taken in the interpretation and use of estimates in cost-effectiveness models due to differences in measures and population diversity.
C1 [Poku, Edith; Brazier, John; Carlton, Jill] Univ Sheffield, Sch Hlth & Related Res, 30 Regent Court, Sheffield S1 2DA, S Yorkshire, England.
   [Ferreira, Alberto] Novartis Pharma AG, CH-4002 Basel, Switzerland.
C3 University of Sheffield; Novartis
RP Poku, E (通讯作者)，Univ Sheffield, Sch Hlth & Related Res, 30 Regent Court, Sheffield S1 2DA, S Yorkshire, England.
EM e.poku@sheffield.ac.uk
RI Carlton, Jill/N-3225-2019; brazier, john e/B-1936-2008; Carlton,
   Jill/E-6673-2010
OI Carlton, Jill/0000-0002-9373-7663; Carlton, Jill/0000-0002-9373-7663;
   Brazier, John/0000-0001-8645-4780
FU Novartis
FX We thank Anthea Sutton for conducting the literature searches and Katy
   Cooper for advice on reviewing methodology. This study was funded by
   Novartis.
CR Aspinall A, 2007, BRIT J OPHTHALMOL, V91, P766, DOI 10.1136/bjo.2006.104679
   Brazier J, 2002, J HEALTH ECON, V21, P271, DOI 10.1016/S0167-6296(01)00130-8
   Brazier J., 2016, MEASURING VALUING HL, V2, DOI 10.1093/med/9780198725923.001.0001
   Brazier JE, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI 10.3310/hta16320
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Brown Melissa M., 2001, International Ophthalmology, V24, P123, DOI 10.1023/A:1021171000838
   Brown MM, 2003, OPHTHALMOLOGY, V110, P1076, DOI 10.1016/S0161-6420(03)00254-9
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   Brown MM, 2001, OPHTHALMOLOGY, V108, P643, DOI 10.1016/S0161-6420(00)00635-7
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Cole SR, 2000, INVEST OPHTH VIS SCI, V41, P1017
   Czoski-Murray C, 2009, VALUE HEALTH, V12, P793, DOI 10.1111/j.1524-4733.2009.00527.x
   Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002
   Drummond MF, 2005, METHODS EC EVALUATIO
   Eong KGA, 2012, EYE, V26, P379, DOI 10.1038/eye.2011.218
   Espallargues M, 2005, INVEST OPHTH VIS SCI, V46, P4016, DOI 10.1167/iovs.05-0072
   Evans K, 2009, CLIN OPHTHALMOL, V3, P433
   FEENY D, 1995, PHARMACOECONOMICS, V7, P490, DOI 10.2165/00019053-199507060-00004
   Fenwick EK, 2012, INVEST OPHTH VIS SCI, V53, P677, DOI 10.1167/iovs.11-8992
   Fryback DG, 1997, MED DECIS MAKING, V17, P276, DOI 10.1177/0272989X9701700303
   International Council of Ophthalmology, 1998, VIS AC MEAS STAND
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P733, DOI 10.1001/archopht.119.5.733
   Kowalski JW, 2012, QUAL LIFE RES, V21, P323, DOI 10.1007/s11136-011-9938-z
   Lee BS, 2008, OPHTHALMOLOGY, V115, P898, DOI 10.1016/j.ophtha.2007.06.008
   Lloyd A, 2008, DIABETIC MED, V25, P618, DOI 10.1111/j.1464-5491.2008.02430.x
   Longworth L, 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18090
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   Mulhern B, 2013, HEALTH TECHNOL ASSES, V17, P1, DOI 10.3310/hta17050
   National Institute for Health and Care Excellence, 2013, GUID METH TECHN APPR
   Papaioannou D, 2010, NICE DSU TECHNICAL S
   Parrish R K 2nd, 1996, Trans Am Ophthalmol Soc, V94, P919
   Reeves BC, 2009, OPHTHALMOLOGY, V116, P2463, DOI 10.1016/j.ophtha.2009.10.031
   Rowen D, 2012, VALUE HEALTH, V15, P1059, DOI 10.1016/j.jval.2012.08.2201
   Rudmin J. W., 2010, CALCULATING EXACT PO
   Sahel JA, 2007, ARCH OPHTHALMOL-CHIC, V125, P945, DOI 10.1001/archopht.125.7.945
   Shah VA, 2004, OPHTHAL EPIDEMIOL, V11, P43, DOI 10.1076/opep.11.1.43.26436
   Sharma S, 2003, BRIT J OPHTHALMOL, V87, P259, DOI 10.1136/bjo.87.3.259
   Sharma S, 2002, BRIT J OPHTHALMOL, V86, P493, DOI 10.1136/bjo.86.5.493
   Solem C, IDENTIFICATION DIS E
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2
   Tosh J, 2012, VALUE HEALTH, V15, P118, DOI 10.1016/j.jval.2011.08.002
   Yanagi Y, 2011, JPN J OPHTHALMOL, V55, P35, DOI 10.1007/s10384-010-0893-y
   Yang YL, 2011, MED DECIS MAKING, V31, P281, DOI 10.1177/0272989X10379646
NR 45
TC 12
Z9 12
U1 1
U2 13
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD DEC 4
PY 2013
VL 13
AR 74
DI 10.1186/1471-2415-13-74
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 290KY
UT WOS:000329757000001
OA Green Published, gold, Green Accepted
DA 2022-11-30
ER

PT J
AU Matsubara, H
   Matsui, Y
   Miyata, R
   Ichio, A
   Chujo, S
   Enomoto, H
   Sugimoto, M
   Kondo, M
AF Matsubara, Hisashi
   Matsui, Yoshitsugu
   Miyata, Ryohei
   Ichio, Atsushi
   Chujo, Shinichiro
   Enomoto, Hiroko
   Sugimoto, Masahiko
   Kondo, Mineo
TI Effects of suspension of anti-vascular endothelial growth factor
   treatment for neovascular age-related macular degeneration in clinical
   setting
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; AMD; Anti-VEGF agents; Intravitreal
   injection; Treatment suspension; Recurrence; Number of hospital visits
ID INTRAVITREAL AFLIBERCEPT; EXTEND REGIMEN; RANIBIZUMAB; PREVALENCE;
   MANAGEMENT
AB Purpose To investigate the outcomes of a suspension of anti-vascular endothelial growth factor (anti-VEGF) treatments in the eyes with neovascular age-related macular degeneration (nAMD). Methods This was a retrospective study that examined eyes having no exudation for 48 weeks while undergoing intravitreal anti-VEGF injections every 12 to 16 weeks. The rate and time of recurrences, best-corrected visual acuity (BCVA), central subfield thickness (CST), number of visits, and reactivity to anti-VEGF were determined after the suspension of the anti-VEGF treatments. Results In 34 eyes of 34 patients, 17 eyes (50.0%) had a recurrence during the 24-month follow-up period. The median time of a recurrence was 10 months. The BCVA was maintained for 24 months after the suspension regardless of the development of any recurrences. In 41.7% of the eyes that resumed treatment, the duration of exudation suppression by the anti-VEGF therapy was shorter than 12 weeks during the 12 months after restarting the anti-VEGF treatments. There was a significant increase in the number of visits during the first year after beginning the suspension versus during the 1 year before the suspension (non-recurrence group; P = 0.007, recurrence group; P = 0.001). Conclusion Although one-half of the eyes had a recurrence within 24 months after a suspension of anti-VEGF treatment, the BCVA was maintained after a resumption of the anti-VEGF treatments. However, the number of hospital visits increases regardless of the recurrences and the lesion stability is altered by the anti-VEGF suspension. Clinicians should explain both the advantages and disadvantages of anti-VEGF suspension to nAMD patients.
C1 [Matsubara, Hisashi; Matsui, Yoshitsugu; Miyata, Ryohei; Chujo, Shinichiro; Enomoto, Hiroko; Sugimoto, Masahiko; Kondo, Mineo] Mie Univ, Dept Ophthalmol, Grad Sch Med, 2-174 Edobashi, Tsu, Mie 5148507, Japan.
   [Ichio, Atsushi] Subarukai Eye Ctr, Higashiomi, Japan.
C3 Mie University
RP Matsubara, H (通讯作者)，Mie Univ, Dept Ophthalmol, Grad Sch Med, 2-174 Edobashi, Tsu, Mie 5148507, Japan.
EM hmatsu@med.mie-u.ac.jp
OI Matsubara, Hisashi/0000-0003-1890-5417
CR Adrean SD, 2018, OPHTHALMOL RETINA, V2, P225, DOI 10.1016/j.oret.2017.07.009
   Arendt P, 2019, RETINA-J RET VIT DIS, V39, P27, DOI 10.1097/IAE.0000000000001923
   Aslanis S, 2021, OPHTHALMOL RETINA
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Fauser S, 2014, AM J OPHTHALMOL, V158, P532, DOI 10.1016/j.ajo.2014.05.025
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Invernizzi A, 2019, AM J OPHTHALMOL, V204, P105, DOI 10.1016/j.ajo.2019.03.001
   Khurana RN, 2019, OPHTHALMOL RETINA, V3, P621, DOI 10.1016/j.oret.2019.04.013
   Koh A, 2017, ASIA-PAC J OPHTHALMO, V6, P296, DOI 10.22608/APO.2016125
   Munk MR, 2018, OPHTHALMOL RETINA, V2, P288, DOI 10.1016/j.oret.2017.07.010
   Nguyen V, 2019, OPHTHALMOL RETINA, V3, P623, DOI 10.1016/j.oret.2019.05.013
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Richard G, 2015, OPHTHALMOLOGY, V122, P2497, DOI 10.1016/j.ophtha.2015.08.014
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross AH, 2020, EYE, V34, P1825, DOI 10.1038/s41433-019-0747-x
   Traine PG, 2019, OPHTHALMOL RETINA, V3, P393, DOI 10.1016/j.oret.2019.01.018
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
NR 20
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUN
PY 2022
VL 260
IS 6
BP 1867
EP 1876
DI 10.1007/s00417-021-05526-0
EA JAN 2022
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0X7EL
UT WOS:000749094300001
PM 35094126
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Hogg, HDJ
   Chung, N
   Reed, J
   Berrett, G
   Pearce, M
   Di Simplicio, S
AF Hogg, H. D. Jeffry
   Chung, N.
   Reed, J.
   Berrett, G.
   Pearce, M.
   Di Simplicio, Sandro
TI An observational clinical study of the influence of phacoemulsification
   on choroidal neovascular membrane activity in age related macular
   degeneration
SO EYE
LA English
DT Article
ID CATARACT-SURGERY; RISK
AB Background Thousands of phacoemulsification surgeries are performed on eyes with age-related macular degeneration (AMD) complicated by choroidal neovascular membrane (CNV) in the United Kingdom each year. As populations age this number is expected to rise. Controversy over phacoemulsification's influence on CNV activity limits the information which clinicians and these patients use to decide on surgery. This observational study aims to resolve this controversy by reporting on intravitreal injection (IVI) frequency as a pragmatic marker of CNV activity in a large cohort. Methods A cohort of eyes with AMD complicated by CNV (n = 327) that underwent cataract surgery at a single tertiary centre from 2014 to 2019 were identified. These cases were matched by interval since CNV diagnosis at a specified 'time zero' within the follow-up of pseudophakic eyes with AMD (n = 327). Data concerning demographics, visual acuity (VA) and intravitreal injection frequency before and after 'time zero'/phacoemulsification were collected. Results Following 'time zero'/phacoemulsification' the mean reduction in annual IVI frequency was 0.6 injections/year (95% CI 0.4,0.9) and 0.4 injections/year (95% CI 0.1,0.7) in the comparison and phacoemulsification cohorts respectively. The mean VA gain 12 months after phacoemulsification in the intervention cohort was 11.3 (95% CI 9.2,13.4) early treatment of diabetic retinopathy study (ETDRS) letters, with 214 eyes (65.4%) having gained >= 5 ETDRS letters after surgery. Conclusions Phacoemulsification has no clinically significant impact on the activity of pre-existent CNV secondary to AMD. Phacoemulsification should be offered to patients with AMD and cataract that limits vision, regardless of CNV activity.
C1 [Hogg, H. D. Jeffry; Chung, N.; Reed, J.; Pearce, M.] Newcastle Univ, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   [Hogg, H. D. Jeffry; Berrett, G.; Di Simplicio, Sandro] Newcastle Upon Tyne Hosp NHS Fdn Trust, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
C3 Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation
   Trust
RP Hogg, HDJ (通讯作者)，Newcastle Univ, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.; Hogg, HDJ (通讯作者)，Newcastle Upon Tyne Hosp NHS Fdn Trust, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
EM Jeffry.hogg@ncl.ac.uk
RI Di Simplicio, Sandro/AAD-3367-2020
OI Di Simplicio, Sandro/0000-0001-5114-3843; Hogg,
   Jeffry/0000-0001-8044-7790
FU NIHR academic clinical fellowship
FX HH was funded by a NIHR academic clinical fellowship.
CR Baatz H, 2008, INVEST OPHTH VIS SCI, V49, P1079, DOI 10.1167/iovs.07-0557
   Boyle J, 2015, PSYCHOL HEALTH MED, V20, P296, DOI 10.1080/13548506.2014.936886
   Casparis H, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006757.pub4
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Daien V, 2018, AM J OPHTHALMOL, V190, P50, DOI 10.1016/j.ajo.2018.03.012
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Figurska M, 2018, MED SCI MONITOR, V24, P6517, DOI 10.12659/MSM.909652
   Hooper CY, 2009, CLIN EXP OPHTHALMOL, V37, P570, DOI 10.1111/j.1442-9071.2009.02095.x
   Ibrahim AM, 2018, SEMIN OPHTHALMOL, V33, P664, DOI 10.1080/08820538.2017.1416410
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Liu YN, 2015, AM J OPHTHALMOL, V159, P565, DOI 10.1016/j.ajo.2014.12.006
   National Institute for Health and Care Excellence (NICE), 2018, NICE GUID NG 82 AG R
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   Saraf SS, 2015, AM J OPHTHALMOL, V160, P487, DOI 10.1016/j.ajo.2015.06.006
   Schmidt-Erfurth U, 2020, OPHTHALMOLOGY, V127, P1211, DOI 10.1016/j.ophtha.2020.03.010
   Starr MR, 2018, AM J OPHTHALMOL, V192, P91, DOI 10.1016/j.ajo.2018.05.014
   The Equator Network,, 2020, STRENGTH REP OBS STU
   The Royal College of Ophthalmologists, 2020, NAT OPHTH DAT AUD FU
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yorgun MA, 2018, INT OPHTHALMOL, V38, P459, DOI 10.1007/s10792-017-0480-z
NR 22
TC 0
Z9 0
U1 0
U2 1
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUL
PY 2022
VL 36
IS 7
BP 1379
EP 1383
DI 10.1038/s41433-021-01653-4
EA JUN 2021
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2J2KS
UT WOS:000667029700007
PM 34172945
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Westborg, I
   Albrecht, S
   Granstam, E
   Karlsson, N
   Kugelberg, M
   Lundstrom, M
   Montan, P
   Behndig, A
AF Westborg, Inger
   Albrecht, Susanne
   Granstam, Elisabet
   Karlsson, Niklas
   Kugelberg, Maria
   Lundstrom, Mats
   Montan, Per
   Behndig, Anders
TI Treatment of age-related macular degeneration after cataract surgery: a
   study from the Swedish National Cataract and Macula Registers
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; blue-blocking IOLs; cataract surgery;
   register-based cohort study
ID ASSESSED VISUAL FUNCTION; QUALITY-OF-LIFE; ACUITY; PROGRESSION;
   MACULOPATHY; RISK
AB Purpose To characterize pre- and perioperative factors associated with treatment for wet age-related macular degeneration (wet AMD) after cataract surgery. Methods This register-based cohort study with data from the Swedish National Cataract Register (NCR) and the Swedish Macula Register (SMR) from 2010 to 2017 compared eyes with and without preoperative AMD that had undergone cataract surgery and was subsequently treated for wet AMD to eyes not treated within the study period. All first-eye surgeries registered in the NCR from 2010 to 2017 and matching eyes found in the SMR that had undergone treatment for wet AMD >= 1 year after the cataract procedure were included. Data for cataract surgery date, age and gender, use of a blue-blocking IOL, preoperative visual acuity, ocular comorbidities, posterior capsule rupture and date of AMD treatment initiation were extracted. Results The only independent factor associated with postoperative treatment of wet AMD in both groups was female gender (67.3% vs. 58.8%, p < 0.001 and 66.4% vs. 60.6%, p = 0.001, respectively). Older age was an independent factor in eyes without preoperative AMD (78.4 +/- 6.5 vs. 73.4 +/- 9.6 years, p < 0.001). A blue-blocking IOL appeared to decrease the likelihood of subsequent wet AMD treatment slightly but not statistically significant in eyes with preoperative AMD (52.7% vs. 56.8%, p = 0.110). Conclusions Some factors (female gender, high age) are associated with undergoing subsequent treatment for wet AMD to a higher extent. If the use of a blue-blocking IOL offers any protection from undergoing AMD treatment after cataract surgery, such an effect must be very small.
C1 [Westborg, Inger; Behndig, Anders] Umea Univ Hosp, Dept Clin Sci Ophthalmol, Umea, Sweden.
   [Albrecht, Susanne] EyeNet Sweden, RC Syd, Karlskrona, Sweden.
   [Granstam, Elisabet] Reg Vastmanland, Dept Ophthalmol, Vasteras, Sweden.
   [Karlsson, Niklas] Orebro Univ Hosp, Orebro, Sweden.
   [Kugelberg, Maria; Montan, Per] St Erik Eye Hosp, Karolinska Inst, Stockholm, Sweden.
   [Lundstrom, Mats] Lund Univ, Fac Med, Dept Clin Sci, Ophthalmol, Lund, Sweden.
C3 Umea University; Orebro University; Karolinska Institutet; Lund
   University
RP Westborg, I (通讯作者)，Umea Univ, Dept Clin Sci Ophthalmol, SE-90187 Umea, Sweden.
EM Inger.westborg@akademiska.se
RI Westborg, Inger/AAD-7108-2021
OI Behndig, Anders/0000-0001-6652-7436; Lundstrom,
   Mats/0000-0002-4489-7118; Granstam, Elisabet/0000-0003-3164-547X
FU Swedish National Board of Health and Welfare Funding Source: Medline;
   Swedish Association of Local Authorities and Regions Funding Source:
   Medline
CR Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Anticipated life expectancy in Sweden sorted on age and gender, 2014, ANTICIPATED LIFE EXP
   Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   Baatz H, 2008, INVEST OPHTH VIS SCI, V49, P1079, DOI 10.1167/iovs.07-0557
   Behndig A, 2011, J CATARACT REFR SURG, V37, P1539, DOI 10.1016/j.jcrs.2011.05.021
   Bockelbrink A, 2008, SURV OPHTHALMOL, V53, P359, DOI 10.1016/j.survophthal.2008.04.001
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   Chatziralli I P, 2011, Bull Soc Belge Ophtalmol, P21
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Dong LM, 2009, ARCH OPHTHALMOL-CHIC, V127, P1412, DOI 10.1001/archophthalmol.2009.152
   Downie LE, 2019, JAMA OPHTHALMOL, V137, P694, DOI 10.1001/jamaophthalmol.2019.0019
   Fong CSU, 2011, BRIT J OPHTHALMOL, V95, P1652, DOI 10.1136/bjo.2010.197517
   Forooghian F, 2009, OPHTHALMOLOGY, V116, P2093, DOI 10.1016/j.ophtha.2009.04.033
   Fraser-Bell S, 2010, AM J OPHTHALMOL, V149, P735, DOI 10.1016/j.ajo.2009.11.013
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   Grimfors M, 2014, J CATARACT REFR SURG, V40, P1163, DOI 10.1016/j.jcrs.2013.11.033
   Hayashi K, 2006, BRIT J OPHTHALMOL, V90, P1019, DOI 10.1136/bjo.2006.090712
   Ho L, 2008, INVEST OPHTH VIS SCI, V49, P4795, DOI 10.1167/iovs.08-2066
   Kessel L, 2015, ACTA OPHTHALMOL, V93, P593, DOI 10.1111/aos.12665
   Klein BEK, 2012, OPHTHALMOLOGY, V119, P1628, DOI 10.1016/j.ophtha.2012.01.050
   Lundstrom M, 2002, BRIT J OPHTHALMOL, V86, P1330, DOI 10.1136/bjo.86.12.1330
   Lundstrom M, 2000, J CATARACT REFR SURG, V26, P408, DOI 10.1016/S0886-3350(99)00418-6
   Huynh N, 2014, OPHTHALMOLOGY, V121, P1229, DOI 10.1016/j.ophtha.2013.12.035
   Panchapakesan J, 2004, EYE, V18, P278, DOI 10.1038/sj.eye.6700641
   Ronbeck M, 2011, OPHTHALMOLOGY, V118, P1732, DOI 10.1016/j.ophtha.2011.04.013
   Tabandeh H, 2012, J CATARACT REFR SURG, V38, P677, DOI 10.1016/j.jcrs.2011.10.036
   Wang J J, 1999, Ophthalmic Epidemiol, V6, P317, DOI 10.1076/opep.6.4.317.4182
   Westborg I, 2018, ANN REPORT SWEDISH M
   Yang H, 2014, CURR OPIN OPHTHALMOL, V25, P40, DOI 10.1097/ICU.0000000000000020
NR 30
TC 2
Z9 2
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD FEB
PY 2021
VL 99
IS 1
BP E124
EP E129
DI 10.1111/aos.14519
EA JUN 2020
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QF1QX
UT WOS:000541765300001
PM 32573070
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Seddon, JM
   Dossett, JP
   Widjajahakim, R
   Rosner, B
AF Seddon, Johanna M.
   Dossett, James P.
   Widjajahakim, Rafael
   Rosner, Bernard
TI Association Between Perifoveal Drusen Burden Determined by OCT and
   Genetic Risk in Early and Intermediate Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; drusen; genetic diseases
ID OPTICAL COHERENCE TOMOGRAPHY; COMPLEMENT FACTOR-H; GEOGRAPHIC ATROPHY;
   CIGARETTE-SMOKING; PROGRESSION; VARIANTS; CFH; POLYMORPHISMS; RARE;
   REPRODUCIBILITY
AB PURPOSE. The purpose of this study was to determine associations between macular drusen parameters derived from an automatic optical coherence tomography (OCT) algorithm, nonadvanced age-related macular degeneration (AMD) stage, and genetic variants.
   METHODS. Eyes classified as early or intermediate AMD with OCT imaging and genetic data were selected (n = 239 eyes). Drusen area and volume measurements were estimated using the Zeiss Cirrus advanced retinal pigment epithelium analysis algorithm in a perifoveal zone centered on the fovea. Associations between drusen measurements and common genetic variants in the complement and high-density lipoprotein (HDL) lipid pathways and the ARMS2/HTRA1 variant were calculated using generalized estimating equations and linear mixed models adjusting for age, sex, smoking, body mass index, and education.
   RESULTS. Drusen area >= the median was independently associated with a higher number of risk alleles for CFH risk score and risk variants in C3 and ARMS2/HTRA1 compared with eyes with no measurable drusen. Similar results were obtained for drusen volume. When all genes were analyzed in the same model, only CFH score and ARMS2/HTRA1 were associated with drusen measurements. HDL pathway genes were not significantly related to drusen parameters. Nonadvanced AMD stages were associated with OCT-derived drusen area and volume.
   CONCLUSIONS. Variants in CFH and ARMS2/HTRA1, commonly associated with advanced AMD, were independently associated with an increase in drusen burden determined by OCT in an allele dose dependent manner, in eyes with early and intermediate AMD. Biomarkers such as a quantitative classification of nonadvanced AMD and other OCT-derived subphenotypes could provide earlier anatomic endpoints for clinical trials and facilitate the development of new therapies for AMD.
C1 [Seddon, Johanna M.; Widjajahakim, Rafael] Univ Massachusetts, Sch Med, Dept Ophthalmol & Visual Sci, 55 Lake Ave North,S3-119, Worcester, MA 01655 USA.
   [Dossett, James P.] Tufts Univ, Sch Med, Boston, MA USA.
   [Rosner, Bernard] Harvard Med Sch, Channing Div Network Med, Boston, MA 02115 USA.
C3 University of Massachusetts System; University of Massachusetts
   Worcester; Tufts University; Harvard University; Harvard Medical School
RP Seddon, JM (通讯作者)，Univ Massachusetts, Sch Med, Dept Ophthalmol & Visual Sci, 55 Lake Ave North,S3-119, Worcester, MA 01655 USA.
EM johanna_seddon@yahoo.com
FU National Institutes of Health [R01 EY011309, R01 EY022445, R01
   EY028602]; Massachusetts Lions Eye Research Fund, Inc; International
   Retina Foundation; American Macular Degeneration Foundation; NATIONAL
   EYE INSTITUTE [R01EY028602, R01EY011309, R01EY022445] Funding Source:
   NIH RePORTER
FX Supported by National Institutes of Health Grants R01 EY011309, R01
   EY022445, and R01 EY028602; Massachusetts Lions Eye Research Fund, Inc;
   International Retina Foundation; and American Macular Degeneration
   Foundation.
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Chavali VRM, 2015, J CLIN MED, V4, P304, DOI 10.3390/jcm4020304
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cheung CMG, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31109-x
   Cruz-Gonzalez F, 2014, OPHTHALMIC GENET, V35, P68, DOI 10.3109/13816810.2013.781193
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Garcia CAD, 2014, OSLI RETINA, V45, P18, DOI 10.3928/23258160-20131217-01
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ferrara D, 2017, INVEST OPHTH VIS SCI, V58, P3519, DOI 10.1167/iovs.17-21696
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Glynn RJ, 2012, OPHTHAL EPIDEMIOL, V19, P159, DOI 10.3109/09286586.2012.674614
   Gregori G, 2014, INVEST OPHTH VIS SCI, V55, P7662, DOI 10.1167/iovs.14-15273
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Ho J, 2015, RETINA-J RET VIT DIS, V35, P467, DOI 10.1097/IAE.0000000000000355
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lei JQ, 2017, GRAEF ARCH CLIN EXP, V255, P1551, DOI 10.1007/s00417-017-3693-y
   Liao SM, 2017, MOL VIS, V23, P318
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maguire MG, 2016, JAMA OPHTHALMOL, V134, P674, DOI 10.1001/jamaophthalmol.2016.0669
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Nathoo NA, 2014, AM J OPHTHALMOL, V158, P757, DOI 10.1016/j.ajo.2014.06.021
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nittala MG, 2012, INVEST OPHTH VIS SCI, V53, P8319, DOI 10.1167/iovs.12-10582
   Oeverhaus M, 2017, OPHTHALMOLOGICA, V238, P6, DOI 10.1159/000468949
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Raychaudhuri S, 2010, NAT GENET, V42, P553, DOI 10.1038/ng0710-553
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosner B, 2017, STAT MED, V36, P2163, DOI 10.1002/sim.7257
   Schlanitz F, 2019, BRIT J OPHTHALMOL, V103, P227, DOI 10.1136/bjophthalmol-2017-311782
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2017, OPHTHALMOLOGY
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2019, AM J OPHTHALMOL, V198, P223, DOI 10.1016/j.ajo.2018.10.022
   Seddon JM, 2017, INVEST OPHTH VIS SCI, V58, P6513, DOI 10.1167/iovs.17-23544
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Seddon JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087047
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Sleiman K, 2017, OPHTHALMOLOGY, V124, P1764, DOI 10.1016/j.ophtha.2017.06.032
   Wagner EK, 2016, SCI REP-UK, V6, DOI 10.1038/srep31531
   Wu MX, 2016, OPHTHALMIC RES, V55, P135, DOI 10.1159/000442257
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Ying GS, 2017, OPHTHAL EPIDEMIOL, V24, P130, DOI 10.1080/09286586.2016.1259636
   Yu Y, 2016, HUM MOL GENET, V25, P5276, DOI 10.1093/hmg/ddw336
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
NR 59
TC 8
Z9 8
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2019
VL 60
IS 13
BP 4469
EP 4478
DI 10.1167/iovs.19-27475
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JI3SA
UT WOS:000493386800005
PM 31658355
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Jemni-Damer, N
   Guedan-Duran, A
   Fuentes-Andion, M
   Serrano-Bengoechea, N
   Alfageme-Lopez, N
   Armada-Maresca, F
   Guinea, GV
   Perez-Rigueiro, J
   Rojo, F
   Gonzalez-Nieto, D
   Kaplan, DL
   Panetsos, F
AF Jemni-Damer, Nahla
   Guedan-Duran, Atocha
   Fuentes-Andion, Maria
   Serrano-Bengoechea, Nora
   Alfageme-Lopez, Nuria
   Armada-Maresca, Felix
   Guinea, Gustavo V.
   Perez-Rigueiro, Jose
   Rojo, Francisco
   Gonzalez-Nieto, Daniel
   Kaplan, David L.
   Panetsos, Fivos
TI Biotechnology and Biomaterial-Based Therapeutic Strategies for
   Age-Related Macular Degeneration. Part II: Cell and Tissue Engineering
   Therapies
SO FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
LA English
DT Review
DE retinal pigment epithelium; Bruch&#8217; s membrane; photoreceptors;
   biomaterials; cell therapy; tissue engineering; biotechnology; cell
   replacement
ID RETINAL-PIGMENT EPITHELIUM; EMBRYONIC STEM-CELLS; CILIARY NEUROTROPHIC
   FACTOR; CENTRAL-NERVOUS-SYSTEM; LONG-TERM SURVIVAL; DRUG-DELIVERY;
   PHOTORECEPTOR PRECURSORS; SUBRETINAL IMPLANTATION; PROGENITOR CELLS;
   BRUCHS MEMBRANE
AB Age-related Macular Degeneration (AMD) is an up-to-date untreatable chronic neurodegenerative eye disease of multifactorial origin, and the main causes of blindness in over 65 y.o. people. It is characterized by a slow progression and the presence of a multitude of factors, highlighting those related to diet, genetic heritage and environmental conditions, present throughout each of the stages of the illness. Current therapeutic approaches, mainly consisting on intraocular drug delivery, are only used for symptoms relief and/or to decelerate the progression of the disease. Furthermore, they are overly simplistic and ignore the complexity of the disease and the enormous differences in the symptomatology between patients. Due to the wide impact of the AMD and the up-to-date absence of clinical solutions, Due to the wide impact of the AMD and the up-to-date absence of clinical solutions, different treatment options have to be considered. Cell therapy is a very promising alternative to drug-based approaches for AMD treatment. Cells delivered to the affected tissue as a suspension have shown poor retention and low survival rate. A solution to these inconveniences has been the encapsulation of these cells on biomaterials, which contrive to their protection, gives them support, and favor their retention of the desired area. We offer a two-papers critical review of the available and under development AMD therapeutic approaches, from a biomaterials and biotechnological point of view. We highlight benefits and limitations and we forecast forthcoming alternatives based on novel biomaterials and biotechnology methods. In this second part we review the preclinical and clinical cell-replacement approaches aiming at the development of efficient AMD-therapies, the employed cell types, as well as the cell-encapsulation and cell-implant systems. We discuss their advantages and disadvantages and how they could improve the survival and integration of the implanted cells.
C1 [Jemni-Damer, Nahla; Guedan-Duran, Atocha; Fuentes-Andion, Maria; Serrano-Bengoechea, Nora; Alfageme-Lopez, Nuria; Panetsos, Fivos] Univ Complutense Madrid, Neurocomp & Neurorobot Res Grp, Madrid, Spain.
   [Jemni-Damer, Nahla; Guedan-Duran, Atocha; Fuentes-Andion, Maria; Serrano-Bengoechea, Nora; Alfageme-Lopez, Nuria; Panetsos, Fivos] San Carlos Clin Hosp, Innovat Grp, Inst Hlth Res, Madrid, Spain.
   [Guedan-Duran, Atocha; Kaplan, David L.] Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA.
   [Serrano-Bengoechea, Nora; Alfageme-Lopez, Nuria; Guinea, Gustavo V.; Perez-Rigueiro, Jose; Rojo, Francisco; Gonzalez-Nieto, Daniel; Panetsos, Fivos] Silk Biomed SL, Madrid, Spain.
   [Armada-Maresca, Felix] La Paz Univ Hosp, Ophthalmol Serv, Madrid, Spain.
   [Guinea, Gustavo V.; Perez-Rigueiro, Jose; Rojo, Francisco; Gonzalez-Nieto, Daniel] Univ Politecn Madrid, Ctr Biomed Technol, Pozuelo De Alarcon, Spain.
   [Guinea, Gustavo V.; Perez-Rigueiro, Jose; Rojo, Francisco] Univ Politecn Madrid, Civil Engn Super Sch, Dept Mat Sci, Madrid, Spain.
   [Guinea, Gustavo V.; Perez-Rigueiro, Jose; Rojo, Francisco; Gonzalez-Nieto, Daniel] Biomed Res Networking Ctr Bioeng Biomat & Nanomed, Madrid, Spain.
C3 Complutense University of Madrid; Tufts University; Hospital
   Universitario La Paz; Universidad Politecnica de Madrid; Centro de
   Tecnologia Biomedica (CTB); Universidad Politecnica de Madrid
RP Panetsos, F (通讯作者)，Univ Complutense Madrid, Neurocomp & Neurorobot Res Grp, Madrid, Spain.; Panetsos, F (通讯作者)，San Carlos Clin Hosp, Innovat Grp, Inst Hlth Res, Madrid, Spain.; Panetsos, F (通讯作者)，Silk Biomed SL, Madrid, Spain.
EM fivos@ucm.es
OI Guedan Duran, Atocha/0000-0002-0544-9574; Fuentes-Andion,
   Maria/0000-0002-3059-8360; Panetsos, Fivos/0000-0003-0897-411X
FU Spanish Ministerio de Economia y Competitividad [MAT2016-76847-R,
   MAT2016-79832-R, MAT2015-66666-C3-3-R]; Comunidad de Madrid, Spain
   [Neurocentro-B2017/BrMD-3760, IND2018/BrMD-9804]; National Institutes of
   Health [P41EB002520]; Spanish Ministerio de Economia y Competitividad;
   Comunidad de Madrid, Spain
FX The authors gratefully acknowledge financial support received from the
   Spanish Ministerio de Economia y Competitividad through grants
   MAT2016-76847-R, MAT2016-79832-R, and MAT2015-66666-C3-3-R; from the
   Comunidad de Madrid, Spain through grants Neurocentro-B2017/BrMD-3760
   and IND2018/BrMD-9804, and from the National Institutes of Health
   (P41EB002520); predoctoral FPI grant from the Spanish Ministerio de
   Economia y Competitividad (AGD) and research contract from the Comunidad
   de Madrid, Spain (MFA).
CR Achberger K, 2019, ELIFE, V8, DOI 10.7554/eLife.46188
   AGUAYO AJ, 1991, PHILOS T R SOC B, V331, P337, DOI 10.1098/rstb.1991.0025
   Al-Nawaiseh S, 2016, JOVE-J VIS EXP, DOI 10.3791/53927
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Aoki H, 2009, DEV DYNAM, V238, P2266, DOI 10.1002/dvdy.22008
   Arnhold S, 2004, INVEST OPHTH VIS SCI, V45, P4251, DOI 10.1167/iovs.03-1108
   Assawachananont J, 2014, STEM CELL REP, V2, P662, DOI 10.1016/j.stemcr.2014.03.011
   AUGUSTIN C, 2012, EUROPEAN OPHTHALMIC, V6, P25
   Ballios BG, 2015, STEM CELL REP, V4, P1031, DOI 10.1016/j.stemcr.2015.04.008
   Ballios BG, 2010, CAN J OPHTHALMOL, V45, P342, DOI 10.3129/i10-070
   Ballios BG, 2010, BIOMATERIALS, V31, P2555, DOI 10.1016/j.biomaterials.2009.12.004
   Bansal P, 2016, J OCUL PHARMACOL TH, V32, P135, DOI 10.1089/jop.2015.0133
   Baranov P, 2014, J TISSUE ENG, V5, DOI 10.1177/2041731414554139
   Barar J, 2016, BIOIMPACTS, V6, P49, DOI 10.15171/bi.2016.07
   Barber AC, 2013, P NATL ACAD SCI USA, V110, P354, DOI 10.1073/pnas.1212677110
   Barnea-Cramer AO, 2016, SCI REP-UK, V6, DOI 10.1038/srep29784
   Behtaj S, 2020, TISSUE ENG REGEN MED, V17, P253, DOI 10.1007/s13770-020-00254-8
   Bennett CR, 2019, SEMIN PEDIATR NEUROL, V31, P30, DOI 10.1016/j.spen.2019.05.006
   Bharti K, 2006, PIGM CELL RES, V19, P380, DOI 10.1111/j.1600-0749.2006.00318.x
   Bharti K, 2018, NAT BIOTECHNOL, V36, P311, DOI 10.1038/nbt.4118
   Bharti K, 2014, INVEST OPHTH VIS SCI, V55, P1191, DOI 10.1167/iovs.13-13481
   BHATT NS, 1994, AM J OPHTHALMOL, V117, P214, DOI 10.1016/S0002-9394(14)73079-X
   Bhatt P, 2019, AAPS PHARMSCITECH, V20, DOI 10.1208/s12249-019-1474-0
   Bhattacharya Sujoy, 2017, Curr Mol Biol Rep, V3, P172, DOI 10.1007/s40610-017-0069-3
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Birch DG, 2013, AM J OPHTHALMOL, V156, P283, DOI 10.1016/j.ajo.2013.03.021
   Bisht R, 2017, MED HYPOTHESES, V103, P5, DOI 10.1016/j.mehy.2017.03.033
   Blenkinsop Timothy A, 2013, Methods Mol Biol, V945, P45, DOI 10.1007/978-1-62703-125-7_4
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Bracha P, 2017, EXPERT OPIN BIOL TH, V17, P1113, DOI 10.1080/14712598.2017.1346079
   BRAY GM, 1987, J EXP BIOL, V132, P5
   Burke JM, 2005, MOL INTERV, V5, P241, DOI 10.1124/mi.5.4.7
   Bush RA, 2004, INVEST OPHTH VIS SCI, V45, P2420, DOI 10.1167/iovs.03-1342
   Caffe AR, 2001, J CHEM NEUROANAT, V22, P263
   Calejo MT, 2017, ACTA BIOMATER, V54, P138, DOI 10.1016/j.actbio.2017.02.035
   Campbell M, 2013, ADV EXP MED BIOL, V763, P70
   Canto-Soler V, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.16-19127
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Carr AJF, 2013, TRENDS NEUROSCI, V36, P385, DOI 10.1016/j.tins.2013.03.006
   Chan BP, 2008, EUR SPINE J, V17, pS467, DOI 10.1007/s00586-008-0745-3
   Chen HY, 2016, MOL VIS, V22, P1077
   Chen MW, 2011, ACTA BIOMATER, V7, P2244, DOI 10.1016/j.actbio.2010.12.031
   Chichagova V, 2018, EYE, V32, P946, DOI 10.1038/s41433-018-0061-z
   Chirila TV, 2008, TISSUE ENG PT A, V14, P1203, DOI [10.1089/ten.tea.2007.0224, 10.1089/tea.2007.0224]
   Christiansen A T, 2012, Stem Cells Int, V2012, P454295, DOI 10.1155/2012/454295
   Cotrim CC, 2017, CLIN OPHTHALMOL, V11, P931, DOI 10.2147/OPTH.S133502
   Crafoord S., 2002, PHOTORECEPTOR SURVIV, DOI [10.1034/j.1600-0420.2002.800408.x, DOI 10.1034/J.1600-0420.2002.800408.X]
   Cunha-Vaz JG, 1997, DOC OPHTHALMOL, V93, P149, DOI 10.1007/BF02569055
   Cunha-Vaz J, 2011, EUR J OPHTHALMOL, V21, pS3, DOI 10.5301/EJO.2010.6049
   Curatola AM, 2005, EXP EYE RES, V81, P147, DOI 10.1016/j.exer.2005.06.001
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Das T, 1999, EXP NEUROL, V157, P58, DOI 10.1006/exnr.1998.6992
   Davis RJ, 2017, STEM CELL REP, V9, P42, DOI 10.1016/j.stemcr.2017.05.016
   Decembrini S, 2014, STEM CELL REP, V2, P853, DOI 10.1016/j.stemcr.2014.04.010
   Del Priore LV, 2004, INVEST OPHTH VIS SCI, V45, P985, DOI 10.1167/iovs.03-0662
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Eberle D, 2014, JOVE-J VIS EXP, DOI 10.3791/50932
   Eberle D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046305
   Eiraku M, 2012, NAT PROTOC, V7, P69, DOI 10.1038/nprot.2011.429
   Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941
   Emerich DF, 2008, CURR OPIN MOL THER, V10, P506
   Engelsberg K, 2005, OPHTHALMIC RES, V37, P104, DOI 10.1159/000084252
   Engelsberg K, 2008, CURR EYE RES, V33, P185, DOI 10.1080/02713680701843784
   Falkner-Radler CI, 2011, BRIT J OPHTHALMOL, V95, P370, DOI 10.1136/bjo.2009.176305
   Fernandez-Garcia L, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00296
   Fields M, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5040044
   Fligor CM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32871-8
   Fontaine V, 1998, J NEUROSCI, V18, P9662
   Forrester JV, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00338
   Fuchs S, 2006, STEM CELL AND GENE-BASED THERAPY, P45, DOI 10.1007/1-84628-142-3_4
   Gagliardi G, 2018, STEM CELL REP, V11, P665, DOI 10.1016/j.stemcr.2018.07.005
   Gaillard F, 2007, VISION RES, V47, P2815, DOI 10.1016/j.visres.2007.06.018
   Gamm DM, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.6.2
   Garita-Hernandez M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12330-2
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Ghosh F, 2009, INVEST OPHTH VIS SCI, V50, P826, DOI 10.1167/iovs.08-2389
   Giordano GG, 1997, J BIOMED MATER RES, V34, P87, DOI 10.1002/(SICI)1097-4636(199701)34:1<87::AID-JBM12>3.0.CO;2-M
   Gonzalez-Cordero A, 2013, NAT BIOTECHNOL, V31, P741, DOI 10.1038/nbt.2643
   Gonzalez-Nieto D, 2018, POLYMERS-BASEL, V10, DOI 10.3390/polym10020184
   Goslings WRO, 1998, INVEST OPHTH VIS SCI, V39, P989
   Guenther E, 1999, VISION RES, V39, P3988, DOI 10.1016/S0042-6989(99)00128-5
   GUERRERONARANJO JL, 2013, INVEST OPHTH VIS SCI, V54
   Gust J, 2011, INVEST OPHTH VIS SCI, V52, P5266, DOI 10.1167/iovs.10-6329
   Haderspeck JC, 2019, EXPERT OPIN DRUG DIS, V14, P47, DOI 10.1080/17460441.2019.1551873
   Hadlock T, 1999, TISSUE ENG, V5, P187, DOI 10.1089/ten.1999.5.187
   Handa JT, 2017, BBA-MOL CELL BIOL L, V1862, P430, DOI 10.1016/j.bbalip.2016.07.013
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Harris TI, 2019, ACS BIOMATER SCI ENG, V5, P4023, DOI 10.1021/acsbiomaterials.9b00183
   Hasegawa Y, 2016, DEVELOPMENT, V143, P3895, DOI 10.1242/dev.134601
   Hertz J, 2014, CELL TRANSPLANT, V23, P855, DOI 10.3727/096368913X667024
   Hiler D, 2015, CELL STEM CELL, V17, P101, DOI 10.1016/j.stem.2015.05.015
   Ho AC, 2017, AM J OPHTHALMOL, V179, P67, DOI 10.1016/j.ajo.2017.04.006
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE
   Homma K, 2013, STEM CELLS, V31, P1149, DOI 10.1002/stem.1372
   Hoon M, 2014, PROG RETIN EYE RES, V42, P44, DOI 10.1016/j.preteyeres.2014.06.003
   Hsiung J, 2015, STEM CELL TRANSL MED, V4, P10, DOI 10.5966/sctm.2014-0205
   Hu YT, 2012, OPHTHALMIC RES, V48, P186, DOI 10.1159/000338749
   Huang B, 2000, VISUAL NEUROSCI, V17, P925, DOI 10.1017/S0952523800176126
   Hynes SR, 2010, GRAEF ARCH CLIN EXP, V248, P763, DOI 10.1007/s00417-009-1263-7
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Ilmarinen T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143669
   Imai H, 2007, CURR EYE RES, V32, P903, DOI 10.1080/02713680701604749
   Iraha S, 2018, STEM CELL REP, V10, P1059, DOI 10.1016/j.stemcr.2018.01.032
   Irisvision, 2020, AG REL MAC DEG GUID
   Jayakody SA, 2015, PROG RETIN EYE RES, V46, P31, DOI 10.1016/j.preteyeres.2015.01.003
   Jemni-Damer N, 2020, J NEURAL ENG, V17, DOI 10.1088/1741-2552/abb9c0
   Jin ZB, 2019, PROG RETIN EYE RES, V69, P38, DOI 10.1016/j.preteyeres.2018.11.003
   Johnson TV, 2008, INVEST OPHTH VIS SCI, V49, P3503, DOI 10.1167/iovs.07-1601
   Johnson TV, 2016, INVEST OPHTH VIS SCI, V57, P253, DOI 10.1167/iovs.15-17769
   Jones BW, 2012, JPN J OPHTHALMOL, V56, P289, DOI 10.1007/s10384-012-0147-2
   Jones BW, 2003, J COMP NEUROL, V464, P1, DOI 10.1002/cne.10703
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   Julien S, 2011, BIOMATERIALS, V32, P3890, DOI 10.1016/j.biomaterials.2011.02.016
   Jung YH, 2018, ADV MATER, V30, DOI 10.1002/adma.201803550
   Kadkhodaeian HA, 2019, TISSUE ENG REGEN MED, V16, P253, DOI 10.1007/s13770-019-00183-1
   Kador KE, 2016, TISSUE ENG PT A, V22, P286, DOI [10.1089/ten.tea.2015.0373, 10.1089/ten.TEA.2015.0373]
   Kador KE, 2012, EXPERT REV OPHTHALMO, V7, P459, DOI 10.1586/EOP.12.56
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kim H, 2012, TRENDS BIOTECHNOL, V30, P55, DOI 10.1016/j.tibtech.2011.07.002
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Koizumi A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000221
   Koss MJ, 2016, GRAEF ARCH CLIN EXP, V254, P1553, DOI 10.1007/s00417-016-3386-y
   Krishna Y, 2011, BRIT J OPHTHALMOL, V95, P569, DOI 10.1136/bjo.2009.169953
   Kundu B, 2013, ADV DRUG DELIVER REV, V65, P457, DOI 10.1016/j.addr.2012.09.043
   Kundu J, 2018, J BIOMED MATER RES B, V106, P891, DOI 10.1002/jbm.b.33901
   Kuno N, 2011, POLYMERS-BASEL, V3, P193, DOI 10.3390/polym3010193
   Lai JY, 2013, J MATER SCI-MATER M, V24, P2201, DOI 10.1007/s10856-013-4961-y
   Lakowski J, 2011, STEM CELLS, V29, P1391, DOI 10.1002/stem.694
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Lawley E, 2015, J BIOMATER APPL, V29, P894, DOI 10.1177/0885328214547751
   Lin TC, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/9428176
   Little CW, 1998, EXP NEUROL, V149, P151, DOI 10.1006/exnr.1997.6642
   Liu BP, 2006, PHILOS T R SOC B, V361, P1593, DOI 10.1098/rstb.2006.1891
   Liu X, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01651-5
   Liu Y, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0053-y
   Liu Y, 2013, TISSUE ENG PT A, V19, P135, DOI [10.1089/ten.tea.2012.0209, 10.1089/ten.TEA.2012.0209]
   Liu ZP, 2014, BIOMATERIALS, V35, P2837, DOI 10.1016/j.biomaterials.2013.12.069
   Llonch S, 2018, DEV BIOL, V433, P132, DOI 10.1016/j.ydbio.2017.09.028
   Lluis F, 2010, J CELL PHYSIOL, V223, P6, DOI 10.1002/jcp.22003
   Lorach H, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.3.30
   Lowe A, 2016, STEM CELL REP, V6, P743, DOI 10.1016/j.stemcr.2016.03.011
   Lu AQ, 2018, STEM CELL REV REP, V14, P247, DOI 10.1007/s12015-017-9773-x
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lu B, 2012, BIOMED MICRODEVICES, V14, P659, DOI 10.1007/s10544-012-9645-8
   Lu JT, 2007, BIOMATERIALS, V28, P1486, DOI 10.1016/j.biomaterials.2006.11.023
   Lu LC, 1998, J BIOMAT SCI-POLYM E, V9, P1187
   Lu LC, 2001, BIOMATERIALS, V22, P291, DOI 10.1016/S0142-9612(00)00179-4
   Luo C, 2011, MOL VIS, V17, P1588
   Maaijwee K, 2008, BRIT J OPHTHALMOL, V92, P526, DOI 10.1136/bjo.2007.131383
   Maaijwee K, 2007, GRAEF ARCH CLIN EXP, V245, P1681, DOI 10.1007/s00417-007-0607-4
   Maaijwee KJM, 2007, BRIT J OPHTHALMOL, V91, P546, DOI 10.1136/bjo.2006.103259
   MacLaren RE, 2007, EYE, V21, P1352, DOI 10.1038/sj.eye.6702842
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Mandai M, 2017, STEM CELL REP, V8, P69, DOI 10.1016/j.stemcr.2016.12.008
   Marmor M. F., 1998, RETINAL PIGMENT EPIT, DOI [10.1007/978-94-011-5137-5_1, DOI 10.1007/978-94-011-5137-5_1]
   Martin-Martin Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45238-4
   May-Simera HL, 2018, CELL REP, V22, P189, DOI 10.1016/j.celrep.2017.12.038
   McCormick R, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00456
   McGill TJ, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.3.43
   McHugh KJ, 2014, INVEST OPHTH VIS SCI, V55, P1754, DOI 10.1167/iovs.13-12833
   McLelland BT, 2018, INVEST OPHTH VIS SCI, V59, P2586, DOI 10.1167/iovs.17-23646
   Mead B, 2015, STEM CELL RES, V14, P243, DOI 10.1016/j.scr.2015.02.003
   Mead B, 2013, INVEST OPHTH VIS SCI, V54, P7544, DOI 10.1167/iovs.13-13045
   MEDAWAR PB, 1948, BRIT J EXP PATHOL, V29, P58
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Michalska-Malecka K, 2015, EUR GERIATR MED, V6, P69, DOI 10.1016/j.eurger.2014.09.007
   Miyagishima KJ, 2016, STEM CELL TRANSL MED, V5, P1562, DOI 10.5966/sctm.2016-0037
   Miyagishima KJ, 2017, STEM CELL TRANSL INV, V4, pe1497
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Nazari H, 2015, PROG RETIN EYE RES, V48, P1, DOI 10.1016/j.preteyeres.2015.06.004
   Neurotech, 2020, NC503 ECT NEUR
   NIEDERKORN J, 1981, INVEST OPHTH VIS SCI, V20, P355
   Niederkorn Jerry Y, 2007, Chem Immunol Allergy, V92, P1, DOI 10.1159/000099234
   Niyadurupola N, 2011, BRIT J OPHTHALMOL, V95, P720, DOI 10.1136/bjo.2010.181404
   Oganesian A, 1999, ARCH OPHTHALMOL-CHIC, V117, P1192
   Ohlemacher Sarah K, 2015, Curr Protoc Stem Cell Biol, V32, DOI 10.1002/9780470151808.sc01h08s32
   Ortin-Martinez A, 2017, STEM CELLS, V35, P932, DOI 10.1002/stem.2552
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Osborne A, 2016, EXP EYE RES, V143, P28, DOI 10.1016/j.exer.2015.09.012
   Park SS, 2017, PROG RETIN EYE RES, V56, P148, DOI 10.1016/j.preteyeres.2016.10.002
   Pearce W, 2015, CURR OPIN OPHTHALMOL, V26, P233, DOI 10.1097/ICU.0000000000000143
   Pearson RA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13029
   Pearson RA, 2012, NATURE, V485, P99, DOI 10.1038/nature10997
   Peng CH, 2016, ONCOTARGET, V7, P64631, DOI 10.18632/oncotarget.11502
   Radtke ND, 2002, AM J OPHTHALMOL, V133, P544, DOI 10.1016/S0002-9394(02)01322-3
   Radtke ND, 2008, AM J OPHTHALMOL, V146, P172, DOI 10.1016/j.ajo.2008.04.009
   Rajala RVS, 2016, NAT MED, V22, P342, DOI 10.1038/nm.4080
   Ramakrishna S, 2001, COMPOS SCI TECHNOL, V61, P1189, DOI 10.1016/S0266-3538(00)00241-4
   Redenti Stephen, 2008, J Ocul Biol Dis Infor, V1, P19, DOI 10.1007/s12177-008-9005-3
   Redenti S, 2009, BIOMATERIALS, V30, P3405, DOI 10.1016/j.biomaterials.2009.02.046
   Rose JB, 2014, MATERIALS, V7, P3106, DOI 10.3390/ma7043106
   Rowland TJ, 2012, J CELL PHYSIOL, V227, P457, DOI 10.1002/jcp.22814
   Rupenthal ID, 2017, CURR OPIN PHARMACOL, V36, P44, DOI 10.1016/j.coph.2017.08.003
   Sabel BA, 2011, PROG BRAIN RES, V192, P199, DOI 10.1016/B978-0-444-53355-5.00013-0
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   Sandhu H., 2019, CELL BASED THERAPY D, P141, DOI [10.1007/978-3-030-05222-5_8, DOI 10.1007/978-3-030-05222-5_8]
   Sanges D, 2016, J CLIN INVEST, V126, P3104, DOI 10.1172/JCI85193
   Santos-Ferreira T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13028
   Santos-Ferreira T, 2016, INVEST OPHTH VIS SCI, V57, P3509, DOI 10.1167/iovs.16-19087
   Sauve Y., 1995, REGENERATION VISUAL
   Schubert C, 2014, BRIT J OPHTHALMOL, V98, P159, DOI 10.1136/bjophthalmol-2013-304446
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   SEATON AD, 1994, INVEST OPHTH VIS SCI, V35, P162
   Seiler MJ, 2012, PROG RETIN EYE RES, V31, P661, DOI 10.1016/j.preteyeres.2012.06.003
   Shadforth AM, 2015, J TISSUE ENG REGEN M, V11, P1915, DOI 10.1002/term.2089
   Shirai H, 2016, P NATL ACAD SCI USA, V113, pE81, DOI 10.1073/pnas.1512590113
   Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103
   Singh D, 2018, BIOMATERIALS, V154, P158, DOI 10.1016/j.biomaterials.2017.10.052
   Singh MS, 2020, PROG RETIN EYE RES, V75, DOI 10.1016/j.preteyeres.2019.100779
   Singh MS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13537
   Singh MS, 2013, P NATL ACAD SCI USA, V110, P1101, DOI 10.1073/pnas.1119416110
   Singh MS, 2011, P ROY SOC B-BIOL SCI, V278, P3009, DOI 10.1098/rspb.2011.1028
   Singh R, 2018, STEM CELL REV REP, V14, P463, DOI 10.1007/s12015-018-9802-4
   Singh RK, 2019, STEM CELLS DEV, V28, P1151, DOI 10.1089/scd.2019.0090
   Singh S, 2001, BIOMATERIALS, V22, P3337, DOI 10.1016/S0142-9612(01)00171-5
   Sodha S, 2011, J BIOMAT SCI-POLYM E, V22, P443, DOI 10.1163/092050610X487738
   Sonoi R, 2017, J BIOSCI BIOENG, V124, P227, DOI 10.1016/j.jbiosc.2017.03.008
   Sortwell CE, 2000, EXP NEUROL, V165, P268, DOI 10.1006/exnr.2000.7476
   Srivastava GK, 2011, J BIOMED MATER RES A, V97A, P243, DOI 10.1002/jbm.a.33050
   Stanzel BV, 2014, STEM CELL REP, V2, P64, DOI 10.1016/j.stemcr.2013.11.005
   Steindl K, 2008, SPEKTRUM AUGENHEILKD, V22, P357, DOI 10.1007/s00717-008-0292-7
   Stern JH, 2018, CELL STEM CELL, V22, P834, DOI 10.1016/j.stem.2018.05.013
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Streilein JW, 2003, J LEUKOCYTE BIOL, V74, P179, DOI 10.1189/jlb.1102574
   Subrizi A, 2012, BIOMATERIALS, V33, P8047, DOI 10.1016/j.biomaterials.2012.07.033
   Tam RY, 2014, NEUROPSYCHOPHARMACOL, V39, P169, DOI 10.1038/npp.2013.237
   Tao S, 2007, LAB CHIP, V7, P695, DOI 10.1039/b618583e
   Tao W, 2002, INVEST OPHTH VIS SCI, V43, P3292
   Taylor AW, 2018, J LEUKOCYTE BIOL, V103, P1179, DOI 10.1002/JLB.3MIR0817-337R
   Taylor AW, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00037
   Taylor L, 2014, INVEST OPHTH VIS SCI, V55, P2200, DOI 10.1167/iovs.13-13535
   Taylor L, 2013, CURR EYE RES, V38, P503, DOI 10.3109/02713683.2013.763989
   Tezel TH, 2007, AM J OPHTHALMOL, V143, P584, DOI 10.1016/j.ajo.2006.12.007
   Thakur A, 2018, J TISSUE ENG, V9, DOI 10.1177/2041731417751286
   Thangaraj G, 2011, EXP EYE RES, V93, P556, DOI 10.1016/j.exer.2011.07.011
   Tomita M, 2005, STEM CELLS, V23, P1579, DOI 10.1634/stemcells.2005-0111
   Tu HY, 2019, EBIOMEDICINE, V39, P562, DOI 10.1016/j.ebiom.2018.11.028
   Tucker BA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018992
   Tucker BA, 2010, BIOMATERIALS, V31, P9, DOI 10.1016/j.biomaterials.2009.09.015
   van Zeeburg EJT, 2012, AM J OPHTHALMOL, V153, P120, DOI 10.1016/j.ajo.2011.06.007
   Ventola C Lee, 2014, P T, V39, P704
   Volkner M, 2016, STEM CELL REP, V6, P525, DOI 10.1016/j.stemcr.2016.03.001
   Waldron PV, 2018, STEM CELL REP, V10, P406, DOI 10.1016/j.stemcr.2017.12.008
   Wang SW, 2002, METHODS, V28, P448, DOI 10.1016/S1046-2023(02)00264-5
   Warnke PH, 2013, ACTA BIOMATER, V9, P9414, DOI 10.1016/j.actbio.2013.07.029
   Weiner Leslie P., 2008, V438, P3, DOI 10.1007/978-1-59745-133-8_1
   Weiss JN, 2015, NEURAL REGEN RES, V10, P982, DOI 10.4103/1673-5374.158365
   Wenk E, 2011, J CONTROL RELEASE, V150, P128, DOI 10.1016/j.jconrel.2010.11.007
   West EL, 2009, PROG BRAIN RES, V175, P3, DOI 10.1016/S0079-6123(09)17501-5
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu HJ, 2007, GRAEF ARCH CLIN EXP, V245, P135, DOI 10.1007/s00417-006-0296-4
   Xian BK, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/7148032
   Xiang P, 2014, BIOMATERIALS, V35, P9777, DOI 10.1016/j.biomaterials.2014.08.040
   Yang TC, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18092013
   Yang Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013469
   Yao J, 2015, TISSUE ENG PT A, V21, P1247, DOI [10.1089/ten.tea.2013.0720, 10.1089/ten.TEA.2013.0720]
   Yao J, 2011, POLYMERS-BASEL, V3, P899, DOI 10.3390/polym3020899
   Zarbin M, 2019, METHODS MOL BIOL, V1834, P367, DOI 10.1007/978-1-4939-8669-9_23
   Zarbin M, 2016, TRENDS MOL MED, V22, P115, DOI 10.1016/j.molmed.2015.12.007
   Zhang DD, 2015, SCI REP-UK, V5, DOI 10.1038/srep14326
   Zhong XF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5047
NR 264
TC 6
Z9 6
U1 4
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-4185
J9 FRONT BIOENG BIOTECH
JI Front. Bioeng. Biotechnol.
PD DEC 10
PY 2020
VL 8
AR 588014
DI 10.3389/fbioe.2020.588014
PG 27
WC Biotechnology & Applied Microbiology; Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA PI7OR
UT WOS:000601276300001
PM 33363125
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kim, MS
   Ryoo, NK
   Park, KH
AF Kim, Min Seok
   Ryoo, Na-Kyung
   Park, Kyu Hyung
TI Laser and anti-vascular endothelial growth factor treatment for
   drusenoid pigment epithelial detachment in age-related macular
   degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; SOFT DRUSEN; PHOTOCOAGULATION;
   CLASSIFICATION; REGRESSION; FEATURES; ATROPHY; EYES
AB This study aims to report the 12 months results of efficacy and safety of laser photocoagulation and anti-vascular endothelial growth factor (VEGF) injections for drusenoid pigment epithelial detachment (dPED). In this prospective study, patients with treatment naive bilateral intermediate age-related macular degeneration, featuring dPED, with visual acuity <= 83 letters were enrolled. The study group received PASCAL laser (532 nm) along the periphery of the dPED, and the fellow eye served as a control group. To prevent complications of choroidal neovascularization, intravitreal anti-VEGF injections to laser treated eye were performed on a 3-month interval up to 1 year. Primary outcomes-drusen area, PED height-and secondary outcomes-best-corrected visual acuity (BCVA), contrast sensitivity, degree of metamorphopsia, NEI-VFQ 25, and fundus autofluorescence-were analyzed. Among 21 patients, a total of 20 patients satisfied the 12 months follow-up. Drusen area and PED height decreased significantly in the laser group, while no significant change appeared in the control group (74.1% vs.- 3.5%, P<0.001; 76.6% vs. 0.1%, P<0.001). Mean BCVA improved 4.6 letters in the laser group (vs. 1.1 letters in the control group, P=0.019). As for safety, one study eye developed retinal pigment epithelial tear, and one control eye developed retinal angiomatous proliferation. Low energy laser photocoagulation and anti-VEGF injection in eyes with dPED showed some improvement in visual acuity. dPED regressed without developing center involving GA in the study eye, but a longer term follow-up is necessary to reveal the efficacy and safety of these treatments. The 2-year results of this study will be followed to reveal long term efficacy and safety of the treatment for dPED.
C1 [Kim, Min Seok; Park, Kyu Hyung] Seoul Natl Univ, Dept Ophthalmol, Coll Med, Seoul, South Korea.
   [Kim, Min Seok; Park, Kyu Hyung] Seoul Natl Univ, Dept Ophthalmol, Bundang Hosp, 173-82 Gumi Ro, Seongnam Si 13620, Gyeonggi Do, South Korea.
   [Ryoo, Na-Kyung] Vet Hlth Serv Med Ctr, Dept Ophthalmol, Seoul, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU);
   Veterans Health Service Medical Center
RP Park, KH (通讯作者)，Seoul Natl Univ, Dept Ophthalmol, Coll Med, Seoul, South Korea.; Park, KH (通讯作者)，Seoul Natl Univ, Dept Ophthalmol, Bundang Hosp, 173-82 Gumi Ro, Seongnam Si 13620, Gyeonggi Do, South Korea.
EM jiani4@snu.ac.kr
OI Reis, AlessanRSS/0000-0001-8486-7469
FU SNUBH Research Fund [14-2015-027]
FX This study was supported by the SNUBH Research Fund (Grant No.
   14-2015-027). The funding organization had no role in the design or
   conduct of this study.
CR [Anonymous], 1998, Ophthalmology, V105, P11
   Baba T, 2012, OPHTHALMOLOGICA, V228, P102, DOI 10.1159/000337251
   BARONDES MJ, 1992, BRIT J OPHTHALMOL, V76, P5, DOI 10.1136/bjo.76.1.5
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   CHISHOLM IH, 1982, BRIT J OPHTHALMOL, V66, P1
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Eng VA, 2019, OSLI RETINA, V50, pE61, DOI 10.3928/23258160-20190301-13
   FIGUEROA MS, 1994, RETINA-J RET VIT DIS, V14, P391, DOI 10.1097/00006982-199414050-00001
   Friberg TR, 2009, OPHTHAL SURG LAS IM, V40, P530, DOI 10.3928/15428877-20091030-01
   Gallego-Pinazo R, 2011, CLIN OPHTHALMOL, V5, P161, DOI 10.2147/OPTH.S15832
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Krishnan R, 2010, CAN J OPHTHALMOL, V45, P83, DOI 10.3129/i09-187
   Lee Na Young, 2008, Korean J Ophthalmol, V22, P194, DOI 10.3341/kjo.2008.22.3.194
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Owens SL, 2006, AM J OPHTHALMOL, V141, P276, DOI 10.1016/j.ajo.2005.08.019
   Owens SL, 2003, EYE, V17, P623, DOI 10.1038/sj.eye.6700442
   Park DW, 2006, OPHTHALMOLOGY, V113, P1974, DOI 10.1016/j.ophtha.2006.08.015
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Querques G, 2018, GRAEF ARCH CLIN EXP, V256, P1, DOI 10.1007/s00417-017-3848-x
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Scanlon PH, 2015, DIABETIC MED, V32, P97, DOI 10.1111/dme.12593
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Virgili G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub3
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P1546, DOI 10.1167/iovs.14-16211
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Xie X, 2018, OPJ, V8, P173, DOI [DOI 10.4236/OPJ.2018.86016, 10.4236/opj.2018.86016]
   Yu JJ, 2019, OPHTHALMOLOGY, V126, P261, DOI 10.1016/j.ophtha.2018.08.017
NR 29
TC 4
Z9 5
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD SEP 1
PY 2020
VL 10
IS 1
AR 14370
DI 10.1038/s41598-020-71401-3
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA NQ9YQ
UT WOS:000571222300027
PM 32873842
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Westborg, I
   Granstam, E
   Rosso, A
   Albrecht, S
   Karlsson, N
   Lovestam-Adrian, M
AF Westborg, Inger
   Granstam, Elisabet
   Rosso, Aldana
   Albrecht, Susanne
   Karlsson, Niklas
   Lovestam-Adrian, Monica
TI Treatment for neovascular age-related macular degeneration in Sweden:
   outcomes at seven years in the Swedish Macula Register
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; anti-vascular endothelial growth
   factor; anti-VEGF; ETDRS; neovascular AMD; Swedish Macula Register
ID ENDOTHELIAL GROWTH-FACTOR; 7-YEAR OUTCOMES; VISUAL-ACUITY; RANIBIZUMAB;
   HORIZON; ANCHOR; MARINA; THERAPY; ATROPHY; LIFE
AB PurposeTo present Swedish Macula Register (SMR) data regarding treatment of neovascular age-related macular degeneration (AMD) in clinical practice since 2008.
   MethodsA retrospective register-based study was conducted. Evaluation of baseline demographics, visual outcome and number of injections during this period is presented.
   ResultsMean age at diagnosis was 79(SD) 8years; 65% were female. The proportion of patients with <2months' duration of symptoms increased from 26% in 2008 to 41% in 2014 (p=0.001). Mean visual acuity (VA) at baseline increased from 54.3 +/- 15.0 early treatment diabetic retinopathy study (ETDRS) letters in 2008 to 57.8 +/- 15.6 letters in 2014 (CI95 2.6; 4.3; p<0.001). Mean VA after 1year of treatment increased from 57.8 +/- 17.7 ETDRS letters for patients who started the treatment in 2008 to 62.8 +/- 16.4 ETDRS letters in patients starting treatment in 2014 (CI95 2.67; 4.64; p<0.001). During all study years, the proportion of patients with an improvement in VA of between 5 and 15 letters was around 30%, while 14% had VA improvement of more than 15 letters. The mean number of injections during the first treatment year increased from 4.3 +/- 1.9 in 2008 to 5.9 +/- 2.9 in 2014 (CI95 1.40; 1.67; p<0.001). Seven-year follow-up of 322 eyes showed a mean change of -1 letters from baseline, with a mean of 21 injections for the entire period.
   ConclusionThe duration of symptoms before treatment decreased, while VA at baseline and after 1year of treatment increased over the years and so did the number of injections. Long-term follow-up demonstrated stable VA.
C1 [Westborg, Inger] Umea Univ Hosp, Dept Clin Sci, Umea, Sweden.
   [Granstam, Elisabet] Uppsala Univ, Cty Council Vastmanland, Clin Res Ctr, Vasteras, Sweden.
   [Rosso, Aldana] Lund Univ, Dept Radiol, Inst Translat Med, Malmo, Sweden.
   [Albrecht, Susanne] Blekinge Hosp, Register Ctr South, Karlskrona, Sweden.
   [Karlsson, Niklas] Orebro Univ Hosp, Dept Ophthalmol, Orebro, Sweden.
   [Lovestam-Adrian, Monica] Lund Univ, Dept Ophthalmol, Lund, Sweden.
C3 Umea University; Uppsala University; Lund University; Orebro University;
   Lund University
RP Westborg, I (通讯作者)，Umea Univ Hosp, Dept Clin Sci, Ophthalmol, Akad Sjukhuset,Ogonmottagningen, S-75185 Uppsala, Sweden.
EM inger.westborg@akademiska.se
RI Westborg, Inger/AAD-7108-2021
OI Rosso, Aldana/0000-0001-6603-2855
CR Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Epstein D, 2016, RETINA-J RET VIT DIS, V36, P1773, DOI 10.1097/IAE.0000000000000978
   Freund KB, 2013, EXPERT OPIN PHARMACO, V14, P1017, DOI 10.1517/14656566.2013.787410
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Granstam E, 2016, ACTA OPHTHALMOL, V94, P646, DOI 10.1111/aos.13187
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Hatz K, 2017, ACTA OPHTHALMOL, V95, pE67, DOI 10.1111/aos.13031
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Kvannli L, 2017, ACTA OPHTHALMOL
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Rasmussen A, 2015, ACTA OPHTHALMOL, V93, P616, DOI 10.1111/aos.12781
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rung L, 2013, CLIN OPHTHALMOL, V7, P395, DOI 10.2147/OPTH.S41585
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Souied EH, 2015, RETINA-J RET VIT DIS, V35, P1743, DOI 10.1097/IAE.0000000000000548
   Tah V, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/627674
   Westborg I, 2017, RETINA
   Westborg I, 2015, ANN REPORT SWEDISH M
   Wolf A, 2014, GRAEF ARCH CLIN EXP, V252, P647, DOI 10.1007/s00417-013-2562-6
NR 27
TC 20
Z9 20
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2017
VL 95
IS 8
BP 787
EP 795
DI 10.1111/aos.13539
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FP5FR
UT WOS:000417645900022
PM 28834299
OA Bronze
DA 2022-11-30
ER

PT J
AU Mojana, F
   Cheng, L
   Bartsch, DUG
   Silva, GA
   Kozak, I
   Nigam, N
   Freeman, WR
AF Mojana, Francesca
   Cheng, Lingyun
   Bartsch, Dirk-Uwe G.
   Silva, Gabriel A.
   Kozak, Igor
   Nigam, Nitin
   Freeman, William R.
TI The role of abnormal vitreomacular adhesion in age-related macular
   degeneration: Spectral optical coherence tomography and surgical results
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID POSTERIOR VITREOUS DETACHMENT; BEAVER DAM EYE; PATHOGENESIS;
   INFLAMMATION; POLYMORPHISM; MACULOPATHY; POPULATION; DRUSEN; RISK; AMD
AB PURPOSE: To assess the incidence of vitreomacular adhesion and traction in age-related macular degeneration (AMD), and to evaluate surgical treatment in a subset of patients with choroidal neovascularization (CNV) nonresponsive to anti-neovascular growth factor (anti,VEGF) treatment.
   DESIGN: Retrospective observational case-control and interventional case series.
   METHODS: Spectral optical coherence tomography, combined with simultaneous scanning laser ophthalmoscope (Spectral OCT/SLO), was performed in 170 eyes of 94 elderly patients, 61 with exudative AMD, 59 with nonexudative AMD, and 50 control eyes. The presence of hyaloid adhesion to the posterior pole, and vitreomacular traction (VMT) were determined. Five patients with VMT underwent surgical hyaloid removal. Best-corrected visual acuity (BCVA) and retinal thickness were evaluated as outcomes.
   RESULTS: Hyaloid adhesion was present in 17 eyes with exudative AMD (27.8%), 15 eyes with nonexudative AMD (25.4%), and eight control eyes (16%). Significant difference was found among the groups (P = .002). Among the eyes with hyaloid adhesion, VMT was shown in 10 eyes (59%) with exudative AMD, two eyes (13%) with nonexudative AMD, and one control eye (12%). VMT was associated with the severity of AMD (P = .0082). The area of hyaloid adhesion was significantly smaller than and concentric to the area of CNV complex in eyes with exudative AMD. Eyes with VMT that underwent surgery experienced a modest improvement of BCVA and decrease of retinal thickness.
   CONCLUSIONS: Hyaloid adhesion to the macula is associated with AMD, and frequently causes VMT in eyes with CNV. Tractional forces may antagonize the effect of anti-VEGF treatment, and cause pharmacological resistance in a subpopulation of patients. Future studies are needed to define the role of vitreoretinal surgery in such cases. Spectral OCT/SLO allows careful diagnosis and follow-up.
C1 [Mojana, Francesca; Cheng, Lingyun; Bartsch, Dirk-Uwe G.; Silva, Gabriel A.; Kozak, Igor; Nigam, Nitin; Freeman, William R.] Univ Calif San Diego, Jacobs Retina Ctr, Shiley Eye Ctr, Dept Ophthalmol, La Jolla, CA 92037 USA.
   [Silva, Gabriel A.] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92037 USA.
C3 University of California System; University of California San Diego;
   University of California System; University of California San Diego
RP Freeman, WR (通讯作者)，Univ Calif San Diego, Dept Ophthalmol, Shiley Eye Ctr, Joan & Irwin Jacobs Retina Ctr, 0946,9415 Campus Point Dr, La Jolla, CA 92037 USA.
EM freeman@eyecenter.ucsd.edu
RI Kozak, Igor/AAC-4645-2019
FU NEI NIH HHS [R01 EY007366, R01 EY016323, R01 EY007366-21, EY16323,
   EY07366] Funding Source: Medline; NINDS NIH HHS [R01 NS054736, R01
   NS054736-02, R01 NS054736-03] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [R01EY016323, R01EY007366] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS054736]
   Funding Source: NIH RePORTER
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Chu TG, 1996, OPHTHALMOLOGY, V103, P315
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   de Boer JF, 2003, OPT LETT, V28, P2067, DOI 10.1364/OL.28.002067
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Freeman WR, 2006, RETINA-J RET VIT DIS, V26, P853, DOI 10.1097/01.iae.0000244722.35073.7c
   Johnson Mark W, 2005, Trans Am Ophthalmol Soc, V103, P537
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Kakehashi A, 1997, BRIT J OPHTHALMOL, V81, P527, DOI 10.1136/bjo.81.7.527
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   LAMBERT HM, 1992, AM J OPHTHALMOL, V113, P257, DOI 10.1016/S0002-9394(14)71576-4
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13
   LIPSITZ SR, 1994, STAT MED, V13, P1149, DOI 10.1002/sim.4780131106
   Mori K, 2007, J HUM GENET, V52, P636, DOI 10.1007/s10038-007-0162-1
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Ondes F, 2000, JPN J OPHTHALMOL, V44, P91, DOI 10.1016/S0021-5155(99)00174-4
   Petrukhin K, 2007, EXPERT OPIN THER TAR, V11, P625, DOI 10.1517/14728222.11.5.625
   Quaranta-El Maftouhi M, 2006, EUR J OPHTHALMOL, V16, P134
   Ramirez JM, 2001, EXP EYE RES, V73, P601, DOI 10.1006/exer.2001.1061
   Schmidt-Erfurth U, 2005, INVEST OPHTH VIS SCI, V46, P3393, DOI 10.1167/iovs.05-0370
   Schubert H D, 1989, Prog Clin Biol Res, V312, P277
   Srinivasan VJ, 2006, OPHTHALMOLOGY, V113, P2054, DOI 10.1016/j.ophtha.2006.05.046
   Uchino E, 2001, ARCH OPHTHALMOL-CHIC, V119, P1475
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Weber-Krause Brigitte, 1996, Ophthalmologe, V93, P660, DOI 10.1007/s003470050054
   Wojtkowski M, 2002, J BIOMED OPT, V7, P457, DOI 10.1117/1.1482379
   Wu KHC, 2003, BRIT J OPHTHALMOL, V87, P1159, DOI 10.1136/bjo.87.9.1159
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 33
TC 134
Z9 144
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD AUG
PY 2008
VL 146
IS 2
BP 218
EP 227
DI 10.1016/j.ajo.2008.04.027
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 333CD
UT WOS:000258128700011
PM 18538742
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Hagstrom, SA
   Ying, GS
   Maguire, MG
   Martin, DF
   Gibson, J
   Lotery, A
   Chakravarthy, U
AF Hagstrom, Stephanie A.
   Ying, Gui-shuang
   Maguire, Maureen G.
   Martin, Daniel F.
   Gibson, Jane
   Lotery, Andrew
   Chakravarthy, Usha
CA CATT Res Grp
   IVAN Study Investigators
TI VEGFR2 Gene Polymorphisms and Response to Anti-Vascular Endothelial
   Growth Factor Therapy in Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID TREATMENTS TRIALS CATT; SUBGROUP ANALYSIS; RANIBIZUMAB; BEVACIZUMAB
AB Purpose: A previously published study demonstrated a pharmacogenetic association between the minor alleles of 2 VEGFR2 single nucleotide polymorphisms (SNPs) and greater improvement in visual acuity (VA) to treatment with ranibizumab, an antievascular endothelial growth factor (VEGF) drug, in patients with neovascular age-related macular degeneration (AMD). We evaluated whether this association was replicated among patients who participated in the Comparison of AMD Treatments Trials (CATT) or the Alternative Treatments to Inhibit VEGF in Patients with Age-Related Choroidal Neovascularisation (IVAN) trial.
   Design: Cohort studies within randomized clinical trials.
   Participants: Eight hundred thirty-five patients participating in CATT and 512 patients participating in IVAN.
   Methods: Each patient was genotyped for the SNPs rs4576072 and rs6828477 in the VEGFR2 gene.
   Main Outcomes Measures: Mean change in VA from baseline to 1 year after initiation of treatment with ranibizumab or bevacizumab. Differences in VA response between the patient group homozygous for the minor allele of each SNP and the other genotype groups were evaluated with analysis of variance. Differences in VA response by the number of minor alleles present for either SNP or both combined were evaluated with tests of linear trend. Analyses were conducted separately for CATT and IVAN participants and with both the studies combined.
   Results: No statistically significant difference in mean change in VA was identified between genotypes of either SNP (P >= 0.05). Furthermore, a stepwise analysis failed to show a significant interaction for either SNP based on the number of minor alleles present. The lack of association was similar in both the CATT and IVAN cohorts and whether the analysis combined patients treated with either ranibizumab or bevacizumab or when restricted to patients treated with ranibizumab only.
   Conclusions: The CATT and IVAN data do not support a pharmacogenetic association between the 2 VEGFR2 SNPs, rs4576072 and rs6828477, and change in VA in response to anti-VEGF therapy in patients with neovascular AMD. (C) 2015 by the American Academy of Ophthalmology.
C1 [Hagstrom, Stephanie A.; Martin, Daniel F.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44195 USA.
   [Hagstrom, Stephanie A.; Martin, Daniel F.] Case Western Reserve Univ, Coll Med, Dept Ophthalmol, Cleveland Clin Lerner, Cleveland, OH 44106 USA.
   [Ying, Gui-shuang; Maguire, Maureen G.] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Gibson, Jane] Univ Southampton, Ctr Biol Sci, Southampton, Hants, England.
   [Lotery, Andrew] Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England.
   [Chakravarthy, Usha] Queens Univ, Dept Ophthalmol, Belfast, Antrim, North Ireland.
C3 Cleveland Clinic Foundation; Case Western Reserve University; Cleveland
   Clinic Foundation; University of Pennsylvania; University of
   Southampton; University of Southampton; Queens University Belfast
RP Hagstrom, SA (通讯作者)，Cleveland Clin, Cole Eye Inst, Ophthalm Res, i31,9500 Euclid Ave, Cleveland, OH 44195 USA.
EM hagstrs@ccf.org
RI Gibson, Jane/I-1630-2012
OI Gibson, Jane/0000-0002-0973-8285; Lotery, Andrew/0000-0001-5541-4305;
   Chakravarthy, Usha/0000-0002-2606-3734
FU National Eye Institute, National Institutes of Health, Bethesda,
   Maryland [U10 EY017823, U10 EY017825, U10 EY017826, U10 EY017828,
   R21EY023689]; National Institute for Health Research Health Technology
   Assessment program, National Institute for Health Research Evaluation,
   Trials and Studies Coordinating Centre, University of Southampton,
   Southampton, United Kingdom [07/36/01]; Macular Society, Andover, United
   Kingdom; NATIONAL EYE INSTITUTE [U10EY017828, U10EY017825, U10EY017826,
   R21EY023689, U10EY017823] Funding Source: NIH RePORTER
FX The Comparison of Age-Related Macular Degeneration Treatments Trials
   trial were supported by the National Eye Institute, National Institutes
   of Health, Bethesda, Maryland (cooperative agreement nos.: U10 EY017823,
   U10 EY017825, U10 EY017826, U10 EY017828, and R21EY023689). The
   Alternative Treatments to Inhibit Vascular Endothelial Growth Factor in
   Patients with Age-Related Choroidal Neovascularisation trial was funded
   by the National Institute for Health Research Health Technology
   Assessment program, National Institute for Health Research Evaluation,
   Trials and Studies Coordinating Centre, University of Southampton,
   Southampton, United Kingdom (project no.: 07/36/01), and by the Macular
   Society, Andover, United Kingdom. The sponsors or funding organizations
   had no role in the design or conduct of this research.
CR Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Ennis S, 2010, EYE, V24, P328, DOI 10.1038/eye.2009.73
   Hagstrom SA, 2014, JAMA OPHTHALMOL, V132, P521, DOI 10.1001/jamaophthalmol.2014.109
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hermann MM, 2014, OPHTHALMOLOGY, V121, P905, DOI 10.1016/j.ophtha.2013.10.047
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Lotery AJ, 2013, OPHTHALMOLOGY, V120, P2637, DOI 10.1016/j.ophtha.2013.07.046
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 12
TC 23
Z9 28
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2015
VL 122
IS 8
BP 1563
EP 1568
DI 10.1016/j.ophtha.2015.04.024
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CN3JV
UT WOS:000358322900013
PM 26028346
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Tufail, A
   Xing, W
   Johnston, R
   Akerele, T
   McKibbin, M
   Downey, L
   Natha, S
   Chakravarthy, U
   Bailey, C
   Khan, R
   Antcliff, R
   Armstrong, S
   Varma, A
   Kumar, V
   Tsaloumas, M
   Mandal, K
   Bunce, C
AF Tufail, Adnan
   Xing, Wen
   Johnston, Robert
   Akerele, Toks
   McKibbin, Martin
   Downey, Louise
   Natha, Salim
   Chakravarthy, Usha
   Bailey, Clare
   Khan, Rehna
   Antcliff, Richard
   Armstrong, Stewart
   Varma, Atul
   Kumar, Vineeth
   Tsaloumas, Marie
   Mandal, Kaveri
   Bunce, Catey
CA UK Age-Related Macular
TI The Neovascular Age-Related Macular Degeneration Database: Multicenter
   Study of 92 976 Ranibizumab Injections
SO OPHTHALMOLOGY
LA English
DT Article
ID VISUAL-ACUITY; BEVACIZUMAB; OUTCOMES; TRIAL
AB Purpose: To study real-world ranibizumab therapy for treatment-naive eyes with neovascular age-related macular degeneration (nAMD) and to benchmark standards of care.
   Design: Multicenter, national nAMD database study.
   Participants: A total of 92 976 treatment episodes from 12 951 eyes of 11 135 patients.
   Methods: Up to 5 years of routinely collected, anonymized data were extracted remotely from 14 United Kingdom centers to a central database using an electronic medical record (EMR) system. Participating centers used ranibizumab to treat nAMD using a loading phase of 3 monthly injections and a pro re nata retreatment regimen. The minimum data set defined before first patient data entry and mandated by the EMR system included age, Early Treatment Diabetic Retinopathy Study visual acuity (VA) at all visits, and injection episodes.
   Main Outcome Measures: Baseline VA, change in VA, number of treatments and clinic visits, and baseline characteristics affecting VA change.
   Results: Information from more than 300 000 clinic visits (2.8 million data points) were collated. Mean age at first treatment was 79.1 years, with a female preponderance of 1.7: 1. Mean VA (letters) for eyes followed up for at least 3 years from a baseline of 55 letters was 57 (+2) letters at 1 year, 56 (+1) letters at 2 years, and 53 (-2) letters at 3 years. The proportion of eyes that avoided moderate vision loss at years 1, 2, and 3 were 90%, 84%, and 82%, respectively. The proportion of eyes with VA of 20/40 or better were: baseline, 16%; year 1, 30%; year 2, 30%; and year 3, 29%. The median number of treatments for eyes followed up for at least 3 years in years 1, 2 and 3 was 5, 4, and 4, respectively, and the median number of outpatient visits was 9.2, 8.2, and 8.2, respectively. Baseline VA was related inversely to mean vision gain at 3 months. Older age was associated with lower presenting VA.
   Conclusions: Real-world visual outcomes achieved at a large number of centers across the United Kingdom do not match the results achieved in most randomized trials, but they were delivered with substantially fewer injections and hospital visits. This study provides important benchmark results that should be of interest to patients, retina specialists, and commissioners of health care. This study demonstrates the EMR system's potential usefulness for future phase 4 and 5 clinical trials. (C) 2014 by the American Academy of Ophthalmology.
RP Tufail, A (通讯作者)，Moorfields Eye Hosp NHS Trust, 162 City Rd, London EC1V 2PD, England.
EM Adnan.tufail@moorfields.nhs.uk
OI McKibbin, Martin/0000-0003-4388-243X; Bunce, Catey/0000-0002-0935-3713;
   Tufail, Adnan/0000-0001-6131-7640
FU Novartis Pharmaceuticals UK Limited, Frimley, UK; Department of Health's
   NIHR Biomedical Research Centre for Ophthalmology at Moorfields Eye
   Hospital; UCL Institute of Ophthalmology
FX Supported in part by an unrestricted grant from Novartis Pharmaceuticals
   UK Limited, Frimley, UK. No member or affiliate of Novartis had any
   input into data analysis, interpretation of the data, or writing the
   manuscript. This research received a proportion of its funding from the
   Department of Health ' s NIHR Biomedical Research Centre for
   Ophthalmology at Moorfields Eye Hospital and UCL Institute of
   Ophthalmology. The views expressed in the publication are those of the
   authors and not necessarily those of the Department of Health.
CR Bandukwala T, 2010, CAN J OPHTHALMOL, V45, P590, DOI 10.3129/i10-082
   Black AD, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000387
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Center for Preventive Ophthalmology and Biostatistics, COMP AG REL MAC DEG
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Classen DC, 2011, NEW ENGL J MED, V365, P855, DOI 10.1056/NEJMsb1103659
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Javitt J, 2005, EYE, V19, P727, DOI 10.1038/sj.eye.6701645
   Johnston RL, 2010, EYE, V24, P888, DOI 10.1038/eye.2009.195
   Lange C, 2009, GRAEF ARCH CLIN EXP, V247, P137, DOI 10.1007/s00417-008-0926-0
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   National Institute for Health and Clinical Excellence, 2012, RAN PEG TREATM AG RE
   Newcombe RG, 1998, STAT MED, V17, P857, DOI 10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E
   NEWCOMBE RG, 1987, BRIT MED J, V295, P656, DOI 10.1136/bmj.295.6599.656
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross AH, 2013, EYE, V27, P56, DOI 10.1038/eye.2012.225
   Rotsos T, 2010, CLIN OPHTHALMOL, V4, P1271, DOI 10.2147/OPTH.S14684
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Sparrow JM, 2012, EYE, V26, P821, DOI 10.1038/eye.2012.51
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Williams TA, 2011, EYE, V25, P1617, DOI 10.1038/eye.2011.224
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 27
TC 221
Z9 226
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2014
VL 121
IS 5
BP 1092
EP 1101
DI 10.1016/j.ophtha.2013.11.031
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AG6BT
UT WOS:000335504200023
PM 24461586
OA hybrid
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Panos, GD
   Gatzioufas, Z
   Petropoulos, IK
   Dardabounis, D
   Thumann, G
   Hafezi, F
AF Panos, Georgios D.
   Gatzioufas, Zisis
   Petropoulos, Ioannis K.
   Dardabounis, Doukas
   Thumann, Gabriele
   Hafezi, Farhad
TI Effect of ranibizumab on serous and vascular pigment epithelial
   detachments associated with exudative age-related macular degeneration
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularisation;
   intravitreal injection; pigment epithelial detachment; ranibizumab
ID OCCULT CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; INTRAVITREAL
   BEVACIZUMAB; CLASSIFICATION; MACULOPATHY
AB Purpose: To report the effect of intravitreal ranibizumab therapy for serous and vascular pigment epithelial detachments (PED) associated with choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD).
   Methods: In a prospective study, best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) data were collected for 62 eyes of 62 patients, with serous or vascular PED associated with CNV secondary to AMD. Intravitreal ranibizumab 0.5 mg was administered with a loading phase of three consecutive monthly injections, followed by monthly review with further treatment, as indicated according to the retreatment criteria of the PrONTO study. The change in visual acuity and PED height from baseline to month 12 after the first injection was determined.
   Results: Sixty-one eyes of 61 patients (one of the patients developed retinal pigment epithelial tear and was excluded from the study) were assessed at the 12-month follow-up examination. There were two types of PED, including vascular PED in 32 patients (Group A) and serous PED (Group B) in 29 patients. The mean improvement of mean BCVA from baseline to 12 months was 0.09 logMAR (Logarithm of the Minimum Angle of Resolution) in Group A and 0.13 logMAR in Group B. Both groups showed significant improvement of the mean BCVA 12 months after the first injection compared with the baseline value (P < 0.05). In relation to the PED height, the mean decrease of mean PED height from baseline to 12 months was 135 mu m in Group A and 180 mu m in Group B. Both groups showed significant reduction of the PED height during the follow-up period (P < 0.01). The PED anatomical response to ranibizumab was not correlated with the BCVA improvement in any of the groups. Apart from one patient who developed pigment epithelial tear no other complications were documented.
   Conclusion: Ranibizumab is an effective and safe treatment for improving vision in patients with serous and vascular PED, although the anatomical response of the PED to ranibizumab may not correlate directly with the visual outcome.
C1 [Panos, Georgios D.; Gatzioufas, Zisis; Petropoulos, Ioannis K.; Thumann, Gabriele; Hafezi, Farhad] Univ Geneva, Univ Hosp Geneva, Dept Ophthalmol, CH-1211 Geneva 4, Switzerland.
   [Panos, Georgios D.; Gatzioufas, Zisis; Petropoulos, Ioannis K.; Thumann, Gabriele; Hafezi, Farhad] Univ Geneva, Fac Med, CH-1211 Geneva 4, Switzerland.
C3 University of Geneva; University of Geneva
RP Panos, GD (通讯作者)，Univ Hosp Geneva, Dept Ophthalmol, Rue Alcide Jentzer 22, CH-1211 Geneva 14, Switzerland.
EM georgios.panos@hcuge.ch
RI Panos, Georgios/AAC-9846-2020; Panos, Georgios D./AFS-1807-2022; Hafezi,
   Farhad/A-1446-2010
OI Panos, Georgios D./0000-0001-8399-7456; Hafezi,
   Farhad/0000-0001-8935-4558; Gatzioufas, Zisis/0000-0001-9099-5336
CR Ach T, 2010, RETINA-J RET VIT DIS, V30, P1420, DOI 10.1097/IAE.0b013e3181d87e97
   Arias L, 2010, CLIN OPHTHALMOL, V4, P369
   Arora S, 2011, EYE, V25, P1034, DOI 10.1038/eye.2011.115
   Axer-Siegel R, 2004, ARCH OPHTHALMOL-CHIC, V122, P453, DOI 10.1001/archopht.122.4.453
   Axer-Siegel R, 2006, OPHTHAL SURG LAS IM, V37, P455, DOI 10.3928/15428877-20061101-02
   Baumal CR, 1997, OPHTHALMOLOGY, V104, P761, DOI 10.1016/S0161-6420(97)30236-X
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   Cheung CMG, 2011, NEW ENGL J MED, V365, P2237, DOI 10.1056/NEJMc1107895
   CHISHOLM IH, 1982, BRIT J OPHTHALMOL, V66, P745
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Inoue M, 2013, RETINA-J RET VIT DIS, V33, P990, DOI 10.1097/IAE.0b013e3182755793
   Introini U, 2012, GRAEF ARCH CLIN EXP, V250, P1283, DOI 10.1007/s00417-012-1955-2
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Pepple K, 2011, SEMIN OPHTHALMOL, V26, P198, DOI 10.3109/08820538.2011.570850
   POLINER LS, 1986, OPHTHALMOLOGY, V93, P543
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SLAKTER JS, 1994, ARCH OPHTHALMOL-CHIC, V112, P465, DOI 10.1001/archopht.1994.01090160041020
   Wygnanski-Jaffe T, 2006, OPHTHAL SURG LAS IM, V37, P358, DOI 10.3928/15428877-20060901-01
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
NR 22
TC 23
Z9 26
U1 0
U2 2
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2013
VL 7
BP 565
EP 569
DI 10.2147/DDDT.S46610
PG 5
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 179IS
UT WOS:000321514200001
PM 23874084
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Narvekar, P
   Bhatt, P
   Fnu, G
   Sutariya, V
AF Narvekar, Priya
   Bhatt, Priyanka
   Fnu, Gulimirerouzi
   Sutariya, Vijaykumar
TI Axitinib-Loaded Poly(Lactic-Co-Glycolic Acid) Nanoparticles for
   Age-Related Macular Degeneration: Formulation Development and In Vitro
   Characterization
SO ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES
LA English
DT Article
DE axitinib; PLGA nanoparticles; age-related macular degeneration; vascular
   endothelial growth factor; antiangiogenesis; sustained release
ID DELIVERY; CELL
AB Despite all the research aiming to treat ocular diseases, age-related macular degeneration (AMD) remains one of the serious diseases worldwide, which needs to be treated. Neovascularization is a key factor in AMD and thus antiangiogenic therapy is beneficial in reducing the development of new abnormal blood vessels. Axitinib, multireceptor tyrosine kinase inhibitor, is a small molecule that works by blocking vascular endothelial growth factor receptors (VEGFR) and platelet-derived growth factor receptors (PDGFR) responsible for developing neovascularization. The goal of this study is to develop a sustained release formulation of axitinib-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles to minimize frequent administration of the drug by intravitreal injection. The nanoparticles were characterized for particle size and zeta potential, as well as using differential scanning calorimetry, transmission electrode microscope, and in vitro drug release profile. The cytotoxicity of the formulation was evaluated on human retinal pigmented epithelium ARPE19 cells by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide salt] assay. The cellular uptake, antimigration assay, and vascular endothelial growth factor (VEGF) expression levels were found out in vitro using cells. The optimized formulation was 131.33 +/- 31.20 nm in size with -4.63 +/- 0.76 mV zeta potential. Entrapment efficiency was found to be 87.9% +/- 2.7%. The cytotoxicity of ARPE19 cells was in vitro compatibility at 10 mu M concentration of drug. Cellular uptake, antimigration assay, and VEGF expression levels for the nanoparticles suggested greater uptake, significant antiangiogenic potential, and inhibition of VEGF activity. The results showed successful development of axitinib-loaded PLGA nanoparticles as an alternative potential treatment for AMD.
C1 [Narvekar, Priya; Bhatt, Priyanka; Fnu, Gulimirerouzi; Sutariya, Vijaykumar] Univ S Florida, Coll Pharm, Dept Pharmaceut Sci, 12901 Bruce B Downs Blvd,MDC30, Tampa, FL 33612 USA.
C3 State University System of Florida; University of South Florida
RP Sutariya, V (通讯作者)，Univ S Florida, Coll Pharm, Dept Pharmaceut Sci, 12901 Bruce B Downs Blvd,MDC30, Tampa, FL 33612 USA.
EM vsutariy@health.usf.edu
RI Bhatt, Priyanka/I-8381-2019
OI Bhatt, Priyanka/0000-0001-9012-7096
CR Al Gwairi O, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/2913612
   Anderson JM, 1997, ADV DRUG DELIVER REV, V28, P5, DOI 10.1016/S0169-409X(97)00048-3
   Atkins M, 2018, MOL CANCER THER, V17, DOI 10.1158/1535-7163.TARG-17-B201
   Bhatt P, 2018, INT J PHARMACEUT, V536, P95, DOI 10.1016/j.ijpharm.2017.11.048
   Bhatt P, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.AM2016-2065
   Bhattacharjee S, 2016, J CONTROL RELEASE, V235, P337, DOI 10.1016/j.jconrel.2016.06.017
   Caceres C, 2016, ANALYST, V141, P1405, DOI 10.1039/c5an02018b
   Carvalho DDM, 2015, FOOD SCI TECH-BRAZIL, V35, P115, DOI 10.1590/1678-457X.6515
   Danhier F, 2012, J CONTROL RELEASE, V161, P505, DOI 10.1016/j.jconrel.2012.01.043
   del Amo EM, 2017, PROG RETIN EYE RES, V57, P134, DOI 10.1016/j.preteyeres.2016.12.001
   Dhule SS, 2012, NANOMED-NANOTECHNOL, V8, P440, DOI 10.1016/j.nano.2011.07.011
   Forest V, 2015, NANO TODAY, V10, P677, DOI 10.1016/j.nantod.2015.07.002
   Fornaguera C, 2015, J CONTROL RELEASE, V211, P134, DOI 10.1016/j.jconrel.2015.06.002
   Halasz K, 2019, CURR DRUG DELIV, V16, P153, DOI 10.2174/1567201815666181017095708
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kelly SJ, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6030092
   Mandal A, 2018, ADV DRUG DELIVER REV, V126, P67, DOI 10.1016/j.addr.2018.01.008
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Patel J, 2018, J MICROENCAPSUL, V35, P204, DOI 10.1080/02652048.2018.1453560
   Patil SV, 2016, RSC ADV, V6, P110206, DOI 10.1039/c6ra23614f
   Patil S, 2018, RSC ADV, V8, P35461, DOI 10.1039/c8ra06298f
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Rini BI, 2015, ANN ONCOL, V26, P1372, DOI 10.1093/annonc/mdv103
   Tandel H, 2018, IN VITRO IN VIVO TOO, P19
   Vhora I, 2018, AAPS PHARMSCITECH, V19, P3550, DOI 10.1208/s12249-018-1161-6
   Wadhwa A., 2018, ASIAN J PHARM CLIN R, V11, P35, DOI [10.22159/ajpcr.2018.v11i7.25149, DOI 10.22159/AJPCR.2018.V11I7.25149]
   Wang X, 2014, SMALL, V10, P385, DOI 10.1002/smll.201301597
   Yewale C, 2018, J DRUG DELIV SCI TEC, V45, P334, DOI 10.1016/j.jddst.2018.03.027
NR 29
TC 14
Z9 14
U1 3
U2 14
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-658X
EI 1557-8127
J9 ASSAY DRUG DEV TECHN
JI ASSAY DRUG DEV. TECHNOL.
PD JUN 1
PY 2019
VL 17
IS 4
SI SI
BP 167
EP 177
DI 10.1089/adt.2019.920
PG 11
WC Biochemical Research Methods; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA IC5WK
UT WOS:000471039500003
PM 31184962
DA 2022-11-30
ER

PT J
AU Jiang, YD
   Chiu, CY
   Yan, Q
   Chen, W
   Gorin, MB
   Conley, YP
   Lakhal-Chaieb, ML
   Cook, RJ
   Amos, CI
   Wilson, AF
   Bailey-Wilson, JE
   McMahon, FJ
   Vazquez, AI
   Yuan, A
   Zhong, XG
   Xiong, MM
   Weeks, DE
   Fan, RZ
AF Jiang, Yingda
   Chiu, Chi-Yang
   Yan, Qi
   Chen, Wei
   Gorin, Michael B.
   Conley, Yvette P.
   Lakhal-Chaieb, M'hamed Lajmi
   Cook, Richard J.
   Amos, Christopher, I
   Wilson, Alexander F.
   Bailey-Wilson, Joan E.
   McMahon, Francis J.
   Vazquez, Ana, I
   Yuan, Ao
   Zhong, Xiaogang
   Xiong, Momiao
   Weeks, Daniel E.
   Fan, Ruzong
TI Gene-Based Association Testing of Dichotomous Traits With Generalized
   Functional Linear Mixed Models Using Extended Pedigrees: Applications to
   Age-Related Macular Degeneration
SO JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION
LA English
DT Article
DE Age-related macular degeneration; Association study; Complex diseases;
   Extended pedigree; Generalized functional linear mixed models; Rare
   variants
ID GENOME-WIDE ASSOCIATION; POPULATION-STRUCTURE; QUANTITATIVE TRAITS;
   RARE; LEVEL; METAANALYSIS; REGRESSION; LOCI; SUSCEPTIBILITY; SCAN
AB Genetics plays a role in age-related macular degeneration (AMD), a common cause of blindness in the elderly. There is a need for powerful methods for carrying out region-based association tests between a dichotomous trait like AMD and genetic variants on family data. Here, we apply our new generalized functional linear mixed models (GFLMM) developed to test for gene-based association in a set of AMD families. Using common and rare variants, we observe significant association with two known AMD genes:CFH and ARMS2. Using rare variants, we find suggestive signals in four genes:ASAH1,CLEC6A,TMEM63C, and SGSM1. Intriguingly, ASAH1 is down-regulated in AMD aqueous humor, andASAH1deficiency leads to retinal inflammation and increased vulnerability to oxidative stress. These findings were made possible by our GFLMM which model the effect of a major gene as a fixed mean, the polygenic contributions as a random variation, and the correlation of pedigree members by kinship coefficients. Simulations indicate that the GFLMM likelihood ratio tests (LRTs) accurately control the Type I error rates. The LRTs have similar or higher power than existing retrospective kernel and burden statistics. Our GFLMM-based statistics provide a new tool for conducting family-based genetic studies of complex diseases.for this article, including a standardized description of the materials available for reproducing the work, are available as an online supplement.
C1 [Jiang, Yingda; Weeks, Daniel E.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.
   [Chiu, Chi-Yang] Univ Tennessee, Dept Prevent Med, Div Biostat, Hlth Sci Ctr, Memphis, TN USA.
   [Yan, Qi; Chen, Wei] Univ Pittsburgh, Childrens Hosp Pittsburgh, Div Pulm Med Allergy & Immunol, Pittsburgh, PA 15261 USA.
   [Gorin, Michael B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Stein Eye Inst, Los Angeles, CA 90095 USA.
   [Conley, Yvette P.] Univ Pittsburgh, Dept Hlth Promot & Dev, Pittsburgh, PA 15261 USA.
   [Lakhal-Chaieb, M'hamed Lajmi] Univ Laval, Dept Math & Stat, Quebec City, PQ, Canada.
   [Cook, Richard J.] Dept Stat & Actuarial Sci, Waterloo, ON, Canada.
   [Amos, Christopher, I] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
   [Chiu, Chi-Yang; Wilson, Alexander F.; Bailey-Wilson, Joan E.; Fan, Ruzong] NHGRI, Computat & Stat Genom Branch, NIH, Baltimore, MD USA.
   [McMahon, Francis J.] NIMH, Human Genet Branch, NIH, Bethesda, MD 20892 USA.
   [McMahon, Francis J.] NIMH, Genet Basis Mood & Anxiety Disorders Sect, NIH, Bethesda, MD 20892 USA.
   [Vazquez, Ana, I] Michigan State Univ, Dept Epidemiol & Biostat, E Lansing, MI USA.
   [Yuan, Ao; Zhong, Xiaogang; Fan, Ruzong] Georgetown Univ, Med Ctr, Dept Biostat Bioinformat & Biomath, Washington, DC 20057 USA.
   [Xiong, Momiao] Univ Texas Houston, Human Genet Ctr, Houston, TX USA.
   [Conley, Yvette P.; Weeks, Daniel E.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA.
   [Chiu, Chi-Yang] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Biostat & Bioinformat Branch, Div Intramural Populat Hlth Res, NIH, Bethesda, MD 20892 USA.
   [Jiang, Yingda] IBM US, 222 S Riverside Plaza Suites 1700 & 1800, Chicago, IL USA.
   [Yan, Qi] Columbia Univ, Dept Obstet & Gynecol, Irving Med Ctr, New York, NY USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; University of Tennessee System; University of Tennessee
   Health Science Center; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); University of Pittsburgh; University of California
   System; University of California Los Angeles; University of California
   Los Angeles Medical Center; David Geffen School of Medicine at UCLA;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Laval University; Baylor College of Medicine; National
   Institutes of Health (NIH) - USA; NIH National Human Genome Research
   Institute (NHGRI); NIH National Institute on Aging (NIA); National
   Institutes of Health (NIH) - USA; NIH National Institute of Mental
   Health (NIMH); National Institutes of Health (NIH) - USA; NIH National
   Institute of Mental Health (NIMH); Michigan State University; Georgetown
   University; University of Texas System; University of Texas Health
   Science Center Houston; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); University of Pittsburgh; National Institutes of
   Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of
   Child Health & Human Development (NICHD); Columbia University;
   NewYork-Presbyterian Hospital
RP Weeks, DE (通讯作者)，Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.; Fan, RZ (通讯作者)，Georgetown Univ, Med Ctr, Dept Biostat Bioinformat & Biomath, Washington, DC 20057 USA.
EM weeks@pitt.edu; rf740@georgetown.edu
RI ; McMahon, Francis/A-7290-2009
OI Chiu, Chi-Yang/0000-0002-4837-3194; Weeks, Daniel/0000-0001-9410-7228;
   Cook, Richard/0000-0002-1414-4908; Conley, Yvette/0000-0002-1784-6067;
   Bailey-Wilson, Joan/0000-0002-9153-2920; McMahon,
   Francis/0000-0002-9469-305X
FU U.S. National Science Foundation [DMS-1915904]; Intramural Research
   Program of the Eunice Kennedy Shriver National Institute of Child Health
   and Human Development at NIH; Intramural Research Program of the
   National Human Genome Research Institute at NIH; Intramural Research
   Programof theNational Institute ofMentalHealth at NIH, National
   Institutes of Health, Bethesda, Maryland; University of Pittsburgh
   [R01EY024226]; NEI [R01 EY09859]; ARRA supplement; Harold and Pauline
   Price Foundation; Arnold and Mabel Beckman Foundation; Research to
   Prevent Blindness, N.Y; Texas Cancer Prevention Research Institute
   [RR170048, RP190641]; NIH [R01EY024226, U01CA196386, U19CA203654,
   R01CA242218, U01CA243483, R01GM101219, R01GM099992, R01HG007358]
FX This study was supported by U.S. National Science Foundation grant
   DMS-1915904 (Ruzong Fan), by the Intramural Research Program of the
   Eunice Kennedy Shriver National Institute of Child Health and Human
   Development at NIH (Chi-Yang Chiu), by the Intramural Research Program
   of the National Human Genome Research Institute at NIH (Ruzong Fan,
   Chi-Yang Chiu, Alexander F. Wilson, E. Bailey-Wilson), by the Intramural
   Research Programof theNational Institute ofMentalHealth at NIH (Francis
   J. McMahon), National Institutes of Health, Bethesda, Maryland, by Wei
   Chen's NIH grants R01EY024226 and R01HG007358 and the University of
   Pittsburgh (Ruzong Fan is an unpaid collaborator on the grant
   R01EY024226), by Christopher I. Amos' Texas Cancer Prevention Research
   Institute grants RR170048 & RP190641, NIH grants U01CA196386,
   U19CA203654, R01CA242218 and U01CA243483, and by Ana I. Vazquez's NIH
   grants R01GM101219 and R01GM099992. Michael B. Gorin received funding
   support from the NEI R01 EY09859 and the ARRA supplement, Harold and
   Pauline Price Foundation, Arnold and Mabel Beckman Foundation and
   unrestricted funds to the Department of Ophthalmology from Research to
   Prevent Blindness, N.Y. The genotyping of the age-related macular
   degeneration dataset was carried out by the Johns Hopkins University
   Genetic Resources Core Facility SNP Center. This work utilized the
   computational resources of the NIH HPC Biowulf cluster at the National
   Institutes of Health, Bethesda, MD (https://hpc.nih.gov).
CR Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   Astle W, 2009, STAT SCI, V24, P451, DOI 10.1214/09-STS307
   Aulchenko YS, 2007, GENETICS, V177, P577, DOI 10.1534/genetics.107.075614
   Bansal V, 2010, NAT REV GENET, V11, P773, DOI 10.1038/nrg2867
   Bates D. M., 2009, ASSESSING PRECISION
   Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   BRESLOW NE, 1993, J AM STAT ASSOC, V88, P9, DOI 10.1080/01621459.1993.10594284
   Cavalli-Sforza LL, 1999, GENETICS HUMAN POPUL
   Chen H, 2016, AM J HUM GENET, V98, P653, DOI 10.1016/j.ajhg.2016.02.012
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cordell HJ, 2002, AM J HUM GENET, V70, P124, DOI 10.1086/338007
   de Boor C., 2001, APPL MATH SCI REV VE, V27
   De G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0048495
   Fan R, 2016, GENET EPIDEMIOL, V40, P702, DOI 10.1002/gepi.21984
   Fan RZ, 2016, GENETICS, V202, P457, DOI 10.1534/genetics.115.180869
   Fan RZ, 2016, GENET EPIDEMIOL, V40, P133, DOI 10.1002/gepi.21947
   Fan RZ, 2015, GENETICS, V200, P1089, DOI 10.1534/genetics.115.178343
   Fan RZ, 2014, GENET EPIDEMIOL, V38, P622, DOI 10.1002/gepi.21840
   Fan RZ, 2013, GENET EPIDEMIOL, V37, P726, DOI 10.1002/gepi.21757
   Fernandez MV, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00209
   Ferraty F, 2010, OXFORD HDB FUNCTIONA
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258
   Friedman D. S., 2004, ARCH OPHTHALMOL-CHIC, V122
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gao XY, 2008, GENET EPIDEMIOL, V32, P361, DOI 10.1002/gepi.20310
   Gianola D, 2016, G3-GENES GENOM GENET, V6, P3241, DOI 10.1534/g3.116.034256
   GILMOUR AR, 1985, BIOMETRIKA, V72, P593, DOI 10.1093/biomet/72.3.593
   Harvillel D. A., 1989, ADV STAT METHODS GEN, DOI DOI 10.1007/BF01066731
   Hayeck TJ, 2015, AM J HUM GENET, V96, P720, DOI 10.1016/j.ajhg.2015.03.004
   Henderson C., 1984, APPL LINEAR MODELS A
   Horvath L., 2012, INFERENCE FUNCTIONAL, DOI [10.1007/978-1-4614-3655-3, DOI 10.1007/978-1-4614-3655-3]
   Ionita-Laza I, 2013, EUR J HUM GENET, V21, P1158, DOI 10.1038/ejhg.2012.308
   Ionita-Laza I, 2013, AM J HUM GENET, V92, P841, DOI 10.1016/j.ajhg.2013.04.015
   Kang HM, 2008, GENETICS, V178, P1709, DOI 10.1534/genetics.107.080101
   Kang HM, 2010, NAT GENET, V42, P348, DOI 10.1038/ng.548
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kiezun A, 2012, NAT GENET, V44, P623, DOI 10.1038/ng.2303
   Korte A, 2012, NAT GENET, V44, P1066, DOI 10.1038/ng.2376
   LANGE K., 2002, MATH STAT METHODS GE, V2nd, DOI [10.1007/978-0-387-21750-5, DOI 10.1007/978-0-387-21750-5]
   Laurie CC, 2010, GENET EPIDEMIOL, V34, P591, DOI 10.1002/gepi.20516
   Lee S, 2012, AM J HUM GENET, V91, P224, DOI 10.1016/j.ajhg.2012.06.007
   Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057
   Lippert C, 2011, NAT METHODS, V8, P833, DOI [10.1038/NMETH.1681, 10.1038/nmeth.1681]
   Listgarten J, 2013, NAT GENET, V45, P470, DOI 10.1038/ng.2620
   Listgarten J, 2012, NAT METHODS, V9, P525, DOI 10.1038/nmeth.2037
   Loh PR, 2015, NAT GENET, V47, P284, DOI 10.1038/ng.3190
   Luo L., 2013, EUROPEAN J HUMAN GEN, V21
   Luo L, 2012, J MED GENET, V49, P513, DOI 10.1136/jmedgenet-2012-100798
   Luo L, 2011, GENOME RES, V21, P1099, DOI 10.1101/gr.115998.110
   Neale Benjamin M, 2010, Proc Natl Acad Sci U S A, V107, P7395, DOI 10.1073/pnas.0912019107
   Petrov AM, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9120867
   Pirinen M, 2013, ANN APPL STAT, V7, P369, DOI 10.1214/12-AOAS586
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Qu SC, 2019, INT J OPHTHALMOL-CHI, V12, P1758, DOI 10.18240/ijo.2019.11.15
   Ramsay J., 2005, FUNCTIONAL DATA ANAL
   Ramsay JO, 2009, USE R, P1, DOI 10.1007/978-0-387-98185-7_1
   Ratnapriya R, 2020, HUM MOL GENET, V29, P2022, DOI 10.1093/hmg/ddaa057
   Ross S., 1996, STOCHASTIC PROCESSES
   Schaffner SF, 2005, GENOME RES, V15, P1576, DOI 10.1101/gr.3709305
   Schaid DJ, 2013, GENET EPIDEMIOL, V37, P409, DOI 10.1002/gepi.21727
   SCHALL R, 1991, BIOMETRIKA, V78, P719
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Segura V, 2012, NAT GENET, V44, P825, DOI 10.1038/ng.2314
   Song MS, 2015, NAT GENET, V47, P550, DOI 10.1038/ng.3244
   Sugano E, 2019, J LIPID RES, V60, P30, DOI 10.1194/jlr.M082198
   Svishcheva GR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128999
   Svishcheva GR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099407
   Svishcheva GR, 2012, NAT GENET, V44, P1166, DOI 10.1038/ng.2410
   Tennessen JA, 2012, SCIENCE, V337, P64, DOI 10.1126/science.1219240
   Thornton T, 2007, AM J HUM GENET, V81, P321, DOI 10.1086/519497
   Vazquez AI, 2010, J ANIM SCI, V88, P497, DOI 10.2527/jas.2009-1952
   Vsevolozhskaya OA, 2016, GENET EPIDEMIOL, V40, P210, DOI 10.1002/gepi.21955
   Vsevolozhskaya OA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105074
   Wang JL, 2016, THEOR POPUL BIOL, V107, P4, DOI 10.1016/j.tpb.2015.08.006
   Wang XF, 2013, GENET EPIDEMIOL, V37, P778, DOI 10.1002/gepi.21763
   Wang YF, 2015, GENET EPIDEMIOL, V39, P259, DOI 10.1002/gepi.21895
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Wu MC, 2011, AM J HUM GENET, V89, P82, DOI 10.1016/j.ajhg.2011.05.029
   Yan Q, 2015, HUM HERED, V79, P60, DOI 10.1159/000375409
   Yang Jian, 2011, Am J Hum Genet, V88, P76, DOI 10.1016/j.ajhg.2010.11.011
   Yang J, 2014, NAT GENET, V46, P100, DOI 10.1038/ng.2876
   Yang J, 2011, EUR J HUM GENET, V19, P807, DOI 10.1038/ejhg.2011.39
   Yang JA, 2010, NAT GENET, V42, P565, DOI 10.1038/ng.608
   Yu JM, 2006, NAT GENET, V38, P203, DOI 10.1038/ng1702
   Zhang FT, 2014, GENOME RES, V24, P989, DOI 10.1101/gr.161760.113
   Zhang ZW, 2010, NAT GENET, V42, P355, DOI 10.1038/ng.546
   Zhao JY, 2016, EUR J HUM GENET, V24, P421, DOI 10.1038/ejhg.2015.147
   Zhao KY, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030004
   Zhou X, 2014, NAT METHODS, V11, P407, DOI [10.1038/NMETH.2848, 10.1038/nmeth.2848]
   Zhou X, 2012, NAT GENET, V44, P821, DOI 10.1038/ng.2310
NR 94
TC 1
Z9 1
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0162-1459
EI 1537-274X
J9 J AM STAT ASSOC
JI J. Am. Stat. Assoc.
PD APR 3
PY 2021
VL 116
IS 534
BP 531
EP 545
DI 10.1080/01621459.2020.1799809
EA SEP 2020
PG 15
WC Statistics & Probability
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Mathematics
GA SO8CA
UT WOS:000567573900001
PM 34321704
OA Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU von der Emde, L
   Pfau, M
   Thiele, S
   Moller, PT
   Hassenrik, R
   Fleckenstein, M
   Holz, FG
   Schmitz-Valckenberg, S
AF von der Emde, Leon
   Pfau, Maximilian
   Thiele, Sarah
   Moeller, Philipp T.
   Hassenrik, Ruth
   Fleckenstein, Monika
   Holz, Frank G.
   Schmitz-Valckenberg, Steffen
TI Mesopic and Dark-Adapted Two-Color Fundus-Controlled Perimetry in
   Choroidal Ne Neovascularization Secondary to Age-Related Macular
   Degeneration
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE retest reliability; two-color FCP; patient reliability indices;
   microperimetry
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; RETINAL SENSITIVITY; MICROPERIMETRIC
   CHANGES; RANIBIZUMAB; VULNERABILITY; LUMINANCE; RECOVERY; THERAPY; SIZE
AB Purpose: To determine the retest variability of mesopic and two-color dark-adapted (DA) fundus-controlled perimetry (FCP), to evaluate the predictive value of patient reliability indices, and to analyze the extent of impairment of rod- and cone function in neovascular age-related macular degeneration (nAMD).
   Methods: A total of 50 eyes of 50 patients with nAMD (mean age, 76.1 years) and 70 eyes of 70 age-similar normal subjects underwent multimodal imaging as well as mesopic and DA two-color perimetry using the S-MAIA device. A subset of patients (n = 28) underwent duplicate testing for retest reliability assessment. Mixed models were used for analysis of the hierarchical data.
   Results: In eyes with nAMD, the coefficient of repeatability was (mean +/- standard deviation [SD]) 5.99 +/- 1.55 dB for mesopic, 6.14 +/- 2.19 dB for DA cyan, and 6.06 +/- 1.09 dB for DA red testing. "Patient reliability indices" explained 55%, 54.2%, and 64.2% of the variance in retest variability. The mean sensitivity loss was greater for DA cyan compared to DA red testing (cyan-red differences [mean +/- SD] -2.63 +/- 3.87 dB, P < 0.001).
   Conclusions: The relatively greater degree of DA cyan versus DA red sensitivity loss indicates preferential rod vulnerability in nAMD, and qualifies rod function-based outcomes measures as potential sensitive and early markers of treatment response in nAMD.
   Translational Relevance: The S-MAIA allows reliable testing of mesopic, DA cyan, and DA red sensitivity in patients with nAMD. Patient reliability indices may serve as eligibility criteria for clinical trials to identify patients with adequate retest reliability.
C1 [von der Emde, Leon; Pfau, Maximilian; Thiele, Sarah; Moeller, Philipp T.; Hassenrik, Ruth; Fleckenstein, Monika; Holz, Frank G.; Schmitz-Valckenberg, Steffen] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
   [Pfau, Maximilian; Thiele, Sarah; Moeller, Philipp T.; Fleckenstein, Monika; Holz, Frank G.; Schmitz-Valckenberg, Steffen] Univ Bonn, GRADE Reading Ctr, Ernst Abbe Str 2, Bonn, Germany.
C3 University of Bonn; University of Bonn
RP Schmitz-Valckenberg, S (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM steffen.schmitz-valckenberg@ukbbonn.de
RI Pfau, Maximilian/N-1888-2019
OI Pfau, Maximilian/0000-0001-9761-9640
FU ProRETINA Foundation; Novartis Pharma GmbH [EYEnovative Forderpreis
   2017]; BONFOR Program of the Faculty of Medicine, University of Bonn
   [O-137.0022, O-137.0025]; German Research Foundation (DFG) [FL658/4-1,
   FL658/4-2]
FX Supported by the ProRETINA Foundation [Doctoral Research Support Grant
   to LvdE], Novartis Pharma GmbH [EYEnovative Forderpreis 2017 to MP],
   BONFOR Program of the Faculty of Medicine, University of Bonn [Grant No
   O-137.0022 and O-137.0025 to MP] and by the German Research Foundation
   (DFG) [FL658/4-1 and FL658/4-2 to MF]. CenterVue SpA, Padova, Italy has
   provided research material (S-MAIA) for the conduct of this study.
   CenterVue had no role in the design or conduct of the experiments.
CR Alexander P, 2012, EYE, V26, P678, DOI 10.1038/eye.2012.7
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Chieh JJ, 2008, RETINA-J RET VIT DIS, V28, P1522, DOI 10.1097/IAE.0b013e318186c634
   Cho HJ, 2013, AM J OPHTHALMOL, V155, P118, DOI 10.1016/j.ajo.2012.07.009
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Dunavoelgyi R, 2011, ACTA OPHTHALMOL, V89, P166, DOI 10.1111/j.1755-3768.2009.01646.x
   Ergun E, 2003, OPHTHALMOLOGY, V110, P65, DOI 10.1016/S0161-6420(02)01566-X
   Fujii GY, 2003, AM J OPHTHALMOL, V136, P1067, DOI 10.1016/S0002-9394(03)00663-9
   Goerdt L, 2017, INVEST OPHTH VIS SCI, V58
   Grenga PL, 2013, CAN J OPHTHALMOL, V48, P394, DOI 10.1016/j.jcjo.2013.04.006
   Hartmann KI, 2015, OSLI RETINA, V46, P824, DOI 10.3928/23258160-20150909-06
   Hautamaki A, 2014, ACTA OPHTHALMOL, V92, P51, DOI 10.1111/j.1755-3768.2012.02556.x
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mettu PS, 2011, RETINA-J RET VIT DIS, V31, P1637, DOI 10.1097/IAE.0b013e31821800e0
   Miller JW, 2016, INVEST OPHTH VIS SCI, V57, P6911, DOI 10.1167/iovs.16-21201
   Munk MR, 2013, AM J OPHTHALMOL, V156, P633, DOI 10.1016/j.ajo.2013.05.037
   Olsson J, 1997, ACTA OPHTHALMOL SCAN, V75, P181
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Ozdemir H, 2012, ACTA OPHTHALMOL, V90, P71, DOI 10.1111/j.1755-3768.2009.01838.x
   Pfau M, 2020, RETINA-J RET VIT DIS, V40, P169, DOI 10.1097/IAE.0000000000002337
   Pfau M, 2018, EYE, V32, P1819, DOI 10.1038/s41433-018-0183-3
   Pfau M, 2018, BRIT J OPHTHALMOL, V102, P1054, DOI 10.1136/bjophthalmol-2017-311012
   Pfau M, 2017, OPHTHALMOLOGICA, V237, P42, DOI 10.1159/000453079
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sabour-Pickett S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/268438
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   STEINMAN RM, 1965, J OPT SOC AM, V55, P1158, DOI 10.1364/JOSA.55.001158
   Sulzbacher F, 2015, INVEST OPHTH VIS SCI, V56, P1158, DOI 10.1167/iovs.14-14298
   Sulzbacher F, 2013, INVEST OPHTH VIS SCI, V54, P1310, DOI 10.1167/iovs.12-11046
   Vujosevic S, 2017, GRAEF ARCH CLIN EXP, V255, P301, DOI 10.1007/s00417-016-3466-z
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
   Yamamoto S, 2012, OPHTHALMOL THER, V1, DOI 10.1007/s40123-012-0005-9
NR 45
TC 18
Z9 18
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD JAN
PY 2019
VL 8
IS 1
AR 7
DI 10.1167/tvst.8.1.7
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HG7LZ
UT WOS:000455173700001
PM 30637177
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Buitendijk, GHS
   Schauwvlieghe, ASME
   Vingerling, JR
   Schlingemann, RO
   Klaver, CCW
AF Buitendijk, Gabrielle H. S.
   Schauwvlieghe, Ann-Sofie M. E.
   Vingerling, Johannes R.
   Schlingemann, Reinier O.
   Klaver, Caroline C. W.
CA Comparing Bevacizumab Ranibizumab
TI Antiplatelet and Anticoagulant Drugs Do Not Affect Visual Outcome in
   Neovascular Age-Related Macular Degeneration in the BRAMD Trial
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MASSIVE INTRAOCULAR HEMORRHAGE; LOW-DOSE ASPIRIN; SUBRETINAL HEMORRHAGE;
   ASSOCIATION; THERAPY; RISK
AB PURPOSE: To determine if use of antiplatelet or anticoagulant (AP/AC) medication influences visual acuity in patients with active neovascular age -related macular degeneration (N-AMD).
   DESIGN: Retrospective analysis of data from a randomized controlled trial.
   METHODS: SETTING: Multicenter. STUDY POPULATION: Total of 330 patients with active N-AMD from the BRAMD study, a comparative trial between bevacizumab and ranibizumab in the Netherlands. OBSERVATION PROCEDURES: Patients underwent an extensive ophthalmic examination. Visual acuity was categorized into functional vision (best -corrected visual acuity [BCVA] z 0.5), visual impairment (BCVA < 0.5), and severe visual impairment (BCVA < 0.3). Fundus photographs were graded for presence of retinal or subretinal hemorrhages. Information on AP/AC medication was obtained through interview. Logistic regression analysis was used to determine associations between AP/AC medication and outcomes. Frequency of hemorrhages in users and nonusers stratified for visual acuity categories was analyzed with ANCOVA. MAIN OUTCOME MEASURES: BCVA and presence of hemorrhages.
   RESULTS: In total, 40.9% of the patients used AP/AC medication, of which 73.3% was aspirin. AP/AC use was not associated with visual impairment (adjusted odds ratio [OR] 0.79; 95% confidence interval [CI] 0.43-1.44) or severe visual impairment (adjusted OR 0.75; 95% CI 0.40-1.43). Patients on AP/AC presented with comparable frequencies of hemorrhages (27% vs 32%, P =.32, respectively). Similar results were found when analyses were restricted to aspirin users only.
   CONCLUSION: In our study, use of AP/AC medication was associated neither with visual decline nor with the occurrence of hemorrhages in patients with active N-AMD. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Buitendijk, Gabrielle H. S.; Vingerling, Johannes R.; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Buitendijk, Gabrielle H. S.; Vingerling, Johannes R.; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Schauwvlieghe, Ann-Sofie M. E.; Schlingemann, Reinier O.] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, Amsterdam, Netherlands.
   [Schlingemann, Reinier O.] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, Amsterdam, Netherlands.
   [Schlingemann, Reinier O.] Univ Amsterdam, Acad Med Ctr, Dept Cell Biol & Histol, Amsterdam, Netherlands.
   [Schlingemann, Reinier O.] Netherlands Inst Neurosci, Amsterdam, Netherlands.
   [Klaver, Caroline C. W.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Nijmegen, Netherlands.
C3 Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam;
   Erasmus MC; University of Amsterdam; Academic Medical Center Amsterdam;
   University of Amsterdam; Academic Medical Center Amsterdam; University
   of Amsterdam; Academic Medical Center Amsterdam; Royal Netherlands
   Academy of Arts & Sciences; Netherlands Institute for Neuroscience
   (NIN-KNAW); Radboud University Nijmegen
RP Klaver, CCW (通讯作者)，Erasmus MC, Room Na 2808,POB 2040, NL-3000 CA Rotterdam, Netherlands.
EM klaver@erasmusmc.nl
RI Klaver, Caroline C.W./A-2013-2016
OI Klaver, Caroline/0000-0002-2355-5258; Verbraak, Frank
   D/0000-0001-7560-1423
FU ZONMW, THE NETHERLANDS ORGANISATION FOR Health Research and Development
   [170885606]; MD Fonds, Utrecht, the Netherlands; Stichting Nederlands
   Oog Onderzoek (SNOO), Rotterdam, The Netherlands; Rotterdamse
   Blindenbelangen Association, Rotterdam, The Netherlands; Oogfonds
   Nederland, Utrecht, The Netherlands; Vereniging Trustfonds Erasmus
   Universiteit Rotterdam, Rotterdam, The Netherlands; Novartis,
   Netherlands; Bayer, Netherlands; Topcon
FX THIS WORK WAS SUPPORTED BY A GRANT FROM ZONMW, THE NETHERLANDS
   ORGANISATION FOR Health Research and Development projectnummer
   170885606; MD Fonds, Utrecht, the Netherlands; the Stichting Nederlands
   Oog Onderzoek (SNOO), Rotterdam, The Netherlands; Rotterdamse
   Blindenbelangen Association, Rotterdam, The Netherlands; Oogfonds
   Nederland, Utrecht, The Netherlands; and Vereniging Trustfonds Erasmus
   Universiteit Rotterdam, Rotterdam, The Netherlands. Financial
   Disclosures: Reinier O. Schlingemann is an advisor of Novartis and Bayer
   (all in the Netherlands); Caroline C.W. Klaver received in-kind research
   funding from Topcon; she is an advisor of Novartis, Bayer, and Thea
   Pharma (all in the Netherlands). The following authors have no financial
   disclosures: Gabrielle H.S. Buitendijk, Ann-Sofie M.E. Schauwvlieghe,
   and Johannes R. Vingerling. The authors attest that they meet the
   current ICMJE criteria for authorship.
CR Aronow ME, 2014, INVEST OPHTHALMOL VI, V55
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Azar G, 2015, EUR J OPHTHALMOL, V25, P163, DOI 10.5301/ejo.5000529
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chew E. Y., 2012, INVEST OPHTHALMOL VI, V53, P1325
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1143, DOI 10.1001/archopht.119.8.1143
   Christen WG, 2014, EXPERT OPIN DRUG SAF, V13, P421, DOI 10.1517/14740338.2014.889680
   Christen WG, 2009, OPHTHALMOLOGY, V116, P2386, DOI 10.1016/j.ophtha.2009.05.031
   de Jong PTVM, 2012, OPHTHALMOLOGY, V119, P112, DOI 10.1016/j.ophtha.2011.06.025
   De Schryver ELLM, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001342.pub3
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   Farrugia G, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/504230
   Goyal S, 2016, CLIN EXP OPHTHALMOL, V44, P610, DOI 10.1111/ceo.12721
   Guirguis-Blake JM, 2016, ANN INTERN MED, V164, P804, DOI 10.7326/M15-2113
   Kahawita SK, 2014, CAN J OPHTHALMOL, V49, P35, DOI 10.1016/j.jcjo.2013.07.016
   Kiernan DF, 2010, RETINA-J RET VIT DIS, V30, P1573, DOI 10.1097/IAE.0b013e3181e2266d
   Klein BEK, 2012, JAMA-J AM MED ASSOC, V308, P2469, DOI 10.1001/jama.2012.65406
   KLEIN ML, 1991, JAMA-J AM MED ASSOC, V266, P2279
   Knox FA, 2002, EYE, V16, P669, DOI 10.1038/sj.eye.6700109
   Kuhli-Hattenbach C, 2012, OPHTHALMOLOGE, V109, P665, DOI 10.1007/s00347-012-2567-2
   Kuhli-Hattenbach C, 2010, AM J OPHTHALMOL, V149, P316, DOI 10.1016/j.ajo.2009.08.033
   LEWIS H, 1988, GRAEF ARCH CLIN EXP, V226, P59, DOI 10.1007/BF02172720
   Li L, 2015, J CLIN PHARM THER, V40, P144, DOI 10.1111/jcpt.12241
   Liew G, 2013, JAMA INTERN MED, V173, P258, DOI 10.1001/jamainternmed.2013.1583
   Mason JO, 2010, RETINA-J RET VIT DIS, V30, P1386, DOI 10.1097/IAE.0b013e3181e09739
   Meek IL, 2010, PHARMACEUTICALS, V3, P2146, DOI 10.3390/ph3072146
   Olson JM, 2013, OPHTHAL SURG LAS IM, V44, P455, DOI 10.3928/23258160-20130909-06
   Robman L, 2017, CONT CLIN TRIAL COMM, V6, P105, DOI 10.1016/j.conctc.2017.03.005
   Schauwvlieghe AME, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153052
   Shi XL, 1999, MOL CELL BIOCHEM, V199, P93, DOI 10.1023/A:1006934612368
   Small KW, 2017, RETINA-J RET VIT DIS, V37, P1630, DOI 10.1097/IAE.0000000000001475
   Sobrin L, 2013, AM J OPHTHALMOL, V156, P213, DOI 10.1016/j.ajo.2013.04.023
   Tilanus MAD, 2000, GRAEF ARCH CLIN EXP, V238, P482, DOI 10.1007/PL00007887
   WANG J, 2016, BIOMED RES INT, V2016, DOI DOI 10.1155/2016/8212063
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Wu Yan, 2013, Med Hypothesis Discov Innov Ophthalmol, V2, P59
   Ye J, 2014, INVEST OPHTH VIS SCI, V55, P2687, DOI 10.1167/iovs.13-13206
   Ying GS, 2016, OPHTHALMOLOGY, V123, P352, DOI 10.1016/j.ophtha.2015.09.046
   Zhang RS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146808
   Zhu W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058821
NR 40
TC 5
Z9 5
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2018
VL 187
BP 130
EP 137
DI 10.1016/j.ajo.2018.01.003
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FZ1IP
UT WOS:000427330400021
PM 29330064
DA 2022-11-30
ER

PT J
AU Zernant, J
   Lee, W
   Collison, FT
   Fishman, GA
   Sergeev, YV
   Schuerch, K
   Sparrow, JR
   Tsang, SH
   Allikmets, R
AF Zernant, Jana
   Lee, Winston
   Collison, Frederick T.
   Fishman, Gerald A.
   Sergeev, Yuri V.
   Schuerch, Kaspar
   Sparrow, Janet R.
   Tsang, Stephen H.
   Allikmets, Rando
TI Frequent hypomorphic alleles account for a significant fraction of ABCA4
   disease and distinguish it from age-related macular degeneration
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID CONE-ROD DYSTROPHY; STARGARDT-DISEASE; RETINITIS-PIGMENTOSA; GENE ABCR;
   FUNCTIONAL-ANALYSIS; MUTATIONS; VARIANTS; PHENOTYPES; RETINOPATHIES;
   ASSOCIATION
AB Background Variation in the ABCA4 gene is causal for, or associated with, a wide range of phenotypes from early onset Mendelian retinal dystrophies to late-onset complex disorders such as age-related macular degeneration (AMD). Despite substantial progress in determining the causal genetic variation, even complete sequencing of the entire open reading frame and splice sites of ABCA4 identifies biallelic mutations in only 60%-70% of cases; 20%-25% remain with one mutation and no mutations are found in 10%-15% of cases with clinically confirmed ABCA4 disease. This study was designed to identify missing causal variants specifically in monoallelic cases of ABCA4 disease.
   Methods Direct sequencing and analysis were performed in a large familial ABCA4 disease cohort of predominately European descent (n=643). Patient phenotypes were assessed from clinical and retinal imaging data.
   Results We determined that a hypomorphic ABCA4 variant c.5603A > T (p.Asn1868Ile), previously considered benign due to high minor allele frequency (MAF) (similar to 7%) in the general population, accounts for 10% of the disease, > 50% of the missing causal alleles in monoallelic cases, similar to 80% of late-onset cases and distinguishes ABCA4 disease from AMD. It results in a distinct clinical phenotype characterised by late-onset of symptoms (4th decade) and foveal sparing (85%). Intragenic modifying effects involving this variant and another, c.2588G > C (p.Gly863Ala) allele, were also identified.
   Conclusions These findings substantiate the causality of frequent missense variants and their phenotypic outcomes as a significant contribution to ABCA4 disease, particularly the late-onset phenotype, and its clinical variation. They also suggest a significant revision of diagnostic screening and assessment of ABCA4 variation in aetiology of retinal diseases.
C1 [Zernant, Jana; Lee, Winston; Schuerch, Kaspar; Sparrow, Janet R.; Tsang, Stephen H.; Allikmets, Rando] Columbia Univ, Dept Ophthalmol, New York, NY USA.
   [Collison, Frederick T.; Fishman, Gerald A.] Pangere Ctr Hereditary Retinal Dis, Chicago Lighthouse, Chicago, IL USA.
   [Sergeev, Yuri V.] NEI, Ophthalm Genet & Visual Funct Branch, NIH, Bethesda, MD 20892 USA.
   [Sparrow, Janet R.; Tsang, Stephen H.; Allikmets, Rando] Columbia Univ, Dept Pathol & Cell Biol, New York, NY USA.
C3 Columbia University; National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI); Columbia University
RP Allikmets, R (通讯作者)，Columbia Univ, Edward S Harkness Eye Inst Res Annex, Dept Ophthalmol, 635 West 165th St,Box 28, New York, NY 10032 USA.
EM rla22@columbia.edu
RI Allikmets, Rando/ABD-4533-2021; Lee, Winston/CAA-0102-2022
OI Lee, Winston/0000-0002-1777-8519
FU National Eye Institute/NIH [EY021163, EY019861, EY019007]; Pangere
   Family Foundation, Pangere Center, Chicago Lighthouse; OPOS Stiftung
   zugunsten Wahrnehmungsbehinderten, St. Gallen, Switzerland;
   AlfredVogt-Stifung, St. Gallen, Switzerland; Research to Prevent
   Blindness (New York, NY); NATIONAL EYE INSTITUTE [R24EY019861,
   ZIAEY000476, R01EY021163, P30EY019007, R01EY024091] Funding Source: NIH
   RePORTER
FX This work was supported, in part, by grants from the National Eye
   Institute/NIH EY021163, EY019861 and EY019007 (Core Support for Vision
   Research); Pangere Family Foundation, Pangere Center, Chicago
   Lighthouse, OPOS Stiftung zugunsten Wahrnehmungsbehinderten, St. Gallen,
   Switzerland and AlfredVogt-Stifung, St. Gallen, Switzerland and
   unrestricted funds from Research to Prevent Blindness (New York, NY) to
   the Department of Ophthalmology, Columbia University.
CR Aguirre-Lamban J, 2011, INVEST OPHTH VIS SCI, V52, P6206, DOI 10.1167/iovs.10-5743
   Allikmets R, 2000, AM J HUM GENET, V67, P793, DOI 10.1086/303100
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Allikmets R., 2007, RETINAL DEGENERATION, P105
   Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393
   Bertelsen M, 2014, INVEST OPHTH VIS SCI, V55, P2766, DOI 10.1167/iovs.13-13391
   Burke TR, 2012, INVEST OPHTH VIS SCI, V53, P4458, DOI 10.1167/iovs.11-9166
   Cella W, 2009, EXP EYE RES, V89, P16, DOI 10.1016/j.exer.2009.02.001
   Cideciyan AV, 2009, HUM MOL GENET, V18, P931, DOI 10.1093/hmg/ddn421
   Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355
   Dawson RJP, 2006, NATURE, V443, P180, DOI 10.1038/nature05155
   Duncker T, 2015, INVEST OPHTH VIS SCI, V56, P7274, DOI 10.1167/iovs.15-17371
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2012, INVEST OPHTH VIS SCI, V53, P2112, DOI 10.1167/iovs.11-8785
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Guymer RH, 2001, ARCH OPHTHALMOL-CHIC, V119, P745, DOI 10.1001/archopht.119.5.745
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Kjellstrom U, 2015, MOL VIS, V21, P767
   Lee W, 2017, EUR J HUM GENET
   Lee W, 2016, HUM GENET, V135, P9, DOI 10.1007/s00439-015-1605-y
   Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057
   Martinez-Mir A, 1998, NAT GENET, V18, P11, DOI 10.1038/ng0198-11
   Maugeri A, 2000, AM J HUM GENET, V67, P960, DOI 10.1086/303079
   Maugeri A, 2002, EUR J HUM GENET, V10, P197, DOI 10.1038/sj.ejhg.5200784
   Maugeri A, 1999, AM J HUM GENET, V64, P1024, DOI 10.1086/302323
   McCafferty CL, 2016, SCI DATA, V3, DOI 10.1038/sdata.2016.112
   McCafferty CL, 2016, SCI REP-UK, V6, DOI 10.1038/srep37298
   MoldayLLAR, 2016, LOCALIZATION FUNCTIO
   Riveiro-Alvarez R, 2015, JAMA OPHTHALMOL, V133, P133, DOI 10.1001/jamaophthalmol.2014.4266
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Sangermano R, 2016, OPHTHALMOLOGY, V123, P1375, DOI 10.1016/j.ophtha.2016.01.053
   Sergeev YV, 2010, HUM MOL GENET, V19, P1302, DOI 10.1093/hmg/ddq006
   Sergeev YV, 2013, HUM MOL GENET, V22, P4756, DOI 10.1093/hmg/ddt329
   Shroyer NF, 2001, HUM MOL GENET, V10, P2671, DOI 10.1093/hmg/10.23.2671
   Shroyer NF, 2001, INVEST OPHTH VIS SCI, V42, P2757
   Sosnay PR, 2016, PEDIATR CLIN N AM, V63, P585, DOI 10.1016/j.pcl.2016.04.002
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Sun H, 2000, NAT GENET, V26, P242, DOI 10.1038/79994
   Tsang SH, 2014, OPHTHALMOLOGY, V121, P1773, DOI 10.1016/j.ophtha.2014.03.010
   Westeneng-van Haaften SC, 2012, OPHTHALMOLOGY, V119, P1199, DOI 10.1016/j.ophtha.2012.01.005
   Xie YJ, 2014, HUM MOL GENET, V23, P5774, DOI 10.1093/hmg/ddu291
   Yamamoto S, 2014, CELL, V159, P200, DOI 10.1016/j.cell.2014.09.002
   Yatsenko AN, 2001, HUM GENET, V108, P346, DOI 10.1007/s004390100493
   Zernant J, 2014, HUM MOL GENET, V23, P6797, DOI 10.1093/hmg/ddu396
   Zernant J, 2014, HUM MUTAT, V35, P1187, DOI 10.1002/humu.22626
   Zernant J, 2011, INVEST OPHTH VIS SCI, V52, P8479, DOI 10.1167/iovs.11-8182
   Zhang N, 2015, HUM MOL GENET, V24, P3220, DOI 10.1093/hmg/ddv073
NR 49
TC 95
Z9 100
U1 2
U2 8
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 1468-6244
J9 J MED GENET
JI J. Med. Genet.
PD JUN
PY 2017
VL 54
IS 6
BP 404
EP 412
DI 10.1136/jmedgenet-2017-104540
PG 9
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA EW3AG
UT WOS:000402366500005
PM 28446513
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Lau, LI
   Chen, SJ
   Cheng, CY
   Yen, MY
   Lee, FL
   Lin, MW
   Hsu, WM
   Wei, YH
AF Lau, Ling-Ing
   Chen, Shih-Jen
   Cheng, Ching-Yu
   Yen, May-Yung
   Lee, Fenq-Lih
   Lin, Ming-Wei
   Hsu, Wen-Ming
   Wei, Yau-Huei
TI Association of the Y402H polymorphism in complement factor H gene and
   neovascular age-related macular degeneration in Chinese patients
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID C-REACTIVE PROTEIN; SUSCEPTIBILITY LOCI; VISUAL IMPAIRMENT; GENOMEWIDE
   SCAN; MACULOPATHY; PREVALENCE; POPULATION; DISEASE; DRUSEN; ACTIVATION
AB PURPOSE. Age-related macular degeneration (AMD), with its complex traits and multiple risk factors, is the leading cause of blindness in the elderly. A strong association between a coding variant, Y402H, in the complement factor H gene (CFH) and AMD has been recently identified in white patients. This study was conducted to investigate the association between the Y402H polymorphism in CFH and neovascular AMD in Chinese patients.
   METHODS. One hundred sixty-three Chinese patients with neovascular AMD and 232 age-matched healthy controls were enrolled in the study. Genomic DNA from white blood cells was extracted. The Y402H polymorphism in CFH, with the substitution of T to C at nucleotide position 1277 in exon 9, was determined by polymerase chain reaction-restriction fragment length polymorphism analysis. The association between the genetic polymorphism and the disease was examined by chi(2) test and logistic regression.
   RESULTS. The frequency of the risk allele, 1277C, was 11.3% in AMD patients compared with 2.8% in controls (P < 0.00001). Genotype frequency differed significantly between the two groups (1277TT 81.0%, 1277TC 15.3%, and 1277CC 3.7% in the AMD group; 1277TT 94.4%, 1277TC 5.6%, and 1277CC 0% in the control group; P < 0.0001). The 1277C allele significantly increased the risk for neovascular AMD and had an odds ratio of 4.4 (95% confidence interval [95% CI], 2.3-8.5; P < 0.00001).
   CONCLUSIONS. The allele frequency of Y402H polymorphism in CFH has an ethnic variation, with much lower 1277C frequency in Chinese than in white patients. Despite this, the polymorphism is significantly associated with neovascular AMD in the Chinese population.
C1 Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei 112, Taiwan.
   Taipei Vet Gen Hosp, Dept Med Res & Educ, Taipei 112, Taiwan.
   Natl Yang Ming Univ, Inst Clin Med, Sch Med, Taipei 112, Taiwan.
   Natl Yang Ming Univ, Dept Ophthalmol, Sch Med, Taipei 112, Taiwan.
   Natl Yang Ming Univ, Dept Family Med, Sch Med, Taipei 112, Taiwan.
   Natl Yang Ming Univ, Dept Biochem & Mol Biol, Sch Med, Taipei 112, Taiwan.
   Natl Yang Ming Univ, Ctr Community Med, Sch Publ Hlth, Taipei 112, Taiwan.
C3 Taipei Veterans General Hospital; Taipei Veterans General Hospital;
   National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung
   University; National Yang Ming Chiao Tung University; National Yang Ming
   Chiao Tung University; National Yang Ming Chiao Tung University
RP Yen, MY (通讯作者)，Taipei Vet Gen Hosp, Dept Ophthalmol, 201 Shih Pai Rd,Sect 2, Taipei 112, Taiwan.
EM myyen@vghtpe.gov.tw
RI Cheng, Ching-Yu/Y-2229-2019; Wei, Yau-Huei/ABA-6841-2021; Cheng,
   Ching-Yu/K-7017-2013
OI Cheng, Ching-Yu/0000-0003-0655-885X; Wei, Yau-Huei/0000-0002-6429-2546;
   Cheng, Ching-Yu/0000-0003-0655-885X; Lau, Ling-Ing/0000-0001-6956-1496
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chu JY, 1998, P NATL ACAD SCI USA, V95, P11763, DOI 10.1073/pnas.95.20.11763
   CLAYTON D, 2001, HDB STAT GENETICS, P519
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Dragon-Durey MA, 2004, J AM SOC NEPHROL, V15, P787, DOI 10.1097/01.ASN.0000115702.28859.A7
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GASS JDM, 1997, STEREOSCOPIC ATLAS M, P70
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Greenfield JR, 2004, CIRCULATION, V109, P3022, DOI 10.1161/01.CIR.0000130640.77501.79
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   KAZATCHKINE MD, 1981, J CLIN INVEST, V67, P223, DOI 10.1172/JCI110017
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kocur I, 2002, BRIT J OPHTHALMOL, V86, P716, DOI 10.1136/bjo.86.7.716
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   MOLD C, 1984, J IMMUNOL, V133, P882
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nielsen DM, 1998, AM J HUM GENET, V63, P1531, DOI 10.1086/302114
   Santangelo Susan L, 2005, Ophthalmic Genet, V26, P61, DOI 10.1080/13816810490967944
   Schmidt S, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-18
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shaw CK, 1999, TISSUE ANTIGENS, V53, P51, DOI 10.1034/j.1399-0039.1999.530106.x
   Souied EH, 2005, MOL VIS, V11, P1135
   Tsai CY, 2005, JPN J OPHTHALMOL, V49, P166, DOI 10.1007/s10384-004-0164-x
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Wener MH, 2000, J RHEUMATOL, V27, P2351
   WU LZ, 1987, JPN J OPHTHALMOL, V31, P349
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 45
TC 101
Z9 120
U1 1
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2006
VL 47
IS 8
BP 3242
EP 3246
DI 10.1167/iovs.05-1532
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 069JC
UT WOS:000239441200003
PM 16877387
DA 2022-11-30
ER

PT J
AU Hernandez, L
   Lanitis, T
   Cele, C
   Toro-Diaz, H
   Gibson, A
   Kuznik, A
AF Hernandez, Luis
   Lanitis, Tereza
   Cele, Clifford
   Toro-Diaz, Hector
   Gibson, Andrea
   Kuznik, Andreas
TI Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular
   Degeneration: A Cost-Effectiveness Analysis
SO JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY
LA English
DT Article
ID TREATMENT DIABETIC-RETINOPATHY; QUALITY-OF-LIFE; VISUAL IMPAIRMENT;
   HEALTH STATES; UNITED-STATES; BEVACIZUMAB; ACUITY; UTILITY; CHARTS;
   PERSPECTIVE
AB BACKGROUND: Age-related macular degeneration (AMD) is the leading cause of vision loss in the United States. The most severe vision loss occurs in patients with neovascular AMD, known as wet AMD (wAMD). The most commonly used antivascular endothelial growth factor (VEGF) therapies approved by the FDA to treat patients with wAMD are ranibizumab, 0.5 mg administered by intravitreal injection once a month (approximately every 28 days), and intravitreal aflibercept injection (IAI), 2 mg every 4 weeks (monthly) for the first 12 weeks (3 months), followed by IAI 2 mg once every 8 weeks (2 months). Given the similar efficacy and safety profiles between IAI and ranibizumab, their associated costs and comparative cost-effectiveness are key factors in determining which one represents a more rational investment of scarce health care resources to help address the increasing cost of prescription drugs in the United States, a source of concern for patients, prescribes, payers, and policymakers.
   OBJECTIVE: To assess the cost-effectiveness of intravitreal aflibercept injection 2 mg every 8 weeks after 3 initial monthly doses (IAI 2q8) versus ranibizumab 0.5 mg monthly (Rq4) and pro re nata (PRN) in the treatment of patients with wAMD from a U.S. payer perspective.
   METHODS: A Markov cohort model was developed to estimate the lifetime quality-adjusted life-years (QALYs) and costs of treating patients with wAMD with IAI 2q8, Rq4, and ranibizumab PRN. The model considered changes in best-corrected visual acuity in the affected and fellow eyes over time, and the effect of blindness on mortality. Efficacy for IAI 2q8 and Rq4 was from VIEW 1 and VIEW 2 studies and from the Comparison of AMD Treatments Trials for ranibizumab PRN. Utilities and costs (in 2016 U.S. dollars) were from published literature. Health outcomes and costs were discounted at an annual rate of 3%.
   RESULTS: Over a lifetime, IAI 2q8 provided equal health benefits with Rq4 (5.44 QALYs) at a lower total cost ($33,745 vs. $48,031) as a result of fewer injections. IAI 2q8 yielded slightly greater QALYs versus ranibizumab PRN (5.44 vs. 5.40) at a slightly higher cost ($33,745 vs. $33,652), with an incremental cost per QALY gained of $2,583. Results were sensitive to variations in drug acquisition costs and number of injections of both drugs and the baseline age of the cohort.
   CONCLUSIONS: IAI 2q8 can be cost saving and cost-effective compared with Rq4 and ranibizumab PRN for the treatment of wAMD in the United States. Copyright (C) 2018, Academy of Managed Care Pharmacy. All rights reserved.
C1 [Hernandez, Luis; Cele, Clifford; Toro-Diaz, Hector] Evidera, Modeling & Simulat, Waltham, MA 02451 USA.
   [Lanitis, Tereza] Evidera, Modeling & Simulat, London, England.
   [Gibson, Andrea] Regeneron Pharmaceut, Med Affairs Ophthalmol, New York, NY USA.
   [Kuznik, Andreas] Regeneron Pharmaceut, Hlth Econ & Outcomes Res, New York, NY USA.
C3 Evidera; Evidera; Regeneron; Regeneron
RP Hernandez, L (通讯作者)，Evidera, 500 Totten Pond Rd,Ste 500, Waltham, MA 02451 USA.
EM luis.hernandez@evidera.com
RI Hernandez, Luis/AAH-1819-2021
OI Hernandez, Luis/0000-0002-9532-546X; Kuznik, Andreas/0000-0002-8634-8360
FU Regeneron Pharmaceuticals, the manufacturer of aflibercept
FX This study was funded by Regeneron Pharmaceuticals, the manufacturer of
   aflibercept. Hernandez, Lanitis, Cele, and Toro-Diaz are employed by
   Evidera, which received funding from Regeneron Pharmaceuticals to
   conduct this study. Gibson and Kuznik are employed by and own stock in
   Regeneron Pharmaceuticals.
CR [Anonymous], 2011, EYLEA AFLIBERCEPT IN
   [Anonymous], 2004, AV BEV INJ INTR US
   Arcinue CA, 2015, AM J OPHTHALMOL, V159, P426, DOI 10.1016/j.ajo.2014.11.022
   BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown MM, 2003, OPHTHALMOLOGY, V110, P1076, DOI 10.1016/S0161-6420(03)00254-9
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   Bucher HC, 1997, J CLIN EPIDEMIOL, V50, P683, DOI 10.1016/S0895-4356(97)00049-8
   CANTRILL HL, 1984, INT OPHTHALMOL CLIN, V24, P13, DOI 10.1097/00004397-198402440-00004
   Christ SL, 2008, INVEST OPHTH VIS SCI, V49, P3318, DOI 10.1167/iovs.08-1676
   Claxton L, 2017, PHARMACOECONOMICS, V35, P237, DOI 10.1007/s40273-016-0459-z
   Czoski-Murray C, 2009, VALUE HEALTH, V12, P793, DOI 10.1111/j.1524-4733.2009.00527.x
   Elshout M, 2014, GRAEF ARCH CLIN EXP, V252, P1911, DOI 10.1007/s00417-014-2641-3
   Falkenstein IA, 2008, OPHTHALMOLOGY, V115, P319, DOI 10.1016/j.ophtha.2007.05.028
   Ferreira A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133968
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Fisher DE, 2015, OPHTHALMOLOGY, V122, P382, DOI 10.1016/j.ophtha.2014.08.006
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Ghosh W, 2016, ADV THER, V33, P1660, DOI 10.1007/s12325-016-0367-9
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Institute for Clinical and Economic Review, 2017, ICER VAL FRAM
   International Council of Ophthalmology, 2002, VIS STAND
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kesselheim AS, 2016, JAMA-J AM MED ASSOC, V316, P858, DOI 10.1001/jama.2016.11237
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   MARCUS DM, 2014, INVEST OPHTH VIS SCI, V55
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Max Planck Institute for Demographic Research (Germany) University of California Berkeley (USA) INED (Paris), 2015, HUM MORT DAT
   Mitchell P, 2012, BRIT J OPHTHALMOL, V96, P688, DOI 10.1136/bjophthalmol-2011-300726
   Mousa SA, 2010, BIODRUGS, V24, P183, DOI 10.2165/11318550-000000000-00000
   Anton ZAM, 2015, VALUE HEALTH, V18, pA880, DOI 10.1016/j.jval.2015.09.067
   National Institute for Health and Care Excellence (NICE), 2013, AFL SOL INJ TREAT WE
   National Institutes of Health National Eye Institute, AG REL MAC DEG AMD
   Ohr M, 2012, THER ADV CHRONIC DIS, V3, P153, DOI 10.1177/2040622312446007
   Panchmatia HR, 2016, ACTA OPHTHALMOL, V94, P441, DOI 10.1111/aos.12964
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Patel JJ, 2012, J EVAL CLIN PRACT, V18, P247, DOI 10.1111/j.1365-2753.2010.01546.x
   Regnier SA, 2015, CLINICOECONOMIC OUTC, V7, P235, DOI 10.2147/CEOR.S82556
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Sanders GD, 2016, JAMA-J AM MED ASSOC, V316, P1093, DOI 10.1001/jama.2016.12195
   Schmid MK, 2015, BRIT J OPHTHALMOL, V99, P141, DOI 10.1136/bjophthalmol-2014-305149
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Stein JD, 2014, OPHTHALMOLOGY, V121, P936, DOI 10.1016/j.ophtha.2013.10.037
   Tempelaar S, 2015, VALUE HEALTH, V18, pA420, DOI 10.1016/j.jval.2015.09.554
   Vottonen P, 2016, ACTA OPHTHALMOL, V94, P652, DOI 10.1111/aos.13185
   Wittenborn J, 2013, COST VISION PROBLEMS
   Wolf S, 2016, OPHTHALMOLOGICA, V236, P95, DOI 10.1159/000447725
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yanagi Y, 2017, J MED ECON, V20, P204, DOI 10.1080/13696998.2016.1245196
   2006, LUCENTIS RANIBIZUMAB
NR 51
TC 18
Z9 20
U1 2
U2 7
PU ACAD MANAGED CARE PHARMACY
PI ALEXANDRIA
PA 100 N PITT ST, 400, ALEXANDRIA, VA 22314-3134 USA
SN 2376-0540
EI 2376-1032
J9 J MANAG CARE SPEC PH
JI J. Manag. Care Spec. Pharm.
PD JUL
PY 2018
VL 24
IS 7
BP 608
EP 616
DI 10.18553/jmcp.2018.24.7.608
PG 9
WC Health Care Sciences & Services; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; Pharmacology & Pharmacy
GA GO3QF
UT WOS:000439907600004
PM 29952707
OA Bronze
DA 2022-11-30
ER

PT J
AU Wu, ZC
   Luu, CD
   Hodgson, LAB
   Caruso, E
   Chen, FK
   Chakravarthy, U
   Arnold, JJ
   Heriot, WJ
   Runciman, J
   Guymer, RH
AF Wu, Zhichao
   Luu, Chi D.
   Hodgson, Lauren A. B.
   Caruso, Emily
   Chen, Fred K.
   Chakravarthy, Usha
   Arnold, Jennifer J.
   Heriot, Wilson J.
   Runciman, Jim
   Guymer, Robyn H.
CA LEAD Study Grp
TI USING MICROPERIMETRY AND LOW-LUMINANCE VISUAL ACUITY TO DETECT THE ONSET
   OF LATE AGE-RELATED MACULAR DEGENERATION A LEAD Study Report
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; microperimetry; low-luminance visual
   acuity; self-monitoring
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL SENSITIVITY; GEOGRAPHIC ATROPHY;
   NEOVASCULARIZATION; EYES
AB Purpose: To evaluate the performance of microperimetry and low-luminance visual acuity for detecting late age-related macular degeneration (AMD) onset. Methods: Two hundred ninety-two individuals with bilateral large drusen in the Laser Intervention in the Early Stages of AMD study underwent best-corrected visual acuity, low-luminance visual acuity, and microperimetry testing as well as multimodal imaging to detect late (neovascular or atrophic) AMD onset. The performance of the change in the measurement from baseline of each of visual function test for detecting late AMD onset was compared. Results: The area under the receiver operating characteristic curve for detecting neovascular and atrophic AMD onset was not significantly different for low-luminance visual acuity (area under the receiver operating characteristic curve = 0.71 and 0.56, respectively) and microperimetry (area under the receiver operating characteristic curve = 0.82 and 0.62, respectively) compared with best-corrected visual acuity (area under the receiver operating characteristic curve = 0.57 and 0.56, respectively; P >= 0.126 for all). There was also only a fair degree of agreement between the three visual function measures for detecting the onset of neovascular and atrophic AMD (kappa >= 0.24). Conclusion: Microperimetry, low-luminance visual acuity, and best-corrected visual acuity demonstrate limited performance for detecting the earliest onset of late AMD. It remains to be established whether they perform better than current methods designed to enable self-detection of neovascular AMD onset, such as Amsler grid testing.
C1 [Wu, Zhichao; Luu, Chi D.; Hodgson, Lauren A. B.; Caruso, Emily; Guymer, Robyn H.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Australia.
   [Wu, Zhichao; Luu, Chi D.; Guymer, Robyn H.] Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Vic, Australia.
   [Chen, Fred K.] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Lions Eye Inst, Perth, WA, Australia.
   [Chen, Fred K.] Royal Perth Hosp, Dept Ophthalmol, Perth, WA, Australia.
   [Chakravarthy, Usha] Belfast Hlth & Social Care Trust, Belfast, Antrim, North Ireland.
   [Arnold, Jennifer J.] Marsden Eye Res, Sydney, NSW, Australia.
   [Heriot, Wilson J.] Retinol Inst Victoria, Glen Iris, Vic, Australia.
   [Runciman, Jim] Adelaide Eye & Retina Ctr, Adelaide, SA, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; Lions Eye Institute; University of Western
   Australia; Royal Perth Hospital; University of Western Australia
RP Wu, ZC (通讯作者)，Ctr Eye Res Australia, Level 7,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM wu.z@unimelb.edu.au
OI Chen, Fred/0000-0003-2809-9930
FU National Health and Medical Research Council of Australia [APP1027624,
   GNT1103013, APP1104985, APP1054712, APP1142962]; BUPA Health Foundation
   (Australia); Centre for Eye Research Australia (CERA)
FX Supported by the National Health and Medical Research Council of
   Australia (project grant no.: APP1027624 [R.H.G. and C.D.L.], and
   fellowship grant no.: GNT1103013 [R.H.G.], APP1104985 [Z.W.], APP1054712
   [F.K.C.], and APP1142962 [F.K.C.]) and BUPA Health Foundation
   (Australia) (R.H.G. and C.D.L.). The Centre for Eye Research Australia
   receives operational infrastructure support from the Victorian
   Government. The web-based Research Electronic Data Capture (REDCap)
   application and open-source platform OpenClinica allowed secure
   electronic data capture. The study is sponsored by the Centre for Eye
   Research Australia (CERA), an independent medical research institute and
   a not-for-profit company.
CR Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   Adams M, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.5.32
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Ciulla TA, 2018, OPHTHALMOL RETINA, V2, P645, DOI 10.1016/j.oret.2018.01.006
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Do DV, 2012, OPHTHALMOLOGY, V119, P771, DOI 10.1016/j.ophtha.2011.10.019
   Faes L, 2014, EYE, V28, P788, DOI 10.1038/eye.2014.104
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Hariri AH, 2016, AM J OPHTHALMOL, V168, P122, DOI 10.1016/j.ajo.2016.05.007
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   Ho CYD, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.2.2
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Lek JJ, 2017, OPHTHALMOL RETINA, V1, P227, DOI 10.1016/j.oret.2016.12.001
   Loewenstein A, 2003, OPHTHALMOLOGY, V110, P966, DOI 10.1016/S0161-6420(03)00074-5
   MCCLISH DK, 1989, MED DECIS MAKING, V9, P190, DOI 10.1177/0272989X8900900307
   Razavi H, 2017, OPHTHALMOLOGY, V124, P270, DOI 10.1016/j.ophtha.2016.08.013
   Song G, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.3.61
   Sulzbacher F, 2012, INVEST OPHTH VIS SCI, V53, P6448, DOI 10.1167/iovs.11-9162
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Vazquez NP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207342
   Wightman AJ, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.6.3
   Wu ZC, 2019, OPHTHALMOL RETINA, V3, P1026, DOI 10.1016/j.oret.2019.07.008
   Wu ZC, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.3.13
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P3714, DOI 10.1167/iovs.15-18294
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P115, DOI 10.1167/iovs.14-15614
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1445, DOI 10.1016/j.ophtha.2014.01.025
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
NR 32
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2021
VL 41
IS 5
BP 1094
EP 1101
DI 10.1097/IAE.0000000000002982
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SO2UF
UT WOS:000658831500028
PM 33009222
DA 2022-11-30
ER

PT J
AU Lauer, N
   Mihlan, M
   Hartmann, A
   Schlotzer-Schrehardt, U
   Keilhauer, C
   Scholl, HPN
   Issa, PC
   Holz, F
   Weber, BHF
   Skerka, C
   Zipfel, PF
AF Lauer, Nadine
   Mihlan, Michael
   Hartmann, Andrea
   Schloetzer-Schrehardt, Ursula
   Keilhauer, Claudia
   Scholl, Hendrik P. N.
   Issa, Peter Charbel
   Holz, Frank
   Weber, Bernhard H. F.
   Skerka, Christine
   Zipfel, Peter F.
TI Complement Regulation at Necrotic Cell Lesions Is Impaired by the
   Age-Related Macular Degeneration-Associated Factor-H His(402) Risk
   Variant
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID C-REACTIVE PROTEIN; VISUAL IMPAIRMENT; DRUSEN; POLYMORPHISM; ACTIVATION;
   DISEASE; COMMON; FORM; CRP; INFLAMMATION
AB Age-related macular degeneration is a leading form of blindness in Western countries and is associated with a common SNP (rs 1061170/Y402H) in the Factor H gene, which encodes the two complement inhibitors Factor H and FHL1. However, the functional consequences of this Tyr(402) His exchange in domain 7 are not precisely defined. In this study, we show that the Tyr(402) His sequence variation affects Factor H surface recruitment by monomeric C-reactive protein (mCRP) to specific patches on the surface of necrotic retinal pigment epithelial cells. Enhanced attachment of the protective Tyr(402) variants of both Factor H and FHL1 by mCRP results in more efficient complement control and further provides an anti-inflammatory environment. In addition, we demonstrate that mCRP is generated on the surface of necrotic retinal pigment epithelial cells and that this newly formed mCRP colocalizes with the cell damage marker annexin V. Bound to the cell surface, Factor H-mCRP complexes allow complement inactivation and reduce the release of the proinflammatory cytokine TNF-alpha. This mCRP-mediated complement inhibitory and anti-inflammatory activity at necrotic membrane lesions is affected by residue 402 of Factor H and defines a new role for mCRP, for Factor H, and also for the mCRP-Factor H complex. The increased protective capacity of the Tyr(402) Factor H variant allows better and more efficient clearance and removal of cellular debris and reduces inflammation and pathology. The Journal of Immunology, 2011, 187: 4374-4383.
C1 [Lauer, Nadine; Mihlan, Michael; Hartmann, Andrea; Skerka, Christine; Zipfel, Peter F.] Leibniz Inst Nat Prod Res & Infect Biol, Dept Infect Biol, D-07745 Jena, Germany.
   [Schloetzer-Schrehardt, Ursula] Univ Erlangen Nurnberg, Dept Ophthalmol, D-91054 Erlangen, Germany.
   [Keilhauer, Claudia] Univ Hosp Wurzburg, Dept Ophthalmol, D-97080 Wurzburg, Germany.
   [Scholl, Hendrik P. N.; Issa, Peter Charbel; Holz, Frank] Univ Eye Hosp Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
   [Scholl, Hendrik P. N.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21287 USA.
   [Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, D-93053 Regensburg, Germany.
   [Zipfel, Peter F.] Univ Jena, D-07745 Jena, Germany.
C3 Hans Knoll Institute (HKI); University of Erlangen Nuremberg; University
   of Wurzburg; University of Bonn; Johns Hopkins University; Johns Hopkins
   Medicine; University of Regensburg; Friedrich Schiller University of
   Jena
RP Zipfel, PF (通讯作者)，Leibniz Inst Nat Prod Res & Infect Biol, Dept Infect Biol, Beutenbergstr 11A, D-07745 Jena, Germany.
EM peter.zipfel@hki-jena.de
RI Issa, Peter Charbel/O-2580-2019; Issa, Peter Charbel/E-8935-2018
OI Issa, Peter Charbel/0000-0002-0351-6673; Issa, Peter
   Charbel/0000-0002-0351-6673; Weber, Bernhard H.F./0000-0002-8808-7723;
   Mihlan, Michael/0000-0002-3946-6583
FU Deutsche Forschungsgemeinschaft [Sk46, Zi432]; National Neurovision
   Research Institute-Foundation Fighting Blindness
   [NNCD-CL-0310.0049-JHU-WG]; American Health Assistance Foundation
   [M2010042]; Pro Retina Foundation; European Commission; European
   Community [LSHG-CT-2005-512036]; German ProRetina Foundation
FX This work was supported by the Deutsche Forschungsgemeinschaft (Sk46 and
   Zi432); the Wynn-Gund Translational Research Acceleration Program
   Enhanced Research and Clinical Training Award, National Neurovision
   Research Institute-Foundation Fighting Blindness
   (NNCD-CL-0310.0049-JHU-WG) (to H.P.N.S.); the Macular Degeneration
   Research Award, American Health Assistance Foundation (M2010042) (to
   H.P.N.S.); Pro Retina Foundation Pro-Re/Seed/Issa.1 (to H.P.N.S. and P.
   C. I.); and the European Commission, 6th European Community Framework
   Program, Integrated Project "EVI-GENORET" (LSHG-CT-2005-512036) (to
   H.P.N.S.). N.L. was supported by a Ph.D. research grant from the German
   ProRetina Foundation.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Biro A, 2007, IMMUNOLOGY, V121, P40, DOI 10.1111/j.1365-2567.2007.02535.x
   Caicedo A, 2005, EXP EYE RES, V81, P38, DOI 10.1016/j.exer.2005.01.013
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eisenhardt SU, 2009, CIRC RES, V105, P128, DOI 10.1161/CIRCRESAHA.108.190611
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1196, DOI 10.1016/0002-9394(71)90963-9
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2008, J BIOL CHEM, V283, P30451, DOI 10.1074/jbc.M803648200
   Heinen S, 2009, BLOOD, V114, P2439, DOI 10.1182/blood-2009-02-205641
   Hellwage J, 1997, BIOCHEM J, V326, P321, DOI 10.1042/bj3260321
   Hotchkiss RS, 2009, NEW ENGL J MED, V361, P1570, DOI 10.1056/NEJMra0901217
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Ji SR, 2007, FASEB J, V21, P284, DOI 10.1096/fj.06-6722com
   Ji SR, 2006, ARTERIOSCL THROM VAS, V26, P935, DOI 10.1161/01.ATV.0000206211.21895.73
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krysko O, 2004, APOPTOSIS, V9, P495, DOI 10.1023/B:APPT.0000031452.75162.75
   Kuhn S, 1996, EUR J IMMUNOL, V26, P2383, DOI 10.1002/eji.1830261017
   KUHN S, 1995, J IMMUNOL, V155, P5663
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Mihlan M, 2009, CELL DEATH DIFFER, V16, P1630, DOI 10.1038/cdd.2009.103
   MISASI R, 1989, EUR J IMMUNOL, V19, P1765, DOI 10.1002/eji.1830190936
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Okemefuna AI, 2010, J BIOL CHEM, V285, P1053, DOI 10.1074/jbc.M109.044529
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   POTEMPA LA, 1983, MOL IMMUNOL, V20, P1165, DOI 10.1016/0161-5890(83)90140-2
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Sohn JH, 2000, INVEST OPHTH VIS SCI, V41, P3492
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Volanakis JE, 2001, MOL IMMUNOL, V38, P189, DOI 10.1016/S0161-5890(01)00042-6
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
NR 42
TC 50
Z9 52
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD OCT 15
PY 2011
VL 187
IS 8
BP 4374
EP 4383
DI 10.4049/jimmunol.1002488
PG 10
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 829YN
UT WOS:000295623100050
PM 21930971
OA Bronze
DA 2022-11-30
ER

PT J
AU Jabs, DA
   Van Natta, ML
   Schneider, MF
   Pak, JW
   Trang, G
   Jones, NG
   Milush, J
   Hunt, PW
AF Jabs, Douglas A.
   Van Natta, Mark L.
   Schneider, Michael F.
   Pak, Jeong Won
   Trang, Garrett
   Jones, Norman G.
   Milush, Jeffrey
   Hunt, Peter W.
TI Association of elevated plasma inflammatory biomarker levels with
   age-related macular degeneration but not cataract in persons with AIDS
SO AIDS
LA English
DT Article
DE AIDS; biomarkers; cataract; macular degeneration; mortality
ID C-REACTIVE PROTEIN; ANTIRETROVIRAL THERAPY; IMMUNE ACTIVATION;
   HIV-INFECTION; COLLABORATIVE ANALYSIS; OCULAR COMPLICATIONS; PREDICT
   MORTALITY; SEVERITY SCALE; RISK; DISEASE
AB Objective: To evaluate the relationship between plasma biomarkers of systemic inflammation and incident age-related macular degeneration (AMD) in persons with the AIDS. Design: Case-control study. Methods: Participants with incident intermediate-stage AMD (N = 26) in the Longitudinal Study of the Ocular Complications of AIDS (LSOCA) and controls (N = 60) without AMD. Cryopreserved baseline plasma specimens were assayed for biomarkers of inflammation, including high-sensitivity C-reactive protein (CRP), interleukin (IL)-6, interferon-gamma inducible protein (IP)-10, soluble CD14 (sCD14), soluble CD163 (sCD163), and intestinal fatty acid-binding protein (I-FABP). Results: After adjustment for age, sex, and race/ethnicity, baseline mean +/- standard deviation (SD) log(10)(mg/ml) plasma levels of CRP (0.52 +/- 0.60 vs. 0.20 +/- 0.43; P = 0.01) and mean +/- SD log(10)(pg/ml) plasma levels of sCD14 (6.31 +/- 0.11 vs. 6.23 +/- 0.14; P = 0.008) were significantly higher among cases (incident AMD) than among controls (no AMD). There was a suggestion that mean +/- SD baseline log(10)(pg/ml) plasma IL-6 levels (0.24 +/- 0.33 vs. 0.11 +/- 0.29; P = 0.10) might be higher among cases than controls. In a separate analysis of 548 participants in LSOCA, elevated baseline levels of plasma inflammatory biomarkers were associated with a greater risk of mortality but not with an increased risk of incident cataract. Conclusion: These data suggest that systemic inflammatory biomarkers are associated with incident AMD but not incident cataract in persons with AIDS, and that systemic inflammation may play a role in the pathogenesis of AMD.
C1 [Jabs, Douglas A.; Van Natta, Mark L.; Schneider, Michael F.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615N Wolfe St, Baltimore, MD 21205 USA.
   [Jabs, Douglas A.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Wilmer Eye Inst, Baltimore, MD 21205 USA.
   [Pak, Jeong Won] Univ Wisconsin, Dept Ophthalmol & Visual, Sci Sch Med & Publ Hlth, Madison, WI USA.
   [Trang, Garrett; Jones, Norman G.; Milush, Jeffrey; Hunt, Peter W.] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA USA.
C3 Johns Hopkins University; Johns Hopkins Bloomberg School of Public
   Health; Johns Hopkins University; Johns Hopkins Medicine; University of
   Wisconsin System; University of Wisconsin Madison; University of
   California System; University of California San Francisco
RP Jabs, DA (通讯作者)，Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615N Wolfe St, Baltimore, MD 21205 USA.
EM djabs@jhmi.edu
OI Trang, Garrett/0000-0002-5823-8148
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Boulware DR, 2011, J INFECT DIS, V203, P1637, DOI 10.1093/infdis/jir134
   Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cooney EL, 2002, CLIN INFECT DIS, V34, P224, DOI 10.1086/323898
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Davalos AR, 2013, J CELL BIOL, V201, P613, DOI 10.1083/jcb.201206006
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Deeks SG, 2011, ANNU REV MED, V62, P141, DOI 10.1146/annurev-med-042909-093756
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170
   French MA, 2009, J INFECT DIS, V200, P1212, DOI 10.1086/605890
   Fukuda S, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2022751118
   Gill J, 2010, CLIN INFECT DIS, V50, P1387, DOI 10.1086/652283
   Harris TB, 1999, AM J MED, V106, P506, DOI 10.1016/S0002-9343(99)00066-2
   Hogg R, 2008, LANCET, V372, P293, DOI 10.1016/S0140-6736(08)61113-7
   Hunt PW, 2014, J INFECT DIS, V210, P1228, DOI 10.1093/infdis/jiu238
   Jabs DA, 2007, OPHTHALMOLOGY, V114, P780, DOI 10.1016/j.ophtha.2006.11.008
   Jabs DA, 2007, OPHTHALMOLOGY, V114, P787, DOI 10.1016/j.ophtha.2006.07.065
   Jabs DA, 2019, AM J OPHTHALMOL, V199, P230, DOI 10.1016/j.ajo.2018.12.002
   Jabs DA, 2017, AM J OPHTHALMOL, V179, P151, DOI 10.1016/j.ajo.2017.05.004
   Jabs DA, 2015, AM J OPHTHALMOL, V159, P1115, DOI 10.1016/j.ajo.2015.01.037
   Jabs DA, 2011, AM J OPHTHALMOL, V151, P198, DOI 10.1016/j.ajo.2010.10.018
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Kaplan RC, 2007, CLIN INFECT DIS, V45, P1074, DOI 10.1086/521935
   Kempen JH, 2014, OPHTHALMOLOGY, V121, P2317, DOI 10.1016/j.ophtha.2014.06.014
   Kilpatrick RD, 2008, J IMMUNOL, V180, P1499, DOI 10.4049/jimmunol.180.3.1499
   Klein BEK, 1998, ARCH OPHTHALMOL-CHIC, V116, P219, DOI 10.1001/archopht.116.2.219
   Knudsen TB, 2016, J INFECT DIS, V214, P1198, DOI 10.1093/infdis/jiw263
   Kuller LH, 2008, PLOS MED, V5, P1496, DOI 10.1371/journal.pmed.0050203
   Lederman MM, 2013, ADV IMMUNOL, V119, P51, DOI 10.1016/B978-0-12-407707-2.00002-3
   Lee S, 2017, J INFECT DIS, V215, P1270, DOI 10.1093/infdis/jix113
   Lohse N, 2007, ANN INTERN MED, V146, P87, DOI 10.7326/0003-4819-146-2-200701160-00003
   Miller YI, 2003, J BIOL CHEM, V278, P1561, DOI 10.1074/jbc.M209634200
   Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303
   Mizutani T, 2015, INVEST OPHTH VIS SCI, V56, P7122, DOI 10.1167/iovs.15-17440
   Munoz A., 2013, RenDez-Vous Techniques, P3
   Murphy EL, 2001, ANN INTERN MED, V135, P17, DOI 10.7326/0003-4819-135-1-200107030-00005
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Pathai S, 2014, J GERONTOL A-BIOL, V69, P833, DOI 10.1093/gerona/glt168
   Rattazzi M, 2003, J HYPERTENS, V21, P1787, DOI 10.1097/00004872-200310000-00002
   Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914
   Rizzardini G, 2020, JAIDS-J ACQ IMM DEF, V85, P498, DOI 10.1097/QAI.0000000000002466
   Schneider MF, 2005, AIDS, V19, P2009, DOI 10.1097/01.aids.0000189864.90053.22
   Tenorio AR, 2014, J INFECT DIS, V210, P1248, DOI 10.1093/infdis/jiu254
NR 46
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD FEB 1
PY 2022
VL 36
IS 2
BP 177
EP 184
DI 10.1097/QAD.0000000000003104
PG 8
WC Immunology; Infectious Diseases; Virology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Infectious Diseases; Virology
GA XS1OI
UT WOS:000732685400003
PM 34934018
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Gomi, F
   Toyoda, R
   Yoon, AH
   Imai, K
AF Gomi, Fumi
   Toyoda, Reiko
   Yoon, Annabelle Hein
   Imai, Kota
TI Factors of Anti-Vascular Endothelial Growth Factor Therapy Withdrawal in
   Patients with Neovascular Age-Related Macular Degeneration: Implications
   for Improving Patient Adherence
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE anti-VEGF therapy; age-related macular degeneration; withdrawal;
   adherence; patient-reported outcomes
ID QUALITY-OF-LIFE; RANIBIZUMAB TREATMENT; EXPERIENCES; INJECTIONS; BURDEN
AB We investigated the factors associated with the discontinuation of anti-vascular endothelial growth factor (VEGF) therapies in patients with neovascular age-related macular degeneration (AMD). Japanese patients with AMD aged >= 50 years, reporting at least one prior injection of an anti-VEGF drug, completed an online survey covering reasons for discontinuation or dissatisfaction with therapy, quality of life (EQ-5D-5L) and patient activation (PAM-13). The respondents were divided into two cohorts: Cohort 1-patients who discontinued anti-VEGF therapy (n = 207); Cohort 2-patients continuing anti-VEGF therapy (n = 65). The most common reason for discontinuing therapy was the "doctor's decision" in 89.4% (Cohort 1-1). In the other 22 (10.6%) patients in Cohort 1 (Cohort 1-2), reasons included "no deterioration in vision", "financial burden" and "ineffective treatment". Patients in Cohort 2 were dissatisfied with "long waiting times" (77%), "financial burden" and "ineffective treatment". Pain/discomfort posed the greatest impact on quality of life. Only 5% of patients in Cohorts 1-1 and 2 and none in Cohort 1-2 were considered advocates for their own health. In conclusion, most patients who discontinued anti-VEGF therapy did so at their doctor's decision. Addressing the reasons associated with discontinuation or dissatisfaction with anti-VEGF therapies might help improve their continuation.
C1 [Gomi, Fumi] Hyogo Coll Med, Dept Ophthalmol, Nishinomiya, Hyogo 6638501, Japan.
   [Toyoda, Reiko; Yoon, Annabelle Hein; Imai, Kota] Novartis Pharma KK, Med Div, Ophthalmol Med Franchise Dept, Tokyo 1056333, Japan.
   [Toyoda, Reiko] CMIC Ashfield Co Ltd, Tokyo 1050023, Japan.
C3 Hyogo College of Medicine; Novartis
RP Imai, K (通讯作者)，Novartis Pharma KK, Med Div, Ophthalmol Med Franchise Dept, Tokyo 1056333, Japan.
EM fgomi@hyo-med.ac.jp; reiko-toyoda.ac@cmic.co.jp;
   annabelle.h.yoon@gmail.com; kota.imai@novartis.com
FU Novartis Pharma K.K.
FX This study was sponsored by Novartis Pharma K.K.
CR Boulanger-Scemama E, 2015, J FR OPHTALMOL, V38, P620, DOI 10.1016/j.jfo.2014.11.015
   Boyle J, 2018, PSYCHOL HEALTH MED, V23, P127, DOI 10.1080/13548506.2016.1274040
   Boyle J, 2015, PSYCHOL HEALTH MED, V20, P296, DOI 10.1080/13548506.2014.936886
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Chatziralli I, 2017, SEMIN OPHTHALMOL, V32, P772, DOI 10.1080/08820538.2016.1181192
   Droege KM, 2014, GRAEF ARCH CLIN EXP, V252, P31, DOI 10.1007/s00417-013-2412-6
   Droege KM, 2013, GRAEF ARCH CLIN EXP, V251, P1281, DOI 10.1007/s00417-012-2177-3
   EuroQol, EQ 5D 5L USER GUIDE
   Figueras-Roca M, 2021, GRAEF ARCH CLIN EXP, V259, P1463, DOI 10.1007/s00417-020-05016-9
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1246, DOI 10.1016/j.ophtha.2013.12.032
   Flaxel C.J., AM ACAD OPHTHALMOLOG
   Gomi F., 2021, NIPPON GANKA GAKKAI, V125, P201
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   Insignia Health, PAT ACT MEAS PAM
   Kim JH, 2017, RETINA-J RET VIT DIS, V37, P2254, DOI 10.1097/IAE.0000000000001494
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Morse AR, 2021, J HEALTH PSYCHOL, V26, P2603, DOI 10.1177/1359105320922303
   Oishi A, 2011, EUR J OPHTHALMOL, V21, P777, DOI 10.5301/EJO.2011.7430
   Overbeek A, 2018, BMC GERIATR, V18, DOI 10.1186/s12877-017-0696-9
   Polar O, 2017, TURK OFTALMOL DERG, V47, P205, DOI 10.4274/tjo.28003
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Rakuten Insight Inc., RAK INS RAK INS
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Spooner KL, 2018, CLIN OPHTHALMOL, V12, P2483, DOI 10.2147/OPTH.S185052
   Takahashi K., 2020, GANKA, V62, P491
   Urbano CA, 2021, OSLI RETINA, V52, P190, DOI 10.3928/23258160-20210330-03
   Van Bulck L, 2018, BMC NEPHROL, V19, DOI 10.1186/s12882-018-0917-2
   Vaze A, 2014, RETINA-J RET VIT DIS, V34, P1774, DOI 10.1097/IAE.0000000000000173
NR 30
TC 3
Z9 3
U1 1
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD JUL
PY 2021
VL 10
IS 14
AR 3106
DI 10.3390/jcm10143106
PG 14
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA TN8KF
UT WOS:000676476400001
PM 34300272
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Strunz, T
   Lauwen, S
   Kiel, C
   den Hollander, A
   Weber, BHF
AF Strunz, Tobias
   Lauwen, Susette
   Kiel, Christina
   den Hollander, Anneke
   Weber, Bernhard H. F.
CA Int AMD Genomics Consortium IAMDGC
TI A transcriptome-wide association study based on 27 tissues identifies
   106 genes potentially relevant for disease pathology in age-related
   macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ALZHEIMERS-DISEASE; PROTEIN; MUTATIONS; ABCA7; SUSCEPTIBILITY;
   DEFICIENCY; EXPRESSION; GENOTYPES; TRAITS; LOCI
AB Genome-wide association studies (GWAS) for late stage age-related macular degeneration (AMD) have identified 52 independent genetic variants with genome-wide significance at 34 genomic loci. Typically, such an approach rarely results in the identification of functional variants implicating a defined gene in the disease process. We now performed a transcriptome-wide association study (TWAS) allowing the prediction of effects of AMD-associated genetic variants on gene expression. The TWAS was based on the genotypes of 16,144 late-stage AMD cases and 17,832 healthy controls, and gene expression was imputed for 27 different human tissues which were obtained from 134 to 421 individuals. A linear regression model including each individuals imputed gene expression data and the respective AMD status identified 106 genes significantly associated to AMD variants in at least one tissue (Q-value < 0.001). Gene enrichment analysis highlighted rather systemic than tissue- or cell-specific processes. Remarkably, 31 of the 106 genes overlapped with significant GWAS signals of other complex traits and diseases, such as neurological or autoimmune conditions. Taken together, our study highlights the fact that expression of genes associated with AMD is not restricted to retinal tissue as could be expected for an eye disease of the posterior pole, but instead is rather ubiquitous suggesting processes underlying AMD pathology to be of systemic nature.
C1 [Strunz, Tobias; Kiel, Christina; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, Regensburg, Germany.
   [Lauwen, Susette; den Hollander, Anneke] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Med Ctr, Nijmegen, Netherlands.
   [Lauwen, Susette; den Hollander, Anneke] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Dept Human Genet, Med Ctr, Nijmegen, Netherlands.
   [Int AMD Genomics Consortium IAMDGC] Univ Miami, Miller Sch Med, Inst Human Genom, Miami, FL 33136 USA.
C3 University of Regensburg; Radboud University Nijmegen; Radboud
   University Nijmegen; University of Miami
RP Weber, BHF (通讯作者)，Univ Regensburg, Inst Human Genet, Regensburg, Germany.
EM bweb@klinik.uni-regensburg.de
RI Mackey, David A/H-5340-2014; Souzeau, Emmanuelle/AAB-5608-2022; Peachey,
   Neal/G-5533-2010; Strunz, Tobias/ABB-6300-2020; Strunz,
   Tobias/ABD-9798-2021
OI Mackey, David A/0000-0001-7914-4709; Souzeau,
   Emmanuelle/0000-0002-2015-6577; Peachey, Neal/0000-0002-4419-7226;
   Strunz, Tobias/0000-0002-3744-9595; Craig, Jamie/0000-0001-9955-9696;
   Scott, William/0000-0001-9336-6404; Van Duijn,
   Cornelia/0000-0002-2374-9204; Blangero, John/0000-0001-6250-5723; Baird,
   Paul/0000-0002-1305-3502; Cree, Angela/0000-0002-1987-8900; Kiel,
   Christina/0000-0003-3154-4847; Hagbi-Levi, Shira/0000-0002-2891-0079;
   Lotery, Andrew/0000-0001-5541-4305; Su, Zhiguang/0000-0001-8635-9310;
   Ahn, Jeeyun/0000-0001-9017-1652; Grassmann, Felix/0000-0003-1390-7528;
   lake, stewart/0000-0003-0078-3319
FU Donders Center for Medical Neuroscience and Radboudumc; Institute of
   Human Genetics Regensburg [TG77]; Helmut Ecker Foundation (Ingolstadt,
   Germany) [05/17]; NIH [R01 EY022310];  [HHSN268201200008I]
FX S.L. is supported by a Junior Researcher grant from the Donders Center
   for Medical Neuroscience and Radboudumc. The work has been supported in
   part by institutional funds (TG77) of the Institute of Human Genetics
   Regensburg and by a grant from the Helmut Ecker Foundation (Ingolstadt,
   Germany) to BHFW (No. 05/17). We would like to acknowledge the
   contribution of the International AMD Genomics Consortium (IAMDGC) that
   is supported by a grant from NIH (R01 EY022310). Genotyping was
   supported by a contract (HHSN268201200008I) to the Center for Inherited
   Disease Research.
CR Aguet F, 2016, BIORXIV
   Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   Amberger JS, 2015, NUCLEIC ACIDS RES, V43, pD789, DOI 10.1093/nar/gku1205
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Ansari M, 2013, HUM MOL GENET, V22, P4857, DOI 10.1093/hmg/ddt336
   Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110
   Audo R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193815
   Benjamini Y, 2000, J EDUC BEHAV STAT, V25, P60, DOI 10.2307/1165312
   Biscetti Leonardo, 2017, Front Biosci (Elite Ed), V9, P174
   Boackle S. A., 2018, COMPLEMENT FACTSB, P423, DOI [10.1016/B978-0-12-810420-0.00040-7, DOI 10.1016/B978-0-12-810420-0.00040-7]
   Camelo S., 2014, AUTOIMMUNE DIS, V2014, P1
   Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128
   Chowaniec Z, 2018, ADV CLIN EXP MED, V27, P429, DOI 10.17219/acem/67968
   Colak E, 2011, OPHTHALMIC RES, V46, P125, DOI 10.1159/000323815
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Cookson W, 2009, NAT REV GENET, V10, P184, DOI 10.1038/nrg2537
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Cuyvers E, 2015, LANCET NEUROL, V14, P814, DOI 10.1016/S1474-4422(15)00133-7
   Eichers ER, 2002, AM J HUM GENET, V70, P955, DOI 10.1086/339688
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gamazon ER, 2015, NAT GENET, V47, P1091, DOI 10.1038/ng.3367
   Grassmann F, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0418-0
   Gusev A, 2016, NAT GENET, V48, P245, DOI 10.1038/ng.3506
   Haas P, 2011, AM J OPHTHALMOL, V152, P396, DOI 10.1016/j.ajo.2011.02.017
   Hara K, 2009, NEW ENGL J MED, V360, P1729, DOI 10.1056/NEJMoa0801560
   Iannaccone A, 2012, ADV EXP MED BIOL, V723, P11, DOI 10.1007/978-1-4614-0631-0_2
   Isaacs A, 2004, J CLIN ENDOCR METAB, V89, P3858, DOI 10.1210/jc.2004-0188
   Jaffe AE, 2018, NAT NEUROSCI, V21, P1117, DOI 10.1038/s41593-018-0197-y
   Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Karch CM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148717
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Kiel C., 2017, SCI REP, V7, P1
   Kim HJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep32548
   Lambert JC, 2013, NAT GENET, V45, P1452, DOI 10.1038/ng.2802
   Logue MW, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2013.12.007
   Mabuchi H, 2014, MOL CELLS, V37, P777, DOI 10.14348/molcells.2014.0265
   Maw MA, 1997, NAT GENET, V17, P198, DOI 10.1038/ng1097-198
   Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00257
   Morohoshi K, 2009, J AUTOIMMUN, V33, P247, DOI 10.1016/j.jaut.2009.09.003
   Ozen A, 2017, NEW ENGL J MED, V377, P52, DOI 10.1056/NEJMoa1615887
   Patel T, 2018, NEUROPATH APPL NEURO, V44, P506, DOI 10.1111/nan.12452
   Paun CC, 2015, INVEST OPHTH VIS SCI, V56, P7766, DOI 10.1167/iovs.15-17035
   Quazi F, 2013, J BIOL CHEM, V288, P34414, DOI 10.1074/jbc.M113.508812
   R Core Team, 2015, R LANG ENV STAT COMP
   Ratnapriya R, 2019, NAT GENET, V51, P606, DOI 10.1038/s41588-019-0351-9
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Settasatian N, 2001, J BIOL CHEM, V276, P26898, DOI 10.1074/jbc.M010708200
   Sharma NK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070193
   Singh A, 2012, AM J OPHTHALMOL, V154, P193, DOI 10.1016/j.ajo.2012.01.036
   Strunz T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24219-z
   Tikka S, 2014, BRAIN PATHOL, V24, P525, DOI 10.1111/bpa.12181
   Tryka KA, 2014, NUCLEIC ACIDS RES, V42, pD975, DOI 10.1093/nar/gkt1211
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Visscher PM, 2017, AM J HUM GENET, V101, P5, DOI 10.1016/j.ajhg.2017.06.005
   Wainberg M., 2018, BIORXIV, V51
   Wu H, 2007, P NATL ACAD SCI USA, V104, P3961, DOI 10.1073/pnas.0609101104
   Wu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089600
   Xue YH, 2010, NUCLEIC ACIDS RES, V38, P360, DOI 10.1093/nar/gkp977
   Yates A, 2016, NUCLEIC ACIDS RES, V44, pD710, DOI 10.1093/nar/gkv1157
   Zhao QF, 2015, MOL NEUROBIOL, V51, P1008, DOI 10.1007/s12035-014-8759-9
NR 63
TC 17
Z9 17
U1 3
U2 8
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 31
PY 2020
VL 10
IS 1
AR 1584
DI 10.1038/s41598-020-58510-9
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA NE8TG
UT WOS:000562877500010
PM 32005911
OA Green Published, Green Accepted, gold
DA 2022-11-30
ER

PT J
AU Du, ZJ
   Li, P
   Wang, L
AF Du, Zhao-Jiang
   Li, Peng
   Wang, Li
TI Magnetic nanoparticles conjugated with "RPE cell -MCP-1 antibody -VEGF
   antibody" compounds for the targeted therapy of age-related macular
   degeneration: a hypothesis
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; retinal pigment epithelium;
   superparamagnetic iron oxide nanoparticles; RPE cell transplantation;
   targeted therapy
ID GLOBAL PREVALENCE; OXIDATIVE STRESS; INDUCTION; DELIVERY
AB Age-related macular degeneration (AMD) is the leading cause of vision loss in the elderly throughout the world. Treatment of AMD utilizing retinal pigment epithelium (RPE) transplantation represents a promising therapy. However, simplex RPE transplantation can only replace the diseased RPE cells, but has no abilities to stop the development of AMD. It has been indicated that oxidization triggers the development of AMD by inducing the dysfunction and degeneration of RPE cells, which results in the upregulation of local monocyte chemotactic protein-1 (MCP-1) expression. MCP-1 induces macrophage recruiment which triggers local inflammation. As a result, the expression of vascular endothelial growth factor (VEGF) is upregulated by MCP-1 mediated inflammation and results in the formation of choroidal neovascularization (CNV). We accordingly propose a targeted therapy of AMD by subretinal transplanting the compound of RPE cell, MCP-1 antibody, and VEGF antibody and using a magnetic system to guide RPE cell compounds conjugated with superparamagnetic iron oxide nanoparticles (SPIONs). Furthermore, SPION-labelled RPE cells can be tracked and detected in vivo by non-invasive magnetic resonance imaging (MRI). This novel RPE cell transplantation methodology seems very promising to provide a new therapeutic approach for the treatment of AMD.
C1 [Du, Zhao-Jiang] Fourth Mil Med Univ, Tangdu Hosp, Dept Ophthalmol, Xian 710038, Shaanxi Provinc, Peoples R China.
   [Li, Peng] 451 Hosp PLA, Dept Ophthalmol, Xian 710054, Shaanxi Provinc, Peoples R China.
   [Wang, Li] Xian Med Univ, Dept Optometry, Xian 710021, Shaanxi Provinc, Peoples R China.
C3 Air Force Military Medical University; Xi'an Medical University
RP Du, ZJ (通讯作者)，Fourth Mil Med Univ, Tangdu Hosp, Dept Ophthalmol, Xian 710038, Shaanxi Provinc, Peoples R China.
EM tomdzj@163.com
FU National Natural Science Foundation of China [81100670]; Scientific
   Research Foundation for the Returned Overseas Chinese Scholars, State
   Education Ministry of China
FX Supported by the National Natural Science Foundation of China (No.
   81100670); the Scientific Research Foundation for the Returned Overseas
   Chinese Scholars, State Education Ministry of China.
CR Cano M, 2014, FREE RADICAL BIO MED, V69, P1, DOI 10.1016/j.freeradbiomed.2014.01.004
   Cheng K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5880
   Dang YL, 2015, CLIN INTERV AGING, V10, P255, DOI 10.2147/CIA.S73705
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Itaya M, 2007, INVEST OPHTH VIS SCI, V48, P5677, DOI 10.1167/iovs.07-0156
   Ito A, 2005, TISSUE ENG, V11, P489, DOI 10.1089/ten.2005.11.489
   Jasmin, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-4
   Jonas JB, 2014, LANCET GLOB HEALTH, V2, pE65, DOI 10.1016/S2214-109X(13)70163-3
   Maier M, 2008, KLIN MONATSBL AUGENH, V225, P653, DOI 10.1055/s-2008-1027455
   Narimatsu T, 2013, INVEST OPHTH VIS SCI, V54, P4555, DOI 10.1167/iovs.12-11572
   Nowak JZ, 2013, PHARMACOL REP, V65, P288, DOI 10.1016/S1734-1140(13)71005-3
   Skaf AR, 2011, SEMIN OPHTHALMOL, V26, P181, DOI 10.3109/08820538.2011.577133
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Suzuki M, 2012, J CELL SCI, V125, P2407, DOI 10.1242/jcs.097683
   Tukmachev D, 2015, NANOSCALE, V7, P3954, DOI 10.1039/c4nr05791k
   Wang W, 2014, COLLOID SURFACE B, V117, P449, DOI 10.1016/j.colsurfb.2013.11.050
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yildirimer L, 2011, NANO TODAY, V6, P585, DOI 10.1016/j.nantod.2011.10.001
   Zhu M, 2014, NANOSCALE RES LETT, V9, DOI 10.1186/1556-276X-9-528
NR 21
TC 1
Z9 1
U1 0
U2 8
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD MAY 18
PY 2017
VL 10
IS 5
BP 812
EP 814
DI 10.18240/ijo.2017.05.25
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EV2AW
UT WOS:000401556300025
PM 28546942
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Thier, A
   Breuning, M
   Wolfram, C
   Zeitz, O
   Holmberg, C
AF Thier, Anne
   Breuning, Martina
   Wolfram, Christian
   Zeitz, Oliver
   Holmberg, Christine
TI Emotional and physical experiences of people with neovascular
   age-related macular degeneration during the injection process in
   Germany: a qualitative study
SO BMJ OPEN
LA English
DT Article
DE neovascular age-related macular degeneration; anti-VEGF therapy;
   qualitative study; patient-doctor relationship
ID VISUAL-ACUITY; RANIBIZUMAB; VERTEPORFIN; THERAPY; HEALTH; SENSE; EYE
AB Objectives In order to better understand the continued barriers to the provision of vascular endothelial inhibitor therapy, this study aims to investigate patients' experiences with neovascular age-related macular degeneration (nvAMD) in Germany during the injection process and how they deal with it. Design and participants This analysis is part of the qualitative arm of a wider mixed-methods study. We recruited participants all over Germany via ophthalmologists, eye clinics, general practitioners, care bases and support groups between June 2018 and December 2020 and selected a subsample of study participants with nvAMD who were either undergoing or had previously undergone vascular endothelial growth factor inhibitor therapy. We conducted narrative, semistructured, face-to-face interviews at the participants' homes, which were audio-recorded. The interviews were thematically analysed. Results Twenty-two participants were included in this analysis. Experiencing neovascular macular degeneration was dominated by the injection experience. Study participants perceived the treatment with vascular endothelial inhibitor injections as uncomfortable, and they described undergoing varying levels of anxiety during the whole injection process. After some years of receiving multiple injections, the pain and not experiencing any positive effects made participants with significant vision loss want to discontinue therapy. Furthermore, they narrated negative injection experiences in association with their interactions with medical staff and doctors. Conclusion Although time in the medical setting is limited, efficient and good doctor-patient relationships seem crucial for satisfying care experiences. A respectful and humane relationship may be one key to achieving treatment adherence.
C1 [Thier, Anne; Holmberg, Christine] Brandenburg Med Sch Theodor Fontane, Inst Social Med & Epidemiol, Brandenburg, Germany.
   [Breuning, Martina] Univ Freiburg, Self Help Res Comprehens Canc Ctr Freiburg, CCCF Med Ctr, Freiburg, Baden Wurttembe, Germany.
   [Wolfram, Christian] Univ Med Ctr Hamburg Eppendorf, Dept Ophthalmol, Hamburg, Germany.
   [Zeitz, Oliver] Charite Univ Med Berlin, Dept Ophthalmol, Berlin, Germany.
   [Holmberg, Christine] Brandenburg Med Sch Theodor Fontane, Fac Hlth Sci Brandenburg, Potsdam, Germany.
C3 University of Freiburg; University of Hamburg; University Medical Center
   Hamburg-Eppendorf; Free University of Berlin; Humboldt University of
   Berlin; Charite Universitatsmedizin Berlin
RP Thier, A (通讯作者)，Brandenburg Med Sch Theodor Fontane, Inst Social Med & Epidemiol, Brandenburg, Germany.
EM anne.thier@mhb-fontane.de
FU FRIEBE foundation [T0498/30395/17]; MHB Open Access Publication Fund -
   German Research Association (DFG)
FX This study was funded by the FRIEBE foundation (T0498/30395/17). We
   acknowledge funding by the MHB Open Access Publication Fund supported by
   the German Research Association (DFG).
CR Bach M, 2007, GRAEF ARCH CLIN EXP, V245, P965, DOI 10.1007/s00417-006-0474-4
   Blodt S, 2021, HEALTH EXPECT, V24, P317, DOI 10.1111/hex.13171
   Braun V, 2012, THEMATIC ANAL, V2, P57
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Burton AE, 2013, BRIT J VISUAL IMPA, V31, P178, DOI 10.1177/0264619613490517
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Charmaz K., 2006, CONSTRUCTING GROUNDE, DOI DOI 10.7748/NR.13.4.84.S4
   Coyne IT, 1997, J ADV NURS, V26, P623, DOI 10.1046/j.1365-2648.1997.t01-25-00999.x
   DOG, 2020, OPHTHALMOLOGE, V117, P746, DOI 10.1007/s00347-020-01117-2
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Emsfors A, 2017, J CLIN NURS, V26, P2680, DOI 10.1111/jocn.13749
   Enoch J, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2021-049495
   Finger RP, 2014, OPHTHALMOLOGE, V111, P438, DOI 10.1007/s00347-013-2922-y
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Gensler G, 2002, J NUTR, V132, P697
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Husler S, 2013, KLIN MONATSBL AUGENH, V230, P1251, DOI 10.1055/s-0033-1351029
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McCloud C, 2015, EYE, V29, P1561, DOI 10.1038/eye.2015.167
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Taylor DJ, 2020, EYE, V34, P461, DOI 10.1038/s41433-019-0445-8
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Thier A, 2022, DISABIL REHABIL, V44, P661, DOI 10.1080/09638288.2020.1775901
   Wachtlin J, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/8024258
   Wickremasinghe SS, 2011, INVEST OPHTH VIS SCI, V52, P4072, DOI 10.1167/iovs.10-6550
   Wintergerst MWM, 2018, OPHTHALMOLOGE, V115, P1035, DOI 10.1007/s00347-017-0610-z
   Ziebland S, 2006, MED EDUC, V40, P405, DOI 10.1111/j.1365-2929.2006.02467.x
   Zolnierek KBH, 2009, MED CARE, V47, P826, DOI 10.1097/MLR.0b013e31819a5acc
NR 35
TC 0
Z9 0
U1 2
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PD JUN
PY 2022
VL 12
IS 6
AR e058266
DI 10.1136/bmjopen-2021-058266
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 2E7AM
UT WOS:000812378000021
PM 35705348
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Corazza, P
   D'Alterio, FM
   Kabbani, J
   Alam, MMR
   Mercuri, S
   Orlans, HO
   Younis, S
AF Corazza, Paolo
   D'Alterio, Francesco Maria
   Kabbani, Jamil
   Alam, Mostafa Mohamed Ragheb
   Mercuri, Stefano
   Orlans, Harry Otway
   Younis, Saad
TI Long-term outcomes of intravitreal anti-VEGF therapies in patients
   affected by neovascular age-related macular degeneration: a real-life
   study
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Anti-VEGF therapy; Choroidal neovascularization; Treat and extend;
   Wet-AMD; Real life data; Intravitreal injections
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; RANIBIZUMAB;
   AFLIBERCEPT; TREAT
AB Purpose To describe real-life data from wet age-related macular degeneration (AMD) patients treated with anti-vascular endothelial growth factors (VEGFs) and to compare our results with previous studies and clinical trials. Methods This retrospective monocentric cohort study analyzed 865 eyes of 780 wet-AMD patients treated with an anti-VEGF treat-and-extend regimen over a long-term follow-up period. Aflibercept and Ranibizumab were considered first-line agents whereas Bevacizumab was reserved for use on a compassionate basis in patients not meeting treatment criteria. All patients underwent a best corrected visual acuity (BCVA) assessment at each follow-up visit. Results One-year follow-up figures were available for 82.5% of patients, whilst follow-up data was recorded for 55.6%, 37.6%, 25.1%, and 15.0% of the cohort at years 2, 3, 4, and 5 respectively. Patients treated with Bevacizumab received fewer yearly injections than those treated with Ranibizumab. However, no significant difference in the number of injections per year was detected in other comparisons between groups. Whilst our data showed no significant difference in mean BCVA between the three groups, there was a gradual deterioration of visual function over time for the patient cohort as a whole. Conclusion No significant differences between the 3 anti-VEGF molecules were recorded in wet-AMD patients in real-life conditions. Despite the long-term therapy, we found a slight reduction in visual function especially after the third year of treatment.
C1 [Corazza, Paolo; D'Alterio, Francesco Maria; Alam, Mostafa Mohamed Ragheb; Mercuri, Stefano; Orlans, Harry Otway; Younis, Saad] Imperial Coll Healthcare NHS Trust, Western Eye Hosp, 171 Marylebone Rd, London NW1 5QH, England.
   [Corazza, Paolo; D'Alterio, Francesco Maria; Younis, Saad] Imperial Coll, Ophthalmol Res Grp ICORG, London, England.
   [Kabbani, Jamil] Imperial Coll, London, England.
   [Alam, Mostafa Mohamed Ragheb] Tanta Univ, Tanta, Egypt.
C3 Imperial College London; Imperial College London; Imperial College
   London; Egyptian Knowledge Bank (EKB); Tanta University
RP Corazza, P (通讯作者)，Imperial Coll Healthcare NHS Trust, Western Eye Hosp, 171 Marylebone Rd, London NW1 5QH, England.; Corazza, P (通讯作者)，Imperial Coll, Ophthalmol Res Grp ICORG, London, England.
EM polcorazza@gmail.com
OI D'Alterio, Francesco Maria/0000-0003-4248-4376
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Adrean SD, 2018, OPHTHALMOLOGY, V125, P1047, DOI 10.1016/j.ophtha.2018.01.012
   Amoaku W, 2018, CLIN OPHTHALMOL, V12, P1731, DOI 10.2147/OPTH.S174560
   [Anonymous], 2008, RAN PEG TREATM AG RE
   [Anonymous], 2016, US REAL WORLD EV SUP
   [Anonymous], 2013, AFL SOL INJ TREAT WE
   Arevalo JF, 2016, RETINA-J RET VIT DIS, V36, P859, DOI 10.1097/IAE.0000000000000827
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Boyle J, 2018, PSYCHOL HEALTH MED, V23, P127, DOI 10.1080/13548506.2016.1274040
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Butt T, 2017, APPL HEALTH ECON HEA, V15, P23, DOI 10.1007/s40258-016-0275-9
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Corazza P, 2021, EUR J OPHTHALMOL, V31, P2481, DOI 10.1177/1120672120963455
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   European Medicines Agency, 2016, WORKSH ID OPP BIG DA
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   Gayadine-Harricham Y, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/7465270
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Invernizzi A, 2019, AM J OPHTHALMOL, V204, P105, DOI 10.1016/j.ajo.2019.03.001
   Liew G, 2016, EYE, V30, P1462, DOI 10.1038/eye.2016.149
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mehta H, 2020, CLIN OPHTHALMOL, V14, P3331, DOI 10.2147/OPTH.S275977
   Miller JW, 1997, DIABETES METAB REV, V13, P37, DOI 10.1002/(SICI)1099-0895(199703)13:1<37::AID-DMR174>3.0.CO;2-K
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Plyukhova AA, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051522
   Qin VL, 2018, RETINA-J RET VIT DIS, V38, P1500, DOI 10.1097/IAE.0000000000001753
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
NR 39
TC 6
Z9 6
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD AUG 14
PY 2021
VL 21
IS 1
AR 300
DI 10.1186/s12886-021-02055-6
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UC6TV
UT WOS:000686657100003
PM 34391401
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ojima, Y
   Hangai, M
   Sakamoto, A
   Tsujikawa, A
   Otani, A
   Tamura, H
   Yoshimura, N
AF Ojima, Yumiko
   Hangai, Masanori
   Sakamoto, Atsushi
   Tsujikawa, Akitaka
   Otani, Atsushi
   Tamura, Hiroshi
   Yoshimura, Nagahisa
TI IMPROVED VISUALIZATION OF POLYPOIDAL CHOROIDAL VASCULOPATHY LESIONS
   USING SPECTRAL-DOMAIN OPTICAL COHERENCE TOMOGRAPHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE spectral-domain optical coherence tomography; time-domain optical
   coherence tomography; polypoidal choroidal vasculopathy; retinal pigment
   epithelium; branching vascular network; Bruch's membrane; indocyanine
   green angiography; polypoidal lesion; pigment epithelial detachment
ID PIGMENT EPITHELIAL DETACHMENTS; ULTRAHIGH-RESOLUTION;
   CLINICOPATHOLOGICAL CORRELATION; PATHOLOGICAL FEATURES
AB Purpose: To report the tomographic features of vascular lesions beneath the retinal pigment epithelium in eyes with polypoidal choroidal vasculopathy by using spectral-domain optical coherence tomography (SD-OCT). Design: Retrospective observational case series.
   Methods: Angiograms and images obtained using the prototype SD-OCT system were compared for 21 eyes of 21 patients with polypoidal choroidal vasculopathy to identify sub-retinal pigment epithelium abnormalities visible on three-dimensional and enhanced SD-OCT images.
   Results: On angiography, a branching vascular network and at least 1 polypoidal lesion were visible in all 21 eyes; 10 eyes also had pigment epithelial detachment (PED). SD-OCT revealed a thin straight line of high reflectivity-Bruch's membrane-associated with the branching vascular network in all 21 eyes, polypoidal lesions, 19 (90%) of the 21 eyes; and PED, 9 (90%) of the 10 eyes with PED. The vascular abnormalities of polypoidal choroidal vasculopathy (polypoidal lesion and branching vascular network) identified with angiograms were visualized on SD-OCT images in 20 of the 21 eyes (95%) as areas of moderate reflectivity between the clearly delineated abnormal section of retinal pigment epithelium and Bruch's membrane.
   Conclusions: Enhanced SD-OCT imaging clearly depicted Bruch's membrane beneath areas of abnormal retinal pigment epithelium in the same locations where the vascular abnormalities of polypoidal choroidal vasculopathy were evident on angiography.
C1 [Ojima, Yumiko; Hangai, Masanori; Sakamoto, Atsushi; Tsujikawa, Akitaka; Otani, Atsushi; Tamura, Hiroshi; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan.
C3 Kyoto University
RP Hangai, M (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Kawahura Cho, Kyoto 6068507, Japan.
EM hangai@kuhp.kyoto-u.ac.jp
RI TAMURA, Hiroshi/H-1855-2011
OI TAMURA, Hiroshi/0000-0002-7740-2732; Tsujikawa,
   Akitaka/0000-0003-0779-7799
FU Japan Society for the Promotion of Science (JSPS) [18591917]
FX Supported partially by a Grant-in-Aid for Scientific Research (18591917)
   from the Japan Society for the Promotion of Science (JSPS).
CR Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Drexler W, 2003, ARCH OPHTHALMOL-CHIC, V121, P695, DOI 10.1001/archopht.121.5.695
   Gass J D, 1966, Trans Am Acad Ophthalmol Otolaryngol, V70, P990
   GASS JDM, 1997, STEREOSCOPIC ATLAS M, V1, P49
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Hangai M, 2007, OPHTHALMOLOGY, V114, P763, DOI 10.1016/j.ophtha.2006.07.055
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Ko TH, 2005, OPHTHALMOLOGY, V112, P1922, DOI 10.1016/j.ophtha.2005.05.027
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Otsuji T, 2000, OPHTHALMIC SURG LAS, V31, P210
   PERKOVICH BT, 1990, RETINA-J RET VIT DIS, V10, P18, DOI 10.1097/00006982-199001010-00003
   Pieroni CG, 2006, BRIT J OPHTHALMOL, V90, P191, DOI 10.1136/bjo.2005.076612
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Sakamoto A, 2008, OPHTHALMOLOGY, V115, P1071, DOI 10.1016/j.ophtha.2007.09.001
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spraul CW, 1997, KLIN MONATSBL AUGENH, V210, P405, DOI 10.1055/s-2008-1035085
   Srinivasan VJ, 2006, OPHTHALMOLOGY, V113, P2054, DOI 10.1016/j.ophtha.2006.05.046
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yasuno Y, 2007, OPT EXPRESS, V15, P6121, DOI 10.1364/OE.15.006121
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 35
TC 57
Z9 67
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2009
VL 29
IS 1
BP 52
EP 59
DI 10.1097/IAE.0b013e3181884fbf
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 393YV
UT WOS:000262413300009
PM 18827738
DA 2022-11-30
ER

PT J
AU Kim, S
   Min, G
   Kim, B
   Lee, D
   Lee, M
   Ko, JH
   Kwon, HS
AF Kim, Seongbeom
   Min, Gihong
   Kim, Bomin
   Lee, Doseop
   Lee, Myongjae
   Ko, Jong-Hee
   Kwon, Hyuk-Sang
TI Novel Dual-Targeting Antibody Fragment IDB0062 Overcomes Anti-Vascular
   Endothelial Growth Factor Drug Limitations in Age-Related Macular
   Degeneration
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE IDB0062; wAMD; non-responsiveness; alternative angiogenesis; bispecific
   antibody fragment; resistance
ID VEGF TRAP; TUMOR; NEUROPILIN-1; RANIBIZUMAB; FUSION; EYE
AB Purpose: Repeated administration of anti-vascular endothelial growth factor drugs to treat age-related macular degeneration leads to resistance. To overcome this drawback, we developed the novel recombinant dual-targeting antibody fragment IDB0062, which is comprised of the anti-vascular endothelial growth factor A Fab and neuropilin 1-targeting peptide, and we assessed its properties. Methods: We compared the in vitro activity of IDB0062 and conventional drugs using cell proliferation, wound healing, and Transwell assays. The in vivo efficacy of IDB0062 was determined using mouse choroidal neovascularization and oxygeninduced retinopathy models. To evaluate the ocular distribution of IDB0062, we intravitreally administered IDB0062 and ranibizumab to cynomolgus monkeys and measured the retinal drug levels. Results: IDB0062 effectively inhibited not only vascular endothelial growth factor A in vitro but also placenta growth factor 2, vascular endothelial growth factor B, and platelet-derived growth factor BB, which induce vascular endothelial growth factor A- independent angiogenesis. In addition, IDB0062 showed non-inferior efficacy compared with aflibercept in vivo despite the low selectivity for mouse vascular endothelial growth factor A. In the monkey intravitreal pharmacokinetic study, IDB0062 improved drug distribution in the retina compared with ranibizumab, confirming the accelerated onset of pharmacological action when IDB0062 is injected in the vitreous humor. Conclusions: Through neuropilin 1 binding, IDB0062 can improve the efficacy and accelerate the onset of pharmacological action in the posterior segment, which is targeted for macular degeneration, thereby improving drug responsiveness in drugresistant patients. Translational Relevance: Considering its novel mechanism of action, IDB0062 may help in controlling resistance to conventional anti-vascular endothelial growth factor drugs in clinical settings.
C1 [Kim, Seongbeom; Min, Gihong; Kim, Bomin; Lee, Doseop; Lee, Myongjae; Ko, Jong-Hee; Kwon, Hyuk-Sang] ILDONG Pharmaceut Co Ltd, Res Lab, Samsung 1 Ro 1 Gil, Hwaseong Si 18449, South Korea.
C3 Samsung
RP Kwon, HS (通讯作者)，ILDONG Pharmaceut Co Ltd, Res Lab, Samsung 1 Ro 1 Gil, Hwaseong Si 18449, South Korea.
EM hskwon@ildong.com
RI Lee, Myongjae/I-8594-2017
OI Lee, Myongjae/0000-0002-0306-6908; Lee, Do Sup/0000-0001-7289-7804; Ko,
   Jong-Hee/0000-0002-6083-6323
FU Ministry of Small and Medium-Sized Enterprises and Startups, Korea,
   under the Regional Specialized Industry Development Program (RD)
   [R0003813]
FX Supported by the Ministry of Small and Medium-Sized Enterprises and
   Startups, Korea, under the Regional Specialized Industry Development
   Program (R&D, R0003813) supervised by the Korea Institute for
   Advancement of Technology.
CR Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Fernandez-Robredo P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169865
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Graziani G, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00125
   Guo HF, 2015, J BIOL CHEM, V290, P29120, DOI 10.1074/jbc.R115.687327
   Holmes DIR, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-2-209
   Kang HJ, 2017, IMMUNOL LETT, V184, P34, DOI 10.1016/j.imlet.2017.02.008
   Koch S, 2014, DEV CELL, V28, P633, DOI 10.1016/j.devcel.2014.02.010
   Maj E, 2016, INT J ONCOL, V49, P1773, DOI 10.3892/ijo.2016.3709
   Mamer SB, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16610-z
   Pan Q, 2007, CANCER CELL, V11, P53, DOI 10.1016/j.ccr.2006.10.018
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Pellet-Many C, 2011, BIOCHEM J, V435, P609, DOI 10.1042/BJ20100580
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Prud'homme GJ, 2012, ONCOTARGET, V3, P921, DOI 10.18632/oncotarget.626
   Regula JT, 2016, EMBO MOL MED, V8, P1265, DOI 10.15252/emmm.201505889
   Shin TH, 2014, MOL CANCER THER, V13, P651, DOI 10.1158/1535-7163.MCT-13-0748
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Stewart MW, 2012, CLIN OPHTHALMOL, V6, P1175, DOI 10.2147/OPTH.S33372
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Sumner G, 2019, BIOANALYSIS, V11, P381, DOI 10.4155/bio-2018-0096
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
NR 22
TC 0
Z9 0
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD DEC
PY 2021
VL 10
IS 14
AR 35
DI 10.1167/tvst.10.14.35
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YC0KR
UT WOS:000739389700001
PM 34967833
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Wang, JY
   Ohno-Matsui, K
   Yoshida, T
   Kojima, A
   Shimada, N
   Nakahama, K
   Safranova, O
   Iwata, N
   Saido, TC
   Mochizuki, M
   Morita, I
AF Wang, Jiying
   Ohno-Matsui, Kyoko
   Yoshida, Takeshi
   Kojima, Ariko
   Shimada, Noriaki
   Nakahama, Ken-ichi
   Safranova, Olga
   Iwata, Nobuhisa
   Saido, Takaomi C.
   Mochizuki, Manabu
   Morita, Ikuo
TI Altered function of factor I caused by amyloid beta: Implication for
   pathogenesis of age-related macular degeneration from drusen
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID PIGMENTED EPITHELIAL-CELLS; CAUSE-SPECIFIC PREVALENCE; FACTOR-H
   POLYMORPHISM; COMPLEMENT ACTIVATION; ALTERNATIVE PATHWAY; VISUAL
   IMPAIRMENT; FACTOR-B; PROTEIN; MACULOPATHY; EXPRESSION
AB The results of recent studies have implicated local inflammation and complement activation as the processes involved in the pathogenesis of age-related macular degeneration (AMD). We have demonstrated that amyloid beta (A beta), which is deposited in drusen, causes an imbalance in the angiogenesis-related factors in retinal pigment epithelial cells. We have also shown that neprilysin gene-disrupted mice accumulate A beta, and develop several features of AMD. The purpose of this study was to investigate the mechanisms involved in the development of AMD that are triggered by A beta. Our results showed that A beta binds to complement factor I which inhibits the ability of factor I to cleave C3b to inactivated iC3b. Factor H and factor I are soluble complement-activation inhibitors, and preincubation of factor I with A beta in the presence of factor H abolished the ability of A beta to cleave C3b, and also abolished the ability of factor I to cleave FGR-AMC. In contrast, A beta did not affect the function of factor H even after binding. The production of iC3b was significantly decreased when C3b and factor H were incubated with the eyes from neprilysin gene-disrupted mice as compared with when C3b and factor H were incubated with eyes from age-matched wild-type mice. These results suggest that A beta activates the complement system within drusen by blocking the function of factor I leading to a low-grade, chronic inflammation in subretinal tissues. These findings link four factors that have been suggested to be associated with AMD: inflammation, complement activation, A beta deposition, and drusen.
C1 [Ohno-Matsui, Kyoko] Tokyo Med & Dent Univ, Dept Ophthalmol & Visual Sci, Bunkyo Ku, Tokyo 113, Japan.
   [Nakahama, Ken-ichi; Safranova, Olga; Morita, Ikuo] Tokyo Med & Dent Univ, Sect Cellular Physiol Chem, Tokyo 113, Japan.
   [Iwata, Nobuhisa; Saido, Takaomi C.] RIKEN, Inst Phys & Chem Res, Brain Sci Inst, Lab Proteolyt Neurosci, Wako, Saitama 35101, Japan.
C3 Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental
   University (TMDU); RIKEN
RP Ohno-Matsui, K (通讯作者)，Tokyo Med & Dent Univ, Dept Ophthalmol & Visual Sci, Bunkyo Ku, 1-5-45 Yushima, Tokyo 113, Japan.
EM k.ohno.oph@tmd.ac.jp
RI Sado, Takaomi/AAN-2759-2021; Saido, Takaomi C/N-5472-2015
OI Sado, Takaomi/0000-0003-1970-6903; Saido, Takaomi C/0000-0003-1970-6903
CR Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BARNUM SR, 1995, CRIT REV ORAL BIOL M, V6, P132, DOI 10.1177/10454411950060020301
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bradt BM, 1998, J EXP MED, V188, P431, DOI 10.1084/jem.188.3.431
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   CAMPOCHIARO PA, 1993, EXP EYE RES, V57, P539, DOI 10.1006/exer.1993.1158
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friese MA, 2003, CLIN EXP IMMUNOL, V132, P485, DOI 10.1046/j.1365-2249.2003.02173.x
   Gasque P, 2004, MOL IMMUNOL, V41, P1089, DOI 10.1016/j.molimm.2004.06.011
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GREEN RG, 1999, AGE RELATED MACULAR, P81
   Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hellwage J, 1997, BIOCHEM J, V326, P321, DOI 10.1042/bj3260321
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   KAI S, 1980, J IMMUNOL, V125, P2409
   Klegeris A, 2000, BRAIN RES, V871, P1, DOI 10.1016/S0006-8993(00)02253-8
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   MAYER MM, 1973, SCI AM, V229, P54, DOI 10.1038/scientificamerican1173-54
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nilsson B., 1998, COMPLEMENT SYSTEM, P23
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Pasch MC, 2000, J INVEST DERMATOL, V114, P78, DOI 10.1046/j.1523-1747.2000.00841.x
   ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016
   Sahu A, 1998, J IMMUNOL, V160, P5596
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Strohmeyer R, 2002, J NEUROIMMUNOL, V131, P135, DOI 10.1016/S0165-5728(02)00272-2
   Strohmeyer R, 2000, MOL BRAIN RES, V81, P7, DOI 10.1016/S0169-328X(00)00149-2
   Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506
   Tsiftsoglou SA, 2005, BIOCHEMISTRY-US, V44, P6239, DOI 10.1021/bi047680t
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735
   Webster S, 1997, NEUROBIOL AGING, V18, P415, DOI 10.1016/S0197-4580(97)00042-0
   WEILER JM, 1976, P NATL ACAD SCI USA, V73, P3268, DOI 10.1073/pnas.73.9.3268
   WHALEY K, 1976, J EXP MED, V144, P1147, DOI 10.1084/jem.144.5.1147
   Wu ZH, 2007, J BIOL CHEM, V282, P22414, DOI 10.1074/jbc.M702321200
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   YATES JRW, 2007, NEW ENGL J MED, V357, P19
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 53
TC 61
Z9 71
U1 0
U2 11
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD JUL 1
PY 2008
VL 181
IS 1
BP 712
EP 720
DI 10.4049/jimmunol.181.1.712
PG 9
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 322WB
UT WOS:000257404900078
PM 18566438
OA Bronze
DA 2022-11-30
ER

PT J
AU Van Meurs, JC
   Van Den Biesen, PR
AF Van Meurs, JC
   Van Den Biesen, PR
TI Autologous retinal pigment epithelium and choroid translocation in
   patients with exudative age-related macular degeneration: Short-term
   follow-up
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RANDOMIZED CLINICAL-TRIAL; NEOVASCULAR MEMBRANES; SURGICAL REMOVAL;
   SUBFOVEAL NEOVASCULARIZATION; FUNDUS AUTOFLUORESCENCE; CELL
   TRANSPLANTATION; GEOGRAPHIC ATROPHY; IN-VIVO; LESIONS; CHORIOCAPILLARIS
AB PURPOSE: To evaluate the feasibilty of translocating autologous retinal pigment epithelium cells and choroid after the removal of a subfoveal choroidal neovascular membrane in patients with exudative age-related macular degeneration.
   DESIGN: Interventional case series.
   METHODS: This was a prospective evaluation of six patients with a follow-up of 7 to 13 months. All patients had large (> 1 disk diameter) subfoveal choroidal membranes, five with subretinal hemorrhage. Preoperative visual acuity ranged from 20/400 to 20/200. After the extraction of the neovascular complex, an autologous peripheral full,thickness patch of retinal pigment epithelium, Bruch membrane, choriocapillary, and choroid was cut out from the midperiphery and repositioned under the macula. Functional tests included Early Treatment Diabetic Retinopathy Study vision testing, fixation testing on a optical coherence tomography monitor, fluorescein and indocyanine green angiography, and scanning laser ophthalmoscopy autofluorescence.
   RESULTS: The retinal pigment epithelium patch appeared flat and had a brown furry aspect in four patients. Fixation was on the patch in these four patients. Postoperative vision ranged from 20/200 to 20/64, with a 2,line increase in three patients. Revascularization was visible on fluorescein and indocyanide angiography in three patients examined in this manner. Normal retinal pigment epithelium autofluorescence was present over the patch in four patients.
   CONCLUSIONS: The translocation of a full,thickness patch with autologous peripheral retinal pigment epithelium to the macula after choroidal neovascular membrane extraction was feasible and may result in a surviving and functioning graft for more than 1 year. Longer follow-up to evaluate its long,term benefit is necessary, as well as refinement of the surgery. (C) 2003 by Elsevier Inc. All rights reserved.
C1 Rotterdam Eye Hosp, NL-3011 BH Rotterdam, Netherlands.
   Univ Med Ctr Utrecht, Dept Ophthalmol, Utrecht, Netherlands.
C3 Rotterdam Eye Hospital; Utrecht University; Utrecht University Medical
   Center
RP Van Meurs, JC (通讯作者)，Rotterdam Eye Hosp, Schiedamsevest 180, NL-3011 BH Rotterdam, Netherlands.
CR Abe T, 2001, GRAEF ARCH CLIN EXP, V239, P927, DOI 10.1007/s00417-001-0393-3
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bressler NM, 2002, AM J OPHTHALMOL, V133, P168, DOI 10.1016/S0002-9394(01)01237-5
   CONVERSE JM, 1956, ANN SURG, V120, P306
   Del Priore LV, 2001, AM J OPHTHALMOL, V131, P472, DOI 10.1016/S0002-9394(00)00850-3
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   HALLER JA, 1967, ANN SURG, V166, P896, DOI 10.1097/00000658-196712000-00003
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   KORTE GE, 1986, ACTA ANAT, V127, P171
   LAFAUT BA, B SOC BELGE OPHTALMO, P49
   Lappas A, 2000, GRAEF ARCH CLIN EXP, V238, P631, DOI 10.1007/s004170000149
   LAVAIL MM, 1992, EXP EYE RES, V55, P555, DOI 10.1016/S0014-4835(05)80168-X
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   PLACE MJ, 1997, GRABB SMITHS PLASTIC, P18
   Sawa M, 2002, GRAEF ARCH CLIN EXP, V240, P12, DOI 10.1007/s004170100358
   Stanga PE, 2002, OPHTHALMOLOGY, V109, P1492, DOI 10.1016/S0161-6420(02)01099-0
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P767
   THOMAS MA, 1994, OPHTHALMOLOGY, V101, P1384
   THOMAS MA, 1991, AM J OPHTHALMOL, V111, P1, DOI 10.1016/S0002-9394(14)76888-6
   Thumann G, 2000, ARCH OPHTHALMOL-CHIC, V118, P1350
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   von Ruckmann A, 1999, GRAEF ARCH CLIN EXP, V237, P1, DOI 10.1007/s004170050186
   Weichel J, 2002, OPHTHALMIC SURG LAS, V33, P340
NR 30
TC 123
Z9 126
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2003
VL 136
IS 4
BP 688
EP 695
DI 10.1016/S0002-9394(03)00384-2
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 725HQ
UT WOS:000185538500012
PM 14516809
DA 2022-11-30
ER

PT J
AU Grewal, DS
   Gill, MK
   Sarezky, D
   Lyon, AT
   Mirza, RG
AF Grewal, D. S.
   Gill, M. K.
   Sarezky, D.
   Lyon, A. T.
   Mirza, R. G.
TI Visual and anatomical outcomes following intravitreal aflibercept in
   eyes with recalcitrant neovascular age-related macular degeneration:
   12-month results
SO EYE
LA English
DT Article
ID RANIBIZUMAB; BEVACIZUMAB; FLUID
AB Purpose To describe the efficacy of intravitreal aflibercept on 12-month visual and anatomical outcomes in patients with neovascular age-related macular degeneration (AMD) recalcitrant to prior monthly intravitreal bevacizumab or ranibizumab.
   Methods Non-comparative case series of 21 eyes of 21 AMD patients with evidence of persistent exudation (intraretinal fluid/cysts, or subretinal fluid (SRF), or both) on spectral domain OCT despite >= 6 prior intravitreal 0.5mg ranibizumab or 1.25mg bevacizumab (mean 29.8 +/- 17.1 injections) over 31.6 +/- 17.4 months who were transitioned to aflibercept.
   Results At baseline, best-corrected visual acuity (BCVA) was 0.42 +/- 0.28 logarithm of minimum-angle of resolution (logMAR), central foveal thickness (CFT) was 329.38 +/- 102.67 mu m and macular volume (MV) was 7.71 +/- 1.32 mm(3). After 12 months of aflibercept (mean 10.2 +/- 1.2 injections), BCVA was 0.40 +/- 0.28 logMAR (P = 0.5), CFT decreased to 292.71 +/- 91.35 mu m (P = 0.038) and MV improved to 7.33 +/- 1.27mm(3) (P = 0.003). In a subset of 15 eyes with a persistent fibrovascular or serous pigment epithelial detachment (PED), mean baseline PED greatest basal diameter (GBD) was 2350.9 +/- 1067.6 mu m and mean maximal height (MH) was 288.7 +/- 175.9 mu m. At 12 months, GBD improved to 1896.3 +/- 782.3 mu m (P = 0.028), while MH decreased to 248.27 +/- 146.2 mu m (P = 0.002).
   Conclusion In patients with recalcitrant AMD, aflibercept led to anatomic improvement at 12 months, reduction in proportion of eyes with SRF and reduction in PED, while preserving visual acuity.
C1 [Grewal, D. S.; Gill, M. K.; Sarezky, D.; Lyon, A. T.; Mirza, R. G.] Northwestern Univ, Feinberg Sch Med, Dept Ophthalmol, Chicago, IL 60611 USA.
C3 Northwestern University; Feinberg School of Medicine
RP Mirza, RG (通讯作者)，Northwestern Univ, Feinberg Sch Med, Dept Ophthalmol, 645 North Michigan Ave,Suite 440, Chicago, IL 60611 USA.
EM r-mirza@northwestern.edu
OI Grewal, Dilraj/0000-0002-2229-5343
FU Research to Prevent Blindness, NY
FX This work was supported in part by an unrestricted grant from Research
   to Prevent Blindness, NY.
CR Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Chaikitmongkol V, 2013, JAMA OPHTHALMOL, V131, P260, DOI 10.1001/jamaophthalmol.2013.1733
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Ehlers JP, 2010, OPHTHAL SURG LAS IM, V41, P182, DOI 10.3928/15428877-20100303-05
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Patel KH, 2013, EYE, V27, P664, DOI 10.1038/eye.2013.31
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 10
TC 60
Z9 65
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUL
PY 2014
VL 28
IS 7
BP 895
EP 899
DI 10.1038/eye.2014.101
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AL5LT
UT WOS:000339175900020
PM 24833178
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Gale, R
   Korobelnik, JF
   Yang, Y
   Wong, TY
AF Gale, Richard
   Korobelnik, Jean-Francois
   Yang, Yit
   Wong, Tien Y.
TI Characteristics and Predictors of Early and Delayed Responders to
   Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A
   Retrospective Analysis from the ANCHOR, MARINA, HARBOR, and CATT Trials
SO OPHTHALMOLOGICA
LA English
DT Article
DE Anti-vascular endothelial growth factor; Age-related macular
   degeneration; Macular degeneration
ID PIGMENT EPITHELIAL DETACHMENT; 2.0 MG RANIBIZUMAB; INTRAVITREAL
   RANIBIZUMAB; TREATMENT REGIMEN; EFFICACY; BEVACIZUMAB; OUTCOMES; SAFETY;
   FLUID
AB Purpose: This retrospective review examined visual acuity (VA) in subjects with neovascular age-related macular degeneration and identified early and delayed response to ranibizumab. Procedures: MARINA, ANCHOR, HARBOR, and CATT published data were examined for response with monthly versus individualized dosing and predictors of early versus delayed response. Results: Data were available for 1,631 subjects; 18-29% were early gainers and 15-16% were delayed gainers. Of the early gainers, 72-83% maintained their best corrected VA gain at month 12 with monthly or individualized dosing. Delayed gainers in HARBOR almost reached the same level of response as early gainers by 12 months who were able to maintain their response. The main predictor of response was baseline VA. Conclusion: There are two distinct types of ranibizumab response; some responded by month 3, while others took up to 12 months. In delayed responders, this may have implications for switching or not switching therapies. (C) 2016 The Author(s) Published by S. Karger AG, Basel
C1 [Gale, Richard] York Hosp, Wigginton Rd, York YO31 8HE, N Yorkshire, England.
   [Korobelnik, Jean-Francois] CHU Bordeaux, Serv Ophtalmol, Bordeaux, France.
   [Korobelnik, Jean-Francois] Univ Bordeaux, ISPED, Bordeaux, France.
   [Korobelnik, Jean-Francois] Bordeaux Populat Hlth Res Ctr, U1219, INSERM, Bordeaux, France.
   [Yang, Yit] Royal Wolverhampton Hosp NHS Trust, Eye Infirm, Wolverhampton, W Midlands, England.
   [Wong, Tien Y.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Wong, Tien Y.] Natl Univ Singapore, Duke NUS Med Sch, Singapore, Singapore.
C3 CHU Bordeaux; UDICE-French Research Universities; Universite de
   Bordeaux; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Universite de Bordeaux;
   National University of Singapore; Singapore National Eye Center;
   National University of Singapore
RP Gale, R (通讯作者)，York Hosp, Wigginton Rd, York YO31 8HE, N Yorkshire, England.
EM richard.gale@york.nhs.uk
RI Wong, Tien Yin/AAC-9724-2020; KOROBELNIK, Jean-Francois/A-5448-2016
OI Wong, Tien Yin/0000-0002-8448-1264; Korobelnik,
   Jean-Francois/0000-0002-4438-9535
CR Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Bloch SB, 2013, AM J OPHTHALMOL, V156, P116, DOI 10.1016/j.ajo.2013.02.012
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Cazet-Supervielle A, 2015, OPHTHALMOLOGICA, V234, P26, DOI 10.1159/000430470
   Droege KM, 2014, GRAEF ARCH CLIN EXP, V252, P31, DOI 10.1007/s00417-013-2412-6
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P676, DOI 10.1016/j.ophtha.2013.09.050
   Hariprasad SM, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/690641
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Keane PA, 2012, INVEST OPHTH VIS SCI, V53, P1152, DOI 10.1167/iovs.11-8130
   Keane PA, 2010, INVEST OPHTH VIS SCI, V51, P5431, DOI 10.1167/iovs.09-4846
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rezaei KA, 2015, GLOBAL TRENDS RETINA
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schlottmann P, EURETINA 2014
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Stoller GL, 2016, JAMA OPHTHALMOL, V134, P545, DOI 10.1001/jamaophthalmol.2016.0379
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Waldstein SM, 2016, JAMA OPHTHALMOL, V134, P182, DOI 10.1001/jamaophthalmol.2015.4948
   Wolf A, 2014, GRAEF ARCH CLIN EXP, V252, P647, DOI 10.1007/s00417-013-2562-6
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zinkernagel MS, 2016, OPHTHALMOLOGICA, V235, P42, DOI 10.1159/000441428
NR 29
TC 9
Z9 9
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2016
VL 236
IS 4
BP 193
EP 200
DI 10.1159/000451065
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EI5UG
UT WOS:000392559700003
PM 27784021
OA hybrid
DA 2022-11-30
ER

PT J
AU Jeffery, RHC
   Mukhtar, SA
   Lopez, D
   Preen, DB
   McAllister, IL
   Mackey, DA
   Morlet, N
   Morgan, WH
   Chen, FK
AF Heath Jeffery, Rachael C.
   Mukhtar, Syed Aqif
   Lopez, Derrick
   Preen, David B.
   McAllister, Ian L.
   Mackey, David A.
   Morlet, Nigel
   Morgan, William H.
   Chen, Fred K.
TI Incidence of Newly Registered Blindness From Age-Related Macular
   Degeneration in Australia Over a 21-Year Period: 1996-2016
SO ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; bevacizumab; blindness; ranibizumab;
   verteporfin
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RANDOMIZED CLINICAL-TRIALS;
   VISUAL IMPAIRMENT; PHOTODYNAMIC THERAPY; LEGAL BLINDNESS; RANIBIZUMAB;
   PREVALENCE; VERTEPORFIN; EYE; TRENDS
AB Purpose: Report the age-standardized annual incidence of blindness registration due to age-related macular degeneration (AMD) in Australia in patients aged 50 years and older. Frequencies of photodynamic therapy (PDT) and intravitreal therapy (IVT) were examined. Design: Retrospective observational study. Setting: Registry of the Association for the Blind of Western Australia with best-corrected visual acuity worse than 20/200 in the better-seeing eye. Participants: Registering as blind aged 50 years or over. Measures: Annual age-standardized incidence of blindness over 3 time periods: 1996-2001 (pre-PDT), 2002-2007 (PDT era) and 2008-2016 (IVT era). The rates of PDT and IVT usage were assessed. Results: Age-standardized annual incidence of blindness rose during the PDT era, reaching 72.5 cases per 100,000 person-years in 2004. The incidence declined from 2007 onwards, reaching 8.2 cases per 100,000 person-years in 2016 (IVT era). The age at AMD blindness registration increased from 82.7 to 84.9 and 83.7 to 86.0 years from the PDT era to the IVT era in both male and females (P < 0.001) respectively. Over the same time period, PDT usage increased in 2002 and declined in 2006, whereas IVT usage increased from 2009 by 3745 per year. Conclusion: The increase in new blindness registrations due to AMD coincided with public funding of verteporfin for PDT, whereas the subsequent decline occurred when bevacizumab was used off-label and ranibizumab and aflibercept were publicly funded. An understanding of the effect of retinal therapy on public health measures may inform improvements in the allocation of limited resources.
C1 [Mukhtar, Syed Aqif; McAllister, Ian L.; Mackey, David A.; Morlet, Nigel; Morgan, William H.; Chen, Fred K.] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Incorporating Lions Eye Inst, Nedlands, WA, Australia.
   [Heath Jeffery, Rachael C.; Morlet, Nigel; Morgan, William H.; Chen, Fred K.] Royal Perth Hosp, Dept Ophthalmol, Perth, WA, Australia.
   [Lopez, Derrick; Preen, David B.] Univ Western Australia, Sch Populat & Global Hlth, Crawley, WA, Australia.
   [Chen, Fred K.] Perth Childrens Hosp, Dept Ophthalmol, Nedlands, WA, Australia.
C3 Lions Eye Institute; University of Western Australia; Royal Perth
   Hospital; University of Western Australia; University of Western
   Australia
RP Chen, FK (通讯作者)，Lions Eye Inst, 2 Verdun St, Nedlands, WA, Australia.
EM fredchen@lei.org.au
RI Mackey AO, David/H-5340-2014
OI Mackey AO, David/0000-0001-7914-4709; Chen, Fred/0000-0003-2809-9930
FU Novartis; Australian National Health and Medical Research Council
   [GNT116360, GNT1188694, GNT1054712, MRF1142962]; McCusker Charitable
   Foundation; Miocevich Retina Fellowship
FX Supported by a grant from Novartis (FKC), the Australian National Health
   and Medical Research Council under GNT116360 (FKC), GNT1188694 (FKC),
   GNT1054712 (FKC) and MRF1142962 (FKC), McCusker Charitable Foundation
   (FKC) and the Miocevich Retina Fellowship (RCHJ).
CR Australian Government Services Australia, MED STAT MED IT REP
   Barry P, 2007, J CATARACT REFR SURG, V33, P978, DOI 10.1016/j.jcrs.2007.02.032
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   Campbell JP, 2012, ARCH OPHTHALMOL-CHIC, V130, P794, DOI 10.1001/archophthalmol.2011.2480
   Carneiro A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6469138
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Crewe J, 2012, BRIT J OPHTHALMOL, V96, P478, DOI 10.1136/bjophthalmol-2011-300908
   Fasler K, 2020, BRIT J OPHTHALMOL, V104, P684, DOI 10.1136/bjophthalmol-2019-314446
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Johnston RL, 2016, OPHTHALMOLOGY, V123, P2386, DOI 10.1016/j.ophtha.2016.07.037
   Jorstad OK, 2020, ACTA OPHTHALMOL, V98, P774, DOI 10.1111/aos.14177
   Keel S, 2017, JAMA OPHTHALMOL, V135, P1242, DOI 10.1001/jamaophthalmol.2017.4182
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1556, DOI 10.1016/j.ophtha.2018.03.059
   Rostron E, 2012, EYE, V26, P933, DOI 10.1038/eye.2012.61
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Skaat A, 2012, AM J OPHTHALMOL, V153, P214, DOI 10.1016/j.ajo.2011.08.035
   Yong VK, 2006, OPHTHAL EPIDEMIOL, V13, P35, DOI 10.1080/09286580500473779
NR 31
TC 4
Z9 4
U1 0
U2 0
PU ASIA-PACIFIC ACAD OPHTHALMOLOGY-APAO
PI KOWLOON
PA 4-F, HONG KONG EYE HOSP, 147K ARGYLE ST, KOWLOON, KOWLOON, HONG KONG
   00000, PEOPLES R CHINA
EI 2162-0989
J9 ASIA-PAC J OPHTHALMO
JI Asia-Pac. J. Ophthalmol.
PD SEP-OCT
PY 2021
VL 10
IS 5
BP 442
EP 449
DI 10.1097/APO.0000000000000415
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UW5KA
UT WOS:000700193400009
PM 34534144
OA gold
DA 2022-11-30
ER

PT J
AU Frenkel, REP
   Shapiro, H
   Stoilov, I
AF Frenkel, Ronald E. P.
   Shapiro, Howard
   Stoilov, Ivaylo
TI Predicting vision gains with anti-VEGF therapy in neovascular
   age-related macular degeneration patients by using low-luminance vision
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID 2.0 MG RANIBIZUMAB; SUBGROUP ANALYSIS; DARK-ADAPTATION; NONRESPONSE;
   EFFICACY; SAFETY
AB Background/aims To evaluate baseline low-luminance visual acuity (LLVA) as a predictor of visual acuity improvement in patients with neovascular (wet) age-related macular degeneration (wAMD) receiving antivascular endothelial growth factor A (anti-VEGF) therapy.
   Methods In the HARBOR trial, 1084 treatment-naive patients >= 50 years of age with subfoveal wAMD received intravitreal ranibizumab 0.5 or 2.0 mg monthly or as needed. To measure LLVA, patients read a normally illuminated ETDRS (Early Treatment Diabetic Retinopathy Study) chart with a neutral density filter placed in front of the study eye. Patients were assigned into quartiles based on the magnitude of the difference between best-corrected visual acuity under optimal luminance (BCVA) and LLVA (BCVA-LLVA gap). The association between mean change in BCVA from baseline and BCVA-LLVA gap at baseline was analysed using a general linear model.
   Results A smaller baseline BCVA-LLVA gap predicted significantly higher BCVA gains over 24 months (p<0.0001 at each month; Pearson correlation), even after controlling for baseline BCVA or stratifying by treatment arm. Patients in the smallest baseline BCVA-LLVA gap quartile gained an average of +13.4 letters compared with +2.4 letters for patients in the widest baseline BCVA-LLVA gap quartile. At months 12 and 24, the smallest baseline BCVA-LLVA gap quartile had the highest proportion of >= 15->= 30-letter gain, and the widest baseline BCVA-LLVA gap quartile had the highest proportion of >= 15-/>= 30-letter loss (p<0.0001; Fisher's exact test).
   Conclusions The baseline BCVA-LLVA gap is a significant predictor of visual acuity response to anti-VEGF treatment in patients with wAMD.
C1 [Frenkel, Ronald E. P.] Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Frenkel, Ronald E. P.] East Florida Eye Inst, 509 SE Riverside Dr 302, Stuart, FL 34994 USA.
   [Frenkel, Ronald E. P.] Eye Res Fdn, Stuart, FL USA.
   [Shapiro, Howard; Stoilov, Ivaylo] Genentech Inc, San Francisco, CA 94080 USA.
C3 Bascom Palmer Eye Institute; Roche Holding; Genentech
RP Frenkel, REP (通讯作者)，East Florida Eye Inst, 509 SE Riverside Dr 302, Stuart, FL 34994 USA.
EM efleye@aol.com
FU Genentech, Inc.
FX Third-party writing assistance for this manuscript was provided by Grace
   H. Lee, PharmD, of Envision Scientific Solutions, and funded by
   Genentech, Inc.
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brockmann C, 2013, EYE, V27, P1169, DOI 10.1038/eye.2013.159
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kim YM, 2012, AM J OPHTHALMOL, V154, P164, DOI 10.1016/j.ajo.2012.01.030
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Oishi A, 2013, GRAEF ARCH CLIN EXP, V251, P435, DOI 10.1007/s00417-012-2034-4
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SANDBERG MA, 1993, INVEST OPHTH VIS SCI, V34, P3477
   Shin HJ, 2011, RETINA-J RET VIT DIS, V31, P1627, DOI 10.1097/IAE.0b013e31820d3d01
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   van Asten F, 2014, OPHTHAL EPIDEMIOL, V21, P347, DOI 10.3109/09286586.2014.949010
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 21
TC 10
Z9 10
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2016
VL 100
IS 8
BP 1052
EP 1057
DI 10.1136/bjophthalmol-2015-307575
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DS4JR
UT WOS:000380747900007
PM 26541435
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Wormald, R
   Evans, J
   Smeeth, L
   Henshaw, K
AF Wormald, R.
   Evans, J.
   Smeeth, L.
   Henshaw, K.
TI Photodynamic therapy for neovascular age-related macular degeneration
   (Withdrawn Paper. 2007, art. no. CD002030)
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
DE glucose [therapeutic use]; macular degeneration [*drug therapy];
   *photochemotherapy; photosensitizing agents [*therapeutic use];
   porphyrins [therapeutic use]; randomized controlled trials; retinal
   neovascularization [*drug therapy]
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RANDOMIZED CLINICAL-TRIALS;
   VERTEPORFIN THERAPY; VISUAL-ACUITY; TAP; OUTCOMES; LESIONS
AB Background
   In neovascular age-related macular degeneration (AMD) new vessels grow under the retina distorting vision and leading to scarring. This is exacerbated if the blood vessels leak. Photodynamic therapy (PDT) has been investigated as a way to treat the neovascular membranes without affecting the retina. \ Objectives
   The aim of this review was to examine the effects of PDT in the treatment of neovascular AMD.
   Search strategy
   We searched CENTRAL (Issue 1, 2007), MEDLINE (1966 to March 2007), EMBASE (1980 to March 2007). We contacted experts in the field and searched the reference lists of relevant studies.
   Selection criteria
   We included randomised trials of PDT in people with choroidal neovascularisation due to AMD. Data collection and analysis Two authors independently extracted the data. Risk ratios were combined using a fixed-effect model after testing for heterogeneity.
   Main results
   Three published trials were identified that randomised 1022 participants to verteporfin therapy compared to 5% dextrose in water. The TAP and VIP trials were performed by the same investigators using largely the same clinical centres and funded by manufacturers of verteporfin. Outcome data were available at 12 and 24 months after the first treatment. Participants received on average five treatments over two years. The risk ratio of losing three or more lines of visual acuity at 24 months comparing the intervention with the control group was 0.77 (95% confidence interval 0.69 to 0.87). The risk ratio of losing six ormore lines of visual acuity at 24 months comparing the intervention with the control group was 0.62 (95% confidence interval 0.50 to 0.76). The results at 12 months were similar to those at 24 months. The most serious adverse outcome, acute (within seven days of treatment) severe visual acuity decrease, occurs in about one in 50 patients. Some outcomes from the more recent VIM trial could be included in the meta-analysis but have not greatly altered the findings.
   Authors' conclusions
   Photodynamic therapy in people with choroidal neovascularisation due to AMD is probably effective in preventing visual loss though there is doubt about the size of the effect. Outcomes and potential adverse effects of this treatment should be monitored closely. Further independent trials of verteporfin are required to establish that the effects seen in this study are consistent and to examine important issues not yet addressed, particularly relating to quality of life and cost. However, the advent of new interventions for AMD make this unlikely.
C1 Univ London London Sch Hyg & Trop Med, Int Ctr Eye Hlth, London WC1E 7HT, England.
C3 University of London; London School of Hygiene & Tropical Medicine
RP Wormald, R (通讯作者)，Univ London London Sch Hyg & Trop Med, Int Ctr Eye Hlth, Keppel St, London WC1E 7HT, England.
EM r.wormald@ucl.ac.uk
RI Evans, Jennifer/F-4672-2012
OI Evans, Jennifer/0000-0002-6137-2030
FU MRC [G108/492] Funding Source: UKRI; Medical Research Council
   [G108/492(60712), G108/492] Funding Source: Medline
CR Armbrecht AM, 2004, BRIT J OPHTHALMOL, V88, P1270, DOI 10.1136/bjo.2003.038604
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Azab M, 2004, RETINA-J RET VIT DIS, V24, P1
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Bhavsar A, 2004, RETINA-J RET VIT DIS, V24, P512
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Borodoker N, 2002, AM J OPHTHALMOL, V133, P211, DOI 10.1016/S0002-9394(01)01341-1
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2002, AM J OPHTHALMOL, V133, P168, DOI 10.1016/S0002-9394(01)01237-5
   Bressler SB, 2004, ARCH OPHTHALMOL-CHIC, V122, P325, DOI 10.1001/archopht.122.3.325
   Do DV, 2004, AM J OPHTHALMOL, V137, P558, DOI 10.1016/j.ajo.2003.08.001
   Glanville JM, 2006, J MED LIBR ASSOC, V94, P130
   Holz FG, 2003, OPHTHALMOLOGY, V110, P400, DOI 10.1016/S0161-6420(02)01770-0
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P982, DOI 10.1136/bjo.2003.039131
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Macdonald GM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub2
   Meads C, 2004, BRIT J OPHTHALMOL, V88, P212, DOI 10.1136/bjo.2003.019471
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Pieramici DJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P660
   *RET PHYS, AMD TREATMENT CHOICE
   Rubin GS, 2002, RETINA-J RET VIT DIS, V22, P536, DOI 10.1097/00006982-200210000-00002
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Schmidt-Erfurth UM, 2004, OPHTHALMOLOGY, V111, P931, DOI 10.1016/j.ophtha.2003.12.025
   Schmidt-Erfurth UM, 2003, OPHTHALMOLOGY, V110, P1306, DOI 10.1016/S0161-6420(03)00452-4
   *SE RET ASS, CURR ENR CLIN TRIALS
   Slakter JS, 2003, INVEST OPHTH VIS SCI, V44, pU297
   STUR M, 2004, INVEST OPHTHALMOL, P2275
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Woodburn KW, 2002, RETINA-J RET VIT DIS, V22, P391, DOI 10.1097/00006982-200208000-00001
NR 31
TC 51
Z9 54
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2007
IS 3
AR CD002030
DI 10.1002/14651858.CD002030.pub3
PG 28
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 191FZ
UT WOS:000248118000133
PM 17636693
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Farinha, C
   Silva, AL
   Coimbra, R
   Nunes, S
   Cachulo, ML
   Marques, JP
   Pires, I
   Cunha-Vaz, J
   Silva, R
AF Farinha, Claudia
   Silva, Ana Luisa
   Coimbra, Rita
   Nunes, Sandrina
   Cachulo, Maria Luz
   Marques, Joao Pedro
   Pires, Isabel
   Cunha-Vaz, Jose
   Silva, Rufino
TI Retinal layer thicknesses and neurodegeneration in early age-related
   macular degeneration: insights from the Coimbra Eye Study
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Early age-related macular degeneration; Microstructural spectral-domain
   optical coherence tomography analysis; Biomarkers of AMD progression;
   Retinal layers and choroidal thicknesses; Subretinal drusenoid deposits
AB Purpose This study aims to analyze the retinal layers and choroidal thickness in a large set of eyes with early age-related macular degeneration (AMD), in order to detect differences by stage suggestive of early neurodegeneration, and to explore biomarkers of different phenotypes.
   Methods This study is a population-based, cross-sectional study. Patients from the incidence AMD study (NCT02748824) with early AMD (Rotterdam 2a, 2b, 3) were included. All performed spectral-domain optical coherence tomography (SD-OCT) (Spectralis, Heidelberg Engineering, Germany) and automatic segmentation of all retinal layers was obtained with built-in software. Manual correction was performed whenever necessary. The mean thicknesses (ETDRS grid) and volume of each layer were recorded. Subfoveal choroidal thickness was manually measured. Estimates for each layer thickness were calculated with linear mixed models and tested for pairwise differences between stages. Associations between layer thickness and microstructural findings were assessed by multivariate regression analysis.
   Results The final cohort comprised 346 eyes (233 patients): 82.66% (n = 286) in stage 2a, 5.49% (n = 19) in stage 2b, and 11.85% (n = 41) in stage 3. A global tendency for lower/inferior thickness of the neuroretinal layers was found comparing stage 3 to 2a: retinal nerve fiber layer (RNFL), ganglion cell layer (GCL), and inner plexiform layer (IPL) were inferior in the inner/outer ETDRS circles and the outer nuclear layer (ONL) and photoreceptors' segments layer in the central circle (p <= 0.002). The retinal pigment epithelium-Bruch's membrane (RPE/BrM) layer was thicker in stage 3 (p <= 0.001). Subretinal drusenoid deposits (SDD) were associated with thinner neuroretinal layers and choroid (p < 0.05).
   Conclusions Our results showed in a large population-based dataset that several inner and outer neuroretinal layers were thinner with a higher stage in early AMD. These findings support the existence of early and progressive neurodegeneration. Neuronal retinal layer thicknesses might thus be used as quantitative biomarkers of disease progression in AMD. The presence of SDD is possibly associated to more prominent and faster neurodegeneration.
C1 [Farinha, Claudia; Coimbra, Rita; Nunes, Sandrina; Cachulo, Maria Luz; Marques, Joao Pedro; Pires, Isabel; Cunha-Vaz, Jose; Silva, Rufino] Assoc Innovat & Biomed Res Light & Image AIBILI, Coimbra, Portugal.
   [Farinha, Claudia; Cachulo, Maria Luz; Marques, Joao Pedro; Pires, Isabel; Silva, Rufino] Ctr Hosp & Univ Coimbra CHUC, Dept Ophthalmol, P-3000 Coimbra, Portugal.
   [Farinha, Claudia; Silva, Ana Luisa; Cachulo, Maria Luz; Marques, Joao Pedro; Pires, Isabel; Cunha-Vaz, Jose; Silva, Rufino] Univ Coimbra FMUC, Fac Med, Coimbra, Portugal.
   [Silva, Rufino] Univ Coimbra iCBR FMUC, Fac Med, Coimbra Inst Clin & Biomed Res, Coimbra, Portugal.
C3 Universidade de Coimbra; Universidade de Coimbra; Centro Hospitalar e
   Universitario de Coimbra (CHUC); Universidade de Coimbra; Universidade
   de Coimbra
RP Farinha, C (通讯作者)，Assoc Innovat & Biomed Res Light & Image AIBILI, Coimbra, Portugal.; Farinha, C (通讯作者)，Ctr Hosp & Univ Coimbra CHUC, Dept Ophthalmol, P-3000 Coimbra, Portugal.; Farinha, C (通讯作者)，Univ Coimbra FMUC, Fac Med, Coimbra, Portugal.
EM 10114@chuc.min-saude.pt
RI Marques, João Pedro/J-3584-2012; Farinha, Claudia/R-1392-2017
OI Marques, João Pedro/0000-0002-1014-0483; Farinha,
   Claudia/0000-0003-4596-0913; Cunha-Vaz, Jose/0000-0002-0947-9850; Silva,
   Rufino/0000-0001-8676-0833; Silva, Ana Luisa Ferreira de
   Jesus/0000-0002-1630-0011
FU Novartis
FX This study was an investigator-initiated study financially supported by
   Novartis.
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Borrelli E, 2017, AM J OPHTHALMOL, V181, P1, DOI 10.1016/j.ajo.2017.06.005
   Brandl C, 2019, INVEST OPHTH VIS SCI, V60, P1581, DOI 10.1167/iovs.18-25332
   Cachulo MD, 2016, ACTA OPHTHALMOL, V94, pE442, DOI 10.1111/aos.12950
   Cachulo MD, 2015, OPHTHALMOLOGICA, V233, P119, DOI 10.1159/000371584
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Echols BS, 2020, OPHTHALMOL RETINA, V4, P1059, DOI 10.1016/j.oret.2020.05.001
   Farinha C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051329
   Finger RP, 2019, OPHTHALMOLOGICA, V241, P61, DOI 10.1159/000491402
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Gattoussi S, 2019, ACTA OPHTHALMOL, V97, P364, DOI 10.1111/aos.13883
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Lamin A, 2019, EYE, V33, P428, DOI 10.1038/s41433-018-0234-9
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Lee MW, 2020, AM J OPHTHALMOL, V212, P17, DOI 10.1016/j.ajo.2019.12.003
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Farinha CVL, 2019, OPHTHALMIC RES, V61, P226, DOI 10.1159/000496393
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Muftuoglu IK, 2018, RETINA-J RET VIT DIS, V38, P1478, DOI 10.1097/IAE.0000000000001759
   Nassisi M, 2018, INVEST OPHTH VIS SCI, V59, P3431, DOI 10.1167/iovs.18-24143
   Nittala MG, 2019, OPHTHALMOL RETINA, V3, P112, DOI 10.1016/j.oret.2018.09.017
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Savastano MC, 2014, INVEST OPHTH VIS SCI, V55, P560, DOI 10.1167/iovs.13-12172
   Sitnilska V, 2020, OPHTHALMOLOGICA, V243, P444, DOI 10.1159/000507196
   Strunz T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58510-9
   Won JC, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003153
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yenice E, 2015, EYE, V29, P1076, DOI 10.1038/eye.2015.86
NR 32
TC 4
Z9 4
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD SEP
PY 2021
VL 259
IS 9
BP 2545
EP 2557
DI 10.1007/s00417-021-05140-0
EA MAR 2021
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UD4CF
UT WOS:000630276600003
PM 33738626
DA 2022-11-30
ER

PT J
AU Park, SJ
   Kwon, KE
   Choi, NK
   Park, KH
   Woo, SJ
AF Park, Sang Jun
   Kwon, Kyoung-eun
   Choi, Nam-Kyong
   Park, Kyu Hyung
   Woo, Se Joon
TI Prevalence and Incidence of Exudative Age-Related Macular Degeneration
   in South Korea A Nationwide Population-Based Study
SO OPHTHALMOLOGY
LA English
DT Article
ID BLUE MOUNTAINS EYE; RISK-FACTORS; JAPANESE POPULATION; CHINESE
   POPULATION; 5-YEAR INCIDENCE; MACULOPATHY; PROGRESSION; OCCLUSION;
   SINGAPORE; DISEASE
AB Purpose: To determine the prevalence and incidence of exudative age-related macular degeneration (AMD) in South Korea.
   Design: Nationwide population-based retrospective study using data from the Korean national health claims database from 2008 through 2012.
   Participants: Entire South Korean population 40 years of age or older (n = 22 376 510).
   Methods: We accessed the national health claims database to identify exudative AMD patients using the registration program database for rare intractable diseases, which included ophthalmologist-confirmed exudative AMD, for copayment reduction.
   Main Outcome Measures: Prevalence and incidence rates of exudative AMD.
   Results: Duringthe 5-year studyperiod, 81 513 patients had exudative AMD(48.2% men) and were included in the prevalence estimates. The prevalence in the general population 40 years of age or older was 36.43 (95% confidence interval [CI], 36.18-36.68) per 10 000 people, that in men was 37.01 (95% CI, 36.65-37.38) per 10 000 people, and that in women was 35.90 (95% CI, 35.56-36.24) per 10 000 people. After excluding prevalent cases during the initial 2-year washout period, 20 196 cases were identified with incident exudative AMD during the final 3-year study period (2010-2012). The incidence in the general population 40 years of age or older was 3.02 (95% CI, 2.98-3.06) per 10 000 person-years, that in men was 3.76 (95% CI, 3.69-3.83) per 10 000 person-years, and that in women was 2.34 (95% CI, 2.29-2.39) per 10 000 person-years. The prevalence and incidence increased with advancing age and peaked at approximately 80 years of age. Both the prevalence and incidence were higher in men than in women in all age groups.
   Conclusions: These detailed estimates of the nationwide, population-based prevalence and incidence of exudative AMD in an Asian population may help to understand the disease pathophysiology and to plan accordingly within the healthcare system. (C) 2015 by the American Academy of Ophthalmology.
C1 [Park, Sang Jun; Park, Kyu Hyung; Woo, Se Joon] Seoul Natl Univ, Dept Ophthalmol, Coll Med, Bundang Hosp, Songnam, South Korea.
   [Park, Sang Jun; Kwon, Kyoung-eun] Seoul Natl Univ, Dept Prevent Med, Coll Med, Seoul 110799, South Korea.
   [Choi, Nam-Kyong] Seoul Natl Univ Hosp, Med Res Collaborating Ctr, Seoul 110744, South Korea.
   [Choi, Nam-Kyong] Seoul Natl Univ, Coll Med, Seoul 110799, South Korea.
   [Choi, Nam-Kyong] Seoul Natl Univ, Med Res Ctr, Inst Environm Med, Seoul 110799, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU); Seoul National University Hospital; Seoul
   National University (SNU); Seoul National University (SNU)
RP Choi, NK (通讯作者)，Seoul Natl Univ, Med Res Ctr, Inst Environm Med, 103 Daehakno, Seoul 110799, South Korea.
EM likei1@snu.ac.kr; sejoon1@snu.ac.kr
OI Choi, Nam-Kyong/0000-0003-1153-9928
FU National Research Foundation of Korea - Ministry of Education, Science,
   and Technology, Seoul, Korea [NRF-2014R1A1A2058601]; Seoul National
   University Bundang Hospital Research Fund, Seongnam, Korea [12-2013-019]
FX Supported by the National Research Foundation of Korea (grant no.:
   NRF-2014R1A1A2058601) funded by the Ministry of Education, Science, and
   Technology, Seoul, Korea (N.-K.C.); and by the Seoul National University
   Bundang Hospital Research Fund, Seongnam, Korea (grant no.: 12-2013-019
   [S.J.W.]).
CR Ahn IM, 2014, STROKE, V45, P1090, DOI 10.1161/STROKEAHA.113.004273
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P764, DOI 10.1016/j.ajo.2012.10.013
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Geirsdottir A, 2012, BRIT J OPHTHALMOL, V96, P444, DOI 10.1136/bjophthalmol-2011-300304
   Jonasson F, 2005, OPHTHALMOLOGY, V112, P132, DOI 10.1016/j.ophtha.2004.07.020
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kim HJ, 2015, INFLAMM BOWEL DIS, V21, P623, DOI 10.1097/MIB.0000000000000313
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lee PP, 2003, ARCH OPHTHALMOL-CHIC, V121, P1303, DOI 10.1001/archopht.121.9.1303
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nakata I, 2013, AM J OPHTHALMOL, V156, P1002, DOI 10.1016/j.ajo.2013.06.007
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Park SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120067
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1933, DOI 10.1016/j.ophtha.2014.04.029
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1274, DOI 10.1016/j.ophtha.2013.12.024
   Park SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080174
   Saari JM, 2014, OPEN OPHTHALMOL J, V8, P95, DOI 10.2174/1874364101408010095
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   World Health Organization, 2007, VIS 2020 RIGHT SIGHT
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
   Ye HH, 2014, INVEST OPHTH VIS SCI, V55, P6374, DOI 10.1167/iovs.14-14899
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
NR 31
TC 57
Z9 57
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2015
VL 122
IS 10
BP 2063
EP U302
DI 10.1016/j.ophtha.2015.06.018
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CU4IP
UT WOS:000363491500023
PM 26208437
DA 2022-11-30
ER

PT J
AU Dillon, L
   Gandhi, S
   Tang, D
   Liew, G
   Hackett, M
   Craig, A
   Mitchell, P
   Keay, L
   Gopinath, B
AF Dillon, Lisa
   Gandhi, Sarthak
   Tang, Diana
   Liew, Gerald
   Hackett, Maree
   Craig, Ashley
   Mitchell, Paul
   Keay, Lisa
   Gopinath, Bamini
TI Perspectives of people with late age-related macular degeneration on
   mental health and mental wellbeing programmes: a qualitative study
SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS
LA English
DT Article
DE mental health; macular degeneration; qualitative study; wellbeing
   programmes; depression
ID DEPRESSIVE SYMPTOMS; VISUAL IMPAIRMENT; META-SYNTHESIS; OLDER-ADULTS;
   PREVALENCE; SERVICES; POPULATION; MANAGEMENT
AB Purpose: People with age-related macular degeneration (AMD) experience high rates of depression, but rarely engage in or have access to tailored mental wellbeing programmes. This qualitative study investigated the perspectives of those primarily with late AMD on mental health and mental wellbeing programmes.
   Methods: Twenty-eight people with late AMD in at least one eye, and one person with early AMD in both eyes, aged 56-87 years (mean age 78 years) attending a private eye clinic between December 2019 and January 2020 in Sydney, New South Wales, Australia, participated. Individual semi-structured interviews were conducted and analysed deductively using content analysis, following the individual level factors for health promotion interventions in the behaviour change wheel: Capability (Physical & Psychological), Opportunity (Physical & Social), and Motivation (Reflective & Automatic).
   Results; Six major themes were identified: Capability: (1) Impact of vision loss on mobility and leisure pursuits; (2) Adjustment to living with vision loss; Opportunity: (3) Program considerations for those with AMD; (4) Stigma and self-perception of vision loss and mental health; Motivation: (5) Accumulation of vision-related issues as a barrier to participation; (6) Examples of others living with vision loss. General personal factors relevant to delivery of a programme in this age group were also identified: Comorbidities; Limitations using technology; Isolation; Financial concerns and Beliefs that undesired effects of aging are inevitable.
   Conclusions: Complex individual, environmental and social factors influence the perspectives of people with late AMD on mental health, and potential participation in mental wellbeing programmes. These factors should be considered when developing and implementing mental wellbeing programmes to improve the emotional and functional rehabilitation outcomes for people with AMD.
C1 [Dillon, Lisa; Keay, Lisa] UNSW Sydney, Sch Optometry & Vis Sci, Kensington, NSW, Australia.
   [Dillon, Lisa; Hackett, Maree; Keay, Lisa] UNSW Sydney, George Inst Global Hlth, Fac Med, Newtown, Tas, Australia.
   [Gandhi, Sarthak] Monash Univ, Fac Med Nursing & Hlth Sci, Melbourne, Vic, Australia.
   [Gandhi, Sarthak] Univ Sydney, Fac Med & Hlth, Sydney, NSW, Australia.
   [Tang, Diana; Liew, Gerald; Mitchell, Paul; Gopinath, Bamini] Univ Sydney, Westmead Inst Med Res, Ctr Vis Res, Dept Ophthalmol, Sydney, NSW, Australia.
   [Hackett, Maree] Univ Cent Lancashire, Fac Hlth & Wellbeing, Preston, Lancs, England.
   [Craig, Ashley] Univ Sydney, Fac Med & Hlth, Northern Clin Sch, John Walsh Ctr Rehabil Res, St Leonards, NSW, Australia.
C3 University of New South Wales Sydney; George Institute for Global
   Health; University of New South Wales Sydney; University of Sydney;
   Monash University; University of Sydney; University of Sydney; Westmead
   Institute for Medical Research; University of Central Lancashire;
   University of Sydney
RP Dillon, L (通讯作者)，UNSW Sydney, Sch Optometry & Vis Sci, Kensington, NSW, Australia.; Dillon, L (通讯作者)，UNSW Sydney, George Inst Global Hlth, Fac Med, Newtown, Tas, Australia.
EM lisa.dillon1@unsw.edu.au
RI Liew, Gerald/AAB-6870-2022; Hackett, Maree/O-8752-2016
OI Dillon, Lisa/0000-0002-8124-6154; Gandhi, Sarthak/0000-0003-4198-8505;
   Tang, Diana/0000-0003-2007-9054; Hackett, Maree/0000-0003-1211-9087;
   Keay, Lisa/0000-0003-2215-0678
FU UNSW SOVS Macular Degeneration Research Grant from the Estate of the
   late Peter Anthony John Vild
FX This study was supported by the UNSW SOVS Macular Degeneration Research
   Grant from the Estate of the late Peter Anthony John Vild. We thank the
   participants that took part in this research.
CR Bennion AE, 2012, SOC SCI MED, V75, P976, DOI 10.1016/j.socscimed.2012.04.023
   BLAZER D, 1987, GERONTOLOGIST, V27, P281, DOI 10.1093/geront/27.3.281
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Burgess PM, 2009, AUST NZ J PSYCHIAT, V43, P615, DOI 10.1080/00048670902970858
   Byers AL, 2012, PSYCHIAT SERV, V63, P66, DOI 10.1176/appi.ps.201100121
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Dillon L, 2020, EYE, V34, P1287, DOI 10.1038/s41433-020-0992-z
   Dixon LB, 2016, WORLD PSYCHIATRY, V15, P13, DOI 10.1002/wps.20306
   Fenwick EK, 2009, OPTOMETRY VISION SCI, V86, P948, DOI 10.1097/OPX.0b013e3181b2f599
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Gresset J, 2002, OPTOMETRY VISION SCI, V79, P416, DOI 10.1097/00006324-200207000-00009
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Holloway EE, 2015, AUST J PRIM HEALTH, V21, P169, DOI 10.1071/PY13085
   Hong T, 2015, BRIT J OPHTHALMOL, V99, P1017, DOI 10.1136/bjophthalmol-2014-306308
   Horowitz A, 2006, J VISUAL IMPAIR BLIN, V100, P871
   Jones GC, 2009, REHABIL PSYCHOL, V54, P164, DOI 10.1037/a0015910
   Lee E-KO, 2016, QUAL SOC WORK, V1, P389
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Michie S, 2013, ANN BEHAV MED, V46, P81, DOI 10.1007/s12160-013-9486-6
   Michie S, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-10
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Newman SC, 1998, PSYCHOL MED, V28, P1339, DOI 10.1017/S0033291798007442
   Nyman SR, 2012, DISABIL REHABIL, V34, P971, DOI 10.3109/09638288.2011.626487
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Peveler R., 2006, PRIM CARE MENT HLTH, V4, P185
   Pollard TL, 2003, OPHTHAL PHYSL OPT, V23, P321, DOI 10.1046/j.1475-1313.2003.00123.x
   Pope C, 2000, BMJ-BRIT MED J, V320, P114, DOI 10.1136/bmj.320.7227.114
   Rees G, 2015, PATIENT EDUC COUNS, V98, P174, DOI 10.1016/j.pec.2014.11.008
   Rees G, 2010, EXPERT REV OPHTHALMO, V5, P385, DOI 10.1586/EOP.10.32
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Saunders B, 2018, QUAL QUANT, V52, P1893, DOI 10.1007/s11135-017-0574-8
   Srivastava P., 2009, INT J QUAL METH, V8, P76, DOI [10.1177/160940690900800107, DOI 10.1177/160940690900800107]
   Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042
   Vaismoradi M, 2013, NURS HEALTH SCI, V15, P398, DOI 10.1111/nhs.12048
   van der Aa HPA, 2016, OPHTHAL PHYSL OPT, V36, P584, DOI 10.1111/opo.12313
   van der Aa HPA, 2015, QUAL LIFE RES, V24, P969, DOI 10.1007/s11136-014-0835-0
   van Nispen RMA, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006543.pub2
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 39
TC 5
Z9 5
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0275-5408
EI 1475-1313
J9 OPHTHAL PHYSL OPT
JI Ophthalmic Physiol. Opt.
PD MAR
PY 2021
VL 41
IS 2
BP 255
EP 265
DI 10.1111/opo.12779
EA JAN 2021
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA QY0PY
UT WOS:000606516600001
PM 33427324
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Minnella, AM
   Piccardi, M
   Placidi, G
   Garcia-Layana, A
   Delcourt, C
   Valentini, P
   Falsini, B
AF Minnella, Angelo Maria
   Piccardi, Marco
   Placidi, Giorgio
   Garcia-Layana, Alfredo
   Delcourt, Cecile
   Valentini, Patrizia
   Falsini, Benedetto
TI Macular Function in Early and Intermediate Age-related Macular
   Degeneration: Correlation with the Simplified Thea Risk Assessment Scale
   (STARS)
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE age-related macular degeneration; focal electroretinogram; risk factors;
   visual acuity
ID CARDIOVASCULAR-DISEASE; TERM INCIDENCE; MACULOPATHY; PREVALENCE;
   SENSITIVITY; DYSFUNCTION
AB Purpose: Early detection of retinal dysfunction in age-related macular degeneration (AMD) may be important for both prevention and treatment. The aim of this study was to evaluate in early and intermediate AMD the correlation of macular function, assessed by the focal electroretinogram (fERG), with the Simplified Thea Risk Assessment Scale (STARS), a simple 13-item self-administered questionnaire.
   Methods: We recorded a fERG (18 degrees, 41 Hz) in 84 patients with AMD (40 male and 44 female, age 55-87 years, visual acuity 20/40-20/20), who had undergone a 5-year clinical ophthalmic and general follow-up. Sixty-six patients had early and 17 patients intermediate AMD. Fifty healthy subjects, in a comparable age range, served as controls. The fERG amplitude (in microVolts) was the main outcome variable. STARS was calculated for each patient.
   Results: Compared with controls, fERG amplitudes were significantly reduced, on average, in both early and intermediate patients with AMD (P < 0.01). In both groups, fERG amplitudes tended to decrease with age and to increase with visual acuity and were negatively correlated with STARS (early r = -0.6, P < 0.01; intermediate, r = -0.50, P < 0.05). fERG losses were greatest in patients with a STARS score of greater than 20.
   Conclusions: In early and intermediate AMD, STARS robustly predicted central retinal function, as assessed by fERG, supporting the combined use of both parameters to estimate the clinical risk of visual function loss.
   Translational Relevance: The STARS may predict macular function in AMD and could be used in the daily clinical practice to estimate the risk of visual function loss in early disease stages.
C1 [Minnella, Angelo Maria; Piccardi, Marco; Placidi, Giorgio; Falsini, Benedetto] Univ Cattolica Sacro Cuore, Ophthalmol, Rome, Italy.
   [Minnella, Angelo Maria; Valentini, Patrizia; Falsini, Benedetto] Fdn Policlin Univ Gemelli IRCCS, Rome, Italy.
   [Garcia-Layana, Alfredo] Univ Navarra, Clin Univ Navarra, Ophthalmol Dept, Pamplona, Spain.
   [Delcourt, Cecile] Univ Bordeaux, Bordeaux Populat Hlth Res Ctr, Team LEHA, INSERM,UMR 1219, Bordeaux, France.
C3 Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   University of Navarra; Institut National de la Sante et de la Recherche
   Medicale (Inserm); UDICE-French Research Universities; Universite de
   Bordeaux
RP Minnella, AM (通讯作者)，Univ Cattolica Sacro Cuore, Fdn Policlin Univ A Gemelli, Inst Ophthalmol, Largo Vito 1, I-00136 Rome, RM, Italy.
EM aminnella59@gmail.com
RI Delcourt, Cecile/I-2627-2013; minnella, angelo maria/AAQ-6250-2020;
   Falsini, Benedetto/AAC-5907-2022
OI Delcourt, Cecile/0000-0002-2099-0481; minnella, angelo
   maria/0000-0001-5896-5313; 
CR Brown EE, 2019, INVEST OPHTH VIS SCI, V60, P1470, DOI 10.1167/iovs.18-26422
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cheung CMG, 2017, SCI REP-UK, V7, DOI 10.1038/srep41386
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Delcourt C, 2017, INVEST OPHTH VIS SCI, V58, P6399, DOI 10.1167/iovs.17-21819
   Falsini B, 2003, INVEST OPHTH VIS SCI, V44, P2133, DOI 10.1167/iovs.02-0716
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   Falsini B, 2010, INVEST OPHTH VIS SCI, V51, P6118, DOI 10.1167/iovs.09-4995
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flynn OJ, 2018, INVEST OPHTH VIS SCI, V59, P2411, DOI 10.1167/iovs.17-22874
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Holopigian K, 1996, OPHTHALMOLOGY, V103, P398
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Luu CD, 2012, ARCH OPHTHALMOL-CHIC, V130, P690, DOI 10.1001/archophthalmol.2012.277
   Piccardi M, 2009, OPHTHALMIC RES, V41, P194, DOI 10.1159/000217723
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   SEIPLE WH, 1986, INVEST OPHTH VIS SCI, V27, P1123
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
NR 24
TC 3
Z9 3
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD SEP
PY 2020
VL 9
IS 10
AR 28
DI 10.1167/tvst.9.10.28
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OO4ZL
UT WOS:000587388500021
PM 33062391
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Koenig, P
   Lee, CV
   Sanowar, S
   Wu, P
   Stinson, J
   Harris, SF
   Fuh, G
AF Koenig, Patrick
   Lee, Chingwei V.
   Sanowar, Sarah
   Wu, Ping
   Stinson, Jeremy
   Harris, Seth F.
   Fuh, Germaine
TI Deep Sequencing-guided Design of a High Affinity Dual Specificity
   Antibody to Target Two Angiogenic Factors in Neovascular Age-related
   Macular Degeneration
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; 2-IN-ONE ANTIBODY; MATURATION; BINDING;
   CONFORMATIONS; LIBRARIES; STRATEGY; DISPLAY; DOMAIN; VEGF
AB The development of dual targeting antibodies promises therapies with improved efficacy over mono-specific antibodies. Here, we engineered a Two-in-One VEGF/angiopoietin 2 antibody with dual action Fab (DAF) as a potential therapeutic for neovascular age-related macular degeneration. Crystal structures of the VEGF/angiopoietin 2 DAF in complex with its two antigens showed highly overlapping binding sites. To achieve sufficient affinity of the DAF to block both angiogenic factors, we turned to deep mutational scanning in the complementarity determining regions (CDRs). By mutating all three CDRs of each antibody chain simultaneously, we were able not only to identify affinity improving single mutations but also mutation pairs from different CDRs that synergistically improve both binding functions. Furthermore, insights into the cooperativity between mutations allowed us to identify fold-stabilizing mutations in the CDRs. The data obtained from deep mutational scanning reveal that the majority of the 52 CDR residues are utilized differently for the two antigen binding function and permit, for the first time, the engineering of several DAF variants with subnanomolar affinity against two structurally unrelated antigens. The improved variants show similar blocking activity of receptor binding as the high affinity mono-specific antibodies against these two proteins, demonstrating the feasibility of generating a dual specificity binding surface with comparable properties to individual high affinity mono-specific antibodies.
C1 [Koenig, Patrick; Lee, Chingwei V.; Sanowar, Sarah; Fuh, Germaine] Genentech Res & Early Dev, Dept Antibody Engn, San Francisco, CA 94080 USA.
   [Stinson, Jeremy] Genentech Res & Early Dev, Dept Mol Biol, San Francisco, CA 94080 USA.
   [Wu, Ping; Harris, Seth F.] Genentech Res & Early Dev, Dept Biol Struct, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding;
   Genentech
RP Fuh, G (通讯作者)，Genentech Res & Early Dev, Dept Antibody Engn, San Francisco, CA 94080 USA.
EM gml@gene.com
FU Genentech, Inc., a member of the Roche Group
FX All authors are paid employees of Genentech, Inc., a member of the Roche
   Group, and are inventors of a patent application based on the work
   described herein.
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   AlLazikani B, 1997, J MOL BIOL, V273, P927, DOI 10.1006/jmbi.1997.1354
   Araya CL, 2012, P NATL ACAD SCI USA, V109, P16858, DOI 10.1073/pnas.1209751109
   Barton WA, 2006, NAT STRUCT MOL BIOL, V13, P524, DOI 10.1038/nsmb1101
   Bostrom J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017887
   Bostrom Jenny, 2009, V525, P353, DOI 10.1007/978-1-59745-554-1_19
   Bostrom J, 2009, SCIENCE, V323, P1610, DOI 10.1126/science.1165480
   Bricogne G., 2011, BUSTER
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Cauerhff A, 2004, P NATL ACAD SCI USA, V101, P3539, DOI 10.1073/pnas.0400060101
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Christinger HW, 1996, PROTEINS, V26, P353, DOI 10.1002/(SICI)1097-0134(199611)26:3<353::AID-PROT9>3.0.CO;2-E
   CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267
   DeLano W.L., 2010, PYMOL MOL GRAPHICS S
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Ferrara N, 2010, NAT MED, V16, P1107, DOI 10.1038/nm1010-1107
   Forsyth CM, 2013, MABS-AUSTIN, V5, P523, DOI 10.4161/mabs.24979
   Fowler DM, 2010, NAT METHODS, V7, P741, DOI 10.1038/nmeth.1492
   Fuh G, 2006, J BIOL CHEM, V281, P6625, DOI 10.1074/jbc.M507783200
   Fujino Y, 2012, BIOCHEM BIOPH RES CO, V428, P395, DOI 10.1016/j.bbrc.2012.10.066
   Hotzel I, 2012, MABS-AUSTIN, V4, P753, DOI 10.4161/mabs.22189
   Klein R, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12789
   Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109
   Lee CV, 2006, BLOOD, V108, P3103, DOI 10.1182/blood-2006-03-011031
   Lee CV, 2014, MABS-AUSTIN, V6, P622, DOI 10.4161/mabs.28483
   Lee CV, 2004, J IMMUNOL METHODS, V284, P119, DOI 10.1016/j.jim.2003.11.001
   Lee CV, 2004, J MOL BIOL, V340, P1073, DOI 10.1016/j.jmb.2004.05.051
   Li B, 2014, MABS-AUSTIN, V6, P437, DOI 10.4161/mabs.27875
   Li YL, 2003, NAT STRUCT BIOL, V10, P482, DOI 10.1038/nsb930
   Liang WC, 2006, J BIOL CHEM, V281, P951, DOI 10.1074/jbc.M508199200
   Mani R, 2008, P NATL ACAD SCI USA, V105, P3461, DOI 10.1073/pnas.0712255105
   MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6
   Morea V, 1998, J MOL BIOL, V275, P269, DOI 10.1006/jmbi.1997.1442
   Morgan M, 2009, BIOINFORMATICS, V25, P2607, DOI 10.1093/bioinformatics/btp450
   Niesen FH, 2007, NAT PROTOC, V2, P2212, DOI 10.1038/nprot.2007.321
   Rajpal A, 2005, P NATL ACAD SCI USA, V102, P8466, DOI 10.1073/pnas.0503543102
   Rennel ES, 2011, MICROCIRCULATION, V18, P598, DOI 10.1111/j.1549-8719.2011.00120.x
   Romero PA, 2009, NAT REV MOL CELL BIO, V10, P866, DOI 10.1038/nrm2805
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Schaefer G, 2011, CANCER CELL, V20, P472, DOI 10.1016/j.ccr.2011.09.003
   Sidhu SS, 2004, J MOL BIOL, V338, P299, DOI 10.1016/j.jmb.2004.02.050
   Skinner MM, 1996, P NATL ACAD SCI USA, V93, P10753, DOI 10.1073/pnas.93.20.10753
   Team RC, 2013, R LANG ENV STAT COMP
   Thurston G, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006650
   Weiss GA, 2000, P NATL ACAD SCI USA, V97, P8950, DOI 10.1073/pnas.160252097
   Whitehead TA, 2012, NAT BIOTECHNOL, V30, P543, DOI 10.1038/nbt.2214
   Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1
   Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749
   Wu HR, 1998, P NATL ACAD SCI USA, V95, P6037, DOI 10.1073/pnas.95.11.6037
NR 50
TC 28
Z9 33
U1 3
U2 12
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI ROCKVILLE
PA 11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD SEP 4
PY 2015
VL 290
IS 36
BP 21773
EP 21786
DI 10.1074/jbc.M115.662783
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA CQ9XI
UT WOS:000360968500001
PM 26088137
OA Green Published, Green Submitted, hybrid
DA 2022-11-30
ER

PT J
AU Schmidt-Erfurth, U
   Klimscha, S
   Waldstein, SM
   Bogunovic, H
AF Schmidt-Erfurth, U.
   Klimscha, S.
   Waldstein, S. M.
   Bogunovic, H.
TI A view of the current and future role of optical coherence tomography in
   the management of age-related macular degeneration
SO EYE
LA English
DT Review
ID SUBRETINAL DRUSENOID DEPOSITS; SD-OCT IMAGES; PIGMENT EPITHELIAL
   DETACHMENTS; ENDOTHELIAL GROWTH-FACTOR; GEOGRAPHIC ATROPHY SEGMENTATION;
   CHOROIDAL NEOVASCULARIZATION; HYPERREFLECTIVE FOCI; TREATMENTS TRIALS;
   VISUAL-ACUITY; FUNDUS AUTOFLUORESCENCE
AB Optical coherence tomography (OCT) has become an established diagnostic technology in the clinical management of age-related macular degeneration (AMD). OCT is being used for primary diagnosis, evaluation of therapeutic efficacy, and long-term monitoring. Computer-based advances in image analysis provide complementary imaging tools such as OCT angiography, further novel automated analysis methods as well as feature detection and prediction of prognosis in disease and therapy by machine learning. In early AMD, pathognomonic features such as drusen, pseudodrusen, and abnormalities of the retinal pigment epithelium (RPE) can be imaged in a qualitative and quantitative way to identify early signs of disease activity and define the risk of progression. In advanced AMD, disease activity can be monitored clearly by qualitative and quantified analyses of fluid pooling, such as intraretinal cystoid fluid, subretinal fluid, and pigment epithelial detachment (PED). Moreover, machine learning methods detect a large spectrum of new biomarkers. Evaluation of treatment efficacy and definition of optimal therapeutic regimens are an important aim in managing neovascular AMD. In atrophic AMD hallmarked by geographic atrophy (GA), advanced spectral domain (SD)-OCT imaging largely replaces conventional fundus autofluorescence (FAF) as it adds insight into the condition of the neurosensory layers and associated alterations at the level of the RPE and choroid. Exploration of imaging features by computerized methods has just begun but has already opened relevant and reliable horizons for the optimal use of OCT imaging for individualized and population-based management of AMD-the leading retinal epidemic of modern times.
C1 [Schmidt-Erfurth, U.; Klimscha, S.; Waldstein, S. M.; Bogunovic, H.] Med Univ Vienna, Vienna Reading Ctr, Christian Doppler Lab Ophthalm Image Anal, Vienna, Austria.
C3 Medical University of Vienna
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Spitalgasse 23, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
RI Bogunovic, Hrvoje/J-3445-2014
OI Bogunovic, Hrvoje/0000-0002-9168-0894; Schmidt-Erfurth,
   Ursula/0000-0002-7788-7311; Riedl, Sophie/0000-0003-0003-0886
FU Austrian Federal Ministry of Science, Research and Economy; National
   Foundation for Research, Technology and Development
FX Financial support by the Austrian Federal Ministry of Science, Research
   and Economy and the National Foundation for Research, Technology and
   Development is gratefully acknowledged.
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Abdelfattah NS, 2016, RETINA
   Aghdam KA, 2015, INVEST OPHTH VIS SCI, V56, P6448, DOI 10.1167/iovs.15-17338
   Akagi-Kurashige Y, 2012, GRAEF ARCH CLIN EXP, V250, P1129, DOI 10.1007/s00417-012-1928-5
   Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Bogunovic H, 2014, INT WORKSH OPHTH MED
   Channa R, 2015, AM J OPHTHALMOL, V159, P9, DOI 10.1016/j.ajo.2014.09.012
   Chen Q, 2013, BIOMED OPT EXPRESS, V4, P2729, DOI 10.1364/BOE.4.002729
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Coscas G, 2013, OPHTHALMOLOGICA, V229, P32, DOI 10.1159/000342159
   Dansingani KK, 2016, AM J OPHTHALMOL, V169, P235, DOI 10.1016/j.ajo.2016.06.031
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Dirani A, 2015, AM J OPHTHALMOL, V160, P732, DOI 10.1016/j.ajo.2015.06.025
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P3761, DOI 10.1167/iovs.10-7021
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Gianniou C, 2015, RETINA-J RET VIT DIS, V35, P1195, DOI 10.1097/IAE.0000000000000465
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hariri AH, 2016, OSLI RETINA, V47, P523, DOI 10.3928/23258160-20160601-03
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hu ZH, 2013, INVEST OPHTH VIS SCI, V54, P8375, DOI 10.1167/iovs.13-12552
   Huisingh C, 2016, INVEST OPHTH VIS SCI, V57, P739, DOI 10.1167/iovs.15-18316
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Kuehlewein L, 2015, RETINA-J RET VIT DIS, V35, P2229, DOI 10.1097/IAE.0000000000000835
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lee H, 2016, RETINA-J RET VIT DIS, V36, P465, DOI 10.1097/IAE.0000000000000645
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Mayr-Sponer U, 2013, OPHTHALMOLOGY, V120, P2620, DOI 10.1016/j.ophtha.2013.05.032
   Moussa K, 2013, RETINA-J RET VIT DIS, V33, P1590, DOI 10.1097/IAE.0b013e31828d6052
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Nathoo NA, 2014, AM J OPHTHALMOL, V158, P757, DOI 10.1016/j.ajo.2014.06.021
   Niu SJ, 2016, OPHTHALMOLOGY, V123, P1737, DOI 10.1016/j.ophtha.2016.04.042
   Niu SJ, 2016, BIOMED OPT EXPRESS, V7, P581, DOI 10.1364/BOE.7.000581
   Or C, 2016, RETINA-J RET VIT DIS, V36, P264, DOI 10.1097/IAE.0000000000000795
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Penha FM, 2013, RETINA-J RET VIT DIS, V33, P459, DOI 10.1097/IAE.0b013e31827d2657
   Querques G, 2015, RETINA-J RET VIT DIS, V35, P2433, DOI 10.1097/IAE.0000000000000761
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Querques G, 2010, RETINA-J RET VIT DIS, V30, P222, DOI 10.1097/IAE.0b013e3181bceef0
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Roberts P, 2016, INVEST OPHTH VIS SCI, V57, P1699, DOI 10.1167/iovs.15-18694
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Saade C, 2014, CLIN EXP OPHTHALMOL, V42, P865, DOI 10.1111/ceo.12353
   Sarraf D, 2013, RETINA-J RET VIT DIS, V33, P1551, DOI 10.1097/IAE.0b013e31828992f5
   Sato T, 2004, RETINA-J RET VIT DIS, V24, P910, DOI 10.1097/00006982-200412000-00011
   Sayegh RG, 2015, INVEST OPHTH VIS SCI, V56, P5246, DOI 10.1167/iovs.14-15114
   Schaal KB, 2016, OPHTHALMOLOGY, V123, P1060, DOI 10.1016/j.ophtha.2016.01.034
   Schaal KB, 2015, OSLI RETINA, V46, P550, DOI 10.3928/23258160-20150521-06
   Schlanitz F, 2015, ARVO ANN M 3 7 MAY A
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Schlanitz FG, 2015, AM J OPHTHALMOL, V160, P335, DOI 10.1016/j.ajo.2015.05.008
   Schlegl Thomas, 2015, Inf Process Med Imaging, V24, P437, DOI 10.1007/978-3-319-19992-4_34
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Schutze C, 2013, INVEST OPHTH VIS SCI, V54, P739, DOI 10.1167/iovs.11-7877
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Segal O, 2016, RETINA-J RET VIT DIS, V36, P2175, DOI 10.1097/IAE.0000000000001033
   Shah VP, 2014, RETINA-J RET VIT DIS, V34, P1281, DOI 10.1097/IAE.0000000000000166
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Shi F, 2015, IEEE T MED IMAGING, V34, P441, DOI 10.1109/TMI.2014.2359980
   Simader C, 2014, AM J OPHTHALMOL, V158, P557, DOI 10.1016/j.ajo.2014.05.026
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Stetson PF, 2014, INVEST OPHTH VIS SCI, V55, P792, DOI 10.1167/iovs.13-13199
   Sulzbacher F, 2015, INVEST OPHTH VIS SCI, V56, P1158, DOI 10.1167/iovs.14-14298
   Suzuki M, 2015, RETINA-J RET VIT DIS, V35, P859, DOI 10.1097/IAE.0000000000000503
   Takahashi H, 2015, BRIT J OPHTHALMOL, V99, P1065, DOI 10.1136/bjophthalmol-2014-306051
   Vogl Wolf-Dieter, 2015, Inf Process Med Imaging, V24, P152, DOI 10.1007/978-3-319-19992-4_12
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Waldstein SM, 2016, JAMA OPHTHALMOL, V134, P182, DOI 10.1001/jamaophthalmol.2015.4948
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
   Waldstein SM, 2014, AM J OPHTHALMOL, V158, P328, DOI 10.1016/j.ajo.2014.04.028
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Xu XY, 2015, IEEE T MED IMAGING, V34, P1616, DOI 10.1109/TMI.2015.2408632
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Zarubina AV, 2016, OPHTHALMOLOGY, V123, P1090, DOI 10.1016/j.ophtha.2015.12.034
   Zhang L, 2014, INVEST OPHTH VIS SCI, V55, P2329, DOI 10.1167/iovs.13-13048
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 98
TC 85
Z9 90
U1 1
U2 29
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JAN
PY 2017
VL 31
IS 1
BP 26
EP 44
DI 10.1038/eye.2016.227
PG 19
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EL1AU
UT WOS:000394353700003
PM 27886184
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Hessellund, A
   Larsen, DA
   Bek, T
AF Hessellund, Anders
   Larsen, Dorte Ancher
   Bek, Toke
TI The predictive value of subjective symptoms and clinical signs for the
   presence of treatment-requiring exudative age-related macular
   degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE exudates; exudative age-related macular degeneration; haemorrhages;
   intravitreal angiostatic treatment; risk factors; specialized centres
   triage
ID THICKNESS
AB . Purpose: The introduction of vascular endothelial growth factor inhibitors for the treatment of exudative age-related macular degeneration (AMD) has increased the referral rates of AMD patients with visual symptoms to treating centres considerably. However, a large proportion of the referred patients do not qualify for treatment implying that considerable resources could be saved if these patients could be identified on the basis of the clinical data available in the referring nonspecialized setting. Methods: A prospective observational study of 1682 consecutive patients referred with suspicion of exudative AMD qualifying for intravitreal angiostatic treatment. On the basis of the structured interviewing about symptoms, ophthalmoscopy, optical coherence tomography scanning, and fluorescein angiography, the patients were divided into two groups: one qualifying for and another not qualifying for treatment. Multiple logistic regression was used to identify independent parameters predicting the need for treatment. Results: The presence of metamorphopsia, dyschromatopsia, retinal haemorrhages and exudates, central retinal thickness, and the absence of micropsia were highly significant individual determinants of treatment-requiring AMD. Sudden onset and worsening of symptoms and the presence of a central dark spot covaried with the occurrence of retinal haemorrhages, whereas reduced visual acuity and blurred vision covaried with the presence of both haemorrhages and exudates. Conclusion: Patients with treatment-requiring AMD can be reliably identified by questioning about the presence of metamorphopsia and dyschromatopsia and the absence of micropsia, combined with ophthalmoscopical detection of retinal haemorrhages and exudates. This information may improve the triage of patients considered for referral.
C1 [Hessellund, Anders; Larsen, Dorte Ancher; Bek, Toke] Arhus Univ Hosp, Dept Ophthalmol, DK-8000 Aarhus C, Denmark.
C3 Aarhus University
RP Bek, T (通讯作者)，Arhus Univ Hosp, Dept Ophthalmol, DK-8000 Aarhus C, Denmark.
EM toke.bek@mail.tele.dk
OI Bek, Toke/0000-0002-0409-2534
FU VELUX Foundation
FX The study was supported by the VELUX Foundation.
CR Bek T, 2000, ACTA OPHTHALMOL SCAN, V78, P632, DOI 10.1034/j.1600-0420.2000.078006632.x
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Dinc UA, 2010, OPHTHALMOLOGICA, V224, P2, DOI 10.1159/000233229
   Harding SP, 2010, EYE, V24, P497, DOI 10.1038/eye.2009.316
   Hasegawa T, 2010, AM J OPHTHALMOL, V149, P322, DOI 10.1016/j.ajo.2009.09.012
   Menon G, 2009, EYE, V23, pS1, DOI 10.1038/eye.2009.13
   Parravano M, 2010, INVEST OPHTH VIS SCI, V51, P4788, DOI 10.1167/iovs.09-4976
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Wittes J, 2009, OPHTHALMOLOGY, V116, pS8, DOI 10.1016/j.ophtha.2009.06.050
   Wolf S, 2008, JPN J OPHTHALMOL, V52, P433, DOI 10.1007/s10384-008-0580-4
NR 12
TC 5
Z9 5
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD AUG
PY 2012
VL 90
IS 5
BP 471
EP 475
DI 10.1111/j.1755-3768.2010.02074.x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 980OV
UT WOS:000306903600038
PM 21232080
OA Bronze
DA 2022-11-30
ER

PT J
AU Buckle, M
   Donachie, PHJ
   Johnston, RL
AF Buckle, Miranda
   Donachie, Paul H. J.
   Johnston, Robert L.
TI Long-term outcomes of intravitreal ranibizumab for neovascular
   age-related macular degeneration in a well defined region of the UK
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MARINA
AB Aims To study long-term, whole population 'real-world' clinical outcomes of ranibizumab therapy in treatment-naive eyes for neovascular age-related macular degeneration.
   Methods Data collected prospectively from a single centre serving a defined population using an electronic medical record included: demographics, Early Treatment Diabetic Retinopathy Study visual acuity (ETDRS VA) at all visits, injection dates, central 1 mm retinal thickness, and operative and postoperative complications.
   Results 1483 eyes from 1278 patients were included in this study. The median age at the time of the patient's first injection was 82.5 years, 64.9% of patients were female, and another ocular pathology was present in 7.3% eyes. The baseline VAwas 23-39, 40-54, 55-70 and >70 ETDRS letters for 17.3%, 23.1%, 42.7% and 16.9% of eyes, respectively. The median VA in all baseline VA groups improved after the loading phase but declined back to the baseline level by 2-5 years. The rate of endophthalmitis following intravitreal injection was 1 in 2124 injections.
   Conclusions These long-term real-world data demonstrate that in general VA increases during the loading phase but returns to near baseline levels after 25 years of treatment for each baseline VA category. Patients should be identified and treated as early as possible, since presenting VA predicts the VA maintained after 5 years of treatment. National Institute of Health and Care Excellence guidance advising treatment only for eyes with vision below 70 letters does not promote best long-term VA outcomes for patients.
C1 [Buckle, Miranda; Donachie, Paul H. J.; Johnston, Robert L.] Gloucestershire Hosp NHS Fdn Trust, Cheltenham, Glos, England.
   Cheltenham Gen Hosp, Eye Dept, Cheltenham GL53 7AN, Glos, England.
C3 Gloucestershire Hospitals NHS Foundation Trust; Gloucestershire
   Hospitals NHS Foundation Trust; Cheltenham General Hospital
RP Johnston, RL (通讯作者)，Cheltenham Gen Hosp, Eye Dept, Sandford Rd, Cheltenham GL53 7AN, Glos, England.
EM rob.johnston@glos.nhs.uk
OI Buckle, Miranda/0000-0002-6722-7125
CR Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Butt T, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006535
   Dawson SR, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-78
   Gillies MC, 2013, INVEST OPHTH VIS SCI, V54, P5754, DOI 10.1167/iovs.13-11993
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Lee AY, 2015, BRIT J OPHTHALMOL, V99, P1045, DOI 10.1136/bjophthalmol-2014-306229
   Muether PS, 2013, GRAEF ARCH CLIN EXP, V251, P453, DOI 10.1007/s00417-012-2038-0
   National Institute for Health and Care Excellence (NICE), 2008, RAN PEG TREATM AG RE
   National Institute for Health and Care Excellence (NICE), 2013, AFL SOL INJ TREAT WE
   Rauch R, 2012, RETINA-J RET VIT DIS, V32, P1260, DOI 10.1097/IAE.0b013e3182018df6
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 17
TC 10
Z9 10
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB
PY 2016
VL 100
IS 2
BP 240
EP 245
DI 10.1136/bjophthalmol-2014-306423
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DD5VP
UT WOS:000369993100017
PM 26124462
DA 2022-11-30
ER

PT J
AU Guthoff, R
   Guthoff, T
   Meigen, T
   Goebel, W
AF Guthoff, Rainer
   Guthoff, Tanja
   Meigen, Thomas
   Goebel, Winfried
TI INTRAVITREOUS INJECTION OF BEVACIZUMAB, TISSUE PLASMINOGEN ACTIVATOR,
   AND GAS IN THE TREATMENT OF SUBMACULAR HEMORRHAGE IN AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; bevacizumab; choroidal
   neovascularization; intravitreal injection; pneumatic displacement;
   submacular hemorrhage; tissue plasminogen activator
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; EXPERIMENTAL SUBRETINAL
   HEMORRHAGE; EXPANSILE GAS; MANAGEMENT
AB Purpose: To investigate the benefit of adding bevacizumab to intravitreal recombinant tissue plasminogen activator (rTPA) and gas as initial therapy in subretinal hemorrhage and choroidal neovascularization because of age-related macular degeneration.
   Methods: Thirty-eight consecutive patients with recent (1-31 days) subretinal hemorrhage who were treated with intravitreal rTPA and gas (26 patients) or with intravitreal bevacizumab, rTPA, and gas (12 patients) were included in this retrospective analysis. In all patients, a standardized antivascular endothelial growth factor therapy was followed. Testing of best-corrected visual acuity, biomicroscopy, and fundus examination were performed at 4 weeks and 7 months.
   Results: The mean pretreatment best-corrected visual acuity in the rTPA/gas group was 0.08 +/- 0.09 and 0.12 +/- 0.13 in the bevacizumab/rTPA/gas group. After 4 weeks, it was significantly higher in the bevacizumab/rTPA/gas group (0.25 +/- 0.26) than in the rTPA/gas (0.08 +/- 0.1) group (P < 0.05). Also, after 7 months, best-corrected visual acuity was significantly higher in the bevacizumab/rTPA/gas group (0.07 +/- 0.07 vs. 0.24 +/- 0.35; P < 0.05). Reading vision could be restored in 0% (rTPA/gas) versus 50% (bevacizumab/rTPA/gas). Stabilization (0 +/- 2 lines) or improvement of best-corrected visual acuity was obtained in 62% (rTPA/gas) versus 84% (bevacizumab/rTPA/gas).
   Conclusion: From our retrospective pilot study, there is a strong indication that the addition of intravitreal bevacizumab is safe and superior to the displacement of submacular hemorrhages alone with rTPA and gas. RETINA 31:36-40, 2011
C1 [Guthoff, Rainer; Guthoff, Tanja; Meigen, Thomas; Goebel, Winfried] Univ Wurzburg, Dept Ophthalmol, D-97080 Wurzburg, Germany.
C3 University of Wurzburg
RP Guthoff, R (通讯作者)，Univ Wurzburg, Dept Ophthalmol, Josef Schneider Str 11, D-97080 Wurzburg, Germany.
EM r.guthoff@uni-wuerzburg.de
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   Fang IM, 2009, EYE, V23, P397, DOI 10.1038/sj.eye.6703017
   Guthoff R, 2004, ACTA OPHTHALMOL SCAN, V82, P686, DOI 10.1111/j.1600-0420.2004.00338.x
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Heriot W, 1996, VAIL VITR M MARCH 10
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   IBANEZ HE, 1995, ARCH OPHTHALMOL-CHIC, V113, P62, DOI 10.1001/archopht.1995.01100010064022
   JOHNSON MW, 1991, RETINA-J RET VIT DIS, V11, P250, DOI 10.1097/00006982-199111020-00011
   Landa G, 2009, OPHTHALMOLOGICA, V223, P370, DOI 10.1159/000227783
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   Sacu S, 2009, EYE, V23, P1404, DOI 10.1038/eye.2008.267
   Sawa M, 2006, RETINA-J RET VIT DIS, V26, P119, DOI 10.1097/00006982-200601000-00025
   Schulze SD, 2002, GRAEF ARCH CLIN EXP, V240, P717, DOI 10.1007/s00417-002-0516-5
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   WADE EC, 1990, ARCH OPHTHALMOL-CHIC, V108, P973, DOI 10.1001/archopht.1990.01070090075043
NR 20
TC 45
Z9 46
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2011
VL 31
IS 1
BP 36
EP 40
DI 10.1097/IAE.0b013e3181e37884
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 699TG
UT WOS:000285685100006
PM 20921929
DA 2022-11-30
ER

PT J
AU Calabrese, A
   Bernard, JB
   Hoffart, L
   Faure, G
   Barouch, F
   Conrath, J
   Castet, E
AF Calabrese, Aurelie
   Bernard, Jean-Baptiste
   Hoffart, Louis
   Faure, Geraldine
   Barouch, Fatiha
   Conrath, John
   Castet, Eric
TI Wet versus Dry Age-Related Macular Degeneration in Patients with Central
   Field Loss: Different Effects on Maximum Reading Speed
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID PREFERRED RETINAL LOCI; GEOGRAPHIC ATROPHY; CENTRAL SCOTOMAS;
   VISUAL-ACUITY; FIXATION; PSYCHOPHYSICS; PREDICTORS; STABILITY; LOCATION;
   PATTERNS
AB PURPOSE. To describe new, efficient predictors of maximum reading speed (MRS) in age-related macular degeneration (AMD) patients with central field loss. Type of AMD (wet versus dry) was scrutinized, because this factor seems to offer a promising model of differential visual adaptation induced by different temporal courses of disease progression.
   METHODS. Linear mixed-effects (LME) analyses were performed on a dataset initially collected to assess the effect of interline spacing on MRS. MRS was measured with MNread-like French sentences in 89 eyes (64 dry and 25 wet) of 61 patients with AMD. Microperimetry examination was performed on each eye. The eyes were included only if they had a dense macular scotoma including the fovea, to ensure that patients used eccentric viewing.
   RESULTS. Analyses show the unique contributions-after adjustment for the effects of other factors-of three new factors: (1) MRS was higher for wet than for dry AMD eyes; (2) an advantage of similar amplitude was found for phakic eyes compared with pseudophakic eyes; and (3) MRS decreased when distance between fixation preferred retinal locus (PRL) and fovea increased. In addition, the instantaneous slope of the relationship between scotoma area and MRS was much shallower than reported in two other studies.
   CONCLUSIONS. The four effects improve the ability to predict MRS reliably for AMD patients. The wet/dry difference is a major finding that may result from the different time courses of the two types of disease, thus involving different types of visuomotor and attentional adaptation processes. (Invest Ophthalmol Vis Sci. 2011; 52: 2417-2424) DOI: 10.1167/iovs.09-5056
C1 [Calabrese, Aurelie; Bernard, Jean-Baptiste; Castet, Eric] Univ Aix Marseille 2, CNRS, Inst Neurosci Cognit Mediterranee, F-13009 Marseille, France.
   [Hoffart, Louis; Faure, Geraldine; Barouch, Fatiha; Conrath, John] Univ Hosp La Timone, Dept Ophthalmol, Marseille, France.
C3 Centre National de la Recherche Scientifique (CNRS); UDICE-French
   Research Universities; Aix-Marseille Universite; UDICE-French Research
   Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de
   Marseille
RP Castet, E (通讯作者)，Univ Aix Marseille 2, CNRS, Inst Neurosci Cognit Mediterranee, 31 Chemin Joseph Aiguier, F-13009 Marseille, France.
EM eric.castet@incm.cnrs-mrs.fr
OI Calabrese, Aurelie/0000-0002-7078-3595
FU French Ministry of Research and Technology; CNRS
FX Supported by a French Ministry of Research and Technology (AC) grant and
   a BDI (Bourse de Doctorat pour Ingenieurs) Grant from the CNRS (J-BB).
CR AKUTSU H, 1992, ARCH OPHTHALMOL-CHIC, V110, P1076, DOI 10.1001/archopht.1992.01080200056024
   Baayen RH, 2008, J MEM LANG, V59, P390, DOI 10.1016/j.jml.2007.12.005
   BERNARD J, 2008, P 2 FRENCH C COMP NE, P97
   Bolker BM, 2009, TRENDS ECOL EVOL, V24, P127, DOI 10.1016/j.tree.2008.10.008
   Calabrese A, 2010, INVEST OPHTH VIS SCI, V51, P1247, DOI 10.1167/iovs.09-3682
   Cheng J, 2010, STAT MED, V29, P504, DOI 10.1002/sim.3775
   Cheung SH, 2005, VISUAL NEUROSCI, V22, P187, DOI 10.1017/S0952523805222071
   Cheung SH, 2008, INVEST OPHTH VIS SCI, V49, P828, DOI 10.1167/iovs.07-0555
   CHYLACK LT, 1989, ARCH OPHTHALMOL-CHIC, V107, P991, DOI 10.1001/archopht.1989.01070020053028
   Cohen J., 2003, APPL MULTIPLE REGRES
   Crossland MD, 2005, OPTOMETRY VISION SCI, V82, P11
   Crossland MD, 2004, OPHTHAL PHYSL OPT, V24, P327, DOI 10.1111/j.1475-1313.2004.00213.x
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   Cudeck R, 2007, ANNU REV PSYCHOL, V58, P615, DOI 10.1146/annurev.psych.58.110405.085520
   CUMMINGS RW, 1985, AM J OPTOM PHYS OPT, V62, P833
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Deruaz Anouk, 2006, BMC Ophthalmol, V6, P35, DOI 10.1186/1471-2415-6-35
   Duret F, 1999, VISION RES, V39, P873, DOI 10.1016/S0042-6989(98)00179-5
   Ergun E, 2003, OPHTHALMOLOGY, V110, P65, DOI 10.1016/S0161-6420(02)01566-X
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fine EM, 1999, VISION RES, V39, P1039, DOI 10.1016/S0042-6989(98)00208-9
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P637, DOI 10.1167/iovs.09-3547
   Fletcher DC, 1999, J REHABIL RES DEV, V36, P356
   Gelman A., 2007, ARM DATA ANAL USING, V1
   Kabanarou SA, 2006, OPTOMETRY VISION SCI, V83, P789, DOI 10.1097/01.opx.0000238642.65218.64
   LEGGE GE, 1992, INVEST OPHTH VIS SCI, V33, P677
   LEGGE GE, 1989, OPTOMETRY VISION SCI, V66, P843, DOI 10.1097/00006324-198912000-00008
   Legge GE, 2007, PSYCHOPHYSICS READIN
   Mutlu FM, 2009, CURR EYE RES, V34, P711, DOI 10.1080/02713680903020009
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Nilsson UL, 1998, OPTOMETRY VISION SCI, V75, P873, DOI 10.1097/00006324-199812000-00009
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   Petre KL, 2000, OPTOMETRY VISION SCI, V77, P34, DOI 10.1097/00006324-200001000-00011
   Pinheiro J.C., 2000, MIXED EFFECTS MODELS
   R Core Team, 2022, R LANG ENV STAT COMP
   Reinhard J, 2007, VISION RES, V47, P2076, DOI 10.1016/j.visres.2007.04.012
   Rohrschneider K, 2004, INVEST OPHTH VIS SCI, V45, P3257, DOI 10.1167/iovs.03-1157
   Rohrschneider K, 2008, PROG RETIN EYE RES, V27, P536, DOI 10.1016/j.preteyeres.2008.07.003
   Rubin GS, 2009, NEURO-OPHTHALMOLOGY, V33, P120, DOI 10.1080/01658100902998732
   Rubin GS, 2001, EYE, V15, P430, DOI 10.1038/eye.2001.148
   Rubin GS, 2000, INVEST OPHTH VIS SCI, V41, P3327
   Safran AB, 1999, BRIT J OPHTHALMOL, V83, P1341, DOI 10.1136/bjo.83.12.1341
   Schuchard RA, 2005, CAN J OPHTHALMOL, V40, P303, DOI 10.1016/S0008-4182(05)80073-0
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   Sunness JS, 1999, MOL VIS, V5
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Tarita-Nistor L, 2008, RETINA-J RET VIT DIS, V28, P125, DOI 10.1097/IAE.0b013e3180ed4571
   Timberlake GT, 2006, J REHABIL RES DEV, V43, P749, DOI 10.1682/JRRD.2005.06.0102
   TIMBERLAKE GT, 1987, INVEST OPHTH VIS SCI, V28, P1268
   Varsori M, 2004, VISION RES, V44, P2691, DOI 10.1016/j.visres.2004.05.027
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 52
TC 45
Z9 46
U1 0
U2 12
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2011
VL 52
IS 5
BP 2417
EP 2424
DI 10.1167/iovs.09-5056
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 750MN
UT WOS:000289551500005
PM 21228374
DA 2022-11-30
ER

PT J
AU Ludtke, L
   Jurgens, C
   Ittermann, T
   Volzke, H
   Tost, F
AF Luedtke, Lisa
   Juergens, Clemens
   Ittermann, Till
   Voelzke, Henry
   Tost, Frank
TI Age-Related Macular Degeneration and Associated Risk Factors in the
   Population-Based Study of Health in Pomerania (SHIP-Trend)
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE Epidemiologic Studies; Epidemiology; Macular Degeneration
ID POOLED FINDINGS; TERM INCIDENCE; MACULOPATHY; SMOKING; PREVALENCE;
   PROGRESSION; DISEASE
AB Background: Age-related macular degeneration (AMD) is the leading cause of visual impairment in developed countries, especially in the older population. The Study of Health in Pomerania (SHIP) is a population-based study designed to investigate risk factors and clinical disorders in the general population. In the present study, we analysed the AMD prevalence and risk factors in the north-eastern German population.
   Material/Methods: From 2008 to 2012, we collected data among participants ages 29-79 years. The study population consisted of 4420 individuals. Non-mydriatic retinal photographs were taken of 3934 participants. AMD stages were graded according to the Rotterdam Classification System and the International Classification System.
   Results: Photographs from 1854 participants were available for grading. The baseline examinations showed small hard drusen (<63 mu m, stage 0b and 0c) were present in 10.7% of the participants (stage 0b in 7.5% and stage 0c in 3.2%). Earliest signs of AMD were detected in 28.68% (stage 0b in 7.5% and stage 1b in 21.18%). Late AMD (geographic atrophy and neovascular AMD, stages 4a and 4b) were identified in 0.43% (stage 4a in 0.16% and stage 4b 0.27%). Risk of AMD increased significantly with age and higher body mass index, waist circumference, hip circumference, and weight-waist-ratio. Smoking, sex, systolic and diastolic blood pressure, HbA1c, cholesterol, HDL-cholesterol, LDL-cholesterol, and triglyceride were not associated with AMD in this study.
   Conclusions: The prevalence of AMD increases with age and obesity-associated factors. These results must be verified in the follow-up. Data concerning the incidence of AMD will be available after the 5- and 10-year follow-ups.
C1 [Luedtke, Lisa; Tost, Frank] Univ Med, Dept Ophthalmol, Greifswald, Germany.
   [Juergens, Clemens; Ittermann, Till; Voelzke, Henry] Univ Med, Inst Community Med, Greifswald, Germany.
   [Voelzke, Henry] Univ Med, German Ctr Cardiovasc Res, Greifswald, Germany.
C3 German Centre for Cardiovascular Research
RP Ludtke, L (通讯作者)，Univ Med, Dept Ophthalmol, Greifswald, Germany.; Jurgens, C (通讯作者)，Univ Med, Inst Community Med, Greifswald, Germany.
EM pf123961@uni-greifswald.de; juergens@uni-greifswald.de
CR [Anonymous], GESUNDHEITSSCHUTZ
   Arslan S, 2018, J AM COLL NUTR
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Borrone R, 2008, EUR J OPHTHALMOL, V18, P949, DOI 10.1177/112067210801800615
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Howard KP, 2014, INVEST OPHTH VIS SCI, V55, P2592, DOI 10.1167/iovs.13-13763
   Jurgens C, 2014, OPHTHALMOLOGE, V111, P443, DOI 10.1007/s00347-013-2924-9
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1527
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Klein R, 2014, OPHTHALMOLOGY, V121, P1604, DOI 10.1016/j.ophtha.2014.03.005
   Klein R, 2014, OPHTHALMOLOGY, V121, P1220, DOI 10.1016/j.ophtha.2014.01.003
   Korb CA, 2014, GRAEF ARCH CLIN EXP, V252, P1403, DOI 10.1007/s00417-014-2591-9
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Myers CE, 2014, OPHTHALMOLOGY, V121, P1949, DOI 10.1016/j.ophtha.2014.04.040
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seshasai S, 2015, INVEST OPHTH VIS SCI, V56, P1880, DOI 10.1167/iovs.14-15933
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Srinivasan S, 2017, EYE, V31, P1176, DOI 10.1038/eye.2017.47
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Volzke H, 2011, INT J EPIDEMIOL, V40, P294, DOI 10.1093/ije/dyp394
NR 27
TC 6
Z9 6
U1 0
U2 1
PU INT SCIENTIFIC INFORMATION, INC
PI MELVILLE
PA 150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA
SN 1643-3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD AUG 25
PY 2019
VL 25
BP 6383
EP 6390
DI 10.12659/MSM.915493
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA IT6EJ
UT WOS:000482962700002
PM 31446436
OA Green Published
DA 2022-11-30
ER

PT J
AU Acar, IE
   Lores-Motta, L
   Colijn, JM
   Meester-Smoor, MA
   Verzijden, T
   Cougnard-Gregoire, A
   Ajana, S
   Merle, BMJ
   de Breuk, A
   Heesterbeek, TJ
   van den Akker, E
   Daha, MR
   Claes, B
   Pauleikhoff, D
   Hense, HW
   van Duijn, CM
   Fauser, S
   Hoyng, CB
   Delcourt, C
   Klaver, CCW
   Galesloot, TE
   den Hollander, AI
AF Acar, Ilhan E.
   Lores-Motta, Laura
   Colijn, Johanna M.
   Meester-Smoor, Magda A.
   Verzijden, Timo
   Cougnard-Gregoire, Audrey
   Ajana, Soufiane
   Merle, Benedicte M. J.
   de Breuk, Anita
   Heesterbeek, Thomas J.
   van den Akker, Erik
   Daha, Mohamed R.
   Claes, Birte
   Pauleikhoff, Daniel
   Hense, Hans-Werner
   van Duijn, Cornelia M.
   Fauser, Sascha
   Hoyng, Carel B.
   Delcourt, Cecile
   Klaver, Caroline C. W.
   Galesloot, Tessel E.
   den Hollander, Anneke, I
CA EYE-RISK Consortium
TI Integrating Metabolomics, Genomics, and Disease Pathways in Age-Related
   Macular Degeneration The EYE-RISK Consortium
SO OPHTHALMOLOGY
LA English
DT Article
ID CHAIN AMINO-ACIDS; COMPLEMENT ACTIVATION; WIDE ASSOCIATION; GENE;
   MACULOPATHY; REVEALS; SMOKING; DRUSEN; PANEL; LOCI
AB Purpose: The current study aimed to identify metabolites associated with age-related macular degeneration (AMD) by performing the largest metabolome association analysis in AMD to date, as well as aiming to determine the effect of AMD-associated genetic variants on metabolite levels and investigate associations between the identified metabolites and activity of the complement system, one of the main AMD-associated disease pathways.
   Design: Case-control association analysis of metabolomics data.
   Participants: Five European cohorts consisting of 2267 AMD patients and 4266 control participants.
   Methods: Metabolomics was performed using a high-throughput proton nuclear magnetic resonance metabolomics platform, which allows quantification of 146 metabolite measurements and 79 derivative values. MetabolomeeAMD associations were studied using univariate logistic regression analyses. The effect of 52 AMD-associated genetic variants on the identified metabolites was investigated using linear regression. In addition, associations between the identified metabolites and activity of the complement pathway (defined by the C3d-to-C3 ratio) were investigated using linear regression.
   Main Outcome Measures: Metabolites associated with AMD.
   Results: We identified 60 metabolites that were associated significantly with AMD, including increased levels of large and extra-large high- density lipoprotein (HDL) subclasses and decreased levels of very low-density lipoprotein (VLDL), amino acids, and citrate. Of 52 AMD-associated genetic variants, 7 variants were associated significantly with 34 of the identified metabolites. The strongest associations were identified for genetic variants located in or near genes involved in lipid metabolism (ABCA1, CETP, APOE, and LIPC) with metabolites belonging to the large and extra-large HDL subclasses. Also, 57 of 60 metabolites were associated significantly with complement activation levels, independent of AMD status. Increased large and extra-large HDL levels and decreased VLDL and amino acid levels were associated with increased complement activation.
   Conclusions: Lipoprotein levels were associated with AMD-associated genetic variants, whereas decreased essential amino acids may point to nutritional deficiencies in AMD. We observed strong associations between the vast majority of the AMD-associated metabolites and systemic complement activation levels, independent of AMD status. This may indicate biological interactions between the main AMD disease pathways and suggests that multiple pathways may need to be targeted simultaneously for successful treatment of AMD. (C) 2020 by the American Academy of Ophthalmology. This is an open access article under the CC BY-NC-ND license
C1 [Acar, Ilhan E.; Lores-Motta, Laura; de Breuk, Anita; Heesterbeek, Thomas J.; Hoyng, Carel B.; Klaver, Caroline C. W.; den Hollander, Anneke, I] Radboud Univ Nijmegen, Dept Ophthalmol, Donders Inst Brain Cognit & Behav, Med Ctr, Nijmegen, Netherlands.
   [Colijn, Johanna M.; Meester-Smoor, Magda A.; Verzijden, Timo; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Colijn, Johanna M.; Meester-Smoor, Magda A.; Verzijden, Timo; van Duijn, Cornelia M.; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Cougnard-Gregoire, Audrey; Ajana, Soufiane; Merle, Benedicte M. J.; Delcourt, Cecile] Univ Bordeaux, INSERM, Bordeaux Populat Hlth Res Ctr, UMR 1219,Team LEHA, Bordeaux, France.
   [van den Akker, Erik] Leiden Univ, Dept Biomed Data Sci, Med Ctr, Leiden, Netherlands.
   [van den Akker, Erik] Delft Univ Technol, Pattern Recognit & Bioinformat, Delft, Netherlands.
   [Daha, Mohamed R.] Leiden Univ, Dept Nephrol, Med Ctr, Leiden, Netherlands.
   [Claes, Birte; Hense, Hans-Werner] Univ Munster, Inst Epidemiol & Social Med, Munster, Germany.
   [Pauleikhoff, Daniel] St Franziskus Hosp, Augenzentrum, Munster, Germany.
   [van Duijn, Cornelia M.] Univ Oxford, Nuffield Dept Populat Hlth NDPH, Oxford, England.
   [Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany.
   [Fauser, Sascha] F Hoffmann La Roche Ltd, Roche Pharma Res & Early Dev, Basel, Switzerland.
   [Galesloot, Tessel E.] Radboud Univ Nijmegen, Radboud Inst Hlth Sci, Med Ctr, Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Erasmus University Rotterdam; Erasmus MC;
   Erasmus University Rotterdam; Erasmus MC; Institut National de la Sante
   et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Universite de Bordeaux; Leiden University; Leiden
   University Medical Center (LUMC); Leiden University - Excl LUMC; Delft
   University of Technology; Leiden University; Leiden University Medical
   Center (LUMC); Leiden University - Excl LUMC; University of Munster; St.
   Franziskus-Hospital; University of Oxford; University of Cologne; Roche
   Holding; Radboud University Nijmegen
RP den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Dept Ophthalmol 409, Med Ctr, Nijmegen, Netherlands.
EM Anneke.denhollander@radboudumc.nl
RI Arango-Gonzalez, Blanca/AAR-7427-2021; Emri, Eszter/ABE-9363-2020;
   Delcourt, Cecile/I-2627-2013; Merle, Benedicte MJ/AAQ-5021-2021; Ajana,
   Soufiane/AAH-5181-2021; COUGNARD-GREGOIRE, Audrey/T-4443-2019; Acar,
   İlhan Erkin/B-7758-2018; Heesterbeek, Thomas Johannes/E-7890-2017
OI Arango-Gonzalez, Blanca/0000-0002-9045-182X; Delcourt,
   Cecile/0000-0002-2099-0481; Merle, Benedicte MJ/0000-0003-1332-0954;
   COUGNARD-GREGOIRE, Audrey/0000-0002-1494-5764; Acar, İlhan
   Erkin/0000-0002-2078-9905; Van Duijn, Cornelia/0000-0002-2374-9204;
   Heesterbeek, Thomas Johannes/0000-0002-3232-2587; Mones,
   Jordi/0000-0003-3685-2160; Sousa, Jose/0000-0001-9570-6054
FU Netherlands Organisation for Scientific Research (VICI grant)
   [016.VICL170.024]; European Union's Horizon 2020 research and innovation
   programme [634479]
FX Supported by the Netherlands Organisation for Scientific Research (VICI
   grant no.: 016.VICL170.024 [A.I.d.H.]); and the European Union's Horizon
   2020 research and innovation programme (grant no.: 634479 [C.D.,
   C.C.W.K, A.I.d.H.]). The sponsor or funding organization had no role in
   the design or conduct of this research.
CR Ali KM, 2012, BRIT J PHARMACOL, V167, P1177, DOI 10.1111/j.1476-5381.2012.02081.x
   Alonso A, 2015, FRONT BIOENG BIOTECH, V3, DOI 10.3389/fbioe.2015.00023
   Amin N, 2017, MOL PSYCHIATR, V22, P537, DOI 10.1038/mp.2016.101
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Blomstrand E, 2006, J NUTR, V136, p269S, DOI 10.1093/jn/136.1.269S
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Chapman NA, 2019, CLIN EXP OPHTHALMOL, V47, P106, DOI 10.1111/ceo.13343
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   Corominas J, 2018, OPHTHALMOLOGY, V125, P1433, DOI 10.1016/j.ophtha.2018.03.040
   Cougnard-Gregoire A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160240
   Dasch B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1501, DOI 10.1001/archopht.123.11.1501
   de Breuk A, 2021, OPHTHALMOLOGY, V128, P1604, DOI 10.1016/j.ophtha.2020.07.037
   Delcourt C, 2010, J NUTR HEALTH AGING, V14, P854, DOI 10.1007/s12603-010-0131-9
   Dodd D, 2017, NATURE, V551, P648, DOI 10.1038/nature24661
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Grassmann F, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0418-0
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Iglesias AI, 2017, HUM MUTAT, V38, P1025, DOI 10.1002/humu.23247
   Ikram MA, 2017, EUR J EPIDEMIOL, V32, P807, DOI 10.1007/s10654-017-0321-4
   Jin HM, 2018, MOL MED REP, V17, P6852, DOI 10.3892/mmr.2018.8687
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kersten E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218457
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Kettunen J, 2012, NAT GENET, V44, P269, DOI 10.1038/ng.1073
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Lains I, 2019, METABOLITES, V9, DOI 10.3390/metabo9070127
   Lains I, 2019, J PROTEOME RES, V18, P1278, DOI 10.1021/acs.jproteome.8b00877
   Lains I, 2019, PROG RETIN EYE RES, V69, P57, DOI 10.1016/j.preteyeres.2018.11.002
   Lains I, 2018, OPHTHALMOLOGY, V125, P245, DOI 10.1016/j.ophtha.2017.08.008
   Lains I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177749
   Li ML, 2016, SCI REP-UK, V6, DOI 10.1038/srep38342
   Lores-Motta L, 2018, OPHTHALMOLOGY, V125, P1064, DOI 10.1016/j.ophtha.2017.12.023
   Luo D, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0555-7
   Matualatupauw JC, 2017, INT J OBESITY, V41, P1348, DOI 10.1038/ijo.2017.120
   McCarthy S, 2016, NAT GENET, V48, P1279, DOI 10.1038/ng.3643
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Neuner B, 2008, OPHTHAL EPIDEMIOL, V15, P148, DOI 10.1080/09286580802105830
   Osborn MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072737
   Paun CC, 2016, SCI REP-UK, V6, DOI 10.1038/srep26568
   Ren J, 2010, ATHEROSCLEROSIS, V211, P327, DOI 10.1016/j.atherosclerosis.2010.02.020
   Saunier V, 2018, JAMA OPHTHALMOL, V136, P473, DOI 10.1001/jamaophthalmol.2018.0504
   Schwarzer G., 2007, R NEWS, V7, P40, DOI DOI 10.1007/978-3-319-21416-0
   Seymour Christopher W, 2011, BMC Res Notes, V4, P169, DOI 10.1186/1756-0500-4-169
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Soininen P, 2015, CIRC-CARDIOVASC GENE, V8, P192, DOI 10.1161/CIRCGENETICS.114.000216
   Su SL, 2012, J ORTHOP RES, V30, P9, DOI 10.1002/jor.21494
   Tynkkynen J, 2018, ALZHEIMERS DEMENT, V14, P723, DOI 10.1016/j.jalz.2018.01.003
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wang J, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/8212063
   Wikoff WR, 2009, P NATL ACAD SCI USA, V106, P3698, DOI 10.1073/pnas.0812874106
   Wurtz P, 2015, CIRCULATION, V131, P774, DOI 10.1161/CIRCULATIONAHA.114.013116
   Zhang YL, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101222
NR 56
TC 22
Z9 22
U1 3
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2020
VL 127
IS 12
BP 1693
EP 1709
DI 10.1016/j.ophtha.2020.06.020
PG 17
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PH9SN
UT WOS:000600742900022
PM 32553749
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Kuo, HK
   Kao, MT
   Chen, YJ
   Chen, CH
   Wu, PC
   Kao, ML
AF Kuo, Hsi-Kung
   Kao, Min-Tse
   Chen, Yung-Jen
   Chen, Chih-Hsin
   Wu, Pei-Chang
   Kao, Min-Lun
TI Transpupillary thermotherapy in chinese patients with choroidal
   Neovascularization secondary to age-related macular degeneration:
   Emphasis on the influence of power setting
SO OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; macular
   burn; retinal pigment epithelium atrophy; transpupillary thermotherapy
ID PHOTODYNAMIC THERAPY; 1-YEAR
AB Purpose: To perform a safety and efficacy study of transpupillary thermotherapy (TTT) in Chinese patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (ARMD). Methods: In a prospective study, patients with subfoveal or juxtafoveal CNV secondary to ARMD underwent TTT with fixed treatment and follow-up protocols. From August 2002 to December 2004, 26 patients (27 eyes) completed >= 6 months of follow-up and were included in this report. Results: Fourteen eyes (52%) had improved or stable visual acuity (loss of < 3 lines) and 13 eyes (48%) had vision loss of >= 3 lines. The serial mean visual acuity initially decreased during follow-up, then stabilized by 6 months. In the subgroup of occult or minimally classic CNV (20 eyes), 13 eyes (65%) had improved or stable vision. The major complication of TTT included laser-related retinal pigment epithelium (RPE) atrophy in 10 eyes (37%). Six eyes had mild RPE atrophy, 4 eyes had severe RPE-choroid atrophy (macular burn). Analysis of possible risk factors for macular burn showed that 3 eyes had to have the power amplified due to nuclear sclerosis, and 1 pseudophakic eye had regular power. Conclusions: TTT in Chinese ARMD patients with occult or minimally classic CNV, according to our protocol, prevented severe vision loss in the majority of patients, but power amplification due to medium lens opacity induced RPE atrophy or burn in some patients. Copyright (c) 2008 S. Karger AG, Basel.
C1 [Kuo, Hsi-Kung; Kao, Min-Tse; Chen, Yung-Jen; Chen, Chih-Hsin; Wu, Pei-Chang; Kao, Min-Lun] Chang Gung Mem Hosp, Dept Ophthalmol, Kaohsiung, Taiwan.
   [Kuo, Hsi-Kung; Chen, Yung-Jen; Wu, Pei-Chang] Chang Gung Univ, Coll Med, Tao Yuan, Taiwan.
C3 Chang Gung Memorial Hospital; Chang Gung University
RP Kuo, HK (通讯作者)，Chang Gung Mem Hosp, Dept Ophthalmol, 123 Ta-Pei Rd, Kaohsiung, Taiwan.
EM d2767@cgmh.org.tw
CR Algvere PV, 2003, ACTA OPHTHALMOL SCAN, V81, P110, DOI 10.1034/j.1600-0420.2003.00041.x
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Atarashi T, 2004, EYE, V18, P615, DOI 10.1038/sj.eye.6700733
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Benhamou N, 2004, AM J OPHTHALMOL, V137, P1132, DOI 10.1016/j.ajo.2003.12.044
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Bloom SM., 1997, LASER SURG POSTERIOR, V2, P382
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   Chew H, 2005, CAN J OPHTHALMOL, V40, P384, DOI 10.1016/S0008-4182(05)80081-X
   Connolly BP, 2003, OPHTHALMOLOGY, V110, P415, DOI 10.1016/S0161-6420(02)01561-0
   Desmettre T, 2001, INVEST OPHTH VIS SCI, V42, P2976
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gustavsson C, 2005, ACTA OPHTHALMOL SCAN, V83, P148, DOI 10.1111/j.1600-0420.2005.00427.x
   HYMAN L, 1987, EYE, V1, P330, DOI 10.1038/eye.1987.53
   Lanzetta P, 2002, OPHTHALMOLOGY, V109, P1098, DOI 10.1016/S0161-6420(02)01034-5
   Maberley DAL, 2005, CAN J OPHTHALMOL, V40, P378, DOI 10.1016/S0008-4182(05)80080-8
   Mainster M A, 1999, Semin Ophthalmol, V14, P200
   Mainster MA, 2000, OPHTHALMIC SURG LAS, V31, P359
   Ming Y, 2004, INVEST OPHTH VIS SCI, V45, P1969, DOI 10.1167/iovs.03-1329
   Nagpal Manish, 2003, Indian Journal of Ophthalmology, V51, P243
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   Rougier MB, 2005, RETINA-J RET VIT DIS, V25, P784, DOI 10.1097/00006982-200509000-00016
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Salinas-Alaman A, 2003, ACTA OPHTHALMOL SCAN, V81, P197, DOI 10.1034/j.1600-0420.2003.t01-1-00025.x
   Shields CL, 1998, OPHTHALMOLOGY, V105, P581, DOI 10.1016/S0161-6420(98)94008-8
   Stolba U, 2006, BRIT J OPHTHALMOL, V90, P158, DOI 10.1136/bjo.2005.076422
   Stoltz RA, 2005, RETINA-J RET VIT DIS, V25, P498, DOI 10.1097/00006982-200506000-00016
   Subramanian Manju L, 2003, Curr Opin Ophthalmol, V14, P155, DOI 10.1097/00055735-200306000-00008
   Thach AB, 2003, ARCH OPHTHALMOL-CHIC, V121, P817, DOI 10.1001/archopht.121.6.817
   Thompson JT, 2001, AM J OPHTHALMOL, V131, P662, DOI 10.1016/S0002-9394(00)00879-5
   WEITER JJ, 2001, OPTICS LASER IRRADIA, P499
NR 34
TC 0
Z9 1
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2008
VL 222
IS 2
BP 117
EP 122
DI 10.1159/000112629
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 265ZK
UT WOS:000253400400010
PM 18303233
DA 2022-11-30
ER

PT J
AU Waksmunski, AR
   Grunin, M
   Kinzy, TG
   Igo, RP
   Haines, JL
   Bailey, JNC
   Fritsche, LG
   Igl, W
   Grassmann, F
   Sengupta, S
   Bragg-Gresham, JL
   Burdon, KP
   Hebbring, SJ
   Wen, C
   Gorski, M
   Kim, IK
   Cho, D
   Zack, D
   Souied, E
   Scholl, HPN
   Bala, E
   Lee, KE
   Hunter, DJ
   Sardell, RJ
   Mitchell, P
   Merriam, JE
   Cipriani, V
   Hoffman, JD
   Schick, T
   Lechanteur, YTE
   Guymer, RH
   Johnson, MP
   Jiang, YD
   Stanton, CM
   Buitendijk, GHS
   Zhan, XW
   Kwong, AM
   Boleda, A
   Brooks, M
   Gieser, L
   Ratnapriya, R
   Branham, KE
   Foerster, JR
   Heckenlively, JR
   Othman, MI
   Vote, BJ
   Liang, HH
   Souzeau, E
   McAllister, IL
   Isaacs, T
   Hall, J
   Lake, S
   Mackey, DA
   Constable, IJ
   Craig, JE
   Kitchner, TE
   Yang, ZL
   Su, ZG
   Luo, HR
   Chen, D
   Ouyang, H
   Flagg, K
   Lin, DN
   Mao, GP
   Ferreyra, H
   Stark, K
   von Strachwitz, CN
   Wolf, A
   Brandl, C
   Rudolph, G
   Olden, M
   Morrison, MA
   Morgan, DJ
   Schu, M
   Ahn, J
   Silvestri, G
   Tsironi, EE
   Park, KH
   Farrer, LA
   Orlin, A
   Brucker, A
   Li, MY
   Curcio, CA
   Mohand-Said, S
   Sahel, JA
   Audo, I
   Benchaboune, M
   Cree, AJ
   Rennie, CA
   Goverdhan, SV
   Hagbi-Levi, S
   Campochiaro, P
   Katsanis, N
   Holz, FG
   Blond, F
   Blanche, H
   Deleuze, JF
   Truitt, B
   Peachey, NS
   Meuer, SM
   Myers, CE
   Moore, EL
   Klein, R
   Hauser, MA
   Postel, EA
   Courtenay, MD
   Schwartz, SG
   Kovach, JL
   Scott, WK
   Liew, G
   Tan, AG
   Gopinath, B
   Merriam, JC
   Smith, RT
   Khan, JC
   Shahid, H
   Moore, AT
   McGrath, JA
   Laux, R
   Brantley, MA
   Agarwal, A
   Ersoy, L
   Caramoy, A
   Langmann, T
   Saksens, NTM
   de Jong, EK
   Hoyng, CB
   Cain, MS
   Richardson, AJ
   Martin, TM
   Blangero, J
   Weeks, DE
   Dhillon, B
   van Duijn, CM
   Doheny, KF
   Romm, J
   Klaver, CCW
   Hayward, C
   Gorin, MB
   Klein, ML
   Baird, PN
   den Hollander, AI
   Fauser, S
   Yates, JRW
   Allikmets, R
   Wang, JJ
   Schaumberg, DA
   Klein, BEK
   Hagstrom, SA
   Chowers, I
   Lotery, AJ
   Leveillard, T
   Zhang, K
   Brilliant, MH
   Hewitt, AW
   Swaroop, A
   Chew, EY
   Pericak-Vance, MA
   DeAngelis, M
   Stambolian, D
   Iyengar, SK
   Weber, BHF
   Abecasis, GR
   Heid, IM
AF Waksmunski, Andrea R.
   Grunin, Michelle
   Kinzy, Tyler G.
   Igo, Robert P., Jr.
   Haines, Jonathan L.
   Bailey, Jessica N. Cooke
   Fritsche, Lars G.
   Igl, Wilmar
   Grassmann, Felix
   Sengupta, Sebanti
   Bragg-Gresham, Jennifer L.
   Burdon, Kathryn P.
   Hebbring, Scott J.
   Wen, Cindy
   Gorski, Mathias
   Kim, Ivana K.
   Cho, David
   Zack, Donald
   Souied, Eric
   Scholl, Hendrik P. N.
   Bala, Elisa
   Lee, Kristine E.
   Hunter, David J.
   Sardell, Rebecca J.
   Mitchell, Paul
   Merriam, Joanna E.
   Cipriani, Valentina
   Hoffman, Joshua D.
   Schick, Tina
   Lechanteur, Yara T. E.
   Guymer, Robyn H.
   Johnson, Matthew P.
   Jiang, Yingda
   Stanton, Chloe M.
   Buitendijk, Gabrielle H. S.
   Zhan, Xiaowei
   Kwong, Alan M.
   Boleda, Alexis
   Brooks, Matthew
   Gieser, Linn
   Ratnapriya, Rinki
   Branham, Kari E.
   Foerster, Johanna R.
   Heckenlively, John R.
   Othman, Mohammad, I
   Vote, Brendan J.
   Liang, Helena Hai
   Souzeau, Emmanuelle
   McAllister, Ian L.
   Isaacs, Timothy
   Hall, Janette
   Lake, Stewart
   Mackey, David A.
   Constable, Ian J.
   Craig, Jamie E.
   Kitchner, Terrie E.
   Yang, Zhenglin
   Su, Zhiguang
   Luo, Hongrong
   Chen, Daniel
   Ouyang, Hong
   Flagg, Ken
   Lin, Danni
   Mao, Guanping
   Ferreyra, Henry
   Stark, Klaus
   von Strachwitz, Claudia N.
   Wolf, Armin
   Brandl, Caroline
   Rudolph, Guenther
   Olden, Matthias
   Morrison, Margaux A.
   Morgan, Denise J.
   Schu, Matthew
   Ahn, Jeeyun
   Silvestri, Giuliana
   Tsironi, Evangelia E.
   Park, Kyu Hyung
   Farrer, Lindsay A.
   Orlin, Anton
   Brucker, Alexander
   Li, Mingyao
   Curcio, Christine A.
   Mohand-Said, Saddek
   Sahel, Jose-Alain
   Audo, Isabelle
   Benchaboune, Mustapha
   Cree, Angela J.
   Rennie, Christina A.
   Goverdhan, Srinivas, V
   Hagbi-Levi, Shira
   Campochiaro, Peter
   Katsanis, Nicholas
   Holz, Frank G.
   Blond, Frederic
   Blanche, Helene
   Deleuze, Jean-Francois
   Truitt, Barbara
   Peachey, Neal S.
   Meuer, Stacy M.
   Myers, Chelsea E.
   Moore, Emily L.
   Klein, Ronald
   Hauser, Michael A.
   Postel, Eric A.
   Courtenay, Monique D.
   Schwartz, Stephen G.
   Kovach, Jaclyn L.
   Scott, William K.
   Liew, Gerald
   Tan, Ava G.
   Gopinath, Bamini
   Merriam, John C.
   Smith, R. Theodore
   Khan, Jane C.
   Shahid, Humma
   Moore, Anthony T.
   McGrath, J. Allie
   Laux, Renee
   Brantley, Milam A., Jr.
   Agarwal, Anita
   Ersoy, Lebriz
   Caramoy, Albert
   Langmann, Thomas
   Saksens, Nicole T. M.
   de Jong, Eiko K.
   Hoyng, Carel B.
   Cain, Melinda S.
   Richardson, Andrea J.
   Martin, Tammy M.
   Blangero, John
   Weeks, Daniel E.
   Dhillon, Bal
   van Duijn, Cornelia M.
   Doheny, Kimberly F.
   Romm, Jane
   Klaver, Caroline C. W.
   Hayward, Caroline
   Gorin, Michael B.
   Klein, Michael L.
   Baird, Paul N.
   den Hollander, Anneke, I
   Fauser, Sascha
   Yates, John R. W.
   Allikmets, Rando
   Wang, Jie Jin
   Schaumberg, Debra A.
   Klein, Barbara E. K.
   Hagstrom, Stephanie A.
   Chowers, Itay
   Lotery, Andrew J.
   Leveillard, Thierry
   Zhang, Kang
   Brilliant, Murray H.
   Hewitt, Alex W.
   Swaroop, Anand
   Chew, Emily Y.
   Pericak-Vance, Margaret A.
   DeAngelis, Margaret
   Stambolian, Dwight
   Iyengar, Sudha K.
   Weber, Bernhard H. F.
   Abecasis, Goncalo R.
   Heid, Iris M.
CA Int Age-Related Macular Degenerati
TI Pathway Analysis Integrating Genome-Wide and Functional Data Identifies
   PLCG2 as a Candidate Gene for Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; pathway analysis; genome-wide
   association study; database; phospholipase C gamma 2
ID GROWTH-FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; CELL-SURVIVAL;
   ACTIVATION; ASSOCIATION; VARIANTS; NETWORKS; THERAPY; RARE
AB PURPOSE. Age-related macular degeneration (AMD) is the worldwide leading cause of blindness among the elderly. Although genome-wide association studies (GWAS) have identified AMD risk variants, their roles in disease etiology are not well-characterized, and they only explain a portion of AMD heritability.
   METHODS. We performed pathway analyses using summary statistics from the International AMD Genomics Consortium's 2016 GWAS and multiple pathway databases to identify biological pathways wherein genetic association signals for AMD may be aggregating. We determined which genes contributed most to significant pathway signals across the databases. We characterized these genes by constructing protein-protein interaction networks and performing motif analysis.
   RESULTS. We determined that eight genes (C2, C3, LIPC, MICA, NOTCH4, PLCG2, PPARA, and RAD51B) "drive'' the statistical signals observed across pathways curated in the Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, and Gene Ontology (GO) databases. We further refined our definition of statistical driver gene to identify PLCG2 as a candidate gene for AMD due to its significant gene-level signals (P < 0.0001) across KEGG, Reactome, GO, and NetPath pathways.
   CONCLUSIONS. We performed pathway analyses on the largest available collection of advanced AMD cases and controls in the world. Eight genes strongly contributed to significant pathways from the three larger databases, and one gene (PLCG2) was central to significant pathways from all four databases. This is, to our knowledge, the first study to identify PLCG2 as a candidate gene for AMD based solely on genetic burden. Our findings reinforce the utility of integrating in silico genetic and biological pathway data to investigate the genetic architecture of AMD.
C1 [Waksmunski, Andrea R.; Haines, Jonathan L.] Case Western Reserve Univ, Dept Genet & Genome Sci, Cleveland, OH 44106 USA.
   [Waksmunski, Andrea R.; Grunin, Michelle; Haines, Jonathan L.; Bailey, Jessica N. Cooke] Case Western Reserve Univ, Cleveland Inst Computat Biol, Cleveland, OH 44106 USA.
   [Waksmunski, Andrea R.; Grunin, Michelle; Kinzy, Tyler G.; Igo, Robert P., Jr.; Haines, Jonathan L.; Bailey, Jessica N. Cooke] Case Western Reserve Univ, Dept Populat & Quantitat Hlth Sci, 2103 Cornell Rd,Suite 1313, Cleveland, OH 44106 USA.
   [Fritsche, Lars G.; Sengupta, Sebanti; Bragg-Gresham, Jennifer L.; Zhan, Xiaowei; Kwong, Alan M.; Foerster, Johanna R.; Abecasis, Goncalo R.] Univ Michigan, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
   [Igl, Wilmar; Gorski, Mathias; Stark, Klaus; Brandl, Caroline; Olden, Matthias; Heid, Iris M.] Univ Regensburg, Dept Genet Epidemiol, Regensburg, Germany.
   [Igo, Robert P., Jr.; Haines, Jonathan L.; Bailey, Jessica N. Cooke; Truitt, Barbara; Laux, Renee; Iyengar, Sudha K.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Sch Med, Cleveland, OH 44106 USA.
   [Grassmann, Felix; Brandl, Caroline; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, Regensburg, Germany.
   [Bragg-Gresham, Jennifer L.] Univ Michigan, Dept Biostat, Dept Internal Med Nephrol, Kidney Epidemiol & Cost Ctr, Ann Arbor, MI 48109 USA.
   [Burdon, Kathryn P.; Vote, Brendan J.; Mackey, David A.; Hewitt, Alex W.] Univ Tasmania, Sch Med, Menzies Res Inst Tasmania, Hobart, Tas, Australia.
   [Hebbring, Scott J.; Kitchner, Terrie E.; Brilliant, Murray H.] Marshfield Clin Res Fdn, Ctr Human Genet, Marshfield, WI USA.
   [Wen, Cindy; Luo, Hongrong; Chen, Daniel; Ouyang, Hong; Flagg, Ken; Lin, Danni; Mao, Guanping; Ferreyra, Henry; Zhang, Kang] Univ Calif San Diego, Dept Ophthalmol, La Jolla, CA 92093 USA.
   [Wen, Cindy; Luo, Hongrong; Chen, Daniel; Ouyang, Hong; Flagg, Ken; Lin, Danni; Mao, Guanping; Ferreyra, Henry; Zhang, Kang] VA San Diego Hlth Syst, La Jolla, CA USA.
   [Kim, Ivana K.] Harvard Med Sch, Retina Serv, Massachusetts Eye & Ear, Dept Ophthalmol, Boston, MA 02115 USA.
   [Cho, David; Stambolian, Dwight] Univ Penn, Dept Ophthalmol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Zack, Donald; Scholl, Hendrik P. N.; Campochiaro, Peter] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Wilmer Eye Inst, Baltimore, MD 21205 USA.
   [Zack, Donald] Johns Hopkins Univ, Dept Mol Biol & Genet, Sch Med, Baltimore, MD 21205 USA.
   [Zack, Donald; Campochiaro, Peter] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.
   [Zack, Donald] Johns Hopkins Univ, Sch Med, Inst Genet Med, Baltimore, MD USA.
   [Zack, Donald] Univ Paris 06, Inst Vis, Paris, France.
   [Souied, Eric] Univ Paris Est Creteil, Hop Intercommunal Creteil, Hop Henri Mondor, Creteil, France.
   [Scholl, Hendrik P. N.; Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Bala, Elisa; Peachey, Neal S.] Louis Stokes Cleveland VA Med Ctr, Cleveland, OH USA.
   [Lee, Kristine E.; Meuer, Stacy M.; Myers, Chelsea E.; Moore, Emily L.; Klein, Ronald; Klein, Barbara E. K.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Hunter, David J.; Schaumberg, Debra A.] Harvard Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
   [Hunter, David J.] Harvard Sch Publ Hlth, Dept Nutr, Boston, MA USA.
   [Sardell, Rebecca J.; Courtenay, Monique D.; Scott, William K.; Pericak-Vance, Margaret A.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA.
   [Mitchell, Paul; Liew, Gerald; Tan, Ava G.; Gopinath, Bamini; Wang, Jie Jin] Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Sydney, NSW, Australia.
   [Mitchell, Paul; Liew, Gerald; Tan, Ava G.; Gopinath, Bamini; Wang, Jie Jin] Univ Sydney, Westmead Millennium Inst Med Res, Sydney, NSW, Australia.
   [Merriam, Joanna E.; Merriam, John C.; Smith, R. Theodore; Allikmets, Rando] Columbia Univ, Dept Ophthalmol, New York, NY 10027 USA.
   [Cipriani, Valentina; Moore, Anthony T.; Yates, John R. W.] UCL, UCL Inst Ophthalmol, London, England.
   [Cipriani, Valentina; Moore, Anthony T.; Yates, John R. W.] Moorfields Eye Hosp, London, England.
   [Hoffman, Joshua D.; McGrath, J. Allie] Vanderbilt Univ, Med Ctr, Ctr Human Genet Res, Nashville, TN USA.
   [Schick, Tina; Ersoy, Lebriz; Caramoy, Albert; Langmann, Thomas; Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany.
   [Lechanteur, Yara T. E.; Saksens, Nicole T. M.; de Jong, Eiko K.; Hoyng, Carel B.; den Hollander, Anneke, I] Radboud Univ Nijmegen, Dept Ophthalmol, Med Ctr, Nijmegen, Netherlands.
   [Guymer, Robyn H.; Liang, Helena Hai; Mackey, David A.; Cain, Melinda S.; Richardson, Andrea J.; Baird, Paul N.; Hewitt, Alex W.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic, Australia.
   [Johnson, Matthew P.; Blangero, John] Univ Texas Brownsville, South Texas Diabet & Obes Inst, Rio Grande Valley Sch Med, Brownsville, TX 78520 USA.
   [Jiang, Yingda; Weeks, Daniel E.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.
   [Stanton, Chloe M.; Hayward, Caroline] Univ Edinburgh, Inst Genet & Mol Med, Human Genet Unit, MRC, Edinburgh, Midlothian, Scotland.
   [Buitendijk, Gabrielle H. S.; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Buitendijk, Gabrielle H. S.; van Duijn, Cornelia M.; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Zhan, Xiaowei] Univ Texas Southwestern Med Ctr Dallas, Quantitat Biomed Res Ctr, Dept Clin Sci, Dallas, TX 75390 USA.
   [Zhan, Xiaowei] Univ Texas Southwestern Med Ctr Dallas, Ctr Genet Host Def, Dallas, TX 75390 USA.
   [Boleda, Alexis; Brooks, Matthew; Gieser, Linn; Ratnapriya, Rinki; Swaroop, Anand] NEI, N NRL, NIH, Bethesda, MD 20892 USA.
   [Branham, Kari E.; Heckenlively, John R.; Othman, Mohammad, I] Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA.
   [Souzeau, Emmanuelle; Hall, Janette; Lake, Stewart; Craig, Jamie E.] Flinders Univ S Australia, Flinders Med Ctr, Dept Ophthalmol, Adelaide, SA, Australia.
   [McAllister, Ian L.; Isaacs, Timothy; Mackey, David A.; Constable, Ian J.; Khan, Jane C.; Hewitt, Alex W.] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Lions Eye Inst, Perth, WA, Australia.
   [Yang, Zhenglin] Hosp Univ Elect Sci & Technol China, Sichuan Prov Key Lab Human Dis Gene Study, Chengdu, Sichuan, Peoples R China.
   [Yang, Zhenglin] Sichuan Prov Peoples Hosp, Chengdu, Sichuan, Peoples R China.
   [Yang, Zhenglin] Chinese Acad Sci, Sichuan Translat Med Hosp, Chengdu, Sichuan, Peoples R China.
   [Su, Zhiguang; Luo, Hongrong; Zhang, Kang] Sichuan Univ, West China Hosp, Mol Med Res Ctr, State Key Lab Biotherapy, Chengdu, Sichuan, Peoples R China.
   [von Strachwitz, Claudia N.] EyeCenter, Stuttgart, Germany.
   [Wolf, Armin; Rudolph, Guenther] Ludwig Maximilians Univ Munchen, Univ Eye Clin, Munich, Germany.
   [Brandl, Caroline] Univ Hosp Regensburg, Dept Ophthalmol, Regensburg, Germany.
   [Morrison, Margaux A.; Morgan, Denise J.; DeAngelis, Margaret] Univ Utah, Dept Ophthalmol & Visual Sci, Salt Lake City, UT USA.
   [Schu, Matthew; Farrer, Lindsay A.] Boston Univ, Dept Med Biomed Genet, Sch Med, Boston, MA 02215 USA.
   [Schu, Matthew; Farrer, Lindsay A.] Boston Univ, Dept Med Biomed Genet, Sch Publ Hlth, Boston, MA 02215 USA.
   [Schu, Matthew] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA.
   [Schu, Matthew] Boston Univ, Sch Publ Hlth, Dept Ophthalmol, Boston, MA USA.
   [Schu, Matthew] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.
   [Schu, Matthew] Boston Univ, Sch Publ Hlth, Dept Neurol, Boston, MA USA.
   [Schu, Matthew] Boston Univ, Dept Epidemiol, Sch Med, Boston, MA USA.
   [Schu, Matthew] Boston Univ, Dept Epidemiol, Sch Public Hlth, Boston, MA USA.
   [Schu, Matthew; Farrer, Lindsay A.] Boston Univ, Dept Biostat, Sch Med, Boston, MA USA.
   [Schu, Matthew; Farrer, Lindsay A.] Boston Univ, Dept Biostat, Sch Publ Hlth, Boston, MA USA.
   [Ahn, Jeeyun] Seoul Natl Univ, Dept Ophthalmol, Seoul Metropolitan Govt, Boramae Med Ctr, Seoul, South Korea.
   [Silvestri, Giuliana] Queens Univ, Ctr Expt Med, Belfast, Antrim, North Ireland.
   [Tsironi, Evangelia E.] Univ Thessaly, Sch Med, Dept Ophthalmol, Larisa, Greece.
   [Park, Kyu Hyung] Seoul Natl Univ, Dept Ophthalmol, Bundang Hosp, Seongnam, South Korea.
   [Orlin, Anton] Weill Cornell Med Coll, Dept Ophthalmol, New York, NY USA.
   [Brucker, Alexander] Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Li, Mingyao] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Curcio, Christine A.] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL 35294 USA.
   [Mohand-Said, Saddek; Sahel, Jose-Alain; Audo, Isabelle; Blond, Frederic; Leveillard, Thierry] INSERM, Paris, France.
   [Mohand-Said, Saddek; Sahel, Jose-Alain; Audo, Isabelle; Blond, Frederic; Leveillard, Thierry] UPMC Univ Paris 06, UMR S 968, Inst Vis, Dept Genet, Paris, France.
   [Mohand-Said, Saddek; Sahel, Jose-Alain; Audo, Isabelle; Blond, Frederic; Leveillard, Thierry] CNRS, Le Ctr Natl Rech Sci, UMR 7210, Paris, France.
   [Mohand-Said, Saddek; Sahel, Jose-Alain; Benchaboune, Mustapha] Ctr Hosp Natl Ophtalmol Quinze Vingts, INSERM DHOS CIC 503, Paris, France.
   [Sahel, Jose-Alain] Fondat Ophtalmol Adolphe de Rothschild, Paris, France.
   [Sahel, Jose-Alain] UCL, Inst Ophthalmol, London, England.
   [Sahel, Jose-Alain] Inst France, Acad Sci, Paris, France.
   [Audo, Isabelle] Inst Ophthalmol, Dept Mol Genet, London, England.
   [Cree, Angela J.; Goverdhan, Srinivas, V; Lotery, Andrew J.] Univ Southampton, Fac Med, Clin & Expt Sci, Southampton, Hants, England.
   [Rennie, Christina A.] Univ Hosp Southampton, Southampton, Hants, England.
   [Grunin, Michelle; Hagbi-Levi, Shira; Chowers, Itay] Hadassah Hebrew Univ, Dept Ophthalmol, Med Ctr, Jerusalem, Israel.
   [Katsanis, Nicholas] Duke Univ, Ctr Human Dis Modeling, Durham, NC USA.
   [Katsanis, Nicholas] Duke Univ, Dept Cell Biol, Durham, NC USA.
   [Katsanis, Nicholas] Duke Univ, Dept Pediat, Durham, NC 27706 USA.
   [Blanche, Helene; Deleuze, Jean-Francois] CEPH Fondat Jean Dausset, Paris, France.
   [Deleuze, Jean-Francois] Commissariat Energie Atom & Energies Alternative, Inst Genom, Ctr Natl Genotypage, Evry, France.
   [Peachey, Neal S.; Hagstrom, Stephanie A.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
   [Hauser, Michael A.; Postel, Eric A.] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   [Hauser, Michael A.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
   [Hauser, Michael A.] Duke Univ, Duke Mol Physiol Inst, Med Ctr, Durham, NC USA.
   [Schwartz, Stephen G.; Kovach, Jaclyn L.] Univ Miami, Bascom Palmer Eye Inst, Miller Sch Med, Naples, FL USA.
   [Smith, R. Theodore] NYU, Sch Med, Dept Ophthalmol, New York, NY USA.
   [Khan, Jane C.] Royal Perth Hosp, Dept Ophthalmol, Perth, WA, Australia.
   [Khan, Jane C.; Shahid, Humma; Yates, John R. W.] Univ Cambridge, Cambridge Inst Med Res, Dept Med Genet, Cambridge, England.
   [Shahid, Humma] Cambridge Univ Hosp NHS Fdn Trust, Dept Ophthalmol, Cambridge, England.
   [Moore, Anthony T.] UCSF Med Sch, Dept Ophthalmol, San Francisco, CA USA.
   [Brantley, Milam A., Jr.; Agarwal, Anita] Vanderbilt Univ, Dept Ophthalmol & Visual Sci, 221 Kirkland Hall, Nashville, TN 37235 USA.
   [Martin, Tammy M.; Klein, Michael L.] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA.
   [Weeks, Daniel E.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA.
   [Dhillon, Bal] Univ Edinburgh, Sch Clin Sci, Edinburgh, Midlothian, Scotland.
   [Doheny, Kimberly F.; Romm, Jane] Johns Hopkins Univ, Sch Med, CIDR, Inst Genet Med, Baltimore, MD USA.
   [Gorin, Michael B.] UCLA, David Geffen Sch Med, Dept Ophthalmol, Stein Eye Inst, Los Angeles, CA 90095 USA.
   [Gorin, Michael B.] UCLA, Dept Human Genet, David Geffen Sch Med, Los Angeles, CA 90095 USA.
   [den Hollander, Anneke, I] Radboud Univ Nijmegen, Dept Human Genet, Med Ctr, Nijmegen, Netherlands.
   [Allikmets, Rando] Columbia Univ, Dept Pathol & Cell Biol, New York, NY USA.
   [Schaumberg, Debra A.] Univ Utah, Sch Med, Ctr Translat Med, Moran Eye Ctr, Salt Lake City, UT USA.
   [Schaumberg, Debra A.] Harvard Med Sch, Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA.
   [Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, Clin Trials Branch, NIH, Bethesda, MD 20892 USA.
   [Haines, Jonathan L.] Case Western Reserve Univ, Sch Med, Inst Computat Biol, Cleveland, OH USA.
C3 Case Western Reserve University; Case Western Reserve University; Case
   Western Reserve University; University of Michigan System; University of
   Michigan; University of Regensburg; Case Western Reserve University;
   University of Regensburg; University of Michigan System; University of
   Michigan; University of Tasmania; Menzies Institute for Medical
   Research; University of California System; University of California San
   Diego; US Department of Veterans Affairs; Veterans Health Administration
   (VHA); VA San Diego Healthcare System; Harvard University; Harvard
   Medical School; Massachusetts Eye & Ear Infirmary; University of
   Pennsylvania; Pennsylvania Medicine; Johns Hopkins University; Johns
   Hopkins Medicine; Johns Hopkins University; Johns Hopkins University;
   Johns Hopkins University; UDICE-French Research Universities; Sorbonne
   Universite; Assistance Publique Hopitaux Paris (APHP); Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire
   Henri-Mondor - APHP; CHI Creteil; University of Bonn; US Department of
   Veterans Affairs; Veterans Health Administration (VHA); Case Western
   Reserve University; Louis Stokes Cleveland Veterans Affairs Medical
   Center; University of Wisconsin System; University of Wisconsin Madison;
   Harvard University; Harvard T.H. Chan School of Public Health; Harvard
   University; Harvard T.H. Chan School of Public Health; University of
   Miami; University of Sydney; University of Sydney; Columbia University;
   University of London; University College London; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   Vanderbilt University; University of Cologne; Radboud University
   Nijmegen; Centre for Eye Research Australia; Royal Victorian Eye & Ear
   Hospital; University of Melbourne; University of Texas System;
   University of Texas Rio Grande Valley; Pennsylvania Commonwealth System
   of Higher Education (PCSHE); University of Pittsburgh; University of
   Edinburgh; Erasmus University Rotterdam; Erasmus MC; Erasmus University
   Rotterdam; Erasmus MC; University of Texas System; University of Texas
   Southwestern Medical Center Dallas; University of Texas System;
   University of Texas Southwestern Medical Center Dallas; National
   Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI);
   University of Michigan System; University of Michigan; Flinders Medical
   Centre; Flinders University South Australia; Lions Eye Institute;
   University of Western Australia; University of Electronic Science &
   Technology of China; Sichuan Provincial People's Hospital; Chinese
   Academy of Sciences; Sichuan University; University of Munich;
   University of Regensburg; Utah System of Higher Education; University of
   Utah; Boston University; Boston University; Boston University; Boston
   University; Boston University; Boston University; Boston University;
   Boston University; Boston University; Boston University; Seoul National
   University (SNU); Seoul National University Hospital; Queens University
   Belfast; University of Thessaly; Seoul National University (SNU);
   Cornell University; University of Pennsylvania; Pennsylvania Medicine;
   University of Pennsylvania; Pennsylvania Medicine; University of Alabama
   System; University of Alabama Birmingham; Institut National de la Sante
   et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Sorbonne Universite; Centre National de la Recherche
   Scientifique (CNRS); CNRS - National Institute for Biology (INSB);
   UDICE-French Research Universities; Universite Paris Cite; CHNO des
   Quinze-Vingts; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Sorbonne Universite;
   University of London; University College London; University of London;
   University College London; University of Southampton; Hebrew University
   of Jerusalem; Hadassah University Medical Center; Duke University; Duke
   University; Duke University; CEA; UDICE-French Research Universities;
   Universite Paris Saclay; Cleveland Clinic Foundation; Duke University;
   Duke University; Duke University; Bascom Palmer Eye Institute; New York
   University; Royal Perth Hospital; University of Western Australia;
   University of Cambridge; University of Cambridge; University of
   California System; University of California San Francisco; Vanderbilt
   University; Oregon Health & Science University; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; University of Edinburgh; Johns Hopkins University;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Radboud University
   Nijmegen; Columbia University; Utah System of Higher Education;
   University of Utah; Harvard University; Brigham & Women's Hospital;
   Harvard Medical School; National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI); Case Western Reserve University
RP Bailey, JNC (通讯作者)，Case Western Reserve Univ, Dept Populat & Quantitat Hlth Sci, 2103 Cornell Rd,Suite 1313, Cleveland, OH 44106 USA.
EM jlh213@case.edu
RI Lechanteur, Yara/ABB-6875-2020; Zhang, Kang/Y-2740-2019; Peachey,
   Neal/G-5533-2010; Farrer, Lindsay/AAS-1035-2020; Su,
   Zhiguang/AFS-0022-2022; Léveillard, Thierry/AAR-1804-2020; Lehtimäki,
   Terho/AAD-1094-2022; Liew, Gerald/AAB-6870-2022; Blangero,
   John/ABA-7175-2021; Mackey, David A/H-5340-2014; Branham,
   Kari/AAA-8336-2022; Souzeau, Emmanuelle/AAB-5608-2022; lake,
   stewart/AAH-6265-2021; Grunin, Michelle/O-6044-2019; Allikmets,
   Rando/ABD-4533-2021; Cooke Bailey, Jessica Nicole/AFQ-5925-2022; Burdon,
   Kathryn/AAD-2334-2022; Fritsche, Lars G/AAF-9387-2019
OI Lechanteur, Yara/0000-0003-0951-4625; Zhang, Kang/0000-0002-4549-1697;
   Peachey, Neal/0000-0002-4419-7226; Léveillard,
   Thierry/0000-0001-5692-8770; Lehtimäki, Terho/0000-0002-2555-4427;
   Mackey, David A/0000-0001-7914-4709; Souzeau,
   Emmanuelle/0000-0002-2015-6577; lake, stewart/0000-0003-0078-3319;
   Grunin, Michelle/0000-0002-3155-2858; Cooke Bailey, Jessica
   Nicole/0000-0002-4001-8702; Burdon, Kathryn/0000-0001-8217-1249;
   Fritsche, Lars G/0000-0002-2110-1690; Baird, Paul/0000-0002-1305-3502;
   Waksmunski, Andrea/0000-0001-7223-7371
FU VSTP Training Grant [T32EY007157-18]; National Institutes of Health
   National Center for Advancing Translational Science (NCATS)
   [KL2TR000440];  [1X01HG006934-01];  [R01 EY022310]; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCES [KL2TR000440] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [R01EY022310, T32EY007157] Funding
   Source: NIH RePORTER
FX Supported by Grants 1X01HG006934-01, R01 EY022310, the National
   Institutes of Health National Center for Advancing Translational Science
   (NCATS) Grant KL2TR000440 (JNCB), and the VSTP Training Grant
   T32EY007157-18 (MG).
CR Abtahian F, 2003, SCIENCE, V299, P247, DOI 10.1126/science.1079477
   Afroz S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00074
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Ayoub T, 2009, J ROY SOC MED, V102, P56, DOI 10.1258/jrsm.2009.080298
   Bailey TL, 2009, NUCLEIC ACIDS RES, V37, pW202, DOI 10.1093/nar/gkp335
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Butkiewicz M, 2016, BIOINFORMATICS, V32, P2361, DOI 10.1093/bioinformatics/btw130
   Chen XD, 2017, INT J OPHTHALMOL-CHI, V10, P507, DOI 10.18240/ijo.2017.04.02
   Conway OJ, 2018, MOL NEURODEGENER, V13, DOI 10.1186/s13024-018-0289-x
   Courtenay MD, 2014, INVEST OPHTH VIS SCI, V55, P4873, DOI 10.1167/iovs.14-14494
   Defoe DM, 2004, EXP EYE RES, V79, P51, DOI 10.1016/j.exer.2004.02.017
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Grassmann F, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0418-0
   Green ML, 2006, NUCLEIC ACIDS RES, V34, P3687, DOI 10.1093/nar/gkl438
   GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729
   Han WH, 2001, ANTIOXID REDOX SIGN, V3, P1065, DOI 10.1089/152308601317203576
   Haw RA, 2011, DATABASE-OXFORD, DOI 10.1093/database/bar031
   HOMMA Y, 1989, BIOCHEM BIOPH RES CO, V164, P406, DOI 10.1016/0006-291X(89)91734-8
   Inoue O, 2003, J CELL BIOL, V160, P769, DOI 10.1083/jcb.200208043
   Kandasamy K, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-1-r3
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Karolchik D, 2004, NUCLEIC ACIDS RES, V32, pD493, DOI 10.1093/nar/gkh103
   Keenan TDL, 2015, RETINA-J RET VIT DIS, V35, P2613, DOI 10.1097/IAE.0000000000000651
   Kulakovskiy IV, 2018, NUCLEIC ACIDS RES, V46, pD252, DOI 10.1093/nar/gkx1106
   Magno L, 2019, ALZHEIMERS RES THER, V11, DOI 10.1186/s13195-019-0469-0
   Manne BK, 2015, J BIOL CHEM, V290, P11557, DOI 10.1074/jbc.M114.629527
   Marshall AJ, 2000, IMMUNOL REV, V176, P30
   Mathelier A, 2016, NUCLEIC ACIDS RES, V44, pD110, DOI 10.1093/nar/gkv1176
   Ohmori T, 2001, BIOCHEMISTRY-US, V40, P12992, DOI 10.1021/bi0109459
   Ombrello MJ, 2012, NEW ENGL J MED, V366, P330, DOI 10.1056/NEJMoa1102140
   Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045
   Rudolph A, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0625-9
   Rudolph A, 2013, ENDOCR-RELAT CANCER, V20, P875, DOI 10.1530/ERC-13-0349
   Sasore T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105280
   Scott AW, 2016, JAMA OPHTHALMOL, V134, P1111, DOI 10.1001/jamaophthalmol.2016.2627
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Sims R, 2017, NAT GENET, V49, P1373, DOI 10.1038/ng.3916
   Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003
   Uckun F, 2007, BRIT J HAEMATOL, V136, P574, DOI 10.1111/j.1365-2141.2006.06468.x
   Winkler TW, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194321
   Wonerow P, 2003, J BIOL CHEM, V278, P37520, DOI 10.1074/jbc.M305077200
   Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006
   Xu KP, 2007, INVEST OPHTH VIS SCI, V48, P2242, DOI 10.1167/iovs.06-0560
   Yan F, 2007, OPHTHALMOLOGICA, V221, P244, DOI 10.1159/000101926
   Yaspan BL, 2019, CURR PROTOC HUM GENE, V100, pe79
   Yaspan BL, 2011, HUM GENET, V129, P563, DOI 10.1007/s00439-011-0956-2
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zhang B, 2013, CELL, V153, P707, DOI 10.1016/j.cell.2013.03.030
NR 48
TC 5
Z9 5
U1 2
U2 18
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2019
VL 60
IS 12
BP 4041
EP 4051
DI 10.1167/iovs.19-27827
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JB8RM
UT WOS:000488842600015
PM 31560769
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Sato, T
   Enoki, T
   Karasawa, Y
   Someya, H
   Taguchi, M
   Harimoto, K
   Takayama, K
   Kanda, T
   Ito, M
   Takeuchi, M
AF Sato, Tomohito
   Enoki, Toshio
   Karasawa, Yoko
   Someya, Hideaki
   Taguchi, Manzo
   Harimoto, Kozo
   Takayama, Kei
   Kanda, Takayuki
   Ito, Masataka
   Takeuchi, Masaru
TI Inflammatory Factors of Macular Atrophy in Eyes With Neovascular
   Age-Related Macular Degeneration Treated With Aflibercept
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE aflibercept; aqueous humor cytokine; interferon-gamma-inducible protein
   10; macrophage inflammatory protein-1 beta; macular atrophy; monocyte
   chemoattractant protein-1; neovascular age-related macular degeneration;
   vascular endothelial growth factor
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; ENDOTHELIAL GROWTH-FACTOR;
   VISUAL-ACUITY; GEOGRAPHIC ATROPHY; RANIBIZUMAB; DISEASE; MIP-1-BETA;
   CHEMOKINE; THERAPY; SUPPRESSION
AB Background: Neovascular age-related macular degeneration (nAMD) is a leading cause of blindness in older people. Low-grade inflammation is well-known as one of the pathogenic mechanisms in nAMD. Anti-vascular endothelial growth factor (VEGF) therapy is the first-line treatment for nAMD, although macula atrophy (MA) developed under anti-VEGF therapy causes irreversible visual function impairment and is recognized as a serious disorder. Here, we show specific expression patterns of aqueous humor (AH) cytokines in nAMD eyes developing MA under intravitreal injection of aflibercept (IVA) as an anti-VEGF antibody and present predictive cytokines as biomarkers for the incidence of MA in nAMD eyes under IVA treatment.
   Methods: Twenty-eight nAMD patients received three consecutive monthly IVA, followed by a pro re nata regimen for 2 years. AH specimens were collected before first IVA (pre-IVA) and before third IVA (post-IVA). AH cytokine levels, visual acuity (VA), and central retinal thickness (CRT) were measured.
   Results: Two-year incidence of MA was 21.4%. In nAMD eyes developing MA [MA (+) group], pre-IVA levels of monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein (MIP)-1 beta, VEGF and post-IVA level of MCP-1 were higher than those in nAMD eyes without MA [MA (-) group]. In hierarchical cluster analysis, pre-IVA MCP-1 and VEGF were grouped into the same subcluster, as were post-IVA MCP-1 and CRT. In principal component analysis, principal component loading (PCL) of pre-IVA interferon-?-inducible protein 10 (IP-10) was 0.61, but PCL of post-IVA IP-10 decreased to -0.09. In receiver operating characteristic analysis and Kaplan-Meier curves, pre-IVA MCP-1, MIP-1 beta, and VEGF and post-IVA interleukin-6, MCP-1, and MIP-1 beta were detected as predictive factors for MA incidence. In 2-year clinical course, changes of VA in groups with high levels of pre-IVA MIP-1 beta (over 39.9 pg/ml) and VEGF (over 150.4 pg/ml) were comparable to those in MA (+) group.
   Conclusion: Substantial loss of IP-10 effects and persistent inflammation contribute to incidence of MA, and screening of AH cytokine levels could be a useful method to predict MA incidence in nAMD eyes under anti-VEGF therapy.
C1 [Sato, Tomohito; Karasawa, Yoko; Someya, Hideaki; Taguchi, Manzo; Harimoto, Kozo; Takayama, Kei; Kanda, Takayuki; Takeuchi, Masaru] Natl Def Med Coll, Dept Ophthalmol, Tokorozawa, Saitama, Japan.
   [Enoki, Toshio] Enoki Eye Clin, Sayama, Osaka, Japan.
   [Ito, Masataka] Natl Def Med Coll, Dept Dev Anat & Regenerat Biol, Tokorozawa, Saitama, Japan.
C3 National Defense Medical College - Japan; National Defense Medical
   College - Japan
RP Takeuchi, M (通讯作者)，Natl Def Med Coll, Dept Ophthalmol, Tokorozawa, Saitama, Japan.
EM masatake@ndmc.ac.jp
FU Japan Society for the Promotion of Science [16K11337]; National Defense
   Medical College; Daiwa Securities Health Foundation; Hisakichi
   Matsubayashi Memorial Fund; Alcon Research Grant; Novartis Research
   Grant
FX This study was supported by Grant-in-Aid for Scientific Research C from
   the Japan Society for the Promotion of Science (16K11337), Grant-in-Aid
   for Encouragement of Young doctors from National Defense Medical
   College, Research Grant from Daiwa Securities Health Foundation,
   Hisakichi Matsubayashi Memorial Fund Subsidy, and Grant-in-Aid for
   Advanced Medical Development from National Defense Medical College. This
   study received funding from Novartis Research Grant and Alcon Research
   Grant. The funders were not involved in the study design, collection,
   analysis, interpretation of data, the writing of this article, or the
   decision to submit it for publication.
CR Agawa T, 2014, RETINA-J RET VIT DIS, V34, P1811, DOI 10.1097/IAE.0000000000000157
   Akhmetov I, 2015, EPMA J, V6, DOI 10.1186/s13167-015-0041-3
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   ANGIOLILLO AL, 1995, J EXP MED, V182, P155, DOI 10.1084/jem.182.1.155
   [Anonymous], 1987, Int Ophthalmol Clin, V27, P265
   Bogunovic H, 2019, IEEE T MED IMAGING, V38, P1858, DOI 10.1109/TMI.2019.2901398
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Christopher M, 2018, INVEST OPHTH VIS SCI, V59, P2748, DOI 10.1167/iovs.17-23387
   COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155
   Cohen MC, 1996, AM J CLIN PATHOL, V105, P589
   Coleman DJ, 2013, BRIT J OPHTHALMOL, V97, P1020, DOI 10.1136/bjophthalmol-2013-303143
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Fasler K, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-027441
   Fauser S, 2014, AM J OPHTHALMOL, V158, P532, DOI 10.1016/j.ajo.2014.05.025
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Forsman RW, 1996, CLIN CHEM, V42, P813
   Fujimura S, 2012, INVEST OPHTH VIS SCI, V53, P1999, DOI 10.1167/iovs.11-8232
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gargeya R, 2017, OPHTHALMOLOGY, V124, P962, DOI 10.1016/j.ophtha.2017.02.008
   Gillies MC, 2020, OPHTHALMOLOGY, V127, P198, DOI 10.1016/j.ophtha.2019.08.023
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grover S, 1999, OPHTHALMOLOGY, V106, P1780, DOI 10.1016/S0161-6420(99)90342-1
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hasegawa M, 1999, CLIN EXP IMMUNOL, V117, P159
   Heller EA, 2006, CIRCULATION, V113, P2301, DOI 10.1161/CIRCULATIONAHA.105.605121
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Ishikawa K, 2012, LAB INVEST, V92, P91, DOI 10.1038/labinvest.2011.141
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   KOCH AE, 1995, CLIN IMMUNOL IMMUNOP, V77, P307, DOI 10.1006/clin.1995.1157
   Lai TT, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36704-6
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lechner J, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0820-y
   Li ZX, 2018, OPHTHALMOLOGY, V125, P1199, DOI 10.1016/j.ophtha.2018.01.023
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsumoto H, 2018, J NEUROSCI, V38, P8745, DOI 10.1523/JNEUROSCI.0897-18.2018
   Rubio-Perez JM, 2012, SCI WORLD J, DOI 10.1100/2012/756357
   Mizutani T, 2013, INVEST OPHTH VIS SCI, V54, P1564, DOI 10.1167/iovs.11-9095
   Moraes G, 2021, OPHTHALMOLOGY, V128, P693, DOI 10.1016/j.ophtha.2020.09.025
   Nezu N, 2021, OPHTHALMOLOGY, V128, P1197, DOI 10.1016/j.ophtha.2021.01.019
   O'Grady NP, 1999, J INFECT DIS, V179, P136, DOI 10.1086/314559
   Ou WC, 2017, AM J OPHTHALMOL, V180, P8, DOI 10.1016/j.ajo.2017.05.014
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Plyukhova AA, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051522
   Redd TK, 2019, BRIT J OPHTHALMOL, V103, P580, DOI 10.1136/bjophthalmol-2018-313156
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ryskamp DA, 2014, J NEUROSCI, V34, P15689, DOI 10.1523/JNEUROSCI.2540-14.2014
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Sato T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55191-x
   Sato T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19594-6
   Saxena S, 2019, INT J RETINA VITR, V5, DOI 10.1186/s40942-019-0157-z
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schulze-Bonsel K, 2006, INVEST OPHTH VIS SCI, V47, P1236, DOI 10.1167/iovs.05-0981
   Sengul EA, 2017, INT J OPHTHALMOL-CHI, V10, P754, DOI 10.18240/ijo.2017.05.16
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spindler J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203337
   Tager AM, 2004, AM J RESP CELL MOL, V31, P395, DOI 10.1165/rcmb.2004-0175OC
   Takeuchi M, 2017, OCUL IMMUNOL INFLAMM, V25, P52, DOI 10.3109/09273948.2016.1158276
   Takeuchi M, 2017, INVEST OPHTH VIS SCI, V58, P528, DOI 10.1167/iovs.16-20324
   Takeuchi M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137358
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Zhang JM, 2007, INT ANESTHESIOL CLIN, V45, P27, DOI 10.1097/AIA.0b013e318034194e
   Zhang XY, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9640131
NR 76
TC 2
Z9 2
U1 3
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD OCT 13
PY 2021
VL 12
AR 738521
DI 10.3389/fimmu.2021.738521
PG 17
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA WQ2DO
UT WOS:000713630800001
PM 34721402
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Kaiserman, I
   Kaiserman, N
   Elhayany, A
   Vinker, S
AF Kaiserman, Igor
   Kaiserman, Nadia
   Elhayany, Asher
   Vinker, Shlomo
TI Cataract surgery is associated with a higher rate of photodynamic
   therapy for age-related macular degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID BLUE MOUNTAINS EYE; BEAVER DAM EYE; RISK-FACTORS; 5-YEAR INCIDENCE; LENS
   OPACITIES; MACULOPATHY; DISEASE; PREVALENCE; RETINA; LIGHT
AB Purpose: To investigate the association between cataract surgery and the rate of photodynamic therapy (PDT) for age-related macular degeneration (AMD).
   Design: Observational population-based retrospective case-control study.
   Participants: All members in a district of the largest health maintenance organization (HMO) in Israel > 50 years old on January 1, 2001, who did not terminate their membership through May 31, 2005 (139 894 members).
   Methods: All PDT procedures for AMD performed in the study population between January 1, 2001 and May 31, 2005 (283 patients) and all cataract surgeries performed between January 1, 2001 and December 31, 2003 (5913 patients) were documented. We extracted clinical information from the chronic disease registry of the HMO as well as demographic and socioeconomic information. For each patient that underwent cataract surgery, 5 HMO members matched in age, gender, chronic diseases (systemic hypertension, diabetes, hyperlipemia, and ischemic heart disease), place of residence, country of birth and socioeconomic status, who did not undergo cataract surgery, were randomly chosen as controls (n = 29 565).
   Main Outcome Measures: The rate for undergoing PDT at different time periods after cataract surgery.
   Results: Fifty (0.85%) cataract patients and 94 control cases (0.32%) underwent PDT after cataract surgery (P < 0.0001, chi-square test). A significant rise in PDT rate was noticed in cataract patients compared to controls during the first 6 months after surgery (P = 0.004, chi-square test). Between 6 and 12 months postoperatively, the PDT rates were similar in both groups. However, a more significant rise in PDT rates occurred between 1 and 1.5 years after surgery (P < 0.0001, chi-square test). The Kaplan-Meier PDT-free survival curve of cataract patients was significantly worse than that of the controls (P < 0.0001, chi-square test; P = 33.7, log-rank test). The hazard ratio for cataract patients compared to controls to undergo PDT after surgery was 2.7 (confidence interval = 2.4-5.7). The most significant factors to reduce the time to PDT were advanced age followed by having had cataract surgery, place of birth, socioeconomic status, and hyperlipidemia (Cox proportional hazards survival regression).
   Conclusions: We identified an increased rate of PDT, presumably for subfoveal AMD, 1 to 1.5 years after cataract surgery.
C1 Barzilai Govt Hosp, Dept Ophthalmol, IL-78306 Ashqelon, Israel.
   Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Ophthalmol, Jerusalem, Israel.
   Clailit Hlth Serv, Dept Family Med, Rehovot, Israel.
   Tel Aviv Univ, Sackler Fac Med, Dept Family Med, IL-69978 Tel Aviv, Israel.
C3 Ben Gurion University; Barzilai Medical Center; Hebrew University of
   Jerusalem; Hadassah University Medical Center; Clalit Health Services;
   Tel Aviv University; Sackler Faculty of Medicine
RP Kaiserman, I (通讯作者)，Barzilai Govt Hosp, Dept Ophthalmol, IL-78306 Ashqelon, Israel.
EM Igor@DrKaiserman.com
OI Kaiserman, Igor/0000-0003-0130-8819
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Chowdhury T, 2002, EYE, V16, P689, DOI 10.1038/sj.eye.6700205
   Cimbalas Andrius, 2003, Medicina (Kaunas), V39, P1237
   COX DR, 1972, J R STAT SOC B, V34, P187
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   GJESSING HARALD G. A., 1953, ACTA OPHTHALMOL, V31, P401
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   LANUM J, 1978, SURV OPHTHALMOL, V22, P221, DOI 10.1016/0039-6257(78)90070-X
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   LIU IY, 1989, AM J PUBLIC HEALTH, V79, P765, DOI 10.2105/AJPH.79.6.765
   MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   PHAM TQ, IN PRESS EYE
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   Rennert G, 2001, ISR MED ASSOC J, V3, P404
   SPERDUTO RD, 1981, ARCH OPHTHALMOL-CHIC, V99, P1004
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Van Der Hoeve J, 1920, AM J OPHTHALMOL, V3, P178
   Wachter A, 2004, OPHTHALMOLOGE, V101, P50, DOI 10.1007/s00347-003-0868-1
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   YOUNG RW, 1994, OPTOMETRY VISION SCI, V71, P125, DOI 10.1097/00006324-199402000-00013
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
NR 33
TC 31
Z9 33
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2007
VL 114
IS 2
BP 278
EP 282
DI 10.1016/j.ophtha.2006.10.019
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 131CC
UT WOS:000243844600013
PM 17270677
DA 2022-11-30
ER

PT J
AU Pinelli, R
   Biagioni, F
   Limanaqi, F
   Bertelli, M
   Scaffidi, E
   Polzella, M
   Busceti, CL
   Fornai, F
AF Pinelli, Roberto
   Biagioni, Francesca
   Limanaqi, Fiona
   Bertelli, Miorica
   Scaffidi, Elena
   Polzella, Maico
   Busceti, Carla Letizia
   Fornai, Francesco
TI A Re-Appraisal of Pathogenic Mechanisms Bridging Wet and Dry Age-Related
   Macular Degeneration Leads to Reconsider a Role for Phytochemicals
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE autophagy; proteasome; immunoproteasome; oxidative stress; inflammation;
   retinal pigment epithelium; retinopathy; lutein; resveratrol
ID RETINAL-PIGMENT EPITHELIUM; GLYCATION END-PRODUCTS; PHOTORECEPTOR OUTER
   SEGMENTS; OXIDATIVE STRESS; UP-REGULATION; RPE CELLS; SYMPATHETIC
   NEUROTRANSMISSION; MITOCHONDRIAL DYSFUNCTION; LUTEIN SUPPLEMENTATION;
   INFLAMMATORY MARKERS
AB Which pathogenic mechanisms underlie age-related macular degeneration (AMD)? Are they different for dry and wet variants, or do they stem from common metabolic alterations? Where shall we look for altered metabolism? Is it the inner choroid, or is it rather the choroid-retinal border? Again, since cell-clearing pathways are crucial to degrade altered proteins, which metabolic system is likely to be the most implicated, and in which cell type? Here we describe the unique clearing activity of the retinal pigment epithelium (RPE) and the relevant role of its autophagy machinery in removing altered debris, thus centering the RPE in the pathogenesis of AMD. The cell-clearing systems within the RPE may act as a kernel to regulate the redox homeostasis and the traffic of multiple proteins and organelles toward either the choroid border or the outer segments of photoreceptors. This is expected to cope with the polarity of various domains within RPE cells, with each one owning a specific metabolic activity. A defective clearance machinery may trigger unconventional solutions to avoid intracellular substrates' accumulation through unconventional secretions. These components may be deposited between the RPE and Bruch's membrane, thus generating the drusen, which remains the classic hallmark of AMD. These deposits may rather represent a witness of an abnormal RPE metabolism than a real pathogenic component. The empowerment of cell clearance, antioxidant, anti-inflammatory, and anti-angiogenic activity of the RPE by specific phytochemicals is here discussed.
C1 [Pinelli, Roberto; Bertelli, Miorica; Scaffidi, Elena] Switzerland Eye Res Inst, SERI, Riva Paradiso 2, CH-6900 Lugano, Switzerland.
   [Biagioni, Francesca; Busceti, Carla Letizia; Fornai, Francesco] IRCCS Neuromed, Via Atinense 18, I-86077 Pozzilli, Italy.
   [Limanaqi, Fiona; Fornai, Francesco] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Via Roma 55, I-56126 Pisa, Italy.
   [Polzella, Maico] Aliveda Labs, Viale Karol Wojtyla 19, I-56042 Pisa, Italy.
C3 IRCCS Neuromed; University of Pisa
RP Fornai, F (通讯作者)，IRCCS Neuromed, Via Atinense 18, I-86077 Pozzilli, Italy.; Fornai, F (通讯作者)，Univ Pisa, Dept Translat Res & New Technol Med & Surg, Via Roma 55, I-56126 Pisa, Italy.
EM pinelli@seri-lugano.ch; francesca.biagioni@neuromed.it;
   f.limanaqi@studenti.unipi.it; medicale@seri-lugano.ch;
   relazioniesterne@seri-lugano.ch; maico@aliveda.com;
   carla.busceti@neuromed.it; francesco.fornai@neuromed.it
RI Polzella, Maico/ABF-8232-2020; Limanaqi, Fiona/AAA-2080-2022; Biagioni,
   Francesca/G-7979-2011
OI Limanaqi, Fiona/0000-0003-0185-2099; FORNAI,
   FRANCESCO/0000-0002-3883-5084; Biagioni, Francesca/0000-0003-3566-4889
FU Ministero della Salute (Ricerca Corrente 2020)
FX This research was funded by Ministero della Salute (Ricerca Corrente
   2020).
CR Abu-Amero KK, 2016, NUTRIENTS, V8, DOI 10.3390/nu8040200
   Akeo K, 2000, PIGM CELL RES, V13, P80, DOI 10.1034/j.1600-0749.2000.130206.x
   Alaimo A, 2020, ARCH TOXICOL, V94, P553, DOI 10.1007/s00204-019-02637-w
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Aranguiz-Urroz P, 2011, BBA-MOL BASIS DIS, V1812, P23, DOI 10.1016/j.bbadis.2010.07.003
   Arunkumar R, 2020, BBA-MOL CELL BIOL L, V1865, DOI 10.1016/j.bbalip.2020.158617
   Atienzar-Aroca S, 2018, J CELL MOL MED, V22, P5244, DOI 10.1111/jcmm.13730
   Barroso-Chinea P, 2020, AUTOPHAGY, V16, P1279, DOI 10.1080/15548627.2019.1668606
   Basler M, 2013, CURR OPIN IMMUNOL, V25, P74, DOI 10.1016/j.coi.2012.11.004
   Bazan NG, 2009, J LIPID RES, V50, pS400, DOI 10.1194/jlr.R800068-JLR200
   Beatty S, 2013, OPHTHALMOLOGY, V120, P600, DOI 10.1016/j.ophtha.2012.08.040
   Bergen AA, 2019, PROG RETIN EYE RES, V70, P55, DOI 10.1016/j.preteyeres.2018.12.003
   Bian QN, 2012, FREE RADICAL BIO MED, V53, P1298, DOI 10.1016/j.freeradbiomed.2012.06.024
   Blasiak J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010210
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Bonilha VL, 2008, CLIN OPHTHALMOL, V2, P413
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Bulteau AL, 2001, J BIOL CHEM, V276, P45662, DOI 10.1074/jbc.M105374200
   Bungau S, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9783429
   Burke JM, 2007, PHOTOCHEM PHOTOBIOL, V83, P920, DOI 10.1111/j.1751-1097.2007.00081.x
   Buscemi S, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091321
   Cai JJ, 2019, EXP CELL RES, V374, P231, DOI 10.1016/j.yexcr.2018.11.028
   Cebrian C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4633
   Chen C, 2019, REDOX BIOL, V20, P390, DOI 10.1016/j.redox.2018.10.021
   Chen ML, 2013, AUTOPHAGY, V9, P2033, DOI 10.4161/auto.26336
   Chen Y, 2013, J BIOL CHEM, V288, P7506, DOI 10.1074/jbc.M112.439935
   Cheng SY, 2020, P NATL ACAD SCI USA, V117, P13094, DOI 10.1073/pnas.2000339117
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Cho MJ, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0327-y
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   D'Agostino M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53226-x
   Damek-Poprawa M, 2009, J BIOL CHEM, V284, P10877, DOI 10.1074/jbc.M808857200
   de Carvalho JER, 2013, INVEST OPHTH VIS SCI, V54, P6489, DOI 10.1167/iovs.13-12374
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Dejneka NS, 2004, MOL VIS, V10, P964
   Du LG, 2019, DRUG DES DEV THER, V13, P747, DOI 10.2147/DDDT.S179894
   Duran J, 2014, HUM MOL GENET, V23, P3147, DOI 10.1093/hmg/ddu024
   Espinosa-Garcia C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21113740
   Ethen CM, 2007, FEBS LETT, V581, P885, DOI 10.1016/j.febslet.2007.01.061
   Farjood F, 2017, MOL VIS, V23, P431
   FEENEYBURNS L, 1979, DEV BIOL, V72, P73, DOI 10.1016/0012-1606(79)90099-X
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Ferguson TA, 2014, AUTOPHAGY, V10, P165, DOI 10.4161/auto.26735
   Fernandes AF, 2008, J BIOL CHEM, V283, P20745, DOI 10.1074/jbc.M800268200
   Fernandez-Godino R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28143-0
   Ferrington DA, 2008, J NEUROCHEM, V106, P158, DOI 10.1111/j.1471-4159.2008.05345.x
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Forte R, 2011, J OCUL PHARMACOL TH, V27, P109, DOI 10.1089/jop.2010.0159
   Frost LS, 2015, MOL NEUROBIOL, V52, P1135, DOI 10.1007/s12035-014-8920-5
   Frost LS, 2013, VISUAL NEUROSCI, V30, P55, DOI 10.1017/S0952523813000096
   Fursova A Zh, 2005, Adv Gerontol, V16, P76
   Gass J D, 1972, Trans Am Ophthalmol Soc, V70, P409
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gesi M, 2001, PHARMACOL TOXICOL, V89, P217, DOI 10.1034/j.1600-0773.2001.d01-151.x
   Girmens JF, 2012, INTRACTABLE RARE DIS, V1, P103, DOI 10.5582/irdr.2012.v1.3.103
   Glenn JV, 2007, FASEB J, V21, P3542, DOI 10.1096/fj.06-7896com
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Gouras P, 2011, EXP EYE RES, V93, P937, DOI 10.1016/j.exer.2011.10.011
   Goyal V, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.5.10
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Grimm S, 2012, BIOCHEM J, V448, P127, DOI 10.1042/BJ20120298
   Guha S, 2014, EXP EYE RES, V126, P68, DOI 10.1016/j.exer.2014.05.013
   Guha S, 2014, ADV EXP MED BIOL, V801, P105, DOI 10.1007/978-1-4614-3209-8_14
   Guixe-Muntet S, 2017, J HEPATOL, V66, P86, DOI 10.1016/j.jhep.2016.07.051
   Guo D, 2018, NEUROREPORT, V29, P368, DOI 10.1097/WNR.0000000000000975
   Gurusamy N, 2010, CARDIOVASC RES, V86, P103, DOI 10.1093/cvr/cvp384
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Harris J, 2011, J BIOL CHEM, V286, P9587, DOI 10.1074/jbc.M110.202911
   Hastings TG, 1996, P NATL ACAD SCI USA, V93, P1956, DOI 10.1073/pnas.93.5.1956
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Hu DN, 2008, PHOTOCHEM PHOTOBIOL, V84, P639, DOI 10.1111/j.1751-1097.2008.00316.x
   Hu ZY, 2017, J BIOL CHEM, V292, P18062, DOI 10.1074/jbc.M116.764795
   Huang FC, 2017, BMC PHARMACOL TOXICO, V18, DOI 10.1186/s40360-016-0109-2
   Huang X, 2018, EXP CELL RES, V371, P269, DOI 10.1016/j.yexcr.2018.08.021
   Hussong SA, 2011, INVEST OPHTH VIS SCI, V52, P714, DOI 10.1167/iovs.10-6032
   Hussong SA, 2010, J NEUROCHEM, V113, P1481, DOI 10.1111/j.1471-4159.2010.06688.x
   Isidoro C, 2009, CURR TOP MED CHEM, V9, P869
   Izumi-Nagai K, 2007, ARTERIOSCL THROM VAS, V27, P2555, DOI 10.1161/ATVBAHA.107.151431
   Jaadane I, 2017, J CELL MOL MED, V21, P3453, DOI 10.1111/jcmm.13255
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jin XH, 2006, INVEST OPHTH VIS SCI, V47, P2562, DOI 10.1167/iovs.05-1429
   JOHNSON LV, 2003, INVEST OPHTH VIS S2, V44
   Johnston-Carey HK, 2016, CRIT REV BIOCHEM MOL, V51, P268, DOI 10.3109/10409238.2016.1172554
   Josifovska N, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030813
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kaarniranta K, 2019, BIOCHIMIE, V159, P49, DOI 10.1016/j.biochi.2018.07.010
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kapphahn RJ, 2007, EXP EYE RES, V84, P646, DOI 10.1016/j.exer.2006.12.002
   Karim MR, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231212
   Karlsen A, 2010, EUR J NUTR, V49, P345, DOI 10.1007/s00394-010-0092-0
   Kaur G, 2018, P NATL ACAD SCI USA, V115, P9014, DOI 10.1073/pnas.1805039115
   Kawa MP, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/483960
   Kellner U, 2008, DOC OPHTHALMOL, V116, P119, DOI 10.1007/s10633-007-9105-6
   Khoo HE, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8040085
   Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012
   Kim YH, 2016, PLATELETS, V27, P735, DOI 10.1080/09537104.2016.1190005
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Kolehmainen M, 2012, MOL NUTR FOOD RES, V56, P1501, DOI 10.1002/mnfr.201200195
   Koskela A, 2016, NUTRIENTS, V8, DOI 10.3390/nu8050284
   Kozhevnikova OS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194804
   Kozlowski MR, 2012, MED HYPOTHESES, V78, P505, DOI 10.1016/j.mehy.2012.01.018
   Krohne TU, 2010, EXP EYE RES, V90, P261, DOI 10.1016/j.exer.2009.10.014
   Kurihara T, 2006, INVEST OPHTH VIS SCI, V47, P5545, DOI 10.1167/iovs.06-0478
   Lancon A, 2016, MOLECULES, V21, DOI 10.3390/molecules21030304
   Lavine JA, 2017, INVEST OPHTH VIS SCI, V58, P299, DOI 10.1167/iovs.16-20204
   Lazzeri G, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/6124745
   Li R, 2019, INT J OPHTHALMOL-CHI, V12, P557, DOI 10.18240/ijo.2019.04.05
   Li Y, 2008, EXP GERONTOL, V43, P1114, DOI 10.1016/j.exger.2008.08.052
   Limanaqi F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21083028
   Limanaqi F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133274
   Limanaqi F, 2019, NEUROSCI BIOBEHAV R, V102, P308, DOI 10.1016/j.neubiorev.2019.05.008
   Limanaqi F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092197
   Limanaqi F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00628
   Limanaqi F, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/4982453
   Lin T, 2013, CYTOKINE, V62, P369, DOI 10.1016/j.cyto.2013.03.027
   Lin YF, 2017, NANOMEDICINE-UK, V12, P2741, DOI 10.2217/nnm-2017-0256
   Liu J, 2016, SCI REP-UK, V6, DOI 10.1038/srep20639
   Liu ZZ, 2014, ADV EXP MED BIOL, V801, P237, DOI 10.1007/978-1-4614-3209-8_31
   Loi M, 2016, AUTOPHAGY, V12, P1681, DOI 10.1080/15548627.2016.1203488
   Luo H, 2014, INT J FOOD SCI NUTR, V65, P594, DOI 10.3109/09637486.2014.886184
   Manfredi LH, 2019, AM J PHYSIOL-CELL PH, V317, pC674, DOI 10.1152/ajpcell.00516.2018
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Matsubara JA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00574
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Ming M, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-53
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Moshetova L K, 2015, Vestn Oftalmol, V131, P34, DOI 10.17116/oftalma2015131334-44
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Munia I, 2020, NUTRIENTS, V12, DOI 10.3390/nu12030879
   Muniz-Feliciano L, 2017, AUTOPHAGY, V13, P2072, DOI 10.1080/15548627.2017.1380124
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   Nagineni CN, 2014, AGING DIS, V5, P88, DOI 10.14366/AD.2014.050088
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   Nakata K, 2005, EXP EYE RES, V80, P821, DOI 10.1016/j.exer.2004.12.011
   Natale G, 2013, EUR J HISTOCHEM, V57, P31, DOI 10.4081/ejh.2013.e5
   Naylor A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010211
   Neal SE, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.4.32
   Ogawa K, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-120
   Ohbayashi N, 2012, J CELL SCI, V125, P1508, DOI 10.1242/jcs.094185
   Osada H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178627
   Ozawa Y, 2012, CURR PHARM DESIGN, V18, P51, DOI 10.2174/138161212798919101
   Ozawa Y, 2008, J BIOL CHEM, V283, P24561, DOI 10.1074/jbc.M802238200
   Pagan-Mercado G, 2019, ADV EXP MED BIOL, V1185, P445, DOI 10.1007/978-3-030-27378-1_73
   Parisi V, 2008, OPHTHALMOLOGY, V115, P324, DOI 10.1016/j.ophtha.2007.05.029
   Park TK, 2017, MOL THER-NUCL ACIDS, V8, P26, DOI 10.1016/j.omtn.2017.05.012
   Parravano M, 2019, ADV THER, V36, P2493, DOI 10.1007/s12325-019-01016-2
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Piippo N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25123-2
   Pinelli R, 2020, ARCH ITAL BIOL, V158, P24, DOI 10.12871/00039829202013
   Pla A, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.46
   Qi XP, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040905
   Qiao ZH, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420-020-0266-3
   Qin SF, 2008, J BIOL CHEM, V283, P6744, DOI 10.1074/jbc.M708848200
   Qureshi N, 2012, BBA-MOL CELL RES, V1823, P2087, DOI 10.1016/j.bbamcr.2012.06.016
   Reme CE, 1999, INVEST OPHTH VIS SCI, V40, P2398
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Richer S, 2014, NUTRIENTS, V6, P4404, DOI 10.3390/nu6104404
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Riva A, 2017, EUR REV MED PHARMACO, V21, P2518
   Rowan S, 2018, BBA-MOL BASIS DIS, V1864, P3631, DOI 10.1016/j.bbadis.2018.08.036
   Rozanowski B, 2008, INVEST OPHTH VIS SCI, V49, P2838, DOI 10.1167/iovs.08-1700
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Ryskalin L, 2018, CURR PROTEIN PEPT SC, V19, P598, DOI 10.2174/1389203718666171117110028
   Saddala MS, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8060147
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Saito Y, 2020, FREE RADICAL BIO MED, V152, P235, DOI 10.1016/j.freeradbiomed.2020.03.012
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sato S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21325-w
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Schuld NJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126768
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Shah N, 2018, BBA-MOL BASIS DIS, V1864, P2610, DOI 10.1016/j.bbadis.2018.04.016
   Shang P, 2017, AGING CELL, V16, P349, DOI 10.1111/acel.12561
   Sheu SJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174736
   Shi CS, 2012, NAT IMMUNOL, V13, P255, DOI 10.1038/ni.2215
   Simon JD, 2008, J PHYS CHEM B, V112, P13201, DOI 10.1021/jp804248h
   Singh R, 2009, NATURE, V458, P1131, DOI 10.1038/nature07976
   Sinha D, 2016, EXP EYE RES, V144, P46, DOI 10.1016/j.exer.2015.08.018
   Smith CP, 2007, EXP EYE RES, V84, P75, DOI 10.1016/j.exer.2006.08.018
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   Sreekumar PG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012578
   Stahl A, 2008, FEBS LETT, V582, P3097, DOI 10.1016/j.febslet.2008.08.005
   Steinle JJ, 2007, EXP EYE RES, V84, P118, DOI 10.1016/j.exer.2006.09.006
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tao Y, 2016, INT J OPHTHALMOL-CHI, V9, P153, DOI 10.18240/ijo.2016.01.25
   Thiele S, 2021, BRIT J OPHTHALMOL, V105, P239, DOI 10.1136/bjophthalmol-2020-316004
   Thompson DA, 2003, PROG RETIN EYE RES, V22, P683, DOI 10.1016/S1350-9462(03)00051-X
   Tian J, 2005, P NATL ACAD SCI USA, V102, P11846, DOI 10.1073/pnas.0504759102
   Tiao MM, 2018, LIPIDS HEALTH DIS, V17, DOI 10.1186/s12944-018-0824-3
   Valapala M, 2014, AUTOPHAGY, V10, P480, DOI 10.4161/auto.27292
   Van Laar VS, 2009, NEUROBIOL DIS, V34, P487, DOI 10.1016/j.nbd.2009.03.004
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Viry E, 2014, AUTOPHAGY, V10, P173, DOI 10.4161/auto.26924
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Wang AL, 2009, AUTOPHAGY, V5, P563, DOI 10.4161/auto.5.4.8163
   Wang B, 2014, J CELL MOL MED, V18, P1599, DOI 10.1111/jcmm.12312
   Wang DM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051540
   Wang SB, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3632169
   Wang S, 2020, MOL THER, V28, P279, DOI 10.1016/j.ymthe.2019.09.025
   Wang S, 2018, REDOX BIOL, V16, P129, DOI 10.1016/j.redox.2018.02.022
   Wang Y, 2015, MOLECULES, V20, P22395, DOI 10.3390/molecules201219785
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
   Yang QB, 2019, INFLAMMOPHARMACOLOGY, V27, P47, DOI 10.1007/s10787-018-00555-4
   Yao JY, 2015, AUTOPHAGY, V11, P939, DOI 10.1080/15548627.2015.1041699
   Yao JY, 2014, INVEST OPHTH VIS SCI, V55, P3237, DOI 10.1167/iovs.13-13336
   Yu YC, 2017, FREE RADICAL BIO MED, V112, P397, DOI 10.1016/j.freeradbiomed.2017.08.012
   Yun YS, 2016, MOL CELL, V61, P625, DOI 10.1016/j.molcel.2016.01.013
   Zamiri P, 2004, INVEST OPHTH VIS SCI, V45, P177, DOI 10.1167/iovs.03-0211
   Zhang J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.330
   Zhang M, 2013, SCIENCE, V340, P559, DOI 10.1126/science.1234740
   Zhang XM, 2019, ARCH BIOCHEM BIOPHYS, V672, DOI 10.1016/j.abb.2019.07.026
   Zhang Y, 2017, MOL VIS, V23, P228
   Zhang YZ, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/9420704
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhao YH, 2020, FRONT BIOSCI-LANDMRK, V25, P1913, DOI 10.2741/4885
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
   Zigler JS, 2011, J CELL SCI, V124, P523, DOI 10.1242/jcs.078790
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 230
TC 6
Z9 7
U1 1
U2 8
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2020
VL 21
IS 15
AR 5563
DI 10.3390/ijms21155563
PG 28
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA MZ3YR
UT WOS:000559058800001
PM 32756487
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Yun, C
   Oh, J
   Ahn, J
   Hwang, SY
   Lee, B
   Kim, SW
   Huh, K
AF Yun, Cheolmin
   Oh, Jaeryung
   Ahn, Jaemoon
   Hwang, Soon-Young
   Lee, Boram
   Kim, Seong-woo
   Huh, Kuhl
TI Comparison of intravitreal aflibercept and ranibizumab injections on
   subfoveal and peripapillary choroidal thickness in eyes with neovascular
   age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Aflibercept; Ranibizumab; Age-related macular degeneration; Choroidal
   thickness; Peripapillary choroidal thickness
ID ENDOTHELIAL GROWTH-FACTOR; OPTICAL COHERENCE TOMOGRAPHY; GEOGRAPHIC
   ATROPHY; FACTOR THERAPY; VEGF TRAP; VASCULOPATHY; DISEASE; BINDING;
   TYPE-3; HEALTH
AB We aimed to compare changes in subfoveal and peripapillary choroidal thickness (CT) after intravitreal aflibercept or ranibizumab injections for neovascular age-related macular degeneration (AMD).
   Medical records of 54 treatment-na < ve, consecutive patients (54 eyes) who were diagnosed with neovascular AMD and received three monthly injections of aflibercept (21 eyes) or ranibizumab (33 eyes) were reviewed. Subfoveal and peripapillary CT were measured with images obtained using spectral domain optical coherence tomography at baseline and at three months.
   Subfoveal CT decreased from 232.2 +/- 94.4 mu m at baseline to 207.1 +/- 89.3 mu m at three months in the aflibercept group (p < 0.001) and from 231.5 +/- 102.9 mu m to 220.0 +/- 98.0 mu m in the ranibizumab group (p = 0.006). The reduction was greater in the aflibercept group than in the ranibizumab group (p = 0.024). Peripapillary CT decreased from 157.2 +/- 62.2 mu m at baseline to 147.4 +/- 62.2 mu m at three months in the aflibercept group (p < 0.001). However, the change in peripapillary CT from 154.9 +/- 46.5 mu m at baseline to 152.3 +/- 50.0 mu m at three months was not significant in the ranibizumab group (p = 0.123).
   Intravitreally injected aflibercept significantly decreased subfoveal CT more than ranibizumab. Choroidal thinning after aflibercept injection was not limited to the subfoveal area, but extended beyond the macula as well.
C1 [Yun, Cheolmin; Oh, Jaeryung; Ahn, Jaemoon; Lee, Boram; Kim, Seong-woo; Huh, Kuhl] Korea Univ, Coll Med, Dept Ophthalmol, 126-1 Anam Dong 5 Ga, Seoul 136705, South Korea.
   [Hwang, Soon-Young] Korea Univ, Coll Med, Dept Biostat, Seoul, South Korea.
C3 Korea University; Korea University Medicine (KU Medicine); Korea
   University; Korea University Medicine (KU Medicine)
RP Oh, J (通讯作者)，Korea Univ, Coll Med, Dept Ophthalmol, 126-1 Anam Dong 5 Ga, Seoul 136705, South Korea.
EM ojr4991@yahoo.co.kr
RI Oh, Jaeryung/ABD-3090-2021
OI Oh, Jaeryung/0000-0002-1036-6562
FU Korea University [K1421461]
FX Korea University provided financial support in the form of research
   grant (grant number K1421461). The sponsor had no role in the design or
   conduct of this research.
CR Adhi M, 2013, CURR OPIN OPHTHALMOL, V24, P213, DOI 10.1097/ICU.0b013e32835f8bf8
   Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Branchini L, 2013, JAMA OPHTHALMOL, V131, P693, DOI 10.1001/jamaophthalmol.2013.692
   Cho HJ, 2016, GRAEF ARCH CLIN EXP, V254, P23, DOI 10.1007/s00417-015-2993-3
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Dell'Omo R, 2012, AM J OPHTHALMOL, V153, P155, DOI 10.1016/j.ajo.2011.06.001
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Fujiwara A, 2012, JPN J OPHTHALMOL, V56, P230, DOI 10.1007/s10384-012-0128-5
   Gharbiya M, 2015, J OCUL PHARMACOL TH, V31, P357, DOI 10.1089/jop.2014.0160
   Griffith JF, 2015, CLIN OPHTHALMOL, V9, P1275, DOI 10.2147/OPTH.S85851
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Gupta P, 2016, AM J OPHTHALMOL, V161, P4, DOI 10.1016/j.ajo.2015.09.018
   Hata M, 2014, INVEST OPHTH VIS SCI, V55, P7874, DOI 10.1167/iovs.14-14610
   Hayreh SS, 2004, INVEST OPHTH VIS SCI, V45, P749, DOI 10.1167/iovs.03-0469
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Huang WB, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-23
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Kawashima Y, 2015, GRAEF ARCH CLIN EXP, V253, P1471, DOI 10.1007/s00417-014-2838-5
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Laviers H, 2014, GRAEF ARCH CLIN EXP, V252, P1871, DOI 10.1007/s00417-014-2840-y
   Lengyel I, 2015, OPHTHALMOLOGY, V122, P1340, DOI 10.1016/j.ophtha.2015.03.005
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Mazaraki K, 2015, BRIT J OPHTHALMOL, V99, P1341, DOI 10.1136/bjophthalmol-2015-306636
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Oh Jaeryung, 2013, Korean J Ophthalmol, V27, P172, DOI 10.3341/kjo.2013.27.3.172
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Papadopoulou DN, 2009, OPHTHALMOLOGY, V116, P1755, DOI 10.1016/j.ophtha.2009.03.017
   PERKOVICH BT, 1990, RETINA-J RET VIT DIS, V10, P18, DOI 10.1097/00006982-199001010-00003
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Pinheiro-Costa J, 2015, OPHTHALMOLOGICA, V233, P155, DOI 10.1159/000381221
   Pournaras CJ, 2008, PROG RETIN EYE RES, V27, P284, DOI 10.1016/j.preteyeres.2008.02.002
   Razavi S, 2015, AM J OPHTHALMOL, V160, P1006, DOI 10.1016/j.ajo.2015.08.009
   Sacu S, 2011, INVEST OPHTH VIS SCI, V52, P3046, DOI 10.1167/iovs.10-5842
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MW, 2012, CLIN OPHTHALMOL, V6, P1175, DOI 10.2147/OPTH.S33372
   Vujosevic S, 2012, RETINA-J RET VIT DIS, V32, P1781, DOI 10.1097/IAE.0b013e31825db73d
   Wei WB, 2013, OPHTHALMOLOGY, V120, P175, DOI 10.1016/j.ophtha.2012.07.048
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Yiu G, 2014, JAMA OPHTHALMOL, V132, P174, DOI 10.1001/jamaophthalmol.2013.7288
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
   Yun C, 2016, GRAEF ARCH CLIN EXP, V254, P427, DOI 10.1007/s00417-015-3054-7
   Yun C, 2015, RETINA-J RET VIT DIS, V35, P1860, DOI 10.1097/IAE.0000000000000539
   Zehetner C, 2015, ACTA OPHTHALMOL, V93, pE154, DOI 10.1111/aos.12604
NR 56
TC 25
Z9 25
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD SEP
PY 2016
VL 254
IS 9
BP 1693
EP 1702
DI 10.1007/s00417-015-3260-3
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DU2HQ
UT WOS:000382032300004
PM 26781585
DA 2022-11-30
ER

PT J
AU Carneiro, AM
   Costa, R
   Falcao, MS
   Barthelmes, D
   Mendonca, LS
   Fonseca, SL
   Goncalves, R
   Goncalves, C
   Falcao-Reis, FM
   Soares, R
AF Carneiro, Angela M.
   Costa, Raquel
   Falcao, Manuel S.
   Barthelmes, Daniel
   Mendonca, Luis S.
   Fonseca, Sofia L.
   Goncalves, Rita
   Goncalves, Conceicao
   Falcao-Reis, Fernando M.
   Soares, Raquel
TI Vascular endothelial growth factor plasma levels before and after
   treatment of neovascular age-related macular degeneration with
   bevacizumab or ranibizumab
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE AMD; anti-VEGF therapy; Avastin (R); Lucentis (R); VEGF; wet AMD
AB Purpose: To evaluate the changes of vascular endothelial growth factor (VEGF) plasma levels after intravitreal injections of ranibizumab or bevacizumab in patients with exudative age-related macular degeneration (AMD).
   Methods: Forty-three patients with exudative AMD and 19 age-and sex-matched control patients without chorioretinal diseases were studied. Nineteen patients were treated with intravitreal ranibizumab 0.5 mg, 24 with intravitreal bevacizumab 1.25 mg. Blood samples were collected just before the first injection, and 28 days after three initial consecutive injections performed in 4-weekly intervals (loading dose). Concentration of VEGF in the plasma was measured by ELISA.
   Results: At baseline, the median VEGF concentrations in controls were 180.97 pg/ml, in the bevacizumab group 189.72 pg/ml and in the ranibizumab group 191.36 pg/ml. VEGF plasma concentrations in patients with wet AMD were comparable to controls (p = 0.225). Twenty-eight days after the third injection, a significant reduction of 42% in the median VEGF plasma levels was found in bevacizumab-treated patients (109.97 pg/ml; p = 0.0002) but not in ranibizumab-treated patients (189.97 pg/ml; p = 0.198) where a reduction of 0.7% in the median value was found.
   Conclusions: Intravitreal bevacizumab significantly reduced VEGF plasma levels until 28 days after intravitreal injection in patients with exudative AMD. Ranibizumab did not achieve a significant plasma VEGF reduction at the same time-point. These findings alert to the potential systemic safety differences between the two drugs after intravitreal administration.
C1 [Carneiro, Angela M.; Falcao, Manuel S.; Falcao-Reis, Fernando M.] Univ Porto, Dept Ophthalmol, Fac Med, Hosp Sao Joao, P-4200319 Oporto, Portugal.
   [Costa, Raquel] Univ Porto, Fac Med, Dept Biochem FCT U38, P-4200319 Oporto, Portugal.
   [Barthelmes, Daniel] Univ Sydney, Save Sight Inst, Sydney, NSW 2006, Australia.
   [Goncalves, Conceicao] Univ Porto, Fac Med, Lab Nobre, P-4200319 Oporto, Portugal.
C3 Sao Joao Hospital; Universidade do Porto; Universidade do Porto;
   University of Sydney; Universidade do Porto
RP Carneiro, AM (通讯作者)，Univ Porto, Dept Ophthalmol, Fac Med, Hosp Sao Joao, Al Prof Hernani Monteiro, P-4200319 Oporto, Portugal.
EM angelacarneiro@netcabo.pt
RI Soares, Raquel/L-2349-2013; Costa, Raquel/C-2045-2012;
   Falcao/AAQ-8509-2020; Carneiro, Angela/N-9680-2013
OI Soares, Raquel/0000-0002-9157-5541; Falcao/0000-0003-4718-0910;
   Carneiro, Angela/0000-0002-3370-7243; Fonseca,
   Sofia/0000-0001-5365-6220; Costa, Raquel/0000-0002-9245-4565;
   Falcao-Reis, Fernando/0000-0002-5995-9430
FU Sociedade Portuguesa de Oftalmologia; Hospital de Sao Joao
FX We thank the technicians Hugo Monteiro, Paulo Rocha and Fatima Matos for
   their dedication and work. Grants from Sociedade Portuguesa de
   Oftalmologia and Hospital de Sao Joao.
CR Ahn JK, 2009, AM J OPHTHALMOL, V148, P718, DOI 10.1016/j.ajo.2009.06.012
   Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bashshur ZF, 2009, AM J OPHTHALMOL, V148, P59, DOI 10.1016/j.ajo.2009.02.006
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Carneiro A, 2009, EXP EYE RES, V88, P522, DOI 10.1016/j.exer.2008.11.011
   Carneiro AM, 2011, OPHTHALMOLOGICA, V225, P211, DOI 10.1159/000323943
   Chan WM, 2008, RETINA-J RET VIT DIS, V28, P1308, DOI 10.1097/IAE.0b013e31818358b2
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Csaky K, 2009, AM J OPHTHALMOL, V148, P647, DOI 10.1016/j.ajo.2009.06.014
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Foran S, 2003, OPHTHALMIC EPIDEMIOL, V10, P215, DOI 10.1076/opep.10.4.215.15906
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Labianca R, 2010, CRIT REV ONCOL HEMAT, V74, P106, DOI 10.1016/j.critrevonc.2010.01.010
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   Matsuyama K, 2009, JPN J OPHTHALMOL, V53, P243, DOI 10.1007/s10384-008-0645-4
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Ranpura V, 2010, ACTA ONCOL, V49, P287, DOI 10.3109/02841860903524396
   Roh MI, 2010, GRAEF ARCH CLIN EXP, V248, P635, DOI 10.1007/s00417-009-1254-8
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sawada O, 2007, ARCH OPHTHALMOL-CHIC, V125, P1363, DOI 10.1001/archopht.125.10.1363
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086
   Schmucker C, 2010, CURR OPIN OPHTHALMOL, V21, P218, DOI 10.1097/ICU.0b013e3283386783
   Triano LR, 2010, DRUGS, V70, P167, DOI 10.2165/11532200-000000000-00000
   Tsai DC, 2006, OPHTHALMOLOGICA, V220, P246, DOI 10.1159/000093079
   Valachis A, 2010, BREAST CANCER RES TR, V122, P1, DOI 10.1007/s10549-009-0727-0
   Zachary I, 2000, ARTERIOSCL THROM VAS, V20, P1512, DOI 10.1161/01.ATV.20.6.1512
NR 48
TC 107
Z9 110
U1 1
U2 12
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD FEB
PY 2012
VL 90
IS 1
BP E25
EP E30
DI 10.1111/j.1755-3768.2011.02240.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 883HK
UT WOS:000299624600005
PM 21958440
DA 2022-11-30
ER

PT J
AU Beer, PM
   Marx, JL
   Yoser, SL
AF Beer, Paul M.
   Marx, Jeffrey L.
   Yoser, Seth L.
CA ADD-V Study Grp
TI Effect of adjuncnave diclofenac with verteporfin therapy to treat
   choroidal neovascularization due to age-related macular degeneration -
   Phase II study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   diclofenac sodium; verteporfin therapy
ID UNIQUE NONSTEROIDAL PRODRUG; INDUCED OCULAR INFLAMMATION; PHOTODYNAMIC
   THERAPY; INTRAVITREAL TRIAMCINOLONE; POTENTIAL UTILITY; NEPAFENAC;
   ACETONIDE
AB Background: To determine short-term effects of topical diclofenac administered in conjunction with verteporfin therapy for predominantly classic subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD).
   Methods: Randomized, multicenter (14), prospective, placebo-controlled, double-masked clinical trial. Patients (n = 61) were randomly assigned to treatment with diclofenac sodium ophthalmic solution 0.1% or placebo and followed for 12 weeks. Patients instilled diclofenac or placebo two drops four times daily, 2-4 days before verteporfin treatment until 2 weeks after treatment, then two drops twice daily for 10 weeks. This exploratory study was not powered to detect differences between treatment groups. Statistical analyses were conducted solely to aid interpretation of results.
   Results: In diclofenac-treated eyes, mean changes in visual acuity letter score from baseline in the diclofenac and placebo groups were +1.8 letters and -1.0 at week 1 (P = 0.505 between groups). Mean visual acuity letter scores decreased in both groups at all subsequent visits, with a mean change at 12 weeks of -7.4 with diclofenac and -2.6 with placebo (P = 0.213). Percentages of eyes with stable or improved vision (change <= 54 or increase >= 5 letters) were similar in the diclofenac and placebo groups at all study visits. No significant between-group differences in changes from baseline in lesion area, greatest linear dimension (GLD), fluorescein leakage, or retinal thickness were detected.
   Conclusion: In patients with predominantly classic subfoveal CNV due to AMD, administration of topical diclofenac with verteporfin therapy was associated with similar vision outcomes to placebo plus verteporfin therapy.
C1 Novartis Ophthalm Med Affairs, E Hanover, NJ 07936 USA.
C3 Novartis
RP Beer, PM (通讯作者)，Novartis Ophthalm Med Affairs, One Hlth Plaza, Bldg 104, E Hanover, NJ 07936 USA.
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   FLACH AJ, 1992, SURV OPHTHALMOL, V36, P259, DOI 10.1016/0039-6257(92)90095-B
   FLACH AJ, 1991, AM J OPHTHALMOL, V112, P514, DOI 10.1016/S0002-9394(14)76851-5
   Gamache DA, 2000, INFLAMMATION, V24, P357, DOI 10.1023/A:1007049015148
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Hyman L, 1992, AGE RELATED MACULAR, P1
   Ke TL, 2000, INFLAMMATION, V24, P371, DOI 10.1023/A:1007001131987
   KRAFF MC, 1990, ARCH OPHTHALMOL-CHIC, V108, P380, DOI 10.1001/archopht.1990.01070050078035
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Quentin C D, 1989, Fortschr Ophthalmol, V86, P546
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Rho DS, 2003, J CATARACT REFR SURG, V29, P2378, DOI 10.1016/S0886-3350(03)00233-5
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Schmidt-Erfurth U, 2005, OPHTHALMOLOGY, V112, P2061, DOI 10.1016/j.ophtha.2005.09.007
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Takahashi K, 2003, INVEST OPHTH VIS SCI, V44, P409, DOI 10.1167/iovs.02-0346
NR 21
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL-AUG
PY 2007
VL 27
IS 6
BP 693
EP 700
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 189NT
UT WOS:000247996400005
DA 2022-11-30
ER

PT J
AU Holz, FG
   Tadayoni, R
   Beatty, S
   Berger, A
   Cereda, MG
   Hykin, P
   Staurenghi, G
   Wittrup-Jensen, K
   Altemark, A
   Nilsson, J
   Kim, K
   Sivaprasad, S
AF Holz, Frank G.
   Tadayoni, Ramin
   Beatty, Stephen
   Berger, Alan
   Cereda, Matteo Giuseppe
   Hykin, Philip
   Staurenghi, Giovanni
   Wittrup-Jensen, Kim
   Altemark, Andreas
   Nilsson, Jonas
   Kim, Kun
   Sivaprasad, Sobha
TI Key drivers of visual acuity gains in neovascular age-related macular
   degeneration in real life: findings from the AURA study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; RANIBIZUMAB; DISEASE; AMD
AB Background/aims To identify predictive markers for the outcomes of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration (nAMD).
   Methods AURA was a retrospective, observational, multicentre study that monitored the 2-year outcomes following intravitreal ranibizumab treatment in patients with nAMD. Using stepwise regression analysis, we evaluated the association between visual acuity outcomes, baseline characteristics and resource utilisation in order to determine which variables are significantly linked to outcomes in AURA. We also examined the relationship between visual acuity outcomes and number of injections received.
   Results Analyses were performed using data from year 1 (n=1695) and year 2 completers (n=1184). Logistic analysis showed that baseline visual acuity score, age at start of therapy, number of ophthalmoscopies and optical coherence tomography (OCT) (combined) and number of injections (ranibizumab) were significant (p<0.05) prognostic factors for vision maintenance (loss <15 letters) or vision gain (>= 15 letters). Patients who received >7 injections (in 1 year) or >14 injections (over 2 years) gained more letters and demonstrated greater vision maintenance (loss of <15 letters) than patients who received fewer injections. There was a significant (p<0.05) association between number of injections and national reimbursement schemes and OCT.
   Conclusions A number of factors that are predictive of treatment outcomes in a real-life setting were identified. Notably, the decline of treatment benefits may be linked to number of injections and a failure to visit clinicians and receive OCT as required. These findings may be helpful in guiding ophthalmologist treatment decisions under limited time and financial constraints.
C1 [Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Tadayoni, Ramin] Univ Paris 07, Hop Lariboisiere, AP HP, Dept Ophthalmol,Sorbonne Paris Cite, Paris, France.
   [Beatty, Stephen] Inst Eye Surg, Dept Ophthalmol, Waterford, Ireland.
   [Berger, Alan] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada.
   [Berger, Alan] St Michaels Hosp, Toronto, ON, Canada.
   [Cereda, Matteo Giuseppe; Staurenghi, Giovanni] Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Milan, Italy.
   [Hykin, Philip; Sivaprasad, Sobha] Moorfields Eye Hosp, NIHR Biomed Ctr Res Ophthalmol, London, England.
   [Wittrup-Jensen, Kim; Altemark, Andreas] Bayer Pharma AG, Berlin, Germany.
   [Nilsson, Jonas; Kim, Kun] Real World Strategy & Analyt, Mapi Grp, Stockholm, Sweden.
   [Sivaprasad, Sobha] Kings Coll Hosp London, Dept Ophthalmol, London, England.
C3 University of Bonn; Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research
   Universities; Universite Paris Cite; University of Toronto; University
   of Toronto; University Toronto Affiliates; Saint Michaels Hospital
   Toronto; University of Milan; Luigi Sacco Hospital; University of
   London; University College London; Moorfields Eye Hospital NHS
   Foundation Trust; Bayer AG; Bayer Healthcare Pharmaceuticals; King's
   College Hospital NHS Foundation Trust; King's College Hospital
RP Sivaprasad, S (通讯作者)，Kings Coll Hosp London, Denmark Hill, London SE5 9RS, England.
EM senswathi@aol.com
RI Sivaprasad, S./D-6876-2015; Staurenghi, Giovanni/K-4388-2017
OI Sivaprasad, S./0000-0001-8952-0659; Staurenghi,
   Giovanni/0000-0002-2299-5251
FU Bayer HealthCare Pharmaceuticals
FX The study was funded by Bayer HealthCare Pharmaceuticals. The sponsor or
   funding organisation participated in the design and conduct of the
   study, data collection, data management, data analysis, interpretation
   of the data and preparation of manuscript.
CR Ablonczy Z, 2014, FASEB J, V28, P2369, DOI 10.1096/fj.13-248021
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Hariprasad SM, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/690641
   Ho QT, 2007, INT J BIOCHEM CELL B, V39, P1349, DOI 10.1016/j.biocel.2007.04.010
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Sharma K, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00151
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Ziemssen F, 2015, OPHTHALMOLOGE, V112, P246, DOI 10.1007/s00347-014-3217-7
NR 17
TC 85
Z9 86
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2016
VL 100
IS 12
BP 1623
EP 1628
DI 10.1136/bjophthalmol-2015-308166
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EC7XD
UT WOS:000388353500007
PM 27030279
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Pang, CE
   Freund, KB
AF Pang, Claudine E.
   Freund, K. Bailey
TI PACHYCHOROID NEOVASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE central serous chorioretinopathy; pachychoroid neovasculopathy;
   pachychoroid pigment epitheliopathy; polypoidal choroidal vasculopathy;
   Type 1 choroidal neovascularization
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; PIGMENT EPITHELIAL DETACHMENTS;
   CLINICOPATHOLOGICAL CORRELATION; MACULAR DEGENERATION;
   NEOVASCULARIZATION; CLASSIFICATION; FEATURES
AB Purpose: To report 3 cases of pachychoroid neovasculopathy, a form of Type 1 (subretinal pigment epithelium) neovascularization, occurring over areas of increased choroidal thickness and dilated choroidal vessels.
   Methods: A retrospective observational case series of three patients who underwent comprehensive ophthalmic examination and multimodal imaging with fundus photography, fundus autofluorescence, spectral domain optical coherence tomography, enhanced depth imaging optical coherence tomography, fluorescein angiography, and indocyanine green angiography.
   Results: In all 3 eyes of 3 patients, aged 55 years to 63 years, there was Type 1 neovascularization overlying a localized area of choroidal thickening and dilated choroidal vessels seen with enhanced depth imaging optical coherence tomography. With indocyanine green angiography, there were large choroidal veins and choroidal hyperperme-ability seen beneath the area of the neovascular tissue in all three eyes. No eyes had evidence of submacular exudative detachment or autofluorescence changes to suggest antecedent acute or chronic central serous chorioretinopathy. No eyes had drusen or degenerative changes to suggest age-related macular degeneration or other degenerative diseases. In one patient, the fellow unaffected eye demonstrated retinal pigment epithelium abnormalities, best seen with fundus autofluorescence, overlying focal dilated choroidal vessels seen with enhanced depth imaging optical coherence tomography and associated choroidal hyperpermeability seen with indocyanine green angiography, consistent with the diagnosis of pachychoroid pigment epitheliopathy. All three eyes showed the appearance of polypoidal structures within the neovascular tissue.
   Conclusion: Pachychoroid neovasculopathy falls within a spectrum of diseases associated with choroidal thickening that includes pachychoroid pigment epitheliopathy, central serous chorioretinopathy, and polypoidal choroidal vasculopathy and should be considered as a possible diagnosis in eyes with features of Type 1 neovascularization and choroidal thickening in the absence of characteristic age-related macular degeneration or degenerative changes. Pachychoroid neovasculopathy may occur as a focal abnormality within the macula, even in myopic eyes with normal subfoveal choroidal thickness. Pachychoroid neovasculopathy can ultimately progress to the development of polypoidal choroidal vasculopathy.
C1 [Pang, Claudine E.; Freund, K. Bailey] Macula Consultants New York, Vitreous, Retina, New York, NY 10022 USA.
   [Pang, Claudine E.; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Freund, K. Bailey] NYU, Dept Ophthalmol, Sch Med, New York, NY 10016 USA.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital; New York University
RP Freund, KB (通讯作者)，Macula Consultants New York, Vitreous, Retina, 460 Pk Ave,Fifth Floor, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU Macula Foundation, Inc, New York, NY
FX Supported by The Macula Foundation, Inc, New York, NY.
CR Ahuja RM, 2001, OPHTHALMOLOGY, V108, P1009, DOI 10.1016/S0161-6420(00)00614-X
   Baillif-Gostoli S, 2010, GRAEF ARCH CLIN EXP, V248, P1845, DOI 10.1007/s00417-010-1328-7
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chung SE, 2013, RETINA-J RET VIT DIS, V33, P834, DOI 10.1097/IAE.0b013e31826af540
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Kim JH, 2013, AM J OPHTHALMOL, V156, P974, DOI 10.1016/j.ajo.2013.06.013
   Klein ML, 2011, AM J OPHTHALMOL, V151, P161, DOI 10.1016/j.ajo.2010.07.020
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Koh A.H.C., 1999, INVESTIG OPHTHALMOL, V40, P5958
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Kokame GT, 2013, OPEN OPHTHALMOL J, V7, P79, DOI 10.2174/1874364101307010082
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   MARSHALL GE, 1994, GRAEF ARCH CLIN EXP, V232, P133, DOI 10.1007/BF00176781
   Mauget-Faysse M, 2006, AM J OPHTHALMOL, V142, P970, DOI 10.1016/j.ajo.2006.06.063
   Miyake M, 2014, INVEST OPHTH VIS SCI, V55, P3223, DOI 10.1167/iovs.14-14059
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   PICCOLINO FC, 1995, EYE, V9, P324, DOI 10.1038/eye.1995.63
   Prunte C, 1996, AM J OPHTHALMOL, V121, P26
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sawa M, 2005, ARCH OPHTHALMOL-CHIC, V123, P122, DOI 10.1001/archopht.123.1.122
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   St Martin JM, 2013, OPTOMETRY VISION SCI, V90, pE293, DOI 10.1097/OPX.0000000000000079
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
NR 37
TC 284
Z9 296
U1 2
U2 27
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2015
VL 35
IS 1
BP 1
EP 9
DI 10.1097/IAE.0000000000000331
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AX6WX
UT WOS:000347060000011
PM 25158945
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Yang, W
   Tan, Y
   Li, CW
   Liu, Y
   Lu, GH
AF Yang, Wen
   Tan, Ying
   Li, Chaowei
   Liu, Yi
   Lu, Guohua
TI Observation of curative effect of intravitreal injection of conbercept
   in wet age-related macular degeneration: Optical coherence tomography
   analysis after injection
SO MICROSCOPY RESEARCH AND TECHNIQUE
LA English
DT Article
DE age-related macular degeneration; conbercept; OCT
AB To observe the clinical efficacy of intravitreal injection of conbercept in the treatment of wet age-related macular degeneration (wAMD), optical coherence tomography (OCT) and the best corrected visual acuity (BCVA) was observed to measure the changes of anatomical changes of central macular thickness (CMT) and the area and volume of retinal pigment epithelium (RPE) uplift. Fifteen patients (15 eyes) with wet AMD were enrolled in this study. All patients underwent intravitreal injection of conbercept of 0.05 mL once. After 1 week, 1 month, and 3 months, OCT and BCVA were used to examine and to compare with the preoperative and postoperative central macular thickness and RPE uplift area. BCVA (median) increased respectively from 0.12 +/- 0.13 to 0.21 +/- 0.15 at 1 week, to 0.90 +/- 0.25 at 1 month, to 0.38 +/- 0.17 at 3 months (p<.001). The thickness of central macular decreased from 500 +/- 25 m to 256 +/- 19 m, 221 +/- 29 m, and 215 +/- 14 m, respectively. The normal physiological structure and stratification of the macular area were clear gradually. Conbercept treatment of wet AMD can significantly improve visual acuity, after 1 month up to the plateau, 3 months of continuous drug injection can make the vision maintained at a high stage, and macular retinal normal structural morphology recovery is good, the treatment has no obvious adverse reactions, and with good security.
C1 [Yang, Wen; Tan, Ying; Li, Chaowei; Liu, Yi; Lu, Guohua] Nanjing Med Univ, Affiliated Changzhou Peoples Hosp 2, Dept Ophthalmol, 68 Gehu Middle Rd, Changzhou 213164, Jiangsu, Peoples R China.
C3 Nanjing Medical University
RP Lu, GH (通讯作者)，Nanjing Med Univ, Affiliated Changzhou Peoples Hosp 2, Dept Ophthalmol, 68 Gehu Middle Rd, Changzhou 213164, Jiangsu, Peoples R China.
EM czeyeye@163.com
CR Cho HJ, 2015, AM J OPHTHALMOL, V160, P1000, DOI 10.1016/j.ajo.2015.07.023
   Ford KM, 2012, MOL VIS, V18, P519
   Horsley MB, 2010, AM J OPHTHALMOL, V150, P558, DOI 10.1016/j.ajo.2010.04.029
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Wang C., 2016, RECENT ADV OPHTHALMO, V36, P471
NR 6
TC 6
Z9 7
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1059-910X
EI 1097-0029
J9 MICROSC RES TECHNIQ
JI Microsc. Res. Tech.
PD APR
PY 2018
VL 81
IS 4
BP 384
EP 388
DI 10.1002/jemt.22989
PG 5
WC Anatomy & Morphology; Biology; Microscopy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Anatomy & Morphology; Life Sciences & Biomedicine - Other Topics;
   Microscopy
GA GA6OY
UT WOS:000428453900004
PM 29319204
DA 2022-11-30
ER

PT J
AU Kam, JH
   Lenassi, E
   Malik, TH
   Pickering, MC
   Jeffery, G
AF Kam, Jaimie Hoh
   Lenassi, Eva
   Malik, Talat H.
   Pickering, Matthew C.
   Jeffery, Glen
TI Complement Component C3 Plays a Critical Role in Protecting the Aging
   Retina in a Murine Model of Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID FACTOR-H POLYMORPHISM; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; DRUSEN
   FORMATION; ACTIVATION; GENE; DEFICIENCY; CELLS; MICE; RISK; PHAGOCYTOSIS
AB Complement component C3 is the central complement component and a key inflammatory protein activated in age-related macular degeneration (AMD). AMD is associated with genetic variation in complement proteins that results in enhanced activation of C3 through the complement alternative pathway. These include complement factor H (CFH), a negative regulator of C3 activation. Both C3 inhibition and/or CFH augmentation are potential therapeutic strategies in AMD. Herein, we examined retinal integrity in aged (12 months) mice deficient in both factors H and C3 (CFH-/-.C3(-/-)), CFH alone (CFH-/-), or C3 alone (C3(-/-)), and wild-type mice (C57BL/6). Retinal function was assessed by electroretinography, and retinal morphological features were analyzed at Light and electron microscope Levels. Retinas were also stained for amyloid beta (A beta) deposition, inflammation, and macrophage accumulation. Contrary to expectation, electroretinograms of CFH-/-.C3(-/-) mice displayed more severely reduced responses than those of other mice. All mutant strains showed significant photoreceptor loss and thickening of Bruch's membrane compared with wild-type C57BL/6, but these changes were greater in CFH-/-.C3(-/-) mice. CFH-/-.C3(-/-) mice had significantly more A beta on Bruch's membrane, fewer macrophages, and high levels of retinal inflammation than the other groups. Our data show that both uncontrolled C3 activation (CFH-/-) and complete absence of C3 (CFH-/-.C3(-/-) and C3(-/-)) negatively affect aged retinas. These findings suggest that strategies that inhibit C3 in AMD may be deleterious.
C1 [Kam, Jaimie Hoh; Lenassi, Eva; Jeffery, Glen] UCL, Inst Ophthalmol, London EC1V 9EL, England.
   [Lenassi, Eva] Hosp Eye, Med Ctr, Ljubljana, Slovenia.
   [Malik, Talat H.; Pickering, Matthew C.] Univ London Imperial Coll Sci Technol & Med, Ctr Complement & Inflammat Res, London, England.
C3 University of London; University College London; Imperial College London
RP Jeffery, G (通讯作者)，UCL, Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
EM g.jeffery@ucl.ac.uk
OI Pickering, Matthew/0000-0002-1153-0192
FU Rosetrees Trust
FX Supported by The Rosetrees Trust.
CR Al-Hussaini H, 2008, MOL VIS, V14, P1784
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   ARDEN GB, 1986, BRIT J OPHTHALMOL, V70, P330, DOI 10.1136/bjo.70.5.330
   Bian ZM, 1999, CURR EYE RES, V18, P349, DOI 10.1076/ceyr.18.5.349.5353
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Brambilla R, 2005, J EXP MED, V202, P145, DOI 10.1084/jem.20041918
   BROUCKAERT P, 1993, IMMUNOBIOLOGY, V187, P317, DOI 10.1016/S0171-2985(11)80347-5
   Chen M, 2010, INVEST OPHTH VIS SCI, V51, P5888, DOI 10.1167/iovs.09-5103
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Dailey AT, 1998, J NEUROSCI, V18, P6713
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   DIERICH MP, 1987, IMMUNOL LETT, V14, P235, DOI 10.1016/0165-2478(87)90107-6
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ELNER SG, 1991, LAB INVEST, V64, P819
   ERDEI A, 1991, IMMUNOL TODAY, V12, P332, DOI 10.1016/0167-5699(91)90011-H
   FARRIES TC, 1991, IMMUNOL TODAY, V12, P295, DOI 10.1016/0167-5699(91)90002-B
   FEARON DT, 1983, ANNU REV IMMUNOL, V1, P243, DOI 10.1146/annurev.iy.01.040183.001331
   FEARON DT, 1984, IMMUNOL TODAY, V5, P105, DOI 10.1016/0167-5699(84)90044-6
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GRAYMORE CN, 1969, EXP EYE RES, V8, P375, DOI 10.1016/S0014-4835(69)80001-1
   HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HARTUNG HP, 1984, CLIN EXP IMMUNOL, V56, P453
   HOGASEN K, 1995, J CLIN INVEST, V95, P1054, DOI 10.1172/JCI117751
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Kida M, 2008, BLOOD CELL MOL DIS, V40, P410, DOI 10.1016/j.bcmd.2007.11.002
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Koenigsknecht-Talboo J, 2005, J NEUROSCI, V25, P8240, DOI 10.1523/JNEUROSCI.1808-05.2005
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Lengyel I, 2004, INVEST OPHTH VIS SCI, V45, P2886, DOI 10.1167/iovs.03-1083
   Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533
   LEVY M, 1986, KIDNEY INT, V30, P949, DOI 10.1038/ki.1986.278
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   MEDRANO CJ, 1995, EXP EYE RES, V61, P273, DOI 10.1016/S0014-4835(05)80122-8
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nordahl EA, 2004, P NATL ACAD SCI USA, V101, P16879, DOI 10.1073/pnas.0406678101
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Puzzo D, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.12.020
   Rougier N, 1998, J AM SOC NEPHROL, V9, P2318
   Stuart LM, 2005, IMMUNITY, V22, P539, DOI 10.1016/j.immuni.2005.05.002
   Tamaoka A, 1997, J NEUROL SCI, V148, P41, DOI 10.1016/S0022-510X(96)00314-0
   Townsend KP, 2005, EUR J IMMUNOL, V35, P901, DOI 10.1002/eji.200425585
   Usami E, 1967, Nippon Ganka Gakkai Zasshi, V71, P39
   Usami E, 1966, Nippon Ganka Gakkai Zasshi, V70, P84
   von Leithner PL, 2009, AM J PATHOL, V175, P412, DOI 10.2353/ajpath.2009.080927
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wyss-Coray T, 2002, P NATL ACAD SCI USA, V99, P10837, DOI 10.1073/pnas.162350199
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu MZ, 2012, INVEST OPHTH VIS SCI, V53, P7684, DOI 10.1167/iovs.12-10069
NR 60
TC 53
Z9 53
U1 1
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD AUG
PY 2013
VL 183
IS 2
BP 480
EP 492
DI 10.1016/j.ajpath.2013.04.008
PG 13
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 194DR
UT WOS:000322611700017
PM 23747511
OA Bronze
DA 2022-11-30
ER

PT J
AU Hong, N
   Shen, Y
   Yu, CY
   Wang, SQ
   Tong, JP
AF Hong, Nan
   Shen, Ye
   Yu, Chen-Ying
   Wang, Shu-Qun
   Tong, Jian-Ping
TI Association of the polymorphism Y402H in the CFH gene with response to
   anti-VEGF treatment in age-related macular degeneration: a systematic
   review and meta-analysis
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
DE age-related macular degeneration; complement factor H; pharmacogenetics;
   polymorphism; vascular endothelial growth factor
ID COMPLEMENT FACTOR-H; ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL
   RANIBIZUMAB; BEVACIZUMAB TREATMENT; CHINESE POPULATION;
   PHARMACOGENETICS; THERAPY; AMD
AB To explore whether the complement factor H (CFH) polymorphism rs1061170/Y402H is associated with responsiveness to antivascular endothelial growth factor (VEGF) agents in age-related macular degeneration (AMD). We reviewed the English literature to examine the association between the polymorphism rs1061170/Y402H of the CFH gene and responsiveness to treatment with anti-VEGF drugs in AMD patients. A meta-analysis of eligible studies was also performed. Pooled odds ratios (ORs) and 95% CIs were estimated using Stata V.12.0. Statistical heterogeneity was measured using Q-statistic testing. Fourteen relevant studies including a total of 2963 AMD patients were eligible. In AMD patients without a treatment history, individuals carrying the rs1061170/Y402H TT genotype were more likely to achieve a better outcome (OR = 1.932, 95% CI = 1.125-3.317, p = 0.017) than those carrying the CC genotype. The polymorphism rs1061170/Y402H might be a genetic predictor of treatment response to anti-VEGF therapy in AMD patients. Further prospective research including a larger number of patients is needed to validate this finding.
C1 [Hong, Nan; Shen, Ye; Yu, Chen-Ying; Wang, Shu-Qun; Tong, Jian-Ping] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Ophthalmol, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China.
C3 Zhejiang University
RP Tong, JP (通讯作者)，Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Ophthalmol, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China.
EM tongjp2000@hotmail.com
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Beykin G, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0019-x
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chang W, 2013, MOL VIS, V19, P702
   Chen H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042464
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Dedania VS, 2015, RETINA-J RET VIT DIS, V35, P381, DOI 10.1097/IAE.0000000000000466
   Dikmetas O, 2013, MOL VIS, V19, P2571
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Garcia M, 2015, ACTA OPHTHALMOL, V93, pE658, DOI 10.1111/aos.12790
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Habibi I, 2013, OPHTHALMIC RES, V49, P177, DOI 10.1159/000345068
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Hautamaki A, 2014, OPHTHALMOLOGY, V121, P973, DOI 10.1016/j.ophtha.2013.11.035
   Hautamaki A, 2013, RETINA-J RET VIT DIS, V33, P1815, DOI 10.1097/IAE.0b013e318285cf92
   Imai Daisuke, 2010, J Ocul Biol Dis Infor, V3, P53, DOI 10.1007/s12177-010-9055-1
   Kang Haeng Ku, 2012, Korean J Ophthalmol, V26, P414, DOI 10.3341/kjo.2012.26.6.414
   Kanoff J, 2013, SEMIN OPHTHALMOL, V28, P355, DOI 10.3109/08820538.2013.825292
   Kitchens JW, 2013, CLIN OPHTHALMOL, V7, P1987, DOI 10.2147/OPTH.S39635
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Kondo N, 2011, OPHTHALMOLOGY, V118, P339, DOI 10.1016/j.ophtha.2010.06.040
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lotery AJ, 2013, OPHTHALMOLOGY, V120, P2637, DOI 10.1016/j.ophtha.2013.07.046
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsumiya W, 2014, PHARMACOGENOMICS, V15, P833, DOI [10.2217/PGS.14.51, 10.2217/pgs.14.51]
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Menghini M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042014
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Park UC, 2014, RETINA-J RET VIT DIS, V34, P288, DOI 10.1097/IAE.0b013e3182979e1e
   Piermarocchi S, 2015, ACTA OPHTHALMOL, V93, pE451, DOI 10.1111/aos.12587
   Quan YL, 2012, INT J OPHTHALMOL-CHI, V5, P242, DOI 10.3980/j.issn.2222-3959.2012.02.25
   REDDY VM, 1995, AM J OPHTHALMOL, V120, P291, DOI 10.1016/S0002-9394(14)72158-0
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saeed MU, 2013, CLIN OPHTHALMOL, V7, P533, DOI 10.2147/OPTH.S31016
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Teper SJ, 2010, MOL VIS, V16, P2598
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Tian J, 2012, PHARMACOGENOMICS, V13, P779, DOI [10.2217/PGS.12.53, 10.2217/pgs.12.53]
   van Asten AF, 2014, OPHTHAL EPIDEMIOL, V21, P347
   Veloso Carlos Eduardo, 2014, Rev. Col. Bras. Cir., V41, P386, DOI 10.1590/0100-69912014006002
   Veritti D, 2012, OPHTHALMOLOGICA, V227, P11, DOI 10.1159/000337154
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Yuan DQ, 2013, OPHTHALMOLOGICA, V230, P227, DOI 10.1159/000355068
   Zintzaras E, 2008, J CLIN EPIDEMIOL, V61, P634, DOI 10.1016/j.jclinepi.2007.12.011
   Zipfel PF, 2001, SEMIN THROMB HEMOST, V27, P191, DOI 10.1055/s-2001-15248
NR 48
TC 24
Z9 24
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUN
PY 2016
VL 94
IS 4
SI SI
BP 334
EP 345
DI 10.1111/aos.13049
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DO2UQ
UT WOS:000377636000005
PM 27151934
OA Bronze
DA 2022-11-30
ER

PT J
AU Yu, QQ
   Yao, Y
   Zhu, J
   Bao, X
   Xie, TH
   Sun, C
   Cao, J
AF Yu Qian-Qian
   Yao Yong
   Zhu Jing
   Bao Xin
   Xie Tian-Hua
   Sun Chao
   Cao Jia
TI Nonsynonymous single nucleotide polymorphisms in the complement
   component 3 gene are associated with risk of age-related macular
   degeneration: A meta-analysis
SO GENE
LA English
DT Article
DE Complement component 3; Age-related macular degeneration; Polymorphism;
   Meta-analysis; Risk
ID GENOME-WIDE ASSOCIATION; FACTOR-H; CHINESE POPULATION; FACTOR-B; C3;
   SUSCEPTIBILITY; DISEASE; ACTIVATION; VARIANT; DRUSEN
AB Nonsynonymous single nucleotide polymorphisms (SNPs) in complement component 3 (CO) are associated with the risk of age-related macular degeneration (AMD), however, this association is not consistent among studies. To thoroughly address this issue, we performed an updated meta-analysis to evaluate the association between nine SNPs in the CC3 gene and AMD risk. A search was conducted of the PubMed database through 3rd Aug, 2014. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength of associations. Based on the search criteria for manuscripts reporting AMD susceptibility related to CO in nine SNPs, 57 case-control studies from 22 different articles were retrieved. Significantly positive associations were found for the rs2230199 C/G SNP and AMD in the Caucasian population, as well as for the rs1047286 C/T SNP. Moreover, a relationship between the rs11569536 G/A SNP and AMD was detected. By contrast, a negative association was observed between rs2250656 A/G SNP and AMD risk. The present meta-analysis suggests that these four SNPs in the CO gene are potentially associated with the risk of AMD development. Further studies using larger sample sizes and accounting for gene-environment interactions should be conducted to elucidate the role of CC3 gene polymorphisms in AMD risk. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Yu Qian-Qian; Yao Yong; Zhu Jing; Bao Xin; Xie Tian-Hua; Sun Chao; Cao Jia] Nanjing Med Univ, Affiliated Wuxi Peoples Hosp, Dept Ophthalmol, Wuxi 214023, Jiangsu, Peoples R China.
C3 Nanjing Medical University
RP Yao, Y (通讯作者)，Nanjing Med Univ, Affiliated Wuxi Peoples Hosp, Dept Ophthalmol, Wuxi 214023, Jiangsu, Peoples R China.
EM yaoyongmeta@sina.com
FU Science and Technology Development Program of Nanjing Medical University
   [2013NJMU159]
FX This work was supported by the Science and Technology Development
   Program of Nanjing Medical University (no. 2013NJMU159).
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Buentello-Volante B, 2012, MOL VIS, V18, P2518
   Cui L, 2010, INVEST OPHTH VIS SCI, V51, P1116, DOI 10.1167/iovs.09-4265
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Edwards AO, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003813
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Havvas O, 2014, EUR J OPHTHALMOL, V24, P751, DOI 10.5301/ejo.5000427
   Hayashino Y, 2005, J EPIDEMIOL, V15, P235, DOI 10.2188/jea.15.235
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kim SJ, 2012, EXP EYE RES, V96, P42, DOI 10.1016/j.exer.2012.01.005
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Mckay GJ, 2010, MOL VIS, V16, P194
   Munafo MR, 2004, TRENDS GENET, V20, P439, DOI 10.1016/j.tig.2004.06.014
   Nishida N, 2006, P NATL ACAD SCI USA, V103, P19737, DOI 10.1073/pnas.0609791104
   Park KH, 2009, INVEST OPHTH VIS SCI, V50, P3386, DOI 10.1167/iovs.08-3231
   Pei XT, 2009, CURR EYE RES, V34, P615, DOI 10.1080/02713680903003484
   Priya RR, 2012, OPHTHALMOLOGY, V119, P2526, DOI 10.1016/j.ophtha.2012.06.042
   Puche N, 2013, RETINA-J RET VIT DIS, V33, P998, DOI 10.1097/IAE.0b013e31827b6483
   Reis S.E., 2006, J IMMUNOL, V63, P155
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Thakkinstian A, 2011, AM J EPIDEMIOL, V173, P1365, DOI 10.1093/aje/kwr025
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Wells GA., NEWCASTLE OTTAWA SCA
   Wu L, 2013, INVEST OPHTH VIS SCI, V54, P170, DOI 10.1167/iovs.12-10453
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zerbib J, 2010, MOL VIS, V16, P1324
NR 44
TC 13
Z9 13
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD MAY 1
PY 2015
VL 561
IS 2
BP 249
EP 255
DI 10.1016/j.gene.2015.02.039
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA CE4LM
UT WOS:000351802100009
PM 25688879
DA 2022-11-30
ER

PT J
AU Ristic, D
   Vukosavljevic, M
   Draganic, B
   Cerovic, V
   Petrovic, N
   Janicijevic-Petrovic, M
AF Ristic, Dragana
   Vukosavljevic, Miroslav
   Draganic, Biljana
   Cerovic, Vesna
   Petrovic, Nenad
   Janicijevic-Petrovic, Mirjana
TI The effect of intravitreal administration of bevacizumab on macular
   edema and visual acuity in age-related macular degeneration with
   subfoveolar choroidal neovascularisation
SO VOJNOSANITETSKI PREGLED
LA English
DT Article
DE antibodies monoclonal; angiogenesis inhibitors; macular degeneration;
   choroidal neovascularisation; treatment outcome
ID AVASTIN; RANIBIZUMAB
AB Background/Aim. Age-related macular degeneration (AMD) is a leading cause of the loss of central visual acuity in population older than 70 years. We can distinguish wet and dry form of AMD. The aim of the study was to present our early results in treatment of the wet (neovascular) form of AMD with intravitreal administration of bevacizumab. Methods. The study included 39 patients. Each patient underwent a complete ophthalmological examination, fluorescein angiography (FA) and optical coherence tomography (OCT). All the patients received 1.25 mg of intravitreal bevacizumab (0.05 mL of commercial phial of Avastin (R)). The total of three doses was given with a one-month interval between doses. Results. Among 39 patients, 24 were women and 15 men. The average best corrected visual acuity (BCVA) was improved from 0.09 before the therapy to 0.24 after the administration of all the three doses of bevacizumab (p < 0.001). The average central macular thickness (CMT) measured by OCT was improved from 474 pm in the beginning to 341 pm after the administration of all the three doses of the drug (p < 0.001). There were no side effects. Conclusions. Our short-term experience indicates that intravitreal administration of three doses of bevacizumab in one-month intervals between the doses leads to a significant reduction of macular edema and improvement of BCVA in patients with neovascular AMD.
C1 [Ristic, Dragana; Vukosavljevic, Miroslav; Draganic, Biljana; Cerovic, Vesna; Petrovic, Nenad] Mil Med Acad, Ophthalmol Clin, Belgrade 11000, Serbia.
   [Vukosavljevic, Miroslav] Univ Def, Mil Med Acad, Fac Med, Belgrade, Serbia.
   [Janicijevic-Petrovic, Mirjana] Clin Ctr Kragujevac, Dept Ophthalmol, Kragujevac, Serbia.
C3 University of Belgrade
RP Ristic, D (通讯作者)，Mil Med Acad, Ophthalmol Clin, Crnotravska 17, Belgrade 11000, Serbia.
EM dadana25@yahoo.com
OI Petrovic, Nenad/0000-0001-5449-2029
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Conrad PW, 2008, CLIN OPHTHALMOL, V2, P727
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Ghazi NG, 2010, CLIN OPHTHALMOL, V4, P307
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Welch DE, 2009, BRIT J OPHTHALMOL, V93, P1033, DOI 10.1136/bjo.2008.148874
NR 12
TC 1
Z9 1
U1 0
U2 5
PU MILITARY MEDICAL ACAD-INI
PI BELGRADE
PA CRNOTRAVSKA 17, PO BOX 33-35, BELGRADE, 11040, SERBIA
SN 0042-8450
J9 VOJNOSANIT PREGL
JI Vojnosanit. Pregl.
PD JUL
PY 2013
VL 70
IS 7
BP 660
EP 663
DI 10.2298/VSP110311047R
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 202AJ
UT WOS:000323185500006
PM 23984614
OA gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Mrejen, S
   Jung, JJ
   Chen, C
   Patel, SN
   Gallego-Pinazo, R
   Yannuzzi, N
   Xu, LN
   Marsiglia, M
   Boddu, S
   Freund, KB
AF Mrejen, Sarah
   Jung, Jesse J.
   Chen, Christine
   Patel, Samir N.
   Gallego-Pinazo, Roberto
   Yannuzzi, Nicolas
   Xu, Luna
   Marsiglia, Marcela
   Boddu, Sucharita
   Freund, K. Bailey
TI Long-Term Visual Outcomes for a Treat and Extend Anti-Vascular
   Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related
   Macular Degeneration
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE anatomical classification; choroidal neovascularization; fluorescein
   angiography classification; intravitreal anti-VEGF injections;
   neovascular age-related macular degeneration; Treat and Extend Regimen
ID CHOROIDAL NEOVASCULARIZATION; INTRAOCULAR-PRESSURE; FACTOR THERAPY;
   RANIBIZUMAB; TYPE-1; TRIAL; RISK; MG
AB With the advent of anti-vascular endothelial growth factor (VEGF) therapy, clinicians are now focused on various treatment strategies to better control neovascular age-related macular degeneration (NVAMD), a leading cause of irreversible blindness. Herein, we retrospectively reviewed consecutive patients with treatment-naive NVAMD initially classified based on fluorescein angiography (FA) alone or with an anatomic classification utilizing both FA and optical coherence tomography (OCT) and correlated long-term visual outcomes of these patients treated with an anti-VEGF Treat-and-Extend Regimen (TER) with baseline characteristics including neovascular phenotype. Overall, 185 patients (210 eyes) were followed over an average of 3.5 years (range 1-6.6) with a retention rate of 62.9%, and visual acuity significantly improved with a TER that required a mean number of 8.3 (+/- 1.6) (+/- standard deviation) intravitreal anti-VEGF injections/year (range 4-13). The number of injections and the anatomic classification were independent predictors of visual acuity at 6 months, 1, 2, 3 and 4 years. Patients with Type 1 neovascularization had better visual outcomes and received more injections than the other neovascular subtypes. There were no serious adverse events. A TER provided sustained long-term visual gains. Eyes with Type 1 neovascularization had better visual outcomes than those with other neovascular subtypes.
C1 [Mrejen, Sarah; Jung, Jesse J.; Marsiglia, Marcela; Freund, K. Bailey] Macula Consultants New York, Vitreous, Retina, New York, NY 10022 USA.
   [Mrejen, Sarah; Jung, Jesse J.; Marsiglia, Marcela; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10065 USA.
   [Mrejen, Sarah] Quinze Vingts Hosp, DHU ViewMaintain, INSERM DHOS CIC 1423, F-75012 Paris, France.
   [Jung, Jesse J.; Boddu, Sucharita; Freund, K. Bailey] NYU, Dept Ophthalmol, Sch Med, New York, NY 10016 USA.
   [Jung, Jesse J.; Marsiglia, Marcela] Edward S Harkness Eye Inst Columbia, New York, NY 10032 USA.
   [Chen, Christine] Monash Univ, Dept Surg, Melbourne, Vic 3800, Australia.
   [Chen, Christine] Univ Melbourne, Ctr Eye Res Australia, East Melbourne, Vic 3002, Australia.
   [Patel, Samir N.; Yannuzzi, Nicolas] Weill Cornell Med Coll, New York, NY 10065 USA.
   [Gallego-Pinazo, Roberto] Univ & Polytech Hosp La Fe, Dept Ophthalmol, Valencia 46026, Spain.
   [Xu, Luna] New York Eye & Ear Infirm, New York, NY 10003 USA.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital; CHNO des Quinze-Vingts; Institut National de la Sante
   et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Sorbonne Universite; New York University; Monash
   University; Centre for Eye Research Australia; University of Melbourne;
   Cornell University; New York Eye & Ear Infirmary of Mount Sinai
RP Freund, KB (通讯作者)，Macula Consultants New York, Vitreous, Retina, New York, NY 10022 USA.
EM sarahmrejen.uretsky@gmail.com; jung.jesse@gmail.com;
   chris_chen30@hotmail.com; snp2002@med.cornell.edu;
   robertogallegopinazo@gmail.com; yannuzzi@gmail.com; luna.xu.v@gmail.com;
   marcelamarsiglia@hotmail.com; sucharita.boddu@med.nyu.edu;
   kbfnyf@aol.com
RI Mrejen, Sarah/G-2089-2016; Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU LuEsther T. Mertz Retinal Research Center; Manhattan Eye, Ear and Throat
   Hospital; Macula Foundation, Inc., New York, NY, USA
FX We would like to thank Kunal K. Dansingani for his suggestions and work
   in reviewing the manuscript. This work has also been supported by a
   research grant from the LuEsther T. Mertz Retinal Research Center,
   Manhattan Eye, Ear and Throat Hospital, and The Macula Foundation, Inc.,
   New York, NY, USA. The funding organizations had no role in the design
   of the study; in the collection, analyses or interpretation of data; in
   the writing of the manuscript and in the decision to publish the
   results.
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Bhavsar KV, 2014, SAUDI J OPHTHALMOL, V28, P129, DOI 10.1016/j.sjopt.2014.03.001
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Ferreras, 2014, J CLIN EXP OPHTHALMO, V5, P1
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Freund K. B., 2014, RETINA UNPUB
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AT, 2012, EYE, V26, P1181, DOI 10.1038/eye.2012.174
   Green W R, 1999, Mol Vis, V5, P27
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Hoang QV, 2013, RETINA-J RET VIT DIS, V33, P179, DOI 10.1097/IAE.0b013e318261a6f7
   Hoang QV, 2012, OPHTHALMOLOGY, V119, P321, DOI 10.1016/j.ophtha.2011.08.011
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Marcus D. M., 2014, ASS RES VIS OPHTH AR
   Marsiglia M, 2015, RETINA-J RET VIT DIS, V35, P966, DOI 10.1097/IAE.0000000000000460
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McBain VA, 2011, RETINA-J RET VIT DIS, V31, P1043, DOI 10.1097/IAE.0b013e3181fe54c7
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shah VP, 2013, JAMA OPHTHALMOL, V131, P967, DOI 10.1001/jamaophthalmol.2013.2120
   Shienbaum G, 2012, AM J OPHTHALMOL, V153, P468, DOI 10.1016/j.ajo.2011.08.011
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
   Xu L., 2014, RETINA, V35, P176
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 41
TC 42
Z9 43
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD JUL
PY 2015
VL 4
IS 7
BP 1380
EP 1402
DI 10.3390/jcm4071380
PG 23
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CT9NR
UT WOS:000363144400003
PM 26239682
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Fierz, W
AF Fierz, Walter
TI Age-Related Macular Degeneration: A Connection between Human Herpes
   Virus-6A-Induced CD46 Downregulation and Complement Activation?
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE human herpes virus-6A; age-related macular degeneration; CD46;
   complement system proteins; autophagy; parainflammation; inflammaging
ID PIGMENT EPITHELIAL-CELLS; BETA-CHEMOKINE RECEPTOR; COFACTOR PROTEIN
   CD46; FACTOR-H POLYMORPHISM; MULTIPLE-SCLEROSIS; HUMAN CYTOMEGALOVIRUS;
   CHRONIC INFLAMMATION; GEOGRAPHIC ATROPHY; SEQUENCE VARIATION; CELLULAR
   RECEPTOR
AB Viruses are able to interfere with the immune system by docking to receptors on host cells that are important for proper functioning of the immune system. A well-known example is the human immunodeficiency virus that uses CD4 cell surface molecules to enter host lymphocytes and thereby deleteriously destroying the helper cell population of the immune system. A more complicated mechanism is seen in multiple sclerosis (MS) where human herpes virus-6A (HHV-6A) infects astrocytes by docking to the CD46 surface receptor. Such HHV-6A infection in the brain of MS patients has recently been postulated to enable Epstein-Barr virus (EBV) to transform latently infected B-lymphocytes in brain lesions leading to the well-known phenomenon of oligoclonal immunoglobulin production that is widely used in the diagnosis of MS. The cellular immune response to HHV-6A and EBV is one part of the pathogenic mechanisms in MS. A more subtle pathogenic mechanism can be seen in the downregulation of CD46 on astrocytes by the infecting HHV-6A. Since CD46 is central in regulating the complement system, a lack of CD46 can lead to hyperactivation of the complement system. In fact, activation of the complement system in brain lesions is a well-known pathogenic mechanism in MS. In this review, it is postulated that a similar mechanism is central in the development of age-related macular degeneration (AMD). One of the earliest changes in the retina of AMD patients is the loss of CD46 expression in the retinal pigment epithelial (RPE) cells in the course of geographic atrophy. Furthermore, CD46 deficient mice spontaneously develop dry-type AMD-like changes in their retina. It is also well known that certain genetic polymorphisms in the complement-inhibiting pathways correlate with higher risks of AMD development. The tenet is that HHV-6A infection of the retina leads to downregulation of CD46 and consequently to hyperactivation of the complement system in the eyes of susceptible individuals.
C1 [Fierz, Walter] Lab Med Zentrum Dr Risch, Vaduz, Liechtenstein.
RP Fierz, W (通讯作者)，Lab Med Zentrum Dr Risch, Vaduz, Liechtenstein.
EM w.f@swissonline.ch
CR Ablashi D, 2014, ARCH VIROL, V159, P863, DOI 10.1007/s00705-013-1902-5
   Agut H, 2017, MED MALADIES INFECT, V47, P83, DOI 10.1016/j.medmal.2016.09.004
   Ahlqvist J, 2006, J MED VIROL, V78, P1542, DOI 10.1002/jmv.20737
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anastasopoulos E, 2012, CURR EYE RES, V37, P1148, DOI 10.3109/02713683.2012.705413
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Bates M, 2009, J MED VIROL, V81, P779, DOI 10.1002/jmv.21455
   Bromfield S, 2012, CURR EYE RES, V37, P549, DOI 10.3109/02713683.2011.647223
   Caselli E, 2017, VIROL J, V14, DOI 10.1186/s12985-016-0672-6
   Caselli E, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002951
   Chaker L, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0329-0
   Chatziralli I, 2017, BIOMED HUB, V2, P1, DOI [10.1159/000454706, DOI 10.1159/000454706]
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Clark DA, 2000, REV MED VIROL, V10, P155, DOI 10.1002/(SICI)1099-1654(200005/06)10:3&lt;155::AID-RMV277&gt;3.0.CO;2-6
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Crane IJ, 1998, CELL IMMUNOL, V184, P37, DOI 10.1006/cimm.1997.1235
   Dagna L, 2013, FUTURE VIROL, V8, P273, DOI 10.2217/FVL.13.7
   DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0
   Dvashi Z, 2014, INVEST OPHTH VIS SCI, V55, P5679, DOI 10.1167/iovs.14-14349
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fierz W, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0719-3
   Franceschi C, 2017, TRENDS ENDOCRIN MET, V28, P199, DOI 10.1016/j.tem.2016.09.005
   Franceschi C, 2014, J GERONTOL A-BIOL, V69, pS4, DOI 10.1093/gerona/glu057
   Francis PJ, 2008, MOL VIS, V14, P1395
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gallenga CE, 2014, INFLAMM RES, V63, P105, DOI 10.1007/s00011-013-0684-2
   Gemenetzi M, 2016, EYE, V30, P1, DOI 10.1038/eye.2015.203
   Gopinath B, 2016, INVEST OPHTH VIS SCI, V57, P5273, DOI 10.1167/iovs.16-19735
   GORDON DL, 1992, J NEUROIMMUNOL, V36, P199, DOI 10.1016/0165-5728(92)90051-L
   Green AJ, 2010, BRAIN, V133, P1591, DOI 10.1093/brain/awq080
   Green YA, 2016, BIOCHEM CELL BIOL, V94, P188, DOI 10.1139/bcb-2015-0120
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   He J, 1996, J VIROL, V70, P1296, DOI 10.1128/JVI.70.2.1296-1300.1996
   Ingram G, 2009, CLIN EXP IMMUNOL, V155, P128, DOI 10.1111/j.1365-2249.2008.03830.x
   Isegawa Y, 1998, J VIROL, V72, P6104, DOI 10.1128/JVI.72.7.6104-6112.1998
   Jabs DA, 2015, AM J OPHTHALMOL, V159, P1115, DOI 10.1016/j.ajo.2015.01.037
   Joubert PE, 2009, CELL HOST MICROBE, V6, P354, DOI 10.1016/j.chom.2009.09.006
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kaarniranta K, 2010, ACTA OPHTHALMOL, V88, P387, DOI 10.1111/j.1755-3768.2009.01840.x
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kawa MP, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/483960
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Knickelbein Jared E, 2015, Int Ophthalmol Clin, V55, P63, DOI 10.1097/IIO.0000000000000073
   Knox KK, 1996, J ACQ IMMUN DEF SYND, V11, P370, DOI 10.1097/00042560-199604010-00007
   KNOX KK, 1995, J ACQ IMMUN DEF SYND, V9, P69
   KOJIMA A, 1993, J IMMUNOL, V151, P1519
   Kraiczy P, 2001, EUR J IMMUNOL, V31, P1674, DOI 10.1002/1521-4141(200106)31:6&lt;1674::AID-IMMU1674&gt;3.0.CO;2-2
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Leibovitch EC, 2014, CURR OPIN VIROL, V9, P127, DOI 10.1016/j.coviro.2014.09.016
   Liao X, 2016, ARCH GERONTOL GERIAT, V64, P123, DOI 10.1016/j.archger.2016.01.011
   LISZEWSKI MK, 1991, ANNU REV IMMUNOL, V9, P431, DOI 10.1146/annurev.iy.09.040191.002243
   Lusso P, 2006, J CLIN VIROL, V37, pS4, DOI 10.1016/S1386-6532(06)70004-X
   Lyzogubov VV, 2016, AM J PATHOL, V186, P2088, DOI 10.1016/j.ajpath.2016.03.021
   Ma BF, 2015, INT J CLIN EXP PATHO, V8, P9592
   Maeki T, 2012, ADV VIROL, V2012, DOI 10.1155/2012/384069
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   McLaughlin BJ, 2003, INVEST OPHTH VIS SCI, V44, P3669, DOI 10.1167/iovs.02-0813
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Milne RSB, 2000, J IMMUNOL, V164, P2396, DOI 10.4049/jimmunol.164.5.2396
   Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Mori Y, 2002, J VIROL, V76, P6750, DOI 10.1128/JVI.76.13.6750-6761.2002
   Murakami Y, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-91
   Nita M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930671
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Parmeggiani F, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/435607
   Pedersen SM, 2006, VIROLOGY, V356, P1, DOI 10.1016/j.virol.2006.07.028
   QAVI HB, 1995, INVEST OPHTH VIS SCI, V36, P2040
   SAIFUDDIN M, 1995, J EXP MED, V182, P501, DOI 10.1084/jem.182.2.501
   Santoro F, 2003, J BIOL CHEM, V278, P25964, DOI 10.1074/jbc.M302373200
   Santoro F, 1999, CELL, V99, P817, DOI 10.1016/S0092-8674(00)81678-5
   Schneider-Schaulies J, 2000, J GEN VIROL, V81, P1413, DOI 10.1099/0022-1317-81-6-1413
   SCHNORR JJ, 1995, EUR J IMMUNOL, V25, P976, DOI 10.1002/eji.1830250418
   SPEAR GT, 1995, J IMMUNOL, V155, P4376
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 80
TC 1
Z9 1
U1 0
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD OCT 17
PY 2017
VL 8
AR 1314
DI 10.3389/fimmu.2017.01314
PG 6
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA FJ8QR
UT WOS:000413034200001
PM 29093709
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lazic, R
   Gabric, N
AF Lazic, Ratimir
   Gabric, Nikica
TI Intravitreally administered bevacizumab (Avastin) in minimally classic
   and occult choroidal neovascularization secondary to age-related macular
   degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   bevacizumab; pegaptanib; anti-VEGF
ID ENDOTHELIAL GROWTH-FACTOR; RANDOMIZED CLINICAL-TRIAL; PHOTODYNAMIC
   THERAPY; VERTEPORFIN THERAPY; TRIAMCINOLONE ACETONIDE; INJECTION
AB Background Anti-vascular endothelial growth factor (anti-VEGF) agents have been shown to be effective in the treatment of neovascular age-related macular degeneration (AMD). Efficacy and safety of intravitreally administered bevacizumab (Avastin), a humanized monoclonal anti-VEGF, was assessed in minimally classic and occult subfoveal choroidal neovascularization (CNV) due to AMD.
   Methods A prospective interventional study was carried out. Bevacizumab (1.25 mg) was administered intravitreally on a 6-week basis until macular edema, subretinal fluid, and/or pigment epithelial detachment had resolved. Administration was repeated in case of relapse. Ophthalmic evaluations included a complete ophthalmic examination, measurement of the visual acuity (VA), optical coherence tomography, and fluorescein angiography. Main outcome measures were the changes between baseline and last follow-up visit in best-corrected VA, central foveal thickness (CFT) and total macular volume (TMV).
   Results From 102 patients [mean age (range) 74.8 (61-85) years], 102 eyes were included. Median (range) duration of follow-up was 18 (6-24) weeks. Statistically significant changes from baseline were observed in best-corrected VA [ increase of 1.29 lines (P=0.001)], CFT [ reduction of 56 mu m (P=0.01)] and TMV [reduction of 0.80 mm(3) (P < 0.0001)]. Positive results were obtained in 65/102 (64%) patients after two to three injections as a mean. In a substantial proportion of patients (38%) followed up for at least 18 weeks, recurrence of leakage requiring additional injections was observed. Treatment was well tolerated; two pigment epithelium rips and ten posterior vitreous detachments were reported.
   Conclusions Short-term results suggest that intravitreally administered bevacizumab (Avastin) is effective in minimally classic and occult CNV due to AMD. Significant improvements in VA, CFT and TMV were obtained and maintained during follow-up. In some patients, however, recurrence of leakage requiring additional intravitreal injection occurred. Maintenance of the effect of bevacizumab and its safety after repeated and prolonged administration have to be investigated in well-controlled studies.
C1 Eye Clin Svjetlost, Zagreb 10000, Croatia.
RP Lazic, R (通讯作者)，B Magovca 23,Bukovacka 27, Zagreb 10000, Croatia.
EM ratimir.lazic@svjetlost.hr
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Bartz-Schmidt KU, 2006, OPHTHALMOLOGE, V103, P461, DOI 10.1007/s00347-006-1351-6
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Grisanti S, 2006, AM J OPHTHALMOL, V142, P158, DOI 10.1016/j.ajo.2006.02.045
   He Aiwu Ruth, 2005, Clin Adv Hematol Oncol, V3, P555
   Ignoffo RJ, 2004, AM J HEALTH-SYST PH, V61, pS21, DOI 10.1093/ajhp/61.suppl_5.S21
   Jaissle GB, 2006, OPHTHALMOLOGE, V103, P471, DOI 10.1007/s00347-006-1355-2
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Ladewig MS, 2006, OPHTHALMOLOGE, V103, P463, DOI 10.1007/s00347-006-1352-5
   LUK M, 2006, BR J OPHTHALMOL, V9, P1178
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   MILLER J, 2005, 23 ANN M JUL 16 20 M
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Nguyen QD, 2005, BRIT J OPHTHALMOL, V89, P1368, DOI 10.1136/bjo.2005.066431
   NIEMEYER M, 2006, IN PRESS OPHTHALMOLO
   Polito A, 2006, ANN ACAD MED SINGAP, V35, P145
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
NR 27
TC 90
Z9 106
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JAN
PY 2007
VL 245
IS 1
BP 68
EP 73
DI 10.1007/s00417-006-0466-4
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 111OE
UT WOS:000242461600010
PM 17111146
DA 2022-11-30
ER

PT J
AU Stanga, PE
   Tsamis, E
   Siso-Fuertes, I
   Dorn, JD
   Merlini, F
   Fisher, A
   Crawford, FIJ
   Kasbia, SS
   Papayannis, A
   Baseler, HA
   Morland, AB
   Hanson, RL
   Humayun, M
   Greenberg, RJ
AF Stanga, Paulo E.
   Tsamis, Emmanouil
   Siso-Fuertes, Irene
   Dorn, Jessy D.
   Merlini, Francesco
   Fisher, Andy
   Crawford, Fiona I. J.
   Kasbia, Shakti S.
   Papayannis, Alessandro
   Baseler, Heidi A.
   Morland, Antony B.
   Hanson, Rachel L.
   Humayun, Mark
   Greenberg, Robert J.
TI Electronic retinal prosthesis for severe loss of vision in geographic
   atrophy in age-related macular degeneration: First-in-human use
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; macular and RPE dystrophies; inner
   retinal; vitreoretinal dystrophies; retinal pathology; research;
   retinitis pigmentosa; pars plana vitrectomy; geographic atrophy;
   artificial vision; electronic retinal implant; electronic retinal
   prosthesis; ARGUS II
ID LEBER CONGENITAL AMAUROSIS; GENE-THERAPY; EPIRETINAL PROSTHESIS; VISUAL
   IMPAIRMENT; FUNCTIONAL VISION; RPE65 MUTATIONS; BLIND SUBJECTS;
   PERFORMANCE; SYSTEM; PREVALENCE
AB Background: To date there are yet no available approved therapies for Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD). Methods: Single site, non-randomized safety and efficacy study presenting the preliminary results in a cohort of five late stage AMD (GA) patients successfully implanted with the Argus II Retinal Prosthesis System (Second Sight Medical Products Inc., Sylmar, CA, USA). Extensive fundus imaging including retinal photographs from which the GA area was measured. A combination of custom and traditional tests designed for very low vision subjects assessed visual function in study subjects. A Functional Low-Vision Observer Rated Assessment was carried out to evaluate the impact of the system on the subject's daily life. In addition, a study to evaluate structural characteristics of the visual cortex of the brain was performed in one subject using magnetic resonance imaging. Results: Seven device-related adverse events were reported, four of which were classed as serious adverse events. Retinal detachment was reported in three patients and was successfully treated within 12 months of onset. Testing showed an improvement in visual function in three of five patients with the system turned on. Magnetic resonance imaging assessed in one patient after implantation indicates a selective increase in cortical myelin and thickness in visual brain regions 1 year post implantation. Conclusions: Epiretinal prostheses can successfully be implanted in those affected by GA secondary to late-stage AMD and can elicit visual percepts by electrical stimulation of residual neuroretinal elements and improve basic visual function in those affected.
C1 [Stanga, Paulo E.; Tsamis, Emmanouil; Siso-Fuertes, Irene; Crawford, Fiona I. J.; Kasbia, Shakti S.; Papayannis, Alessandro] Manchester Royal Eye Hosp, NIHR Manchester Clin Res Facil, Manchester Vis Regenerat MVR Lab, Manchester, Lancs, England.
   [Stanga, Paulo E.; Tsamis, Emmanouil; Siso-Fuertes, Irene; Crawford, Fiona I. J.; Kasbia, Shakti S.; Papayannis, Alessandro] Manchester Univ NHS Fdn Trust, Manchester, Lancs, England.
   [Stanga, Paulo E.] Univ Manchester, Sch Biol Sci, Div Evolut & Genom Sci, Fac Biol Med & Hlth, Manchester, Lancs, England.
   [Stanga, Paulo E.] London Vis Clin, Retina Serv, London, England.
   [Tsamis, Emmanouil] Univ Manchester, Fac Biol Med & Hlth, Sch Hlth Sci, Div Pharm & Optometry, Manchester, Lancs, England.
   [Dorn, Jessy D.; Merlini, Francesco; Greenberg, Robert J.] Second Sight Med Prod Inc, Sylmar, CA USA.
   [Fisher, Andy] Focal Point, Bridgend, Wales.
   [Papayannis, Alessandro] Azienda Sanitaria Univ Giuliano Isontina, SC Oculist Osped Monfalcone & Gorizia, Monfalcone, Italy.
   [Baseler, Heidi A.] Hull York Med Sch, Kingston Upon Hull, Yorks, England.
   [Baseler, Heidi A.; Morland, Antony B.; Hanson, Rachel L.] Univ York, Dept Psychol, York, N Yorkshire, England.
   [Baseler, Heidi A.; Morland, Antony B.; Hanson, Rachel L.] Univ York, York Neuroimaging Ctr, York, N Yorkshire, England.
   [Humayun, Mark] USC Roski Eye Inst, Ophthalmol & Biomed Engn, Los Angeles, CA USA.
C3 Manchester Royal Eye Hospital; University of Manchester; University of
   Manchester; University of Hull; University of York - UK; University of
   York - UK; University of York - UK
RP Stanga, PE (通讯作者)，London Vis Clin, 138 Harley St, London W1G 7LA, England.
EM p.stanga@londonvisionclinic.com
RI Tsamis, Emmanouil/AGZ-0810-2022
OI Baseler, Heidi/0000-0003-0995-8453
FU Second Sight Medical Products Inc., Sylmar, California, USA
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This
   research was sponsored by Second Sight Medical Products Inc., Sylmar,
   California, USA. The sponsor or funding organization participated in the
   design of the study, data management, data analysis, and review of the
   manuscript.
CR Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/ng0501-92
   Ahuja AK, 2011, BRIT J OPHTHALMOL, V95, P539, DOI 10.1136/bjo.2010.179622
   Asaria RHY, 2001, OPHTHALMOLOGY, V108, P1179, DOI 10.1016/S0161-6420(01)00589-9
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Boucard CC, 2009, BRAIN, V132, P1898, DOI 10.1093/brain/awp119
   Brandli A, 2016, EYE BRAIN, V8, P15, DOI 10.2147/EB.S70822
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   da Cruz L, 2016, OPHTHALMOLOGY, V123, P2248, DOI 10.1016/j.ophtha.2016.06.049
   da Cruz L, 2013, BRIT J OPHTHALMOL, V97, P632, DOI 10.1136/bjophthalmol-2012-301525
   Damle S, 2017, RETINA-J RET VIT DIS, V37, P1423, DOI 10.1097/IAE.0000000000001660
   DEJUAN E, 1985, AM J OPHTHALMOL, V99, P272, DOI 10.1016/0002-9394(85)90355-1
   Dorn JD, 2013, JAMA OPHTHALMOL, V131, P183, DOI 10.1001/2013.jamaophthalmol.221
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Geruschat DR, 2016, CLIN EXP OPTOM, V99, P227, DOI 10.1111/cxo.12359
   Geruschat DR, 2015, CLIN EXP OPTOM, V98, P342, DOI 10.1111/cxo.12242
   Glasser MF, 2013, NEUROIMAGE, V80, P105, DOI 10.1016/j.neuroimage.2013.04.127
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   Hernowo AT, 2014, CORTEX, V56, P99, DOI 10.1016/j.cortex.2013.01.003
   Ho AC, 2015, OPHTHALMOLOGY, V122, P1547, DOI 10.1016/j.ophtha.2015.04.032
   Humayun MS, 2012, OPHTHALMOLOGY, V119, P779, DOI 10.1016/j.ophtha.2011.09.028
   Humayun MS, 2009, IEEE ENG MED BIO, P4566, DOI 10.1109/IEMBS.2009.5332695
   Humayun MS, 1996, ARCH OPHTHALMOL-CHIC, V114, P40, DOI 10.1001/archopht.1996.01100130038006
   Jacobson SG, 2012, ARCH OPHTHALMOL-CHIC, V130, P9, DOI 10.1001/archophthalmol.2011.298
   Li ML, 2018, RETINA-J RET VIT DIS, V38, P1937, DOI 10.1097/IAE.0000000000002182
   MacLaren RE, 2014, LANCET, V383, P1129, DOI 10.1016/S0140-6736(13)62117-0
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Malania M, 2017, INVEST OPHTH VIS SCI, V58, P2939, DOI 10.1167/iovs.16-21191
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rizzo S, 2014, AM J OPHTHALMOL, V157, P1282, DOI 10.1016/j.ajo.2014.02.039
   Simonelli F, 2010, MOL THER, V18, P643, DOI 10.1038/mt.2009.277
   Stanga Paulo E., 2001, International Ophthalmology, V23, P297, DOI 10.1023/A:1014482025960
   Stronks HC, 2014, EXPERT REV MED DEVIC, V11, P23, DOI 10.1586/17434440.2014.862494
   U.S. Food Drug Administration, HUM DEV EX HDE
   Weiland JD, 2012, MAGN RESON IMAGING, V20, P382, DOI 10.1016/j.mri.2011.12.005
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 36
TC 0
Z9 0
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAY
PY 2021
VL 31
IS 3
BP 920
EP 931
AR 11206721211000680
DI 10.1177/11206721211000680
EA MAR 2021
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TZ2CF
UT WOS:000678271400001
PM 33736500
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Ladkowska, J
   Gawecki, M
   Szolkiewicz, M
AF Ladkowska, Joanna
   Gawecki, Maciej
   Szolkiewicz, Marek
TI Efficacy of Anti-Vascular Endothelial Growth Factor Treatment in
   Neovascular Age-Related Macular Degeneration and Systemic Cardiovascular
   Risk Factors
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE age-related macular degeneration; anti-vascular endothelial growth
   factor; cardiovascular risk factors; arterial hypertension
ID ANTI-VEGF THERAPY; BLOOD-PRESSURE; RANIBIZUMAB; HYPERTENSION;
   MACULOPATHY; PREVALENCE; PREDICTORS; BIOMARKERS; OUTCOMES; DISEASE
AB This study evaluates whether the presence of cardiovascular risk factors (CRFs) affects functional and morphological responses to anti-vascular endothelial growth factor (VEGF) therapy in patients with neovascular age-related macular degeneration (nAMD). Retrospective analysis included 98 treatment-naive eyes followed for at least 12 months. Patients received intravitreal injections of ranibizumab or aflibercept with the dosage and regimen set according to each manufacturer's recommendations for their product. Parameters evaluated at each follow-up visit included best-corrected visual acuity and central retinal thickness. Additionally, the presence of the following CRFs was evaluated: male sex, age of older than 70 years, history of current or past smoking, systemic arterial hypertension, diabetes mellitus, total hypercholesterolemia, low-density lipoprotein hypercholesterolemia, high-density lipoprotein concentration of 45 mg/dL or less, atherogenic dyslipidemia, family history of cardiovascular disease, and chronic kidney disease. A statistically significant better letter gain in visual acuity (p = 0.012) and greater percentage of responders (p = 0.035)-that is patients in whom best corrected visual acuity was stabilized or improved at 12 months-were noted among patients without a diagnosis of arterial hypertension. A statistically significant better mean visual improvement was also achieved in patients with higher total cholesterol plasma levels (p = 0.004), but this finding was not reflected in the significantly higher percentage of responders. The presence of remaining analyzed risk factors did not substantially affect the results of treatment. Systemic arterial hypertension is an independent factor leading to a poor functional outcome following anti-VEGF therapy in patients with nAMD. Effects of anti-VEGF treatment in patients with high total cholesterol levels should be analyzed in further research.
C1 [Ladkowska, Joanna] Pomeranian Hosp, Dept Ophthalmol, PL-84200 Wejherowo, Poland.
   [Gawecki, Maciej] Dobry Wzrok Ophthalmol Clin, PL-80280 Gdansk, Poland.
   [Szolkiewicz, Marek] Pomeranian Hosp, Kashubian Ctr Heart & Vasc Dis, Dept Cardiol & Intervent Angiol, PL-84200 Wejherowo, Poland.
RP Gawecki, M (通讯作者)，Dobry Wzrok Ophthalmol Clin, PL-80280 Gdansk, Poland.
EM j_ladkowska@wp.pl; maciej@gawecki.com; e.mars@wp.pl
RI Gawęcki, Maciej/AAA-2517-2020
OI Gawęcki, Maciej/0000-0003-2901-0248
CR Arevalo JF, 2016, RETINA-J RET VIT DIS, V36, P859, DOI 10.1097/IAE.0000000000000827
   Bek T, 2018, CLIN OPHTHALMOL, V12, P473, DOI 10.2147/OPTH.S158760
   Bhuachalla BN, 2018, EXP GERONTOL, V106, P80, DOI 10.1016/j.exger.2018.02.029
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Butt AL, 2011, OPHTHALMOLOGY, V118, P1380, DOI 10.1016/j.ophtha.2010.11.007
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Cougnard-Gregoire A, 2013, INVEST OPHTH VIS SCI, V54, P1905, DOI 10.1167/iovs.12-10192
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Di Angelantonio E, 2019, LANCET GLOB HEALTH, V7, pE1332, DOI 10.1016/S2214-109X(19)30318-3
   Eren Esin, 2012, Open Biochem J, V6, P78, DOI 10.2174/1874091X01206010078
   Finger RP, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01554-2
   Fraser-Bell S, 2008, AM J OPHTHALMOL, V145, P308, DOI 10.1016/j.ajo.2007.10.007
   Guber J, 2014, OPEN OPHTHALMOL J, V8, P3, DOI 10.2174/1874364101408010003
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   Ingleheam CF, 2012, INVEST OPHTH VIS SCI, V53, P3325
   Izumi-Nagai K, 2007, ARTERIOSCL THROM VAS, V27, P2555, DOI 10.1161/ATVBAHA.107.151431
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Keles S, 2014, CLIN OPHTHALMOL, V8, P1573, DOI 10.2147/OPTH.S66160
   Kelly UL, 2020, J BIOL CHEM, V295, P13601, DOI 10.1074/jbc.RA119.012305
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Klein R, 2014, OPHTHALMOLOGY, V121, P1604, DOI 10.1016/j.ophtha.2014.03.005
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Lee S, 2013, J KOREAN MED SCI, V28, P769, DOI 10.3346/jkms.2013.28.5.769
   Lipecz A, 2019, GEROSCIENCE, V41, P813, DOI 10.1007/s11357-019-00138-3
   Machalinska A, 2012, ACTA OPHTHALMOL, V90, P695, DOI 10.1111/j.1755-3768.2011.02295.x
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Menger J.F., 2012, INVESTIG OPHTHALMOL, V53, P1
   Metelitsina TI, 2006, BRIT J OPHTHALMOL, V90, P342, DOI 10.1136/bjo.2005.082974
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Piermarocchi S, 2015, ACTA OPHTHALMOL, V93, pE451, DOI 10.1111/aos.12587
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rudnicka AR, 2010, EYE, V24, P1199, DOI 10.1038/eye.2010.8
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Seddon JM, 2017, INVEST OPHTH VIS SCI, V58, P6513, DOI 10.1167/iovs.17-23544
   Semba RD, 2019, LIPIDS HEALTH DIS, V18, DOI 10.1186/s12944-018-0954-7
   Shah AR, 2016, AM J OPHTHALMOL, V163, P154, DOI 10.1016/j.ajo.2015.11.033
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   van Asten F, 2014, OPHTHAL EPIDEMIOL, V21, P347, DOI 10.3109/09286586.2014.949010
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wang YF, 2016, NUTRIENTS, V8, DOI 10.3390/nu8100663
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xin XL, 2018, RETINA-J RET VIT DIS, V38, P497, DOI 10.1097/IAE.0000000000001741
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Zdrojewski L, 2014, FORUM NEFROLOGICZNE, V7, P38
   Zhao L, 2013, CURR MOL MED, V13, P929, DOI 10.2174/15665240113139990048
NR 55
TC 1
Z9 1
U1 0
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD OCT
PY 2021
VL 10
IS 19
AR 4595
DI 10.3390/jcm10194595
PG 14
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA WL3DW
UT WOS:000710291000001
PM 34640613
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Zanzottera, EC
   Messinger, JD
   Ach, T
   Smith, RT
   Freund, KB
   Curcio, CA
AF Zanzottera, Emma C.
   Messinger, Jeffrey D.
   Ach, Thomas
   Smith, R. Theodore
   Freund, K. Bailey
   Curcio, Christine A.
TI The Project MACULA Retinal Pigment Epithelium Grading System for
   Histology and Optical Coherence Tomography in Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; retinal pigment epithelium;
   melanosomes; lipofuscin; histology; apoptosis; migration;
   transdifferentiation; basal laminar deposits; spectral-domain optical
   coherence tomography
ID CHOROIDAL NEOVASCULAR MEMBRANES; GEOGRAPHIC ATROPHY SECONDARY;
   BRUCHS-MEMBRANE; FUNDUS AUTOFLUORESCENCE; CLINICOPATHOLOGICAL
   CORRELATION; MORPHOMETRIC-ANALYSIS; DRUSEN FORMATION; CELL-DEATH; EYES;
   COMPLEMENT
AB PURPOSE. To seek pathways of retinal pigment epithelium (RPE) fate in age-related macular degeneration via a morphology grading system; provide nomenclature, visualization targets, and metrics for clinical imaging and model systems.
   METHODS. Donor eyes with geographic atrophy (GA) or choroidal neovascularization (CNV) and one GA eye with previous clinical spectral-domain optical coherence tomography (SDOCT) imaging were processed for histology, photodocumented, and annotated at predefined locations. Retinal pigment epithelial cells contained spindle-shaped melanosomes, apposed a basal lamina or basal laminar deposit (BLamD), and exhibited recognizable morphologies. Thicknesses and unbiased estimates of frequencies were obtained.
   RESULTS. In 13 GA eyes (449 locations), 'Shedding,' 'Sloughed,' and 'Dissociated' morphologies were abundant; 22.2% of atrophic locations had 'Dissociated' RPE. In 39 CNV eyes (1363 locations), 37.3% of locations with fibrovascular/fibrocellular scar had 'Entombed' RPE; 'Sloughed,' 'Dissociated,' and 'Bilaminar' morphologies were abundant. Of abnormal RPE, CNV and GA both had similar to 35% 'Sloughed'/'Intraretinal,' with more Intraretinal in CNV (9.5% vs. 1.8%). 'Shedding' cells associated with granule aggregations in BLamD. The RPE layer did not thin, and BLamD remained thick, with progression. Granule-containing material consistent with three morphologies correlated to SDOCT hyperreflective foci in the previously examined GA patient.
   CONCLUSIONS. Retinal pigment epithelium morphology indicates multiple pathways in GA and CNV. Atrophic/scarred areas have numerous cells capable of transcribing genes and generating imaging signals. Shed granule aggregates, possibly apoptotic, are visible in SDOCT, as are 'Dissociated' and 'Sloughed' cells. The significance of RPE phenotypes is addressable in longitudinal, high-resolution imaging in clinic populations. Data can motivate future molecular phenotyping studies.
C1 [Zanzottera, Emma C.; Messinger, Jeffrey D.; Ach, Thomas; Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL 35294 USA.
   [Zanzottera, Emma C.] Univ Milan, Sacco Hosp, Dept Clin Sci Luigi Sacco, Eye Clin, Milan, Italy.
   [Smith, R. Theodore; Freund, K. Bailey] Univ Hosp Wurzburg, Dept Ophthalmol, Wurzburg, Germany.
   [Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Milan; Luigi Sacco Hospital; University of Wurzburg;
   Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, EyeSight Fdn Alabama Vis Res Labs, 1670 Univ Blvd Room 360, Birmingham, AL 35294 USA.
EM curcio@uab.edu
RI Ach, Thomas/AAE-7870-2021; Freund, K. Bailey/V-7488-2018
OI Ach, Thomas/0000-0001-6583-8283; Freund, K. Bailey/0000-0002-7888-9773;
   smith, theodore/0000-0002-1693-943X
FU National Eye Institute (NEI) [R01 EY06109, R01 EY015520, R01 EY 021470,
   EY 015520, P30 EY003039]; University of Milan; DFG (German Research
   Foundation) [AC265/1-1, AC265/2-1]; Macula Foundation; International
   Retinal Research Foundation; Arnold and Mabel Beckman Initiative for
   Macular Research; Edward N. and Della L. Thome Memorial Foundation;
   NATIONAL EYE INSTITUTE [R01EY021470, R01EY015520, P30EY003039,
   R01EY006109] Funding Source: NIH RePORTER
FX Supported by National Eye Institute (NEI) R01 EY06109 with institutional
   support from the EyeSight Foundation of Alabama and Research to Prevent
   Blindness, Inc. (CAC, JDM); University of Milan and NEI R01 EY015520
   (ECZ); DFG (German Research Foundation) AC265/1-1 and AC265/2-1 (TA) and
   NEI R01 EY015520 (RTS); NEI R01 EY 021470 and EY 015520 (RTS); and the
   Macula Foundation (KBF). Acquisition of donor eyes was additionally
   supported by the International Retinal Research Foundation, NEI P30
   EY003039, and the Arnold and Mabel Beckman Initiative for Macular
   Research. Creation of Project MACULA was additionally supported from the
   Edward N. and Della L. Thome Memorial Foundation.
CR Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Ahlers C, 2010, INVEST OPHTH VIS SCI, V51, P2149, DOI 10.1167/iovs.09-3817
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   [Anonymous], 1997, DIAGNOSIS TREATMENT
   Biarnes M, 2012, GRAEF ARCH CLIN EXP, V250, P485, DOI 10.1007/s00417-011-1846-y
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   BIRNBACH CD, 1994, OPHTHALMOLOGY, V101, P1211
   Bonilha VL, 2014, OPHTHALMIC GENET, P1
   Booij Judith C, 2010, PLoS One, V5, pe9341, DOI 10.1371/journal.pone.0009341
   Bretillon L, 2008, INVEST OPHTH VIS SCI, V49, P1307, DOI 10.1167/iovs.07-0808
   Burns R P, 1980, Trans Am Ophthalmol Soc, V78, P206
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   CAMPOCHIARO P A, 1984, Archives of Ophthalmology, V102, P1830
   Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022818
   Chen XT, 2013, J NEUROPATH EXP NEUR, V72, P782, DOI 10.1097/NEN.0b013e31829e8375
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Curcio CA, 2000, OPHTHALMOLOGY, V107, P334, DOI 10.1016/S0161-6420(99)00037-8
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2011, P NATL ACAD SCI USA, V108, P18569, DOI 10.1073/pnas.1115497108
   Curcio CA, 2011, INVEST OPHTH VIS SCI, V52, P3943, DOI 10.1167/iovs.10-6377
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Day S, 2011, AM J OPHTHALMOL, V152, P1014, DOI 10.1016/j.ajo.2011.05.008
   Dell'Angelica EC, 2000, FASEB J, V14, P1265, DOI 10.1096/fj.14.10.1265
   Delori F, 2011, INVEST OPHTH VIS SCI, V52, P9379, DOI 10.1167/iovs.11-8319
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   EAGLE RC, 1980, OPHTHALMOLOGY, V87, P1189
   El-Emam S, 2013, RETINA-J RET VIT DIS, V33, P1249, DOI 10.1097/IAE.0b013e31827b6439
   Evans JB, 2013, NAT REV DRUG DISCOV, V12, P501, DOI 10.1038/nrd4038
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fleckenstein M, 2014, INVEST OPHTH VIS SCI, P2911
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P3761, DOI 10.1167/iovs.10-7021
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fu L, 2007, HUM MOL GENET, V16, P2411, DOI 10.1093/hmg/ddm198
   Galluzzi L, 2015, CELL DEATH DIFFER, V22, P58, DOI 10.1038/cdd.2014.137
   Garland DL, 2014, HUM MOL GENET, V23, P52, DOI 10.1093/hmg/ddt395
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gocho K, 2013, INVEST OPHTH VIS SCI, V54, P3673, DOI 10.1167/iovs.12-10672
   Gobel AP, 2011, OPHTHALMOLOGICA, V226, P182, DOI 10.1159/000330420
   Gorczynska I, 2009, BRIT J OPHTHALMOL, V93, P603, DOI 10.1136/bjo.2007.136101
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Grossniklaus HE, 2006, AM J OPHTHALMOL, V141, P93, DOI 10.1016/j.ajo.2005.07.076
   GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   GROSSNIKLAUS HE, 1994, OPHTHALMOLOGY, V101, P1099
   Grossniklaus HE, 2000, ARCH OPHTHALMOL-CHIC, V118, P625
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hariri A, 2015, OPHTHALMOLOGY, V122, P407, DOI 10.1016/j.ophtha.2014.08.035
   Hashimoto T, 1999, JPN J OPHTHALMOL, V43, P375, DOI 10.1016/S0021-5155(99)00094-5
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hu P, 2013, P NATL ACAD SCI USA, V110, pE4069, DOI 10.1073/pnas.1307574110
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   JAFFE GJ, 1988, OPHTHALMOLOGY, V95, P1130
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   JOHNSON NF, 1977, BRIT J OPHTHALMOL, V61, P564, DOI 10.1136/bjo.61.9.564
   Jones BW, 2012, JPN J OPHTHALMOL, V56, P289, DOI 10.1007/s10384-012-0147-2
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Karampelas M, 2013, BRIT J OPHTHALMOL, V97, P1256, DOI 10.1136/bjophthalmol-2013-303219
   Keane PA, 2012, INVEST OPHTH VIS SCI, V53, P1152, DOI 10.1167/iovs.11-8130
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33
   Kim Y, 2014, P NATL ACAD SCI USA, V111, P16082, DOI 10.1073/pnas.1403814111
   King JL, 2012, INVEST OPHTH VIS SCI, V53, P93, DOI 10.1167/iovs.11-8683
   Kirchhof B, 1989, Dev Ophthalmol, V16, P1
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Kliffen M, 1997, MICROSC RES TECHNIQ, V36, P106, DOI 10.1002/(SICI)1097-0029(19970115)36:2<106::AID-JEMT4>3.0.CO;2-N
   Kuwabara T, 1979, RETINAL PIGMENT EPIT, P293
   Lafaut BA, 2001, BRIT J OPHTHALMOL, V85, P454, DOI 10.1136/bjo.85.4.454
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Litts KM, 2015, JAMA OPHTHALMOL, V133, P609, DOI 10.1001/jamaophthalmol.2015.126
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   MANDELCORN MS, 1975, AM J OPHTHALMOL, V80, P227, DOI 10.1016/0002-9394(75)90137-3
   Marmorstein AD, 2002, INVEST OPHTH VIS SCI, V43, P2435
   Marmorstein LY, 2007, HUM MOL GENET, V16, P2423, DOI 10.1093/hmg/ddm199
   Marsiglia M, RETINA IN PRESS
   MCDONNELL PJ, 1986, OPHTHALMOLOGY, V93, P116
   Michels S, 2008, BRIT J OPHTHALMOL, V92, P204, DOI 10.1136/bjo.2007.130047
   MILLER H, 1986, INVEST OPHTH VIS SCI, V27, P1644
   Mones J, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.026
   Moussa K, 2013, RETINA-J RET VIT DIS, V33, P1590, DOI 10.1097/IAE.0b013e31828d6052
   Mukherjee S, 2007, INVEST OPHTH VIS SCI, V48, P1892, DOI 10.1167/iovs.06-1095
   Ooto S, 2014, JAMA OPHTHALMOL, V132, P806, DOI 10.1001/jamaophthalmol.2014.1871
   ORLOW SJ, 1995, J INVEST DERMATOL, V105, P3, DOI 10.1111/1523-1747.ep12312291
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Palczewska G, 2014, NAT MED, V20, P785, DOI 10.1038/nm.3590
   PENFOLD PL, 1986, INVEST OPHTH VIS SCI, V27, P364
   Pircher M, 2011, PROG RETIN EYE RES, V30, P431, DOI 10.1016/j.preteyeres.2011.06.003
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Rossi EA, 2013, BIOMED OPT EXPRESS, V4, P2527, DOI 10.1364/BOE.4.002527
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Sarks J, 2006, BRIT J OPHTHALMOL, V90, P442, DOI 10.1136/bjo.2005.083022
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   Schaal KB, RETINA IN PRESS
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Schraermeyer U, 1999, PIGM CELL RES, V12, P219, DOI 10.1111/j.1600-0749.1999.tb00755.x
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Scoles D, 2013, BIOMED OPT EXPRESS, V4, P1710, DOI 10.1364/BOE.4.001710
   Shi G, 2008, INVEST OPHTH VIS SCI, V49, P4620, DOI 10.1167/iovs.08-1816
   Simader C, 2014, AM J OPHTHALMOL, V158, P557, DOI 10.1016/j.ajo.2014.05.026
   Smith RT, 2014, BIOMED OPT EXPRESS, V5, P4171, DOI 10.1364/BOE.5.004171
   Smith RT, 2009, INVEST OPHTH VIS SCI, V50, P3907, DOI 10.1167/iovs.08-2448
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   STEINBERG RH, 1977, PHILOS T ROY SOC B, V277, P459, DOI 10.1098/rstb.1977.0028
   STEINMETZ RL, 1991, OPHTHALMOLOGY, V98, P953
   TOTH CA, 1995, OPHTHALMOLOGY, V102, P272
   Ufret-Vincenty RL, 2010, INVEST OPHTH VIS SCI, V51, P5878, DOI 10.1167/iovs.09-4457
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   VERBRUGGE LM, 1995, AM J PUBLIC HEALTH, V85, P173, DOI 10.2105/AJPH.85.2.173
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   Wilson JD, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2743971
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3269, DOI 10.1167/iovs.15-16432
   Zarbin MA, 2014, DEV OPHTHALMOL, V53, P1, DOI 10.1159/000358536
   Zhang QX, 2013, SCI REP-UK, V3, DOI 10.1038/srep02644
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
NR 147
TC 97
Z9 98
U1 0
U2 7
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2015
VL 56
IS 5
BP 3253
EP 3268
DI 10.1167/iovs.15-16431
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CK7UJ
UT WOS:000356439200060
PM 25813989
OA Green Published
DA 2022-11-30
ER

PT J
AU Gale, RP
   Mahmood, S
   Devonport, H
   Patel, PJ
   Ross, AH
   Walters, G
   Downey, L
   El-Sherbiny, S
   Freeman, M
   Berry, S
   Jain, N
AF Gale, Richard P.
   Mahmood, Sajjad
   Devonport, Helen
   Patel, Praveen J.
   Ross, Adam H.
   Walters, Gavin
   Downey, Louise
   El-Sherbiny, Samer
   Freeman, Mary
   Berry, Simon
   Jain, Nitin
TI Action on neovascular age-related macular degeneration (nAMD):
   recommendations for management and service provision in the UK hospital
   eye service
SO EYE
LA English
DT Article
ID ANTI-VEGF TREATMENT; TREAT-AND-EXTEND; OPTICAL COHERENCE TOMOGRAPHY;
   GROWTH-FACTOR THERAPY; REAL-WORLD OUTCOMES; INTRAVITREAL RANIBIZUMAB;
   INTRAOCULAR-PRESSURE; SUSTAINED ELEVATION; VISUAL OUTCOMES; SIGHT LOSS
AB This report by a group of UK retina specialists and health professionals considers best practice recommendations for the management of sight-threatening neovascular age-related macular degeneration (nAMD), based on collective experience and expertise in routine clinical practice. The authors provide an update for ophthalmologists, allied healthcare professionals and commissioners on practice principles for optimal patient care and service provision standards. Refinement of care pathways for nAMD has improved access to intravitreal anti-vascular endothelial growth factor therapy but there are still variations in care and reported outcomes between clinic centres. Innovative organisational models of service provision allow providers to better match capacity with increasing demand. The authors review the recent NICE guideline for diagnosis and management of AMD, considerations for switching therapies and stopping treatment and need for regular monitoring of non-affected fellow eyes in patients with unilateral nAMD. Actions for delivery of high-quality care and to improve long-term patient outcomes are discussed. Local pathways need to detail nAMD target time to treat, maintenance of review intervals to ensure proactive treatment regimens are delivered on time and appropriate discharge for patients deemed low risk or no longer benefiting from treatment. Actual visual acuity outcomes achieved and maintenance of the level of vision when disease stability is achieved are considered good measures for judging the quality of care in the treatment of patients with nAMD. Robust community referral pathways must be in place for suspected reactivation of choroidal neovascularisation and rapid referral for second eye involvement. Practical considerations for intravitreal injection therapy are outlined.
C1 [Gale, Richard P.; Mahmood, Sajjad; Devonport, Helen; Patel, Praveen J.; Ross, Adam H.; Walters, Gavin; Downey, Louise; El-Sherbiny, Samer; Freeman, Mary; Berry, Simon; Jain, Nitin] Act nAMD Grp, Birmingham, W Midlands, England.
   [Gale, Richard P.] York Hosp, York, N Yorkshire, England.
   [Mahmood, Sajjad] Manchester Royal Eye Hosp, Manchester, Lancs, England.
   [Devonport, Helen] Bradford Teaching Hosp NHS Fdn Trust, Bradford, W Yorkshire, England.
   [Patel, Praveen J.] Moorfields Eye Hosp NHS Fdn Trust, Natl Inst Hlth Res, Biomed Res Ctr, London, England.
   [Patel, Praveen J.] UCL Inst Ophthalmol, London, England.
   [Ross, Adam H.] Univ Hosp Bristol NHS Fdn Trust, Bristol, Avon, England.
   [Walters, Gavin] Harrogate & Dist NHS Fdn Trust, Harrogate, England.
   [Downey, Louise] Hull & East Yorkshire Hosp NHS Trust, Kingston Upon Hull, N Humberside, England.
   [El-Sherbiny, Samer] South Warwickshire NHS Fdn Trust, Warwick, Warwick, England.
   [Freeman, Mary] Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, S Yorkshire, England.
   [Berry, Simon] Simon Berry Optometrist, Durham, England.
   [Jain, Nitin] Bayer, Reading, Berks, England.
C3 Manchester Royal Eye Hospital; University of London; University College
   London; Moorfields Eye Hospital NHS Foundation Trust; University of
   London; University College London; University of Bristol; University of
   Sheffield; Bayer AG
RP Gale, RP (通讯作者)，Act nAMD Grp, Birmingham, W Midlands, England.; Gale, RP (通讯作者)，York Hosp, York, N Yorkshire, England.
EM Richard.Gale@york.nhs.uk
RI Mahmood, Sajjad/AAK-7645-2021
FU Bayer plc
FX This publication and the expert roundtable meeting on which the paper is
   based were sponsored by Bayer plc. Bayer checked that the content was
   factually accurate, balanced and compliant with the Association of the
   British Pharmaceutical Industry Code of Practice. The views expressed
   are those of the author(s) and are not necessarily those of Bayer or the
   NHS.
CR Almuhtaseb H, 2017, EYE, V31, P878, DOI 10.1038/eye.2017.6
   Amoaku W, 2012, EYE, V26, pS2, DOI 10.1038/eye.2011.343
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   [Anonymous], 2018, NICE GUIDELINE NG82
   [Anonymous], 2017, MONARCH STUDY PROTOC
   [Anonymous], 2018, LUC RAN SOL INJ SUMM
   [Anonymous], 2018, EYL AFL SOL INJ SUMM
   [Anonymous], 2008, RAN PEG TREATM AG RE
   Baker H, 2016, OPHTHAL PHYSL OPT, V36, P545, DOI 10.1111/opo.12312
   Barthelmes D, 2016, BRIT J OPHTHALMOL, V100, P1640, DOI 10.1136/bjophthalmol-2015-308090
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Borooah S, 2015, EYE, V29, P1156, DOI 10.1038/eye.2015.83
   Bressler SB, 2015, JAMA OPHTHALMOL, V133, P589, DOI 10.1001/jamaophthalmol.2015.186
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Burton BJ, 2017, ASS RES VIS OPHTH AR
   Butt T, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006535
   Chew JK, 2017, OPHTHALMOLOGICA, V238, P23, DOI 10.1159/000469652
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Chopra R, 2018, ASS RES VIS OPHTH AR
   DaCosta J, 2014, EYE, V28, P734, DOI 10.1038/eye.2014.69
   Davis A, 2017, EYE, V31, P422, DOI 10.1038/eye.2016.225
   Dedania VS, 2015, RETINA-J RET VIT DIS, V35, P841, DOI 10.1097/IAE.0000000000000520
   Dirani A, 2018, CLIN OPHTHALMOL, V12, P593, DOI 10.2147/OPTH.S160367
   EDNA, 2015, EDNA EARLY DETECTION
   Ehlken C, 2014, EYE, V28, P538, DOI 10.1038/eye.2014.64
   Essex RW, 2016, OPHTHALMOLOGY, V123, P2393, DOI 10.1016/j.ophtha.2016.07.012
   Faes L, 2014, EYE, V28, P788, DOI 10.1038/eye.2014.104
   Ferris FL, 2017, JAMA OPHTHALMOL, V135, P145, DOI 10.1001/jamaophthalmol.2016.4820
   Foot B, 2017, EYE, V31, P771, DOI 10.1038/eye.2017.1
   Framme C, 2017, ASS RES VIS OPHTH AR
   Gale R, 2016, OPHTHALMOLOGICA, V236, P193, DOI 10.1159/000451065
   Hamilton RD, 2018, ASS RES VIS OPHTH AR
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Hunyor AP, 2018, ACTA OPHTHALMOL, V96, P435, DOI 10.1111/aos.13417
   International Council of Ophthalmology, NUMB OPHTH PRACT TRA
   Kelly SP, 2011, CLIN OPHTHALMOL, V5, P1673, DOI 10.2147/OPTH.S26753
   Khan AA, 2015, PUBLIC HEALTH, V129, P117, DOI 10.1016/j.puhe.2014.10.010
   Khan Y, 2016, ASS RES VIS OPHTH AR
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Koh AHC, 2018, ASS RES VIS OPHTH AR
   Kortuem K, 2018, BRIT J OPHTHALMOL, V102, P1391, DOI 10.1136/bjophthalmol-2017-311494
   Lanzetta P, 2017, GRAEF ARCH CLIN EXP, V255, P1259, DOI 10.1007/s00417-017-3647-4
   Lee AY, 2018, BRIT J OPHTHALMOL, V102, P465, DOI 10.1136/bjophthalmol-2017-310939
   Lee AY, 2015, BRIT J OPHTHALMOL, V99, P1045, DOI 10.1136/bjophthalmol-2014-306229
   Lee CS, 2017, RETINA, V38, P951
   Liew G, 2016, EYE, V30, P1462, DOI 10.1038/eye.2016.149
   Madhusudhana KC, 2016, BRIT J OPHTHALMOL, V100, P1617, DOI 10.1136/bjophthalmol-2015-308077
   Mall SP, 2015, EYE, V29, P290, DOI 10.1038/eye.2014.234
   Mantel I, 2018, SURV OPHTHALMOL, V63, P638, DOI 10.1016/j.survophthal.2018.02.004
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McKibbin M, 2015, GRAEF ARCH CLIN EXP, V253, P1479, DOI 10.1007/s00417-014-2839-4
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Merani Rohan, 2015, Int J Retina Vitreous, V1, P9
   Mookhtiar M, 2012, EYE, V26, P619, DOI 10.1038/eye.2011.345
   Muether PS, 2011, GRAEF ARCH CLIN EXP, V249, P633, DOI 10.1007/s00417-010-1520-9
   Murray CD, 2014, EYE, V28, P1218, DOI 10.1038/eye.2014.180
   National Institute for Health and Care Excellence, 2013, PRACT GUID PMG30
   National Institute for Health and Care Excellence, 2013, AFL SOL INJ TREAT WE
   NHS Digital, HOSP OUTP ACT 2016 1
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Patel PJ, 2017, CLIN OPHTHALMOL, V11, P1957, DOI 10.2147/OPTH.S145732
   Quartilho A, 2016, EYE, V30, P602, DOI 10.1038/eye.2015.288
   Raguro A, 2015, ASS RES VIS OPHTH AR
   Rashid A, 2009, ASS RES VIS OPHTH AR
   Rathi S, 2017, OPHTHALMOLOGY, V124, P1729, DOI 10.1016/j.ophtha.2017.05.026
   Real JP, 2015, GRAEF ARCH CLIN EXP, V253, P1859, DOI 10.1007/s00417-014-2885-y
   Reeves BC, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010685
   Rob N, 2013, ASS RES VIS OPHTH AR
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross AH, 2013, EYE, V27, P56, DOI 10.1038/eye.2012.225
   Rostron E, 2012, EYE, V26, P933, DOI 10.1038/eye.2012.61
   Rufai SR, 2017, EYE, V31, P1337, DOI 10.1038/eye.2017.67
   Sarao V, 2016, RETINA-J RET VIT DIS, V36, P770, DOI 10.1097/IAE.0000000000000751
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Scottish Medicines Consortium, 2013, AFL 40MG ML SOL INTR
   Seguin-Greenstein S, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4095852
   Senra H, 2017, AM J OPHTHALMOL, V177, P213, DOI 10.1016/j.ajo.2017.03.005
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Silva R, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329473
   Sim PY, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017771
   Skaat A, 2012, AM J OPHTHALMOL, V153, P214, DOI 10.1016/j.ajo.2011.08.035
   Spooner K, 2017, CLIN OPHTHALMOL, V11, P161, DOI 10.2147/OPTH.S125676
   Talks JS, 2017, EYE, V31, P1613, DOI 10.1038/eye.2017.86
   The College of Optometrists, 2017, GUID PROF PRACT
   The Royal College of Ophthalmologists, 2013, AG REL MAC DEG GUID
   The Royal College of Ophthalmologists, 2017, WAY FORW AG REL MAC
   The Royal College of Ophthalmologists, 2018, OPHTH SERV GUID INTR
   The Vision Academy, 2017, BIL ANT VEGF TREATM
   Townsend D, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007400
   Tsaousis KT, 2016, ACTA OPHTHALMOL, V94, pe353, DOI 10.1111/aos.12832
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Vaze A, 2014, ACTA OPHTHALMOL, V92, pe697, DOI 10.1111/aos.12417
   Yadav S, 2017, BRIT J OPHTHALMOL, V101, P1377, DOI 10.1136/bjophthalmol-2016-310074
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
NR 98
TC 35
Z9 35
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAR
PY 2019
VL 33
SU S
DI 10.1038/s41433-018-0300-3
PG 21
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LF4CN
UT WOS:000527366800001
PM 30926932
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Potter, MJ
   Szabo, SM
   Li, WW
AF Potter, M. J.
   Szabo, S. M.
   Li, W. W.
TI Comparison of visual acuity outcomes in predominantly classic vs occult
   lesions in age-related macular degeneration treated with photodynamic
   therapy
SO EYE
LA English
DT Article
DE photodynamic therapy; age-related; macular degeneration; choroidal
   neovascularization
AB Purpose To determine if patients with occult with no classic and predominantly classic (PC) choroidal neovascular membranes have clinically equivalent visual outcomes after treatment with photodynamic therapy (PDT) with verteporfin.
   Methods This is a retrospective, observational cohort study. Two hundred and seventy-seven consecutive patients with occult or PC choroidal neovascularization secondary to age-related macular degeneration treated with PDT were included. The main outcome was the difference in mean change in Early Treatment of Diabetic Retinopathy Study (ETDRS) acuity lost from baseline in occult vs PC lesions, with the minimal clinically important difference (MCID) set at 7.5 letters.
   Results At baseline, 131 patients had occult and 146 had PC choroidal neovascularization. Twelve-month follow-up data were available for 94 occult and 110 PC participants. Occult patients lost an average of 8.7 letters (1.9 lines), and patients in the PC group an average of 10.0 ETDRS letters (two lines) over 12 months. The mean letters lost at 12 months was not significantly different between the groups, and the MCID was not detected (difference 1.3 letters; P=0.411; 95% confidence interval (-2.3, 5.6)). Patients with occult lesions required a mean of 2.99 treatments vs a mean of 2.96 treatments in the PC group (out of a possible 4; P=0.172).
   Conclusion We were not able to detect a clinically important difference in mean change in visual acuity with PDT treatment between patients with occult and PC lesions.
C1 [Potter, M. J.; Szabo, S. M.; Li, W. W.] Univ British Columbia, Dept Ophthalmol & Visual Sci, Vancouver, BC V5Z 3N9, Canada.
   [Szabo, S. M.] Univ British Columbia, Dept Hlth Care & Epidemiol, Vancouver, BC V5Z 1M9, Canada.
C3 University of British Columbia; University of British Columbia
RP Potter, MJ (通讯作者)，Univ British Columbia, Dept Ophthalmol & Visual Sci, 2550 Willow St, Vancouver, BC V5Z 3N9, Canada.
EM mpotter@interchange.ubc.ca
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Ferris FL, 1996, OPHTHALMOLOGY, V103, P181, DOI 10.1016/S0161-6420(96)30742-2
   GOULD AL, 1980, BIOMETRICS, V36, P721, DOI 10.2307/2556126
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6
   Kaiser RS, 2002, RETINA-J RET VIT DIS, V22, P683, DOI 10.1097/00006982-200212000-00001
   *VERT ROUNDT 2000, 2002, RETINA, V22, P6
NR 10
TC 8
Z9 8
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD FEB
PY 2008
VL 22
IS 2
BP 194
EP 199
DI 10.1038/sj.eye.6702547
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 262IE
UT WOS:000253141400005
PM 16946758
OA Bronze
DA 2022-11-30
ER

PT J
AU Geltzer, A
   Turalba, A
   Vedula, SS
AF Geltzer, A.
   Turalba, A.
   Vedula, S. S.
TI Surgical implantation of steroids with antiangiogenic characteristics
   for treating neovascular age-related macular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID INTRAVITREAL TRIAMCINOLONE ACETONIDE; SUBFOVEAL CHOROIDAL
   NEOVASCULARIZATION; ANECORTAVE ACETATE; PHOTODYNAMIC THERAPY;
   ANGIOSTATIC STEROIDS; DELIVERY; SAFETY
AB Background
   Neovascular age-related macular degeneration (AMD) is associated with rapid vision loss due to choroidal neovascularization (CNV), leakage, and scarring. Steroids have gained attention in their role for the treatment of neovascular AMD for their antiangiogenic and anti-inflammatory properties.
   Objectives
   This review aims to examine effects of steroids with antiangiogenic properties in the treatment of neovascular AMD.
   Search strategy
   We searched for trials in CENTRAL, MEDLINE, EMBASE, and LILACS on 2 October 2006.
   Selection criteria
   We included randomised controlled clinical trials of intra- and peri-ocular steroids in people diagnosed with neovascular AMD.
   Data collection and analysis
   Review authors extracted the data and assessed trial quality independently. We did not pool data since the included studies evaluated difference comparisons.
   Main results
   We report the risk of losing three or more lines vision at 12 months - "vision loss". One trial ( 139 people randomized) reported that a single dose of intravitreal triamcinolone (n = 75) (4 mg) had no significant effect on the risk of vision loss compared to placebo ( n = 76). ( Risk ratio vision loss 0.97, 95% confidence interval (CI) 0.74 to 1.26). Eyes treated with triamcinolone were more likely to develop cataracts and experience increased intraocular pressure (IOP) compared to untreated eyes. One trial ( 128 people randomized) reported the effects of anecortave acetate ( 3 mg ( n = 32), 15 mg ( n = 33) or 30 mg ( n = 33) single dose with retreatment every six months if indicated) compared to placebo ( n = 30). Risk ratio vision loss 0.80 ( 95% CI 0.45 to 1.45) in the 3 mg group, 0.45 ( 95% CI 0.21 to 0.97) in the 15 mg group and 0.91 ( 95% CI 0.52 to 1.58) in the 30 mg group. Side effects were similar in all treatment groups with the anecortave group having a slightly higher incidence of foreign body sensation compared to placebo. There was a high loss to follow- up. The final analysis may have been subject to selection bias as participants who were not selected for retreatment, possibly with worsening disease, were excluded. There was also a possibility of type I error due to multiple statistical comparisons. The sample size was estimated on the basis of a single 2-way comparison but three 2-way comparisons were analysed and presented. One trial reported that anecortave acetate ( n = 263) ( 15 mg administered at beginning of study and six months) gave similar results to photodynamic therapy ( n = 267) ( risk ratio vision loss 1.08, 95% CI 0.91 to 1.29).
C1 Brown Univ, Providence, RI 02906 USA.
C3 Brown University
RP Geltzer, A (通讯作者)，Brown Univ, 389 Benefit St, Providence, RI 02906 USA.
EM youngheeart@mac.com
FU NEI NIH HHS [N01EY21003, N01 EY21003] Funding Source: Medline; NATIONAL
   EYE INSTITUTE [N01EY021003] Funding Source: NIH RePORTER
CR Agurto-Rivera Ricardo, 2005, BMC Ophthalmol, V5, P27
   Augustin AJ, 2005, GRAEF ARCH CLIN EXP, V243, P9, DOI 10.1007/s00417-004-0961-4
   Bakri SJ, 2006, EXPERT OPIN INV DRUG, V15, P163, DOI 10.1517/13543784.15.2.163
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   BenEzra D, 1997, INVEST OPHTH VIS SCI, V38, P1954
   BLEI F, 1993, J CELL PHYSIOL, V155, P568, DOI 10.1002/jcp.1041550315
   Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Carrasquillo KG, 2003, INVEST OPHTH VIS SCI, V44, P290, DOI 10.1167/iovs.01-1156
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Clark AF, 1999, INVEST OPHTH VIS SCI, V40, P2158
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Evans JR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub2
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Arevalo JF, 2005, RETINA-J RET VIT DIS, V25, P719, DOI 10.1097/00006982-200509000-00006
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gillies MC, 2004, ARCH OPHTHALMOL-CHIC, V122, P336, DOI 10.1001/archopht.122.3.336
   Glanville JM, 2006, J MED LIBR ASSOC, V94, P130
   JAFFE GF, 2000, INVEST OPHTHALMOL, V41, P3549
   Jonas JB, 2004, ARCH OPHTHALMOL-CHIC, V122, P218, DOI 10.1001/archopht.122.2.218
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Krzystolik MG, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139
   Kurz Daryl, 2002, Ophthalmol Clin North Am, V15, P405, DOI 10.1016/S0896-1549(02)00034-2
   Musch DC, 1997, NEW ENGL J MED, V337, P83, DOI 10.1056/NEJM199707103370203
   Olsen TW, 2006, AM J OPHTHALMOL, V142, P777, DOI 10.1016/j.ajo.2006.05.045
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   Reddy U, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005138.pub2
   REGILLO CD, 2002, AM ACAD OPHTHALMOLOG, P282
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Schmidt-Erfurth U, 2005, EUR J OPHTHALMOL, V15, P482, DOI 10.1177/112067210501500411
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Tielsch JM, 2002, VISION PROBLEMS US P
   Van de Moere A, 2005, OPHTHALMOLOGY, V112, P1897, DOI 10.1016/j.ophtha.2005.06.018
   Virgili G, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004763.pub2
   WHO, 1997, FACT SHEET
   Wormald R, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub2
   Yasukawa T, 1999, INVEST OPHTH VIS SCI, V40, P2690
NR 44
TC 8
Z9 8
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2007
IS 4
AR CD005022
DI 10.1002/14651858.CD005022.pub2
PG 22
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 220WT
UT WOS:000250188700026
PM 17943833
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Jaffe, GJ
   Kaiser, PK
   Thompson, D
   Gibson, A
   Saroj, N
   Vitti, R
   Berliner, AJ
   Heier, JS
AF Jaffe, Glenn J.
   Kaiser, Peter K.
   Thompson, Desmond
   Gibson, Andrea
   Saroj, Namrata
   Vitti, Robert
   Berliner, Alyson J.
   Heier, Jeffrey S.
TI Differential Response to Anti-VEGF Regimens in Age-Related Macular
   Degeneration Patients with Early Persistent Retinal Fluid
SO OPHTHALMOLOGY
LA English
DT Article
ID VISUAL-ACUITY; RANIBIZUMAB; BEVACIZUMAB; AFLIBERCEPT; MORPHOLOGY;
   TRIALS; TRAP
AB Purpose: To compare the effect of intravitreal aflibercept or ranibizumab drug type and frequency on visual acuity outcomes in eyes with neovascular age-related macular degeneration (NVAMD) and early persistent retinal fluid after 3 initial monthly injections.
   Design: A post hoc analysis of eyes enrolled in VIEW 1 and VIEW 2, 2 similarly designed, randomized, phase 3 trials.
   Participants: A total of 1815 eyes with NVAMD from VIEW 1 and VIEW 2.
   Methods: Analyses included patients with known fluid status at baseline and weeks 4, 8, and 12 in 3 treatment groups: ranibizumab 0.5 mg every 4 weeks (Rq4) (n = 595), intravitreal aflibercept injection (IAI) 2 mg every 4 weeks (2q4) (n = 613), and IAI 2 mg every 8 weeks (2q8) after 3 monthly injections (n = 607).
   Main Outcome Measures: Mean best-corrected visual acuity (BCVA) change from baseline over weeks 16 to 52 and the proportion of eyes that gained >= 15 letters or lost >= 5 letters were evaluated in eyes with and without persistent fluid (cystic intraretinal or subretinal fluid at all 4 initial visits). Visual outcomes also were assessed in eyes with persistent fluid by fluid type (intraretinal and subretinal fluid).
   Results: The proportions of eyes with persistent fluid were 29.4%, 18.8%, and 20.3% in the Rq4, 2q4, and 2q8 groups, respectively. In these eyes, mean BCVA gain from baseline to week 52 was greater with 2q4 compared with Rq4 (P < 0.01) and 2q8 (P < 0.05), whereas it was similar with Rq4 and 2q8 (P = 0.294). At week 52, similar proportions of eyes gained >= 15 letters (31.5%-35.2%), whereas fewer eyes lost >= 5 letters with 2q4 compared with Rq4 and 2q8 (6.5% vs. 16.6% and 16.2%). The pattern of visual outcomes was similar regardless of fluid type. In eyes without persistent fluid, BCVA changes were similar across treatment groups.
   Conclusions: In patients with early persistent fluid, 2q4 may provide additional clinical benefit over 2q8 or Rq4. (C) 2016 by the American Academy of Ophthalmology.
C1 [Jaffe, Glenn J.] Duke Univ, Dept Ophthalmol, Durham, NC USA.
   [Kaiser, Peter K.] Cole Eye Inst, Cleveland, OH USA.
   [Thompson, Desmond; Gibson, Andrea; Saroj, Namrata; Vitti, Robert; Berliner, Alyson J.] Regeneron Pharmaceut Inc, Tarrytown, NY USA.
   [Heier, Jeffrey S.] Ophthalm Consultants Boston, Boston, MA USA.
C3 Duke University; Regeneron; Ophthalmic Consultants of Boston
RP Jaffe, GJ (通讯作者)，Duke Univ, Sch Med, Dept Ophthalmol, Duke Eye Ctr, Box 3802, Durham, NC 27710 USA.
EM glenn.jaffe@duke.edu
OI Kaiser, Peter/0000-0001-5126-045X
FU Acucela; Alcon/LPath; Allergan; Astellas; Corcept; Genentech; Kala
   Pharmaceuticals; Kato Pharmaceuticals; Novartis; Ohr Pharmaceuticals;
   Ophthotech; QLT; Regeneron; Sanofi/Genzyme; Stealth Biotherapeutics;
   Thrombogenics
FX A.G., N.S., R.V., and A.J.B.: Employees - Regeneron Pharmaceuticals,
   Inc. J.S.H.: Consultant - Aerpio, Alcon/LPath, Allergan, Avalanche,
   Bayer, EyeGate, Foresight Biotherapeutics, Forsight Vision4, Genentech,
   Icon Therapeutics, Janssen R&D, Kala Pharmaceuticals, Kanghong, Kato
   Pharmaceuticals, Novartis, Ohr Pharmaceuticals, QLT, Regeneron,
   RetroSense, Santen, Shire, Stealth Biotherapeutics, Thrombogenics,
   Vision Medicines, and Xcovery; Received research funding - Acucela,
   Alcon/LPath, Allergan, Astellas, Corcept, Genentech, Kala
   Pharmaceuticals, Kato Pharmaceuticals, Novartis, Ohr Pharmaceuticals,
   Ophthotech, QLT, Regeneron, Sanofi/Genzyme, Stealth Biotherapeutics, and
   Thrombogenics.
CR American Society of Retina Specialists (ASRS), GLOB TRENDS RET PREF
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
NR 14
TC 53
Z9 53
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2016
VL 123
IS 9
BP 1856
EP 1864
DI 10.1016/j.ophtha.2016.05.016
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EE3QE
UT WOS:000389508500014
PM 27369111
OA hybrid
DA 2022-11-30
ER

PT J
AU Tseng, WA
   Thein, T
   Kinnunen, K
   Lashkari, K
   Gregory, MS
   D'Amore, PA
   Ksander, BR
AF Tseng, Wen Allen
   Thein, Thuzar
   Kinnunen, Kati
   Lashkari, Kameran
   Gregory, Meredith S.
   D'Amore, Patricia A.
   Ksander, Bruce R.
TI NLRP3 Inflammasome Activation in Retinal Pigment Epithelial Cells by
   Lysosomal Destabilization: Implications for Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID HUMAN RPE CELLS; PATTERN-RECOGNITION; NALP3 INFLAMMASOME; INNATE
   IMMUNITY; FACTOR-B; DRUSEN; EXPRESSION; INTERLEUKIN-1-BETA; COMMON;
   DAMAGE
AB PURPOSE. To evaluate the effect of lysosomal destabilization on NLRP3 inflammasome activation in RPE cells and to investigate the mechanisms by which inflammasome activation may contribute to the pathogenesis of age-related macular degeneration (AMD).
   METHODS. Human ocular tissue sections from patients with geographic atrophy or neovascular AMD were stained for NLRP3 and compared to tissues from age-matched controls. Expression of the IL-1 beta precursor, pro-IL-1 beta, was induced in ARPE-19 cells by IL-1 alpha treatment. Immunoblotting was performed to assess expression of NLRP3 inflammasome components (NLRP3, ASC, and procaspase-1) and pro-IL-1 beta in ARPE-19 cells. Lysosomes were destabilized using the lysosomotropic agent L-leucyl-L-leucine methyl ester (Leu-Leu-OMe). Active caspase-1 was detected using FAM-YVAD-FMK, a fluorescent-labeled inhibitor of caspases (FLICA) specific for caspase-1. IL-1 beta was detected by immunoblotting and ELISA, and cytotoxicity was evaluated by LDH quantification.
   RESULTS. RPE of eyes affected by geographic atrophy or neovascular AMD exhibited NLRP3 staining at lesion sites. ARPE-19 cells were found to express NLRP3, ASC, and procaspase-1. IL-1 alpha dose-dependently induced pro-IL-1 beta expression in ARPE-19 cells. Lysosomal destabilization induced by Leu-Leu-OMe triggered caspase-1 activation, IL-1 beta secretion, and ARPE-19 cell death. Blocking Leu-Leu-OMe-induced lysosomal disruption with the compound Gly-Phe-CHN2 or inhibiting caspase-1 with Z-YVAD-FMK abrogated IL-1 beta release and ARPE-19 cytotoxicity.
   CONCLUSIONS. NLRP3 upregulation occurs in the RPE during the pathogenesis of advanced AMD, in both geographic atrophy and neovascular AMD. Destabilization of RPE lysosomes induces NLRP3 inflammasome activation, which may contribute to AMD pathology through the release of the proinflammatory cytokine IL-1 beta and through caspase-1-mediated cell death, known as "pyroptosis." (Invest Ophthalmol Vis Sci. 2013;54:110-120) DOI: 10.1167/iovs.12-10655
C1 [Tseng, Wen Allen; Thein, Thuzar; Kinnunen, Kati; Lashkari, Kameran; Gregory, Meredith S.; D'Amore, Patricia A.; Ksander, Bruce R.] Massachusetts Eye & Ear, Schepens Eye Res Inst, Boston, MA USA.
   [Tseng, Wen Allen; D'Amore, Patricia A.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
   [Lashkari, Kameran; Gregory, Meredith S.; D'Amore, Patricia A.; Ksander, Bruce R.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
   [Kinnunen, Kati] Univ Eastern Finland, Dept Ophthalmol, Kuopio, Finland.
   [Kinnunen, Kati] Kuopio Univ Hosp, Dept Ophthalmol, SF-70210 Kuopio, Finland.
C3 Harvard University; Massachusetts Eye & Ear Infirmary; Schepens Eye
   Research Institute; Harvard University; Harvard Medical School; Harvard
   University; Harvard Medical School; University of Eastern Finland;
   Kuopio University Hospital; University of Eastern Finland
RP Ksander, BR (通讯作者)，20 Staniford St, Boston, MA 02114 USA.
EM bruce.ksander@schepens.harvard.edu
RI Gregory-Ksander, Meredith/AAG-1413-2019; D'Amore, Patricia A/G-5660-2017
OI Gregory-Ksander, Meredith/0000-0002-7193-0032; D'Amore, Patricia
   A/0000-0001-9652-8974; Lashkari, Kameran/0000-0003-3855-0246
FU NIH [EY05435, GM07226, AG039245]; American Health Assistance Foundation;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007226] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [F31AG039245] Funding
   Source: NIH RePORTER
FX Supported by NIH Grants EY05435 (PAD), GM07226, and AG039245 (WAT); and
   a Macular Degeneration Research grant from the American Health
   Assistance Foundation (BRK).
CR Bauernfeind F, 2011, CELL MOL LIFE SCI, V68, P765, DOI 10.1007/s00018-010-0567-4
   Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363
   Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938
   Feldmeyer L, 2007, CURR BIOL, V17, P1140, DOI 10.1016/j.cub.2007.05.074
   Fernandes-Alnemri T, 2009, NATURE, V458, P509, DOI 10.1038/nature07710
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Gnana-Prakasam JP, 2008, BIOCHEM J, V411, P79, DOI 10.1042/BJ20071377
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636
   HERZYK DJ, 1992, J IMMUNOL METHODS, V148, P243, DOI 10.1016/0022-1759(92)90178-V
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631
   Hornung V, 2010, EUR J IMMUNOL, V40, P620, DOI 10.1002/eji.200940185
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Iwata A, 2003, J IMMUNOL, V170, P3386, DOI 10.4049/jimmunol.170.6.3386
   Jasielska M, 2010, INVEST OPHTH VIS SCI, V51, P3874, DOI 10.1167/iovs.09-5003
   Jin ML, 2000, INVEST OPHTH VIS SCI, V41, P4324
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Kanneganti TD, 2010, NAT REV IMMUNOL, V10, P688, DOI 10.1038/nri2851
   Kindzelskii AL, 2004, J GEN PHYSIOL, V124, P139, DOI 10.1085/jgp.200409062
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Kumar MV, 2004, J NEUROIMMUNOL, V153, P7, DOI 10.1016/j.jneuroim.2004.04.018
   Kummer JA, 2007, J HISTOCHEM CYTOCHEM, V55, P443, DOI 10.1369/jhc.6A7101.2006
   Lichtlen P, 2010, INVEST OPHTH VIS SCI, V51, P4738, DOI 10.1167/iovs.09-4890
   Mariathasan S, 2007, NAT REV IMMUNOL, V7, P31, DOI 10.1038/nri1997
   Masters SL, 2011, TRENDS MOL MED, V17, P276, DOI 10.1016/j.molmed.2011.01.005
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Niemi K, 2011, J IMMUNOL, V186, P6119, DOI 10.4049/jimmunol.1002843
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   PLANCK SR, 1993, CURR EYE RES, V12, P205, DOI 10.3109/02713689308999465
   Rajamaki K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011765
   Ravanko K, 2004, CANCER RES, V64, P8831, DOI 10.1158/0008-5472.CAN-03-2993
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040
   Schutt F, 2002, GRAEF ARCH CLIN EXP, V240, P983, DOI 10.1007/s00417-002-0558-8
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Stutz A, 2009, J CLIN INVEST, V119, P3502, DOI 10.1172/JCI40599
   Suzuki T, 2007, PLOS PATHOG, V3, P1082, DOI 10.1371/journal.ppat.0030111
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   THIELE DL, 1990, P NATL ACAD SCI USA, V87, P83, DOI 10.1073/pnas.87.1.83
   Wang XC, 1999, INVEST OPHTH VIS SCI, V40, P477
   Watanabe H, 2007, J INVEST DERMATOL, V127, P1956, DOI 10.1038/sj.jid.5700819
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yang P, 2005, INVEST OPHTH VIS SCI, V46, P1755, DOI 10.1167/iovs.04-1039
   Yilmaz O, 2010, CELL MICROBIOL, V12, P188, DOI 10.1111/j.1462-5822.2009.01390.x
   Zaki MH, 2010, IMMUNITY, V32, P379, DOI 10.1016/j.immuni.2010.03.003
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 59
TC 192
Z9 205
U1 2
U2 23
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2013
VL 54
IS 1
BP 110
EP 120
DI 10.1167/iovs.12-10655
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 081QX
UT WOS:000314338400015
PM 23221073
OA Green Published
DA 2022-11-30
ER

PT J
AU Singh, RP
   Fu, EX
   Smith, SD
   Williams, DR
   Kaiser, PK
AF Singh, R. P.
   Fu, E. X.
   Smith, S. D.
   Williams, D. R.
   Kaiser, P. K.
TI Predictive factors of visual and anatomical outcome after intravitreal
   bevacizumab treatment of neovascular age-related macular degeneration:
   an optical coherence tomography study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OCCULT CHOROIDAL NEOVASCULARIZATION; AVASTIN; SECONDARY
AB Aim: To evaluate the baseline visual and optical coherence tomography (OCT) factors on outcomes after intravitreal bevacizumab treatment of subfoveal neovascular age-related macular degeneration (AMD).
   Methods: A retrospective analysis of 73 eyes treated with intravitreal bevacizumab for subfoveal neovascular AMD was performed. Change in best corrected Snellen visual acuity (BCVA) and central retinal thickness (CRT) on OCT were the primary outcomes. Automated and manual measurements were made for all OCT characteristics.
   Results: Seventy-three (100%) and 58 (79.5%) eyes were followed for 3 and 6 months, respectively. The mean BCVA improved from 20/177 to 20/160 (p = 0.03) at 3 months and to 20/143 (p = 0.04) at 6 months. The mean CRT decreased 93 mu m (p < 0.0001) and 105 mu m (p < 0.0001) at 3 and 6 months, respectively. Baseline BCVA worse than 20/100 was associated with greater visual improvement (p <= 0.04). Eyes with baseline CRT greater than 400 mu m experienced a greater mean CRT reduction (p < 0.05). Treatment-naive patients had a greater mean CRT reduction than those previously treated with any modality (p < 0.05)
   Conclusions: Baseline BCVA and CRT positively influence mean visual and CRT improvement, respectively, after intravitreal bevacizumab in wet AMD. Any prior treatment predicted less CRT reduction.
C1 [Kaiser, P. K.] Cleveland Clin, Cole Eye Inst, Digital OCT Reading Ctr, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation
RP Kaiser, PK (通讯作者)，Cleveland Clin, Cole Eye Inst, Digital OCT Reading Ctr, 9500 Euclid Ave,Desk I3, Cleveland, OH 44195 USA.
EM pkkaiser@aol.com
OI Kaiser, Peter/0000-0001-5126-045X
CR Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Costa RA, 2004, INVEST OPHTH VIS SCI, V45, P2399, DOI 10.1167/iovs.04-0155
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Goff MJ, 2007, RETINA-J RET VIT DIS, V27, P432, DOI 10.1097/IAE.0b013e318042b53f
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Leung CKS, 2007, OPHTHALMOLOGY, V114, P263, DOI 10.1016/j.ophtha.2006.06.059
   Ray R, 2005, AM J OPHTHALMOL, V139, P18, DOI 10.1016/j.ajo.2004.07.050
   ROSENFELD P, 2007, ASS RES VIS OPHTH 20
   Sadda SR, 2007, INVEST OPHTH VIS SCI, V48, P839, DOI 10.1167/iovs.06-0554
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
NR 15
TC 27
Z9 28
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2009
VL 93
IS 10
BP 1353
EP 1358
DI 10.1136/bjo.2008.141879
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 498JN
UT WOS:000270135700018
PM 19556212
DA 2022-11-30
ER

PT J
AU DeAngelis, MM
   Ji, F
   Adams, S
   Morrison, MA
   Harring, AJ
   Sweeney, MO
   Capone, A
   Miller, JW
   Dryja, TP
   Ott, J
   Kim, IK
AF DeAngelis, Margaret M.
   Ji, Fei
   Adams, Scott
   Morrison, Margaux A.
   Harring, Amanda J.
   Sweeney, Meredith O.
   Capone, Antonio, Jr.
   Miller, Joan W.
   Dryja, Thaddeus P.
   Ott, Jurg
   Kim, Ivana K.
TI Alleles in the HtrA serine peptidase 1 gene alter the risk of
   neovascular age-related macular degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; QUANTITATIVE TRAIT LOCI; DISCORDANT SIB PAIRS;
   CIGARETTE-SMOKING; SUSCEPTIBILITY; ASSOCIATION; LOC387715; VARIANT;
   POLYMORPHISM; HAPLOTYPE
AB Objective: To examine if the genes encoding the pleckstrin homology domain-containing protein gene (PLE-KHA1), hypothetical LOC387715/ARMS2 gene, and HtrA serine peptidase 1 gene (HTRA1) located on the long arm of chromosome 10 (10q26 region) confer risk for neovascular age-related macular degeneration (AMD) in an independent or interactive manner when controlling for complement factor H gene (CFH) genotype and smoking exposure.
   Design: Retrospective matched-pair case-control study.
   Participants: Hospital clinic-based sample of 134 unrelated patients with neovascular AMD who have a sibling with normal maculae (268 subjects).
   Methods: Disease status was ascertained by at least 2 investigators by review of fundus photographs and/or fluorescein angiography according to the Age-Related Eye Disease Study grading scale. If necessary, a home retinal examination was performed (n = 6). A combination of direct sequencing and analysis of 8 highly polymorphic microsatellite markers was used to genotype 33 megabases of the 10q26 region on leukocyte DNA. Smoking history was obtained via a standardized questionnaire and measured in pack-years. The family-based association test, haplotype analysis, multiple conditional logistic regression, and linkage analysis were used to determine significant associations.
   Main Outcome Measure: Neovascular AMD status. Results: Of the 23 variants we identified in the 10q26 region, 6 were significant. Four of the 6 were novel and included 2 genotypes that reduced risk of AMD. Many single-nucleotide polymorphisms (SNPs), including the previously reported variants rs-10490924 (hypothetical LOC387715/ARMS2) and rs1 1200638 (HTRA1), defined 2 significant haplotypes associated with increased risk of neovascular AMD. The coding HTRA1 SNP rs2293870, not part of the significant haplotypes containing rs10490924 and rs11200638, showed as strong an association with increased susceptibility to neovascular AMD. Linkage 'analysis supported our findings of SNP association (p<10(-15)). No significant interactions were found between any of the SNPs in the 10q26 and smoking or between these SNPs and CFH genotype.
   Conclusions: Independent of CFH genotype or smoking history, an individual's risk of AMD could be increased or decreased, depending on their genotype or haplotype in the 10q26region.
C1 [DeAngelis, Margaret M.; Adams, Scott; Morrison, Margaux A.; Harring, Amanda J.; Sweeney, Meredith O.; Miller, Joan W.; Dryja, Thaddeus P.; Kim, Ivana K.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA.
   [Ji, Fei; Ott, Jurg] Rockefeller Univ, Lab Stat Genet, New York, NY 10021 USA.
   [Capone, Antonio, Jr.] William Beaumont Hosp, Associated Retinal Consultants PC, Royal Oak, MI 48072 USA.
   [Ott, Jurg] Chinese Acad Sci, Beijing Inst Genom, Beijing, Peoples R China.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Rockefeller University; Beaumont Health; Chinese Academy of
   Sciences; Beijing Institute of Genomics, CAS
RP DeAngelis, MM (通讯作者)，Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA.
EM margaret_deangelis@hms.harvard.edu
RI DeAngelis, e/J-7863-2015
OI Miller, Joan/0000-0003-2046-3996; Kim, Ivana/0000-0003-0310-6129
FU NATIONAL EYE INSTITUTE [R01EY014458, P30EY014104] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH044292, R01MH044292]
   Funding Source: NIH RePORTER; NEI NIH HHS [EY014458, EY14104, R01
   EY014458, P30 EY014104] Funding Source: Medline; NIMH NIH HHS [R37
   MH044292, R01 MH044292, MH44292] Funding Source: Medline
CR *AGE REL EYE DIS S, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Armitage P., 1987, STAT METHODS MED RES
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Chen Jing, 2007, Angiogenesis, V10, P133, DOI 10.1007/s10456-007-9066-0
   Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   DeAngelis MM, 2004, ARCH OPHTHALMOL-CHIC, V122, P575, DOI 10.1001/archopht.122.4.575
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Greally JM, 2007, NATURE, V447, P782, DOI 10.1038/447782a
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Horvath S, 2004, GENET EPIDEMIOL, V26, P61, DOI 10.1002/gepi.10295
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Knebel B, 2005, EXP CLIN ENDOCR DIAB, V113, P94, DOI 10.1055/s-2004-830554
   RISCH N, 1995, SCIENCE, V268, P1584, DOI 10.1126/science.7777857
   Risch NJ, 1996, AM J HUM GENET, V58, P836
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 32
TC 71
Z9 79
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2008
VL 115
IS 7
BP 1209
EP 1215
DI 10.1016/j.ophtha.2007.10.032
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 320CK
UT WOS:000257211100017
PM 18164066
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Foot, B
   Foy, R
   Chakravarthy, U
   Wormald, R
AF Foot, B
   Foy, R
   Chakravarthy, U
   Wormald, R
TI Introduction of photodynamic therapy for the treatment of neovascular
   age-related macular degeneration: tracking a moving target
SO EYE
LA English
DT Article
DE photodynamic therapy; service provision; health technology
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RANDOMIZED CLINICAL-TRIALS;
   HEALTH TECHNOLOGY; VERTEPORFIN
AB Objectives To identify changes in referral and treatment patterns of neovascular age-related macular degeneration with photodynamic therapy (PDT) within ophthalmology units in NHS hospitals and assess how beliefs about what would constitute a worthwhile level of clinical benefit had altered over a 12-month period.
   Methods Two questionnaire surveys ( October 2000 and October 2001) to all clinical directors or lead consultants in UK NHS eye units. These sought data on which ( if any) patients were referred or treated with PDT and the threshold of clinical benefit, in terms of numbers needed to treat, at which they would support the use of PDT.
   Results Response rates were 82% in the first survey and 79% in the second. The availability of PDT had significantly increased ( P = 0.0001). The proportion of units routinely providing PDT for patients with more than 50% classic subfoveal choroidal neovascularization (CNV) increased from 8 to 23%. Between the 2 surveys, there was a significant reduction in the threshold of effectiveness at which respondents would support the use of PDT ( P = 0.012). The proportion of respondents requiring further evidence before supporting the use of PDT decreased from 33 to 17% ( P = 0.009). There was a significant association between the threshold of support and the level of service provision for both surveys ( P = 0.01).
   Conclusions Although substantial variations exist, availability of PDT has increased over the 12-month period. The differing thresholds at which introduction of PDT would be considered justifiable varied widely. PDT is being introduced into the NHS in a fragmented manner. In common with other new health technologies, factors other than the strength of evidence appear to be influencing beliefs about the effectiveness of PDT and its subsequent provision. While it is unlikely that such an action alone will lead to evidence-based practice, the variations in beliefs identified by this survey suggest that sufficient clinical uncertainty exists to support the need for further clinical trials.
C1 Moorfields Eye Hosp, Dept Res & Dev, London EC1V 2PD, England.
   Royal Coll Ophthalmologist, London, England.
   Univ Edinburgh, Dept Reprod & Dev Sci, Edinburgh, Midlothian, Scotland.
   Royal Victoria Hosp, Dept Ophthalmol, Belfast BT12 6BA, Antrim, North Ireland.
   Queens Univ Belfast, Dept Ophthalmol, Belfast, Antrim, North Ireland.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of Edinburgh; Queens University Belfast
RP Foot, B (通讯作者)，Moorfields Eye Hosp, Dept Res & Dev, City Rd, London EC1V 2PD, England.
OI Foy, Robbie/0000-0003-0605-7713; Chakravarthy, Usha/0000-0002-2606-3734
CR Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Bressler NM, 2000, BRIT MED J, V321, P1425, DOI 10.1136/bmj.321.7274.1425
   Foot B, 2002, EYE, V16, P469, DOI 10.1038/sj.eye.6700024
   MOWATT G, 1997, HEALTH TECHNOL ASSES, V1, P1
   *NHS, DEL CAUS BLINDN
   PRESCOTT RJ, 1999, HLTH TECHNOL ASSESS, V3
   Rosen R, 1999, BRIT MED J, V319, P1292, DOI 10.1136/bmj.319.7220.1292
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Steel N, 2000, BRIT MED J, V320, P1446, DOI 10.1136/bmj.320.7247.1446
   WORMALD R, 2001, COCHRANE LIB, V1
NR 11
TC 3
Z9 3
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD JUL
PY 2003
VL 17
IS 5
BP 583
EP 586
DI 10.1038/sj.eye.6700459
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 699QU
UT WOS:000184068100007
PM 12855963
OA Bronze
DA 2022-11-30
ER

PT J
AU Chan, SY
   Wang, Q
   Wang, YX
   Shi, XH
   Jonas, JB
   Bin Wei, W
AF Chan, Szy Yann
   Wang, Qian
   Wang, Ya Xing
   Shi, Xue Hui
   Jonas, Jost B.
   Bin Wei, Wen
TI POLYPOIDAL CHOROIDAL VASCULOPATHY UPON OPTICAL COHERENCE TOMOGRAPHIC
   ANGIOGRAPHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE polypoidal choroidal vasculopathy; optical coherence tomographic
   angiography; maculopathy; choroidal neovascularization
ID RETINAL VASCULAR LAYERS; INDOCYANINE GREEN; DIABETIC-RETINOPATHY
AB Purpose: To study polypoidal lesions and branching choroidal vascular networks in eyes with polypoidal choroidal vasculopathy by optical coherence tomography (OCT)-based angiography (OCTA).
   Methods: In the observational cross-sectional study, patients with polypoidal choroidal vasculopathy, as diagnosed by indocyanine green angiography, underwent OCTA.
   Results: Thirty-two eyes of 31 patients with an age of 61.1 +/- 7.6 years were included. Branching choroidal vascular networks were detected by indocyanine green angiography and OCTA in 25 of 32 (78 +/- 73%) and in 30 of 32 (94 +/- 4%) eyes, respectively, with a marginally significant difference (P = 0.06) in the detection rate between both techniques. A total of 72 polyps (area, 0.06 +/- 0.06 mm(2); range, 0.01-0.27 mm(2)) were detected by indocyanine green angiography, and they were consistently present on the OCTA images. By moving the reference level in the OCT angiograms to the corresponding layer, the polypoidal lesions showed cluster-like structures in 53 of 72 polypoidal lesions (74%). In 60 of the 72 polypoidal lesions (83%), cluster-like structures were detected in the en face structural OCT images at the reference plane of the OCTA images. On the cross-sectional OCT images, some internal channels of flow were seen in 50 of the 72 polypoidal lesions (69%). Larger size of the polypoidal lesions was associated with a higher prevalence of cluster-like structures on the OCTA images, some internal channels of flow on the en face structural images, and clustered vascular structures on the cross-sectional OCT images.
   Conclusion: In conclusion, OCTA is a useful technique for the noninvasive detection of branching choroidal vascular networks including visualization of details such as cluster-like structures and flow. In some eyes, OCTA was superior to indocyanine green angiography to detect polypoidal choroidal vasculopathy and to show branching choroidal vascular networks.
C1 [Chan, Szy Yann; Wang, Qian; Shi, Xue Hui; Bin Wei, Wen] Capital Med Univ, Beijing Ophthalmol & Visual Sci Key Lab, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing, Peoples R China.
   [Wang, Ya Xing; Jonas, Jost B.] Capital Med Univ, Beijing Ophthalmol & Visual Sci Key Lab, Beijing Tongren Eye Ctr, Beijing Inst Ophthalmol, Beijing, Peoples R China.
   [Jonas, Jost B.] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Mannheim, Germany.
C3 Capital Medical University; Capital Medical University; Ruprecht Karls
   University Heidelberg
RP Bin Wei, W (通讯作者)，Capital Med Univ, Beijing Key Lab Intraocular Tumor Diag & Treatmen, Beijing Ophthalmol & Visual Sci Key Lab, Beijing Tongren Hosp,Beijing Tongren Eye Ctr, 1 Dong Jiao Min Xiang, Beijing 100730, Peoples R China.
EM tr_weiwenbin@163.com
RI wang, YA XING/K-9671-2016
OI wang, YA XING/0000-0003-2749-7793
FU Beijing Municipal Administration of Hospitals' Ascent Plan
   [DFL20150201]; Science and Technology Project of Beijing Municipal
   Science and Technology Commission [Z151100001615052]; National Natural
   Science Foundation of China [81570891, 81272981]; Beijing Municipal
   Administration of Hospitals Clinical Medicine Development of Special
   Funding Support [ZYLX201307]; Beijing Natural Science Foundation
   [7151003]; Beijing Municipal Health Bureau [2014-2-003]
FX Supported by the Beijing Municipal Administration of Hospitals' Ascent
   Plan (code: DFL20150201); Science and Technology Project of Beijing
   Municipal Science and Technology Commission (Z151100001615052), the
   National Natural Science Foundation of China (Nr. 81570891), the Beijing
   Municipal Administration of Hospitals Clinical Medicine Development of
   Special Funding Support (ZYLX201307), the National Natural Science
   Foundation of China (81272981), the Beijing Natural Science Foundation
   (7151003), and the Advanced Health Care Professionals Development
   Project of Beijing Municipal Health Bureau (2014-2-003).
CR Chan SY, 2016, RETINA-J RET VIT DIS, V36, P2051, DOI 10.1097/IAE.0000000000001064
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   HOPEROSS M, 1994, OPHTHALMOLOGY, V101, P529
   Hwang TS, 2016, JAMA OPHTHALMOL, V134, P367, DOI 10.1001/jamaophthalmol.2015.5658
   Ishibazawa A, 2015, AM J OPHTHALMOL, V160, P35, DOI 10.1016/j.ajo.2015.04.021
   Jia YL, 2015, P NATL ACAD SCI USA, V112, pE2395, DOI 10.1073/pnas.1500185112
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kim JY, 2016, GRAEF ARCH CLIN EXP, V254, P1505, DOI 10.1007/s00417-015-3228-3
   Kokame GT, 2016, OSLI RETINA, V47, P737, DOI 10.3928/23258160-20160808-07
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Miura M, 2015, INVEST OPHTH VIS SCI, V56, P3179, DOI 10.1167/iovs.14-16252
   OBANA A, 1994, AM J OPHTHALMOL, V118, P749, DOI 10.1016/S0002-9394(14)72554-1
   Rispoli M, 2015, RETINA-J RET VIT DIS, V35, P2332, DOI 10.1097/IAE.0000000000000845
   Semoun O, 2016, BRIT J OPHTHALMOL, V100, P1028, DOI 10.1136/bjophthalmol-2015-307494
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P66, DOI 10.1001/jamaophthalmol.2014.3950
   Srour M, 2016, BRIT J OPHTHALMOL, V100, P1489, DOI 10.1136/bjophthalmol-2015-307892
   Tomiyasu T, 2016, INVEST OPHTH VIS SCI, V57, pOCT324, DOI 10.1167/iovs.15-18898
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
   Wang Q, 2016, AM J OPHTHALMOL, V168, P95, DOI 10.1016/j.ajo.2016.05.005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 23
TC 14
Z9 16
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2018
VL 38
IS 6
BP 1187
EP 1194
DI 10.1097/IAE.0000000000001702
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GP2CC
UT WOS:000440627100018
PM 28613216
DA 2022-11-30
ER

PT J
AU Clark, SJ
   Schmidt, CQ
   White, AM
   Hakobyan, S
   Morgan, BP
   Bishop, PN
AF Clark, Simon J.
   Schmidt, Christoph Q.
   White, Anne M.
   Hakobyan, Svetlana
   Morgan, B. Paul
   Bishop, Paul N.
TI Identification of Factor H-like Protein 1 as the Predominant Complement
   Regulator in Bruch's Membrane: Implications for Age-Related Macular
   Degeneration
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID ALTERNATIVE PATHWAY; HEPARAN-SULFATE; C-TERMINUS; BINDING-PROPERTIES;
   POLYMORPHISM; RECOGNITION; GLYCOSAMINOGLYCAN; VARIANT; RISK; CFHR1
AB The tight regulation of innate immunity on extracellular matrix (ECM) is a vital part of immune homeostasis throughout the human body, and disruption to this regulation in the eye is thought to contribute directly to the progression of age-related macular degeneration (AMD). The plasma complement regulator factor H (FH) is thought to be the main regulator that protects ECM against damaging complement activation. However, in the present study we demonstrate that a truncated form of FH, called FH-like protein 1 (FHL-1), is the main regulatory protein in the layer of ECM under human retina, called Bruch's membrane. Bruch's membrane is a major site of AMD disease pathogenesis and where drusen, the hallmark lesions of AMD, form. We show that FHL-1 can passively diffuse through Bruch's membrane, whereas the full sized, glycosylated, FH cannot. FHL-1 is largely bound to Bruch's membrane through interactions with heparan sulfate, and we show that the common Y402H polymorphism in the CFH gene, associated with an increased risk of AMD, reduces the binding of FHL-1 to this heparan sulfate. We also show that FHL-1 is retained in drusen whereas FH coats the periphery of the lesions, perhaps inhibiting their clearance. Our results identify a novel mechanism of complement regulation in the human eye, which highlights potential new avenues for therapeutic strategies.
C1 [Clark, Simon J.; White, Anne M.; Bishop, Paul N.] Univ Manchester, Ctr Hearing & Vis Res, Inst Human Dev, Manchester M13 9PT, Lancs, England.
   [Clark, Simon J.; White, Anne M.; Bishop, Paul N.] Univ Manchester, Ctr Adv Discovery & Expt Therapeut, Manchester M13 9WL, Lancs, England.
   [Clark, Simon J.; White, Anne M.; Bishop, Paul N.] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester M13 9WL, Lancs, England.
   [Schmidt, Christoph Q.] Univ Ulm, Inst Pharmacol Nat Prod & Clin Pharmacol, D-89081 Ulm, Germany.
   [Hakobyan, Svetlana; Morgan, B. Paul] Cardiff Univ, Sch Med, Inst Infect & Immun, Complement Biol Grp, Cardiff CF14 4XN, S Glam, Wales.
   [Bishop, Paul N.] Manchester Royal Eye Hosp, Cent Manchester Univ Hosp NHS Fdn Trust, Manchester M13 9WL, Lancs, England.
C3 University of Manchester; University of Manchester; University of
   Manchester; Ulm University; Cardiff University; Manchester Royal Eye
   Hospital; University of Manchester
RP Clark, SJ (通讯作者)，Univ Manchester, Ctr Hearing & Vis Res, AV Hill Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.
EM simon.clark-3@manchester.ac.uk
OI Morgan, Paul/0000-0003-4075-7676; Clark, Simon/0000-0001-8394-8355;
   Bishop, Paul/0000-0001-7937-7932
FU Medical Research Council [MR/K024418/1, G0900592, MR/K004441/1]; Faculty
   of Medicine and Human Sciences, University of Manchester; Biotechnology
   and Biological Sciences Research Council; Wellcome Trust; University of
   Manchester Strategic Fund; Medical Research Council [G0900538] Funding
   Source: researchfish; Alzheimer&quot;s Society [104] Funding Source:
   researchfish; MRC [G0900538, MR/K024418/1, MR/K004441/1] Funding Source:
   UKRI
FX S.J.C. is a recipient of Medical Research Council Career Development
   Fellowship MR/K024418/1 and had previously been supported by a Stepping
   Stones Fellowship from the Faculty of Medicine and Human Sciences,
   University of Manchester. The eye tissue holdings were initiated and
   supported by Medical Research Council Grants G0900592 and MR/K004441/1.
   The Bioimaging Facility microscopes used in this study were purchased
   with support from the Biotechnology and Biological Sciences Research
   Council, the Wellcome Trust, and the University of Manchester Strategic
   Fund.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Bruinsma IB, 2010, ACTA NEUROPATHOL, V119, P211, DOI 10.1007/s00401-009-0577-1
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00412
   Clark SJ, 2013, J IMMUNOL, V190, P2049, DOI 10.4049/jimmunol.1201751
   Clark SJ, 2011, INVEST OPHTH VIS SCI, V52, P6511, DOI 10.1167/iovs.11-7909
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   DAY AJ, 1988, IMMUNOGENETICS, V27, P211, DOI 10.1007/BF00346588
   Day AJ, 2011, EXPERT REV OPHTHALMO, V6, P123, DOI 10.1586/EOP.11.10
   de Jorge EG, 2013, P NATL ACAD SCI USA, V110, P4685, DOI 10.1073/pnas.1219260110
   Dee V., 1990, COMPLEMENT INFLAMM, P158
   Eberhardt HU, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078617
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FONTAINE M, 1989, BIOCHEM J, V258, P927, DOI 10.1042/bj2580927
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2008, J BIOL CHEM, V283, P30451, DOI 10.1074/jbc.M803648200
   Hebecker M, 2012, J BIOL CHEM, V287, P19528, DOI 10.1074/jbc.M112.364471
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jozsi M, 2007, MOL IMMUNOL, V44, P2697, DOI 10.1016/j.molimm.2006.12.001
   Jozsi M, 2006, J AM SOC NEPHROL, V17, P170, DOI 10.1681/ASN.2005080868
   Keenan TDL, 2014, INVEST OPHTH VIS SCI, V55, P5370, DOI 10.1167/iovs.14-14126
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Law SKA, 1997, PROTEIN SCI, V6, P263
   Marson A, 2009, GLYCOBIOLOGY, V19, P1537, DOI 10.1093/glycob/cwp132
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   Oppermann M, 2006, CLIN EXP IMMUNOL, V144, P342, DOI 10.1111/j.1365-2249.2006.03071.x
   Park PJ, 2013, EXP EYE RES, V110, P1, DOI 10.1016/j.exer.2013.01.015
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593
   Sanchez-Corral P, 2002, AM J HUM GENET, V71, P1285, DOI 10.1086/344515
   Sarrazin S, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004952
   Schmidt CQ, 2008, CLIN EXP IMMUNOL, V151, P14, DOI 10.1111/j.1365-2249.2007.03553.x
   Schmidt C, 2008, REV ECON POLIT, V118, P3
   Schmidt CQ, 2011, PROTEIN EXPRES PURIF, V76, P254, DOI 10.1016/j.pep.2010.12.002
   SCHWAEBLE W, 1987, EUR J IMMUNOL, V17, P1485, DOI 10.1002/eji.1830171015
   Seddon JM, 2013, FARADAY DISCUSS, V161, P9, DOI 10.1039/c2fd90045a
   SIM E, 1983, BIOSCIENCE REP, V3, P1119, DOI 10.1007/BF01120205
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Sofat R, 2013, J IMMUNOL METHODS, V390, P63, DOI 10.1016/j.jim.2013.01.009
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Strohmeyer R, 2002, J NEUROIMMUNOL, V131, P135, DOI 10.1016/S0165-5728(02)00272-2
   Tortajada A, 2013, J CLIN INVEST, V123, P2434, DOI 10.1172/JCI68280
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Weinberger AWA, 2014, OPHTHALMIC RES, V51, P59, DOI 10.1159/000351624
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
NR 59
TC 78
Z9 80
U1 0
U2 11
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD NOV 15
PY 2014
VL 193
IS 10
BP 4962
EP 4970
DI 10.4049/jimmunol.1401613
PG 9
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA AT6BJ
UT WOS:000345023400025
PM 25305316
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Lin, CH
   Li, CH
   Liao, PL
   Tse, LS
   Huang, WK
   Cheng, HW
   Cheng, YW
AF Lin, C. H.
   Li, C. H.
   Liao, P. L.
   Tse, L. S.
   Huang, W. K.
   Cheng, H. W.
   Cheng, Y. W.
TI Silibinin inhibits VEGF secretion and age-related macular degeneration
   in a hypoxia-dependent manner through the PI-3 kinase/Akt/mTOR pathway
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE silibinin; age-related macular degeneration; neovascularization;
   hypoxia; HIF-1 alpha
ID ENDOTHELIAL GROWTH-FACTOR; BREAST-CANCER CELLS; HUMAN
   HEPATOCELLULAR-CARCINOMA; BRONCHIAL EPITHELIAL-CELLS;
   DIABETIC-RETINOPATHY; EXPRESSION; NEOVASCULARIZATION; ANGIOGENESIS;
   HIF-1-ALPHA; INVOLVEMENT
AB BACKGROUND AND PURPOSE
   Hypoxia-mediated neovascularization plays an important role in age-related macular degeneration (AMD). There are few animal models or effective treatments for AMD. Here, we investigated the effects of the flavonoid silibinin on hypoxia-induced angiogenesis in a rat AMD model.
   EXPERIMENTAL APPROACH
   Retinal pigmented epithelial (RPE) cells were subjected to hypoxia in vitro and the effects of silibinin on activation of key hypoxia-induced pathways were examined by elucidating the hypoxia-inducible factor-1 alpha (HIF-1 alpha) protein level by Western blot. A rat model of AMD was developed by intravitreal injection of VEGF in Brown Norway rats, with or without concomitant exposure of animals to hypoxia. Animals were treated with oral silibinin starting at day 7 post-VEGF injection and AMD changes were followed by fluorescein angiography on days 14 and 28 post-injection.
   KEY RESULTS
   Silibinin pretreatment of RPE cells increased proline hydroxylase-2 expression, inhibited HIF-1 alpha subunit accumulation, and inhibited VEGF secretion. Silibinin-induced HIF-1 alpha and VEGF down-regulation required suppression of hypoxia-induced phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (mTOR) pathway. In the rat model of AMD, silibinin administration prevented VEGF-and VEGF plus hypoxia-induced retinal oedema and neovascularization.
   CONCLUSION AND IMPLICATIONS
   The effects of silibinin, both in vitro and in vivo, support its potential as a therapeutic for the prevention of neovascular AMD.
C1 [Lin, C. H.; Li, C. H.; Tse, L. S.; Huang, W. K.; Cheng, H. W.; Cheng, Y. W.] Taipei Med Univ, Coll Pharm, Sch Pharm, Taipei 11031, Taiwan.
   [Li, C. H.] Taipei Med Univ, Coll Med, Sch Med, Dept Physiol, Taipei 11031, Taiwan.
   [Liao, P. L.] Natl Taiwan Univ, Coll Med, Inst Toxicol, Taipei 10764, Taiwan.
C3 Taipei Medical University; Taipei Medical University; National Taiwan
   University
RP Cheng, YW (通讯作者)，Taipei Med Univ, Coll Pharm, Sch Pharm, Taipei 11031, Taiwan.
EM ywcheng@tmu.edu.tw
RI Liao, Po-Lin/AAT-3072-2021; Lin, Cheng-Hui/AAV-7085-2021
OI Lin, Cheng-Hui/0000-0002-1479-9533; Lin, Chien-Huang/0000-0002-0916-8737
FU National Science Council, Taiwan [NSC97-2320-B002-029-MY3]
FX This study was supported in part by a grant (NSC97-2320-B002-029-MY3)
   from the National Science Council, Taiwan.
CR Abdel-Rahman MH, 2010, EXP EYE RES, V91, P837, DOI 10.1016/j.exer.2010.10.013
   Abu El-Asrar AM, 2011, ACTA DIABET IN PRESS
   Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Befani CD, 2012, J MOL MED, V90, P45, DOI 10.1007/s00109-011-0805-8
   Beinhardt S, 2011, J HEPATOL, V54, P591, DOI 10.1016/j.jhep.2010.09.009
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Caldwell RB, 2005, CURR DRUG TARGETS, V6, P511, DOI 10.2174/1389450054021981
   Canales RD, 2006, NAT BIOTECHNOL, V24, P1115, DOI 10.1038/nbt1236
   Cao RH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002748
   CARMICHAEL J, 1987, CANCER RES, V47, P936
   Chen L, 2009, EXP MOL MED, V41, P849, DOI 10.3858/emm.2009.41.12.103
   Cheung CWY, 2010, ANTI-CANCER AGENT ME, V10, P186
   Chung EK, 2008, CLIN GENITOURIN CANC, V6, pS22, DOI 10.3816/CGC.2008.s.004
   DeClerck K, 2010, FRONT BIOSCI-LANDMRK, V15, P213, DOI 10.2741/3616
   Edelman JL, 2000, EXP EYE RES, V71, P523, DOI 10.1006/exer.2000.0907
   Fan SM, 2011, FREE RADICAL RES, V45, P1307, DOI 10.3109/10715762.2011.618186
   Fenton TR, 2011, INT J BIOCHEM CELL B, V43, P47, DOI 10.1016/j.biocel.2010.09.018
   Garcia-Maceira P, 2009, ONCOGENE, V28, P313, DOI 10.1038/onc.2008.398
   González Viejo I., 2011, Arch Soc Esp Oftalmol, V86, P207, DOI 10.1016/j.oftal.2011.05.008
   Gu M, 2007, CANCER RES, V67, P3483, DOI 10.1158/0008-5472.CAN-06-3955
   Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128
   Halper J, 2010, VET PATHOL, V47, P77, DOI 10.1177/0300985809352981
   Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002
   Jiang H, 2010, AM J PHYSIOL-LUNG C, V298, pL660, DOI 10.1152/ajplung.00394.2009
   Jing Y, 2012, TOXICOL SCI, V125, P10, DOI 10.1093/toxsci/kfr256
   Kaur M, 2007, TOXICOL APPL PHARM, V224, P350, DOI 10.1016/j.taap.2006.11.011
   Kernt M, 2010, BRIT J OPHTHALMOL, V94, P1533, DOI 10.1136/bjo.2010.182162
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kolar P, 2011, CLIN ORTHOP RELAT R, V469, P3118, DOI 10.1007/s11999-011-1865-3
   Li H, 2011, HEPATOLOGY, V54, P910, DOI 10.1002/hep.24479
   Luangdilok S, 2011, EUR J CANCER, V47, P520, DOI 10.1016/j.ejca.2010.10.009
   Manalo KB, 2011, EXPERT OPIN THER PAT, V21, P121, DOI 10.1517/13543776.2011.545347
   Mayer KE, 2005, J VIRAL HEPATITIS, V12, P559, DOI 10.1111/j.1365-2893.2005.00636.x
   Mole DR, 2009, J BIOL CHEM, V284, P16767, DOI 10.1074/jbc.M901790200
   Mozaffarieh M, 2009, MOL VIS, V15, P1194
   Noh EM, 2011, J BREAST CANCER, V14, P8, DOI 10.4048/jbc.2011.14.1.8
   Oh EJ, 2009, BIOMATERIALS, V30, P6026, DOI 10.1016/j.biomaterials.2009.07.024
   Salminen A, 2010, MOL MED, V16, P535, DOI 10.2119/molmed.2010.00070
   Sawada O, 2010, RETINA-J RET VIT DIS, V30, P1034, DOI 10.1097/IAE.0b013e3181ce74c8
   Schnell CR, 2008, CANCER RES, V68, P6598, DOI 10.1158/0008-5472.CAN-08-1044
   Shenoy SK, 2012, ONCOGENE, V31, P282, DOI 10.1038/onc.2011.238
   Singh RP, 2008, CANCER RES, V68, P2043, DOI 10.1158/0008-5472.CAN-07-6247
   Skondra D, 2008, INVEST OPHTH VIS SCI, V49, P726, DOI 10.1167/iovs.07-0405
   Sudhagar S, 2011, BRIT J CANCER, V105, P953, DOI 10.1038/bjc.2011.349
   Taylor AC, 2010, MICROVASC RES, V79, P93, DOI 10.1016/j.mvr.2010.01.006
   Thomas GV, 2006, NAT MED, V12, P122, DOI 10.1038/nm1337
   Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180
   Varghese L, 2005, CLIN CANCER RES, V11, P8441, DOI 10.1158/1078-0432.CCR-05-1646
   Zhong H, 2000, CANCER RES, V60, P1541
   Zi ZL, 1999, P NATL ACAD SCI USA, V96, P7490, DOI 10.1073/pnas.96.13.7490
NR 52
TC 43
Z9 46
U1 0
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD FEB
PY 2013
VL 168
IS 4
BP 920
EP 931
DI 10.1111/j.1476-5381.2012.02227.x
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 078WF
UT WOS:000314130300011
PM 23004355
OA Green Published
DA 2022-11-30
ER

PT J
AU Ahluwalia, A
   Shen, LBL
   Del Priore, LV
AF Ahluwalia, Aneesha
   Shen, Liangbo L.
   Del Priore, Lucian, V
TI Central geographic atrophy vs. neovascular age-related macular
   degeneration: differences in longitudinal vision-related quality of life
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Vision-related quality of life; NEI-VFQ; Age-related macular
   degeneration; Geographic atrophy; Neovascular age-related macular
   degeneration
ID VISUAL FUNCTION QUESTIONNAIRE; EYE DISEASE; FOLLOW-UP; AREDS; ACUITY;
   RESPONSIVENESS; PROGRESSION; SECONDARY; 10-YEAR; IMPACT
AB Objective Prior studies of vision-related quality of life (VRQoL) have examined advanced age-related macular degeneration (AMD) as a single group or focused on neovascular AMD (nAMD), even though advanced AMD can refer to either central geographic atrophy (GA) or nAMD. We compared the natural progression of VRQoL in central GA versus nAMD.
   Methods We included Age-Related Eye Disease Study (AREDS) participants with central GA (n= 206) or nAMD (n= 198) who completed the National Eye Institute Visual Function Questionnaire (NEI-VFQ) between 1997 and 2005. The rate of change of VRQoL was calculated as the slopes of linear models fit to longitudinal individual-level NEI-VFQ scores. Multivariable regressions identified factors associated with experiencing a decline in VRQoL during the study period and cross-sectional VRQoL score.
   Results There was a minor decline in VRQoL prior to the development of nAMD but a significantly steeper decline after progression to nAMD (0.49 +/- 2.91 vs. 3.30 +/- 5.58 NEI-VFQ units/year;p< 0.001). The rates of VRQoL decline were similar before and after the development of central GA (1.99 +/- 4.97 vs. 1.68 +/- 4.65 NEI-VFQ units/year;p= 0.66). Prior to the development of advanced AMD, the rate of VRQoL decline was greater for participants destined to develop central GA versus nAMD (p= 0.007), while postprogression to advanced disease, the rate was greater in nAMD compared with central GA (p= 0.012). Female gender (odds ratio [OR] 2.61, 95% confidence interval [CI] 1.38-5.06;p= 0.003) and higher baseline VRQoL score (OR 1.03, 95% CI 1.01-1.06;p= 0.006) were independently associated with experiencing a longitudinal decline in VRQoL.
   Conclusion The natural progression of VRQoL differed in central GA versus nAMD, both before and after the development of advanced disease, suggesting that future studies should consider separating these phenotypes. Females and those with a higher baseline VRQoL were more likely to experience a longitudinal decline in VRQoL following progression to advanced AMD.
C1 [Ahluwalia, Aneesha; Shen, Liangbo L.; Del Priore, Lucian, V] Yale Univ, Dept Ophthalmol & Visual Sci, Sch Med, 40 Temple St,Suite 1B, New Haven, CT 06510 USA.
C3 Yale University
RP Del Priore, LV (通讯作者)，Yale Univ, Dept Ophthalmol & Visual Sci, Sch Med, 40 Temple St,Suite 1B, New Haven, CT 06510 USA.
EM lucian.delpriore@yale.edu
OI Shen, Liangbo/0000-0002-1823-0854
FU National Institute on Aging of the National Institutes of Health
   [T35AG049685, P30 EY026878]; National Eye Institute (NEI); (Yale Vision
   Science Core)
FX Research reported in this publication was supported by the National
   Institute on Aging of the National Institutes of Health under Award
   Number T35AG049685 (Recipient: Ahluwalia) and P30 EY026878 from the
   National Eye Institute (NEI) (Recipient: Yale Vision Science Core).
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Astarita C, 2018, J CELL PHYSIOL, V233, P6965, DOI 10.1002/jcp.26486
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Chatziralli I, 2017, SEMIN OPHTHALMOL, V32, P772, DOI 10.1080/08820538.2016.1181192
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Clemons TE, 2008, INVEST OPHTH VIS SCI, V49, P4340, DOI 10.1167/iovs.08-1749
   Coleman AL, 2010, AM J OPHTHALMOL, V150, P683, DOI 10.1016/j.ajo.2010.05.030
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Davis LJ, 2006, INVEST OPHTH VIS SCI, V47, P489, DOI 10.1167/iovs.05-0381
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Eid M, 2004, SOC INDIC RES, V65, P245, DOI 10.1023/B:SOCI.0000003801.89195.bc
   Fink BA, 2005, AM J OPHTHALMOL, V140, P459, DOI 10.1016/j.ajo.2005.03.078
   Kandasamy R, 2017, ASIA-PAC J OPHTHALMO, V6, P508, DOI 10.22608/APO.2017262
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kong XR, 2017, OPHTHALMOLOGY, V124, P1640, DOI 10.1016/j.ophtha.2017.04.026
   Lamoureux EL, 2007, INVEST OPHTH VIS SCI, V48, P1476, DOI 10.1167/iovs.06-0610
   Lindblad AS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1207
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Massof RW, 2001, VISION RES, V41, P397, DOI 10.1016/S0042-6989(00)00249-2
   Mejico LJ, 2004, AM J OPHTHALMOL, V137, P908, DOI 10.1016/j.ajo.2003.12.038
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   Nickels S, 2017, HEALTH QUAL LIFE OUT, V15, DOI 10.1186/s12955-017-0732-7
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   Orr P, 2011, INVEST OPHTH VIS SCI, V52, P3354, DOI 10.1167/iovs.10-5645
   Owen Christopher G, 2006, BMC Ophthalmol, V6, P24, DOI 10.1186/1471-2415-6-24
   Ramirez Estudillo Juan Abel, 2017, Int J Retina Vitreous, V3, P21, DOI 10.1186/s40942-017-0071-1
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Revicki DA, 2010, INVEST OPHTH VIS SCI, V51, P712, DOI 10.1167/iovs.09-3766
   Sadda SR, 2016, RETINA-J RET VIT DIS, V36, P1806, DOI 10.1097/IAE.0000000000001283
   Schippert AC, 2018, GERONTOL GERIATR MED, V4, DOI 10.1177/2333721418801601
   Shen LBL, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.1.2
   Sivaprasad S, 2018, AM J OPHTHALMOL, V190, P1, DOI 10.1016/j.ajo.2018.03.006
   Sorman DE, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.01872
   Tufail A, 2020, BRIT J OPHTHALMOL, V104, P672, DOI 10.1136/bjophthalmol-2018-313682
   van der Aa HPA, 2016, OPHTHALMOLOGY, V123, P1164, DOI 10.1016/j.ophtha.2015.11.028
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yuzawa M, 2013, CLIN OPHTHALMOL, V7, P1325, DOI 10.2147/OPTH.S45248
   Zetterberg M, 2016, MATURITAS, V83, P19, DOI 10.1016/j.maturitas.2015.10.005
NR 41
TC 6
Z9 6
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD FEB
PY 2021
VL 259
IS 2
BP 307
EP 316
DI 10.1007/s00417-020-04892-5
EA AUG 2020
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QA9UY
UT WOS:000560977200005
PM 32813108
DA 2022-11-30
ER

EF